<SEC-DOCUMENT>0000875045-20-000036.txt : 20201021
<SEC-HEADER>0000875045-20-000036.hdr.sgml : 20201021
<ACCEPTANCE-DATETIME>20201021171630
ACCESSION NUMBER:		0000875045-20-000036
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		125
CONFORMED PERIOD OF REPORT:	20200930
FILED AS OF DATE:		20201021
DATE AS OF CHANGE:		20201021

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOGEN INC.
		CENTRAL INDEX KEY:			0000875045
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				330112644
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-19311
		FILM NUMBER:		201251112

	BUSINESS ADDRESS:	
		STREET 1:		225 BINNEY STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
		BUSINESS PHONE:		7814642000

	MAIL ADDRESS:	
		STREET 1:		225 BINNEY STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIOGEN IDEC INC.
		DATE OF NAME CHANGE:	20070427

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIOGEN IDEC INC
		DATE OF NAME CHANGE:	20031112

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	IDEC PHARMACEUTICALS CORP / DE
		DATE OF NAME CHANGE:	19970530
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>biib-20200930.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2020 Workiva--><!--r:9d882161-cc57-4e82-9994-8001479894f6,g:a7b2bacf-5ee2-4f5b-9f49-a40e24a2538c,d:b19ff89608c84168a635160f2efa48f3--><html xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:currency="http://xbrl.sec.gov/currency/2019-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns="http://www.w3.org/1999/xhtml" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:biib="http://www.biogenidec.com/20200930" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>biib-20200930</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM180L2ZyYWc6ZDQwZDVmM2RkYjQ3NGI2ZjhmOGZlMGM5NTMwMGM4NDMvdGFibGU6MWZjNTI2YmFkMDEzNGNmZGE5ZDQ3MmI0MTU4NzU5ZGYvdGFibGVyYW5nZToxZmM1MjZiYWQwMTM0Y2ZkYTlkNDcyYjQxNTg3NTlkZl8xLTEtMS0xLTA_a135545f-cf5b-4a0d-adc0-3142eb79a0f0">0000875045</ix:nonNumeric><ix:nonNumeric contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" format="ixt:datemonthday" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM180L2ZyYWc6ZDQwZDVmM2RkYjQ3NGI2ZjhmOGZlMGM5NTMwMGM4NDMvdGFibGU6MWZjNTI2YmFkMDEzNGNmZGE5ZDQ3MmI0MTU4NzU5ZGYvdGFibGVyYW5nZToxZmM1MjZiYWQwMTM0Y2ZkYTlkNDcyYjQxNTg3NTlkZl8yLTEtMS0xLTA_1c57adbe-af96-4058-9733-351c239061a5">12/31</ix:nonNumeric><ix:nonNumeric contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM180L2ZyYWc6ZDQwZDVmM2RkYjQ3NGI2ZjhmOGZlMGM5NTMwMGM4NDMvdGFibGU6MWZjNTI2YmFkMDEzNGNmZGE5ZDQ3MmI0MTU4NzU5ZGYvdGFibGVyYW5nZToxZmM1MjZiYWQwMTM0Y2ZkYTlkNDcyYjQxNTg3NTlkZl8zLTEtMS0xLTA_648683a4-6a62-4c9b-82a1-bd98798805a4">2020</ix:nonNumeric><ix:nonNumeric contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM180L2ZyYWc6ZDQwZDVmM2RkYjQ3NGI2ZjhmOGZlMGM5NTMwMGM4NDMvdGFibGU6MWZjNTI2YmFkMDEzNGNmZGE5ZDQ3MmI0MTU4NzU5ZGYvdGFibGVyYW5nZToxZmM1MjZiYWQwMTM0Y2ZkYTlkNDcyYjQxNTg3NTlkZl80LTEtMS0xLTA_e10d9ffe-072e-423c-bd59-4f2cb21fbb6b">Q3</ix:nonNumeric><ix:nonNumeric contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM180L2ZyYWc6ZDQwZDVmM2RkYjQ3NGI2ZjhmOGZlMGM5NTMwMGM4NDMvdGFibGU6MWZjNTI2YmFkMDEzNGNmZGE5ZDQ3MmI0MTU4NzU5ZGYvdGFibGVyYW5nZToxZmM1MjZiYWQwMTM0Y2ZkYTlkNDcyYjQxNTg3NTlkZl81LTEtMS0xLTA_c9b4644d-4c78-448e-9f4a-64ad0d2e2cac">false</ix:nonNumeric><ix:nonFraction unitRef="shares" contextRef="i4c10ff2cc693457ba96b227c43b75eec_I20201020" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM180L2ZyYWc6ZDQwZDVmM2RkYjQ3NGI2ZjhmOGZlMGM5NTMwMGM4NDMvdGFibGU6MWZjNTI2YmFkMDEzNGNmZGE5ZDQ3MmI0MTU4NzU5ZGYvdGFibGVyYW5nZToxZmM1MjZiYWQwMTM0Y2ZkYTlkNDcyYjQxNTg3NTlkZl82LTItMS0xLTA_4c3a51dc-d487-4ecd-9757-cb3fd2c5b386">153,881,597</ix:nonFraction><ix:nonFraction unitRef="usdPerShare" contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yOC9mcmFnOjkwNzc3OWY3ZDA4YTRkMDQ4MDU4MGQ0ZGI3MjUzYjQzL3RhYmxlOjE4OGNiODVmZGEzOTRmOTc4ZjA3MmQzN2I4MDZiNjU1L3RhYmxlcmFuZ2U6MTg4Y2I4NWZkYTM5NGY5NzhmMDcyZDM3YjgwNmI2NTVfMS0xLTEtMS0w_e65d17f0-5d55-42b4-8de8-b11d25d3c088">0.001</ix:nonFraction><ix:nonFraction unitRef="usdPerShare" contextRef="i626282e786b7454d83b617e9e83963e6_I20191231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yOC9mcmFnOjkwNzc3OWY3ZDA4YTRkMDQ4MDU4MGQ0ZGI3MjUzYjQzL3RhYmxlOjE4OGNiODVmZGEzOTRmOTc4ZjA3MmQzN2I4MDZiNjU1L3RhYmxlcmFuZ2U6MTg4Y2I4NWZkYTM5NGY5NzhmMDcyZDM3YjgwNmI2NTVfMS0zLTEtMS0w_1e4ee9dd-5263-46ab-be6d-81fc70ecf6f7">0.001</ix:nonFraction><ix:nonFraction unitRef="usdPerShare" contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yOC9mcmFnOjkwNzc3OWY3ZDA4YTRkMDQ4MDU4MGQ0ZGI3MjUzYjQzL3RhYmxlOjE4OGNiODVmZGEzOTRmOTc4ZjA3MmQzN2I4MDZiNjU1L3RhYmxlcmFuZ2U6MTg4Y2I4NWZkYTM5NGY5NzhmMDcyZDM3YjgwNmI2NTVfMi0xLTEtMS0w_1e574bc9-af59-4ec6-856c-39056c07b780">0.0005</ix:nonFraction><ix:nonFraction unitRef="usdPerShare" contextRef="i626282e786b7454d83b617e9e83963e6_I20191231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yOC9mcmFnOjkwNzc3OWY3ZDA4YTRkMDQ4MDU4MGQ0ZGI3MjUzYjQzL3RhYmxlOjE4OGNiODVmZGEzOTRmOTc4ZjA3MmQzN2I4MDZiNjU1L3RhYmxlcmFuZ2U6MTg4Y2I4NWZkYTM5NGY5NzhmMDcyZDM3YjgwNmI2NTVfMi0zLTEtMS0w_7d92a603-e856-4916-8f1a-ec0e34be0123">0.0005</ix:nonFraction><ix:nonNumeric contextRef="i617e512b275d4156b3916be2a31cc2a7_D20200101-20200930" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182NC9mcmFnOmE4NjI0NGEyODg1ZjRlYmM5ZDI3ZDlkN2Y2Y2VhN2EyL3RhYmxlOmVkNWJiZjNhNDYzMDRjZTk5MDVlOTY4MWJiNTY0OTQ5L3RhYmxlcmFuZ2U6ZWQ1YmJmM2E0NjMwNGNlOTkwNWU5NjgxYmI1NjQ5NDlfMS0xLTEtMS0w_d3d93b36-ea0d-4c5e-9850-0d381a79dd09">13</ix:nonNumeric><ix:nonNumeric contextRef="ia4d7d03b9bfd4960861926231d1e06cc_D20200101-20200930" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182NC9mcmFnOmE4NjI0NGEyODg1ZjRlYmM5ZDI3ZDlkN2Y2Y2VhN2EyL3RhYmxlOmVkNWJiZjNhNDYzMDRjZTk5MDVlOTY4MWJiNTY0OTQ5L3RhYmxlcmFuZ2U6ZWQ1YmJmM2E0NjMwNGNlOTkwNWU5NjgxYmI1NjQ5NDlfMi0xLTEtMS0w_e8190803-5daf-426f-ab8f-c78207e1b5fe">23</ix:nonNumeric><ix:nonNumeric contextRef="i1efccb25654a4ed989c06bba1bc60507_D20200101-20200930" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182NC9mcmFnOmE4NjI0NGEyODg1ZjRlYmM5ZDI3ZDlkN2Y2Y2VhN2EyL3RhYmxlOmVkNWJiZjNhNDYzMDRjZTk5MDVlOTY4MWJiNTY0OTQ5L3RhYmxlcmFuZ2U6ZWQ1YmJmM2E0NjMwNGNlOTkwNWU5NjgxYmI1NjQ5NDlfMy0xLTEtMS0w_d79d544d-23e1-417d-8206-ca7347448cbc">15</ix:nonNumeric><ix:nonNumeric contextRef="i94a034741132459dbe0b3f97b3a4a689_D20200101-20200930" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182NC9mcmFnOmE4NjI0NGEyODg1ZjRlYmM5ZDI3ZDlkN2Y2Y2VhN2EyL3RhYmxlOmVkNWJiZjNhNDYzMDRjZTk5MDVlOTY4MWJiNTY0OTQ5L3RhYmxlcmFuZ2U6ZWQ1YmJmM2E0NjMwNGNlOTkwNWU5NjgxYmI1NjQ5NDlfNC0xLTEtMS0w_1a7b89e1-e000-4bfc-97ea-19cece6b07e5">28</ix:nonNumeric><ix:nonNumeric contextRef="icaea773c02484e7c915b32abc21d9f16_D20200101-20200930" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182NC9mcmFnOmE4NjI0NGEyODg1ZjRlYmM5ZDI3ZDlkN2Y2Y2VhN2EyL3RhYmxlOmVkNWJiZjNhNDYzMDRjZTk5MDVlOTY4MWJiNTY0OTQ5L3RhYmxlcmFuZ2U6ZWQ1YmJmM2E0NjMwNGNlOTkwNWU5NjgxYmI1NjQ5NDlfNS0xLTEtMS0w_1e448f36-0587-4422-9d5e-69b702ceba5c">4</ix:nonNumeric><ix:nonNumeric contextRef="if93847a57ec24f1cbf59a9b2ee618117_D20200101-20200930" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182NC9mcmFnOmE4NjI0NGEyODg1ZjRlYmM5ZDI3ZDlkN2Y2Y2VhN2EyL3RhYmxlOmVkNWJiZjNhNDYzMDRjZTk5MDVlOTY4MWJiNTY0OTQ5L3RhYmxlcmFuZ2U6ZWQ1YmJmM2E0NjMwNGNlOTkwNWU5NjgxYmI1NjQ5NDlfNi0xLTEtMS0w_bc0f92fa-e959-41ed-b95e-5c6e1713ede6">18</ix:nonNumeric><ix:nonNumeric contextRef="i043f609cf8c0415bb5def38eaa738850_D20200101-20200930" name="biib:IndefiniteLivedIntangibleAssetsUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182NC9mcmFnOmE4NjI0NGEyODg1ZjRlYmM5ZDI3ZDlkN2Y2Y2VhN2EyL3RhYmxlOmVkNWJiZjNhNDYzMDRjZTk5MDVlOTY4MWJiNTY0OTQ5L3RhYmxlcmFuZ2U6ZWQ1YmJmM2E0NjMwNGNlOTkwNWU5NjgxYmI1NjQ5NDlfNy0xLTEtMS0w_3049daf7-8768-4f17-abc9-86fb6111c949">Indefinite until commercialization</ix:nonNumeric><ix:nonNumeric contextRef="i12acb630c412471c8fbf4ad5fba70e7d_D20200101-20200930" name="biib:IndefiniteLivedIntangibleAssetsUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182NC9mcmFnOmE4NjI0NGEyODg1ZjRlYmM5ZDI3ZDlkN2Y2Y2VhN2EyL3RhYmxlOmVkNWJiZjNhNDYzMDRjZTk5MDVlOTY4MWJiNTY0OTQ5L3RhYmxlcmFuZ2U6ZWQ1YmJmM2E0NjMwNGNlOTkwNWU5NjgxYmI1NjQ5NDlfOC0xLTEtMS0w_c6988c99-afdc-44b9-9b08-9d223f6d6a94">Indefinite</ix:nonNumeric><ix:nonFraction unitRef="usd" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="INF" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182NC9mcmFnOmE4NjI0NGEyODg1ZjRlYmM5ZDI3ZDlkN2Y2Y2VhN2EyL3RleHRyZWdpb246YTg2MjQ0YTI4ODVmNGViYzlkMjdkOWQ3ZjZjZWE3YTJfMzk_76cbb0fd-0b23-4c95-b0ba-e374827a8298">0</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="INF" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182NC9mcmFnOmE4NjI0NGEyODg1ZjRlYmM5ZDI3ZDlkN2Y2Y2VhN2EyL3RleHRyZWdpb246YTg2MjQ0YTI4ODVmNGViYzlkMjdkOWQ3ZjZjZWE3YTJfNTI_6c96674b-9444-4c70-9472-7c50b416f15e">0</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930" decimals="INF" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182NC9mcmFnOmE4NjI0NGEyODg1ZjRlYmM5ZDI3ZDlkN2Y2Y2VhN2EyL3RleHRyZWdpb246YTg2MjQ0YTI4ODVmNGViYzlkMjdkOWQ3ZjZjZWE3YTJfNTU_0ebd5b31-41d3-4503-9dee-3b603032fd7e">0</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i9aaf1d46914b4e72aed3585ce98ebf30_I20200930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183MC9mcmFnOjg0ZWEwZjQzMTllNzQ5MDBhOTlhMjNjNjc5YzY0Y2FiL3RhYmxlOmYxNWYyYzE3NWUyMjQyMTNiNTgzYTJkZjAxMDQ5ZGQxL3RhYmxlcmFuZ2U6ZjE1ZjJjMTc1ZTIyNDIxM2I1ODNhMmRmMDEwNDlkZDFfNS0xLTEtMS0w_83d40276-d28a-4890-b8b4-0178b9b1e73e">2.900</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="ia8b495ea13b343bca84608b9acb70bae_I20200930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183MC9mcmFnOjg0ZWEwZjQzMTllNzQ5MDBhOTlhMjNjNjc5YzY0Y2FiL3RhYmxlOmYxNWYyYzE3NWUyMjQyMTNiNTgzYTJkZjAxMDQ5ZGQxL3RhYmxlcmFuZ2U6ZjE1ZjJjMTc1ZTIyNDIxM2I1ODNhMmRmMDEwNDlkZDFfNi0xLTEtMS0w_3b933cd4-b72c-4d35-8e42-24e7ad7197bd">3.625</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="icc2aa37ad604405da57ad8bd76640c2a_I20200930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183MC9mcmFnOjg0ZWEwZjQzMTllNzQ5MDBhOTlhMjNjNjc5YzY0Y2FiL3RhYmxlOmYxNWYyYzE3NWUyMjQyMTNiNTgzYTJkZjAxMDQ5ZGQxL3RhYmxlcmFuZ2U6ZjE1ZjJjMTc1ZTIyNDIxM2I1ODNhMmRmMDEwNDlkZDFfNy0xLTEtMS0w_bc3d3419-c3d8-4e29-98c4-83eac3440cd0">4.050</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i77d457887e524f9da825a576463047de_I20200930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183MC9mcmFnOjg0ZWEwZjQzMTllNzQ5MDBhOTlhMjNjNjc5YzY0Y2FiL3RhYmxlOmYxNWYyYzE3NWUyMjQyMTNiNTgzYTJkZjAxMDQ5ZGQxL3RhYmxlcmFuZ2U6ZjE1ZjJjMTc1ZTIyNDIxM2I1ODNhMmRmMDEwNDlkZDFfOC0xLTEtMS0w_502dea29-9704-4cad-9269-1dc8e060aa41">5.200</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="if6f8f2b74b4b4cb48f44b56c1255fe48_I20200930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183MC9mcmFnOjg0ZWEwZjQzMTllNzQ5MDBhOTlhMjNjNjc5YzY0Y2FiL3RhYmxlOmYxNWYyYzE3NWUyMjQyMTNiNTgzYTJkZjAxMDQ5ZGQxL3RhYmxlcmFuZ2U6ZjE1ZjJjMTc1ZTIyNDIxM2I1ODNhMmRmMDEwNDlkZDFfOS0xLTEtMS0w_931f96aa-1e4b-4a14-a96d-119cfeb28fa9">2.250</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="iae850a600e004e54910f51657134788c_I20200930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183MC9mcmFnOjg0ZWEwZjQzMTllNzQ5MDBhOTlhMjNjNjc5YzY0Y2FiL3RhYmxlOmYxNWYyYzE3NWUyMjQyMTNiNTgzYTJkZjAxMDQ5ZGQxL3RhYmxlcmFuZ2U6ZjE1ZjJjMTc1ZTIyNDIxM2I1ODNhMmRmMDEwNDlkZDFfMTAtMS0xLTEtMA_df88c246-689b-45b9-b4eb-611ed3f82834">3.150</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="ie4a4e14dec0342ad99b8a674ea3866bf_I20200930" decimals="4" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183MC9mcmFnOjg0ZWEwZjQzMTllNzQ5MDBhOTlhMjNjNjc5YzY0Y2FiL3RhYmxlOmYxNjFjZjQwYTA1YzQ0NTk5YWJkMDIxNDg4MDJkY2EwL3RhYmxlcmFuZ2U6ZjE2MWNmNDBhMDVjNDQ1OTlhYmQwMjE0ODgwMmRjYTBfNS00LTEtMS0w_1dc9c7d9-cbf0-4897-8d2d-a79047528b99">0.83</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i8c7ce002196541519d28ce13eee1a198_I20200930" decimals="4" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183MC9mcmFnOjg0ZWEwZjQzMTllNzQ5MDBhOTlhMjNjNjc5YzY0Y2FiL3RhYmxlOmYxNjFjZjQwYTA1YzQ0NTk5YWJkMDIxNDg4MDJkY2EwL3RhYmxlcmFuZ2U6ZjE2MWNmNDBhMDVjNDQ1OTlhYmQwMjE0ODgwMmRjYTBfNi00LTEtMS0w_07437d0a-7ee7-4f2a-9fe9-c0f22f8f5eef">1.18</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930" decimals="0" name="us-gaap:AssetImpairmentCharges" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183MC9mcmFnOjg0ZWEwZjQzMTllNzQ5MDBhOTlhMjNjNjc5YzY0Y2FiL3RleHRyZWdpb246ODRlYTBmNDMxOWU3NDkwMGE5OWEyM2M2NzljNjRjYWJfMTI_c1d25d25-ef2a-42c2-a730-823cd7e5bca4">0</ix:nonFraction><ix:nonNumeric contextRef="i5da3d551e877481482c2c617be75f347_D20200101-20200930" name="biib:CollaborationAgreementTerm" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzg3OTYwOTMwNDMxMzk_81c0182f-ea26-4b51-b761-61b3c8a065e8">P5Y</ix:nonNumeric><ix:nonFraction unitRef="usd" contextRef="i99c8bf62c3f747a6825f635a38c876aa_D20200101-20200930" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTUvZnJhZzozZTE2MThiMmQ5ZTU0NzQ3YjBkNjNiNTQ3NzY0NjU0Ny90ZXh0cmVnaW9uOjNlMTYxOGIyZDllNTQ3NDdiMGQ2M2I1NDc3NjQ2NTQ3XzQ_b32dfb72-3b6c-4992-8621-bd0e2a08eb36">33800000</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="i626282e786b7454d83b617e9e83963e6_I20191231" decimals="-5" format="ixt:numdotdecimal" name="biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMjEvZnJhZzpkMTg2YTllMThmN2M0Y2YyODU2ZGU0MzJjYmU1N2RmYS90ZXh0cmVnaW9uOmQxODZhOWUxOGY3YzRjZjI4NTZkZTQzMmNiZTU3ZGZhXzE2OA_a3e92a68-88aa-492b-9fae-61b0b8e61d40">22.7</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="biib-20200930.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i4c10ff2cc693457ba96b227c43b75eec_I20201020"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-10-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="iba1a633773a34c899b77b4853a665d4e_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i817821ea916346a6b301c5912257c3e5_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id41b722bb5ce413f84c0e1a46961879f_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if88c636dd80d492687ca22f07e75db13_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia428d1f03d1f454a9d5c837ec6e0aa50_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8595ad2d43f34d98abb716a40fde60a6_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0cb93d1ae39f48f3b0fc167540132b77_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5452667727cd4cf08cae4c412b67d3ef_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba6a7aa4c7fa4fda950fccc032894346_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ea06cd6a9974b4999904b90f030878b_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e0b6c1de005431bb80fcd07bc90af2e_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2335a9cc65b041aa8e881414fc49759c_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d14771766d1415790d98b0c80aaa2eb_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:DenmarkManufacturingOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="ibfe5725c9917439e83ae4f911eb7a60e_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i626282e786b7454d83b617e9e83963e6_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec2bbdde63854682b605414cc72c3ab7_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SangamoCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i97a0bebcc8cf4432b262746010427fa4_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SangamoCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79e678cecceb4e00b17b8c2023042ca8_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd729f26efae42a995f0066eb5f4a0ce_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib98dd789f3514452acc95f9b041d2a7e_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied38b94db9a74750b51c6e8392d4c5bf_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9b1433e63154dc793bb3be211f95c71_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1dd367dec9d1416ead31ac17037d6347_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i58e4de16550642ffb8fa1ec5287f1bac_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f5ebc014a364cce887ab9d7243516cc_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icfc9a329a8dd439cb140f840522afc1d_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4bb77bd7d2ce46e59ff6fbd5cb940d75_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb3e0c3b7ac94f2183a66e90c088be58_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i27fd7cabf5714753a2a142cffcd63932_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d122436a2064a36b4342d6417ac828f_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1499259d90804413b1e193e034d9561d_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if01d2b8c98a04ef2a7d2d2754bdfa47f_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7209bbd041614d26ab0622d0fd200deb_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib23988bed8f7484597669fdaf2c6150e_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i030ce533f4cf4aa7852fbd17ed7ca720_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic0a0dcfa5c2c49268190d94b335f065e_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:December2019ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2debfff1a33140e6bcf02b809c593d24_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:December2019ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iadd8187a18d849f6b353e75cae0aabe8_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:December2019ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iada85e2a70f74606baf6a5c38c9ddac3_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:December2019ShareRepurchaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb80294ce54b4a41af5a0f3e17352851_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:December2019ShareRepurchaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c225596be4340518bf78440f40fdbb7_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:December2019ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53ea969c6702421f9bfd2df9bfc3232a_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2edcb252dee41aaaa28a702b70a129d_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iccce420c57a74d908b28fffc261114e2_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89ed42febbd445c9aa4432e778b1d593_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia55221e7b3994df7ab08c27719d7d2f6_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i162af0e1b52e4fd99c7498e910ae472b_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i138fbc630aee4346840425ef11fa647e_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b8029eaee38406ab0f2d229d09c0a8d_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe8d84b11e994911b29ab0046e3c5436_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f84ef87973843b2b12c2e5314f58592_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40f2711483814cfd80a3070c293601a6_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia40deaebb7e14b0ea3390b0988aea61d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc05b78d934b474aac9922457936de4c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb84688ac5bf43faa19f9f893a04a3e2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i03b2cef2a2324bfcbcfdea22ab154bd4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6344cb617db54fbaac18f0e555380783_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d1cce71297346cdaeeb9fb6370ccdeb_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d02929a942940478cbbc1b3ab3918a9_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec296486afe44cb9bee6a9b9fec0c678_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic4379c94e8a84e548bdd2c9f5110296e_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1faac185931341e591596ec3e5440d06_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0319abba8ccc4f0fae4e9db75a3ba5d0_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc0fb387460c4e6fb1f5dd03a311fb08_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0af05fc8fe804816a86f91f4f77cdeac_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae4ebdfec80c40fabeca031863dcc5c5_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i14eda8fe33b0440e8f012764e73abe64_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibea5025954d8442193d586f92fe4b174_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48e09b81ae6e4e27bb99b06fb90ade10_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:December2019ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23f4570c321d470ea07b9b8126846754_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:December2019ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb94151f567e4761811caaa2ee1c1349_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:December2019ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ca2e1e65c424ac7afdfd951e4e64cea_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:December2019ShareRepurchaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6f932e5c68d4df8ab6182786c4e7dff_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:December2019ShareRepurchaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife6f9a28c7c64a109d345b6753d462fb_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:December2019ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e65876e41494343960737c39bc5f276_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i861bb59946a84718b6c99600a2e9b0e5_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99fbd0519e8d401bb929b503f3ecea4e_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9843b0258d7a4100af10e14048f0aa5c_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0376412c3eff4647ac527a583e1fea9e_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e4817878dd24efa84f78403542ee2fa_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife3567f724fc4eafb760a986851063d1_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if307586287e044beb16134d1cd640d29_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i396ceaa32ede4bd18fc264a28d5483b0_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ec1a9946b9d42abaed7abd2237b7dbd_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i94c6f45fdfc542388521216b8e80983e_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib515d9bcec6948d184e2f6536574cb55_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58b6be5e29354a3f95dc35f74e0eb46d_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae71bc1953744eebba86f3934124b00b_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37ac27ae2b114acebcefcb550c5cda84_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibcf7b9d6ba6b4eddabd32ecb80c018cb_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86c3b6289b2b4f52a9c054d27fb6a5b9_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if78608284adf428b9b151aa288371376_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i859bf4d9f138495caa518c457b42a8a6_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic82a5a18c46c4de99def553116869989_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9881e9f358c4093a91f49acc663d493_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45b746c96de74debaf178d86af176ed7_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic161674d27484a338894e49a73880c69_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i30714cf43346412e9fea73f7251cf213_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iccee1e1d95af43b9873f3228bed22351_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i404c8ff0534c49f7a853054388cf47e7_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie09a86c05b2d4dd68ea12c27ea7e151a_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idcbcecd74e024473bdd870830b88f96c_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c8172c9fe75493ca901d5f05ecfa29d_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9f978f94b6e4038af9fb1fcaaf85dee_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie2305062812f448bad777c7ba71b2552_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88af2b9941924871abe610dc3e71811b_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e15f7e0305245ab8755ada973550435_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b39457257df40c0a44aba71b396d988_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i615f50b48b1947daafcc18ec87768baa_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i691108e26c8d4acfa6452b2cc1994da1_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2c93178a13f4173b8c722d0ace0c1e7_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i474ef61edf8a4e488fdbe0a7144141d1_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8445ab6e25754f87a6ebbd9df3b89ca0_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib53a358e088b4743a76a8141b6a1c193_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0efa62d44ea047f48a850ba3d5919a87_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7182b1df2b374d208162f601fa679959_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a7633cfe36348a79a7d0f41758bd6ab_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7289c8815e434ac989c2d260f35da03d_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8e1e308da1c4ce6aad01a86613ea938_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36fedb8b45764716a0240c105927c6d7_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf8bb34fb60b40bcb5c350755c57da7f_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id953e91f8c614de9996090d5eb18e5b1_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8aa3352d77e4f12b7fc3b77907a67f6_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib125f2b4cba94378833a506b5f526ef7_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c3d2fb2bd034a6d943e04d98c6101df_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1d334b7c899449292200b30b2bdc155_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifba3660adeba498985326527c5db09da_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i809df7746fcc437c8e9a75cc7cb10a70_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ffec57fb67a4f9091e91bd4b96b6eff_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab58c905ebd44601ad94f01220bb87b0_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4745753d1ae84b66b7bfd523bb7d93ad_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="product"><xbrli:measure>biib:product</xbrli:measure></xbrli:unit><xbrli:unit id="segment"><xbrli:measure>biib:segment</xbrli:measure></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i6184d003ca324663b6d44d4425fd9798_D20200301-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:BIIB118Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="assets"><xbrli:measure>biib:Assets</xbrli:measure></xbrli:unit><xbrli:context id="i34259f1058d543a0ab98f22062f2e5ab_D20190601-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-06-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if669468af2b1428fbb2d5e8a25e54053_I20190607"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab47d31b221a4694b97e6b5cd3de541b_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ea815a094e741b0a154fa60dcf2c6a5_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">biib:PostacquisitionequitycompensationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3e1580f38914bf3a529df3762a6db10_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d491f3733874ec68a5451b8128278dd_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54fe6174a2224b379d4a176d7fd82015_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:DenmarkManufacturingOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1329de1cf194c709a3e6e578b701fb5_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:DenmarkManufacturingOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie4528167bcf941dbb3558a86eed5211c_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:DenmarkManufacturingOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3413eeb6a8594eb7bd9a9895a6a44b36_I20190801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:DenmarkManufacturingOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8fb970353ed64398943d0ed1643a7bcb_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:DenmarkManufacturingOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i174c6f6dc0974a4a9f1635f5f4a03baf_I20190801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-08-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb5da4324a084eefaa4d376d025b0d68_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe88801f13d247f899ec696c93dcc2e6_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b5da4a47c7b46c7a859d909b06ba52c_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia341fbfc92d14c558a2c51805e16e967_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6fb54144d66b439881fcd02918e4cdeb_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c3d302ecd604f7a8d735759d694817a_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id616d991f56748438a8ba16f0137aa36_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3dbbc7fb0ad74d068c127681fec0fc62_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a70003485d4486a9bb6430b519901d8_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i235abb80d0f443cf952612f002c4c724_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1773b37e68f4ca98e29d05e4707727d_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if638579a7e1847469ac17a832271d4d7_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b652f2150604dc6a33be4ae69220a56_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i90806ea38d7543f29e6a6e61337fe595_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icea39709b7b1472aa5dd7f44966c0bd3_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f9d582c0e524991ad24725e61b062b5_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if85e43e3e237494fa32864c3adac50a1_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic408b141d6a24355afe175433eb9135f_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1323f4a6c7eb4aae984b38b19c87c5bf_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifaaa9079f60b4098abc8790d9255ab3e_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68159e373219432e9ceeac5ce7c38c52_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e0133306cc04c65928c989a2d2dbb45_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5a5e0e77dd24eab8c07703f6d5e5414_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i742235d37c1342388624cde1c677f04b_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a33b9fd26694109b63c4f4ba7b7a6e1_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic87d9b72e03d47c7a87c74570147c7e8_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba79677927674335a48059dc861147c5_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd282900956142e1a6ef766e0cb49611_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4610f1a14c034cb19b7366512e904c92_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i134d08fbd1ff45239e991114f841a948_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i782a7c4ac90845f09d932b45511ff216_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if924a82037ba40d288c2ebf03d3f886f_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64ff52eeaaa44fe1942f08bef012563e_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc93740adfba43e48aeb5c07582509ad_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5dfd6a6fcaa4743b33d7010ee60257f_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71c758edfcc041a19e3af23d14f9b3a5_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a383eb4ffb0459e920cfd44b9b19f2b_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id87093f8e357449d9e8705f5c6ccc183_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icdcc3e6db10041c6adfb46ab9cc43d52_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5469abafd1f421d8fce4ea54f1ec77b_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i746432e17705462ea58e77a00bb3a93e_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7f7847bbcdf4347bcaa5531ac1b24ef_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i010f4a93398d4bb4b566cd786299c56e_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d23abb471e04139a7badc923a7aa0b0_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b01d577ab7e4e2faf2a58cdd2703267_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if30fd82eecb5426b92a98a3e3fefe6f5_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i116d706a2f374c48861e85f661a21b25_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9a7e5c89d394125ac728a112ab5ff87_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56b36d0e49d840c1bb93b2c87291791d_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief040210ae2c41fdad968514993484a7_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f8fe94c6208475b8bc2f93cb71a7939_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48f53b5d6fc04defad6638974299bc5b_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5971788b43b64613b60ad9eb48951064_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8eb6906d8f14c4cb3001d7cfc2f6447_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i108b8c9cd74844ea902eb45e12f344d4_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i492d4f74b2774d46ba24d8836488319c_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04f6a02314ae4524973688bb453aa3e5_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a8274402a6247b58947c615cddc6683_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f5d0029574e4134a8a64eeb2a84b092_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd1e83f10a674384b5a5c22e4838bf7e_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e2a3e2e67994b33aa594e6685bfb7a1_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83b0b2c0884c4420b9ec2c69e43f3b5b_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5887fc680fe24fb89317ffa45e0e7399_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6b4fdc531a146d8b6ab0e3b3a410bb0_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2c497aaf27546a396c0c89e2d199e5d_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03858b8f5bce44fca9ffdbe13c9eb5e2_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82ddc3d73c6440f6b67ce2997a135a27_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i537d78dad03f4414a8201cf28d6fb744_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i27f454fe7d384ff6b0419771f9b3e2d6_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5915a0ecdc446c396b8a751ccb2cb15_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic542c97609834568beaf236a66f61e73_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54cede8da6804f35aad2512972cfec7d_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3fb38646d08e44f09e679dc53de54e79_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49af2b0ec0f64a17a1c3f06e8918b239_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i578fc5ffb2e64484b3d17b8c6505e6fe_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icec0afd4985d4eebbcb6d942dc11861c_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifff8a50ada4a4480aa27d7e429483ebc_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ebf452657754a04b75cb22245331331_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i97559f8bfad646f4a63f6e7d1de603b3_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia54121683d93464386861f04a5eb0f78_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58ceddab404b43efbc2aa182802d7e90_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ff9cdd4f3124c71923b611c196ff399_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55c11d8111cc47e5b6fd6668e6688ebc_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i811b94cd1a9a4cdfa735283523ef7c2f_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba49923c2dbc4cfa9e28cd6dc0232817_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf55884ad575429cb3318dba7371b6ba_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2050ec4e36ba486eaaa52e2629f9eb4d_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa6b881f2fda4822952ca375ff987144_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica095eed2ba44dae9950be250f7d8e18_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id65392444eb84d778e3da80dd59cb0ee_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c5c5deb248640ea8a5b2acc2c061165_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45096669722b441a88f0da5da92b8c28_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb862d5227ae4e258ddf1674e35ea488_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ebacf9f9e6841c3af9fbbaef43f7942_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9481c82cb20488b9ef66d6125fd47af_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0c82a598d09477ca3061b0c8ac0da77_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib99c15bafed34bf3a271edd3287e7b03_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iabb34cdf00c04963ad7af011adaf7ae7_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ac22170fd834262ac66fc712062e281_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iffe091a9dada4645a5db26663b970d61_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7271f995472417c88ca939ff891ec17_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24db87c55fa5436c82745477f49e8563_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i327b2bcbf1a6442493e173a2baeab0c8_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i824479af0d2943a7a9ec0c36b60267a7_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0ec100b681943e69c7c792eab6be4a9_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5f44218395d4becae44e95c8c6bdf51_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib81a7f97279a40f9a38ad04e204987e3_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib7068d1546c040608d8c969370cd8e9d_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7bb0ccb59cdd4f0083748543233c3b52_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7cadb5f8f65e4e73949863a5024f4ff7_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8919ebc1037469d9bed32fa8eec69dc_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icee51ed1fdbc42b88487b41b6379cf78_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f6da514a21b4672a427de97a1d05efb_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ca4c818e3ae4c34bae274600ab49c11_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4c89150d9234c61910e3033151c6c58_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18ff182dc2fa4ee6a2478c6486ebc688_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i51ddcb898ae7480cbdaa9ec0ab68a246_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f1f3b16e8d246ed9cb3f7cd93daf5bb_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e584f31a41a4eae8bf2342da93c54e2_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a59fa0fcf0647fca4a684d8a73ac1ae_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7638af777ff44424ad832076c7ede12d_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic66643a3fa6f4367b9eebb3e83bf3f00_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28632e06900d4c5c9e30bb7d2329c1ff_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c3e816876c048aa84d64152477c9781_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ee8e58d8b904754b7733dede2183d4c_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i529ab974da4c4d049570f91ae707a0ba_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i254d19bbbef947d1a614d21d341de265_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4eca9ea1df2452294cbdfa5fbed58c1_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58eb92d0895f4b14ab4e6bc4e13c9ffc_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab755c39193d4ef0bb6db78729b51f1d_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifee406589c20493a9b2fe20b2c5535a5_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf97ed01b19948c9bae6d6c52e933fcd_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3cc3553689e84e56811b92f0dd3b6b92_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5fea542032c54705846f79614c101fc1_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea33bba3363f4d079ad12fb08f1e1b10_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i882255f3fd6c4303973083ca690aa076_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie37b87d6a1074111b1725e662d8f0afa_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7adfff2dc6d34472b4ddbd0d4f2a4422_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if276cb15ef2546539e317deb2377ba10_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5aba8b2bfc846c9b459ca84fc4e721d_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="wholesaler"><xbrli:measure>biib:wholesaler</xbrli:measure></xbrli:unit><xbrli:context id="i8df56b3f3ec24c9cad78f819aa3968bd_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3302fabf3956449599c4d0d7d34f36d6_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6de66bb341bb422daee145e34cc96b52_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idfabb0fde2e64da393d47657161d482f_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie223070107d841acb3680d718ad02ae6_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52dc933695414f1895f943cb573be8c1_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie32fda1ac1154d048d97699d8290e7fa_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c0c40a4a5f74ba69177a07ee1ff0f2a_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02dda51ececd4bc28da1d9a328686af2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b3ec66c47d44f20873b899460f118cf_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i547ca2c2237a4a379988e41835ac1091_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2a30a4831ac4e68b68264f34f994f66_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a535a6744d640489dfb975ae50eafb4_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4608a28d79084131af5440bda4ce4ba5_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i204f2ca2855b47ec88cf265fde7a6679_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7897f16ad9b249e08151468bc3c92f5c_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i897e79a0b82b448297a7d6e150e50906_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieabb7bcb048b432c908c601e832af027_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65c7f4e2aad74eb78be96cec75c1e6c8_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7eddadc447104f8eb26db7302eace7a5_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide07a6c272e244a3be181989da603c09_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i144bad8e98d44b9283666efd91ae814b_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icfb2a7f321824155859b452e7e1620d7_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8db6af1daf2476691a91e008e2e4614_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i647942c6e60f4fd3a53dd00558c6b691_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b511ee9603b41fda2cc6f8171976d4e_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c11f9b8d3684514917520eb76b5297d_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida3ec850012e473c82f5aebf509be5cc_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i528e10772f27492fa438cba3d636945a_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i083a7fa4caa1424dbbf1d7151d395e24_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:ZINBRYTAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96f6c016546448cb939dbb6557754670_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:ZINBRYTAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6369975ed9d437593f2e153c72f7978_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:ZINBRYTAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6f2c098f47f4305b065fa0a773ea01b_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:ZINBRYTAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7aaebf479efd4e5988b193f96cfea104_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i727d852e008a4093bc7eeae55e9ac6e9_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a892823ca8b4d289bbf6e819b53df89_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a2aaddc244148d29b9babb1a6e4d21a_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id62c1ea890004cc683b1c3e2197b9771_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e78e06924024013a86b44bea5d8c5fc_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64ed3edf8c234417860f788da7ecdef3_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b88a1e534d44643b0824a70718ed27c_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63cfe59d1dc247b88c3f0c79a4c20ddb_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie108e7ffa05346ff9834f57e7ffcdad2_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:ContractManufacturingCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9be493af1ef548c7b50cb146bad36446_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b9c454823f244cd80d1fefee5471031_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i16c121b145194cf6abb5882efd1600bb_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i11500168fa8a442f878e3a3fd7879581_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3481a276c03d48bf9b2c07bcb87daf78_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i21ae35839aed4acb8ce3728a8d65c8c4_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if562d8cc7f4f4e548b86cb2f63c89067_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5dc2c86a61e549f6b10a9b94d684a51a_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic493d11fbb2f44b19c639b7aea48e26a_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide28bbdab94947a3ba38457611aacf91_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5ac9acf99f240868c0779db73b11128_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5ed0dc28e704ee58e687f720a4af0c0_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:TGNMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i617e512b275d4156b3916be2a31cc2a7_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4d7d03b9bfd4960861926231d1e06cc_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1efccb25654a4ed989c06bba1bc60507_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94a034741132459dbe0b3f97b3a4a689_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icaea773c02484e7c915b32abc21d9f16_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:InLicensedPatentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if93847a57ec24f1cbf59a9b2ee618117_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:InLicensedPatentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i043f609cf8c0415bb5def38eaa738850_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12acb630c412471c8fbf4ad5fba70e7d_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3733833dc5534d8e823879ef2ca35162_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2937e4b1496b4a52a0d3e66401ae9216_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d5405f808014e29ae408f670b51a09f_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a4caf6e3ead4de1943986bbd01cf562_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9fa1b53a700943f2bdb14f74caa79af6_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i72583de967dc40ddb4cff73d7209ce4c_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5876b06547fb4838bc5be5aca105c206_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iffeaee7ccfe84deb8024b6a3c6400e05_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i366fc4865f1141d881e72475b885ad6b_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3762ea1be6864e498c8620d932d2da39_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4bcbf6cedff544d5a8a856091fd31a3f_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia08462c38d1441cf88e8ec71551ea0c8_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if0af6974b4d9478091a43d7c360e50da_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7efef111968e4853ba97bc23f3210bf0_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f93695e9414499694873333956d9bdc_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib2ec3058389a4337ac5eba484681aa08_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6a0e49727c84ab293a923c6fa60c4af_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if8d8ff0dd3eb48ac863f558fcbc6892a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i30724e1260114af0b2ee60176aabfc27_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5bdbb9beeae4e419f12246dd08e17c5_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icdb4c26a6ae346b2b90553854ef6c821_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i23dad120af7646aab43c1b2a51494af6_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a733f2e8da94648b74178fe7c59c1c4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1741135b13de43a09abeb81ebbdefb63_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i43071817e6ed461f81f3fd642338f5f0_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2a84d2f950447e889c009b8dc3d1c91_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c062405d6734f55a0f77a7793837fa5_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c442e1cde66431c994c606712e1b32f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i880c27328fde4402bd25776af2e34436_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if8cdd3be786a4c8fb53fbc1511f3e007_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0e3519a323b44aeac235464c19aa330_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic296bd1f024d4dbfafdf14773b56195a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icfebb7d3ca564ab9adac39367dcd18ff_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9aaf1d46914b4e72aed3585ce98ebf30_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69617b3297c54b348a912b5786d5c621_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8b495ea13b343bca84608b9acb70bae_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id243a9da99674c029fed341ed2d8cf28_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc2aa37ad604405da57ad8bd76640c2a_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a88a8981a664b5881775b573a56d09c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6f8f2b74b4b4cb48f44b56c1255fe48_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2.25SeniorNotesdueMay12030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i21d53c4f2fba488bac9f594f9b972c35_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2.25SeniorNotesdueMay12030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i77d457887e524f9da825a576463047de_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie3ab5e1259184cbfbb1c0fa0836b199b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae850a600e004e54910f51657134788c_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A3.15SeniorNotesdueMay12050Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5be3c08b32f44a29a978be98ccdbe750_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A3.15SeniorNotesdueMay12050Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic59436e93fd94dc7975cca19dc9348ab_I20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b095aa200c24bc89b77243d5d674b37_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i481da687b03f42ba833d7ea97207f576_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie818884c1c424a8b87d88e29c4beebaa_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a3eaba5b5f948d7a04bc997b0e062fd_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie4a4e14dec0342ad99b8a674ea3866bf_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c7ce002196541519d28ce13eee1a198_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ca7ffcd21a746b68b8a16da619e41e8_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88ecf4f0a7d947ada40d20f177ef560b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i01bf576ce3184732823152e79c0954dd_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:RepurchaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i83545e7be2ae48768bf0f58e921e708c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:RepurchaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i37325c7e699d4c51b083d0bd7f89fe2a_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e57229498ce4144b42c45e34e9ef425_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4704964df0724cd1b2cac40f12d8482c_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d2e2443e8024c469ef86deaee00b316_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i71ff130217a74446aad53582c9032ff2_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:CorporateDebtSecuritiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e2e5400e66745a59bc4efb5814dc463_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:CorporateDebtSecuritiesNonCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifcf2b581c6394dde8ca839bc55b63d5a_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:GovernmentSecuritiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i332a8e26a3f44d669337bbdf30e280b1_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:GovernmentSecuritiesNonCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib526d2b286604bca80b624a3a4adab69_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:MortgageAndOtherAssetBackedSecuritiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6cf822a887824796933acc64b10aa831_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:MortgageAndOtherAssetBackedSecuritiesNonCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia10b2aa757ad47b49f270ebc491e28d0_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id90fa1852e434ceeabbcb8fdd0d40cbd_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:CorporateDebtSecuritiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86f354cf497b4deeb6d0848b22bfdca5_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:CorporateDebtSecuritiesNonCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0059a0f76db42a38b389323762cb3c7_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:GovernmentSecuritiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id4429d736bb44d669945730bee5061f8_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:GovernmentSecuritiesNonCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5fe904d775af4819805f32f893ad9967_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:MortgageAndOtherAssetBackedSecuritiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i803e14e6eace4d489a23796edd542d13_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:MortgageAndOtherAssetBackedSecuritiesNonCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb9c77d5ac2a4c2c926a9a3dbf9ab8a7_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0da5a59be8a94d28ad89a6d9991c15a1_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9fda89e7ff7d4684af34961dfcf9aa55_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:StrategicInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8f1f5cd45cf4a6db70e9630acf66ec5_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:StrategicInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i309c31a67fb24e66812ca6f278d681d1_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c3108c96711433ebf84541ad9cd5532_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf4f0ead32484685b836bcb55cd6ac1f_I20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:SangamoCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6cbe8727f757473bb189b0e60ca29a33_D20200401-20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:SangamoCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if61ca2beff4e46f2a69e878ff2475931_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i14b94761681149c0bbac66ff547913ee_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2bae98225c1d43d0a893047e90eb67a3_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id558b1125e81440f900acb6908040141_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa7d33c1e10b47fa9f4f7f33d32f8d33_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib2f9b3c22cd24844962bad5e0141c40d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic1855cf25f394029aa9142b5e0a2635f_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a9857ccde3e4f828b0b5370ff0d84e4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i25d3a3cbcff64295ae970930acaf2277_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i921787c0672f4315b77172582046acf3_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc22ccd0077c4fc49c9a6f2ddfe73891_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:JPY</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd041b2211c7473cb6ccaf17dec017b0_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:JPY</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3cd6575c1e949488c892f752b68feb4_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic23424b9be6b4da59f189eb5703a1408_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i192ef770d9d94f289c8016dd9d055c00_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie23a1176752b46eca086057bec4d49b1_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i68711c4f381b4aba952ff728afb1d3f8_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:DerivativeMaturityAxis">biib:ShorttermderivativeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a2d291074a1433481dcb814e41d5746_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:DerivativeMaturityAxis">biib:ShorttermderivativeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf5f0f40953a4421b9784faf958d97fc_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id81d26ae112f445586efe731295329b3_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b20f502d9dc4650852d96fb05490b25_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0abd481cc504df9bbfcf3174b6ce61f_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id2b9b73877d74fc192e42310e8d70481_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic22c771083a443f1ba2c8d2ff484ba65_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i827d32a33a5f4fa8ab22ab96449ad285_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a9063b9b9ab470d9ffe7edfcebe7d66_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3ca7f05924940338725185c031d90c4_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1761a26f1d99415db0e01cea732e296a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic4da688b8e414bdf83ba16881ee41846_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide3b267ed539403d9aea0f7cee18e938_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i982da4cced9d4ae2b09cb6c0c35fbf7b_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="krw"><xbrli:measure>iso4217:KRW</xbrli:measure></xbrli:unit><xbrli:context id="i4d505177b87243539cc2ef4baf3b7b2d_D20181101-20181130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-11-01</xbrli:startDate><xbrli:endDate>2018-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id881e97ef71e48839eea697986831baa_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a87e4910f2b4990a031d8e154d08e7c_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08b50968168f4eb9ae561aa850896bc4_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i085845822f544f7fb9b0bbf69c2e903e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d8de41bd42443beb5e6ef8181fbd9ed_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd9a4c8be88e43a9adf992e1820e2e43_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5aac32d49b464e6cada89854863b83f8_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i10cf9b7a2fa84d7b844aa117861b3c56_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c45d46cb2c8406b930ef51351627297_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9f595a3d9be4f678b3dd5cf54ed7ea2_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie62a8195213a48748ad6794961fbeb22_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8794b47098d4b969e5c6a2e1127c28c_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65313bd95c954aa487ab03b59dcf4f19_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a718d3046ad462ba2ea0e14cf490598_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b73ba8bfb5d4bd599ede52803901f5d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib096f70fe5a64feab15f8a20b058d2bd_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6af0347c89c44263995f095d4ffa6626_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea98908b86804d0caf3c1f88da0f244b_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e60003aa8884f1d8ddcbb0621054f9f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i245f69306a2a48dc9b0a94f444f9a387_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3e04bb2c1a44e15ad29cbaea7a352a5_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c341a47e1aa461fa949701e75d2e42e_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20e561fa07fb43038ef6ed12d48d3e81_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie12a87471fff4dc1b58d09dc7f062be5_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic1f004cc48f2484baa3a2dda6b81675d_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id79a0b775b5b4772916934374fee4ad9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b499d4033fd416886759d4c73cd37e4_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i61badd66b47b4dcd935f8e7dd306447b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="i515423cd9b4842648857d6d91e4a1875_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:FacilityTypeAxis">biib:BiologicsManufacturingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79ca9be67e44499586e22d0729a04cad_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:FacilityTypeAxis">biib:WarehouseUtilitiesAndSupportSpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71a156afed9940d8b31d4a452da92788_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:FacilityTypeAxis">biib:AdministrativeSpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iadc69a90f7b94abab8d83ed70d1edf52_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:FacilityLocationAxis">biib:SolothurnSwitzerlandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4d564a708c64a0f9eae417dc52c7afc_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:FacilityLocationAxis">biib:SolothurnSwitzerlandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f00747e3707421b957d5a8909432bc2_I20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2.25SeniorNotesdueMay12030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id7d171de853046bd832470203f2f56ba_I20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A3.15SeniorNotesdueMay12050Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12ad84388af247dc862a842bb1ccd8e8_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03f25d4fea804740817761d106108f90_I20150915"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2.90SeniorNotesDueSept152020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-09-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e0ab653ffdc4001ba210ff20f499fc3_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2.90SeniorNotesDueSept152020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d1664f9c34948f48657b943f060daf2_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2.90SeniorNotesDueSept152020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50a2f9335d324e4986eea98f35621996_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:December2019ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe1d424343114522b510a64f315d7e68_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a0e6fee3a604c498aef94f0b86c6e9a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1cb136c416a04a05b9c1782e72b65627_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic914b0a393fd452c890e566f2c9c210f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i260d0a847a054ce0bef9b288ccd52ea2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if4823f5499b54f46b268ee3dd309f1da_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6773145664dd45a58afb7773d86b7f79_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21e4efbba1364e8d97adce8a02fa5c1c_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd42a3afee77410b945f7e37289f8773_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f6dc2dc230545079cf4e37cd9490b61_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i320a93a4270b45d2834748a854e79d02_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58631e62f8454d6fa19167c8e8a2bb41_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i76542c629f7a4bfdb85009377f3655e1_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ideb1736cbc354334a8ee23f9cadfc4bd_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1d927cca7f9c4d73aab25d3b3d48868f_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3b032c0499d4048ba5f66ef535061b2_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e4620290d53494a80d6bc03a34181dd_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id17e410580eb4b0eb19f7434c46678d8_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i87b8b8492f694a2a85d10571ab2b857f_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i39a2399061724666bae8d3296c72225d_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i74e5d53de65e4a8a9e4e245845ee99be_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i591bf9ccf21b4e53b95118628d4978da_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i246c949459c344caa446c9c644b413b2_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i002638e6f51c4c26ba598e6a80ddd034_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b77bbc89c154914b55e0fa9c9242c96_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e02b47bfe8d48a5aa515d8c91a8cb66_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81cfc07b94a54ce5b9767acd9ccbed84_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b8b1c75f80b47ab8430787fcd074574_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i52e2a69e04ee42ff88b18c7f1bf6b5bb_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f7aa82595074b70bd32cc3f188787ee_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i292bc1b0a8914e259d69aee92dcb23d9_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69dfd183e47b43278ea75c1422a31eb4_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7e3a2434dd044fda5e6fd81be0904a7_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc695f2ba910436fba8558e4c246c2ed_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iedbf521c84034004b661ca18c9f5b341_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i596f51e2385d4d4ca183e21f84aa0b55_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ff5ee345592411bb43c306a460e9fd1_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0dc320a6c37a4e9690e25e679e491fc4_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8eaafd98479a4bef96cb14d80b992fd6_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50715424610f44fe9d83a26f088cd935_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1cccc5c5e6a64e839db1a1a24f25b45e_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic0ab2edcb2644062923296228b7a8512_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79d195428b514b78a4569da6e0cad1aa_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42f682d87cc74a01aeb1af535a8ccb75_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ee5b72f84e44476b4c4a2b8d8df11ac_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i198a92ee28f54d99b35bfa8c48185fb9_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i31394cacd6624f0892e0c59f72b73473_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07c2927512de4889ac3af77ef26070bf_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e3d3eb860e64b4c8771c3591a944c56_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i418e492358064b87bb88dd6a5d427bd3_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89cc77663484411897a1c618e3902df4_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5177976681f14f4fbb72c76d037197e2_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id458ec3169f34e2088009cbf147e8304_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2274b2b373db4361a50819e797d93268_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ae5101f56364c07bd1fa9851047ae1c_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17644aaa924944b6838681aa26728f55_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93f4c72f492543b38ab5befc540cf70a_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3bcae79b02034b7a8d5846ce264aff93_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2cc8c72a2c4a4404a78a7942a0c6e8b1_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia49dbac3063344639f0b5d7299e025be_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff8fc7508c8d4439986e1175bce454a0_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i107d07150da4422b945e0bd78389de3b_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i909d084c1b604c4bba3bd63551acf4aa_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0bbba4b976ca48c78d5dac97d8fe4cbd_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68ac5428413242c4becdcb7197bed42d_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie898eae73ea9411696b0e278874d55f0_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad40dcf3ae2540a2b934514b7ad07c86_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibdd3d4a6db7c4fd4bf7c980b55c5fecd_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81789b07b22446a88e13e5c1075d8cb7_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id915b8aebcff4bc2a81caf9b4de54dd7_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ca00e2a1cc04153858959116600cdcd_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ba330fe0fb04518b2ecb6db02b6b97f_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e192d624f87417a8539bc84a2a459ff_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if04752de82454bad9a9a42a0c78ff53b_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i493634946d8c4db49d02e47be89e303e_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibed3bf29e7374cc8b7f86449cbcbaa3a_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2cfe6ff0db44473e979cfeaa03760ded_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea41c7a4bbf94cfc8a16ac421e7cc25d_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e43143e39df4b0cbb78c046a10aa64f_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96a2e794f31f442ebbb83e8f8c7d54bd_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc0ae96137314a759fb1044af70f2b95_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i009b72f35e694a53ae5120480a467b8f_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8cb99b7e0ae45fc98016744d8331c55_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic61fb76b8e77432fb9579a89baff9f36_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d623e1e956a426c9eb2bc18c5c9015c_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65d9cd4367bc445dbfb50901412a5ada_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic0de115d377b4cfa9b3de1dd0bfd3954_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2c78ceb3d6b4fd69507a611127e10d7_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d5c287e1fde4ffdb4bdc39ad45f29d2_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94ecbbbd615e4be087860504badd0ccd_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic2ec445a7fb2422f8f336348f12e3320_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice7a7bfef4564888a80b19f37ff797b0_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifeaa9653fb8c46b19f65a83276d1bcde_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6602e12ee323468e9711c40286f62de7_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0dbcccb9a5554bba8ddbf97064cb4c88_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73c8b3f596bb4630bfc6f91e336d5637_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0bd41977205f4c6e822e027dc9f7178f_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c21b1e012c34659a43ce91c598b6e19_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id073fd8d3b31491aacf37c244aa1d475_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83240f344bc5485bb5ee15a465ba0ad3_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6c80504460b4030869aa8a24e3babf4_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c634f032c59460488c598097bac861e_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82c5ee63475c42b9be7685ee220cdbde_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i14dd3353e0b54676b5186391520f2af5_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i289872ca5f294cb881aceaa6ffd07da1_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1cf49fa7c600408b8cf5254dbc554986_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d5bdbbfb1724d7b86e0b6e3ff288ee3_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:DenmarkManufacturingOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib7f7a4e02a2b41bdbe159e1d831b1937_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7dbdd092b034c3189ffed19d675f882_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia88c862a2922421b9916446a96695a69_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:SangamoCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i671e2b4b86c44e18a9a4518a9d0360e3_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c4c8f3f1c614d79bad90fbadf4e582e_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SangamoTherapeuticsInc.AgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e00b6efba394fb5b58ec5d8f15b5e07_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99c8bf62c3f747a6825f635a38c876aa_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5dd593028df14958ab74c65d6932d514_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4289bd550fa4ecf980a7852c83941c9_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iedea87e6fca548b387e737941a938d4d_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76cadd05cfd9487992bcc01b2fbe54ad_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4df0aa1f099c4275a635ce9719f80079_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieaf688a040e748fcb2fb53cc4980b1ae_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6fc4449da6e645b3871baa6066b7ba15_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84416da07ea446c6a74945f76525350d_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AducanumabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0347bcd849ae4267bfea5d50d6b0fbea_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AducanumabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74c4058ef32546ab9478606d50a42ff6_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AducanumabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ab886b24e304952b01a70c3288ca622_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AducanumabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i108d4b03b28442088d579082f1514805_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AducanumabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d21a2127fcd4783820ebe46b0ed050b_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AducanumabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i758bfb8a36214bcd99abf2d550c98467_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AducanumabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd694f937faa421dac86a19acb834bb4_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AducanumabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1927d71684864d0ea1eab5f146d82d5d_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:UCBPharmaS.A.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icab43be754b749fe968e868f7a639cd7_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:UCBPharmaS.A.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8caeb1ba3904b97aa01e55d54bcfdd0_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00bfaa56f846452aa021215b0332f13a_D20200201-20200229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SangamoTherapeuticsInc.AgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-01</xbrli:startDate><xbrli:endDate>2020-02-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i626bc76978584f20bed3f3c65385234a_D20190101-20190131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SkyhawkTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83f7cd89dae046c59b442f0c3d6955d3_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SkyhawkTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b31731f10d3438bbb21a6d76e82951d_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SkyhawkTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib83f121fe8084d6189d5e4c28193f59f_D20191001-20191031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SkyhawkTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65733f4ace874e1e89159f8c95744460_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7967ad33dbdb48e89dd02f434444b459_I20181107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-11-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i071c5b3fcf304751900b25afea18d401_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InventoriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16f85f52b2ce4a3e92746ecfebd0be40_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0fbd288a2a484b2092b7fb912c7e80ae_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4cc37c0d62c49b58b4a17e71a0852f4_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if66718fccef241c1b9e6ef3161a2fd8a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia29071dbf1dd4669a9f529d1af16da0e_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i10d0b368c77e476286c6d631057ae023_I20200131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb12afc98a00406dbfbbf375974469a1_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5da3d551e877481482c2c617be75f347_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64047abc9e1e47a6a0d61a0e7591f7e1_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i80a9168a435d4f6a98b2450218498ef3_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib22568b42dea422aad4788445cea0a41_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00616e2d34c848588546a4eb3b7e17e1_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i035b83abf8f74352b8844936a4c053e5_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if62153afc8b048fea1ecd3d555faaf6d_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i27257060fb394740a54642f97bef35f3_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i068f3b4714364e10a6f8a38a28733f78_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1478c61cb1ee4cfa8414bded1c551b30_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis">biib:NeurimmuneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f3660b791194af5a26e2a9ceab00343_D20171001-20171031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis">biib:NeurimmuneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-01</xbrli:startDate><xbrli:endDate>2017-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61fb7e1bb0fd421bbf82c79ee9784cc5_D20180501-20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis">biib:NeurimmuneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-01</xbrli:startDate><xbrli:endDate>2018-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7b514880c7944a69bca92a1890a1999_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:RegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="biib:InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis">biib:NeurimmuneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id248e9039d774acdb784eeea9df07f64_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis">biib:NeurimmuneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:RegulatoryApprovalMilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="chf"><xbrli:measure>iso4217:CHF</xbrli:measure></xbrli:unit></ix:resources></ix:header></div><div id="ib19ff89608c84168a635160f2efa48f3_1"></div><div style="min-height:18pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;margin-top:8pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:98.900%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:2pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:14pt;font-weight:700;line-height:120%;">UNITED STATES</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:14pt;font-weight:700;line-height:120%;">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Washington,&#160;D.C. 20549</span></div><div style="text-align:center;margin-top:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:18pt;font-weight:700;line-height:120%;">Form&#160;<ix:nonNumeric contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xL2ZyYWc6YjhmMjUxMjZjYWJmNDc4MmI3NzA2YzkzMmZmZDM1OGIvdGV4dHJlZ2lvbjpiOGYyNTEyNmNhYmY0NzgyYjc3MDZjOTMyZmZkMzU4Yl8yMDEz_6f13bb3d-dcd4-46b0-a5ad-760cab70bfa1">10-Q</ix:nonNumeric> </span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:4.756%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:93.044%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:14pt;font-weight:400;font-family:'Arial Unicode MS',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" format="ixt-sec:boolballotbox" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xL2ZyYWc6YjhmMjUxMjZjYWJmNDc4MmI3NzA2YzkzMmZmZDM1OGIvdGFibGU6YmUyZDU5N2ZhZDliNGEzZjkyMDRmMDU1MGYyNWU4NTkvdGFibGVyYW5nZTpiZTJkNTk3ZmFkOWI0YTNmOTIwNGYwNTUwZjI1ZTg1OV8wLTAtMS0xLTA_1e766eeb-3f4d-48da-9c5f-e1a2275530a2">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:12pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="padding-left:36pt;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">For the quarterly period ended <ix:nonNumeric contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xL2ZyYWc6YjhmMjUxMjZjYWJmNDc4MmI3NzA2YzkzMmZmZDM1OGIvdGV4dHJlZ2lvbjpiOGYyNTEyNmNhYmY0NzgyYjc3MDZjOTMyZmZkMzU4Yl8xMjQ_e713cbb9-311b-47e1-9b7d-198bad16cba4">September 30, 2020</ix:nonNumeric> </span></div><div style="text-align:center;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">OR</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:4.756%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:93.044%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:14pt;font-weight:400;font-family:'Arial Unicode MS',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xL2ZyYWc6YjhmMjUxMjZjYWJmNDc4MmI3NzA2YzkzMmZmZDM1OGIvdGFibGU6Zjc0MWEyMDg0MmZlNGQ5MjgwMmU4M2Y4ODExM2EyNzkvdGFibGVyYW5nZTpmNzQxYTIwODQyZmU0ZDkyODAyZTgzZjg4MTEzYTI3OV8wLTAtMS0xLTA_c422bff9-ec89-46e4-8a88-44b00933e71a">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:12pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center;margin-top:7pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Commission File Number <ix:nonNumeric contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xL2ZyYWc6YjhmMjUxMjZjYWJmNDc4MmI3NzA2YzkzMmZmZDM1OGIvdGV4dHJlZ2lvbjpiOGYyNTEyNmNhYmY0NzgyYjc3MDZjOTMyZmZkMzU4Yl8yMDA4_fb803ea4-cc19-4130-a5bb-76addf1d0421">0-19311</ix:nonNumeric></span></div><div style="text-align:center;margin-top:7pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"> </span><img src="biib-20200930_g1.jpg" alt="biib-20200930_g1.jpg" style="height:30px;width:92px;"/></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:24pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xL2ZyYWc6YjhmMjUxMjZjYWJmNDc4MmI3NzA2YzkzMmZmZDM1OGIvdGV4dHJlZ2lvbjpiOGYyNTEyNmNhYmY0NzgyYjc3MDZjOTMyZmZkMzU4Yl8yMDE0_91104669-416b-4c5b-9037-e05162fd92ea">BIOGEN INC.</ix:nonNumeric> </span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:47.948%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:2.560%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:46.192%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xL2ZyYWc6YjhmMjUxMjZjYWJmNDc4MmI3NzA2YzkzMmZmZDM1OGIvdGFibGU6Nzc2YzY5MzRiYTBmNDA3ZmE2NDI4MThiMzcwMDA4MTEvdGFibGVyYW5nZTo3NzZjNjkzNGJhMGY0MDdmYTY0MjgxOGIzNzAwMDgxMV8wLTAtMS0xLTA_bb354328-343e-4344-acf6-6bcf9efc10bb">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xL2ZyYWc6YjhmMjUxMjZjYWJmNDc4MmI3NzA2YzkzMmZmZDM1OGIvdGFibGU6Nzc2YzY5MzRiYTBmNDA3ZmE2NDI4MThiMzcwMDA4MTEvdGFibGVyYW5nZTo3NzZjNjkzNGJhMGY0MDdmYTY0MjgxOGIzNzAwMDgxMV8wLTItMS0xLTA_6736f8f7-b37e-4fcd-af4c-97c3666efcd0">33-0112644</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-style:italic;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-style:italic;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(I.R.S. Employer<br/>Identification No.)</span></td></tr></table></div><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xL2ZyYWc6YjhmMjUxMjZjYWJmNDc4MmI3NzA2YzkzMmZmZDM1OGIvdGV4dHJlZ2lvbjpiOGYyNTEyNmNhYmY0NzgyYjc3MDZjOTMyZmZkMzU4Yl8yMDA5_76723d56-7241-4285-a84b-59702984ff33">225 Binney Street</ix:nonNumeric>, <ix:nonNumeric contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xL2ZyYWc6YjhmMjUxMjZjYWJmNDc4MmI3NzA2YzkzMmZmZDM1OGIvdGV4dHJlZ2lvbjpiOGYyNTEyNmNhYmY0NzgyYjc3MDZjOTMyZmZkMzU4Yl8yMDE1_57dba76c-7089-4444-9cc3-2496140231b6">Cambridge</ix:nonNumeric>, <ix:nonNumeric contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xL2ZyYWc6YjhmMjUxMjZjYWJmNDc4MmI3NzA2YzkzMmZmZDM1OGIvdGV4dHJlZ2lvbjpiOGYyNTEyNmNhYmY0NzgyYjc3MDZjOTMyZmZkMzU4Yl8yMDE2_9be279b7-f9b2-402f-b33c-0d4a9fb6c863">MA</ix:nonNumeric> <ix:nonNumeric contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xL2ZyYWc6YjhmMjUxMjZjYWJmNDc4MmI3NzA2YzkzMmZmZDM1OGIvdGV4dHJlZ2lvbjpiOGYyNTEyNmNhYmY0NzgyYjc3MDZjOTMyZmZkMzU4Yl8yMDE3_e0023c3d-2f0d-4d47-852f-16332cb8e81e">02142</ix:nonNumeric> </span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(<ix:nonNumeric contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xL2ZyYWc6YjhmMjUxMjZjYWJmNDc4MmI3NzA2YzkzMmZmZDM1OGIvdGV4dHJlZ2lvbjpiOGYyNTEyNmNhYmY0NzgyYjc3MDZjOTMyZmZkMzU4Yl8yMDEw_042984c6-156b-4858-8da0-e221e01452fe">617</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xL2ZyYWc6YjhmMjUxMjZjYWJmNDc4MmI3NzA2YzkzMmZmZDM1OGIvdGV4dHJlZ2lvbjpiOGYyNTEyNmNhYmY0NzgyYjc3MDZjOTMyZmZkMzU4Yl8yMDEx_e4ee9bd0-a91a-4a9a-ad54-a8f467d856e0">679-2000</ix:nonNumeric> </span></div><div style="text-align:center;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;">(Address, including zip code, and telephone number, including</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;">area code, of registrant&#8217;s principal executive offices)</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:11pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%;"><tr><td style="width:1.0%;"></td><td style="width:35.463%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:16.080%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.619%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:32.970%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Title of each class</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Trading Symbol(s)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Name of each exchange on which registered</span></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xL2ZyYWc6YjhmMjUxMjZjYWJmNDc4MmI3NzA2YzkzMmZmZDM1OGIvdGFibGU6YTExNTcyMGEyZGE4NGZhZTgxOGE3M2JlNGRlNjgyYWUvdGFibGVyYW5nZTphMTE1NzIwYTJkYTg0ZmFlODE4YTczYmU0ZGU2ODJhZV8xLTAtMS0xLTA_88c46b57-9563-4d90-90ce-8932485e7893">Common Stock, $0.0005 par value</ix:nonNumeric></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xL2ZyYWc6YjhmMjUxMjZjYWJmNDc4MmI3NzA2YzkzMmZmZDM1OGIvdGFibGU6YTExNTcyMGEyZGE4NGZhZTgxOGE3M2JlNGRlNjgyYWUvdGFibGVyYW5nZTphMTE1NzIwYTJkYTg0ZmFlODE4YTczYmU0ZGU2ODJhZV8xLTItMS0xLTA_1c57a10e-8688-43de-971b-43509588e7be">BIIB</ix:nonNumeric></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">The Nasdaq Global Select Market</span></td><td colspan="3" style="display:none;"></td></tr></table></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days:&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xL2ZyYWc6YjhmMjUxMjZjYWJmNDc4MmI3NzA2YzkzMmZmZDM1OGIvdGV4dHJlZ2lvbjpiOGYyNTEyNmNhYmY0NzgyYjc3MDZjOTMyZmZkMzU4Yl8yMDEy_1b60311b-8f98-405b-9052-7ca5c85c92d3">Yes</ix:nonNumeric></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">x</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">No</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">o</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files):&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xL2ZyYWc6YjhmMjUxMjZjYWJmNDc4MmI3NzA2YzkzMmZmZDM1OGIvdGV4dHJlZ2lvbjpiOGYyNTEyNmNhYmY0NzgyYjc3MDZjOTMyZmZkMzU4Yl8yMDE4_8aec3857-5680-4eb3-97c5-8b8ed53f8e51">Yes</ix:nonNumeric></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">x</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">No</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">o</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and "emerging growth company" in Rule 12b-2 of the Exchange Act:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:21.920%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:1.979%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:41.568%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:27.052%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:1.981%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xL2ZyYWc6YjhmMjUxMjZjYWJmNDc4MmI3NzA2YzkzMmZmZDM1OGIvdGFibGU6NGUyZDIwMmJmOGI0NDQ3OGIxMDE5MTE1MmIwNGUzYmUvdGFibGVyYW5nZTo0ZTJkMjAyYmY4YjQ0NDc4YjEwMTkxMTUyYjA0ZTNiZV8wLTAtMS0xLTA_49220310-6229-43e2-9005-8a2b4e6cfb2b">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Wingdings',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">x</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accelerated filer</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:12pt;font-weight:400;font-family:'Arial Unicode MS',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#9744;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-accelerated&#160;filer</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:12pt;font-weight:400;font-family:'Arial Unicode MS',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#9744;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:12pt;font-weight:400;font-family:'Arial Unicode MS',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xL2ZyYWc6YjhmMjUxMjZjYWJmNDc4MmI3NzA2YzkzMmZmZDM1OGIvdGFibGU6NGUyZDIwMmJmOGI0NDQ3OGIxMDE5MTE1MmIwNGUzYmUvdGFibGVyYW5nZTo0ZTJkMjAyYmY4YjQ0NDc4YjEwMTkxMTUyYjA0ZTNiZV8xLTQtMS0xLTA_61888dcb-8d45-4c30-b677-55733390fa4b">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Emerging growth company</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:12pt;font-weight:400;font-family:'Arial Unicode MS',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xL2ZyYWc6YjhmMjUxMjZjYWJmNDc4MmI3NzA2YzkzMmZmZDM1OGIvdGFibGU6NGUyZDIwMmJmOGI0NDQ3OGIxMDE5MTE1MmIwNGUzYmUvdGFibGVyYW5nZTo0ZTJkMjAyYmY4YjQ0NDc4YjEwMTkxMTUyYjA0ZTNiZV8yLTQtMS0xLTA_99d5a1f7-a1dd-4912-a57c-e36074d395b5">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">o</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"><ix:nonNumeric contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xL2ZyYWc6YjhmMjUxMjZjYWJmNDc4MmI3NzA2YzkzMmZmZDM1OGIvdGV4dHJlZ2lvbjpiOGYyNTEyNmNhYmY0NzgyYjc3MDZjOTMyZmZkMzU4Yl8yMDE5_95a885ad-a486-4d29-8165-6e078c74980c">&#9744;</ix:nonNumeric></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;No&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">x</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The number of shares of the issuer&#8217;s Common Stock, $0.0005&#160;par value, outstanding as of October&#160;20, 2020, was <ix:nonFraction unitRef="shares" contextRef="i4c10ff2cc693457ba96b227c43b75eec_I20201020" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xL2ZyYWc6YjhmMjUxMjZjYWJmNDc4MmI3NzA2YzkzMmZmZDM1OGIvdGV4dHJlZ2lvbjpiOGYyNTEyNmNhYmY0NzgyYjc3MDZjOTMyZmZkMzU4Yl8xOTk2_4c3a51dc-d487-4ecd-9757-cb3fd2c5b386">153,881,597</ix:nonFraction> shares.</span></div><div style="margin-top:10pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:98.900%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="position:relative;width:100%;height:18pt;"><div style="position:absolute;bottom:0;width:100%;"><div><span><br/></span></div></div></div><div id="ib19ff89608c84168a635160f2efa48f3_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_7">Table of Contents</a></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">BIOGEN INC.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">FORM&#160;10-Q &#8212; Quarterly Report</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">For the Quarterly Period Ended September 30, 2020 </span></div><div style="text-align:center;margin-top:14pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">TABLE OF CONTENTS</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:8.124%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:79.866%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.710%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Page</span></td></tr><tr><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%;">PART&#160;I&#160;&#8212; </span><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_13">FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item 1.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_16">Financial Statements (unaudited)</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_19">Condensed Consolidated Statements of Income&#160;&#8212; For the Three and </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_19">Nine</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_19"> Months Ended </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_19">September</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_19"> 30, 2020 and 2019</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_19">5</a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_22">Condensed Consolidated Statements of Comprehensive Income &#8212; For the Three and </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_22">Nine</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_22"> Months Ended </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_22">September</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_22"> 30, 2020 and 2019</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_22">6</a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_25">Condensed Consolidated Balance Sheets&#160;&#8212; As of </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_25">September</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_25"> 30, 2020 and December&#160;31, 2019</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_25">7</a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_1">Condensed Consolidated Statements of Cash Flows&#160;&#8212; For the </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_1">Nine</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_1"> Months Ended </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_1">September</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_1"> 30, 2020 and 2019</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_31">8</a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_34">Condensed Consolidated Statements of Equity &#8212; For the Three and </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_34">Nine</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_34"> Months Ended </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_34">September</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_34"> 30, 2020 and 2019</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_34">9</a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_37">Notes to Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_37">13</a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item 2.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_130">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_130">45</a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item 3.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_208">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_208">71</a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item 4.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_211">Controls and Procedures</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_211">73</a></span></div></td></tr><tr><td colspan="9" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%;">PART&#160;II&#160;&#8212; </span><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_214">OTHER INFORMATION</a></span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item 1.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_217">Legal Proceedings</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_217">74</a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item&#160;1A.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_220">Risk Factors</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_220">74</a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item 2.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_223">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_223">92</a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item 6.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_226">Exhibits</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_226">93</a></span></div></td></tr><tr><td colspan="6" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_232">Signatures</a></span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_232">94</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2</span></div></div></div><div id="ib19ff89608c84168a635160f2efa48f3_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_7">Table of Contents</a></span></div></div><div style="margin-top:14pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">NOTE&#160;REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">This report contains forward-looking statements that are being made pursuant to the provisions of the Private Securities Litigation Reform Act of 1995 (the Act) with the intention of obtaining the benefits of the &#8220;Safe Harbor&#8221; provisions of the Act. These forward-looking statements may be accompanied by such words as &#8220;aim,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;forecast,&#8221; &#8220;goal,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;possible,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and other words and terms of similar meaning. Reference is made in particular to forward-looking statements regarding:</span></div><div style="text-indent:-18pt;padding-left:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">the anticipated amount, timing and accounting of revenues; contingent, milestone, royalty and other payments under licensing, collaboration, acquisition or divestiture agreements; tax positions and contingencies; collectability of receivables; pre-approval inventory; cost of sales; research and development costs; compensation and other selling, general and administrative expenses; amortization of intangible assets; foreign currency exchange risk; estimated fair value of assets and liabilities; and impairment assessments;</span></div><div style="text-indent:-18pt;padding-left:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">expectations, plans and prospects relating to sales, pricing, growth and launch of our marketed and pipeline products;</span></div><div style="text-indent:-18pt;padding-left:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">the potential impact of increased product competition in the markets in which we compete, including increased competition from generics, biosimilars, prodrugs and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products;</span></div><div style="text-indent:-18pt;padding-left:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">the timing, outcome and impact of administrative, regulatory, legal and other proceedings related to our patents and other proprietary and intellectual property rights, tax audits, assessments and settlements, pricing matters, sales and promotional practices, product liability and other matters;</span></div><div style="text-indent:-18pt;padding-left:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity;</span></div><div style="text-indent:-18pt;padding-left:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">our plans and investments in our core and emerging growth areas as well as implementation of our corporate strategy;</span></div><div style="text-indent:-18pt;padding-left:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">the drivers for growing our business, including our plans and intention to commit resources relating to research and development programs and business development opportunities as well as the potential benefits and results of certain business development transactions;</span></div><div style="text-indent:-18pt;padding-left:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">our ability to finance our operations and business initiatives and obtain funding for such activities;</span></div><div style="text-indent:-18pt;padding-left:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">the costs and timing of potential clinical trials, filings and approvals, and the potential therapeutic scope of the development and commercialization of our and our collaborators&#8217; pipeline products;</span></div><div style="text-indent:-18pt;padding-left:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">adverse safety events involving our marketed products, generic or biosimilar versions of our marketed products or any other products from the same class as one of our products;</span></div><div style="text-indent:-18pt;padding-left:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">the direct and indirect impact of COVID-19 on our business and operations, including sales, expenses, supply chain, manufacturing, research and development costs, clinical trials and employees;</span></div><div style="text-indent:-18pt;padding-left:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">the potential impact of healthcare reform in the United States (U.S.) and measures being taken worldwide designed to reduce healthcare costs and limit the overall level of government expenditures, including the impact of pricing actions and reduced reimbursement for our products;</span></div><div style="text-indent:-18pt;padding-left:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">our manufacturing capacity, use of third-party contract manufacturing organizations, plans and timing relating to changes in our manufacturing capabilities, activities in new or existing manufacturing facilities and the expected timeline for the Solothurn manufacturing facility to be partially operational;</span></div><div style="text-indent:-18pt;padding-left:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">the impact of the continued uncertainty of the credit and economic conditions in certain countries in Europe and our collection of accounts receivable in such countries;</span></div><div style="text-indent:-18pt;padding-left:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">the potential impact on our results of operations and liquidity of the United Kingdom's (U.K.) departure from the European Union (E.U.);</span></div><div style="text-indent:-18pt;padding-left:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">lease commitments, purchase obligations and the timing and satisfaction of other contractual obligations; and</span></div><div style="text-indent:-18pt;padding-left:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">the impact of new laws, regulatory requirements, judicial decisions and accounting standards.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_7">Table of Contents</a></span></div></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">These forward-looking statements involve risks and uncertainties, including those that are described in </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Item 1A.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Risk Factors</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> included in this report and elsewhere in this report that could cause actual results to differ materially from those reflected in such statements. You should not place undue reliance on these statements. Forward-looking statements speak only as of the date of this report. Except as required by law, we do not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.</span></div><div style="margin-top:14pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">NOTE REGARDING COMPANY AND PRODUCT REFERENCES</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">References in this report to:</span></div><div style="text-indent:-18pt;padding-left:40.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">&#8220;Biogen,&#8221; the &#8220;company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Biogen Inc. and its consolidated subsidiaries; and</span></div><div style="text-indent:-18pt;padding-left:40.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">&#8220;RITUXAN&#8221; refers to both RITUXAN (the trade name for rituximab in the U.S., Canada and Japan) and MabThera (the trade name for rituximab outside the U.S., Canada and Japan).</span></div><div style="margin-top:14pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">NOTE&#160;REGARDING TRADEMARKS</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">AVONEX&#174;, PLEGRIDY&#174;, RITUXAN&#174;, RITUXAN HYCELA&#174;, SPINRAZA&#174;, TECFIDERA&#174;, TYSABRI&#174;, VUMERITY&#174; and ZINBRYTA&#174; are registered trademarks of Biogen. </span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">BENEPALI&#8482;, FLIXABI&#8482;, FUMADERM&#8482;, IMRALDI&#8482; and Healthy Climate, Healthy Lives&#8482; are trademarks of Biogen. </span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">ENBREL&#174;, EYLEA&#174;, FAMPYRA</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">TM</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, GAZYVA&#174;, HUMIRA&#174;, LUCENTIS&#174;, OCREVUS&#174;, REMICADE&#174;, SkySTAR&#8482;</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;"> </sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">and other trademarks referenced in this report are the property of their respective owners. </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">4</span></div></div></div><div id="ib19ff89608c84168a635160f2efa48f3_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_7">Table of Contents</a></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">PART&#160;I FINANCIAL INFORMATION</span></div><div id="ib19ff89608c84168a635160f2efa48f3_16"></div><div style="text-align:center;"><span><br/></span></div><div id="ib19ff89608c84168a635160f2efa48f3_19"></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">CONDENSED CONSOLIDATED STATEMENTS OF INCOME</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(unaudited, in millions, except per share amounts)</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:53.139%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.011%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.011%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.572%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.577%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Three Months Ended September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenues:</span></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Product, net</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iba1a633773a34c899b77b4853a665d4e_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMy0xLTEtMS0w_8575b518-e57a-4d3c-93f1-581e5f29b875">2,690.3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i817821ea916346a6b301c5912257c3e5_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMy0zLTEtMS0w_c29d3d55-9a87-4eee-931d-2324dcd6bf6a">2,894.7</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id41b722bb5ce413f84c0e1a46961879f_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMy01LTEtMS0w_d27730de-b941-48b5-90eb-d6211841d10a">8,390.6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if88c636dd80d492687ca22f07e75db13_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMy03LTEtMS0w_7425d59b-ea0c-4bd0-a1d3-ebf9585105b7">8,455.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenues from anti-CD20 therapeutic programs</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia428d1f03d1f454a9d5c837ec6e0aa50_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfNC0xLTEtMS0w_c1f56fa7-1be0-4bb5-ba7e-24e480a8b04f">560.1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8595ad2d43f34d98abb716a40fde60a6_D20190701-20190930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfNC0zLTEtMS0w_75602dab-cfe0-4dfc-9d5a-a71a0fbc0e87">595.8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0cb93d1ae39f48f3b0fc167540132b77_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfNC01LTEtMS0w_a6f34437-0327-432e-8b18-7c940162f217">1,558.8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5452667727cd4cf08cae4c412b67d3ef_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfNC03LTEtMS0w_e310c53f-a6d7-46df-a0c9-40613445084a">1,689.6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iba6a7aa4c7fa4fda950fccc032894346_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfNS0xLTEtMS0w_115c6619-90cc-4166-9e98-8421288dbead">125.7</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0ea06cd6a9974b4999904b90f030878b_D20190701-20190930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfNS0zLTEtMS0w_e0b7010d-9405-4545-857c-dd8b17f5f536">109.6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6e0b6c1de005431bb80fcd07bc90af2e_D20200101-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfNS01LTEtMS0w_6e209fa4-9bfb-4903-9e13-c617c79d1ea4">642.6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2335a9cc65b041aa8e881414fc49759c_D20190101-20190930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfNS03LTEtMS0w_6c2256eb-a44e-4b76-b3fb-1a5743570bf9">562.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total revenues</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfNi0xLTEtMS0w_e398c84d-477d-425e-939a-3f38f3766fb4">3,376.1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfNi0zLTEtMS0w_2cc12a75-2870-45b7-a3cb-dfb079aa0a3b">3,600.1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfNi01LTEtMS0w_0896cbec-6e02-4a11-b7ad-a2c8e3c5397b">10,592.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfNi03LTEtMS0w_dda4fb54-3b7c-41a8-be7b-5b655c0f74ac">10,706.6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost and expenses:</span></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost of sales, excluding amortization and impairment of acquired intangible assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfOC0xLTEtMS0w_89cc9feb-6ee3-4f9d-a56b-205e40c91a87">449.1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfOC0zLTEtMS0w_c1fed65e-b401-41f6-8374-36a20d66eddd">430.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfOC01LTEtMS0w_2b894967-1e1e-4e90-824f-00e050b5a065">1,314.6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfOC03LTEtMS0w_732c0e0e-908b-4f83-8766-2ff250e36408">1,508.3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfOS0xLTEtMS0w_e4c5d2ed-798f-47ff-a159-57ed95cdedb4">1,140.9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfOS0zLTEtMS0w_68d9543e-65a5-4b98-9413-03448b15e188">540.4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfOS01LTEtMS0w_52459754-6218-4f43-bfe9-18056ed54390">2,264.8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfOS03LTEtMS0w_8e2347c3-6be0-4b7a-822f-887657ad3035">1,588.9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Selling, general and administrative</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMTAtMS0xLTEtMA_1b0ace10-c9fe-4911-9a17-097bf26722fa">573.1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMTAtMy0xLTEtMA_a399c6e0-4b36-44e5-b0ee-8c19cc07cd94">554.5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMTAtNS0xLTEtMA_6931582e-d8c1-4581-92c8-37bda1a0cc2e">1,698.3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMTAtNy0xLTEtMA_106cd886-c4f7-4643-85ac-248a5f9c46a4">1,709.8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortization and impairment of acquired intangible assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930" decimals="-5" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMTEtMS0xLTEtMA_26b35267-3899-4e46-802f-26ad462e98b7">82.6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930" decimals="-5" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMTEtMy0xLTEtMA_92944d6d-69db-4400-b141-cfdfc08b395b">283.9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="-5" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMTEtNS0xLTEtMA_a935bdd1-71ac-4358-a642-223d16557b48">215.6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="-5" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMTEtNy0xLTEtMA_519699f0-5f44-4ce5-8b91-d29ae09cf675">422.2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Collaboration profit (loss) sharing</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930" decimals="-5" name="biib:Collaborationprofitlosssharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMTItMS0xLTEtMA_31831a59-a519-48ea-adb8-b875a3bfadf0">73.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930" decimals="-5" name="biib:Collaborationprofitlosssharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMTItMy0xLTEtMA_4044d6dd-f0f8-4901-8388-4fa2abc2a54a">60.2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="-5" name="biib:Collaborationprofitlosssharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMTItNS0xLTEtMA_fa5ce617-687c-4afb-b1a4-dfea0d503d8c">166.5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="-5" name="biib:Collaborationprofitlosssharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMTItNy0xLTEtMA_f97f65c5-d675-456d-a105-b125e1cce561">181.8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Loss on divestiture of Hiller&#248;d, Denmark manufacturing operations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMTMtMS0xLTEtMA_d7182e00-ff29-44df-b66b-4af3bf2a0440">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i6d14771766d1415790d98b0c80aaa2eb_D20190701-20190930" decimals="-5" sign="-" name="us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMTMtMy0xLTEtMA_835d30f0-93b2-45eb-80ab-4bbc1371f166">17.7</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMTMtNS0xLTEtMA_65f7c8b3-4ad4-4a65-9de2-c75cbdea133c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="-5" name="us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMTMtNy0xLTEtMA_71247e36-fe62-418f-bdf1-b3ffaec64d29">95.5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Gain) loss on fair value remeasurement of contingent consideration</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMTQtMS0xLTEtMA_8d1f997c-9ed7-4203-a725-994f64c09fc0">29.0</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMTQtMy0xLTEtMA_29e7765a-f4c4-47fe-9afe-1cac8eefb99c">57.8</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMTQtNS0xLTEtMA_260cb5ec-9883-4dff-ad93-d42b945c1e2a">23.5</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMTQtNy0xLTEtMA_3271b4c7-6498-4ba5-9b54-a8891e982e05">66.3</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restructuring charges</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMTUtMS0xLTEtMA_7e48b0ce-947a-4092-88b0-4a1f0e701610">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMTUtMy0xLTEtMA_f1b84eed-0666-475a-bc33-89c357bc6105">0.3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMTUtNS0xLTEtMA_48358421-18ff-464f-a293-7f0ea8a5e347">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMTUtNy0xLTEtMA_86425ca9-209b-4b70-9318-3dc15495136a">1.5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Acquired in-process research and development</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMTYtMS0xLTEtMA_f4443cc5-f4aa-4ce2-8246-51e1461dab8f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930" decimals="-5" format="ixt:zerodash" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMTYtMy0xLTEtMA_79bfaa78-f693-4c9a-8818-9d73694bb513">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="-5" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMTYtNS0xLTEtMA_4ba3571f-580e-4065-990b-2818c6d3da0d">75.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="-5" format="ixt:zerodash" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMTYtNy0xLTEtMA_6d637cdd-3a1c-43f0-837a-49bb1fee1f65">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cost and expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMTctMS0xLTEtMA_def27680-ab77-4d27-a513-2210d79b65f1">2,289.7</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMTctMy0xLTEtMA_6ecf8cf4-bed6-4a29-b138-6c5e91887ed0">1,793.8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMTctNS0xLTEtMA_8b14c508-0f17-4e2c-87f1-a1cc26aad613">5,711.3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMTctNy0xLTEtMA_6d1cfa11-e57e-478c-a632-b0825d00bd5e">5,441.7</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income from operations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMTgtMS0xLTEtMA_53b53361-46aa-4f8a-92de-2f5aa9431b7c">1,086.4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMTgtMy0xLTEtMA_d8cc1391-c99a-4ed9-a086-51839302223d">1,806.3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMTgtNS0xLTEtMA_e1faf36a-16e9-4482-a8bf-6dc24c1491db">4,880.7</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMTgtNy0xLTEtMA_878704ab-0bd4-4dc0-957d-b92050e63d30">5,264.9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other income (expense), net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMTktMS0xLTEtMA_9797ad36-a044-4c1a-97da-f19ad648ba5d">128.6</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930" decimals="-5" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMTktMy0xLTEtMA_0be8925c-dba2-459c-b109-b39cec53a3fb">27.3</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMTktNS0xLTEtMA_7640d544-1ef7-487a-9f46-b5d67dd81728">186.1</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="-5" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMTktNy0xLTEtMA_ac50e3ac-4e63-49ed-9c81-925829796b78">132.6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income before income tax expense and equity in loss of investee, net of tax</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMjAtMS0xLTEtMA_ae34b876-a566-4ae1-bd8e-47ace9950311">957.8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMjAtMy0xLTEtMA_3f6061e8-3fb3-4ada-b4f6-ff729de2aade">1,779.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMjAtNS0xLTEtMA_773941a4-3131-4f52-b94c-c4e90b345578">4,694.6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMjAtNy0xLTEtMA_ed0a8024-d863-464d-af95-85ca196686d0">5,397.5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income tax expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMjEtMS0xLTEtMA_594853f9-3e82-4b99-9d31-a15e3f5c7fea">240.8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMjEtMy0xLTEtMA_207d0c7b-2733-4d2c-94f9-41f099278032">211.3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMjEtNS0xLTEtMA_887cc3f8-e861-402e-96a7-5a466e346944">979.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMjEtNy0xLTEtMA_ba8e81a5-26d3-4a23-b0e4-932241365e50">881.9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Equity in (income) loss of investee, net of tax</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930" decimals="-5" sign="-" name="biib:IncomeLossFromEquityMethodInvestmentsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMjItMS0xLTEtMA_b4b24255-d6e9-4e88-961f-dc971692aa5d">13.1</ix:nonFraction></span><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930" decimals="-5" sign="-" name="biib:IncomeLossFromEquityMethodInvestmentsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMjItMy0xLTEtMA_d8064f7d-10cf-4dc0-bee7-71d045b96689">21.8</ix:nonFraction></span><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="-5" sign="-" name="biib:IncomeLossFromEquityMethodInvestmentsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMjItNS0xLTEtMA_34365eb7-d8ea-4eaa-8322-bf1734d3111d">12.7</ix:nonFraction></span><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="-5" sign="-" name="biib:IncomeLossFromEquityMethodInvestmentsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMjItNy0xLTEtMA_7650ed9b-4bf3-4cf2-99cd-46ff98ea46ba">66.8</ix:nonFraction></span><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMjMtMS0xLTEtMA_fe1dc6a4-601b-402c-8c8b-9374964f5e65">703.9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMjMtMy0xLTEtMA_7febf069-8a16-4986-8126-3efe2617ec0f">1,545.9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMjMtNS0xLTEtMA_f8f27ada-4dc3-4eb0-b19a-a8c881272389">3,702.9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMjMtNy0xLTEtMA_4e8739f9-31d9-40e9-ac5f-0fdc7b26eaa1">4,448.8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net&#160;income (loss) attributable to noncontrolling interests, net&#160;of&#160;tax</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930" decimals="-5" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMjQtMS0xLTEtMA_f2e7d887-9ff9-45f9-825d-b6a69c29609a">2.4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930" decimals="-5" format="ixt:zerodash" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMjQtMy0xLTEtMA_352d29f9-5af8-4c45-9428-d5b62ecb61c2">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="-5" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMjQtNS0xLTEtMA_6be69b0e-2074-4c4d-b44c-a937c4e40d11">60.2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="-5" format="ixt:zerodash" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMjQtNy0xLTEtMA_5a8fb04a-b862-4d89-867d-6e941ea91b40">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income attributable to Biogen Inc.</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMjUtMS0xLTEtMA_24ff3b32-0381-4922-9b0e-b3f0e196b243">701.5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMjUtMy0xLTEtMA_1af0114b-dede-4232-b2c9-bba15c4fa899">1,545.9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMjUtNS0xLTEtMA_a84bb2f6-0a9d-40f2-a47b-601a4d70034e">3,642.7</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMjUtNy0xLTEtMA_322e8a0e-3eee-4eb3-93e7-9f2887cb8b31">4,448.8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income per share:</span></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Basic earnings per share attributable to Biogen Inc.</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMjgtMS0xLTEtMA_4f27d0f8-ca89-4aa3-b1a5-c32fd83ff31b">4.47</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMjgtMy0xLTEtMA_821866ef-0d97-4abd-8cfc-df54c58f825f">8.40</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMjgtNS0xLTEtMA_a8da84c4-f0f6-44aa-8427-c87983ccaba1">22.29</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMjgtNy0xLTEtMA_8ad1e440-cf7a-4c67-b0b5-cf1657a37bdf">23.38</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Diluted earnings per share attributable to Biogen Inc.</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMjktMS0xLTEtMA_7d6a7903-be4b-4594-99a0-7fbeb1902aad">4.46</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMjktMy0xLTEtMA_2f141d68-28f7-4a52-b52d-517bb422c030">8.39</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMjktNS0xLTEtMA_15a3577a-d3bd-4c8c-abb8-65247d34738c">22.25</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMjktNy0xLTEtMA_6880f1f2-ad9c-4c8d-894e-e29604d4d14e">23.35</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-average shares used in calculating:</span></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Basic earnings per share attributable to Biogen Inc.</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMzItMS0xLTEtMA_49203b04-689d-41f4-bd88-5507e2e315a3">156.9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMzItMy0xLTEtMA_c5b3d9c6-f2f2-4d2d-96ce-d0581ed875df">184.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMzItNS0xLTEtMA_2f38e537-82c7-45aa-9ac5-d14c2615f22e">163.4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMzItNy0xLTEtMA_73b488a3-eb6a-4552-8630-35bf37aaf6dc">190.3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Diluted earnings per share attributable to Biogen Inc.</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMzMtMS0xLTEtMA_0ec47d91-7ec6-46ff-89ec-919d86d483cb">157.2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMzMtMy0xLTEtMA_5fc7afff-22f0-4421-88eb-75c0644b3e39">184.2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMzMtNS0xLTEtMA_f2c94287-6cc6-4a92-8804-4c50f78ea647">163.7</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMzMtNy0xLTEtMA_8f256159-13c7-4805-bb31-72a7354348cb">190.5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr></table></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">See accompanying notes to these unaudited condensed consolidated financial statements.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">5</span></div></div></div><div id="ib19ff89608c84168a635160f2efa48f3_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_7">Table of Contents</a></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(unaudited, in millions)</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:44.207%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.389%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.389%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.656%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.660%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Three Months Ended September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income attributable to Biogen Inc.</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yMi9mcmFnOmI2NDA3YWZhODM2ZTQzMDQ5ZWY3MWJiNjljN2I1Y2VmL3RhYmxlOjU0NzUyZDViNDMyZTQ4ODE5MGFjMjc2ZjIzNTYxNzlkL3RhYmxlcmFuZ2U6NTQ3NTJkNWI0MzJlNDg4MTkwYWMyNzZmMjM1NjE3OWRfMi0xLTEtMS0w_1001ec26-c1da-4570-b45e-281dd4345d24">701.5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yMi9mcmFnOmI2NDA3YWZhODM2ZTQzMDQ5ZWY3MWJiNjljN2I1Y2VmL3RhYmxlOjU0NzUyZDViNDMyZTQ4ODE5MGFjMjc2ZjIzNTYxNzlkL3RhYmxlcmFuZ2U6NTQ3NTJkNWI0MzJlNDg4MTkwYWMyNzZmMjM1NjE3OWRfMi0zLTEtMS0w_57085c41-f71d-4db1-83af-57546b2a6628">1,545.9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yMi9mcmFnOmI2NDA3YWZhODM2ZTQzMDQ5ZWY3MWJiNjljN2I1Y2VmL3RhYmxlOjU0NzUyZDViNDMyZTQ4ODE5MGFjMjc2ZjIzNTYxNzlkL3RhYmxlcmFuZ2U6NTQ3NTJkNWI0MzJlNDg4MTkwYWMyNzZmMjM1NjE3OWRfMi01LTEtMS0w_122130e2-da78-4760-bcc8-289722ee8906">3,642.7</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yMi9mcmFnOmI2NDA3YWZhODM2ZTQzMDQ5ZWY3MWJiNjljN2I1Y2VmL3RhYmxlOjU0NzUyZDViNDMyZTQ4ODE5MGFjMjc2ZjIzNTYxNzlkL3RhYmxlcmFuZ2U6NTQ3NTJkNWI0MzJlNDg4MTkwYWMyNzZmMjM1NjE3OWRfMi03LTEtMS0w_2548c79c-d323-4bf5-929c-4e5bd9192547">4,448.8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other comprehensive income:</span></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">Unrealized gains (losses) on securities available for sale, net of tax</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yMi9mcmFnOmI2NDA3YWZhODM2ZTQzMDQ5ZWY3MWJiNjljN2I1Y2VmL3RhYmxlOjU0NzUyZDViNDMyZTQ4ODE5MGFjMjc2ZjIzNTYxNzlkL3RhYmxlcmFuZ2U6NTQ3NTJkNWI0MzJlNDg4MTkwYWMyNzZmMjM1NjE3OWRfNC0xLTEtMS0w_a0c682dc-eb97-474d-b905-0c5c47bf96ce">0.1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yMi9mcmFnOmI2NDA3YWZhODM2ZTQzMDQ5ZWY3MWJiNjljN2I1Y2VmL3RhYmxlOjU0NzUyZDViNDMyZTQ4ODE5MGFjMjc2ZjIzNTYxNzlkL3RhYmxlcmFuZ2U6NTQ3NTJkNWI0MzJlNDg4MTkwYWMyNzZmMjM1NjE3OWRfNC0zLTEtMS0w_88adaa37-38e6-424a-9a9a-a5b4a70a119f">0.1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yMi9mcmFnOmI2NDA3YWZhODM2ZTQzMDQ5ZWY3MWJiNjljN2I1Y2VmL3RhYmxlOjU0NzUyZDViNDMyZTQ4ODE5MGFjMjc2ZjIzNTYxNzlkL3RhYmxlcmFuZ2U6NTQ3NTJkNWI0MzJlNDg4MTkwYWMyNzZmMjM1NjE3OWRfNC01LTEtMS0w_82f487b9-8172-4c7a-b9b9-ac7c406728a0">1.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yMi9mcmFnOmI2NDA3YWZhODM2ZTQzMDQ5ZWY3MWJiNjljN2I1Y2VmL3RhYmxlOjU0NzUyZDViNDMyZTQ4ODE5MGFjMjc2ZjIzNTYxNzlkL3RhYmxlcmFuZ2U6NTQ3NTJkNWI0MzJlNDg4MTkwYWMyNzZmMjM1NjE3OWRfNC03LTEtMS0w_9b1f76da-243a-41ed-8a7c-8aca606b5cdf">10.3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">Unrealized gains (losses) on cash flow hedges, net of tax</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yMi9mcmFnOmI2NDA3YWZhODM2ZTQzMDQ5ZWY3MWJiNjljN2I1Y2VmL3RhYmxlOjU0NzUyZDViNDMyZTQ4ODE5MGFjMjc2ZjIzNTYxNzlkL3RhYmxlcmFuZ2U6NTQ3NTJkNWI0MzJlNDg4MTkwYWMyNzZmMjM1NjE3OWRfNS0xLTEtMS0w_1255ec0d-06d6-4aa1-a0a5-58c7679d4e0a">83.7</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yMi9mcmFnOmI2NDA3YWZhODM2ZTQzMDQ5ZWY3MWJiNjljN2I1Y2VmL3RhYmxlOjU0NzUyZDViNDMyZTQ4ODE5MGFjMjc2ZjIzNTYxNzlkL3RhYmxlcmFuZ2U6NTQ3NTJkNWI0MzJlNDg4MTkwYWMyNzZmMjM1NjE3OWRfNS0zLTEtMS0w_11e0c973-a700-4f16-b7f9-666c17f04b71">59.1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yMi9mcmFnOmI2NDA3YWZhODM2ZTQzMDQ5ZWY3MWJiNjljN2I1Y2VmL3RhYmxlOjU0NzUyZDViNDMyZTQ4ODE5MGFjMjc2ZjIzNTYxNzlkL3RhYmxlcmFuZ2U6NTQ3NTJkNWI0MzJlNDg4MTkwYWMyNzZmMjM1NjE3OWRfNS01LTEtMS0w_4352b438-66d6-44b9-bddb-847cb9c1e661">101.1</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yMi9mcmFnOmI2NDA3YWZhODM2ZTQzMDQ5ZWY3MWJiNjljN2I1Y2VmL3RhYmxlOjU0NzUyZDViNDMyZTQ4ODE5MGFjMjc2ZjIzNTYxNzlkL3RhYmxlcmFuZ2U6NTQ3NTJkNWI0MzJlNDg4MTkwYWMyNzZmMjM1NjE3OWRfNS03LTEtMS0w_37e4e9b3-44dd-4000-91ed-e2804d5de705">38.1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">Gains (losses) on net investment hedges</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yMi9mcmFnOmI2NDA3YWZhODM2ZTQzMDQ5ZWY3MWJiNjljN2I1Y2VmL3RhYmxlOjU0NzUyZDViNDMyZTQ4ODE5MGFjMjc2ZjIzNTYxNzlkL3RhYmxlcmFuZ2U6NTQ3NTJkNWI0MzJlNDg4MTkwYWMyNzZmMjM1NjE3OWRfNi0xLTEtMS0w_01400c8a-65ee-40d6-8f0b-e4181795656b">11.3</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930" decimals="-5" name="us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yMi9mcmFnOmI2NDA3YWZhODM2ZTQzMDQ5ZWY3MWJiNjljN2I1Y2VmL3RhYmxlOjU0NzUyZDViNDMyZTQ4ODE5MGFjMjc2ZjIzNTYxNzlkL3RhYmxlcmFuZ2U6NTQ3NTJkNWI0MzJlNDg4MTkwYWMyNzZmMjM1NjE3OWRfNi0zLTEtMS0w_6cb85aa5-70d1-46b8-9fdd-4a5a38dc5500">21.2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="-5" name="us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yMi9mcmFnOmI2NDA3YWZhODM2ZTQzMDQ5ZWY3MWJiNjljN2I1Y2VmL3RhYmxlOjU0NzUyZDViNDMyZTQ4ODE5MGFjMjc2ZjIzNTYxNzlkL3RhYmxlcmFuZ2U6NTQ3NTJkNWI0MzJlNDg4MTkwYWMyNzZmMjM1NjE3OWRfNi01LTEtMS0w_d1fa179d-289e-4053-bb04-e9b585a23822">5.5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="-5" name="us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yMi9mcmFnOmI2NDA3YWZhODM2ZTQzMDQ5ZWY3MWJiNjljN2I1Y2VmL3RhYmxlOjU0NzUyZDViNDMyZTQ4ODE5MGFjMjc2ZjIzNTYxNzlkL3RhYmxlcmFuZ2U6NTQ3NTJkNWI0MzJlNDg4MTkwYWMyNzZmMjM1NjE3OWRfNi03LTEtMS0w_3a28a974-65ec-4380-9b34-a3c8a237ab02">46.9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">Unrealized gains (losses) on pension benefit obligation, net of tax</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yMi9mcmFnOmI2NDA3YWZhODM2ZTQzMDQ5ZWY3MWJiNjljN2I1Y2VmL3RhYmxlOjU0NzUyZDViNDMyZTQ4ODE5MGFjMjc2ZjIzNTYxNzlkL3RhYmxlcmFuZ2U6NTQ3NTJkNWI0MzJlNDg4MTkwYWMyNzZmMjM1NjE3OWRfNy0xLTEtMS0w_5fc07b84-200c-4924-9501-201eb848b505">0.5</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yMi9mcmFnOmI2NDA3YWZhODM2ZTQzMDQ5ZWY3MWJiNjljN2I1Y2VmL3RhYmxlOjU0NzUyZDViNDMyZTQ4ODE5MGFjMjc2ZjIzNTYxNzlkL3RhYmxlcmFuZ2U6NTQ3NTJkNWI0MzJlNDg4MTkwYWMyNzZmMjM1NjE3OWRfNy0zLTEtMS0w_965b0c69-a218-4596-9015-a3da7a5a6217">0.8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yMi9mcmFnOmI2NDA3YWZhODM2ZTQzMDQ5ZWY3MWJiNjljN2I1Y2VmL3RhYmxlOjU0NzUyZDViNDMyZTQ4ODE5MGFjMjc2ZjIzNTYxNzlkL3RhYmxlcmFuZ2U6NTQ3NTJkNWI0MzJlNDg4MTkwYWMyNzZmMjM1NjE3OWRfNy01LTEtMS0w_506e03d9-e61f-4d9e-b988-d478a6da980c">0.4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yMi9mcmFnOmI2NDA3YWZhODM2ZTQzMDQ5ZWY3MWJiNjljN2I1Y2VmL3RhYmxlOjU0NzUyZDViNDMyZTQ4ODE5MGFjMjc2ZjIzNTYxNzlkL3RhYmxlcmFuZ2U6NTQ3NTJkNWI0MzJlNDg4MTkwYWMyNzZmMjM1NjE3OWRfNy03LTEtMS0w_89ce8e40-77d6-458d-86b1-6df80255de8c">1.5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">Currency translation adjustment</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yMi9mcmFnOmI2NDA3YWZhODM2ZTQzMDQ5ZWY3MWJiNjljN2I1Y2VmL3RhYmxlOjU0NzUyZDViNDMyZTQ4ODE5MGFjMjc2ZjIzNTYxNzlkL3RhYmxlcmFuZ2U6NTQ3NTJkNWI0MzJlNDg4MTkwYWMyNzZmMjM1NjE3OWRfOC0xLTEtMS0w_44bb9168-0a08-4ce5-90d5-32fa958c3731">50.9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yMi9mcmFnOmI2NDA3YWZhODM2ZTQzMDQ5ZWY3MWJiNjljN2I1Y2VmL3RhYmxlOjU0NzUyZDViNDMyZTQ4ODE5MGFjMjc2ZjIzNTYxNzlkL3RhYmxlcmFuZ2U6NTQ3NTJkNWI0MzJlNDg4MTkwYWMyNzZmMjM1NjE3OWRfOC0zLTEtMS0w_ea83d609-8106-4c0a-8352-84d119323fcf">79.4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yMi9mcmFnOmI2NDA3YWZhODM2ZTQzMDQ5ZWY3MWJiNjljN2I1Y2VmL3RhYmxlOjU0NzUyZDViNDMyZTQ4ODE5MGFjMjc2ZjIzNTYxNzlkL3RhYmxlcmFuZ2U6NTQ3NTJkNWI0MzJlNDg4MTkwYWMyNzZmMjM1NjE3OWRfOC01LTEtMS0w_5a7ed7f5-4e28-4342-b4c3-646b76ce9f7f">3.9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yMi9mcmFnOmI2NDA3YWZhODM2ZTQzMDQ5ZWY3MWJiNjljN2I1Y2VmL3RhYmxlOjU0NzUyZDViNDMyZTQ4ODE5MGFjMjc2ZjIzNTYxNzlkL3RhYmxlcmFuZ2U6NTQ3NTJkNWI0MzJlNDg4MTkwYWMyNzZmMjM1NjE3OWRfOC03LTEtMS0w_b6feafc1-c78d-42d3-999f-634e81f0a297">51.3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total other comprehensive income (loss), net of tax</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yMi9mcmFnOmI2NDA3YWZhODM2ZTQzMDQ5ZWY3MWJiNjljN2I1Y2VmL3RhYmxlOjU0NzUyZDViNDMyZTQ4ODE5MGFjMjc2ZjIzNTYxNzlkL3RhYmxlcmFuZ2U6NTQ3NTJkNWI0MzJlNDg4MTkwYWMyNzZmMjM1NjE3OWRfOS0xLTEtMS0w_3423f8c0-e9db-4576-b125-9aabbf01f813">44.5</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yMi9mcmFnOmI2NDA3YWZhODM2ZTQzMDQ5ZWY3MWJiNjljN2I1Y2VmL3RhYmxlOjU0NzUyZDViNDMyZTQ4ODE5MGFjMjc2ZjIzNTYxNzlkL3RhYmxlcmFuZ2U6NTQ3NTJkNWI0MzJlNDg4MTkwYWMyNzZmMjM1NjE3OWRfOS0zLTEtMS0w_bf725250-12f5-4b94-b65d-e557dd79fe12">160.6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yMi9mcmFnOmI2NDA3YWZhODM2ZTQzMDQ5ZWY3MWJiNjljN2I1Y2VmL3RhYmxlOjU0NzUyZDViNDMyZTQ4ODE5MGFjMjc2ZjIzNTYxNzlkL3RhYmxlcmFuZ2U6NTQ3NTJkNWI0MzJlNDg4MTkwYWMyNzZmMjM1NjE3OWRfOS01LTEtMS0w_85630377-c25e-4921-a2d7-506a8d8b4caa">90.3</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yMi9mcmFnOmI2NDA3YWZhODM2ZTQzMDQ5ZWY3MWJiNjljN2I1Y2VmL3RhYmxlOjU0NzUyZDViNDMyZTQ4ODE5MGFjMjc2ZjIzNTYxNzlkL3RhYmxlcmFuZ2U6NTQ3NTJkNWI0MzJlNDg4MTkwYWMyNzZmMjM1NjE3OWRfOS03LTEtMS0w_8bee9f0b-34b4-4629-a320-e7feaec625d2">148.1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Comprehensive income attributable to Biogen Inc.</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yMi9mcmFnOmI2NDA3YWZhODM2ZTQzMDQ5ZWY3MWJiNjljN2I1Y2VmL3RhYmxlOjU0NzUyZDViNDMyZTQ4ODE5MGFjMjc2ZjIzNTYxNzlkL3RhYmxlcmFuZ2U6NTQ3NTJkNWI0MzJlNDg4MTkwYWMyNzZmMjM1NjE3OWRfMTAtMS0xLTEtMA_313ef1f7-73de-4bd1-911a-e4e659eb2dcb">657.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yMi9mcmFnOmI2NDA3YWZhODM2ZTQzMDQ5ZWY3MWJiNjljN2I1Y2VmL3RhYmxlOjU0NzUyZDViNDMyZTQ4ODE5MGFjMjc2ZjIzNTYxNzlkL3RhYmxlcmFuZ2U6NTQ3NTJkNWI0MzJlNDg4MTkwYWMyNzZmMjM1NjE3OWRfMTAtMy0xLTEtMA_0cd010d6-2c89-4377-9494-7d2b3aac5de0">1,706.5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yMi9mcmFnOmI2NDA3YWZhODM2ZTQzMDQ5ZWY3MWJiNjljN2I1Y2VmL3RhYmxlOjU0NzUyZDViNDMyZTQ4ODE5MGFjMjc2ZjIzNTYxNzlkL3RhYmxlcmFuZ2U6NTQ3NTJkNWI0MzJlNDg4MTkwYWMyNzZmMjM1NjE3OWRfMTAtNS0xLTEtMA_29e7e8bd-5b44-4c73-bc7f-bfe7b849c7a3">3,552.4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yMi9mcmFnOmI2NDA3YWZhODM2ZTQzMDQ5ZWY3MWJiNjljN2I1Y2VmL3RhYmxlOjU0NzUyZDViNDMyZTQ4ODE5MGFjMjc2ZjIzNTYxNzlkL3RhYmxlcmFuZ2U6NTQ3NTJkNWI0MzJlNDg4MTkwYWMyNzZmMjM1NjE3OWRfMTAtNy0xLTEtMA_113b5877-4c1e-49d3-8f9e-da4145eb3a79">4,596.9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Comprehensive income (loss) attributable to noncontrolling interests, net of tax</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yMi9mcmFnOmI2NDA3YWZhODM2ZTQzMDQ5ZWY3MWJiNjljN2I1Y2VmL3RhYmxlOjU0NzUyZDViNDMyZTQ4ODE5MGFjMjc2ZjIzNTYxNzlkL3RhYmxlcmFuZ2U6NTQ3NTJkNWI0MzJlNDg4MTkwYWMyNzZmMjM1NjE3OWRfMTEtMS0xLTEtMA_2023f476-8bc8-4e99-bbc2-31675d1eae31">1.5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930" decimals="-5" format="ixt:zerodash" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yMi9mcmFnOmI2NDA3YWZhODM2ZTQzMDQ5ZWY3MWJiNjljN2I1Y2VmL3RhYmxlOjU0NzUyZDViNDMyZTQ4ODE5MGFjMjc2ZjIzNTYxNzlkL3RhYmxlcmFuZ2U6NTQ3NTJkNWI0MzJlNDg4MTkwYWMyNzZmMjM1NjE3OWRfMTEtMy0xLTEtMA_e378ebd7-63a4-4ac7-ad0d-9f2b04e3494c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yMi9mcmFnOmI2NDA3YWZhODM2ZTQzMDQ5ZWY3MWJiNjljN2I1Y2VmL3RhYmxlOjU0NzUyZDViNDMyZTQ4ODE5MGFjMjc2ZjIzNTYxNzlkL3RhYmxlcmFuZ2U6NTQ3NTJkNWI0MzJlNDg4MTkwYWMyNzZmMjM1NjE3OWRfMTEtNS0xLTEtMA_2a17180d-6b8a-435f-91cd-53c8486cd56c">61.1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="-5" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yMi9mcmFnOmI2NDA3YWZhODM2ZTQzMDQ5ZWY3MWJiNjljN2I1Y2VmL3RhYmxlOjU0NzUyZDViNDMyZTQ4ODE5MGFjMjc2ZjIzNTYxNzlkL3RhYmxlcmFuZ2U6NTQ3NTJkNWI0MzJlNDg4MTkwYWMyNzZmMjM1NjE3OWRfMTEtNy0xLTEtMA_af9086a4-5315-4b38-be03-ce98634487a3">0.4</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Comprehensive income</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yMi9mcmFnOmI2NDA3YWZhODM2ZTQzMDQ5ZWY3MWJiNjljN2I1Y2VmL3RhYmxlOjU0NzUyZDViNDMyZTQ4ODE5MGFjMjc2ZjIzNTYxNzlkL3RhYmxlcmFuZ2U6NTQ3NTJkNWI0MzJlNDg4MTkwYWMyNzZmMjM1NjE3OWRfMTItMS0xLTEtMA_1234aceb-20e1-4bfe-af90-7bc2650b99ce">658.5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yMi9mcmFnOmI2NDA3YWZhODM2ZTQzMDQ5ZWY3MWJiNjljN2I1Y2VmL3RhYmxlOjU0NzUyZDViNDMyZTQ4ODE5MGFjMjc2ZjIzNTYxNzlkL3RhYmxlcmFuZ2U6NTQ3NTJkNWI0MzJlNDg4MTkwYWMyNzZmMjM1NjE3OWRfMTItMy0xLTEtMA_0e9ae354-00e5-452d-9fc5-6f09ac879bcf">1,706.5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yMi9mcmFnOmI2NDA3YWZhODM2ZTQzMDQ5ZWY3MWJiNjljN2I1Y2VmL3RhYmxlOjU0NzUyZDViNDMyZTQ4ODE5MGFjMjc2ZjIzNTYxNzlkL3RhYmxlcmFuZ2U6NTQ3NTJkNWI0MzJlNDg4MTkwYWMyNzZmMjM1NjE3OWRfMTItNS0xLTEtMA_7efa5beb-d271-4a6b-aa1a-a35224240bb0">3,613.5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yMi9mcmFnOmI2NDA3YWZhODM2ZTQzMDQ5ZWY3MWJiNjljN2I1Y2VmL3RhYmxlOjU0NzUyZDViNDMyZTQ4ODE5MGFjMjc2ZjIzNTYxNzlkL3RhYmxlcmFuZ2U6NTQ3NTJkNWI0MzJlNDg4MTkwYWMyNzZmMjM1NjE3OWRfMTItNy0xLTEtMA_f3001caa-5bb5-4a19-a668-e1cb58ce6de9">4,596.5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td></tr></table></div><div><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">See accompanying notes to these unaudited condensed consolidated financial statements.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">6</span></div></div></div><div id="ib19ff89608c84168a635160f2efa48f3_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_7">Table of Contents</a></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(unaudited, in millions, except per share amounts)</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:64.250%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:15.859%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:15.861%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of September 30, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of December 31, 2019</span></td></tr><tr><td colspan="12" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">ASSETS</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current assets:</span></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfMy0xLTEtMS0w_0aebcca6-af71-47b3-aaee-a776edca7253">2,224.8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i626282e786b7454d83b617e9e83963e6_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfMy0zLTEtMS0w_73e542d8-e283-4add-86fe-b969b3cec744">2,913.7</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Marketable securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfNC0xLTEtMS0w_1eb209b9-2733-4048-82eb-f0b8112f778d">1,355.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i626282e786b7454d83b617e9e83963e6_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfNC0zLTEtMS0w_c0f619aa-4823-40a1-bc83-a4aee00a8404">1,562.2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts receivable, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfNS0xLTEtMS0w_c55bc52f-2287-49d4-9221-6a703b478f8d">2,024.9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i626282e786b7454d83b617e9e83963e6_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfNS0zLTEtMS0w_d948dd7a-c7b0-4475-a393-88be4a645f2b">1,880.5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Due from anti-CD20 therapeutic programs</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930" decimals="-5" name="biib:DuefromantiCD20therapeuticprograms" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfNi0xLTEtMS0w_c87159c3-d6a2-41cf-b177-391321be760e">527.2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i626282e786b7454d83b617e9e83963e6_I20191231" decimals="-5" name="biib:DuefromantiCD20therapeuticprograms" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfNi0zLTEtMS0w_be8fe10a-d8ea-45ef-93f9-c061bceca745">590.2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Inventory</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfNy0xLTEtMS0w_87c4262e-2cf4-4293-ad8b-f8403271196d">1,027.7</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i626282e786b7454d83b617e9e83963e6_I20191231" decimals="-5" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfNy0zLTEtMS0w_a03ec7ad-1fde-403b-b55f-c30ca5c76f55">804.2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other current assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930" decimals="-5" name="us-gaap:OtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfOC0xLTEtMS0w_5abb3f36-de11-432d-9bd9-4f77e6c9c5e1">683.5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i626282e786b7454d83b617e9e83963e6_I20191231" decimals="-5" name="us-gaap:OtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfOC0zLTEtMS0w_c5b40267-abb3-4fcd-a8b5-5d0db7372c93">631.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total current assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfOS0xLTEtMS0w_a00c0544-fdc3-49e9-8b32-f857dca452b0">7,843.1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i626282e786b7454d83b617e9e83963e6_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfOS0zLTEtMS0w_e725a8fd-75c7-4881-9da0-0128addf3553">8,381.8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Marketable securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfMTAtMS0xLTEtMA_8443cbc7-bb41-4663-8132-5d65b1696565">1,009.8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i626282e786b7454d83b617e9e83963e6_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfMTAtMy0xLTEtMA_c97fe349-9a7c-47fb-95c1-59c96e3970fc">1,408.1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Property, plant and equipment, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfMTEtMS0xLTEtMA_072c7b89-ab0c-41e5-9791-bd0b02faab0b">3,359.9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i626282e786b7454d83b617e9e83963e6_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfMTEtMy0xLTEtMA_fa504b08-2444-4cb9-b987-3859efd1bc83">3,247.3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfMTItMS0xLTEtMA_d1cca2fd-37ef-4b02-8f14-a2d7072fc267">434.2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i626282e786b7454d83b617e9e83963e6_I20191231" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfMTItMy0xLTEtMA_9ecacc0f-a489-4ebb-9878-383bacd87523">427.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Intangible assets, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfMTMtMS0xLTEtMA_8d28025b-a8f8-4ebf-bbd9-7e8b1d7b345d">3,323.6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i626282e786b7454d83b617e9e83963e6_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfMTMtMy0xLTEtMA_0c9ac385-b595-4a66-931a-40c178977886">3,527.4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Goodwill</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfMTQtMS0xLTEtMA_a4d66e80-d728-4845-9033-703dfacc0f78">5,755.7</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i626282e786b7454d83b617e9e83963e6_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfMTQtMy0xLTEtMA_b1071b58-4813-44ad-9a61-198a2e9ce0fa">5,757.8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred tax asset</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfMTUtMS0xLTEtMA_78385776-6135-44bd-bde3-31e09a27373f">1,372.9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i626282e786b7454d83b617e9e83963e6_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfMTUtMy0xLTEtMA_690fc1fa-4ced-4afa-951f-a133259e8558">3,232.1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Investments and other assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfMTYtMS0xLTEtMA_62c72308-839e-4a76-959d-0418093c4b49">1,834.9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i626282e786b7454d83b617e9e83963e6_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfMTYtMy0xLTEtMA_a0a6372f-82f3-4874-82a6-76cd56f05cca">1,252.8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfMTctMS0xLTEtMA_ef2f40eb-ae9a-4159-bd42-b4c2a0b876a4">24,934.1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i626282e786b7454d83b617e9e83963e6_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfMTctMy0xLTEtMA_61cbea72-2673-41c5-9bb1-bf07d8479068">27,234.3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td></tr><tr><td colspan="12" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">LIABILITIES AND EQUITY</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current liabilities:</span></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current portion of notes payable</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:NotesPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfMjAtMS0xLTEtMA_2c9b786d-22ce-4376-babf-a003bc5ec21a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i626282e786b7454d83b617e9e83963e6_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NotesPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfMjAtMy0xLTEtMA_77e501fa-cf15-46f8-a8be-822e9bae12ec">1,495.8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Taxes payable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930" decimals="-5" name="us-gaap:TaxesPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfMjEtMS0xLTEtMA_42ac141f-5b5c-4120-9244-6aec55bad717">119.4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i626282e786b7454d83b617e9e83963e6_I20191231" decimals="-5" name="us-gaap:TaxesPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfMjEtMy0xLTEtMA_336662a0-6ec5-43b6-94c0-b70c78abfa51">71.4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts payable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930" decimals="-5" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfMjItMS0xLTEtMA_e4d6e130-a582-4061-a691-3a99ab128dec">398.4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i626282e786b7454d83b617e9e83963e6_I20191231" decimals="-5" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfMjItMy0xLTEtMA_499bf52d-77a1-4454-bdee-8b783acf93cf">530.8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued expenses and other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfMjMtMS0xLTEtMA_488c8d0e-af49-40c7-8f24-d64e0b22b8be">3,286.2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i626282e786b7454d83b617e9e83963e6_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfMjMtMy0xLTEtMA_d9821704-168f-4ee7-a542-d40cf4d60e99">2,765.8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total current liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfMjQtMS0xLTEtMA_a1d25947-47df-412b-a4d5-ebcb95dd5f7e">3,804.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i626282e786b7454d83b617e9e83963e6_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfMjQtMy0xLTEtMA_6da1d3e9-fed9-4bff-bcdd-6290113d1d50">4,863.8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Notes payable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfMjUtMS0xLTEtMA_aca80964-6e3f-4dc4-896a-ab4523b98ce0">7,425.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i626282e786b7454d83b617e9e83963e6_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfMjUtMy0xLTEtMA_2dcc90bf-e1a4-42f8-8a94-23ab17fa32be">4,459.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred tax liability</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfMjYtMS0xLTEtMA_0cf1568d-c4b9-493e-8106-7cdef2af90eb">1,123.4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i626282e786b7454d83b617e9e83963e6_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfMjYtMy0xLTEtMA_e179a697-70d7-45bb-af0a-b6f69c759f4c">2,810.8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Long-term operating lease liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfMjctMS0xLTEtMA_a869c30a-fd4c-4a6e-8cc8-4ec1884745e6">409.1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i626282e786b7454d83b617e9e83963e6_I20191231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfMjctMy0xLTEtMA_1af625de-fa59-4b0c-95dd-74f3e41eb4f1">412.7</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other long-term liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfMjgtMS0xLTEtMA_2b16eb7c-f1c1-4ee4-bde9-782920115bc1">1,428.1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i626282e786b7454d83b617e9e83963e6_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfMjgtMy0xLTEtMA_5e05d579-c2a2-4155-8371-6d29e0543b20">1,348.9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfMjktMS0xLTEtMA_9464a4da-6578-4b0c-8a55-5941c9a898f2">14,189.6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i626282e786b7454d83b617e9e83963e6_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfMjktMy0xLTEtMA_47cf3387-acb6-42cf-a54c-882eca22727b">13,895.2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commitments and contingencies</span></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><ix:nonFraction unitRef="usd" contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfMzAtMS0xLTEtMA_924cc98d-b548-4918-97db-3767207f5fec"></ix:nonFraction></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><ix:nonFraction unitRef="usd" contextRef="i626282e786b7454d83b617e9e83963e6_I20191231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfMzAtMy0xLTEtMA_cf7ffd0f-81f2-4613-9641-f2347c12b7a6"></ix:nonFraction></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Equity:</span></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Biogen Inc. shareholders&#8217; equity:</span></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Preferred stock, par value $0.001 per share</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfMzMtMS0xLTEtMA_18b31f1a-5fd1-4c90-a52f-9dc6ca847ffb">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i626282e786b7454d83b617e9e83963e6_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfMzMtMy0xLTEtMA_28d5e4c5-ce7c-44d8-becb-cbd90aab1a62">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Common stock, par value $0.0005 per share</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930" decimals="-5" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfMzQtMS0xLTEtMA_d72b1f50-2247-45c0-ae1e-b91fd8598f81">0.1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i626282e786b7454d83b617e9e83963e6_I20191231" decimals="-5" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfMzQtMy0xLTEtMA_83a5c8fc-4c35-4126-938d-dc68412e3182">0.1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additional paid-in capital</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:AdditionalPaidInCapital" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfMzUtMS0xLTEtMA_bcebdd5a-c58e-4828-8b2f-7fe98d5b2166">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i626282e786b7454d83b617e9e83963e6_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:AdditionalPaidInCapital" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfMzUtMy0xLTEtMA_b36a7235-b792-4ae9-b76f-1f66420e6878">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated other comprehensive loss</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfMzYtMS0xLTEtMA_e2adcf9c-ce4f-4bcd-b7ee-1e3cc2cc3e2b">225.5</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i626282e786b7454d83b617e9e83963e6_I20191231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfMzYtMy0xLTEtMA_c9797929-50e6-4e4a-b2b2-69220615465c">135.2</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Retained earnings</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfMzctMS0xLTEtMA_a2254215-a1b5-447c-9c02-23eee9482e7c">13,961.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i626282e786b7454d83b617e9e83963e6_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfMzctMy0xLTEtMA_df3051ad-bb74-4fcb-88a5-1bc1e182c5c3">16,455.4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Treasury stock, at cost</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfMzgtMS0xLTEtMA_403054ca-5283-49e5-9f63-821d1433f327">2,977.1</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i626282e786b7454d83b617e9e83963e6_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfMzgtMy0xLTEtMA_32817e8d-55f6-4a04-bd08-8d67c8eaf2a0">2,977.1</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total Biogen Inc. shareholders&#8217; equity</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfMzktMS0xLTEtMA_dd685e25-782e-4d52-9bec-6b77a6426902">10,758.5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i626282e786b7454d83b617e9e83963e6_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfMzktMy0xLTEtMA_ffb1b782-db37-4246-b348-bf803908585a">13,343.2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Noncontrolling interests</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930" decimals="-5" sign="-" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfNDAtMS0xLTEtMA_52891b0d-5908-44c0-bda4-f9e6fa80fd73">14.0</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i626282e786b7454d83b617e9e83963e6_I20191231" decimals="-5" sign="-" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfNDAtMy0xLTEtMA_3f7fffce-e69b-4c34-b089-bd3c179c7de7">4.1</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total equity</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfNDEtMS0xLTEtMA_97976a65-aab3-4165-b55d-1760dc98a058">10,744.5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i626282e786b7454d83b617e9e83963e6_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfNDEtMy0xLTEtMA_717fe15a-32ec-4bdb-ac77-94708ac19868">13,339.1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total liabilities and equity</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfNDItMS0xLTEtMA_6dd68539-65f1-4e7e-83b0-3d53332128b5">24,934.1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i626282e786b7454d83b617e9e83963e6_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfNDItMy0xLTEtMA_0ca6b39b-eeb5-4c4a-9c47-feafe5b9e831">27,234.3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td></tr></table></div><div style="text-align:center;margin-top:14pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">See accompanying notes to these unaudited condensed consolidated financial statements.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">7</span></div></div></div><div id="ib19ff89608c84168a635160f2efa48f3_31"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_7">Table of Contents</a></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(unaudited, in millions)</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:71.187%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.389%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.391%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8.8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfMy0xLTEtMS0w_9ddb2f0f-2521-4146-a392-f4dfe42d1afd">3,702.9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfMy0zLTEtMS0w_12a8f70a-fcf0-4159-a794-b519b7795156">4,448.8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Adjustments to reconcile net income to net cash flows from operating activities:</span></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Depreciation, amortization and impairments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfNS0xLTEtMS0w_6defb791-e1e3-47c0-ab25-65c494fcc980">366.8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfNS0zLTEtMS0w_f8c0cfd3-35cc-4870-9791-30f664c6e483">567.6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Acquired in-process research and development</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="-5" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfNi0xLTEtMS0w_0de193e5-ebf4-49d8-bf87-6a7b38bf17b7">75.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="-5" format="ixt:zerodash" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfNi0zLTEtMS0w_f2ef6769-357d-4295-98c2-05d50b7a0792">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Share-based compensation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfNy0xLTEtMS0w_b36049dc-c0df-4c3c-ac35-42c93ad898fa">149.3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfNy0zLTEtMS0w_c4197393-c1da-4518-add3-12ff9cf82266">143.9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfOS0xLTEtMS0w_62ea0500-e815-4e59-8bbf-107ab79dadfd">23.5</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfOS0zLTEtMS0w_50ee2c99-e1e6-410c-952f-634c0f470ac0">66.3</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Loss on divestiture of Hiller&#248;d, Denmark manufacturing operations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfMTAtMS0xLTEtMA_2d0bdee4-1211-411e-a1bd-413b98d947e8">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="-5" sign="-" name="us-gaap:IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfMTAtMy0xLTEtMA_eccc3d1f-73f8-4645-a959-be91b403340a">95.5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred income taxes</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="-5" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfMTEtMS0xLTEtMA_32f96d7e-1846-4832-aee3-0619b55581e1">211.9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="-5" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfMTEtMy0xLTEtMA_9f9d8d76-e5eb-4408-94a1-5e30d91bb38b">28.4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized (gain) loss on strategic investments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfMTItMS0xLTEtMA_1e38fba7-a283-4484-8601-7c1efa29972b">41.8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="-5" name="us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfMTItMy0xLTEtMA_29f0b60f-6b37-463c-81b0-c73052be50f3">189.8</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Loss on equity method investment</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfMTMtMS0xLTEtMA_6839be61-5d0b-4d01-894d-a388df7ba5ce">14.7</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfMTMtMy0xLTEtMA_0f3a1ffe-f6ac-41a9-a876-40f099b02883">63.5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfMTQtMS0xLTEtMA_07075a7d-f0d0-4314-8a67-51dee8196036">110.1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="-5" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfMTQtMy0xLTEtMA_21c9159e-ddd3-4ef7-9329-1cbaa6ff1f1b">87.4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Changes in operating assets and liabilities, net:</span></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:29.25pt;padding-right:1pt;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts receivable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfMTYtMS0xLTEtMA_f825c5de-0c17-4a58-af39-91d9fbe1ba24">135.7</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfMTYtMy0xLTEtMA_b21a669a-87e1-4033-995e-1969f7a30483">2.4</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:29.25pt;padding-right:1pt;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Due from anti-CD20 therapeutic programs</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInDueFromRelatedParties" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfMTctMS0xLTEtMA_d3a84407-6811-4f39-b5d3-0b7f1eb8c9c9">63.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="-5" name="us-gaap:IncreaseDecreaseInDueFromRelatedParties" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfMTctMy0xLTEtMA_51f786ea-ba68-47d1-bc76-db5637b60d8d">55.4</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:29.25pt;padding-right:1pt;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Inventory</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="-5" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfMTgtMS0xLTEtMA_f04e712d-8d87-4c14-8b32-562678ec1cd5">270.6</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfMTgtMy0xLTEtMA_9101321c-300e-4430-bc85-296bef130498">47.3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:29.25pt;padding-right:1pt;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued expenses and other current liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="-5" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfMTktMS0xLTEtMA_f6927e15-18ee-4a7e-b789-3b266447bf47">372.9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfMTktMy0xLTEtMA_d4382a8d-7f56-4184-8923-073d418dc124">109.1</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:29.25pt;padding-right:1pt;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income tax assets and liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="-5" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfMjAtMS0xLTEtMA_a4ded7a3-1f2e-4b3b-89b0-0715fb9d58aa">15.3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="-5" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfMjAtMy0xLTEtMA_0871d547-48db-4af1-932b-a18ef279bcbd">64.6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:29.25pt;padding-right:1pt;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other changes in operating assets and liabilities, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="-5" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfMjEtMS0xLTEtMA_c653aea4-8dea-46e2-a25f-59da9ae7e77a">97.0</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="-5" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfMjEtMy0xLTEtMA_83982b80-7ab4-4777-881c-8c839890259d">5.6</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:36pt;padding-right:1pt;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash flows provided by operating activities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfMjItMS0xLTEtMA_edfb06ec-c46e-4c2b-a35c-60a0bfc966cc">4,596.9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfMjItMy0xLTEtMA_f24f802a-64cd-499f-af4b-8953dca82b1a">5,118.4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8.8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Proceeds from sales and maturities of marketable securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfMjQtMS0xLTEtMA_becceaf0-0416-4757-ac3f-4581d08a689a">5,240.7</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfMjQtMy0xLTEtMA_1a91ca93-8deb-45a1-8f9f-1fec878cb239">3,867.6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Purchases of marketable securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfMjUtMS0xLTEtMA_ec642556-840f-4fe6-acc1-48d56046ddab">4,649.1</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfMjUtMy0xLTEtMA_b882c919-fda2-49e7-a2b3-0d8826dfe81b">4,052.1</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration paid related to Fumapharm AG acquisition</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireOtherProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfMjYtMS0xLTEtMA_08e4a19e-03ec-41e2-b4c3-a07ce94dbf57">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="-5" name="us-gaap:PaymentsToAcquireOtherProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfMjYtMy0xLTEtMA_3819cdc9-02f3-49c7-a849-5bd025495d86">300.0</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Acquisition of Nightstar Therapeutics plc, net of cash acquired</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireBusinessTwoNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfMjctMS0xLTEtMA_50963e5b-587e-4ec1-8965-5f6db8a19468">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessTwoNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfMjctMy0xLTEtMA_d4214705-6aa3-4f67-b861-daf7d6ed2193">744.4</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Purchase of Sangamo Therapeutics, Inc. stock</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iec2bbdde63854682b605414cc72c3ab7_D20200101-20200930" decimals="-5" name="us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfMjgtMS0xLTEtMA_108068c9-a639-4544-880d-ee5415e175c5">141.8</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i97a0bebcc8cf4432b262746010427fa4_D20190101-20190930" decimals="-5" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfMjgtMy0xLTEtMA_f7b52422-e3cd-4993-b8b0-965ed03c4042">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Purchase of Denali Therapeutics Inc. stock</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i79e678cecceb4e00b17b8c2023042ca8_D20200101-20200930" decimals="-5" name="us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfMjktMS0xLTEtNDc2Mg_457f32f2-47b2-44af-b9aa-eaa2928acaba">423.7</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifd729f26efae42a995f0066eb5f4a0ce_D20190101-20190930" decimals="-5" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfMjktMy0xLTEtNDc2Mg_a2aab3df-f732-4844-bf79-6c6a5b7f7f79">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Proceeds from divestiture of Hiller&#248;d, Denmark manufacturing operations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfMjktMS0xLTEtMA_1b5f2c2d-72a7-4eff-9680-c26b11ce4ff2">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="-5" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfMjktMy0xLTEtMA_4b4cb5f1-831b-4217-8b5b-c93ad913410c">923.7</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Purchases of property, plant and equipment</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="-5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfMzAtMS0xLTEtMA_d4931b98-0aa6-4004-ad6a-af1a1777e093">338.8</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="-5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfMzAtMy0xLTEtMA_19afbb14-5312-4b2d-b5d1-43222fee712c">404.1</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Acquired in-process research and development</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="-5" name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfMzEtMS0xLTEtMA_ab64936a-3e4b-4c2d-a94a-0b5c66f9f7d2">75.0</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="-5" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfMzEtMy0xLTEtMA_c107cb17-ecd7-4f60-bb0e-ef916834104c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Acquisitions of intangible assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfMzItMS0xLTEtMA_4644a345-971b-4d39-ba92-66fdb8bcfcb5">37.0</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="-5" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfMzItMy0xLTEtMA_f7e70d93-2dc6-4c5b-aaa0-a45be1945747">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Proceeds from sales of strategic investments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="-5" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfMzUtMS0xLTEtMA_96e9620f-5f4d-4a6e-a81c-06749dbc4076">0.5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="-5" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfMzUtMy0xLTEtMA_26bfffa1-c1c2-420b-ab10-e91de888d1da">476.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="-5" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfMzYtMS0xLTEtMA_7974cee4-5ed1-405b-9ccb-b2cc05af73ba">18.0</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="-5" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfMzYtMy0xLTEtMA_dfcf654f-f11c-4b75-b0a6-e92df58247ff">4.6</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:36pt;padding-right:1pt;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash flows provided by (used in) investing activities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfMzctMS0xLTEtMA_10bf80e1-4448-48a4-b91d-522e454f0e22">442.2</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfMzctMy0xLTEtMA_b06ea42e-665d-4abd-94c6-c7f641bd9b0d">237.9</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8.8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Purchases of treasury stock</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfMzktMS0xLTEtMA_bf6d07e1-5664-44ad-8faa-a8d2a805e1ca">6,279.1</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfMzktMy0xLTEtMA_7b918d85-abd0-456c-842b-1c35451e2fb4">3,775.2</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Payments related to issuance of stock for share-based compensation arrangements, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="-5" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfNDAtMS0xLTEtMA_b5646ccb-e5ff-46b4-acbe-aebd2ca6a40c">11.8</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="-5" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfNDAtMy0xLTEtMA_ee556e5d-6cf9-44c2-9f80-115b54fee010">16.9</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Proceeds from borrowings</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfNDEtMS0xLTEtMA_b1d8d124-cbf7-4acf-86d8-8b2dbb48e6aa">2,967.3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="-5" format="ixt:zerodash" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfNDEtMy0xLTEtMA_6379f159-f629-4a6a-b768-ca413e8a0010">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Repayment of borrowings</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfNDItMS0xLTEtMA_b53d54ed-cde4-4849-98d0-8742c766cea4">1,500.0</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="-5" format="ixt:zerodash" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfNDItMy0xLTEtMA_b7a79720-696a-49c2-bdf1-629b1d93bc92">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net distribution to noncontrolling interest</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="-5" name="us-gaap:PaymentsToMinorityShareholders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfNDQtMS0xLTEtMA_4b4bec60-62ce-487c-b871-581fdacf21b2">70.9</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="-5" sign="-" name="us-gaap:PaymentsToMinorityShareholders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfNDQtMy0xLTEtMA_d35fec92-28c7-4f5e-8dd6-1ebd74b3e054">4.3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="-5" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfNDUtMS0xLTEtMA_5c177795-3c0e-4916-bda4-d6c31c76f7d2">22.9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="-5" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfNDUtMy0xLTEtMA_0f380800-0cad-4f51-bb8c-a803ec34ca9f">43.8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:36pt;padding-right:1pt;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash flows used in financing activities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfNDYtMS0xLTEtMA_81080bf6-0426-41c3-a396-47263eb196ff">4,871.6</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfNDYtMy0xLTEtMA_b1b956bc-f16e-45cc-94fb-a35b90e5fee9">3,744.0</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net increase (decrease) in cash and cash equivalents</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfNDctMS0xLTEtMA_5c59d231-3400-42eb-b024-8bf21727821b">716.9</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfNDctMy0xLTEtMA_e7d04817-cb91-45bd-818b-428f8d3297f1">1,136.5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Effect of exchange rate changes on cash and cash equivalents</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="-5" name="us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfNDgtMS0xLTEtMA_5e09ca54-b3a1-4ae3-a99b-4acd7362da82">28.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="-5" sign="-" name="us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfNDgtMy0xLTEtMA_4b8af8ba-f523-4ca7-8475-2fc09b758ec3">17.2</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents, beginning of the period</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i626282e786b7454d83b617e9e83963e6_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfNDktMS0xLTEtMA_e1e0aa34-093a-4f92-a56f-34eaf161ed3c">2,913.7</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib98dd789f3514452acc95f9b041d2a7e_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfNDktMy0xLTEtMA_50c89bb6-b266-4a80-aa6d-21f7857d38eb">1,224.6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents, end of the period</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfNTAtMS0xLTEtMA_67143804-b2f4-4892-8da8-17a5943c0be8">2,224.8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8.8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ied38b94db9a74750b51c6e8392d4c5bf_I20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfNTAtMy0xLTEtMA_b84eb52d-9dc9-4ff8-879c-942070475b1e">2,343.9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td></tr></table></div><div style="text-align:center;margin-top:3pt;"><span><br/></span></div><div style="text-align:center;margin-top:3pt;"><span><br/></span></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">See accompanying notes to these unaudited condensed consolidated financial statements.</span></div><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">8</span></div></div></div><div id="ib19ff89608c84168a635160f2efa48f3_34"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_7">Table of Contents</a></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">CONDENSED CONSOLIDATED STATEMENTS OF EQUITY</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(unaudited, in millions)</span></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.675%;"><tr><td style="width:1.0%;"></td><td style="width:19.638%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:3.351%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.342%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:3.677%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.342%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:3.351%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.342%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:3.677%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.342%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:4.871%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.342%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.694%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.342%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:5.523%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.342%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:3.785%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.342%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:4.654%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.342%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.826%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.342%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.586%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.342%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:5.105%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Preferred stock</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Common stock</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additional<br/>paid-in<br/>capital</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated<br/>other<br/>comprehensive<br/>loss</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Retained<br/>earnings</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Treasury stock</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total<br/>Biogen Inc.<br/>shareholders&#8217;<br/>equity</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Noncontrolling<br/>interests</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total<br/>equity</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, June 30, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ic9b1433e63154dc793bb3be211f95c71_I20200630" decimals="-5" format="ixt:zerodash" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfMi0xLTEtMS0w_854dd0ab-541a-4b33-b8b6-e878a1c89f4f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic9b1433e63154dc793bb3be211f95c71_I20200630" decimals="-5" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfMi0zLTEtMS0w_7892ffcc-e37f-4b78-9654-1e67ce9d5c15">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i1dd367dec9d1416ead31ac17037d6347_I20200630" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfMi01LTEtMS0w_581f89e1-1adb-4ff7-8b50-28ce8d7a0e43">182.1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1dd367dec9d1416ead31ac17037d6347_I20200630" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfMi03LTEtMS0w_83d554db-7b3f-4611-970e-7d5d1740a6d8">0.1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i58e4de16550642ffb8fa1ec5287f1bac_I20200630" decimals="-5" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfMi05LTEtMS0w_16ad1f1f-0b0e-4b4e-87b6-596a0513c339">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1f5ebc014a364cce887ab9d7243516cc_I20200630" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfMi0xMS0xLTEtMA_77b8256c-eb74-4ac4-9fca-ef14be8d650d">181.0</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icfc9a329a8dd439cb140f840522afc1d_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfMi0xMy0xLTEtMA_288ca413-a465-4a00-b7f1-3b15cf199fec">14,466.7</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="i4bb77bd7d2ce46e59ff6fbd5cb940d75_I20200630" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfMi0xNS0xLTEtMA_0d55d91c-75d1-4ca6-a976-1cdbbf30c387">23.8</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i4bb77bd7d2ce46e59ff6fbd5cb940d75_I20200630" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfMi0xNy0xLTEtMA_77877115-0e3d-4a3a-b6dd-f09b6f3735a4">2,977.1</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibb3e0c3b7ac94f2183a66e90c088be58_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfMi0xOS0xLTEtMA_cc2ded3b-fc5b-45a0-932e-5e54b0e1418a">11,308.7</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i27fd7cabf5714753a2a142cffcd63932_I20200630" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfMi0yMS0xLTEtMA_8157682d-b54c-49bd-864a-7d242463d42b">19.5</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2d122436a2064a36b4342d6417ac828f_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfMi0yMy0xLTEtMA_65e779d4-d2c4-4c4c-b4fd-2e29240b232d">11,289.2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1499259d90804413b1e193e034d9561d_D20200701-20200930" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfMy0xMy0xLTEtMA_7ffe40d9-dc9a-467d-8455-4b90591fe228">701.5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if01d2b8c98a04ef2a7d2d2754bdfa47f_D20200701-20200930" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfMy0xOS0xLTEtMA_bb8acec1-b48d-4f87-9f29-14f5f87056cb">701.5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7209bbd041614d26ab0622d0fd200deb_D20200701-20200930" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfMy0yMS0xLTEtMA_15e8acb5-cbfd-4b2c-abfb-dfcb99f31650">2.4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfMy0yMy0xLTEtMA_32b9295f-6aac-45c0-9978-e6652fca6935">703.9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other comprehensive income (loss), net of tax</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib23988bed8f7484597669fdaf2c6150e_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfNC0xMS0xLTEtMA_6248e939-2d18-4d7b-b4ad-0946bb018c1d">44.5</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if01d2b8c98a04ef2a7d2d2754bdfa47f_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfNC0xOS0xLTEtMA_68cd728a-39fa-4c46-a469-bfe798569300">44.5</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i7209bbd041614d26ab0622d0fd200deb_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfNC0yMS0xLTEtMA_73f3c1d3-9cb6-440d-8781-d9ad5a54d8f7">0.9</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfNC0yMy0xLTEtMA_6fe6c7f6-e5f0-48ad-90e1-a5e6e7c88541">45.4</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Capital contribution by noncontrolling interest</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if01d2b8c98a04ef2a7d2d2754bdfa47f_D20200701-20200930" decimals="-5" format="ixt:zerodash" name="biib:Noncontrollinginterestincreasedecreaseother" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfNS0xOS0xLTEtMA_cfdc9b9f-0e62-415c-9505-e0144c77ef73">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7209bbd041614d26ab0622d0fd200deb_D20200701-20200930" decimals="-5" name="biib:Noncontrollinginterestincreasedecreaseother" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfNS0yMS0xLTEtMA_f2481f71-8f62-4111-afee-27366e49251e">4.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930" decimals="-5" name="biib:Noncontrollinginterestincreasedecreaseother" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfNS0yMy0xLTEtMA_79efb51e-e543-4261-986c-955a5d84d3b6">4.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Repurchase of common stock pursuant to the December 2019 Share Repurchase Program, at cost</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="i030ce533f4cf4aa7852fbd17ed7ca720_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfOC01LTEtMS0w_f0e4abff-4908-4c86-9677-4cb7d3062ae9">4.5</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="ic0a0dcfa5c2c49268190d94b335f065e_D20200701-20200930" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfOC0xNS0xLTEtMA_30793ca4-246b-4ebb-af84-b6a3f71e89b3">4.5</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ic0a0dcfa5c2c49268190d94b335f065e_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfOC0xNy0xLTEtMA_09a0a592-bb15-445b-b582-86530f93d513">1,250.0</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i2debfff1a33140e6bcf02b809c593d24_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfOC0xOS0xLTEtMA_c2191d22-57c8-455f-8f0a-a242406e6c30">1,250.0</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iadd8187a18d849f6b353e75cae0aabe8_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfOC0yMy0xLTEtMA_7f39e59b-631d-4607-a805-f4330b8fa7df">1,250.0</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Retirement of common stock pursuant to the December 2019 Share Repurchase Program, at cost</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="iada85e2a70f74606baf6a5c38c9ddac3_D20200701-20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfOS01LTEtMS0w_fa76fb9d-40df-4d98-8938-db1dacc22f37">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iada85e2a70f74606baf6a5c38c9ddac3_D20200701-20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfOS03LTEtMS0w_7d661ba7-73f2-4c07-92bc-1b4c5cf3506e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ifb80294ce54b4a41af5a0f3e17352851_D20200701-20200930" decimals="-5" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfOS05LTEtMS0w_89beb0b6-f5bf-4b2a-8918-d1d0256e35ed">45.1</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1c225596be4340518bf78440f40fdbb7_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfOS0xMy0xLTEtMA_39573f2a-ab90-49d0-a385-6a6d9c263a0d">1,204.9</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ic0a0dcfa5c2c49268190d94b335f065e_D20200701-20200930" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfOS0xNS0xLTEtMA_56ef0e5b-98f7-43d8-af59-111e7688756e">4.5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic0a0dcfa5c2c49268190d94b335f065e_D20200701-20200930" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfOS0xNy0xLTEtMA_0c88b38b-0c15-4bc7-bb94-220c0232b3f9">1,250.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2debfff1a33140e6bcf02b809c593d24_D20200701-20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfOS0xOS0xLTEtMA_5108e970-bbc3-49b9-92dc-ba750b13196d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iadd8187a18d849f6b353e75cae0aabe8_D20200701-20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfOS0yMy0xLTEtMA_027a9c7f-0b9c-46ad-abad-1b71bc5f7ef3">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Issuance of common stock under stock option and stock purchase plans</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i030ce533f4cf4aa7852fbd17ed7ca720_D20200701-20200930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfMTAtNS0xLTEtMA_52550e6f-63a1-4feb-a8ac-25a0244d1849">0.1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i030ce533f4cf4aa7852fbd17ed7ca720_D20200701-20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfMTAtNy0xLTEtMA_bcfb4b50-df01-4453-81fa-d4040e3d0036">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i53ea969c6702421f9bfd2df9bfc3232a_D20200701-20200930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfMTAtOS0xLTEtMA_fadaa219-b132-4251-9626-8866439798bc">9.7</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if01d2b8c98a04ef2a7d2d2754bdfa47f_D20200701-20200930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfMTAtMTktMS0xLTA_bf95d674-ef81-4555-91e4-d94a26244722">9.7</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfMTAtMjMtMS0xLTA_b63fcf55-0d3a-46da-bbc3-438375372362">9.7</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Issuance of common stock under stock award plan</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i030ce533f4cf4aa7852fbd17ed7ca720_D20200701-20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfMTEtNS0xLTEtMA_601c7d68-7b14-4262-a931-45a44d6405aa">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i030ce533f4cf4aa7852fbd17ed7ca720_D20200701-20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfMTEtNy0xLTEtMA_040d10fc-beb8-4b82-a330-b81efe07bdfb">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i53ea969c6702421f9bfd2df9bfc3232a_D20200701-20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfMTEtOS0xLTEtMA_69ecb55c-02cc-4c3b-8a54-801b356cd0f2">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1499259d90804413b1e193e034d9561d_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfMTEtMTMtMS0xLTA_bca7de70-9ba8-421a-b581-56fbd7a936b9">2.3</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if01d2b8c98a04ef2a7d2d2754bdfa47f_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfMTEtMTktMS0xLTA_103457d7-afab-42d8-87a2-a984033c926a">2.3</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfMTEtMjMtMS0xLTA_cd132494-6137-4b1d-a946-42ee0c795afa">2.3</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Compensation related to share-based payments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i53ea969c6702421f9bfd2df9bfc3232a_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfMTItOS0xLTEtMA_ffc9456d-1cac-49ed-bd2c-854b6d8de1df">35.4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if01d2b8c98a04ef2a7d2d2754bdfa47f_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfMTItMTktMS0xLTA_814b0914-d220-4525-97ab-6e3a73d1e71e">35.4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfMTItMjMtMS0xLTA_382e99bf-8472-4f73-8598-b161f8acc38f">35.4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, September 30, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ib2edcb252dee41aaaa28a702b70a129d_I20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfMTQtMS0xLTEtMA_a19c6370-9019-4c25-85e2-28f175c92cef">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib2edcb252dee41aaaa28a702b70a129d_I20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfMTQtMy0xLTEtMA_985073c6-3dbf-4178-875a-d14e1a88b1ec">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="iccce420c57a74d908b28fffc261114e2_I20200930" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfMTQtNS0xLTEtMA_f8cd7fc8-6139-435a-80bd-26e99516b72b">177.7</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iccce420c57a74d908b28fffc261114e2_I20200930" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfMTQtNy0xLTEtMA_6900e499-8c1b-463e-87e9-47fa5ad6b9aa">0.1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i89ed42febbd445c9aa4432e778b1d593_I20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfMTQtOS0xLTEtMA_1e8e70ce-4f83-4bc5-b45a-003f2fb77c74">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia55221e7b3994df7ab08c27719d7d2f6_I20200930" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfMTQtMTEtMS0xLTA_1c011cf1-c49d-4315-88ea-5180c80f06b2">225.5</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i162af0e1b52e4fd99c7498e910ae472b_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfMTQtMTMtMS0xLTA_3ee35c60-6370-4f95-85f0-23a08612efd6">13,961.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="i138fbc630aee4346840425ef11fa647e_I20200930" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfMTQtMTUtMS0xLTA_6fb7709e-0c7e-4bfb-98c2-5ddae9331488">23.8</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i138fbc630aee4346840425ef11fa647e_I20200930" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfMTQtMTctMS0xLTA_28635fe5-5d3d-4c68-86fb-9cb449fd5708">2,977.1</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4b8029eaee38406ab0f2d229d09c0a8d_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfMTQtMTktMS0xLTA_afdef4d9-8d72-43a6-bc7c-dfc6e6681493">10,758.5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ibe8d84b11e994911b29ab0046e3c5436_I20200930" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfMTQtMjEtMS0xLTA_31eb7908-d264-4050-8d51-89dfa3222384">14.0</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfMTQtMjMtMS0xLTA_f6da9e4c-ea8a-4834-a1e5-09be76acd0a4">10,744.5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"></td></tr></table></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">See accompanying notes to these unaudited condensed consolidated financial statements.</span></div><div style="text-align:center;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_7">Table of Contents</a></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">CONDENSED CONSOLIDATED STATEMENTS OF EQUITY - (Continued)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(unaudited, in millions)</span></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:20.003%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:3.337%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.341%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:3.661%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.341%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:3.337%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.341%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:3.661%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.341%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:4.852%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.341%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.882%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.341%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:5.501%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.341%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:3.770%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.341%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:4.635%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.341%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.800%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.341%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.233%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.341%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:5.077%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Preferred stock</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Common stock</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additional<br/>paid-in<br/>capital</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated<br/>other<br/>comprehensive<br/>loss</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Retained<br/>earnings</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Treasury stock</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total<br/>Biogen Inc.<br/>shareholders&#8217;<br/>equity</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Noncontrolling<br/>interests</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total<br/>equity</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i8f84ef87973843b2b12c2e5314f58592_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfMi0xLTEtMS0w_061de4cd-546b-4721-8a7f-4becd60a462e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8f84ef87973843b2b12c2e5314f58592_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfMi0zLTEtMS0w_cb95b473-2669-47dc-b71d-56fae0345ea3">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i40f2711483814cfd80a3070c293601a6_I20191231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfMi01LTEtMS0w_8f7ca7cb-7161-4488-b19d-71c6a7a7980e">198.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i40f2711483814cfd80a3070c293601a6_I20191231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfMi03LTEtMS0w_50564d0f-2623-42be-b05e-4f16e8562fbe">0.1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia40deaebb7e14b0ea3390b0988aea61d_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfMi05LTEtMS0w_ce1d089f-11f0-4746-a104-536a3d89ebb3">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ifc05b78d934b474aac9922457936de4c_I20191231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfMi0xMS0xLTEtMA_7818977c-2eb4-480f-83ce-8fe7ad2559bd">135.2</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idb84688ac5bf43faa19f9f893a04a3e2_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfMi0xMy0xLTEtMA_a26adf14-36ed-44d0-b061-a6642a7e4ee9">16,455.4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="i03b2cef2a2324bfcbcfdea22ab154bd4_I20191231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfMi0xNS0xLTEtMA_fa2d3699-8952-4c14-8c4b-211e10862eca">23.8</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i03b2cef2a2324bfcbcfdea22ab154bd4_I20191231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfMi0xNy0xLTEtMA_baa52bfb-d971-4d4e-b39d-44b03902d7d5">2,977.1</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6344cb617db54fbaac18f0e555380783_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfMi0xOS0xLTEtMA_06ee166e-8428-49ac-b296-63b6ca5f7b8c">13,343.2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i2d1cce71297346cdaeeb9fb6370ccdeb_I20191231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfMi0yMS0xLTEtMA_fc09715e-4f5a-48c1-b690-b7d04b4abdf9">4.1</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i626282e786b7454d83b617e9e83963e6_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfMi0yMy0xLTEtMA_d01ba7d6-3fb9-49fc-adab-6497e45f2cd0">13,339.1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2d02929a942940478cbbc1b3ab3918a9_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfMy0xMy0xLTEtMA_618c69a2-6130-4821-9d73-72314150ea29">3,642.7</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iec296486afe44cb9bee6a9b9fec0c678_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfMy0xOS0xLTEtMA_430d4382-c521-458b-a66b-85bc9c90b84b">3,642.7</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic4379c94e8a84e548bdd2c9f5110296e_D20200101-20200930" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfMy0yMS0xLTEtMA_8add9e21-df36-4491-8471-2046823533b5">60.2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfMy0yMy0xLTEtMA_d9e27ff3-9ca2-42c5-b094-2e0dcd4a4ec9">3,702.9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other comprehensive income (loss), net of tax</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1faac185931341e591596ec3e5440d06_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfNC0xMS0xLTEtMA_8abc2cb5-91bf-465f-a206-55ce0943bdb5">90.3</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iec296486afe44cb9bee6a9b9fec0c678_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfNC0xOS0xLTEtMA_ff596b04-cbc9-4969-ba17-bde270969a0d">90.3</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic4379c94e8a84e548bdd2c9f5110296e_D20200101-20200930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfNC0yMS0xLTEtMA_13e8ec5a-05d4-4974-b61e-1306d5ecc96d">0.9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfNC0yMy0xLTEtMA_2109092c-3629-4cb4-b170-63cad45f1879">89.4</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Distribution to noncontrolling interest</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ic4379c94e8a84e548bdd2c9f5110296e_D20200101-20200930" decimals="-5" sign="-" name="biib:Noncontrollinginterestincreasedecreaseother" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfNS0yMS0xLTEtMA_b52b10fb-f1a0-4a9e-a38e-04739e7601c4">75.0</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="-5" sign="-" name="biib:Noncontrollinginterestincreasedecreaseother" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfNS0yMy0xLTEtMA_6fc48388-489e-442a-aa3b-882f5bc08117">75.0</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Capital contribution by noncontrolling interest</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">4.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">4.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Repurchase of common stock pursuant to the March 2019 Share Repurchase Program, at cost</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="i0319abba8ccc4f0fae4e9db75a3ba5d0_D20200101-20200930" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfNi0xNS0xLTEtMA_35d94101-7736-474c-99fd-7690851ebbb1">4.1</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0319abba8ccc4f0fae4e9db75a3ba5d0_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfNi0xNy0xLTEtMA_8418bef5-3a79-41e6-abf4-8c7c6a1c9255">1,279.1</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ibc0fb387460c4e6fb1f5dd03a311fb08_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfNi0xOS0xLTEtMA_3074a64c-dd19-456e-8ec2-78de99ef8570">1,279.1</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0af05fc8fe804816a86f91f4f77cdeac_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfNi0yMy0xLTEtMA_e30128a7-7039-45c8-85b9-5ea44a049a13">1,279.1</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Retirement of common stock pursuant to the March 2019 Share Repurchase Program, at cost</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="iae4ebdfec80c40fabeca031863dcc5c5_D20200101-20200930" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfNy01LTEtMS0w_ee7d44b0-ec4f-40cb-93b8-d8d676c0a1a0">4.1</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i14eda8fe33b0440e8f012764e73abe64_D20200101-20200930" decimals="-5" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfNy05LTEtMS0w_7e195d49-e135-4281-99ff-9c13cf69279f">71.0</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ibea5025954d8442193d586f92fe4b174_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfNy0xMy0xLTEtMA_9de11135-fb94-4cf4-ac21-4d9079bb1fac">1,208.1</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i0319abba8ccc4f0fae4e9db75a3ba5d0_D20200101-20200930" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfNy0xNS0xLTEtMA_6b3f4dff-1388-4fa4-8a6c-9c328db30d2b">4.1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0319abba8ccc4f0fae4e9db75a3ba5d0_D20200101-20200930" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfNy0xNy0xLTEtMA_01a76cf3-aac5-41c5-88e6-6575df33a261">1,279.1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0af05fc8fe804816a86f91f4f77cdeac_D20200101-20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfNy0yMy0xLTEtMA_eca31e0c-aad6-43e9-b3c1-e684c4324ee0">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Repurchase of common stock pursuant to the December 2019 Share Repurchase Program, at cost</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="i48e09b81ae6e4e27bb99b06fb90ade10_D20200101-20200930" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfOC0xNS0xLTEtMA_e01ff6c8-0f28-463f-8b3b-bfe99c5ccb40">16.7</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i48e09b81ae6e4e27bb99b06fb90ade10_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfOC0xNy0xLTEtMA_28b18403-19fb-4e99-bf86-4abe8e49db07">5,000.0</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i23f4570c321d470ea07b9b8126846754_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfOC0xOS0xLTEtMA_e32f3327-e0d3-4232-a300-3daf7552bf02">5,000.0</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="idb94151f567e4761811caaa2ee1c1349_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfOC0yMy0xLTEtMA_3d5cbc33-4437-4043-b403-4dff29ef16e2">5,000.0</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Retirement of common stock pursuant to the December 2019 Share Repurchase Program, at cost</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="i5ca2e1e65c424ac7afdfd951e4e64cea_D20200101-20200930" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfOS01LTEtMS0w_04e06170-56a0-4844-821f-51344355ac62">16.7</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia6f932e5c68d4df8ab6182786c4e7dff_D20200101-20200930" decimals="-5" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfOS05LTEtMS0w_d0213982-2aa5-4957-afde-ef70d70138d4">121.3</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ife6f9a28c7c64a109d345b6753d462fb_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfOS0xMy0xLTEtMA_6cd544ed-f4b2-4e7a-8c69-b4dd787bee34">4,878.7</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i48e09b81ae6e4e27bb99b06fb90ade10_D20200101-20200930" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfOS0xNS0xLTEtMA_50d7b9b9-7ae2-4e44-8613-82ba6d6fc713">16.7</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i48e09b81ae6e4e27bb99b06fb90ade10_D20200101-20200930" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfOS0xNy0xLTEtMA_c9ba8c9b-47e3-45cf-b650-4fe0231adba2">5,000.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idb94151f567e4761811caaa2ee1c1349_D20200101-20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfOS0yMy0xLTEtMA_ecb7732d-b576-4260-8858-289ade1eff66">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Issuance of common stock under stock option and stock purchase plans</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i2e65876e41494343960737c39bc5f276_D20200101-20200930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfMTAtNS0xLTEtMA_1ff54c23-7e60-4899-8bad-4e69e1d20808">0.2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2e65876e41494343960737c39bc5f276_D20200101-20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfMTAtNy0xLTEtMA_0e15d97e-4644-4bb6-8d26-0e6957c89cd7">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i861bb59946a84718b6c99600a2e9b0e5_D20200101-20200930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfMTAtOS0xLTEtMA_c8b37786-2103-4684-bc91-7aea7a20fab7">38.8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iec296486afe44cb9bee6a9b9fec0c678_D20200101-20200930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfMTAtMTktMS0xLTA_841c0bc5-494b-4356-b793-0e0eec32b9bd">38.8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfMTAtMjMtMS0xLTA_529b1a62-5093-4b56-be32-878ff665ca44">38.8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Issuance of common stock under stock award plan</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i2e65876e41494343960737c39bc5f276_D20200101-20200930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfMTEtNS0xLTEtMA_9e7f9c3a-97c2-4ae9-b138-6602c5691485">0.3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2e65876e41494343960737c39bc5f276_D20200101-20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfMTEtNy0xLTEtMA_5e51e6ac-c611-4d31-a761-b266ae22c964">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i861bb59946a84718b6c99600a2e9b0e5_D20200101-20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfMTEtOS0xLTEtMA_2375cc8e-3157-473a-88c3-249f6db46126">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i2d02929a942940478cbbc1b3ab3918a9_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfMTEtMTMtMS0xLTA_bd0f1c42-20b6-4d3e-936f-e141c234b399">50.3</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iec296486afe44cb9bee6a9b9fec0c678_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfMTEtMTktMS0xLTA_28c87073-b2de-4e69-8b6b-3e02476a822a">50.3</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfMTEtMjMtMS0xLTA_4bb033db-3ad7-4a9e-a3a5-a200d61d78a8">50.3</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Compensation related to share-based payments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i861bb59946a84718b6c99600a2e9b0e5_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfMTItOS0xLTEtMA_847f368f-0f0a-4e44-9084-7cd0e77913ed">154.2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iec296486afe44cb9bee6a9b9fec0c678_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfMTItMTktMS0xLTA_8a9cdcb9-58e3-45e8-b478-9056ed955fe5">154.2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfMTItMjMtMS0xLTA_ef5a46bc-1587-44c2-87f6-7b37dae3fb01">154.2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i861bb59946a84718b6c99600a2e9b0e5_D20200101-20200930" decimals="-5" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfMTMtOS0xLTEtMA_51ca5c5d-5ed3-4677-8d73-c9f24a8b17e4">0.7</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2d02929a942940478cbbc1b3ab3918a9_D20200101-20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfMTMtMTMtMS0xLTA_a90f282b-c82f-4a71-bd7b-bb539c7afece">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iec296486afe44cb9bee6a9b9fec0c678_D20200101-20200930" decimals="-5" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfMTMtMTktMS0xLTA_27174f12-e6f6-4a8d-ba0c-4c76cc4bd3a9">0.7</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="-5" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfMTMtMjMtMS0xLTA_306ecf90-2d7d-4cd5-9f27-7a0acc88304c">0.7</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, September 30, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ib2edcb252dee41aaaa28a702b70a129d_I20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfMTQtMS0xLTEtMA_65ff9e1e-ee9d-447e-b289-d839b69cf1e8">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib2edcb252dee41aaaa28a702b70a129d_I20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfMTQtMy0xLTEtMA_c2a1e93f-e071-445b-b25e-3013e626fc60">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="iccce420c57a74d908b28fffc261114e2_I20200930" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfMTQtNS0xLTEtMA_df4a5da2-a67b-4bf3-9949-e017add096ef">177.7</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iccce420c57a74d908b28fffc261114e2_I20200930" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfMTQtNy0xLTEtMA_2eebcb11-7a49-4163-9b5c-f62dbc7a21e3">0.1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i89ed42febbd445c9aa4432e778b1d593_I20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfMTQtOS0xLTEtMA_3aaecedc-2fba-4651-a331-edf0d3f49794">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia55221e7b3994df7ab08c27719d7d2f6_I20200930" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfMTQtMTEtMS0xLTA_4134fdf1-d32e-4093-be6a-489ea936c9a7">225.5</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i162af0e1b52e4fd99c7498e910ae472b_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfMTQtMTMtMS0xLTA_8462e267-f854-455d-9335-f9f41451c8b6">13,961.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="i138fbc630aee4346840425ef11fa647e_I20200930" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfMTQtMTUtMS0xLTA_ccb07589-b9c1-4b9b-adfa-5bded79d4f1d">23.8</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i138fbc630aee4346840425ef11fa647e_I20200930" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfMTQtMTctMS0xLTA_f9e365ab-da39-418d-9a12-0ddc61bbdf64">2,977.1</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4b8029eaee38406ab0f2d229d09c0a8d_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfMTQtMTktMS0xLTA_791e7993-e53a-470c-92bd-5df79566256e">10,758.5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ibe8d84b11e994911b29ab0046e3c5436_I20200930" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfMTQtMjEtMS0xLTA_6a393f2d-28ea-477c-96c7-112de1b11e18">14.0</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#2573ba;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfMTQtMjMtMS0xLTA_ee11b666-7281-4234-ac81-9d0145f98568">10,744.5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td></tr></table></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">See accompanying notes to these unaudited condensed consolidated financial statements.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_7">Table of Contents</a></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">CONDENSED CONSOLIDATED STATEMENTS OF EQUITY - (Continued)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(unaudited, in millions)</span></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.458%;"><tr><td style="width:1.0%;"></td><td style="width:19.465%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:3.361%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.344%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:3.578%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.344%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:3.578%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.344%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:3.578%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.344%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:4.558%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.344%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.169%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.344%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:5.755%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.344%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:3.796%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.344%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:5.537%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.344%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.408%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.344%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.061%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.344%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:5.872%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Preferred stock</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Common stock</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additional<br/>paid-in<br/>capital</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated<br/>other<br/>comprehensive<br/>loss</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Retained<br/>earnings</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Treasury stock</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total<br/>Biogen Inc.<br/>shareholders&#8217;<br/>equity</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Noncontrolling<br/>interests</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total<br/>equity</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, June 30, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i99fbd0519e8d401bb929b503f3ecea4e_I20190630" decimals="-5" format="ixt:zerodash" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJjMjAzMjNmMmFkNzRiYjFhNjM0NzhhZjUwYWFjYTdjL3RhYmxlcmFuZ2U6YmMyMDMyM2YyYWQ3NGJiMWE2MzQ3OGFmNTBhYWNhN2NfMi0xLTEtMS0w_7b8c73de-2f11-4729-a1a9-dc55f815bc5b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i99fbd0519e8d401bb929b503f3ecea4e_I20190630" decimals="-5" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJjMjAzMjNmMmFkNzRiYjFhNjM0NzhhZjUwYWFjYTdjL3RhYmxlcmFuZ2U6YmMyMDMyM2YyYWQ3NGJiMWE2MzQ3OGFmNTBhYWNhN2NfMi0zLTEtMS0w_3a5c023f-627e-42d2-93bd-86c7d6d07c27">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i9843b0258d7a4100af10e14048f0aa5c_I20190630" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJjMjAzMjNmMmFkNzRiYjFhNjM0NzhhZjUwYWFjYTdjL3RhYmxlcmFuZ2U6YmMyMDMyM2YyYWQ3NGJiMWE2MzQ3OGFmNTBhYWNhN2NfMi01LTEtMS0w_e5eab6e3-3a25-4f02-922e-27803b244259">208.6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9843b0258d7a4100af10e14048f0aa5c_I20190630" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJjMjAzMjNmMmFkNzRiYjFhNjM0NzhhZjUwYWFjYTdjL3RhYmxlcmFuZ2U6YmMyMDMyM2YyYWQ3NGJiMWE2MzQ3OGFmNTBhYWNhN2NfMi03LTEtMS0w_6444c42d-aee8-4b41-ba81-d371c0342457">0.1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0376412c3eff4647ac527a583e1fea9e_I20190630" decimals="-5" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJjMjAzMjNmMmFkNzRiYjFhNjM0NzhhZjUwYWFjYTdjL3RhYmxlcmFuZ2U6YmMyMDMyM2YyYWQ3NGJiMWE2MzQ3OGFmNTBhYWNhN2NfMi05LTEtMS0w_edb81842-85e0-499c-9735-1da4b0f21b99">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1e4817878dd24efa84f78403542ee2fa_I20190630" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJjMjAzMjNmMmFkNzRiYjFhNjM0NzhhZjUwYWFjYTdjL3RhYmxlcmFuZ2U6YmMyMDMyM2YyYWQ3NGJiMWE2MzQ3OGFmNTBhYWNhN2NfMi0xMS0xLTEtMA_f99c2600-ab3a-42cb-9102-4814ccf4f272">252.9</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ife3567f724fc4eafb760a986851063d1_I20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJjMjAzMjNmMmFkNzRiYjFhNjM0NzhhZjUwYWFjYTdjL3RhYmxlcmFuZ2U6YmMyMDMyM2YyYWQ3NGJiMWE2MzQ3OGFmNTBhYWNhN2NfMi0xMy0xLTEtMA_c1506582-ef3d-4253-a9f7-0cd29f7bea7b">16,182.8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="if307586287e044beb16134d1cd640d29_I20190630" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJjMjAzMjNmMmFkNzRiYjFhNjM0NzhhZjUwYWFjYTdjL3RhYmxlcmFuZ2U6YmMyMDMyM2YyYWQ3NGJiMWE2MzQ3OGFmNTBhYWNhN2NfMi0xNS0xLTEtMA_58f37c01-b0ad-4407-953e-c922ac6d93f8">23.8</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if307586287e044beb16134d1cd640d29_I20190630" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJjMjAzMjNmMmFkNzRiYjFhNjM0NzhhZjUwYWFjYTdjL3RhYmxlcmFuZ2U6YmMyMDMyM2YyYWQ3NGJiMWE2MzQ3OGFmNTBhYWNhN2NfMi0xNy0xLTEtMA_ab17e5ac-9ed2-4898-8bab-151f809639fa">2,977.1</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i396ceaa32ede4bd18fc264a28d5483b0_I20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJjMjAzMjNmMmFkNzRiYjFhNjM0NzhhZjUwYWFjYTdjL3RhYmxlcmFuZ2U6YmMyMDMyM2YyYWQ3NGJiMWE2MzQ3OGFmNTBhYWNhN2NfMi0xOS0xLTEtMA_dd3903f4-45a9-4a74-a161-0a60f29eee23">12,952.9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0ec1a9946b9d42abaed7abd2237b7dbd_I20190630" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJjMjAzMjNmMmFkNzRiYjFhNjM0NzhhZjUwYWFjYTdjL3RhYmxlcmFuZ2U6YmMyMDMyM2YyYWQ3NGJiMWE2MzQ3OGFmNTBhYWNhN2NfMi0yMS0xLTEtMA_6c71a13e-4896-433b-a55e-f6142fa989bb">4.1</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i94c6f45fdfc542388521216b8e80983e_I20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJjMjAzMjNmMmFkNzRiYjFhNjM0NzhhZjUwYWFjYTdjL3RhYmxlcmFuZ2U6YmMyMDMyM2YyYWQ3NGJiMWE2MzQ3OGFmNTBhYWNhN2NfMi0yMy0xLTEtMA_24d81398-d434-4df2-a276-945be7e13fa9">12,948.8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib515d9bcec6948d184e2f6536574cb55_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJjMjAzMjNmMmFkNzRiYjFhNjM0NzhhZjUwYWFjYTdjL3RhYmxlcmFuZ2U6YmMyMDMyM2YyYWQ3NGJiMWE2MzQ3OGFmNTBhYWNhN2NfMy0xMy0xLTEtMA_aa7aae88-5c71-4532-9061-ca1679d32a2a">1,545.9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i58b6be5e29354a3f95dc35f74e0eb46d_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJjMjAzMjNmMmFkNzRiYjFhNjM0NzhhZjUwYWFjYTdjL3RhYmxlcmFuZ2U6YmMyMDMyM2YyYWQ3NGJiMWE2MzQ3OGFmNTBhYWNhN2NfMy0xOS0xLTEtMA_44025c4b-236c-4084-8de0-ae6bd7d45211">1,545.9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJjMjAzMjNmMmFkNzRiYjFhNjM0NzhhZjUwYWFjYTdjL3RhYmxlcmFuZ2U6YmMyMDMyM2YyYWQ3NGJiMWE2MzQ3OGFmNTBhYWNhN2NfMy0yMy0xLTEtMA_504e12cd-1396-4686-aa26-71f53d3ec790">1,545.9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other comprehensive income (loss), net of tax</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iae71bc1953744eebba86f3934124b00b_D20190701-20190930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJjMjAzMjNmMmFkNzRiYjFhNjM0NzhhZjUwYWFjYTdjL3RhYmxlcmFuZ2U6YmMyMDMyM2YyYWQ3NGJiMWE2MzQ3OGFmNTBhYWNhN2NfNC0xMS0xLTEtMA_5e9a5607-6170-4e6d-a206-59fdb759769f">160.6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i58b6be5e29354a3f95dc35f74e0eb46d_D20190701-20190930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJjMjAzMjNmMmFkNzRiYjFhNjM0NzhhZjUwYWFjYTdjL3RhYmxlcmFuZ2U6YmMyMDMyM2YyYWQ3NGJiMWE2MzQ3OGFmNTBhYWNhN2NfNC0xOS0xLTEtMA_72ded9d0-9e19-4ffc-a583-763abbac43e9">160.6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i37ac27ae2b114acebcefcb550c5cda84_D20190701-20190930" decimals="-5" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJjMjAzMjNmMmFkNzRiYjFhNjM0NzhhZjUwYWFjYTdjL3RhYmxlcmFuZ2U6YmMyMDMyM2YyYWQ3NGJiMWE2MzQ3OGFmNTBhYWNhN2NfNC0yMS0xLTEtMA_434c0d9a-7d05-49c1-b240-78d986da4287">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJjMjAzMjNmMmFkNzRiYjFhNjM0NzhhZjUwYWFjYTdjL3RhYmxlcmFuZ2U6YmMyMDMyM2YyYWQ3NGJiMWE2MzQ3OGFmNTBhYWNhN2NfNC0yMy0xLTEtMA_69a25fa1-b6a7-4617-b185-de025b999158">160.6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Repurchase of common stock pursuant to the March 2019 Share Repurchase Program, at cost</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="ibcf7b9d6ba6b4eddabd32ecb80c018cb_D20190701-20190930" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJjMjAzMjNmMmFkNzRiYjFhNjM0NzhhZjUwYWFjYTdjL3RhYmxlcmFuZ2U6YmMyMDMyM2YyYWQ3NGJiMWE2MzQ3OGFmNTBhYWNhN2NfNi0xNS0xLTEtMA_3cff13fc-3a1e-4703-8afd-97688aa434d5">3.1</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ibcf7b9d6ba6b4eddabd32ecb80c018cb_D20190701-20190930" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJjMjAzMjNmMmFkNzRiYjFhNjM0NzhhZjUwYWFjYTdjL3RhYmxlcmFuZ2U6YmMyMDMyM2YyYWQ3NGJiMWE2MzQ3OGFmNTBhYWNhN2NfNi0xNy0xLTEtMA_d100edf9-a6b4-4ef4-b67c-09f75a61aeb2">717.9</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i86c3b6289b2b4f52a9c054d27fb6a5b9_D20190701-20190930" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJjMjAzMjNmMmFkNzRiYjFhNjM0NzhhZjUwYWFjYTdjL3RhYmxlcmFuZ2U6YmMyMDMyM2YyYWQ3NGJiMWE2MzQ3OGFmNTBhYWNhN2NfNi0xOS0xLTEtMA_336994a4-476c-4010-a655-70898bb10cab">717.9</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if78608284adf428b9b151aa288371376_D20190701-20190930" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJjMjAzMjNmMmFkNzRiYjFhNjM0NzhhZjUwYWFjYTdjL3RhYmxlcmFuZ2U6YmMyMDMyM2YyYWQ3NGJiMWE2MzQ3OGFmNTBhYWNhN2NfNi0yMy0xLTEtMA_644913e9-2677-43f9-b09c-d99b3c6e8d97">717.9</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Retirement of common stock pursuant to the March 2019 Share Repurchase Program, at cost</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="i859bf4d9f138495caa518c457b42a8a6_D20190701-20190930" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJjMjAzMjNmMmFkNzRiYjFhNjM0NzhhZjUwYWFjYTdjL3RhYmxlcmFuZ2U6YmMyMDMyM2YyYWQ3NGJiMWE2MzQ3OGFmNTBhYWNhN2NfNy01LTEtMS0w_8ae5ffc6-bcf3-4d87-a4ee-a09000cf0332">3.1</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ic82a5a18c46c4de99def553116869989_D20190701-20190930" decimals="-5" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJjMjAzMjNmMmFkNzRiYjFhNjM0NzhhZjUwYWFjYTdjL3RhYmxlcmFuZ2U6YmMyMDMyM2YyYWQ3NGJiMWE2MzQ3OGFmNTBhYWNhN2NfNy05LTEtMS0w_adc254aa-c41e-4a17-a0e8-68980eb55d96">55.1</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia9881e9f358c4093a91f49acc663d493_D20190701-20190930" decimals="-5" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJjMjAzMjNmMmFkNzRiYjFhNjM0NzhhZjUwYWFjYTdjL3RhYmxlcmFuZ2U6YmMyMDMyM2YyYWQ3NGJiMWE2MzQ3OGFmNTBhYWNhN2NfNy0xMy0xLTEtMA_82aa8e90-c3e8-4f03-9643-000f2ae01ea0">662.8</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ibcf7b9d6ba6b4eddabd32ecb80c018cb_D20190701-20190930" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJjMjAzMjNmMmFkNzRiYjFhNjM0NzhhZjUwYWFjYTdjL3RhYmxlcmFuZ2U6YmMyMDMyM2YyYWQ3NGJiMWE2MzQ3OGFmNTBhYWNhN2NfNy0xNS0xLTEtMA_ebc00cba-971c-4f67-916f-83d8b413256b">3.1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibcf7b9d6ba6b4eddabd32ecb80c018cb_D20190701-20190930" decimals="-5" sign="-" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJjMjAzMjNmMmFkNzRiYjFhNjM0NzhhZjUwYWFjYTdjL3RhYmxlcmFuZ2U6YmMyMDMyM2YyYWQ3NGJiMWE2MzQ3OGFmNTBhYWNhN2NfNy0xNy0xLTEtMA_bca1b98a-5ac8-4f44-af1d-c28d895b3503">717.9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Issuance of common stock under stock option and stock purchase plans</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i45b746c96de74debaf178d86af176ed7_D20190701-20190930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJjMjAzMjNmMmFkNzRiYjFhNjM0NzhhZjUwYWFjYTdjL3RhYmxlcmFuZ2U6YmMyMDMyM2YyYWQ3NGJiMWE2MzQ3OGFmNTBhYWNhN2NfMTAtNS0xLTEtMA_b8f4de43-21e4-47de-8888-3b69cfffa6d9">0.1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i45b746c96de74debaf178d86af176ed7_D20190701-20190930" decimals="-5" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJjMjAzMjNmMmFkNzRiYjFhNjM0NzhhZjUwYWFjYTdjL3RhYmxlcmFuZ2U6YmMyMDMyM2YyYWQ3NGJiMWE2MzQ3OGFmNTBhYWNhN2NfMTAtNy0xLTEtMA_c01c27bd-547e-4810-8075-7f7e8d43a5df">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic161674d27484a338894e49a73880c69_D20190701-20190930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJjMjAzMjNmMmFkNzRiYjFhNjM0NzhhZjUwYWFjYTdjL3RhYmxlcmFuZ2U6YmMyMDMyM2YyYWQ3NGJiMWE2MzQ3OGFmNTBhYWNhN2NfMTAtOS0xLTEtMA_7b83f58a-6262-4725-a4f7-c8061787df83">7.3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i58b6be5e29354a3f95dc35f74e0eb46d_D20190701-20190930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJjMjAzMjNmMmFkNzRiYjFhNjM0NzhhZjUwYWFjYTdjL3RhYmxlcmFuZ2U6YmMyMDMyM2YyYWQ3NGJiMWE2MzQ3OGFmNTBhYWNhN2NfMTAtMTktMS0xLTA_57400dc9-d144-4539-af21-8b239ca96139">7.3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJjMjAzMjNmMmFkNzRiYjFhNjM0NzhhZjUwYWFjYTdjL3RhYmxlcmFuZ2U6YmMyMDMyM2YyYWQ3NGJiMWE2MzQ3OGFmNTBhYWNhN2NfMTAtMjMtMS0xLTA_b96af225-0ad5-4a78-bc18-89eb32b85352">7.3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Issuance of common stock under stock award plan</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i45b746c96de74debaf178d86af176ed7_D20190701-20190930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJjMjAzMjNmMmFkNzRiYjFhNjM0NzhhZjUwYWFjYTdjL3RhYmxlcmFuZ2U6YmMyMDMyM2YyYWQ3NGJiMWE2MzQ3OGFmNTBhYWNhN2NfMTEtNS0xLTEtMA_c8eb942e-260c-4cdc-bb3a-2e78fad0e996">0.1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i45b746c96de74debaf178d86af176ed7_D20190701-20190930" decimals="-5" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJjMjAzMjNmMmFkNzRiYjFhNjM0NzhhZjUwYWFjYTdjL3RhYmxlcmFuZ2U6YmMyMDMyM2YyYWQ3NGJiMWE2MzQ3OGFmNTBhYWNhN2NfMTEtNy0xLTEtMA_88c99cd2-5bb9-4ee8-8c5e-8b7463fed983">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic161674d27484a338894e49a73880c69_D20190701-20190930" decimals="-5" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJjMjAzMjNmMmFkNzRiYjFhNjM0NzhhZjUwYWFjYTdjL3RhYmxlcmFuZ2U6YmMyMDMyM2YyYWQ3NGJiMWE2MzQ3OGFmNTBhYWNhN2NfMTEtOS0xLTEtMA_1b6db0e2-3374-428e-bdd4-93296e10fcc7">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib515d9bcec6948d184e2f6536574cb55_D20190701-20190930" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJjMjAzMjNmMmFkNzRiYjFhNjM0NzhhZjUwYWFjYTdjL3RhYmxlcmFuZ2U6YmMyMDMyM2YyYWQ3NGJiMWE2MzQ3OGFmNTBhYWNhN2NfMTEtMTMtMS0xLTA_28372c30-5836-410d-98a4-fae35bca3d86">0.7</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i58b6be5e29354a3f95dc35f74e0eb46d_D20190701-20190930" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJjMjAzMjNmMmFkNzRiYjFhNjM0NzhhZjUwYWFjYTdjL3RhYmxlcmFuZ2U6YmMyMDMyM2YyYWQ3NGJiMWE2MzQ3OGFmNTBhYWNhN2NfMTEtMTktMS0xLTA_9006237a-585a-46e9-b5fa-ae995a92e276">0.7</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJjMjAzMjNmMmFkNzRiYjFhNjM0NzhhZjUwYWFjYTdjL3RhYmxlcmFuZ2U6YmMyMDMyM2YyYWQ3NGJiMWE2MzQ3OGFmNTBhYWNhN2NfMTEtMjMtMS0xLTA_48fc3e7c-60cf-46dd-b114-5dd4d2f3ae1a">0.7</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Compensation related to share-based payments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic161674d27484a338894e49a73880c69_D20190701-20190930" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJjMjAzMjNmMmFkNzRiYjFhNjM0NzhhZjUwYWFjYTdjL3RhYmxlcmFuZ2U6YmMyMDMyM2YyYWQ3NGJiMWE2MzQ3OGFmNTBhYWNhN2NfMTItOS0xLTEtMA_9f3ca33a-15cd-4774-a625-71abff4b8c4a">47.8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib515d9bcec6948d184e2f6536574cb55_D20190701-20190930" decimals="-5" format="ixt:zerodash" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJjMjAzMjNmMmFkNzRiYjFhNjM0NzhhZjUwYWFjYTdjL3RhYmxlcmFuZ2U6YmMyMDMyM2YyYWQ3NGJiMWE2MzQ3OGFmNTBhYWNhN2NfMTItMTMtMS0xLTA_ea16e4b7-4d1d-428e-a84b-81879f33bf00">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i58b6be5e29354a3f95dc35f74e0eb46d_D20190701-20190930" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJjMjAzMjNmMmFkNzRiYjFhNjM0NzhhZjUwYWFjYTdjL3RhYmxlcmFuZ2U6YmMyMDMyM2YyYWQ3NGJiMWE2MzQ3OGFmNTBhYWNhN2NfMTItMTktMS0xLTA_01979718-cef3-4452-a7ba-8baa1dbb1ad8">47.8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJjMjAzMjNmMmFkNzRiYjFhNjM0NzhhZjUwYWFjYTdjL3RhYmxlcmFuZ2U6YmMyMDMyM2YyYWQ3NGJiMWE2MzQ3OGFmNTBhYWNhN2NfMTItMjMtMS0xLTA_4e3cd75b-317b-466d-909e-ed1644540d47">47.8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, September 30, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i30714cf43346412e9fea73f7251cf213_I20190930" decimals="-5" format="ixt:zerodash" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJjMjAzMjNmMmFkNzRiYjFhNjM0NzhhZjUwYWFjYTdjL3RhYmxlcmFuZ2U6YmMyMDMyM2YyYWQ3NGJiMWE2MzQ3OGFmNTBhYWNhN2NfMTMtMS0xLTEtMA_739315c1-adcb-444f-a907-51ba6275b53a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i30714cf43346412e9fea73f7251cf213_I20190930" decimals="-5" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJjMjAzMjNmMmFkNzRiYjFhNjM0NzhhZjUwYWFjYTdjL3RhYmxlcmFuZ2U6YmMyMDMyM2YyYWQ3NGJiMWE2MzQ3OGFmNTBhYWNhN2NfMTMtMy0xLTEtMA_2692b341-4c50-48bc-9dfd-6da26e63244c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="iccee1e1d95af43b9873f3228bed22351_I20190930" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJjMjAzMjNmMmFkNzRiYjFhNjM0NzhhZjUwYWFjYTdjL3RhYmxlcmFuZ2U6YmMyMDMyM2YyYWQ3NGJiMWE2MzQ3OGFmNTBhYWNhN2NfMTMtNS0xLTEtMA_51177be1-f3c8-4c67-8dcd-7f4bf65e2421">205.7</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iccee1e1d95af43b9873f3228bed22351_I20190930" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJjMjAzMjNmMmFkNzRiYjFhNjM0NzhhZjUwYWFjYTdjL3RhYmxlcmFuZ2U6YmMyMDMyM2YyYWQ3NGJiMWE2MzQ3OGFmNTBhYWNhN2NfMTMtNy0xLTEtMA_547295a1-698f-449f-ad76-7ce4c56e713f">0.1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i404c8ff0534c49f7a853054388cf47e7_I20190930" decimals="-5" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJjMjAzMjNmMmFkNzRiYjFhNjM0NzhhZjUwYWFjYTdjL3RhYmxlcmFuZ2U6YmMyMDMyM2YyYWQ3NGJiMWE2MzQ3OGFmNTBhYWNhN2NfMTMtOS0xLTEtMA_890f003d-84c9-4f76-9cf5-bd5669d2d574">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie09a86c05b2d4dd68ea12c27ea7e151a_I20190930" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJjMjAzMjNmMmFkNzRiYjFhNjM0NzhhZjUwYWFjYTdjL3RhYmxlcmFuZ2U6YmMyMDMyM2YyYWQ3NGJiMWE2MzQ3OGFmNTBhYWNhN2NfMTMtMTEtMS0xLTA_d2d3387e-85cc-451f-8370-2adbc1e8e39c">92.3</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idcbcecd74e024473bdd870830b88f96c_I20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJjMjAzMjNmMmFkNzRiYjFhNjM0NzhhZjUwYWFjYTdjL3RhYmxlcmFuZ2U6YmMyMDMyM2YyYWQ3NGJiMWE2MzQ3OGFmNTBhYWNhN2NfMTMtMTMtMS0xLTA_38804bc0-6138-4741-a2a4-f9f4c9840591">17,065.2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="i7c8172c9fe75493ca901d5f05ecfa29d_I20190930" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJjMjAzMjNmMmFkNzRiYjFhNjM0NzhhZjUwYWFjYTdjL3RhYmxlcmFuZ2U6YmMyMDMyM2YyYWQ3NGJiMWE2MzQ3OGFmNTBhYWNhN2NfMTMtMTUtMS0xLTA_79704015-b767-4f01-952b-10c22417c9d7">23.8</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i7c8172c9fe75493ca901d5f05ecfa29d_I20190930" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJjMjAzMjNmMmFkNzRiYjFhNjM0NzhhZjUwYWFjYTdjL3RhYmxlcmFuZ2U6YmMyMDMyM2YyYWQ3NGJiMWE2MzQ3OGFmNTBhYWNhN2NfMTMtMTctMS0xLTA_78d12766-56fc-48db-97ff-c2f87f08dec2">2,977.1</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic9f978f94b6e4038af9fb1fcaaf85dee_I20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJjMjAzMjNmMmFkNzRiYjFhNjM0NzhhZjUwYWFjYTdjL3RhYmxlcmFuZ2U6YmMyMDMyM2YyYWQ3NGJiMWE2MzQ3OGFmNTBhYWNhN2NfMTMtMTktMS0xLTA_9a5c36a0-ccf2-4185-b169-600f8c637d87">13,995.9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie2305062812f448bad777c7ba71b2552_I20190930" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJjMjAzMjNmMmFkNzRiYjFhNjM0NzhhZjUwYWFjYTdjL3RhYmxlcmFuZ2U6YmMyMDMyM2YyYWQ3NGJiMWE2MzQ3OGFmNTBhYWNhN2NfMTMtMjEtMS0xLTA_4048cc4f-9e2b-47ec-a459-ce81d9996e26">4.1</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ied38b94db9a74750b51c6e8392d4c5bf_I20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJjMjAzMjNmMmFkNzRiYjFhNjM0NzhhZjUwYWFjYTdjL3RhYmxlcmFuZ2U6YmMyMDMyM2YyYWQ3NGJiMWE2MzQ3OGFmNTBhYWNhN2NfMTMtMjMtMS0xLTA_4a66477d-f60d-4d18-8c57-2693b2b818e2">13,991.8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td></tr></table></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">See accompanying notes to these unaudited condensed consolidated financial statements.</span></div><div style="text-align:center;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_7">Table of Contents</a></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">CONDENSED CONSOLIDATED STATEMENTS OF EQUITY - (Continued)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(unaudited, in millions)</span></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:19.679%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:3.337%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.341%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:3.553%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.341%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:3.337%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.341%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:3.770%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.341%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:4.527%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.341%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.125%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.341%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.042%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.341%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:3.770%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.341%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:4.960%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.341%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.125%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.341%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.016%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.341%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:5.508%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Preferred stock</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Common stock</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additional<br/>paid-in<br/>capital</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated<br/>other<br/>comprehensive<br/>loss</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Retained<br/>earnings</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Treasury stock</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total<br/>Biogen Inc.<br/>shareholders&#8217;<br/>equity</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Noncontrolling<br/>interests</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total<br/>equity</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:7.5pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, December 31, 2018</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i88af2b9941924871abe610dc3e71811b_I20181231" decimals="-5" format="ixt:zerodash" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfMi0xLTEtMS0w_eb2c9145-e091-4a26-8467-c445df786f5d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i88af2b9941924871abe610dc3e71811b_I20181231" decimals="-5" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfMi0zLTEtMS0w_7568e86f-457b-454d-8755-8caf8a6f94e4">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i1e15f7e0305245ab8755ada973550435_I20181231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfMi01LTEtMS0w_0b5dd9cb-0e36-42f8-b071-62d85b966d78">221.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1e15f7e0305245ab8755ada973550435_I20181231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfMi03LTEtMS0w_bedfb757-7840-42d7-870b-fb16c8139c06">0.1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5b39457257df40c0a44aba71b396d988_I20181231" decimals="-5" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfMi05LTEtMS0w_4389b4c7-ac80-43e2-8d16-6f77efbf4e24">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i615f50b48b1947daafcc18ec87768baa_I20181231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfMi0xMS0xLTEtMA_4e957a86-a549-48f5-85f5-4caad461e2c2">240.4</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i691108e26c8d4acfa6452b2cc1994da1_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfMi0xMy0xLTEtMA_d202bf9b-5e5e-40cf-a341-1e3bbbf3eca9">16,257.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="ia2c93178a13f4173b8c722d0ace0c1e7_I20181231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfMi0xNS0xLTEtMA_8667abf5-5f64-4a0e-8cad-1da4bb1e4bdd">23.8</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia2c93178a13f4173b8c722d0ace0c1e7_I20181231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfMi0xNy0xLTEtMA_05f14023-4d70-48f5-a7ad-e88d77820b53">2,977.1</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i474ef61edf8a4e488fdbe0a7144141d1_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfMi0xOS0xLTEtMA_532d8ba9-10cc-4994-8ebe-b02f18bb6a40">13,039.6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8445ab6e25754f87a6ebbd9df3b89ca0_I20181231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfMi0yMS0xLTEtMA_a730b4e9-87a3-49b3-adf1-7538a925c833">8.0</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib98dd789f3514452acc95f9b041d2a7e_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfMi0yMy0xLTEtMA_59f73353-f09c-405b-9390-a98de6be2f62">13,031.6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib53a358e088b4743a76a8141b6a1c193_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfMy0xMy0xLTEtMA_2d9cf740-19aa-466f-8f8d-65ad5002b0cd">4,448.8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0efa62d44ea047f48a850ba3d5919a87_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfMy0xOS0xLTEtMA_3d9f7df2-ad61-4ce8-b7e1-906e9e1ff133">4,448.8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfMy0yMy0xLTEtMA_512e0ac6-4a08-4b0e-bda7-002e7b4ecfd1">4,448.8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other comprehensive income (loss), net of tax</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7182b1df2b374d208162f601fa679959_D20190101-20190930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfNC0xMS0xLTEtMA_1f6d51a7-8437-474f-84f7-8d879a9ae985">148.1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0efa62d44ea047f48a850ba3d5919a87_D20190101-20190930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfNC0xOS0xLTEtMA_57af066a-2126-4c63-999d-64a72c4ae2cb">148.1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i7a7633cfe36348a79a7d0f41758bd6ab_D20190101-20190930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfNC0yMS0xLTEtMA_f383d3d5-e1e4-4d56-bf1d-f283974f7b03">0.4</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfNC0yMy0xLTEtMA_44a1d59e-87b2-43b1-a3d4-941ddefe6e3f">147.7</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Capital contribution by noncontrolling interest</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0efa62d44ea047f48a850ba3d5919a87_D20190101-20190930" decimals="-5" format="ixt:zerodash" name="biib:Noncontrollinginterestincreasedecreaseother" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfNS0xOS0xLTEtMA_ef1c774f-c5a0-42a8-89af-6312e4bcbed8">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7a7633cfe36348a79a7d0f41758bd6ab_D20190101-20190930" decimals="-5" name="biib:Noncontrollinginterestincreasedecreaseother" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfNS0yMS0xLTEtMA_37261d1e-7862-4e9d-9cd4-48bb1da66709">4.3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="-5" name="biib:Noncontrollinginterestincreasedecreaseother" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfNS0yMy0xLTEtMA_e18bd81b-7725-40b2-ad84-ef46d5b5936c">4.3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Repurchase of common stock pursuant to the March 2019 Share Repurchase Program, at cost</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="i7289c8815e434ac989c2d260f35da03d_D20190101-20190930" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfNi0xNS0xLTEtMA_8dd8d142-270b-4134-96d9-8ab9ff52f67e">7.0</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i7289c8815e434ac989c2d260f35da03d_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfNi0xNy0xLTEtMA_ff4972b7-1aaa-4e1d-92b7-92df5e624e90">1,627.8</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie8e1e308da1c4ce6aad01a86613ea938_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfNi0xOS0xLTEtMA_225a52d1-0352-4f76-aa08-d46ef8d4d3ca">1,627.8</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i36fedb8b45764716a0240c105927c6d7_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfNi0yMy0xLTEtMA_c86bdfdd-b9a6-41b4-a175-593bc957194a">1,627.8</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Retirement of common stock pursuant to the March 2019 Share Repurchase Program, at cost</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="icf8bb34fb60b40bcb5c350755c57da7f_D20190101-20190930" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfNy01LTEtMS0w_ebf6ddbb-023f-458e-bfa2-5c5efa80ce02">7.0</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id953e91f8c614de9996090d5eb18e5b1_D20190101-20190930" decimals="-5" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfNy05LTEtMS0w_ab3da853-e384-4ffa-ae81-482f5ead71bd">74.8</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ic8aa3352d77e4f12b7fc3b77907a67f6_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfNy0xMy0xLTEtMA_da3659bb-0b32-41b6-8447-ae421f431238">1,553.0</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i7289c8815e434ac989c2d260f35da03d_D20190101-20190930" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfNy0xNS0xLTEtMA_36dd1679-42da-4bad-8be2-73058768dea5">7.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7289c8815e434ac989c2d260f35da03d_D20190101-20190930" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfNy0xNy0xLTEtMA_63b0868b-1a8a-4db6-9401-1d0a25c591c0">1,627.8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Repurchase of common stock pursuant to the 2018 Share Repurchase Program, at cost</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="ib125f2b4cba94378833a506b5f526ef7_D20190101-20190930" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfOC0xNS0xLTEtMA_7c947ced-c4c9-416b-b676-393a34019c8d">8.9</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib125f2b4cba94378833a506b5f526ef7_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfOC0xNy0xLTEtMA_eee10429-ec12-4aed-8954-47f055c1f232">2,147.4</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8c3d2fb2bd034a6d943e04d98c6101df_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfOC0xOS0xLTEtMA_2f581090-0afe-414b-a031-dbb34d3c187a">2,147.4</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib1d334b7c899449292200b30b2bdc155_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfOC0yMy0xLTEtMA_d9589201-903b-4cec-bd39-5d9936bca719">2,147.4</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Retirement of common stock pursuant to the 2018 Share Repurchase Program, at cost</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="ifba3660adeba498985326527c5db09da_D20190101-20190930" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfOS01LTEtMS0w_82a95453-4088-4bb2-95e3-1aaab8333a67">8.9</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifba3660adeba498985326527c5db09da_D20190101-20190930" decimals="-5" format="ixt:zerodash" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfOS03LTEtMS0w_672313a0-c223-4562-bec6-f5186c5c1318">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i809df7746fcc437c8e9a75cc7cb10a70_D20190101-20190930" decimals="-5" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfOS05LTEtMS0w_1fc0c6eb-62d2-47ce-9f44-ffb6e9f1cc0a">110.5</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i4ffec57fb67a4f9091e91bd4b96b6eff_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfOS0xMy0xLTEtMA_016dca35-869a-41d5-9fca-ef693532214c">2,036.9</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ib125f2b4cba94378833a506b5f526ef7_D20190101-20190930" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfOS0xNS0xLTEtMA_d739bc74-34cf-4775-9f57-7cc2767ea631">8.9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib125f2b4cba94378833a506b5f526ef7_D20190101-20190930" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfOS0xNy0xLTEtMA_06db7642-729a-4f5a-8005-22b87181f20d">2,147.4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8c3d2fb2bd034a6d943e04d98c6101df_D20190101-20190930" decimals="-5" format="ixt:zerodash" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfOS0xOS0xLTEtMA_4dea661f-dcc1-4f97-879e-bf4c8502b5a4">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib1d334b7c899449292200b30b2bdc155_D20190101-20190930" decimals="-5" format="ixt:zerodash" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfOS0yMy0xLTEtMA_3a1fb6bf-7df9-43fe-bfc4-32d8ff1a0a47">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Issuance of common stock under stock option and stock purchase plans</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="iab58c905ebd44601ad94f01220bb87b0_D20190101-20190930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfMTAtNS0xLTEtMA_4f06c713-aa40-46a3-885c-e52f7b8f08b5">0.2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iab58c905ebd44601ad94f01220bb87b0_D20190101-20190930" decimals="-5" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfMTAtNy0xLTEtMA_f7817650-d620-497d-a2ba-7b3e19ecace6">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4745753d1ae84b66b7bfd523bb7d93ad_D20190101-20190930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfMTAtOS0xLTEtMA_840e9eb7-c697-4bb8-a4a8-3e109a750057">33.5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0efa62d44ea047f48a850ba3d5919a87_D20190101-20190930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfMTAtMTktMS0xLTA_ac87b85c-1f3e-4a42-9cb3-cf2646cf1947">33.5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfMTAtMjMtMS0xLTA_94904fac-4af2-4f9e-a09d-54fdd68bd449">33.5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Issuance of common stock under stock award plan</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="iab58c905ebd44601ad94f01220bb87b0_D20190101-20190930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfMTEtNS0xLTEtMA_c4f2b40c-7582-4d39-8a06-5da0dd7a9e42">0.4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iab58c905ebd44601ad94f01220bb87b0_D20190101-20190930" decimals="-5" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfMTEtNy0xLTEtMA_1e33b6e3-b61f-4455-8c1c-634c31015f9e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4745753d1ae84b66b7bfd523bb7d93ad_D20190101-20190930" decimals="-5" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfMTEtOS0xLTEtMA_1dd0ca61-77c1-4286-b542-420afdc03438">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib53a358e088b4743a76a8141b6a1c193_D20190101-20190930" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfMTEtMTMtMS0xLTA_79e7cc85-5627-491f-a6df-7564d8bb3f78">50.7</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0efa62d44ea047f48a850ba3d5919a87_D20190101-20190930" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfMTEtMTktMS0xLTA_5861f494-372b-442a-a157-f96d9aff26f3">50.7</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfMTEtMjMtMS0xLTA_a511a5e3-5268-4f42-8ffd-893628cdfaf8">50.7</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Compensation related to share-based payments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4745753d1ae84b66b7bfd523bb7d93ad_D20190101-20190930" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfMTItOS0xLTEtMA_b63f4f82-647a-435f-b0b9-75216d708951">151.8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib53a358e088b4743a76a8141b6a1c193_D20190101-20190930" decimals="-5" format="ixt:zerodash" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfMTItMTMtMS0xLTA_a029c6fb-5083-442e-86c6-6005e194f4c3">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0efa62d44ea047f48a850ba3d5919a87_D20190101-20190930" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfMTItMTktMS0xLTA_ac7d085e-14b5-4040-9390-847d59bad1fb">151.8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfMTItMjMtMS0xLTA_fd8b63d2-3a0a-4441-8b9f-4d873b0ad471">151.8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, September 30, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i30714cf43346412e9fea73f7251cf213_I20190930" decimals="-5" format="ixt:zerodash" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfMTMtMS0xLTEtMA_d33e0151-84ab-4c70-b082-5d0404ff6afd">&#8212;</ix:nonFraction></span><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i30714cf43346412e9fea73f7251cf213_I20190930" decimals="-5" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfMTMtMy0xLTEtMA_4f06acc5-e7d3-41f0-a331-0eff52bc3ac1">&#8212;</ix:nonFraction></span><span style="font-size:7.5pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="iccee1e1d95af43b9873f3228bed22351_I20190930" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfMTMtNS0xLTEtMA_c932a8ac-210b-43dc-880a-4ff6fb69260d">205.7</ix:nonFraction></span><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iccee1e1d95af43b9873f3228bed22351_I20190930" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfMTMtNy0xLTEtMA_52fdcc06-e4cb-468b-a060-3584d847b96a">0.1</ix:nonFraction></span><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i404c8ff0534c49f7a853054388cf47e7_I20190930" decimals="-5" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfMTMtOS0xLTEtMA_63bbbfb4-05ee-49ce-bf3f-e977f521e1c9">&#8212;</ix:nonFraction></span><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie09a86c05b2d4dd68ea12c27ea7e151a_I20190930" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfMTMtMTEtMS0xLTA_62b90c74-394d-449a-b8dc-dcee702fcef8">92.3</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idcbcecd74e024473bdd870830b88f96c_I20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfMTMtMTMtMS0xLTA_c2f655f2-971f-4c9c-82d9-cdf82a991e1a">17,065.2</ix:nonFraction></span><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:7.5pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="i7c8172c9fe75493ca901d5f05ecfa29d_I20190930" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfMTMtMTUtMS0xLTA_50cacf13-98ee-4e70-9c61-4c48a7229f02">23.8</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i7c8172c9fe75493ca901d5f05ecfa29d_I20190930" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfMTMtMTctMS0xLTA_3dd67f90-e5c9-4754-a114-013c3b6d5004">2,977.1</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic9f978f94b6e4038af9fb1fcaaf85dee_I20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfMTMtMTktMS0xLTA_59971b31-82af-4a62-acce-e5615ad76f91">13,995.9</ix:nonFraction></span><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie2305062812f448bad777c7ba71b2552_I20190930" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfMTMtMjEtMS0xLTA_61ca76c3-8aaf-43ba-844e-5fcee4599913">4.1</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:7.5pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:7.5pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ied38b94db9a74750b51c6e8392d4c5bf_I20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfMTMtMjMtMS0xLTA_f63fcb7f-4e61-4971-bcbf-24e1d3616309">13,991.8</ix:nonFraction></span><span style="font-size:7.5pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td></tr></table></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">See accompanying notes to these unaudited condensed consolidated financial statements.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">12</span></div></div></div><div id="ib19ff89608c84168a635160f2efa48f3_37"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_7">Table of Contents</a></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(unaudited)</span></div></div><div><span><br/></span></div><div id="ib19ff89608c84168a635160f2efa48f3_40"></div><div style="text-indent:-27pt;padding-left:27pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">1.&#160;&#160;&#160;&#160;Summary of Significant Accounting Policies </span></div><ix:nonNumeric contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM180MC9mcmFnOmQzZWY5NTkyOGIyNDQxNWE5OTUzZmZiZDU0NjI5NjVmL3RleHRyZWdpb246ZDNlZjk1OTI4YjI0NDE1YTk5NTNmZmJkNTQ2Mjk2NWZfMTIwMDg_e3e6d03a-ccb2-42da-b101-0f849c0ad42e" continuedAt="i3f6538dcb5284b2588e173330086cc41" escape="true"><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">References in these notes to "Biogen," the "company," "we," "us" and "our" refer to Biogen Inc. and its consolidated subsidiaries.</span></div><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Business Overview</span></div><ix:nonNumeric contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" name="biib:BusinessOverviewPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM180MC9mcmFnOmQzZWY5NTkyOGIyNDQxNWE5OTUzZmZiZDU0NjI5NjVmL3RleHRyZWdpb246ZDNlZjk1OTI4YjI0NDE1YTk5NTNmZmJkNTQ2Mjk2NWZfMTE5OTI_9e43fd5f-1e65-4b88-b490-8c1efdc107b5" continuedAt="if9008886eb8f4825b769850559644ab4" escape="true"><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Biogen is a global biopharmaceutical company focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. Our core growth areas include multiple sclerosis (MS) and neuroimmunology; Alzheimer's disease and dementia; neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS); movement disorders, including Parkinson's disease; and ophthalmology. We are also focused on discovering, developing and delivering worldwide innovative therapies in our emerging growth areas of immunology; neurocognitive disorders; acute neurology; and pain. In addition, we commercialize biosimilars of advanced biologics. We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities. </span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; and FUMADERM for the treatment of severe plaque psoriasis. We also have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of primary progressive MS and relapsing MS; and other potential anti-CD20 therapies pursuant to our collaboration arrangements with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group. For additional information on our collaboration arrangements with Genentech, please read </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Note 18, Collaborative and Other Relationships,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> to our consolidated financial statements included in our Annual Report on Form&#160;10-K for the year ended December 31, 2019 (2019 Form&#160;10-K).</span></div></ix:nonNumeric><div style="text-indent:24.75pt;margin-top:6pt;"><ix:continuation id="if9008886eb8f4825b769850559644ab4" continuedAt="i45a4e705c16a4223879719c3329d9490"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our innovative drug development and commercialization activities are complemented by our biosimilar business that expands access to medicines and reduces the cost burden for healthcare systems. Through Samsung Bioepis Co., Ltd. (Samsung Bioepis), our joint venture with Samsung BioLogics Co., Ltd. (Samsung BioLogics), we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL, IMRALDI, an adalimumab biosimilar referencing HUMIRA, and FLIXABI, an infliximab biosimilar referencing REMICADE, in certain countries in Europe and have exclusive rights to commercialize these products in China. Additionally, we have exclusive rights to commercialize <ix:nonFraction unitRef="product" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="0" format="ixt-sec:numwordsen" name="biib:NumberOfOphthalmolgyBiosimilarProductsExclusiveRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM180MC9mcmFnOmQzZWY5NTkyOGIyNDQxNWE5OTUzZmZiZDU0NjI5NjVmL3RleHRyZWdpb246ZDNlZjk1OTI4YjI0NDE1YTk5NTNmZmJkNTQ2Mjk2NWZfODI0NjMzNzIyMDQzNA_aa815fee-aa8a-4909-9fd8-30b9c6451a4c">two</ix:nonFraction> potential ophthalmology biosimilar products, SB11 referencing LUCENTIS and SB15 referencing EYLEA, in major markets worldwide, including the United States (U.S.), Canada, Europe, Japan and Australia. For additional information on our collaboration arrangements with Samsung Bioepis, please read </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Note 17, Collaborative and Other Relationships,</span></ix:continuation><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i45a4e705c16a4223879719c3329d9490"> to these unaudited condensed consolidated financial statements (condensed consolidated financial statements).</ix:continuation> </span></div><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Basis of Presentation</span></div><ix:nonNumeric contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM180MC9mcmFnOmQzZWY5NTkyOGIyNDQxNWE5OTUzZmZiZDU0NjI5NjVmL3RleHRyZWdpb246ZDNlZjk1OTI4YjI0NDE1YTk5NTNmZmJkNTQ2Mjk2NWZfMTE5OTY_fac5dd14-8e44-44b4-b756-ee0a6cc09737" escape="true"><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In the opinion of management, our condensed consolidated financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair statement of our financial statements for interim periods in accordance with accounting principles generally accepted in the United States (U.S.&#160;GAAP). The information included in this quarterly report on Form&#160;10-Q should be read in conjunction with our audited consolidated financial statements and the accompanying notes included in our 2019 Form&#160;10-K. Our accounting policies are described in the </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Notes to Consolidated Financial Statements</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> in our 2019 Form&#160;10-K and updated, as necessary, in this report. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from our audited financial statements but does not include all disclosures required by U.S.&#160;GAAP. The results of operations for the three and nine months ended September 30, 2020, are not necessarily indicative of the operating results for the full year or for any other subsequent interim period. </span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We operate as <ix:nonFraction unitRef="segment" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:NumberOfReportableSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM180MC9mcmFnOmQzZWY5NTkyOGIyNDQxNWE5OTUzZmZiZDU0NjI5NjVmL3RleHRyZWdpb246ZDNlZjk1OTI4YjI0NDE1YTk5NTNmZmJkNTQ2Mjk2NWZfNDMwMg_83aeb2e4-cec3-49d1-b38e-2ae30913f408">one</ix:nonFraction> operating segment, focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies.</span></div></ix:nonNumeric></ix:nonNumeric><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_7">Table of Contents</a></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(unaudited, continued)</span></div></div><ix:continuation id="i3f6538dcb5284b2588e173330086cc41" continuedAt="if9ead593fe3c4459b37d5a62f42f93c8"><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Consolidation</span></div><ix:nonNumeric contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM180MC9mcmFnOmQzZWY5NTkyOGIyNDQxNWE5OTUzZmZiZDU0NjI5NjVmL3RleHRyZWdpb246ZDNlZjk1OTI4YjI0NDE1YTk5NTNmZmJkNTQ2Mjk2NWZfMTIwMzE_f26e6c24-a09c-447b-9d66-5113c16cae6c" escape="true"><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our condensed consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and those of certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than <ix:nonFraction unitRef="number" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="INF" name="biib:InterestInSubsidiary" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM180MC9mcmFnOmQzZWY5NTkyOGIyNDQxNWE5OTUzZmZiZDU0NjI5NjVmL3RleHRyZWdpb246ZDNlZjk1OTI4YjI0NDE1YTk5NTNmZmJkNTQ2Mjk2NWZfNDgxMg_70ba81c1-ca44-432c-b699-6f088ef43485">100</ix:nonFraction>% of the economics, we record net income (loss) attributable to noncontrolling interests in our condensed consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. </span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In determining whether we are the primary beneficiary of a variable interest entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. These considerations impact the way we account for our existing collaborative relationships and other arrangements. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.</span></div></ix:nonNumeric><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Use of Estimates</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:nonNumeric contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM180MC9mcmFnOmQzZWY5NTkyOGIyNDQxNWE5OTUzZmZiZDU0NjI5NjVmL3RleHRyZWdpb246ZDNlZjk1OTI4YjI0NDE1YTk5NTNmZmJkNTQ2Mjk2NWZfMTIwMjc_4776df8a-bee5-4a50-ba21-49cdb08a31ed" continuedAt="i25cac71e87ce4442af1a0bc73088cf24" escape="true">The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. Actual results may differ from these estimates.</ix:nonNumeric></span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i25cac71e87ce4442af1a0bc73088cf24">The length of time and full extent to which the COVID-19 pandemic directly or indirectly impacts our business, results of operations and financial condition, including sales, expenses, reserves and allowances, manufacturing, clinical trials, research and development costs and employee-related amounts, depends on future developments that are highly uncertain, subject to change and are difficult to predict, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19 as well as the economic impact on local, regional, national and international customers and markets. We have made estimates of the impact of COVID-19 within our condensed consolidated financial statements and there may be changes to those estimates in future periods.</ix:continuation> </span></div><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">New Accounting Pronouncements</span></div><ix:nonNumeric contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM180MC9mcmFnOmQzZWY5NTkyOGIyNDQxNWE5OTUzZmZiZDU0NjI5NjVmL3RleHRyZWdpb246ZDNlZjk1OTI4YjI0NDE1YTk5NTNmZmJkNTQ2Mjk2NWZfMTIwMDU_bbb40b73-9e0c-4ca9-8fc5-13479a0e59e7" continuedAt="i9751a52835df4e01aa045db9366a1d7e" escape="true"><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed below, we do not believe that the adoption of recently issued standards have or may have a material impact on our condensed consolidated financial statements or disclosures.</span></div><div style="text-indent:13.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#528134;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Credit Losses</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2016 the FASB issued Accounting Standards Update (ASU) No. 2016-13, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The FASB subsequently issued amendments to ASU 2016-13, which have the same effective date and transition date of January 1, 2020. This standard requires entities to estimate an expected lifetime credit loss on financial assets ranging from short-term trade accounts receivable to long-term financings and report credit losses using an expected losses model rather than the incurred losses model that was previously used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, this standard now requires allowances to be recorded instead of reducing the amortized cost of the investment. This standard limits the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit losses if fair value increases.</span></div></ix:nonNumeric></ix:continuation><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_7">Table of Contents</a></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(unaudited, continued)</span></div></div><ix:continuation id="if9ead593fe3c4459b37d5a62f42f93c8"><ix:continuation id="i9751a52835df4e01aa045db9366a1d7e"><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">This standard became effective for us on January 1, 2020, and based on the composition of our trade receivables, investment portfolio and other financial assets, current economic conditions and historical credit loss activity, the adoption of this standard did not have a material impact on our condensed consolidated financial statements and related disclosures. During the three and nine months ended September 30, 2020, we recorded an immaterial amount associated with expected credit losses related to outstanding trade receivables in certain foreign countries that have been disproportionately impacted by the COVID-19 pandemic.</span></div><div style="text-indent:13.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#528134;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Fair Value Measurements</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In August 2018 the FASB issued ASU No. 2018-13,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"> Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. This standard modifies certain disclosure requirements on fair value measurements. This standard became effective for us on January 1, 2020, and did not have a material impact on our disclosures. For the new disclosures regarding our Level 3 instruments, please read </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Note 7, Fair Value Measurements,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> to these condensed consolidated financial statements.</span></div><div style="text-indent:13.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#528134;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Internal Use Software</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In August 2018 the FASB issued ASU No. 2018-15, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Intangibles&#8212;Goodwill and Other&#8212;Internal-Use Software (Subtopic 350-40): Customer&#8217;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. This standard clarifies the accounting for implementation costs in cloud computing arrangements. This standard, which became effective for us on January 1, 2020, and was adopted on a prospective basis, resulted in an immaterial amount of additional assets being recorded on our condensed consolidated balance sheets.</span></div><div style="text-indent:13.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#528134;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Collaborative Arrangements</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In November 2018 the FASB issued ASU No. 2018-18, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. This standard makes targeted improvements for collaborative arrangements as follows:</span></div><div style="text-indent:-18pt;padding-left:40.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">Clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under Accounting Standards Codification (ASC) 606, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Revenue from Contracts with Customers</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, when the collaborative arrangement participant is a customer in the context of a unit of account. In those situations, all the guidance in ASC 606 should be applied, including recognition, measurement, presentation and disclosure requirements;</span></div><div style="text-indent:-18pt;padding-left:40.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">Adds unit-of-account guidance to ASC 808, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Collaborative Arrangements</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, to align with the guidance in ASC 606 (that is, a distinct good or service) when an entity is assessing whether the collaborative arrangement or a part of the arrangement is within the scope of ASC 606; and</span></div><div style="text-indent:-18pt;padding-left:40.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">Precludes a company from presenting transactions with collaborative arrangement participants that are not directly related to sales to third parties with revenue recognized under ASC 606 if the collaborative arrangement participant is not a customer.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">This standard became effective for us on January 1, 2020, and did not have a material impact on our condensed consolidated financial statements and related disclosures.</span></div></ix:continuation></ix:continuation><div id="ib19ff89608c84168a635160f2efa48f3_43"></div><div style="text-indent:-27pt;padding-left:27pt;margin-top:14pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">2.&#160;&#160;&#160;&#160;Acquisitions </span></div><ix:nonNumeric contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM180My9mcmFnOmQyNTM3MjRlNzA5OTQyMGVhMTZiYzY2ODQ3MWNhNjU2L3RleHRyZWdpb246ZDI1MzcyNGU3MDk5NDIwZWExNmJjNjY4NDcxY2E2NTZfMjk2Mw_4f8e4266-7685-4607-a538-e464b4a90176" continuedAt="i3638fd0f39cb4d18821976dd921c7b4c" escape="true"><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">BIIB118 Acquisition</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In March 2020 we acquired BIIB118 (formerly known as PF-05251749), a novel CNS-penetrant small molecule inhibitor of casein kinase 1, for the potential treatment of patients with behavioral and neurological symptoms across various psychiatric and neurological diseases from Pfizer Inc. (Pfizer). We plan to develop this Phase 1 asset for the potential treatment of sundowning in Alzheimer's disease and irregular sleep wake rhythm disorder in Parkinson&#8217;s disease. </span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In connection with this acquisition, we made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i6184d003ca324663b6d44d4425fd9798_D20200301-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM180My9mcmFnOmQyNTM3MjRlNzA5OTQyMGVhMTZiYzY2ODQ3MWNhNjU2L3RleHRyZWdpb246ZDI1MzcyNGU3MDk5NDIwZWExNmJjNjY4NDcxY2E2NTZfNTQ3_6579c5bf-3ae3-41e2-8c99-cbea35dd4513">75.0</ix:nonFraction> million to Pfizer, which was accounted for as an asset acquisition and recorded as acquired in-process research and development (IPR&amp;D) in our condensed consolidated statements of income as BIIB118 has not yet reached technological feasibility. We may also pay Pfizer up to $<ix:nonFraction unitRef="usd" contextRef="i6184d003ca324663b6d44d4425fd9798_D20200301-20200331" decimals="-5" format="ixt:numdotdecimal" name="biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM180My9mcmFnOmQyNTM3MjRlNzA5OTQyMGVhMTZiYzY2ODQ3MWNhNjU2L3RleHRyZWdpb246ZDI1MzcyNGU3MDk5NDIwZWExNmJjNjY4NDcxY2E2NTZfODE2_32026869-0a13-4f0e-93e2-db3b39ec2458">635.0</ix:nonFraction> million in potential additional development and commercialization milestone payments as well as tiered royalties in the high single digits to sub-teens.</span></div></ix:nonNumeric><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_7">Table of Contents</a></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(unaudited, continued)</span></div></div><ix:continuation id="i3638fd0f39cb4d18821976dd921c7b4c"><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Acquisition of Nightstar Therapeutics plc</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2019 we completed our acquisition of all of the outstanding shares of Nightstar Therapeutics plc (NST), a clinical-stage gene therapy company focused on adeno-associated virus (AAV) treatments for inherited retinal disorders. As a result of this acquisition, we added <ix:nonFraction unitRef="assets" contextRef="i34259f1058d543a0ab98f22062f2e5ab_D20190601-20190630" decimals="INF" format="ixt-sec:numwordsen" name="biib:ClinicalAssetsAcquired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM180My9mcmFnOmQyNTM3MjRlNzA5OTQyMGVhMTZiYzY2ODQ3MWNhNjU2L3RleHRyZWdpb246ZDI1MzcyNGU3MDk5NDIwZWExNmJjNjY4NDcxY2E2NTZfMTI4Mw_465f2711-e949-4b8e-ad4a-bbaea837742b">two</ix:nonFraction> mid- to late-stage clinical assets as well as preclinical programs in ophthalmology. These assets include BIIB111 (timrepigene emparvovec), which is in Phase 3 development for the potential treatment of choroideremia, a rare, degenerative, X-linked inherited retinal disorder that leads to blindness and currently has no approved treatments, and BIIB112 (RPGR gene therapy), which is in Phase 2/3 development for the potential treatment of X-linked retinitis pigmentosa, which is a rare inherited retinal disease with no currently approved treatments.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the terms of this acquisition, we paid NST shareholders $<ix:nonFraction unitRef="usdPerShare" contextRef="if669468af2b1428fbb2d5e8a25e54053_I20190607" decimals="2" name="us-gaap:BusinessAcquisitionSharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM180My9mcmFnOmQyNTM3MjRlNzA5OTQyMGVhMTZiYzY2ODQ3MWNhNjU2L3RleHRyZWdpb246ZDI1MzcyNGU3MDk5NDIwZWExNmJjNjY4NDcxY2E2NTZfMTkwMg_497b9cb7-6537-45ef-a8bd-28d21aff7597">25.50</ix:nonFraction> in cash for each issued and outstanding NST share, which totaled $<ix:nonFraction unitRef="usd" contextRef="iab47d31b221a4694b97e6b5cd3de541b_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM180My9mcmFnOmQyNTM3MjRlNzA5OTQyMGVhMTZiYzY2ODQ3MWNhNjU2L3RleHRyZWdpb246ZDI1MzcyNGU3MDk5NDIwZWExNmJjNjY4NDcxY2E2NTZfMTk3MA_bf31d747-5705-4a4d-bb0d-634f27f276d1">847.6</ix:nonFraction> million. In addition, we paid $<ix:nonFraction unitRef="usd" contextRef="iab47d31b221a4694b97e6b5cd3de541b_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherPaymentsToAcquireBusinesses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM180My9mcmFnOmQyNTM3MjRlNzA5OTQyMGVhMTZiYzY2ODQ3MWNhNjU2L3RleHRyZWdpb246ZDI1MzcyNGU3MDk5NDIwZWExNmJjNjY4NDcxY2E2NTZfMTk5NQ_99a0197c-4941-4c57-9b0d-0569c39e7698">4.6</ix:nonFraction> million in cash for equity compensation, which is attributable to pre-combination services and was reflected as a component of the total purchase price paid. The fair value of equity compensation attributable to the post-combination service period was $<ix:nonFraction unitRef="usd" contextRef="i4ea815a094e741b0a154fa60dcf2c6a5_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM180My9mcmFnOmQyNTM3MjRlNzA5OTQyMGVhMTZiYzY2ODQ3MWNhNjU2L3RleHRyZWdpb246ZDI1MzcyNGU3MDk5NDIwZWExNmJjNjY4NDcxY2E2NTZfMjI0Mg_29a7ae9e-487a-471d-b126-a44defe44f5d">26.2</ix:nonFraction> million, of which $<ix:nonFraction unitRef="usd" contextRef="id3e1580f38914bf3a529df3762a6db10_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM180My9mcmFnOmQyNTM3MjRlNzA5OTQyMGVhMTZiYzY2ODQ3MWNhNjU2L3RleHRyZWdpb246ZDI1MzcyNGU3MDk5NDIwZWExNmJjNjY4NDcxY2E2NTZfMjI1NQ_0d65cc67-6c1c-42cb-b8e9-c078a9481c00">18.4</ix:nonFraction> million was recognized as a charge to selling, general and administrative expense with the remaining $<ix:nonFraction unitRef="usd" contextRef="i6d491f3733874ec68a5451b8128278dd_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM180My9mcmFnOmQyNTM3MjRlNzA5OTQyMGVhMTZiYzY2ODQ3MWNhNjU2L3RleHRyZWdpb246ZDI1MzcyNGU3MDk5NDIwZWExNmJjNjY4NDcxY2E2NTZfMjM1MQ_87f3629e-8c6b-4a4e-80fe-458f842d3b05">7.8</ix:nonFraction> million as a charge to research and development expense in our condensed consolidated statements of income. These amounts were associated with the accelerated vesting of stock options previously granted to NST employees and were fully paid in cash as of June 30, 2019. We funded this acquisition through available cash and accounted for it as an acquisition of a business. We finalized purchase accounting for this acquisition in the fourth quarter of 2019.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For additional information on our acquisition of NST, please read </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Note 2, Acquisitions,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> to our consolidated financial statements included in our 2019 Form 10-K.</span></div></ix:continuation><div id="ib19ff89608c84168a635160f2efa48f3_46"></div><div style="text-indent:-27pt;padding-left:27pt;margin-top:14pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">3.&#160;&#160;&#160;&#160;Divestitures </span></div><ix:nonNumeric contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" name="us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM180Ni9mcmFnOmViM2ZkM2ZiNWQ5NDQ3Y2U4ODFiZWExYzk3ZDg3MjVmL3RleHRyZWdpb246ZWIzZmQzZmI1ZDk0NDdjZTg4MWJlYTFjOTdkODcyNWZfMzUwOQ_3913c313-73dc-4385-a9bc-ff88c5d78dfe" continuedAt="id610105f0b7d45bdbada4b0df167831f" escape="true"><div style="text-indent:13.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Divestiture of Hiller&#248;d, Denmark Manufacturing Operations </span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In March 2019 we entered into a share purchase agreement with FUJIFILM Corporation (FUJIFILM) to sell all of the outstanding shares of our subsidiary that owned our biologics manufacturing operations in Hiller&#248;d, Denmark. We determined that the assets and liabilities related to our Hiller&#248;d, Denmark manufacturing operations met the criteria to be classified as held for sale. For the nine months ended September 30, 2019, we recorded a loss of approximately $<ix:nonFraction unitRef="usd" contextRef="i54fe6174a2224b379d4a176d7fd82015_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM180Ni9mcmFnOmViM2ZkM2ZiNWQ5NDQ3Y2U4ODFiZWExYzk3ZDg3MjVmL3RleHRyZWdpb246ZWIzZmQzZmI1ZDk0NDdjZTg4MWJlYTFjOTdkODcyNWZfNTE0_44e62935-ce54-4130-a7c4-61876d8243e9">160.2</ix:nonFraction> million in our condensed consolidated statements of income. This estimated loss included a pre-tax loss of $<ix:nonFraction unitRef="usd" contextRef="i54fe6174a2224b379d4a176d7fd82015_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM180Ni9mcmFnOmViM2ZkM2ZiNWQ5NDQ3Y2U4ODFiZWExYzk3ZDg3MjVmL3RleHRyZWdpb246ZWIzZmQzZmI1ZDk0NDdjZTg4MWJlYTFjOTdkODcyNWZfNjE2_0e90593d-f372-4743-92b2-df537e3b821f">95.5</ix:nonFraction> million, which reflected a $<ix:nonFraction unitRef="usd" contextRef="i6d14771766d1415790d98b0c80aaa2eb_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM180Ni9mcmFnOmViM2ZkM2ZiNWQ5NDQ3Y2U4ODFiZWExYzk3ZDg3MjVmL3RleHRyZWdpb246ZWIzZmQzZmI1ZDk0NDdjZTg4MWJlYTFjOTdkODcyNWZfNjM4_e3320d1b-58c4-4dd5-9cef-08771f518cc5">17.7</ix:nonFraction> million decrease to our previously recorded pre-tax loss, reflecting our estimated fair value of the assets and liabilities held for sale as of September 30, 2019, adjusted for our expected costs to sell our Hiller&#248;d, Denmark manufacturing operations of approximately $<ix:nonFraction unitRef="usd" contextRef="i6d14771766d1415790d98b0c80aaa2eb_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM180Ni9mcmFnOmViM2ZkM2ZiNWQ5NDQ3Y2U4ODFiZWExYzk3ZDg3MjVmL3RleHRyZWdpb246ZWIzZmQzZmI1ZDk0NDdjZTg4MWJlYTFjOTdkODcyNWZfODkx_e9f7c25c-7798-4ce8-863f-760efe3e7a8b">11.2</ix:nonFraction> million and included our initial estimate of the fair value of an adverse commitment of approximately $<ix:nonFraction unitRef="usd" contextRef="ic1329de1cf194c709a3e6e578b701fb5_I20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM180Ni9mcmFnOmViM2ZkM2ZiNWQ5NDQ3Y2U4ODFiZWExYzk3ZDg3MjVmL3RleHRyZWdpb246ZWIzZmQzZmI1ZDk0NDdjZTg4MWJlYTFjOTdkODcyNWZfOTg4_37e51106-9043-41db-8056-b7634e95bdbb">114.0</ix:nonFraction> million associated with the guarantee of future minimum batch production at the Hiller&#248;d facility. The value of this adverse commitment was determined using a probability-weighted estimate of future manufacturing activity. In addition, we recorded a tax expense of $<ix:nonFraction unitRef="usd" contextRef="ie4528167bcf941dbb3558a86eed5211c_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM180Ni9mcmFnOmViM2ZkM2ZiNWQ5NDQ3Y2U4ODFiZWExYzk3ZDg3MjVmL3RleHRyZWdpb246ZWIzZmQzZmI1ZDk0NDdjZTg4MWJlYTFjOTdkODcyNWZfMTI0OA_1fe7605c-fdaa-4ca0-ba79-bb1bd49bdb6b">64.7</ix:nonFraction> million related to the transaction during the nine months ended September 30, 2019.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In August 2019 this transaction closed and we received approximately $<ix:nonFraction unitRef="usd" contextRef="i3413eeb6a8594eb7bd9a9895a6a44b36_I20190801" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM180Ni9mcmFnOmViM2ZkM2ZiNWQ5NDQ3Y2U4ODFiZWExYzk3ZDg3MjVmL3RleHRyZWdpb246ZWIzZmQzZmI1ZDk0NDdjZTg4MWJlYTFjOTdkODcyNWZfMTM4NQ_bf7cce42-bd0a-4f5c-870c-8f79d88a5801">881.9</ix:nonFraction> million in cash, which may be adjusted based on the contractual terms discussed below. We determined that the operations disposed of in this transaction did not meet the criteria to be classified as discontinued operations under the applicable guidance.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As part of this transaction, we provided FUJIFILM with certain minimum batch production commitment guarantees. There is a risk that the minimum contractual batch production commitments will not be met. Our estimate of the adverse commitment obligation is approximately $<ix:nonFraction unitRef="usd" contextRef="i8fb970353ed64398943d0ed1643a7bcb_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM180Ni9mcmFnOmViM2ZkM2ZiNWQ5NDQ3Y2U4ODFiZWExYzk3ZDg3MjVmL3RleHRyZWdpb246ZWIzZmQzZmI1ZDk0NDdjZTg4MWJlYTFjOTdkODcyNWZfMTkwMw_da760c9d-7f3a-4623-87be-33a6cccf8ba3">74.0</ix:nonFraction> million as of September 30, 2020 and December 31, 2019. We developed this estimate using a probability-weighted estimate of future manufacturing activity and may adjust this estimate based upon changes in business conditions, which may result in the increase or reduction of this adverse commitment obligation in subsequent periods. We also may be obligated to indemnify FUJIFILM for liabilities that existed relating to certain business activities incurred prior to the closing of this transaction. Our estimate of the fair value of the adverse commitment obligation is a Level 3 measurement and is based on forecasted batch production at the Hiller&#248;d facility.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, we may earn certain contingent payments based on future manufacturing activities at the Hiller&#248;d facility. For the disposition of a business, our policy is to recognize contingent consideration when the consideration is realizable. Consistent with our assessment as of the transaction date, we currently believe the probability of earning these payments is remote and therefore we did not include these contingent payments in our calculation of the fair value of the operations.</span></div></ix:nonNumeric><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_7">Table of Contents</a></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(unaudited, continued)</span></div></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="id610105f0b7d45bdbada4b0df167831f">As part of this transaction, we entered into certain manufacturing services agreements with FUJIFILM pursuant to which FUJIFILM will use the Hiller&#248;d facility to produce commercial products for us, such as TYSABRI, as well as other third-party products. In addition, we sold to FUJIFILM $<ix:nonFraction unitRef="usd" contextRef="i174c6f6dc0974a4a9f1635f5f4a03baf_I20190801" decimals="-5" format="ixt:numdotdecimal" name="biib:InventoryrawmaterialssoldtoFUJIFILM" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM180Ni9mcmFnOmViM2ZkM2ZiNWQ5NDQ3Y2U4ODFiZWExYzk3ZDg3MjVmL3RleHRyZWdpb246ZWIzZmQzZmI1ZDk0NDdjZTg4MWJlYTFjOTdkODcyNWZfMzMwOQ_0c7a9907-06ae-4d90-8fb4-b38af0382525">41.8</ix:nonFraction> million of raw materials that were remaining at the Hiller&#248;d facility on the closing date of this transaction in the third quarter of 2019. These materials were sold at cost, which approximated fair value.</ix:continuation></span></div><div id="ib19ff89608c84168a635160f2efa48f3_52"></div><div style="text-indent:-27pt;padding-left:27pt;margin-top:14pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">4.&#160;&#160;&#160;&#160;Revenues </span></div><ix:nonNumeric contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RleHRyZWdpb246YjUxMDhlMTQ5MTIxNGEyOGE1MWY0ZTljMWQ1NzM2NTVfMjc2OA_54853466-0f89-4853-86d0-81696e1c5a19" continuedAt="i721f52f103984410bc10f654ce56163d" escape="true"><div style="text-indent:13.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2472b9;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Product Revenues</span></div><ix:nonNumeric contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RleHRyZWdpb246YjUxMDhlMTQ5MTIxNGEyOGE1MWY0ZTljMWQ1NzM2NTVfMjc0NQ_bc71c15c-916a-4b45-8ced-05d7b1cb8aca" continuedAt="i070eba9cc94b42c59acfc4fe9db8779c" escape="true"><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Revenues by product are summarized as follows:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:31.550%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.441%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.295%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.441%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.295%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.441%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.445%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="33" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Three Months Ended September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In millions)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">United<br/>States</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Rest of<br/>World</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">United<br/>States</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Rest of<br/>World</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Multiple Sclerosis (MS):</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fumarate*</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idb5da4324a084eefaa4d376d025b0d68_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfNC0yLTEtMS0w_5337013c-fe10-40ee-9700-1e1cb0757a42">684.2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibe88801f13d247f899ec696c93dcc2e6_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfNC00LTEtMS0w_de3c8da3-88b0-4d4f-b61b-ca8c13e611fd">283.3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1b5da4a47c7b46c7a859d909b06ba52c_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfNC02LTEtMS0w_2e479b9a-325b-4537-b5a7-258d47edb363">967.5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia341fbfc92d14c558a2c51805e16e967_D20190701-20190930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfNC04LTEtMS0w_2f021d61-960b-45d2-b245-c680063f4c00">842.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6fb54144d66b439881fcd02918e4cdeb_D20190701-20190930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfNC0xMC0xLTEtMA_273ea71f-462f-4383-8751-3ab1ed2a1e5d">280.4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5c3d302ecd604f7a8d735759d694817a_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfNC0xMi0xLTEtMA_4797de36-bcc7-403a-a68e-ce05abcb012d">1,122.4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interferon**</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id616d991f56748438a8ba16f0137aa36_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfNS0yLTEtMS0w_287d865f-e40c-4f29-8dfc-efa1e5d1b245">327.3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3dbbc7fb0ad74d068c127681fec0fc62_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfNS00LTEtMS0w_49317887-5d60-4210-b111-3657d5addd27">146.8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8a70003485d4486a9bb6430b519901d8_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfNS02LTEtMS0w_72768ea4-465f-4dfe-8997-0b3e0e8e38ea">474.1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i235abb80d0f443cf952612f002c4c724_D20190701-20190930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfNS04LTEtMS0w_4b48117a-d7e2-4f60-b4d1-a5810536c016">360.3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic1773b37e68f4ca98e29d05e4707727d_D20190701-20190930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfNS0xMC0xLTEtMA_b4e5ecc4-8f89-43fe-ab13-7dd47e2b9028">169.7</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if638579a7e1847469ac17a832271d4d7_D20190701-20190930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfNS0xMi0xLTEtMA_f837bc8a-2ec2-4573-9295-8770ed7e768a">530.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">TYSABRI</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b652f2150604dc6a33be4ae69220a56_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfNi0yLTEtMS0w_86860c95-b6b5-4009-9dc8-1998114d7cca">304.2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i90806ea38d7543f29e6a6e61337fe595_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfNi00LTEtMS0w_21517f33-3bb6-4bbc-8835-be0297253641">212.3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icea39709b7b1472aa5dd7f44966c0bd3_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfNi02LTEtMS0w_36e989a2-be39-406c-98f6-b80e3e63b885">516.5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9f9d582c0e524991ad24725e61b062b5_D20190701-20190930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfNi04LTEtMS0w_22dca09d-2d36-47e7-b04e-55c486e3c0ca">263.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if85e43e3e237494fa32864c3adac50a1_D20190701-20190930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfNi0xMC0xLTEtMA_ee127854-e83c-474c-969e-816470b5d133">220.6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic408b141d6a24355afe175433eb9135f_D20190701-20190930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfNi0xMi0xLTEtMA_d3a7eec5-b058-4186-a09a-0b5d12fb57d8">483.6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">FAMPYRA</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1323f4a6c7eb4aae984b38b19c87c5bf_D20200701-20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfNy0yLTEtMS0w_8f0dc8b0-c4c5-4db0-a367-39b57481a804">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifaaa9079f60b4098abc8790d9255ab3e_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfNy00LTEtMS0w_6748629c-a554-434e-a061-b7d99e0805d8">26.8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i68159e373219432e9ceeac5ce7c38c52_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfNy02LTEtMS0w_d4036858-1ad9-4edb-b772-0ac59a15ade4">26.8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5e0133306cc04c65928c989a2d2dbb45_D20190701-20190930" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfNy04LTEtMS0w_a1abbf29-5da2-4407-9c5a-abc7a798e0fc">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if5a5e0e77dd24eab8c07703f6d5e5414_D20190701-20190930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfNy0xMC0xLTEtMA_2bcbcb09-d71d-4038-aa62-8a4094449b29">24.2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i742235d37c1342388624cde1c677f04b_D20190701-20190930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfNy0xMi0xLTEtMA_61fd2800-e4b8-46cf-98bf-286c997455cd">24.2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Subtotal: MS product revenues</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2a33b9fd26694109b63c4f4ba7b7a6e1_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfOC0yLTEtMS0w_c86ae287-bbbf-4ad8-934f-2d43f68911db">1,315.7</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic87d9b72e03d47c7a87c74570147c7e8_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfOC00LTEtMS0w_e162f1a3-f10a-4c41-b798-73fe8066686b">669.2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iba79677927674335a48059dc861147c5_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfOC02LTEtMS0w_0e2178c2-1c5f-4b28-9abf-f7fe67bd2887">1,984.9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idd282900956142e1a6ef766e0cb49611_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfOC04LTEtMS0w_74f30562-cd55-417d-9752-974d925b88d8">1,465.3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4610f1a14c034cb19b7366512e904c92_D20190701-20190930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfOC0xMC0xLTEtMA_4b389a35-373e-49dd-bea9-f726ca3ff85b">694.9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i134d08fbd1ff45239e991114f841a948_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfOC0xMi0xLTEtMA_61e60ea5-647a-4efa-b0dd-3d51b3eb765a">2,160.2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Spinal Muscular Atrophy:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">SPINRAZA</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i782a7c4ac90845f09d932b45511ff216_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfMTEtMi0xLTEtMA_5efc850b-2a44-45f4-9bd2-5810627daf6d">182.5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if924a82037ba40d288c2ebf03d3f886f_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfMTEtNC0xLTEtMA_7690a719-c03c-4aaf-88e5-01dcb4fa9d02">311.9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i64ff52eeaaa44fe1942f08bef012563e_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfMTEtNi0xLTEtMA_036206b0-ee8c-4f2c-95cf-89b1374794c0">494.4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibc93740adfba43e48aeb5c07582509ad_D20190701-20190930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfMTEtOC0xLTEtMA_3d6d6406-ed1f-48fa-864c-4c5a2028c367">236.7</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib5dfd6a6fcaa4743b33d7010ee60257f_D20190701-20190930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfMTEtMTAtMS0xLTA_ebbc8066-1282-4207-9a71-d3ddbf595e36">310.4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i71c758edfcc041a19e3af23d14f9b3a5_D20190701-20190930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfMTEtMTItMS0xLTA_dbdd3155-42ad-4c0a-a245-1447149ea8e8">547.1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Biosimilars:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">BENEPALI</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0a383eb4ffb0459e920cfd44b9b19f2b_D20200701-20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfMTQtMi0xLTEtMA_fbae59aa-bd52-40f4-b36e-d43982452aaa">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id87093f8e357449d9e8705f5c6ccc183_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfMTQtNC0xLTEtMA_6b62a80b-91af-4d08-8f46-1e178095658b">124.2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icdcc3e6db10041c6adfb46ab9cc43d52_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfMTQtNi0xLTEtMA_efe98a49-20e2-46f5-b60d-46630af7af46">124.2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id5469abafd1f421d8fce4ea54f1ec77b_D20190701-20190930" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfMTQtOC0xLTEtMA_bc9af353-5c4d-49c7-b0e7-8a2b9f547ff1">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i746432e17705462ea58e77a00bb3a93e_D20190701-20190930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfMTQtMTAtMS0xLTA_6615b13a-54c7-4b10-96e8-3062b26fb2c7">115.9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic7f7847bbcdf4347bcaa5531ac1b24ef_D20190701-20190930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfMTQtMTItMS0xLTA_c996785a-c461-4bcd-9631-b0d0aa889021">115.9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">IMRALDI</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i010f4a93398d4bb4b566cd786299c56e_D20200701-20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfMTUtMi0xLTEtMA_0da79ea8-f46f-4029-a20e-26c64bbeff3e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6d23abb471e04139a7badc923a7aa0b0_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfMTUtNC0xLTEtMA_4501a78e-37db-4eda-94b3-18c8b9da1497">56.2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2b01d577ab7e4e2faf2a58cdd2703267_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfMTUtNi0xLTEtMA_620a9082-a64c-405e-8dcc-840da1aba85a">56.2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if30fd82eecb5426b92a98a3e3fefe6f5_D20190701-20190930" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfMTUtOC0xLTEtMA_d8e6e181-daa4-4582-92a4-2248c7fd5453">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i116d706a2f374c48861e85f661a21b25_D20190701-20190930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfMTUtMTAtMS0xLTA_4ddcfe87-86ff-4021-9046-e62575818016">49.3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if9a7e5c89d394125ac728a112ab5ff87_D20190701-20190930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfMTUtMTItMS0xLTA_28ab43e5-192f-4ada-bcad-7deacffe0b65">49.3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">FLIXABI</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i56b36d0e49d840c1bb93b2c87291791d_D20200701-20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfMTYtMi0xLTEtMA_213748c5-7617-4086-b138-1e960fa3f351">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ief040210ae2c41fdad968514993484a7_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfMTYtNC0xLTEtMA_0b1d7e95-7ac6-4761-a282-405ff8b628a5">27.5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5f8fe94c6208475b8bc2f93cb71a7939_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfMTYtNi0xLTEtMA_1b88d782-e0b9-4757-9a93-a2aff8acc91f">27.5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i48f53b5d6fc04defad6638974299bc5b_D20190701-20190930" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfMTYtOC0xLTEtMA_bec99bd2-149a-4b2f-8a22-12529b66230f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5971788b43b64613b60ad9eb48951064_D20190701-20190930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfMTYtMTAtMS0xLTA_9624d40e-235d-45cd-bac4-e6af4ea3378c">18.4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib8eb6906d8f14c4cb3001d7cfc2f6447_D20190701-20190930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfMTYtMTItMS0xLTA_841d332a-3f4c-494c-bb3e-c666d202783c">18.4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Subtotal: Biosimilar product revenues</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i108b8c9cd74844ea902eb45e12f344d4_D20200701-20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfMTctMi0xLTEtMA_77bce617-93d6-4aa5-b043-d45f65931515">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i492d4f74b2774d46ba24d8836488319c_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfMTctNC0xLTEtMA_28ef42bb-2c2d-451a-98d4-5cd7061f5c19">207.9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i04f6a02314ae4524973688bb453aa3e5_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfMTctNi0xLTEtMA_69a57231-1cdb-44c3-8de4-8a3bec05ab2b">207.9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7a8274402a6247b58947c615cddc6683_D20190701-20190930" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfMTctOC0xLTEtMA_3132f738-48f0-45b7-b407-22cab17a4e9f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4f5d0029574e4134a8a64eeb2a84b092_D20190701-20190930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfMTctMTAtMS0xLTA_038500db-9cad-42a5-a519-f5d051bc9238">183.6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibd1e83f10a674384b5a5c22e4838bf7e_D20190701-20190930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfMTctMTItMS0xLTA_e7055e42-29fc-459c-b0e1-a938db9d5484">183.6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">FUMADERM</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7e2a3e2e67994b33aa594e6685bfb7a1_D20200701-20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfMjAtMi0xLTEtMA_ddf0c701-a131-4c2e-8cfe-b2a2b844eff4">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i83b0b2c0884c4420b9ec2c69e43f3b5b_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfMjAtNC0xLTEtMA_d7ccf418-86e7-4a75-9908-d4f1da5fde65">3.1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5887fc680fe24fb89317ffa45e0e7399_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfMjAtNi0xLTEtMA_11666f8a-9863-489d-92cb-84a84b24062f">3.1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib6b4fdc531a146d8b6ab0e3b3a410bb0_D20190701-20190930" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfMjAtOC0xLTEtMA_0a07f88c-52b4-4faf-9f5b-abf28359bbe0">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if2c497aaf27546a396c0c89e2d199e5d_D20190701-20190930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfMjAtMTAtMS0xLTA_ae4fb1aa-a46a-437d-bc56-82c233c39c80">3.8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i03858b8f5bce44fca9ffdbe13c9eb5e2_D20190701-20190930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfMjAtMTItMS0xLTA_75e4b40f-1660-4970-867e-2111d71c6fd1">3.8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total product revenues</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i82ddc3d73c6440f6b67ce2997a135a27_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfMjEtMi0xLTEtMA_de59c3bb-1566-4a74-8212-18641c86ecef">1,498.2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i537d78dad03f4414a8201cf28d6fb744_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfMjEtNC0xLTEtMA_0a8e6760-f6f4-486a-b8c9-f22b17dfc11a">1,192.1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iba1a633773a34c899b77b4853a665d4e_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfMjEtNi0xLTEtMA_8d0bb1a5-c246-469e-a606-a57f6678f3d3">2,690.3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i27f454fe7d384ff6b0419771f9b3e2d6_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfMjEtOC0xLTEtMA_f9789120-aee4-4824-95e7-74e5ecdc951b">1,702.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie5915a0ecdc446c396b8a751ccb2cb15_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfMjEtMTAtMS0xLTA_b8ac4026-0e46-4606-81ea-2aacab404f03">1,192.7</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i817821ea916346a6b301c5912257c3e5_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfMjEtMTItMS0xLTA_a15bc43b-81bd-4ee1-a318-3a40d61d4f86">2,894.7</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td></tr></table></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%;"><tr><td style="width:1.0%;"></td><td style="width:33.017%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:31.105%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:32.578%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">*Fumarate includes TECFIDERA and VUMERITY. VUMERITY became commercially available in the U.S. in November 2019.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">**Interferon includes AVONEX and PLEGRIDY.</span></div></ix:nonNumeric></ix:nonNumeric><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_7">Table of Contents</a></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(unaudited, continued)</span></div></div><ix:continuation id="i721f52f103984410bc10f654ce56163d" continuedAt="if82deff241014e66b1423e8b667d55c9"><ix:continuation id="i070eba9cc94b42c59acfc4fe9db8779c"><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%;"><tr><td style="width:1.0%;"></td><td style="width:31.300%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.536%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.503%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.536%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.356%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.536%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.356%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.536%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.356%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.536%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.503%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.536%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.510%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="33" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In millions)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">United<br/>States</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Rest of<br/>World</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">United<br/>States</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Rest of<br/>World</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Multiple Sclerosis (MS):</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fumarate*</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic542c97609834568beaf236a66f61e73_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfNC0yLTEtMS0w_a79ec1e3-7e1b-4a03-8103-5e3ae57a83ad">2,383.4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i54cede8da6804f35aad2512972cfec7d_D20200101-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfNC00LTEtMS0w_4cecb44b-f073-40d0-8176-7d60d7ffc68f">875.2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3fb38646d08e44f09e679dc53de54e79_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfNC02LTEtMS0w_a55f5262-3678-41fd-bb91-1e22d00f6176">3,258.6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i49af2b0ec0f64a17a1c3f06e8918b239_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfNC04LTEtMS0w_40c8db2f-cb20-411f-9bfe-abf8384470a6">2,429.5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i578fc5ffb2e64484b3d17b8c6505e6fe_D20190101-20190930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfNC0xMC0xLTEtMA_a3afd63c-9b02-42d6-bb25-ca6a8c079e71">841.9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icec0afd4985d4eebbcb6d942dc11861c_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfNC0xMi0xLTEtMA_3680a982-c815-4ebd-91e1-72c951ba7ddf">3,271.4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interferon**</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifff8a50ada4a4480aa27d7e429483ebc_D20200101-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfNS0yLTEtMS0w_55eb0ce5-3474-4fb0-86b4-d6b32c32d3f5">965.5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5ebf452657754a04b75cb22245331331_D20200101-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfNS00LTEtMS0w_2f8c372f-f92f-438b-8d17-5777f9d815a7">456.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i97559f8bfad646f4a63f6e7d1de603b3_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfNS02LTEtMS0w_558854fc-0b52-4c52-8e63-819a4baf067b">1,421.5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia54121683d93464386861f04a5eb0f78_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfNS04LTEtMS0w_766bbfea-17ea-4757-91d7-4ec2eb60154d">1,067.3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i58ceddab404b43efbc2aa182802d7e90_D20190101-20190930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfNS0xMC0xLTEtMA_1998b27e-611f-4b16-8331-2fc09f92c803">518.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8ff9cdd4f3124c71923b611c196ff399_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfNS0xMi0xLTEtMA_749e910f-67ec-413c-92e5-760314cb9d06">1,585.3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">TYSABRI</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i55c11d8111cc47e5b6fd6668e6688ebc_D20200101-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfNi0yLTEtMS0w_df6f713d-b388-47f4-a231-dc579fda1290">826.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i811b94cd1a9a4cdfa735283523ef7c2f_D20200101-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfNi00LTEtMS0w_e49c512a-3935-451b-bf14-d2ce1e24e3fc">644.9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iba49923c2dbc4cfa9e28cd6dc0232817_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfNi02LTEtMS0w_74fbdd7a-813b-4b37-9b23-2568eeca22f1">1,470.9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iaf55884ad575429cb3318dba7371b6ba_D20190101-20190930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfNi04LTEtMS0w_a796d1d8-5140-471b-9430-4732513bf3aa">772.3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2050ec4e36ba486eaaa52e2629f9eb4d_D20190101-20190930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfNi0xMC0xLTEtMA_92e67231-dbfc-4fa2-b296-132739c21bc1">647.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifa6b881f2fda4822952ca375ff987144_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfNi0xMi0xLTEtMA_237a96ea-3057-48a0-a49c-7daccfb3bbda">1,419.3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">FAMPYRA</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ica095eed2ba44dae9950be250f7d8e18_D20200101-20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfNy0yLTEtMS0w_2ec18baf-ddf7-4820-b198-09e798e3efce">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id65392444eb84d778e3da80dd59cb0ee_D20200101-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfNy00LTEtMS0w_9522fb52-ec8e-4c44-9332-42a4280d0167">78.1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6c5c5deb248640ea8a5b2acc2c061165_D20200101-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfNy02LTEtMS0w_feae3b86-4422-4025-83cf-4bda99728f4f">78.1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i45096669722b441a88f0da5da92b8c28_D20190101-20190930" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfNy04LTEtMS0w_aafae3e4-7f33-4eab-92d7-90e9ca772148">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifb862d5227ae4e258ddf1674e35ea488_D20190101-20190930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfNy0xMC0xLTEtMA_5cecac5c-7289-435e-a9a5-e4eb3b1eb948">71.2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3ebacf9f9e6841c3af9fbbaef43f7942_D20190101-20190930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfNy0xMi0xLTEtMA_c75c01e3-2745-47e1-ac34-303b8aee4247">71.2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Subtotal: MS product revenues</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if9481c82cb20488b9ef66d6125fd47af_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfOC0yLTEtMS0w_40c45c9c-8a30-46ce-94e1-5cfc677569d0">4,174.9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib0c82a598d09477ca3061b0c8ac0da77_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfOC00LTEtMS0w_2376c882-5c4d-4b6f-865d-d75396fcb42a">2,054.2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib99c15bafed34bf3a271edd3287e7b03_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfOC02LTEtMS0w_832b3863-b622-4f80-8775-2d3906aa5b33">6,229.1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iabb34cdf00c04963ad7af011adaf7ae7_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfOC04LTEtMS0w_8779d56f-1a14-48fe-94e8-5dd66ce3e666">4,269.1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7ac22170fd834262ac66fc712062e281_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfOC0xMC0xLTEtMA_731f23fc-e426-4611-bc3a-7c0dd8d86221">2,078.1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iffe091a9dada4645a5db26663b970d61_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfOC0xMi0xLTEtMA_2afa12d6-8a95-47b7-8b58-4e8f4ca9a8d1">6,347.2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Spinal Muscular Atrophy:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">SPINRAZA</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia7271f995472417c88ca939ff891ec17_D20200101-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfMTEtMi0xLTEtMA_bb74d0b2-4127-4f57-9c9a-df580e24cfb1">628.2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i24db87c55fa5436c82745477f49e8563_D20200101-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfMTEtNC0xLTEtMA_7697b437-f0c0-4b10-99e7-180f69b058f6">925.8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i327b2bcbf1a6442493e173a2baeab0c8_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfMTEtNi0xLTEtMA_b88ef3a5-e00f-4622-a84c-afcef6e05062">1,554.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i824479af0d2943a7a9ec0c36b60267a7_D20190101-20190930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfMTEtOC0xLTEtMA_8baf21b7-9f84-40ac-bbaa-b26b692acb49">690.6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id0ec100b681943e69c7c792eab6be4a9_D20190101-20190930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfMTEtMTAtMS0xLTA_6fccfe02-1260-4f6a-b759-4debf86511c2">863.2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if5f44218395d4becae44e95c8c6bdf51_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfMTEtMTItMS0xLTA_aa7246e4-ba68-407f-b7ce-774aebdb72a4">1,553.8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Biosimilars:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">BENEPALI</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib81a7f97279a40f9a38ad04e204987e3_D20200101-20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfMTQtMi0xLTEtMA_78b7bb64-43f1-495a-af87-f14cbaa96226">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib7068d1546c040608d8c969370cd8e9d_D20200101-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfMTQtNC0xLTEtMA_ed8d5d39-2ed6-4387-8806-3a7b1d0219a4">363.9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7bb0ccb59cdd4f0083748543233c3b52_D20200101-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfMTQtNi0xLTEtMA_9c07a100-0dc0-439c-91cf-d75245864289">363.9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7cadb5f8f65e4e73949863a5024f4ff7_D20190101-20190930" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfMTQtOC0xLTEtMA_840bf836-6cfe-4200-b050-c167c48c9457">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia8919ebc1037469d9bed32fa8eec69dc_D20190101-20190930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfMTQtMTAtMS0xLTA_90f7651b-204a-4ba3-a1c0-cd5999fad2a4">360.2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icee51ed1fdbc42b88487b41b6379cf78_D20190101-20190930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfMTQtMTItMS0xLTA_ec052f0b-8b8d-42c6-bfb5-4a09c8d76e73">360.2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">IMRALDI</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0f6da514a21b4672a427de97a1d05efb_D20200101-20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfMTUtMi0xLTEtMA_5681c1e6-57e4-471b-9800-49a169f18940">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7ca4c818e3ae4c34bae274600ab49c11_D20200101-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfMTUtNC0xLTEtMA_b05047c3-ded8-4e6d-b9f1-f470bd5ada71">162.6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia4c89150d9234c61910e3033151c6c58_D20200101-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfMTUtNi0xLTEtMA_2ceec17a-f394-43eb-8dcb-9c33114c0dd6">162.6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i18ff182dc2fa4ee6a2478c6486ebc688_D20190101-20190930" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfMTUtOC0xLTEtMA_7072549c-de49-4aa5-a07f-dfd74919e3f3">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i51ddcb898ae7480cbdaa9ec0ab68a246_D20190101-20190930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfMTUtMTAtMS0xLTA_8181c081-e690-4e73-89af-4086a7e66218">132.3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6f1f3b16e8d246ed9cb3f7cd93daf5bb_D20190101-20190930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfMTUtMTItMS0xLTA_e940c441-e58b-4dda-8885-ed217cf60703">132.3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">FLIXABI</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8e584f31a41a4eae8bf2342da93c54e2_D20200101-20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfMTYtMi0xLTEtMA_3752b6de-f191-4cd1-8954-6d223f773cad">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3a59fa0fcf0647fca4a684d8a73ac1ae_D20200101-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfMTYtNC0xLTEtMA_883472a3-ee1d-4649-96df-b32af84d6b69">71.8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7638af777ff44424ad832076c7ede12d_D20200101-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfMTYtNi0xLTEtMA_148d6942-f49e-4544-9077-d8d59e82f417">71.8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic66643a3fa6f4367b9eebb3e83bf3f00_D20190101-20190930" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfMTYtOC0xLTEtMA_9c146723-9855-4775-9f48-6942efb2b9f0">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i28632e06900d4c5c9e30bb7d2329c1ff_D20190101-20190930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfMTYtMTAtMS0xLTA_6c142545-d4f8-43f4-9dc4-e437108fc436">49.9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1c3e816876c048aa84d64152477c9781_D20190101-20190930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfMTYtMTItMS0xLTA_15adb16e-ab4b-4b27-9447-65f3fb740cf9">49.9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Subtotal: Biosimilar product revenues</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4ee8e58d8b904754b7733dede2183d4c_D20200101-20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfMTctMi0xLTEtMA_b362bc8c-744c-4a7f-984c-e93acd662bd7">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i529ab974da4c4d049570f91ae707a0ba_D20200101-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfMTctNC0xLTEtMA_2dc5afca-561a-44ff-9934-7acdf782a3cf">598.3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i254d19bbbef947d1a614d21d341de265_D20200101-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfMTctNi0xLTEtMA_ff08ff77-fd61-429b-bf34-4f74939bb160">598.3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id4eca9ea1df2452294cbdfa5fbed58c1_D20190101-20190930" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfMTctOC0xLTEtMA_bb98b925-dd4f-4036-8039-c26e71b0add3">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i58eb92d0895f4b14ab4e6bc4e13c9ffc_D20190101-20190930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfMTctMTAtMS0xLTA_e3312a02-e05d-4c83-9a8a-946376bcca8a">542.4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iab755c39193d4ef0bb6db78729b51f1d_D20190101-20190930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfMTctMTItMS0xLTA_d9020d2c-f5ef-4024-8798-e71595ff574e">542.4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">FUMADERM</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifee406589c20493a9b2fe20b2c5535a5_D20200101-20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfMjAtMi0xLTEtMA_fa7ca09f-d2b1-4ade-ac3c-6154275c9d6d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibf97ed01b19948c9bae6d6c52e933fcd_D20200101-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfMjAtNC0xLTEtMA_5dd74750-3fab-4124-a529-858076d44bf8">9.2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3cc3553689e84e56811b92f0dd3b6b92_D20200101-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfMjAtNi0xLTEtMA_c429215b-a123-414c-829d-f94ae128842b">9.2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5fea542032c54705846f79614c101fc1_D20190101-20190930" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfMjAtOC0xLTEtMA_9e798466-718e-4814-9a75-e312f0b1f55b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iea33bba3363f4d079ad12fb08f1e1b10_D20190101-20190930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfMjAtMTAtMS0xLTA_58d6d7a4-b0d9-413a-aad1-ea0cb619eebd">11.6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i882255f3fd6c4303973083ca690aa076_D20190101-20190930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfMjAtMTItMS0xLTA_cd176eb8-d9fe-4d4e-a535-ef0b99b2ad93">11.6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total product revenues</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie37b87d6a1074111b1725e662d8f0afa_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfMjEtMi0xLTEtMA_71dcb666-0a09-4073-8d01-620e635c362f">4,803.1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7adfff2dc6d34472b4ddbd0d4f2a4422_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfMjEtNC0xLTEtMA_2631da94-e5c4-446e-92cd-66d4e64ead61">3,587.5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id41b722bb5ce413f84c0e1a46961879f_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfMjEtNi0xLTEtMA_d9783895-e8b4-47e2-9050-09ae0f4798c2">8,390.6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if276cb15ef2546539e317deb2377ba10_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfMjEtOC0xLTEtMA_bd318797-4f1a-4212-8797-d5ab321f8578">4,959.7</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib5aba8b2bfc846c9b459ca84fc4e721d_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfMjEtMTAtMS0xLTA_977e1c2f-fcfc-4f9b-9068-8d80fd757bf4">3,495.3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if88c636dd80d492687ca22f07e75db13_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfMjEtMTItMS0xLTA_94f0feb5-6b92-4c7e-be05-a5da5acfb48a">8,455.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td></tr></table></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%;"><tr><td style="width:1.0%;"></td><td style="width:33.017%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:31.105%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:32.578%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">*Fumarate includes TECFIDERA and VUMERITY. VUMERITY became commercially available in the U.S. in November 2019.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">**Interferon includes AVONEX and PLEGRIDY.</span></div></ix:continuation><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We recognized revenues from <ix:nonFraction unitRef="wholesaler" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="INF" format="ixt-sec:numwordsen" name="biib:NumberOfWholesalers" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RleHRyZWdpb246YjUxMDhlMTQ5MTIxNGEyOGE1MWY0ZTljMWQ1NzM2NTVfODI0NjMzNzIxMTU5OQ_59642bb3-d017-4894-b141-87c476d25683"><ix:nonFraction unitRef="wholesaler" contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930" decimals="INF" format="ixt-sec:numwordsen" name="biib:NumberOfWholesalers" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RleHRyZWdpb246YjUxMDhlMTQ5MTIxNGEyOGE1MWY0ZTljMWQ1NzM2NTVfODI0NjMzNzIxMTU5OQ_a050ac89-37fb-4658-b3fa-cb7dccbf5ba1">two</ix:nonFraction></ix:nonFraction> wholesalers accounting for <ix:nonFraction unitRef="number" contextRef="i8df56b3f3ec24c9cad78f819aa3968bd_D20200701-20200930" decimals="INF" name="biib:EntityWidePercentageOfRevenueFromMajorDistributors" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RleHRyZWdpb246YjUxMDhlMTQ5MTIxNGEyOGE1MWY0ZTljMWQ1NzM2NTVfNDU2_719f9b0e-62aa-4fd9-a864-4498fc001382">31.2</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i3302fabf3956449599c4d0d7d34f36d6_D20200701-20200930" decimals="INF" name="biib:EntityWidePercentageOfRevenueFromMajorDistributors" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RleHRyZWdpb246YjUxMDhlMTQ5MTIxNGEyOGE1MWY0ZTljMWQ1NzM2NTVfNDYz_3538e8a1-9cbb-404c-8a07-5406aa06ccc2">15.6</ix:nonFraction>% of gross product revenues for the three months ended September 30, 2020, and <ix:nonFraction unitRef="number" contextRef="i6de66bb341bb422daee145e34cc96b52_D20200101-20200930" decimals="INF" name="biib:EntityWidePercentageOfRevenueFromMajorDistributors" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RleHRyZWdpb246YjUxMDhlMTQ5MTIxNGEyOGE1MWY0ZTljMWQ1NzM2NTVfNTI0_abfe7f7d-1b21-41b5-b6b4-c84aff66410c">30.9</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="idfabb0fde2e64da393d47657161d482f_D20200101-20200930" decimals="INF" name="biib:EntityWidePercentageOfRevenueFromMajorDistributors" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RleHRyZWdpb246YjUxMDhlMTQ5MTIxNGEyOGE1MWY0ZTljMWQ1NzM2NTVfNTMx_619fc6b6-d58d-4c3a-b17e-4ce5ee4f1051">16.0</ix:nonFraction>% of gross product revenues for the nine months ended September 30, 2020.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We recognized revenues from <ix:nonFraction unitRef="wholesaler" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="INF" format="ixt-sec:numwordsen" name="biib:NumberOfWholesalers" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RleHRyZWdpb246YjUxMDhlMTQ5MTIxNGEyOGE1MWY0ZTljMWQ1NzM2NTVfODI0NjMzNzIxMTYwNA_99d61649-333b-4869-9a94-508a350caa7a"><ix:nonFraction unitRef="wholesaler" contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930" decimals="INF" format="ixt-sec:numwordsen" name="biib:NumberOfWholesalers" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RleHRyZWdpb246YjUxMDhlMTQ5MTIxNGEyOGE1MWY0ZTljMWQ1NzM2NTVfODI0NjMzNzIxMTYwNA_f41ac990-1bc0-4e7b-9cfd-b92ee57999b9">two</ix:nonFraction></ix:nonFraction> wholesalers accounting for <ix:nonFraction unitRef="number" contextRef="ie223070107d841acb3680d718ad02ae6_D20190701-20190930" decimals="3" name="biib:EntityWidePercentageOfRevenueFromMajorDistributors" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RleHRyZWdpb246YjUxMDhlMTQ5MTIxNGEyOGE1MWY0ZTljMWQ1NzM2NTVfNjQ3_42c9f646-6d38-45a4-8970-c5aeb4a07306">28.7</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i52dc933695414f1895f943cb573be8c1_D20190701-20190930" decimals="3" name="biib:EntityWidePercentageOfRevenueFromMajorDistributors" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RleHRyZWdpb246YjUxMDhlMTQ5MTIxNGEyOGE1MWY0ZTljMWQ1NzM2NTVfNjU0_a743e5da-b6c3-4c8d-bacf-cf915be27367">18.4</ix:nonFraction>% of gross product revenues for the three months ended September 30, 2019, and <ix:nonFraction unitRef="number" contextRef="ie32fda1ac1154d048d97699d8290e7fa_D20190101-20190930" decimals="3" name="biib:EntityWidePercentageOfRevenueFromMajorDistributors" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RleHRyZWdpb246YjUxMDhlMTQ5MTIxNGEyOGE1MWY0ZTljMWQ1NzM2NTVfNzE1_7adab74f-5ed8-4722-8d03-9901bfe25463">30.1</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i5c0c40a4a5f74ba69177a07ee1ff0f2a_D20190101-20190930" decimals="3" name="biib:EntityWidePercentageOfRevenueFromMajorDistributors" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RleHRyZWdpb246YjUxMDhlMTQ5MTIxNGEyOGE1MWY0ZTljMWQ1NzM2NTVfNzIy_f109fb14-6db3-462c-af76-9725f7c0ef97">17.0</ix:nonFraction>% of gross product revenues for the nine months ended September 30, 2019.</span></div><ix:nonNumeric contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" name="biib:AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RleHRyZWdpb246YjUxMDhlMTQ5MTIxNGEyOGE1MWY0ZTljMWQ1NzM2NTVfMjc0Ng_0dce63f1-8fca-46d9-b176-ebd6816f2487" escape="true"><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">An analysis of the change in reserves for discounts and allowances is summarized as follows:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:47.155%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.526%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.109%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.526%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.109%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.526%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.109%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.526%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.114%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In millions)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Discounts</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contractual<br/>Adjustments</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Returns</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, December 31, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i02dda51ececd4bc28da1d9a328686af2_I20191231" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOjYzY2RiYTA2NWI5YzQxZDBiNTZhMGFiMzRhYTJjMTA2L3RhYmxlcmFuZ2U6NjNjZGJhMDY1YjljNDFkMGI1NmEwYWIzNGFhMmMxMDZfMS0yLTEtMS0w_6b228fcb-c848-44a2-84a0-35b81e855eaf">131.1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8b3ec66c47d44f20873b899460f118cf_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOjYzY2RiYTA2NWI5YzQxZDBiNTZhMGFiMzRhYTJjMTA2L3RhYmxlcmFuZ2U6NjNjZGJhMDY1YjljNDFkMGI1NmEwYWIzNGFhMmMxMDZfMS00LTEtMS0w_2a19b34f-083a-4058-978d-39257371f43d">1,027.3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i547ca2c2237a4a379988e41835ac1091_I20191231" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOjYzY2RiYTA2NWI5YzQxZDBiNTZhMGFiMzRhYTJjMTA2L3RhYmxlcmFuZ2U6NjNjZGJhMDY1YjljNDFkMGI1NmEwYWIzNGFhMmMxMDZfMS02LTEtMS0w_bd67c398-a710-4483-833f-f8ccf1b7efbf">40.5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i626282e786b7454d83b617e9e83963e6_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOjYzY2RiYTA2NWI5YzQxZDBiNTZhMGFiMzRhYTJjMTA2L3RhYmxlcmFuZ2U6NjNjZGJhMDY1YjljNDFkMGI1NmEwYWIzNGFhMmMxMDZfMS04LTEtMS0w_88556235-5673-4ba2-8db8-5ccfad521a48">1,198.9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current provisions relating to sales in current year</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if2a30a4831ac4e68b68264f34f994f66_D20200101-20200930" decimals="-5" name="biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOjYzY2RiYTA2NWI5YzQxZDBiNTZhMGFiMzRhYTJjMTA2L3RhYmxlcmFuZ2U6NjNjZGJhMDY1YjljNDFkMGI1NmEwYWIzNGFhMmMxMDZfMi0yLTEtMS0w_eb9287d5-cf86-46c4-9b55-78dd1f461927">589.6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1a535a6744d640489dfb975ae50eafb4_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOjYzY2RiYTA2NWI5YzQxZDBiNTZhMGFiMzRhYTJjMTA2L3RhYmxlcmFuZ2U6NjNjZGJhMDY1YjljNDFkMGI1NmEwYWIzNGFhMmMxMDZfMi00LTEtMS0w_14fca837-6641-421c-807a-f438798b307b">2,465.8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4608a28d79084131af5440bda4ce4ba5_D20200101-20200930" decimals="-5" name="biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOjYzY2RiYTA2NWI5YzQxZDBiNTZhMGFiMzRhYTJjMTA2L3RhYmxlcmFuZ2U6NjNjZGJhMDY1YjljNDFkMGI1NmEwYWIzNGFhMmMxMDZfMi02LTEtMS0w_3d8c9fdd-794b-42f7-86bd-c6769ecb124e">14.8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOjYzY2RiYTA2NWI5YzQxZDBiNTZhMGFiMzRhYTJjMTA2L3RhYmxlcmFuZ2U6NjNjZGJhMDY1YjljNDFkMGI1NmEwYWIzNGFhMmMxMDZfMi04LTEtMS0w_f30caf26-5438-4b94-bd5a-ea6eee3979fc">3,070.2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Adjustments relating to prior years</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if2a30a4831ac4e68b68264f34f994f66_D20200101-20200930" decimals="-5" name="biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOjYzY2RiYTA2NWI5YzQxZDBiNTZhMGFiMzRhYTJjMTA2L3RhYmxlcmFuZ2U6NjNjZGJhMDY1YjljNDFkMGI1NmEwYWIzNGFhMmMxMDZfMy0yLTEtMS0w_abcd6553-7443-438d-ac27-11cef31faeb0">1.0</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1a535a6744d640489dfb975ae50eafb4_D20200101-20200930" decimals="-5" name="biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOjYzY2RiYTA2NWI5YzQxZDBiNTZhMGFiMzRhYTJjMTA2L3RhYmxlcmFuZ2U6NjNjZGJhMDY1YjljNDFkMGI1NmEwYWIzNGFhMmMxMDZfMy00LTEtMS0w_31f41323-4bf9-4d64-a6e2-7ce9d041ab01">41.6</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4608a28d79084131af5440bda4ce4ba5_D20200101-20200930" decimals="-5" sign="-" name="biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOjYzY2RiYTA2NWI5YzQxZDBiNTZhMGFiMzRhYTJjMTA2L3RhYmxlcmFuZ2U6NjNjZGJhMDY1YjljNDFkMGI1NmEwYWIzNGFhMmMxMDZfMy02LTEtMS0w_18223f3b-4729-4b95-a99a-4fba8ac1423a">1.8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="-5" name="biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOjYzY2RiYTA2NWI5YzQxZDBiNTZhMGFiMzRhYTJjMTA2L3RhYmxlcmFuZ2U6NjNjZGJhMDY1YjljNDFkMGI1NmEwYWIzNGFhMmMxMDZfMy04LTEtMS0w_219509a1-d1fa-4483-9c5c-8a4c1b435992">40.8</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Payments/credits relating to sales in current year</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if2a30a4831ac4e68b68264f34f994f66_D20200101-20200930" decimals="-5" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOjYzY2RiYTA2NWI5YzQxZDBiNTZhMGFiMzRhYTJjMTA2L3RhYmxlcmFuZ2U6NjNjZGJhMDY1YjljNDFkMGI1NmEwYWIzNGFhMmMxMDZfNC0yLTEtMS0w_851b7785-3c92-4b3f-bba0-8beefaead3b1">457.9</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1a535a6744d640489dfb975ae50eafb4_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOjYzY2RiYTA2NWI5YzQxZDBiNTZhMGFiMzRhYTJjMTA2L3RhYmxlcmFuZ2U6NjNjZGJhMDY1YjljNDFkMGI1NmEwYWIzNGFhMmMxMDZfNC00LTEtMS0w_0d783e95-712d-4091-a0bc-b56911558ef2">1,704.5</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4608a28d79084131af5440bda4ce4ba5_D20200101-20200930" decimals="-5" format="ixt:zerodash" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOjYzY2RiYTA2NWI5YzQxZDBiNTZhMGFiMzRhYTJjMTA2L3RhYmxlcmFuZ2U6NjNjZGJhMDY1YjljNDFkMGI1NmEwYWIzNGFhMmMxMDZfNC02LTEtMS0w_4aeeb863-c847-46ec-8a55-1567aaa60f64">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOjYzY2RiYTA2NWI5YzQxZDBiNTZhMGFiMzRhYTJjMTA2L3RhYmxlcmFuZ2U6NjNjZGJhMDY1YjljNDFkMGI1NmEwYWIzNGFhMmMxMDZfNC04LTEtMS0w_7164c526-65c3-4163-8076-49c9f74fe354">2,162.4</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Payments/credits relating to sales in prior years</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if2a30a4831ac4e68b68264f34f994f66_D20200101-20200930" decimals="-5" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOjYzY2RiYTA2NWI5YzQxZDBiNTZhMGFiMzRhYTJjMTA2L3RhYmxlcmFuZ2U6NjNjZGJhMDY1YjljNDFkMGI1NmEwYWIzNGFhMmMxMDZfNS0yLTEtMS0w_24351adc-b8f1-4966-bc39-c32d04de40db">120.3</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1a535a6744d640489dfb975ae50eafb4_D20200101-20200930" decimals="-5" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOjYzY2RiYTA2NWI5YzQxZDBiNTZhMGFiMzRhYTJjMTA2L3RhYmxlcmFuZ2U6NjNjZGJhMDY1YjljNDFkMGI1NmEwYWIzNGFhMmMxMDZfNS00LTEtMS0w_b2e7d76c-89bc-40e4-9583-69d5e036703f">658.4</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i4608a28d79084131af5440bda4ce4ba5_D20200101-20200930" decimals="-5" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOjYzY2RiYTA2NWI5YzQxZDBiNTZhMGFiMzRhYTJjMTA2L3RhYmxlcmFuZ2U6NjNjZGJhMDY1YjljNDFkMGI1NmEwYWIzNGFhMmMxMDZfNS02LTEtMS0w_3732ec9c-ec35-4576-bf09-c5835f4ab024">15.4</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="-5" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOjYzY2RiYTA2NWI5YzQxZDBiNTZhMGFiMzRhYTJjMTA2L3RhYmxlcmFuZ2U6NjNjZGJhMDY1YjljNDFkMGI1NmEwYWIzNGFhMmMxMDZfNS04LTEtMS0w_3ac7b268-ebd9-4ca3-bfba-cb70d9c28e96">794.1</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, September 30, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i204f2ca2855b47ec88cf265fde7a6679_I20200930" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOjYzY2RiYTA2NWI5YzQxZDBiNTZhMGFiMzRhYTJjMTA2L3RhYmxlcmFuZ2U6NjNjZGJhMDY1YjljNDFkMGI1NmEwYWIzNGFhMmMxMDZfNi0yLTEtMS0w_5ef206cb-4327-4962-aef9-c004f9002eba">141.5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7897f16ad9b249e08151468bc3c92f5c_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOjYzY2RiYTA2NWI5YzQxZDBiNTZhMGFiMzRhYTJjMTA2L3RhYmxlcmFuZ2U6NjNjZGJhMDY1YjljNDFkMGI1NmEwYWIzNGFhMmMxMDZfNi00LTEtMS0w_8961b6c5-76a1-4616-b01e-f3e22272951e">1,088.6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i897e79a0b82b448297a7d6e150e50906_I20200930" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOjYzY2RiYTA2NWI5YzQxZDBiNTZhMGFiMzRhYTJjMTA2L3RhYmxlcmFuZ2U6NjNjZGJhMDY1YjljNDFkMGI1NmEwYWIzNGFhMmMxMDZfNi02LTEtMS0w_5da215c0-4375-4edf-8251-4ffd84ba8391">41.7</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOjYzY2RiYTA2NWI5YzQxZDBiNTZhMGFiMzRhYTJjMTA2L3RhYmxlcmFuZ2U6NjNjZGJhMDY1YjljNDFkMGI1NmEwYWIzNGFhMmMxMDZfNi04LTEtMS0w_e33f7ef9-81c2-4c72-8f71-25bcf48fcef9">1,271.8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" name="biib:SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RleHRyZWdpb246YjUxMDhlMTQ5MTIxNGEyOGE1MWY0ZTljMWQ1NzM2NTVfMjc0Mw_d094c2e6-0e65-4657-9c8a-451766640826" escape="true"><div style="text-indent:24.75pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The total reserves above, which are included in our condensed consolidated balance sheets, are summarized as follows:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:65.808%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.525%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:14.720%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.525%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:14.722%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In millions)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">As of September 30, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Reduction of accounts receivable, net</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ieabb7bcb048b432c908c601e832af027_I20200930" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOjc5MTBmMjg4ODcwMzRkYTBhZWU3ZWZmZTE0OGM0NjhjL3RhYmxlcmFuZ2U6NzkxMGYyODg4NzAzNGRhMGFlZTdlZmZlMTQ4YzQ2OGNfMS0yLTEtMS0w_edce7258-2632-4558-8547-d4c27a88455f">227.9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i65c7f4e2aad74eb78be96cec75c1e6c8_I20191231" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOjc5MTBmMjg4ODcwMzRkYTBhZWU3ZWZmZTE0OGM0NjhjL3RhYmxlcmFuZ2U6NzkxMGYyODg4NzAzNGRhMGFlZTdlZmZlMTQ4YzQ2OGNfMS00LTEtMS0w_0ae13f56-ca7e-44d3-b5d8-ebe1c9acf4e1">197.8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Component of accrued expenses and other</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7eddadc447104f8eb26db7302eace7a5_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOjc5MTBmMjg4ODcwMzRkYTBhZWU3ZWZmZTE0OGM0NjhjL3RhYmxlcmFuZ2U6NzkxMGYyODg4NzAzNGRhMGFlZTdlZmZlMTQ4YzQ2OGNfMi0yLTEtMS0w_4295948a-eea5-467b-9d26-a61fba85caa5">1,043.9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ide07a6c272e244a3be181989da603c09_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOjc5MTBmMjg4ODcwMzRkYTBhZWU3ZWZmZTE0OGM0NjhjL3RhYmxlcmFuZ2U6NzkxMGYyODg4NzAzNGRhMGFlZTdlZmZlMTQ4YzQ2OGNfMi00LTEtMS0w_4475e525-6c9d-43b7-8d32-191208d6e82d">1,001.1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total revenue-related reserves</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOjc5MTBmMjg4ODcwMzRkYTBhZWU3ZWZmZTE0OGM0NjhjL3RhYmxlcmFuZ2U6NzkxMGYyODg4NzAzNGRhMGFlZTdlZmZlMTQ4YzQ2OGNfMy0yLTEtMS0w_6122e4fc-04ca-4d8f-a3b9-86cbecbef9df">1,271.8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i626282e786b7454d83b617e9e83963e6_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOjc5MTBmMjg4ODcwMzRkYTBhZWU3ZWZmZTE0OGM0NjhjL3RhYmxlcmFuZ2U6NzkxMGYyODg4NzAzNGRhMGFlZTdlZmZlMTQ4YzQ2OGNfMy00LTEtMS0w_03e53ce3-d95c-4eb6-9420-3e895b0bf937">1,198.9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_7">Table of Contents</a></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(unaudited, continued)</span></div></div><ix:continuation id="if82deff241014e66b1423e8b667d55c9" continuedAt="i0b7d64d46c2e4982ba705620ace5e655"><div style="text-indent:13.5pt;margin-top:7pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2472b9;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Revenues from Anti-CD20 Therapeutic Programs</span></div><ix:nonNumeric contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" name="biib:RevenuesfromantiCD20therapeuticprogramsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RleHRyZWdpb246YjUxMDhlMTQ5MTIxNGEyOGE1MWY0ZTljMWQ1NzM2NTVfMjc2NQ_2fd1f129-44be-4561-9eed-25fd0ea47794" escape="true"><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Revenues from anti-CD20 therapeutic programs are summarized below. For the purposes of this footnote we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:49.338%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.595%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.384%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.595%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.595%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.603%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Three Months Ended September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In millions)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Biogen&#8217;s share of pre-tax profits in the U.S. for RITUXAN and GAZYVA</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i144bad8e98d44b9283666efd91ae814b_D20200701-20200930" decimals="-5" name="biib:ShareOfCoPromotionProfits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOjc5NjAxNjA2MDM1MTRkM2Y4NzhiNzAxZTdhNGNmZWU5L3RhYmxlcmFuZ2U6Nzk2MDE2MDYwMzUxNGQzZjg3OGI3MDFlN2E0Y2ZlZTlfMi0yLTEtMS0w_4ed6d0f9-ab1f-4142-8ff9-9d23560f0740">275.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icfb2a7f321824155859b452e7e1620d7_D20190701-20190930" decimals="-5" name="biib:ShareOfCoPromotionProfits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOjc5NjAxNjA2MDM1MTRkM2Y4NzhiNzAxZTdhNGNmZWU5L3RhYmxlcmFuZ2U6Nzk2MDE2MDYwMzUxNGQzZjg3OGI3MDFlN2E0Y2ZlZTlfMi00LTEtMS0w_6994196c-82e6-4276-bd74-9641b8c6ada8">393.2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic8db6af1daf2476691a91e008e2e4614_D20200101-20200930" decimals="-5" name="biib:ShareOfCoPromotionProfits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOjc5NjAxNjA2MDM1MTRkM2Y4NzhiNzAxZTdhNGNmZWU5L3RhYmxlcmFuZ2U6Nzk2MDE2MDYwMzUxNGQzZjg3OGI3MDFlN2E0Y2ZlZTlfMi02LTEtMS0w_160bf24f-ca8d-4880-9c08-743cc9d50a7f">873.8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i647942c6e60f4fd3a53dd00558c6b691_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="biib:ShareOfCoPromotionProfits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOjc5NjAxNjA2MDM1MTRkM2Y4NzhiNzAxZTdhNGNmZWU5L3RhYmxlcmFuZ2U6Nzk2MDE2MDYwMzUxNGQzZjg3OGI3MDFlN2E0Y2ZlZTlfMi04LTEtMS0w_0a89b965-d901-4a91-b17c-de178f8fb1cb">1,161.2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other revenues from anti-CD20 therapeutic programs</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i144bad8e98d44b9283666efd91ae814b_D20200701-20200930" decimals="-5" name="biib:OtherrevenuesfromantiCD20therapeuticprograms" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOjc5NjAxNjA2MDM1MTRkM2Y4NzhiNzAxZTdhNGNmZWU5L3RhYmxlcmFuZ2U6Nzk2MDE2MDYwMzUxNGQzZjg3OGI3MDFlN2E0Y2ZlZTlfMy0yLTEtMS0w_12337970-f5cf-440f-97fc-522ebd5f462d">285.1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icfb2a7f321824155859b452e7e1620d7_D20190701-20190930" decimals="-5" name="biib:OtherrevenuesfromantiCD20therapeuticprograms" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOjc5NjAxNjA2MDM1MTRkM2Y4NzhiNzAxZTdhNGNmZWU5L3RhYmxlcmFuZ2U6Nzk2MDE2MDYwMzUxNGQzZjg3OGI3MDFlN2E0Y2ZlZTlfMy00LTEtMS0w_621a02cc-2de2-4c34-b977-20e5fe04caac">202.6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic8db6af1daf2476691a91e008e2e4614_D20200101-20200930" decimals="-5" name="biib:OtherrevenuesfromantiCD20therapeuticprograms" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOjc5NjAxNjA2MDM1MTRkM2Y4NzhiNzAxZTdhNGNmZWU5L3RhYmxlcmFuZ2U6Nzk2MDE2MDYwMzUxNGQzZjg3OGI3MDFlN2E0Y2ZlZTlfMy02LTEtMS0w_f4ceddb8-336e-4f9c-b757-8db9a72a5d1b">685.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i647942c6e60f4fd3a53dd00558c6b691_D20190101-20190930" decimals="-5" name="biib:OtherrevenuesfromantiCD20therapeuticprograms" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOjc5NjAxNjA2MDM1MTRkM2Y4NzhiNzAxZTdhNGNmZWU5L3RhYmxlcmFuZ2U6Nzk2MDE2MDYwMzUxNGQzZjg3OGI3MDFlN2E0Y2ZlZTlfMy04LTEtMS0w_e16f2e31-4930-46fc-8711-ab28b8155842">528.4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total revenues from anti-CD20 therapeutic programs</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia428d1f03d1f454a9d5c837ec6e0aa50_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOjc5NjAxNjA2MDM1MTRkM2Y4NzhiNzAxZTdhNGNmZWU5L3RhYmxlcmFuZ2U6Nzk2MDE2MDYwMzUxNGQzZjg3OGI3MDFlN2E0Y2ZlZTlfNC0yLTEtMS0w_d1573c12-40af-4c76-882a-0625cf909262">560.1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8595ad2d43f34d98abb716a40fde60a6_D20190701-20190930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOjc5NjAxNjA2MDM1MTRkM2Y4NzhiNzAxZTdhNGNmZWU5L3RhYmxlcmFuZ2U6Nzk2MDE2MDYwMzUxNGQzZjg3OGI3MDFlN2E0Y2ZlZTlfNC00LTEtMS0w_e45f0745-64df-4a6a-b15e-7192ea91cdb8">595.8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0cb93d1ae39f48f3b0fc167540132b77_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOjc5NjAxNjA2MDM1MTRkM2Y4NzhiNzAxZTdhNGNmZWU5L3RhYmxlcmFuZ2U6Nzk2MDE2MDYwMzUxNGQzZjg3OGI3MDFlN2E0Y2ZlZTlfNC02LTEtMS0w_2355c8ad-e743-418a-967a-56f226dd2b1e">1,558.8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5452667727cd4cf08cae4c412b67d3ef_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOjc5NjAxNjA2MDM1MTRkM2Y4NzhiNzAxZTdhNGNmZWU5L3RhYmxlcmFuZ2U6Nzk2MDE2MDYwMzUxNGQzZjg3OGI3MDFlN2E0Y2ZlZTlfNC04LTEtMS0w_959100d7-f9c3-4823-8e41-79179c49b275">1,689.6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td></tr></table></div></ix:nonNumeric><div style="text-indent:24.75pt;padding-right:2.25pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For additional information on our collaboration arrangements with Genentech, please read </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Note 18,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Collaborative and Other Relationships, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">to our consolidated financial statements included in our 2019 Form 10-K.</span></div><div style="text-indent:13.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2472b9;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Other Revenues</span></div><ix:nonNumeric contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" name="biib:OtherrevenuesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RleHRyZWdpb246YjUxMDhlMTQ5MTIxNGEyOGE1MWY0ZTljMWQ1NzM2NTVfMjcyMw_b578ad20-c4a4-4a16-b72b-dc4d3378f62f" escape="true"><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Other revenues are summarized as follows:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:49.192%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.595%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.595%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.595%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.603%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Three Months Ended September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In millions)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenues from collaborative and other relationships:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Profit (loss) earned under our 50% share of the co-promotion losses on ZINBRYTA in the U.S. with AbbVie Inc.</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7b511ee9603b41fda2cc6f8171976d4e_D20200701-20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmZmNDAzMjM3NTRjMTRkNWFhMjczODI0NTcwZTMyN2E1L3RhYmxlcmFuZ2U6ZmY0MDMyMzc1NGMxNGQ1YWEyNzM4MjQ1NzBlMzI3YTVfMy0yLTEtMS0w_5d974b68-6eed-4deb-962a-3b216e8df94c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6c11f9b8d3684514917520eb76b5297d_D20190701-20190930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmZmNDAzMjM3NTRjMTRkNWFhMjczODI0NTcwZTMyN2E1L3RhYmxlcmFuZ2U6ZmY0MDMyMzc1NGMxNGQ1YWEyNzM4MjQ1NzBlMzI3YTVfMy00LTEtMS0w_7582da50-0078-4124-9b91-75060d20a4e4">0.3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ida3ec850012e473c82f5aebf509be5cc_D20200101-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmZmNDAzMjM3NTRjMTRkNWFhMjczODI0NTcwZTMyN2E1L3RhYmxlcmFuZ2U6ZmY0MDMyMzc1NGMxNGQ1YWEyNzM4MjQ1NzBlMzI3YTVfMy02LTEtMS0w_ab8f6ebb-72f9-43ec-bf6e-fc2a5ac27d61">0.7</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i528e10772f27492fa438cba3d636945a_D20190101-20190930" decimals="-5" sign="-" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmZmNDAzMjM3NTRjMTRkNWFhMjczODI0NTcwZTMyN2E1L3RhYmxlcmFuZ2U6ZmY0MDMyMzc1NGMxNGQ1YWEyNzM4MjQ1NzBlMzI3YTVfMy04LTEtMS0w_16c94a2d-64a2-4c5c-add8-9f621f59be23">0.2</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenues earned under our technical development agreement, manufacturing services agreements and royalty revenues on biosimilar products with Samsung Bioepis</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i083a7fa4caa1424dbbf1d7151d395e24_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmZmNDAzMjM3NTRjMTRkNWFhMjczODI0NTcwZTMyN2E1L3RhYmxlcmFuZ2U6ZmY0MDMyMzc1NGMxNGQ1YWEyNzM4MjQ1NzBlMzI3YTVfNC0yLTEtMS0w_44835de9-cfa6-4c06-a928-c043870bfd93">5.4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i96f6c016546448cb939dbb6557754670_D20190701-20190930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmZmNDAzMjM3NTRjMTRkNWFhMjczODI0NTcwZTMyN2E1L3RhYmxlcmFuZ2U6ZmY0MDMyMzc1NGMxNGQ1YWEyNzM4MjQ1NzBlMzI3YTVfNC00LTEtMS0w_16b5847b-a05e-4e93-971d-48863a6c2867">12.9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib6369975ed9d437593f2e153c72f7978_D20200101-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmZmNDAzMjM3NTRjMTRkNWFhMjczODI0NTcwZTMyN2E1L3RhYmxlcmFuZ2U6ZmY0MDMyMzc1NGMxNGQ1YWEyNzM4MjQ1NzBlMzI3YTVfNC02LTEtMS0w_2fbc8957-cdf8-4d41-aa41-9665ec173a45">13.6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id6f2c098f47f4305b065fa0a773ea01b_D20190101-20190930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmZmNDAzMjM3NTRjMTRkNWFhMjczODI0NTcwZTMyN2E1L3RhYmxlcmFuZ2U6ZmY0MDMyMzc1NGMxNGQ1YWEyNzM4MjQ1NzBlMzI3YTVfNC04LTEtMS0w_5604a553-ef1a-4dc9-a1e7-bfe85a137b42">89.9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other royalty and corporate revenues:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Royalty</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7aaebf479efd4e5988b193f96cfea104_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmZmNDAzMjM3NTRjMTRkNWFhMjczODI0NTcwZTMyN2E1L3RhYmxlcmFuZ2U6ZmY0MDMyMzc1NGMxNGQ1YWEyNzM4MjQ1NzBlMzI3YTVfNi0yLTEtMS0w_d4e262aa-1cb8-4792-ab70-2d871b2bef11">10.3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i727d852e008a4093bc7eeae55e9ac6e9_D20190701-20190930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmZmNDAzMjM3NTRjMTRkNWFhMjczODI0NTcwZTMyN2E1L3RhYmxlcmFuZ2U6ZmY0MDMyMzc1NGMxNGQ1YWEyNzM4MjQ1NzBlMzI3YTVfNi00LTEtMS0w_729665f4-f771-4cd7-b1bd-4047d7de275c">3.3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3a892823ca8b4d289bbf6e819b53df89_D20200101-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmZmNDAzMjM3NTRjMTRkNWFhMjczODI0NTcwZTMyN2E1L3RhYmxlcmFuZ2U6ZmY0MDMyMzc1NGMxNGQ1YWEyNzM4MjQ1NzBlMzI3YTVfNi02LTEtMS0w_02cce8f1-131d-448a-9543-309c418c4955">28.8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7a2aaddc244148d29b9babb1a6e4d21a_D20190101-20190930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmZmNDAzMjM3NTRjMTRkNWFhMjczODI0NTcwZTMyN2E1L3RhYmxlcmFuZ2U6ZmY0MDMyMzc1NGMxNGQ1YWEyNzM4MjQ1NzBlMzI3YTVfNi04LTEtMS0w_4f90557c-dfc3-45f6-b43c-2fbfed1cc700">9.9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other corporate</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id62c1ea890004cc683b1c3e2197b9771_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmZmNDAzMjM3NTRjMTRkNWFhMjczODI0NTcwZTMyN2E1L3RhYmxlcmFuZ2U6ZmY0MDMyMzc1NGMxNGQ1YWEyNzM4MjQ1NzBlMzI3YTVfNy0yLTEtMS0w_a6e47151-b699-4303-bce5-c5c0eae44aa8">110.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0e78e06924024013a86b44bea5d8c5fc_D20190701-20190930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmZmNDAzMjM3NTRjMTRkNWFhMjczODI0NTcwZTMyN2E1L3RhYmxlcmFuZ2U6ZmY0MDMyMzc1NGMxNGQ1YWEyNzM4MjQ1NzBlMzI3YTVfNy00LTEtMS0w_6899c4f9-dd36-41a9-9de4-6ef3b6bfa704">93.1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i64ed3edf8c234417860f788da7ecdef3_D20200101-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmZmNDAzMjM3NTRjMTRkNWFhMjczODI0NTcwZTMyN2E1L3RhYmxlcmFuZ2U6ZmY0MDMyMzc1NGMxNGQ1YWEyNzM4MjQ1NzBlMzI3YTVfNy02LTEtMS0w_873dc85e-f729-4a89-bb39-1695b91c579b">599.5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b88a1e534d44643b0824a70718ed27c_D20190101-20190930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmZmNDAzMjM3NTRjMTRkNWFhMjczODI0NTcwZTMyN2E1L3RhYmxlcmFuZ2U6ZmY0MDMyMzc1NGMxNGQ1YWEyNzM4MjQ1NzBlMzI3YTVfNy04LTEtMS0w_9896e703-c467-4581-9f32-aefde60fbdff">462.4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total other revenues</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iba6a7aa4c7fa4fda950fccc032894346_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmZmNDAzMjM3NTRjMTRkNWFhMjczODI0NTcwZTMyN2E1L3RhYmxlcmFuZ2U6ZmY0MDMyMzc1NGMxNGQ1YWEyNzM4MjQ1NzBlMzI3YTVfOC0yLTEtMS0w_5253c89e-d19a-45a3-9e18-1d6dea309c7a">125.7</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0ea06cd6a9974b4999904b90f030878b_D20190701-20190930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmZmNDAzMjM3NTRjMTRkNWFhMjczODI0NTcwZTMyN2E1L3RhYmxlcmFuZ2U6ZmY0MDMyMzc1NGMxNGQ1YWEyNzM4MjQ1NzBlMzI3YTVfOC00LTEtMS0w_5b225ab9-38de-4701-b0c2-de8f3c578570">109.6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6e0b6c1de005431bb80fcd07bc90af2e_D20200101-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmZmNDAzMjM3NTRjMTRkNWFhMjczODI0NTcwZTMyN2E1L3RhYmxlcmFuZ2U6ZmY0MDMyMzc1NGMxNGQ1YWEyNzM4MjQ1NzBlMzI3YTVfOC02LTEtMS0w_059920dd-6d27-4c72-b146-9e0af95b6f5b">642.6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2335a9cc65b041aa8e881414fc49759c_D20190101-20190930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmZmNDAzMjM3NTRjMTRkNWFhMjczODI0NTcwZTMyN2E1L3RhYmxlcmFuZ2U6ZmY0MDMyMzc1NGMxNGQ1YWEyNzM4MjQ1NzBlMzI3YTVfOC04LTEtMS0w_24bf8ef9-5c22-433a-86fe-81a790fa8ce6">562.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td></tr></table></div></ix:nonNumeric><div style="text-indent:22.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the third quarter of 2019, we amended our agreement with a contract manufacturing customer pursuant to which we licensed certain of our manufacturing-related intellectual property to the customer. In the second quarter of 2020, the customer received regulatory approval for its product that is being manufactured using certain of our manufacturing-related intellectual property. As a result, we are entitled to $<ix:nonFraction unitRef="usd" contextRef="i63cfe59d1dc247b88c3f0c79a4c20ddb_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RleHRyZWdpb246YjUxMDhlMTQ5MTIxNGEyOGE1MWY0ZTljMWQ1NzM2NTVfMTg5MA_9d783c96-964b-49b1-88cc-78531f91cdb9">500.0</ix:nonFraction> million in a series of three payments. The first payment became due upon regulatory approval of such product and was received during the second quarter of 2020. Subsequent payments are due on the first and second anniversaries of the regulatory approval. </span></div></ix:continuation><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i0b7d64d46c2e4982ba705620ace5e655">Other corporate revenues for the nine months ended September 30, 2020, reflect $<ix:nonFraction unitRef="usd" contextRef="ie108e7ffa05346ff9834f57e7ffcdad2_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RleHRyZWdpb246YjUxMDhlMTQ5MTIxNGEyOGE1MWY0ZTljMWQ1NzM2NTVfMjIwMw_fe8df0f7-8cea-4bf6-abf9-de867ad8c4dc">333.2</ix:nonFraction> million related to the delivery of the license for certain of our manufacturing-related intellectual property under the amended agreement discussed above and the performance of manufacturing product supply services for such customer. We have allocated the remaining $<ix:nonFraction unitRef="usd" contextRef="i9be493af1ef548c7b50cb146bad36446_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RleHRyZWdpb246YjUxMDhlMTQ5MTIxNGEyOGE1MWY0ZTljMWQ1NzM2NTVfMTA5OTUxMTYzMDU4OA_8a4560a6-d2a5-493e-9371-332bc9c6dcf3">166.8</ix:nonFraction>&#160;million of the $<ix:nonFraction unitRef="usd" contextRef="i63cfe59d1dc247b88c3f0c79a4c20ddb_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RleHRyZWdpb246YjUxMDhlMTQ5MTIxNGEyOGE1MWY0ZTljMWQ1NzM2NTVfMTA5OTUxMTYzMDY1MA_9d783c96-964b-49b1-88cc-78531f91cdb9">500.0</ix:nonFraction> million transaction price to the performance of manufacturing product supply services for the customer, which we expect to perform through 2026. The value allocated to the manufacturing services was based on expected demand for supply and the fair value of comparable manufacturing and development services.</ix:continuation> </span></div><div id="ib19ff89608c84168a635160f2efa48f3_58"></div><div style="text-indent:-27pt;padding-left:27pt;margin-top:14pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">5.&#160;&#160;&#160;&#160;Inventory </span></div><ix:nonNumeric contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181OC9mcmFnOjE0NzgwNDgyZTZiNTQwMDlhMGRlN2Y1ZTU4NTliYTRiL3RleHRyZWdpb246MTQ3ODA0ODJlNmI1NDAwOWEwZGU3ZjVlNTg1OWJhNGJfNzI_b21ebca1-0b43-46cb-8a36-39428afdcdf5" escape="true"><ix:nonNumeric contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181OC9mcmFnOjE0NzgwNDgyZTZiNTQwMDlhMGRlN2Y1ZTU4NTliYTRiL3RleHRyZWdpb246MTQ3ODA0ODJlNmI1NDAwOWEwZGU3ZjVlNTg1OWJhNGJfODE_f881ecef-423f-461e-ab2a-b989e78b2eb4" escape="true"><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The components of inventory are summarized as follows:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.830%;"><tr><td style="width:1.0%;"></td><td style="width:58.071%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.539%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:18.574%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.539%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:18.577%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In millions)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">As of September 30, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Raw materials</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930" decimals="-5" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181OC9mcmFnOjE0NzgwNDgyZTZiNTQwMDlhMGRlN2Y1ZTU4NTliYTRiL3RhYmxlOjM1NWRiN2Y4YTJkMDQ2M2M4NDJmN2Q3NjdmZmNjYzU5L3RhYmxlcmFuZ2U6MzU1ZGI3ZjhhMmQwNDYzYzg0MmY3ZDc2N2ZmY2NjNTlfMS0yLTEtMS0w_f7bfd884-9e34-41f4-a797-6d92eb56bb82">288.4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i626282e786b7454d83b617e9e83963e6_I20191231" decimals="-5" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181OC9mcmFnOjE0NzgwNDgyZTZiNTQwMDlhMGRlN2Y1ZTU4NTliYTRiL3RhYmxlOjM1NWRiN2Y4YTJkMDQ2M2M4NDJmN2Q3NjdmZmNjYzU5L3RhYmxlcmFuZ2U6MzU1ZGI3ZjhhMmQwNDYzYzg0MmY3ZDc2N2ZmY2NjNTlfMS00LTEtMS0w_3b39a69d-3f6c-42ba-89f7-6b870d7df8a5">169.7</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Work in process</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930" decimals="-5" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181OC9mcmFnOjE0NzgwNDgyZTZiNTQwMDlhMGRlN2Y1ZTU4NTliYTRiL3RhYmxlOjM1NWRiN2Y4YTJkMDQ2M2M4NDJmN2Q3NjdmZmNjYzU5L3RhYmxlcmFuZ2U6MzU1ZGI3ZjhhMmQwNDYzYzg0MmY3ZDc2N2ZmY2NjNTlfMi0yLTEtMS0w_c9ca7b55-ec26-4878-9660-67706eb3d645">539.9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i626282e786b7454d83b617e9e83963e6_I20191231" decimals="-5" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181OC9mcmFnOjE0NzgwNDgyZTZiNTQwMDlhMGRlN2Y1ZTU4NTliYTRiL3RhYmxlOjM1NWRiN2Y4YTJkMDQ2M2M4NDJmN2Q3NjdmZmNjYzU5L3RhYmxlcmFuZ2U6MzU1ZGI3ZjhhMmQwNDYzYzg0MmY3ZDc2N2ZmY2NjNTlfMi00LTEtMS0w_deea4718-616b-4dca-aa1a-c57e430b20b1">460.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Finished goods</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930" decimals="-5" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181OC9mcmFnOjE0NzgwNDgyZTZiNTQwMDlhMGRlN2Y1ZTU4NTliYTRiL3RhYmxlOjM1NWRiN2Y4YTJkMDQ2M2M4NDJmN2Q3NjdmZmNjYzU5L3RhYmxlcmFuZ2U6MzU1ZGI3ZjhhMmQwNDYzYzg0MmY3ZDc2N2ZmY2NjNTlfMy0yLTEtMS0w_f3233c80-7c40-4b31-add6-67b664aa9b0f">199.4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i626282e786b7454d83b617e9e83963e6_I20191231" decimals="-5" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181OC9mcmFnOjE0NzgwNDgyZTZiNTQwMDlhMGRlN2Y1ZTU4NTliYTRiL3RhYmxlOjM1NWRiN2Y4YTJkMDQ2M2M4NDJmN2Q3NjdmZmNjYzU5L3RhYmxlcmFuZ2U6MzU1ZGI3ZjhhMmQwNDYzYzg0MmY3ZDc2N2ZmY2NjNTlfMy00LTEtMS0w_aa7a1e60-6183-4339-9f6b-52db07b72b66">174.5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total inventory</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930" decimals="-5" format="ixt:numdotdecimal" name="biib:Inventorynetcurrentandnoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181OC9mcmFnOjE0NzgwNDgyZTZiNTQwMDlhMGRlN2Y1ZTU4NTliYTRiL3RhYmxlOjM1NWRiN2Y4YTJkMDQ2M2M4NDJmN2Q3NjdmZmNjYzU5L3RhYmxlcmFuZ2U6MzU1ZGI3ZjhhMmQwNDYzYzg0MmY3ZDc2N2ZmY2NjNTlfNC0yLTEtMS0w_01233d3d-c0a3-4fa7-8aaa-deac804213d8">1,027.7</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i626282e786b7454d83b617e9e83963e6_I20191231" decimals="-5" name="biib:Inventorynetcurrentandnoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181OC9mcmFnOjE0NzgwNDgyZTZiNTQwMDlhMGRlN2Y1ZTU4NTliYTRiL3RhYmxlOjM1NWRiN2Y4YTJkMDQ2M2M4NDJmN2Q3NjdmZmNjYzU5L3RhYmxlcmFuZ2U6MzU1ZGI3ZjhhMmQwNDYzYzg0MmY3ZDc2N2ZmY2NjNTlfNC00LTEtMS0w_d676d7a4-29a9-4927-abd3-b6af3d3031c6">804.2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">19</span></div></div></div><div id="ib19ff89608c84168a635160f2efa48f3_61"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_7">Table of Contents</a></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(unaudited, continued)</span></div></div><div style="text-indent:-27pt;padding-left:27pt;margin-top:14pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">6.&#160;&#160;&#160;&#160;Intangible Assets and Goodwill </span></div><ix:nonNumeric contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182MS9mcmFnOjFiMTIxNTdlNmQ0NzRjNDdiNjljYzkwODJhZWQ5M2FjL3RleHRyZWdpb246MWIxMjE1N2U2ZDQ3NGM0N2I2OWNjOTA4MmFlZDkzYWNfMjgwOA_51ecd221-a894-4d17-b791-b92a0a5cf248" continuedAt="ia86b3271c0ea4608aa8a5d2f377b650c" escape="true"><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Intangible Assets</span></div><ix:nonNumeric contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" name="biib:IntangibleAssetsExcludingGoodwillTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182MS9mcmFnOjFiMTIxNTdlNmQ0NzRjNDdiNjljYzkwODJhZWQ5M2FjL3RleHRyZWdpb246MWIxMjE1N2U2ZDQ3NGM0N2I2OWNjOTA4MmFlZDkzYWNfMjgwNg_e74ace3a-8201-4245-8e3f-b5ecaf3b4f47" escape="true"><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Intangible assets, net of accumulated amortization, impairment charges and adjustments, are summarized as follows:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%;"><tr><td style="width:1.0%;"></td><td style="width:22.394%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:15.493%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.710%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.032%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.710%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.710%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.032%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.715%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">As of September 30, 2020</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of December 31, 2019</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Estimated Life</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated<br/>Amortization</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated<br/>Amortization</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Completed technology</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4-28 years</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4b9c454823f244cd80d1fefee5471031_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182MS9mcmFnOjFiMTIxNTdlNmQ0NzRjNDdiNjljYzkwODJhZWQ5M2FjL3RhYmxlOjFmNjNlZjM4OGZlMzRhZTI5MjI3OGQ3Y2VlNGEyYTRjL3RhYmxlcmFuZ2U6MWY2M2VmMzg4ZmUzNGFlMjkyMjc4ZDdjZWU0YTJhNGNfMi0zLTEtMS0w_f4b86bfe-1802-47fc-bf4f-3b158d602c1e">7,394.3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i4b9c454823f244cd80d1fefee5471031_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182MS9mcmFnOjFiMTIxNTdlNmQ0NzRjNDdiNjljYzkwODJhZWQ5M2FjL3RhYmxlOjFmNjNlZjM4OGZlMzRhZTI5MjI3OGQ3Y2VlNGEyYTRjL3RhYmxlcmFuZ2U6MWY2M2VmMzg4ZmUzNGFlMjkyMjc4ZDdjZWU0YTJhNGNfMi01LTEtMS0w_6e738185-69a6-4e07-b8e6-0fecc3d384d5">5,077.7</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4b9c454823f244cd80d1fefee5471031_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182MS9mcmFnOjFiMTIxNTdlNmQ0NzRjNDdiNjljYzkwODJhZWQ5M2FjL3RhYmxlOjFmNjNlZjM4OGZlMzRhZTI5MjI3OGQ3Y2VlNGEyYTRjL3RhYmxlcmFuZ2U6MWY2M2VmMzg4ZmUzNGFlMjkyMjc4ZDdjZWU0YTJhNGNfMi03LTEtMS0w_f9b2cf66-8786-432e-9fac-b1f4beac9f19">2,316.6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i16c121b145194cf6abb5882efd1600bb_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182MS9mcmFnOjFiMTIxNTdlNmQ0NzRjNDdiNjljYzkwODJhZWQ5M2FjL3RhYmxlOjFmNjNlZjM4OGZlMzRhZTI5MjI3OGQ3Y2VlNGEyYTRjL3RhYmxlcmFuZ2U6MWY2M2VmMzg4ZmUzNGFlMjkyMjc4ZDdjZWU0YTJhNGNfMi05LTEtMS0w_be88bec0-5080-44f2-8b56-af297d70854d">7,379.3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i16c121b145194cf6abb5882efd1600bb_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182MS9mcmFnOjFiMTIxNTdlNmQ0NzRjNDdiNjljYzkwODJhZWQ5M2FjL3RhYmxlOjFmNjNlZjM4OGZlMzRhZTI5MjI3OGQ3Y2VlNGEyYTRjL3RhYmxlcmFuZ2U6MWY2M2VmMzg4ZmUzNGFlMjkyMjc4ZDdjZWU0YTJhNGNfMi0xMS0xLTEtMA_01d6f044-58dc-4e59-aee2-19a4f8dd31c6">4,881.4</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i16c121b145194cf6abb5882efd1600bb_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182MS9mcmFnOjFiMTIxNTdlNmQ0NzRjNDdiNjljYzkwODJhZWQ5M2FjL3RhYmxlOjFmNjNlZjM4OGZlMzRhZTI5MjI3OGQ3Y2VlNGEyYTRjL3RhYmxlcmFuZ2U6MWY2M2VmMzg4ZmUzNGFlMjkyMjc4ZDdjZWU0YTJhNGNfMi0xMy0xLTEtMA_4763cc4b-7b5c-4991-b44a-9033df5778a9">2,497.9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">In-process research and development</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Indefinite until commercialization</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i11500168fa8a442f878e3a3fd7879581_I20200930" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182MS9mcmFnOjFiMTIxNTdlNmQ0NzRjNDdiNjljYzkwODJhZWQ5M2FjL3RhYmxlOjFmNjNlZjM4OGZlMzRhZTI5MjI3OGQ3Y2VlNGEyYTRjL3RhYmxlcmFuZ2U6MWY2M2VmMzg4ZmUzNGFlMjkyMjc4ZDdjZWU0YTJhNGNfMy0zLTEtMS0w_6a2f6ea5-0777-4867-9a1e-8b0b6f83e96a">943.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i11500168fa8a442f878e3a3fd7879581_I20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182MS9mcmFnOjFiMTIxNTdlNmQ0NzRjNDdiNjljYzkwODJhZWQ5M2FjL3RhYmxlOjFmNjNlZjM4OGZlMzRhZTI5MjI3OGQ3Y2VlNGEyYTRjL3RhYmxlcmFuZ2U6MWY2M2VmMzg4ZmUzNGFlMjkyMjc4ZDdjZWU0YTJhNGNfMy01LTEtMS0w_090143a9-b666-48ee-844c-d363d811c24b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i11500168fa8a442f878e3a3fd7879581_I20200930" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182MS9mcmFnOjFiMTIxNTdlNmQ0NzRjNDdiNjljYzkwODJhZWQ5M2FjL3RhYmxlOjFmNjNlZjM4OGZlMzRhZTI5MjI3OGQ3Y2VlNGEyYTRjL3RhYmxlcmFuZ2U6MWY2M2VmMzg4ZmUzNGFlMjkyMjc4ZDdjZWU0YTJhNGNfMy03LTEtMS0w_04b6f9a4-17a7-4eaf-9e3c-189f034da095">943.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3481a276c03d48bf9b2c07bcb87daf78_I20191231" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182MS9mcmFnOjFiMTIxNTdlNmQ0NzRjNDdiNjljYzkwODJhZWQ5M2FjL3RhYmxlOjFmNjNlZjM4OGZlMzRhZTI5MjI3OGQ3Y2VlNGEyYTRjL3RhYmxlcmFuZ2U6MWY2M2VmMzg4ZmUzNGFlMjkyMjc4ZDdjZWU0YTJhNGNfMy05LTEtMS0w_35c30c88-a251-46ac-b587-e2d904329683">965.5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3481a276c03d48bf9b2c07bcb87daf78_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182MS9mcmFnOjFiMTIxNTdlNmQ0NzRjNDdiNjljYzkwODJhZWQ5M2FjL3RhYmxlOjFmNjNlZjM4OGZlMzRhZTI5MjI3OGQ3Y2VlNGEyYTRjL3RhYmxlcmFuZ2U6MWY2M2VmMzg4ZmUzNGFlMjkyMjc4ZDdjZWU0YTJhNGNfMy0xMS0xLTEtMA_f115e35e-1e07-4e0c-bd0d-431db9063d03">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3481a276c03d48bf9b2c07bcb87daf78_I20191231" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182MS9mcmFnOjFiMTIxNTdlNmQ0NzRjNDdiNjljYzkwODJhZWQ5M2FjL3RhYmxlOjFmNjNlZjM4OGZlMzRhZTI5MjI3OGQ3Y2VlNGEyYTRjL3RhYmxlcmFuZ2U6MWY2M2VmMzg4ZmUzNGFlMjkyMjc4ZDdjZWU0YTJhNGNfMy0xMy0xLTEtMA_97d38f40-4174-45d5-b5f8-89f673582da8">965.5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Trademarks&#160;and trade names</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Indefinite</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i21ae35839aed4acb8ce3728a8d65c8c4_I20200930" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182MS9mcmFnOjFiMTIxNTdlNmQ0NzRjNDdiNjljYzkwODJhZWQ5M2FjL3RhYmxlOjFmNjNlZjM4OGZlMzRhZTI5MjI3OGQ3Y2VlNGEyYTRjL3RhYmxlcmFuZ2U6MWY2M2VmMzg4ZmUzNGFlMjkyMjc4ZDdjZWU0YTJhNGNfNC0zLTEtMS0w_6f90a60b-5592-4e4c-b5f4-ab514ecfde2c">64.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i21ae35839aed4acb8ce3728a8d65c8c4_I20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182MS9mcmFnOjFiMTIxNTdlNmQ0NzRjNDdiNjljYzkwODJhZWQ5M2FjL3RhYmxlOjFmNjNlZjM4OGZlMzRhZTI5MjI3OGQ3Y2VlNGEyYTRjL3RhYmxlcmFuZ2U6MWY2M2VmMzg4ZmUzNGFlMjkyMjc4ZDdjZWU0YTJhNGNfNC01LTEtMS0w_eb9c0554-7183-4097-9ea2-24980863c06a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i21ae35839aed4acb8ce3728a8d65c8c4_I20200930" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182MS9mcmFnOjFiMTIxNTdlNmQ0NzRjNDdiNjljYzkwODJhZWQ5M2FjL3RhYmxlOjFmNjNlZjM4OGZlMzRhZTI5MjI3OGQ3Y2VlNGEyYTRjL3RhYmxlcmFuZ2U6MWY2M2VmMzg4ZmUzNGFlMjkyMjc4ZDdjZWU0YTJhNGNfNC03LTEtMS0w_ab02a473-bf39-4d8f-8ddf-d0dcd80afc8c">64.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if562d8cc7f4f4e548b86cb2f63c89067_I20191231" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182MS9mcmFnOjFiMTIxNTdlNmQ0NzRjNDdiNjljYzkwODJhZWQ5M2FjL3RhYmxlOjFmNjNlZjM4OGZlMzRhZTI5MjI3OGQ3Y2VlNGEyYTRjL3RhYmxlcmFuZ2U6MWY2M2VmMzg4ZmUzNGFlMjkyMjc4ZDdjZWU0YTJhNGNfNC05LTEtMS0w_274ccb3c-3792-445b-9e02-cf52895cfb8b">64.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if562d8cc7f4f4e548b86cb2f63c89067_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182MS9mcmFnOjFiMTIxNTdlNmQ0NzRjNDdiNjljYzkwODJhZWQ5M2FjL3RhYmxlOjFmNjNlZjM4OGZlMzRhZTI5MjI3OGQ3Y2VlNGEyYTRjL3RhYmxlcmFuZ2U6MWY2M2VmMzg4ZmUzNGFlMjkyMjc4ZDdjZWU0YTJhNGNfNC0xMS0xLTEtMA_c0986cc5-f032-4c82-a039-161b194372ef">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if562d8cc7f4f4e548b86cb2f63c89067_I20191231" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182MS9mcmFnOjFiMTIxNTdlNmQ0NzRjNDdiNjljYzkwODJhZWQ5M2FjL3RhYmxlOjFmNjNlZjM4OGZlMzRhZTI5MjI3OGQ3Y2VlNGEyYTRjL3RhYmxlcmFuZ2U6MWY2M2VmMzg4ZmUzNGFlMjkyMjc4ZDdjZWU0YTJhNGNfNC0xMy0xLTEtMA_7b3c6674-6e7e-40b5-8fa7-05c7de2bc3e1">64.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total intangible assets</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182MS9mcmFnOjFiMTIxNTdlNmQ0NzRjNDdiNjljYzkwODJhZWQ5M2FjL3RhYmxlOjFmNjNlZjM4OGZlMzRhZTI5MjI3OGQ3Y2VlNGEyYTRjL3RhYmxlcmFuZ2U6MWY2M2VmMzg4ZmUzNGFlMjkyMjc4ZDdjZWU0YTJhNGNfNS0zLTEtMS0w_3cc1e840-8f15-4dfc-9e58-fcb4afc2f127">8,401.3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182MS9mcmFnOjFiMTIxNTdlNmQ0NzRjNDdiNjljYzkwODJhZWQ5M2FjL3RhYmxlOjFmNjNlZjM4OGZlMzRhZTI5MjI3OGQ3Y2VlNGEyYTRjL3RhYmxlcmFuZ2U6MWY2M2VmMzg4ZmUzNGFlMjkyMjc4ZDdjZWU0YTJhNGNfNS01LTEtMS0w_8db2bed7-06b6-4716-bf55-7a71e5fb3396">5,077.7</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182MS9mcmFnOjFiMTIxNTdlNmQ0NzRjNDdiNjljYzkwODJhZWQ5M2FjL3RhYmxlOjFmNjNlZjM4OGZlMzRhZTI5MjI3OGQ3Y2VlNGEyYTRjL3RhYmxlcmFuZ2U6MWY2M2VmMzg4ZmUzNGFlMjkyMjc4ZDdjZWU0YTJhNGNfNS03LTEtMS0w_8d28025b-a8f8-4ebf-bbd9-7e8b1d7b345d">3,323.6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i626282e786b7454d83b617e9e83963e6_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182MS9mcmFnOjFiMTIxNTdlNmQ0NzRjNDdiNjljYzkwODJhZWQ5M2FjL3RhYmxlOjFmNjNlZjM4OGZlMzRhZTI5MjI3OGQ3Y2VlNGEyYTRjL3RhYmxlcmFuZ2U6MWY2M2VmMzg4ZmUzNGFlMjkyMjc4ZDdjZWU0YTJhNGNfNS05LTEtMS0w_e0b2d253-7719-448a-ad20-28e0fbb3ab28">8,408.8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i626282e786b7454d83b617e9e83963e6_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182MS9mcmFnOjFiMTIxNTdlNmQ0NzRjNDdiNjljYzkwODJhZWQ5M2FjL3RhYmxlOjFmNjNlZjM4OGZlMzRhZTI5MjI3OGQ3Y2VlNGEyYTRjL3RhYmxlcmFuZ2U6MWY2M2VmMzg4ZmUzNGFlMjkyMjc4ZDdjZWU0YTJhNGNfNS0xMS0xLTEtMA_0341c505-c712-4d33-9cd4-542eb94a162a">4,881.4</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i626282e786b7454d83b617e9e83963e6_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182MS9mcmFnOjFiMTIxNTdlNmQ0NzRjNDdiNjljYzkwODJhZWQ5M2FjL3RhYmxlOjFmNjNlZjM4OGZlMzRhZTI5MjI3OGQ3Y2VlNGEyYTRjL3RhYmxlcmFuZ2U6MWY2M2VmMzg4ZmUzNGFlMjkyMjc4ZDdjZWU0YTJhNGNfNS0xMy0xLTEtMA_0c9ac385-b595-4a66-931a-40c178977886">3,527.4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td></tr></table></div></ix:nonNumeric><div style="text-indent:24.75pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the three and nine months ended September 30, 2020, amortization and impairment of acquired intangible assets totaled $<ix:nonFraction unitRef="usd" contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182MS9mcmFnOjFiMTIxNTdlNmQ0NzRjNDdiNjljYzkwODJhZWQ5M2FjL3RleHRyZWdpb246MWIxMjE1N2U2ZDQ3NGM0N2I2OWNjOTA4MmFlZDkzYWNfMjQ5_26b35267-3899-4e46-802f-26ad462e98b7">82.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182MS9mcmFnOjFiMTIxNTdlNmQ0NzRjNDdiNjljYzkwODJhZWQ5M2FjL3RleHRyZWdpb246MWIxMjE1N2U2ZDQ3NGM0N2I2OWNjOTA4MmFlZDkzYWNfMjU2_a935bdd1-71ac-4358-a642-223d16557b48">215.6</ix:nonFraction> million, respectively, compared to $<ix:nonFraction unitRef="usd" contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182MS9mcmFnOjFiMTIxNTdlNmQ0NzRjNDdiNjljYzkwODJhZWQ5M2FjL3RleHRyZWdpb246MWIxMjE1N2U2ZDQ3NGM0N2I2OWNjOTA4MmFlZDkzYWNfMjg2_92944d6d-69db-4400-b141-cfdfc08b395b">283.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182MS9mcmFnOjFiMTIxNTdlNmQ0NzRjNDdiNjljYzkwODJhZWQ5M2FjL3RleHRyZWdpb246MWIxMjE1N2U2ZDQ3NGM0N2I2OWNjOTA4MmFlZDkzYWNfMjkz_519699f0-5f44-4ce5-8b91-d29ae09cf675">422.2</ix:nonFraction> million, respectively, in the prior year comparative periods. </span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the three and nine months ended September 30, 2020, amortization and impairment of acquired intangible assets reflects the impact of a $<ix:nonFraction unitRef="usd" contextRef="i5dc2c86a61e549f6b10a9b94d684a51a_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182MS9mcmFnOjFiMTIxNTdlNmQ0NzRjNDdiNjljYzkwODJhZWQ5M2FjL3RleHRyZWdpb246MWIxMjE1N2U2ZDQ3NGM0N2I2OWNjOTA4MmFlZDkzYWNfMTA5OTUxMTYzMjM3NQ_7a0f52e8-3a1e-4072-974b-9b4dd78b7d50"><ix:nonFraction unitRef="usd" contextRef="ic493d11fbb2f44b19c639b7aea48e26a_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182MS9mcmFnOjFiMTIxNTdlNmQ0NzRjNDdiNjljYzkwODJhZWQ5M2FjL3RleHRyZWdpb246MWIxMjE1N2U2ZDQ3NGM0N2I2OWNjOTA4MmFlZDkzYWNfMTA5OTUxMTYzMjM3NQ_a83302f0-b098-4f3a-bad6-b51f7efaaf30">19.3</ix:nonFraction></ix:nonFraction>&#160;million impairment charge related to one of our IPR&amp;D intangible assets. </span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the three and nine months ended September 30, 2019, amortization and impairment of acquired intangible assets reflects the impact of a $<ix:nonFraction unitRef="usd" contextRef="ide28bbdab94947a3ba38457611aacf91_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182MS9mcmFnOjFiMTIxNTdlNmQ0NzRjNDdiNjljYzkwODJhZWQ5M2FjL3RleHRyZWdpb246MWIxMjE1N2U2ZDQ3NGM0N2I2OWNjOTA4MmFlZDkzYWNfMTA5OTUxMTYzMTA0Nw_a3f34b73-f583-4010-b9dc-cb7455fc5a38"><ix:nonFraction unitRef="usd" contextRef="if5ac9acf99f240868c0779db73b11128_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182MS9mcmFnOjFiMTIxNTdlNmQ0NzRjNDdiNjljYzkwODJhZWQ5M2FjL3RleHRyZWdpb246MWIxMjE1N2U2ZDQ3NGM0N2I2OWNjOTA4MmFlZDkzYWNfMTA5OTUxMTYzMTA0Nw_e47c7d7e-830f-4929-97a6-929515149d3a">215.9</ix:nonFraction></ix:nonFraction>&#160;million impairment charge related to certain IPR&amp;D assets associated with the Phase 2b study of BG00011 (STX-100) for the potential treatment of idiopathic pulmonary fibrosis, which was discontinued in the third quarter of 2019.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the three and nine months ended September 30, 2020, amortization of acquired intangible assets, excluding impairment charges, totaled $<ix:nonFraction unitRef="usd" contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182MS9mcmFnOjFiMTIxNTdlNmQ0NzRjNDdiNjljYzkwODJhZWQ5M2FjL3RleHRyZWdpb246MWIxMjE1N2U2ZDQ3NGM0N2I2OWNjOTA4MmFlZDkzYWNfMTA5OTUxMTYzMjgyNA_ffd5931e-84dd-4703-a946-a93ae2c6c94a">63.3</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182MS9mcmFnOjFiMTIxNTdlNmQ0NzRjNDdiNjljYzkwODJhZWQ5M2FjL3RleHRyZWdpb246MWIxMjE1N2U2ZDQ3NGM0N2I2OWNjOTA4MmFlZDkzYWNfMTA5OTUxMTYzMjgzOA_3792b087-378d-4500-babd-02bb9eda2cc9">196.3</ix:nonFraction>&#160;million, respectively, compared to $<ix:nonFraction unitRef="usd" contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182MS9mcmFnOjFiMTIxNTdlNmQ0NzRjNDdiNjljYzkwODJhZWQ5M2FjL3RleHRyZWdpb246MWIxMjE1N2U2ZDQ3NGM0N2I2OWNjOTA4MmFlZDkzYWNfMTA5OTUxMTYzMjYwMw_56790484-db0d-4666-9210-0431d087fe2f">68.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182MS9mcmFnOjFiMTIxNTdlNmQ0NzRjNDdiNjljYzkwODJhZWQ5M2FjL3RleHRyZWdpb246MWIxMjE1N2U2ZDQ3NGM0N2I2OWNjOTA4MmFlZDkzYWNfMTA5OTUxMTYzMjYxMg_a5935aaa-f7c3-466c-b2a2-ca9f2f6bb8f5">206.3</ix:nonFraction>&#160;million, respectively, in the prior year comparative periods.</span></div><div style="text-indent:13.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Completed Technology</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Completed technology primarily relates to our acquisition of all remaining rights to TYSABRI from Elan Pharma International Ltd., an affiliate of Elan Corporation plc, and milestone payments made to Alkermes Pharma Ireland Limited, a subsidiary of Alkermes plc, following the approval of VUMERITY in the U.S. in October 2019, net of accumulated amortization.</span></div><div style="text-indent:13.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">IPR&amp;D Related to Business Combinations</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">IPR&amp;D represents the fair value assigned to research and development assets that we acquired as part of a business combination and had not yet reached technological feasibility at the date of acquisition. Included in IPR&amp;D balances are adjustments related to foreign currency exchange rate fluctuations. We review amounts capitalized as acquired IPR&amp;D for impairment annually, as of October 31, and whenever events or changes in circumstances indicate to us that the carrying value of the assets might not be recoverable. The carrying value associated with our IPR&amp;D assets as of September 30, 2020, relates to the various IPR&amp;D programs we acquired in connection with our acquisitions of NST, Convergence Pharmaceuticals Holdings Ltd. (Convergence) and Biogen International Neuroscience GmbH (BIN). The majority of the balance relates to our acquisition of NST in June 2019 whereby we acquired IPR&amp;D programs with an estimated fair value of approximately $<ix:nonFraction unitRef="usd" contextRef="if669468af2b1428fbb2d5e8a25e54053_I20190607" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182MS9mcmFnOjFiMTIxNTdlNmQ0NzRjNDdiNjljYzkwODJhZWQ5M2FjL3RleHRyZWdpb246MWIxMjE1N2U2ZDQ3NGM0N2I2OWNjOTA4MmFlZDkzYWNfMTc2Mg_a7872836-98c8-47e5-ae0f-755a623fbe5f">700.0</ix:nonFraction> million.</span></div><div style="text-indent:13.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Vixotrigine</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In the periods since we acquired vixotrigine (BIIB074), there have been numerous delays in the initiation of Phase 3 studies for the potential treatment of trigeminal neuralgia (TGN) as we engaged with the U.S. Food and Drug Administration (FDA) regarding the design of the Phase 3 studies and awaited data and insights from mid-stage clinical trials of vixotrigine in other indications that have since been completed. The fair value of the TGN asset is not significantly in excess of carrying value. As of September 30, 2020, the carrying value associated with our vixotrigine IPR&amp;D assets was $<ix:nonFraction unitRef="usd" contextRef="id5ed0dc28e704ee58e687f720a4af0c0_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182MS9mcmFnOjFiMTIxNTdlNmQ0NzRjNDdiNjljYzkwODJhZWQ5M2FjL3RleHRyZWdpb246MWIxMjE1N2U2ZDQ3NGM0N2I2OWNjOTA4MmFlZDkzYWNfMjM1Nw_0e893ed1-d7b3-4f76-a7e6-4a1acb6611f4">167.6</ix:nonFraction> million.</span></div></ix:nonNumeric><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_7">Table of Contents</a></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(unaudited, continued)</span></div></div><ix:continuation id="ia86b3271c0ea4608aa8a5d2f377b650c" continuedAt="iedcc423d9b934fd8aac70822b3f49b5e"><div style="text-indent:13.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Estimated Future Amortization of Intangible Assets</span><span style="background-color:rgb(255,255,255, 0.0);color:#679acb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"> </span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">T<ix:nonNumeric contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182MS9mcmFnOjFiMTIxNTdlNmQ0NzRjNDdiNjljYzkwODJhZWQ5M2FjL3RleHRyZWdpb246MWIxMjE1N2U2ZDQ3NGM0N2I2OWNjOTA4MmFlZDkzYWNfMjc4Mw_a663d37b-905e-4590-a996-58c361587c3a" continuedAt="id9217b775d4946c8a429997750b3d0df" escape="true">he estimated future amortization of finite-lived intangible assets for the next five years is expected to be as follows:</ix:nonNumeric></span></div><div style="text-align:justify;margin-top:5pt;margin-bottom:5pt;"><ix:continuation id="id9217b775d4946c8a429997750b3d0df"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:78.724%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:18.346%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In millions)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">As of September 30, 2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020 (remaining three months)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182MS9mcmFnOjFiMTIxNTdlNmQ0NzRjNDdiNjljYzkwODJhZWQ5M2FjL3RhYmxlOjlkNmRhMDM0Yjk0MjRhNTc4OWRhNzM1Mjg5MjY4N2QzL3RhYmxlcmFuZ2U6OWQ2ZGEwMzRiOTQyNGE1Nzg5ZGE3MzUyODkyNjg3ZDNfMS0yLTEtMS0w_3f9bc768-16e2-451b-ab5e-84557055fd3f">60.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182MS9mcmFnOjFiMTIxNTdlNmQ0NzRjNDdiNjljYzkwODJhZWQ5M2FjL3RhYmxlOjlkNmRhMDM0Yjk0MjRhNTc4OWRhNzM1Mjg5MjY4N2QzL3RhYmxlcmFuZ2U6OWQ2ZGEwMzRiOTQyNGE1Nzg5ZGE3MzUyODkyNjg3ZDNfMi0yLTEtMS0w_50a3c271-2f1f-4840-96b9-03b366eca7a6">205.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182MS9mcmFnOjFiMTIxNTdlNmQ0NzRjNDdiNjljYzkwODJhZWQ5M2FjL3RhYmxlOjlkNmRhMDM0Yjk0MjRhNTc4OWRhNzM1Mjg5MjY4N2QzL3RhYmxlcmFuZ2U6OWQ2ZGEwMzRiOTQyNGE1Nzg5ZGE3MzUyODkyNjg3ZDNfMy0yLTEtMS0w_8a0b5d05-1b36-4d7c-9aa5-637ea45a7c00">215.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182MS9mcmFnOjFiMTIxNTdlNmQ0NzRjNDdiNjljYzkwODJhZWQ5M2FjL3RhYmxlOjlkNmRhMDM0Yjk0MjRhNTc4OWRhNzM1Mjg5MjY4N2QzL3RhYmxlcmFuZ2U6OWQ2ZGEwMzRiOTQyNGE1Nzg5ZGE3MzUyODkyNjg3ZDNfNC0yLTEtMS0w_fd5360dc-97ac-47cc-997e-7b99b282678d">215.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2024</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182MS9mcmFnOjFiMTIxNTdlNmQ0NzRjNDdiNjljYzkwODJhZWQ5M2FjL3RhYmxlOjlkNmRhMDM0Yjk0MjRhNTc4OWRhNzM1Mjg5MjY4N2QzL3RhYmxlcmFuZ2U6OWQ2ZGEwMzRiOTQyNGE1Nzg5ZGE3MzUyODkyNjg3ZDNfNS0yLTEtMS0w_33ccbad2-12ee-44ce-b1f2-47ab4dbfaccd">225.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2025</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182MS9mcmFnOjFiMTIxNTdlNmQ0NzRjNDdiNjljYzkwODJhZWQ5M2FjL3RhYmxlOjlkNmRhMDM0Yjk0MjRhNTc4OWRhNzM1Mjg5MjY4N2QzL3RhYmxlcmFuZ2U6OWQ2ZGEwMzRiOTQyNGE1Nzg5ZGE3MzUyODkyNjg3ZDNfNi0yLTEtMS0w_c939fe73-ef86-4403-ad9c-e5e5811f9f71">220.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr></table></ix:continuation></div><div style="text-indent:11.25pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Goodwill</span></div><ix:nonNumeric contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" name="us-gaap:ScheduleOfGoodwillTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182MS9mcmFnOjFiMTIxNTdlNmQ0NzRjNDdiNjljYzkwODJhZWQ5M2FjL3RleHRyZWdpb246MWIxMjE1N2U2ZDQ3NGM0N2I2OWNjOTA4MmFlZDkzYWNfMjc5Ng_f7b03778-bfad-482c-85dd-4a99d749a0b0" escape="true"><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table provides a roll forward of the changes in our goodwill balance:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:78.724%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:18.346%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In millions)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">As of September 30, 2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Goodwill, December 31, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i626282e786b7454d83b617e9e83963e6_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182MS9mcmFnOjFiMTIxNTdlNmQ0NzRjNDdiNjljYzkwODJhZWQ5M2FjL3RhYmxlOjZhM2ZjNWI5YTQ3NTQzYzI4YWE4ZmJhNWE4NjYxOGMzL3RhYmxlcmFuZ2U6NmEzZmM1YjlhNDc1NDNjMjhhYThmYmE1YTg2NjE4YzNfMS0yLTEtMS0w_b1071b58-4813-44ad-9a61-198a2e9ce0fa">5,757.8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:GoodwillOtherIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182MS9mcmFnOjFiMTIxNTdlNmQ0NzRjNDdiNjljYzkwODJhZWQ5M2FjL3RhYmxlOjZhM2ZjNWI5YTQ3NTQzYzI4YWE4ZmJhNWE4NjYxOGMzL3RhYmxlcmFuZ2U6NmEzZmM1YjlhNDc1NDNjMjhhYThmYmE1YTg2NjE4YzNfMy0yLTEtMS0w_84067671-0156-4671-8409-0e4789cf3777">2.1</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Goodwill, September 30, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182MS9mcmFnOjFiMTIxNTdlNmQ0NzRjNDdiNjljYzkwODJhZWQ5M2FjL3RhYmxlOjZhM2ZjNWI5YTQ3NTQzYzI4YWE4ZmJhNWE4NjYxOGMzL3RhYmxlcmFuZ2U6NmEzZmM1YjlhNDc1NDNjMjhhYThmYmE1YTg2NjE4YzNfNC0yLTEtMS0w_a4d66e80-d728-4845-9033-703dfacc0f78">5,755.7</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-indent:24.75pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="iedcc423d9b934fd8aac70822b3f49b5e">As of September 30, 2020, we had <ix:nonFraction unitRef="usd" contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930" decimals="-6" format="ixt-sec:numwordsen" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182MS9mcmFnOjFiMTIxNTdlNmQ0NzRjNDdiNjljYzkwODJhZWQ5M2FjL3RleHRyZWdpb246MWIxMjE1N2U2ZDQ3NGM0N2I2OWNjOTA4MmFlZDkzYWNfMjY0NQ_d53db9d2-4089-4f16-8019-f3c52ace89d0">no</ix:nonFraction> accumulated impairment losses related to goodwill. Other includes adjustments related to foreign currency exchange rate fluctuations.</ix:continuation> </span></div><div id="ib19ff89608c84168a635160f2efa48f3_67"></div><div style="text-indent:-27pt;padding-left:27pt;margin-top:14pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">7.&#160;&#160;&#160;&#160;Fair Value Measurements </span></div><ix:nonNumeric contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RleHRyZWdpb246MjcwNWY4ZDY1MThjNDkyZWJiNWZiYzRmNmYwOGJiMTdfNDUzOQ_5b064bd7-b1c5-4761-8605-677cac55040c" continuedAt="if01d6dc044b74669abee11dc2ffd72dd" escape="true"><ix:nonNumeric contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RleHRyZWdpb246MjcwNWY4ZDY1MThjNDkyZWJiNWZiYzRmNmYwOGJiMTdfNDU0Mg_fd550c8f-e097-42e7-9445-ffa63cf7c9bf" continuedAt="i96641f086edc4e9dbe29bdf74fcb9f79" escape="true"><div style="text-indent:24.75pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:40.420%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.788%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.788%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.788%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.796%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">As of September 30, 2020</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In millions)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Quoted&#160;Prices<br/>in Active<br/>Markets<br/>(Level 1)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level 2)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-style:italic;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash equivalents</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3733833dc5534d8e823879ef2ca35162_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjFkN2EzMDhiOWRlZDRmY2Q5MDg3NDUxMDlkZDExYjhhL3RhYmxlcmFuZ2U6MWQ3YTMwOGI5ZGVkNGZjZDkwODc0NTEwOWRkMTFiOGFfMi0yLTEtMS0w_b5e2c70d-19a7-4f50-ac1e-a967119dcea6">1,570.3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2937e4b1496b4a52a0d3e66401ae9216_I20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjFkN2EzMDhiOWRlZDRmY2Q5MDg3NDUxMDlkZDExYjhhL3RhYmxlcmFuZ2U6MWQ3YTMwOGI5ZGVkNGZjZDkwODc0NTEwOWRkMTFiOGFfMi00LTEtMS0w_190c156d-90b6-42c8-8311-cdcacdff7e53">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6d5405f808014e29ae408f670b51a09f_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjFkN2EzMDhiOWRlZDRmY2Q5MDg3NDUxMDlkZDExYjhhL3RhYmxlcmFuZ2U6MWQ3YTMwOGI5ZGVkNGZjZDkwODc0NTEwOWRkMTFiOGFfMi02LTEtMS0w_425630d2-62ea-4b6b-aab4-a48d6de1705b">1,570.3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8a4caf6e3ead4de1943986bbd01cf562_I20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjFkN2EzMDhiOWRlZDRmY2Q5MDg3NDUxMDlkZDExYjhhL3RhYmxlcmFuZ2U6MWQ3YTMwOGI5ZGVkNGZjZDkwODc0NTEwOWRkMTFiOGFfMi04LTEtMS0w_51fe0fca-a081-484e-9882-784c5e5106d4">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Marketable debt securities:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9fa1b53a700943f2bdb14f74caa79af6_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjFkN2EzMDhiOWRlZDRmY2Q5MDg3NDUxMDlkZDExYjhhL3RhYmxlcmFuZ2U6MWQ3YTMwOGI5ZGVkNGZjZDkwODc0NTEwOWRkMTFiOGFfNC0yLTEtMS0w_0d0cd6fb-f0d9-4e63-8831-0234a4a5e561">1,443.8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i72583de967dc40ddb4cff73d7209ce4c_I20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjFkN2EzMDhiOWRlZDRmY2Q5MDg3NDUxMDlkZDExYjhhL3RhYmxlcmFuZ2U6MWQ3YTMwOGI5ZGVkNGZjZDkwODc0NTEwOWRkMTFiOGFfNC00LTEtMS0w_5489a9c4-89ef-4993-883e-4faa3049b8f2">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5876b06547fb4838bc5be5aca105c206_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjFkN2EzMDhiOWRlZDRmY2Q5MDg3NDUxMDlkZDExYjhhL3RhYmxlcmFuZ2U6MWQ3YTMwOGI5ZGVkNGZjZDkwODc0NTEwOWRkMTFiOGFfNC02LTEtMS0w_8b52d1f9-632e-4640-8592-addf44eae018">1,443.8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iffeaee7ccfe84deb8024b6a3c6400e05_I20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjFkN2EzMDhiOWRlZDRmY2Q5MDg3NDUxMDlkZDExYjhhL3RhYmxlcmFuZ2U6MWQ3YTMwOGI5ZGVkNGZjZDkwODc0NTEwOWRkMTFiOGFfNC04LTEtMS0w_bfd76605-73e5-43ba-9aaa-5aedc1b1e0cd">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Government securities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i366fc4865f1141d881e72475b885ad6b_I20200930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjFkN2EzMDhiOWRlZDRmY2Q5MDg3NDUxMDlkZDExYjhhL3RhYmxlcmFuZ2U6MWQ3YTMwOGI5ZGVkNGZjZDkwODc0NTEwOWRkMTFiOGFfNS0yLTEtMS0w_a4e114fe-1d89-47cf-aa62-cc3ece27ffa7">767.4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3762ea1be6864e498c8620d932d2da39_I20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjFkN2EzMDhiOWRlZDRmY2Q5MDg3NDUxMDlkZDExYjhhL3RhYmxlcmFuZ2U6MWQ3YTMwOGI5ZGVkNGZjZDkwODc0NTEwOWRkMTFiOGFfNS00LTEtMS0w_f9442411-cad1-4b33-b6fa-e39c0c1ed996">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4bcbf6cedff544d5a8a856091fd31a3f_I20200930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjFkN2EzMDhiOWRlZDRmY2Q5MDg3NDUxMDlkZDExYjhhL3RhYmxlcmFuZ2U6MWQ3YTMwOGI5ZGVkNGZjZDkwODc0NTEwOWRkMTFiOGFfNS02LTEtMS0w_9b2bdabc-c69e-41cd-8f6c-b1a6e6e9de39">767.4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia08462c38d1441cf88e8ec71551ea0c8_I20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjFkN2EzMDhiOWRlZDRmY2Q5MDg3NDUxMDlkZDExYjhhL3RhYmxlcmFuZ2U6MWQ3YTMwOGI5ZGVkNGZjZDkwODc0NTEwOWRkMTFiOGFfNS04LTEtMS0w_7fafc3c0-e2ed-40c2-a1bf-192429edb03f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Mortgage and other asset backed securities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if0af6974b4d9478091a43d7c360e50da_I20200930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjFkN2EzMDhiOWRlZDRmY2Q5MDg3NDUxMDlkZDExYjhhL3RhYmxlcmFuZ2U6MWQ3YTMwOGI5ZGVkNGZjZDkwODc0NTEwOWRkMTFiOGFfNi0yLTEtMS0w_53371d9f-777c-4286-bdb7-944f8e2f9031">153.6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7efef111968e4853ba97bc23f3210bf0_I20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjFkN2EzMDhiOWRlZDRmY2Q5MDg3NDUxMDlkZDExYjhhL3RhYmxlcmFuZ2U6MWQ3YTMwOGI5ZGVkNGZjZDkwODc0NTEwOWRkMTFiOGFfNi00LTEtMS0w_bcb89aac-84b9-47ed-83fd-547cdf65cce5">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8f93695e9414499694873333956d9bdc_I20200930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjFkN2EzMDhiOWRlZDRmY2Q5MDg3NDUxMDlkZDExYjhhL3RhYmxlcmFuZ2U6MWQ3YTMwOGI5ZGVkNGZjZDkwODc0NTEwOWRkMTFiOGFfNi02LTEtMS0w_39c4d3c8-2eaa-4a05-a445-8d32add0d8de">153.6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib2ec3058389a4337ac5eba484681aa08_I20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjFkN2EzMDhiOWRlZDRmY2Q5MDg3NDUxMDlkZDExYjhhL3RhYmxlcmFuZ2U6MWQ3YTMwOGI5ZGVkNGZjZDkwODc0NTEwOWRkMTFiOGFfNi04LTEtMS0w_ca170a75-d70e-40f3-8a3d-820336ddad50">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Marketable equity securities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3733833dc5534d8e823879ef2ca35162_I20200930" decimals="-5" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjFkN2EzMDhiOWRlZDRmY2Q5MDg3NDUxMDlkZDExYjhhL3RhYmxlcmFuZ2U6MWQ3YTMwOGI5ZGVkNGZjZDkwODc0NTEwOWRkMTFiOGFfNy0yLTEtMS0w_e1fdac7d-43ee-4acf-9749-cf40ca8490b5">868.5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2937e4b1496b4a52a0d3e66401ae9216_I20200930" decimals="-5" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjFkN2EzMDhiOWRlZDRmY2Q5MDg3NDUxMDlkZDExYjhhL3RhYmxlcmFuZ2U6MWQ3YTMwOGI5ZGVkNGZjZDkwODc0NTEwOWRkMTFiOGFfNy00LTEtMS0w_a9e679df-ab46-46e2-9b49-f18998fb431f">276.5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6d5405f808014e29ae408f670b51a09f_I20200930" decimals="-5" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjFkN2EzMDhiOWRlZDRmY2Q5MDg3NDUxMDlkZDExYjhhL3RhYmxlcmFuZ2U6MWQ3YTMwOGI5ZGVkNGZjZDkwODc0NTEwOWRkMTFiOGFfNy02LTEtMS0w_9faa185f-7e8e-4dc0-bde6-5aee2ef86be3">592.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8a4caf6e3ead4de1943986bbd01cf562_I20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjFkN2EzMDhiOWRlZDRmY2Q5MDg3NDUxMDlkZDExYjhhL3RhYmxlcmFuZ2U6MWQ3YTMwOGI5ZGVkNGZjZDkwODc0NTEwOWRkMTFiOGFfNy04LTEtMS0w_0c7de252-b1a3-4fc9-a02f-d1cb53d2c290">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Derivative contracts</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3733833dc5534d8e823879ef2ca35162_I20200930" decimals="-5" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjFkN2EzMDhiOWRlZDRmY2Q5MDg3NDUxMDlkZDExYjhhL3RhYmxlcmFuZ2U6MWQ3YTMwOGI5ZGVkNGZjZDkwODc0NTEwOWRkMTFiOGFfOC0yLTEtMS0w_7da069c4-631d-4897-afcf-4f41353f838d">26.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2937e4b1496b4a52a0d3e66401ae9216_I20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjFkN2EzMDhiOWRlZDRmY2Q5MDg3NDUxMDlkZDExYjhhL3RhYmxlcmFuZ2U6MWQ3YTMwOGI5ZGVkNGZjZDkwODc0NTEwOWRkMTFiOGFfOC00LTEtMS0w_ce31c5e3-7528-42a6-86d3-805aae4a2184">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6d5405f808014e29ae408f670b51a09f_I20200930" decimals="-5" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjFkN2EzMDhiOWRlZDRmY2Q5MDg3NDUxMDlkZDExYjhhL3RhYmxlcmFuZ2U6MWQ3YTMwOGI5ZGVkNGZjZDkwODc0NTEwOWRkMTFiOGFfOC02LTEtMS0w_3e1fb94d-0848-4163-aeca-31c426e8125a">26.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8a4caf6e3ead4de1943986bbd01cf562_I20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjFkN2EzMDhiOWRlZDRmY2Q5MDg3NDUxMDlkZDExYjhhL3RhYmxlcmFuZ2U6MWQ3YTMwOGI5ZGVkNGZjZDkwODc0NTEwOWRkMTFiOGFfOC04LTEtMS0w_4dc66392-cc8e-4407-a400-d3c7d632d924">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Plan assets for deferred compensation</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3733833dc5534d8e823879ef2ca35162_I20200930" decimals="-5" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjFkN2EzMDhiOWRlZDRmY2Q5MDg3NDUxMDlkZDExYjhhL3RhYmxlcmFuZ2U6MWQ3YTMwOGI5ZGVkNGZjZDkwODc0NTEwOWRkMTFiOGFfOS0yLTEtMS0w_ac876fdc-fbb7-4e95-9a34-35ffbcbca228">26.4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2937e4b1496b4a52a0d3e66401ae9216_I20200930" decimals="-5" format="ixt:zerodash" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjFkN2EzMDhiOWRlZDRmY2Q5MDg3NDUxMDlkZDExYjhhL3RhYmxlcmFuZ2U6MWQ3YTMwOGI5ZGVkNGZjZDkwODc0NTEwOWRkMTFiOGFfOS00LTEtMS0w_4b6fefcb-0fc3-42cb-bc3d-9d73f074c34f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6d5405f808014e29ae408f670b51a09f_I20200930" decimals="-5" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjFkN2EzMDhiOWRlZDRmY2Q5MDg3NDUxMDlkZDExYjhhL3RhYmxlcmFuZ2U6MWQ3YTMwOGI5ZGVkNGZjZDkwODc0NTEwOWRkMTFiOGFfOS02LTEtMS0w_63ad41a7-5f67-4f67-9bdb-a77ec022040d">26.4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8a4caf6e3ead4de1943986bbd01cf562_I20200930" decimals="-5" format="ixt:zerodash" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjFkN2EzMDhiOWRlZDRmY2Q5MDg3NDUxMDlkZDExYjhhL3RhYmxlcmFuZ2U6MWQ3YTMwOGI5ZGVkNGZjZDkwODc0NTEwOWRkMTFiOGFfOS04LTEtMS0w_2366fe31-e7ca-4f13-9f28-a21f4afb799f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:29.25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3733833dc5534d8e823879ef2ca35162_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjFkN2EzMDhiOWRlZDRmY2Q5MDg3NDUxMDlkZDExYjhhL3RhYmxlcmFuZ2U6MWQ3YTMwOGI5ZGVkNGZjZDkwODc0NTEwOWRkMTFiOGFfMTAtMi0xLTEtMA_07295017-524d-4e2b-994d-cf2319837d02">4,856.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2937e4b1496b4a52a0d3e66401ae9216_I20200930" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjFkN2EzMDhiOWRlZDRmY2Q5MDg3NDUxMDlkZDExYjhhL3RhYmxlcmFuZ2U6MWQ3YTMwOGI5ZGVkNGZjZDkwODc0NTEwOWRkMTFiOGFfMTAtNC0xLTEtMA_8fa2274e-eeaf-4b3c-888c-5d9d2e415bdc">276.5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6d5405f808014e29ae408f670b51a09f_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjFkN2EzMDhiOWRlZDRmY2Q5MDg3NDUxMDlkZDExYjhhL3RhYmxlcmFuZ2U6MWQ3YTMwOGI5ZGVkNGZjZDkwODc0NTEwOWRkMTFiOGFfMTAtNi0xLTEtMA_c1a26e71-6d83-43ce-aa69-e3de82abb545">4,579.5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8a4caf6e3ead4de1943986bbd01cf562_I20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjFkN2EzMDhiOWRlZDRmY2Q5MDg3NDUxMDlkZDExYjhhL3RhYmxlcmFuZ2U6MWQ3YTMwOGI5ZGVkNGZjZDkwODc0NTEwOWRkMTFiOGFfMTAtOC0xLTEtMA_a019c09f-6620-4ad2-af91-5fa13db6b5aa">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-style:italic;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Liabilities:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Derivative contracts</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3733833dc5534d8e823879ef2ca35162_I20200930" decimals="-5" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjFkN2EzMDhiOWRlZDRmY2Q5MDg3NDUxMDlkZDExYjhhL3RhYmxlcmFuZ2U6MWQ3YTMwOGI5ZGVkNGZjZDkwODc0NTEwOWRkMTFiOGFfMTItMi0xLTEtMA_41c3c250-afd9-4608-a4af-72e8ee101a6a">99.6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2937e4b1496b4a52a0d3e66401ae9216_I20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjFkN2EzMDhiOWRlZDRmY2Q5MDg3NDUxMDlkZDExYjhhL3RhYmxlcmFuZ2U6MWQ3YTMwOGI5ZGVkNGZjZDkwODc0NTEwOWRkMTFiOGFfMTItNC0xLTEtMA_aada99df-25fe-44f8-ac4f-02c5d785b233">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6d5405f808014e29ae408f670b51a09f_I20200930" decimals="-5" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjFkN2EzMDhiOWRlZDRmY2Q5MDg3NDUxMDlkZDExYjhhL3RhYmxlcmFuZ2U6MWQ3YTMwOGI5ZGVkNGZjZDkwODc0NTEwOWRkMTFiOGFfMTItNi0xLTEtMA_239a7234-80f6-4cae-8edb-cf0fdc12d0f3">99.6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8a4caf6e3ead4de1943986bbd01cf562_I20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjFkN2EzMDhiOWRlZDRmY2Q5MDg3NDUxMDlkZDExYjhhL3RhYmxlcmFuZ2U6MWQ3YTMwOGI5ZGVkNGZjZDkwODc0NTEwOWRkMTFiOGFfMTItOC0xLTEtMA_b164e193-4ae2-409d-99f9-5f1587745e32">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration obligations</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3733833dc5534d8e823879ef2ca35162_I20200930" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjFkN2EzMDhiOWRlZDRmY2Q5MDg3NDUxMDlkZDExYjhhL3RhYmxlcmFuZ2U6MWQ3YTMwOGI5ZGVkNGZjZDkwODc0NTEwOWRkMTFiOGFfMTMtMi0xLTEtMA_86b9197e-6457-48e6-bc47-938934c17cb0">322.6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2937e4b1496b4a52a0d3e66401ae9216_I20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjFkN2EzMDhiOWRlZDRmY2Q5MDg3NDUxMDlkZDExYjhhL3RhYmxlcmFuZ2U6MWQ3YTMwOGI5ZGVkNGZjZDkwODc0NTEwOWRkMTFiOGFfMTMtNC0xLTEtMA_a5fdf05a-1aed-4857-888d-4fd47e368f06">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6d5405f808014e29ae408f670b51a09f_I20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjFkN2EzMDhiOWRlZDRmY2Q5MDg3NDUxMDlkZDExYjhhL3RhYmxlcmFuZ2U6MWQ3YTMwOGI5ZGVkNGZjZDkwODc0NTEwOWRkMTFiOGFfMTMtNi0xLTEtMA_a7cb1983-187e-4037-ae58-ae90ef7a3176">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8a4caf6e3ead4de1943986bbd01cf562_I20200930" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjFkN2EzMDhiOWRlZDRmY2Q5MDg3NDUxMDlkZDExYjhhL3RhYmxlcmFuZ2U6MWQ3YTMwOGI5ZGVkNGZjZDkwODc0NTEwOWRkMTFiOGFfMTMtOC0xLTEtMA_4074f36b-10cf-4087-9afb-aaa6b74cc592">322.6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:29.25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3733833dc5534d8e823879ef2ca35162_I20200930" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjFkN2EzMDhiOWRlZDRmY2Q5MDg3NDUxMDlkZDExYjhhL3RhYmxlcmFuZ2U6MWQ3YTMwOGI5ZGVkNGZjZDkwODc0NTEwOWRkMTFiOGFfMTQtMi0xLTEtMA_1444241e-4c8a-480b-a3a0-03956757c337">422.2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2937e4b1496b4a52a0d3e66401ae9216_I20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjFkN2EzMDhiOWRlZDRmY2Q5MDg3NDUxMDlkZDExYjhhL3RhYmxlcmFuZ2U6MWQ3YTMwOGI5ZGVkNGZjZDkwODc0NTEwOWRkMTFiOGFfMTQtNC0xLTEtMA_409bb2a1-1eee-4ab5-9454-b20231059a18">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6d5405f808014e29ae408f670b51a09f_I20200930" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjFkN2EzMDhiOWRlZDRmY2Q5MDg3NDUxMDlkZDExYjhhL3RhYmxlcmFuZ2U6MWQ3YTMwOGI5ZGVkNGZjZDkwODc0NTEwOWRkMTFiOGFfMTQtNi0xLTEtMA_0bc45279-d9b6-4509-b28d-477411d45ff4">99.6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8a4caf6e3ead4de1943986bbd01cf562_I20200930" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjFkN2EzMDhiOWRlZDRmY2Q5MDg3NDUxMDlkZDExYjhhL3RhYmxlcmFuZ2U6MWQ3YTMwOGI5ZGVkNGZjZDkwODc0NTEwOWRkMTFiOGFfMTQtOC0xLTEtMA_4c8bec28-7024-4213-8aec-f19e4eb37766">322.6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_7">Table of Contents</a></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(unaudited, continued)</span></div></div><ix:continuation id="if01d6dc044b74669abee11dc2ffd72dd" continuedAt="ide47ebb1e4f24fb4b0a17cb7bd4b2f4d"><div style="margin-top:5pt;margin-bottom:5pt;"><ix:continuation id="i96641f086edc4e9dbe29bdf74fcb9f79"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:40.420%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.788%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.788%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.788%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.796%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of December 31, 2019</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In millions)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Quoted&#160;Prices<br/>in Active<br/>Markets<br/>(Level 1)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level 2)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-style:italic;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash equivalents</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie6a0e49727c84ab293a923c6fa60c4af_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjZkMWNjMjhiMDI3YzQ5ZGM5N2U3N2M0Mjc4YTJjZTFlL3RhYmxlcmFuZ2U6NmQxY2MyOGIwMjdjNDlkYzk3ZTc3YzQyNzhhMmNlMWVfMi0yLTEtMS0w_8d754792-c992-46c8-b8c8-a5a209fae134">2,541.1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if8d8ff0dd3eb48ac863f558fcbc6892a_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjZkMWNjMjhiMDI3YzQ5ZGM5N2U3N2M0Mjc4YTJjZTFlL3RhYmxlcmFuZ2U6NmQxY2MyOGIwMjdjNDlkYzk3ZTc3YzQyNzhhMmNlMWVfMi00LTEtMS0w_61e68c97-cafe-4fe1-8a29-cbfbb0f16357">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i30724e1260114af0b2ee60176aabfc27_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjZkMWNjMjhiMDI3YzQ5ZGM5N2U3N2M0Mjc4YTJjZTFlL3RhYmxlcmFuZ2U6NmQxY2MyOGIwMjdjNDlkYzk3ZTc3YzQyNzhhMmNlMWVfMi02LTEtMS0w_e2890c4e-5d2b-484e-9f22-8123dc21dfae">2,541.1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib5bdbb9beeae4e419f12246dd08e17c5_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjZkMWNjMjhiMDI3YzQ5ZGM5N2U3N2M0Mjc4YTJjZTFlL3RhYmxlcmFuZ2U6NmQxY2MyOGIwMjdjNDlkYzk3ZTc3YzQyNzhhMmNlMWVfMi04LTEtMS0w_bf05e3bd-0586-4b3f-95da-04000543c379">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Marketable debt securities:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icdb4c26a6ae346b2b90553854ef6c821_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjZkMWNjMjhiMDI3YzQ5ZGM5N2U3N2M0Mjc4YTJjZTFlL3RhYmxlcmFuZ2U6NmQxY2MyOGIwMjdjNDlkYzk3ZTc3YzQyNzhhMmNlMWVfNC0yLTEtMS0w_a4d74c9e-21fb-49d1-a46f-a400a5d7b94f">1,695.1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i23dad120af7646aab43c1b2a51494af6_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjZkMWNjMjhiMDI3YzQ5ZGM5N2U3N2M0Mjc4YTJjZTFlL3RhYmxlcmFuZ2U6NmQxY2MyOGIwMjdjNDlkYzk3ZTc3YzQyNzhhMmNlMWVfNC00LTEtMS0w_8a3cf966-78a0-440d-8b0b-4df98509174a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9a733f2e8da94648b74178fe7c59c1c4_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjZkMWNjMjhiMDI3YzQ5ZGM5N2U3N2M0Mjc4YTJjZTFlL3RhYmxlcmFuZ2U6NmQxY2MyOGIwMjdjNDlkYzk3ZTc3YzQyNzhhMmNlMWVfNC02LTEtMS0w_976401eb-ce83-40ef-903d-f3b97e68f187">1,695.1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1741135b13de43a09abeb81ebbdefb63_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjZkMWNjMjhiMDI3YzQ5ZGM5N2U3N2M0Mjc4YTJjZTFlL3RhYmxlcmFuZ2U6NmQxY2MyOGIwMjdjNDlkYzk3ZTc3YzQyNzhhMmNlMWVfNC04LTEtMS0w_5f30ac86-b571-4c4e-9449-78a9cf6c4255">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Government securities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i43071817e6ed461f81f3fd642338f5f0_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjZkMWNjMjhiMDI3YzQ5ZGM5N2U3N2M0Mjc4YTJjZTFlL3RhYmxlcmFuZ2U6NmQxY2MyOGIwMjdjNDlkYzk3ZTc3YzQyNzhhMmNlMWVfNS0yLTEtMS0w_847affee-6f77-486c-b32f-2f312fa5acac">1,013.9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id2a84d2f950447e889c009b8dc3d1c91_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjZkMWNjMjhiMDI3YzQ5ZGM5N2U3N2M0Mjc4YTJjZTFlL3RhYmxlcmFuZ2U6NmQxY2MyOGIwMjdjNDlkYzk3ZTc3YzQyNzhhMmNlMWVfNS00LTEtMS0w_b5f5552d-7e5b-4f61-88d1-78ff2194ecf4">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3c062405d6734f55a0f77a7793837fa5_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjZkMWNjMjhiMDI3YzQ5ZGM5N2U3N2M0Mjc4YTJjZTFlL3RhYmxlcmFuZ2U6NmQxY2MyOGIwMjdjNDlkYzk3ZTc3YzQyNzhhMmNlMWVfNS02LTEtMS0w_3af2a8dd-79f0-4eff-bde9-8f248f6f2ec2">1,013.9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9c442e1cde66431c994c606712e1b32f_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjZkMWNjMjhiMDI3YzQ5ZGM5N2U3N2M0Mjc4YTJjZTFlL3RhYmxlcmFuZ2U6NmQxY2MyOGIwMjdjNDlkYzk3ZTc3YzQyNzhhMmNlMWVfNS04LTEtMS0w_da32f75a-cdc3-4f12-9c51-1f41e0ea26df">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Mortgage and other asset backed securities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i880c27328fde4402bd25776af2e34436_I20191231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjZkMWNjMjhiMDI3YzQ5ZGM5N2U3N2M0Mjc4YTJjZTFlL3RhYmxlcmFuZ2U6NmQxY2MyOGIwMjdjNDlkYzk3ZTc3YzQyNzhhMmNlMWVfNi0yLTEtMS0w_5fbdfd8b-a425-4bfc-96da-29b463c266af">261.3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if8cdd3be786a4c8fb53fbc1511f3e007_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjZkMWNjMjhiMDI3YzQ5ZGM5N2U3N2M0Mjc4YTJjZTFlL3RhYmxlcmFuZ2U6NmQxY2MyOGIwMjdjNDlkYzk3ZTc3YzQyNzhhMmNlMWVfNi00LTEtMS0w_e2ad19a0-7eb9-4c8c-88be-468b64d312fb">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia0e3519a323b44aeac235464c19aa330_I20191231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjZkMWNjMjhiMDI3YzQ5ZGM5N2U3N2M0Mjc4YTJjZTFlL3RhYmxlcmFuZ2U6NmQxY2MyOGIwMjdjNDlkYzk3ZTc3YzQyNzhhMmNlMWVfNi02LTEtMS0w_464f5c7d-94e6-4c1d-9a31-44972575e137">261.3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic296bd1f024d4dbfafdf14773b56195a_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjZkMWNjMjhiMDI3YzQ5ZGM5N2U3N2M0Mjc4YTJjZTFlL3RhYmxlcmFuZ2U6NmQxY2MyOGIwMjdjNDlkYzk3ZTc3YzQyNzhhMmNlMWVfNi04LTEtMS0w_b2f6edaa-9458-4907-ad39-bbad082f73b0">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Marketable equity securities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie6a0e49727c84ab293a923c6fa60c4af_I20191231" decimals="-5" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjZkMWNjMjhiMDI3YzQ5ZGM5N2U3N2M0Mjc4YTJjZTFlL3RhYmxlcmFuZ2U6NmQxY2MyOGIwMjdjNDlkYzk3ZTc3YzQyNzhhMmNlMWVfNy0yLTEtMS0w_946d2d02-cccb-42ea-a03f-de5a2a847c5a">337.5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if8d8ff0dd3eb48ac863f558fcbc6892a_I20191231" decimals="-5" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjZkMWNjMjhiMDI3YzQ5ZGM5N2U3N2M0Mjc4YTJjZTFlL3RhYmxlcmFuZ2U6NmQxY2MyOGIwMjdjNDlkYzk3ZTc3YzQyNzhhMmNlMWVfNy00LTEtMS0w_6ca378e1-c7dc-43ec-b176-daaaa2a66e8d">7.9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i30724e1260114af0b2ee60176aabfc27_I20191231" decimals="-5" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjZkMWNjMjhiMDI3YzQ5ZGM5N2U3N2M0Mjc4YTJjZTFlL3RhYmxlcmFuZ2U6NmQxY2MyOGIwMjdjNDlkYzk3ZTc3YzQyNzhhMmNlMWVfNy02LTEtMS0w_3655ad3e-f459-4d46-b1df-2f410401e4d8">329.6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib5bdbb9beeae4e419f12246dd08e17c5_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjZkMWNjMjhiMDI3YzQ5ZGM5N2U3N2M0Mjc4YTJjZTFlL3RhYmxlcmFuZ2U6NmQxY2MyOGIwMjdjNDlkYzk3ZTc3YzQyNzhhMmNlMWVfNy04LTEtMS0w_539a49db-09f7-4277-aadd-5a837c837e71">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Derivative contracts</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie6a0e49727c84ab293a923c6fa60c4af_I20191231" decimals="-5" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjZkMWNjMjhiMDI3YzQ5ZGM5N2U3N2M0Mjc4YTJjZTFlL3RhYmxlcmFuZ2U6NmQxY2MyOGIwMjdjNDlkYzk3ZTc3YzQyNzhhMmNlMWVfOC0yLTEtMS0w_047ad022-e62c-4ca7-85e2-a1b1eb0f978d">43.8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if8d8ff0dd3eb48ac863f558fcbc6892a_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjZkMWNjMjhiMDI3YzQ5ZGM5N2U3N2M0Mjc4YTJjZTFlL3RhYmxlcmFuZ2U6NmQxY2MyOGIwMjdjNDlkYzk3ZTc3YzQyNzhhMmNlMWVfOC00LTEtMS0w_826eb12b-a605-4881-b5ff-6a11b48c19c3">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i30724e1260114af0b2ee60176aabfc27_I20191231" decimals="-5" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjZkMWNjMjhiMDI3YzQ5ZGM5N2U3N2M0Mjc4YTJjZTFlL3RhYmxlcmFuZ2U6NmQxY2MyOGIwMjdjNDlkYzk3ZTc3YzQyNzhhMmNlMWVfOC02LTEtMS0w_50933642-27a9-46dd-a172-b5f4cfc12955">43.8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib5bdbb9beeae4e419f12246dd08e17c5_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjZkMWNjMjhiMDI3YzQ5ZGM5N2U3N2M0Mjc4YTJjZTFlL3RhYmxlcmFuZ2U6NmQxY2MyOGIwMjdjNDlkYzk3ZTc3YzQyNzhhMmNlMWVfOC04LTEtMS0w_36fcbf5d-fa9c-4385-8f66-d8904458bb64">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Plan assets for deferred compensation</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie6a0e49727c84ab293a923c6fa60c4af_I20191231" decimals="-5" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjZkMWNjMjhiMDI3YzQ5ZGM5N2U3N2M0Mjc4YTJjZTFlL3RhYmxlcmFuZ2U6NmQxY2MyOGIwMjdjNDlkYzk3ZTc3YzQyNzhhMmNlMWVfOS0yLTEtMS0w_4b18bdee-4395-47cf-9cb3-22868c579b31">27.7</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if8d8ff0dd3eb48ac863f558fcbc6892a_I20191231" decimals="-5" format="ixt:zerodash" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjZkMWNjMjhiMDI3YzQ5ZGM5N2U3N2M0Mjc4YTJjZTFlL3RhYmxlcmFuZ2U6NmQxY2MyOGIwMjdjNDlkYzk3ZTc3YzQyNzhhMmNlMWVfOS00LTEtMS0w_a7d8292b-e01c-41a6-85b7-abc0f34cfe2c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i30724e1260114af0b2ee60176aabfc27_I20191231" decimals="-5" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjZkMWNjMjhiMDI3YzQ5ZGM5N2U3N2M0Mjc4YTJjZTFlL3RhYmxlcmFuZ2U6NmQxY2MyOGIwMjdjNDlkYzk3ZTc3YzQyNzhhMmNlMWVfOS02LTEtMS0w_1bda800d-f8a9-4569-81c0-d14c1802cb91">27.7</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib5bdbb9beeae4e419f12246dd08e17c5_I20191231" decimals="-5" format="ixt:zerodash" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjZkMWNjMjhiMDI3YzQ5ZGM5N2U3N2M0Mjc4YTJjZTFlL3RhYmxlcmFuZ2U6NmQxY2MyOGIwMjdjNDlkYzk3ZTc3YzQyNzhhMmNlMWVfOS04LTEtMS0w_9202205a-2dd6-4a79-a334-75658601e8c8">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:29.25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie6a0e49727c84ab293a923c6fa60c4af_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjZkMWNjMjhiMDI3YzQ5ZGM5N2U3N2M0Mjc4YTJjZTFlL3RhYmxlcmFuZ2U6NmQxY2MyOGIwMjdjNDlkYzk3ZTc3YzQyNzhhMmNlMWVfMTAtMi0xLTEtMA_59404d0b-9519-43ee-9b87-353099299238">5,920.4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if8d8ff0dd3eb48ac863f558fcbc6892a_I20191231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjZkMWNjMjhiMDI3YzQ5ZGM5N2U3N2M0Mjc4YTJjZTFlL3RhYmxlcmFuZ2U6NmQxY2MyOGIwMjdjNDlkYzk3ZTc3YzQyNzhhMmNlMWVfMTAtNC0xLTEtMA_d6bc97ea-2e98-4ce8-8582-7001779ab02e">7.9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i30724e1260114af0b2ee60176aabfc27_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjZkMWNjMjhiMDI3YzQ5ZGM5N2U3N2M0Mjc4YTJjZTFlL3RhYmxlcmFuZ2U6NmQxY2MyOGIwMjdjNDlkYzk3ZTc3YzQyNzhhMmNlMWVfMTAtNi0xLTEtMA_b1fc3d3f-982f-48a3-9a3c-0e6600868618">5,912.5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib5bdbb9beeae4e419f12246dd08e17c5_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjZkMWNjMjhiMDI3YzQ5ZGM5N2U3N2M0Mjc4YTJjZTFlL3RhYmxlcmFuZ2U6NmQxY2MyOGIwMjdjNDlkYzk3ZTc3YzQyNzhhMmNlMWVfMTAtOC0xLTEtMA_927740c7-c3bf-49b1-bd49-c46558fa982a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-style:italic;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Liabilities:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Derivative contracts</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie6a0e49727c84ab293a923c6fa60c4af_I20191231" decimals="-5" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjZkMWNjMjhiMDI3YzQ5ZGM5N2U3N2M0Mjc4YTJjZTFlL3RhYmxlcmFuZ2U6NmQxY2MyOGIwMjdjNDlkYzk3ZTc3YzQyNzhhMmNlMWVfMTItMi0xLTEtMA_48a7151b-adc6-4a49-902d-e101eaa9464a">8.3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if8d8ff0dd3eb48ac863f558fcbc6892a_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjZkMWNjMjhiMDI3YzQ5ZGM5N2U3N2M0Mjc4YTJjZTFlL3RhYmxlcmFuZ2U6NmQxY2MyOGIwMjdjNDlkYzk3ZTc3YzQyNzhhMmNlMWVfMTItNC0xLTEtMA_f693e1e1-a66c-42a0-99df-5ea1a0e21221">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i30724e1260114af0b2ee60176aabfc27_I20191231" decimals="-5" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjZkMWNjMjhiMDI3YzQ5ZGM5N2U3N2M0Mjc4YTJjZTFlL3RhYmxlcmFuZ2U6NmQxY2MyOGIwMjdjNDlkYzk3ZTc3YzQyNzhhMmNlMWVfMTItNi0xLTEtMA_6d1e08ee-2f1a-4644-bb73-10101c05a7de">8.3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib5bdbb9beeae4e419f12246dd08e17c5_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjZkMWNjMjhiMDI3YzQ5ZGM5N2U3N2M0Mjc4YTJjZTFlL3RhYmxlcmFuZ2U6NmQxY2MyOGIwMjdjNDlkYzk3ZTc3YzQyNzhhMmNlMWVfMTItOC0xLTEtMA_488368e3-df7b-4e8e-97c5-597f2ceb4533">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration obligations</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie6a0e49727c84ab293a923c6fa60c4af_I20191231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjZkMWNjMjhiMDI3YzQ5ZGM5N2U3N2M0Mjc4YTJjZTFlL3RhYmxlcmFuZ2U6NmQxY2MyOGIwMjdjNDlkYzk3ZTc3YzQyNzhhMmNlMWVfMTMtMi0xLTEtMA_0b9919ab-b198-422a-a924-b08821039fdb">346.1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if8d8ff0dd3eb48ac863f558fcbc6892a_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjZkMWNjMjhiMDI3YzQ5ZGM5N2U3N2M0Mjc4YTJjZTFlL3RhYmxlcmFuZ2U6NmQxY2MyOGIwMjdjNDlkYzk3ZTc3YzQyNzhhMmNlMWVfMTMtNC0xLTEtMA_3fd90418-72a4-421c-a014-815cb8ba729b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i30724e1260114af0b2ee60176aabfc27_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjZkMWNjMjhiMDI3YzQ5ZGM5N2U3N2M0Mjc4YTJjZTFlL3RhYmxlcmFuZ2U6NmQxY2MyOGIwMjdjNDlkYzk3ZTc3YzQyNzhhMmNlMWVfMTMtNi0xLTEtMA_bc58c083-2584-436f-90fa-e218375b8fbe">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib5bdbb9beeae4e419f12246dd08e17c5_I20191231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjZkMWNjMjhiMDI3YzQ5ZGM5N2U3N2M0Mjc4YTJjZTFlL3RhYmxlcmFuZ2U6NmQxY2MyOGIwMjdjNDlkYzk3ZTc3YzQyNzhhMmNlMWVfMTMtOC0xLTEtMA_d4e07a9d-3c01-44e2-8ae6-3281639f58f2">346.1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:29.25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie6a0e49727c84ab293a923c6fa60c4af_I20191231" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjZkMWNjMjhiMDI3YzQ5ZGM5N2U3N2M0Mjc4YTJjZTFlL3RhYmxlcmFuZ2U6NmQxY2MyOGIwMjdjNDlkYzk3ZTc3YzQyNzhhMmNlMWVfMTQtMi0xLTEtMA_369e360c-5696-4953-9abd-24470a0793b6">354.4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if8d8ff0dd3eb48ac863f558fcbc6892a_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjZkMWNjMjhiMDI3YzQ5ZGM5N2U3N2M0Mjc4YTJjZTFlL3RhYmxlcmFuZ2U6NmQxY2MyOGIwMjdjNDlkYzk3ZTc3YzQyNzhhMmNlMWVfMTQtNC0xLTEtMA_cc4e647d-0d63-4bec-b63f-c10b04c35bf4">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i30724e1260114af0b2ee60176aabfc27_I20191231" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjZkMWNjMjhiMDI3YzQ5ZGM5N2U3N2M0Mjc4YTJjZTFlL3RhYmxlcmFuZ2U6NmQxY2MyOGIwMjdjNDlkYzk3ZTc3YzQyNzhhMmNlMWVfMTQtNi0xLTEtMA_408e32e3-90ad-4432-8ddb-65a74d4a053d">8.3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib5bdbb9beeae4e419f12246dd08e17c5_I20191231" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjZkMWNjMjhiMDI3YzQ5ZGM5N2U3N2M0Mjc4YTJjZTFlL3RhYmxlcmFuZ2U6NmQxY2MyOGIwMjdjNDlkYzk3ZTc3YzQyNzhhMmNlMWVfMTQtOC0xLTEtMA_4c9dbb21-1803-4a66-980f-2a33d081b2aa">346.1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td></tr></table></ix:continuation></div><div style="text-indent:24.75pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">There have been <ix:nonFraction unitRef="usd" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RleHRyZWdpb246MjcwNWY4ZDY1MThjNDkyZWJiNWZiYzRmNmYwOGJiMTdfMjgz_db99168f-3d3b-4788-8518-fb4c12f1829d">no</ix:nonFraction> material impairments of our assets measured and carried at fair value during the three and nine months ended September 30, 2020. In addition, there were no changes in valuation techniques during the three and nine months ended September 30, 2020. The fair value of Level 2 instruments classified as cash equivalents and marketable debt securities was determined through third-party pricing services. The fair value of Level 2 instruments classified as marketable equity securities represents our investments in Sangamo Therapeutics, Inc. (Sangamo) common stock and Denali Therapeutics Inc. (Denali) common stock and are valued using an option pricing valuation model as the investments are each subject to certain holding period restrictions. For additional information on our investments in Sangamo and Denali common stock, please read </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Note 8, Financial Instruments,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> to these condensed consolidated financial statements.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our investments in marketable equity securities also include shares of Ionis Pharmaceuticals, Inc. (Ionis) common stock acquired in June 2018. Our shares of Ionis common stock were initially subject to certain holding period restrictions that expired during the first quarter of 2020. The fair value of this investment was a Level 1 measurement as of September 30, 2020. </span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For a description of our validation procedures related to prices provided by third-party pricing services and our option pricing valuation model, please read </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Note 1, Summary of Significant Accounting Policies - Fair Value Measurements,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> to our consolidated financial statements included in our 2019 Form 10-K. </span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the significant unobservable inputs in the fair value measurement of our contingent consideration obligations as of September 30, 2020:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:24.266%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.724%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:13.416%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:21.773%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.536%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.020%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="27" style="padding-top:2px;padding-bottom:2px;background-color:#dbdbdb;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#026dce;background-color:rgb(255,255,255, 0.0);">As of September 30, 2020</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In millions)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Valuation Technique</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unobservable Input</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Range</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted Average</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-style:italic;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Liabilities:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dbdbdb;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dbdbdb;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dbdbdb;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:6pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration obligation</span></td><td colspan="3" rowspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dbdbdb;text-align:left;vertical-align:middle;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dbdbdb;text-align:right;vertical-align:middle;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3733833dc5534d8e823879ef2ca35162_I20200930" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjI1NDkxOTNiN2JhMjQ4Y2Q4NzQwYzIzYmFhZDJjM2UwL3RhYmxlcmFuZ2U6MjU0OTE5M2I3YmEyNDhjZDg3NDBjMjNiYWFkMmMzZTBfMy0yLTEtMS0w_86b9197e-6457-48e6-bc47-938934c17cb0">322.6</ix:nonFraction>&#160;</span></td><td rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dbdbdb;text-align:right;vertical-align:middle;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Discounted cash flow</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Discount rate</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dbdbdb;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#026dce;background-color:rgb(255,255,255, 0.0);">0.57% to 0.89%</span></td><td colspan="3" style="background-color:#dbdbdb;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dbdbdb;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#026dce;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="icfebb7d3ca564ab9adac39367dcd18ff_I20200930" decimals="4" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjI1NDkxOTNiN2JhMjQ4Y2Q4NzQwYzIzYmFhZDJjM2UwL3RhYmxlcmFuZ2U6MjU0OTE5M2I3YmEyNDhjZDg3NDBjMjNiYWFkMmMzZTBfMy0xMC0xLTEtMA_9b88da2d-2c01-4dd9-8e54-145d04ab98c7">0.63</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected timing of achievement of development milestones</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dbdbdb;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#026dce;background-color:rgb(255,255,255, 0.0);">2021 to 2027</span></td><td colspan="3" style="background-color:#dbdbdb;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dbdbdb;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#026dce;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td></tr></table></div><div style="text-indent:22.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The weighted average discount rate was calculated based on the relative fair value of our contingent consideration obligations. In addition, we apply various probabilities of technological and regulatory success, ranging from high single digits to certain probability, to the valuation models to estimate the fair values of our contingent consideration obligations.</span></div></ix:continuation><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_7">Table of Contents</a></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(unaudited, continued)</span></div></div><ix:continuation id="ide47ebb1e4f24fb4b0a17cb7bd4b2f4d"><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Debt Instruments</span></div><ix:nonNumeric contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" name="us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RleHRyZWdpb246MjcwNWY4ZDY1MThjNDkyZWJiNWZiYzRmNmYwOGJiMTdfNDU1Mg_f56c6f5e-da6f-4681-9021-f2490a344bce" escape="true"><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair and carrying values of our debt instruments, which are Level&#160;2 liabilities, are summarized as follows:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:42.091%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.369%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.369%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.369%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.374%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">As of September 30, 2020</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of December 31, 2019</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In millions)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair<br/>Value</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Carrying<br/>Value</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair<br/>Value</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Carrying<br/>Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">2.900% Senior Notes due September 15, 2020</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;vertical-align:top;">(1)</sup></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9aaf1d46914b4e72aed3585ce98ebf30_I20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:NotesPayableFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjIyNWM4MTYzZDVmZTRkYzhhMmY0MjFjMmZkNjJiZTU4L3RhYmxlcmFuZ2U6MjI1YzgxNjNkNWZlNGRjOGEyZjQyMWMyZmQ2MmJlNThfMi0yLTEtMS0w_ba549f3a-ec0e-4d5e-8160-cfaa38f72601">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9aaf1d46914b4e72aed3585ce98ebf30_I20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:NotesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjIyNWM4MTYzZDVmZTRkYzhhMmY0MjFjMmZkNjJiZTU4L3RhYmxlcmFuZ2U6MjI1YzgxNjNkNWZlNGRjOGEyZjQyMWMyZmQ2MmJlNThfMi00LTEtMS0w_1c7e405a-eedb-42b7-9c19-ea6f63782ff9">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i69617b3297c54b348a912b5786d5c621_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NotesPayableFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjIyNWM4MTYzZDVmZTRkYzhhMmY0MjFjMmZkNjJiZTU4L3RhYmxlcmFuZ2U6MjI1YzgxNjNkNWZlNGRjOGEyZjQyMWMyZmQ2MmJlNThfMi02LTEtMS0w_df7c2d16-ff20-426d-a46b-998a61c211fa">1,509.6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i69617b3297c54b348a912b5786d5c621_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NotesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjIyNWM4MTYzZDVmZTRkYzhhMmY0MjFjMmZkNjJiZTU4L3RhYmxlcmFuZ2U6MjI1YzgxNjNkNWZlNGRjOGEyZjQyMWMyZmQ2MmJlNThfMi04LTEtMS0w_52f14efa-bc7b-4072-bf23-5930bc989270">1,495.8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.625% Senior Notes due September 15, 2022</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia8b495ea13b343bca84608b9acb70bae_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NotesPayableFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjIyNWM4MTYzZDVmZTRkYzhhMmY0MjFjMmZkNjJiZTU4L3RhYmxlcmFuZ2U6MjI1YzgxNjNkNWZlNGRjOGEyZjQyMWMyZmQ2MmJlNThfMy0yLTEtMS0w_379c7589-e9df-404e-a2c1-48fcefe39005">1,058.4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia8b495ea13b343bca84608b9acb70bae_I20200930" decimals="-5" name="us-gaap:NotesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjIyNWM4MTYzZDVmZTRkYzhhMmY0MjFjMmZkNjJiZTU4L3RhYmxlcmFuZ2U6MjI1YzgxNjNkNWZlNGRjOGEyZjQyMWMyZmQ2MmJlNThfMy00LTEtMS0w_9beaced7-622f-4f80-a2e4-495a2b3a980f">997.5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id243a9da99674c029fed341ed2d8cf28_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NotesPayableFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjIyNWM4MTYzZDVmZTRkYzhhMmY0MjFjMmZkNjJiZTU4L3RhYmxlcmFuZ2U6MjI1YzgxNjNkNWZlNGRjOGEyZjQyMWMyZmQ2MmJlNThfMy02LTEtMS0w_14c54405-e258-4b67-b688-bf988a0da609">1,038.9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id243a9da99674c029fed341ed2d8cf28_I20191231" decimals="-5" name="us-gaap:NotesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjIyNWM4MTYzZDVmZTRkYzhhMmY0MjFjMmZkNjJiZTU4L3RhYmxlcmFuZ2U6MjI1YzgxNjNkNWZlNGRjOGEyZjQyMWMyZmQ2MmJlNThfMy04LTEtMS0w_a37e7e54-3cf1-46df-8356-7be36d20d43c">996.6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.050% Senior Notes due September 15, 2025</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icc2aa37ad604405da57ad8bd76640c2a_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NotesPayableFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjIyNWM4MTYzZDVmZTRkYzhhMmY0MjFjMmZkNjJiZTU4L3RhYmxlcmFuZ2U6MjI1YzgxNjNkNWZlNGRjOGEyZjQyMWMyZmQ2MmJlNThfNC0yLTEtMS0w_b67f3a1d-5fa7-4915-aca9-d6723270621d">1,988.5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icc2aa37ad604405da57ad8bd76640c2a_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NotesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjIyNWM4MTYzZDVmZTRkYzhhMmY0MjFjMmZkNjJiZTU4L3RhYmxlcmFuZ2U6MjI1YzgxNjNkNWZlNGRjOGEyZjQyMWMyZmQ2MmJlNThfNC00LTEtMS0w_efb01c6d-69f5-4cf3-b672-f5ec9fc02449">1,740.7</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6a88a8981a664b5881775b573a56d09c_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NotesPayableFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjIyNWM4MTYzZDVmZTRkYzhhMmY0MjFjMmZkNjJiZTU4L3RhYmxlcmFuZ2U6MjI1YzgxNjNkNWZlNGRjOGEyZjQyMWMyZmQ2MmJlNThfNC02LTEtMS0w_dc9b6393-d09f-4351-a2c3-c40edb7c1248">1,897.2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6a88a8981a664b5881775b573a56d09c_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NotesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjIyNWM4MTYzZDVmZTRkYzhhMmY0MjFjMmZkNjJiZTU4L3RhYmxlcmFuZ2U6MjI1YzgxNjNkNWZlNGRjOGEyZjQyMWMyZmQ2MmJlNThfNC04LTEtMS0w_da0142f0-2704-4629-a0ec-2b63deda101f">1,739.5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.250% Senior Notes due May 1, 2030</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if6f8f2b74b4b4cb48f44b56c1255fe48_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NotesPayableFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjIyNWM4MTYzZDVmZTRkYzhhMmY0MjFjMmZkNjJiZTU4L3RhYmxlcmFuZ2U6MjI1YzgxNjNkNWZlNGRjOGEyZjQyMWMyZmQ2MmJlNThfNS0yLTEtMS0w_972a9712-c0de-47bb-9f8d-2b3a0f44d2c6">1,532.8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if6f8f2b74b4b4cb48f44b56c1255fe48_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NotesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjIyNWM4MTYzZDVmZTRkYzhhMmY0MjFjMmZkNjJiZTU4L3RhYmxlcmFuZ2U6MjI1YzgxNjNkNWZlNGRjOGEyZjQyMWMyZmQ2MmJlNThfNS00LTEtMS0w_0ab68af7-076c-4320-9b30-a4bcd1cb99b5">1,491.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i21d53c4f2fba488bac9f594f9b972c35_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:NotesPayableFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjIyNWM4MTYzZDVmZTRkYzhhMmY0MjFjMmZkNjJiZTU4L3RhYmxlcmFuZ2U6MjI1YzgxNjNkNWZlNGRjOGEyZjQyMWMyZmQ2MmJlNThfNS02LTEtMS0w_2a8c62a4-3ad0-49c1-920a-680f21d9cb0f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i21d53c4f2fba488bac9f594f9b972c35_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:NotesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjIyNWM4MTYzZDVmZTRkYzhhMmY0MjFjMmZkNjJiZTU4L3RhYmxlcmFuZ2U6MjI1YzgxNjNkNWZlNGRjOGEyZjQyMWMyZmQ2MmJlNThfNS04LTEtMS0w_76f1fbd7-dd80-4eb0-83fa-5719bfe8b810">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.200% Senior Notes due September 15, 2045</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i77d457887e524f9da825a576463047de_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NotesPayableFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjIyNWM4MTYzZDVmZTRkYzhhMmY0MjFjMmZkNjJiZTU4L3RhYmxlcmFuZ2U6MjI1YzgxNjNkNWZlNGRjOGEyZjQyMWMyZmQ2MmJlNThfNi0yLTEtMS0w_a451571a-6d81-4cfa-bf48-efbac8a6dae7">2,286.3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i77d457887e524f9da825a576463047de_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NotesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjIyNWM4MTYzZDVmZTRkYzhhMmY0MjFjMmZkNjJiZTU4L3RhYmxlcmFuZ2U6MjI1YzgxNjNkNWZlNGRjOGEyZjQyMWMyZmQ2MmJlNThfNi00LTEtMS0w_ed54f2e6-26be-4764-a938-1f868f4dff31">1,723.3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie3ab5e1259184cbfbb1c0fa0836b199b_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NotesPayableFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjIyNWM4MTYzZDVmZTRkYzhhMmY0MjFjMmZkNjJiZTU4L3RhYmxlcmFuZ2U6MjI1YzgxNjNkNWZlNGRjOGEyZjQyMWMyZmQ2MmJlNThfNi02LTEtMS0w_1fe42105-a819-4523-b489-b2803046208b">2,107.9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie3ab5e1259184cbfbb1c0fa0836b199b_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NotesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjIyNWM4MTYzZDVmZTRkYzhhMmY0MjFjMmZkNjJiZTU4L3RhYmxlcmFuZ2U6MjI1YzgxNjNkNWZlNGRjOGEyZjQyMWMyZmQ2MmJlNThfNi04LTEtMS0w_86900a00-6a87-4dcf-8a41-55ab3b5dca2c">1,722.9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.150% Senior Notes due May 1, 2050</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iae850a600e004e54910f51657134788c_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NotesPayableFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjIyNWM4MTYzZDVmZTRkYzhhMmY0MjFjMmZkNjJiZTU4L3RhYmxlcmFuZ2U6MjI1YzgxNjNkNWZlNGRjOGEyZjQyMWMyZmQ2MmJlNThfNy0yLTEtMS0w_107224cf-7438-43ac-a7af-80b3c87e3d6e">1,470.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iae850a600e004e54910f51657134788c_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NotesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjIyNWM4MTYzZDVmZTRkYzhhMmY0MjFjMmZkNjJiZTU4L3RhYmxlcmFuZ2U6MjI1YzgxNjNkNWZlNGRjOGEyZjQyMWMyZmQ2MmJlNThfNy00LTEtMS0w_2168ec91-731c-496d-ab27-e5eb227e6396">1,472.5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5be3c08b32f44a29a978be98ccdbe750_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:NotesPayableFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjIyNWM4MTYzZDVmZTRkYzhhMmY0MjFjMmZkNjJiZTU4L3RhYmxlcmFuZ2U6MjI1YzgxNjNkNWZlNGRjOGEyZjQyMWMyZmQ2MmJlNThfNy02LTEtMS0w_1a3c1e25-f330-424e-abb2-fa02dac84675">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5be3c08b32f44a29a978be98ccdbe750_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:NotesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjIyNWM4MTYzZDVmZTRkYzhhMmY0MjFjMmZkNjJiZTU4L3RhYmxlcmFuZ2U6MjI1YzgxNjNkNWZlNGRjOGEyZjQyMWMyZmQ2MmJlNThfNy04LTEtMS0w_3964c873-a2c3-4e50-be3f-d5a8764981a0">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjIyNWM4MTYzZDVmZTRkYzhhMmY0MjFjMmZkNjJiZTU4L3RhYmxlcmFuZ2U6MjI1YzgxNjNkNWZlNGRjOGEyZjQyMWMyZmQ2MmJlNThfOC0yLTEtMS0w_5000b5f8-4154-4d87-87bc-2ed4837c4913">8,336.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NotesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjIyNWM4MTYzZDVmZTRkYzhhMmY0MjFjMmZkNjJiZTU4L3RhYmxlcmFuZ2U6MjI1YzgxNjNkNWZlNGRjOGEyZjQyMWMyZmQ2MmJlNThfOC00LTEtMS0w_0d4c8f0e-7d42-4c06-9fbc-5e81d7507000">7,425.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i626282e786b7454d83b617e9e83963e6_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjIyNWM4MTYzZDVmZTRkYzhhMmY0MjFjMmZkNjJiZTU4L3RhYmxlcmFuZ2U6MjI1YzgxNjNkNWZlNGRjOGEyZjQyMWMyZmQ2MmJlNThfOC02LTEtMS0w_78a471d9-d3c9-4cf0-9c93-1d96ee0218cf">6,553.6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i626282e786b7454d83b617e9e83963e6_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NotesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjIyNWM4MTYzZDVmZTRkYzhhMmY0MjFjMmZkNjJiZTU4L3RhYmxlcmFuZ2U6MjI1YzgxNjNkNWZlNGRjOGEyZjQyMWMyZmQ2MmJlNThfOC04LTEtMS0w_b53259ca-54ec-4581-accc-c24ed87b8a10">5,954.8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td></tr></table></div></ix:nonNumeric><div style="text-align:center;margin-top:6pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%;"><tr><td style="width:1.0%;"></td><td style="width:33.017%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:31.105%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:32.578%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="margin-top:1pt;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;vertical-align:top;">(1) </sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">Our <ix:nonFraction unitRef="number" contextRef="i9aaf1d46914b4e72aed3585ce98ebf30_I20200930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RleHRyZWdpb246MjcwNWY4ZDY1MThjNDkyZWJiNWZiYzRmNmYwOGJiMTdfMjQwMQ_d81c31fb-53ee-49c8-ad4c-aed9cbf88b59">2.900</ix:nonFraction>% Senior Notes due September 15, 2020, were redeemed in full in May 2020 using the net proceeds from the issuance on April 30, 2020, of our senior unsecured notes for an aggregate principal amount of $<ix:nonFraction unitRef="usd" contextRef="ic59436e93fd94dc7975cca19dc9348ab_I20200430" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RleHRyZWdpb246MjcwNWY4ZDY1MThjNDkyZWJiNWZiYzRmNmYwOGJiMTdfMjU5MA_558be3ed-8d83-43cb-9467-39257eade898">3.0</ix:nonFraction> billion. For additional information, please read </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;">Note 11, Indebtedness,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;"> to these condensed consolidated financial statements.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair values of each of our series of Senior Notes were determined through market, observable and corroborated sources. For additional information related to our Senior Notes issued on September 15, 2015, please read </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Note 12,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Indebtedness,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> to our consolidated financial statements included in our 2019 Form 10-K. For additional information related to our Senior Notes issued on April 30, 2020, please read </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Note 11, Indebtedness,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> to these condensed consolidated financial statements.</span></div><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Contingent Consideration Obligations</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In connection with our acquisitions of Convergence and BIN, we agreed to make additional payments based upon the achievement of certain milestone events. <ix:nonNumeric contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RleHRyZWdpb246MjcwNWY4ZDY1MThjNDkyZWJiNWZiYzRmNmYwOGJiMTdfNDU0OA_eb8dbcf3-3f4f-4fad-aa94-303ff4edb41d" continuedAt="i31c8fffa34104598b2183f9fccef7061" escape="true">The following table provides a roll forward of the fair values of our contingent consideration obligations, which includes Level 3 measurements:</ix:nonNumeric></span></div><div style="margin-top:5pt;margin-bottom:5pt;"><ix:continuation id="i31c8fffa34104598b2183f9fccef7061"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:47.438%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.034%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.034%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.034%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.040%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Three Months Ended September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In millions)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair value, beginning of period</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1b095aa200c24bc89b77243d5d674b37_I20200630" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjQ2MTYzYzE5MGU1MTRjZmRhMzg3ZWJmNmRlNDg3NGE3L3RhYmxlcmFuZ2U6NDYxNjNjMTkwZTUxNGNmZGEzODdlYmY2ZGU0ODc0YTdfMi0yLTEtMS0w_8b493515-9837-453f-a611-6560d9a9bbe9">351.6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i481da687b03f42ba833d7ea97207f576_I20190630" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjQ2MTYzYzE5MGU1MTRjZmRhMzg3ZWJmNmRlNDg3NGE3L3RhYmxlcmFuZ2U6NDYxNjNjMTkwZTUxNGNmZGEzODdlYmY2ZGU0ODc0YTdfMi00LTEtMS0w_57d03194-1d05-4633-98b2-cdd36421f4e3">401.3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie6a0e49727c84ab293a923c6fa60c4af_I20191231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjQ2MTYzYzE5MGU1MTRjZmRhMzg3ZWJmNmRlNDg3NGE3L3RhYmxlcmFuZ2U6NDYxNjNjMTkwZTUxNGNmZGEzODdlYmY2ZGU0ODc0YTdfMi02LTEtMS0w_4c774113-24d8-469e-9a3a-2229129e4307">346.1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie818884c1c424a8b87d88e29c4beebaa_I20181231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjQ2MTYzYzE5MGU1MTRjZmRhMzg3ZWJmNmRlNDg3NGE3L3RhYmxlcmFuZ2U6NDYxNjNjMTkwZTUxNGNmZGEzODdlYmY2ZGU0ODc0YTdfMi04LTEtMS0w_6ed72130-b8ad-4a1d-bf87-2bc606473ab3">409.8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Changes in fair value</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjQ2MTYzYzE5MGU1MTRjZmRhMzg3ZWJmNmRlNDg3NGE3L3RhYmxlcmFuZ2U6NDYxNjNjMTkwZTUxNGNmZGEzODdlYmY2ZGU0ODc0YTdfMy0yLTEtMS0w_8d1f997c-9ed7-4203-a725-994f64c09fc0">29.0</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjQ2MTYzYzE5MGU1MTRjZmRhMzg3ZWJmNmRlNDg3NGE3L3RhYmxlcmFuZ2U6NDYxNjNjMTkwZTUxNGNmZGEzODdlYmY2ZGU0ODc0YTdfMy00LTEtMS0w_29e7765a-f4c4-47fe-9afe-1cac8eefb99c">57.8</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjQ2MTYzYzE5MGU1MTRjZmRhMzg3ZWJmNmRlNDg3NGE3L3RhYmxlcmFuZ2U6NDYxNjNjMTkwZTUxNGNmZGEzODdlYmY2ZGU0ODc0YTdfMy02LTEtMS0w_260cb5ec-9883-4dff-ad93-d42b945c1e2a">23.5</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjQ2MTYzYzE5MGU1MTRjZmRhMzg3ZWJmNmRlNDg3NGE3L3RhYmxlcmFuZ2U6NDYxNjNjMTkwZTUxNGNmZGEzODdlYmY2ZGU0ODc0YTdfMy04LTEtMS0w_3271b4c7-6498-4ba5-9b54-a8891e982e05">66.3</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Payments</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjQ2MTYzYzE5MGU1MTRjZmRhMzg3ZWJmNmRlNDg3NGE3L3RhYmxlcmFuZ2U6NDYxNjNjMTkwZTUxNGNmZGEzODdlYmY2ZGU0ODc0YTdfNC0yLTEtMS0w_94d7b0ca-850d-4e16-8531-ef2c30bba541">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930" decimals="-5" format="ixt:zerodash" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjQ2MTYzYzE5MGU1MTRjZmRhMzg3ZWJmNmRlNDg3NGE3L3RhYmxlcmFuZ2U6NDYxNjNjMTkwZTUxNGNmZGEzODdlYmY2ZGU0ODc0YTdfNC00LTEtMS0w_c2db3b69-85ab-4d3b-8126-90f9b5d42317">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjQ2MTYzYzE5MGU1MTRjZmRhMzg3ZWJmNmRlNDg3NGE3L3RhYmxlcmFuZ2U6NDYxNjNjMTkwZTUxNGNmZGEzODdlYmY2ZGU0ODc0YTdfNC02LTEtMS0w_5376b5aa-323a-46bc-ba11-3e2af75c55f9">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="-5" format="ixt:zerodash" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjQ2MTYzYzE5MGU1MTRjZmRhMzg3ZWJmNmRlNDg3NGE3L3RhYmxlcmFuZ2U6NDYxNjNjMTkwZTUxNGNmZGEzODdlYmY2ZGU0ODc0YTdfNC04LTEtMS0w_1cd886c1-d184-4601-8bfc-1ffe46222b78">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair value, end of period</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3733833dc5534d8e823879ef2ca35162_I20200930" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjQ2MTYzYzE5MGU1MTRjZmRhMzg3ZWJmNmRlNDg3NGE3L3RhYmxlcmFuZ2U6NDYxNjNjMTkwZTUxNGNmZGEzODdlYmY2ZGU0ODc0YTdfNS0yLTEtMS0w_8453d96c-5759-4b7e-8920-bf83f5e2b890">322.6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7a3eaba5b5f948d7a04bc997b0e062fd_I20190930" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjQ2MTYzYzE5MGU1MTRjZmRhMzg3ZWJmNmRlNDg3NGE3L3RhYmxlcmFuZ2U6NDYxNjNjMTkwZTUxNGNmZGEzODdlYmY2ZGU0ODc0YTdfNS00LTEtMS0w_0e7729da-e520-4883-832f-44d809765293">343.5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3733833dc5534d8e823879ef2ca35162_I20200930" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjQ2MTYzYzE5MGU1MTRjZmRhMzg3ZWJmNmRlNDg3NGE3L3RhYmxlcmFuZ2U6NDYxNjNjMTkwZTUxNGNmZGEzODdlYmY2ZGU0ODc0YTdfNS02LTEtMS0w_4e999c59-2a37-4392-a162-6410f4d50dd4">322.6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7a3eaba5b5f948d7a04bc997b0e062fd_I20190930" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjQ2MTYzYzE5MGU1MTRjZmRhMzg3ZWJmNmRlNDg3NGE3L3RhYmxlcmFuZ2U6NDYxNjNjMTkwZTUxNGNmZGEzODdlYmY2ZGU0ODc0YTdfNS04LTEtMS0w_feed27be-e716-4d96-b59d-4070768b0e42">343.5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td></tr></table></ix:continuation></div><div style="text-indent:24.75pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of September 30, 2020 and December 31, 2019, approximately $<ix:nonFraction unitRef="usd" contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RleHRyZWdpb246MjcwNWY4ZDY1MThjNDkyZWJiNWZiYzRmNmYwOGJiMTdfMzUyNg_57a00105-b617-4358-86b1-6e9e1cf669ab">173.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i626282e786b7454d83b617e9e83963e6_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RleHRyZWdpb246MjcwNWY4ZDY1MThjNDkyZWJiNWZiYzRmNmYwOGJiMTdfMzUzMw_8bb10794-49bf-4ea6-82eb-498da413cc0d">197.7</ix:nonFraction> million, respectively, of the fair value of our total contingent consideration obligations was reflected as a component of other long-term liabilities in our condensed consolidated balance sheets with the remaining balance reflected as a component of accrued expenses and other.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the three and nine months ended September 30, 2020, changes in the fair value of our contingent consideration obligations were primarily due to changes in the probability and the expected timing of the achievement of certain remaining developmental milestones as well as changes in the interest rates used to revalue our contingent consideration liabilities and the passage of time.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the three and nine months ended September 30, 2019, changes in the fair value of our contingent consideration obligations were primarily due to the discontinuation of the Phase 2b study of BG00011 for the potential treatment of idiopathic pulmonary fibrosis resulting in a reduction of our contingent consideration obligations of $<ix:nonFraction unitRef="usd" contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RleHRyZWdpb246MjcwNWY4ZDY1MThjNDkyZWJiNWZiYzRmNmYwOGJiMTdfODI0NjMzNzIxNTAxMA_1b0fee47-9648-48f9-a090-5f4be2e5b141"><ix:nonFraction unitRef="usd" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RleHRyZWdpb246MjcwNWY4ZDY1MThjNDkyZWJiNWZiYzRmNmYwOGJiMTdfODI0NjMzNzIxNTAxMA_5fc9c9e4-f3c4-425f-bf8c-cfec2060ddeb">61.2</ix:nonFraction></ix:nonFraction>&#160;million, partially offset by a decrease in interest rates used to revalue our contingent consideration liabilities and the passage of time.</span></div></ix:continuation><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">23</span></div></div></div><div id="ib19ff89608c84168a635160f2efa48f3_73"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_7">Table of Contents</a></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(unaudited, continued)</span></div></div><div style="text-indent:-27pt;padding-left:27pt;margin-top:14pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">8.&#160;&#160;&#160;&#160;Financial Instruments </span></div><ix:nonNumeric contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" name="us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RleHRyZWdpb246MjRlZmE5YWU4NTFkNGEwZmEzMmRhNmMxZDZiNzg1OTJfMzgxNQ_4131c238-3470-46ba-acdf-ffdeef83c708" continuedAt="i780ee4d109104f6aa921e87ea14103e6" escape="true"><ix:nonNumeric contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RleHRyZWdpb246MjRlZmE5YWU4NTFkNGEwZmEzMmRhNmMxZDZiNzg1OTJfMzgwMA_9251bf95-ae57-4661-9d5f-7a4db6264487" escape="true"><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes our financial assets with maturities of less than 90&#160;days from the date of purchase included in cash and cash equivalents in our condensed consolidated balance sheets:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:58.549%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:18.344%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:18.347%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In millions)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">As of September 30, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1ca7ffcd21a746b68b8a16da619e41e8_I20200930" decimals="-5" name="us-gaap:CashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjI3YmE0YWUzYzZhYjRjNjZiNzFjMzgxYjFmMDM5NzQxL3RhYmxlcmFuZ2U6MjdiYTRhZTNjNmFiNGM2NmI3MWMzODFiMWYwMzk3NDFfMS0yLTEtMS0w_dd7208bf-ae2a-48f7-b1e0-bf733f67cf18">649.2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i88ecf4f0a7d947ada40d20f177ef560b_I20191231" decimals="-5" name="us-gaap:CashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjI3YmE0YWUzYzZhYjRjNjZiNzFjMzgxYjFmMDM5NzQxL3RhYmxlcmFuZ2U6MjdiYTRhZTNjNmFiNGM2NmI3MWMzODFiMWYwMzk3NDFfMS00LTEtMS0w_539bd100-eb31-4c1e-a476-0b04b528eccb">384.4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Overnight reverse repurchase agreements</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i01bf576ce3184732823152e79c0954dd_I20200930" decimals="-5" name="us-gaap:CashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjI3YmE0YWUzYzZhYjRjNjZiNzFjMzgxYjFmMDM5NzQxL3RhYmxlcmFuZ2U6MjdiYTRhZTNjNmFiNGM2NmI3MWMzODFiMWYwMzk3NDFfMi0yLTEtMS0w_b7739699-ab0d-4ccf-9bad-97a46cba197a">465.4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i83545e7be2ae48768bf0f58e921e708c_I20191231" decimals="-5" name="us-gaap:CashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjI3YmE0YWUzYzZhYjRjNjZiNzFjMzgxYjFmMDM5NzQxL3RhYmxlcmFuZ2U6MjdiYTRhZTNjNmFiNGM2NmI3MWMzODFiMWYwMzk3NDFfMi00LTEtMS0w_a0c6c0fe-2f3c-48ac-9cb0-d9fce00c2a5a">368.8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i37325c7e699d4c51b083d0bd7f89fe2a_I20200930" decimals="-5" name="us-gaap:CashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjI3YmE0YWUzYzZhYjRjNjZiNzFjMzgxYjFmMDM5NzQxL3RhYmxlcmFuZ2U6MjdiYTRhZTNjNmFiNGM2NmI3MWMzODFiMWYwMzk3NDFfMy0yLTEtMS0w_07e758d4-e685-4be8-aae2-5062742d4c5c">270.2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3e57229498ce4144b42c45e34e9ef425_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjI3YmE0YWUzYzZhYjRjNjZiNzFjMzgxYjFmMDM5NzQxL3RhYmxlcmFuZ2U6MjdiYTRhZTNjNmFiNGM2NmI3MWMzODFiMWYwMzk3NDFfMy00LTEtMS0w_1803a155-118a-4892-b983-97ab7772f788">1,628.5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Short-term debt securities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4704964df0724cd1b2cac40f12d8482c_I20200930" decimals="-5" name="us-gaap:CashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjI3YmE0YWUzYzZhYjRjNjZiNzFjMzgxYjFmMDM5NzQxL3RhYmxlcmFuZ2U6MjdiYTRhZTNjNmFiNGM2NmI3MWMzODFiMWYwMzk3NDFfNC0yLTEtMS0w_634fb570-3ab5-4708-a61d-e668bd4cce48">185.5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8d2e2443e8024c469ef86deaee00b316_I20191231" decimals="-5" name="us-gaap:CashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjI3YmE0YWUzYzZhYjRjNjZiNzFjMzgxYjFmMDM5NzQxL3RhYmxlcmFuZ2U6MjdiYTRhZTNjNmFiNGM2NmI3MWMzODFiMWYwMzk3NDFfNC00LTEtMS0w_b07a4836-a92b-4244-90b0-9ce74f5bb51c">159.4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjI3YmE0YWUzYzZhYjRjNjZiNzFjMzgxYjFmMDM5NzQxL3RhYmxlcmFuZ2U6MjdiYTRhZTNjNmFiNGM2NmI3MWMzODFiMWYwMzk3NDFfNS0yLTEtMS0w_93ce3a85-b6c2-4821-8717-81bfaee4433b">1,570.3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i626282e786b7454d83b617e9e83963e6_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjI3YmE0YWUzYzZhYjRjNjZiNzFjMzgxYjFmMDM5NzQxL3RhYmxlcmFuZ2U6MjdiYTRhZTNjNmFiNGM2NmI3MWMzODFiMWYwMzk3NDFfNS00LTEtMS0w_6e5574c1-c53e-4046-b1e4-74672b415ce4">2,541.1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td></tr></table></div></ix:nonNumeric><div style="text-indent:24.75pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The carrying values of our commercial paper, including accrued interest, overnight reverse repurchase agreements, money market funds and short-term debt securities approximate fair value due to their short-term maturities. </span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our marketable equity securities gains (losses) are recorded in other income (expense), net in our condensed consolidated statements of income. <ix:nonNumeric contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" name="us-gaap:AvailableForSaleSecuritiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RleHRyZWdpb246MjRlZmE5YWU4NTFkNGEwZmEzMmRhNmMxZDZiNzg1OTJfMzgwMg_527e13ce-fa66-4806-acb0-7d3f8cd005c0" continuedAt="i60f0a3d0309e4ff88aa135e5a2b179f0" escape="true">The following tables summarize our marketable debt and equity securities:</ix:nonNumeric></span></div><ix:continuation id="i60f0a3d0309e4ff88aa135e5a2b179f0"><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%;"><tr><td style="width:1.0%;"></td><td style="width:41.252%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.535%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.576%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.535%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.576%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.535%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.576%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.535%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.580%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">As of September 30, 2020</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In millions)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized<br/>Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i71ff130217a74446aad53582c9032ff2_I20200930" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjU1NzIyM2ZhYzVhZDQyZDNiNTRlMjJlZGUzNzFhNDYwL3RhYmxlcmFuZ2U6NTU3MjIzZmFjNWFkNDJkM2I1NGUyMmVkZTM3MWE0NjBfMi0yLTEtMS0w_ac904e24-7ccb-4d62-b05b-d72d71908570">963.5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i71ff130217a74446aad53582c9032ff2_I20200930" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjU1NzIyM2ZhYzVhZDQyZDNiNTRlMjJlZGUzNzFhNDYwL3RhYmxlcmFuZ2U6NTU3MjIzZmFjNWFkNDJkM2I1NGUyMmVkZTM3MWE0NjBfMi00LTEtMS0w_bfc997a9-e5a3-483b-af88-0f7c82e5a0e0">1.4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i71ff130217a74446aad53582c9032ff2_I20200930" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjU1NzIyM2ZhYzVhZDQyZDNiNTRlMjJlZGUzNzFhNDYwL3RhYmxlcmFuZ2U6NTU3MjIzZmFjNWFkNDJkM2I1NGUyMmVkZTM3MWE0NjBfMi02LTEtMS0w_fd7e971d-7015-4a45-b089-11df22f663ab">0.1</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i71ff130217a74446aad53582c9032ff2_I20200930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjU1NzIyM2ZhYzVhZDQyZDNiNTRlMjJlZGUzNzFhNDYwL3RhYmxlcmFuZ2U6NTU3MjIzZmFjNWFkNDJkM2I1NGUyMmVkZTM3MWE0NjBfMi04LTEtMS0w_5d9aa54b-c6ba-41f4-84aa-f979e5448149">964.8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-current</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6e2e5400e66745a59bc4efb5814dc463_I20200930" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjU1NzIyM2ZhYzVhZDQyZDNiNTRlMjJlZGUzNzFhNDYwL3RhYmxlcmFuZ2U6NTU3MjIzZmFjNWFkNDJkM2I1NGUyMmVkZTM3MWE0NjBfMy0yLTEtMS0w_b008897b-c049-45b1-8f64-6d97786f19df">475.9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6e2e5400e66745a59bc4efb5814dc463_I20200930" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjU1NzIyM2ZhYzVhZDQyZDNiNTRlMjJlZGUzNzFhNDYwL3RhYmxlcmFuZ2U6NTU3MjIzZmFjNWFkNDJkM2I1NGUyMmVkZTM3MWE0NjBfMy00LTEtMS0w_096a6eb3-d583-4287-b9e7-45f30f216027">3.2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i6e2e5400e66745a59bc4efb5814dc463_I20200930" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjU1NzIyM2ZhYzVhZDQyZDNiNTRlMjJlZGUzNzFhNDYwL3RhYmxlcmFuZ2U6NTU3MjIzZmFjNWFkNDJkM2I1NGUyMmVkZTM3MWE0NjBfMy02LTEtMS0w_df7971ea-48dd-4ace-82bd-23c2ffffa3a5">0.1</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6e2e5400e66745a59bc4efb5814dc463_I20200930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjU1NzIyM2ZhYzVhZDQyZDNiNTRlMjJlZGUzNzFhNDYwL3RhYmxlcmFuZ2U6NTU3MjIzZmFjNWFkNDJkM2I1NGUyMmVkZTM3MWE0NjBfMy04LTEtMS0w_e811d484-cd36-4a97-b1f4-8bb7bcfbcb80">479.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Government securities:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifcf2b581c6394dde8ca839bc55b63d5a_I20200930" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjU1NzIyM2ZhYzVhZDQyZDNiNTRlMjJlZGUzNzFhNDYwL3RhYmxlcmFuZ2U6NTU3MjIzZmFjNWFkNDJkM2I1NGUyMmVkZTM3MWE0NjBfNS0yLTEtMS0w_98d7c6dc-d705-4a94-81e4-1ce65edd6302">389.4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifcf2b581c6394dde8ca839bc55b63d5a_I20200930" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjU1NzIyM2ZhYzVhZDQyZDNiNTRlMjJlZGUzNzFhNDYwL3RhYmxlcmFuZ2U6NTU3MjIzZmFjNWFkNDJkM2I1NGUyMmVkZTM3MWE0NjBfNS00LTEtMS0w_d19d8ff6-87e2-4336-96de-60ec228f3150">0.2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifcf2b581c6394dde8ca839bc55b63d5a_I20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjU1NzIyM2ZhYzVhZDQyZDNiNTRlMjJlZGUzNzFhNDYwL3RhYmxlcmFuZ2U6NTU3MjIzZmFjNWFkNDJkM2I1NGUyMmVkZTM3MWE0NjBfNS02LTEtMS0w_a5788420-5b2a-4751-a1ac-27e79320e4da">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifcf2b581c6394dde8ca839bc55b63d5a_I20200930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjU1NzIyM2ZhYzVhZDQyZDNiNTRlMjJlZGUzNzFhNDYwL3RhYmxlcmFuZ2U6NTU3MjIzZmFjNWFkNDJkM2I1NGUyMmVkZTM3MWE0NjBfNS04LTEtMS0w_4c53c1af-3cd9-4c9e-a6e9-8e2f805d87a4">389.6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-current</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i332a8e26a3f44d669337bbdf30e280b1_I20200930" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjU1NzIyM2ZhYzVhZDQyZDNiNTRlMjJlZGUzNzFhNDYwL3RhYmxlcmFuZ2U6NTU3MjIzZmFjNWFkNDJkM2I1NGUyMmVkZTM3MWE0NjBfNi0yLTEtMS0w_3e37b2c8-3957-4e1c-bdf8-05502b29dbc7">376.4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i332a8e26a3f44d669337bbdf30e280b1_I20200930" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjU1NzIyM2ZhYzVhZDQyZDNiNTRlMjJlZGUzNzFhNDYwL3RhYmxlcmFuZ2U6NTU3MjIzZmFjNWFkNDJkM2I1NGUyMmVkZTM3MWE0NjBfNi00LTEtMS0w_18083d8e-295e-427d-a697-157aa15a6139">1.4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i332a8e26a3f44d669337bbdf30e280b1_I20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjU1NzIyM2ZhYzVhZDQyZDNiNTRlMjJlZGUzNzFhNDYwL3RhYmxlcmFuZ2U6NTU3MjIzZmFjNWFkNDJkM2I1NGUyMmVkZTM3MWE0NjBfNi02LTEtMS0w_574a28a7-c3fc-4053-818b-6233679707f9">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i332a8e26a3f44d669337bbdf30e280b1_I20200930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjU1NzIyM2ZhYzVhZDQyZDNiNTRlMjJlZGUzNzFhNDYwL3RhYmxlcmFuZ2U6NTU3MjIzZmFjNWFkNDJkM2I1NGUyMmVkZTM3MWE0NjBfNi04LTEtMS0w_3a4efab2-b29a-4b41-bc27-15da32453b40">377.8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Mortgage and other asset backed securities:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib526d2b286604bca80b624a3a4adab69_I20200930" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjU1NzIyM2ZhYzVhZDQyZDNiNTRlMjJlZGUzNzFhNDYwL3RhYmxlcmFuZ2U6NTU3MjIzZmFjNWFkNDJkM2I1NGUyMmVkZTM3MWE0NjBfOC0yLTEtMS0w_c66b5f92-9e6d-459a-baaa-e08d3451cb47">0.6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib526d2b286604bca80b624a3a4adab69_I20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjU1NzIyM2ZhYzVhZDQyZDNiNTRlMjJlZGUzNzFhNDYwL3RhYmxlcmFuZ2U6NTU3MjIzZmFjNWFkNDJkM2I1NGUyMmVkZTM3MWE0NjBfOC00LTEtMS0w_09d4d6c1-7d10-49ca-b011-2a45dc95fe86">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib526d2b286604bca80b624a3a4adab69_I20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjU1NzIyM2ZhYzVhZDQyZDNiNTRlMjJlZGUzNzFhNDYwL3RhYmxlcmFuZ2U6NTU3MjIzZmFjNWFkNDJkM2I1NGUyMmVkZTM3MWE0NjBfOC02LTEtMS0w_e54356a9-c758-4b4a-b665-bdeed69d9926">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib526d2b286604bca80b624a3a4adab69_I20200930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjU1NzIyM2ZhYzVhZDQyZDNiNTRlMjJlZGUzNzFhNDYwL3RhYmxlcmFuZ2U6NTU3MjIzZmFjNWFkNDJkM2I1NGUyMmVkZTM3MWE0NjBfOC04LTEtMS0w_db24927c-0dcf-4a6a-8487-2961ce15a5cb">0.6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-current</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6cf822a887824796933acc64b10aa831_I20200930" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjU1NzIyM2ZhYzVhZDQyZDNiNTRlMjJlZGUzNzFhNDYwL3RhYmxlcmFuZ2U6NTU3MjIzZmFjNWFkNDJkM2I1NGUyMmVkZTM3MWE0NjBfOS0yLTEtMS0w_832dbb04-c5cc-4ada-a801-76f4b8fb0bd2">152.6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6cf822a887824796933acc64b10aa831_I20200930" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjU1NzIyM2ZhYzVhZDQyZDNiNTRlMjJlZGUzNzFhNDYwL3RhYmxlcmFuZ2U6NTU3MjIzZmFjNWFkNDJkM2I1NGUyMmVkZTM3MWE0NjBfOS00LTEtMS0w_107f30bf-7bf6-404d-8399-0dda801167de">0.6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i6cf822a887824796933acc64b10aa831_I20200930" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjU1NzIyM2ZhYzVhZDQyZDNiNTRlMjJlZGUzNzFhNDYwL3RhYmxlcmFuZ2U6NTU3MjIzZmFjNWFkNDJkM2I1NGUyMmVkZTM3MWE0NjBfOS02LTEtMS0w_82eed26b-5142-4581-9c4b-4d73408ae651">0.2</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6cf822a887824796933acc64b10aa831_I20200930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjU1NzIyM2ZhYzVhZDQyZDNiNTRlMjJlZGUzNzFhNDYwL3RhYmxlcmFuZ2U6NTU3MjIzZmFjNWFkNDJkM2I1NGUyMmVkZTM3MWE0NjBfOS04LTEtMS0w_4773be35-68a1-4102-97aa-5fa559d9d7bb">153.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total marketable debt securities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjU1NzIyM2ZhYzVhZDQyZDNiNTRlMjJlZGUzNzFhNDYwL3RhYmxlcmFuZ2U6NTU3MjIzZmFjNWFkNDJkM2I1NGUyMmVkZTM3MWE0NjBfMTAtMi0xLTEtMA_6a486f55-0fa5-41db-bb71-229e38b29a5a">2,358.4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjU1NzIyM2ZhYzVhZDQyZDNiNTRlMjJlZGUzNzFhNDYwL3RhYmxlcmFuZ2U6NTU3MjIzZmFjNWFkNDJkM2I1NGUyMmVkZTM3MWE0NjBfMTAtNC0xLTEtMA_ae5e98c9-ca66-4261-b50c-ba6edf18187e">6.8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjU1NzIyM2ZhYzVhZDQyZDNiNTRlMjJlZGUzNzFhNDYwL3RhYmxlcmFuZ2U6NTU3MjIzZmFjNWFkNDJkM2I1NGUyMmVkZTM3MWE0NjBfMTAtNi0xLTEtMA_d1ac8797-2a3e-41d1-98dc-a7f6e7297a3c">0.4</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjU1NzIyM2ZhYzVhZDQyZDNiNTRlMjJlZGUzNzFhNDYwL3RhYmxlcmFuZ2U6NTU3MjIzZmFjNWFkNDJkM2I1NGUyMmVkZTM3MWE0NjBfMTAtOC0xLTEtMA_7f11fc94-56b8-403f-b80f-636debe5081b">2,364.8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Marketable equity securities, non-current</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia10b2aa757ad47b49f270ebc491e28d0_I20200930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjU1NzIyM2ZhYzVhZDQyZDNiNTRlMjJlZGUzNzFhNDYwL3RhYmxlcmFuZ2U6NTU3MjIzZmFjNWFkNDJkM2I1NGUyMmVkZTM3MWE0NjBfMTEtMi0xLTEtMA_491a4d3a-0f65-477c-9a62-7188db68a49f">851.7</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia10b2aa757ad47b49f270ebc491e28d0_I20200930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjU1NzIyM2ZhYzVhZDQyZDNiNTRlMjJlZGUzNzFhNDYwL3RhYmxlcmFuZ2U6NTU3MjIzZmFjNWFkNDJkM2I1NGUyMmVkZTM3MWE0NjBfMTEtNC0xLTEtMA_50db46f2-b7d1-4841-8bbf-2efe25e70001">63.6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia10b2aa757ad47b49f270ebc491e28d0_I20200930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjU1NzIyM2ZhYzVhZDQyZDNiNTRlMjJlZGUzNzFhNDYwL3RhYmxlcmFuZ2U6NTU3MjIzZmFjNWFkNDJkM2I1NGUyMmVkZTM3MWE0NjBfMTEtNi0xLTEtMA_d44e74cb-ad03-4427-a090-627d1f376405">46.8</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia10b2aa757ad47b49f270ebc491e28d0_I20200930" decimals="-5" name="us-gaap:AvailableForSaleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjU1NzIyM2ZhYzVhZDQyZDNiNTRlMjJlZGUzNzFhNDYwL3RhYmxlcmFuZ2U6NTU3MjIzZmFjNWFkNDJkM2I1NGUyMmVkZTM3MWE0NjBfMTEtOC0xLTEtMA_40bb3c4d-80c3-4910-9fa0-56758bd7e344">868.5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td></tr></table></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%;"><tr><td style="width:1.0%;"></td><td style="width:41.252%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.535%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.576%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.535%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.576%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.535%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.576%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.535%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.580%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of December 31, 2019</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In millions)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized<br/>Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id90fa1852e434ceeabbcb8fdd0d40cbd_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjNlMTVmNGEwMDdjZTQzZmFiY2Y0MTE0M2ZiYTU2NzllL3RhYmxlcmFuZ2U6M2UxNWY0YTAwN2NlNDNmYWJjZjQxMTQzZmJhNTY3OWVfMi0yLTEtMS0w_855af3fe-6721-483b-b76b-8ca0e4ca15d9">1,057.2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id90fa1852e434ceeabbcb8fdd0d40cbd_I20191231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjNlMTVmNGEwMDdjZTQzZmFiY2Y0MTE0M2ZiYTU2NzllL3RhYmxlcmFuZ2U6M2UxNWY0YTAwN2NlNDNmYWJjZjQxMTQzZmJhNTY3OWVfMi00LTEtMS0w_3848ee4f-a151-42a4-9d20-7b181d6a1fc8">1.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id90fa1852e434ceeabbcb8fdd0d40cbd_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjNlMTVmNGEwMDdjZTQzZmFiY2Y0MTE0M2ZiYTU2NzllL3RhYmxlcmFuZ2U6M2UxNWY0YTAwN2NlNDNmYWJjZjQxMTQzZmJhNTY3OWVfMi02LTEtMS0w_4b4a12ab-cbf9-4126-a329-6f4aa3c866c0">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id90fa1852e434ceeabbcb8fdd0d40cbd_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjNlMTVmNGEwMDdjZTQzZmFiY2Y0MTE0M2ZiYTU2NzllL3RhYmxlcmFuZ2U6M2UxNWY0YTAwN2NlNDNmYWJjZjQxMTQzZmJhNTY3OWVfMi04LTEtMS0w_1622ff4c-e2fa-4f7f-ab39-76ff10a9c93e">1,058.2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-current</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i86f354cf497b4deeb6d0848b22bfdca5_I20191231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjNlMTVmNGEwMDdjZTQzZmFiY2Y0MTE0M2ZiYTU2NzllL3RhYmxlcmFuZ2U6M2UxNWY0YTAwN2NlNDNmYWJjZjQxMTQzZmJhNTY3OWVfMy0yLTEtMS0w_cbcb744c-19cf-42ed-a044-69ff0806e9ea">633.9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i86f354cf497b4deeb6d0848b22bfdca5_I20191231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjNlMTVmNGEwMDdjZTQzZmFiY2Y0MTE0M2ZiYTU2NzllL3RhYmxlcmFuZ2U6M2UxNWY0YTAwN2NlNDNmYWJjZjQxMTQzZmJhNTY3OWVfMy00LTEtMS0w_44d108b4-f96f-42fd-b366-ca6c2bcdd721">3.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i86f354cf497b4deeb6d0848b22bfdca5_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjNlMTVmNGEwMDdjZTQzZmFiY2Y0MTE0M2ZiYTU2NzllL3RhYmxlcmFuZ2U6M2UxNWY0YTAwN2NlNDNmYWJjZjQxMTQzZmJhNTY3OWVfMy02LTEtMS0w_70c0d0de-f389-4226-855f-e0bdfee65807">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i86f354cf497b4deeb6d0848b22bfdca5_I20191231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjNlMTVmNGEwMDdjZTQzZmFiY2Y0MTE0M2ZiYTU2NzllL3RhYmxlcmFuZ2U6M2UxNWY0YTAwN2NlNDNmYWJjZjQxMTQzZmJhNTY3OWVfMy04LTEtMS0w_66f03c17-7c4a-4eb1-8399-2e5680bf9abf">636.9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Government securities:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia0059a0f76db42a38b389323762cb3c7_I20191231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjNlMTVmNGEwMDdjZTQzZmFiY2Y0MTE0M2ZiYTU2NzllL3RhYmxlcmFuZ2U6M2UxNWY0YTAwN2NlNDNmYWJjZjQxMTQzZmJhNTY3OWVfNS0yLTEtMS0w_bb06c119-93d7-431a-8fb0-400d83c7c4af">502.9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia0059a0f76db42a38b389323762cb3c7_I20191231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjNlMTVmNGEwMDdjZTQzZmFiY2Y0MTE0M2ZiYTU2NzllL3RhYmxlcmFuZ2U6M2UxNWY0YTAwN2NlNDNmYWJjZjQxMTQzZmJhNTY3OWVfNS00LTEtMS0w_ac7882f8-6687-450f-ac92-0d71e4d85726">0.4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia0059a0f76db42a38b389323762cb3c7_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjNlMTVmNGEwMDdjZTQzZmFiY2Y0MTE0M2ZiYTU2NzllL3RhYmxlcmFuZ2U6M2UxNWY0YTAwN2NlNDNmYWJjZjQxMTQzZmJhNTY3OWVfNS02LTEtMS0w_5c98f028-25dd-46e3-bf0d-1b09e8d39747">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia0059a0f76db42a38b389323762cb3c7_I20191231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjNlMTVmNGEwMDdjZTQzZmFiY2Y0MTE0M2ZiYTU2NzllL3RhYmxlcmFuZ2U6M2UxNWY0YTAwN2NlNDNmYWJjZjQxMTQzZmJhNTY3OWVfNS04LTEtMS0w_2348f04d-277a-42cf-b444-63bcf78cb7ec">503.3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-current</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id4429d736bb44d669945730bee5061f8_I20191231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjNlMTVmNGEwMDdjZTQzZmFiY2Y0MTE0M2ZiYTU2NzllL3RhYmxlcmFuZ2U6M2UxNWY0YTAwN2NlNDNmYWJjZjQxMTQzZmJhNTY3OWVfNi0yLTEtMS0w_5b2cff5a-f8c5-488a-87b1-4f1352f81b51">510.1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id4429d736bb44d669945730bee5061f8_I20191231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjNlMTVmNGEwMDdjZTQzZmFiY2Y0MTE0M2ZiYTU2NzllL3RhYmxlcmFuZ2U6M2UxNWY0YTAwN2NlNDNmYWJjZjQxMTQzZmJhNTY3OWVfNi00LTEtMS0w_8fce9701-73a7-40cd-95b0-1dfb4e264394">0.8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id4429d736bb44d669945730bee5061f8_I20191231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjNlMTVmNGEwMDdjZTQzZmFiY2Y0MTE0M2ZiYTU2NzllL3RhYmxlcmFuZ2U6M2UxNWY0YTAwN2NlNDNmYWJjZjQxMTQzZmJhNTY3OWVfNi02LTEtMS0w_e880a138-7605-48a2-9840-5aec617af70d">0.3</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id4429d736bb44d669945730bee5061f8_I20191231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjNlMTVmNGEwMDdjZTQzZmFiY2Y0MTE0M2ZiYTU2NzllL3RhYmxlcmFuZ2U6M2UxNWY0YTAwN2NlNDNmYWJjZjQxMTQzZmJhNTY3OWVfNi04LTEtMS0w_eb9e3f09-3690-43f4-a9ef-e5c207bf7ecd">510.6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Mortgage and other asset backed securities:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5fe904d775af4819805f32f893ad9967_I20191231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjNlMTVmNGEwMDdjZTQzZmFiY2Y0MTE0M2ZiYTU2NzllL3RhYmxlcmFuZ2U6M2UxNWY0YTAwN2NlNDNmYWJjZjQxMTQzZmJhNTY3OWVfOC0yLTEtMS0w_ca4e24e1-d13f-4673-b1ee-13fe14657f44">0.7</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5fe904d775af4819805f32f893ad9967_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjNlMTVmNGEwMDdjZTQzZmFiY2Y0MTE0M2ZiYTU2NzllL3RhYmxlcmFuZ2U6M2UxNWY0YTAwN2NlNDNmYWJjZjQxMTQzZmJhNTY3OWVfOC00LTEtMS0w_af910a79-ac03-46e0-92d8-2213830a6cf1">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5fe904d775af4819805f32f893ad9967_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjNlMTVmNGEwMDdjZTQzZmFiY2Y0MTE0M2ZiYTU2NzllL3RhYmxlcmFuZ2U6M2UxNWY0YTAwN2NlNDNmYWJjZjQxMTQzZmJhNTY3OWVfOC02LTEtMS0w_ca941ba2-d345-45ec-8c49-49984d9ab6f6">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5fe904d775af4819805f32f893ad9967_I20191231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjNlMTVmNGEwMDdjZTQzZmFiY2Y0MTE0M2ZiYTU2NzllL3RhYmxlcmFuZ2U6M2UxNWY0YTAwN2NlNDNmYWJjZjQxMTQzZmJhNTY3OWVfOC04LTEtMS0w_2bf6c3ef-6854-4410-9125-2944f87a4d22">0.7</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-current</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i803e14e6eace4d489a23796edd542d13_I20191231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjNlMTVmNGEwMDdjZTQzZmFiY2Y0MTE0M2ZiYTU2NzllL3RhYmxlcmFuZ2U6M2UxNWY0YTAwN2NlNDNmYWJjZjQxMTQzZmJhNTY3OWVfOS0yLTEtMS0w_a4d4020d-556b-4d0b-830f-6991634befe8">260.2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i803e14e6eace4d489a23796edd542d13_I20191231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjNlMTVmNGEwMDdjZTQzZmFiY2Y0MTE0M2ZiYTU2NzllL3RhYmxlcmFuZ2U6M2UxNWY0YTAwN2NlNDNmYWJjZjQxMTQzZmJhNTY3OWVfOS00LTEtMS0w_ae07fb7e-5409-447c-ae17-4b23feb633a7">0.8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i803e14e6eace4d489a23796edd542d13_I20191231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjNlMTVmNGEwMDdjZTQzZmFiY2Y0MTE0M2ZiYTU2NzllL3RhYmxlcmFuZ2U6M2UxNWY0YTAwN2NlNDNmYWJjZjQxMTQzZmJhNTY3OWVfOS02LTEtMS0w_3688c4de-c5ca-45c0-adc9-d5ba09cf3fe1">0.4</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i803e14e6eace4d489a23796edd542d13_I20191231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjNlMTVmNGEwMDdjZTQzZmFiY2Y0MTE0M2ZiYTU2NzllL3RhYmxlcmFuZ2U6M2UxNWY0YTAwN2NlNDNmYWJjZjQxMTQzZmJhNTY3OWVfOS04LTEtMS0w_44bd20fa-d886-4570-aabd-5a703bf215d6">260.6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total marketable debt securities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i626282e786b7454d83b617e9e83963e6_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjNlMTVmNGEwMDdjZTQzZmFiY2Y0MTE0M2ZiYTU2NzllL3RhYmxlcmFuZ2U6M2UxNWY0YTAwN2NlNDNmYWJjZjQxMTQzZmJhNTY3OWVfMTAtMi0xLTEtMA_266e4a81-b3d8-432c-adf5-5c42c9ad7490">2,965.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i626282e786b7454d83b617e9e83963e6_I20191231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjNlMTVmNGEwMDdjZTQzZmFiY2Y0MTE0M2ZiYTU2NzllL3RhYmxlcmFuZ2U6M2UxNWY0YTAwN2NlNDNmYWJjZjQxMTQzZmJhNTY3OWVfMTAtNC0xLTEtMA_17474eb5-02d3-4212-bf34-d32f77d51c60">6.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i626282e786b7454d83b617e9e83963e6_I20191231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjNlMTVmNGEwMDdjZTQzZmFiY2Y0MTE0M2ZiYTU2NzllL3RhYmxlcmFuZ2U6M2UxNWY0YTAwN2NlNDNmYWJjZjQxMTQzZmJhNTY3OWVfMTAtNi0xLTEtMA_8f333537-e56c-4ef1-9ab1-326170ec99ec">0.7</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i626282e786b7454d83b617e9e83963e6_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjNlMTVmNGEwMDdjZTQzZmFiY2Y0MTE0M2ZiYTU2NzllL3RhYmxlcmFuZ2U6M2UxNWY0YTAwN2NlNDNmYWJjZjQxMTQzZmJhNTY3OWVfMTAtOC0xLTEtMA_f7f66203-e1ee-4483-9e3b-e8b1fd355630">2,970.3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Marketable equity securities, non-current</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ieb9c77d5ac2a4c2c926a9a3dbf9ab8a7_I20191231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjNlMTVmNGEwMDdjZTQzZmFiY2Y0MTE0M2ZiYTU2NzllL3RhYmxlcmFuZ2U6M2UxNWY0YTAwN2NlNDNmYWJjZjQxMTQzZmJhNTY3OWVfMTEtMi0xLTEtMA_92645dc9-1174-466a-a0b0-948d313e11c3">218.4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ieb9c77d5ac2a4c2c926a9a3dbf9ab8a7_I20191231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjNlMTVmNGEwMDdjZTQzZmFiY2Y0MTE0M2ZiYTU2NzllL3RhYmxlcmFuZ2U6M2UxNWY0YTAwN2NlNDNmYWJjZjQxMTQzZmJhNTY3OWVfMTEtNC0xLTEtMA_a553bd87-8446-4b4f-aed1-b842a03c7c9d">132.1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ieb9c77d5ac2a4c2c926a9a3dbf9ab8a7_I20191231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjNlMTVmNGEwMDdjZTQzZmFiY2Y0MTE0M2ZiYTU2NzllL3RhYmxlcmFuZ2U6M2UxNWY0YTAwN2NlNDNmYWJjZjQxMTQzZmJhNTY3OWVfMTEtNi0xLTEtMA_b31caf98-7405-4a30-8940-60795b70dbe9">13.0</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ieb9c77d5ac2a4c2c926a9a3dbf9ab8a7_I20191231" decimals="-5" name="us-gaap:AvailableForSaleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjNlMTVmNGEwMDdjZTQzZmFiY2Y0MTE0M2ZiYTU2NzllL3RhYmxlcmFuZ2U6M2UxNWY0YTAwN2NlNDNmYWJjZjQxMTQzZmJhNTY3OWVfMTEtOC0xLTEtMA_9eba1297-a521-4924-87cd-9a2eeb6b1282">337.5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td></tr></table></div></ix:continuation></ix:nonNumeric><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_7">Table of Contents</a></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(unaudited, continued)</span></div></div><ix:continuation id="i780ee4d109104f6aa921e87ea14103e6" continuedAt="i8d7e1e18f7f34e8ea3ef1ae45e1fad74"><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Summary of Contractual Maturities: Available-for-Sale Debt Securities</span></div><ix:nonNumeric contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RleHRyZWdpb246MjRlZmE5YWU4NTFkNGEwZmEzMmRhNmMxZDZiNzg1OTJfMzgwNA_166c6fce-e714-48ea-99fe-c22236954180" escape="true"><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The estimated fair value and amortized cost of our marketable debt securities available-for-sale by contractual maturity are summarized as follows:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%;"><tr><td style="width:1.0%;"></td><td style="width:41.924%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.409%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.409%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.409%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.413%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">As of September 30, 2020</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of December 31, 2019</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In millions)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Estimated<br/>Fair Value</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized<br/>Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Estimated<br/>Fair Value</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized<br/>Cost</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Due in one year or less</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjIxMDliZDc0MjkyZDQzMThiMTI2N2NjYzZjODNmZWJiL3RhYmxlcmFuZ2U6MjEwOWJkNzQyOTJkNDMxOGIxMjY3Y2NjNmM4M2ZlYmJfMi0yLTEtMS0w_de31e9a8-2fa4-4bbb-87e5-ad29981e5906">1,355.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjIxMDliZDc0MjkyZDQzMThiMTI2N2NjYzZjODNmZWJiL3RhYmxlcmFuZ2U6MjEwOWJkNzQyOTJkNDMxOGIxMjY3Y2NjNmM4M2ZlYmJfMi00LTEtMS0w_8d848eab-9eda-48d7-86ac-2e9bb2d8549c">1,353.4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i626282e786b7454d83b617e9e83963e6_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjIxMDliZDc0MjkyZDQzMThiMTI2N2NjYzZjODNmZWJiL3RhYmxlcmFuZ2U6MjEwOWJkNzQyOTJkNDMxOGIxMjY3Y2NjNmM4M2ZlYmJfMi02LTEtMS0w_6c7f1acd-75c0-47c9-b362-3759190648e1">1,562.2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i626282e786b7454d83b617e9e83963e6_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjIxMDliZDc0MjkyZDQzMThiMTI2N2NjYzZjODNmZWJiL3RhYmxlcmFuZ2U6MjEwOWJkNzQyOTJkNDMxOGIxMjY3Y2NjNmM4M2ZlYmJfMi04LTEtMS0w_be475ab6-45e5-4c7f-aa82-33087e768779">1,560.8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Due after one year through five years</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjIxMDliZDc0MjkyZDQzMThiMTI2N2NjYzZjODNmZWJiL3RhYmxlcmFuZ2U6MjEwOWJkNzQyOTJkNDMxOGIxMjY3Y2NjNmM4M2ZlYmJfMy0yLTEtMS0w_565f4edd-feee-471d-8415-16449c310d77">902.2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjIxMDliZDc0MjkyZDQzMThiMTI2N2NjYzZjODNmZWJiL3RhYmxlcmFuZ2U6MjEwOWJkNzQyOTJkNDMxOGIxMjY3Y2NjNmM4M2ZlYmJfMy00LTEtMS0w_7c64e603-6318-4879-b328-f7460bdeee8a">897.9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i626282e786b7454d83b617e9e83963e6_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjIxMDliZDc0MjkyZDQzMThiMTI2N2NjYzZjODNmZWJiL3RhYmxlcmFuZ2U6MjEwOWJkNzQyOTJkNDMxOGIxMjY3Y2NjNmM4M2ZlYmJfMy02LTEtMS0w_3bb30320-fb98-4937-82c2-9b17732fd80c">1,234.5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i626282e786b7454d83b617e9e83963e6_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjIxMDliZDc0MjkyZDQzMThiMTI2N2NjYzZjODNmZWJiL3RhYmxlcmFuZ2U6MjEwOWJkNzQyOTJkNDMxOGIxMjY3Y2NjNmM4M2ZlYmJfMy04LTEtMS0w_a06f1b99-283a-4065-af14-d96a3d055734">1,230.4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Due after five years</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930" decimals="-5" name="biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjIxMDliZDc0MjkyZDQzMThiMTI2N2NjYzZjODNmZWJiL3RhYmxlcmFuZ2U6MjEwOWJkNzQyOTJkNDMxOGIxMjY3Y2NjNmM4M2ZlYmJfNC0yLTEtMS0w_0bd2a527-3293-45f4-b355-bc1e9e2e48f0">107.6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930" decimals="-5" name="biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjIxMDliZDc0MjkyZDQzMThiMTI2N2NjYzZjODNmZWJiL3RhYmxlcmFuZ2U6MjEwOWJkNzQyOTJkNDMxOGIxMjY3Y2NjNmM4M2ZlYmJfNC00LTEtMS0w_4d49e74d-0fec-4e32-82a3-2a2f6e4628fa">107.1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i626282e786b7454d83b617e9e83963e6_I20191231" decimals="-5" name="biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjIxMDliZDc0MjkyZDQzMThiMTI2N2NjYzZjODNmZWJiL3RhYmxlcmFuZ2U6MjEwOWJkNzQyOTJkNDMxOGIxMjY3Y2NjNmM4M2ZlYmJfNC02LTEtMS0w_409e03a3-72b3-4dd8-84f4-53e69a4a8ec7">173.6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i626282e786b7454d83b617e9e83963e6_I20191231" decimals="-5" name="biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjIxMDliZDc0MjkyZDQzMThiMTI2N2NjYzZjODNmZWJiL3RhYmxlcmFuZ2U6MjEwOWJkNzQyOTJkNDMxOGIxMjY3Y2NjNmM4M2ZlYmJfNC04LTEtMS0w_65b3b2bc-9254-43ee-bbaa-ef92b95baffb">173.8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total marketable debt securities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjIxMDliZDc0MjkyZDQzMThiMTI2N2NjYzZjODNmZWJiL3RhYmxlcmFuZ2U6MjEwOWJkNzQyOTJkNDMxOGIxMjY3Y2NjNmM4M2ZlYmJfNS0yLTEtMS0w_0ce1245e-ef5a-4266-8eaf-d2664bec173e">2,364.8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjIxMDliZDc0MjkyZDQzMThiMTI2N2NjYzZjODNmZWJiL3RhYmxlcmFuZ2U6MjEwOWJkNzQyOTJkNDMxOGIxMjY3Y2NjNmM4M2ZlYmJfNS00LTEtMS0w_3416534e-f932-4d6f-b6bf-624e1899df9b">2,358.4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i626282e786b7454d83b617e9e83963e6_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjIxMDliZDc0MjkyZDQzMThiMTI2N2NjYzZjODNmZWJiL3RhYmxlcmFuZ2U6MjEwOWJkNzQyOTJkNDMxOGIxMjY3Y2NjNmM4M2ZlYmJfNS02LTEtMS0w_6edfdbc6-00b6-4ea6-9ba9-eeebab599407">2,970.3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i626282e786b7454d83b617e9e83963e6_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjIxMDliZDc0MjkyZDQzMThiMTI2N2NjYzZjODNmZWJiL3RhYmxlcmFuZ2U6MjEwOWJkNzQyOTJkNDMxOGIxMjY3Y2NjNmM4M2ZlYmJfNS04LTEtMS0w_6673c399-ddf9-4296-b0a3-c2c9a052e2a6">2,965.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td></tr></table></div></ix:nonNumeric><div style="text-indent:24.75pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The average maturity of our marketable debt securities available-for-sale as of September 30, 2020 and December 31, 2019, was approximately <ix:nonNumeric contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" format="ixt-sec:durmonth" name="biib:AverageMaturityOfMarketableSecurities" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RleHRyZWdpb246MjRlZmE5YWU4NTFkNGEwZmEzMmRhNmMxZDZiNzg1OTJfOTkw_610dd2bd-728f-421b-b309-e251ac153c91">12</ix:nonNumeric> months and <ix:nonNumeric contextRef="i0da5a59be8a94d28ad89a6d9991c15a1_D20190101-20191231" format="ixt-sec:durmonth" name="biib:AverageMaturityOfMarketableSecurities" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RleHRyZWdpb246MjRlZmE5YWU4NTFkNGEwZmEzMmRhNmMxZDZiNzg1OTJfMTA5OTUxMTYzNDQ2MQ_4e8a601b-d354-4ced-9d56-e40ff49d488a">14</ix:nonNumeric> months, respectively.</span></div><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Proceeds from Marketable Debt Securities</span></div><ix:nonNumeric contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" name="us-gaap:RealizedGainLossOnInvestmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RleHRyZWdpb246MjRlZmE5YWU4NTFkNGEwZmEzMmRhNmMxZDZiNzg1OTJfMzgwOQ_27b8e4ea-16d6-47ac-8508-101168654c43" escape="true"><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:44.075%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.204%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.384%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.204%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.619%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.624%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Three Months Ended September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In millions)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Proceeds from maturities and sales</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjUzZDc4NDJhNDE4MzQ4NDg5OTU0MGIxYzBjYmI0MDU3L3RhYmxlcmFuZ2U6NTNkNzg0MmE0MTgzNDg0ODk5NTQwYjFjMGNiYjQwNTdfMi0yLTEtMS0w_4cf7b323-a101-4120-a8c6-7c77a4c072fe">1,360.9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930" decimals="-5" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjUzZDc4NDJhNDE4MzQ4NDg5OTU0MGIxYzBjYmI0MDU3L3RhYmxlcmFuZ2U6NTNkNzg0MmE0MTgzNDg0ODk5NTQwYjFjMGNiYjQwNTdfMi00LTEtMS0w_27c0f233-1386-43f1-9019-7ae56f323a90">611.8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjUzZDc4NDJhNDE4MzQ4NDg5OTU0MGIxYzBjYmI0MDU3L3RhYmxlcmFuZ2U6NTNkNzg0MmE0MTgzNDg0ODk5NTQwYjFjMGNiYjQwNTdfMi02LTEtMS0w_45e0d16f-9980-4075-95aa-7108fc9869bb">5,240.7</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjUzZDc4NDJhNDE4MzQ4NDg5OTU0MGIxYzBjYmI0MDU3L3RhYmxlcmFuZ2U6NTNkNzg0MmE0MTgzNDg0ODk5NTQwYjFjMGNiYjQwNTdfMi04LTEtMS0w_b533f998-11a6-453f-ae3d-bde8a28418ac">3,867.6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Realized gains</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjUzZDc4NDJhNDE4MzQ4NDg5OTU0MGIxYzBjYmI0MDU3L3RhYmxlcmFuZ2U6NTNkNzg0MmE0MTgzNDg0ODk5NTQwYjFjMGNiYjQwNTdfMy0yLTEtMS0w_71c1d27d-8d7f-4ab2-a52e-99c0bfd1da4d">1.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjUzZDc4NDJhNDE4MzQ4NDg5OTU0MGIxYzBjYmI0MDU3L3RhYmxlcmFuZ2U6NTNkNzg0MmE0MTgzNDg0ODk5NTQwYjFjMGNiYjQwNTdfMy00LTEtMS0w_884c1720-29d5-4a02-99b7-e028c8e4ebd7">0.7</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjUzZDc4NDJhNDE4MzQ4NDg5OTU0MGIxYzBjYmI0MDU3L3RhYmxlcmFuZ2U6NTNkNzg0MmE0MTgzNDg0ODk5NTQwYjFjMGNiYjQwNTdfMy02LTEtMS0w_48b06321-a6d4-4660-9331-934e4dcb7575">12.8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjUzZDc4NDJhNDE4MzQ4NDg5OTU0MGIxYzBjYmI0MDU3L3RhYmxlcmFuZ2U6NTNkNzg0MmE0MTgzNDg0ODk5NTQwYjFjMGNiYjQwNTdfMy04LTEtMS0w_45326604-484f-4f2c-ad19-9d1fbb1d2e77">2.3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Realized losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjUzZDc4NDJhNDE4MzQ4NDg5OTU0MGIxYzBjYmI0MDU3L3RhYmxlcmFuZ2U6NTNkNzg0MmE0MTgzNDg0ODk5NTQwYjFjMGNiYjQwNTdfNC0yLTEtMS0w_11592c81-5bbc-4144-a7f7-e7c7b1ea808e">0.9</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjUzZDc4NDJhNDE4MzQ4NDg5OTU0MGIxYzBjYmI0MDU3L3RhYmxlcmFuZ2U6NTNkNzg0MmE0MTgzNDg0ODk5NTQwYjFjMGNiYjQwNTdfNC00LTEtMS0w_8e59b325-83ea-4c74-a876-2e26ee5206d8">0.1</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjUzZDc4NDJhNDE4MzQ4NDg5OTU0MGIxYzBjYmI0MDU3L3RhYmxlcmFuZ2U6NTNkNzg0MmE0MTgzNDg0ODk5NTQwYjFjMGNiYjQwNTdfNC02LTEtMS0w_85fee645-e9b7-4007-9da8-83bbcf355808">25.2</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjUzZDc4NDJhNDE4MzQ4NDg5OTU0MGIxYzBjYmI0MDU3L3RhYmxlcmFuZ2U6NTNkNzg0MmE0MTgzNDg0ODk5NTQwYjFjMGNiYjQwNTdfNC04LTEtMS0w_0aaa842f-0c38-4af1-9b07-a6b0ba334dc4">0.7</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr></table></div></ix:nonNumeric><div style="text-indent:11.25pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Strategic Investments</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of September 30, 2020 and December 31, 2019, our strategic investment portfolio was comprised of investments totaling $<ix:nonFraction unitRef="usd" contextRef="i9fda89e7ff7d4684af34961dfcf9aa55_I20200930" decimals="-5" format="ixt:numdotdecimal" name="biib:StrategicInvestmentPortfolio" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RleHRyZWdpb246MjRlZmE5YWU4NTFkNGEwZmEzMmRhNmMxZDZiNzg1OTJfMTI5Mg_79247788-14df-4bf6-a292-85f81781b6cd">925.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="id8f1f5cd45cf4a6db70e9630acf66ec5_I20191231" decimals="-5" format="ixt:numdotdecimal" name="biib:StrategicInvestmentPortfolio" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RleHRyZWdpb246MjRlZmE5YWU4NTFkNGEwZmEzMmRhNmMxZDZiNzg1OTJfMTI5OQ_88d71c69-9eb3-4384-911c-22923da2f116">393.9</ix:nonFraction> million, respectively, which are included in investments and other assets in our condensed consolidated balance sheets. </span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our strategic investment portfolio includes investments in equity securities of certain biotechnology companies, which are reflected within our disclosures included in </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Note 7, Fair Value Measurements,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> to these condensed consolidated financial statements, venture capital funds where the underlying investments are in equity securities of certain biotechnology companies and non-marketable equity securities. </span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The increase in our strategic investment portfolio for the three and nine months ended September 30, 2020, was primarily due to our purchases of Denali and Sangamo common stock, as discussed below.</span></div><div style="text-indent:13.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Denali Therapeutics Inc.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In August 2020 we entered into a collaboration and license agreement with Denali. As part of this collaboration we purchased approximately <ix:nonFraction unitRef="shares" contextRef="i309c31a67fb24e66812ca6f278d681d1_I20200930" decimals="-6" format="ixt:numdotdecimal" name="biib:Investmentincommonstocksharespurchased" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RleHRyZWdpb246MjRlZmE5YWU4NTFkNGEwZmEzMmRhNmMxZDZiNzg1OTJfMTA5OTUxMTYzMjI2Ng_b2235e7e-5bfb-434c-bbd3-ea9181120aca">13</ix:nonFraction>&#160;million shares of Denali common stock in September 2020. This investment is classified as a Level 2 marketable equity security due to certain holding period restrictions and is remeasured each reporting period and carried at fair value. The effects of certain holding period restrictions on the investment are estimated using an option pricing valuation model. The most significant assumptions within the model are the term of the restrictions and the stock price volatility, which is based upon historical volatility of similar companies. We also use a constant maturity risk free-interest rate to match the remaining term of the restrictions on our investment in Denali's common stock and a dividend yield of <ix:nonFraction unitRef="number" contextRef="i7c3108c96711433ebf84541ad9cd5532_D20200101-20200930" decimals="-6" format="ixt-sec:numwordsen" name="biib:DividendYieldPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RleHRyZWdpb246MjRlZmE5YWU4NTFkNGEwZmEzMmRhNmMxZDZiNzg1OTJfODc5NjA5MzAzNjE5MQ_c9753c1d-798f-4772-9d49-7191c41071b0">zero</ix:nonFraction> based upon the fact that Denali and similar companies generally have not historically granted cash dividends.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For additional information on our collaboration agreements with Denali, please read </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Note 17, Collaborative and Other Relationships,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;to these condensed consolidated financial statements.</span></div><div style="text-indent:13.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Sangamo Therapeutics, Inc.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In February 2020 we entered into a collaboration and license agreement with Sangamo. In connection with the closing of this transaction in April 2020 we purchased approximately&#160;<ix:nonFraction unitRef="shares" contextRef="iaf4f0ead32484685b836bcb55cd6ac1f_I20200430" decimals="-6" format="ixt:numdotdecimal" name="biib:Investmentincommonstocksharespurchased" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RleHRyZWdpb246MjRlZmE5YWU4NTFkNGEwZmEzMmRhNmMxZDZiNzg1OTJfMjg5MA_b0c185c2-cac3-4ec4-b4af-83dd36c78fe5">24</ix:nonFraction> million&#160;shares of Sangamo common stock.&#160;This equity method investment will be remeasured each reporting period and carried at fair value due to our election of the fair value option. The effects of certain holding period restrictions on the investment are estimated </span></div></ix:continuation><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_7">Table of Contents</a></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(unaudited, continued)</span></div></div><ix:continuation id="i8d7e1e18f7f34e8ea3ef1ae45e1fad74"><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">using an option pricing valuation model. The most significant assumptions within the model are the term of the restrictions and the stock price volatility, which is based upon historical volatility of similar companies. We also use a constant maturity risk free-interest rate to match the remaining term of the restrictions on our investment in Sangamo&#8217;s common stock and a dividend yield of <ix:nonFraction unitRef="number" contextRef="i6cbe8727f757473bb189b0e60ca29a33_D20200401-20200430" decimals="-6" format="ixt-sec:numwordsen" name="biib:DividendYieldPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RleHRyZWdpb246MjRlZmE5YWU4NTFkNGEwZmEzMmRhNmMxZDZiNzg1OTJfODc5NjA5MzAzNjIxMg_9580ac75-494c-4098-b75b-bef4e8c49e74">zero</ix:nonFraction> based upon the fact that Sangamo and similar companies generally have not historically granted cash dividends.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For additional information on our collaboration agreement with Sangamo, please read </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Note 17, Collaborative and Other Relationships,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;to these condensed consolidated financial statements.</span></div></ix:continuation><div id="ib19ff89608c84168a635160f2efa48f3_79"></div><div style="text-indent:-27pt;padding-left:27pt;margin-top:14pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">9.&#160;&#160;&#160;&#160;Derivative Instruments </span></div><ix:nonNumeric contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" name="us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RleHRyZWdpb246YmEwYjhjZTdlYmE3NDcxN2I0ZTE1YWM2NzA4YjI1ODBfNjk4OQ_f151156a-20b9-458a-b0c5-88a355aa3561" continuedAt="i7600136aab6447a0afdc23b1462ed324" escape="true"><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Foreign Currency Forward Contracts - Hedging Instruments</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Due to the global nature of our operations, portions of our revenues and operating expenses are recorded in currencies other than the U.S.&#160;dollar. The value of revenues and operating expenses measured in U.S.&#160;dollars is therefore subject to changes in foreign currency exchange rates. In order to mitigate these changes, we use foreign currency forward contracts to lock in exchange rates associated with a portion of our forecasted international revenues and operating expenses.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Foreign currency forward contracts in effect as of September 30, 2020 and December 31, 2019, had durations of <ix:nonNumeric contextRef="if61ca2beff4e46f2a69e878ff2475931_D20200101-20200930" format="ixt-sec:durmonth" name="us-gaap:DerivativeRemainingMaturity1" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RleHRyZWdpb246YmEwYjhjZTdlYmE3NDcxN2I0ZTE1YWM2NzA4YjI1ODBfNjI5_247b2796-af07-4ab0-8a07-19872febc0b4">1</ix:nonNumeric> to <ix:nonNumeric contextRef="i14b94761681149c0bbac66ff547913ee_D20200101-20200930" format="ixt-sec:durmonth" name="us-gaap:DerivativeRemainingMaturity1" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RleHRyZWdpb246YmEwYjhjZTdlYmE3NDcxN2I0ZTE1YWM2NzA4YjI1ODBfNjM1_98aed5b0-0cda-4b48-ae26-6d8296051d0c">24</ix:nonNumeric> months and <ix:nonNumeric contextRef="i2bae98225c1d43d0a893047e90eb67a3_D20190101-20191231" format="ixt-sec:durmonth" name="us-gaap:DerivativeRemainingMaturity1" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RleHRyZWdpb246YmEwYjhjZTdlYmE3NDcxN2I0ZTE1YWM2NzA4YjI1ODBfNjQ5_f63a0435-9e1d-413f-88c7-5b8d8fc7fa1a">1</ix:nonNumeric> to <ix:nonNumeric contextRef="id558b1125e81440f900acb6908040141_D20190101-20191231" format="ixt-sec:durmonth" name="us-gaap:DerivativeRemainingMaturity1" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RleHRyZWdpb246YmEwYjhjZTdlYmE3NDcxN2I0ZTE1YWM2NzA4YjI1ODBfNjU1_1f5240ff-21a9-4924-b519-e17fb12255dd">15</ix:nonNumeric> months, respectively. These contracts have been designated as cash flow hedges and unrealized gains or losses on the portion of these foreign currency forward contracts that are included in the effectiveness test are reported in accumulated other comprehensive income (loss) (referred to as AOCI in the tables below). Realized gains and losses of such contracts are recognized in revenues when the sale of product in the currency being hedged is recognized and in operating expenses when the expense in the currency being hedged is recorded. We recognize all cash flow hedge reclassifications from accumulated other comprehensive income (loss) and fair value changes of excluded portions in the same line item in our condensed consolidated statements of income that has been impacted by the hedged item.</span></div><ix:nonNumeric contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" name="us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RleHRyZWdpb246YmEwYjhjZTdlYmE3NDcxN2I0ZTE1YWM2NzA4YjI1ODBfNjk5MQ_bdd80a2e-fb8c-49b4-a625-a78ab89042c2" escape="true"><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The notional value of foreign currency forward contracts that were entered into to hedge forecasted revenues and operating expenses is summarized as follows:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:58.549%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:18.344%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:18.347%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Notional Amount</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In millions)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">As of September 30, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Euro</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iaa7d33c1e10b47fa9f4f7f33d32f8d33_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RhYmxlOmNjNTdkOTQxZGMyMjQyMzliYTIzOWFiNGNmMzVhZGJhL3RhYmxlcmFuZ2U6Y2M1N2Q5NDFkYzIyNDIzOWJhMjM5YWI0Y2YzNWFkYmFfMi0yLTEtMS0w_38270b83-67ca-4bc1-847b-8e68b5e73327">2,717.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib2f9b3c22cd24844962bad5e0141c40d_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RhYmxlOmNjNTdkOTQxZGMyMjQyMzliYTIzOWFiNGNmMzVhZGJhL3RhYmxlcmFuZ2U6Y2M1N2Q5NDFkYzIyNDIzOWJhMjM5YWI0Y2YzNWFkYmFfMi00LTEtMS0w_55f883f2-3a5f-48e2-8dcf-239f067ed7be">1,892.4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">British pound</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic1855cf25f394029aa9142b5e0a2635f_I20200930" decimals="-5" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RhYmxlOmNjNTdkOTQxZGMyMjQyMzliYTIzOWFiNGNmMzVhZGJhL3RhYmxlcmFuZ2U6Y2M1N2Q5NDFkYzIyNDIzOWJhMjM5YWI0Y2YzNWFkYmFfMy0yLTEtMS0w_02298670-fd68-4276-abee-6853c28be216">62.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6a9857ccde3e4f828b0b5370ff0d84e4_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RhYmxlOmNjNTdkOTQxZGMyMjQyMzliYTIzOWFiNGNmMzVhZGJhL3RhYmxlcmFuZ2U6Y2M1N2Q5NDFkYzIyNDIzOWJhMjM5YWI0Y2YzNWFkYmFfMy00LTEtMS0w_c527c851-5bac-4a38-960e-8f68a923f9a6">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Swiss franc</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i25d3a3cbcff64295ae970930acaf2277_I20200930" decimals="-5" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RhYmxlOmNjNTdkOTQxZGMyMjQyMzliYTIzOWFiNGNmMzVhZGJhL3RhYmxlcmFuZ2U6Y2M1N2Q5NDFkYzIyNDIzOWJhMjM5YWI0Y2YzNWFkYmFfNC0yLTEtMS0w_b8e86d68-12f9-488a-b361-f4b55987d234">34.5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i921787c0672f4315b77172582046acf3_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RhYmxlOmNjNTdkOTQxZGMyMjQyMzliYTIzOWFiNGNmMzVhZGJhL3RhYmxlcmFuZ2U6Y2M1N2Q5NDFkYzIyNDIzOWJhMjM5YWI0Y2YzNWFkYmFfNC00LTEtMS0w_11b2a06a-4f52-4ff2-b6dc-8d697842c252">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Japanese yen</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibc22ccd0077c4fc49c9a6f2ddfe73891_I20200930" decimals="-5" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RhYmxlOmNjNTdkOTQxZGMyMjQyMzliYTIzOWFiNGNmMzVhZGJhL3RhYmxlcmFuZ2U6Y2M1N2Q5NDFkYzIyNDIzOWJhMjM5YWI0Y2YzNWFkYmFfNS0yLTEtMS0w_10e538dd-a783-4d08-ab82-33aa864b24a6">27.1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idd041b2211c7473cb6ccaf17dec017b0_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RhYmxlOmNjNTdkOTQxZGMyMjQyMzliYTIzOWFiNGNmMzVhZGJhL3RhYmxlcmFuZ2U6Y2M1N2Q5NDFkYzIyNDIzOWJhMjM5YWI0Y2YzNWFkYmFfNS00LTEtMS0w_e5c1f094-d31d-4af4-8e6c-7d5f9a19d181">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Canadian dollar</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic3cd6575c1e949488c892f752b68feb4_I20200930" decimals="-5" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RhYmxlOmNjNTdkOTQxZGMyMjQyMzliYTIzOWFiNGNmMzVhZGJhL3RhYmxlcmFuZ2U6Y2M1N2Q5NDFkYzIyNDIzOWJhMjM5YWI0Y2YzNWFkYmFfNi0yLTEtMS0w_97316cf1-148b-4b04-a2a2-d3503a4f127d">25.9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic23424b9be6b4da59f189eb5703a1408_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RhYmxlOmNjNTdkOTQxZGMyMjQyMzliYTIzOWFiNGNmMzVhZGJhL3RhYmxlcmFuZ2U6Y2M1N2Q5NDFkYzIyNDIzOWJhMjM5YWI0Y2YzNWFkYmFfNi00LTEtMS0w_a5b89251-f701-49cd-980b-3261d46b10b0">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total foreign currency forward contracts</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i192ef770d9d94f289c8016dd9d055c00_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RhYmxlOmNjNTdkOTQxZGMyMjQyMzliYTIzOWFiNGNmMzVhZGJhL3RhYmxlcmFuZ2U6Y2M1N2Q5NDFkYzIyNDIzOWJhMjM5YWI0Y2YzNWFkYmFfNy0yLTEtMS0w_30b95cbd-4f64-4d66-911b-25fa04ede0c0">2,866.5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie23a1176752b46eca086057bec4d49b1_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RhYmxlOmNjNTdkOTQxZGMyMjQyMzliYTIzOWFiNGNmMzVhZGJhL3RhYmxlcmFuZ2U6Y2M1N2Q5NDFkYzIyNDIzOWJhMjM5YWI0Y2YzNWFkYmFfNy00LTEtMS0w_c1071894-3754-48a3-b6fb-bcc4f93a264e">1,892.4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td></tr></table></div></ix:nonNumeric><div style="text-indent:24.75pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The pre-tax portion of the fair value of these foreign currency forward contracts that were included in accumulated other comprehensive income (loss) in total equity reflected net losses of $<ix:nonFraction unitRef="usd" contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930" decimals="-5" sign="-" format="ixt:numdotdecimal" name="biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RleHRyZWdpb246YmEwYjhjZTdlYmE3NDcxN2I0ZTE1YWM2NzA4YjI1ODBfMTgwNQ_68464160-a9bb-42b5-a629-9c20a3a9cb14">114.6</ix:nonFraction> million and net gains of $<ix:nonFraction unitRef="usd" contextRef="i626282e786b7454d83b617e9e83963e6_I20191231" decimals="-5" format="ixt:numdotdecimal" name="biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RleHRyZWdpb246YmEwYjhjZTdlYmE3NDcxN2I0ZTE1YWM2NzA4YjI1ODBfMTgyNQ_eb687e15-8bc2-4d1d-b266-762dbc39dc17">0.5</ix:nonFraction> million as of September 30, 2020 and December 31, 2019, respectively. We expect the net losses of $<ix:nonFraction unitRef="usd" contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930" decimals="-5" sign="-" format="ixt:numdotdecimal" name="biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RleHRyZWdpb246YmEwYjhjZTdlYmE3NDcxN2I0ZTE1YWM2NzA4YjI1ODBfMTg4Nw_68464160-a9bb-42b5-a629-9c20a3a9cb14">114.6</ix:nonFraction> million to be settled over the next <ix:nonNumeric contextRef="i14b94761681149c0bbac66ff547913ee_D20200101-20200930" format="ixt-sec:durmonth" name="us-gaap:DerivativeRemainingMaturity1" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RleHRyZWdpb246YmEwYjhjZTdlYmE3NDcxN2I0ZTE1YWM2NzA4YjI1ODBfMTkxOA_12b2344c-a9df-444a-974c-35ce5f43a9d9">24</ix:nonNumeric> months, of which $<ix:nonFraction unitRef="usd" contextRef="i68711c4f381b4aba952ff728afb1d3f8_I20200930" decimals="-5" sign="-" format="ixt:numdotdecimal" name="biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RleHRyZWdpb246YmEwYjhjZTdlYmE3NDcxN2I0ZTE1YWM2NzA4YjI1ODBfMTkzOA_cefb19c2-3815-468c-9692-09d51be0a030">94.1</ix:nonFraction> million of these losses are expected to be settled over the next <ix:nonNumeric contextRef="i5a2d291074a1433481dcb814e41d5746_D20200101-20200930" format="ixt-sec:durmonth" name="us-gaap:DerivativeRemainingMaturity1" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RleHRyZWdpb246YmEwYjhjZTdlYmE3NDcxN2I0ZTE1YWM2NzA4YjI1ODBfMTk5OA_95fd8d4f-73ea-4a7b-87c2-4d33d08476d8">12</ix:nonNumeric> months, with any amounts in accumulated other comprehensive income (loss) to be reported as an adjustment to revenues or operating expenses. We consider the impact of our and our counterparties&#8217; credit risk on the fair value of the contracts as well as the ability of each party to execute its contractual obligations. As of September 30, 2020 and December 31, 2019, credit risk did not materially change the fair value of our foreign currency forward contracts.</span></div></ix:nonNumeric><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_7">Table of Contents</a></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(unaudited, continued)</span></div></div><ix:continuation id="i7600136aab6447a0afdc23b1462ed324" continuedAt="iba632da719ed49b79023259623561908"><ix:nonNumeric contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" name="us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RleHRyZWdpb246YmEwYjhjZTdlYmE3NDcxN2I0ZTE1YWM2NzA4YjI1ODBfNzAwMw_0546859a-7321-4be8-a2f4-8d1172d5bb9b" escape="true"><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following tables summarize the effect of foreign currency forward contracts designated as hedging instruments in our condensed consolidated statements of income:</span></div><div style="text-align:justify;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:22.765%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.198%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.345%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:21.154%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.637%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.641%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="33" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Three Months Ended September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net Gains/(Losses)<br/>Reclassified from AOCI into Operating Income (in millions)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net Gains/(Losses)<br/>Recognized in Operating Income (in millions)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Location</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Location</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenues</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ibf5f0f40953a4421b9784faf958d97fc_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RhYmxlOmU0YmIxZjAyN2I3YzRiNmM4ZTk2MzdmYzJiMTRiNWQ3L3RhYmxlcmFuZ2U6ZTRiYjFmMDI3YjdjNGI2YzhlOTYzN2ZjMmIxNGI1ZDdfMy0yLTEtMS0w_1a343e81-b026-4f60-98a6-ce472d0fb4e4">9.1</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibf5f0f40953a4421b9784faf958d97fc_D20200701-20200930" decimals="-5" name="us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RhYmxlOmU0YmIxZjAyN2I3YzRiNmM4ZTk2MzdmYzJiMTRiNWQ3L3RhYmxlcmFuZ2U6ZTRiYjFmMDI3YjdjNGI2YzhlOTYzN2ZjMmIxNGI1ZDdfMy00LTEtMS0w_8f83c939-d0ca-4699-b546-a1512dead8fb">35.2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenues</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id81d26ae112f445586efe731295329b3_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RhYmxlOmU0YmIxZjAyN2I3YzRiNmM4ZTk2MzdmYzJiMTRiNWQ3L3RhYmxlcmFuZ2U6ZTRiYjFmMDI3YjdjNGI2YzhlOTYzN2ZjMmIxNGI1ZDdfMy04LTEtMS0w_c783d04e-7c84-47d0-89e3-35e572a963d2">8.7</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id81d26ae112f445586efe731295329b3_D20200101-20200930" decimals="-5" name="us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RhYmxlOmU0YmIxZjAyN2I3YzRiNmM4ZTk2MzdmYzJiMTRiNWQ3L3RhYmxlcmFuZ2U6ZTRiYjFmMDI3YjdjNGI2YzhlOTYzN2ZjMmIxNGI1ZDdfMy0xMC0xLTEtMA_0ccf4a98-7516-429c-b949-64ed22def7f4">0.8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating expenses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8b20f502d9dc4650852d96fb05490b25_D20200701-20200930" decimals="-5" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RhYmxlOmU0YmIxZjAyN2I3YzRiNmM4ZTk2MzdmYzJiMTRiNWQ3L3RhYmxlcmFuZ2U6ZTRiYjFmMDI3YjdjNGI2YzhlOTYzN2ZjMmIxNGI1ZDdfNC0yLTEtMS0w_eec6800e-f2e1-4096-ba0d-7ae4f4931253">1.5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8b20f502d9dc4650852d96fb05490b25_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RhYmxlOmU0YmIxZjAyN2I3YzRiNmM4ZTk2MzdmYzJiMTRiNWQ3L3RhYmxlcmFuZ2U6ZTRiYjFmMDI3YjdjNGI2YzhlOTYzN2ZjMmIxNGI1ZDdfNC00LTEtMS0w_b4891cb5-a6c6-42b6-929a-d4d7a9c8c0fc">0.8</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating expenses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if0abd481cc504df9bbfcf3174b6ce61f_D20200101-20200930" decimals="-5" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RhYmxlOmU0YmIxZjAyN2I3YzRiNmM4ZTk2MzdmYzJiMTRiNWQ3L3RhYmxlcmFuZ2U6ZTRiYjFmMDI3YjdjNGI2YzhlOTYzN2ZjMmIxNGI1ZDdfNC04LTEtMS0w_90f15808-ca39-4d0c-817f-2d088124d173">0.4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if0abd481cc504df9bbfcf3174b6ce61f_D20200101-20200930" decimals="-5" name="us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RhYmxlOmU0YmIxZjAyN2I3YzRiNmM4ZTk2MzdmYzJiMTRiNWQ3L3RhYmxlcmFuZ2U6ZTRiYjFmMDI3YjdjNGI2YzhlOTYzN2ZjMmIxNGI1ZDdfNC0xMC0xLTEtMA_7750d7c3-b707-4202-80fc-cdbb05b08462">0.4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr></table></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%;"><tr><td style="width:1.0%;"></td><td style="width:22.611%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.536%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.123%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.536%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.418%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.536%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:21.138%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.536%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.712%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.536%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.718%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="33" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net Gains/(Losses)<br/>Reclassified from AOCI into Operating Income (in millions)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net Gains/(Losses)<br/>Recognized in Operating Income (in millions)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Location</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Location</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenues</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id2b9b73877d74fc192e42310e8d70481_D20190701-20190930" decimals="-5" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RhYmxlOjU3MzgwNjVlMjEyYzRjZDU5YzI5MGI0NTIxNjA2NGFmL3RhYmxlcmFuZ2U6NTczODA2NWUyMTJjNGNkNTljMjkwYjQ1MjE2MDY0YWZfMy0yLTEtMS0w_1d090185-2446-434d-af20-be070974a431">41.6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id2b9b73877d74fc192e42310e8d70481_D20190701-20190930" decimals="-5" name="us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RhYmxlOjU3MzgwNjVlMjEyYzRjZDU5YzI5MGI0NTIxNjA2NGFmL3RhYmxlcmFuZ2U6NTczODA2NWUyMTJjNGNkNTljMjkwYjQ1MjE2MDY0YWZfMy00LTEtMS0w_5eae4521-b7f1-432c-8a77-a07ca8d39a82">79.8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenues</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ic22c771083a443f1ba2c8d2ff484ba65_D20190101-20190930" decimals="-5" sign="-" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RhYmxlOjU3MzgwNjVlMjEyYzRjZDU5YzI5MGI0NTIxNjA2NGFmL3RhYmxlcmFuZ2U6NTczODA2NWUyMTJjNGNkNTljMjkwYjQ1MjE2MDY0YWZfMy04LTEtMS0w_3ca64f37-1207-41b5-8a5e-2d78e0236996">1.0</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic22c771083a443f1ba2c8d2ff484ba65_D20190101-20190930" decimals="-5" name="us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RhYmxlOjU3MzgwNjVlMjEyYzRjZDU5YzI5MGI0NTIxNjA2NGFmL3RhYmxlcmFuZ2U6NTczODA2NWUyMTJjNGNkNTljMjkwYjQ1MjE2MDY0YWZfMy0xMC0xLTEtMA_25357134-dc1f-47d2-8793-9631375419cb">8.2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating expenses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i827d32a33a5f4fa8ab22ab96449ad285_D20190701-20190930" decimals="-5" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RhYmxlOjU3MzgwNjVlMjEyYzRjZDU5YzI5MGI0NTIxNjA2NGFmL3RhYmxlcmFuZ2U6NTczODA2NWUyMTJjNGNkNTljMjkwYjQ1MjE2MDY0YWZfNC0yLTEtMS0w_d8a65908-ca27-4986-9667-7ac34ac650f9">1.4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i827d32a33a5f4fa8ab22ab96449ad285_D20190701-20190930" decimals="-5" sign="-" name="us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RhYmxlOjU3MzgwNjVlMjEyYzRjZDU5YzI5MGI0NTIxNjA2NGFmL3RhYmxlcmFuZ2U6NTczODA2NWUyMTJjNGNkNTljMjkwYjQ1MjE2MDY0YWZfNC00LTEtMS0w_24a60359-a78b-4865-bbc4-101232f0126f">2.0</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating expenses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i4a9063b9b9ab470d9ffe7edfcebe7d66_D20190101-20190930" decimals="-5" sign="-" name="us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RhYmxlOjU3MzgwNjVlMjEyYzRjZDU5YzI5MGI0NTIxNjA2NGFmL3RhYmxlcmFuZ2U6NTczODA2NWUyMTJjNGNkNTljMjkwYjQ1MjE2MDY0YWZfNC04LTEtMS0w_40c4648c-9d26-477f-ab32-f0513e7a7103">0.7</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i4a9063b9b9ab470d9ffe7edfcebe7d66_D20190101-20190930" decimals="-5" sign="-" name="us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RhYmxlOjU3MzgwNjVlMjEyYzRjZDU5YzI5MGI0NTIxNjA2NGFmL3RhYmxlcmFuZ2U6NTczODA2NWUyMTJjNGNkNTljMjkwYjQ1MjE2MDY0YWZfNC0xMC0xLTEtMA_957191ee-5701-48d7-aeab-ec3c8ab9eff1">0.8</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr></table></div></ix:nonNumeric><div style="text-indent:11.25pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Interest Rate Contracts - Hedging Instruments</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have entered into interest rate lock contracts or interest rate swap contracts on certain borrowing transactions to manage our exposure to interest rate changes and to reduce our overall cost of borrowing. </span></div><div style="text-indent:13.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#528134;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Interest Rate Swap Contracts</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In connection with the issuance of our <ix:nonFraction unitRef="number" contextRef="i9aaf1d46914b4e72aed3585ce98ebf30_I20200930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RleHRyZWdpb246YmEwYjhjZTdlYmE3NDcxN2I0ZTE1YWM2NzA4YjI1ODBfMjkyOQ_49ef0aba-2838-442e-9f08-785a3a4f19f8">2.90</ix:nonFraction>% Senior Notes due September 15, 2020, we entered into interest rate swaps with an aggregate notional amount of $<ix:nonFraction unitRef="usd" contextRef="ic3ca7f05924940338725185c031d90c4_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RleHRyZWdpb246YmEwYjhjZTdlYmE3NDcxN2I0ZTE1YWM2NzA4YjI1ODBfMzA0Mg_f33e4080-80d4-4f1b-8d0b-2f9b5aaab0db">675.0</ix:nonFraction> million, which were originally set to expire on September 15, 2020. The interest rate swap contracts were designated as hedges of the fair value changes in our <ix:nonFraction unitRef="number" contextRef="i9aaf1d46914b4e72aed3585ce98ebf30_I20200930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RleHRyZWdpb246YmEwYjhjZTdlYmE3NDcxN2I0ZTE1YWM2NzA4YjI1ODBfMzE5Nw_49ef0aba-2838-442e-9f08-785a3a4f19f8">2.90</ix:nonFraction>% Senior Notes attributable to changes in interest rates. The carrying value of our <ix:nonFraction unitRef="number" contextRef="i9aaf1d46914b4e72aed3585ce98ebf30_I20200930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RleHRyZWdpb246YmEwYjhjZTdlYmE3NDcxN2I0ZTE1YWM2NzA4YjI1ODBfMzI4Mg_49ef0aba-2838-442e-9f08-785a3a4f19f8">2.90</ix:nonFraction>% Senior Notes as of December 31, 2019, included approximately $<ix:nonFraction unitRef="usd" contextRef="i1761a26f1d99415db0e01cea732e296a_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RleHRyZWdpb246YmEwYjhjZTdlYmE3NDcxN2I0ZTE1YWM2NzA4YjI1ODBfMzMzMQ_96676a30-9c76-4b51-9c4e-cfa2261bca7d">2.3</ix:nonFraction> million related to changes in the fair value of these interest rate swap contracts. In May 2020 we settled our interest rate swap contracts, in conjunction with our early redemption of our <ix:nonFraction unitRef="number" contextRef="i9aaf1d46914b4e72aed3585ce98ebf30_I20200930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RleHRyZWdpb246YmEwYjhjZTdlYmE3NDcxN2I0ZTE1YWM2NzA4YjI1ODBfMzUwOQ_49ef0aba-2838-442e-9f08-785a3a4f19f8">2.90</ix:nonFraction>% Senior Notes, resulting in a gain of approximately $<ix:nonFraction unitRef="usd" contextRef="ic4da688b8e414bdf83ba16881ee41846_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RleHRyZWdpb246YmEwYjhjZTdlYmE3NDcxN2I0ZTE1YWM2NzA4YjI1ODBfMzU2Mw_1e3bc2cc-675c-4d8c-8ff5-299d72718380">3.3</ix:nonFraction> million for the nine months ended September 30, 2020, which was recorded as a component of interest expense in our condensed consolidated statements of income.</span></div><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Net Investment Hedges - Hedging Instruments</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In February 2012 we entered into a joint venture agreement with Samsung BioLogics establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar products. In June 2018 we exercised our option under our joint venture agreement to increase our ownership percentage in Samsung Bioepis from approximately <ix:nonFraction unitRef="number" contextRef="ide3b267ed539403d9aea0f7cee18e938_I20190930" decimals="2" name="biib:EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RleHRyZWdpb246YmEwYjhjZTdlYmE3NDcxN2I0ZTE1YWM2NzA4YjI1ODBfNDA3NA_62ee03bb-1ff1-4dab-a8ab-5f8ae8bdbbc8">5.0</ix:nonFraction>% to approximately <ix:nonFraction unitRef="number" contextRef="i982da4cced9d4ae2b09cb6c0c35fbf7b_I20200930" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RleHRyZWdpb246YmEwYjhjZTdlYmE3NDcxN2I0ZTE1YWM2NzA4YjI1ODBfNDA5NA_d3369dea-3025-41d6-b93c-e74f0a07172d">49.9</ix:nonFraction>%. The share purchase transaction was completed in November 2018 and, upon closing, we paid <ix:nonFraction unitRef="krw" contextRef="i4d505177b87243539cc2ef4baf3b7b2d_D20181101-20181130" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RleHRyZWdpb246YmEwYjhjZTdlYmE3NDcxN2I0ZTE1YWM2NzA4YjI1ODBfNDE4Nw_7c2debff-1b56-4680-afb0-2af413520cb1">759.5</ix:nonFraction> billion South Korean won ($<ix:nonFraction unitRef="usd" contextRef="i4d505177b87243539cc2ef4baf3b7b2d_D20181101-20181130" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RleHRyZWdpb246YmEwYjhjZTdlYmE3NDcxN2I0ZTE1YWM2NzA4YjI1ODBfNDIwOA_d07e666c-97ca-4f99-b371-3ff8c83ac0c6">676.6</ix:nonFraction> million) to Samsung BioLogics. Our investment in the equity of Samsung Bioepis is exposed to the currency fluctuations in the South Korean won. </span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In order to mitigate the currency fluctuations between the U.S. dollar and South Korean won, we have entered into foreign currency forward contracts. Foreign currency forward contracts in effect as of September 30, 2020, had a remaining duration of <ix:nonNumeric contextRef="id881e97ef71e48839eea697986831baa_D20200101-20200930" format="ixt-sec:durwordsen" name="us-gaap:DerivativeTermOfContract" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RleHRyZWdpb246YmEwYjhjZTdlYmE3NDcxN2I0ZTE1YWM2NzA4YjI1ODBfNDU4MA_c3bffbb1-d427-4962-a8a9-194155354691">one month</ix:nonNumeric>. These contracts have been designated as net investment hedges. We recognize changes in the spot exchange rate in accumulated other comprehensive income (loss). The pre-tax portion of the fair value of these foreign currency forward contracts that were included in accumulated other comprehensive income (loss) in total equity reflected net gains of $<ix:nonFraction unitRef="usd" contextRef="id881e97ef71e48839eea697986831baa_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RleHRyZWdpb246YmEwYjhjZTdlYmE3NDcxN2I0ZTE1YWM2NzA4YjI1ODBfNDk0MA_2c10fd01-2565-434e-9aa8-ab8e87e2fb84">3.5</ix:nonFraction> million and net losses of $<ix:nonFraction unitRef="usd" contextRef="i2a87e4910f2b4990a031d8e154d08e7c_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RleHRyZWdpb246YmEwYjhjZTdlYmE3NDcxN2I0ZTE1YWM2NzA4YjI1ODBfNDk2MQ_75f6fbb5-d6f5-41fa-b3e0-b35220c658f7">1.5</ix:nonFraction> million as of September 30, 2020 and December 31, 2019, respectively. We exclude fair value changes related to the forward rate from our hedging relationship and will amortize the forward points in other income (expense), net in our condensed consolidated statements of income over the term of the contract. The pre-tax portion of the fair value of the forward points that were included in accumulated other comprehensive income (loss) in total equity reflected gains of $<ix:nonFraction unitRef="usd" contextRef="i08b50968168f4eb9ae561aa850896bc4_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RleHRyZWdpb246YmEwYjhjZTdlYmE3NDcxN2I0ZTE1YWM2NzA4YjI1ODBfNTM5Ng_d4f8e1c7-e3b3-485b-a51b-51bed265fa42">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i085845822f544f7fb9b0bbf69c2e903e_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RleHRyZWdpb246YmEwYjhjZTdlYmE3NDcxN2I0ZTE1YWM2NzA4YjI1ODBfNTQwMw_6e04299a-6f9d-4f63-8c62-e574de89611d">2.9</ix:nonFraction> million as of September 30, 2020 and December 31, 2019, respectively.</span></div></ix:continuation><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_7">Table of Contents</a></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(unaudited, continued)</span></div></div><ix:continuation id="iba632da719ed49b79023259623561908"><ix:nonNumeric contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" name="us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RleHRyZWdpb246YmEwYjhjZTdlYmE3NDcxN2I0ZTE1YWM2NzA4YjI1ODBfNzAyMA_480559d6-a690-46e3-828f-b8e3d4998568" escape="true"><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following tables summarize the effect of our net investment hedge in our condensed consolidated financial statements:</span></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:18.372%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:5.195%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:5.195%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:20.715%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:5.195%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:5.195%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:13.980%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:5.195%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:5.202%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="51" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Three Months Ended September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net Gains/(Losses)<br/>Recognized in Other Comprehensive Income (Effective Portion) (in millions)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net Gains/(Losses)<br/>Recognized in Other Comprehensive Income (Amounts Excluded from Effectiveness Testing) <br/>(in millions)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net Gains/(Losses)<br/>Recognized in Net Income <br/>(Amounts Excluded from Effectiveness Testing) (in millions)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Location</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Location</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Location</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gains (losses) on net investment hedge</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i7d8de41bd42443beb5e6ef8181fbd9ed_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RhYmxlOjAzYTQ4ODcwNzEwMjRjNzFiNzg5OWFiMWRjMjVlMDljL3RhYmxlcmFuZ2U6MDNhNDg4NzA3MTAyNGM3MWI3ODk5YWIxZGMyNWUwOWNfMy0yLTEtMS0w_c34c3cd6-0267-4725-8e58-382546e48140">10.4</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icd9a4c8be88e43a9adf992e1820e2e43_D20190701-20190930" decimals="-5" name="us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RhYmxlOjAzYTQ4ODcwNzEwMjRjNzFiNzg5OWFiMWRjMjVlMDljL3RhYmxlcmFuZ2U6MDNhNDg4NzA3MTAyNGM3MWI3ODk5YWIxZGMyNWUwOWNfMy00LTEtMS0w_c9f86094-645e-4b8d-933e-8913551c7f40">22.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gains (losses) on net investment hedge</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i7d8de41bd42443beb5e6ef8181fbd9ed_D20200701-20200930" decimals="-5" sign="-" name="biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RhYmxlOjAzYTQ4ODcwNzEwMjRjNzFiNzg5OWFiMWRjMjVlMDljL3RhYmxlcmFuZ2U6MDNhNDg4NzA3MTAyNGM3MWI3ODk5YWIxZGMyNWUwOWNfMy04LTEtMS0w_a07d3c8f-351c-459b-bcdc-1a10c67e3622">0.2</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icd9a4c8be88e43a9adf992e1820e2e43_D20190701-20190930" decimals="-5" name="biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RhYmxlOjAzYTQ4ODcwNzEwMjRjNzFiNzg5OWFiMWRjMjVlMDljL3RhYmxlcmFuZ2U6MDNhNDg4NzA3MTAyNGM3MWI3ODk5YWIxZGMyNWUwOWNfMy0xMC0xLTEtMA_2fc82527-f2e4-4a04-b3ba-805a8f96617a">1.4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other income (expense)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5aac32d49b464e6cada89854863b83f8_D20200701-20200930" decimals="-5" name="us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RhYmxlOjAzYTQ4ODcwNzEwMjRjNzFiNzg5OWFiMWRjMjVlMDljL3RhYmxlcmFuZ2U6MDNhNDg4NzA3MTAyNGM3MWI3ODk5YWIxZGMyNWUwOWNfMy0xNC0xLTEtMA_1284d328-a52f-4122-85db-cf2f7f6eb742">0.9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i10cf9b7a2fa84d7b844aa117861b3c56_D20190701-20190930" decimals="-5" name="us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RhYmxlOjAzYTQ4ODcwNzEwMjRjNzFiNzg5OWFiMWRjMjVlMDljL3RhYmxlcmFuZ2U6MDNhNDg4NzA3MTAyNGM3MWI3ODk5YWIxZGMyNWUwOWNfMy0xNi0xLTEtMA_753b59b4-b646-4482-ab0e-e8c6949bb2e0">2.2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td></tr></table></div><div style="text-align:center;margin-top:11pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.122%;"><tr><td style="width:1.0%;"></td><td style="width:18.369%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.537%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:5.242%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.537%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:4.947%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.537%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:20.876%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.537%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:5.242%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.537%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:4.947%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.537%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:14.091%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.537%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:5.242%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.537%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:5.248%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="51" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net Gains/(Losses)<br/>Recognized in Other Comprehensive Income (Effective Portion) (in millions)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net Gains/(Losses)<br/>Recognized in Other Comprehensive Income (Amounts Excluded from Effectiveness Testing) <br/>(in millions)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net Gains/(Losses)<br/>Recognized in Net Income <br/>(Amounts Excluded from Effectiveness Testing) (in millions)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Location</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Location</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Location</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gains (losses) on net investment hedge</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id881e97ef71e48839eea697986831baa_D20200101-20200930" decimals="-5" name="us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RhYmxlOmQwZjI1NzBiNTNhMDQ3NDg4NGE2NjM5ZDNlMTkxNzY4L3RhYmxlcmFuZ2U6ZDBmMjU3MGI1M2EwNDc0ODg0YTY2MzlkM2UxOTE3NjhfMy0yLTEtMS0w_fe8a7f7c-2021-4c96-a82a-829f11b0334e">5.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9c45d46cb2c8406b930ef51351627297_D20190101-20190930" decimals="-5" name="us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RhYmxlOmQwZjI1NzBiNTNhMDQ3NDg4NGE2NjM5ZDNlMTkxNzY4L3RhYmxlcmFuZ2U6ZDBmMjU3MGI1M2EwNDc0ODg0YTY2MzlkM2UxOTE3NjhfMy00LTEtMS0w_bbd7fe5d-faee-4140-b1f5-84a9eef1a21a">45.4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gains (losses) on net investment hedge</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id881e97ef71e48839eea697986831baa_D20200101-20200930" decimals="-5" name="biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RhYmxlOmQwZjI1NzBiNTNhMDQ3NDg4NGE2NjM5ZDNlMTkxNzY4L3RhYmxlcmFuZ2U6ZDBmMjU3MGI1M2EwNDc0ODg0YTY2MzlkM2UxOTE3NjhfMy04LTEtMS0w_62110bbd-c802-47d9-bc48-4d902275636c">3.1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9c45d46cb2c8406b930ef51351627297_D20190101-20190930" decimals="-5" name="biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RhYmxlOmQwZjI1NzBiNTNhMDQ3NDg4NGE2NjM5ZDNlMTkxNzY4L3RhYmxlcmFuZ2U6ZDBmMjU3MGI1M2EwNDc0ODg0YTY2MzlkM2UxOTE3NjhfMy0xMC0xLTEtMA_83f3e35c-4a75-4bde-8a4b-12007f453dc5">8.1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other income (expense)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id9f595a3d9be4f678b3dd5cf54ed7ea2_D20200101-20200930" decimals="-5" name="us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RhYmxlOmQwZjI1NzBiNTNhMDQ3NDg4NGE2NjM5ZDNlMTkxNzY4L3RhYmxlcmFuZ2U6ZDBmMjU3MGI1M2EwNDc0ODg0YTY2MzlkM2UxOTE3NjhfMy0xNC0xLTEtMA_b5584e23-3201-480d-9075-716106797bc6">2.6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie62a8195213a48748ad6794961fbeb22_D20190101-20190930" decimals="-5" name="us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RhYmxlOmQwZjI1NzBiNTNhMDQ3NDg4NGE2NjM5ZDNlMTkxNzY4L3RhYmxlcmFuZ2U6ZDBmMjU3MGI1M2EwNDc0ODg0YTY2MzlkM2UxOTE3NjhfMy0xNi0xLTEtMA_8bef624b-536a-464b-a3c3-652263c17711">6.6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td></tr></table></div></ix:nonNumeric><div style="text-indent:24.75pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For additional information on our collaboration arrangements with Samsung Bioepis, please read </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Note 17, Collaborative and Other Relationships,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> to these condensed consolidated financial statements.</span></div><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Foreign Currency Forward Contracts - Other Derivative Instruments</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We also enter into other foreign currency forward contracts, usually with durations of one month or less, to mitigate the foreign currency risk related to certain balance sheet positions. We have not elected hedge accounting for these transactions.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The aggregate notional amount of these outstanding foreign currency forward contracts was $<ix:nonFraction unitRef="usd" contextRef="ie8794b47098d4b969e5c6a2e1127c28c_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RleHRyZWdpb246YmEwYjhjZTdlYmE3NDcxN2I0ZTE1YWM2NzA4YjI1ODBfNjEyMg_ecc7ffa1-5281-4b7f-bd0e-656eb1e8cedd">990.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i65313bd95c954aa487ab03b59dcf4f19_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RleHRyZWdpb246YmEwYjhjZTdlYmE3NDcxN2I0ZTE1YWM2NzA4YjI1ODBfNjEyOQ_90245945-0c44-4094-aca9-50412e2cde0e">793.8</ix:nonFraction> million as of September 30, 2020 and December 31, 2019, respectively. Net gains of $<ix:nonFraction unitRef="usd" contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RleHRyZWdpb246YmEwYjhjZTdlYmE3NDcxN2I0ZTE1YWM2NzA4YjI1ODBfNjE3Ng_f63fc76a-dc60-45cd-8b95-e69ba79cd9e6">7.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RleHRyZWdpb246YmEwYjhjZTdlYmE3NDcxN2I0ZTE1YWM2NzA4YjI1ODBfNjE4Mw_d4790cbd-3b66-440d-8158-841f4fb2cbdb">13.7</ix:nonFraction> million related to these contracts were recorded as a component of other income (expense), net for the three and nine months ended September 30, 2020, respectively, compared to net losses of $<ix:nonFraction unitRef="usd" contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RleHRyZWdpb246YmEwYjhjZTdlYmE3NDcxN2I0ZTE1YWM2NzA4YjI1ODBfNjM0Nw_16fd22e2-1c58-43f4-b40a-c5f7ab522678">10.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RleHRyZWdpb246YmEwYjhjZTdlYmE3NDcxN2I0ZTE1YWM2NzA4YjI1ODBfNjM2OA_69a0f77c-034d-4baa-b08d-c45368a5ba2b">14.2</ix:nonFraction> million, respectively, in the prior year comparative periods.</span></div><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Summary of Derivative Instruments</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">While certain of our derivative instruments are subject to netting arrangements with our counterparties, we do not offset derivative assets and liabilities in our condensed consolidated balance sheets. The amounts in the table below would not be substantially different if the derivative assets and liabilities were offset.</span></div><ix:nonNumeric contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" name="us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RleHRyZWdpb246YmEwYjhjZTdlYmE3NDcxN2I0ZTE1YWM2NzA4YjI1ODBfNjk5OA_a35b2b22-e87f-4e43-b3af-ba83841ebb2d" escape="true"><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the fair value and presentation in our condensed consolidated balance sheets of our outstanding derivative instruments, including those designated as hedging instruments:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:28.328%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:28.328%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:18.372%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:18.376%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In millions)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance Sheet Location</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">As of September 30, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-style:italic;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash Flow Hedging Instruments:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Asset derivative instruments</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other current assets</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8a718d3046ad462ba2ea0e14cf490598_I20200930" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RhYmxlOjViN2YxZGZlMDA1OTQzOWRhMDJlNTY5Njk1ZGZiYzE1L3RhYmxlcmFuZ2U6NWI3ZjFkZmUwMDU5NDM5ZGEwMmU1Njk2OTVkZmJjMTVfMi00LTEtMS0w_0a6dfa80-0b28-4b53-ab86-4bc3721f8fa4">3.4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8b73ba8bfb5d4bd599ede52803901f5d_I20191231" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RhYmxlOjViN2YxZGZlMDA1OTQzOWRhMDJlNTY5Njk1ZGZiYzE1L3RhYmxlcmFuZ2U6NWI3ZjFkZmUwMDU5NDM5ZGEwMmU1Njk2OTVkZmJjMTVfMi02LTEtMS0w_7c8d1ee2-b178-496f-856b-1a5a89f42d50">33.8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Investments and other assets</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib096f70fe5a64feab15f8a20b058d2bd_I20200930" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RhYmxlOjViN2YxZGZlMDA1OTQzOWRhMDJlNTY5Njk1ZGZiYzE1L3RhYmxlcmFuZ2U6NWI3ZjFkZmUwMDU5NDM5ZGEwMmU1Njk2OTVkZmJjMTVfMy00LTEtMS0w_6d109ec2-04b3-4ccc-aadb-1c46aeff8b4e">2.3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6af0347c89c44263995f095d4ffa6626_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RhYmxlOjViN2YxZGZlMDA1OTQzOWRhMDJlNTY5Njk1ZGZiYzE1L3RhYmxlcmFuZ2U6NWI3ZjFkZmUwMDU5NDM5ZGEwMmU1Njk2OTVkZmJjMTVfMy02LTEtMS0w_8587dcc9-df50-4b33-903c-362ae6a1dff4">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Liability derivative instruments</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued expenses and other</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iea98908b86804d0caf3c1f88da0f244b_I20200930" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RhYmxlOjViN2YxZGZlMDA1OTQzOWRhMDJlNTY5Njk1ZGZiYzE1L3RhYmxlcmFuZ2U6NWI3ZjFkZmUwMDU5NDM5ZGEwMmU1Njk2OTVkZmJjMTVfNC00LTEtMS0w_fe8e843c-a70f-4151-adfe-93dd2e4f1aac">70.7</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7e60003aa8884f1d8ddcbb0621054f9f_I20191231" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RhYmxlOjViN2YxZGZlMDA1OTQzOWRhMDJlNTY5Njk1ZGZiYzE1L3RhYmxlcmFuZ2U6NWI3ZjFkZmUwMDU5NDM5ZGEwMmU1Njk2OTVkZmJjMTVfNC02LTEtMS0w_72821239-a398-474c-b66d-bb273c633e48">2.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other long-term liabilities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i245f69306a2a48dc9b0a94f444f9a387_I20200930" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RhYmxlOjViN2YxZGZlMDA1OTQzOWRhMDJlNTY5Njk1ZGZiYzE1L3RhYmxlcmFuZ2U6NWI3ZjFkZmUwMDU5NDM5ZGEwMmU1Njk2OTVkZmJjMTVfNS00LTEtMS0w_02e7da22-3abf-4597-af17-34fb7514b3cf">21.6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic3e04bb2c1a44e15ad29cbaea7a352a5_I20191231" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RhYmxlOjViN2YxZGZlMDA1OTQzOWRhMDJlNTY5Njk1ZGZiYzE1L3RhYmxlcmFuZ2U6NWI3ZjFkZmUwMDU5NDM5ZGEwMmU1Njk2OTVkZmJjMTVfNS02LTEtMS0w_a4e0e25c-c5c1-49b7-a847-532f12f5479a">1.7</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-style:italic;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net Investment Hedging Instruments:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Asset derivative instruments</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other current assets</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9c341a47e1aa461fa949701e75d2e42e_I20200930" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RhYmxlOjViN2YxZGZlMDA1OTQzOWRhMDJlNTY5Njk1ZGZiYzE1L3RhYmxlcmFuZ2U6NWI3ZjFkZmUwMDU5NDM5ZGEwMmU1Njk2OTVkZmJjMTVfOC00LTEtMS0w_a27a00e8-0730-4293-b131-c10a883d4207">10.1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i20e561fa07fb43038ef6ed12d48d3e81_I20191231" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RhYmxlOjViN2YxZGZlMDA1OTQzOWRhMDJlNTY5Njk1ZGZiYzE1L3RhYmxlcmFuZ2U6NWI3ZjFkZmUwMDU5NDM5ZGEwMmU1Njk2OTVkZmJjMTVfOC02LTEtMS0w_f3e5bf61-1a89-4188-afd0-c9ef3b45d63b">2.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-style:italic;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value Hedging Instruments:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Liability derivative instruments</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued expenses and other</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie12a87471fff4dc1b58d09dc7f062be5_I20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RhYmxlOjViN2YxZGZlMDA1OTQzOWRhMDJlNTY5Njk1ZGZiYzE1L3RhYmxlcmFuZ2U6NWI3ZjFkZmUwMDU5NDM5ZGEwMmU1Njk2OTVkZmJjMTVfMTEtNC0xLTEtMA_ee814c5a-534d-466c-bca3-b4da62eeff26">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1761a26f1d99415db0e01cea732e296a_I20191231" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RhYmxlOjViN2YxZGZlMDA1OTQzOWRhMDJlNTY5Njk1ZGZiYzE1L3RhYmxlcmFuZ2U6NWI3ZjFkZmUwMDU5NDM5ZGEwMmU1Njk2OTVkZmJjMTVfMTEtNi0xLTEtMA_96676a30-9c76-4b51-9c4e-cfa2261bca7d">2.3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-style:italic;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other Derivative Instruments:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Asset derivative instruments</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other current assets</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic1f004cc48f2484baa3a2dda6b81675d_I20200930" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RhYmxlOjViN2YxZGZlMDA1OTQzOWRhMDJlNTY5Njk1ZGZiYzE1L3RhYmxlcmFuZ2U6NWI3ZjFkZmUwMDU5NDM5ZGEwMmU1Njk2OTVkZmJjMTVfMTUtNC0xLTEtMA_13278c63-6636-4f49-b8e9-5ffb16424da1">10.2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id79a0b775b5b4772916934374fee4ad9_I20191231" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RhYmxlOjViN2YxZGZlMDA1OTQzOWRhMDJlNTY5Njk1ZGZiYzE1L3RhYmxlcmFuZ2U6NWI3ZjFkZmUwMDU5NDM5ZGEwMmU1Njk2OTVkZmJjMTVfMTUtNi0xLTEtMA_cf3d94e5-13a6-476a-aca3-2174944edbc6">8.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Liability derivative instruments</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued expenses and other</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8b499d4033fd416886759d4c73cd37e4_I20200930" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RhYmxlOjViN2YxZGZlMDA1OTQzOWRhMDJlNTY5Njk1ZGZiYzE1L3RhYmxlcmFuZ2U6NWI3ZjFkZmUwMDU5NDM5ZGEwMmU1Njk2OTVkZmJjMTVfMTYtNC0xLTEtMA_b781a64b-6777-43a2-ba52-b4ee49f1c7c1">7.3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i61badd66b47b4dcd935f8e7dd306447b_I20191231" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RhYmxlOjViN2YxZGZlMDA1OTQzOWRhMDJlNTY5Njk1ZGZiYzE1L3RhYmxlcmFuZ2U6NWI3ZjFkZmUwMDU5NDM5ZGEwMmU1Njk2OTVkZmJjMTVfMTYtNi0xLTEtMA_ca07df39-b261-4c42-8178-4fb2c9cd0007">2.4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">28</span></div></div></div><div id="ib19ff89608c84168a635160f2efa48f3_85"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_7">Table of Contents</a></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(unaudited, continued)</span></div></div><div style="margin-top:14pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">10.&#160;&#160;&#160;&#160;Property, Plant and Equipment </span></div><ix:nonNumeric contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM184NS9mcmFnOjVjYzc3YTNhYzgyZjQzMjU4MjZiNGMxMjBiYTFlYjgxL3RleHRyZWdpb246NWNjNzdhM2FjODJmNDMyNTgyNmI0YzEyMGJhMWViODFfMTIyOA_97f3f86a-12a1-4c59-a348-a5a3b3f8ef4b" escape="true"><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Property, plant and equipment are recorded at historical cost, net of accumulated depreciation. Accumulated depreciation on property, plant and equipment was $<ix:nonFraction unitRef="usd" contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM184NS9mcmFnOjVjYzc3YTNhYzgyZjQzMjU4MjZiNGMxMjBiYTFlYjgxL3RleHRyZWdpb246NWNjNzdhM2FjODJmNDMyNTgyNmI0YzEyMGJhMWViODFfMTcx_a48c3e0e-2d0a-434a-bec3-2a59d54ada00">1,734.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i626282e786b7454d83b617e9e83963e6_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM184NS9mcmFnOjVjYzc3YTNhYzgyZjQzMjU4MjZiNGMxMjBiYTFlYjgxL3RleHRyZWdpb246NWNjNzdhM2FjODJmNDMyNTgyNmI0YzEyMGJhMWViODFfMTc4_9a8d3ca5-8f6a-421f-a055-d465b35f101f">1,590.9</ix:nonFraction> million as of September 30, 2020 and December 31, 2019, respectively. For the three and nine months ended September 30, 2020, depreciation expense totaled $<ix:nonFraction unitRef="usd" contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM184NS9mcmFnOjVjYzc3YTNhYzgyZjQzMjU4MjZiNGMxMjBiYTFlYjgxL3RleHRyZWdpb246NWNjNzdhM2FjODJmNDMyNTgyNmI0YzEyMGJhMWViODFfMjc2_0f3c63e5-7c41-4312-94ee-fd1a35296def">51.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM184NS9mcmFnOjVjYzc3YTNhYzgyZjQzMjU4MjZiNGMxMjBiYTFlYjgxL3RleHRyZWdpb246NWNjNzdhM2FjODJmNDMyNTgyNmI0YzEyMGJhMWViODFfMjgz_a7b42987-3587-4f85-8be5-d6f9aae1d4f1">151.2</ix:nonFraction> million, respectively, compared to $<ix:nonFraction unitRef="usd" contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM184NS9mcmFnOjVjYzc3YTNhYzgyZjQzMjU4MjZiNGMxMjBiYTFlYjgxL3RleHRyZWdpb246NWNjNzdhM2FjODJmNDMyNTgyNmI0YzEyMGJhMWViODFfMzEz_aa28066e-3637-4fcd-aaa3-31a41e9b8086">45.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM184NS9mcmFnOjVjYzc3YTNhYzgyZjQzMjU4MjZiNGMxMjBiYTFlYjgxL3RleHRyZWdpb246NWNjNzdhM2FjODJmNDMyNTgyNmI0YzEyMGJhMWViODFfMzIw_e0c4c345-5b72-457d-af09-a6eb2caed3c8">145.4</ix:nonFraction> million, respectively, in the prior year comparative periods.</span></div><div style="text-indent:13.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Solothurn, Switzerland Manufacturing Facility</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In order to support our future growth and drug development pipeline, we are building a large-scale biologics manufacturing facility in Solothurn, Switzerland. We expect this facility to be partially operational during the first half of 2021. Upon completion, this facility will include <ix:nonFraction unitRef="sqft" contextRef="i515423cd9b4842648857d6d91e4a1875_D20200101-20200930" decimals="INF" format="ixt:numdotdecimal" name="biib:NumberOfSquareFeet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM184NS9mcmFnOjVjYzc3YTNhYzgyZjQzMjU4MjZiNGMxMjBiYTFlYjgxL3RleHRyZWdpb246NWNjNzdhM2FjODJmNDMyNTgyNmI0YzEyMGJhMWViODFfODc5NjA5MzAyMzcxNg_88115ab1-961d-4f12-a906-2fbc8420ea50">393,000</ix:nonFraction> square feet related to a large-scale biologics manufacturing facility, <ix:nonFraction unitRef="sqft" contextRef="i79ca9be67e44499586e22d0729a04cad_D20200101-20200930" decimals="INF" format="ixt:numdotdecimal" name="biib:NumberOfSquareFeet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM184NS9mcmFnOjVjYzc3YTNhYzgyZjQzMjU4MjZiNGMxMjBiYTFlYjgxL3RleHRyZWdpb246NWNjNzdhM2FjODJmNDMyNTgyNmI0YzEyMGJhMWViODFfODc5NjA5MzAyMzczMw_1eefe6fd-761b-42c0-b435-ff76299314c7">290,000</ix:nonFraction> square feet of warehouse, utilities and support space and <ix:nonFraction unitRef="sqft" contextRef="i71a156afed9940d8b31d4a452da92788_D20200101-20200930" decimals="INF" format="ixt:numdotdecimal" name="biib:NumberOfSquareFeet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM184NS9mcmFnOjVjYzc3YTNhYzgyZjQzMjU4MjZiNGMxMjBiYTFlYjgxL3RleHRyZWdpb246NWNjNzdhM2FjODJmNDMyNTgyNmI0YzEyMGJhMWViODFfODc5NjA5MzAyMzcyNQ_66dc68df-1bc0-451d-be7b-27e2fa490f4d">51,000</ix:nonFraction> square feet of administrative space. As of September 30, 2020 and December 31, 2019, we had approximately $<ix:nonFraction unitRef="usd" contextRef="iadc69a90f7b94abab8d83ed70d1edf52_I20200930" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:ConstructionInProgressGross" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM184NS9mcmFnOjVjYzc3YTNhYzgyZjQzMjU4MjZiNGMxMjBiYTFlYjgxL3RleHRyZWdpb246NWNjNzdhM2FjODJmNDMyNTgyNmI0YzEyMGJhMWViODFfOTA3_c6cb6b8f-ff19-449b-b39d-bf2e25ed745e">1.8</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="ia4d564a708c64a0f9eae417dc52c7afc_I20191231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:ConstructionInProgressGross" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM184NS9mcmFnOjVjYzc3YTNhYzgyZjQzMjU4MjZiNGMxMjBiYTFlYjgxL3RleHRyZWdpb246NWNjNzdhM2FjODJmNDMyNTgyNmI0YzEyMGJhMWViODFfOTE0_361c3cb4-0146-4309-9a87-201a30fc6bd3">1.9</ix:nonFraction> billion, respectively, capitalized as construction in progress related to this facility. For the nine months ended September 30, 2020, we placed approximately $<ix:nonFraction unitRef="usd" contextRef="iadc69a90f7b94abab8d83ed70d1edf52_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM184NS9mcmFnOjVjYzc3YTNhYzgyZjQzMjU4MjZiNGMxMjBiYTFlYjgxL3RleHRyZWdpb246NWNjNzdhM2FjODJmNDMyNTgyNmI0YzEyMGJhMWViODFfMTA1MA_a3dfa84b-0f0c-435e-9ee5-8033c7490709">256.8</ix:nonFraction> million of fixed assets in service related to this facility. As of September 30, 2020, we had contractual commitments of approximately $<ix:nonFraction unitRef="usd" contextRef="iadc69a90f7b94abab8d83ed70d1edf52_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherCommitment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM184NS9mcmFnOjVjYzc3YTNhYzgyZjQzMjU4MjZiNGMxMjBiYTFlYjgxL3RleHRyZWdpb246NWNjNzdhM2FjODJmNDMyNTgyNmI0YzEyMGJhMWViODFfMTE2NA_480c8974-ccf9-4047-aadc-8416ca3faaa3">14.8</ix:nonFraction> million outstanding related to the construction of this facility.</span></div></ix:nonNumeric><div id="ib19ff89608c84168a635160f2efa48f3_88"></div><div style="margin-top:14pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">11.</span><span style="background-color:rgb(255,255,255, 0.0);color:#006ebf;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;</span><ix:nonNumeric contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM184OC9mcmFnOjdlZjk5Y2VkNDFiNDQ3Y2U5NGE0NGUyMDdhZGUxNWFkL3RleHRyZWdpb246N2VmOTljZWQ0MWI0NDdjZTk0YTQ0ZTIwN2FkZTE1YWRfMjQyNw_bfc27a1d-6c43-4a2b-bc9f-ca1df5b7fb05" continuedAt="i2e87fd84c77f44d6b3bb56ef3cace4d5" escape="true"><span style="background-color:rgb(255,255,255, 0.0);color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Indebtedness</span><span style="background-color:rgb(255,255,255, 0.0);color:#006ebf;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> </span></ix:nonNumeric></div><ix:continuation id="i2e87fd84c77f44d6b3bb56ef3cace4d5"><div style="text-indent:13.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#006ebf;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">2020 Senior Notes </span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On April 30, 2020, we issued senior unsecured notes for an aggregate principal amount of $<ix:nonFraction unitRef="usd" contextRef="ic59436e93fd94dc7975cca19dc9348ab_I20200430" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM184OC9mcmFnOjdlZjk5Y2VkNDFiNDQ3Y2U5NGE0NGUyMDdhZGUxNWFkL3RleHRyZWdpb246N2VmOTljZWQ0MWI0NDdjZTk0YTQ0ZTIwN2FkZTE1YWRfMTA5_558be3ed-8d83-43cb-9467-39257eade898">3.0</ix:nonFraction> billion (2020 Senior Notes), consisting of the following:</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.5pt;">$<ix:nonFraction unitRef="usd" contextRef="i2f00747e3707421b957d5a8909432bc2_I20200430" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM184OC9mcmFnOjdlZjk5Y2VkNDFiNDQ3Y2U5NGE0NGUyMDdhZGUxNWFkL3RleHRyZWdpb246N2VmOTljZWQ0MWI0NDdjZTk0YTQ0ZTIwN2FkZTE1YWRfMTYz_27fc67cd-957d-4d43-86a3-7b8747a54697">1.5</ix:nonFraction> billion of <ix:nonFraction unitRef="number" contextRef="i2f00747e3707421b957d5a8909432bc2_I20200430" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM184OC9mcmFnOjdlZjk5Y2VkNDFiNDQ3Y2U5NGE0NGUyMDdhZGUxNWFkL3RleHRyZWdpb246N2VmOTljZWQ0MWI0NDdjZTk0YTQ0ZTIwN2FkZTE1YWRfMTY5_c64fb0ed-ec71-495a-adc3-e77572da5efe">2.25</ix:nonFraction>% Senior Notes due May 1, 2030, valued at <ix:nonFraction unitRef="number" contextRef="i2f00747e3707421b957d5a8909432bc2_I20200430" decimals="INF" name="biib:PercentageParValueOfSeniorNotes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM184OC9mcmFnOjdlZjk5Y2VkNDFiNDQ3Y2U5NGE0NGUyMDdhZGUxNWFkL3RleHRyZWdpb246N2VmOTljZWQ0MWI0NDdjZTk0YTQ0ZTIwN2FkZTE1YWRfMjAz_a43020bb-6baf-4e2f-93f5-835161036fc1">99.973</ix:nonFraction>% of par; and</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.5pt;">$<ix:nonFraction unitRef="usd" contextRef="id7d171de853046bd832470203f2f56ba_I20200430" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM184OC9mcmFnOjdlZjk5Y2VkNDFiNDQ3Y2U5NGE0NGUyMDdhZGUxNWFkL3RleHRyZWdpb246N2VmOTljZWQ0MWI0NDdjZTk0YTQ0ZTIwN2FkZTE1YWRfMjE4_353d18ad-2dc5-4198-9495-46fbb5b21e08">1.5</ix:nonFraction> billion of <ix:nonFraction unitRef="number" contextRef="id7d171de853046bd832470203f2f56ba_I20200430" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM184OC9mcmFnOjdlZjk5Y2VkNDFiNDQ3Y2U5NGE0NGUyMDdhZGUxNWFkL3RleHRyZWdpb246N2VmOTljZWQ0MWI0NDdjZTk0YTQ0ZTIwN2FkZTE1YWRfMjI0_47692aaa-0fde-485d-b9a7-ed69e4a2844a">3.15</ix:nonFraction>% Senior Notes due May 1, 2050, valued at <ix:nonFraction unitRef="number" contextRef="id7d171de853046bd832470203f2f56ba_I20200430" decimals="INF" name="biib:PercentageParValueOfSeniorNotes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM184OC9mcmFnOjdlZjk5Y2VkNDFiNDQ3Y2U5NGE0NGUyMDdhZGUxNWFkL3RleHRyZWdpb246N2VmOTljZWQ0MWI0NDdjZTk0YTQ0ZTIwN2FkZTE1YWRfMjU4_b2a10a15-48bf-43be-82dc-f9419c95b7ee">99.174</ix:nonFraction>% of par.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our 2020 Senior Notes are senior unsecured obligations and may be redeemed at our option at any time at <ix:nonFraction unitRef="number" contextRef="i12ad84388af247dc862a842bb1ccd8e8_D20200101-20200930" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM184OC9mcmFnOjdlZjk5Y2VkNDFiNDQ3Y2U5NGE0NGUyMDdhZGUxNWFkL3RleHRyZWdpb246N2VmOTljZWQ0MWI0NDdjZTk0YTQ0ZTIwN2FkZTE1YWRfMzcz_46784166-7bc6-467b-9139-03913ffcdfa9">100</ix:nonFraction>% of the principal amount plus accrued interest and, until a specified period before maturity, a specified make-whole amount. Our 2020 Senior Notes contain a change-of-control provision that, under certain circumstances, may require us to purchase our 2020 Senior Notes at a price equal to <ix:nonFraction unitRef="number" contextRef="i12ad84388af247dc862a842bb1ccd8e8_D20200101-20200930" decimals="INF" name="biib:DebtInstrumentMakeWholeProvisionRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM184OC9mcmFnOjdlZjk5Y2VkNDFiNDQ3Y2U5NGE0NGUyMDdhZGUxNWFkL3RleHRyZWdpb246N2VmOTljZWQ0MWI0NDdjZTk0YTQ0ZTIwN2FkZTE1YWRfNjY0_34c01576-dd54-41d2-9fd5-bd98db1f208f">101</ix:nonFraction>% of the principal amount plus accrued and unpaid interest to the date of repurchase.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We incurred approximately $<ix:nonFraction unitRef="usd" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfFinancingCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM184OC9mcmFnOjdlZjk5Y2VkNDFiNDQ3Y2U5NGE0NGUyMDdhZGUxNWFkL3RleHRyZWdpb246N2VmOTljZWQ0MWI0NDdjZTk0YTQ0ZTIwN2FkZTE1YWRfNzc3_cdae56da-d344-4bcf-afdc-e3e63fda7cec">24.4</ix:nonFraction> million of costs associated with this offering which have been recorded as a reduction to the carrying amount of the debt on our condensed consolidated balance sheet. These costs will be amortized as additional interest expense using the effective interest rate method over the period from issuance through maturity. The discounts will be amortized as additional interest expense over the period from issuance through maturity using the effective interest rate method. Interest on our 2020 Senior Notes is payable May 1 and November 1 of each year, commencing November 1, 2020. </span></div><div style="text-indent:13.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#006ebf;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">2.90% Senior Notes due September 15, 2020 </span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On September 15, 2015, we issued $<ix:nonFraction unitRef="usd" contextRef="i03f25d4fea804740817761d106108f90_I20150915" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM184OC9mcmFnOjdlZjk5Y2VkNDFiNDQ3Y2U5NGE0NGUyMDdhZGUxNWFkL3RleHRyZWdpb246N2VmOTljZWQ0MWI0NDdjZTk0YTQ0ZTIwN2FkZTE1YWRfMTQxNg_d37195e2-d547-4354-9497-b7d96488e559">1.5</ix:nonFraction> billion aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="i03f25d4fea804740817761d106108f90_I20150915" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM184OC9mcmFnOjdlZjk5Y2VkNDFiNDQ3Y2U5NGE0NGUyMDdhZGUxNWFkL3RleHRyZWdpb246N2VmOTljZWQ0MWI0NDdjZTk0YTQ0ZTIwN2FkZTE1YWRfMTQ0OQ_58561b89-1d91-409c-8818-e7f87a977db3">2.90</ix:nonFraction>% Senior Notes due September 15, 2020, at <ix:nonFraction unitRef="number" contextRef="i03f25d4fea804740817761d106108f90_I20150915" decimals="INF" name="biib:PercentageParValueOfSeniorNotes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM184OC9mcmFnOjdlZjk5Y2VkNDFiNDQ3Y2U5NGE0NGUyMDdhZGUxNWFkL3RleHRyZWdpb246N2VmOTljZWQ0MWI0NDdjZTk0YTQ0ZTIwN2FkZTE1YWRfMTQ5Mg_1499e745-3a74-461c-92b0-49216030f4a0">99.792</ix:nonFraction>% of par. Our <ix:nonFraction unitRef="number" contextRef="i03f25d4fea804740817761d106108f90_I20150915" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM184OC9mcmFnOjdlZjk5Y2VkNDFiNDQ3Y2U5NGE0NGUyMDdhZGUxNWFkL3RleHRyZWdpb246N2VmOTljZWQ0MWI0NDdjZTk0YTQ0ZTIwN2FkZTE1YWRfMTUwNw_75d52e16-e036-4316-b55a-2a6034e68951">2.90</ix:nonFraction>% Senior Notes were senior unsecured obligations. We also entered into interest rate swap contracts where we received a fixed rate and paid a variable rate. In May 2020 we used the net proceeds from the sale of our 2020 Senior Notes to redeem our <ix:nonFraction unitRef="number" contextRef="i03f25d4fea804740817761d106108f90_I20150915" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM184OC9mcmFnOjdlZjk5Y2VkNDFiNDQ3Y2U5NGE0NGUyMDdhZGUxNWFkL3RleHRyZWdpb246N2VmOTljZWQ0MWI0NDdjZTk0YTQ0ZTIwN2FkZTE1YWRfMTc1NQ_0a8cd24b-e19f-43be-b96f-8201e4dec1a6">2.90</ix:nonFraction>% Senior Notes prior to their maturity and recognized a net pre-tax charge of $<ix:nonFraction unitRef="usd" contextRef="i5e0ab653ffdc4001ba210ff20f499fc3_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="biib:PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM184OC9mcmFnOjdlZjk5Y2VkNDFiNDQ3Y2U5NGE0NGUyMDdhZGUxNWFkL3RleHRyZWdpb246N2VmOTljZWQ0MWI0NDdjZTk0YTQ0ZTIwN2FkZTE1YWRfMTgzNA_5c25515b-2c6d-4068-9414-a30da6768ec5">9.4</ix:nonFraction> million upon the extinguishment of these notes. This charge, which was recognized in interest expense in other income (expense), net in our condensed consolidated statements of income for the nine months ended September 30, 2020, reflects the payment of a $<ix:nonFraction unitRef="usd" contextRef="i4d1664f9c34948f48657b943f060daf2_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="biib:EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM184OC9mcmFnOjdlZjk5Y2VkNDFiNDQ3Y2U5NGE0NGUyMDdhZGUxNWFkL3RleHRyZWdpb246N2VmOTljZWQ0MWI0NDdjZTk0YTQ0ZTIwN2FkZTE1YWRfMjA3NA_1dd37694-1110-47f1-b5a1-200971820cb7">12.7</ix:nonFraction> million early call premium and the write off of remaining unamortized original debt issuance costs and discount balances, partially offset by a $<ix:nonFraction unitRef="usd" contextRef="ic4da688b8e414bdf83ba16881ee41846_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM184OC9mcmFnOjdlZjk5Y2VkNDFiNDQ3Y2U5NGE0NGUyMDdhZGUxNWFkL3RleHRyZWdpb246N2VmOTljZWQ0MWI0NDdjZTk0YTQ0ZTIwN2FkZTE1YWRfMjIxMw_1e3bc2cc-675c-4d8c-8ff5-299d72718380">3.3</ix:nonFraction> million gain related to the settlement of the associated interest rate swap contracts. For additional information on our interest rate swap contracts, please read </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Note 9, Derivative Instruments,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> to these condensed consolidated financial statements.</span></div></ix:continuation><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">29</span></div></div></div><div id="ib19ff89608c84168a635160f2efa48f3_94"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_7">Table of Contents</a></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(unaudited, continued)</span></div></div><div style="text-indent:-27pt;padding-left:27pt;margin-top:14pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">12.&#160;&#160;&#160;&#160;Equity </span></div><ix:nonNumeric contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RleHRyZWdpb246ZjZlZDhjM2EzZGM0NGZhZGE1YjMzOWE0ZGVhODAwNGRfMTMyNg_3b661ecf-a6b6-482b-b557-c1edc9ed2e87" continuedAt="i9ae22b4b8f1b4fc89f1c0ed0f1eb24d9" escape="true"><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Share Repurchases</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In October 2020 our Board of Directors authorized a program to repurchase up to $5.0 billion of our common stock (2020 Share Repurchase Program). Our 2020 Share Repurchase Program does not have an expiration date. All share repurchases under our 2020 Share Repurchase Program will be retired.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In December 2019 our Board of Directors authorized a program to repurchase up to $<ix:nonFraction unitRef="usd" contextRef="i50a2f9335d324e4986eea98f35621996_I20191231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RleHRyZWdpb246ZjZlZDhjM2EzZGM0NGZhZGE1YjMzOWE0ZGVhODAwNGRfMTAx_3780b78c-4537-4a26-a4da-71ef53015373">5.0</ix:nonFraction> billion of our common stock (December 2019 Share Repurchase Program) that was completed as of September 30, 2020. All shares repurchased under our December 2019 Share Repurchase Program were retired. Under our December 2019 Share Repurchase Program, we repurchased and retired approximately <ix:nonFraction unitRef="shares" contextRef="iadd8187a18d849f6b353e75cae0aabe8_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RleHRyZWdpb246ZjZlZDhjM2EzZGM0NGZhZGE1YjMzOWE0ZGVhODAwNGRfMzkw_e5bfcb8c-22a9-435e-967a-b0369703253a">4.5</ix:nonFraction> million and <ix:nonFraction unitRef="shares" contextRef="idb94151f567e4761811caaa2ee1c1349_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RleHRyZWdpb246ZjZlZDhjM2EzZGM0NGZhZGE1YjMzOWE0ZGVhODAwNGRfMzk3_11541706-2eed-4cfb-9863-c5e228a55e4f">16.7</ix:nonFraction> million shares of our common stock at a cost of approximately $<ix:nonFraction unitRef="usd" contextRef="iadd8187a18d849f6b353e75cae0aabe8_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RleHRyZWdpb246ZjZlZDhjM2EzZGM0NGZhZGE1YjMzOWE0ZGVhODAwNGRfNDU0_7d4a93a3-7627-40d6-9689-3807c748415e">1.3</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="idb94151f567e4761811caaa2ee1c1349_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RleHRyZWdpb246ZjZlZDhjM2EzZGM0NGZhZGE1YjMzOWE0ZGVhODAwNGRfNDYx_fc8ee57f-8537-4f1c-9b35-bb7dfc30655f">5.0</ix:nonFraction> billion during the three and nine months ended September 30, 2020, respectively.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In March 2019 our Board of Directors authorized a program to repurchase up to $<ix:nonFraction unitRef="usd" contextRef="ibe1d424343114522b510a64f315d7e68_I20190930" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RleHRyZWdpb246ZjZlZDhjM2EzZGM0NGZhZGE1YjMzOWE0ZGVhODAwNGRfNjc4_26716486-a99f-4d92-9bf1-c0ee80ac98ef">5.0</ix:nonFraction> billion of our common stock (March 2019 Share Repurchase Program) that was completed as of March 31, 2020. All shares repurchased under our March 2019 Share Repurchase Program were retired. Under our March 2019 Share Repurchase Program, we repurchased and retired approximately <ix:nonFraction unitRef="shares" contextRef="i0af05fc8fe804816a86f91f4f77cdeac_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RleHRyZWdpb246ZjZlZDhjM2EzZGM0NGZhZGE1YjMzOWE0ZGVhODAwNGRfOTQx_0fd551c3-e069-42cf-aef7-4c1fcfb1e1df">4.1</ix:nonFraction> million shares of our common stock at a cost of approximately $<ix:nonFraction unitRef="usd" contextRef="i0af05fc8fe804816a86f91f4f77cdeac_D20200101-20200930" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RleHRyZWdpb246ZjZlZDhjM2EzZGM0NGZhZGE1YjMzOWE0ZGVhODAwNGRfOTk4_d112bc13-3f03-4a52-ac61-d0e83bd32caf">1.3</ix:nonFraction> billion during the nine months ended September 30, 2020. </span></div><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Accumulated Other Comprehensive Income (Loss)</span></div><ix:nonNumeric contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RleHRyZWdpb246ZjZlZDhjM2EzZGM0NGZhZGE1YjMzOWE0ZGVhODAwNGRfMTMxNw_16710951-050f-48bc-bd53-0b228ca12e31" escape="true"><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following tables summarize the changes in accumulated other comprehensive income (loss), net of tax by component:</span></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:31.696%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.295%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.002%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.295%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.466%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.295%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.859%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In millions)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gains (Losses) on Net Investment Hedge</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unfunded Status of Postretirement Benefit Plans, Net of Tax</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Currency Translation Adjustments</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, December 31, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2a0e6fee3a604c498aef94f0b86c6e9a_I20191231" decimals="-5" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmNjZDUwOTcwMTRkZDRmZGZiMzgwMzNkMTE5YjhlYWQ0L3RhYmxlcmFuZ2U6Y2NkNTA5NzAxNGRkNGZkZmIzODAzM2QxMTliOGVhZDRfMS0yLTEtMS0w_056a7324-8d54-4346-8993-cec572598aa4">4.2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1cb136c416a04a05b9c1782e72b65627_I20191231" decimals="-5" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmNjZDUwOTcwMTRkZDRmZGZiMzgwMzNkMTE5YjhlYWQ0L3RhYmxlcmFuZ2U6Y2NkNTA5NzAxNGRkNGZkZmIzODAzM2QxMTliOGVhZDRfMS00LTEtMS0w_839e3d31-bc84-48d8-8747-f78a0930514c">7.8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic914b0a393fd452c890e566f2c9c210f_I20191231" decimals="-5" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmNjZDUwOTcwMTRkZDRmZGZiMzgwMzNkMTE5YjhlYWQ0L3RhYmxlcmFuZ2U6Y2NkNTA5NzAxNGRkNGZkZmIzODAzM2QxMTliOGVhZDRfMS02LTEtMS0w_dbeb7291-3634-473c-bae5-11d21554f5a6">25.1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i260d0a847a054ce0bef9b288ccd52ea2_I20191231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmNjZDUwOTcwMTRkZDRmZGZiMzgwMzNkMTE5YjhlYWQ0L3RhYmxlcmFuZ2U6Y2NkNTA5NzAxNGRkNGZkZmIzODAzM2QxMTliOGVhZDRfMS04LTEtMS0w_b8cedb83-923c-4f8e-a526-2a13ecbb5cff">32.8</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if4823f5499b54f46b268ee3dd309f1da_I20191231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmNjZDUwOTcwMTRkZDRmZGZiMzgwMzNkMTE5YjhlYWQ0L3RhYmxlcmFuZ2U6Y2NkNTA5NzAxNGRkNGZkZmIzODAzM2QxMTliOGVhZDRfMS0xMC0xLTEtMA_c91e74f7-11db-46e4-ac4b-2c86479e6469">139.5</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i626282e786b7454d83b617e9e83963e6_I20191231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmNjZDUwOTcwMTRkZDRmZGZiMzgwMzNkMTE5YjhlYWQ0L3RhYmxlcmFuZ2U6Y2NkNTA5NzAxNGRkNGZkZmIzODAzM2QxMTliOGVhZDRfMS0xMi0xLTEtMA_c9797929-50e6-4e4a-b2b2-69220615465c">135.2</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i6773145664dd45a58afb7773d86b7f79_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmNjZDUwOTcwMTRkZDRmZGZiMzgwMzNkMTE5YjhlYWQ0L3RhYmxlcmFuZ2U6Y2NkNTA5NzAxNGRkNGZkZmIzODAzM2QxMTliOGVhZDRfMi0yLTEtMS0w_471fcdae-31cd-4e42-afa7-f51e21424e69">8.8</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i21e4efbba1364e8d97adce8a02fa5c1c_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmNjZDUwOTcwMTRkZDRmZGZiMzgwMzNkMTE5YjhlYWQ0L3RhYmxlcmFuZ2U6Y2NkNTA5NzAxNGRkNGZkZmIzODAzM2QxMTliOGVhZDRfMi00LTEtMS0w_9f4274fd-d478-4e90-8b6b-36e4c649c932">58.0</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idd42a3afee77410b945f7e37289f8773_D20200101-20200930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmNjZDUwOTcwMTRkZDRmZGZiMzgwMzNkMTE5YjhlYWQ0L3RhYmxlcmFuZ2U6Y2NkNTA5NzAxNGRkNGZkZmIzODAzM2QxMTliOGVhZDRfMi02LTEtMS0w_6e426e23-c1f7-48f7-9d65-f711eab8c7cd">8.1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4f6dc2dc230545079cf4e37cd9490b61_D20200101-20200930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmNjZDUwOTcwMTRkZDRmZGZiMzgwMzNkMTE5YjhlYWQ0L3RhYmxlcmFuZ2U6Y2NkNTA5NzAxNGRkNGZkZmIzODAzM2QxMTliOGVhZDRfMi04LTEtMS0w_c737cd55-963d-4c99-a0b0-d17ded4775a8">0.4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i320a93a4270b45d2834748a854e79d02_D20200101-20200930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmNjZDUwOTcwMTRkZDRmZGZiMzgwMzNkMTE5YjhlYWQ0L3RhYmxlcmFuZ2U6Y2NkNTA5NzAxNGRkNGZkZmIzODAzM2QxMTliOGVhZDRfMi0xMC0xLTEtMA_ecc2e7f7-182a-44c8-a48d-10ea7d87ddb2">3.9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmNjZDUwOTcwMTRkZDRmZGZiMzgwMzNkMTE5YjhlYWQ0L3RhYmxlcmFuZ2U6Y2NkNTA5NzAxNGRkNGZkZmIzODAzM2QxMTliOGVhZDRfMi0xMi0xLTEtMA_553cc9ac-ebb9-47ed-8194-4fd8c71973f2">54.4</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amounts reclassified from accumulated other comprehensive income (loss)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6773145664dd45a58afb7773d86b7f79_D20200101-20200930" decimals="-5" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmNjZDUwOTcwMTRkZDRmZGZiMzgwMzNkMTE5YjhlYWQ0L3RhYmxlcmFuZ2U6Y2NkNTA5NzAxNGRkNGZkZmIzODAzM2QxMTliOGVhZDRfMy0yLTEtMS0w_7882922a-c463-4984-a889-3079939a65d6">9.8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i21e4efbba1364e8d97adce8a02fa5c1c_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmNjZDUwOTcwMTRkZDRmZGZiMzgwMzNkMTE5YjhlYWQ0L3RhYmxlcmFuZ2U6Y2NkNTA5NzAxNGRkNGZkZmIzODAzM2QxMTliOGVhZDRfMy00LTEtMS0w_42bb5d35-374f-4c4e-9c8e-bfa5b4bc7b39">43.1</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="idd42a3afee77410b945f7e37289f8773_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmNjZDUwOTcwMTRkZDRmZGZiMzgwMzNkMTE5YjhlYWQ0L3RhYmxlcmFuZ2U6Y2NkNTA5NzAxNGRkNGZkZmIzODAzM2QxMTliOGVhZDRfMy02LTEtMS0w_e8760713-0375-4007-8f52-6e9b9366b560">2.6</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4f6dc2dc230545079cf4e37cd9490b61_D20200101-20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmNjZDUwOTcwMTRkZDRmZGZiMzgwMzNkMTE5YjhlYWQ0L3RhYmxlcmFuZ2U6Y2NkNTA5NzAxNGRkNGZkZmIzODAzM2QxMTliOGVhZDRfMy04LTEtMS0w_5aa3defe-9666-498f-a243-751a59bcd405">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i320a93a4270b45d2834748a854e79d02_D20200101-20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmNjZDUwOTcwMTRkZDRmZGZiMzgwMzNkMTE5YjhlYWQ0L3RhYmxlcmFuZ2U6Y2NkNTA5NzAxNGRkNGZkZmIzODAzM2QxMTliOGVhZDRfMy0xMC0xLTEtMA_44ed24d2-16c9-447a-9763-95ede1e226f0">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmNjZDUwOTcwMTRkZDRmZGZiMzgwMzNkMTE5YjhlYWQ0L3RhYmxlcmFuZ2U6Y2NkNTA5NzAxNGRkNGZkZmIzODAzM2QxMTliOGVhZDRfMy0xMi0xLTEtMA_0e344ac2-0791-4d53-ba5c-77f3507e83ad">35.9</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6773145664dd45a58afb7773d86b7f79_D20200101-20200930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmNjZDUwOTcwMTRkZDRmZGZiMzgwMzNkMTE5YjhlYWQ0L3RhYmxlcmFuZ2U6Y2NkNTA5NzAxNGRkNGZkZmIzODAzM2QxMTliOGVhZDRfNC0yLTEtMS0w_c6e336d3-176c-4ab5-bd9d-727dd9425b19">1.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i21e4efbba1364e8d97adce8a02fa5c1c_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmNjZDUwOTcwMTRkZDRmZGZiMzgwMzNkMTE5YjhlYWQ0L3RhYmxlcmFuZ2U6Y2NkNTA5NzAxNGRkNGZkZmIzODAzM2QxMTliOGVhZDRfNC00LTEtMS0w_94992aaa-b3e5-468f-a760-9ae9d7de8d5e">101.1</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idd42a3afee77410b945f7e37289f8773_D20200101-20200930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmNjZDUwOTcwMTRkZDRmZGZiMzgwMzNkMTE5YjhlYWQ0L3RhYmxlcmFuZ2U6Y2NkNTA5NzAxNGRkNGZkZmIzODAzM2QxMTliOGVhZDRfNC02LTEtMS0w_877961cf-ddfe-4a93-a71d-16e93ccfa779">5.5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4f6dc2dc230545079cf4e37cd9490b61_D20200101-20200930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmNjZDUwOTcwMTRkZDRmZGZiMzgwMzNkMTE5YjhlYWQ0L3RhYmxlcmFuZ2U6Y2NkNTA5NzAxNGRkNGZkZmIzODAzM2QxMTliOGVhZDRfNC04LTEtMS0w_8a8eb52a-4eda-4e2d-8a04-d9f219a70d27">0.4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i320a93a4270b45d2834748a854e79d02_D20200101-20200930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmNjZDUwOTcwMTRkZDRmZGZiMzgwMzNkMTE5YjhlYWQ0L3RhYmxlcmFuZ2U6Y2NkNTA5NzAxNGRkNGZkZmIzODAzM2QxMTliOGVhZDRfNC0xMC0xLTEtMA_6de00104-cd84-4bce-8a0c-9ff1267436b8">3.9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmNjZDUwOTcwMTRkZDRmZGZiMzgwMzNkMTE5YjhlYWQ0L3RhYmxlcmFuZ2U6Y2NkNTA5NzAxNGRkNGZkZmIzODAzM2QxMTliOGVhZDRfNC0xMi0xLTEtMA_f552a8a2-4146-404c-ab53-8092f75edd6e">90.3</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, September 30, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i58631e62f8454d6fa19167c8e8a2bb41_I20200930" decimals="-5" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmNjZDUwOTcwMTRkZDRmZGZiMzgwMzNkMTE5YjhlYWQ0L3RhYmxlcmFuZ2U6Y2NkNTA5NzAxNGRkNGZkZmIzODAzM2QxMTliOGVhZDRfNS0yLTEtMS0w_e8f5e265-35a7-4523-a1b7-d82b38e2e73b">5.2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i76542c629f7a4bfdb85009377f3655e1_I20200930" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmNjZDUwOTcwMTRkZDRmZGZiMzgwMzNkMTE5YjhlYWQ0L3RhYmxlcmFuZ2U6Y2NkNTA5NzAxNGRkNGZkZmIzODAzM2QxMTliOGVhZDRfNS00LTEtMS0w_334af51e-5352-4d20-b4e9-6e322a5297ed">93.3</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ideb1736cbc354334a8ee23f9cadfc4bd_I20200930" decimals="-5" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmNjZDUwOTcwMTRkZDRmZGZiMzgwMzNkMTE5YjhlYWQ0L3RhYmxlcmFuZ2U6Y2NkNTA5NzAxNGRkNGZkZmIzODAzM2QxMTliOGVhZDRfNS02LTEtMS0w_aba16422-7f25-4727-a140-90c221b31157">30.6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1d927cca7f9c4d73aab25d3b3d48868f_I20200930" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmNjZDUwOTcwMTRkZDRmZGZiMzgwMzNkMTE5YjhlYWQ0L3RhYmxlcmFuZ2U6Y2NkNTA5NzAxNGRkNGZkZmIzODAzM2QxMTliOGVhZDRfNS04LTEtMS0w_9a17f944-891e-4e5c-9d9c-7d7d76b8749c">32.4</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib3b032c0499d4048ba5f66ef535061b2_I20200930" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmNjZDUwOTcwMTRkZDRmZGZiMzgwMzNkMTE5YjhlYWQ0L3RhYmxlcmFuZ2U6Y2NkNTA5NzAxNGRkNGZkZmIzODAzM2QxMTliOGVhZDRfNS0xMC0xLTEtMA_051c3350-ef00-4245-a526-93e7005c3a24">135.6</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmNjZDUwOTcwMTRkZDRmZGZiMzgwMzNkMTE5YjhlYWQ0L3RhYmxlcmFuZ2U6Y2NkNTA5NzAxNGRkNGZkZmIzODAzM2QxMTliOGVhZDRfNS0xMi0xLTEtMA_d31b1a7c-0165-4f46-bb34-9638caa1df0f">225.5</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td></tr></table></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:31.696%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.295%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.002%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.295%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.466%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.295%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.859%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In millions)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gains (Losses) on Net Investment Hedge</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unfunded Status of Postretirement Benefit Plans, Net of Tax</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Currency Translation Adjustments</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, December 31, 2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0e4620290d53494a80d6bc03a34181dd_I20181231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOjBhNGNiZTE2MjZjNzRlZGQ4YjZlMjczZTI5ZmE1ZDgyL3RhYmxlcmFuZ2U6MGE0Y2JlMTYyNmM3NGVkZDhiNmUyNzNlMjlmYTVkODJfMS0yLTEtMS0w_66337559-f88c-4377-8f47-f9fe5d9ed668">4.0</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id17e410580eb4b0eb19f7434c46678d8_I20181231" decimals="-5" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOjBhNGNiZTE2MjZjNzRlZGQ4YjZlMjczZTI5ZmE1ZDgyL3RhYmxlcmFuZ2U6MGE0Y2JlMTYyNmM3NGVkZDhiNmUyNzNlMjlmYTVkODJfMS00LTEtMS0w_adc630e7-7df2-4a7d-b3a6-82e865a3656f">34.7</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i87b8b8492f694a2a85d10571ab2b857f_I20181231" decimals="-5" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOjBhNGNiZTE2MjZjNzRlZGQ4YjZlMjczZTI5ZmE1ZDgyL3RhYmxlcmFuZ2U6MGE0Y2JlMTYyNmM3NGVkZDhiNmUyNzNlMjlmYTVkODJfMS02LTEtMS0w_9e83c5bd-b501-4786-8070-f6a0be429148">3.5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i39a2399061724666bae8d3296c72225d_I20181231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOjBhNGNiZTE2MjZjNzRlZGQ4YjZlMjczZTI5ZmE1ZDgyL3RhYmxlcmFuZ2U6MGE0Y2JlMTYyNmM3NGVkZDhiNmUyNzNlMjlmYTVkODJfMS04LTEtMS0w_37fbde3f-1157-48b8-9aa4-2b4f19d94ae5">31.3</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i74e5d53de65e4a8a9e4e245845ee99be_I20181231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOjBhNGNiZTE2MjZjNzRlZGQ4YjZlMjczZTI5ZmE1ZDgyL3RhYmxlcmFuZ2U6MGE0Y2JlMTYyNmM3NGVkZDhiNmUyNzNlMjlmYTVkODJfMS0xMC0xLTEtMA_99c8ce50-ae7d-4d96-8d09-ddbc89d857a0">243.3</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib98dd789f3514452acc95f9b041d2a7e_I20181231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOjBhNGNiZTE2MjZjNzRlZGQ4YjZlMjczZTI5ZmE1ZDgyL3RhYmxlcmFuZ2U6MGE0Y2JlMTYyNmM3NGVkZDhiNmUyNzNlMjlmYTVkODJfMS0xMi0xLTEtMA_2b7ba45d-ba3f-43b1-ba48-ac8a1649bd46">240.4</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i591bf9ccf21b4e53b95118628d4978da_D20190101-20190930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOjBhNGNiZTE2MjZjNzRlZGQ4YjZlMjczZTI5ZmE1ZDgyL3RhYmxlcmFuZ2U6MGE0Y2JlMTYyNmM3NGVkZDhiNmUyNzNlMjlmYTVkODJfMi0yLTEtMS0w_3d2962b5-73e4-43ed-9894-1129fec49d9a">11.6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i246c949459c344caa446c9c644b413b2_D20190101-20190930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOjBhNGNiZTE2MjZjNzRlZGQ4YjZlMjczZTI5ZmE1ZDgyL3RhYmxlcmFuZ2U6MGE0Y2JlMTYyNmM3NGVkZDhiNmUyNzNlMjlmYTVkODJfMi00LTEtMS0w_a811afc8-dd2b-44b4-b126-586fd719b0da">115.8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i002638e6f51c4c26ba598e6a80ddd034_D20190101-20190930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOjBhNGNiZTE2MjZjNzRlZGQ4YjZlMjczZTI5ZmE1ZDgyL3RhYmxlcmFuZ2U6MGE0Y2JlMTYyNmM3NGVkZDhiNmUyNzNlMjlmYTVkODJfMi02LTEtMS0w_cb7b8c2d-c66f-416d-87f1-c1140424251e">53.5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9b77bbc89c154914b55e0fa9c9242c96_D20190101-20190930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOjBhNGNiZTE2MjZjNzRlZGQ4YjZlMjczZTI5ZmE1ZDgyL3RhYmxlcmFuZ2U6MGE0Y2JlMTYyNmM3NGVkZDhiNmUyNzNlMjlmYTVkODJfMi04LTEtMS0w_4fcb4df9-6e92-41df-8934-2293caca8fca">1.5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2e02b47bfe8d48a5aa515d8c91a8cb66_D20190101-20190930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOjBhNGNiZTE2MjZjNzRlZGQ4YjZlMjczZTI5ZmE1ZDgyL3RhYmxlcmFuZ2U6MGE0Y2JlMTYyNmM3NGVkZDhiNmUyNzNlMjlmYTVkODJfMi0xMC0xLTEtMA_7e53a890-d57a-40c0-bfd1-3aa3ee0b54dd">51.3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOjBhNGNiZTE2MjZjNzRlZGQ4YjZlMjczZTI5ZmE1ZDgyL3RhYmxlcmFuZ2U6MGE0Y2JlMTYyNmM3NGVkZDhiNmUyNzNlMjlmYTVkODJfMi0xMi0xLTEtMA_e012fc87-4239-476e-ac58-9299fe199077">233.7</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amounts reclassified from accumulated other comprehensive income (loss)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i591bf9ccf21b4e53b95118628d4978da_D20190101-20190930" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOjBhNGNiZTE2MjZjNzRlZGQ4YjZlMjczZTI5ZmE1ZDgyL3RhYmxlcmFuZ2U6MGE0Y2JlMTYyNmM3NGVkZDhiNmUyNzNlMjlmYTVkODJfMy0yLTEtMS0w_77bbd4da-2c65-4dc4-965f-37b172a168bb">1.3</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i246c949459c344caa446c9c644b413b2_D20190101-20190930" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOjBhNGNiZTE2MjZjNzRlZGQ4YjZlMjczZTI5ZmE1ZDgyL3RhYmxlcmFuZ2U6MGE0Y2JlMTYyNmM3NGVkZDhiNmUyNzNlMjlmYTVkODJfMy00LTEtMS0w_53180438-48d3-4fcb-9d87-9b2d06a45b45">77.7</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i002638e6f51c4c26ba598e6a80ddd034_D20190101-20190930" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOjBhNGNiZTE2MjZjNzRlZGQ4YjZlMjczZTI5ZmE1ZDgyL3RhYmxlcmFuZ2U6MGE0Y2JlMTYyNmM3NGVkZDhiNmUyNzNlMjlmYTVkODJfMy02LTEtMS0w_c445dbce-7020-4bd2-a36f-c5c696bef65f">6.6</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9b77bbc89c154914b55e0fa9c9242c96_D20190101-20190930" decimals="-5" format="ixt:zerodash" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOjBhNGNiZTE2MjZjNzRlZGQ4YjZlMjczZTI5ZmE1ZDgyL3RhYmxlcmFuZ2U6MGE0Y2JlMTYyNmM3NGVkZDhiNmUyNzNlMjlmYTVkODJfMy04LTEtMS0w_ca4e1441-3ef9-4c5a-b643-da8278553c6c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2e02b47bfe8d48a5aa515d8c91a8cb66_D20190101-20190930" decimals="-5" format="ixt:zerodash" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOjBhNGNiZTE2MjZjNzRlZGQ4YjZlMjczZTI5ZmE1ZDgyL3RhYmxlcmFuZ2U6MGE0Y2JlMTYyNmM3NGVkZDhiNmUyNzNlMjlmYTVkODJfMy0xMC0xLTEtMA_c242e27d-f8ca-402a-adda-e6b129ce8ed2">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOjBhNGNiZTE2MjZjNzRlZGQ4YjZlMjczZTI5ZmE1ZDgyL3RhYmxlcmFuZ2U6MGE0Y2JlMTYyNmM3NGVkZDhiNmUyNzNlMjlmYTVkODJfMy0xMi0xLTEtMA_a334a965-ea4a-43c9-969b-ac4b7703e8f0">85.6</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i591bf9ccf21b4e53b95118628d4978da_D20190101-20190930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOjBhNGNiZTE2MjZjNzRlZGQ4YjZlMjczZTI5ZmE1ZDgyL3RhYmxlcmFuZ2U6MGE0Y2JlMTYyNmM3NGVkZDhiNmUyNzNlMjlmYTVkODJfNC0yLTEtMS0w_f8a9d46d-b4e1-44bd-81fb-6e19431d0434">10.3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i246c949459c344caa446c9c644b413b2_D20190101-20190930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOjBhNGNiZTE2MjZjNzRlZGQ4YjZlMjczZTI5ZmE1ZDgyL3RhYmxlcmFuZ2U6MGE0Y2JlMTYyNmM3NGVkZDhiNmUyNzNlMjlmYTVkODJfNC00LTEtMS0w_e0dfc1ee-a403-48a9-87be-12ed2bcfa52c">38.1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i002638e6f51c4c26ba598e6a80ddd034_D20190101-20190930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOjBhNGNiZTE2MjZjNzRlZGQ4YjZlMjczZTI5ZmE1ZDgyL3RhYmxlcmFuZ2U6MGE0Y2JlMTYyNmM3NGVkZDhiNmUyNzNlMjlmYTVkODJfNC02LTEtMS0w_ed36776e-9f32-44b6-a187-be4a39f242c5">46.9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9b77bbc89c154914b55e0fa9c9242c96_D20190101-20190930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOjBhNGNiZTE2MjZjNzRlZGQ4YjZlMjczZTI5ZmE1ZDgyL3RhYmxlcmFuZ2U6MGE0Y2JlMTYyNmM3NGVkZDhiNmUyNzNlMjlmYTVkODJfNC04LTEtMS0w_3892f178-4899-4816-be7f-a1e81393929e">1.5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2e02b47bfe8d48a5aa515d8c91a8cb66_D20190101-20190930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOjBhNGNiZTE2MjZjNzRlZGQ4YjZlMjczZTI5ZmE1ZDgyL3RhYmxlcmFuZ2U6MGE0Y2JlMTYyNmM3NGVkZDhiNmUyNzNlMjlmYTVkODJfNC0xMC0xLTEtMA_a04af8ea-132d-407e-9dd8-627c6f633484">51.3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOjBhNGNiZTE2MjZjNzRlZGQ4YjZlMjczZTI5ZmE1ZDgyL3RhYmxlcmFuZ2U6MGE0Y2JlMTYyNmM3NGVkZDhiNmUyNzNlMjlmYTVkODJfNC0xMi0xLTEtMA_b1e48196-ca7b-426a-a997-a339201420ff">148.1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, September 30, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i81cfc07b94a54ce5b9767acd9ccbed84_I20190930" decimals="-5" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOjBhNGNiZTE2MjZjNzRlZGQ4YjZlMjczZTI5ZmE1ZDgyL3RhYmxlcmFuZ2U6MGE0Y2JlMTYyNmM3NGVkZDhiNmUyNzNlMjlmYTVkODJfNS0yLTEtMS0w_eefc1aea-429a-4628-ac1f-b23811b66f79">6.3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6b8b1c75f80b47ab8430787fcd074574_I20190930" decimals="-5" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOjBhNGNiZTE2MjZjNzRlZGQ4YjZlMjczZTI5ZmE1ZDgyL3RhYmxlcmFuZ2U6MGE0Y2JlMTYyNmM3NGVkZDhiNmUyNzNlMjlmYTVkODJfNS00LTEtMS0w_13d2a0c8-0dff-4889-8f0a-baf132603ccd">72.8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i52e2a69e04ee42ff88b18c7f1bf6b5bb_I20190930" decimals="-5" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOjBhNGNiZTE2MjZjNzRlZGQ4YjZlMjczZTI5ZmE1ZDgyL3RhYmxlcmFuZ2U6MGE0Y2JlMTYyNmM3NGVkZDhiNmUyNzNlMjlmYTVkODJfNS02LTEtMS0w_3682c8b0-1b85-488f-a54d-bba09ea05b25">50.4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i5f7aa82595074b70bd32cc3f188787ee_I20190930" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOjBhNGNiZTE2MjZjNzRlZGQ4YjZlMjczZTI5ZmE1ZDgyL3RhYmxlcmFuZ2U6MGE0Y2JlMTYyNmM3NGVkZDhiNmUyNzNlMjlmYTVkODJfNS04LTEtMS0w_88585fdf-b0b9-4e63-a1c9-0c890bcd6897">29.8</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i292bc1b0a8914e259d69aee92dcb23d9_I20190930" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOjBhNGNiZTE2MjZjNzRlZGQ4YjZlMjczZTI5ZmE1ZDgyL3RhYmxlcmFuZ2U6MGE0Y2JlMTYyNmM3NGVkZDhiNmUyNzNlMjlmYTVkODJfNS0xMC0xLTEtMA_8fa031a8-450c-418d-a3e5-1056dd80f11d">192.0</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ied38b94db9a74750b51c6e8392d4c5bf_I20190930" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOjBhNGNiZTE2MjZjNzRlZGQ4YjZlMjczZTI5ZmE1ZDgyL3RhYmxlcmFuZ2U6MGE0Y2JlMTYyNmM3NGVkZDhiNmUyNzNlMjlmYTVkODJfNS0xMi0xLTEtMA_3f00bbc8-2305-472d-803d-7dddcafb43de">92.3</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_7">Table of Contents</a></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(unaudited, continued)</span></div></div><ix:continuation id="i9ae22b4b8f1b4fc89f1c0ed0f1eb24d9"><ix:nonNumeric contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" name="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RleHRyZWdpb246ZjZlZDhjM2EzZGM0NGZhZGE1YjMzOWE0ZGVhODAwNGRfMTMzMA_d92a8d89-ead3-44e9-974f-81652adb653a" escape="true"><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the amounts reclassified from accumulated other comprehensive income:</span></div><div style="text-align:justify;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:33.987%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:21.707%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.695%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.695%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.695%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.701%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" rowspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In millions)</span></td><td colspan="3" rowspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income Statement Location</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amounts Reclassified from Accumulated Other Comprehensive Income</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Three Months Ended September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gains (losses) on securities available for sale</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other income (expense)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i69dfd183e47b43278ea75c1422a31eb4_D20200701-20200930" decimals="-5" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmYwMGRlMzM2MDMyNDQ4MTk4NmY2Y2RmZDcxZGVhNmQyL3RhYmxlcmFuZ2U6ZjAwZGUzMzYwMzI0NDgxOTg2ZjZjZGZkNzFkZWE2ZDJfMy0zLTEtMS0w_0d7213bd-a907-4c78-a242-0acc188d4b29">0.1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie7e3a2434dd044fda5e6fd81be0904a7_D20190701-20190930" decimals="-5" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmYwMGRlMzM2MDMyNDQ4MTk4NmY2Y2RmZDcxZGVhNmQyL3RhYmxlcmFuZ2U6ZjAwZGUzMzYwMzI0NDgxOTg2ZjZjZGZkNzFkZWE2ZDJfMy01LTEtMS0w_3a8f212d-ba59-4c8a-96b6-252e54edf09c">0.6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ifc695f2ba910436fba8558e4c246c2ed_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmYwMGRlMzM2MDMyNDQ4MTk4NmY2Y2RmZDcxZGVhNmQyL3RhYmxlcmFuZ2U6ZjAwZGUzMzYwMzI0NDgxOTg2ZjZjZGZkNzFkZWE2ZDJfMy03LTEtMS0w_8cf6368b-719d-4157-bcc2-3f30bb8b0db8">12.4</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iedbf521c84034004b661ca18c9f5b341_D20190101-20190930" decimals="-5" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmYwMGRlMzM2MDMyNDQ4MTk4NmY2Y2RmZDcxZGVhNmQyL3RhYmxlcmFuZ2U6ZjAwZGUzMzYwMzI0NDgxOTg2ZjZjZGZkNzFkZWE2ZDJfMy05LTEtMS0w_6f39191c-efc3-4c35-9d31-432f6c39d8cc">1.6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income tax benefit (expense)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i69dfd183e47b43278ea75c1422a31eb4_D20200701-20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmYwMGRlMzM2MDMyNDQ4MTk4NmY2Y2RmZDcxZGVhNmQyL3RhYmxlcmFuZ2U6ZjAwZGUzMzYwMzI0NDgxOTg2ZjZjZGZkNzFkZWE2ZDJfNC0zLTEtMS0w_01761c1e-252a-4233-8833-3fbd4398eb68">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie7e3a2434dd044fda5e6fd81be0904a7_D20190701-20190930" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmYwMGRlMzM2MDMyNDQ4MTk4NmY2Y2RmZDcxZGVhNmQyL3RhYmxlcmFuZ2U6ZjAwZGUzMzYwMzI0NDgxOTg2ZjZjZGZkNzFkZWE2ZDJfNC01LTEtMS0w_ace9b7b2-1215-4377-bc60-b29e0bb0b895">0.1</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifc695f2ba910436fba8558e4c246c2ed_D20200101-20200930" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmYwMGRlMzM2MDMyNDQ4MTk4NmY2Y2RmZDcxZGVhNmQyL3RhYmxlcmFuZ2U6ZjAwZGUzMzYwMzI0NDgxOTg2ZjZjZGZkNzFkZWE2ZDJfNC03LTEtMS0w_e1f7a964-50da-4989-abf1-253344ad509f">2.6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iedbf521c84034004b661ca18c9f5b341_D20190101-20190930" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmYwMGRlMzM2MDMyNDQ4MTk4NmY2Y2RmZDcxZGVhNmQyL3RhYmxlcmFuZ2U6ZjAwZGUzMzYwMzI0NDgxOTg2ZjZjZGZkNzFkZWE2ZDJfNC05LTEtMS0w_3c44605c-dbed-4fff-9a35-319f989b23fa">0.3</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gains (losses) on cash flow hedges</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenues</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i596f51e2385d4d4ca183e21f84aa0b55_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmYwMGRlMzM2MDMyNDQ4MTk4NmY2Y2RmZDcxZGVhNmQyL3RhYmxlcmFuZ2U6ZjAwZGUzMzYwMzI0NDgxOTg2ZjZjZGZkNzFkZWE2ZDJfNi0zLTEtMS0w_7169eed0-2d5a-471d-bdf0-1e547f173fca">9.1</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4ff5ee345592411bb43c306a460e9fd1_D20190701-20190930" decimals="-5" sign="-" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmYwMGRlMzM2MDMyNDQ4MTk4NmY2Y2RmZDcxZGVhNmQyL3RhYmxlcmFuZ2U6ZjAwZGUzMzYwMzI0NDgxOTg2ZjZjZGZkNzFkZWE2ZDJfNi01LTEtMS0w_a1a74851-db36-4e06-a043-aaf6072beffa">35.2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0dc320a6c37a4e9690e25e679e491fc4_D20200101-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmYwMGRlMzM2MDMyNDQ4MTk4NmY2Y2RmZDcxZGVhNmQyL3RhYmxlcmFuZ2U6ZjAwZGUzMzYwMzI0NDgxOTg2ZjZjZGZkNzFkZWE2ZDJfNi03LTEtMS0w_dd1b14f5-3be0-4927-80af-e81778cfcb72">41.6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8eaafd98479a4bef96cb14d80b992fd6_D20190101-20190930" decimals="-5" sign="-" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmYwMGRlMzM2MDMyNDQ4MTk4NmY2Y2RmZDcxZGVhNmQyL3RhYmxlcmFuZ2U6ZjAwZGUzMzYwMzI0NDgxOTg2ZjZjZGZkNzFkZWE2ZDJfNi05LTEtMS0w_fce56736-e99a-4878-8e15-ee79cd7b8256">79.8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating expenses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i596f51e2385d4d4ca183e21f84aa0b55_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:OperatingExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmYwMGRlMzM2MDMyNDQ4MTk4NmY2Y2RmZDcxZGVhNmQyL3RhYmxlcmFuZ2U6ZjAwZGUzMzYwMzI0NDgxOTg2ZjZjZGZkNzFkZWE2ZDJfNy0zLTEtMS0w_6992a1c3-0944-4851-9940-f8a18d27a2eb">1.5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i4ff5ee345592411bb43c306a460e9fd1_D20190701-20190930" decimals="-5" name="us-gaap:OperatingExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmYwMGRlMzM2MDMyNDQ4MTk4NmY2Y2RmZDcxZGVhNmQyL3RhYmxlcmFuZ2U6ZjAwZGUzMzYwMzI0NDgxOTg2ZjZjZGZkNzFkZWE2ZDJfNy01LTEtMS0w_e125f4c0-7c22-4876-9e73-6693a773b55b">0.8</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0dc320a6c37a4e9690e25e679e491fc4_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:OperatingExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmYwMGRlMzM2MDMyNDQ4MTk4NmY2Y2RmZDcxZGVhNmQyL3RhYmxlcmFuZ2U6ZjAwZGUzMzYwMzI0NDgxOTg2ZjZjZGZkNzFkZWE2ZDJfNy03LTEtMS0w_a5620e3e-efd1-448d-b778-29b79d26d212">1.4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8eaafd98479a4bef96cb14d80b992fd6_D20190101-20190930" decimals="-5" sign="-" name="us-gaap:OperatingExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmYwMGRlMzM2MDMyNDQ4MTk4NmY2Y2RmZDcxZGVhNmQyL3RhYmxlcmFuZ2U6ZjAwZGUzMzYwMzI0NDgxOTg2ZjZjZGZkNzFkZWE2ZDJfNy05LTEtMS0w_dbd401a3-3b84-40c9-8d95-196ee2ec9aeb">2.0</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other income (expense)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i596f51e2385d4d4ca183e21f84aa0b55_D20200701-20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmYwMGRlMzM2MDMyNDQ4MTk4NmY2Y2RmZDcxZGVhNmQyL3RhYmxlcmFuZ2U6ZjAwZGUzMzYwMzI0NDgxOTg2ZjZjZGZkNzFkZWE2ZDJfOC0zLTEtMS0w_ce5a0aab-d582-403d-b5d7-dfabdcf859c6">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4ff5ee345592411bb43c306a460e9fd1_D20190701-20190930" decimals="-5" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmYwMGRlMzM2MDMyNDQ4MTk4NmY2Y2RmZDcxZGVhNmQyL3RhYmxlcmFuZ2U6ZjAwZGUzMzYwMzI0NDgxOTg2ZjZjZGZkNzFkZWE2ZDJfOC01LTEtMS0w_50f44dd0-3c99-4dea-915c-55a8c28706b7">0.1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0dc320a6c37a4e9690e25e679e491fc4_D20200101-20200930" decimals="-5" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmYwMGRlMzM2MDMyNDQ4MTk4NmY2Y2RmZDcxZGVhNmQyL3RhYmxlcmFuZ2U6ZjAwZGUzMzYwMzI0NDgxOTg2ZjZjZGZkNzFkZWE2ZDJfOC03LTEtMS0w_04d4f914-4ac3-4284-a6bd-1dba63087bf2">0.2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8eaafd98479a4bef96cb14d80b992fd6_D20190101-20190930" decimals="-5" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmYwMGRlMzM2MDMyNDQ4MTk4NmY2Y2RmZDcxZGVhNmQyL3RhYmxlcmFuZ2U6ZjAwZGUzMzYwMzI0NDgxOTg2ZjZjZGZkNzFkZWE2ZDJfOC05LTEtMS0w_5ccb7059-0a56-4b0e-8a74-8fe73bbc0ae3">0.2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income tax benefit (expense)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i596f51e2385d4d4ca183e21f84aa0b55_D20200701-20200930" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmYwMGRlMzM2MDMyNDQ4MTk4NmY2Y2RmZDcxZGVhNmQyL3RhYmxlcmFuZ2U6ZjAwZGUzMzYwMzI0NDgxOTg2ZjZjZGZkNzFkZWE2ZDJfOS0zLTEtMS0w_25cb68a4-f0b9-4c78-a21c-7d716562ad5c">0.1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i4ff5ee345592411bb43c306a460e9fd1_D20190701-20190930" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmYwMGRlMzM2MDMyNDQ4MTk4NmY2Y2RmZDcxZGVhNmQyL3RhYmxlcmFuZ2U6ZjAwZGUzMzYwMzI0NDgxOTg2ZjZjZGZkNzFkZWE2ZDJfOS01LTEtMS0w_00bf8257-8c0b-4735-86a5-c5bc3bb7d498">0.1</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0dc320a6c37a4e9690e25e679e491fc4_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmYwMGRlMzM2MDMyNDQ4MTk4NmY2Y2RmZDcxZGVhNmQyL3RhYmxlcmFuZ2U6ZjAwZGUzMzYwMzI0NDgxOTg2ZjZjZGZkNzFkZWE2ZDJfOS03LTEtMS0w_2b906d7b-1858-4240-8c78-5713ff1887d6">0.1</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8eaafd98479a4bef96cb14d80b992fd6_D20190101-20190930" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmYwMGRlMzM2MDMyNDQ4MTk4NmY2Y2RmZDcxZGVhNmQyL3RhYmxlcmFuZ2U6ZjAwZGUzMzYwMzI0NDgxOTg2ZjZjZGZkNzFkZWE2ZDJfOS05LTEtMS0w_8d415fd2-e532-4563-8aae-11f41ae838e5">0.3</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gains (losses) on net investment hedge</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other income (expense)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i50715424610f44fe9d83a26f088cd935_D20200701-20200930" decimals="-5" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmYwMGRlMzM2MDMyNDQ4MTk4NmY2Y2RmZDcxZGVhNmQyL3RhYmxlcmFuZ2U6ZjAwZGUzMzYwMzI0NDgxOTg2ZjZjZGZkNzFkZWE2ZDJfMTEtMy0xLTEtMA_5cc0d2e0-3019-4536-9404-6131f006bb88">0.8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1cccc5c5e6a64e839db1a1a24f25b45e_D20190701-20190930" decimals="-5" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmYwMGRlMzM2MDMyNDQ4MTk4NmY2Y2RmZDcxZGVhNmQyL3RhYmxlcmFuZ2U6ZjAwZGUzMzYwMzI0NDgxOTg2ZjZjZGZkNzFkZWE2ZDJfMTEtNS0xLTEtMA_9f929086-1cd2-4b22-a640-afe47d322424">2.2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic0ab2edcb2644062923296228b7a8512_D20200101-20200930" decimals="-5" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmYwMGRlMzM2MDMyNDQ4MTk4NmY2Y2RmZDcxZGVhNmQyL3RhYmxlcmFuZ2U6ZjAwZGUzMzYwMzI0NDgxOTg2ZjZjZGZkNzFkZWE2ZDJfMTEtNy0xLTEtMA_92905cae-a2ea-4324-8759-aa0e2477366b">2.6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i79d195428b514b78a4569da6e0cad1aa_D20190101-20190930" decimals="-5" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmYwMGRlMzM2MDMyNDQ4MTk4NmY2Y2RmZDcxZGVhNmQyL3RhYmxlcmFuZ2U6ZjAwZGUzMzYwMzI0NDgxOTg2ZjZjZGZkNzFkZWE2ZDJfMTEtOS0xLTEtMA_85403960-0259-485d-9540-ea87b4bdebad">6.6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total reclassifications, net of tax</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i42f682d87cc74a01aeb1af535a8ccb75_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmYwMGRlMzM2MDMyNDQ4MTk4NmY2Y2RmZDcxZGVhNmQyL3RhYmxlcmFuZ2U6ZjAwZGUzMzYwMzI0NDgxOTg2ZjZjZGZkNzFkZWE2ZDJfMTQtMy0xLTEtMA_46e9a57e-9321-4f02-bb16-d25a2dce0c14">6.6</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3ee5b72f84e44476b4c4a2b8d8df11ac_D20190701-20190930" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmYwMGRlMzM2MDMyNDQ4MTk4NmY2Y2RmZDcxZGVhNmQyL3RhYmxlcmFuZ2U6ZjAwZGUzMzYwMzI0NDgxOTg2ZjZjZGZkNzFkZWE2ZDJfMTQtNS0xLTEtMA_b74800ad-4c45-4919-8653-181602e98568">37.1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i198a92ee28f54d99b35bfa8c48185fb9_D20200101-20200930" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmYwMGRlMzM2MDMyNDQ4MTk4NmY2Y2RmZDcxZGVhNmQyL3RhYmxlcmFuZ2U6ZjAwZGUzMzYwMzI0NDgxOTg2ZjZjZGZkNzFkZWE2ZDJfMTQtNy0xLTEtMA_e539aebf-2255-44fc-9dc9-4ee6c1f9e61e">35.9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i31394cacd6624f0892e0c59f72b73473_D20190101-20190930" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmYwMGRlMzM2MDMyNDQ4MTk4NmY2Y2RmZDcxZGVhNmQyL3RhYmxlcmFuZ2U6ZjAwZGUzMzYwMzI0NDgxOTg2ZjZjZGZkNzFkZWE2ZDJfMTQtOS0xLTEtMA_0b793ac4-5663-4a87-89e5-5c892dcc37da">85.6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="ib19ff89608c84168a635160f2efa48f3_97"></div><div style="text-indent:-27pt;padding-left:27pt;margin-top:14pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">13.&#160;&#160;&#160;&#160;Earnings per Share </span></div><ix:nonNumeric contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185Ny9mcmFnOjRjMDNkMjgxZGNhMDQ1YmViZGUwNzJkM2VmODNjYmFhL3RleHRyZWdpb246NGMwM2QyODFkY2EwNDViZWJkZTA3MmQzZWY4M2NiYWFfMjA5_4277d7ef-b762-4a1c-9833-bffd60103ec7" escape="true"><ix:nonNumeric contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185Ny9mcmFnOjRjMDNkMjgxZGNhMDQ1YmViZGUwNzJkM2VmODNjYmFhL3RleHRyZWdpb246NGMwM2QyODFkY2EwNDViZWJkZTA3MmQzZWY4M2NiYWFfMjI1_b54b0214-7a84-48e6-ba0b-0004905a8fa2" escape="true"><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Basic and diluted earnings per share are calculated as follows:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:43.929%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.204%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.204%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.619%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.624%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Three Months Ended September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In millions)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-style:italic;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Numerator:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income attributable to Biogen Inc.</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185Ny9mcmFnOjRjMDNkMjgxZGNhMDQ1YmViZGUwNzJkM2VmODNjYmFhL3RhYmxlOjI0ZWE0ODNhMTM4OTQ2NzM5Njk5ZmFiZmVjYmI4NjZlL3RhYmxlcmFuZ2U6MjRlYTQ4M2ExMzg5NDY3Mzk2OTlmYWJmZWNiYjg2NmVfMy0yLTEtMS0w_24ff3b32-0381-4922-9b0e-b3f0e196b243">701.5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185Ny9mcmFnOjRjMDNkMjgxZGNhMDQ1YmViZGUwNzJkM2VmODNjYmFhL3RhYmxlOjI0ZWE0ODNhMTM4OTQ2NzM5Njk5ZmFiZmVjYmI4NjZlL3RhYmxlcmFuZ2U6MjRlYTQ4M2ExMzg5NDY3Mzk2OTlmYWJmZWNiYjg2NmVfMy00LTEtMS0w_1af0114b-dede-4232-b2c9-bba15c4fa899">1,545.9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185Ny9mcmFnOjRjMDNkMjgxZGNhMDQ1YmViZGUwNzJkM2VmODNjYmFhL3RhYmxlOjI0ZWE0ODNhMTM4OTQ2NzM5Njk5ZmFiZmVjYmI4NjZlL3RhYmxlcmFuZ2U6MjRlYTQ4M2ExMzg5NDY3Mzk2OTlmYWJmZWNiYjg2NmVfMy02LTEtMS0w_a84bb2f6-0a9d-40f2-a47b-601a4d70034e">3,642.7</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185Ny9mcmFnOjRjMDNkMjgxZGNhMDQ1YmViZGUwNzJkM2VmODNjYmFhL3RhYmxlOjI0ZWE0ODNhMTM4OTQ2NzM5Njk5ZmFiZmVjYmI4NjZlL3RhYmxlcmFuZ2U6MjRlYTQ4M2ExMzg5NDY3Mzk2OTlmYWJmZWNiYjg2NmVfMy04LTEtMS0w_322e8a0e-3eee-4eb3-93e7-9f2887cb8b31">4,448.8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-style:italic;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Denominator:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted average number of common shares outstanding</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185Ny9mcmFnOjRjMDNkMjgxZGNhMDQ1YmViZGUwNzJkM2VmODNjYmFhL3RhYmxlOjI0ZWE0ODNhMTM4OTQ2NzM5Njk5ZmFiZmVjYmI4NjZlL3RhYmxlcmFuZ2U6MjRlYTQ4M2ExMzg5NDY3Mzk2OTlmYWJmZWNiYjg2NmVfNS0yLTEtMS0w_49203b04-689d-41f4-bd88-5507e2e315a3">156.9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185Ny9mcmFnOjRjMDNkMjgxZGNhMDQ1YmViZGUwNzJkM2VmODNjYmFhL3RhYmxlOjI0ZWE0ODNhMTM4OTQ2NzM5Njk5ZmFiZmVjYmI4NjZlL3RhYmxlcmFuZ2U6MjRlYTQ4M2ExMzg5NDY3Mzk2OTlmYWJmZWNiYjg2NmVfNS00LTEtMS0w_c5b3d9c6-f2f2-4d2d-96ce-d0581ed875df">184.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185Ny9mcmFnOjRjMDNkMjgxZGNhMDQ1YmViZGUwNzJkM2VmODNjYmFhL3RhYmxlOjI0ZWE0ODNhMTM4OTQ2NzM5Njk5ZmFiZmVjYmI4NjZlL3RhYmxlcmFuZ2U6MjRlYTQ4M2ExMzg5NDY3Mzk2OTlmYWJmZWNiYjg2NmVfNS02LTEtMS0w_2f38e537-82c7-45aa-9ac5-d14c2615f22e">163.4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185Ny9mcmFnOjRjMDNkMjgxZGNhMDQ1YmViZGUwNzJkM2VmODNjYmFhL3RhYmxlOjI0ZWE0ODNhMTM4OTQ2NzM5Njk5ZmFiZmVjYmI4NjZlL3RhYmxlcmFuZ2U6MjRlYTQ4M2ExMzg5NDY3Mzk2OTlmYWJmZWNiYjg2NmVfNS04LTEtMS0w_73b488a3-eb6a-4552-8630-35bf37aaf6dc">190.3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Time-vested restricted stock units</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i07c2927512de4889ac3af77ef26070bf_D20200701-20200930" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185Ny9mcmFnOjRjMDNkMjgxZGNhMDQ1YmViZGUwNzJkM2VmODNjYmFhL3RhYmxlOjI0ZWE0ODNhMTM4OTQ2NzM5Njk5ZmFiZmVjYmI4NjZlL3RhYmxlcmFuZ2U6MjRlYTQ4M2ExMzg5NDY3Mzk2OTlmYWJmZWNiYjg2NmVfOC0yLTEtMS0w_c19ca0f2-c5e5-443d-8a58-5fd7537d0de4">0.1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i9e3d3eb860e64b4c8771c3591a944c56_D20190701-20190930" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185Ny9mcmFnOjRjMDNkMjgxZGNhMDQ1YmViZGUwNzJkM2VmODNjYmFhL3RhYmxlOjI0ZWE0ODNhMTM4OTQ2NzM5Njk5ZmFiZmVjYmI4NjZlL3RhYmxlcmFuZ2U6MjRlYTQ4M2ExMzg5NDY3Mzk2OTlmYWJmZWNiYjg2NmVfOC00LTEtMS0w_f86c128a-94ca-4893-b82e-5c905ef43098">0.1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i418e492358064b87bb88dd6a5d427bd3_D20200101-20200930" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185Ny9mcmFnOjRjMDNkMjgxZGNhMDQ1YmViZGUwNzJkM2VmODNjYmFhL3RhYmxlOjI0ZWE0ODNhMTM4OTQ2NzM5Njk5ZmFiZmVjYmI4NjZlL3RhYmxlcmFuZ2U6MjRlYTQ4M2ExMzg5NDY3Mzk2OTlmYWJmZWNiYjg2NmVfOC02LTEtMS0w_1c8c3272-da17-43d0-a820-60f49a54742e">0.1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i89cc77663484411897a1c618e3902df4_D20190101-20190930" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185Ny9mcmFnOjRjMDNkMjgxZGNhMDQ1YmViZGUwNzJkM2VmODNjYmFhL3RhYmxlOjI0ZWE0ODNhMTM4OTQ2NzM5Njk5ZmFiZmVjYmI4NjZlL3RhYmxlcmFuZ2U6MjRlYTQ4M2ExMzg5NDY3Mzk2OTlmYWJmZWNiYjg2NmVfOC04LTEtMS0w_b92370f7-ac33-48b2-8aed-f920547bec63">0.1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Market stock units</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i5177976681f14f4fbb72c76d037197e2_D20200701-20200930" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185Ny9mcmFnOjRjMDNkMjgxZGNhMDQ1YmViZGUwNzJkM2VmODNjYmFhL3RhYmxlOjI0ZWE0ODNhMTM4OTQ2NzM5Njk5ZmFiZmVjYmI4NjZlL3RhYmxlcmFuZ2U6MjRlYTQ4M2ExMzg5NDY3Mzk2OTlmYWJmZWNiYjg2NmVfOS0yLTEtMS0w_c643e8a4-6d9a-40dd-b6bb-d11b44b28f4e">0.1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="id458ec3169f34e2088009cbf147e8304_D20190701-20190930" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185Ny9mcmFnOjRjMDNkMjgxZGNhMDQ1YmViZGUwNzJkM2VmODNjYmFhL3RhYmxlOjI0ZWE0ODNhMTM4OTQ2NzM5Njk5ZmFiZmVjYmI4NjZlL3RhYmxlcmFuZ2U6MjRlYTQ4M2ExMzg5NDY3Mzk2OTlmYWJmZWNiYjg2NmVfOS00LTEtMS0w_487e9690-b042-4a6b-b7e6-9dc9f0453561">0.1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i2274b2b373db4361a50819e797d93268_D20200101-20200930" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185Ny9mcmFnOjRjMDNkMjgxZGNhMDQ1YmViZGUwNzJkM2VmODNjYmFhL3RhYmxlOjI0ZWE0ODNhMTM4OTQ2NzM5Njk5ZmFiZmVjYmI4NjZlL3RhYmxlcmFuZ2U6MjRlYTQ4M2ExMzg5NDY3Mzk2OTlmYWJmZWNiYjg2NmVfOS02LTEtMS0w_ec1ee38e-3c83-4484-906b-c869dedaaf3d">0.1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i0ae5101f56364c07bd1fa9851047ae1c_D20190101-20190930" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185Ny9mcmFnOjRjMDNkMjgxZGNhMDQ1YmViZGUwNzJkM2VmODNjYmFhL3RhYmxlOjI0ZWE0ODNhMTM4OTQ2NzM5Njk5ZmFiZmVjYmI4NjZlL3RhYmxlcmFuZ2U6MjRlYTQ4M2ExMzg5NDY3Mzk2OTlmYWJmZWNiYjg2NmVfOS04LTEtMS0w_2659db7d-6a0f-4422-a9d5-022262084e83">0.1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Performance stock units settled in stock</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i17644aaa924944b6838681aa26728f55_D20200701-20200930" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185Ny9mcmFnOjRjMDNkMjgxZGNhMDQ1YmViZGUwNzJkM2VmODNjYmFhL3RhYmxlOjI0ZWE0ODNhMTM4OTQ2NzM5Njk5ZmFiZmVjYmI4NjZlL3RhYmxlcmFuZ2U6MjRlYTQ4M2ExMzg5NDY3Mzk2OTlmYWJmZWNiYjg2NmVfMTAtMi0xLTEtMA_9b0cbdd8-3309-4988-9513-0560ca9b07f4">0.1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i93f4c72f492543b38ab5befc540cf70a_D20190701-20190930" decimals="-5" format="ixt:zerodash" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185Ny9mcmFnOjRjMDNkMjgxZGNhMDQ1YmViZGUwNzJkM2VmODNjYmFhL3RhYmxlOjI0ZWE0ODNhMTM4OTQ2NzM5Njk5ZmFiZmVjYmI4NjZlL3RhYmxlcmFuZ2U6MjRlYTQ4M2ExMzg5NDY3Mzk2OTlmYWJmZWNiYjg2NmVfMTAtNC0xLTEtMA_ec333b65-c247-46ec-b86a-d65cf4e25a04">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i3bcae79b02034b7a8d5846ce264aff93_D20200101-20200930" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185Ny9mcmFnOjRjMDNkMjgxZGNhMDQ1YmViZGUwNzJkM2VmODNjYmFhL3RhYmxlOjI0ZWE0ODNhMTM4OTQ2NzM5Njk5ZmFiZmVjYmI4NjZlL3RhYmxlcmFuZ2U6MjRlYTQ4M2ExMzg5NDY3Mzk2OTlmYWJmZWNiYjg2NmVfMTAtNi0xLTEtMA_904eb7cb-316f-487d-9dc6-28b0035a3092">0.1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i2cc8c72a2c4a4404a78a7942a0c6e8b1_D20190101-20190930" decimals="-5" format="ixt:zerodash" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185Ny9mcmFnOjRjMDNkMjgxZGNhMDQ1YmViZGUwNzJkM2VmODNjYmFhL3RhYmxlOjI0ZWE0ODNhMTM4OTQ2NzM5Njk5ZmFiZmVjYmI4NjZlL3RhYmxlcmFuZ2U6MjRlYTQ4M2ExMzg5NDY3Mzk2OTlmYWJmZWNiYjg2NmVfMTAtOC0xLTEtMA_272c713b-96e0-4500-847e-b1b25a535a1c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Dilutive potential common shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930" decimals="-5" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185Ny9mcmFnOjRjMDNkMjgxZGNhMDQ1YmViZGUwNzJkM2VmODNjYmFhL3RhYmxlOjI0ZWE0ODNhMTM4OTQ2NzM5Njk5ZmFiZmVjYmI4NjZlL3RhYmxlcmFuZ2U6MjRlYTQ4M2ExMzg5NDY3Mzk2OTlmYWJmZWNiYjg2NmVfMTEtMi0xLTEtMA_ddf3754f-86c7-4e1b-b932-23ef9a6714cb">0.3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930" decimals="-5" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185Ny9mcmFnOjRjMDNkMjgxZGNhMDQ1YmViZGUwNzJkM2VmODNjYmFhL3RhYmxlOjI0ZWE0ODNhMTM4OTQ2NzM5Njk5ZmFiZmVjYmI4NjZlL3RhYmxlcmFuZ2U6MjRlYTQ4M2ExMzg5NDY3Mzk2OTlmYWJmZWNiYjg2NmVfMTEtNC0xLTEtMA_dbdfb71a-d5dd-4c3a-8951-aad7ec48d087">0.2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="-5" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185Ny9mcmFnOjRjMDNkMjgxZGNhMDQ1YmViZGUwNzJkM2VmODNjYmFhL3RhYmxlOjI0ZWE0ODNhMTM4OTQ2NzM5Njk5ZmFiZmVjYmI4NjZlL3RhYmxlcmFuZ2U6MjRlYTQ4M2ExMzg5NDY3Mzk2OTlmYWJmZWNiYjg2NmVfMTEtNi0xLTEtMA_6b10e7ab-da6b-4343-810f-79be84afaa6d">0.3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="-5" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185Ny9mcmFnOjRjMDNkMjgxZGNhMDQ1YmViZGUwNzJkM2VmODNjYmFhL3RhYmxlOjI0ZWE0ODNhMTM4OTQ2NzM5Njk5ZmFiZmVjYmI4NjZlL3RhYmxlcmFuZ2U6MjRlYTQ4M2ExMzg5NDY3Mzk2OTlmYWJmZWNiYjg2NmVfMTEtOC0xLTEtMA_8819ead5-90d3-46b1-8758-732dbcc918f5">0.2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares used in calculating diluted earnings per share</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185Ny9mcmFnOjRjMDNkMjgxZGNhMDQ1YmViZGUwNzJkM2VmODNjYmFhL3RhYmxlOjI0ZWE0ODNhMTM4OTQ2NzM5Njk5ZmFiZmVjYmI4NjZlL3RhYmxlcmFuZ2U6MjRlYTQ4M2ExMzg5NDY3Mzk2OTlmYWJmZWNiYjg2NmVfMTItMi0xLTEtMA_0ec47d91-7ec6-46ff-89ec-919d86d483cb">157.2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185Ny9mcmFnOjRjMDNkMjgxZGNhMDQ1YmViZGUwNzJkM2VmODNjYmFhL3RhYmxlOjI0ZWE0ODNhMTM4OTQ2NzM5Njk5ZmFiZmVjYmI4NjZlL3RhYmxlcmFuZ2U6MjRlYTQ4M2ExMzg5NDY3Mzk2OTlmYWJmZWNiYjg2NmVfMTItNC0xLTEtMA_5fc7afff-22f0-4421-88eb-75c0644b3e39">184.2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185Ny9mcmFnOjRjMDNkMjgxZGNhMDQ1YmViZGUwNzJkM2VmODNjYmFhL3RhYmxlOjI0ZWE0ODNhMTM4OTQ2NzM5Njk5ZmFiZmVjYmI4NjZlL3RhYmxlcmFuZ2U6MjRlYTQ4M2ExMzg5NDY3Mzk2OTlmYWJmZWNiYjg2NmVfMTItNi0xLTEtMA_f2c94287-6cc6-4a92-8804-4c50f78ea647">163.7</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185Ny9mcmFnOjRjMDNkMjgxZGNhMDQ1YmViZGUwNzJkM2VmODNjYmFhL3RhYmxlOjI0ZWE0ODNhMTM4OTQ2NzM5Njk5ZmFiZmVjYmI4NjZlL3RhYmxlcmFuZ2U6MjRlYTQ4M2ExMzg5NDY3Mzk2OTlmYWJmZWNiYjg2NmVfMTItOC0xLTEtMA_8f256159-13c7-4805-bb31-72a7354348cb">190.5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td></tr></table></div></ix:nonNumeric><div style="text-indent:24.75pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Amounts excluded from the calculation of net income per diluted share because their effects were anti-dilutive were insignificant.</span></div></ix:nonNumeric><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">31</span></div></div></div><div id="ib19ff89608c84168a635160f2efa48f3_100"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_7">Table of Contents</a></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(unaudited, continued)</span></div></div><div style="text-indent:-27pt;padding-left:27pt;margin-top:14pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">14.&#160;&#160;&#160;&#160;Share-based Payments </span></div><ix:nonNumeric contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90ZXh0cmVnaW9uOjJmYTQ0NGE0MTFlZTRhNjRhNjUyOWQxOGUzYzdkNWY4XzcwMw_16da9bd6-8111-4f54-a68b-05b3bb786f6b" escape="true"><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Share-based Compensation Expense</span></div><ix:nonNumeric contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90ZXh0cmVnaW9uOjJmYTQ0NGE0MTFlZTRhNjRhNjUyOWQxOGUzYzdkNWY4XzcwNw_23fe1b45-c1ad-4293-9b4d-3a0e3931705b" escape="true"><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes share-based compensation expense included in our condensed consolidated statements of income:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:49.119%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.613%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.613%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.613%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.614%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Three Months Ended September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In millions)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia49dbac3063344639f0b5d7299e025be_D20200701-20200930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTphYzdjMjYwYjI3NmY0MGEyOTE2NzZlYzQzZGVjYmZlNC90YWJsZXJhbmdlOmFjN2MyNjBiMjc2ZjQwYTI5MTY3NmVjNDNkZWNiZmU0XzItMi0xLTEtMA_8be46168-7edd-4087-9c07-7ec17d5f08c3">14.6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iff8fc7508c8d4439986e1175bce454a0_D20190701-20190930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTphYzdjMjYwYjI3NmY0MGEyOTE2NzZlYzQzZGVjYmZlNC90YWJsZXJhbmdlOmFjN2MyNjBiMjc2ZjQwYTI5MTY3NmVjNDNkZWNiZmU0XzItNC0xLTEtMA_59dca612-16ee-4802-abaa-81ac92403e8a">15.4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i107d07150da4422b945e0bd78389de3b_D20200101-20200930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTphYzdjMjYwYjI3NmY0MGEyOTE2NzZlYzQzZGVjYmZlNC90YWJsZXJhbmdlOmFjN2MyNjBiMjc2ZjQwYTI5MTY3NmVjNDNkZWNiZmU0XzItNi0xLTEtMA_fc5123b9-aa60-4321-8128-9a53050c5310">63.1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i909d084c1b604c4bba3bd63551acf4aa_D20190101-20190930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTphYzdjMjYwYjI3NmY0MGEyOTE2NzZlYzQzZGVjYmZlNC90YWJsZXJhbmdlOmFjN2MyNjBiMjc2ZjQwYTI5MTY3NmVjNDNkZWNiZmU0XzItOC0xLTEtMA_b6da47f4-6f28-49ef-923b-8a64f9e1fd53">65.2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Selling, general and administrative</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0bbba4b976ca48c78d5dac97d8fe4cbd_D20200701-20200930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTphYzdjMjYwYjI3NmY0MGEyOTE2NzZlYzQzZGVjYmZlNC90YWJsZXJhbmdlOmFjN2MyNjBiMjc2ZjQwYTI5MTY3NmVjNDNkZWNiZmU0XzMtMi0xLTEtMA_7b522ec0-22dd-492f-9002-129ab562809a">25.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i68ac5428413242c4becdcb7197bed42d_D20190701-20190930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTphYzdjMjYwYjI3NmY0MGEyOTE2NzZlYzQzZGVjYmZlNC90YWJsZXJhbmdlOmFjN2MyNjBiMjc2ZjQwYTI5MTY3NmVjNDNkZWNiZmU0XzMtNC0xLTEtMA_050a99af-41e1-47da-83c8-f3c0e9571d2e">34.2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie898eae73ea9411696b0e278874d55f0_D20200101-20200930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTphYzdjMjYwYjI3NmY0MGEyOTE2NzZlYzQzZGVjYmZlNC90YWJsZXJhbmdlOmFjN2MyNjBiMjc2ZjQwYTI5MTY3NmVjNDNkZWNiZmU0XzMtNi0xLTEtMA_118d1670-56d0-48be-a91f-4a5850b9b978">98.4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iad40dcf3ae2540a2b934514b7ad07c86_D20190101-20190930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTphYzdjMjYwYjI3NmY0MGEyOTE2NzZlYzQzZGVjYmZlNC90YWJsZXJhbmdlOmFjN2MyNjBiMjc2ZjQwYTI5MTY3NmVjNDNkZWNiZmU0XzMtOC0xLTEtMA_01876264-f382-4332-857f-4aa5e64f57f2">116.8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Subtotal</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTphYzdjMjYwYjI3NmY0MGEyOTE2NzZlYzQzZGVjYmZlNC90YWJsZXJhbmdlOmFjN2MyNjBiMjc2ZjQwYTI5MTY3NmVjNDNkZWNiZmU0XzQtMi0xLTEtMA_4aa18fde-4ece-4a5f-88ae-bf99c5226072">39.6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTphYzdjMjYwYjI3NmY0MGEyOTE2NzZlYzQzZGVjYmZlNC90YWJsZXJhbmdlOmFjN2MyNjBiMjc2ZjQwYTI5MTY3NmVjNDNkZWNiZmU0XzQtNC0xLTEtMA_e676d655-ad41-4899-a535-fa7430c93c2e">49.6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTphYzdjMjYwYjI3NmY0MGEyOTE2NzZlYzQzZGVjYmZlNC90YWJsZXJhbmdlOmFjN2MyNjBiMjc2ZjQwYTI5MTY3NmVjNDNkZWNiZmU0XzQtNi0xLTEtMA_44e41f6a-7bdc-4b1f-af75-b9959d4fa403">161.5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTphYzdjMjYwYjI3NmY0MGEyOTE2NzZlYzQzZGVjYmZlNC90YWJsZXJhbmdlOmFjN2MyNjBiMjc2ZjQwYTI5MTY3NmVjNDNkZWNiZmU0XzQtOC0xLTEtMA_e3cf7536-cf0d-457f-8df2-e310091643b8">182.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Capitalized share-based compensation costs </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTphYzdjMjYwYjI3NmY0MGEyOTE2NzZlYzQzZGVjYmZlNC90YWJsZXJhbmdlOmFjN2MyNjBiMjc2ZjQwYTI5MTY3NmVjNDNkZWNiZmU0XzUtMi0xLTEtMA_79762fc9-b721-42a1-a14d-fa32389d0c68">1.9</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTphYzdjMjYwYjI3NmY0MGEyOTE2NzZlYzQzZGVjYmZlNC90YWJsZXJhbmdlOmFjN2MyNjBiMjc2ZjQwYTI5MTY3NmVjNDNkZWNiZmU0XzUtNC0xLTEtMA_6c6c0065-bc1e-42c9-85fc-fa215e357660">1.7</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTphYzdjMjYwYjI3NmY0MGEyOTE2NzZlYzQzZGVjYmZlNC90YWJsZXJhbmdlOmFjN2MyNjBiMjc2ZjQwYTI5MTY3NmVjNDNkZWNiZmU0XzUtNi0xLTEtMA_536fee6c-9ee8-44af-aee0-0972077d82cb">4.9</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTphYzdjMjYwYjI3NmY0MGEyOTE2NzZlYzQzZGVjYmZlNC90YWJsZXJhbmdlOmFjN2MyNjBiMjc2ZjQwYTI5MTY3NmVjNDNkZWNiZmU0XzUtOC0xLTEtMA_5cf63248-a916-4ce2-83d2-c206aae64a07">7.8</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Share-based compensation expense included in total cost and expenses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930" decimals="-5" name="biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTphYzdjMjYwYjI3NmY0MGEyOTE2NzZlYzQzZGVjYmZlNC90YWJsZXJhbmdlOmFjN2MyNjBiMjc2ZjQwYTI5MTY3NmVjNDNkZWNiZmU0XzYtMi0xLTEtMA_ec173777-3c2c-440c-9bc7-065193278aab">37.7</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930" decimals="-5" name="biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTphYzdjMjYwYjI3NmY0MGEyOTE2NzZlYzQzZGVjYmZlNC90YWJsZXJhbmdlOmFjN2MyNjBiMjc2ZjQwYTI5MTY3NmVjNDNkZWNiZmU0XzYtNC0xLTEtMA_beddc902-c425-4563-83b9-96c4b839966d">47.9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="-5" name="biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTphYzdjMjYwYjI3NmY0MGEyOTE2NzZlYzQzZGVjYmZlNC90YWJsZXJhbmdlOmFjN2MyNjBiMjc2ZjQwYTI5MTY3NmVjNDNkZWNiZmU0XzYtNi0xLTEtMA_33eb72af-c109-43e7-b18f-3e45fa426a3f">156.6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="-5" name="biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTphYzdjMjYwYjI3NmY0MGEyOTE2NzZlYzQzZGVjYmZlNC90YWJsZXJhbmdlOmFjN2MyNjBiMjc2ZjQwYTI5MTY3NmVjNDNkZWNiZmU0XzYtOC0xLTEtMA_8f75e212-bac8-414b-b3d0-e704d0d608e6">174.2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income tax effect</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTphYzdjMjYwYjI3NmY0MGEyOTE2NzZlYzQzZGVjYmZlNC90YWJsZXJhbmdlOmFjN2MyNjBiMjc2ZjQwYTI5MTY3NmVjNDNkZWNiZmU0XzctMi0xLTEtMA_7603c539-2c4a-499c-98c6-ec611fb57153">5.4</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTphYzdjMjYwYjI3NmY0MGEyOTE2NzZlYzQzZGVjYmZlNC90YWJsZXJhbmdlOmFjN2MyNjBiMjc2ZjQwYTI5MTY3NmVjNDNkZWNiZmU0XzctNC0xLTEtMA_aa08f694-bca4-47bb-acf2-85df087eb2a8">8.1</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTphYzdjMjYwYjI3NmY0MGEyOTE2NzZlYzQzZGVjYmZlNC90YWJsZXJhbmdlOmFjN2MyNjBiMjc2ZjQwYTI5MTY3NmVjNDNkZWNiZmU0XzctNi0xLTEtMA_b3317d0b-3c6c-439b-a35d-f5835464969e">25.7</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTphYzdjMjYwYjI3NmY0MGEyOTE2NzZlYzQzZGVjYmZlNC90YWJsZXJhbmdlOmFjN2MyNjBiMjc2ZjQwYTI5MTY3NmVjNDNkZWNiZmU0XzctOC0xLTEtMA_809a0ea6-8ede-4f65-adbe-0d7e7bc187e1">29.1</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Share-based compensation expense included in net income attributable to Biogen Inc.</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibdd3d4a6db7c4fd4bf7c980b55c5fecd_D20200701-20200930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTphYzdjMjYwYjI3NmY0MGEyOTE2NzZlYzQzZGVjYmZlNC90YWJsZXJhbmdlOmFjN2MyNjBiMjc2ZjQwYTI5MTY3NmVjNDNkZWNiZmU0XzgtMi0xLTEtMA_c1736678-1c6f-4757-961a-2f9bb810bf4e">32.3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i81789b07b22446a88e13e5c1075d8cb7_D20190701-20190930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTphYzdjMjYwYjI3NmY0MGEyOTE2NzZlYzQzZGVjYmZlNC90YWJsZXJhbmdlOmFjN2MyNjBiMjc2ZjQwYTI5MTY3NmVjNDNkZWNiZmU0XzgtNC0xLTEtMA_04300ce9-5ee6-46a3-90fd-6b783e45ea84">39.8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id915b8aebcff4bc2a81caf9b4de54dd7_D20200101-20200930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTphYzdjMjYwYjI3NmY0MGEyOTE2NzZlYzQzZGVjYmZlNC90YWJsZXJhbmdlOmFjN2MyNjBiMjc2ZjQwYTI5MTY3NmVjNDNkZWNiZmU0XzgtNi0xLTEtMA_adb344e4-8285-4966-913a-ca7b0ed780f6">130.9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8ca00e2a1cc04153858959116600cdcd_D20190101-20190930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTphYzdjMjYwYjI3NmY0MGEyOTE2NzZlYzQzZGVjYmZlNC90YWJsZXJhbmdlOmFjN2MyNjBiMjc2ZjQwYTI5MTY3NmVjNDNkZWNiZmU0XzgtOC0xLTEtMA_95512d9d-6aa3-4508-8476-129ab81a0047">145.1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90ZXh0cmVnaW9uOjJmYTQ0NGE0MTFlZTRhNjRhNjUyOWQxOGUzYzdkNWY4XzcyMA_e6b3e354-f14c-40c6-8273-0657d8a0aa87" escape="true"><div style="text-indent:24.75pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:49.119%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.613%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.613%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.613%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.614%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Three Months Ended September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In millions)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Market stock units</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8ba330fe0fb04518b2ecb6db02b6b97f_D20200701-20200930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTo0ZDIwYzVkMWQyM2Q0ZmY2OGZmYWZhZDE0MGYzNmRkYy90YWJsZXJhbmdlOjRkMjBjNWQxZDIzZDRmZjY4ZmZhZmFkMTQwZjM2ZGRjXzItMi0xLTEtMA_f59a4d51-e170-46f5-a3c9-f00b77633db5">5.5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4e192d624f87417a8539bc84a2a459ff_D20190701-20190930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTo0ZDIwYzVkMWQyM2Q0ZmY2OGZmYWZhZDE0MGYzNmRkYy90YWJsZXJhbmdlOjRkMjBjNWQxZDIzZDRmZjY4ZmZhZmFkMTQwZjM2ZGRjXzItNC0xLTEtMA_b484c7b3-0dcd-409c-a3f6-7ee53e50f125">9.3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if04752de82454bad9a9a42a0c78ff53b_D20200101-20200930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTo0ZDIwYzVkMWQyM2Q0ZmY2OGZmYWZhZDE0MGYzNmRkYy90YWJsZXJhbmdlOjRkMjBjNWQxZDIzZDRmZjY4ZmZhZmFkMTQwZjM2ZGRjXzItNi0xLTEtMA_9e1125d7-7765-489c-83be-a98fc384c613">32.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i493634946d8c4db49d02e47be89e303e_D20190101-20190930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTo0ZDIwYzVkMWQyM2Q0ZmY2OGZmYWZhZDE0MGYzNmRkYy90YWJsZXJhbmdlOjRkMjBjNWQxZDIzZDRmZjY4ZmZhZmFkMTQwZjM2ZGRjXzItOC0xLTEtMA_eb7e1402-63f4-44fa-88fe-cb1e285d8ab5">24.8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Time-vested restricted stock units</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibed3bf29e7374cc8b7f86449cbcbaa3a_D20200701-20200930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTo0ZDIwYzVkMWQyM2Q0ZmY2OGZmYWZhZDE0MGYzNmRkYy90YWJsZXJhbmdlOjRkMjBjNWQxZDIzZDRmZjY4ZmZhZmFkMTQwZjM2ZGRjXzMtMi0xLTEtMA_00005a90-565e-470b-aa26-be0ea7c184cd">35.3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2cfe6ff0db44473e979cfeaa03760ded_D20190701-20190930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTo0ZDIwYzVkMWQyM2Q0ZmY2OGZmYWZhZDE0MGYzNmRkYy90YWJsZXJhbmdlOjRkMjBjNWQxZDIzZDRmZjY4ZmZhZmFkMTQwZjM2ZGRjXzMtNC0xLTEtMA_7db8408a-f093-44b9-b9fb-f4690faecda1">37.9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iea41c7a4bbf94cfc8a16ac421e7cc25d_D20200101-20200930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTo0ZDIwYzVkMWQyM2Q0ZmY2OGZmYWZhZDE0MGYzNmRkYy90YWJsZXJhbmdlOjRkMjBjNWQxZDIzZDRmZjY4ZmZhZmFkMTQwZjM2ZGRjXzMtNi0xLTEtMA_f772564b-adcc-44fc-9fd4-6b868ebf9822">107.3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7e43143e39df4b0cbb78c046a10aa64f_D20190101-20190930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTo0ZDIwYzVkMWQyM2Q0ZmY2OGZmYWZhZDE0MGYzNmRkYy90YWJsZXJhbmdlOjRkMjBjNWQxZDIzZDRmZjY4ZmZhZmFkMTQwZjM2ZGRjXzMtOC0xLTEtMA_d2c6d1e7-4028-4393-9efe-78415f13dde3">104.4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash settled performance units</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i96a2e794f31f442ebbb83e8f8c7d54bd_D20200701-20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTo0ZDIwYzVkMWQyM2Q0ZmY2OGZmYWZhZDE0MGYzNmRkYy90YWJsZXJhbmdlOjRkMjBjNWQxZDIzZDRmZjY4ZmZhZmFkMTQwZjM2ZGRjXzQtMi0xLTEtMA_c085e734-d6de-4996-a1c5-8006ee404ad4">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icc0ae96137314a759fb1044af70f2b95_D20190701-20190930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTo0ZDIwYzVkMWQyM2Q0ZmY2OGZmYWZhZDE0MGYzNmRkYy90YWJsZXJhbmdlOjRkMjBjNWQxZDIzZDRmZjY4ZmZhZmFkMTQwZjM2ZGRjXzQtNC0xLTEtMA_51339632-832f-4da0-841a-2b59062cf06a">0.3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i009b72f35e694a53ae5120480a467b8f_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTo0ZDIwYzVkMWQyM2Q0ZmY2OGZmYWZhZDE0MGYzNmRkYy90YWJsZXJhbmdlOjRkMjBjNWQxZDIzZDRmZjY4ZmZhZmFkMTQwZjM2ZGRjXzQtNi0xLTEtMA_0ac22cb9-a51f-49ba-9421-228090d8dceb">1.7</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia8cb99b7e0ae45fc98016744d8331c55_D20190101-20190930" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTo0ZDIwYzVkMWQyM2Q0ZmY2OGZmYWZhZDE0MGYzNmRkYy90YWJsZXJhbmdlOjRkMjBjNWQxZDIzZDRmZjY4ZmZhZmFkMTQwZjM2ZGRjXzQtOC0xLTEtMA_74e61451-383f-43ae-8704-31ef4091deb1">0.3</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Performance units</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic61fb76b8e77432fb9579a89baff9f36_D20200701-20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTo0ZDIwYzVkMWQyM2Q0ZmY2OGZmYWZhZDE0MGYzNmRkYy90YWJsZXJhbmdlOjRkMjBjNWQxZDIzZDRmZjY4ZmZhZmFkMTQwZjM2ZGRjXzUtMi0xLTEtMA_076c40be-1c1d-4f47-86e6-afa1bdeb4ada">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5d623e1e956a426c9eb2bc18c5c9015c_D20190701-20190930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTo0ZDIwYzVkMWQyM2Q0ZmY2OGZmYWZhZDE0MGYzNmRkYy90YWJsZXJhbmdlOjRkMjBjNWQxZDIzZDRmZjY4ZmZhZmFkMTQwZjM2ZGRjXzUtNC0xLTEtMA_f50bd205-3e00-49a3-9853-7e1f80e45304">0.2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i65d9cd4367bc445dbfb50901412a5ada_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTo0ZDIwYzVkMWQyM2Q0ZmY2OGZmYWZhZDE0MGYzNmRkYy90YWJsZXJhbmdlOjRkMjBjNWQxZDIzZDRmZjY4ZmZhZmFkMTQwZjM2ZGRjXzUtNi0xLTEtMA_3c409fad-41a9-4220-8e44-2228832f4044">0.1</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic0de115d377b4cfa9b3de1dd0bfd3954_D20190101-20190930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTo0ZDIwYzVkMWQyM2Q0ZmY2OGZmYWZhZDE0MGYzNmRkYy90YWJsZXJhbmdlOjRkMjBjNWQxZDIzZDRmZjY4ZmZhZmFkMTQwZjM2ZGRjXzUtOC0xLTEtMA_181fc03d-f4ba-43b4-bded-06e28e510ae8">1.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Performance stock units settled in stock</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if2c78ceb3d6b4fd69507a611127e10d7_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTo0ZDIwYzVkMWQyM2Q0ZmY2OGZmYWZhZDE0MGYzNmRkYy90YWJsZXJhbmdlOjRkMjBjNWQxZDIzZDRmZjY4ZmZhZmFkMTQwZjM2ZGRjXzYtMi0xLTEtMA_c5d36049-d2e1-4301-ae6c-25f953b2d848">8.4</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1d5c287e1fde4ffdb4bdc39ad45f29d2_D20190701-20190930" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTo0ZDIwYzVkMWQyM2Q0ZmY2OGZmYWZhZDE0MGYzNmRkYy90YWJsZXJhbmdlOjRkMjBjNWQxZDIzZDRmZjY4ZmZhZmFkMTQwZjM2ZGRjXzYtNC0xLTEtMA_20932bbf-1eef-46c3-9f75-d3217f3d2505">1.1</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i94ecbbbd615e4be087860504badd0ccd_D20200101-20200930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTo0ZDIwYzVkMWQyM2Q0ZmY2OGZmYWZhZDE0MGYzNmRkYy90YWJsZXJhbmdlOjRkMjBjNWQxZDIzZDRmZjY4ZmZhZmFkMTQwZjM2ZGRjXzYtNi0xLTEtMA_08091563-4945-4eee-a027-e6d3722a485b">4.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic2ec445a7fb2422f8f336348f12e3320_D20190101-20190930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTo0ZDIwYzVkMWQyM2Q0ZmY2OGZmYWZhZDE0MGYzNmRkYy90YWJsZXJhbmdlOjRkMjBjNWQxZDIzZDRmZjY4ZmZhZmFkMTQwZjM2ZGRjXzYtOC0xLTEtMA_706fb768-a286-4c55-9c55-d4872d998d72">13.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Performance stock units settled in cash</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ice7a7bfef4564888a80b19f37ff797b0_D20200701-20200930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTo0ZDIwYzVkMWQyM2Q0ZmY2OGZmYWZhZDE0MGYzNmRkYy90YWJsZXJhbmdlOjRkMjBjNWQxZDIzZDRmZjY4ZmZhZmFkMTQwZjM2ZGRjXzctMi0xLTEtMA_30afba2f-8458-4ff4-90f8-1df6e5b59e84">4.1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifeaa9653fb8c46b19f65a83276d1bcde_D20190701-20190930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTo0ZDIwYzVkMWQyM2Q0ZmY2OGZmYWZhZDE0MGYzNmRkYy90YWJsZXJhbmdlOjRkMjBjNWQxZDIzZDRmZjY4ZmZhZmFkMTQwZjM2ZGRjXzctNC0xLTEtMA_36adecc6-0588-4ef2-b2f8-b2011e1722f9">1.3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6602e12ee323468e9711c40286f62de7_D20200101-20200930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTo0ZDIwYzVkMWQyM2Q0ZmY2OGZmYWZhZDE0MGYzNmRkYy90YWJsZXJhbmdlOjRkMjBjNWQxZDIzZDRmZjY4ZmZhZmFkMTQwZjM2ZGRjXzctNi0xLTEtMA_f9f7759a-4e3b-4d69-b89e-fa7d54c1e976">9.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0dbcccb9a5554bba8ddbf97064cb4c88_D20190101-20190930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTo0ZDIwYzVkMWQyM2Q0ZmY2OGZmYWZhZDE0MGYzNmRkYy90YWJsZXJhbmdlOjRkMjBjNWQxZDIzZDRmZjY4ZmZhZmFkMTQwZjM2ZGRjXzctOC0xLTEtMA_3d67cde3-08c7-49f2-849b-c6201874d1a4">3.2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Employee stock purchase plan</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i73c8b3f596bb4630bfc6f91e336d5637_D20200701-20200930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTo0ZDIwYzVkMWQyM2Q0ZmY2OGZmYWZhZDE0MGYzNmRkYy90YWJsZXJhbmdlOjRkMjBjNWQxZDIzZDRmZjY4ZmZhZmFkMTQwZjM2ZGRjXzgtMi0xLTEtMA_adfe0019-a42b-4662-88c3-8e9bd8db87c2">3.1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0bd41977205f4c6e822e027dc9f7178f_D20190701-20190930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTo0ZDIwYzVkMWQyM2Q0ZmY2OGZmYWZhZDE0MGYzNmRkYy90YWJsZXJhbmdlOjRkMjBjNWQxZDIzZDRmZjY4ZmZhZmFkMTQwZjM2ZGRjXzgtNC0xLTEtMA_ec0307c4-3f58-45f1-a5b5-d4a7d421a883">1.7</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8c21b1e012c34659a43ce91c598b6e19_D20200101-20200930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTo0ZDIwYzVkMWQyM2Q0ZmY2OGZmYWZhZDE0MGYzNmRkYy90YWJsZXJhbmdlOjRkMjBjNWQxZDIzZDRmZjY4ZmZhZmFkMTQwZjM2ZGRjXzgtNi0xLTEtMA_1523f3db-4ebf-4fcc-a943-b736feec9653">11.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id073fd8d3b31491aacf37c244aa1d475_D20190101-20190930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTo0ZDIwYzVkMWQyM2Q0ZmY2OGZmYWZhZDE0MGYzNmRkYy90YWJsZXJhbmdlOjRkMjBjNWQxZDIzZDRmZjY4ZmZhZmFkMTQwZjM2ZGRjXzgtOC0xLTEtMA_32131a42-55d6-432e-9da1-2569df8e1f05">9.7</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">NST stock options</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i83240f344bc5485bb5ee15a465ba0ad3_D20200701-20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTo0ZDIwYzVkMWQyM2Q0ZmY2OGZmYWZhZDE0MGYzNmRkYy90YWJsZXJhbmdlOjRkMjBjNWQxZDIzZDRmZjY4ZmZhZmFkMTQwZjM2ZGRjXzktMi0xLTEtMA_03589060-9120-4875-bd27-0fff0f79e7f8">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id6c80504460b4030869aa8a24e3babf4_D20190701-20190930" decimals="-5" format="ixt:zerodash" name="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTo0ZDIwYzVkMWQyM2Q0ZmY2OGZmYWZhZDE0MGYzNmRkYy90YWJsZXJhbmdlOjRkMjBjNWQxZDIzZDRmZjY4ZmZhZmFkMTQwZjM2ZGRjXzktNC0xLTEtMA_2c6835fc-c635-4ab1-800d-202751b221c6">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5c634f032c59460488c598097bac861e_D20200101-20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTo0ZDIwYzVkMWQyM2Q0ZmY2OGZmYWZhZDE0MGYzNmRkYy90YWJsZXJhbmdlOjRkMjBjNWQxZDIzZDRmZjY4ZmZhZmFkMTQwZjM2ZGRjXzktNi0xLTEtMA_2ef3bb81-0444-4776-8110-df34e356c5eb">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i82c5ee63475c42b9be7685ee220cdbde_D20190101-20190930" decimals="-5" name="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTo0ZDIwYzVkMWQyM2Q0ZmY2OGZmYWZhZDE0MGYzNmRkYy90YWJsZXJhbmdlOjRkMjBjNWQxZDIzZDRmZjY4ZmZhZmFkMTQwZjM2ZGRjXzktOC0xLTEtMA_bfeff8cb-7c8e-45ba-b736-04139bc82673">26.2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Subtotal</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTo0ZDIwYzVkMWQyM2Q0ZmY2OGZmYWZhZDE0MGYzNmRkYy90YWJsZXJhbmdlOjRkMjBjNWQxZDIzZDRmZjY4ZmZhZmFkMTQwZjM2ZGRjXzEwLTItMS0xLTA_b24ead94-f03e-4a5c-9163-454fb685f538">39.6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTo0ZDIwYzVkMWQyM2Q0ZmY2OGZmYWZhZDE0MGYzNmRkYy90YWJsZXJhbmdlOjRkMjBjNWQxZDIzZDRmZjY4ZmZhZmFkMTQwZjM2ZGRjXzEwLTQtMS0xLTA_f20e9640-fb29-403c-8471-c6f4d212c248">49.6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTo0ZDIwYzVkMWQyM2Q0ZmY2OGZmYWZhZDE0MGYzNmRkYy90YWJsZXJhbmdlOjRkMjBjNWQxZDIzZDRmZjY4ZmZhZmFkMTQwZjM2ZGRjXzEwLTYtMS0xLTA_788f3a25-bac4-4644-97de-0d0f94899877">161.5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTo0ZDIwYzVkMWQyM2Q0ZmY2OGZmYWZhZDE0MGYzNmRkYy90YWJsZXJhbmdlOjRkMjBjNWQxZDIzZDRmZjY4ZmZhZmFkMTQwZjM2ZGRjXzEwLTgtMS0xLTA_5e35db3c-5bbe-4f10-8023-22a8f69ddc05">182.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Capitalized share-based compensation costs</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTo0ZDIwYzVkMWQyM2Q0ZmY2OGZmYWZhZDE0MGYzNmRkYy90YWJsZXJhbmdlOjRkMjBjNWQxZDIzZDRmZjY4ZmZhZmFkMTQwZjM2ZGRjXzExLTItMS0xLTA_645eda68-8d43-47ce-a9dd-5623c5a3737d">1.9</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTo0ZDIwYzVkMWQyM2Q0ZmY2OGZmYWZhZDE0MGYzNmRkYy90YWJsZXJhbmdlOjRkMjBjNWQxZDIzZDRmZjY4ZmZhZmFkMTQwZjM2ZGRjXzExLTQtMS0xLTA_634282ab-216d-464f-aac5-9aa6b793430d">1.7</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTo0ZDIwYzVkMWQyM2Q0ZmY2OGZmYWZhZDE0MGYzNmRkYy90YWJsZXJhbmdlOjRkMjBjNWQxZDIzZDRmZjY4ZmZhZmFkMTQwZjM2ZGRjXzExLTYtMS0xLTA_d345cc92-3e48-4d66-a8bc-5753de15ee2b">4.9</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTo0ZDIwYzVkMWQyM2Q0ZmY2OGZmYWZhZDE0MGYzNmRkYy90YWJsZXJhbmdlOjRkMjBjNWQxZDIzZDRmZjY4ZmZhZmFkMTQwZjM2ZGRjXzExLTgtMS0xLTA_757e142f-e1c2-4c49-a753-db0207ac5f39">7.8</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Share-based compensation expense included in total cost and expenses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930" decimals="-5" name="biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTo0ZDIwYzVkMWQyM2Q0ZmY2OGZmYWZhZDE0MGYzNmRkYy90YWJsZXJhbmdlOjRkMjBjNWQxZDIzZDRmZjY4ZmZhZmFkMTQwZjM2ZGRjXzEyLTItMS0xLTA_6d4ec91b-0800-4533-b983-625ca1017d43">37.7</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930" decimals="-5" name="biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTo0ZDIwYzVkMWQyM2Q0ZmY2OGZmYWZhZDE0MGYzNmRkYy90YWJsZXJhbmdlOjRkMjBjNWQxZDIzZDRmZjY4ZmZhZmFkMTQwZjM2ZGRjXzEyLTQtMS0xLTA_8aba01c6-b18c-4ea8-8bd5-88cc41c03f9f">47.9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="-5" name="biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTo0ZDIwYzVkMWQyM2Q0ZmY2OGZmYWZhZDE0MGYzNmRkYy90YWJsZXJhbmdlOjRkMjBjNWQxZDIzZDRmZjY4ZmZhZmFkMTQwZjM2ZGRjXzEyLTYtMS0xLTA_2ecbd806-915a-4ea2-bcd0-6dee541b05ca">156.6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="-5" name="biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTo0ZDIwYzVkMWQyM2Q0ZmY2OGZmYWZhZDE0MGYzNmRkYy90YWJsZXJhbmdlOjRkMjBjNWQxZDIzZDRmZjY4ZmZhZmFkMTQwZjM2ZGRjXzEyLTgtMS0xLTA_6fbc337b-93f4-4b64-a9f9-7a8bde318d35">174.2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td></tr></table></div></ix:nonNumeric><div style="text-indent:24.75pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We estimate the fair value of our obligations associated with our performance units settled in cash at the end of each reporting period through expected settlement.&#160;Cumulative adjustments to these obligations are recognized each quarter to reflect changes in the stock price and estimated outcome of the performance-related conditions.</span></div></ix:nonNumeric><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">32</span></div></div></div><div id="ib19ff89608c84168a635160f2efa48f3_103"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_7">Table of Contents</a></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(unaudited, continued)</span></div></div><div style="text-indent:-27pt;padding-left:27pt;margin-top:14pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">15.&#160;&#160;&#160;&#160;Income Taxes </span></div><ix:nonNumeric contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90ZXh0cmVnaW9uOjBjNWQ3YWE1NzU0MjRmYWViNjE3OWFjMDU1ZWQ5NzAyXzYyNjI_88efb90a-166b-4021-a6f7-cf364272027c" continuedAt="i9148ae53668448ce88df922dc3dc4d19" escape="true"><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Coronavirus Aid, Relief and Economic Security Act</span></div><div style="text-indent:22.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In response to the COVID-19 pandemic, the Coronavirus Aid, Relief and Economic Security Act (CARES Act) was signed into law in the U.S. in March 2020. The CARES Act adjusted a number of provisions of the tax code, including the calculation and eligibility of certain deductions and the treatment of net operating losses and tax credits. The enactment of the CARES Act did not result in any material adjustments to our income tax provision for the three and nine months ended September 30, 2020, or to our net deferred tax assets as of September 30, 2020.</span></div><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">TECFIDERA</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2020 and September 2020 judgments were entered in favor of the defendants in the patent infringement proceedings relating to TECFIDERA Orange-Book listed patents pursuant to the Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch-Waxman Act, in West Virginia and Delaware. We have appealed the judgments in both actions. For additional information, please read </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Note 19, Litigation,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> to these condensed consolidated financial statements.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Multiple TECFIDERA generic entrants are now in the U.S. market, some of which have deeply discounted prices compared to TECFIDERA. The generic competition for TECFIDERA significantly reduced our TECFIDERA revenues during the third quarter of 2020 and is expected to have a substantial negative impact on our TECFIDERA revenues for as long as there is generic competition.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of September 30, 2020, we have assessed the realizability of our deferred tax assets that are dependent on future expected sales of TECFIDERA in the U.S. and reduced the value of certain deferred tax assets by approximately $<ix:nonFraction unitRef="usd" contextRef="i14dd3353e0b54676b5186391520f2af5_I20200930" decimals="-5" format="ixt:numdotdecimal" name="biib:DeferredTaxAssetsValueReductioninValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90ZXh0cmVnaW9uOjBjNWQ3YWE1NzU0MjRmYWViNjE3OWFjMDU1ZWQ5NzAyXzI5OTY_653ede91-bb7a-48ae-9af7-cf98fcbe8342">1,627.9</ix:nonFraction> million and reduced the value of deferred tax liabilities associated with global intangible low-taxed income (GILTI) and tax credits by approximately $<ix:nonFraction unitRef="usd" contextRef="i14dd3353e0b54676b5186391520f2af5_I20200930" decimals="-5" format="ixt:numdotdecimal" name="biib:DeferredTaxLiabilitiesValueReductioninValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90ZXh0cmVnaW9uOjBjNWQ3YWE1NzU0MjRmYWViNjE3OWFjMDU1ZWQ5NzAyXzMxNDE_d1a66525-03de-404d-b83e-4a8d3609e1dc">1,538.6</ix:nonFraction> million. For the three and nine months ended September 30, 2020, the income tax expense associated with these reductions was approximately $<ix:nonFraction unitRef="usd" contextRef="i289872ca5f294cb881aceaa6ffd07da1_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="biib:IncomeTaxExpenseReductioninDeferredTaxAssetsandLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90ZXh0cmVnaW9uOjBjNWQ3YWE1NzU0MjRmYWViNjE3OWFjMDU1ZWQ5NzAyXzMyNTQ_e88f8798-ce36-4c2d-b481-c3871d70a7c3">33.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i1cf49fa7c600408b8cf5254dbc554986_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="biib:IncomeTaxExpenseReductioninDeferredTaxAssetsandLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90ZXh0cmVnaW9uOjBjNWQ3YWE1NzU0MjRmYWViNjE3OWFjMDU1ZWQ5NzAyXzEwOTk1MTE2MzQxMTU_81bf64d4-83bc-4c27-aba1-fc39f87a1ced">89.3</ix:nonFraction>&#160;million, respectively. </span></div><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Tax Rate</span></div><ix:nonNumeric contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90ZXh0cmVnaW9uOjBjNWQ3YWE1NzU0MjRmYWViNjE3OWFjMDU1ZWQ5NzAyXzYyNjA_4fa41597-2b76-446a-80df-a68bfd254bba" escape="true"><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A reconciliation between the U.S.&#160;federal statutory tax rate and our effective tax rate is summarized as follows:</span></div><div style="text-align:justify;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:44.514%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.350%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.350%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.619%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.384%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.623%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Three Months Ended September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Statutory rate</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90YWJsZTo3YTA2MzIyNzBmMzM0ZjYzODNhNTZiZWNkMzE1ZmJjZS90YWJsZXJhbmdlOjdhMDYzMjI3MGYzMzRmNjM4M2E1NmJlY2QzMTVmYmNlXzItMS0xLTEtMA_74d7cedf-a87d-4fa1-b2ab-a0f0b1b1c8c2">21.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90YWJsZTo3YTA2MzIyNzBmMzM0ZjYzODNhNTZiZWNkMzE1ZmJjZS90YWJsZXJhbmdlOjdhMDYzMjI3MGYzMzRmNjM4M2E1NmJlY2QzMTVmYmNlXzItMy0xLTEtMA_3a9e8f1d-acf9-435d-835c-3824815ffd17">21.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90YWJsZTo3YTA2MzIyNzBmMzM0ZjYzODNhNTZiZWNkMzE1ZmJjZS90YWJsZXJhbmdlOjdhMDYzMjI3MGYzMzRmNjM4M2E1NmJlY2QzMTVmYmNlXzItNS0xLTEtMA_fc19ddae-d4a2-43ed-ac48-770e3c067bfb">21.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90YWJsZTo3YTA2MzIyNzBmMzM0ZjYzODNhNTZiZWNkMzE1ZmJjZS90YWJsZXJhbmdlOjdhMDYzMjI3MGYzMzRmNjM4M2E1NmJlY2QzMTVmYmNlXzItNy0xLTEtMA_5a60f451-230a-4bfe-937b-eecd2722064a">21.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">State taxes</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90YWJsZTo3YTA2MzIyNzBmMzM0ZjYzODNhNTZiZWNkMzE1ZmJjZS90YWJsZXJhbmdlOjdhMDYzMjI3MGYzMzRmNjM4M2E1NmJlY2QzMTVmYmNlXzMtMS0xLTEtMA_4474e265-eac0-4d2c-bb82-c17ad8ec6bea">0.9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90YWJsZTo3YTA2MzIyNzBmMzM0ZjYzODNhNTZiZWNkMzE1ZmJjZS90YWJsZXJhbmdlOjdhMDYzMjI3MGYzMzRmNjM4M2E1NmJlY2QzMTVmYmNlXzMtMy0xLTEtMA_8be6bf49-a357-4290-95e1-635cd8531257">0.9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90YWJsZTo3YTA2MzIyNzBmMzM0ZjYzODNhNTZiZWNkMzE1ZmJjZS90YWJsZXJhbmdlOjdhMDYzMjI3MGYzMzRmNjM4M2E1NmJlY2QzMTVmYmNlXzMtNS0xLTEtMA_72533fc5-df28-4bd7-9a93-47568bbe1df4">0.6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90YWJsZTo3YTA2MzIyNzBmMzM0ZjYzODNhNTZiZWNkMzE1ZmJjZS90YWJsZXJhbmdlOjdhMDYzMjI3MGYzMzRmNjM4M2E1NmJlY2QzMTVmYmNlXzMtNy0xLTEtMA_c0eaad23-50e6-441c-b4f0-3729d8a454b6">0.7</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Taxes on foreign earnings</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="number" contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90YWJsZTo3YTA2MzIyNzBmMzM0ZjYzODNhNTZiZWNkMzE1ZmJjZS90YWJsZXJhbmdlOjdhMDYzMjI3MGYzMzRmNjM4M2E1NmJlY2QzMTVmYmNlXzQtMS0xLTEtMA_8e70ad3f-11c7-4b9e-8ca7-ebd0ddfd673c">3.0</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="number" contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90YWJsZTo3YTA2MzIyNzBmMzM0ZjYzODNhNTZiZWNkMzE1ZmJjZS90YWJsZXJhbmdlOjdhMDYzMjI3MGYzMzRmNjM4M2E1NmJlY2QzMTVmYmNlXzQtMy0xLTEtMA_97d0a73a-e0bf-46e0-818e-697536e4d8fd">5.0</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="number" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90YWJsZTo3YTA2MzIyNzBmMzM0ZjYzODNhNTZiZWNkMzE1ZmJjZS90YWJsZXJhbmdlOjdhMDYzMjI3MGYzMzRmNjM4M2E1NmJlY2QzMTVmYmNlXzQtNS0xLTEtMA_4bcaa2ea-d916-47c4-a5eb-f29d2b745732">3.6</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="number" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90YWJsZTo3YTA2MzIyNzBmMzM0ZjYzODNhNTZiZWNkMzE1ZmJjZS90YWJsZXJhbmdlOjdhMDYzMjI3MGYzMzRmNjM4M2E1NmJlY2QzMTVmYmNlXzQtNy0xLTEtMA_e4075ca0-c15f-447f-aafc-f6a23960f6b2">4.7</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Tax credits</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="number" contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90YWJsZTo3YTA2MzIyNzBmMzM0ZjYzODNhNTZiZWNkMzE1ZmJjZS90YWJsZXJhbmdlOjdhMDYzMjI3MGYzMzRmNjM4M2E1NmJlY2QzMTVmYmNlXzUtMS0xLTEtMA_3d463eff-4e87-4afd-ac50-ce20f661923a">2.3</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="number" contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90YWJsZTo3YTA2MzIyNzBmMzM0ZjYzODNhNTZiZWNkMzE1ZmJjZS90YWJsZXJhbmdlOjdhMDYzMjI3MGYzMzRmNjM4M2E1NmJlY2QzMTVmYmNlXzUtMy0xLTEtMA_ac8746d0-e340-45e6-a829-24c95430f8a4">1.5</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="number" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90YWJsZTo3YTA2MzIyNzBmMzM0ZjYzODNhNTZiZWNkMzE1ZmJjZS90YWJsZXJhbmdlOjdhMDYzMjI3MGYzMzRmNjM4M2E1NmJlY2QzMTVmYmNlXzUtNS0xLTEtMA_7c428ca1-2374-446e-b38a-ca4469cd944d">1.3</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="number" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90YWJsZTo3YTA2MzIyNzBmMzM0ZjYzODNhNTZiZWNkMzE1ZmJjZS90YWJsZXJhbmdlOjdhMDYzMjI3MGYzMzRmNjM4M2E1NmJlY2QzMTVmYmNlXzUtNy0xLTEtMA_51e12d19-576d-46e5-8067-541da65077fe">1.0</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Purchased intangible assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90YWJsZTo3YTA2MzIyNzBmMzM0ZjYzODNhNTZiZWNkMzE1ZmJjZS90YWJsZXJhbmdlOjdhMDYzMjI3MGYzMzRmNjM4M2E1NmJlY2QzMTVmYmNlXzYtMS0xLTEtMA_31706572-8439-4c37-9128-22449b7bd3f4">2.9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90YWJsZTo3YTA2MzIyNzBmMzM0ZjYzODNhNTZiZWNkMzE1ZmJjZS90YWJsZXJhbmdlOjdhMDYzMjI3MGYzMzRmNjM4M2E1NmJlY2QzMTVmYmNlXzYtMy0xLTEtMA_00d1369a-d2f4-400a-8242-896332fe33a2">0.4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90YWJsZTo3YTA2MzIyNzBmMzM0ZjYzODNhNTZiZWNkMzE1ZmJjZS90YWJsZXJhbmdlOjdhMDYzMjI3MGYzMzRmNjM4M2E1NmJlY2QzMTVmYmNlXzYtNS0xLTEtMA_5cba32bd-4cbb-454e-91ed-0448f2459e93">0.8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90YWJsZTo3YTA2MzIyNzBmMzM0ZjYzODNhNTZiZWNkMzE1ZmJjZS90YWJsZXJhbmdlOjdhMDYzMjI3MGYzMzRmNjM4M2E1NmJlY2QzMTVmYmNlXzYtNy0xLTEtMA_543bd5a5-109a-40f5-ba69-691116878d9d">0.4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Divestiture of Denmark manufacturing operations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930" decimals="3" format="ixt:zerodash" name="us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90YWJsZTo3YTA2MzIyNzBmMzM0ZjYzODNhNTZiZWNkMzE1ZmJjZS90YWJsZXJhbmdlOjdhMDYzMjI3MGYzMzRmNjM4M2E1NmJlY2QzMTVmYmNlXzctMS0xLTEtMA_9132b89b-308a-4783-9b4b-7a2f1c057566">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930" decimals="3" format="ixt:zerodash" name="us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90YWJsZTo3YTA2MzIyNzBmMzM0ZjYzODNhNTZiZWNkMzE1ZmJjZS90YWJsZXJhbmdlOjdhMDYzMjI3MGYzMzRmNjM4M2E1NmJlY2QzMTVmYmNlXzctMy0xLTEtMA_d9f8108b-de5e-4bfc-a58d-c5363733d9be">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="3" format="ixt:zerodash" name="us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90YWJsZTo3YTA2MzIyNzBmMzM0ZjYzODNhNTZiZWNkMzE1ZmJjZS90YWJsZXJhbmdlOjdhMDYzMjI3MGYzMzRmNjM4M2E1NmJlY2QzMTVmYmNlXzctNS0xLTEtMA_aaf08030-b50e-4090-a36a-bac9b70465bf">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90YWJsZTo3YTA2MzIyNzBmMzM0ZjYzODNhNTZiZWNkMzE1ZmJjZS90YWJsZXJhbmdlOjdhMDYzMjI3MGYzMzRmNjM4M2E1NmJlY2QzMTVmYmNlXzctNy0xLTEtMA_f9dbc529-83b4-4c42-955a-6b7fa80f57cc">1.5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Internal reorganization of certain intellectual property rights</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930" decimals="3" format="ixt:zerodash" name="biib:EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90YWJsZTo3YTA2MzIyNzBmMzM0ZjYzODNhNTZiZWNkMzE1ZmJjZS90YWJsZXJhbmdlOjdhMDYzMjI3MGYzMzRmNjM4M2E1NmJlY2QzMTVmYmNlXzgtMS0xLTEtMA_84202e1a-8762-4029-807c-b65784c3d591">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="number" contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930" decimals="3" sign="-" name="biib:EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90YWJsZTo3YTA2MzIyNzBmMzM0ZjYzODNhNTZiZWNkMzE1ZmJjZS90YWJsZXJhbmdlOjdhMDYzMjI3MGYzMzRmNjM4M2E1NmJlY2QzMTVmYmNlXzgtMy0xLTEtMA_5bfe5c9a-7dd0-4edc-88ac-fe0317f140b0">1.5</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="3" format="ixt:zerodash" name="biib:EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90YWJsZTo3YTA2MzIyNzBmMzM0ZjYzODNhNTZiZWNkMzE1ZmJjZS90YWJsZXJhbmdlOjdhMDYzMjI3MGYzMzRmNjM4M2E1NmJlY2QzMTVmYmNlXzgtNS0xLTEtMA_a83b62e7-c14e-4e73-bb7d-6bad3fe9727d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="number" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="3" sign="-" name="biib:EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90YWJsZTo3YTA2MzIyNzBmMzM0ZjYzODNhNTZiZWNkMzE1ZmJjZS90YWJsZXJhbmdlOjdhMDYzMjI3MGYzMzRmNjM4M2E1NmJlY2QzMTVmYmNlXzgtNy0xLTEtMA_d8d60ddb-c97c-4b4a-977c-901ed00235b3">2.1</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">TECFIDERA impairment</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90YWJsZTo3YTA2MzIyNzBmMzM0ZjYzODNhNTZiZWNkMzE1ZmJjZS90YWJsZXJhbmdlOjdhMDYzMjI3MGYzMzRmNjM4M2E1NmJlY2QzMTVmYmNlXzktMS0xLTEtMA_e90a447d-3066-43a1-91eb-0babc1ddf610">3.5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930" decimals="3" format="ixt:zerodash" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90YWJsZTo3YTA2MzIyNzBmMzM0ZjYzODNhNTZiZWNkMzE1ZmJjZS90YWJsZXJhbmdlOjdhMDYzMjI3MGYzMzRmNjM4M2E1NmJlY2QzMTVmYmNlXzktMy0xLTEtMA_8b7ba34a-0f20-4ea1-a4c9-494f013aac1b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90YWJsZTo3YTA2MzIyNzBmMzM0ZjYzODNhNTZiZWNkMzE1ZmJjZS90YWJsZXJhbmdlOjdhMDYzMjI3MGYzMzRmNjM4M2E1NmJlY2QzMTVmYmNlXzktNS0xLTEtMA_b058a21d-9c9c-4103-818a-e9531f437d26">1.9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="3" format="ixt:zerodash" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90YWJsZTo3YTA2MzIyNzBmMzM0ZjYzODNhNTZiZWNkMzE1ZmJjZS90YWJsZXJhbmdlOjdhMDYzMjI3MGYzMzRmNjM4M2E1NmJlY2QzMTVmYmNlXzktNy0xLTEtMA_54a53d6d-9178-4e15-a5ed-7f7bb82a4118">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">GILTI</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930" decimals="3" name="biib:EffectiveTaxRateReconciliationGILTItax" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90YWJsZTo3YTA2MzIyNzBmMzM0ZjYzODNhNTZiZWNkMzE1ZmJjZS90YWJsZXJhbmdlOjdhMDYzMjI3MGYzMzRmNjM4M2E1NmJlY2QzMTVmYmNlXzEwLTEtMS0xLTA_38821726-80be-4119-816b-7fde48044538">2.2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930" decimals="3" name="biib:EffectiveTaxRateReconciliationGILTItax" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90YWJsZTo3YTA2MzIyNzBmMzM0ZjYzODNhNTZiZWNkMzE1ZmJjZS90YWJsZXJhbmdlOjdhMDYzMjI3MGYzMzRmNjM4M2E1NmJlY2QzMTVmYmNlXzEwLTMtMS0xLTA_aa83301e-7e46-48ca-840d-a21d9c001f8b">1.6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="3" name="biib:EffectiveTaxRateReconciliationGILTItax" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90YWJsZTo3YTA2MzIyNzBmMzM0ZjYzODNhNTZiZWNkMzE1ZmJjZS90YWJsZXJhbmdlOjdhMDYzMjI3MGYzMzRmNjM4M2E1NmJlY2QzMTVmYmNlXzEwLTUtMS0xLTA_5a186196-8630-4051-96ab-bbaae38422c5">1.3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="3" name="biib:EffectiveTaxRateReconciliationGILTItax" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90YWJsZTo3YTA2MzIyNzBmMzM0ZjYzODNhNTZiZWNkMzE1ZmJjZS90YWJsZXJhbmdlOjdhMDYzMjI3MGYzMzRmNjM4M2E1NmJlY2QzMTVmYmNlXzEwLTctMS0xLTA_85c7cb81-7998-41db-b4f0-8f03d5f12722">1.6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Swiss tax reform</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930" decimals="3" format="ixt:zerodash" name="biib:EffectiveIncomeTaxRateReconciliationChangeInForeignTaxRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90YWJsZTo3YTA2MzIyNzBmMzM0ZjYzODNhNTZiZWNkMzE1ZmJjZS90YWJsZXJhbmdlOjdhMDYzMjI3MGYzMzRmNjM4M2E1NmJlY2QzMTVmYmNlXzEyLTEtMS0xLTA_c11a1763-b3e7-4494-82bc-0e2f274e2b63">&#8212;</ix:nonFraction></span><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="number" contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930" decimals="3" sign="-" name="biib:EffectiveIncomeTaxRateReconciliationChangeInForeignTaxRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90YWJsZTo3YTA2MzIyNzBmMzM0ZjYzODNhNTZiZWNkMzE1ZmJjZS90YWJsZXJhbmdlOjdhMDYzMjI3MGYzMzRmNjM4M2E1NmJlY2QzMTVmYmNlXzEyLTMtMS0xLTA_2c34e3bb-55d4-40ab-a17f-4f91c233edb8">3.1</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="3" format="ixt:zerodash" name="biib:EffectiveIncomeTaxRateReconciliationChangeInForeignTaxRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90YWJsZTo3YTA2MzIyNzBmMzM0ZjYzODNhNTZiZWNkMzE1ZmJjZS90YWJsZXJhbmdlOjdhMDYzMjI3MGYzMzRmNjM4M2E1NmJlY2QzMTVmYmNlXzEyLTUtMS0xLTA_f39aee3e-5656-4d84-a274-cf0da3330350">&#8212;</ix:nonFraction></span><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="number" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="3" sign="-" name="biib:EffectiveIncomeTaxRateReconciliationChangeInForeignTaxRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90YWJsZTo3YTA2MzIyNzBmMzM0ZjYzODNhNTZiZWNkMzE1ZmJjZS90YWJsZXJhbmdlOjdhMDYzMjI3MGYzMzRmNjM4M2E1NmJlY2QzMTVmYmNlXzEyLTctMS0xLTA_f1202452-163d-4706-80b2-7e873e691366">1.0</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other permanent items</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="number" contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90YWJsZTo3YTA2MzIyNzBmMzM0ZjYzODNhNTZiZWNkMzE1ZmJjZS90YWJsZXJhbmdlOjdhMDYzMjI3MGYzMzRmNjM4M2E1NmJlY2QzMTVmYmNlXzEzLTEtMS0xLTA_92753fdc-2ea0-46f3-934a-eef13667c0fb">0.6</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="number" contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90YWJsZTo3YTA2MzIyNzBmMzM0ZjYzODNhNTZiZWNkMzE1ZmJjZS90YWJsZXJhbmdlOjdhMDYzMjI3MGYzMzRmNjM4M2E1NmJlY2QzMTVmYmNlXzEzLTMtMS0xLTA_075126f9-3c36-46a8-aee8-4b997f738d30">0.1</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="3" format="ixt:zerodash" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90YWJsZTo3YTA2MzIyNzBmMzM0ZjYzODNhNTZiZWNkMzE1ZmJjZS90YWJsZXJhbmdlOjdhMDYzMjI3MGYzMzRmNjM4M2E1NmJlY2QzMTVmYmNlXzEzLTUtMS0xLTA_611aaa27-bd4e-45a0-9b6c-33504c9e1f9a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90YWJsZTo3YTA2MzIyNzBmMzM0ZjYzODNhNTZiZWNkMzE1ZmJjZS90YWJsZXJhbmdlOjdhMDYzMjI3MGYzMzRmNjM4M2E1NmJlY2QzMTVmYmNlXzEzLTctMS0xLTA_d8cc623c-6f8c-4d09-b119-9076fdd5a90e">0.2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90YWJsZTo3YTA2MzIyNzBmMzM0ZjYzODNhNTZiZWNkMzE1ZmJjZS90YWJsZXJhbmdlOjdhMDYzMjI3MGYzMzRmNjM4M2E1NmJlY2QzMTVmYmNlXzE0LTEtMS0xLTA_93b1b9f0-1ded-4e8b-8168-aed3cf594acf">0.5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="number" contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90YWJsZTo3YTA2MzIyNzBmMzM0ZjYzODNhNTZiZWNkMzE1ZmJjZS90YWJsZXJhbmdlOjdhMDYzMjI3MGYzMzRmNjM4M2E1NmJlY2QzMTVmYmNlXzE0LTMtMS0xLTA_b66056c1-fbd9-4ea3-8124-4f7bd3386a60">0.8</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90YWJsZTo3YTA2MzIyNzBmMzM0ZjYzODNhNTZiZWNkMzE1ZmJjZS90YWJsZXJhbmdlOjdhMDYzMjI3MGYzMzRmNjM4M2E1NmJlY2QzMTVmYmNlXzE0LTUtMS0xLTA_1b5c447d-6f44-4583-87db-6ee90731fca6">0.2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="number" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90YWJsZTo3YTA2MzIyNzBmMzM0ZjYzODNhNTZiZWNkMzE1ZmJjZS90YWJsZXJhbmdlOjdhMDYzMjI3MGYzMzRmNjM4M2E1NmJlY2QzMTVmYmNlXzE0LTctMS0xLTA_56d88a76-300b-4033-ba4f-3abef9be02f7">0.3</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Effective tax rate</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90YWJsZTo3YTA2MzIyNzBmMzM0ZjYzODNhNTZiZWNkMzE1ZmJjZS90YWJsZXJhbmdlOjdhMDYzMjI3MGYzMzRmNjM4M2E1NmJlY2QzMTVmYmNlXzE1LTEtMS0xLTA_ababdb8e-bd7d-49e8-87bc-19b5b3abae6b">25.1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90YWJsZTo3YTA2MzIyNzBmMzM0ZjYzODNhNTZiZWNkMzE1ZmJjZS90YWJsZXJhbmdlOjdhMDYzMjI3MGYzMzRmNjM4M2E1NmJlY2QzMTVmYmNlXzE1LTMtMS0xLTA_1078ed61-9cdc-420b-bd2b-32367d8fa832">11.9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90YWJsZTo3YTA2MzIyNzBmMzM0ZjYzODNhNTZiZWNkMzE1ZmJjZS90YWJsZXJhbmdlOjdhMDYzMjI3MGYzMzRmNjM4M2E1NmJlY2QzMTVmYmNlXzE1LTUtMS0xLTA_9714196c-0684-4028-8c2e-2b800245300d">20.9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90YWJsZTo3YTA2MzIyNzBmMzM0ZjYzODNhNTZiZWNkMzE1ZmJjZS90YWJsZXJhbmdlOjdhMDYzMjI3MGYzMzRmNjM4M2E1NmJlY2QzMTVmYmNlXzE1LTctMS0xLTA_c5586ad5-9e3b-44ab-9394-52d7ec6a806e">16.3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div></ix:nonNumeric><div style="text-indent:13.5pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#00823b;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Changes in Tax Rate</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the three months ended September 30, 2020, compared to the same period in 2019, the increase in our effective tax rate was primarily due to an internal reorganization of certain intellectual property rights related to the intercompany sale of such intellectual property in 2019, the enactment of a new taxing regime in the country and certain cantons of Switzerland in 2019 (Swiss Tax Reform) and the net $<ix:nonFraction unitRef="usd" contextRef="i289872ca5f294cb881aceaa6ffd07da1_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="biib:IncomeTaxExpenseReductioninDeferredTaxAssetsandLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90ZXh0cmVnaW9uOjBjNWQ3YWE1NzU0MjRmYWViNjE3OWFjMDU1ZWQ5NzAyXzM3Njk_e88f8798-ce36-4c2d-b481-c3871d70a7c3">33.3</ix:nonFraction> million income tax expense related to the establishment of a valuation allowance against certain deferred tax assets, the realization of which is dependent on future sales of TECFIDERA in the U.S., as discussed above. </span></div></ix:nonNumeric><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_7">Table of Contents</a></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(unaudited, continued)</span></div></div><ix:continuation id="i9148ae53668448ce88df922dc3dc4d19"><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the nine months ended September 30, 2020, compared to the same period in 2019, the increase in our effective tax rate was primarily due to the $89.3 million impact from the valuation allowance described above, the internal reorganization of certain intellectual property rights and Swiss Tax Reform, partially offset by the $<ix:nonFraction unitRef="usd" contextRef="i5d5bdbbfb1724d7b86e0b6e3ff288ee3_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90ZXh0cmVnaW9uOjBjNWQ3YWE1NzU0MjRmYWViNjE3OWFjMDU1ZWQ5NzAyXzQyNTg_5acf012c-0386-4f7a-a378-4f8a9ba297bf">64.7</ix:nonFraction> million tax expense recognized in September 30, 2019, related to the divestiture of our Hiller&#248;d, Denmark manufacturing operations. Although we recognized a loss on the divestiture of our Hiller&#248;d, Denmark manufacturing operations, the divestiture required us to write off certain deferred tax assets and resulted in a taxable gain in certain jurisdictions. For additional information on the divestiture of our Hiller&#248;d, Denmark manufacturing operations, please read </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Note 3, Divestitures,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> to our condensed consolidated financial statements included in this report.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As a result of the internal reorganization of certain intellectual property rights, we recorded a deferred tax asset of $<ix:nonFraction unitRef="usd" contextRef="ied38b94db9a74750b51c6e8392d4c5bf_I20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90ZXh0cmVnaW9uOjBjNWQ3YWE1NzU0MjRmYWViNjE3OWFjMDU1ZWQ5NzAyXzQ3MjM_a71043ae-1af6-4ff4-bcb4-dbeaa1c876e3">754.2</ix:nonFraction> million and a deferred tax liability of $<ix:nonFraction unitRef="usd" contextRef="ied38b94db9a74750b51c6e8392d4c5bf_I20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90ZXh0cmVnaW9uOjBjNWQ3YWE1NzU0MjRmYWViNjE3OWFjMDU1ZWQ5NzAyXzQ3NTg_a910f3c6-671f-4af2-a24b-6e55645a5e48">603.4</ix:nonFraction> million as of September 30, 2019.</span></div><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Accounting for Uncertainty in Income Taxes</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We and our subsidiaries are routinely examined by various taxing authorities. We file income tax returns in various U.S. states and in U.S. federal and other foreign jurisdictions. With few exceptions, we are no longer subject to U.S. federal tax examination for years before 2013 or state, local or non-U.S. income tax examinations for years before 2012.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The U.S. Internal Revenue Service and other national tax authorities routinely examine our intercompany transfer pricing with respect to intellectual property related transactions and it is possible that they may disagree with one or more positions we have taken with respect to such valuations.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">It is reasonably possible that we will adjust the value of our uncertain tax positions related to certain transfer pricing, collaboration matters and other issues as we receive additional information from various taxing authorities, including reaching settlements with such authorities.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We estimate that it is reasonably possible that our gross unrecognized tax benefits, exclusive of interest, could decrease by up to approximately $<ix:nonFraction unitRef="usd" contextRef="i626282e786b7454d83b617e9e83963e6_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90ZXh0cmVnaW9uOjBjNWQ3YWE1NzU0MjRmYWViNjE3OWFjMDU1ZWQ5NzAyXzYxMjY_2fac419d-298f-43a0-9089-c365e66d83fc">75.0</ix:nonFraction> million in the next 12 months as a result of various audit closures, settlements and expiration of the statute of limitations.</span></div></ix:continuation><div id="ib19ff89608c84168a635160f2efa48f3_109"></div><div style="text-indent:-27pt;padding-left:27pt;margin-top:14pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">16.&#160;&#160;&#160;&#160;Other Consolidated Financial Statement Detail </span></div><ix:nonNumeric contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" name="us-gaap:AdditionalFinancialInformationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90ZXh0cmVnaW9uOjEyZjQ1MWU3YWJjZjRiMmZiZTg3NmUwN2MxOWU0YWJlXzE0MDA_ab99102e-d47b-4368-9e90-8eec74f80332" continuedAt="i7e0ec30f56d44049b266d0fc55143def" escape="true"><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Other Income (Expense), Net</span></div><ix:nonNumeric contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" name="us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90ZXh0cmVnaW9uOjEyZjQ1MWU3YWJjZjRiMmZiZTg3NmUwN2MxOWU0YWJlXzEzOTU_ceafcba1-8904-45b2-bf0b-cfa15e3abc65" escape="true"><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Components of other income (expense), net, are summarized as follows:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:43.929%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.204%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.204%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.619%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.624%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Three Months Ended September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In millions)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest income</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930" decimals="-5" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90YWJsZTowYjA5OTZlOTE4MjY0YmMyOTFjYmVkODFhNWI1NWU5Yy90YWJsZXJhbmdlOjBiMDk5NmU5MTgyNjRiYzI5MWNiZWQ4MWE1YjU1ZTljXzItMi0xLTEtMA_f353690a-4283-41b5-92ce-e29e883e7bff">6.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930" decimals="-5" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90YWJsZTowYjA5OTZlOTE4MjY0YmMyOTFjYmVkODFhNWI1NWU5Yy90YWJsZXJhbmdlOjBiMDk5NmU5MTgyNjRiYzI5MWNiZWQ4MWE1YjU1ZTljXzItNC0xLTEtMA_44ef183e-4bca-4e03-97e6-d6f9bac4211b">30.5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="-5" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90YWJsZTowYjA5OTZlOTE4MjY0YmMyOTFjYmVkODFhNWI1NWU5Yy90YWJsZXJhbmdlOjBiMDk5NmU5MTgyNjRiYzI5MWNiZWQ4MWE1YjU1ZTljXzItNi0xLTEtMA_d69745ba-5af5-4265-baa2-6ad867760d4a">38.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="-5" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90YWJsZTowYjA5OTZlOTE4MjY0YmMyOTFjYmVkODFhNWI1NWU5Yy90YWJsZXJhbmdlOjBiMDk5NmU5MTgyNjRiYzI5MWNiZWQ4MWE1YjU1ZTljXzItOC0xLTEtMA_eeb6baab-92c9-4c4b-8bd6-25f1aa19985c">90.8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest expense</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90YWJsZTowYjA5OTZlOTE4MjY0YmMyOTFjYmVkODFhNWI1NWU5Yy90YWJsZXJhbmdlOjBiMDk5NmU5MTgyNjRiYzI5MWNiZWQ4MWE1YjU1ZTljXzMtMi0xLTEtMA_14cd2b58-db2b-48c5-b305-aa0ed23cdec6">56.3</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90YWJsZTowYjA5OTZlOTE4MjY0YmMyOTFjYmVkODFhNWI1NWU5Yy90YWJsZXJhbmdlOjBiMDk5NmU5MTgyNjRiYzI5MWNiZWQ4MWE1YjU1ZTljXzMtNC0xLTEtMA_641e0ed9-40d2-47e0-9510-333d04fc4efb">45.8</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90YWJsZTowYjA5OTZlOTE4MjY0YmMyOTFjYmVkODFhNWI1NWU5Yy90YWJsZXJhbmdlOjBiMDk5NmU5MTgyNjRiYzI5MWNiZWQ4MWE1YjU1ZTljXzMtNi0xLTEtMA_f1d9366d-0f5f-4111-af86-14ae0f77fe43">166.5</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90YWJsZTowYjA5OTZlOTE4MjY0YmMyOTFjYmVkODFhNWI1NWU5Yy90YWJsZXJhbmdlOjBiMDk5NmU5MTgyNjRiYzI5MWNiZWQ4MWE1YjU1ZTljXzMtOC0xLTEtMA_6315c6b4-9f5b-4c46-ac7a-3d5b0237d2eb">141.4</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gain (loss) on investments, net</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:RealizedInvestmentGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90YWJsZTowYjA5OTZlOTE4MjY0YmMyOTFjYmVkODFhNWI1NWU5Yy90YWJsZXJhbmdlOjBiMDk5NmU5MTgyNjRiYzI5MWNiZWQ4MWE1YjU1ZTljXzQtMi0xLTEtMA_4f560716-7de6-4963-96bf-839a1042170d">82.1</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930" decimals="-5" sign="-" name="us-gaap:RealizedInvestmentGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90YWJsZTowYjA5OTZlOTE4MjY0YmMyOTFjYmVkODFhNWI1NWU5Yy90YWJsZXJhbmdlOjBiMDk5NmU5MTgyNjRiYzI5MWNiZWQ4MWE1YjU1ZTljXzQtNC0xLTEtMA_1f6958e8-4de1-4c8e-b71a-954a8feeaac6">4.1</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:RealizedInvestmentGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90YWJsZTowYjA5OTZlOTE4MjY0YmMyOTFjYmVkODFhNWI1NWU5Yy90YWJsZXJhbmdlOjBiMDk5NmU5MTgyNjRiYzI5MWNiZWQ4MWE1YjU1ZTljXzQtNi0xLTEtMA_0dff469b-a255-450d-a8fd-2a9513fba712">52.6</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="-5" name="us-gaap:RealizedInvestmentGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90YWJsZTowYjA5OTZlOTE4MjY0YmMyOTFjYmVkODFhNWI1NWU5Yy90YWJsZXJhbmdlOjBiMDk5NmU5MTgyNjRiYzI5MWNiZWQ4MWE1YjU1ZTljXzQtOC0xLTEtMA_3c5f19c5-623e-4f92-a33d-d3aeec9a9f99">198.9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign exchange gains (losses), net</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930" decimals="-5" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90YWJsZTowYjA5OTZlOTE4MjY0YmMyOTFjYmVkODFhNWI1NWU5Yy90YWJsZXJhbmdlOjBiMDk5NmU5MTgyNjRiYzI5MWNiZWQ4MWE1YjU1ZTljXzUtMi0xLTEtMA_a460a07d-81de-4fc2-a8f0-94654ae83e42">3.1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930" decimals="-5" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90YWJsZTowYjA5OTZlOTE4MjY0YmMyOTFjYmVkODFhNWI1NWU5Yy90YWJsZXJhbmdlOjBiMDk5NmU5MTgyNjRiYzI5MWNiZWQ4MWE1YjU1ZTljXzUtNC0xLTEtMA_f097051c-2c6b-49c8-a972-606b8cab4ddd">4.2</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90YWJsZTowYjA5OTZlOTE4MjY0YmMyOTFjYmVkODFhNWI1NWU5Yy90YWJsZXJhbmdlOjBiMDk5NmU5MTgyNjRiYzI5MWNiZWQ4MWE1YjU1ZTljXzUtNi0xLTEtMA_903e5f9e-f72d-416a-807b-a545c633a031">5.4</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="-5" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90YWJsZTowYjA5OTZlOTE4MjY0YmMyOTFjYmVkODFhNWI1NWU5Yy90YWJsZXJhbmdlOjBiMDk5NmU5MTgyNjRiYzI5MWNiZWQ4MWE1YjU1ZTljXzUtOC0xLTEtMA_aab29782-0c10-416f-9a5d-edfaeff9701c">4.7</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other, net</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90YWJsZTowYjA5OTZlOTE4MjY0YmMyOTFjYmVkODFhNWI1NWU5Yy90YWJsZXJhbmdlOjBiMDk5NmU5MTgyNjRiYzI5MWNiZWQ4MWE1YjU1ZTljXzYtMi0xLTEtMA_c6e655f5-38bf-4a82-bfab-9f5d7c6b1a88">0.7</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930" decimals="-5" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90YWJsZTowYjA5OTZlOTE4MjY0YmMyOTFjYmVkODFhNWI1NWU5Yy90YWJsZXJhbmdlOjBiMDk5NmU5MTgyNjRiYzI5MWNiZWQ4MWE1YjU1ZTljXzYtNC0xLTEtMA_cbbc32d1-c235-465e-aa2b-92638d81839e">3.7</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90YWJsZTowYjA5OTZlOTE4MjY0YmMyOTFjYmVkODFhNWI1NWU5Yy90YWJsZXJhbmdlOjBiMDk5NmU5MTgyNjRiYzI5MWNiZWQ4MWE1YjU1ZTljXzYtNi0xLTEtMA_611e127a-8af8-49fa-8aab-ba8991881381">0.4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="-5" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90YWJsZTowYjA5OTZlOTE4MjY0YmMyOTFjYmVkODFhNWI1NWU5Yy90YWJsZXJhbmdlOjBiMDk5NmU5MTgyNjRiYzI5MWNiZWQ4MWE1YjU1ZTljXzYtOC0xLTEtMA_dfa2cb3c-6d7c-4680-9adb-be16cd558645">11.0</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total other income (expense), net</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90YWJsZTowYjA5OTZlOTE4MjY0YmMyOTFjYmVkODFhNWI1NWU5Yy90YWJsZXJhbmdlOjBiMDk5NmU5MTgyNjRiYzI5MWNiZWQ4MWE1YjU1ZTljXzctMi0xLTEtMA_9797ad36-a044-4c1a-97da-f19ad648ba5d">128.6</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930" decimals="-5" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90YWJsZTowYjA5OTZlOTE4MjY0YmMyOTFjYmVkODFhNWI1NWU5Yy90YWJsZXJhbmdlOjBiMDk5NmU5MTgyNjRiYzI5MWNiZWQ4MWE1YjU1ZTljXzctNC0xLTEtMA_0be8925c-dba2-459c-b109-b39cec53a3fb">27.3</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90YWJsZTowYjA5OTZlOTE4MjY0YmMyOTFjYmVkODFhNWI1NWU5Yy90YWJsZXJhbmdlOjBiMDk5NmU5MTgyNjRiYzI5MWNiZWQ4MWE1YjU1ZTljXzctNi0xLTEtMA_7640d544-1ef7-487a-9f46-b5d67dd81728">186.1</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="-5" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90YWJsZTowYjA5OTZlOTE4MjY0YmMyOTFjYmVkODFhNWI1NWU5Yy90YWJsZXJhbmdlOjBiMDk5NmU5MTgyNjRiYzI5MWNiZWQ4MWE1YjU1ZTljXzctOC0xLTEtMA_ac50e3ac-4e63-49ed-9c81-925829796b78">132.6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td></tr></table></div></ix:nonNumeric><div style="text-indent:24.75pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Gain (loss) on investments, net, as reflected in the table above, relate to debt securities, equity securities of certain biotechnology companies, venture capital funds where the underlying investments are in equity securities of certain biotechnology companies and non-marketable equity securities.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the three months ended September 30, 2020, compared to the same period in 2019, the change in other income (expense), net primarily reflects net unrealized losses of approximately $<ix:nonFraction unitRef="usd" contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:UnrealizedGainLossOnInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90ZXh0cmVnaW9uOjEyZjQ1MWU3YWJjZjRiMmZiZTg3NmUwN2MxOWU0YWJlXzU2NA_acb9dcaf-be48-4184-8f68-ea17ee426670">82.1</ix:nonFraction> million recognized on our investments related to our holdings in equity securities, compared to net unrealized losses totaling $<ix:nonFraction unitRef="usd" contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:RealizedInvestmentGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90ZXh0cmVnaW9uOjEyZjQ1MWU3YWJjZjRiMmZiZTg3NmUwN2MxOWU0YWJlXzEwOTk1MTE2MjkzODg_ae791a63-c84a-4ad3-ad00-72970f0db186">4.1</ix:nonFraction> million in the prior year comparative period. The net unrealized losses recognized during the three months ended September 30, 2020, primarily reflect a decrease in the fair value of Ionis common stock of approximately $<ix:nonFraction unitRef="usd" contextRef="ib7f7a4e02a2b41bdbe159e1d831b1937_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90ZXh0cmVnaW9uOjEyZjQ1MWU3YWJjZjRiMmZiZTg3NmUwN2MxOWU0YWJlXzEwOTk1MTE2Mjk0OTM_bfd3e4d7-de6a-4e3e-bf66-f3e2cded84c1">66.2</ix:nonFraction> million and a decrease in the fair value of Denali common stock of approximately $<ix:nonFraction unitRef="usd" contextRef="ia7dbdd092b034c3189ffed19d675f882_D20200701-20200930" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90ZXh0cmVnaW9uOjEyZjQ1MWU3YWJjZjRiMmZiZTg3NmUwN2MxOWU0YWJlXzEwOTk1MTE2Mjk1MDU_b519eb57-e71d-4298-bcb7-1c5e133e699e">29.6</ix:nonFraction> million, partially offset by an increase in the fair value of Sangamo common stock of approximately $<ix:nonFraction unitRef="usd" contextRef="ia88c862a2922421b9916446a96695a69_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90ZXh0cmVnaW9uOjEyZjQ1MWU3YWJjZjRiMmZiZTg3NmUwN2MxOWU0YWJlXzEwOTk1MTE2Mjk1MTM_9e739bda-6e5c-428d-8f9b-ce2833589869">15.2</ix:nonFraction>&#160;million.</span></div></ix:nonNumeric><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_7">Table of Contents</a></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(unaudited, continued)</span></div></div><ix:continuation id="i7e0ec30f56d44049b266d0fc55143def"><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the nine months ended September 30, 2020, compared to the same period in 2019, the change in other income (expense), net primarily reflects net unrealized losses of approximately $<ix:nonFraction unitRef="usd" contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:UnrealizedGainLossOnInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90ZXh0cmVnaW9uOjEyZjQ1MWU3YWJjZjRiMmZiZTg3NmUwN2MxOWU0YWJlXzEwOTk1MTE2Mjk2MjA_3855f299-e7e4-48b6-a6ee-5ac09c2d8003">40.3</ix:nonFraction> million recognized on our investments related to our holdings in equity securities, compared to net unrealized gains totaling $<ix:nonFraction unitRef="usd" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RealizedInvestmentGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90ZXh0cmVnaW9uOjEyZjQ1MWU3YWJjZjRiMmZiZTg3NmUwN2MxOWU0YWJlXzEwOTk1MTE2Mjk2Mjg_30161c7c-ba0b-4705-a670-301beceb0035">198.9</ix:nonFraction>&#160;million in the prior year comparative period. The net unrealized losses recognized during the nine months ended September 30, 2020, primarily reflect a decrease in the fair value of Ionis common stock of approximately $<ix:nonFraction unitRef="usd" contextRef="i671e2b4b86c44e18a9a4518a9d0360e3_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:UnrealizedGainLossOnInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90ZXh0cmVnaW9uOjEyZjQ1MWU3YWJjZjRiMmZiZTg3NmUwN2MxOWU0YWJlXzEwOTk1MTE2Mjk2NjE_bb59f3c4-20ef-45a5-8c1e-7d9cc0836035">56.7</ix:nonFraction>&#160;million and a decrease in the fair value of Denali common stock of approximately $<ix:nonFraction unitRef="usd" contextRef="i79e678cecceb4e00b17b8c2023042ca8_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:UnrealizedGainLossOnInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90ZXh0cmVnaW9uOjEyZjQ1MWU3YWJjZjRiMmZiZTg3NmUwN2MxOWU0YWJlXzEwOTk1MTE2Mjk2Njg_8ce31c9e-38d0-4952-ab77-9047893c2d69">29.6</ix:nonFraction>&#160;million, partially offset by an increase in the fair value of Sangamo common stock of approximately $<ix:nonFraction unitRef="usd" contextRef="i4c4c8f3f1c614d79bad90fbadf4e582e_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:UnrealizedGainLossOnInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90ZXh0cmVnaW9uOjEyZjQ1MWU3YWJjZjRiMmZiZTg3NmUwN2MxOWU0YWJlXzEwOTk1MTE2Mjk2NzY_93d74f39-dbf9-403d-828a-2c33219e9058">56.1</ix:nonFraction>&#160;million.</span></div><ix:nonNumeric contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" name="us-gaap:GainLossOnInvestmentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90ZXh0cmVnaW9uOjEyZjQ1MWU3YWJjZjRiMmZiZTg3NmUwN2MxOWU0YWJlXzE0MTM_5455c2a9-efaf-4062-897e-d40963122bac" escape="true"><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes our gain (loss) on investments, net that relates to our equity securities held as of September 30, 2020 and 2019:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:43.929%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.204%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.204%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.619%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.624%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Three Months Ended September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In millions)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net gains (losses) recognized during the period on equity securities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90YWJsZTozMjBmMzI3OTUxYWY0NWJjOGNiYWU1MWVlNTZlYjg2ZC90YWJsZXJhbmdlOjMyMGYzMjc5NTFhZjQ1YmM4Y2JhZTUxZWU1NmViODZkXzItMi0xLTEtMA_5b47f273-91ce-4a2e-be70-5005f19e305d">82.3</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90YWJsZTozMjBmMzI3OTUxYWY0NWJjOGNiYWU1MWVlNTZlYjg2ZC90YWJsZXJhbmdlOjMyMGYzMjc5NTFhZjQ1YmM4Y2JhZTUxZWU1NmViODZkXzItNC0xLTEtMA_a75f2517-f9a4-4d4f-a03e-dbc64645ac41">4.6</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90YWJsZTozMjBmMzI3OTUxYWY0NWJjOGNiYWU1MWVlNTZlYjg2ZC90YWJsZXJhbmdlOjMyMGYzMjc5NTFhZjQ1YmM4Y2JhZTUxZWU1NmViODZkXzItNi0xLTEtMA_aa6c9bde-0f41-42aa-b821-681c9ff7754b">40.3</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="-5" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90YWJsZTozMjBmMzI3OTUxYWY0NWJjOGNiYWU1MWVlNTZlYjg2ZC90YWJsZXJhbmdlOjMyMGYzMjc5NTFhZjQ1YmM4Y2JhZTUxZWU1NmViODZkXzItOC0xLTEtMA_4ca7d45b-a352-40e5-a93d-1a1c35640948">197.3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: Net gains (losses) recognized during the period on equity securities sold during the period</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90YWJsZTozMjBmMzI3OTUxYWY0NWJjOGNiYWU1MWVlNTZlYjg2ZC90YWJsZXJhbmdlOjMyMGYzMjc5NTFhZjQ1YmM4Y2JhZTUxZWU1NmViODZkXzMtMi0xLTEtMA_2627a5fb-4474-4f43-a94a-0d661d641cc0">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930" decimals="-5" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90YWJsZTozMjBmMzI3OTUxYWY0NWJjOGNiYWU1MWVlNTZlYjg2ZC90YWJsZXJhbmdlOjMyMGYzMjc5NTFhZjQ1YmM4Y2JhZTUxZWU1NmViODZkXzMtNC0xLTEtMA_9cfaf553-19f3-42e1-a759-201c7cf12f48">4.4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90YWJsZTozMjBmMzI3OTUxYWY0NWJjOGNiYWU1MWVlNTZlYjg2ZC90YWJsZXJhbmdlOjMyMGYzMjc5NTFhZjQ1YmM4Y2JhZTUxZWU1NmViODZkXzMtNi0xLTEtMA_3373bb83-bdf6-499f-b59d-7d9815fa4232">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90YWJsZTozMjBmMzI3OTUxYWY0NWJjOGNiYWU1MWVlNTZlYjg2ZC90YWJsZXJhbmdlOjMyMGYzMjc5NTFhZjQ1YmM4Y2JhZTUxZWU1NmViODZkXzMtOC0xLTEtMA_f7b4d3a0-b680-4293-8a17-a4b14af44031">46.8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized gains (losses) recognized during the period on equity securities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90YWJsZTozMjBmMzI3OTUxYWY0NWJjOGNiYWU1MWVlNTZlYjg2ZC90YWJsZXJhbmdlOjMyMGYzMjc5NTFhZjQ1YmM4Y2JhZTUxZWU1NmViODZkXzQtMi0xLTEtMA_f254fccd-f295-4982-b4cb-fdab0d5914f9">82.3</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90YWJsZTozMjBmMzI3OTUxYWY0NWJjOGNiYWU1MWVlNTZlYjg2ZC90YWJsZXJhbmdlOjMyMGYzMjc5NTFhZjQ1YmM4Y2JhZTUxZWU1NmViODZkXzQtNC0xLTEtMA_f2b020b4-6323-47aa-abca-bc019a2c4829">9.0</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90YWJsZTozMjBmMzI3OTUxYWY0NWJjOGNiYWU1MWVlNTZlYjg2ZC90YWJsZXJhbmdlOjMyMGYzMjc5NTFhZjQ1YmM4Y2JhZTUxZWU1NmViODZkXzQtNi0xLTEtMA_ef2d5ff6-0285-4e16-8529-23110aec130c">40.3</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90YWJsZTozMjBmMzI3OTUxYWY0NWJjOGNiYWU1MWVlNTZlYjg2ZC90YWJsZXJhbmdlOjMyMGYzMjc5NTFhZjQ1YmM4Y2JhZTUxZWU1NmViODZkXzQtOC0xLTEtMA_7b5305ff-a631-4a33-b31c-2c5ac576f68c">150.5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td></tr></table></div></ix:nonNumeric><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Accrued Expenses and Other</span></div><ix:nonNumeric contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90ZXh0cmVnaW9uOjEyZjQ1MWU3YWJjZjRiMmZiZTg3NmUwN2MxOWU0YWJlXzE0MTc_7a0dd0c3-dda1-4331-ba4e-d0dd6adbcbde" escape="true"><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Accrued expenses and other consists of the following:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:58.549%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:18.344%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:18.347%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In millions)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">As of September 30, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue-related reserves for discounts and allowances</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7eddadc447104f8eb26db7302eace7a5_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90YWJsZToxOGMzMWVlYTE1NDY0NGNkOGNlZDUzZmNmMmRjYWQxYy90YWJsZXJhbmdlOjE4YzMxZWVhMTU0NjQ0Y2Q4Y2VkNTNmY2YyZGNhZDFjXzEtMi0xLTEtMA_9931ad3d-2c42-4999-9675-275a121b78b2">1,043.9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ide07a6c272e244a3be181989da603c09_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90YWJsZToxOGMzMWVlYTE1NDY0NGNkOGNlZDUzZmNmMmRjYWQxYy90YWJsZXJhbmdlOjE4YzMxZWVhMTU0NjQ0Y2Q4Y2VkNTNmY2YyZGNhZDFjXzEtNC0xLTEtMA_d5a528e4-97d1-4c97-9122-ec27beead75d">1,001.1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Employee compensation and benefits</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930" decimals="-5" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90YWJsZToxOGMzMWVlYTE1NDY0NGNkOGNlZDUzZmNmMmRjYWQxYy90YWJsZXJhbmdlOjE4YzMxZWVhMTU0NjQ0Y2Q4Y2VkNTNmY2YyZGNhZDFjXzItMi0xLTEtMA_58646d63-81cb-4d17-9f3f-536ad5e3a7d1">279.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i626282e786b7454d83b617e9e83963e6_I20191231" decimals="-5" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90YWJsZToxOGMzMWVlYTE1NDY0NGNkOGNlZDUzZmNmMmRjYWQxYy90YWJsZXJhbmdlOjE4YzMxZWVhMTU0NjQ0Y2Q4Y2VkNTNmY2YyZGNhZDFjXzItNC0xLTEtMA_7280befc-9b7d-4de2-b196-1280c4cda8fe">309.1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Royalties and licensing fees</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930" decimals="-5" name="us-gaap:AccruedRoyaltiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90YWJsZToxOGMzMWVlYTE1NDY0NGNkOGNlZDUzZmNmMmRjYWQxYy90YWJsZXJhbmdlOjE4YzMxZWVhMTU0NjQ0Y2Q4Y2VkNTNmY2YyZGNhZDFjXzMtMi0xLTEtMA_b285fed5-06c5-45a1-8513-881f41f628b6">222.8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i626282e786b7454d83b617e9e83963e6_I20191231" decimals="-5" name="us-gaap:AccruedRoyaltiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90YWJsZToxOGMzMWVlYTE1NDY0NGNkOGNlZDUzZmNmMmRjYWQxYy90YWJsZXJhbmdlOjE4YzMxZWVhMTU0NjQ0Y2Q4Y2VkNTNmY2YyZGNhZDFjXzMtNC0xLTEtMA_57499c87-2db9-4159-a25b-e66cb7edc061">220.9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Collaboration expenses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930" decimals="-5" name="biib:Collaborationexpensesaccrual" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90YWJsZToxOGMzMWVlYTE1NDY0NGNkOGNlZDUzZmNmMmRjYWQxYy90YWJsZXJhbmdlOjE4YzMxZWVhMTU0NjQ0Y2Q4Y2VkNTNmY2YyZGNhZDFjXzQtMi0xLTEtMA_40ad3edf-54cf-4b39-82ef-d678a420a2e3">277.9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i626282e786b7454d83b617e9e83963e6_I20191231" decimals="-5" name="biib:Collaborationexpensesaccrual" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90YWJsZToxOGMzMWVlYTE1NDY0NGNkOGNlZDUzZmNmMmRjYWQxYy90YWJsZXJhbmdlOjE4YzMxZWVhMTU0NjQ0Y2Q4Y2VkNTNmY2YyZGNhZDFjXzQtNC0xLTEtMA_6297a58d-427f-4301-b925-98c6ca182381">281.6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current portion of contingent consideration obligations</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90YWJsZToxOGMzMWVlYTE1NDY0NGNkOGNlZDUzZmNmMmRjYWQxYy90YWJsZXJhbmdlOjE4YzMxZWVhMTU0NjQ0Y2Q4Y2VkNTNmY2YyZGNhZDFjXzUtMi0xLTEtMA_493dac42-6f62-4142-a8bf-f7a443340b7b">164.4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i626282e786b7454d83b617e9e83963e6_I20191231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90YWJsZToxOGMzMWVlYTE1NDY0NGNkOGNlZDUzZmNmMmRjYWQxYy90YWJsZXJhbmdlOjE4YzMxZWVhMTU0NjQ0Y2Q4Y2VkNTNmY2YyZGNhZDFjXzUtNC0xLTEtMA_70b2192a-6fb7-4c43-beb7-0fb264247d8c">148.4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Construction in progress</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930" decimals="-5" name="us-gaap:ConstructionPayableCurrentAndNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90YWJsZToxOGMzMWVlYTE1NDY0NGNkOGNlZDUzZmNmMmRjYWQxYy90YWJsZXJhbmdlOjE4YzMxZWVhMTU0NjQ0Y2Q4Y2VkNTNmY2YyZGNhZDFjXzYtMi0xLTEtMA_bf9e27c9-b478-4ba4-a0dd-714281c95e9b">23.4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i626282e786b7454d83b617e9e83963e6_I20191231" decimals="-5" name="us-gaap:ConstructionPayableCurrentAndNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90YWJsZToxOGMzMWVlYTE1NDY0NGNkOGNlZDUzZmNmMmRjYWQxYy90YWJsZXJhbmdlOjE4YzMxZWVhMTU0NjQ0Y2Q4Y2VkNTNmY2YyZGNhZDFjXzYtNC0xLTEtMA_0652ab1a-34ca-4532-8565-1631fa69a3c1">78.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90YWJsZToxOGMzMWVlYTE1NDY0NGNkOGNlZDUzZmNmMmRjYWQxYy90YWJsZXJhbmdlOjE4YzMxZWVhMTU0NjQ0Y2Q4Y2VkNTNmY2YyZGNhZDFjXzctMi0xLTEtMA_2cd2bb6e-86a9-4375-a01e-d595d9450439">1,274.8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i626282e786b7454d83b617e9e83963e6_I20191231" decimals="-5" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90YWJsZToxOGMzMWVlYTE1NDY0NGNkOGNlZDUzZmNmMmRjYWQxYy90YWJsZXJhbmdlOjE4YzMxZWVhMTU0NjQ0Y2Q4Y2VkNTNmY2YyZGNhZDFjXzctNC0xLTEtMA_e15f5447-185a-4860-86ba-cb2737f2eb08">726.7</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total accrued expenses and other</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90YWJsZToxOGMzMWVlYTE1NDY0NGNkOGNlZDUzZmNmMmRjYWQxYy90YWJsZXJhbmdlOjE4YzMxZWVhMTU0NjQ0Y2Q4Y2VkNTNmY2YyZGNhZDFjXzgtMi0xLTEtMA_488c8d0e-af49-40c7-8f24-d64e0b22b8be">3,286.2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i626282e786b7454d83b617e9e83963e6_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90YWJsZToxOGMzMWVlYTE1NDY0NGNkOGNlZDUzZmNmMmRjYWQxYy90YWJsZXJhbmdlOjE4YzMxZWVhMTU0NjQ0Y2Q4Y2VkNTNmY2YyZGNhZDFjXzgtNC0xLTEtMA_d9821704-168f-4ee7-a542-d40cf4d60e99">2,765.8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td></tr></table></div></ix:nonNumeric><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Other Long-term Liabilities</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Other long-term liabilities were $<ix:nonFraction unitRef="usd" contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90ZXh0cmVnaW9uOjEyZjQ1MWU3YWJjZjRiMmZiZTg3NmUwN2MxOWU0YWJlXzk5MQ_2b16eb7c-f1c1-4ee4-bde9-782920115bc1">1,428.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i626282e786b7454d83b617e9e83963e6_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90ZXh0cmVnaW9uOjEyZjQ1MWU3YWJjZjRiMmZiZTg3NmUwN2MxOWU0YWJlXzk5OA_5e05d579-c2a2-4155-8371-6d29e0543b20">1,348.9</ix:nonFraction> million as of September 30, 2020 and December 31, 2019, respectively, and included accrued income taxes totaling $<ix:nonFraction unitRef="usd" contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccruedIncomeTaxesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90ZXh0cmVnaW9uOjEyZjQ1MWU3YWJjZjRiMmZiZTg3NmUwN2MxOWU0YWJlXzEwNzU_41f324b1-6d7b-4ff6-ac74-5c3f8924f669">729.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i626282e786b7454d83b617e9e83963e6_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccruedIncomeTaxesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90ZXh0cmVnaW9uOjEyZjQ1MWU3YWJjZjRiMmZiZTg3NmUwN2MxOWU0YWJlXzEwODI_0d9b06f7-27ed-47ab-95c8-1d2250a98175">803.3</ix:nonFraction> million, respectively. Included within accrued taxes as of September 30, 2020 and December 31, 2019, is an accrual for a one-time mandatory deemed repatriation tax on accumulated foreign subsidiaries' previously untaxed foreign earnings (the Transition Toll Tax) of approximately $<ix:nonFraction unitRef="usd" contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsIncomeTaxExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90ZXh0cmVnaW9uOjEyZjQ1MWU3YWJjZjRiMmZiZTg3NmUwN2MxOWU0YWJlXzEzNTI_93bc5e09-b6ea-4e36-a47b-254523391b4d">635.0</ix:nonFraction> million and approximately $<ix:nonFraction unitRef="usd" contextRef="i9e00b6efba394fb5b58ec5d8f15b5e07_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsIncomeTaxExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90ZXh0cmVnaW9uOjEyZjQ1MWU3YWJjZjRiMmZiZTg3NmUwN2MxOWU0YWJlXzEzNzM_3d224ab2-538f-4ef9-b9a5-aef4989574ff">697.0</ix:nonFraction> million, respectively.</span></div></ix:continuation><div id="ib19ff89608c84168a635160f2efa48f3_112"></div><div style="text-indent:-27pt;padding-left:27pt;margin-top:14pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">17.&#160;&#160;&#160;&#160;Collaborative and Other Relationships </span></div><ix:nonNumeric contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzE1NzE4_457965c3-ab3f-4dfc-94f0-192cea7053ce" continuedAt="i02b7ede525794a6688021d1255b09486" escape="true"><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Eisai Co., Ltd.</span></div><div style="text-indent:13.5pt;margin-top:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">BAN2401 and Elenbecestat Collaboration</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have a collaboration agreement with Eisai Co., Ltd. (Eisai) to jointly develop and commercialize BAN2401, a monoclonal antibody that targets amyloid beta aggregates, and elenbecestat, the oral BACE (base amyloid cleaving enzyme) inhibitor, <ix:nonFraction unitRef="product" contextRef="i99c8bf62c3f747a6825f635a38c876aa_D20200101-20200930" decimals="INF" format="ixt-sec:numwordsen" name="biib:NumberOfProductCandidates" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzg3OTYwOTMwNDMxMTM_5b831a8b-e221-4a05-ab82-69cd87c3a85a">two</ix:nonFraction> Eisai product candidates for the potential treatment of Alzheimer's disease (the BAN2401 and Elenbecestat Collaboration).&#160;In September 2019 we and Eisai discontinued the global Phase 3 studies of elenbecestat in early Alzheimer's disease. </span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Eisai serves as the global operational and regulatory lead for BAN2401 and all costs, including research, development, sales and marketing expenses, are shared equally between us and Eisai. If BAN2401 receives marketing approval, we and Eisai will co-promote BAN2401 and share profits equally. In addition, the BAN2401 and Elenbecestat Collaboration provides both parties with certain rights and obligations in the event of a change in control of either party.</span></div></ix:nonNumeric><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_7">Table of Contents</a></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(unaudited, continued)</span></div></div><ix:continuation id="i02b7ede525794a6688021d1255b09486" continuedAt="ib7e3ebf723c64e118a5c2b8a248637d0"><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The BAN2401 and Elenbecestat Collaboration also provided Eisai with an option to jointly develop and commercialize aducanumab, our anti-amyloid beta antibody candidate for Alzheimer's disease (Aducanumab Option), and an option to jointly develop and commercialize one of our anti-tau monoclonal antibodies (Anti-Tau Option). In October 2017 Eisai exercised its Aducanumab Option and we entered into a new collaboration agreement for the joint development and commercialization of aducanumab (Aducanumab Collaboration Agreement). Eisai has not exercised its Anti-Tau Option.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the Aducanumab Collaboration Agreement, the two companies will continue to jointly develop BAN2401 in accordance with the BAN2401 and Elenbecestat Collaboration; however, we are no longer required to pay Eisai any milestone payments in relation to BAN2401 and we are no longer entitled to any potential development and commercial milestone payments from Eisai in relation to aducanumab. For additional information on our BAN2401 and Elenbecestat Collaboration, please read </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Note 18, Collaborative and Other Relationships,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> to our consolidated financial statements included in our 2019 Form 10-K.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A summary of development and sales and marketing expense related to the BAN2401 and Elenbecestat Collaboration is as follows:</span></div><div style="margin-top:8pt;margin-bottom:5pt;"><ix:nonNumeric contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" name="biib:SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzE1NzE0_0bd735c7-1393-4a0c-b225-0b016db7830a" escape="true"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%;"><tr><td style="width:1.0%;"></td><td style="width:53.085%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.619%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.619%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.619%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.622%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Three Months Ended September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In millions)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total development expense incurred by the collaboration related to the advancement of BAN2401 and elenbecestat</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5dd593028df14958ab74c65d6932d514_D20200701-20200930" decimals="-5" name="biib:ExpenseIncurredByCollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90YWJsZTozZjcyNDU4ODdhZDg0YTA5YjViNmI0NTMwYjcyYzcwMS90YWJsZXJhbmdlOjNmNzI0NTg4N2FkODRhMDliNWI2YjQ1MzBiNzJjNzAxXzItMi0xLTEtMA_f6e32faa-d4eb-4841-81c3-148762b88c4a">75.7</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie4289bd550fa4ecf980a7852c83941c9_D20190701-20190930" decimals="-5" name="biib:ExpenseIncurredByCollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90YWJsZTozZjcyNDU4ODdhZDg0YTA5YjViNmI0NTMwYjcyYzcwMS90YWJsZXJhbmdlOjNmNzI0NTg4N2FkODRhMDliNWI2YjQ1MzBiNzJjNzAxXzItNC0xLTEtMA_142a46d8-889b-467d-80b3-f42c7ef479bb">168.7</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i99c8bf62c3f747a6825f635a38c876aa_D20200101-20200930" decimals="-5" name="biib:ExpenseIncurredByCollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90YWJsZTozZjcyNDU4ODdhZDg0YTA5YjViNmI0NTMwYjcyYzcwMS90YWJsZXJhbmdlOjNmNzI0NTg4N2FkODRhMDliNWI2YjQ1MzBiNzJjNzAxXzItNi0xLTEtMA_fd4f1db0-9640-40e2-8b54-0e570aabc07d">153.2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iedea87e6fca548b387e737941a938d4d_D20190101-20190930" decimals="-5" name="biib:ExpenseIncurredByCollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90YWJsZTozZjcyNDU4ODdhZDg0YTA5YjViNmI0NTMwYjcyYzcwMS90YWJsZXJhbmdlOjNmNzI0NTg4N2FkODRhMDliNWI2YjQ1MzBiNzJjNzAxXzItOC0xLTEtMA_00974f32-4e33-4833-b851-91f22f34de6e">305.3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Biogen's share of BAN2401 and elenbecestat development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5dd593028df14958ab74c65d6932d514_D20200701-20200930" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90YWJsZTozZjcyNDU4ODdhZDg0YTA5YjViNmI0NTMwYjcyYzcwMS90YWJsZXJhbmdlOjNmNzI0NTg4N2FkODRhMDliNWI2YjQ1MzBiNzJjNzAxXzMtMi0xLTEtMA_13c8c4f3-4ea8-4e01-80e2-170aea9c44ca">37.9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie4289bd550fa4ecf980a7852c83941c9_D20190701-20190930" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90YWJsZTozZjcyNDU4ODdhZDg0YTA5YjViNmI0NTMwYjcyYzcwMS90YWJsZXJhbmdlOjNmNzI0NTg4N2FkODRhMDliNWI2YjQ1MzBiNzJjNzAxXzMtNC0xLTEtMA_f883d048-9fc9-42d3-9085-5b388123e0c6">84.3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i99c8bf62c3f747a6825f635a38c876aa_D20200101-20200930" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90YWJsZTozZjcyNDU4ODdhZDg0YTA5YjViNmI0NTMwYjcyYzcwMS90YWJsZXJhbmdlOjNmNzI0NTg4N2FkODRhMDliNWI2YjQ1MzBiNzJjNzAxXzMtNi0xLTEtMA_3408dcec-8b17-4e8a-8423-a59bef7862fa">76.6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iedea87e6fca548b387e737941a938d4d_D20190101-20190930" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90YWJsZTozZjcyNDU4ODdhZDg0YTA5YjViNmI0NTMwYjcyYzcwMS90YWJsZXJhbmdlOjNmNzI0NTg4N2FkODRhMDliNWI2YjQ1MzBiNzJjNzAxXzMtOC0xLTEtMA_0e8d0f79-a61f-4957-a86d-fc6a77fd7ed2">152.6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total sales and marketing expense incurred by the collaboration</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">nm</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i76cadd05cfd9487992bcc01b2fbe54ad_D20190701-20190930" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90YWJsZTozZjcyNDU4ODdhZDg0YTA5YjViNmI0NTMwYjcyYzcwMS90YWJsZXJhbmdlOjNmNzI0NTg4N2FkODRhMDliNWI2YjQ1MzBiNzJjNzAxXzQtNC0xLTEtMA_01e13835-f755-452a-a8e7-a90bde496617">10.2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4df0aa1f099c4275a635ce9719f80079_D20200101-20200930" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90YWJsZTozZjcyNDU4ODdhZDg0YTA5YjViNmI0NTMwYjcyYzcwMS90YWJsZXJhbmdlOjNmNzI0NTg4N2FkODRhMDliNWI2YjQ1MzBiNzJjNzAxXzQtNi0xLTEtMA_7c919780-0c98-44fe-9b85-432c21ed128e">6.3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ieaf688a040e748fcb2fb53cc4980b1ae_D20190101-20190930" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90YWJsZTozZjcyNDU4ODdhZDg0YTA5YjViNmI0NTMwYjcyYzcwMS90YWJsZXJhbmdlOjNmNzI0NTg4N2FkODRhMDliNWI2YjQ1MzBiNzJjNzAxXzQtOC0xLTEtMA_8822a0fe-6b65-4833-ad7e-2af392ce77ab">24.8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Biogen's share of BAN2401 and elenbecestat sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">nm</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i76cadd05cfd9487992bcc01b2fbe54ad_D20190701-20190930" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90YWJsZTozZjcyNDU4ODdhZDg0YTA5YjViNmI0NTMwYjcyYzcwMS90YWJsZXJhbmdlOjNmNzI0NTg4N2FkODRhMDliNWI2YjQ1MzBiNzJjNzAxXzUtNC0xLTEtMA_e302abc7-fdd6-4ad9-8202-fb20db9af238">5.1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4df0aa1f099c4275a635ce9719f80079_D20200101-20200930" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90YWJsZTozZjcyNDU4ODdhZDg0YTA5YjViNmI0NTMwYjcyYzcwMS90YWJsZXJhbmdlOjNmNzI0NTg4N2FkODRhMDliNWI2YjQ1MzBiNzJjNzAxXzUtNi0xLTEtMA_6a43790d-1c02-4a2a-99c6-69d0a642ca76">3.2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ieaf688a040e748fcb2fb53cc4980b1ae_D20190101-20190930" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90YWJsZTozZjcyNDU4ODdhZDg0YTA5YjViNmI0NTMwYjcyYzcwMS90YWJsZXJhbmdlOjNmNzI0NTg4N2FkODRhMDliNWI2YjQ1MzBiNzJjNzAxXzUtOC0xLTEtMA_83b08ca0-e983-4243-9f72-9d2196e96402">12.4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr></table></ix:nonNumeric></div><div style="margin-top:9pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%;"><tr><td style="width:1.0%;"></td><td style="width:33.017%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:31.105%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:32.578%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="margin-top:3pt;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;vertical-align:top;">nm</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;"> - For the three months ended September 30, 2020, sales and marketing expense related to the BAN2401 and Elenbecestat Collaboration was immaterial.</span></div><div style="text-indent:13.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Aducanumab Collaboration Agreement</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the Aducanumab Collaboration Agreement, we and Eisai will co-promote aducanumab with a region-based profit split and we lead the ongoing development of aducanumab. Beginning January 1, 2019, Eisai is reimbursing us for&#160;<ix:nonFraction unitRef="number" contextRef="i99c8bf62c3f747a6825f635a38c876aa_D20200101-20200930" decimals="INF" name="biib:PercentageoffuturedevelopmentcostsrelatedtoEisai" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzI2ODE_b56ebfc6-f9f5-48d3-9c78-2d5b3b8fa0df">45</ix:nonFraction>%&#160;of development costs incurred by the collaboration for the advancement of aducanumab (aducanumab development expense). </span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In March 2019, based on a pre-specified futility analysis, we discontinued the global Phase 3 trials, EMERGE and ENGAGE, designed to evaluate the efficacy and safety of aducanumab in patients with early Alzheimer's disease. A new analysis of a larger dataset from these trials, conducted in consultation with the FDA, showed that the Phase 3 EMERGE study met its pre-specified primary and secondary endpoints. In the first quarter of 2019, as a result of the decision to discontinue the Phase 3 EMERGE and ENGAGE trials following the futility analysis, we accrued approximately $<ix:nonFraction unitRef="usd" contextRef="i6fc4449da6e645b3871baa6066b7ba15_D20190401-20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LossOnContractTermination" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzMzNjU_16c12a3e-6a88-4e34-bffc-02acff25c30d">45.0</ix:nonFraction> million related to the termination of various clinical trials and research and development contracts net of the <ix:nonFraction unitRef="number" contextRef="i99c8bf62c3f747a6825f635a38c876aa_D20200101-20200930" decimals="INF" name="biib:PercentageoffuturedevelopmentcostsrelatedtoEisai" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzM0NzI_b56ebfc6-f9f5-48d3-9c78-2d5b3b8fa0df">45</ix:nonFraction>% Eisai reimbursement of development costs incurred under the Aducanumab Collaboration Agreement.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In July 2020 we completed the submission of a Biologics License Application (BLA) to the FDA for the approval of aducanumab. For the nine months ended September 30, 2020, we recognized net profit-sharing income of $<ix:nonFraction unitRef="usd" contextRef="i99c8bf62c3f747a6825f635a38c876aa_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzM3NzQ_902e9ab8-5862-418b-b24c-d0d883ead2d6">33.8</ix:nonFraction> million to reflect Eisai's <ix:nonFraction unitRef="number" contextRef="i99c8bf62c3f747a6825f635a38c876aa_D20200101-20200930" decimals="INF" name="biib:PercentageoffuturedevelopmentcostsrelatedtoEisai" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzM3OTY_b56ebfc6-f9f5-48d3-9c78-2d5b3b8fa0df">45</ix:nonFraction>% share of the $<ix:nonFraction unitRef="usd" contextRef="i99c8bf62c3f747a6825f635a38c876aa_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="biib:AdditionalMilestonePayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzM4MTI_5d008e04-e178-4fd0-bcf7-9f4a27ef7017">75.0</ix:nonFraction> million milestone expense related to the submission of the BLA to the FDA for the approval of aducanumab.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Sales and marketing expense are shared in proportion to the same region-based profit split that will be utilized to co-promote aducanumab. For additional information on the Aducanumab Collaboration Agreement, please read </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Note 18,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Collaborative and Other Relationships,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> to our consolidated financial statements included in our 2019 Form 10-K.</span></div></ix:continuation><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_7">Table of Contents</a></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(unaudited, continued)</span></div></div><ix:continuation id="ib7e3ebf723c64e118a5c2b8a248637d0" continuedAt="i43ff055ac2b24ee7b61a183b43819aeb"><ix:nonNumeric contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" name="biib:SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzE1NzE5_6c00ea66-6444-4af0-9e35-b258b6b37411" escape="true"><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A summary of development, sales and marketing and milestone expense related to the Aducanumab Collaboration Agreement is as follows:</span></div><div style="margin-top:10pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%;"><tr><td style="width:1.0%;"></td><td style="width:53.085%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.619%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.619%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.619%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.622%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Three Months Ended September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In millions)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total aducanumab development expense</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i84416da07ea446c6a74945f76525350d_D20200701-20200930" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90YWJsZTo5NjIxNWM3MzdiMGY0OWJlODBlZjUyM2Y3MzgwMjY3Mi90YWJsZXJhbmdlOjk2MjE1YzczN2IwZjQ5YmU4MGVmNTIzZjczODAyNjcyXzItMi0xLTEtMA_198ad987-dba2-4813-91ce-476309878254">37.5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0347bcd849ae4267bfea5d50d6b0fbea_D20190701-20190930" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90YWJsZTo5NjIxNWM3MzdiMGY0OWJlODBlZjUyM2Y3MzgwMjY3Mi90YWJsZXJhbmdlOjk2MjE1YzczN2IwZjQ5YmU4MGVmNTIzZjczODAyNjcyXzItNC0xLTEtMA_e5fda941-27d4-4548-b3c3-ea0de6dde137">4.7</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74c4058ef32546ab9478606d50a42ff6_D20200101-20200930" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90YWJsZTo5NjIxNWM3MzdiMGY0OWJlODBlZjUyM2Y3MzgwMjY3Mi90YWJsZXJhbmdlOjk2MjE1YzczN2IwZjQ5YmU4MGVmNTIzZjczODAyNjcyXzItNi0xLTEtMA_6535c145-aa82-4e46-b4e2-d7216009be20">92.5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5ab886b24e304952b01a70c3288ca622_D20190101-20190930" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90YWJsZTo5NjIxNWM3MzdiMGY0OWJlODBlZjUyM2Y3MzgwMjY3Mi90YWJsZXJhbmdlOjk2MjE1YzczN2IwZjQ5YmU4MGVmNTIzZjczODAyNjcyXzItOC0xLTEtMA_9af35c7e-fc2d-451f-85d5-e50b0178a7ad">170.5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Biogen's share of aducanumab development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i84416da07ea446c6a74945f76525350d_D20200701-20200930" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90YWJsZTo5NjIxNWM3MzdiMGY0OWJlODBlZjUyM2Y3MzgwMjY3Mi90YWJsZXJhbmdlOjk2MjE1YzczN2IwZjQ5YmU4MGVmNTIzZjczODAyNjcyXzMtMi0xLTEtMA_2f80f8da-e21a-414b-91e3-428a281f7bc6">20.6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0347bcd849ae4267bfea5d50d6b0fbea_D20190701-20190930" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90YWJsZTo5NjIxNWM3MzdiMGY0OWJlODBlZjUyM2Y3MzgwMjY3Mi90YWJsZXJhbmdlOjk2MjE1YzczN2IwZjQ5YmU4MGVmNTIzZjczODAyNjcyXzMtNC0xLTEtMA_bef39d9c-bda3-44c4-8611-f81754175913">2.6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74c4058ef32546ab9478606d50a42ff6_D20200101-20200930" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90YWJsZTo5NjIxNWM3MzdiMGY0OWJlODBlZjUyM2Y3MzgwMjY3Mi90YWJsZXJhbmdlOjk2MjE1YzczN2IwZjQ5YmU4MGVmNTIzZjczODAyNjcyXzMtNi0xLTEtMA_ed79053f-a5f6-41b5-beca-5cde129324e5">50.9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5ab886b24e304952b01a70c3288ca622_D20190101-20190930" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90YWJsZTo5NjIxNWM3MzdiMGY0OWJlODBlZjUyM2Y3MzgwMjY3Mi90YWJsZXJhbmdlOjk2MjE1YzczN2IwZjQ5YmU4MGVmNTIzZjczODAyNjcyXzMtOC0xLTEtMA_e2c7bc2f-c278-4423-a305-432d6d8c2f91">93.8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total aducanumab sales and marketing expense incurred by the collaboration</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i108d4b03b28442088d579082f1514805_D20200701-20200930" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90YWJsZTo5NjIxNWM3MzdiMGY0OWJlODBlZjUyM2Y3MzgwMjY3Mi90YWJsZXJhbmdlOjk2MjE1YzczN2IwZjQ5YmU4MGVmNTIzZjczODAyNjcyXzQtMi0xLTEtMA_d2b4c255-ea15-4cdf-93ff-fcdc39f01e7c">90.9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1d21a2127fcd4783820ebe46b0ed050b_D20190701-20190930" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90YWJsZTo5NjIxNWM3MzdiMGY0OWJlODBlZjUyM2Y3MzgwMjY3Mi90YWJsZXJhbmdlOjk2MjE1YzczN2IwZjQ5YmU4MGVmNTIzZjczODAyNjcyXzQtNC0xLTEtMA_96659f5c-2213-46d8-9bb7-3e4f9484aa59">0.1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i758bfb8a36214bcd99abf2d550c98467_D20200101-20200930" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90YWJsZTo5NjIxNWM3MzdiMGY0OWJlODBlZjUyM2Y3MzgwMjY3Mi90YWJsZXJhbmdlOjk2MjE1YzczN2IwZjQ5YmU4MGVmNTIzZjczODAyNjcyXzQtNi0xLTEtMA_1b30712b-d085-494e-96bd-e7ab8e3a5be7">158.8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icd694f937faa421dac86a19acb834bb4_D20190101-20190930" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90YWJsZTo5NjIxNWM3MzdiMGY0OWJlODBlZjUyM2Y3MzgwMjY3Mi90YWJsZXJhbmdlOjk2MjE1YzczN2IwZjQ5YmU4MGVmNTIzZjczODAyNjcyXzQtOC0xLTEtMA_510f9b31-7e2b-4145-914e-cef044687040">21.3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Biogen's share of aducanumab sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i108d4b03b28442088d579082f1514805_D20200701-20200930" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90YWJsZTo5NjIxNWM3MzdiMGY0OWJlODBlZjUyM2Y3MzgwMjY3Mi90YWJsZXJhbmdlOjk2MjE1YzczN2IwZjQ5YmU4MGVmNTIzZjczODAyNjcyXzUtMi0xLTEtMA_31bbf993-93a9-46ec-87bb-030c8ca1c321">51.3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1d21a2127fcd4783820ebe46b0ed050b_D20190701-20190930" decimals="-5" format="ixt:zerodash" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90YWJsZTo5NjIxNWM3MzdiMGY0OWJlODBlZjUyM2Y3MzgwMjY3Mi90YWJsZXJhbmdlOjk2MjE1YzczN2IwZjQ5YmU4MGVmNTIzZjczODAyNjcyXzUtNC0xLTEtMA_40720d25-9ad8-4265-b2fb-72c83f3f198c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i758bfb8a36214bcd99abf2d550c98467_D20200101-20200930" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90YWJsZTo5NjIxNWM3MzdiMGY0OWJlODBlZjUyM2Y3MzgwMjY3Mi90YWJsZXJhbmdlOjk2MjE1YzczN2IwZjQ5YmU4MGVmNTIzZjczODAyNjcyXzUtNi0xLTEtMA_cf279716-8cab-4a98-92ba-efe52a931da6">88.8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icd694f937faa421dac86a19acb834bb4_D20190101-20190930" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90YWJsZTo5NjIxNWM3MzdiMGY0OWJlODBlZjUyM2Y3MzgwMjY3Mi90YWJsZXJhbmdlOjk2MjE1YzczN2IwZjQ5YmU4MGVmNTIzZjczODAyNjcyXzUtOC0xLTEtMA_42fa8ddb-ec3f-4105-96cd-d0cf94172c4b">11.7</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total aducanumab collaboration third party milestone expense</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5dd593028df14958ab74c65d6932d514_D20200701-20200930" decimals="-5" format="ixt:zerodash" name="biib:AdditionalMilestonePayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90YWJsZTo5NjIxNWM3MzdiMGY0OWJlODBlZjUyM2Y3MzgwMjY3Mi90YWJsZXJhbmdlOjk2MjE1YzczN2IwZjQ5YmU4MGVmNTIzZjczODAyNjcyXzYtMi0xLTEtMA_cfc98487-11dd-4906-ba4a-2195d3796849">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie4289bd550fa4ecf980a7852c83941c9_D20190701-20190930" decimals="-5" format="ixt:zerodash" name="biib:AdditionalMilestonePayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90YWJsZTo5NjIxNWM3MzdiMGY0OWJlODBlZjUyM2Y3MzgwMjY3Mi90YWJsZXJhbmdlOjk2MjE1YzczN2IwZjQ5YmU4MGVmNTIzZjczODAyNjcyXzYtNC0xLTEtMA_d62bfe23-bccc-4586-9252-2a804fef4b3b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i99c8bf62c3f747a6825f635a38c876aa_D20200101-20200930" decimals="-5" name="biib:AdditionalMilestonePayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90YWJsZTo5NjIxNWM3MzdiMGY0OWJlODBlZjUyM2Y3MzgwMjY3Mi90YWJsZXJhbmdlOjk2MjE1YzczN2IwZjQ5YmU4MGVmNTIzZjczODAyNjcyXzYtNi0xLTEtMA_cb814bed-5212-415c-b2c6-35aca92f7658">75.0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iedea87e6fca548b387e737941a938d4d_D20190101-20190930" decimals="-5" format="ixt:zerodash" name="biib:AdditionalMilestonePayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90YWJsZTo5NjIxNWM3MzdiMGY0OWJlODBlZjUyM2Y3MzgwMjY3Mi90YWJsZXJhbmdlOjk2MjE1YzczN2IwZjQ5YmU4MGVmNTIzZjczODAyNjcyXzYtOC0xLTEtMA_d0bdcbd2-1e57-4c3f-9098-138349c1296d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Eisai's share of aducanumab milestone expense reflected in collaboration profit sharing in our condensed consolidated statements of income</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5dd593028df14958ab74c65d6932d514_D20200701-20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90YWJsZTo5NjIxNWM3MzdiMGY0OWJlODBlZjUyM2Y3MzgwMjY3Mi90YWJsZXJhbmdlOjk2MjE1YzczN2IwZjQ5YmU4MGVmNTIzZjczODAyNjcyXzctMi0xLTEtMA_444d8567-6c74-4a43-be46-c65b4ec55317">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie4289bd550fa4ecf980a7852c83941c9_D20190701-20190930" decimals="-5" format="ixt:zerodash" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90YWJsZTo5NjIxNWM3MzdiMGY0OWJlODBlZjUyM2Y3MzgwMjY3Mi90YWJsZXJhbmdlOjk2MjE1YzczN2IwZjQ5YmU4MGVmNTIzZjczODAyNjcyXzctNC0xLTEtMA_c865e2d9-028b-43c5-89af-8d4f2341b757">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i99c8bf62c3f747a6825f635a38c876aa_D20200101-20200930" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90YWJsZTo5NjIxNWM3MzdiMGY0OWJlODBlZjUyM2Y3MzgwMjY3Mi90YWJsZXJhbmdlOjk2MjE1YzczN2IwZjQ5YmU4MGVmNTIzZjczODAyNjcyXzctNi0xLTEtMA_710bd85b-f617-4a0a-af92-ac7f0901f99a">33.8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iedea87e6fca548b387e737941a938d4d_D20190101-20190930" decimals="-5" format="ixt:zerodash" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90YWJsZTo5NjIxNWM3MzdiMGY0OWJlODBlZjUyM2Y3MzgwMjY3Mi90YWJsZXJhbmdlOjk2MjE1YzczN2IwZjQ5YmU4MGVmNTIzZjczODAyNjcyXzctOC0xLTEtMA_9b04ddfa-1b05-467e-92cd-a1759315d81a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr></table></div></ix:nonNumeric><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, we and Eisai co-promote AVONEX, TYSABRI and TECFIDERA in Japan in certain settings and Eisai distributes AVONEX, TYSABRI, TECFIDERA and PLEGRIDY in India and other Asia-Pacific markets, excluding China.</span></div><div style="text-indent:13.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">UCB Pharma S.A.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have a collaboration agreement with UCB Pharma S.A. (UCB) to jointly develop and commercialize dapirolizumab pegol, an anti-CD40L pegylated Fab, for the potential treatment of systemic lupus erythematosus and other future agreed indications. Either we or UCB may propose development of dapirolizumab pegol in additional indications. If the parties do not agree to add an indication as an agreed indication to the collaboration, we or UCB may, at the sole expense of the applicable party, pursue development in such excluded indication(s), subject to an opt-in right of the non-pursuing party after proof of clinical activity. </span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">All costs incurred for agreed indications, including research, development, sales and marketing expenses, are shared equally between us and UCB. Upon marketing approval, we and UCB will co-promote dapirolizumab pegol and share profits equally. A summary of development expense related to the UCB collaboration agreement is as follows:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%;"><tr><td style="width:1.0%;"></td><td style="width:53.085%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.619%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.619%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.619%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.622%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Three Months Ended September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In millions)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total UCB development expense</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1927d71684864d0ea1eab5f146d82d5d_D20200701-20200930" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90YWJsZTphNDNhNTg0MTQ5NzQ0NTI2YTQ3ZDZkMDE5YzAxMzI4MS90YWJsZXJhbmdlOmE0M2E1ODQxNDk3NDQ1MjZhNDdkNmQwMTljMDEzMjgxXzItMi0xLTEtMA_3ef82553-8cce-4e0d-a11c-ab1c043b4774">10.2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icab43be754b749fe968e868f7a639cd7_D20200101-20200930" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90YWJsZTphNDNhNTg0MTQ5NzQ0NTI2YTQ3ZDZkMDE5YzAxMzI4MS90YWJsZXJhbmdlOmE0M2E1ODQxNDk3NDQ1MjZhNDdkNmQwMTljMDEzMjgxXzItNi0xLTEtMA_324e276e-2a26-4fb8-9dec-0be300fbf476">35.7</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Biogen's share of UCB development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1927d71684864d0ea1eab5f146d82d5d_D20200701-20200930" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90YWJsZTphNDNhNTg0MTQ5NzQ0NTI2YTQ3ZDZkMDE5YzAxMzI4MS90YWJsZXJhbmdlOmE0M2E1ODQxNDk3NDQ1MjZhNDdkNmQwMTljMDEzMjgxXzMtMi0xLTEtMA_541232ae-6839-4bb4-ba55-76e12443760c">5.2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icab43be754b749fe968e868f7a639cd7_D20200101-20200930" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90YWJsZTphNDNhNTg0MTQ5NzQ0NTI2YTQ3ZDZkMDE5YzAxMzI4MS90YWJsZXJhbmdlOmE0M2E1ODQxNDk3NDQ1MjZhNDdkNmQwMTljMDEzMjgxXzMtNi0xLTEtMA_519baa41-1dcb-4b9a-929a-6dc1b6cc9860">17.9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr></table></div><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Other Research and Discovery Arrangements</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">These arrangements may include the potential for future milestone payments based on the achievement of certain clinical and commercial development payable over a period of several years.</span></div></ix:continuation><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_7">Table of Contents</a></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(unaudited, continued)</span></div></div><ix:continuation id="i43ff055ac2b24ee7b61a183b43819aeb" continuedAt="i1b67efaeb2d54d5f807ddef175478614"><div style="text-indent:13.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Denali Therapeutics Inc.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In August 2020 we entered into a collaboration and license agreement with Denali to co-develop and co-commercialize Denali's small molecule inhibitors of leucine-rich repeat kinase 2 (LRRK2) for Parkinson's disease. </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition to the LRRK2 program, we also received an exclusive option to license two preclinical programs from Denali&#8217;s Transport Vehicle (TV) platform, including its Antibody Transport Vehicle: Abeta program, and a second program utilizing its TV technology. Further, we have the right of first negotiation on two additional TV-enabled therapeutics, currently at a preclinical stage, should Denali decide to seek a collaboration for such programs.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As part of this collaboration we purchased approximately $<ix:nonFraction unitRef="usd" contextRef="id8caeb1ba3904b97aa01e55d54bcfdd0_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="biib:GlobalLicensingCollaborationAgreementAmountSharesPurchased" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzEwOTk1MTE2NDQ3MjI_c189351d-c195-4036-8874-44977a957323">465.0</ix:nonFraction>&#160;million of Denali common stock in September 2020, or approximately <ix:nonFraction unitRef="shares" contextRef="i309c31a67fb24e66812ca6f278d681d1_I20200930" decimals="-6" format="ixt:numdotdecimal" name="biib:Investmentincommonstocksharespurchased" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzEwOTk1MTE2NDQ3Mzg_b2235e7e-5bfb-434c-bbd3-ea9181120aca">13</ix:nonFraction>&#160;million shares at approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="id8caeb1ba3904b97aa01e55d54bcfdd0_D20200101-20200930" decimals="2" name="biib:GlobalLicensingCollaborationAgreementSharesPurchasedPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzEwOTk1MTE2NDQ3NTA_84dcbe06-c43a-43aa-9831-da135cd9728b">34.94</ix:nonFraction> per share, which are subject to transfer restrictions. We recorded an asset in investments and other assets in our condensed consolidated balance sheets to reflect the initial fair value of the Denali common stock acquired and a charge of approximately $<ix:nonFraction unitRef="usd" contextRef="id8caeb1ba3904b97aa01e55d54bcfdd0_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzEwOTk1MTE2NDQ3NTg_f269d3ec-542b-4e90-9d21-74dfff2014a8">41.3</ix:nonFraction>&#160;million to research and development expense in our condensed consolidated statements of income to reflect the premium paid for the Denali common stock. We also made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="id8caeb1ba3904b97aa01e55d54bcfdd0_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzEwOTk1MTE2NDUwMDQ_510b0b5e-d33f-40ec-b0f5-320b4d4d97a6">560.0</ix:nonFraction>&#160;million that was recorded as research and development expense.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We may also pay development and commercial milestone payments that could total up to approximately $<ix:nonFraction unitRef="usd" contextRef="id8caeb1ba3904b97aa01e55d54bcfdd0_D20200101-20200930" decimals="-8" format="ixt:numdotdecimal" name="biib:GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzEwOTk1MTE2NDUzMTQ_424a97b9-8b81-4b18-a2e9-8208c92ff11a">1.1</ix:nonFraction>&#160;billion if the milestones related to LRRK2 are achieved as well as tiered royalties on potential net commercial sales of LRRK2 licensed products.</span></div><div style="text-indent:13.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Sangamo Therapeutics, Inc.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In February 2020 we entered into a collaboration and license agreement with Sangamo to develop and commercialize ST-501 for tauopathies, including Alzheimer's disease; ST-502 for synucleinopathies, including Parkinson&#8217;s disease; a third neuromuscular disease target; and up to nine additional neurological disease targets to be identified and selected within a five-year period. The companies are leveraging Sangamo&#8217;s proprietary zinc finger protein technology delivered via AAV with the aim to modulate the expression of key genes involved in neurological diseases. </span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In connection with the closing of this transaction in April 2020 we purchased $<ix:nonFraction unitRef="usd" contextRef="i00bfaa56f846452aa021215b0332f13a_D20200201-20200229" decimals="-5" format="ixt:numdotdecimal" name="biib:GlobalLicensingCollaborationAgreementAmountSharesPurchased" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzY1Nzg_3c7f818b-c28e-4e05-b043-4cb2ed5383e0">225.0</ix:nonFraction> million of Sangamo common stock, or approximately <ix:nonFraction unitRef="shares" contextRef="i00bfaa56f846452aa021215b0332f13a_D20200201-20200229" decimals="-6" format="ixt:numdotdecimal" name="biib:GlobalLicensingCollaborationAgreementSharesPurchased" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzY2MjM_bf80819d-ebb8-4a20-9669-019c769ec3df">24</ix:nonFraction> million shares at approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="i00bfaa56f846452aa021215b0332f13a_D20200201-20200229" decimals="2" name="biib:GlobalLicensingCollaborationAgreementSharesPurchasedPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzY2MzY_024e895d-63fe-4b27-bbfc-ab32901479ac">9.21</ix:nonFraction> per share, which are subject to transfer restrictions. We recorded an asset in investments and other assets in our condensed consolidated balance sheets to reflect the initial fair value of the Sangamo common stock acquired and a charge of&#160;approximately $<ix:nonFraction unitRef="usd" contextRef="i00bfaa56f846452aa021215b0332f13a_D20200201-20200229" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzY4OTM_d64a322b-a8a5-4153-bf92-c27455708fe2">83.0</ix:nonFraction> million&#160;to research and development expense in our condensed consolidated statements of income to reflect the premium paid for the Sangamo common stock. We also made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i00bfaa56f846452aa021215b0332f13a_D20200201-20200229" decimals="-5" format="ixt:numdotdecimal" name="biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzcwNzY_f55e3871-f8d3-49a0-9851-520dba389e12">125.0</ix:nonFraction> million that was recorded as research and development expense.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We may also pay research, development, regulatory and commercial milestone payments that could total up to approximately $<ix:nonFraction unitRef="usd" contextRef="i00bfaa56f846452aa021215b0332f13a_D20200201-20200229" decimals="-8" format="ixt:numdotdecimal" name="biib:GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzcyNTU_deaf01ab-6050-4c4b-8b19-fc0c6b6da9d6">2.4</ix:nonFraction> billion if we select all of the targets allowed under this agreement and all the specified milestones set forth in this agreement are achieved. Of this amount, up to $<ix:nonFraction unitRef="usd" contextRef="i00bfaa56f846452aa021215b0332f13a_D20200201-20200229" decimals="-5" format="ixt:numdotdecimal" name="biib:GlobalLicensingCollaborationAgreementPaymentSelectionofTargets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzc0MTY_81ab86c5-0355-405d-b561-95c9f7ae5a3d">80.0</ix:nonFraction> million relates to the selection of targets, $<ix:nonFraction unitRef="usd" contextRef="i00bfaa56f846452aa021215b0332f13a_D20200201-20200229" decimals="-8" format="ixt:numdotdecimal" name="biib:GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzc0NTY_880bea5c-670a-41fe-b85d-f363de269ed8">1.9</ix:nonFraction> billion relates to the achievement of specified research, clinical development, regulatory and first commercial sale milestones and $<ix:nonFraction unitRef="usd" contextRef="i00bfaa56f846452aa021215b0332f13a_D20200201-20200229" decimals="-5" format="ixt:numdotdecimal" name="biib:GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzc1ODM_1db9f639-27f6-4c4e-8f20-7f73bb37d907">380.0</ix:nonFraction> million relates to the achievement of specified sales-based milestones if annual worldwide net sales of licensed products reach specified levels. In addition, we may pay tiered royalties on potential net commercial sales of any products developed under this collaboration in the high single digit to double digit sub-teen percentages.</span></div><div style="text-indent:13.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Skyhawk Therapeutics, Inc.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In January 2019 we entered into a collaboration and research and development services agreement with Skyhawk Therapeutics, Inc. (Skyhawk) pursuant to which the companies are leveraging Skyhawk's SkySTAR technology platform with the goal of discovering innovative small molecule treatments for patients with neurological diseases, including MS and SMA. We are responsible for the development and potential commercialization of any therapies resulting from this collaboration and we may also pay Skyhawk up to a total of approximately $<ix:nonFraction unitRef="usd" contextRef="i626bc76978584f20bed3f3c65385234a_D20190101-20190131" decimals="-8" format="ixt:numdotdecimal" name="biib:GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzEwOTk1MTE2NDM1MjI_b777ac4d-0d5f-41bd-a7e3-dae7b8cc485a">2.4</ix:nonFraction>&#160;billion in milestone payments as well as potential royalties on net commercial sales. </span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In connection with this agreement, we made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i83f7cd89dae046c59b442f0c3d6955d3_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzEwOTk1MTE2NDM1NTU_8ddd346e-bcd7-4e52-b1f3-b469922fd15e">74.0</ix:nonFraction>&#160;million to Skyhawk, of which $<ix:nonFraction unitRef="usd" contextRef="i83f7cd89dae046c59b442f0c3d6955d3_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzg2NDQ_56618a5a-e97b-48a3-a935-952d76c90eb6">38.5</ix:nonFraction> million was recorded as research and development expense in our condensed consolidated statements of income and $<ix:nonFraction unitRef="usd" contextRef="i6b31731f10d3438bbb21a6d76e82951d_I20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzg3NTE_c99a0e96-8055-495b-a440-cba464f1d2d4">35.5</ix:nonFraction> million was recorded as prepaid research and development expenditures within investments and other assets in our condensed consolidated balance sheets. These prepaid research and development services are </span></div></ix:continuation><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_7">Table of Contents</a></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(unaudited, continued)</span></div></div><ix:continuation id="i1b67efaeb2d54d5f807ddef175478614" continuedAt="i7c8793674f964057a61342c33e083eb3"><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">expensed as the services are provided. In October 2019 we amended this agreement to add an additional discovery program. In connection with this amendment, we made a payment to Skyhawk of $<ix:nonFraction unitRef="usd" contextRef="ib83f121fe8084d6189d5e4c28193f59f_D20191001-20191031" decimals="-5" format="ixt:numdotdecimal" name="biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzkxMzg_a19a7b4e-ca87-4485-aee0-0915e95d024e">15.0</ix:nonFraction> million.</span></div><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Samsung Bioepis</span></div><div style="text-indent:13.5pt;margin-top:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Joint Venture Agreement</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In February 2012 we entered into a joint venture agreement with Samsung BioLogics establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar products.&#160;In June 2018 we exercised our option under our joint venture agreement to increase our ownership percentage in Samsung Bioepis from approximately <ix:nonFraction unitRef="number" contextRef="ide3b267ed539403d9aea0f7cee18e938_I20190930" decimals="2" name="biib:EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzk1MDc_62ee03bb-1ff1-4dab-a8ab-5f8ae8bdbbc8">5.0</ix:nonFraction>% to approximately <ix:nonFraction unitRef="number" contextRef="i982da4cced9d4ae2b09cb6c0c35fbf7b_I20200930" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzk1Mjc_d3369dea-3025-41d6-b93c-e74f0a07172d">49.9</ix:nonFraction>%. The share purchase transaction was completed in November 2018 and, upon closing, we paid <ix:nonFraction unitRef="krw" contextRef="i4d505177b87243539cc2ef4baf3b7b2d_D20181101-20181130" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzk2MjA_7c2debff-1b56-4680-afb0-2af413520cb1">759.5</ix:nonFraction> billion South Korean won ($<ix:nonFraction unitRef="usd" contextRef="i65733f4ace874e1e89159f8c95744460_D20190101-20190331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzk2NDE_c258ea0a-53d2-414d-a0c2-a26fc20da67d">676.6</ix:nonFraction> million) to Samsung BioLogics. As of September 30, 2020, our ownership percentage remained at approximately <ix:nonFraction unitRef="number" contextRef="i982da4cced9d4ae2b09cb6c0c35fbf7b_I20200930" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzk3Mjg_d3369dea-3025-41d6-b93c-e74f0a07172d">49.9</ix:nonFraction>%.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We recognize our share of the results of operations related to our investment in Samsung Bioepis under the equity method of accounting one quarter in arrears when the results of the entity become available, which is reflected as equity in income (loss) of investee, net of tax in our condensed consolidated statements of income. During 2015, as our share of losses exceeded the carrying value of our initial investment, we suspended recognizing additional losses. In the first quarter of 2019 we restarted recognizing our share of Samsung Bioepis' (income) losses, and we began recognizing amortization on certain basis differences resulting from our November 2018 investment. </span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Upon investment, the equity method of accounting requires us to identify and allocate differences between the fair value of our investment and the carrying value of our interest in the underlying net assets of the investee. These basis differences are amortized over their economic life. The total basis difference was approximately $<ix:nonFraction unitRef="usd" contextRef="i7967ad33dbdb48e89dd02f434444b459_I20181107" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzEwNzQz_fcb5c6c9-0a41-4bdd-a377-23dc4dcb3cc2">675</ix:nonFraction> million and relates to inventory, developed technology, IPR&amp;D and deferred tax balances. The basis differences related to inventory were amortized, net of tax, over their estimated useful lives of <ix:nonNumeric contextRef="i071c5b3fcf304751900b25afea18d401_D20200101-20200930" format="ixt-sec:duryear" name="biib:Equitymethodinvestmentbasisdifferenceamortizationperiod" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzEwOTYz_386e5e25-2427-4dcf-959f-ba4d43c0dc38">1.5</ix:nonNumeric> years, and the basis differences related to developed technology and IPR&amp;D for marketed products will be amortized, net of tax, over their estimated useful lives of <ix:nonNumeric contextRef="i16f85f52b2ce4a3e92746ecfebd0be40_D20200101-20200930" format="ixt-sec:duryear" name="biib:Equitymethodinvestmentbasisdifferenceamortizationperiod" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzEwOTc2_b801c911-5dfa-4aa1-9498-770813d29e08">15</ix:nonNumeric> years. </span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our joint venture partner, Samsung BioLogics, is currently subject to an ongoing criminal investigation that we continue to monitor. While this investigation could impact the operations of Samsung Bioepis and its business, we have assessed the value of our investment in Samsung Bioepis and continue to believe that the fair value of the investment is in excess of its net book value.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the three and nine months ended September 30, 2020, we recognized net losses on our investment of $<ix:nonFraction unitRef="usd" contextRef="i0fbd288a2a484b2092b7fb912c7e80ae_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzExNDkx_ceb657d4-09fb-4611-bb03-0e16f8d9587b">13.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia4cc37c0d62c49b58b4a17e71a0852f4_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzExNDk4_1fc74a8d-f49d-4ce4-b033-fa665be4480f">12.7</ix:nonFraction> million, respectively, reflecting our share of Samsung Bioepis' operating results and amortization of basis differences.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of September 30, 2020 and December 31, 2019, the carrying value of our investment in Samsung Bioepis totaled <ix:nonFraction unitRef="krw" contextRef="i982da4cced9d4ae2b09cb6c0c35fbf7b_I20200930" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzExNjY3_d66f5a79-a8a7-4979-84f4-b6eb4c4f6688">652.4</ix:nonFraction> billion South Korean won ($<ix:nonFraction unitRef="usd" contextRef="i982da4cced9d4ae2b09cb6c0c35fbf7b_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzExNjg4_43a1d265-2286-4cde-81e7-642a91432520">557.8</ix:nonFraction> million) and <ix:nonFraction unitRef="krw" contextRef="if66718fccef241c1b9e6ef3161a2fd8a_I20191231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzExNjk2_a0f8beda-3815-4bd3-948d-7e4b0813361e">670.8</ix:nonFraction> billion South Korean won ($<ix:nonFraction unitRef="usd" contextRef="if66718fccef241c1b9e6ef3161a2fd8a_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzExNzE3_084e7577-ea8d-4489-ad11-f62dd362ea16">580.2</ix:nonFraction> million), respectively, which is classified as a component of investments and other assets in our condensed consolidated balance sheets.</span></div><div style="text-indent:13.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">2019 Transaction</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In December 2019 we completed a transaction with Samsung Bioepis and secured the exclusive rights to commercialize two potential ophthalmology biosimilar products, SB11 referencing LUCENTIS and SB15 referencing EYLEA, in major markets worldwide, including the U.S., Canada, Europe, Japan and Australia. Samsung Bioepis will be responsible for development and will supply both products to us.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In connection with this transaction, we made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="ia29071dbf1dd4669a9f529d1af16da0e_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzEyMzI1_9c200e0b-3d24-43e9-8ecc-141ea90a9518">100.0</ix:nonFraction> million to Samsung Bioepis in January 2020, of which $<ix:nonFraction unitRef="usd" contextRef="ia29071dbf1dd4669a9f529d1af16da0e_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzEyMzcz_cc1f9ef8-5164-44de-a634-85c022029041">63.0</ix:nonFraction> million was recorded as research and development expense in 2019 and $<ix:nonFraction unitRef="usd" contextRef="i10d0b368c77e476286c6d631057ae023_I20200131" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzEyNDM3_949ae6c2-1461-4ac6-90a9-d335f858f421">37.0</ix:nonFraction> million was recorded as an intangible asset in 2019. Additionally, during the third quarter of 2020, we paid Samsung Bioepis a $<ix:nonFraction unitRef="usd" contextRef="icb12afc98a00406dbfbbf375974469a1_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="biib:AdditionalMilestonePayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzEwOTk1MTE2NDc1MzE_512024c4-a7a1-4300-bbb4-da04ebad2b0b">15.0</ix:nonFraction>&#160;million development milestone, which was included in research and development expense in our consolidated statements of income. We may pay Samsung Bioepis up to $<ix:nonFraction unitRef="usd" contextRef="i5da3d551e877481482c2c617be75f347_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzEyNTE4_cc8393f7-14bc-43c9-9886-6eb5a62a9312">195.0</ix:nonFraction> million in additional development, regulatory and sales-based milestones.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We also acquired an option to extend the term of our 2013 commercial agreement for BENEPALI, IMRALDI and FLIXABI by an additional <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzg3OTYwOTMwNDMxMzk_81c0182f-ea26-4b51-b761-61b3c8a065e8">five</span> years, subject to payment of an option exercise fee of $<ix:nonFraction unitRef="usd" contextRef="ia29071dbf1dd4669a9f529d1af16da0e_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="biib:ContractOptionExerciseFee" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzEyODc4_675d094e-b732-4519-8922-05abb0e74c01">60.0</ix:nonFraction> million, and obtained exclusive rights to commercialize these products in China.</span></div></ix:continuation><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_7">Table of Contents</a></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(unaudited, continued)</span></div></div><ix:continuation id="i7c8793674f964057a61342c33e083eb3" continuedAt="i1ae31750737d41d7ab5309cf82ba0daa"><div style="text-indent:13.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">2013 Commercial Agreement</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We reflect revenues on sales of BENEPALI, IMRALDI and FLIXABI to third parties in product revenues, net in our condensed consolidated statements of income and record the related cost of revenues and sales and marketing expenses in our condensed consolidated statements of income to their respective line items when these costs are incurred. </span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We share <ix:nonFraction unitRef="number" contextRef="ia4cc37c0d62c49b58b4a17e71a0852f4_D20200101-20200930" decimals="2" name="biib:Biogenshareofcopromotionprofitsorlosses" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzEzMzMx_095ec44b-ee47-4e9e-bd41-05508cb08300">50</ix:nonFraction>% of the profit or loss related to our commercial agreement with Samsung Bioepis, which is recognized in collaboration profit (loss) sharing in our condensed consolidated statements of income. For the three and nine months ended September 30, 2020, we recognized net profit-sharing expense of $<ix:nonFraction unitRef="usd" contextRef="i0fbd288a2a484b2092b7fb912c7e80ae_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="biib:Collaborationprofitlosssharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzEzNjA0_4c4c0b62-25a8-484e-bf13-7b74b4af7f25">72.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia4cc37c0d62c49b58b4a17e71a0852f4_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="biib:Collaborationprofitlosssharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzEzNjEx_2228082f-1797-48c5-ad51-c5b53071238b">200.1</ix:nonFraction> million, respectively, to reflect Samsung Bioepis' <ix:nonFraction unitRef="number" contextRef="ia4cc37c0d62c49b58b4a17e71a0852f4_D20200101-20200930" decimals="2" name="biib:Biogenshareofcopromotionprofitsorlosses" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzEzNjU3_095ec44b-ee47-4e9e-bd41-05508cb08300">50</ix:nonFraction>% sharing of the net collaboration profits, compared to $<ix:nonFraction unitRef="usd" contextRef="i64047abc9e1e47a6a0d61a0e7591f7e1_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="biib:Collaborationprofitlosssharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzEzNzE0_744c5ebc-14a0-421b-982d-d595c3b6dec4">60.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i80a9168a435d4f6a98b2450218498ef3_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="biib:Collaborationprofitlosssharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzEzNzIx_94662f99-7e3a-44fa-ad25-57ac878923a8">181.6</ix:nonFraction> million, respectively, in the prior year comparative periods. As discussed above, we have an option to extend this agreement by an additional five years, subject to the payment of an option exercise fee of $<ix:nonFraction unitRef="usd" contextRef="ia29071dbf1dd4669a9f529d1af16da0e_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="biib:ContractOptionExerciseFee" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzEzOTIy_675d094e-b732-4519-8922-05abb0e74c01">60.0</ix:nonFraction> million.</span></div><div style="text-indent:13.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Other Services</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Simultaneous with the formation of Samsung Bioepis, we also entered into a technical development services agreement, a manufacturing agreement and a license agreement with Samsung Bioepis. For the three and nine months ended September 30, 2020, we recognized $<ix:nonFraction unitRef="usd" contextRef="ib22568b42dea422aad4788445cea0a41_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzE0MTc5_61b43fe3-c850-4ade-991e-424c837a839f">5.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i00616e2d34c848588546a4eb3b7e17e1_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzE0MTg2_8a338065-f358-4cea-89ef-75d0e6815ca6">13.6</ix:nonFraction> million, respectively, in revenues related to these services, which is reflected in collaborative and other relationships revenues as a component of other revenues in our condensed consolidated statements of income, compared to $<ix:nonFraction unitRef="usd" contextRef="i035b83abf8f74352b8844936a4c053e5_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzE0NDA5_278b7681-81eb-4a13-9ebc-af0ef1832552">12.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="if62153afc8b048fea1ecd3d555faaf6d_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzE0NDE2_1c385eac-461c-4c37-a70b-a6f0c07b54fa">89.9</ix:nonFraction> million, respectively, in the prior year comparative periods. </span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Following the divestiture of our Hiller&#248;d, Denmark manufacturing operations in August 2019, FUJIFILM assumed responsibility for the manufacture of clinical and commercial quantities of bulk drug substance of biosimilar products for Samsung Bioepis. We no longer recognize revenues for the manufacturing completed after the Hiller&#248;d, Denmark manufacturing operations divestiture date under our technical development services and manufacturing agreements with Samsung Bioepis. For additional information on the divestiture of our Hiller&#248;d, Denmark manufacturing operations, please read </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Note 3, Divestitures,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> to these condensed consolidated financial statements.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Amounts receivable from Samsung Bioepis related to the agreements discussed above were $<ix:nonFraction unitRef="usd" contextRef="i27257060fb394740a54642f97bef35f3_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DueFromRelatedParties" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzE1MjAx_3a41be02-eba1-434a-8fb1-31e11d70f0f1">4.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i068f3b4714364e10a6f8a38a28733f78_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DueFromRelatedParties" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzE1MjA4_6cefaae1-daf6-4f6f-84f8-4532ef36436b">85.0</ix:nonFraction> million as of September 30, 2020 and December 31, 2019, respectively. Amounts payable to Samsung Bioepis were $<ix:nonFraction unitRef="usd" contextRef="i27257060fb394740a54642f97bef35f3_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzE1MjUz_6b313bbf-ca3e-4457-95de-9dc1a3f98c75">26.4</ix:nonFraction>&#160;million as of September 30, 2020. Amounts payable to Samsung Bioepis as of December 31, 2019, consisted of the $<ix:nonFraction unitRef="usd" contextRef="i068f3b4714364e10a6f8a38a28733f78_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzE1MzYz_7a262d9c-1205-4177-8fe6-d0f3678b5a44">100.0</ix:nonFraction> million upfront payment related to the 2019 transaction, as discussed above.</span></div></ix:continuation><div style="text-indent:24.75pt;margin-top:6pt;"><ix:continuation id="i1ae31750737d41d7ab5309cf82ba0daa" continuedAt="if4b322e3287e4352a8d01c8f6472fbe9"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For additional information on our collaboration arrangements with Samsung Bioepis and our other significant collaboration arrangements, please read </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Note 18,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Collaborative and Other Relationships,</span></ix:continuation><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="if4b322e3287e4352a8d01c8f6472fbe9"> to our consolidated financial statements included in our 2019 Form 10-K.</ix:continuation> </span></div><div id="ib19ff89608c84168a635160f2efa48f3_118"></div><div style="text-indent:-27pt;padding-left:27pt;margin-top:14pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">18.&#160;&#160;&#160;&#160;Investments in Variable Interest Entities </span></div><ix:nonNumeric contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" name="us-gaap:VariableInterestEntityDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTgvZnJhZzo0OWRmMGZhZDBiNTg0NWU5YjcyZTc3Njg4NmQzMGE1Ny90ZXh0cmVnaW9uOjQ5ZGYwZmFkMGI1ODQ1ZTliNzJlNzc2ODg2ZDMwYTU3XzU3MjM_267df1ac-a257-40f5-9677-fc21a32dbe1d" continuedAt="if4d9e6d363ed48a2821e38fc346b1d7c" escape="true"><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Consolidated Variable Interest Entities</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our condensed consolidated financial statements include the financial results of variable interest entities in which we are the primary beneficiary. The following are our significant variable interest entities.</span></div><div style="text-indent:13.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Neurimmune SubOne AG</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have a collaboration and license agreement with Neurimmune SubOne AG (Neurimmune) for the development and commercialization of antibodies for the potential treatment of Alzheimer's disease, including aducanumab (as amended, the Neurimmune Agreement). We are responsible for the development, manufacturing and commercialization of all collaboration products. The Neurimmune Agreement is effective for the longer of the duration of certain patents relating to a licensed product or <ix:nonNumeric contextRef="i1478c61cb1ee4cfa8414bded1c551b30_D20200101-20200930" format="ixt-sec:duryear" name="biib:CollaborationAgreementTerm" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTgvZnJhZzo0OWRmMGZhZDBiNTg0NWU5YjcyZTc3Njg4NmQzMGE1Ny90ZXh0cmVnaW9uOjQ5ZGYwZmFkMGI1ODQ1ZTliNzJlNzc2ODg2ZDMwYTU3Xzc1MQ_0024a72b-6726-40a1-8838-f5c74b5db50f">12</ix:nonNumeric> years from the first commercial sale of a licensed product.  </span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We consolidate the results of Neurimmune as we determined that we are the primary beneficiary of Neurimmune because we have the power through the collaboration to direct the activities that most significantly impact the entity&#8217;s economic performance and we are required to fund <ix:nonFraction unitRef="number" contextRef="i1478c61cb1ee4cfa8414bded1c551b30_D20200101-20200930" decimals="0" name="biib:ResearchAndDevelopmentCostsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTgvZnJhZzo0OWRmMGZhZDBiNTg0NWU5YjcyZTc3Njg4NmQzMGE1Ny90ZXh0cmVnaW9uOjQ5ZGYwZmFkMGI1ODQ1ZTliNzJlNzc2ODg2ZDMwYTU3XzExMTg_7a898314-e9ed-493b-a360-b8b3412169e8">100</ix:nonFraction>% of the research and development costs incurred in support of the collaboration. </span></div></ix:nonNumeric><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_7">Table of Contents</a></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(unaudited, continued)</span></div></div><ix:continuation id="if4d9e6d363ed48a2821e38fc346b1d7c"><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In October 2017 we amended the terms of the Neurimmune Agreement and made a $<ix:nonFraction unitRef="usd" contextRef="i1f3660b791194af5a26e2a9ceab00343_D20171001-20171031" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToMinorityShareholders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTgvZnJhZzo0OWRmMGZhZDBiNTg0NWU5YjcyZTc3Njg4NmQzMGE1Ny90ZXh0cmVnaW9uOjQ5ZGYwZmFkMGI1ODQ1ZTliNzJlNzc2ODg2ZDMwYTU3XzEyNzg_8df2fce6-42a7-45fd-a048-b04c438e5f70">150.0</ix:nonFraction> million payment to Neurimmune in exchange for a <ix:nonFraction unitRef="number" contextRef="i1f3660b791194af5a26e2a9ceab00343_D20171001-20171031" decimals="2" name="biib:Reductioninroyaltyratepayableoncommercialsales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTgvZnJhZzo0OWRmMGZhZDBiNTg0NWU5YjcyZTc3Njg4NmQzMGE1Ny90ZXh0cmVnaW9uOjQ5ZGYwZmFkMGI1ODQ1ZTliNzJlNzc2ODg2ZDMwYTU3XzEzMjE_3cf6e04e-3639-4e14-b3f0-b472f8bf834a">15</ix:nonFraction>% reduction in the previously negotiated royalty rates payable on products developed under the Neurimmune Agreement, including royalties payable on potential commercial sales of aducanumab. In May 2018 we made an additional $<ix:nonFraction unitRef="usd" contextRef="i61fb7e1bb0fd421bbf82c79ee9784cc5_D20180501-20180531" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToMinorityShareholders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTgvZnJhZzo0OWRmMGZhZDBiNTg0NWU5YjcyZTc3Njg4NmQzMGE1Ny90ZXh0cmVnaW9uOjQ5ZGYwZmFkMGI1ODQ1ZTliNzJlNzc2ODg2ZDMwYTU3XzE1NDY_8513e8fb-68b0-43cc-bd4a-757dc809317c">50.0</ix:nonFraction> million payment to Neurimmune to further reduce the previously negotiated royalty rates payable on products developed under the Neurimmune Agreement, including royalties payable on potential commercial sales of aducanumab, by an additional <ix:nonFraction unitRef="number" contextRef="i61fb7e1bb0fd421bbf82c79ee9784cc5_D20180501-20180531" decimals="2" name="biib:Additionalreductioninroyaltyratepayableoncommercialsales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTgvZnJhZzo0OWRmMGZhZDBiNTg0NWU5YjcyZTc3Njg4NmQzMGE1Ny90ZXh0cmVnaW9uOjQ5ZGYwZmFkMGI1ODQ1ZTliNzJlNzc2ODg2ZDMwYTU3XzE3ODE_a20bec30-289c-45a8-8302-b52ac8513291">5</ix:nonFraction>%. Our royalty rates payable on products developed under the Neurimmune Agreement, including royalty rates payable on potential commercial sales of aducanumab, now range from the high single digits to sub-teens. As we consolidate the results of Neurimmune, we treated these payments as distributions and recognized them as charges to noncontrolling interests in the fourth quarter of 2017 and the second quarter of 2018, as applicable.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Additionally, under the terms of the Neurimmune Agreement, we are required to pay Neurimmune a milestone payment of&#160;$<ix:nonFraction unitRef="usd" contextRef="id7b514880c7944a69bca92a1890a1999_I20191231" decimals="-5" format="ixt:numdotdecimal" name="biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTgvZnJhZzo0OWRmMGZhZDBiNTg0NWU5YjcyZTc3Njg4NmQzMGE1Ny90ZXh0cmVnaW9uOjQ5ZGYwZmFkMGI1ODQ1ZTliNzJlNzc2ODg2ZDMwYTU3XzIzMzQ_1044fd74-71ff-4aae-948d-f5199c37ea26">75.0</ix:nonFraction> million&#160;upon the regulatory filing with the FDA for approval of aducanumab and a milestone payment of&#160;$<ix:nonFraction unitRef="usd" contextRef="id248e9039d774acdb784eeea9df07f64_I20191231" decimals="-5" format="ixt:numdotdecimal" name="biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTgvZnJhZzo0OWRmMGZhZDBiNTg0NWU5YjcyZTc3Njg4NmQzMGE1Ny90ZXh0cmVnaW9uOjQ5ZGYwZmFkMGI1ODQ1ZTliNzJlNzc2ODg2ZDMwYTU3XzI0MzE_36dd0589-90a5-412f-af2b-db2dfdc2d456">100.0</ix:nonFraction> million&#160;if aducanumab is launched in the U.S. In July 2020 we completed the submission of a BLA to the FDA for the approval of aducanumab. During the third quarter of 2020, we paid Neurimmune $<ix:nonFraction unitRef="usd" contextRef="id7b514880c7944a69bca92a1890a1999_I20191231" decimals="-5" format="ixt:numdotdecimal" name="biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTgvZnJhZzo0OWRmMGZhZDBiNTg0NWU5YjcyZTc3Njg4NmQzMGE1Ny90ZXh0cmVnaW9uOjQ5ZGYwZmFkMGI1ODQ1ZTliNzJlNzc2ODg2ZDMwYTU3XzI2NzU_1044fd74-71ff-4aae-948d-f5199c37ea26">75.0</ix:nonFraction> million upon the completed submission of the BLA for aducanumab with the FDA, which was recognized as a charge to noncontrolling interests for the nine months ended September 30, 2020. In addition, for the nine months ended September 30, 2020, we recognized net profit-sharing income of $<ix:nonFraction unitRef="usd" contextRef="i99c8bf62c3f747a6825f635a38c876aa_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTgvZnJhZzo0OWRmMGZhZDBiNTg0NWU5YjcyZTc3Njg4NmQzMGE1Ny90ZXh0cmVnaW9uOjQ5ZGYwZmFkMGI1ODQ1ZTliNzJlNzc2ODg2ZDMwYTU3XzI5NjU_27b1e1fe-8928-464c-9920-b06b2781f73c">33.8</ix:nonFraction> million to reflect Eisai's <ix:nonFraction unitRef="number" contextRef="i99c8bf62c3f747a6825f635a38c876aa_D20200101-20200930" decimals="INF" name="biib:PercentageoffuturedevelopmentcostsrelatedtoEisai" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTgvZnJhZzo0OWRmMGZhZDBiNTg0NWU5YjcyZTc3Njg4NmQzMGE1Ny90ZXh0cmVnaW9uOjQ5ZGYwZmFkMGI1ODQ1ZTliNzJlNzc2ODg2ZDMwYTU3XzI5ODc_48b0a58b-fb2a-42f6-8383-7646d1c9a609">45</ix:nonFraction>% share of the $<ix:nonFraction unitRef="usd" contextRef="id7b514880c7944a69bca92a1890a1999_I20191231" decimals="-5" format="ixt:numdotdecimal" name="biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTgvZnJhZzo0OWRmMGZhZDBiNTg0NWU5YjcyZTc3Njg4NmQzMGE1Ny90ZXh0cmVnaW9uOjQ5ZGYwZmFkMGI1ODQ1ZTliNzJlNzc2ODg2ZDMwYTU3XzMwMDM_1044fd74-71ff-4aae-948d-f5199c37ea26">75.0</ix:nonFraction> million milestone payment.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Research and development costs for which we reimburse Neurimmune are reflected in research and development expense in our condensed consolidated statements of income. During the three and nine months ended September 30, 2020 and 2019, amounts reimbursed were immaterial.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The assets and liabilities of Neurimmune are not significant to our condensed consolidated financial position or results of operations as it is a research and development organization. We have provided no financing to Neurimmune other than contractually required amounts.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the Aducanumab Collaboration Agreement, Eisai had an option to share in the benefit and cost associated with the royalty reductions discussed above; however, Eisai did not elect to share in the benefit and cost with respect to either the October 2017 or May 2018 royalty reductions, which will impact the amount of profits (losses) on potential commercial sales of aducanumab to be shared with Eisai.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For additional information on our collaboration arrangements with Eisai, please read </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Note 17, Collaborative and Other Relationships, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">to these condensed consolidated financial statements.</span></div><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Unconsolidated Variable Interest Entities</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have relationships with various variable interest entities that we do not consolidate as we lack the power to direct the activities that significantly impact the economic success of these entities. These relationships include investments in certain biotechnology companies and research collaboration agreements. </span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of September 30, 2020 and December 31, 2019, the carrying value of our investments in certain biotechnology companies representing potential unconsolidated variable interest entities totaled $<ix:nonFraction unitRef="usd" contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930" decimals="-5" format="ixt:numdotdecimal" name="biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTgvZnJhZzo0OWRmMGZhZDBiNTg0NWU5YjcyZTc3Njg4NmQzMGE1Ny90ZXh0cmVnaW9uOjQ5ZGYwZmFkMGI1ODQ1ZTliNzJlNzc2ODg2ZDMwYTU3XzQ5MDM_6e2ebd99-15a0-4b20-b912-20ab809e1c16">21.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i626282e786b7454d83b617e9e83963e6_I20191231" decimals="-5" format="ixt:numdotdecimal" name="biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTgvZnJhZzo0OWRmMGZhZDBiNTg0NWU5YjcyZTc3Njg4NmQzMGE1Ny90ZXh0cmVnaW9uOjQ5ZGYwZmFkMGI1ODQ1ZTliNzJlNzc2ODg2ZDMwYTU3XzQ5MTA_04610f0b-6b64-4924-99fe-3eb85a32c7a9">22.7</ix:nonFraction> million, respectively. Our maximum exposure to loss related to these variable interest entities is limited to the carrying value of our investments.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have also entered into research collaboration agreements with certain variable interest entities where we are required to fund certain development activities. These development activities are included in research and development expense in our condensed consolidated statements of income as they are incurred. We have provided no financing to these variable interest entities other than previously contractually required amounts. </span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For additional information on our investments in Neurimmune and other variable interest entities, please read </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Note 19, Investments in Variable Interest Entities,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> to our consolidated financial statements included in our 2019 Form 10-K.</span></div></ix:continuation><div id="ib19ff89608c84168a635160f2efa48f3_124"></div><div style="text-indent:-27pt;padding-left:27pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">19.&#160;&#160;&#160;&#160;Litigation </span></div><div style="text-indent:22.5pt;padding-left:4.5pt;margin-top:6pt;"><ix:nonNumeric contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930" name="us-gaap:LegalMattersAndContingenciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMjQvZnJhZzpiODYzYmI4YzAwZWE0YzQ1YTFlMDU1M2EyMmMzMzJhOC90ZXh0cmVnaW9uOmI4NjNiYjhjMDBlYTRjNDVhMWUwNTUzYTIyYzMzMmE4XzEzODE1_9f41ae75-2d9e-4b7f-aa54-e5fad970b9f9" continuedAt="i9ebbe2052ad94889b3c5e75a2660eb60" escape="true"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are currently involved in various claims and legal proceedings, including the matters described below. For information as to our accounting policies relating to claims and legal proceedings, including use of estimates and contingencies, please read </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Note 1, Summary of Significant Accounting Policies,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> to our consolidated financial statements included in our 2019 Form 10-K.</span></ix:nonNumeric></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_7">Table of Contents</a></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(unaudited, continued)</span></div></div><ix:continuation id="i9ebbe2052ad94889b3c5e75a2660eb60" continuedAt="ic20823ff282e46af8d6b9460d8ea0ed7"><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">With respect to some loss contingencies, an estimate of the possible loss or range of loss cannot be made until management has further information, including, for example, (i) which claims, if any, will survive dispositive motion practice; (ii) information to be obtained through discovery; (iii) information as to the parties' damages claims and supporting evidence; (iv) the parties&#8217; legal theories; and (v) the parties' settlement positions. </span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The claims and legal proceedings in which we are involved also include challenges to the scope, validity or enforceability of the patents relating to our products, pipeline or processes and challenges to the scope, validity or enforceability of the patents held by others. These include claims by third parties that we infringe their patents. An adverse outcome in any of these proceedings could result in one or more of the following and have a material impact on our business or consolidated results of operations and financial position: (i) loss of patent protection; (ii) inability to continue to engage in certain activities; and (iii) payment of significant damages, royalties, penalties and/or license fees to third parties.</span></div><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Loss Contingencies </span></div><div style="text-indent:13.5pt;margin-top:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">IMRALDI Patent Litigation</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In September 2018 Fresenius Kabi Deutschland GmbH (Fresenius Kabi) commenced proceedings for damages and injunctive relief against Biogen France SAS in the Tribunal de Grande Instance de Paris, alleging that IMRALDI, the adalimumab biosimilar product of Samsung Bioepis UK Limited that Biogen has commercialized in Europe, infringes the French counterpart of European Patent No. 3 148 510 (the '510 Patent), which was issued in June 2018 and expires in May 2035. No hearing has been scheduled. </span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In October 2018 Fresenius Kabi commenced preliminary injunction proceedings against Biogen (Denmark) Manufacturing ApS and Biogen Denmark A/S in Denmark's Maritime and Commercial High Court alleging infringement of Danish Utility Models. In June 2019 the Danish court denied Fresenius Kabi's request for a preliminary injunction. Fresenius Kabi has appealed that decision and a hearing has been set for January 2021. In July 2020 the Danish Patent Board of Appeal revoked the Utility Models that were the subject of Fresenius Kabi&#8217;s October 2018 request for a preliminary injunction and Fresenius Kabi has appealed those revocations.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2020 Fresenius Kabi commenced preliminary injunction proceedings against Biogen (Denmark) Manufacturing ApS and Biogen (Denmark) A/S in Denmark&#8217;s Maritime and Commercial High Court alleging infringement of another Danish Utility Model. A hearing has been scheduled for May 2021.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In November 2018 Fresenius Kabi commenced infringement proceedings for damages and injunctive relief against Biogen Italia S.R.L. in the District Court of Milan relating to the Italian counterpart of the &#8216;510 Patent, and against Biogen GmbH in the D&#252;sseldorf Regional Court relating to the German counterpart of the &#8216;510 Patent. In Italy, Fresenius Kabi has surrendered the Italian counterpart of the &#8216;510 Patent and the court dismissed its infringement action in October 2020. A hearing in the proceeding in Germany has been set for August 2021.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In July 2019 Gedeon Richter PLC (Gedeon Richter) commenced proceedings against Biogen GmbH in the D&#252;sseldorf Regional Court alleging infringement of the German counterpart of European Patent No. 3 212 667 (the '667 Patent), which was issued in September 2018 and expires in October 2035, and seeking damages and injunctive relief. The November 2020 hearing has been postponed and a new hearing date has not been set.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In August 2019 Biogen B.V. (Netherlands) and Samsung Bioepis UK Limited filed an action in the District Court of the Hague, Netherlands to revoke the Dutch counterpart of the '667 Patent. Gedeon Richter filed a separate action for infringement in the same court. A hearing was held in May 2020 and in July 2020 the court revoked the Dutch counterpart of the '667 Patent.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">An estimate of the possible loss or range of loss in the pending IMRALDI patent litigation described above cannot be made at this time. </span></div><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Qui Tam Litigation</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In July 2015 a qui tam action filed by Michael Bawduniak on behalf of the U.S. and certain states was unsealed by the U.S. District Court for the District of Massachusetts. The action alleges sales and promotional activities in violation of the federal False Claims Act and state law counterparts and seeks single and treble damages, civil penalties, interest, attorneys&#8217; fees and costs. No trial date has been set. The U.S. has not made an intervention decision. An estimate of the possible loss or range of loss cannot be made at this time.</span></div></ix:continuation><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_7">Table of Contents</a></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(unaudited, continued)</span></div></div><ix:continuation id="ic20823ff282e46af8d6b9460d8ea0ed7" continuedAt="ia31c378001f644cab03a2a99cc5af2b0"><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Dispute with Former Convergence Shareholders</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In November and December 2019 Shareholder Representative Services LLC, on behalf of the former shareholders of Convergence, sent us correspondence asserting claims of $<ix:nonFraction unitRef="usd" contextRef="i626282e786b7454d83b617e9e83963e6_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LossContingencyEstimateOfPossibleLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMjQvZnJhZzpiODYzYmI4YzAwZWE0YzQ1YTFlMDU1M2EyMmMzMzJhOC90ZXh0cmVnaW9uOmI4NjNiYjhjMDBlYTRjNDVhMWUwNTUzYTIyYzMzMmE4XzU0MzM_d1afe22f-50b0-47e0-bba4-68ee4be39095">200.0</ix:nonFraction> million for alleged breach of the contract under which we acquired Convergence. We dispute the claims.</span></div><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:174%;">Dispute with Jacobs Switzerland GmbH</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Jacobs Switzerland GmbH, the general contractor for the construction of our large-scale biologics manufacturing facility in Solothurn, Switzerland, claims approximately <ix:nonFraction unitRef="chf" contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930" decimals="-6" format="ixt:numdotdecimal" name="biib:DisputedClaimsRelatingtoConstructionCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMjQvZnJhZzpiODYzYmI4YzAwZWE0YzQ1YTFlMDU1M2EyMmMzMzJhOC90ZXh0cmVnaW9uOmI4NjNiYjhjMDBlYTRjNDVhMWUwNTUzYTIyYzMzMmE4XzU3Mzc_a222fd20-aa04-43de-9fd2-df32a5f4a9ba">31.0</ix:nonFraction> million Swiss Francs (approximately $<ix:nonFraction unitRef="usd" contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930" decimals="-6" format="ixt:numdotdecimal" name="biib:DisputedClaimsRelatingtoConstructionCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMjQvZnJhZzpiODYzYmI4YzAwZWE0YzQ1YTFlMDU1M2EyMmMzMzJhOC90ZXh0cmVnaW9uOmI4NjNiYjhjMDBlYTRjNDVhMWUwNTUzYTIyYzMzMmE4XzU3Njg_18262c68-3667-46fb-a25f-0a6de4cd575e">33.0</ix:nonFraction> million) relating to construction costs. We dispute the claim.</span></div><div style="text-indent:13.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Other Matters</span></div><div style="text-indent:11.25pt;margin-top:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Petition for Inter Partes Review</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In July 2018 Mylan Pharmaceuticals, Inc. (Mylan) filed a petition that was granted by the U.S. Patent Trial and Appeal Board (PTAB) for </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">inter partes</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> review of our U.S. Patent No. 8,399,514 (the '514 Patent). The '514 Patent includes claims covering treatment of MS with 480 mg of dimethyl fumarate per day as provided for in our TECFIDERA label. In February 2020 the PTAB issued a final written decision upholding the patentability of the &#8216;514 Patent and in April 2020 Mylan filed an appeal in the U.S. Court of Appeals for the Federal Circuit (the Federal Circuit), which is pending. Oral argument has been scheduled for December 8, 2020.</span></div><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Hatch-Waxman Act Litigation relating to TECFIDERA Orange-Book Listed Patents</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In 2017, 2018 and 2019 we filed patent infringement proceedings relating to TECFIDERA Orange-Book listed patents pursuant to the Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch-Waxman Act (the Delaware Actions), against Accord Healthcare Inc., Alkem Laboratories Ltd., Amneal Pharmaceuticals LLC, Aurobindo Pharma U.S.A., Inc., Cipla Limited, Glenmark Pharmaceuticals Ltd., Graviti Pharmaceuticals Pvt. Ltd., Hetero USA, Inc.,&#160;Lupin Atlantis Holdings SA, Macleods Pharmaceuticals, Ltd., MSN Laboratories Pvt. Ltd., Pharmathen S.A., Prinston Pharmaceutical Inc., Sandoz Inc., Sawai USA, Inc., Shilpa Medicare Limited, Slayback Pharma LLC, Torrent Pharmaceuticals Ltd., TWi Pharmaceuticals, Inc., Windlas Healthcare Pvt. Ltd. and Zydus Pharmaceuticals (USA) Inc. (the Delaware Defendants) in the U.S. District Court for the District of Delaware (the Delaware Court) and against Mylan in the U.S. District Court for the Northern District of West Virginia (the West Virginia Court). The litigation against Aurobindo Pharma U.S.A., Inc., Glenmark Pharmaceuticals Ltd. and Sawai USA, Inc. was dismissed in the fourth quarter of 2019.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On June 22, 2020, the West Virginia Court entered judgment for Mylan that the asserted claims of the &#8216;514 Patent are invalid for lack of written description. We appealed the judgment to the Federal Circuit and the appeal is pending. Oral argument has been scheduled for December 8, 2020.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On September 22, 2020, the Delaware Court entered judgment for the Delaware Defendants on the grounds that the judgment of the West Virginia Court applies to the Delaware Actions under principles of collateral estoppel. We have appealed the judgment and the appeal is pending. Multiple generic versions of TECFIDERA have entered the U.S. market prior to resolution of the appeals.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On August 31, 2020, we filed a patent infringement action under the Hatch-Waxman Act against Sun Pharmaceutical Industries Limited, Sun Pharmaceutical Industries, Inc. and Sun Pharma Global SZE in the Delaware Court. No trial has been scheduled in this action.</span></div><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">European Patent Office Oppositions</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In 2016 the European Patent Office (EPO) revoked our European Patent No. 2 137 537, which covers the treatment of MS with 480 mg of dimethyl fumarate as provided for in our TECFIDERA label. We have appealed to the Technical Boards of Appeal of the EPO and a hearing has been set for January 2021. </span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In March 2018 the EPO revoked Forward Pharma A/S' (Forward Pharma) European Patent No. 2 801 355, which expires in October 2025. Forward Pharma has filed an appeal to the Technical Boards of Appeal of the EPO and a hearing has been set for February 2021. </span></div></ix:continuation><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_7">Table of Contents</a></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(unaudited, continued)</span></div></div><ix:continuation id="ia31c378001f644cab03a2a99cc5af2b0"><div style="text-indent:13.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">TYSABRI Patent Revocation Matters</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In November 2017 Bioeq GMBH, affiliated with the Polpharma Group, brought an action in the Polish Patent Office seeking to revoke Polish Patent No. 215263 (the Polish '263 Patent), which corresponds to our European Patent No. 1 485 127 (the E.U. '127 Patent) and covers administration of natalizumab (TYSABRI) to treat MS. The Polish '263 Patent expires in February 2023. No hearing has been set in this matter.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Swiss Pharma International AG, also affiliated with the Polpharma Group, filed actions in the District Court of the Hague, Netherlands (January 2016), the German Patents Court (March 2016) and the Commercial Court of Rome (November 2017) seeking to invalidate the Dutch, German and Italian counterparts, respectively, of the E.U. '127 Patent, which also cover administration of natalizumab (TYSABRI) to treat MS and expire in February 2023. The Dutch and German counterparts were ruled invalid. The decision in the Dutch action was affirmed on appeal and the German appeal has been withdrawn. No hearing has been set in the Italian action.</span></div><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">'755 Patent Litigation</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In May&#160;2010 Biogen MA Inc. (formerly Biogen Idec MA Inc.) filed a complaint in the U.S.&#160;District Court for the District of New Jersey alleging infringement by Bayer Healthcare Pharmaceuticals Inc. (Bayer) (manufacturer, marketer and seller of BETASERON and manufacturer of EXTAVIA), EMD Serono, Inc. (EMD Serono) (manufacturer, marketer and seller of REBIF), Pfizer (co-marketer of REBIF) and Novartis Pharmaceuticals Corp. (Novartis) (marketer and seller of EXTAVIA) of our U.S. Patent No. 7,588,755 (the '755 Patent), which claims, among other things, the use of interferon beta for immunomodulation. The complaint seeks monetary damages, including lost profits and royalties. </span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Bayer, Pfizer, Novartis and EMD Serono all filed counterclaims seeking declaratory judgments of patent invalidity and non-infringement and seeking monetary relief in the form of costs and attorneys' fees. Bayer had previously filed a complaint against us in the same court, on May 27, 2010, seeking a declaratory judgment that it does not infringe the '755 Patent and that the '755 Patent is invalid, and seeking monetary relief in the form of attorneys' fees, costs and expenses. Bayer has also requested </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">ex parte</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> reexamination by the U.S. Patent and Trademark Office of Claim 1 of the &#8216;755 Patent, which request was granted in January 2020 and is pending.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In September 2020 the Federal Circuit reversed the trial court's judgment against EMD Serono and Pfizer that the '755 patent is valid. We intend to file a petition for panel rehearing and rehearing en banc.</span></div><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Annulment Proceeding in General Court of the European Union relating to TECFIDERA</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In October 2018 Pharmaceutical Works Polpharma SA (Polpharma) filed an application in the General Court of the European Union seeking to annul a decision of the European Medicines Agency (EMA) in which the EMA refused to validate Polpharma&#8217;s application to market a generic version of TECFIDERA on the grounds that TECFIDERA benefits from regulatory data protection (RDP). Polpharma disputes that TECFIDERA benefits from RDP. Biogen and the European Commission were granted leave to intervene in the case in support of the EMA and the case is pending. A hearing was held on</span><span style="background-color:rgb(255,255,255, 0.0);color:#ff0000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">July 13, 2020, and we are awaiting a decision.</span></div><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Government Matters</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have learned that state and U.S. governmental authorities are investigating our sales and promotional practices and have received related subpoenas. We are cooperating with the investigation.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have received subpoenas and other requests from the U.S. government for documents and information relating to our relationship with non-profit organizations that assist patients taking drugs sold by Biogen and the government has challenged some of our contributions to these organizations. We have reached an agreement in principle with the government to resolve this matter. We have accrued the amount of our best estimate of the minimum probable loss in this matter.</span></div><div style="text-indent:13.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Product Liability and Other Legal Proceedings</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are also involved in product liability claims and other legal proceedings generally incidental to our normal business activities. While the outcome of any of these proceedings cannot be accurately predicted, we do not believe the ultimate resolution of any of these existing matters would have a material adverse effect on our business or financial condition.</span></div></ix:continuation><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">44</span></div></div></div><div id="ib19ff89608c84168a635160f2efa48f3_130"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_7">Table of Contents</a></span></div></div><div style="width:100.000%;"><div style="display:inline-block;vertical-align:top;width:46.491%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Item&#160;2.&#160;&#160;&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following discussion should be read in conjunction with our unaudited condensed consolidated financial statements (condensed consolidated financial statements) and the accompanying notes beginning on page&#160;5 of this quarterly report on Form&#160;10-Q and our audited consolidated financial statements and the accompanying notes included in our Annual Report on Form&#160;10-K for the year ended December 31, 2019 (2019 Form&#160;10-K).</span></div><div id="ib19ff89608c84168a635160f2efa48f3_133"></div><div style="margin-top:14pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Executive Summary</span></div><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Introduction</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Biogen is a global biopharmaceutical company focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. Our core growth areas include multiple sclerosis (MS) and neuroimmunology; Alzheimer's disease and dementia; neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS); movement disorders, including Parkinson's disease; and ophthalmology. We are also focused on discovering, developing and delivering worldwide innovative therapies in our emerging growth areas of immunology; neurocognitive disorders; acute neurology; and pain. In addition, we commercialize biosimilars of advanced biologics. We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities.  </span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; and FUMADERM for the treatment of severe plaque psoriasis. We also have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of primary progressive MS and relapsing MS (RMS); and other potential anti-CD20 therapies pursuant to our collaboration arrangements with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group. For additional information on our collaboration arrangements with Genentech, please read </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Note 18,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Collaborative and Other Relationships,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> to our </span></div></div><div style="display:inline-block;vertical-align:top;min-width:6.017%;max-width:7.017%;"></div><div style="display:inline-block;vertical-align:top;width:46.492%;"><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">consolidated financial statements included in our 2019 Form 10-K.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our innovative drug development and commercialization activities are complemented by our biosimilar business that expands access to medicines and reduces the cost burden for healthcare systems. Through Samsung Bioepis Co., Ltd. (Samsung Bioepis), our joint venture with Samsung BioLogics Co., Ltd. (Samsung BioLogics), we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL, IMRALDI, an adalimumab biosimilar referencing HUMIRA, and FLIXABI, an infliximab biosimilar referencing REMICADE, in certain countries in Europe and have exclusive rights to commercialize these products in China. Additionally, we have exclusive rights to commercialize two potential ophthalmology biosimilar products, SB11 referencing LUCENTIS and SB15 referencing EYLEA, in major markets worldwide, including the U.S., Canada, Europe, Japan and Australia. For additional information on our collaboration arrangements with Samsung Bioepis, please read </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Note 17, Collaborative and Other Relationships,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> to our condensed consolidated financial statements included in this report.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are committed to ensuring an uninterrupted supply of medicines to patients around the world. To that end, we continually review our manufacturing capacity, capabilities, processes and facilities. In order to support our future growth and drug development pipeline, we are expanding our large molecule production capacity by building a large-scale biologics manufacturing facility in Solothurn, Switzerland, which we expect to be partially operational during the first half of 2021. We believe that the Solothurn manufacturing facility will provide us with the ability to further expand if our future growth and drug development plans increase.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our revenues depend upon continued sales of our products as well as the financial rights we have in our anti-CD20 therapeutic programs, and, unless we develop, acquire rights to and/or commercialize new products and technologies, we will be substantially dependent on sales from our products and our financial rights in our anti-CD20 therapeutic programs for many years. </span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In the longer term, our revenue growth will depend upon the successful clinical development, regulatory approval and launch of new commercial products as well as additional indications for our existing products, our ability to obtain and maintain patents and other rights related to our marketed products, assets originating from our research and development efforts and/or successful execution of external business development opportunities.</span></div></div></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_7">Table of Contents</a></span></div></div><div style="width:100.000%;"><div style="display:inline-block;vertical-align:top;width:46.491%;"><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Business Environment</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The biopharmaceutical industry and the markets in which we operate are intensely competitive. Many of our competitors are working to develop or have commercialized products similar to those we market or are developing and have considerable experience in undertaking clinical trials and in obtaining regulatory approval to market pharmaceutical products. In addition, the commercialization of certain of our own approved products, products of our collaborators and pipeline product candidates may negatively impact future sales of our existing products. </span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our products and revenue streams continue to face increasing competition in many markets from generic versions, prodrugs and biosimilars of existing products as well as products approved under abbreviated regulatory pathways. Such products are likely to be sold at substantially lower prices than branded products. Accordingly, the introduction of such products as well as other lower-priced competing products may significantly reduce both the price that we are able to charge for our products and the volume of products we sell, which will negatively impact our revenues. In addition, when a generic version of one of our products is commercialized, it may, in some cases, be automatically substituted for our product and reduce our revenues in a short period of time. </span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Sales of our products depend, to a significant extent, on the availability and extent of adequate coverage, pricing and reimbursement from government health administration authorities, private health insurers and other organizations. When a new pharmaceutical product is approved, the availability of government and private reimbursement for that product may be uncertain, as is the pricing and amount for which that product will be reimbursed.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Drug prices are under significant scrutiny in the markets in which our products are prescribed.&#160;We expect drug pricing and other health care costs to continue to be subject to intense political and societal pressures on a global basis.&#160;</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our failure to obtain or maintain adequate coverage, pricing or reimbursement for our products could have an adverse effect on our business, reputation, revenues and results of operations, could curtail or eliminate our ability to adequately fund research and development programs for the discovery and commercialization of new products or could cause a decline or volatility in our stock price.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition to&#160;the impact of competition, pricing actions and other measures being taken worldwide designed to reduce healthcare costs and limit the overall level of government expenditures, our sales and operations could also be affected by other risks of doing business internationally, including the impact of public health epidemics, such as the COVID-19 </span></div></div><div style="display:inline-block;vertical-align:top;min-width:6.017%;max-width:7.017%;"></div><div style="display:inline-block;vertical-align:top;width:46.492%;"><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">pandemic, on employees, the global economy and the delivery of healthcare treatments, foreign currency exchange fluctuations, changes in intellectual property legal protections and changes in trade regulations and procedures.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For additional information on the competition and pricing risks that could negatively impact our product sales, please read </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Item 3. Quantitative and Qualitative Disclosures About Market Risk </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">and </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Item 1A.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Risk Factors</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> included in this report.</span></div><div style="text-indent:13.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">TECFIDERA</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2020 and September 2020 judgments were entered in favor of the defendants in the patent infringement proceedings relating to TECFIDERA Orange-Book listed patents pursuant to the Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch-Waxman Act, in West Virginia and Delaware. We have appealed the judgments in both actions. For additional information, please read </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Note 19, Litigation,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> to our condensed consolidated financial statements included in this report.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Multiple TECFIDERA generic entrants are now in the U.S. market, some of which have deeply discounted prices compared to TECFIDERA. The generic competition for TECFIDERA significantly reduced our TECFIDERA revenues during the third quarter of 2020 and is expected to have a substantial negative impact on our TECFIDERA revenues for as long as there is generic competition. For additional information, please read the discussion under </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Results of Operations - Product Revenues - Multiple Sclerosis (MS) - Fumarate</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> below.</span></div><div style="text-indent:13.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Brexit </span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2016 the U.K. electorate voted in a referendum to voluntarily depart from the E.U., known as Brexit. In March 2017 the U.K. government formally notified the European Council of its intention to leave the E.U. and began to negotiate the terms of its withdrawal and outline the future relationship between the U.K. and the E.U. upon exit, which occurred on January 31, 2020. Following the U.K.&#8217;s departure, there is now a transition period during which existing arrangements will remain in place until the end of 2020, allowing detailed discussions on the future relationship between the U.K. and the E.U. to take place.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The actual effects of Brexit will depend upon many factors and significant uncertainty remains with respect to the future relationship between the U.K. and the E.U. The final outcome of the discussions during the transition period may impact certain of our research, commercial and general business operations in the U.K. and the E.U., including the approval and supply of our products. </span></div></div></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_7">Table of Contents</a></span></div></div><div style="width:100.000%;"><div style="display:inline-block;vertical-align:top;width:46.491%;"><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Compliance with any resulting regulatory mandates may prove challenging and the macroeconomic impact on our sales and consolidated results of operations from these developments remains unknown. We do not expect Brexit to have a material impact on our consolidated results of operations as less than 4.0% of our total product revenues for the three and nine months ended September 30, 2020, were derived from U.K. sales, which is consistent with full year product sales in 2019.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have implemented measures to meet E.U. legal and regulatory requirements and continue to modify our business operations to prepare for the end of the transition period and the finalization of the terms of the U.K.'s separation from the E.U. However, we cannot predict the direction Brexit-related developments will take nor the impact of those developments on our European operations and the economies of the markets where we operate. Therefore, we will continue to monitor developments in this area and assess any potential impact on our business and results of operations.</span></div><div style="text-indent:13.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Business Update Regarding COVID-19</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The COVID-19 pandemic continues to present a substantial public health and economic challenge around the world. The length of time and full extent to which the COVID-19 pandemic directly or indirectly impacts our business, results of operations and financial condition depends on future developments that are highly uncertain, subject to change and are difficult to predict, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19 as well as the economic impact on local, regional, national and international customers and markets.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are monitoring the demand for our products, including the duration and degree to which we may see delays in starting new patients on a product due to hospitals diverting the resources that are necessary to administer certain of our products to care for COVID-19 patients, including products, such as TYSABRI and SPINRAZA, that are administered in a physician's office or hospital setting. We may also see reduced demand for immunosuppressant therapies during the COVID-19 pandemic.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">While we are currently continuing the clinical trials we have underway in sites across the globe, COVID-19 precautions have impacted the timeline for some of our clinical trials and these precautions may, directly or indirectly, have a further impact on timing in the future. For example, our Phase 3 study of BIIB093 (glibenclamide IV) for large hemispheric infarction, a severe form of ischemic stroke, has been delayed as this study involves administration of BIIB093 in an acute hospital setting. To help mitigate the impact of </span></div></div><div style="display:inline-block;vertical-align:top;min-width:6.017%;max-width:7.017%;"></div><div style="display:inline-block;vertical-align:top;width:46.492%;"><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">the COVID-19 pandemic to our clinical trials, we are pursuing innovative approaches such as remote monitoring, remote patient visits and supporting home infusions. These alternative measures have resulted in an immaterial increase to the cost of the clinical trials underway.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For additional information on the various risks posed by the COVID-19 pandemic, please read </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Item 3. Quantitative and Qualitative Disclosures About Market Risk </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">and </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Item 1A.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Risk Factors</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> included in this report.</span></div></div></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">47</span></div></div></div><div id="ib19ff89608c84168a635160f2efa48f3_136"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_7">Table of Contents</a></span></div></div><div style="width:100.000%;"><div style="display:inline-block;vertical-align:top;width:46.491%;"><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Financial Highlights</span></div><div style="text-align:justify;"><img src="biib-20200930_g2.jpg" alt="biib-20200930_g2.jpg" style="height:426px;width:317px;"/></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Diluted earnings per share attributable to Biogen Inc. was $4.46 for the three months ended September 30, 2020, representing a decrease of 46.8% compared to $8.39 in the same period in 2019.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As further described below under </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Results of Operations</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, our net income and diluted earnings per share attributable to Biogen Inc. for the three months ended September 30, 2020, compared to the three months ended September 30, 2019, reflects the following:</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">Total revenues were $3,376.1 million for the third quarter of 2020, representing a $224.0&#160;million, or 6.2%, decrease compared to $3,600.1 million in the same period in 2019.</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">Product revenues, net totaled $2,690.3 million for the third quarter of 2020, representing a $204.4&#160;million, or 7.1%, decrease compared to $2,894.7 million in the same period in 2019. This decrease was primarily due to a $52.7&#160;million, or 9.6%, decrease in SPINRAZA and a $175.3&#160;million, or 8.1%, decrease in MS product revenues, partially offset by a $24.3&#160;million, or 13.2%, increase in revenues from our biosimilar products. </span></div></div><div style="display:inline-block;vertical-align:top;min-width:6.017%;max-width:7.017%;"></div><div style="display:inline-block;vertical-align:top;width:46.492%;"><div style="text-indent:-18pt;padding-left:72pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#9702;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.59pt;">The decrease in MS product revenues was primarily due to a decrease in TECFIDERA demand and pricing as a result of multiple TECFIDERA generic entrants entering the U.S. market during the third quarter of 2020.</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">Revenues from anti-CD20 therapeutic programs (our share of RITUXAN, including RITUXAN HYCELA, and GAZYVA collaboration operating profits) totaled $560.1 million for the third quarter of 2020, representing a $35.7&#160;million, or 6.0%, decrease compared to $595.8 million in the same period in 2019. This decrease was primarily due to a $129.8&#160;million, or 33.0%, decrease in RITUXAN revenues, partially offset by a $84.6&#160;million, or 45.1%, increase in royalty revenues on sales of OCREVUS. We believe that sales of RITUXAN have been adversely affected by the onset of biosimilars competition.</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">Other revenues totaled $125.7 million for the third quarter of 2020, representing a 14.7% increase from $109.6 million in the same period in 2019.</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">Total cost and expenses were $2,289.7 million for the third quarter of 2020, representing a $495.9&#160;million increase compared to $1,793.8 million in the same period in 2019. This increase was primarily due to a $600.5&#160;million</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">increase in research and development expense.</span></div><div style="text-indent:-18pt;padding-left:72pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#9702;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.59pt;">The increase in research and development expense was primarily due to $601.3 million in charges recognized in connection with our collaboration with Denali Therapeutics Inc. (Denali) in the third quarter of 2020.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As described below under </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Financial Condition, Liquidity and Capital Resources:</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">Cash, cash equivalents and marketable securities totaled approximately $4.6 billion and $5.9 billion as of September 30, 2020 and December 31, 2019, respectively.</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">We repurchased and retired approximately 4.5 million shares of our common stock at a cost of approximately $1.3 billion during the third quarter of 2020 under a program authorized by our Board of Directors in December 2019 to repurchase up to $5.0 billion of our common stock (December 2019 Share Repurchase Program). Our December 2019 Share Repurchase Program was completed as of September 30, 2020.</span></div></div></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_7">Table of Contents</a></span></div></div><div style="width:100.000%;"><div style="display:inline-block;vertical-align:top;width:46.491%;"><div style="text-indent:13.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Acquisitions and Collaborative and Other Relationships</span></div><div style="text-indent:11.25pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">BIIB118 Acquisition</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In March 2020 we acquired BIIB118 (formerly known as PF-05251749), a novel CNS-penetrant small molecule inhibitor of casein kinase 1, for the potential treatment of patients with behavioral and neurological symptoms across various psychiatric and neurological diseases from Pfizer Inc. (Pfizer). We plan to develop this Phase 1 asset for the potential treatment of sundowning in Alzheimer's disease and irregular sleep wake rhythm disorder in Parkinson&#8217;s disease. </span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For additional information on our acquisition of BIIB118, please read </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Note 2, Acquisitions, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">to our condensed consolidated financial statements included in this report</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">.</span></div><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Sangamo Therapeutics, Inc.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In April 2020 we closed a collaboration and license agreement with Sangamo Therapeutics, Inc. (Sangamo) to develop and commercialize ST-501 for tauopathies, including Alzheimer's disease; ST-502 for synucleinopathies, including, Parkinson&#8217;s disease; a third neuromuscular disease target; and up to nine additional neurological disease targets to be identified and selected within a five-year period.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For additional information on our collaboration arrangement with Sangamo, please read </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Note 17, Collaborative and Other Relationships,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> to our condensed consolidated financial statements included in this report.</span></div><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Denali Therapeutics Inc.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In August 2020 we entered into a collaboration and license agreement with Denali to co-develop and co-commercialize Denali's small molecule inhibitors of leucine-rich repeat kinase 2 (LRRK2) for Parkinson's disease. </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition to the LRRK2 program, we also received an exclusive option to license two preclinical programs from Denali&#8217;s Transport Vehicle (TV) platform, including its Antibody Transport Vehicle: Abeta program, and a second program utilizing its TV technology. Further, we have the right of first negotiation on two additional TV-enabled therapeutics, currently at a preclinical stage, should Denali decide to seek a collaboration for such programs.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For additional information on our collaboration arrangements with Denali, please read </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Note 17, Collaborative and Other Relationships,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> to our condensed consolidated financial statements included in this report.</span></div></div><div style="display:inline-block;vertical-align:top;min-width:6.017%;max-width:7.017%;"></div><div style="display:inline-block;vertical-align:top;width:46.492%;"><div style="text-indent:13.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Other Key Developments</span></div><div style="text-indent:13.5pt;margin-top:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Aducanumab (AB mAb)</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In July 2020 we completed the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for the approval of aducanumab, an anti-amyloid beta antibody candidate for the potential treatment of Alzheimer's disease that we are developing in collaboration with Eisai Co., Ltd. (Eisai). The completed submission followed ongoing collaboration with the FDA and includes clinical data from the Phase 3 EMERGE and ENGAGE studies as well as the Phase 1b PRIME study. In August 2020 the FDA accepted the BLA and granted Priority Review with a Prescription Drug User Fee Act action date on March 7, 2021.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the first quarter of 2020, we initiated the EMBARK global re-dosing clinical study, which is designed to evaluate aducanumab in eligible Alzheimer's disease patients who were actively enrolled in aducanumab studies (PRIME, EVOLVE, EMERGE and ENGAGE) in March 2019.</span></div><div style="text-indent:13.5pt;margin-top:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">SB11 (referencing LUCENTIS)</span></div><div style="text-indent:13.5pt;margin-top:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In October 2020 we and Samsung Bioepis announced that the European Medicines Agency accepted for review the Marketing Authorization Application for SB11, a proposed biosimilar referencing LUCENTIS (ranibizumab).</span></div><div style="text-indent:13.5pt;margin-top:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Healthy Climate, Healthy Lives</span></div><div style="text-indent:13.5pt;margin-top:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In September 2020 we announced </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Healthy Climate, Healthy Lives</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, a $250.0&#160;million, 20-year initiative to eliminate our fossil fuels across our operations and collaborate with renowned institutions with the aim to improve health, especially for the world's most vulnerable populations.</span></div><div style="text-indent:13.5pt;margin-top:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">2020 Share Repurchase Program</span></div><div style="text-indent:13.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In October 2020 our Board of Directors authorized a program to repurchase up to $5.0 billion of our common stock (2020 Share Repurchase Program). Our 2020 Share Repurchase Program does not have an expiration date. All share repurchases under our 2020 Share Repurchase Program will be retired.</span></div></div></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">49</span></div></div></div><div id="ib19ff89608c84168a635160f2efa48f3_139"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_7">Table of Contents</a></span></div></div><div style="margin-top:13pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Results of Operations</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Revenues</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Revenues are summarized as follows:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.976%;"><tr><td style="width:1.0%;"></td><td style="width:30.362%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.538%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.728%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.538%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.728%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.538%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.728%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.538%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.728%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.538%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.728%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.538%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.728%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.538%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.728%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.538%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.738%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Three Months Ended September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In millions, except percentages)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Product revenues, net:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">United States</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">1,498.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">44.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,702.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">47.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">4,803.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">45.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,959.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">46.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Rest of world</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">1,192.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">35.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,192.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">33.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">3,587.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">33.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,495.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">32.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total product revenues, net</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2,690.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">79.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,894.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">80.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">8,390.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">79.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,455.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">79.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenues from anti-CD20 therapeutic programs</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">560.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">16.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">595.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">1,558.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">14.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,689.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other revenues</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">125.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">3.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">109.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">642.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">6.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">562.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total revenues</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">3,376.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">100.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,600.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">100.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">10,592.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">100.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,706.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">100.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><div><span><br/></span></div><div id="ib19ff89608c84168a635160f2efa48f3_142"></div><div style="width:100.000%;"><div style="display:inline-block;vertical-align:top;width:46.491%;"><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Product Revenues</span></div></div><div style="display:inline-block;vertical-align:top;min-width:6.017%;max-width:7.017%;"></div><div style="display:inline-block;vertical-align:top;width:46.492%;"></div></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Product revenues are summarized as follows:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%;"><tr><td style="width:1.0%;"></td><td style="width:30.177%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.976%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.535%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.976%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.535%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.976%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.535%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.976%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.542%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Three Months Ended September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In millions, except percentages)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Multiple Sclerosis:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fumarate*</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">967.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">36.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,122.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">38.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">3,258.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">38.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,271.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">38.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interferon**</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">474.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">17.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">530.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">1,421.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">17.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,585.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">TYSABRI</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">516.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">19.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">483.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">1,470.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">17.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,419.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">FAMPYRA</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">26.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">1.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">78.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">0.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">71.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Subtotal: MS product revenues</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">1,984.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">73.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,160.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">74.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">6,229.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">74.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,347.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">75.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Spinal Muscular Atrophy:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">SPINRAZA</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">494.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">18.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">547.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">1,554.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">18.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,553.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Biosimilars:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">BENEPALI</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">124.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">4.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">115.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">363.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">4.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">360.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">IMRALDI</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">56.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">49.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">162.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">1.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">132.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">FLIXABI</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">27.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">1.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">71.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">0.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">49.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Subtotal: Biosimilar product revenues</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">207.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">7.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">183.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">598.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">7.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">542.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">FUMADERM</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">3.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">0.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">9.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">0.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total product revenues</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2,690.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">100.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,894.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">100.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">8,390.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">100.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,455.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">100.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">*Fumarate includes TECFIDERA and VUMERITY. VUMERITY became commercially available in the U.S. in November 2019.</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">**Interferon includes AVONEX and PLEGRIDY.</span></div><div style="width:100.000%;"><div style="display:inline-block;vertical-align:top;width:46.491%;"></div><div style="display:inline-block;vertical-align:top;min-width:6.017%;max-width:7.017%;"></div><div style="display:inline-block;vertical-align:top;width:46.492%;"></div></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_7">Table of Contents</a></span></div></div><div style="width:100.000%;"><div style="display:inline-block;vertical-align:top;width:46.491%;"><div style="text-indent:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Multiple Sclerosis (MS)</span></div><div style="text-indent:11.25pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Fumarate</span></div><div><img src="biib-20200930_g3.jpg" alt="biib-20200930_g3.jpg" style="height:293px;width:317px;"/></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Fumarate revenues include sales from TECFIDERA and VUMERITY. In October 2019 the FDA approved VUMERITY for the treatment of RMS and VUMERITY became commercially available in the U.S. in November 2019.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the three and nine months ended September 30, 2020, compared to the same periods in 2019, the decreases of 18.7% and 1.9%, respectively, in U.S. Fumarate revenues were primarily due to a decrease in TECFIDERA demand and pricing as a result of multiple TECFIDERA generic entrants entering the U.S. market during the third quarter of 2020. Decreases were also due to unfavorable pricing, driven by discounts and allowances.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the three months ended September 30, 2020, compared to the same period in 2019, the increase in rest of world Fumarate revenues was primarily due to an increase in sales volume of 5.9%, partially offset by unfavorable foreign currency impact.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the nine months ended September 30, 2020, compared to the same period in 2019, the increase of 4.0% in rest of world Fumarate revenues was primarily due to an increase in sales volumes of 10.0%, which was primarily related to our European and Japanese markets, partially offset by pricing reductions in certain European countries. The increase in volumes was primarily due to continued strong patient growth in our E.U. direct markets, including Italy, Spain and the U.K. as well as growth in Asia (Japan) and Latin America (Brazil).</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2020 and September 2020 judgments were entered in favor of the defendants in the patent infringement proceedings relating to TECFIDERA Orange-Book listed patents pursuant to the Hatch-Waxman Act in West Virginia and Delaware. We have </span></div></div><div style="display:inline-block;vertical-align:top;min-width:6.017%;max-width:7.017%;"></div><div style="display:inline-block;vertical-align:top;width:46.492%;"><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">appealed the judgments in both actions.</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For additional information, please read </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Note 19, Litigation,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> to our condensed consolidated financial statements included in this report.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Multiple TECFIDERA generic entrants are now in the U.S. market, some of which have deeply discounted prices compared to TECFIDERA. The generic competition for TECFIDERA significantly reduced our TECFIDERA revenues during the third quarter of 2020 and is expected to have a substantial negative impact on our TECFIDERA revenues for as long as there is generic competition.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We anticipate an increase in TECFIDERA demand in rest of world in 2020, compared to 2019, notwithstanding the increasing competition from additional treatments for MS and potential disruptions from the COVID-19 pandemic.</span></div><div style="text-indent:13.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Interferon</span></div><div><img src="biib-20200930_g4.jpg" alt="biib-20200930_g4.jpg" style="height:293px;width:317px;"/></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the three and nine months ended September 30, 2020, compared to the same periods in 2019, the decreases of 9.2% and 9.5%, respectively, in U.S. Interferon revenues were primarily due to decreases in Interferon sales volumes of 11.8% and 10.4%, respectively. The net declines in sales volumes reflect the continued decline of the Interferon market as patients transition to other higher efficacy and oral MS therapies, which negatively impacted comparative revenues by $42.5 million and $110.7 million, respectively.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the three and nine months ended September 30, 2020, compared to the same periods in 2019, the decreases of 13.5% and 12.0%, respectively, in rest of world Interferon revenues were primarily due to decreases in Interferon sales volumes of 8.5% and 7.5%, respectively.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We expect that Interferon revenues will continue to decline in both the U.S. and rest of world markets </span></div></div></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_7">Table of Contents</a></span></div></div><div style="width:100.000%;"><div style="display:inline-block;vertical-align:top;width:46.491%;"><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">in 2020, compared to 2019, as a result of increasing competition from our other MS products as well as other treatments for MS, including biosimilars, and pricing reductions in certain European markets.</span></div><div style="text-indent:13.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">TYSABRI</span></div><div><img src="biib-20200930_g5.jpg" alt="biib-20200930_g5.jpg" style="height:333px;width:317px;"/></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the three and nine months ended September 30, 2020, compared to the same periods in 2019, the increases of 15.7% and 7.0%, respectively, in U.S. TYSABRI revenues were primarily due to favorable volume impacts and price increases, partially offset by higher discounts and allowance rates.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the three months ended September 30, 2020, compared to the same period in 2019, the decrease of 3.8% in rest of world TYSABRI revenues was primarily due to an unfavorable foreign currency impact of approximately $11.5 million, partially offset by a favorable volume impact of approximately $3.6 million.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the</span><span style="background-color:rgb(255,255,255, 0.0);color:#ff0000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">nine months ended September 30, 2020, compared to the same period in 2019, rest of world TYSABRI revenues remained flat.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We anticipate TYSABRI demand to be stable on a global basis in 2020, compared to 2019, despite increasing competition from additional treatments for MS, including OCREVUS. We believe that some TYSABRI infusions may be delayed due, directly or indirectly, to the COVID-19 pandemic. </span></div></div><div style="display:inline-block;vertical-align:top;min-width:6.017%;max-width:7.017%;"></div><div style="display:inline-block;vertical-align:top;width:46.492%;"><div style="text-indent:13.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Spinal Muscular Atrophy</span></div><div style="text-indent:13.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">SPINRAZA</span></div><div><img src="biib-20200930_g6.jpg" alt="biib-20200930_g6.jpg" style="height:293px;width:317px;"/></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the three and nine months ended September 30, 2020, compared to the same periods in 2019, the decreases of 22.9% and 9.0%, respectively, in U.S. SPINRAZA revenues were primarily due to a decreases in sales volumes of 22.4% and 7.6%, respectively, resulting from increased competition as well as lower loading and maintenance doses and site of care closures as a result of the COVID-19 pandemic.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the three months ended September 30, 2020, compared to the same period in 2019, rest of world SPINRAZA revenues remained flat.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the nine months ended September 30, 2020, compared to the same period in 2019, the increase of 7.3% in rest of world SPINRAZA revenues was primarily due to an increase in sales volumes of 18.2%, partially offset by the impact of a shift from loading to maintenance doses, lower net prices and the unfavorable impact of foreign currency exchange.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We expect that the rate at which SPINRAZA revenues will grow will be modest in 2020, compared to 2019, primarily due to a lower rate of new patient starts combined with the impact of loading dose dynamics as patients transition to dosing once every four months, lower prices in certain rest of world countries and the potential impact of the COVID-19 pandemic. We are evaluating the impact of the COVID-19 pandemic on the ability of hospitals to provide SPINRAZA dosing to patients. We believe that some SPINRAZA doses may be delayed due, directly or indirectly, to the COVID-19 pandemic.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We face competition from a new gene therapy product that was approved in the U.S. in May 2019 and in the E.U. in May 2020 for the treatment of SMA as well as a new oral product for the treatment of </span></div></div></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_7">Table of Contents</a></span></div></div><div style="width:100.000%;"><div style="display:inline-block;vertical-align:top;width:46.491%;"><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">SMA that was approved in the U.S. in August 2020. Additionally, we are aware of other products now in development that, if launched, may compete with SPINRAZA. Future sales of SPINRAZA may be adversely affected by the commercialization of competing products.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For information on our collaboration arrangements with Ionis Pharmaceuticals, Inc. (Ionis), please read </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Note 18,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Collaborative and Other Relationships,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> to our consolidated financial statements included in our 2019 Form 10-K. </span></div><div style="text-indent:13.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Biosimilars</span></div><div style="text-indent:13.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">BENEPALI, IMRALDI and FLIXABI</span></div><div><img src="biib-20200930_g7.jpg" alt="biib-20200930_g7.jpg" style="height:333px;width:317px;"/></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the three and nine months ended September 30, 2020, compared to the same periods in 2019, the increases of 13.2% and 10.3%, respectively, in biosimilar revenues were primarily due to higher volumes and favorable foreign currency impact, partially offset by the unfavorable impact of price decreases.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In 2020 we expect modest to moderate revenue growth for our biosimilars business depending on the impact of the COVID-19 pandemic. We expect growth to be primarily driven by the continued launch of IMRALDI in Europe, partially offset by price reductions in certain European countries.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For additional information on our collaboration arrangements with Samsung Bioepis, please read </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Note 17, Collaborative and Other Relationships,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> to our condensed consolidated financial statements included in this report.</span></div><div id="ib19ff89608c84168a635160f2efa48f3_145"></div></div><div style="display:inline-block;vertical-align:top;min-width:6.017%;max-width:7.017%;"></div><div style="display:inline-block;vertical-align:top;width:46.492%;"><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Revenues from Anti-CD20 Therapeutic Programs</span></div><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Genentech (Roche Group)</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our share of RITUXAN, including RITUXAN HYCELA, and GAZYVA collaboration operating profits in the U.S. and other revenues from anti-CD20 therapeutic programs are summarized in the table below. For purposes of this discussion, we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.</span></div><div><img src="biib-20200930_g8.jpg" alt="biib-20200930_g8.jpg" style="height:346px;width:317px;"/></div><div style="text-indent:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Biogen&#8217;s Share of Pre-tax Profits in the U.S. for RITUXAN and GAZYVA</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following tables provide a summary of amounts comprising our share of pre-tax profits in the U.S. for RITUXAN and GAZYVA:</span></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.371%;"><tr><td style="width:1.0%;"></td><td style="width:52.064%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:1.382%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:20.735%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:1.382%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:20.737%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Three Months Ended September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In millions)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Product revenues, net</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">814.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,189.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost and expenses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">81.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">141.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Pre-tax profits in the U.S.</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">733.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,048.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Biogen's share of pre-tax profits</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">275.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">393.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td></tr></table></div><div style="text-align:center;margin-top:11pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.371%;"><tr><td style="width:1.0%;"></td><td style="width:52.064%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:1.382%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:20.735%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:1.382%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:20.737%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In millions)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Product revenues, net</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2,700.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,581.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost and expenses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">350.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">473.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Pre-tax profits in the U.S.</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2,350.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,108.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Biogen's share of pre-tax profits</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">873.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,161.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td></tr></table></div></div></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_7">Table of Contents</a></span></div></div><div style="width:100.000%;"><div style="display:inline-block;vertical-align:top;width:46.491%;"><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the three and nine months ended September 30, 2020, compared to the same periods in 2019, the decreases in U.S.&#160;product revenues, net were primarily due to decreased sales volume of RITUXAN in the U.S. of 26.0% and 21.5%, respectively, due to the onset of competition from multiple biosimilars and, we believe, the adverse impacts due, directly or indirectly, to the COVID-19 pandemic.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the three and nine months ended September 30, 2020, compared to the same periods in 2019, product revenues, net also reflects increases in GAZYVA sales volume of 25.4% and 32.5%, respectively.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the three and nine months ended September 30, 2020, compared to the same periods in 2019, the decreases in collaboration costs and expenses were primarily due to lower cost of sales on RITUXAN.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are aware of anti-CD20 molecules, including biosimilar products, in development that if successfully developed and approved, could compete with RITUXAN and GAZYVA in the oncology market. The introduction of one or more competitive products can result in significant reduction in net sales for the relevant product, as other manufacturers typically offer their versions at lower prices. In November 2019 and January 2020 biosimilar products referencing RITUXAN were launched in the U.S. An additional biosimilar entrant is possible. This competition has adversely affected the pre-tax profits of our collaboration arrangements with Genentech and could have a significant adverse affect on our co-promotion profits in the U.S. in future years.</span></div></div><div style="display:inline-block;vertical-align:top;min-width:6.017%;max-width:7.017%;"></div><div style="display:inline-block;vertical-align:top;width:46.492%;"><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Other Revenues from Anti-CD20 Therapeutic Programs</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Other revenues from anti-CD20 therapeutic programs consist of royalty revenues on sales of OCREVUS and our share of pre-tax co-promotion profits from RITUXAN in Canada. </span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the three and nine months ended September 30, 2020, compared to the same periods in 2019, the increases in other revenues from anti-CD20 therapeutic programs were primarily due to sales growth of OCREVUS. Royalty revenues recognized on sales of OCREVUS for the three and nine months ended September 30, 2020, totaled $272.5 million and $643.0 million, respectively, compared to $187.8 million and $482.1 million, respectively, in the prior year comparative periods.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">OCREVUS royalty revenues are based on our estimates from third party and market research data of OCREVUS sales occurring during the corresponding period. Differences between actual and estimated royalty revenues will be adjusted for in the period in which they become known, which is generally expected to be the following quarter.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For additional information on our collaboration arrangements with Genentech, including information regarding the pre-tax profit-sharing formula and its impact on future revenues from anti-CD20 therapeutic programs, please read </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Note&#160;18, Collaborative and Other Relationships,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> to our consolidated financial statements included in our 2019 Form 10-K.</span></div><div id="ib19ff89608c84168a635160f2efa48f3_148"></div></div></div><div style="margin-top:14pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Other Revenues</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Other revenues are summarized as follows:</span></div><div style="margin-top:5pt;margin-bottom:14pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.976%;"><tr><td style="width:1.0%;"></td><td style="width:25.635%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.538%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.319%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.538%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.319%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.538%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.319%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.538%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.319%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.538%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.319%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.538%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.319%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.538%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.319%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.538%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.328%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Three Months Ended September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In millions, except percentages)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenues from collaborative and other relationships</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">5.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">4.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">14.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">89.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other royalty and corporate revenues</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">120.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">95.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">96.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">88.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">628.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">97.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">472.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">84.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total other revenues</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">125.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">100.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">109.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">100.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">642.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">100.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">562.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">100.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><div style="width:100.000%;"><div style="display:inline-block;vertical-align:top;width:46.491%;"><div style="text-indent:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Revenues from Collaborative and Other Relationships</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Revenues from collaborative and other relationships primarily include revenues from our technical development services and manufacturing agreements with Samsung Bioepis and royalty revenues on biosimilar products from Samsung Bioepis.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Following the divestiture of our Hiller&#248;d, Denmark manufacturing operations in August 2019, FUJIFILM Corporation (FUJIFILM) assumed responsibility for the manufacture of clinical and </span></div></div><div style="display:inline-block;vertical-align:top;min-width:6.017%;max-width:7.017%;"></div><div style="display:inline-block;vertical-align:top;width:46.492%;"><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">commercial quantities of bulk drug substance of biosimilar products for Samsung Bioepis. We no longer recognize revenues for the manufacturing completed after the Hiller&#248;d, Denmark manufacturing operations divestiture date under our technical development services and manufacturing agreements with Samsung Bioepis.</span></div></div></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_7">Table of Contents</a></span></div></div><div style="width:100.000%;"><div style="display:inline-block;vertical-align:top;width:46.491%;"><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For additional information on our collaborative and other relationships, including revenues recognized under our technical development services and manufacturing agreements with Samsung Bioepis, please read </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Note 17, Collaborative and Other Relationships,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> to our condensed consolidated financial statements included in this report.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For additional information on the divestiture of our Hiller&#248;d, Denmark manufacturing operations, please read </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Note 3, Divestitures,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> to our condensed consolidated financial statements included in this report.</span></div><div style="text-indent:11.25pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Other Royalty and Corporate Revenues</span></div><div><img src="biib-20200930_g9.jpg" alt="biib-20200930_g9.jpg" style="height:400px;width:317px;"/></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We receive royalties from net sales on products related to patents that we have out-licensed and we record other corporate revenues primarily from amounts earned under contract manufacturing agreements.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the third quarter of 2019, we amended our agreement with a contract manufacturing customer pursuant to which we licensed certain of our manufacturing-related intellectual property to the customer. In the second quarter of 2020, the customer received regulatory approval for its product that is being manufactured using certain of our manufacturing-related intellectual property. As a result, we are entitled to $500.0 million in a series of three payments. The first payment became due upon regulatory approval of such product and was received during the second quarter of 2020. Subsequent </span></div></div><div style="display:inline-block;vertical-align:top;min-width:6.017%;max-width:7.017%;"></div><div style="display:inline-block;vertical-align:top;width:46.492%;"><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">payments are due on the first and second anniversaries of the regulatory approval. </span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Other corporate revenues for the nine months ended September 30, 2020, reflect $333.2 million related to the delivery of the license for certain of our manufacturing-related intellectual property under the amended agreement discussed above and the performance of manufacturing product supply services for such customer. We have allocated the remaining $166.8&#160;million of the $500.0 million transaction price to the performance of manufacturing product supply services for the customer, which we expect to perform through 2026. The value allocated to the manufacturing services was based on expected demand for supply and the fair value of comparable manufacturing and development services.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the three months ended September 30, 2020, compared to the same period in 2019, the increase in other royalty and corporate revenues was primarily due to an increase in royalty revenues and higher contract manufacturing revenues.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the nine months ended September 30, 2020, compared to the same period in 2019, the increase in other royalty and corporate revenues was due to higher contract manufacturing revenues, primarily resulting from $333.2 million in revenues related to the delivery of the license for certain of our manufacturing-related intellectual property to a contract manufacturing customer, as discussed above. The increase was partially offset by revenues recognized in 2019 under the manufacturing and supply agreement with Bioverativ Inc. (Bioverativ) entered into in connection with the spin-off of our hemophilia business as well as revenues recognized in 2019 under our technical development services and manufacturing agreements with Samsung Bioepis prior to the divestiture of our Hiller&#248;d, Denmark manufacturing operations.</span></div><div id="ib19ff89608c84168a635160f2efa48f3_151"></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Reserves for Discounts and Allowances</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Revenues from product sales are recorded net of reserves established for applicable discounts and allowances, including those associated with the implementation of pricing actions in certain international markets where we operate.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to our customer) or a liability (if the amount is payable to a party other than our customer). These estimates reflect our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. Actual amounts may ultimately differ from our estimates. If actual results </span></div></div></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_7">Table of Contents</a></span></div></div><div style="width:100.000%;"><div style="display:inline-block;vertical-align:top;width:46.491%;"><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">vary, we adjust these estimates, which could have an effect on earnings in the period of adjustment.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Reserves for discounts, contractual adjustments and returns that reduced gross product revenues are summarized as follows:</span></div><div><img src="biib-20200930_g10.jpg" alt="biib-20200930_g10.jpg" style="height:600px;width:317px;"/></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the three and nine months ended September 30, 2020, reserves for discounts and allowances as a percentage of gross product revenues were 27.3% and 26.3%, respectively, compared to 24.4% and 23.5%, respectively, in the prior year comparative periods. </span></div></div><div style="display:inline-block;vertical-align:top;min-width:6.017%;max-width:7.017%;"></div><div style="display:inline-block;vertical-align:top;width:46.492%;"><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Discounts</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Discounts include trade term discounts and wholesaler incentives.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the three and nine months ended September 30, 2020, compared to the same periods in 2019, the increases in discounts were primarily driven by increases in gross sales. </span></div><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Contractual Adjustments</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Contractual adjustments primarily relate to Medicaid and managed care rebates, co-payment assistance, Veterans Administration, Public Health Service discounts, specialty pharmacy program fees and other government rebates or applicable allowances.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the three months ended September 30, 2020, compared to the same period in 2019, the decrease in contractual adjustments was primarily due to a favorable change in estimates.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the nine months ended September 30, 2020, compared to the same period in 2019, the increase in contractual adjustments was primarily due to higher managed care rebates and governmental rebates in the U.S. as well as higher governmental rebates and allowances in the rest of world, due in part to increases in SPINRAZA sales volumes worldwide.</span></div><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Returns</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Product return reserves are established for returns made by wholesalers. In accordance with contractual terms, wholesalers are permitted to return product for reasons such as damaged or expired product. The majority of wholesaler returns are due to product expiration. Provisions for product returns are recognized in the period the related revenues are recognized, resulting in a reduction to product sales.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the three and nine months ended September 30, 2020, compared to the same periods in 2019, return reserves were relatively consistent.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For additional information on our revenue reserves, please read </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Note 4, Revenues,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> to our condensed consolidated financial statements included in this report.</span></div></div></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">56</span></div></div></div><div id="ib19ff89608c84168a635160f2efa48f3_154"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_7">Table of Contents</a></span></div></div><div style="margin-top:14pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Cost and Expenses</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A summary of total cost and expenses is as follows:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:43.929%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.525%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.525%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.233%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.233%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.233%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.242%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Three Months Ended September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In millions, except percentages)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change&#160;%</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change&#160;%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost of sales, excluding amortization and impairment of acquired intangible assets</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">449.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">430.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">1,314.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,508.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(12.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">1,140.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">540.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">111.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2,264.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,588.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">42.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Selling, general and administrative</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">573.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">554.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">1,698.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,709.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortization and impairment of acquired intangible assets</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">82.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">283.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(70.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">215.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">422.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(48.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Collaboration profit (loss) sharing</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">73.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">60.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">166.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">181.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(8.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Loss on divestiture of Hiller&#248;d, Denmark manufacturing operations</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(17.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">**</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">95.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">**</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Gain) loss on fair value remeasurement of contingent consideration</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(29.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(57.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(49.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(23.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(66.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(64.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restructuring charges</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(100.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(100.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Acquired in-process research and development</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">**</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">75.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">**</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cost and expenses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2,289.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,793.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">27.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">5,711.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,441.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">** Percentage not meaningful.</span></div><div id="ib19ff89608c84168a635160f2efa48f3_157"></div><div style="width:100.000%;"><div style="display:inline-block;vertical-align:top;width:46.491%;"><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Cost of Sales, Excluding Amortization and Impairment of Acquired Intangible Assets</span></div><div><img src="biib-20200930_g11.jpg" alt="biib-20200930_g11.jpg" style="height:293px;width:317px;"/></div><div style="text-indent:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Product Cost of Sales</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the three months ended September 30, 2020, compared to the same period in 2019, the increase in product cost of sales was primarily due to higher cost of sales associated with higher revenues from contract manufacturing agreements.</span></div></div><div style="display:inline-block;vertical-align:top;min-width:6.017%;max-width:7.017%;"></div><div style="display:inline-block;vertical-align:top;width:46.492%;"><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the nine months ended September 30, 2020, compared to the same period in 2019, the decrease in product cost of sales was primarily due to lower cost of sales from contract manufacturing agreements, primarily resulting from the sale of hemophilia inventory, with a cost basis of $173.5 million, to Bioverativ in the first quarter of 2019 and FUJIFILM assuming responsibility for the manufacture of clinical and commercial quantities of bulk drug substance of biosimilar products for Samsung Bioepis.</span></div><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Royalty Cost of Sales</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the three months ended September 30, 2020, compared to the same period in 2019, the decrease in royalty cost of sales was primarily due to lower royalties payable on lower sales of SPINRAZA. </span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the nine months ended September 30, 2020, compared to the same period in 2019, the increase in royalty cost of sales was primarily due to higher royalties payable on higher sales of TYSABRI and VUMERITY.</span></div></div></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">57</span></div></div></div><div id="ib19ff89608c84168a635160f2efa48f3_160"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_7">Table of Contents</a></span></div></div><div style="width:100.000%;"><div style="display:inline-block;vertical-align:top;width:46.491%;"><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Research and Development</span></div><div><img src="biib-20200930_g12.jpg" alt="biib-20200930_g12.jpg" style="height:366px;width:317px;"/></div></div><div style="display:inline-block;vertical-align:top;min-width:6.017%;max-width:7.017%;"></div><div style="display:inline-block;vertical-align:top;width:46.492%;"><div><img src="biib-20200930_g13.jpg" alt="biib-20200930_g13.jpg" style="height:766px;width:317px;"/></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A significant amount of our research and development costs consist of indirect costs incurred in support of overall research and development activities and non-specific programs, including activities that benefit multiple programs, such as </span></div></div></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_7">Table of Contents</a></span></div></div><div style="width:100.000%;"><div style="display:inline-block;vertical-align:top;width:46.491%;"><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">management costs, as well as depreciation, information technology and facility-based expenses. These costs are considered other research and development costs in the table above and are not allocated to a specific program or stage.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Research and development expense incurred in support of our marketed products includes costs associated with product lifecycle management activities including, if applicable, costs associated with the development of new indications for existing products. Late stage programs are programs in Phase 3 development or in registration stage. Early stage programs are programs in Phase 1 or Phase 2 development. Research and discovery represents costs incurred to support our discovery research and translational science efforts. Costs are reflected in the development stage based upon the program status when incurred. Therefore, the same program could be reflected in different development stages in the same year. For several of our programs, the research and development activities are part of our collaborative and other relationships. Our costs reflect our share of the total costs incurred.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the three months ended September 30, 2020, compared to the same period in 2019, the increase in research and development expense was primarily due to approximately $601.3 million in charges recognized in connection with our collaboration with Denali in the third quarter of 2020.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the nine months ended September 30, 2020, compared to the same period in 2019, the increase in research and development expense was primarily due to approximately $601.3 million and $208.0&#160;million in charges recognized upon the closing of our collaborations with Denali and Sangamo, respectively.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">While we are currently continuing the clinical trials we have underway in sites across the globe, COVID-19 precautions have impacted the timeline for some of our clinical trials and these precautions may, directly or indirectly, have a further impact on timing in the future. For example, our Phase 3 study of BIIB093 for large hemispheric infarction has been delayed as this study involves administration of BIIB093 in an acute hospital setting.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We intend to continue committing significant resources to targeted research and development opportunities where there is a significant unmet need and where a drug candidate has the potential to be highly differentiated.</span></div><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Milestone and Upfront Expenses</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the three months ended September 30, 2020, compared to the same period in 2019, the increase in milestone and upfront expenses was primarily due to a $601.3 million charge to research </span></div></div><div style="display:inline-block;vertical-align:top;min-width:6.017%;max-width:7.017%;"></div><div style="display:inline-block;vertical-align:top;width:46.492%;"><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">and development expense related to our collaboration with Denali in the third quarter of 2020.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the nine months ended September 30, 2020, compared to the same period in 2019, the increase in milestone and upfront expenses was primarily due to approximately $601.3 million and $208.0&#160;million in charges to research and development expense related to our collaboration and license agreements with Denali and Sangamo, respectively.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For additional information on our collaboration agreements with Denali and Sangamo, please read </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Note 17, Collaborative and Other Relationships, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">to our condensed consolidated financial statements included in this report.</span></div><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Early Stage Programs</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the three and nine months ended September 30, 2020, compared to the same periods in 2019, the decreases in spending related to our early stage programs were primarily due to decreases in costs associated with:</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">the discontinuation of gosuranemab (BIIB092) in progressive supraneuclear palsy; and </span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">the advancement of toferson (BIIB067) in ALS into late stage. </span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The decreases were partially offset by increases in costs associated with:</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">spending in the development of BIIB112 (RPGR gene therapy) in X-linked retinitis pigmentosa; and</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">the discontinuation of the Phase 2b study of BG00011 (STX-100) for the potential treatment of idiopathic pulmonary fibrosis (IPF).</span></div><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Late Stage Programs</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the three and nine months ended September 30, 2020, compared to the same periods in 2019, the decreases in spending associated with our late stage programs were primarily due to:</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">a decrease in spending related to the discontinuation of the global Phase 3 trials of aducanumab, net of reimbursement from our collaboration partner Eisai in the first quarter of 2019;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">a decrease in spending related to the discontinuation of the global Phase 3 trials, MISSION AD1 and MISSION AD2, of elenbecestat (development code: E2609) in patients with early Alzheimer's disease in the third quarter of 2019; and</span></div></div></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_7">Table of Contents</a></span></div></div><div style="width:100.000%;"><div style="display:inline-block;vertical-align:top;width:46.491%;"><div style="text-indent:-18pt;padding-left:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">a decrease in spending related to VUMERITY, which was approved by the FDA in the fourth quarter of 2019.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">These decreases were partially offset by an increase in spending due to the advancement of toferson in ALS into late stage, an increase in spending related to BAN2401, a monoclonal antibody that targets amyloid beta aggregates, in early Alzheimer's disease that we are developing in collaboration with Eisai, our EMBARK redosing study for aducanumab and BIIB111 (timrepigene emparvovec) in choroideremia.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In the first quarter of 2019, as a result of the decision to discontinue the Phase 3 EMERGE and ENGAGE trials following a futility analysis, we accrued approximately $45.0 million related to the termination of various clinical trials and research and development contracts net of the expected 45% Eisai reimbursement of development costs incurred by the collaboration for the advancement of aducanumab.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In October 2019 we and Eisai announced that, based on a new analysis, conducted by Biogen in consultation with the FDA, of a larger dataset from the Phase 3 EMERGE and ENGAGE trials that were discontinued in March 2019, we plan to pursue regulatory approval for aducanumab in the U.S. In July 2020 we completed the submission of a BLA to the FDA for the approval of aducanumab.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In March 2019 Eisai initiated a global Phase 3 trial for the development of BAN2401 in early Alzheimer's disease. Under our collaboration arrangement, Eisai serves as the global operational and regulatory lead for BAN2401 and all costs, including research, development, sales and marketing expenses, are shared equally between us and Eisai.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For additional information on our collaboration arrangements with Eisai, please read </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Note 17, Collaborative and Other Relationships, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">to our condensed consolidated financial statements included in this report.</span></div></div><div style="display:inline-block;vertical-align:top;min-width:6.017%;max-width:7.017%;"></div><div style="display:inline-block;vertical-align:top;width:46.492%;"><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Selling, General and Administrative</span></div><div><img src="biib-20200930_g14.jpg" alt="biib-20200930_g14.jpg" style="height:293px;width:317px;"/></div><div style="text-indent:24.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the three months ended September 30, 2020, compared to the same period in 2019, selling, general and administrative expense increased 3.4%, primarily due to increases in personnel in support of the potential launch of aducanumab.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the nine months ended September 30, 2020, compared to the same period in 2019, selling, general and administrative expense remained flat.</span></div><div id="ib19ff89608c84168a635160f2efa48f3_163"></div><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Amortization and Impairment of Acquired Intangible Assets</span></div><div><img src="biib-20200930_g15.jpg" alt="biib-20200930_g15.jpg" style="height:293px;width:317px;"/></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our amortization expense is based on the economic consumption and impairment of intangible assets. Our most significant intangible assets are related to our TYSABRI, AVONEX, SPINRAZA, VUMERITY and TECFIDERA (rest of world) products and other programs acquired through business combinations. </span></div></div></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_7">Table of Contents</a></span></div></div><div style="width:100.000%;"><div style="display:inline-block;vertical-align:top;width:46.491%;"><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the three and nine months ended September 30, 2020, amortization and impairment of acquired intangible assets reflects the impact of a $19.3&#160;million impairment charge related to one of our in-process research and development (IPR&amp;D) intangible assets. </span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the three and nine months ended September 30, 2019, amortization and impairment of acquired intangible assets reflects the impact of a $215.9&#160;million impairment charge related to certain IPR&amp;D assets associated with the Phase 2b study of BG00011 (STX-100) for the potential treatment of IPF, which was discontinued in the third quarter of 2019.</span></div><div style="text-indent:24.75pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the three and nine months ended September 30, 2020, amortization of acquired intangible assets, excluding impairment charges, totaled $63.3&#160;million and $196.3&#160;million, respectively, compared to $68.0&#160;million and $206.3&#160;million, respectively, in the prior year comparative periods.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We monitor events and expectations regarding product performance. If new information indicates that the assumptions underlying our most recent analysis are substantially different than those utilized in our current estimates, our analysis would be updated and may result in a significant change in the anticipated lifetime revenues of the relevant products. The occurrence of an adverse event could substantially increase the amount of amortization expense related to our acquired intangible assets as compared to previous periods or our current expectations, which may result in a significant negative impact on our future results of operations.</span></div><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">IPR&amp;D Related to Business Combinations</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">IPR&amp;D represents the fair value assigned to research and development assets that we acquired as part of a business combination and had not yet reached technological feasibility at the date of acquisition. We review amounts capitalized as acquired IPR&amp;D for impairment annually, as of October 31, and whenever events or changes in circumstances indicate to us that the carrying value of the assets might not be recoverable. </span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Overall, the value of our acquired IPR&amp;D assets is dependent upon several variables, including estimates of future revenues and the effects of competition, our ability to secure sufficient pricing in a competitive market, our ability to confirm safety and efficacy based on data from clinical trials and regulatory feedback, the level of anticipated development costs and the probability and timing of successfully advancing a particular research program from one clinical trial phase to the next. We are continually reevaluating our estimates concerning these and other variables, including our life cycle management strategies, research and development </span></div></div><div style="display:inline-block;vertical-align:top;min-width:6.017%;max-width:7.017%;"></div><div style="display:inline-block;vertical-align:top;width:46.492%;"><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">priorities and development risk, changes in program and portfolio economics and related impact of foreign currency exchange rates and economic trends and evaluating industry and company data regarding the productivity of clinical research and the development process. Changes in our estimates and prioritization of these programs may result in a significant change to our valuation of our IPR&amp;D assets.</span></div><div style="text-indent:13.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Vixotrigine</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In the periods since we acquired vixotrigine (BIIB074), there have been numerous delays in the initiation of Phase 3 studies for the potential treatment of trigeminal neuralgia (TGN) as we engaged with the FDA regarding the design of the Phase 3 studies and awaited data and insights from mid-stage clinical trials of vixotrigine in other indications that have since been completed. The fair value of the TGN asset is not significantly in excess of carrying value. As of September 30, 2020, the carrying value associated with our vixotrigine IPR&amp;D assets was $167.6 million.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For additional information on the amortization and impairment of our acquired intangible assets, please read </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Note 6, Intangible Assets and Goodwill,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> to our condensed consolidated financial statements included in this report.</span></div><div id="ib19ff89608c84168a635160f2efa48f3_166"></div><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Collaboration Profit (Loss) Sharing</span></div><div><img src="biib-20200930_g16.jpg" alt="biib-20200930_g16.jpg" style="height:293px;width:317px;"/></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Collaboration profit (loss) sharing primarily includes Samsung Bioepis' 50% share of the profit or loss related to our biosimilars commercial agreement with Samsung Bioepis.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the three and nine months ended September 30, 2020, we recognized net profit-sharing expense of $72.9 million and $200.1 million, respectively, to reflect Samsung Bioepis' 50% sharing of the net collaboration profits compared to $60.1 million and </span></div></div></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_7">Table of Contents</a></span></div></div><div style="width:100.000%;"><div style="display:inline-block;vertical-align:top;width:46.491%;"><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">$181.6 million, respectively, in the prior year comparative periods. </span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the nine months ended September 30, 2020, we also recognized net profit-sharing income of $33.8 million to reflect Eisai's 45% share of the $75.0 million milestone expense related to the completed submission of the BLA to the FDA for approval of aducanumab.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For additional information on our collaboration arrangements with Samsung Bioepis and Eisai, please read </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Note 17, Collaborative and Other Relationships,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> to our condensed consolidated financial statements included in this report. </span></div><div id="ib19ff89608c84168a635160f2efa48f3_169"></div></div><div style="display:inline-block;vertical-align:top;min-width:6.017%;max-width:7.017%;"></div><div style="display:inline-block;vertical-align:top;width:46.492%;"><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Loss on Divestiture of Hiller&#248;d, Denmark Manufacturing Operations</span></div><div><img src="biib-20200930_g17.jpg" alt="biib-20200930_g17.jpg" style="height:289px;width:317px;"/></div><div style="text-indent:22.5pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In March 2019 we entered into a share purchase agreement with FUJIFILM to sell all of the outstanding shares of our subsidiary that owned our biologics manufacturing operations in Hiller&#248;d, Denmark. The transaction closed in August 2019.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the nine months ended September 30, 2019, we recorded a loss of approximately $160.2 million in our condensed consolidated statements of income. This estimated loss included a pre-tax loss of $95.5 million, which reflected a $17.7 million decrease to our previously recorded pre-tax loss, reflecting our estimated fair value of the assets and liabilities held for sale as of September 30, 2019, adjusted for our expected costs to sell our Hiller&#248;d, Denmark manufacturing operations of approximately $11.2 million and included our initial estimate of the fair value of an adverse commitment of approximately $114.0 million associated with the guarantee of future minimum batch production at the Hiller&#248;d facility. The value of this adverse commitment was determined using a probability-weighted estimate of future manufacturing activity. In addition, we recorded a tax expense of $64.7 million related to the transaction during the nine months ended September 30, 2019.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For additional information on the divestiture of our Hiller&#248;d, Denmark manufacturing operations, please read </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Note 3, Divestitures,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> to our condensed consolidated financial statements included in this report.</span></div></div></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">62</span></div></div></div><div id="ib19ff89608c84168a635160f2efa48f3_172"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_7">Table of Contents</a></span></div></div><div style="width:100.000%;"><div style="display:inline-block;vertical-align:top;width:46.491%;"><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">(Gain) Loss on Fair Value Remeasurement of Contingent Consideration</span></div><div><img src="biib-20200930_g18.jpg" alt="biib-20200930_g18.jpg" style="height:293px;width:317px;"/></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Consideration payable for certain of our business combinations includes future payments that are contingent upon the occurrence of a particular event or events. We record an obligation for such contingent consideration payments at fair value on the acquisition date. We then revalue our contingent consideration obligations each reporting period. Changes in the fair value of our contingent consideration obligations, other than changes due to payments, are recognized as a (gain) loss on fair value remeasurement of contingent consideration in our condensed consolidated statements of income. </span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the three and nine months ended September 30, 2020, changes in the fair value of our contingent consideration obligations were primarily due to changes in the probability and the expected timing of the achievement of certain remaining developmental milestones as well as changes in the interest rates used to revalue our contingent consideration liabilities and the passage of time.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the three and nine months ended September 30, 2019, changes in the fair value of our contingent consideration obligations were primarily due to the discontinuation of our BG00011 program for the potential treatment of IPF, partially offset by a decrease in interest rates used to revalue our contingent consideration liabilities and the passage of time.</span></div><div id="ib19ff89608c84168a635160f2efa48f3_175"></div></div><div style="display:inline-block;vertical-align:top;min-width:6.017%;max-width:7.017%;"></div><div style="display:inline-block;vertical-align:top;width:46.492%;"><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Acquired In-Process Research and Development</span></div><div><img src="biib-20200930_g19.jpg" alt="biib-20200930_g19.jpg" style="height:293px;width:317px;"/></div><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">BIIB118 Acquisition</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In March 2020 we acquired BIIB118 from Pfizer for the potential treatment of patients with behavioral and neurological symptoms across various psychiatric and neurological diseases. In connection with this acquisition, we made an upfront payment of $75.0 million to Pfizer, which was accounted for as an asset acquisition and recorded as acquired IPR&amp;D in our condensed consolidated statements of income as BIIB118 has not yet reached technological feasibility. </span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For additional information on our acquisition of BIIB118, please read </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Note 2, Acquisitions,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> to our condensed consolidated financial statements included in this report.</span></div><div id="ib19ff89608c84168a635160f2efa48f3_178"></div><div style="margin-top:14pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Other Income (Expense), Net</span></div><div><img src="biib-20200930_g20.jpg" alt="biib-20200930_g20.jpg" style="height:266px;width:317px;"/></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the three months ended September 30, 2020, compared to the same period in 2019, the change in other income (expense), net primarily </span></div></div></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_7">Table of Contents</a></span></div></div><div style="width:100.000%;"><div style="display:inline-block;vertical-align:top;width:46.491%;"><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">reflects net unrealized losses of approximately $82.1 million recognized on our investments related to our holdings in equity securities, compared to net unrealized losses totaling $4.1 million in the prior year comparative period. The net unrealized losses recognized during the three months ended September 30, 2020, primarily reflect a decrease in the fair value of Ionis common stock of approximately $66.2 million and a decrease in the fair value of Denali common stock of approximately $29.6 million, partially offset by an increase in the fair value of Sangamo common stock of approximately $15.2&#160;million.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the nine months ended September 30, 2020, compared to the same period in 2019, the change in other income (expense), net primarily reflects net unrealized losses of approximately $40.3 million recognized on our investments related to our holdings in equity securities, compared to net unrealized gains totaling $198.9&#160;million in the prior year comparative period. The net unrealized losses recognized during the nine months ended September 30, 2020, primarily reflect a decrease in the fair value of Ionis common stock of approximately $56.7&#160;million and a decrease in the fair value of Denali common stock of approximately $29.6&#160;million, partially offset by an increase in the fair value of Sangamo common stock of approximately $56.1&#160;million.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We expect interest expense will continue to increase as a result of the issuance of our senior unsecured notes for an aggregate principal amount of $3.0 billion (2020 Senior Notes). For additional information on our 2020 Senior Notes, please read </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Note 11, Indebtedness,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> to our condensed consolidated financial statements included in this report.</span></div><div id="ib19ff89608c84168a635160f2efa48f3_181"></div></div><div style="display:inline-block;vertical-align:top;min-width:6.017%;max-width:7.017%;"></div><div style="display:inline-block;vertical-align:top;width:46.492%;"><div style="margin-top:14pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Income Tax Provision</span></div><div><img src="biib-20200930_g21.jpg" alt="biib-20200930_g21.jpg" style="height:400px;width:317px;"/></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our effective tax rate fluctuates from year to year due to the global nature of our operations. The factors that most significantly impact our effective tax rate include changes in tax laws, variability in the allocation of our taxable earnings among multiple jurisdictions, the amount and characterization of our research and development expenses, the levels of certain deductions and credits, acquisitions and licensing transactions.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the three months ended September 30, 2020, compared to the same period in 2019, the increase in our effective tax rate was primarily due to an internal reorganization of certain intellectual property rights related to the intercompany sale of such intellectual property in 2019, the enactment of a new taxing regime in the country and certain cantons of Switzerland in 2019 (Swiss Tax Reform) and the net $33.3 million</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">income tax expense related to the establishment of a valuation allowance against certain deferred tax assets, the realization of which is dependent on future sales of TECFIDERA in the U.S.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For additional information, please read </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Note 19, Litigation,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> to our condensed consolidated financial statements included in this report.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the nine months ended September 30, 2020, compared to the same period in 2019, the increase in our effective tax rate was primarily due to the $89.3 million impact from the valuation allowance described above, the internal reorganization of certain intellectual property rights and Swiss Tax Reform, </span></div></div></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_7">Table of Contents</a></span></div></div><div style="width:100.000%;"><div style="display:inline-block;vertical-align:top;width:46.491%;"><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">partially offset by the $64.7 million tax expense recognized in September 30, 2019, related to the divestiture of our Hiller&#248;d, Denmark manufacturing operations. Although we recognized a loss on the divestiture of our Hiller&#248;d, Denmark manufacturing operations, the divestiture required us to write off certain deferred tax assets and resulted in a taxable gain in certain jurisdictions. For additional information on the divestiture of our Hiller&#248;d, Denmark manufacturing operations, please read </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Note 3, Divestitures, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">to our condensed consolidated financial statements included in this report.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For additional information on our income taxes please read </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Note 15, Income Taxes,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> to our condensed consolidated financial statements included in this report.</span></div><div id="ib19ff89608c84168a635160f2efa48f3_184"></div><div style="margin-top:14pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Equity in (Income) Loss of Investee, Net of Tax</span></div><div><span><br/></span></div><div><img src="biib-20200930_g22.jpg" alt="biib-20200930_g22.jpg" style="height:266px;width:317px;"/></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In February 2012 we entered into a joint venture agreement with Samsung BioLogics establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar products.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2018 we exercised our option under our joint venture agreement to increase our ownership percentage in Samsung Bioepis from approximately 5.0% to approximately 49.9%. The share purchase transaction was completed in November 2018 and, upon closing, we paid 759.5 billion South Korean won ($676.6 million) to Samsung BioLogics. As of September 30, 2020, our ownership percentage remained at approximately 49.9%.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We recognize our share of the results of operations related to our investment in Samsung Bioepis under the equity method of accounting one quarter in arrears when the results of the entity become available, which is reflected as equity in (income) loss of investee, net of tax in our condensed </span></div></div><div style="display:inline-block;vertical-align:top;min-width:6.017%;max-width:7.017%;"></div><div style="display:inline-block;vertical-align:top;width:46.492%;"><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">consolidated statements of income. During 2015, as our share of losses exceeded the carrying value of our investment, we suspended recognizing additional losses. In the first quarter of 2019 we restarted recognizing our share of Samsung Bioepis' (income) losses, and we began recognizing amortization on certain basis differences resulting from our November 2018 investment. </span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our joint venture partner, Samsung BioLogics, is currently subject to an ongoing criminal investigation that we continue to monitor. While this investigation could impact the operations of Samsung Bioepis and its business, we have assessed the value of our investment in Samsung Bioepis and continue to believe that the fair value of the investment is in excess of its net book value.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the three and nine months ended September 30, 2020, we recognized net losses on our investment of $13.1 million and $12.7 million, respectively, reflecting our share of Samsung Bioepis' operating results and amortization of basis differences.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For additional information on our collaboration arrangements with Samsung Bioepis, please read </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Note 17, Collaborative and Other Relationships,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> to our condensed consolidated financial statements included in this report.</span></div><div id="ib19ff89608c84168a635160f2efa48f3_187"></div><div style="margin-top:14pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Noncontrolling Interest</span></div><div><img src="biib-20200930_g23.jpg" alt="biib-20200930_g23.jpg" style="height:250px;width:317px;"/></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the three and nine months ended September 30, 2020, the change in net income (loss) attributable to noncontrolling interests, net of tax was primarily due to the $75.0 million milestone payment related to the completed submission of the BLA to the FDA for the approval of aducanumab.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For additional information, please read </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Note 18, Investments in Variable Interest Entities,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> to our condensed consolidated financial statements included in this report.</span></div></div></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_7">Table of Contents</a></span></div></div><div style="width:100.000%;"><div style="display:inline-block;vertical-align:top;width:46.491%;"><div style="text-indent:22.5pt;margin-top:6pt;"><span><br/></span></div><div id="ib19ff89608c84168a635160f2efa48f3_190"></div></div><div style="display:inline-block;vertical-align:top;min-width:6.017%;max-width:7.017%;"></div><div style="display:inline-block;vertical-align:top;width:46.492%;"></div></div><div style="margin-top:14pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Financial Condition, Liquidity and Capital Resources</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our financial condition is summarized as follows:</span></div><div style="margin-top:5pt;margin-bottom:14pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:53.870%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:14.543%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:14.397%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.600%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In millions, except percentages)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">As of September 30, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of December 31, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change&#160;%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Financial assets:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2,224.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,913.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(23.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Marketable securities &#8212; current</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">1,355.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,562.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(13.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Marketable securities &#8212; non-current</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">1,009.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,408.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(28.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash, cash equivalents and marketable securities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">4,589.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,884.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(22.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Borrowings:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current portion of notes payable</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,495.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(100.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Notes payable</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">7,425.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,459.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">66.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total borrowings</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">7,425.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,954.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Working capital:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current assets</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">7,843.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,381.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(6.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current liabilities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(3,804.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4,863.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(21.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total working capital</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">4,039.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,518.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><div id="ib19ff89608c84168a635160f2efa48f3_193"></div><div style="width:100.000%;"><div style="display:inline-block;vertical-align:top;width:46.491%;"><div style="text-indent:24.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the nine months ended September 30, 2020, certain significant cash flows were as follows:</span></div><div style="text-indent:-18pt;padding-left:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">$6.3 billion used for share repurchases;</span></div><div style="text-indent:-18pt;padding-left:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">$4.6 billion in net cash flows provided by operating activities;</span></div><div style="text-indent:-18pt;padding-left:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">$3.0 billion in net proceeds received from the issuance of our 2020 Senior Notes;</span></div><div style="text-indent:-18pt;padding-left:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">$1.5 billion payment made for the redemption of our 2.90% Senior Notes due September 15, 2020, prior to their maturity;</span></div><div style="text-indent:-18pt;padding-left:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">$752.7&#160;million in total payments for income taxes;</span></div><div style="text-indent:-18pt;padding-left:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">$423.7&#160;million used to purchase the Denali common stock;</span></div><div style="text-indent:-18pt;padding-left:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">$338.8 million used for purchases of property, plant and equipment;</span></div><div style="text-indent:-18pt;padding-left:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">$141.8 million used to purchase the Sangamo common stock;</span></div><div style="text-indent:-18pt;padding-left:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">$75.0 million milestone payment to Neurimmune SubOne AG (Neurimmune);</span></div><div style="text-indent:-18pt;padding-left:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">$75.0 million payment related to our acquisition of BIIB118 from Pfizer; and</span></div><div style="text-indent:-18pt;padding-left:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">$37.0 million payment to Samsung Bioepis in connection with the 2019 transaction.</span></div><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Overview</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We have historically financed our operating and capital expenditures primarily through cash flows earned through our operations. On April&#160;30, 2020, we </span></div></div><div style="display:inline-block;vertical-align:top;min-width:6.017%;max-width:7.017%;"></div><div style="display:inline-block;vertical-align:top;width:46.492%;"><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">issued our 2020 Senior Notes for an aggregate principal amount of $3.0 billion. We expect our operating expenditures, particularly those related to research and development, clinical trials, commercialization of new products and international expansion to continue to grow. However, we expect to continue funding our current and planned operating requirements primarily through cash flows earned from our operations as well as our existing cash resources and proceeds received from the issuance of our 2020 Senior Notes. Generic competition for TECFIDERA in the U.S. has begun and we believe that this competition will reduce our cash flow from operations in 2020 and will have a significant adverse impact on our future cash flows from operations. We believe that our existing funds, when combined with cash generated from operations and our access to additional financing resources, if needed, are sufficient to satisfy our operating, working capital, strategic alliance, milestone payment, capital expenditure and debt service requirements for the foreseeable future. In addition, we may choose to opportunistically return cash to shareholders and pursue other business initiatives, including acquisition and licensing activities. We may, from time to time, also seek additional funding through a combination of new collaborative agreements, strategic alliances and additional equity and debt financings or from other sources should we identify a significant new opportunity.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For additional information on certain risks that could negatively impact our financial position or future results of operations, please read</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"> Item 3. Quantitative and Qualitative Disclosures About Market Risk</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> and</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"> Item 1A.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Risk Factors</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> included in this report.</span></div></div></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_7">Table of Contents</a></span></div></div><div style="width:100.000%;"><div style="display:inline-block;vertical-align:top;width:46.491%;"><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Cash, Cash Equivalents and Marketable Securities</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Until required for another use in our business, we typically invest our cash reserves in bank deposits, certificates of deposit, commercial paper, corporate notes, U.S.&#160;and foreign government instruments, overnight reverse repurchase agreements and other interest-bearing marketable debt instruments in accordance with our investment policy. It is our policy to mitigate credit risk in our cash reserves and marketable securities by maintaining a well-diversified portfolio that limits the amount of exposure as to institution, maturity and investment type. In March 2020 there was a severe liquidity crisis in the capital markets, particularly with respect to securities with maturities of less than one year, due to the COVID-19 pandemic. This issue impacted pricing of securities in our portfolio as we attempted to decrease our marketable securities level and increase cash, leading to approximately $12.4 million in realized losses for the nine months ended September 30, 2020. We believe that recent actions taken by the U.S. Federal Reserve to enhance liquidity have stabilized the capital markets for the time being.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of September 30, 2020, we had cash, cash equivalents and marketable securities totaling approximately $4.6 billion compared to approximately $5.9 billion as of December 31, 2019. The net decrease in cash, cash equivalents and marketable securities at September 30, 2020, from December 31, 2019, was primarily due to cash used for share repurchases, the redemption of our 2.90% Senior Notes due September 15, 2020, the purchases of Sangamo and Denali common stock, net purchases of property, plant and equipment and payments made to Neurimmune, Pfizer and Samsung Bioepis, partially offset by cash flows from operations and net proceeds from the issuance of our 2020 Senior Notes.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Investments and other assets in our condensed consolidated balance sheets as of September 30, 2020 and December 31, 2019, include the carrying value of our investment in Samsung Bioepis of $557.8 million and $580.2 million, respectively. As Samsung Bioepis is a privately-held entity, our ability to liquidate our investment in Samsung Bioepis may be limited and we may realize significantly less than the value of such investment. This investment is also subject to foreign currency exchange fluctuations. Investments and other assets, as of September 30, 2020 and December 31, 2019, also include the fair value of our investment in Ionis common stock of $272.9 million and $329.6 million, respectively. </span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In connection with our collaboration and license agreement with Sangamo, we purchased approximately 24 million shares of Sangamo common stock in April 2020. As of September 30, 2020, the fair value of this investment was $197.9 million. In </span></div></div><div style="display:inline-block;vertical-align:top;min-width:6.017%;max-width:7.017%;"></div><div style="display:inline-block;vertical-align:top;width:46.492%;"><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">connection with our collaboration with Denali, we purchased approximately 13&#160;million shares of Denali common stock in September 2020. As of September 30, 2020, the fair value of this investment was $394.1&#160;million.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For additional information on our acquisition of BIIB118 from Pfizer, please read </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Note 2, Acquisitions,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> to our condensed consolidated financial statements included in this report. For additional information on our collaboration arrangements with Samsung Bioepis, Sangamo and Denali, please read </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Note 17, Collaborative and Other Relationships, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">to our condensed consolidated financial statements included in this report</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">. </span></div><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Borrowings</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In April 2020 we issued our 2020 Senior Notes for an aggregate principal amount of $3.0 billion, consisting of the following:</span></div><div style="text-indent:-18pt;padding-left:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">$1.5 billion aggregate principal amount of 2.25% Senior Notes due May 1, 2030; and</span></div><div style="text-indent:-18pt;padding-left:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">$1.5 billion aggregate principal amount of 3.15% Senior Notes due May 1, 2050.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following is a summary of our currently outstanding senior secured notes issued in 2015 (2015 Senior Notes):</span></div><div style="text-indent:-18pt;padding-left:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">$1.0 billion aggregate principal amount of 3.625% Senior Notes due September 15, 2022;</span></div><div style="text-indent:-18pt;padding-left:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">$1.75 billion aggregate principal amount of 4.05% Senior Notes due September 15, 2025; and</span></div><div style="text-indent:-18pt;padding-left:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">$1.75 billion aggregate principal amount of 5.20% Senior Notes due September 15,&#160;2045.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our 2020 Senior Notes and our 2015 Senior Notes were issued at a discount, which are amortized as additional interest expense over the period from issuance through maturity.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In May 2020 we redeemed our 2.90% Senior Notes due September 15, 2020, with an aggregate principal amount of $1.5 billion. </span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For a summary of the fair and carrying values of our outstanding borrowings as of September 30, 2020 and December 31, 2019, please read </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Note 7, Fair Value Measurements,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> to our condensed consolidated financial statements included in this report.</span></div><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">2020 Credit Facility</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In January 2020 we entered into a $1.0 billion, five-year senior unsecured revolving credit facility under which we are permitted to draw funds for working capital and general corporate purposes. The terms of the revolving credit facility include a financial </span></div></div></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_7">Table of Contents</a></span></div></div><div style="width:100.000%;"><div style="display:inline-block;vertical-align:top;width:46.491%;"><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">covenant that requires us not to exceed a maximum consolidated leverage ratio. This revolving credit facility replaced the revolving credit facility that we entered into in August 2015. As of September 30, 2020, we had no outstanding borrowings and were in compliance with all covenants under this facility.</span></div><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Working Capital</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Working capital is defined as current assets less current liabilities. The change in working capital at September 30, 2020, from December 31, 2019, reflects a decrease in total current assets of approximately $538.7 million and a decrease in total current liabilities of approximately $1.1 billion.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The decrease in total current assets was primarily driven by a decrease in net cash, cash equivalents and marketable securities, due to the purchase of Sangamo common stock for $225.0 million, the purchase of Denali common stock for $465.0&#160;million and $6.3&#160;billion in purchases of our common stock, partially offset by $4.6&#160;billion in cash flows from operations.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The net decrease in current liabilities was primarily due to the redemption of our 2.90% Senior Notes due September 15, 2020, which were classified within current liabilities as of December 31, 2019, and a reduction in accrued expenses and other, which was primarily related to the $100.0 million upfront payment made to Samsung Bioepis in connection with the 2019 transaction, which was accrued as of December 31, 2019.</span></div><div style="text-indent:11.25pt;margin-top:9pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Share Repurchase Programs</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In October 2020 our Board of Directors authorized our 2020 Share Repurchase Program, </span></div></div><div style="display:inline-block;vertical-align:top;min-width:6.017%;max-width:7.017%;"></div><div style="display:inline-block;vertical-align:top;width:46.492%;"><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">which is a program to repurchase up to $5.0 billion of our common stock. Our 2020 Share Repurchase Program does not have an expiration date. All share repurchases under our 2020 Share Repurchase Program will be retired.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In December 2019 our Board of Directors authorized our December 2019 Share Repurchase Program, which was a program to repurchase up to $5.0 billion of our common stock that was completed as of September 30, 2020. All shares repurchased under our December 2019 Share Repurchase Program were retired. Under our December 2019 Share Repurchase Program, we repurchased and retired approximately 4.5 million and 16.7 million shares of our common stock at a cost of approximately $1.3 billion and $5.0 billion during the three and nine months ended September 30, 2020, respectively.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In March 2019 our Board of Directors authorized a program to repurchase up to $5.0 billion of our common stock (March 2019 Share Repurchase Program) that was completed as of March&#160;31, 2020. All shares repurchased under our March 2019 Share Repurchase Program were retired. Under our March 2019 Share Repurchase Program, we repurchased and retired approximately 4.1 million shares of our common stock at a cost of approximately $1.3 billion during the nine months ended September 30, 2020.</span></div><div style="text-indent:13.5pt;margin-top:5pt;"><span><br/></span></div><div id="ib19ff89608c84168a635160f2efa48f3_196"></div></div></div><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Cash Flows</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes our cash flow activity:</span></div><div style="margin-top:5pt;margin-bottom:14pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%;"><tr><td style="width:1.0%;"></td><td style="width:55.728%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.556%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.556%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.558%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In millions, except percentages)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%&#160;Change</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash flows provided by operating activities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">4,596.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,118.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(10.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash flows used in investing activities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(442.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(237.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">85.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash flows used in financing activities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(4,871.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3,744.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">30.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr></table></div><div style="width:100.000%;"><div style="display:inline-block;vertical-align:top;width:46.491%;"><div style="text-indent:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Operating Activities</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cash flows from operating activities represent the cash receipts and disbursements related to all of our activities other than investing and financing activities. We expect cash provided from operating activities will continue to be our primary source of funds to finance operating needs and capital expenditures for the foreseeable future.</span></div></div><div style="display:inline-block;vertical-align:top;min-width:6.017%;max-width:7.017%;"></div><div style="display:inline-block;vertical-align:top;width:46.492%;"><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Operating cash flow is derived by adjusting our net income for:</span></div><div style="text-indent:-18pt;padding-left:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">non-cash operating items such as depreciation and amortization, impairment charges, unrealized gain (loss) on strategic investments, acquired IPR&amp;D and share-based compensation;</span></div><div style="text-indent:-18pt;padding-left:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">changes in operating assets and liabilities, which reflect timing differences between the receipt and payment of cash associated with transactions and when they are recognized in results of operations;&#160;and</span></div></div></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_7">Table of Contents</a></span></div></div><div style="width:100.000%;"><div style="display:inline-block;vertical-align:top;width:46.491%;"><div style="text-indent:-18pt;padding-left:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">changes in the fair value of contingent payments associated with our acquisitions of businesses and payments related to collaborations.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the nine months ended September 30, 2020, compared to the same period in 2019, the decrease in net cash flows provided by operating activities was primarily due to lower net income as well as increases in certain working capital asset balances.</span></div><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Investing Activities</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the nine months ended September 30, 2020, compared to the same period in 2019, the increase in net cash flows used in investing activities was primarily due to the purchases of the common stock of Sangamo and Denali during 2020, partially offset by higher proceeds received from the sale of investments as compared to the prior year. </span></div><div style="text-indent:13.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Financing Activities</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the nine months ended September 30, 2020, compared to the same period in 2019, the increase in net cash flows used in financing activities was primarily due to the greater number of shares repurchased in 2020 as compared to the comparative period in 2019 and the redemption of our 2.90% Senior Notes due September 15, 2020, partially offset by the net proceeds received from the issuance of our 2020 Senior Notes.</span></div><div id="ib19ff89608c84168a635160f2efa48f3_199"></div><div style="margin-top:14pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Contractual Obligations and Off-Balance Sheet Arrangements</span></div><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Contractual Obligations</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our contractual obligations primarily consist of our obligations under non-cancellable operating leases, long-term debt obligations and defined benefit and other purchase obligations, excluding amounts related to uncertain tax positions, funding commitments, contingent development, regulatory and commercial milestone payments, contingent payments and contingent consideration related to our business combinations, as described below.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">There have been no material changes in our contractual obligations since December 31, 2019.</span></div><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Contingent Payments</span></div><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">TYSABRI</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In 2013 we acquired from Elan Pharma International Ltd. (Elan), an affiliate of Elan Corporation plc, full ownership of all remaining rights to TYSABRI that we did not already own or control. Under the acquisition agreement, we are obligated to make contingent payments to Elan of 18.0% on annual worldwide net sales up to $2.0 billion and 25.0% on annual worldwide net sales that exceed </span></div></div><div style="display:inline-block;vertical-align:top;min-width:6.017%;max-width:7.017%;"></div><div style="display:inline-block;vertical-align:top;width:46.492%;"><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">$2.0 billion. Royalty payments to Elan and other third parties are recognized as cost of sales in our condensed consolidated statements of income. Elan was acquired by Perrigo Company plc (Perrigo) in December 2013 and Perrigo subsequently sold its rights to these payments to a third-party effective January 2017.</span></div><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">SPINRAZA</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In 2016 we exercised our option to develop and commercialize SPINRAZA from Ionis. Under our agreement with Ionis, we make royalty payments to Ionis on annual worldwide net sales of SPINRAZA using a tiered royalty rate between 11.0% and 15.0%, which are recognized as cost of sales in our condensed consolidated statements of income. For additional information on our collaboration arrangements with Ionis, please read </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Note 18, Collaborative and Other Relationships,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> to our consolidated financial statements included in our 2019 Form 10-K.</span></div><div style="text-indent:13.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">VUMERITY</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In October 2019 the FDA approved VUMERITY for the treatment of RMS. Under our agreement with Alkermes Pharma Ireland Limited, a subsidiary of Alkermes plc (Alkermes), we make royalty payments to Alkermes on worldwide net commercial sales of VUMERITY using a royalty rate of 15.0%, which are recorded as cost of sales in our consolidated statements of income. Royalties payable on net commercial sales of VUMERITY are subject, under certain circumstances, to tiered minimum annual payment requirements for a period of five years following FDA approval. For additional information on our collaboration arrangement with Alkermes, please read </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Note 18, Collaborative and Other Relationships,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> to our consolidated financial statements included in our 2019 Form 10-K.</span></div><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Contingent Consideration related to Business Combinations</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In connection with our acquisitions of Convergence Pharmaceuticals Ltd. and Biogen International Neuroscience GmbH, we agreed to make additional payments based upon the achievement of certain milestone events. We recognized the contingent consideration liabilities associated with these transactions at their fair value on the acquisition date and revalue these obligations each reporting period. We may pay up to approximately $735.0 million in remaining milestones related to these acquisitions.</span></div><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Contingent Development, Regulatory and Commercial Milestone Payments</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Based on our development plans as of September 30, 2020, we could trigger potential future </span></div></div></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_7">Table of Contents</a></span></div></div><div style="width:100.000%;"><div style="display:inline-block;vertical-align:top;width:46.491%;"><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">milestone payments to third parties of up to approximately $8.9 billion, including approximately $1.7 billion in development milestones, approximately $1.3 billion in regulatory milestones and approximately $5.9 billion in commercial milestones, as part of our various collaborations, including licensing and development programs. Payments under these agreements generally become due and payable upon achievement of certain development, regulatory or commercial milestones. Because the achievement of these milestones was not considered probable as of September 30, 2020, such contingencies have not been recorded in our financial statements. Amounts related to contingent milestone payments are not considered contractual obligations as they are contingent on the successful achievement of certain development, regulatory or commercial milestones.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Provided various development, regulatory or commercial milestones are achieved, we anticipate that we may pay approximately $4.0 million of milestone payments for the remainder of 2020. We may also pay $100.0 million if aducanumab is launched in the U.S. In July 2020 we completed the submission of a BLA to the FDA for the approval of aducanumab. During the third quarter of 2020, we paid Neurimmune SubOne AG (Neurimmune) $75.0 million upon the completed submission of the BLA for aducanumab with the FDA, which was recognized as a charge to noncontrolling interests for the nine months ended September 30, 2020. In addition, for the nine months ended September 30, 2020, we recognized net profit-sharing income of $33.8 million to reflect Eisai's 45% share of the $75.0 million milestone expense.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For additional information on our collaboration arrangements with Eisai, please read </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Note 17, Collaborative and Other Relationships,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> to our condensed consolidated financial statements included in this report.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For additional information on our collaboration arrangement with Neurimmune, please read </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Note 18, Investments in Variable Interest Entities,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> to our condensed consolidated financial statements included in this report.</span></div><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Other Funding Commitments</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of September 30, 2020, we have several ongoing clinical studies in various clinical trial stages. Our most significant clinical trial expenditures are to contract research organizations (CROs). The contracts with CROs are generally cancellable, with notice, at our option. We recorded accrued expenses of approximately $3.5 million in our condensed consolidated balance sheet for expenditures incurred by CROs as of September 30, 2020. We have approximately $557.8 million in cancellable future </span></div></div><div style="display:inline-block;vertical-align:top;min-width:6.017%;max-width:7.017%;"></div><div style="display:inline-block;vertical-align:top;width:46.492%;"><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">commitments based on existing CRO contracts as of September 30, 2020.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As part of the sale of our Hiller&#248;d, Denmark manufacturing operations to FUJIFILM, we provided FUJIFILM with certain minimum batch production commitment guarantees. There is a risk that the minimum contractual batch production commitments will not be met. Our estimate of the adverse commitment obligation is approximately $74.0 million as of September 30, 2020. We developed this estimate using a probability-weighted estimate of future manufacturing activity and may adjust this estimate based upon changes in business conditions, which may result in the increase or reduction of this adverse commitment obligation in subsequent periods.</span></div><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Tax Related Obligations</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We exclude liabilities pertaining to uncertain tax positions from our summary of contractual obligations as we cannot make a reliable estimate of the period of cash settlement with the respective taxing authorities. As of September 30, 2020, we have approximately $154.8 million of liabilities associated with uncertain tax positions.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of September 30, 2020 and December 31, 2019, included in other long-term liabilities we have accrued approximately $635.0 million and approximately $697.0 million, respectively, under a one-time mandatory deemed repatriation tax on accumulated foreign subsidiaries' previously untaxed foreign earnings (the Transition Toll Tax). The decrease of approximately $62.0 million between September 30, 2020 and December 31, 2019, is related to the amount that is expected to be paid within one year. The Transition Toll Tax will be paid in installments over an eight-year period, which started in 2018, and will not accrue interest.</span></div><div style="text-indent:13.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Other Off-Balance Sheet Arrangements</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We do not have any relationships with entities often referred to as structured finance or special purpose entities that were established for the purpose of facilitating off-balance sheet arrangements. As such, we are not exposed to any financing, liquidity, market or credit risk that could arise if we had engaged in such relationships. We consolidate variable interest entities if we are the primary beneficiary.</span></div><div id="ib19ff89608c84168a635160f2efa48f3_202"></div><div style="margin-top:14pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">New Accounting Standards</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For a discussion of new accounting standards please read </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Note 1, Summary of Significant Accounting Policies,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> to our condensed consolidated financial statements included in this report.</span></div></div></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">70</span></div></div></div><div id="ib19ff89608c84168a635160f2efa48f3_205"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_7">Table of Contents</a></span></div></div><div style="width:100.000%;"><div style="display:inline-block;vertical-align:top;width:46.491%;"><div style="margin-top:14pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Critical Accounting Estimates</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The preparation of our condensed consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the U.S., requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. Actual results may differ from these estimates.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For a discussion of our critical accounting estimates, please read </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Part&#160;II,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Item&#160;7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> in our 2019 Form&#160;10-K. There have been no material changes to our critical accounting estimates since our 2019 Form&#160;10-K.</span></div><div id="ib19ff89608c84168a635160f2efa48f3_208"></div><div style="margin-top:14pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Item&#160;3.&#160;&#160;&#160;&#160;Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are subject to certain risks that may affect our results of operations, cash flows and fair values of assets and liabilities, including volatility in foreign currency exchange rates, interest rate movements and pricing pressures worldwide as well as changes in economic conditions in the markets in which we operate as a result of the COVID-19 pandemic. We manage the impact of foreign currency exchange rates and interest rates through various financial instruments, including derivative instruments such as foreign currency forward contracts, interest rate lock contracts and interest rate swap contracts. We do not enter into financial instruments for trading or speculative purposes. The counterparties to these contracts are major financial institutions, and there is no significant concentration of exposure with any one counterparty.  </span></div><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Foreign Currency Exchange Risk</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our results of operations are subject to foreign currency exchange rate fluctuations due to the global nature of our operations, including the impact of the COVID-19 pandemic. As a result, our consolidated financial position, results of operations and cash flows can be affected by market fluctuations in foreign currency exchange rates, primarily with respect to the Euro, British pound sterling, Canadian dollar, Swiss franc, Japanese yen and South Korean won.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">While the financial results of our global activities are reported in U.S. dollars, the functional currency for </span></div></div><div style="display:inline-block;vertical-align:top;min-width:6.017%;max-width:7.017%;"></div><div style="display:inline-block;vertical-align:top;width:46.492%;"><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">most of our foreign subsidiaries is their respective local currency. Fluctuations in the foreign currency exchange rates of the countries in which we do business will affect our operating results, often in ways that are difficult to predict. In particular, as the U.S. dollar strengthens versus other currencies, the value of the non-U.S. revenues will decline when reported in U.S. dollars. The impact to net income as a result of a strengthening U.S. dollar will be partially mitigated by the value of non-U.S. expenses, which will also decline when reported in U.S. dollars. As the U.S. dollar weakens versus other currencies, the value of the non-U.S. revenues and expenses will increase when reported in U.S. dollars.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have established revenue and operating expense hedging and balance sheet risk management programs to protect against volatility of future foreign currency cash flows and changes in fair value caused by volatility in foreign currency exchange rates.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the second quarter of 2018, the International Practices Task Force of the Center for Audit Quality categorized Argentina as a country with a projected three-year cumulative inflation rate greater than 100%, which indicated that Argentina's economy is highly inflationary. This categorization did not have a material impact on our results of operations or financial position as of September 30, 2020, and is not expected to have a material impact on our results of operations or financial position in the future.</span></div><div style="text-indent:13.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Revenue and Operating Expense Hedging Program</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our foreign currency hedging program is designed to mitigate, over time, a portion of the impact resulting from volatility in exchange rate changes on revenues and operating expenses. We use foreign currency forward contracts to manage foreign currency risk, with the majority of our forward contracts used to hedge certain forecasted revenue and operating expense transactions denominated in foreign currencies in the next 24 months. We do not engage in currency speculation. For a more detailed disclosure of our revenue and operating expense hedging program, please read </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Note 9, Derivative Instruments,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> to our condensed consolidated financial statements included in this report. </span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our ability to mitigate the impact of foreign currency exchange rate changes on revenues and net income diminishes as significant foreign currency exchange rate fluctuations are sustained over extended periods of time. In particular, devaluation or significant deterioration of foreign currency exchange rates are difficult to mitigate and likely to negatively impact earnings. The cash flows from these contracts are reported as operating activities in our condensed consolidated statements of cash flows.</span></div></div></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_7">Table of Contents</a></span></div></div><div style="width:100.000%;"><div style="display:inline-block;vertical-align:top;width:46.491%;"><div style="text-indent:13.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Balance Sheet Risk Management Hedging Program</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We also use forward contracts to mitigate the foreign currency exposure related to certain balance sheet items. The primary objective of our balance sheet risk management program is to mitigate the exposure of foreign currency denominated net monetary assets and liabilities of foreign affiliates. In these instances, we principally utilize currency forward contracts. We have not elected hedge accounting for the balance sheet related items. The cash flows from these contracts are reported as operating activities in our condensed consolidated statements of cash flows.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following quantitative information includes the impact of currency movements on forward contracts used in our revenue, operating expense and balance sheet hedging programs. As of September 30, 2020 and December 31, 2019, a hypothetical adverse 10% movement in foreign currency exchange rates compared to the U.S. dollar across all maturities would result in a hypothetical decrease in the fair value of forward contracts of approximately $394.6 million and $265.0 million, respectively. The estimated fair value change was determined by measuring the impact of the hypothetical exchange rate movement on outstanding forward contracts. Our use of this methodology to quantify the market risk of such instruments is subject to assumptions and actual impact could be significantly different. The quantitative information about market risk is limited because it does not take into account all foreign currency operating transactions. </span></div><div style="text-indent:13.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Net Investment Hedge Program</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our net investment hedging program is designed to mitigate currency fluctuations between the U.S. dollar and the South Korean won as a result of our approximately 49.9% ownership percentage in Samsung Bioepis. We entered into foreign currency forward contracts to manage the foreign currency risk with our forward contracts used to hedge changes in the spot rate over the next one month. As of September 30, 2020 and December 31, 2019, a hypothetical adverse 10.0% movement would result in a hypothetical decrease in fair value of approximately $42.8 million and $43.0 million, respectively. The estimated fair value was determined by measuring the impact of the hypothetical spot rate movement on outstanding forward contracts.</span></div><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Interest Rate Risk</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our investment portfolio includes cash equivalents and short-term investments. The fair value of our marketable securities is subject to change as a result of potential changes in market interest rates, including changes resulting from the impact of the COVID-19 pandemic. The potential change in fair value </span></div></div><div style="display:inline-block;vertical-align:top;min-width:6.017%;max-width:7.017%;"></div><div style="display:inline-block;vertical-align:top;width:46.492%;"><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">for interest rate sensitive instruments has been assessed on a hypothetical 100 basis point adverse movement across all maturities. As of September 30, 2020 and December 31, 2019, we estimate that such hypothetical 100 basis point adverse movement would result in a hypothetical loss in fair value of approximately $16.6 million and $21.0 million, respectively, to our interest rate sensitive instruments. The fair values of our investments were determined using third-party pricing services or other market observable data.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">To achieve a desired mix of fixed and floating interest rate debt, we entered into interest rate swap contracts during 2015 for certain of our fixed-rate debt. These derivative contracts effectively converted a fixed-rate interest coupon to a floating-rate LIBOR-based coupon over the life of the respective note. As of December 31, 2019, a 100 basis-point adverse movement (increase in LIBOR) would increase annual interest expense by approximately $6.8 million. In May 2020 we settled our interest rate swap contracts in conjunction with our early redemption of our 2.90% Senior Notes.</span></div><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Pricing Pressure</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Governments in certain international markets in which we operate have implemented measures, and may in the future implement new or additional measures, to reduce health care costs to limit the overall level of government expenditures. These measures vary by country and may include, among other things, patient access restrictions, suspensions on price increases, prospective and possible retroactive price reductions and other recoupments and increased mandatory discounts or rebates, recoveries of past price increases and greater importation of drugs from lower-cost countries. In addition, certain countries set prices by reference to the prices in other countries where our products are marketed. Thus, our inability to obtain and maintain adequate prices in a particular country may adversely affect our ability to secure acceptable prices in existing and potential new markets, which may limit market growth. The continued implementation of pricing actions throughout Europe may also lead to higher levels of parallel trade.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In the U.S., federal and state legislatures, health agencies and third-party payors continue to focus on containing the cost of health care. Legislative and regulatory proposals, enactments to reform health care insurance programs and increasing pressure from social sources could significantly influence the way our products are prescribed and purchased. It is possible that additional federal health care reform measures will be adopted in the future, which could result in increased pricing pressure and reduced reimbursement for our products and </span></div></div></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_7">Table of Contents</a></span></div></div><div style="width:100.000%;"><div style="display:inline-block;vertical-align:top;width:46.491%;"><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">otherwise have an adverse impact on our consolidated financial position or results of operations. There is also significant economic pressure on state budgets that may result in states increasingly seeking to achieve budget savings through mechanisms that limit coverage or payment for our drugs. Managed care organizations are also continuing to seek price discounts and, in some cases, impose restrictions on the coverage of certain drugs.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our products continue to face increasing competition in many markets from generic versions, prodrugs and biosimilars of existing products as well as products approved under abbreviated regulatory pathways.&#160;Such products are likely to be sold at substantially lower prices than branded products.&#160;Accordingly, the introduction of such products as well as other lower-priced competing products may significantly reduce both the price that we are able to charge for our products and the volume of products we sell, which will negatively impact our revenues. In addition, when a generic version of one of our products is commercialized, it may, in some cases, be automatically substituted for our product and reduce our revenues in a short period of time.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Multiple TECFIDERA generic entrants are now in the U.S. market, some of which have deeply discounted prices compared to TECFIDERA. The generic competition for TECFIDERA significantly reduced our TECFIDERA revenues during the third quarter of 2020 and is expected to have a substantial negative impact on our TECFIDERA revenues for as long as there is generic competition.</span></div><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Credit Risk</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are subject to credit risk from our accounts receivable related to our product sales. The majority of our accounts receivable arise from product sales in the U.S.&#160;and Europe with concentrations of credit risk limited due to the wide variety of customers and markets using our products as well as their dispersion across many different geographic areas. Our accounts receivable are primarily due from wholesale and other third-party distributors, public hospitals, pharmacies and other government entities. We monitor the financial performance and creditworthiness of our customers so that we can properly assess and respond to changes in their credit profile. We operate in certain countries where weakness in economic conditions, including as a result of the COVID-19 pandemic, can result in extended collection periods. We continue to monitor these conditions, including the volatility associated with international economies and the relevant financial markets, and assess their possible impact on our business. To date, we have not experienced any significant losses with respect to the collection of our accounts receivable. </span></div></div><div style="display:inline-block;vertical-align:top;min-width:6.017%;max-width:7.017%;"></div><div style="display:inline-block;vertical-align:top;width:46.492%;"><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We believe that our allowance for doubtful accounts was adequate as of September 30, 2020 and December 31, 2019. However, if significant changes occur in the availability of government funding or the reimbursement practices of these or other governments, we may not be able to collect on amounts due to us from customers in such countries and our results of operations could be adversely affected.</span></div><div id="ib19ff89608c84168a635160f2efa48f3_211"></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Item&#160;4.&#160;&#160;&#160;&#160;Controls and Procedures</span></div><div style="margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Disclosure Controls and Procedures and Internal Control over Financial Reporting</span></div><div style="text-indent:11.25pt;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Controls and Procedures</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have carried out an evaluation, under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules&#160;13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended), as of September 30, 2020. Based upon that evaluation, our principal executive officer and principal financial officer concluded that, as of the end of the period covered by this report, our disclosure controls and procedures are effective in ensuring that (a)&#160;the information required to be disclosed by us in the reports that we file or submit under the Securities Exchange Act is recorded, processed, summarized and reported within the time periods specified in the U.S. Securities and Exchange Commission&#8217;s rules and forms, and (b)&#160;such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and procedures, our management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</span></div><div style="text-indent:11.25pt;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Changes in Internal Control over Financial Reporting</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">There were no changes in our internal control over financial reporting during the quarter ended September 30, 2020, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. </span></div></div></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">73</span></div></div></div><div id="ib19ff89608c84168a635160f2efa48f3_214"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_7">Table of Contents</a></span></div></div><div style="text-align:center;margin-top:14pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Part&#160;II&#160;&#8212; OTHER INFORMATION</span></div><div id="ib19ff89608c84168a635160f2efa48f3_217"></div><div style="margin-top:14pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Item&#160;1.&#160;&#160;&#160;&#160;Legal Proceedings</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For a discussion of legal proceedings as of September 30, 2020, please read </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Note 19, Litigation,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> to our condensed consolidated financial statements included in this report, which is incorporated into this item by reference.</span></div><div id="ib19ff89608c84168a635160f2efa48f3_220"></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Item&#160;1A.&#160;&#160;&#160;&#160;Risk Factors</span></div><div style="text-indent:11.25pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We are substantially dependent on revenues from our products. </span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our revenues depend upon continued sales of our products as well as the financial rights we have in our anti-CD20 therapeutic programs, and, unless we develop, acquire rights to and/or commercialize new products and technologies, we will be substantially dependent on sales from our products and our financial rights in our anti-CD20 therapeutic programs for many years. Additionally, a significant portion of our revenues are concentrated on sales of our products in increasingly competitive markets and in markets affected directly and indirectly by the COVID-19 pandemic. Any of the following negative developments relating to any of our products or any of our anti-CD20 therapeutic programs may adversely affect our revenues and results of operations or could cause a decline in our stock price: </span></div><div style="text-indent:-18pt;padding-left:40.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">the introduction or greater acceptance of competing products, including generics, prodrugs, biosimilars and products approved under abbreviated regulatory pathways;</span></div><div style="text-indent:-18pt;padding-left:40.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">safety or efficacy issues; </span></div><div style="text-indent:-18pt;padding-left:40.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">limitations and additional pressures on product pricing or price increases, including those resulting from governmental or regulatory requirements, increased competition, including from the introduction of generic or biosimilar versions of our products, or changes in, or implementation of, reimbursement policies and practices of payors and other third parties;</span></div><div style="text-indent:-18pt;padding-left:40.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">adverse legal, administrative, regulatory or legislative developments; </span></div><div style="text-indent:-18pt;padding-left:40.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">our ability to maintain a positive reputation among patients, healthcare providers and others, which may be impacted by our pricing and reimbursement decisions; or</span></div><div style="text-indent:-18pt;padding-left:40.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">the inability or reluctance of patients to receive a diagnosis, prescription or administration of our products or a decision to prescribe and administer competitive therapies as a direct or indirect result of the COVID-19 pandemic.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">SPINRAZA has been approved by, among others, the FDA, the European Commission and the Japanese Ministry of Health, Labor and Welfare, and is in the early stages of commercial launch in certain markets.&#160;In addition to risks associated with new product launches and the other factors described in these </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Risk Factors</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, our ability to successfully commercialize SPINRAZA may be adversely affected due to:</span></div><div style="text-indent:-18pt;padding-left:40.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">the introduction of a new gene therapy product that was approved in the U.S. in May 2019 and in the E.U. in May 2020 for the treatment of SMA as well as a new oral product for the treatment of SMA that was approved in the U.S. in August 2020 and the launch of other products now in development that may compete with SPINRAZA;</span></div><div style="text-indent:-18pt;padding-left:40.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">the delay of SPINRAZA doses due, directly or indirectly, to the COVID-19 pandemic;</span></div><div style="text-indent:-18pt;padding-left:40.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">the lack of readiness of healthcare providers within certain SMA markets to treat patients with SMA; or</span></div><div style="text-indent:-18pt;padding-left:40.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">our limited marketing experience within certain SMA markets, which may impact our ability to develop additional relationships with the associated medical and scientific community.</span></div><div style="text-indent:13.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If we are unable to obtain and maintain adequate protection for our data, intellectual property and other proprietary rights, our business may be harmed. </span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our success, including our long-term viability and growth, depends in part on our ability to obtain and defend patent and other intellectual property rights that are important to the commercialization of our products and product candidates. The degree of patent protection afforded to our products and processes in the U.S. and in other important markets remains uncertain and depends, in part, upon decisions of the patent offices, courts, administrative bodies and lawmakers in these countries. We may fail to successfully obtain or preserve patent </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">protection for the technologies incorporated into our products and processes, or the protection we obtain may not be of sufficient breadth and degree to protect our commercial interests in all countries where we conduct business.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We also rely on regulatory data and market exclusivity for protection of our products. Implementation and enforcement of regulatory exclusivity varies widely from country to country. Failure to qualify for regulatory exclusivity, or failure to obtain or maintain the extent or duration of such protections could affect our decision on whether to market our products in particular countries or could otherwise have an adverse impact on our revenues and results of operations.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In many markets, including the U.S., manufacturers may be allowed to rely on the safety and efficacy data of the innovator's product and not need to conduct clinical trials before marketing a competing version of a product after there is no longer patent or regulatory exclusivity. In such cases, manufacturers often charge significantly lower prices and, a major portion of the company's revenues may be reduced in a short period of time. Furthermore, our products may be determined to infringe patents or other intellectual property rights held by third parties, which could result in financial, legal, business or reputational harm to us.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Litigation, interferences, oppositions, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">inter partes</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> reviews, administrative challenges or other similar types of proceedings are and may in the future be necessary in some instances to determine the validity and scope of certain of our patents, regulatory exclusivities or other proprietary rights, and in other instances to determine the validity, scope or non-infringement of certain patent rights claimed by third parties to be pertinent to the manufacture, use or sale of our products.&#160;We also face challenges to our patent and regulatory protections covering our products and processes by third parties, including manufacturers of generics and biosimilars that may choose to launch or attempt to launch their products before the expiration of our patent or regulatory exclusivity.&#160;Litigation, interference, oppositions, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">inter partes</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> reviews, administrative challenges or other similar types of proceedings are unpredictable and are often protracted, expensive and distracting to management. Negative outcomes of such proceedings adversely affect the validity and scope of our patent or other proprietary rights. Settlements of these proceedings often result in reducing the period of patent and other protections, accelerating reduction in revenue from affected products. Adverse outcomes in intellectual property litigation and proceedings also could hinder our ability to manufacture and market our products, require us to seek a license for the infringed product or technology or result in the assessment of significant monetary damages against us that may exceed amounts, if any, accrued in our financial statements. An adverse determination in a judicial or administrative proceeding or a failure to obtain necessary licenses could prevent us from manufacturing or selling our products. Furthermore, payments under any licenses that we are able to obtain would reduce our profits derived from the covered products and services. Any of these circumstances could result in financial, business or reputational harm to us or could cause a decline or volatility in our stock price.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">The ongoing COVID-19 pandemic may, directly or indirectly, adversely affect our business, results of operations and financial condition.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our business could be materially adversely affected, directly or indirectly, by the widespread outbreak of contagious disease, including the ongoing COVID-19 pandemic, which has spread to many of the countries in which we, our customers, our suppliers and our collaboration partners do business. National, state and local governments in affected regions have implemented and may continue to implement safety precautions, including quarantines, border closures, increased border controls, travel restrictions, shelter in place orders and shutdowns, business closures, cancellations of public gatherings and other measures. We, other organizations and individuals are taking additional steps to avoid or reduce infection, including limiting travel and staying home from work. These measures are disrupting and may disrupt normal business operations both in and outside of affected areas and have significant negative impacts on businesses and financial markets worldwide.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We continue to monitor our operations and applicable government recommendations, and we have made modifications to our normal operations because of the COVID-19 pandemic. In the U.S. and in most other key markets, our office-based employees began working from home in early March 2020, while ensuring essential staffing levels in our operations remained in place, including maintaining key personnel in our laboratories and manufacturing facilities, and many may continue to work remotely for an indefinite period of time. Prolonged remote working arrangements could impact employees&#8217; productivity and morale. Operating requirements may continually change due to the COVID-19 pandemic and we may experience unpredictability in our expenses, employee productivity and employee work culture. </span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Notwithstanding the protective measures we have taken to ensure the health and safety of our workers, the COVID-19 pandemic could affect the health and availability of our workforce as well as those of the third parties we rely on taking similar measures. If members of our management and other key personnel in critical functions across our organization are unable to perform their duties or have limited availability due to COVID-19, we may not be able </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">to execute on our business strategy and/or our operations may be negatively impacted. We may also experience limitations in employee resources, including because of sickness of employees or their families or the desire of employees to avoid contact with individuals or large groups of people. In addition, we have experienced and will continue to experience disruptions to our business operations resulting from quarantines, self-isolations and other restrictions on the ability of our employees to perform their jobs.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Additionally, the risk of cyber-attacks or other privacy or data security incidents may be heightened as a result of our moving increasingly towards a remote working environment. Remote working environments may be less secure and more susceptible to hacking attacks, including phishing and social engineering attempts that seek to exploit the COVID-19 pandemic. An extended period of remote working by our employees could also strain our technology resources and introduce operational risks, including heightened cybersecurity risk.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The extent and severity of the impact of the COVID-19 pandemic on our business and clinical trials will be determined largely by the extent of disruptions in the supply chains for our products and product candidates; disruptions in access by patients to our therapies; and delays in the conduct of current and future clinical trials. For example, our Phase 3 study of BIIB093 for large hemispheric infarction has been delayed as this study involves administration of BIIB093 in an acute hospital setting. In addition, the impact of the COVID-19 pandemic on the operations of the FDA and other health authorities may delay potential approvals of our product candidates. We may also see lower new prescriptions or refills of existing prescriptions due to increased unemployment as a result of the COVID-19 pandemic.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">While it is not possible at this time to estimate the entirety of the impact that the COVID-19 pandemic will have on our business, operations, employees, customers, suppliers or our collaboration partners, continued spread of COVID-19, measures taken by governments, actions taken to protect employees and the broad impact of the pandemic on all business activities may materially and adversely affect our business, results of operations and financial condition.</span></div><div style="text-indent:13.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our long-term success depends upon the successful development of new products and additional indications for existing products. </span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our long-term viability and growth will depend upon the successful development of additional indications for our existing products as well as the successful development of new products and technologies from our research and development activities, our biosimilars joint venture with Samsung BioLogics or licenses or acquisitions from third parties. </span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Product development is very expensive and involves a high degree of uncertainty and risk. Only a small number of research and development programs result in the commercialization of a product. Furthermore, the development of novel approaches for the treatment of diseases, including development efforts in new modalities such as those based on the antisense oligonucleotide platform and gene therapy, may present additional challenges and risks, including obtaining regulatory approval from the FDA and other regulatory agencies that have limited experience with the development of such therapies. In addition, clinical trial data are subject to differing interpretations and, even if we view data as sufficient to support the safety, effectiveness and/or approval of an investigational therapy, regulatory authorities may disagree and may require additional data, may limit the scope of the approval or may deny approval altogether. Consequently, it may be difficult to predict the time and cost of product development of novel approaches for the treatment of diseases. </span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, success in preclinical work or early stage clinical trials does not ensure that later stage or larger scale clinical trials will be successful. Clinical trials may indicate that our product candidates lack efficacy, have harmful side effects, result in unexpected adverse events or raise other concerns that may significantly reduce the likelihood of regulatory approval. This may result in terminated programs, significant restrictions on use and safety warnings in an approved label, adverse placement within the treatment paradigm or significant reduction in the commercial potential of the product candidate.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We may be required to delay the development of a product candidate or delay ongoing clinical trials as a direct or indirect result of the COVID-19 pandemic. For example, our Phase 3 study of BIIB093 for large hemispheric infarction has been delayed as this study involves administration of BIIB093 in an acute hospital setting.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We may fail to successfully obtain or preserve patent protection for the technologies incorporated into our product candidates and processes, or the protection we obtain may not be of sufficient breadth and degree to protect our commercial interests in all countries where we conduct business. The degree of patent protection afforded to our product candidates and processes in the U.S. and in other important markets remains uncertain and depends, in part, upon decisions of the patent offices, courts, administrative bodies and lawmakers in these </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">countries. Furthermore, one or more of our competitors may receive patent protection that dominates, blocks or adversely affects our product development or business.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Even if we could successfully develop new products or indications, we may make a strategic decision to discontinue development of a product candidate or indication if, for example, we believe commercialization will be difficult relative to the standard of care or other opportunities in our pipeline.</span></div><div style="text-indent:13.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If we fail to compete effectively, our business and market position would suffer.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The biopharmaceutical industry and the markets in which we operate are intensely competitive. We compete in the marketing and sale of our products, the development of new products and processes, the acquisition of rights to new products with commercial potential and the hiring and retention of personnel. We compete with biotechnology and pharmaceutical companies that have a greater number of products on the market and in the product pipeline, substantially greater financial, marketing, research and development and other resources and other technological or competitive advantages. One or more of our competitors may benefit from significantly greater sales and marketing capabilities, may develop products that are accepted more widely than ours or may receive patent protection that dominates, blocks or adversely affects our product development or business. In addition, as a result of the COVID-19 pandemic, we have suspended the vast majority of our in-person interactions by our customer-facing professionals in healthcare settings, which will limit our ability to market our products and educate physicians, which, in turn, could have an adverse effect on our ability to compete in the marketing and sales of our products. Further, our ability to compete may be impacted by the inability or reluctance of patients to receive a diagnosis, prescription or administration of our products or a decision to prescribe and administer competitive therapies as a direct or indirect result of the COVID-19 pandemic.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our products continue to face increasing competition in many markets from the introduction of generics, prodrugs and biosimilars of existing products as well as products approved under abbreviated regulatory pathways. Such products are likely to be sold at substantially lower prices than branded products.&#160;Accordingly, the introduction of such products as well as other lower-priced competing products may significantly reduce both the price that we are able to charge for our products and the volume of products we sell, which will negatively impact our revenues. In addition, when a generic version of one of our products is commercialized, it may, in some cases, be automatically substituted for our product and reduce our revenues in a short period of time.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In the MS market, we face intense competition as the number of products and competitors continues to expand. Due to our significant reliance on sales of our MS products, including TECFIDERA, our business could be harmed if we are unable to successfully compete in the MS market. More specifically, our ability to compete, maintain and grow our share in the MS market may be adversely affected due to a number of factors, including:</span></div><div style="text-indent:-18pt;padding-left:40.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">the introduction of more efficacious, safer, less expensive or more convenient alternatives to our MS products, including our own products and products of our collaborators; </span></div><div style="text-indent:-18pt;padding-left:40.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">the introduction of generic versions of branded MS products, including our own products, biosimilars, follow-on products, prodrugs or products approved under abbreviated regulatory pathways, which would be significantly less costly than our products to bring to market and would be offered for sale at lower prices, and could result in a significant percentage of the sales of our products being lost to such generic versions of branded MS products, biosimilars, follow-on products, prodrugs or products approved under abbreviated regulatory pathways;</span></div><div style="text-indent:-18pt;padding-left:40.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">the off-label use by physicians of therapies indicated for other conditions to treat MS patients; </span></div><div style="text-indent:-18pt;padding-left:40.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">patient dynamics, including the size of the patient population and our ability to attract and maintain new and current patients to our therapies; </span></div><div style="text-indent:-18pt;padding-left:40.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">damage to physician and patient confidence in any of our MS products, generic or biosimilars of our MS products or any other product from the same class as one of our products, or to our sales and reputation as a result of label changes or adverse experiences or events that may occur with patients treated with our MS products or generic or biosimilars of our MS products; </span></div><div style="text-indent:-18pt;padding-left:40.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">inability to obtain appropriate pricing and reimbursement for our MS products compared to our competitors in key international markets; or</span></div><div style="text-indent:-18pt;padding-left:40.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">our ability to obtain and maintain patent, data or market exclusivity for our MS products.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In the SMA market, we face competition from a new gene therapy product that was approved in the U.S. in May 2019 and in the E.U. in May 2020 for the treatment of SMA as well as a new oral product for the treatment of SMA that was approved in the U.S. in August 2020. Additionally, we are aware of other products now in development that, </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">if launched, may compete with SPINRAZA. Future sales of SPINRAZA may be adversely affected by the commercialization of competing products. In addition, future sales of SPINRAZA may also be adversely affected by the delay of SPINRAZA doses due, directly or indirectly, to the COVID-19 pandemic.</span></div><div style="text-indent:13.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our business may be adversely affected if we do not successfully execute or realize the anticipated benefits of our strategic and growth initiatives.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The successful execution of our strategic and growth initiatives may depend upon internal development projects, commercial initiatives, external opportunities, which may include the acquisition, partnering and in-licensing of products, technologies and companies or the entry into strategic alliances and collaborations, or the disposition of certain of our assets or operations. </span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">While we believe we have a number of promising programs in our pipeline, failure or delay of internal development projects to advance or difficulties in executing on our commercial initiatives could impact our current and future growth, resulting in additional reliance on external development opportunities for growth. </span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Supporting the further development of our existing products and potential new products in our pipeline will require significant capital expenditures and management resources, including investments in research and development, sales and marketing, manufacturing capabilities and other areas of our business. We have in the past made, and may continue to make, significant operating and capital expenditures for potential new products in our pipeline prior to regulatory approval with no assurance that such investment will be recouped, which may adversely affect our financial condition, business and operations.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The availability of high quality, fairly valued external product development is limited and the opportunity for their acquisition is highly competitive. As such, we are not certain that we will be able to identify suitable candidates for acquisition or if we will be able to reach agreement. Furthermore, if we decide to dispose of certain of our assets or operations, we are not certain that we will be able to identify a suitable counterparty or if we will be able to reach agreement.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We may fail to initiate or complete transactions for many reasons and we may not be able to achieve the full strategic and financial benefits expected to result from transactions, or the benefits may be delayed or not occur at all. We may also face additional costs or liabilities in completed transactions that were not contemplated prior to completion.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Any failure in the execution of a transaction, in the integration of an acquired asset or business or in achieving expected synergies could result in slower growth, higher than expected costs, the recording of asset impairment charges and other actions which could adversely affect our business, financial condition and results of operations.</span></div><div style="text-indent:13.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Successful preclinical work or early stage clinical trials does not ensure success in later stage trials, regulatory approval or commercial viability of a product.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Positive results in a clinical trial may not be replicated in subsequent or confirmatory trials. Additionally, success in preclinical work or early stage clinical trials does not ensure that later stage or larger scale clinical trials will be successful or that regulatory approval will be obtained. In addition, even if later stage clinical trials are successful, regulatory authorities may delay or decline approval of our product candidates. Regulatory authorities may disagree with our view of the data, require additional studies or disagree with our trial design or endpoints. Regulatory authorities may also fail to approve the facilities or processes used to manufacture a product candidate, our dosing or delivery methods or companion devices. Regulatory authorities may grant marketing approval that is more restricted than anticipated. These restrictions may include limiting indications to narrow patient populations and the imposition of safety monitoring, educational requirements and risk evaluation and mitigation strategies. The occurrence of any of these events could result in significant costs and expenses, have an adverse effect on our business, financial condition and results of operations and cause our stock price to decline or experience periods of volatility.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Even if we are able to successfully develop new products or indications, sales of new products or products with additional indications may not meet investor expectations. We may also make a strategic decision to discontinue development of a product candidate or indication if, for example, we believe commercialization will be difficult relative to the standard of care or other opportunities in our pipeline.</span></div><div style="text-indent:13.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Clinical trials and the development of biopharmaceutical products is a lengthy and complex process. If we fail to adequately manage our clinical activities, our clinical trials or potential regulatory approvals may be delayed or denied. </span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Conducting clinical trials is a complex, time-consuming and expensive process. Our ability to complete clinical trials in a timely fashion depends on a number of key factors. These factors include protocol design, regulatory and </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">institutional review board approval, patient enrollment rates and compliance with current Good Clinical Practices. If we or our third-party clinical trial providers or third-party CROs do not successfully carry out these clinical activities, our clinical trials or the potential regulatory approval of a product candidate may be delayed or be unsuccessful.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have opened clinical trial sites and are enrolling patients in a number of countries where our experience is limited. In most cases, we use the services of third parties to carry out our clinical trial related activities and rely on such parties to accurately report their results. Our reliance on third parties for these activities may impact our ability to control the timing, conduct, expense and quality of our clinical trials. One CRO has responsibility for a substantial portion of our activities and reporting related to our clinical trials. If this CRO does not adequately perform, many of our trials may be affected. We may need to replace our CROs. Although we believe there are a number of other CROs we could engage to continue these activities, the replacement of an existing CRO may result in the delay of the affected trials or otherwise adversely affect our efforts to obtain regulatory approvals and commercialize our product candidates.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our ability to continue our existing clinical trials or to initiate new clinical trials may be adversely affected, directly or indirectly, by the COVID-19 pandemic. For example, our Phase 3 study of BIIB093 for large hemispheric infarction has been delayed as this study involves administration of BIIB093 in an acute hospital setting. We have open clinical trial sites in countries that have had high incident rates of COVID-19 patients. Restrictions on travel and/or transport of clinical materials, as well as diversion of hospital staff and resources to COVID-19 infected patients, could disrupt trial operations as well as recruitment, possibly resulting in a slowdown in enrollment and/or deviations from or disruptions in key clinical trial activities, such as clinical trial site monitoring. These challenges may lead to difficulties in meeting protocol-specified procedures. In addition, we may need to make certain adjustments to the operation of clinical trials in an effort to minimize risks to trial data integrity during the COVID-19 pandemic.</span></div><div style="text-indent:13.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Adverse safety events or restrictions on use and safety warnings for our products can negatively affect our business, product sales and stock price.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Adverse safety events involving our marketed products, generic or biosimilar versions of our marketed products or any other products from the same class as one of our products may have a negative impact on our business. Discovery of safety issues with our products could create product liability and could cause additional regulatory scrutiny and requirements for additional labeling or safety monitoring, withdrawal of products from the market and the imposition of fines or criminal penalties. Adverse safety events may also damage physician, patient and/or investor confidence in our products and our reputation. Any of these could result in liabilities, loss of revenues, material write-offs of inventory, material impairments of intangible assets, goodwill and fixed assets, material restructuring charges or other adverse impacts on our results of operations. </span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Regulatory authorities are making greater amounts of stand-alone safety information directly available to the public through periodic safety update reports, patient registries and other reporting requirements. The reporting of adverse safety events involving our products or products similar to ours and public rumors about such events may increase claims against us and may also cause our product sales or stock price to decline or experience periods of volatility. </span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Restrictions on use or significant safety warnings that may be required to be included in the label of our products, such as the risk of developing progressive multifocal leukoencephalopathy (PML) or liver injury in the label for certain of our products, may significantly reduce expected revenues for those products and require significant expense and management time. </span></div><div style="text-indent:13.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Sales of our products depend, to a significant extent, on adequate coverage, pricing and reimbursement from third-party payors, which are subject to increasing and intense pressure from political, social, competitive and other sources. Our inability to obtain and maintain adequate coverage, or a reduction in pricing or reimbursement, could have an adverse effect on our business, reputation, revenues and results of operations, could curtail or eliminate our ability to adequately fund research and development programs for the discovery and commercialization of new products or could cause a decline or volatility in our stock price.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Sales of our products depend, to a significant extent, on the availability and extent of adequate coverage, pricing and reimbursement from government health administration authorities, private health insurers and other organizations. When a new pharmaceutical product is approved, the availability of government and private reimbursement for that product may be uncertain, as is the pricing and amount for which that product will be reimbursed. </span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pricing and reimbursement for our products may be adversely affected by a number of factors, including: </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_7">Table of Contents</a></span></div></div><div style="text-indent:-18pt;padding-left:40.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">changes in, and implementation of, federal, state or foreign government regulations or private third-party payors&#8217; reimbursement policies; </span></div><div style="text-indent:-18pt;padding-left:40.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">pressure by employers on private health insurance plans to reduce costs;</span></div><div style="text-indent:-18pt;padding-left:40.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">consolidation and increasing assertiveness of payors, including managed care organizations, health insurers, pharmacy benefit managers, government health administration authorities, private health insurers and other organizations, seeking price discounts or rebates in connection with the placement of our products on their formularies and, in some cases, the imposition of restrictions on access or coverage of particular drugs or pricing determined based on perceived value; and</span></div><div style="text-indent:-18pt;padding-left:40.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">our value-based contracting program pursuant to which we aim to tie the pricing of our products to their clinical values by either aligning price to patient outcomes or adjusting price for patients who discontinue therapy for any reason, including efficacy or tolerability concerns.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our ability to set the price for our products varies significantly from country to country and as a result so can the price of our products. Certain countries set prices by reference to the prices in other countries where our products are marketed. Thus, our inability to obtain and maintain adequate prices in a particular country may not only limit the revenues from our products within that country but may also adversely affect our ability to secure acceptable prices in existing and potential new markets. This may create the opportunity for third-party cross-border trade or influence our decision to sell or not to sell a product, thus adversely affecting our geographic expansion plans and revenues.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Drug prices are under significant scrutiny in the markets in which our products are prescribed.&#160;We expect drug pricing and other health care costs to continue to be subject to intense political and societal pressures on a global basis. In addition, competition from current and future competitors may negatively impact our ability to maintain pricing and our market share. New products or treatments brought to market by our competitors could cause revenues for our products to decrease due to potential price reductions and lower sales volumes. Additionally, the introduction of generic versions of our products, biosimilars, follow-on products, prodrugs or products approved under abbreviated regulatory pathways, may significantly reduce both the price that we are able to charge for our products and the volume of products we sell.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Payors, including managed care organizations, health insurers, pharmacy benefit managers, government health administration authorities, private health insurers and other organizations, increasingly seek ways to reduce their costs. Many payors continue to adopt benefit plan changes that shift a greater portion of prescription costs to patients. Such measures include more limited benefit plan designs, higher patient co-pay or co-insurance obligations and limitations on patients' use of commercial manufacturer co-pay payment assistance programs (including through co-pay accumulator adjustment or maximization programs). Payors also increasingly seek price discounts or rebates in connection with the placement of our products on their formularies or those they manage and control costs by imposing restrictions on access to or usage of our products, such as by requiring prior authorization or step therapy. Significant consolidation in the health insurance industry has resulted in a few large insurers and pharmacy benefit managers exerting greater pressure in pricing and usage negotiations with drug manufacturers, significantly increasing discounts and rebates required of manufacturers and limiting patient access and usage. Further consolidation among insurers, pharmacy benefit managers and other payors would increase the negotiating leverage such entities have over us and other drug manufacturers. Ultimately, additional discounts, rebates, coverage or plan changes, restrictions or exclusions as described above could have a material adverse effect on sales of our affected products.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our failure to obtain or maintain adequate coverage, pricing or reimbursement for our products could have an adverse effect on our business, reputation, revenues and results of operations, could curtail or eliminate our ability to adequately fund research and development programs for the discovery and commercialization of new products or could cause a decline or volatility in our stock price.</span></div><div style="text-indent:13.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">A breakdown or breach of our technology systems could subject us to liability or interrupt the operation of our business.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are increasingly dependent upon technology systems and data to operate our business. In particular, the COVID-19 pandemic has caused us to modify our business practices, including the requirement that most of our office-based employees in the U.S. and our other key markets work from home. As a result, we are increasingly dependent upon our technology systems to operate our business and our ability to effectively manage our business depends on the security, reliability and adequacy of our technology systems and data, which includes use of cloud technologies, including Software as a Service (SaaS), Platform as a Service (PaaS) and Infrastructure as a Service (IaaS). A breakdown, invasion, corruption, destruction or breach of our technology systems, including the cloud technologies that we utilize, and/or unauthorized access to our data and information could subject us to liability or </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">negatively impact the operation of our business. Our technology systems, including the cloud technologies that we utilize, continue to increase in multitude and complexity, making them potentially vulnerable to breakdown, malicious intrusion and random attack.&#160;Likewise, data privacy or security breaches by individuals authorized to access our technology systems, including the cloud technologies that we utilize, may pose a risk that sensitive data, including intellectual property, trade secrets or personal information belonging to us, our patients, customers or other business partners, may be exposed to unauthorized persons or to the public. </span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cyber-attacks are increasing in their frequency, sophistication and intensity, and are becoming increasingly difficult to detect. They are often carried out by motivated, well-resourced, skilled and persistent actors, including nation states, organized crime groups, &#8220;hacktivists&#8221; and employees or contractors acting with malicious intent. Cyber-attacks could include the deployment of harmful malware and key loggers, ransomware, a denial-of-service attack, a malicious website, the use of social engineering and other means to affect the confidentiality, integrity and availability of our technology systems and data. Cyber-attacks could also include supply chain attacks, which could cause a delay in the manufacturing of our products or products produced for contract manufacturing. Our key business partners face similar risks and any security breach of their systems could adversely affect our security posture. In addition, our increased use of cloud technologies could heighten these and other operational risks, and any failure by cloud technology service providers to adequately safeguard their systems and prevent cyber-attacks could disrupt our operations and result in misappropriation, corruption or loss of confidential or propriety information.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">While we continue to build and improve our systems and infrastructure, including our business continuity plans, there can be no assurance that our efforts will prevent breakdowns or breaches in our systems that could adversely affect our business and operations and/or result in the loss of critical or sensitive information, which could result in financial, legal, business, operational or reputational harm to us, loss of competitive advantage or loss of consumer confidence. In addition, our liability insurance may not be sufficient in type or amount to cover us against claims related to security breaches, cyber-attacks and other related breaches. </span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, regulators globally are imposing new data privacy and security requirements, including new and greater monetary fines for privacy violations. For example, the E.U.&#8217;s General Data Protection Regulation, which became effective in 2018, established regulations regarding the handling of personal data, and provides an enforcement authority and imposes large penalties for noncompliance, including the potential for fines of up to &#8364;20.0 million or 4% of the annual global revenues of the infringer, whichever is greater. In addition, new U.S. data privacy and security laws, such as the California Consumer Privacy Act (CCPA) that became effective in January 2020, and others that may be passed, similarly introduce requirements with respect to personal information, and non-compliance with CCPA may result in liability through private actions (subject to statutorily defined damages in the event of certain data breaches) and enforcement. Failure to comply with these current and future laws could result in significant penalties and could have a material adverse effect on our business and results of operations.</span></div><div style="text-indent:13.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We depend on relationships with collaborators, joint venture partners and other third parties for revenues, and for the development, regulatory approval, commercialization and marketing of certain of our products and product candidates, which are outside of our full control.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We rely on a number of significant collaborative and other third-party relationships, including joint venture partners, for revenues, and for the development, regulatory approval, commercialization and marketing of certain of our products and product candidates. We also outsource to third parties certain aspects of our regulatory affairs and clinical development relating to our products and product candidates. Reliance on collaborative and other third-party relationships, including joint venture partners, subjects us to a number of risks, including:</span></div><div style="text-indent:-18pt;padding-left:40.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">we may be unable to control the resources our collaborators, joint venture partners or third parties devote to our programs, products or product candidates;</span></div><div style="text-indent:-18pt;padding-left:40.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">delays and disruptions experienced by our collaborators, joint venture partners or third parties due to the COVID-19 pandemic could adversely impact the ability of such parties to fulfill their obligations, which could affect product sales or the clinical development or regulatory approvals of product candidates under joint control;</span></div><div style="text-indent:-18pt;padding-left:40.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">disputes may arise under an agreement, including with respect to the achievement and payment of milestones or ownership of rights to technology developed with our collaborators, joint venture partners or other third parties, and the underlying agreement with our collaborators, joint venture partners or other third parties may fail to provide us with significant protection or may fail to be effectively enforced if the collaborators, joint ventures partners or third parties fail to perform; </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_7">Table of Contents</a></span></div></div><div style="text-indent:-18pt;padding-left:40.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">the interests of our collaborators, joint venture partners or third parties may not always be aligned with our interests, and such parties may not pursue regulatory approvals or market a product in the same manner or to the same extent that we would, which could adversely affect our revenues; </span></div><div style="text-indent:-18pt;padding-left:40.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">third-party relationships, joint ventures and collaborations often require the parties to cooperate, and failure to do so effectively could adversely affect product sales, or the clinical development or regulatory approvals of product candidates under joint control, could result in termination of the research, development or commercialization of product candidates or could result in litigation or arbitration;</span></div><div style="text-indent:-18pt;padding-left:40.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">any failure on the part of our collaborators, joint venture partners or other third parties to comply with applicable laws, regulatory requirements and/or applicable contractual obligations in the marketing, sale and maintenance of the marketing authorization of our products or to fulfill any responsibilities our collaborators, joint venture partners or other third parties may have to protect and enforce any intellectual property rights underlying our products could have an adverse effect on our revenues as well as involve us in possible legal proceedings; and</span></div><div style="text-indent:-18pt;padding-left:40.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">any improper conduct or actions on the part of our collaborators, joint venture partners or other third parties could subject us to civil or criminal investigations and monetary and injunctive penalties, impact the accuracy and timing of our financial reporting and/or adversely impact our ability to conduct business, our operating results and our reputation.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Given these risks, there is considerable uncertainty regarding the success of our current and future collaborative efforts. If these efforts fail, our product development or commercialization of new products could be delayed, revenues from products could decline and/or we may not realize the anticipated benefits of the collaboration arrangements and/or joint ventures.</span></div><div style="text-indent:13.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our results of operations may be adversely affected by current and potential future healthcare reforms.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In the U.S., federal and state legislatures, health agencies and third-party payors continue to focus on containing the cost of health care. Legislative and regulatory proposals, enactments to reform health care insurance programs and increasing pressure from social sources could significantly influence the manner in which our products are prescribed and purchased. For example, provisions of the Patient Protection and Affordable Care Act (PPACA) have resulted in changes in the way health care is paid for by both governmental and private insurers, including increased rebates owed by manufacturers under the Medicaid Drug Rebate Program, annual fees and taxes on manufacturers of certain branded prescription drugs, the requirement that manufacturers participate in a discount program for certain outpatient drugs under Medicare Part D and the expansion of the number of hospitals eligible for discounts under Section 340B of the Public Health Service Act. These changes have had and are expected to continue to have a significant impact on our business. </span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We may face uncertainties as a result of federal and administrative efforts to repeal, substantially modify or invalidate some or all of the provisions of the PPACA. There is no assurance that the PPACA, as currently enacted or as amended in the future, will not adversely affect our business and financial results, and we cannot predict how future federal or state legislative or administrative changes relating to healthcare reform will affect our business.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The administration has also indicated an intent to address prescription drug pricing and recent Congressional hearings have brought increased public attention to the costs of prescription drugs. These actions and the uncertainty about the future of the PPACA and healthcare laws may put downward pressure on pharmaceutical pricing and increase our regulatory burdens and operating costs.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">There is also significant economic pressure on state budgets that may result in states increasingly seeking to achieve budget savings through mechanisms that limit coverage or payment for our drugs. In recent years, some states have considered legislation and ballot initiatives that would control the prices of drugs, including laws to allow importation of pharmaceutical products from lower cost jurisdictions outside the U.S. and laws intended to impose price controls on state drug purchases. State Medicaid programs are increasingly requesting manufacturers to pay supplemental rebates and requiring prior authorization by the state program for use of any drug for which supplemental rebates are not being paid. Government efforts to reduce Medicaid expenses may lead to increased use of managed care organizations by Medicaid programs. This may result in managed care organizations influencing prescription decisions for a larger segment of the population and a corresponding limitation on prices and reimbursement for our products. </span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In the E.U. and some other international markets, the government provides health care at low cost to consumers and regulates pharmaceutical prices, patient eligibility or reimbursement levels to control costs for the government-sponsored health care system. Many countries have announced or implemented measures, and may in the future implement new or additional measures, to reduce health care costs to limit the overall level of government </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">expenditures. These measures vary by country and may include, among other things, patient access restrictions, suspensions on price increases, prospective and possible retroactive price reductions and other recoupments and increased mandatory discounts or rebates, recoveries of past price increases and greater importation of drugs from lower-cost countries. These measures have negatively impacted our revenues and may continue to adversely affect our revenues and results of operations in the future.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In response to the COVID-19 pandemic, the Coronavirus Aid, Relief and Economic Security Act (CARES Act) was signed into law in the U.S. in March 2020. The CARES Act is aimed at providing emergency assistance and health care for individuals, families and businesses affected by the COVID-19 pandemic and generally supporting the U.S. economy. Due to the recent enactment of the CARES Act, there is a high degree of uncertainty around its implementation. We expect that additional state and federal healthcare reform measures may be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our products or additional pricing pressures. The COVID-19 pandemic may introduce temporary or permanent healthcare reform measures for which we cannot predict the financial implication of on our business.</span></div><div style="text-indent:13.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Management and key personnel changes may disrupt our operations, and we may have difficulty retaining key personnel or attracting and retaining qualified replacements on a timely basis for management and other key personnel who may leave the Company.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have experienced changes in management and other key personnel in critical functions across our organization in recent years. Changes in management and other key personnel have the potential to disrupt our business, and any such disruption could adversely affect our operations, programs, growth, financial condition or results of operations. In addition, new members of management may have different perspectives on programs and opportunities for our business, which may cause us to focus on new business opportunities or reduce or change emphasis on our existing business programs. Further, if members of our management and other key personnel in critical functions across our organization are unable to perform their duties or have limited availability due to COVID-19, we may not be able to execute on our business strategy and/or our operations may be negatively impacted.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our success is dependent upon our ability to attract and retain qualified management and key personnel in a highly competitive environment. Qualified individuals are in high demand, and we may incur significant costs to attract them, particularly at the executive level. We may face difficulty in attracting and retaining key talent for a number of reasons, including management changes, the underperformance or discontinuation of one or more late stage programs, recruitment by competitors or delays in the recruiting and hiring process as a result of the COVID-19 pandemic. We cannot ensure that we will be able to hire or retain the personnel necessary for our operations or that the loss of any such personnel will not have a material impact on our financial condition and results of operations.</span></div><div style="text-indent:13.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If we fail to comply with the extensive legal and regulatory requirements affecting the health care industry, we could face increased costs, penalties and a loss of business.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our activities, and the activities of our collaborators, distributors and other third-party providers, are subject to extensive government regulation and oversight both in the U.S.&#160;and in foreign jurisdictions. The FDA and comparable agencies in other jurisdictions directly regulate many of our most critical business activities, including the conduct of preclinical and clinical studies, product manufacturing, advertising and promotion, product distribution, adverse event reporting and product risk management as well as our compliance with good practice quality guidelines and regulations. Our interactions in the U.S.&#160;or abroad with physicians and other health care providers that prescribe or purchase our products are also subject to government regulation designed to prevent fraud and abuse in the sale and use of products and place significant restrictions on the marketing practices of health care companies. Health care companies such as ours are facing heightened scrutiny of their relationships with health care providers from anti-corruption enforcement officials. In addition, health care companies such as ours have been the target of lawsuits and investigations alleging violations of government regulation, including claims asserting submission of incorrect pricing information, impermissible off-label promotion of pharmaceutical products, payments intended to influence the referral of health care business, submission of false claims for government reimbursement, antitrust violations or violations related to environmental matters. There is also enhanced scrutiny of company-sponsored patient assistance programs, including insurance premium and co-pay assistance programs and donations to third-party charities that provide such assistance. The U.S. government has challenged some of our donations to third-party charities that provide patient assistance. If we, or our vendors or donation recipients, are found to fail to comply with relevant laws, regulations or government guidance in the operation of these programs, we could be subject to significant fines or penalties. Risks relating to compliance with laws and regulations may be heightened as we continue to expand our global operations and enter new therapeutic areas with different patient populations, </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">which may have different product distribution methods, marketing programs or patient assistance programs from those we currently utilize or support. </span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Conditions and regulations governing the health care industry are subject to change, with possible retroactive effect, including:</span></div><div style="text-indent:-18pt;padding-left:40.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">new laws, regulations or judicial decisions, or new interpretations of existing laws, regulations or judicial decisions, related to health care availability, pricing or marketing practices, compliance with wage and hour laws and other employment practices, method of delivery, payment for health care products and services, compliance with health information and data privacy and security laws and regulations, tracking and reporting payments and other transfers of value made to physicians and teaching hospitals, extensive anti-bribery and anti-corruption prohibitions, product serialization and labeling requirements and used product take-back requirements; </span></div><div style="text-indent:-18pt;padding-left:40.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">changes in the FDA and foreign regulatory approval processes that may delay or prevent the approval of new products and result in lost market opportunity; </span></div><div style="text-indent:-18pt;padding-left:40.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">government shutdowns or relocations may result in delays to the review and approval process, slowing the time necessary for new drug candidates to be reviewed and/or approved, which may adversely affect our business;</span></div><div style="text-indent:-18pt;padding-left:40.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">government regulations that may be imposed in response to the COVID-19 pandemic may restrict the movement of our global supply chain, divert hospital resources that are necessary to administer certain of our products and/or delay the review of product candidates;</span></div><div style="text-indent:-18pt;padding-left:40.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">requirements that provide for increased transparency of clinical trial results and quality data, such as the European Medicines Agency's clinical transparency policy, which could impact our ability to protect trade secrets and competitively-sensitive information contained in approval applications or could be misinterpreted leading to reputational damage, misperception or legal action, which could harm our business; and</span></div><div style="text-indent:-18pt;padding-left:40.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">changes in FDA and foreign regulations that may require additional safety monitoring, labeling changes, restrictions on product distribution or use or other measures after the introduction of our products to market, which could increase our costs of doing business, adversely affect the future permitted uses of approved products or otherwise adversely affect the market for our products.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Violations of governmental regulation may be punishable by criminal and civil sanctions against us, including fines and civil monetary penalties and exclusion from participation in government programs, including Medicare and Medicaid, as well as against executives overseeing our business. In addition to penalties for violation of laws and regulations, we could be required to repay amounts we received from government payors or pay additional rebates and interest if we are found to have miscalculated the pricing information we have submitted to the government. We cannot ensure that our compliance controls, policies and procedures will in every instance protect us from acts committed by our employees, collaborators, partners or third-party providers that would violate the laws or regulations of the jurisdictions in which we operate. Whether or not we have complied with the law, an investigation into alleged unlawful conduct could increase our expenses, damage our reputation, divert management time and attention and adversely affect our business.</span></div><div style="text-indent:13.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our sales and operations are subject to the risks of doing business internationally.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are increasing our presence in international markets, particularly emerging markets, subjecting us to many risks that could adversely affect our business and revenues. There is no guarantee that our efforts and strategies to expand sales in international markets will succeed. Emerging market countries may be especially vulnerable to periods of global and local political, legal, regulatory and financial instability and may have a higher incidence of corruption and fraudulent business practices. Further, certain countries may require local clinical trial data as part of the drug registration process in addition to global clinical trials, which can add to overall drug development and registration timelines. We may also be required to increase our reliance on third-party agents and unfamiliar operations and arrangements previously utilized by companies we partner or collaborate with or acquire in emerging markets.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our sales and operations are subject to the risks of doing business internationally, including:</span></div><div style="text-indent:-18pt;padding-left:40.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">the impact of public health epidemics, such as the COVID-19 pandemic, on employees, the global economy and the delivery of healthcare treatments;</span></div><div style="text-indent:-18pt;padding-left:40.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">less favorable intellectual property or other applicable laws; </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_7">Table of Contents</a></span></div></div><div style="text-indent:-18pt;padding-left:40.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">the introduction or greater acceptance of competing products, including generics, biosimilars, prodrugs and products approved under abbreviated regulatory pathways;</span></div><div style="text-indent:-18pt;padding-left:40.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">the inability to obtain necessary foreign regulatory or pricing approvals of products in a timely manner; </span></div><div style="text-indent:-18pt;padding-left:40.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">limitations and additional pressures on our ability to obtain and maintain product pricing or receive price increases, including those resulting from governmental or regulatory requirements;</span></div><div style="text-indent:-18pt;padding-left:40.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">the inability to successfully complete subsequent or confirmatory clinical trials in countries where our experience is limited;</span></div><div style="text-indent:-18pt;padding-left:40.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">longer payment and reimbursement cycles and uncertainties regarding the collectability of accounts receivable; </span></div><div style="text-indent:-18pt;padding-left:40.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">fluctuations in foreign currency exchange rates that may adversely impact our revenues, net income and value of certain of our investments; </span></div><div style="text-indent:-18pt;padding-left:40.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">difficulties in staffing and managing international operations; </span></div><div style="text-indent:-18pt;padding-left:40.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">the imposition of governmental controls; </span></div><div style="text-indent:-18pt;padding-left:40.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">diverse data privacy and protection requirements;</span></div><div style="text-indent:-18pt;padding-left:40.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">increasingly complex standards for complying with foreign laws and regulations that may differ substantially from country to country and may conflict with corresponding U.S. laws and regulations; </span></div><div style="text-indent:-18pt;padding-left:40.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">the far-reaching anti-bribery and anti-corruption legislation in the U.K., including the U.K. Bribery Act 2010, and elsewhere and escalation of investigations and prosecutions pursuant to such laws; </span></div><div style="text-indent:-18pt;padding-left:40.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">the effects of the implementation of the U.K.&#8217;s departure from the E.U., known as Brexit;</span></div><div style="text-indent:-18pt;padding-left:40.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">compliance with complex import and export control laws;</span></div><div style="text-indent:-18pt;padding-left:40.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">restrictions on direct investments by foreign entities and trade restrictions; </span></div><div style="text-indent:-18pt;padding-left:40.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">greater political or economic instability; </span></div><div style="text-indent:-18pt;padding-left:40.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">changes in tax laws; and</span></div><div style="text-indent:-18pt;padding-left:40.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">the imposition of tariffs or embargoes and other trade restrictions, including the recent tariffs imposed by the U.S. and China and the possibility of additional tariffs or other trade restrictions relating to trade between the two countries.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, our international operations are subject to regulation under U.S. law. For example, the U.S. Foreign Corrupt Practices Act (FCPA) prohibits U.S. companies and their representatives from paying, offering to pay, promising to pay or authorizing the payment of anything of value to any foreign government official, government staff member, political party or political candidate for the purpose of obtaining or retaining business or to otherwise obtain favorable treatment or influence a person working in an official capacity. In many countries, the health care professionals we regularly interact with may meet the FCPA's definition of a foreign government official. Failure to comply with domestic or foreign laws could result in various adverse consequences, including: possible delay in approval or refusal to approve a product, recalls, seizures or withdrawal of an approved product from the market, disruption in the supply or availability of our products or suspension of export or import privileges, the imposition of civil or criminal sanctions, the prosecution of executives overseeing our international operations and damage to our reputation. Any significant impairment of our ability to sell products outside of the U.S. could adversely impact our business and financial results.</span></div><div style="text-indent:13.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We are building a large-scale biologics manufacturing facility, which will result in the incurrence of significant investment with no assurance that such investment will be recouped.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We believe we currently have sufficient large-scale manufacturing capacity to meet our near-term manufacturing requirements. However, in order to support our future growth and drug development pipeline, we are expanding our large molecule production capacity by building a large-scale biologics manufacturing facility in Solothurn, Switzerland with no assurance that the additional capacity will be required. We expect the Solothurn manufacturing facility to be partially operational during the first half of 2021; however, there can be no assurance that we will be able to meet our expected timeline or that there will not be any direct or indirect delays resulting from the COVID-19 pandemic. We have had delays, and if there are additional delays, in bringing the Solothurn manufacturing facility online, we may not have sufficient large-scale manufacturing capacity to meet our long-term manufacturing requirements.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_7">Table of Contents</a></span></div></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, we have made significant investments in connection with the building of this manufacturing facility with no assurance that such investment will be recouped. If we are unable to adequately and timely manufacture and supply our products and product candidates or if we do not fully utilize our manufacturing facilities, our business may be harmed. Charges resulting from excess capacity would have a negative effect on our financial condition and results of operations.</span></div><div style="text-indent:13.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Manufacturing issues could substantially increase our costs, limit supply of our products and/or reduce our revenues.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The process of manufacturing our products is complex, highly regulated and subject to numerous risks, including:</span></div><div style="text-indent:-18pt;padding-left:40.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt;">Risks of Reliance on Third Parties and Single Source Providers.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> We rely on third-party suppliers and manufacturers for many aspects of our manufacturing process for our products and product candidates. In some cases, due to the unique manner in which our products are manufactured, we rely on single source providers of raw materials and manufacturing supplies. These third parties are independent entities subject to their own unique operational and financial risks that are outside of our control, including the impact of the COVID-19 pandemic. These third parties may not perform their obligations in a timely and cost-effective manner or in compliance with applicable regulations, and they may be unable or unwilling to increase production capacity commensurate with demand for our existing or future products. Finding alternative providers could take a significant amount of time and involve significant expense due to the specialized nature of the services and the need to obtain regulatory approval of any significant changes to our suppliers or manufacturing methods. We cannot be certain that we could reach agreement with alternative providers or that the FDA or other regulatory authorities would approve our use of such alternatives. </span></div><div style="text-indent:-18pt;padding-left:40.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt;">Risks Relating to Compliance with current Good Manufacturing Practices (cGMP).</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> We and our third-party providers are generally required to maintain compliance with cGMP and other stringent requirements and are subject to inspections by the FDA and comparable agencies in other jurisdictions to confirm such compliance. Any delay, interruption or other issues that arise in the manufacture, fill-finish, packaging or storage of our products as a result of a failure of our facilities or the facilities or operations of third parties to pass any regulatory agency inspection could significantly impair our ability to develop and commercialize our products. Significant noncompliance could also result in the imposition of monetary penalties or other civil or criminal sanctions and damage our reputation.</span></div><div style="text-indent:-18pt;padding-left:40.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt;">Global Bulk Supply Risks. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We rely on our principal manufacturing facilities for the production of drug substance for our large molecule products and product candidates. Our global bulk supply of these products and product candidates depends on the uninterrupted and efficient operation of these facilities, which could be adversely affected by equipment failures, labor shortages, public health epidemics, natural disasters, power failures, cyber-attacks and numerous other factors. In addition, we are building a large-scale biologics manufacturing facility in Solothurn, Switzerland, which we expect to be partially operational during the first half of 2021. However, there can be no assurance that we will be able to meet our expected timeline or that there will not be any direct or indirect delays resulting from the COVID-19 pandemic. We have had delays, and if there are additional delays, in bringing the Solothurn manufacturing facility online, we may not have sufficient large-scale manufacturing capacity to meet our long-term manufacturing requirements.</span></div><div style="text-indent:-18pt;padding-left:40.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt;">Risk of Product Loss.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> The manufacturing process for our products is extremely susceptible to product loss due to contamination, oxidation, equipment failure or improper installation or operation of equipment or vendor or operator error. Even minor deviations from normal manufacturing processes could result in reduced production yields, product defects and other supply disruptions. If microbial, viral or other contaminations are discovered in our products or manufacturing facilities, we may need to close our manufacturing facilities for an extended period of time to investigate and remediate the contaminant. </span></div><div style="text-indent:-18pt;padding-left:40.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt;">Risk Relating to Government Actions</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. We and/or our third-party providers may be required by the U.S. federal government to manufacture medical supplies needed to treat COVID-19 patients under the Defense Production Act or other acts or orders of government entities, which may result in delays in the manufacturing and supply of our products.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Any adverse developments affecting our manufacturing operations or the operations of our third-party suppliers and manufacturers may result in shipment delays, inventory shortages, lot failures, product withdrawals or recalls or other interruptions in the commercial supply of our products. We may also have to take inventory write-offs and incur other charges and expenses for products that fail to meet specifications, undertake costly remediation efforts or seek more costly manufacturing alternatives. Such developments could increase our manufacturing costs, cause us </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">to lose revenues or market share as patients and physicians turn to competing therapeutics, diminish our profitability or damage our reputation. </span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, although we have business continuity plans to reduce the potential for manufacturing disruptions or delays and reduce the severity of a disruptive event, there is no guarantee that these plans will be adequate, which could adversely affect our business and operations.</span></div><div style="text-indent:13.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our success in commercializing biosimilars developed by Samsung Bioepis is subject to risks and uncertainties inherent in the development, manufacture and commercialization of biosimilars. If Samsung Bioepis is unsuccessful in the development, manufacture and commercialization of biosimilars, we may not realize the anticipated benefits of our investment in Samsung Bioepis.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our success in commercializing biosimilars developed by Samsung Bioepis is subject to a number of risks, including:</span></div><div style="text-indent:-18pt;padding-left:40.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt;">Reliance on Third Parties.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> We are dependent on the efforts of Samsung Bioepis and other third parties over whom we have limited or no control in the development and manufacturing of biosimilars products. In addition, following the divestiture of our Hiller&#248;d, Denmark manufacturing operations, we are dependent on FUJIFILM for the manufacture of biosimilar products. If Samsung Bioepis, FUJIFILM or other third parties fail to perform successfully, we may not realize the anticipated benefits of our investment in Samsung Bioepis;</span></div><div style="text-indent:-18pt;padding-left:40.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt;">Regulatory Compliance.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Biosimilar products may face regulatory hurdles or delays due to the evolving and uncertain regulatory and commercial pathway of biosimilars products in certain jurisdictions; </span></div><div style="text-indent:-18pt;padding-left:40.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt;">Intellectual Property and Regulatory Challenges.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Biosimilar products may face extensive patent clearances, patent infringement litigation, injunctions or regulatory challenges, which could prevent the commercial launch of a product or delay it for many years or result in imposition of monetary damages, penalties or other civil sanctions and damage our reputation; </span></div><div style="text-indent:-18pt;padding-left:40.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt;">Failure to Gain Market and Patient Acceptance.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Market success of biosimilar products will be adversely affected if patients, physicians and/or payors do not accept biosimilar products as safe and efficacious products offering a more competitive price or other benefit over existing therapies; </span></div><div style="text-indent:-18pt;padding-left:40.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt;">Ability to Provide Adequate Supply.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;Manufacturing biosimilars is complex.&#160;If we encounter any manufacturing or supply chain difficulties, including as a result of the COVID-19 pandemic, we may be unable to meet higher than anticipated demand. In addition, following the divestiture of our Hiller&#248;d, Denmark manufacturing operations, we are dependent on FUJIFILM for the manufacture of biosimilar products. FUJIFILM may not perform their obligations in a timely and cost-effective manner or in compliance with applicable regulations and may be unable or unwilling to increase production capacity commensurate with demand for our existing or future biosimilar products;</span></div><div style="text-indent:-18pt;padding-left:40.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt;">Competitive Challenges.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Biosimilar products face significant competition, including from innovator products and from biosimilar products offered by other companies. In some jurisdictions, local tendering processes may restrict biosimilar products from being marketed and sold in those jurisdictions. The number of competitors in a jurisdiction, the timing of approval and the ability to market biosimilar products successfully in a timely and cost-effective manner are additional factors that may impact our success and/or the success of Samsung Bioepis in this business area. In addition, as a result of the COVID-19 pandemic, we have suspended the vast majority of our in-person interactions by our customer-facing professionals in healthcare settings, which will limit our ability to market our products and educate physicians, which, in turn, could have an adverse effect on our ability to compete in the marketing and sales of our products; and</span></div><div style="text-indent:-18pt;padding-left:40.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt;">Legal and Regulatory Requirements.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Any improper conduct or actions on the part of Samsung Bioepis or our joint venture partner, Samsung BioLogics, could damage our reputation and be distracting to management. In particular, Samsung BioLogics is currently subject to an ongoing criminal investigation that may impact the operations of Samsung Bioepis and its business or divert the attention of the Samsung Bioepis management team from its ongoing operations and business. </span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If Samsung Bioepis is unsuccessful in the development, manufacture and commercialization of biosimilar products, we may not realize the anticipated benefits of our investment in Samsung Bioepis.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, as Samsung Bioepis is a privately-held entity, our ability to liquidate our investment in Samsung Bioepis may be limited and we may realize significantly less than the value of such investment.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">87</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_7">Table of Contents</a></span></div></div><div style="text-indent:13.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our operating results are subject to significant fluctuations.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our quarterly revenues, expenses and net income (loss) have fluctuated in the past and are likely to fluctuate significantly in the future due to the risks described in these </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Risk Factors</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> as well as the timing of charges and expenses that we may take. We have recorded, or may be required to record, charges that include:</span></div><div style="text-indent:-18pt;padding-left:40.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">the cost of restructurings or other initiatives to streamline our operations and reallocate resources; </span></div><div style="text-indent:-18pt;padding-left:40.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">impairments with respect to investments, fixed assets and long-lived assets, including IPR&amp;D and other intangible assets; </span></div><div style="text-indent:-18pt;padding-left:40.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">inventory write-downs for failed quality specifications, charges for excess or obsolete inventory and charges for inventory write downs relating to product suspensions, expirations or recalls; </span></div><div style="text-indent:-18pt;padding-left:40.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">changes in the fair value of contingent consideration;</span></div><div style="text-indent:-18pt;padding-left:40.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">bad debt expenses and increased bad debt reserves; </span></div><div style="text-indent:-18pt;padding-left:40.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">outcomes of litigation and other legal or administrative proceedings, regulatory matters and tax matters;</span></div><div style="text-indent:-18pt;padding-left:40.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">milestone payments under license and collaboration agreements; </span></div><div style="text-indent:-18pt;padding-left:40.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">payments in connection with acquisitions, divestitures and other business development activities;</span></div><div style="text-indent:-18pt;padding-left:40.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">failure to meet certain contractual commitments, including, for example, the minimum batch production commitment guarantees we provided as part of the transaction with FUJIFILM; and</span></div><div style="text-indent:-18pt;padding-left:40.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">the impact of public health epidemics, such as the COVID-19 pandemic, on employees, the global economy and the delivery of healthcare treatments.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our revenues and certain assets and liabilities are also subject to foreign currency exchange rate fluctuations due to the global nature of our operations. Although we have foreign currency forward contracts to hedge specific forecasted transactions denominated in foreign currencies, our efforts to mitigate the impact of fluctuating currency exchange rates may not be successful. As a result, currency fluctuations among our reporting currency, the U.S.&#160;dollar, and other currencies in which we do business will affect our operating results, often in unpredictable ways. Our net income may also fluctuate due to the impact of charges we may be required to take with respect to foreign currency hedge transactions. In particular, we may incur higher than expected charges from early termination of a hedge relationship.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our operating results during any one period do not necessarily suggest the anticipated results of future periods.</span></div><div style="text-indent:13.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our effective tax rate fluctuates, and we may incur obligations in tax jurisdictions in excess of accrued amounts.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As a global biopharmaceutical company, we are subject to taxation in numerous countries, states and other jurisdictions. As a result, our effective tax rate is derived from a combination of applicable tax rates, including withholding taxes, in the various places that we operate. In preparing our financial statements, we estimate the amount of tax that will become payable in each of such places. Our effective tax rate may be different than experienced in the past due to numerous factors, including changes in the mix of our profitability from country to country, the results of examinations and audits of our tax filings, adjustments to the value of our uncertain tax positions, interpretations by tax authorities or other bodies with jurisdiction, the result of tax cases, changes in accounting for income taxes and changes in tax laws and regulations either prospectively or retrospectively, including in response to the COVID-19 pandemic. Any of these factors could cause us to experience an effective tax rate significantly different from previous periods or our current expectations.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, our inability to secure or sustain acceptable arrangements with tax authorities and future changes in the tax laws, among other things, may result in tax obligations in excess of amounts accrued in our financial statements.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Tax Cuts and Jobs Act of 2017 (2017 Tax Act) resulted in significant changes to the U.S. corporate income tax system. These changes include a federal statutory rate reduction from 35% to 21%, the elimination or reduction of certain domestic deductions and credits and limitations on the deductibility of interest expense and executive compensation. The 2017 Tax Act also transitions international taxation from a worldwide system to a modified territorial system, which has the effect of subjecting certain earnings of our foreign subsidiaries and collaborations to immediate U.S. taxation as global intangible low-taxed income (GILTI) or Subpart F income, and includes base erosion prevention measures on U.S. earnings and the reduced effective tax rate on income that comes from U.S. exports, called Foreign Derived Intangible Income. These changes became effective in 2018.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The 2017 Tax Act also includes the Transition Toll Tax, which is a one-time mandatory deemed repatriation tax </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">on accumulated foreign subsidiaries' previously untaxed foreign earnings. The Transition Toll Tax will be paid over an eight-year period, which started in 2018, and will not accrue interest. </span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our estimates concerning the impact of the 2017 Tax Act on our accounting and on our business remain subject to developing interpretations of the provisions of the 2017 Tax Act. U.S. Treasury regulations, administrative interpretations or court decisions interpreting the 2017 Tax Act may require further adjustments and changes in our estimates, which could have a material adverse effect on our business, results of operations or financial condition. </span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Swiss Federal Act on Tax Reform and AHV Financing (TRAF) resulted in significant changes to the Swiss cantonal income tax system. These changes include the elimination of historic favorable cantonal tax regimes, the introduction of a patent box regime and the introduction of a research and development super deduction. The TRAF also provides for transitional rules to lessen the immediate impact of the elimination of the favorable cantonal tax regimes. These changes became effective on January 1, 2020. In response to the TRAF, each canton must enact cantonal tax reform to comply with the framework provided by the TRAF and are also expected to lower the statutory tax rate to compensate for the elimination of the historic favorable cantonal tax regimes. We accounted for the impact of the TRAF and the specific cantonal tax reform changes in the period in which each canton in which we operate enacted the cantonal tax reform. Zug, a canton in which we operate, enacted cantonal tax reform in the third quarter of 2019 and Solothurn, another canton in which we operate, enacted cantonal tax reform in the first quarter of 2020. Upon the enactment of cantonal tax reform, we were required to remeasure our Swiss deferred tax assets and liabilities, to account for the elimination of the historic favorable cantonal tax regimes, the impact of the transitional rules and the change in the statutory cantonal tax rate. Final interpretation of the transitional and new regimes of the TRAF may require further adjustments and changes in our estimates, which could have a significant adverse effect on our business, results of operations or financial condition.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, the enactment of some or all of the recommendations set forth or that may be forthcoming in the Organization for Economic Cooperation and Development&#8217;s project on &#8220;Base Erosion and Profit Shifting&#8221; (BEPS) by tax authorities and economic blocs in the countries in which we operate, could unfavorably impact our effective tax rate. These initiatives focus on common international principles for the entitlement to taxation of global corporate profits and minimum global tax rates.</span></div><div style="text-indent:13.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our investments in properties may not be fully realized.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We own or lease real estate primarily consisting of buildings that contain research laboratories, office space and manufacturing operations. For strategic or other operational reasons, we may decide to consolidate or co-locate certain aspects of our business operations or dispose of one or more of our properties, some of which may be located in markets that are experiencing high vacancy rates and decreasing property values. If we determine that the fair value of any of our owned properties is lower than their book value, we may not realize the full investment in these properties and incur significant impairment charges or additional depreciation when the expected useful lives of certain assets have been shortened due to the anticipated closing of facilities. If we decide to fully or partially vacate an owned or leased property, we may incur significant cost, including facility closing costs, employee separation and retention expenses, lease termination fees, rent expense in excess of sublease income and impairment of leasehold improvements and accelerated depreciation of assets. Any of these events may have an adverse impact on our results of operations.</span></div><div style="text-indent:13.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our portfolio of marketable securities is subject to market, interest and credit risk that may reduce its value.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We maintain a portfolio of marketable securities for investment of our cash. Changes in the value of our portfolio of marketable securities could adversely affect our earnings. In particular, the value of our investments may decline due to increases in interest rates, downgrades of the bonds and other securities included in our portfolio, instability in the global financial markets that reduces the liquidity of securities included in our portfolio, declines in the value of collateral underlying the securities included in our portfolio and other factors. In addition, the COVID-19 pandemic could adversely affect the financial markets in some or all countries worldwide. Each of these events may cause us to record charges to reduce the carrying value of our investment portfolio or sell investments for less than our acquisition cost. Although we attempt to mitigate these risks through diversification of our investments and continuous monitoring of our portfolio's overall risk profile, the value of our investments may nevertheless decline.</span></div><div style="text-indent:13.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">There can be no assurance that we will continue to repurchase shares or that we will repurchase shares at favorable prices.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">From time to time our Board of Directors authorizes share repurchase programs, including our 2020 Share Repurchase Program. The amount and timing of share repurchases are subject to capital availability and our determination that share repurchases are in the best interest of our shareholders and are in compliance with all respective laws and our agreements applicable to the repurchase of shares. Our ability to repurchase shares will </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">depend upon, among other factors, our cash balances and potential future capital requirements for strategic transactions, our results of operations, our financial condition and other factors beyond our control that we may deem relevant. A reduction in repurchases under, or the completion of, our 2020 Share Repurchase Program could have a negative effect on our stock price. We can provide no assurance that we will repurchase shares at favorable prices, if at all.</span></div><div style="text-indent:13.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We may not be able to access the capital and credit markets on terms that are favorable to us.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We may seek access to the capital and credit markets to supplement our existing funds and cash generated from operations for working capital, capital expenditure and debt service requirements and other business initiatives. The capital and credit markets are experiencing, and have in the past experienced, extreme volatility and disruption, which leads to uncertainty and liquidity issues for both borrowers and investors. In the event of adverse capital and credit market conditions, we may be unable to obtain capital or credit market financing on favorable terms. Changes in credit ratings issued by nationally recognized credit rating agencies could also adversely affect our cost of financing and the market price of our securities.</span></div><div style="text-indent:13.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our indebtedness could adversely affect our business and limit our ability to plan for or respond to changes in our business. </span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our indebtedness, together with our significant contingent liabilities, including milestone and royalty payment obligations, could have important consequences to our business; for example, such obligations could: </span></div><div style="text-indent:-18pt;padding-left:40.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">increase our vulnerability to general adverse economic and industry conditions;</span></div><div style="text-indent:-18pt;padding-left:40.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">limit our ability to access capital markets and incur additional debt in the future;</span></div><div style="text-indent:-18pt;padding-left:40.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">require us to dedicate a substantial portion of our cash flow from operations to payments on our indebtedness, thereby reducing the availability of our cash flow for other purposes, including business development efforts, research and development and mergers and acquisitions;&#160;and</span></div><div style="text-indent:-18pt;padding-left:40.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">limit our flexibility in planning for, or reacting to, changes in our business and the industry in which we operate, thereby placing us at a competitive disadvantage compared to our competitors that have less debt.</span></div><div style="text-indent:13.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our business involves environmental risks, which include the cost of compliance and the risk of contamination or injury.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our business and the business of several of our strategic partners involve the controlled use of hazardous materials, chemicals, biologics and radioactive compounds. Although we believe that our safety procedures for handling and disposing of such materials comply with state, federal and foreign standards, there will always be the risk of accidental contamination or injury. If we were to become liable for an accident, or if we were to suffer an extended facility shutdown, we could incur significant costs, damages and penalties that could harm our business. Manufacturing of our products and product candidates also requires permits from government agencies for water supply and wastewater discharge. If we do not obtain appropriate permits, including permits for sufficient quantities of water and wastewater, we could incur significant costs and limits on our manufacturing volumes that could harm our business.</span></div><div style="text-indent:13.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">The illegal distribution and sale by third parties of counterfeit or unfit versions of our products or stolen products could have a negative impact on our reputation and business.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Third parties might illegally distribute and sell counterfeit or unfit versions of our products, which do not meet our rigorous manufacturing, distribution and testing standards. A patient who receives a counterfeit or unfit drug may be at risk for a number of dangerous health consequences. Our reputation and business could suffer harm as a result of counterfeit or unfit drugs sold under our brand name. In addition, inventory that is stolen from warehouses, plants or while in-transit, and that is subsequently improperly stored and sold through unauthorized channels, could adversely impact patient safety, our reputation and our business.</span></div><div style="text-indent:13.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">The increasing use of social media platforms presents new risks and challenges.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Social media is increasingly being used to communicate about our products and the diseases our therapies are designed to treat. Social media practices in the biopharmaceutical industry continue to evolve and regulations relating to such use are not always clear. This evolution creates uncertainty and risk of noncompliance with regulations applicable to our business. For example, patients may use social media channels to comment on the effectiveness of a product or to report an alleged adverse event. When such disclosures occur, there is a risk that we fail to monitor and comply with applicable adverse event reporting obligations or we may not be able to defend the company or the public's legitimate interests in the face of the political and market pressures generated by social </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">90</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">media due to restrictions on what we may say about our products. There is also a risk of inappropriate disclosure of sensitive information or negative or inaccurate posts or comments about us on any social networking website. If any of these events were to occur or we otherwise fail to comply with applicable regulations, we could incur liability, face overly restrictive regulatory actions or incur other harm to our business.</span></div><div style="text-indent:13.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Some of our collaboration agreements contain change in control provisions that may discourage a third party from attempting to acquire us.</span></div><div style="text-indent:11.25pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Some of our collaboration agreements include change in control provisions that could reduce the potential acquisition price an acquirer is willing to pay or discourage a takeover attempt that could be viewed as beneficial to shareholders.&#160;Upon a change in control, some of these provisions could trigger reduced milestone, profit or royalty payments to us or give our collaboration partner rights to terminate our collaboration agreement, acquire operational control or force the purchase or sale of the programs that are the subject of the collaboration.&#160; </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">91</span></div></div></div><div id="ib19ff89608c84168a635160f2efa48f3_223"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_7">Table of Contents</a></span></div></div><div style="margin-top:14pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Item&#160;2.&#160;&#160;&#160;&#160;Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Issuer Purchases of Equity Securities</span></div><div style="text-indent:24.75pt;margin-top:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes our common stock repurchase activity under our December 2019 Share Repurchase Program during the third quarter of 2020:</span></div><div style="margin-top:6pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%;"><tr><td style="width:1.0%;"></td><td style="width:21.988%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.535%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:17.282%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.535%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:17.282%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.535%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:17.282%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:0.535%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:17.726%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Period</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total&#160;Number&#160;of<br/>Shares&#160;Purchased<br/>(#)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Average&#160;Price<br/>Paid&#160;per&#160;Share<br/>($)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total&#160;Number&#160;of<br/>Shares&#160;Purchased<br/>as&#160;Part&#160;of&#160;Publicly<br/>Announced Programs<br/>(#)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Approximate Dollar Value<br/>of Shares That May Yet Be Purchased Under<br/>Our Programs<br/>($ in millions)</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">July 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">1,250.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">August 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2,025,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">283.69&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2,025,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">675.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">September 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2,458,413&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">274.78&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2,458,413&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">4,483,413&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">278.81&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-indent:24.75pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In October 2020 our Board of Directors authorized our 2020 Share Repurchase Program, which is a program to repurchase up to $5.0 billion of our common stock. Our 2020 Share Repurchase Program does not have an expiration date. All share repurchases under our 2020 Share Repurchase Program will be retired.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In December 2019 our Board of Directors authorized our December 2019 Share Repurchase Program, which was a program to repurchase up to $5.0 billion of our common stock that was completed as of September 30, 2020. All shares repurchased under our December 2019 Share Repurchase Program were retired. Under our December 2019 Share Repurchase Program, we repurchased and retired approximately 4.5 million and 16.7 million shares of our common stock at a cost of approximately $1.3 billion and $5.0 billion during the three and nine months ended September 30, 2020, respectively.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In March 2019 our Board of Directors authorized our March 2019 Share Repurchase Program, which was a program to repurchase up to $5.0 billion of our common stock that was completed as of March&#160;31, 2020. All shares repurchased under our March 2019 Share Repurchase Program were retired. Under our March 2019 Share Repurchase Program, we repurchased and retired approximately 4.1 million shares of our common stock at a cost of approximately $1.3 billion during the nine months ended September 30, 2020.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">92</span></div></div></div><div id="ib19ff89608c84168a635160f2efa48f3_226"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="margin-top:14pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Item&#160;6.&#160;&#160;&#160;&#160;Exhibits</span></div><div style="text-indent:24.75pt;margin-top:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The exhibits listed below are filed or furnished as part of this Quarterly Report on Form&#160;10-Q.</span></div><div id="ib19ff89608c84168a635160f2efa48f3_229"></div><div style="text-align:center;margin-top:14pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">EXHIBIT&#160;INDEX&#160;</span></div><div style="text-align:center;margin-top:19pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:15.444%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:4.024%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:77.232%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Exhibit</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration: underline;">Number</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Description of Exhibit</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.1*+</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="exhibit101-severancepo.htm">Biogen Inc. Executive Severance Policy - U.S. Executive Vice President, as amended effective July 13, 2020.</a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.2*+</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="exhibit102-mcdonnellof.htm">Letter regarding employment arrangement of Michael McDonnell dated July 16, 2020.</a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.3*+</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="exhibit103-capellosepa.htm">Separation Agreement between Biogen Inc. and Jeffrey Capello dated July 16, 2020.</a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31.1+</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="biib-2020930xex311.htm">Certification of the Chief Executive Officer Pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31.2+</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="biib-2020930xex312.htm">Certification of the Chief Financial Officer Pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">32.1++</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="biib-2020930xex321.htm">Certification Pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101++</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">The following materials from Biogen Inc.&#8217;s Quarterly Report on Form&#160;10-Q for the quarter ended September 30, 2020, formatted in iXBRL (Inline Extensible Business Reporting Language): (i)&#160;the Condensed Consolidated Statements of Income, (ii)&#160;the Condensed Consolidated Statements of Comprehensive Income, (iii) the Condensed Consolidated Balance Sheets, (iv)&#160;the Condensed Consolidated Statements of Cash Flows, (v) the Condensed Consolidated Statements of Equity and (vi)&#160;Notes to Condensed Consolidated Financial Statements.</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">104++</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">The cover page from this Quarterly Report on Form 10-Q for the quarter ended September 30, 2020, formatted in Inline XBRL.</span></td></tr></table></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">*&#160;&#160;&#160;&#160;Management contract or compensatory plan or arrangement</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">+&#160;&#160;&#160;&#160;Filed herewith </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">++&#160;&#160;&#160;&#160;Furnished herewith</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">93</span></div></div></div><div id="ib19ff89608c84168a635160f2efa48f3_232"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#ib19ff89608c84168a635160f2efa48f3_7">Table of Contents</a></span></div></div><div style="text-align:center;margin-top:14pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">SIGNATURES</span></div><div style="text-indent:24.75pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="padding-left:297pt;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:44.590%;"><tr><td style="width:1.0%;"></td><td style="width:98.900%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">BIOGEN INC.</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">/s/&#160;&#160;&#160;&#160;Michael R. McDonnell</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Michael R. McDonnell</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Executive Vice President and</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(principal financial officer)</span></td></tr></table></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">October&#160;21, 2020 </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">94</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>exhibit101-severancepo.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i81260211e60c466e9b7430174561404e_1"></div><div style="min-height:72pt;width:100%;"><div style="text-align:right;margin-top:24pt;margin-bottom:0.12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Exhibit 10.1</font></div><div style="text-align:center;margin-top:24pt;margin-bottom:0.12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration: underline;">Severance Plan for U.S. Executive Vice Presidents</font></div></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">As an Executive Vice President, you are entitled to severance benefits in the event your employment is terminated by Biogen other than For Cause or for reason of death or Disability (as these terms are defined in the Biogen Inc. 2017 Omnibus Equity Plan, as amended from time to time, or any successor plan there to (&#8220;OEP&#8221;).</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Benefits</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Your severance benefits are comprised of (i) a lump sum payment (as calculated below), (ii) upon completion of the appropriate forms, continuation of your participation in Biogen&#8217;s group medical and dental insurance plans, to the same extent permitted by COBRA and to the same extent such insurance is then provided to regular employees of Biogen, including payment by you of a portion of the insurance premiums (i.e., the &#8220;Insurance Benefit&#8221;) and (iii) the reasonable cost of up to 12 months of executive-level outplacement services from a recognized provider of such services selected by Biogen, at the expense of Biogen (upon receipt of appropriate documentation). Except as otherwise prohibited by local law, any severance payments contemplated by this plan will be reduced by the number of weeks&#8217; pay corresponding to any periods during which the employee is not actively working, including statutory or contractual notice periods and any garden or other leave.  </font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">The lump sum severance payment is calculated as follows&#58;</font></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;12 + (A x 2)&#93; x B &#61; lump sum payment</font></div><div style="text-indent:-36pt;padding-left:72pt;padding-right:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">where&#58;&#160;&#160;&#160;&#160;A is the number of full years of service with Biogen (but A x 2 may not exceed 9), and B is the monthly equivalent of your target annual cash compensation at the time of your termination (i.e., one-twelfth of the sum of your then annual base salary plus target annual bonus).</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">The following are examples of how the lump sum payment and Insurance Benefit Period are determined&#58;</font></div><div style="padding-left:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">If your employment with Biogen is terminated after 10 months of employment, you will receive a lump sum payment equal to 12 months of your target annual cash compensation and continue to participate in Biogen&#8217;s group medical and dental plans for 12 months, unless you become eligible to participate in another employer&#8217;s medical and dental plans before that date. COBRA continuation of medical and dental benefits is available, at your own expense, for an additional six months after this 12-month Insurance Benefit Period.</font></div><div style="padding-left:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">If your employment with Biogen is terminated after five years, you will receive a lump sum payment equal to 21 months &#91;12+9&#93; of your target annual cash compensation and continue to participate in Biogen&#8217;s group medical and dental plans for 18 months, unless you become eligible to participate in another employer&#8217;s medical and dental plans before that date.</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">If at any time within two years following a Corporate Transaction or Corporate Change in Control (as these terms are defined in Biogen&#8217;s OEP) your employment is terminated by Biogen </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Adopted October 13, 2008</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Revised July 13, 2020&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Page 1 of 8</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="text-align:center;margin-top:24pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration: underline;">Severance Plan for U.S. Executive Vice Presidents</font></div></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">or the succeeding corporate entity, other than For Cause or for reason of death or Disability (as these terms are defined in Biogen&#8217;s OEP), or you experience an Involuntary Employment Action (defined below) and as a result you terminate your employment with Biogen or the succeeding corporate entity, then, regardless of the length of your service with Biogen and the succeeding corporate entity, and in lieu of the formula set forth above, you will receive a lump sum payment equivalent to 24 months of your target annual cash compensation at the time of your termination or at the time of a Corporate Transaction or Corporate Change in Control, whichever is higher. In addition, you will be entitled to continue participating in Biogen&#8217;s group medical and dental plans for 24 months, unless you become eligible to participate in another employer&#8217;s medical and dental plans before that date. The term &#8220;Involuntary Employment Action&#8221; shall have the definition set forth in Biogen&#8217;s OEP, provided, however, that the term &#8220;Corporate Transaction&#8221; used in that definition shall be deemed to mean either a Corporate Transaction or Change in Control, as the case may be, and provided also that prior to your termination of employment you have notified the Chief Legal Counsel or the Head of Human Resources of Biogen in writing of the basis for your Involuntary Employment Action, you have given such notice within one year of the circumstances giving rise to your Involuntary Employment Action and Biogen does not cure such circumstances within 30 days after the date of your notice.</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Delivery of Benefits</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Payment and provision of all the benefits provided under this arrangement are conditioned on your execution and delivery of all necessary forms and an irrevocable general release in favor of Biogen, in form and substance reasonably acceptable to Biogen, with respect to any and all claims relating to your employment and the termination of your employment with Biogen. If you retire or voluntarily terminate your employment with Biogen, or Biogen terminates your employment For Cause or for reason of death or Disability (as these terms are defined in Biogen&#8217;s OEP), or you do not provide the requisite general release, you will not be eligible to receive the severance benefits described above.</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">If all other conditions of this arrangement are met, a lump sum payment (less applicable taxes and other mandatory deductions as required by law) will be paid to you following the termination of your employment, no later than the first to occur of&#58; a) 90 days following your termination of your employment with Biogen and b) March 15 of the year following the calendar year in which termination of employment occurs, unless you are a &#8220;specified employee&#8221; as defined in Section 409A of the Internal Revenue Code of 1986, as amended (i.e., &#8220;Section 409A&#8221;). (If all preconditions to payment, including the delivery of an irrevocable general release, are not satisfied prior to the earlier of these two dates, payment to you may be delayed and you may incur additional tax liabilities under Section 409A.) If you are a &#8220;specified employee&#8221;, to the extent required by Section 409A, payment will not be made to you before the date which is six months after you &#8220;separate from service&#8221; (or, if earlier, your date of death or Disability) unless the payment qualifies as excepted welfare benefits under Section 409A, does not constitute a &#8220;deferral of compensation&#8221; under Section 409A or is otherwise not subject to the requirements of Section 409A.  Each payment made under this arrangement shall be treated as a separate payment and the right to receive a series of installment payments under this arrangement shall be treated as a right to a series of separate payments.</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Adopted October 13, 2008</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Revised July 13, 2020&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Page 2 of 8</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="text-align:center;margin-top:24pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration: underline;">Severance Plan for U.S. Executive Vice Presidents</font></div></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">The Insurance Benefit will be paid on a monthly basis and will continue until the earlier of (i) the date you become eligible to participate in the medical and dental insurance plan of another employer or (ii) the date that is &#91;12 + (A x 2)&#93; months, but not more than 21 months (or 24 months in the case of a Corporate Transaction or Change in Control), following the termination of your employment with Biogen (the &#8220;Insurance Benefit Period&#8221;). You will have the right, at your own expense, to continue your participation in Biogen&#8217;s group medical and dental insurance plans at the expiration of the Insurance Benefit Period, pursuant to the provisions of COBRA, but only for an 18-month period that will be deemed to have commenced at the start of your severance.  You will only be entitled to receive the Insurance Benefit if you timely and properly elect continuation coverage under COBRA. If Biogen determines in its sole discretion that it cannot provide the Insurance Benefit without the possibility of violating applicable law (including, without limitation, the Patient Protection and Affordable Care Act) or it or you incurring additional taxes, including but not limited to under Section 105(h) of the Internal Revenue Code, Biogen will in lieu thereof provide to you a taxable monthly payment in an amount equal to the monthly COBRA premium that Biogen Idec would have otherwise paid under this arrangement in respect of the Insurance Benefit (which amount will be based on the premium for the first month of COBRA coverage) for the Insurance Benefit Period in equal installments in accordance with Biogen&#8217;s normal payroll practices.</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">General</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Biogen shall administer and shall have the discretionary authority to adopt rules for the management and operation of this arrangement, to interpret the provisions of the arrangement and to construe the terms of the severance arrangement in its sole discretion. The decision of Biogen, or the duly authorized delegate, is final and conclusive for all purposes.</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">The severance arrangement may be amended, modified, suspended or terminated by Biogen at any time&#59; provided that the severance arrangement may not be amended or terminated without your written consent for a period of two years following a Corporate Transaction or a Change in Control.</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">This arrangement is unfunded. This arrangement will benefit and bind Biogen and its successors and permitted assigns and you and your heirs, executors and legal representatives. You do not have any right to transfer or assign your benefits under this arrangement.</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">This arrangement shall be construed, administered and enforced according to the laws of the State of Delaware, except to the extent that such laws are preempted by the federal laws of the United States of America.</font></div><div><font><br></font></div><div><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Adopted October 13, 2008</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Revised July 13, 2020&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Page 3 of 8</font></div><div><font><br></font></div></div></div><div id="i81260211e60c466e9b7430174561404e_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="text-align:center;margin-top:24pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration: underline;">Severance Plan for U.S. Executive Vice Presidents</font></div></div><div style="margin-bottom:3pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Additional Summary Plan Description Information</font></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:24.380%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:73.420%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Description</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">This document describes 3 Plan which is subject to the Employee Retirement Income Security Act of 1974 (ERISA). This document constitutes the Summary Plan Description (SPD) and Plan Document. Benefit determinations are controlled exclusively by this SPD and Plan Document.</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Name of Plan</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Severance Plan for U. S. Executive Vice Presidents</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Name and Address of Employer</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Biogen Inc.<br>225 Binney Street, Cambridge<br>Massachusetts 02142</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Plan Identification Number</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Employer IRS Identification #&#58; 04-3002117 Plan #&#58; 523</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Type of Welfare Plan</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Severance</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">ERISA Plan Year Ends</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Type of Administration</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">The Plan is administered by the Plan Administrator</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Plan Administrator, Name, Address, and Telephone Number</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:3pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Biogen Inc. is the Plan Administrator and named fiduciary of the Plan, with authority to delegate its duties.</font></div><div style="margin-bottom:3pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Biogen Inc.</font></div><div style="margin-bottom:0.03pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">225 Binney Street</font></div><div style="margin-bottom:0.03pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cambridge, Massachusetts  02142</font></div><div style="margin-bottom:0.03pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(617) 679-3400</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Agent for Service of Legal Process on the Plan</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Biogen Inc.<br>225 Binney Street<br>Cambridge, Massachusetts 02142</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Funding</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">This Plan is unfunded</font></td></tr></table></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Adopted October 13, 2008</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Revised July 13, 2020&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Page 4 of 8</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="text-align:center;margin-top:24pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration: underline;">Severance Plan for U.S. Executive Vice Presidents</font></div></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:24.380%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:73.420%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Appeal Procedures</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:3pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">You have 180 days from your effective date of termination to file an appeal. Requests for appeals should be sent to the address specified in the claim denial. A decision on review will be made not later than 45 days following receipt of the written request for review. If the Plan Administrator determines that special circumstances require an extension of time for a decision on review, the review period may be extended by an additional 45 days (90 days in total). The Plan Administrator will notify you in writing if an additional 45 day extension is needed.</font></div><div style="margin-bottom:3pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If an extension is necessary due to your failure to submit the information necessary to decide the appeal, the notice of extension will specifically describe the required information, and you will be afforded at least 45 days to provide the specified information. If you deliver the requested information within the time specified, the 45 day extension of the appeal period will begin after you have provided that information. If you fail to deliver the requested information within the time specified, the Plan Administrator may decide your appeal without that information.</font></div><div style="margin-bottom:3pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">You will have the opportunity to submit written comments, documents, or other information in support of your appeal. You will have access to all relevant documents as defined by applicable U.S. Department of Labor regulations. The review of the adverse benefit determination will take into account all new information, whether or not presented or available at the initial determination. No deference will be afforded to the initial determination.</font></div><div style="margin-bottom:3pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The review will be conducted by the Plan Administrator and will be made by a person different from the person who made the initial determination and such person will not be the original decision maker&#8217;s subordinate.</font></div><div style="margin-bottom:3pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A notice that your request on appeal is denied will contain the following information&#58;</font></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:3pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">The specific reason(s) for the determination&#59;</font></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:3pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">A reference to the specific Plan provision(s) on which the determination is based&#59;</font></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:3pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">A statement disclosing any internal rule, guidelines, protocol or similar criterion relied on in making the adverse determination (or a statement that such information will be provided free of charge upon request)&#59;</font></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:3pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">A statement describing your right to bring a lawsuit under Section 502(a) of ERISA if you disagree with the decision&#59;</font></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:3pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">The statement that you are entitled to receive upon request, and without charge, reasonable access to or copies of all documents, records or other information relevant to the determination&#59; and</font></div><div style="text-indent:-18pt;padding-left:36pt;margin-bottom:3pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">The statement that &#8220;You or your plan may have other voluntary alternative dispute resolution options, such as mediation. One way to find out what may be available is to contact your local U.S. Department of Labor Office and your State insurance regulatory agency&#8221;.</font></div><div style="margin-bottom:3pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Notice of the determination may be provided in written or electronic form. Electronic notices will be provided in a form that complies with any applicable legal requirements.</font></div><div style="margin-bottom:3pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Unless there are special circumstances, this administrative appeal process must be completed before you begin any legal action regarding your claim.</font></div></td></tr></table></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Adopted October 13, 2008</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Revised July 13, 2020&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Page 5 of 8</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="text-align:center;margin-top:24pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration: underline;">Severance Plan for U.S. Executive Vice Presidents</font></div></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:24.380%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:73.420%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Your Rights Under ERISA</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:3pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As a participant in this Plan, you are entitled to certain rights and protections under the Employee Retirement Income Security Act of 1974 (ERISA). ERISA provides that all Plan participants shall be entitled to&#58;</font></div><div style="text-indent:-36pt;padding-left:36pt;margin-bottom:3pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;&#160;&#160;&#160;&#160;Receive Information About Your Plan and Benefits</font></div><div style="text-indent:-36pt;padding-left:72pt;margin-bottom:3pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">o &#160;&#160;&#160;&#160;Examine, without charge, at the Plan Administrator&#8217;s office and at other specified locations, all documents governing the Plan, including a copy of the latest annual report (Form 5500 Series), if any, filed by the Plan with the U.S. Department of Labor and available at the Public Disclosure Room of the Employee Benefits Security Administration.</font></div><div style="text-indent:-36pt;padding-left:72pt;margin-bottom:3pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">o &#160;&#160;&#160;&#160;Obtain, upon written request to the Plan Administrator, copies of documents governing the operation of the Plan, including copies of the latest annual report (Form 5500 Series), if any, and updated Summary Plan Description.</font></div><div style="text-indent:-36pt;padding-left:72pt;margin-bottom:3pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">o &#160;&#160;&#160;&#160;The Plan Administrator may make a reasonable charge for the copies.</font></div><div style="text-indent:-36pt;padding-left:72pt;margin-bottom:3pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">o &#160;&#160;&#160;&#160;Receive a summary of the Plan&#8217;s annual financial report, if any. The Plan Administrator is required by law to furnish each participant with a copy of this summary annual report.</font></div><div style="margin-bottom:3pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;&#160;&#160;&#160;&#160;Prudent Actions by Plan Fiduciaries</font></div><div style="text-indent:-36pt;padding-left:72pt;margin-bottom:3pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">o &#160;&#160;&#160;&#160;In addition to creating rights for Plan participants, ERISA imposes duties upon the people who are responsible for the operation of the employee benefit plan. The people who operate your Plan, called &#8220;fiduciaries&#8221; of the Plan, have a duty to do so prudently and in the interest of you and other Plan participants and beneficiaries. No one, including your Employer or any other person, may fire you or otherwise discriminate against you in any way to prevent you from obtaining a benefit or exercising your rights under ERISA.</font></div></td></tr></table></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Adopted October 13, 2008</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Revised July 13, 2020&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Page 6 of 8</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="text-align:center;margin-top:24pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration: underline;">Severance Plan for U.S. Executive Vice Presidents</font></div></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:24.380%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:73.420%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-36pt;padding-left:36pt;margin-bottom:3pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;&#160;&#160;&#160;&#160;Enforce Your Rights</font></div><div style="text-indent:-36pt;padding-left:72pt;margin-bottom:3pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">o &#160;&#160;&#160;&#160;If your claim for a benefit is denied or ignored, in whole or in part, you have a right to know why this was done, to obtain copies of documents relating to the decision without charge, and to appeal any denial, all within certain time schedules.</font></div><div style="text-indent:-36pt;padding-left:72pt;margin-bottom:3pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">o &#160;&#160;&#160;&#160;Under ERISA, there are steps you can take to enforce the above rights. For instance, if you request a copy of Plan documents or the latest annual report from the Plan and do not receive them within 30 days, you may file suit in a federal court. In such a case, the court may require the Plan Administrator to provide the materials and pay you up to $110 a day until you receive the materials, unless the materials were not sent because of reasons beyond the control of the Plan Administrator.</font></div><div style="text-indent:-36pt;padding-left:72pt;margin-bottom:3pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">o &#160;&#160;&#160;&#160;If you have a claim for benefits that is denied or ignored, in whole or in part, you may file suit in a state or federal court. If it should happen that Plan fiduciaries misuse the Plan&#8217;s money, or if you are discriminated against for asserting your rights, you may seek assistance from the U.S. Department of Labor, or you may file suit in a federal court. The court will decide who should pay court costs and legal fees.  If you are successful, the court may order the person you have sued to pay these costs and fees. If you lose, the court may order you to pay these costs and fees, if, for example, it finds your claim is frivolous.</font></div><div style="text-indent:-36pt;padding-left:36pt;margin-bottom:3pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;&#160;&#160;&#160;&#160;Assistance with Your Questions</font></div><div style="text-indent:-36pt;padding-left:72pt;margin-bottom:3pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">o &#160;&#160;&#160;&#160;If you have any questions about your Plan, you should contact the Plan Administrator. If you have any questions about this statement or about your rights under ERISA, or if you need assistance in obtaining documents from the Plan Administrator, you should contact the nearest office of the Employee Benefits Security Administration, U.S. Department of Labor, listed in your telephone directory or the Division of Technical Assistance and Inquiries, Employee Benefits Security Administration, U.S. Department of Labor, 200 Constitution Avenue N.W., Washington, D.C. 20210. You may also obtain certain publications about your rights and responsibilities under ERISA by calling the publications hotline of the Employee Benefits Security Administration.</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other Rights</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">The Plan Administrator, as fiduciary for the Plan, is entitled to legal and equitable relief to enforce its right to recover any overpayments to you under this Plan. This right of recovery is enforceable but will not exceed the benefits paid you. You agree that the Plan Administrator has a lien over such sources of income until any overpayments have been recovered in full.</font></td></tr></table></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Adopted October 13, 2008</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Revised July 13, 2020&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Page 7 of 8</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="text-align:center;margin-top:24pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration: underline;">Severance Plan for U.S. Executive Vice Presidents</font></div></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:24.380%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:73.420%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Discretionary Acts</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:3pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Plan Administrator has discretionary authority to interpret the Plan and to make benefit determinations under the Plan. The Plan Administrator may act directly or through its employees and agents or further delegate their authority through contracts, letters or other documentation or procedures to other affiliates, persons or entities.</font></div><div style="margin-bottom:3pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Once you are deemed to have exhausted your appeal rights under the Plan, you have the right to seek court review under Section 502(a) of ERISA of any benefit determinations with which you disagree. The court will determine the standard of review it will apply in evaluating those decisions.</font></div></td></tr></table></div><div style="margin-bottom:3pt;"><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Adopted October 13, 2008</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Revised July 13, 2020&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Page 8 of 8</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>exhibit102-mcdonnellof.htm
<DESCRIPTION>EX-10.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="ieb57743a0f0648efaface9f225a2d145_1"></div><div style="min-height:72pt;width:100%;"><div><font><br></font></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration: underline;">Exhibit 10.2</font></div><div><img alt="image11.jpg" src="image11.jpg" style="height:55px;width:167px;"></div></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">July 15, 2020</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Dear Michael, </font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">I am pleased to extend you this offer of employment to join Biogen&#160;with the job title of Executive Vice President and Chief Financial Officer.  This position will report to Michel Vounatsos, Chief Executive Officer.  Please note that neither this letter nor any other materials constitute a contract of employment with Biogen.  Your employment at Biogen is employment at-will.  This means that just as you are free to leave your employment at any time, with or without cause or notice, Biogen also has the same right to terminate your employment at any time, with or without cause or notice. The specific offer terms are listed below.</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The position will be based at our Cambridge, MA facility.</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Salary&#58;  </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">This is a </font><font style="background-color:rgb(255,255,255, 0.0);color:#444545;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">full-time</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, exempt position and your starting annual salary will be $850,000.00, and which will be paid biweekly in accordance with our standard payroll processes. </font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Sign-on Bonus&#58;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">  Upon employment, you will receive $1,000,000.00 as a one-time cash bonus. The bonus will be paid to you within two pay periods after your start date provided that you sign the enclosed Cash Sign-On Bonus Agreement, which describes the terms and conditions of the cash sign-on bonus. </font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Annual Bonus Plan&#58;  </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">You will be eligible to participate in the Biogen Annual Bonus Plan, with a target bonus opportunity of 75% your annual base salary.  Based upon your start date, your target bonus amount may be pro-rated.  Eligibility details and other terms of the Plan are included in the current year's Plan document, which will be made available upon your employment with the Company.</font><font style="background-color:rgb(255,255,255, 0.0);color:#c00000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </font></div><div><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Long Term Incentive Plan&#58;  </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">You will be provided a one-time grant of Restricted Stock Units (RSUs) and Market Stock Units (MSUs) in connection with the commencement of your employment.  The approximate grant date value of your RSU award will be $2,250,000.00 and the approximate grant date value of your MSU award will be $2,250,000.00. The number of shares granted to you will be calculated by dividing the grant date value by the closing price of Biogen stock (NASDAQ) on the grant date, with the resulting number of shares rounded to the nearest five shares.  Your RSU and MSU awards will be granted on the first trading day of the month following your start date. Both your RSU award and MSU awards will vest in three equal installments of 33 1&#47;3% beginning on the first anniversary of the grant date. Your grant amount has been determined based upon the start date listed in this offer letter.&#160; If your start date is delayed, the amount of the grant may decrease, the allocation of RSUs and MSUs may change, or other types of equity or non-equity benefits may be substituted for the above.</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The actual terms of your RSU and MSU awards will be communicated to you following the grant date.  Your grant will be awarded under the Biogen Inc. </font><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Omnibus Equity Plan</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> in effect at that time.  </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Please see your LTI Award Agreements, which will be available following your grant date, for specific details on the terms and conditions of your awards.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Please read these documents for information about your Long-term Incentive grants.</font></div><div><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Beginning in the year following your start date, we expect that you will be eligible to participate in the Biogen annual Long Term Incentive (LTI) program.&#160; Approved awards would be made under the Biogen Inc. Omnibus Equity Plan in effect at that time. The details of the LTI awards will be subject to the approval of, and made by, the Compensation and Management Development Committee of the Board of Directors of Biogen.</font></div><div style="text-align:justify;"><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Relocation&#58; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Biogen will provide relocation benefits to facilitate your ability to establish a residence in the Boston, Massachusetts area.  The relocation benefits and payments will be provided to you after you sign a U.S. Domestic Relocation Policy Acknowledgement and Relocation Repayment Agreement, which detail the terms and conditions of your relocation package and will be provided to you by our relocation service provider, Cartus Corporation.  Payments and reimbursements will be made in accordance with Biogen&#8217;s relocation policy.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">By signing below, you understand and agree that the position requires you to maintain a residence in the Cambridge, Massachusetts area as discussed and that relocation benefits provided to you </font></div><div style="position:relative;width:100%;height:24pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div><div><img alt="image11.jpg" src="image11.jpg" style="height:55px;width:167px;"></div></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">by Biogen must be utilized not later than one year from hire or as soon as practicable, subject to travel restrictions or other limitations resulting from the ongoing pandemic.  </font></div><div><font><br></font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Employee Benefits&#58;  </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Biogen offers a robust and highly competitive employee benefits program.  As an employee, you will be able to choose from a menu of options through our flexible benefits program.  These benefits include a 401(k) savings plan&#59; group health care, including medical, dental, prescription drug and vision coverage&#59; life, dependent life and disability insurance&#59; as well as flexible spending accounts for eligible medical and dependent care expenses.  </font></div><div style="text-indent:-139.5pt;padding-left:139.5pt;text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">You are also entitled to up to 20 vacation days (160 hours) per year (pro-rated if you work part-time). Additional benefit offerings include an Employee Stock Purchase Plan (ESPP) and work&#47;life benefits such as a concierge service and access to subsidized back-up dependent care. Please visit Biogen&#8217;s Benefits website using the below link and login information to familiarize yourself with Biogen&#8217;s complete benefit plan offerings.</font></div><div style="text-align:justify;"><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">URL&#58; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#91;website&#93; </font></div><div style="text-indent:36pt;padding-left:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Username&#58; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#91;username&#93;</font></div><div style="text-indent:36pt;padding-left:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Password&#58; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#91;password&#93;</font></div><div style="text-indent:36pt;padding-left:36pt;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Additional Executive Benefits</font></div><div style="text-align:justify;"><font><br></font></div><div style="padding-left:18pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Supplemental Savings Plan&#58;  </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">You will be entitled to participate in Biogen&#8217;s Supplemental Savings Plan (SSP).  This plan allows you to make pre-tax deferrals of up to 80% of your base salary and up to 100% of your Annual Bonus payment and certain other eligible incentive payments.  Your contributions to this plan may be limited by your contributions towards other plans (e.g., 401(k), ESPP, medical, etc.).  You will be provided with SSP enrollment information upon your employment with the Company.</font></div><div style="padding-left:18pt;text-align:justify;"><font><br></font></div><div style="padding-left:18pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Life Insurance&#58;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">  You will be provided life insurance coverage equal to three times your annual base salary, subject to meeting the medical standards stated in the group term life insurance policy for U.S. employees.  Biogen pays the premium for this insurance.  The IRS requires employers to impute the value of company-paid life insurance for coverage over $50,000.  This imputed income will be displayed on your pay stub.</font></div><div style="padding-left:18pt;text-align:justify;"><font><br></font></div><div style="padding-left:18pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Severance&#58;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">  You will be entitled to severance benefits in accordance with the attached Severance Plan for U.S. Executive Vice Presidents, as it may be amended in the future from time to time, and should refer to such document for details regarding terms, conditions, eligibility and potential tax implications.</font></div><div style="padding-left:18pt;text-align:justify;"><font><br></font></div><div style="padding-left:18pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Tax &#38; Financial Planning and Executive Physicals&#58;  </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">You are eligible for annual reimbursement of expenses for qualified services such as federal and state income tax planning and&#47;or preparation, financial and estate planning services, and the purchase of tax and&#47;or financial planning tools.  Additionally, the Company will reimburse you for the expenses of an annual comprehensive physical exam when coordinated by the Executive Health Services team at Mass. General Hospital (MGH).  The combined annual reimbursement you are eligible to receive is $7,500 per calendar year (January 1 &#8211; December 31), subject to the guidelines of the Tax &#38; Financial Planning and Executive Physical Reimbursement Program.  The details of these benefits are available upon your employment with the Company.</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Stock Trading Plan&#58;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">  Upon employment with the Company, you will become subject to Biogen&#8217;s Global Insider Trading Policy, a copy of which will be provided to you. The Biogen Global Insider Trading Policy sets forth guidelines designed to promote compliance with applicable federal and state securities laws that prohibit persons who are aware of material nonpublic information about the company from trading in securities of the company or providing material nonpublic information to other persons who may trade on the basis of that information.  Upon your employment, you will be assigned, based on your job, to a specific trading group that will determine your obligations and restrictions under the policy, and you will be required to complete training on the policy.</font></div><div style="position:relative;width:100%;height:24pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="padding-left:1pt;padding-right:-2.2pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div><div><img alt="image11.jpg" src="image11.jpg" style="height:55px;width:167px;"></div></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Share Ownership Requirement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#58;  A key objective of our long-term incentive plans is to ensure strong alignment between the interests of our senior executives and those of our stockholders.  It is expected that through our annual long-term incentive grants, you will accumulate and retain Biogen shares in an amount equivalent to 3x salary through the first 5 years of employment.</font></div><div><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">You are required to satisfy the following contingencies prior to employment at Biogen.  </font></div><div style="text-indent:-139.5pt;padding-left:139.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt;">Pre-employment screening&#58;  </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Employment at Biogen is contingent upon your successful completion and passing of both a background check and drug screen.  Biogen&#8217;s background check includes verification of employment history, educational and professional licenses, degrees and&#47;or credentials, a criminal records check, a Social Security Number search and verification of any other professional qualifications that your position responsibilities at Biogen may warrant.  Completion of your online Application for Employment authorizes Biogen to conduct these background checks.  If you have any questions about the background check, please contact </font><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">HRConnect&#64;biogen.com</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. </font></div><div style="padding-left:36pt;text-align:justify;"><font><br></font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt;">Authorization to Work in the United States&#58;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">  Please note that Biogen is an E-Verify employer. The Federal government requires you to provide proper identification verifying your eligibility to work in the United States.  Please complete Section 1 of the Employment Eligibility Verification Form I-9, electronically as specified in your emails from Guardian. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">On your first day of employment</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, please bring original and unexpired documents and a scanned copy of your documents to complete the I-9 process. A list of acceptable documents can be found on the last page of the Form I-9 packet.</font></div><div style="padding-left:36pt;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Signed Employee Proprietary Information and Inventions and Non-Compete Agreement&#58; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Prior to and as a condition of employment with Biogen you will be required to sign Biogen&#8217;s</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Proprietary Information and Inventions and Non-Compete Agreement. This is required to, among other things, protect Biogen&#8217;s substantial investment in creating and maintaining its confidential and proprietary information, and to maintain goodwill with our customers, vendors and other business partners. You will receive an email shortly that contains a link to this agreement for your review and electronic signature.</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Michael, we are excited at the prospect of your joining Biogen.  To confirm your acceptance of this offer of employment, please electronically sign this letter by July 17, 2020. You will be provided with a signed copy electronically for your personal records. We would anticipate your first day of employment to be October 19, 2020.  If you have any questions, please feel free to contact me.  </font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Best Regards,</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Eileen Rivera</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cc&#58;  Michel Vounatsos</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">I accept this offer of employment and acknowledge the contingencies of employment described above, including the at-will nature of my employment.</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ACCEPTED&#58;</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">   &#47;s&#47; Michael McDonnell</font></div><div style="text-align:justify;"><font><br></font></div><div><font><br></font></div><div style="position:relative;width:100%;height:24pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="padding-left:1pt;padding-right:-2.2pt;"><font><br></font></div></div></div><div id="ieb57743a0f0648efaface9f225a2d145_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div><div><img alt="image11.jpg" src="image11.jpg" style="height:55px;width:167px;"></div></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">BIOGEN CASH SIGN-ON BONUS AGREEMENT</font></div><div style="text-align:center;"><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">I have accepted a position of employment with Biogen that provides for payment to me of a cash sign-on bonus of $1,000,000.00 following commencement of employment.</font><font style="background-color:rgb(255,255,255, 0.0);color:#444545;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">  </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">I understand that the full benefit of this cash sign-on bonus is conditioned upon my remaining an employee of Biogen for at least 36 months. </font></div><div><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">I hereby accept Biogen&#8217;s offer of a cash sign-on bonus according to the following terms&#58; </font></div><div style="text-align:justify;"><font><br></font></div><div style="text-indent:-18pt;padding-left:18pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The payment of the cash sign-on bonus by Biogen is taxable income to me and will be taxed at the time of payment. </font></div><div style="text-align:justify;"><font><br></font></div><div style="text-indent:-18pt;padding-left:18pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">I acknowledge and agree that if, within 36 months of my start date, I voluntarily terminate my employment or Biogen terminates my employment For Cause, as defined in the Biogen 2017 Inc. Omnibus Equity Plan, or for misconduct or poor performance, as determined in good faith by the Company, I will not have earned the cash sign-on bonus provided to me under this Agreement and I will repay such bonus according to the following schedule&#58; (i) if my employment terminates on or before 12 months from my start date, the full amount of the cash sign-on bonus, net of the applicable proportion of tax withholdings&#59; (ii) if my employment terminates after 12 months and on or before 24 months from my start date, 70% of the amount of the cash sign-on bonus, net of the applicable proportion of tax withholdings&#59; or (iii) if my employment terminates after 24 months and on or before 36 months from my start date, 35% of the amount of the cash sign-on bonus, net of the applicable proportion of tax withholdings.</font></div><div style="padding-left:18pt;text-align:justify;"><font><br></font></div><div style="text-indent:-18pt;padding-left:18pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">I shall pay to Biogen all such repayable amounts within thirty (30) days of the effective date of my employment termination or by the end of the year in which my employment terminates, whichever comes first. I voluntarily authorize Biogen to deduct, withhold and&#47;or retain all or any portion of the amount which I may be required to refund or repay to Biogen hereunder from any wages, salary, vacation pay, severance pay or other pay which may be due and owing to me upon termination of employment, to the extent permitted under applicable law. I shall remain liable to Biogen for any amounts in excess of the sums so deducted, withheld and&#47;or retained by Biogen.</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Except as stated above, I shall have no liability or responsibility to refund or repay to Biogen any amounts paid by Biogen to me in connection with this sign-on bonus.</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Nothing in this Agreement shall alter the at-will employment relationship between Biogen and me (e.g., Biogen and I can end the employment relationship at any time with or without cause). Therefore, I understand that nothing in this Agreement guarantees that the Company will employ me for any specific period of time.</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">My signature below acknowledges that I have read and understand this Agreement and agree to be bound by its terms.</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">  &#47;s&#47; Michael McDonnell&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Michael McDonnell&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;July 16, 2020</font></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:94.875%;"><tr><td style="width:1.0%;"></td><td style="width:39.489%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:2.664%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:32.778%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:2.664%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:16.905%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Employee Signature</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Employee Name (Please Print)</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Date</font></td></tr></table></div><div><font><br></font></div><div style="position:relative;width:100%;height:24pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="padding-left:1pt;padding-right:-2.2pt;"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>4
<FILENAME>exhibit103-capellosepa.htm
<DESCRIPTION>EX-10.3
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i8e86b3ff97904c52be5a759891eed341_1"></div><div style="min-height:11pt;width:100%;"><div><font><br></font></div></div><div style="padding-right:8.5pt;margin-top:3.5pt;"><img alt="image01.jpg" src="image01.jpg" style="height:55px;width:167px;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration: underline;">Exhibit 10.3</font></div><div style="margin-top:0.1pt;"><font><br></font></div><div style="padding-right:232.65pt;text-align:center;"><font><br></font></div><div><font><br></font></div><div style="margin-top:0.35pt;"><font><br></font></div><div style="padding-left:62pt;margin-top:4.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration: underline;">BY ELECTRONIC DELIVERY (&#91;email address&#93;)</font></div><div style="margin-top:0.05pt;"><font><br></font></div><div style="padding-left:62pt;margin-top:4.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">July 16, 2020</font></div><div style="padding-left:62pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Revised August 5, 2020</font></div><div><font><br></font></div><div style="padding-left:62pt;padding-right:448.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Jeff Capello &#91;Address&#93;</font></div><div><font><br></font></div><div style="padding-left:63pt;margin-top:0.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Re&#58;&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Separation Agreement</font></div><div style="margin-top:0.05pt;"><font><br></font></div><div style="padding-left:62pt;margin-top:4.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Dear Jeff&#58;</font></div><div><font><br></font></div><div style="text-indent:36pt;padding-left:62pt;padding-right:48.15pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">The purpose of this Separation Agreement (the &#8220;Agreement&#8221;) is to confirm the terms of your separation from Biogen Inc. or one of its subsidiaries (&#8220;Biogen&#8221; or the &#8220;Company&#8221;). The specific severance pay and benefits being offered to you, and the terms on which they are being offered, are described below. This consideration is conditioned on you timely signing and not revoking this Agreement and complying with all of its provisions.</font></div><div style="margin-top:0.5pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:61.95pt;padding-right:39.8pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:1.05pt;">Transition Period and Separation</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Your employment with the Company will end on September 15, 2020 (the &#34;Separation Date&#34;) provided that you satisfactorily perform your job duties and otherwise comply with Company rules and policies (as determined by the Company reasonably and good faith) from the date you received this Agreement through your Separation Date (&#8220;Transition Employment Period&#8221;).</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:61.95pt;padding-right:39.75pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">You agree to continue performing your job duties to the Company&#8217;s reasonable satisfaction through your last day of work, August 15, 2020. Throughout the Transition Employment Period, you will continue receiving your regular pay and benefits, and will be available to Biogen to assist with the transition of your successor and will respond to any inquiries necessary for an orderly transition.  Upon your Separation Date, Biogen will pay you  all unpaid wages due through that date, including all accrued but unused vacation (which the parties agree is a total of 21 days). Unless otherwise provided for in this Agreement, benefits which have vested under any other employee benefit plan of the Company on or before the Separation Date will be managed in accordance with and subject to the terms and conditions of such plans.</font></div><div style="margin-top:0.5pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:61.95pt;padding-right:51.95pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:1.05pt;">Severance Pay and Benefits</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. In exchange for the mutual promises set forth in this Agreement, including the release of claims, and pursuant to the Severance Plan for U.S. Executive Vice Presidents, Biogen agrees to provide you with the following severance pay and benefits (the &#8220;Severance Pay and Benefits&#8221;), provided you accept this Agreement as described below, and do not revoke your acceptance pursuant to Section 7 below&#58;</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="text-indent:-18pt;padding-left:169.95pt;padding-right:52.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">a.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.68pt;">The Company will provide you with a lump sum payment in the amount of $1,892,625, less lawful deductions. This amount represents sixteen</font></div><div style="padding-left:169.95pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">(16) months of pay at your base salary and target bonus.</font></div><div style="padding-left:62pt;margin-top:4.65pt;"><font><br></font></div><div><font><br></font></div><div style="position:relative;width:100%;height:14pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><div id="i8e86b3ff97904c52be5a759891eed341_4"></div><hr style="page-break-after:always"><div style="min-height:55pt;width:100%;"><div><img alt="image111.jpg" src="image111.jpg" style="height:55px;width:167px;"></div></div><div style="margin-top:0.45pt;"><font><br></font></div><div style="text-indent:-18pt;padding-left:169.95pt;padding-right:42.45pt;margin-top:4.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">b.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt;">Your coverage under the Company&#8217;s group health benefits will end on the last day of the month in which your employment terminates. Thereafter, the Company will subsidize your current level of participation in Biogen&#8217;s group medical, vision and dental insurance plans through December 31, 2021 (&#8220;COBRA Subsidy Period&#8221;), provided that you complete and timely submit your COBRA election form. In particular, during the COBRA Subsidy Period, you will be required timely to pay the employee portion of the premiums and the Company will pay the employer portion of the premiums at the same rate as paid on behalf of current employees, as long as you do not become eligible to participate in another medical, vision and&#47;or dental insurance plan. After the COBRA Subsidy Period, you may continue your group health benefits through COBRA for the period permitted by law, by timely paying the full premiums at your sole expense. A notice regarding your COBRA rights and benefits will be mailed separately by ADP, Biogen&#8217;s COBRA administrator. The benefit period under COBRA will commence on the Separation Date. You agree to promptly notify the Company if you become eligible to participate in another medical, vision and&#47;or dental insurance plan during the COBRA Subsidy Period.</font></div><div style="margin-top:0.35pt;"><font><br></font></div><div style="text-indent:-18pt;padding-left:169.95pt;padding-right:50.95pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">c.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.68pt;">The Company will forgive your obligation to repay Biogen the portion (35%) of your new hire sign-on bonus which would otherwise be due to Biogen based on the repayment terms of your Cash Sign-On Agreement, executed on November 18, 2017. You are responsible for any taxes that might result from the Company forgiving your repayment obligation.</font></div><div style="margin-top:0.45pt;"><font><br></font></div><div style="text-indent:-18pt;padding-left:169.95pt;padding-right:72.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">d.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt;">The Company will provide you with up to twelve (12) months of executive outplacement services from a recognized provider of such services selected by the Company.</font></div><div style="margin-top:0.5pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:61.95pt;padding-right:41.45pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Supplemental Severance Pay</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#58; At the conclusion of the Transition Employment Period and after the Separation Date, if you accept and do not revoke your acceptance of the Reaffirmation of Release of Claims attached to this Agreement as </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration: underline;">Exhibit A</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(&#8220;Reaffirmation Agreement&#8221;), you will receive from Biogen supplemental severance pay (&#8220;Supplemental Severance Pay&#8221;). Payment of the Supplemental Severance Pay is expressly conditioned upon&#58; (a) your signing and not revoking the Reaffirmation Agreement by the later of the 14-day period after your Separation Date or 21 days from your receipt of this Agreement&#59; and (b) the termination of your employment. The Supplemental Severance Pay will be a lump sum payment to you in the amount of $2,600,000, less lawful deductions. This amount is in appreciation for your years of service to the Company and in recognition of your unvested equity. The Supplemental Severance Pay is discretionary and not intended to exactly replicate any benefits you may have been eligible to receive, if you had remained employed, pursuant to the Company&#8217;s equity, incentive or bonus programs.</font></div><div style="position:relative;width:100%;height:96pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:7%;">2</font></div><div><font><br></font></div></div></div><div id="i8e86b3ff97904c52be5a759891eed341_7"></div><hr style="page-break-after:always"><div style="min-height:55pt;width:100%;"><div><img alt="image111.jpg" src="image111.jpg" style="height:55px;width:167px;"></div></div><div style="margin-top:0.45pt;"><font><br></font></div><div style="padding-left:62pt;margin-top:4.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">The Severance Pay and Benefits and Supplemental Severance Pay will be paid within fifteen</font></div><div style="padding-left:62pt;padding-right:43.05pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(15) business days of the effective date of the Reaffirmation Agreement, except for (i) the outplacement benefits described in Section 2(d) which may begin at your initiation after execution of this Agreement but within six months of your Separation Date, and for the COBRA subsidy benefits described in Section 2(b) which will commence after you elect COBRA within the time periods required by applicable law (which will be retroactive to the Separation date if such benefits are timely elected).</font></div><div style="margin-top:0.45pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:61.95pt;padding-right:48.05pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:1.05pt;">Employee Affirmations</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Biogen will pay you all unpaid wages due through your Separation Date, including all accrued but unused vacation</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">You affirm and agree that, with the payments and benefits set forth in this Agreement, you will have received all leave (paid or unpaid), compensation, wages, bonuses, commissions, and&#47;or benefits to which you may be entitled and that no other leave (paid or unpaid), compensation, wages, bonuses, commissions and&#47;or benefits are due to you. You furthermore affirm that you have no known workplace injuries or occupational diseases and have been provided and&#47;or have not been denied any leave requested under the Family and Medical Leave Act. You also affirm that you have not been retaliated against for reporting any allegations of wrongdoing by the Company or its officers, including without limitation, any allegations of corporate fraud. In addition, you affirm that all decisions regarding your pay and benefits through the date of your execution of this letter agreement and general release were not discriminatory based on age, disability, race, color, sex religion, national origin or any other classification protected by law.</font></div><div><font><br></font></div><div style="text-indent:36pt;padding-left:61.95pt;padding-right:39.9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">You represent that, based on your current knowledge and understanding, you have complied with all laws, regulations, rules and policies pertaining to Medicare, Medicaid, or any other federal health care program while employed at Biogen. You further affirm that either (i) you are unaware of any non-compliant conduct by Biogen or its employees&#59; or (ii) you have provided Biogen with any and all information you have, whether based on direct or indirect information, of any wrongdoing, irregularities, improprieties or illegalities regarding the ordering or delivery of any item or performance of any service by Biogen that is reimbursable by Medicare, Medicaid, or any other federal health care program.</font></div><div style="margin-top:0.5pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:61.95pt;padding-right:39.65pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">You acknowledge and agree that, but for executing this Agreement, you would not be receiving the Severance Pay and Benefits, or Supplemental Severance Pay, described herein. If you apply for and accept a position at Biogen (in any capacity, including employee, supplemental staff, contractor, consultant, etc.) either before or within 16 months following your Separation Date, you agree to repay Biogen a prorated amount of the Severance Pay and Benefits you received.</font></div><div style="margin-top:0.5pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:61.95pt;padding-right:40.6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">4.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:1.05pt;">Long-Term Incentive (LTI) Awards</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. You acknowledge and agree that, in accordance with the Company&#8217;s Omnibus Equity Plan and award agreements, all of your LTI awards that are unvested as of the Separation Date will be forfeited and revert to Biogen on the Separation Date and you will have no further or future rights to any of those forfeited and reverted LTI Awards.</font></div><div><font><br></font></div><div style="text-indent:-15pt;padding-left:112.95pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">5.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:6pt;">Release of Claims</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. In consideration for the promises and representations of Biogen as</font></div><div style="position:relative;width:100%;height:76.5pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:7%;">3</font></div><div><font><br></font></div></div></div><div id="i8e86b3ff97904c52be5a759891eed341_10"></div><hr style="page-break-after:always"><div style="min-height:55pt;width:100%;"><div><img alt="image111.jpg" src="image111.jpg" style="height:55px;width:167px;"></div></div><div style="margin-top:0.45pt;"><font><br></font></div><div style="padding-left:62pt;padding-right:41.4pt;margin-top:4.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">described in this Agreement, you hereby agree to forever release and discharge Biogen and any of its divisions, affiliates, subsidiaries, related entities, and its and their current and former directors, officers, employees, attorneys, agents, insurers, successors and assigns, in their individual and official capacities, as well as their health, welfare and benefits plans and programs or the administrators or trustees of the plans and programs (collectively &#8220;Releasees&#8221;)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">from any and all claims, demands, actions, liabilities, obligations, accounts, expenses, attorneys&#8217; fees and causes of action, of every kind and nature, in law, equity or otherwise, whether known or unknown, asserted or unasserted, which you ever had, now have, or which may hereafter accrue in connection with any event, act or occurrence arising prior to the date that you execute this Agreement, including but not limited to all matters that arise in any way out of your employment or separation from employment with Biogen.</font></div><div><font><br></font></div><div style="text-indent:36pt;padding-left:62pt;padding-right:39.1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">This release is to be interpreted broadly and is intended to include, without limitation, any and all claims you may have against Releasees under federal, state or local statutes, ordinances, regulations or rules, including without limitation the following&#58;</font></div><div><font><br></font></div><div style="text-indent:-18pt;padding-left:116pt;padding-right:43pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:4.7pt;">Any and all federal statutory or regulatory claims such as claims under the Age Discrimination in Employment Act, 29 U.S.C. &#167; 621 </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">et</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">seq</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">., Title VII of the Civil Rights Act of 1964, 42 U.S.C. &#167; 2000e </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">et seq.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, the Americans with Disabilities Act of 1990, 42 U.S.C. &#167; 12101 </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">et seq</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">., the Family and Medical Leave Act, 29 U.S.C. &#167; 2601 </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">et seq</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">., the Worker Adjustment and Retraining Notification Act (&#8220;WARN&#8221;), 29</font></div><div style="padding-left:116pt;padding-right:42.65pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">U.S.C. &#167; 2101 </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">et seq</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">., and the Rehabilitation Act of 1973, 29 U.S.C. &#167; 701 </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">et seq</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">., all as amended&#59; all claims arising out of the Fair Credit Reporting Act, 15 U.S.C. &#167;1681 </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">et seq</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">., the Employee Retirement Income Security Act of 1974 (&#8220;ERISA&#8221;), 29 U.S.C.</font></div><div style="padding-left:116pt;padding-right:46.15pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#167;1001 </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">et seq</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">., the Sarbanes-Oxley Act of 2002, the Immigration Reform and Control Act, the Equal Pay Act, Sections 1981 thorough 1988 of Title 42 if the United States Code and the Genetic information Nondiscrimination Act.</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="text-indent:-18pt;padding-left:116pt;padding-right:45.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:4.02pt;">Any and all state statutory or regulatory claims such as claims under the Massachusetts Fair Employment Practices Law, M.G.L. ch. 151B&#59; the Massachusetts Wage Payment Statute, G.L. c. 149, &#167;&#167; 148, 148A, 148B, 149, 150,150A-150C, 151, 152, 152A, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">et seq</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.&#59; and the Massachusetts Wage and Hour laws, G.L. c. 151&#167;1A </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">et seq.&#59; t</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">he North Carolina Equal Employment Practices Act &#8211; N.C. Gen. Stat. &#167;143-</font></div><div style="padding-left:116pt;padding-right:47.05pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">422.1 </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">et seq</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.&#59; the North Carolina Persons With Disabilities Protection Act &#8211; N.C. Gen. Stat. &#167;168A-1 </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">et seq</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.&#59; the North Carolina Retaliatory Employment Discrimination Law &#8211; N.C. Gen. Stat. &#167;95-240 </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">et seq</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.&#59; the North Carolina Wage and Hour Act, as amended, including N.C. Gen. Stat. &#167;95-25.2 </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">et seq</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">., and &#167;95-25.14 </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">et seq</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="margin-top:0.1pt;"><font><br></font></div><div style="text-indent:-18pt;padding-left:115.95pt;padding-right:40.3pt;margin-top:4.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:4.7pt;">Any and all other claims under public policy, contract, tort or common law such as claims for breach of contract, detrimental reliance, breach of the covenant of good faith and fair dealing, wrongful discharge, employment discrimination, harassment, or </font></div><div style="position:relative;width:100%;height:96pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:7%;">4</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:55pt;width:100%;"><div><img alt="image111.jpg" src="image111.jpg" style="height:55px;width:167px;"></div></div><div style="padding-left:115.95pt;padding-right:40.3pt;margin-top:4.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">retaliation, infliction of emotional distress, negligence, defamation, fraud, and non- payment of wages or benefits.</font></div><div><font><br></font></div><div id="i8e86b3ff97904c52be5a759891eed341_13"></div><div style="text-indent:-18pt;padding-left:117pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(d) Any and all claims for recovery of costs, fees, or other expenses including attorneys&#8217; fees incurred in any matter.</font></div><div><font><br></font></div><div style="padding-left:62pt;padding-right:42.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Notwithstanding the foregoing, by signing this Agreement, you are not waiving any rights you may have to&#58; (i) your own vested accrued employee benefits under the Company&#8217;s health, welfare, or retirement benefit plans as of the Separation Date&#59; (ii) benefits and&#47;or the right to seek benefits under applicable workers&#8217; compensation and&#47;or unemployment compensation statutes&#59; (iii) pursue claims which by law cannot be waived by signing this Agreement&#59; (iv) enforce this Agreement&#59;  (v) challenge the validity of this Agreement&#59; and&#47;or (vi) indemnification pursuant to the indemnification agreement between you and Biogen dated December 11, 2017 (the &#8220;Indemnification Agreement&#8221;), under the Company&#8217;s by-laws and certificate of incorporation, and coverage, if any, under a Biogen directors and officers insurance policy.</font></div><div><font><br></font></div><div style="text-indent:36pt;padding-left:61.95pt;padding-right:39.55pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Nothing in this release or elsewhere in this Agreement shall be deemed to prohibit you from filing a charge or complaint of employment related discrimination with the Equal Employment Opportunity Commission (&#8220;EEOC&#8221;) or equivalent state agency, or from participating in any investigation or proceeding conducted by the EEOC or equivalent state agency. Notwithstanding your right to file a charge or complaint with and&#47;or participate in any investigation or proceeding by the EEOC or equivalent state agency, to the fullest extent permitted by law, you expressly waive your right to recover any individual monetary relief or other individual remedies from Biogen or any other Releasees, in any administrative action or proceeding, whether state or federal, and whether brought by you or on your behalf by an administrative agency, related in any way to the matters released herein. Likewise, nothing in this release or elsewhere in this Agreement (including without limitation any confidentiality or non-disparagement obligations below) shall be construed to prevent you from responding truthfully and completely to any lawfully issued court order or subpoena or from communicating with a government agency.</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="text-indent:40.5pt;padding-left:58.5pt;padding-right:40.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">6. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Consideration Period</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. In signing this Agreement, you acknowledge that you understand its provisions, that your agreement is knowing and voluntary, that you are hereby afforded an opportunity to take at least twenty-one (21) days to consider its terms and consult with or seek advice from any person of your choosing, and that you are hereby advised by the Company to consult with an attorney prior to executing the Agreement. You acknowledge that, if you choose to sign this Agreement as by the dates set forth below, you have had a fully adequate opportunity to review the Agreement. You agree that any modifications, material or otherwise, do not restart, extend or affect in any manner the original consideration period.</font></div><div style="margin-top:0.45pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:62pt;padding-right:39.8pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">7.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:1pt;">Revocation Period</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. You further understand that for a period of seven (7) days following your execution of this Agreement, you may revoke the Agreement, and this  Agreement shall not become effective or enforceable until this seven (7) day revocation period has expired, therefore </font></div><div style="position:relative;width:100%;height:96pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:7%;">5</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:55pt;width:100%;"><div><img alt="image111.jpg" src="image111.jpg" style="height:55px;width:167px;"></div></div><div style="padding-left:62pt;padding-right:39.8pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">making the effective date the eighth (8</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;vertical-align:top;">th</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">) day after this Agreement is signed by you, provided that you do not revoke this Agreement during the seven (7) day revocation period (the &#8220;Effective Date&#8221;). Any revocation within the seven (7) day revocation period must be personally delivered or mailed by Federal Express or Express Mail to Ginger Gregory at Biogen, 225 Binney Street, Cambridge, MA 02142, within seven (7) days of your execution of this Agreement. This Agreement shall not become effective or enforceable until the revocation period has expired. If the last day of the revocation period is a Saturday, Sunday, or legal holiday in Massachusetts or the state in which you reside, then the revocation period shall not expire until the next following day which is not a Saturday, Sunday, or legal holiday.</font></div><div style="text-align:justify;"><font><br></font></div><div id="i8e86b3ff97904c52be5a759891eed341_16"></div><div style="padding-left:63pt;margin-top:0.45pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:62pt;padding-right:39.8pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">8.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:1pt;">No Pending Suits</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. You acknowledge and agree that you have no pending lawsuit or complaint against Biogen or any of the other Releasees in any court of law. You further waive the right to seek or receive any money damages based upon any claim that might be asserted arising out of your employment against Biogen or any of the other Releasees.</font></div><div style="margin-top:0.5pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:62pt;padding-right:42.75pt;margin-top:0.05pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">9.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:1pt;">Return of Property</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. You agree to return (and not destroy) all property and documents of Biogen in your custody and possession on or before your Separation Date. This includes, without limitation, all Biogen-related documents, both in paper and electronic form, all Biogen equipment and other property such as laptop or other portable computers, lab notebooks, proprietary and&#47;or confidential company information, parking passes, your office and building keys and&#47;or security cards, and your identification badge. Biogen will make arrangements for your return of any property by providing you with suitable mailing materials. Excepted from this provision is your Company-issued iPhone, which Biogen will permit you to retain provided that&#58;</font></div><div style="padding-left:62pt;padding-right:59.75pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a) your device will be wiped by the Company on August 15, 2020&#59; and (b) you transfer your device to your own personal data plan by September 15, 2020.</font></div><div style="margin-top:0.45pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:61.95pt;padding-right:41.85pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">10.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:31.05pt;">Non-Compete&#47;Non-Solicitation and Confidentiality of Company Information</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. You agree to abide by all common law and statutory obligations relating to the protection and non- disclosure of Biogen&#8217;s trade secrets and confidential and proprietary documents and information. In addition, by accepting this Agreement, you hereby confirm that you have previously executed on or around November 18, 2017 Biogen&#8217;s Proprietary Information and Inventions and Non- Compete Agreement (&#8220;PII Agreement&#8221;), which is incorporated herein by this reference and attached hereto as </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration: underline;">Exhibit B</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, and you hereby reaffirm and&#47;or agree to all obligations under the PII Agreement that survive the termination of your employment, including but not limited to the Non-Solicitation and Non-Compete restrictions therein (paras. 17-22).</font></div><div style="margin-top:0.45pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:62pt;padding-right:50.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">11.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:31pt;">Confidentiality of This Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Except as required by law, you agree not to disclose the existence or content of this Agreement to any person, firm or entity, except to your accountant(s), financial planner(s), attorney(s), and members of your immediate family, and to them only if they agree to keep this Agreement confidential.</font></div><div style="margin-top:0.5pt;"><font><br></font></div><div style="text-indent:54pt;padding-left:25.95pt;padding-right:41.9pt;margin-top:0.05pt;"><font><br></font></div><div><font><br></font></div><div style="position:relative;width:100%;height:96pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:7%;">6</font></div><div><font><br></font></div></div></div><div id="i8e86b3ff97904c52be5a759891eed341_19"></div><hr style="page-break-after:always"><div style="min-height:55pt;width:100%;"><div><img alt="image111.jpg" src="image111.jpg" style="height:55px;width:167px;"></div></div><div style="margin-top:0.45pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:61.95pt;padding-right:41.9pt;margin-top:0.05pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">12.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:31.05pt;">Breach.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">  In the event of your material breach of Paragraphs 9, 10, 11, 13, or 14 of this Agreement or of any provision of the PII Agreement&#58; (a) all of Biogen&#8217;s obligations under this Agreement shall cease&#59; (b) you agree to repay Biogen (i) all compensation paid to you under this Agreement other than wages and accrued vacation earned through your Separation Date, and (ii) the value of all benefits you received under this Agreement&#59; and (c) the general release set forth in paragraph 5 remains in full force and effect. This provision shall in no way affect Biogen&#8217;s ability to recover other damages, or obtain any other form of relief, otherwise available as a result of your breach of the PII Agreement.</font></div><div style="margin-top:0.5pt;"><font><br></font></div><div style="padding-left:62pt;padding-right:39.75pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">13.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:31pt;">Cooperation.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> You agree that you will make yourself available to Biogen, upon reasonable notice, either by telephone or in person to assist Biogen in any matter relating to the services performed by you during your employment with Biogen. You also agree that you will cooperate fully with Biogen in the defense or prosecution of any claims or actions now in existence or which may be brought in the future or on behalf of Biogen or its agents. Your full cooperation in connection with such claims or actions shall include, but not be limited to, your being available to meet with Biogen's counsel to prepare for trial or discovery or an administrative hearing and  to act as a witness when requested by Biogen at reasonable times designated by Biogen. To the extent that the Company requests your cooperation, the Company will seek to accommodate your schedule and will reimburse you for reasonable out-of-pocket and travel expenses consistent with the Company&#8217;s travel and expense reimbursement policy then in effect, provided such expenses are approved by Biogen in advance and are substantiated with receipts or other appropriate documentation required by Biogen. Nothing in this section is intended or should be construed as requiring anything other than your cooperation in providing truthful and accurate information.</font></div><div style="margin-top:0.5pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:61.95pt;padding-right:39.95pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">14.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:31.05pt;">Non-Disparagement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. You agree not to make any statements that are, or could reasonably be interpreted to be, disparaging about, or adverse to the business interests of Biogen, its directors, officers, and employees, including but not limited to, any statements that disparage any product, service, finances, capability or any other aspect of the business of Biogen. Breach of this provision shall constitute a material breach of this Agreement and cause substantial, irreparable harm to Biogen, for which you acknowledge there would be no adequate remedy at law. Biogen agrees that it will instruct the following Biogen employees not to make any statements that are, or could reasonably be interpreted to be, disparaging about you, or adverse to your business interests&#58; Michel Vounatsos, Susan Alexander and Ginger Gregory. It shall not be a breach of this section 14 for any Biogen employee, contractor, officer, director or other personnel to make a truthful statement about your accomplishments at Biogen&#59; and you may state that your employment with Biogen ended based on a mutual parting of ways.</font></div><div style="margin-top:0.5pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:61.95pt;padding-right:40.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">15.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:31.05pt;">Miscellaneous</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Except as expressly provided for herein, this Agreement supersedes any and all prior oral or written agreements and sets forth the entire agreement between Biogen and you with respect to your separation from Biogen, including without limitation, any severance plan or policy. Notwithstanding anything in the foregoing sentence to the contrary, the Indemnification Agreement and your obligations under the PII shall continue in </font></div><div style="position:relative;width:100%;height:96pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:7%;">7</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:55pt;width:100%;"><div><img alt="image111.jpg" src="image111.jpg" style="height:55px;width:167px;"></div></div><div style="padding-left:61.95pt;padding-right:40.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">full force and effect. No variations or modifications may be effective unless reduced to writing and signed by both parties.</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:61.95pt;padding-right:48.15pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">This Agreement shall be deemed to have been made in Massachusetts and shall take effect as an instrument under seal within Massachusetts. The validity, interpretation and performance of this Agreement, shall be governed by, and construed in accordance with, the internal laws of Massachusetts, without giving effect to conflict of law principles. Any action, demand, claim or counterclaim arising under this Agreement shall be commenced in Massachusetts and both parties acknowledge that material witnesses and documents would be located within Massachusetts. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Both you and Biogen waive the right to a trial by jury with respect to any such action or proceeding.</font></div><div><font><br></font></div><div id="i8e86b3ff97904c52be5a759891eed341_22"></div><div style="text-indent:36pt;padding-left:63pt;margin-top:0.45pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">The provisions of this Agreement are severable, and if for any reason any part hereof shall be found to be unenforceable, the remaining provisions shall be enforced in full. This Agreement may be executed in counterparts, each of which shall be an original, but all of which together shall constitute one agreement. Execution of a facsimile copy of this Agreement shall have the same force and effect as execution of an original, and a facsimile or PDF signature shall be deemed an original and valid signature.</font></div><div style="margin-top:0.45pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:62pt;padding-right:45.1pt;margin-top:0.05pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">It is Biogen&#8217;s desire and intent to make certain that you fully understand the provisions and effects of this Agreement. To that end, you are encouraged and given an opportunity to consult with legal counsel. By executing this Agreement, you are acknowledging that you have been afforded sufficient time to understand the provisions and effects of this Agreement and to consult with legal counsel, that your agreements and obligations under this Agreement are made voluntarily, knowingly and without duress and that neither Biogen nor its agents or representatives have made any representations inconsistent with this Agreement.</font></div><div style="margin-top:0.5pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:62pt;padding-right:41.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">16.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:31pt;">No Admissions</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. The parties agree that neither this Agreement nor the furnishing of the consideration for this Agreement and the release shall be deemed or construed at any time for any purpose as an admission by Releasees of any liability or wrongdoing.</font></div><div style="margin-top:0.5pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:62pt;padding-right:73.95pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Nothing in this Agreement shall be construed to prevent you from responding truthfully and completely to any lawfully issued court order or subpoena or from communicating with a government agency.</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:62pt;padding-right:57.15pt;"><font><br></font></div><div style="position:relative;width:100%;height:96pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:7%;">8</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:55pt;width:100%;"><div><img alt="image111.jpg" src="image111.jpg" style="height:55px;width:167px;"></div></div><div style="text-indent:36pt;padding-left:62pt;padding-right:57.15pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">If the foregoing correctly sets forth our agreement, please electronically sign, date and return this Agreement to HR Operations by 5&#58;00 p.m. ET on August 14, 2020. Please print a copy of the Agreement for your records.</font></div><div style="padding-left:278pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Very truly yours,</font></div><div style="padding-left:278pt;padding-right:200.35pt;margin-top:2.85pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:230%;">&#47;s&#47; Ginger Gregory Ginger Gregory</font></div><div style="padding-left:278pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:91%;">EVP, Human Resources</font></div><div style="margin-top:0.5pt;"><font><br></font></div><div style="padding-left:98pt;margin-top:0.05pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">The foregoing Separation Agreement is agreed to and accepted by me on August 6, 2020.</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="padding-left:242pt;padding-right:147.95pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;"> &#160;&#160;&#160;&#160;&#47;s&#47; Jeff Capello&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;  Jeff Capello</font></div><div><font><br></font></div><div style="position:relative;width:100%;height:96pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:7%;">9</font></div><div><font><br></font></div></div></div><div id="i8e86b3ff97904c52be5a759891eed341_25"></div><hr style="page-break-after:always"><div style="min-height:55pt;width:100%;"><div><img alt="image111.jpg" src="image111.jpg" style="height:55px;width:167px;"></div></div><div style="margin-top:0.45pt;"><font><br></font></div><div style="text-indent:101.8pt;padding-left:169.3pt;padding-right:146.3pt;margin-top:4.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:166%;text-decoration: underline;">Exhibit A</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:166%;"> REAFFIRMATION OF RELEASE OF CLAIMS</font></div><div style="margin-top:0.35pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:62pt;padding-right:42.55pt;margin-top:0.05pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:1pt;">This Reaffirmation of Release of Claims (&#8220;Reaffirmation Agreement&#8221;) is being executed by me upon the ending of my employment with Biogen Inc. or one of its subsidiaries (</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">&#8220;Biogen&#8221; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">or </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">&#8220;the Company&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">), pursuant to the Separation Agreement previously signed by the parties (&#8220;Separation Agreement&#8221;). </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">I understand that this Reaffirmation Agreement may not be signed by me until after my last day of employment with Biogen and will be considered null and void if I sign it before such date. I also understand that this Reaffirmation Agreement must be signed before the later of (a) 14 days after my Separation Date&#59; and (b) 21 days from receipt of this Reaffirmation Agreement, in order to be eligible for the Supplemental Severance Pay (as that term is defined in the Separation Agreement).</font></div><div style="text-indent:36pt;padding-left:62pt;padding-right:41.3pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:1pt;">In consideration for the Supplemental Severance Pay (as that term is defined in the Separation Agreement), I hereby reaffirm my agreement to all of the terms and conditions of that Separation Agreement, including my agreement to release any and all claims, known or unknown, against the Releasees, as that term is defined therein. Specifically, I hereby agree to forever release and discharge Biogen and any of its divisions, affiliates, subsidiaries, related entities, and its and their current and former directors, officers, employees, attorneys, agents, insurers, successors and assigns, in their individual and official capacities, as well as their health, welfare and benefits plans and programs or the administrators or trustees of the plans and programs (collectively &#8220;Releasees&#8221;)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">from any and all claims, demands, actions, liabilities, obligations, accounts, expenses, attorneys&#8217; fees and causes of action, of every kind and nature, in law, equity or otherwise, whether known or unknown, asserted or unasserted, which I ever had, now have, or which may hereafter accrue in connection with any event, act or occurrence arising prior to the date that I execute this Reaffirmation Agreement, including but not limited to all matters that arise in any way out of my employment or separation from employment with Biogen.</font></div><div style="margin-top:0.5pt;"><font><br></font></div><div style="padding-left:62pt;padding-right:52.45pt;margin-top:0.05pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">I agree that this release is to be interpreted broadly and is intended to include any claims I may have against Releasees including, without limitation, any and all claims under federal, state or local statutes, ordinances, regulations or rules, including without limitation the following&#58;</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="text-indent:-18pt;padding-left:116pt;padding-right:43pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:8.69pt;">Any and all federal statutory or regulatory claims such as claims under the Age Discrimination in Employment Act, 29 U.S.C. &#167; 621 </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">et</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">seq</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">., Title VII of the Civil Rights Act of 1964, 42 U.S.C. &#167; 2000e </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">et seq.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, the Americans with Disabilities Act of 1990, 42 U.S.C. &#167; 12101 </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">et seq</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">., the Family and Medical Leave Act, 29 U.S.C. &#167; 2601 </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">et seq</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">., the Worker Adjustment and Retraining Notification Act (&#8220;WARN&#8221;), 29</font></div><div style="padding-left:116pt;padding-right:42.65pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">U.S.C. &#167; 2101 </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">et</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">seq</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">., and the Rehabilitation Act of 1973, 29 U.S.C. &#167; 701 </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">et</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">seq</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">., all as amended&#59; all claims arising out of the Fair Credit Reporting Act, 15 U.S.C. &#167;1681 </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">et</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">seq</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">., the Employee Retirement Income Security Act of 1974 (&#8220;ERISA&#8221;), 29 U.S.C.</font></div><div style="position:relative;width:100%;height:96pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:7%;">10</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:55pt;width:100%;"><div><img alt="image111.jpg" src="image111.jpg" style="height:55px;width:167px;"></div></div><div style="padding-left:116pt;padding-right:46.15pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#167;1001 </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">et seq</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">., the Sarbanes-Oxley Act of 2002, the Immigration Reform and Control Act, the Equal Pay Act, Sections 1981 thorough 1988 of Title 42 if the United States Code&#59; and the Genetic information Nondiscrimination Act.</font></div><div style="text-align:justify;"><font><br></font></div><div id="i8e86b3ff97904c52be5a759891eed341_28"></div><div><font><br></font></div><div style="text-indent:-18pt;padding-left:116pt;padding-right:45.25pt;margin-top:4.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:8.01pt;">Any and all state statutory or regulatory claims such as claims under the Massachusetts Fair Employment Practices Law, M.G.L. ch. 151B&#59; the Massachusetts Wage Payment Statute, G.L. c. 149, &#167;&#167; 148, 148A, 148B, 149, 150,150A-150C, 151, 152, 152A, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">et seq</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.&#59; and the Massachusetts Wage and Hour laws, G.L. c. 151&#167;1A </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">et seq.&#59; t</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">he North Carolina Equal Employment Practices Act &#8211; N.C. Gen. Stat. &#167;143-</font></div><div style="padding-left:116pt;padding-right:47.05pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">422.1 </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">et seq</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.&#59; the North Carolina Persons With Disabilities Protection Act &#8211; N.C. Gen. Stat. &#167;168A-1 </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">et seq</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.&#59; the North Carolina Retaliatory Employment Discrimination Law &#8211; N.C. Gen. Stat. &#167;95-240 </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">et seq</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.&#59; the North Carolina Wage and Hour Act, as amended, including N.C. Gen. Stat. &#167;95-25.2 </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">et seq</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">., and &#167;95-25.14 </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">et seq</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="margin-top:0.1pt;"><font><br></font></div><div style="text-indent:-18pt;padding-left:115.95pt;padding-right:40.3pt;margin-top:4.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:8.69pt;">Any and all other claims under public policy, contract, tort or common law such as claims for breach of contract, detrimental reliance, breach of the covenant of good faith and fair dealing, wrongful discharge, employment discrimination, harassment, or retaliation, infliction of emotional distress, negligence, defamation, fraud, and non- payment of wages or benefits.</font></div><div><font><br></font></div><div style="text-indent:-18pt;padding-left:116pt;padding-right:46.85pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:8.01pt;">Any and all claims for recovery of costs, fees, or other expenses including attorneys&#8217; fees incurred in any matter.</font></div><div><font><br></font></div><div style="padding-left:62pt;padding-right:41.45pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">By signing this Reaffirmation Agreement, I understand that I am not waiving any rights I may have to&#58; (i) my own vested accrued employee benefits under the Company&#8217;s health, welfare, or retirement benefit plans as of the Separation Date&#59; (ii) benefits and&#47;or the right to seek benefits under applicable workers&#8217; compensation and&#47;or unemployment compensation statutes&#59; (iii) pursue claims which by law cannot be waived by signing this Reaffirmation Agreement&#59; (iv) enforce the Separation Agreement or this Reaffirmation Agreement&#59; (v) challenge the validity of the Separation Agreement or this Reaffirmation Agreement&#59; and&#47;or (vi) indemnification under the Indemnification Agreement, under the Company&#8217;s by-laws and certificate of incorporation, and coverage, if any, under a Biogen directors and officers insurance policy.</font></div><div style="text-indent:36pt;padding-left:62pt;padding-right:43.2pt;margin-top:5.95pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:1pt;">I further represent that, as of the date I sign this Reaffirmation Agreement, I have not filed any lawsuits, complaints, petitions, claims or other accusatory pleadings against the Company or any of the Releasees in any court of law. I further agree that, to the fullest extent of the law, I will not prosecute in any court, whether state or federal, any claim or demand of any type related to the matters released, it being the intention of the parties that with the execution of this Reaffirmation Agreement, the Releasees will be absolutely, unconditionally and forever discharged of and from all obligations to or on behalf of me related in any way to the matters discharged herein. Additionally, I expressly waive my right to recover any type of personal relief from the Company, including monetary damages or reinstatement, in any administrative </font></div><div style="position:relative;width:100%;height:96pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:7%;">11</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:55pt;width:100%;"><div><img alt="image111.jpg" src="image111.jpg" style="height:55px;width:167px;"></div></div><div style="padding-left:62pt;padding-right:43.2pt;margin-top:5.95pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">action or proceeding, whether state or federal, and whether brought by me or on my behalf by an administrative agency, related in any way to the matters released herein.</font></div><div><font><br></font></div><div id="i8e86b3ff97904c52be5a759891eed341_31"></div><div style="margin-top:0.45pt;"><font><br></font></div><div style="text-indent:36pt;padding-left:62pt;padding-right:55.9pt;margin-top:6.05pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">4.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:1pt;">This Reaffirmation Agreement is also intended to release and discharge any claims I may have under the Age Discrimination in Employment Act (&#8220;ADEA&#8221;) based on any transactions or occurrences between the Company and me after the execution date of the Separation Agreement and through the Effective Date of the Reaffirmation Agreement. To satisfy the requirements of the Older Workers&#8217; Benefit Protection Act, 29 U.S.C. &#167; 626(f), the parties agree as follows&#58;</font></div><div style="text-indent:-18pt;padding-left:115.95pt;padding-right:79.25pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:8.69pt;">I acknowledge that I have read and understand the terms of this Reaffirmation Agreement.</font></div><div style="text-indent:-18pt;padding-left:115.95pt;padding-right:79.3pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:8.01pt;">I understand that I am advised to consult with an attorney concerning this Reaffirmation Agreement and have received all legal advice I deem necessary concerning this Reaffirmation Agreement.</font></div><div style="text-indent:-18pt;padding-left:115.95pt;padding-right:43.3pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:8.69pt;">I have been given until the later of (a) a date that is 14 days after the Separation Date&#59; and (b) 21 days from receipt of this Reaffirmation Agreement, to consider whether or not to enter into this Reaffirmation Agreement, and have taken as much of this time as necessary to consider whether to enter into this Reaffirmation Agreement, and have chosen to enter into this Reaffirmation Agreement freely, knowingly and voluntarily.</font></div><div style="text-indent:-18pt;padding-left:115.95pt;padding-right:39.9pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:8.01pt;">For a seven day period following the execution of this Reaffirmation Agreement, I understand that I may revoke this Reaffirmation Agreement, by personally delivering or mailing by Federal Express or Express Mail, a written revocation to Ginger Gregory at Biogen, 225 Binney Street, Cambridge, MA 02142, within seven (7) days of my execution of this Reaffirmation Agreement, on or before the seventh day in order to be effective. This Reaffirmation Agreement shall not become effective and enforceable until the revocation period has expired. I understand that the Supplemental Severance Pay called for in paragraph 2 of the Separation Agreement is expressly conditioned upon my signing this Reaffirmation Agreement and will not be paid before the eighth day after I sign and deliver this Reaffirmation Agreement to the Company (&#8220;the Effective Date of the Reaffirmation&#8221;). I further understand that any revocation of this Reaffirmation Agreement shall not act as a revocation of the Separation Agreement or otherwise impact the validity of the release of claims contained in the Separation Agreement.</font></div><div style="text-indent:-18pt;padding-left:115.95pt;padding-right:48.85pt;margin-top:5.95pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">e)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:8.69pt;">I understand that this Reaffirmation Agreement shall not apply to any claims for age discrimination that arise after the Effective Date of this Reaffirmation Agreement.</font></div><div style="text-indent:36pt;padding-left:61.95pt;padding-right:42pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">5.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:1.05pt;">With the sole exception of the Severance Pay and Benefits and the Supplemental Severance Pay, I acknowledge that I have received all compensation, wages, bonuses, commissions, payout for accrued paid time off, expense reimbursement and&#47;or benefits of any kind to which I may be entitled and that no other compensation, wages, bonuses, commissions, </font></div><div style="position:relative;width:100%;height:96pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:7%;">12</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:55pt;width:100%;"><div><img alt="image111.jpg" src="image111.jpg" style="height:55px;width:167px;"></div></div><div style="padding-left:61.95pt;padding-right:42pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">payout for accrued paid time off, expense reimbursement and&#47;or benefits of any kind are owed to me by the Company.</font></div><div style="text-indent:36pt;padding-left:61.95pt;padding-right:54.65pt;margin-top:6.05pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">6.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:1.05pt;">Entire Agreement&#59; Integration</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. I understand that this Reaffirmation Agreement and the Separation Agreement, including without limitation the provisions referenced in paragraph 10 of the Separation Agreement and expressly incorporated therein, represent the entire agreement between me and the Company with respect to the subject matter hereof, superseding all previous oral or written communications, representations, understandings or agreements relating to this subject.</font></div><div><font><br></font></div><div id="i8e86b3ff97904c52be5a759891eed341_34"></div><div style="margin-top:0.45pt;"><font><br></font></div><div style="padding-left:62pt;padding-right:66.1pt;margin-top:4.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">I understand that nothing in this Reaffirmation Agreement shall be deemed to prohibit me from filing a charge or complaint of employment related discrimination with the Equal Employment Opportunity Commission (&#8220;EEOC&#8221;) or equivalent state agency, or from participating in any investigation or proceeding conducted by the EEOC or equivalent state agency. Notwithstanding my right to file a charge or complaint with and&#47;or participate in any investigation or proceeding by the EEOC or equivalent state agency, to the fullest extent permitted by law, I expressly waive my right to recover any individual monetary relief or other individual remedies from Biogen or any other Releasees in any administrative action or proceeding, whether state or federal, and whether brought by me or on my behalf by an administrative agency, related in any way to the matters released herein. Likewise, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">nothing in this Reaffirmation Agreement shall be construed to prevent me from responding truthfully and completely to any lawfully issued court order or subpoena or from communicating with a government agency.</font></div><div style="margin-top:0.05pt;"><font><br></font></div><div style="padding-left:62pt;padding-right:41.15pt;margin-top:0.05pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">BY SIGNING BELOW, I certify that I have read and understand all of this Reaffirmation Agreement, that I have received any advice or counsel I deem necessary regarding this Reaffirmation Agreement, and that I am is entering into this Reaffirmation Agreement freely and voluntarily, intending to be bound by its terms.</font></div><div><font><br></font></div><div style="margin-top:0.25pt;"><font><br></font></div><div style="padding-left:61.95pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Dated&#58; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">September 16, 2020</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;By&#58; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">    &#47; s&#47; Jeff Capello&#160;&#160;&#160;&#160;</font></div><div style="padding-left:273.75pt;padding-right:229.4pt;text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Jeff Capello</font></div><div style="text-align:center;"><font><br></font></div><div style="position:relative;width:100%;height:96pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:7%;">13</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>biib-2020930xex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="ie0fd60a2cb0a43a2bde28825ed54a0f0_1"></div><div style="min-height:42.75pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Exhibit 31.1</font></div><div style="text-align:center;margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">I, Michel Vounatsos, certify that&#58;</font></div><div style="margin-top:9pt;"><font><br></font></div><div style="text-indent:-36pt;padding-left:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.01pt;">I have reviewed this quarterly report of Biogen Inc.&#59;</font></div><div style="padding-left:36pt;"><font><br></font></div><div style="text-indent:-36pt;padding-left:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.01pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="padding-left:36pt;"><font><br></font></div><div style="text-indent:-36pt;padding-left:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.01pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="padding-left:36pt;"><font><br></font></div><div style="text-indent:-36pt;padding-left:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">4.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.01pt;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a&#8211;15(e) and 15d&#8211;15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a&#8211;15(f) and 15d&#8211;15(f)) for the registrant and have&#58;</font></div><div style="padding-left:36pt;"><font><br></font></div><div style="text-indent:-36pt;padding-left:72pt;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.62pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="text-indent:-36pt;padding-left:72pt;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.62pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="text-indent:-36pt;padding-left:72pt;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.23pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="text-indent:-36pt;padding-left:72pt;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.62pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="text-indent:-36pt;padding-left:36pt;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">5.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.01pt;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="text-indent:-36pt;padding-left:72pt;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.62pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="text-indent:-36pt;padding-left:72pt;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.62pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:5pt;margin-bottom:14pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:51.462%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:2.581%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:43.557%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Date&#58; October 21, 2020</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; Michel Vounatsos</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Michel Vounatsos</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Chief Executive Officer</font></td></tr></table></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>biib-2020930xex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i9d45e6b2714b4ccab2bdc783c750b7f9_1"></div><div style="min-height:42.75pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Exhibit 31.2</font></div><div style="text-align:center;margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">I, Michael R. McDonnell, certify that&#58;</font></div><div style="margin-top:9pt;"><font><br></font></div><div style="text-indent:-36pt;padding-left:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.01pt;">I have reviewed this quarterly report of Biogen Inc.&#59;</font></div><div style="padding-left:36pt;"><font><br></font></div><div style="text-indent:-36pt;padding-left:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.01pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="padding-left:36pt;"><font><br></font></div><div style="text-indent:-36pt;padding-left:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.01pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="padding-left:36pt;"><font><br></font></div><div style="text-indent:-36pt;padding-left:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">4.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.01pt;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a&#8211;15(e) and 15d&#8211;15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a&#8211;15(f) and 15d&#8211;15(f)) for the registrant and have&#58;</font></div><div style="padding-left:36pt;"><font><br></font></div><div style="text-indent:-36pt;padding-left:72pt;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.62pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="text-indent:-36pt;padding-left:72pt;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.62pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="text-indent:-36pt;padding-left:72pt;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.23pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="text-indent:-36pt;padding-left:72pt;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.62pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="text-indent:-36pt;padding-left:36pt;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">5.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.01pt;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="text-indent:-36pt;padding-left:72pt;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.62pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="text-indent:-36pt;padding-left:72pt;margin-bottom:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.62pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:51.462%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:2.581%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:43.557%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Date&#58; October 21, 2020</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; Michael R. McDonnell</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Michael R. McDonnell</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Executive Vice President and</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Chief Financial Officer</font></td></tr></table></div><div><font><br></font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>biib-2020930xex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i778e6adf216f4ec3a5f7da6c5ef2b2a2_1"></div><div style="min-height:42.75pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Exhibit 32.1</font></div><div style="text-align:center;margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">CERTIFICATION</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-indent:24.75pt;margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a)&#160;and (b)&#160;of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Biogen Inc., a Delaware corporation (the &#8220;Company&#8221;), does hereby certify, to such officer&#8217;s knowledge, that&#58;</font></div><div style="text-indent:24.75pt;margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Quarterly Report on Form 10-Q for the quarter ended September 30, 2020 (the &#8220;Form 10-Q&#8221;) of the Company fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:51.462%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:2.581%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:43.557%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Date&#58; October 21, 2020</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; Michel Vounatsos</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Michel Vounatsos</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Chief Executive Officer</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;principal executive officer&#93;</font></td></tr></table></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:51.462%;"></td><td style="width:0.1%;"></td><td style="width:0.1%;"></td><td style="width:2.581%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:43.557%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Date&#58; October 21, 2020</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47;&#160;Michael R. McDonnell</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Michael R. McDonnell</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Executive Vice President and</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;principal financial officer&#93;</font></td></tr></table></div><div style="text-indent:24.75pt;margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A signed original of this written statement required by Section&#160;906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>biib-20200930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:9d882161-cc57-4e82-9994-8001479894f6,g:a7b2bacf-5ee2-4f5b-9f49-a40e24a2538c-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:biib="http://www.biogenidec.com/20200930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:us-types="http://fasb.org/us-types/2019-01-31" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.biogenidec.com/20200930">
  <xs:import namespace="http://fasb.org/srt/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-types/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/currency/2019-01-31" schemaLocation="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="biib-20200930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="biib-20200930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="biib-20200930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="biib-20200930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.biogenidec.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofIncomeUnaudited" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited">
        <link:definition>1001002 - Statement - Condensed Consolidated Statements of Income (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited">
        <link:definition>1002003 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited_1" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited_1">
        <link:definition>1002003 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsUnaudited" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited">
        <link:definition>1003004 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsUnauditedParenthetical" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical">
        <link:definition>1004005 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlowsUnaudited" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited">
        <link:definition>1005006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementofEquityStatement" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement">
        <link:definition>1006007 - Statement - Condensed Consolidated Statement of Equity Statement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.biogenidec.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>2101101 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2202201 - Disclosure - Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesDetails">
        <link:definition>2403401 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Acquisitions" roleURI="http://www.biogenidec.com/role/Acquisitions">
        <link:definition>2104102 - Disclosure - Acquisitions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofseparatelyidentifiableassetsacquiredandliabilitiesassumedTables" roleURI="http://www.biogenidec.com/role/SummaryofseparatelyidentifiableassetsacquiredandliabilitiesassumedTables">
        <link:definition>2305301 - Disclosure - Summary of separately identifiable assets acquired and liabilities assumed (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessAcquisitionDetailsTextual" roleURI="http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual">
        <link:definition>2406402 - Disclosure - Business Acquisition (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessAcquisitionDetails" roleURI="http://www.biogenidec.com/role/BusinessAcquisitionDetails">
        <link:definition>2407403 - Disclosure - Business Acquisition (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DivestituresDivestitures" roleURI="http://www.biogenidec.com/role/DivestituresDivestitures">
        <link:definition>2108103 - Disclosure - Divestitures Divestitures</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DivestituresDetailsTextual" roleURI="http://www.biogenidec.com/role/DivestituresDetailsTextual">
        <link:definition>2409404 - Disclosure - Divestitures (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Revenues" roleURI="http://www.biogenidec.com/role/Revenues">
        <link:definition>2110104 - Disclosure - Revenues</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesTables" roleURI="http://www.biogenidec.com/role/RevenuesTables">
        <link:definition>2311302 - Disclosure - Revenues (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesbyProductDetails" roleURI="http://www.biogenidec.com/role/RevenuesbyProductDetails">
        <link:definition>2412405 - Disclosure - Revenues by Product (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ReservesforDiscountsandAllowancesDetails1" roleURI="http://www.biogenidec.com/role/ReservesforDiscountsandAllowancesDetails1">
        <link:definition>2413406 - Disclosure - Reserves for Discounts and Allowances (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ReservesforDiscountsandAllowancesDetails2" roleURI="http://www.biogenidec.com/role/ReservesforDiscountsandAllowancesDetails2">
        <link:definition>2414407 - Disclosure - Reserves for Discounts and Allowances (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesfromAntiCD20TherapeuticProgramsDetails" roleURI="http://www.biogenidec.com/role/RevenuesfromAntiCD20TherapeuticProgramsDetails">
        <link:definition>2415408 - Disclosure - Revenues from Anti-CD20 Therapeutic Programs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherRevenuesDetails" roleURI="http://www.biogenidec.com/role/OtherRevenuesDetails">
        <link:definition>2416409 - Disclosure - Other Revenues (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesDetailsTextual" roleURI="http://www.biogenidec.com/role/RevenuesDetailsTextual">
        <link:definition>2417410 - Disclosure - Revenues (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventory" roleURI="http://www.biogenidec.com/role/Inventory">
        <link:definition>2118105 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryTables" roleURI="http://www.biogenidec.com/role/InventoryTables">
        <link:definition>2319303 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryDetails" roleURI="http://www.biogenidec.com/role/InventoryDetails">
        <link:definition>2420411 - Disclosure - Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwill" roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwill">
        <link:definition>2121106 - Disclosure - Intangible Assets and Goodwill</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwillTables" roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables">
        <link:definition>2322304 - Disclosure - Intangible Assets and Goodwill (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwillDetails" roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails">
        <link:definition>2423412 - Disclosure - Intangible Assets and Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwillDetails1" roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails1">
        <link:definition>2424413 - Disclosure - Intangible Assets and Goodwill (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.biogenidec.com/role/FairValueMeasurements">
        <link:definition>2125107 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsTables">
        <link:definition>2326305 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails">
        <link:definition>2427414 - Disclosure - Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetailsTextual" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual">
        <link:definition>2428415 - Disclosure - Fair Value Measurements (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails">
        <link:definition>2429416 - Disclosure - Fair Value Measurements Fair Value Measurements - Contingent Consideration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails1" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails1">
        <link:definition>2430417 - Disclosure - Fair Value Measurements (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails2" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails2">
        <link:definition>2431418 - Disclosure - Fair Value Measurements (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstruments" roleURI="http://www.biogenidec.com/role/FinancialInstruments">
        <link:definition>2132108 - Disclosure - Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsTables" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsTables">
        <link:definition>2333306 - Disclosure - Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetails" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails">
        <link:definition>2434419 - Disclosure - Financial Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetails1" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails1">
        <link:definition>2435420 - Disclosure - Financial Instruments (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetails2" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails2">
        <link:definition>2436421 - Disclosure - Financial Instruments (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetails3" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails3">
        <link:definition>2437422 - Disclosure - Financial Instruments (Details 3)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetailsTextual" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual">
        <link:definition>2438423 - Disclosure - Financial Instruments (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsFinancialInstrumentsDetailsTextual2" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2">
        <link:definition>2439424 - Disclosure - Financial Instruments Financial Instruments (Details Textual 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstruments" roleURI="http://www.biogenidec.com/role/DerivativeInstruments">
        <link:definition>2140109 - Disclosure - Derivative Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstrumentsTables" roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsTables">
        <link:definition>2341307 - Disclosure - Derivative Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstrumentsDetails" roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDetails">
        <link:definition>2442425 - Disclosure - Derivative Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipmentPropertyPlantandEquipment" roleURI="http://www.biogenidec.com/role/PropertyPlantandEquipmentPropertyPlantandEquipment">
        <link:definition>2143110 - Disclosure - Property, Plant and Equipment Property, Plant and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipmentDetails" roleURI="http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails">
        <link:definition>2444426 - Disclosure - Property, Plant and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IndebtednessNotes" roleURI="http://www.biogenidec.com/role/IndebtednessNotes">
        <link:definition>2145111 - Disclosure - Indebtedness (Notes)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IndebtednessDetails" roleURI="http://www.biogenidec.com/role/IndebtednessDetails">
        <link:definition>2446427 - Disclosure - Indebtedness (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Equity" roleURI="http://www.biogenidec.com/role/Equity">
        <link:definition>2147112 - Disclosure - Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveIncomeLossTables" roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables">
        <link:definition>2348308 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareRepurchasesDetails" roleURI="http://www.biogenidec.com/role/ShareRepurchasesDetails">
        <link:definition>2449428 - Disclosure - Share Repurchases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveIncomeLossDetails" roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails">
        <link:definition>2450429 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails" roleURI="http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails">
        <link:definition>2451430 - Disclosure - Reclassification out of Accumulated Other Comprehensive Income (Loss) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsperShare" roleURI="http://www.biogenidec.com/role/EarningsperShare">
        <link:definition>2152113 - Disclosure - Earnings per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsperShareTables" roleURI="http://www.biogenidec.com/role/EarningsperShareTables">
        <link:definition>2353309 - Disclosure - Earnings per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsperShareDetails" roleURI="http://www.biogenidec.com/role/EarningsperShareDetails">
        <link:definition>2454431 - Disclosure - Earnings per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedPayments" roleURI="http://www.biogenidec.com/role/SharebasedPayments">
        <link:definition>2155114 - Disclosure - Share-based Payments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsTables" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsTables">
        <link:definition>2356310 - Disclosure - Share-Based Payments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsDetails" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails">
        <link:definition>2457432 - Disclosure - Share-Based Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsDetails1" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1">
        <link:definition>2458433 - Disclosure - Share-Based Payments (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.biogenidec.com/role/IncomeTaxes">
        <link:definition>2159115 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.biogenidec.com/role/IncomeTaxesTables">
        <link:definition>2360311 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetailsTextual" roleURI="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual">
        <link:definition>2461434 - Disclosure - Income Taxes (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails" roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails">
        <link:definition>2462435 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherConsolidatedFinancialStatementDetail" roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail">
        <link:definition>2163116 - Disclosure - Other Consolidated Financial Statement Detail</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherConsolidatedFinancialStatementDetailTables" roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables">
        <link:definition>2364312 - Disclosure - Other Consolidated Financial Statement Detail (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherConsolidatedFinancialStatementDetailDetails" roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails">
        <link:definition>2465436 - Disclosure - Other Consolidated Financial Statement Detail (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherConsolidatedFinancialStatementDetailsTextual" roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual">
        <link:definition>2466437 - Disclosure - Other Consolidated Financial Statement (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandOtherRelationships" roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationships">
        <link:definition>2167117 - Disclosure - Collaborative and Other Relationships</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandOtherRelationshipsTables" roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables">
        <link:definition>2368313 - Disclosure - Collaborative and Other Relationships (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandOtherRelationshipsCollaborationsDetails" roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails">
        <link:definition>2469438 - Disclosure - Collaborative and Other Relationships - Collaborations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails" roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails">
        <link:definition>2470439 - Disclosure - Collaborative and Other Relationships - Equity Method Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsinVariableInterestEntities" roleURI="http://www.biogenidec.com/role/InvestmentsinVariableInterestEntities">
        <link:definition>2171118 - Disclosure - Investments in Variable Interest Entities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsinVariableInterestEntitiesDetails" roleURI="http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails">
        <link:definition>2472440 - Disclosure - Investments in Variable Interest Entities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Litigation" roleURI="http://www.biogenidec.com/role/Litigation">
        <link:definition>2173119 - Disclosure - Litigation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LitigationDetails" roleURI="http://www.biogenidec.com/role/LitigationDetails">
        <link:definition>2474441 - Disclosure - Litigation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="biib_A3.15SeniorNotesdueMay12050Member" abstract="true" name="A3.15SeniorNotesdueMay12050Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_GovernmentSecuritiesNonCurrentMember" abstract="true" name="GovernmentSecuritiesNonCurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_NeurimmuneMember" abstract="true" name="NeurimmuneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_ReserveforCashDiscountsMember" abstract="true" name="ReserveforCashDiscountsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets" abstract="false" name="AmortizationAndImpairmentOfAcquiredIntangibleAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain" abstract="true" name="InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_OthercorporaterevenuesMember" abstract="true" name="OthercorporaterevenuesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_Revenuesfromanticd20therapeuticprogramsMember" abstract="true" name="Revenuesfromanticd20therapeuticprogramsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" abstract="false" name="InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" abstract="true" name="MortgageAndOtherAssetBackedSecuritiesCurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_EffectiveIncomeTaxRateReconciliationChangeInForeignTaxRatePercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationChangeInForeignTaxRatePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="biib_ContractManufacturingCustomerMember" abstract="true" name="ContractManufacturingCustomerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones" abstract="false" name="GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" abstract="false" name="CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_AcquisitionsAbstract" abstract="true" name="AcquisitionsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate" abstract="false" name="FairValueIndefiniteLivedIntangibleAssetsDiscountRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets" abstract="false" name="GlobalLicensingCollaborationAgreementPaymentSelectionofTargets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_Biogenshareofcopromotionprofitsorlosses" abstract="false" name="Biogenshareofcopromotionprofitsorlosses" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="biib_E2609andBAN2401Member" abstract="true" name="E2609andBAN2401Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones" abstract="false" name="GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_CashSettledPerformanceSharesMember" abstract="true" name="CashSettledPerformanceSharesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" abstract="false" name="UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_A2.90SeniorNotesDueSept152020Member" abstract="true" name="A2.90SeniorNotesDueSept152020Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_FacilityTypeDomain" abstract="true" name="FacilityTypeDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_BIIB112Member" abstract="true" name="BIIB112Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_Collaborationprofitlosssharing" abstract="false" name="Collaborationprofitlosssharing" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_InterferonMember" abstract="true" name="InterferonMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_CashflowsrevenueMember" abstract="true" name="CashflowsrevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_ZINBRYTAMember" abstract="true" name="ZINBRYTAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_AducanumabMember" abstract="true" name="AducanumabMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage" abstract="false" name="DebtInstrumentMakeWholeProvisionRedemptionPricePercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization" abstract="false" name="EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="biib_DisputedClaimsRelatingtoConstructionCosts" abstract="false" name="DisputedClaimsRelatingtoConstructionCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_AVONEXMember" abstract="true" name="AVONEXMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_ClinicalAssetsAcquired" abstract="false" name="ClinicalAssetsAcquired" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="biib_BiosimilarsMember" abstract="true" name="BiosimilarsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_BENEPALIMember" abstract="true" name="BENEPALIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_ContractualAdjustmentsMember" abstract="true" name="ContractualAdjustmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" abstract="false" name="EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="biib_IMRALDIMember" abstract="true" name="IMRALDIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_FUMADERMMember" abstract="true" name="FUMADERMMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_ResearchAndDevelopmentCostsPercentage" abstract="false" name="ResearchAndDevelopmentCostsPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="biib_FLIXABIMember" abstract="true" name="FLIXABIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare" abstract="false" name="GlobalLicensingCollaborationAgreementSharesPurchasedPerShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" abstract="true" name="SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" abstract="false" name="ShareBasedCompensationExpenseIncludedInCostsAndExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_DerivativeMaturityAxis" abstract="true" name="DerivativeMaturityAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" abstract="false" name="SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="biib_October2020ShareRepurchaseProgramMember" abstract="true" name="October2020ShareRepurchaseProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_TysabriProductMember" abstract="true" name="TysabriProductMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_NumberOfSquareFeet" abstract="false" name="NumberOfSquareFeet" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:areaItemType"/>
  <xs:element id="biib_NumberOfNeurologicalDiseaseTargets" abstract="false" name="NumberOfNeurologicalDiseaseTargets" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="biib_BIIB118Member" abstract="true" name="BIIB118Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_PercentageParValueOfSeniorNotes" abstract="false" name="PercentageParValueOfSeniorNotes" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock" abstract="false" name="SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="biib_MSProductRevenuesMember" abstract="true" name="MSProductRevenuesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_SolothurnSwitzerlandMember" abstract="true" name="SolothurnSwitzerlandMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_CashflowsoperatingexpensesMember" abstract="true" name="CashflowsoperatingexpensesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis" abstract="true" name="InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="biib_SkyhawkTherapeuticsMember" abstract="true" name="SkyhawkTherapeuticsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_BusinessOverviewPolicyTextBlock" abstract="false" name="BusinessOverviewPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" abstract="false" name="AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_SangamoTherapeuticsInc.AgreementMember" abstract="true" name="SangamoTherapeuticsInc.AgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_Reductioninroyaltyratepayableoncommercialsales" abstract="false" name="Reductioninroyaltyratepayableoncommercialsales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="biib_InvestmentsInVariableInterestEntitiesAbstract" abstract="true" name="InvestmentsInVariableInterestEntitiesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="biib_PerformanceStockUnitsSettledinStockMember" abstract="true" name="PerformanceStockUnitsSettledinStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" abstract="false" name="PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_Collaborationexpensesaccrual" abstract="false" name="Collaborationexpensesaccrual" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_PlanAssetsForDeferredCompensationFairValueDisclosure" abstract="false" name="PlanAssetsForDeferredCompensationFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" abstract="false" name="EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_InLicensedPatentsMember" abstract="true" name="InLicensedPatentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_EisaiMember" abstract="true" name="EisaiMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_PercentageoffuturedevelopmentcostsrelatedtoEisai" abstract="false" name="PercentageoffuturedevelopmentcostsrelatedtoEisai" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="biib_EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts" abstract="false" name="EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_AverageMaturityOfMarketableSecurities" abstract="false" name="AverageMaturityOfMarketableSecurities" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="biib_PerformanceStockUnitsSettledinCashMember" abstract="true" name="PerformanceStockUnitsSettledinCashMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_NightstarMember" abstract="true" name="NightstarMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_ElenbecestatCollaborationMember" abstract="true" name="ElenbecestatCollaborationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" abstract="false" name="PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_DerivativeMaturityDomain" abstract="true" name="DerivativeMaturityDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_Equitymethodinvestmentbasisdifferenceamortizationperiod" abstract="false" name="Equitymethodinvestmentbasisdifferenceamortizationperiod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="biib_PostacquisitionequitycompensationMember" abstract="true" name="PostacquisitionequitycompensationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_DeferredTaxAssetsValueReductioninValue" abstract="false" name="DeferredTaxAssetsValueReductioninValue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_RegulatoryApprovalMilestoneMember" abstract="true" name="RegulatoryApprovalMilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_BasicAndDilutedEarningsPerShareAbstract" abstract="true" name="BasicAndDilutedEarningsPerShareAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="biib_Expenseincurredbythecollaboration" abstract="false" name="Expenseincurredbythecollaboration" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_DividendYieldPercentage" abstract="false" name="DividendYieldPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" abstract="true" name="SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_IonisPharmaceuticalsMember" abstract="true" name="IonisPharmaceuticalsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_WarehouseUtilitiesAndSupportSpaceMember" abstract="true" name="WarehouseUtilitiesAndSupportSpaceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_DeferredtaxliabilityMember" abstract="true" name="DeferredtaxliabilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_OutLicensedPatentsMember" abstract="true" name="OutLicensedPatentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_RocheGroupGenentechMember" abstract="true" name="RocheGroupGenentechMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_FumarateMember" abstract="true" name="FumarateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_TimeVestedRestrictedStockUnitsMember" abstract="true" name="TimeVestedRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_EntityWidePercentageOfRevenueFromMajorDistributors" abstract="false" name="EntityWidePercentageOfRevenueFromMajorDistributors" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="biib_CollaborationAgreementTerm" abstract="false" name="CollaborationAgreementTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="biib_ContractOptionExerciseFee" abstract="false" name="ContractOptionExerciseFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_DenaliTherapeuticsIncMember" abstract="true" name="DenaliTherapeuticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_DivestituresAbstract" abstract="true" name="DivestituresAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="biib_March2019ShareRepurchaseProgramMember" abstract="true" name="March2019ShareRepurchaseProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock" abstract="false" name="RevenuesfromantiCD20therapeuticprogramsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="biib_IntangibleAssetsExcludingGoodwillTableTextBlock" abstract="false" name="IntangibleAssetsExcludingGoodwillTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" abstract="true" name="MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_FutureContingentMilestoneTypesDomain" abstract="true" name="FutureContingentMilestoneTypesDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_IncomeTaxExpenseReductioninDeferredTaxAssetsandLiabilitiesNet" abstract="false" name="IncomeTaxExpenseReductioninDeferredTaxAssetsandLiabilitiesNet" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_ShareOfCoPromotionProfits" abstract="false" name="ShareOfCoPromotionProfits" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_AdministrativeSpaceMember" abstract="true" name="AdministrativeSpaceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_RegulatoryMilestonesMember" abstract="true" name="RegulatoryMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" abstract="false" name="SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="biib_FAMPYRAMember" abstract="true" name="FAMPYRAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_InventoryrawmaterialssoldtoFUJIFILM" abstract="false" name="InventoryrawmaterialssoldtoFUJIFILM" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_BAN2401Member" abstract="true" name="BAN2401Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" abstract="true" name="SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="biib_OtherrevenuesAbstract" abstract="true" name="OtherrevenuesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="biib_StrategicInvestmentPortfolio" abstract="false" name="StrategicInvestmentPortfolio" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_BiologicsManufacturingMember" abstract="true" name="BiologicsManufacturingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_FutureContingentMilestoneTypesAxis" abstract="true" name="FutureContingentMilestoneTypesAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="biib_EmployeeStockPurchasePlanMember" abstract="true" name="EmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_GlobalLicensingCollaborationAgreementSharesPurchased" abstract="false" name="GlobalLicensingCollaborationAgreementSharesPurchased" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="biib_NumberOfWholesalers" abstract="false" name="NumberOfWholesalers" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="biib_NumberOfOphthalmolgyBiosimilarProductsExclusiveRights" abstract="false" name="NumberOfOphthalmolgyBiosimilarProductsExclusiveRights" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" abstract="true" name="SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" abstract="false" name="Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_GovernmentSecuritiesCurrentMember" abstract="true" name="GovernmentSecuritiesCurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_StrategicInvestmentsMember" abstract="true" name="StrategicInvestmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" abstract="false" name="AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="biib_Inventorynetcurrentandnoncurrent" abstract="false" name="Inventorynetcurrentandnoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" abstract="true" name="SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain" abstract="false" name="PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_FacilityLocationDomain" abstract="true" name="FacilityLocationDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_FacilityLocationAxis" abstract="true" name="FacilityLocationAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" abstract="false" name="AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_ExpenseIncurredByCollaboration" abstract="false" name="ExpenseIncurredByCollaboration" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_TECFIDERAMember" abstract="true" name="TECFIDERAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_NumberOfProductCandidates" abstract="false" name="NumberOfProductCandidates" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="biib_IncomeLossFromEquityMethodInvestmentsNetOfTax" abstract="false" name="IncomeLossFromEquityMethodInvestmentsNetOfTax" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_CorporateDebtSecuritiesCurrentMember" abstract="true" name="CorporateDebtSecuritiesCurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" abstract="false" name="AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_DeferredTaxLiabilitiesValueReductioninValue" abstract="false" name="DeferredTaxLiabilitiesValueReductioninValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_UCBPharmaS.A.Member" abstract="true" name="UCBPharmaS.A.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_TGNMember" abstract="true" name="TGNMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_SPINRAZAMember" abstract="true" name="SPINRAZAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_DistributorOneMember" abstract="true" name="DistributorOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_ResearchanddevelopmentassetDomain" abstract="true" name="ResearchanddevelopmentassetDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_ShorttermderivativeMember" abstract="true" name="ShorttermderivativeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_BioverativMember" abstract="true" name="BioverativMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" abstract="false" name="PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased" abstract="false" name="GlobalLicensingCollaborationAgreementAmountSharesPurchased" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_Expensereflectedwithinstatementsofincome" abstract="false" name="Expensereflectedwithinstatementsofincome" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments" abstract="false" name="GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_SamsungBiosimilarAgreementMember" abstract="true" name="SamsungBiosimilarAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_MarketStockUnitsMember" abstract="true" name="MarketStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_Additionalreductioninroyaltyratepayableoncommercialsales" abstract="false" name="Additionalreductioninroyaltyratepayableoncommercialsales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="biib_SangamoCommonStockMember" abstract="true" name="SangamoCommonStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_CorporateDebtSecuritiesNonCurrentMember" abstract="true" name="CorporateDebtSecuritiesNonCurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_OtherrevenuesfromantiCD20therapeuticprograms" abstract="false" name="OtherrevenuesfromantiCD20therapeuticprograms" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_A2018ShareRepurchaseProgramMember" abstract="true" name="A2018ShareRepurchaseProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" abstract="false" name="UpfrontAndMilestonePaymentsMadeToCollaborativePartner" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_IndefiniteLivedIntangibleAssetsUsefulLife" abstract="false" name="IndefiniteLivedIntangibleAssetsUsefulLife" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="us-types:durationStringItemType"/>
  <xs:element id="biib_BIIB111Member" abstract="true" name="BIIB111Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_A2.25SeniorNotesdueMay12030Member" abstract="true" name="A2.25SeniorNotesdueMay12030Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_DistributorTwoMember" abstract="true" name="DistributorTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_DuefromantiCD20therapeuticprograms" abstract="false" name="DuefromantiCD20therapeuticprograms" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_ResearchanddevelopmentassetAxis" abstract="true" name="ResearchanddevelopmentassetAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="biib_AdditionalMilestonePayment" abstract="false" name="AdditionalMilestonePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_InterestInSubsidiary" abstract="false" name="InterestInSubsidiary" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="biib_FacilityTypeAxis" abstract="true" name="FacilityTypeAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="biib_DenmarkManufacturingOperationsMember" abstract="true" name="DenmarkManufacturingOperationsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_Noncontrollinginterestincreasedecreaseother" abstract="false" name="Noncontrollinginterestincreasedecreaseother" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_EffectiveTaxRateReconciliationGILTItax" abstract="false" name="EffectiveTaxRateReconciliationGILTItax" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract" abstract="true" name="ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="biib_OtherrevenuesTableTextBlock" abstract="false" name="OtherrevenuesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="biib_Investmentincommonstocksharespurchased" abstract="false" name="Investmentincommonstocksharespurchased" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="biib_December2019ShareRepurchaseProgramMember" abstract="true" name="December2019ShareRepurchaseProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>biib-20200930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:9d882161-cc57-4e82-9994-8001479894f6,g:a7b2bacf-5ee2-4f5b-9f49-a40e24a2538c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.biogenidec.com/role/CoverPage" xlink:type="simple" xlink:href="biib-20200930.xsd#CoverPage"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CoverPage" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" xlink:type="simple" xlink:href="biib-20200930.xsd#CondensedConsolidatedStatementsofIncomeUnaudited"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_42e2879b-db44-4c42-b7d6-b7f5dd7a56b7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_a8012a00-f5cb-429a-8c01-89dbfcedee41" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_42e2879b-db44-4c42-b7d6-b7f5dd7a56b7" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_a8012a00-f5cb-429a-8c01-89dbfcedee41" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_4a6eb625-9aba-4d59-96a9-f1c393e6b928" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_42e2879b-db44-4c42-b7d6-b7f5dd7a56b7" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_4a6eb625-9aba-4d59-96a9-f1c393e6b928" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_59639e6e-aeba-4551-8a2f-8debe5a8d2d6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_42e2879b-db44-4c42-b7d6-b7f5dd7a56b7" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_59639e6e-aeba-4551-8a2f-8debe5a8d2d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_7cb94eb6-88b8-4686-97f2-3ad2fcb39cc9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_42e2879b-db44-4c42-b7d6-b7f5dd7a56b7" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_7cb94eb6-88b8-4686-97f2-3ad2fcb39cc9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_3aa0c127-8c50-40f0-b764-6ddb479d81aa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_42e2879b-db44-4c42-b7d6-b7f5dd7a56b7" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_3aa0c127-8c50-40f0-b764-6ddb479d81aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Collaborationprofitlosssharing_9844ad19-a579-4d1e-9da2-ed4b66d01468" xlink:href="biib-20200930.xsd#biib_Collaborationprofitlosssharing"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_42e2879b-db44-4c42-b7d6-b7f5dd7a56b7" xlink:to="loc_biib_Collaborationprofitlosssharing_9844ad19-a579-4d1e-9da2-ed4b66d01468" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_3e70a668-9392-4bb3-ba35-904c2d23d1e5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_42e2879b-db44-4c42-b7d6-b7f5dd7a56b7" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_3e70a668-9392-4bb3-ba35-904c2d23d1e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_d593cf09-2fc9-4f70-9b91-c92ad0f90561" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_42e2879b-db44-4c42-b7d6-b7f5dd7a56b7" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_d593cf09-2fc9-4f70-9b91-c92ad0f90561" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_ed29f5a2-2d4a-49f8-a379-2aef2a12bca4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_42e2879b-db44-4c42-b7d6-b7f5dd7a56b7" xlink:to="loc_us-gaap_RestructuringCharges_ed29f5a2-2d4a-49f8-a379-2aef2a12bca4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_5ac05a2c-2523-4ca9-b43c-6b4234dbcf8f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_99b1c613-ab77-407b-9e17-feb8c3074d55" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_5ac05a2c-2523-4ca9-b43c-6b4234dbcf8f" xlink:to="loc_us-gaap_Revenues_99b1c613-ab77-407b-9e17-feb8c3074d55" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_98ac2456-561d-48d8-a2fe-f690ffd0f418" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_5ac05a2c-2523-4ca9-b43c-6b4234dbcf8f" xlink:to="loc_us-gaap_CostsAndExpenses_98ac2456-561d-48d8-a2fe-f690ffd0f418" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_3ef5c73f-3ac5-4099-9944-ec28e452f535" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_39420124-33b4-4a6b-9919-132d040455d1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_3ef5c73f-3ac5-4099-9944-ec28e452f535" xlink:to="loc_us-gaap_OperatingIncomeLoss_39420124-33b4-4a6b-9919-132d040455d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_7d0ad55b-e959-4fc8-98b6-c332ce958b68" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_3ef5c73f-3ac5-4099-9944-ec28e452f535" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_7d0ad55b-e959-4fc8-98b6-c332ce958b68" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_bd20429b-216d-4d8a-b97f-1ca17b51af2a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_23f2145f-e053-43c4-8224-672fb6778dda" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_bd20429b-216d-4d8a-b97f-1ca17b51af2a" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_23f2145f-e053-43c4-8224-672fb6778dda" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_8a90e3a0-b2db-4fab-ad83-09cb46706acf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_bd20429b-216d-4d8a-b97f-1ca17b51af2a" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_8a90e3a0-b2db-4fab-ad83-09cb46706acf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax_9e6fb337-eb24-459d-a444-21000bc3f090" xlink:href="biib-20200930.xsd#biib_IncomeLossFromEquityMethodInvestmentsNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_bd20429b-216d-4d8a-b97f-1ca17b51af2a" xlink:to="loc_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax_9e6fb337-eb24-459d-a444-21000bc3f090" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_67c852b1-03dc-4fa0-8e89-a234258a582e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_2a82a936-8995-4f40-9ed5-d68c6e86285c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_67c852b1-03dc-4fa0-8e89-a234258a582e" xlink:to="loc_us-gaap_ProfitLoss_2a82a936-8995-4f40-9ed5-d68c6e86285c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_b31d2609-bfbd-4c86-b930-0accf7f4e9a0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_67c852b1-03dc-4fa0-8e89-a234258a582e" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_b31d2609-bfbd-4c86-b930-0accf7f4e9a0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited" xlink:type="simple" xlink:href="biib-20200930.xsd#CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_7c9abd0e-7cd3-4117-9d84-6cb00e9e3807" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_79d05b1c-d0a2-4ce9-9567-f18e6b6daf3f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_7c9abd0e-7cd3-4117-9d84-6cb00e9e3807" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_79d05b1c-d0a2-4ce9-9567-f18e6b6daf3f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_fbbbf3e0-8bce-4a2c-9ae4-0b0834f9f132" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_7c9abd0e-7cd3-4117-9d84-6cb00e9e3807" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_fbbbf3e0-8bce-4a2c-9ae4-0b0834f9f132" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_f6785c56-a20e-43de-8856-e2c2d3306156" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_3a342033-6ecd-4b2a-b1a8-c6fa0828a212" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_f6785c56-a20e-43de-8856-e2c2d3306156" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_3a342033-6ecd-4b2a-b1a8-c6fa0828a212" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_99f32877-c946-483d-92bd-871c499c2895" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_f6785c56-a20e-43de-8856-e2c2d3306156" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_99f32877-c946-483d-92bd-871c499c2895" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_542206b8-7d8b-4826-9a80-1024e9ef0d7a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_f6785c56-a20e-43de-8856-e2c2d3306156" xlink:to="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_542206b8-7d8b-4826-9a80-1024e9ef0d7a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_6222fd68-be8f-4415-9559-42a421da77d5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_f6785c56-a20e-43de-8856-e2c2d3306156" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_6222fd68-be8f-4415-9559-42a421da77d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_cb52a31e-c801-4ef6-a943-81f5e1040fa4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_f6785c56-a20e-43de-8856-e2c2d3306156" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_cb52a31e-c801-4ef6-a943-81f5e1040fa4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited_1" xlink:type="simple" xlink:href="biib-20200930.xsd#CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited_1"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_75ca18e7-d92d-4a36-9589-6495f0796b45" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_fd7672ca-4086-460c-b6d8-47fcf42fa736" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_75ca18e7-d92d-4a36-9589-6495f0796b45" xlink:to="loc_us-gaap_NetIncomeLoss_fd7672ca-4086-460c-b6d8-47fcf42fa736" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_7971cea5-b254-4002-b798-91b231eb7468" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_75ca18e7-d92d-4a36-9589-6495f0796b45" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_7971cea5-b254-4002-b798-91b231eb7468" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" xlink:href="biib-20200930.xsd#CondensedConsolidatedBalanceSheetsUnaudited"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_95796264-044a-4f1f-bd80-592f712e4bb0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_22f7ddb0-f9f7-4408-8a35-3197a0b05ef0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_95796264-044a-4f1f-bd80-592f712e4bb0" xlink:to="loc_us-gaap_AssetsCurrent_22f7ddb0-f9f7-4408-8a35-3197a0b05ef0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_f0a97692-9e0b-45c7-9bf8-806d60c8e156" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_95796264-044a-4f1f-bd80-592f712e4bb0" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_f0a97692-9e0b-45c7-9bf8-806d60c8e156" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_ff78ccf5-642a-4fb8-8794-8b054ae0d12a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_95796264-044a-4f1f-bd80-592f712e4bb0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_ff78ccf5-642a-4fb8-8794-8b054ae0d12a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_186523c8-440b-4c88-872b-b2438dcda7fb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_95796264-044a-4f1f-bd80-592f712e4bb0" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_186523c8-440b-4c88-872b-b2438dcda7fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_c0ff1588-d202-4dc2-801d-50b779ba20c8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_95796264-044a-4f1f-bd80-592f712e4bb0" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_c0ff1588-d202-4dc2-801d-50b779ba20c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_d6352912-7e8c-4af1-8a92-74bf7dd5442c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_95796264-044a-4f1f-bd80-592f712e4bb0" xlink:to="loc_us-gaap_Goodwill_d6352912-7e8c-4af1-8a92-74bf7dd5442c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_7982fe68-ae5d-4595-b09a-0640310d9f04" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_95796264-044a-4f1f-bd80-592f712e4bb0" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_7982fe68-ae5d-4595-b09a-0640310d9f04" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_f45e31ff-3086-4107-877d-e05ae4265e82" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_95796264-044a-4f1f-bd80-592f712e4bb0" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_f45e31ff-3086-4107-877d-e05ae4265e82" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_abc68cac-c2ef-4e45-9107-85900e853ad7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent_bec20318-6e8c-4c3e-a43b-dd7fa78aaee2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_abc68cac-c2ef-4e45-9107-85900e853ad7" xlink:to="loc_us-gaap_NotesPayableCurrent_bec20318-6e8c-4c3e-a43b-dd7fa78aaee2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_07b07536-7c76-4a26-ad30-2430819c6a54" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_abc68cac-c2ef-4e45-9107-85900e853ad7" xlink:to="loc_us-gaap_TaxesPayableCurrent_07b07536-7c76-4a26-ad30-2430819c6a54" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_0105e423-c066-4775-ac30-2eed0ed9a6da" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_abc68cac-c2ef-4e45-9107-85900e853ad7" xlink:to="loc_us-gaap_AccountsPayableCurrent_0105e423-c066-4775-ac30-2eed0ed9a6da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_d0c28979-55ad-41fa-b518-687bfbe682aa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_abc68cac-c2ef-4e45-9107-85900e853ad7" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_d0c28979-55ad-41fa-b518-687bfbe682aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_156db75d-4a4a-4db6-8d40-ffda5b6f1a45" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_77950c23-6c97-44f9-912d-7eb5588a1a6b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_156db75d-4a4a-4db6-8d40-ffda5b6f1a45" xlink:to="loc_us-gaap_PreferredStockValue_77950c23-6c97-44f9-912d-7eb5588a1a6b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_96d88574-6772-46ab-9055-da1ff6d3641b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_156db75d-4a4a-4db6-8d40-ffda5b6f1a45" xlink:to="loc_us-gaap_CommonStockValue_96d88574-6772-46ab-9055-da1ff6d3641b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_b0953dfa-930d-4d80-846c-81d4dd4bac9f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_156db75d-4a4a-4db6-8d40-ffda5b6f1a45" xlink:to="loc_us-gaap_AdditionalPaidInCapital_b0953dfa-930d-4d80-846c-81d4dd4bac9f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_b73df038-746e-41dd-9b8a-34bc26bd4cb2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_156db75d-4a4a-4db6-8d40-ffda5b6f1a45" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_b73df038-746e-41dd-9b8a-34bc26bd4cb2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ca9fab56-29f4-4c8c-b654-214204d4a0e7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_156db75d-4a4a-4db6-8d40-ffda5b6f1a45" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ca9fab56-29f4-4c8c-b654-214204d4a0e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_2f9aa9f2-8f09-4dee-99d7-a22b8c6ae7d6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_156db75d-4a4a-4db6-8d40-ffda5b6f1a45" xlink:to="loc_us-gaap_TreasuryStockValue_2f9aa9f2-8f09-4dee-99d7-a22b8c6ae7d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_fd2b4398-bab3-466b-afbd-c3d0f54bd9ee" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_59968fb4-e09a-49ca-a32a-de155cee0f17" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_fd2b4398-bab3-466b-afbd-c3d0f54bd9ee" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_59968fb4-e09a-49ca-a32a-de155cee0f17" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_dbbec30a-72ad-4bae-8a6f-ca23c05602fe" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_fd2b4398-bab3-466b-afbd-c3d0f54bd9ee" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_dbbec30a-72ad-4bae-8a6f-ca23c05602fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_35fcd971-685a-424f-858f-af487800b11b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_fd2b4398-bab3-466b-afbd-c3d0f54bd9ee" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_35fcd971-685a-424f-858f-af487800b11b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DuefromantiCD20therapeuticprograms_5100a7c1-4fac-47e7-ac9a-77ebe51600dc" xlink:href="biib-20200930.xsd#biib_DuefromantiCD20therapeuticprograms"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_fd2b4398-bab3-466b-afbd-c3d0f54bd9ee" xlink:to="loc_biib_DuefromantiCD20therapeuticprograms_5100a7c1-4fac-47e7-ac9a-77ebe51600dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_29cf6b1e-e4fe-43b6-9edd-57871a09dd1e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_fd2b4398-bab3-466b-afbd-c3d0f54bd9ee" xlink:to="loc_us-gaap_InventoryNet_29cf6b1e-e4fe-43b6-9edd-57871a09dd1e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_b771e99a-2ac8-4bae-a623-6036b207ec88" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_fd2b4398-bab3-466b-afbd-c3d0f54bd9ee" xlink:to="loc_us-gaap_OtherAssetsCurrent_b771e99a-2ac8-4bae-a623-6036b207ec88" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_4e939ca7-ad96-4f07-a52b-a647c9332125" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d1723d0e-36e9-4831-91fa-6c5eb1dd3a01" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_4e939ca7-ad96-4f07-a52b-a647c9332125" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d1723d0e-36e9-4831-91fa-6c5eb1dd3a01" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_21ed71dd-1032-4918-b9a4-1632d811cfb7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_4e939ca7-ad96-4f07-a52b-a647c9332125" xlink:to="loc_us-gaap_Liabilities_21ed71dd-1032-4918-b9a4-1632d811cfb7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_ae54b4c9-4852-492b-a62b-1236a61c6393" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_4e939ca7-ad96-4f07-a52b-a647c9332125" xlink:to="loc_us-gaap_CommitmentsAndContingencies_ae54b4c9-4852-492b-a62b-1236a61c6393" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c8f00a51-1dcf-4373-a8e4-ffb3fefc5e49" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_9d685c3e-c8e5-456f-9ea8-99433f03515f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c8f00a51-1dcf-4373-a8e4-ffb3fefc5e49" xlink:to="loc_us-gaap_StockholdersEquity_9d685c3e-c8e5-456f-9ea8-99433f03515f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_268c42fb-3185-4687-97dd-c2593036ebfb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c8f00a51-1dcf-4373-a8e4-ffb3fefc5e49" xlink:to="loc_us-gaap_MinorityInterest_268c42fb-3185-4687-97dd-c2593036ebfb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_71f1473a-2d08-4acf-90fe-362adfebf7af" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_4bf17536-9c46-41b4-bf2d-60186b103f0b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_71f1473a-2d08-4acf-90fe-362adfebf7af" xlink:to="loc_us-gaap_LiabilitiesCurrent_4bf17536-9c46-41b4-bf2d-60186b103f0b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_07fa3df4-99be-45f0-9f35-bc55f256a822" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_71f1473a-2d08-4acf-90fe-362adfebf7af" xlink:to="loc_us-gaap_LongTermDebt_07fa3df4-99be-45f0-9f35-bc55f256a822" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_736ffe23-490f-48d3-8ccb-06efe76ee07b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_71f1473a-2d08-4acf-90fe-362adfebf7af" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_736ffe23-490f-48d3-8ccb-06efe76ee07b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d311a401-af40-4667-86cb-75c2f5f26df6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_71f1473a-2d08-4acf-90fe-362adfebf7af" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d311a401-af40-4667-86cb-75c2f5f26df6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_2c07877d-7b89-4c6e-a07e-af9c3af8a484" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_71f1473a-2d08-4acf-90fe-362adfebf7af" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_2c07877d-7b89-4c6e-a07e-af9c3af8a484" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="simple" xlink:href="biib-20200930.xsd#CondensedConsolidatedBalanceSheetsUnauditedParenthetical"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="biib-20200930.xsd#CondensedConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_16d593aa-dbbe-49a7-9454-720214560469" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_dc282ac9-dd83-42dc-ac48-7918f9c7e8ff" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_16d593aa-dbbe-49a7-9454-720214560469" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_dc282ac9-dd83-42dc-ac48-7918f9c7e8ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_4cc786e1-9b2d-4862-9b98-18a7d231f5a0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_16d593aa-dbbe-49a7-9454-720214560469" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_4cc786e1-9b2d-4862-9b98-18a7d231f5a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_cac168b3-1984-4625-99b4-be97c04f6528" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_16d593aa-dbbe-49a7-9454-720214560469" xlink:to="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_cac168b3-1984-4625-99b4-be97c04f6528" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired_22d62068-3e2c-4932-af83-4e4df40fb88b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_16d593aa-dbbe-49a7-9454-720214560469" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired_22d62068-3e2c-4932-af83-4e4df40fb88b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_a7b0f6ea-8939-4161-8724-0c14dc41004f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_16d593aa-dbbe-49a7-9454-720214560469" xlink:to="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_a7b0f6ea-8939-4161-8724-0c14dc41004f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_77826632-4db4-46c2-9d47-fb35b25f55ac" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_16d593aa-dbbe-49a7-9454-720214560469" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_77826632-4db4-46c2-9d47-fb35b25f55ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_6670aaec-39ba-4bf9-b23e-1b8ead06d4a5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_16d593aa-dbbe-49a7-9454-720214560469" xlink:to="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_6670aaec-39ba-4bf9-b23e-1b8ead06d4a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_ad1258ed-3380-4bb6-97cd-f6ec24d17187" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_16d593aa-dbbe-49a7-9454-720214560469" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_ad1258ed-3380-4bb6-97cd-f6ec24d17187" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromHedgeInvestingActivities_8627108b-f104-44a6-9f98-652379d820db" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromHedgeInvestingActivities"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_16d593aa-dbbe-49a7-9454-720214560469" xlink:to="loc_us-gaap_ProceedsFromHedgeInvestingActivities_8627108b-f104-44a6-9f98-652379d820db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_a9227d0e-3c12-47e8-9935-96ae37ac19ed" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_16d593aa-dbbe-49a7-9454-720214560469" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_a9227d0e-3c12-47e8-9935-96ae37ac19ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_7f2e6bd7-b777-45a8-b447-94422846cda6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_16d593aa-dbbe-49a7-9454-720214560469" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_7f2e6bd7-b777-45a8-b447-94422846cda6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_465528c4-0775-446e-a68e-2fe12047926e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_34e8c5b5-28d2-4a7d-9f6b-e3199173d150" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_465528c4-0775-446e-a68e-2fe12047926e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_34e8c5b5-28d2-4a7d-9f6b-e3199173d150" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_bb0986fc-8a48-4631-b3a9-ce7839b4f827" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_465528c4-0775-446e-a68e-2fe12047926e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_bb0986fc-8a48-4631-b3a9-ce7839b4f827" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_572024c2-ebf8-40c7-a5b8-6b1bc780e4fe" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_465528c4-0775-446e-a68e-2fe12047926e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_572024c2-ebf8-40c7-a5b8-6b1bc780e4fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2a8281a6-20f3-4000-8952-3ce4fb272726" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_1bf371e5-3005-4e53-abf5-fb28ea0c2db8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2a8281a6-20f3-4000-8952-3ce4fb272726" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_1bf371e5-3005-4e53-abf5-fb28ea0c2db8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_09a6f60d-d173-4862-aea1-91f32ce53f2a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2a8281a6-20f3-4000-8952-3ce4fb272726" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_09a6f60d-d173-4862-aea1-91f32ce53f2a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_bbf12333-bf04-40dd-bcbe-1514d32a1d62" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2a8281a6-20f3-4000-8952-3ce4fb272726" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_bbf12333-bf04-40dd-bcbe-1514d32a1d62" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_b6529ea3-3c4b-4352-a961-367497153254" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2a8281a6-20f3-4000-8952-3ce4fb272726" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_b6529ea3-3c4b-4352-a961-367497153254" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromDerivativeInstrumentFinancingActivities_db90709c-7e21-4d94-833f-bf70771498cf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForProceedsFromDerivativeInstrumentFinancingActivities"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2a8281a6-20f3-4000-8952-3ce4fb272726" xlink:to="loc_us-gaap_PaymentsForProceedsFromDerivativeInstrumentFinancingActivities_db90709c-7e21-4d94-833f-bf70771498cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_29c8620b-fab7-4e4c-8050-df8f84f6b2aa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToMinorityShareholders"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2a8281a6-20f3-4000-8952-3ce4fb272726" xlink:to="loc_us-gaap_PaymentsToMinorityShareholders_29c8620b-fab7-4e4c-8050-df8f84f6b2aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_b4c930f2-3681-400d-b425-aee2d1ac892a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2a8281a6-20f3-4000-8952-3ce4fb272726" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_b4c930f2-3681-400d-b425-aee2d1ac892a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6554eaa5-9797-44b7-a0bb-759dfc47c958" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_f69ac394-ad16-4621-9369-4de4768850e1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6554eaa5-9797-44b7-a0bb-759dfc47c958" xlink:to="loc_us-gaap_ProfitLoss_f69ac394-ad16-4621-9369-4de4768850e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_8ee97e65-4686-4b8d-bb3b-d622114cc4b4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6554eaa5-9797-44b7-a0bb-759dfc47c958" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_8ee97e65-4686-4b8d-bb3b-d622114cc4b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_0fe9b4ed-d9ef-48db-b5c7-c8522fdfa044" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6554eaa5-9797-44b7-a0bb-759dfc47c958" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_0fe9b4ed-d9ef-48db-b5c7-c8522fdfa044" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_c7201594-7cdc-41fc-b9d9-bb7a55ec820d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6554eaa5-9797-44b7-a0bb-759dfc47c958" xlink:to="loc_us-gaap_ShareBasedCompensation_c7201594-7cdc-41fc-b9d9-bb7a55ec820d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_67d24866-08e8-4af1-8daa-8e13fb13d288" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6554eaa5-9797-44b7-a0bb-759dfc47c958" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_67d24866-08e8-4af1-8daa-8e13fb13d288" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_8bff0d68-b33d-4907-ba87-63b5524a5411" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6554eaa5-9797-44b7-a0bb-759dfc47c958" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_8bff0d68-b33d-4907-ba87-63b5524a5411" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax_d029d19a-eb3f-47f8-8a5b-7a77ee2d0334" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6554eaa5-9797-44b7-a0bb-759dfc47c958" xlink:to="loc_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax_d029d19a-eb3f-47f8-8a5b-7a77ee2d0334" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_a59e9b3e-10de-44b1-a9f0-902442022bac" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6554eaa5-9797-44b7-a0bb-759dfc47c958" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_a59e9b3e-10de-44b1-a9f0-902442022bac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_50c903c8-a782-432e-bef8-4b8d5dbfd7ca" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6554eaa5-9797-44b7-a0bb-759dfc47c958" xlink:to="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_50c903c8-a782-432e-bef8-4b8d5dbfd7ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_29c948dc-6bb0-4d79-9427-ca5605fc46c6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6554eaa5-9797-44b7-a0bb-759dfc47c958" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_29c948dc-6bb0-4d79-9427-ca5605fc46c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_757dff06-c5e4-4735-91e6-c034c6103dd5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6554eaa5-9797-44b7-a0bb-759dfc47c958" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_757dff06-c5e4-4735-91e6-c034c6103dd5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties_a93503d8-4c67-4628-be4b-f221416d2100" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedParties"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6554eaa5-9797-44b7-a0bb-759dfc47c958" xlink:to="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties_a93503d8-4c67-4628-be4b-f221416d2100" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_490e4dae-1ce3-4fd4-be87-fbbf54152301" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6554eaa5-9797-44b7-a0bb-759dfc47c958" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_490e4dae-1ce3-4fd4-be87-fbbf54152301" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_7d01fc65-27d1-4fef-821e-025ac4eb76e4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6554eaa5-9797-44b7-a0bb-759dfc47c958" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_7d01fc65-27d1-4fef-821e-025ac4eb76e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_3dbfc527-4cfd-4f69-9aaa-7425673a74c1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6554eaa5-9797-44b7-a0bb-759dfc47c958" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_3dbfc527-4cfd-4f69-9aaa-7425673a74c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_0a50d249-83a4-403d-8f55-d20d540a1bc1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:calculationArc order="16" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6554eaa5-9797-44b7-a0bb-759dfc47c958" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_0a50d249-83a4-403d-8f55-d20d540a1bc1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_33e5f356-de15-475e-9c06-1bc4c39bc36a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="17" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6554eaa5-9797-44b7-a0bb-759dfc47c958" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_33e5f356-de15-475e-9c06-1bc4c39bc36a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement" xlink:type="simple" xlink:href="biib-20200930.xsd#CondensedConsolidatedStatementofEquityStatement"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="biib-20200930.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="biib-20200930.xsd#SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="biib-20200930.xsd#SummaryofSignificantAccountingPoliciesDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/Acquisitions" xlink:type="simple" xlink:href="biib-20200930.xsd#Acquisitions"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/Acquisitions" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryofseparatelyidentifiableassetsacquiredandliabilitiesassumedTables" xlink:type="simple" xlink:href="biib-20200930.xsd#SummaryofseparatelyidentifiableassetsacquiredandliabilitiesassumedTables"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/SummaryofseparatelyidentifiableassetsacquiredandliabilitiesassumedTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual" xlink:type="simple" xlink:href="biib-20200930.xsd#BusinessAcquisitionDetailsTextual"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/BusinessAcquisitionDetails" xlink:type="simple" xlink:href="biib-20200930.xsd#BusinessAcquisitionDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/BusinessAcquisitionDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/DivestituresDivestitures" xlink:type="simple" xlink:href="biib-20200930.xsd#DivestituresDivestitures"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/DivestituresDivestitures" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/DivestituresDetailsTextual" xlink:type="simple" xlink:href="biib-20200930.xsd#DivestituresDetailsTextual"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/DivestituresDetailsTextual" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/Revenues" xlink:type="simple" xlink:href="biib-20200930.xsd#Revenues"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/Revenues" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesTables" xlink:type="simple" xlink:href="biib-20200930.xsd#RevenuesTables"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/RevenuesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesbyProductDetails" xlink:type="simple" xlink:href="biib-20200930.xsd#RevenuesbyProductDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/RevenuesbyProductDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ReservesforDiscountsandAllowancesDetails1" xlink:type="simple" xlink:href="biib-20200930.xsd#ReservesforDiscountsandAllowancesDetails1"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ReservesforDiscountsandAllowancesDetails1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ReservesforDiscountsandAllowancesDetails2" xlink:type="simple" xlink:href="biib-20200930.xsd#ReservesforDiscountsandAllowancesDetails2"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ReservesforDiscountsandAllowancesDetails2" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesfromAntiCD20TherapeuticProgramsDetails" xlink:type="simple" xlink:href="biib-20200930.xsd#RevenuesfromAntiCD20TherapeuticProgramsDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/RevenuesfromAntiCD20TherapeuticProgramsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_f0e311d0-ba80-4354-9c8f-a4205f2f3f61" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareOfCoPromotionProfits_228628cf-8ea9-4a59-b220-f9114288dd27" xlink:href="biib-20200930.xsd#biib_ShareOfCoPromotionProfits"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_f0e311d0-ba80-4354-9c8f-a4205f2f3f61" xlink:to="loc_biib_ShareOfCoPromotionProfits_228628cf-8ea9-4a59-b220-f9114288dd27" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherRevenuesDetails" xlink:type="simple" xlink:href="biib-20200930.xsd#OtherRevenuesDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/OtherRevenuesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesDetailsTextual" xlink:type="simple" xlink:href="biib-20200930.xsd#RevenuesDetailsTextual"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/RevenuesDetailsTextual" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/Inventory" xlink:type="simple" xlink:href="biib-20200930.xsd#Inventory"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/Inventory" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryTables" xlink:type="simple" xlink:href="biib-20200930.xsd#InventoryTables"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/InventoryTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryDetails" xlink:type="simple" xlink:href="biib-20200930.xsd#InventoryDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/InventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_biib_Inventorynetcurrentandnoncurrent_3eac9996-45e6-4b62-89e0-5f126db9d8e0" xlink:href="biib-20200930.xsd#biib_Inventorynetcurrentandnoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_edf08cab-acb3-481a-b409-2c5b6ffea1c3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_Inventorynetcurrentandnoncurrent_3eac9996-45e6-4b62-89e0-5f126db9d8e0" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_edf08cab-acb3-481a-b409-2c5b6ffea1c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_0f56b180-c0b5-439d-941a-5862a370056e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_Inventorynetcurrentandnoncurrent_3eac9996-45e6-4b62-89e0-5f126db9d8e0" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_0f56b180-c0b5-439d-941a-5862a370056e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_183fa147-bd2c-47ae-b3a3-174f529d2b24" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_Inventorynetcurrentandnoncurrent_3eac9996-45e6-4b62-89e0-5f126db9d8e0" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_183fa147-bd2c-47ae-b3a3-174f529d2b24" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwill" xlink:type="simple" xlink:href="biib-20200930.xsd#IntangibleAssetsandGoodwill"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsandGoodwill" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables" xlink:type="simple" xlink:href="biib-20200930.xsd#IntangibleAssetsandGoodwillTables"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails" xlink:type="simple" xlink:href="biib-20200930.xsd#IntangibleAssetsandGoodwillDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_868908b8-d032-45bf-86bc-fc960c7e1fa7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_72b5a357-eff4-485e-8a40-98cad961a30f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_868908b8-d032-45bf-86bc-fc960c7e1fa7" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_72b5a357-eff4-485e-8a40-98cad961a30f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_24947e5f-7ee6-438a-871c-ee6a3f5deefb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_868908b8-d032-45bf-86bc-fc960c7e1fa7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_24947e5f-7ee6-438a-871c-ee6a3f5deefb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_baeb12c9-237a-4e4e-8f3b-d57f62aa8698" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_868908b8-d032-45bf-86bc-fc960c7e1fa7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_baeb12c9-237a-4e4e-8f3b-d57f62aa8698" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_c7e0607e-34d4-445b-bb8f-4acfb4502e2d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2282db3f-a7a8-4737-ada3-9e6497e9df61" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_c7e0607e-34d4-445b-bb8f-4acfb4502e2d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2282db3f-a7a8-4737-ada3-9e6497e9df61" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_78770ab2-6b29-4075-b780-2904299bd59b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_c7e0607e-34d4-445b-bb8f-4acfb4502e2d" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_78770ab2-6b29-4075-b780-2904299bd59b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails1" xlink:type="simple" xlink:href="biib-20200930.xsd#IntangibleAssetsandGoodwillDetails1"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="biib-20200930.xsd#FairValueMeasurements"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurements" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="biib-20200930.xsd#FairValueMeasurementsTables"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="biib-20200930.xsd#FairValueMeasurementsDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_dfbb37d7-a8a4-4fe2-a23e-b33ac4b53008" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_06ea481f-3edd-4808-a32d-1ef1a2545caa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_dfbb37d7-a8a4-4fe2-a23e-b33ac4b53008" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_06ea481f-3edd-4808-a32d-1ef1a2545caa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_64cef1de-4f74-4ef9-8dad-d5c60a3a9a35" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_dfbb37d7-a8a4-4fe2-a23e-b33ac4b53008" xlink:to="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_64cef1de-4f74-4ef9-8dad-d5c60a3a9a35" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:type="simple" xlink:href="biib-20200930.xsd#FairValueMeasurementsDetailsTextual"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails" xlink:type="simple" xlink:href="biib-20200930.xsd#FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:type="simple" xlink:href="biib-20200930.xsd#FairValueMeasurementsDetails1"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:type="simple" xlink:href="biib-20200930.xsd#FairValueMeasurementsDetails2"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstruments" xlink:type="simple" xlink:href="biib-20200930.xsd#FinancialInstruments"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstruments" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:type="simple" xlink:href="biib-20200930.xsd#FinancialInstrumentsTables"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:type="simple" xlink:href="biib-20200930.xsd#FinancialInstrumentsDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:type="simple" xlink:href="biib-20200930.xsd#FinancialInstrumentsDetails1"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_0291d3d0-bb3c-497b-9946-383fe369272d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_89836d77-8580-4cd9-bebd-c4603ea2eb50" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_0291d3d0-bb3c-497b-9946-383fe369272d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_89836d77-8580-4cd9-bebd-c4603ea2eb50" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_f8a1b3d3-02c5-49f2-8eb9-0861b5bbd9d1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_0291d3d0-bb3c-497b-9946-383fe369272d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_f8a1b3d3-02c5-49f2-8eb9-0861b5bbd9d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecurities_1b8f803a-a7a9-4d53-8678-bb591759323c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_0291d3d0-bb3c-497b-9946-383fe369272d" xlink:to="loc_us-gaap_AvailableForSaleSecurities_1b8f803a-a7a9-4d53-8678-bb591759323c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b78cc7f7-0508-4168-b8a4-13c819cd201f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f5db8b08-2efc-4951-9035-dd7ed11c1a47" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b78cc7f7-0508-4168-b8a4-13c819cd201f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f5db8b08-2efc-4951-9035-dd7ed11c1a47" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_61e35fa4-876f-45ba-bf56-aa8b5af15f01" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b78cc7f7-0508-4168-b8a4-13c819cd201f" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_61e35fa4-876f-45ba-bf56-aa8b5af15f01" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_34b47aa9-9bec-4a60-b4f9-40da85988759" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b78cc7f7-0508-4168-b8a4-13c819cd201f" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_34b47aa9-9bec-4a60-b4f9-40da85988759" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:type="simple" xlink:href="biib-20200930.xsd#FinancialInstrumentsDetails2"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecurities_5eebef3b-3a7d-42d6-aa5e-5bdcfce22104" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_ccc00331-8466-4675-a78c-a390402cae57" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecurities_5eebef3b-3a7d-42d6-aa5e-5bdcfce22104" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_ccc00331-8466-4675-a78c-a390402cae57" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_d20fc253-b6c7-4b03-85bb-3498b3775de5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecurities_5eebef3b-3a7d-42d6-aa5e-5bdcfce22104" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_d20fc253-b6c7-4b03-85bb-3498b3775de5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_e23eaea8-6fe9-4f89-ac7b-436cf330a123" xlink:href="biib-20200930.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecurities_5eebef3b-3a7d-42d6-aa5e-5bdcfce22104" xlink:to="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_e23eaea8-6fe9-4f89-ac7b-436cf330a123" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_421bd945-b229-41c2-8c3f-44ee8a8c8ec9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_6b45714e-28e1-45e6-8d34-25f7b179b7cc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_421bd945-b229-41c2-8c3f-44ee8a8c8ec9" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_6b45714e-28e1-45e6-8d34-25f7b179b7cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_c38d05fc-1e12-4d1c-a663-c85f4eecca65" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_421bd945-b229-41c2-8c3f-44ee8a8c8ec9" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_c38d05fc-1e12-4d1c-a663-c85f4eecca65" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_fd921237-8474-4a5d-9957-a9e78ea94955" xlink:href="biib-20200930.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_421bd945-b229-41c2-8c3f-44ee8a8c8ec9" xlink:to="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_fd921237-8474-4a5d-9957-a9e78ea94955" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails3" xlink:type="simple" xlink:href="biib-20200930.xsd#FinancialInstrumentsDetails3"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails3" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual" xlink:type="simple" xlink:href="biib-20200930.xsd#FinancialInstrumentsDetailsTextual"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:type="simple" xlink:href="biib-20200930.xsd#FinancialInstrumentsFinancialInstrumentsDetailsTextual2"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstruments" xlink:type="simple" xlink:href="biib-20200930.xsd#DerivativeInstruments"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstruments" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:type="simple" xlink:href="biib-20200930.xsd#DerivativeInstrumentsTables"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:type="simple" xlink:href="biib-20200930.xsd#DerivativeInstrumentsDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantandEquipmentPropertyPlantandEquipment" xlink:type="simple" xlink:href="biib-20200930.xsd#PropertyPlantandEquipmentPropertyPlantandEquipment"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/PropertyPlantandEquipmentPropertyPlantandEquipment" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="biib-20200930.xsd#PropertyPlantandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IndebtednessNotes" xlink:type="simple" xlink:href="biib-20200930.xsd#IndebtednessNotes"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IndebtednessNotes" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IndebtednessDetails" xlink:type="simple" xlink:href="biib-20200930.xsd#IndebtednessDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IndebtednessDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/Equity" xlink:type="simple" xlink:href="biib-20200930.xsd#Equity"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/Equity" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables" xlink:type="simple" xlink:href="biib-20200930.xsd#AccumulatedOtherComprehensiveIncomeLossTables"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareRepurchasesDetails" xlink:type="simple" xlink:href="biib-20200930.xsd#ShareRepurchasesDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareRepurchasesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="biib-20200930.xsd#AccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="biib-20200930.xsd#ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsperShare" xlink:type="simple" xlink:href="biib-20200930.xsd#EarningsperShare"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/EarningsperShare" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsperShareTables" xlink:type="simple" xlink:href="biib-20200930.xsd#EarningsperShareTables"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/EarningsperShareTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsperShareDetails" xlink:type="simple" xlink:href="biib-20200930.xsd#EarningsperShareDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/EarningsperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5b48715a-aaa6-4b98-90de-1ea6c3bea53e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_8defabc8-9943-4b7c-8ffe-c0ed99649be7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5b48715a-aaa6-4b98-90de-1ea6c3bea53e" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_8defabc8-9943-4b7c-8ffe-c0ed99649be7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_53dc5966-eced-474e-9c6f-07021f9eec1a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5b48715a-aaa6-4b98-90de-1ea6c3bea53e" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_53dc5966-eced-474e-9c6f-07021f9eec1a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_85a15e19-1ce4-43a8-8285-a17c653b02cd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_8ae3aefe-5c6b-49f6-ab05-10c0039e8efa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_85a15e19-1ce4-43a8-8285-a17c653b02cd" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_8ae3aefe-5c6b-49f6-ab05-10c0039e8efa" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/SharebasedPayments" xlink:type="simple" xlink:href="biib-20200930.xsd#SharebasedPayments"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/SharebasedPayments" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:type="simple" xlink:href="biib-20200930.xsd#ShareBasedPaymentsTables"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:type="simple" xlink:href="biib-20200930.xsd#ShareBasedPaymentsDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_f02f369e-8d38-42a9-8e5e-64f765c7932c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_2ca541b4-56b2-4b96-9a2c-63fffe34dfa5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_f02f369e-8d38-42a9-8e5e-64f765c7932c" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_2ca541b4-56b2-4b96-9a2c-63fffe34dfa5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_c38449ed-bfa7-4483-9deb-f36aa28950e6" xlink:href="biib-20200930.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_f02f369e-8d38-42a9-8e5e-64f765c7932c" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_c38449ed-bfa7-4483-9deb-f36aa28950e6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:type="simple" xlink:href="biib-20200930.xsd#ShareBasedPaymentsDetails1"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxes" xlink:type="simple" xlink:href="biib-20200930.xsd#IncomeTaxes"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxes" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="biib-20200930.xsd#IncomeTaxesTables"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:type="simple" xlink:href="biib-20200930.xsd#IncomeTaxesDetailsTextual"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="biib-20200930.xsd#IncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_c3de0fff-53f3-4fc7-b761-09c5fcd6d205" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_ec434a82-dd77-4415-bc01-82fda87c2c39" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_c3de0fff-53f3-4fc7-b761-09c5fcd6d205" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_ec434a82-dd77-4415-bc01-82fda87c2c39" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_8f89bc08-6191-4cd2-a500-6824f01cf202" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_c3de0fff-53f3-4fc7-b761-09c5fcd6d205" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_8f89bc08-6191-4cd2-a500-6824f01cf202" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_882033ab-9ea7-4b37-9f51-e775af147397" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_c3de0fff-53f3-4fc7-b761-09c5fcd6d205" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_882033ab-9ea7-4b37-9f51-e775af147397" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_b6735e0d-0fd0-4d5c-9987-7a56483f9657" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_c3de0fff-53f3-4fc7-b761-09c5fcd6d205" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_b6735e0d-0fd0-4d5c-9987-7a56483f9657" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_d0ba10f6-b936-466c-856d-a116878b1803" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_c3de0fff-53f3-4fc7-b761-09c5fcd6d205" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_d0ba10f6-b936-466c-856d-a116878b1803" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets_7b792620-54fe-4af1-b6c5-7553d643d6c7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_c3de0fff-53f3-4fc7-b761-09c5fcd6d205" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets_7b792620-54fe-4af1-b6c5-7553d643d6c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization_ae7b1b96-0a04-4816-a1a3-03cc7d5a9ed4" xlink:href="biib-20200930.xsd#biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_c3de0fff-53f3-4fc7-b761-09c5fcd6d205" xlink:to="loc_biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization_ae7b1b96-0a04-4816-a1a3-03cc7d5a9ed4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_8fac9961-49a5-4b18-80a6-883717b7c6a6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_c3de0fff-53f3-4fc7-b761-09c5fcd6d205" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_8fac9961-49a5-4b18-80a6-883717b7c6a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EffectiveTaxRateReconciliationGILTItax_c3479b5f-f9d1-48ea-8737-6ac886f42996" xlink:href="biib-20200930.xsd#biib_EffectiveTaxRateReconciliationGILTItax"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_c3de0fff-53f3-4fc7-b761-09c5fcd6d205" xlink:to="loc_biib_EffectiveTaxRateReconciliationGILTItax_c3479b5f-f9d1-48ea-8737-6ac886f42996" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_2d934d50-ca1f-4836-95c0-da1c17691550" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_c3de0fff-53f3-4fc7-b761-09c5fcd6d205" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_2d934d50-ca1f-4836-95c0-da1c17691550" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_9bba7597-1171-45c9-8747-ff23c52d4538" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_c3de0fff-53f3-4fc7-b761-09c5fcd6d205" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_9bba7597-1171-45c9-8747-ff23c52d4538" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:type="simple" xlink:href="biib-20200930.xsd#OtherConsolidatedFinancialStatementDetail"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:type="simple" xlink:href="biib-20200930.xsd#OtherConsolidatedFinancialStatementDetailTables"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:type="simple" xlink:href="biib-20200930.xsd#OtherConsolidatedFinancialStatementDetailDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_a4bd832d-4845-4db9-9db0-a62bc446c20a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_b0df4c17-7b68-4547-8227-6f8031bd12ba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLoss_a4bd832d-4845-4db9-9db0-a62bc446c20a" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_b0df4c17-7b68-4547-8227-6f8031bd12ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_06dac968-e4cc-4e0d-b684-9247f7ce69a3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLoss_a4bd832d-4845-4db9-9db0-a62bc446c20a" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_06dac968-e4cc-4e0d-b684-9247f7ce69a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_9fa2e658-c030-4ab0-80e8-e58da703f1a1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_f682db17-f596-4551-abbb-efd533f6529c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_9fa2e658-c030-4ab0-80e8-e58da703f1a1" xlink:to="loc_us-gaap_InvestmentIncomeInterest_f682db17-f596-4551-abbb-efd533f6529c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_8274d552-dd76-4a8e-b5a1-fc1fde03aef7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_9fa2e658-c030-4ab0-80e8-e58da703f1a1" xlink:to="loc_us-gaap_InterestExpense_8274d552-dd76-4a8e-b5a1-fc1fde03aef7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses_725775d5-e5dd-4e49-90c8-d6fd742fb732" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_9fa2e658-c030-4ab0-80e8-e58da703f1a1" xlink:to="loc_us-gaap_RealizedInvestmentGainsLosses_725775d5-e5dd-4e49-90c8-d6fd742fb732" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_9b223b82-e36b-4964-9410-f4e47671211e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_9fa2e658-c030-4ab0-80e8-e58da703f1a1" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_9b223b82-e36b-4964-9410-f4e47671211e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_ac7da1d6-a9df-4bec-9067-f5fec39cf837" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_9fa2e658-c030-4ab0-80e8-e58da703f1a1" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_ac7da1d6-a9df-4bec-9067-f5fec39cf837" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual" xlink:type="simple" xlink:href="biib-20200930.xsd#OtherConsolidatedFinancialStatementDetailsTextual"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationships" xlink:type="simple" xlink:href="biib-20200930.xsd#CollaborativeandOtherRelationships"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationships" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables" xlink:type="simple" xlink:href="biib-20200930.xsd#CollaborativeandOtherRelationshipsTables"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails" xlink:type="simple" xlink:href="biib-20200930.xsd#CollaborativeandOtherRelationshipsCollaborationsDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails" xlink:type="simple" xlink:href="biib-20200930.xsd#CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/InvestmentsinVariableInterestEntities" xlink:type="simple" xlink:href="biib-20200930.xsd#InvestmentsinVariableInterestEntities"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/InvestmentsinVariableInterestEntities" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails" xlink:type="simple" xlink:href="biib-20200930.xsd#InvestmentsinVariableInterestEntitiesDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/Litigation" xlink:type="simple" xlink:href="biib-20200930.xsd#Litigation"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/Litigation" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/LitigationDetails" xlink:type="simple" xlink:href="biib-20200930.xsd#LitigationDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/LitigationDetails" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>biib-20200930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:9d882161-cc57-4e82-9994-8001479894f6,g:a7b2bacf-5ee2-4f5b-9f49-a40e24a2538c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CoverPage" xlink:type="simple" xlink:href="biib-20200930.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CoverPage" xlink:type="extended" id="i05710ae807bc476c84ad6f5c43c28d0a_CoverPage"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" xlink:type="simple" xlink:href="biib-20200930.xsd#CondensedConsolidatedStatementsofIncomeUnaudited"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" xlink:type="extended" id="ia3ec2cee8b474a459550a22020e63d77_CondensedConsolidatedStatementsofIncomeUnaudited">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_01d2b5a1-e886-42a0-ab31-8cd8ff6d29d2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_b862eae0-e8fa-4f3b-af03-eb008bd2d790" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_01d2b5a1-e886-42a0-ab31-8cd8ff6d29d2" xlink:to="loc_us-gaap_Revenues_b862eae0-e8fa-4f3b-af03-eb008bd2d790" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_15c4f0f1-0b94-4497-b92f-9f5a7ac4daad" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_01d2b5a1-e886-42a0-ab31-8cd8ff6d29d2" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_15c4f0f1-0b94-4497-b92f-9f5a7ac4daad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_d3878afa-bf29-40d1-96e1-d3f4cef3059c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_15c4f0f1-0b94-4497-b92f-9f5a7ac4daad" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_d3878afa-bf29-40d1-96e1-d3f4cef3059c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_32d9de08-fa9b-41bc-8b15-dbfa20787732" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_15c4f0f1-0b94-4497-b92f-9f5a7ac4daad" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_32d9de08-fa9b-41bc-8b15-dbfa20787732" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_10dd93ef-6f1a-42e4-a767-dc74c18d5bbf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_15c4f0f1-0b94-4497-b92f-9f5a7ac4daad" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_10dd93ef-6f1a-42e4-a767-dc74c18d5bbf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_914d210a-a91c-4805-b0de-91fc4a52fe52" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_15c4f0f1-0b94-4497-b92f-9f5a7ac4daad" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_914d210a-a91c-4805-b0de-91fc4a52fe52" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Collaborationprofitlosssharing_7b1dd1f4-96b2-4de5-bfd2-eaeaa45f6b04" xlink:href="biib-20200930.xsd#biib_Collaborationprofitlosssharing"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_15c4f0f1-0b94-4497-b92f-9f5a7ac4daad" xlink:to="loc_biib_Collaborationprofitlosssharing_7b1dd1f4-96b2-4de5-bfd2-eaeaa45f6b04" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_63e7f217-5c15-4e01-8af6-06aeb794fd51" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_15c4f0f1-0b94-4497-b92f-9f5a7ac4daad" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_63e7f217-5c15-4e01-8af6-06aeb794fd51" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_996783e1-582a-4a75-8597-05626c17fb96" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_15c4f0f1-0b94-4497-b92f-9f5a7ac4daad" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_996783e1-582a-4a75-8597-05626c17fb96" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_123a2ea1-4613-4c01-86a1-a2f476899286" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_15c4f0f1-0b94-4497-b92f-9f5a7ac4daad" xlink:to="loc_us-gaap_RestructuringCharges_123a2ea1-4613-4c01-86a1-a2f476899286" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_a9bdb091-f481-4b9f-ac6f-e6a03fe95aec" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_15c4f0f1-0b94-4497-b92f-9f5a7ac4daad" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_a9bdb091-f481-4b9f-ac6f-e6a03fe95aec" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_6094e841-8ab6-4e94-b028-37f014302953" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_15c4f0f1-0b94-4497-b92f-9f5a7ac4daad" xlink:to="loc_us-gaap_CostsAndExpenses_6094e841-8ab6-4e94-b028-37f014302953" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_90d81cc2-7f23-48b5-b42f-b8a68990320f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_01d2b5a1-e886-42a0-ab31-8cd8ff6d29d2" xlink:to="loc_us-gaap_OperatingIncomeLoss_90d81cc2-7f23-48b5-b42f-b8a68990320f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_526ee37f-b126-4c9b-8ed0-6f696dcb35c2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_01d2b5a1-e886-42a0-ab31-8cd8ff6d29d2" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_526ee37f-b126-4c9b-8ed0-6f696dcb35c2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_3043a5b2-aab6-483b-9c6e-c00ae1bab953" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_01d2b5a1-e886-42a0-ab31-8cd8ff6d29d2" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_3043a5b2-aab6-483b-9c6e-c00ae1bab953" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_553ac61e-a8f3-4b8a-be1e-f76b035be0c8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_01d2b5a1-e886-42a0-ab31-8cd8ff6d29d2" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_553ac61e-a8f3-4b8a-be1e-f76b035be0c8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax_7651b790-8d55-4f58-a6ee-e4f39bf4c6c8" xlink:href="biib-20200930.xsd#biib_IncomeLossFromEquityMethodInvestmentsNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_01d2b5a1-e886-42a0-ab31-8cd8ff6d29d2" xlink:to="loc_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax_7651b790-8d55-4f58-a6ee-e4f39bf4c6c8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_22c50a0f-1129-4726-b2c0-07b4b2bddf89" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_01d2b5a1-e886-42a0-ab31-8cd8ff6d29d2" xlink:to="loc_us-gaap_ProfitLoss_22c50a0f-1129-4726-b2c0-07b4b2bddf89" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_d7f06f26-684a-4cc6-9f8a-3b9f2185465e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_01d2b5a1-e886-42a0-ab31-8cd8ff6d29d2" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_d7f06f26-684a-4cc6-9f8a-3b9f2185465e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e707cfeb-bc67-4dc6-b635-5915c9ba4cf2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_01d2b5a1-e886-42a0-ab31-8cd8ff6d29d2" xlink:to="loc_us-gaap_NetIncomeLoss_e707cfeb-bc67-4dc6-b635-5915c9ba4cf2" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_1d9cc095-f10a-48f4-af8a-f24a3cdb4e9d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_01d2b5a1-e886-42a0-ab31-8cd8ff6d29d2" xlink:to="loc_us-gaap_EarningsPerShareAbstract_1d9cc095-f10a-48f4-af8a-f24a3cdb4e9d" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_c158fcd1-880c-463f-8df8-10ea02adc5ec" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1d9cc095-f10a-48f4-af8a-f24a3cdb4e9d" xlink:to="loc_us-gaap_EarningsPerShareBasic_c158fcd1-880c-463f-8df8-10ea02adc5ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_45596c54-5b47-437c-8adf-839ce6fedd06" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1d9cc095-f10a-48f4-af8a-f24a3cdb4e9d" xlink:to="loc_us-gaap_EarningsPerShareDiluted_45596c54-5b47-437c-8adf-839ce6fedd06" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_e7ad4316-f31a-4a18-8f69-b82ed8f09448" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_01d2b5a1-e886-42a0-ab31-8cd8ff6d29d2" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_e7ad4316-f31a-4a18-8f69-b82ed8f09448" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7d32b1db-622b-4111-9971-306e0764ce68" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_e7ad4316-f31a-4a18-8f69-b82ed8f09448" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7d32b1db-622b-4111-9971-306e0764ce68" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4f03ee70-ccc8-4d1d-8827-f9cd19a1cce0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_e7ad4316-f31a-4a18-8f69-b82ed8f09448" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4f03ee70-ccc8-4d1d-8827-f9cd19a1cce0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_872706bf-5053-49d8-a9a5-ed00742a6e6c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_01d2b5a1-e886-42a0-ab31-8cd8ff6d29d2" xlink:to="loc_us-gaap_StatementTable_872706bf-5053-49d8-a9a5-ed00742a6e6c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_dfff9cd9-f57c-4345-bb37-89faf2ece32f" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_872706bf-5053-49d8-a9a5-ed00742a6e6c" xlink:to="loc_srt_ProductOrServiceAxis_dfff9cd9-f57c-4345-bb37-89faf2ece32f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_dfff9cd9-f57c-4345-bb37-89faf2ece32f_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_dfff9cd9-f57c-4345-bb37-89faf2ece32f" xlink:to="loc_srt_ProductsAndServicesDomain_dfff9cd9-f57c-4345-bb37-89faf2ece32f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7008196e-fa16-4c11-8177-071b405a016a" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_dfff9cd9-f57c-4345-bb37-89faf2ece32f" xlink:to="loc_srt_ProductsAndServicesDomain_7008196e-fa16-4c11-8177-071b405a016a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_2b8f0b43-d23a-4a82-9985-8ce9446b54f2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7008196e-fa16-4c11-8177-071b405a016a" xlink:to="loc_us-gaap_ProductMember_2b8f0b43-d23a-4a82-9985-8ce9446b54f2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_8bf97757-2862-4188-a7d5-f07898e569c6" xlink:href="biib-20200930.xsd#biib_Revenuesfromanticd20therapeuticprogramsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7008196e-fa16-4c11-8177-071b405a016a" xlink:to="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_8bf97757-2862-4188-a7d5-f07898e569c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_91756964-4ee1-465a-9d44-a13a01ce71a6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7008196e-fa16-4c11-8177-071b405a016a" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_91756964-4ee1-465a-9d44-a13a01ce71a6" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited" xlink:type="simple" xlink:href="biib-20200930.xsd#CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited" xlink:type="extended" id="ic016ce10866244ec9760e5cc83cf3efb_CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" xlink:href="biib-20200930.xsd#CondensedConsolidatedBalanceSheetsUnaudited"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="extended" id="i89d3afda38f7478eaed007102edc9974_CondensedConsolidatedBalanceSheetsUnaudited"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="simple" xlink:href="biib-20200930.xsd#CondensedConsolidatedBalanceSheetsUnauditedParenthetical"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="extended" id="i3ee98cd933e2437c8f49d0f9c3e3a0cd_CondensedConsolidatedBalanceSheetsUnauditedParenthetical"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="biib-20200930.xsd#CondensedConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended" id="i70bbeaff35944d71a1e8a5a3f9b6d8fd_CondensedConsolidatedStatementsofCashFlowsUnaudited">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_20ac4254-c34c-487d-a98e-2a4edcc1667f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_d30a5ab3-4ab8-4ce6-9e90-7173e7ee7ec7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_20ac4254-c34c-487d-a98e-2a4edcc1667f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_d30a5ab3-4ab8-4ce6-9e90-7173e7ee7ec7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_c347dc6b-df92-4e2e-ae84-928f433b8086" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_d30a5ab3-4ab8-4ce6-9e90-7173e7ee7ec7" xlink:to="loc_us-gaap_ProfitLoss_c347dc6b-df92-4e2e-ae84-928f433b8086" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_92c726be-8237-4da9-89bf-328581e0f279" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_d30a5ab3-4ab8-4ce6-9e90-7173e7ee7ec7" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_92c726be-8237-4da9-89bf-328581e0f279" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_553e7c8f-c7e0-444d-bed7-fb9bb45580bd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_92c726be-8237-4da9-89bf-328581e0f279" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_553e7c8f-c7e0-444d-bed7-fb9bb45580bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_ccbeb86f-77c0-46d9-b2d8-19ef9680bb53" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_92c726be-8237-4da9-89bf-328581e0f279" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_ccbeb86f-77c0-46d9-b2d8-19ef9680bb53" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_a4eb0a96-a04c-4182-b509-8f726769d685" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_92c726be-8237-4da9-89bf-328581e0f279" xlink:to="loc_us-gaap_ShareBasedCompensation_a4eb0a96-a04c-4182-b509-8f726769d685" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_178d3a2a-1ea3-4398-ba3e-ea215e74f007" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_92c726be-8237-4da9-89bf-328581e0f279" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_178d3a2a-1ea3-4398-ba3e-ea215e74f007" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_c9a85058-0a02-4b0f-872f-6070360764e1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_92c726be-8237-4da9-89bf-328581e0f279" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_c9a85058-0a02-4b0f-872f-6070360764e1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax_effabf5d-ed08-44ac-ac30-b323b44f4717" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_92c726be-8237-4da9-89bf-328581e0f279" xlink:to="loc_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax_effabf5d-ed08-44ac-ac30-b323b44f4717" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_6e52a383-c4f5-479f-903c-bc3c5f2a9d35" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_92c726be-8237-4da9-89bf-328581e0f279" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_6e52a383-c4f5-479f-903c-bc3c5f2a9d35" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_d86d0e96-6b84-453d-8bdf-e1d364e5bcb1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_92c726be-8237-4da9-89bf-328581e0f279" xlink:to="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_d86d0e96-6b84-453d-8bdf-e1d364e5bcb1" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_a916bf4f-b2a7-4f80-9f75-97805150a986" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_92c726be-8237-4da9-89bf-328581e0f279" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_a916bf4f-b2a7-4f80-9f75-97805150a986" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_ac2ae5cd-3ff6-4943-86fe-65bce7035867" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_92c726be-8237-4da9-89bf-328581e0f279" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_ac2ae5cd-3ff6-4943-86fe-65bce7035867" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_84aedadb-1bb3-4c6b-822b-80c4757d6e38" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_92c726be-8237-4da9-89bf-328581e0f279" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_84aedadb-1bb3-4c6b-822b-80c4757d6e38" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_ba0dbaea-8b32-48ce-a5d6-16a65e76e067" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_84aedadb-1bb3-4c6b-822b-80c4757d6e38" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_ba0dbaea-8b32-48ce-a5d6-16a65e76e067" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties_6615f20d-1fc5-4db1-bb90-8791c22570a5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedParties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_84aedadb-1bb3-4c6b-822b-80c4757d6e38" xlink:to="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties_6615f20d-1fc5-4db1-bb90-8791c22570a5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_8c8cae87-1b27-4690-84f7-8a1bd08fb2e0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_84aedadb-1bb3-4c6b-822b-80c4757d6e38" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_8c8cae87-1b27-4690-84f7-8a1bd08fb2e0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_85801ed6-e044-40d5-a4ea-70f270270e17" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_84aedadb-1bb3-4c6b-822b-80c4757d6e38" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_85801ed6-e044-40d5-a4ea-70f270270e17" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_ab112b94-e578-45d8-8d3e-74a914bba68e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_84aedadb-1bb3-4c6b-822b-80c4757d6e38" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_ab112b94-e578-45d8-8d3e-74a914bba68e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_ac44e018-22f4-4c39-940f-963802b62766" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_84aedadb-1bb3-4c6b-822b-80c4757d6e38" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_ac44e018-22f4-4c39-940f-963802b62766" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d2875f66-b178-4c9d-a6c4-cd28701ca4fa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_92c726be-8237-4da9-89bf-328581e0f279" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d2875f66-b178-4c9d-a6c4-cd28701ca4fa" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_837de02e-33d5-4354-91cd-48fd9b82fcc5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_20ac4254-c34c-487d-a98e-2a4edcc1667f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_837de02e-33d5-4354-91cd-48fd9b82fcc5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_8142bfa3-fba4-4823-aa5b-c2cdb7207564" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_837de02e-33d5-4354-91cd-48fd9b82fcc5" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_8142bfa3-fba4-4823-aa5b-c2cdb7207564" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_77aba0bb-15d3-43f6-9098-0cab0d8298ec" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_837de02e-33d5-4354-91cd-48fd9b82fcc5" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_77aba0bb-15d3-43f6-9098-0cab0d8298ec" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_43ed7574-ab1d-4e16-879d-be40af54c1aa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_837de02e-33d5-4354-91cd-48fd9b82fcc5" xlink:to="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_43ed7574-ab1d-4e16-879d-be40af54c1aa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired_5df064ba-92a0-4f64-9595-0065f890b8bf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_837de02e-33d5-4354-91cd-48fd9b82fcc5" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired_5df064ba-92a0-4f64-9595-0065f890b8bf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_e7dc7a17-419e-482a-9f88-59f0fcb649fa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_837de02e-33d5-4354-91cd-48fd9b82fcc5" xlink:to="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_e7dc7a17-419e-482a-9f88-59f0fcb649fa" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_1eb226ef-d7ba-4c79-a0b8-3cc00e27ce8e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_837de02e-33d5-4354-91cd-48fd9b82fcc5" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_1eb226ef-d7ba-4c79-a0b8-3cc00e27ce8e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_545e5ada-6e58-475c-81b0-d670f216ceed" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_837de02e-33d5-4354-91cd-48fd9b82fcc5" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_545e5ada-6e58-475c-81b0-d670f216ceed" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_116282a0-a667-428a-8d07-1366614af53a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_837de02e-33d5-4354-91cd-48fd9b82fcc5" xlink:to="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_116282a0-a667-428a-8d07-1366614af53a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_2ecded08-8c24-4ea5-86c6-fdc396e2d880" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_837de02e-33d5-4354-91cd-48fd9b82fcc5" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_2ecded08-8c24-4ea5-86c6-fdc396e2d880" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromHedgeInvestingActivities_d93b846a-6636-4267-923f-b25e11ddc4e2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromHedgeInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_837de02e-33d5-4354-91cd-48fd9b82fcc5" xlink:to="loc_us-gaap_ProceedsFromHedgeInvestingActivities_d93b846a-6636-4267-923f-b25e11ddc4e2" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_81fe824b-7854-4d16-a0a0-1eb5bb4c863a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_837de02e-33d5-4354-91cd-48fd9b82fcc5" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_81fe824b-7854-4d16-a0a0-1eb5bb4c863a" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_06949e0b-6ada-4057-a8e3-dd061faa2f06" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_837de02e-33d5-4354-91cd-48fd9b82fcc5" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_06949e0b-6ada-4057-a8e3-dd061faa2f06" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7da9ee00-d821-43a4-8f0f-0a24fafa615f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_837de02e-33d5-4354-91cd-48fd9b82fcc5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7da9ee00-d821-43a4-8f0f-0a24fafa615f" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_cee2f1b0-5598-43d0-9cb0-69cb222d0795" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_20ac4254-c34c-487d-a98e-2a4edcc1667f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_cee2f1b0-5598-43d0-9cb0-69cb222d0795" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_e73c101f-8d33-4b1e-b5ae-8ef2488c51f6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_cee2f1b0-5598-43d0-9cb0-69cb222d0795" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_e73c101f-8d33-4b1e-b5ae-8ef2488c51f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_f3d10fdf-10f3-4ebd-aa28-9c5be8c977fd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_cee2f1b0-5598-43d0-9cb0-69cb222d0795" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_f3d10fdf-10f3-4ebd-aa28-9c5be8c977fd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_62043084-76cf-4aff-9f40-9817b859f394" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_cee2f1b0-5598-43d0-9cb0-69cb222d0795" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_62043084-76cf-4aff-9f40-9817b859f394" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_b245e943-5c4e-4aa9-9d72-5b84c7b86749" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_cee2f1b0-5598-43d0-9cb0-69cb222d0795" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_b245e943-5c4e-4aa9-9d72-5b84c7b86749" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromDerivativeInstrumentFinancingActivities_5c69467f-1559-4eee-af05-1fefb939eb6c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForProceedsFromDerivativeInstrumentFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_cee2f1b0-5598-43d0-9cb0-69cb222d0795" xlink:to="loc_us-gaap_PaymentsForProceedsFromDerivativeInstrumentFinancingActivities_5c69467f-1559-4eee-af05-1fefb939eb6c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_046467e2-8956-4785-8ac9-dd32a97a4f4e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToMinorityShareholders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_cee2f1b0-5598-43d0-9cb0-69cb222d0795" xlink:to="loc_us-gaap_PaymentsToMinorityShareholders_046467e2-8956-4785-8ac9-dd32a97a4f4e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_8183446e-e41e-431c-89e9-fe6acb8fff61" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_cee2f1b0-5598-43d0-9cb0-69cb222d0795" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_8183446e-e41e-431c-89e9-fe6acb8fff61" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_89454a20-2b0d-42e3-9f5b-4b3ebc68b07f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_cee2f1b0-5598-43d0-9cb0-69cb222d0795" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_89454a20-2b0d-42e3-9f5b-4b3ebc68b07f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_a54f5da1-4008-48fe-9425-159d45a90347" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_20ac4254-c34c-487d-a98e-2a4edcc1667f" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_a54f5da1-4008-48fe-9425-159d45a90347" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_161137d2-6c5f-420e-8068-6405b4360445" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_20ac4254-c34c-487d-a98e-2a4edcc1667f" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_161137d2-6c5f-420e-8068-6405b4360445" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6c36a375-2aaf-4ccb-bb68-4a1fa530a09e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_20ac4254-c34c-487d-a98e-2a4edcc1667f" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6c36a375-2aaf-4ccb-bb68-4a1fa530a09e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4f399d51-a18d-4d90-abd7-8383fa9acc8a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_1c7c9705-edd3-4090-8e99-49b21e82b00e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_20ac4254-c34c-487d-a98e-2a4edcc1667f" xlink:to="loc_us-gaap_StatementTable_1c7c9705-edd3-4090-8e99-49b21e82b00e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_6c6e9230-efae-400b-8363-2f6d749a776d" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1c7c9705-edd3-4090-8e99-49b21e82b00e" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_6c6e9230-efae-400b-8363-2f6d749a776d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_6c6e9230-efae-400b-8363-2f6d749a776d_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_6c6e9230-efae-400b-8363-2f6d749a776d" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_6c6e9230-efae-400b-8363-2f6d749a776d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_323f7ea7-a486-42b7-9a37-e6c8d40295f4" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_6c6e9230-efae-400b-8363-2f6d749a776d" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_323f7ea7-a486-42b7-9a37-e6c8d40295f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SangamoCommonStockMember_609b1082-8d42-436b-9ca4-755aa311bb6d" xlink:href="biib-20200930.xsd#biib_SangamoCommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_323f7ea7-a486-42b7-9a37-e6c8d40295f4" xlink:to="loc_biib_SangamoCommonStockMember_609b1082-8d42-436b-9ca4-755aa311bb6d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DenaliTherapeuticsIncMember_492b7b52-7ad3-4fce-b108-c4884d5cf15f" xlink:href="biib-20200930.xsd#biib_DenaliTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_323f7ea7-a486-42b7-9a37-e6c8d40295f4" xlink:to="loc_biib_DenaliTherapeuticsIncMember_492b7b52-7ad3-4fce-b108-c4884d5cf15f" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement" xlink:type="simple" xlink:href="biib-20200930.xsd#CondensedConsolidatedStatementofEquityStatement"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement" xlink:type="extended" id="i15b9be9d028546ea8e78fc16f805fb46_CondensedConsolidatedStatementofEquityStatement">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_749a2534-8139-480d-a8e1-fe45dc58f884" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_4b65a032-e9d8-433e-b13d-04dcd1273be6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_749a2534-8139-480d-a8e1-fe45dc58f884" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_4b65a032-e9d8-433e-b13d-04dcd1273be6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b787fed6-23c8-4e92-9eb6-ba3787fee203" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_749a2534-8139-480d-a8e1-fe45dc58f884" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b787fed6-23c8-4e92-9eb6-ba3787fee203" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_d48ba5bf-9bb5-4db2-86dc-3ea0070e4272" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_749a2534-8139-480d-a8e1-fe45dc58f884" xlink:to="loc_us-gaap_ProfitLoss_d48ba5bf-9bb5-4db2-86dc-3ea0070e4272" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_04df2972-ff01-4db4-9d4e-cd9a3317f90e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_749a2534-8139-480d-a8e1-fe45dc58f884" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_04df2972-ff01-4db4-9d4e-cd9a3317f90e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Noncontrollinginterestincreasedecreaseother_47930ecd-d6b6-4d01-8e90-a084f95a1064" xlink:href="biib-20200930.xsd#biib_Noncontrollinginterestincreasedecreaseother"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_749a2534-8139-480d-a8e1-fe45dc58f884" xlink:to="loc_biib_Noncontrollinginterestincreasedecreaseother_47930ecd-d6b6-4d01-8e90-a084f95a1064" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_2a812900-78f3-4991-bacc-1bffd310996e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_749a2534-8139-480d-a8e1-fe45dc58f884" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_2a812900-78f3-4991-bacc-1bffd310996e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_519f342b-5bc8-4947-8075-c37d34208ce1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_749a2534-8139-480d-a8e1-fe45dc58f884" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_519f342b-5bc8-4947-8075-c37d34208ce1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_8c4e64a0-1ed0-4d16-a212-7997a4324a8a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_749a2534-8139-480d-a8e1-fe45dc58f884" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_8c4e64a0-1ed0-4d16-a212-7997a4324a8a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_181693a7-337c-4d5e-af73-5c2ed98d1ce4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_749a2534-8139-480d-a8e1-fe45dc58f884" xlink:to="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_181693a7-337c-4d5e-af73-5c2ed98d1ce4" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_0d54cd6d-c735-42b9-af4d-8aeb20bc3a64" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_749a2534-8139-480d-a8e1-fe45dc58f884" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_0d54cd6d-c735-42b9-af4d-8aeb20bc3a64" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_f52766bc-d117-48fb-b3d0-9039aa153cc1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_749a2534-8139-480d-a8e1-fe45dc58f884" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_f52766bc-d117-48fb-b3d0-9039aa153cc1" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_b553752d-5394-449e-bc44-a278c7f6ad43" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_749a2534-8139-480d-a8e1-fe45dc58f884" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_b553752d-5394-449e-bc44-a278c7f6ad43" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_321b5be5-1c05-4c6d-ae99-17a1bdd6af62" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_749a2534-8139-480d-a8e1-fe45dc58f884" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_321b5be5-1c05-4c6d-ae99-17a1bdd6af62" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_03512a83-b37c-4eec-9a00-3879762ab4b2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_749a2534-8139-480d-a8e1-fe45dc58f884" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_03512a83-b37c-4eec-9a00-3879762ab4b2" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther_7288135c-e98b-4ddd-9ddd-78aa40de4bbb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_749a2534-8139-480d-a8e1-fe45dc58f884" xlink:to="loc_us-gaap_StockholdersEquityOther_7288135c-e98b-4ddd-9ddd-78aa40de4bbb" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_daa21a37-2801-4946-9bc2-8edaa934d20e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_33ca3cc1-dc2d-4b02-a534-afaf8f2ef6e8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_1ae07506-7e25-42d0-9cd3-ffc5edc2046c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_749a2534-8139-480d-a8e1-fe45dc58f884" xlink:to="loc_us-gaap_StatementTable_1ae07506-7e25-42d0-9cd3-ffc5edc2046c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_60f6f6ad-2eaa-44b7-bfe2-51d743454658" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1ae07506-7e25-42d0-9cd3-ffc5edc2046c" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_60f6f6ad-2eaa-44b7-bfe2-51d743454658" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_60f6f6ad-2eaa-44b7-bfe2-51d743454658_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_60f6f6ad-2eaa-44b7-bfe2-51d743454658" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_60f6f6ad-2eaa-44b7-bfe2-51d743454658_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_a2445c29-0293-4615-ba16-27ec74f3283a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_60f6f6ad-2eaa-44b7-bfe2-51d743454658" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_a2445c29-0293-4615-ba16-27ec74f3283a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2018ShareRepurchaseProgramMember_ab524aa3-dc33-47d2-91fd-3f015d3af01b" xlink:href="biib-20200930.xsd#biib_A2018ShareRepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_a2445c29-0293-4615-ba16-27ec74f3283a" xlink:to="loc_biib_A2018ShareRepurchaseProgramMember_ab524aa3-dc33-47d2-91fd-3f015d3af01b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_March2019ShareRepurchaseProgramMember_ebe67373-6057-4dbe-bef6-1eef2d41c86d" xlink:href="biib-20200930.xsd#biib_March2019ShareRepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_a2445c29-0293-4615-ba16-27ec74f3283a" xlink:to="loc_biib_March2019ShareRepurchaseProgramMember_ebe67373-6057-4dbe-bef6-1eef2d41c86d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_December2019ShareRepurchaseProgramMember_de5c3d5c-fe57-4815-87d4-957cd93b856d" xlink:href="biib-20200930.xsd#biib_December2019ShareRepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_a2445c29-0293-4615-ba16-27ec74f3283a" xlink:to="loc_biib_December2019ShareRepurchaseProgramMember_de5c3d5c-fe57-4815-87d4-957cd93b856d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_3f4417bd-7826-40c6-9bf5-c62193949a63" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1ae07506-7e25-42d0-9cd3-ffc5edc2046c" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_3f4417bd-7826-40c6-9bf5-c62193949a63" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_3f4417bd-7826-40c6-9bf5-c62193949a63_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3f4417bd-7826-40c6-9bf5-c62193949a63" xlink:to="loc_us-gaap_EquityComponentDomain_3f4417bd-7826-40c6-9bf5-c62193949a63_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_64c03dd4-89b2-41a7-bd68-dfa826c7f2cc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3f4417bd-7826-40c6-9bf5-c62193949a63" xlink:to="loc_us-gaap_EquityComponentDomain_64c03dd4-89b2-41a7-bd68-dfa826c7f2cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_ecc9776d-bbb6-4522-8061-54de81d000bd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_64c03dd4-89b2-41a7-bd68-dfa826c7f2cc" xlink:to="loc_us-gaap_PreferredStockMember_ecc9776d-bbb6-4522-8061-54de81d000bd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_e09d5b2c-29b5-4ccf-99db-5b4ae52ca08d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_64c03dd4-89b2-41a7-bd68-dfa826c7f2cc" xlink:to="loc_us-gaap_CommonStockMember_e09d5b2c-29b5-4ccf-99db-5b4ae52ca08d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_29361323-ebbb-4a33-a17f-f8a6d8f94190" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_64c03dd4-89b2-41a7-bd68-dfa826c7f2cc" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_29361323-ebbb-4a33-a17f-f8a6d8f94190" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_09a53c1c-eebe-4b55-8154-bb1735fdf7fc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_64c03dd4-89b2-41a7-bd68-dfa826c7f2cc" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_09a53c1c-eebe-4b55-8154-bb1735fdf7fc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_5fec6ebd-cab2-4470-b308-2a7184f42566" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_64c03dd4-89b2-41a7-bd68-dfa826c7f2cc" xlink:to="loc_us-gaap_RetainedEarningsMember_5fec6ebd-cab2-4470-b308-2a7184f42566" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_145fd389-3f80-4e3e-90f5-03c2140e4502" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_64c03dd4-89b2-41a7-bd68-dfa826c7f2cc" xlink:to="loc_us-gaap_TreasuryStockMember_145fd389-3f80-4e3e-90f5-03c2140e4502" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_f4628811-9662-4c71-8395-b8b7614c7f61" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_64c03dd4-89b2-41a7-bd68-dfa826c7f2cc" xlink:to="loc_us-gaap_ParentMember_f4628811-9662-4c71-8395-b8b7614c7f61" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_8fd857c9-8ba2-4fac-84a5-e23cf3e82bf7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_64c03dd4-89b2-41a7-bd68-dfa826c7f2cc" xlink:to="loc_us-gaap_NoncontrollingInterestMember_8fd857c9-8ba2-4fac-84a5-e23cf3e82bf7" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="biib-20200930.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended" id="if014eb347f864bbb98636d0967bf652a_SummaryofSignificantAccountingPolicies"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="biib-20200930.xsd#SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended" id="ibc79607b71bf4e639887be1d0a34a0d0_SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="biib-20200930.xsd#SummaryofSignificantAccountingPoliciesDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended" id="if0eaaa93b89549979ea5257359f9bf90_SummaryofSignificantAccountingPoliciesDetails"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/Acquisitions" xlink:type="simple" xlink:href="biib-20200930.xsd#Acquisitions"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/Acquisitions" xlink:type="extended" id="i83ae21fcefc14a8e85b30047df1bc896_Acquisitions"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryofseparatelyidentifiableassetsacquiredandliabilitiesassumedTables" xlink:type="simple" xlink:href="biib-20200930.xsd#SummaryofseparatelyidentifiableassetsacquiredandliabilitiesassumedTables"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/SummaryofseparatelyidentifiableassetsacquiredandliabilitiesassumedTables" xlink:type="extended" id="i0f3bbe439f5a4f2881541bcaa7363bb3_SummaryofseparatelyidentifiableassetsacquiredandliabilitiesassumedTables"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual" xlink:type="simple" xlink:href="biib-20200930.xsd#BusinessAcquisitionDetailsTextual"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual" xlink:type="extended" id="id31fa4f25d3c4c96b658cfd61f5834f9_BusinessAcquisitionDetailsTextual">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_e5bf2439-dc53-4a1e-b560-4e5690995baa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_7eec1df4-7572-4874-a621-7c6e71018c97" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e5bf2439-dc53-4a1e-b560-4e5690995baa" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_7eec1df4-7572-4874-a621-7c6e71018c97" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_bee53e4b-5f7a-4c12-a632-3dd44d0344b7" xlink:href="biib-20200930.xsd#biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e5bf2439-dc53-4a1e-b560-4e5690995baa" xlink:to="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_bee53e4b-5f7a-4c12-a632-3dd44d0344b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ClinicalAssetsAcquired_2d049857-e43a-4262-96ad-1c54a296eac8" xlink:href="biib-20200930.xsd#biib_ClinicalAssetsAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e5bf2439-dc53-4a1e-b560-4e5690995baa" xlink:to="loc_biib_ClinicalAssetsAcquired_2d049857-e43a-4262-96ad-1c54a296eac8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_f28dfd6c-7349-40a1-a0f5-550f08e83df2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e5bf2439-dc53-4a1e-b560-4e5690995baa" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_f28dfd6c-7349-40a1-a0f5-550f08e83df2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_1986f976-986d-4051-a649-d619c79a9aa0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e5bf2439-dc53-4a1e-b560-4e5690995baa" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_1986f976-986d-4051-a649-d619c79a9aa0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPaymentsToAcquireBusinesses_b66f2a55-28a3-4039-9dbc-e1c574466370" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherPaymentsToAcquireBusinesses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e5bf2439-dc53-4a1e-b560-4e5690995baa" xlink:to="loc_us-gaap_OtherPaymentsToAcquireBusinesses_b66f2a55-28a3-4039-9dbc-e1c574466370" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_da9e7ecd-ce89-482a-987f-d707ce64fa94" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e5bf2439-dc53-4a1e-b560-4e5690995baa" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_da9e7ecd-ce89-482a-987f-d707ce64fa94" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate_67ae406e-86b3-4cb3-b986-ee47c090804f" xlink:href="biib-20200930.xsd#biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e5bf2439-dc53-4a1e-b560-4e5690995baa" xlink:to="loc_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate_67ae406e-86b3-4cb3-b986-ee47c090804f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_4c73d718-2718-400a-a5af-01f21c818c5f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e5bf2439-dc53-4a1e-b560-4e5690995baa" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_4c73d718-2718-400a-a5af-01f21c818c5f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxBasisOfInvestmentsCostForIncomeTaxPurposes_1c5bb320-bfc2-4b34-8221-069594560ed4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxBasisOfInvestmentsCostForIncomeTaxPurposes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e5bf2439-dc53-4a1e-b560-4e5690995baa" xlink:to="loc_us-gaap_TaxBasisOfInvestmentsCostForIncomeTaxPurposes_1c5bb320-bfc2-4b34-8221-069594560ed4" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill_630f3b9c-5623-4775-9df5-1ee033a6d493" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e5bf2439-dc53-4a1e-b560-4e5690995baa" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill_630f3b9c-5623-4775-9df5-1ee033a6d493" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d76643d3-0730-4839-805d-c804f3211925" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e5bf2439-dc53-4a1e-b560-4e5690995baa" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d76643d3-0730-4839-805d-c804f3211925" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_2ec98d47-6a99-45a1-af1b-63b8108025eb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d76643d3-0730-4839-805d-c804f3211925" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_2ec98d47-6a99-45a1-af1b-63b8108025eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_2ec98d47-6a99-45a1-af1b-63b8108025eb_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2ec98d47-6a99-45a1-af1b-63b8108025eb" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_2ec98d47-6a99-45a1-af1b-63b8108025eb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_97af5509-5a55-4082-beb7-314764166310" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2ec98d47-6a99-45a1-af1b-63b8108025eb" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_97af5509-5a55-4082-beb7-314764166310" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_fa91730e-f675-4403-beb1-17b821efe82e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d76643d3-0730-4839-805d-c804f3211925" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_fa91730e-f675-4403-beb1-17b821efe82e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_fa91730e-f675-4403-beb1-17b821efe82e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_fa91730e-f675-4403-beb1-17b821efe82e" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_fa91730e-f675-4403-beb1-17b821efe82e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_e0e1fda6-a0b2-4e6c-8ea7-f5ffe7760beb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_fa91730e-f675-4403-beb1-17b821efe82e" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_e0e1fda6-a0b2-4e6c-8ea7-f5ffe7760beb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PostacquisitionequitycompensationMember_e6d7795a-85ec-4b30-8c5d-2f03610f5764" xlink:href="biib-20200930.xsd#biib_PostacquisitionequitycompensationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_e0e1fda6-a0b2-4e6c-8ea7-f5ffe7760beb" xlink:to="loc_biib_PostacquisitionequitycompensationMember_e6d7795a-85ec-4b30-8c5d-2f03610f5764" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchanddevelopmentassetAxis_b1051508-624d-43ef-ab7b-cac87afa2ce7" xlink:href="biib-20200930.xsd#biib_ResearchanddevelopmentassetAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d76643d3-0730-4839-805d-c804f3211925" xlink:to="loc_biib_ResearchanddevelopmentassetAxis_b1051508-624d-43ef-ab7b-cac87afa2ce7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchanddevelopmentassetDomain_b1051508-624d-43ef-ab7b-cac87afa2ce7_default" xlink:href="biib-20200930.xsd#biib_ResearchanddevelopmentassetDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_ResearchanddevelopmentassetAxis_b1051508-624d-43ef-ab7b-cac87afa2ce7" xlink:to="loc_biib_ResearchanddevelopmentassetDomain_b1051508-624d-43ef-ab7b-cac87afa2ce7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchanddevelopmentassetDomain_c25a0d70-e376-4889-9c45-1bab6c34112c" xlink:href="biib-20200930.xsd#biib_ResearchanddevelopmentassetDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_ResearchanddevelopmentassetAxis_b1051508-624d-43ef-ab7b-cac87afa2ce7" xlink:to="loc_biib_ResearchanddevelopmentassetDomain_c25a0d70-e376-4889-9c45-1bab6c34112c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BIIB111Member_067a965d-1422-4371-840e-1faf4579129c" xlink:href="biib-20200930.xsd#biib_BIIB111Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ResearchanddevelopmentassetDomain_c25a0d70-e376-4889-9c45-1bab6c34112c" xlink:to="loc_biib_BIIB111Member_067a965d-1422-4371-840e-1faf4579129c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BIIB112Member_f5f5e5ce-1d0e-4bfe-ba10-4cafe0875819" xlink:href="biib-20200930.xsd#biib_BIIB112Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ResearchanddevelopmentassetDomain_c25a0d70-e376-4889-9c45-1bab6c34112c" xlink:to="loc_biib_BIIB112Member_f5f5e5ce-1d0e-4bfe-ba10-4cafe0875819" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_ca52dd34-a1c8-4edd-99b7-37a770aeaf10" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d76643d3-0730-4839-805d-c804f3211925" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_ca52dd34-a1c8-4edd-99b7-37a770aeaf10" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_ca52dd34-a1c8-4edd-99b7-37a770aeaf10_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_ca52dd34-a1c8-4edd-99b7-37a770aeaf10" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_ca52dd34-a1c8-4edd-99b7-37a770aeaf10_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_908b9cb7-56fa-4ca8-93e0-2f43791b9a73" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_ca52dd34-a1c8-4edd-99b7-37a770aeaf10" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_908b9cb7-56fa-4ca8-93e0-2f43791b9a73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_16dcdd43-6728-4457-badb-a8cf64bc3282" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_908b9cb7-56fa-4ca8-93e0-2f43791b9a73" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_16dcdd43-6728-4457-badb-a8cf64bc3282" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_2959b69d-a0cc-48e7-8b27-45b3f685eea6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_908b9cb7-56fa-4ca8-93e0-2f43791b9a73" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_2959b69d-a0cc-48e7-8b27-45b3f685eea6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_c13fc15c-b122-410b-89e7-8c2df0143fa4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d76643d3-0730-4839-805d-c804f3211925" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_c13fc15c-b122-410b-89e7-8c2df0143fa4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c13fc15c-b122-410b-89e7-8c2df0143fa4_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_c13fc15c-b122-410b-89e7-8c2df0143fa4" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c13fc15c-b122-410b-89e7-8c2df0143fa4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4fd1bbbe-a192-435a-81cf-399f62e6a753" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_c13fc15c-b122-410b-89e7-8c2df0143fa4" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4fd1bbbe-a192-435a-81cf-399f62e6a753" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BIIB118Member_9a604e5a-2db8-420e-9432-c49431ceaf86" xlink:href="biib-20200930.xsd#biib_BIIB118Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4fd1bbbe-a192-435a-81cf-399f62e6a753" xlink:to="loc_biib_BIIB118Member_9a604e5a-2db8-420e-9432-c49431ceaf86" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NightstarMember_2e2eba40-66c7-4934-bf2f-c0225cc4e426" xlink:href="biib-20200930.xsd#biib_NightstarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4fd1bbbe-a192-435a-81cf-399f62e6a753" xlink:to="loc_biib_NightstarMember_2e2eba40-66c7-4934-bf2f-c0225cc4e426" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/BusinessAcquisitionDetails" xlink:type="simple" xlink:href="biib-20200930.xsd#BusinessAcquisitionDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/BusinessAcquisitionDetails" xlink:type="extended" id="i08cf2230d5b847f28f8b722e5f9de807_BusinessAcquisitionDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_f4d75d48-189b-4c6c-bcb1-bc9c5432df08" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_8b756ab3-3f70-4b17-afff-479b49d42f53" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f4d75d48-189b-4c6c-bcb1-bc9c5432df08" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_8b756ab3-3f70-4b17-afff-479b49d42f53" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_d2a8f74c-5145-4511-9289-3123569ce071" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f4d75d48-189b-4c6c-bcb1-bc9c5432df08" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_d2a8f74c-5145-4511-9289-3123569ce071" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_ac30bfe4-c6ba-43e2-b5dd-c0a5973a0881" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f4d75d48-189b-4c6c-bcb1-bc9c5432df08" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_ac30bfe4-c6ba-43e2-b5dd-c0a5973a0881" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_3d840669-1e92-43ba-ba90-9fa71afed1d8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f4d75d48-189b-4c6c-bcb1-bc9c5432df08" xlink:to="loc_us-gaap_Goodwill_3d840669-1e92-43ba-ba90-9fa71afed1d8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_9db3ddb7-6fbe-445f-a089-1c9031f6f91a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f4d75d48-189b-4c6c-bcb1-bc9c5432df08" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_9db3ddb7-6fbe-445f-a089-1c9031f6f91a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets_3550f40b-9522-465d-aeb3-7f55b87f1983" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f4d75d48-189b-4c6c-bcb1-bc9c5432df08" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets_3550f40b-9522-465d-aeb3-7f55b87f1983" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_160f5e33-e879-42ed-bd3b-c4329c0ca85d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f4d75d48-189b-4c6c-bcb1-bc9c5432df08" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_160f5e33-e879-42ed-bd3b-c4329c0ca85d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_04c9e3df-0cc5-4154-ad92-d6bc1beaa33b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f4d75d48-189b-4c6c-bcb1-bc9c5432df08" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_04c9e3df-0cc5-4154-ad92-d6bc1beaa33b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_eb16adf4-ba9a-46dd-b2b0-de5fa0efd75c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_04c9e3df-0cc5-4154-ad92-d6bc1beaa33b" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_eb16adf4-ba9a-46dd-b2b0-de5fa0efd75c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_eb16adf4-ba9a-46dd-b2b0-de5fa0efd75c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_eb16adf4-ba9a-46dd-b2b0-de5fa0efd75c" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_eb16adf4-ba9a-46dd-b2b0-de5fa0efd75c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_909d0f74-e5a2-4583-8654-72e7b71e2193" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_eb16adf4-ba9a-46dd-b2b0-de5fa0efd75c" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_909d0f74-e5a2-4583-8654-72e7b71e2193" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NightstarMember_1ae5aed1-8ea0-40ca-9e0f-ebf6024d0f1b" xlink:href="biib-20200930.xsd#biib_NightstarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_909d0f74-e5a2-4583-8654-72e7b71e2193" xlink:to="loc_biib_NightstarMember_1ae5aed1-8ea0-40ca-9e0f-ebf6024d0f1b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/DivestituresDivestitures" xlink:type="simple" xlink:href="biib-20200930.xsd#DivestituresDivestitures"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/DivestituresDivestitures" xlink:type="extended" id="i60c30e618d134a1fbdd49b78bd366e31_DivestituresDivestitures"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/DivestituresDetailsTextual" xlink:type="simple" xlink:href="biib-20200930.xsd#DivestituresDetailsTextual"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/DivestituresDetailsTextual" xlink:type="extended" id="ib3a2316cf8b24938bd6e88303b5b9133_DivestituresDetailsTextual">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_c3f5a359-a2a8-4791-a59e-07cc3b85137d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_9274cc95-d272-46a9-a72a-d07b29d8a587" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_c3f5a359-a2a8-4791-a59e-07cc3b85137d" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_9274cc95-d272-46a9-a72a-d07b29d8a587" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_9d061b98-5e9b-4c1e-ae62-e9c0d0d32fc7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_c3f5a359-a2a8-4791-a59e-07cc3b85137d" xlink:to="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_9d061b98-5e9b-4c1e-ae62-e9c0d0d32fc7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax_70fa8170-5921-4a30-a7de-1612d370629e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_c3f5a359-a2a8-4791-a59e-07cc3b85137d" xlink:to="loc_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax_70fa8170-5921-4a30-a7de-1612d370629e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_eaf6c9af-abf3-4a62-bfe0-48098c00b044" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_c3f5a359-a2a8-4791-a59e-07cc3b85137d" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_eaf6c9af-abf3-4a62-bfe0-48098c00b044" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_1b4ff7af-78bc-4a41-81e0-04e78ac392d8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_c3f5a359-a2a8-4791-a59e-07cc3b85137d" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_1b4ff7af-78bc-4a41-81e0-04e78ac392d8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_d5939d8c-c898-4f2e-9377-a8189a77003c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_c3f5a359-a2a8-4791-a59e-07cc3b85137d" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_d5939d8c-c898-4f2e-9377-a8189a77003c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InventoryrawmaterialssoldtoFUJIFILM_15e0caeb-8324-486f-8893-0fd1016618fc" xlink:href="biib-20200930.xsd#biib_InventoryrawmaterialssoldtoFUJIFILM"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_c3f5a359-a2a8-4791-a59e-07cc3b85137d" xlink:to="loc_biib_InventoryrawmaterialssoldtoFUJIFILM_15e0caeb-8324-486f-8893-0fd1016618fc" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e6e4b236-33f6-40c7-8d64-0b6a74037aed" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_c3f5a359-a2a8-4791-a59e-07cc3b85137d" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e6e4b236-33f6-40c7-8d64-0b6a74037aed" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_e3724472-3b66-405e-ab43-38933011252b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e6e4b236-33f6-40c7-8d64-0b6a74037aed" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_e3724472-3b66-405e-ab43-38933011252b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_e3724472-3b66-405e-ab43-38933011252b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_e3724472-3b66-405e-ab43-38933011252b" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_e3724472-3b66-405e-ab43-38933011252b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_173520b6-2736-40bb-8d30-fc76e951338e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_e3724472-3b66-405e-ab43-38933011252b" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_173520b6-2736-40bb-8d30-fc76e951338e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DenmarkManufacturingOperationsMember_36d9e423-2964-4aea-a6a9-e314e926b2a6" xlink:href="biib-20200930.xsd#biib_DenmarkManufacturingOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_173520b6-2736-40bb-8d30-fc76e951338e" xlink:to="loc_biib_DenmarkManufacturingOperationsMember_36d9e423-2964-4aea-a6a9-e314e926b2a6" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/Revenues" xlink:type="simple" xlink:href="biib-20200930.xsd#Revenues"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/Revenues" xlink:type="extended" id="i2916b3fb217c41edbc702285807d71ba_Revenues"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesTables" xlink:type="simple" xlink:href="biib-20200930.xsd#RevenuesTables"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenuesTables" xlink:type="extended" id="if7b25aef2e3c4434b0375736fa70a596_RevenuesTables"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesbyProductDetails" xlink:type="simple" xlink:href="biib-20200930.xsd#RevenuesbyProductDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenuesbyProductDetails" xlink:type="extended" id="ie16e4dcc403e4bb0a64b4a387af141d4_RevenuesbyProductDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_59b188df-fb97-4745-badf-a7fdf0f22b40" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_d5d27ca1-9b54-46af-a95d-753a17c8f9b1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_59b188df-fb97-4745-badf-a7fdf0f22b40" xlink:to="loc_us-gaap_Revenues_d5d27ca1-9b54-46af-a95d-753a17c8f9b1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_cb543448-a3b1-4565-9960-ad7b3248f3f5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_59b188df-fb97-4745-badf-a7fdf0f22b40" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_cb543448-a3b1-4565-9960-ad7b3248f3f5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_07ccdc80-1769-4832-951e-28c985b149c7" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_cb543448-a3b1-4565-9960-ad7b3248f3f5" xlink:to="loc_srt_ProductOrServiceAxis_07ccdc80-1769-4832-951e-28c985b149c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_07ccdc80-1769-4832-951e-28c985b149c7_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_07ccdc80-1769-4832-951e-28c985b149c7" xlink:to="loc_srt_ProductsAndServicesDomain_07ccdc80-1769-4832-951e-28c985b149c7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_199d3346-b5a8-4820-95a1-21e8cf8cbfce" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_07ccdc80-1769-4832-951e-28c985b149c7" xlink:to="loc_srt_ProductsAndServicesDomain_199d3346-b5a8-4820-95a1-21e8cf8cbfce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FumarateMember_b280111d-948d-4e1c-a091-c53d3d3608aa" xlink:href="biib-20200930.xsd#biib_FumarateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_199d3346-b5a8-4820-95a1-21e8cf8cbfce" xlink:to="loc_biib_FumarateMember_b280111d-948d-4e1c-a091-c53d3d3608aa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InterferonMember_c1503061-21f4-42bd-94d2-a6a09ac81bd1" xlink:href="biib-20200930.xsd#biib_InterferonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_199d3346-b5a8-4820-95a1-21e8cf8cbfce" xlink:to="loc_biib_InterferonMember_c1503061-21f4-42bd-94d2-a6a09ac81bd1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TysabriProductMember_8d187006-3b97-455f-b64e-477bb7f7e7f7" xlink:href="biib-20200930.xsd#biib_TysabriProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_199d3346-b5a8-4820-95a1-21e8cf8cbfce" xlink:to="loc_biib_TysabriProductMember_8d187006-3b97-455f-b64e-477bb7f7e7f7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FAMPYRAMember_6d76bd9c-37d0-4cb7-9648-787bc63853ae" xlink:href="biib-20200930.xsd#biib_FAMPYRAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_199d3346-b5a8-4820-95a1-21e8cf8cbfce" xlink:to="loc_biib_FAMPYRAMember_6d76bd9c-37d0-4cb7-9648-787bc63853ae" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ZINBRYTAMember_12c63b78-569d-49de-a036-9c6e3e86c741" xlink:href="biib-20200930.xsd#biib_ZINBRYTAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_199d3346-b5a8-4820-95a1-21e8cf8cbfce" xlink:to="loc_biib_ZINBRYTAMember_12c63b78-569d-49de-a036-9c6e3e86c741" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MSProductRevenuesMember_6b468203-238b-4791-a1d1-89aa2b6ae00e" xlink:href="biib-20200930.xsd#biib_MSProductRevenuesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_199d3346-b5a8-4820-95a1-21e8cf8cbfce" xlink:to="loc_biib_MSProductRevenuesMember_6b468203-238b-4791-a1d1-89aa2b6ae00e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SPINRAZAMember_44cdf1a4-fcd8-4495-ad23-2afcefc0394d" xlink:href="biib-20200930.xsd#biib_SPINRAZAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_199d3346-b5a8-4820-95a1-21e8cf8cbfce" xlink:to="loc_biib_SPINRAZAMember_44cdf1a4-fcd8-4495-ad23-2afcefc0394d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BENEPALIMember_0232bc82-1011-4509-be1b-6ab36a4959e6" xlink:href="biib-20200930.xsd#biib_BENEPALIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_199d3346-b5a8-4820-95a1-21e8cf8cbfce" xlink:to="loc_biib_BENEPALIMember_0232bc82-1011-4509-be1b-6ab36a4959e6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IMRALDIMember_570917fb-06e5-4262-98b4-79343478a7c0" xlink:href="biib-20200930.xsd#biib_IMRALDIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_199d3346-b5a8-4820-95a1-21e8cf8cbfce" xlink:to="loc_biib_IMRALDIMember_570917fb-06e5-4262-98b4-79343478a7c0" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FLIXABIMember_79ebdf56-ee59-4fc9-bb71-76a17c793c91" xlink:href="biib-20200930.xsd#biib_FLIXABIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_199d3346-b5a8-4820-95a1-21e8cf8cbfce" xlink:to="loc_biib_FLIXABIMember_79ebdf56-ee59-4fc9-bb71-76a17c793c91" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BiosimilarsMember_32d6abe0-fd9d-4687-8b05-b12f01c371a1" xlink:href="biib-20200930.xsd#biib_BiosimilarsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_199d3346-b5a8-4820-95a1-21e8cf8cbfce" xlink:to="loc_biib_BiosimilarsMember_32d6abe0-fd9d-4687-8b05-b12f01c371a1" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FUMADERMMember_e6d06810-da0e-43ca-9c19-fd4aae3d01b1" xlink:href="biib-20200930.xsd#biib_FUMADERMMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_199d3346-b5a8-4820-95a1-21e8cf8cbfce" xlink:to="loc_biib_FUMADERMMember_e6d06810-da0e-43ca-9c19-fd4aae3d01b1" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_1dac7a53-4278-4647-8266-fcd861eb0ec6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_199d3346-b5a8-4820-95a1-21e8cf8cbfce" xlink:to="loc_us-gaap_ProductMember_1dac7a53-4278-4647-8266-fcd861eb0ec6" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_8a07a6ad-b024-4ce1-8d47-1d426c0bdcc8" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_cb543448-a3b1-4565-9960-ad7b3248f3f5" xlink:to="loc_srt_StatementGeographicalAxis_8a07a6ad-b024-4ce1-8d47-1d426c0bdcc8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_8a07a6ad-b024-4ce1-8d47-1d426c0bdcc8_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_8a07a6ad-b024-4ce1-8d47-1d426c0bdcc8" xlink:to="loc_srt_SegmentGeographicalDomain_8a07a6ad-b024-4ce1-8d47-1d426c0bdcc8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_b38f1ab8-8a21-4ce7-949d-83dbe4c8744a" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_8a07a6ad-b024-4ce1-8d47-1d426c0bdcc8" xlink:to="loc_srt_SegmentGeographicalDomain_b38f1ab8-8a21-4ce7-949d-83dbe4c8744a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_a6e962a1-aabf-49bc-b53a-818ee3f6c02a" xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_b38f1ab8-8a21-4ce7-949d-83dbe4c8744a" xlink:to="loc_country_US_a6e962a1-aabf-49bc-b53a-818ee3f6c02a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_fb2156a1-ede4-4345-acfa-8d013055a938" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_b38f1ab8-8a21-4ce7-949d-83dbe4c8744a" xlink:to="loc_us-gaap_NonUsMember_fb2156a1-ede4-4345-acfa-8d013055a938" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ReservesforDiscountsandAllowancesDetails1" xlink:type="simple" xlink:href="biib-20200930.xsd#ReservesforDiscountsandAllowancesDetails1"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ReservesforDiscountsandAllowancesDetails1" xlink:type="extended" id="ic155572aa49f485abdeb5b22cbff94ea_ReservesforDiscountsandAllowancesDetails1">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_34b85f44-80fa-4299-9fe6-ab0b1d737100" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_921107ec-69be-4d39-beef-7ad192d9a2a9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_34b85f44-80fa-4299-9fe6-ab0b1d737100" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_921107ec-69be-4d39-beef-7ad192d9a2a9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_9f9fa918-7a74-42c1-871e-f2c0979cb3b1" xlink:href="biib-20200930.xsd#biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_34b85f44-80fa-4299-9fe6-ab0b1d737100" xlink:to="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_9f9fa918-7a74-42c1-871e-f2c0979cb3b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_68480d82-6092-4e9b-8363-e349bd1ddbd3" xlink:href="biib-20200930.xsd#biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_34b85f44-80fa-4299-9fe6-ab0b1d737100" xlink:to="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_68480d82-6092-4e9b-8363-e349bd1ddbd3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_6b4d6884-2135-45a3-8348-a2ff7e47f7a8" xlink:href="biib-20200930.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_34b85f44-80fa-4299-9fe6-ab0b1d737100" xlink:to="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_6b4d6884-2135-45a3-8348-a2ff7e47f7a8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_3de5aa28-34bd-49f0-9b23-7bbe6d4b8c1a" xlink:href="biib-20200930.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_34b85f44-80fa-4299-9fe6-ab0b1d737100" xlink:to="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_3de5aa28-34bd-49f0-9b23-7bbe6d4b8c1a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_9f9b7727-26cb-4d92-8e26-d702a26df211" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_d7560ab8-c200-4586-86b5-5642a7e48504" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_34b85f44-80fa-4299-9fe6-ab0b1d737100" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_d7560ab8-c200-4586-86b5-5642a7e48504" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_8314a720-244e-4f7a-97f3-f282444db63b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_d7560ab8-c200-4586-86b5-5642a7e48504" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_8314a720-244e-4f7a-97f3-f282444db63b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_8314a720-244e-4f7a-97f3-f282444db63b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_8314a720-244e-4f7a-97f3-f282444db63b" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_8314a720-244e-4f7a-97f3-f282444db63b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_8078ab82-fd94-4837-bb13-1242ca618a46" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_8314a720-244e-4f7a-97f3-f282444db63b" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_8078ab82-fd94-4837-bb13-1242ca618a46" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReserveforCashDiscountsMember_90f3d801-2b30-4acf-97b7-d45394a67f67" xlink:href="biib-20200930.xsd#biib_ReserveforCashDiscountsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_8078ab82-fd94-4837-bb13-1242ca618a46" xlink:to="loc_biib_ReserveforCashDiscountsMember_90f3d801-2b30-4acf-97b7-d45394a67f67" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ContractualAdjustmentsMember_2886ef9c-a745-4891-8a3d-1fceca5cbfed" xlink:href="biib-20200930.xsd#biib_ContractualAdjustmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_8078ab82-fd94-4837-bb13-1242ca618a46" xlink:to="loc_biib_ContractualAdjustmentsMember_2886ef9c-a745-4891-8a3d-1fceca5cbfed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesReturnsAndAllowancesMember_016ce499-cb7a-484a-81ef-19511da68cfb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SalesReturnsAndAllowancesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_8078ab82-fd94-4837-bb13-1242ca618a46" xlink:to="loc_us-gaap_SalesReturnsAndAllowancesMember_016ce499-cb7a-484a-81ef-19511da68cfb" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ReservesforDiscountsandAllowancesDetails2" xlink:type="simple" xlink:href="biib-20200930.xsd#ReservesforDiscountsandAllowancesDetails2"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ReservesforDiscountsandAllowancesDetails2" xlink:type="extended" id="i188da52e43a34999847bb4405b21f7ba_ReservesforDiscountsandAllowancesDetails2">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_1db4b5b8-aa6b-4090-9f8a-dfce9fb421a0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_14c54d87-029d-4ac4-9edf-38996bd24f4d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1db4b5b8-aa6b-4090-9f8a-dfce9fb421a0" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_14c54d87-029d-4ac4-9edf-38996bd24f4d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_587747a8-e7a8-4e17-a137-188025414833" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1db4b5b8-aa6b-4090-9f8a-dfce9fb421a0" xlink:to="loc_us-gaap_StatementTable_587747a8-e7a8-4e17-a137-188025414833" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_fc98a389-6596-4bba-bd45-d8430e7b6d61" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_587747a8-e7a8-4e17-a137-188025414833" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_fc98a389-6596-4bba-bd45-d8430e7b6d61" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_fc98a389-6596-4bba-bd45-d8430e7b6d61_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_fc98a389-6596-4bba-bd45-d8430e7b6d61" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_fc98a389-6596-4bba-bd45-d8430e7b6d61_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_f21ade67-9d3c-483e-a962-d2d80890a2e2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_fc98a389-6596-4bba-bd45-d8430e7b6d61" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_f21ade67-9d3c-483e-a962-d2d80890a2e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_47cf1ea1-7337-47ab-9eec-9333cfd66b2d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_f21ade67-9d3c-483e-a962-d2d80890a2e2" xlink:to="loc_us-gaap_AccountsReceivableMember_47cf1ea1-7337-47ab-9eec-9333cfd66b2d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_5c3c2550-2ef7-4d88-86d2-9f923494b74e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_f21ade67-9d3c-483e-a962-d2d80890a2e2" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_5c3c2550-2ef7-4d88-86d2-9f923494b74e" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesfromAntiCD20TherapeuticProgramsDetails" xlink:type="simple" xlink:href="biib-20200930.xsd#RevenuesfromAntiCD20TherapeuticProgramsDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenuesfromAntiCD20TherapeuticProgramsDetails" xlink:type="extended" id="iaa46b31095f94036be698e836c34f49f_RevenuesfromAntiCD20TherapeuticProgramsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_7023968b-8bc4-45a1-9209-73afbf8ebd5b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareOfCoPromotionProfits_5256cd5e-edfc-4cde-92b8-2151e77781c1" xlink:href="biib-20200930.xsd#biib_ShareOfCoPromotionProfits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_7023968b-8bc4-45a1-9209-73afbf8ebd5b" xlink:to="loc_biib_ShareOfCoPromotionProfits_5256cd5e-edfc-4cde-92b8-2151e77781c1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms_1d987b2b-e61a-423f-b950-cf1c0fbaee0b" xlink:href="biib-20200930.xsd#biib_OtherrevenuesfromantiCD20therapeuticprograms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_7023968b-8bc4-45a1-9209-73afbf8ebd5b" xlink:to="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms_1d987b2b-e61a-423f-b950-cf1c0fbaee0b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_c7321cb4-8dd8-47ef-9fcb-832e64abdc25" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_7023968b-8bc4-45a1-9209-73afbf8ebd5b" xlink:to="loc_us-gaap_Revenues_c7321cb4-8dd8-47ef-9fcb-832e64abdc25" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_a95f4baf-021d-45b7-bd9a-6fd90e8c93b3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_7023968b-8bc4-45a1-9209-73afbf8ebd5b" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_a95f4baf-021d-45b7-bd9a-6fd90e8c93b3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_46eda230-5873-4b9a-bffd-af486315fa58" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_a95f4baf-021d-45b7-bd9a-6fd90e8c93b3" xlink:to="loc_srt_ProductOrServiceAxis_46eda230-5873-4b9a-bffd-af486315fa58" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_46eda230-5873-4b9a-bffd-af486315fa58_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_46eda230-5873-4b9a-bffd-af486315fa58" xlink:to="loc_srt_ProductsAndServicesDomain_46eda230-5873-4b9a-bffd-af486315fa58_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_22579e70-bbc0-48c3-96e0-cb7ba9f4bbdb" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_46eda230-5873-4b9a-bffd-af486315fa58" xlink:to="loc_srt_ProductsAndServicesDomain_22579e70-bbc0-48c3-96e0-cb7ba9f4bbdb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_3f9330c3-c93b-4d78-a304-f35cc713c54b" xlink:href="biib-20200930.xsd#biib_Revenuesfromanticd20therapeuticprogramsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_22579e70-bbc0-48c3-96e0-cb7ba9f4bbdb" xlink:to="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_3f9330c3-c93b-4d78-a304-f35cc713c54b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_30e004ec-2ad1-4b97-89df-3eed2916de41" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_a95f4baf-021d-45b7-bd9a-6fd90e8c93b3" xlink:to="loc_srt_MajorCustomersAxis_30e004ec-2ad1-4b97-89df-3eed2916de41" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_30e004ec-2ad1-4b97-89df-3eed2916de41_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_30e004ec-2ad1-4b97-89df-3eed2916de41" xlink:to="loc_srt_NameOfMajorCustomerDomain_30e004ec-2ad1-4b97-89df-3eed2916de41_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_cc8b69e6-be78-4d60-a38d-140359669f0b" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_30e004ec-2ad1-4b97-89df-3eed2916de41" xlink:to="loc_srt_NameOfMajorCustomerDomain_cc8b69e6-be78-4d60-a38d-140359669f0b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RocheGroupGenentechMember_b527a3bd-7a63-425d-b99f-461f4cf21cb2" xlink:href="biib-20200930.xsd#biib_RocheGroupGenentechMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_cc8b69e6-be78-4d60-a38d-140359669f0b" xlink:to="loc_biib_RocheGroupGenentechMember_b527a3bd-7a63-425d-b99f-461f4cf21cb2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherRevenuesDetails" xlink:type="simple" xlink:href="biib-20200930.xsd#OtherRevenuesDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/OtherRevenuesDetails" xlink:type="extended" id="id2a8c5d366e745d8a95273a65af47c88_OtherRevenuesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_725cdab2-b8b1-46a8-8417-4de5b06a57e4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_fc32c518-0de7-4b55-9255-3f2c7a2e6f12" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_725cdab2-b8b1-46a8-8417-4de5b06a57e4" xlink:to="loc_us-gaap_Revenues_fc32c518-0de7-4b55-9255-3f2c7a2e6f12" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_1d7e14eb-df1b-4ba7-9a3d-7d3f3f8c09ed" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_725cdab2-b8b1-46a8-8417-4de5b06a57e4" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_1d7e14eb-df1b-4ba7-9a3d-7d3f3f8c09ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_bfbc5de7-851a-4515-b0aa-ee9b558faff8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_725cdab2-b8b1-46a8-8417-4de5b06a57e4" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_bfbc5de7-851a-4515-b0aa-ee9b558faff8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_59de4172-a930-44da-8eaa-54ef91d2ede6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_bfbc5de7-851a-4515-b0aa-ee9b558faff8" xlink:to="loc_us-gaap_TypeOfArrangementAxis_59de4172-a930-44da-8eaa-54ef91d2ede6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_59de4172-a930-44da-8eaa-54ef91d2ede6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_59de4172-a930-44da-8eaa-54ef91d2ede6" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_59de4172-a930-44da-8eaa-54ef91d2ede6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4204154c-7f78-4375-b240-967d0f013f6c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_59de4172-a930-44da-8eaa-54ef91d2ede6" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4204154c-7f78-4375-b240-967d0f013f6c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_95722ecf-ec3c-4919-a238-f527ca5334e9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4204154c-7f78-4375-b240-967d0f013f6c" xlink:to="loc_us-gaap_CollaborativeArrangementMember_95722ecf-ec3c-4919-a238-f527ca5334e9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_3e8c4a91-c937-4d22-a38e-38a7328cc71b" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_bfbc5de7-851a-4515-b0aa-ee9b558faff8" xlink:to="loc_srt_ProductOrServiceAxis_3e8c4a91-c937-4d22-a38e-38a7328cc71b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_3e8c4a91-c937-4d22-a38e-38a7328cc71b_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_3e8c4a91-c937-4d22-a38e-38a7328cc71b" xlink:to="loc_srt_ProductsAndServicesDomain_3e8c4a91-c937-4d22-a38e-38a7328cc71b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c9d0ea88-c582-4b77-afec-49bcd23dbf3c" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_3e8c4a91-c937-4d22-a38e-38a7328cc71b" xlink:to="loc_srt_ProductsAndServicesDomain_c9d0ea88-c582-4b77-afec-49bcd23dbf3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_6a07dfb7-7824-4196-832e-df0e6759b0a8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c9d0ea88-c582-4b77-afec-49bcd23dbf3c" xlink:to="loc_us-gaap_RoyaltyMember_6a07dfb7-7824-4196-832e-df0e6759b0a8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OthercorporaterevenuesMember_add0d0dd-4a1c-49a3-8abc-d18eeb961bf1" xlink:href="biib-20200930.xsd#biib_OthercorporaterevenuesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c9d0ea88-c582-4b77-afec-49bcd23dbf3c" xlink:to="loc_biib_OthercorporaterevenuesMember_add0d0dd-4a1c-49a3-8abc-d18eeb961bf1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_e85d6672-e00f-4953-bcf5-fabae562da04" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c9d0ea88-c582-4b77-afec-49bcd23dbf3c" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_e85d6672-e00f-4953-bcf5-fabae562da04" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_43b72e8a-2dec-4f40-ae22-e5d697e1a041" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_bfbc5de7-851a-4515-b0aa-ee9b558faff8" xlink:to="loc_srt_MajorCustomersAxis_43b72e8a-2dec-4f40-ae22-e5d697e1a041" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_43b72e8a-2dec-4f40-ae22-e5d697e1a041_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_43b72e8a-2dec-4f40-ae22-e5d697e1a041" xlink:to="loc_srt_NameOfMajorCustomerDomain_43b72e8a-2dec-4f40-ae22-e5d697e1a041_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_46d4cfee-3578-4c45-abac-7a74e60c2fc2" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_43b72e8a-2dec-4f40-ae22-e5d697e1a041" xlink:to="loc_srt_NameOfMajorCustomerDomain_46d4cfee-3578-4c45-abac-7a74e60c2fc2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_a2acf4ea-177a-47dd-963e-ab4aeeb08838" xlink:href="biib-20200930.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_46d4cfee-3578-4c45-abac-7a74e60c2fc2" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_a2acf4ea-177a-47dd-963e-ab4aeeb08838" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ZINBRYTAMember_a27265a0-feff-4494-b606-a15bf7a30f02" xlink:href="biib-20200930.xsd#biib_ZINBRYTAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_46d4cfee-3578-4c45-abac-7a74e60c2fc2" xlink:to="loc_biib_ZINBRYTAMember_a27265a0-feff-4494-b606-a15bf7a30f02" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesDetailsTextual" xlink:type="simple" xlink:href="biib-20200930.xsd#RevenuesDetailsTextual"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenuesDetailsTextual" xlink:type="extended" id="ib893f54652364f52bd1fb7c2cd9e3c26_RevenuesDetailsTextual">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_5cf1aaa7-7535-4989-9904-381d5cf21ddf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_dcbaf542-93d5-47bb-8bb0-6edbcb30f3d4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_5cf1aaa7-7535-4989-9904-381d5cf21ddf" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_dcbaf542-93d5-47bb-8bb0-6edbcb30f3d4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_aaa4b1be-1fec-4fff-815f-6403fb333c4c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_5cf1aaa7-7535-4989-9904-381d5cf21ddf" xlink:to="loc_us-gaap_Revenues_aaa4b1be-1fec-4fff-815f-6403fb333c4c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors_cf761ef1-d975-4bc9-8d9a-f2cbe49c6a54" xlink:href="biib-20200930.xsd#biib_EntityWidePercentageOfRevenueFromMajorDistributors"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_5cf1aaa7-7535-4989-9904-381d5cf21ddf" xlink:to="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors_cf761ef1-d975-4bc9-8d9a-f2cbe49c6a54" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NumberOfWholesalers_070366b9-ba95-4449-ac90-14de96f6960a" xlink:href="biib-20200930.xsd#biib_NumberOfWholesalers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_5cf1aaa7-7535-4989-9904-381d5cf21ddf" xlink:to="loc_biib_NumberOfWholesalers_070366b9-ba95-4449-ac90-14de96f6960a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_f6c5c658-7f71-42bb-8b22-5d9ce3191f78" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_5cf1aaa7-7535-4989-9904-381d5cf21ddf" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_f6c5c658-7f71-42bb-8b22-5d9ce3191f78" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_04b7dadc-8d57-4b9f-a25f-5532e1927ed5" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_f6c5c658-7f71-42bb-8b22-5d9ce3191f78" xlink:to="loc_srt_ProductOrServiceAxis_04b7dadc-8d57-4b9f-a25f-5532e1927ed5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_04b7dadc-8d57-4b9f-a25f-5532e1927ed5_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_04b7dadc-8d57-4b9f-a25f-5532e1927ed5" xlink:to="loc_srt_ProductsAndServicesDomain_04b7dadc-8d57-4b9f-a25f-5532e1927ed5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6cbb554f-e253-479c-9c74-8e1d51fcd176" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_04b7dadc-8d57-4b9f-a25f-5532e1927ed5" xlink:to="loc_srt_ProductsAndServicesDomain_6cbb554f-e253-479c-9c74-8e1d51fcd176" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OthercorporaterevenuesMember_d5bb1c22-d2b1-4a84-aa2e-bcd775afe37c" xlink:href="biib-20200930.xsd#biib_OthercorporaterevenuesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_6cbb554f-e253-479c-9c74-8e1d51fcd176" xlink:to="loc_biib_OthercorporaterevenuesMember_d5bb1c22-d2b1-4a84-aa2e-bcd775afe37c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_e766b28e-f0b4-40a8-8051-f9e3d60d5903" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_6cbb554f-e253-479c-9c74-8e1d51fcd176" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_e766b28e-f0b4-40a8-8051-f9e3d60d5903" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_5ac4cd68-3790-4b15-b6ec-2403743809dc" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_f6c5c658-7f71-42bb-8b22-5d9ce3191f78" xlink:to="loc_srt_MajorCustomersAxis_5ac4cd68-3790-4b15-b6ec-2403743809dc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_5ac4cd68-3790-4b15-b6ec-2403743809dc_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_5ac4cd68-3790-4b15-b6ec-2403743809dc" xlink:to="loc_srt_NameOfMajorCustomerDomain_5ac4cd68-3790-4b15-b6ec-2403743809dc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_aad12712-dea4-473e-8185-b1dc8dfc4268" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_5ac4cd68-3790-4b15-b6ec-2403743809dc" xlink:to="loc_srt_NameOfMajorCustomerDomain_aad12712-dea4-473e-8185-b1dc8dfc4268" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DistributorOneMember_5c2a9150-f93b-445d-a568-f1a74421cad3" xlink:href="biib-20200930.xsd#biib_DistributorOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_aad12712-dea4-473e-8185-b1dc8dfc4268" xlink:to="loc_biib_DistributorOneMember_5c2a9150-f93b-445d-a568-f1a74421cad3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DistributorTwoMember_59fba0c9-b3df-4e37-a041-be8758e80a68" xlink:href="biib-20200930.xsd#biib_DistributorTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_aad12712-dea4-473e-8185-b1dc8dfc4268" xlink:to="loc_biib_DistributorTwoMember_59fba0c9-b3df-4e37-a041-be8758e80a68" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BioverativMember_7723fe0d-b390-4a93-b829-9dc54b908557" xlink:href="biib-20200930.xsd#biib_BioverativMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_aad12712-dea4-473e-8185-b1dc8dfc4268" xlink:to="loc_biib_BioverativMember_7723fe0d-b390-4a93-b829-9dc54b908557" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ContractManufacturingCustomerMember_bed550e9-310d-44e2-b8ab-c5761aedeb74" xlink:href="biib-20200930.xsd#biib_ContractManufacturingCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_aad12712-dea4-473e-8185-b1dc8dfc4268" xlink:to="loc_biib_ContractManufacturingCustomerMember_bed550e9-310d-44e2-b8ab-c5761aedeb74" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/Inventory" xlink:type="simple" xlink:href="biib-20200930.xsd#Inventory"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/Inventory" xlink:type="extended" id="id5abd0e8d6e145f4b01ce81779720a76_Inventory"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryTables" xlink:type="simple" xlink:href="biib-20200930.xsd#InventoryTables"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/InventoryTables" xlink:type="extended" id="id3ad79c3b72247b894bcc069e76fa706_InventoryTables"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryDetails" xlink:type="simple" xlink:href="biib-20200930.xsd#InventoryDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/InventoryDetails" xlink:type="extended" id="i319478ec135a42bfa284250fbfe66dd2_InventoryDetails"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwill" xlink:type="simple" xlink:href="biib-20200930.xsd#IntangibleAssetsandGoodwill"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsandGoodwill" xlink:type="extended" id="i2f9ea598627a4bf895b5962dcbcbf7c4_IntangibleAssetsandGoodwill"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables" xlink:type="simple" xlink:href="biib-20200930.xsd#IntangibleAssetsandGoodwillTables"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables" xlink:type="extended" id="i4b17e6547d8d4cb0a97c3865146bd9ec_IntangibleAssetsandGoodwillTables"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails" xlink:type="simple" xlink:href="biib-20200930.xsd#IntangibleAssetsandGoodwillDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails" xlink:type="extended" id="ib0396a05016a486f8df2d54f30ac32a6_IntangibleAssetsandGoodwillDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_5bc1795f-50d9-41e1-8103-19f873f72efd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_3504b9db-bfe8-46d9-9cc5-8ad1e6a7f391" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_5bc1795f-50d9-41e1-8103-19f873f72efd" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_3504b9db-bfe8-46d9-9cc5-8ad1e6a7f391" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_ad94037e-1e9e-4580-895c-9f8ecca86650" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_5bc1795f-50d9-41e1-8103-19f873f72efd" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_ad94037e-1e9e-4580-895c-9f8ecca86650" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_be11953f-0510-4543-a406-2980b63ef929" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_ad94037e-1e9e-4580-895c-9f8ecca86650" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_be11953f-0510-4543-a406-2980b63ef929" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IndefiniteLivedIntangibleAssetsUsefulLife_34e6e80d-955a-48e6-9b71-13fb7edb6980" xlink:href="biib-20200930.xsd#biib_IndefiniteLivedIntangibleAssetsUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_ad94037e-1e9e-4580-895c-9f8ecca86650" xlink:to="loc_biib_IndefiniteLivedIntangibleAssetsUsefulLife_34e6e80d-955a-48e6-9b71-13fb7edb6980" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_0ba637f5-6889-475b-83fc-2e3f64e6c363" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_ad94037e-1e9e-4580-895c-9f8ecca86650" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_0ba637f5-6889-475b-83fc-2e3f64e6c363" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_f01e424c-ab75-4b73-9920-c3f30e3c4bdd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_ad94037e-1e9e-4580-895c-9f8ecca86650" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_f01e424c-ab75-4b73-9920-c3f30e3c4bdd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_af6564ae-45a8-4668-8bfc-cebbf23b05a2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_ad94037e-1e9e-4580-895c-9f8ecca86650" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_af6564ae-45a8-4668-8bfc-cebbf23b05a2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_05b3c575-cb09-4b4a-91bf-fd6e75fdd9b7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_ad94037e-1e9e-4580-895c-9f8ecca86650" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_05b3c575-cb09-4b4a-91bf-fd6e75fdd9b7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_531e7059-ce77-472f-8c57-45e129c11838" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_ad94037e-1e9e-4580-895c-9f8ecca86650" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_531e7059-ce77-472f-8c57-45e129c11838" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_c28e37e5-7b93-40a5-abdb-a241084e5c2f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_ad94037e-1e9e-4580-895c-9f8ecca86650" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_c28e37e5-7b93-40a5-abdb-a241084e5c2f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_8771fd86-6796-4c56-bab8-5f08578e9747" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_ad94037e-1e9e-4580-895c-9f8ecca86650" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_8771fd86-6796-4c56-bab8-5f08578e9747" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_79a6af86-a8ea-4bcf-9551-609d9bdb873d" xlink:href="biib-20200930.xsd#biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_5bc1795f-50d9-41e1-8103-19f873f72efd" xlink:to="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_79a6af86-a8ea-4bcf-9551-609d9bdb873d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_4b9d78b0-729d-4864-8dd8-e8d485ed3aa1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_5bc1795f-50d9-41e1-8103-19f873f72efd" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_4b9d78b0-729d-4864-8dd8-e8d485ed3aa1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_c8bfae87-f514-4605-bb0e-17198a2118cb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_5bc1795f-50d9-41e1-8103-19f873f72efd" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_c8bfae87-f514-4605-bb0e-17198a2118cb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_db52ed6d-07e3-43a1-99d0-b19b3765026a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_5bc1795f-50d9-41e1-8103-19f873f72efd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_db52ed6d-07e3-43a1-99d0-b19b3765026a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_4be0c0c0-bf32-444e-b7b0-37035fcf58ef" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_5bc1795f-50d9-41e1-8103-19f873f72efd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_4be0c0c0-bf32-444e-b7b0-37035fcf58ef" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_94826f71-0ae3-4af7-8ccf-e0f9a8a12e4a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_5bc1795f-50d9-41e1-8103-19f873f72efd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_94826f71-0ae3-4af7-8ccf-e0f9a8a12e4a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_6fe233cb-4358-4849-bb04-11c049271fe2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_5bc1795f-50d9-41e1-8103-19f873f72efd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_6fe233cb-4358-4849-bb04-11c049271fe2" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_e1736a1a-71ba-4910-a34e-073d31fbc466" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_5bc1795f-50d9-41e1-8103-19f873f72efd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_e1736a1a-71ba-4910-a34e-073d31fbc466" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_b96be0bc-cb68-43c5-8d1a-6acdee6585f5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_5bc1795f-50d9-41e1-8103-19f873f72efd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_b96be0bc-cb68-43c5-8d1a-6acdee6585f5" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_f6f95c93-30b7-4d27-bf60-3438102d921c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_5bc1795f-50d9-41e1-8103-19f873f72efd" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_f6f95c93-30b7-4d27-bf60-3438102d921c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchanddevelopmentassetAxis_ceb5bcce-9340-44aa-b1dd-a6a2846f2cc8" xlink:href="biib-20200930.xsd#biib_ResearchanddevelopmentassetAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_f6f95c93-30b7-4d27-bf60-3438102d921c" xlink:to="loc_biib_ResearchanddevelopmentassetAxis_ceb5bcce-9340-44aa-b1dd-a6a2846f2cc8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchanddevelopmentassetDomain_ceb5bcce-9340-44aa-b1dd-a6a2846f2cc8_default" xlink:href="biib-20200930.xsd#biib_ResearchanddevelopmentassetDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_ResearchanddevelopmentassetAxis_ceb5bcce-9340-44aa-b1dd-a6a2846f2cc8" xlink:to="loc_biib_ResearchanddevelopmentassetDomain_ceb5bcce-9340-44aa-b1dd-a6a2846f2cc8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchanddevelopmentassetDomain_ce66f39c-5a4e-4b92-9db8-e3ee9ded26d3" xlink:href="biib-20200930.xsd#biib_ResearchanddevelopmentassetDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_ResearchanddevelopmentassetAxis_ceb5bcce-9340-44aa-b1dd-a6a2846f2cc8" xlink:to="loc_biib_ResearchanddevelopmentassetDomain_ce66f39c-5a4e-4b92-9db8-e3ee9ded26d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TGNMember_d4a58862-5804-4783-abe6-6a2de4792f31" xlink:href="biib-20200930.xsd#biib_TGNMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ResearchanddevelopmentassetDomain_ce66f39c-5a4e-4b92-9db8-e3ee9ded26d3" xlink:to="loc_biib_TGNMember_d4a58862-5804-4783-abe6-6a2de4792f31" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_bb48a466-ec0c-48ee-b5f3-9f3cbef36f5f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_f6f95c93-30b7-4d27-bf60-3438102d921c" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_bb48a466-ec0c-48ee-b5f3-9f3cbef36f5f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_bb48a466-ec0c-48ee-b5f3-9f3cbef36f5f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_bb48a466-ec0c-48ee-b5f3-9f3cbef36f5f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_bb48a466-ec0c-48ee-b5f3-9f3cbef36f5f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e2329fb5-91d0-4fe7-a098-5dfe3bfedae1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_bb48a466-ec0c-48ee-b5f3-9f3cbef36f5f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e2329fb5-91d0-4fe7-a098-5dfe3bfedae1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NightstarMember_ed9306a8-a41d-4bcf-834f-a3c732cba3e5" xlink:href="biib-20200930.xsd#biib_NightstarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e2329fb5-91d0-4fe7-a098-5dfe3bfedae1" xlink:to="loc_biib_NightstarMember_ed9306a8-a41d-4bcf-834f-a3c732cba3e5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_8f33b9da-3758-49c3-b6bc-0e72a1cd61b3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_f6f95c93-30b7-4d27-bf60-3438102d921c" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_8f33b9da-3758-49c3-b6bc-0e72a1cd61b3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8f33b9da-3758-49c3-b6bc-0e72a1cd61b3_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_8f33b9da-3758-49c3-b6bc-0e72a1cd61b3" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8f33b9da-3758-49c3-b6bc-0e72a1cd61b3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_df851199-eb49-4bab-a66a-4bc909d515f4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_8f33b9da-3758-49c3-b6bc-0e72a1cd61b3" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_df851199-eb49-4bab-a66a-4bc909d515f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_a0375f7c-b947-4ee0-b3ce-7a9047384775" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_df851199-eb49-4bab-a66a-4bc909d515f4" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_a0375f7c-b947-4ee0-b3ce-7a9047384775" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember_94b40aec-2383-4b34-bef7-b28d98e0828e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TrademarksAndTradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_df851199-eb49-4bab-a66a-4bc909d515f4" xlink:to="loc_us-gaap_TrademarksAndTradeNamesMember_94b40aec-2383-4b34-bef7-b28d98e0828e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5d81f936-3d94-4b32-a979-c0042bbf9029" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_f6f95c93-30b7-4d27-bf60-3438102d921c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5d81f936-3d94-4b32-a979-c0042bbf9029" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5d81f936-3d94-4b32-a979-c0042bbf9029_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5d81f936-3d94-4b32-a979-c0042bbf9029" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5d81f936-3d94-4b32-a979-c0042bbf9029_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c133b0b5-9041-4404-875d-af32e40da6dc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5d81f936-3d94-4b32-a979-c0042bbf9029" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c133b0b5-9041-4404-875d-af32e40da6dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_21188deb-923a-4067-9e6c-db77ae2ff976" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c133b0b5-9041-4404-875d-af32e40da6dc" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_21188deb-923a-4067-9e6c-db77ae2ff976" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OutLicensedPatentsMember_d247fa09-b5ca-4bf1-a11d-bd70050d8376" xlink:href="biib-20200930.xsd#biib_OutLicensedPatentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c133b0b5-9041-4404-875d-af32e40da6dc" xlink:to="loc_biib_OutLicensedPatentsMember_d247fa09-b5ca-4bf1-a11d-bd70050d8376" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_1dd9f5df-c87f-42d3-8bec-8e059ff5ef53" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c133b0b5-9041-4404-875d-af32e40da6dc" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_1dd9f5df-c87f-42d3-8bec-8e059ff5ef53" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InLicensedPatentsMember_14e4ab6a-c947-4df5-b566-855b6b5a7e19" xlink:href="biib-20200930.xsd#biib_InLicensedPatentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c133b0b5-9041-4404-875d-af32e40da6dc" xlink:to="loc_biib_InLicensedPatentsMember_14e4ab6a-c947-4df5-b566-855b6b5a7e19" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_b3d9f23e-dcfa-44be-aedb-ef0520bc293d" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_f6f95c93-30b7-4d27-bf60-3438102d921c" xlink:to="loc_srt_ProductOrServiceAxis_b3d9f23e-dcfa-44be-aedb-ef0520bc293d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b3d9f23e-dcfa-44be-aedb-ef0520bc293d_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_b3d9f23e-dcfa-44be-aedb-ef0520bc293d" xlink:to="loc_srt_ProductsAndServicesDomain_b3d9f23e-dcfa-44be-aedb-ef0520bc293d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a4cf3d8c-c122-48e8-a28f-572c09caa658" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_b3d9f23e-dcfa-44be-aedb-ef0520bc293d" xlink:to="loc_srt_ProductsAndServicesDomain_a4cf3d8c-c122-48e8-a28f-572c09caa658" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AVONEXMember_923976a0-872a-4c8c-bb6e-026516debb66" xlink:href="biib-20200930.xsd#biib_AVONEXMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a4cf3d8c-c122-48e8-a28f-572c09caa658" xlink:to="loc_biib_AVONEXMember_923976a0-872a-4c8c-bb6e-026516debb66" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TysabriProductMember_f7a29cf3-da17-4005-bab3-fee4546afb24" xlink:href="biib-20200930.xsd#biib_TysabriProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a4cf3d8c-c122-48e8-a28f-572c09caa658" xlink:to="loc_biib_TysabriProductMember_f7a29cf3-da17-4005-bab3-fee4546afb24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FumarateMember_05f1c647-32d1-4aae-8cf3-39d6510579b2" xlink:href="biib-20200930.xsd#biib_FumarateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a4cf3d8c-c122-48e8-a28f-572c09caa658" xlink:to="loc_biib_FumarateMember_05f1c647-32d1-4aae-8cf3-39d6510579b2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_be65b510-8ccf-4c1d-83a4-b7bbe263337c" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_f6f95c93-30b7-4d27-bf60-3438102d921c" xlink:to="loc_srt_RangeAxis_be65b510-8ccf-4c1d-83a4-b7bbe263337c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_be65b510-8ccf-4c1d-83a4-b7bbe263337c_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_be65b510-8ccf-4c1d-83a4-b7bbe263337c" xlink:to="loc_srt_RangeMember_be65b510-8ccf-4c1d-83a4-b7bbe263337c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b0f0e7de-d8ff-4b51-af18-67b7f484a218" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_be65b510-8ccf-4c1d-83a4-b7bbe263337c" xlink:to="loc_srt_RangeMember_b0f0e7de-d8ff-4b51-af18-67b7f484a218" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_7f0e5ea3-4e41-47ef-ad57-44ab8f6c61b2" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_b0f0e7de-d8ff-4b51-af18-67b7f484a218" xlink:to="loc_srt_MinimumMember_7f0e5ea3-4e41-47ef-ad57-44ab8f6c61b2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f8b02225-54c9-476d-9187-640d4f58a48f" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_b0f0e7de-d8ff-4b51-af18-67b7f484a218" xlink:to="loc_srt_MaximumMember_f8b02225-54c9-476d-9187-640d4f58a48f" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails1" xlink:type="simple" xlink:href="biib-20200930.xsd#IntangibleAssetsandGoodwillDetails1"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails1" xlink:type="extended" id="i89109d2d4f884d65924257ef7c58b2b5_IntangibleAssetsandGoodwillDetails1"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="biib-20200930.xsd#FairValueMeasurements"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurements" xlink:type="extended" id="i35faafa02bf84f8bad55e49cc99c0e19_FairValueMeasurements"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="biib-20200930.xsd#FairValueMeasurementsTables"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:type="extended" id="i0c00b70724974513a2efbf6ba44b55d8_FairValueMeasurementsTables"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="biib-20200930.xsd#FairValueMeasurementsDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:type="extended" id="i05b6195fb24f4c1aacc6e9f62d06f177_FairValueMeasurementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a5875a13-2da0-4f41-a032-e56b8329e2a2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_c8141e61-a204-42c2-a281-cefa5968fb55" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a5875a13-2da0-4f41-a032-e56b8329e2a2" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_c8141e61-a204-42c2-a281-cefa5968fb55" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_86572f6d-d9a7-413d-978a-cb65ac0584cc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_c8141e61-a204-42c2-a281-cefa5968fb55" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_86572f6d-d9a7-413d-978a-cb65ac0584cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_e3865726-bfc8-4b9d-8658-dba64be02e6a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_86572f6d-d9a7-413d-978a-cb65ac0584cc" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_e3865726-bfc8-4b9d-8658-dba64be02e6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_379a0b08-a86f-44dc-9902-d55b420e9676" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_86572f6d-d9a7-413d-978a-cb65ac0584cc" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_379a0b08-a86f-44dc-9902-d55b420e9676" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_6ea82cab-dbc9-4f99-8fd6-da08f98e0817" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_86572f6d-d9a7-413d-978a-cb65ac0584cc" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_6ea82cab-dbc9-4f99-8fd6-da08f98e0817" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_ae10e400-4c5d-43a4-b078-ef42042782f9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_86572f6d-d9a7-413d-978a-cb65ac0584cc" xlink:to="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_ae10e400-4c5d-43a4-b078-ef42042782f9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_5a20fa0a-487c-405a-86f8-c4a3795d1f67" xlink:href="biib-20200930.xsd#biib_PlanAssetsForDeferredCompensationFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_86572f6d-d9a7-413d-978a-cb65ac0584cc" xlink:to="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_5a20fa0a-487c-405a-86f8-c4a3795d1f67" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_d959cd0f-8aa6-4e7b-8f5f-bc7cc292c45b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_86572f6d-d9a7-413d-978a-cb65ac0584cc" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_d959cd0f-8aa6-4e7b-8f5f-bc7cc292c45b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_1b27b4a3-5105-44f8-a401-07ce86734288" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_c8141e61-a204-42c2-a281-cefa5968fb55" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_1b27b4a3-5105-44f8-a401-07ce86734288" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_3f932249-d0b2-4c12-a364-865837e971af" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_1b27b4a3-5105-44f8-a401-07ce86734288" xlink:to="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_3f932249-d0b2-4c12-a364-865837e971af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_7bc3c13e-6294-44fe-892a-139fae662103" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_1b27b4a3-5105-44f8-a401-07ce86734288" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_7bc3c13e-6294-44fe-892a-139fae662103" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_6a71d0eb-8246-4c3e-8c8f-f4a45cc302f9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_1b27b4a3-5105-44f8-a401-07ce86734288" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_6a71d0eb-8246-4c3e-8c8f-f4a45cc302f9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ee7b70b3-5af6-46bd-85e7-81ee986a8b06" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a5875a13-2da0-4f41-a032-e56b8329e2a2" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ee7b70b3-5af6-46bd-85e7-81ee986a8b06" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_dc15ae22-419b-4a23-8d2c-2bcd9023d423" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ee7b70b3-5af6-46bd-85e7-81ee986a8b06" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_dc15ae22-419b-4a23-8d2c-2bcd9023d423" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dc15ae22-419b-4a23-8d2c-2bcd9023d423_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_dc15ae22-419b-4a23-8d2c-2bcd9023d423" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dc15ae22-419b-4a23-8d2c-2bcd9023d423_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_93b8b47c-fddf-4fcf-a38b-d823e543e84c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_dc15ae22-419b-4a23-8d2c-2bcd9023d423" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_93b8b47c-fddf-4fcf-a38b-d823e543e84c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_f1ac885e-4e92-4f6b-8dcb-1d0025af1a11" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_93b8b47c-fddf-4fcf-a38b-d823e543e84c" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_f1ac885e-4e92-4f6b-8dcb-1d0025af1a11" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_eb3ecdd5-3997-409b-894d-81a2529a061b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_93b8b47c-fddf-4fcf-a38b-d823e543e84c" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_eb3ecdd5-3997-409b-894d-81a2529a061b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_3cc7547f-b5a2-45b5-8bb9-903658f0ab4b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_93b8b47c-fddf-4fcf-a38b-d823e543e84c" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_3cc7547f-b5a2-45b5-8bb9-903658f0ab4b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_95df519e-9d1a-4331-8788-469c0a139768" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ee7b70b3-5af6-46bd-85e7-81ee986a8b06" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_95df519e-9d1a-4331-8788-469c0a139768" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_95df519e-9d1a-4331-8788-469c0a139768_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_95df519e-9d1a-4331-8788-469c0a139768" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_95df519e-9d1a-4331-8788-469c0a139768_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_7316b172-fee8-4cc5-996e-4eb98e411a7a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_95df519e-9d1a-4331-8788-469c0a139768" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_7316b172-fee8-4cc5-996e-4eb98e411a7a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_970c43f7-e123-46af-939f-f1d2dfa5858f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_7316b172-fee8-4cc5-996e-4eb98e411a7a" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_970c43f7-e123-46af-939f-f1d2dfa5858f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_0b0470c8-fcc1-4887-9ab2-5cbd5987c263" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ee7b70b3-5af6-46bd-85e7-81ee986a8b06" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_0b0470c8-fcc1-4887-9ab2-5cbd5987c263" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_0b0470c8-fcc1-4887-9ab2-5cbd5987c263_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_0b0470c8-fcc1-4887-9ab2-5cbd5987c263" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_0b0470c8-fcc1-4887-9ab2-5cbd5987c263_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_0c509b35-a26d-42f2-8f5f-11f057c29647" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_0b0470c8-fcc1-4887-9ab2-5cbd5987c263" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_0c509b35-a26d-42f2-8f5f-11f057c29647" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_82720f27-95e4-4c1d-9e77-fdd5e17d5b32" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_0c509b35-a26d-42f2-8f5f-11f057c29647" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_82720f27-95e4-4c1d-9e77-fdd5e17d5b32" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_8c20a066-7982-4193-820c-6dd21a436cbe" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_0c509b35-a26d-42f2-8f5f-11f057c29647" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_8c20a066-7982-4193-820c-6dd21a436cbe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_93639212-21ef-4b04-893a-9576c516a1c2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_0c509b35-a26d-42f2-8f5f-11f057c29647" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_93639212-21ef-4b04-893a-9576c516a1c2" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:type="simple" xlink:href="biib-20200930.xsd#FairValueMeasurementsDetailsTextual"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:type="extended" id="i7f19da5b9cd94eab85b1674778e22db8_FairValueMeasurementsDetailsTextual">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_0a03eed1-790c-4d95-a979-30849bb484c8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_cdc385f7-c0c4-470d-82cd-57d65e467053" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_0a03eed1-790c-4d95-a979-30849bb484c8" xlink:to="loc_us-gaap_AssetImpairmentCharges_cdc385f7-c0c4-470d-82cd-57d65e467053" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_48bea35f-d64f-4c59-818e-9ff682bed055" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_0a03eed1-790c-4d95-a979-30849bb484c8" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_48bea35f-d64f-4c59-818e-9ff682bed055" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_a144d8a2-3202-4b97-a7ec-3b4bca47bd86" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_0a03eed1-790c-4d95-a979-30849bb484c8" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_a144d8a2-3202-4b97-a7ec-3b4bca47bd86" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1_dfb31e26-acad-4737-afaa-2bcd3fc89d6f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_0a03eed1-790c-4d95-a979-30849bb484c8" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1_dfb31e26-acad-4737-afaa-2bcd3fc89d6f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_e4ebe23b-b9e1-4191-9650-3b8eafa9b1a2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_0a03eed1-790c-4d95-a979-30849bb484c8" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_e4ebe23b-b9e1-4191-9650-3b8eafa9b1a2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_dd2709bd-9af6-4cc5-86c4-d402e47d8603" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_e4ebe23b-b9e1-4191-9650-3b8eafa9b1a2" xlink:to="loc_us-gaap_DebtInstrumentAxis_dd2709bd-9af6-4cc5-86c4-d402e47d8603" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_dd2709bd-9af6-4cc5-86c4-d402e47d8603_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_dd2709bd-9af6-4cc5-86c4-d402e47d8603" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_dd2709bd-9af6-4cc5-86c4-d402e47d8603_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_896b0f9e-93cf-475b-bf73-96ccd9a7741e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_dd2709bd-9af6-4cc5-86c4-d402e47d8603" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_896b0f9e-93cf-475b-bf73-96ccd9a7741e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_4e82ce4e-993c-4347-bf28-23f95ed6a448" xlink:href="biib-20200930.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_896b0f9e-93cf-475b-bf73-96ccd9a7741e" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_4e82ce4e-993c-4347-bf28-23f95ed6a448" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_eb67bdc6-4fe4-40b0-9f1d-6dad320926a6" xlink:href="biib-20200930.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_896b0f9e-93cf-475b-bf73-96ccd9a7741e" xlink:to="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_eb67bdc6-4fe4-40b0-9f1d-6dad320926a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_5a903c85-1d78-49f6-8eba-82d41f834da1" xlink:href="biib-20200930.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_896b0f9e-93cf-475b-bf73-96ccd9a7741e" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_5a903c85-1d78-49f6-8eba-82d41f834da1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_1a569315-0ecc-4660-9d43-33245f7f1721" xlink:href="biib-20200930.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_896b0f9e-93cf-475b-bf73-96ccd9a7741e" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_1a569315-0ecc-4660-9d43-33245f7f1721" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails" xlink:type="simple" xlink:href="biib-20200930.xsd#FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails" xlink:type="extended" id="i4c631148206c4e8f88d65582e5d5368a_FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_bcf465b4-5db6-4f1e-864a-90c0b5708c7f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_5e683a02-2717-44d3-9f0d-2b7891f8262b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_bcf465b4-5db6-4f1e-864a-90c0b5708c7f" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_5e683a02-2717-44d3-9f0d-2b7891f8262b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_baecc239-6018-4125-b43c-e6288dd84942" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_bcf465b4-5db6-4f1e-864a-90c0b5708c7f" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_baecc239-6018-4125-b43c-e6288dd84942" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9eb9c788-c11f-48c6-a14d-2f760ad2673c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_bcf465b4-5db6-4f1e-864a-90c0b5708c7f" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9eb9c788-c11f-48c6-a14d-2f760ad2673c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9d2c17ce-7a12-48ec-b33d-d6415da7f0bf" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9eb9c788-c11f-48c6-a14d-2f760ad2673c" xlink:to="loc_srt_RangeAxis_9d2c17ce-7a12-48ec-b33d-d6415da7f0bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9d2c17ce-7a12-48ec-b33d-d6415da7f0bf_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_9d2c17ce-7a12-48ec-b33d-d6415da7f0bf" xlink:to="loc_srt_RangeMember_9d2c17ce-7a12-48ec-b33d-d6415da7f0bf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_cb900d39-fee3-405d-bed4-fbfb2f6afd70" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_9d2c17ce-7a12-48ec-b33d-d6415da7f0bf" xlink:to="loc_srt_RangeMember_cb900d39-fee3-405d-bed4-fbfb2f6afd70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f1dec38b-06f2-4521-9215-4e7db9a7a9cf" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_cb900d39-fee3-405d-bed4-fbfb2f6afd70" xlink:to="loc_srt_MinimumMember_f1dec38b-06f2-4521-9215-4e7db9a7a9cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_8679bce9-9c5d-4690-8097-6c0eae8eea18" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_cb900d39-fee3-405d-bed4-fbfb2f6afd70" xlink:to="loc_srt_MaximumMember_8679bce9-9c5d-4690-8097-6c0eae8eea18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_fd1619f6-0571-4428-bd14-a376645dd4eb" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_WeightedAverageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_cb900d39-fee3-405d-bed4-fbfb2f6afd70" xlink:to="loc_srt_WeightedAverageMember_fd1619f6-0571-4428-bd14-a376645dd4eb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_815d59d7-e38d-431a-aaf9-0d349461a461" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9eb9c788-c11f-48c6-a14d-2f760ad2673c" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_815d59d7-e38d-431a-aaf9-0d349461a461" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_815d59d7-e38d-431a-aaf9-0d349461a461_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_815d59d7-e38d-431a-aaf9-0d349461a461" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_815d59d7-e38d-431a-aaf9-0d349461a461_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_f492a1b6-6175-44a1-9667-5eddeeec0d6e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_815d59d7-e38d-431a-aaf9-0d349461a461" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_f492a1b6-6175-44a1-9667-5eddeeec0d6e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_566830cd-1883-4a49-a0bc-64d2f3f9924a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_f492a1b6-6175-44a1-9667-5eddeeec0d6e" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_566830cd-1883-4a49-a0bc-64d2f3f9924a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:type="simple" xlink:href="biib-20200930.xsd#FairValueMeasurementsDetails1"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:type="extended" id="i3ab9bdb0088b43f590ac4d564c4bbabc_FairValueMeasurementsDetails1">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_2b0498d8-0012-40dc-a3e9-6ac6b072a6bd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure_4d70a6e0-0151-41d7-b8de-b44bc28186d4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2b0498d8-0012-40dc-a3e9-6ac6b072a6bd" xlink:to="loc_us-gaap_NotesPayableFairValueDisclosure_4d70a6e0-0151-41d7-b8de-b44bc28186d4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayable_f479e254-2724-49d3-9dd8-f66244a306e6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2b0498d8-0012-40dc-a3e9-6ac6b072a6bd" xlink:to="loc_us-gaap_NotesPayable_f479e254-2724-49d3-9dd8-f66244a306e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_03d71544-6e8c-463b-b33b-96c3a5cb64cd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2b0498d8-0012-40dc-a3e9-6ac6b072a6bd" xlink:to="loc_us-gaap_DebtInstrumentFairValue_03d71544-6e8c-463b-b33b-96c3a5cb64cd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_b736a84d-9295-4596-b120-06c1cacd8404" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2b0498d8-0012-40dc-a3e9-6ac6b072a6bd" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_b736a84d-9295-4596-b120-06c1cacd8404" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_9188ddee-94ed-4365-8d83-6bed3e896dfc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2b0498d8-0012-40dc-a3e9-6ac6b072a6bd" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_9188ddee-94ed-4365-8d83-6bed3e896dfc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_216df135-c215-4d33-9899-1afc6a49ef14" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2b0498d8-0012-40dc-a3e9-6ac6b072a6bd" xlink:to="loc_us-gaap_DebtInstrumentTable_216df135-c215-4d33-9899-1afc6a49ef14" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_b0bab12b-d03b-4316-8248-70213b878b19" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_216df135-c215-4d33-9899-1afc6a49ef14" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_b0bab12b-d03b-4316-8248-70213b878b19" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_b0bab12b-d03b-4316-8248-70213b878b19_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_b0bab12b-d03b-4316-8248-70213b878b19" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_b0bab12b-d03b-4316-8248-70213b878b19_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_c7a4061f-ec3d-4126-9711-2c9c9d504d0f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_b0bab12b-d03b-4316-8248-70213b878b19" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_c7a4061f-ec3d-4126-9711-2c9c9d504d0f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_338fbb6d-5b3d-4738-ba52-f360817f3367" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_c7a4061f-ec3d-4126-9711-2c9c9d504d0f" xlink:to="loc_us-gaap_SeniorNotesMember_338fbb6d-5b3d-4738-ba52-f360817f3367" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_24e089a4-32e3-4e05-b4ce-dc6653d2ce39" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_216df135-c215-4d33-9899-1afc6a49ef14" xlink:to="loc_us-gaap_DebtInstrumentAxis_24e089a4-32e3-4e05-b4ce-dc6653d2ce39" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_24e089a4-32e3-4e05-b4ce-dc6653d2ce39_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_24e089a4-32e3-4e05-b4ce-dc6653d2ce39" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_24e089a4-32e3-4e05-b4ce-dc6653d2ce39_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_4bb4ab34-7009-4e35-9109-0f0e18a8bedb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_24e089a4-32e3-4e05-b4ce-dc6653d2ce39" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_4bb4ab34-7009-4e35-9109-0f0e18a8bedb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_3d764e59-f35a-4650-ba20-23bb863529da" xlink:href="biib-20200930.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4bb4ab34-7009-4e35-9109-0f0e18a8bedb" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_3d764e59-f35a-4650-ba20-23bb863529da" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_e3eae5ca-6603-4308-b61c-f6849409318e" xlink:href="biib-20200930.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4bb4ab34-7009-4e35-9109-0f0e18a8bedb" xlink:to="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_e3eae5ca-6603-4308-b61c-f6849409318e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_d25cb1f8-329f-4688-aee0-c443b1aa0118" xlink:href="biib-20200930.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4bb4ab34-7009-4e35-9109-0f0e18a8bedb" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_d25cb1f8-329f-4688-aee0-c443b1aa0118" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2.25SeniorNotesdueMay12030Member_53ab49de-d554-4915-a41a-cb22602b3449" xlink:href="biib-20200930.xsd#biib_A2.25SeniorNotesdueMay12030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4bb4ab34-7009-4e35-9109-0f0e18a8bedb" xlink:to="loc_biib_A2.25SeniorNotesdueMay12030Member_53ab49de-d554-4915-a41a-cb22602b3449" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_03b04d79-f5c9-46e5-8776-409eb5f81302" xlink:href="biib-20200930.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4bb4ab34-7009-4e35-9109-0f0e18a8bedb" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_03b04d79-f5c9-46e5-8776-409eb5f81302" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A3.15SeniorNotesdueMay12050Member_99602bed-3117-480c-b300-c729eab223c4" xlink:href="biib-20200930.xsd#biib_A3.15SeniorNotesdueMay12050Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4bb4ab34-7009-4e35-9109-0f0e18a8bedb" xlink:to="loc_biib_A3.15SeniorNotesdueMay12050Member_99602bed-3117-480c-b300-c729eab223c4" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:type="simple" xlink:href="biib-20200930.xsd#FairValueMeasurementsDetails2"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:type="extended" id="i1a30225f5495476d9283e2fbfb6b7328_FairValueMeasurementsDetails2">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_190dd044-3645-46e3-807f-b2e51d3d92bf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_a0ebcd72-eb64-493a-a42e-7949a512c085" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_190dd044-3645-46e3-807f-b2e51d3d92bf" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_a0ebcd72-eb64-493a-a42e-7949a512c085" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_f3683b1c-051f-4979-a556-bce2758569e6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_190dd044-3645-46e3-807f-b2e51d3d92bf" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_f3683b1c-051f-4979-a556-bce2758569e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_68a7f349-1cef-423f-9c4b-e2906312d8fd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_190dd044-3645-46e3-807f-b2e51d3d92bf" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_68a7f349-1cef-423f-9c4b-e2906312d8fd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_d9dadfad-2240-4f57-8680-4e814e2c50b5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_6d08f0d2-32bd-4c7c-9b74-cc01dbad14df" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_190dd044-3645-46e3-807f-b2e51d3d92bf" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_6d08f0d2-32bd-4c7c-9b74-cc01dbad14df" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_a6888b2b-1089-4e78-a252-1128bad6c5f2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_6d08f0d2-32bd-4c7c-9b74-cc01dbad14df" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_a6888b2b-1089-4e78-a252-1128bad6c5f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_a6888b2b-1089-4e78-a252-1128bad6c5f2_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_a6888b2b-1089-4e78-a252-1128bad6c5f2" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_a6888b2b-1089-4e78-a252-1128bad6c5f2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_780d2150-4f0d-4502-9569-f4a68ff3ac55" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_a6888b2b-1089-4e78-a252-1128bad6c5f2" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_780d2150-4f0d-4502-9569-f4a68ff3ac55" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_bd0f0ef1-0e10-4952-a70e-5e07b7fe402c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_780d2150-4f0d-4502-9569-f4a68ff3ac55" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_bd0f0ef1-0e10-4952-a70e-5e07b7fe402c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstruments" xlink:type="simple" xlink:href="biib-20200930.xsd#FinancialInstruments"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstruments" xlink:type="extended" id="i4cd0997b133e4354ae472bd369a30bcb_FinancialInstruments"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:type="simple" xlink:href="biib-20200930.xsd#FinancialInstrumentsTables"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:type="extended" id="i7bb2942148ff4fcc9591f26992ae3af3_FinancialInstrumentsTables"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:type="simple" xlink:href="biib-20200930.xsd#FinancialInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:type="extended" id="i7424b428e0f140e8bda21f1e08704403_FinancialInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_d27c144f-346a-4043-b7b2-8d96709feac0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_16813d93-884a-4da0-a501-16d796a1ad5a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValueAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_d27c144f-346a-4043-b7b2-8d96709feac0" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_16813d93-884a-4da0-a501-16d796a1ad5a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_988db62b-b51a-4b60-8a8e-285e9e62709e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_16813d93-884a-4da0-a501-16d796a1ad5a" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_988db62b-b51a-4b60-8a8e-285e9e62709e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_5dbb7e97-b34b-491c-adc0-8a288842a436" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_d27c144f-346a-4043-b7b2-8d96709feac0" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_5dbb7e97-b34b-491c-adc0-8a288842a436" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_5d5b3c0d-a1a9-41d6-abeb-fbacbdcfad4a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_5dbb7e97-b34b-491c-adc0-8a288842a436" xlink:to="loc_us-gaap_InvestmentTypeAxis_5d5b3c0d-a1a9-41d6-abeb-fbacbdcfad4a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_5d5b3c0d-a1a9-41d6-abeb-fbacbdcfad4a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_5d5b3c0d-a1a9-41d6-abeb-fbacbdcfad4a" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_5d5b3c0d-a1a9-41d6-abeb-fbacbdcfad4a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_2f2f05a8-2a07-4c5d-9a40-c5e355caeaab" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_5d5b3c0d-a1a9-41d6-abeb-fbacbdcfad4a" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_2f2f05a8-2a07-4c5d-9a40-c5e355caeaab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_aefcb7d1-b55e-4239-b0e3-f919859cd80a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_2f2f05a8-2a07-4c5d-9a40-c5e355caeaab" xlink:to="loc_us-gaap_CommercialPaperMember_aefcb7d1-b55e-4239-b0e3-f919859cd80a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepurchaseAgreementsMember_210e9d79-d4af-40b5-9ffd-399f58136088" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepurchaseAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_2f2f05a8-2a07-4c5d-9a40-c5e355caeaab" xlink:to="loc_us-gaap_RepurchaseAgreementsMember_210e9d79-d4af-40b5-9ffd-399f58136088" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_8df7b5d5-ccc0-4314-8afa-91f39092e6f8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_2f2f05a8-2a07-4c5d-9a40-c5e355caeaab" xlink:to="loc_us-gaap_MoneyMarketFundsMember_8df7b5d5-ccc0-4314-8afa-91f39092e6f8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember_2559da66-18d4-4f94-85f5-3fb03da7884a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_2f2f05a8-2a07-4c5d-9a40-c5e355caeaab" xlink:to="loc_us-gaap_DebtSecuritiesMember_2559da66-18d4-4f94-85f5-3fb03da7884a" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:type="simple" xlink:href="biib-20200930.xsd#FinancialInstrumentsDetails1"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:type="extended" id="i5826e26f83d449139e015299dd07286c_FinancialInstrumentsDetails1">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_05cf9660-957c-419d-b1db-f0ef8431979e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_64b6c49c-11cf-48e6-834b-c09dfbd0c918" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_05cf9660-957c-419d-b1db-f0ef8431979e" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_64b6c49c-11cf-48e6-834b-c09dfbd0c918" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0e075f94-f3dd-43c2-97a1-1b1afccf19b4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_05cf9660-957c-419d-b1db-f0ef8431979e" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0e075f94-f3dd-43c2-97a1-1b1afccf19b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_24c642e8-419e-4326-80c0-180fede5baa9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_05cf9660-957c-419d-b1db-f0ef8431979e" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_24c642e8-419e-4326-80c0-180fede5baa9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e28d5343-26fa-4536-a881-70e061892bde" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_05cf9660-957c-419d-b1db-f0ef8431979e" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e28d5343-26fa-4536-a881-70e061892bde" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_4a5db10f-2020-4903-bf39-3474b2b6d028" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_05cf9660-957c-419d-b1db-f0ef8431979e" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_4a5db10f-2020-4903-bf39-3474b2b6d028" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_8102f447-4800-4077-987b-96c78e40650c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_05cf9660-957c-419d-b1db-f0ef8431979e" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_8102f447-4800-4077-987b-96c78e40650c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_f98e74af-d505-4b3a-9a35-51fb5111af6e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_05cf9660-957c-419d-b1db-f0ef8431979e" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_f98e74af-d505-4b3a-9a35-51fb5111af6e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecurities_223447a4-9b07-491b-98f7-92e3184bd301" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_05cf9660-957c-419d-b1db-f0ef8431979e" xlink:to="loc_us-gaap_AvailableForSaleSecurities_223447a4-9b07-491b-98f7-92e3184bd301" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_f530b0cb-e794-48c3-a39c-747f116a4e50" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_05cf9660-957c-419d-b1db-f0ef8431979e" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_f530b0cb-e794-48c3-a39c-747f116a4e50" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_343c70be-e888-4f59-bfe8-01fc73d49e62" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_f530b0cb-e794-48c3-a39c-747f116a4e50" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_343c70be-e888-4f59-bfe8-01fc73d49e62" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_343c70be-e888-4f59-bfe8-01fc73d49e62_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_343c70be-e888-4f59-bfe8-01fc73d49e62" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_343c70be-e888-4f59-bfe8-01fc73d49e62_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_8ec8363b-800d-4699-9637-b467a55e0a8a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_343c70be-e888-4f59-bfe8-01fc73d49e62" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_8ec8363b-800d-4699-9637-b467a55e0a8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_2e906477-383b-4301-8331-b89132f91695" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_8ec8363b-800d-4699-9637-b467a55e0a8a" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_2e906477-383b-4301-8331-b89132f91695" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_0bef18bf-d3c1-42ce-bdda-5da715033048" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_8ec8363b-800d-4699-9637-b467a55e0a8a" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_0bef18bf-d3c1-42ce-bdda-5da715033048" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_3040ff4c-f1ff-463e-a32c-e5e82fde2df6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_f530b0cb-e794-48c3-a39c-747f116a4e50" xlink:to="loc_us-gaap_FinancialInstrumentAxis_3040ff4c-f1ff-463e-a32c-e5e82fde2df6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3040ff4c-f1ff-463e-a32c-e5e82fde2df6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_3040ff4c-f1ff-463e-a32c-e5e82fde2df6" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3040ff4c-f1ff-463e-a32c-e5e82fde2df6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7574f9b6-c50b-406b-a375-ac42882d5afb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_3040ff4c-f1ff-463e-a32c-e5e82fde2df6" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7574f9b6-c50b-406b-a375-ac42882d5afb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CorporateDebtSecuritiesCurrentMember_1d8ee664-9473-4aaa-9f80-32fb0fcd7b52" xlink:href="biib-20200930.xsd#biib_CorporateDebtSecuritiesCurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7574f9b6-c50b-406b-a375-ac42882d5afb" xlink:to="loc_biib_CorporateDebtSecuritiesCurrentMember_1d8ee664-9473-4aaa-9f80-32fb0fcd7b52" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CorporateDebtSecuritiesNonCurrentMember_05c5ed23-a36f-46a7-b1a9-0a0a9d6192b4" xlink:href="biib-20200930.xsd#biib_CorporateDebtSecuritiesNonCurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7574f9b6-c50b-406b-a375-ac42882d5afb" xlink:to="loc_biib_CorporateDebtSecuritiesNonCurrentMember_05c5ed23-a36f-46a7-b1a9-0a0a9d6192b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GovernmentSecuritiesCurrentMember_c30d4773-5ecf-4b2d-9d42-e4c30ea0db76" xlink:href="biib-20200930.xsd#biib_GovernmentSecuritiesCurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7574f9b6-c50b-406b-a375-ac42882d5afb" xlink:to="loc_biib_GovernmentSecuritiesCurrentMember_c30d4773-5ecf-4b2d-9d42-e4c30ea0db76" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GovernmentSecuritiesNonCurrentMember_fb8b028e-f573-4d93-bd8a-47d0001ea5b8" xlink:href="biib-20200930.xsd#biib_GovernmentSecuritiesNonCurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7574f9b6-c50b-406b-a375-ac42882d5afb" xlink:to="loc_biib_GovernmentSecuritiesNonCurrentMember_fb8b028e-f573-4d93-bd8a-47d0001ea5b8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_e4ea9f05-a5bf-4f59-bd7f-bfcbdbe77e22" xlink:href="biib-20200930.xsd#biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7574f9b6-c50b-406b-a375-ac42882d5afb" xlink:to="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_e4ea9f05-a5bf-4f59-bd7f-bfcbdbe77e22" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_71250621-4066-45b3-9c69-ab589baab962" xlink:href="biib-20200930.xsd#biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7574f9b6-c50b-406b-a375-ac42882d5afb" xlink:to="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_71250621-4066-45b3-9c69-ab589baab962" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_0b3fac7c-8b8a-459f-9ed2-02a6fe5279ed" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7574f9b6-c50b-406b-a375-ac42882d5afb" xlink:to="loc_us-gaap_EquitySecuritiesMember_0b3fac7c-8b8a-459f-9ed2-02a6fe5279ed" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:type="simple" xlink:href="biib-20200930.xsd#FinancialInstrumentsDetails2"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:type="extended" id="ic8f097c190f449ebbf5a766aa666560f_FinancialInstrumentsDetails2"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails3" xlink:type="simple" xlink:href="biib-20200930.xsd#FinancialInstrumentsDetails3"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails3" xlink:type="extended" id="i7feb5b63916d4a98abf02a7ecd90f409_FinancialInstrumentsDetails3"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual" xlink:type="simple" xlink:href="biib-20200930.xsd#FinancialInstrumentsDetailsTextual"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual" xlink:type="extended" id="ib3ef21257f7643ecab7e097328410652_FinancialInstrumentsDetailsTextual"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:type="simple" xlink:href="biib-20200930.xsd#FinancialInstrumentsFinancialInstrumentsDetailsTextual2"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:type="extended" id="i0e754ec0c5a54ddfa47b2720daba1eac_FinancialInstrumentsFinancialInstrumentsDetailsTextual2">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_6ea9fe48-1011-412a-b97e-7331412acdf8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_StrategicInvestmentPortfolio_250cf924-d64d-43b6-b96c-5808a13320ac" xlink:href="biib-20200930.xsd#biib_StrategicInvestmentPortfolio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6ea9fe48-1011-412a-b97e-7331412acdf8" xlink:to="loc_biib_StrategicInvestmentPortfolio_250cf924-d64d-43b6-b96c-5808a13320ac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_be70e363-6d6a-42df-a4f7-32ea07c10e2d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6ea9fe48-1011-412a-b97e-7331412acdf8" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_be70e363-6d6a-42df-a4f7-32ea07c10e2d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Investmentincommonstocksharespurchased_45b9a458-aa04-4933-98d1-29a0c80c1611" xlink:href="biib-20200930.xsd#biib_Investmentincommonstocksharespurchased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6ea9fe48-1011-412a-b97e-7331412acdf8" xlink:to="loc_biib_Investmentincommonstocksharespurchased_45b9a458-aa04-4933-98d1-29a0c80c1611" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DividendYieldPercentage_e90cde88-0615-4329-9f6d-949c2a608911" xlink:href="biib-20200930.xsd#biib_DividendYieldPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6ea9fe48-1011-412a-b97e-7331412acdf8" xlink:to="loc_biib_DividendYieldPercentage_e90cde88-0615-4329-9f6d-949c2a608911" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NumberOfNeurologicalDiseaseTargets_0f17470b-61b8-46dc-a1e9-a3b391bec229" xlink:href="biib-20200930.xsd#biib_NumberOfNeurologicalDiseaseTargets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6ea9fe48-1011-412a-b97e-7331412acdf8" xlink:to="loc_biib_NumberOfNeurologicalDiseaseTargets_0f17470b-61b8-46dc-a1e9-a3b391bec229" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CollaborationAgreementTerm_ea8d7307-f0fd-44fe-9121-1572c8ca7a5a" xlink:href="biib-20200930.xsd#biib_CollaborationAgreementTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6ea9fe48-1011-412a-b97e-7331412acdf8" xlink:to="loc_biib_CollaborationAgreementTerm_ea8d7307-f0fd-44fe-9121-1572c8ca7a5a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ee78d48f-81ab-46a9-b69a-5e495c509670" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6ea9fe48-1011-412a-b97e-7331412acdf8" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ee78d48f-81ab-46a9-b69a-5e495c509670" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_a0aa7550-af50-4b58-9229-bd148cca0fc7" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ee78d48f-81ab-46a9-b69a-5e495c509670" xlink:to="loc_dei_LegalEntityAxis_a0aa7550-af50-4b58-9229-bd148cca0fc7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_a0aa7550-af50-4b58-9229-bd148cca0fc7_default" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_a0aa7550-af50-4b58-9229-bd148cca0fc7" xlink:to="loc_dei_EntityDomain_a0aa7550-af50-4b58-9229-bd148cca0fc7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_9cc1c115-a31f-44e1-be34-d0baadfc81d0" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_a0aa7550-af50-4b58-9229-bd148cca0fc7" xlink:to="loc_dei_EntityDomain_9cc1c115-a31f-44e1-be34-d0baadfc81d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DenaliTherapeuticsIncMember_c910be69-2981-4154-a37f-7595151a6fce" xlink:href="biib-20200930.xsd#biib_DenaliTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_9cc1c115-a31f-44e1-be34-d0baadfc81d0" xlink:to="loc_biib_DenaliTherapeuticsIncMember_c910be69-2981-4154-a37f-7595151a6fce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SangamoCommonStockMember_b5cb8cbd-f9db-4e95-81b9-2613c950c82f" xlink:href="biib-20200930.xsd#biib_SangamoCommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_9cc1c115-a31f-44e1-be34-d0baadfc81d0" xlink:to="loc_biib_SangamoCommonStockMember_b5cb8cbd-f9db-4e95-81b9-2613c950c82f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_8f824fc3-c6e9-4386-8b60-345a91e66d25" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ee78d48f-81ab-46a9-b69a-5e495c509670" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_8f824fc3-c6e9-4386-8b60-345a91e66d25" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_8f824fc3-c6e9-4386-8b60-345a91e66d25_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_8f824fc3-c6e9-4386-8b60-345a91e66d25" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_8f824fc3-c6e9-4386-8b60-345a91e66d25_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_e2fc9a84-bec0-41b9-9321-55f8b1576e27" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_8f824fc3-c6e9-4386-8b60-345a91e66d25" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_e2fc9a84-bec0-41b9-9321-55f8b1576e27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_91f2829e-7ffa-46dc-ac45-512938074574" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_e2fc9a84-bec0-41b9-9321-55f8b1576e27" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_91f2829e-7ffa-46dc-ac45-512938074574" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_64c7bce6-a7ec-46af-81f3-c23563a41a65" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_e2fc9a84-bec0-41b9-9321-55f8b1576e27" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_64c7bce6-a7ec-46af-81f3-c23563a41a65" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_04ca6024-a664-4e5d-9d14-e304742c2c2a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ee78d48f-81ab-46a9-b69a-5e495c509670" xlink:to="loc_us-gaap_FinancialInstrumentAxis_04ca6024-a664-4e5d-9d14-e304742c2c2a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_04ca6024-a664-4e5d-9d14-e304742c2c2a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_04ca6024-a664-4e5d-9d14-e304742c2c2a" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_04ca6024-a664-4e5d-9d14-e304742c2c2a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e1666687-e8d7-4245-8270-8197cf221cd2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_04ca6024-a664-4e5d-9d14-e304742c2c2a" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e1666687-e8d7-4245-8270-8197cf221cd2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_StrategicInvestmentsMember_723354c9-49af-4f6b-b86f-59516384781d" xlink:href="biib-20200930.xsd#biib_StrategicInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e1666687-e8d7-4245-8270-8197cf221cd2" xlink:to="loc_biib_StrategicInvestmentsMember_723354c9-49af-4f6b-b86f-59516384781d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstruments" xlink:type="simple" xlink:href="biib-20200930.xsd#DerivativeInstruments"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/DerivativeInstruments" xlink:type="extended" id="i96bad93e99bc491db44675a65649919f_DerivativeInstruments"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:type="simple" xlink:href="biib-20200930.xsd#DerivativeInstrumentsTables"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:type="extended" id="i014ed001087f40c885aa17c8b4781fc7_DerivativeInstrumentsTables"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:type="simple" xlink:href="biib-20200930.xsd#DerivativeInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:type="extended" id="i483bff23b7ec47e3be23c5a3cdd9383e_DerivativeInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_e5ae0d2e-0e87-4071-872f-30a9aaeb6a60" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeRemainingMaturity1_1eec08a6-b50b-49d8-9362-cc9c0d2d98cf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeRemainingMaturity1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_e5ae0d2e-0e87-4071-872f-30a9aaeb6a60" xlink:to="loc_us-gaap_DerivativeRemainingMaturity1_1eec08a6-b50b-49d8-9362-cc9c0d2d98cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_6127f9aa-22d7-4cea-ba3f-89ad83435d9c" xlink:href="biib-20200930.xsd#biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_e5ae0d2e-0e87-4071-872f-30a9aaeb6a60" xlink:to="loc_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_6127f9aa-22d7-4cea-ba3f-89ad83435d9c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_4da4a483-0ea8-4ad9-9d6b-dbec12e53545" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_e5ae0d2e-0e87-4071-872f-30a9aaeb6a60" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_4da4a483-0ea8-4ad9-9d6b-dbec12e53545" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_0fcdd977-9c9b-4196-a60e-543ee8076e97" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_e5ae0d2e-0e87-4071-872f-30a9aaeb6a60" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_0fcdd977-9c9b-4196-a60e-543ee8076e97" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_439db85d-1d08-4ee5-b0b0-eaeb1365ce95" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_e5ae0d2e-0e87-4071-872f-30a9aaeb6a60" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_439db85d-1d08-4ee5-b0b0-eaeb1365ce95" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_679927b7-e80c-4e46-81e7-f7358cdee8ab" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_e5ae0d2e-0e87-4071-872f-30a9aaeb6a60" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_679927b7-e80c-4e46-81e7-f7358cdee8ab" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_36c712e8-1a8c-471d-857b-a655c5be1684" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_e5ae0d2e-0e87-4071-872f-30a9aaeb6a60" xlink:to="loc_us-gaap_DerivativeNotionalAmount_36c712e8-1a8c-471d-857b-a655c5be1684" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_130d50a4-ea99-41a3-9f1b-599625273654" xlink:href="biib-20200930.xsd#biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_e5ae0d2e-0e87-4071-872f-30a9aaeb6a60" xlink:to="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_130d50a4-ea99-41a3-9f1b-599625273654" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_8f501ab3-c009-45ab-9c66-de441c591948" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_e5ae0d2e-0e87-4071-872f-30a9aaeb6a60" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_8f501ab3-c009-45ab-9c66-de441c591948" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_9687a4d6-3afa-4e33-ac04-7f074aee242a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_e5ae0d2e-0e87-4071-872f-30a9aaeb6a60" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_9687a4d6-3afa-4e33-ac04-7f074aee242a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTermOfContract_fb0d2e7d-e76f-4954-b1c5-6634f9e53d88" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_e5ae0d2e-0e87-4071-872f-30a9aaeb6a60" xlink:to="loc_us-gaap_DerivativeTermOfContract_fb0d2e7d-e76f-4954-b1c5-6634f9e53d88" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_8dbeb171-594d-4f51-acee-007aae88f3d8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_e5ae0d2e-0e87-4071-872f-30a9aaeb6a60" xlink:to="loc_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_8dbeb171-594d-4f51-acee-007aae88f3d8" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax_533523f0-3b31-4adb-8275-1df857e4e57d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_e5ae0d2e-0e87-4071-872f-30a9aaeb6a60" xlink:to="loc_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax_533523f0-3b31-4adb-8275-1df857e4e57d" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_0eef65c9-e964-4845-ab42-734bcaa7e73d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_e5ae0d2e-0e87-4071-872f-30a9aaeb6a60" xlink:to="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_0eef65c9-e964-4845-ab42-734bcaa7e73d" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_e5f7fc0f-2c5a-471b-b0a8-65ade25f55c1" xlink:href="biib-20200930.xsd#biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_e5ae0d2e-0e87-4071-872f-30a9aaeb6a60" xlink:to="loc_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_e5f7fc0f-2c5a-471b-b0a8-65ade25f55c1" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_abc5f981-b5c9-4a06-a4c2-476a7bd5e7c8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_e5ae0d2e-0e87-4071-872f-30a9aaeb6a60" xlink:to="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_abc5f981-b5c9-4a06-a4c2-476a7bd5e7c8" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_77bfe327-3541-4235-ac8f-28fbb7c54990" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_e5ae0d2e-0e87-4071-872f-30a9aaeb6a60" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_77bfe327-3541-4235-ac8f-28fbb7c54990" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_4b8c8e1c-907e-40ac-8bde-9e2a60300fc7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_e5ae0d2e-0e87-4071-872f-30a9aaeb6a60" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_4b8c8e1c-907e-40ac-8bde-9e2a60300fc7" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_0018cd45-525c-47dd-80ce-b009dafab11b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_e5ae0d2e-0e87-4071-872f-30a9aaeb6a60" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_0018cd45-525c-47dd-80ce-b009dafab11b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DerivativeMaturityAxis_de07e7b4-1138-4ae2-9838-3fdfa18c8f85" xlink:href="biib-20200930.xsd#biib_DerivativeMaturityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_0018cd45-525c-47dd-80ce-b009dafab11b" xlink:to="loc_biib_DerivativeMaturityAxis_de07e7b4-1138-4ae2-9838-3fdfa18c8f85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DerivativeMaturityDomain_de07e7b4-1138-4ae2-9838-3fdfa18c8f85_default" xlink:href="biib-20200930.xsd#biib_DerivativeMaturityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_DerivativeMaturityAxis_de07e7b4-1138-4ae2-9838-3fdfa18c8f85" xlink:to="loc_biib_DerivativeMaturityDomain_de07e7b4-1138-4ae2-9838-3fdfa18c8f85_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DerivativeMaturityDomain_2c2aa811-e31d-4727-aace-cc55bd563549" xlink:href="biib-20200930.xsd#biib_DerivativeMaturityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_DerivativeMaturityAxis_de07e7b4-1138-4ae2-9838-3fdfa18c8f85" xlink:to="loc_biib_DerivativeMaturityDomain_2c2aa811-e31d-4727-aace-cc55bd563549" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShorttermderivativeMember_f0cae686-298a-4e22-99ce-b854b708a143" xlink:href="biib-20200930.xsd#biib_ShorttermderivativeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_DerivativeMaturityDomain_2c2aa811-e31d-4727-aace-cc55bd563549" xlink:to="loc_biib_ShorttermderivativeMember_f0cae686-298a-4e22-99ce-b854b708a143" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_1e109025-df86-44c2-9d9c-4445aba78712" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_0018cd45-525c-47dd-80ce-b009dafab11b" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_1e109025-df86-44c2-9d9c-4445aba78712" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_1e109025-df86-44c2-9d9c-4445aba78712_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_1e109025-df86-44c2-9d9c-4445aba78712" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_1e109025-df86-44c2-9d9c-4445aba78712_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_f8c958a2-474b-48af-8618-74352352c369" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_1e109025-df86-44c2-9d9c-4445aba78712" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_f8c958a2-474b-48af-8618-74352352c369" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_3677c445-ca7e-4459-b98e-5aa09865e09a" xlink:href="biib-20200930.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_f8c958a2-474b-48af-8618-74352352c369" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_3677c445-ca7e-4459-b98e-5aa09865e09a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_6d1f97ed-cd76-4d5f-ab6f-571d72c4eb7e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_0018cd45-525c-47dd-80ce-b009dafab11b" xlink:to="loc_us-gaap_DebtInstrumentAxis_6d1f97ed-cd76-4d5f-ab6f-571d72c4eb7e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_6d1f97ed-cd76-4d5f-ab6f-571d72c4eb7e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_6d1f97ed-cd76-4d5f-ab6f-571d72c4eb7e" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_6d1f97ed-cd76-4d5f-ab6f-571d72c4eb7e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_be5cc1b4-daa4-4311-b052-5b699a76e5f2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_6d1f97ed-cd76-4d5f-ab6f-571d72c4eb7e" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_be5cc1b4-daa4-4311-b052-5b699a76e5f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_5918faed-22fb-4017-81e4-f55c3cd23edc" xlink:href="biib-20200930.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_be5cc1b4-daa4-4311-b052-5b699a76e5f2" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_5918faed-22fb-4017-81e4-f55c3cd23edc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis_e7391b43-6c0c-40d8-85c1-6aafee419b25" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CurrencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_0018cd45-525c-47dd-80ce-b009dafab11b" xlink:to="loc_srt_CurrencyAxis_e7391b43-6c0c-40d8-85c1-6aafee419b25" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_e7391b43-6c0c-40d8-85c1-6aafee419b25_default" xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_AllCurrenciesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CurrencyAxis_e7391b43-6c0c-40d8-85c1-6aafee419b25" xlink:to="loc_currency_AllCurrenciesDomain_e7391b43-6c0c-40d8-85c1-6aafee419b25_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_89aacbbf-3cdd-45b5-8e8c-9a2aa1320a09" xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_AllCurrenciesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CurrencyAxis_e7391b43-6c0c-40d8-85c1-6aafee419b25" xlink:to="loc_currency_AllCurrenciesDomain_89aacbbf-3cdd-45b5-8e8c-9a2aa1320a09" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_EUR_a6acd2d6-e45d-49e1-8802-8eab6240d068" xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_EUR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_89aacbbf-3cdd-45b5-8e8c-9a2aa1320a09" xlink:to="loc_currency_EUR_a6acd2d6-e45d-49e1-8802-8eab6240d068" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_GBP_8969f442-18ed-493a-ab10-4452bfbaa5e1" xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_GBP"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_89aacbbf-3cdd-45b5-8e8c-9a2aa1320a09" xlink:to="loc_currency_GBP_8969f442-18ed-493a-ab10-4452bfbaa5e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_CHF_7610050c-afc0-4a74-83cb-32cb8c43a750" xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_CHF"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_89aacbbf-3cdd-45b5-8e8c-9a2aa1320a09" xlink:to="loc_currency_CHF_7610050c-afc0-4a74-83cb-32cb8c43a750" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_JPY_75a84f63-9a00-4dad-b200-4b0f543b0684" xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_JPY"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_89aacbbf-3cdd-45b5-8e8c-9a2aa1320a09" xlink:to="loc_currency_JPY_75a84f63-9a00-4dad-b200-4b0f543b0684" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_CAD_de9d695b-3137-4532-8e03-cf90e8445581" xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_CAD"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_89aacbbf-3cdd-45b5-8e8c-9a2aa1320a09" xlink:to="loc_currency_CAD_de9d695b-3137-4532-8e03-cf90e8445581" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_3b373247-2e77-4a2a-92fe-aa0efbc49963" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_0018cd45-525c-47dd-80ce-b009dafab11b" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_3b373247-2e77-4a2a-92fe-aa0efbc49963" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3b373247-2e77-4a2a-92fe-aa0efbc49963_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_3b373247-2e77-4a2a-92fe-aa0efbc49963" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_3b373247-2e77-4a2a-92fe-aa0efbc49963_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_8c30cbb2-2af7-40a6-b6f1-31114d8324f6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_3b373247-2e77-4a2a-92fe-aa0efbc49963" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_8c30cbb2-2af7-40a6-b6f1-31114d8324f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseMember_f1481b57-2ad9-4681-bbbf-684d396bbab9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8c30cbb2-2af7-40a6-b6f1-31114d8324f6" xlink:to="loc_us-gaap_InterestExpenseMember_f1481b57-2ad9-4681-bbbf-684d396bbab9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember_08412deb-4196-4291-a799-b4d4fed4cf10" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8c30cbb2-2af7-40a6-b6f1-31114d8324f6" xlink:to="loc_us-gaap_SalesMember_08412deb-4196-4291-a799-b4d4fed4cf10" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenseMember_a94b0b34-e019-450e-97a0-a1c28ca55276" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8c30cbb2-2af7-40a6-b6f1-31114d8324f6" xlink:to="loc_us-gaap_OperatingExpenseMember_a94b0b34-e019-450e-97a0-a1c28ca55276" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_169db320-5f77-48d4-ae8f-077c39669a41" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8c30cbb2-2af7-40a6-b6f1-31114d8324f6" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_169db320-5f77-48d4-ae8f-077c39669a41" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_5ae0b1b2-d807-4f61-86cc-d8ad7a7cc963" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_0018cd45-525c-47dd-80ce-b009dafab11b" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_5ae0b1b2-d807-4f61-86cc-d8ad7a7cc963" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_5ae0b1b2-d807-4f61-86cc-d8ad7a7cc963_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_5ae0b1b2-d807-4f61-86cc-d8ad7a7cc963" xlink:to="loc_us-gaap_HedgingRelationshipDomain_5ae0b1b2-d807-4f61-86cc-d8ad7a7cc963_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_76e5c36c-78f9-47ef-9f7b-1ce6f238f550" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_5ae0b1b2-d807-4f61-86cc-d8ad7a7cc963" xlink:to="loc_us-gaap_HedgingRelationshipDomain_76e5c36c-78f9-47ef-9f7b-1ce6f238f550" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_8cfbe2ec-f8eb-42f2-99ad-8c2520325506" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_76e5c36c-78f9-47ef-9f7b-1ce6f238f550" xlink:to="loc_us-gaap_CashFlowHedgingMember_8cfbe2ec-f8eb-42f2-99ad-8c2520325506" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember_fe807797-088a-404a-aa39-33b1687776ca" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_76e5c36c-78f9-47ef-9f7b-1ce6f238f550" xlink:to="loc_us-gaap_FairValueHedgingMember_fe807797-088a-404a-aa39-33b1687776ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CashflowsrevenueMember_78cdc1a3-bfe0-4ad3-a9d5-77b2c0cea25f" xlink:href="biib-20200930.xsd#biib_CashflowsrevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_76e5c36c-78f9-47ef-9f7b-1ce6f238f550" xlink:to="loc_biib_CashflowsrevenueMember_78cdc1a3-bfe0-4ad3-a9d5-77b2c0cea25f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CashflowsoperatingexpensesMember_55cef47f-785c-4119-9abd-baf263290c1a" xlink:href="biib-20200930.xsd#biib_CashflowsoperatingexpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_76e5c36c-78f9-47ef-9f7b-1ce6f238f550" xlink:to="loc_biib_CashflowsoperatingexpensesMember_55cef47f-785c-4119-9abd-baf263290c1a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_fbcbb538-8324-4497-abd7-ae025adf7527" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_76e5c36c-78f9-47ef-9f7b-1ce6f238f550" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_fbcbb538-8324-4497-abd7-ae025adf7527" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_3f19a8f7-c983-4eed-917a-d25f8048c733" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_0018cd45-525c-47dd-80ce-b009dafab11b" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_3f19a8f7-c983-4eed-917a-d25f8048c733" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_3f19a8f7-c983-4eed-917a-d25f8048c733_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_3f19a8f7-c983-4eed-917a-d25f8048c733" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_3f19a8f7-c983-4eed-917a-d25f8048c733_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_6841accb-4488-41e3-8aaa-ffe61d539bb1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_3f19a8f7-c983-4eed-917a-d25f8048c733" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_6841accb-4488-41e3-8aaa-ffe61d539bb1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_73ac4b29-da81-4ecf-80bf-018c3795bf24" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_6841accb-4488-41e3-8aaa-ffe61d539bb1" xlink:to="loc_us-gaap_ForeignExchangeContractMember_73ac4b29-da81-4ecf-80bf-018c3795bf24" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_b3217944-4adb-47e6-b634-6fd6fb4de268" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_6841accb-4488-41e3-8aaa-ffe61d539bb1" xlink:to="loc_us-gaap_InterestRateSwapMember_b3217944-4adb-47e6-b634-6fd6fb4de268" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_6e772b2e-7a9b-4a16-92eb-c4a6a2b2512c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_0018cd45-525c-47dd-80ce-b009dafab11b" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_6e772b2e-7a9b-4a16-92eb-c4a6a2b2512c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_6e772b2e-7a9b-4a16-92eb-c4a6a2b2512c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_6e772b2e-7a9b-4a16-92eb-c4a6a2b2512c" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_6e772b2e-7a9b-4a16-92eb-c4a6a2b2512c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_217ed057-564e-4e58-a606-ad616b655c33" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_6e772b2e-7a9b-4a16-92eb-c4a6a2b2512c" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_217ed057-564e-4e58-a606-ad616b655c33" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_06bb411f-0cc6-43e6-9847-5442595c4818" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_217ed057-564e-4e58-a606-ad616b655c33" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_06bb411f-0cc6-43e6-9847-5442595c4818" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_11bbab8a-4e00-4832-a7e0-f316ca7362c7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_217ed057-564e-4e58-a606-ad616b655c33" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_11bbab8a-4e00-4832-a7e0-f316ca7362c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_59e77e1f-2a6f-4a75-b935-2c21825690da" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_217ed057-564e-4e58-a606-ad616b655c33" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_59e77e1f-2a6f-4a75-b935-2c21825690da" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_9fb7d812-69fd-49b9-928a-fde5a39f745f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_217ed057-564e-4e58-a606-ad616b655c33" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_9fb7d812-69fd-49b9-928a-fde5a39f745f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_6aa82de5-8439-4831-a933-a74b1e8a7c35" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_0018cd45-525c-47dd-80ce-b009dafab11b" xlink:to="loc_us-gaap_HedgingDesignationAxis_6aa82de5-8439-4831-a933-a74b1e8a7c35" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_6aa82de5-8439-4831-a933-a74b1e8a7c35_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_6aa82de5-8439-4831-a933-a74b1e8a7c35" xlink:to="loc_us-gaap_HedgingDesignationDomain_6aa82de5-8439-4831-a933-a74b1e8a7c35_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_bf848a88-e6b1-4aee-93ae-acfefb00ef3c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_6aa82de5-8439-4831-a933-a74b1e8a7c35" xlink:to="loc_us-gaap_HedgingDesignationDomain_bf848a88-e6b1-4aee-93ae-acfefb00ef3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_0e199054-97d2-435d-b847-426f4342806b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_bf848a88-e6b1-4aee-93ae-acfefb00ef3c" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_0e199054-97d2-435d-b847-426f4342806b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_894d1ef2-499f-4d57-ad00-36d50d62f21d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_bf848a88-e6b1-4aee-93ae-acfefb00ef3c" xlink:to="loc_us-gaap_NondesignatedMember_894d1ef2-499f-4d57-ad00-36d50d62f21d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_313f6e2e-542e-45e3-b75a-f5e36ce51930" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_0018cd45-525c-47dd-80ce-b009dafab11b" xlink:to="loc_srt_RangeAxis_313f6e2e-542e-45e3-b75a-f5e36ce51930" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_313f6e2e-542e-45e3-b75a-f5e36ce51930_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_313f6e2e-542e-45e3-b75a-f5e36ce51930" xlink:to="loc_srt_RangeMember_313f6e2e-542e-45e3-b75a-f5e36ce51930_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8abf7e84-b7cf-48a4-8754-be469b2f3a55" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_313f6e2e-542e-45e3-b75a-f5e36ce51930" xlink:to="loc_srt_RangeMember_8abf7e84-b7cf-48a4-8754-be469b2f3a55" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_30eaab40-a38d-4141-9b5c-e80fa9c63405" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_8abf7e84-b7cf-48a4-8754-be469b2f3a55" xlink:to="loc_srt_MinimumMember_30eaab40-a38d-4141-9b5c-e80fa9c63405" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_46d0ade4-6b77-4168-a169-35858e890eb3" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_8abf7e84-b7cf-48a4-8754-be469b2f3a55" xlink:to="loc_srt_MaximumMember_46d0ade4-6b77-4168-a169-35858e890eb3" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantandEquipmentPropertyPlantandEquipment" xlink:type="simple" xlink:href="biib-20200930.xsd#PropertyPlantandEquipmentPropertyPlantandEquipment"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/PropertyPlantandEquipmentPropertyPlantandEquipment" xlink:type="extended" id="ic70cbb50225749338d8033b414df3a4b_PropertyPlantandEquipmentPropertyPlantandEquipment"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="biib-20200930.xsd#PropertyPlantandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails" xlink:type="extended" id="idc0ce1bc518a48f08ac015c32d181e5c_PropertyPlantandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ef8ba48f-a794-47ed-bbf8-343dba57391d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_ea3e7642-3a1f-44a2-b14a-0c7ae43742c4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ef8ba48f-a794-47ed-bbf8-343dba57391d" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_ea3e7642-3a1f-44a2-b14a-0c7ae43742c4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_47d960ab-eaa9-4f7e-ab66-2e670289c588" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ef8ba48f-a794-47ed-bbf8-343dba57391d" xlink:to="loc_us-gaap_Depreciation_47d960ab-eaa9-4f7e-ab66-2e670289c588" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NumberOfSquareFeet_0f18d657-f993-41b9-b3fc-f26eaa4159d5" xlink:href="biib-20200930.xsd#biib_NumberOfSquareFeet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ef8ba48f-a794-47ed-bbf8-343dba57391d" xlink:to="loc_biib_NumberOfSquareFeet_0f18d657-f993-41b9-b3fc-f26eaa4159d5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_c8fa5c17-0dc8-4d70-af3d-052ef9bdb69e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ef8ba48f-a794-47ed-bbf8-343dba57391d" xlink:to="loc_us-gaap_ConstructionInProgressGross_c8fa5c17-0dc8-4d70-af3d-052ef9bdb69e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_77a80cf8-6c4c-493c-9370-8627e645077e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ef8ba48f-a794-47ed-bbf8-343dba57391d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_77a80cf8-6c4c-493c-9370-8627e645077e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitment_93d39adb-edd5-487e-bab5-7117495ce4a3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCommitment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ef8ba48f-a794-47ed-bbf8-343dba57391d" xlink:to="loc_us-gaap_OtherCommitment_93d39adb-edd5-487e-bab5-7117495ce4a3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_db9609d9-822a-4209-aee7-24b3229d8602" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ef8ba48f-a794-47ed-bbf8-343dba57391d" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_db9609d9-822a-4209-aee7-24b3229d8602" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityLocationAxis_b7230ee9-f549-4ab9-9646-95b9f24f7c41" xlink:href="biib-20200930.xsd#biib_FacilityLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_db9609d9-822a-4209-aee7-24b3229d8602" xlink:to="loc_biib_FacilityLocationAxis_b7230ee9-f549-4ab9-9646-95b9f24f7c41" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityLocationDomain_b7230ee9-f549-4ab9-9646-95b9f24f7c41_default" xlink:href="biib-20200930.xsd#biib_FacilityLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_FacilityLocationAxis_b7230ee9-f549-4ab9-9646-95b9f24f7c41" xlink:to="loc_biib_FacilityLocationDomain_b7230ee9-f549-4ab9-9646-95b9f24f7c41_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityLocationDomain_7880fa0a-c097-411a-8c75-def2d2bde19c" xlink:href="biib-20200930.xsd#biib_FacilityLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_FacilityLocationAxis_b7230ee9-f549-4ab9-9646-95b9f24f7c41" xlink:to="loc_biib_FacilityLocationDomain_7880fa0a-c097-411a-8c75-def2d2bde19c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SolothurnSwitzerlandMember_a68976cf-c889-4ef4-a2a4-164c9ba62bfb" xlink:href="biib-20200930.xsd#biib_SolothurnSwitzerlandMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FacilityLocationDomain_7880fa0a-c097-411a-8c75-def2d2bde19c" xlink:to="loc_biib_SolothurnSwitzerlandMember_a68976cf-c889-4ef4-a2a4-164c9ba62bfb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityTypeAxis_afc2bd50-5b12-4da0-a3ba-da306fa44abf" xlink:href="biib-20200930.xsd#biib_FacilityTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_db9609d9-822a-4209-aee7-24b3229d8602" xlink:to="loc_biib_FacilityTypeAxis_afc2bd50-5b12-4da0-a3ba-da306fa44abf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityTypeDomain_afc2bd50-5b12-4da0-a3ba-da306fa44abf_default" xlink:href="biib-20200930.xsd#biib_FacilityTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_FacilityTypeAxis_afc2bd50-5b12-4da0-a3ba-da306fa44abf" xlink:to="loc_biib_FacilityTypeDomain_afc2bd50-5b12-4da0-a3ba-da306fa44abf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityTypeDomain_0816c29f-f379-44f0-ba6a-b21118c4035f" xlink:href="biib-20200930.xsd#biib_FacilityTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_FacilityTypeAxis_afc2bd50-5b12-4da0-a3ba-da306fa44abf" xlink:to="loc_biib_FacilityTypeDomain_0816c29f-f379-44f0-ba6a-b21118c4035f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BiologicsManufacturingMember_4f882cc6-1ffe-4d9a-b2ca-7d64d1a87be8" xlink:href="biib-20200930.xsd#biib_BiologicsManufacturingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FacilityTypeDomain_0816c29f-f379-44f0-ba6a-b21118c4035f" xlink:to="loc_biib_BiologicsManufacturingMember_4f882cc6-1ffe-4d9a-b2ca-7d64d1a87be8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_WarehouseUtilitiesAndSupportSpaceMember_8c56dfec-7ef6-4de4-b061-03a58ae67964" xlink:href="biib-20200930.xsd#biib_WarehouseUtilitiesAndSupportSpaceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FacilityTypeDomain_0816c29f-f379-44f0-ba6a-b21118c4035f" xlink:to="loc_biib_WarehouseUtilitiesAndSupportSpaceMember_8c56dfec-7ef6-4de4-b061-03a58ae67964" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdministrativeSpaceMember_efbd39c6-1600-4459-9a22-71db625e07bc" xlink:href="biib-20200930.xsd#biib_AdministrativeSpaceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FacilityTypeDomain_0816c29f-f379-44f0-ba6a-b21118c4035f" xlink:to="loc_biib_AdministrativeSpaceMember_efbd39c6-1600-4459-9a22-71db625e07bc" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IndebtednessNotes" xlink:type="simple" xlink:href="biib-20200930.xsd#IndebtednessNotes"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IndebtednessNotes" xlink:type="extended" id="i6b484c4c66a447d1b845dd9286bbfee8_IndebtednessNotes"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IndebtednessDetails" xlink:type="simple" xlink:href="biib-20200930.xsd#IndebtednessDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IndebtednessDetails" xlink:type="extended" id="i6b6cf9b1f59d40cc9d38fca899eceacf_IndebtednessDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_4d6c6733-4a8a-40d3-bec1-313724fc73f6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_2616c64b-aea0-4b88-ba86-761093183ec7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4d6c6733-4a8a-40d3-bec1-313724fc73f6" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_2616c64b-aea0-4b88-ba86-761093183ec7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_ff906f36-73ac-4304-be34-d17f0cb40752" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4d6c6733-4a8a-40d3-bec1-313724fc73f6" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_ff906f36-73ac-4304-be34-d17f0cb40752" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageParValueOfSeniorNotes_b6ba385d-8749-47b2-b986-ab6bc1cecf47" xlink:href="biib-20200930.xsd#biib_PercentageParValueOfSeniorNotes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4d6c6733-4a8a-40d3-bec1-313724fc73f6" xlink:to="loc_biib_PercentageParValueOfSeniorNotes_b6ba385d-8749-47b2-b986-ab6bc1cecf47" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_3ac4a626-79cf-4c87-bce4-c22c3d15ee0b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4d6c6733-4a8a-40d3-bec1-313724fc73f6" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_3ac4a626-79cf-4c87-bce4-c22c3d15ee0b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage_d37a0f0d-6879-47a4-ad02-9dcf15dd91a4" xlink:href="biib-20200930.xsd#biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4d6c6733-4a8a-40d3-bec1-313724fc73f6" xlink:to="loc_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage_d37a0f0d-6879-47a4-ad02-9dcf15dd91a4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_8a3f5554-df15-4905-b040-c42a88083ea9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4d6c6733-4a8a-40d3-bec1-313724fc73f6" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts_8a3f5554-df15-4905-b040-c42a88083ea9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain_745593be-5a34-4c83-8100-aa64cab57183" xlink:href="biib-20200930.xsd#biib_PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4d6c6733-4a8a-40d3-bec1-313724fc73f6" xlink:to="loc_biib_PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain_745593be-5a34-4c83-8100-aa64cab57183" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts_10545696-30b9-42f0-9d76-c4a3c3bfd326" xlink:href="biib-20200930.xsd#biib_EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4d6c6733-4a8a-40d3-bec1-313724fc73f6" xlink:to="loc_biib_EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts_10545696-30b9-42f0-9d76-c4a3c3bfd326" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_473e4719-cce8-463d-bbbd-7e4d3eea715f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4d6c6733-4a8a-40d3-bec1-313724fc73f6" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_473e4719-cce8-463d-bbbd-7e4d3eea715f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_862a0174-e4b7-47af-9fc5-4096776d63e9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4d6c6733-4a8a-40d3-bec1-313724fc73f6" xlink:to="loc_us-gaap_DebtInstrumentTable_862a0174-e4b7-47af-9fc5-4096776d63e9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_15df600d-4585-45d2-a848-c908025f4d67" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_862a0174-e4b7-47af-9fc5-4096776d63e9" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_15df600d-4585-45d2-a848-c908025f4d67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_15df600d-4585-45d2-a848-c908025f4d67_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_15df600d-4585-45d2-a848-c908025f4d67" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_15df600d-4585-45d2-a848-c908025f4d67_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_4242d8df-f20a-49b0-86e7-6f67503bf79c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_15df600d-4585-45d2-a848-c908025f4d67" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_4242d8df-f20a-49b0-86e7-6f67503bf79c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseMember_c788cb0b-cb43-465e-8ab7-6266f915d152" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_4242d8df-f20a-49b0-86e7-6f67503bf79c" xlink:to="loc_us-gaap_InterestExpenseMember_c788cb0b-cb43-465e-8ab7-6266f915d152" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_79bcd0ca-610f-4d17-8e55-fbd89926c380" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_862a0174-e4b7-47af-9fc5-4096776d63e9" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_79bcd0ca-610f-4d17-8e55-fbd89926c380" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_79bcd0ca-610f-4d17-8e55-fbd89926c380_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_79bcd0ca-610f-4d17-8e55-fbd89926c380" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_79bcd0ca-610f-4d17-8e55-fbd89926c380_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_42a162fb-d391-46fa-8a36-662e2f867b70" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_79bcd0ca-610f-4d17-8e55-fbd89926c380" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_42a162fb-d391-46fa-8a36-662e2f867b70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_30baf4cd-ecc9-48bc-b613-9029a000649a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_42a162fb-d391-46fa-8a36-662e2f867b70" xlink:to="loc_us-gaap_InterestRateSwapMember_30baf4cd-ecc9-48bc-b613-9029a000649a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_4d7e1429-525d-4600-a129-faa4b7d7fbac" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_862a0174-e4b7-47af-9fc5-4096776d63e9" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_4d7e1429-525d-4600-a129-faa4b7d7fbac" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_4d7e1429-525d-4600-a129-faa4b7d7fbac_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_4d7e1429-525d-4600-a129-faa4b7d7fbac" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_4d7e1429-525d-4600-a129-faa4b7d7fbac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_3c5219ac-ee85-4e20-bb29-998d6a651cc3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_4d7e1429-525d-4600-a129-faa4b7d7fbac" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_3c5219ac-ee85-4e20-bb29-998d6a651cc3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_1b418c79-6038-4e77-83e3-f8bd2e880e87" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_3c5219ac-ee85-4e20-bb29-998d6a651cc3" xlink:to="loc_us-gaap_SeniorNotesMember_1b418c79-6038-4e77-83e3-f8bd2e880e87" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_148c0ae5-8f05-4e62-9310-77c92102b041" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_862a0174-e4b7-47af-9fc5-4096776d63e9" xlink:to="loc_us-gaap_DebtInstrumentAxis_148c0ae5-8f05-4e62-9310-77c92102b041" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_148c0ae5-8f05-4e62-9310-77c92102b041_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_148c0ae5-8f05-4e62-9310-77c92102b041" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_148c0ae5-8f05-4e62-9310-77c92102b041_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_05952a62-c822-46a6-bf46-27ede2a3f3a3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_148c0ae5-8f05-4e62-9310-77c92102b041" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_05952a62-c822-46a6-bf46-27ede2a3f3a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2.25SeniorNotesdueMay12030Member_af6538eb-d7f6-4d1a-b755-be003613eb21" xlink:href="biib-20200930.xsd#biib_A2.25SeniorNotesdueMay12030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_05952a62-c822-46a6-bf46-27ede2a3f3a3" xlink:to="loc_biib_A2.25SeniorNotesdueMay12030Member_af6538eb-d7f6-4d1a-b755-be003613eb21" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A3.15SeniorNotesdueMay12050Member_08234c34-18ba-4d8f-aacb-4565ad359585" xlink:href="biib-20200930.xsd#biib_A3.15SeniorNotesdueMay12050Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_05952a62-c822-46a6-bf46-27ede2a3f3a3" xlink:to="loc_biib_A3.15SeniorNotesdueMay12050Member_08234c34-18ba-4d8f-aacb-4565ad359585" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2.90SeniorNotesDueSept152020Member_45c113ff-084f-4808-85db-de5bd36143e4" xlink:href="biib-20200930.xsd#biib_A2.90SeniorNotesDueSept152020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_05952a62-c822-46a6-bf46-27ede2a3f3a3" xlink:to="loc_biib_A2.90SeniorNotesDueSept152020Member_45c113ff-084f-4808-85db-de5bd36143e4" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/Equity" xlink:type="simple" xlink:href="biib-20200930.xsd#Equity"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/Equity" xlink:type="extended" id="id388cf69f55f433ea58130017aeeb45f_Equity"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables" xlink:type="simple" xlink:href="biib-20200930.xsd#AccumulatedOtherComprehensiveIncomeLossTables"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables" xlink:type="extended" id="iaa063e68566645b1bfb083c2d81af623_AccumulatedOtherComprehensiveIncomeLossTables"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareRepurchasesDetails" xlink:type="simple" xlink:href="biib-20200930.xsd#ShareRepurchasesDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareRepurchasesDetails" xlink:type="extended" id="i1535065762be4c6eaa93fbf3c3a0ba22_ShareRepurchasesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_12f2bbac-79ef-4af3-a72c-f74162161423" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_a131eb33-a107-4372-a50f-1e0783475516" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_12f2bbac-79ef-4af3-a72c-f74162161423" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_a131eb33-a107-4372-a50f-1e0783475516" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_4962c88f-f86a-4e87-8366-60ee27bc5ec7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_12f2bbac-79ef-4af3-a72c-f74162161423" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_4962c88f-f86a-4e87-8366-60ee27bc5ec7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_ddb8e337-dd7c-4abc-a39b-c9b190c696fb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_12f2bbac-79ef-4af3-a72c-f74162161423" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_ddb8e337-dd7c-4abc-a39b-c9b190c696fb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_65693398-0a2a-498b-ace9-98643d493d26" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_12f2bbac-79ef-4af3-a72c-f74162161423" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_65693398-0a2a-498b-ace9-98643d493d26" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_41a3b8ac-cac7-45a7-ac05-e486d8bd65e4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_12f2bbac-79ef-4af3-a72c-f74162161423" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_41a3b8ac-cac7-45a7-ac05-e486d8bd65e4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_916e1218-a438-463d-b76e-ee7a980f5c6f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_41a3b8ac-cac7-45a7-ac05-e486d8bd65e4" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_916e1218-a438-463d-b76e-ee7a980f5c6f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_916e1218-a438-463d-b76e-ee7a980f5c6f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_916e1218-a438-463d-b76e-ee7a980f5c6f" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_916e1218-a438-463d-b76e-ee7a980f5c6f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_05fdbee8-e0fd-4114-b68e-eb0c3f00f858" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_916e1218-a438-463d-b76e-ee7a980f5c6f" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_05fdbee8-e0fd-4114-b68e-eb0c3f00f858" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_0938c08a-a35c-47b7-b85e-acd1aeb7799a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_05fdbee8-e0fd-4114-b68e-eb0c3f00f858" xlink:to="loc_us-gaap_SubsequentEventMember_0938c08a-a35c-47b7-b85e-acd1aeb7799a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_a0db8c86-f44d-4f5d-84d4-d468596638ea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_41a3b8ac-cac7-45a7-ac05-e486d8bd65e4" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_a0db8c86-f44d-4f5d-84d4-d468596638ea" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_a0db8c86-f44d-4f5d-84d4-d468596638ea_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_a0db8c86-f44d-4f5d-84d4-d468596638ea" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_a0db8c86-f44d-4f5d-84d4-d468596638ea_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_8bc5f572-97e2-4141-a8db-c21ce62ab57d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_a0db8c86-f44d-4f5d-84d4-d468596638ea" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_8bc5f572-97e2-4141-a8db-c21ce62ab57d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_December2019ShareRepurchaseProgramMember_f63fc1c0-8afe-449a-85dc-b047ce5bd6be" xlink:href="biib-20200930.xsd#biib_December2019ShareRepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_8bc5f572-97e2-4141-a8db-c21ce62ab57d" xlink:to="loc_biib_December2019ShareRepurchaseProgramMember_f63fc1c0-8afe-449a-85dc-b047ce5bd6be" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_March2019ShareRepurchaseProgramMember_ece58675-c04f-474d-8ea5-c4aed34bfe92" xlink:href="biib-20200930.xsd#biib_March2019ShareRepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_8bc5f572-97e2-4141-a8db-c21ce62ab57d" xlink:to="loc_biib_March2019ShareRepurchaseProgramMember_ece58675-c04f-474d-8ea5-c4aed34bfe92" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_October2020ShareRepurchaseProgramMember_5f113079-20d1-4d17-8be4-7200d41c30e2" xlink:href="biib-20200930.xsd#biib_October2020ShareRepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_8bc5f572-97e2-4141-a8db-c21ce62ab57d" xlink:to="loc_biib_October2020ShareRepurchaseProgramMember_5f113079-20d1-4d17-8be4-7200d41c30e2" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="biib-20200930.xsd#AccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended" id="idba67bb7b88b419fbdefe206e26a0978_AccumulatedOtherComprehensiveIncomeLossDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_2b1bf00e-5bd5-499d-ae8d-f07455bd73f8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_7e74cc93-f337-41d7-b701-78bcd5e7ee2d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_2b1bf00e-5bd5-499d-ae8d-f07455bd73f8" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_7e74cc93-f337-41d7-b701-78bcd5e7ee2d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_909cb44c-a738-4239-8051-52a1cff4a9c0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_d5fc9af6-ea78-4d57-96e0-75baf7004ead" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_2b1bf00e-5bd5-499d-ae8d-f07455bd73f8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_d5fc9af6-ea78-4d57-96e0-75baf7004ead" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_f53bb292-63dc-4b72-829a-3a62dd84a6f5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_2b1bf00e-5bd5-499d-ae8d-f07455bd73f8" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_f53bb292-63dc-4b72-829a-3a62dd84a6f5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_f0893267-7fe5-43a6-8163-12e8447f5718" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_2b1bf00e-5bd5-499d-ae8d-f07455bd73f8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_f0893267-7fe5-43a6-8163-12e8447f5718" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_52c3769d-e073-4e39-81c8-090a22c19789" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_544d3f80-de49-4cef-99d9-5a654f970ac5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_2b1bf00e-5bd5-499d-ae8d-f07455bd73f8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_544d3f80-de49-4cef-99d9-5a654f970ac5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_6c60bd5c-9842-4a45-942f-f0f0d01e5992" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_2b1bf00e-5bd5-499d-ae8d-f07455bd73f8" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_6c60bd5c-9842-4a45-942f-f0f0d01e5992" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_5fcf54e6-3e2c-46b2-9a4e-9742975d427a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_6c60bd5c-9842-4a45-942f-f0f0d01e5992" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_5fcf54e6-3e2c-46b2-9a4e-9742975d427a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_5fcf54e6-3e2c-46b2-9a4e-9742975d427a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5fcf54e6-3e2c-46b2-9a4e-9742975d427a" xlink:to="loc_us-gaap_EquityComponentDomain_5fcf54e6-3e2c-46b2-9a4e-9742975d427a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b0bbc8b5-1b0b-4fb5-9f51-612a6883afca" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5fcf54e6-3e2c-46b2-9a4e-9742975d427a" xlink:to="loc_us-gaap_EquityComponentDomain_b0bbc8b5-1b0b-4fb5-9f51-612a6883afca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_93dd65c1-06ba-4be8-b48f-3ed2170f902d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b0bbc8b5-1b0b-4fb5-9f51-612a6883afca" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_93dd65c1-06ba-4be8-b48f-3ed2170f902d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_38152238-aa37-4dff-bcd6-217d4396f1af" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b0bbc8b5-1b0b-4fb5-9f51-612a6883afca" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_38152238-aa37-4dff-bcd6-217d4396f1af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_3a4bec21-bb72-471d-89b7-500b39f1ea41" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b0bbc8b5-1b0b-4fb5-9f51-612a6883afca" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_3a4bec21-bb72-471d-89b7-500b39f1ea41" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_2828fe3b-ef41-4fb8-b18d-a0ac570203ae" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b0bbc8b5-1b0b-4fb5-9f51-612a6883afca" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_2828fe3b-ef41-4fb8-b18d-a0ac570203ae" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_11ab4225-5408-443e-b6f7-315ea9087632" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b0bbc8b5-1b0b-4fb5-9f51-612a6883afca" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_11ab4225-5408-443e-b6f7-315ea9087632" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="biib-20200930.xsd#ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended" id="i95ee376caa054bc1bbbc9c244f95c1be_ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_564479f2-8c44-46e2-ad54-f009781b0c34" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_6a520a5d-6162-430a-93cb-420e4bd0ae59" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_564479f2-8c44-46e2-ad54-f009781b0c34" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_6a520a5d-6162-430a-93cb-420e4bd0ae59" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_49c17cd5-4028-4353-a1fc-efe60cd69a2b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_564479f2-8c44-46e2-ad54-f009781b0c34" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_49c17cd5-4028-4353-a1fc-efe60cd69a2b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_e1e26db5-426c-4535-8489-c7c5117a3818" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_564479f2-8c44-46e2-ad54-f009781b0c34" xlink:to="loc_us-gaap_Revenues_e1e26db5-426c-4535-8489-c7c5117a3818" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_20588aa8-3130-4170-8c81-5e12c9002fce" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_564479f2-8c44-46e2-ad54-f009781b0c34" xlink:to="loc_us-gaap_OperatingExpenses_20588aa8-3130-4170-8c81-5e12c9002fce" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_40218c17-0125-426e-9d8d-bbfc13b28120" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_564479f2-8c44-46e2-ad54-f009781b0c34" xlink:to="loc_us-gaap_NetIncomeLoss_40218c17-0125-426e-9d8d-bbfc13b28120" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_938e6a11-b0d6-46c7-b7a0-d2f16733748d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_564479f2-8c44-46e2-ad54-f009781b0c34" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_938e6a11-b0d6-46c7-b7a0-d2f16733748d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_f0d7b2e5-e9fe-48b2-ae96-c9ed953d85e5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_938e6a11-b0d6-46c7-b7a0-d2f16733748d" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_f0d7b2e5-e9fe-48b2-ae96-c9ed953d85e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f0d7b2e5-e9fe-48b2-ae96-c9ed953d85e5_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f0d7b2e5-e9fe-48b2-ae96-c9ed953d85e5" xlink:to="loc_us-gaap_EquityComponentDomain_f0d7b2e5-e9fe-48b2-ae96-c9ed953d85e5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_50ec4908-6201-4f0e-8a16-87ff68738da4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f0d7b2e5-e9fe-48b2-ae96-c9ed953d85e5" xlink:to="loc_us-gaap_EquityComponentDomain_50ec4908-6201-4f0e-8a16-87ff68738da4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_5485237d-43b3-4d11-b410-9dfd86a00497" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_50ec4908-6201-4f0e-8a16-87ff68738da4" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_5485237d-43b3-4d11-b410-9dfd86a00497" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_8f54f0a4-7589-45c2-af97-71c0ca065588" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_50ec4908-6201-4f0e-8a16-87ff68738da4" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_8f54f0a4-7589-45c2-af97-71c0ca065588" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_f6d42db3-90db-4e1c-8707-427c53c0f3fb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_50ec4908-6201-4f0e-8a16-87ff68738da4" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_f6d42db3-90db-4e1c-8707-427c53c0f3fb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_dc0e603a-7e61-4704-ad9e-5ab358ea0fe5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_938e6a11-b0d6-46c7-b7a0-d2f16733748d" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_dc0e603a-7e61-4704-ad9e-5ab358ea0fe5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_dc0e603a-7e61-4704-ad9e-5ab358ea0fe5_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_dc0e603a-7e61-4704-ad9e-5ab358ea0fe5" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_dc0e603a-7e61-4704-ad9e-5ab358ea0fe5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_c11cca39-ab34-4991-8d5b-aec307f7cf7b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_dc0e603a-7e61-4704-ad9e-5ab358ea0fe5" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_c11cca39-ab34-4991-8d5b-aec307f7cf7b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_a3cb841c-96cc-4480-a14c-b8c11643e3e0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_c11cca39-ab34-4991-8d5b-aec307f7cf7b" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_a3cb841c-96cc-4480-a14c-b8c11643e3e0" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsperShare" xlink:type="simple" xlink:href="biib-20200930.xsd#EarningsperShare"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/EarningsperShare" xlink:type="extended" id="i730e539e3af6427999f43b789841390e_EarningsperShare"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsperShareTables" xlink:type="simple" xlink:href="biib-20200930.xsd#EarningsperShareTables"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/EarningsperShareTables" xlink:type="extended" id="i17e1b4fb0084438cbbab39679db66afc_EarningsperShareTables"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsperShareDetails" xlink:type="simple" xlink:href="biib-20200930.xsd#EarningsperShareDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/EarningsperShareDetails" xlink:type="extended" id="i5c95df8c79314c20a311f53539e65786_EarningsperShareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_99d3d4a8-236e-4d29-aaa1-6a2a4e44a3c9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BasicAndDilutedEarningsPerShareAbstract_ffd59753-ab3e-4960-9227-4d04ad674efd" xlink:href="biib-20200930.xsd#biib_BasicAndDilutedEarningsPerShareAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_99d3d4a8-236e-4d29-aaa1-6a2a4e44a3c9" xlink:to="loc_biib_BasicAndDilutedEarningsPerShareAbstract_ffd59753-ab3e-4960-9227-4d04ad674efd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract_1ba27df6-9ccd-4b43-8c08-36682aa40f3a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract_ffd59753-ab3e-4960-9227-4d04ad674efd" xlink:to="loc_us-gaap_NetIncomeLossAbstract_1ba27df6-9ccd-4b43-8c08-36682aa40f3a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_100286d2-4d1f-4089-9063-277788bc33ac" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLossAbstract_1ba27df6-9ccd-4b43-8c08-36682aa40f3a" xlink:to="loc_us-gaap_NetIncomeLoss_100286d2-4d1f-4089-9063-277788bc33ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_7ddb108a-ab17-4e50-b1c1-09a95267f731" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract_ffd59753-ab3e-4960-9227-4d04ad674efd" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_7ddb108a-ab17-4e50-b1c1-09a95267f731" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_cca87c7e-4196-4b47-ab7c-13cf5b4fd3cb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_7ddb108a-ab17-4e50-b1c1-09a95267f731" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_cca87c7e-4196-4b47-ab7c-13cf5b4fd3cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_45e65489-db8b-42e8-9438-2a11e6a5f2f4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_7ddb108a-ab17-4e50-b1c1-09a95267f731" xlink:to="loc_us-gaap_DilutiveSecuritiesAbstract_45e65489-db8b-42e8-9438-2a11e6a5f2f4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_b4b0221f-5c68-4ec5-821a-82cf206494f7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_45e65489-db8b-42e8-9438-2a11e6a5f2f4" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_b4b0221f-5c68-4ec5-821a-82cf206494f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_40ac3d89-fde7-4cfd-86f3-1ec84bf53d64" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_45e65489-db8b-42e8-9438-2a11e6a5f2f4" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_40ac3d89-fde7-4cfd-86f3-1ec84bf53d64" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7b4aa7fe-08d0-42ec-94e6-1641b6b964f9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_7ddb108a-ab17-4e50-b1c1-09a95267f731" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7b4aa7fe-08d0-42ec-94e6-1641b6b964f9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_3ba4eecd-28e6-4d73-a3f9-127bfcc94274" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_99d3d4a8-236e-4d29-aaa1-6a2a4e44a3c9" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_3ba4eecd-28e6-4d73-a3f9-127bfcc94274" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5a03a177-b9e6-4f9c-8d54-08814097c452" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_3ba4eecd-28e6-4d73-a3f9-127bfcc94274" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5a03a177-b9e6-4f9c-8d54-08814097c452" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5a03a177-b9e6-4f9c-8d54-08814097c452_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5a03a177-b9e6-4f9c-8d54-08814097c452" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5a03a177-b9e6-4f9c-8d54-08814097c452_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_58e6e608-69b9-40fe-b3d4-031b8f8f851a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5a03a177-b9e6-4f9c-8d54-08814097c452" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_58e6e608-69b9-40fe-b3d4-031b8f8f851a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_def8a2ec-9abc-41dd-b135-27eb0251684f" xlink:href="biib-20200930.xsd#biib_TimeVestedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_58e6e608-69b9-40fe-b3d4-031b8f8f851a" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_def8a2ec-9abc-41dd-b135-27eb0251684f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MarketStockUnitsMember_c29b8cec-c98b-461c-96cc-8b5007063b31" xlink:href="biib-20200930.xsd#biib_MarketStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_58e6e608-69b9-40fe-b3d4-031b8f8f851a" xlink:to="loc_biib_MarketStockUnitsMember_c29b8cec-c98b-461c-96cc-8b5007063b31" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockMember_72ce6b86-6d92-456d-ab32-3d2f541d6cbe" xlink:href="biib-20200930.xsd#biib_PerformanceStockUnitsSettledinStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_58e6e608-69b9-40fe-b3d4-031b8f8f851a" xlink:to="loc_biib_PerformanceStockUnitsSettledinStockMember_72ce6b86-6d92-456d-ab32-3d2f541d6cbe" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/SharebasedPayments" xlink:type="simple" xlink:href="biib-20200930.xsd#SharebasedPayments"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/SharebasedPayments" xlink:type="extended" id="i4b3ec3f6551140ab827ef29504331f12_SharebasedPayments"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:type="simple" xlink:href="biib-20200930.xsd#ShareBasedPaymentsTables"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:type="extended" id="i6b1bb30cdc9a48c69fa85d4c9f073b50_ShareBasedPaymentsTables"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:type="simple" xlink:href="biib-20200930.xsd#ShareBasedPaymentsDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:type="extended" id="if6f344241432492f9370ef42169b05a1_ShareBasedPaymentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_8856fba5-79e9-45ef-aa0c-132ba289b07d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_02ab4075-5b94-4913-806e-10a698ddce35" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_8856fba5-79e9-45ef-aa0c-132ba289b07d" xlink:to="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_02ab4075-5b94-4913-806e-10a698ddce35" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_0c3d996b-05d8-4aa8-9719-e74b1ab685c3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_02ab4075-5b94-4913-806e-10a698ddce35" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_0c3d996b-05d8-4aa8-9719-e74b1ab685c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_5426eb29-d7b9-4fc4-a4dd-9caddf0b4a49" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_02ab4075-5b94-4913-806e-10a698ddce35" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_5426eb29-d7b9-4fc4-a4dd-9caddf0b4a49" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_a0445a65-f1cb-4a09-a8dd-f8947c11d027" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_02ab4075-5b94-4913-806e-10a698ddce35" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_a0445a65-f1cb-4a09-a8dd-f8947c11d027" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_4673baed-f864-4b5c-8e3a-3e090fb86b00" xlink:href="biib-20200930.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_02ab4075-5b94-4913-806e-10a698ddce35" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_4673baed-f864-4b5c-8e3a-3e090fb86b00" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_15f82707-cc62-40ee-9d4d-44ed9b5ec46d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_02ab4075-5b94-4913-806e-10a698ddce35" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_15f82707-cc62-40ee-9d4d-44ed9b5ec46d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_2923e89e-ef4c-4184-88e0-c63f3d430dc1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_8856fba5-79e9-45ef-aa0c-132ba289b07d" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_2923e89e-ef4c-4184-88e0-c63f3d430dc1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_b468b0f0-f2b7-45c9-9877-cf07589a8b2e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_2923e89e-ef4c-4184-88e0-c63f3d430dc1" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_b468b0f0-f2b7-45c9-9877-cf07589a8b2e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_b468b0f0-f2b7-45c9-9877-cf07589a8b2e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_b468b0f0-f2b7-45c9-9877-cf07589a8b2e" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_b468b0f0-f2b7-45c9-9877-cf07589a8b2e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_f81dcf66-bcc3-45df-91a4-3cf3604308ca" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_b468b0f0-f2b7-45c9-9877-cf07589a8b2e" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_f81dcf66-bcc3-45df-91a4-3cf3604308ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_842b7741-d243-45cf-8cba-3ef760ae3080" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_f81dcf66-bcc3-45df-91a4-3cf3604308ca" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_842b7741-d243-45cf-8cba-3ef760ae3080" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_9b9f4f83-6713-4284-9caa-9dd8cca59f02" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_f81dcf66-bcc3-45df-91a4-3cf3604308ca" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_9b9f4f83-6713-4284-9caa-9dd8cca59f02" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_56884467-e14b-4dc9-a879-ae9630e330c8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_f81dcf66-bcc3-45df-91a4-3cf3604308ca" xlink:to="loc_us-gaap_ParentMember_56884467-e14b-4dc9-a879-ae9630e330c8" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:type="simple" xlink:href="biib-20200930.xsd#ShareBasedPaymentsDetails1"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:type="extended" id="iab5ee0dfc6cf47afa4d5df31e14ae227_ShareBasedPaymentsDetails1">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_204b864d-24d0-4e36-8a97-cfef547acd3b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_24fd2d94-8d0d-4109-8012-2cb43b9026f7" xlink:href="biib-20200930.xsd#biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_204b864d-24d0-4e36-8a97-cfef547acd3b" xlink:to="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_24fd2d94-8d0d-4109-8012-2cb43b9026f7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_4573a8f1-7157-48f6-be74-32397997c62e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_24fd2d94-8d0d-4109-8012-2cb43b9026f7" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_4573a8f1-7157-48f6-be74-32397997c62e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_6af17848-b97e-4737-8869-4f2c394d195e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_24fd2d94-8d0d-4109-8012-2cb43b9026f7" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_6af17848-b97e-4737-8869-4f2c394d195e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_26425fdd-f8ba-4d6e-992c-76c33cdc6be5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_24fd2d94-8d0d-4109-8012-2cb43b9026f7" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_26425fdd-f8ba-4d6e-992c-76c33cdc6be5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_ced7be96-d533-4314-a8eb-4fe9f811569d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_24fd2d94-8d0d-4109-8012-2cb43b9026f7" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_ced7be96-d533-4314-a8eb-4fe9f811569d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_f3b6e9f5-5cfd-4a85-b1b0-04aec729505a" xlink:href="biib-20200930.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_24fd2d94-8d0d-4109-8012-2cb43b9026f7" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_f3b6e9f5-5cfd-4a85-b1b0-04aec729505a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_ab760de6-c83d-4230-ae2e-56e11a812eea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_204b864d-24d0-4e36-8a97-cfef547acd3b" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_ab760de6-c83d-4230-ae2e-56e11a812eea" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_249b90b4-54cd-49d5-a344-aa97048eed53" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_ab760de6-c83d-4230-ae2e-56e11a812eea" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_249b90b4-54cd-49d5-a344-aa97048eed53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_249b90b4-54cd-49d5-a344-aa97048eed53_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_249b90b4-54cd-49d5-a344-aa97048eed53" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_249b90b4-54cd-49d5-a344-aa97048eed53_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e53b09d1-d405-4078-a591-3f1448c6bbaa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_249b90b4-54cd-49d5-a344-aa97048eed53" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e53b09d1-d405-4078-a591-3f1448c6bbaa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NightstarMember_0bf8ab4d-021a-4f2e-b64f-5588c81cb157" xlink:href="biib-20200930.xsd#biib_NightstarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e53b09d1-d405-4078-a591-3f1448c6bbaa" xlink:to="loc_biib_NightstarMember_0bf8ab4d-021a-4f2e-b64f-5588c81cb157" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_990e11e8-dba5-49de-a634-29cf2b8eeb33" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_ab760de6-c83d-4230-ae2e-56e11a812eea" xlink:to="loc_us-gaap_AwardTypeAxis_990e11e8-dba5-49de-a634-29cf2b8eeb33" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_990e11e8-dba5-49de-a634-29cf2b8eeb33_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_990e11e8-dba5-49de-a634-29cf2b8eeb33" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_990e11e8-dba5-49de-a634-29cf2b8eeb33_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b9920bd3-0deb-44de-a9b9-248aa7519a97" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_990e11e8-dba5-49de-a634-29cf2b8eeb33" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b9920bd3-0deb-44de-a9b9-248aa7519a97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MarketStockUnitsMember_a6e88429-0889-48bf-b068-9357a6e78566" xlink:href="biib-20200930.xsd#biib_MarketStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b9920bd3-0deb-44de-a9b9-248aa7519a97" xlink:to="loc_biib_MarketStockUnitsMember_a6e88429-0889-48bf-b068-9357a6e78566" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_5bbb689c-a3aa-437f-ae3e-6eba0154c4ba" xlink:href="biib-20200930.xsd#biib_TimeVestedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b9920bd3-0deb-44de-a9b9-248aa7519a97" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_5bbb689c-a3aa-437f-ae3e-6eba0154c4ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CashSettledPerformanceSharesMember_7fdb14f3-7bc3-4d83-ba21-61f3e2710dea" xlink:href="biib-20200930.xsd#biib_CashSettledPerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b9920bd3-0deb-44de-a9b9-248aa7519a97" xlink:to="loc_biib_CashSettledPerformanceSharesMember_7fdb14f3-7bc3-4d83-ba21-61f3e2710dea" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_1699c51b-338f-4022-8d7c-3b467642bf9a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b9920bd3-0deb-44de-a9b9-248aa7519a97" xlink:to="loc_us-gaap_PerformanceSharesMember_1699c51b-338f-4022-8d7c-3b467642bf9a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockMember_3b3af057-1681-4b50-9b8e-2e796e26eceb" xlink:href="biib-20200930.xsd#biib_PerformanceStockUnitsSettledinStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b9920bd3-0deb-44de-a9b9-248aa7519a97" xlink:to="loc_biib_PerformanceStockUnitsSettledinStockMember_3b3af057-1681-4b50-9b8e-2e796e26eceb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceStockUnitsSettledinCashMember_17147a7f-f026-4593-afde-7fa7f3cab0d8" xlink:href="biib-20200930.xsd#biib_PerformanceStockUnitsSettledinCashMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b9920bd3-0deb-44de-a9b9-248aa7519a97" xlink:to="loc_biib_PerformanceStockUnitsSettledinCashMember_17147a7f-f026-4593-afde-7fa7f3cab0d8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EmployeeStockPurchasePlanMember_84e48f88-9970-4663-ab0c-96e81fc85aaa" xlink:href="biib-20200930.xsd#biib_EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b9920bd3-0deb-44de-a9b9-248aa7519a97" xlink:to="loc_biib_EmployeeStockPurchasePlanMember_84e48f88-9970-4663-ab0c-96e81fc85aaa" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_5db46d0e-71ef-467b-ba07-69867ab2c25d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b9920bd3-0deb-44de-a9b9-248aa7519a97" xlink:to="loc_us-gaap_EmployeeStockOptionMember_5db46d0e-71ef-467b-ba07-69867ab2c25d" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxes" xlink:type="simple" xlink:href="biib-20200930.xsd#IncomeTaxes"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IncomeTaxes" xlink:type="extended" id="i1698793e587540c78be787ce220a5080_IncomeTaxes"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="biib-20200930.xsd#IncomeTaxesTables"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:type="extended" id="i2cb7a8bda47848518731a1acbf8dd6ab_IncomeTaxesTables"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:type="simple" xlink:href="biib-20200930.xsd#IncomeTaxesDetailsTextual"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:type="extended" id="ic4477cebec5643f5bf9c957ba29f0e99_IncomeTaxesDetailsTextual">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_7c2b33a6-b0bc-46de-bb4d-e17807af010b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DeferredTaxAssetsValueReductioninValue_d2277abc-2b56-4d16-8baa-6393c0ce86e1" xlink:href="biib-20200930.xsd#biib_DeferredTaxAssetsValueReductioninValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_7c2b33a6-b0bc-46de-bb4d-e17807af010b" xlink:to="loc_biib_DeferredTaxAssetsValueReductioninValue_d2277abc-2b56-4d16-8baa-6393c0ce86e1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DeferredTaxLiabilitiesValueReductioninValue_157c90d3-7628-4584-bb62-0715030020fb" xlink:href="biib-20200930.xsd#biib_DeferredTaxLiabilitiesValueReductioninValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_7c2b33a6-b0bc-46de-bb4d-e17807af010b" xlink:to="loc_biib_DeferredTaxLiabilitiesValueReductioninValue_157c90d3-7628-4584-bb62-0715030020fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IncomeTaxExpenseReductioninDeferredTaxAssetsandLiabilitiesNet_a1a23e53-d994-4e16-b5e9-fe8e857f44a0" xlink:href="biib-20200930.xsd#biib_IncomeTaxExpenseReductioninDeferredTaxAssetsandLiabilitiesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_7c2b33a6-b0bc-46de-bb4d-e17807af010b" xlink:to="loc_biib_IncomeTaxExpenseReductioninDeferredTaxAssetsandLiabilitiesNet_a1a23e53-d994-4e16-b5e9-fe8e857f44a0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_c234ded6-0be6-4b58-a79d-88cafc158c8b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_7c2b33a6-b0bc-46de-bb4d-e17807af010b" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_c234ded6-0be6-4b58-a79d-88cafc158c8b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_722632e3-c9a3-4556-a1be-c63f773916b6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_7c2b33a6-b0bc-46de-bb4d-e17807af010b" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_722632e3-c9a3-4556-a1be-c63f773916b6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_8d6b5234-362f-4b0d-b03c-3a9a175b379d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_7c2b33a6-b0bc-46de-bb4d-e17807af010b" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_8d6b5234-362f-4b0d-b03c-3a9a175b379d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_b36c1d59-b14f-44aa-a3e9-eccf3cea8f68" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_7c2b33a6-b0bc-46de-bb4d-e17807af010b" xlink:to="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_b36c1d59-b14f-44aa-a3e9-eccf3cea8f68" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_a1e06853-eeac-4ce8-beac-a2ec8d6c21a8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_7c2b33a6-b0bc-46de-bb4d-e17807af010b" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_a1e06853-eeac-4ce8-beac-a2ec8d6c21a8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_04830ab3-3ede-4fb4-a2d3-c748f71af45b" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_a1e06853-eeac-4ce8-beac-a2ec8d6c21a8" xlink:to="loc_srt_ProductOrServiceAxis_04830ab3-3ede-4fb4-a2d3-c748f71af45b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_04830ab3-3ede-4fb4-a2d3-c748f71af45b_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_04830ab3-3ede-4fb4-a2d3-c748f71af45b" xlink:to="loc_srt_ProductsAndServicesDomain_04830ab3-3ede-4fb4-a2d3-c748f71af45b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_fc429de9-badd-47ac-86d5-dfdc3dfe829a" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_04830ab3-3ede-4fb4-a2d3-c748f71af45b" xlink:to="loc_srt_ProductsAndServicesDomain_fc429de9-badd-47ac-86d5-dfdc3dfe829a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TECFIDERAMember_0ae8acb2-048f-4c4b-9cd5-b85317c808dd" xlink:href="biib-20200930.xsd#biib_TECFIDERAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_fc429de9-badd-47ac-86d5-dfdc3dfe829a" xlink:to="loc_biib_TECFIDERAMember_0ae8acb2-048f-4c4b-9cd5-b85317c808dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_3f7ec36b-01b8-4ec4-8bad-a2d665676243" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_a1e06853-eeac-4ce8-beac-a2ec8d6c21a8" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_3f7ec36b-01b8-4ec4-8bad-a2d665676243" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_3f7ec36b-01b8-4ec4-8bad-a2d665676243_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_3f7ec36b-01b8-4ec4-8bad-a2d665676243" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_3f7ec36b-01b8-4ec4-8bad-a2d665676243_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_7950e472-ac37-4252-a865-fe061ada78af" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_3f7ec36b-01b8-4ec4-8bad-a2d665676243" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_7950e472-ac37-4252-a865-fe061ada78af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DenmarkManufacturingOperationsMember_51a9f3db-e0ba-4962-97ee-708c952c3ca8" xlink:href="biib-20200930.xsd#biib_DenmarkManufacturingOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_7950e472-ac37-4252-a865-fe061ada78af" xlink:to="loc_biib_DenmarkManufacturingOperationsMember_51a9f3db-e0ba-4962-97ee-708c952c3ca8" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="biib-20200930.xsd#IncomeTaxesDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:type="extended" id="i5fef09fe349042eb8910f0f1fc0058a5_IncomeTaxesDetails"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:type="simple" xlink:href="biib-20200930.xsd#OtherConsolidatedFinancialStatementDetail"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:type="extended" id="i70415d798c9d44d29ed7200651b06eb8_OtherConsolidatedFinancialStatementDetail"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:type="simple" xlink:href="biib-20200930.xsd#OtherConsolidatedFinancialStatementDetailTables"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:type="extended" id="i0a116d4990074ef4ace4bc4ba7735d7e_OtherConsolidatedFinancialStatementDetailTables"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:type="simple" xlink:href="biib-20200930.xsd#OtherConsolidatedFinancialStatementDetailDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:type="extended" id="i8c1124ec1bc244bb8b3754bb9a209fff_OtherConsolidatedFinancialStatementDetailDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_6e8e1afe-5c4a-4cd1-b9c8-bf1a3fab8ebb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNetAbstract_98c0cc85-e2ef-4226-b9ad-936ecf8c7c17" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestIncomeExpenseNetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6e8e1afe-5c4a-4cd1-b9c8-bf1a3fab8ebb" xlink:to="loc_us-gaap_InterestIncomeExpenseNetAbstract_98c0cc85-e2ef-4226-b9ad-936ecf8c7c17" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_55d353ac-c5d0-4620-91cb-cd6348911026" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_98c0cc85-e2ef-4226-b9ad-936ecf8c7c17" xlink:to="loc_us-gaap_InvestmentIncomeInterest_55d353ac-c5d0-4620-91cb-cd6348911026" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_97430be8-79e1-441f-8831-524d39601abb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_98c0cc85-e2ef-4226-b9ad-936ecf8c7c17" xlink:to="loc_us-gaap_InterestExpense_97430be8-79e1-441f-8831-524d39601abb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses_aa83b847-ce34-49c7-97ca-e14f38bbe4bb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_98c0cc85-e2ef-4226-b9ad-936ecf8c7c17" xlink:to="loc_us-gaap_RealizedInvestmentGainsLosses_aa83b847-ce34-49c7-97ca-e14f38bbe4bb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_402d5458-8fe7-43c3-b3d2-644156d373d5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_98c0cc85-e2ef-4226-b9ad-936ecf8c7c17" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_402d5458-8fe7-43c3-b3d2-644156d373d5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_a6a6319f-8ae0-4923-a41d-9551e1adde85" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_98c0cc85-e2ef-4226-b9ad-936ecf8c7c17" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_a6a6319f-8ae0-4923-a41d-9551e1adde85" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_48190505-0dc9-4512-abf1-ca771f75d78f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_98c0cc85-e2ef-4226-b9ad-936ecf8c7c17" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_48190505-0dc9-4512-abf1-ca771f75d78f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_b8c46a2d-5ade-4dd5-94c9-37b3d4eea302" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6e8e1afe-5c4a-4cd1-b9c8-bf1a3fab8ebb" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_b8c46a2d-5ade-4dd5-94c9-37b3d4eea302" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_86c5c0f2-d994-4fa9-9dff-8fc75898506f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_b8c46a2d-5ade-4dd5-94c9-37b3d4eea302" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_86c5c0f2-d994-4fa9-9dff-8fc75898506f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_70b5f85b-7b23-40a4-b0e6-72c0d5d29a48" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_b8c46a2d-5ade-4dd5-94c9-37b3d4eea302" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_70b5f85b-7b23-40a4-b0e6-72c0d5d29a48" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_7144e95c-0af0-45c0-91ce-be1d7bdf3d29" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_b8c46a2d-5ade-4dd5-94c9-37b3d4eea302" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_7144e95c-0af0-45c0-91ce-be1d7bdf3d29" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_8d10204a-1821-4d28-8086-f2f566f4e35f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6e8e1afe-5c4a-4cd1-b9c8-bf1a3fab8ebb" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_8d10204a-1821-4d28-8086-f2f566f4e35f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_26b6cf63-dff0-4527-9c60-89170dbc296b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_8d10204a-1821-4d28-8086-f2f566f4e35f" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_26b6cf63-dff0-4527-9c60-89170dbc296b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_cf8a8371-cabb-468b-a383-72c9af4b33f3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_8d10204a-1821-4d28-8086-f2f566f4e35f" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_cf8a8371-cabb-468b-a383-72c9af4b33f3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_cedb476b-2bc5-4867-acd3-34d175731e56" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_8d10204a-1821-4d28-8086-f2f566f4e35f" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_cedb476b-2bc5-4867-acd3-34d175731e56" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Collaborationexpensesaccrual_1b160aba-1c40-4345-a0fc-748d6b1f537c" xlink:href="biib-20200930.xsd#biib_Collaborationexpensesaccrual"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_8d10204a-1821-4d28-8086-f2f566f4e35f" xlink:to="loc_biib_Collaborationexpensesaccrual_1b160aba-1c40-4345-a0fc-748d6b1f537c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_76e88f2c-0cd5-4032-a0dc-c4faa667a3e0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_8d10204a-1821-4d28-8086-f2f566f4e35f" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_76e88f2c-0cd5-4032-a0dc-c4faa667a3e0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionPayableCurrentAndNoncurrent_968a9358-5d75-4a18-bdc2-af67b720b006" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionPayableCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_8d10204a-1821-4d28-8086-f2f566f4e35f" xlink:to="loc_us-gaap_ConstructionPayableCurrentAndNoncurrent_968a9358-5d75-4a18-bdc2-af67b720b006" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_e1c27acd-8f72-4af4-997b-08025e32dc14" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_8d10204a-1821-4d28-8086-f2f566f4e35f" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_e1c27acd-8f72-4af4-997b-08025e32dc14" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_76ddf816-af7e-410d-8abd-9c36521dc43f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_8d10204a-1821-4d28-8086-f2f566f4e35f" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_76ddf816-af7e-410d-8abd-9c36521dc43f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_9082f149-2e5b-4f96-bf1e-d537621db5c7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_6e8e1afe-5c4a-4cd1-b9c8-bf1a3fab8ebb" xlink:to="loc_us-gaap_StatementTable_9082f149-2e5b-4f96-bf1e-d537621db5c7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_137c0fc7-bde8-4d2b-a744-786b5f84d170" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_9082f149-2e5b-4f96-bf1e-d537621db5c7" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_137c0fc7-bde8-4d2b-a744-786b5f84d170" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_137c0fc7-bde8-4d2b-a744-786b5f84d170_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_137c0fc7-bde8-4d2b-a744-786b5f84d170" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_137c0fc7-bde8-4d2b-a744-786b5f84d170_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_cca51330-10f0-4f9a-8881-3217ad260a80" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_137c0fc7-bde8-4d2b-a744-786b5f84d170" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_cca51330-10f0-4f9a-8881-3217ad260a80" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_114c1835-02f2-460d-a275-93beb9489526" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_cca51330-10f0-4f9a-8881-3217ad260a80" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_114c1835-02f2-460d-a275-93beb9489526" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual" xlink:type="simple" xlink:href="biib-20200930.xsd#OtherConsolidatedFinancialStatementDetailsTextual"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual" xlink:type="extended" id="i6f4aab34eca74f638c3262c31c2a7822_OtherConsolidatedFinancialStatementDetailsTextual">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_1b808303-9e4f-4970-bbd0-66c3cb7d20f6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses_8de9075f-3464-4326-8ed8-4d4f05c98c78" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1b808303-9e4f-4970-bbd0-66c3cb7d20f6" xlink:to="loc_us-gaap_RealizedInvestmentGainsLosses_8de9075f-3464-4326-8ed8-4d4f05c98c78" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_895be676-86ef-4fd2-8167-6370ac77ce61" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1b808303-9e4f-4970-bbd0-66c3cb7d20f6" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_895be676-86ef-4fd2-8167-6370ac77ce61" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent_f91bc871-2b37-477f-986d-58ff0407eaa4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1b808303-9e4f-4970-bbd0-66c3cb7d20f6" xlink:to="loc_us-gaap_AccruedIncomeTaxesNoncurrent_f91bc871-2b37-477f-986d-58ff0407eaa4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_ed8abae7-7dcb-4a03-a288-3823f5b43ac6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1b808303-9e4f-4970-bbd0-66c3cb7d20f6" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_ed8abae7-7dcb-4a03-a288-3823f5b43ac6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_1e598d8b-fbc3-4685-91e8-5218692e418f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1b808303-9e4f-4970-bbd0-66c3cb7d20f6" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_1e598d8b-fbc3-4685-91e8-5218692e418f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsIncomeTaxExpense_e483e566-95c7-4a4d-ad2e-5d71f8426787" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsIncomeTaxExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1b808303-9e4f-4970-bbd0-66c3cb7d20f6" xlink:to="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsIncomeTaxExpense_e483e566-95c7-4a4d-ad2e-5d71f8426787" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_f7f77b4d-3b28-4ca7-ad04-30a6252eac14" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_1b808303-9e4f-4970-bbd0-66c3cb7d20f6" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_f7f77b4d-3b28-4ca7-ad04-30a6252eac14" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_dff1905e-13b1-43bf-8c5e-cfb8467210ec" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_f7f77b4d-3b28-4ca7-ad04-30a6252eac14" xlink:to="loc_dei_LegalEntityAxis_dff1905e-13b1-43bf-8c5e-cfb8467210ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_dff1905e-13b1-43bf-8c5e-cfb8467210ec_default" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_dff1905e-13b1-43bf-8c5e-cfb8467210ec" xlink:to="loc_dei_EntityDomain_dff1905e-13b1-43bf-8c5e-cfb8467210ec_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_a929f224-e210-4487-99ab-739852c17ec5" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_dff1905e-13b1-43bf-8c5e-cfb8467210ec" xlink:to="loc_dei_EntityDomain_a929f224-e210-4487-99ab-739852c17ec5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IonisPharmaceuticalsMember_bcdc0049-a516-416d-a034-027dd64c319d" xlink:href="biib-20200930.xsd#biib_IonisPharmaceuticalsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_a929f224-e210-4487-99ab-739852c17ec5" xlink:to="loc_biib_IonisPharmaceuticalsMember_bcdc0049-a516-416d-a034-027dd64c319d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DenaliTherapeuticsIncMember_dd7c32d6-627b-4d14-8055-90d3a337c5b3" xlink:href="biib-20200930.xsd#biib_DenaliTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_a929f224-e210-4487-99ab-739852c17ec5" xlink:to="loc_biib_DenaliTherapeuticsIncMember_dd7c32d6-627b-4d14-8055-90d3a337c5b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SangamoCommonStockMember_09a58456-f425-461b-9b43-2fa5a6865da8" xlink:href="biib-20200930.xsd#biib_SangamoCommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_a929f224-e210-4487-99ab-739852c17ec5" xlink:to="loc_biib_SangamoCommonStockMember_09a58456-f425-461b-9b43-2fa5a6865da8" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationships" xlink:type="simple" xlink:href="biib-20200930.xsd#CollaborativeandOtherRelationships"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationships" xlink:type="extended" id="i916b7379eade44a3a9fa0f1f0e41e10c_CollaborativeandOtherRelationships"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables" xlink:type="simple" xlink:href="biib-20200930.xsd#CollaborativeandOtherRelationshipsTables"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables" xlink:type="extended" id="i12a9f32ba422405dbafa1c45b4b81308_CollaborativeandOtherRelationshipsTables"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails" xlink:type="simple" xlink:href="biib-20200930.xsd#CollaborativeandOtherRelationshipsCollaborationsDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails" xlink:type="extended" id="i9ab11fdc6da24b6c95d51375327cea7d_CollaborativeandOtherRelationshipsCollaborationsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4a859010-8282-4797-a6d6-a3bf955603ca" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NumberOfProductCandidates_6f387b04-25a3-415a-96dc-d8127c87b7bf" xlink:href="biib-20200930.xsd#biib_NumberOfProductCandidates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4a859010-8282-4797-a6d6-a3bf955603ca" xlink:to="loc_biib_NumberOfProductCandidates_6f387b04-25a3-415a-96dc-d8127c87b7bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased_e6bf7eff-f78d-46e6-a38f-c42232430c53" xlink:href="biib-20200930.xsd#biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4a859010-8282-4797-a6d6-a3bf955603ca" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased_e6bf7eff-f78d-46e6-a38f-c42232430c53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementSharesPurchased_8ecfb1bc-8731-4576-8d5f-dbdba05c75f6" xlink:href="biib-20200930.xsd#biib_GlobalLicensingCollaborationAgreementSharesPurchased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4a859010-8282-4797-a6d6-a3bf955603ca" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementSharesPurchased_8ecfb1bc-8731-4576-8d5f-dbdba05c75f6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare_e820f98d-ad5e-4d53-a176-8e49c065ad1d" xlink:href="biib-20200930.xsd#biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4a859010-8282-4797-a6d6-a3bf955603ca" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare_e820f98d-ad5e-4d53-a176-8e49c065ad1d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_35edc881-8827-4f97-95e6-b26d503ea110" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4a859010-8282-4797-a6d6-a3bf955603ca" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_35edc881-8827-4f97-95e6-b26d503ea110" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ExpenseIncurredByCollaboration_02a96332-c476-416a-ae4b-66e1815db650" xlink:href="biib-20200930.xsd#biib_ExpenseIncurredByCollaboration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4a859010-8282-4797-a6d6-a3bf955603ca" xlink:to="loc_biib_ExpenseIncurredByCollaboration_02a96332-c476-416a-ae4b-66e1815db650" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expenseincurredbythecollaboration_ea706148-f388-42c3-82d1-42a3bb6e40fc" xlink:href="biib-20200930.xsd#biib_Expenseincurredbythecollaboration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4a859010-8282-4797-a6d6-a3bf955603ca" xlink:to="loc_biib_Expenseincurredbythecollaboration_ea706148-f388-42c3-82d1-42a3bb6e40fc" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expensereflectedwithinstatementsofincome_4be2e766-c1bd-47cc-ad8f-2d8b1207b808" xlink:href="biib-20200930.xsd#biib_Expensereflectedwithinstatementsofincome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4a859010-8282-4797-a6d6-a3bf955603ca" xlink:to="loc_biib_Expensereflectedwithinstatementsofincome_4be2e766-c1bd-47cc-ad8f-2d8b1207b808" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_e9a191bd-1fd7-48c0-aa74-32f322420184" xlink:href="biib-20200930.xsd#biib_PercentageoffuturedevelopmentcostsrelatedtoEisai"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4a859010-8282-4797-a6d6-a3bf955603ca" xlink:to="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_e9a191bd-1fd7-48c0-aa74-32f322420184" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossOnContractTermination_46a7280f-088d-4186-bc30-797d200bf73e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossOnContractTermination"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4a859010-8282-4797-a6d6-a3bf955603ca" xlink:to="loc_us-gaap_LossOnContractTermination_46a7280f-088d-4186-bc30-797d200bf73e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_7aa15d4b-1f38-4e63-a69b-e8d994dc7170" xlink:href="biib-20200930.xsd#biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4a859010-8282-4797-a6d6-a3bf955603ca" xlink:to="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_7aa15d4b-1f38-4e63-a69b-e8d994dc7170" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NumberOfNeurologicalDiseaseTargets_cfa5b324-2c50-4709-95b5-5ad4ec61c57a" xlink:href="biib-20200930.xsd#biib_NumberOfNeurologicalDiseaseTargets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4a859010-8282-4797-a6d6-a3bf955603ca" xlink:to="loc_biib_NumberOfNeurologicalDiseaseTargets_cfa5b324-2c50-4709-95b5-5ad4ec61c57a" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CollaborationAgreementTerm_e67fb0cc-4190-4c74-89b2-562e39adf8c3" xlink:href="biib-20200930.xsd#biib_CollaborationAgreementTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4a859010-8282-4797-a6d6-a3bf955603ca" xlink:to="loc_biib_CollaborationAgreementTerm_e67fb0cc-4190-4c74-89b2-562e39adf8c3" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments_def4d7df-6f33-48e3-b562-c7408c7a5746" xlink:href="biib-20200930.xsd#biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4a859010-8282-4797-a6d6-a3bf955603ca" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments_def4d7df-6f33-48e3-b562-c7408c7a5746" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets_ea46950f-0988-4fa9-b4fc-75c6fb6de229" xlink:href="biib-20200930.xsd#biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4a859010-8282-4797-a6d6-a3bf955603ca" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets_ea46950f-0988-4fa9-b4fc-75c6fb6de229" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones_c7edeacf-d0ba-41f0-84f0-b1392da0771d" xlink:href="biib-20200930.xsd#biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4a859010-8282-4797-a6d6-a3bf955603ca" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones_c7edeacf-d0ba-41f0-84f0-b1392da0771d" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones_cbc1c3d4-d7a8-4a3c-ad8e-471fdcdd8697" xlink:href="biib-20200930.xsd#biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4a859010-8282-4797-a6d6-a3bf955603ca" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones_cbc1c3d4-d7a8-4a3c-ad8e-471fdcdd8697" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_62e44b2b-97e8-4fe7-9a4e-4394e0dbdd88" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4a859010-8282-4797-a6d6-a3bf955603ca" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_62e44b2b-97e8-4fe7-9a4e-4394e0dbdd88" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets_736f5baf-df31-43d7-8e6e-43f5c2713b69" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4a859010-8282-4797-a6d6-a3bf955603ca" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssets_736f5baf-df31-43d7-8e6e-43f5c2713b69" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_8a6944a9-0913-4c8e-b9df-5a4b72576ffd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4a859010-8282-4797-a6d6-a3bf955603ca" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_8a6944a9-0913-4c8e-b9df-5a4b72576ffd" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_efbc8096-f21f-4656-9247-2287e9a34314" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4a859010-8282-4797-a6d6-a3bf955603ca" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_efbc8096-f21f-4656-9247-2287e9a34314" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9984e6c3-6e32-48ff-b1fe-3e815594f24f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4a859010-8282-4797-a6d6-a3bf955603ca" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9984e6c3-6e32-48ff-b1fe-3e815594f24f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_4ff17ec1-5a28-4acb-bfca-322eda7b105d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9984e6c3-6e32-48ff-b1fe-3e815594f24f" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_4ff17ec1-5a28-4acb-bfca-322eda7b105d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_4ff17ec1-5a28-4acb-bfca-322eda7b105d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_4ff17ec1-5a28-4acb-bfca-322eda7b105d" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_4ff17ec1-5a28-4acb-bfca-322eda7b105d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_898ca62f-5d84-42b4-83a6-ab7cefb929f3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_4ff17ec1-5a28-4acb-bfca-322eda7b105d" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_898ca62f-5d84-42b4-83a6-ab7cefb929f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1b362595-c947-458a-80c8-68b8373934bf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_898ca62f-5d84-42b4-83a6-ab7cefb929f3" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1b362595-c947-458a-80c8-68b8373934bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_db193a6e-0c4b-4525-86a3-490a1315ac68" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_898ca62f-5d84-42b4-83a6-ab7cefb929f3" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_db193a6e-0c4b-4525-86a3-490a1315ac68" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_5972eb5e-3fbd-4586-a349-eaf72da49dba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9984e6c3-6e32-48ff-b1fe-3e815594f24f" xlink:to="loc_us-gaap_TypeOfArrangementAxis_5972eb5e-3fbd-4586-a349-eaf72da49dba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5972eb5e-3fbd-4586-a349-eaf72da49dba_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5972eb5e-3fbd-4586-a349-eaf72da49dba" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5972eb5e-3fbd-4586-a349-eaf72da49dba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_25209fb6-48c1-4c24-824e-236377615ffa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5972eb5e-3fbd-4586-a349-eaf72da49dba" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_25209fb6-48c1-4c24-824e-236377615ffa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_38191a66-d9f8-4e85-b7a7-e4267d141e00" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_25209fb6-48c1-4c24-824e-236377615ffa" xlink:to="loc_us-gaap_CollaborativeArrangementMember_38191a66-d9f8-4e85-b7a7-e4267d141e00" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EisaiMember_b55c103c-7204-4a40-a797-497955058cc4" xlink:href="biib-20200930.xsd#biib_EisaiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_25209fb6-48c1-4c24-824e-236377615ffa" xlink:to="loc_biib_EisaiMember_b55c103c-7204-4a40-a797-497955058cc4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UCBPharmaS.A.Member_9e292cfd-695d-4c23-8889-1bd7274f970e" xlink:href="biib-20200930.xsd#biib_UCBPharmaS.A.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_25209fb6-48c1-4c24-824e-236377615ffa" xlink:to="loc_biib_UCBPharmaS.A.Member_9e292cfd-695d-4c23-8889-1bd7274f970e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SangamoTherapeuticsInc.AgreementMember_35709de9-e692-4111-a994-fa05f7e1e18f" xlink:href="biib-20200930.xsd#biib_SangamoTherapeuticsInc.AgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_25209fb6-48c1-4c24-824e-236377615ffa" xlink:to="loc_biib_SangamoTherapeuticsInc.AgreementMember_35709de9-e692-4111-a994-fa05f7e1e18f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SkyhawkTherapeuticsMember_a406d345-ef79-4165-b238-4ead32a30094" xlink:href="biib-20200930.xsd#biib_SkyhawkTherapeuticsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_25209fb6-48c1-4c24-824e-236377615ffa" xlink:to="loc_biib_SkyhawkTherapeuticsMember_a406d345-ef79-4165-b238-4ead32a30094" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DenaliTherapeuticsIncMember_cf4ded89-e6c2-432d-91ec-390e5ab656be" xlink:href="biib-20200930.xsd#biib_DenaliTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_25209fb6-48c1-4c24-824e-236377615ffa" xlink:to="loc_biib_DenaliTherapeuticsIncMember_cf4ded89-e6c2-432d-91ec-390e5ab656be" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DenaliTherapeuticsIncMember_c2589d1a-bae9-4161-ade3-7e5310f0b455" xlink:href="biib-20200930.xsd#biib_DenaliTherapeuticsIncMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_88f904cd-cefb-4864-a1f3-6a2893f45a0d" xlink:href="biib-20200930.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_25209fb6-48c1-4c24-824e-236377615ffa" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_88f904cd-cefb-4864-a1f3-6a2893f45a0d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_13773514-a5e0-45b8-8e68-24f644eddc7a" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9984e6c3-6e32-48ff-b1fe-3e815594f24f" xlink:to="loc_srt_ProductOrServiceAxis_13773514-a5e0-45b8-8e68-24f644eddc7a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_13773514-a5e0-45b8-8e68-24f644eddc7a_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_13773514-a5e0-45b8-8e68-24f644eddc7a" xlink:to="loc_srt_ProductsAndServicesDomain_13773514-a5e0-45b8-8e68-24f644eddc7a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_82372480-b2b4-4f16-97ca-771ceb0a0c62" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_13773514-a5e0-45b8-8e68-24f644eddc7a" xlink:to="loc_srt_ProductsAndServicesDomain_82372480-b2b4-4f16-97ca-771ceb0a0c62" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BAN2401Member_a049ace6-ab63-494d-8b84-136de8c1b6bd" xlink:href="biib-20200930.xsd#biib_BAN2401Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_82372480-b2b4-4f16-97ca-771ceb0a0c62" xlink:to="loc_biib_BAN2401Member_a049ace6-ab63-494d-8b84-136de8c1b6bd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_E2609andBAN2401Member_4d5deaae-d2d6-484c-b2a8-73044a5b88b2" xlink:href="biib-20200930.xsd#biib_E2609andBAN2401Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_82372480-b2b4-4f16-97ca-771ceb0a0c62" xlink:to="loc_biib_E2609andBAN2401Member_4d5deaae-d2d6-484c-b2a8-73044a5b88b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AducanumabMember_56ef2d32-20e9-4204-9454-1c3862b3fa0d" xlink:href="biib-20200930.xsd#biib_AducanumabMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_82372480-b2b4-4f16-97ca-771ceb0a0c62" xlink:to="loc_biib_AducanumabMember_56ef2d32-20e9-4204-9454-1c3862b3fa0d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ElenbecestatCollaborationMember_10b29b1f-837c-41a4-8d8f-6b06553fab45" xlink:href="biib-20200930.xsd#biib_ElenbecestatCollaborationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_82372480-b2b4-4f16-97ca-771ceb0a0c62" xlink:to="loc_biib_ElenbecestatCollaborationMember_10b29b1f-837c-41a4-8d8f-6b06553fab45" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_a23faae6-3743-490c-9941-410ebeb82b2a" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9984e6c3-6e32-48ff-b1fe-3e815594f24f" xlink:to="loc_dei_LegalEntityAxis_a23faae6-3743-490c-9941-410ebeb82b2a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_a23faae6-3743-490c-9941-410ebeb82b2a_default" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_a23faae6-3743-490c-9941-410ebeb82b2a" xlink:to="loc_dei_EntityDomain_a23faae6-3743-490c-9941-410ebeb82b2a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_a8e73bae-7061-41dc-8c4d-583be10d655b" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_a23faae6-3743-490c-9941-410ebeb82b2a" xlink:to="loc_dei_EntityDomain_a8e73bae-7061-41dc-8c4d-583be10d655b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SangamoCommonStockMember_75e42f7d-b5d5-4bc7-8fa8-c587a6721bd1" xlink:href="biib-20200930.xsd#biib_SangamoCommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_a8e73bae-7061-41dc-8c4d-583be10d655b" xlink:to="loc_biib_SangamoCommonStockMember_75e42f7d-b5d5-4bc7-8fa8-c587a6721bd1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_a6ec6ae3-2eba-4bf8-9d8a-7f632076bf68" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9984e6c3-6e32-48ff-b1fe-3e815594f24f" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_a6ec6ae3-2eba-4bf8-9d8a-7f632076bf68" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_a6ec6ae3-2eba-4bf8-9d8a-7f632076bf68_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_a6ec6ae3-2eba-4bf8-9d8a-7f632076bf68" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_a6ec6ae3-2eba-4bf8-9d8a-7f632076bf68_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_8226f260-6cd2-4a84-98c6-1c3a2728a2e1" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_a6ec6ae3-2eba-4bf8-9d8a-7f632076bf68" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_8226f260-6cd2-4a84-98c6-1c3a2728a2e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IonisPharmaceuticalsMember_31f27ae3-db22-4eb1-adec-ee5a316ebf15" xlink:href="biib-20200930.xsd#biib_IonisPharmaceuticalsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_8226f260-6cd2-4a84-98c6-1c3a2728a2e1" xlink:to="loc_biib_IonisPharmaceuticalsMember_31f27ae3-db22-4eb1-adec-ee5a316ebf15" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DenaliTherapeuticsIncMember_8c66aa24-82a6-4ebc-93eb-e507c82254c6" xlink:href="biib-20200930.xsd#biib_DenaliTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_8226f260-6cd2-4a84-98c6-1c3a2728a2e1" xlink:to="loc_biib_DenaliTherapeuticsIncMember_8c66aa24-82a6-4ebc-93eb-e507c82254c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SangamoTherapeuticsInc.AgreementMember_69d4a309-eea0-4f53-8d09-91f11eac5bb8" xlink:href="biib-20200930.xsd#biib_SangamoTherapeuticsInc.AgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_8226f260-6cd2-4a84-98c6-1c3a2728a2e1" xlink:to="loc_biib_SangamoTherapeuticsInc.AgreementMember_69d4a309-eea0-4f53-8d09-91f11eac5bb8" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails" xlink:type="simple" xlink:href="biib-20200930.xsd#CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails" xlink:type="extended" id="i727151c7c2f84decbb671b05bc3ef0f4_CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_07f5c736-608a-4fce-9ae5-1465250f81be" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_75c46f2a-233f-4b14-9828-c1ddd141f82d" xlink:href="biib-20200930.xsd#biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_07f5c736-608a-4fce-9ae5-1465250f81be" xlink:to="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_75c46f2a-233f-4b14-9828-c1ddd141f82d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossOnContractTermination_e95e54aa-2673-4330-9e81-693c6d835e34" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossOnContractTermination"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_07f5c736-608a-4fce-9ae5-1465250f81be" xlink:to="loc_us-gaap_LossOnContractTermination_e95e54aa-2673-4330-9e81-693c6d835e34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_e15d07f8-292b-45f6-97d3-9e53a840c31d" xlink:href="biib-20200930.xsd#biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_07f5c736-608a-4fce-9ae5-1465250f81be" xlink:to="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_e15d07f8-292b-45f6-97d3-9e53a840c31d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_422032e2-94f3-4dd6-9a47-391246673d51" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_07f5c736-608a-4fce-9ae5-1465250f81be" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_422032e2-94f3-4dd6-9a47-391246673d51" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_43748e21-30e0-44e9-b51e-87c7d518c622" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_07f5c736-608a-4fce-9ae5-1465250f81be" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_43748e21-30e0-44e9-b51e-87c7d518c622" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_51595e11-6b7b-413a-b3b9-44a21293b445" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_07f5c736-608a-4fce-9ae5-1465250f81be" xlink:to="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_51595e11-6b7b-413a-b3b9-44a21293b445" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_d2e0c36c-0627-4eee-ab12-75423e1aaa2f" xlink:href="biib-20200930.xsd#biib_Equitymethodinvestmentbasisdifferenceamortizationperiod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_07f5c736-608a-4fce-9ae5-1465250f81be" xlink:to="loc_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_d2e0c36c-0627-4eee-ab12-75423e1aaa2f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_72eff616-50b9-42da-8187-1001ed873e48" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_07f5c736-608a-4fce-9ae5-1465250f81be" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_72eff616-50b9-42da-8187-1001ed873e48" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_b360d335-7001-41fc-82bd-08f317a88ad7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_07f5c736-608a-4fce-9ae5-1465250f81be" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_b360d335-7001-41fc-82bd-08f317a88ad7" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentForAmortization_843a7e7f-af86-4cd3-97af-638319fc2b92" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentForAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_07f5c736-608a-4fce-9ae5-1465250f81be" xlink:to="loc_us-gaap_AdjustmentForAmortization_843a7e7f-af86-4cd3-97af-638319fc2b92" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_ae71d5c2-d9f2-4634-a37e-f013a901f276" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_07f5c736-608a-4fce-9ae5-1465250f81be" xlink:to="loc_us-gaap_EquityMethodInvestments_ae71d5c2-d9f2-4634-a37e-f013a901f276" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_dad4e7fe-02e2-4328-8dee-387ace344602" xlink:href="biib-20200930.xsd#biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_07f5c736-608a-4fce-9ae5-1465250f81be" xlink:to="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_dad4e7fe-02e2-4328-8dee-387ace344602" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_445316d2-6ce9-4de4-bcf0-da0045500ac3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_07f5c736-608a-4fce-9ae5-1465250f81be" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_445316d2-6ce9-4de4-bcf0-da0045500ac3" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets_21238d50-700e-43a3-a65c-b2dbf4517dc3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_07f5c736-608a-4fce-9ae5-1465250f81be" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssets_21238d50-700e-43a3-a65c-b2dbf4517dc3" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_ea79d945-789d-415e-bc67-773405032923" xlink:href="biib-20200930.xsd#biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_07f5c736-608a-4fce-9ae5-1465250f81be" xlink:to="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_ea79d945-789d-415e-bc67-773405032923" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdditionalMilestonePayment_07c2137b-61bd-42f9-9c7b-9c5116b6c7ec" xlink:href="biib-20200930.xsd#biib_AdditionalMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_07f5c736-608a-4fce-9ae5-1465250f81be" xlink:to="loc_biib_AdditionalMilestonePayment_07c2137b-61bd-42f9-9c7b-9c5116b6c7ec" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ContractOptionExerciseFee_7a1dff75-05bb-43bf-af23-fe94b311ef5c" xlink:href="biib-20200930.xsd#biib_ContractOptionExerciseFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_07f5c736-608a-4fce-9ae5-1465250f81be" xlink:to="loc_biib_ContractOptionExerciseFee_7a1dff75-05bb-43bf-af23-fe94b311ef5c" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Biogenshareofcopromotionprofitsorlosses_a62203c5-e6f3-4d10-9685-0fd8283c6474" xlink:href="biib-20200930.xsd#biib_Biogenshareofcopromotionprofitsorlosses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_07f5c736-608a-4fce-9ae5-1465250f81be" xlink:to="loc_biib_Biogenshareofcopromotionprofitsorlosses_a62203c5-e6f3-4d10-9685-0fd8283c6474" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Collaborationprofitlosssharing_c363e14b-c587-4126-80ad-690f7d95d0e8" xlink:href="biib-20200930.xsd#biib_Collaborationprofitlosssharing"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_07f5c736-608a-4fce-9ae5-1465250f81be" xlink:to="loc_biib_Collaborationprofitlosssharing_c363e14b-c587-4126-80ad-690f7d95d0e8" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_f795eb09-9828-4065-89dc-a3a35a7d8038" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_07f5c736-608a-4fce-9ae5-1465250f81be" xlink:to="loc_us-gaap_Revenues_f795eb09-9828-4065-89dc-a3a35a7d8038" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromRelatedParties_5e3b297b-7c06-4d14-9b5f-15498d5f7a21" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DueFromRelatedParties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_07f5c736-608a-4fce-9ae5-1465250f81be" xlink:to="loc_us-gaap_DueFromRelatedParties_5e3b297b-7c06-4d14-9b5f-15498d5f7a21" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_e157ff76-cabd-4085-be6e-2c0695357805" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_07f5c736-608a-4fce-9ae5-1465250f81be" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_e157ff76-cabd-4085-be6e-2c0695357805" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_b995c7f5-63cb-44a4-802b-148ac4eb688a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_07f5c736-608a-4fce-9ae5-1465250f81be" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_b995c7f5-63cb-44a4-802b-148ac4eb688a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_24ea3543-a8fb-479a-91a0-76fe9000535c" xlink:href="biib-20200930.xsd#biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_b995c7f5-63cb-44a4-802b-148ac4eb688a" xlink:to="loc_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_24ea3543-a8fb-479a-91a0-76fe9000535c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain_24ea3543-a8fb-479a-91a0-76fe9000535c_default" xlink:href="biib-20200930.xsd#biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_24ea3543-a8fb-479a-91a0-76fe9000535c" xlink:to="loc_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain_24ea3543-a8fb-479a-91a0-76fe9000535c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain_ba68aec7-867a-42c8-915e-83177a1abd53" xlink:href="biib-20200930.xsd#biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_24ea3543-a8fb-479a-91a0-76fe9000535c" xlink:to="loc_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain_ba68aec7-867a-42c8-915e-83177a1abd53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NeurimmuneMember_e57a13ce-e5ba-403a-ab67-cfcbfe29484a" xlink:href="biib-20200930.xsd#biib_NeurimmuneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain_ba68aec7-867a-42c8-915e-83177a1abd53" xlink:to="loc_biib_NeurimmuneMember_e57a13ce-e5ba-403a-ab67-cfcbfe29484a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesAxis_73936cf0-5a57-482c-a31d-aaae55157acf" xlink:href="biib-20200930.xsd#biib_FutureContingentMilestoneTypesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_b995c7f5-63cb-44a4-802b-148ac4eb688a" xlink:to="loc_biib_FutureContingentMilestoneTypesAxis_73936cf0-5a57-482c-a31d-aaae55157acf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain_73936cf0-5a57-482c-a31d-aaae55157acf_default" xlink:href="biib-20200930.xsd#biib_FutureContingentMilestoneTypesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis_73936cf0-5a57-482c-a31d-aaae55157acf" xlink:to="loc_biib_FutureContingentMilestoneTypesDomain_73936cf0-5a57-482c-a31d-aaae55157acf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain_dbfef656-fbd4-4dc7-a5b7-205c4b553758" xlink:href="biib-20200930.xsd#biib_FutureContingentMilestoneTypesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis_73936cf0-5a57-482c-a31d-aaae55157acf" xlink:to="loc_biib_FutureContingentMilestoneTypesDomain_dbfef656-fbd4-4dc7-a5b7-205c4b553758" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RegulatoryMilestonesMember_4d5c4d5e-f81e-4020-84ba-ccbc8abf13e3" xlink:href="biib-20200930.xsd#biib_RegulatoryMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_dbfef656-fbd4-4dc7-a5b7-205c4b553758" xlink:to="loc_biib_RegulatoryMilestonesMember_4d5c4d5e-f81e-4020-84ba-ccbc8abf13e3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_3fd7eed4-47c8-48fe-a2f0-00228175b120" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_b995c7f5-63cb-44a4-802b-148ac4eb688a" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_3fd7eed4-47c8-48fe-a2f0-00228175b120" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3fd7eed4-47c8-48fe-a2f0-00228175b120_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_3fd7eed4-47c8-48fe-a2f0-00228175b120" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3fd7eed4-47c8-48fe-a2f0-00228175b120_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_a5297e6e-7c4f-4c5a-b4df-776e457bbecd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_3fd7eed4-47c8-48fe-a2f0-00228175b120" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_a5297e6e-7c4f-4c5a-b4df-776e457bbecd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoriesMember_93e99432-bcf3-4acc-9917-31e6cf7d68a3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoriesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_a5297e6e-7c4f-4c5a-b4df-776e457bbecd" xlink:to="loc_us-gaap_InventoriesMember_93e99432-bcf3-4acc-9917-31e6cf7d68a3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_c7386a16-d280-4771-bbcb-eae0525e74af" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_a5297e6e-7c4f-4c5a-b4df-776e457bbecd" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_c7386a16-d280-4771-bbcb-eae0525e74af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_705385a6-5638-4b86-aa7a-da0fc8a100f6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_a5297e6e-7c4f-4c5a-b4df-776e457bbecd" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_705385a6-5638-4b86-aa7a-da0fc8a100f6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DeferredtaxliabilityMember_ca337510-899a-490f-b5b7-2d1630fa85da" xlink:href="biib-20200930.xsd#biib_DeferredtaxliabilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_a5297e6e-7c4f-4c5a-b4df-776e457bbecd" xlink:to="loc_biib_DeferredtaxliabilityMember_ca337510-899a-490f-b5b7-2d1630fa85da" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_f75d2105-4530-4b4c-b776-af0c446a4b46" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_b995c7f5-63cb-44a4-802b-148ac4eb688a" xlink:to="loc_us-gaap_TypeOfArrangementAxis_f75d2105-4530-4b4c-b776-af0c446a4b46" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f75d2105-4530-4b4c-b776-af0c446a4b46_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_f75d2105-4530-4b4c-b776-af0c446a4b46" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f75d2105-4530-4b4c-b776-af0c446a4b46_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8dff4ee7-8e54-47f7-adaf-6f73394d6f63" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_f75d2105-4530-4b4c-b776-af0c446a4b46" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8dff4ee7-8e54-47f7-adaf-6f73394d6f63" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EisaiMember_f1f9dece-098b-4f5a-95c8-54222946c67c" xlink:href="biib-20200930.xsd#biib_EisaiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8dff4ee7-8e54-47f7-adaf-6f73394d6f63" xlink:to="loc_biib_EisaiMember_f1f9dece-098b-4f5a-95c8-54222946c67c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_7d88e705-ff3e-42bd-aa58-86ac25f993bb" xlink:href="biib-20200930.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8dff4ee7-8e54-47f7-adaf-6f73394d6f63" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_7d88e705-ff3e-42bd-aa58-86ac25f993bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_29565492-fcfa-474f-ad95-94e03b57fab9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8dff4ee7-8e54-47f7-adaf-6f73394d6f63" xlink:to="loc_us-gaap_CollaborativeArrangementMember_29565492-fcfa-474f-ad95-94e03b57fab9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_8a7c6198-7160-487f-a776-7a689dd6fdf7" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_b995c7f5-63cb-44a4-802b-148ac4eb688a" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_8a7c6198-7160-487f-a776-7a689dd6fdf7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_8a7c6198-7160-487f-a776-7a689dd6fdf7_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_8a7c6198-7160-487f-a776-7a689dd6fdf7" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_8a7c6198-7160-487f-a776-7a689dd6fdf7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_be72106d-ad4f-4ddb-a886-09a149bf00dc" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_8a7c6198-7160-487f-a776-7a689dd6fdf7" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_be72106d-ad4f-4ddb-a886-09a149bf00dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_86de54a9-e154-49d1-bf08-617979f10e5f" xlink:href="biib-20200930.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_be72106d-ad4f-4ddb-a886-09a149bf00dc" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_86de54a9-e154-49d1-bf08-617979f10e5f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/InvestmentsinVariableInterestEntities" xlink:type="simple" xlink:href="biib-20200930.xsd#InvestmentsinVariableInterestEntities"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/InvestmentsinVariableInterestEntities" xlink:type="extended" id="i49eeca9893974a8bac277a675f4e09d2_InvestmentsinVariableInterestEntities"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails" xlink:type="simple" xlink:href="biib-20200930.xsd#InvestmentsinVariableInterestEntitiesDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails" xlink:type="extended" id="id9455efe70c84c8fb37cca98c825aa63_InvestmentsinVariableInterestEntitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_b71fb38d-237a-43ef-a718-5382c1c2f5c7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CollaborationAgreementTerm_f1816d4a-7591-4eff-8158-29321a4228ce" xlink:href="biib-20200930.xsd#biib_CollaborationAgreementTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_b71fb38d-237a-43ef-a718-5382c1c2f5c7" xlink:to="loc_biib_CollaborationAgreementTerm_f1816d4a-7591-4eff-8158-29321a4228ce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchAndDevelopmentCostsPercentage_78509e1c-e061-4f20-8f35-b8915a888b01" xlink:href="biib-20200930.xsd#biib_ResearchAndDevelopmentCostsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_b71fb38d-237a-43ef-a718-5382c1c2f5c7" xlink:to="loc_biib_ResearchAndDevelopmentCostsPercentage_78509e1c-e061-4f20-8f35-b8915a888b01" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_906505e1-0925-471b-b7d1-f436e67e6f0a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToMinorityShareholders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_b71fb38d-237a-43ef-a718-5382c1c2f5c7" xlink:to="loc_us-gaap_PaymentsToMinorityShareholders_906505e1-0925-471b-b7d1-f436e67e6f0a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Reductioninroyaltyratepayableoncommercialsales_73661947-2f3f-4eb9-a3c6-2fbbad92e53a" xlink:href="biib-20200930.xsd#biib_Reductioninroyaltyratepayableoncommercialsales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_b71fb38d-237a-43ef-a718-5382c1c2f5c7" xlink:to="loc_biib_Reductioninroyaltyratepayableoncommercialsales_73661947-2f3f-4eb9-a3c6-2fbbad92e53a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Additionalreductioninroyaltyratepayableoncommercialsales_45c51f43-ab36-42bd-a78e-4744ff422fdc" xlink:href="biib-20200930.xsd#biib_Additionalreductioninroyaltyratepayableoncommercialsales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_b71fb38d-237a-43ef-a718-5382c1c2f5c7" xlink:to="loc_biib_Additionalreductioninroyaltyratepayableoncommercialsales_45c51f43-ab36-42bd-a78e-4744ff422fdc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_df368e7e-d5e3-4d41-8f77-50d592a7cba2" xlink:href="biib-20200930.xsd#biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_b71fb38d-237a-43ef-a718-5382c1c2f5c7" xlink:to="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_df368e7e-d5e3-4d41-8f77-50d592a7cba2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_9b66d9f0-add3-4706-b62c-86690b2e6511" xlink:href="biib-20200930.xsd#biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_b71fb38d-237a-43ef-a718-5382c1c2f5c7" xlink:to="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_9b66d9f0-add3-4706-b62c-86690b2e6511" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_b410d7c0-1410-4998-93b7-d45301754aae" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_b71fb38d-237a-43ef-a718-5382c1c2f5c7" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_b410d7c0-1410-4998-93b7-d45301754aae" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_b4a32b61-cefd-4596-9b98-d743f1bacd05" xlink:href="biib-20200930.xsd#biib_PercentageoffuturedevelopmentcostsrelatedtoEisai"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_b71fb38d-237a-43ef-a718-5382c1c2f5c7" xlink:to="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_b4a32b61-cefd-4596-9b98-d743f1bacd05" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_46584ca4-e5ec-462f-855e-a77e912aa376" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_b71fb38d-237a-43ef-a718-5382c1c2f5c7" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_46584ca4-e5ec-462f-855e-a77e912aa376" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_a288a30f-aebf-4a15-9f68-c459d56e5225" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_46584ca4-e5ec-462f-855e-a77e912aa376" xlink:to="loc_us-gaap_TypeOfArrangementAxis_a288a30f-aebf-4a15-9f68-c459d56e5225" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a288a30f-aebf-4a15-9f68-c459d56e5225_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_a288a30f-aebf-4a15-9f68-c459d56e5225" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a288a30f-aebf-4a15-9f68-c459d56e5225_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_aac6089e-3223-452b-93ef-e92c5dd8f89c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_a288a30f-aebf-4a15-9f68-c459d56e5225" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_aac6089e-3223-452b-93ef-e92c5dd8f89c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EisaiMember_834454c0-eb40-4b8b-9cd3-5cf08b488211" xlink:href="biib-20200930.xsd#biib_EisaiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_aac6089e-3223-452b-93ef-e92c5dd8f89c" xlink:to="loc_biib_EisaiMember_834454c0-eb40-4b8b-9cd3-5cf08b488211" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesAxis_ed674c8c-4b2e-42dd-ab3f-5997ee677a30" xlink:href="biib-20200930.xsd#biib_FutureContingentMilestoneTypesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_46584ca4-e5ec-462f-855e-a77e912aa376" xlink:to="loc_biib_FutureContingentMilestoneTypesAxis_ed674c8c-4b2e-42dd-ab3f-5997ee677a30" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain_ed674c8c-4b2e-42dd-ab3f-5997ee677a30_default" xlink:href="biib-20200930.xsd#biib_FutureContingentMilestoneTypesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis_ed674c8c-4b2e-42dd-ab3f-5997ee677a30" xlink:to="loc_biib_FutureContingentMilestoneTypesDomain_ed674c8c-4b2e-42dd-ab3f-5997ee677a30_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain_79640f6e-582b-4658-b438-50d0c668a53f" xlink:href="biib-20200930.xsd#biib_FutureContingentMilestoneTypesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis_ed674c8c-4b2e-42dd-ab3f-5997ee677a30" xlink:to="loc_biib_FutureContingentMilestoneTypesDomain_79640f6e-582b-4658-b438-50d0c668a53f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RegulatoryMilestonesMember_978dffce-147d-4205-a81a-45fdaeabcac1" xlink:href="biib-20200930.xsd#biib_RegulatoryMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_79640f6e-582b-4658-b438-50d0c668a53f" xlink:to="loc_biib_RegulatoryMilestonesMember_978dffce-147d-4205-a81a-45fdaeabcac1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RegulatoryApprovalMilestoneMember_cff44abb-47f6-4e6c-9bc2-973242c24a59" xlink:href="biib-20200930.xsd#biib_RegulatoryApprovalMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_79640f6e-582b-4658-b438-50d0c668a53f" xlink:to="loc_biib_RegulatoryApprovalMilestoneMember_cff44abb-47f6-4e6c-9bc2-973242c24a59" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_34e8cbb3-d9ca-4281-a2b6-d0d513fe028c" xlink:href="biib-20200930.xsd#biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_46584ca4-e5ec-462f-855e-a77e912aa376" xlink:to="loc_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_34e8cbb3-d9ca-4281-a2b6-d0d513fe028c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain_34e8cbb3-d9ca-4281-a2b6-d0d513fe028c_default" xlink:href="biib-20200930.xsd#biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_34e8cbb3-d9ca-4281-a2b6-d0d513fe028c" xlink:to="loc_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain_34e8cbb3-d9ca-4281-a2b6-d0d513fe028c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain_8d54a481-4719-4715-a8e5-4d59f2c7368d" xlink:href="biib-20200930.xsd#biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_34e8cbb3-d9ca-4281-a2b6-d0d513fe028c" xlink:to="loc_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain_8d54a481-4719-4715-a8e5-4d59f2c7368d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NeurimmuneMember_cd1dfe3f-a13d-48b9-8819-4e06d40b3ff1" xlink:href="biib-20200930.xsd#biib_NeurimmuneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain_8d54a481-4719-4715-a8e5-4d59f2c7368d" xlink:to="loc_biib_NeurimmuneMember_cd1dfe3f-a13d-48b9-8819-4e06d40b3ff1" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/Litigation" xlink:type="simple" xlink:href="biib-20200930.xsd#Litigation"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/Litigation" xlink:type="extended" id="i9a77b5ddfd0e4fb991379cc59f1a61f7_Litigation"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/LitigationDetails" xlink:type="simple" xlink:href="biib-20200930.xsd#LitigationDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/LitigationDetails" xlink:type="extended" id="i9ca7453c1cfc431aa80855bab5ff1d80_LitigationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_2b7ef046-06f8-4edd-a769-6ad7c424a41a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_1225ddd9-fc3f-43ec-9914-dac5d0457001" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_2b7ef046-06f8-4edd-a769-6ad7c424a41a" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_1225ddd9-fc3f-43ec-9914-dac5d0457001" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DisputedClaimsRelatingtoConstructionCosts_51b7e3c3-e752-4a8b-bef8-7f5309171669" xlink:href="biib-20200930.xsd#biib_DisputedClaimsRelatingtoConstructionCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_2b7ef046-06f8-4edd-a769-6ad7c424a41a" xlink:to="loc_biib_DisputedClaimsRelatingtoConstructionCosts_51b7e3c3-e752-4a8b-bef8-7f5309171669" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_0fcad28d-24df-4b1a-bdb3-2ab235d9281c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_2b7ef046-06f8-4edd-a769-6ad7c424a41a" xlink:to="loc_us-gaap_LossContingencyDamagesSoughtValue_0fcad28d-24df-4b1a-bdb3-2ab235d9281c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_55520dfd-4a77-4f73-81ed-0023d4e36e27" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_2b7ef046-06f8-4edd-a769-6ad7c424a41a" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_55520dfd-4a77-4f73-81ed-0023d4e36e27" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_c6239ac3-335e-4023-a7d7-5896406e7d0f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_55520dfd-4a77-4f73-81ed-0023d4e36e27" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_c6239ac3-335e-4023-a7d7-5896406e7d0f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_c6239ac3-335e-4023-a7d7-5896406e7d0f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_c6239ac3-335e-4023-a7d7-5896406e7d0f" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_c6239ac3-335e-4023-a7d7-5896406e7d0f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_02cb00b2-15ba-4740-98be-f9fec9473cb2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_c6239ac3-335e-4023-a7d7-5896406e7d0f" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_02cb00b2-15ba-4740-98be-f9fec9473cb2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_BR_99cc1597-42e5-499b-ac90-c39a2e5cd51a" xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_BR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_02cb00b2-15ba-4740-98be-f9fec9473cb2" xlink:to="loc_country_BR_99cc1597-42e5-499b-ac90-c39a2e5cd51a" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>biib-20200930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:9d882161-cc57-4e82-9994-8001479894f6,g:a7b2bacf-5ee2-4f5b-9f49-a40e24a2538c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_biib_Expenseincurredbythecollaboration_ee7d893b-caaf-4458-9122-2a2f35ea5916_terseLabel_en-US" xlink:label="lab_biib_Expenseincurredbythecollaboration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense incurred by the collaboration</link:label>
    <link:label id="lab_biib_Expenseincurredbythecollaboration_label_en-US" xlink:label="lab_biib_Expenseincurredbythecollaboration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense incurred by the collaboration</link:label>
    <link:label id="lab_biib_Expenseincurredbythecollaboration_documentation_en-US" xlink:label="lab_biib_Expenseincurredbythecollaboration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense incurred by the collaboration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expenseincurredbythecollaboration" xlink:href="biib-20200930.xsd#biib_Expenseincurredbythecollaboration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Expenseincurredbythecollaboration" xlink:to="lab_biib_Expenseincurredbythecollaboration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets_b078ffdb-9485-4eca-9a53-07291f51a1b7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration paid related to Fumapharm AG acquisition</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Other Productive Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:to="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_9eb98bf6-6dd4-4059-ae7e-115f224c541e_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_74749e37-9576-4bb3-b544-0e64e8af2864_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_9236e183-f163-482a-a67f-7f8644b98d65_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_bad2b7a3-2701-419a-a0ac-293819ac5c5f_verboseLabel_en-US" xlink:label="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_label_en-US" xlink:label="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets Excluding Goodwill [Table Text Block]</link:label>
    <link:label id="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_documentation_en-US" xlink:label="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets excluding goodwill.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IntangibleAssetsExcludingGoodwillTableTextBlock" xlink:href="biib-20200930.xsd#biib_IntangibleAssetsExcludingGoodwillTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IntangibleAssetsExcludingGoodwillTableTextBlock" xlink:to="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_d20821d2-5fd6-475a-87ae-2d2aca4d175d_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Unobservable Inputs (Level 3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_7854b090-a9be-45a4-ba76-c232ea4bb924_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sales and maturities of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_88495c7b-f81d-4fbc-b1f2-5118d100e199_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from maturities and sales</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_2d0a5dd1-5b87-4c37-9111-8db59b931f48_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_16216d7c-1d3d-4e43-bced-1b253d18137a_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected future amortization expense, 2020</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_1f04ad56-d67e-423e-a0fe-9498fac16e78_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ZINBRYTAMember_5ccaa46b-82a8-4d37-8e38-09b5c3249f38_terseLabel_en-US" xlink:label="lab_biib_ZINBRYTAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ZINBRYTA</link:label>
    <link:label id="lab_biib_ZINBRYTAMember_label_en-US" xlink:label="lab_biib_ZINBRYTAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ZINBRYTA [Member]</link:label>
    <link:label id="lab_biib_ZINBRYTAMember_documentation_en-US" xlink:label="lab_biib_ZINBRYTAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ZINBRYTA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ZINBRYTAMember" xlink:href="biib-20200930.xsd#biib_ZINBRYTAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ZINBRYTAMember" xlink:to="lab_biib_ZINBRYTAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDueFromRelatedParties_a6bca963-b7e3-4870-8805-5cdeefcd9a73_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDueFromRelatedParties_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Due from Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:to="lab_us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_30e87bc3-5ca4-424c-857b-86011d287f44_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_62383ff1-9d51-4806-ad15-ba5c1824565a_verboseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost and Net</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_613da301-6cc6-4eee-972f-c280b4fbcf51_negatedLabel_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments/Returns Relating To Sales in Prior Year</link:label>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_label_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments Returns Applied Against Product Revenue Reserves Relating To Prior Year</link:label>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_documentation_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments/ returns applied against product revenue reserves relating to prior year.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" xlink:href="biib-20200930.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" xlink:to="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_d41c2f50-0e09-4702-af0b-0c47aa71a4e6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_01f423da-1589-4711-b780-4580bf288697_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableCurrent_b2c07377-0184-4919-a385-79b2dbf8a853_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of notes payable</link:label>
    <link:label id="lab_us-gaap_NotesPayableCurrent_label_en-US" xlink:label="lab_us-gaap_NotesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableCurrent" xlink:to="lab_us-gaap_NotesPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DeferredTaxLiabilitiesValueReductioninValue_1017be7c-8527-4b4c-963d-7aaa89c14852_terseLabel_en-US" xlink:label="lab_biib_DeferredTaxLiabilitiesValueReductioninValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities, decrease in value</link:label>
    <link:label id="lab_biib_DeferredTaxLiabilitiesValueReductioninValue_label_en-US" xlink:label="lab_biib_DeferredTaxLiabilitiesValueReductioninValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Value, Reduction in Value</link:label>
    <link:label id="lab_biib_DeferredTaxLiabilitiesValueReductioninValue_documentation_en-US" xlink:label="lab_biib_DeferredTaxLiabilitiesValueReductioninValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Value, Reduction in Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DeferredTaxLiabilitiesValueReductioninValue" xlink:href="biib-20200930.xsd#biib_DeferredTaxLiabilitiesValueReductioninValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DeferredTaxLiabilitiesValueReductioninValue" xlink:to="lab_biib_DeferredTaxLiabilitiesValueReductioninValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_ae282f63-d59a-4bf7-823a-c40dcfa7e91a_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_IonisPharmaceuticalsMember_1fdd5a8d-12db-4353-ae42-672db502e829_terseLabel_en-US" xlink:label="lab_biib_IonisPharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ionis</link:label>
    <link:label id="lab_biib_IonisPharmaceuticalsMember_label_en-US" xlink:label="lab_biib_IonisPharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ionis Pharmaceuticals [Member]</link:label>
    <link:label id="lab_biib_IonisPharmaceuticalsMember_documentation_en-US" xlink:label="lab_biib_IonisPharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ionis Pharmaceuticals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IonisPharmaceuticalsMember" xlink:href="biib-20200930.xsd#biib_IonisPharmaceuticalsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IonisPharmaceuticalsMember" xlink:to="lab_biib_IonisPharmaceuticalsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_0149988b-60b0-4814-b5e0-0c214376cff3_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New accounting pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_e67fc368-9c0a-4a95-a3dd-22deb41142fe_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales, excluding amortization and impairment of acquired intangible assets</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DenaliTherapeuticsIncMember_ad34778a-92d5-4bab-bf8a-f03ad0337682_terseLabel_en-US" xlink:label="lab_biib_DenaliTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denali Therapeutics</link:label>
    <link:label id="lab_biib_DenaliTherapeuticsIncMember_label_en-US" xlink:label="lab_biib_DenaliTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denali Therapeutics Inc [Member]</link:label>
    <link:label id="lab_biib_DenaliTherapeuticsIncMember_documentation_en-US" xlink:label="lab_biib_DenaliTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denali Therapeutics Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DenaliTherapeuticsIncMember" xlink:href="biib-20200930.xsd#biib_DenaliTherapeuticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DenaliTherapeuticsIncMember" xlink:to="lab_biib_DenaliTherapeuticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_4f43c582-4d4a-4564-8c96-443deb85925a_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_country_BR_cb0dfe2f-2d9a-4a56-b7a2-1410053eea75_terseLabel_en-US" xlink:label="lab_country_BR" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Brazil</link:label>
    <link:label id="lab_country_BR_label_en-US" xlink:label="lab_country_BR" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BRAZIL</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_BR" xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_BR"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_BR" xlink:to="lab_country_BR" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_c03c8798-7001-408a-9ce6-2a2b467821b8_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net gains (losses) of other income (expense) related to foreign currency forward contracts</link:label>
    <link:label id="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_label_en-US" xlink:label="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:to="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_5190c753-f78d-45d4-9474-ff1b48c2fca3_verboseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_903280e4-4b86-4328-9fc6-be2158cba1e0_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_abea5ab7-380c-46c5-a348-3d5c681c264e_totalLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_us-gaap_Revenues_8659401d-8d6c-49fa-853b-713197734c39_netLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_ce17885f-c540-413b-946f-d2dde476a324_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_48b8cf43-ff5e-4b12-a9fc-780289c0b179_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses and Other</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_666ee78d-e500-4609-a3be-40529d11a9f6_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) on reclassification of cash flow hedges, effective portion</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SPINRAZAMember_d108a064-d34a-49ce-a5ef-7e62b469405f_terseLabel_en-US" xlink:label="lab_biib_SPINRAZAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SPINRAZA</link:label>
    <link:label id="lab_biib_SPINRAZAMember_label_en-US" xlink:label="lab_biib_SPINRAZAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SPINRAZA [Member]</link:label>
    <link:label id="lab_biib_SPINRAZAMember_documentation_en-US" xlink:label="lab_biib_SPINRAZAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SPINRAZA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SPINRAZAMember" xlink:href="biib-20200930.xsd#biib_SPINRAZAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SPINRAZAMember" xlink:to="lab_biib_SPINRAZAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_d553659c-acc6-4325-ab88-b8894b6b136e_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted earnings per share attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_580cf4bf-749a-40c8-b03e-ddff450f1158_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares used in calculating diluted earnings per share</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_7e40249a-9aae-47bd-b244-e852046dd9a6_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_TysabriProductMember_d79d7450-922b-4365-aebb-1c6b44f80826_terseLabel_en-US" xlink:label="lab_biib_TysabriProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TYSABRI</link:label>
    <link:label id="lab_biib_TysabriProductMember_label_en-US" xlink:label="lab_biib_TysabriProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TYSABRI product [Member]</link:label>
    <link:label id="lab_biib_TysabriProductMember_documentation_en-US" xlink:label="lab_biib_TysabriProductMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TYSABRI product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TysabriProductMember" xlink:href="biib-20200930.xsd#biib_TysabriProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TysabriProductMember" xlink:to="lab_biib_TysabriProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_c8be3dc9-f958-4211-9352-fea511a58866_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future minimum batch production for Denmark Manufacturing Operations</link:label>
    <link:label id="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_label_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Commitment, Remaining Minimum Amount Committed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:to="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ShareOfCoPromotionProfits_de5be5ba-ed98-4f15-bee0-8949d7fc65f7_terseLabel_en-US" xlink:label="lab_biib_ShareOfCoPromotionProfits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA</link:label>
    <link:label id="lab_biib_ShareOfCoPromotionProfits_label_en-US" xlink:label="lab_biib_ShareOfCoPromotionProfits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Of Co Promotion Profits</link:label>
    <link:label id="lab_biib_ShareOfCoPromotionProfits_documentation_en-US" xlink:label="lab_biib_ShareOfCoPromotionProfits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share of co promotion profits.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareOfCoPromotionProfits" xlink:href="biib-20200930.xsd#biib_ShareOfCoPromotionProfits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ShareOfCoPromotionProfits" xlink:to="lab_biib_ShareOfCoPromotionProfits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_84365eed-cd90-49c1-a258-8685c613b251_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_f47aef52-9e5b-43fd-a50a-5dbd0011ee57_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable equity securities, amortized cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities, Amortized Cost Basis</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_f6d7f3cf-1bb9-4e33-ade8-acdb4d2c6f95_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_06540b9d-e375-4670-9fee-ae6fcf6cadbf_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2c8c49e5-7000-40d6-8bb9-02969f5187b3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_b0b68fa2-e52c-4c56-99fb-17a0c29d038f_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_a3f8f4a8-9b9f-4767-beb2-4429b5a966ff_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange contract</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeContractMember" xlink:to="lab_us-gaap_ForeignExchangeContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ResearchanddevelopmentassetDomain_bd9eee8b-5594-4481-bcf3-ecc83728375f_terseLabel_en-US" xlink:label="lab_biib_ResearchanddevelopmentassetDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development asset [Domain]</link:label>
    <link:label id="lab_biib_ResearchanddevelopmentassetDomain_label_en-US" xlink:label="lab_biib_ResearchanddevelopmentassetDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development asset [Domain]</link:label>
    <link:label id="lab_biib_ResearchanddevelopmentassetDomain_documentation_en-US" xlink:label="lab_biib_ResearchanddevelopmentassetDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Research and development asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchanddevelopmentassetDomain" xlink:href="biib-20200930.xsd#biib_ResearchanddevelopmentassetDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ResearchanddevelopmentassetDomain" xlink:to="lab_biib_ResearchanddevelopmentassetDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_40f39ccb-a7c5-4937-a6d0-23a7142666f4_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_f4683f9b-b065-49d5-b178-58768f465c86_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_e58e652a-9d16-4378-aa0c-d5668bea1814_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_840a61a8-95a0-45f5-98f0-40b997f5186c_verboseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_8efb292a-93e1-4094-a403-0520bfa100f1_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross unrealized losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_ff956d72-fb68-46fd-a059-d999c030b170_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_984f60ce-8fe6-41d1-a8c6-169a6db61582_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAbstract" xlink:to="lab_us-gaap_NetIncomeLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_8ed58ad2-f371-4f73-872b-f17b87582ff2_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of borrowings</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_EUR_334f9297-77f1-494c-9e92-8da5e2d56dee_verboseLabel_en-US" xlink:label="lab_currency_EUR" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Euro</link:label>
    <link:label id="lab_currency_EUR_label_en-US" xlink:label="lab_currency_EUR" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Euro Member Countries, Euro</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_EUR" xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_EUR"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_EUR" xlink:to="lab_currency_EUR" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_dd825f26-a7b6-454f-bada-437310deb3da_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common stock, at cost, shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_d7e2cf1a-1c61-450b-8591-a1b650186cc9_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common stock, at cost, shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_6c96054e-bad3-4d0b-a940-9f6250c7c58b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration obligations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_969a7c59-6a80-42cf-8963-5affbf6a5ee7_periodStartLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value, beginning of period</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_befca6f5-1371-419d-be3f-7dd7a6c05293_periodEndLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value, end of period</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_39d60e15-a122-4edf-b90d-f13031c413f5_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_ff5e6440-9232-46d7-8e02-9aaa5decd555_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_cbd1160b-ee6b-40c5-a6e2-c34dfc585ade_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesNoncurrent_1f8562c5-76e8-4d7b-9442-1a2b67a23c26_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued income taxes</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_226fd8e1-d9e5-4863-9875-0bcb88092adf_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_66e819bc-f371-45f5-8686-43801e55351b_totalLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net gains (losses) recognized during the period on equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ContractualAdjustmentsMember_d26c2b10-d3b3-4f74-86d1-b7c5bc1173da_terseLabel_en-US" xlink:label="lab_biib_ContractualAdjustmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual adjustments</link:label>
    <link:label id="lab_biib_ContractualAdjustmentsMember_label_en-US" xlink:label="lab_biib_ContractualAdjustmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Adjustments [Member]</link:label>
    <link:label id="lab_biib_ContractualAdjustmentsMember_documentation_en-US" xlink:label="lab_biib_ContractualAdjustmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual adjustments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ContractualAdjustmentsMember" xlink:href="biib-20200930.xsd#biib_ContractualAdjustmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ContractualAdjustmentsMember" xlink:to="lab_biib_ContractualAdjustmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_95cd15bb-2acf-4a7f-8f1c-9fe323a87dbe_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues related to amendment of contract manufacturing agreement</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_ae3d0480-59fd-4390-8116-192c43149773_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Separately Recognized Transactions [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Separately Recognized Transactions [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:to="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_OutLicensedPatentsMember_0665838b-ab83-4cdd-84f7-e61105bed758_terseLabel_en-US" xlink:label="lab_biib_OutLicensedPatentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Out-licensed patents</link:label>
    <link:label id="lab_biib_OutLicensedPatentsMember_label_en-US" xlink:label="lab_biib_OutLicensedPatentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Out Licensed Patents [Member]</link:label>
    <link:label id="lab_biib_OutLicensedPatentsMember_documentation_en-US" xlink:label="lab_biib_OutLicensedPatentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Out-licensed patents.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OutLicensedPatentsMember" xlink:href="biib-20200930.xsd#biib_OutLicensedPatentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OutLicensedPatentsMember" xlink:to="lab_biib_OutLicensedPatentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_55ebfd66-0107-48c9-a29f-aa5708e3cd7d_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockMember_864d28f9-973e-4b0d-bae7-9d1a40e851d2_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_label_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember" xlink:to="lab_us-gaap_PreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DistributorTwoMember_615e6927-151a-4896-97a3-d4cc7d647b7b_terseLabel_en-US" xlink:label="lab_biib_DistributorTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributor Two</link:label>
    <link:label id="lab_biib_DistributorTwoMember_label_en-US" xlink:label="lab_biib_DistributorTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributor Two [Member]</link:label>
    <link:label id="lab_biib_DistributorTwoMember_documentation_en-US" xlink:label="lab_biib_DistributorTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributor two.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DistributorTwoMember" xlink:href="biib-20200930.xsd#biib_DistributorTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DistributorTwoMember" xlink:to="lab_biib_DistributorTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_062eda82-9fe4-4040-b8bb-308bffe05224_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_0ff3b243-b46c-43ba-aa80-1328d015797e_negatedLabel_en-US" xlink:label="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments Relating To Prior Years</link:label>
    <link:label id="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_label_en-US" xlink:label="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments To Product Revenue Reserves Relating To Sales In Prior Years</link:label>
    <link:label id="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_documentation_en-US" xlink:label="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to product revenue reserves relating to sales in prior years.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" xlink:href="biib-20200930.xsd#biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" xlink:to="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_aacd712e-9549-40bc-a158-aa6fa2355d8e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized share-based compensation costs</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Amount Capitalized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_ee0e3d08-a6a9-4734-bc49-181129d0082c_terseLabel_en-US" xlink:label="lab_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of stake in entity</link:label>
    <link:label id="lab_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_label_en-US" xlink:label="lab_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Ownership Percentage Before Additional Purchase Transaction</link:label>
    <link:label id="lab_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_documentation_en-US" xlink:label="lab_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Ownership Percentage Before Additional Purchase Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" xlink:href="biib-20200930.xsd#biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" xlink:to="lab_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_c8d26d1b-e824-4fcb-8a32-12e1a477c125_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_5f54f886-22a8-4737-a86e-17a8b01d36ad_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare_fd2dfac1-dca9-47b4-9daf-2b63627d288c_terseLabel_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Licensing Collaboration Agreement, Shares Purchased Per Share</link:label>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare_label_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Licensing Collaboration Agreement, Shares Purchased Per Share</link:label>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare_documentation_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Licensing Collaboration Agreement, Shares Purchased Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare" xlink:href="biib-20200930.xsd#biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare" xlink:to="lab_biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_78fadee6-ef75-4cc3-a2c2-043c6a14a1c8_verboseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_7cfb31af-747b-453e-be1f-c8a6402cd0c7_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_998d32ab-6958-4798-b610-88946328722a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_92655bb5-bc02-458f-9e04-d2f46677f000_verboseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_09b0ef92-e15b-41dc-ac53-39f56d8015b4_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, beginning of the period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_688b6f77-6cc7-4f3e-a499-ca0e56d914e6_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, end of the period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_da2477cc-1bfc-4e7c-95b0-6e01eaf38fcf_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of assets and liabilities recorded at fair value</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_63300aac-ccb4-4fc3-8680-fcaf0644cc40_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Variable Interest Entities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Variable Interest Entities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:to="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_9f264372-7e10-45da-b1eb-fb972cb6b63b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_MarketStockUnitsMember_8125d2e1-db55-4a19-951f-41bbb8c75ba9_verboseLabel_en-US" xlink:label="lab_biib_MarketStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market stock units</link:label>
    <link:label id="lab_biib_MarketStockUnitsMember_label_en-US" xlink:label="lab_biib_MarketStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market Stock Units [Member]</link:label>
    <link:label id="lab_biib_MarketStockUnitsMember_documentation_en-US" xlink:label="lab_biib_MarketStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market stock units.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MarketStockUnitsMember" xlink:href="biib-20200930.xsd#biib_MarketStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MarketStockUnitsMember" xlink:to="lab_biib_MarketStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_c3bf1551-accf-476b-84a5-6713ecef03a5_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount remaining under 2019 Share Repurchase Program</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Remaining Authorized Repurchase Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_d90103c0-9a36-4010-83a2-491a47c63066_terseLabel_en-US" xlink:label="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.625% Senior Notes due 2022</link:label>
    <link:label id="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_label_en-US" xlink:label="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Three Point Six Two Five Percent Due Twenty Twenty Two [Member]</link:label>
    <link:label id="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_documentation_en-US" xlink:label="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Three Point Six Two Five Percent Due Twenty Twenty Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:href="biib-20200930.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:to="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_15198b78-0dee-4a71-9ddb-3b379a44f301_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due in one year or less, estimated fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPaymentsToAcquireBusinesses_a6976394-cc03-42ad-95a5-1a617fa58aef_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPaymentsToAcquireBusinesses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for pre-combination equity compensation</link:label>
    <link:label id="lab_us-gaap_OtherPaymentsToAcquireBusinesses_label_en-US" xlink:label="lab_us-gaap_OtherPaymentsToAcquireBusinesses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Payments to Acquire Businesses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPaymentsToAcquireBusinesses" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherPaymentsToAcquireBusinesses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPaymentsToAcquireBusinesses" xlink:to="lab_us-gaap_OtherPaymentsToAcquireBusinesses" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_407e5625-1332-456a-a8b5-5c62cd0316fd_verboseLabel_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage and other asset backed securities Current</link:label>
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_label_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage And Other Asset Backed Securities Current [Member]</link:label>
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_documentation_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage and other asset backed securities Current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" xlink:href="biib-20200930.xsd#biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" xlink:to="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_2cb01885-a834-4dab-8317-ba00c052e431_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EffectiveIncomeTaxRateReconciliationChangeInForeignTaxRatePercent_df3f3f12-ff2b-4c56-85ec-713cfe5482b3_terseLabel_en-US" xlink:label="lab_biib_EffectiveIncomeTaxRateReconciliationChangeInForeignTaxRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Swiss tax reform</link:label>
    <link:label id="lab_biib_EffectiveIncomeTaxRateReconciliationChangeInForeignTaxRatePercent_label_en-US" xlink:label="lab_biib_EffectiveIncomeTaxRateReconciliationChangeInForeignTaxRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation Change in Foreign Tax Rate Percent</link:label>
    <link:label id="lab_biib_EffectiveIncomeTaxRateReconciliationChangeInForeignTaxRatePercent_documentation_en-US" xlink:label="lab_biib_EffectiveIncomeTaxRateReconciliationChangeInForeignTaxRatePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation Change in Foreign Tax Rate Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EffectiveIncomeTaxRateReconciliationChangeInForeignTaxRatePercent" xlink:href="biib-20200930.xsd#biib_EffectiveIncomeTaxRateReconciliationChangeInForeignTaxRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EffectiveIncomeTaxRateReconciliationChangeInForeignTaxRatePercent" xlink:to="lab_biib_EffectiveIncomeTaxRateReconciliationChangeInForeignTaxRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2fffacc2-b531-47e0-9c5a-09ad6d6877f9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Asset Class</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_b6add4dd-87c3-49bc-af0f-514e3661ece5_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_A2.90SeniorNotesDueSept152020Member_42fe927d-a544-4f94-835d-3a492cc304cd_terseLabel_en-US" xlink:label="lab_biib_A2.90SeniorNotesDueSept152020Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.90% Senior Notes Due Sept 15, 2020</link:label>
    <link:label id="lab_biib_A2.90SeniorNotesDueSept152020Member_label_en-US" xlink:label="lab_biib_A2.90SeniorNotesDueSept152020Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.90% Senior Notes Due Sept 15, 2020 [Member]</link:label>
    <link:label id="lab_biib_A2.90SeniorNotesDueSept152020Member_documentation_en-US" xlink:label="lab_biib_A2.90SeniorNotesDueSept152020Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.90% Senior Notes Due Sept 15, 2020 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2.90SeniorNotesDueSept152020Member" xlink:href="biib-20200930.xsd#biib_A2.90SeniorNotesDueSept152020Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A2.90SeniorNotesDueSept152020Member" xlink:to="lab_biib_A2.90SeniorNotesDueSept152020Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionSharePrice_9c093c0e-9583-42ae-8bd3-4c9f1074037c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Price per share</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionSharePrice_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionSharePrice" xlink:to="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_d94f4be3-0fc1-4538-8986-59b2f5d68d82_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_8f34d051-995f-460a-94a8-187cba526633_terseLabel_en-US" xlink:label="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense included in total costs and expenses</link:label>
    <link:label id="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_label_en-US" xlink:label="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Expense Included In Costs And Expenses</link:label>
    <link:label id="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_documentation_en-US" xlink:label="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation expense included in costs and expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:href="biib-20200930.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:to="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_IMRALDIMember_564d03fe-82b4-4fba-8350-73ae3ba65a09_terseLabel_en-US" xlink:label="lab_biib_IMRALDIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IMRALDI</link:label>
    <link:label id="lab_biib_IMRALDIMember_label_en-US" xlink:label="lab_biib_IMRALDIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IMRALDI [Member]</link:label>
    <link:label id="lab_biib_IMRALDIMember_documentation_en-US" xlink:label="lab_biib_IMRALDIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IMRALDI [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IMRALDIMember" xlink:href="biib-20200930.xsd#biib_IMRALDIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IMRALDIMember" xlink:to="lab_biib_IMRALDIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_f58cff69-6275-4a22-b3c1-ec14af7a32c6_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockMember_40b8b354-ec8a-4e96-9a17-d1441844f1cb_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember" xlink:to="lab_us-gaap_TreasuryStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_05b30c13-0f54-41d0-a3ac-fa83af73e463_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_56a4f75d-f19a-4906-9eef-2dd0320ff2df_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors_15a71b02-2c61-4d69-9ae7-e2f5adc737c5_terseLabel_en-US" xlink:label="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of revenues from major distributors</link:label>
    <link:label id="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors_label_en-US" xlink:label="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Wide Percentage Of Revenue From Major Distributors</link:label>
    <link:label id="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors_documentation_en-US" xlink:label="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity wide percentage of revenue from major distributors.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors" xlink:href="biib-20200930.xsd#biib_EntityWidePercentageOfRevenueFromMajorDistributors"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors" xlink:to="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_d9dcfc1a-d18a-4baf-9d4d-2252ce415367_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_4c5117b0-a61c-4006-af53-b5a514bb64d4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValue_904b7873-c7bf-48a5-a299-70927d193eaa_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, at cost</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue" xlink:to="lab_us-gaap_TreasuryStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_a8d23fe6-01dc-49f4-a00d-e3e8c926c017_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of roll forward of the changes in goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_9b17b109-377a-42de-9eba-29bcb7f16268_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments_43b5d3a3-e39f-4cb6-b886-1ab7a1774e96_terseLabel_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Licensing Collaboration Agreement, Research, Development, Regulatory and Commercial Milestone Payments</link:label>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments_label_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Licensing Collaboration Agreement, Research, Development, Regulatory and Commercial Milestone Payments</link:label>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments_documentation_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Licensing Collaboration Agreement, Research, Development, Regulatory and Commercial Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments" xlink:href="biib-20200930.xsd#biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments" xlink:to="lab_biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_InvestmentsInVariableInterestEntitiesAbstract_ac69bd7f-4405-4eea-9ca3-3793b79d87ed_terseLabel_en-US" xlink:label="lab_biib_InvestmentsInVariableInterestEntitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Variable Interest Entities [Abstract]</link:label>
    <link:label id="lab_biib_InvestmentsInVariableInterestEntitiesAbstract_label_en-US" xlink:label="lab_biib_InvestmentsInVariableInterestEntitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Variable Interest Entities [Abstract]</link:label>
    <link:label id="lab_biib_InvestmentsInVariableInterestEntitiesAbstract_documentation_en-US" xlink:label="lab_biib_InvestmentsInVariableInterestEntitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments In Variable Interest Entities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InvestmentsInVariableInterestEntitiesAbstract" xlink:href="biib-20200930.xsd#biib_InvestmentsInVariableInterestEntitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InvestmentsInVariableInterestEntitiesAbstract" xlink:to="lab_biib_InvestmentsInVariableInterestEntitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_abedbf26-8457-469a-9121-b92e0945b236_verboseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_1dc1f415-0857-4eed-a379-e27fcfa48620_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_bc4479a6-1bbc-4376-b259-1501b729afc1_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration obligations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_bf4c1dc4-37c2-4e8f-94df-07f2aed5aefd_netLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_af34c1e5-99e2-4fb6-87b8-29ded2fbedb9_verboseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_4328180b-cb61-4cf1-8d84-ed53ffbab57c_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, beginning of period</link:label>
    <link:label id="lab_us-gaap_Goodwill_fdc680d0-dbf6-4878-ab4d-e594d4f16225_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, end of period</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_4e38e339-b2b0-411f-8901-e6ec77afec43_verboseLabel_en-US" xlink:label="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan assets for deferred compensation</link:label>
    <link:label id="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_label_en-US" xlink:label="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Assets For Deferred Compensation Fair Value Disclosure</link:label>
    <link:label id="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_documentation_en-US" xlink:label="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair values as of the balance sheet date of all assets of deferred compensation plans.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure" xlink:href="biib-20200930.xsd#biib_PlanAssetsForDeferredCompensationFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure" xlink:to="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_9d970902-25ca-4ce7-9f35-5bae2d9d44be_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_342213ea-42c6-4900-b60c-b6887f4744a5_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_432cb1d3-07a8-4c86-b809-db2674bcfc72_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain" xlink:to="lab_us-gaap_HedgingDesignationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EffectiveTaxRateReconciliationGILTItax_9708d75c-4223-409d-8e7e-e306ccdfaf57_terseLabel_en-US" xlink:label="lab_biib_EffectiveTaxRateReconciliationGILTItax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GILTI</link:label>
    <link:label id="lab_biib_EffectiveTaxRateReconciliationGILTItax_label_en-US" xlink:label="lab_biib_EffectiveTaxRateReconciliationGILTItax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Tax Rate Reconciliation, GILTI tax</link:label>
    <link:label id="lab_biib_EffectiveTaxRateReconciliationGILTItax_documentation_en-US" xlink:label="lab_biib_EffectiveTaxRateReconciliationGILTItax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Tax Rate Reconciliation, GILTI tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EffectiveTaxRateReconciliationGILTItax" xlink:href="biib-20200930.xsd#biib_EffectiveTaxRateReconciliationGILTItax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EffectiveTaxRateReconciliationGILTItax" xlink:to="lab_biib_EffectiveTaxRateReconciliationGILTItax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_405dd0ee-20aa-4e13-8948-2fc0f420453e_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues by product</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0e199c60-56c7-456d-a9ff-563a5d9578f0_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_3d486dec-82fe-4633-97b6-e886ba8aa606_terseLabel_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_label_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:to="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_4a208b91-8dec-4012-8a6b-79ddaac92f00_terseLabel_en-US" xlink:label="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Provisions Relating To Sales In Current Year</link:label>
    <link:label id="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_label_en-US" xlink:label="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Provisions To Product Revenue Reserves Relating To Sales In Current Year</link:label>
    <link:label id="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_documentation_en-US" xlink:label="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current provisions to product revenue reserves relating to sales in current year.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" xlink:href="biib-20200930.xsd#biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" xlink:to="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_6f60797d-8b19-44ed-8e86-243cee2f48d1_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_f07eb7b7-bd74-48eb-aa05-5ba6e6546f95_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_bed7764c-a689-451f-89fc-526eb99ee5e4_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic earnings per share attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_652e11bf-c508-4ebe-ba9a-cf67587c3370_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable debt and equity securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_101785f7-5409-49be-a646-de501e188ff5_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FumarateMember_ef7063e2-8475-4f1a-bc0a-0619d77c4c96_terseLabel_en-US" xlink:label="lab_biib_FumarateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fumarate</link:label>
    <link:label id="lab_biib_FumarateMember_label_en-US" xlink:label="lab_biib_FumarateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fumarate [Member]</link:label>
    <link:label id="lab_biib_FumarateMember_documentation_en-US" xlink:label="lab_biib_FumarateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fumarate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FumarateMember" xlink:href="biib-20200930.xsd#biib_FumarateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FumarateMember" xlink:to="lab_biib_FumarateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_f80706c6-d2f3-4acf-828d-7afa24d9af56_negatedLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax effect</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense, Tax Benefit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage_5f79bddb-2a9a-4073-a332-83216a312740_terseLabel_en-US" xlink:label="lab_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, make whole provision redemption price, percentage</link:label>
    <link:label id="lab_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage_label_en-US" xlink:label="lab_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Make Whole Provision Redemption Price, Percentage</link:label>
    <link:label id="lab_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage_documentation_en-US" xlink:label="lab_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Make Whole Provision Redemption Price, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage" xlink:href="biib-20200930.xsd#biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage" xlink:to="lab_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_cb5d17e3-b34e-425c-b3b8-05aaf499cfa6_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_74e694ef-fa7d-4bde-8096-48cd12fb0d1c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_8aaf36e8-34a7-4ea4-9582-482a286f520e_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_9b4d46b0-8e9b-4025-8e8c-1eb6d1552277_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Information about Litigation Matters [Abstract]</link:label>
    <link:label id="lab_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_label_en-US" xlink:label="lab_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Information about Litigation Matters [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyInformationAboutLitigationMattersAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" xlink:to="lab_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_ab7eaeb9-6ef2-4e43-8546-c5f656517229_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_A3.15SeniorNotesdueMay12050Member_f8bd133f-76b9-4e11-a6e8-8bb777cdba4b_terseLabel_en-US" xlink:label="lab_biib_A3.15SeniorNotesdueMay12050Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.150% Senior Notes due May 1, 2050</link:label>
    <link:label id="lab_biib_A3.15SeniorNotesdueMay12050Member_label_en-US" xlink:label="lab_biib_A3.15SeniorNotesdueMay12050Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.15% Senior Notes due May 1, 2050 [Member]</link:label>
    <link:label id="lab_biib_A3.15SeniorNotesdueMay12050Member_documentation_en-US" xlink:label="lab_biib_A3.15SeniorNotesdueMay12050Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.15% Senior Notes due May 1, 2050 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A3.15SeniorNotesdueMay12050Member" xlink:href="biib-20200930.xsd#biib_A3.15SeniorNotesdueMay12050Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A3.15SeniorNotesdueMay12050Member" xlink:to="lab_biib_A3.15SeniorNotesdueMay12050Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_cb040107-6af7-4fb0-afcd-b1694b95aae1_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_a33b097e-b2e6-40ba-8b24-b169b54240c2_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsIncomeTaxExpense_a76369b8-ab0c-4ac3-bc98-93564df50bee_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsIncomeTaxExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Income Tax Expense</link:label>
    <link:label id="lab_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsIncomeTaxExpense_label_en-US" xlink:label="lab_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsIncomeTaxExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Income Tax Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsIncomeTaxExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsIncomeTaxExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsIncomeTaxExpense" xlink:to="lab_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsIncomeTaxExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_3c8ad32a-1901-4eaa-9674-ce6eb12e0f6b_verboseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Marketable Securities [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:to="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ElenbecestatCollaborationMember_05e6d7f2-a5b0-4abc-8b20-96ec4027b249_terseLabel_en-US" xlink:label="lab_biib_ElenbecestatCollaborationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Elenbecestat Collaboration</link:label>
    <link:label id="lab_biib_ElenbecestatCollaborationMember_label_en-US" xlink:label="lab_biib_ElenbecestatCollaborationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Elenbecestat Collaboration [Member]</link:label>
    <link:label id="lab_biib_ElenbecestatCollaborationMember_documentation_en-US" xlink:label="lab_biib_ElenbecestatCollaborationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Elenbecestat Collaboration [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ElenbecestatCollaborationMember" xlink:href="biib-20200930.xsd#biib_ElenbecestatCollaborationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ElenbecestatCollaborationMember" xlink:to="lab_biib_ElenbecestatCollaborationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ReserveforCashDiscountsMember_564f6256-98c1-484a-ac18-078262cf31e8_terseLabel_en-US" xlink:label="lab_biib_ReserveforCashDiscountsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discounts</link:label>
    <link:label id="lab_biib_ReserveforCashDiscountsMember_label_en-US" xlink:label="lab_biib_ReserveforCashDiscountsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve for Cash Discounts [Member]</link:label>
    <link:label id="lab_biib_ReserveforCashDiscountsMember_documentation_en-US" xlink:label="lab_biib_ReserveforCashDiscountsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve for Cash Discounts [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReserveforCashDiscountsMember" xlink:href="biib-20200930.xsd#biib_ReserveforCashDiscountsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ReserveforCashDiscountsMember" xlink:to="lab_biib_ReserveforCashDiscountsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_NumberOfWholesalers_e278202a-aa84-4977-bd0a-dbf4b4f4b98c_terseLabel_en-US" xlink:label="lab_biib_NumberOfWholesalers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of wholesalers</link:label>
    <link:label id="lab_biib_NumberOfWholesalers_label_en-US" xlink:label="lab_biib_NumberOfWholesalers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Wholesalers</link:label>
    <link:label id="lab_biib_NumberOfWholesalers_documentation_en-US" xlink:label="lab_biib_NumberOfWholesalers" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Wholesalers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NumberOfWholesalers" xlink:href="biib-20200930.xsd#biib_NumberOfWholesalers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NumberOfWholesalers" xlink:to="lab_biib_NumberOfWholesalers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentForAmortization_a4f22112-3de2-482a-9af2-c6d6b8847d40_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentForAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of basis differences</link:label>
    <link:label id="lab_us-gaap_AdjustmentForAmortization_label_en-US" xlink:label="lab_us-gaap_AdjustmentForAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentForAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentForAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentForAmortization" xlink:to="lab_us-gaap_AdjustmentForAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_c70d8e72-e3d3-4cb4-84fe-a16c39739c52_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_e9edcd84-a79e-46a1-91bb-333c3903a663_negatedPeriodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance, shares</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_0a2d6bf1-f935-4c3c-acfa-a7cbbb9de84d_negatedPeriodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance, shares</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7323c718-1d8d-47ab-8a81-667c757d99d0_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities, net:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_af8d8994-584c-4e22-9be8-e7ed2679e3f0_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income before income tax expense and equity in loss of investee, net of tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_ffca0ca4-0416-4ad4-ac0e-2bc782e85110_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares used in calculating:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_582e1552-bf41-48bb-8a66-2934e8f5ebf6_terseLabel_en-US" xlink:label="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.050% Senior Notes due 2025</link:label>
    <link:label id="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_label_en-US" xlink:label="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Four Point Zero Five Percent Due Twenty Twenty Five [Member]</link:label>
    <link:label id="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_documentation_en-US" xlink:label="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Four Point Zero Five Percent Due Twenty Twenty Five [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:href="biib-20200930.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:to="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_b3ccb34c-910b-4ff5-954b-38177a2c56d7_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quoted Prices in Active Markets (Level 1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_13e21dff-57a7-4377-95ff-23d10dedcd6e_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_8e672516-9b41-44ba-befa-0aa881c560ac_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate_969a9c44-7bad-49fa-b846-8e7af48e72d4_terseLabel_en-US" xlink:label="lab_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value, in-process research and development, discount rate</link:label>
    <link:label id="lab_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate_label_en-US" xlink:label="lab_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Indefinite Lived Intangible Assets, Discount Rate</link:label>
    <link:label id="lab_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate_documentation_en-US" xlink:label="lab_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Indefinite Lived Intangible Assets, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate" xlink:href="biib-20200930.xsd#biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate" xlink:to="lab_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_InLicensedPatentsMember_b5a3afd3-20dd-43d9-9365-7672039fc0a2_terseLabel_en-US" xlink:label="lab_biib_InLicensedPatentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired and in-licensed rights and patents</link:label>
    <link:label id="lab_biib_InLicensedPatentsMember_label_en-US" xlink:label="lab_biib_InLicensedPatentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Licensed Patents [Member]</link:label>
    <link:label id="lab_biib_InLicensedPatentsMember_documentation_en-US" xlink:label="lab_biib_InLicensedPatentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In-licensed patents.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InLicensedPatentsMember" xlink:href="biib-20200930.xsd#biib_InLicensedPatentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InLicensedPatentsMember" xlink:to="lab_biib_InLicensedPatentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_A2018ShareRepurchaseProgramMember_ee0846f4-d9ad-486d-8bf3-6a8adb732939_terseLabel_en-US" xlink:label="lab_biib_A2018ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Share Repurchase Program</link:label>
    <link:label id="lab_biib_A2018ShareRepurchaseProgramMember_label_en-US" xlink:label="lab_biib_A2018ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Share Repurchase Program [Member]</link:label>
    <link:label id="lab_biib_A2018ShareRepurchaseProgramMember_documentation_en-US" xlink:label="lab_biib_A2018ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Share Repurchase Program [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2018ShareRepurchaseProgramMember" xlink:href="biib-20200930.xsd#biib_A2018ShareRepurchaseProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A2018ShareRepurchaseProgramMember" xlink:to="lab_biib_A2018ShareRepurchaseProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_8a42e59e-3314-4318-a8d1-6b3451c41fb9_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseMember_37b65dc4-865b-47f6-9514-b26f65154b47_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseMember_label_en-US" xlink:label="lab_us-gaap_InterestExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseMember" xlink:to="lab_us-gaap_InterestExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_4d6195f0-23c1-4ae0-b29d-9ea7b4bcde3c_terseLabel_en-US" xlink:label="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront and milestone payments made to collaborative partner</link:label>
    <link:label id="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_label_en-US" xlink:label="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront And Milestone Payments Made To Collaborative Partner</link:label>
    <link:label id="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_documentation_en-US" xlink:label="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total upfront and milestone payments made to collaborative partner.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:href="biib-20200930.xsd#biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:to="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_aea8a1c3-b998-4e75-89d0-9ed897290e26_verboseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentAssetsMember_6ecea7c4-1f58-41a0-b1e2-989b8d7a6932_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherCurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentAssetsMember" xlink:to="lab_us-gaap_OtherCurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_eaa48ce3-2ad0-4f61-a9d1-2ecdd48704e9_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchased intangible assets</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Depreciation and Amortization, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_7c28b977-2c59-4331-a516-82a105a08b32_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on equity method investment</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_2580d093-b4fe-400d-b48b-9ef5079a5acb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Our share of Samsung Bioepis gains (losses)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_e7758db1-4bc0-4cbe-89a7-ac37c9f79ff0_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_ccf10c9b-1d7c-4a7b-a3fa-5b3d0a05786d_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax_3b00a1dc-a369-4910-ac13-4f30b4788c15_terseLabel_en-US" xlink:label="lab_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative qualifying as net investment hedge, excluded component</link:label>
    <link:label id="lab_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax_label_en-US" xlink:label="lab_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Derivative Qualifying as Hedge, Excluded Component, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax" xlink:to="lab_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_47092a6d-8541-436b-a131-7aff2d40ee17_verboseLabel_en-US" xlink:label="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in biotechnology companies that are determined to be unconsolidated variable interest entities</link:label>
    <link:label id="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_label_en-US" xlink:label="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in biotechnology companies that are determined to be unconsolidated variable interest entities</link:label>
    <link:label id="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_documentation_en-US" xlink:label="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in biotechnology companies that are determined to be unconsolidated variable interest entities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" xlink:href="biib-20200930.xsd#biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" xlink:to="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_90d85cad-015a-4140-a961-cfbc8771908f_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_50ddba26-a758-4a00-99ea-f1465e1d8d01_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Divestitures</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DivestituresAbstract_587738e2-e9c1-4b01-a867-925f532dee05_terseLabel_en-US" xlink:label="lab_biib_DivestituresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Divestitures [Abstract]</link:label>
    <link:label id="lab_biib_DivestituresAbstract_label_en-US" xlink:label="lab_biib_DivestituresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Divestitures [Abstract]</link:label>
    <link:label id="lab_biib_DivestituresAbstract_documentation_en-US" xlink:label="lab_biib_DivestituresAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Divestitures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DivestituresAbstract" xlink:href="biib-20200930.xsd#biib_DivestituresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DivestituresAbstract" xlink:to="lab_biib_DivestituresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_68f3bef9-89ff-4600-9aa4-73c71a868506_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_949fc760-eb55-403e-83a2-baee73673222_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Equivalents</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_4f7ed4df-dc43-4ed0-8da5-03d0a08a0732_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssets_e2483332-e0c2-49a4-8604-e98e800fdcbc_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid research and development expenses</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssets" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_176308b4-d131-4ab0-9b78-3afefa7599b7_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_8545dfe4-85a3-4fd8-884d-e29f47fafb10_verboseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_ecaad8e0-f5cf-41da-88d7-77504ff14939_verboseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_a20fed2e-43d9-44eb-9f29-699dd26bad1c_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_717c78d5-0ca7-4f37-a76d-7c4c70211792_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other income (expense), net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_6bd368db-a393-44ae-99fb-ce414be3c31e_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_85a9dc1f-49ef-459f-ba91-50def367c1ec_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesMember" xlink:to="lab_us-gaap_EquitySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_709a4661-2ed2-43f2-b5f6-0e2c313d39c8_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_206f8372-ab85-42d1-8cf1-2b73706d7c06_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense included in condensed consolidated statements of income</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_GBP_8bcf7aa5-db22-453d-ab09-e92ad68de8d3_terseLabel_en-US" xlink:label="lab_currency_GBP" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">British pound</link:label>
    <link:label id="lab_currency_GBP_label_en-US" xlink:label="lab_currency_GBP" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United Kingdom, Pounds</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_GBP" xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_GBP"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_GBP" xlink:to="lab_currency_GBP" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_151d8cf9-2d74-4fb0-88a8-0a442245b048_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_8f203662-013c-49ef-9980-6015d8d9676c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Separately Recognized Transactions [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Separately Recognized Transactions [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:to="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_5fd15113-2023-4342-bc9d-0d748b037016_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under award plan, shares</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FUMADERMMember_de7cbcbc-78ae-45cf-b6c8-2368dc006472_terseLabel_en-US" xlink:label="lab_biib_FUMADERMMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FUMADERM</link:label>
    <link:label id="lab_biib_FUMADERMMember_label_en-US" xlink:label="lab_biib_FUMADERMMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FUMADERM [Member]</link:label>
    <link:label id="lab_biib_FUMADERMMember_documentation_en-US" xlink:label="lab_biib_FUMADERMMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FUMADERM [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FUMADERMMember" xlink:href="biib-20200930.xsd#biib_FUMADERMMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FUMADERMMember" xlink:to="lab_biib_FUMADERMMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_d714eebb-085a-46d6-b741-ece65597fc57_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income (loss) attributable to noncontrolling interests, net of tax</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_41ce8df9-40c0-4606-b47e-9beefc95d1dd_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gains (losses) on pension benefit obligation, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_f3804acb-50b8-428a-b5b7-9fe06fdb8668_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FacilityLocationDomain_7f0e53de-6ccf-4a3c-b95e-753c89a5aaf4_terseLabel_en-US" xlink:label="lab_biib_FacilityLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Location [Domain]</link:label>
    <link:label id="lab_biib_FacilityLocationDomain_label_en-US" xlink:label="lab_biib_FacilityLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Location [Domain]</link:label>
    <link:label id="lab_biib_FacilityLocationDomain_documentation_en-US" xlink:label="lab_biib_FacilityLocationDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">-- None. No documentation exists for this element. --</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityLocationDomain" xlink:href="biib-20200930.xsd#biib_FacilityLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FacilityLocationDomain" xlink:to="lab_biib_FacilityLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_51510e6c-9a06-4376-9b48-9fa5412adb82_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_f5092a75-7d1f-476c-a76c-9ec67f1634d8_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BiologicsManufacturingMember_ed1435e4-f09f-4960-b6ce-17f3fd289235_terseLabel_en-US" xlink:label="lab_biib_BiologicsManufacturingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biologics Manufacturing</link:label>
    <link:label id="lab_biib_BiologicsManufacturingMember_label_en-US" xlink:label="lab_biib_BiologicsManufacturingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biologics Manufacturing [Member]</link:label>
    <link:label id="lab_biib_BiologicsManufacturingMember_documentation_en-US" xlink:label="lab_biib_BiologicsManufacturingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biologics Manufacturing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BiologicsManufacturingMember" xlink:href="biib-20200930.xsd#biib_BiologicsManufacturingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BiologicsManufacturingMember" xlink:to="lab_biib_BiologicsManufacturingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BioverativMember_da46eaac-6702-4359-b27c-1058aaa3e949_terseLabel_en-US" xlink:label="lab_biib_BioverativMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bioverativ</link:label>
    <link:label id="lab_biib_BioverativMember_label_en-US" xlink:label="lab_biib_BioverativMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bioverativ [Member]</link:label>
    <link:label id="lab_biib_BioverativMember_documentation_en-US" xlink:label="lab_biib_BioverativMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bioverativ [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BioverativMember" xlink:href="biib-20200930.xsd#biib_BioverativMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BioverativMember" xlink:to="lab_biib_BioverativMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_2904f3b7-7003-41b1-a1bb-47f36a11f863_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss recorded on Samsung Bioepis joint venture</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments, Net of Dividends or Distributions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_0ef4fbf7-ba7f-421d-bfc3-58babd537522_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_a0c4a672-eed8-412a-8f71-603de51dc7f8_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_NumberOfProductCandidates_fe25bd76-823a-42c7-8f4d-ce6979d0e527_terseLabel_en-US" xlink:label="lab_biib_NumberOfProductCandidates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of product candidates</link:label>
    <link:label id="lab_biib_NumberOfProductCandidates_label_en-US" xlink:label="lab_biib_NumberOfProductCandidates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Product Candidates</link:label>
    <link:label id="lab_biib_NumberOfProductCandidates_documentation_en-US" xlink:label="lab_biib_NumberOfProductCandidates" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Product Candidates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NumberOfProductCandidates" xlink:href="biib-20200930.xsd#biib_NumberOfProductCandidates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NumberOfProductCandidates" xlink:to="lab_biib_NumberOfProductCandidates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_5eae21c7-c988-4803-a613-441e244b471c_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation between the U.S. federal statutory tax rate and effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_4755e8fd-e127-4c6e-ab07-2d9caf5c4aed_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_44e02ed7-00ca-4c2b-a9a8-949537c3ff2e_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_0f3eece4-8682-478a-879a-9413d1a8c5b5_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_3bbda5d7-fce2-414a-8ba6-33cc9ee360bc_verboseLabel_en-US" xlink:label="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from marketable debt securities</link:label>
    <link:label id="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized Gain (Loss) on Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RealizedGainLossOnInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock" xlink:to="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_397da191-0031-4503-8f89-270642a04b2b_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected future amortization expense, 2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_44e1c58a-e762-426c-a117-96569ae6db7d_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of contingent consideration obligations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_aeddecb0-3f57-461e-9715-ea82e24f9d75_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_2f39d410-fd5d-4cc4-b77e-c0aae3bd3623_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_67697f66-8c22-4bf6-8efd-f29534c1111f_verboseLabel_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation</link:label>
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_label_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Matters and Contingencies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LegalMattersAndContingenciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:to="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnInvestmentsTextBlock_7e870963-3b42-4575-b9ee-677a369b7822_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) on investments in equity securities</link:label>
    <link:label id="lab_us-gaap_GainLossOnInvestmentsTextBlock_label_en-US" xlink:label="lab_us-gaap_GainLossOnInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Securities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestmentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnInvestmentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnInvestmentsTextBlock" xlink:to="lab_us-gaap_GainLossOnInvestmentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_ae06f78f-0ad0-406e-860d-0497be1b0b12_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under stock option and stock purchase plans</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Treasury Stock Reissued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_7642b57c-46c8-41b2-a575-7f2e989d3f9a_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TECFIDERA impairment</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesReturnsAndAllowancesMember_712a6554-dd47-426c-a34a-f015e384e510_terseLabel_en-US" xlink:label="lab_us-gaap_SalesReturnsAndAllowancesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Returns</link:label>
    <link:label id="lab_us-gaap_SalesReturnsAndAllowancesMember_label_en-US" xlink:label="lab_us-gaap_SalesReturnsAndAllowancesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Returns and Allowances [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesReturnsAndAllowancesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SalesReturnsAndAllowancesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesReturnsAndAllowancesMember" xlink:to="lab_us-gaap_SalesReturnsAndAllowancesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PercentageParValueOfSeniorNotes_b105c9e3-f0d8-4ba8-afc8-ac141c363ac3_terseLabel_en-US" xlink:label="lab_biib_PercentageParValueOfSeniorNotes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage par value of senior notes</link:label>
    <link:label id="lab_biib_PercentageParValueOfSeniorNotes_label_en-US" xlink:label="lab_biib_PercentageParValueOfSeniorNotes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Par Value Of Senior Notes</link:label>
    <link:label id="lab_biib_PercentageParValueOfSeniorNotes_documentation_en-US" xlink:label="lab_biib_PercentageParValueOfSeniorNotes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Par Value Of Senior Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageParValueOfSeniorNotes" xlink:href="biib-20200930.xsd#biib_PercentageParValueOfSeniorNotes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageParValueOfSeniorNotes" xlink:to="lab_biib_PercentageParValueOfSeniorNotes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_27066b84-7987-4852-9e94-965a938b4c54_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_a8a3bcb9-c672-41cb-8d57-ad89ae54a406_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_265d553d-cf1f-4b64-a854-632e4fc2c63e_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_32de4749-54ec-46ec-92de-43e48d44477a_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms_d4235ef6-bf22-413c-9d52-f6f2bcb5bf04_terseLabel_en-US" xlink:label="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenues from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms_label_en-US" xlink:label="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenues from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms_documentation_en-US" xlink:label="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenues from anti-CD20 therapeutic programs consists of revenue on sales of RITUXAN outside the U.S., which consist of our share of pre-tax co-promotion profits in Canada and royalty revenue on sales of Ocrevus.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms" xlink:href="biib-20200930.xsd#biib_OtherrevenuesfromantiCD20therapeuticprograms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms" xlink:to="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_bec0a041-41e4-43eb-8504-d6d784c9fe5f_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FacilityTypeDomain_7791ed55-928e-48c5-8bef-48fe9deedd41_terseLabel_en-US" xlink:label="lab_biib_FacilityTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Type [Domain]</link:label>
    <link:label id="lab_biib_FacilityTypeDomain_label_en-US" xlink:label="lab_biib_FacilityTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Type [Domain]</link:label>
    <link:label id="lab_biib_FacilityTypeDomain_documentation_en-US" xlink:label="lab_biib_FacilityTypeDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityTypeDomain" xlink:href="biib-20200930.xsd#biib_FacilityTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FacilityTypeDomain" xlink:to="lab_biib_FacilityTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets_7ed94d88-653e-4cea-a3a5-30bf1eb9c5a7_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_47dee469-6a1e-4f23-9342-9cf99bd1ce05_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BENEPALIMember_f3efb9d7-4795-4890-8853-5d3ccc8814a4_terseLabel_en-US" xlink:label="lab_biib_BENEPALIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BENEPALI</link:label>
    <link:label id="lab_biib_BENEPALIMember_label_en-US" xlink:label="lab_biib_BENEPALIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BENEPALI [Member]</link:label>
    <link:label id="lab_biib_BENEPALIMember_documentation_en-US" xlink:label="lab_biib_BENEPALIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BENEPALI [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BENEPALIMember" xlink:href="biib-20200930.xsd#biib_BENEPALIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BENEPALIMember" xlink:to="lab_biib_BENEPALIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_4343e53e-0e6f-4c01-a949-53bb1f3ebda4_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetInvestmentHedgingMember_d2e8bfc4-a555-4718-b95a-825f7a6cd0ea_terseLabel_en-US" xlink:label="lab_us-gaap_NetInvestmentHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Investment Hedging</link:label>
    <link:label id="lab_us-gaap_NetInvestmentHedgingMember_label_en-US" xlink:label="lab_us-gaap_NetInvestmentHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Investment Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetInvestmentHedgingMember" xlink:to="lab_us-gaap_NetInvestmentHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentAssetsMember_90ea8d11-7dfe-44e7-ac2d-fca8db09058c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other noncurrent assets</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentAssetsMember" xlink:to="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BIIB118Member_e05a176d-6cd9-4745-8e70-67fd83e1a2af_terseLabel_en-US" xlink:label="lab_biib_BIIB118Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BIIB118</link:label>
    <link:label id="lab_biib_BIIB118Member_label_en-US" xlink:label="lab_biib_BIIB118Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BIIB118 [Member]</link:label>
    <link:label id="lab_biib_BIIB118Member_documentation_en-US" xlink:label="lab_biib_BIIB118Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BIIB118 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BIIB118Member" xlink:href="biib-20200930.xsd#biib_BIIB118Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BIIB118Member" xlink:to="lab_biib_BIIB118Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_c0cb2619-c6da-4d97-84ab-89e7ade8174a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation related to share-based payments</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_3f9f33c7-dae3-4af8-8df0-5b2aceeb1163_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_43f2429d-a3ab-4803-bd59-9701783bb2eb_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected costs to sell disposal group</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateSwapMember_a7d8d0a8-d2a8-452e-8930-6f17dcca400a_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate swap</link:label>
    <link:label id="lab_us-gaap_InterestRateSwapMember_label_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateSwapMember" xlink:to="lab_us-gaap_InterestRateSwapMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_20183be4-392e-41d3-967d-6958339561db_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_a4f5167d-de7d-420d-9f49-d410b8d44b8f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_e9078b1d-80bf-4293-9555-041a5a2b514c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_48b79eee-6ffe-4c46-bfa0-3da4caaf44fb_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of the effect of cash flow derivatives designated as hedging instruments on the condensed consolidated statements of income</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_5e0ecad6-9850-411d-b764-093a55510d49_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_33e558ff-1148-412f-8a00-d37a80a92d48_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Inventorynetcurrentandnoncurrent_8d67dcd0-abd5-498c-891c-832849d7a081_totalLabel_en-US" xlink:label="lab_biib_Inventorynetcurrentandnoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total inventory</link:label>
    <link:label id="lab_biib_Inventorynetcurrentandnoncurrent_label_en-US" xlink:label="lab_biib_Inventorynetcurrentandnoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, net current and noncurrent</link:label>
    <link:label id="lab_biib_Inventorynetcurrentandnoncurrent_documentation_en-US" xlink:label="lab_biib_Inventorynetcurrentandnoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, net current and noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Inventorynetcurrentandnoncurrent" xlink:href="biib-20200930.xsd#biib_Inventorynetcurrentandnoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Inventorynetcurrentandnoncurrent" xlink:to="lab_biib_Inventorynetcurrentandnoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_eeedcd6a-466c-4813-87ed-1b1fad7b4e96_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative contracts</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Contract, Asset, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:to="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DisputedClaimsRelatingtoConstructionCosts_c9d40f29-6ff1-426d-b042-5e078c5d17d4_terseLabel_en-US" xlink:label="lab_biib_DisputedClaimsRelatingtoConstructionCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disputed claims relating to construction costs</link:label>
    <link:label id="lab_biib_DisputedClaimsRelatingtoConstructionCosts_label_en-US" xlink:label="lab_biib_DisputedClaimsRelatingtoConstructionCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disputed Claims Relating to Construction Costs</link:label>
    <link:label id="lab_biib_DisputedClaimsRelatingtoConstructionCosts_documentation_en-US" xlink:label="lab_biib_DisputedClaimsRelatingtoConstructionCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disputed Claims Relating to Construction Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DisputedClaimsRelatingtoConstructionCosts" xlink:href="biib-20200930.xsd#biib_DisputedClaimsRelatingtoConstructionCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DisputedClaimsRelatingtoConstructionCosts" xlink:to="lab_biib_DisputedClaimsRelatingtoConstructionCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PostacquisitionequitycompensationMember_b73bb9d7-0f81-47e5-9d9f-c9297551e154_terseLabel_en-US" xlink:label="lab_biib_PostacquisitionequitycompensationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Post-acquisition equity compensation</link:label>
    <link:label id="lab_biib_PostacquisitionequitycompensationMember_label_en-US" xlink:label="lab_biib_PostacquisitionequitycompensationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Post-acquisition equity compensation [Member]</link:label>
    <link:label id="lab_biib_PostacquisitionequitycompensationMember_documentation_en-US" xlink:label="lab_biib_PostacquisitionequitycompensationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Post-acquisition equity compensation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PostacquisitionequitycompensationMember" xlink:href="biib-20200930.xsd#biib_PostacquisitionequitycompensationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PostacquisitionequitycompensationMember" xlink:to="lab_biib_PostacquisitionequitycompensationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain_8269bd12-e541-4fd5-a6b5-d2d430368b3a_terseLabel_en-US" xlink:label="lab_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments By Consolidated And Nonconsolidated Entities [Domain]</link:label>
    <link:label id="lab_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain_label_en-US" xlink:label="lab_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments By Consolidated And Nonconsolidated Entities [Domain]</link:label>
    <link:label id="lab_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain_documentation_en-US" xlink:label="lab_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Investments By Consolidated And Nonconsolidated Entities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain" xlink:href="biib-20200930.xsd#biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain" xlink:to="lab_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_StrategicInvestmentsMember_7cf1cebf-e45b-48d8-b4d9-4f786c32b1c8_terseLabel_en-US" xlink:label="lab_biib_StrategicInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strategic Investments</link:label>
    <link:label id="lab_biib_StrategicInvestmentsMember_label_en-US" xlink:label="lab_biib_StrategicInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strategic Investments [Member]</link:label>
    <link:label id="lab_biib_StrategicInvestmentsMember_documentation_en-US" xlink:label="lab_biib_StrategicInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strategic investments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_StrategicInvestmentsMember" xlink:href="biib-20200930.xsd#biib_StrategicInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_StrategicInvestmentsMember" xlink:to="lab_biib_StrategicInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_a451175e-f010-4525-8248-4858126989c8_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_08de5d1f-bcc7-4f58-9171-91b75f6d9d1d_terseLabel_en-US" xlink:label="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total reserves included in consolidated balance sheets</link:label>
    <link:label id="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_label_en-US" xlink:label="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Product Revenue Reserves Included In Consolidated Balance Sheets [Table Text Block]</link:label>
    <link:label id="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_documentation_en-US" xlink:label="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of total product revenue reserves included in consolidated balance sheets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" xlink:href="biib-20200930.xsd#biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" xlink:to="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_ef0fbabd-3c48-40fd-a13e-dbaef7dbb5a3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FutureContingentMilestoneTypesDomain_16c41519-e9da-4404-92bf-88befd043969_terseLabel_en-US" xlink:label="lab_biib_FutureContingentMilestoneTypesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Contingent Milestone Types [Domain]</link:label>
    <link:label id="lab_biib_FutureContingentMilestoneTypesDomain_label_en-US" xlink:label="lab_biib_FutureContingentMilestoneTypesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Contingent Milestone Types [Domain]</link:label>
    <link:label id="lab_biib_FutureContingentMilestoneTypesDomain_documentation_en-US" xlink:label="lab_biib_FutureContingentMilestoneTypesDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Future Contingent Milestone Types [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain" xlink:href="biib-20200930.xsd#biib_FutureContingentMilestoneTypesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain" xlink:to="lab_biib_FutureContingentMilestoneTypesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_d56d6960-e282-4d5c-b316-2e5f7aa75d98_verboseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_5e093fdf-e7e6-4f0d-b32a-bc332cac5378_verboseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_55000f12-6ea8-4a0a-8f98-588e2f484bbe_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biogen Idec Inc. shareholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_3569960b-f8bf-4688-94ed-ce61eba7bfa4_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ContractOptionExerciseFee_5defd229-fe64-431a-8bb0-955a922baf0d_terseLabel_en-US" xlink:label="lab_biib_ContractOptionExerciseFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Option Exercise Fee</link:label>
    <link:label id="lab_biib_ContractOptionExerciseFee_label_en-US" xlink:label="lab_biib_ContractOptionExerciseFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Option Exercise Fee</link:label>
    <link:label id="lab_biib_ContractOptionExerciseFee_documentation_en-US" xlink:label="lab_biib_ContractOptionExerciseFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Option Exercise Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ContractOptionExerciseFee" xlink:href="biib-20200930.xsd#biib_ContractOptionExerciseFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ContractOptionExerciseFee" xlink:to="lab_biib_ContractOptionExerciseFee" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_ab88693b-675b-4b67-948a-2ba94027f825_terseLabel_en-US" xlink:label="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.900% Senior Notes due 2020</link:label>
    <link:label id="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_label_en-US" xlink:label="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Two Point Nine Percent Due Twenty Twenty [Member]</link:label>
    <link:label id="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_documentation_en-US" xlink:label="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Two Point Nine Percent Due Twenty Twenty [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:href="biib-20200930.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:to="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_b82b8b08-033b-45f2-ba0a-a24c60960709_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_75b08fe0-5b72-46d0-81f5-5497cf5c7a34_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total intangible assets, gross</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_6893d6ed-8de3-4b73-9a72-3062c20d3e1a_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated life, (in years)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2982fbe4-ba89-4540-a34e-a3788dcfbc9e_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statutory rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_TECFIDERAMember_cc1f11ac-bae4-4e1d-a521-5d893cde55b8_terseLabel_en-US" xlink:label="lab_biib_TECFIDERAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TECFIDERA</link:label>
    <link:label id="lab_biib_TECFIDERAMember_label_en-US" xlink:label="lab_biib_TECFIDERAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TECFIDERA [Member]</link:label>
    <link:label id="lab_biib_TECFIDERAMember_documentation_en-US" xlink:label="lab_biib_TECFIDERAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TECFIDERA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TECFIDERAMember" xlink:href="biib-20200930.xsd#biib_TECFIDERAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TECFIDERAMember" xlink:to="lab_biib_TECFIDERAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_71e26f51-1c87-45c3-9358-689c4ca1325e_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of basis differences</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Difference Between Carrying Amount and Underlying Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:to="lab_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_ecf8164a-6bbc-4f63-8bbb-805ca9bdb980_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_f31e0751-8fe3-4cca-9a1a-02ea9d695809_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_45ed5c8e-3f4b-4fcd-a257-66d45f8e6d23_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_8f3597f4-a469-489e-9a2c-53ad53e9d8c9_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_7ccd8915-fa32-46a4-b103-31baa28585b7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_95dd649d-d659-42af-bac0-a1043e57fe74_terseLabel_en-US" xlink:label="lab_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investment basis difference amortization period</link:label>
    <link:label id="lab_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_label_en-US" xlink:label="lab_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investment basis difference amortization period</link:label>
    <link:label id="lab_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_documentation_en-US" xlink:label="lab_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investment basis difference amortization period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod" xlink:href="biib-20200930.xsd#biib_Equitymethodinvestmentbasisdifferenceamortizationperiod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod" xlink:to="lab_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_08650b0f-f4b5-4242-9070-de2d30fe0dc6_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_0608eb6b-9c69-4ff0-996e-ca43f6bf455d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_2735dac3-0ee1-4017-a139-f0221c8ef971_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Estimate of Possible Loss</link:label>
    <link:label id="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_label_en-US" xlink:label="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Estimate of Possible Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:to="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AdministrativeSpaceMember_0d40202a-d0a4-42af-9694-79d8d6f3bc08_terseLabel_en-US" xlink:label="lab_biib_AdministrativeSpaceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Administrative Space</link:label>
    <link:label id="lab_biib_AdministrativeSpaceMember_label_en-US" xlink:label="lab_biib_AdministrativeSpaceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Administrative Space [Member]</link:label>
    <link:label id="lab_biib_AdministrativeSpaceMember_documentation_en-US" xlink:label="lab_biib_AdministrativeSpaceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Administrative Space</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdministrativeSpaceMember" xlink:href="biib-20200930.xsd#biib_AdministrativeSpaceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AdministrativeSpaceMember" xlink:to="lab_biib_AdministrativeSpaceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_8c4b1d84-461b-467d-8b87-758d4688d32c_verboseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost and expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2f321b65-8543-4328-b781-b0399e747cdf_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_f42ce09a-61f5-4884-af9c-e70fbc783804_periodStartLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income (loss), net of tax beginning balance</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2b3c586e-f862-4c61-ac84-cb725f657744_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, January 1, 2018</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_1017d9dc-5db1-4f2d-9508-49f380f80662_periodEndLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income (loss), net of tax ending balance</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_9ebff3e7-03c9-42ba-9f33-9f7446d265c8_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net&#160;income (loss) attributable to noncontrolling interests, net&#160;of&#160;tax</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ClinicalAssetsAcquired_3641a77f-ea17-4213-9d43-39b157abc046_terseLabel_en-US" xlink:label="lab_biib_ClinicalAssetsAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Assets Acquired</link:label>
    <link:label id="lab_biib_ClinicalAssetsAcquired_label_en-US" xlink:label="lab_biib_ClinicalAssetsAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Assets Acquired</link:label>
    <link:label id="lab_biib_ClinicalAssetsAcquired_documentation_en-US" xlink:label="lab_biib_ClinicalAssetsAcquired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Assets Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ClinicalAssetsAcquired" xlink:href="biib-20200930.xsd#biib_ClinicalAssetsAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ClinicalAssetsAcquired" xlink:to="lab_biib_ClinicalAssetsAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TrademarksAndTradeNamesMember_97ed282a-fe73-439f-8125-621d24bb6ebd_terseLabel_en-US" xlink:label="lab_us-gaap_TrademarksAndTradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks and Trade Names</link:label>
    <link:label id="lab_us-gaap_TrademarksAndTradeNamesMember_label_en-US" xlink:label="lab_us-gaap_TrademarksAndTradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks and Trade Names [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TrademarksAndTradeNamesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TrademarksAndTradeNamesMember" xlink:to="lab_us-gaap_TrademarksAndTradeNamesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_5b5ebde5-7520-4223-ab1a-a5714a80ba0e_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DerivativeMaturityAxis_94efd4aa-4ad1-4169-860d-e89563af2cdc_terseLabel_en-US" xlink:label="lab_biib_DerivativeMaturityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Maturity [Axis]</link:label>
    <link:label id="lab_biib_DerivativeMaturityAxis_label_en-US" xlink:label="lab_biib_DerivativeMaturityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Maturity [Axis]</link:label>
    <link:label id="lab_biib_DerivativeMaturityAxis_documentation_en-US" xlink:label="lab_biib_DerivativeMaturityAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Maturity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DerivativeMaturityAxis" xlink:href="biib-20200930.xsd#biib_DerivativeMaturityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DerivativeMaturityAxis" xlink:to="lab_biib_DerivativeMaturityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ca09a49a-7652-4043-a6e3-a789e2f07bd1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_2ace1d8d-ff0c-4726-8ab0-4eb41d01ff83_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_7d127847-4c73-4838-87be-657172f460a4_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_f24acd07-8983-4325-9042-7d94ff7f07f5_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased_e4691aac-2c3b-4451-9dd9-e4b7a1a84bf2_terseLabel_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Licensing Collaboration Agreement, Amount, Shares Purchased</link:label>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased_label_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Licensing Collaboration Agreement, Amount, Shares Purchased</link:label>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased_documentation_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Licensing Collaboration Agreement, Amount, Shares Purchased</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased" xlink:href="biib-20200930.xsd#biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased" xlink:to="lab_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SkyhawkTherapeuticsMember_3c588c36-9909-4028-bcd9-e0299e00c5ae_terseLabel_en-US" xlink:label="lab_biib_SkyhawkTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Skyhawk Therapeutics</link:label>
    <link:label id="lab_biib_SkyhawkTherapeuticsMember_label_en-US" xlink:label="lab_biib_SkyhawkTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Skyhawk Therapeutics [Member]</link:label>
    <link:label id="lab_biib_SkyhawkTherapeuticsMember_documentation_en-US" xlink:label="lab_biib_SkyhawkTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Skyhawk Therapeutics [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SkyhawkTherapeuticsMember" xlink:href="biib-20200930.xsd#biib_SkyhawkTherapeuticsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SkyhawkTherapeuticsMember" xlink:to="lab_biib_SkyhawkTherapeuticsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_NumberOfSquareFeet_b088f52f-b1f7-45b6-b050-fd9351d1e81b_terseLabel_en-US" xlink:label="lab_biib_NumberOfSquareFeet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of square feet</link:label>
    <link:label id="lab_biib_NumberOfSquareFeet_label_en-US" xlink:label="lab_biib_NumberOfSquareFeet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Square Feet</link:label>
    <link:label id="lab_biib_NumberOfSquareFeet_documentation_en-US" xlink:label="lab_biib_NumberOfSquareFeet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Square Feet</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NumberOfSquareFeet" xlink:href="biib-20200930.xsd#biib_NumberOfSquareFeet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NumberOfSquareFeet" xlink:to="lab_biib_NumberOfSquareFeet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionPayableCurrentAndNoncurrent_3b36339e-d339-47e0-9ddb-6b1bfb9c03fd_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionPayableCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionPayableCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_ConstructionPayableCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionPayableCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionPayableCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionPayableCurrentAndNoncurrent" xlink:to="lab_us-gaap_ConstructionPayableCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_def2b0c3-baea-4a36-a4fd-eab984b85e12_negatedLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credits and net operating loss utilization</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinStockMember_235812ef-ccd0-4f63-b1c9-afe18fdaa799_terseLabel_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance stock units settled in stock</link:label>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinStockMember_label_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Stock Units Settled in Stock [Member]</link:label>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinStockMember_documentation_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Stock Units Settled in Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockMember" xlink:href="biib-20200930.xsd#biib_PerformanceStockUnitsSettledinStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PerformanceStockUnitsSettledinStockMember" xlink:to="lab_biib_PerformanceStockUnitsSettledinStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_InterferonMember_b2dd4d8d-bba0-4310-af84-dc676f985959_terseLabel_en-US" xlink:label="lab_biib_InterferonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interferon</link:label>
    <link:label id="lab_biib_InterferonMember_label_en-US" xlink:label="lab_biib_InterferonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interferon [Member]</link:label>
    <link:label id="lab_biib_InterferonMember_documentation_en-US" xlink:label="lab_biib_InterferonMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interferon</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InterferonMember" xlink:href="biib-20200930.xsd#biib_InterferonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InterferonMember" xlink:to="lab_biib_InterferonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_701abd1b-1e65-4993-a551-79543c8df743_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_3e61d94f-4b4b-4c64-9d74-b89a43842dd2_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_ef8a6560-d02f-4709-9d36-e8c8943cfff4_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_8fa51c83-8c2d-48b0-b3a6-fd1f4b8afad0_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_fa9dc658-4498-448a-93a2-c721bbbe1663_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_CorporateDebtSecuritiesNonCurrentMember_31126de8-b6c4-446d-ba2a-5a3785ee22c8_verboseLabel_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesNonCurrentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities Non-current</link:label>
    <link:label id="lab_biib_CorporateDebtSecuritiesNonCurrentMember_label_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesNonCurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities Non Current [Member]</link:label>
    <link:label id="lab_biib_CorporateDebtSecuritiesNonCurrentMember_documentation_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesNonCurrentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities Non Current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CorporateDebtSecuritiesNonCurrentMember" xlink:href="biib-20200930.xsd#biib_CorporateDebtSecuritiesNonCurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CorporateDebtSecuritiesNonCurrentMember" xlink:to="lab_biib_CorporateDebtSecuritiesNonCurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_6f019ca9-ef68-456f-b7ea-56d999cfca34_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SamsungBiosimilarAgreementMember_02a86b7d-6128-4456-af25-e8d4032d5cdc_terseLabel_en-US" xlink:label="lab_biib_SamsungBiosimilarAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Samsung Bioepis</link:label>
    <link:label id="lab_biib_SamsungBiosimilarAgreementMember_label_en-US" xlink:label="lab_biib_SamsungBiosimilarAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Samsung Biosimilar Agreement [Member]</link:label>
    <link:label id="lab_biib_SamsungBiosimilarAgreementMember_documentation_en-US" xlink:label="lab_biib_SamsungBiosimilarAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Samsung bio-similar agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember" xlink:href="biib-20200930.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SamsungBiosimilarAgreementMember" xlink:to="lab_biib_SamsungBiosimilarAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_ec92b94d-446f-4e5b-8c18-10f887601993_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets and Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_AllCurrenciesDomain_e38cf03b-8b80-420e-99bc-15c88bb2ca8a_terseLabel_en-US" xlink:label="lab_currency_AllCurrenciesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Currencies [Domain]</link:label>
    <link:label id="lab_currency_AllCurrenciesDomain_label_en-US" xlink:label="lab_currency_AllCurrenciesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Currencies [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain" xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_AllCurrenciesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_AllCurrenciesDomain" xlink:to="lab_currency_AllCurrenciesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ResearchAndDevelopmentCostsPercentage_84eb9aff-44c0-4bf8-a523-0b61760fcc83_terseLabel_en-US" xlink:label="lab_biib_ResearchAndDevelopmentCostsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development costs, percentage</link:label>
    <link:label id="lab_biib_ResearchAndDevelopmentCostsPercentage_label_en-US" xlink:label="lab_biib_ResearchAndDevelopmentCostsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Costs, Percentage</link:label>
    <link:label id="lab_biib_ResearchAndDevelopmentCostsPercentage_documentation_en-US" xlink:label="lab_biib_ResearchAndDevelopmentCostsPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Costs, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchAndDevelopmentCostsPercentage" xlink:href="biib-20200930.xsd#biib_ResearchAndDevelopmentCostsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ResearchAndDevelopmentCostsPercentage" xlink:to="lab_biib_ResearchAndDevelopmentCostsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ShorttermderivativeMember_074909c2-3417-495c-8a0a-9d1162741424_terseLabel_en-US" xlink:label="lab_biib_ShorttermderivativeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term derivative</link:label>
    <link:label id="lab_biib_ShorttermderivativeMember_label_en-US" xlink:label="lab_biib_ShorttermderivativeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term derivative [Member]</link:label>
    <link:label id="lab_biib_ShorttermderivativeMember_documentation_en-US" xlink:label="lab_biib_ShorttermderivativeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term derivative [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShorttermderivativeMember" xlink:href="biib-20200930.xsd#biib_ShorttermderivativeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ShorttermderivativeMember" xlink:to="lab_biib_ShorttermderivativeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_64a9714b-c07a-47d7-87ea-f659a30e179f_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of assets and liabilities recorded at fair value</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8c536d28-79c4-42ac-a501-8f4c0c0fe77c_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_8cda8285-9bd0-4cfe-9671-4fa2c3f7b211_verboseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_1d9d49d6-a9ea-41f7-be4c-54dc52720215_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_850532ca-d328-4856-8bda-b0575fd273ef_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_cc7fcf9d-1140-4eff-a2f6-b9e04e3b7400_negatedLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Gain) loss on fair value remeasurement of contingent consideration</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_12ce43bd-26ee-4ef9-aca9-5724da6662bf_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_d3a3de2e-ce28-4382-8aad-3a9290f5e8a8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration impairment</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7f3d720a-0849-4b95-aac7-1651a25d5bc6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_18098347-b658-41b8-b1a5-462456bb021c_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Gain (Loss), Alternative [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Gain (Loss), Alternative [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract" xlink:to="lab_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_7d04c4c7-a669-4e6a-8504-da9c83e249bf_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State taxes</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_04121307-db82-4f5f-889b-d967a682a255_verboseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as hedging instrument</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_19c99418-bb84-4885-a568-52c4e1a877bb_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyDamagesSoughtValue_aff9b416-8b89-4f8b-9ffc-b4bcd05296e0_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Brazil tax assessment, including interest and penalties</link:label>
    <link:label id="lab_us-gaap_LossContingencyDamagesSoughtValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Damages Sought, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDamagesSoughtValue" xlink:to="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c041b70a-1938-4529-8aab-45f95da5f1ca_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_e0b50ccc-7cac-46d3-b10f-18ace094c3c5_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Fair Value [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesFairValueLineItems" xlink:to="lab_us-gaap_DerivativesFairValueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_45ecf811-f1d1-4a0a-bfad-28ed2794cb3b_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_31dcc9d2-5bdb-436b-8b74-4bfbba0b4bb5_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonUsMember_5bb1cfbe-1cb7-4c7b-a38d-c700e91dd90b_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rest of World</link:label>
    <link:label id="lab_us-gaap_NonUsMember_label_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember" xlink:to="lab_us-gaap_NonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_61650916-ab30-470b-ab0c-6dbdc3e625b9_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ac34f26c-bcc0-46a0-9f2f-1bfa72d0a752_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_0b2d4bc0-2545-4697-b436-0df25b48238f_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due in one year or less, amortized cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_8e8f4038-2573-499d-8b79-c6b1c037ce36_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_3493d2ba-d6cd-4256-82a0-5762023c1c16_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of treasury stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_e9d24077-15c4-440c-9b7f-f7846c0414d1_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for repurchase of common stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_8a90e13e-9729-4447-8674-fd2c9a9b9707_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_331785b9-68db-4591-9f83-f38aee6f00ad_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under stock option and stock purchase plans, shares</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Treasury Stock Reissued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesMember_2c86d6cc-f1b0-4907-a310-b1cd1176ce0f_terseLabel_en-US" xlink:label="lab_us-gaap_SalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_SalesMember_label_en-US" xlink:label="lab_us-gaap_SalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesMember" xlink:to="lab_us-gaap_SalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_d54bec2e-88ca-4a22-a707-9185ea66230a_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_ac98d201-798e-44c2-a946-0d177dc087a4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_c925dfa8-c875-4c6e-bb22-8c35e53ed01f_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted earnings per share attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_c8e85029-96ab-4b74-a22b-dd48bd2788f8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense)</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_InterestInSubsidiary_e42ec8e4-ad04-4713-9977-619b2a945278_verboseLabel_en-US" xlink:label="lab_biib_InterestInSubsidiary" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest in subsidiary (less than given percentage)</link:label>
    <link:label id="lab_biib_InterestInSubsidiary_label_en-US" xlink:label="lab_biib_InterestInSubsidiary" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest In Subsidiary</link:label>
    <link:label id="lab_biib_InterestInSubsidiary_documentation_en-US" xlink:label="lab_biib_InterestInSubsidiary" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest in subsidiary.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InterestInSubsidiary" xlink:href="biib-20200930.xsd#biib_InterestInSubsidiary"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InterestInSubsidiary" xlink:to="lab_biib_InterestInSubsidiary" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_6cc75e00-cc28-412d-b4e8-cbb879ea48b3_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_c70a319c-89e3-4637-9947-b71afa6c7bc4_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_9c54e73f-19db-47b2-80bb-1edf9c7f9c23_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AcquisitionsAbstract_0b0075ff-cd73-4230-bf65-44a541beefb3_terseLabel_en-US" xlink:label="lab_biib_AcquisitionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions [Abstract]</link:label>
    <link:label id="lab_biib_AcquisitionsAbstract_label_en-US" xlink:label="lab_biib_AcquisitionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions [Abstract]</link:label>
    <link:label id="lab_biib_AcquisitionsAbstract_documentation_en-US" xlink:label="lab_biib_AcquisitionsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AcquisitionsAbstract" xlink:href="biib-20200930.xsd#biib_AcquisitionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AcquisitionsAbstract" xlink:to="lab_biib_AcquisitionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_NeurimmuneMember_b8ca854f-e978-48cd-ae1e-93610373ce5b_terseLabel_en-US" xlink:label="lab_biib_NeurimmuneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neurimmune</link:label>
    <link:label id="lab_biib_NeurimmuneMember_label_en-US" xlink:label="lab_biib_NeurimmuneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neurimmune [Member]</link:label>
    <link:label id="lab_biib_NeurimmuneMember_documentation_en-US" xlink:label="lab_biib_NeurimmuneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neurimmune.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NeurimmuneMember" xlink:href="biib-20200930.xsd#biib_NeurimmuneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NeurimmuneMember" xlink:to="lab_biib_NeurimmuneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_E2609andBAN2401Member_32dd22ba-33a0-482c-b043-cbb6cf5d0060_terseLabel_en-US" xlink:label="lab_biib_E2609andBAN2401Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BAN2401 and Elenbecestat</link:label>
    <link:label id="lab_biib_E2609andBAN2401Member_label_en-US" xlink:label="lab_biib_E2609andBAN2401Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">E2609 and BAN2401 [Member]</link:label>
    <link:label id="lab_biib_E2609andBAN2401Member_documentation_en-US" xlink:label="lab_biib_E2609andBAN2401Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">E2609 and BAN2401 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_E2609andBAN2401Member" xlink:href="biib-20200930.xsd#biib_E2609andBAN2401Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_E2609andBAN2401Member" xlink:to="lab_biib_E2609andBAN2401Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_7e0be7fd-b946-480f-9d51-d806505c9700_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_f52ff772-623e-4e73-9280-18a6fbc5bcd8_verboseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_86aa7a82-cc34-46a4-bc2e-e4ac9106df17_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_a1239105-52ae-44df-84d0-76568403ac05_verboseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepurchaseAgreementsMember_6189feb1-c22c-4748-a104-fc63ad2a1fb2_terseLabel_en-US" xlink:label="lab_us-gaap_RepurchaseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Overnight reverse repurchase agreements</link:label>
    <link:label id="lab_us-gaap_RepurchaseAgreementsMember_label_en-US" xlink:label="lab_us-gaap_RepurchaseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepurchaseAgreementsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepurchaseAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepurchaseAgreementsMember" xlink:to="lab_us-gaap_RepurchaseAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_204c69ad-4573-436f-9737-9312f0d4590e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_3c40fb74-425c-4eab-9fbd-da67f8eb69a0_terseLabel_en-US" xlink:label="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of share based compensation expense associated with different programs [Abstract]</link:label>
    <link:label id="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_label_en-US" xlink:label="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of share based compensation expense associated with different programs [Abstract]</link:label>
    <link:label id="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_documentation_en-US" xlink:label="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of share-based compensation expense associated with different programs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" xlink:href="biib-20200930.xsd#biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" xlink:to="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_c168e383-d6f5-4162-a449-984c9a5ef672_terseLabel_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_label_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service, Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductAndServiceOtherMember" xlink:to="lab_us-gaap_ProductAndServiceOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_a4e8a72c-66b2-4b52-948b-4cd9a6b21d6b_negatedLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_7985454e-a06e-421a-bff0-469a36cfa458_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_665964cf-e20e-4760-9cbd-7f056f8a0884_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected future amortization expense, 2021</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_7fed70e0-1e96-4302-a75a-645d69b4821b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_27d852f2-72c8-457c-ac85-dbbd664f9d9d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired in-process research and development</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire in Process Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:to="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_aedf8af2-b7a5-4883-b575-1d658ef585fa_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_65792816-fcf5-4e97-a38a-21d472d903ff_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones_f55b8c80-e682-49f8-932e-d50556137da5_terseLabel_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Licensing Collaboration Agreement, Payment, Achievement of Specific Sales Based Milestones</link:label>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones_label_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Licensing Collaboration Agreement, Payment, Achievement of Specific Sales Based Milestones</link:label>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones_documentation_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Licensing Collaboration Agreement, Payment, Achievement of Specific Sales Based Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones" xlink:href="biib-20200930.xsd#biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones" xlink:to="lab_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_e79e2ced-2a67-456c-8075-da883b0b1792_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_2283e6c3-ca06-4194-9e55-9f782c66c16b_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_0f01be86-74c4-4590-a63b-6e0adf42a057_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_09859a7a-dddd-476d-90bd-d8973761fa72_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueAbstract_c4205b66-9365-4a26-80c9-44d30089b0b6_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueAbstract_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueAbstract" xlink:to="lab_us-gaap_DisaggregationOfRevenueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_75496f3f-eab5-43a7-939e-424076a93062_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income to net cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_02baca95-b776-4d41-be0a-301babe55b0c_terseLabel_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed technology</link:label>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_label_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed Technology Rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:to="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_f5952628-5ae1-4050-a804-b5101a7c058a_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on divestiture of Hiller&#248;d, Denmark manufacturing operations</link:label>
    <link:label id="lab_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_label_en-US" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Not Discontinued Operation, Loss (Gain) on Write-down</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" xlink:to="lab_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_14293321-78b7-4b5c-bbff-70dce1c3d092_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash flows used in financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Collaborationexpensesaccrual_832a60cf-ca71-4527-8341-72dfb868c061_terseLabel_en-US" xlink:label="lab_biib_Collaborationexpensesaccrual" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration expenses</link:label>
    <link:label id="lab_biib_Collaborationexpensesaccrual_label_en-US" xlink:label="lab_biib_Collaborationexpensesaccrual" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration expenses accrual</link:label>
    <link:label id="lab_biib_Collaborationexpensesaccrual_documentation_en-US" xlink:label="lab_biib_Collaborationexpensesaccrual" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration expenses accrual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Collaborationexpensesaccrual" xlink:href="biib-20200930.xsd#biib_Collaborationexpensesaccrual"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Collaborationexpensesaccrual" xlink:to="lab_biib_Collaborationexpensesaccrual" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_1be617c7-578d-4aeb-99bd-dbff3d826136_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Net gains (losses) recognized during the period on equity securities sold during the period</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Realized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_61c8b808-831b-433e-af4a-fb66f6d3fb85_verboseLabel_en-US" xlink:label="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Consolidated Financial Statement Detail</link:label>
    <link:label id="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Financial Information Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:to="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_52b02c95-1e68-45e0-bd48-a042a23551a1_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_114aa566-2f50-4bea-978e-e0aebd39843a_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_95a66b43-0dd9-4a9a-91e3-dfbef85e2593_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_304405e5-d691-41af-b69c-431fcf07eb03_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_9fe903cd-d3e3-475b-905c-a755c3529367_verboseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payments</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_OtherrevenuesTableTextBlock_68a454e1-6f16-4565-ac43-e45908b19e27_terseLabel_en-US" xlink:label="lab_biib_OtherrevenuesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenues</link:label>
    <link:label id="lab_biib_OtherrevenuesTableTextBlock_label_en-US" xlink:label="lab_biib_OtherrevenuesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenues [Table Text Block]</link:label>
    <link:label id="lab_biib_OtherrevenuesTableTextBlock_documentation_en-US" xlink:label="lab_biib_OtherrevenuesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenues [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherrevenuesTableTextBlock" xlink:href="biib-20200930.xsd#biib_OtherrevenuesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OtherrevenuesTableTextBlock" xlink:to="lab_biib_OtherrevenuesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromHedgeInvestingActivities_c50e815d-b2b0-4fbd-9777-af113f376d62_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromHedgeInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from settlement of net investment hedge</link:label>
    <link:label id="lab_us-gaap_ProceedsFromHedgeInvestingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromHedgeInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Hedge, Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromHedgeInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromHedgeInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromHedgeInvestingActivities" xlink:to="lab_us-gaap_ProceedsFromHedgeInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DerivativeMaturityDomain_6db25cea-e649-4d3e-8af7-e139c295fa7e_terseLabel_en-US" xlink:label="lab_biib_DerivativeMaturityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Maturity [Domain]</link:label>
    <link:label id="lab_biib_DerivativeMaturityDomain_label_en-US" xlink:label="lab_biib_DerivativeMaturityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Maturity [Domain]</link:label>
    <link:label id="lab_biib_DerivativeMaturityDomain_documentation_en-US" xlink:label="lab_biib_DerivativeMaturityDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Derivative Maturity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DerivativeMaturityDomain" xlink:href="biib-20200930.xsd#biib_DerivativeMaturityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DerivativeMaturityDomain" xlink:to="lab_biib_DerivativeMaturityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FutureContingentMilestoneTypesAxis_a3491214-73a1-4472-942e-49595179a9d8_terseLabel_en-US" xlink:label="lab_biib_FutureContingentMilestoneTypesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Contingent Milestone Types [Axis]</link:label>
    <link:label id="lab_biib_FutureContingentMilestoneTypesAxis_label_en-US" xlink:label="lab_biib_FutureContingentMilestoneTypesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Contingent Milestone Types [Axis]</link:label>
    <link:label id="lab_biib_FutureContingentMilestoneTypesAxis_documentation_en-US" xlink:label="lab_biib_FutureContingentMilestoneTypesAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Contingent Milestone Types [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesAxis" xlink:href="biib-20200930.xsd#biib_FutureContingentMilestoneTypesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis" xlink:to="lab_biib_FutureContingentMilestoneTypesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_d42a746c-2ec9-472a-bee3-03420977b938_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts reclassified from accumulated other comprehensive income, net of tax</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EmployeeStockPurchasePlanMember_e77e7222-c738-4874-9ba3-2219f4bc1980_verboseLabel_en-US" xlink:label="lab_biib_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee stock purchase plan</link:label>
    <link:label id="lab_biib_EmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_biib_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_biib_EmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_biib_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee stock purchase plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EmployeeStockPurchasePlanMember" xlink:href="biib-20200930.xsd#biib_EmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EmployeeStockPurchasePlanMember" xlink:to="lab_biib_EmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_492fba60-e841-402c-97da-6f436cf12cbc_periodStartLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_5041dbaf-d700-451c-a2ae-38b850447c15_periodEndLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_6d5ce4a0-0f2a-4d1b-8d11-ae42a41b8ed8_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Reserves</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_16664d56-a6fa-4409-84dd-05b1e258142c_verboseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue-related reserves for discounts and allowances</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_6854aabf-43d8-4d48-8600-c3feae2e13b1_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative liability, fair value</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Fair Value, Gross Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_ba3a2988-9674-43bb-bac5-cb9f322b5d93_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_a007d892-00d3-4386-a17e-b23f8bf7244b_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_JPY_814634fc-2acb-4098-ba2d-c8ebb9b093ca_terseLabel_en-US" xlink:label="lab_currency_JPY" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Japan, Yen</link:label>
    <link:label id="lab_currency_JPY_label_en-US" xlink:label="lab_currency_JPY" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Japan, Yen</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_JPY" xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_JPY"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_JPY" xlink:to="lab_currency_JPY" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_7066dfd6-32b5-4225-b729-9b39d6bc8ddc_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_3cf6beb4-eec2-42c9-949f-722fb345aa4a_terseLabel_en-US" xlink:label="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Analysis of change In reserves</link:label>
    <link:label id="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_label_en-US" xlink:label="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Analysis Of Amount Of And Change In Product Revenue Reserves [Table Text Block]</link:label>
    <link:label id="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_documentation_en-US" xlink:label="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Analysis of amount of and change in product revenue reserves.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" xlink:href="biib-20200930.xsd#biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" xlink:to="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_5eb8d5f8-0486-4392-ba1e-6f2e1915f679_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_1560075d-9649-45e1-9c31-edf9924cb947_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_131eae4a-e832-4788-90e5-c755a4a5debe_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_1f2cd871-e5cb-42a7-98ae-a343cd0e94e6_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_c898a5d5-41c3-48de-9be4-477c9dc676de_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange gains (losses), net</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax_d11ebfa9-ff13-4299-b02a-fba7b8b3ad85_negatedLabel_en-US" xlink:label="lab_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity in (income) loss of investee, net of tax</link:label>
    <link:label id="lab_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax_label_en-US" xlink:label="lab_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments, Net of Tax</link:label>
    <link:label id="lab_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax_documentation_en-US" xlink:label="lab_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax" xlink:href="biib-20200930.xsd#biib_IncomeLossFromEquityMethodInvestmentsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax" xlink:to="lab_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_cf78ddea-9cc8-4482-9e9e-feefe91b5c26_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_A2.25SeniorNotesdueMay12030Member_ab7e87f4-b323-4de4-a818-d928498cf21e_terseLabel_en-US" xlink:label="lab_biib_A2.25SeniorNotesdueMay12030Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.250% Senior Notes due May 1, 2030</link:label>
    <link:label id="lab_biib_A2.25SeniorNotesdueMay12030Member_label_en-US" xlink:label="lab_biib_A2.25SeniorNotesdueMay12030Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.25% Senior Notes due May 1, 2030 [Member]</link:label>
    <link:label id="lab_biib_A2.25SeniorNotesdueMay12030Member_documentation_en-US" xlink:label="lab_biib_A2.25SeniorNotesdueMay12030Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.25% Senior Notes due May 1, 2030 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2.25SeniorNotesdueMay12030Member" xlink:href="biib-20200930.xsd#biib_A2.25SeniorNotesdueMay12030Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A2.25SeniorNotesdueMay12030Member" xlink:to="lab_biib_A2.25SeniorNotesdueMay12030Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_96574afe-bb25-4e50-8d05-70105c6ef1e1_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income per share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_a931d7ff-2b70-4009-8750-82709f838a01_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_bf563874-3f8a-4e57-8ead-85ece8ab4268_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage and other asset backed securities</link:label>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset-backed Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetBackedSecuritiesMember" xlink:to="lab_us-gaap_AssetBackedSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_b569d284-6798-45a2-923e-6f9ff429cc32_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_8bd32dca-dd0e-4007-97de-1ccbe26f8ddc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_395ab80c-1fac-482c-96c6-52863d7fea97_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities, other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_UCBPharmaS.A.Member_201723a2-0e70-499f-a288-54de4dbcdd31_terseLabel_en-US" xlink:label="lab_biib_UCBPharmaS.A.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UCB Pharma S.A. [Member]</link:label>
    <link:label id="lab_biib_UCBPharmaS.A.Member_label_en-US" xlink:label="lab_biib_UCBPharmaS.A.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UCB Pharma S.A. [Member]</link:label>
    <link:label id="lab_biib_UCBPharmaS.A.Member_documentation_en-US" xlink:label="lab_biib_UCBPharmaS.A.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UCB Pharma S.A. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UCBPharmaS.A.Member" xlink:href="biib-20200930.xsd#biib_UCBPharmaS.A.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_UCBPharmaS.A.Member" xlink:to="lab_biib_UCBPharmaS.A.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_e495bbe4-cdf0-400c-ae5e-160b8d15c2f9_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gains (losses) on securities available for sale</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:to="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_dc4e8bb4-1d17-4545-8390-fd58df82d87b_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax asset</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_0149a8b0-cf31-47a9-8e7e-9ef55cf2e9a3_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unfunded status of postretirement benefit plans</link:label>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_f0660070-a230-4db1-9ec7-09187376810e_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsAbstract_95bbb0a7-b551-49fc-8ec3-153082aec1de_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsAbstract_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ValuationAndQualifyingAccountsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract" xlink:to="lab_srt_ValuationAndQualifyingAccountsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_f37b5374-0584-47a5-a534-8b029da07ee3_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_808db845-1c18-4598-b023-6a42761040f3_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross unrealized gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_d3f819a2-c97c-4742-a1ec-e2a627b99be6_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_520a4094-9816-48e7-be06-d352cea0316d_totalLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subtotal</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_938437c4-0abf-4993-a72c-f1b8663178e0_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subtotal</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_c763550c-077b-4782-bcbb-f2e63f8c829b_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_53f10942-1472-4c70-a307-b236315b6b37_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties and licensing fees</link:label>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Royalties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedRoyaltiesCurrent" xlink:to="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization_5f86f687-b4a7-4b26-bfb0-a2b69e512f38_terseLabel_en-US" xlink:label="lab_biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal reorganization of certain intellectual property rights</link:label>
    <link:label id="lab_biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization_label_en-US" xlink:label="lab_biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Intellectual Property Rights Reorganization</link:label>
    <link:label id="lab_biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization_documentation_en-US" xlink:label="lab_biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Intellectual Property Rights Reorganization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization" xlink:href="biib-20200930.xsd#biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization" xlink:to="lab_biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BiosimilarsMember_b0fd1a71-a758-4acd-850b-1653aae7a3ce_terseLabel_en-US" xlink:label="lab_biib_BiosimilarsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biosimilars</link:label>
    <link:label id="lab_biib_BiosimilarsMember_label_en-US" xlink:label="lab_biib_BiosimilarsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biosimilars [Member]</link:label>
    <link:label id="lab_biib_BiosimilarsMember_documentation_en-US" xlink:label="lab_biib_BiosimilarsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biosimilars</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BiosimilarsMember" xlink:href="biib-20200930.xsd#biib_BiosimilarsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BiosimilarsMember" xlink:to="lab_biib_BiosimilarsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockRetiredCostMethodAmount_f228d42b-88c3-42cb-99cd-7c48b988c8ec_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement of common stock pursuant to Share Repurchase Progams, at cost</link:label>
    <link:label id="lab_us-gaap_TreasuryStockRetiredCostMethodAmount_label_en-US" xlink:label="lab_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Retired, Cost Method, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:to="lab_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_f1fd34bc-bc4c-4a38-9b9b-41ae2a11eb3a_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of share-based compensation expense associated with each of our share-based compensating programs</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Cost by Plan [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_35e46511-bd6c-4bd7-95b1-484df669555f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of Sangamo Therapeutics, Inc. stock</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Interest in Subsidiaries and Affiliates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:to="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_def211ed-61b2-4c6b-acb0-00b0630d12ab_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_fde9c3bf-dd2d-48e7-988f-d2004714f250_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected future amortization expense, 2022</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableFairValueDisclosure_78b3aeed-d90b-4769-8a4e-2576b0959ea7_verboseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes payable, fair value</link:label>
    <link:label id="lab_us-gaap_NotesPayableFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_NotesPayableFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableFairValueDisclosure" xlink:to="lab_us-gaap_NotesPayableFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_36eb4103-c8f5-4eca-b2fa-a32813cbaf1d_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized (gain) loss on strategic investments</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:to="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_2ba5b200-b05a-4123-80be-332b2620a7db_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated future amortization for acquired intangible assets</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4561b936-8618-4d17-bbf6-1af4409947e5_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_f3a4b4d1-2862-4881-bb34-7501b1f119ca_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_dc14fa16-d97a-4ec8-986d-8466f3e199cd_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance units</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DilutiveSecuritiesAbstract_7f6051d4-bb23-412b-b792-160d5f5b3fc0_verboseLabel_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of dilutive securities:</link:label>
    <link:label id="lab_us-gaap_DilutiveSecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract" xlink:to="lab_us-gaap_DilutiveSecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_9ca9cbe7-e002-45f3-849e-107e9ad82498_terseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on net investment hedges in AOCI</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Foreign Currency Derivatives, Net, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" xlink:to="lab_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_229599ad-3ca0-4945-b983-f5b75909ef6a_terseLabel_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to Related Parties</link:label>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_0a66c343-e5d0-46ca-a27d-4a33d125b816_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains (losses) on net investment hedge</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Derivative Qualifying as Hedge, Excluded Component, Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DenmarkManufacturingOperationsMember_0bb75f2e-f382-46f5-83c2-bbf73e34b6d0_terseLabel_en-US" xlink:label="lab_biib_DenmarkManufacturingOperationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denmark Manufacturing Operations</link:label>
    <link:label id="lab_biib_DenmarkManufacturingOperationsMember_label_en-US" xlink:label="lab_biib_DenmarkManufacturingOperationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denmark Manufacturing Operations [Member]</link:label>
    <link:label id="lab_biib_DenmarkManufacturingOperationsMember_documentation_en-US" xlink:label="lab_biib_DenmarkManufacturingOperationsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denmark Manufacturing Operations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DenmarkManufacturingOperationsMember" xlink:href="biib-20200930.xsd#biib_DenmarkManufacturingOperationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DenmarkManufacturingOperationsMember" xlink:to="lab_biib_DenmarkManufacturingOperationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_427d9b59-cd2a-4c1f-9903-112a8e260e24_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive potential common shares</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number Diluted Shares Outstanding Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax_687b1dd2-99b3-46a1-b8f6-dd87c400b6c7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on divestiture of Hiller&#248;d, Denmark manufacturing operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Individually Significant Component Disposed of or Held-for-sale, Excluding Discontinued Operations, Attributable to Parent, before Income Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax" xlink:to="lab_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_24573c94-4051-4cf1-91f0-482bec82f880_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after one year through five years, estimated fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after One Through Five Years, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_7eb4b40d-db94-4524-be4c-8c45d2f241a9_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gains (losses) recognized during the period on equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_0dcf8923-b2a5-4bc4-b8af-0723c0724b52_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net gains recognized on the increase in fair value of equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_NightstarMember_8bb459fc-17cd-4df8-be26-cd6de97c7529_terseLabel_en-US" xlink:label="lab_biib_NightstarMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nightstar</link:label>
    <link:label id="lab_biib_NightstarMember_label_en-US" xlink:label="lab_biib_NightstarMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nightstar [Member]</link:label>
    <link:label id="lab_biib_NightstarMember_documentation_en-US" xlink:label="lab_biib_NightstarMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nightstar [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NightstarMember" xlink:href="biib-20200930.xsd#biib_NightstarMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NightstarMember" xlink:to="lab_biib_NightstarMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_d9614f1b-316f-489c-add4-8015ebbcf8d5_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under stock award plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_8b47eba7-0821-4739-b1b7-6ae9e5c69ef4_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired_a80865d7-f540-41c5-b39c-8ced09ab94ad_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of Nightstar Therapeutics plc, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Business Two, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax_8b9d050e-37bb-4c79-bbfa-0d9b954cb80b_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on divestiture of Hiller&#248;d, Denmark manufacturing operations, net of tax</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operation, Provision for Loss (Gain) on Disposal, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax" xlink:to="lab_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeRemainingMaturity1_3853b657-fc22-47c1-8f07-fcdbc4114378_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeRemainingMaturity1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range of durations of foreign currency forward contracts</link:label>
    <link:label id="lab_us-gaap_DerivativeRemainingMaturity1_label_en-US" xlink:label="lab_us-gaap_DerivativeRemainingMaturity1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Remaining Maturity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeRemainingMaturity1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeRemainingMaturity1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeRemainingMaturity1" xlink:to="lab_us-gaap_DerivativeRemainingMaturity1" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_CAD_4c81d183-1cca-40ba-9a1e-b8ce93cca751_verboseLabel_en-US" xlink:label="lab_currency_CAD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canadian dollar</link:label>
    <link:label id="lab_currency_CAD_label_en-US" xlink:label="lab_currency_CAD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canada, Dollars</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_CAD" xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_CAD"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_CAD" xlink:to="lab_currency_CAD" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_86ad4f09-b91c-4c2e-a259-e6664ad106a5_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_GovernmentSecuritiesCurrentMember_bb02671f-b810-49e2-ad71-31bd35041f59_verboseLabel_en-US" xlink:label="lab_biib_GovernmentSecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government securities Current</link:label>
    <link:label id="lab_biib_GovernmentSecuritiesCurrentMember_label_en-US" xlink:label="lab_biib_GovernmentSecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Securities Current [Member]</link:label>
    <link:label id="lab_biib_GovernmentSecuritiesCurrentMember_documentation_en-US" xlink:label="lab_biib_GovernmentSecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government securities Current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GovernmentSecuritiesCurrentMember" xlink:href="biib-20200930.xsd#biib_GovernmentSecuritiesCurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GovernmentSecuritiesCurrentMember" xlink:to="lab_biib_GovernmentSecuritiesCurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_acaa25f8-2193-46ce-90a8-caddcc44fe93_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_d652946a-ae3c-42a5-b4fd-adeffe341cb4_terseLabel_en-US" xlink:label="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_label_en-US" xlink:label="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from anti-CD20 therapeutic programs [Table Text Block]</link:label>
    <link:label id="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_documentation_en-US" xlink:label="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from anti-CD20 therapeutic programs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock" xlink:href="biib-20200930.xsd#biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock" xlink:to="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_19f0dbed-b597-4d1d-a5d3-e1209dac87cd_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration expected to be received for sale of Denmark Manufacturing Operations</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_c88ca486-c2c3-469d-9d8f-6eae5d3d02f6_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_c6d4df93-2864-4a89-b4b3-7a13e5f1889d_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_CollaborationAgreementTerm_0a7bd0cb-c749-4801-8d5e-0451d7425c22_terseLabel_en-US" xlink:label="lab_biib_CollaborationAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration agreement term</link:label>
    <link:label id="lab_biib_CollaborationAgreementTerm_label_en-US" xlink:label="lab_biib_CollaborationAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement Term</link:label>
    <link:label id="lab_biib_CollaborationAgreementTerm_documentation_en-US" xlink:label="lab_biib_CollaborationAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CollaborationAgreementTerm" xlink:href="biib-20200930.xsd#biib_CollaborationAgreementTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CollaborationAgreementTerm" xlink:to="lab_biib_CollaborationAgreementTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_0da9e340-11d7-4664-803c-0d58978f91d9_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of financial assets with maturities of less than 90 days included within cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_65015f99-ec37-46ba-b817-f1f3c363b891_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_7cafaf0e-d5e3-441c-88fc-3a9e5920ebb3_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_RegulatoryApprovalMilestoneMember_06b7fae5-9905-4b1c-bb6e-2a7fa1edd43f_terseLabel_en-US" xlink:label="lab_biib_RegulatoryApprovalMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory Approval Milestone [Member]</link:label>
    <link:label id="lab_biib_RegulatoryApprovalMilestoneMember_label_en-US" xlink:label="lab_biib_RegulatoryApprovalMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory Approval Milestone [Member]</link:label>
    <link:label id="lab_biib_RegulatoryApprovalMilestoneMember_documentation_en-US" xlink:label="lab_biib_RegulatoryApprovalMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory Approval Milestone [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RegulatoryApprovalMilestoneMember" xlink:href="biib-20200930.xsd#biib_RegulatoryApprovalMilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RegulatoryApprovalMilestoneMember" xlink:to="lab_biib_RegulatoryApprovalMilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_247451e0-ab1b-4069-a779-276251d4053b_terseLabel_en-US" xlink:label="lab_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Activity Related to Aducanumab Collaboration</link:label>
    <link:label id="lab_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_label_en-US" xlink:label="lab_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Activity Related to Aducanumab Collaboration [Table Text Block]</link:label>
    <link:label id="lab_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_documentation_en-US" xlink:label="lab_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Table Text Block] for Summary of Activity Related to Aducanumab Collaboration [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock" xlink:href="biib-20200930.xsd#biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock" xlink:to="lab_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RealizedInvestmentGainsLosses_67e12dec-ad34-4878-9398-45991f7858fd_terseLabel_en-US" xlink:label="lab_us-gaap_RealizedInvestmentGainsLosses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) on investments, net</link:label>
    <link:label id="lab_us-gaap_RealizedInvestmentGainsLosses_label_en-US" xlink:label="lab_us-gaap_RealizedInvestmentGainsLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized Investment Gains (Losses)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RealizedInvestmentGainsLosses" xlink:to="lab_us-gaap_RealizedInvestmentGainsLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_RocheGroupGenentechMember_4f0a18b8-785d-45aa-aba8-e9f733e9fcb6_terseLabel_en-US" xlink:label="lab_biib_RocheGroupGenentechMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Genentech</link:label>
    <link:label id="lab_biib_RocheGroupGenentechMember_label_en-US" xlink:label="lab_biib_RocheGroupGenentechMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Roche Group Genentech Member</link:label>
    <link:label id="lab_biib_RocheGroupGenentechMember_documentation_en-US" xlink:label="lab_biib_RocheGroupGenentechMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Roche group Genentech.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RocheGroupGenentechMember" xlink:href="biib-20200930.xsd#biib_RocheGroupGenentechMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RocheGroupGenentechMember" xlink:to="lab_biib_RocheGroupGenentechMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_45e1ac16-b06d-404c-8c5f-bc3ee10fec73_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_f87745bf-8c5b-4c4e-9888-d14c38741485_terseLabel_en-US" xlink:label="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.200% Senior Notes due 2045</link:label>
    <link:label id="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_label_en-US" xlink:label="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Five Point Two Percent Due Twenty Forty Five [Member]</link:label>
    <link:label id="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_documentation_en-US" xlink:label="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Five Point Two Percent Due Twenty Forty Five [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:href="biib-20200930.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:to="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_db20fc25-fd08-4f99-9676-ae6623515842_terseLabel_en-US" xlink:label="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Future Milestone Payments Commitment To Third Party Approximately</link:label>
    <link:label id="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_label_en-US" xlink:label="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Future Milestone Payments Commitment To Third Party Approximately</link:label>
    <link:label id="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_documentation_en-US" xlink:label="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential future milestone payments commitment to third party approximately.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:href="biib-20200930.xsd#biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:to="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_8ce1e7e2-2037-4171-beb4-b445facce047_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity [Line Items]</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityLineItems" xlink:to="lab_us-gaap_VariableInterestEntityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_42e5e319-4e07-48ed-b145-48b94e38c5c1_verboseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_fd9fd856-7b2a-444b-becf-88370b8ea894_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_d02c3b49-5151-44ce-8ff1-24418358202d_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNotionalAmount" xlink:to="lab_us-gaap_DerivativeNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_e7a7958e-11ba-49a5-8ea2-447fa157e32a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, redemption price, percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SolothurnSwitzerlandMember_f8d515f1-2948-47fa-b3cc-4948254d84f2_terseLabel_en-US" xlink:label="lab_biib_SolothurnSwitzerlandMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Solothurn, Switzerland</link:label>
    <link:label id="lab_biib_SolothurnSwitzerlandMember_label_en-US" xlink:label="lab_biib_SolothurnSwitzerlandMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Solothurn, Switzerland [Member]</link:label>
    <link:label id="lab_biib_SolothurnSwitzerlandMember_documentation_en-US" xlink:label="lab_biib_SolothurnSwitzerlandMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Solothurn, Switzerland [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SolothurnSwitzerlandMember" xlink:href="biib-20200930.xsd#biib_SolothurnSwitzerlandMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SolothurnSwitzerlandMember" xlink:to="lab_biib_SolothurnSwitzerlandMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FacilityTypeAxis_0315538a-491a-410e-9525-4caf33b1aec5_terseLabel_en-US" xlink:label="lab_biib_FacilityTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Type [Axis]</link:label>
    <link:label id="lab_biib_FacilityTypeAxis_label_en-US" xlink:label="lab_biib_FacilityTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Type [Axis]</link:label>
    <link:label id="lab_biib_FacilityTypeAxis_documentation_en-US" xlink:label="lab_biib_FacilityTypeAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityTypeAxis" xlink:href="biib-20200930.xsd#biib_FacilityTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FacilityTypeAxis" xlink:to="lab_biib_FacilityTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_c0345d3f-caff-4113-b508-21d653c09db0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on interest rate swap</link:label>
    <link:label id="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_cebc445e-63c6-47c8-a69a-7935813416a6_verboseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on interest rate swap</link:label>
    <link:label id="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_e13668c5-8083-4560-9977-9b1ed8d99e6b_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, gain on derivative</link:label>
    <link:label id="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_label_en-US" xlink:label="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Derivative Instruments, Net, Pretax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:to="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_9599da93-d32a-420a-880f-4a0b05c24b1e_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_375eff1d-6b7c-4463-8031-88346ef97dc5_verboseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of stake in entity maximum</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_a44f3c02-0b6c-4f57-aff7-6423d5b57bf8_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets (Excluding Goodwill)</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_af74e8aa-6498-4e9d-a556-4efd65b0e082_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indebtedness</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_3b7327b2-9386-4d04-8936-99981dcf5d2b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_GovernmentSecuritiesNonCurrentMember_be84d136-2f17-47ff-b04c-a5b2c52283f5_verboseLabel_en-US" xlink:label="lab_biib_GovernmentSecuritiesNonCurrentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government securities Non-current</link:label>
    <link:label id="lab_biib_GovernmentSecuritiesNonCurrentMember_label_en-US" xlink:label="lab_biib_GovernmentSecuritiesNonCurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Securities Non-current [Member]</link:label>
    <link:label id="lab_biib_GovernmentSecuritiesNonCurrentMember_documentation_en-US" xlink:label="lab_biib_GovernmentSecuritiesNonCurrentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Securities Non Current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GovernmentSecuritiesNonCurrentMember" xlink:href="biib-20200930.xsd#biib_GovernmentSecuritiesNonCurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GovernmentSecuritiesNonCurrentMember" xlink:to="lab_biib_GovernmentSecuritiesNonCurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_OtherrevenuesAbstract_02c0cf16-909a-480b-aed7-b5fb9542a2e1_terseLabel_en-US" xlink:label="lab_biib_OtherrevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenues [Abstract]</link:label>
    <link:label id="lab_biib_OtherrevenuesAbstract_label_en-US" xlink:label="lab_biib_OtherrevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenues [Abstract]</link:label>
    <link:label id="lab_biib_OtherrevenuesAbstract_documentation_en-US" xlink:label="lab_biib_OtherrevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherrevenuesAbstract" xlink:href="biib-20200930.xsd#biib_OtherrevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OtherrevenuesAbstract" xlink:to="lab_biib_OtherrevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_c92595e0-8b05-4493-a125-576d2ae0fad7_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Domain]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecurities_298e836b-7441-4b5a-b7b1-a18fcd0156f7_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable equity securities, fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecurities_fdc305a9-b8f9-4150-814c-4b5c49a42e0f_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_NumberOfOphthalmolgyBiosimilarProductsExclusiveRights_1831803a-d8dd-43e6-9b11-0028e492ea14_terseLabel_en-US" xlink:label="lab_biib_NumberOfOphthalmolgyBiosimilarProductsExclusiveRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of potential products, exclusive rights</link:label>
    <link:label id="lab_biib_NumberOfOphthalmolgyBiosimilarProductsExclusiveRights_label_en-US" xlink:label="lab_biib_NumberOfOphthalmolgyBiosimilarProductsExclusiveRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Ophthalmolgy Biosimilar Products, Exclusive Rights</link:label>
    <link:label id="lab_biib_NumberOfOphthalmolgyBiosimilarProductsExclusiveRights_documentation_en-US" xlink:label="lab_biib_NumberOfOphthalmolgyBiosimilarProductsExclusiveRights" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Ophthalmolgy Biosimilar Products, Exclusive Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NumberOfOphthalmolgyBiosimilarProductsExclusiveRights" xlink:href="biib-20200930.xsd#biib_NumberOfOphthalmolgyBiosimilarProductsExclusiveRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NumberOfOphthalmolgyBiosimilarProductsExclusiveRights" xlink:to="lab_biib_NumberOfOphthalmolgyBiosimilarProductsExclusiveRights" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_6e07f292-b8c4-4ea1-bc16-f77eceed0c33_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2dbc531b-b284-4846-90f0-6297403cefb1_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeTermOfContract_c786db6d-eb32-45f6-9d11-8775a2ed22a7_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining duration of Net Investment Hedges</link:label>
    <link:label id="lab_us-gaap_DerivativeTermOfContract_label_en-US" xlink:label="lab_us-gaap_DerivativeTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTermOfContract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTermOfContract" xlink:to="lab_us-gaap_DerivativeTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_51cf61ff-d888-4fc8-9f60-e807a3b5d112_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_07649609-d306-40e6-9860-8717ba6f8fae_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_40ad2588-024e-46d7-aa81-4d8d13461bee_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</link:label>
    <link:label id="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_label_en-US" xlink:label="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems" xlink:to="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Biogenshareofcopromotionprofitsorlosses_4ab7be87-9eea-4f38-adf6-545156b211c3_terseLabel_en-US" xlink:label="lab_biib_Biogenshareofcopromotionprofitsorlosses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biogen share of co-promotion profits or losses</link:label>
    <link:label id="lab_biib_Biogenshareofcopromotionprofitsorlosses_label_en-US" xlink:label="lab_biib_Biogenshareofcopromotionprofitsorlosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biogen share of co-promotion profits or losses</link:label>
    <link:label id="lab_biib_Biogenshareofcopromotionprofitsorlosses_documentation_en-US" xlink:label="lab_biib_Biogenshareofcopromotionprofitsorlosses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biogen share of co-promotion profits or losses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Biogenshareofcopromotionprofitsorlosses" xlink:href="biib-20200930.xsd#biib_Biogenshareofcopromotionprofitsorlosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Biogenshareofcopromotionprofitsorlosses" xlink:to="lab_biib_Biogenshareofcopromotionprofitsorlosses" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Investmentincommonstocksharespurchased_a3b7dc95-503f-4620-aa6a-6f44ddfc5e3f_terseLabel_en-US" xlink:label="lab_biib_Investmentincommonstocksharespurchased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in common stock, shares purchased</link:label>
    <link:label id="lab_biib_Investmentincommonstocksharespurchased_label_en-US" xlink:label="lab_biib_Investmentincommonstocksharespurchased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in common stock, shares purchased</link:label>
    <link:label id="lab_biib_Investmentincommonstocksharespurchased_documentation_en-US" xlink:label="lab_biib_Investmentincommonstocksharespurchased" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in common stock, shares purchased</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Investmentincommonstocksharespurchased" xlink:href="biib-20200930.xsd#biib_Investmentincommonstocksharespurchased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Investmentincommonstocksharespurchased" xlink:to="lab_biib_Investmentincommonstocksharespurchased" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_b2ab795f-8f2a-4b6f-94f4-a1620a41e59b_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_8edb5315-71b7-4fee-ac32-c5dc6897cf00_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_f6c4b649-2cb7-42e5-8c50-566a23ded7e0_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillOtherIncreaseDecrease_f54acf96-1a4e-4af7-9841-179cb8b8e4cd_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_GoodwillOtherIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Other Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillOtherIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillOtherIncreaseDecrease" xlink:to="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeniorNotesMember_b0575085-36b1-4be6-a5ca-1a3f2cbb3d71_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes</link:label>
    <link:label id="lab_us-gaap_SeniorNotesMember_label_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotesMember" xlink:to="lab_us-gaap_SeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Collaborationprofitlosssharing_78f85b5e-c27f-4e1b-9a9a-0d593ab96bfc_terseLabel_en-US" xlink:label="lab_biib_Collaborationprofitlosssharing" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration profit (loss) sharing</link:label>
    <link:label id="lab_biib_Collaborationprofitlosssharing_label_en-US" xlink:label="lab_biib_Collaborationprofitlosssharing" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration profit (loss) sharing</link:label>
    <link:label id="lab_biib_Collaborationprofitlosssharing_documentation_en-US" xlink:label="lab_biib_Collaborationprofitlosssharing" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration profit (loss) sharing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Collaborationprofitlosssharing" xlink:href="biib-20200930.xsd#biib_Collaborationprofitlosssharing"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Collaborationprofitlosssharing" xlink:to="lab_biib_Collaborationprofitlosssharing" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7b15bc00-b672-4b2d-b3b0-462398a95c04_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable equity securities, gross unrealized losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_March2019ShareRepurchaseProgramMember_d063b202-b618-43d5-899c-4ab95e025d01_terseLabel_en-US" xlink:label="lab_biib_March2019ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Share Repurchase Program</link:label>
    <link:label id="lab_biib_March2019ShareRepurchaseProgramMember_label_en-US" xlink:label="lab_biib_March2019ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">March 2019 Share Repurchase Program [Member]</link:label>
    <link:label id="lab_biib_March2019ShareRepurchaseProgramMember_documentation_en-US" xlink:label="lab_biib_March2019ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">March 2019 Share Repurchase Program [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_March2019ShareRepurchaseProgramMember" xlink:href="biib-20200930.xsd#biib_March2019ShareRepurchaseProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_March2019ShareRepurchaseProgramMember" xlink:to="lab_biib_March2019ShareRepurchaseProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_6a852ce3-3a8f-4ede-a460-bce5a4b78aeb_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:to="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_7c18501a-4b0a-4dde-9937-7753341cab70_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_2df19c25-c37d-439d-a7b0-48f48b70e06d_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and diluted earnings per share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_f836741e-7155-4ee1-afcf-b488d2a17932_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other changes in operating assets and liabilities, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets and Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_3b8e7c62-8276-4993-afe2-42cdb961047e_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToMinorityShareholders_f6559bc6-afea-4b01-aa12-30b837aba458_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToMinorityShareholders" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net distribution to noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_PaymentsToMinorityShareholders_be340b43-341c-4d14-8f75-1762b3072318_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToMinorityShareholders" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Noncontrolling Interests</link:label>
    <link:label id="lab_us-gaap_PaymentsToMinorityShareholders_label_en-US" xlink:label="lab_us-gaap_PaymentsToMinorityShareholders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Noncontrolling Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToMinorityShareholders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToMinorityShareholders" xlink:to="lab_us-gaap_PaymentsToMinorityShareholders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_36b77c5c-527b-47b5-99ef-55b10aa91633_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized gains</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Realized Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BAN2401Member_01676e14-43ee-4b7f-b8f3-c6b3abd768d2_terseLabel_en-US" xlink:label="lab_biib_BAN2401Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BAN2401</link:label>
    <link:label id="lab_biib_BAN2401Member_label_en-US" xlink:label="lab_biib_BAN2401Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BAN2401 [Member]</link:label>
    <link:label id="lab_biib_BAN2401Member_documentation_en-US" xlink:label="lab_biib_BAN2401Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BAN2401 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BAN2401Member" xlink:href="biib-20200930.xsd#biib_BAN2401Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BAN2401Member" xlink:to="lab_biib_BAN2401Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_947ffe40-fc18-4495-88b0-784717eda784_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets, other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_905d14e6-8631-4f85-81db-7f723ea6aeb1_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AVONEXMember_44fed1e6-b49d-4a06-a1bc-120c9f16da5f_terseLabel_en-US" xlink:label="lab_biib_AVONEXMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AVONEX</link:label>
    <link:label id="lab_biib_AVONEXMember_label_en-US" xlink:label="lab_biib_AVONEXMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AVONEX [Member]</link:label>
    <link:label id="lab_biib_AVONEXMember_documentation_en-US" xlink:label="lab_biib_AVONEXMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AVONEX</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AVONEXMember" xlink:href="biib-20200930.xsd#biib_AVONEXMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AVONEXMember" xlink:to="lab_biib_AVONEXMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_01598ba5-6213-4974-8281-085f143abc9d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash and Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_721e8cc1-5ab9-40ac-9c50-069516567688_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration expenses</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinCashMember_8568cdcc-c648-4743-aa61-494e320f9964_terseLabel_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinCashMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance stock units settled in cash</link:label>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinCashMember_label_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinCashMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Stock Units Settled in Cash [Member]</link:label>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinCashMember_documentation_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinCashMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Stock Units Settled in Cash [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceStockUnitsSettledinCashMember" xlink:href="biib-20200930.xsd#biib_PerformanceStockUnitsSettledinCashMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PerformanceStockUnitsSettledinCashMember" xlink:to="lab_biib_PerformanceStockUnitsSettledinCashMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_cb98d4d4-15cd-43ef-a6af-31860bf0feea_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Other Observable Inputs (Level 2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_53e29b48-9096-447b-867e-9024354be236_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SangamoCommonStockMember_81f0ed49-807a-414b-abcc-1fe79d330947_terseLabel_en-US" xlink:label="lab_biib_SangamoCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sangamo</link:label>
    <link:label id="lab_biib_SangamoCommonStockMember_label_en-US" xlink:label="lab_biib_SangamoCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sangamo Common Stock [Member]</link:label>
    <link:label id="lab_biib_SangamoCommonStockMember_documentation_en-US" xlink:label="lab_biib_SangamoCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sangamo Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SangamoCommonStockMember" xlink:href="biib-20200930.xsd#biib_SangamoCommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SangamoCommonStockMember" xlink:to="lab_biib_SangamoCommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_f652d46d-92a8-485e-b2ae-d766c713345c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions of intangible assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_88a7890e-8218-4000-a394-59ebd764baa8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement of common stock pursuant to Share Repurchase Programs, at cost, shares</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased and Retired During Period, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_43b461ef-49b8-4fb5-8074-15834abaa81a_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, by Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_50c68e6a-b8bf-410b-82b5-11af4f8b757f_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_OthercorporaterevenuesMember_35dab593-9607-498c-b268-57aff13546f8_terseLabel_en-US" xlink:label="lab_biib_OthercorporaterevenuesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other corporate revenues</link:label>
    <link:label id="lab_biib_OthercorporaterevenuesMember_label_en-US" xlink:label="lab_biib_OthercorporaterevenuesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other corporate revenues [Member]</link:label>
    <link:label id="lab_biib_OthercorporaterevenuesMember_documentation_en-US" xlink:label="lab_biib_OthercorporaterevenuesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other corporate revenues [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OthercorporaterevenuesMember" xlink:href="biib-20200930.xsd#biib_OthercorporaterevenuesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OthercorporaterevenuesMember" xlink:to="lab_biib_OthercorporaterevenuesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_TimeVestedRestrictedStockUnitsMember_e1f66199-4862-4cff-a695-270c9d39f26b_verboseLabel_en-US" xlink:label="lab_biib_TimeVestedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time-vested restricted stock units</link:label>
    <link:label id="lab_biib_TimeVestedRestrictedStockUnitsMember_label_en-US" xlink:label="lab_biib_TimeVestedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time Vested Restricted Stock Units [Member]</link:label>
    <link:label id="lab_biib_TimeVestedRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_biib_TimeVestedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time vested restricted stock units.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember" xlink:href="biib-20200930.xsd#biib_TimeVestedRestrictedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TimeVestedRestrictedStockUnitsMember" xlink:to="lab_biib_TimeVestedRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_CHF_ec35a37e-e7cf-4968-8fa5-2f45bd24908b_terseLabel_en-US" xlink:label="lab_currency_CHF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Swiss franc</link:label>
    <link:label id="lab_currency_CHF_label_en-US" xlink:label="lab_currency_CHF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Switzerland, Francs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_CHF" xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_CHF"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_CHF" xlink:to="lab_currency_CHF" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_CashflowsrevenueMember_7e21ac18-3d33-4920-bc66-3b79db89787f_terseLabel_en-US" xlink:label="lab_biib_CashflowsrevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows, revenue</link:label>
    <link:label id="lab_biib_CashflowsrevenueMember_label_en-US" xlink:label="lab_biib_CashflowsrevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows, revenue [Member]</link:label>
    <link:label id="lab_biib_CashflowsrevenueMember_documentation_en-US" xlink:label="lab_biib_CashflowsrevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows, revenue [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CashflowsrevenueMember" xlink:href="biib-20200930.xsd#biib_CashflowsrevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CashflowsrevenueMember" xlink:to="lab_biib_CashflowsrevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_996b66ba-c3d1-43a2-9a49-42a6b0340dfb_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product, net</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Expensereflectedwithinstatementsofincome_c32fc352-eb12-48b5-8593-b1bd024752a6_terseLabel_en-US" xlink:label="lab_biib_Expensereflectedwithinstatementsofincome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense reflected within statements of income</link:label>
    <link:label id="lab_biib_Expensereflectedwithinstatementsofincome_label_en-US" xlink:label="lab_biib_Expensereflectedwithinstatementsofincome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense reflected within statements of income</link:label>
    <link:label id="lab_biib_Expensereflectedwithinstatementsofincome_documentation_en-US" xlink:label="lab_biib_Expensereflectedwithinstatementsofincome" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense reflected within statements of income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expensereflectedwithinstatementsofincome" xlink:href="biib-20200930.xsd#biib_Expensereflectedwithinstatementsofincome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Expensereflectedwithinstatementsofincome" xlink:to="lab_biib_Expensereflectedwithinstatementsofincome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets_375c04d2-b11d-4973-9804-b6f4b6f18e5f_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denmark assets held for sale</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Disposition of Asset, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract_bd7730d2-cab8-4f8d-b3e5-4930d78a2ace_terseLabel_en-US" xlink:label="lab_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification Out of Accumulated Other Comprehensive Income (Loss) [Abstract]</link:label>
    <link:label id="lab_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract_label_en-US" xlink:label="lab_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification Out of Accumulated Other Comprehensive Income (Loss) [Abstract]</link:label>
    <link:label id="lab_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract_documentation_en-US" xlink:label="lab_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification Out of Accumulated Other Comprehensive Income (Loss) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract" xlink:href="biib-20200930.xsd#biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract" xlink:to="lab_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_ccd18847-8767-4b20-8c97-4d05e1eb527d_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_4a620d10-a9f4-4514-bfdb-3de670d51a88_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired in-process research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development in Process</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentInProcess" xlink:to="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ef986154-f0eb-4571-a4b6-1aafe3b7e31b_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_017d5817-61e8-468d-b105-e81bd3718604_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:to="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain_f23c0946-0c16-4bd5-9cf7-17c225c0b5cf_terseLabel_en-US" xlink:label="lab_biib_PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-tax charge, payment of early call premium and write off of remaining unamortized debt issuance costs, net of derivative gain</link:label>
    <link:label id="lab_biib_PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain_label_en-US" xlink:label="lab_biib_PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-tax Charge, Payment of Early Call Premium and Write off of Remaining Unamortized Debt Issuance Costs, Net of Derivative Gain</link:label>
    <link:label id="lab_biib_PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain_documentation_en-US" xlink:label="lab_biib_PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-tax Charge, Payment of Early Call Premium and Write off of Remaining Unamortized Debt Issuance Costs, Net of Derivative Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain" xlink:href="biib-20200930.xsd#biib_PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain" xlink:to="lab_biib_PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_d3c8fdbb-0054-4224-bcb9-525aace80797_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Contingent Consideration [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Contingent Consideration [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_632e5a44-80af-4eff-85b0-95edbe39588d_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments and other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_62be658a-e60c-4e9d-a365-feecc4e30662_terseLabel_en-US" xlink:label="lab_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains (losses) on net investment hedges</link:label>
    <link:label id="lab_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives used in Net Investment Hedge, Net of Tax, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" xlink:to="lab_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_0d76379f-7407-490e-bfea-945a7892cb3e_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_678ff154-6652-4d30-a0e0-7727ec194113_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_232350f4-af2a-4154-a47e-4e46f74a76a3_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesMember_00cc33e4-03f6-4758-a912-7e8245280046_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term debt securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesMember" xlink:to="lab_us-gaap_DebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_267a8b7f-5012-464c-8c2c-1cae50943f9f_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_08e6c964-a9ea-4071-b792-29f854a39d66_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxBasisOfInvestmentsCostForIncomeTaxPurposes_97f1ddda-0359-4bca-8ede-1e1905525d75_terseLabel_en-US" xlink:label="lab_us-gaap_TaxBasisOfInvestmentsCostForIncomeTaxPurposes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Basis of Investments, Cost for Income Tax Purposes</link:label>
    <link:label id="lab_us-gaap_TaxBasisOfInvestmentsCostForIncomeTaxPurposes_label_en-US" xlink:label="lab_us-gaap_TaxBasisOfInvestmentsCostForIncomeTaxPurposes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Basis of Investments, Cost for Income Tax Purposes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxBasisOfInvestmentsCostForIncomeTaxPurposes" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxBasisOfInvestmentsCostForIncomeTaxPurposes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxBasisOfInvestmentsCostForIncomeTaxPurposes" xlink:to="lab_us-gaap_TaxBasisOfInvestmentsCostForIncomeTaxPurposes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_20c152f1-1f13-4315-9816-a831cd2dd9d4_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes payable</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_c4f25207-326d-47b8-b52d-8c1452b462fd_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected future amortization expense, 2019 (remaining three months)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_79944060-ce27-4248-803d-36c8dcd563cc_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected future amortization expense, 2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_1671bcc2-1118-41f5-8abe-28eb7f59e7ce_verboseLabel_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage and other asset backed securities Non-current</link:label>
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_label_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage And Other Asset Backed Securities Non Current [Member]</link:label>
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_documentation_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage And Other Asset Backed Securities Non Current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" xlink:href="biib-20200930.xsd#biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" xlink:to="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_98e0b279-098c-4fdc-8a8f-d21e75464111_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_54ce7970-f4ed-4f51-8c6f-81603274d11b_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_3e91f8dd-0abf-47f6-82fb-f945c05ed6f7_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_74ce01f3-acf3-4892-aa2d-912df975be3d_negatedLabel_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments/Returns Relating To Sales in Current Year</link:label>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_label_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments Returns Applied Against Product Revenue Reserves Relating To Current Year</link:label>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_documentation_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments/ returns applied against product revenue reserves relating to current year.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" xlink:href="biib-20200930.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" xlink:to="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_7a1b6c69-0d25-439e-8d28-9d65b8ecab8a_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from borrowings</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SangamoTherapeuticsInc.AgreementMember_9a8f26cb-02a6-480a-8a08-9ab13b5725cd_terseLabel_en-US" xlink:label="lab_biib_SangamoTherapeuticsInc.AgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sangamo Therapeutics, Inc. Agreement</link:label>
    <link:label id="lab_biib_SangamoTherapeuticsInc.AgreementMember_label_en-US" xlink:label="lab_biib_SangamoTherapeuticsInc.AgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sangamo Therapeutics, Inc. Agreement [Member]</link:label>
    <link:label id="lab_biib_SangamoTherapeuticsInc.AgreementMember_documentation_en-US" xlink:label="lab_biib_SangamoTherapeuticsInc.AgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sangamo Therapeutics, Inc. Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SangamoTherapeuticsInc.AgreementMember" xlink:href="biib-20200930.xsd#biib_SangamoTherapeuticsInc.AgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SangamoTherapeuticsInc.AgreementMember" xlink:to="lab_biib_SangamoTherapeuticsInc.AgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1_03812387-38a9-49f5-b97d-a1e8ad48379b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction in contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_6bd4ed8c-4ea0-4bc6-830d-233c5de19190_negatedLabel_en-US" xlink:label="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain/Loss on fair value of foreign currency forward contracts</link:label>
    <link:label id="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_label_en-US" xlink:label="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Losses) on Foreign Currency Derivatives, Net, before Tax</link:label>
    <link:label id="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_documentation_en-US" xlink:label="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of net unrealized gain (loss) related to the change in fair value of foreign currency exchange rate derivatives designated as cash flow hedging instruments. Recorded in accumulated other comprehensive income to the extent that the cash flow hedge is determined to be effective.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" xlink:href="biib-20200930.xsd#biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" xlink:to="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_5da66e90-10e6-4d67-8398-6f745296dab8_terseLabel_en-US" xlink:label="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of future development costs related to Eisai</link:label>
    <link:label id="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_label_en-US" xlink:label="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of future development costs related to Eisai</link:label>
    <link:label id="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_documentation_en-US" xlink:label="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of future development costs related to Eisai</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai" xlink:href="biib-20200930.xsd#biib_PercentageoffuturedevelopmentcostsrelatedtoEisai"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai" xlink:to="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DueFromRelatedParties_0b4c31a8-0661-461a-b8ae-acba6a444ac7_terseLabel_en-US" xlink:label="lab_us-gaap_DueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due from Related Parties</link:label>
    <link:label id="lab_us-gaap_DueFromRelatedParties_label_en-US" xlink:label="lab_us-gaap_DueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due from Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromRelatedParties" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DueFromRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueFromRelatedParties" xlink:to="lab_us-gaap_DueFromRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_46aabe09-b367-4f3e-bb08-fe69c5750cf6_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_dc3b5de7-509a-4073-b0ad-f41d66164c3f_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of fair value and presentation of derivatives</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_WarehouseUtilitiesAndSupportSpaceMember_f4a01fa5-1818-41a6-9791-f3f26f74a255_terseLabel_en-US" xlink:label="lab_biib_WarehouseUtilitiesAndSupportSpaceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warehouse, Utilities and Support Space</link:label>
    <link:label id="lab_biib_WarehouseUtilitiesAndSupportSpaceMember_label_en-US" xlink:label="lab_biib_WarehouseUtilitiesAndSupportSpaceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warehouse, Utilities and Support Space [Member]</link:label>
    <link:label id="lab_biib_WarehouseUtilitiesAndSupportSpaceMember_documentation_en-US" xlink:label="lab_biib_WarehouseUtilitiesAndSupportSpaceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warehouse, Utilities and Support Space</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_WarehouseUtilitiesAndSupportSpaceMember" xlink:href="biib-20200930.xsd#biib_WarehouseUtilitiesAndSupportSpaceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_WarehouseUtilitiesAndSupportSpaceMember" xlink:to="lab_biib_WarehouseUtilitiesAndSupportSpaceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_1d9fb020-631e-4866-882c-b457e333f0fc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of the effect of derivatives designated as net investment hedging instruments on our consolidated statement of income</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_3195eb64-da71-4f93-a819-6aa2f997b5da_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Investments</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_63e4d537-05fe-476d-87bb-7d01edc3eed1_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_73b4399b-2077-4756-b384-9dcbafbe1738_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accrued expenses and other</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_CashSettledPerformanceSharesMember_fcb5b54d-7aeb-43ee-832c-a1c492a00411_terseLabel_en-US" xlink:label="lab_biib_CashSettledPerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash settled performance shares</link:label>
    <link:label id="lab_biib_CashSettledPerformanceSharesMember_label_en-US" xlink:label="lab_biib_CashSettledPerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash settled performance shares [Member]</link:label>
    <link:label id="lab_biib_CashSettledPerformanceSharesMember_documentation_en-US" xlink:label="lab_biib_CashSettledPerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash settled performance shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CashSettledPerformanceSharesMember" xlink:href="biib-20200930.xsd#biib_CashSettledPerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CashSettledPerformanceSharesMember" xlink:to="lab_biib_CashSettledPerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ParentMember_2394a9f7-c309-41f0-b766-cf144b6d9110_terseLabel_en-US" xlink:label="lab_us-gaap_ParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Parent</link:label>
    <link:label id="lab_us-gaap_ParentMember_7aadc2ad-ede7-4b43-ac77-7cb6c05a696a_verboseLabel_en-US" xlink:label="lab_us-gaap_ParentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total share-based compensation expense, net of tax</link:label>
    <link:label id="lab_us-gaap_ParentMember_label_en-US" xlink:label="lab_us-gaap_ParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ParentMember" xlink:to="lab_us-gaap_ParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossOnContractTermination_03877736-b8c2-4a46-b7da-4143b8c152a1_terseLabel_en-US" xlink:label="lab_us-gaap_LossOnContractTermination" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on research and development contracts terminated with Eisai</link:label>
    <link:label id="lab_us-gaap_LossOnContractTermination_label_en-US" xlink:label="lab_us-gaap_LossOnContractTermination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on Contract Termination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossOnContractTermination" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossOnContractTermination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossOnContractTermination" xlink:to="lab_us-gaap_LossOnContractTermination" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_4cd46aeb-3181-4c71-a0dc-24a7303d5ef8_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_097d004b-6545-4012-8c7a-21e71b40b1c5_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax assets and liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Income Taxes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_24c49528-dc91-4672-a71a-f84d65b1e94c_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesMember_a8bd8caa-321f-4363-9398-793c9e7f25dc_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesMember" xlink:to="lab_us-gaap_AccruedLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_56d436e6-3bb9-4c40-ba4f-e97ca3e84606_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones_06387ea9-378c-49d5-a42f-5cb1a41d8e98_terseLabel_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Licensing Collaboration Agreement, Payment, Achievement of First Commercial Sale Milestones</link:label>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones_label_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Licensing Collaboration Agreement, Payment, Achievement of First Commercial Sale Milestones</link:label>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones_documentation_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Licensing Collaboration Agreement, Payment, Achievement of First Commercial Sale Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones" xlink:href="biib-20200930.xsd#biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones" xlink:to="lab_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNetAbstract_b44fdd30-970e-46a8-92bc-25c92cc041cd_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNetAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNetAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNetAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNetAbstract" xlink:to="lab_us-gaap_InventoryNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_eab224a9-0509-47b3-bc52-775a3771a46e_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_CashflowsoperatingexpensesMember_e913a7bf-7c14-4e8c-a34a-c84d297a5767_terseLabel_en-US" xlink:label="lab_biib_CashflowsoperatingexpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows, operating expenses</link:label>
    <link:label id="lab_biib_CashflowsoperatingexpensesMember_label_en-US" xlink:label="lab_biib_CashflowsoperatingexpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows, operating expenses [Member]</link:label>
    <link:label id="lab_biib_CashflowsoperatingexpensesMember_documentation_en-US" xlink:label="lab_biib_CashflowsoperatingexpensesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows, operating expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CashflowsoperatingexpensesMember" xlink:href="biib-20200930.xsd#biib_CashflowsoperatingexpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CashflowsoperatingexpensesMember" xlink:to="lab_biib_CashflowsoperatingexpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_0106821e-380f-4ca7-9ef5-57f3fd292b0f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_220880a5-b5ee-4bd7-bf65-d7b64115e92c_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax expense on disposal group</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operation, Tax Effect of Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:to="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_9ef2d580-50d4-4913-86af-a76c4eb4d678_negatedLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized losses</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Realized Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_a1092cae-6dd1-4573-a1d5-a0ad66a5e4a5_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liability</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayable_4f0c3448-d7d7-4cdf-ac52-78ddf270da2b_verboseLabel_en-US" xlink:label="lab_us-gaap_NotesPayable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes payable, carrying value</link:label>
    <link:label id="lab_us-gaap_NotesPayable_label_en-US" xlink:label="lab_us-gaap_NotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayable" xlink:to="lab_us-gaap_NotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_December2019ShareRepurchaseProgramMember_413a8f77-aca7-4d5b-ac67-d954d150fbbb_terseLabel_en-US" xlink:label="lab_biib_December2019ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 2019 Share Repurchase Program</link:label>
    <link:label id="lab_biib_December2019ShareRepurchaseProgramMember_label_en-US" xlink:label="lab_biib_December2019ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 2019 Share Repurchase Program [Member]</link:label>
    <link:label id="lab_biib_December2019ShareRepurchaseProgramMember_documentation_en-US" xlink:label="lab_biib_December2019ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 2019 Share Repurchase Program [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_December2019ShareRepurchaseProgramMember" xlink:href="biib-20200930.xsd#biib_December2019ShareRepurchaseProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_December2019ShareRepurchaseProgramMember" xlink:to="lab_biib_December2019ShareRepurchaseProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_30dee2ea-4c26-4377-8eed-3534af7f0788_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction of accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_82db89da-4cb3-4998-aca3-197bcde26b3e_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S.</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_d1fd94a2-ebf2-4396-9881-5cd562c8bc69_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gains (losses) on cash flow hedges, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_8a24166a-830f-484c-9fbd-cfa927d26c6e_verboseLabel_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after five years, estimated fair value</link:label>
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_label_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available For Sale Securities Debt Maturities After Five Years Fair Value</link:label>
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_documentation_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">This item represents the fair value of debt securities, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" xlink:href="biib-20200930.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" xlink:to="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_e8faccd7-ce64-420b-a2d8-d100179cfdc3_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable equity securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_555fe389-b2da-48bd-9575-65f52d58a772_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior notes interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfFinancingCosts_79c00074-be2a-4d69-88a9-72716e97fc48_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of financing costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Financing Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfFinancingCosts" xlink:to="lab_us-gaap_PaymentsOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_25e560af-bc11-4692-9583-4064e41ead95_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems" xlink:to="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_055cf7a7-9e84-4695-a5e2-576866158f45_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_79834667-53f9-4f93-9507-ac59c490d4b0_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Reductioninroyaltyratepayableoncommercialsales_5d9e2cd7-bd6e-4798-92ea-9da9e89dac72_terseLabel_en-US" xlink:label="lab_biib_Reductioninroyaltyratepayableoncommercialsales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction in royalty rate payable on commercial sales</link:label>
    <link:label id="lab_biib_Reductioninroyaltyratepayableoncommercialsales_label_en-US" xlink:label="lab_biib_Reductioninroyaltyratepayableoncommercialsales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction in royalty rate payable on commercial sales</link:label>
    <link:label id="lab_biib_Reductioninroyaltyratepayableoncommercialsales_documentation_en-US" xlink:label="lab_biib_Reductioninroyaltyratepayableoncommercialsales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction in royalty rate payable on commercial sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Reductioninroyaltyratepayableoncommercialsales" xlink:href="biib-20200930.xsd#biib_Reductioninroyaltyratepayableoncommercialsales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Reductioninroyaltyratepayableoncommercialsales" xlink:to="lab_biib_Reductioninroyaltyratepayableoncommercialsales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_465f70c8-a23f-4f38-92bc-b726319ac915_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed assets placed into service</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_82186cdc-3a7e-4ac7-9720-f86eb533037a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract" xlink:to="lab_us-gaap_BusinessCombinationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AverageMaturityOfMarketableSecurities_2414cf0b-5268-4160-8cbe-e98ef4beb4c8_verboseLabel_en-US" xlink:label="lab_biib_AverageMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average maturity of marketable securities, months</link:label>
    <link:label id="lab_biib_AverageMaturityOfMarketableSecurities_label_en-US" xlink:label="lab_biib_AverageMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average Maturity Of Marketable Securities</link:label>
    <link:label id="lab_biib_AverageMaturityOfMarketableSecurities_documentation_en-US" xlink:label="lab_biib_AverageMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average remaining time to maturity of marketable debt securities, available-for-sale securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AverageMaturityOfMarketableSecurities" xlink:href="biib-20200930.xsd#biib_AverageMaturityOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AverageMaturityOfMarketableSecurities" xlink:to="lab_biib_AverageMaturityOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f7cf8c4d-6f8d-4ee1-a485-b62ed7324786_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_cc1055d5-8d23-4694-96e6-5620aba38b08_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_a377df3b-bba1-41c2-9285-8ee1dfd95ad2_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_0122c8ad-a750-4f36-a8f4-81be9a8650e7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_da245b8a-87f2-4d84-9230-088879ab14fd_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total transaction value</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_CorporateDebtSecuritiesCurrentMember_c024a5cf-7448-4851-9a56-e75fe964057d_verboseLabel_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities Current</link:label>
    <link:label id="lab_biib_CorporateDebtSecuritiesCurrentMember_label_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities Current [Member]</link:label>
    <link:label id="lab_biib_CorporateDebtSecuritiesCurrentMember_documentation_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities Current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CorporateDebtSecuritiesCurrentMember" xlink:href="biib-20200930.xsd#biib_CorporateDebtSecuritiesCurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CorporateDebtSecuritiesCurrentMember" xlink:to="lab_biib_CorporateDebtSecuritiesCurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_ac9ed00d-44ce-4a72-8891-339bb3d11ae1_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_6e6370e4-dd06-4017-afa4-c28d04fad85e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_2709ceab-447a-4d37-8ffa-731e969992bd_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_a2ada4bf-d265-4433-a3d9-1f176b907e58_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of contractual maturities: available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_10d69847-8768-46da-9fed-fc89ac05a941_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial and Nonfinancial Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCharges_a9e1d58c-87d0-4942-938f-0d4458f5f364_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring charges</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_WeightedAverageMember_bf9fab38-512a-4f6c-baf0-c5528c67b9d3_terseLabel_en-US" xlink:label="lab_srt_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average</link:label>
    <link:label id="lab_srt_WeightedAverageMember_label_en-US" xlink:label="lab_srt_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_WeightedAverageMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_WeightedAverageMember" xlink:to="lab_srt_WeightedAverageMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BusinessOverviewPolicyTextBlock_07d59922-32b7-40db-af38-bacae048a293_verboseLabel_en-US" xlink:label="lab_biib_BusinessOverviewPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Overview</link:label>
    <link:label id="lab_biib_BusinessOverviewPolicyTextBlock_label_en-US" xlink:label="lab_biib_BusinessOverviewPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Overview [Policy Text Block]</link:label>
    <link:label id="lab_biib_BusinessOverviewPolicyTextBlock_documentation_en-US" xlink:label="lab_biib_BusinessOverviewPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Describes an overview of the company and its operations.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessOverviewPolicyTextBlock" xlink:href="biib-20200930.xsd#biib_BusinessOverviewPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BusinessOverviewPolicyTextBlock" xlink:to="lab_biib_BusinessOverviewPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_86692258-947f-421f-9aa2-a725fc606c34_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash flows provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock_9d10327d-8fee-49fb-93ed-6c39863744e2_terseLabel_en-US" xlink:label="lab_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Activity Related to BAN2401 and Elenbecestat Collaboration</link:label>
    <link:label id="lab_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock_label_en-US" xlink:label="lab_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Activity Related to E2609 and BAN2401 Collaboration [Table Text Block]</link:label>
    <link:label id="lab_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock_documentation_en-US" xlink:label="lab_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Table Text Block] for Summary of Activity Related to E2609 and BAN2401 Collaboration [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" xlink:href="biib-20200930.xsd#biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" xlink:to="lab_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3a82ea71-147c-48a4-9ca2-e1ec39b784c1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_96bdf79d-5c4a-40cb-a24f-ba0b0f01bb11_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Permanent items</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_f5c2abbc-6689-43da-9039-8ea5aec5334f_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency forward contracts that were entered into to hedge forecasted revenue</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AdditionalMilestonePayment_fedb93b8-bc09-4e61-b7fc-40b3f3bae53f_terseLabel_en-US" xlink:label="lab_biib_AdditionalMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Milestone Payment</link:label>
    <link:label id="lab_biib_AdditionalMilestonePayment_label_en-US" xlink:label="lab_biib_AdditionalMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Milestone Payment</link:label>
    <link:label id="lab_biib_AdditionalMilestonePayment_documentation_en-US" xlink:label="lab_biib_AdditionalMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional milestone payment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdditionalMilestonePayment" xlink:href="biib-20200930.xsd#biib_AdditionalMilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AdditionalMilestonePayment" xlink:to="lab_biib_AdditionalMilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_October2020ShareRepurchaseProgramMember_a3bc5a91-6525-4284-b40c-6a95614eeb59_terseLabel_en-US" xlink:label="lab_biib_October2020ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">October 2020 Share Repurchase Program</link:label>
    <link:label id="lab_biib_October2020ShareRepurchaseProgramMember_label_en-US" xlink:label="lab_biib_October2020ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">October 2020 Share Repurchase Program [Member]</link:label>
    <link:label id="lab_biib_October2020ShareRepurchaseProgramMember_documentation_en-US" xlink:label="lab_biib_October2020ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">October 2020 Share Repurchase Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_October2020ShareRepurchaseProgramMember" xlink:href="biib-20200930.xsd#biib_October2020ShareRepurchaseProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_October2020ShareRepurchaseProgramMember" xlink:to="lab_biib_October2020ShareRepurchaseProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_fd93c04c-914e-41b8-ad11-b687112d5b62_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from divestiture of Hiller&#248;d, Denmark manufacturing operations</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract_35a0da3b-6b8d-462f-8213-ac9ade35be15_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, All Other Investments [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, All Other Investments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:to="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_13c38e19-63f2-474c-bf8b-70595da7bec7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_f4e3e504-2d5f-41f1-9069-ae6c5883212b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_ae3bac5c-7f57-4c37-a620-30e53f6d147b_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_ab01bcf3-1f40-4bc6-8659-dfff5fd39a10_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), before reclassifications, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), before Reclassifications, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_e1af48ed-defa-4034-8470-372f1b3b9236_verboseLabel_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after five years, amortized cost</link:label>
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_label_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available For Sale Securities Debt Maturities After Five Years Amortized Cost</link:label>
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_documentation_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">This item represents debt securities, at cost, net of adjustments made for accretion, amortization, other-than-temporary impairments, and hedging, if any, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" xlink:href="biib-20200930.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" xlink:to="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_TGNMember_8c5338a1-7745-4898-80a4-6e9e2359b73f_terseLabel_en-US" xlink:label="lab_biib_TGNMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TGN [Member]</link:label>
    <link:label id="lab_biib_TGNMember_label_en-US" xlink:label="lab_biib_TGNMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TGN [Member]</link:label>
    <link:label id="lab_biib_TGNMember_documentation_en-US" xlink:label="lab_biib_TGNMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TGN</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TGNMember" xlink:href="biib-20200930.xsd#biib_TGNMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TGNMember" xlink:to="lab_biib_TGNMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ExpenseIncurredByCollaboration_a91dead2-6947-4fd8-8124-1bd7cf1a5fc2_terseLabel_en-US" xlink:label="lab_biib_ExpenseIncurredByCollaboration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense Incurred By Collaboration</link:label>
    <link:label id="lab_biib_ExpenseIncurredByCollaboration_label_en-US" xlink:label="lab_biib_ExpenseIncurredByCollaboration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense Incurred By Collaboration</link:label>
    <link:label id="lab_biib_ExpenseIncurredByCollaboration_documentation_en-US" xlink:label="lab_biib_ExpenseIncurredByCollaboration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total expense incurred by collaboration.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ExpenseIncurredByCollaboration" xlink:href="biib-20200930.xsd#biib_ExpenseIncurredByCollaboration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ExpenseIncurredByCollaboration" xlink:to="lab_biib_ExpenseIncurredByCollaboration" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_RegulatoryMilestonesMember_d2760cd1-7e3c-4bab-9362-b74952b7e618_terseLabel_en-US" xlink:label="lab_biib_RegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory Milestones [Member]</link:label>
    <link:label id="lab_biib_RegulatoryMilestonesMember_label_en-US" xlink:label="lab_biib_RegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory Milestones [Member]</link:label>
    <link:label id="lab_biib_RegulatoryMilestonesMember_documentation_en-US" xlink:label="lab_biib_RegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory Milestones [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RegulatoryMilestonesMember" xlink:href="biib-20200930.xsd#biib_RegulatoryMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RegulatoryMilestonesMember" xlink:to="lab_biib_RegulatoryMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_16ae17d7-e94a-4d4d-908b-c082e0fbf243_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of significant accounting policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_bd3747f6-2986-40c0-b51d-c804c119070f_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Expense included in consolidated statements of income</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DividendYieldPercentage_f7bfca2c-3d47-4b7d-86c9-3e646bb01a98_terseLabel_en-US" xlink:label="lab_biib_DividendYieldPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend yield percentage</link:label>
    <link:label id="lab_biib_DividendYieldPercentage_label_en-US" xlink:label="lab_biib_DividendYieldPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend Yield Percentage</link:label>
    <link:label id="lab_biib_DividendYieldPercentage_documentation_en-US" xlink:label="lab_biib_DividendYieldPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend Yield Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DividendYieldPercentage" xlink:href="biib-20200930.xsd#biib_DividendYieldPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DividendYieldPercentage" xlink:to="lab_biib_DividendYieldPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoriesMember_f2199798-4ad6-4d84-bee3-3c433048e642_terseLabel_en-US" xlink:label="lab_us-gaap_InventoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoriesMember_label_en-US" xlink:label="lab_us-gaap_InventoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoriesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoriesMember" xlink:to="lab_us-gaap_InventoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_602a68e5-35fa-4cf6-8581-8618256eb466_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of post-combination equity compensation</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_fe36d740-9773-4735-b789-0e27a09156b5_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NST stock options</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Separately Recognized Transactions, Expenses and Losses Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" xlink:to="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_fdd90d6b-ba47-4c47-9770-018a4a93032c_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_29f522e8-9586-49d1-b7be-d45b44002126_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gains (losses) on securities available for sale, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_07ab9dc1-016b-49bd-a305-ab025a270e16_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_f6c3e46d-2e28-4112-993e-aff72e1814ab_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_7e5f04c6-f9b4-4db9-847a-9f9c5d9d427d_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cost and expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_db8341c5-0959-47bf-bd99-b65e243236a6_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_26f715fe-3c39-4b35-b504-77ceeeb1f3e5_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset impairment charges</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges" xlink:to="lab_us-gaap_AssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_a0bac274-c941-44cb-b377-aff93fc724d7_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instruments, fair value</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValue" xlink:to="lab_us-gaap_DebtInstrumentFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_e26987a7-2e7e-4f15-8965-afac56ce59d2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_571a7441-70ab-4b7f-a696-c54180c23978_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments related to issuance of stock for share-based compensation arrangements, net</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_ea16d5f1-18b3-4910-a399-1d2729956904_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5d0c47c2-d28d-4456-9bef-19691f99ad67_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_c720b863-f443-4cac-a95b-92d23163118c_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets_c5b9ef09-ac88-4d5a-8c70-8a005b5441d4_terseLabel_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Licensing Collaboration Agreement, Payment, Selection of Targets</link:label>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets_label_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Licensing Collaboration Agreement, Payment, Selection of Targets</link:label>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets_documentation_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Licensing Collaboration Agreement, Payment, Selection of Targets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets" xlink:href="biib-20200930.xsd#biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets" xlink:to="lab_biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_InventoryrawmaterialssoldtoFUJIFILM_0bb48724-fee5-434e-ab4e-10d0752b658a_terseLabel_en-US" xlink:label="lab_biib_InventoryrawmaterialssoldtoFUJIFILM" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory raw materials sold to FUJIFILM</link:label>
    <link:label id="lab_biib_InventoryrawmaterialssoldtoFUJIFILM_label_en-US" xlink:label="lab_biib_InventoryrawmaterialssoldtoFUJIFILM" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory raw materials sold to FUJIFILM</link:label>
    <link:label id="lab_biib_InventoryrawmaterialssoldtoFUJIFILM_documentation_en-US" xlink:label="lab_biib_InventoryrawmaterialssoldtoFUJIFILM" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory raw materials sold to FUJIFILM</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InventoryrawmaterialssoldtoFUJIFILM" xlink:href="biib-20200930.xsd#biib_InventoryrawmaterialssoldtoFUJIFILM"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InventoryrawmaterialssoldtoFUJIFILM" xlink:to="lab_biib_InventoryrawmaterialssoldtoFUJIFILM" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_02530210-81fd-4a74-aba3-aaf7b9cd8371_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of contingent consideration obligations</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_534872b0-a9cd-4084-8c78-5660d59c3ffd_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In-process research and development</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_a4888a46-8e0e-45cf-998b-9fd19c6ed8f5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife_5711c8c8-c566-4d69-bed6-ae394cf4e0b7_terseLabel_en-US" xlink:label="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite lived intangible assets useful life</link:label>
    <link:label id="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife_label_en-US" xlink:label="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite Lived Intangible Assets Useful Life</link:label>
    <link:label id="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife_documentation_en-US" xlink:label="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite lived intangible assets useful life.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IndefiniteLivedIntangibleAssetsUsefulLife" xlink:href="biib-20200930.xsd#biib_IndefiniteLivedIntangibleAssetsUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IndefiniteLivedIntangibleAssetsUsefulLife" xlink:to="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_d51d1d34-5718-4bc4-a088-ed87ff1c3698_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_22ea015b-c4d1-40f5-a122-041c798a8d0c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyTable" xlink:to="lab_us-gaap_IncomeTaxContingencyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_086e2df8-93bc-46f5-81f1-27698644ce91_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0dec03e9-c63d-4745-84f0-76990690628f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CurrencyAxis_4b139a38-1dcb-4784-9ece-6b1c400fcccf_terseLabel_en-US" xlink:label="lab_srt_CurrencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency [Axis]</link:label>
    <link:label id="lab_srt_CurrencyAxis_label_en-US" xlink:label="lab_srt_CurrencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CurrencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CurrencyAxis" xlink:to="lab_srt_CurrencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_24883be5-7e9c-4db6-ac54-1932c41d5b4e_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable equity securities, gross unrealized gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_427d4c90-f25b-47c5-9b69-30c4de447074_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative contracts</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Contracts, Liability, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:to="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_71959c7a-52ea-4017-82f7-137258e77710_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BIIB111Member_a8bd9d11-3e43-4f21-931f-ef441c78f7d8_terseLabel_en-US" xlink:label="lab_biib_BIIB111Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BIIB111</link:label>
    <link:label id="lab_biib_BIIB111Member_label_en-US" xlink:label="lab_biib_BIIB111Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BIIB111 [Member]</link:label>
    <link:label id="lab_biib_BIIB111Member_documentation_en-US" xlink:label="lab_biib_BIIB111Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BIIB111 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BIIB111Member" xlink:href="biib-20200930.xsd#biib_BIIB111Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BIIB111Member" xlink:to="lab_biib_BIIB111Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_84e849fe-3a23-4f0e-885e-497341affc45_terseLabel_en-US" xlink:label="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in unrecognized tax benefits is reasonably possible</link:label>
    <link:label id="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_label_en-US" xlink:label="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in Unrecognized Tax Benefits is Reasonably Possible</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:to="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_d0aebd3e-4f77-47d6-ba26-5434262984f8_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_StrategicInvestmentPortfolio_d5b1d623-73fa-4238-a238-93e01f8ded5c_verboseLabel_en-US" xlink:label="lab_biib_StrategicInvestmentPortfolio" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strategic investment portfolio</link:label>
    <link:label id="lab_biib_StrategicInvestmentPortfolio_label_en-US" xlink:label="lab_biib_StrategicInvestmentPortfolio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strategic Investment Portfolio</link:label>
    <link:label id="lab_biib_StrategicInvestmentPortfolio_documentation_en-US" xlink:label="lab_biib_StrategicInvestmentPortfolio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strategic investment portfolio.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_StrategicInvestmentPortfolio" xlink:href="biib-20200930.xsd#biib_StrategicInvestmentPortfolio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_StrategicInvestmentPortfolio" xlink:to="lab_biib_StrategicInvestmentPortfolio" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DeferredTaxAssetsValueReductioninValue_53bb329e-b264-4cb9-a9d1-7ad86a1b29de_terseLabel_en-US" xlink:label="lab_biib_DeferredTaxAssetsValueReductioninValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets, decrease in value</link:label>
    <link:label id="lab_biib_DeferredTaxAssetsValueReductioninValue_label_en-US" xlink:label="lab_biib_DeferredTaxAssetsValueReductioninValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Value, Reduction in Value</link:label>
    <link:label id="lab_biib_DeferredTaxAssetsValueReductioninValue_documentation_en-US" xlink:label="lab_biib_DeferredTaxAssetsValueReductioninValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Value, Reduction in Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DeferredTaxAssetsValueReductioninValue" xlink:href="biib-20200930.xsd#biib_DeferredTaxAssetsValueReductioninValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DeferredTaxAssetsValueReductioninValue" xlink:to="lab_biib_DeferredTaxAssetsValueReductioninValue" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FLIXABIMember_b5249f34-c444-4b4a-ba87-df2b815c9e9e_terseLabel_en-US" xlink:label="lab_biib_FLIXABIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FLIXABI</link:label>
    <link:label id="lab_biib_FLIXABIMember_label_en-US" xlink:label="lab_biib_FLIXABIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FLIXABI [Member]</link:label>
    <link:label id="lab_biib_FLIXABIMember_documentation_en-US" xlink:label="lab_biib_FLIXABIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FLIXABI [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FLIXABIMember" xlink:href="biib-20200930.xsd#biib_FLIXABIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FLIXABIMember" xlink:to="lab_biib_FLIXABIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_b877873d-a69a-4c27-bc96-ac4d3cff1280_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis" xlink:to="lab_us-gaap_HedgingDesignationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BIIB112Member_d01dde9c-6cd0-42d3-a157-bd5c8c37da1e_terseLabel_en-US" xlink:label="lab_biib_BIIB112Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BIIB112</link:label>
    <link:label id="lab_biib_BIIB112Member_label_en-US" xlink:label="lab_biib_BIIB112Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BIIB112 [Member]</link:label>
    <link:label id="lab_biib_BIIB112Member_documentation_en-US" xlink:label="lab_biib_BIIB112Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BIIB112 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BIIB112Member" xlink:href="biib-20200930.xsd#biib_BIIB112Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BIIB112Member" xlink:to="lab_biib_BIIB112Member" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DuefromantiCD20therapeuticprograms_fff8510b-32ad-44db-99da-c1ee3738fd7f_verboseLabel_en-US" xlink:label="lab_biib_DuefromantiCD20therapeuticprograms" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_DuefromantiCD20therapeuticprograms_label_en-US" xlink:label="lab_biib_DuefromantiCD20therapeuticprograms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_DuefromantiCD20therapeuticprograms_documentation_en-US" xlink:label="lab_biib_DuefromantiCD20therapeuticprograms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable from anti-CD20 therapeutic programs for our share of the pre-tax co-promotion profits generated from our co-promotion arrangement for sales of RITUXAN.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DuefromantiCD20therapeuticprograms" xlink:href="biib-20200930.xsd#biib_DuefromantiCD20therapeuticprograms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DuefromantiCD20therapeuticprograms" xlink:to="lab_biib_DuefromantiCD20therapeuticprograms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_802efa77-ef23-4125-812e-c903a4441389_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_4d775114-e8fc-42bf-b7e2-adb3f4b9986d_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_4a3aff80-4eed-4401-a5f7-6f487f3dcc63_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_db23fdc0-3fdc-4108-928a-6bd8f86e0171_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromDerivativeInstrumentFinancingActivities_9048f886-21b2-4b0a-83e3-9e1f79f83c0a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromDerivativeInstrumentFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash proceeds from settlement of swap</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromDerivativeInstrumentFinancingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromDerivativeInstrumentFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Derivative Instrument, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromDerivativeInstrumentFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForProceedsFromDerivativeInstrumentFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromDerivativeInstrumentFinancingActivities" xlink:to="lab_us-gaap_PaymentsForProceedsFromDerivativeInstrumentFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_13d290e6-5f9b-4bdd-920c-40616b44ed8a_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sales of strategic investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_ea58ecac-cb1c-4b30-8718-93f4ae4ef7c6_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of available-for-sale securities, equity</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Available-for-sale Securities, Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" xlink:to="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_afb37d36-199c-4afc-979d-7c20d9035856_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) recognized in net income, excluded component</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_9289efde-c1e4-48e1-8452-e5c17ea264d1_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Noncontrollinginterestincreasedecreaseother_4e2af46a-5ebe-4ff3-be37-fda77df4b795_terseLabel_en-US" xlink:label="lab_biib_Noncontrollinginterestincreasedecreaseother" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest, increase (decrease) other</link:label>
    <link:label id="lab_biib_Noncontrollinginterestincreasedecreaseother_label_en-US" xlink:label="lab_biib_Noncontrollinginterestincreasedecreaseother" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest, increase (decrease) other</link:label>
    <link:label id="lab_biib_Noncontrollinginterestincreasedecreaseother_documentation_en-US" xlink:label="lab_biib_Noncontrollinginterestincreasedecreaseother" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest, increase (decrease) other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Noncontrollinginterestincreasedecreaseother" xlink:href="biib-20200930.xsd#biib_Noncontrollinginterestincreasedecreaseother"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Noncontrollinginterestincreasedecreaseother" xlink:to="lab_biib_Noncontrollinginterestincreasedecreaseother" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_30963956-fbee-4369-ae7c-aa628627111e_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type Categorization [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5abac1f7-3c2b-4235-b88d-182b7e2a933e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_8a749dc0-0df5-405b-89f2-fadbaab61d92_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FacilityLocationAxis_764b3b1d-0c20-4474-999e-ab6a54567c26_terseLabel_en-US" xlink:label="lab_biib_FacilityLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Location [Axis]</link:label>
    <link:label id="lab_biib_FacilityLocationAxis_label_en-US" xlink:label="lab_biib_FacilityLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Location [Axis]</link:label>
    <link:label id="lab_biib_FacilityLocationAxis_documentation_en-US" xlink:label="lab_biib_FacilityLocationAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">-- None. No documentation exists for this element. --</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityLocationAxis" xlink:href="biib-20200930.xsd#biib_FacilityLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FacilityLocationAxis" xlink:to="lab_biib_FacilityLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_c154f462-1ecc-4237-a8b0-3101e79ffd45_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_e09da7c8-88e9-4879-97d3-b0cb8a0640de_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation between the U.S. federal statutory tax rate and effective tax rate</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_f32adf26-a4d6-44df-991f-8803a8c977e0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:to="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_5cf03ad6-bd8e-4c96-ac12-bff1d3ca62da_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value $0.0005 per share</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_e9b7d3ed-f3f8-4c56-988b-6c54b895d3a7_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes on foreign earnings</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNetAbstract_8853f0cb-328a-4518-b250-c24bc6b9f0b2_verboseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNetAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income (Expense), Net</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNetAbstract_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income (Expense), Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNetAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestIncomeExpenseNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract" xlink:to="lab_us-gaap_InterestIncomeExpenseNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_7d938270-a468-4bd3-b7e1-3f1355e1e20f_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DeferredtaxliabilityMember_9908bfe6-0a55-4c4b-8055-c7b896e14234_terseLabel_en-US" xlink:label="lab_biib_DeferredtaxliabilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liability</link:label>
    <link:label id="lab_biib_DeferredtaxliabilityMember_label_en-US" xlink:label="lab_biib_DeferredtaxliabilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liability [Member]</link:label>
    <link:label id="lab_biib_DeferredtaxliabilityMember_documentation_en-US" xlink:label="lab_biib_DeferredtaxliabilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liability [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DeferredtaxliabilityMember" xlink:href="biib-20200930.xsd#biib_DeferredtaxliabilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DeferredtaxliabilityMember" xlink:to="lab_biib_DeferredtaxliabilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_645b41b6-81db-4af9-adae-09cfe7bc8753_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_9f3944df-b522-44cf-bd06-b86721ba95ca_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_8e6e631f-20f0-4902-94be-2ed5e063711d_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_88f255df-4cd1-4af9-b02e-e6385039be19_terseLabel_en-US" xlink:label="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated additional payments upon achievement of development and commercial milestones</link:label>
    <link:label id="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_label_en-US" xlink:label="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Additional Payments Upon Achievement Of Development And Commercial Milestones</link:label>
    <link:label id="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_documentation_en-US" xlink:label="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated additional payments upon achievement of development and commercial milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" xlink:href="biib-20200930.xsd#biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" xlink:to="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_c3d8b6eb-4eef-4ab1-b22c-b571b3618c19_verboseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock units</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyMember_a90d464e-0c93-46de-87f8-ad9d07fe74f1_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty</link:label>
    <link:label id="lab_us-gaap_RoyaltyMember_label_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyMember" xlink:to="lab_us-gaap_RoyaltyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_921a0e81-8b70-47f4-9421-f998a634f1a7_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of roll forward of the changes in goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityOther_c1da7293-92b1-4635-95c1-559cbbc7b1ca_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityOther_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityOther" xlink:to="lab_us-gaap_StockholdersEquityOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_840666a8-f081-4259-9c51-01770ad0a692_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic earnings per share attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_8e325b95-4935-4a5a-8724-4effc1b63c4b_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average number of common shares outstanding</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_84feb369-220a-408a-800b-82133330a214_verboseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative and Other Relationships</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_a4b4cbe5-317c-487c-b96a-e6466d8c8764_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_a0ab7cc1-b29a-4499-861b-bc58f2f4c5ba_terseLabel_en-US" xlink:label="lab_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization and impairment of acquired intangible assets</link:label>
    <link:label id="lab_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_label_en-US" xlink:label="lab_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization and Impairment of Acquired Intangible Assets</link:label>
    <link:label id="lab_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_documentation_en-US" xlink:label="lab_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization and Impairment of Acquired Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets" xlink:href="biib-20200930.xsd#biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets" xlink:to="lab_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_49e78640-92a9-4950-a70d-1fb0604ac9a3_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Nonoperating Income (Expense) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_d31f8cee-25f5-4dcf-b339-74ee9300636d_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressGross" xlink:to="lab_us-gaap_ConstructionInProgressGross" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_MSProductRevenuesMember_ea3e5bb6-b311-40ae-ae8d-881cbb40e221_terseLabel_en-US" xlink:label="lab_biib_MSProductRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MS Product Revenues</link:label>
    <link:label id="lab_biib_MSProductRevenuesMember_label_en-US" xlink:label="lab_biib_MSProductRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MS Product Revenues [Member]</link:label>
    <link:label id="lab_biib_MSProductRevenuesMember_documentation_en-US" xlink:label="lab_biib_MSProductRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MS Product Revenues [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MSProductRevenuesMember" xlink:href="biib-20200930.xsd#biib_MSProductRevenuesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MSProductRevenuesMember" xlink:to="lab_biib_MSProductRevenuesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_a0625604-7abe-4ae6-9f94-5c31a540ad88_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_ba74a44d-4a93-4dd2-9b59-9d06f634ed21_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Contractual Maturities: Available-for-Sale Securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities, Debt Maturities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_773544e7-3335-4360-8492-1687d7fb56c6_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to acquire additional investment in equity method investment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_8174bd46-a58b-43a2-9360-5f7eea63bbf0_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of fair and carrying value of debt instruments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_3f0992e2-9061-466d-86bc-5494a9c5eafb_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Biogen Inc. shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenseMember_a06324c8-e93e-482b-95d1-9d1d74d94fb8_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expense</link:label>
    <link:label id="lab_us-gaap_OperatingExpenseMember_label_en-US" xlink:label="lab_us-gaap_OperatingExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenseMember" xlink:to="lab_us-gaap_OperatingExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ResearchanddevelopmentassetAxis_0b028ea9-c6fc-4e68-99ae-28945f169606_terseLabel_en-US" xlink:label="lab_biib_ResearchanddevelopmentassetAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development asset [Axis]</link:label>
    <link:label id="lab_biib_ResearchanddevelopmentassetAxis_label_en-US" xlink:label="lab_biib_ResearchanddevelopmentassetAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development asset [Axis]</link:label>
    <link:label id="lab_biib_ResearchanddevelopmentassetAxis_documentation_en-US" xlink:label="lab_biib_ResearchanddevelopmentassetAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchanddevelopmentassetAxis" xlink:href="biib-20200930.xsd#biib_ResearchanddevelopmentassetAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ResearchanddevelopmentassetAxis" xlink:to="lab_biib_ResearchanddevelopmentassetAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_4198a66e-bc25-4076-8bd0-bff87d6d80d2_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization and impairment of acquired intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_e12ce60c-224f-4c2a-925f-69675c5f4143_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d15be2a5-d1d3-45dd-bb79-a51fb93c6b75_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_IncomeTaxExpenseReductioninDeferredTaxAssetsandLiabilitiesNet_dbffe545-da9b-405b-9ebc-80d5caf01d99_terseLabel_en-US" xlink:label="lab_biib_IncomeTaxExpenseReductioninDeferredTaxAssetsandLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense associated with reductions in deferred tax assets and liabilities</link:label>
    <link:label id="lab_biib_IncomeTaxExpenseReductioninDeferredTaxAssetsandLiabilitiesNet_label_en-US" xlink:label="lab_biib_IncomeTaxExpenseReductioninDeferredTaxAssetsandLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense, Reduction in Deferred Tax Assets and Liabilities, Net</link:label>
    <link:label id="lab_biib_IncomeTaxExpenseReductioninDeferredTaxAssetsandLiabilitiesNet_documentation_en-US" xlink:label="lab_biib_IncomeTaxExpenseReductioninDeferredTaxAssetsandLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense, Reduction in Deferred Tax Assets and Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IncomeTaxExpenseReductioninDeferredTaxAssetsandLiabilitiesNet" xlink:href="biib-20200930.xsd#biib_IncomeTaxExpenseReductioninDeferredTaxAssetsandLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IncomeTaxExpenseReductioninDeferredTaxAssetsandLiabilitiesNet" xlink:to="lab_biib_IncomeTaxExpenseReductioninDeferredTaxAssetsandLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ContractManufacturingCustomerMember_eba9e7a9-479c-4958-b7f9-a062c8be3fe8_terseLabel_en-US" xlink:label="lab_biib_ContractManufacturingCustomerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Manufacturing Customer</link:label>
    <link:label id="lab_biib_ContractManufacturingCustomerMember_label_en-US" xlink:label="lab_biib_ContractManufacturingCustomerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Manufacturing Customer [Member]</link:label>
    <link:label id="lab_biib_ContractManufacturingCustomerMember_documentation_en-US" xlink:label="lab_biib_ContractManufacturingCustomerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Manufacturing Customer [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ContractManufacturingCustomerMember" xlink:href="biib-20200930.xsd#biib_ContractManufacturingCustomerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ContractManufacturingCustomerMember" xlink:to="lab_biib_ContractManufacturingCustomerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_d61f8332-bafa-4923-b0f0-6c8961afbebc_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_43e36073-5ecd-47ab-9e27-1fac988ebe74_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_9c37f82c-95db-436c-a6cb-d80239f57eac_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_91afe58a-feb7-4788-9519-f3ba344a2f09_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Foreign Currency Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_786d1b3b-33a5-400b-ae9f-93e04dc9303f_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research and Development</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FAMPYRAMember_598c05b7-1e41-4533-8415-0f5633dda910_terseLabel_en-US" xlink:label="lab_biib_FAMPYRAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FAMPYRA</link:label>
    <link:label id="lab_biib_FAMPYRAMember_label_en-US" xlink:label="lab_biib_FAMPYRAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FAMPYRA [Member]</link:label>
    <link:label id="lab_biib_FAMPYRAMember_documentation_en-US" xlink:label="lab_biib_FAMPYRAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FAMPYRA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FAMPYRAMember" xlink:href="biib-20200930.xsd#biib_FAMPYRAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FAMPYRAMember" xlink:to="lab_biib_FAMPYRAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_2362dc61-49a6-4c09-a087-5efdfbb3c5a3_terseLabel_en-US" xlink:label="lab_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments By Consolidated And Nonconsolidated Entities [Axis]</link:label>
    <link:label id="lab_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_label_en-US" xlink:label="lab_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments By Consolidated And Nonconsolidated Entities [Axis]</link:label>
    <link:label id="lab_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_documentation_en-US" xlink:label="lab_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments By Consolidated And Nonconsolidated Entities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis" xlink:href="biib-20200930.xsd#biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis" xlink:to="lab_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_d946665b-c8cf-4950-800c-7f6745cd4b4a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total purchase price</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_25d0a7d3-9be6-4011-98f0-529dfe84639d_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gains (losses) on cash flow hedges</link:label>
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:to="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_34ffd84d-b7f2-450f-8266-d128d73b22b1_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, amortization and impairments</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_41110d40-05a5-4f65-bfeb-28261f03913a_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_e0926d2b-dbfc-476f-b9c6-bc03569da292_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueHedgingMember_e3e089a8-4310-4984-9f9c-54df09f292b0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hedging [Member]</link:label>
    <link:label id="lab_us-gaap_FairValueHedgingMember_label_en-US" xlink:label="lab_us-gaap_FairValueHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueHedgingMember" xlink:to="lab_us-gaap_FairValueHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_4b152126-4359-47fa-bc18-3debef62ea83_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EisaiMember_ed2a3ae2-ef7a-46f7-80c3-1d22e78b3496_terseLabel_en-US" xlink:label="lab_biib_EisaiMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eisai</link:label>
    <link:label id="lab_biib_EisaiMember_label_en-US" xlink:label="lab_biib_EisaiMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eisai [Member]</link:label>
    <link:label id="lab_biib_EisaiMember_documentation_en-US" xlink:label="lab_biib_EisaiMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eisai [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EisaiMember" xlink:href="biib-20200930.xsd#biib_EisaiMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EisaiMember" xlink:to="lab_biib_EisaiMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementSharesPurchased_580864cf-a58d-49cd-9b4a-84781092fc69_terseLabel_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementSharesPurchased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Licensing Collaboration Agreement, Shares, Purchased</link:label>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementSharesPurchased_label_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementSharesPurchased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Licensing Collaboration Agreement, Shares, Purchased</link:label>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementSharesPurchased_documentation_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementSharesPurchased" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Licensing Collaboration Agreement, Shares, Purchased</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementSharesPurchased" xlink:href="biib-20200930.xsd#biib_GlobalLicensingCollaborationAgreementSharesPurchased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GlobalLicensingCollaborationAgreementSharesPurchased" xlink:to="lab_biib_GlobalLicensingCollaborationAgreementSharesPurchased" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_ae5ebdfa-6334-48c1-9c33-440f2f225944_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value $0.001 per share</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_b54569e4-edf9-4aca-a657-7516b5588241_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitment_87fc67f9-df0f-4075-862c-dc543f8f5c09_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual commitments for the construction of the facility</link:label>
    <link:label id="lab_us-gaap_OtherCommitment_label_en-US" xlink:label="lab_us-gaap_OtherCommitment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitment" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCommitment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitment" xlink:to="lab_us-gaap_OtherCommitment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_021461e4-5da1-4012-994e-25a82c2058c9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common stock, at cost</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_c1d10eb1-4856-407f-b484-2fe3ede32485_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AducanumabMember_30bc7989-6bef-4252-b136-2413ece025da_terseLabel_en-US" xlink:label="lab_biib_AducanumabMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aducanumab</link:label>
    <link:label id="lab_biib_AducanumabMember_label_en-US" xlink:label="lab_biib_AducanumabMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aducanumab [Member]</link:label>
    <link:label id="lab_biib_AducanumabMember_documentation_en-US" xlink:label="lab_biib_AducanumabMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aducanumab [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AducanumabMember" xlink:href="biib-20200930.xsd#biib_AducanumabMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AducanumabMember" xlink:to="lab_biib_AducanumabMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_396ca2bb-204e-4ffb-9de6-fdc10b8e67c3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liability</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DistributorOneMember_ab2932c1-1c6b-4ff8-b249-bbaf9d91a772_terseLabel_en-US" xlink:label="lab_biib_DistributorOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributor One</link:label>
    <link:label id="lab_biib_DistributorOneMember_label_en-US" xlink:label="lab_biib_DistributorOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributor One [Member]</link:label>
    <link:label id="lab_biib_DistributorOneMember_documentation_en-US" xlink:label="lab_biib_DistributorOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributor one.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DistributorOneMember" xlink:href="biib-20200930.xsd#biib_DistributorOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DistributorOneMember" xlink:to="lab_biib_DistributorOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill_72fe78ba-af7c-45e3-946c-3690d2d168fd_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities, goodwill</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_6df139a3-4465-4f49-82f5-e45be2adea55_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract_f43f5763-8625-46f7-a51f-8ad769e175f0_verboseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents, at Carrying Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract" xlink:to="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestments_e96db373-1780-467e-97b6-4a7586ed926e_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in Samsung Bioepis</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestments" xlink:to="lab_us-gaap_EquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_38215dd8-6929-47f5-8c5c-2c427541e4b1_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_c2552365-2e48-4c38-80da-c9497bc645c6_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_fab8a99d-d75e-4fb9-995a-a7b2c0028b5f_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Axis]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_ddac3366-408b-4e50-905e-4ef9c9cc6eae_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_97001ad2-a27c-48ba-9f45-1d7978fe5556_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash flows provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_da22df8a-4c04-4282-8b3a-4dec17e00ed3_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BasicAndDilutedEarningsPerShareAbstract_f7bf5316-4783-4fe1-8db5-9c52169cbf50_verboseLabel_en-US" xlink:label="lab_biib_BasicAndDilutedEarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and diluted earnings per share</link:label>
    <link:label id="lab_biib_BasicAndDilutedEarningsPerShareAbstract_label_en-US" xlink:label="lab_biib_BasicAndDilutedEarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic And Diluted Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_biib_BasicAndDilutedEarningsPerShareAbstract_documentation_en-US" xlink:label="lab_biib_BasicAndDilutedEarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and diluted earnings per share.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BasicAndDilutedEarningsPerShareAbstract" xlink:href="biib-20200930.xsd#biib_BasicAndDilutedEarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract" xlink:to="lab_biib_BasicAndDilutedEarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_666247ad-0dbf-4933-bff4-bfefe507bf40_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_label_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingRelationshipDomain" xlink:to="lab_us-gaap_HedgingRelationshipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_badb5e59-86d3-4172-a167-dfe0486d0cf8_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_8bbd4481-0a90-4c16-a26b-bf2a0f1172ab_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Component of accrued expenses and other</link:label>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_2a476f1a-799a-4e7c-a1f8-7a08bf789701_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts_85665986-bef6-4ca8-9508-78c2a70ed202_terseLabel_en-US" xlink:label="lab_biib_EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of early call premium and write off of remaining unamortized debt issuance costs</link:label>
    <link:label id="lab_biib_EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts_label_en-US" xlink:label="lab_biib_EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Early Call Premium and Write off of Remaining Unamortized Debt Issuance Costs</link:label>
    <link:label id="lab_biib_EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts_documentation_en-US" xlink:label="lab_biib_EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Early Call Premium and Write off of Remaining Unamortized Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts" xlink:href="biib-20200930.xsd#biib_EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts" xlink:to="lab_biib_EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_aadf8c58-fcf5-4fca-a6c6-41fd423d85e2_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedging [Member]</link:label>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_label_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowHedgingMember" xlink:to="lab_us-gaap_CashFlowHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_b614094d-4c2e-438c-bb4c-df4cbfcc2b3e_verboseLabel_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes payable</link:label>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_label_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxesPayableCurrent" xlink:to="lab_us-gaap_TaxesPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_ed2a63e1-3728-4ac6-ac0c-64750a6eeedc_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_e67c4980-df69-4602-b945-1a020f37347f_verboseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government securities</link:label>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_label_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury and Government [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasuryAndGovernmentMember" xlink:to="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_ce2de326-f5ce-43df-b3e1-10f266a32424_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated impairment losses related to goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impaired, Accumulated Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_60abf4be-43aa-4adf-b664-66303e4bbd29_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after one year through five years, amortized cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after One Through Five Years, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_d87c9ee1-4bbf-48d1-babb-837bdd551536_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Additionalreductioninroyaltyratepayableoncommercialsales_785c7967-285d-4ee9-bb3b-86c9a51e0734_terseLabel_en-US" xlink:label="lab_biib_Additionalreductioninroyaltyratepayableoncommercialsales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional reduction in royalty rate payable on commercial sales</link:label>
    <link:label id="lab_biib_Additionalreductioninroyaltyratepayableoncommercialsales_label_en-US" xlink:label="lab_biib_Additionalreductioninroyaltyratepayableoncommercialsales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional reduction in royalty rate payable on commercial sales</link:label>
    <link:label id="lab_biib_Additionalreductioninroyaltyratepayableoncommercialsales_documentation_en-US" xlink:label="lab_biib_Additionalreductioninroyaltyratepayableoncommercialsales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional reduction in royalty rate payable on commercial sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Additionalreductioninroyaltyratepayableoncommercialsales" xlink:href="biib-20200930.xsd#biib_Additionalreductioninroyaltyratepayableoncommercialsales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Additionalreductioninroyaltyratepayableoncommercialsales" xlink:to="lab_biib_Additionalreductioninroyaltyratepayableoncommercialsales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NondesignatedMember_3bffc83d-f3cb-48f1-be76-8704978f2e2c_terseLabel_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not designated as hedging instrument</link:label>
    <link:label id="lab_us-gaap_NondesignatedMember_label_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NondesignatedMember" xlink:to="lab_us-gaap_NondesignatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_2355a99b-dab2-4df7-9aa8-ebe10549b10b_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_928cfacf-efed-4d61-9455-23a7902c5e59_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_392bf321-58bc-497e-9690-70e3f35f4803_terseLabel_en-US" xlink:label="lab_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains (losses) on net investment hedge, excluded component</link:label>
    <link:label id="lab_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_label_en-US" xlink:label="lab_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives used in net investment hedge, net of tax, excluded component increase (decrease)</link:label>
    <link:label id="lab_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_documentation_en-US" xlink:label="lab_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives used in net investment hedge, net of tax, excluded component increase (decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" xlink:href="biib-20200930.xsd#biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" xlink:to="lab_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_NumberOfNeurologicalDiseaseTargets_ae221877-a97c-4689-9ea6-c49d42eb0b6f_terseLabel_en-US" xlink:label="lab_biib_NumberOfNeurologicalDiseaseTargets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of neurological disease targets</link:label>
    <link:label id="lab_biib_NumberOfNeurologicalDiseaseTargets_label_en-US" xlink:label="lab_biib_NumberOfNeurologicalDiseaseTargets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Neurological Disease Targets</link:label>
    <link:label id="lab_biib_NumberOfNeurologicalDiseaseTargets_documentation_en-US" xlink:label="lab_biib_NumberOfNeurologicalDiseaseTargets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Neurological Disease Targets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NumberOfNeurologicalDiseaseTargets" xlink:href="biib-20200930.xsd#biib_NumberOfNeurologicalDiseaseTargets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NumberOfNeurologicalDiseaseTargets" xlink:to="lab_biib_NumberOfNeurologicalDiseaseTargets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_037cb06a-13c9-463b-b6d3-800e610a32d7_verboseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Variable Interest Entities</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableInterestEntityDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:to="lab_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_4be1b700-26b1-49f5-ae02-5ca46d7eb8d2_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative asset, fair value</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Fair Value, Gross Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_a0c2bbdc-7f82-4b8d-91a7-2aa8bf5995dd_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Revenuesfromanticd20therapeuticprogramsMember_539a5aa2-1b7c-492f-a6b4-3d06cb6ecdaa_terseLabel_en-US" xlink:label="lab_biib_Revenuesfromanticd20therapeuticprogramsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_Revenuesfromanticd20therapeuticprogramsMember_label_en-US" xlink:label="lab_biib_Revenuesfromanticd20therapeuticprogramsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from anti-cd20 therapeutic programs [Member]</link:label>
    <link:label id="lab_biib_Revenuesfromanticd20therapeuticprogramsMember_documentation_en-US" xlink:label="lab_biib_Revenuesfromanticd20therapeuticprogramsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from anti-cd20 therapeutic programs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Revenuesfromanticd20therapeuticprogramsMember" xlink:href="biib-20200930.xsd#biib_Revenuesfromanticd20therapeuticprogramsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Revenuesfromanticd20therapeuticprogramsMember" xlink:to="lab_biib_Revenuesfromanticd20therapeuticprogramsMember" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>biib-20200930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:9d882161-cc57-4e82-9994-8001479894f6,g:a7b2bacf-5ee2-4f5b-9f49-a40e24a2538c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.biogenidec.com/role/CoverPage" xlink:type="simple" xlink:href="biib-20200930.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_aa5c5cc3-9a03-43eb-9984-9c0beebe2523" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_2f120a6e-9051-413f-b665-ba1ece360ec8" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa5c5cc3-9a03-43eb-9984-9c0beebe2523" xlink:to="loc_dei_DocumentType_2f120a6e-9051-413f-b665-ba1ece360ec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_f62bcbe7-8ed8-453d-9dfc-9e21594fce0c" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa5c5cc3-9a03-43eb-9984-9c0beebe2523" xlink:to="loc_dei_DocumentQuarterlyReport_f62bcbe7-8ed8-453d-9dfc-9e21594fce0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_7e70aa1d-53c8-4ec8-b0c6-f9d623e60123" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa5c5cc3-9a03-43eb-9984-9c0beebe2523" xlink:to="loc_dei_DocumentPeriodEndDate_7e70aa1d-53c8-4ec8-b0c6-f9d623e60123" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_76ac0e6f-cdf1-4dd3-b0e7-3bb844b8761f" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa5c5cc3-9a03-43eb-9984-9c0beebe2523" xlink:to="loc_dei_DocumentTransitionReport_76ac0e6f-cdf1-4dd3-b0e7-3bb844b8761f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_1651e1f5-102b-4b57-baff-65aec56dd829" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa5c5cc3-9a03-43eb-9984-9c0beebe2523" xlink:to="loc_dei_EntityFileNumber_1651e1f5-102b-4b57-baff-65aec56dd829" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_051ccd1a-f150-4d80-860d-e8987638fde1" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa5c5cc3-9a03-43eb-9984-9c0beebe2523" xlink:to="loc_dei_EntityRegistrantName_051ccd1a-f150-4d80-860d-e8987638fde1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_cc7f1d60-dca8-499b-bf56-1d5ea4e992fb" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa5c5cc3-9a03-43eb-9984-9c0beebe2523" xlink:to="loc_dei_EntityCentralIndexKey_cc7f1d60-dca8-499b-bf56-1d5ea4e992fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_0ab95b6a-ccdb-4f4d-999a-a5b6188ad0a1" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa5c5cc3-9a03-43eb-9984-9c0beebe2523" xlink:to="loc_dei_CurrentFiscalYearEndDate_0ab95b6a-ccdb-4f4d-999a-a5b6188ad0a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_a4c55a50-f375-4e25-8d96-58b2076645a3" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa5c5cc3-9a03-43eb-9984-9c0beebe2523" xlink:to="loc_dei_DocumentFiscalYearFocus_a4c55a50-f375-4e25-8d96-58b2076645a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_7cb0be76-1946-4560-8a35-617936207d58" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa5c5cc3-9a03-43eb-9984-9c0beebe2523" xlink:to="loc_dei_DocumentFiscalPeriodFocus_7cb0be76-1946-4560-8a35-617936207d58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_88187929-4532-4ba0-91be-f42670db56f7" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa5c5cc3-9a03-43eb-9984-9c0beebe2523" xlink:to="loc_dei_AmendmentFlag_88187929-4532-4ba0-91be-f42670db56f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_b7d4d25c-eeba-46bf-8d5f-a700890887df" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa5c5cc3-9a03-43eb-9984-9c0beebe2523" xlink:to="loc_dei_EntityIncorporationStateCountryCode_b7d4d25c-eeba-46bf-8d5f-a700890887df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_3b248c45-d620-4397-aae6-9ec590316d93" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa5c5cc3-9a03-43eb-9984-9c0beebe2523" xlink:to="loc_dei_EntityTaxIdentificationNumber_3b248c45-d620-4397-aae6-9ec590316d93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_30a4d551-d903-44fb-ab10-221bffaa1441" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa5c5cc3-9a03-43eb-9984-9c0beebe2523" xlink:to="loc_dei_EntityAddressAddressLine1_30a4d551-d903-44fb-ab10-221bffaa1441" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_be88082f-3375-4972-80b1-bc514f95833b" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa5c5cc3-9a03-43eb-9984-9c0beebe2523" xlink:to="loc_dei_EntityAddressCityOrTown_be88082f-3375-4972-80b1-bc514f95833b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_a12ff062-768d-47ee-9a23-68a055eb5869" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa5c5cc3-9a03-43eb-9984-9c0beebe2523" xlink:to="loc_dei_EntityAddressStateOrProvince_a12ff062-768d-47ee-9a23-68a055eb5869" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_c8f1d90b-da4f-4f21-9ae2-40588faf5893" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa5c5cc3-9a03-43eb-9984-9c0beebe2523" xlink:to="loc_dei_EntityAddressPostalZipCode_c8f1d90b-da4f-4f21-9ae2-40588faf5893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_5af6fbec-6302-4db9-8985-22391adc03fc" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa5c5cc3-9a03-43eb-9984-9c0beebe2523" xlink:to="loc_dei_CityAreaCode_5af6fbec-6302-4db9-8985-22391adc03fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_4019f8f3-cb3c-439e-888c-7fa3486a0e7c" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa5c5cc3-9a03-43eb-9984-9c0beebe2523" xlink:to="loc_dei_LocalPhoneNumber_4019f8f3-cb3c-439e-888c-7fa3486a0e7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_cedd3d36-83f9-41ed-883e-e98094605f74" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa5c5cc3-9a03-43eb-9984-9c0beebe2523" xlink:to="loc_dei_Security12bTitle_cedd3d36-83f9-41ed-883e-e98094605f74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_ed0a21c9-b5b8-4122-a40d-a6328496a573" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa5c5cc3-9a03-43eb-9984-9c0beebe2523" xlink:to="loc_dei_TradingSymbol_ed0a21c9-b5b8-4122-a40d-a6328496a573" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_cede3b74-ee97-43fc-adfe-251eb4f5b0c9" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa5c5cc3-9a03-43eb-9984-9c0beebe2523" xlink:to="loc_dei_SecurityExchangeName_cede3b74-ee97-43fc-adfe-251eb4f5b0c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_d0d8ba65-e4fe-4ad9-a08b-115e219bc683" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa5c5cc3-9a03-43eb-9984-9c0beebe2523" xlink:to="loc_dei_EntityCurrentReportingStatus_d0d8ba65-e4fe-4ad9-a08b-115e219bc683" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_9c40d1ce-d4b1-41db-b217-f0a0055a1d2f" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa5c5cc3-9a03-43eb-9984-9c0beebe2523" xlink:to="loc_dei_EntityInteractiveDataCurrent_9c40d1ce-d4b1-41db-b217-f0a0055a1d2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_6680de15-81c6-4b4f-99dc-2f0c05875373" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa5c5cc3-9a03-43eb-9984-9c0beebe2523" xlink:to="loc_dei_EntityFilerCategory_6680de15-81c6-4b4f-99dc-2f0c05875373" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_fde2d081-d21e-42f2-8093-fd6476a5f053" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa5c5cc3-9a03-43eb-9984-9c0beebe2523" xlink:to="loc_dei_EntitySmallBusiness_fde2d081-d21e-42f2-8093-fd6476a5f053" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_169705e0-c009-4ad8-ad6d-c36e8444c3ee" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa5c5cc3-9a03-43eb-9984-9c0beebe2523" xlink:to="loc_dei_EntityEmergingGrowthCompany_169705e0-c009-4ad8-ad6d-c36e8444c3ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_bb34816c-30c9-4e85-9359-4ba90e5cf4df" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa5c5cc3-9a03-43eb-9984-9c0beebe2523" xlink:to="loc_dei_EntityShellCompany_bb34816c-30c9-4e85-9359-4ba90e5cf4df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_75118a44-8a1d-4e9a-9e6c-67a559c7bc28" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa5c5cc3-9a03-43eb-9984-9c0beebe2523" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_75118a44-8a1d-4e9a-9e6c-67a559c7bc28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" xlink:type="simple" xlink:href="biib-20200930.xsd#CondensedConsolidatedStatementsofIncomeUnaudited"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_2d9a2bb7-851b-4073-b1a1-cc1580d09454" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_872706bf-5053-49d8-a9a5-ed00742a6e6c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2d9a2bb7-851b-4073-b1a1-cc1580d09454" xlink:to="loc_us-gaap_StatementTable_872706bf-5053-49d8-a9a5-ed00742a6e6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_dfff9cd9-f57c-4345-bb37-89faf2ece32f" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_872706bf-5053-49d8-a9a5-ed00742a6e6c" xlink:to="loc_srt_ProductOrServiceAxis_dfff9cd9-f57c-4345-bb37-89faf2ece32f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7008196e-fa16-4c11-8177-071b405a016a" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_dfff9cd9-f57c-4345-bb37-89faf2ece32f" xlink:to="loc_srt_ProductsAndServicesDomain_7008196e-fa16-4c11-8177-071b405a016a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_2b8f0b43-d23a-4a82-9985-8ce9446b54f2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7008196e-fa16-4c11-8177-071b405a016a" xlink:to="loc_us-gaap_ProductMember_2b8f0b43-d23a-4a82-9985-8ce9446b54f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_8bf97757-2862-4188-a7d5-f07898e569c6" xlink:href="biib-20200930.xsd#biib_Revenuesfromanticd20therapeuticprogramsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7008196e-fa16-4c11-8177-071b405a016a" xlink:to="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_8bf97757-2862-4188-a7d5-f07898e569c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_91756964-4ee1-465a-9d44-a13a01ce71a6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7008196e-fa16-4c11-8177-071b405a016a" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_91756964-4ee1-465a-9d44-a13a01ce71a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_01d2b5a1-e886-42a0-ab31-8cd8ff6d29d2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_872706bf-5053-49d8-a9a5-ed00742a6e6c" xlink:to="loc_us-gaap_StatementLineItems_01d2b5a1-e886-42a0-ab31-8cd8ff6d29d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_b862eae0-e8fa-4f3b-af03-eb008bd2d790" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_01d2b5a1-e886-42a0-ab31-8cd8ff6d29d2" xlink:to="loc_us-gaap_Revenues_b862eae0-e8fa-4f3b-af03-eb008bd2d790" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_15c4f0f1-0b94-4497-b92f-9f5a7ac4daad" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_01d2b5a1-e886-42a0-ab31-8cd8ff6d29d2" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_15c4f0f1-0b94-4497-b92f-9f5a7ac4daad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_d3878afa-bf29-40d1-96e1-d3f4cef3059c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_15c4f0f1-0b94-4497-b92f-9f5a7ac4daad" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_d3878afa-bf29-40d1-96e1-d3f4cef3059c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_32d9de08-fa9b-41bc-8b15-dbfa20787732" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_15c4f0f1-0b94-4497-b92f-9f5a7ac4daad" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_32d9de08-fa9b-41bc-8b15-dbfa20787732" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_10dd93ef-6f1a-42e4-a767-dc74c18d5bbf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_15c4f0f1-0b94-4497-b92f-9f5a7ac4daad" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_10dd93ef-6f1a-42e4-a767-dc74c18d5bbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_914d210a-a91c-4805-b0de-91fc4a52fe52" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_15c4f0f1-0b94-4497-b92f-9f5a7ac4daad" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_914d210a-a91c-4805-b0de-91fc4a52fe52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Collaborationprofitlosssharing_7b1dd1f4-96b2-4de5-bfd2-eaeaa45f6b04" xlink:href="biib-20200930.xsd#biib_Collaborationprofitlosssharing"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_15c4f0f1-0b94-4497-b92f-9f5a7ac4daad" xlink:to="loc_biib_Collaborationprofitlosssharing_7b1dd1f4-96b2-4de5-bfd2-eaeaa45f6b04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_63e7f217-5c15-4e01-8af6-06aeb794fd51" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_15c4f0f1-0b94-4497-b92f-9f5a7ac4daad" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_63e7f217-5c15-4e01-8af6-06aeb794fd51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_996783e1-582a-4a75-8597-05626c17fb96" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_15c4f0f1-0b94-4497-b92f-9f5a7ac4daad" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_996783e1-582a-4a75-8597-05626c17fb96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_123a2ea1-4613-4c01-86a1-a2f476899286" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_15c4f0f1-0b94-4497-b92f-9f5a7ac4daad" xlink:to="loc_us-gaap_RestructuringCharges_123a2ea1-4613-4c01-86a1-a2f476899286" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_a9bdb091-f481-4b9f-ac6f-e6a03fe95aec" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_15c4f0f1-0b94-4497-b92f-9f5a7ac4daad" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_a9bdb091-f481-4b9f-ac6f-e6a03fe95aec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_6094e841-8ab6-4e94-b028-37f014302953" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_15c4f0f1-0b94-4497-b92f-9f5a7ac4daad" xlink:to="loc_us-gaap_CostsAndExpenses_6094e841-8ab6-4e94-b028-37f014302953" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_90d81cc2-7f23-48b5-b42f-b8a68990320f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_01d2b5a1-e886-42a0-ab31-8cd8ff6d29d2" xlink:to="loc_us-gaap_OperatingIncomeLoss_90d81cc2-7f23-48b5-b42f-b8a68990320f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_526ee37f-b126-4c9b-8ed0-6f696dcb35c2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_01d2b5a1-e886-42a0-ab31-8cd8ff6d29d2" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_526ee37f-b126-4c9b-8ed0-6f696dcb35c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_3043a5b2-aab6-483b-9c6e-c00ae1bab953" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_01d2b5a1-e886-42a0-ab31-8cd8ff6d29d2" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_3043a5b2-aab6-483b-9c6e-c00ae1bab953" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_553ac61e-a8f3-4b8a-be1e-f76b035be0c8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_01d2b5a1-e886-42a0-ab31-8cd8ff6d29d2" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_553ac61e-a8f3-4b8a-be1e-f76b035be0c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax_7651b790-8d55-4f58-a6ee-e4f39bf4c6c8" xlink:href="biib-20200930.xsd#biib_IncomeLossFromEquityMethodInvestmentsNetOfTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_01d2b5a1-e886-42a0-ab31-8cd8ff6d29d2" xlink:to="loc_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax_7651b790-8d55-4f58-a6ee-e4f39bf4c6c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_22c50a0f-1129-4726-b2c0-07b4b2bddf89" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_01d2b5a1-e886-42a0-ab31-8cd8ff6d29d2" xlink:to="loc_us-gaap_ProfitLoss_22c50a0f-1129-4726-b2c0-07b4b2bddf89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_d7f06f26-684a-4cc6-9f8a-3b9f2185465e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_01d2b5a1-e886-42a0-ab31-8cd8ff6d29d2" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_d7f06f26-684a-4cc6-9f8a-3b9f2185465e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e707cfeb-bc67-4dc6-b635-5915c9ba4cf2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_01d2b5a1-e886-42a0-ab31-8cd8ff6d29d2" xlink:to="loc_us-gaap_NetIncomeLoss_e707cfeb-bc67-4dc6-b635-5915c9ba4cf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_1d9cc095-f10a-48f4-af8a-f24a3cdb4e9d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_01d2b5a1-e886-42a0-ab31-8cd8ff6d29d2" xlink:to="loc_us-gaap_EarningsPerShareAbstract_1d9cc095-f10a-48f4-af8a-f24a3cdb4e9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_c158fcd1-880c-463f-8df8-10ea02adc5ec" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1d9cc095-f10a-48f4-af8a-f24a3cdb4e9d" xlink:to="loc_us-gaap_EarningsPerShareBasic_c158fcd1-880c-463f-8df8-10ea02adc5ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_45596c54-5b47-437c-8adf-839ce6fedd06" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1d9cc095-f10a-48f4-af8a-f24a3cdb4e9d" xlink:to="loc_us-gaap_EarningsPerShareDiluted_45596c54-5b47-437c-8adf-839ce6fedd06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_e7ad4316-f31a-4a18-8f69-b82ed8f09448" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_01d2b5a1-e886-42a0-ab31-8cd8ff6d29d2" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_e7ad4316-f31a-4a18-8f69-b82ed8f09448" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7d32b1db-622b-4111-9971-306e0764ce68" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_e7ad4316-f31a-4a18-8f69-b82ed8f09448" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7d32b1db-622b-4111-9971-306e0764ce68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4f03ee70-ccc8-4d1d-8827-f9cd19a1cce0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_e7ad4316-f31a-4a18-8f69-b82ed8f09448" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4f03ee70-ccc8-4d1d-8827-f9cd19a1cce0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited" xlink:type="simple" xlink:href="biib-20200930.xsd#CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_e8e68007-f7eb-42b2-a304-622acd206d18" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7f94737b-dd2c-4320-ae10-e798d02663ea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_e8e68007-f7eb-42b2-a304-622acd206d18" xlink:to="loc_us-gaap_NetIncomeLoss_7f94737b-dd2c-4320-ae10-e798d02663ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_5242c66e-416e-4d4f-850f-aa27dc255676" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_e8e68007-f7eb-42b2-a304-622acd206d18" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_5242c66e-416e-4d4f-850f-aa27dc255676" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_0e7cfc9b-5845-4ad1-8dde-5cb91f111388" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_5242c66e-416e-4d4f-850f-aa27dc255676" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_0e7cfc9b-5845-4ad1-8dde-5cb91f111388" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_3633a6cb-bb1b-4a31-baff-77b5b097124f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_5242c66e-416e-4d4f-850f-aa27dc255676" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_3633a6cb-bb1b-4a31-baff-77b5b097124f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_89d27b02-eaa2-4522-b94c-9ec0f073b63f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_5242c66e-416e-4d4f-850f-aa27dc255676" xlink:to="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_89d27b02-eaa2-4522-b94c-9ec0f073b63f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_78792370-8540-4a85-b935-afd2b70014ac" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_5242c66e-416e-4d4f-850f-aa27dc255676" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_78792370-8540-4a85-b935-afd2b70014ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_ca43a128-96e9-49a1-a306-aa25fd71f56e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_5242c66e-416e-4d4f-850f-aa27dc255676" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_ca43a128-96e9-49a1-a306-aa25fd71f56e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_8e0d06f1-f014-4ae0-b938-590639e4df38" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_5242c66e-416e-4d4f-850f-aa27dc255676" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_8e0d06f1-f014-4ae0-b938-590639e4df38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_42c1a4f2-14e5-4d9f-8147-e8ee2fb59414" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_5242c66e-416e-4d4f-850f-aa27dc255676" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_42c1a4f2-14e5-4d9f-8147-e8ee2fb59414" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_ad16f164-3097-419f-89ed-2e83def123ff" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_5242c66e-416e-4d4f-850f-aa27dc255676" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_ad16f164-3097-419f-89ed-2e83def123ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_036178a9-b8d2-415b-b8e0-24bc51f2584e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_5242c66e-416e-4d4f-850f-aa27dc255676" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_036178a9-b8d2-415b-b8e0-24bc51f2584e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited_1" xlink:type="simple" xlink:href="biib-20200930.xsd#CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited_1"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" xlink:href="biib-20200930.xsd#CondensedConsolidatedBalanceSheetsUnaudited"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_dbc960db-af4f-4816-b9f5-972b0cdc3e7a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_efe773ed-18df-4066-bfa5-90208c4a0bc2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_dbc960db-af4f-4816-b9f5-972b0cdc3e7a" xlink:to="loc_us-gaap_AssetsAbstract_efe773ed-18df-4066-bfa5-90208c4a0bc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_56dec193-7e06-4f84-9e89-43678019be1c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_efe773ed-18df-4066-bfa5-90208c4a0bc2" xlink:to="loc_us-gaap_AssetsCurrentAbstract_56dec193-7e06-4f84-9e89-43678019be1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e113c88b-a2a3-493f-b284-143d4fa117ff" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_56dec193-7e06-4f84-9e89-43678019be1c" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e113c88b-a2a3-493f-b284-143d4fa117ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_d095de31-d917-4b49-9a46-a34ecbdfcc50" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_56dec193-7e06-4f84-9e89-43678019be1c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_d095de31-d917-4b49-9a46-a34ecbdfcc50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_70829ace-e2a2-4b6d-abb8-07b9a2a47f86" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_56dec193-7e06-4f84-9e89-43678019be1c" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_70829ace-e2a2-4b6d-abb8-07b9a2a47f86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DuefromantiCD20therapeuticprograms_4b87daf9-1af9-4db2-8f4d-b6bb942be8d5" xlink:href="biib-20200930.xsd#biib_DuefromantiCD20therapeuticprograms"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_56dec193-7e06-4f84-9e89-43678019be1c" xlink:to="loc_biib_DuefromantiCD20therapeuticprograms_4b87daf9-1af9-4db2-8f4d-b6bb942be8d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_a222c22a-e725-4bf3-a35f-e33a419c0f7b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_56dec193-7e06-4f84-9e89-43678019be1c" xlink:to="loc_us-gaap_InventoryNet_a222c22a-e725-4bf3-a35f-e33a419c0f7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_5bbf48ab-2669-4df2-8bd0-393aa14e8b80" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_56dec193-7e06-4f84-9e89-43678019be1c" xlink:to="loc_us-gaap_OtherAssetsCurrent_5bbf48ab-2669-4df2-8bd0-393aa14e8b80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_f0f25d39-fed4-490a-8e4a-3cf9b026993c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_56dec193-7e06-4f84-9e89-43678019be1c" xlink:to="loc_us-gaap_AssetsCurrent_f0f25d39-fed4-490a-8e4a-3cf9b026993c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_de162e49-8aa7-4e20-893e-30cbb0286131" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_efe773ed-18df-4066-bfa5-90208c4a0bc2" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_de162e49-8aa7-4e20-893e-30cbb0286131" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_afa77d12-35fd-4e48-b9ca-ebbc680451ef" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_efe773ed-18df-4066-bfa5-90208c4a0bc2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_afa77d12-35fd-4e48-b9ca-ebbc680451ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_66bc84a1-a7c4-4a7c-8e3f-90fb85acf2cb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_efe773ed-18df-4066-bfa5-90208c4a0bc2" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_66bc84a1-a7c4-4a7c-8e3f-90fb85acf2cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_0ae7139d-1adb-427e-b358-5bb14eb957e1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_efe773ed-18df-4066-bfa5-90208c4a0bc2" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_0ae7139d-1adb-427e-b358-5bb14eb957e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_a5c9f7a8-75f5-4a93-bb9a-4d415dc4fdc1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_efe773ed-18df-4066-bfa5-90208c4a0bc2" xlink:to="loc_us-gaap_Goodwill_a5c9f7a8-75f5-4a93-bb9a-4d415dc4fdc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_2794f5a0-b5eb-497e-a2ba-39de6bd5e81d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_efe773ed-18df-4066-bfa5-90208c4a0bc2" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_2794f5a0-b5eb-497e-a2ba-39de6bd5e81d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_a8b523f3-e49e-4a93-947e-f8cd91e486fe" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_efe773ed-18df-4066-bfa5-90208c4a0bc2" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_a8b523f3-e49e-4a93-947e-f8cd91e486fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_e56fb2b5-7eac-4446-a00b-530853cc6e25" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_efe773ed-18df-4066-bfa5-90208c4a0bc2" xlink:to="loc_us-gaap_Assets_e56fb2b5-7eac-4446-a00b-530853cc6e25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_76765a17-cc77-456c-b28d-ca885000226e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_dbc960db-af4f-4816-b9f5-972b0cdc3e7a" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_76765a17-cc77-456c-b28d-ca885000226e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_87206c91-40ba-47af-b0c1-d883f43226da" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_76765a17-cc77-456c-b28d-ca885000226e" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_87206c91-40ba-47af-b0c1-d883f43226da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent_930b940f-4bdd-4662-b839-80a62a2d70c1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_87206c91-40ba-47af-b0c1-d883f43226da" xlink:to="loc_us-gaap_NotesPayableCurrent_930b940f-4bdd-4662-b839-80a62a2d70c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_da6667c3-2c60-4f1e-9da9-859b1fd07bff" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_87206c91-40ba-47af-b0c1-d883f43226da" xlink:to="loc_us-gaap_TaxesPayableCurrent_da6667c3-2c60-4f1e-9da9-859b1fd07bff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_9295b3bb-e9cc-4ebf-8524-69639bf6550e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_87206c91-40ba-47af-b0c1-d883f43226da" xlink:to="loc_us-gaap_AccountsPayableCurrent_9295b3bb-e9cc-4ebf-8524-69639bf6550e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_ae417c1c-4cd7-4b1c-ad51-13da73e75ea8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_87206c91-40ba-47af-b0c1-d883f43226da" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_ae417c1c-4cd7-4b1c-ad51-13da73e75ea8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_658f6583-9930-4842-8c78-89e00bf30e09" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_87206c91-40ba-47af-b0c1-d883f43226da" xlink:to="loc_us-gaap_LiabilitiesCurrent_658f6583-9930-4842-8c78-89e00bf30e09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_cce417d8-a12b-4707-995a-005f8f216adb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_76765a17-cc77-456c-b28d-ca885000226e" xlink:to="loc_us-gaap_LongTermDebt_cce417d8-a12b-4707-995a-005f8f216adb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_82ff4d57-7243-4756-8d58-44520e07ecc6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_76765a17-cc77-456c-b28d-ca885000226e" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_82ff4d57-7243-4756-8d58-44520e07ecc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_a32986e2-539e-485f-9284-2ec2d0154440" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_76765a17-cc77-456c-b28d-ca885000226e" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_a32986e2-539e-485f-9284-2ec2d0154440" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_8f56737c-0424-4e5c-b4ba-58ef3093476a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_76765a17-cc77-456c-b28d-ca885000226e" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_8f56737c-0424-4e5c-b4ba-58ef3093476a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_bcce3ea8-c138-412d-a2b2-b304cae3eabf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_76765a17-cc77-456c-b28d-ca885000226e" xlink:to="loc_us-gaap_Liabilities_bcce3ea8-c138-412d-a2b2-b304cae3eabf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_db15a6b9-5eaa-4a15-9aae-150e737c0cda" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_76765a17-cc77-456c-b28d-ca885000226e" xlink:to="loc_us-gaap_CommitmentsAndContingencies_db15a6b9-5eaa-4a15-9aae-150e737c0cda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_0a34e172-0080-42f3-8f34-1fafac431bb3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_76765a17-cc77-456c-b28d-ca885000226e" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_0a34e172-0080-42f3-8f34-1fafac431bb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_122d6b20-d417-4a95-a229-e5c2a2f6ff71" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_0a34e172-0080-42f3-8f34-1fafac431bb3" xlink:to="loc_us-gaap_StockholdersEquityAbstract_122d6b20-d417-4a95-a229-e5c2a2f6ff71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_e257239b-c647-401e-992b-d6c55a72b7be" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_122d6b20-d417-4a95-a229-e5c2a2f6ff71" xlink:to="loc_us-gaap_PreferredStockValue_e257239b-c647-401e-992b-d6c55a72b7be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_156dded8-b4d0-461e-a2ab-8f9e53bdfd29" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_122d6b20-d417-4a95-a229-e5c2a2f6ff71" xlink:to="loc_us-gaap_CommonStockValue_156dded8-b4d0-461e-a2ab-8f9e53bdfd29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_5cc734fa-c96c-4144-a724-6536ccf56cbc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_122d6b20-d417-4a95-a229-e5c2a2f6ff71" xlink:to="loc_us-gaap_AdditionalPaidInCapital_5cc734fa-c96c-4144-a724-6536ccf56cbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_6900cfff-e801-46c6-b487-9911a2e6d645" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_122d6b20-d417-4a95-a229-e5c2a2f6ff71" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_6900cfff-e801-46c6-b487-9911a2e6d645" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_02960acf-b29a-4e62-9d6e-4163a677a85b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_122d6b20-d417-4a95-a229-e5c2a2f6ff71" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_02960acf-b29a-4e62-9d6e-4163a677a85b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_e8972263-61aa-491e-9e9f-4d8f3dc8e8c4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_122d6b20-d417-4a95-a229-e5c2a2f6ff71" xlink:to="loc_us-gaap_TreasuryStockValue_e8972263-61aa-491e-9e9f-4d8f3dc8e8c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_873e68c6-cec2-40d7-9c4a-bacab90d2c0a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_122d6b20-d417-4a95-a229-e5c2a2f6ff71" xlink:to="loc_us-gaap_StockholdersEquity_873e68c6-cec2-40d7-9c4a-bacab90d2c0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_06e53445-e205-46da-bf52-5a40b20fea32" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_0a34e172-0080-42f3-8f34-1fafac431bb3" xlink:to="loc_us-gaap_MinorityInterest_06e53445-e205-46da-bf52-5a40b20fea32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2e9cd824-bb47-45fa-97cc-771fc02d4f28" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_0a34e172-0080-42f3-8f34-1fafac431bb3" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2e9cd824-bb47-45fa-97cc-771fc02d4f28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_de1d23a6-b5f9-4ab1-90b6-9dddbf65d369" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_76765a17-cc77-456c-b28d-ca885000226e" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_de1d23a6-b5f9-4ab1-90b6-9dddbf65d369" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="simple" xlink:href="biib-20200930.xsd#CondensedConsolidatedBalanceSheetsUnauditedParenthetical"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0dbc8cdb-7a57-42e6-b5eb-d0b6e347d2e8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_8ef31de7-4791-40d2-b0cc-e257f19517a7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0dbc8cdb-7a57-42e6-b5eb-d0b6e347d2e8" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_8ef31de7-4791-40d2-b0cc-e257f19517a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_664b1adc-c6c1-41d3-b1fa-f72b09185870" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0dbc8cdb-7a57-42e6-b5eb-d0b6e347d2e8" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_664b1adc-c6c1-41d3-b1fa-f72b09185870" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="biib-20200930.xsd#CondensedConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_1df2ec5b-79f5-4df2-8ecd-a5d402ce05f2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_1c7c9705-edd3-4090-8e99-49b21e82b00e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_1df2ec5b-79f5-4df2-8ecd-a5d402ce05f2" xlink:to="loc_us-gaap_StatementTable_1c7c9705-edd3-4090-8e99-49b21e82b00e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_6c6e9230-efae-400b-8363-2f6d749a776d" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1c7c9705-edd3-4090-8e99-49b21e82b00e" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_6c6e9230-efae-400b-8363-2f6d749a776d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_323f7ea7-a486-42b7-9a37-e6c8d40295f4" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_6c6e9230-efae-400b-8363-2f6d749a776d" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_323f7ea7-a486-42b7-9a37-e6c8d40295f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SangamoCommonStockMember_609b1082-8d42-436b-9ca4-755aa311bb6d" xlink:href="biib-20200930.xsd#biib_SangamoCommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_323f7ea7-a486-42b7-9a37-e6c8d40295f4" xlink:to="loc_biib_SangamoCommonStockMember_609b1082-8d42-436b-9ca4-755aa311bb6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DenaliTherapeuticsIncMember_492b7b52-7ad3-4fce-b108-c4884d5cf15f" xlink:href="biib-20200930.xsd#biib_DenaliTherapeuticsIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_323f7ea7-a486-42b7-9a37-e6c8d40295f4" xlink:to="loc_biib_DenaliTherapeuticsIncMember_492b7b52-7ad3-4fce-b108-c4884d5cf15f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_20ac4254-c34c-487d-a98e-2a4edcc1667f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1c7c9705-edd3-4090-8e99-49b21e82b00e" xlink:to="loc_us-gaap_StatementLineItems_20ac4254-c34c-487d-a98e-2a4edcc1667f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_d30a5ab3-4ab8-4ce6-9e90-7173e7ee7ec7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_20ac4254-c34c-487d-a98e-2a4edcc1667f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_d30a5ab3-4ab8-4ce6-9e90-7173e7ee7ec7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_c347dc6b-df92-4e2e-ae84-928f433b8086" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_d30a5ab3-4ab8-4ce6-9e90-7173e7ee7ec7" xlink:to="loc_us-gaap_ProfitLoss_c347dc6b-df92-4e2e-ae84-928f433b8086" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_92c726be-8237-4da9-89bf-328581e0f279" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_d30a5ab3-4ab8-4ce6-9e90-7173e7ee7ec7" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_92c726be-8237-4da9-89bf-328581e0f279" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_553e7c8f-c7e0-444d-bed7-fb9bb45580bd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_92c726be-8237-4da9-89bf-328581e0f279" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_553e7c8f-c7e0-444d-bed7-fb9bb45580bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_ccbeb86f-77c0-46d9-b2d8-19ef9680bb53" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_92c726be-8237-4da9-89bf-328581e0f279" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_ccbeb86f-77c0-46d9-b2d8-19ef9680bb53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_a4eb0a96-a04c-4182-b509-8f726769d685" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_92c726be-8237-4da9-89bf-328581e0f279" xlink:to="loc_us-gaap_ShareBasedCompensation_a4eb0a96-a04c-4182-b509-8f726769d685" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_178d3a2a-1ea3-4398-ba3e-ea215e74f007" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_92c726be-8237-4da9-89bf-328581e0f279" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_178d3a2a-1ea3-4398-ba3e-ea215e74f007" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_c9a85058-0a02-4b0f-872f-6070360764e1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_92c726be-8237-4da9-89bf-328581e0f279" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_c9a85058-0a02-4b0f-872f-6070360764e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax_effabf5d-ed08-44ac-ac30-b323b44f4717" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_92c726be-8237-4da9-89bf-328581e0f279" xlink:to="loc_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax_effabf5d-ed08-44ac-ac30-b323b44f4717" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_6e52a383-c4f5-479f-903c-bc3c5f2a9d35" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_92c726be-8237-4da9-89bf-328581e0f279" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_6e52a383-c4f5-479f-903c-bc3c5f2a9d35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_d86d0e96-6b84-453d-8bdf-e1d364e5bcb1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_92c726be-8237-4da9-89bf-328581e0f279" xlink:to="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_d86d0e96-6b84-453d-8bdf-e1d364e5bcb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_a916bf4f-b2a7-4f80-9f75-97805150a986" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_92c726be-8237-4da9-89bf-328581e0f279" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_a916bf4f-b2a7-4f80-9f75-97805150a986" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_ac2ae5cd-3ff6-4943-86fe-65bce7035867" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_92c726be-8237-4da9-89bf-328581e0f279" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_ac2ae5cd-3ff6-4943-86fe-65bce7035867" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_84aedadb-1bb3-4c6b-822b-80c4757d6e38" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_92c726be-8237-4da9-89bf-328581e0f279" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_84aedadb-1bb3-4c6b-822b-80c4757d6e38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_ba0dbaea-8b32-48ce-a5d6-16a65e76e067" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_84aedadb-1bb3-4c6b-822b-80c4757d6e38" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_ba0dbaea-8b32-48ce-a5d6-16a65e76e067" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties_6615f20d-1fc5-4db1-bb90-8791c22570a5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedParties"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_84aedadb-1bb3-4c6b-822b-80c4757d6e38" xlink:to="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties_6615f20d-1fc5-4db1-bb90-8791c22570a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_8c8cae87-1b27-4690-84f7-8a1bd08fb2e0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_84aedadb-1bb3-4c6b-822b-80c4757d6e38" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_8c8cae87-1b27-4690-84f7-8a1bd08fb2e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_85801ed6-e044-40d5-a4ea-70f270270e17" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_84aedadb-1bb3-4c6b-822b-80c4757d6e38" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_85801ed6-e044-40d5-a4ea-70f270270e17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_ab112b94-e578-45d8-8d3e-74a914bba68e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_84aedadb-1bb3-4c6b-822b-80c4757d6e38" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_ab112b94-e578-45d8-8d3e-74a914bba68e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_ac44e018-22f4-4c39-940f-963802b62766" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_84aedadb-1bb3-4c6b-822b-80c4757d6e38" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_ac44e018-22f4-4c39-940f-963802b62766" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d2875f66-b178-4c9d-a6c4-cd28701ca4fa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_92c726be-8237-4da9-89bf-328581e0f279" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d2875f66-b178-4c9d-a6c4-cd28701ca4fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_837de02e-33d5-4354-91cd-48fd9b82fcc5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_20ac4254-c34c-487d-a98e-2a4edcc1667f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_837de02e-33d5-4354-91cd-48fd9b82fcc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_8142bfa3-fba4-4823-aa5b-c2cdb7207564" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_837de02e-33d5-4354-91cd-48fd9b82fcc5" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_8142bfa3-fba4-4823-aa5b-c2cdb7207564" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_77aba0bb-15d3-43f6-9098-0cab0d8298ec" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_837de02e-33d5-4354-91cd-48fd9b82fcc5" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_77aba0bb-15d3-43f6-9098-0cab0d8298ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_43ed7574-ab1d-4e16-879d-be40af54c1aa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_837de02e-33d5-4354-91cd-48fd9b82fcc5" xlink:to="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_43ed7574-ab1d-4e16-879d-be40af54c1aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired_5df064ba-92a0-4f64-9595-0065f890b8bf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_837de02e-33d5-4354-91cd-48fd9b82fcc5" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired_5df064ba-92a0-4f64-9595-0065f890b8bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_e7dc7a17-419e-482a-9f88-59f0fcb649fa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_837de02e-33d5-4354-91cd-48fd9b82fcc5" xlink:to="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_e7dc7a17-419e-482a-9f88-59f0fcb649fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_1eb226ef-d7ba-4c79-a0b8-3cc00e27ce8e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_837de02e-33d5-4354-91cd-48fd9b82fcc5" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_1eb226ef-d7ba-4c79-a0b8-3cc00e27ce8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_545e5ada-6e58-475c-81b0-d670f216ceed" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_837de02e-33d5-4354-91cd-48fd9b82fcc5" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_545e5ada-6e58-475c-81b0-d670f216ceed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_116282a0-a667-428a-8d07-1366614af53a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_837de02e-33d5-4354-91cd-48fd9b82fcc5" xlink:to="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_116282a0-a667-428a-8d07-1366614af53a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_2ecded08-8c24-4ea5-86c6-fdc396e2d880" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_837de02e-33d5-4354-91cd-48fd9b82fcc5" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_2ecded08-8c24-4ea5-86c6-fdc396e2d880" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromHedgeInvestingActivities_d93b846a-6636-4267-923f-b25e11ddc4e2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromHedgeInvestingActivities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_837de02e-33d5-4354-91cd-48fd9b82fcc5" xlink:to="loc_us-gaap_ProceedsFromHedgeInvestingActivities_d93b846a-6636-4267-923f-b25e11ddc4e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_81fe824b-7854-4d16-a0a0-1eb5bb4c863a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_837de02e-33d5-4354-91cd-48fd9b82fcc5" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_81fe824b-7854-4d16-a0a0-1eb5bb4c863a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_06949e0b-6ada-4057-a8e3-dd061faa2f06" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_837de02e-33d5-4354-91cd-48fd9b82fcc5" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_06949e0b-6ada-4057-a8e3-dd061faa2f06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7da9ee00-d821-43a4-8f0f-0a24fafa615f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_837de02e-33d5-4354-91cd-48fd9b82fcc5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7da9ee00-d821-43a4-8f0f-0a24fafa615f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_cee2f1b0-5598-43d0-9cb0-69cb222d0795" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_20ac4254-c34c-487d-a98e-2a4edcc1667f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_cee2f1b0-5598-43d0-9cb0-69cb222d0795" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_e73c101f-8d33-4b1e-b5ae-8ef2488c51f6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_cee2f1b0-5598-43d0-9cb0-69cb222d0795" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_e73c101f-8d33-4b1e-b5ae-8ef2488c51f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_f3d10fdf-10f3-4ebd-aa28-9c5be8c977fd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_cee2f1b0-5598-43d0-9cb0-69cb222d0795" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_f3d10fdf-10f3-4ebd-aa28-9c5be8c977fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_62043084-76cf-4aff-9f40-9817b859f394" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_cee2f1b0-5598-43d0-9cb0-69cb222d0795" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_62043084-76cf-4aff-9f40-9817b859f394" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_b245e943-5c4e-4aa9-9d72-5b84c7b86749" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_cee2f1b0-5598-43d0-9cb0-69cb222d0795" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_b245e943-5c4e-4aa9-9d72-5b84c7b86749" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromDerivativeInstrumentFinancingActivities_5c69467f-1559-4eee-af05-1fefb939eb6c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForProceedsFromDerivativeInstrumentFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_cee2f1b0-5598-43d0-9cb0-69cb222d0795" xlink:to="loc_us-gaap_PaymentsForProceedsFromDerivativeInstrumentFinancingActivities_5c69467f-1559-4eee-af05-1fefb939eb6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_046467e2-8956-4785-8ac9-dd32a97a4f4e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToMinorityShareholders"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_cee2f1b0-5598-43d0-9cb0-69cb222d0795" xlink:to="loc_us-gaap_PaymentsToMinorityShareholders_046467e2-8956-4785-8ac9-dd32a97a4f4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_8183446e-e41e-431c-89e9-fe6acb8fff61" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_cee2f1b0-5598-43d0-9cb0-69cb222d0795" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_8183446e-e41e-431c-89e9-fe6acb8fff61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_89454a20-2b0d-42e3-9f5b-4b3ebc68b07f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_cee2f1b0-5598-43d0-9cb0-69cb222d0795" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_89454a20-2b0d-42e3-9f5b-4b3ebc68b07f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_a54f5da1-4008-48fe-9425-159d45a90347" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_20ac4254-c34c-487d-a98e-2a4edcc1667f" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_a54f5da1-4008-48fe-9425-159d45a90347" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_161137d2-6c5f-420e-8068-6405b4360445" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_20ac4254-c34c-487d-a98e-2a4edcc1667f" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_161137d2-6c5f-420e-8068-6405b4360445" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6c36a375-2aaf-4ccb-bb68-4a1fa530a09e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_20ac4254-c34c-487d-a98e-2a4edcc1667f" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6c36a375-2aaf-4ccb-bb68-4a1fa530a09e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4f399d51-a18d-4d90-abd7-8383fa9acc8a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_20ac4254-c34c-487d-a98e-2a4edcc1667f" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4f399d51-a18d-4d90-abd7-8383fa9acc8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement" xlink:type="simple" xlink:href="biib-20200930.xsd#CondensedConsolidatedStatementofEquityStatement"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_0c6dcedc-7cb7-4532-a23b-ad328018b2f4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_1ae07506-7e25-42d0-9cd3-ffc5edc2046c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_0c6dcedc-7cb7-4532-a23b-ad328018b2f4" xlink:to="loc_us-gaap_StatementTable_1ae07506-7e25-42d0-9cd3-ffc5edc2046c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_60f6f6ad-2eaa-44b7-bfe2-51d743454658" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1ae07506-7e25-42d0-9cd3-ffc5edc2046c" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_60f6f6ad-2eaa-44b7-bfe2-51d743454658" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_a2445c29-0293-4615-ba16-27ec74f3283a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_60f6f6ad-2eaa-44b7-bfe2-51d743454658" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_a2445c29-0293-4615-ba16-27ec74f3283a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2018ShareRepurchaseProgramMember_ab524aa3-dc33-47d2-91fd-3f015d3af01b" xlink:href="biib-20200930.xsd#biib_A2018ShareRepurchaseProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_a2445c29-0293-4615-ba16-27ec74f3283a" xlink:to="loc_biib_A2018ShareRepurchaseProgramMember_ab524aa3-dc33-47d2-91fd-3f015d3af01b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_March2019ShareRepurchaseProgramMember_ebe67373-6057-4dbe-bef6-1eef2d41c86d" xlink:href="biib-20200930.xsd#biib_March2019ShareRepurchaseProgramMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_a2445c29-0293-4615-ba16-27ec74f3283a" xlink:to="loc_biib_March2019ShareRepurchaseProgramMember_ebe67373-6057-4dbe-bef6-1eef2d41c86d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_December2019ShareRepurchaseProgramMember_de5c3d5c-fe57-4815-87d4-957cd93b856d" xlink:href="biib-20200930.xsd#biib_December2019ShareRepurchaseProgramMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_a2445c29-0293-4615-ba16-27ec74f3283a" xlink:to="loc_biib_December2019ShareRepurchaseProgramMember_de5c3d5c-fe57-4815-87d4-957cd93b856d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_3f4417bd-7826-40c6-9bf5-c62193949a63" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1ae07506-7e25-42d0-9cd3-ffc5edc2046c" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_3f4417bd-7826-40c6-9bf5-c62193949a63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_64c03dd4-89b2-41a7-bd68-dfa826c7f2cc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3f4417bd-7826-40c6-9bf5-c62193949a63" xlink:to="loc_us-gaap_EquityComponentDomain_64c03dd4-89b2-41a7-bd68-dfa826c7f2cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_ecc9776d-bbb6-4522-8061-54de81d000bd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_64c03dd4-89b2-41a7-bd68-dfa826c7f2cc" xlink:to="loc_us-gaap_PreferredStockMember_ecc9776d-bbb6-4522-8061-54de81d000bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_e09d5b2c-29b5-4ccf-99db-5b4ae52ca08d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_64c03dd4-89b2-41a7-bd68-dfa826c7f2cc" xlink:to="loc_us-gaap_CommonStockMember_e09d5b2c-29b5-4ccf-99db-5b4ae52ca08d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_29361323-ebbb-4a33-a17f-f8a6d8f94190" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_64c03dd4-89b2-41a7-bd68-dfa826c7f2cc" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_29361323-ebbb-4a33-a17f-f8a6d8f94190" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_09a53c1c-eebe-4b55-8154-bb1735fdf7fc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_64c03dd4-89b2-41a7-bd68-dfa826c7f2cc" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_09a53c1c-eebe-4b55-8154-bb1735fdf7fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_5fec6ebd-cab2-4470-b308-2a7184f42566" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_64c03dd4-89b2-41a7-bd68-dfa826c7f2cc" xlink:to="loc_us-gaap_RetainedEarningsMember_5fec6ebd-cab2-4470-b308-2a7184f42566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_145fd389-3f80-4e3e-90f5-03c2140e4502" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_64c03dd4-89b2-41a7-bd68-dfa826c7f2cc" xlink:to="loc_us-gaap_TreasuryStockMember_145fd389-3f80-4e3e-90f5-03c2140e4502" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_f4628811-9662-4c71-8395-b8b7614c7f61" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ParentMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_64c03dd4-89b2-41a7-bd68-dfa826c7f2cc" xlink:to="loc_us-gaap_ParentMember_f4628811-9662-4c71-8395-b8b7614c7f61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_8fd857c9-8ba2-4fac-84a5-e23cf3e82bf7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_64c03dd4-89b2-41a7-bd68-dfa826c7f2cc" xlink:to="loc_us-gaap_NoncontrollingInterestMember_8fd857c9-8ba2-4fac-84a5-e23cf3e82bf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_749a2534-8139-480d-a8e1-fe45dc58f884" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1ae07506-7e25-42d0-9cd3-ffc5edc2046c" xlink:to="loc_us-gaap_StatementLineItems_749a2534-8139-480d-a8e1-fe45dc58f884" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_4b65a032-e9d8-433e-b13d-04dcd1273be6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_749a2534-8139-480d-a8e1-fe45dc58f884" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_4b65a032-e9d8-433e-b13d-04dcd1273be6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b787fed6-23c8-4e92-9eb6-ba3787fee203" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_749a2534-8139-480d-a8e1-fe45dc58f884" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b787fed6-23c8-4e92-9eb6-ba3787fee203" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_d48ba5bf-9bb5-4db2-86dc-3ea0070e4272" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_749a2534-8139-480d-a8e1-fe45dc58f884" xlink:to="loc_us-gaap_ProfitLoss_d48ba5bf-9bb5-4db2-86dc-3ea0070e4272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_04df2972-ff01-4db4-9d4e-cd9a3317f90e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_749a2534-8139-480d-a8e1-fe45dc58f884" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_04df2972-ff01-4db4-9d4e-cd9a3317f90e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Noncontrollinginterestincreasedecreaseother_47930ecd-d6b6-4d01-8e90-a084f95a1064" xlink:href="biib-20200930.xsd#biib_Noncontrollinginterestincreasedecreaseother"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_749a2534-8139-480d-a8e1-fe45dc58f884" xlink:to="loc_biib_Noncontrollinginterestincreasedecreaseother_47930ecd-d6b6-4d01-8e90-a084f95a1064" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_2a812900-78f3-4991-bacc-1bffd310996e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_749a2534-8139-480d-a8e1-fe45dc58f884" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_2a812900-78f3-4991-bacc-1bffd310996e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_519f342b-5bc8-4947-8075-c37d34208ce1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_749a2534-8139-480d-a8e1-fe45dc58f884" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_519f342b-5bc8-4947-8075-c37d34208ce1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_8c4e64a0-1ed0-4d16-a212-7997a4324a8a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_749a2534-8139-480d-a8e1-fe45dc58f884" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_8c4e64a0-1ed0-4d16-a212-7997a4324a8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_181693a7-337c-4d5e-af73-5c2ed98d1ce4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_749a2534-8139-480d-a8e1-fe45dc58f884" xlink:to="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_181693a7-337c-4d5e-af73-5c2ed98d1ce4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_0d54cd6d-c735-42b9-af4d-8aeb20bc3a64" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_749a2534-8139-480d-a8e1-fe45dc58f884" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_0d54cd6d-c735-42b9-af4d-8aeb20bc3a64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_f52766bc-d117-48fb-b3d0-9039aa153cc1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_749a2534-8139-480d-a8e1-fe45dc58f884" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_f52766bc-d117-48fb-b3d0-9039aa153cc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_b553752d-5394-449e-bc44-a278c7f6ad43" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_749a2534-8139-480d-a8e1-fe45dc58f884" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_b553752d-5394-449e-bc44-a278c7f6ad43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_321b5be5-1c05-4c6d-ae99-17a1bdd6af62" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_749a2534-8139-480d-a8e1-fe45dc58f884" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_321b5be5-1c05-4c6d-ae99-17a1bdd6af62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_03512a83-b37c-4eec-9a00-3879762ab4b2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_749a2534-8139-480d-a8e1-fe45dc58f884" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_03512a83-b37c-4eec-9a00-3879762ab4b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther_7288135c-e98b-4ddd-9ddd-78aa40de4bbb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityOther"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_749a2534-8139-480d-a8e1-fe45dc58f884" xlink:to="loc_us-gaap_StockholdersEquityOther_7288135c-e98b-4ddd-9ddd-78aa40de4bbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_daa21a37-2801-4946-9bc2-8edaa934d20e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_749a2534-8139-480d-a8e1-fe45dc58f884" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_daa21a37-2801-4946-9bc2-8edaa934d20e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_33ca3cc1-dc2d-4b02-a534-afaf8f2ef6e8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_749a2534-8139-480d-a8e1-fe45dc58f884" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_33ca3cc1-dc2d-4b02-a534-afaf8f2ef6e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="biib-20200930.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_5bd9e24c-9211-4714-9737-1890838c567d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_9cc753a7-57a5-4d0b-8edd-90d3d654847c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5bd9e24c-9211-4714-9737-1890838c567d" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_9cc753a7-57a5-4d0b-8edd-90d3d654847c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="biib-20200930.xsd#SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_15db0e6b-450e-40b3-aad1-e67c7ee44e77" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessOverviewPolicyTextBlock_c64218c6-c7db-4b38-b548-b801f70cd8c1" xlink:href="biib-20200930.xsd#biib_BusinessOverviewPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_15db0e6b-450e-40b3-aad1-e67c7ee44e77" xlink:to="loc_biib_BusinessOverviewPolicyTextBlock_c64218c6-c7db-4b38-b548-b801f70cd8c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_f415ec70-a715-411d-b846-a12159e0e89f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_15db0e6b-450e-40b3-aad1-e67c7ee44e77" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_f415ec70-a715-411d-b846-a12159e0e89f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_376da6e5-4ea7-4be2-b9c4-1d86fd97888c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_15db0e6b-450e-40b3-aad1-e67c7ee44e77" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_376da6e5-4ea7-4be2-b9c4-1d86fd97888c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_fda57248-1bad-4e2c-b754-808cbad35412" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_15db0e6b-450e-40b3-aad1-e67c7ee44e77" xlink:to="loc_us-gaap_UseOfEstimates_fda57248-1bad-4e2c-b754-808cbad35412" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_bcd45994-2704-419f-a1ed-8c4d932397ab" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_15db0e6b-450e-40b3-aad1-e67c7ee44e77" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_bcd45994-2704-419f-a1ed-8c4d932397ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="biib-20200930.xsd#SummaryofSignificantAccountingPoliciesDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_c0dbeb8b-7abe-4d34-be74-79bb8b5b6e3e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NumberOfOphthalmolgyBiosimilarProductsExclusiveRights_213e7809-a26b-4627-8209-dcc8b1379c72" xlink:href="biib-20200930.xsd#biib_NumberOfOphthalmolgyBiosimilarProductsExclusiveRights"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c0dbeb8b-7abe-4d34-be74-79bb8b5b6e3e" xlink:to="loc_biib_NumberOfOphthalmolgyBiosimilarProductsExclusiveRights_213e7809-a26b-4627-8209-dcc8b1379c72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_4921080a-1e12-4b5e-a981-c5a4e88b20c3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c0dbeb8b-7abe-4d34-be74-79bb8b5b6e3e" xlink:to="loc_us-gaap_NumberOfReportableSegments_4921080a-1e12-4b5e-a981-c5a4e88b20c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InterestInSubsidiary_b02fdf83-ed65-409d-bed6-cc489b81ebbf" xlink:href="biib-20200930.xsd#biib_InterestInSubsidiary"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c0dbeb8b-7abe-4d34-be74-79bb8b5b6e3e" xlink:to="loc_biib_InterestInSubsidiary_b02fdf83-ed65-409d-bed6-cc489b81ebbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/Acquisitions" xlink:type="simple" xlink:href="biib-20200930.xsd#Acquisitions"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Acquisitions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_f49802ca-7253-4012-ada5-a5ea607f6097" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_19f66421-24a0-4d2c-be20-5cf67c05ae3b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_f49802ca-7253-4012-ada5-a5ea607f6097" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_19f66421-24a0-4d2c-be20-5cf67c05ae3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryofseparatelyidentifiableassetsacquiredandliabilitiesassumedTables" xlink:type="simple" xlink:href="biib-20200930.xsd#SummaryofseparatelyidentifiableassetsacquiredandliabilitiesassumedTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SummaryofseparatelyidentifiableassetsacquiredandliabilitiesassumedTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_biib_AcquisitionsAbstract_d73515ca-c44a-40e1-a036-21214c2fd9c6" xlink:href="biib-20200930.xsd#biib_AcquisitionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_5cea1b0b-6963-4cae-a19f-69fd6a6e9d6a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_AcquisitionsAbstract_d73515ca-c44a-40e1-a036-21214c2fd9c6" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_5cea1b0b-6963-4cae-a19f-69fd6a6e9d6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual" xlink:type="simple" xlink:href="biib-20200930.xsd#BusinessAcquisitionDetailsTextual"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_biib_AcquisitionsAbstract_d8bff58d-3c0f-40a8-a4e5-ef433166c07d" xlink:href="biib-20200930.xsd#biib_AcquisitionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d76643d3-0730-4839-805d-c804f3211925" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_AcquisitionsAbstract_d8bff58d-3c0f-40a8-a4e5-ef433166c07d" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d76643d3-0730-4839-805d-c804f3211925" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_2ec98d47-6a99-45a1-af1b-63b8108025eb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d76643d3-0730-4839-805d-c804f3211925" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_2ec98d47-6a99-45a1-af1b-63b8108025eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_97af5509-5a55-4082-beb7-314764166310" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2ec98d47-6a99-45a1-af1b-63b8108025eb" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_97af5509-5a55-4082-beb7-314764166310" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_fa91730e-f675-4403-beb1-17b821efe82e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d76643d3-0730-4839-805d-c804f3211925" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_fa91730e-f675-4403-beb1-17b821efe82e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_e0e1fda6-a0b2-4e6c-8ea7-f5ffe7760beb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_fa91730e-f675-4403-beb1-17b821efe82e" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_e0e1fda6-a0b2-4e6c-8ea7-f5ffe7760beb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PostacquisitionequitycompensationMember_e6d7795a-85ec-4b30-8c5d-2f03610f5764" xlink:href="biib-20200930.xsd#biib_PostacquisitionequitycompensationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_e0e1fda6-a0b2-4e6c-8ea7-f5ffe7760beb" xlink:to="loc_biib_PostacquisitionequitycompensationMember_e6d7795a-85ec-4b30-8c5d-2f03610f5764" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchanddevelopmentassetAxis_b1051508-624d-43ef-ab7b-cac87afa2ce7" xlink:href="biib-20200930.xsd#biib_ResearchanddevelopmentassetAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d76643d3-0730-4839-805d-c804f3211925" xlink:to="loc_biib_ResearchanddevelopmentassetAxis_b1051508-624d-43ef-ab7b-cac87afa2ce7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchanddevelopmentassetDomain_c25a0d70-e376-4889-9c45-1bab6c34112c" xlink:href="biib-20200930.xsd#biib_ResearchanddevelopmentassetDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ResearchanddevelopmentassetAxis_b1051508-624d-43ef-ab7b-cac87afa2ce7" xlink:to="loc_biib_ResearchanddevelopmentassetDomain_c25a0d70-e376-4889-9c45-1bab6c34112c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BIIB111Member_067a965d-1422-4371-840e-1faf4579129c" xlink:href="biib-20200930.xsd#biib_BIIB111Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ResearchanddevelopmentassetDomain_c25a0d70-e376-4889-9c45-1bab6c34112c" xlink:to="loc_biib_BIIB111Member_067a965d-1422-4371-840e-1faf4579129c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BIIB112Member_f5f5e5ce-1d0e-4bfe-ba10-4cafe0875819" xlink:href="biib-20200930.xsd#biib_BIIB112Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ResearchanddevelopmentassetDomain_c25a0d70-e376-4889-9c45-1bab6c34112c" xlink:to="loc_biib_BIIB112Member_f5f5e5ce-1d0e-4bfe-ba10-4cafe0875819" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_ca52dd34-a1c8-4edd-99b7-37a770aeaf10" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d76643d3-0730-4839-805d-c804f3211925" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_ca52dd34-a1c8-4edd-99b7-37a770aeaf10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_908b9cb7-56fa-4ca8-93e0-2f43791b9a73" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_ca52dd34-a1c8-4edd-99b7-37a770aeaf10" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_908b9cb7-56fa-4ca8-93e0-2f43791b9a73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_16dcdd43-6728-4457-badb-a8cf64bc3282" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_908b9cb7-56fa-4ca8-93e0-2f43791b9a73" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_16dcdd43-6728-4457-badb-a8cf64bc3282" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_2959b69d-a0cc-48e7-8b27-45b3f685eea6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_908b9cb7-56fa-4ca8-93e0-2f43791b9a73" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_2959b69d-a0cc-48e7-8b27-45b3f685eea6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_c13fc15c-b122-410b-89e7-8c2df0143fa4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d76643d3-0730-4839-805d-c804f3211925" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_c13fc15c-b122-410b-89e7-8c2df0143fa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4fd1bbbe-a192-435a-81cf-399f62e6a753" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_c13fc15c-b122-410b-89e7-8c2df0143fa4" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4fd1bbbe-a192-435a-81cf-399f62e6a753" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BIIB118Member_9a604e5a-2db8-420e-9432-c49431ceaf86" xlink:href="biib-20200930.xsd#biib_BIIB118Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4fd1bbbe-a192-435a-81cf-399f62e6a753" xlink:to="loc_biib_BIIB118Member_9a604e5a-2db8-420e-9432-c49431ceaf86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NightstarMember_2e2eba40-66c7-4934-bf2f-c0225cc4e426" xlink:href="biib-20200930.xsd#biib_NightstarMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4fd1bbbe-a192-435a-81cf-399f62e6a753" xlink:to="loc_biib_NightstarMember_2e2eba40-66c7-4934-bf2f-c0225cc4e426" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_e5bf2439-dc53-4a1e-b560-4e5690995baa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d76643d3-0730-4839-805d-c804f3211925" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_e5bf2439-dc53-4a1e-b560-4e5690995baa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_7eec1df4-7572-4874-a621-7c6e71018c97" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e5bf2439-dc53-4a1e-b560-4e5690995baa" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_7eec1df4-7572-4874-a621-7c6e71018c97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_bee53e4b-5f7a-4c12-a632-3dd44d0344b7" xlink:href="biib-20200930.xsd#biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e5bf2439-dc53-4a1e-b560-4e5690995baa" xlink:to="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_bee53e4b-5f7a-4c12-a632-3dd44d0344b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ClinicalAssetsAcquired_2d049857-e43a-4262-96ad-1c54a296eac8" xlink:href="biib-20200930.xsd#biib_ClinicalAssetsAcquired"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e5bf2439-dc53-4a1e-b560-4e5690995baa" xlink:to="loc_biib_ClinicalAssetsAcquired_2d049857-e43a-4262-96ad-1c54a296eac8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_f28dfd6c-7349-40a1-a0f5-550f08e83df2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e5bf2439-dc53-4a1e-b560-4e5690995baa" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_f28dfd6c-7349-40a1-a0f5-550f08e83df2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_1986f976-986d-4051-a649-d619c79a9aa0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e5bf2439-dc53-4a1e-b560-4e5690995baa" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_1986f976-986d-4051-a649-d619c79a9aa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPaymentsToAcquireBusinesses_b66f2a55-28a3-4039-9dbc-e1c574466370" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherPaymentsToAcquireBusinesses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e5bf2439-dc53-4a1e-b560-4e5690995baa" xlink:to="loc_us-gaap_OtherPaymentsToAcquireBusinesses_b66f2a55-28a3-4039-9dbc-e1c574466370" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_da9e7ecd-ce89-482a-987f-d707ce64fa94" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e5bf2439-dc53-4a1e-b560-4e5690995baa" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_da9e7ecd-ce89-482a-987f-d707ce64fa94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate_67ae406e-86b3-4cb3-b986-ee47c090804f" xlink:href="biib-20200930.xsd#biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e5bf2439-dc53-4a1e-b560-4e5690995baa" xlink:to="loc_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate_67ae406e-86b3-4cb3-b986-ee47c090804f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_4c73d718-2718-400a-a5af-01f21c818c5f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e5bf2439-dc53-4a1e-b560-4e5690995baa" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_4c73d718-2718-400a-a5af-01f21c818c5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxBasisOfInvestmentsCostForIncomeTaxPurposes_1c5bb320-bfc2-4b34-8221-069594560ed4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxBasisOfInvestmentsCostForIncomeTaxPurposes"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e5bf2439-dc53-4a1e-b560-4e5690995baa" xlink:to="loc_us-gaap_TaxBasisOfInvestmentsCostForIncomeTaxPurposes_1c5bb320-bfc2-4b34-8221-069594560ed4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill_630f3b9c-5623-4775-9df5-1ee033a6d493" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e5bf2439-dc53-4a1e-b560-4e5690995baa" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill_630f3b9c-5623-4775-9df5-1ee033a6d493" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/BusinessAcquisitionDetails" xlink:type="simple" xlink:href="biib-20200930.xsd#BusinessAcquisitionDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/BusinessAcquisitionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_biib_AcquisitionsAbstract_f1b18ac6-0c7d-4dfe-b0fa-9ceaf3b5a12f" xlink:href="biib-20200930.xsd#biib_AcquisitionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_04c9e3df-0cc5-4154-ad92-d6bc1beaa33b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_AcquisitionsAbstract_f1b18ac6-0c7d-4dfe-b0fa-9ceaf3b5a12f" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_04c9e3df-0cc5-4154-ad92-d6bc1beaa33b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_eb16adf4-ba9a-46dd-b2b0-de5fa0efd75c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_04c9e3df-0cc5-4154-ad92-d6bc1beaa33b" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_eb16adf4-ba9a-46dd-b2b0-de5fa0efd75c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_909d0f74-e5a2-4583-8654-72e7b71e2193" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_eb16adf4-ba9a-46dd-b2b0-de5fa0efd75c" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_909d0f74-e5a2-4583-8654-72e7b71e2193" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NightstarMember_1ae5aed1-8ea0-40ca-9e0f-ebf6024d0f1b" xlink:href="biib-20200930.xsd#biib_NightstarMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_909d0f74-e5a2-4583-8654-72e7b71e2193" xlink:to="loc_biib_NightstarMember_1ae5aed1-8ea0-40ca-9e0f-ebf6024d0f1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_f4d75d48-189b-4c6c-bcb1-bc9c5432df08" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_04c9e3df-0cc5-4154-ad92-d6bc1beaa33b" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_f4d75d48-189b-4c6c-bcb1-bc9c5432df08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_8b756ab3-3f70-4b17-afff-479b49d42f53" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f4d75d48-189b-4c6c-bcb1-bc9c5432df08" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_8b756ab3-3f70-4b17-afff-479b49d42f53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_d2a8f74c-5145-4511-9289-3123569ce071" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f4d75d48-189b-4c6c-bcb1-bc9c5432df08" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_d2a8f74c-5145-4511-9289-3123569ce071" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_ac30bfe4-c6ba-43e2-b5dd-c0a5973a0881" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f4d75d48-189b-4c6c-bcb1-bc9c5432df08" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_ac30bfe4-c6ba-43e2-b5dd-c0a5973a0881" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_3d840669-1e92-43ba-ba90-9fa71afed1d8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f4d75d48-189b-4c6c-bcb1-bc9c5432df08" xlink:to="loc_us-gaap_Goodwill_3d840669-1e92-43ba-ba90-9fa71afed1d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_9db3ddb7-6fbe-445f-a089-1c9031f6f91a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f4d75d48-189b-4c6c-bcb1-bc9c5432df08" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_9db3ddb7-6fbe-445f-a089-1c9031f6f91a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets_3550f40b-9522-465d-aeb3-7f55b87f1983" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f4d75d48-189b-4c6c-bcb1-bc9c5432df08" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets_3550f40b-9522-465d-aeb3-7f55b87f1983" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_160f5e33-e879-42ed-bd3b-c4329c0ca85d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f4d75d48-189b-4c6c-bcb1-bc9c5432df08" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_160f5e33-e879-42ed-bd3b-c4329c0ca85d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/DivestituresDivestitures" xlink:type="simple" xlink:href="biib-20200930.xsd#DivestituresDivestitures"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DivestituresDivestitures" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_biib_DivestituresAbstract_8cc0a4d3-b0f0-48a4-9f39-c306daded1d8" xlink:href="biib-20200930.xsd#biib_DivestituresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_9e2203ab-9302-4426-954d-e1bee31d5cbd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DivestituresAbstract_8cc0a4d3-b0f0-48a4-9f39-c306daded1d8" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_9e2203ab-9302-4426-954d-e1bee31d5cbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/DivestituresDetailsTextual" xlink:type="simple" xlink:href="biib-20200930.xsd#DivestituresDetailsTextual"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DivestituresDetailsTextual" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_biib_DivestituresAbstract_77e0aa64-af26-43e8-b039-e7e3c429d748" xlink:href="biib-20200930.xsd#biib_DivestituresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e6e4b236-33f6-40c7-8d64-0b6a74037aed" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DivestituresAbstract_77e0aa64-af26-43e8-b039-e7e3c429d748" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e6e4b236-33f6-40c7-8d64-0b6a74037aed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_e3724472-3b66-405e-ab43-38933011252b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e6e4b236-33f6-40c7-8d64-0b6a74037aed" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_e3724472-3b66-405e-ab43-38933011252b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_173520b6-2736-40bb-8d30-fc76e951338e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_e3724472-3b66-405e-ab43-38933011252b" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_173520b6-2736-40bb-8d30-fc76e951338e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DenmarkManufacturingOperationsMember_36d9e423-2964-4aea-a6a9-e314e926b2a6" xlink:href="biib-20200930.xsd#biib_DenmarkManufacturingOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_173520b6-2736-40bb-8d30-fc76e951338e" xlink:to="loc_biib_DenmarkManufacturingOperationsMember_36d9e423-2964-4aea-a6a9-e314e926b2a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_c3f5a359-a2a8-4791-a59e-07cc3b85137d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e6e4b236-33f6-40c7-8d64-0b6a74037aed" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_c3f5a359-a2a8-4791-a59e-07cc3b85137d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_9274cc95-d272-46a9-a72a-d07b29d8a587" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_c3f5a359-a2a8-4791-a59e-07cc3b85137d" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_9274cc95-d272-46a9-a72a-d07b29d8a587" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_9d061b98-5e9b-4c1e-ae62-e9c0d0d32fc7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_c3f5a359-a2a8-4791-a59e-07cc3b85137d" xlink:to="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_9d061b98-5e9b-4c1e-ae62-e9c0d0d32fc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax_70fa8170-5921-4a30-a7de-1612d370629e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_c3f5a359-a2a8-4791-a59e-07cc3b85137d" xlink:to="loc_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax_70fa8170-5921-4a30-a7de-1612d370629e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_eaf6c9af-abf3-4a62-bfe0-48098c00b044" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_c3f5a359-a2a8-4791-a59e-07cc3b85137d" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_eaf6c9af-abf3-4a62-bfe0-48098c00b044" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_1b4ff7af-78bc-4a41-81e0-04e78ac392d8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_c3f5a359-a2a8-4791-a59e-07cc3b85137d" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_1b4ff7af-78bc-4a41-81e0-04e78ac392d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_d5939d8c-c898-4f2e-9377-a8189a77003c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_c3f5a359-a2a8-4791-a59e-07cc3b85137d" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_d5939d8c-c898-4f2e-9377-a8189a77003c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InventoryrawmaterialssoldtoFUJIFILM_15e0caeb-8324-486f-8893-0fd1016618fc" xlink:href="biib-20200930.xsd#biib_InventoryrawmaterialssoldtoFUJIFILM"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_c3f5a359-a2a8-4791-a59e-07cc3b85137d" xlink:to="loc_biib_InventoryrawmaterialssoldtoFUJIFILM_15e0caeb-8324-486f-8893-0fd1016618fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/Revenues" xlink:type="simple" xlink:href="biib-20200930.xsd#Revenues"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Revenues" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_92ec49ca-1cc1-4007-9df5-ee91f5302508" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_bdca0a8d-c4b4-4329-ae3e-5ce65957af1f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_92ec49ca-1cc1-4007-9df5-ee91f5302508" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_bdca0a8d-c4b4-4329-ae3e-5ce65957af1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesTables" xlink:type="simple" xlink:href="biib-20200930.xsd#RevenuesTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_599f611c-66e2-47cc-9dac-fd26b0f999a9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_cc90e9d5-9662-41e5-bae0-b5f382033ee5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_599f611c-66e2-47cc-9dac-fd26b0f999a9" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_cc90e9d5-9662-41e5-bae0-b5f382033ee5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_d8394539-af30-4ee5-8c31-965647b1fe5b" xlink:href="biib-20200930.xsd#biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_599f611c-66e2-47cc-9dac-fd26b0f999a9" xlink:to="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_d8394539-af30-4ee5-8c31-965647b1fe5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_ce11ed94-470a-4444-8607-cbc899d8aa6f" xlink:href="biib-20200930.xsd#biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_599f611c-66e2-47cc-9dac-fd26b0f999a9" xlink:to="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_ce11ed94-470a-4444-8607-cbc899d8aa6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_5a1bda78-db78-4e69-bc88-3eb9bd81993c" xlink:href="biib-20200930.xsd#biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_599f611c-66e2-47cc-9dac-fd26b0f999a9" xlink:to="loc_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_5a1bda78-db78-4e69-bc88-3eb9bd81993c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherrevenuesTableTextBlock_e16da57a-3047-4409-a165-7a8957faec2a" xlink:href="biib-20200930.xsd#biib_OtherrevenuesTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_599f611c-66e2-47cc-9dac-fd26b0f999a9" xlink:to="loc_biib_OtherrevenuesTableTextBlock_e16da57a-3047-4409-a165-7a8957faec2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesbyProductDetails" xlink:type="simple" xlink:href="biib-20200930.xsd#RevenuesbyProductDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesbyProductDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueAbstract_21172979-e7ad-4735-b8c5-5719a29b7a1e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_cb543448-a3b1-4565-9960-ad7b3248f3f5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueAbstract_21172979-e7ad-4735-b8c5-5719a29b7a1e" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_cb543448-a3b1-4565-9960-ad7b3248f3f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_07ccdc80-1769-4832-951e-28c985b149c7" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_cb543448-a3b1-4565-9960-ad7b3248f3f5" xlink:to="loc_srt_ProductOrServiceAxis_07ccdc80-1769-4832-951e-28c985b149c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_199d3346-b5a8-4820-95a1-21e8cf8cbfce" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_07ccdc80-1769-4832-951e-28c985b149c7" xlink:to="loc_srt_ProductsAndServicesDomain_199d3346-b5a8-4820-95a1-21e8cf8cbfce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FumarateMember_b280111d-948d-4e1c-a091-c53d3d3608aa" xlink:href="biib-20200930.xsd#biib_FumarateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_199d3346-b5a8-4820-95a1-21e8cf8cbfce" xlink:to="loc_biib_FumarateMember_b280111d-948d-4e1c-a091-c53d3d3608aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InterferonMember_c1503061-21f4-42bd-94d2-a6a09ac81bd1" xlink:href="biib-20200930.xsd#biib_InterferonMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_199d3346-b5a8-4820-95a1-21e8cf8cbfce" xlink:to="loc_biib_InterferonMember_c1503061-21f4-42bd-94d2-a6a09ac81bd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TysabriProductMember_8d187006-3b97-455f-b64e-477bb7f7e7f7" xlink:href="biib-20200930.xsd#biib_TysabriProductMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_199d3346-b5a8-4820-95a1-21e8cf8cbfce" xlink:to="loc_biib_TysabriProductMember_8d187006-3b97-455f-b64e-477bb7f7e7f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FAMPYRAMember_6d76bd9c-37d0-4cb7-9648-787bc63853ae" xlink:href="biib-20200930.xsd#biib_FAMPYRAMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_199d3346-b5a8-4820-95a1-21e8cf8cbfce" xlink:to="loc_biib_FAMPYRAMember_6d76bd9c-37d0-4cb7-9648-787bc63853ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ZINBRYTAMember_12c63b78-569d-49de-a036-9c6e3e86c741" xlink:href="biib-20200930.xsd#biib_ZINBRYTAMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_199d3346-b5a8-4820-95a1-21e8cf8cbfce" xlink:to="loc_biib_ZINBRYTAMember_12c63b78-569d-49de-a036-9c6e3e86c741" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MSProductRevenuesMember_6b468203-238b-4791-a1d1-89aa2b6ae00e" xlink:href="biib-20200930.xsd#biib_MSProductRevenuesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_199d3346-b5a8-4820-95a1-21e8cf8cbfce" xlink:to="loc_biib_MSProductRevenuesMember_6b468203-238b-4791-a1d1-89aa2b6ae00e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SPINRAZAMember_44cdf1a4-fcd8-4495-ad23-2afcefc0394d" xlink:href="biib-20200930.xsd#biib_SPINRAZAMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_199d3346-b5a8-4820-95a1-21e8cf8cbfce" xlink:to="loc_biib_SPINRAZAMember_44cdf1a4-fcd8-4495-ad23-2afcefc0394d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BENEPALIMember_0232bc82-1011-4509-be1b-6ab36a4959e6" xlink:href="biib-20200930.xsd#biib_BENEPALIMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_199d3346-b5a8-4820-95a1-21e8cf8cbfce" xlink:to="loc_biib_BENEPALIMember_0232bc82-1011-4509-be1b-6ab36a4959e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IMRALDIMember_570917fb-06e5-4262-98b4-79343478a7c0" xlink:href="biib-20200930.xsd#biib_IMRALDIMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_199d3346-b5a8-4820-95a1-21e8cf8cbfce" xlink:to="loc_biib_IMRALDIMember_570917fb-06e5-4262-98b4-79343478a7c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FLIXABIMember_79ebdf56-ee59-4fc9-bb71-76a17c793c91" xlink:href="biib-20200930.xsd#biib_FLIXABIMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_199d3346-b5a8-4820-95a1-21e8cf8cbfce" xlink:to="loc_biib_FLIXABIMember_79ebdf56-ee59-4fc9-bb71-76a17c793c91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BiosimilarsMember_32d6abe0-fd9d-4687-8b05-b12f01c371a1" xlink:href="biib-20200930.xsd#biib_BiosimilarsMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_199d3346-b5a8-4820-95a1-21e8cf8cbfce" xlink:to="loc_biib_BiosimilarsMember_32d6abe0-fd9d-4687-8b05-b12f01c371a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FUMADERMMember_e6d06810-da0e-43ca-9c19-fd4aae3d01b1" xlink:href="biib-20200930.xsd#biib_FUMADERMMember"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_199d3346-b5a8-4820-95a1-21e8cf8cbfce" xlink:to="loc_biib_FUMADERMMember_e6d06810-da0e-43ca-9c19-fd4aae3d01b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_1dac7a53-4278-4647-8266-fcd861eb0ec6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_199d3346-b5a8-4820-95a1-21e8cf8cbfce" xlink:to="loc_us-gaap_ProductMember_1dac7a53-4278-4647-8266-fcd861eb0ec6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_8a07a6ad-b024-4ce1-8d47-1d426c0bdcc8" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_cb543448-a3b1-4565-9960-ad7b3248f3f5" xlink:to="loc_srt_StatementGeographicalAxis_8a07a6ad-b024-4ce1-8d47-1d426c0bdcc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_b38f1ab8-8a21-4ce7-949d-83dbe4c8744a" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_8a07a6ad-b024-4ce1-8d47-1d426c0bdcc8" xlink:to="loc_srt_SegmentGeographicalDomain_b38f1ab8-8a21-4ce7-949d-83dbe4c8744a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_a6e962a1-aabf-49bc-b53a-818ee3f6c02a" xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_b38f1ab8-8a21-4ce7-949d-83dbe4c8744a" xlink:to="loc_country_US_a6e962a1-aabf-49bc-b53a-818ee3f6c02a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_fb2156a1-ede4-4345-acfa-8d013055a938" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_b38f1ab8-8a21-4ce7-949d-83dbe4c8744a" xlink:to="loc_us-gaap_NonUsMember_fb2156a1-ede4-4345-acfa-8d013055a938" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_59b188df-fb97-4745-badf-a7fdf0f22b40" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_cb543448-a3b1-4565-9960-ad7b3248f3f5" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_59b188df-fb97-4745-badf-a7fdf0f22b40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_d5d27ca1-9b54-46af-a95d-753a17c8f9b1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_59b188df-fb97-4745-badf-a7fdf0f22b40" xlink:to="loc_us-gaap_Revenues_d5d27ca1-9b54-46af-a95d-753a17c8f9b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ReservesforDiscountsandAllowancesDetails1" xlink:type="simple" xlink:href="biib-20200930.xsd#ReservesforDiscountsandAllowancesDetails1"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ReservesforDiscountsandAllowancesDetails1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract_e318ffe6-561a-41d3-b61a-d92254bc6759" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ValuationAndQualifyingAccountsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_d7560ab8-c200-4586-86b5-5642a7e48504" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract_e318ffe6-561a-41d3-b61a-d92254bc6759" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_d7560ab8-c200-4586-86b5-5642a7e48504" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_8314a720-244e-4f7a-97f3-f282444db63b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_d7560ab8-c200-4586-86b5-5642a7e48504" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_8314a720-244e-4f7a-97f3-f282444db63b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_8078ab82-fd94-4837-bb13-1242ca618a46" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_8314a720-244e-4f7a-97f3-f282444db63b" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_8078ab82-fd94-4837-bb13-1242ca618a46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReserveforCashDiscountsMember_90f3d801-2b30-4acf-97b7-d45394a67f67" xlink:href="biib-20200930.xsd#biib_ReserveforCashDiscountsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_8078ab82-fd94-4837-bb13-1242ca618a46" xlink:to="loc_biib_ReserveforCashDiscountsMember_90f3d801-2b30-4acf-97b7-d45394a67f67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ContractualAdjustmentsMember_2886ef9c-a745-4891-8a3d-1fceca5cbfed" xlink:href="biib-20200930.xsd#biib_ContractualAdjustmentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_8078ab82-fd94-4837-bb13-1242ca618a46" xlink:to="loc_biib_ContractualAdjustmentsMember_2886ef9c-a745-4891-8a3d-1fceca5cbfed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesReturnsAndAllowancesMember_016ce499-cb7a-484a-81ef-19511da68cfb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SalesReturnsAndAllowancesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_8078ab82-fd94-4837-bb13-1242ca618a46" xlink:to="loc_us-gaap_SalesReturnsAndAllowancesMember_016ce499-cb7a-484a-81ef-19511da68cfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_34b85f44-80fa-4299-9fe6-ab0b1d737100" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_d7560ab8-c200-4586-86b5-5642a7e48504" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_34b85f44-80fa-4299-9fe6-ab0b1d737100" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_921107ec-69be-4d39-beef-7ad192d9a2a9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_34b85f44-80fa-4299-9fe6-ab0b1d737100" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_921107ec-69be-4d39-beef-7ad192d9a2a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_9f9fa918-7a74-42c1-871e-f2c0979cb3b1" xlink:href="biib-20200930.xsd#biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_34b85f44-80fa-4299-9fe6-ab0b1d737100" xlink:to="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_9f9fa918-7a74-42c1-871e-f2c0979cb3b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_68480d82-6092-4e9b-8363-e349bd1ddbd3" xlink:href="biib-20200930.xsd#biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_34b85f44-80fa-4299-9fe6-ab0b1d737100" xlink:to="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_68480d82-6092-4e9b-8363-e349bd1ddbd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_6b4d6884-2135-45a3-8348-a2ff7e47f7a8" xlink:href="biib-20200930.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_34b85f44-80fa-4299-9fe6-ab0b1d737100" xlink:to="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_6b4d6884-2135-45a3-8348-a2ff7e47f7a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_3de5aa28-34bd-49f0-9b23-7bbe6d4b8c1a" xlink:href="biib-20200930.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_34b85f44-80fa-4299-9fe6-ab0b1d737100" xlink:to="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_3de5aa28-34bd-49f0-9b23-7bbe6d4b8c1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_9f9b7727-26cb-4d92-8e26-d702a26df211" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_34b85f44-80fa-4299-9fe6-ab0b1d737100" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_9f9b7727-26cb-4d92-8e26-d702a26df211" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ReservesforDiscountsandAllowancesDetails2" xlink:type="simple" xlink:href="biib-20200930.xsd#ReservesforDiscountsandAllowancesDetails2"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ReservesforDiscountsandAllowancesDetails2" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract_6afde9f3-5f12-4e2e-b515-aff4898c2f7d" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ValuationAndQualifyingAccountsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_587747a8-e7a8-4e17-a137-188025414833" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract_6afde9f3-5f12-4e2e-b515-aff4898c2f7d" xlink:to="loc_us-gaap_StatementTable_587747a8-e7a8-4e17-a137-188025414833" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_fc98a389-6596-4bba-bd45-d8430e7b6d61" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_587747a8-e7a8-4e17-a137-188025414833" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_fc98a389-6596-4bba-bd45-d8430e7b6d61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_f21ade67-9d3c-483e-a962-d2d80890a2e2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_fc98a389-6596-4bba-bd45-d8430e7b6d61" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_f21ade67-9d3c-483e-a962-d2d80890a2e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_47cf1ea1-7337-47ab-9eec-9333cfd66b2d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_f21ade67-9d3c-483e-a962-d2d80890a2e2" xlink:to="loc_us-gaap_AccountsReceivableMember_47cf1ea1-7337-47ab-9eec-9333cfd66b2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_5c3c2550-2ef7-4d88-86d2-9f923494b74e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_f21ade67-9d3c-483e-a962-d2d80890a2e2" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_5c3c2550-2ef7-4d88-86d2-9f923494b74e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_1db4b5b8-aa6b-4090-9f8a-dfce9fb421a0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_587747a8-e7a8-4e17-a137-188025414833" xlink:to="loc_us-gaap_StatementLineItems_1db4b5b8-aa6b-4090-9f8a-dfce9fb421a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_14c54d87-029d-4ac4-9edf-38996bd24f4d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1db4b5b8-aa6b-4090-9f8a-dfce9fb421a0" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_14c54d87-029d-4ac4-9edf-38996bd24f4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesfromAntiCD20TherapeuticProgramsDetails" xlink:type="simple" xlink:href="biib-20200930.xsd#RevenuesfromAntiCD20TherapeuticProgramsDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesfromAntiCD20TherapeuticProgramsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_79351f29-1274-4c19-a082-2196044d1779" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_a95f4baf-021d-45b7-bd9a-6fd90e8c93b3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_79351f29-1274-4c19-a082-2196044d1779" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_a95f4baf-021d-45b7-bd9a-6fd90e8c93b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_46eda230-5873-4b9a-bffd-af486315fa58" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_a95f4baf-021d-45b7-bd9a-6fd90e8c93b3" xlink:to="loc_srt_ProductOrServiceAxis_46eda230-5873-4b9a-bffd-af486315fa58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_22579e70-bbc0-48c3-96e0-cb7ba9f4bbdb" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_46eda230-5873-4b9a-bffd-af486315fa58" xlink:to="loc_srt_ProductsAndServicesDomain_22579e70-bbc0-48c3-96e0-cb7ba9f4bbdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_3f9330c3-c93b-4d78-a304-f35cc713c54b" xlink:href="biib-20200930.xsd#biib_Revenuesfromanticd20therapeuticprogramsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_22579e70-bbc0-48c3-96e0-cb7ba9f4bbdb" xlink:to="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_3f9330c3-c93b-4d78-a304-f35cc713c54b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_30e004ec-2ad1-4b97-89df-3eed2916de41" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_a95f4baf-021d-45b7-bd9a-6fd90e8c93b3" xlink:to="loc_srt_MajorCustomersAxis_30e004ec-2ad1-4b97-89df-3eed2916de41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_cc8b69e6-be78-4d60-a38d-140359669f0b" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_30e004ec-2ad1-4b97-89df-3eed2916de41" xlink:to="loc_srt_NameOfMajorCustomerDomain_cc8b69e6-be78-4d60-a38d-140359669f0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RocheGroupGenentechMember_b527a3bd-7a63-425d-b99f-461f4cf21cb2" xlink:href="biib-20200930.xsd#biib_RocheGroupGenentechMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_cc8b69e6-be78-4d60-a38d-140359669f0b" xlink:to="loc_biib_RocheGroupGenentechMember_b527a3bd-7a63-425d-b99f-461f4cf21cb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_7023968b-8bc4-45a1-9209-73afbf8ebd5b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_a95f4baf-021d-45b7-bd9a-6fd90e8c93b3" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_7023968b-8bc4-45a1-9209-73afbf8ebd5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareOfCoPromotionProfits_5256cd5e-edfc-4cde-92b8-2151e77781c1" xlink:href="biib-20200930.xsd#biib_ShareOfCoPromotionProfits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_7023968b-8bc4-45a1-9209-73afbf8ebd5b" xlink:to="loc_biib_ShareOfCoPromotionProfits_5256cd5e-edfc-4cde-92b8-2151e77781c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms_1d987b2b-e61a-423f-b950-cf1c0fbaee0b" xlink:href="biib-20200930.xsd#biib_OtherrevenuesfromantiCD20therapeuticprograms"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_7023968b-8bc4-45a1-9209-73afbf8ebd5b" xlink:to="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms_1d987b2b-e61a-423f-b950-cf1c0fbaee0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_c7321cb4-8dd8-47ef-9fcb-832e64abdc25" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_7023968b-8bc4-45a1-9209-73afbf8ebd5b" xlink:to="loc_us-gaap_Revenues_c7321cb4-8dd8-47ef-9fcb-832e64abdc25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherRevenuesDetails" xlink:type="simple" xlink:href="biib-20200930.xsd#OtherRevenuesDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/OtherRevenuesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherrevenuesAbstract_03089a9c-ed6b-4443-90f7-9a7350562414" xlink:href="biib-20200930.xsd#biib_OtherrevenuesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_bfbc5de7-851a-4515-b0aa-ee9b558faff8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_OtherrevenuesAbstract_03089a9c-ed6b-4443-90f7-9a7350562414" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_bfbc5de7-851a-4515-b0aa-ee9b558faff8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_59de4172-a930-44da-8eaa-54ef91d2ede6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_bfbc5de7-851a-4515-b0aa-ee9b558faff8" xlink:to="loc_us-gaap_TypeOfArrangementAxis_59de4172-a930-44da-8eaa-54ef91d2ede6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4204154c-7f78-4375-b240-967d0f013f6c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_59de4172-a930-44da-8eaa-54ef91d2ede6" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4204154c-7f78-4375-b240-967d0f013f6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_95722ecf-ec3c-4919-a238-f527ca5334e9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4204154c-7f78-4375-b240-967d0f013f6c" xlink:to="loc_us-gaap_CollaborativeArrangementMember_95722ecf-ec3c-4919-a238-f527ca5334e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_3e8c4a91-c937-4d22-a38e-38a7328cc71b" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_bfbc5de7-851a-4515-b0aa-ee9b558faff8" xlink:to="loc_srt_ProductOrServiceAxis_3e8c4a91-c937-4d22-a38e-38a7328cc71b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c9d0ea88-c582-4b77-afec-49bcd23dbf3c" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_3e8c4a91-c937-4d22-a38e-38a7328cc71b" xlink:to="loc_srt_ProductsAndServicesDomain_c9d0ea88-c582-4b77-afec-49bcd23dbf3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_6a07dfb7-7824-4196-832e-df0e6759b0a8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c9d0ea88-c582-4b77-afec-49bcd23dbf3c" xlink:to="loc_us-gaap_RoyaltyMember_6a07dfb7-7824-4196-832e-df0e6759b0a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OthercorporaterevenuesMember_add0d0dd-4a1c-49a3-8abc-d18eeb961bf1" xlink:href="biib-20200930.xsd#biib_OthercorporaterevenuesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c9d0ea88-c582-4b77-afec-49bcd23dbf3c" xlink:to="loc_biib_OthercorporaterevenuesMember_add0d0dd-4a1c-49a3-8abc-d18eeb961bf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_e85d6672-e00f-4953-bcf5-fabae562da04" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c9d0ea88-c582-4b77-afec-49bcd23dbf3c" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_e85d6672-e00f-4953-bcf5-fabae562da04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_43b72e8a-2dec-4f40-ae22-e5d697e1a041" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_bfbc5de7-851a-4515-b0aa-ee9b558faff8" xlink:to="loc_srt_MajorCustomersAxis_43b72e8a-2dec-4f40-ae22-e5d697e1a041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_46d4cfee-3578-4c45-abac-7a74e60c2fc2" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_43b72e8a-2dec-4f40-ae22-e5d697e1a041" xlink:to="loc_srt_NameOfMajorCustomerDomain_46d4cfee-3578-4c45-abac-7a74e60c2fc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_a2acf4ea-177a-47dd-963e-ab4aeeb08838" xlink:href="biib-20200930.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_46d4cfee-3578-4c45-abac-7a74e60c2fc2" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_a2acf4ea-177a-47dd-963e-ab4aeeb08838" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ZINBRYTAMember_a27265a0-feff-4494-b606-a15bf7a30f02" xlink:href="biib-20200930.xsd#biib_ZINBRYTAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_46d4cfee-3578-4c45-abac-7a74e60c2fc2" xlink:to="loc_biib_ZINBRYTAMember_a27265a0-feff-4494-b606-a15bf7a30f02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_725cdab2-b8b1-46a8-8417-4de5b06a57e4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_bfbc5de7-851a-4515-b0aa-ee9b558faff8" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_725cdab2-b8b1-46a8-8417-4de5b06a57e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_fc32c518-0de7-4b55-9255-3f2c7a2e6f12" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_725cdab2-b8b1-46a8-8417-4de5b06a57e4" xlink:to="loc_us-gaap_Revenues_fc32c518-0de7-4b55-9255-3f2c7a2e6f12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_1d7e14eb-df1b-4ba7-9a3d-7d3f3f8c09ed" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_725cdab2-b8b1-46a8-8417-4de5b06a57e4" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_1d7e14eb-df1b-4ba7-9a3d-7d3f3f8c09ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesDetailsTextual" xlink:type="simple" xlink:href="biib-20200930.xsd#RevenuesDetailsTextual"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesDetailsTextual" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_bb154bc1-530d-46f7-83b4-a4c257c49b48" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_f6c5c658-7f71-42bb-8b22-5d9ce3191f78" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_bb154bc1-530d-46f7-83b4-a4c257c49b48" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_f6c5c658-7f71-42bb-8b22-5d9ce3191f78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_04b7dadc-8d57-4b9f-a25f-5532e1927ed5" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_f6c5c658-7f71-42bb-8b22-5d9ce3191f78" xlink:to="loc_srt_ProductOrServiceAxis_04b7dadc-8d57-4b9f-a25f-5532e1927ed5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6cbb554f-e253-479c-9c74-8e1d51fcd176" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_04b7dadc-8d57-4b9f-a25f-5532e1927ed5" xlink:to="loc_srt_ProductsAndServicesDomain_6cbb554f-e253-479c-9c74-8e1d51fcd176" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OthercorporaterevenuesMember_d5bb1c22-d2b1-4a84-aa2e-bcd775afe37c" xlink:href="biib-20200930.xsd#biib_OthercorporaterevenuesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_6cbb554f-e253-479c-9c74-8e1d51fcd176" xlink:to="loc_biib_OthercorporaterevenuesMember_d5bb1c22-d2b1-4a84-aa2e-bcd775afe37c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_e766b28e-f0b4-40a8-8051-f9e3d60d5903" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_6cbb554f-e253-479c-9c74-8e1d51fcd176" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_e766b28e-f0b4-40a8-8051-f9e3d60d5903" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_5ac4cd68-3790-4b15-b6ec-2403743809dc" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_f6c5c658-7f71-42bb-8b22-5d9ce3191f78" xlink:to="loc_srt_MajorCustomersAxis_5ac4cd68-3790-4b15-b6ec-2403743809dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_aad12712-dea4-473e-8185-b1dc8dfc4268" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_5ac4cd68-3790-4b15-b6ec-2403743809dc" xlink:to="loc_srt_NameOfMajorCustomerDomain_aad12712-dea4-473e-8185-b1dc8dfc4268" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DistributorOneMember_5c2a9150-f93b-445d-a568-f1a74421cad3" xlink:href="biib-20200930.xsd#biib_DistributorOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_aad12712-dea4-473e-8185-b1dc8dfc4268" xlink:to="loc_biib_DistributorOneMember_5c2a9150-f93b-445d-a568-f1a74421cad3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DistributorTwoMember_59fba0c9-b3df-4e37-a041-be8758e80a68" xlink:href="biib-20200930.xsd#biib_DistributorTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_aad12712-dea4-473e-8185-b1dc8dfc4268" xlink:to="loc_biib_DistributorTwoMember_59fba0c9-b3df-4e37-a041-be8758e80a68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BioverativMember_7723fe0d-b390-4a93-b829-9dc54b908557" xlink:href="biib-20200930.xsd#biib_BioverativMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_aad12712-dea4-473e-8185-b1dc8dfc4268" xlink:to="loc_biib_BioverativMember_7723fe0d-b390-4a93-b829-9dc54b908557" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ContractManufacturingCustomerMember_bed550e9-310d-44e2-b8ab-c5761aedeb74" xlink:href="biib-20200930.xsd#biib_ContractManufacturingCustomerMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_aad12712-dea4-473e-8185-b1dc8dfc4268" xlink:to="loc_biib_ContractManufacturingCustomerMember_bed550e9-310d-44e2-b8ab-c5761aedeb74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_5cf1aaa7-7535-4989-9904-381d5cf21ddf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_f6c5c658-7f71-42bb-8b22-5d9ce3191f78" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_5cf1aaa7-7535-4989-9904-381d5cf21ddf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_dcbaf542-93d5-47bb-8bb0-6edbcb30f3d4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_5cf1aaa7-7535-4989-9904-381d5cf21ddf" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_dcbaf542-93d5-47bb-8bb0-6edbcb30f3d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_aaa4b1be-1fec-4fff-815f-6403fb333c4c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_5cf1aaa7-7535-4989-9904-381d5cf21ddf" xlink:to="loc_us-gaap_Revenues_aaa4b1be-1fec-4fff-815f-6403fb333c4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors_cf761ef1-d975-4bc9-8d9a-f2cbe49c6a54" xlink:href="biib-20200930.xsd#biib_EntityWidePercentageOfRevenueFromMajorDistributors"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_5cf1aaa7-7535-4989-9904-381d5cf21ddf" xlink:to="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors_cf761ef1-d975-4bc9-8d9a-f2cbe49c6a54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NumberOfWholesalers_070366b9-ba95-4449-ac90-14de96f6960a" xlink:href="biib-20200930.xsd#biib_NumberOfWholesalers"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_5cf1aaa7-7535-4989-9904-381d5cf21ddf" xlink:to="loc_biib_NumberOfWholesalers_070366b9-ba95-4449-ac90-14de96f6960a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/Inventory" xlink:type="simple" xlink:href="biib-20200930.xsd#Inventory"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Inventory" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_13ffbb86-620c-48cd-b5ae-f62db8a22d1d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_cec0d4de-5c4c-4edf-af3f-ed94f2387d12" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_13ffbb86-620c-48cd-b5ae-f62db8a22d1d" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_cec0d4de-5c4c-4edf-af3f-ed94f2387d12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryTables" xlink:type="simple" xlink:href="biib-20200930.xsd#InventoryTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/InventoryTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_b16201b8-887b-428e-8480-5d6959546ef6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_eecdfeee-ae38-4fea-a5f1-dee4fe34c495" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_b16201b8-887b-428e-8480-5d6959546ef6" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_eecdfeee-ae38-4fea-a5f1-dee4fe34c495" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryDetails" xlink:type="simple" xlink:href="biib-20200930.xsd#InventoryDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/InventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_7ef5e1ce-0330-4e43-ae71-92d9fc236f52" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNetAbstract_67b42150-2339-4603-a51e-d8a3a56a6dc4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_7ef5e1ce-0330-4e43-ae71-92d9fc236f52" xlink:to="loc_us-gaap_InventoryNetAbstract_67b42150-2339-4603-a51e-d8a3a56a6dc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_c47517bd-284c-4107-aa3c-017c77acbff3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_67b42150-2339-4603-a51e-d8a3a56a6dc4" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_c47517bd-284c-4107-aa3c-017c77acbff3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_8cec9474-2c35-4986-93e4-fd2290116d98" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_67b42150-2339-4603-a51e-d8a3a56a6dc4" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_8cec9474-2c35-4986-93e4-fd2290116d98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_d3f9df5c-4a33-4289-a0fe-579fec5d7116" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_67b42150-2339-4603-a51e-d8a3a56a6dc4" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_d3f9df5c-4a33-4289-a0fe-579fec5d7116" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Inventorynetcurrentandnoncurrent_d36e1cf9-9f4e-43f6-b492-4199bca237d8" xlink:href="biib-20200930.xsd#biib_Inventorynetcurrentandnoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_67b42150-2339-4603-a51e-d8a3a56a6dc4" xlink:to="loc_biib_Inventorynetcurrentandnoncurrent_d36e1cf9-9f4e-43f6-b492-4199bca237d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwill" xlink:type="simple" xlink:href="biib-20200930.xsd#IntangibleAssetsandGoodwill"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsandGoodwill" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3950f2de-10d9-4e79-a681-5ad31b2a0a02" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_be485696-088b-4ca9-9d32-f62d3058f26f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3950f2de-10d9-4e79-a681-5ad31b2a0a02" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_be485696-088b-4ca9-9d32-f62d3058f26f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables" xlink:type="simple" xlink:href="biib-20200930.xsd#IntangibleAssetsandGoodwillTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4176ce79-f903-480f-a7bc-b2b980127d59" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_820378ee-5466-452f-8876-fc4671e3ba4b" xlink:href="biib-20200930.xsd#biib_IntangibleAssetsExcludingGoodwillTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4176ce79-f903-480f-a7bc-b2b980127d59" xlink:to="loc_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_820378ee-5466-452f-8876-fc4671e3ba4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_3caeadaa-0780-4b1b-9283-783929bbb403" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4176ce79-f903-480f-a7bc-b2b980127d59" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_3caeadaa-0780-4b1b-9283-783929bbb403" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_d4a3bda8-e82d-4eaf-afa4-00028983096f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4176ce79-f903-480f-a7bc-b2b980127d59" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_d4a3bda8-e82d-4eaf-afa4-00028983096f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails" xlink:type="simple" xlink:href="biib-20200930.xsd#IntangibleAssetsandGoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b3ab640c-bbdf-425a-a58b-32677b2b5b23" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_f6f95c93-30b7-4d27-bf60-3438102d921c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b3ab640c-bbdf-425a-a58b-32677b2b5b23" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_f6f95c93-30b7-4d27-bf60-3438102d921c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchanddevelopmentassetAxis_ceb5bcce-9340-44aa-b1dd-a6a2846f2cc8" xlink:href="biib-20200930.xsd#biib_ResearchanddevelopmentassetAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_f6f95c93-30b7-4d27-bf60-3438102d921c" xlink:to="loc_biib_ResearchanddevelopmentassetAxis_ceb5bcce-9340-44aa-b1dd-a6a2846f2cc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchanddevelopmentassetDomain_ce66f39c-5a4e-4b92-9db8-e3ee9ded26d3" xlink:href="biib-20200930.xsd#biib_ResearchanddevelopmentassetDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ResearchanddevelopmentassetAxis_ceb5bcce-9340-44aa-b1dd-a6a2846f2cc8" xlink:to="loc_biib_ResearchanddevelopmentassetDomain_ce66f39c-5a4e-4b92-9db8-e3ee9ded26d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TGNMember_d4a58862-5804-4783-abe6-6a2de4792f31" xlink:href="biib-20200930.xsd#biib_TGNMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ResearchanddevelopmentassetDomain_ce66f39c-5a4e-4b92-9db8-e3ee9ded26d3" xlink:to="loc_biib_TGNMember_d4a58862-5804-4783-abe6-6a2de4792f31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_bb48a466-ec0c-48ee-b5f3-9f3cbef36f5f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_f6f95c93-30b7-4d27-bf60-3438102d921c" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_bb48a466-ec0c-48ee-b5f3-9f3cbef36f5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e2329fb5-91d0-4fe7-a098-5dfe3bfedae1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_bb48a466-ec0c-48ee-b5f3-9f3cbef36f5f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e2329fb5-91d0-4fe7-a098-5dfe3bfedae1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NightstarMember_ed9306a8-a41d-4bcf-834f-a3c732cba3e5" xlink:href="biib-20200930.xsd#biib_NightstarMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e2329fb5-91d0-4fe7-a098-5dfe3bfedae1" xlink:to="loc_biib_NightstarMember_ed9306a8-a41d-4bcf-834f-a3c732cba3e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_8f33b9da-3758-49c3-b6bc-0e72a1cd61b3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_f6f95c93-30b7-4d27-bf60-3438102d921c" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_8f33b9da-3758-49c3-b6bc-0e72a1cd61b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_df851199-eb49-4bab-a66a-4bc909d515f4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_8f33b9da-3758-49c3-b6bc-0e72a1cd61b3" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_df851199-eb49-4bab-a66a-4bc909d515f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_a0375f7c-b947-4ee0-b3ce-7a9047384775" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_df851199-eb49-4bab-a66a-4bc909d515f4" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_a0375f7c-b947-4ee0-b3ce-7a9047384775" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember_94b40aec-2383-4b34-bef7-b28d98e0828e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TrademarksAndTradeNamesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_df851199-eb49-4bab-a66a-4bc909d515f4" xlink:to="loc_us-gaap_TrademarksAndTradeNamesMember_94b40aec-2383-4b34-bef7-b28d98e0828e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5d81f936-3d94-4b32-a979-c0042bbf9029" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_f6f95c93-30b7-4d27-bf60-3438102d921c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5d81f936-3d94-4b32-a979-c0042bbf9029" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c133b0b5-9041-4404-875d-af32e40da6dc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5d81f936-3d94-4b32-a979-c0042bbf9029" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c133b0b5-9041-4404-875d-af32e40da6dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_21188deb-923a-4067-9e6c-db77ae2ff976" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c133b0b5-9041-4404-875d-af32e40da6dc" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_21188deb-923a-4067-9e6c-db77ae2ff976" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OutLicensedPatentsMember_d247fa09-b5ca-4bf1-a11d-bd70050d8376" xlink:href="biib-20200930.xsd#biib_OutLicensedPatentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c133b0b5-9041-4404-875d-af32e40da6dc" xlink:to="loc_biib_OutLicensedPatentsMember_d247fa09-b5ca-4bf1-a11d-bd70050d8376" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_1dd9f5df-c87f-42d3-8bec-8e059ff5ef53" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c133b0b5-9041-4404-875d-af32e40da6dc" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_1dd9f5df-c87f-42d3-8bec-8e059ff5ef53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InLicensedPatentsMember_14e4ab6a-c947-4df5-b566-855b6b5a7e19" xlink:href="biib-20200930.xsd#biib_InLicensedPatentsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c133b0b5-9041-4404-875d-af32e40da6dc" xlink:to="loc_biib_InLicensedPatentsMember_14e4ab6a-c947-4df5-b566-855b6b5a7e19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_b3d9f23e-dcfa-44be-aedb-ef0520bc293d" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_f6f95c93-30b7-4d27-bf60-3438102d921c" xlink:to="loc_srt_ProductOrServiceAxis_b3d9f23e-dcfa-44be-aedb-ef0520bc293d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a4cf3d8c-c122-48e8-a28f-572c09caa658" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_b3d9f23e-dcfa-44be-aedb-ef0520bc293d" xlink:to="loc_srt_ProductsAndServicesDomain_a4cf3d8c-c122-48e8-a28f-572c09caa658" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AVONEXMember_923976a0-872a-4c8c-bb6e-026516debb66" xlink:href="biib-20200930.xsd#biib_AVONEXMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a4cf3d8c-c122-48e8-a28f-572c09caa658" xlink:to="loc_biib_AVONEXMember_923976a0-872a-4c8c-bb6e-026516debb66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TysabriProductMember_f7a29cf3-da17-4005-bab3-fee4546afb24" xlink:href="biib-20200930.xsd#biib_TysabriProductMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a4cf3d8c-c122-48e8-a28f-572c09caa658" xlink:to="loc_biib_TysabriProductMember_f7a29cf3-da17-4005-bab3-fee4546afb24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FumarateMember_05f1c647-32d1-4aae-8cf3-39d6510579b2" xlink:href="biib-20200930.xsd#biib_FumarateMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a4cf3d8c-c122-48e8-a28f-572c09caa658" xlink:to="loc_biib_FumarateMember_05f1c647-32d1-4aae-8cf3-39d6510579b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_be65b510-8ccf-4c1d-83a4-b7bbe263337c" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_f6f95c93-30b7-4d27-bf60-3438102d921c" xlink:to="loc_srt_RangeAxis_be65b510-8ccf-4c1d-83a4-b7bbe263337c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b0f0e7de-d8ff-4b51-af18-67b7f484a218" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_be65b510-8ccf-4c1d-83a4-b7bbe263337c" xlink:to="loc_srt_RangeMember_b0f0e7de-d8ff-4b51-af18-67b7f484a218" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_7f0e5ea3-4e41-47ef-ad57-44ab8f6c61b2" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_b0f0e7de-d8ff-4b51-af18-67b7f484a218" xlink:to="loc_srt_MinimumMember_7f0e5ea3-4e41-47ef-ad57-44ab8f6c61b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f8b02225-54c9-476d-9187-640d4f58a48f" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_b0f0e7de-d8ff-4b51-af18-67b7f484a218" xlink:to="loc_srt_MaximumMember_f8b02225-54c9-476d-9187-640d4f58a48f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_5bc1795f-50d9-41e1-8103-19f873f72efd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_f6f95c93-30b7-4d27-bf60-3438102d921c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_5bc1795f-50d9-41e1-8103-19f873f72efd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_3504b9db-bfe8-46d9-9cc5-8ad1e6a7f391" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_5bc1795f-50d9-41e1-8103-19f873f72efd" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_3504b9db-bfe8-46d9-9cc5-8ad1e6a7f391" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_ad94037e-1e9e-4580-895c-9f8ecca86650" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_5bc1795f-50d9-41e1-8103-19f873f72efd" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_ad94037e-1e9e-4580-895c-9f8ecca86650" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_be11953f-0510-4543-a406-2980b63ef929" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_ad94037e-1e9e-4580-895c-9f8ecca86650" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_be11953f-0510-4543-a406-2980b63ef929" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IndefiniteLivedIntangibleAssetsUsefulLife_34e6e80d-955a-48e6-9b71-13fb7edb6980" xlink:href="biib-20200930.xsd#biib_IndefiniteLivedIntangibleAssetsUsefulLife"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_ad94037e-1e9e-4580-895c-9f8ecca86650" xlink:to="loc_biib_IndefiniteLivedIntangibleAssetsUsefulLife_34e6e80d-955a-48e6-9b71-13fb7edb6980" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_0ba637f5-6889-475b-83fc-2e3f64e6c363" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_ad94037e-1e9e-4580-895c-9f8ecca86650" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_0ba637f5-6889-475b-83fc-2e3f64e6c363" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_f01e424c-ab75-4b73-9920-c3f30e3c4bdd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_ad94037e-1e9e-4580-895c-9f8ecca86650" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_f01e424c-ab75-4b73-9920-c3f30e3c4bdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_af6564ae-45a8-4668-8bfc-cebbf23b05a2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_ad94037e-1e9e-4580-895c-9f8ecca86650" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_af6564ae-45a8-4668-8bfc-cebbf23b05a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_05b3c575-cb09-4b4a-91bf-fd6e75fdd9b7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_ad94037e-1e9e-4580-895c-9f8ecca86650" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_05b3c575-cb09-4b4a-91bf-fd6e75fdd9b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_531e7059-ce77-472f-8c57-45e129c11838" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_ad94037e-1e9e-4580-895c-9f8ecca86650" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_531e7059-ce77-472f-8c57-45e129c11838" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_c28e37e5-7b93-40a5-abdb-a241084e5c2f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_ad94037e-1e9e-4580-895c-9f8ecca86650" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_c28e37e5-7b93-40a5-abdb-a241084e5c2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_8771fd86-6796-4c56-bab8-5f08578e9747" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_ad94037e-1e9e-4580-895c-9f8ecca86650" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_8771fd86-6796-4c56-bab8-5f08578e9747" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_79a6af86-a8ea-4bcf-9551-609d9bdb873d" xlink:href="biib-20200930.xsd#biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_5bc1795f-50d9-41e1-8103-19f873f72efd" xlink:to="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_79a6af86-a8ea-4bcf-9551-609d9bdb873d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_4b9d78b0-729d-4864-8dd8-e8d485ed3aa1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_5bc1795f-50d9-41e1-8103-19f873f72efd" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_4b9d78b0-729d-4864-8dd8-e8d485ed3aa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_c8bfae87-f514-4605-bb0e-17198a2118cb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_5bc1795f-50d9-41e1-8103-19f873f72efd" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_c8bfae87-f514-4605-bb0e-17198a2118cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_db52ed6d-07e3-43a1-99d0-b19b3765026a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_5bc1795f-50d9-41e1-8103-19f873f72efd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_db52ed6d-07e3-43a1-99d0-b19b3765026a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_4be0c0c0-bf32-444e-b7b0-37035fcf58ef" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_5bc1795f-50d9-41e1-8103-19f873f72efd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_4be0c0c0-bf32-444e-b7b0-37035fcf58ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_94826f71-0ae3-4af7-8ccf-e0f9a8a12e4a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_5bc1795f-50d9-41e1-8103-19f873f72efd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_94826f71-0ae3-4af7-8ccf-e0f9a8a12e4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_6fe233cb-4358-4849-bb04-11c049271fe2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_5bc1795f-50d9-41e1-8103-19f873f72efd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_6fe233cb-4358-4849-bb04-11c049271fe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_e1736a1a-71ba-4910-a34e-073d31fbc466" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_5bc1795f-50d9-41e1-8103-19f873f72efd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_e1736a1a-71ba-4910-a34e-073d31fbc466" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_b96be0bc-cb68-43c5-8d1a-6acdee6585f5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_5bc1795f-50d9-41e1-8103-19f873f72efd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_b96be0bc-cb68-43c5-8d1a-6acdee6585f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails1" xlink:type="simple" xlink:href="biib-20200930.xsd#IntangibleAssetsandGoodwillDetails1"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0208f5bb-2570-4167-9839-7da207790d93" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_635e8946-ade5-44fc-8026-53ec024934ec" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0208f5bb-2570-4167-9839-7da207790d93" xlink:to="loc_us-gaap_GoodwillRollForward_635e8946-ade5-44fc-8026-53ec024934ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_b6dff1bd-3778-4377-866c-e38c2b22c128" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_635e8946-ade5-44fc-8026-53ec024934ec" xlink:to="loc_us-gaap_Goodwill_b6dff1bd-3778-4377-866c-e38c2b22c128" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease_9504e7b7-c43f-4baf-869a-be0079571947" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillOtherIncreaseDecrease"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_635e8946-ade5-44fc-8026-53ec024934ec" xlink:to="loc_us-gaap_GoodwillOtherIncreaseDecrease_9504e7b7-c43f-4baf-869a-be0079571947" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_76a52091-40a5-4f6f-b20e-f8c764805df9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_635e8946-ade5-44fc-8026-53ec024934ec" xlink:to="loc_us-gaap_Goodwill_76a52091-40a5-4f6f-b20e-f8c764805df9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_c2a65bc8-dc5d-45ef-a99f-d4f40c91deab" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0208f5bb-2570-4167-9839-7da207790d93" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_c2a65bc8-dc5d-45ef-a99f-d4f40c91deab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="biib-20200930.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_0b63de3c-4e3d-4a8d-8b04-3aaac9881522" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_563b8ae1-c807-43a3-b6d1-d45cc7c14663" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_0b63de3c-4e3d-4a8d-8b04-3aaac9881522" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_563b8ae1-c807-43a3-b6d1-d45cc7c14663" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="biib-20200930.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_c4a89728-50e2-4395-808e-8f3c114d9c58" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_33a942fe-7d2d-43e0-be0a-c64ceedec76d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_c4a89728-50e2-4395-808e-8f3c114d9c58" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_33a942fe-7d2d-43e0-be0a-c64ceedec76d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_f796f279-f6c6-4283-b355-a18fe67beddb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_c4a89728-50e2-4395-808e-8f3c114d9c58" xlink:to="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_f796f279-f6c6-4283-b355-a18fe67beddb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_fe252275-f98d-47c2-9b87-bd802153d755" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_c4a89728-50e2-4395-808e-8f3c114d9c58" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_fe252275-f98d-47c2-9b87-bd802153d755" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="biib-20200930.xsd#FairValueMeasurementsDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_1ac763db-6c3f-4224-ae05-a62017deb3de" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ee7b70b3-5af6-46bd-85e7-81ee986a8b06" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1ac763db-6c3f-4224-ae05-a62017deb3de" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ee7b70b3-5af6-46bd-85e7-81ee986a8b06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_dc15ae22-419b-4a23-8d2c-2bcd9023d423" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ee7b70b3-5af6-46bd-85e7-81ee986a8b06" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_dc15ae22-419b-4a23-8d2c-2bcd9023d423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_93b8b47c-fddf-4fcf-a38b-d823e543e84c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_dc15ae22-419b-4a23-8d2c-2bcd9023d423" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_93b8b47c-fddf-4fcf-a38b-d823e543e84c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_f1ac885e-4e92-4f6b-8dcb-1d0025af1a11" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_93b8b47c-fddf-4fcf-a38b-d823e543e84c" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_f1ac885e-4e92-4f6b-8dcb-1d0025af1a11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_eb3ecdd5-3997-409b-894d-81a2529a061b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_93b8b47c-fddf-4fcf-a38b-d823e543e84c" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_eb3ecdd5-3997-409b-894d-81a2529a061b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_3cc7547f-b5a2-45b5-8bb9-903658f0ab4b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_93b8b47c-fddf-4fcf-a38b-d823e543e84c" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_3cc7547f-b5a2-45b5-8bb9-903658f0ab4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_95df519e-9d1a-4331-8788-469c0a139768" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ee7b70b3-5af6-46bd-85e7-81ee986a8b06" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_95df519e-9d1a-4331-8788-469c0a139768" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_7316b172-fee8-4cc5-996e-4eb98e411a7a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_95df519e-9d1a-4331-8788-469c0a139768" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_7316b172-fee8-4cc5-996e-4eb98e411a7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_970c43f7-e123-46af-939f-f1d2dfa5858f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_7316b172-fee8-4cc5-996e-4eb98e411a7a" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_970c43f7-e123-46af-939f-f1d2dfa5858f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_0b0470c8-fcc1-4887-9ab2-5cbd5987c263" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ee7b70b3-5af6-46bd-85e7-81ee986a8b06" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_0b0470c8-fcc1-4887-9ab2-5cbd5987c263" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_0c509b35-a26d-42f2-8f5f-11f057c29647" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_0b0470c8-fcc1-4887-9ab2-5cbd5987c263" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_0c509b35-a26d-42f2-8f5f-11f057c29647" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_82720f27-95e4-4c1d-9e77-fdd5e17d5b32" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_0c509b35-a26d-42f2-8f5f-11f057c29647" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_82720f27-95e4-4c1d-9e77-fdd5e17d5b32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_8c20a066-7982-4193-820c-6dd21a436cbe" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_0c509b35-a26d-42f2-8f5f-11f057c29647" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_8c20a066-7982-4193-820c-6dd21a436cbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_93639212-21ef-4b04-893a-9576c516a1c2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_0c509b35-a26d-42f2-8f5f-11f057c29647" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_93639212-21ef-4b04-893a-9576c516a1c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a5875a13-2da0-4f41-a032-e56b8329e2a2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ee7b70b3-5af6-46bd-85e7-81ee986a8b06" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a5875a13-2da0-4f41-a032-e56b8329e2a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_c8141e61-a204-42c2-a281-cefa5968fb55" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a5875a13-2da0-4f41-a032-e56b8329e2a2" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_c8141e61-a204-42c2-a281-cefa5968fb55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_86572f6d-d9a7-413d-978a-cb65ac0584cc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_c8141e61-a204-42c2-a281-cefa5968fb55" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_86572f6d-d9a7-413d-978a-cb65ac0584cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_e3865726-bfc8-4b9d-8658-dba64be02e6a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_86572f6d-d9a7-413d-978a-cb65ac0584cc" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_e3865726-bfc8-4b9d-8658-dba64be02e6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_379a0b08-a86f-44dc-9902-d55b420e9676" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_86572f6d-d9a7-413d-978a-cb65ac0584cc" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_379a0b08-a86f-44dc-9902-d55b420e9676" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_6ea82cab-dbc9-4f99-8fd6-da08f98e0817" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_86572f6d-d9a7-413d-978a-cb65ac0584cc" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_6ea82cab-dbc9-4f99-8fd6-da08f98e0817" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_ae10e400-4c5d-43a4-b078-ef42042782f9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_86572f6d-d9a7-413d-978a-cb65ac0584cc" xlink:to="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_ae10e400-4c5d-43a4-b078-ef42042782f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_5a20fa0a-487c-405a-86f8-c4a3795d1f67" xlink:href="biib-20200930.xsd#biib_PlanAssetsForDeferredCompensationFairValueDisclosure"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_86572f6d-d9a7-413d-978a-cb65ac0584cc" xlink:to="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_5a20fa0a-487c-405a-86f8-c4a3795d1f67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_d959cd0f-8aa6-4e7b-8f5f-bc7cc292c45b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_86572f6d-d9a7-413d-978a-cb65ac0584cc" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_d959cd0f-8aa6-4e7b-8f5f-bc7cc292c45b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_1b27b4a3-5105-44f8-a401-07ce86734288" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_c8141e61-a204-42c2-a281-cefa5968fb55" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_1b27b4a3-5105-44f8-a401-07ce86734288" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_3f932249-d0b2-4c12-a364-865837e971af" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_1b27b4a3-5105-44f8-a401-07ce86734288" xlink:to="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_3f932249-d0b2-4c12-a364-865837e971af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_7bc3c13e-6294-44fe-892a-139fae662103" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_1b27b4a3-5105-44f8-a401-07ce86734288" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_7bc3c13e-6294-44fe-892a-139fae662103" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_6a71d0eb-8246-4c3e-8c8f-f4a45cc302f9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_1b27b4a3-5105-44f8-a401-07ce86734288" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_6a71d0eb-8246-4c3e-8c8f-f4a45cc302f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:type="simple" xlink:href="biib-20200930.xsd#FairValueMeasurementsDetailsTextual"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_fbc7a9eb-d077-43e9-8045-196b534a6ca9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_e4ebe23b-b9e1-4191-9650-3b8eafa9b1a2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_fbc7a9eb-d077-43e9-8045-196b534a6ca9" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_e4ebe23b-b9e1-4191-9650-3b8eafa9b1a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_dd2709bd-9af6-4cc5-86c4-d402e47d8603" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_e4ebe23b-b9e1-4191-9650-3b8eafa9b1a2" xlink:to="loc_us-gaap_DebtInstrumentAxis_dd2709bd-9af6-4cc5-86c4-d402e47d8603" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_896b0f9e-93cf-475b-bf73-96ccd9a7741e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_dd2709bd-9af6-4cc5-86c4-d402e47d8603" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_896b0f9e-93cf-475b-bf73-96ccd9a7741e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_4e82ce4e-993c-4347-bf28-23f95ed6a448" xlink:href="biib-20200930.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_896b0f9e-93cf-475b-bf73-96ccd9a7741e" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_4e82ce4e-993c-4347-bf28-23f95ed6a448" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_eb67bdc6-4fe4-40b0-9f1d-6dad320926a6" xlink:href="biib-20200930.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_896b0f9e-93cf-475b-bf73-96ccd9a7741e" xlink:to="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_eb67bdc6-4fe4-40b0-9f1d-6dad320926a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_5a903c85-1d78-49f6-8eba-82d41f834da1" xlink:href="biib-20200930.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_896b0f9e-93cf-475b-bf73-96ccd9a7741e" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_5a903c85-1d78-49f6-8eba-82d41f834da1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_1a569315-0ecc-4660-9d43-33245f7f1721" xlink:href="biib-20200930.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_896b0f9e-93cf-475b-bf73-96ccd9a7741e" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_1a569315-0ecc-4660-9d43-33245f7f1721" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_0a03eed1-790c-4d95-a979-30849bb484c8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_e4ebe23b-b9e1-4191-9650-3b8eafa9b1a2" xlink:to="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_0a03eed1-790c-4d95-a979-30849bb484c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_cdc385f7-c0c4-470d-82cd-57d65e467053" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_0a03eed1-790c-4d95-a979-30849bb484c8" xlink:to="loc_us-gaap_AssetImpairmentCharges_cdc385f7-c0c4-470d-82cd-57d65e467053" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_48bea35f-d64f-4c59-818e-9ff682bed055" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_0a03eed1-790c-4d95-a979-30849bb484c8" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_48bea35f-d64f-4c59-818e-9ff682bed055" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_a144d8a2-3202-4b97-a7ec-3b4bca47bd86" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_0a03eed1-790c-4d95-a979-30849bb484c8" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_a144d8a2-3202-4b97-a7ec-3b4bca47bd86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1_dfb31e26-acad-4737-afaa-2bcd3fc89d6f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_0a03eed1-790c-4d95-a979-30849bb484c8" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1_dfb31e26-acad-4737-afaa-2bcd3fc89d6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails" xlink:type="simple" xlink:href="biib-20200930.xsd#FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_54c75fa4-3eb7-4838-a3a9-e055168d9f65" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9eb9c788-c11f-48c6-a14d-2f760ad2673c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_54c75fa4-3eb7-4838-a3a9-e055168d9f65" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9eb9c788-c11f-48c6-a14d-2f760ad2673c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9d2c17ce-7a12-48ec-b33d-d6415da7f0bf" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9eb9c788-c11f-48c6-a14d-2f760ad2673c" xlink:to="loc_srt_RangeAxis_9d2c17ce-7a12-48ec-b33d-d6415da7f0bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_cb900d39-fee3-405d-bed4-fbfb2f6afd70" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_9d2c17ce-7a12-48ec-b33d-d6415da7f0bf" xlink:to="loc_srt_RangeMember_cb900d39-fee3-405d-bed4-fbfb2f6afd70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f1dec38b-06f2-4521-9215-4e7db9a7a9cf" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_cb900d39-fee3-405d-bed4-fbfb2f6afd70" xlink:to="loc_srt_MinimumMember_f1dec38b-06f2-4521-9215-4e7db9a7a9cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_8679bce9-9c5d-4690-8097-6c0eae8eea18" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_cb900d39-fee3-405d-bed4-fbfb2f6afd70" xlink:to="loc_srt_MaximumMember_8679bce9-9c5d-4690-8097-6c0eae8eea18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_fd1619f6-0571-4428-bd14-a376645dd4eb" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_WeightedAverageMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_cb900d39-fee3-405d-bed4-fbfb2f6afd70" xlink:to="loc_srt_WeightedAverageMember_fd1619f6-0571-4428-bd14-a376645dd4eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_815d59d7-e38d-431a-aaf9-0d349461a461" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9eb9c788-c11f-48c6-a14d-2f760ad2673c" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_815d59d7-e38d-431a-aaf9-0d349461a461" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_f492a1b6-6175-44a1-9667-5eddeeec0d6e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_815d59d7-e38d-431a-aaf9-0d349461a461" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_f492a1b6-6175-44a1-9667-5eddeeec0d6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_566830cd-1883-4a49-a0bc-64d2f3f9924a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_f492a1b6-6175-44a1-9667-5eddeeec0d6e" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_566830cd-1883-4a49-a0bc-64d2f3f9924a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_bcf465b4-5db6-4f1e-864a-90c0b5708c7f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9eb9c788-c11f-48c6-a14d-2f760ad2673c" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_bcf465b4-5db6-4f1e-864a-90c0b5708c7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_5e683a02-2717-44d3-9f0d-2b7891f8262b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_bcf465b4-5db6-4f1e-864a-90c0b5708c7f" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_5e683a02-2717-44d3-9f0d-2b7891f8262b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_baecc239-6018-4125-b43c-e6288dd84942" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_bcf465b4-5db6-4f1e-864a-90c0b5708c7f" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_baecc239-6018-4125-b43c-e6288dd84942" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:type="simple" xlink:href="biib-20200930.xsd#FairValueMeasurementsDetails1"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_96e33cf6-4bf7-420f-ae18-8d989fd30262" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_216df135-c215-4d33-9899-1afc6a49ef14" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_96e33cf6-4bf7-420f-ae18-8d989fd30262" xlink:to="loc_us-gaap_DebtInstrumentTable_216df135-c215-4d33-9899-1afc6a49ef14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_b0bab12b-d03b-4316-8248-70213b878b19" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_216df135-c215-4d33-9899-1afc6a49ef14" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_b0bab12b-d03b-4316-8248-70213b878b19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_c7a4061f-ec3d-4126-9711-2c9c9d504d0f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_b0bab12b-d03b-4316-8248-70213b878b19" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_c7a4061f-ec3d-4126-9711-2c9c9d504d0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_338fbb6d-5b3d-4738-ba52-f360817f3367" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_c7a4061f-ec3d-4126-9711-2c9c9d504d0f" xlink:to="loc_us-gaap_SeniorNotesMember_338fbb6d-5b3d-4738-ba52-f360817f3367" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_24e089a4-32e3-4e05-b4ce-dc6653d2ce39" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_216df135-c215-4d33-9899-1afc6a49ef14" xlink:to="loc_us-gaap_DebtInstrumentAxis_24e089a4-32e3-4e05-b4ce-dc6653d2ce39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_4bb4ab34-7009-4e35-9109-0f0e18a8bedb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_24e089a4-32e3-4e05-b4ce-dc6653d2ce39" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_4bb4ab34-7009-4e35-9109-0f0e18a8bedb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_3d764e59-f35a-4650-ba20-23bb863529da" xlink:href="biib-20200930.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4bb4ab34-7009-4e35-9109-0f0e18a8bedb" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_3d764e59-f35a-4650-ba20-23bb863529da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_e3eae5ca-6603-4308-b61c-f6849409318e" xlink:href="biib-20200930.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4bb4ab34-7009-4e35-9109-0f0e18a8bedb" xlink:to="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_e3eae5ca-6603-4308-b61c-f6849409318e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_d25cb1f8-329f-4688-aee0-c443b1aa0118" xlink:href="biib-20200930.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4bb4ab34-7009-4e35-9109-0f0e18a8bedb" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_d25cb1f8-329f-4688-aee0-c443b1aa0118" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2.25SeniorNotesdueMay12030Member_53ab49de-d554-4915-a41a-cb22602b3449" xlink:href="biib-20200930.xsd#biib_A2.25SeniorNotesdueMay12030Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4bb4ab34-7009-4e35-9109-0f0e18a8bedb" xlink:to="loc_biib_A2.25SeniorNotesdueMay12030Member_53ab49de-d554-4915-a41a-cb22602b3449" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_03b04d79-f5c9-46e5-8776-409eb5f81302" xlink:href="biib-20200930.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4bb4ab34-7009-4e35-9109-0f0e18a8bedb" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_03b04d79-f5c9-46e5-8776-409eb5f81302" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A3.15SeniorNotesdueMay12050Member_99602bed-3117-480c-b300-c729eab223c4" xlink:href="biib-20200930.xsd#biib_A3.15SeniorNotesdueMay12050Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4bb4ab34-7009-4e35-9109-0f0e18a8bedb" xlink:to="loc_biib_A3.15SeniorNotesdueMay12050Member_99602bed-3117-480c-b300-c729eab223c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_2b0498d8-0012-40dc-a3e9-6ac6b072a6bd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_216df135-c215-4d33-9899-1afc6a49ef14" xlink:to="loc_us-gaap_DebtInstrumentLineItems_2b0498d8-0012-40dc-a3e9-6ac6b072a6bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure_4d70a6e0-0151-41d7-b8de-b44bc28186d4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2b0498d8-0012-40dc-a3e9-6ac6b072a6bd" xlink:to="loc_us-gaap_NotesPayableFairValueDisclosure_4d70a6e0-0151-41d7-b8de-b44bc28186d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayable_f479e254-2724-49d3-9dd8-f66244a306e6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2b0498d8-0012-40dc-a3e9-6ac6b072a6bd" xlink:to="loc_us-gaap_NotesPayable_f479e254-2724-49d3-9dd8-f66244a306e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_03d71544-6e8c-463b-b33b-96c3a5cb64cd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2b0498d8-0012-40dc-a3e9-6ac6b072a6bd" xlink:to="loc_us-gaap_DebtInstrumentFairValue_03d71544-6e8c-463b-b33b-96c3a5cb64cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_b736a84d-9295-4596-b120-06c1cacd8404" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2b0498d8-0012-40dc-a3e9-6ac6b072a6bd" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_b736a84d-9295-4596-b120-06c1cacd8404" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_9188ddee-94ed-4365-8d83-6bed3e896dfc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2b0498d8-0012-40dc-a3e9-6ac6b072a6bd" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_9188ddee-94ed-4365-8d83-6bed3e896dfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:type="simple" xlink:href="biib-20200930.xsd#FairValueMeasurementsDetails2"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_fa1a7e0a-6711-4c28-8b66-41bb92c211a9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_6d08f0d2-32bd-4c7c-9b74-cc01dbad14df" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_fa1a7e0a-6711-4c28-8b66-41bb92c211a9" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_6d08f0d2-32bd-4c7c-9b74-cc01dbad14df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_a6888b2b-1089-4e78-a252-1128bad6c5f2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_6d08f0d2-32bd-4c7c-9b74-cc01dbad14df" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_a6888b2b-1089-4e78-a252-1128bad6c5f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_780d2150-4f0d-4502-9569-f4a68ff3ac55" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_a6888b2b-1089-4e78-a252-1128bad6c5f2" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_780d2150-4f0d-4502-9569-f4a68ff3ac55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_bd0f0ef1-0e10-4952-a70e-5e07b7fe402c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_780d2150-4f0d-4502-9569-f4a68ff3ac55" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_bd0f0ef1-0e10-4952-a70e-5e07b7fe402c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_190dd044-3645-46e3-807f-b2e51d3d92bf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_6d08f0d2-32bd-4c7c-9b74-cc01dbad14df" xlink:to="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_190dd044-3645-46e3-807f-b2e51d3d92bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_a0ebcd72-eb64-493a-a42e-7949a512c085" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_190dd044-3645-46e3-807f-b2e51d3d92bf" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_a0ebcd72-eb64-493a-a42e-7949a512c085" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_f3683b1c-051f-4979-a556-bce2758569e6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_190dd044-3645-46e3-807f-b2e51d3d92bf" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_f3683b1c-051f-4979-a556-bce2758569e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_68a7f349-1cef-423f-9c4b-e2906312d8fd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_190dd044-3645-46e3-807f-b2e51d3d92bf" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_68a7f349-1cef-423f-9c4b-e2906312d8fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_d9dadfad-2240-4f57-8680-4e814e2c50b5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_190dd044-3645-46e3-807f-b2e51d3d92bf" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_d9dadfad-2240-4f57-8680-4e814e2c50b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstruments" xlink:type="simple" xlink:href="biib-20200930.xsd#FinancialInstruments"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_5cd8aae7-edf5-4eed-ae41-94ee749403ac" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_f6409843-5701-4b57-8f98-464252ab1b67" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_5cd8aae7-edf5-4eed-ae41-94ee749403ac" xlink:to="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_f6409843-5701-4b57-8f98-464252ab1b67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:type="simple" xlink:href="biib-20200930.xsd#FinancialInstrumentsTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_e450f077-9419-45e4-8aa2-2764bfd18139" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_83011b4d-789c-4446-83ad-ec444a75ff02" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_e450f077-9419-45e4-8aa2-2764bfd18139" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_83011b4d-789c-4446-83ad-ec444a75ff02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesTextBlock_2c2c7537-28cd-4f00-b04e-f3661e1e0912" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_e450f077-9419-45e4-8aa2-2764bfd18139" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesTextBlock_2c2c7537-28cd-4f00-b04e-f3661e1e0912" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_e5a1e823-e0df-459b-9fc0-c3b04316b51a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_e450f077-9419-45e4-8aa2-2764bfd18139" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_e5a1e823-e0df-459b-9fc0-c3b04316b51a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_ee674cc6-e114-45e7-94e3-04204abf3664" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RealizedGainLossOnInvestmentsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_e450f077-9419-45e4-8aa2-2764bfd18139" xlink:to="loc_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_ee674cc6-e114-45e7-94e3-04204abf3664" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:type="simple" xlink:href="biib-20200930.xsd#FinancialInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_375b0cfa-0ee1-4a25-bdb4-bbcc5d708c4d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_5dbb7e97-b34b-491c-adc0-8a288842a436" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_375b0cfa-0ee1-4a25-bdb4-bbcc5d708c4d" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_5dbb7e97-b34b-491c-adc0-8a288842a436" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_5d5b3c0d-a1a9-41d6-abeb-fbacbdcfad4a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_5dbb7e97-b34b-491c-adc0-8a288842a436" xlink:to="loc_us-gaap_InvestmentTypeAxis_5d5b3c0d-a1a9-41d6-abeb-fbacbdcfad4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_2f2f05a8-2a07-4c5d-9a40-c5e355caeaab" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_5d5b3c0d-a1a9-41d6-abeb-fbacbdcfad4a" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_2f2f05a8-2a07-4c5d-9a40-c5e355caeaab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_aefcb7d1-b55e-4239-b0e3-f919859cd80a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_2f2f05a8-2a07-4c5d-9a40-c5e355caeaab" xlink:to="loc_us-gaap_CommercialPaperMember_aefcb7d1-b55e-4239-b0e3-f919859cd80a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepurchaseAgreementsMember_210e9d79-d4af-40b5-9ffd-399f58136088" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepurchaseAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_2f2f05a8-2a07-4c5d-9a40-c5e355caeaab" xlink:to="loc_us-gaap_RepurchaseAgreementsMember_210e9d79-d4af-40b5-9ffd-399f58136088" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_8df7b5d5-ccc0-4314-8afa-91f39092e6f8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_2f2f05a8-2a07-4c5d-9a40-c5e355caeaab" xlink:to="loc_us-gaap_MoneyMarketFundsMember_8df7b5d5-ccc0-4314-8afa-91f39092e6f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember_2559da66-18d4-4f94-85f5-3fb03da7884a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_2f2f05a8-2a07-4c5d-9a40-c5e355caeaab" xlink:to="loc_us-gaap_DebtSecuritiesMember_2559da66-18d4-4f94-85f5-3fb03da7884a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_d27c144f-346a-4043-b7b2-8d96709feac0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_5dbb7e97-b34b-491c-adc0-8a288842a436" xlink:to="loc_us-gaap_CashAndCashEquivalentsLineItems_d27c144f-346a-4043-b7b2-8d96709feac0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_16813d93-884a-4da0-a501-16d796a1ad5a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_d27c144f-346a-4043-b7b2-8d96709feac0" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_16813d93-884a-4da0-a501-16d796a1ad5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_988db62b-b51a-4b60-8a8e-285e9e62709e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_16813d93-884a-4da0-a501-16d796a1ad5a" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_988db62b-b51a-4b60-8a8e-285e9e62709e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:type="simple" xlink:href="biib-20200930.xsd#FinancialInstrumentsDetails1"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_25ee9bba-8ec7-4194-af89-4912ed01ae04" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_f530b0cb-e794-48c3-a39c-747f116a4e50" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_25ee9bba-8ec7-4194-af89-4912ed01ae04" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_f530b0cb-e794-48c3-a39c-747f116a4e50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_343c70be-e888-4f59-bfe8-01fc73d49e62" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_f530b0cb-e794-48c3-a39c-747f116a4e50" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_343c70be-e888-4f59-bfe8-01fc73d49e62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_8ec8363b-800d-4699-9637-b467a55e0a8a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_343c70be-e888-4f59-bfe8-01fc73d49e62" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_8ec8363b-800d-4699-9637-b467a55e0a8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_2e906477-383b-4301-8331-b89132f91695" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_8ec8363b-800d-4699-9637-b467a55e0a8a" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_2e906477-383b-4301-8331-b89132f91695" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_0bef18bf-d3c1-42ce-bdda-5da715033048" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_8ec8363b-800d-4699-9637-b467a55e0a8a" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_0bef18bf-d3c1-42ce-bdda-5da715033048" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_3040ff4c-f1ff-463e-a32c-e5e82fde2df6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_f530b0cb-e794-48c3-a39c-747f116a4e50" xlink:to="loc_us-gaap_FinancialInstrumentAxis_3040ff4c-f1ff-463e-a32c-e5e82fde2df6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7574f9b6-c50b-406b-a375-ac42882d5afb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_3040ff4c-f1ff-463e-a32c-e5e82fde2df6" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7574f9b6-c50b-406b-a375-ac42882d5afb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CorporateDebtSecuritiesCurrentMember_1d8ee664-9473-4aaa-9f80-32fb0fcd7b52" xlink:href="biib-20200930.xsd#biib_CorporateDebtSecuritiesCurrentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7574f9b6-c50b-406b-a375-ac42882d5afb" xlink:to="loc_biib_CorporateDebtSecuritiesCurrentMember_1d8ee664-9473-4aaa-9f80-32fb0fcd7b52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CorporateDebtSecuritiesNonCurrentMember_05c5ed23-a36f-46a7-b1a9-0a0a9d6192b4" xlink:href="biib-20200930.xsd#biib_CorporateDebtSecuritiesNonCurrentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7574f9b6-c50b-406b-a375-ac42882d5afb" xlink:to="loc_biib_CorporateDebtSecuritiesNonCurrentMember_05c5ed23-a36f-46a7-b1a9-0a0a9d6192b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GovernmentSecuritiesCurrentMember_c30d4773-5ecf-4b2d-9d42-e4c30ea0db76" xlink:href="biib-20200930.xsd#biib_GovernmentSecuritiesCurrentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7574f9b6-c50b-406b-a375-ac42882d5afb" xlink:to="loc_biib_GovernmentSecuritiesCurrentMember_c30d4773-5ecf-4b2d-9d42-e4c30ea0db76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GovernmentSecuritiesNonCurrentMember_fb8b028e-f573-4d93-bd8a-47d0001ea5b8" xlink:href="biib-20200930.xsd#biib_GovernmentSecuritiesNonCurrentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7574f9b6-c50b-406b-a375-ac42882d5afb" xlink:to="loc_biib_GovernmentSecuritiesNonCurrentMember_fb8b028e-f573-4d93-bd8a-47d0001ea5b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_e4ea9f05-a5bf-4f59-bd7f-bfcbdbe77e22" xlink:href="biib-20200930.xsd#biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7574f9b6-c50b-406b-a375-ac42882d5afb" xlink:to="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_e4ea9f05-a5bf-4f59-bd7f-bfcbdbe77e22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_71250621-4066-45b3-9c69-ab589baab962" xlink:href="biib-20200930.xsd#biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7574f9b6-c50b-406b-a375-ac42882d5afb" xlink:to="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_71250621-4066-45b3-9c69-ab589baab962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_0b3fac7c-8b8a-459f-9ed2-02a6fe5279ed" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7574f9b6-c50b-406b-a375-ac42882d5afb" xlink:to="loc_us-gaap_EquitySecuritiesMember_0b3fac7c-8b8a-459f-9ed2-02a6fe5279ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_05cf9660-957c-419d-b1db-f0ef8431979e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_f530b0cb-e794-48c3-a39c-747f116a4e50" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_05cf9660-957c-419d-b1db-f0ef8431979e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_64b6c49c-11cf-48e6-834b-c09dfbd0c918" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_05cf9660-957c-419d-b1db-f0ef8431979e" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_64b6c49c-11cf-48e6-834b-c09dfbd0c918" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0e075f94-f3dd-43c2-97a1-1b1afccf19b4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_05cf9660-957c-419d-b1db-f0ef8431979e" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0e075f94-f3dd-43c2-97a1-1b1afccf19b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_24c642e8-419e-4326-80c0-180fede5baa9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_05cf9660-957c-419d-b1db-f0ef8431979e" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_24c642e8-419e-4326-80c0-180fede5baa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e28d5343-26fa-4536-a881-70e061892bde" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_05cf9660-957c-419d-b1db-f0ef8431979e" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e28d5343-26fa-4536-a881-70e061892bde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_4a5db10f-2020-4903-bf39-3474b2b6d028" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_05cf9660-957c-419d-b1db-f0ef8431979e" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_4a5db10f-2020-4903-bf39-3474b2b6d028" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_8102f447-4800-4077-987b-96c78e40650c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_05cf9660-957c-419d-b1db-f0ef8431979e" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_8102f447-4800-4077-987b-96c78e40650c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_f98e74af-d505-4b3a-9a35-51fb5111af6e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_05cf9660-957c-419d-b1db-f0ef8431979e" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_f98e74af-d505-4b3a-9a35-51fb5111af6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecurities_223447a4-9b07-491b-98f7-92e3184bd301" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecurities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_05cf9660-957c-419d-b1db-f0ef8431979e" xlink:to="loc_us-gaap_AvailableForSaleSecurities_223447a4-9b07-491b-98f7-92e3184bd301" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:type="simple" xlink:href="biib-20200930.xsd#FinancialInstrumentsDetails2"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_dbf6b5c7-6c64-4ae4-b01c-34d1bbb2ec4d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_2d307b9d-26dd-463e-9024-8a2dac0f25e5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_dbf6b5c7-6c64-4ae4-b01c-34d1bbb2ec4d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_2d307b9d-26dd-463e-9024-8a2dac0f25e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_eb0ce84e-2c03-43e6-9cec-f2113b5bb8d5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_2d307b9d-26dd-463e-9024-8a2dac0f25e5" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_eb0ce84e-2c03-43e6-9cec-f2113b5bb8d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_9ede8893-dee6-4d50-a7f2-6b7ff13733e6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_2d307b9d-26dd-463e-9024-8a2dac0f25e5" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_9ede8893-dee6-4d50-a7f2-6b7ff13733e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_c230346b-4976-4764-b310-503e46f093d5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_2d307b9d-26dd-463e-9024-8a2dac0f25e5" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_c230346b-4976-4764-b310-503e46f093d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_24e1f2ab-37f7-4b5f-81f2-030497bdf93c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_2d307b9d-26dd-463e-9024-8a2dac0f25e5" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_24e1f2ab-37f7-4b5f-81f2-030497bdf93c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_4f0a8903-a9ef-4414-bf7f-58b8cd24d747" xlink:href="biib-20200930.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_2d307b9d-26dd-463e-9024-8a2dac0f25e5" xlink:to="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_4f0a8903-a9ef-4414-bf7f-58b8cd24d747" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_98e0e0c5-3dcb-4c17-9bba-5c2a1184513a" xlink:href="biib-20200930.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_2d307b9d-26dd-463e-9024-8a2dac0f25e5" xlink:to="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_98e0e0c5-3dcb-4c17-9bba-5c2a1184513a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_547615f9-725b-403e-bde2-e813f4aaae52" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_2d307b9d-26dd-463e-9024-8a2dac0f25e5" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_547615f9-725b-403e-bde2-e813f4aaae52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecurities_c73bd558-443d-4d14-a23d-af5e3372e98b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecurities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_2d307b9d-26dd-463e-9024-8a2dac0f25e5" xlink:to="loc_us-gaap_AvailableForSaleSecurities_c73bd558-443d-4d14-a23d-af5e3372e98b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails3" xlink:type="simple" xlink:href="biib-20200930.xsd#FinancialInstrumentsDetails3"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails3" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_783c0ad9-b94d-44a8-830b-724e43f5968c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_f35c350c-f01c-4aa3-b552-fd8ca46ca002" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_783c0ad9-b94d-44a8-830b-724e43f5968c" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_f35c350c-f01c-4aa3-b552-fd8ca46ca002" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_472625ef-c971-4487-824f-a1025f368c17" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_783c0ad9-b94d-44a8-830b-724e43f5968c" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_472625ef-c971-4487-824f-a1025f368c17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_be3c7179-631d-4277-b7ef-e394ac21e9bc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_783c0ad9-b94d-44a8-830b-724e43f5968c" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_be3c7179-631d-4277-b7ef-e394ac21e9bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual" xlink:type="simple" xlink:href="biib-20200930.xsd#FinancialInstrumentsDetailsTextual"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_d1539b52-4f84-403e-aa5e-64b69ebea0c4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AverageMaturityOfMarketableSecurities_3b143320-93bd-4e4c-a338-e5186a6b196f" xlink:href="biib-20200930.xsd#biib_AverageMaturityOfMarketableSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_d1539b52-4f84-403e-aa5e-64b69ebea0c4" xlink:to="loc_biib_AverageMaturityOfMarketableSecurities_3b143320-93bd-4e4c-a338-e5186a6b196f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:type="simple" xlink:href="biib-20200930.xsd#FinancialInstrumentsFinancialInstrumentsDetailsTextual2"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_f2a9979b-f421-4fa5-b3e8-96a41a7e5389" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ee78d48f-81ab-46a9-b69a-5e495c509670" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_f2a9979b-f421-4fa5-b3e8-96a41a7e5389" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ee78d48f-81ab-46a9-b69a-5e495c509670" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_a0aa7550-af50-4b58-9229-bd148cca0fc7" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ee78d48f-81ab-46a9-b69a-5e495c509670" xlink:to="loc_dei_LegalEntityAxis_a0aa7550-af50-4b58-9229-bd148cca0fc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_9cc1c115-a31f-44e1-be34-d0baadfc81d0" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_a0aa7550-af50-4b58-9229-bd148cca0fc7" xlink:to="loc_dei_EntityDomain_9cc1c115-a31f-44e1-be34-d0baadfc81d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DenaliTherapeuticsIncMember_c910be69-2981-4154-a37f-7595151a6fce" xlink:href="biib-20200930.xsd#biib_DenaliTherapeuticsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_9cc1c115-a31f-44e1-be34-d0baadfc81d0" xlink:to="loc_biib_DenaliTherapeuticsIncMember_c910be69-2981-4154-a37f-7595151a6fce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SangamoCommonStockMember_b5cb8cbd-f9db-4e95-81b9-2613c950c82f" xlink:href="biib-20200930.xsd#biib_SangamoCommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_9cc1c115-a31f-44e1-be34-d0baadfc81d0" xlink:to="loc_biib_SangamoCommonStockMember_b5cb8cbd-f9db-4e95-81b9-2613c950c82f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_8f824fc3-c6e9-4386-8b60-345a91e66d25" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ee78d48f-81ab-46a9-b69a-5e495c509670" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_8f824fc3-c6e9-4386-8b60-345a91e66d25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_e2fc9a84-bec0-41b9-9321-55f8b1576e27" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_8f824fc3-c6e9-4386-8b60-345a91e66d25" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_e2fc9a84-bec0-41b9-9321-55f8b1576e27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_91f2829e-7ffa-46dc-ac45-512938074574" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_e2fc9a84-bec0-41b9-9321-55f8b1576e27" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_91f2829e-7ffa-46dc-ac45-512938074574" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_64c7bce6-a7ec-46af-81f3-c23563a41a65" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_e2fc9a84-bec0-41b9-9321-55f8b1576e27" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_64c7bce6-a7ec-46af-81f3-c23563a41a65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_04ca6024-a664-4e5d-9d14-e304742c2c2a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ee78d48f-81ab-46a9-b69a-5e495c509670" xlink:to="loc_us-gaap_FinancialInstrumentAxis_04ca6024-a664-4e5d-9d14-e304742c2c2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e1666687-e8d7-4245-8270-8197cf221cd2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_04ca6024-a664-4e5d-9d14-e304742c2c2a" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e1666687-e8d7-4245-8270-8197cf221cd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_StrategicInvestmentsMember_723354c9-49af-4f6b-b86f-59516384781d" xlink:href="biib-20200930.xsd#biib_StrategicInvestmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e1666687-e8d7-4245-8270-8197cf221cd2" xlink:to="loc_biib_StrategicInvestmentsMember_723354c9-49af-4f6b-b86f-59516384781d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_6ea9fe48-1011-412a-b97e-7331412acdf8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ee78d48f-81ab-46a9-b69a-5e495c509670" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_6ea9fe48-1011-412a-b97e-7331412acdf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_StrategicInvestmentPortfolio_250cf924-d64d-43b6-b96c-5808a13320ac" xlink:href="biib-20200930.xsd#biib_StrategicInvestmentPortfolio"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6ea9fe48-1011-412a-b97e-7331412acdf8" xlink:to="loc_biib_StrategicInvestmentPortfolio_250cf924-d64d-43b6-b96c-5808a13320ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_be70e363-6d6a-42df-a4f7-32ea07c10e2d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6ea9fe48-1011-412a-b97e-7331412acdf8" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_be70e363-6d6a-42df-a4f7-32ea07c10e2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Investmentincommonstocksharespurchased_45b9a458-aa04-4933-98d1-29a0c80c1611" xlink:href="biib-20200930.xsd#biib_Investmentincommonstocksharespurchased"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6ea9fe48-1011-412a-b97e-7331412acdf8" xlink:to="loc_biib_Investmentincommonstocksharespurchased_45b9a458-aa04-4933-98d1-29a0c80c1611" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DividendYieldPercentage_e90cde88-0615-4329-9f6d-949c2a608911" xlink:href="biib-20200930.xsd#biib_DividendYieldPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6ea9fe48-1011-412a-b97e-7331412acdf8" xlink:to="loc_biib_DividendYieldPercentage_e90cde88-0615-4329-9f6d-949c2a608911" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NumberOfNeurologicalDiseaseTargets_0f17470b-61b8-46dc-a1e9-a3b391bec229" xlink:href="biib-20200930.xsd#biib_NumberOfNeurologicalDiseaseTargets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6ea9fe48-1011-412a-b97e-7331412acdf8" xlink:to="loc_biib_NumberOfNeurologicalDiseaseTargets_0f17470b-61b8-46dc-a1e9-a3b391bec229" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CollaborationAgreementTerm_ea8d7307-f0fd-44fe-9121-1572c8ca7a5a" xlink:href="biib-20200930.xsd#biib_CollaborationAgreementTerm"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6ea9fe48-1011-412a-b97e-7331412acdf8" xlink:to="loc_biib_CollaborationAgreementTerm_ea8d7307-f0fd-44fe-9121-1572c8ca7a5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstruments" xlink:type="simple" xlink:href="biib-20200930.xsd#DerivativeInstruments"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_6bdf56d9-6fe6-4ffc-bb5f-ff2253bbb154" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_c4584094-bb9b-4b98-a9d4-005aefa17f51" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_6bdf56d9-6fe6-4ffc-bb5f-ff2253bbb154" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_c4584094-bb9b-4b98-a9d4-005aefa17f51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:type="simple" xlink:href="biib-20200930.xsd#DerivativeInstrumentsTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_8daafc36-9b0b-4fc7-9e1a-78d154d954b5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_b8f74810-30c1-43ff-a489-72d8f0afae3c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_8daafc36-9b0b-4fc7-9e1a-78d154d954b5" xlink:to="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_b8f74810-30c1-43ff-a489-72d8f0afae3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_ce109c0e-cdbd-4a2d-9dbd-ff07bba850cf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_8daafc36-9b0b-4fc7-9e1a-78d154d954b5" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_ce109c0e-cdbd-4a2d-9dbd-ff07bba850cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_5e77b481-3974-4f5a-b42a-9f03afab024f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_8daafc36-9b0b-4fc7-9e1a-78d154d954b5" xlink:to="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_5e77b481-3974-4f5a-b42a-9f03afab024f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_af4dd514-9f27-4502-9c44-d55c061f6f14" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_8daafc36-9b0b-4fc7-9e1a-78d154d954b5" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_af4dd514-9f27-4502-9c44-d55c061f6f14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:type="simple" xlink:href="biib-20200930.xsd#DerivativeInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_eae59d65-b22e-401d-bb91-b4c982f34fd2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_0018cd45-525c-47dd-80ce-b009dafab11b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_eae59d65-b22e-401d-bb91-b4c982f34fd2" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_0018cd45-525c-47dd-80ce-b009dafab11b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DerivativeMaturityAxis_de07e7b4-1138-4ae2-9838-3fdfa18c8f85" xlink:href="biib-20200930.xsd#biib_DerivativeMaturityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_0018cd45-525c-47dd-80ce-b009dafab11b" xlink:to="loc_biib_DerivativeMaturityAxis_de07e7b4-1138-4ae2-9838-3fdfa18c8f85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DerivativeMaturityDomain_2c2aa811-e31d-4727-aace-cc55bd563549" xlink:href="biib-20200930.xsd#biib_DerivativeMaturityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DerivativeMaturityAxis_de07e7b4-1138-4ae2-9838-3fdfa18c8f85" xlink:to="loc_biib_DerivativeMaturityDomain_2c2aa811-e31d-4727-aace-cc55bd563549" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShorttermderivativeMember_f0cae686-298a-4e22-99ce-b854b708a143" xlink:href="biib-20200930.xsd#biib_ShorttermderivativeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DerivativeMaturityDomain_2c2aa811-e31d-4727-aace-cc55bd563549" xlink:to="loc_biib_ShorttermderivativeMember_f0cae686-298a-4e22-99ce-b854b708a143" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_1e109025-df86-44c2-9d9c-4445aba78712" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_0018cd45-525c-47dd-80ce-b009dafab11b" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_1e109025-df86-44c2-9d9c-4445aba78712" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_f8c958a2-474b-48af-8618-74352352c369" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_1e109025-df86-44c2-9d9c-4445aba78712" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_f8c958a2-474b-48af-8618-74352352c369" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_3677c445-ca7e-4459-b98e-5aa09865e09a" xlink:href="biib-20200930.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_f8c958a2-474b-48af-8618-74352352c369" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_3677c445-ca7e-4459-b98e-5aa09865e09a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_6d1f97ed-cd76-4d5f-ab6f-571d72c4eb7e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_0018cd45-525c-47dd-80ce-b009dafab11b" xlink:to="loc_us-gaap_DebtInstrumentAxis_6d1f97ed-cd76-4d5f-ab6f-571d72c4eb7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_be5cc1b4-daa4-4311-b052-5b699a76e5f2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_6d1f97ed-cd76-4d5f-ab6f-571d72c4eb7e" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_be5cc1b4-daa4-4311-b052-5b699a76e5f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_5918faed-22fb-4017-81e4-f55c3cd23edc" xlink:href="biib-20200930.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_be5cc1b4-daa4-4311-b052-5b699a76e5f2" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_5918faed-22fb-4017-81e4-f55c3cd23edc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis_e7391b43-6c0c-40d8-85c1-6aafee419b25" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CurrencyAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_0018cd45-525c-47dd-80ce-b009dafab11b" xlink:to="loc_srt_CurrencyAxis_e7391b43-6c0c-40d8-85c1-6aafee419b25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_89aacbbf-3cdd-45b5-8e8c-9a2aa1320a09" xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_AllCurrenciesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CurrencyAxis_e7391b43-6c0c-40d8-85c1-6aafee419b25" xlink:to="loc_currency_AllCurrenciesDomain_89aacbbf-3cdd-45b5-8e8c-9a2aa1320a09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_EUR_a6acd2d6-e45d-49e1-8802-8eab6240d068" xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_EUR"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_89aacbbf-3cdd-45b5-8e8c-9a2aa1320a09" xlink:to="loc_currency_EUR_a6acd2d6-e45d-49e1-8802-8eab6240d068" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_GBP_8969f442-18ed-493a-ab10-4452bfbaa5e1" xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_GBP"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_89aacbbf-3cdd-45b5-8e8c-9a2aa1320a09" xlink:to="loc_currency_GBP_8969f442-18ed-493a-ab10-4452bfbaa5e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_CHF_7610050c-afc0-4a74-83cb-32cb8c43a750" xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_CHF"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_89aacbbf-3cdd-45b5-8e8c-9a2aa1320a09" xlink:to="loc_currency_CHF_7610050c-afc0-4a74-83cb-32cb8c43a750" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_JPY_75a84f63-9a00-4dad-b200-4b0f543b0684" xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_JPY"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_89aacbbf-3cdd-45b5-8e8c-9a2aa1320a09" xlink:to="loc_currency_JPY_75a84f63-9a00-4dad-b200-4b0f543b0684" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_CAD_de9d695b-3137-4532-8e03-cf90e8445581" xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_CAD"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_89aacbbf-3cdd-45b5-8e8c-9a2aa1320a09" xlink:to="loc_currency_CAD_de9d695b-3137-4532-8e03-cf90e8445581" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_3b373247-2e77-4a2a-92fe-aa0efbc49963" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_0018cd45-525c-47dd-80ce-b009dafab11b" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_3b373247-2e77-4a2a-92fe-aa0efbc49963" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_8c30cbb2-2af7-40a6-b6f1-31114d8324f6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_3b373247-2e77-4a2a-92fe-aa0efbc49963" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_8c30cbb2-2af7-40a6-b6f1-31114d8324f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseMember_f1481b57-2ad9-4681-bbbf-684d396bbab9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8c30cbb2-2af7-40a6-b6f1-31114d8324f6" xlink:to="loc_us-gaap_InterestExpenseMember_f1481b57-2ad9-4681-bbbf-684d396bbab9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember_08412deb-4196-4291-a799-b4d4fed4cf10" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SalesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8c30cbb2-2af7-40a6-b6f1-31114d8324f6" xlink:to="loc_us-gaap_SalesMember_08412deb-4196-4291-a799-b4d4fed4cf10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenseMember_a94b0b34-e019-450e-97a0-a1c28ca55276" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8c30cbb2-2af7-40a6-b6f1-31114d8324f6" xlink:to="loc_us-gaap_OperatingExpenseMember_a94b0b34-e019-450e-97a0-a1c28ca55276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_169db320-5f77-48d4-ae8f-077c39669a41" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8c30cbb2-2af7-40a6-b6f1-31114d8324f6" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_169db320-5f77-48d4-ae8f-077c39669a41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_5ae0b1b2-d807-4f61-86cc-d8ad7a7cc963" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_0018cd45-525c-47dd-80ce-b009dafab11b" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_5ae0b1b2-d807-4f61-86cc-d8ad7a7cc963" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_76e5c36c-78f9-47ef-9f7b-1ce6f238f550" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_5ae0b1b2-d807-4f61-86cc-d8ad7a7cc963" xlink:to="loc_us-gaap_HedgingRelationshipDomain_76e5c36c-78f9-47ef-9f7b-1ce6f238f550" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_8cfbe2ec-f8eb-42f2-99ad-8c2520325506" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_76e5c36c-78f9-47ef-9f7b-1ce6f238f550" xlink:to="loc_us-gaap_CashFlowHedgingMember_8cfbe2ec-f8eb-42f2-99ad-8c2520325506" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember_fe807797-088a-404a-aa39-33b1687776ca" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueHedgingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_76e5c36c-78f9-47ef-9f7b-1ce6f238f550" xlink:to="loc_us-gaap_FairValueHedgingMember_fe807797-088a-404a-aa39-33b1687776ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CashflowsrevenueMember_78cdc1a3-bfe0-4ad3-a9d5-77b2c0cea25f" xlink:href="biib-20200930.xsd#biib_CashflowsrevenueMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_76e5c36c-78f9-47ef-9f7b-1ce6f238f550" xlink:to="loc_biib_CashflowsrevenueMember_78cdc1a3-bfe0-4ad3-a9d5-77b2c0cea25f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CashflowsoperatingexpensesMember_55cef47f-785c-4119-9abd-baf263290c1a" xlink:href="biib-20200930.xsd#biib_CashflowsoperatingexpensesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_76e5c36c-78f9-47ef-9f7b-1ce6f238f550" xlink:to="loc_biib_CashflowsoperatingexpensesMember_55cef47f-785c-4119-9abd-baf263290c1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_fbcbb538-8324-4497-abd7-ae025adf7527" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_76e5c36c-78f9-47ef-9f7b-1ce6f238f550" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_fbcbb538-8324-4497-abd7-ae025adf7527" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_3f19a8f7-c983-4eed-917a-d25f8048c733" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_0018cd45-525c-47dd-80ce-b009dafab11b" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_3f19a8f7-c983-4eed-917a-d25f8048c733" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_6841accb-4488-41e3-8aaa-ffe61d539bb1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_3f19a8f7-c983-4eed-917a-d25f8048c733" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_6841accb-4488-41e3-8aaa-ffe61d539bb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_73ac4b29-da81-4ecf-80bf-018c3795bf24" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_6841accb-4488-41e3-8aaa-ffe61d539bb1" xlink:to="loc_us-gaap_ForeignExchangeContractMember_73ac4b29-da81-4ecf-80bf-018c3795bf24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_b3217944-4adb-47e6-b634-6fd6fb4de268" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_6841accb-4488-41e3-8aaa-ffe61d539bb1" xlink:to="loc_us-gaap_InterestRateSwapMember_b3217944-4adb-47e6-b634-6fd6fb4de268" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_6e772b2e-7a9b-4a16-92eb-c4a6a2b2512c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_0018cd45-525c-47dd-80ce-b009dafab11b" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_6e772b2e-7a9b-4a16-92eb-c4a6a2b2512c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_217ed057-564e-4e58-a606-ad616b655c33" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_6e772b2e-7a9b-4a16-92eb-c4a6a2b2512c" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_217ed057-564e-4e58-a606-ad616b655c33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_06bb411f-0cc6-43e6-9847-5442595c4818" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_217ed057-564e-4e58-a606-ad616b655c33" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_06bb411f-0cc6-43e6-9847-5442595c4818" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_11bbab8a-4e00-4832-a7e0-f316ca7362c7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_217ed057-564e-4e58-a606-ad616b655c33" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_11bbab8a-4e00-4832-a7e0-f316ca7362c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_59e77e1f-2a6f-4a75-b935-2c21825690da" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_217ed057-564e-4e58-a606-ad616b655c33" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_59e77e1f-2a6f-4a75-b935-2c21825690da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_9fb7d812-69fd-49b9-928a-fde5a39f745f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_217ed057-564e-4e58-a606-ad616b655c33" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_9fb7d812-69fd-49b9-928a-fde5a39f745f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_6aa82de5-8439-4831-a933-a74b1e8a7c35" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_0018cd45-525c-47dd-80ce-b009dafab11b" xlink:to="loc_us-gaap_HedgingDesignationAxis_6aa82de5-8439-4831-a933-a74b1e8a7c35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_bf848a88-e6b1-4aee-93ae-acfefb00ef3c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_6aa82de5-8439-4831-a933-a74b1e8a7c35" xlink:to="loc_us-gaap_HedgingDesignationDomain_bf848a88-e6b1-4aee-93ae-acfefb00ef3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_0e199054-97d2-435d-b847-426f4342806b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_bf848a88-e6b1-4aee-93ae-acfefb00ef3c" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_0e199054-97d2-435d-b847-426f4342806b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_894d1ef2-499f-4d57-ad00-36d50d62f21d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_bf848a88-e6b1-4aee-93ae-acfefb00ef3c" xlink:to="loc_us-gaap_NondesignatedMember_894d1ef2-499f-4d57-ad00-36d50d62f21d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_313f6e2e-542e-45e3-b75a-f5e36ce51930" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_0018cd45-525c-47dd-80ce-b009dafab11b" xlink:to="loc_srt_RangeAxis_313f6e2e-542e-45e3-b75a-f5e36ce51930" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8abf7e84-b7cf-48a4-8754-be469b2f3a55" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_313f6e2e-542e-45e3-b75a-f5e36ce51930" xlink:to="loc_srt_RangeMember_8abf7e84-b7cf-48a4-8754-be469b2f3a55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_30eaab40-a38d-4141-9b5c-e80fa9c63405" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_8abf7e84-b7cf-48a4-8754-be469b2f3a55" xlink:to="loc_srt_MinimumMember_30eaab40-a38d-4141-9b5c-e80fa9c63405" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_46d0ade4-6b77-4168-a169-35858e890eb3" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_8abf7e84-b7cf-48a4-8754-be469b2f3a55" xlink:to="loc_srt_MaximumMember_46d0ade4-6b77-4168-a169-35858e890eb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_e5ae0d2e-0e87-4071-872f-30a9aaeb6a60" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_0018cd45-525c-47dd-80ce-b009dafab11b" xlink:to="loc_us-gaap_DerivativesFairValueLineItems_e5ae0d2e-0e87-4071-872f-30a9aaeb6a60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeRemainingMaturity1_1eec08a6-b50b-49d8-9362-cc9c0d2d98cf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeRemainingMaturity1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_e5ae0d2e-0e87-4071-872f-30a9aaeb6a60" xlink:to="loc_us-gaap_DerivativeRemainingMaturity1_1eec08a6-b50b-49d8-9362-cc9c0d2d98cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_6127f9aa-22d7-4cea-ba3f-89ad83435d9c" xlink:href="biib-20200930.xsd#biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_e5ae0d2e-0e87-4071-872f-30a9aaeb6a60" xlink:to="loc_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_6127f9aa-22d7-4cea-ba3f-89ad83435d9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_4da4a483-0ea8-4ad9-9d6b-dbec12e53545" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_e5ae0d2e-0e87-4071-872f-30a9aaeb6a60" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_4da4a483-0ea8-4ad9-9d6b-dbec12e53545" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_0fcdd977-9c9b-4196-a60e-543ee8076e97" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_e5ae0d2e-0e87-4071-872f-30a9aaeb6a60" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_0fcdd977-9c9b-4196-a60e-543ee8076e97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_439db85d-1d08-4ee5-b0b0-eaeb1365ce95" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_e5ae0d2e-0e87-4071-872f-30a9aaeb6a60" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_439db85d-1d08-4ee5-b0b0-eaeb1365ce95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_679927b7-e80c-4e46-81e7-f7358cdee8ab" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_e5ae0d2e-0e87-4071-872f-30a9aaeb6a60" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_679927b7-e80c-4e46-81e7-f7358cdee8ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_36c712e8-1a8c-471d-857b-a655c5be1684" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_e5ae0d2e-0e87-4071-872f-30a9aaeb6a60" xlink:to="loc_us-gaap_DerivativeNotionalAmount_36c712e8-1a8c-471d-857b-a655c5be1684" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_130d50a4-ea99-41a3-9f1b-599625273654" xlink:href="biib-20200930.xsd#biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_e5ae0d2e-0e87-4071-872f-30a9aaeb6a60" xlink:to="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_130d50a4-ea99-41a3-9f1b-599625273654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_8f501ab3-c009-45ab-9c66-de441c591948" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_e5ae0d2e-0e87-4071-872f-30a9aaeb6a60" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_8f501ab3-c009-45ab-9c66-de441c591948" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_9687a4d6-3afa-4e33-ac04-7f074aee242a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_e5ae0d2e-0e87-4071-872f-30a9aaeb6a60" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_9687a4d6-3afa-4e33-ac04-7f074aee242a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTermOfContract_fb0d2e7d-e76f-4954-b1c5-6634f9e53d88" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeTermOfContract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_e5ae0d2e-0e87-4071-872f-30a9aaeb6a60" xlink:to="loc_us-gaap_DerivativeTermOfContract_fb0d2e7d-e76f-4954-b1c5-6634f9e53d88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_8dbeb171-594d-4f51-acee-007aae88f3d8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_e5ae0d2e-0e87-4071-872f-30a9aaeb6a60" xlink:to="loc_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_8dbeb171-594d-4f51-acee-007aae88f3d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax_533523f0-3b31-4adb-8275-1df857e4e57d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_e5ae0d2e-0e87-4071-872f-30a9aaeb6a60" xlink:to="loc_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax_533523f0-3b31-4adb-8275-1df857e4e57d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_0eef65c9-e964-4845-ab42-734bcaa7e73d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_e5ae0d2e-0e87-4071-872f-30a9aaeb6a60" xlink:to="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_0eef65c9-e964-4845-ab42-734bcaa7e73d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_e5f7fc0f-2c5a-471b-b0a8-65ade25f55c1" xlink:href="biib-20200930.xsd#biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_e5ae0d2e-0e87-4071-872f-30a9aaeb6a60" xlink:to="loc_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_e5f7fc0f-2c5a-471b-b0a8-65ade25f55c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_abc5f981-b5c9-4a06-a4c2-476a7bd5e7c8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_e5ae0d2e-0e87-4071-872f-30a9aaeb6a60" xlink:to="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_abc5f981-b5c9-4a06-a4c2-476a7bd5e7c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_77bfe327-3541-4235-ac8f-28fbb7c54990" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_e5ae0d2e-0e87-4071-872f-30a9aaeb6a60" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_77bfe327-3541-4235-ac8f-28fbb7c54990" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_4b8c8e1c-907e-40ac-8bde-9e2a60300fc7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_e5ae0d2e-0e87-4071-872f-30a9aaeb6a60" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_4b8c8e1c-907e-40ac-8bde-9e2a60300fc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantandEquipmentPropertyPlantandEquipment" xlink:type="simple" xlink:href="biib-20200930.xsd#PropertyPlantandEquipmentPropertyPlantandEquipment"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/PropertyPlantandEquipmentPropertyPlantandEquipment" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_6adeabe8-7d7b-4c71-bc1f-839dacd22b86" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_0ad6f782-aa0d-4324-8599-ed2bfcae0293" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_6adeabe8-7d7b-4c71-bc1f-839dacd22b86" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_0ad6f782-aa0d-4324-8599-ed2bfcae0293" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="biib-20200930.xsd#PropertyPlantandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_422e3f6b-4af8-4dcb-8726-45fe180b0426" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_db9609d9-822a-4209-aee7-24b3229d8602" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_422e3f6b-4af8-4dcb-8726-45fe180b0426" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_db9609d9-822a-4209-aee7-24b3229d8602" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityLocationAxis_b7230ee9-f549-4ab9-9646-95b9f24f7c41" xlink:href="biib-20200930.xsd#biib_FacilityLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_db9609d9-822a-4209-aee7-24b3229d8602" xlink:to="loc_biib_FacilityLocationAxis_b7230ee9-f549-4ab9-9646-95b9f24f7c41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityLocationDomain_7880fa0a-c097-411a-8c75-def2d2bde19c" xlink:href="biib-20200930.xsd#biib_FacilityLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityLocationAxis_b7230ee9-f549-4ab9-9646-95b9f24f7c41" xlink:to="loc_biib_FacilityLocationDomain_7880fa0a-c097-411a-8c75-def2d2bde19c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SolothurnSwitzerlandMember_a68976cf-c889-4ef4-a2a4-164c9ba62bfb" xlink:href="biib-20200930.xsd#biib_SolothurnSwitzerlandMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityLocationDomain_7880fa0a-c097-411a-8c75-def2d2bde19c" xlink:to="loc_biib_SolothurnSwitzerlandMember_a68976cf-c889-4ef4-a2a4-164c9ba62bfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityTypeAxis_afc2bd50-5b12-4da0-a3ba-da306fa44abf" xlink:href="biib-20200930.xsd#biib_FacilityTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_db9609d9-822a-4209-aee7-24b3229d8602" xlink:to="loc_biib_FacilityTypeAxis_afc2bd50-5b12-4da0-a3ba-da306fa44abf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityTypeDomain_0816c29f-f379-44f0-ba6a-b21118c4035f" xlink:href="biib-20200930.xsd#biib_FacilityTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityTypeAxis_afc2bd50-5b12-4da0-a3ba-da306fa44abf" xlink:to="loc_biib_FacilityTypeDomain_0816c29f-f379-44f0-ba6a-b21118c4035f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BiologicsManufacturingMember_4f882cc6-1ffe-4d9a-b2ca-7d64d1a87be8" xlink:href="biib-20200930.xsd#biib_BiologicsManufacturingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityTypeDomain_0816c29f-f379-44f0-ba6a-b21118c4035f" xlink:to="loc_biib_BiologicsManufacturingMember_4f882cc6-1ffe-4d9a-b2ca-7d64d1a87be8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_WarehouseUtilitiesAndSupportSpaceMember_8c56dfec-7ef6-4de4-b061-03a58ae67964" xlink:href="biib-20200930.xsd#biib_WarehouseUtilitiesAndSupportSpaceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityTypeDomain_0816c29f-f379-44f0-ba6a-b21118c4035f" xlink:to="loc_biib_WarehouseUtilitiesAndSupportSpaceMember_8c56dfec-7ef6-4de4-b061-03a58ae67964" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdministrativeSpaceMember_efbd39c6-1600-4459-9a22-71db625e07bc" xlink:href="biib-20200930.xsd#biib_AdministrativeSpaceMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityTypeDomain_0816c29f-f379-44f0-ba6a-b21118c4035f" xlink:to="loc_biib_AdministrativeSpaceMember_efbd39c6-1600-4459-9a22-71db625e07bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ef8ba48f-a794-47ed-bbf8-343dba57391d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_db9609d9-822a-4209-aee7-24b3229d8602" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ef8ba48f-a794-47ed-bbf8-343dba57391d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_ea3e7642-3a1f-44a2-b14a-0c7ae43742c4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ef8ba48f-a794-47ed-bbf8-343dba57391d" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_ea3e7642-3a1f-44a2-b14a-0c7ae43742c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_47d960ab-eaa9-4f7e-ab66-2e670289c588" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ef8ba48f-a794-47ed-bbf8-343dba57391d" xlink:to="loc_us-gaap_Depreciation_47d960ab-eaa9-4f7e-ab66-2e670289c588" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NumberOfSquareFeet_0f18d657-f993-41b9-b3fc-f26eaa4159d5" xlink:href="biib-20200930.xsd#biib_NumberOfSquareFeet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ef8ba48f-a794-47ed-bbf8-343dba57391d" xlink:to="loc_biib_NumberOfSquareFeet_0f18d657-f993-41b9-b3fc-f26eaa4159d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_c8fa5c17-0dc8-4d70-af3d-052ef9bdb69e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ef8ba48f-a794-47ed-bbf8-343dba57391d" xlink:to="loc_us-gaap_ConstructionInProgressGross_c8fa5c17-0dc8-4d70-af3d-052ef9bdb69e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_77a80cf8-6c4c-493c-9370-8627e645077e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ef8ba48f-a794-47ed-bbf8-343dba57391d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_77a80cf8-6c4c-493c-9370-8627e645077e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitment_93d39adb-edd5-487e-bab5-7117495ce4a3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCommitment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ef8ba48f-a794-47ed-bbf8-343dba57391d" xlink:to="loc_us-gaap_OtherCommitment_93d39adb-edd5-487e-bab5-7117495ce4a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IndebtednessNotes" xlink:type="simple" xlink:href="biib-20200930.xsd#IndebtednessNotes"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IndebtednessNotes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_cb6fa6b7-d6dc-49b9-907b-c89de93e29bd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_2b0c26e8-cabd-4c8c-83d6-c0a72b741cc8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_cb6fa6b7-d6dc-49b9-907b-c89de93e29bd" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_2b0c26e8-cabd-4c8c-83d6-c0a72b741cc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IndebtednessDetails" xlink:type="simple" xlink:href="biib-20200930.xsd#IndebtednessDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IndebtednessDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_ae4ab636-81c2-4167-b59e-a112b3925d17" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_862a0174-e4b7-47af-9fc5-4096776d63e9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_ae4ab636-81c2-4167-b59e-a112b3925d17" xlink:to="loc_us-gaap_DebtInstrumentTable_862a0174-e4b7-47af-9fc5-4096776d63e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_15df600d-4585-45d2-a848-c908025f4d67" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_862a0174-e4b7-47af-9fc5-4096776d63e9" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_15df600d-4585-45d2-a848-c908025f4d67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_4242d8df-f20a-49b0-86e7-6f67503bf79c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_15df600d-4585-45d2-a848-c908025f4d67" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_4242d8df-f20a-49b0-86e7-6f67503bf79c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseMember_c788cb0b-cb43-465e-8ab7-6266f915d152" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_4242d8df-f20a-49b0-86e7-6f67503bf79c" xlink:to="loc_us-gaap_InterestExpenseMember_c788cb0b-cb43-465e-8ab7-6266f915d152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_79bcd0ca-610f-4d17-8e55-fbd89926c380" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_862a0174-e4b7-47af-9fc5-4096776d63e9" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_79bcd0ca-610f-4d17-8e55-fbd89926c380" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_42a162fb-d391-46fa-8a36-662e2f867b70" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_79bcd0ca-610f-4d17-8e55-fbd89926c380" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_42a162fb-d391-46fa-8a36-662e2f867b70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_30baf4cd-ecc9-48bc-b613-9029a000649a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_42a162fb-d391-46fa-8a36-662e2f867b70" xlink:to="loc_us-gaap_InterestRateSwapMember_30baf4cd-ecc9-48bc-b613-9029a000649a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_4d7e1429-525d-4600-a129-faa4b7d7fbac" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_862a0174-e4b7-47af-9fc5-4096776d63e9" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_4d7e1429-525d-4600-a129-faa4b7d7fbac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_3c5219ac-ee85-4e20-bb29-998d6a651cc3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_4d7e1429-525d-4600-a129-faa4b7d7fbac" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_3c5219ac-ee85-4e20-bb29-998d6a651cc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_1b418c79-6038-4e77-83e3-f8bd2e880e87" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_3c5219ac-ee85-4e20-bb29-998d6a651cc3" xlink:to="loc_us-gaap_SeniorNotesMember_1b418c79-6038-4e77-83e3-f8bd2e880e87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_148c0ae5-8f05-4e62-9310-77c92102b041" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_862a0174-e4b7-47af-9fc5-4096776d63e9" xlink:to="loc_us-gaap_DebtInstrumentAxis_148c0ae5-8f05-4e62-9310-77c92102b041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_05952a62-c822-46a6-bf46-27ede2a3f3a3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_148c0ae5-8f05-4e62-9310-77c92102b041" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_05952a62-c822-46a6-bf46-27ede2a3f3a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2.25SeniorNotesdueMay12030Member_af6538eb-d7f6-4d1a-b755-be003613eb21" xlink:href="biib-20200930.xsd#biib_A2.25SeniorNotesdueMay12030Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_05952a62-c822-46a6-bf46-27ede2a3f3a3" xlink:to="loc_biib_A2.25SeniorNotesdueMay12030Member_af6538eb-d7f6-4d1a-b755-be003613eb21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A3.15SeniorNotesdueMay12050Member_08234c34-18ba-4d8f-aacb-4565ad359585" xlink:href="biib-20200930.xsd#biib_A3.15SeniorNotesdueMay12050Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_05952a62-c822-46a6-bf46-27ede2a3f3a3" xlink:to="loc_biib_A3.15SeniorNotesdueMay12050Member_08234c34-18ba-4d8f-aacb-4565ad359585" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2.90SeniorNotesDueSept152020Member_45c113ff-084f-4808-85db-de5bd36143e4" xlink:href="biib-20200930.xsd#biib_A2.90SeniorNotesDueSept152020Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_05952a62-c822-46a6-bf46-27ede2a3f3a3" xlink:to="loc_biib_A2.90SeniorNotesDueSept152020Member_45c113ff-084f-4808-85db-de5bd36143e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_4d6c6733-4a8a-40d3-bec1-313724fc73f6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_862a0174-e4b7-47af-9fc5-4096776d63e9" xlink:to="loc_us-gaap_DebtInstrumentLineItems_4d6c6733-4a8a-40d3-bec1-313724fc73f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_2616c64b-aea0-4b88-ba86-761093183ec7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4d6c6733-4a8a-40d3-bec1-313724fc73f6" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_2616c64b-aea0-4b88-ba86-761093183ec7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_ff906f36-73ac-4304-be34-d17f0cb40752" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4d6c6733-4a8a-40d3-bec1-313724fc73f6" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_ff906f36-73ac-4304-be34-d17f0cb40752" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageParValueOfSeniorNotes_b6ba385d-8749-47b2-b986-ab6bc1cecf47" xlink:href="biib-20200930.xsd#biib_PercentageParValueOfSeniorNotes"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4d6c6733-4a8a-40d3-bec1-313724fc73f6" xlink:to="loc_biib_PercentageParValueOfSeniorNotes_b6ba385d-8749-47b2-b986-ab6bc1cecf47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_3ac4a626-79cf-4c87-bce4-c22c3d15ee0b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4d6c6733-4a8a-40d3-bec1-313724fc73f6" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_3ac4a626-79cf-4c87-bce4-c22c3d15ee0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage_d37a0f0d-6879-47a4-ad02-9dcf15dd91a4" xlink:href="biib-20200930.xsd#biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4d6c6733-4a8a-40d3-bec1-313724fc73f6" xlink:to="loc_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage_d37a0f0d-6879-47a4-ad02-9dcf15dd91a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_8a3f5554-df15-4905-b040-c42a88083ea9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4d6c6733-4a8a-40d3-bec1-313724fc73f6" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts_8a3f5554-df15-4905-b040-c42a88083ea9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain_745593be-5a34-4c83-8100-aa64cab57183" xlink:href="biib-20200930.xsd#biib_PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4d6c6733-4a8a-40d3-bec1-313724fc73f6" xlink:to="loc_biib_PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain_745593be-5a34-4c83-8100-aa64cab57183" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts_10545696-30b9-42f0-9d76-c4a3c3bfd326" xlink:href="biib-20200930.xsd#biib_EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4d6c6733-4a8a-40d3-bec1-313724fc73f6" xlink:to="loc_biib_EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts_10545696-30b9-42f0-9d76-c4a3c3bfd326" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_473e4719-cce8-463d-bbbd-7e4d3eea715f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4d6c6733-4a8a-40d3-bec1-313724fc73f6" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_473e4719-cce8-463d-bbbd-7e4d3eea715f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/Equity" xlink:type="simple" xlink:href="biib-20200930.xsd#Equity"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Equity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_da48193d-8581-42d4-971d-23c21cfab3d8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_6406d1d9-2e71-403a-bcae-d80a962fadc0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_da48193d-8581-42d4-971d-23c21cfab3d8" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_6406d1d9-2e71-403a-bcae-d80a962fadc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables" xlink:type="simple" xlink:href="biib-20200930.xsd#AccumulatedOtherComprehensiveIncomeLossTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_4014ab9c-6e61-40e7-acd8-7d2ff809f10d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_10906f4e-1c53-4d24-b496-cf848ccd71bd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_4014ab9c-6e61-40e7-acd8-7d2ff809f10d" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_10906f4e-1c53-4d24-b496-cf848ccd71bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_cd82d6e3-0d4e-4cc2-9358-a4af535de908" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_4014ab9c-6e61-40e7-acd8-7d2ff809f10d" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_cd82d6e3-0d4e-4cc2-9358-a4af535de908" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareRepurchasesDetails" xlink:type="simple" xlink:href="biib-20200930.xsd#ShareRepurchasesDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareRepurchasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_200ac604-7180-428d-999d-900625e4e8cc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_41a3b8ac-cac7-45a7-ac05-e486d8bd65e4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_200ac604-7180-428d-999d-900625e4e8cc" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_41a3b8ac-cac7-45a7-ac05-e486d8bd65e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_916e1218-a438-463d-b76e-ee7a980f5c6f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_41a3b8ac-cac7-45a7-ac05-e486d8bd65e4" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_916e1218-a438-463d-b76e-ee7a980f5c6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_05fdbee8-e0fd-4114-b68e-eb0c3f00f858" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_916e1218-a438-463d-b76e-ee7a980f5c6f" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_05fdbee8-e0fd-4114-b68e-eb0c3f00f858" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_0938c08a-a35c-47b7-b85e-acd1aeb7799a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_05fdbee8-e0fd-4114-b68e-eb0c3f00f858" xlink:to="loc_us-gaap_SubsequentEventMember_0938c08a-a35c-47b7-b85e-acd1aeb7799a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_a0db8c86-f44d-4f5d-84d4-d468596638ea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_41a3b8ac-cac7-45a7-ac05-e486d8bd65e4" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_a0db8c86-f44d-4f5d-84d4-d468596638ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_8bc5f572-97e2-4141-a8db-c21ce62ab57d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_a0db8c86-f44d-4f5d-84d4-d468596638ea" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_8bc5f572-97e2-4141-a8db-c21ce62ab57d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_December2019ShareRepurchaseProgramMember_f63fc1c0-8afe-449a-85dc-b047ce5bd6be" xlink:href="biib-20200930.xsd#biib_December2019ShareRepurchaseProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_8bc5f572-97e2-4141-a8db-c21ce62ab57d" xlink:to="loc_biib_December2019ShareRepurchaseProgramMember_f63fc1c0-8afe-449a-85dc-b047ce5bd6be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_March2019ShareRepurchaseProgramMember_ece58675-c04f-474d-8ea5-c4aed34bfe92" xlink:href="biib-20200930.xsd#biib_March2019ShareRepurchaseProgramMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_8bc5f572-97e2-4141-a8db-c21ce62ab57d" xlink:to="loc_biib_March2019ShareRepurchaseProgramMember_ece58675-c04f-474d-8ea5-c4aed34bfe92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_October2020ShareRepurchaseProgramMember_5f113079-20d1-4d17-8be4-7200d41c30e2" xlink:href="biib-20200930.xsd#biib_October2020ShareRepurchaseProgramMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_8bc5f572-97e2-4141-a8db-c21ce62ab57d" xlink:to="loc_biib_October2020ShareRepurchaseProgramMember_5f113079-20d1-4d17-8be4-7200d41c30e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_12f2bbac-79ef-4af3-a72c-f74162161423" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_41a3b8ac-cac7-45a7-ac05-e486d8bd65e4" xlink:to="loc_us-gaap_ClassOfStockLineItems_12f2bbac-79ef-4af3-a72c-f74162161423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_a131eb33-a107-4372-a50f-1e0783475516" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_12f2bbac-79ef-4af3-a72c-f74162161423" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_a131eb33-a107-4372-a50f-1e0783475516" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_4962c88f-f86a-4e87-8366-60ee27bc5ec7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_12f2bbac-79ef-4af3-a72c-f74162161423" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_4962c88f-f86a-4e87-8366-60ee27bc5ec7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_ddb8e337-dd7c-4abc-a39b-c9b190c696fb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_12f2bbac-79ef-4af3-a72c-f74162161423" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_ddb8e337-dd7c-4abc-a39b-c9b190c696fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_65693398-0a2a-498b-ace9-98643d493d26" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_12f2bbac-79ef-4af3-a72c-f74162161423" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_65693398-0a2a-498b-ace9-98643d493d26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="biib-20200930.xsd#AccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_187dadd9-f8cf-49fc-b51c-57bc37c3f504" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_6c60bd5c-9842-4a45-942f-f0f0d01e5992" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_187dadd9-f8cf-49fc-b51c-57bc37c3f504" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_6c60bd5c-9842-4a45-942f-f0f0d01e5992" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_5fcf54e6-3e2c-46b2-9a4e-9742975d427a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_6c60bd5c-9842-4a45-942f-f0f0d01e5992" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_5fcf54e6-3e2c-46b2-9a4e-9742975d427a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b0bbc8b5-1b0b-4fb5-9f51-612a6883afca" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5fcf54e6-3e2c-46b2-9a4e-9742975d427a" xlink:to="loc_us-gaap_EquityComponentDomain_b0bbc8b5-1b0b-4fb5-9f51-612a6883afca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_93dd65c1-06ba-4be8-b48f-3ed2170f902d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b0bbc8b5-1b0b-4fb5-9f51-612a6883afca" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_93dd65c1-06ba-4be8-b48f-3ed2170f902d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_38152238-aa37-4dff-bcd6-217d4396f1af" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b0bbc8b5-1b0b-4fb5-9f51-612a6883afca" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_38152238-aa37-4dff-bcd6-217d4396f1af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_3a4bec21-bb72-471d-89b7-500b39f1ea41" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b0bbc8b5-1b0b-4fb5-9f51-612a6883afca" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_3a4bec21-bb72-471d-89b7-500b39f1ea41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_2828fe3b-ef41-4fb8-b18d-a0ac570203ae" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b0bbc8b5-1b0b-4fb5-9f51-612a6883afca" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_2828fe3b-ef41-4fb8-b18d-a0ac570203ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_11ab4225-5408-443e-b6f7-315ea9087632" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b0bbc8b5-1b0b-4fb5-9f51-612a6883afca" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_11ab4225-5408-443e-b6f7-315ea9087632" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_2b1bf00e-5bd5-499d-ae8d-f07455bd73f8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_6c60bd5c-9842-4a45-942f-f0f0d01e5992" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_2b1bf00e-5bd5-499d-ae8d-f07455bd73f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_7e74cc93-f337-41d7-b701-78bcd5e7ee2d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_2b1bf00e-5bd5-499d-ae8d-f07455bd73f8" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_7e74cc93-f337-41d7-b701-78bcd5e7ee2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_909cb44c-a738-4239-8051-52a1cff4a9c0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_2b1bf00e-5bd5-499d-ae8d-f07455bd73f8" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_909cb44c-a738-4239-8051-52a1cff4a9c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_d5fc9af6-ea78-4d57-96e0-75baf7004ead" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_2b1bf00e-5bd5-499d-ae8d-f07455bd73f8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_d5fc9af6-ea78-4d57-96e0-75baf7004ead" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_f53bb292-63dc-4b72-829a-3a62dd84a6f5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_2b1bf00e-5bd5-499d-ae8d-f07455bd73f8" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_f53bb292-63dc-4b72-829a-3a62dd84a6f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_f0893267-7fe5-43a6-8163-12e8447f5718" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_2b1bf00e-5bd5-499d-ae8d-f07455bd73f8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_f0893267-7fe5-43a6-8163-12e8447f5718" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_52c3769d-e073-4e39-81c8-090a22c19789" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_2b1bf00e-5bd5-499d-ae8d-f07455bd73f8" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_52c3769d-e073-4e39-81c8-090a22c19789" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_544d3f80-de49-4cef-99d9-5a654f970ac5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_2b1bf00e-5bd5-499d-ae8d-f07455bd73f8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_544d3f80-de49-4cef-99d9-5a654f970ac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="biib-20200930.xsd#ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract_ada1af8d-f712-447b-ac1c-d3328b99b817" xlink:href="biib-20200930.xsd#biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_938e6a11-b0d6-46c7-b7a0-d2f16733748d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract_ada1af8d-f712-447b-ac1c-d3328b99b817" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_938e6a11-b0d6-46c7-b7a0-d2f16733748d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_f0d7b2e5-e9fe-48b2-ae96-c9ed953d85e5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_938e6a11-b0d6-46c7-b7a0-d2f16733748d" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_f0d7b2e5-e9fe-48b2-ae96-c9ed953d85e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_50ec4908-6201-4f0e-8a16-87ff68738da4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f0d7b2e5-e9fe-48b2-ae96-c9ed953d85e5" xlink:to="loc_us-gaap_EquityComponentDomain_50ec4908-6201-4f0e-8a16-87ff68738da4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_5485237d-43b3-4d11-b410-9dfd86a00497" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_50ec4908-6201-4f0e-8a16-87ff68738da4" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_5485237d-43b3-4d11-b410-9dfd86a00497" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_8f54f0a4-7589-45c2-af97-71c0ca065588" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_50ec4908-6201-4f0e-8a16-87ff68738da4" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_8f54f0a4-7589-45c2-af97-71c0ca065588" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_f6d42db3-90db-4e1c-8707-427c53c0f3fb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_50ec4908-6201-4f0e-8a16-87ff68738da4" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_f6d42db3-90db-4e1c-8707-427c53c0f3fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_dc0e603a-7e61-4704-ad9e-5ab358ea0fe5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_938e6a11-b0d6-46c7-b7a0-d2f16733748d" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_dc0e603a-7e61-4704-ad9e-5ab358ea0fe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_c11cca39-ab34-4991-8d5b-aec307f7cf7b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_dc0e603a-7e61-4704-ad9e-5ab358ea0fe5" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_c11cca39-ab34-4991-8d5b-aec307f7cf7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_a3cb841c-96cc-4480-a14c-b8c11643e3e0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_c11cca39-ab34-4991-8d5b-aec307f7cf7b" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_a3cb841c-96cc-4480-a14c-b8c11643e3e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_564479f2-8c44-46e2-ad54-f009781b0c34" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_938e6a11-b0d6-46c7-b7a0-d2f16733748d" xlink:to="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_564479f2-8c44-46e2-ad54-f009781b0c34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_6a520a5d-6162-430a-93cb-420e4bd0ae59" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_564479f2-8c44-46e2-ad54-f009781b0c34" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_6a520a5d-6162-430a-93cb-420e4bd0ae59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_49c17cd5-4028-4353-a1fc-efe60cd69a2b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_564479f2-8c44-46e2-ad54-f009781b0c34" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_49c17cd5-4028-4353-a1fc-efe60cd69a2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_e1e26db5-426c-4535-8489-c7c5117a3818" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_564479f2-8c44-46e2-ad54-f009781b0c34" xlink:to="loc_us-gaap_Revenues_e1e26db5-426c-4535-8489-c7c5117a3818" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_20588aa8-3130-4170-8c81-5e12c9002fce" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_564479f2-8c44-46e2-ad54-f009781b0c34" xlink:to="loc_us-gaap_OperatingExpenses_20588aa8-3130-4170-8c81-5e12c9002fce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_40218c17-0125-426e-9d8d-bbfc13b28120" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_564479f2-8c44-46e2-ad54-f009781b0c34" xlink:to="loc_us-gaap_NetIncomeLoss_40218c17-0125-426e-9d8d-bbfc13b28120" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsperShare" xlink:type="simple" xlink:href="biib-20200930.xsd#EarningsperShare"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EarningsperShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_4a039b0e-db98-4a3e-9747-4fade50d5415" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_2416c52b-1b8f-4a89-8812-e19e23bd1dc2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_4a039b0e-db98-4a3e-9747-4fade50d5415" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_2416c52b-1b8f-4a89-8812-e19e23bd1dc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsperShareTables" xlink:type="simple" xlink:href="biib-20200930.xsd#EarningsperShareTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EarningsperShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_da9033a2-bd13-4ccb-a0ba-713ca5b70c49" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_586885b9-a071-4022-a282-0c307c8327ad" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_da9033a2-bd13-4ccb-a0ba-713ca5b70c49" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_586885b9-a071-4022-a282-0c307c8327ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsperShareDetails" xlink:type="simple" xlink:href="biib-20200930.xsd#EarningsperShareDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EarningsperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_e870c2db-66b7-4c17-a4ba-c5d18b736dc6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_3ba4eecd-28e6-4d73-a3f9-127bfcc94274" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_e870c2db-66b7-4c17-a4ba-c5d18b736dc6" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_3ba4eecd-28e6-4d73-a3f9-127bfcc94274" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5a03a177-b9e6-4f9c-8d54-08814097c452" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_3ba4eecd-28e6-4d73-a3f9-127bfcc94274" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5a03a177-b9e6-4f9c-8d54-08814097c452" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_58e6e608-69b9-40fe-b3d4-031b8f8f851a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5a03a177-b9e6-4f9c-8d54-08814097c452" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_58e6e608-69b9-40fe-b3d4-031b8f8f851a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_def8a2ec-9abc-41dd-b135-27eb0251684f" xlink:href="biib-20200930.xsd#biib_TimeVestedRestrictedStockUnitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_58e6e608-69b9-40fe-b3d4-031b8f8f851a" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_def8a2ec-9abc-41dd-b135-27eb0251684f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MarketStockUnitsMember_c29b8cec-c98b-461c-96cc-8b5007063b31" xlink:href="biib-20200930.xsd#biib_MarketStockUnitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_58e6e608-69b9-40fe-b3d4-031b8f8f851a" xlink:to="loc_biib_MarketStockUnitsMember_c29b8cec-c98b-461c-96cc-8b5007063b31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockMember_72ce6b86-6d92-456d-ab32-3d2f541d6cbe" xlink:href="biib-20200930.xsd#biib_PerformanceStockUnitsSettledinStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_58e6e608-69b9-40fe-b3d4-031b8f8f851a" xlink:to="loc_biib_PerformanceStockUnitsSettledinStockMember_72ce6b86-6d92-456d-ab32-3d2f541d6cbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_99d3d4a8-236e-4d29-aaa1-6a2a4e44a3c9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_3ba4eecd-28e6-4d73-a3f9-127bfcc94274" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_99d3d4a8-236e-4d29-aaa1-6a2a4e44a3c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BasicAndDilutedEarningsPerShareAbstract_ffd59753-ab3e-4960-9227-4d04ad674efd" xlink:href="biib-20200930.xsd#biib_BasicAndDilutedEarningsPerShareAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_99d3d4a8-236e-4d29-aaa1-6a2a4e44a3c9" xlink:to="loc_biib_BasicAndDilutedEarningsPerShareAbstract_ffd59753-ab3e-4960-9227-4d04ad674efd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract_1ba27df6-9ccd-4b43-8c08-36682aa40f3a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract_ffd59753-ab3e-4960-9227-4d04ad674efd" xlink:to="loc_us-gaap_NetIncomeLossAbstract_1ba27df6-9ccd-4b43-8c08-36682aa40f3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_100286d2-4d1f-4089-9063-277788bc33ac" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_1ba27df6-9ccd-4b43-8c08-36682aa40f3a" xlink:to="loc_us-gaap_NetIncomeLoss_100286d2-4d1f-4089-9063-277788bc33ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_7ddb108a-ab17-4e50-b1c1-09a95267f731" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract_ffd59753-ab3e-4960-9227-4d04ad674efd" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_7ddb108a-ab17-4e50-b1c1-09a95267f731" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_cca87c7e-4196-4b47-ab7c-13cf5b4fd3cb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_7ddb108a-ab17-4e50-b1c1-09a95267f731" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_cca87c7e-4196-4b47-ab7c-13cf5b4fd3cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_45e65489-db8b-42e8-9438-2a11e6a5f2f4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_7ddb108a-ab17-4e50-b1c1-09a95267f731" xlink:to="loc_us-gaap_DilutiveSecuritiesAbstract_45e65489-db8b-42e8-9438-2a11e6a5f2f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_b4b0221f-5c68-4ec5-821a-82cf206494f7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_45e65489-db8b-42e8-9438-2a11e6a5f2f4" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_b4b0221f-5c68-4ec5-821a-82cf206494f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_40ac3d89-fde7-4cfd-86f3-1ec84bf53d64" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_45e65489-db8b-42e8-9438-2a11e6a5f2f4" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_40ac3d89-fde7-4cfd-86f3-1ec84bf53d64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7b4aa7fe-08d0-42ec-94e6-1641b6b964f9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_7ddb108a-ab17-4e50-b1c1-09a95267f731" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7b4aa7fe-08d0-42ec-94e6-1641b6b964f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/SharebasedPayments" xlink:type="simple" xlink:href="biib-20200930.xsd#SharebasedPayments"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SharebasedPayments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_140b3028-2521-4e3e-8c8f-577b5d8b3a7e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_93e04e36-f63f-4042-b596-b78db7f0916f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_140b3028-2521-4e3e-8c8f-577b5d8b3a7e" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_93e04e36-f63f-4042-b596-b78db7f0916f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:type="simple" xlink:href="biib-20200930.xsd#ShareBasedPaymentsTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1e53812f-fe95-45c3-ac2d-dd07d3a37808" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_ddddd047-60f8-48a5-8c03-ddf534031d7f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1e53812f-fe95-45c3-ac2d-dd07d3a37808" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_ddddd047-60f8-48a5-8c03-ddf534031d7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_c487d3bc-0524-4111-a632-ce6eeb7f13c0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1e53812f-fe95-45c3-ac2d-dd07d3a37808" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_c487d3bc-0524-4111-a632-ce6eeb7f13c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:type="simple" xlink:href="biib-20200930.xsd#ShareBasedPaymentsDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_42af1f03-26ed-46ec-bf49-8328e010975b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_2923e89e-ef4c-4184-88e0-c63f3d430dc1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_42af1f03-26ed-46ec-bf49-8328e010975b" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_2923e89e-ef4c-4184-88e0-c63f3d430dc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_b468b0f0-f2b7-45c9-9877-cf07589a8b2e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_2923e89e-ef4c-4184-88e0-c63f3d430dc1" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_b468b0f0-f2b7-45c9-9877-cf07589a8b2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_f81dcf66-bcc3-45df-91a4-3cf3604308ca" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_b468b0f0-f2b7-45c9-9877-cf07589a8b2e" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_f81dcf66-bcc3-45df-91a4-3cf3604308ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_842b7741-d243-45cf-8cba-3ef760ae3080" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_f81dcf66-bcc3-45df-91a4-3cf3604308ca" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_842b7741-d243-45cf-8cba-3ef760ae3080" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_9b9f4f83-6713-4284-9caa-9dd8cca59f02" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_f81dcf66-bcc3-45df-91a4-3cf3604308ca" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_9b9f4f83-6713-4284-9caa-9dd8cca59f02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_56884467-e14b-4dc9-a879-ae9630e330c8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ParentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_f81dcf66-bcc3-45df-91a4-3cf3604308ca" xlink:to="loc_us-gaap_ParentMember_56884467-e14b-4dc9-a879-ae9630e330c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_8856fba5-79e9-45ef-aa0c-132ba289b07d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_2923e89e-ef4c-4184-88e0-c63f3d430dc1" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_8856fba5-79e9-45ef-aa0c-132ba289b07d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_02ab4075-5b94-4913-806e-10a698ddce35" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_8856fba5-79e9-45ef-aa0c-132ba289b07d" xlink:to="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_02ab4075-5b94-4913-806e-10a698ddce35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_0c3d996b-05d8-4aa8-9719-e74b1ab685c3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_02ab4075-5b94-4913-806e-10a698ddce35" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_0c3d996b-05d8-4aa8-9719-e74b1ab685c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_5426eb29-d7b9-4fc4-a4dd-9caddf0b4a49" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_02ab4075-5b94-4913-806e-10a698ddce35" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_5426eb29-d7b9-4fc4-a4dd-9caddf0b4a49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_a0445a65-f1cb-4a09-a8dd-f8947c11d027" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_02ab4075-5b94-4913-806e-10a698ddce35" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_a0445a65-f1cb-4a09-a8dd-f8947c11d027" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_4673baed-f864-4b5c-8e3a-3e090fb86b00" xlink:href="biib-20200930.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_02ab4075-5b94-4913-806e-10a698ddce35" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_4673baed-f864-4b5c-8e3a-3e090fb86b00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_15f82707-cc62-40ee-9d4d-44ed9b5ec46d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_02ab4075-5b94-4913-806e-10a698ddce35" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_15f82707-cc62-40ee-9d4d-44ed9b5ec46d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:type="simple" xlink:href="biib-20200930.xsd#ShareBasedPaymentsDetails1"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a346a7ee-c82f-4a3d-a806-a398f7dd4158" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_ab760de6-c83d-4230-ae2e-56e11a812eea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a346a7ee-c82f-4a3d-a806-a398f7dd4158" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_ab760de6-c83d-4230-ae2e-56e11a812eea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_249b90b4-54cd-49d5-a344-aa97048eed53" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_ab760de6-c83d-4230-ae2e-56e11a812eea" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_249b90b4-54cd-49d5-a344-aa97048eed53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e53b09d1-d405-4078-a591-3f1448c6bbaa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_249b90b4-54cd-49d5-a344-aa97048eed53" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e53b09d1-d405-4078-a591-3f1448c6bbaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NightstarMember_0bf8ab4d-021a-4f2e-b64f-5588c81cb157" xlink:href="biib-20200930.xsd#biib_NightstarMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e53b09d1-d405-4078-a591-3f1448c6bbaa" xlink:to="loc_biib_NightstarMember_0bf8ab4d-021a-4f2e-b64f-5588c81cb157" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_990e11e8-dba5-49de-a634-29cf2b8eeb33" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_ab760de6-c83d-4230-ae2e-56e11a812eea" xlink:to="loc_us-gaap_AwardTypeAxis_990e11e8-dba5-49de-a634-29cf2b8eeb33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b9920bd3-0deb-44de-a9b9-248aa7519a97" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_990e11e8-dba5-49de-a634-29cf2b8eeb33" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b9920bd3-0deb-44de-a9b9-248aa7519a97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MarketStockUnitsMember_a6e88429-0889-48bf-b068-9357a6e78566" xlink:href="biib-20200930.xsd#biib_MarketStockUnitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b9920bd3-0deb-44de-a9b9-248aa7519a97" xlink:to="loc_biib_MarketStockUnitsMember_a6e88429-0889-48bf-b068-9357a6e78566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_5bbb689c-a3aa-437f-ae3e-6eba0154c4ba" xlink:href="biib-20200930.xsd#biib_TimeVestedRestrictedStockUnitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b9920bd3-0deb-44de-a9b9-248aa7519a97" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_5bbb689c-a3aa-437f-ae3e-6eba0154c4ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CashSettledPerformanceSharesMember_7fdb14f3-7bc3-4d83-ba21-61f3e2710dea" xlink:href="biib-20200930.xsd#biib_CashSettledPerformanceSharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b9920bd3-0deb-44de-a9b9-248aa7519a97" xlink:to="loc_biib_CashSettledPerformanceSharesMember_7fdb14f3-7bc3-4d83-ba21-61f3e2710dea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_1699c51b-338f-4022-8d7c-3b467642bf9a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b9920bd3-0deb-44de-a9b9-248aa7519a97" xlink:to="loc_us-gaap_PerformanceSharesMember_1699c51b-338f-4022-8d7c-3b467642bf9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockMember_3b3af057-1681-4b50-9b8e-2e796e26eceb" xlink:href="biib-20200930.xsd#biib_PerformanceStockUnitsSettledinStockMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b9920bd3-0deb-44de-a9b9-248aa7519a97" xlink:to="loc_biib_PerformanceStockUnitsSettledinStockMember_3b3af057-1681-4b50-9b8e-2e796e26eceb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceStockUnitsSettledinCashMember_17147a7f-f026-4593-afde-7fa7f3cab0d8" xlink:href="biib-20200930.xsd#biib_PerformanceStockUnitsSettledinCashMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b9920bd3-0deb-44de-a9b9-248aa7519a97" xlink:to="loc_biib_PerformanceStockUnitsSettledinCashMember_17147a7f-f026-4593-afde-7fa7f3cab0d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EmployeeStockPurchasePlanMember_84e48f88-9970-4663-ab0c-96e81fc85aaa" xlink:href="biib-20200930.xsd#biib_EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b9920bd3-0deb-44de-a9b9-248aa7519a97" xlink:to="loc_biib_EmployeeStockPurchasePlanMember_84e48f88-9970-4663-ab0c-96e81fc85aaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_5db46d0e-71ef-467b-ba07-69867ab2c25d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b9920bd3-0deb-44de-a9b9-248aa7519a97" xlink:to="loc_us-gaap_EmployeeStockOptionMember_5db46d0e-71ef-467b-ba07-69867ab2c25d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_204b864d-24d0-4e36-8a97-cfef547acd3b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_ab760de6-c83d-4230-ae2e-56e11a812eea" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_204b864d-24d0-4e36-8a97-cfef547acd3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_24fd2d94-8d0d-4109-8012-2cb43b9026f7" xlink:href="biib-20200930.xsd#biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_204b864d-24d0-4e36-8a97-cfef547acd3b" xlink:to="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_24fd2d94-8d0d-4109-8012-2cb43b9026f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_4573a8f1-7157-48f6-be74-32397997c62e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_24fd2d94-8d0d-4109-8012-2cb43b9026f7" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_4573a8f1-7157-48f6-be74-32397997c62e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_6af17848-b97e-4737-8869-4f2c394d195e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_24fd2d94-8d0d-4109-8012-2cb43b9026f7" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_6af17848-b97e-4737-8869-4f2c394d195e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_26425fdd-f8ba-4d6e-992c-76c33cdc6be5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_24fd2d94-8d0d-4109-8012-2cb43b9026f7" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_26425fdd-f8ba-4d6e-992c-76c33cdc6be5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_ced7be96-d533-4314-a8eb-4fe9f811569d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_24fd2d94-8d0d-4109-8012-2cb43b9026f7" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_ced7be96-d533-4314-a8eb-4fe9f811569d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_f3b6e9f5-5cfd-4a85-b1b0-04aec729505a" xlink:href="biib-20200930.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_24fd2d94-8d0d-4109-8012-2cb43b9026f7" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_f3b6e9f5-5cfd-4a85-b1b0-04aec729505a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxes" xlink:type="simple" xlink:href="biib-20200930.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_d5700734-41f9-4f07-9f2a-9df3209b0fc9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_edb64086-7168-4f50-9038-324aa7f961b0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d5700734-41f9-4f07-9f2a-9df3209b0fc9" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_edb64086-7168-4f50-9038-324aa7f961b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="biib-20200930.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_18d51327-f544-4dfb-ac3f-de1f12dc9c0c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_8686b5b8-848b-4c68-9682-31be614279d5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_18d51327-f544-4dfb-ac3f-de1f12dc9c0c" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_8686b5b8-848b-4c68-9682-31be614279d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:type="simple" xlink:href="biib-20200930.xsd#IncomeTaxesDetailsTextual"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_e9ef3261-34bd-4fab-be98-ac6fe156a058" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_a1e06853-eeac-4ce8-beac-a2ec8d6c21a8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e9ef3261-34bd-4fab-be98-ac6fe156a058" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_a1e06853-eeac-4ce8-beac-a2ec8d6c21a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_04830ab3-3ede-4fb4-a2d3-c748f71af45b" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_a1e06853-eeac-4ce8-beac-a2ec8d6c21a8" xlink:to="loc_srt_ProductOrServiceAxis_04830ab3-3ede-4fb4-a2d3-c748f71af45b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_fc429de9-badd-47ac-86d5-dfdc3dfe829a" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_04830ab3-3ede-4fb4-a2d3-c748f71af45b" xlink:to="loc_srt_ProductsAndServicesDomain_fc429de9-badd-47ac-86d5-dfdc3dfe829a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TECFIDERAMember_0ae8acb2-048f-4c4b-9cd5-b85317c808dd" xlink:href="biib-20200930.xsd#biib_TECFIDERAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_fc429de9-badd-47ac-86d5-dfdc3dfe829a" xlink:to="loc_biib_TECFIDERAMember_0ae8acb2-048f-4c4b-9cd5-b85317c808dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_3f7ec36b-01b8-4ec4-8bad-a2d665676243" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_a1e06853-eeac-4ce8-beac-a2ec8d6c21a8" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_3f7ec36b-01b8-4ec4-8bad-a2d665676243" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_7950e472-ac37-4252-a865-fe061ada78af" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_3f7ec36b-01b8-4ec4-8bad-a2d665676243" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_7950e472-ac37-4252-a865-fe061ada78af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DenmarkManufacturingOperationsMember_51a9f3db-e0ba-4962-97ee-708c952c3ca8" xlink:href="biib-20200930.xsd#biib_DenmarkManufacturingOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_7950e472-ac37-4252-a865-fe061ada78af" xlink:to="loc_biib_DenmarkManufacturingOperationsMember_51a9f3db-e0ba-4962-97ee-708c952c3ca8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_7c2b33a6-b0bc-46de-bb4d-e17807af010b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_a1e06853-eeac-4ce8-beac-a2ec8d6c21a8" xlink:to="loc_us-gaap_IncomeTaxContingencyLineItems_7c2b33a6-b0bc-46de-bb4d-e17807af010b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DeferredTaxAssetsValueReductioninValue_d2277abc-2b56-4d16-8baa-6393c0ce86e1" xlink:href="biib-20200930.xsd#biib_DeferredTaxAssetsValueReductioninValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_7c2b33a6-b0bc-46de-bb4d-e17807af010b" xlink:to="loc_biib_DeferredTaxAssetsValueReductioninValue_d2277abc-2b56-4d16-8baa-6393c0ce86e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DeferredTaxLiabilitiesValueReductioninValue_157c90d3-7628-4584-bb62-0715030020fb" xlink:href="biib-20200930.xsd#biib_DeferredTaxLiabilitiesValueReductioninValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_7c2b33a6-b0bc-46de-bb4d-e17807af010b" xlink:to="loc_biib_DeferredTaxLiabilitiesValueReductioninValue_157c90d3-7628-4584-bb62-0715030020fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IncomeTaxExpenseReductioninDeferredTaxAssetsandLiabilitiesNet_a1a23e53-d994-4e16-b5e9-fe8e857f44a0" xlink:href="biib-20200930.xsd#biib_IncomeTaxExpenseReductioninDeferredTaxAssetsandLiabilitiesNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_7c2b33a6-b0bc-46de-bb4d-e17807af010b" xlink:to="loc_biib_IncomeTaxExpenseReductioninDeferredTaxAssetsandLiabilitiesNet_a1a23e53-d994-4e16-b5e9-fe8e857f44a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_c234ded6-0be6-4b58-a79d-88cafc158c8b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_7c2b33a6-b0bc-46de-bb4d-e17807af010b" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_c234ded6-0be6-4b58-a79d-88cafc158c8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_722632e3-c9a3-4556-a1be-c63f773916b6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_7c2b33a6-b0bc-46de-bb4d-e17807af010b" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_722632e3-c9a3-4556-a1be-c63f773916b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_8d6b5234-362f-4b0d-b03c-3a9a175b379d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_7c2b33a6-b0bc-46de-bb4d-e17807af010b" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_8d6b5234-362f-4b0d-b03c-3a9a175b379d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_b36c1d59-b14f-44aa-a3e9-eccf3cea8f68" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_7c2b33a6-b0bc-46de-bb4d-e17807af010b" xlink:to="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_b36c1d59-b14f-44aa-a3e9-eccf3cea8f68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="biib-20200930.xsd#IncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_27d92a48-023d-4ad8-a3f6-e0a522f4b142" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_214ad5ae-4d25-4fa2-8194-14ce1661bfea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_27d92a48-023d-4ad8-a3f6-e0a522f4b142" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_214ad5ae-4d25-4fa2-8194-14ce1661bfea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_72affcf7-1120-4643-a927-bd794a304802" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_214ad5ae-4d25-4fa2-8194-14ce1661bfea" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_72affcf7-1120-4643-a927-bd794a304802" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_c4acfb18-ca3b-493b-a67a-53e6ded4e49e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_214ad5ae-4d25-4fa2-8194-14ce1661bfea" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_c4acfb18-ca3b-493b-a67a-53e6ded4e49e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_2bfdadfd-d5a4-440f-9f54-db7e5b434108" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_214ad5ae-4d25-4fa2-8194-14ce1661bfea" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_2bfdadfd-d5a4-440f-9f54-db7e5b434108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_54d578e7-4564-47c6-95c8-54e80f768ac6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_214ad5ae-4d25-4fa2-8194-14ce1661bfea" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_54d578e7-4564-47c6-95c8-54e80f768ac6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_b2b0251d-5f81-4cd4-b3b9-2847fce723b5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_214ad5ae-4d25-4fa2-8194-14ce1661bfea" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_b2b0251d-5f81-4cd4-b3b9-2847fce723b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets_9c1ec972-8ea3-4304-a173-76dfb8ed1cc2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_214ad5ae-4d25-4fa2-8194-14ce1661bfea" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets_9c1ec972-8ea3-4304-a173-76dfb8ed1cc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization_2dcb7727-c118-40e4-aba7-0940e64f2100" xlink:href="biib-20200930.xsd#biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_214ad5ae-4d25-4fa2-8194-14ce1661bfea" xlink:to="loc_biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization_2dcb7727-c118-40e4-aba7-0940e64f2100" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_4c67e562-f0b0-422c-86db-e61559e1a30d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_214ad5ae-4d25-4fa2-8194-14ce1661bfea" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_4c67e562-f0b0-422c-86db-e61559e1a30d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EffectiveTaxRateReconciliationGILTItax_dccfdc95-026b-4266-afcd-71bc2d1ac00e" xlink:href="biib-20200930.xsd#biib_EffectiveTaxRateReconciliationGILTItax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_214ad5ae-4d25-4fa2-8194-14ce1661bfea" xlink:to="loc_biib_EffectiveTaxRateReconciliationGILTItax_dccfdc95-026b-4266-afcd-71bc2d1ac00e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EffectiveIncomeTaxRateReconciliationChangeInForeignTaxRatePercent_62e43578-5469-4b96-9c1e-5a42ecf423c7" xlink:href="biib-20200930.xsd#biib_EffectiveIncomeTaxRateReconciliationChangeInForeignTaxRatePercent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_214ad5ae-4d25-4fa2-8194-14ce1661bfea" xlink:to="loc_biib_EffectiveIncomeTaxRateReconciliationChangeInForeignTaxRatePercent_62e43578-5469-4b96-9c1e-5a42ecf423c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_935c1711-7f5f-4db8-9c4b-bce8408fb5f2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_214ad5ae-4d25-4fa2-8194-14ce1661bfea" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_935c1711-7f5f-4db8-9c4b-bce8408fb5f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_71d8dd7d-edda-4427-94c0-2700eeec2309" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_214ad5ae-4d25-4fa2-8194-14ce1661bfea" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_71d8dd7d-edda-4427-94c0-2700eeec2309" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_c43021ea-b05e-4cb7-aa07-b93eca294c2d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_214ad5ae-4d25-4fa2-8194-14ce1661bfea" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_c43021ea-b05e-4cb7-aa07-b93eca294c2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:type="simple" xlink:href="biib-20200930.xsd#OtherConsolidatedFinancialStatementDetail"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_cf504cdb-bf49-4d42-9de6-77616dcac36f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_9a280f2c-8c2e-41e4-a8d3-4ed8c134ed5e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_cf504cdb-bf49-4d42-9de6-77616dcac36f" xlink:to="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_9a280f2c-8c2e-41e4-a8d3-4ed8c134ed5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:type="simple" xlink:href="biib-20200930.xsd#OtherConsolidatedFinancialStatementDetailTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_65b9d386-f99e-4347-bc2f-28224e98b180" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_d878604b-3f01-4c46-96fc-9cfe776d901e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_65b9d386-f99e-4347-bc2f-28224e98b180" xlink:to="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_d878604b-3f01-4c46-96fc-9cfe776d901e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestmentsTextBlock_12ec3b63-2441-47b4-a363-fbf99bdd2aa2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnInvestmentsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_65b9d386-f99e-4347-bc2f-28224e98b180" xlink:to="loc_us-gaap_GainLossOnInvestmentsTextBlock_12ec3b63-2441-47b4-a363-fbf99bdd2aa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_eaa23652-09f7-4b5e-875f-20be03ceba73" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_65b9d386-f99e-4347-bc2f-28224e98b180" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_eaa23652-09f7-4b5e-875f-20be03ceba73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:type="simple" xlink:href="biib-20200930.xsd#OtherConsolidatedFinancialStatementDetailDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9d63fd7a-9399-43a8-a7b6-3540a4c6d2a4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_9082f149-2e5b-4f96-bf1e-d537621db5c7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9d63fd7a-9399-43a8-a7b6-3540a4c6d2a4" xlink:to="loc_us-gaap_StatementTable_9082f149-2e5b-4f96-bf1e-d537621db5c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_137c0fc7-bde8-4d2b-a744-786b5f84d170" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_9082f149-2e5b-4f96-bf1e-d537621db5c7" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_137c0fc7-bde8-4d2b-a744-786b5f84d170" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_cca51330-10f0-4f9a-8881-3217ad260a80" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_137c0fc7-bde8-4d2b-a744-786b5f84d170" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_cca51330-10f0-4f9a-8881-3217ad260a80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_114c1835-02f2-460d-a275-93beb9489526" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_cca51330-10f0-4f9a-8881-3217ad260a80" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_114c1835-02f2-460d-a275-93beb9489526" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_6e8e1afe-5c4a-4cd1-b9c8-bf1a3fab8ebb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_9082f149-2e5b-4f96-bf1e-d537621db5c7" xlink:to="loc_us-gaap_StatementLineItems_6e8e1afe-5c4a-4cd1-b9c8-bf1a3fab8ebb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNetAbstract_98c0cc85-e2ef-4226-b9ad-936ecf8c7c17" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestIncomeExpenseNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6e8e1afe-5c4a-4cd1-b9c8-bf1a3fab8ebb" xlink:to="loc_us-gaap_InterestIncomeExpenseNetAbstract_98c0cc85-e2ef-4226-b9ad-936ecf8c7c17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_55d353ac-c5d0-4620-91cb-cd6348911026" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_98c0cc85-e2ef-4226-b9ad-936ecf8c7c17" xlink:to="loc_us-gaap_InvestmentIncomeInterest_55d353ac-c5d0-4620-91cb-cd6348911026" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_97430be8-79e1-441f-8831-524d39601abb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_98c0cc85-e2ef-4226-b9ad-936ecf8c7c17" xlink:to="loc_us-gaap_InterestExpense_97430be8-79e1-441f-8831-524d39601abb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses_aa83b847-ce34-49c7-97ca-e14f38bbe4bb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_98c0cc85-e2ef-4226-b9ad-936ecf8c7c17" xlink:to="loc_us-gaap_RealizedInvestmentGainsLosses_aa83b847-ce34-49c7-97ca-e14f38bbe4bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_402d5458-8fe7-43c3-b3d2-644156d373d5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_98c0cc85-e2ef-4226-b9ad-936ecf8c7c17" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_402d5458-8fe7-43c3-b3d2-644156d373d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_a6a6319f-8ae0-4923-a41d-9551e1adde85" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_98c0cc85-e2ef-4226-b9ad-936ecf8c7c17" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_a6a6319f-8ae0-4923-a41d-9551e1adde85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_48190505-0dc9-4512-abf1-ca771f75d78f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_98c0cc85-e2ef-4226-b9ad-936ecf8c7c17" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_48190505-0dc9-4512-abf1-ca771f75d78f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_b8c46a2d-5ade-4dd5-94c9-37b3d4eea302" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6e8e1afe-5c4a-4cd1-b9c8-bf1a3fab8ebb" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_b8c46a2d-5ade-4dd5-94c9-37b3d4eea302" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_86c5c0f2-d994-4fa9-9dff-8fc75898506f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_b8c46a2d-5ade-4dd5-94c9-37b3d4eea302" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_86c5c0f2-d994-4fa9-9dff-8fc75898506f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_70b5f85b-7b23-40a4-b0e6-72c0d5d29a48" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_b8c46a2d-5ade-4dd5-94c9-37b3d4eea302" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_70b5f85b-7b23-40a4-b0e6-72c0d5d29a48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_7144e95c-0af0-45c0-91ce-be1d7bdf3d29" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_b8c46a2d-5ade-4dd5-94c9-37b3d4eea302" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_7144e95c-0af0-45c0-91ce-be1d7bdf3d29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_8d10204a-1821-4d28-8086-f2f566f4e35f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6e8e1afe-5c4a-4cd1-b9c8-bf1a3fab8ebb" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_8d10204a-1821-4d28-8086-f2f566f4e35f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_26b6cf63-dff0-4527-9c60-89170dbc296b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_8d10204a-1821-4d28-8086-f2f566f4e35f" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_26b6cf63-dff0-4527-9c60-89170dbc296b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_cf8a8371-cabb-468b-a383-72c9af4b33f3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_8d10204a-1821-4d28-8086-f2f566f4e35f" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_cf8a8371-cabb-468b-a383-72c9af4b33f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_cedb476b-2bc5-4867-acd3-34d175731e56" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_8d10204a-1821-4d28-8086-f2f566f4e35f" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_cedb476b-2bc5-4867-acd3-34d175731e56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Collaborationexpensesaccrual_1b160aba-1c40-4345-a0fc-748d6b1f537c" xlink:href="biib-20200930.xsd#biib_Collaborationexpensesaccrual"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_8d10204a-1821-4d28-8086-f2f566f4e35f" xlink:to="loc_biib_Collaborationexpensesaccrual_1b160aba-1c40-4345-a0fc-748d6b1f537c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_76e88f2c-0cd5-4032-a0dc-c4faa667a3e0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_8d10204a-1821-4d28-8086-f2f566f4e35f" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_76e88f2c-0cd5-4032-a0dc-c4faa667a3e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionPayableCurrentAndNoncurrent_968a9358-5d75-4a18-bdc2-af67b720b006" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionPayableCurrentAndNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_8d10204a-1821-4d28-8086-f2f566f4e35f" xlink:to="loc_us-gaap_ConstructionPayableCurrentAndNoncurrent_968a9358-5d75-4a18-bdc2-af67b720b006" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_e1c27acd-8f72-4af4-997b-08025e32dc14" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_8d10204a-1821-4d28-8086-f2f566f4e35f" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_e1c27acd-8f72-4af4-997b-08025e32dc14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_76ddf816-af7e-410d-8abd-9c36521dc43f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_8d10204a-1821-4d28-8086-f2f566f4e35f" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_76ddf816-af7e-410d-8abd-9c36521dc43f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual" xlink:type="simple" xlink:href="biib-20200930.xsd#OtherConsolidatedFinancialStatementDetailsTextual"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_45cac93c-9c8d-4a77-9f04-5e039094440c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_f7f77b4d-3b28-4ca7-ad04-30a6252eac14" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_45cac93c-9c8d-4a77-9f04-5e039094440c" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_f7f77b4d-3b28-4ca7-ad04-30a6252eac14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_dff1905e-13b1-43bf-8c5e-cfb8467210ec" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_f7f77b4d-3b28-4ca7-ad04-30a6252eac14" xlink:to="loc_dei_LegalEntityAxis_dff1905e-13b1-43bf-8c5e-cfb8467210ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_a929f224-e210-4487-99ab-739852c17ec5" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_dff1905e-13b1-43bf-8c5e-cfb8467210ec" xlink:to="loc_dei_EntityDomain_a929f224-e210-4487-99ab-739852c17ec5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IonisPharmaceuticalsMember_bcdc0049-a516-416d-a034-027dd64c319d" xlink:href="biib-20200930.xsd#biib_IonisPharmaceuticalsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_a929f224-e210-4487-99ab-739852c17ec5" xlink:to="loc_biib_IonisPharmaceuticalsMember_bcdc0049-a516-416d-a034-027dd64c319d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DenaliTherapeuticsIncMember_dd7c32d6-627b-4d14-8055-90d3a337c5b3" xlink:href="biib-20200930.xsd#biib_DenaliTherapeuticsIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_a929f224-e210-4487-99ab-739852c17ec5" xlink:to="loc_biib_DenaliTherapeuticsIncMember_dd7c32d6-627b-4d14-8055-90d3a337c5b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SangamoCommonStockMember_09a58456-f425-461b-9b43-2fa5a6865da8" xlink:href="biib-20200930.xsd#biib_SangamoCommonStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_a929f224-e210-4487-99ab-739852c17ec5" xlink:to="loc_biib_SangamoCommonStockMember_09a58456-f425-461b-9b43-2fa5a6865da8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_1b808303-9e4f-4970-bbd0-66c3cb7d20f6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_f7f77b4d-3b28-4ca7-ad04-30a6252eac14" xlink:to="loc_us-gaap_ClassOfStockLineItems_1b808303-9e4f-4970-bbd0-66c3cb7d20f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses_8de9075f-3464-4326-8ed8-4d4f05c98c78" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1b808303-9e4f-4970-bbd0-66c3cb7d20f6" xlink:to="loc_us-gaap_RealizedInvestmentGainsLosses_8de9075f-3464-4326-8ed8-4d4f05c98c78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_895be676-86ef-4fd2-8167-6370ac77ce61" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1b808303-9e4f-4970-bbd0-66c3cb7d20f6" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_895be676-86ef-4fd2-8167-6370ac77ce61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent_f91bc871-2b37-477f-986d-58ff0407eaa4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1b808303-9e4f-4970-bbd0-66c3cb7d20f6" xlink:to="loc_us-gaap_AccruedIncomeTaxesNoncurrent_f91bc871-2b37-477f-986d-58ff0407eaa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_ed8abae7-7dcb-4a03-a288-3823f5b43ac6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1b808303-9e4f-4970-bbd0-66c3cb7d20f6" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_ed8abae7-7dcb-4a03-a288-3823f5b43ac6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_1e598d8b-fbc3-4685-91e8-5218692e418f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1b808303-9e4f-4970-bbd0-66c3cb7d20f6" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_1e598d8b-fbc3-4685-91e8-5218692e418f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsIncomeTaxExpense_e483e566-95c7-4a4d-ad2e-5d71f8426787" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsIncomeTaxExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1b808303-9e4f-4970-bbd0-66c3cb7d20f6" xlink:to="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsIncomeTaxExpense_e483e566-95c7-4a4d-ad2e-5d71f8426787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationships" xlink:type="simple" xlink:href="biib-20200930.xsd#CollaborativeandOtherRelationships"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationships" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_660c198c-5e6c-495b-a83e-014c01691acd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_8ce46cba-b1aa-41cc-b61e-81f47c567361" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_660c198c-5e6c-495b-a83e-014c01691acd" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_8ce46cba-b1aa-41cc-b61e-81f47c567361" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables" xlink:type="simple" xlink:href="biib-20200930.xsd#CollaborativeandOtherRelationshipsTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_cea8415b-f939-40c8-95dd-6b7023eb6f32" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock_57df4133-cf13-44b0-8808-1c4145bc5ee0" xlink:href="biib-20200930.xsd#biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_cea8415b-f939-40c8-95dd-6b7023eb6f32" xlink:to="loc_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock_57df4133-cf13-44b0-8808-1c4145bc5ee0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_f9c9a413-6a75-4c51-8900-62d54e7882e2" xlink:href="biib-20200930.xsd#biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_cea8415b-f939-40c8-95dd-6b7023eb6f32" xlink:to="loc_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_f9c9a413-6a75-4c51-8900-62d54e7882e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails" xlink:type="simple" xlink:href="biib-20200930.xsd#CollaborativeandOtherRelationshipsCollaborationsDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_07d6c4ed-f0e5-490a-a04b-06da4c4c9b11" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9984e6c3-6e32-48ff-b1fe-3e815594f24f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_07d6c4ed-f0e5-490a-a04b-06da4c4c9b11" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9984e6c3-6e32-48ff-b1fe-3e815594f24f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_4ff17ec1-5a28-4acb-bfca-322eda7b105d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9984e6c3-6e32-48ff-b1fe-3e815594f24f" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_4ff17ec1-5a28-4acb-bfca-322eda7b105d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_898ca62f-5d84-42b4-83a6-ab7cefb929f3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_4ff17ec1-5a28-4acb-bfca-322eda7b105d" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_898ca62f-5d84-42b4-83a6-ab7cefb929f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1b362595-c947-458a-80c8-68b8373934bf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_898ca62f-5d84-42b4-83a6-ab7cefb929f3" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1b362595-c947-458a-80c8-68b8373934bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_db193a6e-0c4b-4525-86a3-490a1315ac68" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_898ca62f-5d84-42b4-83a6-ab7cefb929f3" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_db193a6e-0c4b-4525-86a3-490a1315ac68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_5972eb5e-3fbd-4586-a349-eaf72da49dba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9984e6c3-6e32-48ff-b1fe-3e815594f24f" xlink:to="loc_us-gaap_TypeOfArrangementAxis_5972eb5e-3fbd-4586-a349-eaf72da49dba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_25209fb6-48c1-4c24-824e-236377615ffa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5972eb5e-3fbd-4586-a349-eaf72da49dba" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_25209fb6-48c1-4c24-824e-236377615ffa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_38191a66-d9f8-4e85-b7a7-e4267d141e00" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_25209fb6-48c1-4c24-824e-236377615ffa" xlink:to="loc_us-gaap_CollaborativeArrangementMember_38191a66-d9f8-4e85-b7a7-e4267d141e00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EisaiMember_b55c103c-7204-4a40-a797-497955058cc4" xlink:href="biib-20200930.xsd#biib_EisaiMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_25209fb6-48c1-4c24-824e-236377615ffa" xlink:to="loc_biib_EisaiMember_b55c103c-7204-4a40-a797-497955058cc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UCBPharmaS.A.Member_9e292cfd-695d-4c23-8889-1bd7274f970e" xlink:href="biib-20200930.xsd#biib_UCBPharmaS.A.Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_25209fb6-48c1-4c24-824e-236377615ffa" xlink:to="loc_biib_UCBPharmaS.A.Member_9e292cfd-695d-4c23-8889-1bd7274f970e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SangamoTherapeuticsInc.AgreementMember_35709de9-e692-4111-a994-fa05f7e1e18f" xlink:href="biib-20200930.xsd#biib_SangamoTherapeuticsInc.AgreementMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_25209fb6-48c1-4c24-824e-236377615ffa" xlink:to="loc_biib_SangamoTherapeuticsInc.AgreementMember_35709de9-e692-4111-a994-fa05f7e1e18f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SkyhawkTherapeuticsMember_a406d345-ef79-4165-b238-4ead32a30094" xlink:href="biib-20200930.xsd#biib_SkyhawkTherapeuticsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_25209fb6-48c1-4c24-824e-236377615ffa" xlink:to="loc_biib_SkyhawkTherapeuticsMember_a406d345-ef79-4165-b238-4ead32a30094" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DenaliTherapeuticsIncMember_cf4ded89-e6c2-432d-91ec-390e5ab656be" xlink:href="biib-20200930.xsd#biib_DenaliTherapeuticsIncMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_25209fb6-48c1-4c24-824e-236377615ffa" xlink:to="loc_biib_DenaliTherapeuticsIncMember_cf4ded89-e6c2-432d-91ec-390e5ab656be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DenaliTherapeuticsIncMember_c2589d1a-bae9-4161-ade3-7e5310f0b455" xlink:href="biib-20200930.xsd#biib_DenaliTherapeuticsIncMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_88f904cd-cefb-4864-a1f3-6a2893f45a0d" xlink:href="biib-20200930.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_25209fb6-48c1-4c24-824e-236377615ffa" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_88f904cd-cefb-4864-a1f3-6a2893f45a0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_13773514-a5e0-45b8-8e68-24f644eddc7a" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9984e6c3-6e32-48ff-b1fe-3e815594f24f" xlink:to="loc_srt_ProductOrServiceAxis_13773514-a5e0-45b8-8e68-24f644eddc7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_82372480-b2b4-4f16-97ca-771ceb0a0c62" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_13773514-a5e0-45b8-8e68-24f644eddc7a" xlink:to="loc_srt_ProductsAndServicesDomain_82372480-b2b4-4f16-97ca-771ceb0a0c62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BAN2401Member_a049ace6-ab63-494d-8b84-136de8c1b6bd" xlink:href="biib-20200930.xsd#biib_BAN2401Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_82372480-b2b4-4f16-97ca-771ceb0a0c62" xlink:to="loc_biib_BAN2401Member_a049ace6-ab63-494d-8b84-136de8c1b6bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_E2609andBAN2401Member_4d5deaae-d2d6-484c-b2a8-73044a5b88b2" xlink:href="biib-20200930.xsd#biib_E2609andBAN2401Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_82372480-b2b4-4f16-97ca-771ceb0a0c62" xlink:to="loc_biib_E2609andBAN2401Member_4d5deaae-d2d6-484c-b2a8-73044a5b88b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AducanumabMember_56ef2d32-20e9-4204-9454-1c3862b3fa0d" xlink:href="biib-20200930.xsd#biib_AducanumabMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_82372480-b2b4-4f16-97ca-771ceb0a0c62" xlink:to="loc_biib_AducanumabMember_56ef2d32-20e9-4204-9454-1c3862b3fa0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ElenbecestatCollaborationMember_10b29b1f-837c-41a4-8d8f-6b06553fab45" xlink:href="biib-20200930.xsd#biib_ElenbecestatCollaborationMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_82372480-b2b4-4f16-97ca-771ceb0a0c62" xlink:to="loc_biib_ElenbecestatCollaborationMember_10b29b1f-837c-41a4-8d8f-6b06553fab45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_a23faae6-3743-490c-9941-410ebeb82b2a" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9984e6c3-6e32-48ff-b1fe-3e815594f24f" xlink:to="loc_dei_LegalEntityAxis_a23faae6-3743-490c-9941-410ebeb82b2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_a8e73bae-7061-41dc-8c4d-583be10d655b" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_a23faae6-3743-490c-9941-410ebeb82b2a" xlink:to="loc_dei_EntityDomain_a8e73bae-7061-41dc-8c4d-583be10d655b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SangamoCommonStockMember_75e42f7d-b5d5-4bc7-8fa8-c587a6721bd1" xlink:href="biib-20200930.xsd#biib_SangamoCommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_a8e73bae-7061-41dc-8c4d-583be10d655b" xlink:to="loc_biib_SangamoCommonStockMember_75e42f7d-b5d5-4bc7-8fa8-c587a6721bd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_a6ec6ae3-2eba-4bf8-9d8a-7f632076bf68" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9984e6c3-6e32-48ff-b1fe-3e815594f24f" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_a6ec6ae3-2eba-4bf8-9d8a-7f632076bf68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_8226f260-6cd2-4a84-98c6-1c3a2728a2e1" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_a6ec6ae3-2eba-4bf8-9d8a-7f632076bf68" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_8226f260-6cd2-4a84-98c6-1c3a2728a2e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IonisPharmaceuticalsMember_31f27ae3-db22-4eb1-adec-ee5a316ebf15" xlink:href="biib-20200930.xsd#biib_IonisPharmaceuticalsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_8226f260-6cd2-4a84-98c6-1c3a2728a2e1" xlink:to="loc_biib_IonisPharmaceuticalsMember_31f27ae3-db22-4eb1-adec-ee5a316ebf15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DenaliTherapeuticsIncMember_8c66aa24-82a6-4ebc-93eb-e507c82254c6" xlink:href="biib-20200930.xsd#biib_DenaliTherapeuticsIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_8226f260-6cd2-4a84-98c6-1c3a2728a2e1" xlink:to="loc_biib_DenaliTherapeuticsIncMember_8c66aa24-82a6-4ebc-93eb-e507c82254c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SangamoTherapeuticsInc.AgreementMember_69d4a309-eea0-4f53-8d09-91f11eac5bb8" xlink:href="biib-20200930.xsd#biib_SangamoTherapeuticsInc.AgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_8226f260-6cd2-4a84-98c6-1c3a2728a2e1" xlink:to="loc_biib_SangamoTherapeuticsInc.AgreementMember_69d4a309-eea0-4f53-8d09-91f11eac5bb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4a859010-8282-4797-a6d6-a3bf955603ca" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9984e6c3-6e32-48ff-b1fe-3e815594f24f" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4a859010-8282-4797-a6d6-a3bf955603ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NumberOfProductCandidates_6f387b04-25a3-415a-96dc-d8127c87b7bf" xlink:href="biib-20200930.xsd#biib_NumberOfProductCandidates"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4a859010-8282-4797-a6d6-a3bf955603ca" xlink:to="loc_biib_NumberOfProductCandidates_6f387b04-25a3-415a-96dc-d8127c87b7bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased_e6bf7eff-f78d-46e6-a38f-c42232430c53" xlink:href="biib-20200930.xsd#biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4a859010-8282-4797-a6d6-a3bf955603ca" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased_e6bf7eff-f78d-46e6-a38f-c42232430c53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementSharesPurchased_8ecfb1bc-8731-4576-8d5f-dbdba05c75f6" xlink:href="biib-20200930.xsd#biib_GlobalLicensingCollaborationAgreementSharesPurchased"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4a859010-8282-4797-a6d6-a3bf955603ca" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementSharesPurchased_8ecfb1bc-8731-4576-8d5f-dbdba05c75f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare_e820f98d-ad5e-4d53-a176-8e49c065ad1d" xlink:href="biib-20200930.xsd#biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4a859010-8282-4797-a6d6-a3bf955603ca" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare_e820f98d-ad5e-4d53-a176-8e49c065ad1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_35edc881-8827-4f97-95e6-b26d503ea110" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4a859010-8282-4797-a6d6-a3bf955603ca" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_35edc881-8827-4f97-95e6-b26d503ea110" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ExpenseIncurredByCollaboration_02a96332-c476-416a-ae4b-66e1815db650" xlink:href="biib-20200930.xsd#biib_ExpenseIncurredByCollaboration"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4a859010-8282-4797-a6d6-a3bf955603ca" xlink:to="loc_biib_ExpenseIncurredByCollaboration_02a96332-c476-416a-ae4b-66e1815db650" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expenseincurredbythecollaboration_ea706148-f388-42c3-82d1-42a3bb6e40fc" xlink:href="biib-20200930.xsd#biib_Expenseincurredbythecollaboration"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4a859010-8282-4797-a6d6-a3bf955603ca" xlink:to="loc_biib_Expenseincurredbythecollaboration_ea706148-f388-42c3-82d1-42a3bb6e40fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expensereflectedwithinstatementsofincome_4be2e766-c1bd-47cc-ad8f-2d8b1207b808" xlink:href="biib-20200930.xsd#biib_Expensereflectedwithinstatementsofincome"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4a859010-8282-4797-a6d6-a3bf955603ca" xlink:to="loc_biib_Expensereflectedwithinstatementsofincome_4be2e766-c1bd-47cc-ad8f-2d8b1207b808" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_e9a191bd-1fd7-48c0-aa74-32f322420184" xlink:href="biib-20200930.xsd#biib_PercentageoffuturedevelopmentcostsrelatedtoEisai"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4a859010-8282-4797-a6d6-a3bf955603ca" xlink:to="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_e9a191bd-1fd7-48c0-aa74-32f322420184" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossOnContractTermination_46a7280f-088d-4186-bc30-797d200bf73e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossOnContractTermination"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4a859010-8282-4797-a6d6-a3bf955603ca" xlink:to="loc_us-gaap_LossOnContractTermination_46a7280f-088d-4186-bc30-797d200bf73e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_7aa15d4b-1f38-4e63-a69b-e8d994dc7170" xlink:href="biib-20200930.xsd#biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4a859010-8282-4797-a6d6-a3bf955603ca" xlink:to="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_7aa15d4b-1f38-4e63-a69b-e8d994dc7170" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NumberOfNeurologicalDiseaseTargets_cfa5b324-2c50-4709-95b5-5ad4ec61c57a" xlink:href="biib-20200930.xsd#biib_NumberOfNeurologicalDiseaseTargets"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4a859010-8282-4797-a6d6-a3bf955603ca" xlink:to="loc_biib_NumberOfNeurologicalDiseaseTargets_cfa5b324-2c50-4709-95b5-5ad4ec61c57a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CollaborationAgreementTerm_e67fb0cc-4190-4c74-89b2-562e39adf8c3" xlink:href="biib-20200930.xsd#biib_CollaborationAgreementTerm"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4a859010-8282-4797-a6d6-a3bf955603ca" xlink:to="loc_biib_CollaborationAgreementTerm_e67fb0cc-4190-4c74-89b2-562e39adf8c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments_def4d7df-6f33-48e3-b562-c7408c7a5746" xlink:href="biib-20200930.xsd#biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4a859010-8282-4797-a6d6-a3bf955603ca" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments_def4d7df-6f33-48e3-b562-c7408c7a5746" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets_ea46950f-0988-4fa9-b4fc-75c6fb6de229" xlink:href="biib-20200930.xsd#biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4a859010-8282-4797-a6d6-a3bf955603ca" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets_ea46950f-0988-4fa9-b4fc-75c6fb6de229" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones_c7edeacf-d0ba-41f0-84f0-b1392da0771d" xlink:href="biib-20200930.xsd#biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4a859010-8282-4797-a6d6-a3bf955603ca" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones_c7edeacf-d0ba-41f0-84f0-b1392da0771d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones_cbc1c3d4-d7a8-4a3c-ad8e-471fdcdd8697" xlink:href="biib-20200930.xsd#biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4a859010-8282-4797-a6d6-a3bf955603ca" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones_cbc1c3d4-d7a8-4a3c-ad8e-471fdcdd8697" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_62e44b2b-97e8-4fe7-9a4e-4394e0dbdd88" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4a859010-8282-4797-a6d6-a3bf955603ca" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_62e44b2b-97e8-4fe7-9a4e-4394e0dbdd88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets_736f5baf-df31-43d7-8e6e-43f5c2713b69" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4a859010-8282-4797-a6d6-a3bf955603ca" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssets_736f5baf-df31-43d7-8e6e-43f5c2713b69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_8a6944a9-0913-4c8e-b9df-5a4b72576ffd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4a859010-8282-4797-a6d6-a3bf955603ca" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_8a6944a9-0913-4c8e-b9df-5a4b72576ffd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_efbc8096-f21f-4656-9247-2287e9a34314" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4a859010-8282-4797-a6d6-a3bf955603ca" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_efbc8096-f21f-4656-9247-2287e9a34314" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails" xlink:type="simple" xlink:href="biib-20200930.xsd#CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f68a1d4b-b2d2-4f34-afec-c92f65519328" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_b995c7f5-63cb-44a4-802b-148ac4eb688a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f68a1d4b-b2d2-4f34-afec-c92f65519328" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_b995c7f5-63cb-44a4-802b-148ac4eb688a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_24ea3543-a8fb-479a-91a0-76fe9000535c" xlink:href="biib-20200930.xsd#biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_b995c7f5-63cb-44a4-802b-148ac4eb688a" xlink:to="loc_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_24ea3543-a8fb-479a-91a0-76fe9000535c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain_ba68aec7-867a-42c8-915e-83177a1abd53" xlink:href="biib-20200930.xsd#biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_24ea3543-a8fb-479a-91a0-76fe9000535c" xlink:to="loc_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain_ba68aec7-867a-42c8-915e-83177a1abd53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NeurimmuneMember_e57a13ce-e5ba-403a-ab67-cfcbfe29484a" xlink:href="biib-20200930.xsd#biib_NeurimmuneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain_ba68aec7-867a-42c8-915e-83177a1abd53" xlink:to="loc_biib_NeurimmuneMember_e57a13ce-e5ba-403a-ab67-cfcbfe29484a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesAxis_73936cf0-5a57-482c-a31d-aaae55157acf" xlink:href="biib-20200930.xsd#biib_FutureContingentMilestoneTypesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_b995c7f5-63cb-44a4-802b-148ac4eb688a" xlink:to="loc_biib_FutureContingentMilestoneTypesAxis_73936cf0-5a57-482c-a31d-aaae55157acf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain_dbfef656-fbd4-4dc7-a5b7-205c4b553758" xlink:href="biib-20200930.xsd#biib_FutureContingentMilestoneTypesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis_73936cf0-5a57-482c-a31d-aaae55157acf" xlink:to="loc_biib_FutureContingentMilestoneTypesDomain_dbfef656-fbd4-4dc7-a5b7-205c4b553758" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RegulatoryMilestonesMember_4d5c4d5e-f81e-4020-84ba-ccbc8abf13e3" xlink:href="biib-20200930.xsd#biib_RegulatoryMilestonesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_dbfef656-fbd4-4dc7-a5b7-205c4b553758" xlink:to="loc_biib_RegulatoryMilestonesMember_4d5c4d5e-f81e-4020-84ba-ccbc8abf13e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_3fd7eed4-47c8-48fe-a2f0-00228175b120" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_b995c7f5-63cb-44a4-802b-148ac4eb688a" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_3fd7eed4-47c8-48fe-a2f0-00228175b120" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_a5297e6e-7c4f-4c5a-b4df-776e457bbecd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_3fd7eed4-47c8-48fe-a2f0-00228175b120" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_a5297e6e-7c4f-4c5a-b4df-776e457bbecd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoriesMember_93e99432-bcf3-4acc-9917-31e6cf7d68a3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_a5297e6e-7c4f-4c5a-b4df-776e457bbecd" xlink:to="loc_us-gaap_InventoriesMember_93e99432-bcf3-4acc-9917-31e6cf7d68a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_c7386a16-d280-4771-bbcb-eae0525e74af" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_a5297e6e-7c4f-4c5a-b4df-776e457bbecd" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_c7386a16-d280-4771-bbcb-eae0525e74af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_705385a6-5638-4b86-aa7a-da0fc8a100f6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_a5297e6e-7c4f-4c5a-b4df-776e457bbecd" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_705385a6-5638-4b86-aa7a-da0fc8a100f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DeferredtaxliabilityMember_ca337510-899a-490f-b5b7-2d1630fa85da" xlink:href="biib-20200930.xsd#biib_DeferredtaxliabilityMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_a5297e6e-7c4f-4c5a-b4df-776e457bbecd" xlink:to="loc_biib_DeferredtaxliabilityMember_ca337510-899a-490f-b5b7-2d1630fa85da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_f75d2105-4530-4b4c-b776-af0c446a4b46" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_b995c7f5-63cb-44a4-802b-148ac4eb688a" xlink:to="loc_us-gaap_TypeOfArrangementAxis_f75d2105-4530-4b4c-b776-af0c446a4b46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8dff4ee7-8e54-47f7-adaf-6f73394d6f63" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_f75d2105-4530-4b4c-b776-af0c446a4b46" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8dff4ee7-8e54-47f7-adaf-6f73394d6f63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EisaiMember_f1f9dece-098b-4f5a-95c8-54222946c67c" xlink:href="biib-20200930.xsd#biib_EisaiMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8dff4ee7-8e54-47f7-adaf-6f73394d6f63" xlink:to="loc_biib_EisaiMember_f1f9dece-098b-4f5a-95c8-54222946c67c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_7d88e705-ff3e-42bd-aa58-86ac25f993bb" xlink:href="biib-20200930.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8dff4ee7-8e54-47f7-adaf-6f73394d6f63" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_7d88e705-ff3e-42bd-aa58-86ac25f993bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_29565492-fcfa-474f-ad95-94e03b57fab9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8dff4ee7-8e54-47f7-adaf-6f73394d6f63" xlink:to="loc_us-gaap_CollaborativeArrangementMember_29565492-fcfa-474f-ad95-94e03b57fab9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_8a7c6198-7160-487f-a776-7a689dd6fdf7" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_b995c7f5-63cb-44a4-802b-148ac4eb688a" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_8a7c6198-7160-487f-a776-7a689dd6fdf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_be72106d-ad4f-4ddb-a886-09a149bf00dc" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_8a7c6198-7160-487f-a776-7a689dd6fdf7" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_be72106d-ad4f-4ddb-a886-09a149bf00dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_86de54a9-e154-49d1-bf08-617979f10e5f" xlink:href="biib-20200930.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_be72106d-ad4f-4ddb-a886-09a149bf00dc" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_86de54a9-e154-49d1-bf08-617979f10e5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_07f5c736-608a-4fce-9ae5-1465250f81be" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_b995c7f5-63cb-44a4-802b-148ac4eb688a" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_07f5c736-608a-4fce-9ae5-1465250f81be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_75c46f2a-233f-4b14-9828-c1ddd141f82d" xlink:href="biib-20200930.xsd#biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_07f5c736-608a-4fce-9ae5-1465250f81be" xlink:to="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_75c46f2a-233f-4b14-9828-c1ddd141f82d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossOnContractTermination_e95e54aa-2673-4330-9e81-693c6d835e34" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossOnContractTermination"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_07f5c736-608a-4fce-9ae5-1465250f81be" xlink:to="loc_us-gaap_LossOnContractTermination_e95e54aa-2673-4330-9e81-693c6d835e34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_e15d07f8-292b-45f6-97d3-9e53a840c31d" xlink:href="biib-20200930.xsd#biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_07f5c736-608a-4fce-9ae5-1465250f81be" xlink:to="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_e15d07f8-292b-45f6-97d3-9e53a840c31d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_422032e2-94f3-4dd6-9a47-391246673d51" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_07f5c736-608a-4fce-9ae5-1465250f81be" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_422032e2-94f3-4dd6-9a47-391246673d51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_43748e21-30e0-44e9-b51e-87c7d518c622" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_07f5c736-608a-4fce-9ae5-1465250f81be" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_43748e21-30e0-44e9-b51e-87c7d518c622" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_51595e11-6b7b-413a-b3b9-44a21293b445" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_07f5c736-608a-4fce-9ae5-1465250f81be" xlink:to="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_51595e11-6b7b-413a-b3b9-44a21293b445" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_d2e0c36c-0627-4eee-ab12-75423e1aaa2f" xlink:href="biib-20200930.xsd#biib_Equitymethodinvestmentbasisdifferenceamortizationperiod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_07f5c736-608a-4fce-9ae5-1465250f81be" xlink:to="loc_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_d2e0c36c-0627-4eee-ab12-75423e1aaa2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_72eff616-50b9-42da-8187-1001ed873e48" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_07f5c736-608a-4fce-9ae5-1465250f81be" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_72eff616-50b9-42da-8187-1001ed873e48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_b360d335-7001-41fc-82bd-08f317a88ad7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_07f5c736-608a-4fce-9ae5-1465250f81be" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_b360d335-7001-41fc-82bd-08f317a88ad7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentForAmortization_843a7e7f-af86-4cd3-97af-638319fc2b92" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentForAmortization"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_07f5c736-608a-4fce-9ae5-1465250f81be" xlink:to="loc_us-gaap_AdjustmentForAmortization_843a7e7f-af86-4cd3-97af-638319fc2b92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_ae71d5c2-d9f2-4634-a37e-f013a901f276" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_07f5c736-608a-4fce-9ae5-1465250f81be" xlink:to="loc_us-gaap_EquityMethodInvestments_ae71d5c2-d9f2-4634-a37e-f013a901f276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_dad4e7fe-02e2-4328-8dee-387ace344602" xlink:href="biib-20200930.xsd#biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_07f5c736-608a-4fce-9ae5-1465250f81be" xlink:to="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_dad4e7fe-02e2-4328-8dee-387ace344602" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_445316d2-6ce9-4de4-bcf0-da0045500ac3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_07f5c736-608a-4fce-9ae5-1465250f81be" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_445316d2-6ce9-4de4-bcf0-da0045500ac3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets_21238d50-700e-43a3-a65c-b2dbf4517dc3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_07f5c736-608a-4fce-9ae5-1465250f81be" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssets_21238d50-700e-43a3-a65c-b2dbf4517dc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_ea79d945-789d-415e-bc67-773405032923" xlink:href="biib-20200930.xsd#biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_07f5c736-608a-4fce-9ae5-1465250f81be" xlink:to="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_ea79d945-789d-415e-bc67-773405032923" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdditionalMilestonePayment_07c2137b-61bd-42f9-9c7b-9c5116b6c7ec" xlink:href="biib-20200930.xsd#biib_AdditionalMilestonePayment"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_07f5c736-608a-4fce-9ae5-1465250f81be" xlink:to="loc_biib_AdditionalMilestonePayment_07c2137b-61bd-42f9-9c7b-9c5116b6c7ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ContractOptionExerciseFee_7a1dff75-05bb-43bf-af23-fe94b311ef5c" xlink:href="biib-20200930.xsd#biib_ContractOptionExerciseFee"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_07f5c736-608a-4fce-9ae5-1465250f81be" xlink:to="loc_biib_ContractOptionExerciseFee_7a1dff75-05bb-43bf-af23-fe94b311ef5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Biogenshareofcopromotionprofitsorlosses_a62203c5-e6f3-4d10-9685-0fd8283c6474" xlink:href="biib-20200930.xsd#biib_Biogenshareofcopromotionprofitsorlosses"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_07f5c736-608a-4fce-9ae5-1465250f81be" xlink:to="loc_biib_Biogenshareofcopromotionprofitsorlosses_a62203c5-e6f3-4d10-9685-0fd8283c6474" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Collaborationprofitlosssharing_c363e14b-c587-4126-80ad-690f7d95d0e8" xlink:href="biib-20200930.xsd#biib_Collaborationprofitlosssharing"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_07f5c736-608a-4fce-9ae5-1465250f81be" xlink:to="loc_biib_Collaborationprofitlosssharing_c363e14b-c587-4126-80ad-690f7d95d0e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_f795eb09-9828-4065-89dc-a3a35a7d8038" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_07f5c736-608a-4fce-9ae5-1465250f81be" xlink:to="loc_us-gaap_Revenues_f795eb09-9828-4065-89dc-a3a35a7d8038" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromRelatedParties_5e3b297b-7c06-4d14-9b5f-15498d5f7a21" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DueFromRelatedParties"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_07f5c736-608a-4fce-9ae5-1465250f81be" xlink:to="loc_us-gaap_DueFromRelatedParties_5e3b297b-7c06-4d14-9b5f-15498d5f7a21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_e157ff76-cabd-4085-be6e-2c0695357805" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_07f5c736-608a-4fce-9ae5-1465250f81be" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_e157ff76-cabd-4085-be6e-2c0695357805" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/InvestmentsinVariableInterestEntities" xlink:type="simple" xlink:href="biib-20200930.xsd#InvestmentsinVariableInterestEntities"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/InvestmentsinVariableInterestEntities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_d111578c-cebd-4dd3-a1af-9c84c92b334f" xlink:href="biib-20200930.xsd#biib_InvestmentsInVariableInterestEntitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_a6ff3ae5-6410-4b90-9535-0976346126e4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableInterestEntityDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_d111578c-cebd-4dd3-a1af-9c84c92b334f" xlink:to="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_a6ff3ae5-6410-4b90-9535-0976346126e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails" xlink:type="simple" xlink:href="biib-20200930.xsd#InvestmentsinVariableInterestEntitiesDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_ce38ad58-5cf3-4d11-8372-7ecd301ab5e9" xlink:href="biib-20200930.xsd#biib_InvestmentsInVariableInterestEntitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_46584ca4-e5ec-462f-855e-a77e912aa376" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_ce38ad58-5cf3-4d11-8372-7ecd301ab5e9" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_46584ca4-e5ec-462f-855e-a77e912aa376" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_a288a30f-aebf-4a15-9f68-c459d56e5225" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_46584ca4-e5ec-462f-855e-a77e912aa376" xlink:to="loc_us-gaap_TypeOfArrangementAxis_a288a30f-aebf-4a15-9f68-c459d56e5225" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_aac6089e-3223-452b-93ef-e92c5dd8f89c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_a288a30f-aebf-4a15-9f68-c459d56e5225" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_aac6089e-3223-452b-93ef-e92c5dd8f89c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EisaiMember_834454c0-eb40-4b8b-9cd3-5cf08b488211" xlink:href="biib-20200930.xsd#biib_EisaiMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_aac6089e-3223-452b-93ef-e92c5dd8f89c" xlink:to="loc_biib_EisaiMember_834454c0-eb40-4b8b-9cd3-5cf08b488211" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesAxis_ed674c8c-4b2e-42dd-ab3f-5997ee677a30" xlink:href="biib-20200930.xsd#biib_FutureContingentMilestoneTypesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_46584ca4-e5ec-462f-855e-a77e912aa376" xlink:to="loc_biib_FutureContingentMilestoneTypesAxis_ed674c8c-4b2e-42dd-ab3f-5997ee677a30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain_79640f6e-582b-4658-b438-50d0c668a53f" xlink:href="biib-20200930.xsd#biib_FutureContingentMilestoneTypesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis_ed674c8c-4b2e-42dd-ab3f-5997ee677a30" xlink:to="loc_biib_FutureContingentMilestoneTypesDomain_79640f6e-582b-4658-b438-50d0c668a53f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RegulatoryMilestonesMember_978dffce-147d-4205-a81a-45fdaeabcac1" xlink:href="biib-20200930.xsd#biib_RegulatoryMilestonesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_79640f6e-582b-4658-b438-50d0c668a53f" xlink:to="loc_biib_RegulatoryMilestonesMember_978dffce-147d-4205-a81a-45fdaeabcac1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RegulatoryApprovalMilestoneMember_cff44abb-47f6-4e6c-9bc2-973242c24a59" xlink:href="biib-20200930.xsd#biib_RegulatoryApprovalMilestoneMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_79640f6e-582b-4658-b438-50d0c668a53f" xlink:to="loc_biib_RegulatoryApprovalMilestoneMember_cff44abb-47f6-4e6c-9bc2-973242c24a59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_34e8cbb3-d9ca-4281-a2b6-d0d513fe028c" xlink:href="biib-20200930.xsd#biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_46584ca4-e5ec-462f-855e-a77e912aa376" xlink:to="loc_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_34e8cbb3-d9ca-4281-a2b6-d0d513fe028c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain_8d54a481-4719-4715-a8e5-4d59f2c7368d" xlink:href="biib-20200930.xsd#biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis_34e8cbb3-d9ca-4281-a2b6-d0d513fe028c" xlink:to="loc_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain_8d54a481-4719-4715-a8e5-4d59f2c7368d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NeurimmuneMember_cd1dfe3f-a13d-48b9-8819-4e06d40b3ff1" xlink:href="biib-20200930.xsd#biib_NeurimmuneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain_8d54a481-4719-4715-a8e5-4d59f2c7368d" xlink:to="loc_biib_NeurimmuneMember_cd1dfe3f-a13d-48b9-8819-4e06d40b3ff1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_b71fb38d-237a-43ef-a718-5382c1c2f5c7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_46584ca4-e5ec-462f-855e-a77e912aa376" xlink:to="loc_us-gaap_VariableInterestEntityLineItems_b71fb38d-237a-43ef-a718-5382c1c2f5c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CollaborationAgreementTerm_f1816d4a-7591-4eff-8158-29321a4228ce" xlink:href="biib-20200930.xsd#biib_CollaborationAgreementTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_b71fb38d-237a-43ef-a718-5382c1c2f5c7" xlink:to="loc_biib_CollaborationAgreementTerm_f1816d4a-7591-4eff-8158-29321a4228ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchAndDevelopmentCostsPercentage_78509e1c-e061-4f20-8f35-b8915a888b01" xlink:href="biib-20200930.xsd#biib_ResearchAndDevelopmentCostsPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_b71fb38d-237a-43ef-a718-5382c1c2f5c7" xlink:to="loc_biib_ResearchAndDevelopmentCostsPercentage_78509e1c-e061-4f20-8f35-b8915a888b01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_906505e1-0925-471b-b7d1-f436e67e6f0a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToMinorityShareholders"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_b71fb38d-237a-43ef-a718-5382c1c2f5c7" xlink:to="loc_us-gaap_PaymentsToMinorityShareholders_906505e1-0925-471b-b7d1-f436e67e6f0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Reductioninroyaltyratepayableoncommercialsales_73661947-2f3f-4eb9-a3c6-2fbbad92e53a" xlink:href="biib-20200930.xsd#biib_Reductioninroyaltyratepayableoncommercialsales"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_b71fb38d-237a-43ef-a718-5382c1c2f5c7" xlink:to="loc_biib_Reductioninroyaltyratepayableoncommercialsales_73661947-2f3f-4eb9-a3c6-2fbbad92e53a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Additionalreductioninroyaltyratepayableoncommercialsales_45c51f43-ab36-42bd-a78e-4744ff422fdc" xlink:href="biib-20200930.xsd#biib_Additionalreductioninroyaltyratepayableoncommercialsales"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_b71fb38d-237a-43ef-a718-5382c1c2f5c7" xlink:to="loc_biib_Additionalreductioninroyaltyratepayableoncommercialsales_45c51f43-ab36-42bd-a78e-4744ff422fdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_df368e7e-d5e3-4d41-8f77-50d592a7cba2" xlink:href="biib-20200930.xsd#biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_b71fb38d-237a-43ef-a718-5382c1c2f5c7" xlink:to="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_df368e7e-d5e3-4d41-8f77-50d592a7cba2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_9b66d9f0-add3-4706-b62c-86690b2e6511" xlink:href="biib-20200930.xsd#biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_b71fb38d-237a-43ef-a718-5382c1c2f5c7" xlink:to="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_9b66d9f0-add3-4706-b62c-86690b2e6511" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_b410d7c0-1410-4998-93b7-d45301754aae" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_b71fb38d-237a-43ef-a718-5382c1c2f5c7" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_b410d7c0-1410-4998-93b7-d45301754aae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_b4a32b61-cefd-4596-9b98-d743f1bacd05" xlink:href="biib-20200930.xsd#biib_PercentageoffuturedevelopmentcostsrelatedtoEisai"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_b71fb38d-237a-43ef-a718-5382c1c2f5c7" xlink:to="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_b4a32b61-cefd-4596-9b98-d743f1bacd05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/Litigation" xlink:type="simple" xlink:href="biib-20200930.xsd#Litigation"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Litigation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_8d4cf557-df99-474f-ade4-18127aa182d4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyInformationAboutLitigationMattersAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock_5c8e3c35-8527-459e-933c-dda5e142d654" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LegalMattersAndContingenciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_8d4cf557-df99-474f-ade4-18127aa182d4" xlink:to="loc_us-gaap_LegalMattersAndContingenciesTextBlock_5c8e3c35-8527-459e-933c-dda5e142d654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/LitigationDetails" xlink:type="simple" xlink:href="biib-20200930.xsd#LitigationDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/LitigationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_f5d962bd-f364-455a-9c94-4c02230c0cb4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyInformationAboutLitigationMattersAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_55520dfd-4a77-4f73-81ed-0023d4e36e27" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_f5d962bd-f364-455a-9c94-4c02230c0cb4" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_55520dfd-4a77-4f73-81ed-0023d4e36e27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_c6239ac3-335e-4023-a7d7-5896406e7d0f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_55520dfd-4a77-4f73-81ed-0023d4e36e27" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_c6239ac3-335e-4023-a7d7-5896406e7d0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_02cb00b2-15ba-4740-98be-f9fec9473cb2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_c6239ac3-335e-4023-a7d7-5896406e7d0f" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_02cb00b2-15ba-4740-98be-f9fec9473cb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_BR_99cc1597-42e5-499b-ac90-c39a2e5cd51a" xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_BR"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_02cb00b2-15ba-4740-98be-f9fec9473cb2" xlink:to="loc_country_BR_99cc1597-42e5-499b-ac90-c39a2e5cd51a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_2b7ef046-06f8-4edd-a769-6ad7c424a41a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_55520dfd-4a77-4f73-81ed-0023d4e36e27" xlink:to="loc_us-gaap_IncomeTaxContingencyLineItems_2b7ef046-06f8-4edd-a769-6ad7c424a41a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_1225ddd9-fc3f-43ec-9914-dac5d0457001" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_2b7ef046-06f8-4edd-a769-6ad7c424a41a" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_1225ddd9-fc3f-43ec-9914-dac5d0457001" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DisputedClaimsRelatingtoConstructionCosts_51b7e3c3-e752-4a8b-bef8-7f5309171669" xlink:href="biib-20200930.xsd#biib_DisputedClaimsRelatingtoConstructionCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_2b7ef046-06f8-4edd-a769-6ad7c424a41a" xlink:to="loc_biib_DisputedClaimsRelatingtoConstructionCosts_51b7e3c3-e752-4a8b-bef8-7f5309171669" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_0fcad28d-24df-4b1a-bdb3-2ab235d9281c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_2b7ef046-06f8-4edd-a769-6ad7c424a41a" xlink:to="loc_us-gaap_LossContingencyDamagesSoughtValue_0fcad28d-24df-4b1a-bdb3-2ab235d9281c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>biib-20200930_g1.jpg
<TEXT>
begin 644 biib-20200930_g1.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
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M4D]&24Q%  $!   ,2$QI;F\"$   ;6YT<E)'0B!865H@!\X  @ )  8 ,0
M86-S<$U31E0     245#('-21T(                  /;6  $     TRU(
M4" @
M       18W!R=    5     S9&5S8P   80   !L=W1P=    ?     48FMP
M=    @0    4<EA96@   A@    49UA96@   BP    48EA96@   D     4
M9&UN9    E0   !P9&UD9    L0   "(=G5E9    TP   "&=FEE=P   ]0
M   D;'5M:0   _@    4;65A<P  ! P    D=&5C:   !#     ,<E120P
M!#P   @,9U120P  !#P   @,8E120P  !#P   @,=&5X=     !#;W!Y<FEG
M:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K87)D($-O;7!A;GD  &1E<V,
M    $G-21T(@245#-C$Y-C8M,BXQ               2<U)'0B!)14,V,3DV
M-BTR+C$
M             %A96B        #S40 !     1;,6%E:(
M      !865H@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:
M6%E:(        "2@   /A   ML]D97-C         !9)14,@:'1T<#HO+W=W
M=RYI96,N8V@              !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M                                                        9&5S
M8P         N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A
M8V4@+2!S4D="               N245#(#8Q.38V+3(N,2!$969A=6QT(%)'
M0B!C;VQO=7(@<W!A8V4@+2!S4D="                             &1E
M<V,         +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V
M,3DV-BTR+C$              "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I
M;VX@:6X@245#-C$Y-C8M,BXQ                                  !V
M:65W       3I/X %%\N !#/%  #[<P !!,+  -<G@    %865H@      !,
M"58 4    %<?YVUE87,          0                        */
M G-I9R      0U)4(&-U<G8        $      4 "@ / !0 &0 > ", *  M
M #( -P [ $  10!* $\ 5 !9 %X 8P!H &T <@!W 'P @0"& (L D "5 )H
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M# P,# P,_\  $0@!(@-H P$B  (1 0,1 ?_$ !\   $% 0$! 0$!
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M5AT8'D&OVK@O.98W!>RJN\Z=D_-='^C]+]3VJ=^6S)****^R- HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MFCV):***_3"3Y1_X+6?\H]O%7_7[I_\ Z5Q5^(-?M]_P6L_Y1[>*O^OW3_\
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M8?#Z;PYXRTF.^MV!:VND 6[T^3_GI#)@E&X&>H8<,""17X/?M9?LSZU^R/\
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M#^IV>L:/J"E[:\M)1+#. Q4E6'!PP(^H-<>,CCE!?6E/EO\ :YK7^?4ZL)+
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MDAAC2&*,;51!A5'L*DK]3R;):6 IZ:S>[_1=E^9E*5PHHHKVR0HHHH ^4?\
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ML3#@BUC/$I!_Y:/\G'"N"&K\U?BC\8O%7QM\32:QXN\0:MXBU*0G]_?7+2E
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M,<7SN?QZ#]:]8HKUL)P=@Z;O6;F_N7W+7\2>=F/X9\#:9X23_0[95DQ@RO\
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MQ]@,U^D?_!/#_@BI>IK&G^-/C):10V]NXN+/PLQ$C3,.5:\(RH4<'R@23T?
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M^?X*RZ'\RYSFM7,<7+%5>NR[+HOE^=V%%%?6W_!);]@:+]L#XMW&M>)+=Y/
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MP_:XT_\ 8Q_9YU3Q9.L5SJTQ^PZ+9N3B[O'!*9QSL0!G;I\J$9!(KV:OQ/\
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M_P#E^!_-'XM\(ZKX!\2WNC:WI]YI.K:;*8;JTNXC%- XZJRMR#_C6?7[;_\
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M=O'%OXB\&ZY?:'JEN1EX'_=SK_<EC.5D0_W7!'Y U^;Y]X<X;%MUL+-QJ/\
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M#V(!K^<WXI?#V^^$OQ+\0>%]2&-0\.ZC/IMQQ@,\4C(2/8[<CV(K^DZOP_\
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MFOY)S'"_5L75P_\ )*4?N;1_4V7XGZQA:>(_FBG]Z3/P;_X*O_\ *0GXE_\
M7[;_ /I)!7SO7T1_P5?_ .4A/Q+_ .OVW_\ 22"OG>OZBR'_ )%F'_Z]P_\
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M4E_:6(U?\2?_ *4S^GLDIQ>78?3[$/\ TE&7_P (3HO_ $"-+_\  5/\*/\
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M^(F1QQ>7O%P7OTM?6/5?+?Y/N?>< YU+"X]863]RKIZ2Z/Y[?-=C];J^=_\
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M['Q__/B?_@,O\CPNBO=/^'9WQZ_Z)?XG_P"_2?\ Q5'_  [.^/7_ $2_Q/\
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M M]_Z M?M57\^^)G_(W7^"/YL_=O#C_D4O\ QR_)!1117YZ??!1110 4444
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MMG.8I+AWCQ[!2 /85Q-?UU@5-8:FJGQ<JOZVU/Y5QKB\1-PVYG;TOH%>S?\
M!.OQC-X%_;G^%=] TBO-XBM=..WKMNG^S-^!64Y]L]>E>,UZ!^R38R:G^U7\
M,K:$A9;CQ9I42$G #&\B Y^IK/,X*>$JPELXR3^YE9;-PQ=*<=U*+_%']%E?
M._\ P5A_Y1Z_$O\ Z\K?_P!*X*^B*^=_^"L/_*/7XE_]>5O_ .E<%?R_D/\
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M.':H5Z_=Q7W)O_VY&5XV\:Z3\.?".I:]KE];Z9H^DV[W5Y=3MB."-1DD_P"
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M4>OPT_Z\KC_TKGK\R\4_^1;2_P"OB_\ 29'Z-X9_\C&I_@?_ *5$^B*^ O\
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M'Y?C'A]YM@'2I_Q(OFCZ]5\U^-CZ3A//EE>.52I\$M)>G1_)_A<_H2HKSO\
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M\!?:W_ :_G-UG1[KP]K%UI]["]O>6,SV\\3_ 'HI$8JRGW!!'X5_3)7XO_\
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MA/Q+_P"OVW_])(*^=Z^B/^"K_P#RD)^)?_7[;_\ I)!7SO7]6Y#_ ,BS#_\
M7N'_ *2C^8,[_P"1C7_QS_\ 2F%?='_!OQ_R>7XF_P"Q+NO_ $NL*^%Z^Z/^
M#?C_ )/+\3?]B7=?^EUA7G\8_P#(EQ'^']4=W"?_ ".,/_B/V$HHHK^83^D@
MHHHH *_"[_@L;_RD>^(W_<,_]-=I7[HU^%W_  6-_P"4CWQ&_P"X9_Z:[2OT
MKPM_Y&M3_KV__2H'YWXF?\BNG_U\7_I,SYDHHHK]Z/P\^PO^"&O_ "?KI_\
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MU6V$5W=IS;Z;&<%K>WSR>0-TAY; P%'!^KJ_ >.>+EF4_J>$?[J+U?\ ,_\
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MU=;+JG<^KZ***^=/H HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\.>'4;@KIFFPV:G\(U%1B/%7"I?N:$F_-I?ES%4/#'$M_OJ\4O)-_G8_$O\
M9Y_X),?&K]H*YMY1X7F\):/*P+ZCX@#62A3SE82/.?(Y!";3Q\PSFOTH_8N_
MX)%_#O\ 92N+76]27_A-O&5N1(FI7\(6WLG'>W@R54CC#N68$9!7.*^L**^$
MSKCK,\QBZ5_9P?2/7U>[_!/L?;9/P3EV DJMN>:ZRZ>BV7XOS"BBBOC3ZX*X
M7]I'X\Z/^S+\$?$/C?7&W66AVQE6%6P]U,2%BA7_ &G<JN>@SD\ UW5?G/\
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M47!RW<_-%?TV5^)G_!9[]F;2/V>?VL5O/#]K#8:-XTL!JRVD*;(K6XWM',J
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MBA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?$QY\/-37=-/\C\UQ6#KX>7)B(.+\TU^8VBBBNHY0HHHH **** "BO0O@_\
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M2/IY^?X+J4445\&?<!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MOP4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
?!1110 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>biib-20200930_g10.jpg
<TEXT>
begin 644 biib-20200930_g10.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?@3XCT'3M*UF*X=9+Z*_TXW4CW!D;8I5AM&W QUYKZ6M;JVO;:.\LKB.:&5
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MOAXOPXO_ !M\7V\!>.[+1M2NGMO$>DWMC/(5O(YI7$SQO#O61OFWD,2S(A4
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MER6*CW.:]:T[7]"U>XN+32=:M+J6TDV7<5O<J[0MS\KA22IX/!]*_$WXL?M
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MIBO8* /C3XL_\$(O^"6'Q?\ 'WC?X\_M.?!";QSK_BV_N]1UOQ#XT\8Z@_\
M9\+LTA@MMD\<=E;Q D)Y:J54#+'&:^?O^"+O[1OCKX'_ /!*3]H[XTCQ?K7C
M3X5?!_QSX[N?@%KOBFZ>:?5?"&DVQFM0)F^:6W#Q2HK]CO0!5157R3_@IK_P
M6"_99_:W_;/\3?\ !,;XO_M;+\%O@/X U%['XV^(1;7HUCQ[>Q2%)O#UB;:%
MVMK)71DN;AMK2@%$RAS)]W_"'XB?L%_\%)/^"=WQ&_9@_P""=OQ'T"_\#CP#
MJ7P_ACT/2KFTM-&^U:9)!'"$FBC;"QS*V0#GN2<T ?'/['W_  1@^ '[:O\
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M6UU"LD<JGJK*P(8>QJ>B@"MI&CZ1X?TR'1=!TNVL;.V39;VEI L442_W550
MH]@*LT44 %%%% &<OA#PFGB1O&2^%].&KO#Y3:J+*/[28_[AEQNV^V<5HT44
M %9WB7P?X2\:6::=XQ\+:=JUO'()(X-3L8YT5QT8*X(!]ZT:* &PPPVT*6]O
M$L<<:A41%P% X  '04ZBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MG_\ /C#_ -^A0!3_ .$Q\,?]!J#_ +ZH_P"$Q\,?]!J#_OJKG]G:?_SXP_\
M?H4?V=I__/C#_P!^A0!3_P"$Q\,?]!J#_OJC_A,?#'_0:@_[ZJY_9VG_ //C
M#_WZ%']G:?\ \^,/_?H4 4_^$Q\,?]!J#_OJC_A,?#'_ $&H/^^JN?V=I_\
MSXP_]^A1_9VG_P#/C#_WZ% %/_A,?#'_ $&H/^^J/^$Q\,?]!J#_ +ZJY_9V
MG_\ /C#_ -^A1_9VG_\ /C#_ -^A0!3_ .$Q\,?]!J#_ +ZH_P"$Q\,?]!J#
M_OJKG]G:?_SXP_\ ?H4?V=I__/C#_P!^A0!3_P"$Q\,?]!J#_OJC_A,?#'_0
M:@_[ZJY_9VG_ //C#_WZ%']G:?\ \^,/_?H4 4_^$Q\,?]!J#_OJC_A,?#'_
M $&H/^^JN?V=I_\ SXP_]^A1_9VG_P#/C#_WZ% %/_A,?#'_ $&H/^^J/^$Q
M\,?]!J#_ +ZJY_9VG_\ /C#_ -^A1_9VG_\ /C#_ -^A0!3_ .$Q\,?]!J#_
M +ZH_P"$Q\,?]!J#_OJKG]G:?_SXP_\ ?H4?V=I__/C#_P!^A0!3_P"$Q\,?
M]!J#_OJC_A,?#'_0:@_[ZJY_9VG_ //C#_WZ%']G:?\ \^,/_?H4 4_^$Q\,
M?]!J#_OJC_A,?#'_ $&H/^^JN?V=I_\ SXP_]^A1_9VG_P#/C#_WZ% %/_A,
M?#'_ $&H/^^J/^$Q\,?]!J#_ +ZJY_9VG_\ /C#_ -^A1_9VG_\ /C#_ -^A
M0!3_ .$Q\,?]!J#_ +ZH_P"$Q\,?]!J#_OJKG]G:?_SXP_\ ?H4?V=I__/C#
M_P!^A0!3_P"$Q\,?]!J#_OJC_A,?#'_0:@_[ZJY_9VG_ //C#_WZ%']G:?\
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MB@ HHHH **** /"_^">__)$]6_['O6?_ $I->Z5X7_P3W_Y(GJW_ &/>L_\
MI2:]TH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/^&U?VA_^BE_^4:T_P#C-'_#:O[0_P#T4O\ \HUI_P#&:/[$_P"HFE_X'_P
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M_P# MJC^&/\ R3;P]_V [3_T2E;E &/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MQ<.[E1V4$+GG&>: /3J*** /TP^&/_)-O#W_ & [3_T2E;E8?PQ_Y)MX>_[
M=I_Z)2MR@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** /"_^">__ "1/5O\ L>]9_P#2DU[I7A?_  3W
M_P"2)ZM_V/>L_P#I2:]TH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\P?$W_(
MQZA_U_2_^AFJ-7O$W_(QZA_U_2_^AFJ- !1110 4444 %%%% !1110 4444
M%%%% 'Z8?#'_ ))MX>_[ =I_Z)2MRL/X8_\ )-O#W_8#M/\ T2E;E !1110
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M^!;4 ;%%8_\ P@^D?\_-[_X%M1_P@^D?\_-[_P"!;4 ;%%8__"#Z1_S\WO\
MX%M1_P (/I'_ #\WO_@6U &Q16/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\ @6U
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M#Z1_S\WO_@6U'_"#Z1_S\WO_ (%M0!L45C_\(/I'_/S>_P#@6U'_  @^D?\
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MX>_[ =I_Z)2MRL/X8_\ )-O#W_8#M/\ T2E;E !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >%_\$]_
M^2)ZM_V/>L_^E)KW2O"_^">__)$]6_['O6?_ $I->Z4 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110!^8/B;_D8]0_Z_I?\ T,U1J]XF_P"1CU#_ *_I?_0S5&@
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M4[ZS-L+J26\FN)RBD1MY8;;\G &XFO=O^$Q\,?\ 0:@_[ZH_X3'PQ_T&H/\
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ML7WP^M?&NJ0^%[B_WA_/;24N!;?> /EA!%QC9CBOL'_A,?#'_0:@_P"^J/\
MA,?#'_0:@_[ZH N:=IVGZ/I\&DZ380VMI:PK#:VMM$$CAC4!5157 50   .
M!4U9O_"8^&/^@U!_WU1_PF/AC_H-0?\ ?5 &E15"V\4>'[R=;6UU6)Y'.$13
MR35^@ HHHH **** "BBB@ HHHH **** /!_^"?EI:S_!75GFMHW/_"=:R,L@
M)_X^37N7]G:?_P ^,/\ WZ%>(_\ !/?_ )(GJW_8]ZS_ .E)KW2@"'^SM/\
M^?&'_OT*/[.T_P#Y\8?^_0J:B@"'^SM/_P"?&'_OT*/[.T__ )\8?^_0J:B@
M"'^SM/\ ^?&'_OT*/[.T_P#Y\8?^_0J:B@"'^SM/_P"?&'_OT*/[.T__ )\8
M?^_0J:B@"'^SM/\ ^?&'_OT*/[.T_P#Y\8?^_0J:B@"'^SM/_P"?&'_OT*/[
M.T__ )\8?^_0J:B@"'^SM/\ ^?&'_OT*/[.T_P#Y\8?^_0J:B@"'^SM/_P"?
M&'_OT*/[.T__ )\8?^_0J:B@"'^SM/\ ^?&'_OT*/[.T_P#Y\8?^_0J:B@"'
M^SM/_P"?&'_OT*/[.T__ )\8?^_0J:B@"'^SM/\ ^?&'_OT*/[.T_P#Y\8?^
M_0J:B@"'^SM/_P"?&'_OT*/[.T__ )\8?^_0J:B@"'^SM/\ ^?&'_OT*/[.T
M_P#Y\8?^_0J:B@"'^SM/_P"?&'_OT*/[.T__ )\8?^_0J:B@"'^SM/\ ^?&'
M_OT*/[.T_P#Y\8?^_0J:B@"'^SM/_P"?&'_OT*/[.T__ )\8?^_0J:B@"'^S
MM/\ ^?&'_OT*/[.T_P#Y\8?^_0J:B@#\P/$H \1Z@ /^7V7_ -#-4JO>)O\
MD8]0_P"OZ7_T,U1H **** "BBB@ HHHH **** "BBB@ HHHH _2OX9V%BWPW
M\/LUE"2=#M,DQC_GBE;?]G:?_P ^,/\ WZ%9/PQ_Y)MX>_[ =I_Z)2MR@"'^
MSM/_ .?&'_OT*_/S]HJXM(?CIXJB5@H76IAM"\#YJ_0FOSJ_:3_Y+WXM_P"P
MY/\ ^A5Z.79G7RRI*=))MJVM_P!&CQ\YR3"YW1C2KRDE%W]UI=+=4SE_MMM_
MSU_\=-'VVV_YZ_\ CIJA17L?ZVYE_)#[G_\ )'SW_$/\F_Y^5/OC_P#(%_[;
M;?\ /7_QTT?;;;_GK_XZ:H5!J>JZ7HMFVHZQJ5O:6ZNJM/<S+&@9F"J"S$#)
M9@H]20.]'^MN9?R0^Y__ "0?\0_R;_GY4^^/_P @:WVVV_YZ_P#CIH^VVW_/
M7_QTU0JNVK:4FHKI#:G;B[9-RVIF7S"OJ%SG%'^MN9?R0^Y__)!_Q#_)O^?E
M3[X__(&O]MMO^>O_ (Z:/MMM_P ]?_'35"H(-3TVZNI;&VU""2>#'GPQR@O'
MGIN .1^-'^MN9?R0^Y__ "0?\0_R;_GY4^^/_P @:WVVV_YZ_P#CIH^VVW_/
M7_QTU0HH_P!;<R_DA]S_ /D@_P"(?Y-_S\J??'_Y O\ VVV_YZ_^.FC[;;?\
M]?\ QTU0HH_UMS+^2'W/_P"2#_B'^3?\_*GWQ_\ D"_]MMO^>O\ XZ:^]OV5
MK6PN/V??#$S6L3EK)_F:,9/[UZ_/JOT'_9*_Y-T\+?\ 7B__ *.DKS\QSO%Y
MG15.K&*2=]$_3JWW/6R?AC 9)B)5J$I-M6]YIJUT^D5V/0$L;*-@\=G$K#H5
MC (J6BBO&/HPHHHH **** "BBB@ HHHH **** /"_P#@GO\ \D3U;_L>]9_]
M*37NE>%_\$]_^2)ZM_V/>L_^E)KW2@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M /S!\3?\C'J'_7]+_P"AFJ-7O$W_ ",>H?\ 7]+_ .AFJ- !1110 4444 %%
M%% !1110 4444 %%%% 'Z8?#'_DFWA[_ + =I_Z)2MRL/X8_\DV\/?\ 8#M/
M_1*5N4 %?G5^TG_R7OQ;_P!AR?\ ]"K]%:_.K]I/_DO?BW_L.3_^A4 <1111
M0 5^>O[;'QU^,/QN^,/Q5_9XLOCM9> -#^'>H^$8]/\ #D&DVLNI^)Y+V\M)
M&O1)<ABL-N[(0L*G)"[R =I_0JO@[_@J=\3?^">WCC0];^'WQ\\/Z=:>/] U
M32K>QO-?\.W%K<S637MK).;2]5 )H?(DGR$D)4A_E!P: /J_X/?##XQ>%? 6
MK^"OC=\?[GQU<WMQ*NGZ^F@6VE7=M:/"J")A;?NWD5]["4*OW@"ORY/S%^U-
M_P $S/\ @G?\"_V5_&?Q+U7PC<Z+JVA:%<7]KX^N/$EY)JR:DJ$P3"9YOGE>
M;8 @&UF8*%&16G_P3,U<>$[SXRZSX'\1>*[C]G_2KZQG^%U_XN^UR.L:6DCZ
ME]E-R//>T60($R"#@XRV\GP?3_\ @H1^Q]^VM\=O^%H_M??':Q\-_#7P5K&_
MX??"NZL[J5M7NH_NZOJ?E1,C8S^[M\D+SNXW&8 ]<^-O[1/[27PX_P""-?A3
MQGK^N7FG_$WQ=HNCZ(FKW+&.ZAEO953[0Y^\LYMLL6X99&W<$5C?MI_L.?!W
M]@[]E>+]JK]E;2KC0?B%\+[O3[]_$BZC,9_$$374,-W%?;G*S+,)6=@1C(VC
M"DBO3O\ @H7IMO\ MK?\$[;KXD?LNW(\5M97UGXE\+K9V\@.I?8;K]ZB(ZAR
MVQ9PJ[<LRA0#N%>9_MM_MQ_!3]N?]DZ#]F#]ECQ$WB+X@?%:[T[3X?#4-G+]
MHT2,74,UU+>@J! D*Q,K,3C)W#*@D 'WCX8UZS\5>&]/\4:=G[/J5C%=09/.
MR1 Z_H17D?Q__P""=_[&W[4GCI/B7\>?@K!X@UR.PCLDOY-8OH"($9F1-L$Z
M+P78YQGGK6YXQ^.OPK_9L\0_#+X">)'U#[;XSG.B>%OLMH'C+VT,>?-;</+&
MTKS@URW_  4F_:!U+]G+]C_Q3XK\*O(?$VLQ)H'A""W_ -=+J=Z?)B\L=W0%
MY0._E&@#Y^_X)'_LZ?!?3_VBOC9^T_\  SP/%H7@Q=;;P7X"MX+N:9)K6U,3
M7MT'F=W=)IXX74YXVLO; ^^*\T_8Z_9^TW]EG]F/P7\!]/2/S- T2./498ON
MS7KYEN91[-.\C#V(':O2Z "OT'_9*_Y-T\+?]>+_ /HZ2OSXK]!_V2O^3=/"
MW_7B_P#Z.DH ]%HHHH **** "BBB@ HHHH **** "BBB@#PO_@GO_P D3U;_
M +'O6?\ TI->Z5X7_P $]_\ DB>K?]CWK/\ Z4FO=* "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH _,'Q-_R,>H?]?TO_H9JC5[Q-_R,>H?]?TO_H9JC0 4444
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M_?5'_"8^&/\ H-0?]]5<_L[3_P#GQA_[]"C^SM/_ .?&'_OT* *?_"8^&/\
MH-0?]]4?\)CX8_Z#4'_?57/[.T__ )\8?^_0H_L[3_\ GQA_[]"@"G_PF/AC
M_H-0?]]4?\)CX8_Z#4'_ 'U5S^SM/_Y\8?\ OT*/[.T__GQA_P"_0H I_P#"
M8^&/^@U!_P!]4?\ "8^&/^@U!_WU5S^SM/\ ^?&'_OT*/[.T_P#Y\8?^_0H
MI_\ "8^&/^@U!_WU1_PF/AC_ *#4'_?57/[.T_\ Y\8?^_0H_L[3_P#GQA_[
M]"@"G_PF/AC_ *#4'_?5'_"8^&/^@U!_WU5S^SM/_P"?&'_OT*/[.T__ )\8
M?^_0H I_\)CX8_Z#4'_?5'_"8^&/^@U!_P!]5<_L[3_^?&'_ +]"C^SM/_Y\
M8?\ OT* *?\ PF/AC_H-0?\ ?5'_  F/AC_H-0?]]5<_L[3_ /GQA_[]"C^S
MM/\ ^?&'_OT* *?_  F/AC_H-0?]]4?\)CX8_P"@U!_WU5S^SM/_ .?&'_OT
M*/[.T_\ Y\8?^_0H I_\)CX8_P"@U!_WU1_PF/AC_H-0?]]5<_L[3_\ GQA_
M[]"C^SM/_P"?&'_OT* *?_"8^&/^@U!_WU1_PF/AC_H-0?\ ?57/[.T__GQA
M_P"_0H_L[3_^?&'_ +]"@"G_ ,)CX8_Z#4'_ 'U1_P )CX8_Z#4'_?57/[.T
M_P#Y\8?^_0H_L[3_ /GQA_[]"@#\QO$;*_B&_=3D&]E(/_ S5*KOB4 >(]0
M'_+[+_Z&:I4 %%%% !1110 4444 %%%% !1110 4444 ?H_\-O%OAN'X=:!%
M+K$*LNBVH8$]"(5K;_X3'PQ_T&H/^^JH?#.PL6^&_A]FLH23H=IDF,?\\4K;
M_L[3_P#GQA_[]"@"G_PF/AC_ *#4'_?5?GS^T7<07?QT\5W-M('C?6IRC#H1
MNK]$O[.T_P#Y\8?^_0K\[_VD$2/X\^+$C4*!KD^ !@#YJ .)HHHH **** "B
MBB@ HHHH **** "BBB@ K[X_94\3Z!9?L^>&+6[U6*.1+)PR,>1^]>O@>OT"
M_9-LK.7]G?PO)):1,QLGRS1@D_OGH [NV\4>'[R=;6UU6)Y'.$13R35^HDL;
M*-@\=G$K#H5C (J6@ HHHH **** "BBB@ HHHH **** /"_^">__ "1/5O\
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M_GQA_P"_0J:B@"'^SM/_ .?&'_OT*/[.T_\ Y\8?^_0J:B@"'^SM/_Y\8?\
MOT*/[.T__GQA_P"_0J:B@"'^SM/_ .?&'_OT*/[.T_\ Y\8?^_0J:B@"'^SM
M/_Y\8?\ OT*/[.T__GQA_P"_0J:B@"'^SM/_ .?&'_OT*/[.T_\ Y\8?^_0J
M:B@"'^SM/_Y\8?\ OT*/[.T__GQA_P"_0J:B@"'^SM/_ .?&'_OT*/[.T_\
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MXL2-0H&N3X & /FK]%J_.K]I/_DO?BW_ +#D_P#Z%0!Q%%%% !1110 4444
M%%%% !1110 4444 %?H%^R;96<O[._A>22TB9C9/EFC!)_?/7Y^U^@_[)7_)
MNGA;_KQ?_P!'24 >@)8V4;!X[.)6'0K& 14M%% !1110 4444 %%%% !1110
M 4444 >%_P#!/?\ Y(GJW_8]ZS_Z4FO=*\+_ .">_P#R1/5O^Q[UG_TI->Z4
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !7Z#_LE?\FZ>%O\ KQ?_ -'25^?%?H/^R5_R;IX6_P"O%_\
MT=)0!Z+1110 4444 %%%% !1110 4444 %%%% 'S]^P-X@T73/@UJUMJ&HQQ
M2?\ "<ZRVUSSC[2W->W_ /"8^&/^@U!_WU7C/_!/RTM9_@KJSS6T;G_A.M9&
M60$_\?)KW+^SM/\ ^?&'_OT* *?_  F/AC_H-0?]]4?\)CX8_P"@U!_WU5S^
MSM/_ .?&'_OT*/[.T_\ Y\8?^_0H I_\)CX8_P"@U!_WU1_PF/AC_H-0?]]5
M<_L[3_\ GQA_[]"C^SM/_P"?&'_OT* *?_"8^&/^@U!_WU1_PF/AC_H-0?\
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M\)CX8_Z#4'_?5'_"8^&/^@U!_P!]5<_L[3_^?&'_ +]"C^SM/_Y\8?\ OT*
M*?\ PF/AC_H-0?\ ?5'_  F/AC_H-0?]]5<_L[3_ /GQA_[]"C^SM/\ ^?&'
M_OT* *?_  F/AC_H-0?]]4?\)CX8_P"@U!_WU5S^SM/_ .?&'_OT*/[.T_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7_P3W_Y(GJW_ &/>L_\ I2:]TKPO_@GO_P D3U;_ +'O6?\ TI->Z4 %%%%
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MHK'_ .$EU?\ Z%"]_P"^EH_X275_^A0O?^^EH V**Q_^$EU?_H4+W_OI:/\
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M[_PDNK_]"A>_]]+7Y_?M$327'QR\53RV[1,^M3%HWZK\W0T <91110 4444
M%%%% !1110 4444 %%%% !7Z#_LE?\FZ>%O^O%__ $=)7Y\5]Y_LKZ[J5K^S
M]X9MX?#-U.JV3@2HRX;]Z_2@#UFBLNSU[4KFZ2";PS=0JS8:5V7"^YK4H **
M** "BBB@ HHHH _*K]LO]EK_ (*I^!O'O[4_[//['_[,>C^-/!?[6MW;7-I\
M4)_'EGIO_"#/<Z7;Z7JJ7MI-B:Y7R86>(P9(#C&]\H/>?BA^Q9X^\._M,?L,
M_"_X.?#RXE^'_P  K?5Y/$?C*-H84T^W@\.-I=C:A"XD=KF23+!%8*L1+'D9
M\VU[P#^VS_P4P_;[^/OPK_X>!^/O@5\//@CKFD:!H'A'X60VUIJFJR76F0WS
MZG=WDJ,_ER&7;&BC850XVLK-)[-^RY_P2S^+/[./QVT+XS>)O^"J_P"T?\2;
M'1OM7G^"O'OBV"ZTG4?.M98!Y\20*6\MI1*F",21(>V* /K^BBB@#PO_ ()[
M_P#)$]6_['O6?_2DU[I7A?\ P3W_ .2)ZM_V/>L_^E)KW2@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** /S!\3?\C'J'_7]+_Z&:HU>\3?\C'J'_7]+_P"AFJ-
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M + =I_Z)2MR@ K\ZOVD_^2]^+?\ L.3_ /H5?HK7YU?M)_\ )>_%O_8<G_\
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M(GJW_8]ZS_Z4FO=* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M% &/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\ ?2UL44 8_P#PDNK_ /0H7O\
MWTM'_"2ZO_T*%[_WTM;%% &/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\ ?2UL
M44 8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_WTM;%% &/_P )+J__ $*%[_WT
MM'_"2ZO_ -"A>_\ ?2UL44 8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_WTM;%
M% &/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\ ?2UL44 8_P#PDNK_ /0H7O\
MWTM'_"2ZO_T*%[_WTM;%% &/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\ ?2UL
M44 8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_WTM;%% &/_P )+J__ $*%[_WT
MM'_"2ZO_ -"A>_\ ?2UL44 8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_WTM;%
M% &/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\ ?2UL44 8_P#PDNK_ /0H7O\
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M1/%7CW3/@KX+GU;6/ >JKI\=LMK>!MD$L%Q"D=S&1.K0L\B,I#*:^H?V9O\
M@JW>_M*?&[1/@I-_P3(_:S^'BZU]ISXP^)OPEATS0]/\FVEG_P!)N5O9#'O\
MKRDPAW2R1KQNR/FG5_VE_P!I+_@G5_P4]_:$D^%__!+7X[?%7X>?%#5M'UZ\
M\4^#_"RN(-8BTNW@F%G(7*7EJZJF=YB>&9)E D4@K]%?LN?\%3/BS^T=\=M"
M^#/B;_@E1^T?\-K'6?M7G^-?'OA*"UTG3O)M99QY\J3L5\QHA$F <R2H.^:
M/K^BBB@#PO\ X)[_ /)$]6_['O6?_2DU[I7A?_!/?_DB>K?]CWK/_I2:]TH
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MB<9  R02@;Z"_:T_:S\#?LG^ X-;UJPN=;\2:Y<_8/!?@W2EWW^O7[8"00H
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M$KQ)H=[K-Y>ZG;Z3X;\.Z8!]IUC4[@E8+6+/ +89B><*C$!B I\6\??\IK/
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7_Z%"]_[Z6OS^_:(FDN/CEXJGEMVB9]:F+1OU7YNAH XRBBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!^8/B;_D8]0_Z_I?\ T,U1J]XF_P"1CU#_ *_I?_0S5&@ HHHH
M **** "BBB@ HHHH **** "BBB@#],/AC_R3;P]_V [3_P!$I6Y6'\,?^2;>
M'O\ L!VG_HE*W* "OSJ_:3_Y+WXM_P"PY/\ ^A5^BM?G5^TG_P E[\6_]AR?
M_P!"H XBBBB@ HHHH **** "BBB@ HHHH **** "OT'_ &2O^3=/"W_7B_\
MZ.DK\^*_0?\ 9*_Y-T\+?]>+_P#HZ2@#T6BBB@ HHHH **** "BBB@ HHHH
M**** /"_^">__)$]6_['O6?_ $I->Z5X7_P3W_Y(GJW_ &/>L_\ I2:]TH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@#\P?$W_ ",>H?\ 7]+_ .AFJ-7O$W_(
MQZA_U_2_^AFJ- !1110 4444 %%%% !1110 4444 %%%% 'Z8?#'_DFWA[_L
M!VG_ *)2MRL/X8_\DV\/?]@.T_\ 1*5N4 %?G5^TG_R7OQ;_ -AR?_T*OT5K
M\ZOVD_\ DO?BW_L.3_\ H5 '$4444 %%%% !1110 4444 %%%% !1110 5^@
M_P"R5_R;IX6_Z\7_ /1TE?GQ7Z#_ +)7_)NGA;_KQ?\ ]'24 >BT444 %%%%
M !1110 4444 %%%% !1110!X7_P3W_Y(GJW_ &/>L_\ I2:]TKPO_@GO_P D
M3U;_ +'O6?\ TI->Z4 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!^8/B;_ )&/
M4/\ K^E_]#-4:O>)O^1CU#_K^E_]#-4: "BBB@ HHHH **** "BBB@ HHHH
M**** /TP^&/_ "3;P]_V [3_ -$I6Y6'\,?^2;>'O^P':?\ HE*W* "OSJ_:
M3_Y+WXM_[#D__H5?HK7YU?M)_P#)>_%O_8<G_P#0J .(HHHH **** "BBB@
MHHHH **** "BBB@ K]!_V2O^3=/"W_7B_P#Z.DK\^*_0?]DK_DW3PM_UXO\
M^CI* /1:*** "BBB@ HHHH **** "BBB@ HHHH ^>OV"]8O[#X.:M!;:!<7*
M_P#"<:R?,B(QG[2W'->V_P#"2ZO_ -"A>_\ ?2UY'_P3W_Y(GJW_ &/>L_\
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MK8HH _,#Q&Q;Q#?L5()O920>WSFJ57O$W_(QZA_U_2_^AFJ- !1110 4444
M%%%% !1110 4444 %%%% 'Z-?#?Q%JL?P[T&-/"EVX71;4!U9<-^Y7FMK_A)
M=7_Z%"]_[Z6H_AC_ ,DV\/?]@.T_]$I6Y0!C_P#"2ZO_ -"A>_\ ?2U^?W[1
M$TEQ\<O%4\MNT3/K4Q:-^J_-T-?HS7YU?M)_\E[\6_\ 8<G_ /0J .(HHHH
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MZ#_LE?\ )NGA;_KQ?_T=)7Y\5^@_[)7_ ";IX6_Z\7_]'24 >BT444 %%%%
M!1110 4444 %%%% !1110!X7_P $]_\ DB>K?]CWK/\ Z4FO=*\+_P"">_\
MR1/5O^Q[UG_TI->Z4 <U\8K_ .*VE?"OQ!J?P,\/Z/JWC&WTJ:3PUI?B"]>V
MLKN\528XII8U9HD9L*7 .W.<'%?E-^UKXB_X*/\ [<'QR^)7[*VH?\$H]&T7
MQ3X]_9SMO#M])XQ^+>C7^C>'[>XU/4$CUU9+<-/<>7(9#%&D*3K) '*J-I/Z
M_5DQ^ _!</CN;XGQ>%[)?$5QI,>ESZT+=?M,EE'*\J6Y?J8UDED<+T!=CWH
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M $&[+_P&/^-?&_\ P5A^.?\ P35T+PR?V>?^"G_AW1;NTU+PU<:KX4UCQ;X
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MR"?MLN2/7>:I4 %%%% !1110 4444 %%%% !1110 4444 ?IA\,?^2;>'O\
ML!VG_HE*W*XWX;V?C)OAWH)@UFT5#HMKL5K8D@>2N.];7V+QO_T&[+_P&/\
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M)\&:_JUKK^O>$M,O;ZQ.;&]N[".2:W.<_([*2G//!%<)_P -D?LW_P#11O\
MRD7G_P 9H_X;(_9O_P"BC?\ E(O/_C-']F9E_P ^9_\ @+_R#^VLF_Z":?\
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M5MK++/#;M&,'(.TG&.:/[3S+_G]/_P "?^8?V+DW_0-3_P# (_Y'TI]MN?\
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M -'1UR'_  3W_P"2)ZM_V/>L_P#I2:Z_]K7_ )-T\4_]>*?^CHZ /SXHHHH
M**** "BBB@ HHHH **** "BBB@ KM_V;/^2]^$O^PY!_Z%7$5V_[-G_)>_"7
M_8<@_P#0J /T5HHHH P_B=_R3;Q#_P!@.[_]$O7YGU^F'Q._Y)MXA_[ =W_Z
M)>OS/H **** (KX7K6,RZ<\:W!B;R&E!*!\?*6QSC.,U^0G@73?V2?"/Q,\$
M^&O^"G?PSUS2_'DS>)$^)WB3XA65])!K%X\\)L)[6\C+)Y"Q[E1HBB)SS\P9
MOU[OC>BQF.FK$;GRF^SB8G87Q\N['.,XSBOA[XR_%K]M3Q'\=_A[H'C/_@G_
M *9?:[_PC?B6SAT]OB%IT^C:NLL=BLLQ:0"5(4VJ6BDBWL) J[B"0 ?7/P]\
M(?".^^#&A^#/!D>GZ]X+31;:#1Q-=#4K>ZLD1?)/FR%_/&U5(=BQ. <D\U\X
M?LW6-EIO_!7#]H"PTZSBMX(O _A98H8(PB(/L_0 < 5Z#^R7\#_BA^Q-^PAH
M?PCLM%3QUXM\,:3=3KI&GZDEI%>W4US+<FUAGN,+&BF7RU=\ A,D#.!X+\,Y
MO^"B'@C]L_XA_M2W?_!.*_EM?'FBZ1IR:2OQ5T(/8_8X]C2-)YQ\P-UP%&/>
M@#MOVG8K?X@?\%9/V?/AOXGM_M.D:!X:U[Q):V4JYBDOQ&8XI6!X+1&-74]5
M;D=32_MHQ0> ?^"D/[+_ ,3_  [;>3J>N7^N^'-:DA7F]L7M8VCCD_O+')(\
MBCL23VKJ?VX/@7\:+KXN?#+]L;]F[PM;^(O%?PTNKVWU+PE/?I:'7=(O(O+G
MBCFD^19H\%D#8!+D\E55N=\%> ?VBOVN?VRO!/[2OQN^!EY\-_!GPJTO4/\
MA%="UO5;>YU#5M5O8Q#+/(ENS+%%'&HVACNW*",ACM /K>O-/VA/C+\#?V0/
M@5JWC_Q]96&GZ#;)(D&B65I&K:I=3;B+2&$ "669BW&.[,V%#$7/"WBO]H&^
M_:%\4>$O%7PML++X=V.E6DOA;Q7%J4;W&HW;JIN(GA$A>,(2P!**#C@FOCF^
M\+?\%!_%7[8&H?M'?'?_ ()^WWCJS\,WLD/PFT"W^)VAVNFZ% '(^VF*29FF
MO) $;S7"E#T4;4\L ]W_ ."5'P'^(/[/?[&^C>%/B;HO]CZKJNJ7VM-X=!)&
MBQ74QDCL^>A1,%E_A9V'45]'5Q?P(\=_%KXA^"7U_P",_P "I_AYK"WTD2Z!
M<^(K35&:$*I6;SK4E &)8;>HV<]17:4 7O#/_(QZ?_U_1?\ H8K]/J_,'PS_
M ,C'I_\ U_1?^ABOT^H **** /S!\3?\C'J'_7]+_P"AFJ-7O$W_ ",>H?\
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M %%%% 'A?_!/?_DB>K?]CWK/_I2:Z_\ :U_Y-T\4_P#7BG_HZ.N0_P"">_\
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MA;5_&=AH7BGPMK_A"QT^8K=,RB>SDM@&5UP<1<KW.0#CO?\ @GK^UEINM?\
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M/_)Z#_XY1_:67?\ /Z'_ ($O\P./HKL/^%"?%G_H5/\ R>@_^.4?\*$^+/\
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M?PK^"O@BS\/Z#8EF@L+,,<NWWI'=R7D<\9=R6.!D\5[%^S9_R7OPE_V'(/\
MT*N(KM_V;/\ DO?A+_L.0?\ H5 'Z*T444 8?Q._Y)MXA_[ =W_Z)>OS/K],
M/B=_R3;Q#_V [O\ ]$O7YGT %%%% '@7[8O_  4%^"G[*5L_A:Z\56U_XU+6
M4L7A>UL+J\F2UENXHI)I5M4<P@1N[)YA7>P55W%@#Z#\%OVD?A/^T?X*U'QO
M\#/$#ZY!IEW)975O<6%Q8317B1K)Y$D=U&CQMMD0Y*XPP/-?('[<OP&_:6^
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MHHH **** "BBB@ HHHH *[?]FS_DO?A+_L.0?^A5Q%=O^S9_R7OPE_V'(/\
MT*@#]%:*** ,/XG?\DV\0_\ 8#N__1+U^9]?IA\3O^2;>(?^P'=_^B7K\SZ
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M'7UKJPF:8#'5'"A.[2OLUI\T@.QHHHKT "BBB@ HHHH **** "BBB@ HHHH
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MI-=?^UK_ ,FZ>*?^O%/_ $='0!^?%%%% !1110 4444 %%%% !1110 4444
M%=G^SNMR_P <O"JV<JI*=:A\MW7(!W=Q7&5V_P"S9_R7OPE_V'(/_0J /OW[
M%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QK8HH XWXD6?C)?AWKYGUFT9!H
MMUO5;8@D>2V>]?G+7Z8?$[_DFWB'_L!W?_HEZ_,^@ HHHH **** "BBB@ HH
MHH **** "BBB@"[X<#'Q#8!" ?ML6"?7>*_2?[%XW_Z#=E_X#'_&OS9\,_\
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MQ9XZU35-)T>5#\C0V=S</%\O0!U<#Z\TZ68X:$VU>*YG)I)/F3VB]5;JNJU
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M;Z*^D/\ A0GPF_Z%3_R>G_\ CE'_  H3X3?]"I_Y/3__ !RC_6S+OY)_<O\
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MNP''_P#"A/A-_P!"I_Y/3_\ QRC_ (4)\)O^A4_\GI__ (Y7845\K_:68_\
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M7A?C_P#Y'34_^OQ_YU[I7A?C_P#Y'34_^OQ_YU\QQ;_NE/\ Q?H!CT445\&
M4444 %%%% !1110 4444 %%%% !7M_PS_P"1%T[_ *XG_P!"->(5[?\ #/\
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MB_\ 0!5NOV.C_!CZ( KPOQ__ ,CIJ?\ U^/_ #KW2O"_'_\ R.FI_P#7X_\
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M> QW;-W!; ZVBE6Q5:O3C"=K+:T8K\DGU^\#P+]@G]AT_L8:-X_U+Q/\4/\
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M_"V/_P :H_X<A?LF_P#11OBG_P"%L?\ XU7V-10!\<_\.0OV3?\ HHWQ3_\
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M;PEHTOASPIIGAZ>99'L-/AMWD08#E(U4D>QQ6A0!\<_\.0OV3?\ HHWQ3_\
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M!_X.#_\ @E!\0?%VD>%(/VCKW1(O$5T+?PYX@\7^!M8T;2-4D)P!%?7MK'
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M?&]_)=ZUXB^$'AS4-8NY7W/<74NFP-+*3W+.6;_@5 'MU%%% !1110 4444
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MO?6-];I<65[9SK+#<0NH9)$=25=64@A@2"""*_'C_@F]_P %!_\ @FK\!O\
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MAZ_2>B@#D/V?_@CX$_9I^!GA#]GKX864EOX>\$^&[+1-&CF<-)]GMH5B1G8
M;G(7<S8^9B3WKKZ** /SJ_X+Y>%/^"C'[6/[,7Q _8&_92_X)VWWC?1/&NBZ
M6T/Q.3XI:%IT%K<0ZC!=R0&PO9XIG(%L%WY"GS01G:17TQ^P1\7OVOOB5X)O
M?#_[67["E_\ !2;PY8Z?::)]M^(ND^(/[<'ER+,Z_P!G.WV?RS''Q)][SAMS
MM:O?:* /S6^-OQV_X*?_ !IOM7\'?"/_ ((;6'@KXP:C:S:3IGQK\7>.=!NM
M,\.QR*T0U*.[@4W4^R,[TA10X. 5;:5;[ _X)V_L8^$O^">_[%GP_P#V/O!N
MK'4;?P9HI@O-4:+R_M]]-*]Q=W.W)V"2XFE<*2=JL%R<9KVFB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^/7_  4R\1?%KP:?#TXOO#WB[P!I%C):WP>)Q>PW=C'&Z1K&DRFW974^8&#
MI\P!])T5^7?[(&N_\%6?^"N_P.U/_@H%\,O^"A4WP(\,>)M9U-/@I\.M$^'F
MEZG;16%G=2VL=SJ\UY&\UQ)-+ ^^-"JJ!N3APBX7Q>_X+!_M<>*/^" 7B_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:C:3-9:3MN K 2(+DW%P\2"*U>-?,DE0#ZT_;+_9<^.WQ7_X*Q?L7_M+^ /
MWV_P3\)O^%B_\+ UO^T[6+^RO[4T*"UL?W,DJS3^;,C)^Y239C+[5P:^OZ*
M/D#]LO\ 9<^.WQ7_ ."L7[%_[2_@#P-]O\$_";_A8O\ PL#6_P"T[6+^RO[4
MT*"UL?W,DJS3^;,C)^Y239C+[5P:\MO_ (:_\%"OV&O^"F_[0_[37[/G["4G
MQQ\#?'ZU\*7MO)H?Q+T?0[O0+W2=.>QFAFCU.2/SA*6,BM&2%  ZD[?T1HH
M^&?VX?B7\6?&/Q!\0?!GX[?\$(;WX\^"+6<1^!_%-EJ_AO5+?44DAC9VEMM0
MDCETQEE+)N^;/EAP>PZ#_@AO^QU\=/V)/V*KOX7_ !XT"W\-W6L_$+6_$7A[
MX>VFO?VG%X(TF\F5[;15N@2LWE;7<LA*EIFY)R3]C44 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 ?&'_!1;_DMNE_]BK!_P"E-S7@5?HQ\1OV>O@_\6=;B\1_$#PA
M_:%[!:K;13?VA<1;8@S,%Q'(H/+L<XSS]*P/^&*OV9O^B:?^5F]_^/4 ? U?
MI'\#/^2)>#O^Q5T__P!)HZY7_ABK]F;_ *)I_P"5F]_^/5Z3H6B:9X:T2S\.
M:);>19:?:QVUI#O9O+B10J+EB2<  9))]: +5%%% !1110!^57A;XQ:!_P $
M//\ @I_\?-:_:ZTS4]&^ _[2OB.T\7^#OBQ;:1/=:;HVOE'6]TW4&@1VMVDD
MD+1NPV[44YPSF/ZM^$W_  6:_8$_:-_:#\-?LT?LL_%:Y^*'B+Q \SWMSX'T
M2YO-.T"UCMI9S=:A>;%AMXV,0A4;F=I98UV@$D?4=]8V.IV<NG:E9Q7%O,A2
M:">,.DBGJK*>"#Z&J?AKPAX3\%V!TKP=X7T[2;4N7-MIEE'!&6/4[4 &?>@#
M\K/^"9O[;/[,W_!)76OC]^PY_P %"OB=:_##Q-IOQM\0^,?#.J^*H98[;Q=X
M?U%TDMK^TF"%;B3]VRO&N7! 7!975.!\":'XO\?_ /!(W_@HU^W/J'@;4O#G
MA7X^:GXI\1?#K3]8L7MKJ\T.+3S#!J+PN T8N#N< C)V[AE65C^R'B+P;X0\
M7_9_^$L\*:;JGV27S;3^T;&.?R7X^9-X.T\#D<\5I4 ?!_Q\54_X-I?$"(H
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MQ%F4-F.-AU1AC.>/I6%_PV1^S?\ ]%&_\I%Y_P#&:\*_X*"_\EFTS_L6(?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 ?'G_  4%_P"2S:9_V+$/_I1<UX57VO\ M!_LG?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
E10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>biib-20200930_g11.jpg
<TEXT>
begin 644 biib-20200930_g11.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ KA_VF_C+_P ,Y_LV_$+]H3_A&_[9_P"$$\#ZMXB_
MLC[9]G^W?8K.6Y\CS=C^5O\ *V[]C;=V=K8P>XKQ#_@IK_RC<_:#_P"R'^+/
M_3/=4 ?*/P#_ ."M7_!7C]IOX,^&_P!H#X+_ /!"&RU7PIXNTJ+4M!U&3]JC
M1K=KBVD&4<Q36"R)GT90?:OT.TK5KMO#-MKGBNPBTFX:Q2;4;62[61+.0H&D
M0RC"L$.1OX!QFORN_P""/_P@_P""RVK?\$Y?@9K?PA_;-^#.C^!9O ^GR:-H
M.L?"JZNK^WL<<0R7"WJJ\FW(WA ,]J[7]N+X>:%_P4-_X+C^ O\ @G%^T3<7
M][\&_ _[/MS\4-5\#QZA-;6?BK5WUD:; EX(F4SPP+ME12<;UD!!5F! /TDT
MW4]-UBRCU/2-0@NK:49BN+:4.CC.,AE)!Y%)JNL:3H5B^IZYJEM9VT9&^XNY
MUC1<G RS$ <\5^97@GX'^ /^"6__  71^$G[/O['.G3>%OA?^T7\//$<GB[X
M;6=[*^DV.KZ1!]IBU2WAD9A;R21A8&";5(W<9/'G'_!,_P#X)D?LI_MQ?M'_
M +:7C[]KWP3+X]TG2/VOO%VG>'/!VL:I<KI6F7!,+W-^EO%(B/<S))!$97!9
M$ME"%=S9 /V$!!&0:\:_9(_;.\'?M=^(/BWX>\)>$-3TJ3X1?%?4? >K2:B\
M;+?7=I#!*]Q#L)Q$PN% #8;*G(KUNXT32[K1'\.7%FKV4EJ;:2W8G#1%=I4G
MKC;Q7Y'_ /!&_P#X)*?\$Y?%OQP_:5\7>(_V4_#]WJ7PH_:XUC2_AY=R3W.[
M1+2QAT^>TABQ* 5CE9G&[<<GDF@#[A_91_;M\2?'C]K_ /:;_9X\;>&]%T;1
M?@3XCT'3M*UF*X=9+Z*_TXW4CW!D;8I5AM&W QUYKZ6M;JVO;:.\LKB.:&5
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MOAXOPXO_ !M\7V\!>.[+1M2NGMO$>DWMC/(5O(YI7$SQO#O61OFWD,2S(A4
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MER6*CW.:]:T[7]"U>XN+32=:M+J6TDV7<5O<J[0MS\KA22IX/!]*_$WXL?M
M?$_X;_\ ! K]AC]G[X<#QJ+7XTZSX:\+>,5^'$D::_>Z&899KO3].>66)4NK
MD(D2L9$!!=2<,:=\4/V?] ^$NK?#OXM?\$E_^")_[2WP4^*O@GQCIDC:W=:3
MI]MINO:']H5=1T[53'K5R]U'+ 6.YXW?>B_.H)- '[9ZKJ^DZ'9/J>MZG;V=
MM'CS+BZG6-%R<#+,0!S7SGI/[;_C'4_^"N&I_P#!.[_A#]*_X1VR_9]@^(,7
MB%)9#>/=R:R;#[.1GR_*V?/G&[=WQ7RYXW^ WPU_X*C_ /!<OXL? W]L;1I/
M%/PU_9P^'?AMO!_PXU&[D72KW5M9A>ZFU6>!& N)$C'V<;\H!MXR,G!_8C_9
M-^''[&?_  <D^/?A!\&;N^@\'2?LBP:CX:\-76I37,/AR"7Q' 'L+4S,S1V_
MGI/.L6=J&Z95 4*H /U5HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH *X?]IOX-?\ #1G[-OQ"_9[_ .$D_L;_
M (3OP/JWAW^U_L?VC[#]MLY;;S_*WIYNSS=VS>N[;C<N<CN** /*/V%OV8/^
M&+/V/_AW^RC_ ,)Q_P )+_P@/A>VT?\ M_\ LS[']O\ *&/-\CS9?*S_ '=[
M8]37E7[>'_!.;QO^T3\</ ?[9O[*W[0[_"CXV?#JPNM+TSQ+<: FK:;K.CW!
MW3:7J%FTD?F1;RSHZN&C9V8 ML*?5E% 'Q]^R5_P38^,OA/]KN]_X*!_MW_M
M.VGQ5^*B>%6\->$+;0/"HT;0_">EO)YDR6MN997EFE;.Z>1@VUV3!&"/0OV$
M_P!AC_ABG7OC=K?_  M'_A)O^%R?'#6?B'Y7]B?8O[(^WK OV'/GR_:/+\G_
M %V(]V[_ %:XY]_HH *^+_"7_!,7]ISX#?M9^//CI^R3_P % D\&>!OBC\0X
M?&/COX::Y\*+76OM-\PB2]%MJ#7<,EL+A(MO^K?RR01NVX/VA5%_$_AJ/6AX
M;D\0V*ZBR[EL&NT$Q&,YV9W8Q[4 >'?LM_L,?\,U?M8_M!?M0?\ "T?[:_X7
MMX@T74_[#_L3[-_8?]GV!M/+\[SW^T^9G?NV1;>F&ZUG_!7_ ()W>'/AE^U+
M^TS^T)XP\<P>*=(_:3_L&/5/!UUH/DQ:9;:?I4FG2P/-Y[_:UG25F/[N+8/E
M^?.ZOH^B@#X ^$O_  3,_P""F'[&GA0?L]_L-_\ !2OPY8_"2RGF'A'1/B?\
M*AK>J^%+221G%I!>1WD(O(T+-L\]1M7"= *^T?@-X'^)7PW^$6A^"OC#\8[C
MX@^)[&U9=;\97.C0:<VJ3M(SF7[+!^[@4;@JQKD*J@9/6NNHH KZM8?VII5S
MIGF^7]IMWBW[<[=RD9QWZUX1_P $N/V&/^':_P"PGX&_8I_X6C_PFG_"%_VG
M_P 5-_8G]G?;/MFJ7=__ ,>_GS^7L^U>7_K&W;-W&[:/?Z* / /V3?V&/^&7
MOVD_C]^T+_PM'^W/^%Y>,-/UW^R/[$^S?V)]FL_LWD^;Y\GVG=][?LBQTVGK
M6/\ !W_@G;_PJ;XY?M/?&C_A<']H?\-'W&GR_P!F_P#"/^5_PCOV72WL,>9]
MH;[7NW^9]V'&-O/WJ^EZ* /&/^">/[(?_#!7[%OP_P#V0?\ A87_  E?_""Z
M.]A_PD/]D_8?MVZ>67?Y'FR^5_K,8\QNF<\XKYQ\-_\ !+?]MC]COQCXIM?^
M"8G[<WAWP7\-O%_B.ZUQ_A=\1_AS_;=GX=OKEM]P^F7$-S!+'"S_ #"V<%$/
M()))/WK67JOC?P7H7B72?!FN>+]+L]8U[S_[#TF[U"..YU'R$$DWD1,P:;RT
M(9]@.U2"<"@#YX\3_P#!//Q#^TS^PKXJ_8U_X*(_M#7/Q:N_&4\D^H^+M+\,
M6WA]].<212VGV&WA,BPFVDB1T9VD+D'S-P9E/F6@?L6_\%M-$\.P?"*/_@K]
MX1?P]9P"VM_&MQ\"(;CQ0]NH 42-)>FU>8(,&=HV+'YV4DFONBB@".UADM[6
M.":X:5TC"M*PY<@8+''<]:^,/C?_ ,$X_P!K7P]^W#XO_;E_8 _; T#P!JOQ
M0T#2]+^)WACQQX#.N:?J$FG1-!97T!CN8)(9HH69/+R4;<Q)YQ7VG10!\=_\
M$]?^"5?BS]B;]J?XO_M:_$/]K;5?BEXF^,VG:./$MSK'AB*PD2^LUE$DR-%,
MR"!O-"16ZQH((HHTWR8W'T7_ ()E_L,?\.Z/V3M/_9?_ .%H_P#"8_8/$&KZ
MG_;G]B?V?O\ MU_-=^7Y/GS8V>;LW;SNVYPN<#W^J0\2^'#K7_"-C7[+^T=F
M_P"P?:D\_;C.=F=V,<YQ0!\<^"_^"+GPMC_X)>^)/^"8WQ?^*=[XDTGQ!KVK
M:Q#XMTS21IMWIUY=:K)J=M-!&9I@)+>9DP2^) A!"ARM>1?M._\ !&'_ (*-
M?M\?LOWG[(W[9_\ P5=TS4/#-FEL=&OO"_P@2UNM7NK>5&BN]8S?#[3M17(@
MA:)3,T<K,YB"M^F%5;'7-%U2ZN;'3-8M;B:SDV7<,%PKM W]UP#E3P>#Z4 .
MTFP_LO2K;3/-\S[-;I%OVXW;5 SCMTKP#Q=^P5_PE7_!3WPC_P %'_\ A:WD
M?\(M\)[WP5_PAO\ 86[[5]HO&N?M?VOSQLV[MOE>2V<9WCI7T/10!\&_\%,_
M^"&7@W_@H/\ M9?#+]K[PO\ 'JX^'7B'P5=6*^*X+;PW_:$7BVRLM0AOK.WF
M NH!"\4B2@2D2G$JC;B-0?<_BK^PQ_PLW_@HA\*/V]O^%H_8O^%8^#]=T+_A
M%/[$\W^TO[25!YWVKSU\GR]GW/*?=G[RU[GJOB'0-">"+6]<L[-KJ3R[9;JY
M2,S/Q\J[B-QY' ]:N4 > ?LF_L,?\,O?M)_'[]H7_A:/]N?\+R\8:?KO]D?V
M)]F_L3[-9_9O)\WSY/M.[[V_9%CIM/6LSX'?\$Y_"_PN_: _:8^,'C?QO!XM
MT7]I.]TU]7\)7.A?9X].M;;3'L);9YO/?[4LR.Q)V1;0=N&ZU]$3:YHEOJL6
M@W&L6J7T\9>"R>X42R*,Y94)R1P>0.U6J /@#X1?\$S_ /@IQ^QOX/C_ &=O
MV)O^"F7ANU^$VGR2)X2TSXG_  H&M:QX6LV<LMI!=Q7D"WD:%CL\Y!M&$ VJ
M*^U?@?X,^(?P\^$VA>"_BS\7+CQYXET^Q$>M>,+K2(-/?5;C)+3?9H/W4 .<
M!$X4 #GK6]I'B'0/$"2RZ!KEG?+!(8YFL[E)1&_]UMI.#[&K-Q<6]G;R7=W.
MD442%Y99&"JB@9))/  '>@#P/]K+]AC_ (:A_:3^ /[0O_"T?[#_ .%&^,-0
MUW^R/[$^T_VW]IL_LWD^;Y\?V;;][?LESTVCK7J^G_ _X+:3\6K[X^Z5\(/"
M]MX[U32UTS4_&MOX?MDU>[LE*,MK+>!/.DA!CC(C9BH,:\?*,=#IFJ:9K5E'
MJ>CZC!=VTHS%<6TRR(XSCAE)!YJ>@#Y._9?_ ."4?P]^"?P'_:)_9R^+/CL>
M/?#/[1'Q:\5>,=<M3HO]G'3[;6X8(7T]2)Y3(T0ARMR/+)9@1&A4$^%W7_!'
M'_@HEK7[.L7_  3P\1_\%64G_9\CT]-$F6#X90Q^,+GPXN$717U#[080GD 0
M&X$.YD&"A4E#^DM% 'S#\>O^"9?@CXHW7[,^F?#3QI'X+\._LT^-+#6=!T"'
M13>+?V=G9&TAL1(9XS!A-O[TB4_+RISFNG_;+_8F_P"&N/B)\#_'O_"S/^$?
M_P"%-?%BV\:_9/[&^U_VQY-M/!]DW>=']GSY^[S<28VXV'.1[O10!\@?M._\
M$U/CKXW_ &T6_;O_ &,_VV_^%/>-M5\ P^$?%L&J?#>V\36&K6,%RUQ!((9K
MFW:WF5FVEU<@JJC:/F+=?H?[!/B&'_@HOX;_ ."A_BWXY1ZIJNC?L_CX;ZGH
M,7A86ZZC<-J2W\FJB87#"$,X91;"-@N[/FG&*]]U/QIX.T3Q'I?@[6?%FF6F
MKZX)SHNE75_''<Z@(%#S&")B&E\M65GV@[003@&M.@#P#Q%^PQ_;_P#P4U\.
M?\%&/^%H^5_PC_P?O/ O_"'?V)N\_P _4!>?;/M?GC;MQL\KR3G[V\=*\1^(
M/[#7_!97QUX)\0? 74?^"K/@6]\&>);.YTZ\\1:A\!XAXAMM/G5HW@0Q7RVK
MR")R@F:,,3\^-U?<-]XAT#2[ZWTO4]<L[>YNVVVEM/<HDDYZ812<L?I5R@#S
M[]E#]FWP#^QY^S;X)_9>^%TUY+H'@;P];Z3IUQJ,H>XG6)<&64J "[MN=MH"
MY8X & /GW_@H-_P3/^.G[6/[57P@_;#_ &;OVTK;X/\ C'X0Z5KEEI=S=_#.
M'Q''=+J<4<,K&.:\@1,1*ZX*OGS,@J5&?KD:YHAU<^'QK%J;\1>:;'[0OG!/
M[VS.[;[XQ5J@#Y4_9X_96_X*G?#SXQZ+XQ_:$_X*R:-\1O!UE),=:\%VO[/&
MG:))J2M!(D8%[#?2/!LE:.3(1MWE[3@,2.L_8_\ V&/^&4?CM\>OC7_PM'^W
M_P#A=_Q B\3_ -F?V)]E_L79:K!]G\SSY/M.=N[?MCZXV]Z]_J#4M3TW1[*3
M4]7U""UMHAF6XN90B(,XR68@#DT ?./PD_X)M^"O!7C+]IK4OB3XQC\7>'?V
ME]<^U:[X:ET<VJZ?9MI:Z=-9F43N;C>@9O,"Q%=V .-U?.ND_P#!'+]OVS_9
MHU#_ ()V7/\ P5,1O@ ="N-#TF,?#.(^*TT5HVCBT>;4/M0B:V1"L3NL2R20
MJ8U,2L-GZ-VMU:WUM'>V5S'-#*@>*6)PRNIY!!'!'O4E 'QMKW_!'#X;^./^
M"8?PW_X)V>.?C!J_]J?"FWTJZ\#_ !2\/6(L-0TG7-.W&UU6WA:241L-[J8S
M(V4=@'5MKJWX?_LL_P#!9P>)]#TKXN_\%3/ USX7T?4[6;4[KPS\"H;;6/$5
MK%*K26\TDMY)!:&95*O)#&2H8[-IP1]ET4 ?'_[6O_!.+XX^*/VO-/\ ^"@'
M[!W[36G_  O^)[^%5\,^,[+Q)X5_MC0_%FE)+YL"W,"S1213PN?EG1MQ553@
M9SE_L:_\$I?BO^S[_P % ?$W_!1SX\?MGW7Q,\:>-OA@/"WB33V\&1Z9:0S"
M^@N$ELO+N7%O;1PVT,"VQ1F+!YFF9I&6OM2B@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH \'_X*A:]^T1X7_P"">'QD\0?LG0:A)\1+3P!J$GA;^QXV>]2<1'<]LJ@L
MUPL>]HPH+&14 !.*_,;_ ()U?L]_\&O?[7'[./@KP3XPUSP5K'Q<UK1;,^,I
M_'_CF_TOQ==^(WC4W9$L]S%*\_VGS,"W)3@;<KR?U_\ VA/CGX,_9H^"WB+X
M\_$2SU6?0O"]@;W5DT33'O+H0!E#ND,?S2;0=Q"Y.U3@'I7Y9_\ !33]MS_@
MVR_;)_9,\;^)-6U7X;>/OB!K_AR[A\&_\(UX-E7QC/K,D++9I"RVR7<<GGF/
M(E(CXQ("N00#[L_:]_:[^''_  2__9R\#>%M%\">(_'WB/5K[3? _P *? .F
M7JR:KXFU+R1'!$UQ,<(H2/?-<R9"@$D,S*K>9>&O^"G7[77P6^-_P]^&/_!2
M/]@S3_A9X?\ BSXDB\.>"_'/A/XEP^(K*UUV=6:UTK4$%M T$DVQE29-\;.,
M8 #,OQ%^U3^S!^U/X>_X)O?L$?M)?M<1?%*,? R=Q\:I/ 6KWEIXJ\/:-J%L
MD,6I"2V/VE9+*&*!9]A\P!Y PQO*^C>&+?\ X(0_'?XJ?"[PE:_\%7?C5\8=
M=O/B!HVH>!/!.J_''Q#XDC?6(KE&M)I[*42+;B-CEI)Q&$3?EE!- 'TG\>?^
M"M?QO\+?\%#O$G_!-#]F?]AB?XB^.M+\%:?XCTW5Y_'<>F::MM.2)YKYWM7^
MR0PDQ*"AF>:29$5$Y8;G[+O_  4U^-GQA\;_ !6_9,^,?['B^"/VC/AGX0;Q
M%I?PW?QQ#<:5XPL9$9;2YLM5$ $<,EQY<$CO"?(:9<ARKHOS/XF_;2^"'[%?
M_!R%\8?%'[1^K'PYX0\0_ OPSILWCF[M7;3]'O?.:2"*\F52+:.<+*JRN0GF
M1HA.7%=G^R)\4?"'_!1'_@O%XI_;L_9BOY]:^$7PO_9ZC^',GCVWMW2P\0:]
M<:N=0>"TD=5^T10Q,V]ER%D"'[LB,P!QG_!OW^U+_P %(/''PGN/#?BS]D&#
MQ%X)O/C3XFB\0?$W6/CA'->:'_IK^;:QZ?)9M)<QV[ 1H5F17'("CBO>]2_X
M*C?M:?M ?%WQUX&_X)H?L%V7Q3\+?#+Q'<>'O%/Q$\7_ !)A\.Z=?ZS;@?:=
M/TU#;SO<F,L$:X;9$&X&5*NWBG_!#/\ ;-_9K_9EL/%W_!.+]H#XE)X1^-5Q
M^T)XM6P\!:WI=U#=7R7-\\UO- QB\N2*2/+)(&VL!D'!!/S7^QK\-OV0/V*?
M%'Q._8[_ ."D_P"WS\?/@!XXT'XDZUJ?A_\ LSXV:WX:\.>+=#NIS-;:K8?9
MG6V>1PQ6501)N R-VY4 /T7T;_@L-X6\0_\ !-SXL?MU6?P&U;3_ !3\%&U;
M3?B+\(]>UA+>\TK7=.V?:-/>[CBD1D(='2X6-E9'!V@[E7R?QK_P6_\ VN?A
MW^S_ .'_ -O_ ,<?\$N=1TO]G&_MM*N]9\5R_$BVD\066GWK11C5$TE;?+VP
MDF78K2)+)&R2LL(8A?-/B5X._8"L/^"&'[9GQ*_X)^?&3QA\0M%\3V6K/XO\
M:^,]9U#49]6UF*QMO,E2ZOT62Z01R1*9E+HSJX#$JV/4/^"H  _X-B_$0 _Y
MM_\ #?\ Z!I] &C\9O\ @M%^TS\"O!NE?MC_ !#_ ."<M]I_[+VHZK812_$B
MY\>VXU^UTJ]G2&UUJ;11"6BMY&EB(A:;S@LJ%PC$H./_ ."U'QNU+]G_ /X*
MS_\ !/\ ^+'ACX7:OXYU2WF^)]GH7A3P_)&EQJU_>Z)I]E:0B64B.&-I[B+S
M)G.V*/?(<A"*W_\ @O$JI_P;=^/T10 /A_X1  ' ']J:37%_\%COCQX>_9D_
MX*=?\$[?CMXP\-:CJFB^'4^(LVNII>F27DUG8/HFFQ7-]Y,09W2UA>2Z?:"P
M2W=@#C% 'T!\)?\ @IQ^T=X._:^\'_L=_P#!1+]C.Q^$^I?%*VNW^%GBOPSX
M^3Q!I&K7=M&)9],GD^S0/;7*QD,I92DI.U<'&;7QK_X*6_'[Q)^U/XK_ &./
M^"=?[']M\6_$OPYMK.3XF^*?$?C>/0-!\.W%U&9;>P$WD327=TT8+,D: 1@C
M<V0RK\_?M3?M8? 7_@JK_P %#_V3_@;^P9X^L?B-#\+?B6/B3\2?&7AI'GTW
MPYIEK;.D-O-<A=GFW4CF,1*2P9%W 9KQ'4?AG^SK^R%_P5 _:/\ !W_!1;]K
MKXV_ K3/BKX['C7X5^-_!?Q5UCPUX;\2V=S%^_M99K)Q#]LM9,1D3%6V]/EV
M;@#]"?V6O^"G-[\</ 'QET?XN?L\:A\.OB]\!+9Y/B)\,-0UV*\15>RDO+.Y
MM;Z*/9/:W,<;[)?+!!5LH1M+^=?L#_\ !5K]L_\ X*->&/AY\<_@K_P3<CT3
MX3^(KF.#Q3XS\3?$^!)K=A(8[IM.M/LJR7T-NZLAF?R?,=)%1"$W-Q/[(7@W
M_@F?JWP__:@^-7["?[4/C[XP>)+CX8'2O'_C3QGXRU37DE1+&^:T@BOKY<3L
MBI)D1NXC5D!V[@*]I_X(!PQ0?\$:_P!GM(8E0'P#$Q"K@9,\I)^I))/N: /K
MG5M-M=9TNYT>]W^3=V[PS>6Y5MK*5.".0<'J.E?B[_P4J_8\_P"#;K]DSX5>
M/O@/X+T'3= _:(T71B/ FE>$/$VM7WC)?$L]JL^E>7MFED>2666V;,F4*RY)
M Y'[)?$+QSH/PP\ ZY\2O%37"Z7X>T>YU/4FM;9YI1;P1-+)LC0%I&VH<*H)
M)P!R:_,_]O3_ (*T?\&_O[3?[*/C;2]<\=^"?BIKOBOPW<6FA>%],\%7%SX@
MU+4I(&BM(X4>V6>WN!)Y821BAB*J=RX% #_^"AGQO_;@^ W_  0X^!_P@^(7
MQ!U'PY\<_C)JW@SX8^)/%*78.H:9?:E&3>2F5#_Q\^3;S1O(IR'=V5@0&'#_
M /!4C_@GQ^S!_P $6OV8O"'_  4D_P""?/@FZ\!^,/@QXQT-?$][8ZS<R/XS
MT*ZO(;.]LM2$CE;HRM+&Y<@%6#%=O&UO[1_[*'[;-Y_P;L_L\ZY\0/ ^N>)/
MB[^S]XA\+_$:_P#"=RKS:I<6^FSSXLV4@N9X=/N5W1G+YMW3YFX,G_!5O_@H
M/^RQ_P %E/V5O!W_  3A_P""?/Q'_P"%@^,_CAXQT+^V-/TG3IQ+X2T.VO(;
MV\O]2WH!:>3Y,:LC'<2QVAL<@'Z\P3PW,"7-O(KQR(&1U.0P(R"*=7C_ ,;O
MVT/@A^S;\>OA#^R]XXBU8>(_C-?ZCI_@>#3-.$T ;3X(IIS.^X&)%CE3!PW?
MIBO8* /C3XL_\$(O^"6'Q?\ 'WC?X\_M.?!";QSK_BV_N]1UOQ#XT\8Z@_\
M9\+LTA@MMD\<=E;Q D)Y:J54#+'&:^?O^"+O[1OCKX'_ /!*3]H[XTCQ?K7C
M3X5?!_QSX[N?@%KOBFZ>:?5?"&DVQFM0)F^:6W#Q2HK]CO0!5157R3_@IK_P
M6"_99_:W_;/\3?\ !,;XO_M;+\%O@/X U%['XV^(1;7HUCQ[>Q2%)O#UB;:%
MVMK)71DN;AMK2@%$RAS)]W_"'XB?L%_\%)/^"=WQ&_9@_P""=OQ'T"_\#CP#
MJ7P_ACT/2KFTM-&^U:9)!'"$FBC;"QS*V0#GN2<T ?'/['W_  1@^ '[:O\
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M6UU"LD<JGJK*P(8>QJ>B@"MI&CZ1X?TR'1=!TNVL;.V39;VEI L442_W550
MH]@*LT44 %%%% &<OA#PFGB1O&2^%].&KO#Y3:J+*/[28_[AEQNV^V<5HT44
M %9WB7P?X2\:6::=XQ\+:=JUO'()(X-3L8YT5QT8*X(!]ZT:* &PPPVT*6]O
M$L<<:A41%P% X  '04ZBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M]ZS_ .E)KW2@#'_X0?2/^?F]_P# MJ/^$'TC_GYO?_ MJV** ,?_ (0?2/\
MGYO?_ MJ/^$'TC_GYO?_  +:MBB@#'_X0?2/^?F]_P# MJ/^$'TC_GYO?_ M
MJV** ,?_ (0?2/\ GYO?_ MJ/^$'TC_GYO?_  +:MBB@#'_X0?2/^?F]_P#
MMJ/^$'TC_GYO?_ MJV** ,?_ (0?2/\ GYO?_ MJ/^$'TC_GYO?_  +:MBB@
M#'_X0?2/^?F]_P# MJ/^$'TC_GYO?_ MJV** ,?_ (0?2/\ GYO?_ MJ/^$'
MTC_GYO?_  +:MBB@#'_X0?2/^?F]_P# MJ/^$'TC_GYO?_ MJV** ,?_ (0?
M2/\ GYO?_ MJ/^$'TC_GYO?_  +:MBB@#'_X0?2/^?F]_P# MJ/^$'TC_GYO
M?_ MJV** ,?_ (0?2/\ GYO?_ MJ/^$'TC_GYO?_  +:MBB@#'_X0?2/^?F]
M_P# MJ/^$'TC_GYO?_ MJV** ,?_ (0?2/\ GYO?_ MJ/^$'TC_GYO?_  +:
MMBB@#'_X0?2/^?F]_P# MJ/^$'TC_GYO?_ MJV** ,?_ (0?2/\ GYO?_ MJ
M/^$'TC_GYO?_  +:MBB@#'_X0?2/^?F]_P# MJ/^$'TC_GYO?_ MJV** ,?_
M (0?2/\ GYO?_ MJ/^$'TC_GYO?_  +:MBB@#'_X0?2/^?F]_P# MJ/^$'TC
M_GYO?_ MJV** ,?_ (0?2/\ GYO?_ MJ/^$'TC_GYO?_  +:MBB@#'_X0?2/
M^?F]_P# MJ/^$'TC_GYO?_ MJV** ,?_ (0?2/\ GYO?_ MJ/^$'TC_GYO?_
M  +:MBB@#'_X0?2/^?F]_P# MJ/^$'TC_GYO?_ MJV** ,?_ (0?2/\ GYO?
M_ MJ/^$'TC_GYO?_  +:MBB@#'_X0?2/^?F]_P# MJ/^$'TC_GYO?_ MJV**
M ,?_ (0?2/\ GYO?_ MJ/^$'TC_GYO?_  +:MBB@#'_X0?2/^?F]_P# MJ/^
M$'TC_GYO?_ MJV** ,?_ (0?2/\ GYO?_ MJ/^$'TC_GYO?_  +:MBB@#'_X
M0?2/^?F]_P# MJ/^$'TC_GYO?_ MJV** ,?_ (0?2/\ GYO?_ MJ/^$'TC_G
MYO?_  +:MBB@#'_X0?2/^?F]_P# MJ/^$'TC_GYO?_ MJV** ,?_ (0?2/\
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M@?&K3?".I?\ !+?QA<_#[4/BIIO@:+XI^(/'-GI5I=7-Y-Y<=Q:6HAGGN8B
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M !F^&7AGQ%I6F_$_X:?$W1-.)GTNYN([7S].N;6&-[>6-I$"Q@;?F!8NJ%'
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MW';RZM<Q0L\5HDLGR1M*ZK&';Y5+@G@&O@7XR_\ !5__ (*D_LD^ +K]I/\
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MV$/B>?BO^T)<_'?XHVOA[6K[P?J7A;X>0>';F:7[!BST^&TMYIE:7[0A(F+
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M8:W>ZNKB$6\<3WIV6@0K,6=59FWJ.,9H ]SHK\Y_V>OC3^WQ^QQ_P5@\'_\
M!./]I/\ :V@^/WA#XG?#G4_$NB^(-1\'VFDZYX5FLF(*W'V(".:UE*LBR.-Q
MD8*"HC(DK?\ !=?Q_P#\%;?V8_@5\2OVROV7OVUO!_@#X?>!-#T^YTSPQ;?#
M:UU76-1GDN(+>837-\'AA3?,679&QVK@X)R #](:*YOX.:]JWBKX1>%?%&O7
M?GWVI>&[&ZO9_+5?,FDMT=VVJ !EB3@  9X%?G!_P7N_X*@_M:? KPAXT^&?
M_!.+QO::%XA^#WA>T\7?&?QU-HUIJ,>AVUW<1VNFZ+'%=12PF\NVF:X(=<QV
M]ON'^L% 'ZAT5S?P<U[5O%7PB\*^*->N_/OM2\-V-U>S^6J^9-);H[MM4 #+
M$G   SP*\"_X*Q?MU>-_V'/V?-#F^!W@^P\1_%;XG^.M-\"_"C0M5=A:3:U?
MNRQS7.PAOL\2(\C8(R0BEEW[@ ?4-%?#?[*7[.7_  4$L_C!H_CGQU_P7$LO
MB?+I5^LGQ(^'&F_#704TV6,@K):0/;M]IL=CX"RGYF\OYE&XX^Y* "BBB@ K
MX\^-'[4_QX\)?%?Q!X:\/^._L]E8ZI+#:P?V7:OL0'@9:(D_B2:^PZ_/O]HO
M_DNGBK_L-3?^A5]/PMAZ&(Q5158*24>J3Z^9\/QSB\5A,#2E0J2@W+[+:Z/L
M;7_#9'[2'_11O_*19_\ QFC_ (;(_:0_Z*-_Y2+/_P",UYC17W']F9;_ ,^8
M?^ K_(_,O[:SG_H)J?\ @<O\ST[_ (;(_:0_Z*-_Y2+/_P",T?\ #9'[2'_1
M1O\ RD6?_P 9KS&BC^S,M_Y\P_\  5_D']M9S_T$U/\ P.7^9Z=_PV1^TA_T
M4;_RD6?_ ,9H_P"&R/VD/^BC?^4BS_\ C->8T4?V9EO_ #YA_P" K_(/[:SG
M_H)J?^!R_P ST[_ALC]I#_HHW_E(L_\ XS1_PV1^TA_T4;_RD6?_ ,9KS&BC
M^S,M_P"?,/\ P%?Y!_;6<_\ 034_\#E_F>G?\-D?M(?]%&_\I%G_ /&:/^&R
M/VD/^BC?^4BS_P#C->8T4?V9EO\ SYA_X"O\@_MK.?\ H)J?^!R_S/3O^&R/
MVD/^BC?^4BS_ /C-'_#9'[2'_11O_*19_P#QFO,:*/[,RW_GS#_P%?Y!_;6<
M_P#034_\#E_F>G?\-D?M(?\ 11O_ "D6?_QFOKGX >*M>\;?!W0O%7B>_P#M
M5_>6K/<S^4B;V$C#.U %' '0"OSXK[W_ &5O^3??#'_7D_\ Z->OF>*,)A,/
M@H2I4XQ?-T271]C[3@?,,?B\RJ1KU932A>TI-J_,N[/0:***^&/U$**** "B
MBB@ HHHH **** "BBB@#YZ_8+UB_L/@YJT%MH%Q<K_PG&LGS(B,9^TMQS7MO
M_"2ZO_T*%[_WTM>1_P#!/?\ Y(GJW_8]ZS_Z4FO=* ,?_A)=7_Z%"]_[Z6C_
M (275_\ H4+W_OI:V** ,?\ X275_P#H4+W_ +Z6C_A)=7_Z%"]_[Z6MBB@#
M'_X275_^A0O?^^EH_P"$EU?_ *%"]_[Z6MBB@#'_ .$EU?\ Z%"]_P"^EH_X
M275_^A0O?^^EK8HH Q_^$EU?_H4+W_OI:/\ A)=7_P"A0O?^^EK8HH Q_P#A
M)=7_ .A0O?\ OI:/^$EU?_H4+W_OI:V** ,?_A)=7_Z%"]_[Z6C_ (275_\
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M9V)E(]BML4L"5!&;^U[_ ,$</^"='[>/Q&E^*_[5GP'O_%&N3:9#I\TZ>/\
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M/[O0X=(N?#.JAYH7M(E18D+,Q?<GEHRR;O,5D5PP8!J /S!_X*M?L5_LG_\
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MP7\9_AG\-KFQ^.'[04OQ3U=[R6[M=>3PM::4WV8QILME@M3Y;X978/U;S<=
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M !1110 45^:GB3_D8K__ *_9?_0S5*OM5P?=7]O_ .2__;'YI+Q$Y9-?5O\
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M2O"_^">__)$]6_['O6?_ $I->Z4 %%%% !1110 4444 %%%% !1110 4444
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MHN[U?%5PGAY]3N;V:&=V6.2SO$4*Z@-M;:Y8LQ;V/]M;]L+X#>-?VXK[X5_
MG_@CG<?M3?%OX.PV+:_XR30=(M[?PC/.GVJUM$U74$8BX"MYPC3 0G*DNKA.
MR_9Y_:/_ &L?VD?VQO FO_M*?\$-=:^'4ND6>J6NG?%[7_B#H^J2>&(9K21Y
M$BCA7S@+EX8;=O+(SYBELJI% 'W-1110!X7_ ,$]_P#DB>K?]CWK/_I2:]TK
MPO\ X)[_ /)$]6_['O6?_2DU[I0 4444 %%%% !1110 4444 %%%% !1110
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M@YJS:3J5O%%_PG&LY66$L<_:6YS7MOV+QO\ ]!NR_P# 8_XT ;%%8_V+QO\
M]!NR_P# 8_XT?8O&_P#T&[+_ ,!C_C0!L45C_8O&_P#T&[+_ ,!C_C1]B\;_
M /0;LO\ P&/^- &Q16/]B\;_ /0;LO\ P&/^-'V+QO\ ]!NR_P# 8_XT ;%%
M8_V+QO\ ]!NR_P# 8_XT?8O&_P#T&[+_ ,!C_C0!L45C_8O&_P#T&[+_ ,!C
M_C1]B\;_ /0;LO\ P&/^- &Q16/]B\;_ /0;LO\ P&/^-'V+QO\ ]!NR_P#
M8_XT ;%%8_V+QO\ ]!NR_P# 8_XT?8O&_P#T&[+_ ,!C_C0!L45C_8O&_P#T
M&[+_ ,!C_C1]B\;_ /0;LO\ P&/^- &Q16/]B\;_ /0;LO\ P&/^-'V+QO\
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MK<OASQ_;M<M%!';QDQV\$<:XBBC7Y5&=N3DDD^B?\$PM<_X-2;S]N3P/;?\
M!->"S'QK;^T_^$+,6G>-(V_Y!EV;S#:F@M1_H7VK_6'_ '?GVT ?KE1110!X
M7_P3W_Y(GJW_ &/>L_\ I2:]TKPO_@GO_P D3U;_ +'O6?\ TI->Z4 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110!^:GB3_ )&*_P#^OV7_ -#-4JN^)/\ D8K_
M /Z_9?\ T,U2K]JA\"/YJJ?Q'ZA1115$!1110 4444 %%%% !1110 4444 ?
MH]\-_P#DG>@?]@6U_P#1*UM5B_#?_DG>@?\ 8%M?_1*UM5^,5OXTO5G](X;_
M ':'HOR"OS[_ &B_^2Z>*O\ L-3?^A5^@E?GW^T7_P ET\5?]AJ;_P!"KZCA
M#_?*G^']4?#>(/\ R+Z/^/\ 1G%T445]^?DX4444 %%%% !1110 4444 %%%
M% !7WO\ LK?\F^^&/^O)_P#T:]?!%?>_[*W_ ";[X8_Z\G_]&O7RO%W^X0_Q
M?HS[SP^_Y&M7_ __ $J)Z#1117YZ?K@4444 %%%% !7D_P"V3\9_VCO@3\(X
M_&W[+O[(UW\:O$KZQ#;2>#K+QE9Z&Z6K)(7NOM-VK1D(RHNS&X^9D=#7K%>7
M_M9^ /VHOB/\.+'0_P!DG]H+2_AMXDA\06UQ?:[JWA2+6([C3T#^=:B&1E",
MY*$29RNP^M 'RA_P\L_X+.?]*\OB#_Q)#P[_ /&J] _9<_;A_P""FOQ@^.VA
M?#K]H3_@C9K'PI\'ZC]J_M?Q]=?&S1=7CTOR[666+-I;1B67S)DCA^4_*9@Y
MX4U'^TU^S)_P6.\>_'+7O%O[,7_!3[P=X \"WDD!T'PCJ?P5L]5GT]5MXTE#
MW4D@:7=,LD@)' D"_P -2?LN?LS_ /!8;X??';0O%_[4_P#P4W\'_$+P':?:
MO[=\'Z5\%[/29]0WVLJ0;;N.0M%LG:&4X'S",KT:@#Z_HHHH \+_ .">_P#R
M1/5O^Q[UG_TI->Z5X7_P3W_Y(GJW_8]ZS_Z4FO=* "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH _-3Q)_R,5_\ ]?LO_H9JE5WQ)_R,5_\ ]?LO_H9JE7[5#X$?
MS54_B/U"BBBJ("BBB@ HHHH **** "BBB@ HHHH _1[X;_\ ).] _P"P+:_^
MB5K:K%^&_P#R3O0/^P+:_P#HE:VJ_&*W\:7JS^D<-_NT/1?D%?(?QE_9]_X2
M+XJ:_KO_  EWD_:]3ED\K[!NVY/3/F#/Y5]>5X7X_P#^1TU/_K\?^=>+FV>9
MID5*-7 U.24G9NT7IO\ :3.;,,KP&:TU3Q4.9)W6K6OR:/$?^&8_^IW_ /*;
M_P#;*/\ AF/_ *G?_P IO_VRO5J*\'_B(G&/_05_Y)3_ /D#R?\ 4[AS_GQ_
MY-/_ .2/*?\ AF/_ *G?_P IO_VRC_AF/_J=_P#RF_\ VRO5J*/^(B<8_P#0
M5_Y)3_\ D _U.X<_Y\?^33_^2/*?^&8_^IW_ /*;_P#;*/\ AF/_ *G?_P I
MO_VRO5J*/^(B<8_]!7_DE/\ ^0#_ %.X<_Y\?^33_P#DCRG_ (9C_P"IW_\
M*;_]LH_X9C_ZG?\ \IO_ -LKU:BC_B(G&/\ T%?^24__ ) /]3N'/^?'_DT_
M_DCRG_AF/_J=_P#RF_\ VRC_ (9C_P"IW_\ *;_]LKU:BC_B(G&/_05_Y)3_
M /D _P!3N'/^?'_DT_\ Y(\I_P"&8_\ J=__ "F__;*/^&8_^IW_ /*;_P#;
M*]6HH_XB)QC_ -!7_DE/_P"0#_4[AS_GQ_Y-/_Y(\I_X9C_ZG?\ \IO_ -LK
MZS^ OA[_ (13X0Z'X>^V>?\ 9;5E\[R]F[]XQZ9..OK7D5>W_#/_ )$73O\
MKB?_ $(UZF4\4Y]GM>5''5N>*5TN6*UNE?W8I[-G?E^0Y5E55U,+3Y9-6>LG
MIOU;[&[1117OGKA1110 4444 %%%% 'Y9^)OV%/@G_P44_X*G_'WX;?\%./B
M!XLU1?#,^B/\$OA</'5[H^ER^')=/0R:G:0VLL37<AO!/'-(K-Y<D>UL H*^
MC?V7/^"$?_!,K]C3X[:%^TG^SW\$-8T?QAX;^U?V1J-U\0-:OHX?M%K+:RY@
MN;N2)\PSR+\RG!8$8(!'RWXR_8B_8I_;N_X*U?'OPM_P5MUQ_$FJ>&I=&;X$
M^!?$'CN[TK3(?#,NG0M/=6$5O<0F>0WBS)<?,VUU4LH#(3],?LH_\$=/^"-G
M[*WQ]T#X]?LI_ 7PWHOC[0?M7]@ZG8>/-2O9H?/M9K>?;#->R(^8)IE.4. Q
M(P0" #[+HHHH \+_ .">_P#R1/5O^Q[UG_TI->Z5X7_P3W_Y(GJW_8]ZS_Z4
MFO=* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH _-3Q)_R,5_\ ]?LO_H9JE5WQ
M)_R,5_\ ]?LO_H9JE7[5#X$?S54_B/U"BBBJ("BBB@ HHHH **** "BBB@ H
MHHH _1[X;_\ ).] _P"P+:_^B5K:K%^&_P#R3O0/^P+:_P#HE:VJ_&*W\:7J
MS^D<-_NT/1?D%>%^/_\ D=-3_P"OQ_YU[I7A?C__ )'34_\ K\?^=?'<6_[I
M3_Q?H;F/1117P8!1110 4444 %%%% !1110 4444 %>W_#/_ )$73O\ KB?_
M $(UXA7M_P ,_P#D1=._ZXG_ -"-?4\)_P"_3_P_J@-VBBBOOP"BBB@ HHHH
M **** /E3]H?_@B)_P $L?VK_C'K7[0/[0G[(6C>)?&/B*2%]:URZUG48I+I
MHH(X(R5AN408BBC7A1]WGG)J3]G#_@B;_P $N/V1OC/HW[0W[.?[(VC^%_&7
MA[[1_8VNVNL:C+);>?;2VTN%FN70[H9I4Y4\.2,'!'-_M)?\%C?#OPI_:7U[
M]D;]G']C7XO?'?QKX.MK2;QTOPUT.%]/\.M<QB6""YNYY403O&0X0 C&?FW*
MZKL?LS?\%&OVD?CQ\;M$^%'C[_@E'\;/AKI.J_:?M?C;Q<VG?V=IWE6TLR^;
MY,[/^\>-85PI^>5<X&30!]9T444 >%_\$]_^2)ZM_P!CWK/_ *4FO=*^?OV!
MO$&BZ9\&M6MM0U&.*3_A.=9;:YYQ]I;FO;_^$Q\,?]!J#_OJ@#2HK-_X3'PQ
M_P!!J#_OJC_A,?#'_0:@_P"^J -*BLW_ (3'PQ_T&H/^^J/^$Q\,?]!J#_OJ
M@#2HK-_X3'PQ_P!!J#_OJC_A,?#'_0:@_P"^J -*BLW_ (3'PQ_T&H/^^J/^
M$Q\,?]!J#_OJ@#2HK-_X3'PQ_P!!J#_OJC_A,?#'_0:@_P"^J -*BLW_ (3'
MPQ_T&H/^^J/^$Q\,?]!J#_OJ@#2HK-_X3'PQ_P!!J#_OJC_A,?#'_0:@_P"^
MJ -*BLW_ (3'PQ_T&H/^^J/^$Q\,?]!J#_OJ@#2HK-_X3'PQ_P!!J#_OJC_A
M,?#'_0:@_P"^J -*BLW_ (3'PQ_T&H/^^J/^$Q\,?]!J#_OJ@#2HK-_X3'PQ
M_P!!J#_OJC_A,?#'_0:@_P"^J -*BLW_ (3'PQ_T&H/^^J/^$Q\,?]!J#_OJ
M@#2HK-_X3'PQ_P!!J#_OJC_A,?#'_0:@_P"^J -*BLW_ (3'PQ_T&H/^^J/^
M$Q\,?]!J#_OJ@#2HK-_X3'PQ_P!!J#_OJC_A,?#'_0:@_P"^J -*BLW_ (3'
MPQ_T&H/^^J/^$Q\,?]!J#_OJ@#2HK-_X3'PQ_P!!J#_OJC_A,?#'_0:@_P"^
MJ /SF\2?\C%?_P#7[+_Z&:I5Z_K'[-:WFKW5VOC; EN7<#^S<]6)_P">E5O^
M&8_^IW_\IO\ ]LK[9>(?!\59XG_R2I_\@?A\^#^(G-M4/_)H?_)'E-%>K?\
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MFHH A_L[3_\ GQA_[]"C^SM/_P"?&'_OT*FHH A_L[3_ /GQA_[]"C^SM/\
M^?&'_OT*FHH A_L[3_\ GQA_[]"C^SM/_P"?&'_OT*FHH A_L[3_ /GQA_[]
M"C^SM/\ ^?&'_OT*FHH A_L[3_\ GQA_[]"C^SM/_P"?&'_OT*FHH A_L[3_
M /GQA_[]"C^SM/\ ^?&'_OT*FHH A_L[3_\ GQA_[]"C^SM/_P"?&'_OT*FH
MH A_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*FHH A_L[3_\ GQA_[]"C^SM/_P"?
M&'_OT*FHH A_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*FHH ^>=0 %_. /\ ELW\
MS4-3:C_R$)_^NS?S-0U^,S^-@%%%%2 4444 %%%% !1110 4444 %%%% 'O>
M@6%BVA63-90DFTCR3&/[HJW_ &=I_P#SXP_]^A47A_\ Y -C_P!><7_H JW7
M['1_@Q]$!#_9VG_\^,/_ 'Z%>(>/$2/QEJ21J% NWP , <U[K7A?C_\ Y'34
M_P#K\?\ G7S'%O\ NE/_ !?H!CT445\& 4444 %%%% !1110 4444 %%%% !
M7M7PWLK.7P/ITDEI$S&$Y9HP2?F->*U[?\,_^1%T[_KB?_0C7U/"?^_3_P /
MZH#82QLHV#QV<2L.A6, BI:**^_ **** "BBB@ KS#]K?X%?$_\ : ^% \)_
M!;]IKQ-\)?%6GZI%J6A>+_#=K!=!)XU=1#=VEPIBO;1A(=\#%=Q5"&4J#7I]
M% 'Y^ZE\8/\ @XZ^ S'PYJW['WP%^/=O"=EIXE\&^.YO"US<QC@27-MJ.Z-)
M3U98F*?W:LZ/H'_!P1^UK(-$^*'B/X0?LM^$YSMU"X\%E_%?BUT_BC@EGQ86
M^X942[7="=P4X%??-% &/\//"'_"OO &A^ ?^$GU?6_[#T>VT_\ MKQ!>?:;
M^_\ )B6/[1<RX'FSOMWN^!N=F.!FMBBB@#PO_@GO_P D3U;_ +'O6?\ TI->
MZ5X7_P $]_\ DB>K?]CWK/\ Z4FO=* "BBB@#XX_X*!?\%H_V3_V(/'&F?!=
M_B#;Z[X_'BWP]:^)_".C:#J6JW.D:3?7T$5Q<S"PAD$,XMI6EA@D(DF8QA$?
M> ?H+]E_]K#X _MF?"\?&3]F[QZ?$/A[^T9["2[DTJZL98;J''FP207<44T3
MKN7*N@/(K\P/V[/V6_V]OV!OC?XU^-?P%^&/@OXN_#OXS?M0^!/&J:5<^(SH
M_B:RU^+6;$0:3YT\;6TEI-.B11R,P\@2LS* &W?6_P +O^"S?P2\5_L;_&G]
MJGQ]\&/%O@7Q!\!9;NV^*OPSUVWB_M2QU&&!6BA22,F.=)\HD<_"D#)"JN:
M,3_@L!_P6X\)_P#!+&;0_"WAGX!W7Q3\4WMK'JOB31;+Q&-,B\.:))=QV,5_
M=3_9[C'G7DT<,46P;RLK;E$>&^Z*_G"_;:_;%_8F^(7_  2%^)WC?Q5^V!X)
M\9?M.?'GQWX:\4_$#2M&O))7TJVM]2MWM="MB4Q]FTZS!C^\=TGG/N;<#7Z:
M?\%0O^"ROP1\!_L'^&_B+^R3^T;X>2?XW>*7\&>"_BF\K_V5X:^9DU#6)G*@
MG['&DA1 "SS>6 K ,* .AT/_ (+<^$_''_!6K0O^"9WPT^ =UK/A_5+K6]*N
M?B^?$8BM%UO2-.:]U"PM[06[?:?(W6\$DOG(%EE=0K>5\W<?MT?\%*/&'[/?
M[0?@O]B3]E3]FVX^+WQL\<Z+/KEKX7?Q'%H^G:+HL+M&^IW][)'((XS(KHB*
MA,C1LN58H'_,^?\ ;3_X)$?LV?\ !2S]AK3?V<?VM/"ES\+?@YX%\<Z=XH\5
M&[D<0W=[II"W-X^P%KB[N6DD9@/FDD8\"OM3]M/X6_M/_L\?\%1O _\ P5V_
M9D_9]U3XS>$M3^#$OP[^(G@WPG=6Z:U9V+7_ /:5MJ5C'<.BW.9#&C1A@P5/
M1RR@'K7[&'_!2#XA_%_]I7Q%^PM^V/\ LSM\'_C-H/AB+Q-I^BVWBB+6=+\2
M:&\WD&_L;Q(XRVR;]W)$Z!E/0MA]GUE7XWZ%\9OVH_VC_P#@Y@_9X^+?Q'_9
MIUOX3Z"_P?\ $MMI'A+Q3>VSZ[)I,=M>%M0U"&VDD2T26]GCBBA,C-_HI8XW
MC/[(4 ?G]\9O^"T/[1?P4_:X\ ? ;QI_P2W\8:)X&^(/QKMOAQHWQ0\5>.;.
MQ2ZN9KIH5O;;3XX9IIX6C1YT+M$&4*"REA7Z U^>'_!>#_DLO["W_9Y_A;^4
MU?H?0 4444 %%%% !1110 4V>>"U@>YN9DCCC0M))(P"JH&223T %.K\\O\
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M-!;E5L6O<H+\S&4RI;DQJFX+@!E'O?A__@E__P %5OV9;'XR>,/A%_P4:^'
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MG]TO_DS[MMOVP/V=;RYCM+?XA[I)7"1K_9%V,L3@#F*O2Z_-3PW_ ,C%8?\
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M11(%BBB0*J*.  !P![40Q%&E1E&$7S25FV].C=E9=N^@#Z]O^&?_ "(NG?\
M7$_^A&O$*]O^&?\ R(NG?]<3_P"A&O<X3_WZ?^']4!NT445]^ 4444 %%%%
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MZ&O>:\+\?_\ (Z:G_P!?C_SKYCBW_=*?^+] ,>BBBO@P"BBB@ HHHH ****
M"BBB@ HHHH *]<\ Z[J5KX/L;>'PS=3*L1 E1EPWS'I7D=>W_#/_ )$73O\
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M5D^7S'<O@### QX'IG_! '_@DYHEFNGZ-^S/JEI;J25@M?BEXFC0$G)(5=2
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M/X*?LY?L4:W\&+WP'9:]K7Q%T6X\'_#7X7:78HTNNW]S$8(8(;9!Q#$9$=W
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MA!_UV7^8KZ&KYYT[_D(0?]=E_F*^AJ^BX1^"MZQ_4 HHHK[(#YYU'_D(3_\
M79OYFH:FU'_D(3_]=F_F:AK\9G\; ****D HHHH **** "BBB@ HHHH ****
M /H'P_\ \@&Q_P"O.+_T 5;JIX?_ .0#8_\ 7G%_Z *MU^QT?X,?1 %>%^/_
M /D=-3_Z_'_G7NE>%^/_ /D=-3_Z_'_G7S'%O^Z4_P#%^@&/1117P8!1110
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MKA?^'(7[)O\ T4;XI_\ A;'_ .-4?\.0OV3?^BC?%/\ \+8__&J/]4/^G_\
MY+_]L!W5;'@#_D=-,_Z_$_G7EO\ PY"_9-_Z*-\4_P#PMC_\:H_X<A?LF_\
M11OBG_X6Q_\ C5:4>%/8UHU/;7LT_A[?]O ?8U%?'/\ PY"_9-_Z*-\4_P#P
MMC_\:H_X<A?LF_\ 11OBG_X6Q_\ C5?8 ?7?B#_D WW_ %YR_P#H!KY^KA?^
M'(7[)O\ T4;XI_\ A;'_ .-4?\.0OV3?^BC?%/\ \+8__&J\/-\F_M6<)>TY
M>6_2^_S0'=45PO\ PY"_9-_Z*-\4_P#PMC_\:H_X<A?LF_\ 11OBG_X6Q_\
MC5>/_JA_T_\ _)?_ +8#NJS/!G@OPG\._"UEX(\"^';/2=(TV 0V&FV$ CAM
MXP<A44<*.3P*YC_AR%^R;_T4;XI_^%L?_C5'_#D+]DW_ **-\4__  MC_P#&
MJ?\ JB[6]O\ ^2__ &P'=45PO_#D+]DW_HHWQ3_\+8__ !JN%_::_P""0G[-
M/PH^ GBGXB^&O'_Q)DO](TMI[5+WQBSQ,P8#YE$8)'/J*7^J'_3_ /\ )?\
M[8#W2BO,O!/_  18_96U[P9I&N7OQ$^*"S7NF6\\JQ>-"%#/&K' \K@9-:?_
M  Y"_9-_Z*-\4_\ PMC_ /&J/]4/^G__ )+_ /; =U17"_\ #D+]DW_HHWQ3
M_P#"V/\ \:H_X<A?LF_]%&^*?_A;'_XU1_JA_P!/_P#R7_[8#NJ*X7_AR%^R
M;_T4;XI_^%L?_C5'_#D+]DW_ **-\4__  MC_P#&J/\ 5#_I_P#^2_\ VP'H
M&G?\A"#_ *[+_,5]#5\<_P##D+]DW_HHWQ3_ /"V/_QJC_AR%^R;_P!%&^*?
M_A;'_P"-5[>493_949KGYN:W2VU_-]P/L:BOCG_AR%^R;_T4;XI_^%L?_C5'
M_#D+]DW_ **-\4__  MC_P#&J]D#T#4?^0A/_P!=F_F:AKA?^'(7[)O_ $4;
MXI_^%L?_ (U1_P .0OV3?^BC?%/_ ,+8_P#QJOC'PC=W]O\ ^2__ &P'=45P
MO_#D+]DW_HHWQ3_\+8__ !JC_AR%^R;_ -%&^*?_ (6Q_P#C5+_5#_I__P"2
M_P#VP'=45PO_  Y"_9-_Z*-\4_\ PMC_ /&J/^'(7[)O_11OBG_X6Q_^-4?Z
MH?\ 3_\ \E_^V [JBO"_VFO^"0G[-/PH^ GBGXB^&O'_ ,29+_2-+:>U2]\8
ML\3,& ^91&"1SZBNG\$_\$6/V5M>\&:1KE[\1/B@LU[IEO/*L7C0A0SQJQP/
M*X&31_JA_P!/_P#R7_[8#TVBN%_X<A?LF_\ 11OBG_X6Q_\ C5'_  Y"_9-_
MZ*-\4_\ PMC_ /&J/]4/^G__ )+_ /; =U17"_\ #D+]DW_HHWQ3_P#"V/\
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M[_#/5OC+\<_B)I/A3PKH5OY^K:[K=XL%O;H2%7+-U9F*JJC+,S*J@D@5\J^
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M(CJ2KJRD$,"00010!8HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/4?"GBV.:VT>[^(<OC:TO? ]A>W#B&/4II;0RW,5GO(D,3J",K$90S!C[?\
ML&?LE?&+_@F9_P $T-2/P0TK2_CW\8/%.KS^._%$EIXEATRS\9ZWJ,T#W+VU
M[,ICCC^S*JQ2N K^4KE5\PJ #Y?_ ."^7[7GQ7^-'[/'BW]B3XQ_L)^*OAE\
M,_$/CRTT/5?VD_'ELM_X>T&SM]4C,>KQP::EQ.//\I5A,WD ?:5#NO(K]8_
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M_P +'_LW_A2VG^++7_A'/['\[^V?[;M+2WW?:/.7[/Y/V7=CRY/,WXRFW)]
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MEQ-*X4D[58+DXS0![31110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !6!\3?A1\+?C7X0G^'OQD^&N@>+= NI(WNM#\3:-!?V<S(P=&:&=61B
MK ,"1P0"*WZ* (K"PL=*L8=+TNRBMK:VB6*WM[>,)'%&H 5%4<*H   '  J6
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH SO%_@_PC\0?"]_X(\>^
M%M.US1=5M7MM4TC5[&.YM;R!QAHI8I 4D0C@JP((ZBF^#/!/@SX<>%;#P)\/
M/".F:#H>E6RV^F:-HMA':VEG"O2.*&)52-1V50 *TZ* "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M5G-H]SX]N8+"VT=5\E[YM(O%NDC"_+_Q^&<8'&>G%>J?\$H_B9\/] _X-O\
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M[]H;X?6/BGP?XDM1;ZSHNH;@DRAU=&#(5>-T=5=)$971E5E((!KYF\/_ /!
M;_@F'I^FQZ?XR^#WB/QH]J]K_9-[XW^)&MZE<:1%;3QSPPV4DEWNM(Q)%&66
M+;Y@0*^]1MH XW]LO_E8(_8O_P"R?_$7_P!((*/^"7Q%K_P5Q_X*#:5<,$N5
M\<>!YV@)^812:"Y1\>C '!]J^O\ QG^RY\"?B#^T%X+_ &I_%_@;[7X\^'FG
MZC8^#]=_M.ZC_L^"_C6.[3R$E$,N]%49D1RN,J5->7?M'?\ !(S_ ()[_M8?
M&=_VA_C;\ Y;OQM-9P6MYXBT+QCK&BW%Y%#@1+<?V;=P"XV *H,H8A55<X
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
>**** "BBB@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>biib-20200930_g12.jpg
<TEXT>
begin 644 biib-20200930_g12.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ KA_VF_C+_P ,Y_LV_$+]H3_A&_[9_P"$$\#ZMXB_
MLC[9]G^W?8K.6Y\CS=C^5O\ *V[]C;=V=K8P>XKQ#_@IK_RC<_:#_P"R'^+/
M_3/=4 ?*/P#_ ."M7_!7C]IOX,^&_P!H#X+_ /!"&RU7PIXNTJ+4M!U&3]JC
M1K=KBVD&4<Q36"R)GT90?:OT.TK5KMO#-MKGBNPBTFX:Q2;4;62[61+.0H&D
M0RC"L$.1OX!QFORN_P""/_P@_P""RVK?\$Y?@9K?PA_;-^#.C^!9O ^GR:-H
M.L?"JZNK^WL<<0R7"WJJ\FW(WA ,]J[7]N+X>:%_P4-_X+C^ O\ @G%^T3<7
M][\&_ _[/MS\4-5\#QZA-;6?BK5WUD:; EX(F4SPP+ME12<;UD!!5F! /TDT
MW4]-UBRCU/2-0@NK:49BN+:4.CC.,AE)!Y%)JNL:3H5B^IZYJEM9VT9&^XNY
MUC1<G RS$ <\5^97@GX'^ /^"6__  71^$G[/O['.G3>%OA?^T7\//$<GB[X
M;6=[*^DV.KZ1!]IBU2WAD9A;R21A8&";5(W<9/'G'_!,_P#X)D?LI_MQ?M'_
M +:7C[]KWP3+X]TG2/VOO%VG>'/!VL:I<KI6F7!,+W-^EO%(B/<S))!$97!9
M$ME"%=S9 /V$!!&0:\:_9(_;.\'?M=^(/BWX>\)>$-3TJ3X1?%?4? >K2:B\
M;+?7=I#!*]Q#L)Q$PN% #8;*G(KUNXT32[K1'\.7%FKV4EJ;:2W8G#1%=I4G
MKC;Q7Y'_ /!&_P#X)*?\$Y?%OQP_:5\7>(_V4_#]WJ7PH_:XUC2_AY=R3W.[
M1+2QAT^>TABQ* 5CE9G&[<<GDF@#[A_91_;M\2?'C]K_ /:;_9X\;>&]%T;1
M?@3XCT'3M*UF*X=9+Z*_TXW4CW!D;8I5AM&W QUYKZ6M;JVO;:.\LKB.:&5
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MOAXOPXO_ !M\7V\!>.[+1M2NGMO$>DWMC/(5O(YI7$SQO#O61OFWD,2S(A4
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MER6*CW.:]:T[7]"U>XN+32=:M+J6TDV7<5O<J[0MS\KA22IX/!]*_$WXL?M
M?$_X;_\ ! K]AC]G[X<#QJ+7XTZSX:\+>,5^'$D::_>Z&899KO3].>66)4NK
MD(D2L9$!!=2<,:=\4/V?] ^$NK?#OXM?\$E_^")_[2WP4^*O@GQCIDC:W=:3
MI]MINO:']H5=1T[53'K5R]U'+ 6.YXW?>B_.H)- '[9ZKJ^DZ'9/J>MZG;V=
MM'CS+BZG6-%R<#+,0!S7SGI/[;_C'4_^"N&I_P#!.[_A#]*_X1VR_9]@^(,7
MB%)9#>/=R:R;#[.1GR_*V?/G&[=WQ7RYXW^ WPU_X*C_ /!<OXL? W]L;1I/
M%/PU_9P^'?AMO!_PXU&[D72KW5M9A>ZFU6>!& N)$C'V<;\H!MXR,G!_8C_9
M-^''[&?_  <D^/?A!\&;N^@\'2?LBP:CX:\-76I37,/AR"7Q' 'L+4S,S1V_
MGI/.L6=J&Z95 4*H /U5HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH *X?]IOX-?\ #1G[-OQ"_9[_ .$D_L;_
M (3OP/JWAW^U_L?VC[#]MLY;;S_*WIYNSS=VS>N[;C<N<CN** /*/V%OV8/^
M&+/V/_AW^RC_ ,)Q_P )+_P@/A>VT?\ M_\ LS[']O\ *&/-\CS9?*S_ '=[
M8]37E7[>'_!.;QO^T3\</ ?[9O[*W[0[_"CXV?#JPNM+TSQ+<: FK:;K.CW!
MW3:7J%FTD?F1;RSHZN&C9V8 ML*?5E% 'Q]^R5_P38^,OA/]KN]_X*!_MW_M
M.VGQ5^*B>%6\->$+;0/"HT;0_">EO)YDR6MN997EFE;.Z>1@VUV3!&"/0OV$
M_P!AC_ABG7OC=K?_  M'_A)O^%R?'#6?B'Y7]B?8O[(^WK OV'/GR_:/+\G_
M %V(]V[_ %:XY]_HH *^+_"7_!,7]ISX#?M9^//CI^R3_P % D\&>!OBC\0X
M?&/COX::Y\*+76OM-\PB2]%MJ#7<,EL+A(MO^K?RR01NVX/VA5%_$_AJ/6AX
M;D\0V*ZBR[EL&NT$Q&,YV9W8Q[4 >'?LM_L,?\,U?M8_M!?M0?\ "T?[:_X7
MMX@T74_[#_L3[-_8?]GV!M/+\[SW^T^9G?NV1;>F&ZUG_!7_ ()W>'/AE^U+
M^TS^T)XP\<P>*=(_:3_L&/5/!UUH/DQ:9;:?I4FG2P/-Y[_:UG25F/[N+8/E
M^?.ZOH^B@#X ^$O_  3,_P""F'[&GA0?L]_L-_\ !2OPY8_"2RGF'A'1/B?\
M*AK>J^%+221G%I!>1WD(O(T+-L\]1M7"= *^T?@-X'^)7PW^$6A^"OC#\8[C
MX@^)[&U9=;\97.C0:<VJ3M(SF7[+!^[@4;@JQKD*J@9/6NNHH KZM8?VII5S
MIGF^7]IMWBW[<[=RD9QWZUX1_P $N/V&/^':_P"PGX&_8I_X6C_PFG_"%_VG
M_P 5-_8G]G?;/MFJ7=__ ,>_GS^7L^U>7_K&W;-W&[:/?Z* / /V3?V&/^&7
MOVD_C]^T+_PM'^W/^%Y>,-/UW^R/[$^S?V)]FL_LWD^;Y\GVG=][?LBQTVGK
M6/\ !W_@G;_PJ;XY?M/?&C_A<']H?\-'W&GR_P!F_P#"/^5_PCOV72WL,>9]
MH;[7NW^9]V'&-O/WJ^EZ* /&/^">/[(?_#!7[%OP_P#V0?\ A87_  E?_""Z
M.]A_PD/]D_8?MVZ>67?Y'FR^5_K,8\QNF<\XKYQ\-_\ !+?]MC]COQCXIM?^
M"8G[<WAWP7\-O%_B.ZUQ_A=\1_AS_;=GX=OKEM]P^F7$-S!+'"S_ #"V<%$/
M()))/WK67JOC?P7H7B72?!FN>+]+L]8U[S_[#TF[U"..YU'R$$DWD1,P:;RT
M(9]@.U2"<"@#YX\3_P#!//Q#^TS^PKXJ_8U_X*(_M#7/Q:N_&4\D^H^+M+\,
M6WA]].<212VGV&WA,BPFVDB1T9VD+D'S-P9E/F6@?L6_\%M-$\.P?"*/_@K]
MX1?P]9P"VM_&MQ\"(;CQ0]NH 42-)>FU>8(,&=HV+'YV4DFONBB@".UADM[6
M.":X:5TC"M*PY<@8+''<]:^,/C?_ ,$X_P!K7P]^W#XO_;E_8 _; T#P!JOQ
M0T#2]+^)WACQQX#.N:?J$FG1-!97T!CN8)(9HH69/+R4;<Q)YQ7VG10!\=_\
M$]?^"5?BS]B;]J?XO_M:_$/]K;5?BEXF^,VG:./$MSK'AB*PD2^LUE$DR-%,
MR"!O-"16ZQH((HHTWR8W'T7_ ()E_L,?\.Z/V3M/_9?_ .%H_P#"8_8/$&KZ
MG_;G]B?V?O\ MU_-=^7Y/GS8V>;LW;SNVYPN<#W^J0\2^'#K7_"-C7[+^T=F
M_P"P?:D\_;C.=F=V,<YQ0!\<^"_^"+GPMC_X)>^)/^"8WQ?^*=[XDTGQ!KVK
M:Q#XMTS21IMWIUY=:K)J=M-!&9I@)+>9DP2^) A!"ARM>1?M._\ !&'_ (*-
M?M\?LOWG[(W[9_\ P5=TS4/#-FEL=&OO"_P@2UNM7NK>5&BN]8S?#[3M17(@
MA:)3,T<K,YB"M^F%5;'7-%U2ZN;'3-8M;B:SDV7<,%PKM W]UP#E3P>#Z4 .
MTFP_LO2K;3/-\S[-;I%OVXW;5 SCMTKP#Q=^P5_PE7_!3WPC_P %'_\ A:WD
M?\(M\)[WP5_PAO\ 86[[5]HO&N?M?VOSQLV[MOE>2V<9WCI7T/10!\&_\%,_
M^"&7@W_@H/\ M9?#+]K[PO\ 'JX^'7B'P5=6*^*X+;PW_:$7BVRLM0AOK.WF
M NH!"\4B2@2D2G$JC;B-0?<_BK^PQ_PLW_@HA\*/V]O^%H_8O^%8^#]=T+_A
M%/[$\W^TO[25!YWVKSU\GR]GW/*?=G[RU[GJOB'0-">"+6]<L[-KJ3R[9;JY
M2,S/Q\J[B-QY' ]:N4 > ?LF_L,?\,O?M)_'[]H7_A:/]N?\+R\8:?KO]D?V
M)]F_L3[-9_9O)\WSY/M.[[V_9%CIM/6LSX'?\$Y_"_PN_: _:8^,'C?QO!XM
MT7]I.]TU]7\)7.A?9X].M;;3'L);9YO/?[4LR.Q)V1;0=N&ZU]$3:YHEOJL6
M@W&L6J7T\9>"R>X42R*,Y94)R1P>0.U6J /@#X1?\$S_ /@IQ^QOX/C_ &=O
MV)O^"F7ANU^$VGR2)X2TSXG_  H&M:QX6LV<LMI!=Q7D"WD:%CL\Y!M&$ VJ
M*^U?@?X,^(?P\^$VA>"_BS\7+CQYXET^Q$>M>,+K2(-/?5;C)+3?9H/W4 .<
M!$X4 #GK6]I'B'0/$"2RZ!KEG?+!(8YFL[E)1&_]UMI.#[&K-Q<6]G;R7=W.
MD442%Y99&"JB@9))/  '>@#P/]K+]AC_ (:A_:3^ /[0O_"T?[#_ .%&^,-0
MUW^R/[$^T_VW]IL_LWD^;Y\?V;;][?LESTVCK7J^G_ _X+:3\6K[X^Z5\(/"
M]MX[U32UTS4_&MOX?MDU>[LE*,MK+>!/.DA!CC(C9BH,:\?*,=#IFJ:9K5E'
MJ>CZC!=VTHS%<6TRR(XSCAE)!YJ>@#Y._9?_ ."4?P]^"?P'_:)_9R^+/CL>
M/?#/[1'Q:\5>,=<M3HO]G'3[;6X8(7T]2)Y3(T0ARMR/+)9@1&A4$^%W7_!'
M'_@HEK7[.L7_  3P\1_\%64G_9\CT]-$F6#X90Q^,+GPXN$717U#[080GD 0
M&X$.YD&"A4E#^DM% 'S#\>O^"9?@CXHW7[,^F?#3QI'X+\._LT^-+#6=!T"'
M13>+?V=G9&TAL1(9XS!A-O[TB4_+RISFNG_;+_8F_P"&N/B)\#_'O_"S/^$?
M_P"%-?%BV\:_9/[&^U_VQY-M/!]DW>=']GSY^[S<28VXV'.1[O10!\@?M._\
M$U/CKXW_ &T6_;O_ &,_VV_^%/>-M5\ P^$?%L&J?#>V\36&K6,%RUQ!((9K
MFW:WF5FVEU<@JJC:/F+=?H?[!/B&'_@HOX;_ ."A_BWXY1ZIJNC?L_CX;ZGH
M,7A86ZZC<-J2W\FJB87#"$,X91;"-@N[/FG&*]]U/QIX.T3Q'I?@[6?%FF6F
MKZX)SHNE75_''<Z@(%#S&")B&E\M65GV@[003@&M.@#P#Q%^PQ_;_P#P4U\.
M?\%&/^%H^5_PC_P?O/ O_"'?V)N\_P _4!>?;/M?GC;MQL\KR3G[V\=*\1^(
M/[#7_!97QUX)\0? 74?^"K/@6]\&>);.YTZ\\1:A\!XAXAMM/G5HW@0Q7RVK
MR")R@F:,,3\^-U?<-]XAT#2[ZWTO4]<L[>YNVVVEM/<HDDYZ812<L?I5R@#S
M[]E#]FWP#^QY^S;X)_9>^%TUY+H'@;P];Z3IUQJ,H>XG6)<&64J "[MN=MH"
MY8X & /GW_@H-_P3/^.G[6/[57P@_;#_ &;OVTK;X/\ C'X0Z5KEEI=S=_#.
M'Q''=+J<4<,K&.:\@1,1*ZX*OGS,@J5&?KD:YHAU<^'QK%J;\1>:;'[0OG!/
M[VS.[;[XQ5J@#Y4_9X_96_X*G?#SXQZ+XQ_:$_X*R:-\1O!UE),=:\%VO[/&
MG:))J2M!(D8%[#?2/!LE:.3(1MWE[3@,2.L_8_\ V&/^&4?CM\>OC7_PM'^W
M_P#A=_Q B\3_ -F?V)]E_L79:K!]G\SSY/M.=N[?MCZXV]Z]_J#4M3TW1[*3
M4]7U""UMHAF6XN90B(,XR68@#DT ?./PD_X)M^"O!7C+]IK4OB3XQC\7>'?V
ME]<^U:[X:ET<VJZ?9MI:Z=-9F43N;C>@9O,"Q%=V .-U?.ND_P#!'+]OVS_9
MHU#_ ()V7/\ P5,1O@ ="N-#TF,?#.(^*TT5HVCBT>;4/M0B:V1"L3NL2R20
MJ8U,2L-GZ-VMU:WUM'>V5S'-#*@>*6)PRNIY!!'!'O4E 'QMKW_!'#X;^./^
M"8?PW_X)V>.?C!J_]J?"FWTJZ\#_ !2\/6(L-0TG7-.W&UU6WA:241L-[J8S
M(V4=@'5MKJWX?_LL_P#!9P>)]#TKXN_\%3/ USX7T?4[6;4[KPS\"H;;6/$5
MK%*K26\TDMY)!:&95*O)#&2H8[-IP1]ET4 ?'_[6O_!.+XX^*/VO-/\ ^"@'
M[!W[36G_  O^)[^%5\,^,[+Q)X5_MC0_%FE)+YL"W,"S1213PN?EG1MQ553@
M9SE_L:_\$I?BO^S[_P % ?$W_!1SX\?MGW7Q,\:>-OA@/"WB33V\&1Z9:0S"
M^@N$ELO+N7%O;1PVT,"VQ1F+!YFF9I&6OM2B@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH \'_X*A:]^T1X7_P"">'QD\0?LG0:A)\1+3P!J$GA;^QXV>]2<1'<]LJ@L
MUPL>]HPH+&14 !.*_,;_ ()U?L]_\&O?[7'[./@KP3XPUSP5K'Q<UK1;,^,I
M_'_CF_TOQ==^(WC4W9$L]S%*\_VGS,"W)3@;<KR?U_\ VA/CGX,_9H^"WB+X
M\_$2SU6?0O"]@;W5DT33'O+H0!E#ND,?S2;0=Q"Y.U3@'I7Y9_\ !33]MS_@
MVR_;)_9,\;^)-6U7X;>/OB!K_AR[A\&_\(UX-E7QC/K,D++9I"RVR7<<GGF/
M(E(CXQ("N00#[L_:]_:[^''_  2__9R\#>%M%\">(_'WB/5K[3? _P *? .F
M7JR:KXFU+R1'!$UQ,<(H2/?-<R9"@$D,S*K>9>&O^"G7[77P6^-_P]^&/_!2
M/]@S3_A9X?\ BSXDB\.>"_'/A/XEP^(K*UUV=6:UTK4$%M T$DVQE29-\;.,
M8 #,OQ%^U3^S!^U/X>_X)O?L$?M)?M<1?%*,? R=Q\:I/ 6KWEIXJ\/:-J%L
MD,6I"2V/VE9+*&*!9]A\P!Y PQO*^C>&+?\ X(0_'?XJ?"[PE:_\%7?C5\8=
M=O/B!HVH>!/!.J_''Q#XDC?6(KE&M)I[*42+;B-CEI)Q&$3?EE!- 'TG\>?^
M"M?QO\+?\%#O$G_!-#]F?]AB?XB^.M+\%:?XCTW5Y_'<>F::MM.2)YKYWM7^
MR0PDQ*"AF>:29$5$Y8;G[+O_  4U^-GQA\;_ !6_9,^,?['B^"/VC/AGX0;Q
M%I?PW?QQ#<:5XPL9$9;2YLM5$ $<,EQY<$CO"?(:9<ARKHOS/XF_;2^"'[%?
M_!R%\8?%'[1^K'PYX0\0_ OPSILWCF[M7;3]'O?.:2"*\F52+:.<+*JRN0GF
M1HA.7%=G^R)\4?"'_!1'_@O%XI_;L_9BOY]:^$7PO_9ZC^',GCVWMW2P\0:]
M<:N=0>"TD=5^T10Q,V]ER%D"'[LB,P!QG_!OW^U+_P %(/''PGN/#?BS]D&#
MQ%X)O/C3XFB\0?$W6/CA'->:'_IK^;:QZ?)9M)<QV[ 1H5F17'("CBO>]2_X
M*C?M:?M ?%WQUX&_X)H?L%V7Q3\+?#+Q'<>'O%/Q$\7_ !)A\.Z=?ZS;@?:=
M/TU#;SO<F,L$:X;9$&X&5*NWBG_!#/\ ;-_9K_9EL/%W_!.+]H#XE)X1^-5Q
M^T)XM6P\!:WI=U#=7R7-\\UO- QB\N2*2/+)(&VL!D'!!/S7^QK\-OV0/V*?
M%'Q._8[_ ."D_P"WS\?/@!XXT'XDZUJ?A_\ LSXV:WX:\.>+=#NIS-;:K8?9
MG6V>1PQ6501)N R-VY4 /T7T;_@L-X6\0_\ !-SXL?MU6?P&U;3_ !3\%&U;
M3?B+\(]>UA+>\TK7=.V?:-/>[CBD1D(='2X6-E9'!V@[E7R?QK_P6_\ VN?A
MW^S_ .'_ -O_ ,<?\$N=1TO]G&_MM*N]9\5R_$BVD\066GWK11C5$TE;?+VP
MDF78K2)+)&R2LL(8A?-/B5X._8"L/^"&'[9GQ*_X)^?&3QA\0M%\3V6K/XO\
M:^,]9U#49]6UF*QMO,E2ZOT62Z01R1*9E+HSJX#$JV/4/^"H  _X-B_$0 _Y
MM_\ #?\ Z!I] &C\9O\ @M%^TS\"O!NE?MC_ !#_ ."<M]I_[+VHZK812_$B
MY\>VXU^UTJ]G2&UUJ;11"6BMY&EB(A:;S@LJ%PC$H./_ ."U'QNU+]G_ /X*
MS_\ !/\ ^+'ACX7:OXYU2WF^)]GH7A3P_)&EQJU_>Z)I]E:0B64B.&-I[B+S
M)G.V*/?(<A"*W_\ @O$JI_P;=^/T10 /A_X1  ' ']J:37%_\%COCQX>_9D_
MX*=?\$[?CMXP\-:CJFB^'4^(LVNII>F27DUG8/HFFQ7-]Y,09W2UA>2Z?:"P
M2W=@#C% 'T!\)?\ @IQ^T=X._:^\'_L=_P#!1+]C.Q^$^I?%*VNW^%GBOPSX
M^3Q!I&K7=M&)9],GD^S0/;7*QD,I92DI.U<'&;7QK_X*6_'[Q)^U/XK_ &./
M^"=?[']M\6_$OPYMK.3XF^*?$?C>/0-!\.W%U&9;>P$WD327=TT8+,D: 1@C
M<V0RK\_?M3?M8? 7_@JK_P %#_V3_@;^P9X^L?B-#\+?B6/B3\2?&7AI'GTW
MPYIEK;.D-O-<A=GFW4CF,1*2P9%W 9KQ'4?AG^SK^R%_P5 _:/\ !W_!1;]K
MKXV_ K3/BKX['C7X5^-_!?Q5UCPUX;\2V=S%^_M99K)Q#]LM9,1D3%6V]/EV
M;@#]"?V6O^"G-[\</ 'QET?XN?L\:A\.OB]\!+9Y/B)\,-0UV*\15>RDO+.Y
MM;Z*/9/:W,<;[)?+!!5LH1M+^=?L#_\ !5K]L_\ X*->&/AY\<_@K_P3<CT3
MX3^(KF.#Q3XS\3?$^!)K=A(8[IM.M/LJR7T-NZLAF?R?,=)%1"$W-Q/[(7@W
M_@F?JWP__:@^-7["?[4/C[XP>)+CX8'2O'_C3QGXRU37DE1+&^:T@BOKY<3L
MBI)D1NXC5D!V[@*]I_X(!PQ0?\$:_P!GM(8E0'P#$Q"K@9,\I)^I))/N: /K
MG5M-M=9TNYT>]W^3=V[PS>6Y5MK*5.".0<'J.E?B[_P4J_8\_P"#;K]DSX5>
M/O@/X+T'3= _:(T71B/ FE>$/$VM7WC)?$L]JL^E>7MFED>2666V;,F4*RY)
M Y'[)?$+QSH/PP\ ZY\2O%37"Z7X>T>YU/4FM;9YI1;P1-+)LC0%I&VH<*H)
M)P!R:_,_]O3_ (*T?\&_O[3?[*/C;2]<\=^"?BIKOBOPW<6FA>%],\%7%SX@
MU+4I(&BM(X4>V6>WN!)Y821BAB*J=RX% #_^"AGQO_;@^ W_  0X^!_P@^(7
MQ!U'PY\<_C)JW@SX8^)/%*78.H:9?:E&3>2F5#_Q\^3;S1O(IR'=V5@0&'#_
M /!4C_@GQ^S!_P $6OV8O"'_  4D_P""?/@FZ\!^,/@QXQT-?$][8ZS<R/XS
MT*ZO(;.]LM2$CE;HRM+&Y<@%6#%=O&UO[1_[*'[;-Y_P;L_L\ZY\0/ ^N>)/
MB[^S]XA\+_$:_P#"=RKS:I<6^FSSXLV4@N9X=/N5W1G+YMW3YFX,G_!5O_@H
M/^RQ_P %E/V5O!W_  3A_P""?/Q'_P"%@^,_CAXQT+^V-/TG3IQ+X2T.VO(;
MV\O]2WH!:>3Y,:LC'<2QVAL<@'Z\P3PW,"7-O(KQR(&1U.0P(R"*=7C_ ,;O
MVT/@A^S;\>OA#^R]XXBU8>(_C-?ZCI_@>#3-.$T ;3X(IIS.^X&)%CE3!PW?
MIBO8* /C3XL_\$(O^"6'Q?\ 'WC?X\_M.?!";QSK_BV_N]1UOQ#XT\8Z@_\
M9\+LTA@MMD\<=E;Q D)Y:J54#+'&:^?O^"+O[1OCKX'_ /!*3]H[XTCQ?K7C
M3X5?!_QSX[N?@%KOBFZ>:?5?"&DVQFM0)F^:6W#Q2HK]CO0!5157R3_@IK_P
M6"_99_:W_;/\3?\ !,;XO_M;+\%O@/X U%['XV^(1;7HUCQ[>Q2%)O#UB;:%
MVMK)71DN;AMK2@%$RAS)]W_"'XB?L%_\%)/^"=WQ&_9@_P""=OQ'T"_\#CP#
MJ7P_ACT/2KFTM-&^U:9)!'"$FBC;"QS*V0#GN2<T ?'/['W_  1@^ '[:O\
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M6UU"LD<JGJK*P(8>QJ>B@"MI&CZ1X?TR'1=!TNVL;.V39;VEI L442_W550
MH]@*LT44 %%%% &<OA#PFGB1O&2^%].&KO#Y3:J+*/[28_[AEQNV^V<5HT44
M %9WB7P?X2\:6::=XQ\+:=JUO'()(X-3L8YT5QT8*X(!]ZT:* &PPPVT*6]O
M$L<<:A41%P% X  '04ZBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M.\8^%M4BOM,U:QAO--O8#E+B"5 \<B^S*P(]C7@G[:O[47[9OP:\6^'OAO\
ML:_\$_\ 4?C'JNMV,]UJ&MWOC6U\/Z+H:(ZHHGN9T<RRL6)$,:EBJD\"O=?
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MB#_T,'_DI%_\11_PMKX@_P#0P?\ DI%_\17.45/]I9C_ ,_I_P#@3_S Z/\
MX6U\0?\ H8/_ "4B_P#B*/\ A;7Q!_Z&#_R4B_\ B*YRBC^TLQ_Y_3_\"?\
MF!T?_"VOB#_T,'_DI%_\11_PMKX@_P#0P?\ DI%_\17.44?VEF/_ #^G_P"!
M/_,#H_\ A;7Q!_Z&#_R4B_\ B*/^%M?$'_H8/_)2+_XBN<HH_M+,?^?T_P#P
M)_Y@='_PMKX@_P#0P?\ DI%_\11_PMKX@_\ 0P?^2D7_ ,17.44?VEF/_/Z?
M_@3_ ,P.C_X6U\0?^A@_\E(O_B*/^%M?$'_H8/\ R4B_^(KG**/[2S'_ )_3
M_P# G_F!]!Z//+=:1:W4[[GDMD9VQC)*@D\59JIX?_Y -C_UYQ?^@"K=?J])
MMTHM]D 4445H 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% 'PSIO_!1KXC?#VY_;M^-/Q6\16-SX7_9XU&.V\$^$7M8H&B%O
MX=@OF\R55$DIO+N<*I=B%P%3'.?&/V.?BG_P4_\ V<_CE^RWXT_;)_;(?XEZ
M+^U;87T?B;P!>^$+/3_^$)U-M'?6+3[#)  [HBHUM*K809W88[2N!_P6<TW_
M ((C> _VJ=5\;?M3^$/B]XP\?7/AVQUOXJ_#KX+/?7%IJFD:?AK6]\16T4D=
ML(8D08:62-O+52?E"M7V+\4KG]D#Q[^W-^R]XR^(>L>*++QO)X;\2ZC\$-%6
M 1Z1,TNEQ?V@9@B,/M<=C(/+0R !#*4!PQH ^IZ*** /"_\ @GO_ ,D3U;_L
M>]9_]*37NE>%_P#!/?\ Y(GJW_8]ZS_Z4FO=* "BBB@ HHHH **** "BBB@
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M]XGU6:"SN+R[O;N92\$,2WBI'''\KA=S8*G=Z'\/_@O^W-^P5_P5-^!7AO\
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M?_ MJ/\ A!](_P"?F]_\"VK8HH Q_P#A!](_Y^;W_P "VH_X0?2/^?F]_P#
MMJV** ,?_A!](_Y^;W_P+:C_ (0?2/\ GYO?_ MJV** ,?\ X0?2/^?F]_\
M MJ/^$'TC_GYO?\ P+:MBB@#'_X0?2/^?F]_\"VH_P"$'TC_ )^;W_P+:MBB
M@#'_ .$'TC_GYO?_  +:C_A!](_Y^;W_ ,"VK8HH Q_^$'TC_GYO?_ MJ/\
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MYQ?^@"K=?L='^#'T0&/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\ @6U;%%:@8_\
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MC2Y+M',?[N_@B9XV:&8+(FY3Y9^:@#WRBOS^_;0_X+0_M%_L@?&K3?".I?\
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M_P#(0G_Z[-_,U#7XS/XV 4445(!1110 4444 %%%% !1110 4444 ?0/A_\
MY -C_P!><7_H JW53P__ ,@&Q_Z\XO\ T 5;K]CH_P &/H@"BBBM0/S9_P""
MN?['/[8/A'X\>-/^"EO[)-IX(\6P7G[-&L?#SX@>"O&U]-9W-II8:XO#J&EW
M*(ZB4;SNADVJP0X+%P8_3?\ @E__ ,%*KCX[^,+3]B/]H/\ 9:\1_!WXN^&?
MA=IOB&UT/6=2MM2L]>\/_N[9-0LKZVPLJ>:RJR%5*L^ 6*2!-+_@J+^S'^VE
MXX^&GQ+^*O[+_P"V[K/AG3YOA3J=IJOPIO/AY:>(+'6FBM+HXM"7BN;2YG5_
M*W1NZDA#Y;$8)_P3G_X)P^*_@K\0K?\ ;:_:>_:)UCXG_%C6/A?IOA+3;R\\
M,P:+9>&= 0I=?V9;64+.0WG@-)+*[.S)_#E@P!YQ_P '(W_)L'P/_P"SL/ W
M_HZXK]#J^ ?^"C7_  25_;H_X*!^+X[:Y_X*FZ=X5\ Z-X\T[Q9X,\%#X"V=
M]+HU]9#,!>^_M&&2Z =I&(=0#OP0<"O;H_"7[;W[._["'Q//Q7_:$N?CO\4;
M7P]K5]X/U+PM\/(/#MS-+]@Q9Z?#:6\TRM+]H0D3%@29@" $R0#K_P!OW]D?
M3OV\/V/?'/[(NK^.)_#=KXXTR.QN=;MK$7,EJBW$4K%8V= Q(CVC+8&[/.,'
MX$_;?TW_ (*!?\$/OA;H?[<_AW_@HKXO^,WPR\,^(M*TWXG_  T^)NB:<3/I
M=S<1VOGZ=<VL,;V\L;2(%C V_,"Q=4*/]6?"?]FK_@H//_P3$^'_ ,&-3_;9
MOO"?Q\LM'L;WQ'\2M4\.6_B!OMK2FXN+*:WG=4N(PLAM?,W [8PZX.!7D/BO
M_@DC^W1^V=XN\*Z9_P %1O\ @H7I'CKX9>$O$5OK9^&'P]^'$>AVWB&\MVWP
M'4+DS22/"ISF!1M;.0RL P ,7_@M-)X@^(O[<_[+/P3_ &0[)]/_ &G[74=<
MU[X>>.[[44AT?PQH8MEBU4ZE"T$S7T-S"IA6WC"/N4D2Q@E9.-\/Z9^U%\$/
M^"V7P)\3?\%:_$7A_P ?:QXM\-:_H?[.WBCX:1-I^B^&-3^RJVIQW>G31M<-
M/<V[+&ES]ID0!MOE#)>+ZM_X*%_\$VO%?[6'Q5^&W[5W[./[1EU\)OC/\)GO
M4\*^+1H,>JV-Y8W:!+FPO;.1T$L3@$!@P*>8Y 8D;>+^#G_!,#]J/QW^V7X(
M_;?_ ."D/[9&E?$K6OA99W\?PR\%>"_! T31='NKR+R;B^EWSRRW4S1@ !MH
M0HA!.   ?/\ %IO[4WQO_P""S?[1/C/_ ()$^)_#?P_G\/:=H6@?M!^(_B9&
MVI:/XIUR&U<6*V6G01K/%-:P>;%)<&X2-R<"(G+R=_\ \$0Y=;^'G[6O[5'P
M)_:JT^:\_:<C\2Z+KGQ7\;VNHQSZ3XHTR:T<:1)IJ)! ;2W@@9H_LTBLZ-)D
MRODI%WOQ5_X)>?M5?#3]L+Q[^V;_ ,$V?VS=)^'&H?%A+-_B5X%\;^!AK>C:
ME?6T1BBOX&2>*6VEV$[E&X.SL2<84=Y_P3N_X)O>(_V0?B#\3/VE_C_^T/=_
M%CXR_&"]LI?&OC.70X]+M8K6SB:.TL;.TC=Q!#$C%<[R7VID+MQ0!W/_  4I
M_91U;]N/]@[XI?LG^'M?@TO4_&OA.>RTF_N\^3%>*5EM_-V@D1F6- Y )"EB
M 3@5^<7[7/[7G_!1"Z_X(X^._P!C?XH?\$P/&G@SQ9X>^"]UHOQ!^(NNZQI@
M\'VFF6=@8[N_M+F.X>6ZEE@B;R;:.,D2S*-[!"3^CG[+7[-'[1?P)_9DUKX-
M?%+]M'6?B+XRU"\U6?2_B5JWA]8KC31<[OLR"VDGF646Q(VAGVOMP0H.*^9O
M'G_!*G_@HS^V!IEM\#_^"B?_  4[TWQA\'EO[>?Q+X1^'_PNA\/7OC"."19$
MM[V[2X<V\+.BL\< ^;H"I"LH![A_P1@A\3P?\$F/V<XO&"3+>CX/:#M6<'<(
M/L<?D=>WD^7CVQ7TU570]$T?PSHMGX<\/:7!8Z?I]K';6-E:Q".*WAC4*D:*
M.%55   X  %6J "BBB@ HHHH **** "BBB@#\Y_B5^R?X8_;E_;H^+GQI_8$
M_:V^)_[.7QG^'.I:;X.^*OB'3="LK[1O%I6RCNK1YM.FF*W30V\T:)/((\*=
MH5@,CU7]CC_@D_J_P0_:('[9/[77[8WC/]H'XM66D3Z5X9\1>*K"#3M/\-V<
M^//73].MR8K:24#;)(&)9> %W-N\=_;"_8(_;K\"_MQ^-_V]_@%_P5P\!_ /
M1/&MKIFFWNCZ_P##VRFMKZ.TMDCB%[)=7"PW4ZMYWESE!,D4@B#[% KU[]E/
M]GS_ (*Y^"OCKX<\8_M-_P#!4GP/\2/ 20W,VJ^$-&^#MEI4^J1O:RI \=W%
M*S1JD[PRDJ"&6,KT:@#['HHHH \+_P"">_\ R1/5O^Q[UG_TI->Z5X7_ ,$]
M_P#DB>K?]CWK/_I2:]TH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#YYU'_D(3
M_P#79OYFH:FU'_D(3_\ 79OYFH:_&9_&P"BBBI **** "BBB@ HHHH ****
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M[_X%M0!L45C_ /"#Z1_S\WO_ (%M1_P@^D?\_-[_ .!;4 ;%%8__  @^D?\
M/S>_^!;4?\(/I'_/S>_^!;4 ;%%8_P#P@^D?\_-[_P"!;4?\(/I'_/S>_P#@
M6U &Q16/_P (/I'_ #\WO_@6U'_"#Z1_S\WO_@6U &Q16/\ \(/I'_/S>_\
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MHJ_&9_&P"BBBI **** "BBB@ HHHH **** "BBB@#Z!\/_\ (!L?^O.+_P!
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M#X?_ .0#8_\ 7G%_Z *MU4\/_P#(!L?^O.+_ - %6Z_8Z/\ !CZ( KPOQ_\
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MU<Z8+4$>2RO= 2;R,[AT!Z5ZA110!X7_ ,$]_P#DB>K?]CWK/_I2:]TKPO\
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MCT/X%>"/A!<W7B:'>5TWQ-XAO;J>"WM AQO>WA3[0SC(7=$O5N.0_P""IO\
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MTGQ7^P]^V[X7^'6GV^EM::SX6\6_#.+6K>\G\PLMXEP)HY87"G9Y?*, #P:
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MO_EA^!_\1J\3?^@__P I4?\ Y6?M#^P'^WY_PW)_PEG_ !:?_A%_^$7^P?\
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M-$O[AHI&((V1( #[<HHHH \+_P"">_\ R1/5O^Q[UG_TI->K_$S_ )$74?\
MKB/_ $(5Y1_P3W_Y(GJW_8]ZS_Z4FO5_B9_R(NH_]<1_Z$*Y,?\ [C5_PR_)
M@>(4445^1 %%%% !7XOU^T%?B_7]H?1"_P"9U_W+?^[!_+/TEO\ F5?]Q_\
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M  3EMM3/[(GP"L?#6H:W$L6LZ]<7US?ZE>QJ01&]U=R22B/< WE*RQ[@#MR
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M#Z1_S\WO_@6U;%% &/\ \(/I'_/S>_\ @6U'_"#Z1_S\WO\ X%M6Q10!C_\
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M#X?_ .0#8_\ 7G%_Z *MU4\/_P#(!L?^O.+_ - %6Z_8Z/\ !CZ( KPOQ_\
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M )$74?\ KB/_ $(5Y1_P3W_Y(GJW_8]ZS_Z4FO5_B9_R(NH_]<1_Z$*Y,?\
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M6Z_.K_@V[T[3](^!7[2.DZ38PVMK:_MD^.H;:VMX@D<4:_80J*HP%4   #@
M5^BM !1110 4444 ?/.H_P#(0G_Z[-_,U#4VH_\ (0G_ .NS?S-0U^,S^-@%
M%%<7X^_:*^!GPPWIXY^*>C6,T?W[3[6);@?]LH]S_P#CM=> RW,<UQ"H8*C.
MK-_9A%RE]T4V<N,QV!R^BZV*JQIP764E%?>VD=I7YC_\%"_^3P/%_P#W#_\
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MK=?L='^#'T0!7A?C_P#Y'34_^OQ_YU[I7A?C_P#Y'34_^OQ_YU\QQ;_NE/\
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M_P""@GPW\;^ +7[5_;_A?0/A0FF7=[NM94@\NY$A,>R=H9#Q\RQLO\5?"/\
MPI'_ (-D_P#I+GXP_P#$D-1_^*KVO_@G9\+/^"%WAS]L?P?K7[''_!1;Q)X[
M^)$/]H?\(YX4O_C9>ZO%?9T^Y6XW6DIVR[+<SR#/W3&''*B@#]0J*** /"_^
M">__ "1/5O\ L>]9_P#2DUZO\3/^1%U'_KB/_0A7E'_!/?\ Y(GJW_8]ZS_Z
M4FO5_B9_R(NH_P#7$?\ H0KDQ_\ N-7_  R_)@>(4445^1 %%%% !1110 44
M44 %%%% !1110 5L> /^1TTS_K\3^=8];'@#_D=-,_Z_$_G73@O]\I_XE^:
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M7@N*^%LRQ4<-@\?1J5)7M&%6$I.R;=HJ3;LDV[+9-F-\4_B!^U_H?[6WPL\
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M %%%% !7M_PS_P"1%T[_ *XG_P!"->(5[?\ #/\ Y$73O^N)_P#0C7U/"?\
MOT_\/ZH#=HHHK[\ HHHH **** "O&?VYO&>A>"/A!8ZCXB_8SUOXYVUSXEM+
M5O!^@^'K/4Y;8NLG^GO#=L(Q'$ 0SCYAY@P.37LU% 'Y\_M(?%KX+_ 7XU:Y
M\)?"W_!O;XW^(EAH\D*V_C+P5\)- FTS41)!'*3 \KHY"%S&V5'SQL.G-:_[
M&?[17@GQW^TGX;\*:1_P0C^)'P9N+K[9Y?Q)U_X::)I]IH^VSG<^9<6TK2Q^
M:%-N-H^9IU4\$UD_$?\ :H_X*Q_M<?MB_%G]GG_@G5_PIWP%X+^"NK6.B>(O
M&/Q0L;[4-0UK5I[**\:.UM[9@D4$:3*I,@)8[65CN*IZ-^RY\,_^"WGA_P".
MVA:O^U]^TW\!_$/P[A^U?\)#H_@SP7?VFI7&;658/)EE8HFVX,+-D<HK@<D4
M ?7]%%% 'A?_  3W_P"2)ZM_V/>L_P#I2:]7^)G_ "(NH_\ 7$?^A"O%_P!@
MNV\22_!S5FTG4K>*+_A.-9RLL)8Y^TMSFO5?'UKXKC\'WSW^JVLD(B&]$@()
M&X=#7)C_ /<:O^&7Y,#R.BBBOR( HHHH **** "BBB@ HHHH **** "MCP!_
MR.FF?]?B?SK'K3\%K<OXKT];.54E-ROENZY .>XKIP7^^4_\2_- >\T5C_8O
M&_\ T&[+_P !C_C1]B\;_P#0;LO_  &/^-?KX&EJ%U]@L)[[R]_DPL^W.,X!
M.,UY_P#\+_\ ^I2_\G__ +772:U9^,ET:[,^LVC(+:3>JVQ!(VG/>O%:^5XC
MS+&X"I35"=KIWT3[=TP/1O\ A?\ _P!2E_Y/_P#VNC_A?_\ U*7_ )/_ /VN
MO.:*^;_UASC_ )^_^2Q_R ]&_P"%_P#_ %*7_D__ /:ZR_&GQ)\(_$7PO>^"
MO'?PPM-6TG4(3%>V%]<B2.53Z@Q]0<$$<@@$$$ UQM%73XESRE44X5FI)W32
MBFFMFG;<BI3IUJ;IU$G%JS3U33W375'XOT445_L&?Y;!7W7_ ,$6_BOI/PIL
M?BAJ>MI;K;3#13)<75\L"1;?M_5F!'.[VZ5\*5]1_P#!-+X%_"GXQWWBZ_\
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M,L=F2JSQ,^9IK73K>^R/I8QC"*C%62-BBL?[%XW_ .@W9?\ @,?\:/L7C?\
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M]-TZD5*+W35T_5,\)U7]AWX,Q7SZU\-+WQ!X'U!SN-WX2UR6W#'MF-BR;?\
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M_*?J'%F!_P!WQ<*\>U:'+)_]Q*7+%?\ @EGYY?\ !0H@_M?^+B#D'^S\$?\
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M@?,(RO1J /K^BBB@#PO_ ()[_P#)$]6_['O6?_2DUZO\3/\ D1=1_P"N(_\
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M_F:AJ;4?^0A/_P!=F_F:AK\9G\; ****D HHHH **** "BBB@ HHHH ****
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MHIH) Z./4$<$4T:IIC:B='748#=K%YK6HF7S F<;MN<[<\9Z5^<?_!*OPO\
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M ()=^']1/A#]I'QOXY^"GBV(?Z9X,^+'PRU;3]0MB.H8PP30GGN)#GM3+/\
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M:7=[6W=]=?S 6O;_ (9_\B+IW_7$_P#H1KQ"O;_AG_R(NG?]<3_Z$:]KA/\
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M_0 HHHKX\ HHHH **** "BBB@ HHHH **** )M._Y"$'_79?YBOH:OGG3O\
MD(0?]=E_F*^AJ^VX1^"MZQ_4 HHHK[(#YYU'_D(3_P#79OYFH:FU'_D(3_\
M79OYFH:_&9_&P"BBBI **** "BBB@ HHHH **** "BBB@#Z!\/\ _(!L?^O.
M+_T 5;JIX?\ ^0#8_P#7G%_Z *MU^QT?X,?1 %>%^/\ _D=-3_Z_'_G7NE>%
M^/\ _D=-3_Z_'_G7S'%O^Z4_\7Z 8]%%%?!@%%%% !1110 4444 %%%% !11
M10 5[?\ #/\ Y$73O^N)_P#0C7B%>W_#/_D1=._ZXG_T(U]3PG_OT_\ #^J
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M4 HHHK[(#YYU'_D(3_\ 79OYFH:FU'_D(3_]=F_F:AK\9G\; ****D HHHH
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M!7^0'QA_PR5_P4]_Z.8^%G_A(77_ ,71_P ,E?\ !3W_ *.8^%G_ (2%U_\
M%U]GT4?V;EW_ #YA_P" K_(#X(^-7P2_X*8?"#X5:Y\3-1_:-^&EQ!HUB;B6
M&T\)3B1P"!A2[%<\]Q6WX:_9B_X*<>(?#FGZ_#^TK\+T2^LHKA$D\(7.Y0Z!
M@#A\9Y[5]*_M=^%/$?CG]FGQCX1\(Z1+?ZE?Z.T5G9P %Y7W*=HSWXKK_A]8
MW>E^ =#TS4+=HI[?1[:*>)^J.L2AE/N""*/[-R[_ )\P_P# 5_D!\D?\,E?\
M%/?^CF/A9_X2%U_\71_PR5_P4]_Z.8^%G_A(77_Q=?9]%']FY=_SYA_X"O\
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M0 4444 %%%% !5.R\1^'M2U&XT?3M=LKB[M#_I5K!=(\D/./G4'*_C7Y^?\
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M 3X6?M2?!'Q/^SS\;/#$6L>%?%^CRZ;K6GR\%XG'WD;JDB,%=''*.BL,%0:
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M^UM^PS\)/VE_$=O'%JOC;X?:5JNL1PIMC6]EMD-P$'9/.\S;[8KV*@ HHHH
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M\7?BKJWQ0\?Z2NF3W5QX9MM3NHHX;>:&!&E)CW&9U"%XQ,RLH*,!]7_MH_\
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MPI10N1(=E?K]6<OA#PFGB1O&2^%].&KO#Y3:J+*/[28_[AEQNV^V<4 >6?\
M!/']G?6?V2_V%/A%^S5XFECDU;P5\/=*TK6GADWQF^CMD%SL/=/.\S;[8KV2
MBB@ HHHH **** "OS?\ ^"]<<;_M'?L%%XU)'[7_ (?QD?[2_P" _*OT@HH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "L7QWXP_X0K2(]5_L[[3YER(
MO+\[9C*L<YP?[OZUM5Q?QU_Y%&V_["2?^BY*X,SK5</@*E2F[22T S?^%_\
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MAEXI\,>/(]?T;6KNTB$UQITLGD0/:72Q?.H=2LN"%.<!@#[+HKY<_:._:/\
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MX*T>"/'7_!+CQQ_P4D\'_!_55NOA]H>MR>*/AKKNH+9WNGZOI1D2[TN:=8Y
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MR37]%U>UCCEAN(A.(89+>ZA>X@S"Z$.LF]'(#  '[#445\1^//\ @J#^T_\
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MK&\=I;22VJ+?![F5(!*_V95!,IP 5H ^RJ*^(O!/_!4+]J'X6_M5> ?V;?\
M@HO^P[8_"BQ^+MY+I_PV\:^&?B+%XAT^35E3S%TF](MH#;W#KQ&XW+(YVJ"
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M^^O?AE\%/ <&F_$N]L+"2Z_L.SU_PI86,.JS1QJS>1;R1Y9P"070 $L 6_\
M!2G_ (*,?LM?MF_MP?L2> OV3O'-I\0=-T']IC1K_P 1^-/#T#S:9ID\J,MM
MIYN]HC:XF3SY3"I+(ML"X7*Y_7RXMX+N![6Z@26*5"DD<BAE=2,$$'J".U5?
M#_AKPYX2TU=&\*^'[+3+-&+)::?:)#$I/)(5  "?I0!=K\K/V%OVP?V=/^"3
MW[5/[6?[*_[?GQ-L_AOJ'C']H#6_BIX%\2>*P\-EXFT/5XK=E%M<;2DLL#0;
M'C!W;W*JI*N%_5.L_7?"?A7Q0]K)XE\-:?J+6,XFLFOK))C;RCHZ;P=C>XP:
M /R)_8 LM8_X*':7_P %/]!^%^AZEX=G^+UZVG^$(]>LWL9GBOO#ES!874T4
M@5X4N(WAGVN P2?D YKS+]A?QY_P3#\#?LH^%OA9^V-_P5%_:8^!'Q1^'?AZ
MVT#Q_P#"W7_V@_$>A-I%]9Q+ ZV5DKA/LKA!)#';[E2-U0 ;<#]TZR=:\!^!
M_$FJVVO>(O!FDW]]9?\ 'G>WNG12RP<Y^1V4E>>>"* /@GQ1_P $]_V7?VC/
M^" US^R1_P $_;C7)O"!\-7VO?!;4M9%S%J U6+4I]4M)@URD<\0DO-RAF56
M$,W3!Y\>_P""/'[0OB7_ (++_M]6O_!1CQWX=N;31/@)\%]+\&:+;75L8XV\
M:ZI;K/K]W ",J8T'V4CC,<D9 YK];:* /Q2^(_PR^ /[)/\ P5K_ &AH_P#@
MH?\ M6_&KX'^&?C'KFF^*/A1\0? GQ/U?PWX?U]!:&.[L+N:Q81+=VS@!!,0
M?+R<@,F_ZG_X)F>$/^"8/B#XR?%OXT_L._M9?$+XR^,H/!=IHWC;Q=XQ\<:K
MXAA6T=II;6WCO;U=DK*89#MCD?RU;D+O&?OK7O#OA_Q3IDFB^)]"L]2LY<>;
M:7]JDT3XZ95P0?RI^CZ+HWAW38M&\/Z3;6-G NV"TLX%BCC'HJJ  /I0!^'G
MA#X6_$_QE_P:]?LJ?&'X7?#Z_P#%LWP6^)ND?$76O#&DVYFNM2TS3==U(74<
M48_UA5)O,(_NQ,>U>J_\%AO^"BW[(W_!6']ANS_X)W_\$]OBC:?%'XE_'7Q#
MH-OI.CZ!8SR2^'K.WU*UOKG4-0#(OV*.%+?8XD*L!(3C:K$?KO6;H_@SP?X=
MU*[UCP_X4TVQN]0???W5G8QQ27+9SF1E +G))R<]: /R_P#^"@_[3WPW_8N_
MX. ?@'\6OC.^H1^$+;]GG6M/\2>)H[&6Y30H)=0*)?W7E*S) )A#&\N,)Y^Y
MB%!-:UY^T#\)O^"HO_!<G]G;QU^Q7XKC\9^"OV:?"GC#5/B)\0M"C=]*%UK=
MA%86FEQW14)--E/-*H6&QGP<H^WZG^('[#WB_P 9?\%4O O[?,?B[25\/>%?
MA#JO@^]\/S12&ZN)[N[6=95.-GEA05()SD]*^A_#WACPUX1TT:-X3\/6.EV8
M=G%KIUHD$88G);:@ R>Y[T ?!O\ P1$1!\>?VY9 @W']K[706QR0+6UP/U/Y
MT?\ !"957QW^VX%4 ?\ #<'C,X [^595^@%% 'XE>#_V7_BM^V3_ ,$7_P#@
MHA^SU\$-)DU#Q5JW[8GC:\T?3(3^\OGL-7TC4&MHQWDE2U:-!W9U'>I?"OQ=
M_P""&WQ5_9RW?'K_ (*Z?M+>&WU'0CIOCCX3>-/VA?%!U&RE>(Q7>DW&EN6D
MN "9(618Y$D' W \_MA63-X#\#W'B5/&=QX,TF36(U"IJSZ=$;E0!@ 2E=PX
M]Z /S8_:A\!_#+X9_MB_\$M_AQ\&HM17P=H5UKUCX4CUDR&Z33HO"\"6JS>8
M XD$2H"& ((P0"*[_P#X*QDC_@I1^P&P.#_PM_Q ,CT_L8U]_44 ?EOJG[7G
M[/'_  3>_P""Z_[1OQ'_ &W/B$/A]X<^*GPV\%R^ O$.L:9=-9:L;"WFM[J.
M.:*)U\Q)#RA.<<U^H6FZC9:QIUOJVFW"S6UU DUO*O1T8!E89]00:FHH _#_
M $3X8_LV?L<_\%%?VE/AE_P4<_;(^.7P(B^)?Q8O_'WPN\6>$_BUK'AGPSXH
MTW4#YDD)ELF6 WEJ^(7\TJ^W8!E5!/UK_P $]O'_ /P2)_9]TG]H#]M;]G+]
ML+QCX_L--TO2F^,/Q-\?^+M3UQ&2RANOLD,5]?)FZ=(W= D+2??AC'S%5K[]
M\1>%_#/B_33HWBSP[8ZI9LX9K34;1)XBPZ':X(R/I4^F:7IFBV$6E:-IT%I:
MP)L@MK6%8XXU]%50 !["@#\+[+X=_M/>!?V@+;_@Z=\8_LVZ8GAG5=>DFUCX
M/P^'T.MZ-\/IK..SA\3AP?FU00K]HE7!S;R'YT3<$^A/^"U/[5?PRT+X]?L!
M?M@^"DG\;>"A\2M1UZ*[\,63WSW&D/I<3RWL,48+R^5;L]QL4%_W1 &[BOU3
MKYL_;._8C\:?M-?M5?LV_'_PWXRTO3K#X)>-]2UO6K&^CD,VH17-C]F6. H"
MH8-\QW$#% 'Q]^W?^V/^SE_P5@_:;_92_9,_8#^)EE\2=3\*_'_0OBEXX\1>
M%XY)K/POH>CI.[M<7&T)#-,TXC1"=P<!64%T#>5?&+X9? C]DW_@L!^T#J?_
M  4)_:E^-7P2\'?&J[T;Q#\*OB-X"^)FK^'-"UIX;+R+S3KZ>P81K=0./W8F
M(Q'N.5\Q _[,Z'X4\+>&)+J7PUX:T_3VOI_.O6L;-(C<2?WWV ;V]SDU+KOA
M_0?%&F2:)XET2TU&RF \ZTOK99HGP<C*."#^(H _/_\ X)K>$?\ @EWXB^//
MQ1^-'[$?[77Q$^-'CFS\ 0Z)XP\5>,/'FJ^(X(;"25YK>V2]O5,<C!XG8)'(
M_EAFR%W\[?\ P;+(B_\ !#CX$*% !T_7,@#UU_4LU]S:+H>B>&],BT7P[H]K
M86<"[8+2RMUBBC'HJJ !^ JU0!^,/_!.+4_^"=3?\&P?P"\(?\%0-6CT[X=^
M)O%FM:;8:S,MZATW5QXAUVXM;A;FS4R63*+>4+.2J D(QQ)M;I/V)/CW%\._
M^"I'PL_9G_X)P?\ !2OX@_M-_!_Q+H&MW/Q>T3QKK?\ PDL'@.W@M=^G7,.L
M>2IA\VX_<+;EFZ;6R70I^NUY9VFH6LEC?VL<\$J%)89D#(ZGJ"#P1[51\,^#
MO"/@JR;3?!WA;3=)MWD+O;Z98QP(S?WBJ  GWH _#C]F/X<?LF?L8?''XV_L
MK?\ !2C]NOX]? 'Q4/BYK?B3P;>:-\9];\,^&O&&@7THFM]1M6MG6V>XZI,"
M=X8*I+,CJGZ(_P#!'OP/_P $][3PU\3OBY^P!\<_&?Q*M/%/C.*'QQXW\9^(
M-1U674]4M;5,-'=WZ*]RJQ3QJ94+H2-H8E"!];>)O!WA'QK9+IOC'PMINK6Z
M2!TM]3L8YT5O[P5P0#[U>L[.TT^UCL;"UC@@B0)%#"@5$4=  . /:@"2BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHKQ?\ X*%_
M%GX@? W]C[Q?\4OA;K_]EZ]I?]G_ &&^^RQ3^5YFH6T+_),CHV8Y'7E3C.1@
M@&N_*\OK9OF=# T6E.K.,(MWLG.2BKV3=KO6R;MT9Y^;9C0R?*Z^/K)N%&$I
MR2M=J$7)I7:5[+2[2OU1[117XO?\/9/^"@/_ $7W_P M72O_ )%H_P"'LG_!
M0'_HOO\ Y:NE?_(M?LW_ !+YQG_T$8?_ ,#J?_*C\2_XF+X)_P"@?$?^ 4__
M )<?M#17Q?\ \$A?VLOV@/VH?^%A?\+T\?\ ]N?V'_9/]E_\2JTMO(\[[;YO
M_'O%'NSY4?WLXV\8R<_:%?D_$W#V-X5SNKE>+E&52GRW<&W'WHJ:LVHO:2OH
MM;^I^O<+\1X'BW(J.:X.,HTZG-9324O=E*#NDY+>+M9O2WH%%%%>$>^%%%?
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M%K47A;49+#Q/XA\)_#77=8TC2[F,D21RWMG9R0DKCYBC.!W/!P ?8E%>5?M
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M_@X8_9\\*_\ !2?X\?L^_'7XGWEE\-_!%IHUIX(GTSX3>(;J]?5 DJ:K'/\
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M_@I3^Q/^SCX.\ ^/_C[\;8_!ND?$VTFN?!UYXDT#4+,7,<5H+R0SK);AK(K
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M+([S311JB(S%G  YKY@_X?W_ +!3_/:Z'\:)XCS'/#\ /$Y21>S+FQ!P1R*
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M;?BI\/\ 5=+\>Z=9"RMO'G@?Q5?:#JYM0<B"2XL98S/&.PEW[?X<9-+\)?\
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M:'5M'\2:N+2.XM791<0^4&4IG@*&PP0HWT=\(OV\_P#@H=^SS^W%\+?V$_\
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MLQ_\%PKA1<7/_!5/X4VTCC=);V_[-^^.)CR55FU8,RCH">2!S7T;^U+^RI\
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MAWQ!JMQ\$/'GA+QMI=C:W%A?7<MW'9ZLEY*DMG)%-/)OF"NK!R%!";VN:?\
M\$J_VJOA[_P09^-G[*MU8:=XL^.WQHN=<\6>)M+T?48;>SDU_5+F*5[6&>YD
M2,+'%%&A=W"ED8@X(S^G5% ''_L]^%M=\#? +P/X*\4V/V74]'\'Z98ZC;>:
MK^3/%:QQR)N0E6PRD94D''!(KYK_ ."RG[+/[1/[0_PW^#OQ*_99\"V/BWQ?
M\$_CYX>^(</@R^UR+31X@MK$7"364=S-^Z@E83*5>0A0%;.3@'[$HH _/G]M
MOX&_MY?\%&/V3?"7QATC]E7_ (4W\</@;\;=,\<?#GP-XN\<Z9JEOXC&GQJQ
MBEN].EDA@CN!<3QA7(8/:KN*1R;QQ7[4'AS_ (*(?\%C9?AS^RM\1_\ @GWK
MGP'^&>D^/M+\2_&'Q1XV\7Z9?27L.GR><NDZ9%92NT_G28_TE@B*$!(_A;].
MZ* /@G]K_P""7[;OP5_X*U^'?^"EO[+/[*L?QIT:^_9\F^&7B+PC8^.=.T*_
MTV1=;_M6.^5]1=(9D8D1; VX88XZ9X_]J7X7_MD^#?\ @I#\*/\ @J='_P $
M_;_XK:--\ H_"7B+X7:=XBTJ?6OAWKDM[]OENK8SRK;7;8D:S>6!\D([;Q&5
M#?I-10!^=W[(OP6_X*+?$W_@M5JG_!13]J?]FBV^'?@+5/V:)_!OA?1U\76&
MHWFCRKK]I=QVE\()26NI52ZN2T*-!'&\41E:12*]2_X)._LN?';]FCQ;^U+J
M?QM\#?V)!\1_VI_$WC#P8_\ :=K<_P!HZ+=QVHM[K%O*YAWF-_W<NR1=OS(,
MC/U_10!\F?\ !<[]F;XW?MB_\$J_BS^S=^SCX)_X2/QIXFL]+30]%_M*VL_M
M+0ZO97$@\ZZDCB3$4,C?.ZYVX&20#ZG^U]^RGI'[9'[$OC;]D3Q?JCZ7'XU\
M$S:.VH)&)#87+1#RI]N</Y<RH^W(W;,9&<U[!10!^6_P'U']LC]F[X0Z!^S9
M\<_^" .F?$GQOX4TJ#1K?Q]X&U3PN-"\4);QB*._DFO6CFLGE"!G66/(8LV
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<H **** "BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>biib-20200930_g13.jpg
<TEXT>
begin 644 biib-20200930_g13.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?@3XCT'3M*UF*X=9+Z*_TXW4CW!D;8I5AM&W QUYKZ6M;JVO;:.\LKB.:&5
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MOAXOPXO_ !M\7V\!>.[+1M2NGMO$>DWMC/(5O(YI7$SQO#O61OFWD,2S(A4
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MER6*CW.:]:T[7]"U>XN+32=:M+J6TDV7<5O<J[0MS\KA22IX/!]*_$WXL?M
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MIBO8* /C3XL_\$(O^"6'Q?\ 'WC?X\_M.?!";QSK_BV_N]1UOQ#XT\8Z@_\
M9\+LTA@MMD\<=E;Q D)Y:J54#+'&:^?O^"+O[1OCKX'_ /!*3]H[XTCQ?K7C
M3X5?!_QSX[N?@%KOBFZ>:?5?"&DVQFM0)F^:6W#Q2HK]CO0!5157R3_@IK_P
M6"_99_:W_;/\3?\ !,;XO_M;+\%O@/X U%['XV^(1;7HUCQ[>Q2%)O#UB;:%
MVMK)71DN;AMK2@%$RAS)]W_"'XB?L%_\%)/^"=WQ&_9@_P""=OQ'T"_\#CP#
MJ7P_ACT/2KFTM-&^U:9)!'"$FBC;"QS*V0#GN2<T ?'/['W_  1@^ '[:O\
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M6UU"LD<JGJK*P(8>QJ>B@"MI&CZ1X?TR'1=!TNVL;.V39;VEI L442_W550
MH]@*LT44 %%%% &<OA#PFGB1O&2^%].&KO#Y3:J+*/[28_[AEQNV^V<5HT44
M %9WB7P?X2\:6::=XQ\+:=JUO'()(X-3L8YT5QT8*X(!]ZT:* &PPPVT*6]O
M$L<<:A41%P% X  '04ZBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MNF:=]C\"V5^\\_A3P];:I;2Z=X<MR4"@PPJ]Q<%=OF7$DA8$H#7[ _\ !/\
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M "BBB@#PO_@GO_R1/5O^Q[UG_P!*37NE>%_\$]_^2)ZM_P!CWK/_ *4FO=*
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M^!;5L44 8_\ P@^D?\_-[_X%M1_P@^D?\_-[_P"!;5L44 8__"#Z1_S\WO\
MX%M1_P (/I'_ #\WO_@6U;%% &/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\ @6U;
M%% &/_P@^D?\_-[_ .!;4?\ "#Z1_P _-[_X%M6Q10!C_P#"#Z1_S\WO_@6U
M'_"#Z1_S\WO_ (%M6Q10!C_\(/I'_/S>_P#@6U'_  @^D?\ /S>_^!;5L44
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M3;P]_P!@.T_]$I6Y0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH \+_X)[_\D3U;_L>]9_\ 2DU[I7A?_!/?_DB>K?\ 8]ZS
M_P"E)KW2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** /S!\3?\ (QZA_P!?TO\
MZ&:HU>\3?\C'J'_7]+_Z&:HT %%%% !1110 4444 %%%% !1110 4444 ?IA
M\,?^2;>'O^P':?\ HE*W*P_AC_R3;P]_V [3_P!$I6Y0 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '
MA?\ P3W_ .2)ZM_V/>L_^E)KW2O"_P#@GO\ \D3U;_L>]9_]*37NE !1110
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M [3_ -$I6Y0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% 'A?_!/?_DB>K?]CWK/_I2:]TKPO_@GO_R1
M/5O^Q[UG_P!*37NE !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?F#XF_Y&/4/^
MOZ7_ -#-4:O>)O\ D8]0_P"OZ7_T,U1H **** "BBB@ HHHH **** "BBB@
MHHHH _3#X8_\DV\/?]@.T_\ 1*5N5A_#'_DFWA[_ + =I_Z)2MR@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** /"_\ @GO_ ,D3U;_L>]9_]*37NE?/7[!?ANPU;X.:M=7,UPK#QQK*
MXBG*C'VENPKVW_A!](_Y^;W_ ,"VH V**Q_^$'TC_GYO?_ MJ/\ A!](_P"?
MF]_\"VH V**Q_P#A!](_Y^;W_P "VH_X0?2/^?F]_P# MJ -BBL?_A!](_Y^
M;W_P+:C_ (0?2/\ GYO?_ MJ -BBL?\ X0?2/^?F]_\  MJ/^$'TC_GYO?\
MP+:@#8HK'_X0?2/^?F]_\"VH_P"$'TC_ )^;W_P+:@#8HK'_ .$'TC_GYO?_
M  +:C_A!](_Y^;W_ ,"VH V**Q_^$'TC_GYO?_ MJ/\ A!](_P"?F]_\"VH
MV**Q_P#A!](_Y^;W_P "VH_X0?2/^?F]_P# MJ -BBL?_A!](_Y^;W_P+:C_
M (0?2/\ GYO?_ MJ -BBL?\ X0?2/^?F]_\  MJ/^$'TC_GYO?\ P+:@#8HK
M'_X0?2/^?F]_\"VH_P"$'TC_ )^;W_P+:@#8HK'_ .$'TC_GYO?_  +:C_A!
M](_Y^;W_ ,"VH V**Q_^$'TC_GYO?_ MJ/\ A!](_P"?F]_\"VH V**Q_P#A
M!](_Y^;W_P "VH_X0?2/^?F]_P# MJ -BBL?_A!](_Y^;W_P+:C_ (0?2/\
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M!](_Y^;W_P "VH_X0?2/^?F]_P# MJ -BBL?_A!](_Y^;W_P+:C_ (0?2/\
MGYO?_ MJ -BBL?\ X0?2/^?F]_\  MJ/^$'TC_GYO?\ P+:@#8HK'_X0?2/^
M?F]_\"VH_P"$'TC_ )^;W_P+:@#8HK'_ .$'TC_GYO?_  +:C_A!](_Y^;W_
M ,"VH V**R[/PEIMC=)=PW%T6C;*A[EB/Q%:E !1110 4444 %%%% !1110
M4444 >%_\$]_^2)ZM_V/>L_^E)KW2O"_^">__)$]6_['O6?_ $I->Z4 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_8#M/_1*5N4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110!X7_P3W_Y(GJW_ &/>L_\ I2:]TKPO_@GO
M_P D3U;_ +'O6?\ TI->Z4 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M4 %%%% !1110 4444 %%%% 'Y@^)O^1CU#_K^E_]#-4:O>)O^1CU#_K^E_\
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M)I6E6OB*XMK#SH[>69)I((642N' ^\2"  010!])T5X3_P $Q?\ E'Y\(_\
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M+-H4WA75'^/UFD]Y)H$$_D_Z"5\_]TMVTY&5A)PHZ >9GO\ 1_B'^SQ\%/\
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M"_\ @GO_ ,D3U;_L>]9_]*37NE>%_P#!/?\ Y(GJW_8]ZS_Z4FO=* "BBB@
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M#Z1_S\WO_@6U'_"#Z1_S\WO_ (%M6Q10!C_\(/I'_/S>_P#@6U'_  @^D?\
M/S>_^!;5L44 8_\ P@^D?\_-[_X%M1_P@^D?\_-[_P"!;5L44 8__"#Z1_S\
MWO\ X%M1_P (/I'_ #\WO_@6U;%% &/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\
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M^!;5L44 8_\ P@^D?\_-[_X%M1_P@^D?\_-[_P"!;5L44 8__"#Z1_S\WO\
MX%M1_P (/I'_ #\WO_@6U;%% &/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\ @6U;
M%% &/_P@^D?\_-[_ .!;4?\ "#Z1_P _-[_X%M6Q10!C_P#"#Z1_S\WO_@6U
M'_"#Z1_S\WO_ (%M6Q10!C_\(/I'_/S>_P#@6U'_  @^D?\ /S>_^!;5L44
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M !1110 4444 %%%% 'Z8?#'_ ))MX>_[ =I_Z)2MRL/X8_\ )-O#W_8#M/\
MT2E;E !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 >%_\$]_^2)ZM_V/>L_^E)KW2O"_^">__)$]6_['
MO6?_ $I->Z4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!^8/B;_D8]0_Z_I?\
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MF'#QNN"RJ&.[S,1@'*?\%8?B]_P6#_8Z^(7A'X_>'OVX?!^D_#/Q/^T!X?\
M">D_#OP_\,[2>[ETF^N&!-WJ%\LK"7RXF4^2B\OE77'/ZBU^>/\ P<C?\FP?
M _\ [.P\#?\ HZXK]";Z^LM,LIM2U*\BM[>WB:6XN)Y B1(HRS,QX4  DD\
M"@#YI_X++?M"_&#]E+_@F+\8/VAO@%XO_L'QAX6\-QW6@ZQ_9]O=?99C=01E
MO*N8Y(G^5V&'1ASTSBO'_P!DOX&?\%)O&/CCPKX\US_@X"T_XBZ-IMY8:CXO
M\!:9\"O"D+7EKN1YK&6YM',UKO7=%YJ@.N<@9%?7'Q0\"_LW_MF_ 6\^'/Q"
M_L/QO\/?&D*V]Q#:ZOOL]51)@X19K>0;QYD/(5N=A!R,BOR\_P""Y?["_P"Q
ME_P31_9[\&_MP_L _"_1_A+\<O"?Q%T2S^'D/@=VLG\5//=)'/I4ULC;+M'@
M\QW!4L1&58E796 /I_\ X*P?M2_M8^&/VGOV;_\ @G]^R;\4]/\ ACJ?Q]UO
M74U?XKZCH,.I/HUII5E'=/;6D%QF%[F<.44R X;8 ,MN7C?AG\6?V\?V&/\
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MM+HVJ/) P/1HV8QGW0U] T %%%% !1110 4444 %%%% !1110 4444 >%_\
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M/\5Y/ 5_HWA+QC;Z_?Z3<13-!-]EBGFL9HVFMUGD#&.42)@L"C D'L/V#_\
M@GE^R_\ L#_#P:1\"O@SI?A_7M:T^S_X3/6XKRXOKW5;J*(*3+>7;R3RQJQ<
MHA;:NX[57)KWBB@#Y%_:)_X(2_\ !+3]J_XKZQ\;?C_^SAJ.O^)=?U!+[5+T
M_$KQ':Q27"(J+(EO;:A'#$0J@#RT7UZDFNNTW_@GE\,?V=?V'?B3^R/^P?HD
M?@M_&6AZPNE3^(O$6IZO#::K>V(M%NI)+V:XG*+LB8QJVWY#@ LQ/T910!\R
M^#?^"47[*5O_ ,$Y?!G_  32^*WA2X\4>!?"FC6$$F-5NK">YO[>3SS?++:R
MQRQ2-=%Y@%< %]N"HQ7-_ #_ ((7?\$X_P!GGXR:1^T#HOPMUWQ1XO\ #DGF
M>&-8^(7C;4M>.C/D$/;17DSQ1N& 99-I=2 58'FOKZB@#QW]LO\ 8%_90_;]
M\$Z;X&_:G^%4/B"'0[_[=X=U*WO[BQU#1[KC]]:W=L\<T+':A(5MK;%W!MHQ
MQ7[)?_!(_P#8?_8S^*EU\>_A;\/]8U;Q_=6!L#XY\<^+;_7=4AM#U@AFO9I/
M(4C(/EA2P)!)'%?2]% 'S+^U?_P2&_8;_;%^+47[0/Q+\ :UHWQ 2P6QF\;^
M!/%U_H.I75JH $,\ME-&)U "J#(&8*JJ"%&*[S]CC]@_]E3]@7P#??#G]E?X
M4P>'+/5]0-_KMY+?3WM]JMV1S/=75R\DT[\G&YR%W':%!(KUZB@#R7X%_L,_
MLL?LU_ #6/V7/@M\+%T?P'K\VI2ZOH+:S>W0N&OPPNR9KB:291(&;A7 7/R[
M:\0^#?\ P01_X)F?!3XIZ)\7-'^#^NZ_J/A6[6Z\(67C;QWJNMV&A3+C9);6
MUY<21!UPI5G#E2H*D$ U]DT4 %%%% !1110 4444 %%%% !1110 4444 %%%
M% 'A?_!/?_DB>K?]CWK/_I2:]TKPO_@GO_R1/5O^Q[UG_P!*37NE !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 ?F#XF_Y&/4/^OZ7_ -#-4:O>)O\ D8]0_P"O
MZ7_T,U1H **** "BBB@ HHHH **** "BBB@ HHHH _3#X8_\DV\/?]@.T_\
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MW:>+].L[BUO/$'A:R^&&A1M<095I+5YH&,D&X93> &7.1R* /JFBBO%?C_\
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M4 %%%% !1110 4444 ?F#XF_Y&/4/^OZ7_T,U1J]XF_Y&/4/^OZ7_P!#-4:
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M*37NE !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 ?F#XF_Y&/4/^OZ7_P!#-4:O
M>)O^1CU#_K^E_P#0S5&@ HHHH **** "BBB@ HHHH **** "BBB@#],/AC_R
M3;P]_P!@.T_]$I6Y6'\,?^2;>'O^P':?^B4K<H *\.\>?\CEJ?\ U^/_ #KW
M&O#O'G_(Y:G_ -?C_P Z ,BBBB@ HHHH **** "BBB@ HHHH **** "O;/AK
M_P B-IW_ %Q/_H1KQ.O;/AK_ ,B-IW_7$_\ H1H W**** "BBB@ HHHH ***
M* "BBB@ HHHH \+_ .">_P#R1/5O^Q[UG_TI->Z5X7_P3W_Y(GJW_8]ZS_Z4
MFO=* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH _,'Q-_R,>H?]?TO_ *&:HU>\
M3?\ (QZA_P!?TO\ Z&:HT %%%% !1110 4444 %%%% !1110 4444 ?IA\,?
M^2;>'O\ L!VG_HE*W*P_AC_R3;P]_P!@.T_]$I6Y0 5X=X\_Y'+4_P#K\?\
MG7N->'>//^1RU/\ Z_'_ )T 9%%%% !1110 4444 %%%% !1110 4444 %>V
M?#7_ )$;3O\ KB?_ $(UXG7MGPU_Y$;3O^N)_P#0C0!N4444 %%%% !1110
M4444 %%%% !1110!X7_P3W_Y(GJW_8]ZS_Z4FO=*\+_X)[_\D3U;_L>]9_\
M2DU[I0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% 'S[?_\ ']/_ -=F_F:AJ:__
M ./Z?_KLW\S4- !1110 4444 %%%% !1110 4444 %%%% 'OOA__ ) -C_UY
MQ?\ H JW53P__P @&Q_Z\XO_ $ 5;H *\.\>?\CEJ?\ U^/_ #KW&O#O'G_(
MY:G_ -?C_P Z ,BBBB@ HHHH **** "BBB@ HHHH **** "O;/AK_P B-IW_
M %Q/_H1KQ.O;/AK_ ,B-IW_7$_\ H1H W**** "BBB@ HHHH **** "BBB@
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M** "BBB@ HHHH **** "BBB@ KVSX:_\B-IW_7$_^A&O$Z]L^&O_ "(VG?\
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M'\0(/#NKZ.FNZ/;:@FDZ_8&UO[(31+((+F$DF&9-VUXR2596':MBBB@#PO\
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M>/!I_CN"QVI:3:GIT%O-.5VQ+$)%,8=8CM(<,]>@_#_]N#_@CS_P4-_X* ?
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MX0?2/^?F]_\  MJV** ,?_A!](_Y^;W_ ,"VH_X0?2/^?F]_\"VK8HH Q_\
MA!](_P"?F]_\"VH_X0?2/^?F]_\  MJV** ,?_A!](_Y^;W_ ,"VH_X0?2/^
M?F]_\"VK8HH Q_\ A!](_P"?F]_\"VH_X0?2/^?F]_\  MJV** ,?_A!](_Y
M^;W_ ,"VH_X0?2/^?F]_\"VK8HH Q_\ A!](_P"?F]_\"VH_X0?2/^?F]_\
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MX;>,$D*BCA1R>!0!\T_&K]M3]N_X1_%+7_!7AS_@E;XI\=Z%!>;/"GBWPO\
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M1110!X7_ ,$]_P#DB>K?]CWK/_I2:]TKPO\ X)[_ /)$]6_['O6?_2DU[I0
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MVSX:_P#(C:=_UQ/_ *$:\3KVSX:_\B-IW_7$_P#H1H W**** "BBB@ HHHH
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MKOAWQ!ITMAK>C:E );>]MI5*212*>&5E)!%?"VA_\&\__!/_ $W]KJ3Q]?\
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MQN\0>*]#EAOM;N=3M)9;EX+>X>40*4CM8(D7$<:Q\#YC7[,?L9_\$Z?V/_\
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M&5K=_LDZ)(A<EOF4L,G!% 'P)^P/\%_CSXE_X.3/'GQ5^+_[0NG?$[Q)X$^
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M7*;[:\LKA98I5_O*ZDAA[@U:KXG_ ."-GP;_ &F/!O[.GP_\?>+/VPKOQ=X
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M(/\ T*N(KM_V;/\ DO?A+_L.0?\ H5 'Z*T444 %%%% !1110 4444 %%%%
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M_A/6;ZRN=:E\*0SQ7>K>'X-0\K4HH594E 'E.'&!F..3.5)S\W_\%$_VD?\
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M/_K\?^=>XUX=X\_Y'+4_^OQ_YT 9%%%% !1110 4444 %%%% !1110 4444
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M_P#UV;^9J&IK_P#X_I_^NS?S-0T %%%% !1110 4444 %%%% !1110 4444
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M[#D'_H5<179_L[K<O\<O"JV<JI*=:A\MW7(!W=Q0!^C-%8_V+QO_ -!NR_\
M 8_XT?8O&_\ T&[+_P !C_C0!L45C_8O&_\ T&[+_P !C_C1]B\;_P#0;LO_
M  &/^- &Q16/]B\;_P#0;LO_  &/^-'V+QO_ -!NR_\  8_XT ;%%8_V+QO_
M -!NR_\  8_XT?8O&_\ T&[+_P !C_C0!L45C_8O&_\ T&[+_P !C_C1]B\;
M_P#0;LO_  &/^- &Q16/]B\;_P#0;LO_  &/^-'V+QO_ -!NR_\  8_XT ;%
M%8_V+QO_ -!NR_\  8_XT?8O&_\ T&[+_P !C_C0!L45C_8O&_\ T&[+_P !
MC_C1]B\;_P#0;LO_  &/^- &Q16/]B\;_P#0;LO_  &/^-'V+QO_ -!NR_\
M 8_XT ;%%8_V+QO_ -!NR_\  8_XT?8O&_\ T&[+_P !C_C0!XK?_P#']/\
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M /0J_%O&S_D28;_KY_[:SR<V_@Q]3AZ***_FP\$**** "BBB@ HHHH ****
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M %%%% !1110!X7_P3W_Y(GJW_8]ZS_Z4FNO_ &M?^3=/%/\ UXI_Z.CKD/\
M@GO_ ,D3U;_L>]9_]*377_M:_P#)NGBG_KQ3_P!'1T ?GQ1110 4444 %%%%
M !1110 4444 %%%% !7;_LV?\E[\)?\ 8<@_]"KB*[?]FS_DO?A+_L.0?^A4
M ?HK1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\^W
M_P#Q_3_]=F_F:AJ:_P#^/Z?_ *[-_,U#0 4444 %%%% !1110 4444 %%%%
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MH_PR_:#_ &BOBMJNO:MX-\.7-MX'\)S>'H]+MO#GVI3'<.Z M)<3M&-N^0@
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M,/\ Y8']K8;L_P /\SZ6HKYI_P"&@/BY_P!#;_Y(6_\ \;H_X: ^+G_0V_\
MDA;_ /QNC_B-7"W_ #YK?^ P_P#E@?VMANS_  _S/T3\/_\ (!L?^O.+_P!
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MJW_8]ZS_ .E)KK_VM?\ DW3Q3_UXI_Z.CKD/^">__)$]6_['O6?_ $I-=?\
MM:_\FZ>*?^O%/_1T= 'Y\4444 %%%0:GJNEZ+9MJ.L:E;VENKJK3W,RQH&9@
MJ@LQ R68*/4D#O0!/115?4-6TK251]5U.WMED?9&;B94#-Z#)Y/M0!8HHHH
M***KV.K:5J;2IINIV]PT#[)A!,KF-O1L'@\=#0!8HHHH *[?]FS_ )+WX2_[
M#D'_ *%7$5V_[-G_ "7OPE_V'(/_ $*@#]%:*** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** /R]\3_\ (RZC_P!?TW_H9JC5[Q/_ ,C+
MJ/\ U_3?^AFJ-?P17_CR]7^9\8]PHHHK(04444 %%%% !1110 4444 %%%%
M'Z:?#'_DFWA[_L!VG_HE*W*P_AC_ ,DV\/?]@.T_]$I6Y7]XX#_<:7^&/Y(^
MRA\""OSG_:6_Y+[XN_[#D_\ Z%7Z,5^>W[1UE;2?';Q6[Q9)UN;)W'^]7S/&
M7 &<^(."IX3+JE.$J<N=^T<DK6:TY83=[OLO4^<XGS*AEN%A.JFTY6TMV\VC
MSBBM+[!:?\\O_'C1]@M/^>7_ (\:_._^):.._P#H)PW_ ('5_P#E)\5_K5E_
M\L_N7_R1FT5I?8+3_GE_X\:/L%I_SR_\>-'_ !+1QW_T$X;_ ,#J_P#RD/\
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M':?^B4K<K^U,!_N-+_#'\D?60^!!7Y]_M%_\ET\5?]AJ;_T*OT$K\^_VB_\
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M>TZ]H_Y%/^R?^GC_ ,<_^O1_9/\ T\?^.?\ UZN44?\ $#/"S_H7_P#E6O\
M_+2?]8,W_P"?O_DL?\BG_9/_ $\?^.?_ %Z/[)_Z>/\ QS_Z]7**/^(&>%G_
M $+_ /RK7_\ EH?ZP9O_ ,_?_)8_Y%/^R?\ IX_\<_\ KT?V3_T\?^.?_7JY
M11_Q SPL_P"A?_Y5K_\ RT/]8,W_ .?O_DL?\BG_ &3_ -/'_CG_ ->C^R?^
MGC_QS_Z]7**/^(&>%G_0O_\ *M?_ .6A_K!F_P#S]_\ )8_Y%/\ LG_IX_\
M'/\ Z]']D_\ 3Q_XY_\ 7JY11_Q SPL_Z%__ )5K_P#RT/\ 6#-_^?O_ )+'
M_(I_V3_T\?\ CG_UZ/[)_P"GC_QS_P"O5RBC_B!GA9_T+_\ RK7_ /EH?ZP9
MO_S]_P#)8_Y'Z._#1=GPX\/KGIHEH/\ R"M;=8OPW_Y)WH'_ &!;7_T2M;5>
M<Z4*#]G!6C'1>BT1^]4&Y4(-]E^05^??[1?_ "73Q5_V&IO_ $*OT$K\^_VB
M_P#DNGBK_L-3?^A5]9PA_OE3_#^J/A/$'_D7T?\ '^C.+HHHK[\_)P)"@LQ
M ')-<Y\)?BCX4^-7PZTKXH^")IGTO6;83V9N(PD@7)&&4$[3QTS7R[_P5)\/
MZ[J/C_X3:]\3?AUXL\7_  -TV_U-_B?X>\'PSSR/.T""PGN[>W823VL<F]F
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MG%W^X0_Q?HSV_#[_ )&M7_ __2HGH-%%%?GI^N!1110 4444 %%%% !1110
M4444 >%_\$]_^2)ZM_V/>L_^E)KK_P!K7_DW3Q3_ ->*?^CHZY#_ ()[_P#)
M$]6_['O6?_2DUU_[6O\ R;IXI_Z\4_\ 1T= 'Y\4444 %%%% !1110 4444
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M]_\ DB>K?]CWK/\ Z4FNO_:U_P"3=/%/_7BG_HZ.N0_X)[_\D3U;_L>]9_\
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M#_P3B^(5IX;TWX(7FBGXS>.WT*SU%9=3U6[AMK/P[;+>0RQ><L$SWEPZJ6C
M@CW(SLK 'ZST5\M?\%@OVYO'G[!/['Q\?_!?PU8ZQ\1O&?BW3/!7PST[5,_9
M9-<U&1DA>4 @LD:)-+M'WC&%) )(^9OV@O'W_!37_@D ?AI^U1^T?^WTWQW^
M&VO>.-,\-?&CP[K/@'3=)&AKJ#>4NK:9-9QHZ1PS?*89"0ZN@X)W( ?I]117
M@'_!1G]L?4_V/_@9!<?#+PU%XE^*?CO6(?"_PA\&E^=8UZYRL1D&1MMH%#7$
M\A(58H6RP++D ]_HKX6_X(#_ +3'[7'[2_[,_P 4)?VU/C-#X\\9> OC]XB\
M&?\ "0VV@6>FQRVVGQ62J$AM(84VF1YG!92^'P2< #[IH **** "BBB@#\U/
M$G_(Q7__ %^R_P#H9JE5WQ)_R,5__P!?LO\ Z&:I5^U0^!'\U5/XC]0HHHJB
M HHHH **** "BBB@ HHHH **** /T>^&_P#R3O0/^P+:_P#HE:VJQ?AO_P D
M[T#_ + MK_Z)6MJOQBM_&EZL_I'#?[M#T7Y!7Y]_M%_\ET\5?]AJ;_T*OT$K
M\^_VB_\ DNGBK_L-3?\ H5?4<(?[Y4_P_JCX;Q!_Y%]'_'^C.+HHHK[\_)PH
MHHH **** "BBB@ HHHH **** "OO?]E;_DWWPQ_UY/\ ^C7KX(K[W_96_P"3
M??#'_7D__HUZ^5XN_P!PA_B_1GWGA]_R-:O^!_\ I43T&BBBOST_7 HHHH *
M*** "BBB@ HHHH **** /"_^">__ "1/5O\ L>]9_P#2DUU_[6O_ ";IXI_Z
M\4_]'1UR'_!/?_DB>K?]CWK/_I2:Z_\ :U_Y-T\4_P#7BG_HZ.@#\^**** "
MBBB@ HHHH **** "BBB@ HHHH *[?]FS_DO?A+_L.0?^A5Q%=O\ LV?\E[\)
M?]AR#_T*@#]%:*** "BBB@ KY#_X*3?\$]_A9^UMXDLOC?X0_:"\4?##XS_#
MGP=J T/Q3X&U6!;Q](N5D\RTO;2976YLY'CDP&"X<-AOO _7E?/_ .VG_P $
MTOV0?VY#'XN^.7P8M]6\7:1HD]AX<\36FN7^E7]FCAV6$75A/#+Y/F.6,98K
M\S?*<G(!\3?\$>?VIOVT_@9\6OV>_P#@G]^T1\5?"WQ.\&?$O]F'3?&G@/5=
M)\.+I>L>#[:WL[81Z??1PNT=Q;B-A#'<D+)*Z G!W+7V!\8?^"0W_!+W]ICQ
M_P"+/C)\:?V0/!?B[Q+XRF4>)?$>J))/=2R00QV@"2^9NMBB0(F(3'@H2?F)
M)K?\$O\ _@E_^SM_P3Q^"/AN/PA\&]%TSXF7G@;2-.^(WBRWO[G4+G4;V"UA
M6X2.ZNW:1;8SHS)"GEQ !,1KM4#D?C+_ ,$"/^";7QO^)?B?XI^)? GC73KW
MQOK%UJGC.P\/?%'6[&QUJ[N7+SRS6T=T(QYA9MPC"+R>* /F3_@DK\5OVE/A
MK^PQ^V%\'_V'9;SXLV/P8^+6O^'/V:)-7U5;I)X1%&8;%+F5PD\%L[I(,L%<
M2$!E5EV_*/\ P4,UW]J#]G[_ ((<ZI^RQ\0_^"8OQ-\)-?>+]'UWXA?%[Q;X
MNT2Z.O>(Y]7M[F[OKE+:X>9I+FX'EI][RT\I"VU,U^\G[//[.7P-_9.^$FD_
M C]G+X9:7X1\):)&R:;HNDQ%8T+$L[LS$O+(S$LTCLSN22S$G-4/VI?V4?@%
M^VG\'+WX ?M,> O^$E\(ZC>6MU>:3_:EU9^9-;3)/"WFVDL4HVR(K8#@'&""
M"10!^=O_  6Q^*7Q/^(7[#G[.'[97QR_9\\0?"N#X9?M=>$?$OCOPKX@U*UN
MYM)TJWNKJV^URRVCO%M9I8"I#<"8 \\5W'_!SYJ&F>/_ /@F7IO[//AC54N?
M$WQA^*GA7P[X&L[*8/+?W<FH13@Q!<EE"1$[AP"R<_,,_?\ \5/A7\.?CA\.
M=:^$7Q=\&:?XB\,^(M/DL=;T35;<2P7<#C#(ZG\P1@@@$$$ U\V_LT?\$2_^
M"=_[*/Q=T?XX?#/X5:S?>(/"UO);^"I?%WC74]:A\,0N-K1Z?#>SR);?+\H8
M N!P&&3D ^F]4\?>!-$\5Z7X#UKQKI-GKFMI,VBZ-=:E%'=WZQ)OE,$+,'E"
M*"S;0=H&3@5^:_Q)\4?\%!/"?_!63QM^U=XY_P""6_C_ .+&A>"])'A?X S^
M&_%NBVUAI.GS(KZEJ>R[N5<WMW)MC,FQ"D$0B^8$FOO;Q_\ LC_L]?%']HOP
M!^UEXZ^'WV[X@?"ZWU*#P+K_ /:UW%_9D>H6YMKL>1'*L$WF1,5S+&Y7.5VG
MFO2* /R9_P"#9?X\_&GQ(WQ[^&_B#]D?Q+H>@:I^T;XUU_4O&UWK5C)::5JD
MDEB'T.2*.0RO<1CDRHIB..&-?K-7G?[.7[*/P"_9*T;Q-X?_ &?? 7_"/V?C
M'QI?^+/$</\ :EU=_:]8O=GVFYS<RR&/?Y:?NT*QKM^55R<^B4 %%%% !111
M0!^:GB3_ )&*_P#^OV7_ -#-4JN^)/\ D8K_ /Z_9?\ T,U2K]JA\"/YJJ?Q
M'ZA1115$!1110 4444 %%%% !1110 4444 ?H]\-_P#DG>@?]@6U_P#1*UM5
MB_#?_DG>@?\ 8%M?_1*UM5^,5OXTO5G](X;_ ':'HOR"OS[_ &B_^2Z>*O\
ML-3?^A5^@E?GW^T7_P ET\5?]AJ;_P!"KZCA#_?*G^']4?#>(/\ R+Z/^/\
M1G%T445]^?DX4444 %%%% !1110 4444 %%%% !7WO\ LK?\F^^&/^O)_P#T
M:]?!%?>_[*W_ ";[X8_Z\G_]&O7RO%W^X0_Q?HS[SP^_Y&M7_ __ $J)Z#11
M17YZ?K@4444 %%%% !1110 4444 %%%% 'A?_!/?_DB>K?\ 8]ZS_P"E)KK_
M -K7_DW3Q3_UXI_Z.CKD/^">_P#R1/5O^Q[UG_TI-=?^UK_R;IXI_P"O%/\
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M ,D[T#_L"VO_ *)6MJOQVM_&EZL_HO#?[M#T7Y!7Y]_M%_\ )=/%7_8:F_\
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MX#'_ !H V**Q_L7C?_H-V7_@,?\ &C[%XW_Z#=E_X#'_ !H _.SQ)_R,5_\
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MBGAJ4Z%"-.33LK72MMY7?YBQM>EB<5.K3BXJ3;LW?5ZO6R_(_1[X;_\ ).]
M_P"P+:_^B5K:KC_AY9^,F\ :&8-9M%0Z/;;%:V)('E+CO6Q]B\;_ /0;LO\
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M_P#4_?\ E*_^VU[%10!X[_PR;_U/W_E*_P#MM'_#)O\ U/W_ )2O_MM>Q44
M>._\,F_]3]_Y2O\ [;1_PR;_ -3]_P"4K_[;7L5% 'CO_#)O_4_?^4K_ .VT
M?\,F_P#4_?\ E*_^VU[%10!X[_PR;_U/W_E*_P#MM=/\%_V:_P#A&/BOX?\
M$/\ PFGG_8]4BE\G^SMN_!Z9\PX_*N[K7\!_\CEIG_7XG\Z /<:*** *GB#_
M ) -]_UYR_\ H!KP*O??$'_(!OO^O.7_ - ->!4 %%%% !1576-;T;P[I[:M
MX@U>UL;5'1'N;RX6*-6=PB*68@ LS*H'<L .35J@ HHHH ***1W2-#)(X55&
M69C@ >M "T57TS5=+UJS74-'U*WN[=R0D]M,LB-@X.&4D&K% !152_\ $&@Z
M5=PV&IZW:6T]R<6\,]RJ/*<XPH)RWX5;H FL/^/Z#_KLO\Q7T%7S[8?\?T'_
M %V7^8KZ"H **** /S4\2?\ (Q7_ /U^R_\ H9JE5WQ)_P C%?\ _7[+_P"A
MFJ5?M4/@1_-53^(_4****H@**** "BBB@ HHHH **** "BBB@#]'OAO_ ,D[
MT#_L"VO_ *)6MJL7X;_\D[T#_L"VO_HE:VJ_&*W\:7JS^D<-_NT/1?D%>%^/
M_P#D=-3_ .OQ_P"=>Z5X7X__ .1TU/\ Z_'_ )U\=Q;_ +I3_P 7Z&YCT445
M\& 4444 %%%% !1110 4444 %%%% !7M_P ,_P#D1=._ZXG_ -"->(5[?\,_
M^1%T[_KB?_0C7U/"?^_3_P /ZH#=HHHK[\ HHHH **** "BBB@ HHHH ****
M /"_^">__)$]6_['O6?_ $I->L?$K_D1M1_ZXC_T(5Y/_P $]_\ DB>K?]CW
MK/\ Z4FO6/B5_P B-J/_ %Q'_H0H \3HHHH **** "BBB@ HHHH **** "BB
MB@ K7\!_\CEIG_7XG\ZR*U_ ?_(Y:9_U^)_.@#W&BBB@"IX@_P"0#??]><O_
M * :\"KWWQ!_R ;[_KSE_P#0#7@5 !1110!^5/\ P44_:7^/G[1WQ]^-O[*6
MG_M+Z?\ "[PW\)]6\"Q:7X2MM#LI]8\92ZAJ%C,VH"6\#%(+61XRJP(=Q5/,
M(#%6_0W]F/X9?M!_"CP?J/AK]H?]I=_BG?MJS3:1X@N/"5IH]Q!9&*,"WFCM
M,12NLBR-YH5,AP"ORY/PE_P6M^,?_!*KXD>'/$7PK_:?\+:39?%'POK6B6FF
MZAXH\)W=G=W&G/J-E+<M8ZBL8$]O]EEN-RQRDJ1(=JL :[[_ ((GQZO;>,OC
ME9?!;7_&^I_LU0Z_I"_ B\\=/>/(W^B.=46Q:] G:Q6?RA&6&TX."6\PD \C
M_:7_ &"?@/\ LB_\%4?V0OB#\-KGQ3J7B'QG\2/$!\0ZYXL\67>ISSJE@)$C
M43.8XE5I7P$5>" 2<"OT:_:/_9I^"'[7'PFOO@;^T1X%C\2>%=2G@FOM)EO9
M[=97AE66,[[>1)!M=5/##..<BOS0_P""D/\ P5)_8'\1_P#!0S]EW7]%_:-T
MV>S^$_Q%\1?\+#G73+T#1MUHEN-X, +_ +U'3]WNY'IS7Z>? KX[?";]I?X4
MZ1\</@;XRA\0>%==25])UBW@EC2X6.9X7(655<8DC=>5'W?3!H _*#]O[_@D
M)_P3GT[]K[]GG]AW]EW]FJST'Q)X[\5R>(/'>J0:_J5T]EX4TY&>YC*W%S(B
M?:6W1H^W.^$@?>P?I7_@IS#<_M6?M]?L^?\ !,_Q)K=_;?#OQ39ZSXN^*.EZ
M??26[:[9V$1^R6$CQE6\AYU?S$!&X%2"&133/^"7Q_X;$_;H_:"_X*<ZCBYT
M0ZLOPS^$LYY3^Q=-8/=W,1/6.XN=DH/&&\T>P7_@IO>M^R=_P4$_9Y_X*4^+
MM+O9/ASX=L]9\'?$W6+*SDG_ +!MKZ(_8KV5(PS" 3LXD?&% 4#+.H(!S>N_
M!+X:?\$K_P#@JG\!M+_90T8^$_AW\?[?6O#?CGP-97TIT[^T;.VCGL=0BAD=
M@DY9Q$S+CY >,NV?T=K\Y/%GQL^%_P#P5$_X*M_ -_V4/$<7B_P)\ K;6_$_
MC[QMIMN[:='?7EM'!86$4[*%DGWQB1E7/R%B#F-@/LKP5^U]\(?'O[5?C3]C
MC06U/_A,? 6B6.JZ\)K(+:BWNU5H?+EW'>V'&1@8]Z /D;]N3]D[_@W^^"OC
MKQ#XT_;MT/PKIGBWQV]YK^H7GB'Q+JDFI7OFROYDMLD4Q= 'RJ) H"[0%%>E
M?\$-=)^/.C_L :/:_'&Y\1R6K>(=2D^'G_"8.S:JOA=ILZ<+G?\ ,&V;BJM]
MV,Q@ *% H?%K_@K-_P $8/$L&O>'_C]\9O!-W=:%-=:7KOA[Q?X0GGNXGA=D
MFM_L\UJS2C<#@(&5^JD@YK,_X(%^$_'OAK]D;Q?JFI^#M=\-> _$'Q@U_5_@
MQX8\1I(ESI7A.=XFLXO+D.Z.,MYS*IZ[BX)#@D ^Z+#_ (_H/^NR_P Q7T%7
MS[8?\?T'_79?YBOH*@ HHHH _-3Q)_R,5_\ ]?LO_H9JE5WQ)_R,5_\ ]?LO
M_H9JE7[5#X$?S54_B/U"BBBJ("BBB@ HHHH **** "BBB@ HHHH _1[X;_\
M).] _P"P+:_^B5K:K%^&_P#R3O0/^P+:_P#HE:VJ_&*W\:7JS^D<-_NT/1?D
M%>%^/_\ D=-3_P"OQ_YU[I7A?C__ )'34_\ K\?^=?'<6_[I3_Q?H;F/1117
MP8!1110 4444 %%%% !1110 4444 %>W_#/_ )$73O\ KB?_ $(UXA7M_P ,
M_P#D1=._ZXG_ -"-?4\)_P"_3_P_J@-VBBBOOP"BBB@ HHHH **** "BBB@
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MP41\$>"_ G_!1;]AS3/!'A#2]&MI/B3XEDDM]*T^.W1G.FQ$L5C4 DDDY]Z
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MXD2W>N>'D1]<\,ZUHUWI>IV4;XV2M:WD4<AC.5_>*&3+ $@G%?*G_!0WX@^
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M^/\ SKW2O"_'_P#R.FI_]?C_ ,Z^.XM_W2G_ (OT-S'HHHKX, HHHH ****
M"BBB@ HHHH **** "O;_ (9_\B+IW_7$_P#H1KQ"O;_AG_R(NG?]<3_Z$:^I
MX3_WZ?\ A_5 ;M%%%??@%%%% !1110 4444 %%%% !1110!X7_P3W_Y(GJW_
M &/>L_\ I2:]8^)7_(C:C_UQ'_H0KR?_ ()[_P#)$]6_['O6?_2DUZQ\2O\
MD1M1_P"N(_\ 0A0!XG1110 5\(?\%4/C7^V[X7^&'C#P1_PQ/:^)O K>*O#<
MWA[QSX>^(=C!+L76-.D6"[L;SRW21KA3"'B:1/WB,P0!C7W?69XQ\%^$OB#H
M$GA7QQX=L]5TV6>&:6QOH!)$TD,J31,5/&4DC1P>S*#VH ^5_P#@FU^RG\<?
MAE\<OCI^U]\=_AMH/P[U'XU:SH\]G\,?#FK1WT6B0Z?:R0F>XGA589;JX>5I
M)#$"N1G<Q8@>%_MI0_\ !4GXZ_MA_!?XU^#O^"5FI/I'P/\ &FLW\+M\9O#@
M/B*WN(5MXW0/.K6V5028=6(#;2 17Z7T4 ?*_P"V'^S+\3/^"G__  3,\1?!
M#XN?"\?"SQSXHT_[19^']2UVWU1=&U*TO/-M!)=6>Z.2.40Q[VCW%4N&&"RX
MKP']IO4_^"IW_!03]ER3]@'Q-^P)/\.M8\4K8Z;\1OBEK/C'3KK0[&TAGBDN
M+JQB@D,URTWE?+%M!028)XWC])J* / OVGO%7Q5_9T^#GA7P)\&OV);_ ..7
MAV*Q72M>T>UU^PM[BSM8(8U@D,%Z EX'*D,JD%2 V".GA?[+W[+?[0'[1'[9
M_A+]M']HO]F;2?@CX*^$FA:C8?!_X3V5_:7-V;_45$=[JUW]C @AW0@1K",L
M"JL<%,O]XT4 >7>"O&_[4NI?M5^-/ OC;X+:9IWPHTW1+&;P5XWAU:*2ZU:^
M=5-U!);B8R1+&Q8!FC0-C@FOG_\ :6^/G[7O_"V-4\+>&O\ @B^/B#JVD7\D
M/P^\?:EXNT1M.FBSF&[DDF'GV0!.YHL;_E.&Y!K[1HH ^=?^"9'[&?BG]B_]
MGJ^T+XJ^*K37OB'X[\7:CXR^)>M6"%;>XUJ_=7F6'< QB151 3C<59\+OVCZ
MA\!_\CEIG_7XG\ZR*U_ ?_(Y:9_U^)_.@#W&BBB@"IX@_P"0#??]><O_ * :
M\"KWCQ9=V]AX6U*^NY-D4.GS22M@G"A"2<#GH*^5?^&@/A'_ -#;_P"2%Q_\
M;KSL=G&4Y9*,<9B(4G+;GG&-[=N9JYG.K2I_')+U9V5%<;_PT!\(_P#H;?\
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MRI]\?_D#W;P#;3V7@31;.Y3;)#I-LDBY!PPB4$<>]:U5/#__ " ;'_KSB_\
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M&O'S+"RP6.J4)0<.5[-J37;WDDI:;222:U6AE4CR3:M8O>&/^1ET[_K^A_\
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M;)=?:;:.-%W.TB>61D>5G.&&"IA:U*FIRM9V?Q1OKJM+WV\@/2J*_/WX"?\
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MUK>SZ6JH"A2U$1EW-G@_ODP,'//I6_<W-M96TEY>7"10Q(7EEE<*J*!DL2>
M .<U<O$SCZ"BWBOB5U^[I:J[6GN=TU\A_P!H8U?:_!?Y'L__  UK_P!4_P#_
M "J__:J/^&M?^J?_ /E5_P#M5?!]O_P5?_84O?&2>#=+^,-Q>[]173TUFP\,
MZA/IK73.$6,7<<!B;+%1O#%.1\U>G_'S]I_X!?LNZ!:^)_C[\3].\,V5]*\=
MD][O9[AU ++&D:L[D @D 'J*[ZO&_BE1K0I5)S4Y_"G1A>7HO9W?R+>,S%-)
MMW?DO\CZA_X:U_ZI_P#^57_[51_PUK_U3_\ \JO_ -JKYH^ O[07PA_:<^'-
MO\6O@=XN_MOP]=W$L%OJ'V"XMM\D3%''EW$:.,,",E<'MFNSKBK>)7B!AJTJ
M5;$N,HNS3I4TTUNFG"Z?D0\?C8NSEKZ+_(]D_P"&M?\ JG__ )5?_M5'_#6O
M_5/_ /RJ_P#VJO@KQ5_P5S_X)]>"O$^I>#?$WQUNK?4M(OYK+4+<>"=:D$4\
M3E)%W)9E6PRD94D'&02*]3_9T_:>^!W[67@:Y^)/P \:-KVBVFJ2:=/>MI5U
M9[;E(XY'0)=11NV%E0[@"N21G(('=B>-O%/!8?V^(E4A#3WI4(*.NVKII:]"
MY8O,81O)M+T7^1]1?\-:_P#5/_\ RJ__ &JNG^"W[2__  E/Q8\/^'?^$*\C
M[9JD47G?VENV9/7'EC/YU\Z5W'[-/_)??"/_ &'(/_0JC*?$KC7$YK0HU<5>
M,IQ37)3U3DD]H7V%2Q^+E4BG+JNB_P C]&****_JT^D,/XG?\DV\0_\ 8#N_
M_1+U^9=?IM\2/^2=Z_\ ]@6Z_P#1+5^<-?,<0>$W_$2*E.M]<]A[%-6]GSWY
MK/\ Y^0M:WF?$<6YS_9=:E'DYN9/K;MY,QZ*V**^>_XE<_ZF_P#Y;_\ W8^0
M_P!;?^G/_DW_ -J85\;T6,QTU8C<^4WV<3$["^/EW8YQG&<5\0?&3XL_MI^(
M_CO\/M \9?L :9?:Y_PC?B2SAT]OB%IT^CZNLL=BLLI:0"5(4VJ6BDBWL) J
M[B"1]^50OO"OAO4_$-AXLU#1+:;4]+BGBTV^DA!EMDFV"54;JH?RTSCKM'I7
MJY5]&^&65)3>81J-II<U":M>+CIRXB/?5.][:.+U-:7&,:;NZ%_^WO+T1\R?
M #X3?'S]@[]@?PK\+/ GP^@^)WB[PYN:_P!#LM=CT^.5;B\EGG2WGN1MQ")B
M$# ;Q'T4M@>7?M(Z9^V?_P %'_"=C^S)J?[(U_\ "WP3J&MVESXX\5>*_$=G
M/-]EMYEF^SVEO;LS/(S*I$A^7Y<':#FOONBNW#_1_JT<;/'/,(2Q#FYJH\/.
M\9-WNHK$J&CUC>+L][JR*CQHU-S^KKFO>_,_\K'AO[1GQL_:&^#^MZ7+\*/V
M3=1^).B75K*=5NM%\2VEI=:?,K#8H@N"#.KJ2<J1MV\YR*\=^&/PS_:B_:A_
M;;\)?M=?'OX+K\,O#'PTT34;7P=X<OM:@O=2U*[OH3!-<3^02D,8B8@(3N#(
MN,AB1]J45SX7Z.BP6%E3HYA!5)1E!U/83<N62:EH\3R)N+<;J.WGJ3'C+DC9
M8=7VOS/_ "L>4>%O%?[0%]^T)XH\)>*?A=867P\L=*M)?"WBN+48WN-1NW53
M<1/")"\80E@"44''!-?.?@'PG^TU_P $_/BE\2]"^%_[+NH?$[P%\0?&=SXL
M\/W/AO7+2VNM*O[I$6XL[F*Y9?W68TV2KN"JO.2Q"_<=%+"_1T^K*<'F,)4Y
MQC&4'AY)-QM:5UB5)2NKMII:M6L[!'C+ENOJZL^G-_P#YA_X)[_L]?%CX1:'
MX\^*OQ[L[+3_ !E\4_&]SXCU;0=-NQ/#H\3@+#9^:ORRNBYW.N0<@9.,GZ&K
M8HKBS#Z-5;,L9/$U<V2<K:+#V22222_?O1))*[;LM6R)\8.I)R='_P F_P#M
M2KX8_P"1ET[_ *_H?_0Q7ZA5^:GAO_D8K#_K]B_]#%?I77M</^&/_$-HU(?6
M_;^WL_X?)R\E_P"_.]^;RM;J?9\(YM_:D*SY.7EY>M][^2[!1117T1]B?/.H
M_P#(0G_Z[-_,U#4VH_\ (0G_ .NS?S-0U^,S^-@%%%%2 4444 %%%% !1110
M 4444 %%%% 'T#X?_P"0#8_]><7_ * *MU4\/_\ (!L?^O.+_P! %6Z_8Z/\
M&/H@"O"_'_\ R.FI_P#7X_\ .O=*\+\?_P#(Z:G_ -?C_P Z^8XM_P!TI_XO
MT QZ***^# \'_P""EW['^L_MW?L8>+_V9_#7C.WT'5-9^QW.E:A?0&6U^TVE
MW#=Q1W" $M"[0A&P"0&W!6*[3\7_  T_X*'_ +2'[%/QZ^,?C#_@H%^QQ#:^
M&9_%OAFS\>_$/X9^((]1TCPY<MI5E;6TKVDP2Y%M(##(9.3&9!'AG #?HE^T
M'\,O'GQ<^&-WX.^&/QPUGX=:\US!<:;XKT.SM[F6UDBE5]K07*M%-$X!1XV&
M&5CR.M?"/A__ ()E?M.?M/\ QM^,/PM_;,_;(U/7?AW=>+O#EWXLTG0/AG!H
M2>._LVFV4L*M<^=,8H(VBCBD2#&]XF.Z,X5?8P%6A]7E"NUR[V][FU<;V:TU
MLK7ZKM<#[\^,6G?%;Q!\+=6T_P" WC#1]$\5W-JO]A:SK>FM>V=O)N4[Y(4=
M#(I7<,!AR0<U^??PLTK]H7X(?\%D_AX/^"E?B+3/'_BKQ_X+UO3/@3XQ\'*+
M#2=$%K$+C4K6736B\Q+B2)A_I+3R@K(D8'),?UU^UA\%_P!M?QYKFB^)_P!C
MS]K_ $KX<C3K*6WU7P[K_@&#6;'52S*8Y2YDCEMWC 8#82&#<C@5YQ^S]_P3
ME^-2?M4:+^VQ^W5^U=_PM+QQX2TB[T[P%I&C>%8M&T;PVETACN98HE=WGGDC
M)0R.0=K$$-MC*986I2HT)\TH^\FK6?-=K36VU[7UM:ZW8%3XP_\ !*OQ_P"/
MOVL_B#^UG\+/V]/'WPRU3Q[IVE6ESIW@W2[((JV%L(8O.>X61IAN,C[5\H?/
M@YP#2_\ !+/]IO\ :0\<_$'XV_L6_M;>+M/\6>-_@/XETZR?QUING)9KK^FZ
MC;RSV<TL$8V1SA(7WA,#YE')5G?;^-/[.G_!4[4?BEK_ (A_9W_X*(^%M%\*
M:U>>;IOASQ1\)8+Z;0$**K)!<K.IN!N#./-7@MMZ"MS]B#_@GQ9_L:_#[QQ]
MI^-.L^,OB5\3=4EU7QY\3=5LHX;B_OS&R1/';H2D$,.]C'$&8*78;L$!:G5A
M+".-2<9.T5&RU5K;OE6B6F[OIVN!\\:'_P $C_VO?V/OV?K^W_8\_P""H/C7
M3-8\/G4-8T;PUJGAK3F\/75Q)))=2026[H\B+)(S@R-)(5W9 .T"OJ#_ ()I
M_M;ZC^W5^PS\//VJ-:T"#3-1\4Z5-_:ME:[O)2\MKJ:SN#&&)(C:6WD9022%
M8 EL9/AOC7]A+_@KE\4_!E[\$/B)_P %8-#/A+5;1K+6M=T3X-6UGKMY9N"L
ML2NMSY4#NA*F5!N7.0.U>W7_ .Q&/ '[!</[#_[(?QAU3X6G2M!M]-\,^-;2
MU^V7NG,DZ32W+()(?,EF(EWD,@W3,0 /EIXFK3K4TJE2,IN7Q)-66M[^ZF];
M/9O1]P/=Z^%O^"/7_)Q'[9__ &<QJ7_HE*^GOBQ\+OVA/$7P!L_AQ\%?VEX_
M!OC2UMK*)_'VH>#H=8\XQ!1.[6<TR*6FPW)D)0MGG%?,?[)'_!+O]N#]E3XT
M:_\ %"T_X*<Z?K.F^.OB OBKXCZ"?@9:6YUV9F7SXDG^WR&S$B*4#1KA,Y"D
MBL</[%86K&51)RM96ET:?1-?B!]SU[?\,_\ D1=._P"N)_\ 0C7B%>W_  S_
M .1%T[_KB?\ T(U[/"?^_3_P_J@-VBBBOOP"BBB@ HHHH **** "BBB@ HHH
MH \+_P"">_\ R1/5O^Q[UG_TI-==^UM_R;GXJ_Z\4_\ 1R5R/_!/?_DB>K?]
MCWK/_I2:Z[]K;_DW/Q5_UXI_Z.2O%XD_Y)W&?]>JG_I#,J_\"7H_R/SUHHHK
M^'3Y *BOA>M8S+ISQK<&)O(:4$H'Q\I;'.,XS4M17QO18S'35B-SY3?9Q,3L
M+X^7=CG&<9Q36X'Y#^!=._9*\(_$OP3X:_X*<_#37-+\>3/XD3XF^)/B#97T
MD&L7CSP&PGM;R,LGD+'N5&B*(G//S!F^J_\ @JAXU\,?"'_@E1<:1\$/$['P
MOJ=MI&@Z?JVFZD;UFTB22-6,<[.QG#VZ&/<S'<'.3SFLWXR?%G]M/Q'\=_A]
MH'C+]@#3+[7/^$;\26<.GM\0M.GT?5UECL5EE+2 2I"FU2T4D6]A(%7<02.E
MA_X)J>(-2_X)/Q?L$>)_&5E-XCATN2XMM60R&UM]2^W/?1QJ2-WD*[>3NVYV
M98*"=M?KF-S#"/&9=CL=5Y>6K"3IJK&K3Y?:5'*48QOR*%DDG>\6HKX&>G.I
M'GA.;ZK2]UN_NM_P.ABC]K3]HK]D+X'^'OB/\0/V(-"\-_ ^QAL[-[#1/$_V
MC6O#VFRE(X;BZMO)6)SETWQHQ8-(0S9!)^Q+C1/!/C>+3?$=[HFF:JL*"XTF
M]N+6.8Q"10=\3,#MW+CE<9&*^,/CO?\ _!0+]LCX /\ L=:]^Q[-X*U/Q MI
M8^-O'^I^)K*XTFTMHI8WFN+1(G,LYD\OY8\ IOP3QN'TM\5_$WQ@^ _PY\/Z
M+^SY^SG>?$J2S2+3Y=/B\5V6EO:VT4.U9FDNR%DR5"[5YR<]*^4SC"TJD:/(
MJ<,1.=2_)53BX6CRRE.5244VW-7<DY))M:IOFJQ3M:RDV]GT];^IXQ_P13_Y
M,=M_^QUU[_TNDKZUKXQ_X)<>&_VSOV>?!6F_LZ_&C]C>ZT31Y-:U74;SQK_P
MGFE7,=KY[R3QQFU@E>5R6*QY4\%MQP :^C_"WBO]H"^_:$\4>$O%/PNL++X>
M6.E6DOA;Q7%J,;W&HW;JIN(GA$A>,(2P!**#C@FN?BG#^VXAQ=:G4A*+<IIJ
MI"2<7*RLXR=Y:WY?BMK:PL3&]>337?='-_M^?M$M^RW^R3XR^+FGRD:O!IIL
MO#<2#<\FI7)$%L%7J^V1PY YVQM4O[!W[.R_LL?LF^#/@U=1 :I9:4MSX@ES
MN,NI7!,UR2W\6)7903_"B^E<9^UM\!/BU^TC^U+\&O#EQX3S\*O!>L2^*_%>
MJ27\&V[U2!66PM! 7\UMK[F8[#&5E(W9&*^D:Y,56HX;(*.%IR3E4DZD[.]K
M7A3B[;-+GE;M-$2:C145UU?Y+]?O"NX_9I_Y+[X1_P"PY!_Z%7#UW'[-/_)?
M?"/_ &'(/_0JY<B_Y'>%_P"OD/\ TI$T?XT?5'Z,4445_<Y]@8OQ(_Y)WK__
M &!;K_T2U?G#7Z/?$C_DG>O_ /8%NO\ T2U?G#7W?!_\"KZK\F?EGB'_ +SA
M_27YH****^Q/SH**"0H+,0 !R37.?"7XH^%/C5\.M*^*/@B:9]+UFV$]F;B,
M)(%R1AE!.T\=,TN:*ER]2E"3@Y6T7Z_\,SHZ*\4_:%_X*+?L6?LK>)F\%?'C
MX\Z=H>L1Q1RR:4EC=7ES&CC*,T=M%(R@CD$@<<U['I&JV&NZ3:ZYI4_FVMY;
MI/;2["N^-U#*<$ C((." :B%:C4FX1DFUND]5Z]C2IAL12IQJ3@U&6S::3]'
MU^18HKPSPY_P4L_8<\8_&FP_9Y\(_M Z=JOB_4[V2SLM+TW3[N='G0,60SI"
M84("M]YQTKW"YN;:RMI+R\N$AAA0O++*X544#)8D\  <YHIUJ-9-TY)VWL[A
M6PV(P[2JP<6U=735UW5^@^BOFZW_ ."M7[!E]XT3P7I7QDN+[?J::<NM6'AC
M49],-TSA%C%Y' 86RQ4!PQ3D?-BOI&E2Q%"O?V<E*W9W*KX3%86WMH.-]KIJ
M_P!X45Y=^T9^V9^SG^RF^EV/QI\?_8=2UQF&BZ)I^G7%]?WVW[QCM[:-Y"H_
MOD!<\9SQ4G[.?[8?[/'[5MOJ?_"DO'PU"\T258];TB]T^>ROK!FSM\VWN$21
M0<'#;2I((!)!I?6,/[7V7.N;M=7^X/J>+]A[?V<N3^:SMVWVWT]3UKPW_P C
M%8?]?L7_ *&*_2NOS4\-_P#(Q6'_ %^Q?^ABOTKKXWC#XZ/_ &]^A^C^'?\
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M2-?\;?!/XAR^&;_QIH-BMK;>((=A>*X:!/DAGPK"1$ 5<J, @YXKXT?LK?\
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M7_H8K]*Z\;C#XZ/_ &]^A]'X=_P\3ZP_]N,?[%XW_P"@W9?^ Q_QH^Q>-_\
MH-V7_@,?\:V**^+/TD^>+X,+V8.03YK9(]<U%4VH_P#(0G_Z[-_,U#7XS/XV
M 5\__MI_L1_##]K_ ,4>#=?3XQ>(?A]\3_ 37>H>!/&/@S5(H=3L(IU2&Y5H
MI%9;BUDQ&LB,N#PNY0[!OH"O*/VF/V'OV6?VP9='O/VAOA/!KM[X?,O]A:K;
MZG=Z??:>)-OF"&ZLY8IHPVQ<A7 .T5IAZGLJJES->:5_P;2?GY ?!G_!,/\
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M\6/C'XR\+W(T1;E]3B\82'0K$6D6Z.>?3IRUI+"NP-(&3YU#?,,YKUO]FO\
M8$_91_9%\,^)/!WP"^&]WI&F^+E1?$%M?^*M3U,72HDB* U]<S-&-LK@["N<
M\YP,>+C_ (('?\$TVECT^X^&?BN?P_%(KQ^#;GXEZU)I *MN4?9VNCE0>=I.
MWMC'%84L1"&)E6]K)/ORJ[[W7-9>6Z] .N_X(V?M#?$/]J;_ ()J?"SXT?%+
M0+'3M:OM(N+*>+3-.2SMY8[.\GLXIHX(U5(E>.!'V(JH"QV +M \C_9Q)_;;
M_P""T7Q1_:;N#]I\&_LXZ&/AWX'<\Q2:_<[I-6N4])(E+VS>J21GZ?='A#P?
MX4^'WA73O W@7PY8Z/HVD64=II6E:;:K#;VEO&H5(HXT 5$50  !@ 5R7[.?
M[+_P,_9,\#W?PY^ '@?^PM)U#7+K6-0A?4[J\ENK^Y8--<2S74LDLCL57)9C
M@* ,  5G]9I*5:<(V<[I=DF]?PT]&P.KUOQKX-\,ZMIN@^(_%NF:??:S,T.C
MV5]?QQ2WTB@%DA1F!E8 @D*"1D5\&?M*ZE^VE9?\%0Y/C9JW_!/_ ,9?%/P#
M\,O#\-I\'%\.>)-*M;-=2O;9'U+5IDNIU=KE=QLX\KM1(Y&'+AJ^R/BO^S#\
M#?C?\1? OQ8^*'@?^U/$'PUU6;4O!.H?VG<P?V=<S(J22;(952;*HHVRJZC'
M '-=]6="O##OF2YFTT[WTN^C3OMI\V@/S"_X(B_'7XS>)/VN?VF?#GB#]DWQ
M)H=AXF^-VJ:IXAUJ[UFQDB\,WH@4C3;A8Y"TLI( WQ!DYZU^GM<+\'OV:O@G
M\ O$7C3Q7\)?!?\ 9.H?$+Q-+X@\87']I7,_]H:E( KS[9I'6+( ^2,(@[+7
M=4\=B*>)Q#J0C967X*W=@>U:+9^,FT:T,&LVBH;:/8K6Q) VC'>K7V+QO_T&
M[+_P&/\ C5WP_P#\@&Q_Z\XO_0!5NOUBC_!CZ(#'^Q>-_P#H-V7_ (#'_&O'
MO&BW*>*]06\E5Y1<MYCHN 3GL*]YKPOQ_P#\CIJ?_7X_\Z^8XM_W2G_B_0#'
MHHHKX, HHHH **** "BBB@ HHHH **** "O7/ -KXKD\'V+V&JVL<)B.Q'@)
M(&X]37D=>W_#/_D1=._ZXG_T(U]3PG_OT_\ #^J LV=IXM2Z1[[5K5X@W[Q$
MMR"1[&M2BBOOP"BBB@ HHHH **** "BBB@ HHHH \+_X)[_\D3U;_L>]9_\
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M ,D3U;_L>]9_]*37>?M):1J.O? _Q#I&DV_FW$]HJQ1[PNX^8AZL0!TK@_\
M@GO_ ,D3U;_L>]9_]*37J_Q,_P"1%U'_ *XC_P!"%3/$U,%!XB"3E#WE?:ZU
M5]M-#'$4(8G#SHRVDFG;>S5CX/\ ^%(_%#_H6/\ R=@_^+H_X4C\4/\ H6/_
M "=@_P#BZ^@:*\C_ (BSQ'_SZI?^ S_^6'QG_$/\F_Y^5/OC_P#('S]_PI'X
MH?\ 0L?^3L'_ ,71_P *1^*'_0L?^3L'_P 77T#11_Q%GB/_ )]4O_ 9_P#R
MP/\ B'^3?\_*GWQ_^0/G[_A2/Q0_Z%C_ ,G8/_BZ/^%(_%#_ *%C_P G8/\
MXNOH&BC_ (BSQ'_SZI?^ S_^6!_Q#_)O^?E3[X__ "!\_?\ "D?BA_T+'_D[
M!_\ %T?\*1^*'_0L?^3L'_Q=?0-%'_$6>(_^?5+_ ,!G_P#+ _XA_DW_ #\J
M??'_ .0/G[_A2/Q0_P"A8_\ )V#_ .+H_P"%(_%#_H6/_)V#_P"+KZ!HH_XB
MSQ'_ ,^J7_@,_P#Y8'_$/\F_Y^5/OC_\@?/W_"D?BA_T+'_D[!_\71_PI'XH
M?]"Q_P"3L'_Q=?0-%'_$6>(_^?5+_P !G_\ + _XA_DW_/RI]\?_ ) ^?O\
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M]F+X5_M!7"V_Q%_:FT+P%/<ZW!I>F:;=://?WU]-*5"-'#$5&PLX7<S 9SG
M&:\Q^(PTI?B%KRZ$!]B&LW7V/;C'E><VS&./NXKH?V7O^3F/AW_V/6D?^EL5
M?08YUJF E*E-PE:]TDVM+_:37X'@X)488Z,:L%.-[6;:3UMT:?XD7[1OP?\
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MK?7WM/,,5X=XZIEE&C3KQ<X.3=TTO>M?57>ENVOD?F'7L_\ P3L_Y/F^%?\
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M^2AZ]_V&KK_T<U8U?HCJ7_!!K]IO5]1N-5U#XA?"R2XNIGEGDQJXW.Q)8X#
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M7@D*,PV.1M)''?UKL?\ AP3^T?\ ]#Y\+/SUC_XJC_B*7#__ #ZJ_P#@,/\
MY,/^(:9[_P _*7WR_P#D#\]**_0O_AP3^T?_ -#Y\+/SUC_XJC_AP3^T?_T/
MGPL_/6/_ (JC_B*7#_\ SZJ_^ P_^3#_ (AIGO\ S\I??+_Y _/2BOT+_P"'
M!/[1_P#T/GPL_/6/_BJ/^'!/[1__ $/GPL_/6/\ XJC_ (BEP_\ \^JO_@,/
M_DP_XAIGO_/RE]\O_D#\]*_>O_@E=_RC\^&7_8%F_P#2J>OA_P#X<$_M'_\
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MS39+KX=?$OPAXFU"'4[35(T+0FXE>=C<QR. L@DR2KMM*G!%?_@LM\/?BU\
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M_P /;_3M0;4?BMJ]N^4N;\6T#B#2H7 9+9B'E8!I%!P(?O#]N6S^$7_!8?\
MX(I_%/P=^P%XNL?%FD^(?#$MOX,;2+*2TANK[2[F*YCL8DF2,INEM%A7*A1N
M'..: /F+]HW_ ((K?L__ +,W_!(R_P#VP?@['K6C_M,?#7X=+\19_C?%XAO)
M-;O];M;8:AJ#SR/*PFBF5;B/RG!4*RYR02?TV_8S^.=Q^T]^R'\+?VC[VSCM
MKCQ[\/-&\075K$"%@FO+*&>2,9[*\C+^%?F=^TA_P6J_9O\ VF/^"/=_^RW\
M&M8OM;_:-^)WPZ7X<_\ "D+72+E=>L]>N[8:??PS0-&/*CAW7+F5]J%8QR"<
M#]+_ -B_X&77[,/['_PL_9PU"[CN+KP'\.]&\/W=S$Q9)IK2RA@DD4GLSHS#
MIUZ#I0!Z91110 4444 %%%% !7PO_P %X/VH?CO\(/@?\-/V8OV6?&LOA?XA
M?M%?%G2OA]I/BVV!\[0+.[8B[OX2#E9$78@889!*SJ5=%(^Z*^$_^"\_[-'Q
MV^*7P2^&/[4_[+W@>?Q5X\_9S^+FE?$&P\(V@)N-?L+5C]LLH5 RTK+L<*,L
MZQ.BAG900"I-_P &UW_!*@_",^!K'X/ZQ;>+U@,L7Q>C\67W_"4KJ>,_VI]L
M\W!G\S]YMV^5GCR]O%9O_!'[XI>.OV_OV$/BW^Q%^WCXAN?%OB;X4_$/Q!\(
M_B#KL%]-:W/B&TM2(ENGFA=9$D>-WB:16$C&$N6+,6.U/_P<C_\ !)=?@P/B
M?:?M!3SZ^]N$A^%L>@77_"4/J1^4:9]A\O(N#*1%G/E;N?,V_-7)_P#!*#PY
MK/\ P3;_ & ?BS^WY_P4/TBZ\#:S\7?BKJWQ0\?Z2NF3W5QX9MM3NHHX;>:&
M!&E)CW&9U"%XQ,RLH*,  ?'W_!2G]GC_ ((F?"+P==?!O_@D?:VVD_MD^'O&
MUKH_PRTGX1^(=4GUVUUNWU!(KR"[9I7C2..)+GS7N& 7RS\WK^Y?A%/$D?A3
M2X_&4T$FL+IT U62U&(FN?+7S2G^SOW8]J_'_P#X+&?M\_\ !&[]M;]C3Q'\
M'?V5[WPU\6?CIXQG@'PHT_X<^$)IO$$.O/<1R1WB7$<"R6Q0[GD9G5G7<A#%
MB*_6']GG2?B9H'P!\#:%\:=4^W>,;+P?ID'BV]\P/]HU-+6-;J3<.&W3!SD=
M<T >$?'+]G#XS^,?^"MGP%_:<\.>#?M/@?P7\-_&.E>)M;_M&V3['=WQL?LL
M?DM()I-_DR?,B,J[?F*Y&?AS_@ZA_P""</[.[_L0?&+_ (*&:UJ'C+5?B EY
MX:CT:#4?&5V^D:*IO=.TZ06FGJZP)O@WEMROF2:1QAB"/V*K\C_^#K+]OW]D
M"Q_X)\?%/]@>[^-EBGQ=O6\.7EKX*-C=>?) -5LKLOYOE>3CR(W?!?.%QUXH
M _27]M#XF>./@M^QW\6/C'\,;$77B7PG\--=UGP];&(2"6^M=/GG@3:>&S(B
M#'?.*_*[]G#_ ()5?L%?&W_@B-'_ ,% /BMJ%_JOQG\0_"Z_\?ZQ^T#<^+KS
M^W--\0QP37/G)="8"(6LT0A\L #$!# L2:_37]D+]O\ _8S_ ."A'AW7M;_9
M(^-6G>.M-T"XBM-?DM-.NH4MY)D9DC9;F*/=N56Z CCFOR&^-WB;_@W1M?A7
MKUW^Q9\4/'WQ$UOQ5--<^!OV4_!GB7Q$VAZWXEF.ZW6;0&54CC6X"2212@1!
M(RHC;Y8R ?IW_P $4OVM?&O[<?\ P2W^#W[2_P 2[XW?B36O#TUGX@O64*UW
M>V%Y/I\UPP4 !I7M3*0 !F3@ 8KZEKYG_P"".G['GBG]@C_@FA\)/V5O'@B7
MQ!X=\/R7'B**&42+!J%[=3W]S"'!(<1RW+QAAP1&".,5],4 %%%% !1110 5
MQW[0GP$^%G[4GP1\3_L\_&SPQ%K'A7Q?H\NFZUI\O!>)Q]Y&ZI(C!71QRCHK
M#!4&NQHH _';P[_P4Q_:K_X)G?"3Q/\ \$>O&_AW4_'7[2?A_4+'PS^RYK$U
M@SP^.-"U R1Z;JERY!1?[/2.1;G>0N;=$+$B64>_?![_ (-JO^":8^!WACPS
M^UY\%(?BK\0[6*XOO&GQ!U'Q!J=K=:]K-Y*;B]NI#;7,6\-*Q5"X+"-$!).2
M<K]MR.,_\'(G[$KF-2?^%?\ C[DCGC2Y_P#$_G7Z04 ?B#_P2/\ ^"'?_!++
M]I'XF_M9:!\:_P!E"SURT^'/[3^O^%?!<,GBC5X?[-TBW$7DVH,-VAD"[C\\
MA9SGEC7:_M'_ /!.O]C#X\_\'#_PL_8R^+OP,LM<^&?@W]A>RM_#7A6ZU*\6
M.RCL->O;6T E283/Y<)* N[$YRQ)YKWK_@@__P EE_;I_P"SS_%/\H:\B_;B
M_;'_ &:?V&_^#FWP?\:/VK/BK:>#O#$O[&HTV/5KVTN)D-U+XDU!XXML$;OD
MK&YSC'R]>E #?^"D_P"PCHG_  1+^ 3?\%*/^"5/BSQ;X$C^&NM:;<>//A+-
MXRO]2\-^+-&GO(;6>*2UO9IO)F4S(PE1AL02%0'VL/U:\$>+M)\?^"](\>:
MSFQUO2[>_LC(N&,,T:R)D=CM85^4O_!2W]OGPC_P6M^ 4O\ P3/_ ."4>D>(
M_B+-\2M:TVV\>?%./PE?V?ASP?H\%[#=3S37=W%$)96\A5$:!MZF15)DVH?U
M9\#>$-)^'W@G1_ 6@A_L.B:5;Z?9>8V6\J&-8TR>YVJ* /FVR_9P^,\/_!;7
M4_VNY/!N/AY<?LL6/@^'Q#_:-M\VM1^)+N]>U\CS//&+>5'\PQ^6=VT/N!4>
M:?&;_@@I_P $<HO"GC[XT?M+_"2;5+O44U'7/%WQ+\8>.-1>_L%.^>2X2<SJ
MEJD(R4"(JJ$&0W.?O*OPW_:T_P""PO["7_!23]L;6/V9OVLOVJ[/X7_LO_"K
MQ'Y>O^%[NRU#^U?BSK%K,1Y4_P!EA<VND0RIGRV99)B%) )!MP#V7]A7]MC]
MJ#]G_P#X-D?%'[7OQ"\2ZUK6O^%/#?B'_A5WB+Q4K2WUYIPNWM='N[D2Y,@5
MW0KNSNAB3D@@US_C+_@B?^S[X(_X(Y3_ +7WAH:[;_M0Z'\*?^%FM\<T\2WK
M:_/XFBL/[3FS.92&B=@]L$*D!&#??^>OK#]HNY_9]_X*\?\ !'?XJ_#/_@GO
MXUTGQ%H6L^#;[0/!_P#8]C)86BZC91QRVUBB31Q>4F]((_NA%5N.!7RIXQ_X
M+8?LV^-_^",4W[+WAG5]2NOVEM>^%/\ PK$? V/1+H>(H?%,MC_9<R&U,8*Q
MQR%Y]YPI10N1(=E 'Z.?\$]_VB=7_:V_89^$G[2_B.WCBU7QM\/M*U76(X4V
MQK>RVR&X"#LGG>9M]L5[%7C?_!/']G?6?V2_V%/A%^S5XFECDU;P5\/=*TK6
MGADWQF^CMD%SL/=/.\S;[8KV2@ HHHH **** *7B3PYH'C'P[?\ A'Q7HUMJ
M6EZK92V>I:=>PK)#=6\J%)(I$;(=&5BI4\$$BOR6T7]LS4O^#='7/B!^PG\:
M?#OB#Q=\-KS3+KQ+^Q[-;P375SJ4L]PJ2>#7D4,WF0W5Q&T;D,1!(SDY:.(?
MKM7YO_\ !>N.-_VCOV"B\:DC]K_P_C(_VE_P'Y4 1_LQ?\$ _P!G'XX?!"3X
ML_\ !6WX26?Q-^.7Q(\02>+_ (A:I-K%[:#2[R>)4BTFW:SN(_\ 1K.$+"J%
MF0,'*_+M ^9?V4/^"'?_  2R^(O_  6<_:P_9=\9_LH6=[X#^'7AKP1=>#-
M;Q1JZ+ILM]IOG7;"5+L2R>9)\V)'8+T7 XK]OJ_/#]AO_E8:_;F_[$_X;_\
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M:A#IN@17T36TM_?7UU!%# D44KN#N(#A-^U26H ^Y?V!_P!IL?MF_L6?"_\
M:GDTF.PN/'7@JPU74+" DQVUW)$/M$2$DDHLPD52>2H!->:?M2_LX?&?XC_\
M%1_V4?VC/!G@W[9X-^&FC_$*#QMK/]HVT?\ 9TFIZ=I\-B/*DD66;S)()5S$
MCA-N7V@@GTG]@/\ 9D;]C']BGX7?LL7&K17]UX&\%6&E:C?P9\NYNTB'VB5
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%PY9I)VNGH]M4VOQ/?R[,L%FN&^L86?-"[5[-:KR:3"BBBN [@HHHH ****
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M_:'TGXEZWID_P83XB>)=+N+");IET[3="TG2;BW^T)+%Y6PH'WO+EFYW5D?
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M$EU+#-]N>:W*V5M"D6XSAY7DDDBB2$LX8?/7_!4C]N/]EW_@JWHGP6_8-_8
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M44 %%%% !6=XQ_Y%'5?^P;/_ .BVK1K.\8_\BCJO_8-G_P#1;5AB?]VGZ/\
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MV,7_  DG]C?VA]B^SW]M>9^S^=#YF[[/L_UBXWYYQ@^[T4 ?"^C?L&?\%I]
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MQ!\#KOQSJ?B.3X1ZU\*;6YO(OMTCS2VD6LB[218Q,^Y6,#, -ISDFN&^$O\
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MN$C420EEW!5&[;N5D^ W[/'_  5CM/BYH/B[]J7_ (*'>"-6\):'</)?^#_
M?P?33W\0@PNB"YO+B[F>!5=ED*P*-Q0 L%R#]6T4 %?C;_P2D_9E_;@\1ZW^
MU?\ &G]AS]LC1_ -]JW[7OCO1O$OAGQOX(&NZ3<"WNHG@O[8+/#):W:"YE1^
M7CF580R#R@3^R59?A;P1X+\#Q7L/@KPAI>CIJ6HRZAJ*:7I\=N+J[EQYMQ((
MU&^5\#<[99L#)- 'R1\)O^"0>B?#'_@G;\8OV-+WX]:CKWC?X\V>OW/Q,^+V
ML:,CW&I:WJULT$U]]C2556*,%=ELLH "GYP69J^B/@+^SWHOP>_9/\%_LI>)
M-1A\3:=X6^'FG>$[^[N+#R8]5@MK".S=VAWOY:RJA)CWM@/C<V,GT.B@#\X?
M#G_!'S_@H3\#?@UJO[$'[*7_  5'M_#'P&U%KRVT>SUSX:)J/BCPQI5T[M-I
MUGJ/VI%D7$D@2>2,21!QLQL6NZ_;+_X)Y?L"_!;_ ()2^&OV:OB-\7;SX2>
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MWMC$\T\TDTOGO<%T7]TL2U]VT4 > ?LT_L,?\,[_ +9W[0W[7?\ PM'^V/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K,\;>(_^$.\&
M:OXN^Q_:?[*TNXO/L_F;/-\J-GV[L';G;C.#C/0UIUS'QL_Y(SXN_P"Q8O\
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ME6P\X+=IK[T?FC17W5_PQO\ LW_]$Y_\J]Y_\>H_X8W_ &;_ /HG/_E7O/\
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M:;^R9\5_#W@[QK%>V\]AJGBOPXVJ:?-$C@RV\T*2QN%D3*[T<,IP17RUX?\
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MT-S=DBUMY9U5YB!DA%)RV!R<59H **** "BBB@ HHHH **** "BBB@ HHHH
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M&NMWEZ\U]IFDG6=/L;=UF;+>9;IJ,K1MGY/+0+@* .Y_X*4?\$//V)/V5_\
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M.T8^<]$_X(?_ +%^L?\ !(N#]HK4;;4I/CS>_"1?B"_[0+^)[S^WU\2MIHU
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MZ;-80""Y61)8E VOCOR&&*ZC_@V61%_X(<? A0H .GZYD >NOZEF@#T/4/\
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M^*L%E8PFVNO+*V6ZT$EY<& K.Z;4CB\R-/,D9CM[+QU_P5&_:4^+G[2WCO\
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MQ>X@%Q:75O=Q*J7-M<0Y>.3:A.UN,;6;Y:_9H_X+=_M]_MV?LHV'[6/[&/\
MP2,?7-(M5OO^$EM]?^+]O9>=<6T\JM::4S60>_8PK$YF:.)%EE:!1*T;-7#?
M\&[-Q\$KS_@HE^W3=_LW>"_$^@^ I9_AN_A*S\87VI7-_<6)TO5#%>M)J<DE
MVT5TO^E1><VX0W$0 50%'MG_  :X*J_\$*?@:54 D^)B2!U/_"3ZK0!Z-=_\
M%E/V9[3_ ()5Z3_P5<.BZU-X6UW2(FTCPK;1I)J=YJTETUB-*B .UYA>(\)8
M< 1L^, U\,?\%S/VT_V]/$/_  2E\8^!OVU?^"=<?PRTKXB:CX;B\,:YX<^(
M\'B#^S+V+7M/OA8ZK$MO";9VM[:<K-&9(S(BQ':SKGSGX+_"SXE>-_\ @U^^
M"_Q6^&?@K4/$\WP=^/\ +\0M7\,Z3"9;G4]-TWQ7J9NHXT'WRL<K2D?W86/.
M,'TW_@OK_P %=_V&OVP/^"5>M_"W]DCXKVOQ'U7Q-J?AS4=3AT"RF=O"^G1:
MS92&\U'<@^Q;IQ!:".7;(TETH"D!B #]FJ^0OVM_^"DOQ>\#?M;:9^P-^P[^
MRS%\6_BFWA<>)O%S:MXL31-%\*Z2TOE0RW=T89F>:5QA8$3=M(?D'%?7M?F3
MXH^._P ,O^"8_P#P76^+GQB_;(\1KX1^'O[1GPY\-_\ "#_$76(G72;;4]&A
M>UN-)EN "MO(Z'[0-^U2-O.6 H POV)OCU\2_CW_ ,'(?C>\^-7[/^H?#/QE
MX9_9!@T7Q-X6N]7BU&W2X7Q)#<I/:7L2JMW;207,+K)L1@2Z,BLC"O:G_P""
MI/[8/[1OQ#\;:;_P30_8!L/BAX)^'GB2Y\/ZQ\0?&'Q-A\.VFMZM:D"ZL]+C
M-M,TZQL0GVIRD1;.,@;CXI^Q/^UC\+?VRO\ @Y-\??%OX("YO/"$'[(T.FZ!
MXGDL)(+?Q%'%XC@,E]:F15:6W$SS6ZRXVN;5RI*[2?FC]@SX>_L;?L7:3XR_
M8H_X*3?\% OC]^S]\1O!/C?5Y+.RLOCCKGAGP]XGTB>Z>>UU?35@=;9Q*KD.
M%/F%U)8;F( !^@'BO_@MYX?TS_@G%J__  4(\,_LR:Y=?\*^^(">%/C7\/-6
MUE;35?!-S%>1VFHEC'!,MT]LT\$H0",212!BT15E'M7_  4._;^\&_L&?L9:
MG^UQ:^%/^$XD:73;3P;X8TS4Q _B6^OYXH;6W@F$<N-XD,FX(_R(Q"GI7CO_
M  3T_9=_X)L?&K]BGXQ^ ?V1OB5XN^(GP\^,?B#6+3QYXL\8:M?W]SK.HW%C
M%;7=S'<W\:R3_(R8G&X-(A(<D9KX2_X)W>*OC)^W/^U%^SC_ ,$M?CQI-Y*O
M["FIZWK'Q=NKF%A;:KJFCW3:9X8\MF^\4C=)@3N\Q5<@]P ?H_\ M;_\%(OB
M/\#OB;X!_9&^ O[*\WQ/^/\ X\\,/K\O@"R\6PV.F>'-,B*QW%_?ZG+$0MNL
MY:&,K#NF:-E 1BBM'^RK_P %%_C%XN_:IG_85_;D_97C^$GQ.NO"\GB/P=)H
M_BZ/7-$\5:9%*(KAK6Z6&%HIX69=]O(F_9\^=N*^/?\ @JG\)O _P*_X+)^'
M_P!LO]KCXP?%SX=?!/Q]\&XO!Q^*/PJ\9:GHH\/:];Z@T\=GJ4^G?O$LYXV!
M0O\ (9N3@1,R^F?L+>'O^"/GQ&_;V\)^,/V</V__ (H?';XK^#_#FJSZ"WB;
MXJZSXLLM&L+B)8+LM-<AX+?S Z )YBL[*I"ML)  _P#X(]_&?X=_LZ?!W]OS
MX\_%O7ETSPSX/_;B^*&KZ[?,I8Q6T$=A(Y51R[$+A4'+,0HR2*GN_P#@M!^W
M=X>_9^M_V_\ QE_P28U&R_9YGM(]6FU6#XF6TOBNT\/R$%-9DTG[.$\LQ,LI
MA$^Y4;>7V O7AGP3_9U^(O[6/_!,3_@I[\ /A'9R77B;7_VROB;_ &'8Q-A[
MVX@?2[E+92>-TIA\H9P,R#) YKL?BE_P6Z_8<^('_!'[4_@5X0\12W_QI\3_
M  BF\ 6?P$@T&Y;Q!%XCGTXZ<VGO8^7O$<<S,2Y^5HT.TEB%(!],_M[_ /!8
MGP1^QKX.^ OQ'^'7P5U/XLZ)\?M;AL/"C>%M4$-W.MS9K<6+VT+PL+E[AI88
MU1GA"^8&9P 16/X<_P""I'[5'P;_ &EOAW\#?^"C7["=C\*=#^,.L_V)\/?&
M_AKXDP^(;.+6W4M!I&H!;:$P3R@;8Y$WH[\+E0[I\>_MS^&_%W_!.[]G[_@F
M%X<^*G@[4O$&K?"OQEIP\7:/HEFU]=1FVTA&O1;Q1Y:X:W43,BIDOY"@<D5Z
M9_P4._;3_9L_X*N?%S]F7]C7_@G]\3=/^)VO6OQ[\/?$+QAJ_AJ*2:T\*>']
M),LD]S=3;0L$S^:(TB8ARV48*SH& />?CO\ \%8_CIX8_P""@/BS_@F[^S+^
MPG=?$CQQHG@C3O$>FZK)X[ATO3?L]P2)I+Z26V;[)%"3&JE&FDF>556-!N=>
M/^&/_!9S]JWXG_$'QA^Q9HW_  36OA^TWX&OU/B/P))\0($\-VFD20130ZP^
MMF#'E2B>)4MUA:9F?' 61DT/V>%4_P#!QU^T4Y49'[/_ (1 ..<?:)*3]C5$
M/_!P7^V?(4&X?#[X= -CD V$V1^@_*@#UK_@GY_P4=UC]JJ7XL?"_P#:/^"
M^$GQ/^!FLV]E\2_"\_B*/4;*VM[FV:ZM-0@O%2,/;S0I)(-R@J$Y)!!KR'P?
M_P %9_V]?VE?!-_^TO\ L-?\$L9/'/P8M;BZ_L#Q#XC^*%OHNM>,+6WD:.2Z
MT[36M92J%HW\H3.K3 # 4G XGX:_"S6/CE_P54_X*<_!#P[JJV%_XS^$O@71
M+.\9BJP3W7A>]MXY20"?E,@.<$\5\M_\$_\ 6O\ @G-\'_V6]#^ G[=?_!2S
M]I']GSXM_#:Q.B^.?AAJG[07B#0;>QGMW9%DTZVB<0R6LJ!98Q;;E ? X )
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ME\<?M%V%WJGPRTT^)8]&TU])MK**]GU&YO)8Y/+18)XF6,1EY,L!@@ _*?Q
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M444 %1WEI;W]I+8W<>^*:-HY4R1N4C!&1R.#4E% '._\*H\ ?] #_P FI?\
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M** ,D^ O Q\3#QJ?!FD_VR%VC5O[.B^U 8QCS=N_&..M:U%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %<M\<_\ DB7C'_L5=0_])I*ZFN6^
M.?\ R1+QC_V*NH?^DTE 'YN4444 >^_\$Z?^2VZI_P!BK/\ ^E-M7V?7QA_P
M3I_Y+;JG_8JS_P#I3;5]GT %%%% !7A'_!33]MG_ (=T?L.>//VSO^%9_P#"
M8_\ "$V]C+_PC?\ ;/\ 9_VW[1?VUGC[1Y,WE[?M&_\ U;9V8XSD>[U\(?\
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MJWQU\3:KXK^)?Q$72X+*:\\17TL$SWT%HA:."-);:W98-S#Y&&[YN.C\"_\
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MSLWTM10!^/O["_[.G[8WC']N_P#;>^,W[$O[66E_#_7U_:#NM'U[0?&/@_\
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M"JQQNRF1W9Y,*2 0<_4%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
' %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>biib-20200930_g14.jpg
<TEXT>
begin 644 biib-20200930_g14.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?@3XCT'3M*UF*X=9+Z*_TXW4CW!D;8I5AM&W QUYKZ6M;JVO;:.\LKB.:&5
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MOAXOPXO_ !M\7V\!>.[+1M2NGMO$>DWMC/(5O(YI7$SQO#O61OFWD,2S(A4
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MER6*CW.:]:T[7]"U>XN+32=:M+J6TDV7<5O<J[0MS\KA22IX/!]*_$WXL?M
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MIBO8* /C3XL_\$(O^"6'Q?\ 'WC?X\_M.?!";QSK_BV_N]1UOQ#XT\8Z@_\
M9\+LTA@MMD\<=E;Q D)Y:J54#+'&:^?O^"+O[1OCKX'_ /!*3]H[XTCQ?K7C
M3X5?!_QSX[N?@%KOBFZ>:?5?"&DVQFM0)F^:6W#Q2HK]CO0!5157R3_@IK_P
M6"_99_:W_;/\3?\ !,;XO_M;+\%O@/X U%['XV^(1;7HUCQ[>Q2%)O#UB;:%
MVMK)71DN;AMK2@%$RAS)]W_"'XB?L%_\%)/^"=WQ&_9@_P""=OQ'T"_\#CP#
MJ7P_ACT/2KFTM-&^U:9)!'"$FBC;"QS*V0#GN2<T ?'/['W_  1@^ '[:O\
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M6UU"LD<JGJK*P(8>QJ>B@"MI&CZ1X?TR'1=!TNVL;.V39;VEI L442_W550
MH]@*LT44 %%%% &<OA#PFGB1O&2^%].&KO#Y3:J+*/[28_[AEQNV^V<5HT44
M %9WB7P?X2\:6::=XQ\+:=JUO'()(X-3L8YT5QT8*X(!]ZT:* &PPPVT*6]O
M$L<<:A41%P% X  '04ZBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BO$OV"-4U/5_@UJMSJVHSW4B^-]819+B9G8*+D@+EB> .@[5[;0 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110!X7_P $]_\ DB>K?]CWK/\ Z4FO=*\+_P""
M>_\ R1/5O^Q[UG_TI->Z4 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >%_P#!/?\
MY(GJW_8]ZS_Z4FO=*\+_ .">_P#R1/5O^Q[UG_TI->Z4 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 ?/7[!=MXDE^#FK-I.I6\47_  G&LY66$L<_:6YS7MOV+QO_
M -!NR_\  8_XUY'_ ,$]_P#DB>K?]CWK/_I2:]TH Q_L7C?_ *#=E_X#'_&C
M[%XW_P"@W9?^ Q_QK8HH Q_L7C?_ *#=E_X#'_&C[%XW_P"@W9?^ Q_QK8HH
M Q_L7C?_ *#=E_X#'_&C[%XW_P"@W9?^ Q_QK8HH Q_L7C?_ *#=E_X#'_&C
M[%XW_P"@W9?^ Q_QK8HH Q_L7C?_ *#=E_X#'_&C[%XW_P"@W9?^ Q_QK8HH
M Q_L7C?_ *#=E_X#'_&C[%XW_P"@W9?^ Q_QK8HH Q_L7C?_ *#=E_X#'_&C
M[%XW_P"@W9?^ Q_QK8HH Q_L7C?_ *#=E_X#'_&C[%XW_P"@W9?^ Q_QK8HH
M Q_L7C?_ *#=E_X#'_&C[%XW_P"@W9?^ Q_QK8HH Q_L7C?_ *#=E_X#'_&C
M[%XW_P"@W9?^ Q_QK8HH Q_L7C?_ *#=E_X#'_&C[%XW_P"@W9?^ Q_QK8HH
M Q_L7C?_ *#=E_X#'_&C[%XW_P"@W9?^ Q_QK8HH Q_L7C?_ *#=E_X#'_&C
M[%XW_P"@W9?^ Q_QK8HH Q_L7C?_ *#=E_X#'_&C[%XW_P"@W9?^ Q_QK8HH
M Q_L7C?_ *#=E_X#'_&C[%XW_P"@W9?^ Q_QK8HH Q_L7C?_ *#=E_X#'_&C
M[%XW_P"@W9?^ Q_QK8HH Q_L7C?_ *#=E_X#'_&C[%XW_P"@W9?^ Q_QK8HH
M Q_L7C?_ *#=E_X#'_&C[%XW_P"@W9?^ Q_QK8HH Q_L7C?_ *#=E_X#'_&C
M[%XW_P"@W9?^ Q_QK8HH Q_L7C?_ *#=E_X#'_&C[%XW_P"@W9?^ Q_QK8HH
M Q_L7C?_ *#=E_X#'_&C[%XW_P"@W9?^ Q_QK8HH Q_L7C?_ *#=E_X#'_&C
M[%XW_P"@W9?^ Q_QK8HH Q_L7C?_ *#=E_X#'_&C[%XW_P"@W9?^ Q_QK8HH
M Q_L7C?_ *#=E_X#'_&C[%XW_P"@W9?^ Q_QK8HH Q_L7C?_ *#=E_X#'_&C
M[%XW_P"@W9?^ Q_QK8HH Q_L7C?_ *#=E_X#'_&C[%XW_P"@W9?^ Q_QK8HH
M Q_L7C?_ *#=E_X#'_&C[%XW_P"@W9?^ Q_QK8HH Q_L7C?_ *#=E_X#'_&C
M[%XW_P"@W9?^ Q_QK8HH Q_L7C?_ *#=E_X#'_&C[%XW_P"@W9?^ Q_QK8HH
M Q_L7C?_ *#=E_X#'_&C[%XW_P"@W9?^ Q_QK8HH Q_L7C?_ *#=E_X#'_&C
M[%XW_P"@W9?^ Q_QK8HH Q_L7C?_ *#=E_X#'_&C[%XW_P"@W9?^ Q_QK8HH
M Q_L7C?_ *#=E_X#'_&C[%XW_P"@W9?^ Q_QK8HH R[.T\6I=(]]JUJ\0;]X
MB6Y!(]C6I110 4444 %%%% !1110 4444 %%%% 'A?\ P3W_ .2)ZM_V/>L_
M^E)KW2O"_P#@GO\ \D3U;_L>]9_]*37NE !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M.BO!_P!;_P#IQ_Y-_P#:@?1E%?.=%'^M_P#TX_\ )O\ [4#Z,HKYSHH_UO\
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M/%$N^4LNV-CM7'!.1]M_"O6M3\2?##PWXBUJY\Z\O]!L[F[FV*OF2O C,V%
M R23@ #TI5,.Z="-7F34KK2]TTD]=/-;7 WJ*Y7XY_&'PA^SW\&/%?QU^($[
MQZ)X/\/7FL:H8@"[0V\+2LJ D9=@NU1W8@=Z^$?@7#_P4D_;6\'Z!^T)XO\
M^"H&C_ [5_'FG1ZUX#^#_AKP5I&I#3=+G7S+-KHWQ^T7LLD)1W&%49.W;DJM
M4<*ZL'-R48K2[OO\DWZ@?HQ17R)_P4C_ &HOVD?@'X3^#G[-WP!\1Z1#\5/C
M/XPMO"]MXVU32EEM-'5(0]]J:VIRLCJ,%(6ROS'.=H!\]\9?$S]L[_@F5^T9
M\';']H/]L2?XS_#'XP>-8O!>J-XD\)6.F:AX>UBY0FSNK>6S51) [JRR1R B
M-5RI).1=/ U*E-24E=WLM;NV]M+=':[5P/OVBOA[]KGXV_M<?&7_ (*7^'/^
M";W[/7Q[3X/:*OPFE\<^(O&T'AVUU#4M7 OC9K862W8:)-IVR,X4O@2=DPT_
M[%WQO_:S^&/_  48\<?\$XOVBOCG%\6]+TKX8VOC;PYX]FT"VT[4+!)+Q+5M
M-O4M0(G<ES*C8#E$W'(8!#ZC/V7/S*]N:VM[7M?:WRO<#[:HHKX2^-7[+7_!
M5#X9?"WQ-\>8_P#@L;-)K7AO1[O6$TB^^$>C6F@LD$;S&VE W2)&54H9RQ<#
MY\9&*QH48UI6<U'UOK]R?X@?K=X?_P"0#8_]><7_ * *MUX)_P $NOVH_%G[
M:G_!/GX3_M1>//!\>@ZUXO\ "<-SJFFVZNL*SH[PO+$')812&/S4!+$)(HW-
MU/O=?KU.+C32?1 %>%^/_P#D=-3_ .OQ_P"=>Z5X7X__ .1TU/\ Z_'_ )U\
MMQ;_ +I3_P 7Z 8]%%?'/_!2O]JSXS_#3]H7X&_LD_"KXUZ/\)K7XMWNLG6?
MBKK>DV]Y_9RV%O')'96J79^S?:;AY0@,H('R[59CBOB:%&>(J<D?-_)*[\]E
MT ^O-%UO1O$>EP:YX>U>UO[*Y3?;7EE<++%*O]Y74D,/<&K5?%/_  1O^#?[
M2_@W]G7X?^/?%G[85WXN\ ZIX&(L? >J>#-/@DTJY,RF.6&_ME222,*LJF.5
M6SY@(8;<'RO_ (.$_P!@KX#^+OV//BW^VCXLNO%.H^+]&T#31H5I<>*[M=*T
MUEO+: R162.L6YD=]Q<-EFS@'%=,,'2ECOJ[J:-VNDWK>VSM\_U _2JBN7^!
M_P#R17P?_P!BMI__ *31U8^*_P +/ 7QP^&NN_!_XI>'UU;PYXETR;3M;TQY
MY(A=6TJE9(R\3*ZY4D95@1V(KBLE.SV Z"BOQ[_X*\_\$C_^";OP-^$7@GX+
M?LL?LL:=I7Q:^,GQ#TWPMX)O_P#A(]5N&TY&F62\OC%+=LC1Q0@(Q92%\\-V
MR/HG_@J9IVI_#'X'?LW_ /!,KX'^*]4\,Z'\3?'>B> ]4U+3+LQWD/A:RMU6
MZABD7E7>)(5+#@KO4C#FO16!HU%3=.;]YO>-K*.[TD[]?N8'WEIVLZ1K"RMI
M&JVUT(93',;:=7\MQU5MI."/0\T^_P!0L-*LWU#5+Z&VMXAF2>XE"(@SC)8\
M"OS1_;,_92^ O_!(_P")_P !/VN_V(O!@\!6UU\6-)\#?$?0M,U.X-GK^AZB
MLJ,]S'+(PDF@:/>CGYMS[F)V#&Y\7_A7X"_;Y_X+8^(_V7OVO(9M<^'_ ,,O
MA#8Z[X*^'=W>RPZ?J=]=3JEQJ<L2,OVAH@_DC=E5P..N4L#3DE4C-\EF[VUT
M:35KVZKKLP/T5MKFWO+=+NTN$EBD4-'+&X974]""."*?7YS_ +%EWX&_8G_X
M+,_$'_@F[\"-4GMOAEX@^%MKXRTSP:VI27-OX8UM9D2>"V$K,T,<\#^>R9QD
MQX 7 'Z):B+]M/G72VB6Z,+?9C/G8),';NQSC.,X[5S8G#_5YI)W32:>VC\@
M([K7=$LM1ATB]UFTAN[D9M[66X59)?\ =4G+?A7O/PS_ .1%T[_KB?\ T(U_
M.A\!/ ?_  2GM?V6_&\/_!7B]=/VIUU;63\06\6ZA?#Q+]O-Q,=/?2E5OWJ-
M!]E:$P!HV9NZ8%?M'_P1'TK]IO0_^"5GP:TK]L0ZG_PL*'PY,-876W+7J0?;
M;@V2W!;YO.6S-L'#_.'#!_FS7V/#^!CA<74DI-V5M59/5:Q=W=>>FZ[@?5-%
M%%?7 %%%% !1110 4444 %%%% !1110!X7_P3W_Y(GJW_8]ZS_Z4FO=*\+_X
M)[_\D3U;_L>]9_\ 2DU[I0 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'SSJ/\
MR$)_^NS?S-0U-J/_ "$)_P#KLW\S4-?C,_C8'S_^VG^Q'\,/VO\ Q1X-U]/C
M%XA^'WQ/\!-=ZAX$\8^#-4BAU.PBG5(;E6BD5EN+63$:R(RX/"[E#L&^-?\
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M,=2OO#-Y-JUDL4,6M""3RFC)8B2,2!3N('TKVJ&&&WA2WMXECC10J(BX"@<
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M% &/]B\;_P#0;LO_  &/^-'V+QO_ -!NR_\  8_XUL44 8_V+QO_ -!NR_\
M 8_XT?8O&_\ T&[+_P !C_C6Q10!C_8O&_\ T&[+_P !C_C1]B\;_P#0;LO_
M  &/^-;%% &/]B\;_P#0;LO_  &/^-'V+QO_ -!NR_\  8_XUL44 8_V+QO_
M -!NR_\  8_XT?8O&_\ T&[+_P !C_C6Q10!C_8O&_\ T&[+_P !C_C1]B\;
M_P#0;LO_  &/^-;%% &/]B\;_P#0;LO_  &/^-'V+QO_ -!NR_\  8_XUL44
M 8_V+QO_ -!NR_\  8_XT?8O&_\ T&[+_P !C_C6Q10!C_8O&_\ T&[+_P !
MC_C1]B\;_P#0;LO_  &/^-;%% &/]B\;_P#0;LO_  &/^-'V+QO_ -!NR_\
M 8_XUL44 8_V+QO_ -!NR_\  8_XT?8O&_\ T&[+_P !C_C6Q10!\\7P87LP
M<@GS6R1ZYJ*IM1_Y"$__ %V;^9J&OQF?QL HHHJ0"BBB@ HHHH **** "BBB
M@ HHHH ]JT6S\9-HUH8-9M%0VT>Q6MB2!M&.]6OL7C?_ *#=E_X#'_&KOA__
M ) -C_UYQ?\ H JW7['1_@Q]$!C_ &+QO_T&[+_P&/\ C7CWC1;E/%>H+>2J
M\HN6\QT7 )SV%>\UX7X__P"1TU/_ *_'_G7S'%O^Z4_\7Z 8]%%%?!@%%%%
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MA[8K2\'?\%X/AQX+UJU\.?\ !0/]C?XS?LUF\N%@M_%/Q#\*-/X9>5B L?\
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M#Z1_S\WO_@6U'_"#Z1_S\WO_ (%M6Q10!C_\(/I'_/S>_P#@6U'_  @^D?\
M/S>_^!;5L44 8_\ P@^D?\_-[_X%M1_P@^D?\_-[_P"!;5L44 8__"#Z1_S\
MWO\ X%M1_P (/I'_ #\WO_@6U;%% &/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\
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M8U[1II=/U;0(-+M[9])ANXXW^S-;W$4F^)M@<LC'/[O+[O\ :H_9=_X*8?\
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M/_.O=*\+\?\ _(Z:G_U^/_.OF.+?]TI_XOT QZ***^# **** "BBB@ HHHH
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M5+MD]>Y[U[S7A?C_ /Y'34_^OQ_YU\QQ;_NE/_%^@&/1117P8!1110 4444
M%%%% !1110 4444 %>N> ?">FW_@^QO)KBZ#/$20ERRC[QZ"O(Z]O^&?_(BZ
M=_UQ/_H1KZGA/_?I_P"']4!9L_"6FV-TEW#<71:-LJ'N6(_$5J445]^ 4444
M %%%% !117,_&#XT?"+]GWX?WOQ7^.OQ-T'P?X8TUHEU#Q!XEU6*RL[8RR+%
M&'FE944M(Z(,GEF ')H _.Z[_90\5?\ !3?_ (*6?M$^"OVL/VL?BYX6\/\
MPBU30=/^'?PN^'?CB;0+-M+N]-CN/[8G\CY[MIY_/19,C88I8\G:%3Z$_9F_
MX(X?LW?LJ_&[1/CWX!^,OQLU;5M!^T_9-/\ %WQ<U'5-.E\^VEMV\VVF<I+A
M)F9<CY7"L.5%?)G[4/PE_P"#>7]K+]J#5_VO?'W_  5]MM(\9:O;16QN/"7[
M3%GI\-G;I#'%Y%NB.3#&WEAV16VL[,Q&37>?L ? /_@CIX*_:X\)>)OV5O\
M@K#XD^)?CVV^W_V#X)O_ -I--?AU+=87"3[K .3/Y<#33#CY#$'_ (* /TJH
MHHH \+_X)[_\D3U;_L>]9_\ 2DU[I7A?_!/?_DB>K?\ 8]ZS_P"E)KW2@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** /GG4?^0A/_UV;^9J&IM1_P"0A/\ ]=F_
MF:AK\9G\; ****D HHHH **** "BBB@ HHHH **** /H'P__ ,@&Q_Z\XO\
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MO@YJUU<S7"L/'&LKB*<J,?:6["O;?^$'TC_GYO?_  +:O(_^">__ "1/5O\
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MX_\ 6')_^?O_ )++_(#KO^$'TC_GYO?_  +:C_A!](_Y^;W_ ,"VKD?^%_\
M_4I?^3__ -KH_P"%_P#_ %*7_D__ /:Z/]8<G_Y^_P#DLO\ (#KO^$'TC_GY
MO?\ P+:C_A!](_Y^;W_P+:N1_P"%_P#_ %*7_D__ /:Z/^%__P#4I?\ D_\
M_:Z/]8<G_P"?O_DLO\@.N_X0?2/^?F]_\"VH_P"$'TC_ )^;W_P+:N1_X7__
M -2E_P"3_P#]KH_X7_\ ]2E_Y/\ _P!KH_UAR?\ Y^_^2R_R Z[_ (0?2/\
MGYO?_ MJ/^$'TC_GYO?_  +:N1_X7_\ ]2E_Y/\ _P!KH_X7_P#]2E_Y/_\
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M_P#KLW\S4-3:C_R$)_\ KLW\S4-?C,_C8!1114@%%%% !1110 4444 %%%%
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M_H!KY^KX?B[^+2]'^@!1117QX'Y??\%)/V9/VP/V8_B)\:OVJ?@3X8\(^/\
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M_79OYFH:FU'_ )"$_P#UV;^9J&OQF?QL HHHJ0"BBB@ HHHH **** "BBB@
MHHHH ^@?#_\ R ;'_KSB_P#0!5NJGA__ ) -C_UYQ?\ H JW7['1_@Q]$ 5X
M7X__ .1TU/\ Z_'_ )U[I7A?C_\ Y'34_P#K\?\ G7S'%O\ NE/_ !?H!CT4
M45\& 4444 %%%% !1110 4444 %%%% !7M_PS_Y$73O^N)_]"->(5[?\,_\
MD1=._P"N)_\ 0C7U/"?^_3_P_J@-VBBBOOP"BBB@ HHHH **** "BBB@ HHH
MH \+_P"">_\ R1/5O^Q[UG_TI->K_$S_ )$74?\ KB/_ $(5XW^P-X@T73/@
MUJUMJ&HQQ2?\)SK+;7/./M+<UZK\0O$^@7O@R_M;358I)'B 5%/)^85R8_\
MW&K_ (9?DP/'Z***_(@"BBB@ HHHH **** "BBB@ HHHH *V/ '_ ".FF?\
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MBBB@";3O^0A!_P!=E_F*^AJ^>=._Y"$'_79?YBOH:OMN$?@K>L?U ****^R
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MS<Q_Y\S_ / 7_D![317BW_#Q3]BC_HX31?\ OW/_ /&Z/^'BG[%'_1PFB_\
M?N?_ .-T?V;F/_/F?_@+_P @/::*\4?_ (*,?L3HRJ?V@]'^8X&(;@_GB/BG
M?\/%/V*/^CA-%_[]S_\ QNC^S<Q_Y\S_ / 7_D![317BW_#Q3]BC_HX31?\
MOW/_ /&Z/^'BG[%'_1PFB_\ ?N?_ .-T?V;F/_/F?_@+_P @/::*\6_X>*?L
M4?\ 1PFB_P#?N?\ ^-T?\/%/V*/^CA-%_P"_<_\ \;H_LW,?^?,__ 7_ ) >
MTUL> /\ D=-,_P"OQ/YU\_?\/%/V*/\ HX31?^_<_P#\;K1\(?\ !2/]A[2_
M$]CJ-_\ M$Z+'##<JTC^3<' !ZX$>:Z,)EV81Q5-NC))27V7W] /N2BOG/\
MX>W?\$Z/^CI-%_\  "\_^,T?\/;O^"='_1TFB_\ @!>?_&:_4P/H'Q!_R ;[
M_KSE_P#0#7S]5;6/^"LW_!.VZTBZM8/VH=%9Y+9U1?L-X,DJ0!S#7C__  \4
M_8H_Z.$T7_OW/_\ &Z^.XHPN)Q%6DZ4'*R>R;[=@/::*\6_X>*?L4?\ 1PFB
M_P#?N?\ ^-T?\/%/V*/^CA-%_P"_<_\ \;KY7^S<Q_Y\S_\  7_D![317BW_
M  \4_8H_Z.$T7_OW/_\ &Z/^'BG[%'_1PFB_]^Y__C=']FYC_P ^9_\ @+_R
M ]IHKQ;_ (>*?L4?]'":+_W[G_\ C=-?_@HO^Q/&A=OV@]'P/[L,Y/Y".C^S
M<Q_Y\S_\!?\ D![717BH_P""BO[%! (_:$T;GUBG_P#C=+_P\4_8H_Z.$T7_
M +]S_P#QNC^S<Q_Y\S_\!?\ D![317BW_#Q3]BC_ *.$T7_OW/\ _&Z/^'BG
M[%'_ $<)HO\ W[G_ /C=']FYC_SYG_X"_P#(#VFBO%O^'BG[%'_1PFB_]^Y_
M_C='_#Q3]BC_ *.$T7_OW/\ _&Z/[-S'_GS/_P !?^0'M^G?\A"#_KLO\Q7T
M-7P=9?\ !1C]B:*\BED_:%T4*LJECY<_ !_ZYU[+_P /;O\ @G1_T=)HO_@!
M>?\ QFOL.%L-B,/"K[6#C>VZ:[]P/HRBOG/_ (>W?\$Z/^CI-%_\ +S_ .,T
M?\/;O^"='_1TFB_^ %Y_\9KZL";4?^0A/_UV;^9J&O&KW_@HQ^Q-+>2RQ_M"
MZ*5:5BI\N?D$_P#7.H_^'BG[%'_1PFB_]^Y__C=?DTLMS%R?[F?_ ("_\@/:
M:*\6_P"'BG[%'_1PFB_]^Y__ (W1_P /%/V*/^CA-%_[]S__ !NI_LW,?^?,
M_P#P%_Y >TT5XM_P\4_8H_Z.$T7_ +]S_P#QNC_AXI^Q1_T<)HO_ '[G_P#C
M=']FYC_SYG_X"_\ (#VFBO%'_P""B_[$\:%V_:#T? _NPSD_D(Z4?\%%?V*"
M 1^T)HW/K%/_ /&Z/[-S'_GS/_P%_P"0'M5%>+?\/%/V*/\ HX31?^_<_P#\
M;H_X>*?L4?\ 1PFB_P#?N?\ ^-T?V;F/_/F?_@+_ ,@/::*\6_X>*?L4?]'"
M:+_W[G_^-T?\/%/V*/\ HX31?^_<_P#\;H_LW,?^?,__  %_Y >TT5XM_P /
M%/V*/^CA-%_[]S__ !NC_AXI^Q1_T<)HO_?N?_XW1_9N8_\ /F?_ ("_\@/N
MKP__ ,@&Q_Z\XO\ T 5;KYJT?_@K-_P3MM=(M;6?]J'15>.V177[#>'!"@$<
M0U9_X>W?\$Z/^CI-%_\  "\_^,U^KTDU2BGV0'T97A?C_P#Y'34_^OQ_YUC_
M /#V[_@G1_T=)HO_ ( 7G_QFO)_%_P#P4C_8>U3Q/?:C8?M$Z+)#-<LT;^3<
M#()ZX,>:^=XGP]?$86"I0<G?HF^GD!ZQ17BW_#Q3]BC_ *.$T7_OW/\ _&Z/
M^'BG[%'_ $<)HO\ W[G_ /C=?%?V;F/_ #YG_P" O_(#VFBO%O\ AXI^Q1_T
M<)HO_?N?_P"-T?\ #Q3]BC_HX31?^_<__P ;H_LW,?\ GS/_ ,!?^0'M-%>+
M?\/%/V*/^CA-%_[]S_\ QNC_ (>*?L4?]'":+_W[G_\ C=']FYC_ ,^9_P#@
M+_R ]IHKQ2/_ (*,?L3RKN7]H/1QSCYH;@?SCIW_  \4_8H_Z.$T7_OW/_\
M&Z/[-S'_ )\S_P# 7_D![317BW_#Q3]BC_HX31?^_<__ ,;H_P"'BG[%'_1P
MFB_]^Y__ (W1_9N8_P#/F?\ X"_\@/::*\6_X>*?L4?]'":+_P!^Y_\ XW1_
MP\4_8H_Z.$T7_OW/_P#&Z/[-S'_GS/\ \!?^0'M->W_#/_D1=._ZXG_T(U\3
M_P##Q3]BC_HX31?^_<__ ,;KU/P-_P %6_\ @GKH_A.RTS4?VG=%CGAB(D3[
M'=G!W$]1"17TG#&$Q6'QLY5:<HKEZIKJNX'U%17A7@#_ (*8?L+?%+QKIGP[
M\ _M$Z3J6M:S=I:Z9816ETK3S,<*@+Q!02?4BO=:^W **** "BBB@ HHHH *
M*** "BBB@#E_%7P0^"WCK5V\0>-OA#X7UB_=%1[[5?#]M<3,JC"@O(A8@#H,
M\5G?\,O_ +-/_1O'@7_PDK/_ .-5W-% '#?\,O\ [-/_ $;QX%_\)*S_ /C5
M'_#+_P"S3_T;QX%_\)*S_P#C5=S10!PW_#+_ .S3_P!&\>!?_"2L_P#XU1_P
MR_\ LT_]&\>!?_"2L_\ XU7<T4 <-_PR_P#LT_\ 1O'@7_PDK/\ ^-4?\,O_
M +-/_1O'@7_PDK/_ .-5W-% 'RY^T_\ L_\ P&T?XP_!JQTGX)>$;6"_\:RQ
M7T-MX;M42XC^SL=D@6,!USS@Y%>U?\,O_LT_]&\>!?\ PDK/_P"-5J^-_A3X
M1^(/B+PYXH\1PSM=^%M2:^TDPSE%68H4)8?Q#!Z5TE '#?\ #+_[-/\ T;QX
M%_\ "2L__C5'_#+_ .S3_P!&\>!?_"2L_P#XU7<T4 <-_P ,O_LT_P#1O'@7
M_P )*S_^-4?\,O\ [-/_ $;QX%_\)*S_ /C5=S10!PW_  R_^S3_ -&\>!?_
M  DK/_XU1_PR_P#LT_\ 1O'@7_PDK/\ ^-5W-% '#?\ #+_[-/\ T;QX%_\
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M .$E9_\ QJC_ (9?_9I_Z-X\"_\ A)6?_P :KN:* .&_X9?_ &:?^C>/ O\
MX25G_P#&J/\ AE_]FG_HWCP+_P"$E9__ !JNYHH X;_AE_\ 9I_Z-X\"_P#A
M)6?_ ,:H_P"&7_V:?^C>/ O_ (25G_\ &J[FB@#AO^&7_P!FG_HWCP+_ .$E
M9_\ QJC_ (9?_9I_Z-X\"_\ A)6?_P :KN:* .&_X9?_ &:?^C>/ O\ X25G
M_P#&J/\ AE_]FG_HWCP+_P"$E9__ !JNYHH X;_AE_\ 9I_Z-X\"_P#A)6?_
M ,:H_P"&7_V:?^C>/ O_ (25G_\ &J[FB@#AO^&7_P!FG_HWCP+_ .$E9_\
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M $;QX%_\)*S_ /C5=S10!PW_  R_^S3_ -&\>!?_  DK/_XU1_PR_P#LT_\
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M3:7K32F/3]6NXIDN'U&U@=VW6R7$6YG7(9<T ?L77B'A3]LK_A)_^"A?B_\
M8-_X5QY'_"*?"_2O&'_"5?VQN^U?;;RYMOLOV;R1LV?9]WF>:V[?C8N,GV^N
M'TK]G#X,:)^T-K'[5>E^#?*\?:]X7M/#NK:]_:-RWGZ;;323PP>09#"NV261
MMZH'.[!8@   ^0O&/_!1+_@L!';ZQ\2?AQ_P1'NKOP3HLMP\4&O_ !GL++Q%
MK%I$6S/!IRV\AB<JI98'8R/P ,L*]S_9]_X*7_LQ?M"?\$^H?^"E&C:]=Z1\
M.X_#%]K6M-JT 6ZTI;$RK>02QH3NECDAD0!2?,(4IN#KGAO^"FG_  4*\5_
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MV/\ @X9^RO\ $']B:#Q\P'@%_P!K[PV/%(N,?9C-\_V83Y^7R\?:-V[C;NH
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M,D'V@)M9GCWEF(0)^RFE:5IFA:9;:)HNG06=G9P)!:6EK$(XH(D4*B(J@!5
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M-#_9K_9E\)1^//VC/B>KVGPP^'\$@(M\A@^L:@>EOI]OAG9W*^88V4$!9'C
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M -/]I+_@KE^VC^SE>?LX?"'5O^"7]I>?&/\ :"N?%, ^&LGQRLHHM ?2'@=
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M:O@;KGB&#1?C-;? 7X7Q:3XXO-"EPCRB%3<+-&W2>.V"DH2"K1N^W]>** /
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M9(@[K$ 5 .!^D&@:#HOA70K+PQX;TN"QT[3;2.UL+*VC"1V\,:A$C11PJJH
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M-? ;X.>&8M'\+>$=&@TO0]-B8L(;>) JY8\NQQN9V)9F)8DDDUU5% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
C %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>biib-20200930_g15.jpg
<TEXT>
begin 644 biib-20200930_g15.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ KA_VF_C+_P ,Y_LV_$+]H3_A&_[9_P"$$\#ZMXB_
MLC[9]G^W?8K.6Y\CS=C^5O\ *V[]C;=V=K8P>XKQ#_@IK_RC<_:#_P"R'^+/
M_3/=4 ?*/P#_ ."M7_!7C]IOX,^&_P!H#X+_ /!"&RU7PIXNTJ+4M!U&3]JC
M1K=KBVD&4<Q36"R)GT90?:OT.TK5KMO#-MKGBNPBTFX:Q2;4;62[61+.0H&D
M0RC"L$.1OX!QFORN_P""/_P@_P""RVK?\$Y?@9K?PA_;-^#.C^!9O ^GR:-H
M.L?"JZNK^WL<<0R7"WJJ\FW(WA ,]J[7]N+X>:%_P4-_X+C^ O\ @G%^T3<7
M][\&_ _[/MS\4-5\#QZA-;6?BK5WUD:; EX(F4SPP+ME12<;UD!!5F! /TDT
MW4]-UBRCU/2-0@NK:49BN+:4.CC.,AE)!Y%)JNL:3H5B^IZYJEM9VT9&^XNY
MUC1<G RS$ <\5^97@GX'^ /^"6__  71^$G[/O['.G3>%OA?^T7\//$<GB[X
M;6=[*^DV.KZ1!]IBU2WAD9A;R21A8&";5(W<9/'G'_!,_P#X)D?LI_MQ?M'_
M +:7C[]KWP3+X]TG2/VOO%VG>'/!VL:I<KI6F7!,+W-^EO%(B/<S))!$97!9
M$ME"%=S9 /V$!!&0:\:_9(_;.\'?M=^(/BWX>\)>$-3TJ3X1?%?4? >K2:B\
M;+?7=I#!*]Q#L)Q$PN% #8;*G(KUNXT32[K1'\.7%FKV4EJ;:2W8G#1%=I4G
MKC;Q7Y'_ /!&_P#X)*?\$Y?%OQP_:5\7>(_V4_#]WJ7PH_:XUC2_AY=R3W.[
M1+2QAT^>TABQ* 5CE9G&[<<GDF@#[A_91_;M\2?'C]K_ /:;_9X\;>&]%T;1
M?@3XCT'3M*UF*X=9+Z*_TXW4CW!D;8I5AM&W QUYKZ6M;JVO;:.\LKB.:&5
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MOAXOPXO_ !M\7V\!>.[+1M2NGMO$>DWMC/(5O(YI7$SQO#O61OFWD,2S(A4
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MER6*CW.:]:T[7]"U>XN+32=:M+J6TDV7<5O<J[0MS\KA22IX/!]*_$WXL?M
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MIBO8* /C3XL_\$(O^"6'Q?\ 'WC?X\_M.?!";QSK_BV_N]1UOQ#XT\8Z@_\
M9\+LTA@MMD\<=E;Q D)Y:J54#+'&:^?O^"+O[1OCKX'_ /!*3]H[XTCQ?K7C
M3X5?!_QSX[N?@%KOBFZ>:?5?"&DVQFM0)F^:6W#Q2HK]CO0!5157R3_@IK_P
M6"_99_:W_;/\3?\ !,;XO_M;+\%O@/X U%['XV^(1;7HUCQ[>Q2%)O#UB;:%
MVMK)71DN;AMK2@%$RAS)]W_"'XB?L%_\%)/^"=WQ&_9@_P""=OQ'T"_\#CP#
MJ7P_ACT/2KFTM-&^U:9)!'"$FBC;"QS*V0#GN2<T ?'/['W_  1@^ '[:O\
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M6UU"LD<JGJK*P(8>QJ>B@"MI&CZ1X?TR'1=!TNVL;.V39;VEI L442_W550
MH]@*LT44 %%%% &<OA#PFGB1O&2^%].&KO#Y3:J+*/[28_[AEQNV^V<5HT44
M %9WB7P?X2\:6::=XQ\+:=JUO'()(X-3L8YT5QT8*X(!]ZT:* &PPPVT*6]O
M$L<<:A41%P% X  '04ZBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MG_\ /C#_ -^A0!3_ .$Q\,?]!J#_ +ZH_P"$Q\,?]!J#_OJKG]G:?_SXP_\
M?H4?V=I__/C#_P!^A0!3_P"$Q\,?]!J#_OJC_A,?#'_0:@_[ZJY_9VG_ //C
M#_WZ%']G:?\ \^,/_?H4 4_^$Q\,?]!J#_OJC_A,?#'_ $&H/^^JN?V=I_\
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M_P!^A0!3_P"$Q\,?]!J#_OJC_A,?#'_0:@_[ZJY_9VG_ //C#_WZ%']G:?\
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MB@ HHHH **** /"_^">__)$]6_['O6?_ $I->Z5X7_P3W_Y(GJW_ &/>L_\
MI2:]TH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M2E_Y/_\ VNN#_6')_P#G[_Y++_(#T:BO.?\ A?\ _P!2E_Y/_P#VNC_A?_\
MU*7_ )/_ /VNC_6')_\ G[_Y++_(#T:BO.?^%_\ _4I?^3__ -KH_P"%_P#_
M %*7_D__ /:Z/]8<G_Y^_P#DLO\ (#T:BO.?^%__ /4I?^3_ /\ :Z/^%_\
M_4I?^3__ -KH_P!8<G_Y^_\ DLO\@/1J*\Y_X7__ -2E_P"3_P#]KH_X7_\
M]2E_Y/\ _P!KH_UAR?\ Y^_^2R_R ]&HKSG_ (7_ /\ 4I?^3_\ ]KH_X7__
M -2E_P"3_P#]KH_UAR?_ )^_^2R_R ]&HKSG_A?_ /U*7_D__P#:Z[CPSK7_
M  D6A6VM?9O)^T(6\K?NV\D=<#/3TKJPF:8#'5'"A.[2OLUI\T@+U%%%>@ 4
M444 %%%% !1110 4444 %%%% 'A?_!/?_DB>K?\ 8]ZS_P"E)KW2OGK]@O6+
M^P^#FK06V@7%RO\ PG&LGS(B,9^TMQS7MO\ PDNK_P#0H7O_ 'TM &Q16/\
M\)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+0!L45C_\ "2ZO_P!"A>_]]+1_PDNK
M_P#0H7O_ 'TM &Q16/\ \)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+0!L45C_\
M"2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM &Q16/\ \)+J_P#T*%[_ -]+1_PD
MNK_]"A>_]]+0!L45C_\ "2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM &Q16/\
M\)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+0!L45C_\ "2ZO_P!"A>_]]+1_PDNK
M_P#0H7O_ 'TM &Q16/\ \)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+0!L45C_\
M"2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM &Q16/\ \)+J_P#T*%[_ -]+1_PD
MNK_]"A>_]]+0!L45C_\ "2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM &Q16/\
M\)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+0!L45C_\ "2ZO_P!"A>_]]+1_PDNK
M_P#0H7O_ 'TM &Q16/\ \)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+0!L45C_\
M"2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM &Q16/\ \)+J_P#T*%[_ -]+1_PD
MNK_]"A>_]]+0!L45C_\ "2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM &Q16/\
M\)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+0!L45C_\ "2ZO_P!"A>_]]+1_PDNK
M_P#0H7O_ 'TM &Q16/\ \)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+0!L45C_\
M"2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM &Q16/\ \)+J_P#T*%[_ -]+1_PD
MNK_]"A>_]]+0!L45C_\ "2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM &Q16/\
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M?4-6M9/B[8OXA@TY%+R71LD@(#)&"YM]Q<;2"1SCZY_9]^.GP]_:;^"7A?\
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M7T'"?^_3_P /ZH#L**R[/7M2N;I()O#-U"K-AI79<+[FM2OOP"BBB@ HHHH
M**** "BBB@ HHHH \+_X)[_\D3U;_L>]9_\ 2DU[I7A?_!/?_DB>K?\ 8]ZS
M_P"E)KW2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH *\+\?_P#(Z:G_ -?C_P Z]TKPOQ__ ,CIJ?\
MU^/_ #KY/BW_ '2G_B_0#'HHHKX,#P?_ (*7?L?ZS^W=^QAXO_9G\->,[?0=
M4UG['<Z5J%] 9;7[3:7<-W%'<( 2T+M"$; ) ;<%8KM/Q?\ #3_@H?\ M(?L
M4_'KXQ^,/^"@7['$-KX9G\6^&;/Q[\0_AGX@CU'2/#ERVE65M;2O:3!+D6T@
M,,ADY,9D$>&< -^B7[0?PR\>?%SX8W?@[X8_'#6?AUKS7,%QIOBO0[.WN9;6
M2*57VM!<JT4T3@%'C8896/(ZU\(^'_\ @F5^TY^T_P#&WXP_"W]LS]LC4]=^
M'=UXN\.7?BS2= ^&<&A)X[^S:;92PJUSYTQB@C:*.*1(,;WB8[HSA5]C 5:'
MU>4*[7+O;WN;5QO9K36RM?JNUP-S_@L'^V1\#V^,G@3_ ()R?&3XW6'P_P#!
MGC/2E\4_%SQ-J%V\ O/#4=P\46CVKH"QDOKB!XY"I&RWBD^\),5YM^PQ^W'^
MQ!J'_!:WXT7/PY^.7AC^P/'/@[P;X>^'(TXE(-2N;>V6$V=LH0 %#M3;@ 8
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MB?\ T(UXA7M_PS_Y$73O^N)_]"->OPG_ +]/_#^J W:***^_ **** "BBB@
MHHHH **** "BBB@#PO\ X)[_ /)$]6_['O6?_2DU[I7A?_!/?_DB>K?]CWK/
M_I2:]TH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "O"_'__ ".FI_\ 7X_\Z]TKPOQ__P CIJ?_ %^/
M_.OD^+?]TI_XOT QZ***^# **** "BBB@ HHHH **** "BBB@ KV_P"&?_(B
MZ=_UQ/\ Z$:\0KV_X9_\B+IW_7$_^A&OJ>$_]^G_ (?U0&[1117WX!1110 4
M444 %%%% !1110 4444 >%_\$]_^2)ZM_P!CWK/_ *4FO=*\+_X)[_\ )$]6
M_P"Q[UG_ -*37NE !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 5X7X__ .1TU/\ Z_'_ )U[I7A?C_\
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M 4444 %%%% !7A?C_P#Y'34_^OQ_YU[I7A?C_P#Y'34_^OQ_YU\GQ;_NE/\
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MI->Z5X7_ ,$]_P#DB>K?]CWK/_I2:]TH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O"_'_ /R.FI_]
M?C_SKW2O"_'_ /R.FI_]?C_SKY/BW_=*?^+] ,>BBBO@P"BBB@ HHHH ****
M "BBB@ HHHH *]O^&?\ R(NG?]<3_P"A&O$*]O\ AG_R(NG?]<3_ .A&OJ>$
M_P#?I_X?U0&[1117WX!1110 4444 %%%% 'Y?:E^Q#X1_P""G/\ P4\_:+\
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M+:MBB@#'_P"$'TC_ )^;W_P+:C_A!](_Y^;W_P "VK8HH Q_^$'TC_GYO?\
MP+:C_A!](_Y^;W_P+:MBB@#'_P"$'TC_ )^;W_P+:C_A!](_Y^;W_P "VK8H
MH Q_^$'TC_GYO?\ P+:C_A!](_Y^;W_P+:MBB@#'_P"$'TC_ )^;W_P+:C_A
M!](_Y^;W_P "VK8HH Q_^$'TC_GYO?\ P+:C_A!](_Y^;W_P+:MBB@#'_P"$
M'TC_ )^;W_P+:C_A!](_Y^;W_P "VK8HH Q_^$'TC_GYO?\ P+:C_A!](_Y^
M;W_P+:MBB@#'_P"$'TC_ )^;W_P+:C_A!](_Y^;W_P "VK8HH Q_^$'TC_GY
MO?\ P+:C_A!](_Y^;W_P+:MBB@#'_P"$'TC_ )^;W_P+:C_A!](_Y^;W_P "
MVK8HH Q_^$'TC_GYO?\ P+:C_A!](_Y^;W_P+:MBB@#'_P"$'TC_ )^;W_P+
M:C_A!](_Y^;W_P "VK8HH Q_^$'TC_GYO?\ P+:C_A!](_Y^;W_P+:MBB@#'
M_P"$'TC_ )^;W_P+:C_A!](_Y^;W_P "VK8HH Q_^$'TC_GYO?\ P+:C_A!]
M(_Y^;W_P+:MBB@#'_P"$'TC_ )^;W_P+:C_A!](_Y^;W_P "VK8HH Q_^$'T
MC_GYO?\ P+:C_A!](_Y^;W_P+:MBB@#'_P"$'TC_ )^;W_P+:O'O&EM'9^*]
M0M8F8K'<LJEVR>O<]Z]YKPOQ_P#\CIJ?_7X_\Z^3XM_W2G_B_0#'HHHKX, H
MHHH **** "BBB@ HHHH **** "O7/ /A/3;_ ,'V-Y-<709XB2$N64?>/05Y
M'7M_PS_Y$73O^N)_]"-?4\)_[]/_  _J@+-GX2TVQNDNX;BZ+1ME0]RQ'XBM
M2BBOOP"BBB@ HHHH ***\O\ VL_B5^TW\+/AQ8^(?V4?V:+7XJ^(YO$%M:WO
MAV[\9VVAK;:>X?SKP7%PK*YC(0>4!N;?P>#0!\$>%OVM/V4_^"9?_!73]I'6
MO^"B%T/!&L_%V_T75OA7\6->T::73]6T"#2[>V?28;N.-_LS6]Q%)OB;8'+(
MQS^[R^[_ &J/V7?^"F'_  61_9W\<?\ !.^8>,[KX/P^(;WXP?%C0]&FAT^R
MT:[TN:VM=(ENI(T%V\MRZND8+"/:[KR)-OM/[:/QT_X*?2_%7Q!\(OAC_P $
M5?!_QJ^&MK/;G1?$OB7XTZ+8QZKFWC>1VT^\@=H2DK2Q#=DD1[APPJ7]B?XZ
M?\%.6^+/A_X0?%K_ ((O^$?@E\,[AKIM7\3^&OC1HVH1Z45M99(BNGV<"-*9
M9TAA.W&T2[SPIH ^UJ*** /"_P#@GO\ \D3U;_L>]9_]*37NE>%_\$]_^2)Z
MM_V/>L_^E)KW2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *GB
M#_D WW_7G+_Z :^?J^@?$'_(!OO^O.7_ - -?/U?#\7?Q:7H_P! "BBBOCP"
MBJNL:WHWAW3VU;Q!J]K8VJ.B/<WEPL4:L[A$4LQ !9F50.Y8 <FK5 !155M<
MT1-570GUBU%\Z;TLS<+YK+_>"9R1P><=JM4 %%5;37=$O[^?2['6+6>ZM?\
MCYMH;A6DB_WE!ROXU+>7MGIUJ]]J%W%!!$NZ6::0*J#U)/ %%F!+14&G:GIN
ML6BZAI.H074#YV3VTJNC?0J2#4] !15:^UG1]+F@M]3U6VMY+J39;1SSJAE;
M^ZH)^8\C@>M6: )M._Y"$'_79?YBOH:OGG3O^0A!_P!=E_F*^AJ^VX1^"MZQ
M_4 HHHK[( HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O"_'_\
MR.FI_P#7X_\ .O=*\+\?_P#(Z:G_ -?C_P Z^3XM_P!TI_XOT QZ***^# **
M** "BBB@ HHHH **** "BBB@ KV_X9_\B+IW_7$_^A&O$*]O^&?_ "(NG?\
M7$_^A&OJ>$_]^G_A_5 ;M%%%??@%%%% !1110 5Y/^V3\(OVHOC7\(X_!W[(
MO[7W_"DO%2ZQ#<2>,O\ A7]EXDWVBI()+7[)>NL8WLT;>9G<OEX'WC7K%?,7
M_!67PU_P3I\7_LRZ=X=_X*=ZV;'X=W7C2PCL)!J>IVADU=HYUMD\S32)N5,W
M!.SUZ"@#QW_AWA_P77_Z6*O_ #4;PQ_\D5Z!^RY^QI_P5A^%'QVT+Q_^TO\
M\%H/^%L^";#[5_;?P_\ ^&=-"T'^U=]K+'#_ *=:S--!Y4SQ3_*#O\G8?E<F
MOA3]H?\ 8_\ ^#17]E#XQZU^S]^T)XJN/#7C'P[)"FM:'=>//&<LEJTL$<\8
M+0S.AS%+&W#'[W/.17HG_!,WPK_P;!Z;^V[X)O?^"=_Q+_M#XQ)_:7_"'V?_
M  D_BJX\S.FW0N_W=^QMVQ9FY/[P<8ROS!: /UFHHHH \+_X)[_\D3U;_L>]
M9_\ 2DU[I7A?_!/?_DB>K?\ 8]ZS_P"E)KW2@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** *GB#_D WW_7G+_Z :^?J^@?$'_(!OO\ KSE_] -?
M/U?#\7?Q:7H_T ****^/ _*O_@HG^TK\?/VCOC[\;/V4]._:6T_X7>'/A1JW
M@6+2_"5MH=E/K'C*74-0L9FU 2W@8I!:R/&56!#N*IYA 8JWZ ? /X-_'WP3
M\,M>^'G[1G[45W\2[S4+N9=*\4)X7M-$OK.QD@2,0NMI^ZDE1Q(XF"+G>H*_
M+D_#_P#P6J^,7_!*SXC^'/$7PL_:?\+:38_%#PQK6B6FFZAXH\*7=G=W&G/J
M-E+<M8ZBL8$]O]EEN,K'*2I$AVJP!KL/^".VO+X(O_V@-?\ AOXK\;7?[+>B
MZEIMS\%]3\=?;I9$ACL9)-7^Q&[7[2]BDH01D@@X.W<_F$^[7I.>6QE&/+;H
MXK7X5=2W;;UMVOT0&-^VI_P1W_X)1_LU?L4?$'XP:WX$N_#VN>&O#5UJ=E\3
M[KQ??RZXFKI&3;3K/)/^\G>X\M5C "NSA0HR,:/Q=U+_ (*&_$[_ (-X+/6/
M![^(9?C=JOPRTN;4&L=Z:S=6IGA-PR;</]KDL-S,!^\+,X \P@5\VZ5_P52_
M8'_X*)?M*_\ "Z/V\OVEM-\(_"'X>:^7^%GP4O=/O9FUV\B^[KNL^1"\;@9/
MDVNXA>=PQN,_U;_P5X^)FI_M8_\ !('6?BY^QAKNJ>+?"NM7=A=ZS)X4BGCN
M]6\.Q7P34(X5*I*!B-MXP,QI(#E2<[RAC*=2C3Q%V^=.\DVE_=3>_G9VZ=&!
M\>?'[P'_ ,$K[CX*_#J'_@BM?HW[3)\1Z0? #>$M0OFUS*RH;YM:5F/EPB#S
MFG-P%4%<?<W _IO^WW^R_P#L(?'+P+8?%']OSPWIU]X5^'B7-W%<ZYK=U::?
M8_:##&\TRP2HLOW(U7S P7<< $YK\^?^"B/[2/\ P2@^.?[#NC?"?_@G!I?A
MC5/C+>:IHP^"FC_#7PPUKX@T74([N!S)NBB26TV0I*',A&3ZGYA^@G[0G[=G
M[)7[)MIX6^%O[<OQ8TG0-3\4:#YPDUG29I=/OY(0BW ,B1-$I#D,$?;D$%0<
M'&>*^LOV3@I\UY;WY[:7L^UKVTT?-N!\9_L#^&?V9[+_ (*PV]]_P2%U"Z;X
M)P?#Z[3XW)H=Y>2^&O[69C_9ZVYN24:\X5CY.0L0;!&Z4']2Z_+_ .&_Q%_9
MQ_:G_P""TGPH^+/_  3#T6"?P]X4\)^((/C_ .-_">@R6.C:E;SVP&FV4TGE
MQQW5PMP!(" QP4(9A"P3[O\ !7[7OPB\>_M5>-/V.=!;4_\ A,? >B6.JZ\)
MK(+:_9[M5:'RY=QWMAQD8&*Y<RA4G4C*SNH)N_Q+5KWOPMMHT!\#_P#!./\
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M5\\Z=_R$(/\ KLO\Q7T-7J\(_!6]8_J 4445]D 4444 %%%% !1110 4444
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M2R #;PN200-W]D?]I[]O;XB?M"^'_!WQI_X(9_\ "G?#-Y]K_M/XC_\ "V=
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MBBB@ HHHH **** "BBB@ KPOQ_\ \CIJ?_7X_P#.O=*\+\?_ /(Z:G_U^/\
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M=%KZ_HH **** /"_^">__)$]6_['O6?_ $I->Z5X7_P3W_Y(GJW_ &/>L_\
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M_?5'_"8^&/\ H-0?]]5<_L[3_P#GQA_[]"C^SM/_ .?&'_OT* *?_"8^&/\
MH-0?]]4?\)CX8_Z#4'_?57/[.T__ )\8?^_0H_L[3_\ GQA_[]"@"G_PF/AC
M_H-0?]]4?\)CX8_Z#4'_ 'U5S^SM/_Y\8?\ OT*/[.T__GQA_P"_0H I_P#"
M8^&/^@U!_P!]4?\ "8^&/^@U!_WU5S^SM/\ ^?&'_OT*/[.T_P#Y\8?^_0H
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M%)?C)\6/$'B/PY_P4O\ ^%9>$!=X\(>%_!_PVT^]FBB"*!+>75YEY7+[B8T
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MT\*:C9*FD+=>%-,M9+"[5_WDBW=B<3(R_+Y;#Y"N0>37T'4U8*G-Q4K^:O\
MJD_P ]PT/Q;X;AT6SBEUB%66UC# GH0HJU_PF/AC_H-0?]]4N@6%BVA63-90
MDFTCR3&/[HJW_9VG_P#/C#_WZ%?K]'^#'T0%/_A,?#'_ $&H/^^J\9\;W$%W
MXMU"YMI \;W3%&'0C->Y?V=I_P#SXP_]^A7B'CQ$C\9:DD:A0+M\ # '-?,<
M6_[I3_Q?H!D4445\& 4444 %%%% !1110 4444 %%%% !7L'P^\3Z!9>#+"U
MN]5BCD2(AD8\CYC7C]>U?#>RLY? ^G226D3,83EFC!)^8U]3PG_OT_\ #^J
MT[;Q1X?O)UM;758GD<X1%/)-7ZB2QLHV#QV<2L.A6, BI:^_ **** "BBB@
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M1+)]GN8<GRITW;'3)VNK#)Q6Q110!X7_ ,$]_P#DB>K?]CWK/_I2:]TKPO\
MX)[_ /)$]6_['O6?_2DU[I0 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% %3Q!_R ;[_ *\Y?_0#7S]7T#X@_P"0#??]><O_ * :^?J^'XN_BTO1
M_H 4445\> 4444 %%%% !1110 4444 %%%% $VG?\A"#_KLO\Q7T-7SSIW_(
M0@_Z[+_,5]#5]MPC\%;UC^H!1117V0'SSJ/_ "$)_P#KLW\S4-3:C_R$)_\
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M ()L?&SXM>(/CI\1_P!GV]N_%7BF\^U:_JUI\0->LC=RX"[C';7T<:\ <*H
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M'6= \.7UPRV'B+4+"Z$(M9XPP6Y\E3/=>2V0/+1BI'7]"_BO^S#\#?C?\1?
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MGO\ \D3U;_L>]9_]*37NE !1110 4444 %%%% !1110 4444 %%%% !1110
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M+_X)[_\ )$]6_P"Q[UG_ -*37NE !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 5/$'_ " ;[_KSE_\ 0#7S]7T#X@_Y -]_UYR_^@&OGZOA^+OX
MM+T?Z %%%%?'@%%%% !1110 4444 %%%% !1110!-IW_ "$(/^NR_P Q7T-7
MSSIW_(0@_P"NR_S%?0U?;<(_!6]8_J 4445]D!\\ZC_R$)_^NS?S-0U-J/\
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M ".FI_\ 7X_\Z]TKPOQ__P CIJ?_ %^/_.OF.+?]TI_XOT QZ***^# ****
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M?_Y -C_UYQ?^@"K=5/#_ /R ;'_KSB_] %6Z_8Z/\&/H@"O"_'__ ".FI_\
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M'XU_#3X4P>%?CS^T1_PM+6H[R62#Q@WANVTJ2YM&(,*/#;$Q%D7Y3(N-_#$
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M_P!?C_SKW2O"_'__ ".FI_\ 7X_\Z^8XM_W2G_B_0#'HHHKX, HHHH ****
M"BBB@ HHHH **** "O;_ (9_\B+IW_7$_P#H1KQ"O;_AG_R(NG?]<3_Z$:^I
MX3_WZ?\ A_5 ;M%%%??@%%%% !1110 4444 %%%% !1110!X7_P3W_Y(GJW_
M &/>L_\ I2:]7^)G_(BZC_UQ'_H0KRC_ ()[_P#)$]6_['O6?_2DUZO\3/\
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M0?\ (!OO^O.7_P! -?/U?#\7?Q:7H_T ****^/ **** "BBB@ HHHH ****
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MYU[I7A?C_P#Y'34_^OQ_YU\QQ;_NE/\ Q?H!CT445\& 4444 %%%% !1110
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M^U@XWMNFN_<#Z,HKYS_X>W?\$Z/^CI-%_P# "\_^,T?\/;O^"='_ $=)HO\
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M'_1PFB_]^Y__ (W1_9N8_P#/F?\ X"_\@/::*\6_X>*?L4?]'":+_P!^Y_\
MXW1_P\4_8H_Z.$T7_OW/_P#&Z/[-S'_GS/\ \!?^0'M-%>+?\/%/V*/^CA-%
M_P"_<_\ \;H_X>*?L4?]'":+_P!^Y_\ XW1_9N8_\^9_^ O_ " ^ZO#_ /R
M;'_KSB_] %6Z^:M'_P""LW_!.VUTBUM9_P!J'15>.V177[#>'!"@$<0U9_X>
MW?\ !.C_ *.DT7_P O/_ (S7ZO235**?9 ?1E>%^/_\ D=-3_P"OQ_YUC_\
M#V[_ ()T?]'2:+_X 7G_ ,9KR?Q?_P %(_V'M4\3WVHV'[1.BR0S7+-&_DW
MR">N#'FOG>)\/7Q&%@J4')WZ)OIY >L45XM_P\4_8H_Z.$T7_OW/_P#&Z/\
MAXI^Q1_T<)HO_?N?_P"-U\5_9N8_\^9_^ O_ " ]IHKQ;_AXI^Q1_P!'":+_
M -^Y_P#XW1_P\4_8H_Z.$T7_ +]S_P#QNC^S<Q_Y\S_\!?\ D![317BW_#Q3
M]BC_ *.$T7_OW/\ _&Z/^'BG[%'_ $<)HO\ W[G_ /C=']FYC_SYG_X"_P#(
M#VFBO%(_^"C'[$\J[E_:#T<<X^:&X'\XZ=_P\4_8H_Z.$T7_ +]S_P#QNC^S
M<Q_Y\S_\!?\ D![317BW_#Q3]BC_ *.$T7_OW/\ _&Z/^'BG[%'_ $<)HO\
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MBB@#E_%7P0^"WCK5V\0>-OA#X7UB_=%1[[5?#]M<3,JC"@O(A8@#H,\5G?\
M#+_[-/\ T;QX%_\ "2L__C5=S10!PW_#+_[-/_1O'@7_ ,)*S_\ C5'_  R_
M^S3_ -&\>!?_  DK/_XU7<T4 <-_PR_^S3_T;QX%_P#"2L__ (U1_P ,O_LT
M_P#1O'@7_P )*S_^-5W-% '#?\,O_LT_]&\>!?\ PDK/_P"-4?\ #+_[-/\
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M$E9__&J/^&7_ -FG_HWCP+_X25G_ /&J[FB@#YV_;0_9W_9_T#]ECQOK.A?
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M_P!FG_HWCP+_ .$E9_\ QJNYHH X;_AE_P#9I_Z-X\"_^$E9_P#QJC_AE_\
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MNKOP3HLMP\4&O_&>PLO$6L6D1;,\&G+;R&)RJEE@=C(_  RPKW/]GW_@I?\
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M>)K?_@AU\"X_%:2K<&RUQK<3YW?96U[43 >>WE%-O^SMK[RH **** "BBB@
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M/&GP;\!WNHQ65Q\2O"WCK3_&6D:2\KA$DOOL2136L18JN\QDDLH56)Q7/_\
M!5K_ )3:_P#!.'_L8/B-_P"FG3J^G/\ @K(GP^D_X)A?M!K\4?LW]B?\*<\1
M&Z^U8QO&G3&+;G_EIYOE[,<[]F.<4 >]:+K6C^)-&M/$7A[5+>^L+^VCN;&]
MM)EDBN(74,DB.I(964@@C@@@UXS\;OVRO^%-_MM? O\ 8Y_X5Q_:7_"Z=/\
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MA?XJ:;KNG)X&NK!FF^SZM>7CSB6U2**3?)#Y32OY)X1I-J>H?\&K=MXDM?\
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M\+6_M+_A=&C^&[#_ (13^PO)_L?^R;/[-O\ M7GM]H\W[V/*CV=,OUKZ'HH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
)44 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>biib-20200930_g16.jpg
<TEXT>
begin 644 biib-20200930_g16.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ KA_VF_C+_P ,Y_LV_$+]H3_A&_[9_P"$$\#ZMXB_
MLC[9]G^W?8K.6Y\CS=C^5O\ *V[]C;=V=K8P>XKQ#_@IK_RC<_:#_P"R'^+/
M_3/=4 ?*/P#_ ."M7_!7C]IOX,^&_P!H#X+_ /!"&RU7PIXNTJ+4M!U&3]JC
M1K=KBVD&4<Q36"R)GT90?:OT.TK5KMO#-MKGBNPBTFX:Q2;4;62[61+.0H&D
M0RC"L$.1OX!QFORN_P""/_P@_P""RVK?\$Y?@9K?PA_;-^#.C^!9O ^GR:-H
M.L?"JZNK^WL<<0R7"WJJ\FW(WA ,]J[7]N+X>:%_P4-_X+C^ O\ @G%^T3<7
M][\&_ _[/MS\4-5\#QZA-;6?BK5WUD:; EX(F4SPP+ME12<;UD!!5F! /TDT
MW4]-UBRCU/2-0@NK:49BN+:4.CC.,AE)!Y%)JNL:3H5B^IZYJEM9VT9&^XNY
MUC1<G RS$ <\5^97@GX'^ /^"6__  71^$G[/O['.G3>%OA?^T7\//$<GB[X
M;6=[*^DV.KZ1!]IBU2WAD9A;R21A8&";5(W<9/'G'_!,_P#X)D?LI_MQ?M'_
M +:7C[]KWP3+X]TG2/VOO%VG>'/!VL:I<KI6F7!,+W-^EO%(B/<S))!$97!9
M$ME"%=S9 /V$!!&0:\:_9(_;.\'?M=^(/BWX>\)>$-3TJ3X1?%?4? >K2:B\
M;+?7=I#!*]Q#L)Q$PN% #8;*G(KUNXT32[K1'\.7%FKV4EJ;:2W8G#1%=I4G
MKC;Q7Y'_ /!&_P#X)*?\$Y?%OQP_:5\7>(_V4_#]WJ7PH_:XUC2_AY=R3W.[
M1+2QAT^>TABQ* 5CE9G&[<<GDF@#[A_91_;M\2?'C]K_ /:;_9X\;>&]%T;1
M?@3XCT'3M*UF*X=9+Z*_TXW4CW!D;8I5AM&W QUYKZ6M;JVO;:.\LKB.:&5
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MOAXOPXO_ !M\7V\!>.[+1M2NGMO$>DWMC/(5O(YI7$SQO#O61OFWD,2S(A4
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MER6*CW.:]:T[7]"U>XN+32=:M+J6TDV7<5O<J[0MS\KA22IX/!]*_$WXL?M
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MIBO8* /C3XL_\$(O^"6'Q?\ 'WC?X\_M.?!";QSK_BV_N]1UOQ#XT\8Z@_\
M9\+LTA@MMD\<=E;Q D)Y:J54#+'&:^?O^"+O[1OCKX'_ /!*3]H[XTCQ?K7C
M3X5?!_QSX[N?@%KOBFZ>:?5?"&DVQFM0)F^:6W#Q2HK]CO0!5157R3_@IK_P
M6"_99_:W_;/\3?\ !,;XO_M;+\%O@/X U%['XV^(1;7HUCQ[>Q2%)O#UB;:%
MVMK)71DN;AMK2@%$RAS)]W_"'XB?L%_\%)/^"=WQ&_9@_P""=OQ'T"_\#CP#
MJ7P_ACT/2KFTM-&^U:9)!'"$FBC;"QS*V0#GN2<T ?'/['W_  1@^ '[:O\
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M6UU"LD<JGJK*P(8>QJ>B@"MI&CZ1X?TR'1=!TNVL;.V39;VEI L442_W550
MH]@*LT44 %%%% &<OA#PFGB1O&2^%].&KO#Y3:J+*/[28_[AEQNV^V<5HT44
M %9WB7P?X2\:6::=XQ\+:=JUO'()(X-3L8YT5QT8*X(!]ZT:* &PPPVT*6]O
M$L<<:A41%P% X  '04ZBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BO$OV"-4U/5_@UJMSJVHSW4B^-]819+B9G8*+D@+EB> .@[5[;0 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110!X7_P $]_\ DB>K?]CWK/\ Z4FO=*\+_P""
M>_\ R1/5O^Q[UG_TI->Z4 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >%_P#!/?\
MY(GJW_8]ZS_Z4FO=*\+_ .">_P#R1/5O^Q[UG_TI->Z4 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M$'J2>!197UEJ5I'?Z=>17$$J[HIH) Z./4$<$4 2U[?\,_\ D1=._P"N)_\
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M-!T_P%X2GB74M7N+Z>2::%I99'FN'=V+.S'DX&<  <5^DU?D9^SG_P %9_\
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MK=?JM'^#'T0!7A?C_P#Y'34_^OQ_YU[I7A?C_P#Y'34_^OQ_YU\QQ;_NE/\
MQ?H!CT445\& 4444 %%%% !1110 4444 %%%% !7M_PS_P"1%T[_ *XG_P!"
M->(5[?\ #/\ Y$73O^N)_P#0C7U/"?\ OT_\/ZH#=HHHK[\ HHHH **** "B
MBB@ HHHH **** /"_P#@GO\ \D3U;_L>]9_]*37NE>%_\$]_^2)ZM_V/>L_^
ME)KW2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** /GG4?\ D(3_ /79OYFH:FU'
M_D(3_P#79OYFH:_&9_&P"BBBI XW]GOX+:#^SK\%O#GP0\+ZK>7VG^&M.6SM
M+N_V>=*@).7V +GGL!79444Y2<Y.3W8!5#4O"GA?6=2M=9UCPW87=Y9'-E=W
M-FDDMN?5&8$I^!%7Z*2;0!5"S\*>%].UFX\1Z?X;L(-0NQBZOX;-%FF'H[@;
MF_$U?HHNT 5G^(?"7A7Q=;)9>+/#.GZI#&VY(=1LDG53Z@." :T**$VGH RV
MMK:RMTL[.W2**) L442!511P  . /:GT44 ?0/A__D V/_7G%_Z *MU4\/\
M_(!L?^O.+_T 5;K]CH_P8^B *\+\?_\ (Z:G_P!?C_SKW2O"_'__ ".FI_\
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MR\67XC^Q7#G2UU.Y$ 1C(1;P.@D+JOS-A=P&:^=?V./^"S%[^V3\5/!GP?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% 'SSJ/_ "$)_P#KLW\S4-3:C_R$)_\ KLW\
MS4-?C,_C8!1114@%%%% !1110 4444 %%%% !1110!] ^'_^0#8_]><7_H J
MW53P_P#\@&Q_Z\XO_0!5NOV.C_!CZ( KPOQ__P CIJ?_ %^/_.O=*\+\?_\
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M9N"=GKT% 'CO_#O#_@NO_P!+%7_FHWAC_P"2*] _9<_8T_X*P_"CX[:%X_\
MVE_^"T'_  MGP38?:O[;^'__  SIH6@_VKOM98X?].M9FF@\J9XI_E!W^3L/
MRN37PI^T/^Q__P &BO[*'QCUK]G[]H3Q5<>&O&/AV2%-:T.Z\>>,Y9+5I8(Y
MXP6AF=#F*6-N&/WN><BO1/\ @F;X5_X-@]-_;=\$WO\ P3O^)?\ :'QB3^TO
M^$/L_P#A)_%5QYF=-NA=_N[]C;MBS-R?W@XQE?F"T ?K-1110!\]?L%^&[#5
MO@YJUU<S7"L/'&LKB*<J,?:6["O;?^$'TC_GYO?_  +:O(_^">__ "1/5O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@#YYU'_D(3_]=F_F:AJ;4?\ D(3_ /79OYFH:_&9
M_&P"BBBI **** "BBB@ HHHH **** "BBB@#Z!\/_P#(!L?^O.+_ - %6ZJ>
M'_\ D V/_7G%_P"@"K=?L='^#'T0!7A?C_\ Y'34_P#K\?\ G7NE>%^/_P#D
M=-3_ .OQ_P"=?,<6_P"Z4_\ %^@&/1117P8!1110 4444 %%%% !1110 444
M4 %>W_#/_D1=._ZXG_T(UXA7M_PS_P"1%T[_ *XG_P!"-?4\)_[]/_#^J W:
M***^_ **** "BBB@ HHHH _-/XA^&O\ @L3^RE_P4>^,WQ<_89_8 \'>-_A;
M\3;C2K_5$\0?%2RT^74-6M].AMWU"W5L26>Y5$,D,BRB0VZRJ8][!O;?V7/V
MF/\ @L-\0?CMH7A#]J?_ ()D>#_A[X#N_M7]N^,-*^-%GJT^G[+65X-MI'&&
MEWSK#$<'Y1(6Z+7U_10 4444 >%_\$]_^2)ZM_V/>L_^E)KW2O"_^">__)$]
M6_['O6?_ $I->Z4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\\ZC_ ,A"?_KL
MW\S4-3:C_P A"?\ Z[-_,U#7XS/XV 4445(!1110 4444 %%%% !1110 444
M4 ?0/A__ ) -C_UYQ?\ H JW53P__P @&Q_Z\XO_ $ 5;K]CH_P8^B *\+\?
M_P#(Z:G_ -?C_P Z]TKPOQ__ ,CIJ?\ U^/_ #KYCBW_ '2G_B_0#'HHHKX,
M HHHH **** "BBB@ HHHH **** "O;_AG_R(NG?]<3_Z$:\0KV_X9_\ (BZ=
M_P!<3_Z$:^IX3_WZ?^']4!NT445]^ 4444 %%%% !117,_&#XT?"+]GWX?WO
MQ7^.OQ-T'P?X8TUHEU#Q!XEU6*RL[8RR+%&'FE944M(Z(,GEF ')H _.Z[_9
M0\5?\%-_^"EG[1/@K]K#]K'XN>%O#_PBU30=/^'?PN^'?CB;0+-M+N]-CN/[
M8G\CY[MIY_/19,C88I8\G:%3Z$_9F_X(X?LW?LJ_&[1/CWX!^,OQLU;5M!^T
M_9-/\7?%S4=4TZ7S[:6W;S;:9RDN$F9ER/E<*PY45\F?M0_"7_@WE_:R_:@U
M?]KWQ]_P5]MM(\9:O;16QN/"7[3%GI\-G;I#'%Y%NB.3#&WEAV16VL[,Q&37
M>?L ? /_ ((Z>"OVN/"7B;]E;_@K#XD^)?CVV^W_ -@^";_]I--?AU+=87"3
M[K .3/Y<#33#CY#$'_@H _2JBBB@#PO_ ()[_P#)$]6_['O6?_2DU[I7A?\
MP3W_ .2)ZM_V/>L_^E)KW2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /GG4?^
M0A/_ -=F_F:AJ;4?^0A/_P!=F_F:AK\9G\; ****D HHHH **** "BBB@ HH
MHH **** /H'P_P#\@&Q_Z\XO_0!5NJGA_P#Y -C_ -><7_H JW7['1_@Q]$
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M%VWB27X.:LVDZE;Q1?\ "<:SE982QS]I;G->J^/K7Q7'X/OGO]5M9(1$-Z)
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M%GX<?!G]BW4_C1\,_B'X\OO&7P_O?"_BFQL9]$O;X*;C3+U+MU,<"NB[)EW
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MB_\ 0!5NOV.C_!CZ( KPOQ__ ,CIJ?\ U^/_ #KW2O"_'_\ R.FI_P#7X_\
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M!_UV7^8KZ&KYYT[_ )"$'_79?YBOH:OKN$?@K>L?U ****^R ^>=1_Y"$_\
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M **** "BBB@ HHHH *V/ '_(Z:9_U^)_.L>MCP!_R.FF?]?B?SKIP7^^4_\
M$OS0'NE%%%?KX%3Q!_R ;[_KSE_] -?/U?0/B#_D WW_ %YR_P#H!KY^KX?B
M[^+2]'^@!1117QX!1110 4444 %%%% !1110 4444 3:=_R$(/\ KLO\Q7T-
M7SSIW_(0@_Z[+_,5]#5]MPC\%;UC^H!1117V0'SSJ/\ R$)_^NS?S-0U-J/_
M "$)_P#KLW\S4-?C,_C8!1114@%%%% !1110 4444 %%%% !1110!] ^'_\
MD V/_7G%_P"@"K=5/#__ " ;'_KSB_\ 0!5NOV.C_!CZ( KPOQ__ ,CIJ?\
MU^/_ #KW2O"_'_\ R.FI_P#7X_\ .OF.+?\ =*?^+] ,>BBBO@P"BBB@ HHH
MH **** "BBB@ HHHH *]O^&?_(BZ=_UQ/_H1KQ"O;_AG_P B+IW_ %Q/_H1K
MZGA/_?I_X?U0&[1117WX!1110 4444 %%%% !1110 4444 >%_\ !/?_ )(G
MJW_8]ZS_ .E)KU?XF?\ (BZC_P!<1_Z$*\H_X)[_ /)$]6_['O6?_2DUZO\
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M*** "O;_ (9_\B+IW_7$_P#H1KQ"O;_AG_R(NG?]<3_Z$:^IX3_WZ?\ A_5
M;M%%%??@%%%% !1110 4444 %%%% !1110!X7_P3W_Y(GJW_ &/>L_\ I2:]
M7^)G_(BZC_UQ'_H0KRC_ ()[_P#)$]6_['O6?_2DUZO\3/\ D1=1_P"N(_\
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M *$:\0KV_P"&?_(BZ=_UQ/\ Z$:^IX3_ -^G_A_5 ;M%%%??@%%%% !1110
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M?.?_  ]N_P""='_1TFB_^ %Y_P#&:/\ A[=_P3H_Z.DT7_P O/\ XS7ZF!]
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M_=AG)_(1T?V;F/\ SYG_ . O_(#VNBO%1_P45_8H(!'[0FC<^L4__P ;I?\
MAXI^Q1_T<)HO_?N?_P"-T?V;F/\ SYG_ . O_(#VFBO%O^'BG[%'_1PFB_\
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M"[?M!Z/@?W89R?R$=*/^"BO[%! (_:$T;GUBG_\ C=']FYC_ ,^9_P#@+_R
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M &:?^C>/ O\ X25G_P#&J/\ AE_]FG_HWCP+_P"$E9__ !JNYHH X;_AE_\
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MHH X;_AE_P#9I_Z-X\"_^$E9_P#QJC_AE_\ 9I_Z-X\"_P#A)6?_ ,:KN:*
M.&_X9?\ V:?^C>/ O_A)6?\ \:H_X9?_ &:?^C>/ O\ X25G_P#&J[FB@#AO
M^&7_ -FG_HWCP+_X25G_ /&J/^&7_P!FG_HWCP+_ .$E9_\ QJNYHH X;_AE
M_P#9I_Z-X\"_^$E9_P#QJC_AE_\ 9I_Z-X\"_P#A)6?_ ,:KN:* .&_X9?\
MV:?^C>/ O_A)6?\ \:H_X9?_ &:?^C>/ O\ X25G_P#&J[FB@#AO^&7_ -FG
M_HWCP+_X25G_ /&J\O\ VT/V=_V?] _98\;ZSH7P,\'65Y;Z([V]U:>&+2.2
M)MR\JRQ@J?<5]$UB?$CX?>'/BKX%U/X=^+HI7TW5K8P7BP2E'*$@\,.AXH X
M;X;?LS_LX7?P[T"ZNOV?O!$LLNBVKR22>%+-F=C"I)),>22>];?_  R_^S3_
M -&\>!?_  DK/_XU78:-I5IH.CVFAZ>K""RMHX( [9(1%"KD]S@"K- '#?\
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M -&\>!?_  DK/_XU1_PR_P#LT_\ 1O'@7_PDK/\ ^-5W-% '#?\ #+_[-/\
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M_P#XU1_PR_\ LT_]&\>!?_"2L_\ XU7<T4 <-_PR_P#LT_\ 1O'@7_PDK/\
M^-4?\,O_ +-/_1O'@7_PDK/_ .-5W-% '#?\,O\ [-/_ $;QX%_\)*S_ /C5
M'_#+_P"S3_T;QX%_\)*S_P#C5=S10!\N?L(_L_\ P&\1_![5+[Q#\$O"-_.G
MC75XDFO?#=K*ZQK<$*@+1DA0. .@KVK_ (9?_9I_Z-X\"_\ A)6?_P :K5^%
MOPI\(_![P[/X7\%PSI:7&I7%](+B<R-YTS[W.3VST':NDH X;_AE_P#9I_Z-
MX\"_^$E9_P#QJC_AE_\ 9I_Z-X\"_P#A)6?_ ,:KN:* .&_X9?\ V:?^C>/
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MC[)H?PKLHUN?%6H> _B]9:_K?A>RS\US<V*V\2W"1K\TABD C4,S$*I(P?\
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M&?A?X<>#-7^(?C?68M.T70=+N-1U?4)\[+6U@C:665L G:J*S''85^=^C_\
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MX-DH/$UO_P $.O@7'XK25;@V6N-;B?.[[*VO:B8#SV\HIM_V=M?>5 !1110
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MK$^F_8?LOD\8\CS?.\WG=M\L8W'P7QW^W]_P5\?6-?\ $GP7_P""*LVI^#=
MU"[BM)O$_P :+#3-9\06\$C+Y]K8"WD,.\*61)6W."N!R,_6,?[.'P8A_:2F
M_:[C\&X^(=QX'B\'S>(?[1N?FT6.\DO4M?(\SR!BXE=_,$?F'=M+[0%'A/\
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M73I_BRZ_X2/^V/)_L;^Q+2TN-OV?R6^T>=]JVY\R/R]F</NP.'_X(A-XO?\
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M_P 5--UW3D\#75@S3?9]6O+QYQ+:I%%)ODA\II7\D\(TFU/4/^#5NV\26O\
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MG_:"M_ FL1ZOX2\!0^"['POX9AOX\^5<W-A:-*;QT))4R2=V5MR,R'[NHHH
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6BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>biib-20200930_g17.jpg
<TEXT>
begin 644 biib-20200930_g17.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?@3XCT'3M*UF*X=9+Z*_TXW4CW!D;8I5AM&W QUYKZ6M;JVO;:.\LKB.:&5
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MOAXOPXO_ !M\7V\!>.[+1M2NGMO$>DWMC/(5O(YI7$SQO#O61OFWD,2S(A4
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MER6*CW.:]:T[7]"U>XN+32=:M+J6TDV7<5O<J[0MS\KA22IX/!]*_$WXL?M
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MIBO8* /C3XL_\$(O^"6'Q?\ 'WC?X\_M.?!";QSK_BV_N]1UOQ#XT\8Z@_\
M9\+LTA@MMD\<=E;Q D)Y:J54#+'&:^?O^"+O[1OCKX'_ /!*3]H[XTCQ?K7C
M3X5?!_QSX[N?@%KOBFZ>:?5?"&DVQFM0)F^:6W#Q2HK]CO0!5157R3_@IK_P
M6"_99_:W_;/\3?\ !,;XO_M;+\%O@/X U%['XV^(1;7HUCQ[>Q2%)O#UB;:%
MVMK)71DN;AMK2@%$RAS)]W_"'XB?L%_\%)/^"=WQ&_9@_P""=OQ'T"_\#CP#
MJ7P_ACT/2KFTM-&^U:9)!'"$FBC;"QS*V0#GN2<T ?'/['W_  1@^ '[:O\
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M6UU"LD<JGJK*P(8>QJ>B@"MI&CZ1X?TR'1=!TNVL;.V39;VEI L442_W550
MH]@*LT44 %%%% &<OA#PFGB1O&2^%].&KO#Y3:J+*/[28_[AEQNV^V<5HT44
M %9WB7P?X2\:6::=XQ\+:=JUO'()(X-3L8YT5QT8*X(!]ZT:* &PPPVT*6]O
M$L<<:A41%P% X  '04ZBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** *5]XBT339_LM_J4<4@ .QCSBHO^$Q\,?]!J#_OJKTMG:3-OFM8W;U9
M33?[.T__ )\8?^_0H I_\)CX8_Z#4'_?5'_"8^&/^@U!_P!]5<_L[3_^?&'_
M +]"C^SM/_Y\8?\ OT* *?\ PF/AC_H-0?\ ?5'_  F/AC_H-0?]]5<_L[3_
M /GQA_[]"C^SM/\ ^?&'_OT* *?_  F/AC_H-0?]]4?\)CX8_P"@U!_WU5S^
MSM/_ .?&'_OT*/[.T_\ Y\8?^_0H I_\)CX8_P"@U!_WU1_PF/AC_H-0?]]5
M<_L[3_\ GQA_[]"C^SM/_P"?&'_OT* *?_"8^&/^@U!_WU1_PF/AC_H-0?\
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M\)CX8_Z#4'_?5'_"8^&/^@U!_P!]5<_L[3_^?&'_ +]"C^SM/_Y\8?\ OT*
M*?\ PF/AC_H-0?\ ?5'_  F/AC_H-0?]]5<_L[3_ /GQA_[]"C^SM/\ ^?&'
M_OT* *?_  F/AC_H-0?]]4?\)CX8_P"@U!_WU5S^SM/_ .?&'_OT*/[.T_\
MY\8?^_0H I_\)CX8_P"@U!_WU1_PF/AC_H-0?]]5<_L[3_\ GQA_[]"C^SM/
M_P"?&'_OT* *?_"8^&/^@U!_WU1_PF/AC_H-0?\ ?57/[.T__GQA_P"_0H_L
M[3_^?&'_ +]"@"G_ ,)CX8_Z#4'_ 'U1_P )CX8_Z#4'_?57/[.T_P#Y\8?^
M_0H_L[3_ /GQA_[]"@"G_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]5<_L[3_P#G
MQA_[]"C^SM/_ .?&'_OT* *?_"8^&/\ H-0?]]4?\)CX8_Z#4'_?57/[.T__
M )\8?^_0H_L[3_\ GQA_[]"@"G_PF/AC_H-0?]]4?\)CX8_Z#4'_ 'U5S^SM
M/_Y\8?\ OT*/[.T__GQA_P"_0H I_P#"8^&/^@U!_P!]4?\ "8^&/^@U!_WU
M5S^SM/\ ^?&'_OT*/[.T_P#Y\8?^_0H I_\ "8^&/^@U!_WU1_PF/AC_ *#4
M'_?57/[.T_\ Y\8?^_0H_L[3_P#GQA_[]"@"G_PF/AC_ *#4'_?5'_"8^&/^
M@U!_WU5S^SM/_P"?&'_OT*/[.T__ )\8?^_0H I_\)CX8_Z#4'_?5'_"8^&/
M^@U!_P!]5<_L[3_^?&'_ +]"C^SM/_Y\8?\ OT* *?\ PF/AC_H-0?\ ?5'_
M  F/AC_H-0?]]5<_L[3_ /GQA_[]"C^SM/\ ^?&'_OT* *?_  F/AC_H-0?]
M]4?\)CX8_P"@U!_WU5S^SM/_ .?&'_OT*/[.T_\ Y\8?^_0H I_\)CX8_P"@
MU!_WU1_PF/AC_H-0?]]5<_L[3_\ GQA_[]"C^SM/_P"?&'_OT* *?_"8^&/^
M@U!_WU1_PF/AC_H-0?\ ?57/[.T__GQA_P"_0H_L[3_^?&'_ +]"@"G_ ,)C
MX8_Z#4'_ 'U1_P )CX8_Z#4'_?57/[.T_P#Y\8?^_0H_L[3_ /GQA_[]"@"G
M_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]5<_L[3_P#GQA_[]"C^SM/_ .?&'_OT
M* *?_"8^&/\ H-0?]]4?\)CX8_Z#4'_?57/[.T__ )\8?^_0H_L[3_\ GQA_
M[]"@"G_PF/AC_H-0?]]4?\)CX8_Z#4'_ 'U5S^SM/_Y\8?\ OT*/[.T__GQA
M_P"_0H K6WBCP_>3K:VNJQ/(YPB*>2:OU$EC91L'CLXE8="L8!%2T %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M!G:EX9T_5;HW=Q/<JQ4#$5P5''L*@_X0?2/^?F]_\"VK8HH Q_\ A!](_P"?
MF]_\"VH_X0?2/^?F]_\  MJV** ,?_A!](_Y^;W_ ,"VH_X0?2/^?F]_\"VK
M8HH Q_\ A!](_P"?F]_\"VH_X0?2/^?F]_\  MJV** ,?_A!](_Y^;W_ ,"V
MH_X0?2/^?F]_\"VK8HH Q_\ A!](_P"?F]_\"VH_X0?2/^?F]_\  MJV** ,
M?_A!](_Y^;W_ ,"VH_X0?2/^?F]_\"VK8HH Q_\ A!](_P"?F]_\"VH_X0?2
M/^?F]_\  MJV** ,?_A!](_Y^;W_ ,"VH_X0?2/^?F]_\"VK8HH Q_\ A!](
M_P"?F]_\"VH_X0?2/^?F]_\  MJV** ,?_A!](_Y^;W_ ,"VH_X0?2/^?F]_
M\"VK8HH Q_\ A!](_P"?F]_\"VH_X0?2/^?F]_\  MJV** ,?_A!](_Y^;W_
M ,"VH_X0?2/^?F]_\"VK8HH Q_\ A!](_P"?F]_\"VH_X0?2/^?F]_\  MJV
M** ,?_A!](_Y^;W_ ,"VH_X0?2/^?F]_\"VK8HH Q_\ A!](_P"?F]_\"VH_
MX0?2/^?F]_\  MJV** ,?_A!](_Y^;W_ ,"VH_X0?2/^?F]_\"VK8HH Q_\
MA!](_P"?F]_\"VH_X0?2/^?F]_\  MJV** ,?_A!](_Y^;W_ ,"VH_X0?2/^
M?F]_\"VK8HH Q_\ A!](_P"?F]_\"VH_X0?2/^?F]_\  MJV** ,?_A!](_Y
M^;W_ ,"VH_X0?2/^?F]_\"VK8HH Q_\ A!](_P"?F]_\"VH_X0?2/^?F]_\
M MJV** ,?_A!](_Y^;W_ ,"VH_X0?2/^?F]_\"VK8HH Q_\ A!](_P"?F]_\
M"VH_X0?2/^?F]_\  MJV** ,?_A!](_Y^;W_ ,"VH_X0?2/^?F]_\"VK8HH
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M67?\_H?^!+_,"W_P@^D?\_-[_P"!;4?\(/I'_/S>_P#@6U5/^%M?#[_H8/\
MR4E_^(H_X6U\/O\ H8/_ "4E_P#B*/[2R[_G]#_P)?Y@6_\ A!](_P"?F]_\
M"VH_X0?2/^?F]_\  MJJ?\+:^'W_ $,'_DI+_P#$4?\ "VOA]_T,'_DI+_\
M$4?VEEW_ #^A_P"!+_,"W_P@^D?\_-[_ .!;4?\ "#Z1_P _-[_X%M53_A;7
MP^_Z&#_R4E_^(K<TS4[+6+"/4].G\R"9<QOM(R,XZ$ UK1Q>%Q$N6E4C)^33
M_("E9^$M-L;I+N&XNBT;94/<L1^(K4HHKH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %Q/_H1KZ;A/_?I_X?U0&[1117WX!1110 4444 %%%% !1110 4444 %%%%
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MEW+/>7$'[HRO-&C*JG*AW5@NT;OM>IQL:,*]J=ME>SND[:I/6ZOYOU *]O\
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M^^J/^$Q\,?\ 0:@_[ZJY_9VG_P#/C#_WZ%']G:?_ ,^,/_?H4 4_^$Q\,?\
M0:@_[ZH_X3'PQ_T&H/\ OJKG]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ% %/\
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M#_OJKG]G:?\ \^,/_?H4?V=I_P#SXP_]^A0!3_X3'PQ_T&H/^^J/^$Q\,?\
M0:@_[ZJY_9VG_P#/C#_WZ%']G:?_ ,^,/_?H4 4_^$Q\,?\ 0:@_[ZH_X3'P
MQ_T&H/\ OJKG]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ% %/\ X3'PQ_T&H/\
MOJC_ (3'PQ_T&H/^^JN?V=I__/C#_P!^A1_9VG_\^,/_ 'Z% %/_ (3'PQ_T
M&H/^^J/^$Q\,?]!J#_OJKG]G:?\ \^,/_?H4?V=I_P#SXP_]^A0!3_X3'PQ_
MT&H/^^J/^$Q\,?\ 0:@_[ZJY_9VG_P#/C#_WZ%']G:?_ ,^,/_?H4 4_^$Q\
M,?\ 0:@_[ZH_X3'PQ_T&H/\ OJKG]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ%
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M^T/\9-?N/GO+G7/B5+IVGQR'J+6PL5CCM8\\B-2P'K5G1_\ @B_\7_V6)?\
MA*?^";G_  4M^+O@F]MSOC\$?$_5_P#A+_"=[C_EB]I<A)K??]UIHI?,48*C
M(Y /OFBL?X>/X^D\ :&_Q6ATB/Q0VCVQ\21Z \K6"W_E+]H%L90)#")=^PN
MQ7;NYS6Q0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !7A?C_\ Y'34_P#K\?\ G7NE>%^/_P#D
M=-3_ .OQ_P"=?)\6_P"Z4_\ %^@&/1117P8!1110 4444 %%%% !1110 444
M4 %>W_#/_D1=._ZXG_T(UXA7M_PS_P"1%T[_ *XG_P!"-?4\)_[]/_#^J W:
M***^_ **** "BBB@ HHHH _*3XI_\%+=!_8H\<_\%$O$OQ=^/\>F_$W0[[3C
M\(_!7B#7_FFMW\-VT>DG3+*5\2*][+(\WD(><M)7/_LO_L.Q_P#!+W]K7]BS
M7O OCWQI-\3_ (^6NM6'[15CK_BB[O5\57">'GU.YO9H9W98Y+.\10KJ VUM
MKEBS%O8_VUOVPO@-XU_;BOOA7\"?^".=Q^U-\6_@[#8MK_C)-!TBWM_",\Z?
M:K6T35=01B+@*WG"-,!"<J2ZN$[+]GG]H_\ :Q_:1_;&\":_^TI_P0UUKX=2
MZ19ZI:Z=\7M?^(.CZI)X8AFM)'D2*.%?. N7AAMV\LC/F*6RJD4 ?<U%%% !
M15*^\1:)IL_V6_U*.*0 '8QYQ47_  F/AC_H-0?]]4 :5%9O_"8^&/\ H-0?
M]]4?\)CX8_Z#4'_?5 &E16;_ ,)CX8_Z#4'_ 'U1_P )CX8_Z#4'_?5 &E16
M;_PF/AC_ *#4'_?5'_"8^&/^@U!_WU0!I45F_P#"8^&/^@U!_P!]4?\ "8^&
M/^@U!_WU0!I45F_\)CX8_P"@U!_WU1_PF/AC_H-0?]]4 :5%9O\ PF/AC_H-
M0?\ ?5'_  F/AC_H-0?]]4 :5%9O_"8^&/\ H-0?]]4?\)CX8_Z#4'_?5 &E
M16;_ ,)CX8_Z#4'_ 'U1_P )CX8_Z#4'_?5 &E16;_PF/AC_ *#4'_?5'_"8
M^&/^@U!_WU0!I45F_P#"8^&/^@U!_P!]4?\ "8^&/^@U!_WU0!I45F_\)CX8
M_P"@U!_WU1_PF/AC_H-0?]]4 :5%9O\ PF/AC_H-0?\ ?5'_  F/AC_H-0?]
M]4 :5%9O_"8^&/\ H-0?]]4?\)CX8_Z#4'_?5 &E16;_ ,)CX8_Z#4'_ 'U1
M_P )CX8_Z#4'_?5 &E16;_PF/AC_ *#4'_?5'_"8^&/^@U!_WU0!I45F_P#"
M8^&/^@U!_P!]4?\ "8^&/^@U!_WU0!I45F_\)CX8_P"@U!_WU1_PF/AC_H-0
M?]]4 :5%9O\ PF/AC_H-0?\ ?5'_  F/AC_H-0?]]4 :5%9O_"8^&/\ H-0?
M]]4?\)CX8_Z#4'_?5 &E16;_ ,)CX8_Z#4'_ 'U1_P )CX8_Z#4'_?5 &E16
M;_PF/AC_ *#4'_?5'_"8^&/^@U!_WU0!I45F_P#"8^&/^@U!_P!]4?\ "8^&
M/^@U!_WU0!I45F_\)CX8_P"@U!_WU1_PF/AC_H-0?]]4 :5%9O\ PF/AC_H-
M0?\ ?5'_  F/AC_H-0?]]4 :5%9O_"8^&/\ H-0?]]4?\)CX8_Z#4'_?5 &E
M7A?C_P#Y'34_^OQ_YU[%_P )CX8_Z#4'_?5>,^-[B"[\6ZA<VT@>-[IBC#H1
MFOD^+?\ =*?^+] ,NBBBO@P"BBB@ HHHH **** "BBB@ HHHH *]O^&?_(BZ
M=_UQ/_H1KQ"O8/A]XGT"R\&6%K=ZK%'(D1#(QY'S&OJ>$_\ ?I_X?U0'6450
MMO%'A^\G6UM=5B>1SA$4\DU?K[\ HHHH **** "BBB@#\Q/$_P 5/^"@/[!W
M_!2_X\>)/V;_ /@E-XX^*OPP^*%_I&L7NL:;XGT^S/\ ;<.F0037-HTK$O;R
M(J1O#(JLDT$CJY5P@]\_9<_X*%_MN_'+X[:%\+?B]_P2$^)'PN\.ZI]J_M'Q
MUK_B_3;JTTSR[66:/S(H#YC>9)&D(V]&E4G@&O+?BEXH_P""CW_!2']M3XL?
ML^_LF?MAVW[/OPI^!^JV&@:YXDTGPA;:QKWBG7)[**]F1/M)"6EM"D\2!E(9
MFR?G#8C?\&_&/_!1G_@G9^W+\*_V6_VO/VN[3]H#X8?'&75-+\+>+-2\(V^C
MZ[X8UJRLI+Y89A;$I=VTT44BAV)</C_5JF) #]#J*** (Y;.TF;?-:QNWJR
MFF_V=I__ #XP_P#?H5-10!#_ &=I_P#SXP_]^A1_9VG_ //C#_WZ%344 0_V
M=I__ #XP_P#?H4?V=I__ #XP_P#?H5-10!#_ &=I_P#SXP_]^A1_9VG_ //C
M#_WZ%344 0_V=I__ #XP_P#?H4?V=I__ #XP_P#?H5-10!#_ &=I_P#SXP_]
M^A1_9VG_ //C#_WZ%344 0_V=I__ #XP_P#?H4?V=I__ #XP_P#?H5-10!#_
M &=I_P#SXP_]^A1_9VG_ //C#_WZ%344 0_V=I__ #XP_P#?H4?V=I__ #XP
M_P#?H5-10!#_ &=I_P#SXP_]^A1_9VG_ //C#_WZ%344 0_V=I__ #XP_P#?
MH4?V=I__ #XP_P#?H5-10!#_ &=I_P#SXP_]^A1_9VG_ //C#_WZ%344 0_V
M=I__ #XP_P#?H4?V=I__ #XP_P#?H5-10!#_ &=I_P#SXP_]^A1_9VG_ //C
M#_WZ%344 0_V=I__ #XP_P#?H4?V=I__ #XP_P#?H5-10!#_ &=I_P#SXP_]
M^A1_9VG_ //C#_WZ%344 0_V=I__ #XP_P#?H4?V=I__ #XP_P#?H5-10!#_
M &=I_P#SXP_]^A1_9VG_ //C#_WZ%344 0_V=I__ #XP_P#?H4?V=I__ #XP
M_P#?H5-10!#_ &=I_P#SXP_]^A1_9VG_ //C#_WZ%344 0_V=I__ #XP_P#?
MH4?V=I__ #XP_P#?H5-10!#_ &=I_P#SXP_]^A1_9VG_ //C#_WZ%344 0_V
M=I__ #XP_P#?H4?V=I__ #XP_P#?H5-10!#_ &=I_P#SXP_]^A1_9VG_ //C
M#_WZ%344 0_V=I__ #XP_P#?H4?V=I__ #XP_P#?H5-10!#_ &=I_P#SXP_]
M^A1_9VG_ //C#_WZ%344 0_V=I__ #XP_P#?H5XAX\1(_&6I)&H4"[?  P!S
M7NM>%^/_ /D=-3_Z_'_G7R?%O^Z4_P#%^@&/1117P8!1110 4444 %%%% !1
M110 4444 %>U?#>RLY? ^G226D3,83EFC!)^8UXK7M_PS_Y$73O^N)_]"-?4
M\)_[]/\ P_J@-A+&RC8/'9Q*PZ%8P"*EHHK[\ HHHH **** "HKN^LM/B$U_
M>10(6"AYI H)/09/>I:^7?\ @KAX@_X)G^%?V8-.\0?\%698D^&MIXVL)=/D
MFMM7F":RL<[6S;=)5IR0HGZCR_[W.* /,_VI_P#@GK^U%X7_ &KO%7[8_P#P
M30_;NT3X4>*_']I91?$SP+XVT"+5= \07-K"(+>^"EO,L[A80B,T:GS H)(R
MV^7]DS_@GM^TMK7[5_AS]M+_ (*4?MS:-\6O&_@?3KZT^&/@_P &:#%I6@^&
M7O(3#=WB(K>9=W,D.Z,/(HV*6^]A/+^,OVD/VMO^#,S]KKXU:Y^T3^T3XOL_
M$GC/Q))"^MZW+X<\?V[7+101V\9,=O!'&N(HHU^51G;DY))/HG_!,+7/^#4F
M\_;D\#VW_!->"S'QK;^T_P#A"S%IWC2-O^09=F\PVIH+4?Z%]J_UA_W?GVT
M?KE1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M#[X[:%XO_:G_ ."F_@_XA> [3[5_;O@_2O@O9Z3/J&^UE2#;=QR%HMD[0RG
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M! !]ET444 9VI:SJ%C=&"W\/7-RNT'S8F&/IS4'_  DNK_\ 0H7O_?2UL44
M8_\ PDNK_P#0H7O_ 'TM'_"2ZO\ ]"A>_P#?2UL44 8__"2ZO_T*%[_WTM'_
M  DNK_\ 0H7O_?2UL44 8_\ PDNK_P#0H7O_ 'TM'_"2ZO\ ]"A>_P#?2UL4
M4 8__"2ZO_T*%[_WTM'_  DNK_\ 0H7O_?2UL44 8_\ PDNK_P#0H7O_ 'TM
M'_"2ZO\ ]"A>_P#?2UL44 8__"2ZO_T*%[_WTM'_  DNK_\ 0H7O_?2UL44
M8_\ PDNK_P#0H7O_ 'TM'_"2ZO\ ]"A>_P#?2UL44 8__"2ZO_T*%[_WTM'_
M  DNK_\ 0H7O_?2UL44 8_\ PDNK_P#0H7O_ 'TM'_"2ZO\ ]"A>_P#?2UL4
M4 8__"2ZO_T*%[_WTM'_  DNK_\ 0H7O_?2UL44 8_\ PDNK_P#0H7O_ 'TM
M'_"2ZO\ ]"A>_P#?2UL44 8__"2ZO_T*%[_WTM'_  DNK_\ 0H7O_?2UL44
M8_\ PDNK_P#0H7O_ 'TM'_"2ZO\ ]"A>_P#?2UL44 8__"2ZO_T*%[_WTM'_
M  DNK_\ 0H7O_?2UL44 8_\ PDNK_P#0H7O_ 'TM'_"2ZO\ ]"A>_P#?2UL4
M4 8__"2ZO_T*%[_WTM'_  DNK_\ 0H7O_?2UL44 8_\ PDNK_P#0H7O_ 'TM
M'_"2ZO\ ]"A>_P#?2UL44 8__"2ZO_T*%[_WTM'_  DNK_\ 0H7O_?2UL44
M8_\ PDNK_P#0H7O_ 'TM'_"2ZO\ ]"A>_P#?2UL44 8__"2ZO_T*%[_WTM'_
M  DNK_\ 0H7O_?2UL44 8_\ PDNK_P#0H7O_ 'TM'_"2ZO\ ]"A>_P#?2UL4
M4 8__"2ZO_T*%[_WTM'_  DNK_\ 0H7O_?2UL44 8_\ PDNK_P#0H7O_ 'TM
M'_"2ZO\ ]"A>_P#?2UL44 8__"2ZO_T*%[_WTM'_  DNK_\ 0H7O_?2UL44
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^$EU?_H4+W_OI:/^$EU?_H4+W_OI: -BBL?_ (275_\ H4+W_OI:/^$EU?\
MZ%"]_P"^EH V**Q_^$EU?_H4+W_OI:/^$EU?_H4+W_OI: -BBL?_ (275_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !7A?C_\ Y'34_P#K\?\ G7NE>%^/_P#D=-3_ .OQ_P"=?)\6_P"Z4_\
M%^@&/1117P8!1110 4444 %%%% !1110 4444 %>W_#/_D1=._ZXG_T(UXA7
MM_PS_P"1%T[_ *XG_P!"-?4\)_[]/_#^J W:***^_ **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "O"_'_P#R.FI_]?C_ ,Z]TKPOQ_\ \CIJ
M?_7X_P#.OD^+?]TI_P"+] ,>BBBO@P"BBB@ HHHH **** "BBB@ HHHH *]O
M^&?_ "(NG?\ 7$_^A&O$*]O^&?\ R(NG?]<3_P"A&OJ>$_\ ?I_X?U0&[111
M7WX!1110 4444 %%%% !1110 4444 >$?'[]K3XV_"#XBR^"_ O[#WCGQWI\
M=K%*GB#0;F!;=V<9:,!^<KT-<5_P\$_:>_Z1=?%/_P #K2OJRB@#Y3_X>"?M
M/?\ 2+KXI_\ @=:4?\/!/VGO^D77Q3_\#K2OJRB@#Y3_ .'@G[3W_2+KXI_^
M!UI1_P /!/VGO^D77Q3_ / ZTKZLHH ^4_\ AX)^T]_TBZ^*?_@=:4?\/!/V
MGO\ I%U\4_\ P.M*^K** /E/_AX)^T]_TBZ^*?\ X'6E'_#P3]I[_I%U\4__
M  .M*^K** /E/_AX)^T]_P!(NOBG_P"!UI1_P\$_:>_Z1=?%/_P.M*^K** /
ME/\ X>"?M/?](NOBG_X'6E'_  \$_:>_Z1=?%/\ \#K2OJRB@#Y3_P"'@G[3
MW_2+KXI_^!UI1_P\$_:>_P"D77Q3_P# ZTKZLHH ^4_^'@G[3W_2+KXI_P#@
M=:4?\/!/VGO^D77Q3_\  ZTKZLHH ^5%_P""@7[3K,%;_@E_\3T!."\NI6:*
MON68@*/4D@#O5G_AO7]H[_I'EXG_ /#@Z'_\D5]+^(/^0#??]><O_H!KY^KY
MS/<WQ.63@J23YD][]/1H#)_X;U_:._Z1Y>)__#@Z'_\ )%'_  WK^T=_TCR\
M3_\ AP=#_P#DBM:BO!_ULS'^2'W/_P"2 R?^&]?VCO\ I'EXG_\ #@Z'_P#)
M%'_#>O[1W_2/+Q/_ .'!T/\ ^2*UJ*/];,Q_DA]S_P#D@,G_ (;U_:._Z1Y>
M)_\ PX.A_P#R11_PWK^T=_TCR\3_ /AP=#_^2*UJ*/\ 6S,?Y(?<_P#Y(#)_
MX;U_:._Z1Y>)_P#PX.A__)%'_#>O[1W_ $CR\3_^'!T/_P"2*UJ*/];,Q_DA
M]S_^2 R?^&]?VCO^D>7B?_PX.A__ "11_P -Z_M'?](\O$__ (<'0_\ Y(K6
MHH_ULS'^2'W/_P"2 R?^&]?VCO\ I'EXG_\ #@Z'_P#)%'_#>O[1W_2/+Q/_
M .'!T/\ ^2*UJ*/];,Q_DA]S_P#D@,@_MZ_M' 9'_!/#Q0Q_NIX_T,D_0"?)
M/M5;_AX)^T]_TBZ^*?\ X'6E=-IW_(0@_P"NR_S%?0U?19%FN(S.-1U4ERVV
MOUOW; ^4_P#AX)^T]_TBZ^*?_@=:4?\ #P3]I[_I%U\4_P#P.M*^K**]\#Y3
M_P"'@G[3W_2+KXI_^!UI1_P\$_:>_P"D77Q3_P# ZTKZLHH ^4_^'@G[3W_2
M+KXI_P#@=:4?\/!/VGO^D77Q3_\  ZTKZLHH ^4_^'@G[3W_ $BZ^*?_ ('6
ME'_#P3]I[_I%U\4__ ZTKZLHH ^4_P#AX)^T]_TBZ^*?_@=:4?\ #P3]I[_I
M%U\4_P#P.M*^K** /E/_ (>"?M/?](NOBG_X'6E'_#P3]I[_ *1=?%/_ ,#K
M2OJRB@#Y3_X>"?M/?](NOBG_ .!UI1_P\$_:>_Z1=?%/_P #K2OJRB@#Y3_X
M>"?M/?\ 2+KXI_\ @=:4?\/!/VGO^D77Q3_\#K2OJRB@#Y3_ .'@G[3W_2+K
MXI_^!UI1_P /!/VGO^D77Q3_ / ZTKZLHH ^4_\ AX)^T]_TBZ^*?_@=:5IV
MOCCQ1XWMT\7:_P#!KQGH-[J*B>ZT:Y\+7L\EF[<F)I(H2CD>JD@U],T5Y^8Y
M;0S.FH56TD[Z6_5,#YJ^WZC_ -"/XM_\(S4O_C%'V_4?^A'\6_\ A&:E_P#&
M*^E:*\C_ %3R[^>?WK_Y$#YJ^WZC_P!"/XM_\(S4O_C%'V_4?^A'\6_^$9J7
M_P 8KZ5HH_U3R[^>?WK_ .1 ^:OM^H_]"/XM_P#",U+_ .,4?;]1_P"A'\6_
M^$9J7_QBOI6BC_5/+OYY_>O_ )$#YJ^WZC_T(_BW_P (S4O_ (Q1]OU'_H1_
M%O\ X1FI?_&*^E:*/]4\N_GG]Z_^1 ^:OM^H_P#0C^+?_",U+_XQ1]OU'_H1
M_%O_ (1FI?\ QBOI6BC_ %3R[^>?WK_Y$#YJ^WZC_P!"/XM_\(S4O_C%'V_4
M?^A'\6_^$9J7_P 8KZ5HH_U3R[^>?WK_ .1 ^:OM^H_]"/XM_P#",U+_ .,5
MFWO[:/[0'P]NG\&>&/\ @GE\2_$MA8'9;:Y:^5;1W8/S;EBF"R)@DC# 'C-?
M4]%=^79+A<LJNI2E)MJVK7KT2 ^<_A9^VI^T#X_^(>D>#/$W_!/;XB>&+#4;
ML0W7B#5+NV:WL4(/[R0+R5&.WK7T9117L %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 5QGB_X\?#_P1\9O!_P(UZZG37_'%CJEWH2)$#$T=@+<
MS[V)&T_Z3'M&#N^;IBNKU9=3?2[E-%DA2\-NXM'N 3&LNT[2P'.W.,X[5_.?
M\*=%_P"">/P[^.'PO\$?\%TO@=XIT'XLW,GC6/XY^-OC%IFJS6OB349;JU.D
MW5AJ,):,VB1>8L;P&..(YR<.KN ?T<45Y1X%^)7[(7[-G[,W@BYT;XY^$]$^
M&,&C6.E^"?$>N^.(7LKVU6WS:I%?W4Q^U,T,18,9'=U1F);!-5_^'A/[ O\
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M+=88+6"-0D<4<: *B*H"A0    !@5:HH **** "BBB@ HHHH J>(/^0#??\
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M%U:P)N>2V=47.,DJ0!S7C_\ PJ7X@_\ 0O\ _DW%_P#%UZC]B\;_ /0;LO\
MP&/^-'V+QO\ ]!NR_P# 8_XUY68Y1ALSE%U6UR]K=?5,#R[_ (5+\0?^A?\
M_)N+_P"+H_X5+\0?^A?_ /)N+_XNO4?L7C?_ *#=E_X#'_&C[%XW_P"@W9?^
M Q_QKS?]4\N_GG]Z_P#D0/+O^%2_$'_H7_\ R;B_^+H_X5+\0?\ H7__ ";B
M_P#BZ]1^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\ &C_5/+OYY_>O_D0/+O\
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MX*(?_B:/^%7?#/\ Z)WH7_@HA_\ B: .%_X;G_9'_P"B]:#_ -_G_P#B:/\
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M_P#T7K0?^_S_ /Q-=U_PJ[X9_P#1.]"_\%$/_P 31_PJ[X9_]$[T+_P40_\
MQ- '"_\ #<_[(_\ T7K0?^_S_P#Q-'_#<_[(_P#T7K0?^_S_ /Q-=U_PJ[X9
M_P#1.]"_\%$/_P 31_PJ[X9_]$[T+_P40_\ Q- '"_\ #<_[(_\ T7K0?^_S
M_P#Q-'_#<_[(_P#T7K0?^_S_ /Q-=U_PJ[X9_P#1.]"_\%$/_P 31_PJ[X9_
M]$[T+_P40_\ Q- '"_\ #<_[(_\ T7K0?^_S_P#Q-'_#<_[(_P#T7K0?^_S_
M /Q-=U_PJ[X9_P#1.]"_\%$/_P 31_PJ[X9_]$[T+_P40_\ Q- '"_\ #<_[
M(_\ T7K0?^_S_P#Q-'_#<_[(_P#T7K0?^_S_ /Q-=U_PJ[X9_P#1.]"_\%$/
M_P 31_PJ[X9_]$[T+_P40_\ Q- '!3_MV_LB6T+3R?'C1"JC)$;2.?P"H2?P
MIR?MT_LC.H<?'G0L$9&9'!_(KQ61^VQ\/O .E_LI>.=0TSP1H]O<1:&[13P:
M9$CH=R\A@N0:[?X9_#3X<3_#CP_//\/]$=WT2T9W?2H26)A3))V\F@# _P"&
MY_V1_P#HO6@_]_G_ /B:/^&Y_P!D?_HO6@_]_G_^)KNO^%7?#/\ Z)WH7_@H
MA_\ B:/^%7?#/_HG>A?^"B'_ .)H X7_ (;G_9'_ .B]:#_W^?\ ^)H_X;G_
M &1_^B]:#_W^?_XFNZ_X5=\,_P#HG>A?^"B'_P")H_X5=\,_^B=Z%_X*(?\
MXF@#A?\ AN?]D?\ Z+UH/_?Y_P#XFC_AN?\ 9'_Z+UH/_?Y__B:[K_A5WPS_
M .B=Z%_X*(?_ (FC_A5WPS_Z)WH7_@HA_P#B: .%_P"&Y_V1_P#HO6@_]_G_
M /B:/^&Y_P!D?_HO6@_]_G_^)KNO^%7?#/\ Z)WH7_@HA_\ B:/^%7?#/_HG
M>A?^"B'_ .)H X7_ (;G_9'_ .B]:#_W^?\ ^)H_X;G_ &1_^B]:#_W^?_XF
MNZ_X5=\,_P#HG>A?^"B'_P")H_X5=\,_^B=Z%_X*(?\ XF@#A?\ AN?]D?\
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M &1_^B]:#_W^?_XFC_AN?]D?_HO6@_\ ?Y__ (FNZ_X5=\,_^B=Z%_X*(?\
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M$IK_ ,5_L^:6]Y/9>)-0^)=M8>(]?TNTD=+G4;/26MV.U?+D*0O)OE$?RG+
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M_LFVQN_VL8SGG/7G-?*DO_!$W]MOQQ\"M&_X)]?&_P#X*=-X@_9IT62SM9-
ML_AY%9^*-6T2TE1[;1KG4UN"JPH(XD,R1!W6( J <#](- T'1?"NA67ACPWI
M<%CIVFVD=K865M&$CMX8U")&BCA550  .@% %NBBB@ HHHH **** "OS8_X.
M&?LK_$']B:#Q\P'@%_VOO#8\4BXQ]F,WS_9A/GY?+Q]HW;N-NZOTGKR?]MS]
MB_X'?M__ +-^O_LO_M!:-<7.@ZZB/'=V$PBO-,NXFWP7EM*0?+FC<!E)!4C*
MLK(S*0#UBOS6_P"#;Y1'IG[7L/@OR_\ A7Z?MD>,%\"BW/[@6VZ'/D]O*\O[
M/C'&=W?-<;^VS^R[_P '!W[/O[(.I^%/@=_P4"_X7!X?TB.&TU&#0_AU#8?$
M*]T(MLN%M+SS)HY[Y(>%DV+/(075O-PK?7'[.?['/AOX7_\ !,;P_P#LR_\
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M2_!"T_X*16/@/X1>)8=.^U> #\%;75)TGM)HK@2_VC]O@F(:>%'V@  ?+R*
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
..*** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>biib-20200930_g18.jpg
<TEXT>
begin 644 biib-20200930_g18.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_[@ .061O8F4 90     !_]L 0P " 0$!
M 0$" 0$! @(" @($ P(" @(%! 0#! 8%!@8&!08&!@<)" 8'"0<&!@@+" D*
M"@H*"@8("PP+"@P)"@H*_]L 0P$" @(" @(% P,%"@<&!PH*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*_\  $0@"
M2@)Z P$B  (1 0,1 ?_$ !\   $% 0$! 0$!           ! @,$!08'" D*
M"__$ +40  (! P,"! ,%!00$   !?0$" P $$042(3%!!A-180<B<10R@9&A
M""-"L<$54M'P)#-B<H()"A87&!D:)28G*"DJ-#4V-S@Y.D-$149'2$E*4U15
M5E=865IC9&5F9VAI:G-T=79W>'EZ@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>H
MJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KAXN/DY>;GZ.GJ\?+S]/7V
M]_CY^O_$ !\!  ,! 0$! 0$! 0$        ! @,$!08'" D*"__$ +41  (!
M @0$ P0'!00$  $"=P ! @,1! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P
M%6)RT0H6)#3A)?$7&!D:)B<H*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E
M9F=H:6IS='5V=WAY>H*#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6V
MM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P#
M 0 "$0,1 #\ _?RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?@3XCT'3M*UF*X=9+Z*_TXW4CW!D;8I5AM&W QUYKZ6M;JVO;:.\LKB.:&5
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MOAXOPXO_ !M\7V\!>.[+1M2NGMO$>DWMC/(5O(YI7$SQO#O61OFWD,2S(A4
M^YO"G[;G@OQ9^WUXL_X)_P!KX-U2+7O"7P\L/%UWKLDD?V.>WNK@P+"@!WB1
M2N22,8Z&N6U;]M[QEIO_  5QTS_@G:/!^E?\([??L^S_ !!E\0M)(+Q+N/61
M8"W SY?E;/GSC=N[XKX6'_!+7_@G_P#M!_\ !P_\</A_\9?V8]"U_1KOX+:7
MXPN;"\FN0DFN7NJ2?:KX[)0?,DR<C.WG@"M_]J/]BOX0?M%?\'#/PY_9H\80
MW]M\.='_ &+"-6\(:5JD]K!K6FVWB&2&#3+EXG61[42&WE:/>!)]F5'W(S*P
M!^JNE:QI&O62ZEH>JVU[;.2$N+2=9$8@X(#*2#@\5'?^)?#FE:A!I.J:_96U
MU=?\>MM<72))-SCY5)RW/I7YL?LS?L]?"?\ X)U_\%^7_9@_9$\-MX0^&OQ1
M_9IF\3^(? ME>S/IT>MV6L+;1W\,<CL(G-N3&0N =S'&3Q\PM\"?V:?V5/&?
MQ5U/_@NE_P $J/B1\2M3UWX@ZOJEU^TUI>C3^)]%DT26=FM'DDMKCS]'BA@V
MH(DC!0+C"\* #]TJ^./^"B/_  4W^//[(W[47PB_9"_9H_8AC^,_C/XNZ7K=
M[I5C+\3;?PVMLNF11S2CS+FUFC?,3.V6=/\ 5X 8L*^C_P!F;4O@MJW[.G@2
M^_9OUR'4OA^WA#3E\$WT%Y+<+-I2VT:VI\V8F5SY00$R$R9!W_-FOSM_X*\>
M'_VA_%'_  6W_8NT7]E;XB>'?"GCF7PE\0#I&N^*M"?4K&W4:=&9A);QR1LY
M:(2*N&&UF!YQ@@'TW^S!^UI_P5-^*7QJTGP1^TO_ ,$B;/X5>#+N.X.J^.8O
MVA=(UYK!D@D>)?L5M:I)+YDJI%E6&SS-QR%(KZHU/5-,T6RDU/6-1@M+:(9E
MN+F98T09QRS$ <U\V_LM_"W_ (*O>$_BQ#J_[7G[6/PG\8>#5L9EGT;PA\-;
MG2[UK@@>4XGDNY5"J<Y7;SZBOB7]B?\ X)U_LQ_MP?\ !1[]N#6_VL_"$WC?
M0=!^-MM#HO@K4]1N$TF"[DT]3+?26\4BK/<%!'&CR!O*57V8,C&@#]<89H;F
M%+BWE62.10R.C9# \@@CJ*XKX]_%ZW^$OP<\=>/=#FL+W6/"/@S4=;CTF>X&
M7-O:R3()%4[PC,@!/'!X-?F%^RY\5?&W_!-_]CW_ (*'_"?X&ZQ?S:!^SMXJ
MU:Y^#NFZE=27H\/17>CI=PVJ&8LS6T$SB0(Q/_+0DDNQ,^B?\$6?V/%_X(UW
M'[2!L]2?XZ:O\$)_'.H_'5O$-VVMW6N7.D->S227!E_>VDC.T+V[ QR0,0P+
M,7H _0C_ ()Y?M+^)/VR?V(?AA^U-XP\.V.D:IX[\(VNKWVF::[M;VTDJY*1
MER6*CW.:]:T[7]"U>XN+32=:M+J6TDV7<5O<J[0MS\KA22IX/!]*_$WXL?M
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MIBO8* /C3XL_\$(O^"6'Q?\ 'WC?X\_M.?!";QSK_BV_N]1UOQ#XT\8Z@_\
M9\+LTA@MMD\<=E;Q D)Y:J54#+'&:^?O^"+O[1OCKX'_ /!*3]H[XTCQ?K7C
M3X5?!_QSX[N?@%KOBFZ>:?5?"&DVQFM0)F^:6W#Q2HK]CO0!5157R3_@IK_P
M6"_99_:W_;/\3?\ !,;XO_M;+\%O@/X U%['XV^(1;7HUCQ[>Q2%)O#UB;:%
MVMK)71DN;AMK2@%$RAS)]W_"'XB?L%_\%)/^"=WQ&_9@_P""=OQ'T"_\#CP#
MJ7P_ACT/2KFTM-&^U:9)!'"$FBC;"QS*V0#GN2<T ?'/['W_  1@^ '[:O\
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M6UU"LD<JGJK*P(8>QJ>B@"MI&CZ1X?TR'1=!TNVL;.V39;VEI L442_W550
MH]@*LT44 %%%% &<OA#PFGB1O&2^%].&KO#Y3:J+*/[28_[AEQNV^V<5HT44
M %9WB7P?X2\:6::=XQ\+:=JUO'()(X-3L8YT5QT8*X(!]ZT:* &PPPVT*6]O
M$L<<:A41%P% X  '04ZBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BO$OV"-4U/5_@UJMSJVHSW4B^-]819+B9G8*+D@+EB> .@[5[;0 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110!X7_P $]_\ DB>K?]CWK/\ Z4FO=*^?OV!O
M$&BZ9\&M6MM0U&.*3_A.=9;:YYQ]I;FO;_\ A,?#'_0:@_[ZH TJ*S?^$Q\,
M?]!J#_OJC_A,?#'_ $&H/^^J -*BLW_A,?#'_0:@_P"^J/\ A,?#'_0:@_[Z
MH TJ*S?^$Q\,?]!J#_OJC_A,?#'_ $&H/^^J -*BLW_A,?#'_0:@_P"^J/\
MA,?#'_0:@_[ZH TJ*S?^$Q\,?]!J#_OJC_A,?#'_ $&H/^^J -*BLW_A,?#'
M_0:@_P"^J/\ A,?#'_0:@_[ZH TJ*S?^$Q\,?]!J#_OJC_A,?#'_ $&H/^^J
M -*BLW_A,?#'_0:@_P"^J/\ A,?#'_0:@_[ZH TJ*S?^$Q\,?]!J#_OJC_A,
M?#'_ $&H/^^J -*BLW_A,?#'_0:@_P"^J/\ A,?#'_0:@_[ZH TJ*S?^$Q\,
M?]!J#_OJC_A,?#'_ $&H/^^J -*BLW_A,?#'_0:@_P"^J/\ A,?#'_0:@_[Z
MH TJ*S?^$Q\,?]!J#_OJC_A,?#'_ $&H/^^J -*BLW_A,?#'_0:@_P"^J/\
MA,?#'_0:@_[ZH TJ*S?^$Q\,?]!J#_OJC_A,?#'_ $&H/^^J -*BLW_A,?#'
M_0:@_P"^J/\ A,?#'_0:@_[ZH TJ*S?^$Q\,?]!J#_OJC_A,?#'_ $&H/^^J
M -*BLW_A,?#'_0:@_P"^J/\ A,?#'_0:@_[ZH TJ*S?^$Q\,?]!J#_OJC_A,
M?#'_ $&H/^^J -*BLW_A,?#'_0:@_P"^J/\ A,?#'_0:@_[ZH TJ*S?^$Q\,
M?]!J#_OJC_A,?#'_ $&H/^^J -*BLW_A,?#'_0:@_P"^J/\ A,?#'_0:@_[Z
MH TJ*S?^$Q\,?]!J#_OJC_A,?#'_ $&H/^^J -*BLW_A,?#'_0:@_P"^J/\
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M:?\ \^,/_?H4?V=I_P#SXP_]^A4U% $/]G:?_P ^,/\ WZ%']G:?_P ^,/\
MWZ%344 0_P!G:?\ \^,/_?H4?V=I_P#SXP_]^A4U% $/]G:?_P ^,/\ WZ%'
M]G:?_P ^,/\ WZ%344 0_P!G:?\ \^,/_?H4?V=I_P#SXP_]^A4U% $/]G:?
M_P ^,/\ WZ%']G:?_P ^,/\ WZ%344 0_P!G:?\ \^,/_?H4?V=I_P#SXP_]
M^A4U% $/]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ%344 0_P!G:?\ \^,/_?H4
M?V=I_P#SXP_]^A4U% $/]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ%344 0_P!G
M:?\ \^,/_?H4?V=I_P#SXP_]^A4U% $/]G:?_P ^,/\ WZ%']G:?_P ^,/\
MWZ%344 0_P!G:?\ \^,/_?H4?V=I_P#SXP_]^A4U% $/]G:?_P ^,/\ WZ%'
M]G:?_P ^,/\ WZ%344 0_P!G:?\ \^,/_?H4?V=I_P#SXP_]^A4U% $/]G:?
M_P ^,/\ WZ%']G:?_P ^,/\ WZ%344 0_P!G:?\ \^,/_?H4?V=I_P#SXP_]
M^A4U% $/]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ%344 0_P!G:?\ \^,/_?H4
M?V=I_P#SXP_]^A4U% $/]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ%344 0_P!G
M:?\ \^,/_?H4?V=I_P#SXP_]^A4U% $/]G:?_P ^,/\ WZ%']G:?_P ^,/\
MWZ%344 0_P!G:?\ \^,/_?H4?V=I_P#SXP_]^A4U% $/]G:?_P ^,/\ WZ%'
M]G:?_P ^,/\ WZ%344 0_P!G:?\ \^,/_?H4?V=I_P#SXP_]^A4U% $/]G:?
M_P ^,/\ WZ%']G:?_P ^,/\ WZ%344 0_P!G:?\ \^,/_?H4?V=I_P#SXP_]
M^A4U% $/]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ%344 1)8V4;!X[.)6'0K&
M14M%% !1110 4444 %%%% !1110 4444 >%_\$]_^2)ZM_V/>L_^E)KW2O"_
M^">__)$]6_['O6?_ $I->Z4 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M:*^.OM?_  4)_P"CT?#'_AH(O_DZC[7_ ,%"?^CT?#'_ (:"+_Y.H_UAR?\
MY^_^2R_R ^Q:*^.OM?\ P4)_Z/1\,?\ AH(O_DZC[7_P4)_Z/1\,?^&@B_\
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M?_!0G_H]'PQ_X:"+_P"3J/M?_!0G_H]'PQ_X:"+_ .3J/]8<G_Y^_P#DLO\
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M ^K**^4_^%2?\%??^CN/A9_X0LE'_"I/^"OO_1W'PL_\(62NP#ZLHKX[>?\
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M"$D%Q<0X.5CD/"-TYKZ,KT "BBB@ HHHH **** "BBB@ HHHH \+_P"">_\
MR1/5O^Q[UG_TI->K_$S_ )$74?\ KB/_ $(5Y1_P3W_Y(GJW_8]ZS_Z4FO5_
MB9_R(NH_]<1_Z$*Y,?\ [C5_PR_)@>(4445^1 %%%% !1110 4444 %%%% !
M1110 5L> /\ D=-,_P"OQ/YUCUL> /\ D=-,_P"OQ/YUTX+_ 'RG_B7YH#W2
MBBBOU\"IX@_Y -]_UYR_^@&OGZOH'Q!_R ;[_KSE_P#0#7S]7P_%W\6EZ/\
M0 HHHKX\ HHHH **** "BBB@ HHHH **** )M._Y"$'_ %V7^8KZ&KYYT[_D
M(0?]=E_F*^AJ^VX1^"MZQ_4 HHHK[(#YYU'_ )"$_P#UV;^9J&IM1_Y"$_\
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M .@&OGZOH'Q!_P @&^_Z\Y?_ $ U\_5\/Q=_%I>C_0 HHHKX\ HHHH ****
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MFF?]?B?SK'K3\%VT=YXKT^UE9@LERJL4;!Z]CVKIP7^^4_\ $OS0'O-%8_\
MP@^D?\_-[_X%M1_P@^D?\_-[_P"!;5^O@7?$'_(!OO\ KSE_] -?/U>U:UX,
MTJ#1KN9+F[)2VD8!KIB.%->*U\/Q=_%I>C_0 HHHKX\ HHHH **** "BBB@
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M+":[BS&S2)]KD$.XE%AD8@9Y_6"N?&854(PFDTI*]GNK-KLO5:=0/!/VH_\
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M4B(TB,RML*E2 P[,OK1H8E2E)I:=$^JW3:T C_X)W_M.?M0?$;XN_';]B_\
M::\5^&O%7BOX+7VD6]M\1_"FFFQMM9BU*SEGC$]N&98+J$QXD6/Y06V@?)N?
M"_X-VS!9?\$EOAUX5FM3;ZIH.K>(M/U^U<_O(;U-<OF=7_VMKH>>@(':OIS]
MG+]EK]GW]DCP&WPT_9R^%FF^%='ENVNKJ"Q#O)=W# !IIYI6:6>0@ ;Y&9L
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MY[N=R\UPZQ*H:61R6=SEF)R236DL9*K']XKOFYO+7XD_)V6P'YK_ +">A_\
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MOC.VBGL?#O@CQ7K4^H_9DA2V5XK/3]WV2%E@ZMY:R,DA&Y@U:O\ P1Z^%/\
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M #\WO_@6U'_"#Z1_S\WO_@6U;%% &/\ \(/I'_/S>_\ @6U'_"#Z1_S\WO\
MX%M6Q10!C_\ "#Z1_P _-[_X%M1_P@^D?\_-[_X%M6Q10!C_ /"#Z1_S\WO_
M (%M1_P@^D?\_-[_ .!;5L44 <[K7@S2H-&NYDN;LE+:1@&NF(X4UXK7T#X@
M_P"0#??]><O_ * :^?J^'XN_BTO1_H 4445\>!\(_P#!4[XU_MN>%OACXO\
M!'_#%%KXF\"MXJ\-S>'O'/A[XA6,$NQ=7TZ18+NQO/+=)&G4PAXFD3]XC,$
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M1_VGOV]OB)^T+X?\'?&G_@AG_P *=\,WGVO^T_B/_P +9T#4_P"R-EI,\?\
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MZO\ ]"A>_P#?2T ;%%8__"2ZO_T*%[_WTM'_  DNK_\ 0H7O_?2T ;%%8_\
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MHK'_ .$EU?\ Z%"]_P"^EH_X275_^A0O?^^EH V**Q_^$EU?_H4+W_OI:/\
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M6?\ TI->Z4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!4\0?\
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M!OO^O.7_ - -?/U?0/B#_D WW_7G+_Z :^?J^'XN_BTO1_H 4445\> 4444
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MHQ]I;L*]M_X0?2/^?F]_\"VH V**Q_\ A!](_P"?F]_\"VH_X0?2/^?F]_\
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M4 %%%% $VG?\A"#_ *[+_,5]#5\\6*A[V%#G!E4''UKV_P#X0?2/^?F]_P#
MMJ^VX1^"MZQ_4#8HK'_X0?2/^?F]_P# MJ/^$'TC_GYO?_ MJ^R V**Q_P#A
M!](_Y^;W_P "VH_X0?2/^?F]_P# MJ -BBL?_A!](_Y^;W_P+:C_ (0?2/\
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M.45T?_"I?B#_ -"__P"3<7_Q='_"I?B#_P!"_P#^3<7_ ,71_9N8_P#/F?\
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M$Q\,?]!J#_OJO&?^"?EI:S_!75GFMHW/_"=:R,L@)_X^37N7]G:?_P ^,/\
MWZ% %/\ X3'PQ_T&H/\ OJC_ (3'PQ_T&H/^^JN?V=I__/C#_P!^A1_9VG_\
M^,/_ 'Z% %/_ (3'PQ_T&H/^^J/^$Q\,?]!J#_OJKG]G:?\ \^,/_?H4?V=I
M_P#SXP_]^A0!3_X3'PQ_T&H/^^J/^$Q\,?\ 0:@_[ZJY_9VG_P#/C#_WZ%']
MG:?_ ,^,/_?H4 4_^$Q\,?\ 0:@_[ZH_X3'PQ_T&H/\ OJKG]G:?_P ^,/\
MWZ%']G:?_P ^,/\ WZ% %/\ X3'PQ_T&H/\ OJC_ (3'PQ_T&H/^^JN?V=I_
M_/C#_P!^A1_9VG_\^,/_ 'Z% %/_ (3'PQ_T&H/^^J/^$Q\,?]!J#_OJKG]G
M:?\ \^,/_?H4?V=I_P#SXP_]^A0!3_X3'PQ_T&H/^^J/^$Q\,?\ 0:@_[ZJY
M_9VG_P#/C#_WZ%']G:?_ ,^,/_?H4 4_^$Q\,?\ 0:@_[ZH_X3'PQ_T&H/\
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M"BBB@ HHHH **** "BBB@ HHHH \+_X)[_\ )$]6_P"Q[UG_ -*37NE>%_\
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M_)#_ .V4?\* _P"IM_\ )#_[97HU%<'^KV3_ //K_P FE_F!YS_PH#_J;?\
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MM%^T^=]G0KYNS;NY)Z9..OK5ZBNK"97@,#4<Z$+-JV[>GS; ****]  HHHH
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M% &/]B\;_P#0;LO_  &/^-'V+QO_ -!NR_\  8_XUL44 8_V+QO_ -!NR_\
M 8_XT?8O&_\ T&[+_P !C_C6Q10!C_8O&_\ T&[+_P !C_C1]B\;_P#0;LO_
M  &/^-;%% &/]B\;_P#0;LO_  &/^-'V+QO_ -!NR_\  8_XUL44 8_V+QO_
M -!NR_\  8_XT?8O&_\ T&[+_P !C_C6Q10!C_8O&_\ T&[+_P !C_C1]B\;
M_P#0;LO_  &/^-;%% &/]B\;_P#0;LO_  &/^-'V+QO_ -!NR_\  8_XUL44
M 8_V+QO_ -!NR_\  8_XT?8O&_\ T&[+_P !C_C6Q10!C_8O&_\ T&[+_P !
MC_C1]B\;_P#0;LO_  &/^-;%% &/]B\;_P#0;LO_  &/^-'V+QO_ -!NR_\
M 8_XUL44 8_V+QO_ -!NR_\  8_XT?8O&_\ T&[+_P !C_C6Q10!C_8O&_\
MT&[+_P !C_C1]B\;_P#0;LO_  &/^-;%% &/]B\;_P#0;LO_  &/^-'V+QO_
M -!NR_\  8_XUL44 9=G:>+4ND>^U:U>(-^\1+<@D>QK4HHH **** "BBB@
MHHHH **** "BBB@#PO\ X)[_ /)$]6_['O6?_2DU[I7A?_!/?_DB>K?]CWK/
M_I2:]TH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MZD_^(H ]:HKR7_AN[]D/_HO&B?\ ?4G_ ,11_P -W?LA_P#1>-$_[ZD_^(H
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MX JS0!S_ /PJ;X5_]$T\/_\ @F@_^(H_X5-\*_\ HFGA_P#\$T'_ ,17044
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M^#WAV?POX+AG2TN-2N+Z07$YD;SIGWN<GMGH.U=)0!S_ /PJ;X5_]$T\/_\
M@F@_^(H_X5-\*_\ HFGA_P#\$T'_ ,17044 <_\ \*F^%?\ T33P_P#^":#_
M .(H_P"%3?"O_HFGA_\ \$T'_P 17044 <__ ,*F^%?_ $33P_\ ^":#_P"(
MH_X5-\*_^B:>'_\ P30?_$5T%% &+I_PV^'>DWL>HZ7X!T6VN(6W0SV^E0HZ
M'U#!<@_2MJBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \$_X*%?\
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M#M TWQ3;Z-'JMK=,G[]KN[4I;K'&YD<.N\;"FW=Q7S%>_P#!6W]MC]F'XK>
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M78\7)\1+67Q/#H<LPCCUM]&$./((97\H3%@C>9O,?SUSW[5_[".J_P#!./\
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M-?\ BO\ 9\TM[R>R\2:A\2[:P\1Z_I=I(Z7.HV>DM;L=J^7(4A>3?*(_E.6
M'W5^S=^T)\+OVK_@/X3_ &D/@MK;:CX6\9Z+#J>C7,D>R3RI!RDB<[)$;<CI
M_"Z,.U?FK^RI\5_^"FO[#G[!<'_!,CQ'_P $R_%.N^.O!^@ZAX=\+_%33==T
MY/ UU8,TWV?5KR\><2VJ112;Y(?*:5_)/"-)M3U#_@U;MO$EK_P1'^%D>O-(
M;<ZKXB.D,X(#6IUJ\PRAN0ID\TC@=<]Z /T0HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@#P#_@HA_P3Q^%7_!1+X2Z7X)\9^*-9\)^*/"6
MO0Z_\._B'X7F$6J>%]7A.8[J!OXE. 'C) 8 $%71'3X&_P""CO[,G_!<.W^$
MWAGX4_'?]JK4OC5\#=<\0P:+\9K;X"_"^+2?'%YH4N$>40J;A9HVZ3QVP4E"
M05:-WV_KQ10!X%\3_P!E?XD6G[)'A'X"_P#!.SX[Q_ >3PA'IZ^%[Z3P1'J\
M"Z=! \8T^XLKQD8K(KJ7=B)E=-Q^;-?.?B+_ (),?MS?MB>-O"*_\%0?^"A>
MD^./AUX-\3VVOQ?"_P"'GPWCT.TUV^MFWV[7]TTTDKQ*W6!1A@3AE8!A^A-%
M !1110!^9/P4_P""(?\ P48_9V^-?Q$_:%^%'_!972H_&/Q.U<WGBGQ/X@_9
MJL=4U&:(']U9K<7&J,T5M& H6&,)&-JX4!5"_9?@_P#98\?^._V0==_99_;T
M^-UI\99_%>F:CI?B?Q%:>#8?#JWMA=*R");6WFE6%XXVP)%?=N4/P17M=% '
MYJ2_\$3?VV_''P*T;_@GU\;_ /@ITWB#]FG19+.UDT"S^'D5GXHU;1+25'MM
M&N=36X*K"@CB0S)$'=8@"H!P/T@T#0=%\*Z%9>&/#>EP6.G:;:1VMA96T82.
MWAC4(D:*.%55   Z 5;HH **** "BBB@ HHHH *\G_;<_8O^!W[?_P"S?K_[
M+_[06C7%SH.NHCQW=A,(KS3+N)M\%Y;2D'RYHW 9205(RK*R,RGUBB@#\I/V
MV?V7?^#@[]GW]D'4_"GP._X*!?\ "X/#^D1PVFHP:'\.H;#XA7NA%MEPMI>>
M9-'/?)#PLFQ9Y""ZMYN%;ZX_9S_8Y\-_"_\ X)C>'_V9?^"?7B[Q1\#V?P];
MW/AGQ)XI\'K<:YI5Z\R7,T^HV%Z(Q-<R/YB31N%7YV5,($ ^HZ* /SK^+W_!
M*[_@J/\ MI^#Y/V?/VZ/^"J>BWOPHU"XA_X2S0?AG\)8-'U+Q):QNK_9I;Q[
MB3[*C%06\M6!Y4J5.*_0+P;X0\-_#[PAI7@+P;I,5AI&B:;!I^E6,.=EM;0Q
MK'%&N<G"HJ@9]*TJ* "OA;_@J]_P2I_:_P#^"G/AOQ+\$+3_ (*16/@/X1>)
M8=.^U> #\%;75)TGM)HK@2_VC]O@F(:>%'V@  ?+R*^Z:* /&OV._@W^V-\'
MM$UNQ_; _;3L/C->WMW"^B7UC\+[7PP-,B56$D9CM[B83[V*G<Q4KMQ@YKY:
M^(7_  3&_P""L?[2/@RZ_9M_:J_X*^6.J?"G5X?L?BUO!7P=M-%\1>(M./$M
MG)=+.\5H)4RCO$AW*64J59@?T*HH Y_X3_"SP#\#OACX?^#?PK\-0:-X:\+:
M-;:5H6E6V=EK:01K'%&"22<*HY)))R222370444 %%%% !1110 4444 ?.'Q
MN_X)]_\ "X_^"D/P2_X*#?\ "V_[._X4YX?U_3/^$1_L'SO[7_M.U>W\S[5Y
MZ_9_+W[MOE2;\8RO6OH^BB@#YX_8/_8)_P"&)?&?QT\7?\+6_P"$F_X73\:-
M4\?_ &?^POL7]C?; @^Q;O/E^T;-G^NQ'NS]P5Y5^V3_ ,$K_P!I;XW?\%#M
M%_X*+?LI_M]VGP?\3Z3\)$\!26-[\)+?Q(D]K_:-U?22[I[Z%$+-.B[?+)7R
M<[_G('VY10!\(Z5_P1G^)GQR^+WA3XM?\%0/^"@7B?\ :"M_ FL1ZOX2\!0^
M"['POX9AOX\^5<W-A:-*;QT))4R2=V5MR,R'[NHHH *_-#X>_P#!$K_@H5\&
MOVG?B5^UG\)O^"PVEVOC'XG:H\NL:[XA_9PL=7O[>Q#DP:=#<7.J$PVT2A%$
M42QH?+0E?D0+^E]% 'C'PH_9J^+.J_LO>(/V=/V\OCY8?&R?Q5:ZAIVO:U!X
M&A\.176EW</DM9FUMYI5&$:0>8'W'?VP*^./^')'[;NI_L_VO_!.GQ1_P5"E
MO?V9+4Q61T2/X>0Q>+;C0(I0\>AMJ@G,8B"JL7GK#N*+LV",^77Z744 9G@K
MP;X7^'/@W2/A[X'T2#3=%T'3+?3M'TZV7$=K:P1K%%$@[*J*J@>@K3HHH **
M** "BBB@ KYP_;T_X)]_\-O?$?X"_$#_ (6W_P (Q_PI#XP:?XZ^R?V#]M_M
MK[*0?L>_SXOLV['^MQ)C^X:^CZ* "OGCX&_L$_\ "F/^"AOQS_;T_P"%K?VE
M_P +HT?PW8?\(I_87D_V/_9-G]FW_:O/;[1YOWL>5'LZ9?K7T/10!\?_ /!2
MO_@F7\7_ -MOX]_ O]I?X!_M@P?"+Q?\"[GQ!/HM_<_#J+Q$EX^J0V<+$Q2W
M=NB;$MG&&$F[SL_*4Y\_\<_\$:/VG/VNFL?!W_!3;_@JCXK^+GP[L]0AO+KX
M:>#_ (=V'@S3=8>)U=([][26::ZAW*I\O>N"H*E&&:_0"B@"KH>AZ-X8T2S\
M-^'-*M[#3]/M8[:PL;2$1Q6\,:A$C1% "JJ@  <  "K5%% 'Q-_P58_X)C?M
M?_\ !2GPGXB^!GAS_@HQ8_#OX2^*M)L;;6? ;_!BUU>>6>WN4N?/&H-?03*&
MDBA.P  ;",D,17LG[#W[/W[8W[/OA[5O#W[6/[;MA\98WALH?"[67PLM?#/]
MC10I(LJM]GN9_M/F!H>6VE/).,[SCW6B@#\__BC_ ,$WO^"M_P"T'H&K?L_?
M'#_@K[I[_"O7UDM/$,WA+X.6FE^)=2TN0D26/VM9VBMR\9\MID0DC.5(9E/V
MM\#?@I\-?V</@]X:^ WP<\,Q:/X6\(Z-!I>AZ;$Q80V\2!5RQY=CC<SL2S,2
MQ)))KJJ* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>biib-20200930_g19.jpg
<TEXT>
begin 644 biib-20200930_g19.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_[@ .061O8F4 90     !_]L 0P " 0$!
M 0$" 0$! @(" @($ P(" @(%! 0#! 8%!@8&!08&!@<)" 8'"0<&!@@+" D*
M"@H*"@8("PP+"@P)"@H*_]L 0P$" @(" @(% P,%"@<&!PH*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*_\  $0@"
M2@)Z P$B  (1 0,1 ?_$ !\   $% 0$! 0$!           ! @,$!08'" D*
M"__$ +40  (! P,"! ,%!00$   !?0$" P $$042(3%!!A-180<B<10R@9&A
M""-"L<$54M'P)#-B<H()"A87&!D:)28G*"DJ-#4V-S@Y.D-$149'2$E*4U15
M5E=865IC9&5F9VAI:G-T=79W>'EZ@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>H
MJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KAXN/DY>;GZ.GJ\?+S]/7V
M]_CY^O_$ !\!  ,! 0$! 0$! 0$        ! @,$!08'" D*"__$ +41  (!
M @0$ P0'!00$  $"=P ! @,1! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P
M%6)RT0H6)#3A)?$7&!D:)B<H*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E
M9F=H:6IS='5V=WAY>H*#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6V
MM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P#
M 0 "$0,1 #\ _?RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?@3XCT'3M*UF*X=9+Z*_TXW4CW!D;8I5AM&W QUYKZ6M;JVO;:.\LKB.:&5
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MOAXOPXO_ !M\7V\!>.[+1M2NGMO$>DWMC/(5O(YI7$SQO#O61OFWD,2S(A4
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MER6*CW.:]:T[7]"U>XN+32=:M+J6TDV7<5O<J[0MS\KA22IX/!]*_$WXL?M
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MIBO8* /C3XL_\$(O^"6'Q?\ 'WC?X\_M.?!";QSK_BV_N]1UOQ#XT\8Z@_\
M9\+LTA@MMD\<=E;Q D)Y:J54#+'&:^?O^"+O[1OCKX'_ /!*3]H[XTCQ?K7C
M3X5?!_QSX[N?@%KOBFZ>:?5?"&DVQFM0)F^:6W#Q2HK]CO0!5157R3_@IK_P
M6"_99_:W_;/\3?\ !,;XO_M;+\%O@/X U%['XV^(1;7HUCQ[>Q2%)O#UB;:%
MVMK)71DN;AMK2@%$RAS)]W_"'XB?L%_\%)/^"=WQ&_9@_P""=OQ'T"_\#CP#
MJ7P_ACT/2KFTM-&^U:9)!'"$FBC;"QS*V0#GN2<T ?'/['W_  1@^ '[:O\
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M6UU"LD<JGJK*P(8>QJ>B@"MI&CZ1X?TR'1=!TNVL;.V39;VEI L442_W550
MH]@*LT44 %%%% &<OA#PFGB1O&2^%].&KO#Y3:J+*/[28_[AEQNV^V<5HT44
M %9WB7P?X2\:6::=XQ\+:=JUO'()(X-3L8YT5QT8*X(!]ZT:* &PPPVT*6]O
M$L<<:A41%P% X  '04ZBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M[_$__/O!^7_UJ/\ A=_B?_GW@_+_ .M7%T4?ZPYQ_P _?_)8_P"0':?\+O\
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M_P#(!L?^O.+_ - %6ZJ>'_\ D V/_7G%_P"@"K=?L='^#'T0!1116H!1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110!X7_P3W_Y(GJW_8]ZS_Z4FO=*\+_X)[_\D3U;_L>]9_\ 2DU[I0 4444
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MPO\ X)[_ /)$]6_['O6?_2DU[I0 4444 %%%% !1110 4444 %%%% !1110
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M444 %%%% !1110 4444 %%%% 'T#X?\ ^0#8_P#7G%_Z *MU4\/_ /(!L?\
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MG_\ /C#_ -^A0!3_ .$Q\,?]!J#_ +ZH_P"$Q\,?]!J#_OJKG]G:?_SXP_\
M?H4?V=I__/C#_P!^A0!3_P"$Q\,?]!J#_OJC_A,?#'_0:@_[ZJY_9VG_ //C
M#_WZ%']G:?\ \^,/_?H4 4_^$Q\,?]!J#_OJC_A,?#'_ $&H/^^JN?V=I_\
MSXP_]^A1_9VG_P#/C#_WZ% %/_A,?#'_ $&H/^^J/^$Q\,?]!J#_ +ZJY_9V
MG_\ /C#_ -^A1_9VG_\ /C#_ -^A0!3_ .$Q\,?]!J#_ +ZH_P"$Q\,?]!J#
M_OJKG]G:?_SXP_\ ?H4?V=I__/C#_P!^A0!3_P"$Q\,?]!J#_OJC_A,?#'_0
M:@_[ZJY_9VG_ //C#_WZ%']G:?\ \^,/_?H4 4_^$Q\,?]!J#_OJC_A,?#'_
M $&H/^^JN?V=I_\ SXP_]^A1_9VG_P#/C#_WZ% %/_A,?#'_ $&H/^^J/^$Q
M\,?]!J#_ +ZJY_9VG_\ /C#_ -^A1_9VG_\ /C#_ -^A0!3_ .$Q\,?]!J#_
M +ZH_P"$Q\,?]!J#_OJKG]G:?_SXP_\ ?H4?V=I__/C#_P!^A0!3_P"$Q\,?
M]!J#_OJC_A,?#'_0:@_[ZJY_9VG_ //C#_WZ%']G:?\ \^,/_?H4 ?/U^RO?
M3.IR#*Q!_&HJFU  7\X _P"6S?S-0U^,S^-@%%%%2 4444 %%%% !1110 44
M44 %%%% 'N&A^+?#<.BV<4NL0JRVL88$]"%%6O\ A,?#'_0:@_[ZI= L+%M"
MLF:RA)-I'DF,?W15O^SM/_Y\8?\ OT*_8Z/\&/H@*?\ PF/AC_H-0?\ ?5'_
M  F/AC_H-0?]]5<_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*U I_\)CX8_Z#4'_?
M5'_"8^&/^@U!_P!]5<_L[3_^?&'_ +]"C^SM/_Y\8?\ OT* *?\ PF/AC_H-
M0?\ ?5'_  F/AC_H-0?]]5<_L[3_ /GQA_[]"C^SM/\ ^?&'_OT* *?_  F/
MAC_H-0?]]4?\)CX8_P"@U!_WU5S^SM/_ .?&'_OT*/[.T_\ Y\8?^_0H I_\
M)CX8_P"@U!_WU1_PF/AC_H-0?]]5<_L[3_\ GQA_[]"C^SM/_P"?&'_OT* *
M?_"8^&/^@U!_WU1_PF/AC_H-0?\ ?57/[.T__GQA_P"_0H_L[3_^?&'_ +]"
M@"G_ ,)CX8_Z#4'_ 'U1_P )CX8_Z#4'_?57/[.T_P#Y\8?^_0H_L[3_ /GQ
MA_[]"@"G_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]5<_L[3_P#GQA_[]"C^SM/_
M .?&'_OT* *UMXH\/WDZVMKJL3R.<(BGDFK]1)8V4;!X[.)6'0K& 14M !11
M10 4444 %%%% 'Y?:E^Q#X1_X*<_\%//VB_ /[?WQ?\ B!+IOPWN="A^%GPG
MT/QQ=:-IJ:!<Z<DC:P(K5T>Z:6[\^)IMV$>%HV)VHJ?07[+G_!#+_@GM^QU\
M=M"_:.^!W@[QA:>*?#GVK^R[C5?B-JU_ OVBUEM9-T%Q</&^8IY -RG!(88(
M!KY:_P""P7P&_P"" OPQ_:O;XW?M]?%;Q[;?%WQG;13V/AWP1XKUJ?4?LR0I
M;*\5GI^[[)"RP=6\M9&20C<P:M7_ ((]?"G_ ((8?%+]HZ#XL_L"?'7XC:C\
M2/ %O<W%QX.\=>-=<CNK:&XMY+22633]1*BXC"7.-Z!UC=XR2K%: /U/HHHH
M \+_ .">_P#R1/5O^Q[UG_TI->Z5X7_P3W_Y(GJW_8]ZS_Z4FO=* "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH ^>=1_P"0A/\ ]=F_F:AJ;4?^0A/_ -=F_F:A
MK\9G\; ****D HHHH **** "BBB@ HHHH **** /H'P__P @&Q_Z\XO_ $ 5
M;JIX?_Y -C_UYQ?^@"K=?L='^#'T0!1116H!1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 445Y?\ M9_$K]IOX6?#BQ\0_LH_LT6O
MQ5\1S>(+:UO?#MWXSMM#6VT]P_G7@N+A65S&0@\H#<V_@\&@#X(\+?M:?LI_
M\$R_^"NG[2.M?\%$+H>"-9^+M_HNK?"OXL:]HTTNGZMH$&EV]L^DPW<<;_9F
MM[B*3?$VP.61CG]WE]W^U1^R[_P4P_X+(_L[^./^"=\P\9W7P?A\0WOQ@^+&
MAZ--#I]EHUWI<UM:Z1+=21H+MY;EU=(P6$>UW7D2;?:?VT?CI_P4^E^*OB#X
M1?#'_@BKX/\ C5\-;6>W.B^)?$OQIT6QCU7-O&\CMI]Y [0E)6EB&[)(CW#A
MA4O[$_QT_P""G+?%GP_\(/BU_P $7_"/P2^&=PUTVK^)_#7QHT;4(]**VLLD
M173[.!&E,LZ0PG;C:)=YX4T ?:U%%% 'A?\ P3W_ .2)ZM_V/>L_^E)KW2O"
M_P#@GO\ \D3U;_L>]9_]*37NE !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?/.
MH_\ (0G_ .NS?S-0U-J/_(0G_P"NS?S-0U^,S^-@%%%%2 4444 %%%% !111
M0 4444 %%%% 'T#X?_Y -C_UYQ?^@"K=5/#_ /R ;'_KSB_] %6Z_8Z/\&/H
M@"BBBM0"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M KR?]LGX1?M1?&OX1Q^#OV1?VOO^%)>*EUB&XD\9?\*_LO$F^T5)!):_9+UU
MC&]FC;S,[E\O ^\:]8KYB_X*R^&O^"=/B_\ 9ET[P[_P4[ULV/P[NO&EA'82
M#4]3M#)J[1SK;)YFFD3<J9N"=GKT% 'CO_#O#_@NO_TL5?\ FHWAC_Y(KT#]
MES]C3_@K#\*/CMH7C_\ :7_X+0?\+9\$V'VK^V_A_P#\,Z:%H/\ :N^UECA_
MTZUF::#RIGBG^4'?Y.P_*Y-?"G[0_P"Q_P#\&BO[*'QCUK]G[]H3Q5<>&O&/
MAV2%-:T.Z\>>,Y9+5I8(YXP6AF=#F*6-N&/WN><BO1/^"9OA7_@V#TW]MWP3
M>_\ !._XE_VA\8D_M+_A#[/_ (2?Q5<>9G3;H7?[N_8V[8LS<G]X.,97Y@M
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M8_\ 7G%_Z *MU^QT?X,?1 %%%%:@%%%% !1110 4444 %%%% !1110 4444
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M_P#R ;'_ *\XO_0!5NJGA_\ Y -C_P!><7_H JW7['1_@Q]$ 4445J 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>'?\%"_BM^R
MS\(?V<;KQ!^VM\%Y/&_PQN=6M;?Q79S> ?\ A)+#380QF34+^S\N4_989(4+
M2B-S&[1MC^(>XT$!@58 @CD&@#XJ^"_P'_X-XOVBO#L/BKX&?L__ +'_ (IL
MIHPX?1_!'AF62/(SMDC$.^)AW1U5AW K.\=_%3_@WZ_X)T>,]/\ B7H_@;]G
M7PI\0+*1XO#EG\,? >DW'BJ2::-H#%9V^EV[7FZ59&A)4!2)"K$*37=?'K_@
MAU_P25_:7\23^,/B[^PCX&N-5NI3+>:AHMK+I$US(3DO*VGR0&1CW9LD]S7<
M_LM?\$S?V OV*+PZO^RW^R7X*\(:F4*'7+'2%EU$H1@I]LFWS[2.J[\>U 'K
M?P\\7_\ "PO &A^/O^$8U?1/[<T>VU#^QO$%E]FO[#SHED^SW,.3Y4Z;MCID
M[75ADXK8HHH \+_X)[_\D3U;_L>]9_\ 2DU[I7A?_!/?_DB>K?\ 8]ZS_P"E
M)KW2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** /GG4?^0A/_UV;^9J&IM1_P"0
MA/\ ]=F_F:AK\9G\; ****D HHHH **** "BBB@ HHHH **** /H'P__ ,@&
MQ_Z\XO\ T 5;JIX?_P"0#8_]><7_ * *MU^QT?X,?1 %%%%:@%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'A
M?_!/?_DB>K?]CWK/_I2:]TKYZ_8+MO$DOP<U9M)U*WBB_P"$XUG*RPECG[2W
M.:]M^Q>-_P#H-V7_ (#'_&@#8HK'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\
M@,?\: -BBL?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QH V**Q_L7C?\
MZ#=E_P" Q_QH^Q>-_P#H-V7_ (#'_&@#8HK'^Q>-_P#H-V7_ (#'_&C[%XW_
M .@W9?\ @,?\: -BBL?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QH V**
MQ_L7C?\ Z#=E_P" Q_QH^Q>-_P#H-V7_ (#'_&@#8HK'^Q>-_P#H-V7_ (#'
M_&C[%XW_ .@W9?\ @,?\: -BBL?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P"
MQ_QH V**Q_L7C?\ Z#=E_P" Q_QH^Q>-_P#H-V7_ (#'_&@#8HK'^Q>-_P#H
M-V7_ (#'_&C[%XW_ .@W9?\ @,?\: -BBL?[%XW_ .@W9?\ @,?\:/L7C?\
MZ#=E_P" Q_QH V**Q_L7C?\ Z#=E_P" Q_QH^Q>-_P#H-V7_ (#'_&@#8HK'
M^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\ @,?\: -BBL?[%XW_ .@W9?\ @,?\
M:/L7C?\ Z#=E_P" Q_QH V**Q_L7C?\ Z#=E_P" Q_QH^Q>-_P#H-V7_ (#'
M_&@#8HK'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\ @,?\: -BBL?[%XW_ .@W
M9?\ @,?\:/L7C?\ Z#=E_P" Q_QH \1U'_D(3_\ 79OYFH:EO@PO9@Y!/FMD
MCUS45?C,_C8!1114@%%%% !1110 4444 %%%% !1110!] ^'_P#D V/_ %YQ
M?^@"K=<[HMGXR;1K0P:S:*AMH]BM;$D#:,=ZM?8O&_\ T&[+_P !C_C7['1_
M@Q]$!L45C_8O&_\ T&[+_P !C_C1]B\;_P#0;LO_  &/^-:@;%%8_P!B\;_]
M!NR_\!C_ (T?8O&__0;LO_ 8_P"- &Q16/\ 8O&__0;LO_ 8_P"-'V+QO_T&
M[+_P&/\ C0!L45C_ &+QO_T&[+_P&/\ C1]B\;_]!NR_\!C_ (T ;%%8_P!B
M\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"- &Q16/\ 8O&__0;LO_ 8_P"-'V+Q
MO_T&[+_P&/\ C0!L45C_ &+QO_T&[+_P&/\ C1]B\;_]!NR_\!C_ (T ;%%8
M_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"- &Q1679VGBU+I'OM6M7B#?O$
M2W()'L:U* "BBB@ HHHH **** "BBB@ HHHH \+_ .">_P#R1/5O^Q[UG_TI
M->Z5X7_P3W_Y(GJW_8]ZS_Z4FO=* "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@#YYU'_D(3_P#79OYFH:FU'_D(3_\
M79OYFH:_&9_&P"BBBI **** "BBB@ HHHH **** "BBB@#Z!\/\ _(!L?^O.
M+_T 5;JIX?\ ^0#8_P#7G%_Z *MU^QT?X,?1 %%%%:@%%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'A?_  3W
M_P"2)ZM_V/>L_P#I2:]TKPO_ ()[_P#)$]6_['O6?_2DU[I0 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% 'SSJ/_(0G_P"NS?S-0U-J/_(0G_Z[-_,U#7XS/XV
M4445(!1110 4444 %%%% !1110 4444 ?0/A_P#Y -C_ -><7_H JW53P_\
M\@&Q_P"O.+_T 5;K]CH_P8^B ****U **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** /"_^">__ "1/5O\ L>]9
M_P#2DU[I7A?_  3W_P"2)ZM_V/>L_P#I2:]TH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@#YYU'_D(3_\ 79OYFH:FU'_D(3_]=F_F:AK\9G\; ****D HHHH
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MD[)UR23D@'H/[07C[_@IK_P2 /PT_:H_:/\ V^F^._PVU[QQIGAKXT>'=9\
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M\6J6\VIM+%97"12W4ELLP24H)!(P99$;#CUG_A[=_P $Z/\ HZ31?_ "\_\
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MP3H_Z.DT7_P O/\ XS0!]&45\Y_\/;O^"='_ $=)HO\ X 7G_P 9H_X>W?\
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MT_\ 1O'@7_PDK/\ ^-4?\,O_ +-/_1O'@7_PDK/_ .-5W-% 'RY^T_\ L_\
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M .&_X9?_ &:?^C>/ O\ X25G_P#&J/\ AE_]FG_HWCP+_P"$E9__ !JNYHH
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MAO\ AE_]FG_HWCP+_P"$E9__ !JC_AE_]FG_ *-X\"_^$E9__&J[FB@#AO\
MAE_]FG_HWCP+_P"$E9__ !JC_AE_]FG_ *-X\"_^$E9__&J[FB@#AO\ AE_]
MFG_HWCP+_P"$E9__ !JC_AE_]FG_ *-X\"_^$E9__&J[FB@#AO\ AE_]FG_H
MWCP+_P"$E9__ !JC_AE_]FG_ *-X\"_^$E9__&J[FB@#AO\ AE_]FG_HWCP+
M_P"$E9__ !JC_AE_]FG_ *-X\"_^$E9__&J[FB@#AO\ AE_]FG_HWCP+_P"$
ME9__ !JC_AE_]FG_ *-X\"_^$E9__&J[FB@#AO\ AE_]FG_HWCP+_P"$E9__
M !JC_AE_]FG_ *-X\"_^$E9__&J[FB@#Y<_81_9_^ WB/X/:I?>(?@EX1OYT
M\:ZO$DU[X;M976-;@A4!:,D*!P!T%>U?\,O_ +-/_1O'@7_PDK/_ .-5J_"W
MX4^$?@]X=G\+^"X9TM+C4KB^D%Q.9&\Z9][G)[9Z#M724 <-_P ,O_LT_P#1
MO'@7_P )*S_^-4?\,O\ [-/_ $;QX%_\)*S_ /C5=S10!PW_  R_^S3_ -&\
M>!?_  DK/_XU1_PR_P#LT_\ 1O'@7_PDK/\ ^-5W-% '#?\ #+_[-/\ T;QX
M%_\ "2L__C5'_#+_ .S3_P!&\>!?_"2L_P#XU7<T4 <AHG[/GP#\,ZM;Z_X<
M^"'A#3[ZTD$EK>V/AJUBFA<=&1UC!4^X-=?110 4444 %%%% !1110 4444
M%%%% !1110 4444 >"?\%"O^"A7P?_X)V?"'3_B%\1-"UGQ+K_B?7(-"\ >
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MA\->%;/1+F\\;6^LSXE\*W-FA-_9W? *R0,K Y4%UV.HPZY^>?AG_P %5/\
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MX6_8;_Y6&OVYO^Q/^&__ *9Z -/]I+_@KE^VC^SE>?LX?"'5O^"7]I>?&/\
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M_P %(K'P'\(O$L.G?:O !^"MKJDZ3VDT5P)?[1^WP3$-/"C[0  /EY%?=-%
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M(]7\)> H?!=CX7\,PW\>?*N;FPM&E-XZ$DJ9).[*VY&9#]W444 %?FA\/?\
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MK+X66OAG^QHH4D656^SW,_VGS T/+;2GDG&=YQ[K10!^?_Q1_P"";W_!6_\
M:#T#5OV?OCA_P5]T]_A7KZR6GB&;PE\'+32_$NI:7(2)+'[6L[16Y>,^6TR(
M21G*D,RG[6^!OP4^&O[.'P>\-? ;X.>&8M'\+>$=&@TO0]-B8L(;>) JY8\N
MQQN9V)9F)8DDDUU5% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
(% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>biib-20200930_g2.jpg
<TEXT>
begin 644 biib-20200930_g2.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M=2B%T^KZG#<:A9BXVQN+>)29$!1SM4Y+@'["V-_8ZI9QZAIMY%<6\R!X9X)
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MXFB\0?$W6/CA'->:'_IK^;:QZ?)9M)<QV[ 1H5F17'("CBO>]2_X*C?M:?M
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M9]6UF*QMO,E2ZOT62Z01R1*9E+HSJX#$JV/4/^"H  _X-B_$0 _YM_\ #?\
MZ!I] &C\9O\ @M%^TS\"O!NE?MC_ !#_ ."<M]I_[+VHZK812_$BY\>VXU^U
MTJ]G2&UUJ;11"6BMY&EB(A:;S@LJ%PC$H./_ ."U'QNU+]G_ /X*S_\ !/\
M^+'ACX7:OXYU2WF^)]GH7A3P_)&EQJU_>Z)I]E:0B64B.&-I[B+S)G.V*/?(
M<A"*W_\ @O$JI_P;=^/T10 /A_X1  ' ']J:37%_\%COCQX>_9D_X*=?\$[?
MCMXP\-:CJFB^'4^(LVNII>F27DUG8/HFFQ7-]Y,09W2UA>2Z?:"P2W=@#C%
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MVB(M6U_]I/XM^$;CQQ'\:)]>NXM6TC5KA7N=-:T9)%6WAMU^S*(D 0A6& "
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M\&>$/'WC:YOI]3^).O7-Z+K4=>:>_P W,\:*HM1(^U2%C"!=CHOZ[T %%%%
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MP?%&FW=[XP\%^%K_ $+PLT]UFUTV&]DC:ZGBBQQ<2+$D1DSGR\KCDY])HHH
M**** ,ZY\(>$[SQ#!XNN_"^G2ZK;1F.VU.2RC:XB0YRJR$;E')X![FM&BB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M ':O<?[.T_\ Y\8?^_0H I_\)CX8_P"@U!_WU1_PF/AC_H-0?]]5<_L[3_\
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M#4'_ 'U5S^SM/_Y\8?\ OT*/[.T__GQA_P"_0H I_P#"8^&/^@U!_P!]4?\
M"8^&/^@U!_WU5S^SM/\ ^?&'_OT*/[.T_P#Y\8?^_0H I_\ "8^&/^@U!_WU
M1_PF/AC_ *#4'_?57/[.T_\ Y\8?^_0H_L[3_P#GQA_[]"@"G_PF/AC_ *#4
M'_?5'_"8^&/^@U!_WU5S^SM/_P"?&'_OT*/[.T__ )\8?^_0H I_\)CX8_Z#
M4'_?5'_"8^&/^@U!_P!]5<_L[3_^?&'_ +]"C^SM/_Y\8?\ OT* *?\ PF/A
MC_H-0?\ ?5'_  F/AC_H-0?]]5<_L[3_ /GQA_[]"C^SM/\ ^?&'_OT* *?_
M  F/AC_H-0?]]4?\)CX8_P"@U!_WU5S^SM/_ .?&'_OT*/[.T_\ Y\8?^_0H
M I_\)CX8_P"@U!_WU1_PF/AC_H-0?]]5<_L[3_\ GQA_[]"C^SM/_P"?&'_O
MT* *?_"8^&/^@U!_WU1_PF/AC_H-0?\ ?57/[.T__GQA_P"_0H_L[3_^?&'_
M +]"@"G_ ,)CX8_Z#4'_ 'U1_P )CX8_Z#4'_?57/[.T_P#Y\8?^_0H_L[3_
M /GQA_[]"@"G_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]5<_L[3_P#GQA_[]"C^
MSM/_ .?&'_OT* *?_"8^&/\ H-0?]]4?\)CX8_Z#4'_?57/[.T__ )\8?^_0
MH_L[3_\ GQA_[]"@"G_PF/AC_H-0?]]4?\)CX8_Z#4'_ 'U5S^SM/_Y\8?\
MOT*/[.T__GQA_P"_0H I_P#"8^&/^@U!_P!]4?\ "8^&/^@U!_WU5S^SM/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#PO
M_@GO_P D3U;_ +'O6?\ TI->Z5X7_P $]_\ DB>K?]CWK/\ Z4FO=* "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** /"_\ @GO_ ,D3U;_L>]9_]*37NE>%_P#!/?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_"_QJ4H^L6OS1VT<=@L3_!JQEZ23_)F_1117(=04444 %%%% !1110 4444
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M4M/N5F@N[>1 \<L<B$JZ,K!E8$@@@BKM !1110!X7_P3W_Y(GJW_ &/>L_\
MI2:]TKPO_@GO_P D3U;_ +'O6?\ TI->Z4 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M#^S]X8T_XB^-!KO@_P"%7AFPUDRQ+J]PUOY,DX$;9CQ';2S<ML15.3A:Y?\
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M]]+1_P )+J__ $*%[_WTM;%% &/_ ,)+J_\ T*%[_P!]+1_PDNK_ /0H7O\
MWTM;%% &/_PDNK_]"A>_]]+1_P )+J__ $*%[_WTM;%% &/_ ,)+J_\ T*%[
M_P!]+1_PDNK_ /0H7O\ WTM;%% &/_PDNK_]"A>_]]+1_P )+J__ $*%[_WT
MM;%% &/_ ,)+J_\ T*%[_P!]+1_PDNK_ /0H7O\ WTM;%% &/_PDNK_]"A>_
M]]+1_P )+J__ $*%[_WTM;%% &/_ ,)+J_\ T*%[_P!]+1_PDNK_ /0H7O\
MWTM;%% &/_PDNK_]"A>_]]+1_P )+J__ $*%[_WTM;%% &/_ ,)+J_\ T*%[
M_P!]+1_PDNK_ /0H7O\ WTM;%% &/_PDNK_]"A>_]]+1_P )+J__ $*%[_WT
MM;%% &/_ ,)+J_\ T*%[_P!]+1_PDNK_ /0H7O\ WTM;%% &/_PDNK_]"A>_
M]]+1_P )+J__ $*%[_WTM;%% &/_ ,)+J_\ T*%[_P!]+1_PDNK_ /0H7O\
MWTM;%% &/_PDNK_]"A>_]]+1_P )+J__ $*%[_WTM;%% &/_ ,)+J_\ T*%[
M_P!]+1_PDNK_ /0H7O\ WTM;%% &/_PDNK_]"A>_]]+1_P )+J__ $*%[_WT
MM;%% &/_ ,)+J_\ T*%[_P!]+1_PDNK_ /0H7O\ WTM;%% &/_PDNK_]"A>_
M]]+1_P )+J__ $*%[_WTM;%% &/_ ,)+J_\ T*%[_P!]+1_PDNK_ /0H7O\
MWTM;%% &/_PDNK_]"A>_]]+1_P )+J__ $*%[_WTM;%% &/_ ,)+J_\ T*%[
M_P!]+1_PDNK_ /0H7O\ WTM;%% &/_PDNK_]"A>_]]+1_P )+J__ $*%[_WT
MM;%% &/_ ,)+J_\ T*%[_P!]+1_PDNK_ /0H7O\ WTM;%% &/_PDNK_]"A>_
M]]+1_P )+J__ $*%[_WTM;%% &/_ ,)+J_\ T*%[_P!]+1_PDNK_ /0H7O\
MWTM;%% &79Z]J5S=)!-X9NH59L-*[+A?<UJ444 %%%% !1110 4444 %%%%
M!1110!0U?PKX8U_4-.U;7?#EA>W6D7)N=)N;NS222RF*-&9(68$QN4=T++@[
M68=":OT44 %%%% !1110 4444 %%%% 'A?\ P3W_ .2)ZM_V/>L_^E)KW2O"
M_P#@GO\ \D3U;_L>]9_]*37NE !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'A?_!/
M?_DB>K?]CWK/_I2:]TKPO_@GO_R1/5O^Q[UG_P!*37NE !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% 'A?_!/?_DB>K?\ 8]ZS_P"E)KW2O"_^">__ "1/5O\ L>]9
M_P#2DU[I0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110!X7_P $]_\ DB>K?]CWK/\
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ML(3+>7DYPD2=-QQVYKSC_AN?]D?_ *+UH/\ W^?_ .)H PO^">__ "1/5O\
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MW\/-/TZ\U'1Y'6*6XTZ_M8U%W '*H^-O/0,%8J ?;W[2?[0/P[_93^ 7B_\
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M&'1QZ%3P16/_ ,*N^&?_ $3O0O\ P40__$UNT4 >"?\ !/;3=.7X):JJZ?
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M_9VG_P#/C#_WZ%']G:?_ ,^,/_?H5-10!#_9VG_\^,/_ 'Z%']G:?_SXP_\
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MG<.IH ^KZ*** "BBB@ HHHH **** "BBB@ HHHH \+_X)[_\D3U;_L>]9_\
M2DU[I7A?_!/?_DB>K?\ 8]ZS_P"E)KW2@ HHHH **** "BBB@ HHHH ****
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MA\2_B3JFL>,-4MX]FFGQ+JKRH]T_"*L:E5VYY*D'"J?2OC-W,CF1@,L<G:H
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MY?.7RR[^5GJ@;^&OINO"/VZ?%'PLT32/ OA_XL_L-:_\<;#Q'XYM=*BL=%\
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M444 %%%% !1110 4444 %%%% !1110 4444 ?GC?_ME?\%A?VSOCY\5_"O\
MP39\ ? /PM\//A%\0KSP/J'B;XU3ZO<7^NZU9)$UV;>#3B%AMT,R@&0$O\K!
MCEE3U_\ 9"TC_@MS9?&6"?\ ;M\8?LS7O@#^SYQ<0?"W3]>CU8W6!Y)5KT^5
MY><[L\XQBODKX86/_!47]H']N_\ :5^)W_!++Q3\+_A%\--'^*=SX6\8Z?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M,)%$@55'H .!4E%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_DB>K?\ 8]ZS_P"E)KW2O"_^">__ "1/5O\ L>]9_P#2DU[I0 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBO*_VQOVOO@A^Q/\
M#-;^-'QM^*'A?PY%9Z7>2:';>)O$%O8?VS?0VLLZ6-OYSKYT\@C(6-,N>P-
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MAOQ?;^'_ !??:3'?#07>USJ5[;V\Q\J2Z6QCQ$) 5$C1D@X% 'V-^R=^TO\
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MQ16/]B\;_P#0;LO_  &/^-'V+QO_ -!NR_\  8_XT ;%%8_V+QO_ -!NR_\
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M+1VEA:QVUK&\K.5C10J@LQ+,0 .223W)JU0!\@_\%&? O[>WB#]FWX._ /\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 >%_\$]_^2)ZM_P!CWK/_ *4FO=*\
M+_X)[_\ )$]6_P"Q[UG_ -*37NE !1110 4444 %%%% !1110 4444 %%%%
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MTXXZDI*-5.#_ +WZ/9_??R W:* 01D'(/0BBNT HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH \+_X)[_\D3U;_L>]9_\ 2DU[I7A?_!/?_DB>K?\
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M6/\ +)VDO277TDK]Y'?45Y3_ ,)W\=?A&?*^)OA4>+-'0_\ (P^'(=MS&O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MM[>Z;J$6W[583W!$7G1DR%D8@N BJ#N; !XCX!^-VJ?MR_\ !>KX)?$#XZ_
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M"O%?B'PWIMY=G,DEG;:E,81GN$201CL%C"C@5^@M?.W_  2B_8=E_P""=/[
M_@#]E#5O$,.L:WH5C/=>*-7MRQCO-5N[B2ZNF0L S1K),T:,P#%(T) )(KZ)
MH R?'7B'5/"GA&_\1Z)X5N]<N[2 R0:38LHFNFR/D0MQGZ^E>0_\-8?&S_HQ
M_P =_P#@5;?_ !5>Z44 ?.'_  3Q\4ZS+\#=2E?P7?(S^--5=D++E"TVXJ?=
M22I]U->[_P#"2ZO_ -"A>_\ ?2UY'_P3W_Y(GJW_ &/>L_\ I2:]TH Q_P#A
M)=7_ .A0O?\ OI:/^$EU?_H4+W_OI:V** ,?_A)=7_Z%"]_[Z6C_ (275_\
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M^$EU?_H4+W_OI:V** ,?_A)=7_Z%"]_[Z6C_ (275_\ H4+W_OI:V** ,?\
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M_AZA1117RY]P%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% 'A?_!/?_DB>K?\ 8]ZS_P"E
M)KW2O"_^">__ "1/5O\ L>]9_P#2DU[I0 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0!X7_P $]_\ DB>K?]CWK/\ Z4FO=*\+_P"">_\ R1/5O^Q[UG_TI->Z4 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 >%_P#!/?\ Y(GJW_8]ZS_Z4FO=*\+_ .">
M_P#R1/5O^Q[UG_TI->Z4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >%_\$]_^2)Z
MM_V/>L_^E)KW2O"_^">__)$]6_['O6?_ $I->Z4 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M\4__  MC_P#&J/\ AR%^R;_T4;XI_P#A;'_XU7V-10!^?_[37_!(3]FGX4?
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M_A;'_P"-4?\ #D+]DW_HHWQ3_P#"V/\ \:K[&HH ^.?^'(7[)O\ T4;XI_\
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M_P#&J^QJ* /CG_AR%^R;_P!%&^*?_A;'_P"-4?\ #D+]DW_HHWQ3_P#"V/\
M\:K[&HH ^.?^'(7[)O\ T4;XI_\ A;'_ .-4?\.0OV3?^BC?%/\ \+8__&J^
MQJ* /CG_ (<A?LF_]%&^*?\ X6Q_^-4?\.0OV3?^BC?%/_PMC_\ &J^QJ* /
MSK_9/_X)-?LY?&/X;W_BGQ5X]^(T5S;^)]1L(UL/%[1H8H9BB$@QGYL#DYYK
MT[_AR%^R;_T4;XI_^%L?_C5?0O[-?P9U/X&> KWPAJNM07\EUXAOM16:WC95
M59Y2X3![@'!KT&@#XY_X<A?LF_\ 11OBG_X6Q_\ C5'_  Y"_9-_Z*-\4_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MS:A>I+<W<0/W96262$N.2C%3P!0!]=?L=?M[_LI_MZ^$M5\7?LO_ !2CUU=
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MG*;R>Y8U]%4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M\0?B1!I$_G6NG7]^ZE;"&3HZ0QHHR,KO:0*64*Q^MZ* "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M'L'[-_\ T(GQ._\ #>WG^%?$?ZO9Y_T#R^X^S_M[)O\ G_'[SZ;HKP'X9?\
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M#B@#]SB0!DFJ>C^(= \0QR3:!KEG?)#)LE:SN4E"-_=)4G!]J^&?VV/V??\
M@E+_ ,$\?V!Q^S]XH_98U:X^'GCOXE6%KHOPB^'4UZU]XQ\37.P6]G$JW,;.
M9!:*61I5C*P88-G:WQ+XY\(7_P"PU^VA^RM\?OV?O^"2OB7]E%?&GQ\T'X?>
M)=1B^)&C7>G^*M)U;S87L+O3+"^F?S4V^>DSQ@(T9W,7\J@#].?^&W/&G_#X
M'_AV_P#\(;I?_"._\,V?\+)_X2'S)/MOVW_A(/[+^R[<^7Y/E_/G&[=WQQ7T
MG7P!_P [37_=@'_N[U]_T 5M0UC2-):!-5U6VMC<S"&V%Q.J&60]$7)^9CV
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M87MA)YCD13[02 %&G^V9^WGK7_!2?_@DA^SK\"OA)K!M/'G[9>NZ;X/UX6(
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M=U_P<V_\$1K&+S[W]LJ\A3(&^7X4^*E&3T&3I=>G_LG?\%H_^";'[</Q>A^
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MSQ#X<DN_$5]\-OA=/X;$%KX)O-;GAEU":WN?M+^8'6)X@@BC"I*1R1D_>=%
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MK+^V=>U!HS<W$=K$2EM&1%&JQ*S!0O4YKZ HHH **** "BBB@ HHHH ****
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MZ5_W[;_&@#JO^$Y\$_\ 0X:5_P"#"/\ ^*H_X3GP3_T.&E?^#"/_ .*KE?\
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M*-1:B'3HXXW4.DDGF,"Y,I&<*M? WC+_ ()9_MU^%O\ @C!^S1^SQI5SI?Q
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M]ESX[:M_P7/\%_MC:?X&\SX<:3^SAJ/A;4/$?]IVH\K5I=86XCMOLYE\]LQ
MMY@C,8Z%@>*^:_V[+']H+]N'X5^*_@K\=O\ @W*EU[XE:OI-UI7AOQS/XO\
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M6%[$B"X@8X# HIC9U4Y.< 'U-17YL?L]?\%I_P!O;]N+X(7GQJ_8F_X),_\
M"0V?A[6-1T_Q&WB3XO6^G07-S:SR*+737>S#WDK1+$[.T<<4;RB(-*RL5]5U
M'_@M=\%Y/^"6.@?\%-O"'PH\0:NGBF]MM%T/X=B>.#4)?$,U^=._LR29QY<0
M6Y20&9ACRTWA265" ?:5%?+_ .SE^T)_P5*\5?%[1?"O[4G_  3L\'^#_"&L
M1W#7OBOPM\:(=7FT)T@DDBCN+1[.%I_,=4AWPNP5G#$;<D?4% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 0ZC:S7MC+:V]Z]N[KA9XP-R'U&:P_\ A"_$'_10
M]2_[X3_"NBHKGK8:C7E>=_DVOR: YW_A"_$'_10]2_[X3_"C_A"_$'_10]2_
M[X3_  KHJ*R_L_"^?_@4O\P/*/C!HNH:/_9WV_Q#<W_F>=L^T*!Y>-F<8]<_
MI7%5ZQ\7_"7B#Q3_ &=_86G^?Y'G>;^]1=N[9C[Q&>AKBO\ A4OQ!_Z%_P#\
MFXO_ (NOA,YRW%/,JGL:4G'2SM)_9774#G*]/^'?AC6-1\'6=Y:^,KVTC?S-
MMO"JE4Q(PXSZXS^-<G_PJ7X@_P#0O_\ DW%_\77I_P /-)U#0O!UGI6JV_E7
M$7F>9'O#8S(Q'()'0BNKA[+JZQLO;TY17*]^:.MUUT^X"O\ \(7X@_Z*'J7_
M 'PG^%'_  A?B#_HH>I?]\)_A7145]C_ &?A?/\ \"E_F!AZ=X4UJROHKJX\
M;7UPB-EH)%7:X]#BMRBBNBC0IT(VA?YMO\VP/SP_8;_Y6&OVYO\ L3_AO_Z9
MZO\ _!M5'&G_  3:NF2-07^,/C(N0/O'^V)QD^O  _"OT HK4#\,?A_^S?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MVC^."0MI\7[*>H/\'EU( P#Q'_;3_;S;;O\ E[_L_?NQSY0'M7UC_P %%O\
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M?#;XVWL?B3Q'#)-X0C\1>#]4TBV\21H,NVG7%[;1178QR!&Q+CE PYK\]_\
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M31;6.VC\0?L*P:GK0A7;]LNX?%XMHII,?>=80L8)Y"J!TK] Z /S\_X))?\
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M5HF@^((]<TBUA\0ZAIKVVH1Q2Q).LMA<0R$A)I  6*_-G&0"/8** /D/X/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
E110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>biib-20200930_g20.jpg
<TEXT>
begin 644 biib-20200930_g20.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?@3XCT'3M*UF*X=9+Z*_TXW4CW!D;8I5AM&W QUYKZ6M;JVO;:.\LKB.:&5
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MOAXOPXO_ !M\7V\!>.[+1M2NGMO$>DWMC/(5O(YI7$SQO#O61OFWD,2S(A4
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MER6*CW.:]:T[7]"U>XN+32=:M+J6TDV7<5O<J[0MS\KA22IX/!]*_$WXL?M
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MIBO8* /C3XL_\$(O^"6'Q?\ 'WC?X\_M.?!";QSK_BV_N]1UOQ#XT\8Z@_\
M9\+LTA@MMD\<=E;Q D)Y:J54#+'&:^?O^"+O[1OCKX'_ /!*3]H[XTCQ?K7C
M3X5?!_QSX[N?@%KOBFZ>:?5?"&DVQFM0)F^:6W#Q2HK]CO0!5157R3_@IK_P
M6"_99_:W_;/\3?\ !,;XO_M;+\%O@/X U%['XV^(1;7HUCQ[>Q2%)O#UB;:%
MVMK)71DN;AMK2@%$RAS)]W_"'XB?L%_\%)/^"=WQ&_9@_P""=OQ'T"_\#CP#
MJ7P_ACT/2KFTM-&^U:9)!'"$FBC;"QS*V0#GN2<T ?'/['W_  1@^ '[:O\
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M6UU"LD<JGJK*P(8>QJ>B@"MI&CZ1X?TR'1=!TNVL;.V39;VEI L442_W550
MH]@*LT44 %%%% &<OA#PFGB1O&2^%].&KO#Y3:J+*/[28_[AEQNV^V<5HT44
M %9WB7P?X2\:6::=XQ\+:=JUO'()(X-3L8YT5QT8*X(!]ZT:* &PPPVT*6]O
M$L<<:A41%P% X  '04ZBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** *5]XBT339_LM_J4<4@ .QCSBHO^$Q\,?]!J#_OJO(/V#;FYUWX.:K>Z
MY</>3+XVU>-9;MS(P1;DA5RV3@#H.U>U_P!G:?\ \^,/_?H4 4_^$Q\,?]!J
M#_OJC_A,?#'_ $&H/^^JN?V=I_\ SXP_]^A1_9VG_P#/C#_WZ% %/_A,?#'_
M $&H/^^J/^$Q\,?]!J#_ +ZJY_9VG_\ /C#_ -^A1_9VG_\ /C#_ -^A0!3_
M .$Q\,?]!J#_ +ZH_P"$Q\,?]!J#_OJKG]G:?_SXP_\ ?H4?V=I__/C#_P!^
MA0!3_P"$Q\,?]!J#_OJC_A,?#'_0:@_[ZJY_9VG_ //C#_WZ%']G:?\ \^,/
M_?H4 4_^$Q\,?]!J#_OJC_A,?#'_ $&H/^^JN?V=I_\ SXP_]^A1_9VG_P#/
MC#_WZ% %/_A,?#'_ $&H/^^J/^$Q\,?]!J#_ +ZJY_9VG_\ /C#_ -^A1_9V
MG_\ /C#_ -^A0!3_ .$Q\,?]!J#_ +ZH_P"$Q\,?]!J#_OJKG]G:?_SXP_\
M?H4?V=I__/C#_P!^A0!3_P"$Q\,?]!J#_OJC_A,?#'_0:@_[ZJY_9VG_ //C
M#_WZ%']G:?\ \^,/_?H4 4_^$Q\,?]!J#_OJC_A,?#'_ $&H/^^JN?V=I_\
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M_P!^A0!3_P"$Q\,?]!J#_OJC_A,?#'_0:@_[ZJY_9VG_ //C#_WZ%']G:?\
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MB@ HHHH **** /"_^">__)$]6_['O6?_ $I->Z5X7_P3W_Y(GJW_ &/>L_\
MI2:]TH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MI0!C_8O&_P#T&[+_ ,!C_C1]B\;_ /0;LO\ P&/^-;%% &/]B\;_ /0;LO\
MP&/^-'V+QO\ ]!NR_P# 8_XUL44 8_V+QO\ ]!NR_P# 8_XT?8O&_P#T&[+_
M ,!C_C6Q10!C_8O&_P#T&[+_ ,!C_C1]B\;_ /0;LO\ P&/^-;%% &/]B\;_
M /0;LO\ P&/^-'V+QO\ ]!NR_P# 8_XUL44 8_V+QO\ ]!NR_P# 8_XT?8O&
M_P#T&[+_ ,!C_C6Q10!C_8O&_P#T&[+_ ,!C_C1]B\;_ /0;LO\ P&/^-;%%
M &/]B\;_ /0;LO\ P&/^-'V+QO\ ]!NR_P# 8_XUL44 8_V+QO\ ]!NR_P#
M8_XT?8O&_P#T&[+_ ,!C_C6Q10!C_8O&_P#T&[+_ ,!C_C1]B\;_ /0;LO\
MP&/^-;%% &/]B\;_ /0;LO\ P&/^-'V+QO\ ]!NR_P# 8_XUL44 8_V+QO\
M]!NR_P# 8_XT?8O&_P#T&[+_ ,!C_C6Q10!C_8O&_P#T&[+_ ,!C_C1]B\;_
M /0;LO\ P&/^-;%% &/]B\;_ /0;LO\ P&/^-'V+QO\ ]!NR_P# 8_XUL44
M8_V+QO\ ]!NR_P# 8_XT?8O&_P#T&[+_ ,!C_C6Q10!C_8O&_P#T&[+_ ,!C
M_C1]B\;_ /0;LO\ P&/^-;%% &/]B\;_ /0;LO\ P&/^-'V+QO\ ]!NR_P#
M8_XUL44 8_V+QO\ ]!NR_P# 8_XT?8O&_P#T&[+_ ,!C_C6Q10!C_8O&_P#T
M&[+_ ,!C_C1]B\;_ /0;LO\ P&/^-;%% &/]B\;_ /0;LO\ P&/^-'V+QO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^$EU?_H4+W_OI: -BBL?_A)=7_Z%"]_[Z6C_ (275_\ H4+W_OI: -BBL?\
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M7_Z%"]_[Z6C_ (275_\ H4+W_OI: -BO"_'_ /R.FI_]?C_SKUS_ (275_\
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MM?\ :'^,FOW'SWESKGQ*ET[3XY#U%K86*QQVL>>1&I8#UJSH_P#P1?\ B_\
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M_P#\CIJ?_7X_\Z]TKPOQ_P#\CIJ?_7X_\Z^3XM_W2G_B_0#'HHHKX, HHHH
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M%T[_ *XG_P!"->(5[?\ #/\ Y$73O^N)_P#0C7U/"?\ OT_\/ZH#=HHHK[\
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MZOPQ_P!_)?\ XBJ5%'^M_P#TX_\ )O\ [4"[_P /3_\ @GM_T=7X8_[^2_\
MQ%'_  ]/_P"">W_1U?AC_OY+_P#$52HH_P!;_P#IQ_Y-_P#:@7?^'I__  3V
M_P"CJ_#'_?R7_P"(H_X>G_\ !/;_ *.K\,?]_)?_ (BJ5:'A32M,UOQ)9:1K
M6G07EI<7"I<6MU"LD<JGJK*P(8>QK2CQ7[:M&G[&UVE\7?\ [= 9_P /3_\
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M^7<0MRKKD X(KU[_ (4'\"_^B+>$O_"<M?\ XW1_PH/X%_\ 1%O"7_A.6O\
M\;KR\VRO^U*,8<_+9WVO^J \?HKV#_A0?P+_ .B+>$O_  G+7_XW1_PH/X%_
M]$6\)?\ A.6O_P ;KP?]4/\ I_\ ^2__ &P'C]%>P?\ "@_@7_T1;PE_X3EK
M_P#&Z/\ A0?P+_Z(MX2_\)RU_P#C='^J'_3_ /\ )?\ [8#Q^BO8/^%!_ O_
M *(MX2_\)RU_^-T?\*#^!?\ T1;PE_X3EK_\;H_U0_Z?_P#DO_VP'C]%>P?\
M*#^!?_1%O"7_ (3EK_\ &Z/^%!_ O_HBWA+_ ,)RU_\ C='^J'_3_P#\E_\
MM@/'Z*]@_P"%!_ O_HBWA+_PG+7_ .-T?\*#^!?_ $1;PE_X3EK_ /&Z/]4/
M^G__ )+_ /; >/T5[!_PH/X%_P#1%O"7_A.6O_QNC_A0?P+_ .B+>$O_  G+
M7_XW1_JA_P!/_P#R7_[8#Q^K4/\ P4)_8M^$D2_#GXD?M#Z!I&N:4/*U#3;I
MY/,@<_, V$(^ZP/7O7JW_"@_@7_T1;PE_P"$Y:__ !NC_A0?P+_Z(MX2_P#"
M<M?_ (W7J93D7]EUY5/:<UU;:W5/N^P'!^ ?^"B7[$WQ1\9:=\/OA_\ M&>'
M]5UK5KD0:=IUL\GF3R'HJY0#/!KVBN;TGX-?"#0=1AUC0_A5X;LKNW??;W5I
MH5O')$WJK*@*GW%=)7T !1110 4444 %>7_M9^ /VHOB/\.+'0_V2?V@M+^&
MWB2'Q!;7%]KNK>%(M8CN-/0/YUJ(9&4(SDH1)G*[#ZUZA10!\>?M-?LR?\%C
MO'OQRU[Q;^S%_P %/O!W@#P+>20'0?".I_!6SU6?3U6WC24/=22!I=TRR2 D
M<"0+_#4G[+G[,_\ P6&^'WQVT+Q?^U/_ ,%-_!_Q"\!VGVK^W?!^E?!>STF?
M4-]K*D&V[CD+1;)VAE.!\PC*]&KYR\3?L*?!/_@HI_P5/^/OPV_X*<?$#Q9J
MB^&9]$?X)?"X>.KW1]+E\.2Z>ADU.TAM98FNY#>">.:16;RY(]K8!05]&_LN
M?\$(_P#@F5^QI\=M"_:3_9[^"&L:/XP\-_:O[(U&Z^(&M7T</VBUEM9<P7-W
M)$^89Y%^93@L",$ @ ^OZ*** /"_^">__)$]6_['O6?_ $I->K_$S_D1=1_Z
MXC_T(5Y1_P $]_\ DB>K?]CWK/\ Z4FO5_B9_P B+J/_ %Q'_H0KDQ_^XU?\
M,OR8'B%%%%?D0!1110 4444 %%%% !1110 4444 %;'@#_D=-,_Z_$_G6/6Q
MX _Y'33/^OQ/YUTX+_?*?^)?F@/=****_7P*GB#_ ) -]_UYR_\ H!KY^KZ!
M\0?\@&^_Z\Y?_0#7S]7P_%W\6EZ/] "BBBOCP/AW_@IC^RS^VOK_ (#\6^*_
M@K^VAJS^&];\3>'[@?#74_AM;:S]AE75-/7S+.YCDBN(XHWC%R\;^8N$D&4#
M%A[3^QA^Q O[+/B#QW\7/'_QDU7XC_$SXGZA9W7CKQOJNG0V(NELX3!:6UO:
M0?N[:"*-F"H"S?,<L0% ]YHKJEC*TL/['1+R25]MVE?I?SZ[ ?)'_!,_X3>/
M_P!D?X@?&3]C/7/ NKP^#=+\<3^+?A7XE&FR_P!FW&C:LQF?3DG"^7Y]I<K,
MKQE@Y65'"[3NKR?X)?\ !'S]O?\ 9Z^(WC;XN_#3_@K'IH\4_$+5?MWBGQ+K
M?[/EEJ&H7F.(X//GU)F2", !(4VQK@848&/T/HJ_K]=3E*-O>M>Z3O;U3W>K
M\P.&_9V\#_'#X=_#"V\,?M#?'>W^)'B>*YF>Y\4VOA*'1$GC9R8X_LL,LBKL
M7"[@QW8R<5YY^R'^P]_PS1\9OC/^T)XO^)W_  F/B[XQ^,TU2]U,Z+]B&FZ9
M!%Y5CI:*9YC(L",Z^;N7>"N47;S[Y17/[>I:23MS;V276_RU[ >7?M._!#XO
M?&O_ (07_A4O[2.I_#G_ (1?Q_I^N^(O[,TTW/\ PD>FP;_.TB7]]%Y<<VY<
MR?/C8/D:N1_:K^!_[>GC?X@V7CW]D']M71_ =C%HJ66H^#?$WP\AU>RO)UEE
M?[8L_FI-#)MD5"BY5A&I/(KW^BG"O4IVM9V[I/?U6OZ= /E#]EO_ ()V?%/P
M=^T]+^V[^VA^T_)\5OB9!X<?0?# L/#46CZ1X;L)'WRI;6Z.YDE<Y!F<ABKL
MI!X(@\,_"7Q[\?\ _@K=JW[2OC7P-J^D^"_@CX&/A7P!<:QIDMLNM:UJ.)]1
MU"U\Q5,EO%;^7:>8H*.Y?:S;#CZVHK1XRK*4I/=KE72R\DM-KKYOJ!-IW_(0
M@_Z[+_,5]#5\\Z=_R$(/^NR_S%?0U?6<(_!6]8_J 4445]D!\\ZC_P A"?\
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M**_7P"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /GG4?\
MD(3_ /79OYFH:FU'_D(3_P#79OYFH:_&9_&P"BBBI **** "BBB@ HHHH **
M** "BBB@#Z!\/_\ (!L?^O.+_P! %6ZJ>'_^0#8_]><7_H JW7['1_@Q]$ 4
M445J 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>
M;_M:0?M;7'P&UF']AN\^'\'Q,,EK_8$OQ0%X=$"?:(_M'G_8@9\^1YNS:/\
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MJW_8]ZS_ .E)KU?XF?\ (BZC_P!<1_Z$*Y,?_N-7_#+\F!XA1117Y$ 4444
M%%%% !1110 4444 %%%% !6GX+MH[SQ7I]K*S!9+E58HV#U['M696QX _P"1
MTTS_ *_$_G73@O\ ?*?^)?F@/7/^$'TC_GYO?_ MJ/\ A!](_P"?F]_\"VK8
MHK]? Q_^$'TC_GYO?_ MJ/\ A!](_P"?F]_\"VK8HH Q_P#A!](_Y^;W_P "
MVH_X0?2/^?F]_P# MJV** ,?_A!](_Y^;W_P+:C_ (0?2/\ GYO?_ MJV**
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MEF( SSU8;"Q6+:LTX.#M=/1R2W6C^)--= /U2HHHK]0 **** "BBB@ HHHH
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M*H  Z5V8;&2J8I-K63@M-E%-:?A'[@/HJBL?_A!](_Y^;W_P+:C_ (0?2/\
MGYO?_ MJ_4@-BBL?_A!](_Y^;W_P+:C_ (0?2/\ GYO?_ MJ -BBL?\ X0?2
M/^?F]_\  MJ/^$'TC_GYO?\ P+:@#8HK'_X0?2/^?F]_\"VH_P"$'TC_ )^;
MW_P+:@#8HK'_ .$'TC_GYO?_  +:C_A!](_Y^;W_ ,"VH V**Q_^$'TC_GYO
M?_ MJ/\ A!](_P"?F]_\"VH V**Q_P#A!](_Y^;W_P "VH_X0?2/^?F]_P#
MMJ -BBL?_A!](_Y^;W_P+:C_ (0?2/\ GYO?_ MJ -BBL?\ X0?2/^?F]_\
M MJ/^$'TC_GYO?\ P+:@#8HK'_X0?2/^?F]_\"VH_P"$'TC_ )^;W_P+:@#Q
M'4?^0A/_ -=F_F:AJ6^4)>S(,X$K 9^M15^,S^-@%%%%2 4444 %%%% !111
M0 4444 %%%% 'T#X?_Y -C_UYQ?^@"K=<[HO@S2I]&M)GN;L%[:-B%NF Y45
M:_X0?2/^?F]_\"VK]CH_P8^B V**Q_\ A!](_P"?F]_\"VH_X0?2/^?F]_\
M MJU V**Q_\ A!](_P"?F]_\"VH_X0?2/^?F]_\  MJ -BBL?_A!](_Y^;W_
M ,"VH_X0?2/^?F]_\"VH V**Q_\ A!](_P"?F]_\"VH_X0?2/^?F]_\  MJ
M-BBL?_A!](_Y^;W_ ,"VH_X0?2/^?F]_\"VH V**Q_\ A!](_P"?F]_\"VH_
MX0?2/^?F]_\  MJ -BBL?_A!](_Y^;W_ ,"VH_X0?2/^?F]_\"VH V**Q_\
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M_@Q]$ 4445J 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 >%_\$]_^2)ZM_V/>L_^E)KW2O"_^">__)$]6_['
MO6?_ $I->Z4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\\ZC_ ,A"?_KLW\S4
M-3:C_P A"?\ Z[-_,U#7XS/XV 45YQ^TK^UQ^SK^R!X2L_&G[1/Q.M/#MGJ5
M\++28#;375WJ-R1D0VUK;I)/</C^&-&(R,XKR;_@GQ_P5(^ O[<^@:-X5T_7
MI-/^(\_AIM9UCPG/X;U*R6*!94C>6"6[A1+B,-+$-T;ORXK6.&Q$J+JJ+Y5U
MMH!]045X5\4?VM/$&D_MQ?#W]B;X5>&[#4]3UGP]?>*_B!J%Z[XT'0(#]GA=
M%0C=-<7C+$F3A521B#Q7%?\ !1/_ (*&_'']B*UU+6?AO^P5XI^)NAZ#X/;Q
M%XB\6P>);72=)TZ!9)UDA::5)'DF1(/,,:1L=LL>,EL54,)7J3C&*UDKK5+K
M;K8#ZJHKB/V9OC)_PT5^S?\ #[]H+_A'/['_ .$[\$:3XA_LC[9]H^P_;;.*
MY\CS=B>;L\W;OV+NVYVKG ^4]!_X*??M@_M(Z_XSUW]@;_@G[:_$#P#X(\37
M>A2>*_$OQ+M]$D\07MJ0+A+&W:"0[ 2 LLC!6W#(4AE54\+6J2DDDN7>[22^
M;=@/N.BO"?V4/^"@GP6_:C_8]D_;)D2Z\'Z'I%OJ!\96/B/"S>'I[ O]LBG*
M\$1A"X8#+(5)56)4>(^"?^"DW_!0K]H'PU#\=?V5O^"5LWB#X8:@IG\-ZEXI
M^*ECHNKZ_9Y.V[ALY(G$"./F02/\ZX8$!@:J."Q#E)-)<KL[M+7M=M*X'W)1
M3+662>VCFF@,3N@9HF.2A(Y!^E>%_MK_ +6'QT_9HM=(@^!7[$WBOXP7VJ6E
MY<7)T;6;73;'2TMQ&?\ 2KJXR(RXD)4!6)$3^E8TZ<ZLU".[\TOQ>@'N]%>,
M?\$]?VN_^&\?V._!G[6/_"O?^$5_X2^"\D_L#^UOMWV3R+VXM<>?Y47F;O(W
M_P"K7&['.,FC\+_VM-?U7]N3XA?L2_%7PW8:9J>C^';'Q7\/M0LG?&O:!.?L
M\[NKD[9K>\5HGP<,LD; #FK>'K1G.#6L+W^3L_7^F!][>'_^0#8_]><7_H J
MW53P_P#\@&Q_Z\XO_0!5NOURC_!CZ( HHHK4 HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \+_P"">_\ R1/5
MO^Q[UG_TI->Z5X7_ ,$]_P#DB>K?]CWK/_I2:]TH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@#YYU'_D(3_P#79OYFH:FU'_D(3_\ 79OYFH:_&9_&P/E#_@H+
M^R=^TG\0OCU\'?VT/V2Y_"FJ^,O@[)K,:>"_',\L%AK%IJ5ND$QBN(E8VURB
MQ_(Q7:=PW$!=K^.?\$C_ /@H'J5CX/\ @U^Q9^T?^S1KG@#7?$_@^[F^%_BF
M34[;4=*\5PVBM+<K%+%AK:98_G,+J2% RP+(&^LOVFO@5^TE\3]<T3Q9^S=^
MV-J'POO]*MYX+ZQG\'VFN:7JJ2,C SVT[1NLB%#M>*5&P[ Y!KYD_P""7W_!
M._XAVV@?!S]JC]K'XWZWXFUWX?>$KRT^&_@>?PK%HUIX2^VH8;IY(PS375R\
M0V>9*R@*W"9"D>K2JT)9>XUFG;;?F3]YI=FKO[F^M@-G]B21_%/_  6C_;1\
M0>(G+WWAW3/A_H^B1R*0;:PETJ:XD5<_PO,H?COSW%>L_P#!7+_E&%\>O^R6
M:Q_Z3/7(^+/A-X_^ /\ P5LT3]ICP1X%U?5_!?QK\#_\(E\0)]&TV6Y71=9T
M\M/INHW7EJ3'!)!YMIYC (C[-S+N&=[_ (*&?L7_ +4O[:/A74OA3\+?VV[/
MX;>!O$7A:;1O%7AN;X76^M2:CYI<22K=/=PR09C94VJ.-N[.3Q#E2EC*51R2
MC:'?[*2:T3=[I@=7_P $SO\ E&_^S]_V1'PI_P"F>UKX*_82\,_M[_&7P%\5
MOC#_ ,$F_B=X*^''P5\9^/=8N_ NB_$RT?5;QM0\PQW=_:&&$"PMI9D&R"7[
M5L*,=N#AOMC]@']DC]J7]D/P;8?"OXQ_MI6?Q-\(^'?"EAH7@[18/AC;Z&^E
M0VD:0QLT\=U,]Q^Z14P^#D;B237CW@#_ ()D?MN_LC+XB^&O_!/_ /;QT/PE
M\--?UR[U33/"OC/X;IJ]QX6EN6W2I93B=!)&&^98Y5VC'.XEW;6G5H0G62G%
M\S33:;C:[;TMOMNN]MP/F'Q3XE\&Q?\ !M!\;/!'P4\&:[X=\2>"_$5UX<^*
M%CK>K+?7C:^FMV+:O+)<QQQK.)(9RV0B (P3'RY/I>M?"/\ X*,_ O\ X)P6
M'[?'@[_@H)JL'B?PE\-+7Q5_PJY?#.GCPA'I$%DEP=(C@\OSODM5\L7'FEW9
M,C:6#+]8_LQ?\$T/@O\ L_?L8^(OV-O%.M:CXWL/'DFJ77Q'U_6<1W/B"_U%
M-EW=,$)\EBH14VDL@C0[F8%CX;J?_!)S]M_Q-\#(/V%_%G_!2;[1\"8+6+3'
MMK?X>PQ>*+G0XB!'I3W_ )YC"B-5B,XBW,JX*%24KH6-PTY22DDN=R]Y7O%I
M72T?;K;=:@?8_P"S'\:+7]H_]G#P#^T#9Z2;"/QOX-TS75L&?<;;[7:QSF+=
M@;MI<KGOC-;WQ,_Y)OX@_P"P'=_^B7KS/XO_ +*_C37/ OPK^&O[-?Q[U#X4
MZ)\-O%.CW5S8:1IS72ZUH5A$8CHCYGC,<4B"-3(?,QY8^1LU+^V!\$_VI?C?
MX;T[P]^S1^UQ9_"C:MU'X@FN_AU;^(?[4AE151%$UQ#]GV8<[E)+;^VT5XW+
M1E434DDV][Z+I>R?X7 \3_X-[/\ E#Q\&/\ KQU?_P!/5_69^W!/+X5_X+,_
ML6>(?#;%;_Q#8^/M&UJ*,?-=:?'I4%P@;_9CE)D^OT-='_P3;_X)W?M5_L ^
M'?#OP=UK]O>R\<?##PSI]Y!IW@I?A);:9,))YI)_--\+V:4[999&VD'(;&0
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M10!C_8O&_P#T&[+_ ,!C_C1]B\;_ /0;LO\ P&/^-;%% &/]B\;_ /0;LO\
MP&/^-'V+QO\ ]!NR_P# 8_XUL44 8_V+QO\ ]!NR_P# 8_XT?8O&_P#T&[+_
M ,!C_C6Q10!C_8O&_P#T&[+_ ,!C_C1]B\;_ /0;LO\ P&/^-;%% &/]B\;_
M /0;LO\ P&/^-'V+QO\ ]!NR_P# 8_XUL44 8_V+QO\ ]!NR_P# 8_XT?8O&
M_P#T&[+_ ,!C_C6Q10!C_8O&_P#T&[+_ ,!C_C1]B\;_ /0;LO\ P&/^-;%%
M &/]B\;_ /0;LO\ P&/^-'V+QO\ ]!NR_P# 8_XUL44 8_V+QO\ ]!NR_P#
M8_XT?8O&_P#T&[+_ ,!C_C6Q10!\\7P87LP<@GS6R1ZYJ*O:Y/A3X!ED:630
M<LS$L?M4O)/_  *F_P#"I?A]_P!"_P#^3<O_ ,77Y_+A3,7)OFA][_\ D0/%
MJ*]I_P"%2_#[_H7_ /R;E_\ BZ/^%2_#[_H7_P#R;E_^+I?ZIYC_ #P^]_\
MR('BU%>T_P#"I?A]_P!"_P#^3<O_ ,71_P *E^'W_0O_ /DW+_\ %T?ZIYC_
M #P^]_\ R('BU%>T_P#"I?A]_P!"_P#^3<O_ ,71_P *E^'W_0O_ /DW+_\
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M=U_PJ[X9_P#1.]"_\%$/_P 31_PJ[X9_]$[T+_P40_\ Q- '"_\ #<_[(_\
MT7K0?^_S_P#Q-'_#<_[(_P#T7K0?^_S_ /Q-=U_PJ[X9_P#1.]"_\%$/_P 3
M1_PJ[X9_]$[T+_P40_\ Q- '"_\ #<_[(_\ T7K0?^_S_P#Q-'_#<_[(_P#T
M7K0?^_S_ /Q-=U_PJ[X9_P#1.]"_\%$/_P 31_PJ[X9_]$[T+_P40_\ Q- '
M"_\ #<_[(_\ T7K0?^_S_P#Q-'_#<_[(_P#T7K0?^_S_ /Q-=U_PJ[X9_P#1
M.]"_\%$/_P 31_PJ[X9_]$[T+_P40_\ Q- '"_\ #<_[(_\ T7K0?^_S_P#Q
M-,G_ &[?V1+:%IY/CQHA51DB-I'/X!4)/X5WO_"KOAG_ -$[T+_P40__ !->
M6_ML?#[P#I?[*7CG4-,\$:/;W$6ANT4\&F1(Z'<O(8+D&@#73]NG]D9U#CX\
MZ%@C(S(X/Y%>*7_AN?\ 9'_Z+UH/_?Y__B:W_AG\-/AQ/\./#\\_P_T1W?1+
M1G=]*A)8F%,DG;R:V_\ A5WPS_Z)WH7_ (*(?_B: .%_X;G_ &1_^B]:#_W^
M?_XFC_AN?]D?_HO6@_\ ?Y__ (FNZ_X5=\,_^B=Z%_X*(?\ XFC_ (5=\,_^
MB=Z%_P""B'_XF@#A?^&Y_P!D?_HO6@_]_G_^)H_X;G_9'_Z+UH/_ '^?_P")
MKNO^%7?#/_HG>A?^"B'_ .)H_P"%7?#/_HG>A?\ @HA_^)H X7_AN?\ 9'_Z
M+UH/_?Y__B:/^&Y_V1_^B]:#_P!_G_\ B:[K_A5WPS_Z)WH7_@HA_P#B:/\
MA5WPS_Z)WH7_ (*(?_B: .%_X;G_ &1_^B]:#_W^?_XFC_AN?]D?_HO6@_\
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M7) 7)4\ =!7MO_"KOAG_ -$[T+_P40__ !- '"_\-S_LC_\ 1>M!_P"_S_\
MQ-'_  W/^R/_ -%ZT'_O\_\ \37=?\*N^&?_ $3O0O\ P40__$T?\*N^&?\
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MMB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **\$_X*%?\ !0KX/_\
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MW5WX)T66X>*#7_C/867B+6+2(MF>#3EMY#$Y52RP.QD?@ 985[G^S[_P4O\
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MF:CI?B?Q%:>#8?#JWMA=*R");6WFE6%XXVP)%?=N4/P10!Y1_P %"8OA^/\
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MV%Z(Q-<R/YB31N%7YV5,($  /CS_ (+C?!W_ (*<Q_ /QS\2OCU\9?!WC_\
M9@T7Q0-:\>?"+P3IS>'?$6H>%H;]9H;0ZG,ER)6B40--Y8MVE6%PK*6 K]0?
M@OXU\#_$GX.^$_B+\,8MGAK7_#-AJ7AY/)\O;8SVZ2P#9_!^[9/E[=*^$/B]
M_P $KO\ @J/^VGX/D_9\_;H_X*IZ+>_"C4+B'_A+-!^&?PE@T?4O$EK&ZO\
M9I;Q[B3[*C%06\M6!Y4J5.*_0+P;X0\-_#[PAI7@+P;I,5AI&B:;!I^E6,.=
MEM;0QK'%&N<G"HJ@9]* .9\3?LX?!CQC\>?"W[3GB/P;]I\<>"]'U#2O#.M_
MVC<I]CM+[ROM4?DK((9-_DQ_,Z,R[?E*Y.?BC_@ZG_Y0<_%W_L(>&_\ T_V%
M?H?7PM_P5>_X)4_M?_\ !3GPWXE^"%I_P4BL? ?PB\2PZ=]J\ 'X*VNJ3I/:
M317 E_M'[?!,0T\*/M   ^7D4 ?5_P"U!\%;7]I3]FCXB?LZ7VKMI\'C_P "
MZOX<FOT3<;9+ZREM3*!D9*B7=C(Z5^9OPL^.'_!2[]F#_@FA-_P31\:_\$R/
M%+>.O!WPYO?"-G\58]<TX> QI45O)!'K4]Z9O.18[7$SVXA:5S&1A6?:GZ#_
M +'?P;_;&^#VB:W8_M@?MIV'QFO;V[A?1+ZQ^%]KX8&F1*K"2,QV]Q,)][%3
MN8J5VXP<U\M?$+_@F-_P5C_:1\&77[-O[57_  5\L=4^%.KP_8_%K>"O@[::
M+XB\1:<>);.2Z6=XK02IE'>)#N4LI4JS @&Q_P &R4'B:W_X(=? N/Q6DJW!
MLM<:W$^=WV5M>U$P'GMY13;_ +.VOO*N?^$_PL\ _ [X8^'_ (-_"OPU!HWA
MKPMHUMI6A:5;9V6MI!&L<48)))PJCDDDG))))-=!0 4444 %%%% !1110!^,
MG[?/[!^B77_!:WP%^Q#X/^)VK^'_ (*?M>7EQXY^-OPXTQ52TU;4_#\,UW)L
M8$-#'?,D'V@)M9GCWEF(0)^RFE:5IFA:9;:)HNG06=G9P)!:6EK$(XH(D4*B
M(J@!5    X &*^=_C=_P3[_X7'_P4A^"7_!0;_A;?]G?\*<\/Z_IG_"(_P!@
M^=_:_P#:=J]OYGVKSU^S^7OW;?*DWXQE>M?1] 'YX?\ !!__ )++^W3_ -GG
M^*?Y0UG^,O\ E:]\)_\ 9D$G_J37M?3'[!_[!/\ PQ+XS^.GB[_A:W_"3?\
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M\0_VC<_-HL=Y)>I:^1YGD#%Q*[^8(_,.[:7V@*/"?^"E_P#P43U/]EBTT/\
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MI\)^(O@9X<_X*,6/P[^$OBK2;&VUGP&_P8M=7GEGM[E+GSQJ#7T$RAI(H3L
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E%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>biib-20200930_g21.jpg
<TEXT>
begin 644 biib-20200930_g21.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?@3XCT'3M*UF*X=9+Z*_TXW4CW!D;8I5AM&W QUYKZ6M;JVO;:.\LKB.:&5
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MOAXOPXO_ !M\7V\!>.[+1M2NGMO$>DWMC/(5O(YI7$SQO#O61OFWD,2S(A4
M^YO"G[;G@OQ9^WUXL_X)_P!KX-U2+7O"7P\L/%UWKLDD?V.>WNK@P+"@!WB1
M2N22,8Z&N6U;]M[QEIO_  5QTS_@G:/!^E?\([??L^S_ !!E\0M)(+Q+N/61
M8"W SY?E;/GSC=N[XKX6'_!+7_@G_P#M!_\ !P_\</A_\9?V8]"U_1KOX+:7
MXPN;"\FN0DFN7NJ2?:KX[)0?,DR<C.WG@"M_]J/]BOX0?M%?\'#/PY_9H\80
MW]M\.='_ &+"-6\(:5JD]K!K6FVWB&2&#3+EXG61[42&WE:/>!)]F5'W(S*P
M!^JNE:QI&O62ZEH>JVU[;.2$N+2=9$8@X(#*2#@\5'?^)?#FE:A!I.J:_96U
MU=?\>MM<72))-SCY5)RW/I7YL?LS?L]?"?\ X)U_\%^7_9@_9$\-MX0^&OQ1
M_9IF\3^(? ME>S/IT>MV6L+;1W\,<CL(G-N3&0N =S'&3Q\PM\"?V:?V5/&?
MQ5U/_@NE_P $J/B1\2M3UWX@ZOJEU^TUI>C3^)]%DT26=FM'DDMKCS]'BA@V
MH(DC!0+C"\* #]TJ^./^"B/_  4W^//[(W[47PB_9"_9H_8AC^,_C/XNZ7K=
M[I5C+\3;?PVMLNF11S2CS+FUFC?,3.V6=/\ 5X 8L*^C_P!F;4O@MJW[.G@2
M^_9OUR'4OA^WA#3E\$WT%Y+<+-I2VT:VI\V8F5SY00$R$R9!W_-FOSM_X*\>
M'_VA_%'_  6W_8NT7]E;XB>'?"GCF7PE\0#I&N^*M"?4K&W4:=&9A);QR1LY
M:(2*N&&UF!YQ@@'TW^S!^UI_P5-^*7QJTGP1^TO_ ,$B;/X5>#+N.X.J^.8O
MVA=(UYK!D@D>)?L5M:I)+YDJI%E6&SS-QR%(KZHU/5-,T6RDU/6-1@M+:(9E
MN+F98T09QRS$ <U\V_LM_"W_ (*O>$_BQ#J_[7G[6/PG\8>#5L9EGT;PA\-;
MG2[UK@@>4XGDNY5"J<Y7;SZBOB7]B?\ X)U_LQ_MP?\ !1[]N#6_VL_"$WC?
M0=!^-MM#HO@K4]1N$TF"[DT]3+?26\4BK/<%!'&CR!O*57V8,C&@#]<89H;F
M%+BWE62.10R.C9# \@@CJ*XKX]_%ZW^$OP<\=>/=#FL+W6/"/@S4=;CTF>X&
M7-O:R3()%4[PC,@!/'!X-?F%^RY\5?&W_!-_]CW_ (*'_"?X&ZQ?S:!^SMXJ
MU:Y^#NFZE=27H\/17>CI=PVJ&8LS6T$SB0(Q/_+0DDNQ,^B?\$6?V/%_X(UW
M'[2!L]2?XZ:O\$)_'.H_'5O$-VVMW6N7.D->S227!E_>VDC.T+V[ QR0,0P+
M,7H _0C_ ()Y?M+^)/VR?V(?AA^U-XP\.V.D:IX[\(VNKWVF::[M;VTDJY*1
MER6*CW.:]:T[7]"U>XN+32=:M+J6TDV7<5O<J[0MS\KA22IX/!]*_$WXL?M
M?$_X;_\ ! K]AC]G[X<#QJ+7XTZSX:\+>,5^'$D::_>Z&899KO3].>66)4NK
MD(D2L9$!!=2<,:=\4/V?] ^$NK?#OXM?\$E_^")_[2WP4^*O@GQCIDC:W=:3
MI]MINO:']H5=1T[53'K5R]U'+ 6.YXW?>B_.H)- '[9ZKJ^DZ'9/J>MZG;V=
MM'CS+BZG6-%R<#+,0!S7SGI/[;_C'4_^"N&I_P#!.[_A#]*_X1VR_9]@^(,7
MB%)9#>/=R:R;#[.1GR_*V?/G&[=WQ7RYXW^ WPU_X*C_ /!<OXL? W]L;1I/
M%/PU_9P^'?AMO!_PXU&[D72KW5M9A>ZFU6>!& N)$C'V<;\H!MXR,G!_8C_9
M-^''[&?_  <D^/?A!\&;N^@\'2?LBP:CX:\-76I37,/AR"7Q' 'L+4S,S1V_
MGI/.L6=J&Z95 4*H /U5HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH *X?]IOX-?\ #1G[-OQ"_9[_ .$D_L;_
M (3OP/JWAW^U_L?VC[#]MLY;;S_*WIYNSS=VS>N[;C<N<CN** /*/V%OV8/^
M&+/V/_AW^RC_ ,)Q_P )+_P@/A>VT?\ M_\ LS[']O\ *&/-\CS9?*S_ '=[
M8]37E7[>'_!.;QO^T3\</ ?[9O[*W[0[_"CXV?#JPNM+TSQ+<: FK:;K.CW!
MW3:7J%FTD?F1;RSHZN&C9V8 ML*?5E% 'Q]^R5_P38^,OA/]KN]_X*!_MW_M
M.VGQ5^*B>%6\->$+;0/"HT;0_">EO)YDR6MN997EFE;.Z>1@VUV3!&"/0OV$
M_P!AC_ABG7OC=K?_  M'_A)O^%R?'#6?B'Y7]B?8O[(^WK OV'/GR_:/+\G_
M %V(]V[_ %:XY]_HH *^+_"7_!,7]ISX#?M9^//CI^R3_P % D\&>!OBC\0X
M?&/COX::Y\*+76OM-\PB2]%MJ#7<,EL+A(MO^K?RR01NVX/VA5%_$_AJ/6AX
M;D\0V*ZBR[EL&NT$Q&,YV9W8Q[4 >'?LM_L,?\,U?M8_M!?M0?\ "T?[:_X7
MMX@T74_[#_L3[-_8?]GV!M/+\[SW^T^9G?NV1;>F&ZUG_!7_ ()W>'/AE^U+
M^TS^T)XP\<P>*=(_:3_L&/5/!UUH/DQ:9;:?I4FG2P/-Y[_:UG25F/[N+8/E
M^?.ZOH^B@#X ^$O_  3,_P""F'[&GA0?L]_L-_\ !2OPY8_"2RGF'A'1/B?\
M*AK>J^%+221G%I!>1WD(O(T+-L\]1M7"= *^T?@-X'^)7PW^$6A^"OC#\8[C
MX@^)[&U9=;\97.C0:<VJ3M(SF7[+!^[@4;@JQKD*J@9/6NNHH KZM8?VII5S
MIGF^7]IMWBW[<[=RD9QWZUX1_P $N/V&/^':_P"PGX&_8I_X6C_PFG_"%_VG
M_P 5-_8G]G?;/MFJ7=__ ,>_GS^7L^U>7_K&W;-W&[:/?Z* / /V3?V&/^&7
MOVD_C]^T+_PM'^W/^%Y>,-/UW^R/[$^S?V)]FL_LWD^;Y\GVG=][?LBQTVGK
M6/\ !W_@G;_PJ;XY?M/?&C_A<']H?\-'W&GR_P!F_P#"/^5_PCOV72WL,>9]
MH;[7NW^9]V'&-O/WJ^EZ* /&/^">/[(?_#!7[%OP_P#V0?\ A87_  E?_""Z
M.]A_PD/]D_8?MVZ>67?Y'FR^5_K,8\QNF<\XKYQ\-_\ !+?]MC]COQCXIM?^
M"8G[<WAWP7\-O%_B.ZUQ_A=\1_AS_;=GX=OKEM]P^F7$-S!+'"S_ #"V<%$/
M()))/WK67JOC?P7H7B72?!FN>+]+L]8U[S_[#TF[U"..YU'R$$DWD1,P:;RT
M(9]@.U2"<"@#YX\3_P#!//Q#^TS^PKXJ_8U_X*(_M#7/Q:N_&4\D^H^+M+\,
M6WA]].<212VGV&WA,BPFVDB1T9VD+D'S-P9E/F6@?L6_\%M-$\.P?"*/_@K]
MX1?P]9P"VM_&MQ\"(;CQ0]NH 42-)>FU>8(,&=HV+'YV4DFONBB@".UADM[6
M.":X:5TC"M*PY<@8+''<]:^,/C?_ ,$X_P!K7P]^W#XO_;E_8 _; T#P!JOQ
M0T#2]+^)WACQQX#.N:?J$FG1-!97T!CN8)(9HH69/+R4;<Q)YQ7VG10!\=_\
M$]?^"5?BS]B;]J?XO_M:_$/]K;5?BEXF^,VG:./$MSK'AB*PD2^LUE$DR-%,
MR"!O-"16ZQH((HHTWR8W'T7_ ()E_L,?\.Z/V3M/_9?_ .%H_P#"8_8/$&KZ
MG_;G]B?V?O\ MU_-=^7Y/GS8V>;LW;SNVYPN<#W^J0\2^'#K7_"-C7[+^T=F
M_P"P?:D\_;C.=F=V,<YQ0!\<^"_^"+GPMC_X)>^)/^"8WQ?^*=[XDTGQ!KVK
M:Q#XMTS21IMWIUY=:K)J=M-!&9I@)+>9DP2^) A!"ARM>1?M._\ !&'_ (*-
M?M\?LOWG[(W[9_\ P5=TS4/#-FEL=&OO"_P@2UNM7NK>5&BN]8S?#[3M17(@
MA:)3,T<K,YB"M^F%5;'7-%U2ZN;'3-8M;B:SDV7<,%PKM W]UP#E3P>#Z4 .
MTFP_LO2K;3/-\S[-;I%OVXW;5 SCMTKP#Q=^P5_PE7_!3WPC_P %'_\ A:WD
M?\(M\)[WP5_PAO\ 86[[5]HO&N?M?VOSQLV[MOE>2V<9WCI7T/10!\&_\%,_
M^"&7@W_@H/\ M9?#+]K[PO\ 'JX^'7B'P5=6*^*X+;PW_:$7BVRLM0AOK.WF
M NH!"\4B2@2D2G$JC;B-0?<_BK^PQ_PLW_@HA\*/V]O^%H_8O^%8^#]=T+_A
M%/[$\W^TO[25!YWVKSU\GR]GW/*?=G[RU[GJOB'0-">"+6]<L[-KJ3R[9;JY
M2,S/Q\J[B-QY' ]:N4 > ?LF_L,?\,O?M)_'[]H7_A:/]N?\+R\8:?KO]D?V
M)]F_L3[-9_9O)\WSY/M.[[V_9%CIM/6LSX'?\$Y_"_PN_: _:8^,'C?QO!XM
MT7]I.]TU]7\)7.A?9X].M;;3'L);9YO/?[4LR.Q)V1;0=N&ZU]$3:YHEOJL6
M@W&L6J7T\9>"R>X42R*,Y94)R1P>0.U6J /@#X1?\$S_ /@IQ^QOX/C_ &=O
MV)O^"F7ANU^$VGR2)X2TSXG_  H&M:QX6LV<LMI!=Q7D"WD:%CL\Y!M&$ VJ
M*^U?@?X,^(?P\^$VA>"_BS\7+CQYXET^Q$>M>,+K2(-/?5;C)+3?9H/W4 .<
M!$X4 #GK6]I'B'0/$"2RZ!KEG?+!(8YFL[E)1&_]UMI.#[&K-Q<6]G;R7=W.
MD442%Y99&"JB@9))/  '>@#P/]K+]AC_ (:A_:3^ /[0O_"T?[#_ .%&^,-0
MUW^R/[$^T_VW]IL_LWD^;Y\?V;;][?LESTVCK7J^G_ _X+:3\6K[X^Z5\(/"
M]MX[U32UTS4_&MOX?MDU>[LE*,MK+>!/.DA!CC(C9BH,:\?*,=#IFJ:9K5E'
MJ>CZC!=VTHS%<6TRR(XSCAE)!YJ>@#Y._9?_ ."4?P]^"?P'_:)_9R^+/CL>
M/?#/[1'Q:\5>,=<M3HO]G'3[;6X8(7T]2)Y3(T0ARMR/+)9@1&A4$^%W7_!'
M'_@HEK7[.L7_  3P\1_\%64G_9\CT]-$F6#X90Q^,+GPXN$717U#[080GD 0
M&X$.YD&"A4E#^DM% 'S#\>O^"9?@CXHW7[,^F?#3QI'X+\._LT^-+#6=!T"'
M13>+?V=G9&TAL1(9XS!A-O[TB4_+RISFNG_;+_8F_P"&N/B)\#_'O_"S/^$?
M_P"%-?%BV\:_9/[&^U_VQY-M/!]DW>=']GSY^[S<28VXV'.1[O10!\@?M._\
M$U/CKXW_ &T6_;O_ &,_VV_^%/>-M5\ P^$?%L&J?#>V\36&K6,%RUQ!((9K
MFW:WF5FVEU<@JJC:/F+=?H?[!/B&'_@HOX;_ ."A_BWXY1ZIJNC?L_CX;ZGH
M,7A86ZZC<-J2W\FJB87#"$,X91;"-@N[/FG&*]]U/QIX.T3Q'I?@[6?%FF6F
MKZX)SHNE75_''<Z@(%#S&")B&E\M65GV@[003@&M.@#P#Q%^PQ_;_P#P4U\.
M?\%&/^%H^5_PC_P?O/ O_"'?V)N\_P _4!>?;/M?GC;MQL\KR3G[V\=*\1^(
M/[#7_!97QUX)\0? 74?^"K/@6]\&>);.YTZ\\1:A\!XAXAMM/G5HW@0Q7RVK
MR")R@F:,,3\^-U?<-]XAT#2[ZWTO4]<L[>YNVVVEM/<HDDYZ812<L?I5R@#S
M[]E#]FWP#^QY^S;X)_9>^%TUY+H'@;P];Z3IUQJ,H>XG6)<&64J "[MN=MH"
MY8X & /GW_@H-_P3/^.G[6/[57P@_;#_ &;OVTK;X/\ C'X0Z5KEEI=S=_#.
M'Q''=+J<4<,K&.:\@1,1*ZX*OGS,@J5&?KD:YHAU<^'QK%J;\1>:;'[0OG!/
M[VS.[;[XQ5J@#Y4_9X_96_X*G?#SXQZ+XQ_:$_X*R:-\1O!UE),=:\%VO[/&
MG:))J2M!(D8%[#?2/!LE:.3(1MWE[3@,2.L_8_\ V&/^&4?CM\>OC7_PM'^W
M_P#A=_Q B\3_ -F?V)]E_L79:K!]G\SSY/M.=N[?MCZXV]Z]_J#4M3TW1[*3
M4]7U""UMHAF6XN90B(,XR68@#DT ?./PD_X)M^"O!7C+]IK4OB3XQC\7>'?V
ME]<^U:[X:ET<VJZ?9MI:Z=-9F43N;C>@9O,"Q%=V .-U?.ND_P#!'+]OVS_9
MHU#_ ()V7/\ P5,1O@ ="N-#TF,?#.(^*TT5HVCBT>;4/M0B:V1"L3NL2R20
MJ8U,2L-GZ-VMU:WUM'>V5S'-#*@>*6)PRNIY!!'!'O4E 'QMKW_!'#X;^./^
M"8?PW_X)V>.?C!J_]J?"FWTJZ\#_ !2\/6(L-0TG7-.W&UU6WA:241L-[J8S
M(V4=@'5MKJWX?_LL_P#!9P>)]#TKXN_\%3/ USX7T?4[6;4[KPS\"H;;6/$5
MK%*K26\TDMY)!:&95*O)#&2H8[-IP1]ET4 ?'_[6O_!.+XX^*/VO-/\ ^"@'
M[!W[36G_  O^)[^%5\,^,[+Q)X5_MC0_%FE)+YL"W,"S1213PN?EG1MQ553@
M9SE_L:_\$I?BO^S[_P % ?$W_!1SX\?MGW7Q,\:>-OA@/"WB33V\&1Z9:0S"
M^@N$ELO+N7%O;1PVT,"VQ1F+!YFF9I&6OM2B@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH \'_X*A:]^T1X7_P"">'QD\0?LG0:A)\1+3P!J$GA;^QXV>]2<1'<]LJ@L
MUPL>]HPH+&14 !.*_,;_ ()U?L]_\&O?[7'[./@KP3XPUSP5K'Q<UK1;,^,I
M_'_CF_TOQ==^(WC4W9$L]S%*\_VGS,"W)3@;<KR?U_\ VA/CGX,_9H^"WB+X
M\_$2SU6?0O"]@;W5DT33'O+H0!E#ND,?S2;0=Q"Y.U3@'I7Y9_\ !33]MS_@
MVR_;)_9,\;^)-6U7X;>/OB!K_AR[A\&_\(UX-E7QC/K,D++9I"RVR7<<GGF/
M(E(CXQ("N00#[L_:]_:[^''_  2__9R\#>%M%\">(_'WB/5K[3? _P *? .F
M7JR:KXFU+R1'!$UQ,<(H2/?-<R9"@$D,S*K>9>&O^"G7[77P6^-_P]^&/_!2
M/]@S3_A9X?\ BSXDB\.>"_'/A/XEP^(K*UUV=6:UTK4$%M T$DVQE29-\;.,
M8 #,OQ%^U3^S!^U/X>_X)O?L$?M)?M<1?%*,? R=Q\:I/ 6KWEIXJ\/:-J%L
MD,6I"2V/VE9+*&*!9]A\P!Y PQO*^C>&+?\ X(0_'?XJ?"[PE:_\%7?C5\8=
M=O/B!HVH>!/!.J_''Q#XDC?6(KE&M)I[*42+;B-CEI)Q&$3?EE!- 'TG\>?^
M"M?QO\+?\%#O$G_!-#]F?]AB?XB^.M+\%:?XCTW5Y_'<>F::MM.2)YKYWM7^
MR0PDQ*"AF>:29$5$Y8;G[+O_  4U^-GQA\;_ !6_9,^,?['B^"/VC/AGX0;Q
M%I?PW?QQ#<:5XPL9$9;2YLM5$ $<,EQY<$CO"?(:9<ARKHOS/XF_;2^"'[%?
M_!R%\8?%'[1^K'PYX0\0_ OPSILWCF[M7;3]'O?.:2"*\F52+:.<+*JRN0GF
M1HA.7%=G^R)\4?"'_!1'_@O%XI_;L_9BOY]:^$7PO_9ZC^',GCVWMW2P\0:]
M<:N=0>"TD=5^T10Q,V]ER%D"'[LB,P!QG_!OW^U+_P %(/''PGN/#?BS]D&#
MQ%X)O/C3XFB\0?$W6/CA'->:'_IK^;:QZ?)9M)<QV[ 1H5F17'("CBO>]2_X
M*C?M:?M ?%WQUX&_X)H?L%V7Q3\+?#+Q'<>'O%/Q$\7_ !)A\.Z=?ZS;@?:=
M/TU#;SO<F,L$:X;9$&X&5*NWBG_!#/\ ;-_9K_9EL/%W_!.+]H#XE)X1^-5Q
M^T)XM6P\!:WI=U#=7R7-\\UO- QB\N2*2/+)(&VL!D'!!/S7^QK\-OV0/V*?
M%'Q._8[_ ."D_P"WS\?/@!XXT'XDZUJ?A_\ LSXV:WX:\.>+=#NIS-;:K8?9
MG6V>1PQ6501)N R-VY4 /T7T;_@L-X6\0_\ !-SXL?MU6?P&U;3_ !3\%&U;
M3?B+\(]>UA+>\TK7=.V?:-/>[CBD1D(='2X6-E9'!V@[E7R?QK_P6_\ VN?A
MW^S_ .'_ -O_ ,<?\$N=1TO]G&_MM*N]9\5R_$BVD\066GWK11C5$TE;?+VP
MDF78K2)+)&R2LL(8A?-/B5X._8"L/^"&'[9GQ*_X)^?&3QA\0M%\3V6K/XO\
M:^,]9U#49]6UF*QMO,E2ZOT62Z01R1*9E+HSJX#$JV/4/^"H  _X-B_$0 _Y
MM_\ #?\ Z!I] &C\9O\ @M%^TS\"O!NE?MC_ !#_ ."<M]I_[+VHZK812_$B
MY\>VXU^UTJ]G2&UUJ;11"6BMY&EB(A:;S@LJ%PC$H./_ ."U'QNU+]G_ /X*
MS_\ !/\ ^+'ACX7:OXYU2WF^)]GH7A3P_)&EQJU_>Z)I]E:0B64B.&-I[B+S
M)G.V*/?(<A"*W_\ @O$JI_P;=^/T10 /A_X1  ' ']J:37%_\%COCQX>_9D_
MX*=?\$[?CMXP\-:CJFB^'4^(LVNII>F27DUG8/HFFQ7-]Y,09W2UA>2Z?:"P
M2W=@#C% 'T!\)?\ @IQ^T=X._:^\'_L=_P#!1+]C.Q^$^I?%*VNW^%GBOPSX
M^3Q!I&K7=M&)9],GD^S0/;7*QD,I92DI.U<'&;7QK_X*6_'[Q)^U/XK_ &./
M^"=?[']M\6_$OPYMK.3XF^*?$?C>/0-!\.W%U&9;>P$WD327=TT8+,D: 1@C
M<V0RK\_?M3?M8? 7_@JK_P %#_V3_@;^P9X^L?B-#\+?B6/B3\2?&7AI'GTW
MPYIEK;.D-O-<A=GFW4CF,1*2P9%W 9KQ'4?AG^SK^R%_P5 _:/\ !W_!1;]K
MKXV_ K3/BKX['C7X5^-_!?Q5UCPUX;\2V=S%^_M99K)Q#]LM9,1D3%6V]/EV
M;@#]"?V6O^"G-[\</ 'QET?XN?L\:A\.OB]\!+9Y/B)\,-0UV*\15>RDO+.Y
MM;Z*/9/:W,<;[)?+!!5LH1M+^=?L#_\ !5K]L_\ X*->&/AY\<_@K_P3<CT3
MX3^(KF.#Q3XS\3?$^!)K=A(8[IM.M/LJR7T-NZLAF?R?,=)%1"$W-Q/[(7@W
M_@F?JWP__:@^-7["?[4/C[XP>)+CX8'2O'_C3QGXRU37DE1+&^:T@BOKY<3L
MBI)D1NXC5D!V[@*]I_X(!PQ0?\$:_P!GM(8E0'P#$Q"K@9,\I)^I))/N: /K
MG5M-M=9TNYT>]W^3=V[PS>6Y5MK*5.".0<'J.E?B[_P4J_8\_P"#;K]DSX5>
M/O@/X+T'3= _:(T71B/ FE>$/$VM7WC)?$L]JL^E>7MFED>2666V;,F4*RY)
M Y'[)?$+QSH/PP\ ZY\2O%37"Z7X>T>YU/4FM;9YI1;P1-+)LC0%I&VH<*H)
M)P!R:_,_]O3_ (*T?\&_O[3?[*/C;2]<\=^"?BIKOBOPW<6FA>%],\%7%SX@
MU+4I(&BM(X4>V6>WN!)Y821BAB*J=RX% #_^"AGQO_;@^ W_  0X^!_P@^(7
MQ!U'PY\<_C)JW@SX8^)/%*78.H:9?:E&3>2F5#_Q\^3;S1O(IR'=V5@0&'#_
M /!4C_@GQ^S!_P $6OV8O"'_  4D_P""?/@FZ\!^,/@QXQT-?$][8ZS<R/XS
MT*ZO(;.]LM2$CE;HRM+&Y<@%6#%=O&UO[1_[*'[;-Y_P;L_L\ZY\0/ ^N>)/
MB[^S]XA\+_$:_P#"=RKS:I<6^FSSXLV4@N9X=/N5W1G+YMW3YFX,G_!5O_@H
M/^RQ_P %E/V5O!W_  3A_P""?/Q'_P"%@^,_CAXQT+^V-/TG3IQ+X2T.VO(;
MV\O]2WH!:>3Y,:LC'<2QVAL<@'Z\P3PW,"7-O(KQR(&1U.0P(R"*=7C_ ,;O
MVT/@A^S;\>OA#^R]XXBU8>(_C-?ZCI_@>#3-.$T ;3X(IIS.^X&)%CE3!PW?
MIBO8* /C3XL_\$(O^"6'Q?\ 'WC?X\_M.?!";QSK_BV_N]1UOQ#XT\8Z@_\
M9\+LTA@MMD\<=E;Q D)Y:J54#+'&:^?O^"+O[1OCKX'_ /!*3]H[XTCQ?K7C
M3X5?!_QSX[N?@%KOBFZ>:?5?"&DVQFM0)F^:6W#Q2HK]CO0!5157R3_@IK_P
M6"_99_:W_;/\3?\ !,;XO_M;+\%O@/X U%['XV^(1;7HUCQ[>Q2%)O#UB;:%
MVMK)71DN;AMK2@%$RAS)]W_"'XB?L%_\%)/^"=WQ&_9@_P""=OQ'T"_\#CP#
MJ7P_ACT/2KFTM-&^U:9)!'"$FBC;"QS*V0#GN2<T ?'/['W_  1@^ '[:O\
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M6UU"LD<JGJK*P(8>QJ>B@"MI&CZ1X?TR'1=!TNVL;.V39;VEI L442_W550
MH]@*LT44 %%%% &<OA#PFGB1O&2^%].&KO#Y3:J+*/[28_[AEQNV^V<5HT44
M %9WB7P?X2\:6::=XQ\+:=JUO'()(X-3L8YT5QT8*X(!]ZT:* &PPPVT*6]O
M$L<<:A41%P% X  '04ZBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^$EU?_H4+W_OI:/^$EU?_H4+W_OI:V** ,?_ (275_\ H4+W_OI:/^$EU?\
MZ%"]_P"^EK8HH Q_^$EU?_H4+W_OI:/^$EU?_H4+W_OI:V** ,?_ (275_\
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M^TLQ_P"?T_\ P)_Y@='_ ,+:^(/_ $,'_DI%_P#$4?\ "VOB#_T,'_DI%_\
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M/5O^Q[UG_P!*37NE>%_\$]_^2)ZM_P!CWK/_ *4FO=* "BBB@ HHHH ****
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MF)9G<EF8DL23FLWP]^R_\#/"W[1/B#]K#1? ^SX@^*-#M]'UGQ%-J=U,TEA
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MG_TI->Z5X7_P3W_Y(GJW_8]ZS_Z4FO=* "BBB@ HHHH **** "BBB@ HHHH
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MZ!\/_P#(!L?^O.+_ - %6ZJ>'_\ D V/_7G%_P"@"K=?L='^#'T0!7A?C_\
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MV6/VS/V;?VT?"%]XT_9R^)4.NV^DWILM:LI;.>TO=,N<']U<VMPB30MP<;E
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M/[#FFZ+\2]1ET3XIVNLZ'XZ\-2.LJZLP\._;[>_)8%Q)!/ 2S C<L[!L_*0
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M?_(BZ=_UQ/\ Z$:^IX3_ -^G_A_5 ;"6-E&P>.SB5AT*Q@$5+117WX!1110
M4444 %%%% 'YA?\ !;_XA?\ ! 1OBII_AW_@H]X$O?$?Q,\/Z+%>"X^'NFZH
M=<T337<^5)=W>FM&(H2[G9'<2'F7<B?/N.5_P1S_ &G?^"&/PW_:8;]D[_@G
M=^S-X^\*_$?Q;;3-K>K>+?!6IF^,$-O)=D7E]?R22V\3B E4)6-Y-@"[B*G_
M &A?V'_VA?B+X._X*3_#SPU\(-2G\5?$R\T+7/AYXDN-/80^*+2WT:T>#3;>
M=L"1X+BSN+?R\C8\ZG@.#3O O[:D'_!2S_@IY^S7X^_9@_9@^*'A+5_AK9>(
M9/CEXC\:^";C1HM(TNZTQHAH$\LH'VN1K_R9%B&0CPB5>CE #],_!'@+P-\,
MO#4'@OX;^"])\/Z/:O(UKI.AZ=%:6T+22-)(5BB544M([NV!RS$GDDUK444
M>%_\$]_^2)ZM_P!CWK/_ *4FO=*\+_X)[_\ )$]6_P"Q[UG_ -*37NE !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M]@S]E_X3:]\-/B8^E7.J6'B[QU):S:AJ=K816YU*-44&TD91Y,B?O$D6WCD
M1V<M[)^RY\9?^"U7BOX[:%H'[6W[%_P?\)_#VX^U?\)!X@\+?$::_O[7;:RM
M!Y4#( ^ZX$*-D\*[-VKX]_X*.R_'[]M-_P!M_P"(.I_M??$?X?>%/V5?"LUG
MX ^'?PX\1OHXU/5$\/C4WU35I(AYMU$\D@2*(,J!(B1SN+?2WQE^+_Q-^'G[
M7W[!%IX6^*.N+:_$&RUW1/&'A%-7F-MK=JOAD7JWLL&[8\EK/#&PE(W 3L"<
M-P ?==%%% 'A?_!/?_DB>K?]CWK/_I2:]TKPO_@GO_R1/5O^Q[UG_P!*37NE
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 ?/.H_P#(0G_Z[-_,U#4VH_\ (0G_
M .NS?S-0U^,S^-@%%%%2 4444 %%%% !1110 4444 %%%% 'T#X?_P"0#8_]
M><7_ * *MU4\/_\ (!L?^O.+_P! %6Z_8Z/\&/H@"O"_'_\ R.FI_P#7X_\
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MX275_P#H4+W_ +Z6MBB@#'_X275_^A0O?^^EH_X275_^A0O?^^EK8HH Q_\
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MGA__ ) -C_UYQ?\ H JW7['1_@Q]$ 5X7X__ .1TU/\ Z_'_ )U[I7A?C_\
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M5UH1^$\_Q2U*PFL+/PN-*A_T2Q%XQAM;I;DW#31$),PD250R2L[97Q/^)?\
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M.H_\A"?_ *[-_,U#4VH_\A"?_KLW\S4-?C,_C8!1114@%%%% !1110 4444
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M^'$OQ#U%'GT_38;:>\O/[.T^!2EC"T5M*))V.UB/+5E,K*X!]]4444 >%_\
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M ,B+IW_7$_\ H1KQ"O;_ (9_\B+IW_7$_P#H1KZGA/\ WZ?^']4!NT445]^
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MWK/_ *4FO=* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%"]_[Z6@#8HK'_X275_^A0O?^^EH_P"$EU?_ *%"]_[Z6@#8HK'_ .$EU?\
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M)[_\D3U;_L>]9_\ 2DU[I7A?_!/?_DB>K?\ 8]ZS_P"E)KW2@ HHHH ****
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MDT:[C?PI=H&MI 79EPORGFO%:^@?$'_(!OO^O.7_ - -?/U?#\7?Q:7H_P!
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MO>:\+\?_ /(Z:G_U^/\ SKYCBW_=*?\ B_0#'HHHKX, HHHH **** "BBB@
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M3P__ ,@&Q_Z\XO\ T 5;K]CH_P &/H@"O"_'_P#R.FI_]?C_ ,Z]TKPOQ_\
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MQ_\ \CIJ?_7X_P#.OF.+?]TI_P"+] ,>BBBO@P"BBB@ HHHH **** "BBB@
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MCIIG_7XG\ZY\%_OE/_$OS0'NE%%%?KX%3Q!_R ;[_KSE_P#0#7S]7T#X@_Y
M-]_UYR_^@&OGZOA^+OXM+T?Z %%%%?'@%%8'Q1^*7P\^"G@#5/BI\6/&%CH'
MAW1+;[1JVL:E-Y<%K'D+N9NW) ]R0*\M_91_X*1_L4_MP^*O$'@O]E;XX0>+
MM0\+6\4^N1VNBW]O'!'*S*C++<01QR@E6'[MFQCFM(T:TJ;J*+<5N[:+U8'N
M-%>8_M0?MF_LO?L7^%[+QE^U#\9=*\'Z?J4SPZ=)J/F.]W(BAG6*.)7>0@$$
MA5.,BKO[,7[4_P !_P!LGX26GQT_9N\=_P#"1^%;ZZGMK75/[+NK/?+"Y21?
M*NHHY!A@1DJ >V11[&LJ7M.5\NU[:??L!Z#117S3\??^"N_[ W[-GQ.U/X/_
M !)^,=W-K^@QK)XGM?#GA74M730T89#7DEE;RI <<E6.\#DJ.,E*C6KRY:<7
M)^2N!]+45Q=A^T9\"M5^!/\ PT[IOQ6T2?X?C0WU@^+8[U39"R12SS%^P4*P
M(/S J5(W#%<9^S9^W]^S#^U?XKO/ ?PC\6:NNNVFCQZPFC>)?"FHZ-=7>ER.
M$CU"WCOH(FN+9F( EC#*"R@XW#+5&LXN7*[+?3;U ]GHKBM._:"^%VL_'[4O
MV9M&UJ:[\6Z+X;@US6K2VLI'AT^TGE:* 33@>7'+(4=DA+>8R(S[=HS7:U$H
MRCN@)M._Y"$'_79?YBOH:OGG3O\ D(0?]=E_F*^AJ^TX1^"MZQ_4 HHHK[(#
MYYU'_D(3_P#79OYFH:FU'_D(3_\ 79OYFH:_&9_&P"BBO//VH/V9/AM^UW\)
MKCX(_%VZUM?#M]>V\^IVNA:S+827J1.'^SR2PD2")R,.JLI(XR*(*+DE)V7W
M@=SIVN:)K$DT6D:Q:W36S[+A;:X5S$W/RMM)VG@\'TJR[I&ADD<*JC+,QP /
M6ORI_P""B7[$'[*__!/7QE\!_'?_  3H\$R_#_XU:W\6]+T;P[H_AC5[N0^(
M]+9C]OAO()97$MLJ;#)*P^7< S8;CV+_ (*<PW/[57[>_P"SY_P31\2:]?6O
MP\\5VFL^+?BAI>GWTENVNV=A"?LEA(\95O(>97\Q 1N!4C#(IKT%@:<W"4)O
MEDI.[5FE'5Z7=_+75Z ?=VF:KI>M6:ZAH^I6]W;N2$GMIED1L'!PRD@\U/7Y
MQ^(/@G\-O^"6/_!5#X"Z7^R?H[>$_AY\?8-;\-^._ ME>RG3CJ%G;1SV.H10
MR,PCG+.(F9<?(I &9&S^CE<V(H1H\LH.\9*ZTL]VG=7?5=P*U]K.CZ7-!;ZG
MJMM;R74FRVCGG5#*W]U03\QY' ]:LU^6W_!.7]BW]F;_ (*C>&OB]^U)^WIX
M+'Q$\>ZC\6M<\/2V^L:I<I_PB=A:.J6^G6D<<B?9=B/OW !SO!)R"3R/P-_:
M5_: ^)G_  1"_:=^%7PK^)&O^*?$'P9\6ZSX2\,^*[6[:?4[_P ,0W$#^>LR
M_,\JV#W:JXY"QQX.179++%S.$9ZQ<5*ZLES:73OJD_)=P/UPL-4TS55D?3-1
M@N5AE:*4P3*X1QU4X/##N.M*VHZ>E^NEM?0BZ>(R);&4>8R X+!>I ) STYK
M\T?V?O&G[ OP2_;X\/>/?^">?BGPKIWPETC]GO5M5^.-_P"#KL/I%I;0RVTF
MEW%^4)5=1^6[SYG^DE-^X$$U]"?\$_- U/XA>+]<_P""@'[0"1Z3XX^,MM'%
MX!\+ZI.B77A[P9 3)86*QD[A--N-[<!?^6DZJ0/*Q6-;!>RBY-NUE:ZL[OHU
M?31-^ENX'UA1117 !] ^'_\ D V/_7G%_P"@"K=5/#__ " ;'_KSB_\ 0!5N
MOV.C_!CZ( KPOQ__ ,CIJ?\ U^/_ #KW2O"_'_\ R.FI_P#7X_\ .OF.+?\
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M3?75?D 5[?\ #/\ Y$73O^N)_P#0C7B%>W_#/_D1=._ZXG_T(U]-PG_OT_\
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MLF^*_ACX:^#WPKU/0(/#_B&YLGU3QAXFU:XM([?1]/CLYYO.@$L**D[;=SS
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M;]%%><W=W ^@?#__ " ;'_KSB_\ 0!5NJGA__D V/_7G%_Z *MU^Q4?X,?1
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M+*M3 8N-J<O>B[IVDMUH^JU^7F?GO'>4NO0ACJ:]Z/NR]'L_D]/GY'>_L_\
M@[^V?$3^)KR+-OIW^JR.&F(X_P"^1S]2M>UU\T>!OVB/VEO"WAFWTOP[_P $
MWOBA?6A7S8M02 *+H-R)0-AP",8&3@8&:U_^&J_VLO\ I&7\4_\ OV/_ (W7
MR'&%/.>(,\J8B-/]W'W8>]'X5UWZN[^=NA]+PYE2RC*X4FO?>LO5]/EM\CZ
MHKY__P"&J_VLO^D9?Q3_ ._8_P#C='_#5?[67_2,OXI_]^Q_\;KY?_5[./\
MGU_Y-'_,]T^@**^?_P#AJO\ :R_Z1E_%/_OV/_C='_#5?[67_2,OXI_]^Q_\
M;H_U>SC_ )]?^31_S ^AM._Y"$'_ %V7^8KZ&K\]K?\ :P_:RM[B.?\ X=D_
M%,['#8\L<X.?^>=>A_\ #RG]K+_I$_\ %/\ \"Q_\CU]3PYE^+P$:BKQM>UM
M4]K]FP/L:BOCG_AY3^UE_P!(G_BG_P"!8_\ D>C_ (>4_M9?](G_ (I_^!8_
M^1Z^E ] U'_D(3_]=F_F:AKP*X_:P_:RN+B2?_AV3\4QO<MCRQQDY_YYTS_A
MJO\ :R_Z1E_%/_OV/_C=?F4N'LX<F_9?^31_S ^@**^?_P#AJO\ :R_Z1E_%
M/_OV/_C='_#5?[67_2,OXI_]^Q_\;I?ZO9Q_SZ_\FC_F!] 45\__ /#5?[67
M_2,OXI_]^Q_\;H_X:K_:R_Z1E_%/_OV/_C='^KV<?\^O_)H_Y@=3^T7X.VM!
MXULHNN(+W [_ ,#G_P!!_P"^:7]G3P=Q/XUO8O6"RR/^^W'_ *#_ -]5YW\1
M?VMOVBK#P/J=YXT_X)O_ !)L=+CM6-Y>7C+'% O]]F,>%P<'/KBK?A7]I_\
M:=L/#5C:Z'_P30^*$EFMJAMY8U!612 0X(CYSG.>^:^\>9Y__J9_9'LWSWY;
M\T?X6]M][^[_ (3Y3_5JE_K)_:/V;7M_?VO]VO\ B/H^BOG_ /X:K_:R_P"D
M9?Q3_P"_8_\ C='_  U7^UE_TC+^*?\ W['_ ,;KX/\ U>SC_GU_Y-'_ #/J
MSZ HKY__ .&J_P!K+_I&7\4_^_8_^-T?\-5_M9?](R_BG_W['_QNC_5[./\
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MH_Y@?0%%?/\ _P -5_M9?](R_BG_ -^Q_P#&Z/\ AJO]K+_I&7\4_P#OV/\
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M)M?$7POIVJ:@EO>>(=2N0;?3XV/,T@\E<JO4\BOJ2OKP"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** /"_VL/\ DMGP/_['N7_TF:O=*@N]
M+TR_G@N;[3H)I+63?;230JS1-C&Y21\IQW%3T %%%% !1110 4444 %%%% !
M1110 4444 %%%% !7D/[>6FV%_\ LE^-9KVT25[72'FMF<9\N3[NX>AVLP_$
MUZ]45]86.J6DFGZG917%O*NV6">,.CCT*G@BFFXNZ%*,9*S5S'^%W_),_#O_
M & K3_T2E;M-BBB@B6""-41%"HB# 4#H .PIU(84444 %%%% !1110 4444
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M*?V3/V>/%G[2?QD\2VFG>&O"FA3ZC>W%S.JB?:A,<$>?OR2OMC1!DN[JH!)
MH \;^%7[0WQ$_P""J7_!-GPG^T1^PU\=5^#^N?$#3[:Y@\27OAFVU^3098;H
MQ:A:"VG*13R+)#<0*[8' DV_PU\M?M,>*?\ @IY_P23^(WP9^*?C#_@HW/\
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M['@4 ?07P#^-G@3]I+X(>$?V@OAA?/<^'?&OANRUO1995"R&VN85F0.H)VN
MX#+GY6!':O!?VI?VC_C/\./^"H_[*/[.?@SQE]C\&_$O1_B%/XVT;^SK:3^T
M9-,T[3YK$^;)&TL/ER3RMB)T#[L/N  &U_P2'^"7CS]G/_@F+\#?@Q\4--FL
M?$6B?#G3DUG3[A2)+*XDC\Y[=P>CQF3RV'8H:^C: /S1_P""\OQ+_P""O'[*
M7P(^)O[:G[,O[:W@WP'\._ VGZ3)HWA2S^&]KJFL:C+/=6EG/]HNK]9(85$M
MP[KLC8[%"G!.1]YZ]\7[/X9_LRWOQ]\<F6YM_#_@23Q!K!@10\J061N9=H
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M;^R5^S_^R1\%HOV>?@/X&ETOP?#+<R+I&I:U>ZKN-PQ:8-+?S32NK$GY6<J
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M&D^.M?\ A)XD\9R>'[Q+K0-)^(/Q"U?6]-T^5?NLMI=7#PR8 QB57&.U?;(
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M=Y??]@GN6B==Q)\MPT?.-N.*^U[6UMK&VCLK*WCAAAC"111(%5% P% '  '
M I]% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M>\,>/M.L[;0H=7@C\_3=3LX+?4KL0SOL:V?:(U(=/E)9F !^K-%%% !1110
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M&UAGN[U[I+3C[4ZL(SNV$'/& #[8;XT_!Q/B+'\'V^+/AD>+95+1>%CKUO\
MVBX$;2$BVW^:0(U9_N_=4GH,T0?&GX.77Q";X1VWQ9\,R>*U5F;PQ'KUN=1
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MG[.7[$T?ACPCX4U#4FT_X11?$*XN5$DGBB33YG_M.XMGD^>662YP86V[O+'
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M&=5UZ2;6/@_#X?0ZWHWP^FLX[.'Q.'!^;5!"OVB5<'-O(?G1-P3]N_AG\2O
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MKF9X'L(@F+Q;E'C9)(R5+2$E@N'/AOQ$_9[^*_[/G_!LKX)T/XX^#)_#FO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
C **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>biib-20200930_g22.jpg
<TEXT>
begin 644 biib-20200930_g22.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?@3XCT'3M*UF*X=9+Z*_TXW4CW!D;8I5AM&W QUYKZ6M;JVO;:.\LKB.:&5
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MOAXOPXO_ !M\7V\!>.[+1M2NGMO$>DWMC/(5O(YI7$SQO#O61OFWD,2S(A4
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MER6*CW.:]:T[7]"U>XN+32=:M+J6TDV7<5O<J[0MS\KA22IX/!]*_$WXL?M
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MIBO8* /C3XL_\$(O^"6'Q?\ 'WC?X\_M.?!";QSK_BV_N]1UOQ#XT\8Z@_\
M9\+LTA@MMD\<=E;Q D)Y:J54#+'&:^?O^"+O[1OCKX'_ /!*3]H[XTCQ?K7C
M3X5?!_QSX[N?@%KOBFZ>:?5?"&DVQFM0)F^:6W#Q2HK]CO0!5157R3_@IK_P
M6"_99_:W_;/\3?\ !,;XO_M;+\%O@/X U%['XV^(1;7HUCQ[>Q2%)O#UB;:%
MVMK)71DN;AMK2@%$RAS)]W_"'XB?L%_\%)/^"=WQ&_9@_P""=OQ'T"_\#CP#
MJ7P_ACT/2KFTM-&^U:9)!'"$FBC;"QS*V0#GN2<T ?'/['W_  1@^ '[:O\
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M6UU"LD<JGJK*P(8>QJ>B@"MI&CZ1X?TR'1=!TNVL;.V39;VEI L442_W550
MH]@*LT44 %%%% &<OA#PFGB1O&2^%].&KO#Y3:J+*/[28_[AEQNV^V<5HT44
M %9WB7P?X2\:6::=XQ\+:=JUO'()(X-3L8YT5QT8*X(!]ZT:* &PPPVT*6]O
M$L<<:A41%P% X  '04ZBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BO$OV"-4U/5_@UJMSJVHSW4B^-]819+B9G8*+D@+EB> .@[5[;0 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%% !1110 4444 %%%% !1110 5[?\,_^1%T[_KB?_0C7B%>W_#/_ )$73O\
MKB?_ $(U]3PG_OT_\/ZH#=HHHK[\ HHHH **** "BBB@ HHHH **** /"_\
M@GO_ ,D3U;_L>]9_]*37NE>%_P#!/?\ Y(GJW_8]ZS_Z4FO=* "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "O7/ -KXKD\'V+V&JVL<)B.Q'@)(&X]37D=>W_  S_ .1%T[_KB?\
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M(NG?]<3_ .A&O$*]O^&?_(BZ=_UQ/_H1KZGA/_?I_P"']4!NT445]^ 4444
M%%%% !1110 4444 %%%% 'A?_!/?_DB>K?\ 8]ZS_P"E)KW2O"_^">__ "1/
M5O\ L>]9_P#2DU[I0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M34_^OQ_YU[I7A?C_ /Y'34_^OQ_YU\GQ;_NE/_%^@&/1117P8!1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MZ6X\M2)S*%V]4"D\DU)^RYXS_P""Y^K?';0M/_;&^"_[.&D_#B3[5_PD>H>
MO$>L3ZM%BUE-OY$=P/*;-P(%?=TC+D<@5XGKOPB_:Y_X*8?\%"/V@OA1XN_X
M*&_%3X(^"/@OK.BZ1X4\$?!W48-)U"_AN],CO/[5N[QHWDECF=G6-=NP>4ZC
M!1L^V?LN?\$G?%G[-'QVT+XVZG_P5*_:G^(\&B?:M_@SXC_$R/4-%U'SK66W
M'VBW%LAD\LRB5/F&V2*-N<8(!]?T444 >%_\$]_^2)ZM_P!CWK/_ *4FO=*\
M+_X)[_\ )$]6_P"Q[UG_ -*37NE !1110 4444 %%%% !1110 4444 %%%%
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MW2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BJVL3RVND75U
M^UX[9V1L9P0I(/->/_\ "VOB#_T,'_DI%_\ $5Y68YOALLE%54WS=K=/5H#V
MFBO%O^%M?$'_ *&#_P E(O\ XBC_ (6U\0?^A@_\E(O_ (BO-_ULR[^2?W+_
M .2 ]IHKQ;_A;7Q!_P"A@_\ )2+_ .(H_P"%M?$'_H8/_)2+_P"(H_ULR[^2
M?W+_ .2 ]IHKQ;_A;7Q!_P"A@_\ )2+_ .(H_P"%M?$'_H8/_)2+_P"(H_UL
MR[^2?W+_ .2 ]IHKQ;_A;7Q!_P"A@_\ )2+_ .(H_P"%M?$'_H8/_)2+_P"(
MH_ULR[^2?W+_ .2 ]IHKQ;_A;7Q!_P"A@_\ )2+_ .(H_P"%M?$'_H8/_)2+
M_P"(H_ULR[^2?W+_ .2 ]IHKQ;_A;7Q!_P"A@_\ )2+_ .(H_P"%M?$'_H8/
M_)2+_P"(H_ULR[^2?W+_ .2 ]IHKQNR^*WCZ6\BBDU[*M*H8?98N03_NU[)7
MJ9=FN'S-2=)-<MM[=?1L HHHKTP"BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH *\+\?_ /(Z:G_U^/\ SKW2O"_'_P#R.FI_]?C_ ,Z^3XM_W2G_
M (OT QZ***^# **** "BBB@ HHHH **** "BBB@ KV_X9_\ (BZ=_P!<3_Z$
M:\0KV_X9_P#(BZ=_UQ/_ *$:^IX3_P!^G_A_5 ;M%%%??@%%%% !1110 444
M4 ?*_P"UW_P6:_8&_8J^,2?L\?%CXD:SJ?CW[#'>7?A#P5X2OM:OK*WD ,<E
MPMI$ZP[@RL%=@Y5U;;M8$U/V9O\ @L[^R%^UA\;M$^ 'PN\+_%2WUW7_ +3]
MAF\2?"K5=-LE\BVEN7\RYN(5CC^2%PNXC<Q51RP%?)NG_P#!1G]E[_@EQ_P5
MJ_:C\(_&3P)X^U:'XE:SH.OCQEX:^'E[?_V?<1Z1!%)I4\B1YEC4%)H7A\Q%
M\^6-]C)EOJ;]ES_@M]^Q%^U_\=M"_9U^$-I\2%\1>(?M7]G-K_PSU+3[0>1:
MRW4GF7$\2QQ_NX7QN(W-M4<D4 ?7]%%% 'SU^P7K%_8?!S5H+;0+BY7_ (3C
M63YD1&,_:6XYKVW_ (275_\ H4+W_OI:\C_X)[_\D3U;_L>]9_\ 2DU[I0!C
M_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+6Q10!C_\)+J__0H7O_?2T?\
M"2ZO_P!"A>_]]+6Q10!C_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+6Q10
M!C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+6Q10!C_P#"2ZO_ -"A>_\ ?2T?
M\)+J_P#T*%[_ -]+6Q10!C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+6Q10!C
M_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+6Q10!C_\)+J__0H7O_?2T?\
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MHH Q_P#A)=7_ .A0O?\ OI:\>\:327'BO4)Y;=HF>Y8M&_5>>AKWFO"_'_\
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M/?\ Y(GJW_8]ZS_Z4FO=*\+_ .">_P#R1/5O^Q[UG_TI->Z4 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110!4\0?\@&^_P"O.7_T U\_5] ^(/\
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MLJ_%GX/6-W\/;$VOV'PMI=W<:9;VPMO]0L9LI(F1$[*&"^H->-:7_P $)/\
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M_P#_ &NC_A?_ /U*7_D__P#:Z/\ 6')_^?O_ )++_(#T:BO.?^%__P#4I?\
MD_\ _:Z/^%__ /4I?^3_ /\ :Z/]8<G_ .?O_DLO\@/1J*\Y_P"%_P#_ %*7
M_D__ /:Z/^%__P#4I?\ D_\ _:Z/]8<G_P"?O_DLO\@/1J*\Y_X7_P#]2E_Y
M/_\ VNC_ (7_ /\ 4I?^3_\ ]KH_UAR?_G[_ .2R_P @/1J*AT^Z^WV$%]Y>
MSSH5?;G.,@'&:FKV8M22: *\+\?_ /(Z:G_U^/\ SKW2O"_'_P#R.FI_]?C_
M ,Z^4XM_W2G_ (OT QZ***^# **** "BBB@ HHHH **** "BBB@ KV_X9_\
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M)!\SR-PH%54PE>E*,9)>]MJK;VWO9:]P/0Z*^'-3_P""HO[6O[.'CSP?;?\
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M/#__ " ;'_KSB_\ 0!5NOV.C_!CZ( KPOQ__ ,CIJ?\ U^/_ #KW2O"_'_\
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M**^/ **** "BBB@ HHHH **** "BBB@";3O^0A!_UV7^8KZ&KYYT[_D(0?\
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M )$74?\ KB/_ $(5R8__ '&K_AE^3 \0HHHK\B **** "BBB@ HHHH ****
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M ^(/^0#??]><O_H!KY^KX?B[^+2]'^@!1117QX!1110 4444 %%%% !1110
M4444 3:=_P A"#_KLO\ ,5]#5\\Z=_R$(/\ KLO\Q7T-7VW"/P5O6/Z@%%%%
M?9 ?/.H_\A"?_KLW\S4-3:C_ ,A"?_KLW\S4-?C,_C8!1114@%%%% !1110
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M*-\4_P#PMC_\:K2CPI[&M&I[:]FG\/;_ +> ^QJ*^.?^'(7[)O\ T4;XI_\
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MBN%_X<A?LF_]%&^*?_A;'_XU1_PY"_9-_P"BC?%/_P +8_\ QJC_ %0_Z?\
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MJH)(%?*O@'_@X/\ ^"4'Q!\7:1X4@_:.O=$B\170M_#GB#Q?X&UC1M(U20G
M$5]>VL< ![%W0'UH ^TJ*\^_:<_:G^ O[&_P9U']H/\ :1\?Q^&_"&E2V\5[
MJS6%Q=[9)Y5BA18K:.261GD=5 1"<FO"/V=_^"Y7_!-/]IKXR:9^S_X#^.=]
MI?B_7FV^'-&\9^#M4T-M8/9;9[ZWBCE<\!8PV]B0%4F@#W?XQ_!G4_B;X]\
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M);B>)%6(G#;0*^V_A_\  _XL_P#!)7_@G+\._P!GK]AG]FR7XVWO@40V>KZ
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M??VJ/V?[CX*^)/'^A7VF#P[?>)[+7FTJ='WV-ZUQ8L8I5$L<,QC4AL*5)!H
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M%MIC;],+"PLM*L8=,TVTC@MK:)8K>") J1HH 55 X    'M0!XK;?L:_9_\
M@I'>_P#!0C_A8^?M?P/MOAY_PB/]C_<\G6)]2^W?:O.YSY_E>3Y7&W=YASM#
M?VS?VF?V6_\ @G7^REK_ ,6?BYHVF6'AB!);:Q\)Z7IL7F>(=1N=Y33K:V5<
M3SW+E@5VD8+N^%5V'N-?C]?>!_\ @L7XX_X*-:K^VK^U?_P2$U7XJV7@?4Y[
M7]GWPG8?'3POI^B>%+7>1_:AMY[EWN=1F54;SY AC_A12L0B %\)?!?]HS_@
MFW_P:K?%'2OB!8R^%O&6J^$M=U8>&HI6#>%;;6KS8M@AZQR1P7!9AP4ED<=5
MS7T?\6_V3O@W%_P;E:Q^S9'X6T]?#^E_LNO=6<9@4(E_;Z-]NCOCQCS?MB"Y
M+]2^6ZFO7/$7P\^+O_!2C_@GY\0O@1^U]^S5>?!+6/'NAZGH#>'[KQ98>()+
M)'A M]0$]BQA8B4B01YR#%SUKXNU=O\ @M9XV_X)XK_P2%O_ /@G^=.\8W7@
MR/X>:M\?)/'FGOX5_L 0BREU945_M;S260*^0(Q()'+[1CRJ /MG_@D%\3?%
M7QC_ ."7'P"^(_CC49+S5]1^%6C?VC>S.6DN98[5(FF<GJ[E-['U8U]&UP_[
M,WP(\+_LN_LZ>!/V;O!5Q)-I/@/PCIV@6%Q,H$D\=I;I )7 XWOLW-[L:[B@
M HHHH **** "OQ]_;];]K;_@C=^U1K.D_P#!//1-*O/"O[:NNIHOA7P[J%^M
MO;>!OB5=2Q0'5H48%?L]Q#(\S1@%?.@&[:B(C_L%7Q1_P5O_ &1_VA/VG?C5
M^R/XM^!WP^_MS3_AC^TAH_BGQS<?VM:6W]FZ3 09;G;<2HTVW_GG$'D/930!
M[5_P3S_8>^'7_!/7]EC0/V</ -Y+J5S:[[_Q9XFO,FZ\1:U/A[S4;AF)9GED
MZ;BQ5%1,D(*^7?V&_P#E8:_;F_[$_P"&_P#Z9Z_0^OC3]E3]E'X^_#;_ (+)
M_M6?M6>-? 7V+P#\2O#?@FU\%:]_:EK)_:,UAIODW:^1'*TT/ER?+F5$#=5+
M#F@#RO\ X*M?\IM?^"</_8P?$;_TTZ=7M?\ P6T_9&^"?[5W_!-WXMV_Q3\(
M:=/JOA/X?ZOX@\(>(IK91=Z)J5C:274$\$^-\0WQ*KA2-\;.IX->5_\ !8+]
MG[]MGQ/^W1^R)^V%^R#^RA/\6[;X*:CXQNO%>A6WC;2M$<#4+/3[>V42ZA-&
M#N,<[917QY6&V[E)P/VH[3_@MK_P4Z^$VJ_L>2?L6>&OV8/!'C2V.F?$#Q]X
MI^*EAXFU.32)<+=6UA9Z6"@DEC+1DS2!61W7,9(>@#Z<_P""1?QP\=?M(_\
M!,GX'?&OXG:E+?>(M<^'6G/K6H3L3)>W,<?DO<.3U>0QF1CZN:W/C=^QK_PN
M3]MKX%_MC?\ "Q_[-_X4MI_BRU_X1S^Q_._MG^V[2TM]WVCSE^S^3]EW8\N3
MS-^,IMR?0/V?_@CX$_9I^!GA#]GKX864EOX>\$^&[+1-&CF<-)]GMH5B1G8
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MZ^!NK6>/$6JZ]+-<QR6J::5\Z[DNI)4VLBL!YH5F4HP7Z0_X-@OB7XP^)?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
=HH **** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>biib-20200930_g23.jpg
<TEXT>
begin 644 biib-20200930_g23.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?@3XCT'3M*UF*X=9+Z*_TXW4CW!D;8I5AM&W QUYKZ6M;JVO;:.\LKB.:&5
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MOAXOPXO_ !M\7V\!>.[+1M2NGMO$>DWMC/(5O(YI7$SQO#O61OFWD,2S(A4
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MER6*CW.:]:T[7]"U>XN+32=:M+J6TDV7<5O<J[0MS\KA22IX/!]*_$WXL?M
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MIBO8* /C3XL_\$(O^"6'Q?\ 'WC?X\_M.?!";QSK_BV_N]1UOQ#XT\8Z@_\
M9\+LTA@MMD\<=E;Q D)Y:J54#+'&:^?O^"+O[1OCKX'_ /!*3]H[XTCQ?K7C
M3X5?!_QSX[N?@%KOBFZ>:?5?"&DVQFM0)F^:6W#Q2HK]CO0!5157R3_@IK_P
M6"_99_:W_;/\3?\ !,;XO_M;+\%O@/X U%['XV^(1;7HUCQ[>Q2%)O#UB;:%
MVMK)71DN;AMK2@%$RAS)]W_"'XB?L%_\%)/^"=WQ&_9@_P""=OQ'T"_\#CP#
MJ7P_ACT/2KFTM-&^U:9)!'"$FBC;"QS*V0#GN2<T ?'/['W_  1@^ '[:O\
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M6UU"LD<JGJK*P(8>QJ>B@"MI&CZ1X?TR'1=!TNVL;.V39;VEI L442_W550
MH]@*LT44 %%%% &<OA#PFGB1O&2^%].&KO#Y3:J+*/[28_[AEQNV^V<5HT44
M %9WB7P?X2\:6::=XQ\+:=JUO'()(X-3L8YT5QT8*X(!]ZT:* &PPPVT*6]O
M$L<<:A41%P% X  '04ZBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BO$OV"-4U/5_@UJMSJVHSW4B^-]819+B9G8*+D@+EB> .@[5[;0 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQ<^+_P 0[&RTW7/&-[H%OI%I9Z9:9,%C8V%NSI;1!F+-EY&=@&)SN+>17O\
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M:L_X*8Z5\7/##:5-!'X5LO@78>''2Z9D,=S]K@O)G(15=?+VX;S,Y&T9^DJ
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MYO?_  +:@#8HK'_X0?2/^?F]_P# MJ/^$'TC_GYO?_ MJ -BBL?_ (0?2/\
MGYO?_ MJ/^$'TC_GYO?_  +:@#8HK'_X0?2/^?F]_P# MJ/^$'TC_GYO?_ M
MJ -BBL?_ (0?2/\ GYO?_ MJ/^$'TC_GYO?_  +:@#8HK'_X0?2/^?F]_P#
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MW\D_N7_R0'O=%>"?\)9XD_Z#$_\ WU1_PEGB3_H,3_\ ?5'^MF7?R3^Y?_)
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 ?/.H_\A"?_KLW\S4-3:C_ ,A"?_KLW\S4-?C,_C8!1114@%%%
M% !1110 4444 %%%% !1110!] ^'_P#D V/_ %YQ?^@"K=5/#_\ R ;'_KSB
M_P#0!5NOV.C_  8^B ****U **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** /"_^">__)$]6_['O6?_ $I->Z5X
M7_P3W_Y(GJW_ &/>L_\ I2:]TH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#YY
MU'_D(3_]=F_F:AJ;4?\ D(3_ /79OYFH:_&9_&P"BBBI **** "BBB@ HHHH
M **** "BBB@#Z!\/_P#(!L?^O.+_ - %6ZJ>'_\ D V/_7G%_P"@"K=?L='^
M#'T0!1116H!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110!X7_P3W_Y(GJW_8]ZS_Z4FO=*\+_X)[_\D3U;_L>]
M9_\ 2DU[I0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'SSJ/\ R$)_^NS?S-0U
M-J/_ "$)_P#KLW\S4-?C,_C8!1114@%%%% !1110 4444 %%%% !1110!] ^
M'_\ D V/_7G%_P"@"K=5/#__ " ;'_KSB_\ 0!5NOV.C_!CZ( HHHK4 HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\P_:W\8_M5
M^#OA2K_L9_!WP[XQ\<:CJD-C9Q>+_$)T[2M)B=7+ZA=LBM--%$54&&$>:YD
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M-6NKF:X5AXXUE<13E1C[2W85[;_P@^D?\_-[_P"!;4 ;%%8__"#Z1_S\WO\
MX%M1_P (/I'_ #\WO_@6U &Q16/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\ @6U
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M3_\ 79OYFH:FU'_D(3_]=F_F:AK\9G\; ****D HHHH **** "BBB@ HHHH
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M@SXC_$R/4-%U'SK66W'VBW%LAD\LRB5/F&V2*-N<8(!]?T444 >%_P#!/?\
MY(GJW_8]ZS_Z4FO=*\+_ .">_P#R1/5O^Q[UG_TI->Z4 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110!\\ZC_ ,A"?_KLW\S4-3:C_P A"?\ Z[-_
M,U#7XS/XV 4445(!1110 4444 %%%% !1110 4444 ?0/A__ ) -C_UYQ?\
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M^!;4 ;%%8_\ P@^D?\_-[_X%M1_P@^D?\_-[_P"!;4 ;%%8__"#Z1_S\WO\
MX%M1_P (/I'_ #\WO_@6U &Q16/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\ @6U
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MF_F:AJ;4?^0A/_UV;^9J&OQF?QL HHHJ0"BBB@ HHHH **** "BBB@ HHHH
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M]N7]G_PW\ OVOM8U?7=-TZ^LM1\30>&]6N-&@\0W4-M+#)'<"V<2"UD>9I3
MLB_,D?S$+@_CA^W)X\_X( _&W]K-OBC\(;NY\+>);OX,^);NR_X5-X>UG0/%
M">.S?Z7_ &8HLK:&*0WK(U]Q+'Y;9=Y#P''WAXZ_X*9_%3_@E-_P0]^&O[4'
M_!0;P]JNM_%VZ\-Z=HB:!>92ZU/Q#/;32V\-[* 1 X@MVDN)&Y#12@!I"JL
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MHO\ L9VWP?\ $OQ,TV\N_A?XAT#QW%K^CZ[-:()+G3WE6&%K:ZCC(< AE?<
M""R!_M6@ HHHH **** "BBB@#YYU'_D(3_\ 79OYFH:FU'_D(3_]=F_F:AK\
M9G\; ****D HHHH **** "BBB@ HHHH **** /H'P_\ \@&Q_P"O.+_T 5;J
MIX?_ .0#8_\ 7G%_Z *MU^QT?X,?1 %%%%:@%%%% !117BG[:W[?_P"R]^P7
MX+M/$/[0OQ4L]%U'75N(O".A)8W-]?ZU<Q1[C';VEG')/*JED#NJ;4WKN9<B
M@#VNBOE[_@FU_P %4_V<_P#@HCX T.S\%^*9+?XBQ^!-+U[QKX/N?#6IZ?\
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M/Q$TBS2YGT#5X"=LC0.56Y@=25DA9E#@*2?E% 'SC_P7:,Z_M%_L'/X>\O\
MMO\ X:]T$0XSYOV JWVW&.=OE[=W;[N:_1:OB;X&_P#!,K]ISQ9^U[X._;3_
M ."D7[7^D_%/7OA?IM[;?"_PKX3\$+HFCZ-<W<8BN=3E5II7N;IXP%&=JQ[0
MRY(7;]LT %%%% !1110 4444 ?/.H_\ (0G_ .NS?S-0U-J/_(0G_P"NS?S-
M0U^,S^-@%%%%2 4444 %%%% !1110 4444 %%%% 'T#X?_Y -C_UYQ?^@"K=
M5/#_ /R ;'_KSB_] %6Z_8Z/\&/H@"BBBM0"BBB@ KX,_P""HG[&_P"UU>?M
M/>$O^"D/[&4?@KQ+KW@?X9ZYX3\1?#_Q[>36D5YIEWF5KJPNHT<6]XIW*2ZA
M70!=W56^\Z^;/VY_V:?VO?BE<W/Q&_9:_;KU/X;?9_"-QI^K>#KWP#9^(M)U
M@#SI!*(97AF@N2)#'YD4PRJH"K;>0#YZ_P""+W_!2F;Q?X(^"_[ ?[1?[+?B
M3X6^.H_@%HNJ_#O4]1U&VU+2_&>A6]A:Q&[M;JWQY4K((YGM77=&.&8LN"O_
M  0",S_$?]N)_$6S^W_^&U/%PO\ .?,^S#R?LW7GR\>9L]LUK?\ !(__ ()H
M>.O 7A_X._MK?M:_'S7O&_CS0O@/H_AKP'X6OO"L.B67@+3)K&V>:R%LA:2>
M\&U89+F9@[;6!1>%3HOC)_P3$_:C\!_M;>./VP?^":W[8ND?"S4_BO;6B_$_
MPCXM\#+KFDZC?6T9BAU2W431-;7(C)#*-R2LQ9N>* .(_P""2OGK_P %=/\
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M& B3RHE:6-/,D$0S@G*_I)IVG6&CZ?!I.E645M:VL*PVUM!&$2*-0%5%4<
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M3?\ HHWQ3_\ "V/_ ,:H_P!4/^G_ /Y+_P#; =U17"_\.0OV3?\ HHWQ3_\
M"V/_ ,:H_P"'(7[)O_11OBG_ .%L?_C5'^J'_3__ ,E_^V [JBN%_P"'(7[)
MO_11OBG_ .%L?_C5'_#D+]DW_HHWQ3_\+8__ !JC_5#_ *?_ /DO_P!L!W5;
M'@#_ )'33/\ K\3^=>6_\.0OV3?^BC?%/_PMC_\ &J/^'(7[)O\ T4;XI_\
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M1/B@LU[IEO/*L7C0A0SQJQP/*X&31_JA_P!/_P#R7_[8#TVBN%_X<A?LF_\
M11OBG_X6Q_\ C5'_  Y"_9-_Z*-\4_\ PMC_ /&J/]4/^G__ )+_ /; =U17
M"_\ #D+]DW_HHWQ3_P#"V/\ \:H_X<A?LF_]%&^*?_A;'_XU1_JA_P!/_P#R
M7_[8#NJ*X7_AR%^R;_T4;XI_^%L?_C5'_#D+]DW_ **-\4__  MC_P#&J/\
M5#_I_P#^2_\ VP'UWX?_ .0#8_\ 7G%_Z *MU\<_\.0OV3?^BC?%/_PMC_\
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M1CX%?"RQ^!GP1\&_!+2]5FO[;P=X5T[0[>^N!B2XCM+:.W61ADX9A&">3R:
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MO[<T_P"&/[2&C^*?'-Q_:UI;?V;I,!!EN=MQ*C3;?^><0>0]E- 'M7_!//\
M8>^'7_!/7]EC0/V</ -Y+J5S:[[_ ,6>)KS)NO$6M3X>\U&X9B69Y9.FXL51
M43)""OEW]AO_ )6&OVYO^Q/^&_\ Z9Z_0^OC3]E3]E'X^_#;_@LG^U9^U9XU
M\!?8O /Q*\-^";7P5KW]J6LG]HS6&F^3=KY$<K30^7)\N940-U4L.: /*_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
8B@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>biib-20200930_g3.jpg
<TEXT>
begin 644 biib-20200930_g3.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MWAX%_8*OO!NJ3Z[X\\$ZIXEL=<BDC%I;063JCQ2 G>78L,8!'K78?LX_LQ_
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MR1;_ +#'@"/X>Z)\;=.\:^'?B7X9T:]G^P:Q!IVE1WME,\,CLHFCG8MO R0
M/7(!^H.KZUH^@63:GKNK6UE;(0&N+N=8T!)P 68@<FIXI8IXEFAD5T=0R.IR
M&!Z$'N*_$[7O&W@#]N#_ (*7?M'>)OVU_P#@GC\;_P!I+P_\*/'8\$?#/PEX
M'TZQO/#OA:"VAQ<W$MM<ZI:![VZD/F&1DDPF K  *GT]_P $2/!/QM^#'QQ^
M.'PDT7]EWXN?"[]GB>72=:^#?A;XMB#[3H%W+'(FJV%J8KRZQ:F58Y8X_-P@
M+<9=B0#ZM_;0^-?[8_P4\,:+JG['/[$$'QOU.^OY(M9TJ?XGV7A@:9 $RLPE
MNX9%GW-\NQ0".N:^+/ O_!;3_@J-\2?VFO'7['_@[_@AK9W7Q ^&^G:=?>,-
M%;]J#28ULH+Z)9K9A.^G"*7>C*<1NQ7.& -?IW7YP_L2?\K(7[;7_9/_  #_
M .FN"@#T]_\ @HU^U+X9_:B_9$_9L^.W[)VC_#O7/VA?^$^_X3;PW+XQ37)_
M#7]@V7VJS^SWMJL<%Q]H0QR/E/D$NS[RDG[&TS6M'UI)9-'U:VNU@F:*9K:=
M9!'(.J-M)PP[@\U^:/\ P6=^!6@?M+_\%<_V /@=XM\0ZSINCZ_)\4H]:DT'
M4Y;*YNK*/0K&:XL_.A99(X[B*-[:0HRMY4\@!!(-9VM?LC_ '_@F-_P7&_9,
M\,_L-^!$^'WA[X[^&?'VB_$GPOHU[/\ V=JD>CZ3%J%E.T,CLHF6:3_6#!VC
M'=L@'ZAW]_8Z79R:CJ=[#;6\*%IIYY B(H[ECP!]:CDUC2(=*_MV;5;9+'R1
M-]L:=1%Y9&0^_.-N.<YQ7Y+_  *_X)^_ +]NG_@N'^W0O[4VB7'BKP?X7U;P
M$]MX"N=2GBTN^U"?P_\ )>W4,3H+B2".)TB$A95^U2MMW;2.,_:H'PP^)?\
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M*-_L\? 6WN3\.?@3X?T+QW\,O!EW>S74.DW&H^&[[4;NTA\QBRPM<6B;8P<
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M&M:A^&MYJ$\MAITFJ6D\.HPVP9R\45P""ZAN-JA<!0* /M/_ ()^?MN>"_\
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MMW=D>[M_)E59@!(8[J8.S84  _8>]O;/3;22_P!1NXK>"%"\LTT@1$4=22>
M/<TFGZCI^K64>I:5?0W-O,NZ*>WE#HX]0PX(^E?D-_P43^)&G?M0?\%F=8_9
M5_:2_9+^+_QQ^$?PA^&&F:MI_P */A9%;2VM[KE_)O\ [5U6*>_LQ/'%%^YB
M3<ZJX)VC<P?L?^";7@+XA? '_@I/JL_[*7_!/SXW?!+]G3QA\-;J;QAX+^(E
MC:0Z99>*K:97M[[3HK?4+L0--;[H712BLP4E3M4J ?J+<:UHUIJ4&C7>K6L5
MY=*QMK62=5DE ZE5)RV.^.E?.O\ P2]_;<\:?MX?!GQI\3/'/@W2]$N?#'Q<
M\1>$;:VTF21DFM].N1%',WF$GS'!RP'&>@KXE_X)!_\ !.K]EO\ X*D?L3K_
M ,%)_P!N7PA-XZ^+GQL\0:UJDWC"77;J.\\*0VVJ75G9V>DRQ2*;%;9;8-&8
MP&5FP2555'J?_!L-HFL>&OV!_'/ASQ#XKEU[4-/_ &A/&%M?:Y,V7U&:.YB5
M[EB.ID8%S_O4 ?HU1110 4444 %%%% !1110 4444 %%%% 'SA^Q/_P3[_X8
M\_:"_:#^.W_"V_\ A(O^%[?$"+Q/_97]@_9/[#V1R)]G\WSY/M.=^=^V+I]W
MFNJ_;Z_8C^%O_!0O]E[7_P!F'XKZCJ&FVFJM!=:5KVCRA+W1M1MY%FM;V!CT
M>.10<<;E+*2 Q->RT4 ?GOXD_P""3/[=7[5[^#OA5_P4H_X*(Z/\1OA-X,UZ
MSU>[\)>%/ADFBW?C6XM&W6_]K7'VF4"(, SPPH%D)SE6577Z)\9_L,?\)=_P
M4H\%_P#!0S_A:/V?_A$/A?J/@_\ X1#^Q-_VO[7=+<?:OM?GCR]NW;Y?E-G.
M=XZ5[_10 5\K?MR?\$Z?B/\ M(?M#?#K]L#]FC]JV;X0_%#X=:3J>CVFMW'@
MJW\0V.H:9?!/-MY[.::'YE9-R2+(""S9#?+M^J:"0!DF@#Y9\0_\$\_B?\2_
MVFOV6OVK_C/^U!;:]XI_9ULO%L>MR6?@1+&+QA/KFFQV)E5$NV73A"(P^P"?
MS.F4^]73_M+?L,?\-$?MG?L\_M=_\+1_L?\ X4+J'B2Z_P"$>_L3[1_;O]K:
M<EEM\_ST^R^5LWY\N7?G;A/O5[EHWB;PYXB\W_A'_$%C?>0^V?['=I+Y;>C;
M2<'ZU=H ^+?C1_P3,_:'\&?M9>+/VU/^";_[6]A\+O$GQ'M[1/B=X-\6^#AK
M?A[Q%<6T?EP7PC6:&6TN53*L\;$29)(!+%O9_P!COX._MG_#-/$6N_MF_M>Z
M9\3]3UMK3^R=-\/> (=!TWP_'$)O,2$+-++<-*9$+22OD>4H4 9S[710 5\X
M?!'_ ()]_P#"G/\ @I#\;?\ @H-_PMO^T?\ A<?A_0-,_P"$1_L'R?[(_LRU
M2W\S[5Y[?:/,V;MOE1[,XRW6OH^B@#P#]H?]AC_A??[=G[.G[:W_  M'^R?^
M% _\)=_Q3/\ 8GG_ -N_VYI<=A_Q\>>GV7R/+\S_ %<OF9V_)C=1^T/^PQ_P
MOO\ ;L_9T_;6_P"%H_V3_P *!_X2[_BF?[$\_P#MW^W-+CL/^/CST^R^1Y?F
M?ZN7S,[?DQNKW^B@#P#]FG]AC_AG?]L[]H;]KO\ X6C_ &Q_POK4/#=U_P (
M]_8GV?\ L+^R=.>RV^?Y[_:O-W[\^7%LQMP_WJX;]K__ ()L_$OXB_M0:9^W
MG^Q)^TV?A#\8;3PU_P (YK]W?>&H]8T7Q7I D\V.UO[-I(SOC?E+B-PZ@!<$
M!=OUQ10!\\?LE? __@H;X-^(VH?$/]M/]MSPWXZT^XT5[+3/ G@OX9QZ+IUC
M.TT3_;6N)+B>YGDV1M&$8JBB1C@G!'AG@C_@EM^W+^Q9J^O^#_\ @F1^W;X:
M\(?"K7]>NM7L?AE\2?AO_;4/A:XN9#+<+IMS#=02"W9V++;R JAR=S,S,?N;
M2/&_@OQ!X@U7PEH'B_2[[5=">%=;TRSU".6XT]I4WQ">-6+1%U!9=X&X#(R*
MU* ///V7_AM\=/A5\);;PK^T?^T2WQ2\7&\GN-1\6CPO;Z-'()'+)#%9V[,D
M4<:X1<LS$#+,22:\D_X+!_L?>,/VUOV#_%/PV^$\RP_$#P_=6?BSX:W)(!37
MM,F6ZM4!;A?-V/;[CPHG)[5]/44 ?/\ XL^$OPK_ ."K/_!/>V^'W[4OP6\0
M:#I'Q-\(VLWB'PCX@TR;3=6\/WQ"2%=EP@>"XMKA<H[*03&K8=&^;XO_ &J?
MV1/^#@7]EO\ 8ZU[P5^R3_P40M/BII/AS35ATFPNOAY!;>.9])7"/;VU^9)8
MKB\C@SLE:,32,N5(D*J?U0I&944N[  #))/ % 'R;^Q#^Q[X(^$W_!+W2O@+
M^Q!J7CCX-WVO:!+?6OB7QYX5#^)M.URXPT]]J=G=JBW%T)5PZ,!$RHJQDQ;#
M7D/Q:_X)B?\ !6O]K?P+?_LY?M<_\%:M"D^%^MQ"T\6V_P ._@W;:5K/B"P)
M'F6K7+W$B6@D PQC5P02I5D8J?T$T;Q'X>\1I++X>UZROUA?9,UE=)*(V_NM
MM)P?8U:NKJVLK:2\O;B.&&)"\LLKA510,DDG@ #O0!\@?\%-/AM\0/AS_P $
MR#^PO^P]\)]7NM2\;:1IOPI\'PZ3IEQ<VOAK2KJ);&>_O9D5OLUK;6"S$SR$
M#S!&N=SBOI']GKX)^$/V:_@-X+_9Z\ 1LNB>!_"UAH6E&0#>T%K;I CMCJS!
M S'N23WKJ].U+3M8LH]2TF_@NK:9<Q7%M*'1QTR&4D&IJ /EC_@H9_P3\^)W
M[47Q/^%/[4G[,G[0\7PS^+GP:O=3;PMK.I^'5U;3-0LM1@2"]L;RV,D99'2-
M-LBMN3YL#<59/-O O_!)+]I/Q/\ \%!/@]_P4I_:U_;PA\8^-/A?!KUHWA/0
MOA\NG:&UE?Z9+9PV]DOVMY+9XI+B>>6>7SWN-T<>(EB4G[PJG'XAT";6'\/1
M:Y9M?Q)ODL5N4,R+_>*9W <CG'>@#PS]GC]AC_A0G[=G[1?[:W_"T?[6_P"%
M_?\ "(_\4S_8GD?V%_8>ER6'_'QY[_:O/\SS/]7%Y>-OSYW5'\)?V!]%^'?[
M8G[1O[4OB3QS#XAT[]H;2_"UA?\ @^XT/RH]+@TC3;FQ=&G\YOM2W"W!8CRX
MM@7;\^<CZ#JKIVN:)J\UQ;Z3K%K=26DGEW4=O<*[0O\ W7"D[3P>#0!^?'PU
M_P""/_[</P2^%6I?L.?!_P#X*8?V7^SG>-=VVFZ1<_#Z.X\6Z+H]R[M-I%KJ
MK7 0(1)(JW+0M+&K_(%VJ1]-?\$R_P!B;_AW1^PYX#_8Q_X69_PF/_"$V]]%
M_P ))_8W]G_;?M%_<WF?L_G3>7M^T;/]8V=F>,X'N&IZIIFBV4FIZQJ,%I;1
M#,MQ<S+&B#..68@#FGV=Y::A:QWUA=1SP2H'BFA<,CJ>A!'!'O0!\^?\%$/V
M"?\ AO?2O@]IG_"UO^$4_P"%3_'CP_\ $C?_ &%]N_M3^RUN1]@QY\7D>;]H
M_P!=\^S9_JVSQS?_  5U_P""6?@[_@JS^SE9_!Z^^)UQX#\4:#K*ZCX3\=V6
ME?;9M,+HT%W"T(F@,T-Q;221/'YJ@GRV.[9M/U#JVN:)H,*7&N:Q:V4<D@CC
MDN[A8U9ST4%B,D^E6J /CCXI_P#!);_A9?\ P3X^!/["'_"__L7_  I36/!U
M_P#\)5_PBOF?VS_8*HNS[-]J7[/Y^WKYLGEYZ25Z1XS_ &&/^$N_X*4>"_\
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MEXR@NKGPAXHT[58[&_FL;V33;V.=;>ZB;;+ Y0G9(C<,APRG@@5HT <_\6/
MO_"T/A9XE^&G]J?8?^$B\/WFF?;?(\W[/]H@>+S-FY=^W?G;N&<8R.M>8?\
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MX)!?O<R7$]S-(J1/$L9*H!,Y(8X(^BJ* /@'P%_P2@_;8_97UGQ=\)_V"?\
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M$NHRPV?B#Q)?7B16[WJ1.IFBAMW5T1CA74]5E8&7]DGX?>'?^"9?_!<'5?\
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M6'B+X))\2O$^EZK!JZWTZ66BZ1I&EW,"K$\8MPI4-&K2,6= "%Q?^=%'_/\
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M"VM?\%(_%%E8_#CQ+XET]O!7BU_MUO+I^K26L]U:75O=6J>;9.889B)6*)_
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BO$OV"
M-4U/5_@UJMSJVHSW4B^-]819+B9G8*+D@+EB> .@[5[;0 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M3_U'XQZKK=C/=:AK=[XUM?#^BZ&B.J*)[F=',LK%B1#&I8JI/ KT3]D'Q_\
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MIL]Q%D>8L<DDDFT\$(P/!((!]"_L]?MD?\%9_B-\3?#1^-O_  20L/!'P_\
M$EXB7>L+\;+"]U;P[;.I*7%W8BW7S#]T/%&^^,OSG8U?9%?EU^U?=_M\?\$>
M?%/PC_:;UK_@H=XQ^-_@;Q9\4=)\'?%;P7\0]#TV)=FI,ZC4=,:TAC:T:)E)
M%N"RG<H+%5(K]1: "BBB@ HHHH ^(/\ @IU_P4O^)7P4\6^)?V,/V1?@+J'C
MGXHI\&-5\;Z_JX\40Z-8>#=$19K=-1DN'CE::X$RDQVT:;FVJ2R@[AZK_P $
M]?CQ^V9\8_ @L_VNOV28/A_)8^'=*N-#\4:=\1;;7[;Q0LT3^9( D,,UK*FR
M-G25,'SQM9MK8\9_X*W_ /!//X8?M":=XX_:Z^%O[1?BKX:_&#P1\&-6TG5]
M0\%:I;L-:\/M!<7*Z;JEG*KB6W=UE*-\C DD%O+39RO_  2Y_:F_;4^'W[9T
M7_!,3]K7XK>%OBI:)^SYIGQ%\(_$#P_X<32;[3K1[F&R&EZE:PNT(DPX>-UP
M650QW>9B, ])^,W["'_!5#XE_$3Q/X\\%?\ !:C6O ]A=:O=W'@KPGHGP5T.
M>RT6T:1C;6]Q)/NEOBB; [N5W'. *UO^")O[:_QK_;K_ &*F^)/[0]OHTWB[
MPQXXUCPEJOB#PW"8].\0MI\PC&I6R] D@8 [?E+HY4*"$7H?V[_^"7G[-'_!
M2"TAU+XS?$/XB:=%%H,NF0R>!?B%=:;:O [LY>2"-C;W# D\RHXP,$$#%>+_
M /!N_P#''7/%7[%?CWX3>)=>\/:EX8^!/QC\1> ?!OCC0]'M=,L=?T+3S%)!
MJ'EVRI;@LLS%I$ #@!F+.7<@'UI^UUX._:G\??!>Z\)?L=?&/0/ 'C2]O[9(
M_%WB'P^-5BTVT\P?:)([5B$FFV9"*Y"9/)KX _:R\8?\%1_^"/5S\-_VF/B'
M_P %&9/V@? ?B+XEZ3X5\?> _%OPYTO2+DI?NR"[TR:Q =94*L1 24Z$[@IQ
M^BGCW]IG]G_X9_ ;5?VH/&7Q?T"W^'VBZ7+J-_XMAU))[(6\9*LR21%A*2XV
M*B;F9R$4%B!7PW^S3\*?C!_P6._:(\(?\%'?VK_!M]X3^!7@'4QJW[-WPAU1
M-MWK-V/]3XKU= 2%?'S6L'.Q2&SM)>X /I[]M7]G3]N3XZ:IX?N_V0/^"C-S
M\";;3;>X37;2#X3Z1XE_MAW:,Q.6U Y@\L*XPG#>9D_=%?''[('C_P#X*DZ1
M_P %MKG]B3XD_P#!36Z^-'P]^&WPT'B3XKB;X.Z!H,<5_?))%IVE^99Q-,),
M2P7NY9$W+$4((W _I-\5_B=X-^"GPN\1_&/XBZJMCX?\*:%=ZQK=ZW2"TMH6
MFE?GKA$8XKX?_P"#>CX8^,O$/[-7C7_@HM\9=*:V\=_M2^/KSQO?12\O9:*)
M'ATFR!QS%'!ODC_V+E?2@#GO^"Z_C_\ X*V_LQ_ KXE?ME?LO?MK>#_ 'P^\
M":'I]SIGABV^&UKJNL:C/)<06\PFN;X/#"F^8LNR-CM7!P3D??OP<U[5O%7P
MB\*^*->N_/OM2\-V-U>S^6J^9-);H[MM4 #+$G   SP*^1/^#D+_ )0E?'S_
M +%_3_\ T[65?6'[/?\ R0/P/_V)^F?^DL= '7U^3'_!5/\ X*P?MEZ%^T?X
M>TC]@_X@VGA[X6_#WXW^&_AY\5?%+:'97Y\3>(-3G#7&CVK7,,JQI96T9$\L
M>V0372Q@C837V_\ MZ?&?X^:O^P%\1?'?_!,^VTOXA_$EM.&F^#8]!UBTF2.
M\ENHK:>=)&D$)EM8I9;@([ %H I!S@_D-^W]XV^/O[/O_!/'X ?LI0?\$I/B
M=X"T3P9\?/"FH1>)_%/C+1;R?Q1K*SW$THE-O<.QO+V>260R/\BL2"0H44 ?
MT T5R7P)\?\ C?XI?"/0_B!\1_@_JG@'7-4M#+J/@_6KV"YNM+<.R^7));LT
M3D@!LHQ&&'>NMH **** "BBB@ HHHH **** "BBB@ HHHH \+_X)[_\ )$]6
M_P"Q[UG_ -*37NE>%_\ !/?_ )(GJW_8]ZS_ .E)KW2@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "OSC_ &V?V+O^"F%A\1/AQ%\)?^"E6KZGX<U3X[17>C6?
MB+X+V.L7G@L2VFI2K<&\BFA^T6L&3"J7,9QYL69/E"M^CE% 'S%^SI_P3AOO
MV3OV0O''P(^!G[2WB*S^(OQ!UW4_$_B3XT:OI-K>ZA<^)[XHTVJ-9D+;E08X
MU%OPFQ-I))9CX9\6O^"8_P#P5N_:T\":A^SE^UK_ ,%;-"?X8:Y#]C\6P?#O
MX-6^E:SX@L#Q+:M<O<2):+(.',:N""4*LC,I_1"B@#XY_P""@?P,_:0\(_LM
M?!7]CO\ X)MW/B'P8L?Q!\->'+CQ%X<F91X6\)64$AN9YI#]Y!#;QPA2=TCR
MH,\DUE_\%:O^"4'QJ_X*:^+?AO?>%?VVH?A]X9^'NI_VNW@C5?AG%XBTS6=6
M1P8+NZBDO;=)A$N56&59$^=^/G8'[:HH ^7OV8_V7O\ @IQ\,/B]I_BW]I3_
M (*FZ/\ $_P?;6\Z7W@RS^ &GZ ]T[1,L3B\@O97C$;E7VA#NV[3@'-<[\>_
MV7O^"PFI_%_Q'XF_9A_X*=^#]"\&Z]?>=I7A;Q?\&+?4)_#:&-5:.WNTN%:Y
M&\-(/.7@MM^Z!7V'10!\O?\ !/K_ ()A>"_V*?AQ\0-/^(GQ3U;XK^//C#J\
MNJ?%WQ_XDM$MI/$,[QO$(EMXF*VULB22!(0S;?-<!L;57P/X5_\ !)7_ (*:
M_LB_"V[_ &2_V(?^"J6D^'/A!Y]V/"T/B[X41ZIX@\)6MQ*\CV]K=K=1I<;6
MD=E>5%*EN N!7Z.T4 ?*'P]_X)@2_LX?\$P!_P $Z_V-_P!I7Q!\.]7M]/*V
M/Q8%B+S4XK^6]%W=7S1++"&:5C*FT2*$20#)"\]5^V?_ ,$^?#'[<7['VF_L
MS?%7XG:O:^(- FTO5?#7Q)TN()J&E>(=/ ,&KQ(S$;R_F;D+<I-(H<$AQ]"T
M4 ? T'_!*O\ ;4_:4^+7PZ\2_P#!3?\ ;VT;XE^"_A1XGMO$GAWP-X,^&T>A
M0ZYK5L"+6_U.3SY=_EEF;[/&JQDN1P"0WWS110 4444 %%%% 'RO_P %%_\
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MG[0W@+_A(=-\-^++'Q-HMM_:EU:?9]4LV9K:XW6TL;/L+M\C$HV?F4UZ)10
M4444 %%%% !1110 4444 %%%% !1110 4444 >%_\$]_^2)ZM_V/>L_^E)KW
M2O"_^">__)$]6_['O6?_ $I->Z4 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!^
M?.O_ +<'[4-EKU[96OQ/VQ0W<B1K_8MD<*&( R8?2JG_  W3^U1_T5+_ ,HE
MC_\ &*\S\5?\C/J7_7_-_P"AFJ%?O=/)\H<%_L]/;^2/^1^(SS;-5-_OY_\
M@4O\SUO_ (;I_:H_Z*E_Y1+'_P",4?\ #=/[5'_14O\ RB6/_P 8KR2BK_L;
M)_\ H'I_^ 1_R)_M;-?^@B?_ ('+_,];_P"&Z?VJ/^BI?^42Q_\ C%'_  W3
M^U1_T5+_ ,HEC_\ &*\DHH_L;)_^@>G_ . 1_P @_M;-?^@B?_@<O\SUO_AN
MG]JC_HJ7_E$L?_C%'_#=/[5'_14O_*)8_P#QBO)**/[&R?\ Z!Z?_@$?\@_M
M;-?^@B?_ ('+_,];_P"&Z?VJ/^BI?^42Q_\ C%'_  W3^U1_T5+_ ,HEC_\
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M^ Q_QH^Q>-_^@W9?^ Q_QH V**Q_L7C?_H-V7_@,?\:/L7C?_H-V7_@,?\:
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M<[C9W:>MU>+:=GI=::.R-<9AEA:W(G=63VL[-)ZK6SUUU9^IWPJ_Y)?X;_[
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M/S?9\X[=-M]T]#YXK](/V.?^39_"7_7@_P#Z.DK\WZ_2#]CG_DV?PE_UX/\
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MX(5AUXKV#X_>/O G@70O'_PUT?QC=:]J?BO6+62:T^PO%:Z0('$A(,GWY7P
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M110 4444 %%%% !1110 4444 %%%% !1110 4444 ?E%XJ_Y&?4O^O\ F_\
M0S5"K_BK_D9]2_Z_YO\ T,U0K^C:?\->A^ U/C?J%%%%62%%%% !1110 444
M4 %%%% !1110!^IWPJ_Y)?X;_P"P!9_^B$K>K!^%7_)+_#?_ & +/_T0E;U?
MSKB/]XGZO\S]ZP_\"'HOR"OS0_:B_P"3A_&/_8?N/_0J_2^OS0_:B_Y.'\8_
M]A^X_P#0J^VX!_Y&%7_#^J/C^-_]QI?XOT9P5%%%?JA^:A1110 4444 %%%%
M !1110 4444 %?I!^QS_ ,FS^$O^O!__ $=)7YOU^D'['/\ R;/X2_Z\'_\
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MH_L[3_\ GQA_[]"@"G_PF/AC_H-0?]]4?\)CX8_Z#4'_ 'U5S^SM/_Y\8?\
MOT*/[.T__GQA_P"_0H I_P#"8^&/^@U!_P!]4?\ "8^&/^@U!_WU5S^SM/\
M^?&'_OT*/[.T_P#Y\8?^_0H I_\ "8^&/^@U!_WU1_PF/AC_ *#4'_?57/[.
MT_\ Y\8?^_0H_L[3_P#GQA_[]"@"G_PF/AC_ *#4'_?5'_"8^&/^@U!_WU5S
M^SM/_P"?&'_OT*/[.T__ )\8?^_0H I_\)CX8_Z#4'_?5'_"8^&/^@U!_P!]
M5<_L[3_^?&'_ +]"C^SM/_Y\8?\ OT* *?\ PF/AC_H-0?\ ?5'_  F/AC_H
M-0?]]5<_L[3_ /GQA_[]"C^SM/\ ^?&'_OT* *?_  F/AC_H-0?]]4?\)CX8
M_P"@U!_WU5S^SM/_ .?&'_OT*/[.T_\ Y\8?^_0H I_\)CX8_P"@U!_WU1_P
MF/AC_H-0?]]5<_L[3_\ GQA_[]"C^SM/_P"?&'_OT* /RG\4,K^)=1=3D&^F
M(/\ P,U1KY6\?_M._'&U\=ZW:V_C?;''J]RJ+_9EMP!*P _U=9'_  U)\=O^
MAZ_\IEK_ /&J_J"EE6(=..JV7?\ R/YNJ9KAU4>CW\O\S[ HKX__ .&I/CM_
MT/7_ )3+7_XU1_PU)\=O^AZ_\IEK_P#&JT_LG$]U^/\ D1_:V&[/\/\ ,^P*
M*^/_ /AJ3X[?]#U_Y3+7_P"-4?\ #4GQV_Z'K_RF6O\ \:H_LG$]U^/^0?VM
MANS_  _S/L"BOC__ (:D^.W_ $/7_E,M?_C5'_#4GQV_Z'K_ ,IEK_\ &J/[
M)Q/=?C_D']K8;L_P_P S[ HKX_\ ^&I/CM_T/7_E,M?_ (U1_P -2?';_H>O
M_*9:_P#QJC^R<3W7X_Y!_:V&[/\ #_,^P**^/_\ AJ3X[?\ 0]?^4RU_^-4?
M\-2?';_H>O\ RF6O_P :H_LG$]U^/^0?VMANS_#_ #/L"BOC_P#X:D^.W_0]
M?^4RU_\ C5'_  U)\=O^AZ_\IEK_ /&J/[)Q/=?C_D']K8;L_P /\S]_?A?X
MM\-P_#/P[%+K$*LNA6@8$]"(4K=_X3'PQ_T&H/\ OJN=_9_6+5?@-X)U34+>
M&2>Y\(Z;+/(85&YVM8R3@#'))KKO[.T__GQA_P"_0K^8L2K8F:\W^9_1V&=\
M/!^2_(I_\)CX8_Z#4'_?5?E3^UM^TC\%M%_:8\<:5J7C01SV_B*X25!I]PP#
M!N1E8R#^!K]8O[.T_P#Y\8?^_0K^?_\ X*((D?[<GQ32-0H'C2]P , ?/7Z%
MX9X:GB<SKQDWI#I_B1\%XBXFIALNHRBEK/KZ,]:_X:D^!/\ T/7_ )3+K_XU
M1_PU)\"?^AZ_\IEU_P#&J^/Z*_:/[)PW=_A_D?D/]K8GLOQ_S/L#_AJ3X$_]
M#U_Y3+K_ .-4?\-2? G_ *'K_P IEU_\:KX_HH_LG#=W^'^0?VMB>R_'_,^P
M/^&I/@3_ -#U_P"4RZ_^-4?\-2? G_H>O_*9=?\ QJOC^BC^R<-W?X?Y!_:V
M)[+\?\S[ _X:D^!/_0]?^4RZ_P#C5'_#4GP)_P"AZ_\ *9=?_&J^/Z*/[)PW
M=_A_D']K8GLOQ_S/L#_AJ3X$_P#0]?\ E,NO_C5'_#4GP)_Z'K_RF77_ ,:K
MX_HH_LG#=W^'^0?VMB>R_'_,^P/^&I/@3_T/7_E,NO\ XU1_PU)\"?\ H>O_
M "F77_QJOC^BC^R<-W?X?Y!_:V)[+\?\S[ _X:D^!/\ T/7_ )3+K_XU7ZB?
ML0?$GP/K_P"RIX,UC2?$,4EO/ITC1.R,A(\^0=& (Z=Q7\_=?O-_P2QLK.7_
M ()__#.22TB9CHTV6:,$G_2IJ_.?$O!4L-D]*46_XBW_ ,,O(_0/#O&U<3FU
M6,DO@>W^*/F>[VWBCP_>3K:VNJQ/(YPB*>2:OU$EC91L'CLXE8="L8!%2U^*
M'["%%%% !1110 4444 ?GS+_ ,%%OB%\&)O^"@WQN^*?Q'2YL_@-J-I!X#\$
MWZ11PZ=&OARWN+4C:JR/]OOIR,NS9( 3 &*\F_9"TC]N[]B_]H3]DOQU\??V
MZ_B+\4;C]J:SU&W^*G@#QO>I/8:#J3:(^KP2Z1"%'V%+=XS!(B_(RL2%3Y57
M2_X*G:[_ ,$&IOVZH#^TW^R=XN^,?QUT+3;"\U_P[\*O#.K:K/';1A9+(ZM;
MV<T5K<87842XWMY?EAE\MD!]+^"_[>/[(?[>_P"WO\)->O/V(/VF= \=>#[7
M7H? ?B;Q[\,KW2-!T7[5ITAO9)W,QB$DL%OY".ZL=SJBXWDT ?H%1110!X7_
M ,$]_P#DB>K?]CWK/_I2:]TKPO\ X)[_ /)$]6_['O6?_2DU[I0 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% '\UGQ'_P"2AZ]_V&KK_P!'-6-6S\1_^2AZ]_V&
MKK_T<U8U?V!1_A1]$?R=5_BR]6%%%%:$!1110 4444 %%%% !1110 4444 ?
MT<?LW_\ )N_@+_L2]+_])(J[2N+_ &;_ /DW?P%_V)>E_P#I)%7:5_(>+_WN
MI_B?YG]687_=:?\ A7Y!7\_7_!1/_D^;XJ?]CI>_^AU_0+7\_7_!1/\ Y/F^
M*G_8Z7O_ *'7Z5X5_P#(VK_X/_;D?GGB;_R*Z'^/_P!M9XQ1117[D?BP4444
M %%%% !1110 4444 %%%% !7[U_\$KO^4?GPR_[ LW_I5/7X*5^]?_!*[_E'
MY\,O^P+-_P"E4]?F7BG_ ,B2C_U\7_I,C]'\,_\ D<UO^O;_ /2HGT#1117X
M0?MH4444 %%%% !1110!^4D?[??P[_X)@?\ !5G]IGPQXN_9<^-/C#0/B=K&
MA^('\8^"?AE=:@+'48M)@AEL&D&%N;;;LDBEC8F.26:)D&WS&^G/V7/^"T/[
M/?[67QVT+]G[P/\ L\_'C0M4U_[5]EU7QG\)[O3--@\BUEN6\ZYD.V/<L+*N
M?O.R+U:N'^/G[8O_  4U_:8_:\\>?LC?\$LO!WPPT+1_A')8V?Q(^*_Q:-Y/
M ^JW5LETNFZ=:VGS.\<,D9DDD!7+%?DPADD_9U_;)_X*5?L[_MB^"/V+O^"I
MO@KX9:Q:?%B#44^&'Q6^$KW<-K+J-E;-=3:;J%K=_-%*T"NT<B;4)0*!(68Q
M@'WG1110!X7_ ,$]_P#DB>K?]CWK/_I2:]TKPO\ X)[_ /)$]6_['O6?_2DU
M[I0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% '\UGQ'_P"2AZ]_V&KK_P!'-6-6
MS\1_^2AZ]_V&KK_T<U8U?V!1_A1]$?R=5_BR]6%%%%:$!1110 4444 %%%%
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M)KW2O"_^">__ "1/5O\ L>]9_P#2DU[I0 4444 %%%% !1110 4444 %%%%
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M?^OB_P#29'Z/X9_\CFM_U[?_ *5$^@:***_"#]M"BBB@ HHHH **** /B/\
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ME9_"KP)?_:O[=\>Q?'W1-;;2]EK-)#BRM1YLWF3I%#\OW/.WGA30!]ET444
M>%_\$]_^2)ZM_P!CWK/_ *4FO=*\+_X)[_\ )$]6_P"Q[UG_ -*37NE !111
M0 45^:7[='_!5_\ :8\6?%35_@A_P3^_9MNM=LOAA\=O!OA3QO\ $35_'D.B
M6-YK5SJMEO\ #\$0@FFFCE$JVUQ.0JQ+(YVR#;O^J9?VQOC-\,?V%_B)^UQ^
MUG^RG/\ #G7?ASX=UK5]0\#V_C&VUI;V"PM&N4>"]MT5628+M7<B,ASN48H
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M]E/X>WUQ=Z3X%\-V^EV]]=@"6\=%S+<.!PK22%Y"HX!? X KX0_92_X(?_\
M!27]B^'Q7-\"O^"S^CVVJ>.O$,NN>,_$6L_LR6&HZGK5\^<R7%W<ZJ\KA<MM
M3=L3>Y5078G[!\?_ +-?[6GQ#_80OOV;K_\ ;HNM,^+%]IJP/\<O#_@B.QEB
MF%X)O/BTV&Z5(_W*^056<9!+YYVT >!_\%Y?V^='_9=^%G@3]E:#XUV?PRUG
M]H#6+S1)_B9J<C1P>$_#]LD+:OJ".H)-V(;B*&W08)EN0P9?+KXV^''[=/\
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MX5?XN^&.FVVJ;]+\07-[IVK6DDA1H9%N"3%* IVE3ECCJ 16)\(_AG^S_P#
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M8_\ QBC_ (;I_:H_Z*E_Y1+'_P",5[/^H><?\_*?WR_^1/)_UVRK^2?W1_\
MDC[Y_P"$'TC_ )^;W_P+:E7P7I:@JMY? 'J!>-S7P+_PW3^U1_T5+_RB6/\
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M!](_Y^;W_P "VKX&_P"&Z?VJ/^BI?^42Q_\ C%'_  W3^U1_T5+_ ,HEC_\
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MYF^9WT?*FNK2T?G86MAL-E=6$ZD'SQT2C+GYKIV<N5+E5M5S-/HF]5Y/\.?
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M %X)_P"CHZZ,+0^LXJG1O;FDE?M=V,,36^KX:=6U^5-V]%<],HK\DZ*_0/\
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MXD\66'@1?V:I8=-U"\CM!J?_  DEQ)?H78()<#Y"02#L'';FJWA/]G7P_?\
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M2DD[+1727Y]3TK]F[X5>$_%&I#QO\5+623PU!J4&FPVB2M&VI7\[!8X%92"
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M+?[3?PR\,_"KXG'0_!\ER-/O=,M[^WM+QLS68F7=Y+GU7'?G!&<GDQ?LN_\
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MXGP+IUE(9+73-/\ #\MM;QN>K[(X0"W)Y.2,G&,FLK4?VYOAQJO@G3_AU?\
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MU=?^CFK&K8^(C%OB!KK%2"=9NB0>W[UJQZ_L"C_"CZ(_DZK_ !9>K"BBBM"
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M_L"S?^E4]?@I7[K_ /!+O7=2M?V!OAK;P^&;J=5T:4"5&7#?Z5-TK\R\4_\
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MX- B\4ZEX?\ #-\UG,=62P6Y:UAEB(>%GDVRL4(;#/M*D@C,_93_ &R/B/\
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M;3NW*[A&\W+=-)6Z[(\_'XC#8O$RJ<\G[JY?<44FK)1LIRM%1V:;=^F[/?\
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M+/\ U!_^5/\ [F'_ !"W_J+_ /*?_P!N?BS17[3?\.0OV3?^BC?%/_PMC_\
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M?B)\4%FO=,MYY5B\:$*&>-6.!Y7 R:/^(L_]0?\ Y4_^YA_Q"W_J+_\ *?\
M]N?C917[3?\ #D+]DW_HHWQ3_P#"V/\ \:H_X<A?LF_]%&^*?_A;'_XU1_Q%
MG_J#_P#*G_W,/^(6_P#47_Y3_P#MS\6:*_:;_AR%^R;_ -%&^*?_ (6Q_P#C
M5'_#D+]DW_HHWQ3_ /"V/_QJC_B+/_4'_P"5/_N8?\0M_P"HO_RG_P#;GXLT
M5^TW_#D+]DW_ **-\4__  MC_P#&J/\ AR%^R;_T4;XI_P#A;'_XU1_Q%G_J
M#_\ *G_W,/\ B%O_ %%_^4__ +<^DOV;_P#DW?P%_P!B7I?_ *215VE?'/\
MPY"_9-_Z*-\4_P#PMC_\:H_X<A?LF_\ 11OBG_X6Q_\ C5?D-:I[6K*=K7;?
MWGZM2A[*E&'9)?<?8U?S]?\ !1/_ )/F^*G_ &.E[_Z'7Z?_ /#D+]DW_HHW
MQ3_\+8__ !JC_AR%^R;_ -%&^*?_ (6Q_P#C5?2\*\2_ZLXNI7]E[3FCRVYN
M6VJ=]I'SO$_#O^L>%A1]K[/EE>_+S7TMW1^+-%?M-_PY"_9-_P"BC?%/_P +
M8_\ QJC_ (<A?LF_]%&^*?\ X6Q_^-5]S_Q%G_J#_P#*G_W,^+_XA;_U%_\
ME/\ ^W/Q9HK]IO\ AR%^R;_T4;XI_P#A;'_XU1_PY"_9-_Z*-\4__"V/_P :
MH_XBS_U!_P#E3_[F'_$+?^HO_P I_P#VY^+-%?M-_P .0OV3?^BC?%/_ ,+8
M_P#QJC_AR%^R;_T4;XI_^%L?_C5'_$6?^H/_ ,J?_<P_XA;_ -1?_E/_ .W/
MQ9HK]6/V3_\ @DU^SE\8_AO?^*?%7CWXC17-OXGU&PC6P\7M&ABAF*(2#&?F
MP.3GFO3O^'(7[)O_ $4;XI_^%L?_ (U1_P 19_Z@_P#RI_\ <P_XA;_U%_\
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MOVHXB+C7?[$MO%K^&=27PY-J.[;]F75VMQ9$YZ/YOEGLYH ^QJ*** "BBB@
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M]]8WUNEQ97MG.LL-Q"ZADD1U)5U92"&!((((H L4444 %%%% !1110 4444
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MY&F<CB4G8,;25#;@ ?J=7B'A3]C7_A&/^"A?B_\ ;R_X6/Y__"5_"_2O!_\
MPBO]C[?LOV*\N;G[5]I\X[]_VC;Y?E+MV9WMG ]OHH ^?/V\OVG?V7/^">'[
M'NM>+OB?X,TR30KFWDT;PW\.-*TJ,OXIU&Z5UBTBUM$0B5[ABRLH0@*7=AM#
M&OST\>?!+]HO_@F1_P &BOC#X8?$:]ETOQNG@R<:II<<Y/\ 8D&NZZB2Z>&R
M<-';7[HX!($C2 $C!,WA#PA_P67U_P#;]UC]O#]L'_@CKJWQ/UCPY=3V7P-\
M.67QY\*V.B>!M-8[6N(;>6YD:?4)@ 7NGVL.BJH"+']S_%WX,?%C_@J'_P $
MUO'O[/O[5'[/]Q\%?$GC_0K[3!X=OO$]EKS:5.C[[&]:XL6,4JB6.&8QJ0V%
M*D@T >8?M_?LH?!S3?\ @WA\>_L^6?A:PCT#P1^SG+J&AP"!0L-WI6F?;;>=
M>.)3/;JY?[S,[$DECGZ"_P"":/Q,\4?&?_@G7\"?BSXWOY+O6O$7P@\.:AK%
MW*^Y[BZETV!I92>Y9RS?\"KX+^(Q_P""TO[2_P"P/!_P2:\4?L!R>$_%FK^'
M+3P5XX^/-YXYTZX\,C18PD%SJD$44GVF>:XMD(^S>6K*T[$XV[1^G7P0^$WA
M?X!_!?PA\"O! D&B^"O"^GZ#I E(WBUL[:.WBW8XSLC7.* .HHHHH **** "
MBBB@ K\WO^#BVZU+XFZ%^S+^P]?ZK<V7A#XY_M):!H/Q!:VN&B-[I$<@DDLB
MRD$>8[1L.^Z%?>OTAKY<_P""MW_!/WQ!_P %"/V9M/\ "?PL\>0>$_B;\/\
MQAI_C3X4>*;E"8;#7K%F:#SMH+>2X=T8@-L)23:_EA" >^W/P8^$=Y\)'^ E
MS\,]";P0^B?V.WA(Z7%_9W]G^7Y7V7[/MV"+9\NS&,<5\ _\&W]_J/A;X-_M
M#?L47E]=:IX6^ _[3/BGP=X'DU%S-Y6CQ7 :*VRY.[;)YS^WG#VKFOVJO^"V
MG_!2O]C7]FF37_VC?^"2>H^%/%L<UMH]W\0Y?&UI>^!["]N'$,>I32VAEN8K
M/>1(8G4$96(RAF#'V_\ 8,_9*^,7_!,S_@FAJ1^"&E:7\>_C!XIU>?QWXHDM
M/$L.F6?C/6]1F@>Y>VO9E,<<?V956*5P%?RE<JOF%0 ?+_\ P7R_:\^*_P :
M/V>/%O[$GQC_ &$_%7PR^&?B'QY::'JO[2?CRV6_\/:#9V^J1F/5XX--2XG'
MG^4JPF;R /M*AW7D5^L?@#3M*TCP)HFDZ%KAU.QM=(MH;/4FG$INXEB54FWK
MP^Y0&W#@YS7YJ?MK_%S_ (*R?\%,/V;?$O["GP]_X)*:Q\+!\0;1-(\4_$+X
MG?$+2I=,T&Q>1#/-%%:.\MX^%*KY8R"0^TXQ7Z,? KX66/P,^"/@WX):7JLU
M_;>#O"NG:';WUP,27$=I;1VZR,,G#,(P3R>30!YU\3/V-?\ A8O[>?PM_;<_
MX6/]C_X5KX/\0:%_PC']C^9_:/\ :AM3YWVGSE\GROLWW/+??O\ O+CGY&_X
M.EOAW\/](_X(S_&SQ_I/@71K77M6U#PQ_:NMV^F1)=WFS6]-C3S9E4/)M1$0
M;B<*B@< "OTHK\TO^#@CP!_P4G_;3_9I\>?L _LL_P#!.:^\6:!XC71;FR^*
M0^*N@V$'F6][;7LL/V"\GBGR#"8MQ(!)W#(XH ^X/VUO!?Q'^)/[&OQ;^'?P
M<N)(O%^O_#+7M.\*RQ2!&34I].GBMF#$C:1,R$'(Q7Y<?LG?\%$?^"9?@3_@
MW^A_8]\<^*]"LO'FF_"W4O!GB/X%75GCQ)?^*'2:WEMDTS;Y\LMQ>OY@D"D*
M9=S,I1MOZ7_L=_'/]K#XWZ)K>H?M5_L-W_P0O+"[ACT?3[[XAZ5X@.JQ,K%Y
M0^G,RP["%7:_+;LCH:^*?C7\6O\ @J+^TYHVL_#7X7_\$/=.^%GQ<\4Z/-H=
M]\;/&/CC0KVP\+P3QF":]AN[53=7I2-CY:(N0VTE&"E& /6O^#;KXH>+/B[_
M ,$3_@1XJ\:7TMS>VFAZCH\<\Q))MM/U:]L+903U"P6T2?\  :^X:\H_89_9
M-\&?L+?LB> /V2? -_)>:=X&\/16']H2Q!&OK@EI+BY* D(99WEE*@G;YF,G
M%>KT %%%% !1110 5#J&GV&K6$^E:K90W-K<PM%<VUQ$'CEC8$,C*>&4@D$'
M@@U-10!^)GQH^&_[:_[$W[05]_P0"_9&\20Z?\,_VG-6N-7^$OC6?4S]K^&O
MAUQ//XGTR",_-)L1'-L,K@7#$.97+1_KY^S;^SO\)_V3/@3X6_9P^!WAF/2/
M"O@_2(]/T>R3EMBY+22-_'+(Y:1W/+N[,>2:^7_VI?V1_P!H3XC?\%LOV7/V
MN?!GP^^V?#SX<^#_ !?8^,O$/]K6D?\ 9\][82Q6J>1)*L\N]V49BC<+G+%1
MS7VO0!^>'_!!_P#Y++^W3_V>?XI_E#6?XR_Y6O?"?_9D$G_J37M>J?\ !)?]
ME'X^_LR_$S]J_P 0?&_P%_8EG\2_VF]?\6>"9O[4M;G^T='N1%Y-SBWE<P[M
MI_=RA)!CE17DW[:OP>_X*%?"O_@M[X:_X*'?LM_L(W?QF\(V?[-J^![Z&R^)
M&B:"\.HOK5[=N/\ B83J[!(FA.1&5/FX#95@ "Q_P<U? +P%=_\ !.;Q!^VQ
MX<TVUT/XL?!/5]&\1?#_ ,?6,*Q:C83KJEK"T(G WM&R3,1&25\Q8VQE17WS
M\'O&EY\2/A)X6^(FH6:V]QKWARQU&>W3.(GGMTE91GG +$?A7YV_M,_LZ_\
M!5?_ (+,6&C?LU?M6?LT^'OV;/@&OB"RU+XC:<WQ'MO$GB3Q;#:S+/%8PMIZ
M_9K6)I$1F9G+*R(X+;3&WZ86%A9:58PZ9IMI'!;6T2Q6\$2!4C10 JJ!P
M /:@#Q6V_8U^S_\ !2.]_P""A'_"Q\_:_@?;?#S_ (1'^Q_N>3K$^I?;OM7G
M<Y\_RO)\KC;N\PYVAO[9O[3/[+?_  3K_92U_P"+/Q<T;3+#PQ DMM8^$]+T
MV+S/$.HW.\IIUM;*N)Y[ERP*[2,%W?"J[#W&OQ^OO __  6+\<?\%&M5_;5_
M:O\ ^"0FJ_%6R\#ZG/:_L^^$[#XZ>%]/T3PI:[R/[4-O/<N]SJ,RJC>?($,?
M\**5B$0 OA+X+_M&?\$V_P#@U6^*.E?$"QE\+>,M5\):[JP\-12L&\*VVM7F
MQ;!#UCDC@N"S#@I+(XZKFOH_XM_LG?!N+_@W*UC]FR/PMIZ^']+_ &77NK.,
MP*$2_M]&^W1WQXQYOVQ!<E^I?+=37KGB+X>?%W_@I1_P3\^(7P(_:^_9JO/@
MEK'CW0]3T!O#]UXLL/$$EDCP@6^H">Q8PL1*1((\Y!BYZU\7:NW_  6L\;?\
M$\5_X)"W_P#P3_.G>,;KP9'\/-6^/DGCS3W\*_V (192ZLJ*_P!K>:2R!7R!
M&)!(Y?:,>50!]L_\$@OB;XJ^,?\ P2X^ 7Q'\<:C)>:OJ/PJT;^T;V9RTES+
M':I$TSD]7<IO8^K&OHVN'_9F^!'A?]EW]G3P)^S=X*N))M)\!^$=.T"PN)E
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M#3?)NU\B.5IH?+D^7,J(&ZJ6'- 'E?\ P5:_Y3:_\$X?^Q@^(W_IITZO:_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% '"_M!?M*_!3]EGP9;?$'X\>
M-/["TB\U--.MKO\ LVYNM]R\<DBQ[+>.1AE(9#DC'RXSD@'Q[_A\;_P3A_Z.
M,_\ +0UC_P"1*\R_X.!_^3-/#/\ V4ZR_P#3=J-?CW7ZIPEP/E.?9.L7B)S4
MG)KW7%+3UBW^)^8\4\:9ID>;/"T(0<4D_>4F]?22_(_='_A\;_P3A_Z.,_\
M+0UC_P"1*]A_9]_:5^"G[4W@RY^(/P'\:?V[I%GJ;Z=<W?\ 9MS:[+E(XY&C
MV7$<;'"31G(&/FQG(('\YM?L)_P;\?\ )FGB;_LIU[_Z;M.HXMX&RG(<G>+P
M\YN2DE[SBUKZ13_$?"O&F:9YFRPM>$%%IOW5)/3UD_R/NBBBBORL_30HHHH
M**^0/VR_VH_CM\*/^"L7[%_[-'@#QS]@\$_%G_A8O_"P-$_LRUE_M7^R]"@N
MK']])$TT'E3.S_N7CWYP^Y<"C_@O5^U'\=OV+O\ @D]\5OVE_P!FCQS_ ,(U
MXV\-?V%_8FM_V9:WGV;[1KNGVLW[FZBEA?=#/*GS(<;LC# $ 'U_17B'Q_\
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M+EE7.X@4 >^T5^-7P6_X*=_#3_@H?_P5$\<>&/$7_!2#XX> /!VB>.O#FB?
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M*** "BBB@ HHHH ^%_\ @X'_ .3-/#/_ &4ZR_\ 3=J-?CW7[\?\%!/V+/\
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MI/B71+SPYK]A'=V.H6LEM>VLRY2:&12KHP[@J2#]:XGX3?LN? GX&_$KQ_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
7 **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>biib-20200930_g4.jpg
<TEXT>
begin 644 biib-20200930_g4.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?@3XCT'3M*UF*X=9+Z*_TXW4CW!D;8I5AM&W QUYKZ6M;JVO;:.\LKB.:&5
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MOAXOPXO_ !M\7V\!>.[+1M2NGMO$>DWMC/(5O(YI7$SQO#O61OFWD,2S(A4
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MER6*CW.:]:T[7]"U>XN+32=:M+J6TDV7<5O<J[0MS\KA22IX/!]*_$WXL?M
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MIBO8* /C3XL_\$(O^"6'Q?\ 'WC?X\_M.?!";QSK_BV_N]1UOQ#XT\8Z@_\
M9\+LTA@MMD\<=E;Q D)Y:J54#+'&:^?O^"+O[1OCKX'_ /!*3]H[XTCQ?K7C
M3X5?!_QSX[N?@%KOBFZ>:?5?"&DVQFM0)F^:6W#Q2HK]CO0!5157R3_@IK_P
M6"_99_:W_;/\3?\ !,;XO_M;+\%O@/X U%['XV^(1;7HUCQ[>Q2%)O#UB;:%
MVMK)71DN;AMK2@%$RAS)]W_"'XB?L%_\%)/^"=WQ&_9@_P""=OQ'T"_\#CP#
MJ7P_ACT/2KFTM-&^U:9)!'"$FBC;"QS*V0#GN2<T ?'/['W_  1@^ '[:O\
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M6UU"LD<JGJK*P(8>QJ>B@"MI&CZ1X?TR'1=!TNVL;.V39;VEI L442_W550
MH]@*LT44 %%%% &<OA#PFGB1O&2^%].&KO#Y3:J+*/[28_[AEQNV^V<5HT44
M %9WB7P?X2\:6::=XQ\+:=JUO'()(X-3L8YT5QT8*X(!]ZT:* &PPPVT*6]O
M$L<<:A41%P% X  '04ZBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MG_\ /C#_ -^A0!3_ .$Q\,?]!J#_ +ZH_P"$Q\,?]!J#_OJKG]G:?_SXP_\
M?H4?V=I__/C#_P!^A0!3_P"$Q\,?]!J#_OJC_A,?#'_0:@_[ZJY_9VG_ //C
M#_WZ%']G:?\ \^,/_?H4 4_^$Q\,?]!J#_OJC_A,?#'_ $&H/^^JN?V=I_\
MSXP_]^A1_9VG_P#/C#_WZ% %/_A,?#'_ $&H/^^J/^$Q\,?]!J#_ +ZJY_9V
MG_\ /C#_ -^A1_9VG_\ /C#_ -^A0!3_ .$Q\,?]!J#_ +ZH_P"$Q\,?]!J#
M_OJKG]G:?_SXP_\ ?H4?V=I__/C#_P!^A0!3_P"$Q\,?]!J#_OJC_A,?#'_0
M:@_[ZJY_9VG_ //C#_WZ%']G:?\ \^,/_?H4 4_^$Q\,?]!J#_OJC_A,?#'_
M $&H/^^JN?V=I_\ SXP_]^A1_9VG_P#/C#_WZ% %/_A,?#'_ $&H/^^J/^$Q
M\,?]!J#_ +ZJY_9VG_\ /C#_ -^A1_9VG_\ /C#_ -^A0!3_ .$Q\,?]!J#_
M +ZH_P"$Q\,?]!J#_OJKG]G:?_SXP_\ ?H4?V=I__/C#_P!^A0!3_P"$Q\,?
M]!J#_OJC_A,?#'_0:@_[ZJY_9VG_ //C#_WZ%']G:?\ \^,/_?H4 4_^$Q\,
M?]!J#_OJC_A,?#'_ $&H/^^JN?V=I_\ SXP_]^A1_9VG_P#/C#_WZ% %/_A,
M?#'_ $&H/^^J/^$Q\,?]!J#_ +ZJY_9VG_\ /C#_ -^A1_9VG_\ /C#_ -^A
M0!3_ .$Q\,?]!J#_ +ZH_P"$Q\,?]!J#_OJKG]G:?_SXP_\ ?H4?V=I__/C#
M_P!^A0!3_P"$Q\,?]!J#_OJC_A,?#'_0:@_[ZJY_9VG_ //C#_WZ%']G:?\
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MB@ HHHH **** /"_^">__)$]6_['O6?_ $I->Z5X7_P3W_Y(GJW_ &/>L_\
MI2:]TH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@#XS_P""J?QV_;D^$_PG^*&D_#G]BG3_ (C?"^^^$FJ_;?%6C_$.
MSTW5-"F-E=+=//97P1+F!(]DBF&7S#AU\MB17F?_  3$_9+_ &F_&7[<+_\
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M  '\._\ @J!_P3YTGX?^"=(T*TD^*GBJ22VT;38K6-W.EPDL5C50222<]>:
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MC_T*OK>$<LP.:8RI#%0YDHW6K6MUV:/E^*<QQF6X6G/#2Y6Y6>B?3S3/>?\
MAZ5_U0O_ ,N?_P"YJ/\ AZ5_U0O_ ,N?_P"YJ^2:*^__ -4>'O\ GS_Y-/\
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M 0:_5ZB@#Y\\:?&C]ONZ_88U#XV_#;]C6ULOC:VG;]+^"OB'QII]S''<B_\
M*,<FI031VS!K4&<$2+@L$)+ BI/VF/V@?VU?@I\'_!GC_P"#G[#=Q\6-=O\
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M"BBB@ HHHH **** "BBB@ HHHH \+_X)[_\ )$]6_P"Q[UG_ -*37NE>%_\
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MT_\ Y(G_ %IS[_G]_P"2Q_\ D3ZV_P"'I7_5"_\ RY__ +FH_P"'I7_5"_\
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M_5WPKKG_  DWA?3?$GV7R/[0L(;GR=^[R_,0/MS@9QG&<#/I5^L'X5?\DO\
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M&H/^^J -*BLW_A,?#'_0:@_[ZH_X3'PQ_P!!J#_OJ@#2HK-_X3'PQ_T&H/\
MOJC_ (3'PQ_T&H/^^J -*BLW_A,?#'_0:@_[ZH_X3'PQ_P!!J#_OJ@#2HK-_
MX3'PQ_T&H/\ OJC_ (3'PQ_T&H/^^J -*BLW_A,?#'_0:@_[ZH_X3'PQ_P!!
MJ#_OJ@#2HK-_X3'PQ_T&H/\ OJC_ (3'PQ_T&H/^^J -*BLW_A,?#'_0:@_[
MZH_X3'PQ_P!!J#_OJ@#2HK-_X3'PQ_T&H/\ OJC_ (3'PQ_T&H/^^J -*BLW
M_A,?#'_0:@_[ZH_X3'PQ_P!!J#_OJ@#2HK-_X3'PQ_T&H/\ OJC_ (3'PQ_T
M&H/^^J -*BLW_A,?#'_0:@_[ZH_X3'PQ_P!!J#_OJ@#2HK-_X3'PQ_T&H/\
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M?/3>FJV:=UHTT]4UV85J%3#U.2:U^_1ZIIK1KT/U.^%7_)+_  W_ -@"S_\
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M\._"KPSJVJSQVT862R.K6]G-%:W&%V%$N-[>7Y89?+9 ?2_@O^WC^R'^WO\
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M_P#SXP_]^A4U% $/]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ%344 0_P!G:?\
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MJTYSA&#NH14;]WN[7UMK;Y'ZD?"RPL6^&/AQFLH23H-GDF,?\\$K>_L[3_\
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M^.W_ $/7_E,M?_C5']DXGNOQ_P @_M;#=G^'^9]@45\?_P##4GQV_P"AZ_\
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M[E^5S' [K%'$2,MN^3:WF>:?M->$_P#@D+^T[\<M>^.FI?\ !QEXK\%SZ])
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MW_H9JA7(^,?VG?@=;>+M5MI_&^UX]2G5U_LVY.")&!_Y9UF_\-2? G_H>O\
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M7B;_ ,BNA_C_ /;6>,4445^Y'XL%%%% !1110 4444 %%%% !1110 5^]?\
MP2N_Y1^?#+_L"S?^E4]?@I7[U_\ !*[_ )1^?#+_ + LW_I5/7YEXI_\B2C_
M -?%_P"DR/T?PS_Y'-;_ *]O_P!*B?0-%%%?A!^VA1110 4444 %?/G_  4M
M\<_L\?#[]G6#7OVF_P!B+Q#\?O#A\26T2>!?#/POM_%US'<F.8I>&QG^0)&
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M ,C:O_@_]N1^>>)O_(KH?X__ &UGCE%%%?N1^+!1110 4444 %%%% !1110
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M  9\1_B9'J&BZCYUK+;C[1;BV0R>691*GS#;)%&W.,'YKU[]B/Q;_P %._\
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M1_A1]$?R=5_BR]6%%%%:$!1110 4444 %%%% !1110 4444 ?T<?LW_\F[^
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M-SX@UJTL8[B[AM;>2\N5B66>5Q'%$I8C<[NRJJCEF8  DU;H **** "BBB@
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M'V6XDR?-$;Q,CR'.]E5\_-7N_P#P=->>O_!(O7Y-%"?VZGQ \+GPR3_K!?\
M]JP[/+QSOV^9TYQNH _1:OD+]L'_ (*6?%+X<_M6Z5^P1^Q%^RX/C!\7+GPJ
MWB?Q):ZAXKCT71_"^D>9Y44]Y=M%*3++)A4@5=Q#*Q(!&?KVOSH_X)_B4_\
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M1110 4444 %%%% !1110 4444 %?O7_P2N_Y1^?#+_L"S?\ I5/7X*5^]?\
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M&SC_ *!ZG_@$O\CA_M;*O^@B'_@<?\SH?C_\!/#G[0WAS0/#7B;6;VRB\/\
MCK0?%-M)8%-TESI6HP7\,3;U(\MY(%5L8.TG!!P:[JO)/^&Z?V5_^BI?^42^
M_P#C%'_#=/[*_P#T5+_RB7W_ ,8H_L;./^@>I_X!+_(/[6RK_H(A_P"!Q_S/
M6Z*\D_X;I_97_P"BI?\ E$OO_C%'_#=/[*__ $5+_P HE]_\8H_L;./^@>I_
MX!+_ "#^ULJ_Z"(?^!Q_S/6Z*\D_X;I_97_Z*E_Y1+[_ .,4?\-T_LK_ /14
MO_*)??\ QBC^QLX_Z!ZG_@$O\@_M;*O^@B'_ (''_,];HKR3_ANG]E?_ **E
M_P"42^_^,4?\-T_LK_\ 14O_ "B7W_QBC^QLX_Z!ZG_@$O\ (/[6RK_H(A_X
M''_,];HKR3_ANG]E?_HJ7_E$OO\ XQ1_PW3^RO\ ]%2_\HE]_P#&*/[&SC_H
M'J?^ 2_R#^ULJ_Z"(?\ @<?\SUNBO)/^&Z?V5_\ HJ7_ )1+[_XQ5_PO^V'^
MSGXT\16?A3PU\1/M.H:A<+!:6_\ 9%XGF2,< ;GA"CZD@4I91FT(N4L/-)?W
M)?Y#CFF63DHQKP;?]Z/^9Z91117G'>9'C_5+[1/ >MZUI<_E7-GI%S/;R[0V
MR1(F93@@@X('!&*^!?\ ANG]JC_HJ7_E$L?_ (Q7WG\5?^27^)/^P!>?^B'K
M\L:_1.!\#@L70K.O2C.S5N:*=M'W1\'QEC,7A:U%4:DHW3O9M=NQZW_PW3^U
M1_T5+_RB6/\ \8H_X;I_:H_Z*E_Y1+'_ .,5Y)17W7]C9/\ ] ]/_P  C_D?
M%_VMFO\ T$3_ / Y?YGK?_#=/[5'_14O_*)8_P#QBC_ANG]JC_HJ7_E$L?\
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ME)!X/%<I6U++,BKP4Z="G)/JHQ:_(RJYCG5&?)4K5$^SE)?J>M_\-T_M4?\
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M;S=3\0:M;Z?8H<X\V60(I/HH+9)[ $U[Y)^V?^S_ /"7P1XKT?\ 9!_9JO\
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M)_V +S_T0]?EC7ZG?%7_ ))?XD_[ %Y_Z(>ORQK].\/_ /=Z_K'\F?G7'/\
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MHQDG->[>,HI_NXQT;26^GX[:BBZ="K@ZE:46HOWK2C)KWY2U2;>VOX;G7?\
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M?^E(\S.O^1/B?^O<_P#TEGX*4445_5Y_+P4444 %%%% !1110 4444 %%%%
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M^VA1110 4444 %%%% !1110 4444 >%_\$]_^2)ZM_V/>L_^E)JE_P %4?\
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M_#-[,HO'M;:9Y;J[>)266+:VP$X^8 ='4GYQ\2_L]?$+PI\!_#?[1FJK8_\
M".>*M3NK#2C'<[I_-MV99-Z8^494X.3FOHLEK82C4KQHR2HRJVIVMRM^SBY*
M-M+<RD]-+J1X&;T<55A1=5-U8T[U+_$ESR47*^M^5Q6NMG$^@?V7_CY_P5H^
M)7A;2/#?[+.J:]>Z!X66WTJTMM(T6Q2SMO+C78D[/&%8E<%FE)SDDFN,_P""
MH-_\*M1_:SU&?X80Z.DZZ19)XO\ ^$>4"P.N"/%X8-ORE=V Q'5PY.22:M>
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M?\19_P"H/_RI_P#<S\N_XA;_ -1?_E/_ .W/Q9HK]IO^'(7[)O\ T4;XI_\
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M_P#E/_[<_%FBOVF_X<A?LF_]%&^*?_A;'_XU1_PY"_9-_P"BC?%/_P +8_\
MQJC_ (BS_P!0?_E3_P"YA_Q"W_J+_P#*?_VY^+->S_\ !.S_ )/F^%?_ &.E
ME_Z'7Z?_ /#D+]DW_HHWQ3_\+8__ !JC_AR%^R;_ -%&^*?_ (6Q_P#C5<^+
M\4OK6%J4?JEN:+5_:;75K_ ;X7PT^K8JG6^MWY9)V]GO9W_G/L:BOCG_ (<A
M?LF_]%&^*?\ X6Q_^-4?\.0OV3?^BC?%/_PMC_\ &J_)3]3/I+]I#_DW?Q[_
M -B7JG_I)+7\X]?M-_PY"_9-_P"BC?%/_P +8_\ QJC_ (<A?LF_]%&^*?\
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MTW_#D+]DW_HHWQ3_ /"V/_QJC_AR%^R;_P!%&^*?_A;'_P"-4?\ $6?^H/\
M\J?_ ',/^(6_]1?_ )3_ /MS\6:*_:;_ (<A?LF_]%&^*?\ X6Q_^-4?\.0O
MV3?^BC?%/_PMC_\ &J/^(L_]0?\ Y4_^YA_Q"W_J+_\ *?\ ]N?27[-__)N_
M@+_L2]+_ /22*NTKXY_X<A?LF_\ 11OBG_X6Q_\ C5'_  Y"_9-_Z*-\4_\
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M+/\ U!_^5/\ [F'_ !"W_J+_ /*?_P!N?BS17[3?\.0OV3?^BC?%/_PMC_\
M&J/^'(7[)O\ T4;XI_\ A;'_ .-4?\19_P"H/_RI_P#<P_XA;_U%_P#E/_[<
M_%FBOVF_X<A?LF_]%&^*?_A;'_XU1_PY"_9-_P"BC?%/_P +8_\ QJC_ (BS
M_P!0?_E3_P"YA_Q"W_J+_P#*?_VY^+-?O7_P2N_Y1^?#+_L"S?\ I5/7G7_#
MD+]DW_HHWQ3_ /"V/_QJC_AR%^R;_P!%&^*?_A;'_P"-5\QQ5QM_K-@H8?ZO
M[/EES7Y^;HU:W+'N?1\,\'?ZN8R>(]OS\T>6W+R]4[WYGV/L:BOEOX2_\$CO
MV:_@U\2]$^*GA?QU\1;C4=!U!+RS@U+Q<9;=Y$.0)$\L;U]1GFOJ2OA#[<**
M** "BBB@ HHHH **** "BBB@ HHHH **** "BN7^,WQJ^$O[._PSU;XR_'/X
MB:3X4\*Z%;^?JVNZW>+!;VZ$A5RS=69BJJHRS,RJH)(%?*O@'_@X/_X)0?$'
MQ=I'A2#]HZ]T2+Q%="W\.>(/%_@;6-&TC5)"< 17U[:QP 'L7= ?6@#[2HKS
M[]IS]J?X"_L;_!G4?V@_VD?'\?AOPAI4MO%>ZLUA<7>V2>58H46*VCDED9Y'
M50$0G)KPC]G?_@N5_P $T_VFOC)IG[/_ (#^.=]I?B_7FV^'-&\9^#M4T-M8
M/9;9[ZWBCE<\!8PV]B0%4F@#W?XQ_!G4_B;X]\ >+['6H+6/P=XA?4;F&:-B
MUPIB*;%(Z')SS7H-%</I7[1_P8UO]H;6/V5-+\9>;X^T'PO:>(M6T'^SKE?(
MTVYFD@AG\\QB%MTD4B[%<N-N2H!!(!W%%?$OC?\ X.(_^"2'@+QAJ/A+5/VE
MKZ\CT346L=>U[1O .M7NE:9<*VPI+>06C0\-P2K,HSR:^O? WQ0^'/Q,^'>G
M?%SX?>.=*UGPOJ^FKJ&F>(-.ODEL[FU9=XF653M*;><YXP<]* -VBOCSP;_P
M7M_X)5>//BM8?";P[^TZK2:OKAT;1?$USX7U.#0-1U'<5^S0:K);K:2,6! 8
M2[&(^5FR,_8= !1110 4444 %%%% !116?XK\5^%_ GAC4/&OC?Q'8Z/HVDV
M4MYJNJZG=I!;6=O&I>2:61R%C15!8LQ  !)H T**^(8_^#BS_@D;)K MS^TG
MJ*:*VH?85\;2?#_6UT W.[9L_M V?D8W<>9N\OONQS7U=X[^/WP9^&WP-U']
MI;Q=\1-.A\!:5X>;7;SQ3:RFZM!IJQ><;I&@#F6,Q_,#&&W C&<B@#L*X[]H
M+X9WWQE^"_B+X7Z9J<5E<:WIS6T5U.A9(R2#D@<D<5\M_#__ (.%?^"3_P 0
M_B!I'P\MOVBM0T27Q%=K:^'M7\7>!-9T?3=1E8@*J7=Y:QQ+G/!D9 ?7)%?:
MM &?X2T:7PYX4TSP]/,LCV&GPV[R(,!RD:J2/8XK0KA_$W[1_P &/!WQY\+?
MLQ^(_&7V;QQXTT?4-5\,Z)_9UR_VRTL?*^U2><L9ACV>='\KNK-N^4-@X\1_
M:U_X+7_\$N?V&?B1>_![]J#]KK1O#OBK3?)_M+P];:1J&I7EGYT*3Q>;%8V\
MS1;HI(W&X#*NIZ$4 ?4U%!( R37QIKO_  < _P#!)[P]\1+KX?WO[3_FP:?K
M(TG4O%]GX4U2?P[9WQ8*(9-6CMC9KR5!D\PQC=RXYP ?9=%165[9ZE9PZCIU
MW%<6]Q$LD$\$@=)$895E8<$$$$$<$&I: "BBB@ HHHH ***Y/XZ?&[X;?LV_
M"#Q#\>/C%K%UIWA;PKIKZAK^HV6C7>H/:6J8\R;R+2*69U0?,Q5&VJ&8X520
M =916!\+?BC\/OC9\-M"^,'PI\66FN>&?$VE0:EH6L6+DQ7=K,@>.1<@$94C
M@@$'((!!%?)7C'_@X>_X(_> YF7Q'^UC="'^TKVQ@O['X:^)+NTNYK27R9S;
MW$&G/%<1K)E?-B=XV(.UFQ0!]J45\&6__!S;_P $1KMI%M?VRKR0Q.4E$?PI
M\5'8PZJ<:7P?:O0?C3_P7&_X)@?L]:CX-TCXM?M'7NG7?Q ^'VG^-_"5K:_#
MOQ!>R7V@WQD%K>%;6PD,.\Q.#%+LE3;\Z+D9 /H']H+X9WWQE^"_B+X7Z9J<
M5E<:WIS6T5U.A9(R2#D@<D<5T/A+1I?#GA33/#T\RR/8:?#;O(@P'*1JI(]C
MBO!/V4/^"MG_  3C_;>\6GX??LR_M8^&_$/B,1M(GAJY2XTW4Y54;G*6E]%#
M/(%'+;4.T<G KZ+H **X>/\ :/\ @Q-^TE-^R)'XRS\0[?P/%XPF\/?V=<_+
MHLEY)9)=>?Y?D'-Q$Z>6)/,&W<4VD,?F/XF_\'"7_!)WX4>/=9^'WB']H[4+
MR?PUJ,MAXIU+0? 6M:CI^C7$;['2XNK>T>(%6R#M9L8.<4 ?:E%<[\+/BW\,
M?C?\-M)^,7PA\>:7XC\+:[8K>:1KVD7BS6MU <_.KJ<<$$$'E2I! (('RWIO
M_!?7_@E'JWQ3A^%ME^U'$1<:[_8EMXM?PSJ2^')M1W;?LRZNUN+(G/1_-\L]
MG- 'V-1110 4444 %%%% !15+Q)K^G>%/#M_XIU=;DVFFV4MU="RL9;J8QQH
M7;RX85>29\ XCC5G8X"J20*X_P#9E_:@^ W[8_P7TC]H7]FKXBVOBGP?KGFC
M3M7MK>:#<T4C12(\4Z)+"ZNC*4D16&.1R* .]HKY)^-__!=+_@EG^SKXX\1_
M#OXL_M-3V>I^$O$']A>(3IO@#7]2MK34Q$)7L_M-E8RP/,BGYT1V,9^5]K<5
MP4?_  <V_P#!$:6YDLXOVRKQIH@#+$OPI\5%D!Z9']EY&: /O.BODOQY_P %
MS/\ @EU\,_@]\./CUXT_:2N[3PM\7#JX^'E]'\/?$$\NK'2[A;:^Q;16#3P^
M5*ZK^^C3>#N3<N35W]G?_@ME_P $LOVI_B':_"3X-_MB>'Y_%%_.(=/\/^(-
M/OM#O+R4G BABU."W:60GHB L>PH ]F_9K^#.I_ SP%>^$-5UJ"_DNO$-]J*
MS6\;*JK/*7"8/< X->@T5P_C?]H_X,?#CXV^!?V<_&?C+['XR^)=OJT_@G1O
M[.N9/[1CTR&*:^/FQQM%#Y<<\38E="^[";B"  =Q17S#^UY_P6:_X)D?L'^/
M)OA;^U3^UGHWAGQ+;11276@0Z7?ZC>0)*@>-I(;&WF>,,C*P+ 9!!Z5]+:3J
MMAKFE6VMZ5/YMK>6Z3VTNTKOC=0RG! (R".",T 6**^-_'/_  7W_P""5'P]
M^)6I_#77?VEWF_L+5QI7B#Q-I7A'5;W0M+O2X3R)]3@MGM4(8@%O,**3\S#!
MQ]@:1J^D^(=)M=?T#5+>^L;ZW2XLKVSG66&XA=0R2(ZDJZLI!# D$$$4 6**
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _,_P#X*P:!IO[5
M/_!8W]C#]@SXL6R7WPSN'\2>.O$GAR[^:UUZ^TVR=[&*:,_+,D3Q.6C8%62>
M0,"#7W7^U1^S!\(OVO/V<?%?[,GQB\*V6H>&O%&AS:?/;SVZL+5BA$5Q%G_5
MRPOMDC=<%&12""*^>O\ @K'^P;\=?VAM>^%'[97[%>NZ/8?'3X ^(;G5/!MG
MXAD:/3_$-A=1K%J&D7$BX,8GB0*LF<+EUR@E,B?,G[>7_!87_@H3IGPVT#]E
MO7O^">6I?LZ^,?C+J)\&67Q:^)OC>SNO"WAJ\N8RCRI=Z>LHEDVEO),@B!8;
M\.(W6@#W#_@VH^.'C;]HS_@C3\)/$?Q4NYM2U/0!J&A1:A?9=Y[>POIH+1LM
MDDQP+%%NZYBKYC_X**_M5_$/]M[X]?LT_L]_M8?L7^+/V8_"EI\==&\16GQ8
M^)X2Y%QJ%H7,&B6,NG+-#:W-V6P);B>)%6(G#;0*^V_A_P# _P"+/_!)7_@G
M+\._V>OV&?V;)?C;>^!1#9ZOH \4VNA76HQS&>XO]1BENLQ>:;J0R" GE9"@
M;*@U\S_MC:%_P4L_X+/:#X2_9&UK_@G1JWP&^&T?CS2]=^(/Q"^(7C33KF\2
MULI_.^RZ?9V;O(TSD<2D[!C:2H;< #]3J\0\*?L:_P#",?\ !0OQ?^WE_P +
M'\__ (2OX7Z5X/\ ^$5_L?;]E^Q7ES<_:OM/G'?O^T;?+\I=NS.]LX'M]% '
MSY^WE^T[^RY_P3P_8]UKQ=\3_!FF2:%<V\FC>&_AQI6E1E_%.HW2NL6D6MHB
M$2O<,65E"$!2[L-H8U^>GCSX)?M%_P#!,C_@T5\8?##XC7LNE^-T\&3C5-+C
MG)_L2#7==1)=/#9.&CMK]T< D"1I "1@F;PAX0_X++Z_^W[K'[>'[8/_  1U
MU;XGZQX<NI[+X&^'++X\^%;'1/ VFL=K7$-O+<R-/J$P +W3[6'154!%C^Y_
MB[\&/BQ_P5#_ .":WCW]GW]JC]G^X^"OB3Q_H5]I@\.WWB>RUYM*G1]]C>M<
M6+&*51+'#,8U(;"E20: /,/V_OV4/@YIO_!O#X]_9\L_"UA'H'@C]G.74-#@
M$"A8;O2M,^VV\Z\<2F>W5R_WF9V))+'/T%_P31^)GBCXS_\ !.OX$_%GQO?R
M7>M>(OA!X<U#6+N5]SW%U+IL#2RD]RSEF_X%7P7\1C_P6E_:7_8'@_X)->*/
MV Y/"?BS5_#EIX*\<?'F\\<Z=<>&1HL82"YU2"**3[3/-<6R$?9O+5E:=B<;
M=H_3KX(?";PO\ _@OX0^!7@@2#1?!7A?3]!T@2D;Q:V=M';Q;L<9V1KG% '4
M4444 %%%% !1110 5^;W_!Q;=:E\3="_9E_8>O\ 5;FR\(?'/]I+0-!^(+6U
MPT1O=(CD$DED64@CS':-AWW0K[U^D-?+G_!6[_@G[X@_X*$?LS:?X3^%GCR#
MPG\3?A_XPT_QI\*/%-RA,-AKUBS-!YVT%O)<.Z,0&V$I)M?RPA /?;GX,?".
M\^$C_ 2Y^&>A-X(?1/[';PD=+B_L[^S_ "_*^R_9]NP1;/EV8QCBO@'_ (-O
M[_4?"WP;_:&_8HO+ZZU3PM\!_P!IGQ3X.\#R:BYF\K1XK@-%;9<G=MD\Y_;S
MA[5S7[57_!;3_@I7^QK^S3)K_P"T;_P23U'PIXMCFMM'N_B'+XVM+WP/87MP
MXACU*:6T,MS%9[R)#$Z@C*Q&4,P8^W_L&?LE?&+_ ()F?\$T-2/P0TK2_CW\
M8/%.KS^._%$EIXEATRS\9ZWJ,T#W+VU[,ICCC^S*JQ2N K^4KE5\PJ #Y?\
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MZ???$/2O$!U6)E8O*'TYF6'80J[7Y;=D=#7Q3\:_BU_P5%_:<T;6?AK\+_\
M@A[IWPL^+GBG1YM#OOC9XQ\<:%>V'A>">,P37L-W:J;J]*1L?+1%R&VDHP4H
MP!ZU_P &W7Q0\6?%W_@B?\"/%7C2^EN;VTT/4='CGF))-MI^K7MA;*">H6"V
MB3_@-?<->4?L,_LF^#/V%OV1/ '[)/@&_DO-.\#>'HK#^T)8@C7UP2TEQ<E
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MQ_:UI;?V;I,!!EN=MQ*C3;?^><0>0]E- 'M7_!//]A[X=?\ !/7]EC0/V</
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M .Q]X-U8ZC;^#-%,%YJC1>7]OOII7N+NYVY.P27$TKA23M5@N3C- 'M-%%%
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MFI.37NN*6GK%O\3\QXIXTS3(\V>%H0@XI)^\I-Z^DE^1^Z/_  ^-_P""</\
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MO^"S?_!.[XG^+IA9Z##XB^(VA3ZK.0L$5_J>A6MK8P,YX#RRDJH[E3CI3?\
M@Z7\2Z;!_P $:O'WPKBF67Q!\0?$GAG0?"6DHX\_4K_^W+*Z$$*=9'\JVE;
M[*37V5^U/^R1^SE^VS\(;OX$_M2?"G3O%_A>\G2=M/OS)&\$Z9V3PS1,DMO*
MH9@)(W5@&89PQ!\,^ __  0]_P"">7P"^+VB?'?2_AUXC\5>*?"TOF>$=1^(
M?CS5->707XPUI#>3O%$ZD*5DV%T*@JP(S0!XS_P4F^'/ACQE_P %HO\ @FUX
M,\>Z%::E:V=Q\2[S[-<Q"2,7=EH%A=6\H##K'<012*>S(#VK<_X*.6EMI?\
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M<=5_9*^'WP=M/^%?:]]L/B#P_K=]<ZHNJM=KMN7N9;V266=I !N+L>@QC H
M^/?^#G.T_9Y_X<4^.EUB+0UL(3X>_P"%:_8Q%Y:WGVZV%O\ 8=ORX^R&X'[O
MCR/-Q\N:_0'X3?\ )*_#/_8OV7_HA*^1M*_X-Y_^"55MX6N_ 7B;X'^(?$WA
MZ2P>QTG0/%/Q*UV]M- MF=6:/34>\S8D[%4R1%9-FY-^QW5OM'2=*L-#TJVT
M32H/*M;.W2"VBW%MD:*%49)). !R3F@#YG_;L_X)??L(?\%)?%FFW'QUTFXA
M^(/@JS3^QO%O@SQ,^F>(-%MYF=D'F0MGRF82L@E1U#&0H 2Q/R=^SJ?VD?\
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M_P!;N'O^?W_DL_\ Y$_,?]5L^_Y\_P#DT?\ Y(['_@FG_P D%U+_ +&NX_\
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M?LE?!'X.V6@^ ]7M;R'6M)MKNX:;4C=Q&*YEN+IY#<332(=IF:0R !0& 50
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
C%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>biib-20200930_g5.jpg
<TEXT>
begin 644 biib-20200930_g5.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?@3XCT'3M*UF*X=9+Z*_TXW4CW!D;8I5AM&W QUYKZ6M;JVO;:.\LKB.:&5
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MOAXOPXO_ !M\7V\!>.[+1M2NGMO$>DWMC/(5O(YI7$SQO#O61OFWD,2S(A4
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MER6*CW.:]:T[7]"U>XN+32=:M+J6TDV7<5O<J[0MS\KA22IX/!]*_$WXL?M
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MIBO8* /C3XL_\$(O^"6'Q?\ 'WC?X\_M.?!";QSK_BV_N]1UOQ#XT\8Z@_\
M9\+LTA@MMD\<=E;Q D)Y:J54#+'&:^?O^"+O[1OCKX'_ /!*3]H[XTCQ?K7C
M3X5?!_QSX[N?@%KOBFZ>:?5?"&DVQFM0)F^:6W#Q2HK]CO0!5157R3_@IK_P
M6"_99_:W_;/\3?\ !,;XO_M;+\%O@/X U%['XV^(1;7HUCQ[>Q2%)O#UB;:%
MVMK)71DN;AMK2@%$RAS)]W_"'XB?L%_\%)/^"=WQ&_9@_P""=OQ'T"_\#CP#
MJ7P_ACT/2KFTM-&^U:9)!'"$FBC;"QS*V0#GN2<T ?'/['W_  1@^ '[:O\
MP2GL?VP/VB(M6U_]I/XM^$;CQQ'\:)]>NXM6TC5KA7N=-:T9)%6WAMU^S*(D
M 0A6& " OOO[".A^"O\ @NA_P1;^"NO_ +9VHZ]JD.IQ!_&=MHOB&?36\07>
MEW%YILBWDELR2&*=HC.\:,F6*$$ 8/@O[&7_  6C_9N_8T_X),67[+/[16M7
MOAS]HCX/>$)_ \OP8OM)N&UK4M8ME>VTZ*UB5#]HCN%^S$2H2@#G)P 3W?P?
M^.^G?\&Y_P#P;T?#+6OVCO UY>^+M,TUK>U\(0?NY9_$.K7-YJ:V$\N"(1")
M)5ED.=JVS!0[;%8 \]_;I_8<_94_X)I?ML?LDZC_ ,$L?!TWP\^,/CGXT6&C
M:]X.\+:S>26WB/P6%=M6EO[:25U,,"B,^:0" [M\S1JT?KW_  4@\/6_[>W_
M  6!^"W_  2O^*5]?R_"32_A=J/Q2^)/A:QOYK:+Q04NWL-/M;IHF5FMXKB,
MR&/(5]Y!Y"%?%O\ @EK_ ,%!?^"5>@?&6;]JW]K?_@HIX6^(W[5'Q:DMM*NK
MVS\/ZJ-/\,6LTH%MX=T99+7;!;([JKR9!F?+LQR2?9O^"COBBP_8&_X+'_!3
M_@J+\6[>]MOA)KGPMU'X5_$'Q9;64L\'AB5KU[_3[B[$8)2"6>4Q^9C:NPD_
MP@@&1X&^#/P]_P""3'_!<+X2?L\_LGZ9+X7^$G[3W@/Q#%J_P\@U"633+#Q#
MHEO]L74K:.5V\AY+?; RKA6W$X)V[?T^K\P?"OQF^''_  5<_P""Z'PA^./[
M)VM+XM^%?[+_ ("\17&O_$*QM9/[+NM?UNW^QQZ9;S,H$\J0;9R4RJ[6YR!G
M].KMKA+61[.)7E$9,2,V S8X!/89H ^,OBW^V?\ \%>/!NI>(O%_@'_@D5HV
MM^#?#M[="VMY_CG:1Z_KMC"[@7=M:1V<D<;21J'2W>4RG<JX#' G_:"_X+(_
M##X:_P#!'>;_ (+!_!KX977C7PXVCZ5?6'A2^U<:7/(UWJUMIDMO+.L5PL4E
MO+-(&VHZLT!4'#!Q^<O[*/Q?_P""=GQI_9XU;XH?\%6/CG\5_'7[6TOB36+#
MQ%\$D^)7B?2]5@U=;Z=++1=(TC2[F!5B>,6X4J&C5I&+.@!"XO\ SHH_Y_Z*
M=0!]X_&/_@LK^UK^SIX>T3]JSX]?\$T+[PS^S=K&L:?:W7CN[^(EJ_B#1;"^
MG2&UU2^TA(3Y$;-+%N@\XR1^8 Q#_NZ]L_X* ?\ !13Q#^RG\0OAY^S+^SW^
MS_<_%CXT?%6>[/A+P3%KL>F6MM8VB![K4;Z\D1Q;V\8(Q\A,A#*O(->8?\',
MRJG_  0W^.R(H &G:&  . /[?TVO/OVZ?'V@_L+?\%;/V?/^"B_Q_-U8_"'5
M_@UJ'PVU_P 8BTDFM/"VJ2W"WMI/=E%8Q1W!)A$F, HQ8@+F@#C_ !E^TI^T
M%\8/^"\'[%?PI_:J_9=/PQ\<^#](^)5Y<0Z9XF36M&U>POM!A6WNK.]6*)B1
M)97*2021J\15#\RR*Q_6&OR=^(G[<WP"_;5_X."?V.)_V9?$*>+/"OA30OB+
M:R^/M+@=M*U'4)=#5YK&VN2H6Y>VC6W>0QED7[:@SNW ?K%0!\'?%_\ X((_
M\$=4\+^._C+^TU\)9]9O-174-;\7?$KQKXYU%KZQ0F2>2=)_/5+6.%<E!&BJ
MJH,AN<^'?L%_MK?M,?L^_P#!M!XN_:Z\?>)]8UO5_"&@>(_^%3^(O%B-)>WV
MF+<O;:/=7(D^:0+(ZX#?>BC3L0:\9_:Y_P""PG["_P#P4D_;!UW]E[]J[]K2
MV^%?[+_PN\0^1XA\-2VFH#5OBUJUM,?W4QM87-KI$4D>=A99)B%. Q4V_P!Z
M_'O4/V</^"OW_!('XL_"O_@GMXYT?Q%H6J>#[[PWX4_L?3Y+&SBU.S@BFMK%
M8YHXO*C#BV3A0BJ_'3% 'R?XD_X(I?L^^'?^".<O[8>F?V]!^U%IGPH/Q/?X
MYGQ+>C7Y/$Z:?_:<FZ=I<>2S!K;85P(R&(WC?7V7\+/"/@S_ (+*?\$L_A)X
MG_: UWQ-I=OXY\)Z+X@\2Q^"?$4VD27-\+;%S;F6 A_L[3&3,8(R O(Q7QOX
MF_X+8_LV>(_^"+LW[+^EZOJ=Q^TMJGPF/PQ/P/\ [#NCXB3Q4]A_9<B-:F/=
MY2R%I]['!1=N?,.ROM7X"^(/@Q_P1X_X)8_"S0?VQ/B78>%-*^'W@G1=$\3:
MU)#-<01ZH\2)*BBW1V93<LX5@I!&"30!\T?\&VWPG\#? ?QO^VC\%/AEI<ME
MX=\)_M2:MI.AVD]Y+</#:VZ"*)6EF9I)"%499V+$\DDU%\:?@[\.?^"DG_!?
MGQ=^R-^VW;3^(?AK\)/@IINO^ /AC>:E-!IFKZA>3HMSJ\T,;K]I>+S3;C=E
M5PO&0<^3_P#!"O\ X*G_ + 6A_M=_M0>!-5_:/TR'5OC?^U=J%_\*[)M,O2W
MB"VO9A':R1D08C$CLH E*$9Y KZ?_P""O$'_  1GNOC;X)G_ ."@/Q^OOA+\
M4],T":[\"^/_  SX@U+0=8CTUI7CE@CU"T38Z;R_[F0LR^8S*JB1BP!YU^P-
MJ7P^_8)_X+L?%#_@E5^SOJUQ:_";Q#\([/QUH_@=]6DNK?PEKRS1I<6UH)79
MH(KBWE%RT>< F/: N*_46OR(_P""+G[*_P #OBC_ ,%./''_  40_9&\%^)X
M?@EX<^'!\&>$/'WC:YOI]3^).O7-Z+K4=>:>_P W,\:*HM1(^U2%C"!=CHOZ
M[T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %8]M\// %EXC?QC9^!M'A
MU>3/F:K%ID2W+9ZYE"[CGZUL44 %9.@^ O WA6_N=5\+^#-)TVZO"3=W-AIT
M4,DY)S\[(H+<\\UK44 ?,W@+]A'Q'X=_X*<_%;]N#Q)XCT74?#'Q$^&.B^%X
M/#3VSO/%)9R.TCS!U\MHW#8 !)]17TAHVBZ-X=TR'1/#^DVUA96Z[;>TLX%B
MBB7.<*B@!1D]A5FB@ K-\3>#/!_C6UCL?&7A33=6@B??%#J=C'.B-_> <$ ^
M]:5% #+:VMK.W2TL[=(HHD"111H%5% P  . !Z4^BB@ HHHH S_#_A+PKX2B
MF@\*^&=/TQ+F8S7":?91PB60]78(!N8^IYIWB'PSX;\6Z:VB^*_#]CJ=F[!G
MM-0M$FB8CH2K@@G\*O44 5]*TC2M!TZ+2-#TRWLK2!=L%K:0K''&.N%50 !]
M*L444 %9%I\/O 5AXCD\86/@C2(=7ESYNJ1:;$MR^>N90NXY^M:]% !6=H_A
M#PEX>O[S5= \+Z=8W6H2;[^YL[*.*2Y;GYI&4 N>3R<]:T:* /-O$W[*7P@\
M8_M2^%_VP?%&FW=[XP\%^%K_ $+PLT]UFUTV&]DC:ZGBBQQ<2+$D1DSGR\KC
MDY])HHH **** ,ZY\(>$[SQ#!XNN_"^G2ZK;1F.VU.2RC:XB0YRJR$;E')X!
M[FM&BB@ J*_L+'5;*73=3LHKFVGC,<]O/&'21",%64\$$=C4M% %30O#^@^%
M]+BT/PSHEIIUE"#Y-G8VRPQ1Y.3M1  .23P*MT44 9W_  A_A+_A)/\ A,O^
M$7T[^V/)\G^U?L4?VGR_[GFXW;?;.*T:** "H-3TO3-;T^;2=9TZ"[M+B,I<
M6UU"LD<JGJK*P(8>QJ>B@"MI&CZ1X?TR'1=!TNVL;.V39;VEI L442_W550
MH]@*LT44 %%%% &<OA#PFGB1O&2^%].&KO#Y3:J+*/[28_[AEQNV^V<5HT44
M %9WB7P?X2\:6::=XQ\+:=JUO'()(X-3L8YT5QT8*X(!]ZT:* &PPPVT*6]O
M$L<<:A41%P% X  '04ZBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MQIX2\*^"/^#F#X/>&_!?AG3](TZW_9.UD06&EV4=O#&/[7DX5(P%'X"O6?\
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M;RZM<Q0L\5HDLGR1M*ZK&';Y5+@G@&O@7XR_\%7_ /@J3^R3X NOVD_VOO\
M@CK;:'\*]':*7Q;>^#_CAI^MZSH-FSJC7+6JV\:700L-RQNH .2P52U 'Z*T
M5D^ _&_ACXF>!M&^)'@G5%OM&\0:3;:EI%ZBD"XM9XEEBD (! 9'4X//-:U
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M.UB.A(J]]B\;_P#0;LO_  &/^-?,/_#TK_JA?_ES_P#W-1_P]*_ZH7_Y<_\
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MF[:6_5H^Y**_.[_ANG]JC_HJ7_E$L?\ XQ1_PW3^U1_T5+_RB6/_ ,8KW_\
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MX7? '3_A[HMUHWQC87O]F7LMM<OX7E2/5Y(YY %+"0M$<KY:EEQ@ G&<#"^
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M0 4444 %%%% !1110 4444 %%%% !1110!^47BK_ )&?4O\ K_F_]#-4*O\
MBK_D9]2_Z_YO_0S5"OZ-I_PUZ'X#4^-^H44459(4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MF\-IHD_C+5'TB[T3[2SP0WHE$:O&SY(1LY(/"\8[UA>!_C3X23X=Q?"?XO>
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M_P ->A^ U/C?J%%%%62%%%% !1110 4444 %%%% !1110!^IWPJ_Y)?X;_[
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M/?\ Y(GJW_8]ZS_Z4FO=* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^ U/C?J%%%%62%%%% !1110 4444 %%%% !1110!^IWPJ_Y)?X;_ .P!9_\
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MG_TI->Z4 8__  DNK_\ 0H7O_?2T?\)+J_\ T*%[_P!]+6Q10!C_ /"2ZO\
M]"A>_P#?2T?\)+J__0H7O_?2UL44 8__  DNK_\ 0H7O_?2T?\)+J_\ T*%[
M_P!]+6Q10!C_ /"2ZO\ ]"A>_P#?2T?\)+J__0H7O_?2UL44 8__  DNK_\
M0H7O_?2T?\)+J_\ T*%[_P!]+6Q10!C_ /"2ZO\ ]"A>_P#?2T?\)+J__0H7
MO_?2UL44 8__  DNK_\ 0H7O_?2T?\)+J_\ T*%[_P!]+6Q10!C_ /"2ZO\
M]"A>_P#?2T?\)+J__0H7O_?2UL44 8__  DNK_\ 0H7O_?2T?\)+J_\ T*%[
M_P!]+6Q10!C_ /"2ZO\ ]"A>_P#?2T?\)+J__0H7O_?2UL44 8__  DNK_\
M0H7O_?2T?\)+J_\ T*%[_P!]+6Q10!C_ /"2ZO\ ]"A>_P#?2T?\)+J__0H7
MO_?2UL44 8__  DNK_\ 0H7O_?2T?\)+J_\ T*%[_P!]+6Q10!C_ /"2ZO\
M]"A>_P#?2T?\)+J__0H7O_?2UL44 8__  DNK_\ 0H7O_?2T?\)+J_\ T*%[
M_P!]+6Q10!C_ /"2ZO\ ]"A>_P#?2T?\)+J__0H7O_?2UL44 8__  DNK_\
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M0'W_ /+,R8^;% 'U_1110!X7_P $]_\ DB>K?]CWK/\ Z4FO=*\+_P"">_\
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MMB9KS?YG]'89WP\'Y+\@K\T/VHO^3A_&/_8?N/\ T*OTOK\T/VHO^3A_&/\
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MKQ9:>/?A?^RM\-_#>NV'F?8=:T#P/I]G=V^^-HW\N:&%73<CNAP1E68'@D4
M>D4444 >%_\ !/?_ )(GJW_8]ZS_ .E)KW2O"_\ @GO_ ,D3U;_L>]9_]*37
MNE !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 ?S6?$?_DH>O?\ 8:NO_1S5C5L_
M$?\ Y*'KW_8:NO\ T<U8U?V!1_A1]$?R=5_BR]6%%%%:$!1110 4444 %%%%
M !1110 4444 ?T<?LW_\F[^ O^Q+TO\ ])(J[2N+_9O_ .3=_ 7_ &)>E_\
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M1110 4444 %%%% !1110 4444 %?O7_P2N_Y1^?#+_L"S?\ I5/7X*5^]?\
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MS\"^&_$VOV=]KGB'5M7MC:75Q+'9NZ6UM' <!7;>712-P<^7]9_ WX@?M?\
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MPY528XPR1AL#<4+;5W;0 ?1/_"2ZO_T*%[_WTM'_  DNK_\ 0H7O_?2UL44
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MQ;X@:ZQ4@G6;HD'M^]:L>MGXC_\ )0]>_P"PU=?^CFK&K^P*/\*/HC^3JO\
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M\,W4*LV&E=EPON:U***_"#]M"BBB@ HHHH **** "BBB@ HHHH \+_X)[_\
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M?_[FH_U1XA_Y\_\ DT/_ )(/]:<A_P"?W_DLO_D3ZVHKY)_X>E?]4+_\N?\
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M&K9^(_\ R4/7O^PU=?\ HYJQJ_L"C_"CZ(_DZK_%EZL****T("BBB@ HHHH
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MO^J%_P#ES_\ W-7R311_JCP]_P ^?_)I_P#R0?ZTY]_S^_\ )8__ ")];?\
M#TK_ *H7_P"7/_\ <U'_  ]*_P"J%_\ ES__ '-7R311_JCP]_SY_P#)I_\
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MYK!_:'^)_AWQYKFE^&? =M)'X:\*Z8NFZ(\X_>7"*?GG?T+GG'' ' )(K2^
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M?#^*?_(DH_\ 7Q?^DR/L_#/_ )'-;_KV_P#TJ)] T445^$'[:%%%% !1110
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M_(SZ;_U_P_\ H8K]7:_._$#^)A_27_MI][P-_#K^L?U"BBBOSH^]/YK/B/\
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MJ&'(I+V]O-1NI+[4+N6>>5MTLTTA9W/J2>2:BHHLKW"[M8****8C^CC]F_\
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M *^+_P!)D?:^&?\ R.:W_7M_^E1/H&BBBOP@_;0HHHH **** "BBB@ HHHH
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MZ*/[.P?\OXO_ ##^T<9_-^"_R/H#_ANC_JEW_E;_ /M%>G?L8?MD2>*_VKO
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MH:_H)K^?K_@HG_R?-\5/^QTO?_0Z_2O"O_D;5_\ !_[<C\\\3?\ D5T/\?\
M[:SQBBBBOW(_%@HHHH **** "BBB@ HHHH **** "OW7_P""7>NZE:_L#?#6
MWA\,W4ZKHTH$J,N&_P!*FZ5^%%?O7_P2N_Y1^?#+_L"S?^E4]?F7BG_R)*/_
M %\7_I,C]'\,_P#D<UO^O;_]*B>VV>O:E<W203>&;J%6;#2NRX7W-:E%%?A!
M^VA1110 4444 %%%% !1110 4444 >%_\$]_^2)ZM_V/>L_^E)JE_P %4?\
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M)*:E.+Y;V]V3CUUZ;]>RV.7-L)AL'BU##MN#C"2YK7]Z*ET]?^"]SZ!\'_\
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M_P"QTLO_ $.NO-O^15B/\$__ $EG+E7_ "-*'^./_I2/Z!:***_DL_J4XO\
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M 4444 %%%% !1110 4444 ?T<?LW_P#)N_@+_L2]+_\ 22*NTKB_V;_^3=_
M7_8EZ7_Z215VE?R'B_\ >ZG^)_F?U9A?]UI_X5^05_/U_P %$_\ D^;XJ?\
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M">D__;3]>\+OX6*]8?\ MP4445^0GZL?S6?$?_DH>O?]AJZ_]'-6-6S\1_\
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M^C9/BG_X1 _^2*/^'>_[67_1LGQ3_P#"('_R17[^45]9_K_Q;_T$_P#DE/\
M^0/E_P#47A7_ *!__)Y__)'X!_\ #O?]K+_HV3XI_P#A$#_Y(H_X=[_M9?\
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M.]_VLO\ HV3XI_\ A$#_ .2*_?RBC_7_ (M_Z"?_ "2G_P#(!_J+PK_T#_\
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MH_X=[_M9?]&R?%/_ ,(@?_)%?OY11_K_ ,6_]!/_ ))3_P#D _U%X5_Z!_\
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MT;)\4_\ PB!_\D4?\.]_VLO^C9/BG_X1 _\ DBOW\HH_U_XM_P"@G_R2G_\
M(!_J+PK_ - __D\__DC^>_PG^Q1^T;XXTV35_"OP"^(VHVT5U);R3V'A%946
M6-MKH2+CA@>".U:G_#O?]K+_ *-D^*?_ (1 _P#DBOV(_P"">_\ R1/5O^Q[
MUG_TI->Z4?Z_\6_]!/\ Y)3_ /D _P!1>%?^@?\ \GG_ /)'X!_\.]_VLO\
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M*_M/_L\>!OVC_ T4D6C^._"6GZ]IT$S R0Q7=NDZQOC^-=^UO=37;4 %%%%
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M*QTS7KRS:PU"%&$<UO<VKP2@Q[W"M\H(/*\XKQO]G[_@AI_P3E_9W^,6D_M
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M/ZA_P;R_$#X_VGB6Q?P[XS_9OELM#N!,I66YU72Q96T(_P"FGGW*(5ZJRD$
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M7]GK7O\ @IOX'T[]EWPEX0U%#XEU'P,X\;VN@.KD:+;7)N/LAED1S:13F-I
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M5]Z_!WP9??#GX1>%?A[J=XMQ<Z#X<L=.N+A"<2O!;I$S#/."5)_&O$_V5/\
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MZ?+::M8?"G1CJ%E/&4DMI)+5)3"ZGD.F_8P[%37T?0  , 44 %%%% !1110
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M?#_COX Z;X(\6:9'>Z5K/@^&QU.SESMGMYK41R1G'.&5B#]:\2_:^_X(W_\
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MY;AH^<;<<5]KVMK;6-M'965O'###&$BBB0*J*!@* .  . !0 ^BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH YCXV?$;_ (4]\&O%
MWQ<_L;^T?^$6\,7^K_V?]H\G[5]FMY)O*\S:VS=LV[MK8SG!QBOSP_XB,O\
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M&/\ @JS^QG\.O'7[.<7B;QIXK'Q$_P"$!^(1\4W%HW@S[-H4$M]MLXT,5_\
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M7_A9OBWQ)XYCT#0= N[F/S8-/27R)Y+RZ,8+.D:A8L@,Q(95M?!#_@KQX/\
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M>*/A'\8Y=!;Q!XME\:II-YI\<NL62)I3V?DR-*9Y/,M9F651"4?(D4D'[?\
M^";7PFN/A;\']7AUK_@G!\./V9]2N=?*2>$?AOK.GZC!JEM';P^5?SW%E96J
MM*6>:+8Z,X$(;>?,P #Z(HKP'Q_^W)_PK;_@H[\/_P!@GQ/\+O*L?B7\.]6U
M_P +^.?[;_U^IZ=,GVG2_L?D_P -JXN//$W^QY?\=>:?L@?\%?\ PG^UK_P4
M9^,/[ 6G_!JXT2/X9?;1H7C277?.B\3O87<-EJ:QV_V=/(-O<SI&<2R[N3\N
M,4 ?9-%?$GA+_@MI\)G_ &!/B=_P47^*/PLOM$\#>#?B-J_ACP5;Z1JPU*\\
M:Q6MZEC:7-NAAA$4EU<ET$.9%C$98RL =O)^)?\ @KU^VE^R]:^$_C#_ ,%%
M_P#@FFGPO^$/B[6K/3+OQEH7Q0@UN\\'2W;!+9M7LUMHMD19@))(W81'Y2&<
MJC 'Z#UE^(/&_@OPE?:;IGBKQ?I>F7.M7@M-'M]0U".%[ZX()$,*NP,LF 3M
M7)P.E?)?[=?_  59\9_LC_ME_#C]B7X7_L>ZO\5/%?Q2\):CJ?A:'1O%,-@S
M7EM)@6\OG0F.&W\L232W32 1)$Q$<API\!_;V\:_M,>/OBW^PAK_ .UG\#M%
M^'OB[_AK!(Y/#V@>*UUFV%L+&;RI1<B*/)8$Y4H,%?<4 ?J-67;^-_!=WXNN
M/A_:^+]+EUZTLTN[O1(]0C:\AMW;:LSPAMZQD\!B,$\9KY0_:@_X*4?&_1/V
MP6_8*_8*_9/M_BW\0]$\-P:_\0K_ %SQBFA:+X4LKAL6L<]QY$SRW,P&Y850
M$(ROEAO"_.W_  3J^/'CKX^_\' _QQUOXL? K4_AMXOT/]GK0]'\4^$-2U&*
M]6TNXM2\P/;W<("7=M)%-#+',%0LL@!56!4 'ZF4444 %%%% !1110 4444
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M9-8-?^.+.^C@D4\I(D5Q&KH>5<,#@C%?:W_!S+&D7_!#;X[11(%5=.T,*JC
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M?^".VFZW^T-^S!X9U/Q1XCUWQ/9W/CB"P6'6K?9JEU%#+%=IAU>(!=N25^0
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MY;K!2*92_FJCE0(]N3ET#97_  3H_:@^'G[7W_!PA\>?C1\'[*[E\(7'[/\
MH=IX:\0W.G2VT?B&WAU!4:_@$JJSP--YT4<N,2+ &7*D&OU!\0^&/#7B[3O[
M(\5^'K'4[3S%?[+J-HD\>Y>C;7!&1V/:KD444$2PPQJB(H5$48"@= !V% #J
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
7"BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>biib-20200930_g6.jpg
<TEXT>
begin 644 biib-20200930_g6.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?@3XCT'3M*UF*X=9+Z*_TXW4CW!D;8I5AM&W QUYKZ6M;JVO;:.\LKB.:&5
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MOAXOPXO_ !M\7V\!>.[+1M2NGMO$>DWMC/(5O(YI7$SQO#O61OFWD,2S(A4
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MER6*CW.:]:T[7]"U>XN+32=:M+J6TDV7<5O<J[0MS\KA22IX/!]*_$WXL?M
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MIBO8* /C3XL_\$(O^"6'Q?\ 'WC?X\_M.?!";QSK_BV_N]1UOQ#XT\8Z@_\
M9\+LTA@MMD\<=E;Q D)Y:J54#+'&:^?O^"+O[1OCKX'_ /!*3]H[XTCQ?K7C
M3X5?!_QSX[N?@%KOBFZ>:?5?"&DVQFM0)F^:6W#Q2HK]CO0!5157R3_@IK_P
M6"_99_:W_;/\3?\ !,;XO_M;+\%O@/X U%['XV^(1;7HUCQ[>Q2%)O#UB;:%
MVMK)71DN;AMK2@%$RAS)]W_"'XB?L%_\%)/^"=WQ&_9@_P""=OQ'T"_\#CP#
MJ7P_ACT/2KFTM-&^U:9)!'"$FBC;"QS*V0#GN2<T ?'/['W_  1@^ '[:O\
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M6UU"LD<JGJK*P(8>QJ>B@"MI&CZ1X?TR'1=!TNVL;.V39;VEI L442_W550
MH]@*LT44 %%%% &<OA#PFGB1O&2^%].&KO#Y3:J+*/[28_[AEQNV^V<5HT44
M %9WB7P?X2\:6::=XQ\+:=JUO'()(X-3L8YT5QT8*X(!]ZT:* &PPPVT*6]O
M$L<<:A41%P% X  '04ZBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BO$OV"-4U/5_@UJMSJVHSW4B^-]819+B9G8*+D@+EB> .@[5[;0 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110!X7_P $]_\ DB>K?]CWK/\ Z4FO=*\+_P""
M>_\ R1/5O^Q[UG_TI->Z4 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >%_P#!/?\
MY(GJW_8]ZS_Z4FO=*^>OV"]8O[#X.:M!;:!<7*_\)QK)\R(C&?M+<<U[;_PD
MNK_]"A>_]]+0!L45C_\ "2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM &Q16/\
M\)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+0!L45C_\ "2ZO_P!"A>_]]+1_PDNK
M_P#0H7O_ 'TM &Q16/\ \)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+0!L45C_\
M"2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM &Q16/\ \)+J_P#T*%[_ -]+1_PD
MNK_]"A>_]]+0!L45C_\ "2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM &Q16/\
M\)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+0!L45C_\ "2ZO_P!"A>_]]+1_PDNK
M_P#0H7O_ 'TM &Q16/\ \)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+0!L45C_\
M"2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM &Q16/\ \)+J_P#T*%[_ -]+1_PD
MNK_]"A>_]]+0!L45C_\ "2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM &Q16/\
M\)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+0!L45C_\ "2ZO_P!"A>_]]+1_PDNK
M_P#0H7O_ 'TM &Q16/\ \)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+0!L45C_\
M"2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM &Q16/\ \)+J_P#T*%[_ -]+1_PD
MNK_]"A>_]]+0!L45C_\ "2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM &Q16/\
M\)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+0!L45C_\ "2ZO_P!"A>_]]+1_PDNK
M_P#0H7O_ 'TM &Q16/\ \)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+0!L45C_\
M"2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM &Q16/\ \)+J_P#T*%[_ -]+1_PD
MNK_]"A>_]]+0!L45C_\ "2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM &Q16/\
M\)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+0!L45C_\ "2ZO_P!"A>_]]+1_PDNK
M_P#0H7O_ 'TM &Q16/\ \)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+0!L45C_\
M"2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM &Q16/\ \)+J_P#T*%[_ -]+1_PD
MNK_]"A>_]]+0!L45C_\ "2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM &Q16/\
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MK5KIMZCRQVTKW5H%6X@?;%-\H5MC[2JL"!\.?LV_&3_@JI\&O^"SWA#]B_\
M;1_;4\._$3PYXN^"6I^+IM \+?#>QTBRTZZBO/L\:1S[7NY@NQCEI%!W %#C
M- 'Z8T45\&?\%E?V@/VK_AS\:_V:O@+^S'^V);_!"'XJ>,=<T_Q5XUN_"6E:
MQ';6]IIGVN-FBU)#&H#(5R'C^_R3@"@#[SHKY<_8*^"/[:_@SQ7??$CX^_\
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M+_P3^M%\+>&_C%\-_$5W\;?ACH5\[:78)96LDVF:K]E+,MM))<)Y *A1@,%
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M #\WO_@6U'_"#Z1_S\WO_@6U;%% &/\ \(/I'_/S>_\ @6U'_"#Z1_S\WO\
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M+_X)[_\ )$]6_P"Q[UG_ -*37NE !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?
M#NN?\AJ\_P"OJ3_T(U5JUKG_ "&KS_KZD_\ 0C56OYBJ?Q'ZGY+/XV%%%%02
M%%%% !1110 4444 %%%% !1110!]L^"?^1,TC_L%V_\ Z+6M.LSP3_R)FD?]
M@NW_ /1:UIU_3.%_W:'HOR/UBC_"CZ(*^._C3_R5CQ!_V%)?YU]B5\=_&G_D
MK'B#_L*2_P Z^#\1?^1=1_Q_HSYSBC_=:?\ B_0Y>BBBOR(^*"BBB@ HHHH
M**** "BBB@ HHHH *^N_V?\ _DCNA?\ 7JW_ *,:OD2OKO\ 9_\ ^2.Z%_UZ
MM_Z,:OO_  [_ .1M5_P/_P!*B?2<,?[Y/_#^J.QHHHK]A/N HHHH **** "B
MBB@#\^9?^"BWQ"^#$W_!0;XW?%/XCI<V?P&U&T@\!^";](HX=.C7PY;W%J1M
M59'^WWTY&79LD )@#%>3?LA:1^W=^Q?^T)^R7XZ^/O[=?Q%^*-Q^U-9ZC;_%
M3P!XWO4GL-!U)M$?5X)=(A"C["EN\9@D1?D96)"I\JKI?\%3M=_X(-3?MU0'
M]IO]D[Q=\8_CKH6FV%YK_AWX5>&=6U6>.VC"R61U:WLYHK6XPNPHEQO;R_+#
M+Y;(#Z7\%_V\?V0_V]_V]_A)KUY^Q!^TSH'CKP?:Z]#X#\3>/?AE>Z1H.B_:
MM.D-[).YF,0DE@M_(1W5CN=47&\F@#] J*** /"_^">__)$]6_['O6?_ $I-
M>Z5X7_P3W_Y(GJW_ &/>L_\ I2:]TH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@#X=US_D-7G_ %]2?^A&JM6M<_Y#5Y_U]2?^A&JM?S%4_B/U/R6?QL****@D
M**** "BBB@ HHHH **** "BBB@#[9\$_\B9I'_8+M_\ T6M:=9G@G_D3-(_[
M!=O_ .BUK3K^F<+_ +M#T7Y'ZQ1_A1]$%?'?QI_Y*QX@_P"PI+_.OL2OCOXT
M_P#)6/$'_84E_G7P?B+_ ,BZC_C_ $9\YQ1_NM/_ !?H<O1117Y$?%!1110
M4444 %%%% !1110 4444 %?7?[/_ /R1W0O^O5O_ $8U?(E?7?[/_P#R1W0O
M^O5O_1C5]_X=_P#(VJ_X'_Z5$^DX8_WR?^']4=C1117["?<!1110 4444 %%
M%% 'Y21_M]_#O_@F!_P59_:9\,>+OV7/C3XPT#XG:QH?B!_&/@GX976H"QU&
M+28(9;!I!A;FVV[)(I8V)CDEFB9!M\QOIS]ES_@M#^SW^UE\=M"_9^\#_L\_
M'C0M4U_[5]EU7QG\)[O3--@\BUEN6\ZYD.V/<L+*N?O.R+U:N'^/G[8O_!37
M]IC]KSQY^R-_P2R\'?##0M'^$<EC9_$CXK_%HWD\#ZK=6R72Z;IUK:?,[QPR
M1F220%<L5^3"&23]G7]LG_@I5^SO^V+X(_8N_P""IO@KX9:Q:?%B#44^&'Q6
M^$KW<-K+J-E;-=3:;J%K=_-%*T"NT<B;4)0*!(68Q@'WG1110!\]?L%ZQ?V'
MP<U:"VT"XN5_X3C63YD1&,_:6XYKVW_A)=7_ .A0O?\ OI:\C_X)[_\ )$]6
M_P"Q[UG_ -*37NE &/\ \)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+6Q10!C_\
M"2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM;%% &/\ \)+J_P#T*%[_ -]+1_PD
MNK_]"A>_]]+6Q10!C_\ "2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM;%% &/\
M\)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+6Q10!C_\ "2ZO_P!"A>_]]+1_PDNK
M_P#0H7O_ 'TM;%% &/\ \)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+6Q10!C_\
M"2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM;%% &/\ \)+J_P#T*%[_ -]+1_PD
MNK_]"A>_]]+6Q10!C_\ "2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM;%% &/\
M\)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+6Q10!C_\ "2ZO_P!"A>_]]+1_PDNK
M_P#0H7O_ 'TM;%% &/\ \)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+6Q10!C_\
M"2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM;%% &/\ \)+J_P#T*%[_ -]+1_PD
MNK_]"A>_]]+6Q10!C_\ "2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM;%% &/\
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MZ^1[O^R9^VQ8_M-^ _&%QJOPJU;PKX[^'6J3Z7XZ^'MS<QW5U8WJ1F1%AEC
M6YBE4'RI0 'P<#C)\A\8?M_?\%&? O@B^^.OB?\ X)5W%GX&TJT>^U.V?XI6
M3Z]#8(I>2Y-FD) 94!8P;M_!&1V\[_X)3:O\;/%'_!3G]J_QA\7O!,7AK4-3
M@\,7&K>';;4$NQI;O;2M9VTLT7[M[A+7_6;"0'+C/%>O_P#!0+]IWQAXRU6Y
M_P""=?[(%K%K7Q9\;Z.\&O7P^:R\#Z-.OES:E?./N2&-SY,7WF9E;!S&LA+!
M8>AFKP\:,91:A)WE*T(N*E*TE):*^C=]+6NWJ.A3IXSV:@FFHMW;M%-)O5/9
M7W=^AVGQK_X*!^!?A_\ \$]KS_@H5\,_"\GBS04\.V>KZ;I$]]]@DN4GGBA\
MIY/+E\IT,A##:WS1D>]<Y\)OVLO^"D/COQ=X=M/&G_!+.U\.>&M7OK4:GXD7
MX[:9>'3K.5EWW/V9+97F*(2_E@AFQ@$$UL^-O^"=?@GQ'_P3CC_X)S^'?'-W
MI6BIX<L=)/B!K)9YV$-Q%/+,8]RKOE>-SC.%,G0@8/S_ /M5V7[8O_!*;P%I
M'[6&C?MJ>)/B=X$T/6M/L?'G@7QYI5F3+83S)!YME/;Q(T,B,Z[4 QR"2P4H
MV>$H99B8RH45&524Y*//[1-QLN1+E:C=N_Q=;7T)H4\)53ITTG-R:7-S;:<M
MK-*^^Y^A=?-G[4/[=GC[X;_M%Z)^QS^S%^SVWQ(^)6K>&9/$5_:7?B*/2M.T
M72EF, N;BX:.0DM*-HC5<_,O/S*#])U\"_M5Q?$OXE_\%7]$\/\ ["EW8^'O
MBUX3^%Y_X6%XR\22^;HS>'Y[H/!ILMDL9EN9S,4F5XY(MBD99^ GGY10HU\1
M+VJ348R>K:BFMG*S3M?MJW9'-@J<*E5\ZNDF]=OG;6WIU/;/V4_VY_''Q9^/
MGB7]D3]H_P" $GPX^)OAOP_%KZ:;;:_'JNGZMI+RK#]LMKE$0X65U1D9<@MC
M)(8+]'5\%_L;Q_$?X:_\%3/&?A']MV>UU[XQ^*?AG#=^#?&GAR41Z*_AB&[Q
M)IT%H8UDM9EN5\Q_,>;S-N0R8'F?>E&;T*-#$Q5)))QB]&W%MK5QO=VOWU3N
MA8VG"G57(M&D]-MNE];>I]L^"?\ D3-(_P"P7;_^BUK3K,\$_P#(F:1_V"[?
M_P!%K6G7]"X7_=H>B_(_3:/\*/H@KX[^-/\ R5CQ!_V%)?YU]B5\=_&G_DK'
MB#_L*2_SKX/Q%_Y%U'_'^C/G.*/]UI_XOT.7HHHK\B/BCY^_X*D^'?VBO%?[
M"OCO0?V65U5_%\]I;>5!H-R8=0GLQ=1&\BM7'(F:V$RJ!\QR0N6*U\0?L26_
M_!&O7/VL_$'AV[\"_P#"O/%=GXJT&[^&NC^-8]2T76;6YBL;4R1/+*X$LKWB
MONBDD?SBYX<.,_IA\=->^-7ACX<W.O? #X?:3XJ\26UQ T/A_6=:.G17L/F+
MYR+<;'$4GE[BA92NX 'BOSG^+GPK_:__ ."AGBWXT?LWWO['MAX#/B7QKX7N
MO$?C#Q-XSTZ^D\'"VT^Q?=:):%WN+B6*+Y60HH28HY4E@/K,BJ\V!J49SY(;
MN2FHR5W!.\7K))+2W>44[R/9R^=\/*G*7+'NI)-7<=UNTNGS2W/8O^"L>HV/
MPK_:8_9M_::T6WB\6^*_"'B76+70?A%#!--J'BE+VUCBFFL5BBD"36H"S;Y0
MD8^7,B$*&Y?P9\5+_P#:P_X*\_"[QG\6OA+JWP5U7X=^"M:?PQX<\;VQ35O&
MYO+=H95A>)6MF@M4:24H)WD#,3Y87>R^H_MT? ?]I#0/VK_A)^W?^S9\-(OB
M'<_#W2]3T7Q)X'EUB*RN[NQNX]OVFTEG(C\U"7+*2"^%49R<<W;^"OVMOVY?
MVXOA#\>?B3^R]?\ PC\!?!I]5U"*3Q/K=I<:KKE]>6ZP"&.&V=_)B38C%G.&
M&['. +PU2@LO@VXZ4JD>;F2E%MS]Q0OK>^]F_>;37+I5*5/ZK'5:0DKW5U?F
M]WEZWOV>^^FGCWP]^+_[1/CS_@L!^T-JGP+_ &?]%\<^-_#,>F:!H6M^,M<-
MCI/A#1(83YJ*Z1RRM-=W#%@D:C[LK$[<BOKO]BG]M/Q%^T'X[\>_ /XX_"!/
M 7Q5^&US:Q^*-"MM2%[:7EI<(9+:]M9]JF2)UR=I&4WKDY;CS3QI\+OVD?V)
M_P!NCXA?M8? /]G6[^*7@OXR:5I8\7Z%X?U>VM=5T75;"-XHIXTN659X)4D8
ML%8,'=B<!1OV/V+?@7^TQ/\ M _&']OKX_\ PTM/"7B;X@:78Z7X/^'8UB*Z
MDTZPL82(S=W$68S+,X1B%)\L;L]<+&/E@L5A74M%)4Z:@U+WN9**<7'FT7Q7
M]U+12O=ZSB70JT>:RLHQ2=];JR:M?;?IYWUUC_X*1_M9?&+X/?#/QO\ "_P=
M^P3XI\:>'YO"LEK/XMC$,FB6T$]NR2R300B2Y>*!6+2*L/*H<$#FO1O^"87@
MGP7\._V OA9X/^'OQ3M/&ND6GAA#;>)K!76&\9Y'DDV+( Z*DCO&$<*ZB/:R
MJP*CS+Q%^VK_ ,%*-6\/77@OPS_P28URR\77-J\$%YJ?Q&TF;1+:5@5$SSJP
M,T:YW% JLX&W@G-;?[-W[/'[1G_!/3_@E]HWP2^"7A;2OB%\3?"^F236NCS:
M@MM97U]=7[7%Q$LTSQ!8XUGE"LS(6\H' +;:YJ])0RN.'?)&;G'::DI:-<TG
MS-1MIK=)\STT,JD%'!JD[*3DMI)WT:N]7:WR6K['T]J'ASP]J^HV6L:KH5G=
M7>FR-)IUU<6J/):NR[6:-B"4)4D$KC(XKX@^/%[H_P"VA_P58^$WA#X#:?'>
M#]GJ_O=6^*'CRT \K3WN(A'#H:RCB2:1D8R1Y^12W\22*/2/^"B>L?\ !176
M/V6=&\*_L7?"<3^-_$XAM_&-[8>(K"TN/#MLT(-Q]D>[G2-IBY,:2*S; "P&
M=KKR/[#=S^T[^S=X?\+?LY^%/^"2^J^"?"']H(NN^*[SXQ:#J%P'D8"?4KI8
M7\V[F/WFVC) "J JJHC 47AL++%1G%SM*,8\\%9--2DTY)O1OE26KU>EDYPU
M-TJ+JJ2<M4ES)6TLVTWYZ+KOZ_:-?7?[/_\ R1W0O^O5O_1C5\B5]=_L_P#_
M "1W0O\ KU;_ -&-7O\ AW_R-JO^!_\ I43TN&/]\G_A_5'8T445^PGW 444
M4 %%%% !7SY_P4M\<_L\?#[]G6#7OVF_V(O$/Q^\.'Q);1)X%\,_"^W\77,=
MR8YBEX;&?Y D8#J9>JF4#^(U]!UY?^UGJO[8.C_#BQNOV)_"?@/6/%;>(+9-
M1M?B'?W5O9)IA#_:'1K8%S.#Y>P'Y3EL]J /S1_X:F_X([_]*OOQ@_\ $%=(
MKU_]@KX^?\$V?&O[6/A3PS\ ?^"#WQ(^#'BVY^W?V3\2M?\ V4-.\-6FC[;"
MX>7S-2A^>V\V)9+<8_UC3K&>'->N?M->-/\ @NSI7QRUZP_9%^"G[-NJ_#J.
M2#_A&[_QUXDUB#595-O&9O/2W'EJ1.90NWJ@4GDFI/V7/&?_  7/U;X[:%I_
M[8WP7_9PTGX<2?:O^$CU#P%XCUB?5HL6LIM_(CN!Y39N! K[ND9<CD"@#Z_H
MHHH \+_X)[_\D3U;_L>]9_\ 2DU[I7A?_!/?_DB>K?\ 8]ZS_P"E)KW2@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** /AW7/^0U>?\ 7U)_Z$:JU:US_D-7G_7U
M)_Z$:JU_,53^(_4_)9_&PKRG]HGX+?M!?$?6='\3_L_?M8WWPWO=-@FAO+*;
MPK:ZSINIH[(P,UO,T;JZ%#M>.5#AV!R*]6HIT:LZ%13C:_FDU]S37X#A.5.7
M,OQ2?X/0^'_^"</[!GCNWT3X3_M+?M/?&+6/$.L^!?"]W:_#_P &S^&H])M?
M"_VQ3%<NZ M+<W#QC;OD( 4\)D*1Z]^T-\%O^"A7BKXD7>O?LV?MK>'/"/AN
M_MH8QH&N_#6'49=,D5-KS03^:IE+GY]DB[5/ .#BOH*BNZMFN)K8MUY*+W23
MC%I)N]DFK;N][7;;;W9O/&59UG4=O1I-)7OM:W]>9XE^RE^Q;I/[)OPD\1^%
MO"WQ'U'6?&_C&_NM6\6_$?6[1);S4]7F4C[4\6=HCC)&R ':H!&269C\]?L\
M_P#!*?\ ;A_9>B\0R?"7_@I_IL%_XLUJ35?$^MZG\"+2]O\ 5+M_XYKB?4&D
M<#)VKG:NYB "S$_>5%$,WQ\'4?,GSV<KQC*]MOBB[)=$M/N".-Q$7+5/FWND
M]MMTSR#Q1\'/VK=7_9IL?ASHG[7\6G_$JSFCEG^)<7@&V,-X5F9S&^FM*8E1
MHB(CAR1C>.>*\/\ $/\ P3E_:Q_:=\2^'K3]OK]L[3?%O@7PWK<&K#P%X.\#
MQZ5!K-U"VZ)KR<RN[1@YS$!@@\%2 U?9]%31S/%8>[I\J;;=^2-U?L[77E:U
MNEA4\76I7Y;)][*ZOV=M/EMT/-_C-\'/BG\1OBA\._&_@3]H'4?"6D>$=8GN
M_$_ANST\S1>*('1%2VE?SD\I4*LP.V3.[H*\K_:1_82^*GBC]IJT_;/_ &2/
MVAHOA[X__P"$;&@>(;?5_#JZII6OV"R>9&DT7F1M'(C8Q(I)PB@!>2?IRBLZ
M&.Q.':<&M$ULFFF[M.ZUU[WMI;9$T\15I-<O16V6S[]_F?-'[,G["OQ)\#_M
M(ZI^V9^U7^T"OQ$^(U[X:'A_2/[,\/KIFEZ#IGFB9X+>$/(SLT@+&5F!^9AC
MDFOI>BBL\3BJV+J<]1ZI)*R222V22LDB*M6=:7-+T[:>B/MGP3_R)FD?]@NW
M_P#1:UIUF>"?^1,TC_L%V_\ Z+6M.OZ1PO\ NT/1?D?JE'^%'T05\=_&G_DK
M'B#_ +"DO\Z^Q*^._C3_ ,E8\0?]A27^=?!^(O\ R+J/^/\ 1GSG%'^ZT_\
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M_C1]B\;_ /0;LO\ P&/^- &Q16/]B\;_ /0;LO\ P&/^-'V+QO\ ]!NR_P#
M8_XT ;%%8_V+QO\ ]!NR_P# 8_XT?8O&_P#T&[+_ ,!C_C0!L45C_8O&_P#T
M&[+_ ,!C_C1]B\;_ /0;LO\ P&/^- &Q16/]B\;_ /0;LO\ P&/^-'V+QO\
M]!NR_P# 8_XT ;%%8_V+QO\ ]!NR_P# 8_XT?8O&_P#T&[+_ ,!C_C0!L45C
M_8O&_P#T&[+_ ,!C_C1]B\;_ /0;LO\ P&/^- &Q16/]B\;_ /0;LO\ P&/^
M-'V+QO\ ]!NR_P# 8_XT ;%%8_V+QO\ ]!NR_P# 8_XT?8O&_P#T&[+_ ,!C
M_C0!L45C_8O&_P#T&[+_ ,!C_C1]B\;_ /0;LO\ P&/^- &Q16/]B\;_ /0;
MLO\ P&/^-'V+QO\ ]!NR_P# 8_XT ;%%8_V+QO\ ]!NR_P# 8_XT?8O&_P#T
M&[+_ ,!C_C0!L45C_8O&_P#T&[+_ ,!C_C1]B\;_ /0;LO\ P&/^- &Q16/]
MB\;_ /0;LO\ P&/^-'V+QO\ ]!NR_P# 8_XT ;%%8_V+QO\ ]!NR_P# 8_XT
M?8O&_P#T&[+_ ,!C_C0!L45C_8O&_P#T&[+_ ,!C_C1]B\;_ /0;LO\ P&/^
M- &Q16/]B\;_ /0;LO\ P&/^-'V+QO\ ]!NR_P# 8_XT ?&NN?\ (:O/^OJ3
M_P!"-5:LZR&&L78<@G[3)DCUW&JU?S%4_B/U/R6?QL****@D**** "BBB@ H
MHHH **** "BBB@#[9\$_\B9I'_8+M_\ T6M:=<KX/L_&3>$=+,.LVBH=.@V*
MUL20/+7'>M+[%XW_ .@W9?\ @,?\:_IG"_[M#T7Y'ZQ1_A1]$;%?'?QI_P"2
ML>(/^PI+_.OJS[%XW_Z#=E_X#'_&OD[XOK<I\3]=6\E5Y1J,GF.BX!.>PKX/
MQ%_Y%U'_ !_HSYSBC_=:?^+]#G****_(CXH**** "BBB@ HHHH **** "BBB
M@ KZ[_9__P"2.Z%_UZM_Z,:OD2OJCX&VOBN3X3Z*]AJMK'";9MB/ 20-[=37
MW_AW_P C:K_@?_I43Z3AC_?)_P"']4>B45EV=IXM2Z1[[5K5X@W[Q$MR"1[&
MM2OV$^X"BBB@ HHHH **** /B/\ :D_X(/?LR?M8?M4:M^V)XP_:-^/7AWQC
MJEK%:QOX*^)K:=;Z?;)#''Y%JJP,T$3&,2,BMM:1W8C+5N_LN?\ !&OX3?LI
M?';0OC[X9_;#_:/\57V@_:O(T'Q[\7I]4TFZ\^UEMCY]J\8$NU9BZ9/RR(C?
MPUK_ +7?_!9K]@;]BKXQ)^SQ\6/B1K.I^/?L,=Y=^$/!7A*^UJ^LK>0 QR7"
MVD3K#N#*P5V#E75MNU@34_9F_P""SO[(7[6'QNT3X ?"[PO\5+?7=?\ M/V&
M;Q)\*M5TVR7R+:6Y?S+FXA6./Y(7"[B-S%5'+ 4 ?6=%%% 'A?\ P3W_ .2)
MZM_V/>L_^E)KW2O"_P#@GO\ \D3U;_L>]9_]*37NE !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 ?#NN?\ (:O/^OJ3_P!"-5:M:Y_R&KS_ *^I/_0C56OYBJ?Q
M'ZGY+/XV%%%%02%%%% !1110 4444 %%%% !1110!]L^"?\ D3-(_P"P7;_^
MBUK3K,\$_P#(F:1_V"[?_P!%K6G7],X7_=H>B_(_6*/\*/H@KX[^-/\ R5CQ
M!_V%)?YU]B5\=_&G_DK'B#_L*2_SKX/Q%_Y%U'_'^C/G.*/]UI_XOT.7HHHK
M\B/B@HHHH **** "BBB@ HHHH **** "OKO]G_\ Y([H7_7JW_HQJ^1*^N_V
M?_\ DCNA?]>K?^C&K[_P[_Y&U7_ _P#TJ)])PQ_OD_\ #^J.QHHHK]A/N HH
MHH **** "BBO-_VM/B-^T1\*/@-K/CK]E3]G*/XL>.;.2U&D>!)?%EMH:Z@K
MW$:3-]LNOW47EPM)+AOO>7M'+"@#\XM/_P""C/[+W_!+C_@K5^U'X1^,G@3Q
M]JT/Q*UG0=?'C+PU\/+V_P#[/N(](@BDTJ>1(\RQJ"DT+P^8B^?+&^QDRWU-
M^RY_P6^_8B_:_P#CMH7[.OPAM/B0OB+Q#]J_LYM?^&>I:?:#R+66ZD\RXGB6
M./\ =POC<1N;:HY(KR__ (>#?\' /_2O=I__ (E-X;_PKT3]E']L3_@L#\5/
MC[H'@+]J3_@CE9_"KP)?_:O[=\>Q?'W1-;;2]EK-)#BRM1YLWF3I%#\OW/.W
MGA30!]ET444 >%_\$]_^2)ZM_P!CWK/_ *4FO=*\+_X)[_\ )$]6_P"Q[UG_
M -*37NE !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !117
MBG[:_P#P4 _9=_8*\%6GB']H;XJV>BZCKJW$7A'0DL;F^O\ 6KF*/<8[>TM(
MY)Y54M&'=4VIO7<RY% 'M=%?+W_!-K_@JG^SG_P41\ :'9^"_%,EO\18_ FE
MZ]XU\'W/AK4]/_LY[B&+S&@:]@C6YMQ,Y1)HFD5AM.XYS7E7Q#_X*M_MXZO^
MV;\8/V3?V-?^"4EM\6K;X-ZCI%GK_BB?X\Z?X?\ ,DU#3HKZ+%M=V3$8#R)\
MLC_ZO)*[@H /O:BO./V5/B3^T/\ %CX.VGC/]J+]FB+X2>+YKN>.[\%P^-K;
MQ MO$CD12_;+:..-_,7#;0N5S@YKY>_X+ ?\%N?"?_!+&?0_"OAGX!W7Q3\4
MWMK'JOB31;+Q&-,B\.:))=QV,-_=3_9[C'G7DT<,46P%RLK;E$>& /NBBO+?
MVO/BI^TY\'OA3'XL_9,_90A^,GBEM6AMY/",WCZT\-A+1DD,EU]KNHI$.QEC
M7R]N6\S(/RFOB;XG_P#!:/\ X*3_ +/OQ<^%7PG_ &C?^"+=EX5G^+WCRU\+
M>%Y;;]I73-3E>XE=1)+Y%KISOY<*-O=VVHHP"R[A0!^E=%%?&O\ P4Y_X*>?
MM%_L"P:UK?PK_P"";7C#XK^'/#'@MO$OBCQO'XNL]$T;3K9&F\V$SS)+)+-&
MD/F-''$QQ(F,DX !]E45P_[,GQE_X:,_9M^'O[0G_"-_V-_PG?@?2?$7]D?;
M/M'V'[;9Q7/D>;L3S=GF[=^Q=VW.U<X'<4 %%%% !1110!\.ZY_R&KS_ *^I
M/_0C56K6N?\ (:O/^OJ3_P!"-5:_F*I_$?J?DL_C84445!(4444 %%%% !11
M10 4444 %%%% 'VSX)_Y$S2/^P7;_P#HM:TZS/!/_(F:1_V"[?\ ]%K6G7],
MX7_=H>B_(_6*/\*/H@KX[^-/_)6/$'_84E_G7V)7QW\:?^2L>(/^PI+_ #KX
M/Q%_Y%U'_'^C/G.*/]UI_P"+]#EZ***_(CXH**** "BBB@ HHHH **** "BB
MB@ KZ[_9_P#^2.Z%_P!>K?\ HQJ^1*^N_P!G_P#Y([H7_7JW_HQJ^_\ #O\
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M9X[\=SZ2+"37M6OI][SM )9O+Q$L,>/,?)C+<;MH /IVOF#_ (+6_P#*(_\
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M%N;:0/&_BN[*,.A&^OF^*_\ =*?^+]#R\X_@Q]3RNBBBOA3Y\**** "BBB@
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M?^_0H_L[3_\ GQA_[]"JWBF]N=.\,ZCJ%E)LF@L)I(GP#M94)!P>#R*^7?\
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M,/\ WZ%']G:?_P ^,/\ WZ%?*G_#2_QM_P"AU_\ *;;?_&Z/^&E_C;_T.O\
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M_P!#K_Y3;;_XW1_PTO\ &W_H=?\ RFVW_P ;H_XB'DO_ #[J?='_ .3#_6?
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M$ZLK77VGW]3[$HHHK^@#]*,SQM_R)FK_ /8+N/\ T6U?$U?;/C;_ )$S5_\
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M^C6K)K6\>?\ (\:S_P!A:X_]&M637X[/XV?$/<****D04444 %%%% !1110
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MM^9ZA17E?[/W[2=Y\6O$_B#X7>/_ (<W/A#QGX7\E]5T2>]2ZBDAE&8YX9D
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M"MW7]?(^VZ*^)/\ AKO]H?\ Z*%_Y2;3_P"-4?\ #7?[0_\ T4+_ ,I-I_\
M&J/[&Q7>/X_Y!]0K=U_7R/MNBOB3_AKO]H?_ **%_P"4FT_^-4?\-=_M#_\
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MO/;RO?\ 0]F^'VM>,/$/@ZQUGQ]X)7PYJ\\;&]T5=32\%JP=@%\Y %DRH#9
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M R%E^8$@ $UK?LX?"?XF^"O%GQ)^.GC#P/I^BZEXWFM9[#P3I>HI(EM]E@=
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MO$FG-I&OZ9!>6KR1N]O<1AD+(ZNAP>X958>A JW7ZE?\.0OV3?\ HHWQ3_\
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ML(UL/%[1H8H9BB$@QGYL#DYYKT[_ (<A?LF_]%&^*?\ X6Q_^-4?ZI?]/O\
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M+CG !]ET5%97MGJ5G#J.G7<5Q;W$2R03P2!TD1AE65AP00001P0:EH ****
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M?M'7NG7?Q ^'VG^-_"5K:_#OQ!>R7V@WQD%K>%;6PD,.\Q.#%+LE3;\Z+D9
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M?%'2OB!8R^%O&6J^$M=U8>&HI6#>%;;6KS8M@AZQR1P7!9AP4ED<=5S7T?\
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M-\"/"_[+O[.G@3]F[P5<23:3X#\(Z=H%A<3*!)/':6Z0"5P.-[[-S>[&NXH
M**** "BBB@ K\??V_6_:V_X(W?M4:SI/_!//1-*O/"O[:NNIHOA7P[J%^MO;
M>!OB5=2Q0'5H48%?L]Q#(\S1@%?.@&[:B(C_ +!5\4?\%;_V1_VA/VG?C5^R
M/XM^!WP^_MS3_AC^TAH_BGQS<?VM:6W]FZ3 09;G;<2HTVW_ )YQ!Y#V4T >
MU?\ !//]A[X=?\$]?V6- _9P\ WDNI7-KOO_ !9XFO,FZ\1:U/A[S4;AF)9G
MEDZ;BQ5%1,D(*^7?V&_^5AK]N;_L3_AO_P"F>OT/KXT_94_91^/OPV_X+)_M
M6?M6>-? 7V+P#\2O#?@FU\%:]_:EK)_:,UAIODW:^1'*TT/ER?+F5$#=5+#F
M@#RO_@JU_P IM?\ @G#_ -C!\1O_ $TZ=7M?_!;3]D;X)_M7?\$W?BW;_%/P
MAIT^J^$_A_J_B#PAXBFME%WHFI6-I)=03P3XWQ#?$JN%(WQLZG@UY7_P6"_9
M^_;9\3_MT?LB?MA?L@_LH3_%NV^"FH^,;KQ7H5MXVTK1' U"ST^WME$NH31@
M[C'.V45\>5AMNY2<#]J.T_X+:_\ !3KX3:K^QY)^Q9X:_9@\$>-+8Z9\0/'W
MBGXJ6'B;4Y-(EPMU;6%GI8*"26,M&3-(%9'=<QDAZ /IS_@D7\</'7[2/_!,
MGX'?&OXG:E+?>(M<^'6G/K6H3L3)>W,<?DO<.3U>0QF1CZN:W/C=^QK_ ,+D
M_;:^!?[8W_"Q_P"S?^%+:?XLM?\ A'/['\[^V?[;M+2WW?:/.7[/Y/V7=CRY
M/,WXRFW)] _9_P#@CX$_9I^!GA#]GKX864EOX>\$^&[+1-&CF<-)]GMH5B1G
M8 ;G(7<S8^9B3WKKZ /SW_X.7/AW\/\ 3_\ @C3^T'\0K#P+HT&OZAIF@I?Z
MY#ID2WERJ:YIJ(LDP7>X50% ).  !Q7UKXU\->._&?[$VK^#_A=J!M/$VK?"
MRXL_#MTLNPPW\NFLENX;C;B5D.>V*^/?^"^7A3_@HQ^UC^S%\0/V!OV4O^"=
MM]XWT3QKHNEM#\3D^*6A:=!:W$.HP7<D!L+V>*9R!;!=^0I\T$9VD5],?L$?
M%[]K[XE>";WP_P#M9?L*7_P4F\.6.GVFB?;?B+I/B#^W!Y<BS.O]G.WV?RS'
M'Q)][SAMSM:@#\[?^";W_!0?_@FK\!O^"&L/['GQU\3Z%HGC[PYX5USPMXZ^
M!NK6>/$6JZ]+-<QR6J::5\Z[DNI)4VLBL!YH5F4HP7Z0_P"#8+XE^,/B7_P1
M7^$K^-[N:XN] ?5]#@GN,[S:VNIW,=NG/:.+9"!V6(#M7*_&WX[?\%/_ (TW
MVK^#OA'_ ,$-K#P5\8-1M9M)TSXU^+O'.@W6F>'8Y%:(:E'=P*;J?9&=Z0HH
M<' *MM*M]@?\$[?V,?"7_!/?]BSX?_L?>#=6.HV_@S13!>:HT7E_;[Z:5[B[
MN=N3L$EQ-*X4D[58+DXS0![31110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !6!\3?A1\+?C7X0G^'OQD^&N@>+= NI(WNM#\3:-!?V<S(P=&
M:&=61BK ,"1P0"*WZ* (K"PL=*L8=+TNRBMK:VB6*WM[>,)'%&H 5%4<*H
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M[^WA,\62,E,LN<L * /I&BOD_P"'W[0OPI^%O[7W[7'B_P <?MMZ_P"*=/\
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M;5=8U5&OOLB:=I\-YF%  1(\VTL/GQCR\/[9^RI^S=^W9^S1\3=6\1?M%_\
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M^SKCQSX\\8:AK^JI9;MWV:*>^FD,$>1DK&%W8&[.!7T50 4444 %>2_MC_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
K %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>biib-20200930_g7.jpg
<TEXT>
begin 644 biib-20200930_g7.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?@3XCT'3M*UF*X=9+Z*_TXW4CW!D;8I5AM&W QUYKZ6M;JVO;:.\LKB.:&5
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MOAXOPXO_ !M\7V\!>.[+1M2NGMO$>DWMC/(5O(YI7$SQO#O61OFWD,2S(A4
M^YO"G[;G@OQ9^WUXL_X)_P!KX-U2+7O"7P\L/%UWKLDD?V.>WNK@P+"@!WB1
M2N22,8Z&N6U;]M[QEIO_  5QTS_@G:/!^E?\([??L^S_ !!E\0M)(+Q+N/61
M8"W SY?E;/GSC=N[XKX6'_!+7_@G_P#M!_\ !P_\</A_\9?V8]"U_1KOX+:7
MXPN;"\FN0DFN7NJ2?:KX[)0?,DR<C.WG@"M_]J/]BOX0?M%?\'#/PY_9H\80
MW]M\.='_ &+"-6\(:5JD]K!K6FVWB&2&#3+EXG61[42&WE:/>!)]F5'W(S*P
M!^JNE:QI&O62ZEH>JVU[;.2$N+2=9$8@X(#*2#@\5'?^)?#FE:A!I.J:_96U
MU=?\>MM<72))-SCY5)RW/I7YL?LS?L]?"?\ X)U_\%^7_9@_9$\-MX0^&OQ1
M_9IF\3^(? ME>S/IT>MV6L+;1W\,<CL(G-N3&0N =S'&3Q\PM\"?V:?V5/&?
MQ5U/_@NE_P $J/B1\2M3UWX@ZOJEU^TUI>C3^)]%DT26=FM'DDMKCS]'BA@V
MH(DC!0+C"\* #]TJ^./^"B/_  4W^//[(W[47PB_9"_9H_8AC^,_C/XNZ7K=
M[I5C+\3;?PVMLNF11S2CS+FUFC?,3.V6=/\ 5X 8L*^C_P!F;4O@MJW[.G@2
M^_9OUR'4OA^WA#3E\$WT%Y+<+-I2VT:VI\V8F5SY00$R$R9!W_-FOSM_X*\>
M'_VA_%'_  6W_8NT7]E;XB>'?"GCF7PE\0#I&N^*M"?4K&W4:=&9A);QR1LY
M:(2*N&&UF!YQ@@'TW^S!^UI_P5-^*7QJTGP1^TO_ ,$B;/X5>#+N.X.J^.8O
MVA=(UYK!D@D>)?L5M:I)+YDJI%E6&SS-QR%(KZHU/5-,T6RDU/6-1@M+:(9E
MN+F98T09QRS$ <U\V_LM_"W_ (*O>$_BQ#J_[7G[6/PG\8>#5L9EGT;PA\-;
MG2[UK@@>4XGDNY5"J<Y7;SZBOB7]B?\ X)U_LQ_MP?\ !1[]N#6_VL_"$WC?
M0=!^-MM#HO@K4]1N$TF"[DT]3+?26\4BK/<%!'&CR!O*57V8,C&@#]<89H;F
M%+BWE62.10R.C9# \@@CJ*XKX]_%ZW^$OP<\=>/=#FL+W6/"/@S4=;CTF>X&
M7-O:R3()%4[PC,@!/'!X-?F%^RY\5?&W_!-_]CW_ (*'_"?X&ZQ?S:!^SMXJ
MU:Y^#NFZE=27H\/17>CI=PVJ&8LS6T$SB0(Q/_+0DDNQ,^B?\$6?V/%_X(UW
M'[2!L]2?XZ:O\$)_'.H_'5O$-VVMW6N7.D->S227!E_>VDC.T+V[ QR0,0P+
M,7H _0C_ ()Y?M+^)/VR?V(?AA^U-XP\.V.D:IX[\(VNKWVF::[M;VTDJY*1
MER6*CW.:]:T[7]"U>XN+32=:M+J6TDV7<5O<J[0MS\KA22IX/!]*_$WXL?M
M?$_X;_\ ! K]AC]G[X<#QJ+7XTZSX:\+>,5^'$D::_>Z&899KO3].>66)4NK
MD(D2L9$!!=2<,:=\4/V?] ^$NK?#OXM?\$E_^")_[2WP4^*O@GQCIDC:W=:3
MI]MINO:']H5=1T[53'K5R]U'+ 6.YXW?>B_.H)- '[9ZKJ^DZ'9/J>MZG;V=
MM'CS+BZG6-%R<#+,0!S7SGI/[;_C'4_^"N&I_P#!.[_A#]*_X1VR_9]@^(,7
MB%)9#>/=R:R;#[.1GR_*V?/G&[=WQ7RYXW^ WPU_X*C_ /!<OXL? W]L;1I/
M%/PU_9P^'?AMO!_PXU&[D72KW5M9A>ZFU6>!& N)$C'V<;\H!MXR,G!_8C_9
M-^''[&?_  <D^/?A!\&;N^@\'2?LBP:CX:\-76I37,/AR"7Q' 'L+4S,S1V_
MGI/.L6=J&Z95 4*H /U5HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH *X?]IOX-?\ #1G[-OQ"_9[_ .$D_L;_
M (3OP/JWAW^U_L?VC[#]MLY;;S_*WIYNSS=VS>N[;C<N<CN** /*/V%OV8/^
M&+/V/_AW^RC_ ,)Q_P )+_P@/A>VT?\ M_\ LS[']O\ *&/-\CS9?*S_ '=[
M8]37E7[>'_!.;QO^T3\</ ?[9O[*W[0[_"CXV?#JPNM+TSQ+<: FK:;K.CW!
MW3:7J%FTD?F1;RSHZN&C9V8 ML*?5E% 'Q]^R5_P38^,OA/]KN]_X*!_MW_M
M.VGQ5^*B>%6\->$+;0/"HT;0_">EO)YDR6MN997EFE;.Z>1@VUV3!&"/0OV$
M_P!AC_ABG7OC=K?_  M'_A)O^%R?'#6?B'Y7]B?8O[(^WK OV'/GR_:/+\G_
M %V(]V[_ %:XY]_HH *^+_"7_!,7]ISX#?M9^//CI^R3_P % D\&>!OBC\0X
M?&/COX::Y\*+76OM-\PB2]%MJ#7<,EL+A(MO^K?RR01NVX/VA5%_$_AJ/6AX
M;D\0V*ZBR[EL&NT$Q&,YV9W8Q[4 >'?LM_L,?\,U?M8_M!?M0?\ "T?[:_X7
MMX@T74_[#_L3[-_8?]GV!M/+\[SW^T^9G?NV1;>F&ZUG_!7_ ()W>'/AE^U+
M^TS^T)XP\<P>*=(_:3_L&/5/!UUH/DQ:9;:?I4FG2P/-Y[_:UG25F/[N+8/E
M^?.ZOH^B@#X ^$O_  3,_P""F'[&GA0?L]_L-_\ !2OPY8_"2RGF'A'1/B?\
M*AK>J^%+221G%I!>1WD(O(T+-L\]1M7"= *^T?@-X'^)7PW^$6A^"OC#\8[C
MX@^)[&U9=;\97.C0:<VJ3M(SF7[+!^[@4;@JQKD*J@9/6NNHH KZM8?VII5S
MIGF^7]IMWBW[<[=RD9QWZUX1_P $N/V&/^':_P"PGX&_8I_X6C_PFG_"%_VG
M_P 5-_8G]G?;/MFJ7=__ ,>_GS^7L^U>7_K&W;-W&[:/?Z* / /V3?V&/^&7
MOVD_C]^T+_PM'^W/^%Y>,-/UW^R/[$^S?V)]FL_LWD^;Y\GVG=][?LBQTVGK
M6/\ !W_@G;_PJ;XY?M/?&C_A<']H?\-'W&GR_P!F_P#"/^5_PCOV72WL,>9]
MH;[7NW^9]V'&-O/WJ^EZ* /&/^">/[(?_#!7[%OP_P#V0?\ A87_  E?_""Z
M.]A_PD/]D_8?MVZ>67?Y'FR^5_K,8\QNF<\XKYQ\-_\ !+?]MC]COQCXIM?^
M"8G[<WAWP7\-O%_B.ZUQ_A=\1_AS_;=GX=OKEM]P^F7$-S!+'"S_ #"V<%$/
M()))/WK67JOC?P7H7B72?!FN>+]+L]8U[S_[#TF[U"..YU'R$$DWD1,P:;RT
M(9]@.U2"<"@#YX\3_P#!//Q#^TS^PKXJ_8U_X*(_M#7/Q:N_&4\D^H^+M+\,
M6WA]].<212VGV&WA,BPFVDB1T9VD+D'S-P9E/F6@?L6_\%M-$\.P?"*/_@K]
MX1?P]9P"VM_&MQ\"(;CQ0]NH 42-)>FU>8(,&=HV+'YV4DFONBB@".UADM[6
M.":X:5TC"M*PY<@8+''<]:^,/C?_ ,$X_P!K7P]^W#XO_;E_8 _; T#P!JOQ
M0T#2]+^)WACQQX#.N:?J$FG1-!97T!CN8)(9HH69/+R4;<Q)YQ7VG10!\=_\
M$]?^"5?BS]B;]J?XO_M:_$/]K;5?BEXF^,VG:./$MSK'AB*PD2^LUE$DR-%,
MR"!O-"16ZQH((HHTWR8W'T7_ ()E_L,?\.Z/V3M/_9?_ .%H_P#"8_8/$&KZ
MG_;G]B?V?O\ MU_-=^7Y/GS8V>;LW;SNVYPN<#W^J0\2^'#K7_"-C7[+^T=F
M_P"P?:D\_;C.=F=V,<YQ0!\<^"_^"+GPMC_X)>^)/^"8WQ?^*=[XDTGQ!KVK
M:Q#XMTS21IMWIUY=:K)J=M-!&9I@)+>9DP2^) A!"ARM>1?M._\ !&'_ (*-
M?M\?LOWG[(W[9_\ P5=TS4/#-FEL=&OO"_P@2UNM7NK>5&BN]8S?#[3M17(@
MA:)3,T<K,YB"M^F%5;'7-%U2ZN;'3-8M;B:SDV7<,%PKM W]UP#E3P>#Z4 .
MTFP_LO2K;3/-\S[-;I%OVXW;5 SCMTKP#Q=^P5_PE7_!3WPC_P %'_\ A:WD
M?\(M\)[WP5_PAO\ 86[[5]HO&N?M?VOSQLV[MOE>2V<9WCI7T/10!\&_\%,_
M^"&7@W_@H/\ M9?#+]K[PO\ 'JX^'7B'P5=6*^*X+;PW_:$7BVRLM0AOK.WF
M NH!"\4B2@2D2G$JC;B-0?<_BK^PQ_PLW_@HA\*/V]O^%H_8O^%8^#]=T+_A
M%/[$\W^TO[25!YWVKSU\GR]GW/*?=G[RU[GJOB'0-">"+6]<L[-KJ3R[9;JY
M2,S/Q\J[B-QY' ]:N4 > ?LF_L,?\,O?M)_'[]H7_A:/]N?\+R\8:?KO]D?V
M)]F_L3[-9_9O)\WSY/M.[[V_9%CIM/6LSX'?\$Y_"_PN_: _:8^,'C?QO!XM
MT7]I.]TU]7\)7.A?9X].M;;3'L);9YO/?[4LR.Q)V1;0=N&ZU]$3:YHEOJL6
M@W&L6J7T\9>"R>X42R*,Y94)R1P>0.U6J /@#X1?\$S_ /@IQ^QOX/C_ &=O
MV)O^"F7ANU^$VGR2)X2TSXG_  H&M:QX6LV<LMI!=Q7D"WD:%CL\Y!M&$ VJ
M*^U?@?X,^(?P\^$VA>"_BS\7+CQYXET^Q$>M>,+K2(-/?5;C)+3?9H/W4 .<
M!$X4 #GK6]I'B'0/$"2RZ!KEG?+!(8YFL[E)1&_]UMI.#[&K-Q<6]G;R7=W.
MD442%Y99&"JB@9))/  '>@#P/]K+]AC_ (:A_:3^ /[0O_"T?[#_ .%&^,-0
MUW^R/[$^T_VW]IL_LWD^;Y\?V;;][?LESTVCK7J^G_ _X+:3\6K[X^Z5\(/"
M]MX[U32UTS4_&MOX?MDU>[LE*,MK+>!/.DA!CC(C9BH,:\?*,=#IFJ:9K5E'
MJ>CZC!=VTHS%<6TRR(XSCAE)!YJ>@#Y._9?_ ."4?P]^"?P'_:)_9R^+/CL>
M/?#/[1'Q:\5>,=<M3HO]G'3[;6X8(7T]2)Y3(T0ARMR/+)9@1&A4$^%W7_!'
M'_@HEK7[.L7_  3P\1_\%64G_9\CT]-$F6#X90Q^,+GPXN$717U#[080GD 0
M&X$.YD&"A4E#^DM% 'S#\>O^"9?@CXHW7[,^F?#3QI'X+\._LT^-+#6=!T"'
M13>+?V=G9&TAL1(9XS!A-O[TB4_+RISFNG_;+_8F_P"&N/B)\#_'O_"S/^$?
M_P"%-?%BV\:_9/[&^U_VQY-M/!]DW>=']GSY^[S<28VXV'.1[O10!\@?M._\
M$U/CKXW_ &T6_;O_ &,_VV_^%/>-M5\ P^$?%L&J?#>V\36&K6,%RUQ!((9K
MFW:WF5FVEU<@JJC:/F+=?H?[!/B&'_@HOX;_ ."A_BWXY1ZIJNC?L_CX;ZGH
M,7A86ZZC<-J2W\FJB87#"$,X91;"-@N[/FG&*]]U/QIX.T3Q'I?@[6?%FF6F
MKZX)SHNE75_''<Z@(%#S&")B&E\M65GV@[003@&M.@#P#Q%^PQ_;_P#P4U\.
M?\%&/^%H^5_PC_P?O/ O_"'?V)N\_P _4!>?;/M?GC;MQL\KR3G[V\=*\1^(
M/[#7_!97QUX)\0? 74?^"K/@6]\&>);.YTZ\\1:A\!XAXAMM/G5HW@0Q7RVK
MR")R@F:,,3\^-U?<-]XAT#2[ZWTO4]<L[>YNVVVEM/<HDDYZ812<L?I5R@#S
M[]E#]FWP#^QY^S;X)_9>^%TUY+H'@;P];Z3IUQJ,H>XG6)<&64J "[MN=MH"
MY8X & /GW_@H-_P3/^.G[6/[57P@_;#_ &;OVTK;X/\ C'X0Z5KEEI=S=_#.
M'Q''=+J<4<,K&.:\@1,1*ZX*OGS,@J5&?KD:YHAU<^'QK%J;\1>:;'[0OG!/
M[VS.[;[XQ5J@#Y4_9X_96_X*G?#SXQZ+XQ_:$_X*R:-\1O!UE),=:\%VO[/&
MG:))J2M!(D8%[#?2/!LE:.3(1MWE[3@,2.L_8_\ V&/^&4?CM\>OC7_PM'^W
M_P#A=_Q B\3_ -F?V)]E_L79:K!]G\SSY/M.=N[?MCZXV]Z]_J#4M3TW1[*3
M4]7U""UMHAF6XN90B(,XR68@#DT ?./PD_X)M^"O!7C+]IK4OB3XQC\7>'?V
ME]<^U:[X:ET<VJZ?9MI:Z=-9F43N;C>@9O,"Q%=V .-U?.ND_P#!'+]OVS_9
MHU#_ ()V7/\ P5,1O@ ="N-#TF,?#.(^*TT5HVCBT>;4/M0B:V1"L3NL2R20
MJ8U,2L-GZ-VMU:WUM'>V5S'-#*@>*6)PRNIY!!'!'O4E 'QMKW_!'#X;^./^
M"8?PW_X)V>.?C!J_]J?"FWTJZ\#_ !2\/6(L-0TG7-.W&UU6WA:241L-[J8S
M(V4=@'5MKJWX?_LL_P#!9P>)]#TKXN_\%3/ USX7T?4[6;4[KPS\"H;;6/$5
MK%*K26\TDMY)!:&95*O)#&2H8[-IP1]ET4 ?'_[6O_!.+XX^*/VO-/\ ^"@'
M[!W[36G_  O^)[^%5\,^,[+Q)X5_MC0_%FE)+YL"W,"S1213PN?EG1MQ553@
M9SE_L:_\$I?BO^S[_P % ?$W_!1SX\?MGW7Q,\:>-OA@/"WB33V\&1Z9:0S"
M^@N$ELO+N7%O;1PVT,"VQ1F+!YFF9I&6OM2B@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH \'_X*A:]^T1X7_P"">'QD\0?LG0:A)\1+3P!J$GA;^QXV>]2<1'<]LJ@L
MUPL>]HPH+&14 !.*_,;_ ()U?L]_\&O?[7'[./@KP3XPUSP5K'Q<UK1;,^,I
M_'_CF_TOQ==^(WC4W9$L]S%*\_VGS,"W)3@;<KR?U_\ VA/CGX,_9H^"WB+X
M\_$2SU6?0O"]@;W5DT33'O+H0!E#ND,?S2;0=Q"Y.U3@'I7Y9_\ !33]MS_@
MVR_;)_9,\;^)-6U7X;>/OB!K_AR[A\&_\(UX-E7QC/K,D++9I"RVR7<<GGF/
M(E(CXQ("N00#[L_:]_:[^''_  2__9R\#>%M%\">(_'WB/5K[3? _P *? .F
M7JR:KXFU+R1'!$UQ,<(H2/?-<R9"@$D,S*K>9>&O^"G7[77P6^-_P]^&/_!2
M/]@S3_A9X?\ BSXDB\.>"_'/A/XEP^(K*UUV=6:UTK4$%M T$DVQE29-\;.,
M8 #,OQ%^U3^S!^U/X>_X)O?L$?M)?M<1?%*,? R=Q\:I/ 6KWEIXJ\/:-J%L
MD,6I"2V/VE9+*&*!9]A\P!Y PQO*^C>&+?\ X(0_'?XJ?"[PE:_\%7?C5\8=
M=O/B!HVH>!/!.J_''Q#XDC?6(KE&M)I[*42+;B-CEI)Q&$3?EE!- 'TG\>?^
M"M?QO\+?\%#O$G_!-#]F?]AB?XB^.M+\%:?XCTW5Y_'<>F::MM.2)YKYWM7^
MR0PDQ*"AF>:29$5$Y8;G[+O_  4U^-GQA\;_ !6_9,^,?['B^"/VC/AGX0;Q
M%I?PW?QQ#<:5XPL9$9;2YLM5$ $<,EQY<$CO"?(:9<ARKHOS/XF_;2^"'[%?
M_!R%\8?%'[1^K'PYX0\0_ OPSILWCF[M7;3]'O?.:2"*\F52+:.<+*JRN0GF
M1HA.7%=G^R)\4?"'_!1'_@O%XI_;L_9BOY]:^$7PO_9ZC^',GCVWMW2P\0:]
M<:N=0>"TD=5^T10Q,V]ER%D"'[LB,P!QG_!OW^U+_P %(/''PGN/#?BS]D&#
MQ%X)O/C3XFB\0?$W6/CA'->:'_IK^;:QZ?)9M)<QV[ 1H5F17'("CBO>]2_X
M*C?M:?M ?%WQUX&_X)H?L%V7Q3\+?#+Q'<>'O%/Q$\7_ !)A\.Z=?ZS;@?:=
M/TU#;SO<F,L$:X;9$&X&5*NWBG_!#/\ ;-_9K_9EL/%W_!.+]H#XE)X1^-5Q
M^T)XM6P\!:WI=U#=7R7-\\UO- QB\N2*2/+)(&VL!D'!!/S7^QK\-OV0/V*?
M%'Q._8[_ ."D_P"WS\?/@!XXT'XDZUJ?A_\ LSXV:WX:\.>+=#NIS-;:K8?9
MG6V>1PQ6501)N R-VY4 /T7T;_@L-X6\0_\ !-SXL?MU6?P&U;3_ !3\%&U;
M3?B+\(]>UA+>\TK7=.V?:-/>[CBD1D(='2X6-E9'!V@[E7R?QK_P6_\ VN?A
MW^S_ .'_ -O_ ,<?\$N=1TO]G&_MM*N]9\5R_$BVD\066GWK11C5$TE;?+VP
MDF78K2)+)&R2LL(8A?-/B5X._8"L/^"&'[9GQ*_X)^?&3QA\0M%\3V6K/XO\
M:^,]9U#49]6UF*QMO,E2ZOT62Z01R1*9E+HSJX#$JV/4/^"H  _X-B_$0 _Y
MM_\ #?\ Z!I] &C\9O\ @M%^TS\"O!NE?MC_ !#_ ."<M]I_[+VHZK812_$B
MY\>VXU^UTJ]G2&UUJ;11"6BMY&EB(A:;S@LJ%PC$H./_ ."U'QNU+]G_ /X*
MS_\ !/\ ^+'ACX7:OXYU2WF^)]GH7A3P_)&EQJU_>Z)I]E:0B64B.&-I[B+S
M)G.V*/?(<A"*W_\ @O$JI_P;=^/T10 /A_X1  ' ']J:37%_\%COCQX>_9D_
MX*=?\$[?CMXP\-:CJFB^'4^(LVNII>F27DUG8/HFFQ7-]Y,09W2UA>2Z?:"P
M2W=@#C% 'T!\)?\ @IQ^T=X._:^\'_L=_P#!1+]C.Q^$^I?%*VNW^%GBOPSX
M^3Q!I&K7=M&)9],GD^S0/;7*QD,I92DI.U<'&;7QK_X*6_'[Q)^U/XK_ &./
M^"=?[']M\6_$OPYMK.3XF^*?$?C>/0-!\.W%U&9;>P$WD327=TT8+,D: 1@C
M<V0RK\_?M3?M8? 7_@JK_P %#_V3_@;^P9X^L?B-#\+?B6/B3\2?&7AI'GTW
MPYIEK;.D-O-<A=GFW4CF,1*2P9%W 9KQ'4?AG^SK^R%_P5 _:/\ !W_!1;]K
MKXV_ K3/BKX['C7X5^-_!?Q5UCPUX;\2V=S%^_M99K)Q#]LM9,1D3%6V]/EV
M;@#]"?V6O^"G-[\</ 'QET?XN?L\:A\.OB]\!+9Y/B)\,-0UV*\15>RDO+.Y
MM;Z*/9/:W,<;[)?+!!5LH1M+^=?L#_\ !5K]L_\ X*->&/AY\<_@K_P3<CT3
MX3^(KF.#Q3XS\3?$^!)K=A(8[IM.M/LJR7T-NZLAF?R?,=)%1"$W-Q/[(7@W
M_@F?JWP__:@^-7["?[4/C[XP>)+CX8'2O'_C3QGXRU37DE1+&^:T@BOKY<3L
MBI)D1NXC5D!V[@*]I_X(!PQ0?\$:_P!GM(8E0'P#$Q"K@9,\I)^I))/N: /K
MG5M-M=9TNYT>]W^3=V[PS>6Y5MK*5.".0<'J.E?B[_P4J_8\_P"#;K]DSX5>
M/O@/X+T'3= _:(T71B/ FE>$/$VM7WC)?$L]JL^E>7MFED>2666V;,F4*RY)
M Y'[)?$+QSH/PP\ ZY\2O%37"Z7X>T>YU/4FM;9YI1;P1-+)LC0%I&VH<*H)
M)P!R:_,_]O3_ (*T?\&_O[3?[*/C;2]<\=^"?BIKOBOPW<6FA>%],\%7%SX@
MU+4I(&BM(X4>V6>WN!)Y821BAB*J=RX% #_^"AGQO_;@^ W_  0X^!_P@^(7
MQ!U'PY\<_C)JW@SX8^)/%*78.H:9?:E&3>2F5#_Q\^3;S1O(IR'=V5@0&'#_
M /!4C_@GQ^S!_P $6OV8O"'_  4D_P""?/@FZ\!^,/@QXQT-?$][8ZS<R/XS
MT*ZO(;.]LM2$CE;HRM+&Y<@%6#%=O&UO[1_[*'[;-Y_P;L_L\ZY\0/ ^N>)/
MB[^S]XA\+_$:_P#"=RKS:I<6^FSSXLV4@N9X=/N5W1G+YMW3YFX,G_!5O_@H
M/^RQ_P %E/V5O!W_  3A_P""?/Q'_P"%@^,_CAXQT+^V-/TG3IQ+X2T.VO(;
MV\O]2WH!:>3Y,:LC'<2QVAL<@'Z\P3PW,"7-O(KQR(&1U.0P(R"*=7C_ ,;O
MVT/@A^S;\>OA#^R]XXBU8>(_C-?ZCI_@>#3-.$T ;3X(IIS.^X&)%CE3!PW?
MIBO8* /C3XL_\$(O^"6'Q?\ 'WC?X\_M.?!";QSK_BV_N]1UOQ#XT\8Z@_\
M9\+LTA@MMD\<=E;Q D)Y:J54#+'&:^?O^"+O[1OCKX'_ /!*3]H[XTCQ?K7C
M3X5?!_QSX[N?@%KOBFZ>:?5?"&DVQFM0)F^:6W#Q2HK]CO0!5157R3_@IK_P
M6"_99_:W_;/\3?\ !,;XO_M;+\%O@/X U%['XV^(1;7HUCQ[>Q2%)O#UB;:%
MVMK)71DN;AMK2@%$RAS)]W_"'XB?L%_\%)/^"=WQ&_9@_P""=OQ'T"_\#CP#
MJ7P_ACT/2KFTM-&^U:9)!'"$FBC;"QS*V0#GN2<T ?'/['W_  1@^ '[:O\
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M6UU"LD<JGJK*P(8>QJ>B@"MI&CZ1X?TR'1=!TNVL;.V39;VEI L442_W550
MH]@*LT44 %%%% &<OA#PFGB1O&2^%].&KO#Y3:J+*/[28_[AEQNV^V<5HT44
M %9WB7P?X2\:6::=XQ\+:=JUO'()(X-3L8YT5QT8*X(!]ZT:* &PPPVT*6]O
M$L<<:A41%P% X  '04ZBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MG_\ /C#_ -^A0!3_ .$Q\,?]!J#_ +ZH_P"$Q\,?]!J#_OJKG]G:?_SXP_\
M?H4?V=I__/C#_P!^A0!3_P"$Q\,?]!J#_OJC_A,?#'_0:@_[ZJY_9VG_ //C
M#_WZ%']G:?\ \^,/_?H4 4_^$Q\,?]!J#_OJC_A,?#'_ $&H/^^JN?V=I_\
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M_P!^A0!3_P"$Q\,?]!J#_OJC_A,?#'_0:@_[ZJY_9VG_ //C#_WZ%']G:?\
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MB@ HHHH **** /"_^">__)$]6_['O6?_ $I->Z5X7_P3W_Y(GJW_ &/>L_\
MI2:]TH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\:V** /,IOCUX4MYGMYOB59!T8JP_L:YX(.#_!3?^&@/"'_13++_ ,$MS_\
M$5\]ZS_R&+O_ *^9/_0C5:OTR/!F5N*?//[X_P#R)^/S\0,YC)KV=/[I?_)G
MT;_PT!X0_P"BF67_ ();G_XBC_AH#PA_T4RR_P#!+<__ !%?.5%5_J7E?\\_
MOC_\B3_Q$'.O^?=/[I?_ "9]&_\ #0'A#_HIEE_X);G_ .(H_P"&@/"'_13+
M+_P2W/\ \17SE11_J7E?\\_OC_\ (A_Q$'.O^?=/[I?_ "9]&_\ #0'A#_HI
MEE_X);G_ .(H_P"&@/"'_13++_P2W/\ \17SE11_J7E?\\_OC_\ (A_Q$'.O
M^?=/[I?_ "9]&_\ #0'A#_HIEE_X);G_ .(H_P"&@/"'_13++_P2W/\ \17S
ME11_J7E?\\_OC_\ (A_Q$'.O^?=/[I?_ "9]&_\ #0'A#_HIEE_X);G_ .(H
M_P"&@/"'_13++_P2W/\ \17SE11_J7E?\\_OC_\ (A_Q$'.O^?=/[I?_ "9]
M&_\ #0'A#_HIEE_X);G_ .(H_P"&@/"'_13++_P2W/\ \17SE11_J7E?\\_O
MC_\ (A_Q$'.O^?=/[I?_ "9]?V0\7:A9Q:A9Z_9/#/$LD3_9&&Y6&0<'D<&I
M?L7C?_H-V7_@,?\ &IO!G_(GZ3_V#(/_ $6M:5?FE2*A4<5T9^O49NI1C-[M
M)F/]B\;_ /0;LO\ P&/^-'V+QO\ ]!NR_P# 8_XUL45!H8_V+QO_ -!NR_\
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MX#'_ !H^Q>-_^@W9?^ Q_P :V** ,NSM/%J72/?:M:O$&_>(EN02/8UJ444
M%%%% !1110 4444 %%%% !1110!X7_P3W_Y(GJW_ &/>L_\ I2:]TKPO_@GO
M_P D3U;_ +'O6?\ TI->Z4 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MIH'C']M'P%J'C&R_9RTR_P#%'B&U^%A@M=2\-CQ!")-,BMOM9\BX9LD76YL
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MC\"_@#-\5_"_C'X>V_AKQ7X=TG6[>TU;2)K><21W%NMRRI-$P5 8U(.XL3C
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MLWT2['T?"W%&/SS&SHUXQ24;^ZFG>Z763[G74445\@?=A1110 4444 %%%%
M!1110 4444 >%_\ !/?_ )(GJW_8]ZS_ .E)KW2OGK]@O6+^P^#FK06V@7%R
MO_"<:R?,B(QG[2W'->V_\)+J_P#T*%[_ -]+0!L45C_\)+J__0H7O_?2T?\
M"2ZO_P!"A>_]]+0!L45C_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+0!L4
M5C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+0!L45C_P#"2ZO_ -"A>_\ ?2T?
M\)+J_P#T*%[_ -]+0!L45C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+0!L45C
M_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+0!L45C_\)+J__0H7O_?2T?\
M"2ZO_P!"A>_]]+0!L45C_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+0!L4
M5C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+0!L45C_P#"2ZO_ -"A>_\ ?2T?
M\)+J_P#T*%[_ -]+0!L45C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+0!L45C
M_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+0!L45C_\)+J__0H7O_?2T?\
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MA0E*I]J4I+2VC?9ZJ^]GKKKJ&=5<//$PC2VC",7KS:I=UH[;76FFFE@KZN^
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MC\ :[81:NTFIM<V&MBZD$68PZ[H95X8HIV@8Z[LKYA_P3B_Y/8\!?]A"X_\
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MQX_8:#KNJV=UJ.EZ+=W-O8QA[V>WMF=+=2<!G8#" X/)Q7UC\.?C5XO^'O\
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M_?5'_"8^&/\ H-0?]]5<_L[3_P#GQA_[]"C^SM/_ .?&'_OT* *?_"8^&/\
MH-0?]]4?\)CX8_Z#4'_?57/[.T__ )\8?^_0H_L[3_\ GQA_[]"@"G_PF/AC
M_H-0?]]4?\)CX8_Z#4'_ 'U5S^SM/_Y\8?\ OT*/[.T__GQA_P"_0H I_P#"
M8^&/^@U!_P!]4?\ "8^&/^@U!_WU5S^SM/\ ^?&'_OT*/[.T_P#Y\8?^_0H
MI_\ "8^&/^@U!_WU1_PF/AC_ *#4'_?57/[.T_\ Y\8?^_0H_L[3_P#GQA_[
M]"@"G_PF/AC_ *#4'_?5'_"8^&/^@U!_WU5S^SM/_P"?&'_OT*/[.T__ )\8
M?^_0H I_\)CX8_Z#4'_?5'_"8^&/^@U!_P!]5<_L[3_^?&'_ +]"C^SM/_Y\
M8?\ OT* *?\ PF/AC_H-0?\ ?5'_  F/AC_H-0?]]5<_L[3_ /GQA_[]"C^S
MM/\ ^?&'_OT* *?_  F/AC_H-0?]]4?\)CX8_P"@U!_WU5S^SM/_ .?&'_OT
M*/[.T_\ Y\8?^_0H I_\)CX8_P"@U!_WU1_PF/AC_H-0?]]5<_L[3_\ GQA_
M[]"C^SM/_P"?&'_OT* *?_"8^&/^@U!_WU1_PF/AC_H-0?\ ?57/[.T__GQA
M_P"_0H_L[3_^?&'_ +]"@#\(?&[*_C35W4Y!U2X(/_;1JRZU/'  \:ZP /\
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M?_ 7P1?6DF^*;PAILD38(RIM8R#@\]*Z^OS*K_$EZL_6Z7\*/H@K\6_VW_\
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MB>K?]CWK/_I2:]TH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MVW[%XW_Z#=E_X#'_ !KR/_@GO_R1/5O^Q[UG_P!*37NE &/]B\;_ /0;LO\
MP&/^-'V+QO\ ]!NR_P# 8_XUL44 8_V+QO\ ]!NR_P# 8_XT?8O&_P#T&[+_
M ,!C_C6Q10!C_8O&_P#T&[+_ ,!C_C1]B\;_ /0;LO\ P&/^-;%% &/]B\;_
M /0;LO\ P&/^-'V+QO\ ]!NR_P# 8_XUL44 8_V+QO\ ]!NR_P# 8_XT?8O&
M_P#T&[+_ ,!C_C6Q10!C_8O&_P#T&[+_ ,!C_C1]B\;_ /0;LO\ P&/^-;%%
M &/]B\;_ /0;LO\ P&/^-'V+QO\ ]!NR_P# 8_XUL44 8_V+QO\ ]!NR_P#
M8_XT?8O&_P#T&[+_ ,!C_C6Q10!C_8O&_P#T&[+_ ,!C_C1]B\;_ /0;LO\
MP&/^-;%% &/]B\;_ /0;LO\ P&/^-'V+QO\ ]!NR_P# 8_XUL44 8_V+QO\
M]!NR_P# 8_XT?8O&_P#T&[+_ ,!C_C6Q10!C_8O&_P#T&[+_ ,!C_C1]B\;_
M /0;LO\ P&/^-;%% &/]B\;_ /0;LO\ P&/^-'V+QO\ ]!NR_P# 8_XUL44
M8_V+QO\ ]!NR_P# 8_XT?8O&_P#T&[+_ ,!C_C6Q10!C_8O&_P#T&[+_ ,!C
M_C1]B\;_ /0;LO\ P&/^-;%% &/]B\;_ /0;LO\ P&/^-'V+QO\ ]!NR_P#
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M./\ E(+\8/\ L>[[_P!&&O4RG^-+T/)SK^!'U_0\*HHHKWCYP**** "BBB@
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M0 4444 %%%% !1110 4444 ?RN?%'_DIGB+_ +#MW_Z.>L*MWXH_\E,\1?\
M8=N__1SUA5]G'X4?"/<****8@HHHH **** "BBB@ HHHH **** /ZA?V6_\
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MQ0\:6+AK'Q9\8_$USXCNK8@Y#1QW)^SHX;Y@XB#J<$,,"OLNB@   & ****
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M>\,Z/)-;B_M[V!H+HRW$;BX:62)BIG,GF]"'!4$ 'Q+\1?$_C+_@X+^*5_\
M /X2:I>:+^QKX)\2+#\1?'5I*T4_Q9U*TE#G2--=2"NEQR*IFNA_K64",\!J
MT_\ @XJ\-:-\*?V7?V<OB]INE1Z;X)^"O[4_@77O$,-E"([;2]%MVGM@^U1A
M$C:6"->P#XKO=,_X-MO^"-&BV,>F:-^RIK-I;1 B*WMOC!XLCC0$Y.%750!R
M2?QKZDM?V4_V?(/V:(OV/+SX9VFH_#:+PTN@?\(MK=Q-J$4FG*@189)+EY)9
M2% ^=W9\@-NW &@#XC_X.?-0TSQ__P $R]-_9Y\,:JESXF^,/Q4\*^'? UG9
M3!Y;^[DU"*<&(+DLH2(G<. 63GYAG[@_:I_:&\%?LE_LV^.?VF/B)*!HW@;P
MO>:S>Q^8%:?R(F=8$)_CD<+&H[LZCO7AG[-'_!$O_@G?^RC\7='^.'PS^%6L
MWWB#PM;R6_@J7Q=XUU/6H?#$+C:T>GPWL\B6WR_*& +@<!ADY]O_ &I?V5O@
M1^VE\%-4_9U_:5\%R^(O!FMRV\FK:)'K-Y8K=&"=)X@\EG-%(5$L:-MW;25&
M010!\O\ _!OQ^SUXU^%?[ EK^T!\:H2WQ)_:#\27WQ.\>74D9#F?5'\VVCY^
M956U\AO+/W'ED&.M?9>C^._ 7BG7]7\&>'_&6D:EJNA-$FOZ39ZC%-<:<95+
M1K<1*Q:'>JL5#@;@"1G%:.GZ?8Z380:7I=G%;VUM"L5O;P(%2*-0 JJ!P
M !T KSWX4?LC_L]?!#XV_$C]HSX7_#[^S/&7Q<N--G^(6L_VM=S_ -JR6$,D
M-H?*FE:*#RXYI%Q"D8;=EMQ ( /AOP?_ ,$XOV^/^"<?PV\:?"7]C/\ X*(_
M#?P+^SG+?ZGKMK=?$/P-+>ZO\.;*<O/=+87"W,=O-'&3)*C7(PI))!.YFD_X
M-5/@W?\ PI_X)>7?B*--5_L+QY\5_$'B/P=+KB[;RXT=F@L[:>48'S2"S:3.
M &#AAPPKUCQ]_P $ ?\ @F-\3_BAJ_Q,\=_";Q-J,?B#Q%<:]KGA2?XCZT=#
MOM2GN&N9;B2Q^U>4=TS&0Q@"/)QLQQ7V+X?\/Z#X3T&R\+>%M%M--TS3;2.U
MT[3K"W6&"U@C4)'%'&@"HBJ H4     4 6Z*** "BBB@ HHHH *;//!:P/<W
M,R1QQH6DDD8!54#)))Z "G5^>7_!67]L+X_:-^U_\._^">_PK_:,T3X):+X\
M^&^O^(];^)&KZ):7MUJKVO[J/0].%[_HR3N"SNS*[A'0H 1AP#]!-'UC2/$.
MD6OB#P_JEM?6%];)<65[9SK+#<0NH9)$=25=64@A@2"""*LU\6_\$6?@C^U3
M\-?V2OA5XO\ BE^VA=_$'P+KOP2\-3>&O!6J^!M/L9_#,CZ?:R)%%?6@1[J!
M8F,069"XVJQD8DU\D?\ !S]_P3C_ &=-/_90^('_  4"U&[\8:K\0IO%GAB/
M3!JGC*\DTO1T:]LK*1;2P#B",/$&+;E8[Y'<8)R #]B:IR^(= M]7C\/SZY9
MI?S)OBL7N4$SKSR$SN(X/..U9/Q>B^(-Q\)O%$'PEFAC\5OX=O5\,R7&WRUU
M P/]F+;OEVB79G/&.M?@-\-_AM_P1<B_X)G^)[/]MJ6_/[;0LM77Q1;>([_5
M#\0V\<F67["EK"&\R0M+]D\HQJT+(RF0G,AH _H;)"@LQ  ')-4M'\1^'O$2
MROX?UZROA ^R<V=TDHC;^ZVTG!]C7RM\"OV1M3_:V_X)0_"_]GS_ (*L>&-1
M\0:T_@W2+GXB:7J.MW-K<7%Y;HLBK>36LJ2/(-J><-^'=7W;LG/YV>+_  '_
M ,$M;?\ ;6_9T3_@WIU:S'Q@A^*VG2?$-?A=K&H3:1_P@B;SJK:NTCM;^5_J
M54$^8Y<@!FV8 /W)IES<VUG;O=WEPD442%Y99'"JB@9))/  ]:?7XT_\%,_V
MIOV8_P!I/_@KCXC_ &,/V[O%'C#4_@]\%_"VCM8?!#P)9ZC=W_Q%\6ZG +Y)
M);73AY]U;6MD5;:2J1OM)?\ >E' /V.TK6-)UVR74M$U2VO+9R=EQ:SK(C8X
M.&4D&K%?$'_!&BV_X)$F+XDZO_P2\\#2^#-4EO=.L_BEX%U*WU.PO]*NK87/
MV8W&G:@Y-LS":<>9$H639@LS187[?H **** "BBB@#^5SXH_\E,\1?\ 8=N_
M_1SUA5N_%'_DIGB+_L.W?_HYZPJ^SC\*/A'N%%%%,04444 %%%% !1110 44
M44 %%%% ']0O[+?_ ";+\.O^Q$TC_P!(HJ[NN$_9;_Y-E^'7_8B:1_Z115W=
M?&S^-GW-/X%Z!7\VG_!3C_E(+\8/^Q[OO_1AK^DNOYM/^"G'_*07XP?]CW??
M^C#7J93_ !I>AY.=?P(^OZ'A5%%%>\?.!1110 4444 %%%% !1110 4444 %
M?T6_\$@/^4;/PH_[ 4W_ *63U_.E7]%O_!(#_E&S\*/^P%-_Z63UY6;?P(^O
MZ'KY-_O,O3]4?2=%%%> ?2A1110 4444 %%%% !1110 4444 >%_\$]_^2)Z
MM_V/>L_^E)KW2OGK]@O6+^P^#FK06V@7%RO_  G&LGS(B,9^TMQS7HGQKUW4
MKKX6ZQ;S>&;J%6MU!E=EPOSKUK?#4?K&)A2O;F:5_5V.?%XCZKA*E>U^2+E;
MO97L>@T5\1T5]O\ ZC_]1'_DG_VQ^<_\1'_ZA?\ R?\ ^T/MRBOB.H[JZMK&
MUDO;R=8H88R\LCG 10,DD^@%'^H__41_Y)_]L'_$1O\ J%_\G_\ M#[@HK\'
M;+_@I-^U[^T3\8_AQ\2?V3_V1Y=2^'^NV/B<^&;7Q#\1X-)E\90VDEK$]V8?
ML\HM!$^[RA*Q,GFL?D !;ZP^)L'[5'Q<_9QTU_@OJ^F_"GQ_K-O92Z@_B.RB
MUC_A'P^UKJ()&?*N9D^9%.1&Q&<XKBH\+4<1&3I5V[?].VKZ)Z-R2=[Z:^>V
MIZ.(XTKX64(UL/&/-_T]3Y=6GS)1;5K:Z>6ZL?IE17X/?M%^)?\ @H!_P3.G
M\#_'?QK^VX_QE\(:WX[T[P]XP\(>)/!.GZ;.5O'91<V$MH RR)@D1'*]"=P!
MQ]0_M3_!+]K/XMW^C7'[-/[;D_PC@L89UU>VA^'6FZ[_ &F[%#&Y:\.8=@5Q
MA.&W\]!2APHYJ:4Y<T;7CRQOKLT_:<O?KT"IQM&FX2=./).]I<\K76Z:]ES7
MV^S;5>9^H%%?A'^S1XR_X*!:=_P57N/V4_'7[>4_Q1\%^!? @USXAB7X9Z-H
MZ)>W:O'9:?OM8VE#XDBNMP=<K&5((R#^@%:83A%8N$I*LXV;6L%NM]IM>6^Z
M9EC>.G@JD8N@I<T5*ZF]GM\5.+VUVV:/MRBOP'^'7Q&_;H_:<_:%^-F@Z1_P
M5:T_X4:9X*^+^H^&/"_A:Z^&OA^_DFMHA&\922Y$<KX\P)SO)VY+$FOO#X'>
M#_B?X!^%FD^$?C-\87\?^)K-)1JGBZ30+?2SJ!:9W0FUM_W46V-DCPO7R]QY
M)J,+PFL6WRU6EKJXQL[.W2HW]Z1IC>-W@DN:C%R=M%.5U=7W=)1^YL_0BBOB
M.N@^%$TEO\2=$GBMVE9-0C*QIU;GH*Z*_!?L:$JGM[\J;^'LO\1RX;Q!^L8F
M%+ZM;F:5^?N[?R'UY16/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\ ?2U\,?I!
ML45C_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+0!L5\5_\%<OCW_P2ZTCP
MRW[/'_!2SP9I<UIJ/AJ?5?"6M>,? ]S=Z3'=GS8A'!J,<+I9W8**2I>)BDB8
M+!B*^O/^$EU?_H4+W_OI:J:[/=>*="OO#.I>&M0@@U&REMIIHMA9%D0J2 >_
M- 'XX?\ ! 2Q\)Z7^U9\+;7_ ()S>*?'-]\()/V<;.7]H^SO[K49_"]EXV:"
MW*K8M>Y07YF,IE2W)C5-P7 #*.[_ .#IC_@H?^QE#^Q=X]_8.D^.E@/BW9^(
MO#%Y<^#/L%UYZ0"]L[TOYGE>3C[,1)@/G!QUXK]-/@1X"M?V>/@;X+^ 'A/2
M-8U'2_ WA+3?#^G7]^8Q/<P65K';)))MPN]EC!. !DG '2NK_P"$EU?_ *%"
M]_[Z6@#YS?\ ;A^%'_!1/]AGXT^(_P#@EY\=8/%OBG3O!6M:5X;U72+>YM'L
MO$,FF2M8A3<Q1D.)7A8, 0..:_-?]E[]K/\ X((^ /\ @C2/@+^TSX1\'VOQ
M1M/ ]WIGQ*\ ^)O!;GQCJ'BTQNEPW[R#[2]S+=$-%.'_ '0:,%X_*(3]M/\
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M["K'_"2ZO_T*%[_WTM &Q16/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\ ?2T
M;%%8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_WTM '\NGQ1_Y*9XB_[#MW_P"C
MGK"K<^)S%OB3XA8J03KEV2#V_?/6'7V<?A1\(]PHHHIB"BBB@ HHHH ****
M"BBB@ HHHH _J%_9;_Y-E^'7_8B:1_Z115W=>7?LP^(M5C_9J^'D:>%+MPO@
M;20'5EPW^AQ<UW/_  DNK_\ 0H7O_?2U\;/XV?<T_@7H;%?S:?\ !3C_ )2"
M_&#_ +'N^_\ 1AK^C/\ X275_P#H4+W_ +Z6OYR/^"ETTEQ^WY\7)Y;=HF?Q
MS?%HWZK^\Z&O4RG^-+T/)SK^!'U_0\.HHHKWCYP**** "BBB@ HHHH ****
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M84[1DTM)=';^8^IX?VA_@[<3);P^,,N[!5']GW'))P/^6==K7Q9HW_(8M/\
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MX,.K2WUM8:DD1GBGM9ILR>5)$"65R=C%5'J?ENOT,_:L^)/PLT;_ ((T^%?
MGP]^$5YX)T;Q3\4VN/ ^E:WJ7VK4]5T^VMV-QJUQ)M0%GN'$8"*$5/+"Y'-?
MGG4X:4I0=^C=BL5&,:BMU2;MW/ZA?V6_^39?AU_V(FD?^D45=W7"?LM_\FR_
M#K_L1-(_](HJ[NOE9_&S["G\"] K^;3_ (*<?\I!?C!_V/=]_P"C#7])=?S:
M?\%./^4@OQ@_['N^_P#1AKU,I_C2]#R<Z_@1]?T/"J***]X^</0/V7/V<_&O
M[6'QRT3X$^ KVRM+[6'E:2_U*0I;V=O#$\TT\A )VI'&YP!DD #DU] ?'?\
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M[=59.-2,EW75^EK;?U<5!J=.47V=M%ZWOOI_P#A_@?\ L_? GX#_ ++OA?\
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M\=O^2(>,O^Q4U'_TFDK\,:^PX8J5(4JO*VM5^I\+Q?2I5*U+GBGH]UZ'H_\
MPUM^T'_T4#_RE6G_ ,:H_P"&MOV@_P#HH'_E*M/_ (U7G%%?4^WK_P S^]GQ
MWU7#?R+[D>AW?[6_[1HM938^/T,WEMY(ETJUVEL<9Q%G&:^2/B_^VK_P4&\:
M_&7P/;>//V;=-U+6K?P]XAL;:RGUW2)]+U&.X2S6=F#Q!O* 1"T<D98A@%S\
MQKW:&&6XF2W@C+O(P5$49+$G  KZ7U/]B7]FWX;^&_$-G\>_C!;0>-_#DNF1
M76HZ9X0DOO\ A&6O$D=K=)?-0S>:J1^84&%\I1\W;@Q^(J<L8NI)7:T6M]5Y
M/;^KGI9;A*//*4:4'9/5Z6O%Z7NM_P M=#Y _9,\;_M0?L2?L6Z%\$_!VOCQ
M%J?AC3[J6VT:T%K''//-<RW+6\4]S&=J!IBJLY PN<#H/(?AQ^T5_P %+? O
M[8?Q _:NC_98O#=>/]&TK3KJW'C#0=T*6<>P,2<J<CG"JI]2:^E/%6E:3HOB
M>_T;P]XACUBQMKR2*RU2&W>);R)6(64(_P R!A@[6Y&<&OJ'2_V4_@UX._95
M\=_\)_X?EO/BAH'AJSUR\D-]-&F@K=RA;>T:-'"O-Y2F1PZG;YJKVK'$35&%
M%*I-*-E%*VGV4]5T3L_7N;X6E[>I7DZ4&Y)N3=]=>9KW6MVKKTWL? W[5/CC
M]KY?VH?AS^VM\*H8O%VL^!M,U#2;W0F^R6LS6=VI#26YD01%QN;(8;B-H'?&
M-JGQB_;8_:W_ &KOA=\<?B/X$N?!&A_"2?4;[2KC66T][^]N[N!861(K=2%C
M 1"2^0PSCG&/M/\ 9P^%_P )[#X*>,?VGOC/X9G\1V'AN]M=,T7PO%?/;1WU
M[/SNGEC^=8T4AL*1NY';!T/%_@'X/?'C]FCQ#^T#\(OA</!>L^!M4M(/$FBV
M>J375G>6=TVR*>/SB7CD5^"H.W:"W4\34JWKR3E+E<HWVY>;2W][I';2_P R
MJ5&V'BU"'.H2Y='S<GO7_N[.6^MK^1XIH'[:W[<EW\9-?\.^('M+7P9:Z?;R
M:!X@CM[%IKVX8#SHVB"ED"G(!**#CJ:^8?%W_!/KX2Z)\(=;\)_"V3QC!,NA
MWD>C:1#X]U".U:=XW*(8VG$6UI&Y#?*=QW<$U]#U[/X-^.O[+7AOP]IF@ZU^
MQ=9:W<16<,>M:K>>-+Y)[V8*!))&L>$@R<X4 XXY-=.*BZD?WD74W[75^UVO
MZ6IRX.4:,_W4HTEI>R=G;:]D_/[W8^8O^"<^F?%?]C7]GS3/".D:YJ>DZQJ-
MA;/XDT^^U!-1C@N8U9=L/F&6.)1N/RQ$*?>O??\ AK;]H/\ Z*!_Y2K3_P"-
M5J_MK_!3P7\"OC6?#/P^EO%TC4M%L]5M+#47W7.GBX3<;>4]2RD$\\[67))Y
M/D=:X.KRX6"I2:C;0QQV'C/&5'7BG.[OI?\ KR/6?!W[5_Q^NO%VE6L_CW<D
MFI0*Z_V5:C(,B@CB*OV?K\'/ W_([:/_ -A6W_\ 1BU^\=?-<43G.5+F=_B_
M0^MX/I4J<*W)%+6.RMW"BBBOE#[,_E<^*/\ R4SQ%_V';O\ ]'/6%6[\4?\
MDIGB+_L.W?\ Z.>L*OLX_"CX1[A7HWP&_:T_:%_9ECU.U^"?Q&ETBUUKR_[7
MTZ:PMKRTO/+W;#+;W4<D3E=S8)4D9-><T42C&2LU=!&4H.\79GT%^W9^WO\
M%W]K?QWJNDR_$;4Y? $>L->>'_#CV4%E#&=N!)+#;JJR2C+?.Y=@&/S<FCX2
M?\%.?VL_@Y\/=+^%OA_7_#FHZ+H4#0Z%;^(?!>G7SZ>A<N5CEEA,F-S$X9F
M)KY]HK-4:7(H<JLC1UZW.Y\SNSMOCY^T=\;?VH?';?$KX\?$*]\1:P8!!%/=
M!$CMX021%%%&JQPH"2=J*HRQ.,DFO3?A;_P5#_;)^$7@32?A_P"&O'^F7EKX
M<A\KPO>:]X8L=0O-$CP $M;BXB>2-0  JY(4 !0  *^?**ITJ<HJ+2LA*K5C
M)R4G=GH?P_\ VK?V@?AE\<)_VC_"OQ(NO^$TO)+A[[7-2@BO7NO/4K,)5N$=
M) ZD@@J>.F,"O1OB3_P5._;,^)7@+4?AD_CO2O#^C:S 8=;MO!_ABRTI]0C(
M(*2RV\2R%2"05#!6#$$$'%?.U%)TJ4G=Q0*M5BFE)V?F=C\.?C_\7/A-X(\7
M_#CX?^+?[/T;QYIT5CXKL_L%O+]NMXV9D3?)&SQ8+,<QE2<\DUUW[./[<G[0
M'[+7A[4/!_POU+0Y='U.]%Y=Z7K_ (7LM1B-R$""5?M$3,C;0!\I ..0:\@H
MIRIPDFFMQ1J5(M--Z'<_M ?M)?&S]J/QS_PL7XZ^/;G7M46W6WMFEC2*&U@4
MDK###$JQPH"2=J*!DDG))-<-115)**LMB92E)W;NS^H7]EO_ )-E^'7_ &(F
MD?\ I%%7=UPG[+?_ ";+\.O^Q$TC_P!(HJ[NOCI_&S[BG\"] K^;3_@IQ_RD
M%^,'_8]WW_HPU_277\VG_!3C_E(+\8/^Q[OO_1AKU,I_C2]#R<Z_@1]?T/"J
M***]X^<.D^$WQ?\ B9\"?'=G\3?A#XSO= U[3]XM-2L' = ZE'7!!#*RD@J0
M00<$5] ?&O\ X*F_M+?$SX#^&_A;IGQ:O-/N9](O[3Q\VD>'[#3!J7FWDKQH
M)+2%',9@9%=1M5V+%@Q)8_+=%9RI4YR3:U1I"M5A%QBVDSUC]F_]MC]H+]E3
M3M4T#X2>(=,72=;GBFU?1]:\/6>H6US)&&$;E;B)RK*&894KUYS5C]HW]N_]
MI[]JC0K'P;\6OB!&WA[2Y_.T[PSHNEV^GZ?!+@CS/(MT17<;FPS[B-S8(R:\
M?HI^RI\_-97[A[6KR<G,[=CUG]G;]MO]H?\ 9?T/4_!_PQ\4V4OA[69UGU3P
MSK^C6VI:=/,H 6;R+E'59 %4;UP2%4$D 8P_VA?VF_C=^U/XRA\<_''QQ+K%
MY:6BVFGPK;QV]M8VZ_=A@@B58XD'HJC)Y.3S7!44*G!2YDM1.I4<.2[MV/H;
MX;_\%2_VT_A9X!TOX?>&OB3830^'[0VGAK5-7\-6-[J&C0$;?*MKJ>)I(U"\
M 9.T8"X  'E7PX^/_P 8?A-\9K7]H7P-XXN+?QG:7\U[%K]W#'>2M<3*ZRRN
M+A761F$CY+@\MGKS7'44*E35[):[C=6K*UY/3;R/5O@5^VW^TY^S3XV\1?$7
MX*_$I='UCQ8K+X@NWT.QNA=JTAE8%+B"1$!<D_(J^G3BNL^(/_!4G]N+XI>!
M]5^'/CCXM:9=Z/K=C)9ZG:Q>!-$@:6&12K*)(;-9$)!^\K CL17S[12=&DY<
MSBK^@*M6C'E4G;U"OZ+?^"0'_*-GX4?]@*;_ -+)Z_G2K^BW_@D!_P HV?A1
M_P!@*;_TLGKSLV_@1]?T/3R;_>9>GZH^DZ***\ ^E"BBB@ HHHH **** "BB
MB@ HHHH \+_X)[_\D3U;_L>]9_\ 2DU;_P""B?\ R99X^_[!47_I3%53_@GO
M_P D3U;_ +'O6?\ TI-97_!636]3\.?\$[OBCK>C7/DW5OHD+0R[%;:?M< Z
M,"#P>XKHPC4<53;Z27YG-C(N6$J)=8O\C\D**^:?^&@/BY_T-O\ Y(6__P ;
MH_X: ^+G_0V_^2%O_P#&Z_0/KM+L_P"OF?F?]G5^Z_'_ "/I:I+2<6MU%<F!
M)1'(K&.495\'.".X-?,O_#0'Q<_Z&W_R0M__ (W1_P - ?%S_H;?_)"W_P#C
M='UVEV?]?,/[.K]U^/\ D?IAX.^/G[+?_"I?&&LW'[*EA;7+:II,L_A^/QS<
M+::A*&N2KI$R&1(XR26C5R")%&5 Y\RU#]H32_B3\?\ 4OC;^T+\.(/%<&L;
MA?:'::C)IZ1J(EBA$4B!F3RE1 N<YV_,3DFOAS_AH#XN?]#;_P"2%O\ _&Z/
M^&@/BY_T-O\ Y(6__P ;KEA+"0E)VEKYNZ6FSO?I_5CLG#&SC&-XV7DK-W>Z
MY;/?KY]V?HWI/[6OP.^#.D:I<_LO?L]W>A>)M6TZ2R_X2CQ!XD:^ET^&08D%
MO$$50Y'1R<C'0C(K@?V>/V@3\$KK7-#\0^#H/$OA3Q7IPL?$_AVXNF@^U1JV
MZ.1)5!,4L;$E6P<;CQG!'Q%_PT!\7/\ H;?_ "0M_P#XW1_PT!\7/^AM_P#)
M"W_^-TU/!J,HV;OO=W>FVM[Z=.Q+IXYSC)2BN79)66N^B5M>M]S] ?&W[37P
MUT?X0:Q\$_V</A%=>&-/\3SP2>*-7U?6C>WM]'"V^.W4A$6*-6))QDMD@XR<
M\%KWC_P3JGP=T+X>:=\++2RUS2]0N)]1\61W>Z;4HI"2D+1^6-H0$ '>V<=!
M7QW_ ,- ?%S_ *&W_P D+?\ ^-T?\- ?%S_H;?\ R0M__C=7"MA8+1/>^_6U
MM===.Y-2AC*CU<=K;:)7OHK::]M3]*]?_;7_ &>_&'PO\,_"7Q9^Q]=2Z/X7
MM0EG9:?\1Y[2"2<KB2Y>..U^>5CN.YBS#<W/)SXA\5_$OPU\5^*%U3X5?#";
MPEI@M41M*FUZ342906W2>;(B'D%1MQ@;>O-?(?\ PT!\7/\ H;?_ "0M_P#X
MW1_PT!\7/^AM_P#)"W_^-U-&IA*#O!2^]M:^3=AUJ6-Q"M4<>G1)Z;:J*9]+
M5ZI^Q!_R=W\._P#L:[3_ -#KX5_X: ^+G_0V_P#DA;__ !NO;?\ @F[\:_B;
MKO[>?PFT?5?$WFVUSXWLHYH_L4*[E,G(R$!'X56(QE)X>:L]G^1.%P%:.)@V
MUHUW[^A_1#1117YZ?IQROQV_Y(AXR_[%34?_ $FDK\,:_<G]H*[M[#X"^-[Z
M[DV10^$-2DE;!.%%K(2<#GI7X"?\- ?"/_H;?_)"X_\ C=?5\.3A&G4YG;5?
MJ?&<54ZDZM+E3>C_ $.RHKC?^&@/A'_T-O\ Y(7'_P ;H_X: ^$?_0V_^2%Q
M_P#&Z^E]M2_F7WGR?L*_\K^YG:VPN#<1BT#^;O'E>7G=NSQC'.<U]=>&?VF?
M"'QD^%7C"[_:A_9[M]:U.#4]#L-;U/P[<2Z=J>H29N(HII5&5DGC"$!<*&W;
M2  ,?"4/[0WPHMYDN(/&+))&P9'6QN 5(Y!!\NOH#PY_P6/\3:?\.=>TS5?C
MQ<3>(KBXL/[%U9_"L,D\<4?G";?.UMYA;#1[6)9AAL%<G/#C5"K&/+9M-:\U
MFM5V_'[ST,O<Z$I<_,DT].523T>Z=M>WK8]2\-_!OX _LT?MW^(/!OQ,^(=M
M'HO@ZR_M'PU<:[:R2Q7-^T4$MK!=+ A)"&8NV  Q@Q@;L5Z+\'_AS\/->^$O
MQVUG4_VOM!\0S^*-,LYM?UU-(O573V-T[^;*KQAF#,2H" XQT K\\-<_:<^'
MGB;6+KQ#XB^(5Q?7][.TUY>7=M<R2S2,<L[,R$L2>236OX2_;6T#P+X6\0^"
MO"OQ+^RZ9XJM8K?7K;^QG?[5%&Y=%W/"63#$G*%2>^:SJX?VD$_;>][M]K:-
M-O9^OK:^AM1Q/LJC7L/=O)KXK^\FDMTG;;TO;4]T^"WQZ\'_  CT?QE\"_B-
MX9/C/P#XDND6Y?3;DVL\<T$A\F]MG=3M) !V,!D!0> 5;VK1?''PB\-?\$^/
MBD_PR^&VJ:!X=UF_L--TC4?$FHK<7^NZ@TH:491$C6."% 0J \^82<Y%?&OP
M8_X* Z;\!+^^O?A[X\L434X4BU&TU+PU]KAN%0EE!6:%L8))!7!IWQG_ ."A
M;?'Z[LYOB;\5_M5OIL933-.M=&>VM+-3U$<,42HI.!EL;C@9/ IU:,*M;=)7
M3;YMVK?9VOI:]]O,5"O4HT&N5N5I)+EV3O\ :WMK>UM]-B:?0==M=(@\07.B
MW<=A=2,EM?26S"&5E^\JN1M8CN >*]!^!/[4'Q*_9QF>W\&^'O#MRS7ZW+KK
MOA^*YE$@  "R,!)&,#HK+SS7DFK_ +;>B:[\-=)^$&J_$WS?#NA7DUUI6G?V
M*R^1-*29&\P0B1LDGAF('8"O2= _X+#^/_#VD6>F6_Q/T6XETZVCM].U&]\#
M02W5M'&H6,+(UMD[0  6R>*WK3]I#E:C)=G+ITZ/YG-0INE4YDYQ:2U4;Z]>
MJ^7?K8]"_P""B7@S2_#WQET;QC;6]]9W_C7P9I_B'7-(U*^DN)M-O9PXD@+R
MDO@;!A6.1G PNT#P.L3QW^U]X5^)WBN[\<?$#XHW6K:M?N'NKZ\M+AG<@  ?
MZO 4  !1@     5D?\- ?"/_ *&W_P D+C_XW6F'E"E0C"4TVEW,L5&I6Q$J
MD8-)OL>C^!O^1VT?_L*V_P#Z,6OWCK^>SP!\>_A-<>.]$@A\5Y=]7ME4?89^
M295 _@K^A.OG.))PG*ERN^_Z'U?"L)PA5YE;;]0HHHKY@^M/Y7/BC_R4SQ%_
MV';O_P!'/6%6[\4?^2F>(O\ L.W?_HYZPJ^SC\*/A'N%%%%,04444 %%%% !
M1110 4444 %%%% ']0O[+?\ R;+\.O\ L1-(_P#2**N[KA/V6_\ DV7X=?\
M8B:1_P"D45=W7QL_C9]S3^!>@5_-I_P4X_Y2"_&#_L>[[_T8:_I+K^;3_@IQ
M_P I!?C!_P!CW??^C#7J93_&EZ'DYU_ CZ_H>%4445[Q\X%%%% !1110 444
M4 %%%% !1110 5_1;_P2 _Y1L_"C_L!3?^ED]?SI5_1;_P $@/\ E&S\*/\
ML!3?^ED]>5FW\"/K^AZ^3?[S+T_5'TG1117@'TH4444 %%%% !1110 4444
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M^"(Q_P ^4M?R_P!>YE'P3^1\]G?QP]&%%%%>P>(%%%% !1110 4444 %%%%
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M11/?R(^-P!2,$C) (F_,.BG5I5*BMS?AOY;_ /#BI5:=*5^5WMIKL^^S_P"
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M_P#&J^QJ* /CG_AR%^R;_P!%&^*?_A;'_P"-4?\ #D+]DW_HHWQ3_P#"V/\
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M6Q_^-5]C44 ?'/\ PY"_9-_Z*-\4_P#PMC_\:H_X<A?LF_\ 11OBG_X6Q_\
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M?_!,C_@T5\8?##XC7LNE^-T\&3C5-+CG)_L2#7==1)=/#9.&CMK]T< D"1I
M"1@D ^R_!O\ P7M_X)5>//BM8?";P[^TZK2:OKAT;1?$USX7U.#0-1U'<5^S
M0:K);K:2,6! 82[&(^5FR,_8=?!_[?W[*'P<TW_@WA\>_L^6?A:PCT#P1^SG
M+J&AP"!0L-WI6F?;;>=>.)3/;JY?[S,[$DECGZ"_X)H_$SQ1\9_^"=?P)^+/
MC>_DN]:\1?"#PYJ&L7<K[GN+J738&EE)[EG+-_P*@#VZBBB@ HHHH **** "
ML_Q7XK\+^!/#&H>-?&_B.QT?1M)LI;S5=5U.[2"VL[>-2\DTLCD+&BJ"Q9B
M "36A7YO?\'%MUJ7Q-T+]F7]AZ_U6YLO"'QS_:2T#0?B"UM<-$;W2(Y!))9%
ME((\QVC8=]T*^] 'H<?_  <6?\$C9-8%N?VD]1316U#["OC:3X?ZVN@&YW;-
MG]H&S\C&[CS-WE]]V.:^KO'?Q^^#/PV^!NH_M+>+OB)IT/@+2O#S:[>>*;64
MW5H--6+SC=(T <RQF/Y@8PVX$8SD5:N?@Q\([SX2/\!+GX9Z$W@A]$_L=O"1
MTN+^SO[/\OROLOV?;L$6SY=F,8XKX!_X-O[_ %'PM\&_VAOV*+R^NM4\+? ?
M]IGQ3X.\#R:BYF\K1XK@-%;9<G=MD\Y_;SA[4 >G_#__ (.%?^"3_P 0_B!I
M'P\MOVBM0T27Q%=K:^'M7\7>!-9T?3=1E8@*J7=Y:QQ+G/!D9 ?7)%?:M?D+
M_P %\OVO/BO\:/V>/%O[$GQC_83\5?#+X9^(?'EIH>J_M)^/+9;_ ,/:#9V^
MJ1F/5XX--2XG'G^4JPF;R /M*AW7D5^L?@#3M*TCP)HFDZ%KAU.QM=(MH;/4
MFG$INXEB54FWKP^Y0&W#@YS0!SWB;]H_X,>#OCSX6_9C\1^,OLWCCQIH^H:K
MX9T3^SKE_MEI8^5]JD\Y8S#'L\Z/Y7=6;=\H;!QXC^UK_P %K_\ @ES^PS\2
M+WX/?M0?M=:-X=\5:;Y/]I>'K;2-0U*\L_.A2>+S8K&WF:+=%)&XW 95U/0B
MNW^)G[&O_"Q?V\_A;^VY_P +'^Q_\*U\'^(-"_X1C^Q_,_M'^U#:GSOM/G+Y
M/E?9ON>6^_?]Y<<_(W_!TM\._A_I'_!&?XV>/])\"Z-:Z]JVH>&/[5UNWTR)
M+N\V:WIL:>;,JAY-J(B#<3A44#@ 4 ?I02 ,DU\::[_P< _\$GO#WQ$NOA_>
M_M/^;!I^LC2=2\7V?A35)_#MG?%@HADU:.V-FO)4&3S#&-W+CG'OW[:W@OXC
M_$G]C7XM_#OX.7$D7B_7_AEKVG>%98I C)J4^G3Q6S!B1M(F9"#D8K\N/V3O
M^"B/_!,OP)_P;_0_L>^.?%>A67CS3?A;J7@SQ'\"KJSQXDO_ !0Z36\MLFF;
M?/EEN+U_,$@4A3+N9E*-M /V/LKVSU*SAU'3KN*XM[B)9()X) Z2(PRK*PX(
M((((X(-2U\/?\&W7Q0\6?%W_ ((G_ CQ5XTOI;F]M-#U'1XYYB23;:?JU[86
MR@GJ%@MHD_X#7W#0 4444 %%%% !7)_'3XW?#;]FWX0>(?CQ\8M8NM.\+>%=
M-?4-?U&RT:[U![2U3'F3>1:12S.J#YF*HVU0S'"J2.LJ'4-/L-6L)]*U6RAN
M;6YA:*YMKB(/'+&P(9&4\,I!((/!!H QOA;\4?A]\;/AMH7Q@^%/BRTUSPSX
MFTJ#4M"UBQ<F*[M9D#QR+D C*D<$ @Y! ((KY*\8_P#!P]_P1^\!S,OB/]K&
MZ$/]I7MC!?V/PU\27=I=S6DODSFWN(-.>*XC63*^;$[QL0=K-BOB#XT?#?\
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MW;?!34?&-UXKT*V\;:5HC@:A9Z?;VRB74)HP=QCG;**^/*PVW<I.!^U':?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%>(_M)_\%&OV-/V0
MO'5I\-?VB/C'_P (]K=]I,>IVME_PCVHW>^U>66)9-]M;R(,O#*-I(;Y<XP0
M3Y[_ ,/P_P#@EU_T<]_Y96M__(5:QH5Y*Z@VO1F,L1AX2M*:3]4?6%%?)_\
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M8WX:@#]B_P!GCXR6'Q]_9W\#?M!V^E-I=KXU\%Z9XACL;B4,;2.\M([D1LV
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MX6%^U/X6\'^,/^)3:77V_1;S[1]HM?\ 28I/*W[%_>1[)%Q\KC)K[7K\GO\
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M3X#ZQ:>(?$'P?\2:UXY^*%SI4JSKX9L$@@6&&Y="1%)-)&4,;88&2#(Q(IH
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M/@%_PM3Q)!XA_P"$L^P>38K;^3]@\W.'=MV?,7^_C&.U<M_PQQ_U4;_RD?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>biib-20200930_g8.jpg
<TEXT>
begin 644 biib-20200930_g8.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?@3XCT'3M*UF*X=9+Z*_TXW4CW!D;8I5AM&W QUYKZ6M;JVO;:.\LKB.:&5
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MOAXOPXO_ !M\7V\!>.[+1M2NGMO$>DWMC/(5O(YI7$SQO#O61OFWD,2S(A4
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MER6*CW.:]:T[7]"U>XN+32=:M+J6TDV7<5O<J[0MS\KA22IX/!]*_$WXL?M
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MIBO8* /C3XL_\$(O^"6'Q?\ 'WC?X\_M.?!";QSK_BV_N]1UOQ#XT\8Z@_\
M9\+LTA@MMD\<=E;Q D)Y:J54#+'&:^?O^"+O[1OCKX'_ /!*3]H[XTCQ?K7C
M3X5?!_QSX[N?@%KOBFZ>:?5?"&DVQFM0)F^:6W#Q2HK]CO0!5157R3_@IK_P
M6"_99_:W_;/\3?\ !,;XO_M;+\%O@/X U%['XV^(1;7HUCQ[>Q2%)O#UB;:%
MVMK)71DN;AMK2@%$RAS)]W_"'XB?L%_\%)/^"=WQ&_9@_P""=OQ'T"_\#CP#
MJ7P_ACT/2KFTM-&^U:9)!'"$FBC;"QS*V0#GN2<T ?'/['W_  1@^ '[:O\
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M6UU"LD<JGJK*P(8>QJ>B@"MI&CZ1X?TR'1=!TNVL;.V39;VEI L442_W550
MH]@*LT44 %%%% &<OA#PFGB1O&2^%].&KO#Y3:J+*/[28_[AEQNV^V<5HT44
M %9WB7P?X2\:6::=XQ\+:=JUO'()(X-3L8YT5QT8*X(!]ZT:* &PPPVT*6]O
M$L<<:A41%P% X  '04ZBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** *5]XBT339_LM_J4<4@ .QCSBHO^$Q\,?]!J#_OJO(/V#;FYUWX.:K>Z
MY</>3+XVU>-9;MS(P1;DA5RV3@#H.U>U_P!G:?\ \^,/_?H4 4_^$Q\,?]!J
M#_OJC_A,?#'_ $&H/^^JN?V=I_\ SXP_]^A1_9VG_P#/C#_WZ% %/_A,?#'_
M $&H/^^J/^$Q\,?]!J#_ +ZJY_9VG_\ /C#_ -^A1_9VG_\ /C#_ -^A0!3_
M .$Q\,?]!J#_ +ZH_P"$Q\,?]!J#_OJKG]G:?_SXP_\ ?H4?V=I__/C#_P!^
MA0!3_P"$Q\,?]!J#_OJC_A,?#'_0:@_[ZJY_9VG_ //C#_WZ%']G:?\ \^,/
M_?H4 4_^$Q\,?]!J#_OJC_A,?#'_ $&H/^^JN?V=I_\ SXP_]^A1_9VG_P#/
MC#_WZ% %/_A,?#'_ $&H/^^J/^$Q\,?]!J#_ +ZJY_9VG_\ /C#_ -^A1_9V
MG_\ /C#_ -^A0!3_ .$Q\,?]!J#_ +ZH_P"$Q\,?]!J#_OJKG]G:?_SXP_\
M?H4?V=I__/C#_P!^A0!3_P"$Q\,?]!J#_OJC_A,?#'_0:@_[ZJY_9VG_ //C
M#_WZ%']G:?\ \^,/_?H4 4_^$Q\,?]!J#_OJC_A,?#'_ $&H/^^JN?V=I_\
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M_P!^A0!3_P"$Q\,?]!J#_OJC_A,?#'_0:@_[ZJY_9VG_ //C#_WZ%']G:?\
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MB@ HHHH **** /"_^">__)$]6_['O6?_ $I->Z5X7_P3W_Y(GJW_ &/>L_\
MI2:]TH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_9VG_P#/C#_WZ%']G:?_ ,^,/_?H4 4_^$Q\,?\ 0:@_[ZH_X3'PQ_T&H/\
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M3LT;P]K_ .V)\4D\)6OBN]GM- >+PKJ.IM=S0HKR*%L+:=DPK*<L #G@G!H
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M#]H?X*^'/@U97?[/NE> -!\$Z=XEMM3U+Q$!<0WAUO4I;0>0CE(XXHX]TCA
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M\.O#WQ(^.VF_:]:B\'#5HK/2YM0O]3\^6S2XEDA14A@E;YBZJSQ':2&4&?\
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M9/[5_P"$;UF:P_M'_A-/(^T>6V-_E_8GV9]-QQZU]YU^#'_!0/\ Y/9^)_\
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M2/UWP<X\XLXJX@KX;-,1[2$:3DER4XVESP5[PC%[-];'O5%%%?CI_1H4444
M%%%% !1110 4444 %%%% 'A?_!/?_DB>K?\ 8]ZS_P"E)KW2O"_^">__ "1/
M5O\ L>]9_P#2DU[I0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !63XI\!^"_&]
MQI%WXO\ "]EJ4N@:LFJ:+)>6ZR&RO4CDC6XBS]R0)+*H8<X=AWK\_?$/_!?S
M^P=?OM#_ .&3?-^Q7DL'F_\ ">;=^QRN['V$XSC.,FJ?_$0C_P!6B_\ E_?_
M '!7VL?#OC&236%_\GI__)GYG+QB\.(2<7CM5_TZK?\ RL_22BOS;_XB$?\
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M%"]_[Z6MBB@#'_X275_^A0O?^^EH_P"$EU?_ *%"]_[Z6MBB@#'_ .$EU?\
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M6Z*]Q\,_L.^+[C]N"']B/QWXKM]'U-M3>UFUFUM#=1*GV5KJ.98R\997CV$
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MUZ%%%% !1110 4444 %%%% !1110!X7_ ,$]_P#DB>K?]CWK/_I2:]TKPO\
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M/>L_^E)KW2O"_P#@GO\ \D3U;_L>]9_]*37NE !1110 4444 %%%% !1110
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M^ Q_QH^Q>-_^@W9?^ Q_QK8HH _G.^( 8>/-;#D$_P!KW.2/7S6K(K8^(?\
MR/\ KG_88N?_ $:U8]?VI1_@Q]$?YFXG_>9^K_,****T,0HHHH **** "BBB
M@ HHHH **** /Z ?V?;/QDWP$\$&#6;14/A#3=BM;$D#[+'CO77_ &+QO_T&
M[+_P&/\ C6-^SO\ \F_^!?\ L3M,_P#22*NQK^,,;_OE3_$_S9_I7EO_ "+J
M/^"/Y(Q_L7C?_H-V7_@,?\:_"S]OA;E/VT/B8MY*KRCQ?>>8Z+@$[^PK]ZZ_
M!C_@H'_R>S\3_P#L<;S_ -#K]1\(O^1QB/\ KW_[<C\*^D-_R3N#_P"OK_\
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M'O6?_2DU[I0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MU_ '_0?_ /)67_XFO&:*/];,Q_DA]S_^2#_B&N1?\_*GWQ_^0/9O^%K^ /\
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M8O\ XFC_ %LR[^2?W+_Y(/\ B&N>_P#/RG]\O_D#V:BO&?\ A:_C_P#Z#_\
MY*Q?_$T?\+7\?_\ 0?\ _)6+_P")H_ULR[^2?W+_ .2#_B&N>_\ /RG]\O\
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M888MTF+8/W V>,T ?6=%%% 'A?\ P3W_ .2)ZM_V/>L_^E)KW2O"_P#@GO\
M\D3U;_L>]9_]*37NE !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1139YX+6![FYF2..-"TDDC *J@9))/0 4 .HJMH^L:1XATBU\0>']
M4MKZPOK9+BRO;.=98;B%U#)(CJ2KJRD$,"00015F@ HHJHVO:&NL+X>;6;07
M[1>8MB;A?.*?W@F=V/?&* +=%%% !115?5=7TG0[)]3UO4[>SMH\>9<74ZQH
MN3@99B .: +%%1VMU:WUM'>V5S'-#*@>*6)PRNIY!!'!'O4E !1110 4444
M?RF?%+_DIOB/_L/7G_HYZPJW?BE_R4WQ'_V'KS_T<]85?MU/X%Z'\]5/XC]0
MHHHJB HHHH **** "BBB@ HHHH **** /ZE/V5_^38?AQ_V(6C_^D4-=Y7!_
MLK_\FP_#C_L0M'_](H:[ROQ2M_&EZL_H+#_P(>B_(*_FF_X*?_\ *0OXQ?\
M8^W_ /Z,-?TLU_--_P %/_\ E(7\8O\ L?;_ /\ 1AKZK@__ 'RI_A_5'QG'
M?^X4O\7Z,\(HHHK]!/S **** "BBB@ HHHH **** "BBB@ K^CK_ (([_P#*
M-+X3?]@&?_TLN*_G%K^CK_@CO_RC2^$W_8!G_P#2RXKY/C#_ '"G_B_1GVW
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MK?MAZ-X;\1> ];O=)\2Z#J^DW\=W!=6LC1R+'&(";D$IE&AWAP5QR<4 <O\
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MAKZK@_\ WRI_A_5'QG'?^X4O\7Z,\(HHHK]!/S **** "BBB@ HHHH ****
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M_P"1*/\ A[M_P3Q_Z.#_ /+3U;_Y$H_U:XC_ .@*K_X+G_D'^NW!G_0RP_\
MX.I__)'TE17SGIW_  5G_P""?FJZA!I=A\?O,GN9EB@C_P"$5U4;G8@ 9-K@
M<D=:^C*X<9EN8Y<XK%T9T^;;FBXWMO:Z5['J9=G63YPI/ 8FG6Y;7Y)QG:^U
M^5NU[.U][!1117$>F?RF?%+_ )*;XC_[#UY_Z.>L*MWXI?\ )3?$?_8>O/\
MT<]85?MU/X%Z'\]5/XC]0HHHJB HHHH **** "BBB@ HHHH **** /ZE/V5_
M^38?AQ_V(6C_ /I%#7>5P?[*_P#R;#\./^Q"T?\ ](H:[ROQ2M_&EZL_H+#_
M ,"'HOR"OYIO^"G_ /RD+^,7_8^W_P#Z,-?TLU_--_P4_P#^4A?QB_['V_\
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M<3152*:O?1[Z.W2_YF.*PTL)7=*33:MJKVU2?5)]>P5_1U_P1W_Y1I?";_L
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M_)ZG_P F'_$9/$C_ *#O_*5'_P"5GZ2?\1"/_5HO_E_?_<%'_$0C_P!6B_\
ME_?_ '!7YMT4?\0ZX-_Z!?\ R>I_\F'_ !&3Q(_Z#O\ RE1_^5GZ2?\ $0C_
M -6B_P#E_?\ W!1_Q$(_]6B_^7]_]P5^;=%'_$.N#?\ H%_\GJ?_ "8?\1D\
M2/\ H._\I4?_ )6?I)_Q$(_]6B_^7]_]P4?\1"/_ %:+_P"7]_\ <%?FW11_
MQ#K@W_H%_P#)ZG_R8?\ $9/$C_H._P#*5'_Y6?I)_P 1"/\ U:+_ .7]_P#<
M%'_$0C_U:+_Y?W_W!7YMT4?\0ZX-_P"@7_R>I_\ )A_Q&3Q(_P"@[_RE1_\
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MV+2(5FUN'3]:L[NYTR,C(>X@@E:2)<<DE<* =V,5S?P(_90^/7[2B7]U\(?
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MM9/+N+AE$L:P1(^%Y))W*>,KGT?_ (*7?L5V-YXG^*7[5OP*^/FD>--'\/\
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M]G:?_P ^,/\ WZ%?S5_\%/$2/_@H3\84C4*!X\O\ # '[PU_2U7\TW_!3_\
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M/Q[Q0R#*<YQ6&EC*?.XJ5M9*UVNS1Z)_POO_ *E3_P GO_M='_"^_P#J5/\
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M<**JKA:-5/FOJT]WHUHFM=/E^HJ.,KT&N1K1-;)W3=VGIK\[^6R/HO\ :/\
MVU_AWXS_ &>M,_9$_9B^!+> ?A_9^(CKVJ_VCKK:EJ6MZCY1B6:>8HBHJQD
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M?\FP_$?_ +$+6/\ TBFK^6NOZE/VJ/\ DV'XC_\ 8A:Q_P"D4U?RUU][P=_
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M ",JG^#_ -N1]+4445^=GZD%%%% !1110 4444 %%%% !1110!X7_P $]_\
MDB>K?]CWK/\ Z4FN=_X+$?\ *-+XL_\ 8!@_]++>NB_X)[_\D3U;_L>]9_\
M2DUSO_!8C_E&E\6?^P#!_P"EEO79EW_(PH_XH_FCAS/_ )%M?_!+_P!)9_.+
M1117[(?@H5^@_P"P?\?_ -F+]H#P1\*/V=?C#K_B;P9XM^%>D^+H/#^J:9IB
MWVD:G9:A97<UQ+<1*RRQSQ(78; 0_EXSEP$_/BOKK]@7]HC]D_1O&7AKPW\5
MOV5=-37=)T#6H#X]L/'<^E_:XVT^];9=0.DD+R.KF!9%\MLNA^<J%/G9I2]I
MA6TFVKM6M=:-==&K-I[[GJY/6]EC$G**3LGS)V?O)VT5T[I-/3;5GEW[7/['
MNK?LS:=X1\<>'_BOHWCWP%XZLKFX\%^,="66.*[6WD$=Q%)!* ]O-&[*&C.<
M%L9W!@O??L)?LW>$_".F6_[?W[6%S)H_PM\&:LD^B61^6\\9ZO"V^'3[)#]^
M,2(/-E^ZJJRY&':/AOVB_P!L/3?CNW@+P'H_P6T[PK\-/ANLT?ASP'INJSS$
MQW$ZS7C37D@\R6:9E ,FT!< A0<Y]Q^/?_!3S]C#]I.308OBG_P3:U&:Q\+:
M.FE^&]'T[XVW5G8Z;:KCY(8(;!44G W-C<VU020J@857F+PT:;@VW?F:Y;I7
MTW:7,UNUHM;=#HHK*XXJ=5324;<J:FTY6U>D6^5.]D]6K7ZGRM^T?\<?$O[2
MWQW\5?'GQ?:Q6^H>*=9FOI;6 DI;JQPD*D\D(@5 3R0N3S7TKX6_XQ'_ ."1
M.L>+W_T?Q;^TAXF_LK3">)(_#>FL3<2+GD"2X8Q,.C)(A]*^5OBSXB^'GBSX
MAZGXA^%'PWE\(>'KF5&TSPY-K;ZDUDH10RFYD1&ERP9LE1C=CMFO1/VR?VN1
M^U3JG@NP\/\ P]_X1+POX!\%6?ASPWX<75OMOE1P@[YWE\J+=)*Q!8[!]U<D
MD9/35H2JJE3C&T$TVM-.75+?O;:ZT.2CB(4I5ZLI7J--)ZZN3M*6R^S?>SU6
MFC-#]CW]M6R_93\$_$+P+K'P+T/QWI_Q"L]/MK_3_$-[-':HEK-),-Z0[6DR
M[(<;U V<YSQZI\4/ 7[,?[7'[!_C']K[X,_ 6U^%WC'X5Z[IEKXNT;0M1FGT
MK6+*_F$$,T23,6@E60\JIQM5B=Q8%/%/V:_BI^R1X+T/5?#?[3W[+^I>-S>7
M<4VF:YHGC.72[O3552'B""-XYE<E3\^"I7CJ:[;]H#]NCX;Z]^SNW[(W[)G[
M/2_#GP)?:S'JGB::_P!?DU/4]?N8L>49YF51'&I"L(E!&Y%((Y!PK49O%J5*
M$E+F3<K^ZTK7TYM;I6^'?7S.G#UZ:P3C6J1E'EDE'E]Y2=VM>72TG?XMKKK8
M^:J^Q/\ @M?D?M)>!4LL?V4OP4\-#0@N=HM/*EV[>V-_F=./QS7S[XK^+?PS
MUW]G/PK\']&^!&GZ9XHT+5KRZUCQ]%?AKC68968QV[Q>4-BQ @ ^8V=O05[/
MX;_;K_9V^)?PB\%_#G]MG]EN_P#'>I_#?3ETSPIXDT#Q>VE7%SI:-NBTZ\'E
M/YD2?=5T(95X !+,VM=5_;TZR@WR\R:NKV=K-:VZ=[V9CAGA_J]3#RJ)<W*T
MVG:ZO>+LF^N]K71M_P#!538?A1^RP^I[O[7/[.^D"Y,H&_[+EOL^>^,;\9_Q
MKS+_ ()@?\I"_@[_ -C[8?\ HP5S'[7_ .U-XN_; ^-%Q\6O$^AV6C6T5A;Z
M9X>\/:9G[-H^FVZ[8+2+.,JH+$G RSL0%!"CI_\ @F!_RD+^#O\ V/MA_P"C
M!4*C.AE,H3WY9-^5[NWRO8MUZ>(SN$Z>W-!+SM97^=KG]+-%%%?D9^X'!_M4
M?\FP_$?_ +$+6/\ TBFK^6NOZE/VJ/\ DV'XC_\ 8A:Q_P"D4U?RUU][P=_
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M*E*.\HM+YJQ^#=%?JM_Q#D_&'_H9OA9_X$:Y_P#'*/\ B')^,/\ T,WPL_\
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M<MU[4 7***JC7-%;5SX?76+4WZP^:UD+A?.$><;]F=VWWQB@"U1110 4444
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M679>"?!FF^()_%FG>$=+M]5NEVW.IPV$:7$P]&D"[F_$UJ44 %%%% !1110
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MQ/<IX<;1?..N#6])%@ 9_.7[+Y/^L_U<N_[OR?>H ]]HK\H?'?[:'QA^/_\
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M:SV.@6-E=1[)8;.))%R#A@@!&1QUJY10!^?_ .VC\0?B[\5_%GB?X/?M(_\
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M7VD>!O.^'?A[X#ZUX=UCQ#_:=JOV?4I[])8H/(:43ON0$[UC*#H6!XKZ_HH
M^'O^"M_[#?QM^,OQ6^"O[<O[,'PO\-?$+QM\#]4U1;WX6^+KJ&"S\8:+J5ND
M-W:I-<*T,-TGEJ\+R (&8LQ)15,/[.OQ.^+_ ,2OC9X7TBS_ .""S?##2X-3
M63Q'X^\7ZEX9MO[#"*762SBLVEGO)/,554IY87.\L,8/W/10 5^8G[,&A?\
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M<QS,+??("NV<QLO5@HYK[[HH ^0/V1_V7/CM\,?^"(?A[]D'QSX&^P_$2Q^
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M"\ _M@?L,_LS?LR_LN?LJ_"C2OB;:>&KWPQX.^*>NZMK$5D=)\.P6T=O?:Q
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MX\5^*OVN_",VBZ-&P,T\%N+H7%QMZ^5$9X=[]%\U<X!H ]._X*A?M0?M2_\
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MIX,S2.!N+';L&[["^/\ ^U'\=O!/_!9C]GW]E'PQXY^R^ /&_P -_%FJ>*-
M_LRU?[;=V:1FVD\]XC/'L+'Y8W56S\P-?)W[.'[''@+]OOXM?\%./V4OB$XM
M[;Q3\6=-CTW5%CW2:5J,=@TMI>Q]#NAG2.3 (W!2I.&->=?L(_MC?$#]J?\
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M6D<DDH9Y4&$0D9Y P<>+WG_!=G_@ES8?%RP^#UU^TILGU/6DT>S\2-X7U,:
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MS'M\K?\ !&'_ (*;?MX_&W]JN/P#_P % -;MQH'[0?PYN/B5^SQIZZ-:6O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MK2TB&V.$37,DDKJJX5=[L0H '  KJJ** "BBB@ HHHH **** "BBB@ HHHH
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M&?CGPFVB-K.E6U[)YS:3J-OJ31NWDR%MMPC,I#$X&=B $WA7_@KG^T?\0?\
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M_P""DFN^ =2/PPT+4QK-G\,-!U%QI<]U*;72?*NX&39;#Y1<8\Z3&78FM_\
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MH^HFRAL["Q2>!9&#_.\DCE</@;67Y_J#PK^RY\"?!/[1'BO]J[PQX&^R^/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
8B@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>biib-20200930_g9.jpg
<TEXT>
begin 644 biib-20200930_g9.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?@3XCT'3M*UF*X=9+Z*_TXW4CW!D;8I5AM&W QUYKZ6M;JVO;:.\LKB.:&5
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MOAXOPXO_ !M\7V\!>.[+1M2NGMO$>DWMC/(5O(YI7$SQO#O61OFWD,2S(A4
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MER6*CW.:]:T[7]"U>XN+32=:M+J6TDV7<5O<J[0MS\KA22IX/!]*_$WXL?M
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MIBO8* /C3XL_\$(O^"6'Q?\ 'WC?X\_M.?!";QSK_BV_N]1UOQ#XT\8Z@_\
M9\+LTA@MMD\<=E;Q D)Y:J54#+'&:^?O^"+O[1OCKX'_ /!*3]H[XTCQ?K7C
M3X5?!_QSX[N?@%KOBFZ>:?5?"&DVQFM0)F^:6W#Q2HK]CO0!5157R3_@IK_P
M6"_99_:W_;/\3?\ !,;XO_M;+\%O@/X U%['XV^(1;7HUCQ[>Q2%)O#UB;:%
MVMK)71DN;AMK2@%$RAS)]W_"'XB?L%_\%)/^"=WQ&_9@_P""=OQ'T"_\#CP#
MJ7P_ACT/2KFTM-&^U:9)!'"$FBC;"QS*V0#GN2<T ?'/['W_  1@^ '[:O\
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M6UU"LD<JGJK*P(8>QJ>B@"MI&CZ1X?TR'1=!TNVL;.V39;VEI L442_W550
MH]@*LT44 %%%% &<OA#PFGB1O&2^%].&KO#Y3:J+*/[28_[AEQNV^V<5HT44
M %9WB7P?X2\:6::=XQ\+:=JUO'()(X-3L8YT5QT8*X(!]ZT:* &PPPVT*6]O
M$L<<:A41%P% X  '04ZBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MG_\ /C#_ -^A0!3_ .$Q\,?]!J#_ +ZH_P"$Q\,?]!J#_OJKG]G:?_SXP_\
M?H4?V=I__/C#_P!^A0!3_P"$Q\,?]!J#_OJC_A,?#'_0:@_[ZJY_9VG_ //C
M#_WZ%']G:?\ \^,/_?H4 4_^$Q\,?]!J#_OJC_A,?#'_ $&H/^^JN?V=I_\
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M_P!^A0!3_P"$Q\,?]!J#_OJC_A,?#'_0:@_[ZJY_9VG_ //C#_WZ%']G:?\
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MB@ HHHH **** /"_^">__)$]6_['O6?_ $I->Z5X7_P3W_Y(GJW_ &/>L_\
MI2:]TH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[_X%M0!L45C_ /"#Z1_S\WO_ (%M1_P@^D?\_-[_ .!;4 ;%%8__  @^D?\
M/S>_^!;4?\(/I'_/S>_^!;4 ;%%8_P#P@^D?\_-[_P"!;4?\(/I'_/S>_P#@
M6U &Q16/_P (/I'_ #\WO_@6U'_"#Z1_S\WO_@6U &Q16/\ \(/I'_/S>_\
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M:U>&ZFNKW4IQG$EQ<W#O+*1N? 9BJ[VV@9->KT45$ZDZLW*;NWU8'T#X?_Y
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M_P#Y -C_ -><7_H JW7['1_@Q]$ 4445J 4444 %%%% !1110 4444 %%%%
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M_OT*/[.T_P#Y\8?^_0H I_\ "8^&/^@U!_WU1_PF/AC_ *#4'_?57/[.T_\
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MO)JWB.>QT#4Y8KK0=%OXGM=.BM+B3>ZF.TVSQ2MN<-."2Q%<9_P5,_X)!_\
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M3X2ZA_P09U9QX"M/#>NO^U(O@_4;Z;PHMB;4#2/-:X8Q->-<^9M6$DCRU8@
M2$_L/_PF/AC_ *#4'_?5?D?XL^,W['/[;'_!8W]FCQ;_ ,$@=)L-7U[P1JFI
MW/QS^(GP_P##<ECI,/AB2U"BPU"Y$4<=T\KAA$AW[7(P03Q^OG]G:?\ \^,/
M_?H4 4_^$Q\,?]!J#_OJC_A,?#'_ $&H/^^JN?V=I_\ SXP_]^A1_9VG_P#/
MC#_WZ% %:V\4>'[R=;6UU6)Y'.$13R35^HDL;*-@\=G$K#H5C (J6@ HHHH
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M#[_H8/\ R4E_^(H_X6U\/O\ H8/_ "4E_P#B*/[2R[_G]#_P)?Y@='17.?\
M"VOA]_T,'_DI+_\ $4?\+:^'W_0P?^2DO_Q%']I9=_S^A_X$O\P.CHKG/^%M
M?#[_ *&#_P E)?\ XBC_ (6U\/O^A@_\E)?_ (BC^TLN_P"?T/\ P)?Y@='5
M;6-%T?Q#ITNCZ_I-M?6DZ[9K6\@66.0>C*P(/XUB_P#"VOA]_P!#!_Y*2_\
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M4FO=* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH ^>=1_Y"$_\ UV;^9J&IM1_Y
M"$__ %V;^9J&OQF?QL HHHJ0"BBB@ HHHH **** "BBB@ HHHH ^@?#_ /R
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M_F:AJ;4?^0A/_P!=F_F:AK\9G\; ****D HHHH **** "BBB@ HHHH ****
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MY[E?.'7BMHUL)_9TZ<9-:+2RUE=-]=>VVB5^X'Z!U[?\,_\ D1=._P"N)_\
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M2*&*- %C1$5555     P*O4 >%_\$]_^2)ZM_P!CWK/_ *4FO=*\+_X)[_\
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M_0:@_P"^J/\ A,?#'_0:@_[ZJY_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H4 4_\
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M_P#79OYFH:FU'_D(3_\ 79OYFH:_&9_&P"BBBI **** "BBB@ HHHH ****
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M'>'_  77_P"EBK_S4;PQ_P#)%>@?LN?L:?\ !6'X4?';0O'_ .TO_P %H/\
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M%^/_ /D=-3_Z_'_G7S'%O^Z4_P#%^@&/1117P8!1110 4444 %%%% !1110
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M@ HHHH **** /GG4?^0A/_UV;^9J&IM1_P"0A/\ ]=F_F:AK\9G\; ****D
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M444 >%_\$]_^2)ZM_P!CWK/_ *4FO=*\+_X)[_\ )$]6_P"Q[UG_ -*37NE
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M%"]_[Z6MBB@#'_X275_^A0O?^^EH_P"$EU?_ *%"]_[Z6MBB@#'_ .$EU?\
MZ%"]_P"^EH_X275_^A0O?^^EK8HH Q_^$EU?_H4+W_OI:/\ A)=7_P"A0O?^
M^EK8HH Q_P#A)=7_ .A0O?\ OI:/^$EU?_H4+W_OI:V** ,?_A)=7_Z%"]_[
MZ6C_ (275_\ H4+W_OI:V** ,?\ X275_P#H4+W_ +Z6C_A)=7_Z%"]_[Z6M
MBB@#'_X275_^A0O?^^EH_P"$EU?_ *%"]_[Z6MBB@#'_ .$EU?\ Z%"]_P"^
MEH_X275_^A0O?^^EK8HH Q_^$EU?_H4+W_OI:/\ A)=7_P"A0O?^^EK8HH Q
M_P#A)=7_ .A0O?\ OI:/^$EU?_H4+W_OI:V** ,?_A)=7_Z%"]_[Z6C_ (27
M5_\ H4+W_OI:V** ,?\ X275_P#H4+W_ +Z6C_A)=7_Z%"]_[Z6MBB@#'_X2
M75_^A0O?^^EH_P"$EU?_ *%"]_[Z6MBB@#'_ .$EU?\ Z%"]_P"^EH_X275_
M^A0O?^^EK8HH Q_^$EU?_H4+W_OI:/\ A)=7_P"A0O?^^EK8HH ^>+YBU[,Q
M4@F5B0>W-15-J/\ R$)_^NS?S-0U^,S^-@%%%%2 4444 %%%% !1110 4444
M %%%% 'M6B^(M5CT:TC3PI=N%MHP'5EPWRCFK7_"2ZO_ -"A>_\ ?2U=\/\
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M* "BBB@ HHHH **** "O;_AG_P B+IW_ %Q/_H1KQ"O;_AG_ ,B+IW_7$_\
MH1KZGA/_ 'Z?^']4!NT445]^ 4444 %%%% !00&!5@"".0:** /E/X]?\$.O
M^"2O[2_B2?QA\7?V$? UQJMU*9;S4-%M9=(FN9"<EY6T^2 R,>[-DGN:[G]E
MK_@F;^P%^Q1>'5_V6_V2_!7A#4RA0ZY8Z0LNHE",%/MDV^?:1U7?CVKW.B@
MHHHH \+_ .">_P#R1/5O^Q[UG_TI->Z5X7_P3W_Y(GJW_8]ZS_Z4FO=* "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH ^>=1_P"0A/\ ]=F_F:AJ;4?^0A/_ -=F
M_F:AK\9G\; ****D HHHH **** "BBB@ HHHH **** /H'P__P @&Q_Z\XO_
M $ 5;JIX?_Y -C_UYQ?^@"K=?L='^#'T0!7A?C__ )'34_\ K\?^=>Z5X7X_
M_P"1TU/_ *_'_G7S'%O^Z4_\7Z 8]%%%?!@%%%% !1110 4444 %%%% !111
M0 5[?\,_^1%T[_KB?_0C7B%>W_#/_D1=._ZXG_T(U]3PG_OT_P##^J W:***
M^_ **** "BBB@ HHHH **** "BBB@#PO_@GO_P D3U;_ +'O6?\ TI->Z5X7
M_P $]_\ DB>K?]CWK/\ Z4FO=* "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^>
M=1_Y"$__ %V;^9J&IM1_Y"$__79OYFH:_&9_&P"BBBI **** "BBB@ HHHH
M**** "BBB@#Z!\/_ /(!L?\ KSB_] %6ZJ>'_P#D V/_ %YQ?^@"K=?L='^#
M'T0!7A?C_P#Y'34_^OQ_YU[I7A?C_P#Y'34_^OQ_YU\QQ;_NE/\ Q?H!CT44
M5\& 4444 %%%% !1110 4444 %%%% !7M_PS_P"1%T[_ *XG_P!"->(5[?\
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MK8HH Q_^$EU?_H4+W_OI:/\ A)=7_P"A0O?^^EK8HH Q_P#A)=7_ .A0O?\
MOI:/^$EU?_H4+W_OI:V** ,?_A)=7_Z%"]_[Z6C_ (275_\ H4+W_OI:V**
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M/_.O=*\+\?\ _(Z:G_U^/_.OF.+?]TI_XOT QZ***^# **** "BBB@ HHHH
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M^J>*?%R:#G[!9WVH3F5K6W) )CC0(N<8+!R/EQ7U910 4444 %%%% !1110
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M?_\ U*7_ )/_ /VNO.:*/]8<X_Y^_P#DL?\ (#T;_A?_ /U*7_D__P#:Z/\
MA?\ _P!2E_Y/_P#VNO.:*/\ 6'./^?O_ )+'_(#T;_A?_P#U*7_D_P#_ &NC
M_A?_ /U*7_D__P#:Z\YHH_UASC_G[_Y+'_(#T;_A?_\ U*7_ )/_ /VNC_A?
M_P#U*7_D_P#_ &NO.:*/]8<X_P"?O_DL?\@/1O\ A?\ _P!2E_Y/_P#VNKF@
M?&K^W-:MM'_X1KROM,P3S/MF[;GOC8,UY;6QX _Y'33/^OQ/YUOAL^S:IB80
ME4T;2VCW] /=****_1P"BBB@ HHHH _,_P#X+E?\$\_AG\0?A)\</VYO@?\
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MXH_%#5_B9X[^$WB;48O$'B*?7M<\*3_$C6O[#OM2GN#<RW$EC]J\H[IF,AC
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M:6,3;#_RSE#QG^)#0!\3?\%"F_;BU?\ X*>> _B"O_!/+QG\8_@W\(="76?
MFF>%?$FE6EO=^,;C<C:G>+>W"%S9P$I;IL.R25Y0^<"O'_\ @CS^U!^T7XE_
MX+*?M=P^(/V#/&.AIX\\6>$V\:2W?B+3)!X"-OHUWY O/+E/VC[1U3[/OVY^
M;%?L%7G?PK_91^ 7P3^,?Q$^/_PQ\!?V9XN^+%Y877C_ %;^U+J;^U9K*%X+
M9O*EE:*#9&[+B%$#9RP8@&@#T2BBB@ HHHH **** /GG4?\ D(3_ /79OYFH
M:FU'_D(3_P#79OYFH:_&9_&P"BBBI **** "BBB@ HHHH **** "BBB@#Z!\
M/_\ (!L?^O.+_P! %6ZJ>'_^0#8_]><7_H JW7['1_@Q]$ 5X7X__P"1TU/_
M *_'_G7NE>%^/_\ D=-3_P"OQ_YU\QQ;_NE/_%^@&/1117P8!1110 4444 %
M%%% !1110 4444 %>W_#/_D1=._ZXG_T(UXA7M_PS_Y$73O^N)_]"-?4\)_[
M]/\ P_J@-VBBBOOP"BBB@ HHHH **** "BBB@ HHHH ^>OV"[;Q)+\'-6;2=
M2MXHO^$XUG*RPECG[2W.:]5\?6OBN/P??/?ZK:R0B(;T2 @D;AT->=_\$]_^
M2)ZM_P!CWK/_ *4FO5_B9_R(NH_]<1_Z$*Y,?_N-7_#+\F!XA1117Y$ 5\O_
M +?G_!4W]G?]B*TD\%WOC:TU/XB,^G3P^#++2[W4+A+*>^@AEGG6SC<VX$,D
MC1^84\QU15W%@#]05^7W_!23]F3]L#]F/XB?&K]JGX$^&/"/C_P3\9M<\#W/
MB?1M7U=].US2-0TS4+*"UAM9F1H9;:9PBG>08S+D#$9+]V74:%?$*-5]K*]K
MNZTN_*[\[6 ^^_V9OVL_@'^V!X,OO'W[/OC:76M.TO57TS5!=:-=Z?/9WBQQ
MR-!+!=Q12HP26-N5P0PP37S/;_\ !6?X\:?^U]\-OV</B3_P3D\4^"?#WQ/\
M2WVC^'_&?BSQC:0SRM:Q-*\JZ?%%)(5*["-\D>1(,$X(KU[]AW]NW1?VN]5\
M<?#KQ/\ !77_ (:?$OX<:A:6OQ \!^)'AEFLFN8FDM9XKB$E+F"6-&*2#&0N
M<;2C-XM_P4Z_Y21_L-?]E$\2?^FV&MJ%"DL5*C4I]&U=W:M%R3NK)WTZ6L!]
M>_'/XCZ_\(OA+K?Q'\*_"S6_&VHZ5:B6S\*^&T1KW47+JHCBWD+GYMQ). JD
M]J^>OV%O^"D'Q8_:K_:5^(W[,7QJ_8VOOA)KWP_T33-4EMM2\:6^J3W,-Z&:
M(.EO"J0'8%; D<_-@A2*^L:^%OV5_P#E/'^U3_V3OP7_ .DE88:-*>'JJ4=4
MKIZZ>]%=[=7T ]K_ &[?VZK?]CVV\%^!_!/PHOOB'\3/B;KKZ1\// .G:A'9
MMJ,T:!YYYKF166WMH496DE*MMWKD;=S+R7[.'_!0?XMZW^U%#^Q7^VK^S)'\
M+?'^L>'I=<\%7&E>*X]9TGQ):0G_ $A(9UBC:.XB&6:)E)V(SY *AO.OVFM[
M?\%_?V9AK@'V-?A5XL.A>;T^W>5()]F?XO(VYQSMI?\ @IGYJ_\ !43]A5]!
M\L:Q_P )KXK"$9\S[$=,M_M73G;Y?7M^M=5/#T'"%-QUE"4N:[NFN:UM;6]W
M73J_(#[OKXU\:?\ !2?]I3XD_'#Q]\)O^"?O[%,'Q5T[X4ZF=*\<>*=;\?0Z
M%:R:NB[I=+L0\,AGFC^Z[MM5'X(PR,WV57PA_P &^6#^R;\1WO\ /]M-^T'X
MM/B0OC>;[SX=V_ONV>7UYZ=L5RX:%-4*E:<>;ELDG>VM]=&GT[]0/I']A[]L
M?P!^W1\ ++XY>!-$U#1I1?W.E^(_#6KJ!>:'JML^RYLIP.-R-@@\;D=&PI.T
M>X^"UN7\5Z>MG*J2FY7RW=<@'/<5^?O_  1A\P?&K]LR/2-G]B#]J?7#:"$G
M9]L*I]JQVSN\O.._MBOT'\ ?\CIIG_7XG\ZV]E"CFL80VYH_C9V^5P/7/L7C
M?_H-V7_@,?\ &C[%XW_Z#=E_X#'_ !K8HK]5 Q_L7C?_ *#=E_X#'_&C[%XW
M_P"@W9?^ Q_QJ[X@_P"0#??]><O_ * :^?J\/-\Y_LJ<(^SYN:_6VWR8'NGV
M+QO_ -!NR_\  8_XT?8O&_\ T&[+_P !C_C7A=%>/_K?_P!./_)O_M0/=/L7
MC?\ Z#=E_P" Q_QH^Q>-_P#H-V7_ (#'_&O"Z*/];_\ IQ_Y-_\ :@>Z?8O&
M_P#T&[+_ ,!C_C1]B\;_ /0;LO\ P&/^->%T4?ZW_P#3C_R;_P"U ]T^Q>-_
M^@W9?^ Q_P :/L7C?_H-V7_@,?\ &O"Z*/\ 6_\ Z<?^3?\ VH'NGV+QO_T&
M[+_P&/\ C1]B\;_]!NR_\!C_ (UX711_K?\ ]./_ ";_ .U ]T^Q>-_^@W9?
M^ Q_QH^Q>-_^@W9?^ Q_QKPNBC_6_P#Z<?\ DW_VH'NGV+QO_P!!NR_\!C_C
M1]B\;_\ 0;LO_ 8_XUXCIW_(0@_Z[+_,5]#5[>49M_:L9ODY>6W6^]_)=@,?
M[%XW_P"@W9?^ Q_QH^Q>-_\ H-V7_@,?\:V**]D#YXO@PO9@Y!/FMDCUS453
M:C_R$)_^NS?S-0U^,S^-@%%%%2 4444 %%%% !1110 4444 %%%% 'M6BV?C
M)M&M#!K-HJ&VCV*UL20-HQWJU]B\;_\ 0;LO_ 8_XU=\/_\ (!L?^O.+_P!
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M? ?X9ZQ\/_VPM/NO%.I^./$7[2OA>*2[USQ7=W-K8V\]Q(\EO:VI<0PQYC3
M"$@# /)K/!X>GB:RIRE:^VE]?O0'ZI4445R@3:=_R$(/^NR_S%?0U?/.G?\
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M_0 HHHKX\ HHHH **** "BBB@ HHHH **** )M._Y"$'_79?YBOH:OGG3O\
MD(0?]=E_F*^AJ^VX1^"MZQ_4 HHHK[(#YYU'_D(3_P#79OYFH:YS5OC5\,X=
M4N89?$N&2X=6'V.;@AC_ +%5_P#A=WPO_P"AG_\ )*?_ .(K\SEPWQ$Y-K!U
M?_!<_P#(\QYUDZ?^\T__  ./^9U=%<I_PN[X7_\ 0S_^24__ ,11_P +N^%_
M_0S_ /DE/_\ $5/^K7$?_0'5_P#!<_\ (/[:R;_H)I_^!Q_S.KHKE/\ A=WP
MO_Z&?_R2G_\ B*/^%W?"_P#Z&?\ \DI__B*/]6N(_P#H#J_^"Y_Y!_;63?\
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MZ5?#OBJDXQ5%.4KZ*4>EK[M+KW"/%60SHRJJM[L6DWRRZWM]GR9]O5L> /\
MD=-,_P"OQ/YUXC_PTY_U)'_E2_\ M==-\&OV@O\ A(OBIH&A?\(CY/VO4XH_
M-^W[MN3UQY8S^=51X!XMP]:-6IAK1BTV^>GLG=_:)I\6\/UJBIPK7;=E[L]W
M_P!NGUY1117UQ]&5/$'_ " ;[_KSE_\ 0#7S]7T#X@_Y -]_UYR_^@&OGZOA
M^+OXM+T?Z %%%%?'@%%%% !17)^"_C/X(\>_$;QC\+?#]S,VK>!KVTM==CEC
M"J'N;2.ZC\LY)8>7*F3@8;([5Q?[6O[>/[+W[#]EH=S^T;X_NM)G\3RW$?AW
M3].\/WVI7.HO (VE6.*TAD8;1+'DMM'S#FM(T:LYJ$8MM]%OM?\ +4#V"BO"
M_P!D[_@I+^QO^VQX@U7P5\ /BS]M\1Z';BXU;POK&CW>F:E;0DJ/--O=Q1N\
M>70%T#*I=02"P!]TI5*52C/EFFGV>@!17RA\6?\ @ME_P3I^#'Q"U_X9^,?B
M[K<FH^$]4GT[Q5-I/@#6;RUTFYA<I+'-<0VK1Y0@Y*,P&#7T3\'?C)\+/V@?
MAMI7QA^"OCK3O$OAG7+<S:7K.ES^9#.H8JPSU5E965D8!E965@""*NIAL12@
MIS@TGLVF@.FHHHK$";3O^0A!_P!=E_F*^AJ^>=._Y"$'_79?YBOH:OMN$?@K
M>L?U ****^R _-3Q)_R,5_\ ]?LO_H9JE5WQ)_R,5_\ ]?LO_H9JE7[5#X$?
MS54_B/U"BBBJ(/G[]LO_ (*&?!']DVV?PK=^*[:_\;%K&:+PM:Z?=7LR6DMW
M#%)-*MK&YA C=V3S"N]@JKN+ 'O_ (._M0?!_P#:%^'VK?$;X(ZY=Z_::-<3
M6M]:+I-S:74=U'$LIMC!<QQR+(5=, KSO&*^/_V[/@%^TU\ ?&OQ6_:'^#^@
M>&O&7A/XI:MX2G\0:7J6I-9:OIEY87MK%;Q6\K*T4D$K!5.\@H9,XPA+_3?[
M)/[7^E?M+ZCXM\#Z_P#"K6? ?CSP+>VUOXS\'ZZT4DMHUQ&9+>6.:(E+B&1%
M8JXQD+G&TJ6\JCBJ\L=*E5?+V5GKK*S4KV=TKV^5M&>]B,#A899"O03E_-+F
M6FD+IQMS)*3Y4[[ZW]Y(\J\5?MR_M^^#/!M[\:?$G_!,R>T\&:7:O>ZC;/\
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MGPO_ &:/!.J?#?X\^-K+POKK^*M2OUTS4W*RFVFG9HI<*#PR\BO0_P#AN?\
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M/%OQ-_X)H^-/V>KK]E'4_&GA>T^'EWH T1_#&A7EQID,.GA @MX6LS$]NH4
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MA\0_VC?%%I$FDR644OA75;BS@:)F+%GC2<PRD$GEU88&",5XG_P0H^ 'B/\
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MX[_!/]H+X3_"O6OB?X*U_4O'NM:/9;]/\*^'?#5FE_J):1 T4+3RI&#T8[F
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M7_\ HX&'_P )B+_XNC_AE;XO_P#1P,/_ (3$7_Q==!_PW/\ LC_]%ZT'_O\
M/_\ $T?\-S_LC_\ 1>M!_P"_S_\ Q-'+A?\ H'I?^":7_P @1_9.%_FJ?^#:
MO_R9AVG[+GQ>MKN*Y;X^0N(Y%8I_PC,0W8.<9W<5ZW]B\;_]!NR_\!C_ (UP
M'_#<_P"R/_T7K0?^_P __P 31_PW/^R/_P!%ZT'_ +_/_P#$TK4E\%.$?\,(
MPOZ\J5_F=6&PE+"I\CD[_P TY2^[F;M\CO\ [%XW_P"@W9?^ Q_QH^Q>-_\
MH-V7_@,?\:X#_AN?]D?_ *+UH/\ W^?_ .)H_P"&Y_V1_P#HO6@_]_G_ /B:
M#I/.M0_X)YZC?W\]^WQ7A4SS-(5_L8G&23C_ %OO4/\ P[HU#_HK4/\ X)3_
M /'J]+_X;G_9'_Z+UH/_ '^?_P")H_X;G_9'_P"B]:#_ -_G_P#B:]M<19RE
M;VO_ )+'_(^:?!_#K=W0_P#)I_\ R1YI_P .Z-0_Z*U#_P""4_\ QZC_ (=T
M:A_T5J'_ ,$I_P#CU>E_\-S_ +(__1>M!_[_ #__ !-'_#<_[(__ $7K0?\
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MU#_HK4/_ ()3_P#'J/\ AW1J'_16H?\ P2G_ ./5Z7_PW/\ LC_]%ZT'_O\
M/_\ $T?\-S_LC_\ 1>M!_P"_S_\ Q->A_K'G/_/W_P EC_D>3_J=PY_SX_\
M)I__ "1YI_P[HU#_ **U#_X)3_\ 'JBO_P#@G6T5C-)J?Q=M%MEB8W#3Z-A
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MO .E_LI>.=0TSP1H]O<1:&[13P:9$CH=R\A@N0:[?X9_#3X<3_#CP_//\/\
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M_P 36[10!A?\*N^&?_1.]"_\%$/_ ,31_P *N^&?_1.]"_\ !1#_ /$UNT4
M8]C\/O .EWD>H:9X(T>WN(FW13P:9$CH?4,%R#6Q110 4444 %%%% !1110
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M[1N4^QVE]Y7VJ/R5D$,F_P F/YG1F7;\I7)S\4?\'4__ "@Y^+O_ &$/#?\
MZ?["@#[[\;^,_"_PX\&:O\0_&^LQ:=HN@Z7<:CJ^H3YV6MK!&TLLK8!.U45F
M..PK\[]'_P""UO[</C[X%WO[>OPH_P""3FIZM^SI90W.H0^(+KXEVEMXHU'0
M[=V$VK0:08"-BJDCK"TVYUCW*VU@U?=7[4'P5M?VE/V:/B)^SI?:NVGP>/\
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M)=_;'W_.UB?3?L/V7R>,>1YOG>;SNV^6,;CX+X[_ &_O^"OCZQK_ (D^"_\
MP15FU/P;H&H7<5I-XG^-%AIFL^(+>"1E\^UL!;R&'>%+(DK;G!7 Y&?K&/\
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M +;G[%_P._;_ /V;]?\ V7_V@M&N+G0==1'CN["817FF7<3;X+RVE(/ES1N
MRD@J1E65D9E/K%% 'Y2?ML_LN_\ !P=^S[^R#J?A3X'?\% O^%P>'](CAM-1
M@T/X=0V'Q"O="+;+A;2\\R:.>^2'A9-BSR$%U;S<*WUQ^SG^QSX;^%__  3&
M\/\ [,O_  3Z\7>*/@>S^'K>Y\,^)/%/@];C7-*O7F2YFGU&PO1&)KF1_,2:
M-PJ_.RIA @'U'10!^=?Q>_X)7?\ !4?]M/P?)^SY^W1_P53T6]^%&H7$/_"6
M:#\,_A+!H^I>)+6-U?[-+>/<2?948J"WEJP/*E2IQ7Z!>#?"'AOX?>$-*\!>
M#=)BL-(T338-/TJQASLMK:&-8XHUSDX5%4#/I6E10 5\+?\ !5[_ ()4_M?_
M /!3GPWXE^"%I_P4BL? ?PB\2PZ=]J\ 'X*VNJ3I/:317 E_M'[?!,0T\*/M
M   ^7D5]TT4 >-?L=_!O]L;X/:)K=C^V!^VG8?&:]O;N%]$OK'X7VOA@:9$J
ML)(S';W$PGWL5.YBI7;C!S7RU\0O^"8W_!6/]I'P9=?LV_M5?\%?+'5/A3J\
M/V/Q:W@KX.VFB^(O$6G'B6SDNEG>*T$J91WB0[E+*5*LP/Z%44 <_P#"?X6>
M ?@=\,?#_P &_A7X:@T;PUX6T:VTK0M*ML[+6T@C6.*,$DDX51R223DDDDFN
M@HHH **** "BBB@ HHHH ^</C=_P3[_X7'_P4A^"7_!0;_A;?]G?\*<\/Z_I
MG_"(_P!@^=_:_P#:=J]OYGVKSU^S^7OW;?*DWXQE>M?1]%% 'SQ^P?\ L$_\
M,2^,_CIXN_X6M_PDW_"Z?C1JGC_[/_87V+^QOM@0?8MWGR_:-FS_ %V(]V?N
M"O*OVR?^"5_[2WQN_P""AVB_\%%OV4_V^[3X/^)])^$B> I+&]^$EOXD2>U_
MM&ZOI)=T]]"B%FG1=OEDKY.=_P Y ^W** /A'2O^",_Q,^.7Q>\*?%K_ (*@
M?\% O$_[05OX$UB/5_"7@*'P78^%_#,-_'GRKFYL+1I3>.A)*F23NRMN1F0_
M=U%% !7YH?#W_@B5_P %"O@U^T[\2OVL_A-_P6&TNU\8_$[5'EUC7?$/[.%C
MJ]_;V(<F#3H;BYU0F&VB4(HBB6-#Y:$K\B!?TOHH \8^%'[-7Q9U7]E[Q!^S
MI^WE\?+#XV3^*K74-.U[6H/ T/AR*ZTN[A\EK,VMO-*HPC2#S ^X[^V!7QQ_
MPY(_;=U/]G^U_P""=/BC_@J%+>_LR6IBLCHD?P\AB\6W&@12AX]#;5!.8Q$%
M58O/6'<479L$9\NOTNHH S/!7@WPO\.?!ND?#WP/HD&FZ+H.F6^G:/IULN([
M6U@C6**)!V5455 ]!6G110 4444 %%%% !7SA^WI_P $^_\ AM[XC_ 7X@?\
M+;_X1C_A2'Q@T_QU]D_L'[;_ &U]E(/V/?Y\7V;=C_6XDQ_<-?1]% !7SQ\#
M?V"?^%,?\%#?CG^WI_PM;^TO^%T:/X;L/^$4_L+R?['_ +)L_LV_[5Y[?:/-
M^]CRH]G3+]:^AZ* /C__ (*5_P#!,OXO_MM_'OX%_M+_  #_ &P8/A%XO^!=
MSX@GT6_N?AU%XB2\?5(;.%B8I;NW1-B6SC#"3=YV?E*<^?\ CG_@C1^TY^UT
MUCX._P""FW_!5'Q7\7/AW9ZA#>77PT\'_#NP\&:;K#Q.KI'?O:2S374.Y5/E
M[UP5!4HPS7Z 44 5=#T/1O#&B6?AOPYI5O8:?I]K';6%C:0B.*WAC4(D:(H
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M[2WE0JY!E?:"=JY. 3BM.@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MFZ9-=V_@_P 1Z3 EG;+?)"K/%;2VZG;+M.7G(Z1N0 <Y_P %2_\ @G3\(?\
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M-3@A,_\ 9U\L=O%Y,KIPKH65G("A@'=//?V^/V@O@C^UI\8/^"?_ ,>OV?\
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MIFZC-H9M.E#F'9+M8O.B"( LQ4 FOV&H **** "BBB@ HHHH **** "BBB@
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M%)894#*ZD8*D'@@CM4E% %#PYX6\,^#]-&B^$O#MAI=FKEUM-.LT@B#'J=J
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>image01.jpg
<TEXT>
begin 644 image01.jpg
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MACOHH(/985;DL/JZOV(B3$S%^(2E$4@TCB,8(*X4V:?S3)1C)L9'[0&F^I^
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M)=;2 ("!)2O/QO6S5";&""LEHDJ)*"@1!66BH$P2CC!R_!K*XUOQW1#'L=*
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M'=,V7B2=<46YTPX"L&2GPS+??&D$WQ5\5TSO)[XP;5M^OB?DYWM"DO)8R_X
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MYWUN5N]V-=E/LN-1G"W;VAXC7__ZUV?=@ [^?!!=\,",RXKL'^=6X_19_P8
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..MG,     245.1*Y"8((!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>image11.jpg
<TEXT>
begin 644 image11.jpg
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M4B?0]?\[^$M:@8H%V,6/[ECVQM2@9-#_7)H,^E'#3;8L__QW?'@5JR@
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MO7_VW>V)PQ=GK#['$_8J@R*))(@6^A%4/]'$ENYGDLB33<H_\HT7(84
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M&65)(90:@''=OD$4RH\:R@DDF@&Z;2)X;LQUW[G\)P?/:7._VZ5HSAQ_19A
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MEXGBWO;LH:V9#G60=+>.FS<YH:GJU,+45C(1PA%B7BRG-%%<8\LJ7_(4200
M  !:0LBC'6YK;* ?)6P)EBN**UO,!5M2R(M1>V,(190P3L*4<812@6I/]*29
M2N1HH!X=E+N&PSF5]^\NCI7!VS?I\Y_[F]9W4<8.6I[AMD30DA[3[U,33>($
M47E,RNI]4^EO^^HN5N])=*HZ14 ?O/_1=6P&B7!*+!>8(&ZPRQI?F!Q"N $
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M\8<6%6QWYZO^V5_.C15WN_P)S$Y51]&IZ@(Y?-W]9^K8!%*'CR_D7<B+: H
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MT.4'VF6T=&Y8S]CZF:849@6>>-3KE'LX^<H_#30!A!" 01YT3<[YNHPH(4A
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M?:N'S\+EZ4R/[\=/9JI,CE:DU^/=SF5JS4#A+TF/1=R@</J[>@]S$&>5>0(
M0@C R-(P)(1E"N>+'<4VR'*![DP(80(R6-8C96*\WJI8Y/<J2^NEWP:E#M8+
M7_;XNKQE*#)'?;1!WKO8 8 0 I A&4(;),]"AK^O$5GM1I9$-W&B,GC 9ZM+
M8C<LF(KN Y!Y,(80@/R0IRGLC$1],CR.<M' :VYWT2[\_?M)9JID+%(W*+9&
M:)T% $((0$Y9S-%G-247HR2$W;3A:A_OL\%D<!6;E['U%D((((0 C"CE46\
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M98/M=A!))2]5>*:RF)$$F)'CS HAA;T:_HG-*4T8^<4FA;/,-"19Q(D$A!
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M  "@2_CT:;4A^C[EA%YG S7[ (00  # *''ZP?<^N9+W+R&*D2=5A[".U0)
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MTCF+D$$ ]@<10@  R#EB]HX+:(D(CS$1Q'A+ ""$   P,E+(:_C5R&SMOKS
MHX++B H" "$$ (!1%4,>$:O2:):EV>3?'8DC $ ( 0  4MB:\HV+8872+_@,
M$00 0@@  "!C<LBED,_7>WH(OQY/J*FA:Q@ ""$  (#.Q+!$K:GB\BR'O'S,
M*K7F4U[%/,0 0 @!  #T)XAE(8A\X0DI61QSN"WD;UT((.8>!@!""   P* @
MEMA%20CBK)!$?IE&UC(? ]B0%BZ!#3%-'P @!?Z_  , +;03RT&_RX
(245.1*Y"8((!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>38
<FILENAME>image111.jpg
<TEXT>
begin 644 image111.jpg
MB5!.1PT*&@H    -24A$4@   0<   !T" 8   "(:O=\    !F)+1T0 _P#_
M /^@O:>3    "7!(67,   [$   .Q &5*PX;   @ $E$051XG.V]>;QD57WH
M^UUK3U5UQIZ[Z896H!F:J9D5G%"C1N4A&(6$Q"%17J[FJ5QY065T@(0K1I,;
M\S3$: :4CR1$KS@;06CFP6Z@FX8&M+OI>3A]IJK:PUJ_]\>NJC/4KM-UI@9D
M?W5S3I^JVGO5'G[K-R\E(APLOG['#;)U]R;ZAG=C5?HWI2!P.EC<NYCE"U8
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M9_.$,7C']3%)A%A;2S[2B*0Y$&$B!!J..<QP^@KAQ&7"G$ZA&AN&RA:+)<W
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M1-;#QA7&/G!I?H3V"IR\-,BLS+WPE!XZ77 RQZ&PT1#[0I?#YOA<]/</35M
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;H(SQY<[_#^4&*9QP&&,S     $E%3D2N0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>biib-20200930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:biib="http://www.biogenidec.com/20200930"
  xmlns:country="http://xbrl.sec.gov/country/2017-01-31"
  xmlns:currency="http://xbrl.sec.gov/currency/2019-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2019-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="biib-20200930.xsd" xlink:type="simple"/>
    <context id="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4c10ff2cc693457ba96b227c43b75eec_I20201020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2020-10-20</instant>
        </period>
    </context>
    <context id="iba1a633773a34c899b77b4853a665d4e_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i817821ea916346a6b301c5912257c3e5_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="id41b722bb5ce413f84c0e1a46961879f_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if88c636dd80d492687ca22f07e75db13_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ia428d1f03d1f454a9d5c837ec6e0aa50_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i8595ad2d43f34d98abb716a40fde60a6_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i0cb93d1ae39f48f3b0fc167540132b77_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5452667727cd4cf08cae4c412b67d3ef_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="iba6a7aa4c7fa4fda950fccc032894346_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0ea06cd6a9974b4999904b90f030878b_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i6e0b6c1de005431bb80fcd07bc90af2e_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i2335a9cc65b041aa8e881414fc49759c_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i6d14771766d1415790d98b0c80aaa2eb_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:DenmarkManufacturingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ibfe5725c9917439e83ae4f911eb7a60e_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i626282e786b7454d83b617e9e83963e6_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iec2bbdde63854682b605414cc72c3ab7_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SangamoCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i97a0bebcc8cf4432b262746010427fa4_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SangamoCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i79e678cecceb4e00b17b8c2023042ca8_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ifd729f26efae42a995f0066eb5f4a0ce_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ib98dd789f3514452acc95f9b041d2a7e_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ied38b94db9a74750b51c6e8392d4c5bf_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="ic9b1433e63154dc793bb3be211f95c71_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i1dd367dec9d1416ead31ac17037d6347_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i58e4de16550642ffb8fa1ec5287f1bac_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i1f5ebc014a364cce887ab9d7243516cc_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="icfc9a329a8dd439cb140f840522afc1d_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i4bb77bd7d2ce46e59ff6fbd5cb940d75_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ibb3e0c3b7ac94f2183a66e90c088be58_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i27fd7cabf5714753a2a142cffcd63932_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i2d122436a2064a36b4342d6417ac828f_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i1499259d90804413b1e193e034d9561d_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if01d2b8c98a04ef2a7d2d2754bdfa47f_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7209bbd041614d26ab0622d0fd200deb_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ib23988bed8f7484597669fdaf2c6150e_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i030ce533f4cf4aa7852fbd17ed7ca720_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic0a0dcfa5c2c49268190d94b335f065e_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:December2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i2debfff1a33140e6bcf02b809c593d24_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:December2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iadd8187a18d849f6b353e75cae0aabe8_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:December2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iada85e2a70f74606baf6a5c38c9ddac3_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:December2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ifb80294ce54b4a41af5a0f3e17352851_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:December2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i1c225596be4340518bf78440f40fdbb7_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:December2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i53ea969c6702421f9bfd2df9bfc3232a_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ib2edcb252dee41aaaa28a702b70a129d_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="iccce420c57a74d908b28fffc261114e2_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i89ed42febbd445c9aa4432e778b1d593_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ia55221e7b3994df7ab08c27719d7d2f6_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i162af0e1b52e4fd99c7498e910ae472b_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i138fbc630aee4346840425ef11fa647e_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i4b8029eaee38406ab0f2d229d09c0a8d_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ibe8d84b11e994911b29ab0046e3c5436_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i8f84ef87973843b2b12c2e5314f58592_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i40f2711483814cfd80a3070c293601a6_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia40deaebb7e14b0ea3390b0988aea61d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ifc05b78d934b474aac9922457936de4c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="idb84688ac5bf43faa19f9f893a04a3e2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i03b2cef2a2324bfcbcfdea22ab154bd4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6344cb617db54fbaac18f0e555380783_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2d1cce71297346cdaeeb9fb6370ccdeb_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2d02929a942940478cbbc1b3ab3918a9_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iec296486afe44cb9bee6a9b9fec0c678_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic4379c94e8a84e548bdd2c9f5110296e_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i1faac185931341e591596ec3e5440d06_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0319abba8ccc4f0fae4e9db75a3ba5d0_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ibc0fb387460c4e6fb1f5dd03a311fb08_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0af05fc8fe804816a86f91f4f77cdeac_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iae4ebdfec80c40fabeca031863dcc5c5_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i14eda8fe33b0440e8f012764e73abe64_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ibea5025954d8442193d586f92fe4b174_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i48e09b81ae6e4e27bb99b06fb90ade10_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:December2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i23f4570c321d470ea07b9b8126846754_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:December2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="idb94151f567e4761811caaa2ee1c1349_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:December2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5ca2e1e65c424ac7afdfd951e4e64cea_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:December2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia6f932e5c68d4df8ab6182786c4e7dff_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:December2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ife6f9a28c7c64a109d345b6753d462fb_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:December2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i2e65876e41494343960737c39bc5f276_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i861bb59946a84718b6c99600a2e9b0e5_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i99fbd0519e8d401bb929b503f3ecea4e_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i9843b0258d7a4100af10e14048f0aa5c_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i0376412c3eff4647ac527a583e1fea9e_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i1e4817878dd24efa84f78403542ee2fa_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="ife3567f724fc4eafb760a986851063d1_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="if307586287e044beb16134d1cd640d29_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i396ceaa32ede4bd18fc264a28d5483b0_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i0ec1a9946b9d42abaed7abd2237b7dbd_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i94c6f45fdfc542388521216b8e80983e_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="ib515d9bcec6948d184e2f6536574cb55_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i58b6be5e29354a3f95dc35f74e0eb46d_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="iae71bc1953744eebba86f3934124b00b_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i37ac27ae2b114acebcefcb550c5cda84_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ibcf7b9d6ba6b4eddabd32ecb80c018cb_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i86c3b6289b2b4f52a9c054d27fb6a5b9_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="if78608284adf428b9b151aa288371376_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i859bf4d9f138495caa518c457b42a8a6_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ic82a5a18c46c4de99def553116869989_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ia9881e9f358c4093a91f49acc663d493_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i45b746c96de74debaf178d86af176ed7_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ic161674d27484a338894e49a73880c69_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i30714cf43346412e9fea73f7251cf213_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="iccee1e1d95af43b9873f3228bed22351_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i404c8ff0534c49f7a853054388cf47e7_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="ie09a86c05b2d4dd68ea12c27ea7e151a_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="idcbcecd74e024473bdd870830b88f96c_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i7c8172c9fe75493ca901d5f05ecfa29d_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="ic9f978f94b6e4038af9fb1fcaaf85dee_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="ie2305062812f448bad777c7ba71b2552_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i88af2b9941924871abe610dc3e71811b_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i1e15f7e0305245ab8755ada973550435_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i5b39457257df40c0a44aba71b396d988_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i615f50b48b1947daafcc18ec87768baa_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i691108e26c8d4acfa6452b2cc1994da1_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ia2c93178a13f4173b8c722d0ace0c1e7_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i474ef61edf8a4e488fdbe0a7144141d1_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i8445ab6e25754f87a6ebbd9df3b89ca0_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ib53a358e088b4743a76a8141b6a1c193_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i0efa62d44ea047f48a850ba3d5919a87_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i7182b1df2b374d208162f601fa679959_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i7a7633cfe36348a79a7d0f41758bd6ab_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i7289c8815e434ac989c2d260f35da03d_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ie8e1e308da1c4ce6aad01a86613ea938_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i36fedb8b45764716a0240c105927c6d7_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="icf8bb34fb60b40bcb5c350755c57da7f_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="id953e91f8c614de9996090d5eb18e5b1_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ic8aa3352d77e4f12b7fc3b77907a67f6_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ib125f2b4cba94378833a506b5f526ef7_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i8c3d2fb2bd034a6d943e04d98c6101df_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ib1d334b7c899449292200b30b2bdc155_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ifba3660adeba498985326527c5db09da_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i809df7746fcc437c8e9a75cc7cb10a70_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i4ffec57fb67a4f9091e91bd4b96b6eff_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="iab58c905ebd44601ad94f01220bb87b0_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i4745753d1ae84b66b7bfd523bb7d93ad_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i6184d003ca324663b6d44d4425fd9798_D20200301-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:BIIB118Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i34259f1058d543a0ab98f22062f2e5ab_D20190601-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <startDate>2019-06-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="if669468af2b1428fbb2d5e8a25e54053_I20190607">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-07</instant>
        </period>
    </context>
    <context id="iab47d31b221a4694b97e6b5cd3de541b_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i4ea815a094e741b0a154fa60dcf2c6a5_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">biib:PostacquisitionequitycompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="id3e1580f38914bf3a529df3762a6db10_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i6d491f3733874ec68a5451b8128278dd_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i54fe6174a2224b379d4a176d7fd82015_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:DenmarkManufacturingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ic1329de1cf194c709a3e6e578b701fb5_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:DenmarkManufacturingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="ie4528167bcf941dbb3558a86eed5211c_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:DenmarkManufacturingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i3413eeb6a8594eb7bd9a9895a6a44b36_I20190801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:DenmarkManufacturingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-01</instant>
        </period>
    </context>
    <context id="i8fb970353ed64398943d0ed1643a7bcb_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:DenmarkManufacturingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i174c6f6dc0974a4a9f1635f5f4a03baf_I20190801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2019-08-01</instant>
        </period>
    </context>
    <context id="idb5da4324a084eefaa4d376d025b0d68_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ibe88801f13d247f899ec696c93dcc2e6_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i1b5da4a47c7b46c7a859d909b06ba52c_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia341fbfc92d14c558a2c51805e16e967_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i6fb54144d66b439881fcd02918e4cdeb_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i5c3d302ecd604f7a8d735759d694817a_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="id616d991f56748438a8ba16f0137aa36_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i3dbbc7fb0ad74d068c127681fec0fc62_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i8a70003485d4486a9bb6430b519901d8_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i235abb80d0f443cf952612f002c4c724_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ic1773b37e68f4ca98e29d05e4707727d_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="if638579a7e1847469ac17a832271d4d7_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i0b652f2150604dc6a33be4ae69220a56_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i90806ea38d7543f29e6a6e61337fe595_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="icea39709b7b1472aa5dd7f44966c0bd3_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9f9d582c0e524991ad24725e61b062b5_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="if85e43e3e237494fa32864c3adac50a1_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ic408b141d6a24355afe175433eb9135f_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i1323f4a6c7eb4aae984b38b19c87c5bf_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ifaaa9079f60b4098abc8790d9255ab3e_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i68159e373219432e9ceeac5ce7c38c52_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5e0133306cc04c65928c989a2d2dbb45_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="if5a5e0e77dd24eab8c07703f6d5e5414_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i742235d37c1342388624cde1c677f04b_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i2a33b9fd26694109b63c4f4ba7b7a6e1_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic87d9b72e03d47c7a87c74570147c7e8_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iba79677927674335a48059dc861147c5_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="idd282900956142e1a6ef766e0cb49611_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i4610f1a14c034cb19b7366512e904c92_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i134d08fbd1ff45239e991114f841a948_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i782a7c4ac90845f09d932b45511ff216_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if924a82037ba40d288c2ebf03d3f886f_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i64ff52eeaaa44fe1942f08bef012563e_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ibc93740adfba43e48aeb5c07582509ad_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ib5dfd6a6fcaa4743b33d7010ee60257f_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i71c758edfcc041a19e3af23d14f9b3a5_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i0a383eb4ffb0459e920cfd44b9b19f2b_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id87093f8e357449d9e8705f5c6ccc183_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="icdcc3e6db10041c6adfb46ab9cc43d52_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id5469abafd1f421d8fce4ea54f1ec77b_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i746432e17705462ea58e77a00bb3a93e_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ic7f7847bbcdf4347bcaa5531ac1b24ef_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i010f4a93398d4bb4b566cd786299c56e_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i6d23abb471e04139a7badc923a7aa0b0_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i2b01d577ab7e4e2faf2a58cdd2703267_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if30fd82eecb5426b92a98a3e3fefe6f5_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i116d706a2f374c48861e85f661a21b25_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="if9a7e5c89d394125ac728a112ab5ff87_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i56b36d0e49d840c1bb93b2c87291791d_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ief040210ae2c41fdad968514993484a7_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5f8fe94c6208475b8bc2f93cb71a7939_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i48f53b5d6fc04defad6638974299bc5b_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i5971788b43b64613b60ad9eb48951064_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ib8eb6906d8f14c4cb3001d7cfc2f6447_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i108b8c9cd74844ea902eb45e12f344d4_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i492d4f74b2774d46ba24d8836488319c_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i04f6a02314ae4524973688bb453aa3e5_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7a8274402a6247b58947c615cddc6683_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i4f5d0029574e4134a8a64eeb2a84b092_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ibd1e83f10a674384b5a5c22e4838bf7e_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i7e2a3e2e67994b33aa594e6685bfb7a1_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i83b0b2c0884c4420b9ec2c69e43f3b5b_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5887fc680fe24fb89317ffa45e0e7399_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ib6b4fdc531a146d8b6ab0e3b3a410bb0_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="if2c497aaf27546a396c0c89e2d199e5d_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i03858b8f5bce44fca9ffdbe13c9eb5e2_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i82ddc3d73c6440f6b67ce2997a135a27_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i537d78dad03f4414a8201cf28d6fb744_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i27f454fe7d384ff6b0419771f9b3e2d6_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ie5915a0ecdc446c396b8a751ccb2cb15_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ic542c97609834568beaf236a66f61e73_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i54cede8da6804f35aad2512972cfec7d_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i3fb38646d08e44f09e679dc53de54e79_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i49af2b0ec0f64a17a1c3f06e8918b239_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i578fc5ffb2e64484b3d17b8c6505e6fe_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="icec0afd4985d4eebbcb6d942dc11861c_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ifff8a50ada4a4480aa27d7e429483ebc_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5ebf452657754a04b75cb22245331331_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i97559f8bfad646f4a63f6e7d1de603b3_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia54121683d93464386861f04a5eb0f78_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i58ceddab404b43efbc2aa182802d7e90_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i8ff9cdd4f3124c71923b611c196ff399_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i55c11d8111cc47e5b6fd6668e6688ebc_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i811b94cd1a9a4cdfa735283523ef7c2f_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iba49923c2dbc4cfa9e28cd6dc0232817_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iaf55884ad575429cb3318dba7371b6ba_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i2050ec4e36ba486eaaa52e2629f9eb4d_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ifa6b881f2fda4822952ca375ff987144_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ica095eed2ba44dae9950be250f7d8e18_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id65392444eb84d778e3da80dd59cb0ee_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i6c5c5deb248640ea8a5b2acc2c061165_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i45096669722b441a88f0da5da92b8c28_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ifb862d5227ae4e258ddf1674e35ea488_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i3ebacf9f9e6841c3af9fbbaef43f7942_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="if9481c82cb20488b9ef66d6125fd47af_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ib0c82a598d09477ca3061b0c8ac0da77_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ib99c15bafed34bf3a271edd3287e7b03_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iabb34cdf00c04963ad7af011adaf7ae7_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i7ac22170fd834262ac66fc712062e281_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="iffe091a9dada4645a5db26663b970d61_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ia7271f995472417c88ca939ff891ec17_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i24db87c55fa5436c82745477f49e8563_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i327b2bcbf1a6442493e173a2baeab0c8_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i824479af0d2943a7a9ec0c36b60267a7_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="id0ec100b681943e69c7c792eab6be4a9_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="if5f44218395d4becae44e95c8c6bdf51_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ib81a7f97279a40f9a38ad04e204987e3_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ib7068d1546c040608d8c969370cd8e9d_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7bb0ccb59cdd4f0083748543233c3b52_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7cadb5f8f65e4e73949863a5024f4ff7_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ia8919ebc1037469d9bed32fa8eec69dc_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="icee51ed1fdbc42b88487b41b6379cf78_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i0f6da514a21b4672a427de97a1d05efb_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7ca4c818e3ae4c34bae274600ab49c11_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia4c89150d9234c61910e3033151c6c58_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i18ff182dc2fa4ee6a2478c6486ebc688_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i51ddcb898ae7480cbdaa9ec0ab68a246_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i6f1f3b16e8d246ed9cb3f7cd93daf5bb_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i8e584f31a41a4eae8bf2342da93c54e2_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i3a59fa0fcf0647fca4a684d8a73ac1ae_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7638af777ff44424ad832076c7ede12d_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic66643a3fa6f4367b9eebb3e83bf3f00_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i28632e06900d4c5c9e30bb7d2329c1ff_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i1c3e816876c048aa84d64152477c9781_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i4ee8e58d8b904754b7733dede2183d4c_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i529ab974da4c4d049570f91ae707a0ba_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i254d19bbbef947d1a614d21d341de265_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id4eca9ea1df2452294cbdfa5fbed58c1_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i58eb92d0895f4b14ab4e6bc4e13c9ffc_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="iab755c39193d4ef0bb6db78729b51f1d_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ifee406589c20493a9b2fe20b2c5535a5_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ibf97ed01b19948c9bae6d6c52e933fcd_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i3cc3553689e84e56811b92f0dd3b6b92_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5fea542032c54705846f79614c101fc1_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="iea33bba3363f4d079ad12fb08f1e1b10_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i882255f3fd6c4303973083ca690aa076_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ie37b87d6a1074111b1725e662d8f0afa_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7adfff2dc6d34472b4ddbd0d4f2a4422_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if276cb15ef2546539e317deb2377ba10_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ib5aba8b2bfc846c9b459ca84fc4e721d_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i8df56b3f3ec24c9cad78f819aa3968bd_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i3302fabf3956449599c4d0d7d34f36d6_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i6de66bb341bb422daee145e34cc96b52_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="idfabb0fde2e64da393d47657161d482f_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie223070107d841acb3680d718ad02ae6_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i52dc933695414f1895f943cb573be8c1_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ie32fda1ac1154d048d97699d8290e7fa_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i5c0c40a4a5f74ba69177a07ee1ff0f2a_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i02dda51ececd4bc28da1d9a328686af2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8b3ec66c47d44f20873b899460f118cf_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i547ca2c2237a4a379988e41835ac1091_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if2a30a4831ac4e68b68264f34f994f66_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i1a535a6744d640489dfb975ae50eafb4_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4608a28d79084131af5440bda4ce4ba5_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i204f2ca2855b47ec88cf265fde7a6679_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i7897f16ad9b249e08151468bc3c92f5c_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i897e79a0b82b448297a7d6e150e50906_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ieabb7bcb048b432c908c601e832af027_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i65c7f4e2aad74eb78be96cec75c1e6c8_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7eddadc447104f8eb26db7302eace7a5_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ide07a6c272e244a3be181989da603c09_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i144bad8e98d44b9283666efd91ae814b_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="icfb2a7f321824155859b452e7e1620d7_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ic8db6af1daf2476691a91e008e2e4614_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i647942c6e60f4fd3a53dd00558c6b691_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i7b511ee9603b41fda2cc6f8171976d4e_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i6c11f9b8d3684514917520eb76b5297d_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ida3ec850012e473c82f5aebf509be5cc_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i528e10772f27492fa438cba3d636945a_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i083a7fa4caa1424dbbf1d7151d395e24_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i96f6c016546448cb939dbb6557754670_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ib6369975ed9d437593f2e153c72f7978_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id6f2c098f47f4305b065fa0a773ea01b_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i7aaebf479efd4e5988b193f96cfea104_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i727d852e008a4093bc7eeae55e9ac6e9_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i3a892823ca8b4d289bbf6e819b53df89_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7a2aaddc244148d29b9babb1a6e4d21a_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="id62c1ea890004cc683b1c3e2197b9771_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0e78e06924024013a86b44bea5d8c5fc_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i64ed3edf8c234417860f788da7ecdef3_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0b88a1e534d44643b0824a70718ed27c_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i63cfe59d1dc247b88c3f0c79a4c20ddb_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie108e7ffa05346ff9834f57e7ffcdad2_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:ContractManufacturingCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9be493af1ef548c7b50cb146bad36446_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i4b9c454823f244cd80d1fefee5471031_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i16c121b145194cf6abb5882efd1600bb_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i11500168fa8a442f878e3a3fd7879581_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i3481a276c03d48bf9b2c07bcb87daf78_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i21ae35839aed4acb8ce3728a8d65c8c4_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="if562d8cc7f4f4e548b86cb2f63c89067_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5dc2c86a61e549f6b10a9b94d684a51a_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic493d11fbb2f44b19c639b7aea48e26a_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ide28bbdab94947a3ba38457611aacf91_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="if5ac9acf99f240868c0779db73b11128_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="id5ed0dc28e704ee58e687f720a4af0c0_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:TGNMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i617e512b275d4156b3916be2a31cc2a7_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia4d7d03b9bfd4960861926231d1e06cc_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i1efccb25654a4ed989c06bba1bc60507_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i94a034741132459dbe0b3f97b3a4a689_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="icaea773c02484e7c915b32abc21d9f16_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:InLicensedPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if93847a57ec24f1cbf59a9b2ee618117_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:InLicensedPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i043f609cf8c0415bb5def38eaa738850_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i12acb630c412471c8fbf4ad5fba70e7d_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i3733833dc5534d8e823879ef2ca35162_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i2937e4b1496b4a52a0d3e66401ae9216_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i6d5405f808014e29ae408f670b51a09f_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i8a4caf6e3ead4de1943986bbd01cf562_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i9fa1b53a700943f2bdb14f74caa79af6_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i72583de967dc40ddb4cff73d7209ce4c_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i5876b06547fb4838bc5be5aca105c206_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="iffeaee7ccfe84deb8024b6a3c6400e05_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i366fc4865f1141d881e72475b885ad6b_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i3762ea1be6864e498c8620d932d2da39_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i4bcbf6cedff544d5a8a856091fd31a3f_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ia08462c38d1441cf88e8ec71551ea0c8_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="if0af6974b4d9478091a43d7c360e50da_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i7efef111968e4853ba97bc23f3210bf0_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i8f93695e9414499694873333956d9bdc_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ib2ec3058389a4337ac5eba484681aa08_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ie6a0e49727c84ab293a923c6fa60c4af_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if8d8ff0dd3eb48ac863f558fcbc6892a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i30724e1260114af0b2ee60176aabfc27_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib5bdbb9beeae4e419f12246dd08e17c5_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="icdb4c26a6ae346b2b90553854ef6c821_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i23dad120af7646aab43c1b2a51494af6_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9a733f2e8da94648b74178fe7c59c1c4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1741135b13de43a09abeb81ebbdefb63_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i43071817e6ed461f81f3fd642338f5f0_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id2a84d2f950447e889c009b8dc3d1c91_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3c062405d6734f55a0f77a7793837fa5_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9c442e1cde66431c994c606712e1b32f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i880c27328fde4402bd25776af2e34436_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if8cdd3be786a4c8fb53fbc1511f3e007_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia0e3519a323b44aeac235464c19aa330_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic296bd1f024d4dbfafdf14773b56195a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="icfebb7d3ca564ab9adac39367dcd18ff_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i9aaf1d46914b4e72aed3585ce98ebf30_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i69617b3297c54b348a912b5786d5c621_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia8b495ea13b343bca84608b9acb70bae_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="id243a9da99674c029fed341ed2d8cf28_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="icc2aa37ad604405da57ad8bd76640c2a_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i6a88a8981a664b5881775b573a56d09c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if6f8f2b74b4b4cb48f44b56c1255fe48_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2.25SeniorNotesdueMay12030Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i21d53c4f2fba488bac9f594f9b972c35_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2.25SeniorNotesdueMay12030Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i77d457887e524f9da825a576463047de_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ie3ab5e1259184cbfbb1c0fa0836b199b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iae850a600e004e54910f51657134788c_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A3.15SeniorNotesdueMay12050Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i5be3c08b32f44a29a978be98ccdbe750_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A3.15SeniorNotesdueMay12050Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic59436e93fd94dc7975cca19dc9348ab_I20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="i1b095aa200c24bc89b77243d5d674b37_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i481da687b03f42ba833d7ea97207f576_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="ie818884c1c424a8b87d88e29c4beebaa_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i7a3eaba5b5f948d7a04bc997b0e062fd_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="ie4a4e14dec0342ad99b8a674ea3866bf_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i8c7ce002196541519d28ce13eee1a198_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i1ca7ffcd21a746b68b8a16da619e41e8_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i88ecf4f0a7d947ada40d20f177ef560b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i01bf576ce3184732823152e79c0954dd_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:RepurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i83545e7be2ae48768bf0f58e921e708c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:RepurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i37325c7e699d4c51b083d0bd7f89fe2a_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i3e57229498ce4144b42c45e34e9ef425_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4704964df0724cd1b2cac40f12d8482c_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i8d2e2443e8024c469ef86deaee00b316_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i71ff130217a74446aad53582c9032ff2_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:CorporateDebtSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i6e2e5400e66745a59bc4efb5814dc463_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:CorporateDebtSecuritiesNonCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ifcf2b581c6394dde8ca839bc55b63d5a_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:GovernmentSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i332a8e26a3f44d669337bbdf30e280b1_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:GovernmentSecuritiesNonCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ib526d2b286604bca80b624a3a4adab69_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:MortgageAndOtherAssetBackedSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i6cf822a887824796933acc64b10aa831_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:MortgageAndOtherAssetBackedSecuritiesNonCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ia10b2aa757ad47b49f270ebc491e28d0_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="id90fa1852e434ceeabbcb8fdd0d40cbd_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:CorporateDebtSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i86f354cf497b4deeb6d0848b22bfdca5_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:CorporateDebtSecuritiesNonCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia0059a0f76db42a38b389323762cb3c7_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:GovernmentSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id4429d736bb44d669945730bee5061f8_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:GovernmentSecuritiesNonCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5fe904d775af4819805f32f893ad9967_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:MortgageAndOtherAssetBackedSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i803e14e6eace4d489a23796edd542d13_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:MortgageAndOtherAssetBackedSecuritiesNonCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ieb9c77d5ac2a4c2c926a9a3dbf9ab8a7_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0da5a59be8a94d28ad89a6d9991c15a1_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9fda89e7ff7d4684af34961dfcf9aa55_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:StrategicInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="id8f1f5cd45cf4a6db70e9630acf66ec5_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:StrategicInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i309c31a67fb24e66812ca6f278d681d1_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i7c3108c96711433ebf84541ad9cd5532_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iaf4f0ead32484685b836bcb55cd6ac1f_I20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:SangamoCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="i6cbe8727f757473bb189b0e60ca29a33_D20200401-20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:SangamoCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="if61ca2beff4e46f2a69e878ff2475931_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i14b94761681149c0bbac66ff547913ee_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i2bae98225c1d43d0a893047e90eb67a3_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id558b1125e81440f900acb6908040141_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iaa7d33c1e10b47fa9f4f7f33d32f8d33_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ib2f9b3c22cd24844962bad5e0141c40d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic1855cf25f394029aa9142b5e0a2635f_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i6a9857ccde3e4f828b0b5370ff0d84e4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i25d3a3cbcff64295ae970930acaf2277_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i921787c0672f4315b77172582046acf3_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ibc22ccd0077c4fc49c9a6f2ddfe73891_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:JPY</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="idd041b2211c7473cb6ccaf17dec017b0_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:JPY</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic3cd6575c1e949488c892f752b68feb4_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ic23424b9be6b4da59f189eb5703a1408_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i192ef770d9d94f289c8016dd9d055c00_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ie23a1176752b46eca086057bec4d49b1_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i68711c4f381b4aba952ff728afb1d3f8_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:DerivativeMaturityAxis">biib:ShorttermderivativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i5a2d291074a1433481dcb814e41d5746_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:DerivativeMaturityAxis">biib:ShorttermderivativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ibf5f0f40953a4421b9784faf958d97fc_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id81d26ae112f445586efe731295329b3_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i8b20f502d9dc4650852d96fb05490b25_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if0abd481cc504df9bbfcf3174b6ce61f_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id2b9b73877d74fc192e42310e8d70481_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ic22c771083a443f1ba2c8d2ff484ba65_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i827d32a33a5f4fa8ab22ab96449ad285_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i4a9063b9b9ab470d9ffe7edfcebe7d66_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ic3ca7f05924940338725185c031d90c4_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i1761a26f1d99415db0e01cea732e296a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic4da688b8e414bdf83ba16881ee41846_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ide3b267ed539403d9aea0f7cee18e938_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i982da4cced9d4ae2b09cb6c0c35fbf7b_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i4d505177b87243539cc2ef4baf3b7b2d_D20181101-20181130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-11-01</startDate>
            <endDate>2018-11-30</endDate>
        </period>
    </context>
    <context id="id881e97ef71e48839eea697986831baa_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i2a87e4910f2b4990a031d8e154d08e7c_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i08b50968168f4eb9ae561aa850896bc4_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i085845822f544f7fb9b0bbf69c2e903e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7d8de41bd42443beb5e6ef8181fbd9ed_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="icd9a4c8be88e43a9adf992e1820e2e43_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i5aac32d49b464e6cada89854863b83f8_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i10cf9b7a2fa84d7b844aa117861b3c56_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i9c45d46cb2c8406b930ef51351627297_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="id9f595a3d9be4f678b3dd5cf54ed7ea2_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie62a8195213a48748ad6794961fbeb22_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ie8794b47098d4b969e5c6a2e1127c28c_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i65313bd95c954aa487ab03b59dcf4f19_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8a718d3046ad462ba2ea0e14cf490598_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i8b73ba8bfb5d4bd599ede52803901f5d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib096f70fe5a64feab15f8a20b058d2bd_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i6af0347c89c44263995f095d4ffa6626_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iea98908b86804d0caf3c1f88da0f244b_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i7e60003aa8884f1d8ddcbb0621054f9f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i245f69306a2a48dc9b0a94f444f9a387_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ic3e04bb2c1a44e15ad29cbaea7a352a5_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9c341a47e1aa461fa949701e75d2e42e_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i20e561fa07fb43038ef6ed12d48d3e81_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie12a87471fff4dc1b58d09dc7f062be5_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ic1f004cc48f2484baa3a2dda6b81675d_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="id79a0b775b5b4772916934374fee4ad9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8b499d4033fd416886759d4c73cd37e4_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i61badd66b47b4dcd935f8e7dd306447b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i515423cd9b4842648857d6d91e4a1875_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:FacilityTypeAxis">biib:BiologicsManufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i79ca9be67e44499586e22d0729a04cad_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:FacilityTypeAxis">biib:WarehouseUtilitiesAndSupportSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i71a156afed9940d8b31d4a452da92788_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:FacilityTypeAxis">biib:AdministrativeSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iadc69a90f7b94abab8d83ed70d1edf52_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:FacilityLocationAxis">biib:SolothurnSwitzerlandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ia4d564a708c64a0f9eae417dc52c7afc_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:FacilityLocationAxis">biib:SolothurnSwitzerlandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2f00747e3707421b957d5a8909432bc2_I20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2.25SeniorNotesdueMay12030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="id7d171de853046bd832470203f2f56ba_I20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A3.15SeniorNotesdueMay12050Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="i12ad84388af247dc862a842bb1ccd8e8_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i03f25d4fea804740817761d106108f90_I20150915">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2.90SeniorNotesDueSept152020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-09-15</instant>
        </period>
    </context>
    <context id="i5e0ab653ffdc4001ba210ff20f499fc3_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2.90SeniorNotesDueSept152020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4d1664f9c34948f48657b943f060daf2_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2.90SeniorNotesDueSept152020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i50a2f9335d324e4986eea98f35621996_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:December2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ibe1d424343114522b510a64f315d7e68_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:March2019ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i2a0e6fee3a604c498aef94f0b86c6e9a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1cb136c416a04a05b9c1782e72b65627_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic914b0a393fd452c890e566f2c9c210f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i260d0a847a054ce0bef9b288ccd52ea2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if4823f5499b54f46b268ee3dd309f1da_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6773145664dd45a58afb7773d86b7f79_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i21e4efbba1364e8d97adce8a02fa5c1c_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="idd42a3afee77410b945f7e37289f8773_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4f6dc2dc230545079cf4e37cd9490b61_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i320a93a4270b45d2834748a854e79d02_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i58631e62f8454d6fa19167c8e8a2bb41_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i76542c629f7a4bfdb85009377f3655e1_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ideb1736cbc354334a8ee23f9cadfc4bd_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i1d927cca7f9c4d73aab25d3b3d48868f_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ib3b032c0499d4048ba5f66ef535061b2_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i0e4620290d53494a80d6bc03a34181dd_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="id17e410580eb4b0eb19f7434c46678d8_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i87b8b8492f694a2a85d10571ab2b857f_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i39a2399061724666bae8d3296c72225d_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i74e5d53de65e4a8a9e4e245845ee99be_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i591bf9ccf21b4e53b95118628d4978da_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i246c949459c344caa446c9c644b413b2_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i002638e6f51c4c26ba598e6a80ddd034_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i9b77bbc89c154914b55e0fa9c9242c96_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i2e02b47bfe8d48a5aa515d8c91a8cb66_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i81cfc07b94a54ce5b9767acd9ccbed84_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i6b8b1c75f80b47ab8430787fcd074574_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i52e2a69e04ee42ff88b18c7f1bf6b5bb_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i5f7aa82595074b70bd32cc3f188787ee_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i292bc1b0a8914e259d69aee92dcb23d9_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i69dfd183e47b43278ea75c1422a31eb4_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie7e3a2434dd044fda5e6fd81be0904a7_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ifc695f2ba910436fba8558e4c246c2ed_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iedbf521c84034004b661ca18c9f5b341_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i596f51e2385d4d4ca183e21f84aa0b55_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4ff5ee345592411bb43c306a460e9fd1_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i0dc320a6c37a4e9690e25e679e491fc4_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i8eaafd98479a4bef96cb14d80b992fd6_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i50715424610f44fe9d83a26f088cd935_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i1cccc5c5e6a64e839db1a1a24f25b45e_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ic0ab2edcb2644062923296228b7a8512_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i79d195428b514b78a4569da6e0cad1aa_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i42f682d87cc74a01aeb1af535a8ccb75_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i3ee5b72f84e44476b4c4a2b8d8df11ac_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i198a92ee28f54d99b35bfa8c48185fb9_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i31394cacd6624f0892e0c59f72b73473_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i07c2927512de4889ac3af77ef26070bf_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9e3d3eb860e64b4c8771c3591a944c56_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i418e492358064b87bb88dd6a5d427bd3_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i89cc77663484411897a1c618e3902df4_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i5177976681f14f4fbb72c76d037197e2_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id458ec3169f34e2088009cbf147e8304_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i2274b2b373db4361a50819e797d93268_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0ae5101f56364c07bd1fa9851047ae1c_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i17644aaa924944b6838681aa26728f55_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i93f4c72f492543b38ab5befc540cf70a_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i3bcae79b02034b7a8d5846ce264aff93_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i2cc8c72a2c4a4404a78a7942a0c6e8b1_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ia49dbac3063344639f0b5d7299e025be_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iff8fc7508c8d4439986e1175bce454a0_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i107d07150da4422b945e0bd78389de3b_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i909d084c1b604c4bba3bd63551acf4aa_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i0bbba4b976ca48c78d5dac97d8fe4cbd_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i68ac5428413242c4becdcb7197bed42d_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ie898eae73ea9411696b0e278874d55f0_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iad40dcf3ae2540a2b934514b7ad07c86_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ibdd3d4a6db7c4fd4bf7c980b55c5fecd_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i81789b07b22446a88e13e5c1075d8cb7_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="id915b8aebcff4bc2a81caf9b4de54dd7_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i8ca00e2a1cc04153858959116600cdcd_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i8ba330fe0fb04518b2ecb6db02b6b97f_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4e192d624f87417a8539bc84a2a459ff_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="if04752de82454bad9a9a42a0c78ff53b_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i493634946d8c4db49d02e47be89e303e_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ibed3bf29e7374cc8b7f86449cbcbaa3a_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i2cfe6ff0db44473e979cfeaa03760ded_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="iea41c7a4bbf94cfc8a16ac421e7cc25d_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7e43143e39df4b0cbb78c046a10aa64f_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i96a2e794f31f442ebbb83e8f8c7d54bd_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="icc0ae96137314a759fb1044af70f2b95_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i009b72f35e694a53ae5120480a467b8f_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia8cb99b7e0ae45fc98016744d8331c55_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ic61fb76b8e77432fb9579a89baff9f36_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5d623e1e956a426c9eb2bc18c5c9015c_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i65d9cd4367bc445dbfb50901412a5ada_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic0de115d377b4cfa9b3de1dd0bfd3954_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="if2c78ceb3d6b4fd69507a611127e10d7_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i1d5c287e1fde4ffdb4bdc39ad45f29d2_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i94ecbbbd615e4be087860504badd0ccd_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic2ec445a7fb2422f8f336348f12e3320_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ice7a7bfef4564888a80b19f37ff797b0_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ifeaa9653fb8c46b19f65a83276d1bcde_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i6602e12ee323468e9711c40286f62de7_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0dbcccb9a5554bba8ddbf97064cb4c88_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i73c8b3f596bb4630bfc6f91e336d5637_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0bd41977205f4c6e822e027dc9f7178f_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i8c21b1e012c34659a43ce91c598b6e19_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id073fd8d3b31491aacf37c244aa1d475_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i83240f344bc5485bb5ee15a465ba0ad3_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id6c80504460b4030869aa8a24e3babf4_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i5c634f032c59460488c598097bac861e_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i82c5ee63475c42b9be7685ee220cdbde_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i14dd3353e0b54676b5186391520f2af5_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i289872ca5f294cb881aceaa6ffd07da1_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i1cf49fa7c600408b8cf5254dbc554986_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5d5bdbbfb1724d7b86e0b6e3ff288ee3_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:DenmarkManufacturingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ib7f7a4e02a2b41bdbe159e1d831b1937_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia7dbdd092b034c3189ffed19d675f882_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia88c862a2922421b9916446a96695a69_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:SangamoCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i671e2b4b86c44e18a9a4518a9d0360e3_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4c4c8f3f1c614d79bad90fbadf4e582e_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SangamoTherapeuticsInc.AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9e00b6efba394fb5b58ec5d8f15b5e07_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i99c8bf62c3f747a6825f635a38c876aa_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5dd593028df14958ab74c65d6932d514_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie4289bd550fa4ecf980a7852c83941c9_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="iedea87e6fca548b387e737941a938d4d_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i76cadd05cfd9487992bcc01b2fbe54ad_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i4df0aa1f099c4275a635ce9719f80079_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ieaf688a040e748fcb2fb53cc4980b1ae_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i6fc4449da6e645b3871baa6066b7ba15_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i84416da07ea446c6a74945f76525350d_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AducanumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0347bcd849ae4267bfea5d50d6b0fbea_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AducanumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i74c4058ef32546ab9478606d50a42ff6_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AducanumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5ab886b24e304952b01a70c3288ca622_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AducanumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i108d4b03b28442088d579082f1514805_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AducanumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i1d21a2127fcd4783820ebe46b0ed050b_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AducanumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i758bfb8a36214bcd99abf2d550c98467_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AducanumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="icd694f937faa421dac86a19acb834bb4_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AducanumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i1927d71684864d0ea1eab5f146d82d5d_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:UCBPharmaS.A.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="icab43be754b749fe968e868f7a639cd7_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:UCBPharmaS.A.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id8caeb1ba3904b97aa01e55d54bcfdd0_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i00bfaa56f846452aa021215b0332f13a_D20200201-20200229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SangamoTherapeuticsInc.AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2020-02-29</endDate>
        </period>
    </context>
    <context id="i626bc76978584f20bed3f3c65385234a_D20190101-20190131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SkyhawkTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-01-31</endDate>
        </period>
    </context>
    <context id="i83f7cd89dae046c59b442f0c3d6955d3_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SkyhawkTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i6b31731f10d3438bbb21a6d76e82951d_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SkyhawkTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="ib83f121fe8084d6189d5e4c28193f59f_D20191001-20191031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SkyhawkTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-10-31</endDate>
        </period>
    </context>
    <context id="i65733f4ace874e1e89159f8c95744460_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i7967ad33dbdb48e89dd02f434444b459_I20181107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-11-07</instant>
        </period>
    </context>
    <context id="i071c5b3fcf304751900b25afea18d401_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InventoriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i16f85f52b2ce4a3e92746ecfebd0be40_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0fbd288a2a484b2092b7fb912c7e80ae_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia4cc37c0d62c49b58b4a17e71a0852f4_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if66718fccef241c1b9e6ef3161a2fd8a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia29071dbf1dd4669a9f529d1af16da0e_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i10d0b368c77e476286c6d631057ae023_I20200131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-31</instant>
        </period>
    </context>
    <context id="icb12afc98a00406dbfbbf375974469a1_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5da3d551e877481482c2c617be75f347_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i64047abc9e1e47a6a0d61a0e7591f7e1_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i80a9168a435d4f6a98b2450218498ef3_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ib22568b42dea422aad4788445cea0a41_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i00616e2d34c848588546a4eb3b7e17e1_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i035b83abf8f74352b8844936a4c053e5_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="if62153afc8b048fea1ecd3d555faaf6d_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i27257060fb394740a54642f97bef35f3_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i068f3b4714364e10a6f8a38a28733f78_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1478c61cb1ee4cfa8414bded1c551b30_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis">biib:NeurimmuneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i1f3660b791194af5a26e2a9ceab00343_D20171001-20171031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis">biib:NeurimmuneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2017-10-31</endDate>
        </period>
    </context>
    <context id="i61fb7e1bb0fd421bbf82c79ee9784cc5_D20180501-20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis">biib:NeurimmuneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-01</startDate>
            <endDate>2018-05-31</endDate>
        </period>
    </context>
    <context id="id7b514880c7944a69bca92a1890a1999_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:RegulatoryMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis">biib:NeurimmuneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id248e9039d774acdb784eeea9df07f64_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:RegulatoryApprovalMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis">biib:NeurimmuneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="product">
        <measure>biib:product</measure>
    </unit>
    <unit id="segment">
        <measure>biib:segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="assets">
        <measure>biib:Assets</measure>
    </unit>
    <unit id="wholesaler">
        <measure>biib:wholesaler</measure>
    </unit>
    <unit id="krw">
        <measure>iso4217:KRW</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="chf">
        <measure>iso4217:CHF</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM180L2ZyYWc6ZDQwZDVmM2RkYjQ3NGI2ZjhmOGZlMGM5NTMwMGM4NDMvdGFibGU6MWZjNTI2YmFkMDEzNGNmZGE5ZDQ3MmI0MTU4NzU5ZGYvdGFibGVyYW5nZToxZmM1MjZiYWQwMTM0Y2ZkYTlkNDcyYjQxNTg3NTlkZl8xLTEtMS0xLTA_a135545f-cf5b-4a0d-adc0-3142eb79a0f0">0000875045</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM180L2ZyYWc6ZDQwZDVmM2RkYjQ3NGI2ZjhmOGZlMGM5NTMwMGM4NDMvdGFibGU6MWZjNTI2YmFkMDEzNGNmZGE5ZDQ3MmI0MTU4NzU5ZGYvdGFibGVyYW5nZToxZmM1MjZiYWQwMTM0Y2ZkYTlkNDcyYjQxNTg3NTlkZl8yLTEtMS0xLTA_1c57adbe-af96-4058-9733-351c239061a5">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM180L2ZyYWc6ZDQwZDVmM2RkYjQ3NGI2ZjhmOGZlMGM5NTMwMGM4NDMvdGFibGU6MWZjNTI2YmFkMDEzNGNmZGE5ZDQ3MmI0MTU4NzU5ZGYvdGFibGVyYW5nZToxZmM1MjZiYWQwMTM0Y2ZkYTlkNDcyYjQxNTg3NTlkZl8zLTEtMS0xLTA_648683a4-6a62-4c9b-82a1-bd98798805a4">2020</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM180L2ZyYWc6ZDQwZDVmM2RkYjQ3NGI2ZjhmOGZlMGM5NTMwMGM4NDMvdGFibGU6MWZjNTI2YmFkMDEzNGNmZGE5ZDQ3MmI0MTU4NzU5ZGYvdGFibGVyYW5nZToxZmM1MjZiYWQwMTM0Y2ZkYTlkNDcyYjQxNTg3NTlkZl80LTEtMS0xLTA_e10d9ffe-072e-423c-bd59-4f2cb21fbb6b">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM180L2ZyYWc6ZDQwZDVmM2RkYjQ3NGI2ZjhmOGZlMGM5NTMwMGM4NDMvdGFibGU6MWZjNTI2YmFkMDEzNGNmZGE5ZDQ3MmI0MTU4NzU5ZGYvdGFibGVyYW5nZToxZmM1MjZiYWQwMTM0Y2ZkYTlkNDcyYjQxNTg3NTlkZl81LTEtMS0xLTA_c9b4644d-4c78-448e-9f4a-64ad0d2e2cac">false</dei:AmendmentFlag>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i4c10ff2cc693457ba96b227c43b75eec_I20201020"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM180L2ZyYWc6ZDQwZDVmM2RkYjQ3NGI2ZjhmOGZlMGM5NTMwMGM4NDMvdGFibGU6MWZjNTI2YmFkMDEzNGNmZGE5ZDQ3MmI0MTU4NzU5ZGYvdGFibGVyYW5nZToxZmM1MjZiYWQwMTM0Y2ZkYTlkNDcyYjQxNTg3NTlkZl82LTItMS0xLTA_4c3a51dc-d487-4ecd-9757-cb3fd2c5b386"
      unitRef="shares">153881597</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yOC9mcmFnOjkwNzc3OWY3ZDA4YTRkMDQ4MDU4MGQ0ZGI3MjUzYjQzL3RhYmxlOjE4OGNiODVmZGEzOTRmOTc4ZjA3MmQzN2I4MDZiNjU1L3RhYmxlcmFuZ2U6MTg4Y2I4NWZkYTM5NGY5NzhmMDcyZDM3YjgwNmI2NTVfMS0xLTEtMS0w_e65d17f0-5d55-42b4-8de8-b11d25d3c088"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i626282e786b7454d83b617e9e83963e6_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yOC9mcmFnOjkwNzc3OWY3ZDA4YTRkMDQ4MDU4MGQ0ZGI3MjUzYjQzL3RhYmxlOjE4OGNiODVmZGEzOTRmOTc4ZjA3MmQzN2I4MDZiNjU1L3RhYmxlcmFuZ2U6MTg4Y2I4NWZkYTM5NGY5NzhmMDcyZDM3YjgwNmI2NTVfMS0zLTEtMS0w_1e4ee9dd-5263-46ab-be6d-81fc70ecf6f7"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yOC9mcmFnOjkwNzc3OWY3ZDA4YTRkMDQ4MDU4MGQ0ZGI3MjUzYjQzL3RhYmxlOjE4OGNiODVmZGEzOTRmOTc4ZjA3MmQzN2I4MDZiNjU1L3RhYmxlcmFuZ2U6MTg4Y2I4NWZkYTM5NGY5NzhmMDcyZDM3YjgwNmI2NTVfMi0xLTEtMS0w_1e574bc9-af59-4ec6-856c-39056c07b780"
      unitRef="usdPerShare">0.0005</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i626282e786b7454d83b617e9e83963e6_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yOC9mcmFnOjkwNzc3OWY3ZDA4YTRkMDQ4MDU4MGQ0ZGI3MjUzYjQzL3RhYmxlOjE4OGNiODVmZGEzOTRmOTc4ZjA3MmQzN2I4MDZiNjU1L3RhYmxlcmFuZ2U6MTg4Y2I4NWZkYTM5NGY5NzhmMDcyZDM3YjgwNmI2NTVfMi0zLTEtMS0w_7d92a603-e856-4916-8f1a-ec0e34be0123"
      unitRef="usdPerShare">0.0005</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i617e512b275d4156b3916be2a31cc2a7_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182NC9mcmFnOmE4NjI0NGEyODg1ZjRlYmM5ZDI3ZDlkN2Y2Y2VhN2EyL3RhYmxlOmVkNWJiZjNhNDYzMDRjZTk5MDVlOTY4MWJiNTY0OTQ5L3RhYmxlcmFuZ2U6ZWQ1YmJmM2E0NjMwNGNlOTkwNWU5NjgxYmI1NjQ5NDlfMS0xLTEtMS0w_d3d93b36-ea0d-4c5e-9850-0d381a79dd09">P13Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="ia4d7d03b9bfd4960861926231d1e06cc_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182NC9mcmFnOmE4NjI0NGEyODg1ZjRlYmM5ZDI3ZDlkN2Y2Y2VhN2EyL3RhYmxlOmVkNWJiZjNhNDYzMDRjZTk5MDVlOTY4MWJiNTY0OTQ5L3RhYmxlcmFuZ2U6ZWQ1YmJmM2E0NjMwNGNlOTkwNWU5NjgxYmI1NjQ5NDlfMi0xLTEtMS0w_e8190803-5daf-426f-ab8f-c78207e1b5fe">P23Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i1efccb25654a4ed989c06bba1bc60507_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182NC9mcmFnOmE4NjI0NGEyODg1ZjRlYmM5ZDI3ZDlkN2Y2Y2VhN2EyL3RhYmxlOmVkNWJiZjNhNDYzMDRjZTk5MDVlOTY4MWJiNTY0OTQ5L3RhYmxlcmFuZ2U6ZWQ1YmJmM2E0NjMwNGNlOTkwNWU5NjgxYmI1NjQ5NDlfMy0xLTEtMS0w_d79d544d-23e1-417d-8206-ca7347448cbc">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i94a034741132459dbe0b3f97b3a4a689_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182NC9mcmFnOmE4NjI0NGEyODg1ZjRlYmM5ZDI3ZDlkN2Y2Y2VhN2EyL3RhYmxlOmVkNWJiZjNhNDYzMDRjZTk5MDVlOTY4MWJiNTY0OTQ5L3RhYmxlcmFuZ2U6ZWQ1YmJmM2E0NjMwNGNlOTkwNWU5NjgxYmI1NjQ5NDlfNC0xLTEtMS0w_1a7b89e1-e000-4bfc-97ea-19cece6b07e5">P28Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="icaea773c02484e7c915b32abc21d9f16_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182NC9mcmFnOmE4NjI0NGEyODg1ZjRlYmM5ZDI3ZDlkN2Y2Y2VhN2EyL3RhYmxlOmVkNWJiZjNhNDYzMDRjZTk5MDVlOTY4MWJiNTY0OTQ5L3RhYmxlcmFuZ2U6ZWQ1YmJmM2E0NjMwNGNlOTkwNWU5NjgxYmI1NjQ5NDlfNS0xLTEtMS0w_1e448f36-0587-4422-9d5e-69b702ceba5c">P4Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="if93847a57ec24f1cbf59a9b2ee618117_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182NC9mcmFnOmE4NjI0NGEyODg1ZjRlYmM5ZDI3ZDlkN2Y2Y2VhN2EyL3RhYmxlOmVkNWJiZjNhNDYzMDRjZTk5MDVlOTY4MWJiNTY0OTQ5L3RhYmxlcmFuZ2U6ZWQ1YmJmM2E0NjMwNGNlOTkwNWU5NjgxYmI1NjQ5NDlfNi0xLTEtMS0w_bc0f92fa-e959-41ed-b95e-5c6e1713ede6">P18Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <biib:IndefiniteLivedIntangibleAssetsUsefulLife
      contextRef="i043f609cf8c0415bb5def38eaa738850_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182NC9mcmFnOmE4NjI0NGEyODg1ZjRlYmM5ZDI3ZDlkN2Y2Y2VhN2EyL3RhYmxlOmVkNWJiZjNhNDYzMDRjZTk5MDVlOTY4MWJiNTY0OTQ5L3RhYmxlcmFuZ2U6ZWQ1YmJmM2E0NjMwNGNlOTkwNWU5NjgxYmI1NjQ5NDlfNy0xLTEtMS0w_3049daf7-8768-4f17-abc9-86fb6111c949">Indefinite until commercialization</biib:IndefiniteLivedIntangibleAssetsUsefulLife>
    <biib:IndefiniteLivedIntangibleAssetsUsefulLife
      contextRef="i12acb630c412471c8fbf4ad5fba70e7d_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182NC9mcmFnOmE4NjI0NGEyODg1ZjRlYmM5ZDI3ZDlkN2Y2Y2VhN2EyL3RhYmxlOmVkNWJiZjNhNDYzMDRjZTk5MDVlOTY4MWJiNTY0OTQ5L3RhYmxlcmFuZ2U6ZWQ1YmJmM2E0NjMwNGNlOTkwNWU5NjgxYmI1NjQ5NDlfOC0xLTEtMS0w_c6988c99-afdc-44b9-9b08-9d223f6d6a94">Indefinite</biib:IndefiniteLivedIntangibleAssetsUsefulLife>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182NC9mcmFnOmE4NjI0NGEyODg1ZjRlYmM5ZDI3ZDlkN2Y2Y2VhN2EyL3RleHRyZWdpb246YTg2MjQ0YTI4ODVmNGViYzlkMjdkOWQ3ZjZjZWE3YTJfMzk_76cbb0fd-0b23-4c95-b0ba-e374827a8298"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182NC9mcmFnOmE4NjI0NGEyODg1ZjRlYmM5ZDI3ZDlkN2Y2Y2VhN2EyL3RleHRyZWdpb246YTg2MjQ0YTI4ODVmNGViYzlkMjdkOWQ3ZjZjZWE3YTJfNTI_6c96674b-9444-4c70-9472-7c50b416f15e"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182NC9mcmFnOmE4NjI0NGEyODg1ZjRlYmM5ZDI3ZDlkN2Y2Y2VhN2EyL3RleHRyZWdpb246YTg2MjQ0YTI4ODVmNGViYzlkMjdkOWQ3ZjZjZWE3YTJfNTU_0ebd5b31-41d3-4503-9dee-3b603032fd7e"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i9aaf1d46914b4e72aed3585ce98ebf30_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183MC9mcmFnOjg0ZWEwZjQzMTllNzQ5MDBhOTlhMjNjNjc5YzY0Y2FiL3RhYmxlOmYxNWYyYzE3NWUyMjQyMTNiNTgzYTJkZjAxMDQ5ZGQxL3RhYmxlcmFuZ2U6ZjE1ZjJjMTc1ZTIyNDIxM2I1ODNhMmRmMDEwNDlkZDFfNS0xLTEtMS0w_83d40276-d28a-4890-b8b4-0178b9b1e73e"
      unitRef="number">0.02900</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ia8b495ea13b343bca84608b9acb70bae_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183MC9mcmFnOjg0ZWEwZjQzMTllNzQ5MDBhOTlhMjNjNjc5YzY0Y2FiL3RhYmxlOmYxNWYyYzE3NWUyMjQyMTNiNTgzYTJkZjAxMDQ5ZGQxL3RhYmxlcmFuZ2U6ZjE1ZjJjMTc1ZTIyNDIxM2I1ODNhMmRmMDEwNDlkZDFfNi0xLTEtMS0w_3b933cd4-b72c-4d35-8e42-24e7ad7197bd"
      unitRef="number">0.03625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="icc2aa37ad604405da57ad8bd76640c2a_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183MC9mcmFnOjg0ZWEwZjQzMTllNzQ5MDBhOTlhMjNjNjc5YzY0Y2FiL3RhYmxlOmYxNWYyYzE3NWUyMjQyMTNiNTgzYTJkZjAxMDQ5ZGQxL3RhYmxlcmFuZ2U6ZjE1ZjJjMTc1ZTIyNDIxM2I1ODNhMmRmMDEwNDlkZDFfNy0xLTEtMS0w_bc3d3419-c3d8-4e29-98c4-83eac3440cd0"
      unitRef="number">0.04050</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i77d457887e524f9da825a576463047de_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183MC9mcmFnOjg0ZWEwZjQzMTllNzQ5MDBhOTlhMjNjNjc5YzY0Y2FiL3RhYmxlOmYxNWYyYzE3NWUyMjQyMTNiNTgzYTJkZjAxMDQ5ZGQxL3RhYmxlcmFuZ2U6ZjE1ZjJjMTc1ZTIyNDIxM2I1ODNhMmRmMDEwNDlkZDFfOC0xLTEtMS0w_502dea29-9704-4cad-9269-1dc8e060aa41"
      unitRef="number">0.05200</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if6f8f2b74b4b4cb48f44b56c1255fe48_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183MC9mcmFnOjg0ZWEwZjQzMTllNzQ5MDBhOTlhMjNjNjc5YzY0Y2FiL3RhYmxlOmYxNWYyYzE3NWUyMjQyMTNiNTgzYTJkZjAxMDQ5ZGQxL3RhYmxlcmFuZ2U6ZjE1ZjJjMTc1ZTIyNDIxM2I1ODNhMmRmMDEwNDlkZDFfOS0xLTEtMS0w_931f96aa-1e4b-4a14-a96d-119cfeb28fa9"
      unitRef="number">0.02250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iae850a600e004e54910f51657134788c_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183MC9mcmFnOjg0ZWEwZjQzMTllNzQ5MDBhOTlhMjNjNjc5YzY0Y2FiL3RhYmxlOmYxNWYyYzE3NWUyMjQyMTNiNTgzYTJkZjAxMDQ5ZGQxL3RhYmxlcmFuZ2U6ZjE1ZjJjMTc1ZTIyNDIxM2I1ODNhMmRmMDEwNDlkZDFfMTAtMS0xLTEtMA_df88c246-689b-45b9-b4eb-611ed3f82834"
      unitRef="number">0.03150</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="ie4a4e14dec0342ad99b8a674ea3866bf_I20200930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183MC9mcmFnOjg0ZWEwZjQzMTllNzQ5MDBhOTlhMjNjNjc5YzY0Y2FiL3RhYmxlOmYxNjFjZjQwYTA1YzQ0NTk5YWJkMDIxNDg4MDJkY2EwL3RhYmxlcmFuZ2U6ZjE2MWNmNDBhMDVjNDQ1OTlhYmQwMjE0ODgwMmRjYTBfNS00LTEtMS0w_1dc9c7d9-cbf0-4897-8d2d-a79047528b99"
      unitRef="number">0.0083</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i8c7ce002196541519d28ce13eee1a198_I20200930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183MC9mcmFnOjg0ZWEwZjQzMTllNzQ5MDBhOTlhMjNjNjc5YzY0Y2FiL3RhYmxlOmYxNjFjZjQwYTA1YzQ0NTk5YWJkMDIxNDg4MDJkY2EwL3RhYmxlcmFuZ2U6ZjE2MWNmNDBhMDVjNDQ1OTlhYmQwMjE0ODgwMmRjYTBfNi00LTEtMS0w_07437d0a-7ee7-4f2a-9fe9-c0f22f8f5eef"
      unitRef="number">0.0118</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:AssetImpairmentCharges
      contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183MC9mcmFnOjg0ZWEwZjQzMTllNzQ5MDBhOTlhMjNjNjc5YzY0Y2FiL3RleHRyZWdpb246ODRlYTBmNDMxOWU3NDkwMGE5OWEyM2M2NzljNjRjYWJfMTI_c1d25d25-ef2a-42c2-a730-823cd7e5bca4"
      unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <biib:CollaborationAgreementTerm
      contextRef="i5da3d551e877481482c2c617be75f347_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzg3OTYwOTMwNDMxMzk_81c0182f-ea26-4b51-b761-61b3c8a065e8">P5Y</biib:CollaborationAgreementTerm>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i99c8bf62c3f747a6825f635a38c876aa_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTUvZnJhZzozZTE2MThiMmQ5ZTU0NzQ3YjBkNjNiNTQ3NzY0NjU0Ny90ZXh0cmVnaW9uOjNlMTYxOGIyZDllNTQ3NDdiMGQ2M2I1NDc3NjQ2NTQ3XzQ_b32dfb72-3b6c-4992-8621-bd0e2a08eb36"
      unitRef="usd">33800000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities
      contextRef="i626282e786b7454d83b617e9e83963e6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMjEvZnJhZzpkMTg2YTllMThmN2M0Y2YyODU2ZGU0MzJjYmU1N2RmYS90ZXh0cmVnaW9uOmQxODZhOWUxOGY3YzRjZjI4NTZkZTQzMmNiZTU3ZGZhXzE2OA_a3e92a68-88aa-492b-9fae-61b0b8e61d40"
      unitRef="usd">22700000</biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities>
    <dei:DocumentType
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xL2ZyYWc6YjhmMjUxMjZjYWJmNDc4MmI3NzA2YzkzMmZmZDM1OGIvdGV4dHJlZ2lvbjpiOGYyNTEyNmNhYmY0NzgyYjc3MDZjOTMyZmZkMzU4Yl8yMDEz_6f13bb3d-dcd4-46b0-a5ad-760cab70bfa1">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xL2ZyYWc6YjhmMjUxMjZjYWJmNDc4MmI3NzA2YzkzMmZmZDM1OGIvdGFibGU6YmUyZDU5N2ZhZDliNGEzZjkyMDRmMDU1MGYyNWU4NTkvdGFibGVyYW5nZTpiZTJkNTk3ZmFkOWI0YTNmOTIwNGYwNTUwZjI1ZTg1OV8wLTAtMS0xLTA_1e766eeb-3f4d-48da-9c5f-e1a2275530a2">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xL2ZyYWc6YjhmMjUxMjZjYWJmNDc4MmI3NzA2YzkzMmZmZDM1OGIvdGV4dHJlZ2lvbjpiOGYyNTEyNmNhYmY0NzgyYjc3MDZjOTMyZmZkMzU4Yl8xMjQ_e713cbb9-311b-47e1-9b7d-198bad16cba4">2020-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xL2ZyYWc6YjhmMjUxMjZjYWJmNDc4MmI3NzA2YzkzMmZmZDM1OGIvdGFibGU6Zjc0MWEyMDg0MmZlNGQ5MjgwMmU4M2Y4ODExM2EyNzkvdGFibGVyYW5nZTpmNzQxYTIwODQyZmU0ZDkyODAyZTgzZjg4MTEzYTI3OV8wLTAtMS0xLTA_c422bff9-ec89-46e4-8a88-44b00933e71a">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xL2ZyYWc6YjhmMjUxMjZjYWJmNDc4MmI3NzA2YzkzMmZmZDM1OGIvdGV4dHJlZ2lvbjpiOGYyNTEyNmNhYmY0NzgyYjc3MDZjOTMyZmZkMzU4Yl8yMDA4_fb803ea4-cc19-4130-a5bb-76addf1d0421">0-19311</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xL2ZyYWc6YjhmMjUxMjZjYWJmNDc4MmI3NzA2YzkzMmZmZDM1OGIvdGV4dHJlZ2lvbjpiOGYyNTEyNmNhYmY0NzgyYjc3MDZjOTMyZmZkMzU4Yl8yMDE0_91104669-416b-4c5b-9037-e05162fd92ea">BIOGEN INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xL2ZyYWc6YjhmMjUxMjZjYWJmNDc4MmI3NzA2YzkzMmZmZDM1OGIvdGFibGU6Nzc2YzY5MzRiYTBmNDA3ZmE2NDI4MThiMzcwMDA4MTEvdGFibGVyYW5nZTo3NzZjNjkzNGJhMGY0MDdmYTY0MjgxOGIzNzAwMDgxMV8wLTAtMS0xLTA_bb354328-343e-4344-acf6-6bcf9efc10bb">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xL2ZyYWc6YjhmMjUxMjZjYWJmNDc4MmI3NzA2YzkzMmZmZDM1OGIvdGFibGU6Nzc2YzY5MzRiYTBmNDA3ZmE2NDI4MThiMzcwMDA4MTEvdGFibGVyYW5nZTo3NzZjNjkzNGJhMGY0MDdmYTY0MjgxOGIzNzAwMDgxMV8wLTItMS0xLTA_6736f8f7-b37e-4fcd-af4c-97c3666efcd0">33-0112644</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xL2ZyYWc6YjhmMjUxMjZjYWJmNDc4MmI3NzA2YzkzMmZmZDM1OGIvdGV4dHJlZ2lvbjpiOGYyNTEyNmNhYmY0NzgyYjc3MDZjOTMyZmZkMzU4Yl8yMDA5_76723d56-7241-4285-a84b-59702984ff33">225 Binney Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xL2ZyYWc6YjhmMjUxMjZjYWJmNDc4MmI3NzA2YzkzMmZmZDM1OGIvdGV4dHJlZ2lvbjpiOGYyNTEyNmNhYmY0NzgyYjc3MDZjOTMyZmZkMzU4Yl8yMDE1_57dba76c-7089-4444-9cc3-2496140231b6">Cambridge</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xL2ZyYWc6YjhmMjUxMjZjYWJmNDc4MmI3NzA2YzkzMmZmZDM1OGIvdGV4dHJlZ2lvbjpiOGYyNTEyNmNhYmY0NzgyYjc3MDZjOTMyZmZkMzU4Yl8yMDE2_9be279b7-f9b2-402f-b33c-0d4a9fb6c863">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xL2ZyYWc6YjhmMjUxMjZjYWJmNDc4MmI3NzA2YzkzMmZmZDM1OGIvdGV4dHJlZ2lvbjpiOGYyNTEyNmNhYmY0NzgyYjc3MDZjOTMyZmZkMzU4Yl8yMDE3_e0023c3d-2f0d-4d47-852f-16332cb8e81e">02142</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xL2ZyYWc6YjhmMjUxMjZjYWJmNDc4MmI3NzA2YzkzMmZmZDM1OGIvdGV4dHJlZ2lvbjpiOGYyNTEyNmNhYmY0NzgyYjc3MDZjOTMyZmZkMzU4Yl8yMDEw_042984c6-156b-4858-8da0-e221e01452fe">617</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xL2ZyYWc6YjhmMjUxMjZjYWJmNDc4MmI3NzA2YzkzMmZmZDM1OGIvdGV4dHJlZ2lvbjpiOGYyNTEyNmNhYmY0NzgyYjc3MDZjOTMyZmZkMzU4Yl8yMDEx_e4ee9bd0-a91a-4a9a-ad54-a8f467d856e0">679-2000</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xL2ZyYWc6YjhmMjUxMjZjYWJmNDc4MmI3NzA2YzkzMmZmZDM1OGIvdGFibGU6YTExNTcyMGEyZGE4NGZhZTgxOGE3M2JlNGRlNjgyYWUvdGFibGVyYW5nZTphMTE1NzIwYTJkYTg0ZmFlODE4YTczYmU0ZGU2ODJhZV8xLTAtMS0xLTA_88c46b57-9563-4d90-90ce-8932485e7893">Common Stock, $0.0005 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xL2ZyYWc6YjhmMjUxMjZjYWJmNDc4MmI3NzA2YzkzMmZmZDM1OGIvdGFibGU6YTExNTcyMGEyZGE4NGZhZTgxOGE3M2JlNGRlNjgyYWUvdGFibGVyYW5nZTphMTE1NzIwYTJkYTg0ZmFlODE4YTczYmU0ZGU2ODJhZV8xLTItMS0xLTA_1c57a10e-8688-43de-971b-43509588e7be">BIIB</dei:TradingSymbol>
    <dei:EntityCurrentReportingStatus
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xL2ZyYWc6YjhmMjUxMjZjYWJmNDc4MmI3NzA2YzkzMmZmZDM1OGIvdGV4dHJlZ2lvbjpiOGYyNTEyNmNhYmY0NzgyYjc3MDZjOTMyZmZkMzU4Yl8yMDEy_1b60311b-8f98-405b-9052-7ca5c85c92d3">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xL2ZyYWc6YjhmMjUxMjZjYWJmNDc4MmI3NzA2YzkzMmZmZDM1OGIvdGV4dHJlZ2lvbjpiOGYyNTEyNmNhYmY0NzgyYjc3MDZjOTMyZmZkMzU4Yl8yMDE4_8aec3857-5680-4eb3-97c5-8b8ed53f8e51">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xL2ZyYWc6YjhmMjUxMjZjYWJmNDc4MmI3NzA2YzkzMmZmZDM1OGIvdGFibGU6NGUyZDIwMmJmOGI0NDQ3OGIxMDE5MTE1MmIwNGUzYmUvdGFibGVyYW5nZTo0ZTJkMjAyYmY4YjQ0NDc4YjEwMTkxMTUyYjA0ZTNiZV8wLTAtMS0xLTA_49220310-6229-43e2-9005-8a2b4e6cfb2b">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xL2ZyYWc6YjhmMjUxMjZjYWJmNDc4MmI3NzA2YzkzMmZmZDM1OGIvdGFibGU6NGUyZDIwMmJmOGI0NDQ3OGIxMDE5MTE1MmIwNGUzYmUvdGFibGVyYW5nZTo0ZTJkMjAyYmY4YjQ0NDc4YjEwMTkxMTUyYjA0ZTNiZV8xLTQtMS0xLTA_61888dcb-8d45-4c30-b677-55733390fa4b">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xL2ZyYWc6YjhmMjUxMjZjYWJmNDc4MmI3NzA2YzkzMmZmZDM1OGIvdGFibGU6NGUyZDIwMmJmOGI0NDQ3OGIxMDE5MTE1MmIwNGUzYmUvdGFibGVyYW5nZTo0ZTJkMjAyYmY4YjQ0NDc4YjEwMTkxMTUyYjA0ZTNiZV8yLTQtMS0xLTA_99d5a1f7-a1dd-4912-a57c-e36074d395b5">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xL2ZyYWc6YjhmMjUxMjZjYWJmNDc4MmI3NzA2YzkzMmZmZDM1OGIvdGV4dHJlZ2lvbjpiOGYyNTEyNmNhYmY0NzgyYjc3MDZjOTMyZmZkMzU4Yl8yMDE5_95a885ad-a486-4d29-8165-6e078c74980c">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i4c10ff2cc693457ba96b227c43b75eec_I20201020"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xL2ZyYWc6YjhmMjUxMjZjYWJmNDc4MmI3NzA2YzkzMmZmZDM1OGIvdGV4dHJlZ2lvbjpiOGYyNTEyNmNhYmY0NzgyYjc3MDZjOTMyZmZkMzU4Yl8xOTk2_4c3a51dc-d487-4ecd-9757-cb3fd2c5b386"
      unitRef="shares">153881597</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:Revenues
      contextRef="iba1a633773a34c899b77b4853a665d4e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMy0xLTEtMS0w_8575b518-e57a-4d3c-93f1-581e5f29b875"
      unitRef="usd">2690300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i817821ea916346a6b301c5912257c3e5_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMy0zLTEtMS0w_c29d3d55-9a87-4eee-931d-2324dcd6bf6a"
      unitRef="usd">2894700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id41b722bb5ce413f84c0e1a46961879f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMy01LTEtMS0w_d27730de-b941-48b5-90eb-d6211841d10a"
      unitRef="usd">8390600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if88c636dd80d492687ca22f07e75db13_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMy03LTEtMS0w_7425d59b-ea0c-4bd0-a1d3-ebf9585105b7"
      unitRef="usd">8455000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia428d1f03d1f454a9d5c837ec6e0aa50_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfNC0xLTEtMS0w_c1f56fa7-1be0-4bb5-ba7e-24e480a8b04f"
      unitRef="usd">560100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8595ad2d43f34d98abb716a40fde60a6_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfNC0zLTEtMS0w_75602dab-cfe0-4dfc-9d5a-a71a0fbc0e87"
      unitRef="usd">595800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0cb93d1ae39f48f3b0fc167540132b77_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfNC01LTEtMS0w_a6f34437-0327-432e-8b18-7c940162f217"
      unitRef="usd">1558800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5452667727cd4cf08cae4c412b67d3ef_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfNC03LTEtMS0w_e310c53f-a6d7-46df-a0c9-40613445084a"
      unitRef="usd">1689600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iba6a7aa4c7fa4fda950fccc032894346_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfNS0xLTEtMS0w_115c6619-90cc-4166-9e98-8421288dbead"
      unitRef="usd">125700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0ea06cd6a9974b4999904b90f030878b_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfNS0zLTEtMS0w_e0b7010d-9405-4545-857c-dd8b17f5f536"
      unitRef="usd">109600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6e0b6c1de005431bb80fcd07bc90af2e_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfNS01LTEtMS0w_6e209fa4-9bfb-4903-9e13-c617c79d1ea4"
      unitRef="usd">642600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2335a9cc65b041aa8e881414fc49759c_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfNS03LTEtMS0w_6c2256eb-a44e-4b76-b3fb-1a5743570bf9"
      unitRef="usd">562000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfNi0xLTEtMS0w_e398c84d-477d-425e-939a-3f38f3766fb4"
      unitRef="usd">3376100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfNi0zLTEtMS0w_2cc12a75-2870-45b7-a3cb-dfb079aa0a3b"
      unitRef="usd">3600100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfNi01LTEtMS0w_0896cbec-6e02-4a11-b7ad-a2c8e3c5397b"
      unitRef="usd">10592000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfNi03LTEtMS0w_dda4fb54-3b7c-41a8-be7b-5b655c0f74ac"
      unitRef="usd">10706600000</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfOC0xLTEtMS0w_89cc9feb-6ee3-4f9d-a56b-205e40c91a87"
      unitRef="usd">449100000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfOC0zLTEtMS0w_c1fed65e-b401-41f6-8374-36a20d66eddd"
      unitRef="usd">430000000.0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfOC01LTEtMS0w_2b894967-1e1e-4e90-824f-00e050b5a065"
      unitRef="usd">1314600000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfOC03LTEtMS0w_732c0e0e-908b-4f83-8766-2ff250e36408"
      unitRef="usd">1508300000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfOS0xLTEtMS0w_e4c5d2ed-798f-47ff-a159-57ed95cdedb4"
      unitRef="usd">1140900000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfOS0zLTEtMS0w_68d9543e-65a5-4b98-9413-03448b15e188"
      unitRef="usd">540400000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfOS01LTEtMS0w_52459754-6218-4f43-bfe9-18056ed54390"
      unitRef="usd">2264800000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfOS03LTEtMS0w_8e2347c3-6be0-4b7a-822f-887657ad3035"
      unitRef="usd">1588900000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMTAtMS0xLTEtMA_1b0ace10-c9fe-4911-9a17-097bf26722fa"
      unitRef="usd">573100000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMTAtMy0xLTEtMA_a399c6e0-4b36-44e5-b0ee-8c19cc07cd94"
      unitRef="usd">554500000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMTAtNS0xLTEtMA_6931582e-d8c1-4581-92c8-37bda1a0cc2e"
      unitRef="usd">1698300000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMTAtNy0xLTEtMA_106cd886-c4f7-4643-85ac-248a5f9c46a4"
      unitRef="usd">1709800000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets
      contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMTEtMS0xLTEtMA_26b35267-3899-4e46-802f-26ad462e98b7"
      unitRef="usd">82600000</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets
      contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMTEtMy0xLTEtMA_92944d6d-69db-4400-b141-cfdfc08b395b"
      unitRef="usd">283900000</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMTEtNS0xLTEtMA_a935bdd1-71ac-4358-a642-223d16557b48"
      unitRef="usd">215600000</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMTEtNy0xLTEtMA_519699f0-5f44-4ce5-8b91-d29ae09cf675"
      unitRef="usd">422200000</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <biib:Collaborationprofitlosssharing
      contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMTItMS0xLTEtMA_31831a59-a519-48ea-adb8-b875a3bfadf0"
      unitRef="usd">73000000.0</biib:Collaborationprofitlosssharing>
    <biib:Collaborationprofitlosssharing
      contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMTItMy0xLTEtMA_4044d6dd-f0f8-4901-8388-4fa2abc2a54a"
      unitRef="usd">60200000</biib:Collaborationprofitlosssharing>
    <biib:Collaborationprofitlosssharing
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMTItNS0xLTEtMA_fa5ce617-687c-4afb-b1a4-dfea0d503d8c"
      unitRef="usd">166500000</biib:Collaborationprofitlosssharing>
    <biib:Collaborationprofitlosssharing
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMTItNy0xLTEtMA_f97f65c5-d675-456d-a105-b125e1cce561"
      unitRef="usd">181800000</biib:Collaborationprofitlosssharing>
    <us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown
      contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMTMtMS0xLTEtMA_d7182e00-ff29-44df-b66b-4af3bf2a0440"
      unitRef="usd">0</us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown>
    <us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown
      contextRef="i6d14771766d1415790d98b0c80aaa2eb_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMTMtMy0xLTEtMA_835d30f0-93b2-45eb-80ab-4bbc1371f166"
      unitRef="usd">-17700000</us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown>
    <us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMTMtNS0xLTEtMA_65f7c8b3-4ad4-4a65-9de2-c75cbdea133c"
      unitRef="usd">0</us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown>
    <us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMTMtNy0xLTEtMA_71247e36-fe62-418f-bdf1-b3ffaec64d29"
      unitRef="usd">95500000</us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMTQtMS0xLTEtMA_8d1f997c-9ed7-4203-a725-994f64c09fc0"
      unitRef="usd">29000000.0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMTQtMy0xLTEtMA_29e7765a-f4c4-47fe-9afe-1cac8eefb99c"
      unitRef="usd">57800000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMTQtNS0xLTEtMA_260cb5ec-9883-4dff-ad93-d42b945c1e2a"
      unitRef="usd">23500000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMTQtNy0xLTEtMA_3271b4c7-6498-4ba5-9b54-a8891e982e05"
      unitRef="usd">66300000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:RestructuringCharges
      contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMTUtMS0xLTEtMA_7e48b0ce-947a-4092-88b0-4a1f0e701610"
      unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMTUtMy0xLTEtMA_f1b84eed-0666-475a-bc33-89c357bc6105"
      unitRef="usd">300000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMTUtNS0xLTEtMA_48358421-18ff-464f-a293-7f0ea8a5e347"
      unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMTUtNy0xLTEtMA_86425ca9-209b-4b70-9318-3dc15495136a"
      unitRef="usd">1500000</us-gaap:RestructuringCharges>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMTYtMS0xLTEtMA_f4443cc5-f4aa-4ce2-8246-51e1461dab8f"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMTYtMy0xLTEtMA_79bfaa78-f693-4c9a-8818-9d73694bb513"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMTYtNS0xLTEtMA_4ba3571f-580e-4065-990b-2818c6d3da0d"
      unitRef="usd">75000000.0</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMTYtNy0xLTEtMA_6d637cdd-3a1c-43f0-837a-49bb1fee1f65"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:CostsAndExpenses
      contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMTctMS0xLTEtMA_def27680-ab77-4d27-a513-2210d79b65f1"
      unitRef="usd">2289700000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMTctMy0xLTEtMA_6ecf8cf4-bed6-4a29-b138-6c5e91887ed0"
      unitRef="usd">1793800000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMTctNS0xLTEtMA_8b14c508-0f17-4e2c-87f1-a1cc26aad613"
      unitRef="usd">5711300000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMTctNy0xLTEtMA_6d1cfa11-e57e-478c-a632-b0825d00bd5e"
      unitRef="usd">5441700000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMTgtMS0xLTEtMA_53b53361-46aa-4f8a-92de-2f5aa9431b7c"
      unitRef="usd">1086400000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMTgtMy0xLTEtMA_d8cc1391-c99a-4ed9-a086-51839302223d"
      unitRef="usd">1806300000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMTgtNS0xLTEtMA_e1faf36a-16e9-4482-a8bf-6dc24c1491db"
      unitRef="usd">4880700000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMTgtNy0xLTEtMA_878704ab-0bd4-4dc0-957d-b92050e63d30"
      unitRef="usd">5264900000</us-gaap:OperatingIncomeLoss>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMTktMS0xLTEtMA_9797ad36-a044-4c1a-97da-f19ad648ba5d"
      unitRef="usd">-128600000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMTktMy0xLTEtMA_0be8925c-dba2-459c-b109-b39cec53a3fb"
      unitRef="usd">-27300000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMTktNS0xLTEtMA_7640d544-1ef7-487a-9f46-b5d67dd81728"
      unitRef="usd">-186100000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMTktNy0xLTEtMA_ac50e3ac-4e63-49ed-9c81-925829796b78"
      unitRef="usd">132600000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMjAtMS0xLTEtMA_ae34b876-a566-4ae1-bd8e-47ace9950311"
      unitRef="usd">957800000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMjAtMy0xLTEtMA_3f6061e8-3fb3-4ada-b4f6-ff729de2aade"
      unitRef="usd">1779000000.0</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMjAtNS0xLTEtMA_773941a4-3131-4f52-b94c-c4e90b345578"
      unitRef="usd">4694600000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMjAtNy0xLTEtMA_ed0a8024-d863-464d-af95-85ca196686d0"
      unitRef="usd">5397500000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMjEtMS0xLTEtMA_594853f9-3e82-4b99-9d31-a15e3f5c7fea"
      unitRef="usd">240800000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMjEtMy0xLTEtMA_207d0c7b-2733-4d2c-94f9-41f099278032"
      unitRef="usd">211300000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMjEtNS0xLTEtMA_887cc3f8-e861-402e-96a7-5a466e346944"
      unitRef="usd">979000000.0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMjEtNy0xLTEtMA_ba8e81a5-26d3-4a23-b0e4-932241365e50"
      unitRef="usd">881900000</us-gaap:IncomeTaxExpenseBenefit>
    <biib:IncomeLossFromEquityMethodInvestmentsNetOfTax
      contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMjItMS0xLTEtMA_b4b24255-d6e9-4e88-961f-dc971692aa5d"
      unitRef="usd">-13100000</biib:IncomeLossFromEquityMethodInvestmentsNetOfTax>
    <biib:IncomeLossFromEquityMethodInvestmentsNetOfTax
      contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMjItMy0xLTEtMA_d8064f7d-10cf-4dc0-bee7-71d045b96689"
      unitRef="usd">-21800000</biib:IncomeLossFromEquityMethodInvestmentsNetOfTax>
    <biib:IncomeLossFromEquityMethodInvestmentsNetOfTax
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMjItNS0xLTEtMA_34365eb7-d8ea-4eaa-8322-bf1734d3111d"
      unitRef="usd">-12700000</biib:IncomeLossFromEquityMethodInvestmentsNetOfTax>
    <biib:IncomeLossFromEquityMethodInvestmentsNetOfTax
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMjItNy0xLTEtMA_7650ed9b-4bf3-4cf2-99cd-46ff98ea46ba"
      unitRef="usd">-66800000</biib:IncomeLossFromEquityMethodInvestmentsNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMjMtMS0xLTEtMA_fe1dc6a4-601b-402c-8c8b-9374964f5e65"
      unitRef="usd">703900000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMjMtMy0xLTEtMA_7febf069-8a16-4986-8126-3efe2617ec0f"
      unitRef="usd">1545900000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMjMtNS0xLTEtMA_f8f27ada-4dc3-4eb0-b19a-a8c881272389"
      unitRef="usd">3702900000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMjMtNy0xLTEtMA_4e8739f9-31d9-40e9-ac5f-0fdc7b26eaa1"
      unitRef="usd">4448800000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMjQtMS0xLTEtMA_f2e7d887-9ff9-45f9-825d-b6a69c29609a"
      unitRef="usd">2400000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMjQtMy0xLTEtMA_352d29f9-5af8-4c45-9428-d5b62ecb61c2"
      unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMjQtNS0xLTEtMA_6be69b0e-2074-4c4d-b44c-a937c4e40d11"
      unitRef="usd">60200000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMjQtNy0xLTEtMA_5a8fb04a-b862-4d89-867d-6e941ea91b40"
      unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMjUtMS0xLTEtMA_24ff3b32-0381-4922-9b0e-b3f0e196b243"
      unitRef="usd">701500000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMjUtMy0xLTEtMA_1af0114b-dede-4232-b2c9-bba15c4fa899"
      unitRef="usd">1545900000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMjUtNS0xLTEtMA_a84bb2f6-0a9d-40f2-a47b-601a4d70034e"
      unitRef="usd">3642700000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMjUtNy0xLTEtMA_322e8a0e-3eee-4eb3-93e7-9f2887cb8b31"
      unitRef="usd">4448800000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMjgtMS0xLTEtMA_4f27d0f8-ca89-4aa3-b1a5-c32fd83ff31b"
      unitRef="usdPerShare">4.47</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMjgtMy0xLTEtMA_821866ef-0d97-4abd-8cfc-df54c58f825f"
      unitRef="usdPerShare">8.40</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMjgtNS0xLTEtMA_a8da84c4-f0f6-44aa-8427-c87983ccaba1"
      unitRef="usdPerShare">22.29</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMjgtNy0xLTEtMA_8ad1e440-cf7a-4c67-b0b5-cf1657a37bdf"
      unitRef="usdPerShare">23.38</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMjktMS0xLTEtMA_7d6a7903-be4b-4594-99a0-7fbeb1902aad"
      unitRef="usdPerShare">4.46</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMjktMy0xLTEtMA_2f141d68-28f7-4a52-b52d-517bb422c030"
      unitRef="usdPerShare">8.39</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMjktNS0xLTEtMA_15a3577a-d3bd-4c8c-abb8-65247d34738c"
      unitRef="usdPerShare">22.25</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMjktNy0xLTEtMA_6880f1f2-ad9c-4c8d-894e-e29604d4d14e"
      unitRef="usdPerShare">23.35</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMzItMS0xLTEtMA_49203b04-689d-41f4-bd88-5507e2e315a3"
      unitRef="shares">156900000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMzItMy0xLTEtMA_c5b3d9c6-f2f2-4d2d-96ce-d0581ed875df"
      unitRef="shares">184000000.0</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMzItNS0xLTEtMA_2f38e537-82c7-45aa-9ac5-d14c2615f22e"
      unitRef="shares">163400000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMzItNy0xLTEtMA_73b488a3-eb6a-4552-8630-35bf37aaf6dc"
      unitRef="shares">190300000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMzMtMS0xLTEtMA_0ec47d91-7ec6-46ff-89ec-919d86d483cb"
      unitRef="shares">157200000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMzMtMy0xLTEtMA_5fc7afff-22f0-4421-88eb-75c0644b3e39"
      unitRef="shares">184200000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMzMtNS0xLTEtMA_f2c94287-6cc6-4a92-8804-4c50f78ea647"
      unitRef="shares">163700000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xOS9mcmFnOmI3MzdlZGQ0MDQ5ODQ0MjNiOWI3Mjk5NDVmZTczYTQ2L3RhYmxlOjM1NGRkYTY1ODUzNzQzYWFhZDY2ODFiZjBiNTFlNDIzL3RhYmxlcmFuZ2U6MzU0ZGRhNjU4NTM3NDNhYWFkNjY4MWJmMGI1MWU0MjNfMzMtNy0xLTEtMA_8f256159-13c7-4805-bb31-72a7354348cb"
      unitRef="shares">190500000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yMi9mcmFnOmI2NDA3YWZhODM2ZTQzMDQ5ZWY3MWJiNjljN2I1Y2VmL3RhYmxlOjU0NzUyZDViNDMyZTQ4ODE5MGFjMjc2ZjIzNTYxNzlkL3RhYmxlcmFuZ2U6NTQ3NTJkNWI0MzJlNDg4MTkwYWMyNzZmMjM1NjE3OWRfMi0xLTEtMS0w_1001ec26-c1da-4570-b45e-281dd4345d24"
      unitRef="usd">701500000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yMi9mcmFnOmI2NDA3YWZhODM2ZTQzMDQ5ZWY3MWJiNjljN2I1Y2VmL3RhYmxlOjU0NzUyZDViNDMyZTQ4ODE5MGFjMjc2ZjIzNTYxNzlkL3RhYmxlcmFuZ2U6NTQ3NTJkNWI0MzJlNDg4MTkwYWMyNzZmMjM1NjE3OWRfMi0zLTEtMS0w_57085c41-f71d-4db1-83af-57546b2a6628"
      unitRef="usd">1545900000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yMi9mcmFnOmI2NDA3YWZhODM2ZTQzMDQ5ZWY3MWJiNjljN2I1Y2VmL3RhYmxlOjU0NzUyZDViNDMyZTQ4ODE5MGFjMjc2ZjIzNTYxNzlkL3RhYmxlcmFuZ2U6NTQ3NTJkNWI0MzJlNDg4MTkwYWMyNzZmMjM1NjE3OWRfMi01LTEtMS0w_122130e2-da78-4760-bcc8-289722ee8906"
      unitRef="usd">3642700000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yMi9mcmFnOmI2NDA3YWZhODM2ZTQzMDQ5ZWY3MWJiNjljN2I1Y2VmL3RhYmxlOjU0NzUyZDViNDMyZTQ4ODE5MGFjMjc2ZjIzNTYxNzlkL3RhYmxlcmFuZ2U6NTQ3NTJkNWI0MzJlNDg4MTkwYWMyNzZmMjM1NjE3OWRfMi03LTEtMS0w_2548c79c-d323-4bf5-929c-4e5bd9192547"
      unitRef="usd">4448800000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yMi9mcmFnOmI2NDA3YWZhODM2ZTQzMDQ5ZWY3MWJiNjljN2I1Y2VmL3RhYmxlOjU0NzUyZDViNDMyZTQ4ODE5MGFjMjc2ZjIzNTYxNzlkL3RhYmxlcmFuZ2U6NTQ3NTJkNWI0MzJlNDg4MTkwYWMyNzZmMjM1NjE3OWRfNC0xLTEtMS0w_a0c682dc-eb97-474d-b905-0c5c47bf96ce"
      unitRef="usd">100000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yMi9mcmFnOmI2NDA3YWZhODM2ZTQzMDQ5ZWY3MWJiNjljN2I1Y2VmL3RhYmxlOjU0NzUyZDViNDMyZTQ4ODE5MGFjMjc2ZjIzNTYxNzlkL3RhYmxlcmFuZ2U6NTQ3NTJkNWI0MzJlNDg4MTkwYWMyNzZmMjM1NjE3OWRfNC0zLTEtMS0w_88adaa37-38e6-424a-9a9a-a5b4a70a119f"
      unitRef="usd">100000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yMi9mcmFnOmI2NDA3YWZhODM2ZTQzMDQ5ZWY3MWJiNjljN2I1Y2VmL3RhYmxlOjU0NzUyZDViNDMyZTQ4ODE5MGFjMjc2ZjIzNTYxNzlkL3RhYmxlcmFuZ2U6NTQ3NTJkNWI0MzJlNDg4MTkwYWMyNzZmMjM1NjE3OWRfNC01LTEtMS0w_82f487b9-8172-4c7a-b9b9-ac7c406728a0"
      unitRef="usd">1000000.0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yMi9mcmFnOmI2NDA3YWZhODM2ZTQzMDQ5ZWY3MWJiNjljN2I1Y2VmL3RhYmxlOjU0NzUyZDViNDMyZTQ4ODE5MGFjMjc2ZjIzNTYxNzlkL3RhYmxlcmFuZ2U6NTQ3NTJkNWI0MzJlNDg4MTkwYWMyNzZmMjM1NjE3OWRfNC03LTEtMS0w_9b1f76da-243a-41ed-8a7c-8aca606b5cdf"
      unitRef="usd">10300000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax
      contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yMi9mcmFnOmI2NDA3YWZhODM2ZTQzMDQ5ZWY3MWJiNjljN2I1Y2VmL3RhYmxlOjU0NzUyZDViNDMyZTQ4ODE5MGFjMjc2ZjIzNTYxNzlkL3RhYmxlcmFuZ2U6NTQ3NTJkNWI0MzJlNDg4MTkwYWMyNzZmMjM1NjE3OWRfNS0xLTEtMS0w_1255ec0d-06d6-4aa1-a0a5-58c7679d4e0a"
      unitRef="usd">-83700000</us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax
      contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yMi9mcmFnOmI2NDA3YWZhODM2ZTQzMDQ5ZWY3MWJiNjljN2I1Y2VmL3RhYmxlOjU0NzUyZDViNDMyZTQ4ODE5MGFjMjc2ZjIzNTYxNzlkL3RhYmxlcmFuZ2U6NTQ3NTJkNWI0MzJlNDg4MTkwYWMyNzZmMjM1NjE3OWRfNS0zLTEtMS0w_11e0c973-a700-4f16-b7f9-666c17f04b71"
      unitRef="usd">59100000</us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yMi9mcmFnOmI2NDA3YWZhODM2ZTQzMDQ5ZWY3MWJiNjljN2I1Y2VmL3RhYmxlOjU0NzUyZDViNDMyZTQ4ODE5MGFjMjc2ZjIzNTYxNzlkL3RhYmxlcmFuZ2U6NTQ3NTJkNWI0MzJlNDg4MTkwYWMyNzZmMjM1NjE3OWRfNS01LTEtMS0w_4352b438-66d6-44b9-bddb-847cb9c1e661"
      unitRef="usd">-101100000</us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yMi9mcmFnOmI2NDA3YWZhODM2ZTQzMDQ5ZWY3MWJiNjljN2I1Y2VmL3RhYmxlOjU0NzUyZDViNDMyZTQ4ODE5MGFjMjc2ZjIzNTYxNzlkL3RhYmxlcmFuZ2U6NTQ3NTJkNWI0MzJlNDg4MTkwYWMyNzZmMjM1NjE3OWRfNS03LTEtMS0w_37e4e9b3-44dd-4000-91ed-e2804d5de705"
      unitRef="usd">38100000</us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax>
    <us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease
      contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yMi9mcmFnOmI2NDA3YWZhODM2ZTQzMDQ5ZWY3MWJiNjljN2I1Y2VmL3RhYmxlOjU0NzUyZDViNDMyZTQ4ODE5MGFjMjc2ZjIzNTYxNzlkL3RhYmxlcmFuZ2U6NTQ3NTJkNWI0MzJlNDg4MTkwYWMyNzZmMjM1NjE3OWRfNi0xLTEtMS0w_01400c8a-65ee-40d6-8f0b-e4181795656b"
      unitRef="usd">-11300000</us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease>
    <us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease
      contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yMi9mcmFnOmI2NDA3YWZhODM2ZTQzMDQ5ZWY3MWJiNjljN2I1Y2VmL3RhYmxlOjU0NzUyZDViNDMyZTQ4ODE5MGFjMjc2ZjIzNTYxNzlkL3RhYmxlcmFuZ2U6NTQ3NTJkNWI0MzJlNDg4MTkwYWMyNzZmMjM1NjE3OWRfNi0zLTEtMS0w_6cb85aa5-70d1-46b8-9fdd-4a5a38dc5500"
      unitRef="usd">21200000</us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease>
    <us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yMi9mcmFnOmI2NDA3YWZhODM2ZTQzMDQ5ZWY3MWJiNjljN2I1Y2VmL3RhYmxlOjU0NzUyZDViNDMyZTQ4ODE5MGFjMjc2ZjIzNTYxNzlkL3RhYmxlcmFuZ2U6NTQ3NTJkNWI0MzJlNDg4MTkwYWMyNzZmMjM1NjE3OWRfNi01LTEtMS0w_d1fa179d-289e-4053-bb04-e9b585a23822"
      unitRef="usd">5500000</us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease>
    <us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yMi9mcmFnOmI2NDA3YWZhODM2ZTQzMDQ5ZWY3MWJiNjljN2I1Y2VmL3RhYmxlOjU0NzUyZDViNDMyZTQ4ODE5MGFjMjc2ZjIzNTYxNzlkL3RhYmxlcmFuZ2U6NTQ3NTJkNWI0MzJlNDg4MTkwYWMyNzZmMjM1NjE3OWRfNi03LTEtMS0w_3a28a974-65ec-4380-9b34-a3c8a237ab02"
      unitRef="usd">46900000</us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yMi9mcmFnOmI2NDA3YWZhODM2ZTQzMDQ5ZWY3MWJiNjljN2I1Y2VmL3RhYmxlOjU0NzUyZDViNDMyZTQ4ODE5MGFjMjc2ZjIzNTYxNzlkL3RhYmxlcmFuZ2U6NTQ3NTJkNWI0MzJlNDg4MTkwYWMyNzZmMjM1NjE3OWRfNy0xLTEtMS0w_5fc07b84-200c-4924-9501-201eb848b505"
      unitRef="usd">500000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yMi9mcmFnOmI2NDA3YWZhODM2ZTQzMDQ5ZWY3MWJiNjljN2I1Y2VmL3RhYmxlOjU0NzUyZDViNDMyZTQ4ODE5MGFjMjc2ZjIzNTYxNzlkL3RhYmxlcmFuZ2U6NTQ3NTJkNWI0MzJlNDg4MTkwYWMyNzZmMjM1NjE3OWRfNy0zLTEtMS0w_965b0c69-a218-4596-9015-a3da7a5a6217"
      unitRef="usd">-800000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yMi9mcmFnOmI2NDA3YWZhODM2ZTQzMDQ5ZWY3MWJiNjljN2I1Y2VmL3RhYmxlOjU0NzUyZDViNDMyZTQ4ODE5MGFjMjc2ZjIzNTYxNzlkL3RhYmxlcmFuZ2U6NTQ3NTJkNWI0MzJlNDg4MTkwYWMyNzZmMjM1NjE3OWRfNy01LTEtMS0w_506e03d9-e61f-4d9e-b988-d478a6da980c"
      unitRef="usd">-400000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yMi9mcmFnOmI2NDA3YWZhODM2ZTQzMDQ5ZWY3MWJiNjljN2I1Y2VmL3RhYmxlOjU0NzUyZDViNDMyZTQ4ODE5MGFjMjc2ZjIzNTYxNzlkL3RhYmxlcmFuZ2U6NTQ3NTJkNWI0MzJlNDg4MTkwYWMyNzZmMjM1NjE3OWRfNy03LTEtMS0w_89ce8e40-77d6-458d-86b1-6df80255de8c"
      unitRef="usd">-1500000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yMi9mcmFnOmI2NDA3YWZhODM2ZTQzMDQ5ZWY3MWJiNjljN2I1Y2VmL3RhYmxlOjU0NzUyZDViNDMyZTQ4ODE5MGFjMjc2ZjIzNTYxNzlkL3RhYmxlcmFuZ2U6NTQ3NTJkNWI0MzJlNDg4MTkwYWMyNzZmMjM1NjE3OWRfOC0xLTEtMS0w_44bb9168-0a08-4ce5-90d5-32fa958c3731"
      unitRef="usd">50900000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yMi9mcmFnOmI2NDA3YWZhODM2ZTQzMDQ5ZWY3MWJiNjljN2I1Y2VmL3RhYmxlOjU0NzUyZDViNDMyZTQ4ODE5MGFjMjc2ZjIzNTYxNzlkL3RhYmxlcmFuZ2U6NTQ3NTJkNWI0MzJlNDg4MTkwYWMyNzZmMjM1NjE3OWRfOC0zLTEtMS0w_ea83d609-8106-4c0a-8352-84d119323fcf"
      unitRef="usd">79400000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yMi9mcmFnOmI2NDA3YWZhODM2ZTQzMDQ5ZWY3MWJiNjljN2I1Y2VmL3RhYmxlOjU0NzUyZDViNDMyZTQ4ODE5MGFjMjc2ZjIzNTYxNzlkL3RhYmxlcmFuZ2U6NTQ3NTJkNWI0MzJlNDg4MTkwYWMyNzZmMjM1NjE3OWRfOC01LTEtMS0w_5a7ed7f5-4e28-4342-b4c3-646b76ce9f7f"
      unitRef="usd">3900000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yMi9mcmFnOmI2NDA3YWZhODM2ZTQzMDQ5ZWY3MWJiNjljN2I1Y2VmL3RhYmxlOjU0NzUyZDViNDMyZTQ4ODE5MGFjMjc2ZjIzNTYxNzlkL3RhYmxlcmFuZ2U6NTQ3NTJkNWI0MzJlNDg4MTkwYWMyNzZmMjM1NjE3OWRfOC03LTEtMS0w_b6feafc1-c78d-42d3-999f-634e81f0a297"
      unitRef="usd">51300000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yMi9mcmFnOmI2NDA3YWZhODM2ZTQzMDQ5ZWY3MWJiNjljN2I1Y2VmL3RhYmxlOjU0NzUyZDViNDMyZTQ4ODE5MGFjMjc2ZjIzNTYxNzlkL3RhYmxlcmFuZ2U6NTQ3NTJkNWI0MzJlNDg4MTkwYWMyNzZmMjM1NjE3OWRfOS0xLTEtMS0w_3423f8c0-e9db-4576-b125-9aabbf01f813"
      unitRef="usd">-44500000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yMi9mcmFnOmI2NDA3YWZhODM2ZTQzMDQ5ZWY3MWJiNjljN2I1Y2VmL3RhYmxlOjU0NzUyZDViNDMyZTQ4ODE5MGFjMjc2ZjIzNTYxNzlkL3RhYmxlcmFuZ2U6NTQ3NTJkNWI0MzJlNDg4MTkwYWMyNzZmMjM1NjE3OWRfOS0zLTEtMS0w_bf725250-12f5-4b94-b65d-e557dd79fe12"
      unitRef="usd">160600000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yMi9mcmFnOmI2NDA3YWZhODM2ZTQzMDQ5ZWY3MWJiNjljN2I1Y2VmL3RhYmxlOjU0NzUyZDViNDMyZTQ4ODE5MGFjMjc2ZjIzNTYxNzlkL3RhYmxlcmFuZ2U6NTQ3NTJkNWI0MzJlNDg4MTkwYWMyNzZmMjM1NjE3OWRfOS01LTEtMS0w_85630377-c25e-4921-a2d7-506a8d8b4caa"
      unitRef="usd">-90300000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yMi9mcmFnOmI2NDA3YWZhODM2ZTQzMDQ5ZWY3MWJiNjljN2I1Y2VmL3RhYmxlOjU0NzUyZDViNDMyZTQ4ODE5MGFjMjc2ZjIzNTYxNzlkL3RhYmxlcmFuZ2U6NTQ3NTJkNWI0MzJlNDg4MTkwYWMyNzZmMjM1NjE3OWRfOS03LTEtMS0w_8bee9f0b-34b4-4629-a320-e7feaec625d2"
      unitRef="usd">148100000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yMi9mcmFnOmI2NDA3YWZhODM2ZTQzMDQ5ZWY3MWJiNjljN2I1Y2VmL3RhYmxlOjU0NzUyZDViNDMyZTQ4ODE5MGFjMjc2ZjIzNTYxNzlkL3RhYmxlcmFuZ2U6NTQ3NTJkNWI0MzJlNDg4MTkwYWMyNzZmMjM1NjE3OWRfMTAtMS0xLTEtMA_313ef1f7-73de-4bd1-911a-e4e659eb2dcb"
      unitRef="usd">657000000.0</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yMi9mcmFnOmI2NDA3YWZhODM2ZTQzMDQ5ZWY3MWJiNjljN2I1Y2VmL3RhYmxlOjU0NzUyZDViNDMyZTQ4ODE5MGFjMjc2ZjIzNTYxNzlkL3RhYmxlcmFuZ2U6NTQ3NTJkNWI0MzJlNDg4MTkwYWMyNzZmMjM1NjE3OWRfMTAtMy0xLTEtMA_0cd010d6-2c89-4377-9494-7d2b3aac5de0"
      unitRef="usd">1706500000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yMi9mcmFnOmI2NDA3YWZhODM2ZTQzMDQ5ZWY3MWJiNjljN2I1Y2VmL3RhYmxlOjU0NzUyZDViNDMyZTQ4ODE5MGFjMjc2ZjIzNTYxNzlkL3RhYmxlcmFuZ2U6NTQ3NTJkNWI0MzJlNDg4MTkwYWMyNzZmMjM1NjE3OWRfMTAtNS0xLTEtMA_29e7e8bd-5b44-4c73-bc7f-bfe7b849c7a3"
      unitRef="usd">3552400000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yMi9mcmFnOmI2NDA3YWZhODM2ZTQzMDQ5ZWY3MWJiNjljN2I1Y2VmL3RhYmxlOjU0NzUyZDViNDMyZTQ4ODE5MGFjMjc2ZjIzNTYxNzlkL3RhYmxlcmFuZ2U6NTQ3NTJkNWI0MzJlNDg4MTkwYWMyNzZmMjM1NjE3OWRfMTAtNy0xLTEtMA_113b5877-4c1e-49d3-8f9e-da4145eb3a79"
      unitRef="usd">4596900000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yMi9mcmFnOmI2NDA3YWZhODM2ZTQzMDQ5ZWY3MWJiNjljN2I1Y2VmL3RhYmxlOjU0NzUyZDViNDMyZTQ4ODE5MGFjMjc2ZjIzNTYxNzlkL3RhYmxlcmFuZ2U6NTQ3NTJkNWI0MzJlNDg4MTkwYWMyNzZmMjM1NjE3OWRfMTEtMS0xLTEtMA_2023f476-8bc8-4e99-bbc2-31675d1eae31"
      unitRef="usd">1500000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yMi9mcmFnOmI2NDA3YWZhODM2ZTQzMDQ5ZWY3MWJiNjljN2I1Y2VmL3RhYmxlOjU0NzUyZDViNDMyZTQ4ODE5MGFjMjc2ZjIzNTYxNzlkL3RhYmxlcmFuZ2U6NTQ3NTJkNWI0MzJlNDg4MTkwYWMyNzZmMjM1NjE3OWRfMTEtMy0xLTEtMA_e378ebd7-63a4-4ac7-ad0d-9f2b04e3494c"
      unitRef="usd">0</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yMi9mcmFnOmI2NDA3YWZhODM2ZTQzMDQ5ZWY3MWJiNjljN2I1Y2VmL3RhYmxlOjU0NzUyZDViNDMyZTQ4ODE5MGFjMjc2ZjIzNTYxNzlkL3RhYmxlcmFuZ2U6NTQ3NTJkNWI0MzJlNDg4MTkwYWMyNzZmMjM1NjE3OWRfMTEtNS0xLTEtMA_2a17180d-6b8a-435f-91cd-53c8486cd56c"
      unitRef="usd">61100000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yMi9mcmFnOmI2NDA3YWZhODM2ZTQzMDQ5ZWY3MWJiNjljN2I1Y2VmL3RhYmxlOjU0NzUyZDViNDMyZTQ4ODE5MGFjMjc2ZjIzNTYxNzlkL3RhYmxlcmFuZ2U6NTQ3NTJkNWI0MzJlNDg4MTkwYWMyNzZmMjM1NjE3OWRfMTEtNy0xLTEtMA_af9086a4-5315-4b38-be03-ce98634487a3"
      unitRef="usd">-400000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yMi9mcmFnOmI2NDA3YWZhODM2ZTQzMDQ5ZWY3MWJiNjljN2I1Y2VmL3RhYmxlOjU0NzUyZDViNDMyZTQ4ODE5MGFjMjc2ZjIzNTYxNzlkL3RhYmxlcmFuZ2U6NTQ3NTJkNWI0MzJlNDg4MTkwYWMyNzZmMjM1NjE3OWRfMTItMS0xLTEtMA_1234aceb-20e1-4bfe-af90-7bc2650b99ce"
      unitRef="usd">658500000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yMi9mcmFnOmI2NDA3YWZhODM2ZTQzMDQ5ZWY3MWJiNjljN2I1Y2VmL3RhYmxlOjU0NzUyZDViNDMyZTQ4ODE5MGFjMjc2ZjIzNTYxNzlkL3RhYmxlcmFuZ2U6NTQ3NTJkNWI0MzJlNDg4MTkwYWMyNzZmMjM1NjE3OWRfMTItMy0xLTEtMA_0e9ae354-00e5-452d-9fc5-6f09ac879bcf"
      unitRef="usd">1706500000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yMi9mcmFnOmI2NDA3YWZhODM2ZTQzMDQ5ZWY3MWJiNjljN2I1Y2VmL3RhYmxlOjU0NzUyZDViNDMyZTQ4ODE5MGFjMjc2ZjIzNTYxNzlkL3RhYmxlcmFuZ2U6NTQ3NTJkNWI0MzJlNDg4MTkwYWMyNzZmMjM1NjE3OWRfMTItNS0xLTEtMA_7efa5beb-d271-4a6b-aa1a-a35224240bb0"
      unitRef="usd">3613500000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yMi9mcmFnOmI2NDA3YWZhODM2ZTQzMDQ5ZWY3MWJiNjljN2I1Y2VmL3RhYmxlOjU0NzUyZDViNDMyZTQ4ODE5MGFjMjc2ZjIzNTYxNzlkL3RhYmxlcmFuZ2U6NTQ3NTJkNWI0MzJlNDg4MTkwYWMyNzZmMjM1NjE3OWRfMTItNy0xLTEtMA_f3001caa-5bb5-4a19-a668-e1cb58ce6de9"
      unitRef="usd">4596500000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfMy0xLTEtMS0w_0aebcca6-af71-47b3-aaee-a776edca7253"
      unitRef="usd">2224800000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i626282e786b7454d83b617e9e83963e6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfMy0zLTEtMS0w_73e542d8-e283-4add-86fe-b969b3cec744"
      unitRef="usd">2913700000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfNC0xLTEtMS0w_1eb209b9-2733-4048-82eb-f0b8112f778d"
      unitRef="usd">1355000000.0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i626282e786b7454d83b617e9e83963e6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfNC0zLTEtMS0w_c0f619aa-4823-40a1-bc83-a4aee00a8404"
      unitRef="usd">1562200000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfNS0xLTEtMS0w_c55bc52f-2287-49d4-9221-6a703b478f8d"
      unitRef="usd">2024900000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i626282e786b7454d83b617e9e83963e6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfNS0zLTEtMS0w_d948dd7a-c7b0-4475-a393-88be4a645f2b"
      unitRef="usd">1880500000</us-gaap:AccountsReceivableNetCurrent>
    <biib:DuefromantiCD20therapeuticprograms
      contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfNi0xLTEtMS0w_c87159c3-d6a2-41cf-b177-391321be760e"
      unitRef="usd">527200000</biib:DuefromantiCD20therapeuticprograms>
    <biib:DuefromantiCD20therapeuticprograms
      contextRef="i626282e786b7454d83b617e9e83963e6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfNi0zLTEtMS0w_be8fe10a-d8ea-45ef-93f9-c061bceca745"
      unitRef="usd">590200000</biib:DuefromantiCD20therapeuticprograms>
    <us-gaap:InventoryNet
      contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfNy0xLTEtMS0w_87c4262e-2cf4-4293-ad8b-f8403271196d"
      unitRef="usd">1027700000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i626282e786b7454d83b617e9e83963e6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfNy0zLTEtMS0w_a03ec7ad-1fde-403b-b55f-c30ca5c76f55"
      unitRef="usd">804200000</us-gaap:InventoryNet>
    <us-gaap:OtherAssetsCurrent
      contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfOC0xLTEtMS0w_5abb3f36-de11-432d-9bd9-4f77e6c9c5e1"
      unitRef="usd">683500000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i626282e786b7454d83b617e9e83963e6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfOC0zLTEtMS0w_c5b40267-abb3-4fcd-a8b5-5d0db7372c93"
      unitRef="usd">631000000.0</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfOS0xLTEtMS0w_a00c0544-fdc3-49e9-8b32-f857dca452b0"
      unitRef="usd">7843100000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i626282e786b7454d83b617e9e83963e6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfOS0zLTEtMS0w_e725a8fd-75c7-4881-9da0-0128addf3553"
      unitRef="usd">8381800000</us-gaap:AssetsCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfMTAtMS0xLTEtMA_8443cbc7-bb41-4663-8132-5d65b1696565"
      unitRef="usd">1009800000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i626282e786b7454d83b617e9e83963e6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfMTAtMy0xLTEtMA_c97fe349-9a7c-47fb-95c1-59c96e3970fc"
      unitRef="usd">1408100000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfMTEtMS0xLTEtMA_072c7b89-ab0c-41e5-9791-bd0b02faab0b"
      unitRef="usd">3359900000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i626282e786b7454d83b617e9e83963e6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfMTEtMy0xLTEtMA_fa504b08-2444-4cb9-b987-3859efd1bc83"
      unitRef="usd">3247300000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfMTItMS0xLTEtMA_d1cca2fd-37ef-4b02-8f14-a2d7072fc267"
      unitRef="usd">434200000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i626282e786b7454d83b617e9e83963e6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfMTItMy0xLTEtMA_9ecacc0f-a489-4ebb-9878-383bacd87523"
      unitRef="usd">427000000.0</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfMTMtMS0xLTEtMA_8d28025b-a8f8-4ebf-bbd9-7e8b1d7b345d"
      unitRef="usd">3323600000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i626282e786b7454d83b617e9e83963e6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfMTMtMy0xLTEtMA_0c9ac385-b595-4a66-931a-40c178977886"
      unitRef="usd">3527400000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfMTQtMS0xLTEtMA_a4d66e80-d728-4845-9033-703dfacc0f78"
      unitRef="usd">5755700000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i626282e786b7454d83b617e9e83963e6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfMTQtMy0xLTEtMA_b1071b58-4813-44ad-9a61-198a2e9ce0fa"
      unitRef="usd">5757800000</us-gaap:Goodwill>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfMTUtMS0xLTEtMA_78385776-6135-44bd-bde3-31e09a27373f"
      unitRef="usd">1372900000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i626282e786b7454d83b617e9e83963e6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfMTUtMy0xLTEtMA_690fc1fa-4ced-4afa-951f-a133259e8558"
      unitRef="usd">3232100000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfMTYtMS0xLTEtMA_62c72308-839e-4a76-959d-0418093c4b49"
      unitRef="usd">1834900000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i626282e786b7454d83b617e9e83963e6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfMTYtMy0xLTEtMA_a0a6372f-82f3-4874-82a6-76cd56f05cca"
      unitRef="usd">1252800000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfMTctMS0xLTEtMA_ef2f40eb-ae9a-4159-bd42-b4c2a0b876a4"
      unitRef="usd">24934100000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i626282e786b7454d83b617e9e83963e6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfMTctMy0xLTEtMA_61cbea72-2673-41c5-9bb1-bf07d8479068"
      unitRef="usd">27234300000</us-gaap:Assets>
    <us-gaap:NotesPayableCurrent
      contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfMjAtMS0xLTEtMA_2c9b786d-22ce-4376-babf-a003bc5ec21a"
      unitRef="usd">0</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="i626282e786b7454d83b617e9e83963e6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfMjAtMy0xLTEtMA_77e501fa-cf15-46f8-a8be-822e9bae12ec"
      unitRef="usd">1495800000</us-gaap:NotesPayableCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfMjEtMS0xLTEtMA_42ac141f-5b5c-4120-9244-6aec55bad717"
      unitRef="usd">119400000</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="i626282e786b7454d83b617e9e83963e6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfMjEtMy0xLTEtMA_336662a0-6ec5-43b6-94c0-b70c78abfa51"
      unitRef="usd">71400000</us-gaap:TaxesPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfMjItMS0xLTEtMA_e4d6e130-a582-4061-a691-3a99ab128dec"
      unitRef="usd">398400000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i626282e786b7454d83b617e9e83963e6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfMjItMy0xLTEtMA_499bf52d-77a1-4454-bdee-8b783acf93cf"
      unitRef="usd">530800000</us-gaap:AccountsPayableCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfMjMtMS0xLTEtMA_488c8d0e-af49-40c7-8f24-d64e0b22b8be"
      unitRef="usd">3286200000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i626282e786b7454d83b617e9e83963e6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfMjMtMy0xLTEtMA_d9821704-168f-4ee7-a542-d40cf4d60e99"
      unitRef="usd">2765800000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfMjQtMS0xLTEtMA_a1d25947-47df-412b-a4d5-ebcb95dd5f7e"
      unitRef="usd">3804000000.0</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i626282e786b7454d83b617e9e83963e6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfMjQtMy0xLTEtMA_6da1d3e9-fed9-4bff-bcdd-6290113d1d50"
      unitRef="usd">4863800000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebt
      contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfMjUtMS0xLTEtMA_aca80964-6e3f-4dc4-896a-ab4523b98ce0"
      unitRef="usd">7425000000.0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i626282e786b7454d83b617e9e83963e6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfMjUtMy0xLTEtMA_2dcc90bf-e1a4-42f8-8a94-23ab17fa32be"
      unitRef="usd">4459000000.0</us-gaap:LongTermDebt>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfMjYtMS0xLTEtMA_0cf1568d-c4b9-493e-8106-7cdef2af90eb"
      unitRef="usd">1123400000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i626282e786b7454d83b617e9e83963e6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfMjYtMy0xLTEtMA_e179a697-70d7-45bb-af0a-b6f69c759f4c"
      unitRef="usd">2810800000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfMjctMS0xLTEtMA_a869c30a-fd4c-4a6e-8cc8-4ec1884745e6"
      unitRef="usd">409100000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i626282e786b7454d83b617e9e83963e6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfMjctMy0xLTEtMA_1af625de-fa59-4b0c-95dd-74f3e41eb4f1"
      unitRef="usd">412700000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfMjgtMS0xLTEtMA_2b16eb7c-f1c1-4ee4-bde9-782920115bc1"
      unitRef="usd">1428100000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i626282e786b7454d83b617e9e83963e6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfMjgtMy0xLTEtMA_5e05d579-c2a2-4155-8371-6d29e0543b20"
      unitRef="usd">1348900000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfMjktMS0xLTEtMA_9464a4da-6578-4b0c-8a55-5941c9a898f2"
      unitRef="usd">14189600000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i626282e786b7454d83b617e9e83963e6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfMjktMy0xLTEtMA_47cf3387-acb6-42cf-a54c-882eca22727b"
      unitRef="usd">13895200000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfMzAtMS0xLTEtMA_924cc98d-b548-4918-97db-3767207f5fec"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i626282e786b7454d83b617e9e83963e6_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfMzAtMy0xLTEtMA_cf7ffd0f-81f2-4613-9641-f2347c12b7a6"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfMzMtMS0xLTEtMA_18b31f1a-5fd1-4c90-a52f-9dc6ca847ffb"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i626282e786b7454d83b617e9e83963e6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfMzMtMy0xLTEtMA_28d5e4c5-ce7c-44d8-becb-cbd90aab1a62"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockValue
      contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfMzQtMS0xLTEtMA_d72b1f50-2247-45c0-ae1e-b91fd8598f81"
      unitRef="usd">100000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i626282e786b7454d83b617e9e83963e6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfMzQtMy0xLTEtMA_83a5c8fc-4c35-4126-938d-dc68412e3182"
      unitRef="usd">100000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfMzUtMS0xLTEtMA_bcebdd5a-c58e-4828-8b2f-7fe98d5b2166"
      unitRef="usd">0</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i626282e786b7454d83b617e9e83963e6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfMzUtMy0xLTEtMA_b36a7235-b792-4ae9-b76f-1f66420e6878"
      unitRef="usd">0</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfMzYtMS0xLTEtMA_e2adcf9c-ce4f-4bcd-b7ee-1e3cc2cc3e2b"
      unitRef="usd">-225500000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i626282e786b7454d83b617e9e83963e6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfMzYtMy0xLTEtMA_c9797929-50e6-4e4a-b2b2-69220615465c"
      unitRef="usd">-135200000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfMzctMS0xLTEtMA_a2254215-a1b5-447c-9c02-23eee9482e7c"
      unitRef="usd">13961000000.0</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i626282e786b7454d83b617e9e83963e6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfMzctMy0xLTEtMA_df3051ad-bb74-4fcb-88a5-1bc1e182c5c3"
      unitRef="usd">16455400000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:TreasuryStockValue
      contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfMzgtMS0xLTEtMA_403054ca-5283-49e5-9f63-821d1433f327"
      unitRef="usd">2977100000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="i626282e786b7454d83b617e9e83963e6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfMzgtMy0xLTEtMA_32817e8d-55f6-4a04-bd08-8d67c8eaf2a0"
      unitRef="usd">2977100000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquity
      contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfMzktMS0xLTEtMA_dd685e25-782e-4d52-9bec-6b77a6426902"
      unitRef="usd">10758500000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i626282e786b7454d83b617e9e83963e6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfMzktMy0xLTEtMA_ffb1b782-db37-4246-b348-bf803908585a"
      unitRef="usd">13343200000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfNDAtMS0xLTEtMA_52891b0d-5908-44c0-bda4-f9e6fa80fd73"
      unitRef="usd">-14000000.0</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="i626282e786b7454d83b617e9e83963e6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfNDAtMy0xLTEtMA_3f7fffce-e69b-4c34-b089-bd3c179c7de7"
      unitRef="usd">-4100000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfNDEtMS0xLTEtMA_97976a65-aab3-4165-b55d-1760dc98a058"
      unitRef="usd">10744500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i626282e786b7454d83b617e9e83963e6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfNDEtMy0xLTEtMA_717fe15a-32ec-4bdb-ac77-94708ac19868"
      unitRef="usd">13339100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfNDItMS0xLTEtMA_6dd68539-65f1-4e7e-83b0-3d53332128b5"
      unitRef="usd">24934100000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i626282e786b7454d83b617e9e83963e6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18yNS9mcmFnOmQ5NmNhZmM1ZmM4ODRjN2Y5NmZhOWU5MzIxNDc3YjU1L3RhYmxlOjg2NzE0MGZlMjMxYjQ0ZDk4ZDM5ODU5YzQ4M2Q0Zjk2L3RhYmxlcmFuZ2U6ODY3MTQwZmUyMzFiNDRkOThkMzk4NTljNDgzZDRmOTZfNDItMy0xLTEtMA_0ca6b39b-eeb5-4c4a-9c47-feafe5b9e831"
      unitRef="usd">27234300000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfMy0xLTEtMS0w_9ddb2f0f-2521-4146-a392-f4dfe42d1afd"
      unitRef="usd">3702900000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfMy0zLTEtMS0w_12a8f70a-fcf0-4159-a794-b519b7795156"
      unitRef="usd">4448800000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfNS0xLTEtMS0w_6defb791-e1e3-47c0-ab25-65c494fcc980"
      unitRef="usd">366800000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfNS0zLTEtMS0w_f8c0cfd3-35cc-4870-9791-30f664c6e483"
      unitRef="usd">567600000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfNi0xLTEtMS0w_0de193e5-ebf4-49d8-bf87-6a7b38bf17b7"
      unitRef="usd">75000000.0</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfNi0zLTEtMS0w_f2ef6769-357d-4295-98c2-05d50b7a0792"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ShareBasedCompensation
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfNy0xLTEtMS0w_b36049dc-c0df-4c3c-ac35-42c93ad898fa"
      unitRef="usd">149300000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfNy0zLTEtMS0w_c4197393-c1da-4518-add3-12ff9cf82266"
      unitRef="usd">143900000</us-gaap:ShareBasedCompensation>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfOS0xLTEtMS0w_62ea0500-e815-4e59-8bbf-107ab79dadfd"
      unitRef="usd">23500000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfOS0zLTEtMS0w_50ee2c99-e1e6-410c-952f-634c0f470ac0"
      unitRef="usd">66300000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfMTAtMS0xLTEtMA_2d0bdee4-1211-411e-a1bd-413b98d947e8"
      unitRef="usd">0</us-gaap:IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax>
    <us-gaap:IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfMTAtMy0xLTEtMA_eccc3d1f-73f8-4645-a959-be91b403340a"
      unitRef="usd">-95500000</us-gaap:IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfMTEtMS0xLTEtMA_32f96d7e-1846-4832-aee3-0619b55581e1"
      unitRef="usd">211900000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfMTEtMy0xLTEtMA_9f9d8d76-e5eb-4408-94a1-5e30d91bb38b"
      unitRef="usd">28400000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfMTItMS0xLTEtMA_1e38fba7-a283-4484-8601-7c1efa29972b"
      unitRef="usd">-41800000</us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi>
    <us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfMTItMy0xLTEtMA_29f0b60f-6b37-463c-81b0-c73052be50f3"
      unitRef="usd">189800000</us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfMTMtMS0xLTEtMA_6839be61-5d0b-4d01-894d-a388df7ba5ce"
      unitRef="usd">14700000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfMTMtMy0xLTEtMA_0f3a1ffe-f6ac-41a9-a876-40f099b02883"
      unitRef="usd">63500000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfMTQtMS0xLTEtMA_07075a7d-f0d0-4314-8a67-51dee8196036"
      unitRef="usd">-110100000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfMTQtMy0xLTEtMA_21c9159e-ddd3-4ef7-9329-1cbaa6ff1f1b"
      unitRef="usd">-87400000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfMTYtMS0xLTEtMA_f825c5de-0c17-4a58-af39-91d9fbe1ba24"
      unitRef="usd">135700000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfMTYtMy0xLTEtMA_b21a669a-87e1-4033-995e-1969f7a30483"
      unitRef="usd">2400000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInDueFromRelatedParties
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfMTctMS0xLTEtMA_d3a84407-6811-4f39-b5d3-0b7f1eb8c9c9"
      unitRef="usd">-63000000.0</us-gaap:IncreaseDecreaseInDueFromRelatedParties>
    <us-gaap:IncreaseDecreaseInDueFromRelatedParties
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfMTctMy0xLTEtMA_51f786ea-ba68-47d1-bc76-db5637b60d8d"
      unitRef="usd">55400000</us-gaap:IncreaseDecreaseInDueFromRelatedParties>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfMTgtMS0xLTEtMA_f04e712d-8d87-4c14-8b32-562678ec1cd5"
      unitRef="usd">270600000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfMTgtMy0xLTEtMA_9101321c-300e-4430-bc85-296bef130498"
      unitRef="usd">-47300000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfMTktMS0xLTEtMA_f6927e15-18ee-4a7e-b789-3b266447bf47"
      unitRef="usd">372900000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfMTktMy0xLTEtMA_d4382a8d-7f56-4184-8923-073d418dc124"
      unitRef="usd">-109100000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfMjAtMS0xLTEtMA_a4ded7a3-1f2e-4b3b-89b0-0715fb9d58aa"
      unitRef="usd">15300000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfMjAtMy0xLTEtMA_0871d547-48db-4af1-932b-a18ef279bcbd"
      unitRef="usd">64600000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfMjEtMS0xLTEtMA_c653aea4-8dea-46e2-a25f-59da9ae7e77a"
      unitRef="usd">97000000.0</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfMjEtMy0xLTEtMA_83982b80-7ab4-4777-881c-8c839890259d"
      unitRef="usd">5600000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfMjItMS0xLTEtMA_edfb06ec-c46e-4c2b-a35c-60a0bfc966cc"
      unitRef="usd">4596900000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfMjItMy0xLTEtMA_f24f802a-64cd-499f-af4b-8953dca82b1a"
      unitRef="usd">5118400000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfMjQtMS0xLTEtMA_becceaf0-0416-4757-ac3f-4581d08a689a"
      unitRef="usd">5240700000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfMjQtMy0xLTEtMA_1a91ca93-8deb-45a1-8f9f-1fec878cb239"
      unitRef="usd">3867600000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfMjUtMS0xLTEtMA_ec642556-840f-4fe6-acc1-48d56046ddab"
      unitRef="usd">4649100000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfMjUtMy0xLTEtMA_b882c919-fda2-49e7-a2b3-0d8826dfe81b"
      unitRef="usd">4052100000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireOtherProductiveAssets
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfMjYtMS0xLTEtMA_08e4a19e-03ec-41e2-b4c3-a07ce94dbf57"
      unitRef="usd">0</us-gaap:PaymentsToAcquireOtherProductiveAssets>
    <us-gaap:PaymentsToAcquireOtherProductiveAssets
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfMjYtMy0xLTEtMA_3819cdc9-02f3-49c7-a849-5bd025495d86"
      unitRef="usd">300000000.0</us-gaap:PaymentsToAcquireOtherProductiveAssets>
    <us-gaap:PaymentsToAcquireBusinessTwoNetOfCashAcquired
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfMjctMS0xLTEtMA_50963e5b-587e-4ec1-8965-5f6db8a19468"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessTwoNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessTwoNetOfCashAcquired
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfMjctMy0xLTEtMA_d4214705-6aa3-4f67-b861-daf7d6ed2193"
      unitRef="usd">744400000</us-gaap:PaymentsToAcquireBusinessTwoNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates
      contextRef="iec2bbdde63854682b605414cc72c3ab7_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfMjgtMS0xLTEtMA_108068c9-a639-4544-880d-ee5415e175c5"
      unitRef="usd">141800000</us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates>
    <us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates
      contextRef="i97a0bebcc8cf4432b262746010427fa4_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfMjgtMy0xLTEtMA_f7b52422-e3cd-4993-b8b0-965ed03c4042"
      unitRef="usd">0</us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates>
    <us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates
      contextRef="i79e678cecceb4e00b17b8c2023042ca8_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfMjktMS0xLTEtNDc2Mg_457f32f2-47b2-44af-b9aa-eaa2928acaba"
      unitRef="usd">423700000</us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates>
    <us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates
      contextRef="ifd729f26efae42a995f0066eb5f4a0ce_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfMjktMy0xLTEtNDc2Mg_a2aab3df-f732-4844-bf79-6c6a5b7f7f79"
      unitRef="usd">0</us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfMjktMS0xLTEtMA_1b5f2c2d-72a7-4eff-9680-c26b11ce4ff2"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfMjktMy0xLTEtMA_4b4cb5f1-831b-4217-8b5b-c93ad913410c"
      unitRef="usd">923700000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfMzAtMS0xLTEtMA_d4931b98-0aa6-4004-ad6a-af1a1777e093"
      unitRef="usd">338800000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfMzAtMy0xLTEtMA_19afbb14-5312-4b2d-b5d1-43222fee712c"
      unitRef="usd">404100000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfMzEtMS0xLTEtMA_ab64936a-3e4b-4c2d-a94a-0b5c66f9f7d2"
      unitRef="usd">75000000.0</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfMzEtMy0xLTEtMA_c107cb17-ecd7-4f60-bb0e-ef916834104c"
      unitRef="usd">0</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfMzItMS0xLTEtMA_4644a345-971b-4d39-ba92-66fdb8bcfcb5"
      unitRef="usd">37000000.0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfMzItMy0xLTEtMA_f7e70d93-2dc6-4c5b-aaa0-a45be1945747"
      unitRef="usd">0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesEquity
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfMzUtMS0xLTEtMA_96e9620f-5f4d-4a6e-a81c-06749dbc4076"
      unitRef="usd">500000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesEquity>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesEquity
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfMzUtMy0xLTEtMA_26bfffa1-c1c2-420b-ab10-e91de888d1da"
      unitRef="usd">476000000.0</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesEquity>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfMzYtMS0xLTEtMA_7974cee4-5ed1-405b-9ccb-b2cc05af73ba"
      unitRef="usd">18000000.0</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfMzYtMy0xLTEtMA_dfcf654f-f11c-4b75-b0a6-e92df58247ff"
      unitRef="usd">4600000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfMzctMS0xLTEtMA_10bf80e1-4448-48a4-b91d-522e454f0e22"
      unitRef="usd">-442200000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfMzctMy0xLTEtMA_b06ea42e-665d-4abd-94c6-c7f641bd9b0d"
      unitRef="usd">-237900000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfMzktMS0xLTEtMA_bf6d07e1-5664-44ad-8faa-a8d2a805e1ca"
      unitRef="usd">6279100000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfMzktMy0xLTEtMA_7b918d85-abd0-456c-842b-1c35451e2fb4"
      unitRef="usd">3775200000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfNDAtMS0xLTEtMA_b5646ccb-e5ff-46b4-acbe-aebd2ca6a40c"
      unitRef="usd">11800000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfNDAtMy0xLTEtMA_ee556e5d-6cf9-44c2-9f80-115b54fee010"
      unitRef="usd">16900000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfNDEtMS0xLTEtMA_b1d8d124-cbf7-4acf-86d8-8b2dbb48e6aa"
      unitRef="usd">2967300000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfNDEtMy0xLTEtMA_6379f159-f629-4a6a-b768-ca413e8a0010"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfNDItMS0xLTEtMA_b53d54ed-cde4-4849-98d0-8742c766cea4"
      unitRef="usd">1500000000.0</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfNDItMy0xLTEtMA_b7a79720-696a-49c2-bdf1-629b1d93bc92"
      unitRef="usd">0</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:PaymentsToMinorityShareholders
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfNDQtMS0xLTEtMA_4b4bec60-62ce-487c-b871-581fdacf21b2"
      unitRef="usd">70900000</us-gaap:PaymentsToMinorityShareholders>
    <us-gaap:PaymentsToMinorityShareholders
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfNDQtMy0xLTEtMA_d35fec92-28c7-4f5e-8dd6-1ebd74b3e054"
      unitRef="usd">-4300000</us-gaap:PaymentsToMinorityShareholders>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfNDUtMS0xLTEtMA_5c177795-3c0e-4916-bda4-d6c31c76f7d2"
      unitRef="usd">22900000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfNDUtMy0xLTEtMA_0f380800-0cad-4f51-bb8c-a803ec34ca9f"
      unitRef="usd">43800000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfNDYtMS0xLTEtMA_81080bf6-0426-41c3-a396-47263eb196ff"
      unitRef="usd">-4871600000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfNDYtMy0xLTEtMA_b1b956bc-f16e-45cc-94fb-a35b90e5fee9"
      unitRef="usd">-3744000000.0</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfNDctMS0xLTEtMA_5c59d231-3400-42eb-b024-8bf21727821b"
      unitRef="usd">-716900000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfNDctMy0xLTEtMA_e7d04817-cb91-45bd-818b-428f8d3297f1"
      unitRef="usd">1136500000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfNDgtMS0xLTEtMA_5e09ca54-b3a1-4ae3-a99b-4acd7362da82"
      unitRef="usd">28000000.0</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfNDgtMy0xLTEtMA_4b8af8ba-f523-4ca7-8475-2fc09b758ec3"
      unitRef="usd">-17200000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i626282e786b7454d83b617e9e83963e6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfNDktMS0xLTEtMA_e1e0aa34-093a-4f92-a56f-34eaf161ed3c"
      unitRef="usd">2913700000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ib98dd789f3514452acc95f9b041d2a7e_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfNDktMy0xLTEtMA_50c89bb6-b266-4a80-aa6d-21f7857d38eb"
      unitRef="usd">1224600000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfNTAtMS0xLTEtMA_67143804-b2f4-4892-8da8-17a5943c0be8"
      unitRef="usd">2224800000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ied38b94db9a74750b51c6e8392d4c5bf_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zMS9mcmFnOmVjNDE1ZmY1ZDkyZjRhZThhOGVlZGI4ZDJhN2E4ZWY1L3RhYmxlOjc0NGQwNTM2OTkwODQ4ZTdiOGMzODhhMDRkYjBkYzY5L3RhYmxlcmFuZ2U6NzQ0ZDA1MzY5OTA4NDhlN2I4YzM4OGEwNGRiMGRjNjlfNTAtMy0xLTEtMA_b84eb52d-9dc9-4ff8-879c-942070475b1e"
      unitRef="usd">2343900000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ic9b1433e63154dc793bb3be211f95c71_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfMi0xLTEtMS0w_854dd0ab-541a-4b33-b8b6-e878a1c89f4f"
      unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic9b1433e63154dc793bb3be211f95c71_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfMi0zLTEtMS0w_7892ffcc-e37f-4b78-9654-1e67ce9d5c15"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i1dd367dec9d1416ead31ac17037d6347_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfMi01LTEtMS0w_581f89e1-1adb-4ff7-8b50-28ce8d7a0e43"
      unitRef="shares">182100000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1dd367dec9d1416ead31ac17037d6347_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfMi03LTEtMS0w_83d554db-7b3f-4611-970e-7d5d1740a6d8"
      unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i58e4de16550642ffb8fa1ec5287f1bac_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfMi05LTEtMS0w_16ad1f1f-0b0e-4b4e-87b6-596a0513c339"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1f5ebc014a364cce887ab9d7243516cc_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfMi0xMS0xLTEtMA_77b8256c-eb74-4ac4-9fca-ef14be8d650d"
      unitRef="usd">-181000000.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icfc9a329a8dd439cb140f840522afc1d_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfMi0xMy0xLTEtMA_288ca413-a465-4a00-b7f1-3b15cf199fec"
      unitRef="usd">14466700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i4bb77bd7d2ce46e59ff6fbd5cb940d75_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfMi0xNS0xLTEtMA_0d55d91c-75d1-4ca6-a976-1cdbbf30c387"
      unitRef="shares">23800000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4bb77bd7d2ce46e59ff6fbd5cb940d75_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfMi0xNy0xLTEtMA_77877115-0e3d-4a3a-b6dd-f09b6f3735a4"
      unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibb3e0c3b7ac94f2183a66e90c088be58_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfMi0xOS0xLTEtMA_cc2ded3b-fc5b-45a0-932e-5e54b0e1418a"
      unitRef="usd">11308700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i27fd7cabf5714753a2a142cffcd63932_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfMi0yMS0xLTEtMA_8157682d-b54c-49bd-864a-7d242463d42b"
      unitRef="usd">-19500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2d122436a2064a36b4342d6417ac828f_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfMi0yMy0xLTEtMA_65e779d4-d2c4-4c4c-b4fd-2e29240b232d"
      unitRef="usd">11289200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i1499259d90804413b1e193e034d9561d_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfMy0xMy0xLTEtMA_7ffe40d9-dc9a-467d-8455-4b90591fe228"
      unitRef="usd">701500000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="if01d2b8c98a04ef2a7d2d2754bdfa47f_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfMy0xOS0xLTEtMA_bb8acec1-b48d-4f87-9f29-14f5f87056cb"
      unitRef="usd">701500000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i7209bbd041614d26ab0622d0fd200deb_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfMy0yMS0xLTEtMA_15e8acb5-cbfd-4b2c-abfb-dfcb99f31650"
      unitRef="usd">2400000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfMy0yMy0xLTEtMA_32b9295f-6aac-45c0-9978-e6652fca6935"
      unitRef="usd">703900000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ib23988bed8f7484597669fdaf2c6150e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfNC0xMS0xLTEtMA_6248e939-2d18-4d7b-b4ad-0946bb018c1d"
      unitRef="usd">-44500000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="if01d2b8c98a04ef2a7d2d2754bdfa47f_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfNC0xOS0xLTEtMA_68cd728a-39fa-4c46-a469-bfe798569300"
      unitRef="usd">-44500000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i7209bbd041614d26ab0622d0fd200deb_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfNC0yMS0xLTEtMA_73f3c1d3-9cb6-440d-8781-d9ad5a54d8f7"
      unitRef="usd">-900000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfNC0yMy0xLTEtMA_6fe6c7f6-e5f0-48ad-90e1-a5e6e7c88541"
      unitRef="usd">-45400000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <biib:Noncontrollinginterestincreasedecreaseother
      contextRef="if01d2b8c98a04ef2a7d2d2754bdfa47f_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfNS0xOS0xLTEtMA_cfdc9b9f-0e62-415c-9505-e0144c77ef73"
      unitRef="usd">0</biib:Noncontrollinginterestincreasedecreaseother>
    <biib:Noncontrollinginterestincreasedecreaseother
      contextRef="i7209bbd041614d26ab0622d0fd200deb_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfNS0yMS0xLTEtMA_f2481f71-8f62-4111-afee-27366e49251e"
      unitRef="usd">4000000.0</biib:Noncontrollinginterestincreasedecreaseother>
    <biib:Noncontrollinginterestincreasedecreaseother
      contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfNS0yMy0xLTEtMA_79efb51e-e543-4261-986c-955a5d84d3b6"
      unitRef="usd">4000000.0</biib:Noncontrollinginterestincreasedecreaseother>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i030ce533f4cf4aa7852fbd17ed7ca720_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfOC01LTEtMS0w_f0e4abff-4908-4c86-9677-4cb7d3062ae9"
      unitRef="shares">-4500000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="ic0a0dcfa5c2c49268190d94b335f065e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfOC0xNS0xLTEtMA_30793ca4-246b-4ebb-af84-b6a3f71e89b3"
      unitRef="shares">4500000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ic0a0dcfa5c2c49268190d94b335f065e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfOC0xNy0xLTEtMA_09a0a592-bb15-445b-b582-86530f93d513"
      unitRef="usd">1250000000.0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i2debfff1a33140e6bcf02b809c593d24_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfOC0xOS0xLTEtMA_c2191d22-57c8-455f-8f0a-a242406e6c30"
      unitRef="usd">1250000000.0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="iadd8187a18d849f6b353e75cae0aabe8_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfOC0yMy0xLTEtMA_7f39e59b-631d-4607-a805-f4330b8fa7df"
      unitRef="usd">1250000000.0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="iada85e2a70f74606baf6a5c38c9ddac3_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfOS01LTEtMS0w_fa76fb9d-40df-4d98-8938-db1dacc22f37"
      unitRef="shares">0</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="iada85e2a70f74606baf6a5c38c9ddac3_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfOS03LTEtMS0w_7d661ba7-73f2-4c07-92bc-1b4c5cf3506e"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="ifb80294ce54b4a41af5a0f3e17352851_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfOS05LTEtMS0w_89beb0b6-f5bf-4b2a-8918-d1d0256e35ed"
      unitRef="usd">45100000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i1c225596be4340518bf78440f40fdbb7_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfOS0xMy0xLTEtMA_39573f2a-ab90-49d0-a385-6a6d9c263a0d"
      unitRef="usd">1204900000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="ic0a0dcfa5c2c49268190d94b335f065e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfOS0xNS0xLTEtMA_56ef0e5b-98f7-43d8-af59-111e7688756e"
      unitRef="shares">4500000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="ic0a0dcfa5c2c49268190d94b335f065e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfOS0xNy0xLTEtMA_0c88b38b-0c15-4bc7-bb94-220c0232b3f9"
      unitRef="usd">-1250000000.0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i2debfff1a33140e6bcf02b809c593d24_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfOS0xOS0xLTEtMA_5108e970-bbc3-49b9-92dc-ba750b13196d"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="iadd8187a18d849f6b353e75cae0aabe8_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfOS0yMy0xLTEtMA_027a9c7f-0b9c-46ad-abad-1b71bc5f7ef3"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued
      contextRef="i030ce533f4cf4aa7852fbd17ed7ca720_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfMTAtNS0xLTEtMA_52550e6f-63a1-4feb-a8ac-25a0244d1849"
      unitRef="shares">100000</us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="i030ce533f4cf4aa7852fbd17ed7ca720_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfMTAtNy0xLTEtMA_bcfb4b50-df01-4453-81fa-d4040e3d0036"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="i53ea969c6702421f9bfd2df9bfc3232a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfMTAtOS0xLTEtMA_fadaa219-b132-4251-9626-8866439798bc"
      unitRef="usd">9700000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="if01d2b8c98a04ef2a7d2d2754bdfa47f_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfMTAtMTktMS0xLTA_bf95d674-ef81-4555-91e4-d94a26244722"
      unitRef="usd">9700000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfMTAtMjMtMS0xLTA_b63fcf55-0d3a-46da-bbc3-438375372362"
      unitRef="usd">9700000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i030ce533f4cf4aa7852fbd17ed7ca720_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfMTEtNS0xLTEtMA_601c7d68-7b14-4262-a931-45a44d6405aa"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i030ce533f4cf4aa7852fbd17ed7ca720_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfMTEtNy0xLTEtMA_040d10fc-beb8-4b82-a330-b81efe07bdfb"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i53ea969c6702421f9bfd2df9bfc3232a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfMTEtOS0xLTEtMA_69ecb55c-02cc-4c3b-8a54-801b356cd0f2"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i1499259d90804413b1e193e034d9561d_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfMTEtMTMtMS0xLTA_bca7de70-9ba8-421a-b581-56fbd7a936b9"
      unitRef="usd">-2300000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="if01d2b8c98a04ef2a7d2d2754bdfa47f_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfMTEtMTktMS0xLTA_103457d7-afab-42d8-87a2-a984033c926a"
      unitRef="usd">-2300000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfMTEtMjMtMS0xLTA_cd132494-6137-4b1d-a946-42ee0c795afa"
      unitRef="usd">-2300000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i53ea969c6702421f9bfd2df9bfc3232a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfMTItOS0xLTEtMA_ffc9456d-1cac-49ed-bd2c-854b6d8de1df"
      unitRef="usd">-35400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if01d2b8c98a04ef2a7d2d2754bdfa47f_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfMTItMTktMS0xLTA_814b0914-d220-4525-97ab-6e3a73d1e71e"
      unitRef="usd">-35400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfMTItMjMtMS0xLTA_382e99bf-8472-4f73-8598-b161f8acc38f"
      unitRef="usd">-35400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ib2edcb252dee41aaaa28a702b70a129d_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfMTQtMS0xLTEtMA_a19c6370-9019-4c25-85e2-28f175c92cef"
      unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib2edcb252dee41aaaa28a702b70a129d_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfMTQtMy0xLTEtMA_985073c6-3dbf-4178-875a-d14e1a88b1ec"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="iccce420c57a74d908b28fffc261114e2_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfMTQtNS0xLTEtMA_f8cd7fc8-6139-435a-80bd-26e99516b72b"
      unitRef="shares">177700000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iccce420c57a74d908b28fffc261114e2_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfMTQtNy0xLTEtMA_6900e499-8c1b-463e-87e9-47fa5ad6b9aa"
      unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i89ed42febbd445c9aa4432e778b1d593_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfMTQtOS0xLTEtMA_1e8e70ce-4f83-4bc5-b45a-003f2fb77c74"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia55221e7b3994df7ab08c27719d7d2f6_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfMTQtMTEtMS0xLTA_1c011cf1-c49d-4315-88ea-5180c80f06b2"
      unitRef="usd">-225500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i162af0e1b52e4fd99c7498e910ae472b_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfMTQtMTMtMS0xLTA_3ee35c60-6370-4f95-85f0-23a08612efd6"
      unitRef="usd">13961000000.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i138fbc630aee4346840425ef11fa647e_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfMTQtMTUtMS0xLTA_6fb7709e-0c7e-4bfb-98c2-5ddae9331488"
      unitRef="shares">23800000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i138fbc630aee4346840425ef11fa647e_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfMTQtMTctMS0xLTA_28635fe5-5d3d-4c68-86fb-9cb449fd5708"
      unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4b8029eaee38406ab0f2d229d09c0a8d_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfMTQtMTktMS0xLTA_afdef4d9-8d72-43a6-bc7c-dfc6e6681493"
      unitRef="usd">10758500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibe8d84b11e994911b29ab0046e3c5436_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfMTQtMjEtMS0xLTA_31eb7908-d264-4050-8d51-89dfa3222384"
      unitRef="usd">-14000000.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJkZTI4YTAxODM4YTQxN2JhMmQ3MTJhNGEwOTAzMTczL3RhYmxlcmFuZ2U6YmRlMjhhMDE4MzhhNDE3YmEyZDcxMmE0YTA5MDMxNzNfMTQtMjMtMS0xLTA_f6da9e4c-ea8a-4834-a1e5-09be76acd0a4"
      unitRef="usd">10744500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i8f84ef87973843b2b12c2e5314f58592_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfMi0xLTEtMS0w_061de4cd-546b-4721-8a7f-4becd60a462e"
      unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8f84ef87973843b2b12c2e5314f58592_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfMi0zLTEtMS0w_cb95b473-2669-47dc-b71d-56fae0345ea3"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i40f2711483814cfd80a3070c293601a6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfMi01LTEtMS0w_8f7ca7cb-7161-4488-b19d-71c6a7a7980e"
      unitRef="shares">198000000.0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i40f2711483814cfd80a3070c293601a6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfMi03LTEtMS0w_50564d0f-2623-42be-b05e-4f16e8562fbe"
      unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia40deaebb7e14b0ea3390b0988aea61d_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfMi05LTEtMS0w_ce1d089f-11f0-4746-a104-536a3d89ebb3"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifc05b78d934b474aac9922457936de4c_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfMi0xMS0xLTEtMA_7818977c-2eb4-480f-83ce-8fe7ad2559bd"
      unitRef="usd">-135200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idb84688ac5bf43faa19f9f893a04a3e2_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfMi0xMy0xLTEtMA_a26adf14-36ed-44d0-b061-a6642a7e4ee9"
      unitRef="usd">16455400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i03b2cef2a2324bfcbcfdea22ab154bd4_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfMi0xNS0xLTEtMA_fa2d3699-8952-4c14-8c4b-211e10862eca"
      unitRef="shares">23800000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i03b2cef2a2324bfcbcfdea22ab154bd4_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfMi0xNy0xLTEtMA_baa52bfb-d971-4d4e-b39d-44b03902d7d5"
      unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6344cb617db54fbaac18f0e555380783_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfMi0xOS0xLTEtMA_06ee166e-8428-49ac-b296-63b6ca5f7b8c"
      unitRef="usd">13343200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2d1cce71297346cdaeeb9fb6370ccdeb_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfMi0yMS0xLTEtMA_fc09715e-4f5a-48c1-b690-b7d04b4abdf9"
      unitRef="usd">-4100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i626282e786b7454d83b617e9e83963e6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfMi0yMy0xLTEtMA_d01ba7d6-3fb9-49fc-adab-6497e45f2cd0"
      unitRef="usd">13339100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i2d02929a942940478cbbc1b3ab3918a9_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfMy0xMy0xLTEtMA_618c69a2-6130-4821-9d73-72314150ea29"
      unitRef="usd">3642700000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="iec296486afe44cb9bee6a9b9fec0c678_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfMy0xOS0xLTEtMA_430d4382-c521-458b-a66b-85bc9c90b84b"
      unitRef="usd">3642700000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ic4379c94e8a84e548bdd2c9f5110296e_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfMy0yMS0xLTEtMA_8add9e21-df36-4491-8471-2046823533b5"
      unitRef="usd">60200000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfMy0yMy0xLTEtMA_d9e27ff3-9ca2-42c5-b094-2e0dcd4a4ec9"
      unitRef="usd">3702900000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i1faac185931341e591596ec3e5440d06_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfNC0xMS0xLTEtMA_8abc2cb5-91bf-465f-a206-55ce0943bdb5"
      unitRef="usd">-90300000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="iec296486afe44cb9bee6a9b9fec0c678_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfNC0xOS0xLTEtMA_ff596b04-cbc9-4969-ba17-bde270969a0d"
      unitRef="usd">-90300000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ic4379c94e8a84e548bdd2c9f5110296e_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfNC0yMS0xLTEtMA_13e8ec5a-05d4-4974-b61e-1306d5ecc96d"
      unitRef="usd">900000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfNC0yMy0xLTEtMA_2109092c-3629-4cb4-b170-63cad45f1879"
      unitRef="usd">-89400000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <biib:Noncontrollinginterestincreasedecreaseother
      contextRef="ic4379c94e8a84e548bdd2c9f5110296e_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfNS0yMS0xLTEtMA_b52b10fb-f1a0-4a9e-a38e-04739e7601c4"
      unitRef="usd">-75000000.0</biib:Noncontrollinginterestincreasedecreaseother>
    <biib:Noncontrollinginterestincreasedecreaseother
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfNS0yMy0xLTEtMA_6fc48388-489e-442a-aa3b-882f5bc08117"
      unitRef="usd">-75000000.0</biib:Noncontrollinginterestincreasedecreaseother>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i0319abba8ccc4f0fae4e9db75a3ba5d0_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfNi0xNS0xLTEtMA_35d94101-7736-474c-99fd-7690851ebbb1"
      unitRef="shares">4100000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i0319abba8ccc4f0fae4e9db75a3ba5d0_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfNi0xNy0xLTEtMA_8418bef5-3a79-41e6-abf4-8c7c6a1c9255"
      unitRef="usd">1279100000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ibc0fb387460c4e6fb1f5dd03a311fb08_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfNi0xOS0xLTEtMA_3074a64c-dd19-456e-8ec2-78de99ef8570"
      unitRef="usd">1279100000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i0af05fc8fe804816a86f91f4f77cdeac_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfNi0yMy0xLTEtMA_e30128a7-7039-45c8-85b9-5ea44a049a13"
      unitRef="usd">1279100000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="iae4ebdfec80c40fabeca031863dcc5c5_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfNy01LTEtMS0w_ee7d44b0-ec4f-40cb-93b8-d8d676c0a1a0"
      unitRef="shares">4100000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i14eda8fe33b0440e8f012764e73abe64_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfNy05LTEtMS0w_7e195d49-e135-4281-99ff-9c13cf69279f"
      unitRef="usd">71000000.0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="ibea5025954d8442193d586f92fe4b174_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfNy0xMy0xLTEtMA_9de11135-fb94-4cf4-ac21-4d9079bb1fac"
      unitRef="usd">1208100000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="i0319abba8ccc4f0fae4e9db75a3ba5d0_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfNy0xNS0xLTEtMA_6b3f4dff-1388-4fa4-8a6c-9c328db30d2b"
      unitRef="shares">4100000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i0319abba8ccc4f0fae4e9db75a3ba5d0_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfNy0xNy0xLTEtMA_01a76cf3-aac5-41c5-88e6-6575df33a261"
      unitRef="usd">-1279100000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i0af05fc8fe804816a86f91f4f77cdeac_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfNy0yMy0xLTEtMA_eca31e0c-aad6-43e9-b3c1-e684c4324ee0"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i48e09b81ae6e4e27bb99b06fb90ade10_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfOC0xNS0xLTEtMA_e01ff6c8-0f28-463f-8b3b-bfe99c5ccb40"
      unitRef="shares">16700000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i48e09b81ae6e4e27bb99b06fb90ade10_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfOC0xNy0xLTEtMA_28b18403-19fb-4e99-bf86-4abe8e49db07"
      unitRef="usd">5000000000.0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i23f4570c321d470ea07b9b8126846754_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfOC0xOS0xLTEtMA_e32f3327-e0d3-4232-a300-3daf7552bf02"
      unitRef="usd">5000000000.0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="idb94151f567e4761811caaa2ee1c1349_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfOC0yMy0xLTEtMA_3d5cbc33-4437-4043-b403-4dff29ef16e2"
      unitRef="usd">5000000000.0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="i5ca2e1e65c424ac7afdfd951e4e64cea_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfOS01LTEtMS0w_04e06170-56a0-4844-821f-51344355ac62"
      unitRef="shares">16700000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="ia6f932e5c68d4df8ab6182786c4e7dff_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfOS05LTEtMS0w_d0213982-2aa5-4957-afde-ef70d70138d4"
      unitRef="usd">121300000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="ife6f9a28c7c64a109d345b6753d462fb_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfOS0xMy0xLTEtMA_6cd544ed-f4b2-4e7a-8c69-b4dd787bee34"
      unitRef="usd">4878700000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="i48e09b81ae6e4e27bb99b06fb90ade10_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfOS0xNS0xLTEtMA_50d7b9b9-7ae2-4e44-8613-82ba6d6fc713"
      unitRef="shares">16700000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i48e09b81ae6e4e27bb99b06fb90ade10_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfOS0xNy0xLTEtMA_c9ba8c9b-47e3-45cf-b650-4fe0231adba2"
      unitRef="usd">-5000000000.0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="idb94151f567e4761811caaa2ee1c1349_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfOS0yMy0xLTEtMA_ecb7732d-b576-4260-8858-289ade1eff66"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued
      contextRef="i2e65876e41494343960737c39bc5f276_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfMTAtNS0xLTEtMA_1ff54c23-7e60-4899-8bad-4e69e1d20808"
      unitRef="shares">200000</us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="i2e65876e41494343960737c39bc5f276_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfMTAtNy0xLTEtMA_0e15d97e-4644-4bb6-8d26-0e6957c89cd7"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="i861bb59946a84718b6c99600a2e9b0e5_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfMTAtOS0xLTEtMA_c8b37786-2103-4684-bc91-7aea7a20fab7"
      unitRef="usd">38800000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="iec296486afe44cb9bee6a9b9fec0c678_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfMTAtMTktMS0xLTA_841c0bc5-494b-4356-b793-0e0eec32b9bd"
      unitRef="usd">38800000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfMTAtMjMtMS0xLTA_529b1a62-5093-4b56-be32-878ff665ca44"
      unitRef="usd">38800000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i2e65876e41494343960737c39bc5f276_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfMTEtNS0xLTEtMA_9e7f9c3a-97c2-4ae9-b138-6602c5691485"
      unitRef="shares">300000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i2e65876e41494343960737c39bc5f276_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfMTEtNy0xLTEtMA_5e51e6ac-c611-4d31-a761-b266ae22c964"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i861bb59946a84718b6c99600a2e9b0e5_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfMTEtOS0xLTEtMA_2375cc8e-3157-473a-88c3-249f6db46126"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i2d02929a942940478cbbc1b3ab3918a9_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfMTEtMTMtMS0xLTA_bd0f1c42-20b6-4d3e-936f-e141c234b399"
      unitRef="usd">-50300000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="iec296486afe44cb9bee6a9b9fec0c678_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfMTEtMTktMS0xLTA_28c87073-b2de-4e69-8b6b-3e02476a822a"
      unitRef="usd">-50300000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfMTEtMjMtMS0xLTA_4bb033db-3ad7-4a9e-a3a5-a200d61d78a8"
      unitRef="usd">-50300000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i861bb59946a84718b6c99600a2e9b0e5_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfMTItOS0xLTEtMA_847f368f-0f0a-4e44-9084-7cd0e77913ed"
      unitRef="usd">-154200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iec296486afe44cb9bee6a9b9fec0c678_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfMTItMTktMS0xLTA_8a9cdcb9-58e3-45e8-b478-9056ed955fe5"
      unitRef="usd">-154200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfMTItMjMtMS0xLTA_ef5a46bc-1587-44c2-87f6-7b37dae3fb01"
      unitRef="usd">-154200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:StockholdersEquityOther
      contextRef="i861bb59946a84718b6c99600a2e9b0e5_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfMTMtOS0xLTEtMA_51ca5c5d-5ed3-4677-8d73-c9f24a8b17e4"
      unitRef="usd">700000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i2d02929a942940478cbbc1b3ab3918a9_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfMTMtMTMtMS0xLTA_a90f282b-c82f-4a71-bd7b-bb539c7afece"
      unitRef="usd">0</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="iec296486afe44cb9bee6a9b9fec0c678_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfMTMtMTktMS0xLTA_27174f12-e6f6-4a8d-ba0c-4c76cc4bd3a9"
      unitRef="usd">700000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfMTMtMjMtMS0xLTA_306ecf90-2d7d-4cd5-9f27-7a0acc88304c"
      unitRef="usd">700000</us-gaap:StockholdersEquityOther>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ib2edcb252dee41aaaa28a702b70a129d_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfMTQtMS0xLTEtMA_65ff9e1e-ee9d-447e-b289-d839b69cf1e8"
      unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib2edcb252dee41aaaa28a702b70a129d_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfMTQtMy0xLTEtMA_c2a1e93f-e071-445b-b25e-3013e626fc60"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="iccce420c57a74d908b28fffc261114e2_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfMTQtNS0xLTEtMA_df4a5da2-a67b-4bf3-9949-e017add096ef"
      unitRef="shares">177700000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iccce420c57a74d908b28fffc261114e2_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfMTQtNy0xLTEtMA_2eebcb11-7a49-4163-9b5c-f62dbc7a21e3"
      unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i89ed42febbd445c9aa4432e778b1d593_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfMTQtOS0xLTEtMA_3aaecedc-2fba-4651-a331-edf0d3f49794"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia55221e7b3994df7ab08c27719d7d2f6_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfMTQtMTEtMS0xLTA_4134fdf1-d32e-4093-be6a-489ea936c9a7"
      unitRef="usd">-225500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i162af0e1b52e4fd99c7498e910ae472b_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfMTQtMTMtMS0xLTA_8462e267-f854-455d-9335-f9f41451c8b6"
      unitRef="usd">13961000000.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i138fbc630aee4346840425ef11fa647e_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfMTQtMTUtMS0xLTA_ccb07589-b9c1-4b9b-adfa-5bded79d4f1d"
      unitRef="shares">23800000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i138fbc630aee4346840425ef11fa647e_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfMTQtMTctMS0xLTA_f9e365ab-da39-418d-9a12-0ddc61bbdf64"
      unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4b8029eaee38406ab0f2d229d09c0a8d_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfMTQtMTktMS0xLTA_791e7993-e53a-470c-92bd-5df79566256e"
      unitRef="usd">10758500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibe8d84b11e994911b29ab0046e3c5436_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfMTQtMjEtMS0xLTA_6a393f2d-28ea-477c-96c7-112de1b11e18"
      unitRef="usd">-14000000.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEyNDdmZmQ3ZjU4YzRjMDU5OTcwYmIxNzE0NmNjOWVhL3RhYmxlcmFuZ2U6YTI0N2ZmZDdmNThjNGMwNTk5NzBiYjE3MTQ2Y2M5ZWFfMTQtMjMtMS0xLTA_ee11b666-7281-4234-ac81-9d0145f98568"
      unitRef="usd">10744500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i99fbd0519e8d401bb929b503f3ecea4e_I20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJjMjAzMjNmMmFkNzRiYjFhNjM0NzhhZjUwYWFjYTdjL3RhYmxlcmFuZ2U6YmMyMDMyM2YyYWQ3NGJiMWE2MzQ3OGFmNTBhYWNhN2NfMi0xLTEtMS0w_7b8c73de-2f11-4729-a1a9-dc55f815bc5b"
      unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i99fbd0519e8d401bb929b503f3ecea4e_I20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJjMjAzMjNmMmFkNzRiYjFhNjM0NzhhZjUwYWFjYTdjL3RhYmxlcmFuZ2U6YmMyMDMyM2YyYWQ3NGJiMWE2MzQ3OGFmNTBhYWNhN2NfMi0zLTEtMS0w_3a5c023f-627e-42d2-93bd-86c7d6d07c27"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i9843b0258d7a4100af10e14048f0aa5c_I20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJjMjAzMjNmMmFkNzRiYjFhNjM0NzhhZjUwYWFjYTdjL3RhYmxlcmFuZ2U6YmMyMDMyM2YyYWQ3NGJiMWE2MzQ3OGFmNTBhYWNhN2NfMi01LTEtMS0w_e5eab6e3-3a25-4f02-922e-27803b244259"
      unitRef="shares">208600000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9843b0258d7a4100af10e14048f0aa5c_I20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJjMjAzMjNmMmFkNzRiYjFhNjM0NzhhZjUwYWFjYTdjL3RhYmxlcmFuZ2U6YmMyMDMyM2YyYWQ3NGJiMWE2MzQ3OGFmNTBhYWNhN2NfMi03LTEtMS0w_6444c42d-aee8-4b41-ba81-d371c0342457"
      unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0376412c3eff4647ac527a583e1fea9e_I20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJjMjAzMjNmMmFkNzRiYjFhNjM0NzhhZjUwYWFjYTdjL3RhYmxlcmFuZ2U6YmMyMDMyM2YyYWQ3NGJiMWE2MzQ3OGFmNTBhYWNhN2NfMi05LTEtMS0w_edb81842-85e0-499c-9735-1da4b0f21b99"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1e4817878dd24efa84f78403542ee2fa_I20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJjMjAzMjNmMmFkNzRiYjFhNjM0NzhhZjUwYWFjYTdjL3RhYmxlcmFuZ2U6YmMyMDMyM2YyYWQ3NGJiMWE2MzQ3OGFmNTBhYWNhN2NfMi0xMS0xLTEtMA_f99c2600-ab3a-42cb-9102-4814ccf4f272"
      unitRef="usd">-252900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ife3567f724fc4eafb760a986851063d1_I20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJjMjAzMjNmMmFkNzRiYjFhNjM0NzhhZjUwYWFjYTdjL3RhYmxlcmFuZ2U6YmMyMDMyM2YyYWQ3NGJiMWE2MzQ3OGFmNTBhYWNhN2NfMi0xMy0xLTEtMA_c1506582-ef3d-4253-a9f7-0cd29f7bea7b"
      unitRef="usd">16182800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="if307586287e044beb16134d1cd640d29_I20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJjMjAzMjNmMmFkNzRiYjFhNjM0NzhhZjUwYWFjYTdjL3RhYmxlcmFuZ2U6YmMyMDMyM2YyYWQ3NGJiMWE2MzQ3OGFmNTBhYWNhN2NfMi0xNS0xLTEtMA_58f37c01-b0ad-4407-953e-c922ac6d93f8"
      unitRef="shares">23800000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if307586287e044beb16134d1cd640d29_I20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJjMjAzMjNmMmFkNzRiYjFhNjM0NzhhZjUwYWFjYTdjL3RhYmxlcmFuZ2U6YmMyMDMyM2YyYWQ3NGJiMWE2MzQ3OGFmNTBhYWNhN2NfMi0xNy0xLTEtMA_ab17e5ac-9ed2-4898-8bab-151f809639fa"
      unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i396ceaa32ede4bd18fc264a28d5483b0_I20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJjMjAzMjNmMmFkNzRiYjFhNjM0NzhhZjUwYWFjYTdjL3RhYmxlcmFuZ2U6YmMyMDMyM2YyYWQ3NGJiMWE2MzQ3OGFmNTBhYWNhN2NfMi0xOS0xLTEtMA_dd3903f4-45a9-4a74-a161-0a60f29eee23"
      unitRef="usd">12952900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0ec1a9946b9d42abaed7abd2237b7dbd_I20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJjMjAzMjNmMmFkNzRiYjFhNjM0NzhhZjUwYWFjYTdjL3RhYmxlcmFuZ2U6YmMyMDMyM2YyYWQ3NGJiMWE2MzQ3OGFmNTBhYWNhN2NfMi0yMS0xLTEtMA_6c71a13e-4896-433b-a55e-f6142fa989bb"
      unitRef="usd">-4100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i94c6f45fdfc542388521216b8e80983e_I20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJjMjAzMjNmMmFkNzRiYjFhNjM0NzhhZjUwYWFjYTdjL3RhYmxlcmFuZ2U6YmMyMDMyM2YyYWQ3NGJiMWE2MzQ3OGFmNTBhYWNhN2NfMi0yMy0xLTEtMA_24d81398-d434-4df2-a276-945be7e13fa9"
      unitRef="usd">12948800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="ib515d9bcec6948d184e2f6536574cb55_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJjMjAzMjNmMmFkNzRiYjFhNjM0NzhhZjUwYWFjYTdjL3RhYmxlcmFuZ2U6YmMyMDMyM2YyYWQ3NGJiMWE2MzQ3OGFmNTBhYWNhN2NfMy0xMy0xLTEtMA_aa7aae88-5c71-4532-9061-ca1679d32a2a"
      unitRef="usd">1545900000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i58b6be5e29354a3f95dc35f74e0eb46d_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJjMjAzMjNmMmFkNzRiYjFhNjM0NzhhZjUwYWFjYTdjL3RhYmxlcmFuZ2U6YmMyMDMyM2YyYWQ3NGJiMWE2MzQ3OGFmNTBhYWNhN2NfMy0xOS0xLTEtMA_44025c4b-236c-4084-8de0-ae6bd7d45211"
      unitRef="usd">1545900000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJjMjAzMjNmMmFkNzRiYjFhNjM0NzhhZjUwYWFjYTdjL3RhYmxlcmFuZ2U6YmMyMDMyM2YyYWQ3NGJiMWE2MzQ3OGFmNTBhYWNhN2NfMy0yMy0xLTEtMA_504e12cd-1396-4686-aa26-71f53d3ec790"
      unitRef="usd">1545900000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="iae71bc1953744eebba86f3934124b00b_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJjMjAzMjNmMmFkNzRiYjFhNjM0NzhhZjUwYWFjYTdjL3RhYmxlcmFuZ2U6YmMyMDMyM2YyYWQ3NGJiMWE2MzQ3OGFmNTBhYWNhN2NfNC0xMS0xLTEtMA_5e9a5607-6170-4e6d-a206-59fdb759769f"
      unitRef="usd">160600000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i58b6be5e29354a3f95dc35f74e0eb46d_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJjMjAzMjNmMmFkNzRiYjFhNjM0NzhhZjUwYWFjYTdjL3RhYmxlcmFuZ2U6YmMyMDMyM2YyYWQ3NGJiMWE2MzQ3OGFmNTBhYWNhN2NfNC0xOS0xLTEtMA_72ded9d0-9e19-4ffc-a583-763abbac43e9"
      unitRef="usd">160600000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i37ac27ae2b114acebcefcb550c5cda84_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJjMjAzMjNmMmFkNzRiYjFhNjM0NzhhZjUwYWFjYTdjL3RhYmxlcmFuZ2U6YmMyMDMyM2YyYWQ3NGJiMWE2MzQ3OGFmNTBhYWNhN2NfNC0yMS0xLTEtMA_434c0d9a-7d05-49c1-b240-78d986da4287"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJjMjAzMjNmMmFkNzRiYjFhNjM0NzhhZjUwYWFjYTdjL3RhYmxlcmFuZ2U6YmMyMDMyM2YyYWQ3NGJiMWE2MzQ3OGFmNTBhYWNhN2NfNC0yMy0xLTEtMA_69a25fa1-b6a7-4617-b185-de025b999158"
      unitRef="usd">160600000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="ibcf7b9d6ba6b4eddabd32ecb80c018cb_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJjMjAzMjNmMmFkNzRiYjFhNjM0NzhhZjUwYWFjYTdjL3RhYmxlcmFuZ2U6YmMyMDMyM2YyYWQ3NGJiMWE2MzQ3OGFmNTBhYWNhN2NfNi0xNS0xLTEtMA_3cff13fc-3a1e-4703-8afd-97688aa434d5"
      unitRef="shares">3100000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ibcf7b9d6ba6b4eddabd32ecb80c018cb_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJjMjAzMjNmMmFkNzRiYjFhNjM0NzhhZjUwYWFjYTdjL3RhYmxlcmFuZ2U6YmMyMDMyM2YyYWQ3NGJiMWE2MzQ3OGFmNTBhYWNhN2NfNi0xNy0xLTEtMA_d100edf9-a6b4-4ef4-b67c-09f75a61aeb2"
      unitRef="usd">717900000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i86c3b6289b2b4f52a9c054d27fb6a5b9_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJjMjAzMjNmMmFkNzRiYjFhNjM0NzhhZjUwYWFjYTdjL3RhYmxlcmFuZ2U6YmMyMDMyM2YyYWQ3NGJiMWE2MzQ3OGFmNTBhYWNhN2NfNi0xOS0xLTEtMA_336994a4-476c-4010-a655-70898bb10cab"
      unitRef="usd">717900000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="if78608284adf428b9b151aa288371376_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJjMjAzMjNmMmFkNzRiYjFhNjM0NzhhZjUwYWFjYTdjL3RhYmxlcmFuZ2U6YmMyMDMyM2YyYWQ3NGJiMWE2MzQ3OGFmNTBhYWNhN2NfNi0yMy0xLTEtMA_644913e9-2677-43f9-b09c-d99b3c6e8d97"
      unitRef="usd">717900000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="i859bf4d9f138495caa518c457b42a8a6_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJjMjAzMjNmMmFkNzRiYjFhNjM0NzhhZjUwYWFjYTdjL3RhYmxlcmFuZ2U6YmMyMDMyM2YyYWQ3NGJiMWE2MzQ3OGFmNTBhYWNhN2NfNy01LTEtMS0w_8ae5ffc6-bcf3-4d87-a4ee-a09000cf0332"
      unitRef="shares">3100000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="ic82a5a18c46c4de99def553116869989_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJjMjAzMjNmMmFkNzRiYjFhNjM0NzhhZjUwYWFjYTdjL3RhYmxlcmFuZ2U6YmMyMDMyM2YyYWQ3NGJiMWE2MzQ3OGFmNTBhYWNhN2NfNy05LTEtMS0w_adc254aa-c41e-4a17-a0e8-68980eb55d96"
      unitRef="usd">55100000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="ia9881e9f358c4093a91f49acc663d493_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJjMjAzMjNmMmFkNzRiYjFhNjM0NzhhZjUwYWFjYTdjL3RhYmxlcmFuZ2U6YmMyMDMyM2YyYWQ3NGJiMWE2MzQ3OGFmNTBhYWNhN2NfNy0xMy0xLTEtMA_82aa8e90-c3e8-4f03-9643-000f2ae01ea0"
      unitRef="usd">662800000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="ibcf7b9d6ba6b4eddabd32ecb80c018cb_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJjMjAzMjNmMmFkNzRiYjFhNjM0NzhhZjUwYWFjYTdjL3RhYmxlcmFuZ2U6YmMyMDMyM2YyYWQ3NGJiMWE2MzQ3OGFmNTBhYWNhN2NfNy0xNS0xLTEtMA_ebc00cba-971c-4f67-916f-83d8b413256b"
      unitRef="shares">3100000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="ibcf7b9d6ba6b4eddabd32ecb80c018cb_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJjMjAzMjNmMmFkNzRiYjFhNjM0NzhhZjUwYWFjYTdjL3RhYmxlcmFuZ2U6YmMyMDMyM2YyYWQ3NGJiMWE2MzQ3OGFmNTBhYWNhN2NfNy0xNy0xLTEtMA_bca1b98a-5ac8-4f44-af1d-c28d895b3503"
      unitRef="usd">-717900000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued
      contextRef="i45b746c96de74debaf178d86af176ed7_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJjMjAzMjNmMmFkNzRiYjFhNjM0NzhhZjUwYWFjYTdjL3RhYmxlcmFuZ2U6YmMyMDMyM2YyYWQ3NGJiMWE2MzQ3OGFmNTBhYWNhN2NfMTAtNS0xLTEtMA_b8f4de43-21e4-47de-8888-3b69cfffa6d9"
      unitRef="shares">100000</us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="i45b746c96de74debaf178d86af176ed7_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJjMjAzMjNmMmFkNzRiYjFhNjM0NzhhZjUwYWFjYTdjL3RhYmxlcmFuZ2U6YmMyMDMyM2YyYWQ3NGJiMWE2MzQ3OGFmNTBhYWNhN2NfMTAtNy0xLTEtMA_c01c27bd-547e-4810-8075-7f7e8d43a5df"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="ic161674d27484a338894e49a73880c69_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJjMjAzMjNmMmFkNzRiYjFhNjM0NzhhZjUwYWFjYTdjL3RhYmxlcmFuZ2U6YmMyMDMyM2YyYWQ3NGJiMWE2MzQ3OGFmNTBhYWNhN2NfMTAtOS0xLTEtMA_7b83f58a-6262-4725-a4f7-c8061787df83"
      unitRef="usd">7300000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="i58b6be5e29354a3f95dc35f74e0eb46d_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJjMjAzMjNmMmFkNzRiYjFhNjM0NzhhZjUwYWFjYTdjL3RhYmxlcmFuZ2U6YmMyMDMyM2YyYWQ3NGJiMWE2MzQ3OGFmNTBhYWNhN2NfMTAtMTktMS0xLTA_57400dc9-d144-4539-af21-8b239ca96139"
      unitRef="usd">7300000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJjMjAzMjNmMmFkNzRiYjFhNjM0NzhhZjUwYWFjYTdjL3RhYmxlcmFuZ2U6YmMyMDMyM2YyYWQ3NGJiMWE2MzQ3OGFmNTBhYWNhN2NfMTAtMjMtMS0xLTA_b96af225-0ad5-4a78-bc18-89eb32b85352"
      unitRef="usd">7300000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i45b746c96de74debaf178d86af176ed7_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJjMjAzMjNmMmFkNzRiYjFhNjM0NzhhZjUwYWFjYTdjL3RhYmxlcmFuZ2U6YmMyMDMyM2YyYWQ3NGJiMWE2MzQ3OGFmNTBhYWNhN2NfMTEtNS0xLTEtMA_c8eb942e-260c-4cdc-bb3a-2e78fad0e996"
      unitRef="shares">100000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i45b746c96de74debaf178d86af176ed7_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJjMjAzMjNmMmFkNzRiYjFhNjM0NzhhZjUwYWFjYTdjL3RhYmxlcmFuZ2U6YmMyMDMyM2YyYWQ3NGJiMWE2MzQ3OGFmNTBhYWNhN2NfMTEtNy0xLTEtMA_88c99cd2-5bb9-4ee8-8c5e-8b7463fed983"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ic161674d27484a338894e49a73880c69_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJjMjAzMjNmMmFkNzRiYjFhNjM0NzhhZjUwYWFjYTdjL3RhYmxlcmFuZ2U6YmMyMDMyM2YyYWQ3NGJiMWE2MzQ3OGFmNTBhYWNhN2NfMTEtOS0xLTEtMA_1b6db0e2-3374-428e-bdd4-93296e10fcc7"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ib515d9bcec6948d184e2f6536574cb55_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJjMjAzMjNmMmFkNzRiYjFhNjM0NzhhZjUwYWFjYTdjL3RhYmxlcmFuZ2U6YmMyMDMyM2YyYWQ3NGJiMWE2MzQ3OGFmNTBhYWNhN2NfMTEtMTMtMS0xLTA_28372c30-5836-410d-98a4-fae35bca3d86"
      unitRef="usd">-700000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i58b6be5e29354a3f95dc35f74e0eb46d_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJjMjAzMjNmMmFkNzRiYjFhNjM0NzhhZjUwYWFjYTdjL3RhYmxlcmFuZ2U6YmMyMDMyM2YyYWQ3NGJiMWE2MzQ3OGFmNTBhYWNhN2NfMTEtMTktMS0xLTA_9006237a-585a-46e9-b5fa-ae995a92e276"
      unitRef="usd">-700000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJjMjAzMjNmMmFkNzRiYjFhNjM0NzhhZjUwYWFjYTdjL3RhYmxlcmFuZ2U6YmMyMDMyM2YyYWQ3NGJiMWE2MzQ3OGFmNTBhYWNhN2NfMTEtMjMtMS0xLTA_48fc3e7c-60cf-46dd-b114-5dd4d2f3ae1a"
      unitRef="usd">-700000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic161674d27484a338894e49a73880c69_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJjMjAzMjNmMmFkNzRiYjFhNjM0NzhhZjUwYWFjYTdjL3RhYmxlcmFuZ2U6YmMyMDMyM2YyYWQ3NGJiMWE2MzQ3OGFmNTBhYWNhN2NfMTItOS0xLTEtMA_9f3ca33a-15cd-4774-a625-71abff4b8c4a"
      unitRef="usd">-47800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib515d9bcec6948d184e2f6536574cb55_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJjMjAzMjNmMmFkNzRiYjFhNjM0NzhhZjUwYWFjYTdjL3RhYmxlcmFuZ2U6YmMyMDMyM2YyYWQ3NGJiMWE2MzQ3OGFmNTBhYWNhN2NfMTItMTMtMS0xLTA_ea16e4b7-4d1d-428e-a84b-81879f33bf00"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i58b6be5e29354a3f95dc35f74e0eb46d_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJjMjAzMjNmMmFkNzRiYjFhNjM0NzhhZjUwYWFjYTdjL3RhYmxlcmFuZ2U6YmMyMDMyM2YyYWQ3NGJiMWE2MzQ3OGFmNTBhYWNhN2NfMTItMTktMS0xLTA_01979718-cef3-4452-a7ba-8baa1dbb1ad8"
      unitRef="usd">-47800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJjMjAzMjNmMmFkNzRiYjFhNjM0NzhhZjUwYWFjYTdjL3RhYmxlcmFuZ2U6YmMyMDMyM2YyYWQ3NGJiMWE2MzQ3OGFmNTBhYWNhN2NfMTItMjMtMS0xLTA_4e3cd75b-317b-466d-909e-ed1644540d47"
      unitRef="usd">-47800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i30714cf43346412e9fea73f7251cf213_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJjMjAzMjNmMmFkNzRiYjFhNjM0NzhhZjUwYWFjYTdjL3RhYmxlcmFuZ2U6YmMyMDMyM2YyYWQ3NGJiMWE2MzQ3OGFmNTBhYWNhN2NfMTMtMS0xLTEtMA_739315c1-adcb-444f-a907-51ba6275b53a"
      unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i30714cf43346412e9fea73f7251cf213_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJjMjAzMjNmMmFkNzRiYjFhNjM0NzhhZjUwYWFjYTdjL3RhYmxlcmFuZ2U6YmMyMDMyM2YyYWQ3NGJiMWE2MzQ3OGFmNTBhYWNhN2NfMTMtMy0xLTEtMA_2692b341-4c50-48bc-9dfd-6da26e63244c"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="iccee1e1d95af43b9873f3228bed22351_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJjMjAzMjNmMmFkNzRiYjFhNjM0NzhhZjUwYWFjYTdjL3RhYmxlcmFuZ2U6YmMyMDMyM2YyYWQ3NGJiMWE2MzQ3OGFmNTBhYWNhN2NfMTMtNS0xLTEtMA_51177be1-f3c8-4c67-8dcd-7f4bf65e2421"
      unitRef="shares">205700000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iccee1e1d95af43b9873f3228bed22351_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJjMjAzMjNmMmFkNzRiYjFhNjM0NzhhZjUwYWFjYTdjL3RhYmxlcmFuZ2U6YmMyMDMyM2YyYWQ3NGJiMWE2MzQ3OGFmNTBhYWNhN2NfMTMtNy0xLTEtMA_547295a1-698f-449f-ad76-7ce4c56e713f"
      unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i404c8ff0534c49f7a853054388cf47e7_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJjMjAzMjNmMmFkNzRiYjFhNjM0NzhhZjUwYWFjYTdjL3RhYmxlcmFuZ2U6YmMyMDMyM2YyYWQ3NGJiMWE2MzQ3OGFmNTBhYWNhN2NfMTMtOS0xLTEtMA_890f003d-84c9-4f76-9cf5-bd5669d2d574"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie09a86c05b2d4dd68ea12c27ea7e151a_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJjMjAzMjNmMmFkNzRiYjFhNjM0NzhhZjUwYWFjYTdjL3RhYmxlcmFuZ2U6YmMyMDMyM2YyYWQ3NGJiMWE2MzQ3OGFmNTBhYWNhN2NfMTMtMTEtMS0xLTA_d2d3387e-85cc-451f-8370-2adbc1e8e39c"
      unitRef="usd">-92300000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idcbcecd74e024473bdd870830b88f96c_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJjMjAzMjNmMmFkNzRiYjFhNjM0NzhhZjUwYWFjYTdjL3RhYmxlcmFuZ2U6YmMyMDMyM2YyYWQ3NGJiMWE2MzQ3OGFmNTBhYWNhN2NfMTMtMTMtMS0xLTA_38804bc0-6138-4741-a2a4-f9f4c9840591"
      unitRef="usd">17065200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i7c8172c9fe75493ca901d5f05ecfa29d_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJjMjAzMjNmMmFkNzRiYjFhNjM0NzhhZjUwYWFjYTdjL3RhYmxlcmFuZ2U6YmMyMDMyM2YyYWQ3NGJiMWE2MzQ3OGFmNTBhYWNhN2NfMTMtMTUtMS0xLTA_79704015-b767-4f01-952b-10c22417c9d7"
      unitRef="shares">23800000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7c8172c9fe75493ca901d5f05ecfa29d_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJjMjAzMjNmMmFkNzRiYjFhNjM0NzhhZjUwYWFjYTdjL3RhYmxlcmFuZ2U6YmMyMDMyM2YyYWQ3NGJiMWE2MzQ3OGFmNTBhYWNhN2NfMTMtMTctMS0xLTA_78d12766-56fc-48db-97ff-c2f87f08dec2"
      unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic9f978f94b6e4038af9fb1fcaaf85dee_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJjMjAzMjNmMmFkNzRiYjFhNjM0NzhhZjUwYWFjYTdjL3RhYmxlcmFuZ2U6YmMyMDMyM2YyYWQ3NGJiMWE2MzQ3OGFmNTBhYWNhN2NfMTMtMTktMS0xLTA_9a5c36a0-ccf2-4185-b169-600f8c637d87"
      unitRef="usd">13995900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie2305062812f448bad777c7ba71b2552_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJjMjAzMjNmMmFkNzRiYjFhNjM0NzhhZjUwYWFjYTdjL3RhYmxlcmFuZ2U6YmMyMDMyM2YyYWQ3NGJiMWE2MzQ3OGFmNTBhYWNhN2NfMTMtMjEtMS0xLTA_4048cc4f-9e2b-47ec-a459-ce81d9996e26"
      unitRef="usd">-4100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ied38b94db9a74750b51c6e8392d4c5bf_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmJjMjAzMjNmMmFkNzRiYjFhNjM0NzhhZjUwYWFjYTdjL3RhYmxlcmFuZ2U6YmMyMDMyM2YyYWQ3NGJiMWE2MzQ3OGFmNTBhYWNhN2NfMTMtMjMtMS0xLTA_4a66477d-f60d-4d18-8c57-2693b2b818e2"
      unitRef="usd">13991800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i88af2b9941924871abe610dc3e71811b_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfMi0xLTEtMS0w_eb2c9145-e091-4a26-8467-c445df786f5d"
      unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i88af2b9941924871abe610dc3e71811b_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfMi0zLTEtMS0w_7568e86f-457b-454d-8755-8caf8a6f94e4"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i1e15f7e0305245ab8755ada973550435_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfMi01LTEtMS0w_0b5dd9cb-0e36-42f8-b071-62d85b966d78"
      unitRef="shares">221000000.0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1e15f7e0305245ab8755ada973550435_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfMi03LTEtMS0w_bedfb757-7840-42d7-870b-fb16c8139c06"
      unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5b39457257df40c0a44aba71b396d988_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfMi05LTEtMS0w_4389b4c7-ac80-43e2-8d16-6f77efbf4e24"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i615f50b48b1947daafcc18ec87768baa_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfMi0xMS0xLTEtMA_4e957a86-a549-48f5-85f5-4caad461e2c2"
      unitRef="usd">-240400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i691108e26c8d4acfa6452b2cc1994da1_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfMi0xMy0xLTEtMA_d202bf9b-5e5e-40cf-a341-1e3bbbf3eca9"
      unitRef="usd">16257000000.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ia2c93178a13f4173b8c722d0ace0c1e7_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfMi0xNS0xLTEtMA_8667abf5-5f64-4a0e-8cad-1da4bb1e4bdd"
      unitRef="shares">23800000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia2c93178a13f4173b8c722d0ace0c1e7_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfMi0xNy0xLTEtMA_05f14023-4d70-48f5-a7ad-e88d77820b53"
      unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i474ef61edf8a4e488fdbe0a7144141d1_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfMi0xOS0xLTEtMA_532d8ba9-10cc-4994-8ebe-b02f18bb6a40"
      unitRef="usd">13039600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8445ab6e25754f87a6ebbd9df3b89ca0_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfMi0yMS0xLTEtMA_a730b4e9-87a3-49b3-adf1-7538a925c833"
      unitRef="usd">-8000000.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib98dd789f3514452acc95f9b041d2a7e_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfMi0yMy0xLTEtMA_59f73353-f09c-405b-9390-a98de6be2f62"
      unitRef="usd">13031600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="ib53a358e088b4743a76a8141b6a1c193_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfMy0xMy0xLTEtMA_2d9cf740-19aa-466f-8f8d-65ad5002b0cd"
      unitRef="usd">4448800000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i0efa62d44ea047f48a850ba3d5919a87_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfMy0xOS0xLTEtMA_3d9f7df2-ad61-4ce8-b7e1-906e9e1ff133"
      unitRef="usd">4448800000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfMy0yMy0xLTEtMA_512e0ac6-4a08-4b0e-bda7-002e7b4ecfd1"
      unitRef="usd">4448800000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i7182b1df2b374d208162f601fa679959_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfNC0xMS0xLTEtMA_1f6d51a7-8437-474f-84f7-8d879a9ae985"
      unitRef="usd">148100000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i0efa62d44ea047f48a850ba3d5919a87_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfNC0xOS0xLTEtMA_57af066a-2126-4c63-999d-64a72c4ae2cb"
      unitRef="usd">148100000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i7a7633cfe36348a79a7d0f41758bd6ab_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfNC0yMS0xLTEtMA_f383d3d5-e1e4-4d56-bf1d-f283974f7b03"
      unitRef="usd">-400000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfNC0yMy0xLTEtMA_44a1d59e-87b2-43b1-a3d4-941ddefe6e3f"
      unitRef="usd">147700000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <biib:Noncontrollinginterestincreasedecreaseother
      contextRef="i0efa62d44ea047f48a850ba3d5919a87_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfNS0xOS0xLTEtMA_ef1c774f-c5a0-42a8-89af-6312e4bcbed8"
      unitRef="usd">0</biib:Noncontrollinginterestincreasedecreaseother>
    <biib:Noncontrollinginterestincreasedecreaseother
      contextRef="i7a7633cfe36348a79a7d0f41758bd6ab_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfNS0yMS0xLTEtMA_37261d1e-7862-4e9d-9cd4-48bb1da66709"
      unitRef="usd">4300000</biib:Noncontrollinginterestincreasedecreaseother>
    <biib:Noncontrollinginterestincreasedecreaseother
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfNS0yMy0xLTEtMA_e18bd81b-7725-40b2-ad84-ef46d5b5936c"
      unitRef="usd">4300000</biib:Noncontrollinginterestincreasedecreaseother>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i7289c8815e434ac989c2d260f35da03d_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfNi0xNS0xLTEtMA_8dd8d142-270b-4134-96d9-8ab9ff52f67e"
      unitRef="shares">7000000.0</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i7289c8815e434ac989c2d260f35da03d_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfNi0xNy0xLTEtMA_ff4972b7-1aaa-4e1d-92b7-92df5e624e90"
      unitRef="usd">1627800000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ie8e1e308da1c4ce6aad01a86613ea938_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfNi0xOS0xLTEtMA_225a52d1-0352-4f76-aa08-d46ef8d4d3ca"
      unitRef="usd">1627800000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i36fedb8b45764716a0240c105927c6d7_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfNi0yMy0xLTEtMA_c86bdfdd-b9a6-41b4-a175-593bc957194a"
      unitRef="usd">1627800000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="icf8bb34fb60b40bcb5c350755c57da7f_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfNy01LTEtMS0w_ebf6ddbb-023f-458e-bfa2-5c5efa80ce02"
      unitRef="shares">7000000.0</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="id953e91f8c614de9996090d5eb18e5b1_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfNy05LTEtMS0w_ab3da853-e384-4ffa-ae81-482f5ead71bd"
      unitRef="usd">74800000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="ic8aa3352d77e4f12b7fc3b77907a67f6_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfNy0xMy0xLTEtMA_da3659bb-0b32-41b6-8447-ae421f431238"
      unitRef="usd">1553000000.0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="i7289c8815e434ac989c2d260f35da03d_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfNy0xNS0xLTEtMA_36dd1679-42da-4bad-8be2-73058768dea5"
      unitRef="shares">7000000.0</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i7289c8815e434ac989c2d260f35da03d_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfNy0xNy0xLTEtMA_63b0868b-1a8a-4db6-9401-1d0a25c591c0"
      unitRef="usd">-1627800000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="ib125f2b4cba94378833a506b5f526ef7_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfOC0xNS0xLTEtMA_7c947ced-c4c9-416b-b676-393a34019c8d"
      unitRef="shares">8900000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ib125f2b4cba94378833a506b5f526ef7_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfOC0xNy0xLTEtMA_eee10429-ec12-4aed-8954-47f055c1f232"
      unitRef="usd">2147400000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i8c3d2fb2bd034a6d943e04d98c6101df_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfOC0xOS0xLTEtMA_2f581090-0afe-414b-a031-dbb34d3c187a"
      unitRef="usd">2147400000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ib1d334b7c899449292200b30b2bdc155_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfOC0yMy0xLTEtMA_d9589201-903b-4cec-bd39-5d9936bca719"
      unitRef="usd">2147400000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="ifba3660adeba498985326527c5db09da_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfOS01LTEtMS0w_82a95453-4088-4bb2-95e3-1aaab8333a67"
      unitRef="shares">8900000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="ifba3660adeba498985326527c5db09da_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfOS03LTEtMS0w_672313a0-c223-4562-bec6-f5186c5c1318"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i809df7746fcc437c8e9a75cc7cb10a70_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfOS05LTEtMS0w_1fc0c6eb-62d2-47ce-9f44-ffb6e9f1cc0a"
      unitRef="usd">110500000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i4ffec57fb67a4f9091e91bd4b96b6eff_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfOS0xMy0xLTEtMA_016dca35-869a-41d5-9fca-ef693532214c"
      unitRef="usd">2036900000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="ib125f2b4cba94378833a506b5f526ef7_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfOS0xNS0xLTEtMA_d739bc74-34cf-4775-9f57-7cc2767ea631"
      unitRef="shares">8900000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="ib125f2b4cba94378833a506b5f526ef7_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfOS0xNy0xLTEtMA_06db7642-729a-4f5a-8005-22b87181f20d"
      unitRef="usd">-2147400000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i8c3d2fb2bd034a6d943e04d98c6101df_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfOS0xOS0xLTEtMA_4dea661f-dcc1-4f97-879e-bf4c8502b5a4"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="ib1d334b7c899449292200b30b2bdc155_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfOS0yMy0xLTEtMA_3a1fb6bf-7df9-43fe-bfc4-32d8ff1a0a47"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued
      contextRef="iab58c905ebd44601ad94f01220bb87b0_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfMTAtNS0xLTEtMA_4f06c713-aa40-46a3-885c-e52f7b8f08b5"
      unitRef="shares">200000</us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="iab58c905ebd44601ad94f01220bb87b0_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfMTAtNy0xLTEtMA_f7817650-d620-497d-a2ba-7b3e19ecace6"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="i4745753d1ae84b66b7bfd523bb7d93ad_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfMTAtOS0xLTEtMA_840e9eb7-c697-4bb8-a4a8-3e109a750057"
      unitRef="usd">33500000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="i0efa62d44ea047f48a850ba3d5919a87_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfMTAtMTktMS0xLTA_ac87b85c-1f3e-4a42-9cb3-cf2646cf1947"
      unitRef="usd">33500000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfMTAtMjMtMS0xLTA_94904fac-4af2-4f9e-a09d-54fdd68bd449"
      unitRef="usd">33500000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="iab58c905ebd44601ad94f01220bb87b0_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfMTEtNS0xLTEtMA_c4f2b40c-7582-4d39-8a06-5da0dd7a9e42"
      unitRef="shares">400000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="iab58c905ebd44601ad94f01220bb87b0_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfMTEtNy0xLTEtMA_1e33b6e3-b61f-4455-8c1c-634c31015f9e"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i4745753d1ae84b66b7bfd523bb7d93ad_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfMTEtOS0xLTEtMA_1dd0ca61-77c1-4286-b542-420afdc03438"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ib53a358e088b4743a76a8141b6a1c193_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfMTEtMTMtMS0xLTA_79e7cc85-5627-491f-a6df-7564d8bb3f78"
      unitRef="usd">-50700000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i0efa62d44ea047f48a850ba3d5919a87_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfMTEtMTktMS0xLTA_5861f494-372b-442a-a157-f96d9aff26f3"
      unitRef="usd">-50700000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfMTEtMjMtMS0xLTA_a511a5e3-5268-4f42-8ffd-893628cdfaf8"
      unitRef="usd">-50700000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4745753d1ae84b66b7bfd523bb7d93ad_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfMTItOS0xLTEtMA_b63f4f82-647a-435f-b0b9-75216d708951"
      unitRef="usd">-151800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib53a358e088b4743a76a8141b6a1c193_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfMTItMTMtMS0xLTA_a029c6fb-5083-442e-86c6-6005e194f4c3"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0efa62d44ea047f48a850ba3d5919a87_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfMTItMTktMS0xLTA_ac7d085e-14b5-4040-9390-847d59bad1fb"
      unitRef="usd">-151800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfMTItMjMtMS0xLTA_fd8b63d2-3a0a-4441-8b9f-4d873b0ad471"
      unitRef="usd">-151800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i30714cf43346412e9fea73f7251cf213_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfMTMtMS0xLTEtMA_d33e0151-84ab-4c70-b082-5d0404ff6afd"
      unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i30714cf43346412e9fea73f7251cf213_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfMTMtMy0xLTEtMA_4f06acc5-e7d3-41f0-a331-0eff52bc3ac1"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="iccee1e1d95af43b9873f3228bed22351_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfMTMtNS0xLTEtMA_c932a8ac-210b-43dc-880a-4ff6fb69260d"
      unitRef="shares">205700000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iccee1e1d95af43b9873f3228bed22351_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfMTMtNy0xLTEtMA_52fdcc06-e4cb-468b-a060-3584d847b96a"
      unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i404c8ff0534c49f7a853054388cf47e7_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfMTMtOS0xLTEtMA_63bbbfb4-05ee-49ce-bf3f-e977f521e1c9"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie09a86c05b2d4dd68ea12c27ea7e151a_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfMTMtMTEtMS0xLTA_62b90c74-394d-449a-b8dc-dcee702fcef8"
      unitRef="usd">-92300000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idcbcecd74e024473bdd870830b88f96c_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfMTMtMTMtMS0xLTA_c2f655f2-971f-4c9c-82d9-cdf82a991e1a"
      unitRef="usd">17065200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i7c8172c9fe75493ca901d5f05ecfa29d_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfMTMtMTUtMS0xLTA_50cacf13-98ee-4e70-9c61-4c48a7229f02"
      unitRef="shares">23800000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7c8172c9fe75493ca901d5f05ecfa29d_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfMTMtMTctMS0xLTA_3dd67f90-e5c9-4754-a114-013c3b6d5004"
      unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic9f978f94b6e4038af9fb1fcaaf85dee_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfMTMtMTktMS0xLTA_59971b31-82af-4a62-acce-e5615ad76f91"
      unitRef="usd">13995900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie2305062812f448bad777c7ba71b2552_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfMTMtMjEtMS0xLTA_61ca76c3-8aaf-43ba-844e-5fcee4599913"
      unitRef="usd">-4100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ied38b94db9a74750b51c6e8392d4c5bf_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18zNC9mcmFnOjcyMGQ4N2M1MDZmNTQwOGI5MjczYzU1MDQ1MTg2ZWQ2L3RhYmxlOmEwZmU1ZDUyNDI0MTQzYjZhNTlmYjA0M2U5YzgxMTFjL3RhYmxlcmFuZ2U6YTBmZTVkNTI0MjQxNDNiNmE1OWZiMDQzZTljODExMWNfMTMtMjMtMS0xLTA_f63fcb7f-4e61-4971-bcbf-24e1d3616309"
      unitRef="usd">13991800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM180MC9mcmFnOmQzZWY5NTkyOGIyNDQxNWE5OTUzZmZiZDU0NjI5NjVmL3RleHRyZWdpb246ZDNlZjk1OTI4YjI0NDE1YTk5NTNmZmJkNTQ2Mjk2NWZfMTIwMDg_e3e6d03a-ccb2-42da-b101-0f849c0ad42e">&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;References in these notes to "Biogen," the "company," "we," "us" and "our" refer to Biogen Inc. and its consolidated subsidiaries.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:11.25pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Business Overview&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Biogen is a global biopharmaceutical company focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. Our core growth areas include multiple sclerosis (MS) and neuroimmunology; Alzheimer's disease and dementia; neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS); movement disorders, including Parkinson's disease; and ophthalmology. We are also focused on discovering, developing and delivering worldwide innovative therapies in our emerging growth areas of immunology; neurocognitive disorders; acute neurology; and pain. In addition, we commercialize biosimilars of advanced biologics. We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Our marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; and FUMADERM for the treatment of severe plaque psoriasis. We also have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of primary progressive MS and relapsing MS; and other potential anti-CD20 therapies pursuant to our collaboration arrangements with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group. For additional information on our collaboration arrangements with Genentech, please read &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Note 18, Collaborative and Other Relationships,&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; to our consolidated financial statements included in our Annual Report on Form&#160;10-K for the year ended December 31, 2019 (2019 Form&#160;10-K).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Our innovative drug development and commercialization activities are complemented by our biosimilar business that expands access to medicines and reduces the cost burden for healthcare systems. Through Samsung Bioepis Co., Ltd. (Samsung Bioepis), our joint venture with Samsung BioLogics Co., Ltd. (Samsung BioLogics), we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL, IMRALDI, an adalimumab biosimilar referencing HUMIRA, and FLIXABI, an infliximab biosimilar referencing REMICADE, in certain countries in Europe and have exclusive rights to commercialize these products in China. Additionally, we have exclusive rights to commercialize two potential ophthalmology biosimilar products, SB11 referencing LUCENTIS and SB15 referencing EYLEA, in major markets worldwide, including the United States (U.S.), Canada, Europe, Japan and Australia. For additional information on our collaboration arrangements with Samsung Bioepis, please read &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Note 17, Collaborative and Other Relationships,&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; to these unaudited condensed consolidated financial statements (condensed consolidated financial statements). &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:11.25pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In the opinion of management, our condensed consolidated financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair statement of our financial statements for interim periods in accordance with accounting principles generally accepted in the United States (U.S.&#160;GAAP). The information included in this quarterly report on Form&#160;10-Q should be read in conjunction with our audited consolidated financial statements and the accompanying notes included in our 2019 Form&#160;10-K. Our accounting policies are described in the &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Notes to Consolidated Financial Statements&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; in our 2019 Form&#160;10-K and updated, as necessary, in this report. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from our audited financial statements but does not include all disclosures required by U.S.&#160;GAAP. The results of operations for the three and nine months ended September 30, 2020, are not necessarily indicative of the operating results for the full year or for any other subsequent interim period. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We operate as one operating segment, focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:11.25pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Our condensed consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and those of certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than 100% of the economics, we record net income (loss) attributable to noncontrolling interests in our condensed consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In determining whether we are the primary beneficiary of a variable interest entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. These considerations impact the way we account for our existing collaborative relationships and other arrangements. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:11.25pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. Actual results may differ from these estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The length of time and full extent to which the COVID-19 pandemic directly or indirectly impacts our business, results of operations and financial condition, including sales, expenses, reserves and allowances, manufacturing, clinical trials, research and development costs and employee-related amounts, depends on future developments that are highly uncertain, subject to change and are difficult to predict, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19 as well as the economic impact on local, regional, national and international customers and markets. We have made estimates of the impact of COVID-19 within our condensed consolidated financial statements and there may be changes to those estimates in future periods. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:11.25pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;New Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed below, we do not believe that the adoption of recently issued standards have or may have a material impact on our condensed consolidated financial statements or disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:13.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#528134;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Credit Losses&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In June 2016 the FASB issued Accounting Standards Update (ASU) No. 2016-13, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;. The FASB subsequently issued amendments to ASU 2016-13, which have the same effective date and transition date of January 1, 2020. This standard requires entities to estimate an expected lifetime credit loss on financial assets ranging from short-term trade accounts receivable to long-term financings and report credit losses using an expected losses model rather than the incurred losses model that was previously used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, this standard now requires allowances to be recorded instead of reducing the amortized cost of the investment. This standard limits the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit losses if fair value increases.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;This standard became effective for us on January 1, 2020, and based on the composition of our trade receivables, investment portfolio and other financial assets, current economic conditions and historical credit loss activity, the adoption of this standard did not have a material impact on our condensed consolidated financial statements and related disclosures. During the three and nine months ended September 30, 2020, we recorded an immaterial amount associated with expected credit losses related to outstanding trade receivables in certain foreign countries that have been disproportionately impacted by the COVID-19 pandemic.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:13.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#528134;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In August 2018 the FASB issued ASU No. 2018-13,&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt; Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;. This standard modifies certain disclosure requirements on fair value measurements. This standard became effective for us on January 1, 2020, and did not have a material impact on our disclosures. For the new disclosures regarding our Level 3 instruments, please read &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Note 7, Fair Value Measurements,&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:13.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#528134;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Internal Use Software&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In August 2018 the FASB issued ASU No. 2018-15, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Intangibles&#x2014;Goodwill and Other&#x2014;Internal-Use Software (Subtopic 350-40): Customer&#x2019;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;. This standard clarifies the accounting for implementation costs in cloud computing arrangements. This standard, which became effective for us on January 1, 2020, and was adopted on a prospective basis, resulted in an immaterial amount of additional assets being recorded on our condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:13.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#528134;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Collaborative Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In November 2018 the FASB issued ASU No. 2018-18, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;. This standard makes targeted improvements for collaborative arrangements as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:40.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;"&gt;Clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under Accounting Standards Codification (ASC) 606, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;, when the collaborative arrangement participant is a customer in the context of a unit of account. In those situations, all the guidance in ASC 606 should be applied, including recognition, measurement, presentation and disclosure requirements;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:40.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;"&gt;Adds unit-of-account guidance to ASC 808, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;, to align with the guidance in ASC 606 (that is, a distinct good or service) when an entity is assessing whether the collaborative arrangement or a part of the arrangement is within the scope of ASC 606; and&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:40.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;"&gt;Precludes a company from presenting transactions with collaborative arrangement participants that are not directly related to sales to third parties with revenue recognized under ASC 606 if the collaborative arrangement participant is not a customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;This standard became effective for us on January 1, 2020, and did not have a material impact on our condensed consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <biib:BusinessOverviewPolicyTextBlock
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM180MC9mcmFnOmQzZWY5NTkyOGIyNDQxNWE5OTUzZmZiZDU0NjI5NjVmL3RleHRyZWdpb246ZDNlZjk1OTI4YjI0NDE1YTk5NTNmZmJkNTQ2Mjk2NWZfMTE5OTI_9e43fd5f-1e65-4b88-b490-8c1efdc107b5">&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Biogen is a global biopharmaceutical company focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. Our core growth areas include multiple sclerosis (MS) and neuroimmunology; Alzheimer's disease and dementia; neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS); movement disorders, including Parkinson's disease; and ophthalmology. We are also focused on discovering, developing and delivering worldwide innovative therapies in our emerging growth areas of immunology; neurocognitive disorders; acute neurology; and pain. In addition, we commercialize biosimilars of advanced biologics. We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Our marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; and FUMADERM for the treatment of severe plaque psoriasis. We also have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of primary progressive MS and relapsing MS; and other potential anti-CD20 therapies pursuant to our collaboration arrangements with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group. For additional information on our collaboration arrangements with Genentech, please read &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Note 18, Collaborative and Other Relationships,&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; to our consolidated financial statements included in our Annual Report on Form&#160;10-K for the year ended December 31, 2019 (2019 Form&#160;10-K).&lt;/span&gt;&lt;/div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Our innovative drug development and commercialization activities are complemented by our biosimilar business that expands access to medicines and reduces the cost burden for healthcare systems. Through Samsung Bioepis Co., Ltd. (Samsung Bioepis), our joint venture with Samsung BioLogics Co., Ltd. (Samsung BioLogics), we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL, IMRALDI, an adalimumab biosimilar referencing HUMIRA, and FLIXABI, an infliximab biosimilar referencing REMICADE, in certain countries in Europe and have exclusive rights to commercialize these products in China. Additionally, we have exclusive rights to commercialize two potential ophthalmology biosimilar products, SB11 referencing LUCENTIS and SB15 referencing EYLEA, in major markets worldwide, including the United States (U.S.), Canada, Europe, Japan and Australia. For additional information on our collaboration arrangements with Samsung Bioepis, please read &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Note 17, Collaborative and Other Relationships,&lt;/span&gt; to these unaudited condensed consolidated financial statements (condensed consolidated financial statements).</biib:BusinessOverviewPolicyTextBlock>
    <biib:NumberOfOphthalmolgyBiosimilarProductsExclusiveRights
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM180MC9mcmFnOmQzZWY5NTkyOGIyNDQxNWE5OTUzZmZiZDU0NjI5NjVmL3RleHRyZWdpb246ZDNlZjk1OTI4YjI0NDE1YTk5NTNmZmJkNTQ2Mjk2NWZfODI0NjMzNzIyMDQzNA_aa815fee-aa8a-4909-9fd8-30b9c6451a4c"
      unitRef="product">2</biib:NumberOfOphthalmolgyBiosimilarProductsExclusiveRights>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM180MC9mcmFnOmQzZWY5NTkyOGIyNDQxNWE5OTUzZmZiZDU0NjI5NjVmL3RleHRyZWdpb246ZDNlZjk1OTI4YjI0NDE1YTk5NTNmZmJkNTQ2Mjk2NWZfMTE5OTY_fac5dd14-8e44-44b4-b756-ee0a6cc09737">&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In the opinion of management, our condensed consolidated financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair statement of our financial statements for interim periods in accordance with accounting principles generally accepted in the United States (U.S.&#160;GAAP). The information included in this quarterly report on Form&#160;10-Q should be read in conjunction with our audited consolidated financial statements and the accompanying notes included in our 2019 Form&#160;10-K. Our accounting policies are described in the &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Notes to Consolidated Financial Statements&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; in our 2019 Form&#160;10-K and updated, as necessary, in this report. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from our audited financial statements but does not include all disclosures required by U.S.&#160;GAAP. The results of operations for the three and nine months ended September 30, 2020, are not necessarily indicative of the operating results for the full year or for any other subsequent interim period. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We operate as one operating segment, focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM180MC9mcmFnOmQzZWY5NTkyOGIyNDQxNWE5OTUzZmZiZDU0NjI5NjVmL3RleHRyZWdpb246ZDNlZjk1OTI4YjI0NDE1YTk5NTNmZmJkNTQ2Mjk2NWZfNDMwMg_83aeb2e4-cec3-49d1-b38e-2ae30913f408"
      unitRef="segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM180MC9mcmFnOmQzZWY5NTkyOGIyNDQxNWE5OTUzZmZiZDU0NjI5NjVmL3RleHRyZWdpb246ZDNlZjk1OTI4YjI0NDE1YTk5NTNmZmJkNTQ2Mjk2NWZfMTIwMzE_f26e6c24-a09c-447b-9d66-5113c16cae6c">&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Our condensed consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and those of certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than 100% of the economics, we record net income (loss) attributable to noncontrolling interests in our condensed consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In determining whether we are the primary beneficiary of a variable interest entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. These considerations impact the way we account for our existing collaborative relationships and other arrangements. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <biib:InterestInSubsidiary
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM180MC9mcmFnOmQzZWY5NTkyOGIyNDQxNWE5OTUzZmZiZDU0NjI5NjVmL3RleHRyZWdpb246ZDNlZjk1OTI4YjI0NDE1YTk5NTNmZmJkNTQ2Mjk2NWZfNDgxMg_70ba81c1-ca44-432c-b699-6f088ef43485"
      unitRef="number">1</biib:InterestInSubsidiary>
    <us-gaap:UseOfEstimates
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM180MC9mcmFnOmQzZWY5NTkyOGIyNDQxNWE5OTUzZmZiZDU0NjI5NjVmL3RleHRyZWdpb246ZDNlZjk1OTI4YjI0NDE1YTk5NTNmZmJkNTQ2Mjk2NWZfMTIwMjc_4776df8a-bee5-4a50-ba21-49cdb08a31ed">The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. Actual results may differ from these estimates.The length of time and full extent to which the COVID-19 pandemic directly or indirectly impacts our business, results of operations and financial condition, including sales, expenses, reserves and allowances, manufacturing, clinical trials, research and development costs and employee-related amounts, depends on future developments that are highly uncertain, subject to change and are difficult to predict, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19 as well as the economic impact on local, regional, national and international customers and markets. We have made estimates of the impact of COVID-19 within our condensed consolidated financial statements and there may be changes to those estimates in future periods.</us-gaap:UseOfEstimates>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM180MC9mcmFnOmQzZWY5NTkyOGIyNDQxNWE5OTUzZmZiZDU0NjI5NjVmL3RleHRyZWdpb246ZDNlZjk1OTI4YjI0NDE1YTk5NTNmZmJkNTQ2Mjk2NWZfMTIwMDU_bbb40b73-9e0c-4ca9-8fc5-13479a0e59e7">&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed below, we do not believe that the adoption of recently issued standards have or may have a material impact on our condensed consolidated financial statements or disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:13.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#528134;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Credit Losses&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In June 2016 the FASB issued Accounting Standards Update (ASU) No. 2016-13, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;. The FASB subsequently issued amendments to ASU 2016-13, which have the same effective date and transition date of January 1, 2020. This standard requires entities to estimate an expected lifetime credit loss on financial assets ranging from short-term trade accounts receivable to long-term financings and report credit losses using an expected losses model rather than the incurred losses model that was previously used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, this standard now requires allowances to be recorded instead of reducing the amortized cost of the investment. This standard limits the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit losses if fair value increases.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;This standard became effective for us on January 1, 2020, and based on the composition of our trade receivables, investment portfolio and other financial assets, current economic conditions and historical credit loss activity, the adoption of this standard did not have a material impact on our condensed consolidated financial statements and related disclosures. During the three and nine months ended September 30, 2020, we recorded an immaterial amount associated with expected credit losses related to outstanding trade receivables in certain foreign countries that have been disproportionately impacted by the COVID-19 pandemic.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:13.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#528134;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In August 2018 the FASB issued ASU No. 2018-13,&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt; Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;. This standard modifies certain disclosure requirements on fair value measurements. This standard became effective for us on January 1, 2020, and did not have a material impact on our disclosures. For the new disclosures regarding our Level 3 instruments, please read &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Note 7, Fair Value Measurements,&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:13.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#528134;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Internal Use Software&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In August 2018 the FASB issued ASU No. 2018-15, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Intangibles&#x2014;Goodwill and Other&#x2014;Internal-Use Software (Subtopic 350-40): Customer&#x2019;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;. This standard clarifies the accounting for implementation costs in cloud computing arrangements. This standard, which became effective for us on January 1, 2020, and was adopted on a prospective basis, resulted in an immaterial amount of additional assets being recorded on our condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:13.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#528134;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Collaborative Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In November 2018 the FASB issued ASU No. 2018-18, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;. This standard makes targeted improvements for collaborative arrangements as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:40.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;"&gt;Clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under Accounting Standards Codification (ASC) 606, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;, when the collaborative arrangement participant is a customer in the context of a unit of account. In those situations, all the guidance in ASC 606 should be applied, including recognition, measurement, presentation and disclosure requirements;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:40.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;"&gt;Adds unit-of-account guidance to ASC 808, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;, to align with the guidance in ASC 606 (that is, a distinct good or service) when an entity is assessing whether the collaborative arrangement or a part of the arrangement is within the scope of ASC 606; and&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:40.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;"&gt;Precludes a company from presenting transactions with collaborative arrangement participants that are not directly related to sales to third parties with revenue recognized under ASC 606 if the collaborative arrangement participant is not a customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;This standard became effective for us on January 1, 2020, and did not have a material impact on our condensed consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM180My9mcmFnOmQyNTM3MjRlNzA5OTQyMGVhMTZiYzY2ODQ3MWNhNjU2L3RleHRyZWdpb246ZDI1MzcyNGU3MDk5NDIwZWExNmJjNjY4NDcxY2E2NTZfMjk2Mw_4f8e4266-7685-4607-a538-e464b4a90176">&lt;div style="text-indent:11.25pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;BIIB118 Acquisition&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In March 2020 we acquired BIIB118 (formerly known as PF-05251749), a novel CNS-penetrant small molecule inhibitor of casein kinase 1, for the potential treatment of patients with behavioral and neurological symptoms across various psychiatric and neurological diseases from Pfizer Inc. (Pfizer). We plan to develop this Phase 1 asset for the potential treatment of sundowning in Alzheimer's disease and irregular sleep wake rhythm disorder in Parkinson&#x2019;s disease. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In connection with this acquisition, we made an upfront payment of $75.0 million to Pfizer, which was accounted for as an asset acquisition and recorded as acquired in-process research and development (IPR&amp;amp;D) in our condensed consolidated statements of income as BIIB118 has not yet reached technological feasibility. We may also pay Pfizer up to $635.0 million in potential additional development and commercialization milestone payments as well as tiered royalties in the high single digits to sub-teens.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:11.25pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Acquisition of Nightstar Therapeutics plc&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In June 2019 we completed our acquisition of all of the outstanding shares of Nightstar Therapeutics plc (NST), a clinical-stage gene therapy company focused on adeno-associated virus (AAV) treatments for inherited retinal disorders. As a result of this acquisition, we added two mid- to late-stage clinical assets as well as preclinical programs in ophthalmology. These assets include BIIB111 (timrepigene emparvovec), which is in Phase 3 development for the potential treatment of choroideremia, a rare, degenerative, X-linked inherited retinal disorder that leads to blindness and currently has no approved treatments, and BIIB112 (RPGR gene therapy), which is in Phase 2/3 development for the potential treatment of X-linked retinitis pigmentosa, which is a rare inherited retinal disease with no currently approved treatments.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Under the terms of this acquisition, we paid NST shareholders $25.50 in cash for each issued and outstanding NST share, which totaled $847.6 million. In addition, we paid $4.6 million in cash for equity compensation, which is attributable to pre-combination services and was reflected as a component of the total purchase price paid. The fair value of equity compensation attributable to the post-combination service period was $26.2 million, of which $18.4 million was recognized as a charge to selling, general and administrative expense with the remaining $7.8 million as a charge to research and development expense in our condensed consolidated statements of income. These amounts were associated with the accelerated vesting of stock options previously granted to NST employees and were fully paid in cash as of June 30, 2019. We funded this acquisition through available cash and accounted for it as an acquisition of a business. We finalized purchase accounting for this acquisition in the fourth quarter of 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;For additional information on our acquisition of NST, please read &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Note 2, Acquisitions,&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; to our consolidated financial statements included in our 2019 Form 10-K.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i6184d003ca324663b6d44d4425fd9798_D20200301-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM180My9mcmFnOmQyNTM3MjRlNzA5OTQyMGVhMTZiYzY2ODQ3MWNhNjU2L3RleHRyZWdpb246ZDI1MzcyNGU3MDk5NDIwZWExNmJjNjY4NDcxY2E2NTZfNTQ3_6579c5bf-3ae3-41e2-8c99-cbea35dd4513"
      unitRef="usd">75000000.0</us-gaap:ResearchAndDevelopmentInProcess>
    <biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones
      contextRef="i6184d003ca324663b6d44d4425fd9798_D20200301-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM180My9mcmFnOmQyNTM3MjRlNzA5OTQyMGVhMTZiYzY2ODQ3MWNhNjU2L3RleHRyZWdpb246ZDI1MzcyNGU3MDk5NDIwZWExNmJjNjY4NDcxY2E2NTZfODE2_32026869-0a13-4f0e-93e2-db3b39ec2458"
      unitRef="usd">635000000.0</biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones>
    <biib:ClinicalAssetsAcquired
      contextRef="i34259f1058d543a0ab98f22062f2e5ab_D20190601-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM180My9mcmFnOmQyNTM3MjRlNzA5OTQyMGVhMTZiYzY2ODQ3MWNhNjU2L3RleHRyZWdpb246ZDI1MzcyNGU3MDk5NDIwZWExNmJjNjY4NDcxY2E2NTZfMTI4Mw_465f2711-e949-4b8e-ad4a-bbaea837742b"
      unitRef="assets">2</biib:ClinicalAssetsAcquired>
    <us-gaap:BusinessAcquisitionSharePrice
      contextRef="if669468af2b1428fbb2d5e8a25e54053_I20190607"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM180My9mcmFnOmQyNTM3MjRlNzA5OTQyMGVhMTZiYzY2ODQ3MWNhNjU2L3RleHRyZWdpb246ZDI1MzcyNGU3MDk5NDIwZWExNmJjNjY4NDcxY2E2NTZfMTkwMg_497b9cb7-6537-45ef-a8bd-28d21aff7597"
      unitRef="usdPerShare">25.50</us-gaap:BusinessAcquisitionSharePrice>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="iab47d31b221a4694b97e6b5cd3de541b_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM180My9mcmFnOmQyNTM3MjRlNzA5OTQyMGVhMTZiYzY2ODQ3MWNhNjU2L3RleHRyZWdpb246ZDI1MzcyNGU3MDk5NDIwZWExNmJjNjY4NDcxY2E2NTZfMTk3MA_bf31d747-5705-4a4d-bb0d-634f27f276d1"
      unitRef="usd">847600000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:OtherPaymentsToAcquireBusinesses
      contextRef="iab47d31b221a4694b97e6b5cd3de541b_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM180My9mcmFnOmQyNTM3MjRlNzA5OTQyMGVhMTZiYzY2ODQ3MWNhNjU2L3RleHRyZWdpb246ZDI1MzcyNGU3MDk5NDIwZWExNmJjNjY4NDcxY2E2NTZfMTk5NQ_99a0197c-4941-4c57-9b0d-0569c39e7698"
      unitRef="usd">4600000</us-gaap:OtherPaymentsToAcquireBusinesses>
    <us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized
      contextRef="i4ea815a094e741b0a154fa60dcf2c6a5_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM180My9mcmFnOmQyNTM3MjRlNzA5OTQyMGVhMTZiYzY2ODQ3MWNhNjU2L3RleHRyZWdpb246ZDI1MzcyNGU3MDk5NDIwZWExNmJjNjY4NDcxY2E2NTZfMjI0Mg_29a7ae9e-487a-471d-b126-a44defe44f5d"
      unitRef="usd">26200000</us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized>
    <us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized
      contextRef="id3e1580f38914bf3a529df3762a6db10_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM180My9mcmFnOmQyNTM3MjRlNzA5OTQyMGVhMTZiYzY2ODQ3MWNhNjU2L3RleHRyZWdpb246ZDI1MzcyNGU3MDk5NDIwZWExNmJjNjY4NDcxY2E2NTZfMjI1NQ_0d65cc67-6c1c-42cb-b8e9-c078a9481c00"
      unitRef="usd">18400000</us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized>
    <us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized
      contextRef="i6d491f3733874ec68a5451b8128278dd_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM180My9mcmFnOmQyNTM3MjRlNzA5OTQyMGVhMTZiYzY2ODQ3MWNhNjU2L3RleHRyZWdpb246ZDI1MzcyNGU3MDk5NDIwZWExNmJjNjY4NDcxY2E2NTZfMjM1MQ_87f3629e-8c6b-4a4e-80fe-458f842d3b05"
      unitRef="usd">7800000</us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized>
    <us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM180Ni9mcmFnOmViM2ZkM2ZiNWQ5NDQ3Y2U4ODFiZWExYzk3ZDg3MjVmL3RleHRyZWdpb246ZWIzZmQzZmI1ZDk0NDdjZTg4MWJlYTFjOTdkODcyNWZfMzUwOQ_3913c313-73dc-4385-a9bc-ff88c5d78dfe">&lt;div style="text-indent:13.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Divestiture of Hiller&#xf8;d, Denmark Manufacturing Operations &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In March 2019 we entered into a share purchase agreement with FUJIFILM Corporation (FUJIFILM) to sell all of the outstanding shares of our subsidiary that owned our biologics manufacturing operations in Hiller&#xf8;d, Denmark. We determined that the assets and liabilities related to our Hiller&#xf8;d, Denmark manufacturing operations met the criteria to be classified as held for sale. For the nine months ended September 30, 2019, we recorded a loss of approximately $160.2 million in our condensed consolidated statements of income. This estimated loss included a pre-tax loss of $95.5 million, which reflected a $17.7 million decrease to our previously recorded pre-tax loss, reflecting our estimated fair value of the assets and liabilities held for sale as of September 30, 2019, adjusted for our expected costs to sell our Hiller&#xf8;d, Denmark manufacturing operations of approximately $11.2 million and included our initial estimate of the fair value of an adverse commitment of approximately $114.0 million associated with the guarantee of future minimum batch production at the Hiller&#xf8;d facility. The value of this adverse commitment was determined using a probability-weighted estimate of future manufacturing activity. In addition, we recorded a tax expense of $64.7 million related to the transaction during the nine months ended September 30, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In August 2019 this transaction closed and we received approximately $881.9 million in cash, which may be adjusted based on the contractual terms discussed below. We determined that the operations disposed of in this transaction did not meet the criteria to be classified as discontinued operations under the applicable guidance.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As part of this transaction, we provided FUJIFILM with certain minimum batch production commitment guarantees. There is a risk that the minimum contractual batch production commitments will not be met. Our estimate of the adverse commitment obligation is approximately $74.0 million as of September 30, 2020 and December 31, 2019. We developed this estimate using a probability-weighted estimate of future manufacturing activity and may adjust this estimate based upon changes in business conditions, which may result in the increase or reduction of this adverse commitment obligation in subsequent periods. We also may be obligated to indemnify FUJIFILM for liabilities that existed relating to certain business activities incurred prior to the closing of this transaction. Our estimate of the fair value of the adverse commitment obligation is a Level 3 measurement and is based on forecasted batch production at the Hiller&#xf8;d facility.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In addition, we may earn certain contingent payments based on future manufacturing activities at the Hiller&#xf8;d facility. For the disposition of a business, our policy is to recognize contingent consideration when the consideration is realizable. Consistent with our assessment as of the transaction date, we currently believe the probability of earning these payments is remote and therefore we did not include these contingent payments in our calculation of the fair value of the operations.&lt;/span&gt;&lt;/div&gt;As part of this transaction, we entered into certain manufacturing services agreements with FUJIFILM pursuant to which FUJIFILM will use the Hiller&#xf8;d facility to produce commercial products for us, such as TYSABRI, as well as other third-party products. In addition, we sold to FUJIFILM $41.8 million of raw materials that were remaining at the Hiller&#xf8;d facility on the closing date of this transaction in the third quarter of 2019. These materials were sold at cost, which approximated fair value.</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
    <us-gaap:DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax
      contextRef="i54fe6174a2224b379d4a176d7fd82015_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM180Ni9mcmFnOmViM2ZkM2ZiNWQ5NDQ3Y2U4ODFiZWExYzk3ZDg3MjVmL3RleHRyZWdpb246ZWIzZmQzZmI1ZDk0NDdjZTg4MWJlYTFjOTdkODcyNWZfNTE0_44e62935-ce54-4130-a7c4-61876d8243e9"
      unitRef="usd">160200000</us-gaap:DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax>
    <us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown
      contextRef="i54fe6174a2224b379d4a176d7fd82015_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM180Ni9mcmFnOmViM2ZkM2ZiNWQ5NDQ3Y2U4ODFiZWExYzk3ZDg3MjVmL3RleHRyZWdpb246ZWIzZmQzZmI1ZDk0NDdjZTg4MWJlYTFjOTdkODcyNWZfNjE2_0e90593d-f372-4743-92b2-df537e3b821f"
      unitRef="usd">95500000</us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown>
    <us-gaap:DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax
      contextRef="i6d14771766d1415790d98b0c80aaa2eb_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM180Ni9mcmFnOmViM2ZkM2ZiNWQ5NDQ3Y2U4ODFiZWExYzk3ZDg3MjVmL3RleHRyZWdpb246ZWIzZmQzZmI1ZDk0NDdjZTg4MWJlYTFjOTdkODcyNWZfNjM4_e3320d1b-58c4-4dd5-9cef-08771f518cc5"
      unitRef="usd">17700000</us-gaap:DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense
      contextRef="i6d14771766d1415790d98b0c80aaa2eb_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM180Ni9mcmFnOmViM2ZkM2ZiNWQ5NDQ3Y2U4ODFiZWExYzk3ZDg3MjVmL3RleHRyZWdpb246ZWIzZmQzZmI1ZDk0NDdjZTg4MWJlYTFjOTdkODcyNWZfODkx_e9f7c25c-7798-4ce8-863f-760efe3e7a8b"
      unitRef="usd">11200000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense>
    <us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted
      contextRef="ic1329de1cf194c709a3e6e578b701fb5_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM180Ni9mcmFnOmViM2ZkM2ZiNWQ5NDQ3Y2U4ODFiZWExYzk3ZDg3MjVmL3RleHRyZWdpb246ZWIzZmQzZmI1ZDk0NDdjZTg4MWJlYTFjOTdkODcyNWZfOTg4_37e51106-9043-41db-8056-b7634e95bdbb"
      unitRef="usd">114000000.0</us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted>
    <us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation
      contextRef="ie4528167bcf941dbb3558a86eed5211c_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM180Ni9mcmFnOmViM2ZkM2ZiNWQ5NDQ3Y2U4ODFiZWExYzk3ZDg3MjVmL3RleHRyZWdpb246ZWIzZmQzZmI1ZDk0NDdjZTg4MWJlYTFjOTdkODcyNWZfMTI0OA_1fe7605c-fdaa-4ca0-ba79-bb1bd49bdb6b"
      unitRef="usd">64700000</us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration
      contextRef="i3413eeb6a8594eb7bd9a9895a6a44b36_I20190801"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM180Ni9mcmFnOmViM2ZkM2ZiNWQ5NDQ3Y2U4ODFiZWExYzk3ZDg3MjVmL3RleHRyZWdpb246ZWIzZmQzZmI1ZDk0NDdjZTg4MWJlYTFjOTdkODcyNWZfMTM4NQ_bf7cce42-bd0a-4f5c-870c-8f79d88a5801"
      unitRef="usd">881900000</us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration>
    <us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted
      contextRef="i8fb970353ed64398943d0ed1643a7bcb_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM180Ni9mcmFnOmViM2ZkM2ZiNWQ5NDQ3Y2U4ODFiZWExYzk3ZDg3MjVmL3RleHRyZWdpb246ZWIzZmQzZmI1ZDk0NDdjZTg4MWJlYTFjOTdkODcyNWZfMTkwMw_da760c9d-7f3a-4623-87be-33a6cccf8ba3"
      unitRef="usd">74000000.0</us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted>
    <biib:InventoryrawmaterialssoldtoFUJIFILM
      contextRef="i174c6f6dc0974a4a9f1635f5f4a03baf_I20190801"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM180Ni9mcmFnOmViM2ZkM2ZiNWQ5NDQ3Y2U4ODFiZWExYzk3ZDg3MjVmL3RleHRyZWdpb246ZWIzZmQzZmI1ZDk0NDdjZTg4MWJlYTFjOTdkODcyNWZfMzMwOQ_0c7a9907-06ae-4d90-8fb4-b38af0382525"
      unitRef="usd">41800000</biib:InventoryrawmaterialssoldtoFUJIFILM>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RleHRyZWdpb246YjUxMDhlMTQ5MTIxNGEyOGE1MWY0ZTljMWQ1NzM2NTVfMjc2OA_54853466-0f89-4853-86d0-81696e1c5a19">&lt;div style="text-indent:13.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#2472b9;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Product Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Revenues by product are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:31.550%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.441%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.295%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.441%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.295%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.441%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.445%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="33" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;United&lt;br/&gt;States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Rest of&lt;br/&gt;World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;United&lt;br/&gt;States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Rest of&lt;br/&gt;World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Multiple Sclerosis (MS):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fumarate*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;684.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;283.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;967.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;842.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;280.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,122.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Interferon**&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;327.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;146.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;474.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;360.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;169.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;530.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;TYSABRI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;304.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;212.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;516.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;263.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;220.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;483.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;FAMPYRA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;26.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;26.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;24.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;24.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Subtotal: MS product revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;1,315.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;669.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;1,984.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,465.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;694.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,160.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Spinal Muscular Atrophy:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;SPINRAZA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;182.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;311.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;494.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;236.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;310.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;547.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Biosimilars:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;BENEPALI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;124.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;124.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;115.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;115.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;IMRALDI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;56.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;56.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;49.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;49.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;FLIXABI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;27.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;27.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;18.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;18.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Subtotal: Biosimilar product revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;207.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;207.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;183.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;183.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;FUMADERM&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total product revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;1,498.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;1,192.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;2,690.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,702.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,192.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,894.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:33.017%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:31.105%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:32.578%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;"&gt;*Fumarate includes TECFIDERA and VUMERITY. VUMERITY became commercially available in the U.S. in November 2019.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;"&gt;**Interferon includes AVONEX and PLEGRIDY.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:31.300%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.536%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.503%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.536%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.356%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.536%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.356%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.536%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.356%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.536%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.503%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.536%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.510%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="33" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;United&lt;br/&gt;States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Rest of&lt;br/&gt;World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;United&lt;br/&gt;States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Rest of&lt;br/&gt;World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Multiple Sclerosis (MS):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fumarate*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;2,383.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;875.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;3,258.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,429.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;841.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,271.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Interferon**&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;965.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;456.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;1,421.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,067.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;518.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,585.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;TYSABRI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;826.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;644.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;1,470.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;772.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;647.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,419.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;FAMPYRA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;78.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;78.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;71.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;71.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Subtotal: MS product revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;4,174.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;2,054.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;6,229.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,269.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,078.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,347.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Spinal Muscular Atrophy:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;SPINRAZA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;628.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;925.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;1,554.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;690.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;863.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,553.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Biosimilars:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;BENEPALI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;363.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;363.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;360.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;360.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;IMRALDI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;162.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;162.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;132.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;132.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;FLIXABI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;71.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;71.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;49.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;49.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Subtotal: Biosimilar product revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;598.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;598.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;542.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;542.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;FUMADERM&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;9.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;9.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total product revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;4,803.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;3,587.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;8,390.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,959.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,495.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,455.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:33.017%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:31.105%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:32.578%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;"&gt;*Fumarate includes TECFIDERA and VUMERITY. VUMERITY became commercially available in the U.S. in November 2019.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;"&gt;**Interferon includes AVONEX and PLEGRIDY.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We recognized revenues from two wholesalers accounting for 31.2% and 15.6% of gross product revenues for the three months ended September 30, 2020, and 30.9% and 16.0% of gross product revenues for the nine months ended September 30, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We recognized revenues from two wholesalers accounting for 28.7% and 18.4% of gross product revenues for the three months ended September 30, 2019, and 30.1% and 17.0% of gross product revenues for the nine months ended September 30, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;An analysis of the change in reserves for discounts and allowances is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:47.155%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.526%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.109%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.526%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.109%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.526%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.109%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.526%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.114%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Discounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Contractual&lt;br/&gt;Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance, December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;131.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;1,027.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;40.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;1,198.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Current provisions relating to sales in current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;589.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;2,465.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;14.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;3,070.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Adjustments relating to prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(41.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(40.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Payments/credits relating to sales in current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(457.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(1,704.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(2,162.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Payments/credits relating to sales in prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(120.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(658.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(15.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(794.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance, September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;141.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;1,088.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;41.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;1,271.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The total reserves above, which are included in our condensed consolidated balance sheets, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:65.808%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.525%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.720%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.525%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.722%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;As of September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Reduction of accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;227.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;197.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Component of accrued expenses and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;1,043.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,001.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total revenue-related reserves&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;1,271.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,198.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:13.5pt;margin-top:7pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#2472b9;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Revenues from Anti-CD20 Therapeutic Programs&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Revenues from anti-CD20 therapeutic programs are summarized below. For the purposes of this footnote we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:49.338%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.595%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.595%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.595%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.603%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Biogen&#x2019;s share of pre-tax profits in the U.S. for RITUXAN and GAZYVA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;275.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;393.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;873.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,161.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other revenues from anti-CD20 therapeutic programs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;285.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;202.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;685.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;528.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total revenues from anti-CD20 therapeutic programs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;560.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;595.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;1,558.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,689.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;padding-right:2.25pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;For additional information on our collaboration arrangements with Genentech, please read &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Note 18,&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Collaborative and Other Relationships, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;to our consolidated financial statements included in our 2019 Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:13.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#2472b9;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Other Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Other revenues are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:49.192%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.595%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.595%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.595%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.603%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Revenues from collaborative and other relationships:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Profit (loss) earned under our 50% share of the co-promotion losses on ZINBRYTA in the U.S. with AbbVie Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Revenues earned under our technical development agreement, manufacturing services agreements and royalty revenues on biosimilar products with Samsung Bioepis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;13.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;89.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other royalty and corporate revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Royalty&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;10.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;28.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;110.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;93.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;599.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;462.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;125.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;109.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;642.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;562.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;During the third quarter of 2019, we amended our agreement with a contract manufacturing customer pursuant to which we licensed certain of our manufacturing-related intellectual property to the customer. In the second quarter of 2020, the customer received regulatory approval for its product that is being manufactured using certain of our manufacturing-related intellectual property. As a result, we are entitled to $500.0 million in a series of three payments. The first payment became due upon regulatory approval of such product and was received during the second quarter of 2020. Subsequent payments are due on the first and second anniversaries of the regulatory approval. &lt;/span&gt;&lt;/div&gt;Other corporate revenues for the nine months ended September 30, 2020, reflect $333.2 million related to the delivery of the license for certain of our manufacturing-related intellectual property under the amended agreement discussed above and the performance of manufacturing product supply services for such customer. We have allocated the remaining $166.8&#160;million of the $500.0 million transaction price to the performance of manufacturing product supply services for the customer, which we expect to perform through 2026. The value allocated to the manufacturing services was based on expected demand for supply and the fair value of comparable manufacturing and development services.</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RleHRyZWdpb246YjUxMDhlMTQ5MTIxNGEyOGE1MWY0ZTljMWQ1NzM2NTVfMjc0NQ_bc71c15c-916a-4b45-8ced-05d7b1cb8aca">&lt;div style="text-indent:22.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Revenues by product are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:31.550%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.441%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.295%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.441%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.295%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.441%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.445%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="33" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;United&lt;br/&gt;States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Rest of&lt;br/&gt;World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;United&lt;br/&gt;States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Rest of&lt;br/&gt;World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Multiple Sclerosis (MS):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fumarate*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;684.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;283.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;967.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;842.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;280.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,122.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Interferon**&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;327.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;146.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;474.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;360.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;169.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;530.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;TYSABRI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;304.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;212.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;516.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;263.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;220.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;483.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;FAMPYRA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;26.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;26.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;24.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;24.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Subtotal: MS product revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;1,315.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;669.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;1,984.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,465.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;694.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,160.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Spinal Muscular Atrophy:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;SPINRAZA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;182.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;311.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;494.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;236.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;310.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;547.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Biosimilars:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;BENEPALI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;124.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;124.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;115.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;115.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;IMRALDI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;56.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;56.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;49.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;49.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;FLIXABI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;27.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;27.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;18.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;18.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Subtotal: Biosimilar product revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;207.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;207.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;183.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;183.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;FUMADERM&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total product revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;1,498.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;1,192.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;2,690.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,702.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,192.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,894.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:33.017%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:31.105%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:32.578%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;"&gt;*Fumarate includes TECFIDERA and VUMERITY. VUMERITY became commercially available in the U.S. in November 2019.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;"&gt;**Interferon includes AVONEX and PLEGRIDY.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:31.300%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.536%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.503%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.536%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.356%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.536%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.356%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.536%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.356%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.536%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.503%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.536%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.510%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="33" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;United&lt;br/&gt;States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Rest of&lt;br/&gt;World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;United&lt;br/&gt;States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Rest of&lt;br/&gt;World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Multiple Sclerosis (MS):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fumarate*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;2,383.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;875.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;3,258.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,429.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;841.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,271.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Interferon**&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;965.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;456.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;1,421.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,067.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;518.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,585.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;TYSABRI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;826.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;644.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;1,470.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;772.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;647.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,419.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;FAMPYRA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;78.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;78.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;71.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;71.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Subtotal: MS product revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;4,174.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;2,054.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;6,229.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,269.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,078.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,347.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Spinal Muscular Atrophy:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;SPINRAZA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;628.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;925.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;1,554.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;690.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;863.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,553.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Biosimilars:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;BENEPALI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;363.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;363.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;360.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;360.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;IMRALDI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;162.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;162.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;132.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;132.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;FLIXABI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;71.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;71.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;49.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;49.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Subtotal: Biosimilar product revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;598.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;598.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;542.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;542.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;FUMADERM&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;9.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;9.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total product revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;4,803.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;3,587.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;8,390.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,959.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,495.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,455.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:33.017%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:31.105%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:32.578%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;"&gt;*Fumarate includes TECFIDERA and VUMERITY. VUMERITY became commercially available in the U.S. in November 2019.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;"&gt;**Interferon includes AVONEX and PLEGRIDY.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:Revenues
      contextRef="idb5da4324a084eefaa4d376d025b0d68_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfNC0yLTEtMS0w_5337013c-fe10-40ee-9700-1e1cb0757a42"
      unitRef="usd">684200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibe88801f13d247f899ec696c93dcc2e6_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfNC00LTEtMS0w_de3c8da3-88b0-4d4f-b61b-ca8c13e611fd"
      unitRef="usd">283300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1b5da4a47c7b46c7a859d909b06ba52c_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfNC02LTEtMS0w_2e479b9a-325b-4537-b5a7-258d47edb363"
      unitRef="usd">967500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia341fbfc92d14c558a2c51805e16e967_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfNC04LTEtMS0w_2f021d61-960b-45d2-b245-c680063f4c00"
      unitRef="usd">842000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6fb54144d66b439881fcd02918e4cdeb_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfNC0xMC0xLTEtMA_273ea71f-462f-4383-8751-3ab1ed2a1e5d"
      unitRef="usd">280400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5c3d302ecd604f7a8d735759d694817a_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfNC0xMi0xLTEtMA_4797de36-bcc7-403a-a68e-ce05abcb012d"
      unitRef="usd">1122400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id616d991f56748438a8ba16f0137aa36_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfNS0yLTEtMS0w_287d865f-e40c-4f29-8dfc-efa1e5d1b245"
      unitRef="usd">327300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3dbbc7fb0ad74d068c127681fec0fc62_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfNS00LTEtMS0w_49317887-5d60-4210-b111-3657d5addd27"
      unitRef="usd">146800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8a70003485d4486a9bb6430b519901d8_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfNS02LTEtMS0w_72768ea4-465f-4dfe-8997-0b3e0e8e38ea"
      unitRef="usd">474100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i235abb80d0f443cf952612f002c4c724_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfNS04LTEtMS0w_4b48117a-d7e2-4f60-b4d1-a5810536c016"
      unitRef="usd">360300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic1773b37e68f4ca98e29d05e4707727d_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfNS0xMC0xLTEtMA_b4e5ecc4-8f89-43fe-ab13-7dd47e2b9028"
      unitRef="usd">169700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if638579a7e1847469ac17a832271d4d7_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfNS0xMi0xLTEtMA_f837bc8a-2ec2-4573-9295-8770ed7e768a"
      unitRef="usd">530000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0b652f2150604dc6a33be4ae69220a56_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfNi0yLTEtMS0w_86860c95-b6b5-4009-9dc8-1998114d7cca"
      unitRef="usd">304200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i90806ea38d7543f29e6a6e61337fe595_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfNi00LTEtMS0w_21517f33-3bb6-4bbc-8835-be0297253641"
      unitRef="usd">212300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icea39709b7b1472aa5dd7f44966c0bd3_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfNi02LTEtMS0w_36e989a2-be39-406c-98f6-b80e3e63b885"
      unitRef="usd">516500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9f9d582c0e524991ad24725e61b062b5_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfNi04LTEtMS0w_22dca09d-2d36-47e7-b04e-55c486e3c0ca"
      unitRef="usd">263000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if85e43e3e237494fa32864c3adac50a1_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfNi0xMC0xLTEtMA_ee127854-e83c-474c-969e-816470b5d133"
      unitRef="usd">220600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic408b141d6a24355afe175433eb9135f_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfNi0xMi0xLTEtMA_d3a7eec5-b058-4186-a09a-0b5d12fb57d8"
      unitRef="usd">483600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1323f4a6c7eb4aae984b38b19c87c5bf_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfNy0yLTEtMS0w_8f0dc8b0-c4c5-4db0-a367-39b57481a804"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifaaa9079f60b4098abc8790d9255ab3e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfNy00LTEtMS0w_6748629c-a554-434e-a061-b7d99e0805d8"
      unitRef="usd">26800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i68159e373219432e9ceeac5ce7c38c52_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfNy02LTEtMS0w_d4036858-1ad9-4edb-b772-0ac59a15ade4"
      unitRef="usd">26800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5e0133306cc04c65928c989a2d2dbb45_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfNy04LTEtMS0w_a1abbf29-5da2-4407-9c5a-abc7a798e0fc"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if5a5e0e77dd24eab8c07703f6d5e5414_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfNy0xMC0xLTEtMA_2bcbcb09-d71d-4038-aa62-8a4094449b29"
      unitRef="usd">24200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i742235d37c1342388624cde1c677f04b_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfNy0xMi0xLTEtMA_61fd2800-e4b8-46cf-98bf-286c997455cd"
      unitRef="usd">24200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2a33b9fd26694109b63c4f4ba7b7a6e1_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfOC0yLTEtMS0w_c86ae287-bbbf-4ad8-934f-2d43f68911db"
      unitRef="usd">1315700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic87d9b72e03d47c7a87c74570147c7e8_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfOC00LTEtMS0w_e162f1a3-f10a-4c41-b798-73fe8066686b"
      unitRef="usd">669200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iba79677927674335a48059dc861147c5_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfOC02LTEtMS0w_0e2178c2-1c5f-4b28-9abf-f7fe67bd2887"
      unitRef="usd">1984900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idd282900956142e1a6ef766e0cb49611_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfOC04LTEtMS0w_74f30562-cd55-417d-9752-974d925b88d8"
      unitRef="usd">1465300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4610f1a14c034cb19b7366512e904c92_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfOC0xMC0xLTEtMA_4b389a35-373e-49dd-bea9-f726ca3ff85b"
      unitRef="usd">694900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i134d08fbd1ff45239e991114f841a948_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfOC0xMi0xLTEtMA_61e60ea5-647a-4efa-b0dd-3d51b3eb765a"
      unitRef="usd">2160200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i782a7c4ac90845f09d932b45511ff216_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfMTEtMi0xLTEtMA_5efc850b-2a44-45f4-9bd2-5810627daf6d"
      unitRef="usd">182500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if924a82037ba40d288c2ebf03d3f886f_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfMTEtNC0xLTEtMA_7690a719-c03c-4aaf-88e5-01dcb4fa9d02"
      unitRef="usd">311900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i64ff52eeaaa44fe1942f08bef012563e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfMTEtNi0xLTEtMA_036206b0-ee8c-4f2c-95cf-89b1374794c0"
      unitRef="usd">494400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibc93740adfba43e48aeb5c07582509ad_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfMTEtOC0xLTEtMA_3d6d6406-ed1f-48fa-864c-4c5a2028c367"
      unitRef="usd">236700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib5dfd6a6fcaa4743b33d7010ee60257f_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfMTEtMTAtMS0xLTA_ebbc8066-1282-4207-9a71-d3ddbf595e36"
      unitRef="usd">310400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i71c758edfcc041a19e3af23d14f9b3a5_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfMTEtMTItMS0xLTA_dbdd3155-42ad-4c0a-a245-1447149ea8e8"
      unitRef="usd">547100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0a383eb4ffb0459e920cfd44b9b19f2b_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfMTQtMi0xLTEtMA_fbae59aa-bd52-40f4-b36e-d43982452aaa"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id87093f8e357449d9e8705f5c6ccc183_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfMTQtNC0xLTEtMA_6b62a80b-91af-4d08-8f46-1e178095658b"
      unitRef="usd">124200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icdcc3e6db10041c6adfb46ab9cc43d52_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfMTQtNi0xLTEtMA_efe98a49-20e2-46f5-b60d-46630af7af46"
      unitRef="usd">124200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id5469abafd1f421d8fce4ea54f1ec77b_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfMTQtOC0xLTEtMA_bc9af353-5c4d-49c7-b0e7-8a2b9f547ff1"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i746432e17705462ea58e77a00bb3a93e_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfMTQtMTAtMS0xLTA_6615b13a-54c7-4b10-96e8-3062b26fb2c7"
      unitRef="usd">115900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic7f7847bbcdf4347bcaa5531ac1b24ef_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfMTQtMTItMS0xLTA_c996785a-c461-4bcd-9631-b0d0aa889021"
      unitRef="usd">115900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i010f4a93398d4bb4b566cd786299c56e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfMTUtMi0xLTEtMA_0da79ea8-f46f-4029-a20e-26c64bbeff3e"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6d23abb471e04139a7badc923a7aa0b0_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfMTUtNC0xLTEtMA_4501a78e-37db-4eda-94b3-18c8b9da1497"
      unitRef="usd">56200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2b01d577ab7e4e2faf2a58cdd2703267_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfMTUtNi0xLTEtMA_620a9082-a64c-405e-8dcc-840da1aba85a"
      unitRef="usd">56200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if30fd82eecb5426b92a98a3e3fefe6f5_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfMTUtOC0xLTEtMA_d8e6e181-daa4-4582-92a4-2248c7fd5453"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i116d706a2f374c48861e85f661a21b25_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfMTUtMTAtMS0xLTA_4ddcfe87-86ff-4021-9046-e62575818016"
      unitRef="usd">49300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if9a7e5c89d394125ac728a112ab5ff87_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfMTUtMTItMS0xLTA_28ab43e5-192f-4ada-bcad-7deacffe0b65"
      unitRef="usd">49300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i56b36d0e49d840c1bb93b2c87291791d_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfMTYtMi0xLTEtMA_213748c5-7617-4086-b138-1e960fa3f351"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ief040210ae2c41fdad968514993484a7_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfMTYtNC0xLTEtMA_0b1d7e95-7ac6-4761-a282-405ff8b628a5"
      unitRef="usd">27500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5f8fe94c6208475b8bc2f93cb71a7939_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfMTYtNi0xLTEtMA_1b88d782-e0b9-4757-9a93-a2aff8acc91f"
      unitRef="usd">27500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i48f53b5d6fc04defad6638974299bc5b_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfMTYtOC0xLTEtMA_bec99bd2-149a-4b2f-8a22-12529b66230f"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5971788b43b64613b60ad9eb48951064_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfMTYtMTAtMS0xLTA_9624d40e-235d-45cd-bac4-e6af4ea3378c"
      unitRef="usd">18400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib8eb6906d8f14c4cb3001d7cfc2f6447_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfMTYtMTItMS0xLTA_841d332a-3f4c-494c-bb3e-c666d202783c"
      unitRef="usd">18400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i108b8c9cd74844ea902eb45e12f344d4_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfMTctMi0xLTEtMA_77bce617-93d6-4aa5-b043-d45f65931515"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i492d4f74b2774d46ba24d8836488319c_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfMTctNC0xLTEtMA_28ef42bb-2c2d-451a-98d4-5cd7061f5c19"
      unitRef="usd">207900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i04f6a02314ae4524973688bb453aa3e5_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfMTctNi0xLTEtMA_69a57231-1cdb-44c3-8de4-8a3bec05ab2b"
      unitRef="usd">207900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7a8274402a6247b58947c615cddc6683_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfMTctOC0xLTEtMA_3132f738-48f0-45b7-b407-22cab17a4e9f"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4f5d0029574e4134a8a64eeb2a84b092_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfMTctMTAtMS0xLTA_038500db-9cad-42a5-a519-f5d051bc9238"
      unitRef="usd">183600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibd1e83f10a674384b5a5c22e4838bf7e_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfMTctMTItMS0xLTA_e7055e42-29fc-459c-b0e1-a938db9d5484"
      unitRef="usd">183600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7e2a3e2e67994b33aa594e6685bfb7a1_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfMjAtMi0xLTEtMA_ddf0c701-a131-4c2e-8cfe-b2a2b844eff4"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i83b0b2c0884c4420b9ec2c69e43f3b5b_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfMjAtNC0xLTEtMA_d7ccf418-86e7-4a75-9908-d4f1da5fde65"
      unitRef="usd">3100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5887fc680fe24fb89317ffa45e0e7399_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfMjAtNi0xLTEtMA_11666f8a-9863-489d-92cb-84a84b24062f"
      unitRef="usd">3100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib6b4fdc531a146d8b6ab0e3b3a410bb0_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfMjAtOC0xLTEtMA_0a07f88c-52b4-4faf-9f5b-abf28359bbe0"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if2c497aaf27546a396c0c89e2d199e5d_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfMjAtMTAtMS0xLTA_ae4fb1aa-a46a-437d-bc56-82c233c39c80"
      unitRef="usd">3800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i03858b8f5bce44fca9ffdbe13c9eb5e2_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfMjAtMTItMS0xLTA_75e4b40f-1660-4970-867e-2111d71c6fd1"
      unitRef="usd">3800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i82ddc3d73c6440f6b67ce2997a135a27_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfMjEtMi0xLTEtMA_de59c3bb-1566-4a74-8212-18641c86ecef"
      unitRef="usd">1498200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i537d78dad03f4414a8201cf28d6fb744_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfMjEtNC0xLTEtMA_0a8e6760-f6f4-486a-b8c9-f22b17dfc11a"
      unitRef="usd">1192100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iba1a633773a34c899b77b4853a665d4e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfMjEtNi0xLTEtMA_8d0bb1a5-c246-469e-a606-a57f6678f3d3"
      unitRef="usd">2690300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i27f454fe7d384ff6b0419771f9b3e2d6_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfMjEtOC0xLTEtMA_f9789120-aee4-4824-95e7-74e5ecdc951b"
      unitRef="usd">1702000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie5915a0ecdc446c396b8a751ccb2cb15_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfMjEtMTAtMS0xLTA_b8ac4026-0e46-4606-81ea-2aacab404f03"
      unitRef="usd">1192700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i817821ea916346a6b301c5912257c3e5_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmVjOWYwNmZlZjExZTRjNWFhNTgwZmRjN2NkYmYxZGU2L3RhYmxlcmFuZ2U6ZWM5ZjA2ZmVmMTFlNGM1YWE1ODBmZGM3Y2RiZjFkZTZfMjEtMTItMS0xLTA_a15bc43b-81bd-4ee1-a318-3a40d61d4f86"
      unitRef="usd">2894700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic542c97609834568beaf236a66f61e73_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfNC0yLTEtMS0w_a79ec1e3-7e1b-4a03-8103-5e3ae57a83ad"
      unitRef="usd">2383400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i54cede8da6804f35aad2512972cfec7d_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfNC00LTEtMS0w_4cecb44b-f073-40d0-8176-7d60d7ffc68f"
      unitRef="usd">875200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3fb38646d08e44f09e679dc53de54e79_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfNC02LTEtMS0w_a55f5262-3678-41fd-bb91-1e22d00f6176"
      unitRef="usd">3258600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i49af2b0ec0f64a17a1c3f06e8918b239_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfNC04LTEtMS0w_40c8db2f-cb20-411f-9bfe-abf8384470a6"
      unitRef="usd">2429500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i578fc5ffb2e64484b3d17b8c6505e6fe_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfNC0xMC0xLTEtMA_a3afd63c-9b02-42d6-bb25-ca6a8c079e71"
      unitRef="usd">841900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icec0afd4985d4eebbcb6d942dc11861c_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfNC0xMi0xLTEtMA_3680a982-c815-4ebd-91e1-72c951ba7ddf"
      unitRef="usd">3271400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifff8a50ada4a4480aa27d7e429483ebc_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfNS0yLTEtMS0w_55eb0ce5-3474-4fb0-86b4-d6b32c32d3f5"
      unitRef="usd">965500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5ebf452657754a04b75cb22245331331_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfNS00LTEtMS0w_2f8c372f-f92f-438b-8d17-5777f9d815a7"
      unitRef="usd">456000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i97559f8bfad646f4a63f6e7d1de603b3_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfNS02LTEtMS0w_558854fc-0b52-4c52-8e63-819a4baf067b"
      unitRef="usd">1421500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia54121683d93464386861f04a5eb0f78_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfNS04LTEtMS0w_766bbfea-17ea-4757-91d7-4ec2eb60154d"
      unitRef="usd">1067300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i58ceddab404b43efbc2aa182802d7e90_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfNS0xMC0xLTEtMA_1998b27e-611f-4b16-8331-2fc09f92c803"
      unitRef="usd">518000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8ff9cdd4f3124c71923b611c196ff399_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfNS0xMi0xLTEtMA_749e910f-67ec-413c-92e5-760314cb9d06"
      unitRef="usd">1585300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i55c11d8111cc47e5b6fd6668e6688ebc_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfNi0yLTEtMS0w_df6f713d-b388-47f4-a231-dc579fda1290"
      unitRef="usd">826000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i811b94cd1a9a4cdfa735283523ef7c2f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfNi00LTEtMS0w_e49c512a-3935-451b-bf14-d2ce1e24e3fc"
      unitRef="usd">644900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iba49923c2dbc4cfa9e28cd6dc0232817_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfNi02LTEtMS0w_74fbdd7a-813b-4b37-9b23-2568eeca22f1"
      unitRef="usd">1470900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iaf55884ad575429cb3318dba7371b6ba_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfNi04LTEtMS0w_a796d1d8-5140-471b-9430-4732513bf3aa"
      unitRef="usd">772300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2050ec4e36ba486eaaa52e2629f9eb4d_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfNi0xMC0xLTEtMA_92e67231-dbfc-4fa2-b296-132739c21bc1"
      unitRef="usd">647000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifa6b881f2fda4822952ca375ff987144_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfNi0xMi0xLTEtMA_237a96ea-3057-48a0-a49c-7daccfb3bbda"
      unitRef="usd">1419300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ica095eed2ba44dae9950be250f7d8e18_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfNy0yLTEtMS0w_2ec18baf-ddf7-4820-b198-09e798e3efce"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id65392444eb84d778e3da80dd59cb0ee_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfNy00LTEtMS0w_9522fb52-ec8e-4c44-9332-42a4280d0167"
      unitRef="usd">78100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6c5c5deb248640ea8a5b2acc2c061165_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfNy02LTEtMS0w_feae3b86-4422-4025-83cf-4bda99728f4f"
      unitRef="usd">78100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i45096669722b441a88f0da5da92b8c28_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfNy04LTEtMS0w_aafae3e4-7f33-4eab-92d7-90e9ca772148"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifb862d5227ae4e258ddf1674e35ea488_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfNy0xMC0xLTEtMA_5cecac5c-7289-435e-a9a5-e4eb3b1eb948"
      unitRef="usd">71200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3ebacf9f9e6841c3af9fbbaef43f7942_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfNy0xMi0xLTEtMA_c75c01e3-2745-47e1-ac34-303b8aee4247"
      unitRef="usd">71200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if9481c82cb20488b9ef66d6125fd47af_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfOC0yLTEtMS0w_40c45c9c-8a30-46ce-94e1-5cfc677569d0"
      unitRef="usd">4174900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib0c82a598d09477ca3061b0c8ac0da77_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfOC00LTEtMS0w_2376c882-5c4d-4b6f-865d-d75396fcb42a"
      unitRef="usd">2054200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib99c15bafed34bf3a271edd3287e7b03_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfOC02LTEtMS0w_832b3863-b622-4f80-8775-2d3906aa5b33"
      unitRef="usd">6229100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iabb34cdf00c04963ad7af011adaf7ae7_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfOC04LTEtMS0w_8779d56f-1a14-48fe-94e8-5dd66ce3e666"
      unitRef="usd">4269100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7ac22170fd834262ac66fc712062e281_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfOC0xMC0xLTEtMA_731f23fc-e426-4611-bc3a-7c0dd8d86221"
      unitRef="usd">2078100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iffe091a9dada4645a5db26663b970d61_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfOC0xMi0xLTEtMA_2afa12d6-8a95-47b7-8b58-4e8f4ca9a8d1"
      unitRef="usd">6347200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia7271f995472417c88ca939ff891ec17_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfMTEtMi0xLTEtMA_bb74d0b2-4127-4f57-9c9a-df580e24cfb1"
      unitRef="usd">628200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i24db87c55fa5436c82745477f49e8563_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfMTEtNC0xLTEtMA_7697b437-f0c0-4b10-99e7-180f69b058f6"
      unitRef="usd">925800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i327b2bcbf1a6442493e173a2baeab0c8_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfMTEtNi0xLTEtMA_b88ef3a5-e00f-4622-a84c-afcef6e05062"
      unitRef="usd">1554000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i824479af0d2943a7a9ec0c36b60267a7_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfMTEtOC0xLTEtMA_8baf21b7-9f84-40ac-bbaa-b26b692acb49"
      unitRef="usd">690600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id0ec100b681943e69c7c792eab6be4a9_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfMTEtMTAtMS0xLTA_6fccfe02-1260-4f6a-b759-4debf86511c2"
      unitRef="usd">863200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if5f44218395d4becae44e95c8c6bdf51_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfMTEtMTItMS0xLTA_aa7246e4-ba68-407f-b7ce-774aebdb72a4"
      unitRef="usd">1553800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib81a7f97279a40f9a38ad04e204987e3_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfMTQtMi0xLTEtMA_78b7bb64-43f1-495a-af87-f14cbaa96226"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib7068d1546c040608d8c969370cd8e9d_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfMTQtNC0xLTEtMA_ed8d5d39-2ed6-4387-8806-3a7b1d0219a4"
      unitRef="usd">363900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7bb0ccb59cdd4f0083748543233c3b52_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfMTQtNi0xLTEtMA_9c07a100-0dc0-439c-91cf-d75245864289"
      unitRef="usd">363900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7cadb5f8f65e4e73949863a5024f4ff7_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfMTQtOC0xLTEtMA_840bf836-6cfe-4200-b050-c167c48c9457"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia8919ebc1037469d9bed32fa8eec69dc_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfMTQtMTAtMS0xLTA_90f7651b-204a-4ba3-a1c0-cd5999fad2a4"
      unitRef="usd">360200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icee51ed1fdbc42b88487b41b6379cf78_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfMTQtMTItMS0xLTA_ec052f0b-8b8d-42c6-bfb5-4a09c8d76e73"
      unitRef="usd">360200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0f6da514a21b4672a427de97a1d05efb_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfMTUtMi0xLTEtMA_5681c1e6-57e4-471b-9800-49a169f18940"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7ca4c818e3ae4c34bae274600ab49c11_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfMTUtNC0xLTEtMA_b05047c3-ded8-4e6d-b9f1-f470bd5ada71"
      unitRef="usd">162600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia4c89150d9234c61910e3033151c6c58_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfMTUtNi0xLTEtMA_2ceec17a-f394-43eb-8dcb-9c33114c0dd6"
      unitRef="usd">162600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i18ff182dc2fa4ee6a2478c6486ebc688_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfMTUtOC0xLTEtMA_7072549c-de49-4aa5-a07f-dfd74919e3f3"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i51ddcb898ae7480cbdaa9ec0ab68a246_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfMTUtMTAtMS0xLTA_8181c081-e690-4e73-89af-4086a7e66218"
      unitRef="usd">132300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6f1f3b16e8d246ed9cb3f7cd93daf5bb_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfMTUtMTItMS0xLTA_e940c441-e58b-4dda-8885-ed217cf60703"
      unitRef="usd">132300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8e584f31a41a4eae8bf2342da93c54e2_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfMTYtMi0xLTEtMA_3752b6de-f191-4cd1-8954-6d223f773cad"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3a59fa0fcf0647fca4a684d8a73ac1ae_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfMTYtNC0xLTEtMA_883472a3-ee1d-4649-96df-b32af84d6b69"
      unitRef="usd">71800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7638af777ff44424ad832076c7ede12d_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfMTYtNi0xLTEtMA_148d6942-f49e-4544-9077-d8d59e82f417"
      unitRef="usd">71800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic66643a3fa6f4367b9eebb3e83bf3f00_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfMTYtOC0xLTEtMA_9c146723-9855-4775-9f48-6942efb2b9f0"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i28632e06900d4c5c9e30bb7d2329c1ff_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfMTYtMTAtMS0xLTA_6c142545-d4f8-43f4-9dc4-e437108fc436"
      unitRef="usd">49900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1c3e816876c048aa84d64152477c9781_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfMTYtMTItMS0xLTA_15adb16e-ab4b-4b27-9447-65f3fb740cf9"
      unitRef="usd">49900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4ee8e58d8b904754b7733dede2183d4c_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfMTctMi0xLTEtMA_b362bc8c-744c-4a7f-984c-e93acd662bd7"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i529ab974da4c4d049570f91ae707a0ba_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfMTctNC0xLTEtMA_2dc5afca-561a-44ff-9934-7acdf782a3cf"
      unitRef="usd">598300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i254d19bbbef947d1a614d21d341de265_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfMTctNi0xLTEtMA_ff08ff77-fd61-429b-bf34-4f74939bb160"
      unitRef="usd">598300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id4eca9ea1df2452294cbdfa5fbed58c1_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfMTctOC0xLTEtMA_bb98b925-dd4f-4036-8039-c26e71b0add3"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i58eb92d0895f4b14ab4e6bc4e13c9ffc_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfMTctMTAtMS0xLTA_e3312a02-e05d-4c83-9a8a-946376bcca8a"
      unitRef="usd">542400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iab755c39193d4ef0bb6db78729b51f1d_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfMTctMTItMS0xLTA_d9020d2c-f5ef-4024-8798-e71595ff574e"
      unitRef="usd">542400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifee406589c20493a9b2fe20b2c5535a5_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfMjAtMi0xLTEtMA_fa7ca09f-d2b1-4ade-ac3c-6154275c9d6d"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibf97ed01b19948c9bae6d6c52e933fcd_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfMjAtNC0xLTEtMA_5dd74750-3fab-4124-a529-858076d44bf8"
      unitRef="usd">9200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3cc3553689e84e56811b92f0dd3b6b92_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfMjAtNi0xLTEtMA_c429215b-a123-414c-829d-f94ae128842b"
      unitRef="usd">9200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5fea542032c54705846f79614c101fc1_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfMjAtOC0xLTEtMA_9e798466-718e-4814-9a75-e312f0b1f55b"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iea33bba3363f4d079ad12fb08f1e1b10_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfMjAtMTAtMS0xLTA_58d6d7a4-b0d9-413a-aad1-ea0cb619eebd"
      unitRef="usd">11600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i882255f3fd6c4303973083ca690aa076_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfMjAtMTItMS0xLTA_cd176eb8-d9fe-4d4e-a535-ef0b99b2ad93"
      unitRef="usd">11600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie37b87d6a1074111b1725e662d8f0afa_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfMjEtMi0xLTEtMA_71dcb666-0a09-4073-8d01-620e635c362f"
      unitRef="usd">4803100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7adfff2dc6d34472b4ddbd0d4f2a4422_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfMjEtNC0xLTEtMA_2631da94-e5c4-446e-92cd-66d4e64ead61"
      unitRef="usd">3587500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id41b722bb5ce413f84c0e1a46961879f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfMjEtNi0xLTEtMA_d9783895-e8b4-47e2-9050-09ae0f4798c2"
      unitRef="usd">8390600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if276cb15ef2546539e317deb2377ba10_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfMjEtOC0xLTEtMA_bd318797-4f1a-4212-8797-d5ab321f8578"
      unitRef="usd">4959700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib5aba8b2bfc846c9b459ca84fc4e721d_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfMjEtMTAtMS0xLTA_977e1c2f-fcfc-4f9b-9068-8d80fd757bf4"
      unitRef="usd">3495300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if88c636dd80d492687ca22f07e75db13_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmY1Mjk1ZTFmZTM2YTQ5MjhhMGRmNTFiNzIyZTY4Y2VhL3RhYmxlcmFuZ2U6ZjUyOTVlMWZlMzZhNDkyOGEwZGY1MWI3MjJlNjhjZWFfMjEtMTItMS0xLTA_94f0feb5-6b92-4c7e-be05-a5da5acfb48a"
      unitRef="usd">8455000000.0</us-gaap:Revenues>
    <biib:NumberOfWholesalers
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RleHRyZWdpb246YjUxMDhlMTQ5MTIxNGEyOGE1MWY0ZTljMWQ1NzM2NTVfODI0NjMzNzIxMTU5OQ_59642bb3-d017-4894-b141-87c476d25683"
      unitRef="wholesaler">2</biib:NumberOfWholesalers>
    <biib:NumberOfWholesalers
      contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RleHRyZWdpb246YjUxMDhlMTQ5MTIxNGEyOGE1MWY0ZTljMWQ1NzM2NTVfODI0NjMzNzIxMTU5OQ_a050ac89-37fb-4658-b3fa-cb7dccbf5ba1"
      unitRef="wholesaler">2</biib:NumberOfWholesalers>
    <biib:EntityWidePercentageOfRevenueFromMajorDistributors
      contextRef="i8df56b3f3ec24c9cad78f819aa3968bd_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RleHRyZWdpb246YjUxMDhlMTQ5MTIxNGEyOGE1MWY0ZTljMWQ1NzM2NTVfNDU2_719f9b0e-62aa-4fd9-a864-4498fc001382"
      unitRef="number">0.312</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
    <biib:EntityWidePercentageOfRevenueFromMajorDistributors
      contextRef="i3302fabf3956449599c4d0d7d34f36d6_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RleHRyZWdpb246YjUxMDhlMTQ5MTIxNGEyOGE1MWY0ZTljMWQ1NzM2NTVfNDYz_3538e8a1-9cbb-404c-8a07-5406aa06ccc2"
      unitRef="number">0.156</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
    <biib:EntityWidePercentageOfRevenueFromMajorDistributors
      contextRef="i6de66bb341bb422daee145e34cc96b52_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RleHRyZWdpb246YjUxMDhlMTQ5MTIxNGEyOGE1MWY0ZTljMWQ1NzM2NTVfNTI0_abfe7f7d-1b21-41b5-b6b4-c84aff66410c"
      unitRef="number">0.309</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
    <biib:EntityWidePercentageOfRevenueFromMajorDistributors
      contextRef="idfabb0fde2e64da393d47657161d482f_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RleHRyZWdpb246YjUxMDhlMTQ5MTIxNGEyOGE1MWY0ZTljMWQ1NzM2NTVfNTMx_619fc6b6-d58d-4c3a-b17e-4ce5ee4f1051"
      unitRef="number">0.160</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
    <biib:NumberOfWholesalers
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RleHRyZWdpb246YjUxMDhlMTQ5MTIxNGEyOGE1MWY0ZTljMWQ1NzM2NTVfODI0NjMzNzIxMTYwNA_99d61649-333b-4869-9a94-508a350caa7a"
      unitRef="wholesaler">2</biib:NumberOfWholesalers>
    <biib:NumberOfWholesalers
      contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RleHRyZWdpb246YjUxMDhlMTQ5MTIxNGEyOGE1MWY0ZTljMWQ1NzM2NTVfODI0NjMzNzIxMTYwNA_f41ac990-1bc0-4e7b-9cfd-b92ee57999b9"
      unitRef="wholesaler">2</biib:NumberOfWholesalers>
    <biib:EntityWidePercentageOfRevenueFromMajorDistributors
      contextRef="ie223070107d841acb3680d718ad02ae6_D20190701-20190930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RleHRyZWdpb246YjUxMDhlMTQ5MTIxNGEyOGE1MWY0ZTljMWQ1NzM2NTVfNjQ3_42c9f646-6d38-45a4-8970-c5aeb4a07306"
      unitRef="number">0.287</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
    <biib:EntityWidePercentageOfRevenueFromMajorDistributors
      contextRef="i52dc933695414f1895f943cb573be8c1_D20190701-20190930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RleHRyZWdpb246YjUxMDhlMTQ5MTIxNGEyOGE1MWY0ZTljMWQ1NzM2NTVfNjU0_a743e5da-b6c3-4c8d-bacf-cf915be27367"
      unitRef="number">0.184</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
    <biib:EntityWidePercentageOfRevenueFromMajorDistributors
      contextRef="ie32fda1ac1154d048d97699d8290e7fa_D20190101-20190930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RleHRyZWdpb246YjUxMDhlMTQ5MTIxNGEyOGE1MWY0ZTljMWQ1NzM2NTVfNzE1_7adab74f-5ed8-4722-8d03-9901bfe25463"
      unitRef="number">0.301</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
    <biib:EntityWidePercentageOfRevenueFromMajorDistributors
      contextRef="i5c0c40a4a5f74ba69177a07ee1ff0f2a_D20190101-20190930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RleHRyZWdpb246YjUxMDhlMTQ5MTIxNGEyOGE1MWY0ZTljMWQ1NzM2NTVfNzIy_f109fb14-6db3-462c-af76-9725f7c0ef97"
      unitRef="number">0.170</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
    <biib:AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RleHRyZWdpb246YjUxMDhlMTQ5MTIxNGEyOGE1MWY0ZTljMWQ1NzM2NTVfMjc0Ng_0dce63f1-8fca-46d9-b176-ebd6816f2487">&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;An analysis of the change in reserves for discounts and allowances is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:47.155%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.526%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.109%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.526%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.109%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.526%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.109%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.526%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.114%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Discounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Contractual&lt;br/&gt;Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance, December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;131.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;1,027.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;40.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;1,198.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Current provisions relating to sales in current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;589.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;2,465.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;14.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;3,070.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Adjustments relating to prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(41.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(40.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Payments/credits relating to sales in current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(457.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(1,704.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(2,162.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Payments/credits relating to sales in prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(120.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(658.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(15.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(794.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance, September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;141.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;1,088.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;41.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;1,271.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</biib:AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i02dda51ececd4bc28da1d9a328686af2_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOjYzY2RiYTA2NWI5YzQxZDBiNTZhMGFiMzRhYTJjMTA2L3RhYmxlcmFuZ2U6NjNjZGJhMDY1YjljNDFkMGI1NmEwYWIzNGFhMmMxMDZfMS0yLTEtMS0w_6b228fcb-c848-44a2-84a0-35b81e855eaf"
      unitRef="usd">131100000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i8b3ec66c47d44f20873b899460f118cf_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOjYzY2RiYTA2NWI5YzQxZDBiNTZhMGFiMzRhYTJjMTA2L3RhYmxlcmFuZ2U6NjNjZGJhMDY1YjljNDFkMGI1NmEwYWIzNGFhMmMxMDZfMS00LTEtMS0w_2a19b34f-083a-4058-978d-39257371f43d"
      unitRef="usd">1027300000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i547ca2c2237a4a379988e41835ac1091_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOjYzY2RiYTA2NWI5YzQxZDBiNTZhMGFiMzRhYTJjMTA2L3RhYmxlcmFuZ2U6NjNjZGJhMDY1YjljNDFkMGI1NmEwYWIzNGFhMmMxMDZfMS02LTEtMS0w_bd67c398-a710-4483-833f-f8ccf1b7efbf"
      unitRef="usd">40500000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i626282e786b7454d83b617e9e83963e6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOjYzY2RiYTA2NWI5YzQxZDBiNTZhMGFiMzRhYTJjMTA2L3RhYmxlcmFuZ2U6NjNjZGJhMDY1YjljNDFkMGI1NmEwYWIzNGFhMmMxMDZfMS04LTEtMS0w_88556235-5673-4ba2-8db8-5ccfad521a48"
      unitRef="usd">1198900000</us-gaap:ValuationAllowancesAndReservesBalance>
    <biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear
      contextRef="if2a30a4831ac4e68b68264f34f994f66_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOjYzY2RiYTA2NWI5YzQxZDBiNTZhMGFiMzRhYTJjMTA2L3RhYmxlcmFuZ2U6NjNjZGJhMDY1YjljNDFkMGI1NmEwYWIzNGFhMmMxMDZfMi0yLTEtMS0w_eb9287d5-cf86-46c4-9b55-78dd1f461927"
      unitRef="usd">589600000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
    <biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear
      contextRef="i1a535a6744d640489dfb975ae50eafb4_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOjYzY2RiYTA2NWI5YzQxZDBiNTZhMGFiMzRhYTJjMTA2L3RhYmxlcmFuZ2U6NjNjZGJhMDY1YjljNDFkMGI1NmEwYWIzNGFhMmMxMDZfMi00LTEtMS0w_14fca837-6641-421c-807a-f438798b307b"
      unitRef="usd">2465800000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
    <biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear
      contextRef="i4608a28d79084131af5440bda4ce4ba5_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOjYzY2RiYTA2NWI5YzQxZDBiNTZhMGFiMzRhYTJjMTA2L3RhYmxlcmFuZ2U6NjNjZGJhMDY1YjljNDFkMGI1NmEwYWIzNGFhMmMxMDZfMi02LTEtMS0w_3d8c9fdd-794b-42f7-86bd-c6769ecb124e"
      unitRef="usd">14800000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
    <biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOjYzY2RiYTA2NWI5YzQxZDBiNTZhMGFiMzRhYTJjMTA2L3RhYmxlcmFuZ2U6NjNjZGJhMDY1YjljNDFkMGI1NmEwYWIzNGFhMmMxMDZfMi04LTEtMS0w_f30caf26-5438-4b94-bd5a-ea6eee3979fc"
      unitRef="usd">3070200000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
    <biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears
      contextRef="if2a30a4831ac4e68b68264f34f994f66_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOjYzY2RiYTA2NWI5YzQxZDBiNTZhMGFiMzRhYTJjMTA2L3RhYmxlcmFuZ2U6NjNjZGJhMDY1YjljNDFkMGI1NmEwYWIzNGFhMmMxMDZfMy0yLTEtMS0w_abcd6553-7443-438d-ac27-11cef31faeb0"
      unitRef="usd">1000000.0</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
    <biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears
      contextRef="i1a535a6744d640489dfb975ae50eafb4_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOjYzY2RiYTA2NWI5YzQxZDBiNTZhMGFiMzRhYTJjMTA2L3RhYmxlcmFuZ2U6NjNjZGJhMDY1YjljNDFkMGI1NmEwYWIzNGFhMmMxMDZfMy00LTEtMS0w_31f41323-4bf9-4d64-a6e2-7ce9d041ab01"
      unitRef="usd">41600000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
    <biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears
      contextRef="i4608a28d79084131af5440bda4ce4ba5_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOjYzY2RiYTA2NWI5YzQxZDBiNTZhMGFiMzRhYTJjMTA2L3RhYmxlcmFuZ2U6NjNjZGJhMDY1YjljNDFkMGI1NmEwYWIzNGFhMmMxMDZfMy02LTEtMS0w_18223f3b-4729-4b95-a99a-4fba8ac1423a"
      unitRef="usd">-1800000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
    <biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOjYzY2RiYTA2NWI5YzQxZDBiNTZhMGFiMzRhYTJjMTA2L3RhYmxlcmFuZ2U6NjNjZGJhMDY1YjljNDFkMGI1NmEwYWIzNGFhMmMxMDZfMy04LTEtMS0w_219509a1-d1fa-4483-9c5c-8a4c1b435992"
      unitRef="usd">40800000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear
      contextRef="if2a30a4831ac4e68b68264f34f994f66_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOjYzY2RiYTA2NWI5YzQxZDBiNTZhMGFiMzRhYTJjMTA2L3RhYmxlcmFuZ2U6NjNjZGJhMDY1YjljNDFkMGI1NmEwYWIzNGFhMmMxMDZfNC0yLTEtMS0w_851b7785-3c92-4b3f-bba0-8beefaead3b1"
      unitRef="usd">457900000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear
      contextRef="i1a535a6744d640489dfb975ae50eafb4_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOjYzY2RiYTA2NWI5YzQxZDBiNTZhMGFiMzRhYTJjMTA2L3RhYmxlcmFuZ2U6NjNjZGJhMDY1YjljNDFkMGI1NmEwYWIzNGFhMmMxMDZfNC00LTEtMS0w_0d783e95-712d-4091-a0bc-b56911558ef2"
      unitRef="usd">1704500000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear
      contextRef="i4608a28d79084131af5440bda4ce4ba5_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOjYzY2RiYTA2NWI5YzQxZDBiNTZhMGFiMzRhYTJjMTA2L3RhYmxlcmFuZ2U6NjNjZGJhMDY1YjljNDFkMGI1NmEwYWIzNGFhMmMxMDZfNC02LTEtMS0w_4aeeb863-c847-46ec-8a55-1567aaa60f64"
      unitRef="usd">0</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOjYzY2RiYTA2NWI5YzQxZDBiNTZhMGFiMzRhYTJjMTA2L3RhYmxlcmFuZ2U6NjNjZGJhMDY1YjljNDFkMGI1NmEwYWIzNGFhMmMxMDZfNC04LTEtMS0w_7164c526-65c3-4163-8076-49c9f74fe354"
      unitRef="usd">2162400000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear
      contextRef="if2a30a4831ac4e68b68264f34f994f66_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOjYzY2RiYTA2NWI5YzQxZDBiNTZhMGFiMzRhYTJjMTA2L3RhYmxlcmFuZ2U6NjNjZGJhMDY1YjljNDFkMGI1NmEwYWIzNGFhMmMxMDZfNS0yLTEtMS0w_24351adc-b8f1-4966-bc39-c32d04de40db"
      unitRef="usd">120300000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear
      contextRef="i1a535a6744d640489dfb975ae50eafb4_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOjYzY2RiYTA2NWI5YzQxZDBiNTZhMGFiMzRhYTJjMTA2L3RhYmxlcmFuZ2U6NjNjZGJhMDY1YjljNDFkMGI1NmEwYWIzNGFhMmMxMDZfNS00LTEtMS0w_b2e7d76c-89bc-40e4-9583-69d5e036703f"
      unitRef="usd">658400000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear
      contextRef="i4608a28d79084131af5440bda4ce4ba5_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOjYzY2RiYTA2NWI5YzQxZDBiNTZhMGFiMzRhYTJjMTA2L3RhYmxlcmFuZ2U6NjNjZGJhMDY1YjljNDFkMGI1NmEwYWIzNGFhMmMxMDZfNS02LTEtMS0w_3732ec9c-ec35-4576-bf09-c5835f4ab024"
      unitRef="usd">15400000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOjYzY2RiYTA2NWI5YzQxZDBiNTZhMGFiMzRhYTJjMTA2L3RhYmxlcmFuZ2U6NjNjZGJhMDY1YjljNDFkMGI1NmEwYWIzNGFhMmMxMDZfNS04LTEtMS0w_3ac7b268-ebd9-4ca3-bfba-cb70d9c28e96"
      unitRef="usd">794100000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i204f2ca2855b47ec88cf265fde7a6679_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOjYzY2RiYTA2NWI5YzQxZDBiNTZhMGFiMzRhYTJjMTA2L3RhYmxlcmFuZ2U6NjNjZGJhMDY1YjljNDFkMGI1NmEwYWIzNGFhMmMxMDZfNi0yLTEtMS0w_5ef206cb-4327-4962-aef9-c004f9002eba"
      unitRef="usd">141500000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i7897f16ad9b249e08151468bc3c92f5c_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOjYzY2RiYTA2NWI5YzQxZDBiNTZhMGFiMzRhYTJjMTA2L3RhYmxlcmFuZ2U6NjNjZGJhMDY1YjljNDFkMGI1NmEwYWIzNGFhMmMxMDZfNi00LTEtMS0w_8961b6c5-76a1-4616-b01e-f3e22272951e"
      unitRef="usd">1088600000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i897e79a0b82b448297a7d6e150e50906_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOjYzY2RiYTA2NWI5YzQxZDBiNTZhMGFiMzRhYTJjMTA2L3RhYmxlcmFuZ2U6NjNjZGJhMDY1YjljNDFkMGI1NmEwYWIzNGFhMmMxMDZfNi02LTEtMS0w_5da215c0-4375-4edf-8251-4ffd84ba8391"
      unitRef="usd">41700000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOjYzY2RiYTA2NWI5YzQxZDBiNTZhMGFiMzRhYTJjMTA2L3RhYmxlcmFuZ2U6NjNjZGJhMDY1YjljNDFkMGI1NmEwYWIzNGFhMmMxMDZfNi04LTEtMS0w_e33f7ef9-81c2-4c72-8f71-25bcf48fcef9"
      unitRef="usd">1271800000</us-gaap:ValuationAllowancesAndReservesBalance>
    <biib:SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RleHRyZWdpb246YjUxMDhlMTQ5MTIxNGEyOGE1MWY0ZTljMWQ1NzM2NTVfMjc0Mw_d094c2e6-0e65-4657-9c8a-451766640826">&lt;div style="text-indent:24.75pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The total reserves above, which are included in our condensed consolidated balance sheets, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:65.808%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.525%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.720%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.525%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.722%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;As of September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Reduction of accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;227.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;197.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Component of accrued expenses and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;1,043.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,001.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total revenue-related reserves&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;1,271.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,198.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</biib:SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ieabb7bcb048b432c908c601e832af027_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOjc5MTBmMjg4ODcwMzRkYTBhZWU3ZWZmZTE0OGM0NjhjL3RhYmxlcmFuZ2U6NzkxMGYyODg4NzAzNGRhMGFlZTdlZmZlMTQ4YzQ2OGNfMS0yLTEtMS0w_edce7258-2632-4558-8547-d4c27a88455f"
      unitRef="usd">227900000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i65c7f4e2aad74eb78be96cec75c1e6c8_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOjc5MTBmMjg4ODcwMzRkYTBhZWU3ZWZmZTE0OGM0NjhjL3RhYmxlcmFuZ2U6NzkxMGYyODg4NzAzNGRhMGFlZTdlZmZlMTQ4YzQ2OGNfMS00LTEtMS0w_0ae13f56-ca7e-44d3-b5d8-ebe1c9acf4e1"
      unitRef="usd">197800000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i7eddadc447104f8eb26db7302eace7a5_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOjc5MTBmMjg4ODcwMzRkYTBhZWU3ZWZmZTE0OGM0NjhjL3RhYmxlcmFuZ2U6NzkxMGYyODg4NzAzNGRhMGFlZTdlZmZlMTQ4YzQ2OGNfMi0yLTEtMS0w_4295948a-eea5-467b-9d26-a61fba85caa5"
      unitRef="usd">1043900000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ide07a6c272e244a3be181989da603c09_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOjc5MTBmMjg4ODcwMzRkYTBhZWU3ZWZmZTE0OGM0NjhjL3RhYmxlcmFuZ2U6NzkxMGYyODg4NzAzNGRhMGFlZTdlZmZlMTQ4YzQ2OGNfMi00LTEtMS0w_4475e525-6c9d-43b7-8d32-191208d6e82d"
      unitRef="usd">1001100000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOjc5MTBmMjg4ODcwMzRkYTBhZWU3ZWZmZTE0OGM0NjhjL3RhYmxlcmFuZ2U6NzkxMGYyODg4NzAzNGRhMGFlZTdlZmZlMTQ4YzQ2OGNfMy0yLTEtMS0w_6122e4fc-04ca-4d8f-a3b9-86cbecbef9df"
      unitRef="usd">1271800000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i626282e786b7454d83b617e9e83963e6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOjc5MTBmMjg4ODcwMzRkYTBhZWU3ZWZmZTE0OGM0NjhjL3RhYmxlcmFuZ2U6NzkxMGYyODg4NzAzNGRhMGFlZTdlZmZlMTQ4YzQ2OGNfMy00LTEtMS0w_03e53ce3-d95c-4eb6-9420-3e895b0bf937"
      unitRef="usd">1198900000</us-gaap:ValuationAllowancesAndReservesBalance>
    <biib:RevenuesfromantiCD20therapeuticprogramsTableTextBlock
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RleHRyZWdpb246YjUxMDhlMTQ5MTIxNGEyOGE1MWY0ZTljMWQ1NzM2NTVfMjc2NQ_2fd1f129-44be-4561-9eed-25fd0ea47794">&lt;div style="text-indent:22.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Revenues from anti-CD20 therapeutic programs are summarized below. For the purposes of this footnote we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:49.338%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.595%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.595%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.595%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.603%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Biogen&#x2019;s share of pre-tax profits in the U.S. for RITUXAN and GAZYVA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;275.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;393.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;873.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,161.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other revenues from anti-CD20 therapeutic programs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;285.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;202.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;685.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;528.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total revenues from anti-CD20 therapeutic programs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;560.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;595.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;1,558.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,689.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</biib:RevenuesfromantiCD20therapeuticprogramsTableTextBlock>
    <biib:ShareOfCoPromotionProfits
      contextRef="i144bad8e98d44b9283666efd91ae814b_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOjc5NjAxNjA2MDM1MTRkM2Y4NzhiNzAxZTdhNGNmZWU5L3RhYmxlcmFuZ2U6Nzk2MDE2MDYwMzUxNGQzZjg3OGI3MDFlN2E0Y2ZlZTlfMi0yLTEtMS0w_4ed6d0f9-ab1f-4142-8ff9-9d23560f0740"
      unitRef="usd">275000000.0</biib:ShareOfCoPromotionProfits>
    <biib:ShareOfCoPromotionProfits
      contextRef="icfb2a7f321824155859b452e7e1620d7_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOjc5NjAxNjA2MDM1MTRkM2Y4NzhiNzAxZTdhNGNmZWU5L3RhYmxlcmFuZ2U6Nzk2MDE2MDYwMzUxNGQzZjg3OGI3MDFlN2E0Y2ZlZTlfMi00LTEtMS0w_6994196c-82e6-4276-bd74-9641b8c6ada8"
      unitRef="usd">393200000</biib:ShareOfCoPromotionProfits>
    <biib:ShareOfCoPromotionProfits
      contextRef="ic8db6af1daf2476691a91e008e2e4614_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOjc5NjAxNjA2MDM1MTRkM2Y4NzhiNzAxZTdhNGNmZWU5L3RhYmxlcmFuZ2U6Nzk2MDE2MDYwMzUxNGQzZjg3OGI3MDFlN2E0Y2ZlZTlfMi02LTEtMS0w_160bf24f-ca8d-4880-9c08-743cc9d50a7f"
      unitRef="usd">873800000</biib:ShareOfCoPromotionProfits>
    <biib:ShareOfCoPromotionProfits
      contextRef="i647942c6e60f4fd3a53dd00558c6b691_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOjc5NjAxNjA2MDM1MTRkM2Y4NzhiNzAxZTdhNGNmZWU5L3RhYmxlcmFuZ2U6Nzk2MDE2MDYwMzUxNGQzZjg3OGI3MDFlN2E0Y2ZlZTlfMi04LTEtMS0w_0a89b965-d901-4a91-b17c-de178f8fb1cb"
      unitRef="usd">1161200000</biib:ShareOfCoPromotionProfits>
    <biib:OtherrevenuesfromantiCD20therapeuticprograms
      contextRef="i144bad8e98d44b9283666efd91ae814b_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOjc5NjAxNjA2MDM1MTRkM2Y4NzhiNzAxZTdhNGNmZWU5L3RhYmxlcmFuZ2U6Nzk2MDE2MDYwMzUxNGQzZjg3OGI3MDFlN2E0Y2ZlZTlfMy0yLTEtMS0w_12337970-f5cf-440f-97fc-522ebd5f462d"
      unitRef="usd">285100000</biib:OtherrevenuesfromantiCD20therapeuticprograms>
    <biib:OtherrevenuesfromantiCD20therapeuticprograms
      contextRef="icfb2a7f321824155859b452e7e1620d7_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOjc5NjAxNjA2MDM1MTRkM2Y4NzhiNzAxZTdhNGNmZWU5L3RhYmxlcmFuZ2U6Nzk2MDE2MDYwMzUxNGQzZjg3OGI3MDFlN2E0Y2ZlZTlfMy00LTEtMS0w_621a02cc-2de2-4c34-b977-20e5fe04caac"
      unitRef="usd">202600000</biib:OtherrevenuesfromantiCD20therapeuticprograms>
    <biib:OtherrevenuesfromantiCD20therapeuticprograms
      contextRef="ic8db6af1daf2476691a91e008e2e4614_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOjc5NjAxNjA2MDM1MTRkM2Y4NzhiNzAxZTdhNGNmZWU5L3RhYmxlcmFuZ2U6Nzk2MDE2MDYwMzUxNGQzZjg3OGI3MDFlN2E0Y2ZlZTlfMy02LTEtMS0w_f4ceddb8-336e-4f9c-b757-8db9a72a5d1b"
      unitRef="usd">685000000.0</biib:OtherrevenuesfromantiCD20therapeuticprograms>
    <biib:OtherrevenuesfromantiCD20therapeuticprograms
      contextRef="i647942c6e60f4fd3a53dd00558c6b691_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOjc5NjAxNjA2MDM1MTRkM2Y4NzhiNzAxZTdhNGNmZWU5L3RhYmxlcmFuZ2U6Nzk2MDE2MDYwMzUxNGQzZjg3OGI3MDFlN2E0Y2ZlZTlfMy04LTEtMS0w_e16f2e31-4930-46fc-8711-ab28b8155842"
      unitRef="usd">528400000</biib:OtherrevenuesfromantiCD20therapeuticprograms>
    <us-gaap:Revenues
      contextRef="ia428d1f03d1f454a9d5c837ec6e0aa50_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOjc5NjAxNjA2MDM1MTRkM2Y4NzhiNzAxZTdhNGNmZWU5L3RhYmxlcmFuZ2U6Nzk2MDE2MDYwMzUxNGQzZjg3OGI3MDFlN2E0Y2ZlZTlfNC0yLTEtMS0w_d1573c12-40af-4c76-882a-0625cf909262"
      unitRef="usd">560100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8595ad2d43f34d98abb716a40fde60a6_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOjc5NjAxNjA2MDM1MTRkM2Y4NzhiNzAxZTdhNGNmZWU5L3RhYmxlcmFuZ2U6Nzk2MDE2MDYwMzUxNGQzZjg3OGI3MDFlN2E0Y2ZlZTlfNC00LTEtMS0w_e45f0745-64df-4a6a-b15e-7192ea91cdb8"
      unitRef="usd">595800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0cb93d1ae39f48f3b0fc167540132b77_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOjc5NjAxNjA2MDM1MTRkM2Y4NzhiNzAxZTdhNGNmZWU5L3RhYmxlcmFuZ2U6Nzk2MDE2MDYwMzUxNGQzZjg3OGI3MDFlN2E0Y2ZlZTlfNC02LTEtMS0w_2355c8ad-e743-418a-967a-56f226dd2b1e"
      unitRef="usd">1558800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5452667727cd4cf08cae4c412b67d3ef_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOjc5NjAxNjA2MDM1MTRkM2Y4NzhiNzAxZTdhNGNmZWU5L3RhYmxlcmFuZ2U6Nzk2MDE2MDYwMzUxNGQzZjg3OGI3MDFlN2E0Y2ZlZTlfNC04LTEtMS0w_959100d7-f9c3-4823-8e41-79179c49b275"
      unitRef="usd">1689600000</us-gaap:Revenues>
    <biib:OtherrevenuesTableTextBlock
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RleHRyZWdpb246YjUxMDhlMTQ5MTIxNGEyOGE1MWY0ZTljMWQ1NzM2NTVfMjcyMw_b578ad20-c4a4-4a16-b72b-dc4d3378f62f">&lt;div style="text-indent:22.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Other revenues are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:49.192%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.595%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.595%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.595%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.603%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Revenues from collaborative and other relationships:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Profit (loss) earned under our 50% share of the co-promotion losses on ZINBRYTA in the U.S. with AbbVie Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Revenues earned under our technical development agreement, manufacturing services agreements and royalty revenues on biosimilar products with Samsung Bioepis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;13.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;89.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other royalty and corporate revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Royalty&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;10.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;28.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;110.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;93.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;599.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;462.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;125.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;109.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;642.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;562.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</biib:OtherrevenuesTableTextBlock>
    <us-gaap:Revenues
      contextRef="i7b511ee9603b41fda2cc6f8171976d4e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmZmNDAzMjM3NTRjMTRkNWFhMjczODI0NTcwZTMyN2E1L3RhYmxlcmFuZ2U6ZmY0MDMyMzc1NGMxNGQ1YWEyNzM4MjQ1NzBlMzI3YTVfMy0yLTEtMS0w_5d974b68-6eed-4deb-962a-3b216e8df94c"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6c11f9b8d3684514917520eb76b5297d_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmZmNDAzMjM3NTRjMTRkNWFhMjczODI0NTcwZTMyN2E1L3RhYmxlcmFuZ2U6ZmY0MDMyMzc1NGMxNGQ1YWEyNzM4MjQ1NzBlMzI3YTVfMy00LTEtMS0w_7582da50-0078-4124-9b91-75060d20a4e4"
      unitRef="usd">300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ida3ec850012e473c82f5aebf509be5cc_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmZmNDAzMjM3NTRjMTRkNWFhMjczODI0NTcwZTMyN2E1L3RhYmxlcmFuZ2U6ZmY0MDMyMzc1NGMxNGQ1YWEyNzM4MjQ1NzBlMzI3YTVfMy02LTEtMS0w_ab8f6ebb-72f9-43ec-bf6e-fc2a5ac27d61"
      unitRef="usd">700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i528e10772f27492fa438cba3d636945a_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmZmNDAzMjM3NTRjMTRkNWFhMjczODI0NTcwZTMyN2E1L3RhYmxlcmFuZ2U6ZmY0MDMyMzc1NGMxNGQ1YWEyNzM4MjQ1NzBlMzI3YTVfMy04LTEtMS0w_16c94a2d-64a2-4c5c-add8-9f621f59be23"
      unitRef="usd">-200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i083a7fa4caa1424dbbf1d7151d395e24_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmZmNDAzMjM3NTRjMTRkNWFhMjczODI0NTcwZTMyN2E1L3RhYmxlcmFuZ2U6ZmY0MDMyMzc1NGMxNGQ1YWEyNzM4MjQ1NzBlMzI3YTVfNC0yLTEtMS0w_44835de9-cfa6-4c06-a928-c043870bfd93"
      unitRef="usd">5400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i96f6c016546448cb939dbb6557754670_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmZmNDAzMjM3NTRjMTRkNWFhMjczODI0NTcwZTMyN2E1L3RhYmxlcmFuZ2U6ZmY0MDMyMzc1NGMxNGQ1YWEyNzM4MjQ1NzBlMzI3YTVfNC00LTEtMS0w_16b5847b-a05e-4e93-971d-48863a6c2867"
      unitRef="usd">12900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib6369975ed9d437593f2e153c72f7978_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmZmNDAzMjM3NTRjMTRkNWFhMjczODI0NTcwZTMyN2E1L3RhYmxlcmFuZ2U6ZmY0MDMyMzc1NGMxNGQ1YWEyNzM4MjQ1NzBlMzI3YTVfNC02LTEtMS0w_2fbc8957-cdf8-4d41-aa41-9665ec173a45"
      unitRef="usd">13600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id6f2c098f47f4305b065fa0a773ea01b_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmZmNDAzMjM3NTRjMTRkNWFhMjczODI0NTcwZTMyN2E1L3RhYmxlcmFuZ2U6ZmY0MDMyMzc1NGMxNGQ1YWEyNzM4MjQ1NzBlMzI3YTVfNC04LTEtMS0w_5604a553-ef1a-4dc9-a1e7-bfe85a137b42"
      unitRef="usd">89900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7aaebf479efd4e5988b193f96cfea104_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmZmNDAzMjM3NTRjMTRkNWFhMjczODI0NTcwZTMyN2E1L3RhYmxlcmFuZ2U6ZmY0MDMyMzc1NGMxNGQ1YWEyNzM4MjQ1NzBlMzI3YTVfNi0yLTEtMS0w_d4e262aa-1cb8-4792-ab70-2d871b2bef11"
      unitRef="usd">10300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i727d852e008a4093bc7eeae55e9ac6e9_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmZmNDAzMjM3NTRjMTRkNWFhMjczODI0NTcwZTMyN2E1L3RhYmxlcmFuZ2U6ZmY0MDMyMzc1NGMxNGQ1YWEyNzM4MjQ1NzBlMzI3YTVfNi00LTEtMS0w_729665f4-f771-4cd7-b1bd-4047d7de275c"
      unitRef="usd">3300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3a892823ca8b4d289bbf6e819b53df89_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmZmNDAzMjM3NTRjMTRkNWFhMjczODI0NTcwZTMyN2E1L3RhYmxlcmFuZ2U6ZmY0MDMyMzc1NGMxNGQ1YWEyNzM4MjQ1NzBlMzI3YTVfNi02LTEtMS0w_02cce8f1-131d-448a-9543-309c418c4955"
      unitRef="usd">28800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7a2aaddc244148d29b9babb1a6e4d21a_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmZmNDAzMjM3NTRjMTRkNWFhMjczODI0NTcwZTMyN2E1L3RhYmxlcmFuZ2U6ZmY0MDMyMzc1NGMxNGQ1YWEyNzM4MjQ1NzBlMzI3YTVfNi04LTEtMS0w_4f90557c-dfc3-45f6-b43c-2fbfed1cc700"
      unitRef="usd">9900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id62c1ea890004cc683b1c3e2197b9771_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmZmNDAzMjM3NTRjMTRkNWFhMjczODI0NTcwZTMyN2E1L3RhYmxlcmFuZ2U6ZmY0MDMyMzc1NGMxNGQ1YWEyNzM4MjQ1NzBlMzI3YTVfNy0yLTEtMS0w_a6e47151-b699-4303-bce5-c5c0eae44aa8"
      unitRef="usd">110000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0e78e06924024013a86b44bea5d8c5fc_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmZmNDAzMjM3NTRjMTRkNWFhMjczODI0NTcwZTMyN2E1L3RhYmxlcmFuZ2U6ZmY0MDMyMzc1NGMxNGQ1YWEyNzM4MjQ1NzBlMzI3YTVfNy00LTEtMS0w_6899c4f9-dd36-41a9-9de4-6ef3b6bfa704"
      unitRef="usd">93100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i64ed3edf8c234417860f788da7ecdef3_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmZmNDAzMjM3NTRjMTRkNWFhMjczODI0NTcwZTMyN2E1L3RhYmxlcmFuZ2U6ZmY0MDMyMzc1NGMxNGQ1YWEyNzM4MjQ1NzBlMzI3YTVfNy02LTEtMS0w_873dc85e-f729-4a89-bb39-1695b91c579b"
      unitRef="usd">599500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0b88a1e534d44643b0824a70718ed27c_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmZmNDAzMjM3NTRjMTRkNWFhMjczODI0NTcwZTMyN2E1L3RhYmxlcmFuZ2U6ZmY0MDMyMzc1NGMxNGQ1YWEyNzM4MjQ1NzBlMzI3YTVfNy04LTEtMS0w_9896e703-c467-4581-9f32-aefde60fbdff"
      unitRef="usd">462400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iba6a7aa4c7fa4fda950fccc032894346_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmZmNDAzMjM3NTRjMTRkNWFhMjczODI0NTcwZTMyN2E1L3RhYmxlcmFuZ2U6ZmY0MDMyMzc1NGMxNGQ1YWEyNzM4MjQ1NzBlMzI3YTVfOC0yLTEtMS0w_5253c89e-d19a-45a3-9e18-1d6dea309c7a"
      unitRef="usd">125700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0ea06cd6a9974b4999904b90f030878b_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmZmNDAzMjM3NTRjMTRkNWFhMjczODI0NTcwZTMyN2E1L3RhYmxlcmFuZ2U6ZmY0MDMyMzc1NGMxNGQ1YWEyNzM4MjQ1NzBlMzI3YTVfOC00LTEtMS0w_5b225ab9-38de-4701-b0c2-de8f3c578570"
      unitRef="usd">109600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6e0b6c1de005431bb80fcd07bc90af2e_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmZmNDAzMjM3NTRjMTRkNWFhMjczODI0NTcwZTMyN2E1L3RhYmxlcmFuZ2U6ZmY0MDMyMzc1NGMxNGQ1YWEyNzM4MjQ1NzBlMzI3YTVfOC02LTEtMS0w_059920dd-6d27-4c72-b146-9e0af95b6f5b"
      unitRef="usd">642600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2335a9cc65b041aa8e881414fc49759c_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RhYmxlOmZmNDAzMjM3NTRjMTRkNWFhMjczODI0NTcwZTMyN2E1L3RhYmxlcmFuZ2U6ZmY0MDMyMzc1NGMxNGQ1YWEyNzM4MjQ1NzBlMzI3YTVfOC04LTEtMS0w_24bf8ef9-5c22-433a-86fe-81a790fa8ce6"
      unitRef="usd">562000000.0</us-gaap:Revenues>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i63cfe59d1dc247b88c3f0c79a4c20ddb_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RleHRyZWdpb246YjUxMDhlMTQ5MTIxNGEyOGE1MWY0ZTljMWQ1NzM2NTVfMTg5MA_9d783c96-964b-49b1-88cc-78531f91cdb9"
      unitRef="usd">500000000.0</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:Revenues
      contextRef="ie108e7ffa05346ff9834f57e7ffcdad2_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RleHRyZWdpb246YjUxMDhlMTQ5MTIxNGEyOGE1MWY0ZTljMWQ1NzM2NTVfMjIwMw_fe8df0f7-8cea-4bf6-abf9-de867ad8c4dc"
      unitRef="usd">333200000</us-gaap:Revenues>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i9be493af1ef548c7b50cb146bad36446_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RleHRyZWdpb246YjUxMDhlMTQ5MTIxNGEyOGE1MWY0ZTljMWQ1NzM2NTVfMTA5OTUxMTYzMDU4OA_8a4560a6-d2a5-493e-9371-332bc9c6dcf3"
      unitRef="usd">166800000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i63cfe59d1dc247b88c3f0c79a4c20ddb_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181Mi9mcmFnOmI1MTA4ZTE0OTEyMTRhMjhhNTFmNGU5YzFkNTczNjU1L3RleHRyZWdpb246YjUxMDhlMTQ5MTIxNGEyOGE1MWY0ZTljMWQ1NzM2NTVfMTA5OTUxMTYzMDY1MA_9d783c96-964b-49b1-88cc-78531f91cdb9"
      unitRef="usd">500000000.0</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181OC9mcmFnOjE0NzgwNDgyZTZiNTQwMDlhMGRlN2Y1ZTU4NTliYTRiL3RleHRyZWdpb246MTQ3ODA0ODJlNmI1NDAwOWEwZGU3ZjVlNTg1OWJhNGJfNzI_b21ebca1-0b43-46cb-8a36-39428afdcdf5">&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The components of inventory are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.830%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:58.071%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.539%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:18.574%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.539%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:18.577%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;As of September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;288.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;169.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;539.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;460.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;199.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;174.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;1,027.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;804.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181OC9mcmFnOjE0NzgwNDgyZTZiNTQwMDlhMGRlN2Y1ZTU4NTliYTRiL3RleHRyZWdpb246MTQ3ODA0ODJlNmI1NDAwOWEwZGU3ZjVlNTg1OWJhNGJfODE_f881ecef-423f-461e-ab2a-b989e78b2eb4">&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The components of inventory are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.830%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:58.071%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.539%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:18.574%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.539%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:18.577%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;As of September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;288.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;169.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;539.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;460.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;199.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;174.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;1,027.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;804.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181OC9mcmFnOjE0NzgwNDgyZTZiNTQwMDlhMGRlN2Y1ZTU4NTliYTRiL3RhYmxlOjM1NWRiN2Y4YTJkMDQ2M2M4NDJmN2Q3NjdmZmNjYzU5L3RhYmxlcmFuZ2U6MzU1ZGI3ZjhhMmQwNDYzYzg0MmY3ZDc2N2ZmY2NjNTlfMS0yLTEtMS0w_f7bfd884-9e34-41f4-a797-6d92eb56bb82"
      unitRef="usd">288400000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i626282e786b7454d83b617e9e83963e6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181OC9mcmFnOjE0NzgwNDgyZTZiNTQwMDlhMGRlN2Y1ZTU4NTliYTRiL3RhYmxlOjM1NWRiN2Y4YTJkMDQ2M2M4NDJmN2Q3NjdmZmNjYzU5L3RhYmxlcmFuZ2U6MzU1ZGI3ZjhhMmQwNDYzYzg0MmY3ZDc2N2ZmY2NjNTlfMS00LTEtMS0w_3b39a69d-3f6c-42ba-89f7-6b870d7df8a5"
      unitRef="usd">169700000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181OC9mcmFnOjE0NzgwNDgyZTZiNTQwMDlhMGRlN2Y1ZTU4NTliYTRiL3RhYmxlOjM1NWRiN2Y4YTJkMDQ2M2M4NDJmN2Q3NjdmZmNjYzU5L3RhYmxlcmFuZ2U6MzU1ZGI3ZjhhMmQwNDYzYzg0MmY3ZDc2N2ZmY2NjNTlfMi0yLTEtMS0w_c9ca7b55-ec26-4878-9660-67706eb3d645"
      unitRef="usd">539900000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i626282e786b7454d83b617e9e83963e6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181OC9mcmFnOjE0NzgwNDgyZTZiNTQwMDlhMGRlN2Y1ZTU4NTliYTRiL3RhYmxlOjM1NWRiN2Y4YTJkMDQ2M2M4NDJmN2Q3NjdmZmNjYzU5L3RhYmxlcmFuZ2U6MzU1ZGI3ZjhhMmQwNDYzYzg0MmY3ZDc2N2ZmY2NjNTlfMi00LTEtMS0w_deea4718-616b-4dca-aa1a-c57e430b20b1"
      unitRef="usd">460000000.0</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181OC9mcmFnOjE0NzgwNDgyZTZiNTQwMDlhMGRlN2Y1ZTU4NTliYTRiL3RhYmxlOjM1NWRiN2Y4YTJkMDQ2M2M4NDJmN2Q3NjdmZmNjYzU5L3RhYmxlcmFuZ2U6MzU1ZGI3ZjhhMmQwNDYzYzg0MmY3ZDc2N2ZmY2NjNTlfMy0yLTEtMS0w_f3233c80-7c40-4b31-add6-67b664aa9b0f"
      unitRef="usd">199400000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i626282e786b7454d83b617e9e83963e6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181OC9mcmFnOjE0NzgwNDgyZTZiNTQwMDlhMGRlN2Y1ZTU4NTliYTRiL3RhYmxlOjM1NWRiN2Y4YTJkMDQ2M2M4NDJmN2Q3NjdmZmNjYzU5L3RhYmxlcmFuZ2U6MzU1ZGI3ZjhhMmQwNDYzYzg0MmY3ZDc2N2ZmY2NjNTlfMy00LTEtMS0w_aa7a1e60-6183-4339-9f6b-52db07b72b66"
      unitRef="usd">174500000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <biib:Inventorynetcurrentandnoncurrent
      contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181OC9mcmFnOjE0NzgwNDgyZTZiNTQwMDlhMGRlN2Y1ZTU4NTliYTRiL3RhYmxlOjM1NWRiN2Y4YTJkMDQ2M2M4NDJmN2Q3NjdmZmNjYzU5L3RhYmxlcmFuZ2U6MzU1ZGI3ZjhhMmQwNDYzYzg0MmY3ZDc2N2ZmY2NjNTlfNC0yLTEtMS0w_01233d3d-c0a3-4fa7-8aaa-deac804213d8"
      unitRef="usd">1027700000</biib:Inventorynetcurrentandnoncurrent>
    <biib:Inventorynetcurrentandnoncurrent
      contextRef="i626282e786b7454d83b617e9e83963e6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM181OC9mcmFnOjE0NzgwNDgyZTZiNTQwMDlhMGRlN2Y1ZTU4NTliYTRiL3RhYmxlOjM1NWRiN2Y4YTJkMDQ2M2M4NDJmN2Q3NjdmZmNjYzU5L3RhYmxlcmFuZ2U6MzU1ZGI3ZjhhMmQwNDYzYzg0MmY3ZDc2N2ZmY2NjNTlfNC00LTEtMS0w_d676d7a4-29a9-4927-abd3-b6af3d3031c6"
      unitRef="usd">804200000</biib:Inventorynetcurrentandnoncurrent>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182MS9mcmFnOjFiMTIxNTdlNmQ0NzRjNDdiNjljYzkwODJhZWQ5M2FjL3RleHRyZWdpb246MWIxMjE1N2U2ZDQ3NGM0N2I2OWNjOTA4MmFlZDkzYWNfMjgwOA_51ecd221-a894-4d17-b791-b92a0a5cf248">&lt;div style="text-indent:11.25pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Intangible assets, net of accumulated amortization, impairment charges and adjustments, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:22.394%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:15.493%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:7.710%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.032%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:7.710%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:7.710%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.032%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:7.715%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;As of September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Estimated Life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Completed technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4-28 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;7,394.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(5,077.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;2,316.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,379.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(4,881.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,497.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;In-process research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Indefinite until commercialization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;943.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;943.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;965.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;965.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Trademarks&#160;and trade names&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;64.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;64.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;64.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;64.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;8,401.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(5,077.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;3,323.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,408.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(4,881.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,527.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;For the three and nine months ended September 30, 2020, amortization and impairment of acquired intangible assets totaled $82.6 million and $215.6 million, respectively, compared to $283.9 million and $422.2 million, respectively, in the prior year comparative periods. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;For the three and nine months ended September 30, 2020, amortization and impairment of acquired intangible assets reflects the impact of a $19.3&#160;million impairment charge related to one of our IPR&amp;amp;D intangible assets. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;For the three and nine months ended September 30, 2019, amortization and impairment of acquired intangible assets reflects the impact of a $215.9&#160;million impairment charge related to certain IPR&amp;amp;D assets associated with the Phase 2b study of BG00011 (STX-100) for the potential treatment of idiopathic pulmonary fibrosis, which was discontinued in the third quarter of 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;For the three and nine months ended September 30, 2020, amortization of acquired intangible assets, excluding impairment charges, totaled $63.3&#160;million and $196.3&#160;million, respectively, compared to $68.0&#160;million and $206.3&#160;million, respectively, in the prior year comparative periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:13.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Completed Technology&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Completed technology primarily relates to our acquisition of all remaining rights to TYSABRI from Elan Pharma International Ltd., an affiliate of Elan Corporation plc, and milestone payments made to Alkermes Pharma Ireland Limited, a subsidiary of Alkermes plc, following the approval of VUMERITY in the U.S. in October 2019, net of accumulated amortization.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:13.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;IPR&amp;amp;D Related to Business Combinations&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;IPR&amp;amp;D represents the fair value assigned to research and development assets that we acquired as part of a business combination and had not yet reached technological feasibility at the date of acquisition. Included in IPR&amp;amp;D balances are adjustments related to foreign currency exchange rate fluctuations. We review amounts capitalized as acquired IPR&amp;amp;D for impairment annually, as of October 31, and whenever events or changes in circumstances indicate to us that the carrying value of the assets might not be recoverable. The carrying value associated with our IPR&amp;amp;D assets as of September 30, 2020, relates to the various IPR&amp;amp;D programs we acquired in connection with our acquisitions of NST, Convergence Pharmaceuticals Holdings Ltd. (Convergence) and Biogen International Neuroscience GmbH (BIN). The majority of the balance relates to our acquisition of NST in June 2019 whereby we acquired IPR&amp;amp;D programs with an estimated fair value of approximately $700.0 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:13.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Vixotrigine&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In the periods since we acquired vixotrigine (BIIB074), there have been numerous delays in the initiation of Phase 3 studies for the potential treatment of trigeminal neuralgia (TGN) as we engaged with the U.S. Food and Drug Administration (FDA) regarding the design of the Phase 3 studies and awaited data and insights from mid-stage clinical trials of vixotrigine in other indications that have since been completed. The fair value of the TGN asset is not significantly in excess of carrying value. As of September 30, 2020, the carrying value associated with our vixotrigine IPR&amp;amp;D assets was $167.6 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:13.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Estimated Future Amortization of Intangible Assets&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#679acb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The estimated future amortization of finite-lived intangible assets for the next five years is expected to be as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:78.724%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:18.346%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;As of September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020 (remaining three months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;60.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;205.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;215.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;215.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;225.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;220.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:11.25pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table provides a roll forward of the changes in our goodwill balance:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:78.724%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:18.346%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;As of September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Goodwill, December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;5,757.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(2.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Goodwill, September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;5,755.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;As of September 30, 2020, we had no accumulated impairment losses related to goodwill. Other includes adjustments related to foreign currency exchange rate fluctuations.</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <biib:IntangibleAssetsExcludingGoodwillTableTextBlock
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182MS9mcmFnOjFiMTIxNTdlNmQ0NzRjNDdiNjljYzkwODJhZWQ5M2FjL3RleHRyZWdpb246MWIxMjE1N2U2ZDQ3NGM0N2I2OWNjOTA4MmFlZDkzYWNfMjgwNg_e74ace3a-8201-4245-8e3f-b5ecaf3b4f47">&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Intangible assets, net of accumulated amortization, impairment charges and adjustments, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:22.394%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:15.493%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:7.710%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.032%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:7.710%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:7.710%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.032%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:7.715%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;As of September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Estimated Life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Completed technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4-28 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;7,394.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(5,077.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;2,316.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,379.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(4,881.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,497.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;In-process research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Indefinite until commercialization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;943.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;943.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;965.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;965.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Trademarks&#160;and trade names&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;64.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;64.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;64.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;64.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;8,401.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(5,077.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;3,323.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,408.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(4,881.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,527.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</biib:IntangibleAssetsExcludingGoodwillTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i4b9c454823f244cd80d1fefee5471031_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182MS9mcmFnOjFiMTIxNTdlNmQ0NzRjNDdiNjljYzkwODJhZWQ5M2FjL3RhYmxlOjFmNjNlZjM4OGZlMzRhZTI5MjI3OGQ3Y2VlNGEyYTRjL3RhYmxlcmFuZ2U6MWY2M2VmMzg4ZmUzNGFlMjkyMjc4ZDdjZWU0YTJhNGNfMi0zLTEtMS0w_f4b86bfe-1802-47fc-bf4f-3b158d602c1e"
      unitRef="usd">7394300000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i4b9c454823f244cd80d1fefee5471031_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182MS9mcmFnOjFiMTIxNTdlNmQ0NzRjNDdiNjljYzkwODJhZWQ5M2FjL3RhYmxlOjFmNjNlZjM4OGZlMzRhZTI5MjI3OGQ3Y2VlNGEyYTRjL3RhYmxlcmFuZ2U6MWY2M2VmMzg4ZmUzNGFlMjkyMjc4ZDdjZWU0YTJhNGNfMi01LTEtMS0w_6e738185-69a6-4e07-b8e6-0fecc3d384d5"
      unitRef="usd">5077700000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i4b9c454823f244cd80d1fefee5471031_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182MS9mcmFnOjFiMTIxNTdlNmQ0NzRjNDdiNjljYzkwODJhZWQ5M2FjL3RhYmxlOjFmNjNlZjM4OGZlMzRhZTI5MjI3OGQ3Y2VlNGEyYTRjL3RhYmxlcmFuZ2U6MWY2M2VmMzg4ZmUzNGFlMjkyMjc4ZDdjZWU0YTJhNGNfMi03LTEtMS0w_f9b2cf66-8786-432e-9fac-b1f4beac9f19"
      unitRef="usd">2316600000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i16c121b145194cf6abb5882efd1600bb_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182MS9mcmFnOjFiMTIxNTdlNmQ0NzRjNDdiNjljYzkwODJhZWQ5M2FjL3RhYmxlOjFmNjNlZjM4OGZlMzRhZTI5MjI3OGQ3Y2VlNGEyYTRjL3RhYmxlcmFuZ2U6MWY2M2VmMzg4ZmUzNGFlMjkyMjc4ZDdjZWU0YTJhNGNfMi05LTEtMS0w_be88bec0-5080-44f2-8b56-af297d70854d"
      unitRef="usd">7379300000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i16c121b145194cf6abb5882efd1600bb_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182MS9mcmFnOjFiMTIxNTdlNmQ0NzRjNDdiNjljYzkwODJhZWQ5M2FjL3RhYmxlOjFmNjNlZjM4OGZlMzRhZTI5MjI3OGQ3Y2VlNGEyYTRjL3RhYmxlcmFuZ2U6MWY2M2VmMzg4ZmUzNGFlMjkyMjc4ZDdjZWU0YTJhNGNfMi0xMS0xLTEtMA_01d6f044-58dc-4e59-aee2-19a4f8dd31c6"
      unitRef="usd">4881400000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i16c121b145194cf6abb5882efd1600bb_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182MS9mcmFnOjFiMTIxNTdlNmQ0NzRjNDdiNjljYzkwODJhZWQ5M2FjL3RhYmxlOjFmNjNlZjM4OGZlMzRhZTI5MjI3OGQ3Y2VlNGEyYTRjL3RhYmxlcmFuZ2U6MWY2M2VmMzg4ZmUzNGFlMjkyMjc4ZDdjZWU0YTJhNGNfMi0xMy0xLTEtMA_4763cc4b-7b5c-4991-b44a-9033df5778a9"
      unitRef="usd">2497900000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i11500168fa8a442f878e3a3fd7879581_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182MS9mcmFnOjFiMTIxNTdlNmQ0NzRjNDdiNjljYzkwODJhZWQ5M2FjL3RhYmxlOjFmNjNlZjM4OGZlMzRhZTI5MjI3OGQ3Y2VlNGEyYTRjL3RhYmxlcmFuZ2U6MWY2M2VmMzg4ZmUzNGFlMjkyMjc4ZDdjZWU0YTJhNGNfMy0zLTEtMS0w_6a2f6ea5-0777-4867-9a1e-8b0b6f83e96a"
      unitRef="usd">943000000.0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i11500168fa8a442f878e3a3fd7879581_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182MS9mcmFnOjFiMTIxNTdlNmQ0NzRjNDdiNjljYzkwODJhZWQ5M2FjL3RhYmxlOjFmNjNlZjM4OGZlMzRhZTI5MjI3OGQ3Y2VlNGEyYTRjL3RhYmxlcmFuZ2U6MWY2M2VmMzg4ZmUzNGFlMjkyMjc4ZDdjZWU0YTJhNGNfMy01LTEtMS0w_090143a9-b666-48ee-844c-d363d811c24b"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i11500168fa8a442f878e3a3fd7879581_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182MS9mcmFnOjFiMTIxNTdlNmQ0NzRjNDdiNjljYzkwODJhZWQ5M2FjL3RhYmxlOjFmNjNlZjM4OGZlMzRhZTI5MjI3OGQ3Y2VlNGEyYTRjL3RhYmxlcmFuZ2U6MWY2M2VmMzg4ZmUzNGFlMjkyMjc4ZDdjZWU0YTJhNGNfMy03LTEtMS0w_04b6f9a4-17a7-4eaf-9e3c-189f034da095"
      unitRef="usd">943000000.0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i3481a276c03d48bf9b2c07bcb87daf78_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182MS9mcmFnOjFiMTIxNTdlNmQ0NzRjNDdiNjljYzkwODJhZWQ5M2FjL3RhYmxlOjFmNjNlZjM4OGZlMzRhZTI5MjI3OGQ3Y2VlNGEyYTRjL3RhYmxlcmFuZ2U6MWY2M2VmMzg4ZmUzNGFlMjkyMjc4ZDdjZWU0YTJhNGNfMy05LTEtMS0w_35c30c88-a251-46ac-b587-e2d904329683"
      unitRef="usd">965500000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i3481a276c03d48bf9b2c07bcb87daf78_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182MS9mcmFnOjFiMTIxNTdlNmQ0NzRjNDdiNjljYzkwODJhZWQ5M2FjL3RhYmxlOjFmNjNlZjM4OGZlMzRhZTI5MjI3OGQ3Y2VlNGEyYTRjL3RhYmxlcmFuZ2U6MWY2M2VmMzg4ZmUzNGFlMjkyMjc4ZDdjZWU0YTJhNGNfMy0xMS0xLTEtMA_f115e35e-1e07-4e0c-bd0d-431db9063d03"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i3481a276c03d48bf9b2c07bcb87daf78_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182MS9mcmFnOjFiMTIxNTdlNmQ0NzRjNDdiNjljYzkwODJhZWQ5M2FjL3RhYmxlOjFmNjNlZjM4OGZlMzRhZTI5MjI3OGQ3Y2VlNGEyYTRjL3RhYmxlcmFuZ2U6MWY2M2VmMzg4ZmUzNGFlMjkyMjc4ZDdjZWU0YTJhNGNfMy0xMy0xLTEtMA_97d38f40-4174-45d5-b5f8-89f673582da8"
      unitRef="usd">965500000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i21ae35839aed4acb8ce3728a8d65c8c4_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182MS9mcmFnOjFiMTIxNTdlNmQ0NzRjNDdiNjljYzkwODJhZWQ5M2FjL3RhYmxlOjFmNjNlZjM4OGZlMzRhZTI5MjI3OGQ3Y2VlNGEyYTRjL3RhYmxlcmFuZ2U6MWY2M2VmMzg4ZmUzNGFlMjkyMjc4ZDdjZWU0YTJhNGNfNC0zLTEtMS0w_6f90a60b-5592-4e4c-b5f4-ab514ecfde2c"
      unitRef="usd">64000000.0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i21ae35839aed4acb8ce3728a8d65c8c4_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182MS9mcmFnOjFiMTIxNTdlNmQ0NzRjNDdiNjljYzkwODJhZWQ5M2FjL3RhYmxlOjFmNjNlZjM4OGZlMzRhZTI5MjI3OGQ3Y2VlNGEyYTRjL3RhYmxlcmFuZ2U6MWY2M2VmMzg4ZmUzNGFlMjkyMjc4ZDdjZWU0YTJhNGNfNC01LTEtMS0w_eb9c0554-7183-4097-9ea2-24980863c06a"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i21ae35839aed4acb8ce3728a8d65c8c4_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182MS9mcmFnOjFiMTIxNTdlNmQ0NzRjNDdiNjljYzkwODJhZWQ5M2FjL3RhYmxlOjFmNjNlZjM4OGZlMzRhZTI5MjI3OGQ3Y2VlNGEyYTRjL3RhYmxlcmFuZ2U6MWY2M2VmMzg4ZmUzNGFlMjkyMjc4ZDdjZWU0YTJhNGNfNC03LTEtMS0w_ab02a473-bf39-4d8f-8ddf-d0dcd80afc8c"
      unitRef="usd">64000000.0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="if562d8cc7f4f4e548b86cb2f63c89067_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182MS9mcmFnOjFiMTIxNTdlNmQ0NzRjNDdiNjljYzkwODJhZWQ5M2FjL3RhYmxlOjFmNjNlZjM4OGZlMzRhZTI5MjI3OGQ3Y2VlNGEyYTRjL3RhYmxlcmFuZ2U6MWY2M2VmMzg4ZmUzNGFlMjkyMjc4ZDdjZWU0YTJhNGNfNC05LTEtMS0w_274ccb3c-3792-445b-9e02-cf52895cfb8b"
      unitRef="usd">64000000.0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="if562d8cc7f4f4e548b86cb2f63c89067_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182MS9mcmFnOjFiMTIxNTdlNmQ0NzRjNDdiNjljYzkwODJhZWQ5M2FjL3RhYmxlOjFmNjNlZjM4OGZlMzRhZTI5MjI3OGQ3Y2VlNGEyYTRjL3RhYmxlcmFuZ2U6MWY2M2VmMzg4ZmUzNGFlMjkyMjc4ZDdjZWU0YTJhNGNfNC0xMS0xLTEtMA_c0986cc5-f032-4c82-a039-161b194372ef"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="if562d8cc7f4f4e548b86cb2f63c89067_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182MS9mcmFnOjFiMTIxNTdlNmQ0NzRjNDdiNjljYzkwODJhZWQ5M2FjL3RhYmxlOjFmNjNlZjM4OGZlMzRhZTI5MjI3OGQ3Y2VlNGEyYTRjL3RhYmxlcmFuZ2U6MWY2M2VmMzg4ZmUzNGFlMjkyMjc4ZDdjZWU0YTJhNGNfNC0xMy0xLTEtMA_7b3c6674-6e7e-40b5-8fa7-05c7de2bc3e1"
      unitRef="usd">64000000.0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182MS9mcmFnOjFiMTIxNTdlNmQ0NzRjNDdiNjljYzkwODJhZWQ5M2FjL3RhYmxlOjFmNjNlZjM4OGZlMzRhZTI5MjI3OGQ3Y2VlNGEyYTRjL3RhYmxlcmFuZ2U6MWY2M2VmMzg4ZmUzNGFlMjkyMjc4ZDdjZWU0YTJhNGNfNS0zLTEtMS0w_3cc1e840-8f15-4dfc-9e58-fcb4afc2f127"
      unitRef="usd">8401300000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182MS9mcmFnOjFiMTIxNTdlNmQ0NzRjNDdiNjljYzkwODJhZWQ5M2FjL3RhYmxlOjFmNjNlZjM4OGZlMzRhZTI5MjI3OGQ3Y2VlNGEyYTRjL3RhYmxlcmFuZ2U6MWY2M2VmMzg4ZmUzNGFlMjkyMjc4ZDdjZWU0YTJhNGNfNS01LTEtMS0w_8db2bed7-06b6-4716-bf55-7a71e5fb3396"
      unitRef="usd">5077700000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182MS9mcmFnOjFiMTIxNTdlNmQ0NzRjNDdiNjljYzkwODJhZWQ5M2FjL3RhYmxlOjFmNjNlZjM4OGZlMzRhZTI5MjI3OGQ3Y2VlNGEyYTRjL3RhYmxlcmFuZ2U6MWY2M2VmMzg4ZmUzNGFlMjkyMjc4ZDdjZWU0YTJhNGNfNS03LTEtMS0w_8d28025b-a8f8-4ebf-bbd9-7e8b1d7b345d"
      unitRef="usd">3323600000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="i626282e786b7454d83b617e9e83963e6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182MS9mcmFnOjFiMTIxNTdlNmQ0NzRjNDdiNjljYzkwODJhZWQ5M2FjL3RhYmxlOjFmNjNlZjM4OGZlMzRhZTI5MjI3OGQ3Y2VlNGEyYTRjL3RhYmxlcmFuZ2U6MWY2M2VmMzg4ZmUzNGFlMjkyMjc4ZDdjZWU0YTJhNGNfNS05LTEtMS0w_e0b2d253-7719-448a-ad20-28e0fbb3ab28"
      unitRef="usd">8408800000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i626282e786b7454d83b617e9e83963e6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182MS9mcmFnOjFiMTIxNTdlNmQ0NzRjNDdiNjljYzkwODJhZWQ5M2FjL3RhYmxlOjFmNjNlZjM4OGZlMzRhZTI5MjI3OGQ3Y2VlNGEyYTRjL3RhYmxlcmFuZ2U6MWY2M2VmMzg4ZmUzNGFlMjkyMjc4ZDdjZWU0YTJhNGNfNS0xMS0xLTEtMA_0341c505-c712-4d33-9cd4-542eb94a162a"
      unitRef="usd">4881400000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i626282e786b7454d83b617e9e83963e6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182MS9mcmFnOjFiMTIxNTdlNmQ0NzRjNDdiNjljYzkwODJhZWQ5M2FjL3RhYmxlOjFmNjNlZjM4OGZlMzRhZTI5MjI3OGQ3Y2VlNGEyYTRjL3RhYmxlcmFuZ2U6MWY2M2VmMzg4ZmUzNGFlMjkyMjc4ZDdjZWU0YTJhNGNfNS0xMy0xLTEtMA_0c9ac385-b595-4a66-931a-40c178977886"
      unitRef="usd">3527400000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets
      contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182MS9mcmFnOjFiMTIxNTdlNmQ0NzRjNDdiNjljYzkwODJhZWQ5M2FjL3RleHRyZWdpb246MWIxMjE1N2U2ZDQ3NGM0N2I2OWNjOTA4MmFlZDkzYWNfMjQ5_26b35267-3899-4e46-802f-26ad462e98b7"
      unitRef="usd">82600000</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182MS9mcmFnOjFiMTIxNTdlNmQ0NzRjNDdiNjljYzkwODJhZWQ5M2FjL3RleHRyZWdpb246MWIxMjE1N2U2ZDQ3NGM0N2I2OWNjOTA4MmFlZDkzYWNfMjU2_a935bdd1-71ac-4358-a642-223d16557b48"
      unitRef="usd">215600000</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets
      contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182MS9mcmFnOjFiMTIxNTdlNmQ0NzRjNDdiNjljYzkwODJhZWQ5M2FjL3RleHRyZWdpb246MWIxMjE1N2U2ZDQ3NGM0N2I2OWNjOTA4MmFlZDkzYWNfMjg2_92944d6d-69db-4400-b141-cfdfc08b395b"
      unitRef="usd">283900000</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182MS9mcmFnOjFiMTIxNTdlNmQ0NzRjNDdiNjljYzkwODJhZWQ5M2FjL3RleHRyZWdpb246MWIxMjE1N2U2ZDQ3NGM0N2I2OWNjOTA4MmFlZDkzYWNfMjkz_519699f0-5f44-4ce5-8b91-d29ae09cf675"
      unitRef="usd">422200000</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets
      contextRef="i5dc2c86a61e549f6b10a9b94d684a51a_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182MS9mcmFnOjFiMTIxNTdlNmQ0NzRjNDdiNjljYzkwODJhZWQ5M2FjL3RleHRyZWdpb246MWIxMjE1N2U2ZDQ3NGM0N2I2OWNjOTA4MmFlZDkzYWNfMTA5OTUxMTYzMjM3NQ_7a0f52e8-3a1e-4072-974b-9b4dd78b7d50"
      unitRef="usd">19300000</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets
      contextRef="ic493d11fbb2f44b19c639b7aea48e26a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182MS9mcmFnOjFiMTIxNTdlNmQ0NzRjNDdiNjljYzkwODJhZWQ5M2FjL3RleHRyZWdpb246MWIxMjE1N2U2ZDQ3NGM0N2I2OWNjOTA4MmFlZDkzYWNfMTA5OTUxMTYzMjM3NQ_a83302f0-b098-4f3a-bad6-b51f7efaaf30"
      unitRef="usd">19300000</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets
      contextRef="ide28bbdab94947a3ba38457611aacf91_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182MS9mcmFnOjFiMTIxNTdlNmQ0NzRjNDdiNjljYzkwODJhZWQ5M2FjL3RleHRyZWdpb246MWIxMjE1N2U2ZDQ3NGM0N2I2OWNjOTA4MmFlZDkzYWNfMTA5OTUxMTYzMTA0Nw_a3f34b73-f583-4010-b9dc-cb7455fc5a38"
      unitRef="usd">215900000</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets
      contextRef="if5ac9acf99f240868c0779db73b11128_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182MS9mcmFnOjFiMTIxNTdlNmQ0NzRjNDdiNjljYzkwODJhZWQ5M2FjL3RleHRyZWdpb246MWIxMjE1N2U2ZDQ3NGM0N2I2OWNjOTA4MmFlZDkzYWNfMTA5OTUxMTYzMTA0Nw_e47c7d7e-830f-4929-97a6-929515149d3a"
      unitRef="usd">215900000</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182MS9mcmFnOjFiMTIxNTdlNmQ0NzRjNDdiNjljYzkwODJhZWQ5M2FjL3RleHRyZWdpb246MWIxMjE1N2U2ZDQ3NGM0N2I2OWNjOTA4MmFlZDkzYWNfMTA5OTUxMTYzMjgyNA_ffd5931e-84dd-4703-a946-a93ae2c6c94a"
      unitRef="usd">63300000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182MS9mcmFnOjFiMTIxNTdlNmQ0NzRjNDdiNjljYzkwODJhZWQ5M2FjL3RleHRyZWdpb246MWIxMjE1N2U2ZDQ3NGM0N2I2OWNjOTA4MmFlZDkzYWNfMTA5OTUxMTYzMjgzOA_3792b087-378d-4500-babd-02bb9eda2cc9"
      unitRef="usd">196300000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182MS9mcmFnOjFiMTIxNTdlNmQ0NzRjNDdiNjljYzkwODJhZWQ5M2FjL3RleHRyZWdpb246MWIxMjE1N2U2ZDQ3NGM0N2I2OWNjOTA4MmFlZDkzYWNfMTA5OTUxMTYzMjYwMw_56790484-db0d-4666-9210-0431d087fe2f"
      unitRef="usd">68000000.0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182MS9mcmFnOjFiMTIxNTdlNmQ0NzRjNDdiNjljYzkwODJhZWQ5M2FjL3RleHRyZWdpb246MWIxMjE1N2U2ZDQ3NGM0N2I2OWNjOTA4MmFlZDkzYWNfMTA5OTUxMTYzMjYxMg_a5935aaa-f7c3-466c-b2a2-ca9f2f6bb8f5"
      unitRef="usd">206300000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets
      contextRef="if669468af2b1428fbb2d5e8a25e54053_I20190607"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182MS9mcmFnOjFiMTIxNTdlNmQ0NzRjNDdiNjljYzkwODJhZWQ5M2FjL3RleHRyZWdpb246MWIxMjE1N2U2ZDQ3NGM0N2I2OWNjOTA4MmFlZDkzYWNfMTc2Mg_a7872836-98c8-47e5-ae0f-755a623fbe5f"
      unitRef="usd">700000000.0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="id5ed0dc28e704ee58e687f720a4af0c0_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182MS9mcmFnOjFiMTIxNTdlNmQ0NzRjNDdiNjljYzkwODJhZWQ5M2FjL3RleHRyZWdpb246MWIxMjE1N2U2ZDQ3NGM0N2I2OWNjOTA4MmFlZDkzYWNfMjM1Nw_0e893ed1-d7b3-4f76-a7e6-4a1acb6611f4"
      unitRef="usd">167600000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182MS9mcmFnOjFiMTIxNTdlNmQ0NzRjNDdiNjljYzkwODJhZWQ5M2FjL3RleHRyZWdpb246MWIxMjE1N2U2ZDQ3NGM0N2I2OWNjOTA4MmFlZDkzYWNfMjc4Mw_a663d37b-905e-4590-a996-58c361587c3a">he estimated future amortization of finite-lived intangible assets for the next five years is expected to be as follows:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:78.724%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:18.346%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;As of September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020 (remaining three months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;60.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;205.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;215.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;215.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;225.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;220.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
      contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182MS9mcmFnOjFiMTIxNTdlNmQ0NzRjNDdiNjljYzkwODJhZWQ5M2FjL3RhYmxlOjlkNmRhMDM0Yjk0MjRhNTc4OWRhNzM1Mjg5MjY4N2QzL3RhYmxlcmFuZ2U6OWQ2ZGEwMzRiOTQyNGE1Nzg5ZGE3MzUyODkyNjg3ZDNfMS0yLTEtMS0w_3f9bc768-16e2-451b-ab5e-84557055fd3f"
      unitRef="usd">60000000.0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182MS9mcmFnOjFiMTIxNTdlNmQ0NzRjNDdiNjljYzkwODJhZWQ5M2FjL3RhYmxlOjlkNmRhMDM0Yjk0MjRhNTc4OWRhNzM1Mjg5MjY4N2QzL3RhYmxlcmFuZ2U6OWQ2ZGEwMzRiOTQyNGE1Nzg5ZGE3MzUyODkyNjg3ZDNfMi0yLTEtMS0w_50a3c271-2f1f-4840-96b9-03b366eca7a6"
      unitRef="usd">205000000.0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182MS9mcmFnOjFiMTIxNTdlNmQ0NzRjNDdiNjljYzkwODJhZWQ5M2FjL3RhYmxlOjlkNmRhMDM0Yjk0MjRhNTc4OWRhNzM1Mjg5MjY4N2QzL3RhYmxlcmFuZ2U6OWQ2ZGEwMzRiOTQyNGE1Nzg5ZGE3MzUyODkyNjg3ZDNfMy0yLTEtMS0w_8a0b5d05-1b36-4d7c-9aa5-637ea45a7c00"
      unitRef="usd">215000000.0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182MS9mcmFnOjFiMTIxNTdlNmQ0NzRjNDdiNjljYzkwODJhZWQ5M2FjL3RhYmxlOjlkNmRhMDM0Yjk0MjRhNTc4OWRhNzM1Mjg5MjY4N2QzL3RhYmxlcmFuZ2U6OWQ2ZGEwMzRiOTQyNGE1Nzg5ZGE3MzUyODkyNjg3ZDNfNC0yLTEtMS0w_fd5360dc-97ac-47cc-997e-7b99b282678d"
      unitRef="usd">215000000.0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182MS9mcmFnOjFiMTIxNTdlNmQ0NzRjNDdiNjljYzkwODJhZWQ5M2FjL3RhYmxlOjlkNmRhMDM0Yjk0MjRhNTc4OWRhNzM1Mjg5MjY4N2QzL3RhYmxlcmFuZ2U6OWQ2ZGEwMzRiOTQyNGE1Nzg5ZGE3MzUyODkyNjg3ZDNfNS0yLTEtMS0w_33ccbad2-12ee-44ce-b1f2-47ab4dbfaccd"
      unitRef="usd">225000000.0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182MS9mcmFnOjFiMTIxNTdlNmQ0NzRjNDdiNjljYzkwODJhZWQ5M2FjL3RhYmxlOjlkNmRhMDM0Yjk0MjRhNTc4OWRhNzM1Mjg5MjY4N2QzL3RhYmxlcmFuZ2U6OWQ2ZGEwMzRiOTQyNGE1Nzg5ZGE3MzUyODkyNjg3ZDNfNi0yLTEtMS0w_c939fe73-ef86-4403-ad9c-e5e5811f9f71"
      unitRef="usd">220000000.0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182MS9mcmFnOjFiMTIxNTdlNmQ0NzRjNDdiNjljYzkwODJhZWQ5M2FjL3RleHRyZWdpb246MWIxMjE1N2U2ZDQ3NGM0N2I2OWNjOTA4MmFlZDkzYWNfMjc5Ng_f7b03778-bfad-482c-85dd-4a99d749a0b0">&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table provides a roll forward of the changes in our goodwill balance:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:78.724%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:18.346%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;As of September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Goodwill, December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;5,757.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(2.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Goodwill, September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;5,755.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="i626282e786b7454d83b617e9e83963e6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182MS9mcmFnOjFiMTIxNTdlNmQ0NzRjNDdiNjljYzkwODJhZWQ5M2FjL3RhYmxlOjZhM2ZjNWI5YTQ3NTQzYzI4YWE4ZmJhNWE4NjYxOGMzL3RhYmxlcmFuZ2U6NmEzZmM1YjlhNDc1NDNjMjhhYThmYmE1YTg2NjE4YzNfMS0yLTEtMS0w_b1071b58-4813-44ad-9a61-198a2e9ce0fa"
      unitRef="usd">5757800000</us-gaap:Goodwill>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182MS9mcmFnOjFiMTIxNTdlNmQ0NzRjNDdiNjljYzkwODJhZWQ5M2FjL3RhYmxlOjZhM2ZjNWI5YTQ3NTQzYzI4YWE4ZmJhNWE4NjYxOGMzL3RhYmxlcmFuZ2U6NmEzZmM1YjlhNDc1NDNjMjhhYThmYmE1YTg2NjE4YzNfMy0yLTEtMS0w_84067671-0156-4671-8409-0e4789cf3777"
      unitRef="usd">-2100000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:Goodwill
      contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182MS9mcmFnOjFiMTIxNTdlNmQ0NzRjNDdiNjljYzkwODJhZWQ5M2FjL3RhYmxlOjZhM2ZjNWI5YTQ3NTQzYzI4YWE4ZmJhNWE4NjYxOGMzL3RhYmxlcmFuZ2U6NmEzZmM1YjlhNDc1NDNjMjhhYThmYmE1YTg2NjE4YzNfNC0yLTEtMS0w_a4d66e80-d728-4845-9033-703dfacc0f78"
      unitRef="usd">5755700000</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182MS9mcmFnOjFiMTIxNTdlNmQ0NzRjNDdiNjljYzkwODJhZWQ5M2FjL3RleHRyZWdpb246MWIxMjE1N2U2ZDQ3NGM0N2I2OWNjOTA4MmFlZDkzYWNfMjY0NQ_d53db9d2-4089-4f16-8019-f3c52ace89d0"
      unitRef="usd">0</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RleHRyZWdpb246MjcwNWY4ZDY1MThjNDkyZWJiNWZiYzRmNmYwOGJiMTdfNDUzOQ_5b064bd7-b1c5-4761-8605-677cac55040c">&lt;div style="text-indent:24.75pt;margin-top:3pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:40.420%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.788%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.788%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.788%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.796%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;As of September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Quoted&#160;Prices&lt;br/&gt;in Active&lt;br/&gt;Markets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Significant&#160;Other&lt;br/&gt;Observable&#160;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-style:italic;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;1,570.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;1,570.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Marketable debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;1,443.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;1,443.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;767.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;767.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Mortgage and other asset backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;153.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;153.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;868.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;276.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;592.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;26.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;26.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Plan assets for deferred compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;26.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;26.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:29.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;4,856.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;276.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;4,579.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-style:italic;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;99.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;99.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Contingent consideration obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;322.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;322.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:29.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;422.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;99.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;322.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:40.420%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.788%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.788%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.788%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.796%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Quoted&#160;Prices&lt;br/&gt;in Active&lt;br/&gt;Markets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Significant&#160;Other&lt;br/&gt;Observable&#160;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-style:italic;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,541.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,541.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Marketable debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,695.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,695.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,013.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,013.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Mortgage and other asset backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;261.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;261.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;337.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;329.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;43.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;43.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Plan assets for deferred compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;27.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;27.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:29.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,920.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,912.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-style:italic;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Contingent consideration obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;346.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;346.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:29.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;354.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;346.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;There have been no material impairments of our assets measured and carried at fair value during the three and nine months ended September 30, 2020. In addition, there were no changes in valuation techniques during the three and nine months ended September 30, 2020. The fair value of Level 2 instruments classified as cash equivalents and marketable debt securities was determined through third-party pricing services. The fair value of Level 2 instruments classified as marketable equity securities represents our investments in Sangamo Therapeutics, Inc. (Sangamo) common stock and Denali Therapeutics Inc. (Denali) common stock and are valued using an option pricing valuation model as the investments are each subject to certain holding period restrictions. For additional information on our investments in Sangamo and Denali common stock, please read &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Note 8, Financial Instruments,&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Our investments in marketable equity securities also include shares of Ionis Pharmaceuticals, Inc. (Ionis) common stock acquired in June 2018. Our shares of Ionis common stock were initially subject to certain holding period restrictions that expired during the first quarter of 2020. The fair value of this investment was a Level 1 measurement as of September 30, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;For a description of our validation procedures related to prices provided by third-party pricing services and our option pricing valuation model, please read &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Note 1, Summary of Significant Accounting Policies - Fair Value Measurements,&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; to our consolidated financial statements included in our 2019 Form 10-K. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table summarizes the significant unobservable inputs in the fair value measurement of our contingent consideration obligations as of September 30, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:24.266%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.724%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.416%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:21.773%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.536%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.020%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="27" style="padding-top:2px;padding-bottom:2px;background-color:#dbdbdb;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#026dce;background-color:rgb(255,255,255, 0.0);"&gt;As of September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Valuation Technique&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unobservable Input&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Range&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted Average&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-style:italic;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Contingent consideration obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dbdbdb;text-align:left;vertical-align:middle;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dbdbdb;text-align:right;vertical-align:middle;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;322.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dbdbdb;text-align:right;vertical-align:middle;padding-right:1pt;"/&gt;&lt;td colspan="3" rowspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Discounted cash flow&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dbdbdb;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#026dce;background-color:rgb(255,255,255, 0.0);"&gt;0.57% to 0.89%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dbdbdb;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#026dce;background-color:rgb(255,255,255, 0.0);"&gt;0.63%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected timing of achievement of development milestones&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dbdbdb;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#026dce;background-color:rgb(255,255,255, 0.0);"&gt;2021 to 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dbdbdb;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#026dce;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The weighted average discount rate was calculated based on the relative fair value of our contingent consideration obligations. In addition, we apply various probabilities of technological and regulatory success, ranging from high single digits to certain probability, to the valuation models to estimate the fair values of our contingent consideration obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:11.25pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Debt Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The fair and carrying values of our debt instruments, which are Level&#160;2 liabilities, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:42.091%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.369%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.369%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.369%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.374%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;As of September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Carrying&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Carrying&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%;"&gt;2.900% Senior Notes due September 15, 2020&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,509.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,495.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3.625% Senior Notes due September 15, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;1,058.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;997.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,038.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;996.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4.050% Senior Notes due September 15, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;1,988.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;1,740.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,897.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,739.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.250% Senior Notes due May 1, 2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;1,532.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;1,491.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.200% Senior Notes due September 15, 2045&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;2,286.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;1,723.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,107.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,722.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3.150% Senior Notes due May 1, 2050&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;1,470.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;1,472.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;8,336.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;7,425.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,553.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,954.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:6pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:33.017%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:31.105%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:32.578%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;"&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;vertical-align:top;"&gt;(1) &lt;/sup&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;"&gt;Our 2.900% Senior Notes due September 15, 2020, were redeemed in full in May 2020 using the net proceeds from the issuance on April 30, 2020, of our senior unsecured notes for an aggregate principal amount of $3.0 billion. For additional information, please read &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Note 11, Indebtedness,&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;"&gt; to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The fair values of each of our series of Senior Notes were determined through market, observable and corroborated sources. For additional information related to our Senior Notes issued on September 15, 2015, please read &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Note 12,&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Indebtedness,&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; to our consolidated financial statements included in our 2019 Form 10-K. For additional information related to our Senior Notes issued on April 30, 2020, please read &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Note 11, Indebtedness,&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:11.25pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Contingent Consideration Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In connection with our acquisitions of Convergence and BIN, we agreed to make additional payments based upon the achievement of certain milestone events. The following table provides a roll forward of the fair values of our contingent consideration obligations, which includes Level 3 measurements:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:47.438%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.034%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.034%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.034%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.040%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair value, beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;351.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;401.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;346.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;409.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Changes in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(29.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(57.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(23.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(66.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair value, end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;322.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;343.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;322.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;343.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As of September 30, 2020 and December 31, 2019, approximately $173.2 million and $197.7 million, respectively, of the fair value of our total contingent consideration obligations was reflected as a component of other long-term liabilities in our condensed consolidated balance sheets with the remaining balance reflected as a component of accrued expenses and other.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;For the three and nine months ended September 30, 2020, changes in the fair value of our contingent consideration obligations were primarily due to changes in the probability and the expected timing of the achievement of certain remaining developmental milestones as well as changes in the interest rates used to revalue our contingent consideration liabilities and the passage of time.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;For the three and nine months ended September 30, 2019, changes in the fair value of our contingent consideration obligations were primarily due to the discontinuation of the Phase 2b study of BG00011 for the potential treatment of idiopathic pulmonary fibrosis resulting in a reduction of our contingent consideration obligations of $61.2&#160;million, partially offset by a decrease in interest rates used to revalue our contingent consideration liabilities and the passage of time.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RleHRyZWdpb246MjcwNWY4ZDY1MThjNDkyZWJiNWZiYzRmNmYwOGJiMTdfNDU0Mg_fd550c8f-e097-42e7-9445-ffa63cf7c9bf">&lt;div style="text-indent:24.75pt;margin-top:3pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:40.420%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.788%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.788%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.788%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.796%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;As of September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Quoted&#160;Prices&lt;br/&gt;in Active&lt;br/&gt;Markets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Significant&#160;Other&lt;br/&gt;Observable&#160;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-style:italic;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;1,570.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;1,570.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Marketable debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;1,443.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;1,443.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;767.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;767.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Mortgage and other asset backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;153.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;153.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;868.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;276.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;592.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;26.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;26.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Plan assets for deferred compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;26.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;26.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:29.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;4,856.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;276.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;4,579.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-style:italic;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;99.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;99.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Contingent consideration obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;322.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;322.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:29.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;422.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;99.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;322.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:40.420%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.788%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.788%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.788%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.796%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Quoted&#160;Prices&lt;br/&gt;in Active&lt;br/&gt;Markets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Significant&#160;Other&lt;br/&gt;Observable&#160;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-style:italic;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,541.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,541.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Marketable debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,695.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,695.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,013.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,013.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Mortgage and other asset backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;261.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;261.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;337.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;329.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;43.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;43.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Plan assets for deferred compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;27.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;27.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:29.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,920.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,912.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-style:italic;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Contingent consideration obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;346.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;346.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:29.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;354.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;346.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i3733833dc5534d8e823879ef2ca35162_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjFkN2EzMDhiOWRlZDRmY2Q5MDg3NDUxMDlkZDExYjhhL3RhYmxlcmFuZ2U6MWQ3YTMwOGI5ZGVkNGZjZDkwODc0NTEwOWRkMTFiOGFfMi0yLTEtMS0w_b5e2c70d-19a7-4f50-ac1e-a967119dcea6"
      unitRef="usd">1570300000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i2937e4b1496b4a52a0d3e66401ae9216_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjFkN2EzMDhiOWRlZDRmY2Q5MDg3NDUxMDlkZDExYjhhL3RhYmxlcmFuZ2U6MWQ3YTMwOGI5ZGVkNGZjZDkwODc0NTEwOWRkMTFiOGFfMi00LTEtMS0w_190c156d-90b6-42c8-8311-cdcacdff7e53"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i6d5405f808014e29ae408f670b51a09f_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjFkN2EzMDhiOWRlZDRmY2Q5MDg3NDUxMDlkZDExYjhhL3RhYmxlcmFuZ2U6MWQ3YTMwOGI5ZGVkNGZjZDkwODc0NTEwOWRkMTFiOGFfMi02LTEtMS0w_425630d2-62ea-4b6b-aab4-a48d6de1705b"
      unitRef="usd">1570300000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i8a4caf6e3ead4de1943986bbd01cf562_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjFkN2EzMDhiOWRlZDRmY2Q5MDg3NDUxMDlkZDExYjhhL3RhYmxlcmFuZ2U6MWQ3YTMwOGI5ZGVkNGZjZDkwODc0NTEwOWRkMTFiOGFfMi04LTEtMS0w_51fe0fca-a081-484e-9882-784c5e5106d4"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9fa1b53a700943f2bdb14f74caa79af6_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjFkN2EzMDhiOWRlZDRmY2Q5MDg3NDUxMDlkZDExYjhhL3RhYmxlcmFuZ2U6MWQ3YTMwOGI5ZGVkNGZjZDkwODc0NTEwOWRkMTFiOGFfNC0yLTEtMS0w_0d0cd6fb-f0d9-4e63-8831-0234a4a5e561"
      unitRef="usd">1443800000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i72583de967dc40ddb4cff73d7209ce4c_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjFkN2EzMDhiOWRlZDRmY2Q5MDg3NDUxMDlkZDExYjhhL3RhYmxlcmFuZ2U6MWQ3YTMwOGI5ZGVkNGZjZDkwODc0NTEwOWRkMTFiOGFfNC00LTEtMS0w_5489a9c4-89ef-4993-883e-4faa3049b8f2"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5876b06547fb4838bc5be5aca105c206_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjFkN2EzMDhiOWRlZDRmY2Q5MDg3NDUxMDlkZDExYjhhL3RhYmxlcmFuZ2U6MWQ3YTMwOGI5ZGVkNGZjZDkwODc0NTEwOWRkMTFiOGFfNC02LTEtMS0w_8b52d1f9-632e-4640-8592-addf44eae018"
      unitRef="usd">1443800000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iffeaee7ccfe84deb8024b6a3c6400e05_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjFkN2EzMDhiOWRlZDRmY2Q5MDg3NDUxMDlkZDExYjhhL3RhYmxlcmFuZ2U6MWQ3YTMwOGI5ZGVkNGZjZDkwODc0NTEwOWRkMTFiOGFfNC04LTEtMS0w_bfd76605-73e5-43ba-9aaa-5aedc1b1e0cd"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i366fc4865f1141d881e72475b885ad6b_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjFkN2EzMDhiOWRlZDRmY2Q5MDg3NDUxMDlkZDExYjhhL3RhYmxlcmFuZ2U6MWQ3YTMwOGI5ZGVkNGZjZDkwODc0NTEwOWRkMTFiOGFfNS0yLTEtMS0w_a4e114fe-1d89-47cf-aa62-cc3ece27ffa7"
      unitRef="usd">767400000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3762ea1be6864e498c8620d932d2da39_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjFkN2EzMDhiOWRlZDRmY2Q5MDg3NDUxMDlkZDExYjhhL3RhYmxlcmFuZ2U6MWQ3YTMwOGI5ZGVkNGZjZDkwODc0NTEwOWRkMTFiOGFfNS00LTEtMS0w_f9442411-cad1-4b33-b6fa-e39c0c1ed996"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4bcbf6cedff544d5a8a856091fd31a3f_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjFkN2EzMDhiOWRlZDRmY2Q5MDg3NDUxMDlkZDExYjhhL3RhYmxlcmFuZ2U6MWQ3YTMwOGI5ZGVkNGZjZDkwODc0NTEwOWRkMTFiOGFfNS02LTEtMS0w_9b2bdabc-c69e-41cd-8f6c-b1a6e6e9de39"
      unitRef="usd">767400000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia08462c38d1441cf88e8ec71551ea0c8_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjFkN2EzMDhiOWRlZDRmY2Q5MDg3NDUxMDlkZDExYjhhL3RhYmxlcmFuZ2U6MWQ3YTMwOGI5ZGVkNGZjZDkwODc0NTEwOWRkMTFiOGFfNS04LTEtMS0w_7fafc3c0-e2ed-40c2-a1bf-192429edb03f"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if0af6974b4d9478091a43d7c360e50da_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjFkN2EzMDhiOWRlZDRmY2Q5MDg3NDUxMDlkZDExYjhhL3RhYmxlcmFuZ2U6MWQ3YTMwOGI5ZGVkNGZjZDkwODc0NTEwOWRkMTFiOGFfNi0yLTEtMS0w_53371d9f-777c-4286-bdb7-944f8e2f9031"
      unitRef="usd">153600000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7efef111968e4853ba97bc23f3210bf0_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjFkN2EzMDhiOWRlZDRmY2Q5MDg3NDUxMDlkZDExYjhhL3RhYmxlcmFuZ2U6MWQ3YTMwOGI5ZGVkNGZjZDkwODc0NTEwOWRkMTFiOGFfNi00LTEtMS0w_bcb89aac-84b9-47ed-83fd-547cdf65cce5"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8f93695e9414499694873333956d9bdc_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjFkN2EzMDhiOWRlZDRmY2Q5MDg3NDUxMDlkZDExYjhhL3RhYmxlcmFuZ2U6MWQ3YTMwOGI5ZGVkNGZjZDkwODc0NTEwOWRkMTFiOGFfNi02LTEtMS0w_39c4d3c8-2eaa-4a05-a445-8d32add0d8de"
      unitRef="usd">153600000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib2ec3058389a4337ac5eba484681aa08_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjFkN2EzMDhiOWRlZDRmY2Q5MDg3NDUxMDlkZDExYjhhL3RhYmxlcmFuZ2U6MWQ3YTMwOGI5ZGVkNGZjZDkwODc0NTEwOWRkMTFiOGFfNi04LTEtMS0w_ca170a75-d70e-40f3-8a3d-820336ddad50"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i3733833dc5534d8e823879ef2ca35162_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjFkN2EzMDhiOWRlZDRmY2Q5MDg3NDUxMDlkZDExYjhhL3RhYmxlcmFuZ2U6MWQ3YTMwOGI5ZGVkNGZjZDkwODc0NTEwOWRkMTFiOGFfNy0yLTEtMS0w_e1fdac7d-43ee-4acf-9749-cf40ca8490b5"
      unitRef="usd">868500000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i2937e4b1496b4a52a0d3e66401ae9216_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjFkN2EzMDhiOWRlZDRmY2Q5MDg3NDUxMDlkZDExYjhhL3RhYmxlcmFuZ2U6MWQ3YTMwOGI5ZGVkNGZjZDkwODc0NTEwOWRkMTFiOGFfNy00LTEtMS0w_a9e679df-ab46-46e2-9b49-f18998fb431f"
      unitRef="usd">276500000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i6d5405f808014e29ae408f670b51a09f_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjFkN2EzMDhiOWRlZDRmY2Q5MDg3NDUxMDlkZDExYjhhL3RhYmxlcmFuZ2U6MWQ3YTMwOGI5ZGVkNGZjZDkwODc0NTEwOWRkMTFiOGFfNy02LTEtMS0w_9faa185f-7e8e-4dc0-bde6-5aee2ef86be3"
      unitRef="usd">592000000.0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i8a4caf6e3ead4de1943986bbd01cf562_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjFkN2EzMDhiOWRlZDRmY2Q5MDg3NDUxMDlkZDExYjhhL3RhYmxlcmFuZ2U6MWQ3YTMwOGI5ZGVkNGZjZDkwODc0NTEwOWRkMTFiOGFfNy04LTEtMS0w_0c7de252-b1a3-4fc9-a02f-d1cb53d2c290"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i3733833dc5534d8e823879ef2ca35162_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjFkN2EzMDhiOWRlZDRmY2Q5MDg3NDUxMDlkZDExYjhhL3RhYmxlcmFuZ2U6MWQ3YTMwOGI5ZGVkNGZjZDkwODc0NTEwOWRkMTFiOGFfOC0yLTEtMS0w_7da069c4-631d-4897-afcf-4f41353f838d"
      unitRef="usd">26000000.0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i2937e4b1496b4a52a0d3e66401ae9216_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjFkN2EzMDhiOWRlZDRmY2Q5MDg3NDUxMDlkZDExYjhhL3RhYmxlcmFuZ2U6MWQ3YTMwOGI5ZGVkNGZjZDkwODc0NTEwOWRkMTFiOGFfOC00LTEtMS0w_ce31c5e3-7528-42a6-86d3-805aae4a2184"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i6d5405f808014e29ae408f670b51a09f_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjFkN2EzMDhiOWRlZDRmY2Q5MDg3NDUxMDlkZDExYjhhL3RhYmxlcmFuZ2U6MWQ3YTMwOGI5ZGVkNGZjZDkwODc0NTEwOWRkMTFiOGFfOC02LTEtMS0w_3e1fb94d-0848-4163-aeca-31c426e8125a"
      unitRef="usd">26000000.0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i8a4caf6e3ead4de1943986bbd01cf562_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjFkN2EzMDhiOWRlZDRmY2Q5MDg3NDUxMDlkZDExYjhhL3RhYmxlcmFuZ2U6MWQ3YTMwOGI5ZGVkNGZjZDkwODc0NTEwOWRkMTFiOGFfOC04LTEtMS0w_4dc66392-cc8e-4407-a400-d3c7d632d924"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure
      contextRef="i3733833dc5534d8e823879ef2ca35162_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjFkN2EzMDhiOWRlZDRmY2Q5MDg3NDUxMDlkZDExYjhhL3RhYmxlcmFuZ2U6MWQ3YTMwOGI5ZGVkNGZjZDkwODc0NTEwOWRkMTFiOGFfOS0yLTEtMS0w_ac876fdc-fbb7-4e95-9a34-35ffbcbca228"
      unitRef="usd">26400000</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure
      contextRef="i2937e4b1496b4a52a0d3e66401ae9216_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjFkN2EzMDhiOWRlZDRmY2Q5MDg3NDUxMDlkZDExYjhhL3RhYmxlcmFuZ2U6MWQ3YTMwOGI5ZGVkNGZjZDkwODc0NTEwOWRkMTFiOGFfOS00LTEtMS0w_4b6fefcb-0fc3-42cb-bc3d-9d73f074c34f"
      unitRef="usd">0</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure
      contextRef="i6d5405f808014e29ae408f670b51a09f_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjFkN2EzMDhiOWRlZDRmY2Q5MDg3NDUxMDlkZDExYjhhL3RhYmxlcmFuZ2U6MWQ3YTMwOGI5ZGVkNGZjZDkwODc0NTEwOWRkMTFiOGFfOS02LTEtMS0w_63ad41a7-5f67-4f67-9bdb-a77ec022040d"
      unitRef="usd">26400000</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure
      contextRef="i8a4caf6e3ead4de1943986bbd01cf562_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjFkN2EzMDhiOWRlZDRmY2Q5MDg3NDUxMDlkZDExYjhhL3RhYmxlcmFuZ2U6MWQ3YTMwOGI5ZGVkNGZjZDkwODc0NTEwOWRkMTFiOGFfOS04LTEtMS0w_2366fe31-e7ca-4f13-9f28-a21f4afb799f"
      unitRef="usd">0</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i3733833dc5534d8e823879ef2ca35162_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjFkN2EzMDhiOWRlZDRmY2Q5MDg3NDUxMDlkZDExYjhhL3RhYmxlcmFuZ2U6MWQ3YTMwOGI5ZGVkNGZjZDkwODc0NTEwOWRkMTFiOGFfMTAtMi0xLTEtMA_07295017-524d-4e2b-994d-cf2319837d02"
      unitRef="usd">4856000000.0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i2937e4b1496b4a52a0d3e66401ae9216_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjFkN2EzMDhiOWRlZDRmY2Q5MDg3NDUxMDlkZDExYjhhL3RhYmxlcmFuZ2U6MWQ3YTMwOGI5ZGVkNGZjZDkwODc0NTEwOWRkMTFiOGFfMTAtNC0xLTEtMA_8fa2274e-eeaf-4b3c-888c-5d9d2e415bdc"
      unitRef="usd">276500000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i6d5405f808014e29ae408f670b51a09f_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjFkN2EzMDhiOWRlZDRmY2Q5MDg3NDUxMDlkZDExYjhhL3RhYmxlcmFuZ2U6MWQ3YTMwOGI5ZGVkNGZjZDkwODc0NTEwOWRkMTFiOGFfMTAtNi0xLTEtMA_c1a26e71-6d83-43ce-aa69-e3de82abb545"
      unitRef="usd">4579500000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i8a4caf6e3ead4de1943986bbd01cf562_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjFkN2EzMDhiOWRlZDRmY2Q5MDg3NDUxMDlkZDExYjhhL3RhYmxlcmFuZ2U6MWQ3YTMwOGI5ZGVkNGZjZDkwODc0NTEwOWRkMTFiOGFfMTAtOC0xLTEtMA_a019c09f-6620-4ad2-af91-5fa13db6b5aa"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i3733833dc5534d8e823879ef2ca35162_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjFkN2EzMDhiOWRlZDRmY2Q5MDg3NDUxMDlkZDExYjhhL3RhYmxlcmFuZ2U6MWQ3YTMwOGI5ZGVkNGZjZDkwODc0NTEwOWRkMTFiOGFfMTItMi0xLTEtMA_41c3c250-afd9-4608-a4af-72e8ee101a6a"
      unitRef="usd">99600000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i2937e4b1496b4a52a0d3e66401ae9216_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjFkN2EzMDhiOWRlZDRmY2Q5MDg3NDUxMDlkZDExYjhhL3RhYmxlcmFuZ2U6MWQ3YTMwOGI5ZGVkNGZjZDkwODc0NTEwOWRkMTFiOGFfMTItNC0xLTEtMA_aada99df-25fe-44f8-ac4f-02c5d785b233"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i6d5405f808014e29ae408f670b51a09f_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjFkN2EzMDhiOWRlZDRmY2Q5MDg3NDUxMDlkZDExYjhhL3RhYmxlcmFuZ2U6MWQ3YTMwOGI5ZGVkNGZjZDkwODc0NTEwOWRkMTFiOGFfMTItNi0xLTEtMA_239a7234-80f6-4cae-8edb-cf0fdc12d0f3"
      unitRef="usd">99600000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i8a4caf6e3ead4de1943986bbd01cf562_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjFkN2EzMDhiOWRlZDRmY2Q5MDg3NDUxMDlkZDExYjhhL3RhYmxlcmFuZ2U6MWQ3YTMwOGI5ZGVkNGZjZDkwODc0NTEwOWRkMTFiOGFfMTItOC0xLTEtMA_b164e193-4ae2-409d-99f9-5f1587745e32"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i3733833dc5534d8e823879ef2ca35162_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjFkN2EzMDhiOWRlZDRmY2Q5MDg3NDUxMDlkZDExYjhhL3RhYmxlcmFuZ2U6MWQ3YTMwOGI5ZGVkNGZjZDkwODc0NTEwOWRkMTFiOGFfMTMtMi0xLTEtMA_86b9197e-6457-48e6-bc47-938934c17cb0"
      unitRef="usd">322600000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i2937e4b1496b4a52a0d3e66401ae9216_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjFkN2EzMDhiOWRlZDRmY2Q5MDg3NDUxMDlkZDExYjhhL3RhYmxlcmFuZ2U6MWQ3YTMwOGI5ZGVkNGZjZDkwODc0NTEwOWRkMTFiOGFfMTMtNC0xLTEtMA_a5fdf05a-1aed-4857-888d-4fd47e368f06"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i6d5405f808014e29ae408f670b51a09f_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjFkN2EzMDhiOWRlZDRmY2Q5MDg3NDUxMDlkZDExYjhhL3RhYmxlcmFuZ2U6MWQ3YTMwOGI5ZGVkNGZjZDkwODc0NTEwOWRkMTFiOGFfMTMtNi0xLTEtMA_a7cb1983-187e-4037-ae58-ae90ef7a3176"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i8a4caf6e3ead4de1943986bbd01cf562_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjFkN2EzMDhiOWRlZDRmY2Q5MDg3NDUxMDlkZDExYjhhL3RhYmxlcmFuZ2U6MWQ3YTMwOGI5ZGVkNGZjZDkwODc0NTEwOWRkMTFiOGFfMTMtOC0xLTEtMA_4074f36b-10cf-4087-9afb-aaa6b74cc592"
      unitRef="usd">322600000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i3733833dc5534d8e823879ef2ca35162_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjFkN2EzMDhiOWRlZDRmY2Q5MDg3NDUxMDlkZDExYjhhL3RhYmxlcmFuZ2U6MWQ3YTMwOGI5ZGVkNGZjZDkwODc0NTEwOWRkMTFiOGFfMTQtMi0xLTEtMA_1444241e-4c8a-480b-a3a0-03956757c337"
      unitRef="usd">422200000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i2937e4b1496b4a52a0d3e66401ae9216_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjFkN2EzMDhiOWRlZDRmY2Q5MDg3NDUxMDlkZDExYjhhL3RhYmxlcmFuZ2U6MWQ3YTMwOGI5ZGVkNGZjZDkwODc0NTEwOWRkMTFiOGFfMTQtNC0xLTEtMA_409bb2a1-1eee-4ab5-9454-b20231059a18"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i6d5405f808014e29ae408f670b51a09f_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjFkN2EzMDhiOWRlZDRmY2Q5MDg3NDUxMDlkZDExYjhhL3RhYmxlcmFuZ2U6MWQ3YTMwOGI5ZGVkNGZjZDkwODc0NTEwOWRkMTFiOGFfMTQtNi0xLTEtMA_0bc45279-d9b6-4509-b28d-477411d45ff4"
      unitRef="usd">99600000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i8a4caf6e3ead4de1943986bbd01cf562_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjFkN2EzMDhiOWRlZDRmY2Q5MDg3NDUxMDlkZDExYjhhL3RhYmxlcmFuZ2U6MWQ3YTMwOGI5ZGVkNGZjZDkwODc0NTEwOWRkMTFiOGFfMTQtOC0xLTEtMA_4c8bec28-7024-4213-8aec-f19e4eb37766"
      unitRef="usd">322600000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ie6a0e49727c84ab293a923c6fa60c4af_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjZkMWNjMjhiMDI3YzQ5ZGM5N2U3N2M0Mjc4YTJjZTFlL3RhYmxlcmFuZ2U6NmQxY2MyOGIwMjdjNDlkYzk3ZTc3YzQyNzhhMmNlMWVfMi0yLTEtMS0w_8d754792-c992-46c8-b8c8-a5a209fae134"
      unitRef="usd">2541100000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="if8d8ff0dd3eb48ac863f558fcbc6892a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjZkMWNjMjhiMDI3YzQ5ZGM5N2U3N2M0Mjc4YTJjZTFlL3RhYmxlcmFuZ2U6NmQxY2MyOGIwMjdjNDlkYzk3ZTc3YzQyNzhhMmNlMWVfMi00LTEtMS0w_61e68c97-cafe-4fe1-8a29-cbfbb0f16357"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i30724e1260114af0b2ee60176aabfc27_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjZkMWNjMjhiMDI3YzQ5ZGM5N2U3N2M0Mjc4YTJjZTFlL3RhYmxlcmFuZ2U6NmQxY2MyOGIwMjdjNDlkYzk3ZTc3YzQyNzhhMmNlMWVfMi02LTEtMS0w_e2890c4e-5d2b-484e-9f22-8123dc21dfae"
      unitRef="usd">2541100000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ib5bdbb9beeae4e419f12246dd08e17c5_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjZkMWNjMjhiMDI3YzQ5ZGM5N2U3N2M0Mjc4YTJjZTFlL3RhYmxlcmFuZ2U6NmQxY2MyOGIwMjdjNDlkYzk3ZTc3YzQyNzhhMmNlMWVfMi04LTEtMS0w_bf05e3bd-0586-4b3f-95da-04000543c379"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="icdb4c26a6ae346b2b90553854ef6c821_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjZkMWNjMjhiMDI3YzQ5ZGM5N2U3N2M0Mjc4YTJjZTFlL3RhYmxlcmFuZ2U6NmQxY2MyOGIwMjdjNDlkYzk3ZTc3YzQyNzhhMmNlMWVfNC0yLTEtMS0w_a4d74c9e-21fb-49d1-a46f-a400a5d7b94f"
      unitRef="usd">1695100000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i23dad120af7646aab43c1b2a51494af6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjZkMWNjMjhiMDI3YzQ5ZGM5N2U3N2M0Mjc4YTJjZTFlL3RhYmxlcmFuZ2U6NmQxY2MyOGIwMjdjNDlkYzk3ZTc3YzQyNzhhMmNlMWVfNC00LTEtMS0w_8a3cf966-78a0-440d-8b0b-4df98509174a"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9a733f2e8da94648b74178fe7c59c1c4_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjZkMWNjMjhiMDI3YzQ5ZGM5N2U3N2M0Mjc4YTJjZTFlL3RhYmxlcmFuZ2U6NmQxY2MyOGIwMjdjNDlkYzk3ZTc3YzQyNzhhMmNlMWVfNC02LTEtMS0w_976401eb-ce83-40ef-903d-f3b97e68f187"
      unitRef="usd">1695100000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1741135b13de43a09abeb81ebbdefb63_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjZkMWNjMjhiMDI3YzQ5ZGM5N2U3N2M0Mjc4YTJjZTFlL3RhYmxlcmFuZ2U6NmQxY2MyOGIwMjdjNDlkYzk3ZTc3YzQyNzhhMmNlMWVfNC04LTEtMS0w_5f30ac86-b571-4c4e-9449-78a9cf6c4255"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i43071817e6ed461f81f3fd642338f5f0_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjZkMWNjMjhiMDI3YzQ5ZGM5N2U3N2M0Mjc4YTJjZTFlL3RhYmxlcmFuZ2U6NmQxY2MyOGIwMjdjNDlkYzk3ZTc3YzQyNzhhMmNlMWVfNS0yLTEtMS0w_847affee-6f77-486c-b32f-2f312fa5acac"
      unitRef="usd">1013900000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id2a84d2f950447e889c009b8dc3d1c91_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjZkMWNjMjhiMDI3YzQ5ZGM5N2U3N2M0Mjc4YTJjZTFlL3RhYmxlcmFuZ2U6NmQxY2MyOGIwMjdjNDlkYzk3ZTc3YzQyNzhhMmNlMWVfNS00LTEtMS0w_b5f5552d-7e5b-4f61-88d1-78ff2194ecf4"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3c062405d6734f55a0f77a7793837fa5_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjZkMWNjMjhiMDI3YzQ5ZGM5N2U3N2M0Mjc4YTJjZTFlL3RhYmxlcmFuZ2U6NmQxY2MyOGIwMjdjNDlkYzk3ZTc3YzQyNzhhMmNlMWVfNS02LTEtMS0w_3af2a8dd-79f0-4eff-bde9-8f248f6f2ec2"
      unitRef="usd">1013900000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9c442e1cde66431c994c606712e1b32f_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjZkMWNjMjhiMDI3YzQ5ZGM5N2U3N2M0Mjc4YTJjZTFlL3RhYmxlcmFuZ2U6NmQxY2MyOGIwMjdjNDlkYzk3ZTc3YzQyNzhhMmNlMWVfNS04LTEtMS0w_da32f75a-cdc3-4f12-9c51-1f41e0ea26df"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i880c27328fde4402bd25776af2e34436_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjZkMWNjMjhiMDI3YzQ5ZGM5N2U3N2M0Mjc4YTJjZTFlL3RhYmxlcmFuZ2U6NmQxY2MyOGIwMjdjNDlkYzk3ZTc3YzQyNzhhMmNlMWVfNi0yLTEtMS0w_5fbdfd8b-a425-4bfc-96da-29b463c266af"
      unitRef="usd">261300000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if8cdd3be786a4c8fb53fbc1511f3e007_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjZkMWNjMjhiMDI3YzQ5ZGM5N2U3N2M0Mjc4YTJjZTFlL3RhYmxlcmFuZ2U6NmQxY2MyOGIwMjdjNDlkYzk3ZTc3YzQyNzhhMmNlMWVfNi00LTEtMS0w_e2ad19a0-7eb9-4c8c-88be-468b64d312fb"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia0e3519a323b44aeac235464c19aa330_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjZkMWNjMjhiMDI3YzQ5ZGM5N2U3N2M0Mjc4YTJjZTFlL3RhYmxlcmFuZ2U6NmQxY2MyOGIwMjdjNDlkYzk3ZTc3YzQyNzhhMmNlMWVfNi02LTEtMS0w_464f5c7d-94e6-4c1d-9a31-44972575e137"
      unitRef="usd">261300000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic296bd1f024d4dbfafdf14773b56195a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjZkMWNjMjhiMDI3YzQ5ZGM5N2U3N2M0Mjc4YTJjZTFlL3RhYmxlcmFuZ2U6NmQxY2MyOGIwMjdjNDlkYzk3ZTc3YzQyNzhhMmNlMWVfNi04LTEtMS0w_b2f6edaa-9458-4907-ad39-bbad082f73b0"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ie6a0e49727c84ab293a923c6fa60c4af_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjZkMWNjMjhiMDI3YzQ5ZGM5N2U3N2M0Mjc4YTJjZTFlL3RhYmxlcmFuZ2U6NmQxY2MyOGIwMjdjNDlkYzk3ZTc3YzQyNzhhMmNlMWVfNy0yLTEtMS0w_946d2d02-cccb-42ea-a03f-de5a2a847c5a"
      unitRef="usd">337500000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="if8d8ff0dd3eb48ac863f558fcbc6892a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjZkMWNjMjhiMDI3YzQ5ZGM5N2U3N2M0Mjc4YTJjZTFlL3RhYmxlcmFuZ2U6NmQxY2MyOGIwMjdjNDlkYzk3ZTc3YzQyNzhhMmNlMWVfNy00LTEtMS0w_6ca378e1-c7dc-43ec-b176-daaaa2a66e8d"
      unitRef="usd">7900000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i30724e1260114af0b2ee60176aabfc27_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjZkMWNjMjhiMDI3YzQ5ZGM5N2U3N2M0Mjc4YTJjZTFlL3RhYmxlcmFuZ2U6NmQxY2MyOGIwMjdjNDlkYzk3ZTc3YzQyNzhhMmNlMWVfNy02LTEtMS0w_3655ad3e-f459-4d46-b1df-2f410401e4d8"
      unitRef="usd">329600000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ib5bdbb9beeae4e419f12246dd08e17c5_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjZkMWNjMjhiMDI3YzQ5ZGM5N2U3N2M0Mjc4YTJjZTFlL3RhYmxlcmFuZ2U6NmQxY2MyOGIwMjdjNDlkYzk3ZTc3YzQyNzhhMmNlMWVfNy04LTEtMS0w_539a49db-09f7-4277-aadd-5a837c837e71"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="ie6a0e49727c84ab293a923c6fa60c4af_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjZkMWNjMjhiMDI3YzQ5ZGM5N2U3N2M0Mjc4YTJjZTFlL3RhYmxlcmFuZ2U6NmQxY2MyOGIwMjdjNDlkYzk3ZTc3YzQyNzhhMmNlMWVfOC0yLTEtMS0w_047ad022-e62c-4ca7-85e2-a1b1eb0f978d"
      unitRef="usd">43800000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="if8d8ff0dd3eb48ac863f558fcbc6892a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjZkMWNjMjhiMDI3YzQ5ZGM5N2U3N2M0Mjc4YTJjZTFlL3RhYmxlcmFuZ2U6NmQxY2MyOGIwMjdjNDlkYzk3ZTc3YzQyNzhhMmNlMWVfOC00LTEtMS0w_826eb12b-a605-4881-b5ff-6a11b48c19c3"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i30724e1260114af0b2ee60176aabfc27_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjZkMWNjMjhiMDI3YzQ5ZGM5N2U3N2M0Mjc4YTJjZTFlL3RhYmxlcmFuZ2U6NmQxY2MyOGIwMjdjNDlkYzk3ZTc3YzQyNzhhMmNlMWVfOC02LTEtMS0w_50933642-27a9-46dd-a172-b5f4cfc12955"
      unitRef="usd">43800000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="ib5bdbb9beeae4e419f12246dd08e17c5_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjZkMWNjMjhiMDI3YzQ5ZGM5N2U3N2M0Mjc4YTJjZTFlL3RhYmxlcmFuZ2U6NmQxY2MyOGIwMjdjNDlkYzk3ZTc3YzQyNzhhMmNlMWVfOC04LTEtMS0w_36fcbf5d-fa9c-4385-8f66-d8904458bb64"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure
      contextRef="ie6a0e49727c84ab293a923c6fa60c4af_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjZkMWNjMjhiMDI3YzQ5ZGM5N2U3N2M0Mjc4YTJjZTFlL3RhYmxlcmFuZ2U6NmQxY2MyOGIwMjdjNDlkYzk3ZTc3YzQyNzhhMmNlMWVfOS0yLTEtMS0w_4b18bdee-4395-47cf-9cb3-22868c579b31"
      unitRef="usd">27700000</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure
      contextRef="if8d8ff0dd3eb48ac863f558fcbc6892a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjZkMWNjMjhiMDI3YzQ5ZGM5N2U3N2M0Mjc4YTJjZTFlL3RhYmxlcmFuZ2U6NmQxY2MyOGIwMjdjNDlkYzk3ZTc3YzQyNzhhMmNlMWVfOS00LTEtMS0w_a7d8292b-e01c-41a6-85b7-abc0f34cfe2c"
      unitRef="usd">0</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure
      contextRef="i30724e1260114af0b2ee60176aabfc27_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjZkMWNjMjhiMDI3YzQ5ZGM5N2U3N2M0Mjc4YTJjZTFlL3RhYmxlcmFuZ2U6NmQxY2MyOGIwMjdjNDlkYzk3ZTc3YzQyNzhhMmNlMWVfOS02LTEtMS0w_1bda800d-f8a9-4569-81c0-d14c1802cb91"
      unitRef="usd">27700000</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure
      contextRef="ib5bdbb9beeae4e419f12246dd08e17c5_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjZkMWNjMjhiMDI3YzQ5ZGM5N2U3N2M0Mjc4YTJjZTFlL3RhYmxlcmFuZ2U6NmQxY2MyOGIwMjdjNDlkYzk3ZTc3YzQyNzhhMmNlMWVfOS04LTEtMS0w_9202205a-2dd6-4a79-a334-75658601e8c8"
      unitRef="usd">0</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ie6a0e49727c84ab293a923c6fa60c4af_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjZkMWNjMjhiMDI3YzQ5ZGM5N2U3N2M0Mjc4YTJjZTFlL3RhYmxlcmFuZ2U6NmQxY2MyOGIwMjdjNDlkYzk3ZTc3YzQyNzhhMmNlMWVfMTAtMi0xLTEtMA_59404d0b-9519-43ee-9b87-353099299238"
      unitRef="usd">5920400000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="if8d8ff0dd3eb48ac863f558fcbc6892a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjZkMWNjMjhiMDI3YzQ5ZGM5N2U3N2M0Mjc4YTJjZTFlL3RhYmxlcmFuZ2U6NmQxY2MyOGIwMjdjNDlkYzk3ZTc3YzQyNzhhMmNlMWVfMTAtNC0xLTEtMA_d6bc97ea-2e98-4ce8-8582-7001779ab02e"
      unitRef="usd">7900000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i30724e1260114af0b2ee60176aabfc27_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjZkMWNjMjhiMDI3YzQ5ZGM5N2U3N2M0Mjc4YTJjZTFlL3RhYmxlcmFuZ2U6NmQxY2MyOGIwMjdjNDlkYzk3ZTc3YzQyNzhhMmNlMWVfMTAtNi0xLTEtMA_b1fc3d3f-982f-48a3-9a3c-0e6600868618"
      unitRef="usd">5912500000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ib5bdbb9beeae4e419f12246dd08e17c5_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjZkMWNjMjhiMDI3YzQ5ZGM5N2U3N2M0Mjc4YTJjZTFlL3RhYmxlcmFuZ2U6NmQxY2MyOGIwMjdjNDlkYzk3ZTc3YzQyNzhhMmNlMWVfMTAtOC0xLTEtMA_927740c7-c3bf-49b1-bd49-c46558fa982a"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="ie6a0e49727c84ab293a923c6fa60c4af_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjZkMWNjMjhiMDI3YzQ5ZGM5N2U3N2M0Mjc4YTJjZTFlL3RhYmxlcmFuZ2U6NmQxY2MyOGIwMjdjNDlkYzk3ZTc3YzQyNzhhMmNlMWVfMTItMi0xLTEtMA_48a7151b-adc6-4a49-902d-e101eaa9464a"
      unitRef="usd">8300000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="if8d8ff0dd3eb48ac863f558fcbc6892a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjZkMWNjMjhiMDI3YzQ5ZGM5N2U3N2M0Mjc4YTJjZTFlL3RhYmxlcmFuZ2U6NmQxY2MyOGIwMjdjNDlkYzk3ZTc3YzQyNzhhMmNlMWVfMTItNC0xLTEtMA_f693e1e1-a66c-42a0-99df-5ea1a0e21221"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i30724e1260114af0b2ee60176aabfc27_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjZkMWNjMjhiMDI3YzQ5ZGM5N2U3N2M0Mjc4YTJjZTFlL3RhYmxlcmFuZ2U6NmQxY2MyOGIwMjdjNDlkYzk3ZTc3YzQyNzhhMmNlMWVfMTItNi0xLTEtMA_6d1e08ee-2f1a-4644-bb73-10101c05a7de"
      unitRef="usd">8300000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="ib5bdbb9beeae4e419f12246dd08e17c5_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjZkMWNjMjhiMDI3YzQ5ZGM5N2U3N2M0Mjc4YTJjZTFlL3RhYmxlcmFuZ2U6NmQxY2MyOGIwMjdjNDlkYzk3ZTc3YzQyNzhhMmNlMWVfMTItOC0xLTEtMA_488368e3-df7b-4e8e-97c5-597f2ceb4533"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ie6a0e49727c84ab293a923c6fa60c4af_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjZkMWNjMjhiMDI3YzQ5ZGM5N2U3N2M0Mjc4YTJjZTFlL3RhYmxlcmFuZ2U6NmQxY2MyOGIwMjdjNDlkYzk3ZTc3YzQyNzhhMmNlMWVfMTMtMi0xLTEtMA_0b9919ab-b198-422a-a924-b08821039fdb"
      unitRef="usd">346100000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="if8d8ff0dd3eb48ac863f558fcbc6892a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjZkMWNjMjhiMDI3YzQ5ZGM5N2U3N2M0Mjc4YTJjZTFlL3RhYmxlcmFuZ2U6NmQxY2MyOGIwMjdjNDlkYzk3ZTc3YzQyNzhhMmNlMWVfMTMtNC0xLTEtMA_3fd90418-72a4-421c-a014-815cb8ba729b"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i30724e1260114af0b2ee60176aabfc27_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjZkMWNjMjhiMDI3YzQ5ZGM5N2U3N2M0Mjc4YTJjZTFlL3RhYmxlcmFuZ2U6NmQxY2MyOGIwMjdjNDlkYzk3ZTc3YzQyNzhhMmNlMWVfMTMtNi0xLTEtMA_bc58c083-2584-436f-90fa-e218375b8fbe"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ib5bdbb9beeae4e419f12246dd08e17c5_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjZkMWNjMjhiMDI3YzQ5ZGM5N2U3N2M0Mjc4YTJjZTFlL3RhYmxlcmFuZ2U6NmQxY2MyOGIwMjdjNDlkYzk3ZTc3YzQyNzhhMmNlMWVfMTMtOC0xLTEtMA_d4e07a9d-3c01-44e2-8ae6-3281639f58f2"
      unitRef="usd">346100000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ie6a0e49727c84ab293a923c6fa60c4af_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjZkMWNjMjhiMDI3YzQ5ZGM5N2U3N2M0Mjc4YTJjZTFlL3RhYmxlcmFuZ2U6NmQxY2MyOGIwMjdjNDlkYzk3ZTc3YzQyNzhhMmNlMWVfMTQtMi0xLTEtMA_369e360c-5696-4953-9abd-24470a0793b6"
      unitRef="usd">354400000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="if8d8ff0dd3eb48ac863f558fcbc6892a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjZkMWNjMjhiMDI3YzQ5ZGM5N2U3N2M0Mjc4YTJjZTFlL3RhYmxlcmFuZ2U6NmQxY2MyOGIwMjdjNDlkYzk3ZTc3YzQyNzhhMmNlMWVfMTQtNC0xLTEtMA_cc4e647d-0d63-4bec-b63f-c10b04c35bf4"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i30724e1260114af0b2ee60176aabfc27_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjZkMWNjMjhiMDI3YzQ5ZGM5N2U3N2M0Mjc4YTJjZTFlL3RhYmxlcmFuZ2U6NmQxY2MyOGIwMjdjNDlkYzk3ZTc3YzQyNzhhMmNlMWVfMTQtNi0xLTEtMA_408e32e3-90ad-4432-8ddb-65a74d4a053d"
      unitRef="usd">8300000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ib5bdbb9beeae4e419f12246dd08e17c5_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjZkMWNjMjhiMDI3YzQ5ZGM5N2U3N2M0Mjc4YTJjZTFlL3RhYmxlcmFuZ2U6NmQxY2MyOGIwMjdjNDlkYzk3ZTc3YzQyNzhhMmNlMWVfMTQtOC0xLTEtMA_4c9dbb21-1803-4a66-980f-2a33d081b2aa"
      unitRef="usd">346100000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:AssetImpairmentCharges
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RleHRyZWdpb246MjcwNWY4ZDY1MThjNDkyZWJiNWZiYzRmNmYwOGJiMTdfMjgz_db99168f-3d3b-4788-8518-fb4c12f1829d"
      unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i3733833dc5534d8e823879ef2ca35162_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjI1NDkxOTNiN2JhMjQ4Y2Q4NzQwYzIzYmFhZDJjM2UwL3RhYmxlcmFuZ2U6MjU0OTE5M2I3YmEyNDhjZDg3NDBjMjNiYWFkMmMzZTBfMy0yLTEtMS0w_86b9197e-6457-48e6-bc47-938934c17cb0"
      unitRef="usd">322600000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="icfebb7d3ca564ab9adac39367dcd18ff_I20200930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjI1NDkxOTNiN2JhMjQ4Y2Q4NzQwYzIzYmFhZDJjM2UwL3RhYmxlcmFuZ2U6MjU0OTE5M2I3YmEyNDhjZDg3NDBjMjNiYWFkMmMzZTBfMy0xMC0xLTEtMA_9b88da2d-2c01-4dd9-8e54-145d04ab98c7"
      unitRef="number">0.0063</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RleHRyZWdpb246MjcwNWY4ZDY1MThjNDkyZWJiNWZiYzRmNmYwOGJiMTdfNDU1Mg_f56c6f5e-da6f-4681-9021-f2490a344bce">&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The fair and carrying values of our debt instruments, which are Level&#160;2 liabilities, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:42.091%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.369%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.369%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.369%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.374%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;As of September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Carrying&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Carrying&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%;"&gt;2.900% Senior Notes due September 15, 2020&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,509.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,495.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3.625% Senior Notes due September 15, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;1,058.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;997.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,038.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;996.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4.050% Senior Notes due September 15, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;1,988.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;1,740.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,897.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,739.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.250% Senior Notes due May 1, 2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;1,532.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;1,491.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.200% Senior Notes due September 15, 2045&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;2,286.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;1,723.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,107.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,722.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3.150% Senior Notes due May 1, 2050&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;1,470.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;1,472.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;8,336.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;7,425.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,553.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,954.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="i9aaf1d46914b4e72aed3585ce98ebf30_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjIyNWM4MTYzZDVmZTRkYzhhMmY0MjFjMmZkNjJiZTU4L3RhYmxlcmFuZ2U6MjI1YzgxNjNkNWZlNGRjOGEyZjQyMWMyZmQ2MmJlNThfMi0yLTEtMS0w_ba549f3a-ec0e-4d5e-8160-cfaa38f72601"
      unitRef="usd">0</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="i9aaf1d46914b4e72aed3585ce98ebf30_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjIyNWM4MTYzZDVmZTRkYzhhMmY0MjFjMmZkNjJiZTU4L3RhYmxlcmFuZ2U6MjI1YzgxNjNkNWZlNGRjOGEyZjQyMWMyZmQ2MmJlNThfMi00LTEtMS0w_1c7e405a-eedb-42b7-9c19-ea6f63782ff9"
      unitRef="usd">0</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="i69617b3297c54b348a912b5786d5c621_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjIyNWM4MTYzZDVmZTRkYzhhMmY0MjFjMmZkNjJiZTU4L3RhYmxlcmFuZ2U6MjI1YzgxNjNkNWZlNGRjOGEyZjQyMWMyZmQ2MmJlNThfMi02LTEtMS0w_df7c2d16-ff20-426d-a46b-998a61c211fa"
      unitRef="usd">1509600000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="i69617b3297c54b348a912b5786d5c621_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjIyNWM4MTYzZDVmZTRkYzhhMmY0MjFjMmZkNjJiZTU4L3RhYmxlcmFuZ2U6MjI1YzgxNjNkNWZlNGRjOGEyZjQyMWMyZmQ2MmJlNThfMi04LTEtMS0w_52f14efa-bc7b-4072-bf23-5930bc989270"
      unitRef="usd">1495800000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="ia8b495ea13b343bca84608b9acb70bae_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjIyNWM4MTYzZDVmZTRkYzhhMmY0MjFjMmZkNjJiZTU4L3RhYmxlcmFuZ2U6MjI1YzgxNjNkNWZlNGRjOGEyZjQyMWMyZmQ2MmJlNThfMy0yLTEtMS0w_379c7589-e9df-404e-a2c1-48fcefe39005"
      unitRef="usd">1058400000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="ia8b495ea13b343bca84608b9acb70bae_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjIyNWM4MTYzZDVmZTRkYzhhMmY0MjFjMmZkNjJiZTU4L3RhYmxlcmFuZ2U6MjI1YzgxNjNkNWZlNGRjOGEyZjQyMWMyZmQ2MmJlNThfMy00LTEtMS0w_9beaced7-622f-4f80-a2e4-495a2b3a980f"
      unitRef="usd">997500000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="id243a9da99674c029fed341ed2d8cf28_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjIyNWM4MTYzZDVmZTRkYzhhMmY0MjFjMmZkNjJiZTU4L3RhYmxlcmFuZ2U6MjI1YzgxNjNkNWZlNGRjOGEyZjQyMWMyZmQ2MmJlNThfMy02LTEtMS0w_14c54405-e258-4b67-b688-bf988a0da609"
      unitRef="usd">1038900000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="id243a9da99674c029fed341ed2d8cf28_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjIyNWM4MTYzZDVmZTRkYzhhMmY0MjFjMmZkNjJiZTU4L3RhYmxlcmFuZ2U6MjI1YzgxNjNkNWZlNGRjOGEyZjQyMWMyZmQ2MmJlNThfMy04LTEtMS0w_a37e7e54-3cf1-46df-8356-7be36d20d43c"
      unitRef="usd">996600000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="icc2aa37ad604405da57ad8bd76640c2a_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjIyNWM4MTYzZDVmZTRkYzhhMmY0MjFjMmZkNjJiZTU4L3RhYmxlcmFuZ2U6MjI1YzgxNjNkNWZlNGRjOGEyZjQyMWMyZmQ2MmJlNThfNC0yLTEtMS0w_b67f3a1d-5fa7-4915-aca9-d6723270621d"
      unitRef="usd">1988500000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="icc2aa37ad604405da57ad8bd76640c2a_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjIyNWM4MTYzZDVmZTRkYzhhMmY0MjFjMmZkNjJiZTU4L3RhYmxlcmFuZ2U6MjI1YzgxNjNkNWZlNGRjOGEyZjQyMWMyZmQ2MmJlNThfNC00LTEtMS0w_efb01c6d-69f5-4cf3-b672-f5ec9fc02449"
      unitRef="usd">1740700000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="i6a88a8981a664b5881775b573a56d09c_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjIyNWM4MTYzZDVmZTRkYzhhMmY0MjFjMmZkNjJiZTU4L3RhYmxlcmFuZ2U6MjI1YzgxNjNkNWZlNGRjOGEyZjQyMWMyZmQ2MmJlNThfNC02LTEtMS0w_dc9b6393-d09f-4351-a2c3-c40edb7c1248"
      unitRef="usd">1897200000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="i6a88a8981a664b5881775b573a56d09c_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjIyNWM4MTYzZDVmZTRkYzhhMmY0MjFjMmZkNjJiZTU4L3RhYmxlcmFuZ2U6MjI1YzgxNjNkNWZlNGRjOGEyZjQyMWMyZmQ2MmJlNThfNC04LTEtMS0w_da0142f0-2704-4629-a0ec-2b63deda101f"
      unitRef="usd">1739500000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="if6f8f2b74b4b4cb48f44b56c1255fe48_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjIyNWM4MTYzZDVmZTRkYzhhMmY0MjFjMmZkNjJiZTU4L3RhYmxlcmFuZ2U6MjI1YzgxNjNkNWZlNGRjOGEyZjQyMWMyZmQ2MmJlNThfNS0yLTEtMS0w_972a9712-c0de-47bb-9f8d-2b3a0f44d2c6"
      unitRef="usd">1532800000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="if6f8f2b74b4b4cb48f44b56c1255fe48_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjIyNWM4MTYzZDVmZTRkYzhhMmY0MjFjMmZkNjJiZTU4L3RhYmxlcmFuZ2U6MjI1YzgxNjNkNWZlNGRjOGEyZjQyMWMyZmQ2MmJlNThfNS00LTEtMS0w_0ab68af7-076c-4320-9b30-a4bcd1cb99b5"
      unitRef="usd">1491000000.0</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="i21d53c4f2fba488bac9f594f9b972c35_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjIyNWM4MTYzZDVmZTRkYzhhMmY0MjFjMmZkNjJiZTU4L3RhYmxlcmFuZ2U6MjI1YzgxNjNkNWZlNGRjOGEyZjQyMWMyZmQ2MmJlNThfNS02LTEtMS0w_2a8c62a4-3ad0-49c1-920a-680f21d9cb0f"
      unitRef="usd">0</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="i21d53c4f2fba488bac9f594f9b972c35_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjIyNWM4MTYzZDVmZTRkYzhhMmY0MjFjMmZkNjJiZTU4L3RhYmxlcmFuZ2U6MjI1YzgxNjNkNWZlNGRjOGEyZjQyMWMyZmQ2MmJlNThfNS04LTEtMS0w_76f1fbd7-dd80-4eb0-83fa-5719bfe8b810"
      unitRef="usd">0</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="i77d457887e524f9da825a576463047de_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjIyNWM4MTYzZDVmZTRkYzhhMmY0MjFjMmZkNjJiZTU4L3RhYmxlcmFuZ2U6MjI1YzgxNjNkNWZlNGRjOGEyZjQyMWMyZmQ2MmJlNThfNi0yLTEtMS0w_a451571a-6d81-4cfa-bf48-efbac8a6dae7"
      unitRef="usd">2286300000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="i77d457887e524f9da825a576463047de_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjIyNWM4MTYzZDVmZTRkYzhhMmY0MjFjMmZkNjJiZTU4L3RhYmxlcmFuZ2U6MjI1YzgxNjNkNWZlNGRjOGEyZjQyMWMyZmQ2MmJlNThfNi00LTEtMS0w_ed54f2e6-26be-4764-a938-1f868f4dff31"
      unitRef="usd">1723300000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="ie3ab5e1259184cbfbb1c0fa0836b199b_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjIyNWM4MTYzZDVmZTRkYzhhMmY0MjFjMmZkNjJiZTU4L3RhYmxlcmFuZ2U6MjI1YzgxNjNkNWZlNGRjOGEyZjQyMWMyZmQ2MmJlNThfNi02LTEtMS0w_1fe42105-a819-4523-b489-b2803046208b"
      unitRef="usd">2107900000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="ie3ab5e1259184cbfbb1c0fa0836b199b_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjIyNWM4MTYzZDVmZTRkYzhhMmY0MjFjMmZkNjJiZTU4L3RhYmxlcmFuZ2U6MjI1YzgxNjNkNWZlNGRjOGEyZjQyMWMyZmQ2MmJlNThfNi04LTEtMS0w_86900a00-6a87-4dcf-8a41-55ab3b5dca2c"
      unitRef="usd">1722900000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="iae850a600e004e54910f51657134788c_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjIyNWM4MTYzZDVmZTRkYzhhMmY0MjFjMmZkNjJiZTU4L3RhYmxlcmFuZ2U6MjI1YzgxNjNkNWZlNGRjOGEyZjQyMWMyZmQ2MmJlNThfNy0yLTEtMS0w_107224cf-7438-43ac-a7af-80b3c87e3d6e"
      unitRef="usd">1470000000.0</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="iae850a600e004e54910f51657134788c_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjIyNWM4MTYzZDVmZTRkYzhhMmY0MjFjMmZkNjJiZTU4L3RhYmxlcmFuZ2U6MjI1YzgxNjNkNWZlNGRjOGEyZjQyMWMyZmQ2MmJlNThfNy00LTEtMS0w_2168ec91-731c-496d-ab27-e5eb227e6396"
      unitRef="usd">1472500000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="i5be3c08b32f44a29a978be98ccdbe750_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjIyNWM4MTYzZDVmZTRkYzhhMmY0MjFjMmZkNjJiZTU4L3RhYmxlcmFuZ2U6MjI1YzgxNjNkNWZlNGRjOGEyZjQyMWMyZmQ2MmJlNThfNy02LTEtMS0w_1a3c1e25-f330-424e-abb2-fa02dac84675"
      unitRef="usd">0</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="i5be3c08b32f44a29a978be98ccdbe750_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjIyNWM4MTYzZDVmZTRkYzhhMmY0MjFjMmZkNjJiZTU4L3RhYmxlcmFuZ2U6MjI1YzgxNjNkNWZlNGRjOGEyZjQyMWMyZmQ2MmJlNThfNy04LTEtMS0w_3964c873-a2c3-4e50-be3f-d5a8764981a0"
      unitRef="usd">0</us-gaap:NotesPayable>
    <us-gaap:DebtInstrumentFairValue
      contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjIyNWM4MTYzZDVmZTRkYzhhMmY0MjFjMmZkNjJiZTU4L3RhYmxlcmFuZ2U6MjI1YzgxNjNkNWZlNGRjOGEyZjQyMWMyZmQ2MmJlNThfOC0yLTEtMS0w_5000b5f8-4154-4d87-87bc-2ed4837c4913"
      unitRef="usd">8336000000.0</us-gaap:DebtInstrumentFairValue>
    <us-gaap:NotesPayable
      contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjIyNWM4MTYzZDVmZTRkYzhhMmY0MjFjMmZkNjJiZTU4L3RhYmxlcmFuZ2U6MjI1YzgxNjNkNWZlNGRjOGEyZjQyMWMyZmQ2MmJlNThfOC00LTEtMS0w_0d4c8f0e-7d42-4c06-9fbc-5e81d7507000"
      unitRef="usd">7425000000.0</us-gaap:NotesPayable>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i626282e786b7454d83b617e9e83963e6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjIyNWM4MTYzZDVmZTRkYzhhMmY0MjFjMmZkNjJiZTU4L3RhYmxlcmFuZ2U6MjI1YzgxNjNkNWZlNGRjOGEyZjQyMWMyZmQ2MmJlNThfOC02LTEtMS0w_78a471d9-d3c9-4cf0-9c93-1d96ee0218cf"
      unitRef="usd">6553600000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:NotesPayable
      contextRef="i626282e786b7454d83b617e9e83963e6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjIyNWM4MTYzZDVmZTRkYzhhMmY0MjFjMmZkNjJiZTU4L3RhYmxlcmFuZ2U6MjI1YzgxNjNkNWZlNGRjOGEyZjQyMWMyZmQ2MmJlNThfOC04LTEtMS0w_b53259ca-54ec-4581-accc-c24ed87b8a10"
      unitRef="usd">5954800000</us-gaap:NotesPayable>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i9aaf1d46914b4e72aed3585ce98ebf30_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RleHRyZWdpb246MjcwNWY4ZDY1MThjNDkyZWJiNWZiYzRmNmYwOGJiMTdfMjQwMQ_d81c31fb-53ee-49c8-ad4c-aed9cbf88b59"
      unitRef="number">0.02900</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ic59436e93fd94dc7975cca19dc9348ab_I20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RleHRyZWdpb246MjcwNWY4ZDY1MThjNDkyZWJiNWZiYzRmNmYwOGJiMTdfMjU5MA_558be3ed-8d83-43cb-9467-39257eade898"
      unitRef="usd">3000000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RleHRyZWdpb246MjcwNWY4ZDY1MThjNDkyZWJiNWZiYzRmNmYwOGJiMTdfNDU0OA_eb8dbcf3-3f4f-4fad-aa94-303ff4edb41d">The following table provides a roll forward of the fair values of our contingent consideration obligations, which includes Level 3 measurements:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:47.438%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.034%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.034%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.034%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.040%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair value, beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;351.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;401.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;346.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;409.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Changes in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(29.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(57.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(23.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(66.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair value, end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;322.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;343.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;322.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;343.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i1b095aa200c24bc89b77243d5d674b37_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjQ2MTYzYzE5MGU1MTRjZmRhMzg3ZWJmNmRlNDg3NGE3L3RhYmxlcmFuZ2U6NDYxNjNjMTkwZTUxNGNmZGEzODdlYmY2ZGU0ODc0YTdfMi0yLTEtMS0w_8b493515-9837-453f-a611-6560d9a9bbe9"
      unitRef="usd">351600000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i481da687b03f42ba833d7ea97207f576_I20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjQ2MTYzYzE5MGU1MTRjZmRhMzg3ZWJmNmRlNDg3NGE3L3RhYmxlcmFuZ2U6NDYxNjNjMTkwZTUxNGNmZGEzODdlYmY2ZGU0ODc0YTdfMi00LTEtMS0w_57d03194-1d05-4633-98b2-cdd36421f4e3"
      unitRef="usd">401300000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ie6a0e49727c84ab293a923c6fa60c4af_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjQ2MTYzYzE5MGU1MTRjZmRhMzg3ZWJmNmRlNDg3NGE3L3RhYmxlcmFuZ2U6NDYxNjNjMTkwZTUxNGNmZGEzODdlYmY2ZGU0ODc0YTdfMi02LTEtMS0w_4c774113-24d8-469e-9a3a-2229129e4307"
      unitRef="usd">346100000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ie818884c1c424a8b87d88e29c4beebaa_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjQ2MTYzYzE5MGU1MTRjZmRhMzg3ZWJmNmRlNDg3NGE3L3RhYmxlcmFuZ2U6NDYxNjNjMTkwZTUxNGNmZGEzODdlYmY2ZGU0ODc0YTdfMi04LTEtMS0w_6ed72130-b8ad-4a1d-bf87-2bc606473ab3"
      unitRef="usd">409800000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjQ2MTYzYzE5MGU1MTRjZmRhMzg3ZWJmNmRlNDg3NGE3L3RhYmxlcmFuZ2U6NDYxNjNjMTkwZTUxNGNmZGEzODdlYmY2ZGU0ODc0YTdfMy0yLTEtMS0w_8d1f997c-9ed7-4203-a725-994f64c09fc0"
      unitRef="usd">29000000.0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjQ2MTYzYzE5MGU1MTRjZmRhMzg3ZWJmNmRlNDg3NGE3L3RhYmxlcmFuZ2U6NDYxNjNjMTkwZTUxNGNmZGEzODdlYmY2ZGU0ODc0YTdfMy00LTEtMS0w_29e7765a-f4c4-47fe-9afe-1cac8eefb99c"
      unitRef="usd">57800000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjQ2MTYzYzE5MGU1MTRjZmRhMzg3ZWJmNmRlNDg3NGE3L3RhYmxlcmFuZ2U6NDYxNjNjMTkwZTUxNGNmZGEzODdlYmY2ZGU0ODc0YTdfMy02LTEtMS0w_260cb5ec-9883-4dff-ad93-d42b945c1e2a"
      unitRef="usd">23500000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjQ2MTYzYzE5MGU1MTRjZmRhMzg3ZWJmNmRlNDg3NGE3L3RhYmxlcmFuZ2U6NDYxNjNjMTkwZTUxNGNmZGEzODdlYmY2ZGU0ODc0YTdfMy04LTEtMS0w_3271b4c7-6498-4ba5-9b54-a8891e982e05"
      unitRef="usd">66300000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjQ2MTYzYzE5MGU1MTRjZmRhMzg3ZWJmNmRlNDg3NGE3L3RhYmxlcmFuZ2U6NDYxNjNjMTkwZTUxNGNmZGEzODdlYmY2ZGU0ODc0YTdfNC0yLTEtMS0w_94d7b0ca-850d-4e16-8531-ef2c30bba541"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjQ2MTYzYzE5MGU1MTRjZmRhMzg3ZWJmNmRlNDg3NGE3L3RhYmxlcmFuZ2U6NDYxNjNjMTkwZTUxNGNmZGEzODdlYmY2ZGU0ODc0YTdfNC00LTEtMS0w_c2db3b69-85ab-4d3b-8126-90f9b5d42317"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjQ2MTYzYzE5MGU1MTRjZmRhMzg3ZWJmNmRlNDg3NGE3L3RhYmxlcmFuZ2U6NDYxNjNjMTkwZTUxNGNmZGEzODdlYmY2ZGU0ODc0YTdfNC02LTEtMS0w_5376b5aa-323a-46bc-ba11-3e2af75c55f9"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjQ2MTYzYzE5MGU1MTRjZmRhMzg3ZWJmNmRlNDg3NGE3L3RhYmxlcmFuZ2U6NDYxNjNjMTkwZTUxNGNmZGEzODdlYmY2ZGU0ODc0YTdfNC04LTEtMS0w_1cd886c1-d184-4601-8bfc-1ffe46222b78"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i3733833dc5534d8e823879ef2ca35162_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjQ2MTYzYzE5MGU1MTRjZmRhMzg3ZWJmNmRlNDg3NGE3L3RhYmxlcmFuZ2U6NDYxNjNjMTkwZTUxNGNmZGEzODdlYmY2ZGU0ODc0YTdfNS0yLTEtMS0w_8453d96c-5759-4b7e-8920-bf83f5e2b890"
      unitRef="usd">322600000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i7a3eaba5b5f948d7a04bc997b0e062fd_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjQ2MTYzYzE5MGU1MTRjZmRhMzg3ZWJmNmRlNDg3NGE3L3RhYmxlcmFuZ2U6NDYxNjNjMTkwZTUxNGNmZGEzODdlYmY2ZGU0ODc0YTdfNS00LTEtMS0w_0e7729da-e520-4883-832f-44d809765293"
      unitRef="usd">343500000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i3733833dc5534d8e823879ef2ca35162_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjQ2MTYzYzE5MGU1MTRjZmRhMzg3ZWJmNmRlNDg3NGE3L3RhYmxlcmFuZ2U6NDYxNjNjMTkwZTUxNGNmZGEzODdlYmY2ZGU0ODc0YTdfNS02LTEtMS0w_4e999c59-2a37-4392-a162-6410f4d50dd4"
      unitRef="usd">322600000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i7a3eaba5b5f948d7a04bc997b0e062fd_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RhYmxlOjQ2MTYzYzE5MGU1MTRjZmRhMzg3ZWJmNmRlNDg3NGE3L3RhYmxlcmFuZ2U6NDYxNjNjMTkwZTUxNGNmZGEzODdlYmY2ZGU0ODc0YTdfNS04LTEtMS0w_feed27be-e716-4d96-b59d-4070768b0e42"
      unitRef="usd">343500000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RleHRyZWdpb246MjcwNWY4ZDY1MThjNDkyZWJiNWZiYzRmNmYwOGJiMTdfMzUyNg_57a00105-b617-4358-86b1-6e9e1cf669ab"
      unitRef="usd">173200000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i626282e786b7454d83b617e9e83963e6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RleHRyZWdpb246MjcwNWY4ZDY1MThjNDkyZWJiNWZiYzRmNmYwOGJiMTdfMzUzMw_8bb10794-49bf-4ea6-82eb-498da413cc0d"
      unitRef="usd">197700000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1
      contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RleHRyZWdpb246MjcwNWY4ZDY1MThjNDkyZWJiNWZiYzRmNmYwOGJiMTdfODI0NjMzNzIxNTAxMA_1b0fee47-9648-48f9-a090-5f4be2e5b141"
      unitRef="usd">61200000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM182Ny9mcmFnOjI3MDVmOGQ2NTE4YzQ5MmViYjVmYmM0ZjZmMDhiYjE3L3RleHRyZWdpb246MjcwNWY4ZDY1MThjNDkyZWJiNWZiYzRmNmYwOGJiMTdfODI0NjMzNzIxNTAxMA_5fc9c9e4-f3c4-425f-bf8c-cfec2060ddeb"
      unitRef="usd">61200000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1>
    <us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RleHRyZWdpb246MjRlZmE5YWU4NTFkNGEwZmEzMmRhNmMxZDZiNzg1OTJfMzgxNQ_4131c238-3470-46ba-acdf-ffdeef83c708">&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table summarizes our financial assets with maturities of less than 90&#160;days from the date of purchase included in cash and cash equivalents in our condensed consolidated balance sheets:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:58.549%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:18.344%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:18.347%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;As of September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;649.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;384.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Overnight reverse repurchase agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;465.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;368.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;270.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,628.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Short-term debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;185.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;159.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;1,570.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,541.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The carrying values of our commercial paper, including accrued interest, overnight reverse repurchase agreements, money market funds and short-term debt securities approximate fair value due to their short-term maturities. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Our marketable equity securities gains (losses) are recorded in other income (expense), net in our condensed consolidated statements of income. The following tables summarize our marketable debt and equity securities:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:41.252%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.576%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.576%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.576%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.580%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;As of September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;963.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;964.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;475.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;479.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Government securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;389.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;389.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;376.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;377.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Mortgage and other asset backed securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;152.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;153.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total marketable debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;2,358.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;2,364.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Marketable equity securities, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;851.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;63.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(46.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;868.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:41.252%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.576%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.576%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.576%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.580%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,057.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,058.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;633.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;636.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Government securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;502.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;503.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;510.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;510.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Mortgage and other asset backed securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;260.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;260.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total marketable debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,965.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,970.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Marketable equity securities, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;218.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;132.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(13.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;337.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:11.25pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Summary of Contractual Maturities: Available-for-Sale Debt Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The estimated fair value and amortized cost of our marketable debt securities available-for-sale by contractual maturity are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:41.924%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.409%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.409%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.409%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.413%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;As of September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Due in one year or less&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;1,355.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;1,353.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,562.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,560.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Due after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;902.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;897.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,234.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,230.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Due after five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;107.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;107.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;173.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;173.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total marketable debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;2,364.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;2,358.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,970.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,965.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The average maturity of our marketable debt securities available-for-sale as of September 30, 2020 and December 31, 2019, was approximately 12 months and 14 months, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:11.25pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Proceeds from Marketable Debt Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:44.075%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.204%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.204%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.619%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.624%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Proceeds from maturities and sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;1,360.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;611.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;5,240.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,867.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Realized gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;12.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Realized losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(25.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:11.25pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Strategic Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As of September 30, 2020 and December 31, 2019, our strategic investment portfolio was comprised of investments totaling $925.1 million and $393.9 million, respectively, which are included in investments and other assets in our condensed consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Our strategic investment portfolio includes investments in equity securities of certain biotechnology companies, which are reflected within our disclosures included in &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Note 7, Fair Value Measurements,&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; to these condensed consolidated financial statements, venture capital funds where the underlying investments are in equity securities of certain biotechnology companies and non-marketable equity securities. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The increase in our strategic investment portfolio for the three and nine months ended September 30, 2020, was primarily due to our purchases of Denali and Sangamo common stock, as discussed below.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:13.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Denali Therapeutics Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;In August 2020 we entered into a collaboration and license agreement with Denali. As part of this collaboration we purchased approximately 13&#160;million shares of Denali common stock in September 2020. This investment is classified as a Level 2 marketable equity security due to certain holding period restrictions and is remeasured each reporting period and carried at fair value. The effects of certain holding period restrictions on the investment are estimated using an option pricing valuation model. The most significant assumptions within the model are the term of the restrictions and the stock price volatility, which is based upon historical volatility of similar companies. We also use a constant maturity risk free-interest rate to match the remaining term of the restrictions on our investment in Denali's common stock and a dividend yield of zero based upon the fact that Denali and similar companies generally have not historically granted cash dividends.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;For additional information on our collaboration agreements with Denali, please read &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Note 17, Collaborative and Other Relationships,&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:13.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Sangamo Therapeutics, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In February 2020 we entered into a collaboration and license agreement with Sangamo. In connection with the closing of this transaction in April 2020 we purchased approximately&#160;24 million&#160;shares of Sangamo common stock.&#160;This equity method investment will be remeasured each reporting period and carried at fair value due to our election of the fair value option. The effects of certain holding period restrictions on the investment are estimated &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;using an option pricing valuation model. The most significant assumptions within the model are the term of the restrictions and the stock price volatility, which is based upon historical volatility of similar companies. We also use a constant maturity risk free-interest rate to match the remaining term of the restrictions on our investment in Sangamo&#x2019;s common stock and a dividend yield of zero based upon the fact that Sangamo and similar companies generally have not historically granted cash dividends.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;For additional information on our collaboration agreement with Sangamo, please read &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Note 17, Collaborative and Other Relationships,&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RleHRyZWdpb246MjRlZmE5YWU4NTFkNGEwZmEzMmRhNmMxZDZiNzg1OTJfMzgwMA_9251bf95-ae57-4661-9d5f-7a4db6264487">&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table summarizes our financial assets with maturities of less than 90&#160;days from the date of purchase included in cash and cash equivalents in our condensed consolidated balance sheets:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:58.549%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:18.344%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:18.347%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;As of September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;649.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;384.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Overnight reverse repurchase agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;465.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;368.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;270.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,628.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Short-term debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;185.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;159.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;1,570.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,541.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="i1ca7ffcd21a746b68b8a16da619e41e8_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjI3YmE0YWUzYzZhYjRjNjZiNzFjMzgxYjFmMDM5NzQxL3RhYmxlcmFuZ2U6MjdiYTRhZTNjNmFiNGM2NmI3MWMzODFiMWYwMzk3NDFfMS0yLTEtMS0w_dd7208bf-ae2a-48f7-b1e0-bf733f67cf18"
      unitRef="usd">649200000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="i88ecf4f0a7d947ada40d20f177ef560b_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjI3YmE0YWUzYzZhYjRjNjZiNzFjMzgxYjFmMDM5NzQxL3RhYmxlcmFuZ2U6MjdiYTRhZTNjNmFiNGM2NmI3MWMzODFiMWYwMzk3NDFfMS00LTEtMS0w_539bd100-eb31-4c1e-a476-0b04b528eccb"
      unitRef="usd">384400000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="i01bf576ce3184732823152e79c0954dd_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjI3YmE0YWUzYzZhYjRjNjZiNzFjMzgxYjFmMDM5NzQxL3RhYmxlcmFuZ2U6MjdiYTRhZTNjNmFiNGM2NmI3MWMzODFiMWYwMzk3NDFfMi0yLTEtMS0w_b7739699-ab0d-4ccf-9bad-97a46cba197a"
      unitRef="usd">465400000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="i83545e7be2ae48768bf0f58e921e708c_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjI3YmE0YWUzYzZhYjRjNjZiNzFjMzgxYjFmMDM5NzQxL3RhYmxlcmFuZ2U6MjdiYTRhZTNjNmFiNGM2NmI3MWMzODFiMWYwMzk3NDFfMi00LTEtMS0w_a0c6c0fe-2f3c-48ac-9cb0-d9fce00c2a5a"
      unitRef="usd">368800000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="i37325c7e699d4c51b083d0bd7f89fe2a_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjI3YmE0YWUzYzZhYjRjNjZiNzFjMzgxYjFmMDM5NzQxL3RhYmxlcmFuZ2U6MjdiYTRhZTNjNmFiNGM2NmI3MWMzODFiMWYwMzk3NDFfMy0yLTEtMS0w_07e758d4-e685-4be8-aae2-5062742d4c5c"
      unitRef="usd">270200000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="i3e57229498ce4144b42c45e34e9ef425_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjI3YmE0YWUzYzZhYjRjNjZiNzFjMzgxYjFmMDM5NzQxL3RhYmxlcmFuZ2U6MjdiYTRhZTNjNmFiNGM2NmI3MWMzODFiMWYwMzk3NDFfMy00LTEtMS0w_1803a155-118a-4892-b983-97ab7772f788"
      unitRef="usd">1628500000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="i4704964df0724cd1b2cac40f12d8482c_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjI3YmE0YWUzYzZhYjRjNjZiNzFjMzgxYjFmMDM5NzQxL3RhYmxlcmFuZ2U6MjdiYTRhZTNjNmFiNGM2NmI3MWMzODFiMWYwMzk3NDFfNC0yLTEtMS0w_634fb570-3ab5-4708-a61d-e668bd4cce48"
      unitRef="usd">185500000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="i8d2e2443e8024c469ef86deaee00b316_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjI3YmE0YWUzYzZhYjRjNjZiNzFjMzgxYjFmMDM5NzQxL3RhYmxlcmFuZ2U6MjdiYTRhZTNjNmFiNGM2NmI3MWMzODFiMWYwMzk3NDFfNC00LTEtMS0w_b07a4836-a92b-4244-90b0-9ce74f5bb51c"
      unitRef="usd">159400000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjI3YmE0YWUzYzZhYjRjNjZiNzFjMzgxYjFmMDM5NzQxL3RhYmxlcmFuZ2U6MjdiYTRhZTNjNmFiNGM2NmI3MWMzODFiMWYwMzk3NDFfNS0yLTEtMS0w_93ce3a85-b6c2-4821-8717-81bfaee4433b"
      unitRef="usd">1570300000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="i626282e786b7454d83b617e9e83963e6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjI3YmE0YWUzYzZhYjRjNjZiNzFjMzgxYjFmMDM5NzQxL3RhYmxlcmFuZ2U6MjdiYTRhZTNjNmFiNGM2NmI3MWMzODFiMWYwMzk3NDFfNS00LTEtMS0w_6e5574c1-c53e-4046-b1e4-74672b415ce4"
      unitRef="usd">2541100000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesTextBlock
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RleHRyZWdpb246MjRlZmE5YWU4NTFkNGEwZmEzMmRhNmMxZDZiNzg1OTJfMzgwMg_527e13ce-fa66-4806-acb0-7d3f8cd005c0">The following tables summarize our marketable debt and equity securities:&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:41.252%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.576%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.576%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.576%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.580%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;As of September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;963.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;964.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;475.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;479.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Government securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;389.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;389.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;376.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;377.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Mortgage and other asset backed securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;152.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;153.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total marketable debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;2,358.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;2,364.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Marketable equity securities, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;851.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;63.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(46.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;868.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:41.252%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.576%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.576%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.576%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.580%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,057.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,058.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;633.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;636.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Government securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;502.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;503.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;510.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;510.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Mortgage and other asset backed securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;260.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;260.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total marketable debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,965.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,970.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Marketable equity securities, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;218.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;132.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(13.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;337.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AvailableForSaleSecuritiesTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i71ff130217a74446aad53582c9032ff2_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjU1NzIyM2ZhYzVhZDQyZDNiNTRlMjJlZGUzNzFhNDYwL3RhYmxlcmFuZ2U6NTU3MjIzZmFjNWFkNDJkM2I1NGUyMmVkZTM3MWE0NjBfMi0yLTEtMS0w_ac904e24-7ccb-4d62-b05b-d72d71908570"
      unitRef="usd">963500000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i71ff130217a74446aad53582c9032ff2_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjU1NzIyM2ZhYzVhZDQyZDNiNTRlMjJlZGUzNzFhNDYwL3RhYmxlcmFuZ2U6NTU3MjIzZmFjNWFkNDJkM2I1NGUyMmVkZTM3MWE0NjBfMi00LTEtMS0w_bfc997a9-e5a3-483b-af88-0f7c82e5a0e0"
      unitRef="usd">1400000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i71ff130217a74446aad53582c9032ff2_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjU1NzIyM2ZhYzVhZDQyZDNiNTRlMjJlZGUzNzFhNDYwL3RhYmxlcmFuZ2U6NTU3MjIzZmFjNWFkNDJkM2I1NGUyMmVkZTM3MWE0NjBfMi02LTEtMS0w_fd7e971d-7015-4a45-b089-11df22f663ab"
      unitRef="usd">100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i71ff130217a74446aad53582c9032ff2_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjU1NzIyM2ZhYzVhZDQyZDNiNTRlMjJlZGUzNzFhNDYwL3RhYmxlcmFuZ2U6NTU3MjIzZmFjNWFkNDJkM2I1NGUyMmVkZTM3MWE0NjBfMi04LTEtMS0w_5d9aa54b-c6ba-41f4-84aa-f979e5448149"
      unitRef="usd">964800000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i6e2e5400e66745a59bc4efb5814dc463_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjU1NzIyM2ZhYzVhZDQyZDNiNTRlMjJlZGUzNzFhNDYwL3RhYmxlcmFuZ2U6NTU3MjIzZmFjNWFkNDJkM2I1NGUyMmVkZTM3MWE0NjBfMy0yLTEtMS0w_b008897b-c049-45b1-8f64-6d97786f19df"
      unitRef="usd">475900000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i6e2e5400e66745a59bc4efb5814dc463_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjU1NzIyM2ZhYzVhZDQyZDNiNTRlMjJlZGUzNzFhNDYwL3RhYmxlcmFuZ2U6NTU3MjIzZmFjNWFkNDJkM2I1NGUyMmVkZTM3MWE0NjBfMy00LTEtMS0w_096a6eb3-d583-4287-b9e7-45f30f216027"
      unitRef="usd">3200000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i6e2e5400e66745a59bc4efb5814dc463_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjU1NzIyM2ZhYzVhZDQyZDNiNTRlMjJlZGUzNzFhNDYwL3RhYmxlcmFuZ2U6NTU3MjIzZmFjNWFkNDJkM2I1NGUyMmVkZTM3MWE0NjBfMy02LTEtMS0w_df7971ea-48dd-4ace-82bd-23c2ffffa3a5"
      unitRef="usd">100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6e2e5400e66745a59bc4efb5814dc463_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjU1NzIyM2ZhYzVhZDQyZDNiNTRlMjJlZGUzNzFhNDYwL3RhYmxlcmFuZ2U6NTU3MjIzZmFjNWFkNDJkM2I1NGUyMmVkZTM3MWE0NjBfMy04LTEtMS0w_e811d484-cd36-4a97-b1f4-8bb7bcfbcb80"
      unitRef="usd">479000000.0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ifcf2b581c6394dde8ca839bc55b63d5a_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjU1NzIyM2ZhYzVhZDQyZDNiNTRlMjJlZGUzNzFhNDYwL3RhYmxlcmFuZ2U6NTU3MjIzZmFjNWFkNDJkM2I1NGUyMmVkZTM3MWE0NjBfNS0yLTEtMS0w_98d7c6dc-d705-4a94-81e4-1ce65edd6302"
      unitRef="usd">389400000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ifcf2b581c6394dde8ca839bc55b63d5a_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjU1NzIyM2ZhYzVhZDQyZDNiNTRlMjJlZGUzNzFhNDYwL3RhYmxlcmFuZ2U6NTU3MjIzZmFjNWFkNDJkM2I1NGUyMmVkZTM3MWE0NjBfNS00LTEtMS0w_d19d8ff6-87e2-4336-96de-60ec228f3150"
      unitRef="usd">200000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ifcf2b581c6394dde8ca839bc55b63d5a_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjU1NzIyM2ZhYzVhZDQyZDNiNTRlMjJlZGUzNzFhNDYwL3RhYmxlcmFuZ2U6NTU3MjIzZmFjNWFkNDJkM2I1NGUyMmVkZTM3MWE0NjBfNS02LTEtMS0w_a5788420-5b2a-4751-a1ac-27e79320e4da"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ifcf2b581c6394dde8ca839bc55b63d5a_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjU1NzIyM2ZhYzVhZDQyZDNiNTRlMjJlZGUzNzFhNDYwL3RhYmxlcmFuZ2U6NTU3MjIzZmFjNWFkNDJkM2I1NGUyMmVkZTM3MWE0NjBfNS04LTEtMS0w_4c53c1af-3cd9-4c9e-a6e9-8e2f805d87a4"
      unitRef="usd">389600000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i332a8e26a3f44d669337bbdf30e280b1_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjU1NzIyM2ZhYzVhZDQyZDNiNTRlMjJlZGUzNzFhNDYwL3RhYmxlcmFuZ2U6NTU3MjIzZmFjNWFkNDJkM2I1NGUyMmVkZTM3MWE0NjBfNi0yLTEtMS0w_3e37b2c8-3957-4e1c-bdf8-05502b29dbc7"
      unitRef="usd">376400000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i332a8e26a3f44d669337bbdf30e280b1_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjU1NzIyM2ZhYzVhZDQyZDNiNTRlMjJlZGUzNzFhNDYwL3RhYmxlcmFuZ2U6NTU3MjIzZmFjNWFkNDJkM2I1NGUyMmVkZTM3MWE0NjBfNi00LTEtMS0w_18083d8e-295e-427d-a697-157aa15a6139"
      unitRef="usd">1400000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i332a8e26a3f44d669337bbdf30e280b1_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjU1NzIyM2ZhYzVhZDQyZDNiNTRlMjJlZGUzNzFhNDYwL3RhYmxlcmFuZ2U6NTU3MjIzZmFjNWFkNDJkM2I1NGUyMmVkZTM3MWE0NjBfNi02LTEtMS0w_574a28a7-c3fc-4053-818b-6233679707f9"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i332a8e26a3f44d669337bbdf30e280b1_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjU1NzIyM2ZhYzVhZDQyZDNiNTRlMjJlZGUzNzFhNDYwL3RhYmxlcmFuZ2U6NTU3MjIzZmFjNWFkNDJkM2I1NGUyMmVkZTM3MWE0NjBfNi04LTEtMS0w_3a4efab2-b29a-4b41-bc27-15da32453b40"
      unitRef="usd">377800000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ib526d2b286604bca80b624a3a4adab69_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjU1NzIyM2ZhYzVhZDQyZDNiNTRlMjJlZGUzNzFhNDYwL3RhYmxlcmFuZ2U6NTU3MjIzZmFjNWFkNDJkM2I1NGUyMmVkZTM3MWE0NjBfOC0yLTEtMS0w_c66b5f92-9e6d-459a-baaa-e08d3451cb47"
      unitRef="usd">600000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ib526d2b286604bca80b624a3a4adab69_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjU1NzIyM2ZhYzVhZDQyZDNiNTRlMjJlZGUzNzFhNDYwL3RhYmxlcmFuZ2U6NTU3MjIzZmFjNWFkNDJkM2I1NGUyMmVkZTM3MWE0NjBfOC00LTEtMS0w_09d4d6c1-7d10-49ca-b011-2a45dc95fe86"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ib526d2b286604bca80b624a3a4adab69_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjU1NzIyM2ZhYzVhZDQyZDNiNTRlMjJlZGUzNzFhNDYwL3RhYmxlcmFuZ2U6NTU3MjIzZmFjNWFkNDJkM2I1NGUyMmVkZTM3MWE0NjBfOC02LTEtMS0w_e54356a9-c758-4b4a-b665-bdeed69d9926"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib526d2b286604bca80b624a3a4adab69_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjU1NzIyM2ZhYzVhZDQyZDNiNTRlMjJlZGUzNzFhNDYwL3RhYmxlcmFuZ2U6NTU3MjIzZmFjNWFkNDJkM2I1NGUyMmVkZTM3MWE0NjBfOC04LTEtMS0w_db24927c-0dcf-4a6a-8487-2961ce15a5cb"
      unitRef="usd">600000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i6cf822a887824796933acc64b10aa831_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjU1NzIyM2ZhYzVhZDQyZDNiNTRlMjJlZGUzNzFhNDYwL3RhYmxlcmFuZ2U6NTU3MjIzZmFjNWFkNDJkM2I1NGUyMmVkZTM3MWE0NjBfOS0yLTEtMS0w_832dbb04-c5cc-4ada-a801-76f4b8fb0bd2"
      unitRef="usd">152600000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i6cf822a887824796933acc64b10aa831_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjU1NzIyM2ZhYzVhZDQyZDNiNTRlMjJlZGUzNzFhNDYwL3RhYmxlcmFuZ2U6NTU3MjIzZmFjNWFkNDJkM2I1NGUyMmVkZTM3MWE0NjBfOS00LTEtMS0w_107f30bf-7bf6-404d-8399-0dda801167de"
      unitRef="usd">600000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i6cf822a887824796933acc64b10aa831_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjU1NzIyM2ZhYzVhZDQyZDNiNTRlMjJlZGUzNzFhNDYwL3RhYmxlcmFuZ2U6NTU3MjIzZmFjNWFkNDJkM2I1NGUyMmVkZTM3MWE0NjBfOS02LTEtMS0w_82eed26b-5142-4581-9c4b-4d73408ae651"
      unitRef="usd">200000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6cf822a887824796933acc64b10aa831_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjU1NzIyM2ZhYzVhZDQyZDNiNTRlMjJlZGUzNzFhNDYwL3RhYmxlcmFuZ2U6NTU3MjIzZmFjNWFkNDJkM2I1NGUyMmVkZTM3MWE0NjBfOS04LTEtMS0w_4773be35-68a1-4102-97aa-5fa559d9d7bb"
      unitRef="usd">153000000.0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjU1NzIyM2ZhYzVhZDQyZDNiNTRlMjJlZGUzNzFhNDYwL3RhYmxlcmFuZ2U6NTU3MjIzZmFjNWFkNDJkM2I1NGUyMmVkZTM3MWE0NjBfMTAtMi0xLTEtMA_6a486f55-0fa5-41db-bb71-229e38b29a5a"
      unitRef="usd">2358400000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjU1NzIyM2ZhYzVhZDQyZDNiNTRlMjJlZGUzNzFhNDYwL3RhYmxlcmFuZ2U6NTU3MjIzZmFjNWFkNDJkM2I1NGUyMmVkZTM3MWE0NjBfMTAtNC0xLTEtMA_ae5e98c9-ca66-4261-b50c-ba6edf18187e"
      unitRef="usd">6800000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjU1NzIyM2ZhYzVhZDQyZDNiNTRlMjJlZGUzNzFhNDYwL3RhYmxlcmFuZ2U6NTU3MjIzZmFjNWFkNDJkM2I1NGUyMmVkZTM3MWE0NjBfMTAtNi0xLTEtMA_d1ac8797-2a3e-41d1-98dc-a7f6e7297a3c"
      unitRef="usd">400000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjU1NzIyM2ZhYzVhZDQyZDNiNTRlMjJlZGUzNzFhNDYwL3RhYmxlcmFuZ2U6NTU3MjIzZmFjNWFkNDJkM2I1NGUyMmVkZTM3MWE0NjBfMTAtOC0xLTEtMA_7f11fc94-56b8-403f-b80f-636debe5081b"
      unitRef="usd">2364800000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesAmortizedCost
      contextRef="ia10b2aa757ad47b49f270ebc491e28d0_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjU1NzIyM2ZhYzVhZDQyZDNiNTRlMjJlZGUzNzFhNDYwL3RhYmxlcmFuZ2U6NTU3MjIzZmFjNWFkNDJkM2I1NGUyMmVkZTM3MWE0NjBfMTEtMi0xLTEtMA_491a4d3a-0f65-477c-9a62-7188db68a49f"
      unitRef="usd">851700000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ia10b2aa757ad47b49f270ebc491e28d0_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjU1NzIyM2ZhYzVhZDQyZDNiNTRlMjJlZGUzNzFhNDYwL3RhYmxlcmFuZ2U6NTU3MjIzZmFjNWFkNDJkM2I1NGUyMmVkZTM3MWE0NjBfMTEtNC0xLTEtMA_50db46f2-b7d1-4841-8bbf-2efe25e70001"
      unitRef="usd">63600000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ia10b2aa757ad47b49f270ebc491e28d0_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjU1NzIyM2ZhYzVhZDQyZDNiNTRlMjJlZGUzNzFhNDYwL3RhYmxlcmFuZ2U6NTU3MjIzZmFjNWFkNDJkM2I1NGUyMmVkZTM3MWE0NjBfMTEtNi0xLTEtMA_d44e74cb-ad03-4427-a090-627d1f376405"
      unitRef="usd">46800000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecurities
      contextRef="ia10b2aa757ad47b49f270ebc491e28d0_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjU1NzIyM2ZhYzVhZDQyZDNiNTRlMjJlZGUzNzFhNDYwL3RhYmxlcmFuZ2U6NTU3MjIzZmFjNWFkNDJkM2I1NGUyMmVkZTM3MWE0NjBfMTEtOC0xLTEtMA_40bb3c4d-80c3-4910-9fa0-56758bd7e344"
      unitRef="usd">868500000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="id90fa1852e434ceeabbcb8fdd0d40cbd_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjNlMTVmNGEwMDdjZTQzZmFiY2Y0MTE0M2ZiYTU2NzllL3RhYmxlcmFuZ2U6M2UxNWY0YTAwN2NlNDNmYWJjZjQxMTQzZmJhNTY3OWVfMi0yLTEtMS0w_855af3fe-6721-483b-b76b-8ca0e4ca15d9"
      unitRef="usd">1057200000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="id90fa1852e434ceeabbcb8fdd0d40cbd_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjNlMTVmNGEwMDdjZTQzZmFiY2Y0MTE0M2ZiYTU2NzllL3RhYmxlcmFuZ2U6M2UxNWY0YTAwN2NlNDNmYWJjZjQxMTQzZmJhNTY3OWVfMi00LTEtMS0w_3848ee4f-a151-42a4-9d20-7b181d6a1fc8"
      unitRef="usd">1000000.0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="id90fa1852e434ceeabbcb8fdd0d40cbd_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjNlMTVmNGEwMDdjZTQzZmFiY2Y0MTE0M2ZiYTU2NzllL3RhYmxlcmFuZ2U6M2UxNWY0YTAwN2NlNDNmYWJjZjQxMTQzZmJhNTY3OWVfMi02LTEtMS0w_4b4a12ab-cbf9-4126-a329-6f4aa3c866c0"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id90fa1852e434ceeabbcb8fdd0d40cbd_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjNlMTVmNGEwMDdjZTQzZmFiY2Y0MTE0M2ZiYTU2NzllL3RhYmxlcmFuZ2U6M2UxNWY0YTAwN2NlNDNmYWJjZjQxMTQzZmJhNTY3OWVfMi04LTEtMS0w_1622ff4c-e2fa-4f7f-ab39-76ff10a9c93e"
      unitRef="usd">1058200000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i86f354cf497b4deeb6d0848b22bfdca5_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjNlMTVmNGEwMDdjZTQzZmFiY2Y0MTE0M2ZiYTU2NzllL3RhYmxlcmFuZ2U6M2UxNWY0YTAwN2NlNDNmYWJjZjQxMTQzZmJhNTY3OWVfMy0yLTEtMS0w_cbcb744c-19cf-42ed-a044-69ff0806e9ea"
      unitRef="usd">633900000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i86f354cf497b4deeb6d0848b22bfdca5_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjNlMTVmNGEwMDdjZTQzZmFiY2Y0MTE0M2ZiYTU2NzllL3RhYmxlcmFuZ2U6M2UxNWY0YTAwN2NlNDNmYWJjZjQxMTQzZmJhNTY3OWVfMy00LTEtMS0w_44d108b4-f96f-42fd-b366-ca6c2bcdd721"
      unitRef="usd">3000000.0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i86f354cf497b4deeb6d0848b22bfdca5_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjNlMTVmNGEwMDdjZTQzZmFiY2Y0MTE0M2ZiYTU2NzllL3RhYmxlcmFuZ2U6M2UxNWY0YTAwN2NlNDNmYWJjZjQxMTQzZmJhNTY3OWVfMy02LTEtMS0w_70c0d0de-f389-4226-855f-e0bdfee65807"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i86f354cf497b4deeb6d0848b22bfdca5_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjNlMTVmNGEwMDdjZTQzZmFiY2Y0MTE0M2ZiYTU2NzllL3RhYmxlcmFuZ2U6M2UxNWY0YTAwN2NlNDNmYWJjZjQxMTQzZmJhNTY3OWVfMy04LTEtMS0w_66f03c17-7c4a-4eb1-8399-2e5680bf9abf"
      unitRef="usd">636900000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ia0059a0f76db42a38b389323762cb3c7_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjNlMTVmNGEwMDdjZTQzZmFiY2Y0MTE0M2ZiYTU2NzllL3RhYmxlcmFuZ2U6M2UxNWY0YTAwN2NlNDNmYWJjZjQxMTQzZmJhNTY3OWVfNS0yLTEtMS0w_bb06c119-93d7-431a-8fb0-400d83c7c4af"
      unitRef="usd">502900000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ia0059a0f76db42a38b389323762cb3c7_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjNlMTVmNGEwMDdjZTQzZmFiY2Y0MTE0M2ZiYTU2NzllL3RhYmxlcmFuZ2U6M2UxNWY0YTAwN2NlNDNmYWJjZjQxMTQzZmJhNTY3OWVfNS00LTEtMS0w_ac7882f8-6687-450f-ac92-0d71e4d85726"
      unitRef="usd">400000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ia0059a0f76db42a38b389323762cb3c7_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjNlMTVmNGEwMDdjZTQzZmFiY2Y0MTE0M2ZiYTU2NzllL3RhYmxlcmFuZ2U6M2UxNWY0YTAwN2NlNDNmYWJjZjQxMTQzZmJhNTY3OWVfNS02LTEtMS0w_5c98f028-25dd-46e3-bf0d-1b09e8d39747"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia0059a0f76db42a38b389323762cb3c7_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjNlMTVmNGEwMDdjZTQzZmFiY2Y0MTE0M2ZiYTU2NzllL3RhYmxlcmFuZ2U6M2UxNWY0YTAwN2NlNDNmYWJjZjQxMTQzZmJhNTY3OWVfNS04LTEtMS0w_2348f04d-277a-42cf-b444-63bcf78cb7ec"
      unitRef="usd">503300000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="id4429d736bb44d669945730bee5061f8_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjNlMTVmNGEwMDdjZTQzZmFiY2Y0MTE0M2ZiYTU2NzllL3RhYmxlcmFuZ2U6M2UxNWY0YTAwN2NlNDNmYWJjZjQxMTQzZmJhNTY3OWVfNi0yLTEtMS0w_5b2cff5a-f8c5-488a-87b1-4f1352f81b51"
      unitRef="usd">510100000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="id4429d736bb44d669945730bee5061f8_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjNlMTVmNGEwMDdjZTQzZmFiY2Y0MTE0M2ZiYTU2NzllL3RhYmxlcmFuZ2U6M2UxNWY0YTAwN2NlNDNmYWJjZjQxMTQzZmJhNTY3OWVfNi00LTEtMS0w_8fce9701-73a7-40cd-95b0-1dfb4e264394"
      unitRef="usd">800000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="id4429d736bb44d669945730bee5061f8_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjNlMTVmNGEwMDdjZTQzZmFiY2Y0MTE0M2ZiYTU2NzllL3RhYmxlcmFuZ2U6M2UxNWY0YTAwN2NlNDNmYWJjZjQxMTQzZmJhNTY3OWVfNi02LTEtMS0w_e880a138-7605-48a2-9840-5aec617af70d"
      unitRef="usd">300000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id4429d736bb44d669945730bee5061f8_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjNlMTVmNGEwMDdjZTQzZmFiY2Y0MTE0M2ZiYTU2NzllL3RhYmxlcmFuZ2U6M2UxNWY0YTAwN2NlNDNmYWJjZjQxMTQzZmJhNTY3OWVfNi04LTEtMS0w_eb9e3f09-3690-43f4-a9ef-e5c207bf7ecd"
      unitRef="usd">510600000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i5fe904d775af4819805f32f893ad9967_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjNlMTVmNGEwMDdjZTQzZmFiY2Y0MTE0M2ZiYTU2NzllL3RhYmxlcmFuZ2U6M2UxNWY0YTAwN2NlNDNmYWJjZjQxMTQzZmJhNTY3OWVfOC0yLTEtMS0w_ca4e24e1-d13f-4673-b1ee-13fe14657f44"
      unitRef="usd">700000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i5fe904d775af4819805f32f893ad9967_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjNlMTVmNGEwMDdjZTQzZmFiY2Y0MTE0M2ZiYTU2NzllL3RhYmxlcmFuZ2U6M2UxNWY0YTAwN2NlNDNmYWJjZjQxMTQzZmJhNTY3OWVfOC00LTEtMS0w_af910a79-ac03-46e0-92d8-2213830a6cf1"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i5fe904d775af4819805f32f893ad9967_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjNlMTVmNGEwMDdjZTQzZmFiY2Y0MTE0M2ZiYTU2NzllL3RhYmxlcmFuZ2U6M2UxNWY0YTAwN2NlNDNmYWJjZjQxMTQzZmJhNTY3OWVfOC02LTEtMS0w_ca941ba2-d345-45ec-8c49-49984d9ab6f6"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5fe904d775af4819805f32f893ad9967_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjNlMTVmNGEwMDdjZTQzZmFiY2Y0MTE0M2ZiYTU2NzllL3RhYmxlcmFuZ2U6M2UxNWY0YTAwN2NlNDNmYWJjZjQxMTQzZmJhNTY3OWVfOC04LTEtMS0w_2bf6c3ef-6854-4410-9125-2944f87a4d22"
      unitRef="usd">700000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i803e14e6eace4d489a23796edd542d13_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjNlMTVmNGEwMDdjZTQzZmFiY2Y0MTE0M2ZiYTU2NzllL3RhYmxlcmFuZ2U6M2UxNWY0YTAwN2NlNDNmYWJjZjQxMTQzZmJhNTY3OWVfOS0yLTEtMS0w_a4d4020d-556b-4d0b-830f-6991634befe8"
      unitRef="usd">260200000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i803e14e6eace4d489a23796edd542d13_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjNlMTVmNGEwMDdjZTQzZmFiY2Y0MTE0M2ZiYTU2NzllL3RhYmxlcmFuZ2U6M2UxNWY0YTAwN2NlNDNmYWJjZjQxMTQzZmJhNTY3OWVfOS00LTEtMS0w_ae07fb7e-5409-447c-ae17-4b23feb633a7"
      unitRef="usd">800000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i803e14e6eace4d489a23796edd542d13_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjNlMTVmNGEwMDdjZTQzZmFiY2Y0MTE0M2ZiYTU2NzllL3RhYmxlcmFuZ2U6M2UxNWY0YTAwN2NlNDNmYWJjZjQxMTQzZmJhNTY3OWVfOS02LTEtMS0w_3688c4de-c5ca-45c0-adc9-d5ba09cf3fe1"
      unitRef="usd">400000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i803e14e6eace4d489a23796edd542d13_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjNlMTVmNGEwMDdjZTQzZmFiY2Y0MTE0M2ZiYTU2NzllL3RhYmxlcmFuZ2U6M2UxNWY0YTAwN2NlNDNmYWJjZjQxMTQzZmJhNTY3OWVfOS04LTEtMS0w_44bd20fa-d886-4570-aabd-5a703bf215d6"
      unitRef="usd">260600000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i626282e786b7454d83b617e9e83963e6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjNlMTVmNGEwMDdjZTQzZmFiY2Y0MTE0M2ZiYTU2NzllL3RhYmxlcmFuZ2U6M2UxNWY0YTAwN2NlNDNmYWJjZjQxMTQzZmJhNTY3OWVfMTAtMi0xLTEtMA_266e4a81-b3d8-432c-adf5-5c42c9ad7490"
      unitRef="usd">2965000000.0</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i626282e786b7454d83b617e9e83963e6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjNlMTVmNGEwMDdjZTQzZmFiY2Y0MTE0M2ZiYTU2NzllL3RhYmxlcmFuZ2U6M2UxNWY0YTAwN2NlNDNmYWJjZjQxMTQzZmJhNTY3OWVfMTAtNC0xLTEtMA_17474eb5-02d3-4212-bf34-d32f77d51c60"
      unitRef="usd">6000000.0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i626282e786b7454d83b617e9e83963e6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjNlMTVmNGEwMDdjZTQzZmFiY2Y0MTE0M2ZiYTU2NzllL3RhYmxlcmFuZ2U6M2UxNWY0YTAwN2NlNDNmYWJjZjQxMTQzZmJhNTY3OWVfMTAtNi0xLTEtMA_8f333537-e56c-4ef1-9ab1-326170ec99ec"
      unitRef="usd">700000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i626282e786b7454d83b617e9e83963e6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjNlMTVmNGEwMDdjZTQzZmFiY2Y0MTE0M2ZiYTU2NzllL3RhYmxlcmFuZ2U6M2UxNWY0YTAwN2NlNDNmYWJjZjQxMTQzZmJhNTY3OWVfMTAtOC0xLTEtMA_f7f66203-e1ee-4483-9e3b-e8b1fd355630"
      unitRef="usd">2970300000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesAmortizedCost
      contextRef="ieb9c77d5ac2a4c2c926a9a3dbf9ab8a7_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjNlMTVmNGEwMDdjZTQzZmFiY2Y0MTE0M2ZiYTU2NzllL3RhYmxlcmFuZ2U6M2UxNWY0YTAwN2NlNDNmYWJjZjQxMTQzZmJhNTY3OWVfMTEtMi0xLTEtMA_92645dc9-1174-466a-a0b0-948d313e11c3"
      unitRef="usd">218400000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ieb9c77d5ac2a4c2c926a9a3dbf9ab8a7_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjNlMTVmNGEwMDdjZTQzZmFiY2Y0MTE0M2ZiYTU2NzllL3RhYmxlcmFuZ2U6M2UxNWY0YTAwN2NlNDNmYWJjZjQxMTQzZmJhNTY3OWVfMTEtNC0xLTEtMA_a553bd87-8446-4b4f-aed1-b842a03c7c9d"
      unitRef="usd">132100000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ieb9c77d5ac2a4c2c926a9a3dbf9ab8a7_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjNlMTVmNGEwMDdjZTQzZmFiY2Y0MTE0M2ZiYTU2NzllL3RhYmxlcmFuZ2U6M2UxNWY0YTAwN2NlNDNmYWJjZjQxMTQzZmJhNTY3OWVfMTEtNi0xLTEtMA_b31caf98-7405-4a30-8940-60795b70dbe9"
      unitRef="usd">13000000.0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecurities
      contextRef="ieb9c77d5ac2a4c2c926a9a3dbf9ab8a7_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjNlMTVmNGEwMDdjZTQzZmFiY2Y0MTE0M2ZiYTU2NzllL3RhYmxlcmFuZ2U6M2UxNWY0YTAwN2NlNDNmYWJjZjQxMTQzZmJhNTY3OWVfMTEtOC0xLTEtMA_9eba1297-a521-4924-87cd-9a2eeb6b1282"
      unitRef="usd">337500000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RleHRyZWdpb246MjRlZmE5YWU4NTFkNGEwZmEzMmRhNmMxZDZiNzg1OTJfMzgwNA_166c6fce-e714-48ea-99fe-c22236954180">&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The estimated fair value and amortized cost of our marketable debt securities available-for-sale by contractual maturity are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:41.924%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.409%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.409%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.409%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.413%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;As of September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Due in one year or less&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;1,355.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;1,353.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,562.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,560.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Due after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;902.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;897.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,234.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,230.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Due after five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;107.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;107.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;173.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;173.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total marketable debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;2,364.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;2,358.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,970.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,965.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjIxMDliZDc0MjkyZDQzMThiMTI2N2NjYzZjODNmZWJiL3RhYmxlcmFuZ2U6MjEwOWJkNzQyOTJkNDMxOGIxMjY3Y2NjNmM4M2ZlYmJfMi0yLTEtMS0w_de31e9a8-2fa4-4bbb-87e5-ad29981e5906"
      unitRef="usd">1355000000.0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjIxMDliZDc0MjkyZDQzMThiMTI2N2NjYzZjODNmZWJiL3RhYmxlcmFuZ2U6MjEwOWJkNzQyOTJkNDMxOGIxMjY3Y2NjNmM4M2ZlYmJfMi00LTEtMS0w_8d848eab-9eda-48d7-86ac-2e9bb2d8549c"
      unitRef="usd">1353400000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="i626282e786b7454d83b617e9e83963e6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjIxMDliZDc0MjkyZDQzMThiMTI2N2NjYzZjODNmZWJiL3RhYmxlcmFuZ2U6MjEwOWJkNzQyOTJkNDMxOGIxMjY3Y2NjNmM4M2ZlYmJfMi02LTEtMS0w_6c7f1acd-75c0-47c9-b362-3759190648e1"
      unitRef="usd">1562200000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i626282e786b7454d83b617e9e83963e6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjIxMDliZDc0MjkyZDQzMThiMTI2N2NjYzZjODNmZWJiL3RhYmxlcmFuZ2U6MjEwOWJkNzQyOTJkNDMxOGIxMjY3Y2NjNmM4M2ZlYmJfMi04LTEtMS0w_be475ab6-45e5-4c7f-aa82-33087e768779"
      unitRef="usd">1560800000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
      contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjIxMDliZDc0MjkyZDQzMThiMTI2N2NjYzZjODNmZWJiL3RhYmxlcmFuZ2U6MjEwOWJkNzQyOTJkNDMxOGIxMjY3Y2NjNmM4M2ZlYmJfMy0yLTEtMS0w_565f4edd-feee-471d-8415-16449c310d77"
      unitRef="usd">902200000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjIxMDliZDc0MjkyZDQzMThiMTI2N2NjYzZjODNmZWJiL3RhYmxlcmFuZ2U6MjEwOWJkNzQyOTJkNDMxOGIxMjY3Y2NjNmM4M2ZlYmJfMy00LTEtMS0w_7c64e603-6318-4879-b328-f7460bdeee8a"
      unitRef="usd">897900000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
      contextRef="i626282e786b7454d83b617e9e83963e6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjIxMDliZDc0MjkyZDQzMThiMTI2N2NjYzZjODNmZWJiL3RhYmxlcmFuZ2U6MjEwOWJkNzQyOTJkNDMxOGIxMjY3Y2NjNmM4M2ZlYmJfMy02LTEtMS0w_3bb30320-fb98-4937-82c2-9b17732fd80c"
      unitRef="usd">1234500000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="i626282e786b7454d83b617e9e83963e6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjIxMDliZDc0MjkyZDQzMThiMTI2N2NjYzZjODNmZWJiL3RhYmxlcmFuZ2U6MjEwOWJkNzQyOTJkNDMxOGIxMjY3Y2NjNmM4M2ZlYmJfMy04LTEtMS0w_a06f1b99-283a-4065-af14-d96a3d055734"
      unitRef="usd">1230400000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost
      contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjIxMDliZDc0MjkyZDQzMThiMTI2N2NjYzZjODNmZWJiL3RhYmxlcmFuZ2U6MjEwOWJkNzQyOTJkNDMxOGIxMjY3Y2NjNmM4M2ZlYmJfNC0yLTEtMS0w_0bd2a527-3293-45f4-b355-bc1e9e2e48f0"
      unitRef="usd">107600000</biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost>
    <biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue
      contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjIxMDliZDc0MjkyZDQzMThiMTI2N2NjYzZjODNmZWJiL3RhYmxlcmFuZ2U6MjEwOWJkNzQyOTJkNDMxOGIxMjY3Y2NjNmM4M2ZlYmJfNC00LTEtMS0w_4d49e74d-0fec-4e32-82a3-2a2f6e4628fa"
      unitRef="usd">107100000</biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue>
    <biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost
      contextRef="i626282e786b7454d83b617e9e83963e6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjIxMDliZDc0MjkyZDQzMThiMTI2N2NjYzZjODNmZWJiL3RhYmxlcmFuZ2U6MjEwOWJkNzQyOTJkNDMxOGIxMjY3Y2NjNmM4M2ZlYmJfNC02LTEtMS0w_409e03a3-72b3-4dd8-84f4-53e69a4a8ec7"
      unitRef="usd">173600000</biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost>
    <biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue
      contextRef="i626282e786b7454d83b617e9e83963e6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjIxMDliZDc0MjkyZDQzMThiMTI2N2NjYzZjODNmZWJiL3RhYmxlcmFuZ2U6MjEwOWJkNzQyOTJkNDMxOGIxMjY3Y2NjNmM4M2ZlYmJfNC04LTEtMS0w_65b3b2bc-9254-43ee-bbaa-ef92b95baffb"
      unitRef="usd">173800000</biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecurities
      contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjIxMDliZDc0MjkyZDQzMThiMTI2N2NjYzZjODNmZWJiL3RhYmxlcmFuZ2U6MjEwOWJkNzQyOTJkNDMxOGIxMjY3Y2NjNmM4M2ZlYmJfNS0yLTEtMS0w_0ce1245e-ef5a-4266-8eaf-d2664bec173e"
      unitRef="usd">2364800000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjIxMDliZDc0MjkyZDQzMThiMTI2N2NjYzZjODNmZWJiL3RhYmxlcmFuZ2U6MjEwOWJkNzQyOTJkNDMxOGIxMjY3Y2NjNmM4M2ZlYmJfNS00LTEtMS0w_3416534e-f932-4d6f-b6bf-624e1899df9b"
      unitRef="usd">2358400000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecurities
      contextRef="i626282e786b7454d83b617e9e83963e6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjIxMDliZDc0MjkyZDQzMThiMTI2N2NjYzZjODNmZWJiL3RhYmxlcmFuZ2U6MjEwOWJkNzQyOTJkNDMxOGIxMjY3Y2NjNmM4M2ZlYmJfNS02LTEtMS0w_6edfdbc6-00b6-4ea6-9ba9-eeebab599407"
      unitRef="usd">2970300000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i626282e786b7454d83b617e9e83963e6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjIxMDliZDc0MjkyZDQzMThiMTI2N2NjYzZjODNmZWJiL3RhYmxlcmFuZ2U6MjEwOWJkNzQyOTJkNDMxOGIxMjY3Y2NjNmM4M2ZlYmJfNS04LTEtMS0w_6673c399-ddf9-4296-b0a3-c2c9a052e2a6"
      unitRef="usd">2965000000.0</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <biib:AverageMaturityOfMarketableSecurities
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RleHRyZWdpb246MjRlZmE5YWU4NTFkNGEwZmEzMmRhNmMxZDZiNzg1OTJfOTkw_610dd2bd-728f-421b-b309-e251ac153c91">P12M</biib:AverageMaturityOfMarketableSecurities>
    <biib:AverageMaturityOfMarketableSecurities
      contextRef="i0da5a59be8a94d28ad89a6d9991c15a1_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RleHRyZWdpb246MjRlZmE5YWU4NTFkNGEwZmEzMmRhNmMxZDZiNzg1OTJfMTA5OTUxMTYzNDQ2MQ_4e8a601b-d354-4ced-9d56-e40ff49d488a">P14M</biib:AverageMaturityOfMarketableSecurities>
    <us-gaap:RealizedGainLossOnInvestmentsTableTextBlock
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RleHRyZWdpb246MjRlZmE5YWU4NTFkNGEwZmEzMmRhNmMxZDZiNzg1OTJfMzgwOQ_27b8e4ea-16d6-47ac-8508-101168654c43">&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:44.075%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.204%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.204%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.619%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.624%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Proceeds from maturities and sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;1,360.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;611.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;5,240.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,867.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Realized gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;12.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Realized losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(25.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RealizedGainLossOnInvestmentsTableTextBlock>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjUzZDc4NDJhNDE4MzQ4NDg5OTU0MGIxYzBjYmI0MDU3L3RhYmxlcmFuZ2U6NTNkNzg0MmE0MTgzNDg0ODk5NTQwYjFjMGNiYjQwNTdfMi0yLTEtMS0w_4cf7b323-a101-4120-a8c6-7c77a4c072fe"
      unitRef="usd">1360900000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjUzZDc4NDJhNDE4MzQ4NDg5OTU0MGIxYzBjYmI0MDU3L3RhYmxlcmFuZ2U6NTNkNzg0MmE0MTgzNDg0ODk5NTQwYjFjMGNiYjQwNTdfMi00LTEtMS0w_27c0f233-1386-43f1-9019-7ae56f323a90"
      unitRef="usd">611800000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjUzZDc4NDJhNDE4MzQ4NDg5OTU0MGIxYzBjYmI0MDU3L3RhYmxlcmFuZ2U6NTNkNzg0MmE0MTgzNDg0ODk5NTQwYjFjMGNiYjQwNTdfMi02LTEtMS0w_45e0d16f-9980-4075-95aa-7108fc9869bb"
      unitRef="usd">5240700000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjUzZDc4NDJhNDE4MzQ4NDg5OTU0MGIxYzBjYmI0MDU3L3RhYmxlcmFuZ2U6NTNkNzg0MmE0MTgzNDg0ODk5NTQwYjFjMGNiYjQwNTdfMi04LTEtMS0w_b533f998-11a6-453f-ae3d-bde8a28418ac"
      unitRef="usd">3867600000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain
      contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjUzZDc4NDJhNDE4MzQ4NDg5OTU0MGIxYzBjYmI0MDU3L3RhYmxlcmFuZ2U6NTNkNzg0MmE0MTgzNDg0ODk5NTQwYjFjMGNiYjQwNTdfMy0yLTEtMS0w_71c1d27d-8d7f-4ab2-a52e-99c0bfd1da4d"
      unitRef="usd">1000000.0</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain
      contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjUzZDc4NDJhNDE4MzQ4NDg5OTU0MGIxYzBjYmI0MDU3L3RhYmxlcmFuZ2U6NTNkNzg0MmE0MTgzNDg0ODk5NTQwYjFjMGNiYjQwNTdfMy00LTEtMS0w_884c1720-29d5-4a02-99b7-e028c8e4ebd7"
      unitRef="usd">700000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjUzZDc4NDJhNDE4MzQ4NDg5OTU0MGIxYzBjYmI0MDU3L3RhYmxlcmFuZ2U6NTNkNzg0MmE0MTgzNDg0ODk5NTQwYjFjMGNiYjQwNTdfMy02LTEtMS0w_48b06321-a6d4-4660-9331-934e4dcb7575"
      unitRef="usd">12800000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjUzZDc4NDJhNDE4MzQ4NDg5OTU0MGIxYzBjYmI0MDU3L3RhYmxlcmFuZ2U6NTNkNzg0MmE0MTgzNDg0ODk5NTQwYjFjMGNiYjQwNTdfMy04LTEtMS0w_45326604-484f-4f2c-ad19-9d1fbb1d2e77"
      unitRef="usd">2300000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss
      contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjUzZDc4NDJhNDE4MzQ4NDg5OTU0MGIxYzBjYmI0MDU3L3RhYmxlcmFuZ2U6NTNkNzg0MmE0MTgzNDg0ODk5NTQwYjFjMGNiYjQwNTdfNC0yLTEtMS0w_11592c81-5bbc-4144-a7f7-e7c7b1ea808e"
      unitRef="usd">900000</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss
      contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjUzZDc4NDJhNDE4MzQ4NDg5OTU0MGIxYzBjYmI0MDU3L3RhYmxlcmFuZ2U6NTNkNzg0MmE0MTgzNDg0ODk5NTQwYjFjMGNiYjQwNTdfNC00LTEtMS0w_8e59b325-83ea-4c74-a876-2e26ee5206d8"
      unitRef="usd">100000</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjUzZDc4NDJhNDE4MzQ4NDg5OTU0MGIxYzBjYmI0MDU3L3RhYmxlcmFuZ2U6NTNkNzg0MmE0MTgzNDg0ODk5NTQwYjFjMGNiYjQwNTdfNC02LTEtMS0w_85fee645-e9b7-4007-9da8-83bbcf355808"
      unitRef="usd">25200000</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RhYmxlOjUzZDc4NDJhNDE4MzQ4NDg5OTU0MGIxYzBjYmI0MDU3L3RhYmxlcmFuZ2U6NTNkNzg0MmE0MTgzNDg0ODk5NTQwYjFjMGNiYjQwNTdfNC04LTEtMS0w_0aaa842f-0c38-4af1-9b07-a6b0ba334dc4"
      unitRef="usd">700000</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <biib:StrategicInvestmentPortfolio
      contextRef="i9fda89e7ff7d4684af34961dfcf9aa55_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RleHRyZWdpb246MjRlZmE5YWU4NTFkNGEwZmEzMmRhNmMxZDZiNzg1OTJfMTI5Mg_79247788-14df-4bf6-a292-85f81781b6cd"
      unitRef="usd">925100000</biib:StrategicInvestmentPortfolio>
    <biib:StrategicInvestmentPortfolio
      contextRef="id8f1f5cd45cf4a6db70e9630acf66ec5_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RleHRyZWdpb246MjRlZmE5YWU4NTFkNGEwZmEzMmRhNmMxZDZiNzg1OTJfMTI5OQ_88d71c69-9eb3-4384-911c-22923da2f116"
      unitRef="usd">393900000</biib:StrategicInvestmentPortfolio>
    <biib:Investmentincommonstocksharespurchased
      contextRef="i309c31a67fb24e66812ca6f278d681d1_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RleHRyZWdpb246MjRlZmE5YWU4NTFkNGEwZmEzMmRhNmMxZDZiNzg1OTJfMTA5OTUxMTYzMjI2Ng_b2235e7e-5bfb-434c-bbd3-ea9181120aca"
      unitRef="shares">13000000</biib:Investmentincommonstocksharespurchased>
    <biib:DividendYieldPercentage
      contextRef="i7c3108c96711433ebf84541ad9cd5532_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RleHRyZWdpb246MjRlZmE5YWU4NTFkNGEwZmEzMmRhNmMxZDZiNzg1OTJfODc5NjA5MzAzNjE5MQ_c9753c1d-798f-4772-9d49-7191c41071b0"
      unitRef="number">0</biib:DividendYieldPercentage>
    <biib:Investmentincommonstocksharespurchased
      contextRef="iaf4f0ead32484685b836bcb55cd6ac1f_I20200430"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RleHRyZWdpb246MjRlZmE5YWU4NTFkNGEwZmEzMmRhNmMxZDZiNzg1OTJfMjg5MA_b0c185c2-cac3-4ec4-b4af-83dd36c78fe5"
      unitRef="shares">24000000</biib:Investmentincommonstocksharespurchased>
    <biib:DividendYieldPercentage
      contextRef="i6cbe8727f757473bb189b0e60ca29a33_D20200401-20200430"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183My9mcmFnOjI0ZWZhOWFlODUxZDRhMGZhMzJkYTZjMWQ2Yjc4NTkyL3RleHRyZWdpb246MjRlZmE5YWU4NTFkNGEwZmEzMmRhNmMxZDZiNzg1OTJfODc5NjA5MzAzNjIxMg_9580ac75-494c-4098-b75b-bef4e8c49e74"
      unitRef="number">0</biib:DividendYieldPercentage>
    <us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RleHRyZWdpb246YmEwYjhjZTdlYmE3NDcxN2I0ZTE1YWM2NzA4YjI1ODBfNjk4OQ_f151156a-20b9-458a-b0c5-88a355aa3561">&lt;div style="text-indent:11.25pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Foreign Currency Forward Contracts - Hedging Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Due to the global nature of our operations, portions of our revenues and operating expenses are recorded in currencies other than the U.S.&#160;dollar. The value of revenues and operating expenses measured in U.S.&#160;dollars is therefore subject to changes in foreign currency exchange rates. In order to mitigate these changes, we use foreign currency forward contracts to lock in exchange rates associated with a portion of our forecasted international revenues and operating expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Foreign currency forward contracts in effect as of September 30, 2020 and December 31, 2019, had durations of 1 to 24 months and 1 to 15 months, respectively. These contracts have been designated as cash flow hedges and unrealized gains or losses on the portion of these foreign currency forward contracts that are included in the effectiveness test are reported in accumulated other comprehensive income (loss) (referred to as AOCI in the tables below). Realized gains and losses of such contracts are recognized in revenues when the sale of product in the currency being hedged is recognized and in operating expenses when the expense in the currency being hedged is recorded. We recognize all cash flow hedge reclassifications from accumulated other comprehensive income (loss) and fair value changes of excluded portions in the same line item in our condensed consolidated statements of income that has been impacted by the hedged item.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The notional value of foreign currency forward contracts that were entered into to hedge forecasted revenues and operating expenses is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:58.549%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:18.344%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:18.347%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Notional Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;As of September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Euro&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;2,717.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,892.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;British pound&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;62.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Swiss franc&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;34.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Japanese yen&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;27.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Canadian dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;25.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total foreign currency forward contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;2,866.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,892.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The pre-tax portion of the fair value of these foreign currency forward contracts that were included in accumulated other comprehensive income (loss) in total equity reflected net losses of $114.6 million and net gains of $0.5 million as of September 30, 2020 and December 31, 2019, respectively. We expect the net losses of $114.6 million to be settled over the next 24 months, of which $94.1 million of these losses are expected to be settled over the next 12 months, with any amounts in accumulated other comprehensive income (loss) to be reported as an adjustment to revenues or operating expenses. We consider the impact of our and our counterparties&#x2019; credit risk on the fair value of the contracts as well as the ability of each party to execute its contractual obligations. As of September 30, 2020 and December 31, 2019, credit risk did not materially change the fair value of our foreign currency forward contracts.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following tables summarize the effect of foreign currency forward contracts designated as hedging instruments in our condensed consolidated statements of income:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:22.765%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.198%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.345%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:21.154%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.637%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.641%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="33" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net Gains/(Losses)&lt;br/&gt;Reclassified from AOCI into Operating Income (in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net Gains/(Losses)&lt;br/&gt;Recognized in Operating Income (in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(9.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;35.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(8.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:22.611%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.536%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.123%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.536%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.418%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.536%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:21.138%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.536%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.712%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.536%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.718%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="33" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net Gains/(Losses)&lt;br/&gt;Reclassified from AOCI into Operating Income (in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net Gains/(Losses)&lt;br/&gt;Recognized in Operating Income (in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;41.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;79.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:11.25pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Interest Rate Contracts - Hedging Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We have entered into interest rate lock contracts or interest rate swap contracts on certain borrowing transactions to manage our exposure to interest rate changes and to reduce our overall cost of borrowing. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:13.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#528134;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Interest Rate Swap Contracts&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In connection with the issuance of our 2.90% Senior Notes due September 15, 2020, we entered into interest rate swaps with an aggregate notional amount of $675.0 million, which were originally set to expire on September 15, 2020. The interest rate swap contracts were designated as hedges of the fair value changes in our 2.90% Senior Notes attributable to changes in interest rates. The carrying value of our 2.90% Senior Notes as of December 31, 2019, included approximately $2.3 million related to changes in the fair value of these interest rate swap contracts. In May 2020 we settled our interest rate swap contracts, in conjunction with our early redemption of our 2.90% Senior Notes, resulting in a gain of approximately $3.3 million for the nine months ended September 30, 2020, which was recorded as a component of interest expense in our condensed consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:11.25pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Net Investment Hedges - Hedging Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In February 2012 we entered into a joint venture agreement with Samsung BioLogics establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar products. In June 2018 we exercised our option under our joint venture agreement to increase our ownership percentage in Samsung Bioepis from approximately 5.0% to approximately 49.9%. The share purchase transaction was completed in November 2018 and, upon closing, we paid 759.5 billion South Korean won ($676.6 million) to Samsung BioLogics. Our investment in the equity of Samsung Bioepis is exposed to the currency fluctuations in the South Korean won. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In order to mitigate the currency fluctuations between the U.S. dollar and South Korean won, we have entered into foreign currency forward contracts. Foreign currency forward contracts in effect as of September 30, 2020, had a remaining duration of one month. These contracts have been designated as net investment hedges. We recognize changes in the spot exchange rate in accumulated other comprehensive income (loss). The pre-tax portion of the fair value of these foreign currency forward contracts that were included in accumulated other comprehensive income (loss) in total equity reflected net gains of $3.5 million and net losses of $1.5 million as of September 30, 2020 and December 31, 2019, respectively. We exclude fair value changes related to the forward rate from our hedging relationship and will amortize the forward points in other income (expense), net in our condensed consolidated statements of income over the term of the contract. The pre-tax portion of the fair value of the forward points that were included in accumulated other comprehensive income (loss) in total equity reflected gains of $0.3 million and $2.9 million as of September 30, 2020 and December 31, 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following tables summarize the effect of our net investment hedge in our condensed consolidated financial statements:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:18.372%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:5.195%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:5.195%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:20.715%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:5.195%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:5.195%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.980%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:5.195%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:5.202%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="51" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net Gains/(Losses)&lt;br/&gt;Recognized in Other Comprehensive Income (Effective Portion) (in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net Gains/(Losses)&lt;br/&gt;Recognized in Other Comprehensive Income (Amounts Excluded from Effectiveness Testing) &lt;br/&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net Gains/(Losses)&lt;br/&gt;Recognized in Net Income &lt;br/&gt;(Amounts Excluded from Effectiveness Testing) (in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gains (losses) on net investment hedge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(10.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;22.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gains (losses) on net investment hedge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other income (expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:11pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.122%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:18.369%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.537%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:5.242%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.537%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:4.947%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.537%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:20.876%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.537%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:5.242%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.537%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:4.947%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.537%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.091%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.537%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:5.242%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.537%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:5.248%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="51" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net Gains/(Losses)&lt;br/&gt;Recognized in Other Comprehensive Income (Effective Portion) (in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net Gains/(Losses)&lt;br/&gt;Recognized in Other Comprehensive Income (Amounts Excluded from Effectiveness Testing) &lt;br/&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net Gains/(Losses)&lt;br/&gt;Recognized in Net Income &lt;br/&gt;(Amounts Excluded from Effectiveness Testing) (in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gains (losses) on net investment hedge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;45.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gains (losses) on net investment hedge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other income (expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;For additional information on our collaboration arrangements with Samsung Bioepis, please read &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Note 17, Collaborative and Other Relationships,&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:11.25pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Foreign Currency Forward Contracts - Other Derivative Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We also enter into other foreign currency forward contracts, usually with durations of one month or less, to mitigate the foreign currency risk related to certain balance sheet positions. We have not elected hedge accounting for these transactions.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The aggregate notional amount of these outstanding foreign currency forward contracts was $990.0 million and $793.8 million as of September 30, 2020 and December 31, 2019, respectively. Net gains of $7.8 million and $13.7 million related to these contracts were recorded as a component of other income (expense), net for the three and nine months ended September 30, 2020, respectively, compared to net losses of $10.3 million and $14.2 million, respectively, in the prior year comparative periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:11.25pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Summary of Derivative Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;While certain of our derivative instruments are subject to netting arrangements with our counterparties, we do not offset derivative assets and liabilities in our condensed consolidated balance sheets. The amounts in the table below would not be substantially different if the derivative assets and liabilities were offset.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table summarizes the fair value and presentation in our condensed consolidated balance sheets of our outstanding derivative instruments, including those designated as hedging instruments:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:28.328%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:28.328%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:18.372%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:18.376%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance Sheet Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;As of September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-style:italic;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash Flow Hedging Instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Asset derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;33.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Investments and other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Liability derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accrued expenses and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;70.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;21.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-style:italic;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net Investment Hedging Instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Asset derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;10.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-style:italic;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair Value Hedging Instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Liability derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accrued expenses and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-style:italic;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other Derivative Instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Asset derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;10.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Liability derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accrued expenses and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;7.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
    <us-gaap:DerivativeRemainingMaturity1
      contextRef="if61ca2beff4e46f2a69e878ff2475931_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RleHRyZWdpb246YmEwYjhjZTdlYmE3NDcxN2I0ZTE1YWM2NzA4YjI1ODBfNjI5_247b2796-af07-4ab0-8a07-19872febc0b4">P1M</us-gaap:DerivativeRemainingMaturity1>
    <us-gaap:DerivativeRemainingMaturity1
      contextRef="i14b94761681149c0bbac66ff547913ee_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RleHRyZWdpb246YmEwYjhjZTdlYmE3NDcxN2I0ZTE1YWM2NzA4YjI1ODBfNjM1_98aed5b0-0cda-4b48-ae26-6d8296051d0c">P24M</us-gaap:DerivativeRemainingMaturity1>
    <us-gaap:DerivativeRemainingMaturity1
      contextRef="i2bae98225c1d43d0a893047e90eb67a3_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RleHRyZWdpb246YmEwYjhjZTdlYmE3NDcxN2I0ZTE1YWM2NzA4YjI1ODBfNjQ5_f63a0435-9e1d-413f-88c7-5b8d8fc7fa1a">P1M</us-gaap:DerivativeRemainingMaturity1>
    <us-gaap:DerivativeRemainingMaturity1
      contextRef="id558b1125e81440f900acb6908040141_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RleHRyZWdpb246YmEwYjhjZTdlYmE3NDcxN2I0ZTE1YWM2NzA4YjI1ODBfNjU1_1f5240ff-21a9-4924-b519-e17fb12255dd">P15M</us-gaap:DerivativeRemainingMaturity1>
    <us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RleHRyZWdpb246YmEwYjhjZTdlYmE3NDcxN2I0ZTE1YWM2NzA4YjI1ODBfNjk5MQ_bdd80a2e-fb8c-49b4-a625-a78ab89042c2">&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The notional value of foreign currency forward contracts that were entered into to hedge forecasted revenues and operating expenses is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:58.549%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:18.344%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:18.347%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Notional Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;As of September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Euro&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;2,717.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,892.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;British pound&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;62.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Swiss franc&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;34.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Japanese yen&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;27.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Canadian dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;25.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total foreign currency forward contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;2,866.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,892.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock>
    <us-gaap:DerivativeNotionalAmount
      contextRef="iaa7d33c1e10b47fa9f4f7f33d32f8d33_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RhYmxlOmNjNTdkOTQxZGMyMjQyMzliYTIzOWFiNGNmMzVhZGJhL3RhYmxlcmFuZ2U6Y2M1N2Q5NDFkYzIyNDIzOWJhMjM5YWI0Y2YzNWFkYmFfMi0yLTEtMS0w_38270b83-67ca-4bc1-847b-8e68b5e73327"
      unitRef="usd">2717000000.0</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ib2f9b3c22cd24844962bad5e0141c40d_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RhYmxlOmNjNTdkOTQxZGMyMjQyMzliYTIzOWFiNGNmMzVhZGJhL3RhYmxlcmFuZ2U6Y2M1N2Q5NDFkYzIyNDIzOWJhMjM5YWI0Y2YzNWFkYmFfMi00LTEtMS0w_55f883f2-3a5f-48e2-8dcf-239f067ed7be"
      unitRef="usd">1892400000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ic1855cf25f394029aa9142b5e0a2635f_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RhYmxlOmNjNTdkOTQxZGMyMjQyMzliYTIzOWFiNGNmMzVhZGJhL3RhYmxlcmFuZ2U6Y2M1N2Q5NDFkYzIyNDIzOWJhMjM5YWI0Y2YzNWFkYmFfMy0yLTEtMS0w_02298670-fd68-4276-abee-6853c28be216"
      unitRef="usd">62000000.0</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i6a9857ccde3e4f828b0b5370ff0d84e4_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RhYmxlOmNjNTdkOTQxZGMyMjQyMzliYTIzOWFiNGNmMzVhZGJhL3RhYmxlcmFuZ2U6Y2M1N2Q5NDFkYzIyNDIzOWJhMjM5YWI0Y2YzNWFkYmFfMy00LTEtMS0w_c527c851-5bac-4a38-960e-8f68a923f9a6"
      unitRef="usd">0</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i25d3a3cbcff64295ae970930acaf2277_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RhYmxlOmNjNTdkOTQxZGMyMjQyMzliYTIzOWFiNGNmMzVhZGJhL3RhYmxlcmFuZ2U6Y2M1N2Q5NDFkYzIyNDIzOWJhMjM5YWI0Y2YzNWFkYmFfNC0yLTEtMS0w_b8e86d68-12f9-488a-b361-f4b55987d234"
      unitRef="usd">34500000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i921787c0672f4315b77172582046acf3_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RhYmxlOmNjNTdkOTQxZGMyMjQyMzliYTIzOWFiNGNmMzVhZGJhL3RhYmxlcmFuZ2U6Y2M1N2Q5NDFkYzIyNDIzOWJhMjM5YWI0Y2YzNWFkYmFfNC00LTEtMS0w_11b2a06a-4f52-4ff2-b6dc-8d697842c252"
      unitRef="usd">0</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ibc22ccd0077c4fc49c9a6f2ddfe73891_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RhYmxlOmNjNTdkOTQxZGMyMjQyMzliYTIzOWFiNGNmMzVhZGJhL3RhYmxlcmFuZ2U6Y2M1N2Q5NDFkYzIyNDIzOWJhMjM5YWI0Y2YzNWFkYmFfNS0yLTEtMS0w_10e538dd-a783-4d08-ab82-33aa864b24a6"
      unitRef="usd">27100000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="idd041b2211c7473cb6ccaf17dec017b0_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RhYmxlOmNjNTdkOTQxZGMyMjQyMzliYTIzOWFiNGNmMzVhZGJhL3RhYmxlcmFuZ2U6Y2M1N2Q5NDFkYzIyNDIzOWJhMjM5YWI0Y2YzNWFkYmFfNS00LTEtMS0w_e5c1f094-d31d-4af4-8e6c-7d5f9a19d181"
      unitRef="usd">0</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ic3cd6575c1e949488c892f752b68feb4_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RhYmxlOmNjNTdkOTQxZGMyMjQyMzliYTIzOWFiNGNmMzVhZGJhL3RhYmxlcmFuZ2U6Y2M1N2Q5NDFkYzIyNDIzOWJhMjM5YWI0Y2YzNWFkYmFfNi0yLTEtMS0w_97316cf1-148b-4b04-a2a2-d3503a4f127d"
      unitRef="usd">25900000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ic23424b9be6b4da59f189eb5703a1408_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RhYmxlOmNjNTdkOTQxZGMyMjQyMzliYTIzOWFiNGNmMzVhZGJhL3RhYmxlcmFuZ2U6Y2M1N2Q5NDFkYzIyNDIzOWJhMjM5YWI0Y2YzNWFkYmFfNi00LTEtMS0w_a5b89251-f701-49cd-980b-3261d46b10b0"
      unitRef="usd">0</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i192ef770d9d94f289c8016dd9d055c00_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RhYmxlOmNjNTdkOTQxZGMyMjQyMzliYTIzOWFiNGNmMzVhZGJhL3RhYmxlcmFuZ2U6Y2M1N2Q5NDFkYzIyNDIzOWJhMjM5YWI0Y2YzNWFkYmFfNy0yLTEtMS0w_30b95cbd-4f64-4d66-911b-25fa04ede0c0"
      unitRef="usd">2866500000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ie23a1176752b46eca086057bec4d49b1_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RhYmxlOmNjNTdkOTQxZGMyMjQyMzliYTIzOWFiNGNmMzVhZGJhL3RhYmxlcmFuZ2U6Y2M1N2Q5NDFkYzIyNDIzOWJhMjM5YWI0Y2YzNWFkYmFfNy00LTEtMS0w_c1071894-3754-48a3-b6fb-bcc4f93a264e"
      unitRef="usd">1892400000</us-gaap:DerivativeNotionalAmount>
    <biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax
      contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RleHRyZWdpb246YmEwYjhjZTdlYmE3NDcxN2I0ZTE1YWM2NzA4YjI1ODBfMTgwNQ_68464160-a9bb-42b5-a629-9c20a3a9cb14"
      unitRef="usd">-114600000</biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax>
    <biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax
      contextRef="i626282e786b7454d83b617e9e83963e6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RleHRyZWdpb246YmEwYjhjZTdlYmE3NDcxN2I0ZTE1YWM2NzA4YjI1ODBfMTgyNQ_eb687e15-8bc2-4d1d-b266-762dbc39dc17"
      unitRef="usd">500000</biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax>
    <biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax
      contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RleHRyZWdpb246YmEwYjhjZTdlYmE3NDcxN2I0ZTE1YWM2NzA4YjI1ODBfMTg4Nw_68464160-a9bb-42b5-a629-9c20a3a9cb14"
      unitRef="usd">-114600000</biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax>
    <us-gaap:DerivativeRemainingMaturity1
      contextRef="i14b94761681149c0bbac66ff547913ee_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RleHRyZWdpb246YmEwYjhjZTdlYmE3NDcxN2I0ZTE1YWM2NzA4YjI1ODBfMTkxOA_12b2344c-a9df-444a-974c-35ce5f43a9d9">P24M</us-gaap:DerivativeRemainingMaturity1>
    <biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax
      contextRef="i68711c4f381b4aba952ff728afb1d3f8_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RleHRyZWdpb246YmEwYjhjZTdlYmE3NDcxN2I0ZTE1YWM2NzA4YjI1ODBfMTkzOA_cefb19c2-3815-468c-9692-09d51be0a030"
      unitRef="usd">-94100000</biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax>
    <us-gaap:DerivativeRemainingMaturity1
      contextRef="i5a2d291074a1433481dcb814e41d5746_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RleHRyZWdpb246YmEwYjhjZTdlYmE3NDcxN2I0ZTE1YWM2NzA4YjI1ODBfMTk5OA_95fd8d4f-73ea-4a7b-87c2-4d33d08476d8">P12M</us-gaap:DerivativeRemainingMaturity1>
    <us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RleHRyZWdpb246YmEwYjhjZTdlYmE3NDcxN2I0ZTE1YWM2NzA4YjI1ODBfNzAwMw_0546859a-7321-4be8-a2f4-8d1172d5bb9b">&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following tables summarize the effect of foreign currency forward contracts designated as hedging instruments in our condensed consolidated statements of income:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:22.765%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.198%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.345%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:21.154%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.637%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.641%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="33" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net Gains/(Losses)&lt;br/&gt;Reclassified from AOCI into Operating Income (in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net Gains/(Losses)&lt;br/&gt;Recognized in Operating Income (in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(9.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;35.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(8.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:22.611%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.536%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.123%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.536%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.418%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.536%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:21.138%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.536%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.712%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.536%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.718%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="33" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net Gains/(Losses)&lt;br/&gt;Reclassified from AOCI into Operating Income (in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net Gains/(Losses)&lt;br/&gt;Recognized in Operating Income (in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;41.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;79.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet
      contextRef="ibf5f0f40953a4421b9784faf958d97fc_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RhYmxlOmU0YmIxZjAyN2I3YzRiNmM4ZTk2MzdmYzJiMTRiNWQ3L3RhYmxlcmFuZ2U6ZTRiYjFmMDI3YjdjNGI2YzhlOTYzN2ZjMmIxNGI1ZDdfMy0yLTEtMS0w_1a343e81-b026-4f60-98a6-ce472d0fb4e4"
      unitRef="usd">-9100000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet
      contextRef="ibf5f0f40953a4421b9784faf958d97fc_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RhYmxlOmU0YmIxZjAyN2I3YzRiNmM4ZTk2MzdmYzJiMTRiNWQ3L3RhYmxlcmFuZ2U6ZTRiYjFmMDI3YjdjNGI2YzhlOTYzN2ZjMmIxNGI1ZDdfMy00LTEtMS0w_8f83c939-d0ca-4699-b546-a1512dead8fb"
      unitRef="usd">35200000</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet
      contextRef="id81d26ae112f445586efe731295329b3_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RhYmxlOmU0YmIxZjAyN2I3YzRiNmM4ZTk2MzdmYzJiMTRiNWQ3L3RhYmxlcmFuZ2U6ZTRiYjFmMDI3YjdjNGI2YzhlOTYzN2ZjMmIxNGI1ZDdfMy04LTEtMS0w_c783d04e-7c84-47d0-89e3-35e572a963d2"
      unitRef="usd">-8700000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet
      contextRef="id81d26ae112f445586efe731295329b3_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RhYmxlOmU0YmIxZjAyN2I3YzRiNmM4ZTk2MzdmYzJiMTRiNWQ3L3RhYmxlcmFuZ2U6ZTRiYjFmMDI3YjdjNGI2YzhlOTYzN2ZjMmIxNGI1ZDdfMy0xMC0xLTEtMA_0ccf4a98-7516-429c-b949-64ed22def7f4"
      unitRef="usd">800000</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet
      contextRef="i8b20f502d9dc4650852d96fb05490b25_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RhYmxlOmU0YmIxZjAyN2I3YzRiNmM4ZTk2MzdmYzJiMTRiNWQ3L3RhYmxlcmFuZ2U6ZTRiYjFmMDI3YjdjNGI2YzhlOTYzN2ZjMmIxNGI1ZDdfNC0yLTEtMS0w_eec6800e-f2e1-4096-ba0d-7ae4f4931253"
      unitRef="usd">1500000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet
      contextRef="i8b20f502d9dc4650852d96fb05490b25_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RhYmxlOmU0YmIxZjAyN2I3YzRiNmM4ZTk2MzdmYzJiMTRiNWQ3L3RhYmxlcmFuZ2U6ZTRiYjFmMDI3YjdjNGI2YzhlOTYzN2ZjMmIxNGI1ZDdfNC00LTEtMS0w_b4891cb5-a6c6-42b6-929a-d4d7a9c8c0fc"
      unitRef="usd">-800000</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet
      contextRef="if0abd481cc504df9bbfcf3174b6ce61f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RhYmxlOmU0YmIxZjAyN2I3YzRiNmM4ZTk2MzdmYzJiMTRiNWQ3L3RhYmxlcmFuZ2U6ZTRiYjFmMDI3YjdjNGI2YzhlOTYzN2ZjMmIxNGI1ZDdfNC04LTEtMS0w_90f15808-ca39-4d0c-817f-2d088124d173"
      unitRef="usd">400000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet
      contextRef="if0abd481cc504df9bbfcf3174b6ce61f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RhYmxlOmU0YmIxZjAyN2I3YzRiNmM4ZTk2MzdmYzJiMTRiNWQ3L3RhYmxlcmFuZ2U6ZTRiYjFmMDI3YjdjNGI2YzhlOTYzN2ZjMmIxNGI1ZDdfNC0xMC0xLTEtMA_7750d7c3-b707-4202-80fc-cdbb05b08462"
      unitRef="usd">400000</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet
      contextRef="id2b9b73877d74fc192e42310e8d70481_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RhYmxlOjU3MzgwNjVlMjEyYzRjZDU5YzI5MGI0NTIxNjA2NGFmL3RhYmxlcmFuZ2U6NTczODA2NWUyMTJjNGNkNTljMjkwYjQ1MjE2MDY0YWZfMy0yLTEtMS0w_1d090185-2446-434d-af20-be070974a431"
      unitRef="usd">41600000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet
      contextRef="id2b9b73877d74fc192e42310e8d70481_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RhYmxlOjU3MzgwNjVlMjEyYzRjZDU5YzI5MGI0NTIxNjA2NGFmL3RhYmxlcmFuZ2U6NTczODA2NWUyMTJjNGNkNTljMjkwYjQ1MjE2MDY0YWZfMy00LTEtMS0w_5eae4521-b7f1-432c-8a77-a07ca8d39a82"
      unitRef="usd">79800000</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet
      contextRef="ic22c771083a443f1ba2c8d2ff484ba65_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RhYmxlOjU3MzgwNjVlMjEyYzRjZDU5YzI5MGI0NTIxNjA2NGFmL3RhYmxlcmFuZ2U6NTczODA2NWUyMTJjNGNkNTljMjkwYjQ1MjE2MDY0YWZfMy04LTEtMS0w_3ca64f37-1207-41b5-8a5e-2d78e0236996"
      unitRef="usd">-1000000.0</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet
      contextRef="ic22c771083a443f1ba2c8d2ff484ba65_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RhYmxlOjU3MzgwNjVlMjEyYzRjZDU5YzI5MGI0NTIxNjA2NGFmL3RhYmxlcmFuZ2U6NTczODA2NWUyMTJjNGNkNTljMjkwYjQ1MjE2MDY0YWZfMy0xMC0xLTEtMA_25357134-dc1f-47d2-8793-9631375419cb"
      unitRef="usd">8200000</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet
      contextRef="i827d32a33a5f4fa8ab22ab96449ad285_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RhYmxlOjU3MzgwNjVlMjEyYzRjZDU5YzI5MGI0NTIxNjA2NGFmL3RhYmxlcmFuZ2U6NTczODA2NWUyMTJjNGNkNTljMjkwYjQ1MjE2MDY0YWZfNC0yLTEtMS0w_d8a65908-ca27-4986-9667-7ac34ac650f9"
      unitRef="usd">1400000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet
      contextRef="i827d32a33a5f4fa8ab22ab96449ad285_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RhYmxlOjU3MzgwNjVlMjEyYzRjZDU5YzI5MGI0NTIxNjA2NGFmL3RhYmxlcmFuZ2U6NTczODA2NWUyMTJjNGNkNTljMjkwYjQ1MjE2MDY0YWZfNC00LTEtMS0w_24a60359-a78b-4865-bbc4-101232f0126f"
      unitRef="usd">-2000000.0</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet
      contextRef="i4a9063b9b9ab470d9ffe7edfcebe7d66_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RhYmxlOjU3MzgwNjVlMjEyYzRjZDU5YzI5MGI0NTIxNjA2NGFmL3RhYmxlcmFuZ2U6NTczODA2NWUyMTJjNGNkNTljMjkwYjQ1MjE2MDY0YWZfNC04LTEtMS0w_40c4648c-9d26-477f-ab32-f0513e7a7103"
      unitRef="usd">-700000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet
      contextRef="i4a9063b9b9ab470d9ffe7edfcebe7d66_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RhYmxlOjU3MzgwNjVlMjEyYzRjZDU5YzI5MGI0NTIxNjA2NGFmL3RhYmxlcmFuZ2U6NTczODA2NWUyMTJjNGNkNTljMjkwYjQ1MjE2MDY0YWZfNC0xMC0xLTEtMA_957191ee-5701-48d7-aeab-ec3c8ab9eff1"
      unitRef="usd">-800000</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i9aaf1d46914b4e72aed3585ce98ebf30_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RleHRyZWdpb246YmEwYjhjZTdlYmE3NDcxN2I0ZTE1YWM2NzA4YjI1ODBfMjkyOQ_49ef0aba-2838-442e-9f08-785a3a4f19f8"
      unitRef="number">0.0290</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ic3ca7f05924940338725185c031d90c4_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RleHRyZWdpb246YmEwYjhjZTdlYmE3NDcxN2I0ZTE1YWM2NzA4YjI1ODBfMzA0Mg_f33e4080-80d4-4f1b-8d0b-2f9b5aaab0db"
      unitRef="usd">675000000.0</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i9aaf1d46914b4e72aed3585ce98ebf30_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RleHRyZWdpb246YmEwYjhjZTdlYmE3NDcxN2I0ZTE1YWM2NzA4YjI1ODBfMzE5Nw_49ef0aba-2838-442e-9f08-785a3a4f19f8"
      unitRef="number">0.0290</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i9aaf1d46914b4e72aed3585ce98ebf30_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RleHRyZWdpb246YmEwYjhjZTdlYmE3NDcxN2I0ZTE1YWM2NzA4YjI1ODBfMzI4Mg_49ef0aba-2838-442e-9f08-785a3a4f19f8"
      unitRef="number">0.0290</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i1761a26f1d99415db0e01cea732e296a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RleHRyZWdpb246YmEwYjhjZTdlYmE3NDcxN2I0ZTE1YWM2NzA4YjI1ODBfMzMzMQ_96676a30-9c76-4b51-9c4e-cfa2261bca7d"
      unitRef="usd">2300000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i9aaf1d46914b4e72aed3585ce98ebf30_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RleHRyZWdpb246YmEwYjhjZTdlYmE3NDcxN2I0ZTE1YWM2NzA4YjI1ODBfMzUwOQ_49ef0aba-2838-442e-9f08-785a3a4f19f8"
      unitRef="number">0.0290</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="ic4da688b8e414bdf83ba16881ee41846_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RleHRyZWdpb246YmEwYjhjZTdlYmE3NDcxN2I0ZTE1YWM2NzA4YjI1ODBfMzU2Mw_1e3bc2cc-675c-4d8c-8ff5-299d72718380"
      unitRef="usd">3300000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <biib:EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction
      contextRef="ide3b267ed539403d9aea0f7cee18e938_I20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RleHRyZWdpb246YmEwYjhjZTdlYmE3NDcxN2I0ZTE1YWM2NzA4YjI1ODBfNDA3NA_62ee03bb-1ff1-4dab-a8ab-5f8ae8bdbbc8"
      unitRef="number">0.050</biib:EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i982da4cced9d4ae2b09cb6c0c35fbf7b_I20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RleHRyZWdpb246YmEwYjhjZTdlYmE3NDcxN2I0ZTE1YWM2NzA4YjI1ODBfNDA5NA_d3369dea-3025-41d6-b93c-e74f0a07172d"
      unitRef="number">0.499</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="i4d505177b87243539cc2ef4baf3b7b2d_D20181101-20181130"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RleHRyZWdpb246YmEwYjhjZTdlYmE3NDcxN2I0ZTE1YWM2NzA4YjI1ODBfNDE4Nw_7c2debff-1b56-4680-afb0-2af413520cb1"
      unitRef="krw">759500000000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="i4d505177b87243539cc2ef4baf3b7b2d_D20181101-20181130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RleHRyZWdpb246YmEwYjhjZTdlYmE3NDcxN2I0ZTE1YWM2NzA4YjI1ODBfNDIwOA_d07e666c-97ca-4f99-b371-3ff8c83ac0c6"
      unitRef="usd">676600000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:DerivativeTermOfContract
      contextRef="id881e97ef71e48839eea697986831baa_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RleHRyZWdpb246YmEwYjhjZTdlYmE3NDcxN2I0ZTE1YWM2NzA4YjI1ODBfNDU4MA_c3bffbb1-d427-4962-a8a9-194155354691">P1M</us-gaap:DerivativeTermOfContract>
    <us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax
      contextRef="id881e97ef71e48839eea697986831baa_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RleHRyZWdpb246YmEwYjhjZTdlYmE3NDcxN2I0ZTE1YWM2NzA4YjI1ODBfNDk0MA_2c10fd01-2565-434e-9aa8-ab8e87e2fb84"
      unitRef="usd">3500000</us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax>
    <us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax
      contextRef="i2a87e4910f2b4990a031d8e154d08e7c_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RleHRyZWdpb246YmEwYjhjZTdlYmE3NDcxN2I0ZTE1YWM2NzA4YjI1ODBfNDk2MQ_75f6fbb5-d6f5-41fa-b3e0-b35220c658f7"
      unitRef="usd">1500000</us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax>
    <us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax
      contextRef="i08b50968168f4eb9ae561aa850896bc4_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RleHRyZWdpb246YmEwYjhjZTdlYmE3NDcxN2I0ZTE1YWM2NzA4YjI1ODBfNTM5Ng_d4f8e1c7-e3b3-485b-a51b-51bed265fa42"
      unitRef="usd">300000</us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax>
    <us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax
      contextRef="i085845822f544f7fb9b0bbf69c2e903e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RleHRyZWdpb246YmEwYjhjZTdlYmE3NDcxN2I0ZTE1YWM2NzA4YjI1ODBfNTQwMw_6e04299a-6f9d-4f63-8c62-e574de89611d"
      unitRef="usd">2900000</us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax>
    <us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RleHRyZWdpb246YmEwYjhjZTdlYmE3NDcxN2I0ZTE1YWM2NzA4YjI1ODBfNzAyMA_480559d6-a690-46e3-828f-b8e3d4998568">&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following tables summarize the effect of our net investment hedge in our condensed consolidated financial statements:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:18.372%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:5.195%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:5.195%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:20.715%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:5.195%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:5.195%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.980%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:5.195%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:5.202%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="51" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net Gains/(Losses)&lt;br/&gt;Recognized in Other Comprehensive Income (Effective Portion) (in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net Gains/(Losses)&lt;br/&gt;Recognized in Other Comprehensive Income (Amounts Excluded from Effectiveness Testing) &lt;br/&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net Gains/(Losses)&lt;br/&gt;Recognized in Net Income &lt;br/&gt;(Amounts Excluded from Effectiveness Testing) (in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gains (losses) on net investment hedge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(10.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;22.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gains (losses) on net investment hedge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other income (expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:11pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.122%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:18.369%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.537%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:5.242%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.537%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:4.947%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.537%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:20.876%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.537%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:5.242%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.537%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:4.947%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.537%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.091%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.537%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:5.242%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.537%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:5.248%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="51" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net Gains/(Losses)&lt;br/&gt;Recognized in Other Comprehensive Income (Effective Portion) (in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net Gains/(Losses)&lt;br/&gt;Recognized in Other Comprehensive Income (Amounts Excluded from Effectiveness Testing) &lt;br/&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net Gains/(Losses)&lt;br/&gt;Recognized in Net Income &lt;br/&gt;(Amounts Excluded from Effectiveness Testing) (in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gains (losses) on net investment hedge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;45.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gains (losses) on net investment hedge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other income (expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease
      contextRef="i7d8de41bd42443beb5e6ef8181fbd9ed_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RhYmxlOjAzYTQ4ODcwNzEwMjRjNzFiNzg5OWFiMWRjMjVlMDljL3RhYmxlcmFuZ2U6MDNhNDg4NzA3MTAyNGM3MWI3ODk5YWIxZGMyNWUwOWNfMy0yLTEtMS0w_c34c3cd6-0267-4725-8e58-382546e48140"
      unitRef="usd">-10400000</us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease>
    <us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease
      contextRef="icd9a4c8be88e43a9adf992e1820e2e43_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RhYmxlOjAzYTQ4ODcwNzEwMjRjNzFiNzg5OWFiMWRjMjVlMDljL3RhYmxlcmFuZ2U6MDNhNDg4NzA3MTAyNGM3MWI3ODk5YWIxZGMyNWUwOWNfMy00LTEtMS0w_c9f86094-645e-4b8d-933e-8913551c7f40"
      unitRef="usd">22000000.0</us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease>
    <biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease
      contextRef="i7d8de41bd42443beb5e6ef8181fbd9ed_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RhYmxlOjAzYTQ4ODcwNzEwMjRjNzFiNzg5OWFiMWRjMjVlMDljL3RhYmxlcmFuZ2U6MDNhNDg4NzA3MTAyNGM3MWI3ODk5YWIxZGMyNWUwOWNfMy04LTEtMS0w_a07d3c8f-351c-459b-bcdc-1a10c67e3622"
      unitRef="usd">-200000</biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease>
    <biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease
      contextRef="icd9a4c8be88e43a9adf992e1820e2e43_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RhYmxlOjAzYTQ4ODcwNzEwMjRjNzFiNzg5OWFiMWRjMjVlMDljL3RhYmxlcmFuZ2U6MDNhNDg4NzA3MTAyNGM3MWI3ODk5YWIxZGMyNWUwOWNfMy0xMC0xLTEtMA_2fc82527-f2e4-4a04-b3ba-805a8f96617a"
      unitRef="usd">1400000</biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease>
    <us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet
      contextRef="i5aac32d49b464e6cada89854863b83f8_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RhYmxlOjAzYTQ4ODcwNzEwMjRjNzFiNzg5OWFiMWRjMjVlMDljL3RhYmxlcmFuZ2U6MDNhNDg4NzA3MTAyNGM3MWI3ODk5YWIxZGMyNWUwOWNfMy0xNC0xLTEtMA_1284d328-a52f-4122-85db-cf2f7f6eb742"
      unitRef="usd">900000</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
    <us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet
      contextRef="i10cf9b7a2fa84d7b844aa117861b3c56_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RhYmxlOjAzYTQ4ODcwNzEwMjRjNzFiNzg5OWFiMWRjMjVlMDljL3RhYmxlcmFuZ2U6MDNhNDg4NzA3MTAyNGM3MWI3ODk5YWIxZGMyNWUwOWNfMy0xNi0xLTEtMA_753b59b4-b646-4482-ab0e-e8c6949bb2e0"
      unitRef="usd">2200000</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
    <us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease
      contextRef="id881e97ef71e48839eea697986831baa_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RhYmxlOmQwZjI1NzBiNTNhMDQ3NDg4NGE2NjM5ZDNlMTkxNzY4L3RhYmxlcmFuZ2U6ZDBmMjU3MGI1M2EwNDc0ODg0YTY2MzlkM2UxOTE3NjhfMy0yLTEtMS0w_fe8a7f7c-2021-4c96-a82a-829f11b0334e"
      unitRef="usd">5000000.0</us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease>
    <us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease
      contextRef="i9c45d46cb2c8406b930ef51351627297_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RhYmxlOmQwZjI1NzBiNTNhMDQ3NDg4NGE2NjM5ZDNlMTkxNzY4L3RhYmxlcmFuZ2U6ZDBmMjU3MGI1M2EwNDc0ODg0YTY2MzlkM2UxOTE3NjhfMy00LTEtMS0w_bbd7fe5d-faee-4140-b1f5-84a9eef1a21a"
      unitRef="usd">45400000</us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease>
    <biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease
      contextRef="id881e97ef71e48839eea697986831baa_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RhYmxlOmQwZjI1NzBiNTNhMDQ3NDg4NGE2NjM5ZDNlMTkxNzY4L3RhYmxlcmFuZ2U6ZDBmMjU3MGI1M2EwNDc0ODg0YTY2MzlkM2UxOTE3NjhfMy04LTEtMS0w_62110bbd-c802-47d9-bc48-4d902275636c"
      unitRef="usd">3100000</biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease>
    <biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease
      contextRef="i9c45d46cb2c8406b930ef51351627297_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RhYmxlOmQwZjI1NzBiNTNhMDQ3NDg4NGE2NjM5ZDNlMTkxNzY4L3RhYmxlcmFuZ2U6ZDBmMjU3MGI1M2EwNDc0ODg0YTY2MzlkM2UxOTE3NjhfMy0xMC0xLTEtMA_83f3e35c-4a75-4bde-8a4b-12007f453dc5"
      unitRef="usd">8100000</biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease>
    <us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet
      contextRef="id9f595a3d9be4f678b3dd5cf54ed7ea2_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RhYmxlOmQwZjI1NzBiNTNhMDQ3NDg4NGE2NjM5ZDNlMTkxNzY4L3RhYmxlcmFuZ2U6ZDBmMjU3MGI1M2EwNDc0ODg0YTY2MzlkM2UxOTE3NjhfMy0xNC0xLTEtMA_b5584e23-3201-480d-9075-716106797bc6"
      unitRef="usd">2600000</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
    <us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet
      contextRef="ie62a8195213a48748ad6794961fbeb22_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RhYmxlOmQwZjI1NzBiNTNhMDQ3NDg4NGE2NjM5ZDNlMTkxNzY4L3RhYmxlcmFuZ2U6ZDBmMjU3MGI1M2EwNDc0ODg0YTY2MzlkM2UxOTE3NjhfMy0xNi0xLTEtMA_8bef624b-536a-464b-a3c3-652263c17711"
      unitRef="usd">6600000</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ie8794b47098d4b969e5c6a2e1127c28c_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RleHRyZWdpb246YmEwYjhjZTdlYmE3NDcxN2I0ZTE1YWM2NzA4YjI1ODBfNjEyMg_ecc7ffa1-5281-4b7f-bd0e-656eb1e8cedd"
      unitRef="usd">990000000.0</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i65313bd95c954aa487ab03b59dcf4f19_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RleHRyZWdpb246YmEwYjhjZTdlYmE3NDcxN2I0ZTE1YWM2NzA4YjI1ODBfNjEyOQ_90245945-0c44-4094-aca9-50412e2cde0e"
      unitRef="usd">793800000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
      contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RleHRyZWdpb246YmEwYjhjZTdlYmE3NDcxN2I0ZTE1YWM2NzA4YjI1ODBfNjE3Ng_f63fc76a-dc60-45cd-8b95-e69ba79cd9e6"
      unitRef="usd">7800000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
    <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RleHRyZWdpb246YmEwYjhjZTdlYmE3NDcxN2I0ZTE1YWM2NzA4YjI1ODBfNjE4Mw_d4790cbd-3b66-440d-8158-841f4fb2cbdb"
      unitRef="usd">13700000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
    <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
      contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RleHRyZWdpb246YmEwYjhjZTdlYmE3NDcxN2I0ZTE1YWM2NzA4YjI1ODBfNjM0Nw_16fd22e2-1c58-43f4-b40a-c5f7ab522678"
      unitRef="usd">10300000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
    <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RleHRyZWdpb246YmEwYjhjZTdlYmE3NDcxN2I0ZTE1YWM2NzA4YjI1ODBfNjM2OA_69a0f77c-034d-4baa-b08d-c45368a5ba2b"
      unitRef="usd">-14200000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
    <us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RleHRyZWdpb246YmEwYjhjZTdlYmE3NDcxN2I0ZTE1YWM2NzA4YjI1ODBfNjk5OA_a35b2b22-e87f-4e43-b3af-ba83841ebb2d">&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table summarizes the fair value and presentation in our condensed consolidated balance sheets of our outstanding derivative instruments, including those designated as hedging instruments:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:28.328%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:28.328%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:18.372%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:18.376%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance Sheet Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;As of September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-style:italic;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash Flow Hedging Instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Asset derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;33.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Investments and other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Liability derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accrued expenses and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;70.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;21.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-style:italic;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net Investment Hedging Instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Asset derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;10.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-style:italic;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair Value Hedging Instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Liability derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accrued expenses and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-style:italic;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other Derivative Instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Asset derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;10.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Liability derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accrued expenses and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;7.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i8a718d3046ad462ba2ea0e14cf490598_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RhYmxlOjViN2YxZGZlMDA1OTQzOWRhMDJlNTY5Njk1ZGZiYzE1L3RhYmxlcmFuZ2U6NWI3ZjFkZmUwMDU5NDM5ZGEwMmU1Njk2OTVkZmJjMTVfMi00LTEtMS0w_0a6dfa80-0b28-4b53-ab86-4bc3721f8fa4"
      unitRef="usd">3400000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i8b73ba8bfb5d4bd599ede52803901f5d_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RhYmxlOjViN2YxZGZlMDA1OTQzOWRhMDJlNTY5Njk1ZGZiYzE1L3RhYmxlcmFuZ2U6NWI3ZjFkZmUwMDU5NDM5ZGEwMmU1Njk2OTVkZmJjMTVfMi02LTEtMS0w_7c8d1ee2-b178-496f-856b-1a5a89f42d50"
      unitRef="usd">33800000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="ib096f70fe5a64feab15f8a20b058d2bd_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RhYmxlOjViN2YxZGZlMDA1OTQzOWRhMDJlNTY5Njk1ZGZiYzE1L3RhYmxlcmFuZ2U6NWI3ZjFkZmUwMDU5NDM5ZGEwMmU1Njk2OTVkZmJjMTVfMy00LTEtMS0w_6d109ec2-04b3-4ccc-aadb-1c46aeff8b4e"
      unitRef="usd">2300000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i6af0347c89c44263995f095d4ffa6626_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RhYmxlOjViN2YxZGZlMDA1OTQzOWRhMDJlNTY5Njk1ZGZiYzE1L3RhYmxlcmFuZ2U6NWI3ZjFkZmUwMDU5NDM5ZGEwMmU1Njk2OTVkZmJjMTVfMy02LTEtMS0w_8587dcc9-df50-4b33-903c-362ae6a1dff4"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="iea98908b86804d0caf3c1f88da0f244b_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RhYmxlOjViN2YxZGZlMDA1OTQzOWRhMDJlNTY5Njk1ZGZiYzE1L3RhYmxlcmFuZ2U6NWI3ZjFkZmUwMDU5NDM5ZGEwMmU1Njk2OTVkZmJjMTVfNC00LTEtMS0w_fe8e843c-a70f-4151-adfe-93dd2e4f1aac"
      unitRef="usd">70700000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i7e60003aa8884f1d8ddcbb0621054f9f_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RhYmxlOjViN2YxZGZlMDA1OTQzOWRhMDJlNTY5Njk1ZGZiYzE1L3RhYmxlcmFuZ2U6NWI3ZjFkZmUwMDU5NDM5ZGEwMmU1Njk2OTVkZmJjMTVfNC02LTEtMS0w_72821239-a398-474c-b66d-bb273c633e48"
      unitRef="usd">2000000.0</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i245f69306a2a48dc9b0a94f444f9a387_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RhYmxlOjViN2YxZGZlMDA1OTQzOWRhMDJlNTY5Njk1ZGZiYzE1L3RhYmxlcmFuZ2U6NWI3ZjFkZmUwMDU5NDM5ZGEwMmU1Njk2OTVkZmJjMTVfNS00LTEtMS0w_02e7da22-3abf-4597-af17-34fb7514b3cf"
      unitRef="usd">21600000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="ic3e04bb2c1a44e15ad29cbaea7a352a5_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RhYmxlOjViN2YxZGZlMDA1OTQzOWRhMDJlNTY5Njk1ZGZiYzE1L3RhYmxlcmFuZ2U6NWI3ZjFkZmUwMDU5NDM5ZGEwMmU1Njk2OTVkZmJjMTVfNS02LTEtMS0w_a4e0e25c-c5c1-49b7-a847-532f12f5479a"
      unitRef="usd">1700000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i9c341a47e1aa461fa949701e75d2e42e_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RhYmxlOjViN2YxZGZlMDA1OTQzOWRhMDJlNTY5Njk1ZGZiYzE1L3RhYmxlcmFuZ2U6NWI3ZjFkZmUwMDU5NDM5ZGEwMmU1Njk2OTVkZmJjMTVfOC00LTEtMS0w_a27a00e8-0730-4293-b131-c10a883d4207"
      unitRef="usd">10100000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i20e561fa07fb43038ef6ed12d48d3e81_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RhYmxlOjViN2YxZGZlMDA1OTQzOWRhMDJlNTY5Njk1ZGZiYzE1L3RhYmxlcmFuZ2U6NWI3ZjFkZmUwMDU5NDM5ZGEwMmU1Njk2OTVkZmJjMTVfOC02LTEtMS0w_f3e5bf61-1a89-4188-afd0-c9ef3b45d63b"
      unitRef="usd">2000000.0</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="ie12a87471fff4dc1b58d09dc7f062be5_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RhYmxlOjViN2YxZGZlMDA1OTQzOWRhMDJlNTY5Njk1ZGZiYzE1L3RhYmxlcmFuZ2U6NWI3ZjFkZmUwMDU5NDM5ZGEwMmU1Njk2OTVkZmJjMTVfMTEtNC0xLTEtMA_ee814c5a-534d-466c-bca3-b4da62eeff26"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i1761a26f1d99415db0e01cea732e296a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RhYmxlOjViN2YxZGZlMDA1OTQzOWRhMDJlNTY5Njk1ZGZiYzE1L3RhYmxlcmFuZ2U6NWI3ZjFkZmUwMDU5NDM5ZGEwMmU1Njk2OTVkZmJjMTVfMTEtNi0xLTEtMA_96676a30-9c76-4b51-9c4e-cfa2261bca7d"
      unitRef="usd">2300000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="ic1f004cc48f2484baa3a2dda6b81675d_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RhYmxlOjViN2YxZGZlMDA1OTQzOWRhMDJlNTY5Njk1ZGZiYzE1L3RhYmxlcmFuZ2U6NWI3ZjFkZmUwMDU5NDM5ZGEwMmU1Njk2OTVkZmJjMTVfMTUtNC0xLTEtMA_13278c63-6636-4f49-b8e9-5ffb16424da1"
      unitRef="usd">10200000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="id79a0b775b5b4772916934374fee4ad9_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RhYmxlOjViN2YxZGZlMDA1OTQzOWRhMDJlNTY5Njk1ZGZiYzE1L3RhYmxlcmFuZ2U6NWI3ZjFkZmUwMDU5NDM5ZGEwMmU1Njk2OTVkZmJjMTVfMTUtNi0xLTEtMA_cf3d94e5-13a6-476a-aca3-2174944edbc6"
      unitRef="usd">8000000.0</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i8b499d4033fd416886759d4c73cd37e4_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RhYmxlOjViN2YxZGZlMDA1OTQzOWRhMDJlNTY5Njk1ZGZiYzE1L3RhYmxlcmFuZ2U6NWI3ZjFkZmUwMDU5NDM5ZGEwMmU1Njk2OTVkZmJjMTVfMTYtNC0xLTEtMA_b781a64b-6777-43a2-ba52-b4ee49f1c7c1"
      unitRef="usd">7300000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i61badd66b47b4dcd935f8e7dd306447b_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM183OS9mcmFnOmJhMGI4Y2U3ZWJhNzQ3MTdiNGUxNWFjNjcwOGIyNTgwL3RhYmxlOjViN2YxZGZlMDA1OTQzOWRhMDJlNTY5Njk1ZGZiYzE1L3RhYmxlcmFuZ2U6NWI3ZjFkZmUwMDU5NDM5ZGEwMmU1Njk2OTVkZmJjMTVfMTYtNi0xLTEtMA_ca07df39-b261-4c42-8178-4fb2c9cd0007"
      unitRef="usd">2400000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM184NS9mcmFnOjVjYzc3YTNhYzgyZjQzMjU4MjZiNGMxMjBiYTFlYjgxL3RleHRyZWdpb246NWNjNzdhM2FjODJmNDMyNTgyNmI0YzEyMGJhMWViODFfMTIyOA_97f3f86a-12a1-4c59-a348-a5a3b3f8ef4b">&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Property, plant and equipment are recorded at historical cost, net of accumulated depreciation. Accumulated depreciation on property, plant and equipment was $1,734.8 million and $1,590.9 million as of September 30, 2020 and December 31, 2019, respectively. For the three and nine months ended September 30, 2020, depreciation expense totaled $51.5 million and $151.2 million, respectively, compared to $45.5 million and $145.4 million, respectively, in the prior year comparative periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:13.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Solothurn, Switzerland Manufacturing Facility&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In order to support our future growth and drug development pipeline, we are building a large-scale biologics manufacturing facility in Solothurn, Switzerland. We expect this facility to be partially operational during the first half of 2021. Upon completion, this facility will include 393,000 square feet related to a large-scale biologics manufacturing facility, 290,000 square feet of warehouse, utilities and support space and 51,000 square feet of administrative space. As of September 30, 2020 and December 31, 2019, we had approximately $1.8 billion and $1.9 billion, respectively, capitalized as construction in progress related to this facility. For the nine months ended September 30, 2020, we placed approximately $256.8 million of fixed assets in service related to this facility. As of September 30, 2020, we had contractual commitments of approximately $14.8 million outstanding related to the construction of this facility.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM184NS9mcmFnOjVjYzc3YTNhYzgyZjQzMjU4MjZiNGMxMjBiYTFlYjgxL3RleHRyZWdpb246NWNjNzdhM2FjODJmNDMyNTgyNmI0YzEyMGJhMWViODFfMTcx_a48c3e0e-2d0a-434a-bec3-2a59d54ada00"
      unitRef="usd">1734800000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i626282e786b7454d83b617e9e83963e6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM184NS9mcmFnOjVjYzc3YTNhYzgyZjQzMjU4MjZiNGMxMjBiYTFlYjgxL3RleHRyZWdpb246NWNjNzdhM2FjODJmNDMyNTgyNmI0YzEyMGJhMWViODFfMTc4_9a8d3ca5-8f6a-421f-a055-d465b35f101f"
      unitRef="usd">1590900000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:Depreciation
      contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM184NS9mcmFnOjVjYzc3YTNhYzgyZjQzMjU4MjZiNGMxMjBiYTFlYjgxL3RleHRyZWdpb246NWNjNzdhM2FjODJmNDMyNTgyNmI0YzEyMGJhMWViODFfMjc2_0f3c63e5-7c41-4312-94ee-fd1a35296def"
      unitRef="usd">51500000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM184NS9mcmFnOjVjYzc3YTNhYzgyZjQzMjU4MjZiNGMxMjBiYTFlYjgxL3RleHRyZWdpb246NWNjNzdhM2FjODJmNDMyNTgyNmI0YzEyMGJhMWViODFfMjgz_a7b42987-3587-4f85-8be5-d6f9aae1d4f1"
      unitRef="usd">151200000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM184NS9mcmFnOjVjYzc3YTNhYzgyZjQzMjU4MjZiNGMxMjBiYTFlYjgxL3RleHRyZWdpb246NWNjNzdhM2FjODJmNDMyNTgyNmI0YzEyMGJhMWViODFfMzEz_aa28066e-3637-4fcd-aaa3-31a41e9b8086"
      unitRef="usd">45500000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM184NS9mcmFnOjVjYzc3YTNhYzgyZjQzMjU4MjZiNGMxMjBiYTFlYjgxL3RleHRyZWdpb246NWNjNzdhM2FjODJmNDMyNTgyNmI0YzEyMGJhMWViODFfMzIw_e0c4c345-5b72-457d-af09-a6eb2caed3c8"
      unitRef="usd">145400000</us-gaap:Depreciation>
    <biib:NumberOfSquareFeet
      contextRef="i515423cd9b4842648857d6d91e4a1875_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM184NS9mcmFnOjVjYzc3YTNhYzgyZjQzMjU4MjZiNGMxMjBiYTFlYjgxL3RleHRyZWdpb246NWNjNzdhM2FjODJmNDMyNTgyNmI0YzEyMGJhMWViODFfODc5NjA5MzAyMzcxNg_88115ab1-961d-4f12-a906-2fbc8420ea50"
      unitRef="sqft">393000</biib:NumberOfSquareFeet>
    <biib:NumberOfSquareFeet
      contextRef="i79ca9be67e44499586e22d0729a04cad_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM184NS9mcmFnOjVjYzc3YTNhYzgyZjQzMjU4MjZiNGMxMjBiYTFlYjgxL3RleHRyZWdpb246NWNjNzdhM2FjODJmNDMyNTgyNmI0YzEyMGJhMWViODFfODc5NjA5MzAyMzczMw_1eefe6fd-761b-42c0-b435-ff76299314c7"
      unitRef="sqft">290000</biib:NumberOfSquareFeet>
    <biib:NumberOfSquareFeet
      contextRef="i71a156afed9940d8b31d4a452da92788_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM184NS9mcmFnOjVjYzc3YTNhYzgyZjQzMjU4MjZiNGMxMjBiYTFlYjgxL3RleHRyZWdpb246NWNjNzdhM2FjODJmNDMyNTgyNmI0YzEyMGJhMWViODFfODc5NjA5MzAyMzcyNQ_66dc68df-1bc0-451d-be7b-27e2fa490f4d"
      unitRef="sqft">51000</biib:NumberOfSquareFeet>
    <us-gaap:ConstructionInProgressGross
      contextRef="iadc69a90f7b94abab8d83ed70d1edf52_I20200930"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM184NS9mcmFnOjVjYzc3YTNhYzgyZjQzMjU4MjZiNGMxMjBiYTFlYjgxL3RleHRyZWdpb246NWNjNzdhM2FjODJmNDMyNTgyNmI0YzEyMGJhMWViODFfOTA3_c6cb6b8f-ff19-449b-b39d-bf2e25ed745e"
      unitRef="usd">1800000000</us-gaap:ConstructionInProgressGross>
    <us-gaap:ConstructionInProgressGross
      contextRef="ia4d564a708c64a0f9eae417dc52c7afc_I20191231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM184NS9mcmFnOjVjYzc3YTNhYzgyZjQzMjU4MjZiNGMxMjBiYTFlYjgxL3RleHRyZWdpb246NWNjNzdhM2FjODJmNDMyNTgyNmI0YzEyMGJhMWViODFfOTE0_361c3cb4-0146-4309-9a87-201a30fc6bd3"
      unitRef="usd">1900000000</us-gaap:ConstructionInProgressGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="iadc69a90f7b94abab8d83ed70d1edf52_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM184NS9mcmFnOjVjYzc3YTNhYzgyZjQzMjU4MjZiNGMxMjBiYTFlYjgxL3RleHRyZWdpb246NWNjNzdhM2FjODJmNDMyNTgyNmI0YzEyMGJhMWViODFfMTA1MA_a3dfa84b-0f0c-435e-9ee5-8033c7490709"
      unitRef="usd">256800000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:OtherCommitment
      contextRef="iadc69a90f7b94abab8d83ed70d1edf52_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM184NS9mcmFnOjVjYzc3YTNhYzgyZjQzMjU4MjZiNGMxMjBiYTFlYjgxL3RleHRyZWdpb246NWNjNzdhM2FjODJmNDMyNTgyNmI0YzEyMGJhMWViODFfMTE2NA_480c8974-ccf9-4047-aadc-8416ca3faaa3"
      unitRef="usd">14800000</us-gaap:OtherCommitment>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM184OC9mcmFnOjdlZjk5Y2VkNDFiNDQ3Y2U5NGE0NGUyMDdhZGUxNWFkL3RleHRyZWdpb246N2VmOTljZWQ0MWI0NDdjZTk0YTQ0ZTIwN2FkZTE1YWRfMjQyNw_bfc27a1d-6c43-4a2b-bc9f-ca1df5b7fb05">&lt;span style="background-color:rgb(255,255,255, 0.0);color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%;"&gt;Indebtedness&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#006ebf;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"&gt; &lt;/span&gt;&lt;div style="text-indent:13.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#006ebf;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;2020 Senior Notes &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On April 30, 2020, we issued senior unsecured notes for an aggregate principal amount of $3.0 billion (2020 Senior Notes), consisting of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.5pt;"&gt;$1.5 billion of 2.25% Senior Notes due May 1, 2030, valued at 99.973% of par; and&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.5pt;"&gt;$1.5 billion of 3.15% Senior Notes due May 1, 2050, valued at 99.174% of par.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Our 2020 Senior Notes are senior unsecured obligations and may be redeemed at our option at any time at 100% of the principal amount plus accrued interest and, until a specified period before maturity, a specified make-whole amount. Our 2020 Senior Notes contain a change-of-control provision that, under certain circumstances, may require us to purchase our 2020 Senior Notes at a price equal to 101% of the principal amount plus accrued and unpaid interest to the date of repurchase.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We incurred approximately $24.4 million of costs associated with this offering which have been recorded as a reduction to the carrying amount of the debt on our condensed consolidated balance sheet. These costs will be amortized as additional interest expense using the effective interest rate method over the period from issuance through maturity. The discounts will be amortized as additional interest expense over the period from issuance through maturity using the effective interest rate method. Interest on our 2020 Senior Notes is payable May 1 and November 1 of each year, commencing November 1, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:13.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#006ebf;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;2.90% Senior Notes due September 15, 2020 &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On September 15, 2015, we issued $1.5 billion aggregate principal amount of 2.90% Senior Notes due September 15, 2020, at 99.792% of par. Our 2.90% Senior Notes were senior unsecured obligations. We also entered into interest rate swap contracts where we received a fixed rate and paid a variable rate. In May 2020 we used the net proceeds from the sale of our 2020 Senior Notes to redeem our 2.90% Senior Notes prior to their maturity and recognized a net pre-tax charge of $9.4 million upon the extinguishment of these notes. This charge, which was recognized in interest expense in other income (expense), net in our condensed consolidated statements of income for the nine months ended September 30, 2020, reflects the payment of a $12.7 million early call premium and the write off of remaining unamortized original debt issuance costs and discount balances, partially offset by a $3.3 million gain related to the settlement of the associated interest rate swap contracts. For additional information on our interest rate swap contracts, please read &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Note 9, Derivative Instruments,&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ic59436e93fd94dc7975cca19dc9348ab_I20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM184OC9mcmFnOjdlZjk5Y2VkNDFiNDQ3Y2U5NGE0NGUyMDdhZGUxNWFkL3RleHRyZWdpb246N2VmOTljZWQ0MWI0NDdjZTk0YTQ0ZTIwN2FkZTE1YWRfMTA5_558be3ed-8d83-43cb-9467-39257eade898"
      unitRef="usd">3000000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i2f00747e3707421b957d5a8909432bc2_I20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM184OC9mcmFnOjdlZjk5Y2VkNDFiNDQ3Y2U5NGE0NGUyMDdhZGUxNWFkL3RleHRyZWdpb246N2VmOTljZWQ0MWI0NDdjZTk0YTQ0ZTIwN2FkZTE1YWRfMTYz_27fc67cd-957d-4d43-86a3-7b8747a54697"
      unitRef="usd">1500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i2f00747e3707421b957d5a8909432bc2_I20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM184OC9mcmFnOjdlZjk5Y2VkNDFiNDQ3Y2U5NGE0NGUyMDdhZGUxNWFkL3RleHRyZWdpb246N2VmOTljZWQ0MWI0NDdjZTk0YTQ0ZTIwN2FkZTE1YWRfMTY5_c64fb0ed-ec71-495a-adc3-e77572da5efe"
      unitRef="number">0.0225</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <biib:PercentageParValueOfSeniorNotes
      contextRef="i2f00747e3707421b957d5a8909432bc2_I20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM184OC9mcmFnOjdlZjk5Y2VkNDFiNDQ3Y2U5NGE0NGUyMDdhZGUxNWFkL3RleHRyZWdpb246N2VmOTljZWQ0MWI0NDdjZTk0YTQ0ZTIwN2FkZTE1YWRfMjAz_a43020bb-6baf-4e2f-93f5-835161036fc1"
      unitRef="number">0.99973</biib:PercentageParValueOfSeniorNotes>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="id7d171de853046bd832470203f2f56ba_I20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM184OC9mcmFnOjdlZjk5Y2VkNDFiNDQ3Y2U5NGE0NGUyMDdhZGUxNWFkL3RleHRyZWdpb246N2VmOTljZWQ0MWI0NDdjZTk0YTQ0ZTIwN2FkZTE1YWRfMjE4_353d18ad-2dc5-4198-9495-46fbb5b21e08"
      unitRef="usd">1500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="id7d171de853046bd832470203f2f56ba_I20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM184OC9mcmFnOjdlZjk5Y2VkNDFiNDQ3Y2U5NGE0NGUyMDdhZGUxNWFkL3RleHRyZWdpb246N2VmOTljZWQ0MWI0NDdjZTk0YTQ0ZTIwN2FkZTE1YWRfMjI0_47692aaa-0fde-485d-b9a7-ed69e4a2844a"
      unitRef="number">0.0315</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <biib:PercentageParValueOfSeniorNotes
      contextRef="id7d171de853046bd832470203f2f56ba_I20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM184OC9mcmFnOjdlZjk5Y2VkNDFiNDQ3Y2U5NGE0NGUyMDdhZGUxNWFkL3RleHRyZWdpb246N2VmOTljZWQ0MWI0NDdjZTk0YTQ0ZTIwN2FkZTE1YWRfMjU4_b2a10a15-48bf-43be-82dc-f9419c95b7ee"
      unitRef="number">0.99174</biib:PercentageParValueOfSeniorNotes>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="i12ad84388af247dc862a842bb1ccd8e8_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM184OC9mcmFnOjdlZjk5Y2VkNDFiNDQ3Y2U5NGE0NGUyMDdhZGUxNWFkL3RleHRyZWdpb246N2VmOTljZWQ0MWI0NDdjZTk0YTQ0ZTIwN2FkZTE1YWRfMzcz_46784166-7bc6-467b-9139-03913ffcdfa9"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <biib:DebtInstrumentMakeWholeProvisionRedemptionPricePercentage
      contextRef="i12ad84388af247dc862a842bb1ccd8e8_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM184OC9mcmFnOjdlZjk5Y2VkNDFiNDQ3Y2U5NGE0NGUyMDdhZGUxNWFkL3RleHRyZWdpb246N2VmOTljZWQ0MWI0NDdjZTk0YTQ0ZTIwN2FkZTE1YWRfNjY0_34c01576-dd54-41d2-9fd5-bd98db1f208f"
      unitRef="number">1.01</biib:DebtInstrumentMakeWholeProvisionRedemptionPricePercentage>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM184OC9mcmFnOjdlZjk5Y2VkNDFiNDQ3Y2U5NGE0NGUyMDdhZGUxNWFkL3RleHRyZWdpb246N2VmOTljZWQ0MWI0NDdjZTk0YTQ0ZTIwN2FkZTE1YWRfNzc3_cdae56da-d344-4bcf-afdc-e3e63fda7cec"
      unitRef="usd">24400000</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i03f25d4fea804740817761d106108f90_I20150915"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM184OC9mcmFnOjdlZjk5Y2VkNDFiNDQ3Y2U5NGE0NGUyMDdhZGUxNWFkL3RleHRyZWdpb246N2VmOTljZWQ0MWI0NDdjZTk0YTQ0ZTIwN2FkZTE1YWRfMTQxNg_d37195e2-d547-4354-9497-b7d96488e559"
      unitRef="usd">1500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i03f25d4fea804740817761d106108f90_I20150915"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM184OC9mcmFnOjdlZjk5Y2VkNDFiNDQ3Y2U5NGE0NGUyMDdhZGUxNWFkL3RleHRyZWdpb246N2VmOTljZWQ0MWI0NDdjZTk0YTQ0ZTIwN2FkZTE1YWRfMTQ0OQ_58561b89-1d91-409c-8818-e7f87a977db3"
      unitRef="number">0.0290</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <biib:PercentageParValueOfSeniorNotes
      contextRef="i03f25d4fea804740817761d106108f90_I20150915"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM184OC9mcmFnOjdlZjk5Y2VkNDFiNDQ3Y2U5NGE0NGUyMDdhZGUxNWFkL3RleHRyZWdpb246N2VmOTljZWQ0MWI0NDdjZTk0YTQ0ZTIwN2FkZTE1YWRfMTQ5Mg_1499e745-3a74-461c-92b0-49216030f4a0"
      unitRef="number">0.99792</biib:PercentageParValueOfSeniorNotes>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i03f25d4fea804740817761d106108f90_I20150915"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM184OC9mcmFnOjdlZjk5Y2VkNDFiNDQ3Y2U5NGE0NGUyMDdhZGUxNWFkL3RleHRyZWdpb246N2VmOTljZWQ0MWI0NDdjZTk0YTQ0ZTIwN2FkZTE1YWRfMTUwNw_75d52e16-e036-4316-b55a-2a6034e68951"
      unitRef="number">0.0290</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i03f25d4fea804740817761d106108f90_I20150915"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM184OC9mcmFnOjdlZjk5Y2VkNDFiNDQ3Y2U5NGE0NGUyMDdhZGUxNWFkL3RleHRyZWdpb246N2VmOTljZWQ0MWI0NDdjZTk0YTQ0ZTIwN2FkZTE1YWRfMTc1NQ_0a8cd24b-e19f-43be-b96f-8201e4dec1a6"
      unitRef="number">0.0290</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <biib:PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain
      contextRef="i5e0ab653ffdc4001ba210ff20f499fc3_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM184OC9mcmFnOjdlZjk5Y2VkNDFiNDQ3Y2U5NGE0NGUyMDdhZGUxNWFkL3RleHRyZWdpb246N2VmOTljZWQ0MWI0NDdjZTk0YTQ0ZTIwN2FkZTE1YWRfMTgzNA_5c25515b-2c6d-4068-9414-a30da6768ec5"
      unitRef="usd">9400000</biib:PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain>
    <biib:EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts
      contextRef="i4d1664f9c34948f48657b943f060daf2_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM184OC9mcmFnOjdlZjk5Y2VkNDFiNDQ3Y2U5NGE0NGUyMDdhZGUxNWFkL3RleHRyZWdpb246N2VmOTljZWQ0MWI0NDdjZTk0YTQ0ZTIwN2FkZTE1YWRfMjA3NA_1dd37694-1110-47f1-b5a1-200971820cb7"
      unitRef="usd">12700000</biib:EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="ic4da688b8e414bdf83ba16881ee41846_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM184OC9mcmFnOjdlZjk5Y2VkNDFiNDQ3Y2U5NGE0NGUyMDdhZGUxNWFkL3RleHRyZWdpb246N2VmOTljZWQ0MWI0NDdjZTk0YTQ0ZTIwN2FkZTE1YWRfMjIxMw_1e3bc2cc-675c-4d8c-8ff5-299d72718380"
      unitRef="usd">3300000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RleHRyZWdpb246ZjZlZDhjM2EzZGM0NGZhZGE1YjMzOWE0ZGVhODAwNGRfMTMyNg_3b661ecf-a6b6-482b-b557-c1edc9ed2e87">&lt;div style="text-indent:11.25pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Share Repurchases&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In October 2020 our Board of Directors authorized a program to repurchase up to $5.0 billion of our common stock (2020 Share Repurchase Program). Our 2020 Share Repurchase Program does not have an expiration date. All share repurchases under our 2020 Share Repurchase Program will be retired.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In December 2019 our Board of Directors authorized a program to repurchase up to $5.0 billion of our common stock (December 2019 Share Repurchase Program) that was completed as of September 30, 2020. All shares repurchased under our December 2019 Share Repurchase Program were retired. Under our December 2019 Share Repurchase Program, we repurchased and retired approximately 4.5 million and 16.7 million shares of our common stock at a cost of approximately $1.3 billion and $5.0 billion during the three and nine months ended September 30, 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In March 2019 our Board of Directors authorized a program to repurchase up to $5.0 billion of our common stock (March 2019 Share Repurchase Program) that was completed as of March 31, 2020. All shares repurchased under our March 2019 Share Repurchase Program were retired. Under our March 2019 Share Repurchase Program, we repurchased and retired approximately 4.1 million shares of our common stock at a cost of approximately $1.3 billion during the nine months ended September 30, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:11.25pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Accumulated Other Comprehensive Income (Loss)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following tables summarize the changes in accumulated other comprehensive income (loss), net of tax by component:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:31.696%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.295%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.002%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.295%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.466%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.295%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.859%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gains (Losses) on Net Investment Hedge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unfunded Status of Postretirement Benefit Plans, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Currency Translation Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance, December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;7.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;25.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(32.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(139.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(135.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(8.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(58.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;8.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(54.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;9.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(43.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(2.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(35.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(101.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(90.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance, September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(93.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;30.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(32.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(135.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(225.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:31.696%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.295%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.002%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.295%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.466%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.295%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.859%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gains (Losses) on Net Investment Hedge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unfunded Status of Postretirement Benefit Plans, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Currency Translation Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance, December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(4.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;34.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(31.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(243.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(240.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;115.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;53.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;51.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;233.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(77.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(6.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(85.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;38.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;46.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;51.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;148.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance, September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;72.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;50.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(29.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(192.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(92.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table summarizes the amounts reclassified from accumulated other comprehensive income:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:33.987%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:21.707%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.695%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.695%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.695%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.701%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" rowspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Income Statement Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amounts Reclassified from Accumulated Other Comprehensive Income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gains (losses) on securities available for sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other income (expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(12.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Income tax benefit (expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gains (losses) on cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(9.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;35.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;41.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;79.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other income (expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Income tax benefit (expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gains (losses) on net investment hedge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other income (expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total reclassifications, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(6.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;37.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;35.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;85.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i50a2f9335d324e4986eea98f35621996_I20191231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RleHRyZWdpb246ZjZlZDhjM2EzZGM0NGZhZGE1YjMzOWE0ZGVhODAwNGRfMTAx_3780b78c-4537-4a26-a4da-71ef53015373"
      unitRef="usd">5000000000.0</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="iadd8187a18d849f6b353e75cae0aabe8_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RleHRyZWdpb246ZjZlZDhjM2EzZGM0NGZhZGE1YjMzOWE0ZGVhODAwNGRfMzkw_e5bfcb8c-22a9-435e-967a-b0369703253a"
      unitRef="shares">4500000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="idb94151f567e4761811caaa2ee1c1349_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RleHRyZWdpb246ZjZlZDhjM2EzZGM0NGZhZGE1YjMzOWE0ZGVhODAwNGRfMzk3_11541706-2eed-4cfb-9863-c5e228a55e4f"
      unitRef="shares">16700000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="iadd8187a18d849f6b353e75cae0aabe8_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RleHRyZWdpb246ZjZlZDhjM2EzZGM0NGZhZGE1YjMzOWE0ZGVhODAwNGRfNDU0_7d4a93a3-7627-40d6-9689-3807c748415e"
      unitRef="usd">1300000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="idb94151f567e4761811caaa2ee1c1349_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RleHRyZWdpb246ZjZlZDhjM2EzZGM0NGZhZGE1YjMzOWE0ZGVhODAwNGRfNDYx_fc8ee57f-8537-4f1c-9b35-bb7dfc30655f"
      unitRef="usd">5000000000.0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="ibe1d424343114522b510a64f315d7e68_I20190930"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RleHRyZWdpb246ZjZlZDhjM2EzZGM0NGZhZGE1YjMzOWE0ZGVhODAwNGRfNjc4_26716486-a99f-4d92-9bf1-c0ee80ac98ef"
      unitRef="usd">5000000000.0</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i0af05fc8fe804816a86f91f4f77cdeac_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RleHRyZWdpb246ZjZlZDhjM2EzZGM0NGZhZGE1YjMzOWE0ZGVhODAwNGRfOTQx_0fd551c3-e069-42cf-aef7-4c1fcfb1e1df"
      unitRef="shares">4100000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i0af05fc8fe804816a86f91f4f77cdeac_D20200101-20200930"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RleHRyZWdpb246ZjZlZDhjM2EzZGM0NGZhZGE1YjMzOWE0ZGVhODAwNGRfOTk4_d112bc13-3f03-4a52-ac61-d0e83bd32caf"
      unitRef="usd">1300000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RleHRyZWdpb246ZjZlZDhjM2EzZGM0NGZhZGE1YjMzOWE0ZGVhODAwNGRfMTMxNw_16710951-050f-48bc-bd53-0b228ca12e31">&lt;div style="text-indent:22.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following tables summarize the changes in accumulated other comprehensive income (loss), net of tax by component:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:31.696%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.295%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.002%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.295%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.466%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.295%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.859%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gains (Losses) on Net Investment Hedge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unfunded Status of Postretirement Benefit Plans, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Currency Translation Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance, December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;7.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;25.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(32.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(139.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(135.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(8.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(58.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;8.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(54.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;9.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(43.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(2.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(35.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(101.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(90.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance, September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(93.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;30.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(32.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(135.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(225.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:31.696%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.295%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.002%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.295%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.466%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.295%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.859%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gains (Losses) on Net Investment Hedge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unfunded Status of Postretirement Benefit Plans, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Currency Translation Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance, December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(4.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;34.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(31.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(243.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(240.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;115.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;53.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;51.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;233.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(77.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(6.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(85.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;38.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;46.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;51.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;148.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance, September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;72.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;50.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(29.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(192.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(92.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i2a0e6fee3a604c498aef94f0b86c6e9a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmNjZDUwOTcwMTRkZDRmZGZiMzgwMzNkMTE5YjhlYWQ0L3RhYmxlcmFuZ2U6Y2NkNTA5NzAxNGRkNGZkZmIzODAzM2QxMTliOGVhZDRfMS0yLTEtMS0w_056a7324-8d54-4346-8993-cec572598aa4"
      unitRef="usd">4200000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i1cb136c416a04a05b9c1782e72b65627_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmNjZDUwOTcwMTRkZDRmZGZiMzgwMzNkMTE5YjhlYWQ0L3RhYmxlcmFuZ2U6Y2NkNTA5NzAxNGRkNGZkZmIzODAzM2QxMTliOGVhZDRfMS00LTEtMS0w_839e3d31-bc84-48d8-8747-f78a0930514c"
      unitRef="usd">7800000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ic914b0a393fd452c890e566f2c9c210f_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmNjZDUwOTcwMTRkZDRmZGZiMzgwMzNkMTE5YjhlYWQ0L3RhYmxlcmFuZ2U6Y2NkNTA5NzAxNGRkNGZkZmIzODAzM2QxMTliOGVhZDRfMS02LTEtMS0w_dbeb7291-3634-473c-bae5-11d21554f5a6"
      unitRef="usd">25100000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i260d0a847a054ce0bef9b288ccd52ea2_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmNjZDUwOTcwMTRkZDRmZGZiMzgwMzNkMTE5YjhlYWQ0L3RhYmxlcmFuZ2U6Y2NkNTA5NzAxNGRkNGZkZmIzODAzM2QxMTliOGVhZDRfMS04LTEtMS0w_b8cedb83-923c-4f8e-a526-2a13ecbb5cff"
      unitRef="usd">-32800000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="if4823f5499b54f46b268ee3dd309f1da_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmNjZDUwOTcwMTRkZDRmZGZiMzgwMzNkMTE5YjhlYWQ0L3RhYmxlcmFuZ2U6Y2NkNTA5NzAxNGRkNGZkZmIzODAzM2QxMTliOGVhZDRfMS0xMC0xLTEtMA_c91e74f7-11db-46e4-ac4b-2c86479e6469"
      unitRef="usd">-139500000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i626282e786b7454d83b617e9e83963e6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmNjZDUwOTcwMTRkZDRmZGZiMzgwMzNkMTE5YjhlYWQ0L3RhYmxlcmFuZ2U6Y2NkNTA5NzAxNGRkNGZkZmIzODAzM2QxMTliOGVhZDRfMS0xMi0xLTEtMA_c9797929-50e6-4e4a-b2b2-69220615465c"
      unitRef="usd">-135200000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i6773145664dd45a58afb7773d86b7f79_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmNjZDUwOTcwMTRkZDRmZGZiMzgwMzNkMTE5YjhlYWQ0L3RhYmxlcmFuZ2U6Y2NkNTA5NzAxNGRkNGZkZmIzODAzM2QxMTliOGVhZDRfMi0yLTEtMS0w_471fcdae-31cd-4e42-afa7-f51e21424e69"
      unitRef="usd">-8800000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i21e4efbba1364e8d97adce8a02fa5c1c_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmNjZDUwOTcwMTRkZDRmZGZiMzgwMzNkMTE5YjhlYWQ0L3RhYmxlcmFuZ2U6Y2NkNTA5NzAxNGRkNGZkZmIzODAzM2QxMTliOGVhZDRfMi00LTEtMS0w_9f4274fd-d478-4e90-8b6b-36e4c649c932"
      unitRef="usd">-58000000.0</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="idd42a3afee77410b945f7e37289f8773_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmNjZDUwOTcwMTRkZDRmZGZiMzgwMzNkMTE5YjhlYWQ0L3RhYmxlcmFuZ2U6Y2NkNTA5NzAxNGRkNGZkZmIzODAzM2QxMTliOGVhZDRfMi02LTEtMS0w_6e426e23-c1f7-48f7-9d65-f711eab8c7cd"
      unitRef="usd">8100000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i4f6dc2dc230545079cf4e37cd9490b61_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmNjZDUwOTcwMTRkZDRmZGZiMzgwMzNkMTE5YjhlYWQ0L3RhYmxlcmFuZ2U6Y2NkNTA5NzAxNGRkNGZkZmIzODAzM2QxMTliOGVhZDRfMi04LTEtMS0w_c737cd55-963d-4c99-a0b0-d17ded4775a8"
      unitRef="usd">400000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i320a93a4270b45d2834748a854e79d02_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmNjZDUwOTcwMTRkZDRmZGZiMzgwMzNkMTE5YjhlYWQ0L3RhYmxlcmFuZ2U6Y2NkNTA5NzAxNGRkNGZkZmIzODAzM2QxMTliOGVhZDRfMi0xMC0xLTEtMA_ecc2e7f7-182a-44c8-a48d-10ea7d87ddb2"
      unitRef="usd">3900000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmNjZDUwOTcwMTRkZDRmZGZiMzgwMzNkMTE5YjhlYWQ0L3RhYmxlcmFuZ2U6Y2NkNTA5NzAxNGRkNGZkZmIzODAzM2QxMTliOGVhZDRfMi0xMi0xLTEtMA_553cc9ac-ebb9-47ed-8194-4fd8c71973f2"
      unitRef="usd">-54400000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i6773145664dd45a58afb7773d86b7f79_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmNjZDUwOTcwMTRkZDRmZGZiMzgwMzNkMTE5YjhlYWQ0L3RhYmxlcmFuZ2U6Y2NkNTA5NzAxNGRkNGZkZmIzODAzM2QxMTliOGVhZDRfMy0yLTEtMS0w_7882922a-c463-4984-a889-3079939a65d6"
      unitRef="usd">9800000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i21e4efbba1364e8d97adce8a02fa5c1c_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmNjZDUwOTcwMTRkZDRmZGZiMzgwMzNkMTE5YjhlYWQ0L3RhYmxlcmFuZ2U6Y2NkNTA5NzAxNGRkNGZkZmIzODAzM2QxMTliOGVhZDRfMy00LTEtMS0w_42bb5d35-374f-4c4e-9c8e-bfa5b4bc7b39"
      unitRef="usd">-43100000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="idd42a3afee77410b945f7e37289f8773_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmNjZDUwOTcwMTRkZDRmZGZiMzgwMzNkMTE5YjhlYWQ0L3RhYmxlcmFuZ2U6Y2NkNTA5NzAxNGRkNGZkZmIzODAzM2QxMTliOGVhZDRfMy02LTEtMS0w_e8760713-0375-4007-8f52-6e9b9366b560"
      unitRef="usd">-2600000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i4f6dc2dc230545079cf4e37cd9490b61_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmNjZDUwOTcwMTRkZDRmZGZiMzgwMzNkMTE5YjhlYWQ0L3RhYmxlcmFuZ2U6Y2NkNTA5NzAxNGRkNGZkZmIzODAzM2QxMTliOGVhZDRfMy04LTEtMS0w_5aa3defe-9666-498f-a243-751a59bcd405"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i320a93a4270b45d2834748a854e79d02_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmNjZDUwOTcwMTRkZDRmZGZiMzgwMzNkMTE5YjhlYWQ0L3RhYmxlcmFuZ2U6Y2NkNTA5NzAxNGRkNGZkZmIzODAzM2QxMTliOGVhZDRfMy0xMC0xLTEtMA_44ed24d2-16c9-447a-9763-95ede1e226f0"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmNjZDUwOTcwMTRkZDRmZGZiMzgwMzNkMTE5YjhlYWQ0L3RhYmxlcmFuZ2U6Y2NkNTA5NzAxNGRkNGZkZmIzODAzM2QxMTliOGVhZDRfMy0xMi0xLTEtMA_0e344ac2-0791-4d53-ba5c-77f3507e83ad"
      unitRef="usd">-35900000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i6773145664dd45a58afb7773d86b7f79_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmNjZDUwOTcwMTRkZDRmZGZiMzgwMzNkMTE5YjhlYWQ0L3RhYmxlcmFuZ2U6Y2NkNTA5NzAxNGRkNGZkZmIzODAzM2QxMTliOGVhZDRfNC0yLTEtMS0w_c6e336d3-176c-4ab5-bd9d-727dd9425b19"
      unitRef="usd">1000000.0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i21e4efbba1364e8d97adce8a02fa5c1c_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmNjZDUwOTcwMTRkZDRmZGZiMzgwMzNkMTE5YjhlYWQ0L3RhYmxlcmFuZ2U6Y2NkNTA5NzAxNGRkNGZkZmIzODAzM2QxMTliOGVhZDRfNC00LTEtMS0w_94992aaa-b3e5-468f-a760-9ae9d7de8d5e"
      unitRef="usd">-101100000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="idd42a3afee77410b945f7e37289f8773_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmNjZDUwOTcwMTRkZDRmZGZiMzgwMzNkMTE5YjhlYWQ0L3RhYmxlcmFuZ2U6Y2NkNTA5NzAxNGRkNGZkZmIzODAzM2QxMTliOGVhZDRfNC02LTEtMS0w_877961cf-ddfe-4a93-a71d-16e93ccfa779"
      unitRef="usd">5500000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i4f6dc2dc230545079cf4e37cd9490b61_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmNjZDUwOTcwMTRkZDRmZGZiMzgwMzNkMTE5YjhlYWQ0L3RhYmxlcmFuZ2U6Y2NkNTA5NzAxNGRkNGZkZmIzODAzM2QxMTliOGVhZDRfNC04LTEtMS0w_8a8eb52a-4eda-4e2d-8a04-d9f219a70d27"
      unitRef="usd">400000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i320a93a4270b45d2834748a854e79d02_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmNjZDUwOTcwMTRkZDRmZGZiMzgwMzNkMTE5YjhlYWQ0L3RhYmxlcmFuZ2U6Y2NkNTA5NzAxNGRkNGZkZmIzODAzM2QxMTliOGVhZDRfNC0xMC0xLTEtMA_6de00104-cd84-4bce-8a0c-9ff1267436b8"
      unitRef="usd">3900000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmNjZDUwOTcwMTRkZDRmZGZiMzgwMzNkMTE5YjhlYWQ0L3RhYmxlcmFuZ2U6Y2NkNTA5NzAxNGRkNGZkZmIzODAzM2QxMTliOGVhZDRfNC0xMi0xLTEtMA_f552a8a2-4146-404c-ab53-8092f75edd6e"
      unitRef="usd">-90300000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i58631e62f8454d6fa19167c8e8a2bb41_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmNjZDUwOTcwMTRkZDRmZGZiMzgwMzNkMTE5YjhlYWQ0L3RhYmxlcmFuZ2U6Y2NkNTA5NzAxNGRkNGZkZmIzODAzM2QxMTliOGVhZDRfNS0yLTEtMS0w_e8f5e265-35a7-4523-a1b7-d82b38e2e73b"
      unitRef="usd">5200000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i76542c629f7a4bfdb85009377f3655e1_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmNjZDUwOTcwMTRkZDRmZGZiMzgwMzNkMTE5YjhlYWQ0L3RhYmxlcmFuZ2U6Y2NkNTA5NzAxNGRkNGZkZmIzODAzM2QxMTliOGVhZDRfNS00LTEtMS0w_334af51e-5352-4d20-b4e9-6e322a5297ed"
      unitRef="usd">-93300000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ideb1736cbc354334a8ee23f9cadfc4bd_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmNjZDUwOTcwMTRkZDRmZGZiMzgwMzNkMTE5YjhlYWQ0L3RhYmxlcmFuZ2U6Y2NkNTA5NzAxNGRkNGZkZmIzODAzM2QxMTliOGVhZDRfNS02LTEtMS0w_aba16422-7f25-4727-a140-90c221b31157"
      unitRef="usd">30600000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i1d927cca7f9c4d73aab25d3b3d48868f_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmNjZDUwOTcwMTRkZDRmZGZiMzgwMzNkMTE5YjhlYWQ0L3RhYmxlcmFuZ2U6Y2NkNTA5NzAxNGRkNGZkZmIzODAzM2QxMTliOGVhZDRfNS04LTEtMS0w_9a17f944-891e-4e5c-9d9c-7d7d76b8749c"
      unitRef="usd">-32400000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ib3b032c0499d4048ba5f66ef535061b2_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmNjZDUwOTcwMTRkZDRmZGZiMzgwMzNkMTE5YjhlYWQ0L3RhYmxlcmFuZ2U6Y2NkNTA5NzAxNGRkNGZkZmIzODAzM2QxMTliOGVhZDRfNS0xMC0xLTEtMA_051c3350-ef00-4245-a526-93e7005c3a24"
      unitRef="usd">-135600000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmNjZDUwOTcwMTRkZDRmZGZiMzgwMzNkMTE5YjhlYWQ0L3RhYmxlcmFuZ2U6Y2NkNTA5NzAxNGRkNGZkZmIzODAzM2QxMTliOGVhZDRfNS0xMi0xLTEtMA_d31b1a7c-0165-4f46-bb34-9638caa1df0f"
      unitRef="usd">-225500000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i0e4620290d53494a80d6bc03a34181dd_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOjBhNGNiZTE2MjZjNzRlZGQ4YjZlMjczZTI5ZmE1ZDgyL3RhYmxlcmFuZ2U6MGE0Y2JlMTYyNmM3NGVkZDhiNmUyNzNlMjlmYTVkODJfMS0yLTEtMS0w_66337559-f88c-4377-8f47-f9fe5d9ed668"
      unitRef="usd">-4000000.0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="id17e410580eb4b0eb19f7434c46678d8_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOjBhNGNiZTE2MjZjNzRlZGQ4YjZlMjczZTI5ZmE1ZDgyL3RhYmxlcmFuZ2U6MGE0Y2JlMTYyNmM3NGVkZDhiNmUyNzNlMjlmYTVkODJfMS00LTEtMS0w_adc630e7-7df2-4a7d-b3a6-82e865a3656f"
      unitRef="usd">34700000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i87b8b8492f694a2a85d10571ab2b857f_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOjBhNGNiZTE2MjZjNzRlZGQ4YjZlMjczZTI5ZmE1ZDgyL3RhYmxlcmFuZ2U6MGE0Y2JlMTYyNmM3NGVkZDhiNmUyNzNlMjlmYTVkODJfMS02LTEtMS0w_9e83c5bd-b501-4786-8070-f6a0be429148"
      unitRef="usd">3500000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i39a2399061724666bae8d3296c72225d_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOjBhNGNiZTE2MjZjNzRlZGQ4YjZlMjczZTI5ZmE1ZDgyL3RhYmxlcmFuZ2U6MGE0Y2JlMTYyNmM3NGVkZDhiNmUyNzNlMjlmYTVkODJfMS04LTEtMS0w_37fbde3f-1157-48b8-9aa4-2b4f19d94ae5"
      unitRef="usd">-31300000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i74e5d53de65e4a8a9e4e245845ee99be_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOjBhNGNiZTE2MjZjNzRlZGQ4YjZlMjczZTI5ZmE1ZDgyL3RhYmxlcmFuZ2U6MGE0Y2JlMTYyNmM3NGVkZDhiNmUyNzNlMjlmYTVkODJfMS0xMC0xLTEtMA_99c8ce50-ae7d-4d96-8d09-ddbc89d857a0"
      unitRef="usd">-243300000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ib98dd789f3514452acc95f9b041d2a7e_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOjBhNGNiZTE2MjZjNzRlZGQ4YjZlMjczZTI5ZmE1ZDgyL3RhYmxlcmFuZ2U6MGE0Y2JlMTYyNmM3NGVkZDhiNmUyNzNlMjlmYTVkODJfMS0xMi0xLTEtMA_2b7ba45d-ba3f-43b1-ba48-ac8a1649bd46"
      unitRef="usd">-240400000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i591bf9ccf21b4e53b95118628d4978da_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOjBhNGNiZTE2MjZjNzRlZGQ4YjZlMjczZTI5ZmE1ZDgyL3RhYmxlcmFuZ2U6MGE0Y2JlMTYyNmM3NGVkZDhiNmUyNzNlMjlmYTVkODJfMi0yLTEtMS0w_3d2962b5-73e4-43ed-9894-1129fec49d9a"
      unitRef="usd">11600000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i246c949459c344caa446c9c644b413b2_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOjBhNGNiZTE2MjZjNzRlZGQ4YjZlMjczZTI5ZmE1ZDgyL3RhYmxlcmFuZ2U6MGE0Y2JlMTYyNmM3NGVkZDhiNmUyNzNlMjlmYTVkODJfMi00LTEtMS0w_a811afc8-dd2b-44b4-b126-586fd719b0da"
      unitRef="usd">115800000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i002638e6f51c4c26ba598e6a80ddd034_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOjBhNGNiZTE2MjZjNzRlZGQ4YjZlMjczZTI5ZmE1ZDgyL3RhYmxlcmFuZ2U6MGE0Y2JlMTYyNmM3NGVkZDhiNmUyNzNlMjlmYTVkODJfMi02LTEtMS0w_cb7b8c2d-c66f-416d-87f1-c1140424251e"
      unitRef="usd">53500000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i9b77bbc89c154914b55e0fa9c9242c96_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOjBhNGNiZTE2MjZjNzRlZGQ4YjZlMjczZTI5ZmE1ZDgyL3RhYmxlcmFuZ2U6MGE0Y2JlMTYyNmM3NGVkZDhiNmUyNzNlMjlmYTVkODJfMi04LTEtMS0w_4fcb4df9-6e92-41df-8934-2293caca8fca"
      unitRef="usd">1500000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i2e02b47bfe8d48a5aa515d8c91a8cb66_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOjBhNGNiZTE2MjZjNzRlZGQ4YjZlMjczZTI5ZmE1ZDgyL3RhYmxlcmFuZ2U6MGE0Y2JlMTYyNmM3NGVkZDhiNmUyNzNlMjlmYTVkODJfMi0xMC0xLTEtMA_7e53a890-d57a-40c0-bfd1-3aa3ee0b54dd"
      unitRef="usd">51300000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOjBhNGNiZTE2MjZjNzRlZGQ4YjZlMjczZTI5ZmE1ZDgyL3RhYmxlcmFuZ2U6MGE0Y2JlMTYyNmM3NGVkZDhiNmUyNzNlMjlmYTVkODJfMi0xMi0xLTEtMA_e012fc87-4239-476e-ac58-9299fe199077"
      unitRef="usd">233700000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i591bf9ccf21b4e53b95118628d4978da_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOjBhNGNiZTE2MjZjNzRlZGQ4YjZlMjczZTI5ZmE1ZDgyL3RhYmxlcmFuZ2U6MGE0Y2JlMTYyNmM3NGVkZDhiNmUyNzNlMjlmYTVkODJfMy0yLTEtMS0w_77bbd4da-2c65-4dc4-965f-37b172a168bb"
      unitRef="usd">-1300000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i246c949459c344caa446c9c644b413b2_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOjBhNGNiZTE2MjZjNzRlZGQ4YjZlMjczZTI5ZmE1ZDgyL3RhYmxlcmFuZ2U6MGE0Y2JlMTYyNmM3NGVkZDhiNmUyNzNlMjlmYTVkODJfMy00LTEtMS0w_53180438-48d3-4fcb-9d87-9b2d06a45b45"
      unitRef="usd">-77700000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i002638e6f51c4c26ba598e6a80ddd034_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOjBhNGNiZTE2MjZjNzRlZGQ4YjZlMjczZTI5ZmE1ZDgyL3RhYmxlcmFuZ2U6MGE0Y2JlMTYyNmM3NGVkZDhiNmUyNzNlMjlmYTVkODJfMy02LTEtMS0w_c445dbce-7020-4bd2-a36f-c5c696bef65f"
      unitRef="usd">-6600000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i9b77bbc89c154914b55e0fa9c9242c96_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOjBhNGNiZTE2MjZjNzRlZGQ4YjZlMjczZTI5ZmE1ZDgyL3RhYmxlcmFuZ2U6MGE0Y2JlMTYyNmM3NGVkZDhiNmUyNzNlMjlmYTVkODJfMy04LTEtMS0w_ca4e1441-3ef9-4c5a-b643-da8278553c6c"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i2e02b47bfe8d48a5aa515d8c91a8cb66_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOjBhNGNiZTE2MjZjNzRlZGQ4YjZlMjczZTI5ZmE1ZDgyL3RhYmxlcmFuZ2U6MGE0Y2JlMTYyNmM3NGVkZDhiNmUyNzNlMjlmYTVkODJfMy0xMC0xLTEtMA_c242e27d-f8ca-402a-adda-e6b129ce8ed2"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOjBhNGNiZTE2MjZjNzRlZGQ4YjZlMjczZTI5ZmE1ZDgyL3RhYmxlcmFuZ2U6MGE0Y2JlMTYyNmM3NGVkZDhiNmUyNzNlMjlmYTVkODJfMy0xMi0xLTEtMA_a334a965-ea4a-43c9-969b-ac4b7703e8f0"
      unitRef="usd">-85600000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i591bf9ccf21b4e53b95118628d4978da_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOjBhNGNiZTE2MjZjNzRlZGQ4YjZlMjczZTI5ZmE1ZDgyL3RhYmxlcmFuZ2U6MGE0Y2JlMTYyNmM3NGVkZDhiNmUyNzNlMjlmYTVkODJfNC0yLTEtMS0w_f8a9d46d-b4e1-44bd-81fb-6e19431d0434"
      unitRef="usd">10300000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i246c949459c344caa446c9c644b413b2_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOjBhNGNiZTE2MjZjNzRlZGQ4YjZlMjczZTI5ZmE1ZDgyL3RhYmxlcmFuZ2U6MGE0Y2JlMTYyNmM3NGVkZDhiNmUyNzNlMjlmYTVkODJfNC00LTEtMS0w_e0dfc1ee-a403-48a9-87be-12ed2bcfa52c"
      unitRef="usd">38100000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i002638e6f51c4c26ba598e6a80ddd034_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOjBhNGNiZTE2MjZjNzRlZGQ4YjZlMjczZTI5ZmE1ZDgyL3RhYmxlcmFuZ2U6MGE0Y2JlMTYyNmM3NGVkZDhiNmUyNzNlMjlmYTVkODJfNC02LTEtMS0w_ed36776e-9f32-44b6-a187-be4a39f242c5"
      unitRef="usd">46900000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i9b77bbc89c154914b55e0fa9c9242c96_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOjBhNGNiZTE2MjZjNzRlZGQ4YjZlMjczZTI5ZmE1ZDgyL3RhYmxlcmFuZ2U6MGE0Y2JlMTYyNmM3NGVkZDhiNmUyNzNlMjlmYTVkODJfNC04LTEtMS0w_3892f178-4899-4816-be7f-a1e81393929e"
      unitRef="usd">1500000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i2e02b47bfe8d48a5aa515d8c91a8cb66_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOjBhNGNiZTE2MjZjNzRlZGQ4YjZlMjczZTI5ZmE1ZDgyL3RhYmxlcmFuZ2U6MGE0Y2JlMTYyNmM3NGVkZDhiNmUyNzNlMjlmYTVkODJfNC0xMC0xLTEtMA_a04af8ea-132d-407e-9dd8-627c6f633484"
      unitRef="usd">51300000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOjBhNGNiZTE2MjZjNzRlZGQ4YjZlMjczZTI5ZmE1ZDgyL3RhYmxlcmFuZ2U6MGE0Y2JlMTYyNmM3NGVkZDhiNmUyNzNlMjlmYTVkODJfNC0xMi0xLTEtMA_b1e48196-ca7b-426a-a997-a339201420ff"
      unitRef="usd">148100000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i81cfc07b94a54ce5b9767acd9ccbed84_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOjBhNGNiZTE2MjZjNzRlZGQ4YjZlMjczZTI5ZmE1ZDgyL3RhYmxlcmFuZ2U6MGE0Y2JlMTYyNmM3NGVkZDhiNmUyNzNlMjlmYTVkODJfNS0yLTEtMS0w_eefc1aea-429a-4628-ac1f-b23811b66f79"
      unitRef="usd">6300000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i6b8b1c75f80b47ab8430787fcd074574_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOjBhNGNiZTE2MjZjNzRlZGQ4YjZlMjczZTI5ZmE1ZDgyL3RhYmxlcmFuZ2U6MGE0Y2JlMTYyNmM3NGVkZDhiNmUyNzNlMjlmYTVkODJfNS00LTEtMS0w_13d2a0c8-0dff-4889-8f0a-baf132603ccd"
      unitRef="usd">72800000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i52e2a69e04ee42ff88b18c7f1bf6b5bb_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOjBhNGNiZTE2MjZjNzRlZGQ4YjZlMjczZTI5ZmE1ZDgyL3RhYmxlcmFuZ2U6MGE0Y2JlMTYyNmM3NGVkZDhiNmUyNzNlMjlmYTVkODJfNS02LTEtMS0w_3682c8b0-1b85-488f-a54d-bba09ea05b25"
      unitRef="usd">50400000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i5f7aa82595074b70bd32cc3f188787ee_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOjBhNGNiZTE2MjZjNzRlZGQ4YjZlMjczZTI5ZmE1ZDgyL3RhYmxlcmFuZ2U6MGE0Y2JlMTYyNmM3NGVkZDhiNmUyNzNlMjlmYTVkODJfNS04LTEtMS0w_88585fdf-b0b9-4e63-a1c9-0c890bcd6897"
      unitRef="usd">-29800000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i292bc1b0a8914e259d69aee92dcb23d9_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOjBhNGNiZTE2MjZjNzRlZGQ4YjZlMjczZTI5ZmE1ZDgyL3RhYmxlcmFuZ2U6MGE0Y2JlMTYyNmM3NGVkZDhiNmUyNzNlMjlmYTVkODJfNS0xMC0xLTEtMA_8fa031a8-450c-418d-a3e5-1056dd80f11d"
      unitRef="usd">-192000000.0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ied38b94db9a74750b51c6e8392d4c5bf_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOjBhNGNiZTE2MjZjNzRlZGQ4YjZlMjczZTI5ZmE1ZDgyL3RhYmxlcmFuZ2U6MGE0Y2JlMTYyNmM3NGVkZDhiNmUyNzNlMjlmYTVkODJfNS0xMi0xLTEtMA_3f00bbc8-2305-472d-803d-7dddcafb43de"
      unitRef="usd">-92300000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RleHRyZWdpb246ZjZlZDhjM2EzZGM0NGZhZGE1YjMzOWE0ZGVhODAwNGRfMTMzMA_d92a8d89-ead3-44e9-974f-81652adb653a">&lt;div style="text-indent:22.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table summarizes the amounts reclassified from accumulated other comprehensive income:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:33.987%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:21.707%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.695%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.695%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.695%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.701%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" rowspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Income Statement Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amounts Reclassified from Accumulated Other Comprehensive Income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gains (losses) on securities available for sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other income (expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(12.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Income tax benefit (expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gains (losses) on cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(9.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;35.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;41.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;79.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other income (expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Income tax benefit (expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gains (losses) on net investment hedge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other income (expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total reclassifications, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(6.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;37.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;35.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;85.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i69dfd183e47b43278ea75c1422a31eb4_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmYwMGRlMzM2MDMyNDQ4MTk4NmY2Y2RmZDcxZGVhNmQyL3RhYmxlcmFuZ2U6ZjAwZGUzMzYwMzI0NDgxOTg2ZjZjZGZkNzFkZWE2ZDJfMy0zLTEtMS0w_0d7213bd-a907-4c78-a242-0acc188d4b29"
      unitRef="usd">100000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ie7e3a2434dd044fda5e6fd81be0904a7_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmYwMGRlMzM2MDMyNDQ4MTk4NmY2Y2RmZDcxZGVhNmQyL3RhYmxlcmFuZ2U6ZjAwZGUzMzYwMzI0NDgxOTg2ZjZjZGZkNzFkZWE2ZDJfMy01LTEtMS0w_3a8f212d-ba59-4c8a-96b6-252e54edf09c"
      unitRef="usd">600000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ifc695f2ba910436fba8558e4c246c2ed_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmYwMGRlMzM2MDMyNDQ4MTk4NmY2Y2RmZDcxZGVhNmQyL3RhYmxlcmFuZ2U6ZjAwZGUzMzYwMzI0NDgxOTg2ZjZjZGZkNzFkZWE2ZDJfMy03LTEtMS0w_8cf6368b-719d-4157-bcc2-3f30bb8b0db8"
      unitRef="usd">-12400000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="iedbf521c84034004b661ca18c9f5b341_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmYwMGRlMzM2MDMyNDQ4MTk4NmY2Y2RmZDcxZGVhNmQyL3RhYmxlcmFuZ2U6ZjAwZGUzMzYwMzI0NDgxOTg2ZjZjZGZkNzFkZWE2ZDJfMy05LTEtMS0w_6f39191c-efc3-4c35-9d31-432f6c39d8cc"
      unitRef="usd">1600000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i69dfd183e47b43278ea75c1422a31eb4_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmYwMGRlMzM2MDMyNDQ4MTk4NmY2Y2RmZDcxZGVhNmQyL3RhYmxlcmFuZ2U6ZjAwZGUzMzYwMzI0NDgxOTg2ZjZjZGZkNzFkZWE2ZDJfNC0zLTEtMS0w_01761c1e-252a-4233-8833-3fbd4398eb68"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ie7e3a2434dd044fda5e6fd81be0904a7_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmYwMGRlMzM2MDMyNDQ4MTk4NmY2Y2RmZDcxZGVhNmQyL3RhYmxlcmFuZ2U6ZjAwZGUzMzYwMzI0NDgxOTg2ZjZjZGZkNzFkZWE2ZDJfNC01LTEtMS0w_ace9b7b2-1215-4377-bc60-b29e0bb0b895"
      unitRef="usd">-100000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ifc695f2ba910436fba8558e4c246c2ed_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmYwMGRlMzM2MDMyNDQ4MTk4NmY2Y2RmZDcxZGVhNmQyL3RhYmxlcmFuZ2U6ZjAwZGUzMzYwMzI0NDgxOTg2ZjZjZGZkNzFkZWE2ZDJfNC03LTEtMS0w_e1f7a964-50da-4989-abf1-253344ad509f"
      unitRef="usd">2600000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="iedbf521c84034004b661ca18c9f5b341_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmYwMGRlMzM2MDMyNDQ4MTk4NmY2Y2RmZDcxZGVhNmQyL3RhYmxlcmFuZ2U6ZjAwZGUzMzYwMzI0NDgxOTg2ZjZjZGZkNzFkZWE2ZDJfNC05LTEtMS0w_3c44605c-dbed-4fff-9a35-319f989b23fa"
      unitRef="usd">-300000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:Revenues
      contextRef="i596f51e2385d4d4ca183e21f84aa0b55_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmYwMGRlMzM2MDMyNDQ4MTk4NmY2Y2RmZDcxZGVhNmQyL3RhYmxlcmFuZ2U6ZjAwZGUzMzYwMzI0NDgxOTg2ZjZjZGZkNzFkZWE2ZDJfNi0zLTEtMS0w_7169eed0-2d5a-471d-bdf0-1e547f173fca"
      unitRef="usd">-9100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4ff5ee345592411bb43c306a460e9fd1_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmYwMGRlMzM2MDMyNDQ4MTk4NmY2Y2RmZDcxZGVhNmQyL3RhYmxlcmFuZ2U6ZjAwZGUzMzYwMzI0NDgxOTg2ZjZjZGZkNzFkZWE2ZDJfNi01LTEtMS0w_a1a74851-db36-4e06-a043-aaf6072beffa"
      unitRef="usd">-35200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0dc320a6c37a4e9690e25e679e491fc4_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmYwMGRlMzM2MDMyNDQ4MTk4NmY2Y2RmZDcxZGVhNmQyL3RhYmxlcmFuZ2U6ZjAwZGUzMzYwMzI0NDgxOTg2ZjZjZGZkNzFkZWE2ZDJfNi03LTEtMS0w_dd1b14f5-3be0-4927-80af-e81778cfcb72"
      unitRef="usd">41600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8eaafd98479a4bef96cb14d80b992fd6_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmYwMGRlMzM2MDMyNDQ4MTk4NmY2Y2RmZDcxZGVhNmQyL3RhYmxlcmFuZ2U6ZjAwZGUzMzYwMzI0NDgxOTg2ZjZjZGZkNzFkZWE2ZDJfNi05LTEtMS0w_fce56736-e99a-4878-8e15-ee79cd7b8256"
      unitRef="usd">-79800000</us-gaap:Revenues>
    <us-gaap:OperatingExpenses
      contextRef="i596f51e2385d4d4ca183e21f84aa0b55_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmYwMGRlMzM2MDMyNDQ4MTk4NmY2Y2RmZDcxZGVhNmQyL3RhYmxlcmFuZ2U6ZjAwZGUzMzYwMzI0NDgxOTg2ZjZjZGZkNzFkZWE2ZDJfNy0zLTEtMS0w_6992a1c3-0944-4851-9940-f8a18d27a2eb"
      unitRef="usd">-1500000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i4ff5ee345592411bb43c306a460e9fd1_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmYwMGRlMzM2MDMyNDQ4MTk4NmY2Y2RmZDcxZGVhNmQyL3RhYmxlcmFuZ2U6ZjAwZGUzMzYwMzI0NDgxOTg2ZjZjZGZkNzFkZWE2ZDJfNy01LTEtMS0w_e125f4c0-7c22-4876-9e73-6693a773b55b"
      unitRef="usd">800000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i0dc320a6c37a4e9690e25e679e491fc4_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmYwMGRlMzM2MDMyNDQ4MTk4NmY2Y2RmZDcxZGVhNmQyL3RhYmxlcmFuZ2U6ZjAwZGUzMzYwMzI0NDgxOTg2ZjZjZGZkNzFkZWE2ZDJfNy03LTEtMS0w_a5620e3e-efd1-448d-b778-29b79d26d212"
      unitRef="usd">-1400000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i8eaafd98479a4bef96cb14d80b992fd6_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmYwMGRlMzM2MDMyNDQ4MTk4NmY2Y2RmZDcxZGVhNmQyL3RhYmxlcmFuZ2U6ZjAwZGUzMzYwMzI0NDgxOTg2ZjZjZGZkNzFkZWE2ZDJfNy05LTEtMS0w_dbd401a3-3b84-40c9-8d95-196ee2ec9aeb"
      unitRef="usd">-2000000.0</us-gaap:OperatingExpenses>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i596f51e2385d4d4ca183e21f84aa0b55_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmYwMGRlMzM2MDMyNDQ4MTk4NmY2Y2RmZDcxZGVhNmQyL3RhYmxlcmFuZ2U6ZjAwZGUzMzYwMzI0NDgxOTg2ZjZjZGZkNzFkZWE2ZDJfOC0zLTEtMS0w_ce5a0aab-d582-403d-b5d7-dfabdcf859c6"
      unitRef="usd">0</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i4ff5ee345592411bb43c306a460e9fd1_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmYwMGRlMzM2MDMyNDQ4MTk4NmY2Y2RmZDcxZGVhNmQyL3RhYmxlcmFuZ2U6ZjAwZGUzMzYwMzI0NDgxOTg2ZjZjZGZkNzFkZWE2ZDJfOC01LTEtMS0w_50f44dd0-3c99-4dea-915c-55a8c28706b7"
      unitRef="usd">100000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i0dc320a6c37a4e9690e25e679e491fc4_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmYwMGRlMzM2MDMyNDQ4MTk4NmY2Y2RmZDcxZGVhNmQyL3RhYmxlcmFuZ2U6ZjAwZGUzMzYwMzI0NDgxOTg2ZjZjZGZkNzFkZWE2ZDJfOC03LTEtMS0w_04d4f914-4ac3-4284-a6bd-1dba63087bf2"
      unitRef="usd">200000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i8eaafd98479a4bef96cb14d80b992fd6_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmYwMGRlMzM2MDMyNDQ4MTk4NmY2Y2RmZDcxZGVhNmQyL3RhYmxlcmFuZ2U6ZjAwZGUzMzYwMzI0NDgxOTg2ZjZjZGZkNzFkZWE2ZDJfOC05LTEtMS0w_5ccb7059-0a56-4b0e-8a74-8fe73bbc0ae3"
      unitRef="usd">200000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i596f51e2385d4d4ca183e21f84aa0b55_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmYwMGRlMzM2MDMyNDQ4MTk4NmY2Y2RmZDcxZGVhNmQyL3RhYmxlcmFuZ2U6ZjAwZGUzMzYwMzI0NDgxOTg2ZjZjZGZkNzFkZWE2ZDJfOS0zLTEtMS0w_25cb68a4-f0b9-4c78-a21c-7d716562ad5c"
      unitRef="usd">100000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i4ff5ee345592411bb43c306a460e9fd1_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmYwMGRlMzM2MDMyNDQ4MTk4NmY2Y2RmZDcxZGVhNmQyL3RhYmxlcmFuZ2U6ZjAwZGUzMzYwMzI0NDgxOTg2ZjZjZGZkNzFkZWE2ZDJfOS01LTEtMS0w_00bf8257-8c0b-4735-86a5-c5bc3bb7d498"
      unitRef="usd">-100000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i0dc320a6c37a4e9690e25e679e491fc4_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmYwMGRlMzM2MDMyNDQ4MTk4NmY2Y2RmZDcxZGVhNmQyL3RhYmxlcmFuZ2U6ZjAwZGUzMzYwMzI0NDgxOTg2ZjZjZGZkNzFkZWE2ZDJfOS03LTEtMS0w_2b906d7b-1858-4240-8c78-5713ff1887d6"
      unitRef="usd">-100000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i8eaafd98479a4bef96cb14d80b992fd6_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmYwMGRlMzM2MDMyNDQ4MTk4NmY2Y2RmZDcxZGVhNmQyL3RhYmxlcmFuZ2U6ZjAwZGUzMzYwMzI0NDgxOTg2ZjZjZGZkNzFkZWE2ZDJfOS05LTEtMS0w_8d415fd2-e532-4563-8aae-11f41ae838e5"
      unitRef="usd">-300000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i50715424610f44fe9d83a26f088cd935_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmYwMGRlMzM2MDMyNDQ4MTk4NmY2Y2RmZDcxZGVhNmQyL3RhYmxlcmFuZ2U6ZjAwZGUzMzYwMzI0NDgxOTg2ZjZjZGZkNzFkZWE2ZDJfMTEtMy0xLTEtMA_5cc0d2e0-3019-4536-9404-6131f006bb88"
      unitRef="usd">800000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i1cccc5c5e6a64e839db1a1a24f25b45e_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmYwMGRlMzM2MDMyNDQ4MTk4NmY2Y2RmZDcxZGVhNmQyL3RhYmxlcmFuZ2U6ZjAwZGUzMzYwMzI0NDgxOTg2ZjZjZGZkNzFkZWE2ZDJfMTEtNS0xLTEtMA_9f929086-1cd2-4b22-a640-afe47d322424"
      unitRef="usd">2200000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ic0ab2edcb2644062923296228b7a8512_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmYwMGRlMzM2MDMyNDQ4MTk4NmY2Y2RmZDcxZGVhNmQyL3RhYmxlcmFuZ2U6ZjAwZGUzMzYwMzI0NDgxOTg2ZjZjZGZkNzFkZWE2ZDJfMTEtNy0xLTEtMA_92905cae-a2ea-4324-8759-aa0e2477366b"
      unitRef="usd">2600000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i79d195428b514b78a4569da6e0cad1aa_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmYwMGRlMzM2MDMyNDQ4MTk4NmY2Y2RmZDcxZGVhNmQyL3RhYmxlcmFuZ2U6ZjAwZGUzMzYwMzI0NDgxOTg2ZjZjZGZkNzFkZWE2ZDJfMTEtOS0xLTEtMA_85403960-0259-485d-9540-ea87b4bdebad"
      unitRef="usd">6600000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="i42f682d87cc74a01aeb1af535a8ccb75_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmYwMGRlMzM2MDMyNDQ4MTk4NmY2Y2RmZDcxZGVhNmQyL3RhYmxlcmFuZ2U6ZjAwZGUzMzYwMzI0NDgxOTg2ZjZjZGZkNzFkZWE2ZDJfMTQtMy0xLTEtMA_46e9a57e-9321-4f02-bb16-d25a2dce0c14"
      unitRef="usd">-6600000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i3ee5b72f84e44476b4c4a2b8d8df11ac_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmYwMGRlMzM2MDMyNDQ4MTk4NmY2Y2RmZDcxZGVhNmQyL3RhYmxlcmFuZ2U6ZjAwZGUzMzYwMzI0NDgxOTg2ZjZjZGZkNzFkZWE2ZDJfMTQtNS0xLTEtMA_b74800ad-4c45-4919-8653-181602e98568"
      unitRef="usd">37100000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i198a92ee28f54d99b35bfa8c48185fb9_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmYwMGRlMzM2MDMyNDQ4MTk4NmY2Y2RmZDcxZGVhNmQyL3RhYmxlcmFuZ2U6ZjAwZGUzMzYwMzI0NDgxOTg2ZjZjZGZkNzFkZWE2ZDJfMTQtNy0xLTEtMA_e539aebf-2255-44fc-9dc9-4ee6c1f9e61e"
      unitRef="usd">35900000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i31394cacd6624f0892e0c59f72b73473_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185NC9mcmFnOmY2ZWQ4YzNhM2RjNDRmYWRhNWIzMzlhNGRlYTgwMDRkL3RhYmxlOmYwMGRlMzM2MDMyNDQ4MTk4NmY2Y2RmZDcxZGVhNmQyL3RhYmxlcmFuZ2U6ZjAwZGUzMzYwMzI0NDgxOTg2ZjZjZGZkNzFkZWE2ZDJfMTQtOS0xLTEtMA_0b793ac4-5663-4a87-89e5-5c892dcc37da"
      unitRef="usd">85600000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185Ny9mcmFnOjRjMDNkMjgxZGNhMDQ1YmViZGUwNzJkM2VmODNjYmFhL3RleHRyZWdpb246NGMwM2QyODFkY2EwNDViZWJkZTA3MmQzZWY4M2NiYWFfMjA5_4277d7ef-b762-4a1c-9833-bffd60103ec7">&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Basic and diluted earnings per share are calculated as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:43.929%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.204%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.204%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.619%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.624%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-style:italic;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net income attributable to Biogen Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;701.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,545.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;3,642.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,448.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-style:italic;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted average number of common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;156.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;184.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;163.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;190.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Time-vested restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Market stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Performance stock units settled in stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Dilutive potential common shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Shares used in calculating diluted earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;157.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;184.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;163.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;190.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Amounts excluded from the calculation of net income per diluted share because their effects were anti-dilutive were insignificant.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185Ny9mcmFnOjRjMDNkMjgxZGNhMDQ1YmViZGUwNzJkM2VmODNjYmFhL3RleHRyZWdpb246NGMwM2QyODFkY2EwNDViZWJkZTA3MmQzZWY4M2NiYWFfMjI1_b54b0214-7a84-48e6-ba0b-0004905a8fa2">&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Basic and diluted earnings per share are calculated as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:43.929%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.204%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.204%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.619%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.624%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-style:italic;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net income attributable to Biogen Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;701.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,545.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;3,642.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,448.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-style:italic;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted average number of common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;156.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;184.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;163.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;190.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Time-vested restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Market stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Performance stock units settled in stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Dilutive potential common shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Shares used in calculating diluted earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;157.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;184.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;163.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;190.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185Ny9mcmFnOjRjMDNkMjgxZGNhMDQ1YmViZGUwNzJkM2VmODNjYmFhL3RhYmxlOjI0ZWE0ODNhMTM4OTQ2NzM5Njk5ZmFiZmVjYmI4NjZlL3RhYmxlcmFuZ2U6MjRlYTQ4M2ExMzg5NDY3Mzk2OTlmYWJmZWNiYjg2NmVfMy0yLTEtMS0w_24ff3b32-0381-4922-9b0e-b3f0e196b243"
      unitRef="usd">701500000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185Ny9mcmFnOjRjMDNkMjgxZGNhMDQ1YmViZGUwNzJkM2VmODNjYmFhL3RhYmxlOjI0ZWE0ODNhMTM4OTQ2NzM5Njk5ZmFiZmVjYmI4NjZlL3RhYmxlcmFuZ2U6MjRlYTQ4M2ExMzg5NDY3Mzk2OTlmYWJmZWNiYjg2NmVfMy00LTEtMS0w_1af0114b-dede-4232-b2c9-bba15c4fa899"
      unitRef="usd">1545900000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185Ny9mcmFnOjRjMDNkMjgxZGNhMDQ1YmViZGUwNzJkM2VmODNjYmFhL3RhYmxlOjI0ZWE0ODNhMTM4OTQ2NzM5Njk5ZmFiZmVjYmI4NjZlL3RhYmxlcmFuZ2U6MjRlYTQ4M2ExMzg5NDY3Mzk2OTlmYWJmZWNiYjg2NmVfMy02LTEtMS0w_a84bb2f6-0a9d-40f2-a47b-601a4d70034e"
      unitRef="usd">3642700000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185Ny9mcmFnOjRjMDNkMjgxZGNhMDQ1YmViZGUwNzJkM2VmODNjYmFhL3RhYmxlOjI0ZWE0ODNhMTM4OTQ2NzM5Njk5ZmFiZmVjYmI4NjZlL3RhYmxlcmFuZ2U6MjRlYTQ4M2ExMzg5NDY3Mzk2OTlmYWJmZWNiYjg2NmVfMy04LTEtMS0w_322e8a0e-3eee-4eb3-93e7-9f2887cb8b31"
      unitRef="usd">4448800000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185Ny9mcmFnOjRjMDNkMjgxZGNhMDQ1YmViZGUwNzJkM2VmODNjYmFhL3RhYmxlOjI0ZWE0ODNhMTM4OTQ2NzM5Njk5ZmFiZmVjYmI4NjZlL3RhYmxlcmFuZ2U6MjRlYTQ4M2ExMzg5NDY3Mzk2OTlmYWJmZWNiYjg2NmVfNS0yLTEtMS0w_49203b04-689d-41f4-bd88-5507e2e315a3"
      unitRef="shares">156900000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185Ny9mcmFnOjRjMDNkMjgxZGNhMDQ1YmViZGUwNzJkM2VmODNjYmFhL3RhYmxlOjI0ZWE0ODNhMTM4OTQ2NzM5Njk5ZmFiZmVjYmI4NjZlL3RhYmxlcmFuZ2U6MjRlYTQ4M2ExMzg5NDY3Mzk2OTlmYWJmZWNiYjg2NmVfNS00LTEtMS0w_c5b3d9c6-f2f2-4d2d-96ce-d0581ed875df"
      unitRef="shares">184000000.0</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185Ny9mcmFnOjRjMDNkMjgxZGNhMDQ1YmViZGUwNzJkM2VmODNjYmFhL3RhYmxlOjI0ZWE0ODNhMTM4OTQ2NzM5Njk5ZmFiZmVjYmI4NjZlL3RhYmxlcmFuZ2U6MjRlYTQ4M2ExMzg5NDY3Mzk2OTlmYWJmZWNiYjg2NmVfNS02LTEtMS0w_2f38e537-82c7-45aa-9ac5-d14c2615f22e"
      unitRef="shares">163400000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185Ny9mcmFnOjRjMDNkMjgxZGNhMDQ1YmViZGUwNzJkM2VmODNjYmFhL3RhYmxlOjI0ZWE0ODNhMTM4OTQ2NzM5Njk5ZmFiZmVjYmI4NjZlL3RhYmxlcmFuZ2U6MjRlYTQ4M2ExMzg5NDY3Mzk2OTlmYWJmZWNiYjg2NmVfNS04LTEtMS0w_73b488a3-eb6a-4552-8630-35bf37aaf6dc"
      unitRef="shares">190300000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i07c2927512de4889ac3af77ef26070bf_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185Ny9mcmFnOjRjMDNkMjgxZGNhMDQ1YmViZGUwNzJkM2VmODNjYmFhL3RhYmxlOjI0ZWE0ODNhMTM4OTQ2NzM5Njk5ZmFiZmVjYmI4NjZlL3RhYmxlcmFuZ2U6MjRlYTQ4M2ExMzg5NDY3Mzk2OTlmYWJmZWNiYjg2NmVfOC0yLTEtMS0w_c19ca0f2-c5e5-443d-8a58-5fd7537d0de4"
      unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i9e3d3eb860e64b4c8771c3591a944c56_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185Ny9mcmFnOjRjMDNkMjgxZGNhMDQ1YmViZGUwNzJkM2VmODNjYmFhL3RhYmxlOjI0ZWE0ODNhMTM4OTQ2NzM5Njk5ZmFiZmVjYmI4NjZlL3RhYmxlcmFuZ2U6MjRlYTQ4M2ExMzg5NDY3Mzk2OTlmYWJmZWNiYjg2NmVfOC00LTEtMS0w_f86c128a-94ca-4893-b82e-5c905ef43098"
      unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i418e492358064b87bb88dd6a5d427bd3_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185Ny9mcmFnOjRjMDNkMjgxZGNhMDQ1YmViZGUwNzJkM2VmODNjYmFhL3RhYmxlOjI0ZWE0ODNhMTM4OTQ2NzM5Njk5ZmFiZmVjYmI4NjZlL3RhYmxlcmFuZ2U6MjRlYTQ4M2ExMzg5NDY3Mzk2OTlmYWJmZWNiYjg2NmVfOC02LTEtMS0w_1c8c3272-da17-43d0-a820-60f49a54742e"
      unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i89cc77663484411897a1c618e3902df4_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185Ny9mcmFnOjRjMDNkMjgxZGNhMDQ1YmViZGUwNzJkM2VmODNjYmFhL3RhYmxlOjI0ZWE0ODNhMTM4OTQ2NzM5Njk5ZmFiZmVjYmI4NjZlL3RhYmxlcmFuZ2U6MjRlYTQ4M2ExMzg5NDY3Mzk2OTlmYWJmZWNiYjg2NmVfOC04LTEtMS0w_b92370f7-ac33-48b2-8aed-f920547bec63"
      unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i5177976681f14f4fbb72c76d037197e2_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185Ny9mcmFnOjRjMDNkMjgxZGNhMDQ1YmViZGUwNzJkM2VmODNjYmFhL3RhYmxlOjI0ZWE0ODNhMTM4OTQ2NzM5Njk5ZmFiZmVjYmI4NjZlL3RhYmxlcmFuZ2U6MjRlYTQ4M2ExMzg5NDY3Mzk2OTlmYWJmZWNiYjg2NmVfOS0yLTEtMS0w_c643e8a4-6d9a-40dd-b6bb-d11b44b28f4e"
      unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="id458ec3169f34e2088009cbf147e8304_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185Ny9mcmFnOjRjMDNkMjgxZGNhMDQ1YmViZGUwNzJkM2VmODNjYmFhL3RhYmxlOjI0ZWE0ODNhMTM4OTQ2NzM5Njk5ZmFiZmVjYmI4NjZlL3RhYmxlcmFuZ2U6MjRlYTQ4M2ExMzg5NDY3Mzk2OTlmYWJmZWNiYjg2NmVfOS00LTEtMS0w_487e9690-b042-4a6b-b7e6-9dc9f0453561"
      unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i2274b2b373db4361a50819e797d93268_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185Ny9mcmFnOjRjMDNkMjgxZGNhMDQ1YmViZGUwNzJkM2VmODNjYmFhL3RhYmxlOjI0ZWE0ODNhMTM4OTQ2NzM5Njk5ZmFiZmVjYmI4NjZlL3RhYmxlcmFuZ2U6MjRlYTQ4M2ExMzg5NDY3Mzk2OTlmYWJmZWNiYjg2NmVfOS02LTEtMS0w_ec1ee38e-3c83-4484-906b-c869dedaaf3d"
      unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i0ae5101f56364c07bd1fa9851047ae1c_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185Ny9mcmFnOjRjMDNkMjgxZGNhMDQ1YmViZGUwNzJkM2VmODNjYmFhL3RhYmxlOjI0ZWE0ODNhMTM4OTQ2NzM5Njk5ZmFiZmVjYmI4NjZlL3RhYmxlcmFuZ2U6MjRlYTQ4M2ExMzg5NDY3Mzk2OTlmYWJmZWNiYjg2NmVfOS04LTEtMS0w_2659db7d-6a0f-4422-a9d5-022262084e83"
      unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i17644aaa924944b6838681aa26728f55_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185Ny9mcmFnOjRjMDNkMjgxZGNhMDQ1YmViZGUwNzJkM2VmODNjYmFhL3RhYmxlOjI0ZWE0ODNhMTM4OTQ2NzM5Njk5ZmFiZmVjYmI4NjZlL3RhYmxlcmFuZ2U6MjRlYTQ4M2ExMzg5NDY3Mzk2OTlmYWJmZWNiYjg2NmVfMTAtMi0xLTEtMA_9b0cbdd8-3309-4988-9513-0560ca9b07f4"
      unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i93f4c72f492543b38ab5befc540cf70a_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185Ny9mcmFnOjRjMDNkMjgxZGNhMDQ1YmViZGUwNzJkM2VmODNjYmFhL3RhYmxlOjI0ZWE0ODNhMTM4OTQ2NzM5Njk5ZmFiZmVjYmI4NjZlL3RhYmxlcmFuZ2U6MjRlYTQ4M2ExMzg5NDY3Mzk2OTlmYWJmZWNiYjg2NmVfMTAtNC0xLTEtMA_ec333b65-c247-46ec-b86a-d65cf4e25a04"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i3bcae79b02034b7a8d5846ce264aff93_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185Ny9mcmFnOjRjMDNkMjgxZGNhMDQ1YmViZGUwNzJkM2VmODNjYmFhL3RhYmxlOjI0ZWE0ODNhMTM4OTQ2NzM5Njk5ZmFiZmVjYmI4NjZlL3RhYmxlcmFuZ2U6MjRlYTQ4M2ExMzg5NDY3Mzk2OTlmYWJmZWNiYjg2NmVfMTAtNi0xLTEtMA_904eb7cb-316f-487d-9dc6-28b0035a3092"
      unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i2cc8c72a2c4a4404a78a7942a0c6e8b1_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185Ny9mcmFnOjRjMDNkMjgxZGNhMDQ1YmViZGUwNzJkM2VmODNjYmFhL3RhYmxlOjI0ZWE0ODNhMTM4OTQ2NzM5Njk5ZmFiZmVjYmI4NjZlL3RhYmxlcmFuZ2U6MjRlYTQ4M2ExMzg5NDY3Mzk2OTlmYWJmZWNiYjg2NmVfMTAtOC0xLTEtMA_272c713b-96e0-4500-847e-b1b25a535a1c"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185Ny9mcmFnOjRjMDNkMjgxZGNhMDQ1YmViZGUwNzJkM2VmODNjYmFhL3RhYmxlOjI0ZWE0ODNhMTM4OTQ2NzM5Njk5ZmFiZmVjYmI4NjZlL3RhYmxlcmFuZ2U6MjRlYTQ4M2ExMzg5NDY3Mzk2OTlmYWJmZWNiYjg2NmVfMTEtMi0xLTEtMA_ddf3754f-86c7-4e1b-b932-23ef9a6714cb"
      unitRef="shares">300000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185Ny9mcmFnOjRjMDNkMjgxZGNhMDQ1YmViZGUwNzJkM2VmODNjYmFhL3RhYmxlOjI0ZWE0ODNhMTM4OTQ2NzM5Njk5ZmFiZmVjYmI4NjZlL3RhYmxlcmFuZ2U6MjRlYTQ4M2ExMzg5NDY3Mzk2OTlmYWJmZWNiYjg2NmVfMTEtNC0xLTEtMA_dbdfb71a-d5dd-4c3a-8951-aad7ec48d087"
      unitRef="shares">200000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185Ny9mcmFnOjRjMDNkMjgxZGNhMDQ1YmViZGUwNzJkM2VmODNjYmFhL3RhYmxlOjI0ZWE0ODNhMTM4OTQ2NzM5Njk5ZmFiZmVjYmI4NjZlL3RhYmxlcmFuZ2U6MjRlYTQ4M2ExMzg5NDY3Mzk2OTlmYWJmZWNiYjg2NmVfMTEtNi0xLTEtMA_6b10e7ab-da6b-4343-810f-79be84afaa6d"
      unitRef="shares">300000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185Ny9mcmFnOjRjMDNkMjgxZGNhMDQ1YmViZGUwNzJkM2VmODNjYmFhL3RhYmxlOjI0ZWE0ODNhMTM4OTQ2NzM5Njk5ZmFiZmVjYmI4NjZlL3RhYmxlcmFuZ2U6MjRlYTQ4M2ExMzg5NDY3Mzk2OTlmYWJmZWNiYjg2NmVfMTEtOC0xLTEtMA_8819ead5-90d3-46b1-8758-732dbcc918f5"
      unitRef="shares">200000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185Ny9mcmFnOjRjMDNkMjgxZGNhMDQ1YmViZGUwNzJkM2VmODNjYmFhL3RhYmxlOjI0ZWE0ODNhMTM4OTQ2NzM5Njk5ZmFiZmVjYmI4NjZlL3RhYmxlcmFuZ2U6MjRlYTQ4M2ExMzg5NDY3Mzk2OTlmYWJmZWNiYjg2NmVfMTItMi0xLTEtMA_0ec47d91-7ec6-46ff-89ec-919d86d483cb"
      unitRef="shares">157200000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185Ny9mcmFnOjRjMDNkMjgxZGNhMDQ1YmViZGUwNzJkM2VmODNjYmFhL3RhYmxlOjI0ZWE0ODNhMTM4OTQ2NzM5Njk5ZmFiZmVjYmI4NjZlL3RhYmxlcmFuZ2U6MjRlYTQ4M2ExMzg5NDY3Mzk2OTlmYWJmZWNiYjg2NmVfMTItNC0xLTEtMA_5fc7afff-22f0-4421-88eb-75c0644b3e39"
      unitRef="shares">184200000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185Ny9mcmFnOjRjMDNkMjgxZGNhMDQ1YmViZGUwNzJkM2VmODNjYmFhL3RhYmxlOjI0ZWE0ODNhMTM4OTQ2NzM5Njk5ZmFiZmVjYmI4NjZlL3RhYmxlcmFuZ2U6MjRlYTQ4M2ExMzg5NDY3Mzk2OTlmYWJmZWNiYjg2NmVfMTItNi0xLTEtMA_f2c94287-6cc6-4a92-8804-4c50f78ea647"
      unitRef="shares">163700000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM185Ny9mcmFnOjRjMDNkMjgxZGNhMDQ1YmViZGUwNzJkM2VmODNjYmFhL3RhYmxlOjI0ZWE0ODNhMTM4OTQ2NzM5Njk5ZmFiZmVjYmI4NjZlL3RhYmxlcmFuZ2U6MjRlYTQ4M2ExMzg5NDY3Mzk2OTlmYWJmZWNiYjg2NmVfMTItOC0xLTEtMA_8f256159-13c7-4805-bb31-72a7354348cb"
      unitRef="shares">190500000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90ZXh0cmVnaW9uOjJmYTQ0NGE0MTFlZTRhNjRhNjUyOWQxOGUzYzdkNWY4XzcwMw_16da9bd6-8111-4f54-a68b-05b3bb786f6b">&lt;div style="text-indent:11.25pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Share-based Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table summarizes share-based compensation expense included in our condensed consolidated statements of income:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:49.119%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.613%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.613%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.613%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.614%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Research and development &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;14.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;63.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;65.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;25.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;34.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;98.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;116.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;39.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;49.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;161.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;182.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Capitalized share-based compensation costs &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(1.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(4.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(7.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Share-based compensation expense included in total cost and expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;37.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;47.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;156.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;174.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Income tax effect&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(5.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(8.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(25.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(29.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Share-based compensation expense included in net income attributable to Biogen Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;32.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;39.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;130.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;145.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:49.119%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.613%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.613%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.613%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.614%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Market stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;32.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;24.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Time-vested restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;35.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;37.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;107.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;104.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash settled performance units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Performance units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Performance stock units settled in stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(8.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;13.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Performance stock units settled in cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;9.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Employee stock purchase plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;11.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;NST stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;26.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;39.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;49.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;161.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;182.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Capitalized share-based compensation costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(1.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(4.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(7.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Share-based compensation expense included in total cost and expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;37.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;47.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;156.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;174.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We estimate the fair value of our obligations associated with our performance units settled in cash at the end of each reporting period through expected settlement.&#160;Cumulative adjustments to these obligations are recognized each quarter to reflect changes in the stock price and estimated outcome of the performance-related conditions.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90ZXh0cmVnaW9uOjJmYTQ0NGE0MTFlZTRhNjRhNjUyOWQxOGUzYzdkNWY4XzcwNw_23fe1b45-c1ad-4293-9b4d-3a0e3931705b">&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table summarizes share-based compensation expense included in our condensed consolidated statements of income:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:49.119%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.613%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.613%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.613%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.614%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Research and development &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;14.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;63.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;65.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;25.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;34.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;98.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;116.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;39.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;49.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;161.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;182.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Capitalized share-based compensation costs &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(1.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(4.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(7.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Share-based compensation expense included in total cost and expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;37.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;47.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;156.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;174.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Income tax effect&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(5.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(8.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(25.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(29.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Share-based compensation expense included in net income attributable to Biogen Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;32.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;39.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;130.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;145.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia49dbac3063344639f0b5d7299e025be_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTphYzdjMjYwYjI3NmY0MGEyOTE2NzZlYzQzZGVjYmZlNC90YWJsZXJhbmdlOmFjN2MyNjBiMjc2ZjQwYTI5MTY3NmVjNDNkZWNiZmU0XzItMi0xLTEtMA_8be46168-7edd-4087-9c07-7ec17d5f08c3"
      unitRef="usd">14600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iff8fc7508c8d4439986e1175bce454a0_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTphYzdjMjYwYjI3NmY0MGEyOTE2NzZlYzQzZGVjYmZlNC90YWJsZXJhbmdlOmFjN2MyNjBiMjc2ZjQwYTI5MTY3NmVjNDNkZWNiZmU0XzItNC0xLTEtMA_59dca612-16ee-4802-abaa-81ac92403e8a"
      unitRef="usd">15400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i107d07150da4422b945e0bd78389de3b_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTphYzdjMjYwYjI3NmY0MGEyOTE2NzZlYzQzZGVjYmZlNC90YWJsZXJhbmdlOmFjN2MyNjBiMjc2ZjQwYTI5MTY3NmVjNDNkZWNiZmU0XzItNi0xLTEtMA_fc5123b9-aa60-4321-8128-9a53050c5310"
      unitRef="usd">63100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i909d084c1b604c4bba3bd63551acf4aa_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTphYzdjMjYwYjI3NmY0MGEyOTE2NzZlYzQzZGVjYmZlNC90YWJsZXJhbmdlOmFjN2MyNjBiMjc2ZjQwYTI5MTY3NmVjNDNkZWNiZmU0XzItOC0xLTEtMA_b6da47f4-6f28-49ef-923b-8a64f9e1fd53"
      unitRef="usd">65200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0bbba4b976ca48c78d5dac97d8fe4cbd_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTphYzdjMjYwYjI3NmY0MGEyOTE2NzZlYzQzZGVjYmZlNC90YWJsZXJhbmdlOmFjN2MyNjBiMjc2ZjQwYTI5MTY3NmVjNDNkZWNiZmU0XzMtMi0xLTEtMA_7b522ec0-22dd-492f-9002-129ab562809a"
      unitRef="usd">25000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i68ac5428413242c4becdcb7197bed42d_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTphYzdjMjYwYjI3NmY0MGEyOTE2NzZlYzQzZGVjYmZlNC90YWJsZXJhbmdlOmFjN2MyNjBiMjc2ZjQwYTI5MTY3NmVjNDNkZWNiZmU0XzMtNC0xLTEtMA_050a99af-41e1-47da-83c8-f3c0e9571d2e"
      unitRef="usd">34200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie898eae73ea9411696b0e278874d55f0_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTphYzdjMjYwYjI3NmY0MGEyOTE2NzZlYzQzZGVjYmZlNC90YWJsZXJhbmdlOmFjN2MyNjBiMjc2ZjQwYTI5MTY3NmVjNDNkZWNiZmU0XzMtNi0xLTEtMA_118d1670-56d0-48be-a91f-4a5850b9b978"
      unitRef="usd">98400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iad40dcf3ae2540a2b934514b7ad07c86_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTphYzdjMjYwYjI3NmY0MGEyOTE2NzZlYzQzZGVjYmZlNC90YWJsZXJhbmdlOmFjN2MyNjBiMjc2ZjQwYTI5MTY3NmVjNDNkZWNiZmU0XzMtOC0xLTEtMA_01876264-f382-4332-857f-4aa5e64f57f2"
      unitRef="usd">116800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTphYzdjMjYwYjI3NmY0MGEyOTE2NzZlYzQzZGVjYmZlNC90YWJsZXJhbmdlOmFjN2MyNjBiMjc2ZjQwYTI5MTY3NmVjNDNkZWNiZmU0XzQtMi0xLTEtMA_4aa18fde-4ece-4a5f-88ae-bf99c5226072"
      unitRef="usd">39600000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTphYzdjMjYwYjI3NmY0MGEyOTE2NzZlYzQzZGVjYmZlNC90YWJsZXJhbmdlOmFjN2MyNjBiMjc2ZjQwYTI5MTY3NmVjNDNkZWNiZmU0XzQtNC0xLTEtMA_e676d655-ad41-4899-a535-fa7430c93c2e"
      unitRef="usd">49600000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTphYzdjMjYwYjI3NmY0MGEyOTE2NzZlYzQzZGVjYmZlNC90YWJsZXJhbmdlOmFjN2MyNjBiMjc2ZjQwYTI5MTY3NmVjNDNkZWNiZmU0XzQtNi0xLTEtMA_44e41f6a-7bdc-4b1f-af75-b9959d4fa403"
      unitRef="usd">161500000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTphYzdjMjYwYjI3NmY0MGEyOTE2NzZlYzQzZGVjYmZlNC90YWJsZXJhbmdlOmFjN2MyNjBiMjc2ZjQwYTI5MTY3NmVjNDNkZWNiZmU0XzQtOC0xLTEtMA_e3cf7536-cf0d-457f-8df2-e310091643b8"
      unitRef="usd">182000000.0</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTphYzdjMjYwYjI3NmY0MGEyOTE2NzZlYzQzZGVjYmZlNC90YWJsZXJhbmdlOmFjN2MyNjBiMjc2ZjQwYTI5MTY3NmVjNDNkZWNiZmU0XzUtMi0xLTEtMA_79762fc9-b721-42a1-a14d-fa32389d0c68"
      unitRef="usd">1900000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTphYzdjMjYwYjI3NmY0MGEyOTE2NzZlYzQzZGVjYmZlNC90YWJsZXJhbmdlOmFjN2MyNjBiMjc2ZjQwYTI5MTY3NmVjNDNkZWNiZmU0XzUtNC0xLTEtMA_6c6c0065-bc1e-42c9-85fc-fa215e357660"
      unitRef="usd">1700000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTphYzdjMjYwYjI3NmY0MGEyOTE2NzZlYzQzZGVjYmZlNC90YWJsZXJhbmdlOmFjN2MyNjBiMjc2ZjQwYTI5MTY3NmVjNDNkZWNiZmU0XzUtNi0xLTEtMA_536fee6c-9ee8-44af-aee0-0972077d82cb"
      unitRef="usd">4900000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTphYzdjMjYwYjI3NmY0MGEyOTE2NzZlYzQzZGVjYmZlNC90YWJsZXJhbmdlOmFjN2MyNjBiMjc2ZjQwYTI5MTY3NmVjNDNkZWNiZmU0XzUtOC0xLTEtMA_5cf63248-a916-4ce2-83d2-c206aae64a07"
      unitRef="usd">7800000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses
      contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTphYzdjMjYwYjI3NmY0MGEyOTE2NzZlYzQzZGVjYmZlNC90YWJsZXJhbmdlOmFjN2MyNjBiMjc2ZjQwYTI5MTY3NmVjNDNkZWNiZmU0XzYtMi0xLTEtMA_ec173777-3c2c-440c-9bc7-065193278aab"
      unitRef="usd">37700000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
    <biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses
      contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTphYzdjMjYwYjI3NmY0MGEyOTE2NzZlYzQzZGVjYmZlNC90YWJsZXJhbmdlOmFjN2MyNjBiMjc2ZjQwYTI5MTY3NmVjNDNkZWNiZmU0XzYtNC0xLTEtMA_beddc902-c425-4563-83b9-96c4b839966d"
      unitRef="usd">47900000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
    <biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTphYzdjMjYwYjI3NmY0MGEyOTE2NzZlYzQzZGVjYmZlNC90YWJsZXJhbmdlOmFjN2MyNjBiMjc2ZjQwYTI5MTY3NmVjNDNkZWNiZmU0XzYtNi0xLTEtMA_33eb72af-c109-43e7-b18f-3e45fa426a3f"
      unitRef="usd">156600000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
    <biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTphYzdjMjYwYjI3NmY0MGEyOTE2NzZlYzQzZGVjYmZlNC90YWJsZXJhbmdlOmFjN2MyNjBiMjc2ZjQwYTI5MTY3NmVjNDNkZWNiZmU0XzYtOC0xLTEtMA_8f75e212-bac8-414b-b3d0-e704d0d608e6"
      unitRef="usd">174200000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTphYzdjMjYwYjI3NmY0MGEyOTE2NzZlYzQzZGVjYmZlNC90YWJsZXJhbmdlOmFjN2MyNjBiMjc2ZjQwYTI5MTY3NmVjNDNkZWNiZmU0XzctMi0xLTEtMA_7603c539-2c4a-499c-98c6-ec611fb57153"
      unitRef="usd">5400000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTphYzdjMjYwYjI3NmY0MGEyOTE2NzZlYzQzZGVjYmZlNC90YWJsZXJhbmdlOmFjN2MyNjBiMjc2ZjQwYTI5MTY3NmVjNDNkZWNiZmU0XzctNC0xLTEtMA_aa08f694-bca4-47bb-acf2-85df087eb2a8"
      unitRef="usd">8100000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTphYzdjMjYwYjI3NmY0MGEyOTE2NzZlYzQzZGVjYmZlNC90YWJsZXJhbmdlOmFjN2MyNjBiMjc2ZjQwYTI5MTY3NmVjNDNkZWNiZmU0XzctNi0xLTEtMA_b3317d0b-3c6c-439b-a35d-f5835464969e"
      unitRef="usd">25700000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTphYzdjMjYwYjI3NmY0MGEyOTE2NzZlYzQzZGVjYmZlNC90YWJsZXJhbmdlOmFjN2MyNjBiMjc2ZjQwYTI5MTY3NmVjNDNkZWNiZmU0XzctOC0xLTEtMA_809a0ea6-8ede-4f65-adbe-0d7e7bc187e1"
      unitRef="usd">29100000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ibdd3d4a6db7c4fd4bf7c980b55c5fecd_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTphYzdjMjYwYjI3NmY0MGEyOTE2NzZlYzQzZGVjYmZlNC90YWJsZXJhbmdlOmFjN2MyNjBiMjc2ZjQwYTI5MTY3NmVjNDNkZWNiZmU0XzgtMi0xLTEtMA_c1736678-1c6f-4757-961a-2f9bb810bf4e"
      unitRef="usd">32300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i81789b07b22446a88e13e5c1075d8cb7_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTphYzdjMjYwYjI3NmY0MGEyOTE2NzZlYzQzZGVjYmZlNC90YWJsZXJhbmdlOmFjN2MyNjBiMjc2ZjQwYTI5MTY3NmVjNDNkZWNiZmU0XzgtNC0xLTEtMA_04300ce9-5ee6-46a3-90fd-6b783e45ea84"
      unitRef="usd">39800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id915b8aebcff4bc2a81caf9b4de54dd7_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTphYzdjMjYwYjI3NmY0MGEyOTE2NzZlYzQzZGVjYmZlNC90YWJsZXJhbmdlOmFjN2MyNjBiMjc2ZjQwYTI5MTY3NmVjNDNkZWNiZmU0XzgtNi0xLTEtMA_adb344e4-8285-4966-913a-ca7b0ed780f6"
      unitRef="usd">130900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i8ca00e2a1cc04153858959116600cdcd_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTphYzdjMjYwYjI3NmY0MGEyOTE2NzZlYzQzZGVjYmZlNC90YWJsZXJhbmdlOmFjN2MyNjBiMjc2ZjQwYTI5MTY3NmVjNDNkZWNiZmU0XzgtOC0xLTEtMA_95512d9d-6aa3-4508-8476-129ab81a0047"
      unitRef="usd">145100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90ZXh0cmVnaW9uOjJmYTQ0NGE0MTFlZTRhNjRhNjUyOWQxOGUzYzdkNWY4XzcyMA_e6b3e354-f14c-40c6-8273-0657d8a0aa87">&lt;div style="text-indent:24.75pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:49.119%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.613%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.613%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.613%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.614%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Market stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;32.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;24.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Time-vested restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;35.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;37.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;107.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;104.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash settled performance units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Performance units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Performance stock units settled in stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(8.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;13.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Performance stock units settled in cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;9.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Employee stock purchase plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;11.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;NST stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;26.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;39.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;49.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;161.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;182.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Capitalized share-based compensation costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(1.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(4.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(7.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Share-based compensation expense included in total cost and expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;37.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;47.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;156.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;174.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i8ba330fe0fb04518b2ecb6db02b6b97f_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTo0ZDIwYzVkMWQyM2Q0ZmY2OGZmYWZhZDE0MGYzNmRkYy90YWJsZXJhbmdlOjRkMjBjNWQxZDIzZDRmZjY4ZmZhZmFkMTQwZjM2ZGRjXzItMi0xLTEtMA_f59a4d51-e170-46f5-a3c9-f00b77633db5"
      unitRef="usd">5500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4e192d624f87417a8539bc84a2a459ff_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTo0ZDIwYzVkMWQyM2Q0ZmY2OGZmYWZhZDE0MGYzNmRkYy90YWJsZXJhbmdlOjRkMjBjNWQxZDIzZDRmZjY4ZmZhZmFkMTQwZjM2ZGRjXzItNC0xLTEtMA_b484c7b3-0dcd-409c-a3f6-7ee53e50f125"
      unitRef="usd">9300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if04752de82454bad9a9a42a0c78ff53b_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTo0ZDIwYzVkMWQyM2Q0ZmY2OGZmYWZhZDE0MGYzNmRkYy90YWJsZXJhbmdlOjRkMjBjNWQxZDIzZDRmZjY4ZmZhZmFkMTQwZjM2ZGRjXzItNi0xLTEtMA_9e1125d7-7765-489c-83be-a98fc384c613"
      unitRef="usd">32000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i493634946d8c4db49d02e47be89e303e_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTo0ZDIwYzVkMWQyM2Q0ZmY2OGZmYWZhZDE0MGYzNmRkYy90YWJsZXJhbmdlOjRkMjBjNWQxZDIzZDRmZjY4ZmZhZmFkMTQwZjM2ZGRjXzItOC0xLTEtMA_eb7e1402-63f4-44fa-88fe-cb1e285d8ab5"
      unitRef="usd">24800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ibed3bf29e7374cc8b7f86449cbcbaa3a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTo0ZDIwYzVkMWQyM2Q0ZmY2OGZmYWZhZDE0MGYzNmRkYy90YWJsZXJhbmdlOjRkMjBjNWQxZDIzZDRmZjY4ZmZhZmFkMTQwZjM2ZGRjXzMtMi0xLTEtMA_00005a90-565e-470b-aa26-be0ea7c184cd"
      unitRef="usd">35300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2cfe6ff0db44473e979cfeaa03760ded_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTo0ZDIwYzVkMWQyM2Q0ZmY2OGZmYWZhZDE0MGYzNmRkYy90YWJsZXJhbmdlOjRkMjBjNWQxZDIzZDRmZjY4ZmZhZmFkMTQwZjM2ZGRjXzMtNC0xLTEtMA_7db8408a-f093-44b9-b9fb-f4690faecda1"
      unitRef="usd">37900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iea41c7a4bbf94cfc8a16ac421e7cc25d_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTo0ZDIwYzVkMWQyM2Q0ZmY2OGZmYWZhZDE0MGYzNmRkYy90YWJsZXJhbmdlOjRkMjBjNWQxZDIzZDRmZjY4ZmZhZmFkMTQwZjM2ZGRjXzMtNi0xLTEtMA_f772564b-adcc-44fc-9fd4-6b868ebf9822"
      unitRef="usd">107300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7e43143e39df4b0cbb78c046a10aa64f_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTo0ZDIwYzVkMWQyM2Q0ZmY2OGZmYWZhZDE0MGYzNmRkYy90YWJsZXJhbmdlOjRkMjBjNWQxZDIzZDRmZjY4ZmZhZmFkMTQwZjM2ZGRjXzMtOC0xLTEtMA_d2c6d1e7-4028-4393-9efe-78415f13dde3"
      unitRef="usd">104400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i96a2e794f31f442ebbb83e8f8c7d54bd_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTo0ZDIwYzVkMWQyM2Q0ZmY2OGZmYWZhZDE0MGYzNmRkYy90YWJsZXJhbmdlOjRkMjBjNWQxZDIzZDRmZjY4ZmZhZmFkMTQwZjM2ZGRjXzQtMi0xLTEtMA_c085e734-d6de-4996-a1c5-8006ee404ad4"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="icc0ae96137314a759fb1044af70f2b95_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTo0ZDIwYzVkMWQyM2Q0ZmY2OGZmYWZhZDE0MGYzNmRkYy90YWJsZXJhbmdlOjRkMjBjNWQxZDIzZDRmZjY4ZmZhZmFkMTQwZjM2ZGRjXzQtNC0xLTEtMA_51339632-832f-4da0-841a-2b59062cf06a"
      unitRef="usd">300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i009b72f35e694a53ae5120480a467b8f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTo0ZDIwYzVkMWQyM2Q0ZmY2OGZmYWZhZDE0MGYzNmRkYy90YWJsZXJhbmdlOjRkMjBjNWQxZDIzZDRmZjY4ZmZhZmFkMTQwZjM2ZGRjXzQtNi0xLTEtMA_0ac22cb9-a51f-49ba-9421-228090d8dceb"
      unitRef="usd">-1700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia8cb99b7e0ae45fc98016744d8331c55_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTo0ZDIwYzVkMWQyM2Q0ZmY2OGZmYWZhZDE0MGYzNmRkYy90YWJsZXJhbmdlOjRkMjBjNWQxZDIzZDRmZjY4ZmZhZmFkMTQwZjM2ZGRjXzQtOC0xLTEtMA_74e61451-383f-43ae-8704-31ef4091deb1"
      unitRef="usd">-300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic61fb76b8e77432fb9579a89baff9f36_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTo0ZDIwYzVkMWQyM2Q0ZmY2OGZmYWZhZDE0MGYzNmRkYy90YWJsZXJhbmdlOjRkMjBjNWQxZDIzZDRmZjY4ZmZhZmFkMTQwZjM2ZGRjXzUtMi0xLTEtMA_076c40be-1c1d-4f47-86e6-afa1bdeb4ada"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5d623e1e956a426c9eb2bc18c5c9015c_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTo0ZDIwYzVkMWQyM2Q0ZmY2OGZmYWZhZDE0MGYzNmRkYy90YWJsZXJhbmdlOjRkMjBjNWQxZDIzZDRmZjY4ZmZhZmFkMTQwZjM2ZGRjXzUtNC0xLTEtMA_f50bd205-3e00-49a3-9853-7e1f80e45304"
      unitRef="usd">200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i65d9cd4367bc445dbfb50901412a5ada_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTo0ZDIwYzVkMWQyM2Q0ZmY2OGZmYWZhZDE0MGYzNmRkYy90YWJsZXJhbmdlOjRkMjBjNWQxZDIzZDRmZjY4ZmZhZmFkMTQwZjM2ZGRjXzUtNi0xLTEtMA_3c409fad-41a9-4220-8e44-2228832f4044"
      unitRef="usd">-100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic0de115d377b4cfa9b3de1dd0bfd3954_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTo0ZDIwYzVkMWQyM2Q0ZmY2OGZmYWZhZDE0MGYzNmRkYy90YWJsZXJhbmdlOjRkMjBjNWQxZDIzZDRmZjY4ZmZhZmFkMTQwZjM2ZGRjXzUtOC0xLTEtMA_181fc03d-f4ba-43b4-bded-06e28e510ae8"
      unitRef="usd">1000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if2c78ceb3d6b4fd69507a611127e10d7_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTo0ZDIwYzVkMWQyM2Q0ZmY2OGZmYWZhZDE0MGYzNmRkYy90YWJsZXJhbmdlOjRkMjBjNWQxZDIzZDRmZjY4ZmZhZmFkMTQwZjM2ZGRjXzYtMi0xLTEtMA_c5d36049-d2e1-4301-ae6c-25f953b2d848"
      unitRef="usd">-8400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1d5c287e1fde4ffdb4bdc39ad45f29d2_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTo0ZDIwYzVkMWQyM2Q0ZmY2OGZmYWZhZDE0MGYzNmRkYy90YWJsZXJhbmdlOjRkMjBjNWQxZDIzZDRmZjY4ZmZhZmFkMTQwZjM2ZGRjXzYtNC0xLTEtMA_20932bbf-1eef-46c3-9f75-d3217f3d2505"
      unitRef="usd">-1100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i94ecbbbd615e4be087860504badd0ccd_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTo0ZDIwYzVkMWQyM2Q0ZmY2OGZmYWZhZDE0MGYzNmRkYy90YWJsZXJhbmdlOjRkMjBjNWQxZDIzZDRmZjY4ZmZhZmFkMTQwZjM2ZGRjXzYtNi0xLTEtMA_08091563-4945-4eee-a027-e6d3722a485b"
      unitRef="usd">4000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic2ec445a7fb2422f8f336348f12e3320_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTo0ZDIwYzVkMWQyM2Q0ZmY2OGZmYWZhZDE0MGYzNmRkYy90YWJsZXJhbmdlOjRkMjBjNWQxZDIzZDRmZjY4ZmZhZmFkMTQwZjM2ZGRjXzYtOC0xLTEtMA_706fb768-a286-4c55-9c55-d4872d998d72"
      unitRef="usd">13000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ice7a7bfef4564888a80b19f37ff797b0_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTo0ZDIwYzVkMWQyM2Q0ZmY2OGZmYWZhZDE0MGYzNmRkYy90YWJsZXJhbmdlOjRkMjBjNWQxZDIzZDRmZjY4ZmZhZmFkMTQwZjM2ZGRjXzctMi0xLTEtMA_30afba2f-8458-4ff4-90f8-1df6e5b59e84"
      unitRef="usd">4100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ifeaa9653fb8c46b19f65a83276d1bcde_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTo0ZDIwYzVkMWQyM2Q0ZmY2OGZmYWZhZDE0MGYzNmRkYy90YWJsZXJhbmdlOjRkMjBjNWQxZDIzZDRmZjY4ZmZhZmFkMTQwZjM2ZGRjXzctNC0xLTEtMA_36adecc6-0588-4ef2-b2f8-b2011e1722f9"
      unitRef="usd">1300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6602e12ee323468e9711c40286f62de7_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTo0ZDIwYzVkMWQyM2Q0ZmY2OGZmYWZhZDE0MGYzNmRkYy90YWJsZXJhbmdlOjRkMjBjNWQxZDIzZDRmZjY4ZmZhZmFkMTQwZjM2ZGRjXzctNi0xLTEtMA_f9f7759a-4e3b-4d69-b89e-fa7d54c1e976"
      unitRef="usd">9000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0dbcccb9a5554bba8ddbf97064cb4c88_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTo0ZDIwYzVkMWQyM2Q0ZmY2OGZmYWZhZDE0MGYzNmRkYy90YWJsZXJhbmdlOjRkMjBjNWQxZDIzZDRmZjY4ZmZhZmFkMTQwZjM2ZGRjXzctOC0xLTEtMA_3d67cde3-08c7-49f2-849b-c6201874d1a4"
      unitRef="usd">3200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i73c8b3f596bb4630bfc6f91e336d5637_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTo0ZDIwYzVkMWQyM2Q0ZmY2OGZmYWZhZDE0MGYzNmRkYy90YWJsZXJhbmdlOjRkMjBjNWQxZDIzZDRmZjY4ZmZhZmFkMTQwZjM2ZGRjXzgtMi0xLTEtMA_adfe0019-a42b-4662-88c3-8e9bd8db87c2"
      unitRef="usd">3100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0bd41977205f4c6e822e027dc9f7178f_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTo0ZDIwYzVkMWQyM2Q0ZmY2OGZmYWZhZDE0MGYzNmRkYy90YWJsZXJhbmdlOjRkMjBjNWQxZDIzZDRmZjY4ZmZhZmFkMTQwZjM2ZGRjXzgtNC0xLTEtMA_ec0307c4-3f58-45f1-a5b5-d4a7d421a883"
      unitRef="usd">1700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i8c21b1e012c34659a43ce91c598b6e19_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTo0ZDIwYzVkMWQyM2Q0ZmY2OGZmYWZhZDE0MGYzNmRkYy90YWJsZXJhbmdlOjRkMjBjNWQxZDIzZDRmZjY4ZmZhZmFkMTQwZjM2ZGRjXzgtNi0xLTEtMA_1523f3db-4ebf-4fcc-a943-b736feec9653"
      unitRef="usd">11000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id073fd8d3b31491aacf37c244aa1d475_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTo0ZDIwYzVkMWQyM2Q0ZmY2OGZmYWZhZDE0MGYzNmRkYy90YWJsZXJhbmdlOjRkMjBjNWQxZDIzZDRmZjY4ZmZhZmFkMTQwZjM2ZGRjXzgtOC0xLTEtMA_32131a42-55d6-432e-9da1-2569df8e1f05"
      unitRef="usd">9700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized
      contextRef="i83240f344bc5485bb5ee15a465ba0ad3_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTo0ZDIwYzVkMWQyM2Q0ZmY2OGZmYWZhZDE0MGYzNmRkYy90YWJsZXJhbmdlOjRkMjBjNWQxZDIzZDRmZjY4ZmZhZmFkMTQwZjM2ZGRjXzktMi0xLTEtMA_03589060-9120-4875-bd27-0fff0f79e7f8"
      unitRef="usd">0</us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized>
    <us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized
      contextRef="id6c80504460b4030869aa8a24e3babf4_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTo0ZDIwYzVkMWQyM2Q0ZmY2OGZmYWZhZDE0MGYzNmRkYy90YWJsZXJhbmdlOjRkMjBjNWQxZDIzZDRmZjY4ZmZhZmFkMTQwZjM2ZGRjXzktNC0xLTEtMA_2c6835fc-c635-4ab1-800d-202751b221c6"
      unitRef="usd">0</us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized>
    <us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized
      contextRef="i5c634f032c59460488c598097bac861e_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTo0ZDIwYzVkMWQyM2Q0ZmY2OGZmYWZhZDE0MGYzNmRkYy90YWJsZXJhbmdlOjRkMjBjNWQxZDIzZDRmZjY4ZmZhZmFkMTQwZjM2ZGRjXzktNi0xLTEtMA_2ef3bb81-0444-4776-8110-df34e356c5eb"
      unitRef="usd">0</us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized>
    <us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized
      contextRef="i82c5ee63475c42b9be7685ee220cdbde_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTo0ZDIwYzVkMWQyM2Q0ZmY2OGZmYWZhZDE0MGYzNmRkYy90YWJsZXJhbmdlOjRkMjBjNWQxZDIzZDRmZjY4ZmZhZmFkMTQwZjM2ZGRjXzktOC0xLTEtMA_bfeff8cb-7c8e-45ba-b736-04139bc82673"
      unitRef="usd">26200000</us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTo0ZDIwYzVkMWQyM2Q0ZmY2OGZmYWZhZDE0MGYzNmRkYy90YWJsZXJhbmdlOjRkMjBjNWQxZDIzZDRmZjY4ZmZhZmFkMTQwZjM2ZGRjXzEwLTItMS0xLTA_b24ead94-f03e-4a5c-9163-454fb685f538"
      unitRef="usd">39600000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTo0ZDIwYzVkMWQyM2Q0ZmY2OGZmYWZhZDE0MGYzNmRkYy90YWJsZXJhbmdlOjRkMjBjNWQxZDIzZDRmZjY4ZmZhZmFkMTQwZjM2ZGRjXzEwLTQtMS0xLTA_f20e9640-fb29-403c-8471-c6f4d212c248"
      unitRef="usd">49600000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTo0ZDIwYzVkMWQyM2Q0ZmY2OGZmYWZhZDE0MGYzNmRkYy90YWJsZXJhbmdlOjRkMjBjNWQxZDIzZDRmZjY4ZmZhZmFkMTQwZjM2ZGRjXzEwLTYtMS0xLTA_788f3a25-bac4-4644-97de-0d0f94899877"
      unitRef="usd">161500000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTo0ZDIwYzVkMWQyM2Q0ZmY2OGZmYWZhZDE0MGYzNmRkYy90YWJsZXJhbmdlOjRkMjBjNWQxZDIzZDRmZjY4ZmZhZmFkMTQwZjM2ZGRjXzEwLTgtMS0xLTA_5e35db3c-5bbe-4f10-8023-22a8f69ddc05"
      unitRef="usd">182000000.0</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTo0ZDIwYzVkMWQyM2Q0ZmY2OGZmYWZhZDE0MGYzNmRkYy90YWJsZXJhbmdlOjRkMjBjNWQxZDIzZDRmZjY4ZmZhZmFkMTQwZjM2ZGRjXzExLTItMS0xLTA_645eda68-8d43-47ce-a9dd-5623c5a3737d"
      unitRef="usd">1900000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTo0ZDIwYzVkMWQyM2Q0ZmY2OGZmYWZhZDE0MGYzNmRkYy90YWJsZXJhbmdlOjRkMjBjNWQxZDIzZDRmZjY4ZmZhZmFkMTQwZjM2ZGRjXzExLTQtMS0xLTA_634282ab-216d-464f-aac5-9aa6b793430d"
      unitRef="usd">1700000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTo0ZDIwYzVkMWQyM2Q0ZmY2OGZmYWZhZDE0MGYzNmRkYy90YWJsZXJhbmdlOjRkMjBjNWQxZDIzZDRmZjY4ZmZhZmFkMTQwZjM2ZGRjXzExLTYtMS0xLTA_d345cc92-3e48-4d66-a8bc-5753de15ee2b"
      unitRef="usd">4900000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTo0ZDIwYzVkMWQyM2Q0ZmY2OGZmYWZhZDE0MGYzNmRkYy90YWJsZXJhbmdlOjRkMjBjNWQxZDIzZDRmZjY4ZmZhZmFkMTQwZjM2ZGRjXzExLTgtMS0xLTA_757e142f-e1c2-4c49-a753-db0207ac5f39"
      unitRef="usd">7800000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses
      contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTo0ZDIwYzVkMWQyM2Q0ZmY2OGZmYWZhZDE0MGYzNmRkYy90YWJsZXJhbmdlOjRkMjBjNWQxZDIzZDRmZjY4ZmZhZmFkMTQwZjM2ZGRjXzEyLTItMS0xLTA_6d4ec91b-0800-4533-b983-625ca1017d43"
      unitRef="usd">37700000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
    <biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses
      contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTo0ZDIwYzVkMWQyM2Q0ZmY2OGZmYWZhZDE0MGYzNmRkYy90YWJsZXJhbmdlOjRkMjBjNWQxZDIzZDRmZjY4ZmZhZmFkMTQwZjM2ZGRjXzEyLTQtMS0xLTA_8aba01c6-b18c-4ea8-8bd5-88cc41c03f9f"
      unitRef="usd">47900000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
    <biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTo0ZDIwYzVkMWQyM2Q0ZmY2OGZmYWZhZDE0MGYzNmRkYy90YWJsZXJhbmdlOjRkMjBjNWQxZDIzZDRmZjY4ZmZhZmFkMTQwZjM2ZGRjXzEyLTYtMS0xLTA_2ecbd806-915a-4ea2-bcd0-6dee541b05ca"
      unitRef="usd">156600000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
    <biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDAvZnJhZzoyZmE0NDRhNDExZWU0YTY0YTY1MjlkMThlM2M3ZDVmOC90YWJsZTo0ZDIwYzVkMWQyM2Q0ZmY2OGZmYWZhZDE0MGYzNmRkYy90YWJsZXJhbmdlOjRkMjBjNWQxZDIzZDRmZjY4ZmZhZmFkMTQwZjM2ZGRjXzEyLTgtMS0xLTA_6fbc337b-93f4-4b64-a9f9-7a8bde318d35"
      unitRef="usd">174200000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90ZXh0cmVnaW9uOjBjNWQ3YWE1NzU0MjRmYWViNjE3OWFjMDU1ZWQ5NzAyXzYyNjI_88efb90a-166b-4021-a6f7-cf364272027c">&lt;div style="text-indent:11.25pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Coronavirus Aid, Relief and Economic Security Act&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;In response to the COVID-19 pandemic, the Coronavirus Aid, Relief and Economic Security Act (CARES Act) was signed into law in the U.S. in March 2020. The CARES Act adjusted a number of provisions of the tax code, including the calculation and eligibility of certain deductions and the treatment of net operating losses and tax credits. The enactment of the CARES Act did not result in any material adjustments to our income tax provision for the three and nine months ended September 30, 2020, or to our net deferred tax assets as of September 30, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:11.25pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;TECFIDERA&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In June 2020 and September 2020 judgments were entered in favor of the defendants in the patent infringement proceedings relating to TECFIDERA Orange-Book listed patents pursuant to the Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch-Waxman Act, in West Virginia and Delaware. We have appealed the judgments in both actions. For additional information, please read &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Note 19, Litigation,&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Multiple TECFIDERA generic entrants are now in the U.S. market, some of which have deeply discounted prices compared to TECFIDERA. The generic competition for TECFIDERA significantly reduced our TECFIDERA revenues during the third quarter of 2020 and is expected to have a substantial negative impact on our TECFIDERA revenues for as long as there is generic competition.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As of September 30, 2020, we have assessed the realizability of our deferred tax assets that are dependent on future expected sales of TECFIDERA in the U.S. and reduced the value of certain deferred tax assets by approximately $1,627.9 million and reduced the value of deferred tax liabilities associated with global intangible low-taxed income (GILTI) and tax credits by approximately $1,538.6 million. For the three and nine months ended September 30, 2020, the income tax expense associated with these reductions was approximately $33.3 million and $89.3&#160;million, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:11.25pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Tax Rate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;A reconciliation between the U.S.&#160;federal statutory tax rate and our effective tax rate is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:44.514%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.350%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.350%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.619%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.623%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;State taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Taxes on foreign earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(3.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(5.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(3.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(4.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(2.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Purchased intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Divestiture of Denmark manufacturing operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Internal reorganization of certain intellectual property rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;TECFIDERA impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;GILTI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Swiss tax reform&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&lt;/span&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(3.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&lt;/span&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other permanent items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Effective tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;25.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;20.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;16.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:13.5pt;margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#00823b;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Changes in Tax Rate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;For the three months ended September 30, 2020, compared to the same period in 2019, the increase in our effective tax rate was primarily due to an internal reorganization of certain intellectual property rights related to the intercompany sale of such intellectual property in 2019, the enactment of a new taxing regime in the country and certain cantons of Switzerland in 2019 (Swiss Tax Reform) and the net $33.3 million income tax expense related to the establishment of a valuation allowance against certain deferred tax assets, the realization of which is dependent on future sales of TECFIDERA in the U.S., as discussed above. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;For the nine months ended September 30, 2020, compared to the same period in 2019, the increase in our effective tax rate was primarily due to the $89.3 million impact from the valuation allowance described above, the internal reorganization of certain intellectual property rights and Swiss Tax Reform, partially offset by the $64.7 million tax expense recognized in September 30, 2019, related to the divestiture of our Hiller&#xf8;d, Denmark manufacturing operations. Although we recognized a loss on the divestiture of our Hiller&#xf8;d, Denmark manufacturing operations, the divestiture required us to write off certain deferred tax assets and resulted in a taxable gain in certain jurisdictions. For additional information on the divestiture of our Hiller&#xf8;d, Denmark manufacturing operations, please read &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Note 3, Divestitures,&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; to our condensed consolidated financial statements included in this report.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As a result of the internal reorganization of certain intellectual property rights, we recorded a deferred tax asset of $754.2 million and a deferred tax liability of $603.4 million as of September 30, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:11.25pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Accounting for Uncertainty in Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We and our subsidiaries are routinely examined by various taxing authorities. We file income tax returns in various U.S. states and in U.S. federal and other foreign jurisdictions. With few exceptions, we are no longer subject to U.S. federal tax examination for years before 2013 or state, local or non-U.S. income tax examinations for years before 2012.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The U.S. Internal Revenue Service and other national tax authorities routinely examine our intercompany transfer pricing with respect to intellectual property related transactions and it is possible that they may disagree with one or more positions we have taken with respect to such valuations.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;It is reasonably possible that we will adjust the value of our uncertain tax positions related to certain transfer pricing, collaboration matters and other issues as we receive additional information from various taxing authorities, including reaching settlements with such authorities.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We estimate that it is reasonably possible that our gross unrecognized tax benefits, exclusive of interest, could decrease by up to approximately $75.0 million in the next 12 months as a result of various audit closures, settlements and expiration of the statute of limitations.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <biib:DeferredTaxAssetsValueReductioninValue
      contextRef="i14dd3353e0b54676b5186391520f2af5_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90ZXh0cmVnaW9uOjBjNWQ3YWE1NzU0MjRmYWViNjE3OWFjMDU1ZWQ5NzAyXzI5OTY_653ede91-bb7a-48ae-9af7-cf98fcbe8342"
      unitRef="usd">1627900000</biib:DeferredTaxAssetsValueReductioninValue>
    <biib:DeferredTaxLiabilitiesValueReductioninValue
      contextRef="i14dd3353e0b54676b5186391520f2af5_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90ZXh0cmVnaW9uOjBjNWQ3YWE1NzU0MjRmYWViNjE3OWFjMDU1ZWQ5NzAyXzMxNDE_d1a66525-03de-404d-b83e-4a8d3609e1dc"
      unitRef="usd">1538600000</biib:DeferredTaxLiabilitiesValueReductioninValue>
    <biib:IncomeTaxExpenseReductioninDeferredTaxAssetsandLiabilitiesNet
      contextRef="i289872ca5f294cb881aceaa6ffd07da1_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90ZXh0cmVnaW9uOjBjNWQ3YWE1NzU0MjRmYWViNjE3OWFjMDU1ZWQ5NzAyXzMyNTQ_e88f8798-ce36-4c2d-b481-c3871d70a7c3"
      unitRef="usd">33300000</biib:IncomeTaxExpenseReductioninDeferredTaxAssetsandLiabilitiesNet>
    <biib:IncomeTaxExpenseReductioninDeferredTaxAssetsandLiabilitiesNet
      contextRef="i1cf49fa7c600408b8cf5254dbc554986_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90ZXh0cmVnaW9uOjBjNWQ3YWE1NzU0MjRmYWViNjE3OWFjMDU1ZWQ5NzAyXzEwOTk1MTE2MzQxMTU_81bf64d4-83bc-4c27-aba1-fc39f87a1ced"
      unitRef="usd">89300000</biib:IncomeTaxExpenseReductioninDeferredTaxAssetsandLiabilitiesNet>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90ZXh0cmVnaW9uOjBjNWQ3YWE1NzU0MjRmYWViNjE3OWFjMDU1ZWQ5NzAyXzYyNjA_4fa41597-2b76-446a-80df-a68bfd254bba">&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;A reconciliation between the U.S.&#160;federal statutory tax rate and our effective tax rate is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:44.514%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.350%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.350%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.619%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.623%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;State taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Taxes on foreign earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(3.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(5.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(3.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(4.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(2.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Purchased intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Divestiture of Denmark manufacturing operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Internal reorganization of certain intellectual property rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;TECFIDERA impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;GILTI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Swiss tax reform&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&lt;/span&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(3.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&lt;/span&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other permanent items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Effective tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;25.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;20.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;16.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90YWJsZTo3YTA2MzIyNzBmMzM0ZjYzODNhNTZiZWNkMzE1ZmJjZS90YWJsZXJhbmdlOjdhMDYzMjI3MGYzMzRmNjM4M2E1NmJlY2QzMTVmYmNlXzItMS0xLTEtMA_74d7cedf-a87d-4fa1-b2ab-a0f0b1b1c8c2"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90YWJsZTo3YTA2MzIyNzBmMzM0ZjYzODNhNTZiZWNkMzE1ZmJjZS90YWJsZXJhbmdlOjdhMDYzMjI3MGYzMzRmNjM4M2E1NmJlY2QzMTVmYmNlXzItMy0xLTEtMA_3a9e8f1d-acf9-435d-835c-3824815ffd17"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90YWJsZTo3YTA2MzIyNzBmMzM0ZjYzODNhNTZiZWNkMzE1ZmJjZS90YWJsZXJhbmdlOjdhMDYzMjI3MGYzMzRmNjM4M2E1NmJlY2QzMTVmYmNlXzItNS0xLTEtMA_fc19ddae-d4a2-43ed-ac48-770e3c067bfb"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90YWJsZTo3YTA2MzIyNzBmMzM0ZjYzODNhNTZiZWNkMzE1ZmJjZS90YWJsZXJhbmdlOjdhMDYzMjI3MGYzMzRmNjM4M2E1NmJlY2QzMTVmYmNlXzItNy0xLTEtMA_5a60f451-230a-4bfe-937b-eecd2722064a"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90YWJsZTo3YTA2MzIyNzBmMzM0ZjYzODNhNTZiZWNkMzE1ZmJjZS90YWJsZXJhbmdlOjdhMDYzMjI3MGYzMzRmNjM4M2E1NmJlY2QzMTVmYmNlXzMtMS0xLTEtMA_4474e265-eac0-4d2c-bb82-c17ad8ec6bea"
      unitRef="number">0.009</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90YWJsZTo3YTA2MzIyNzBmMzM0ZjYzODNhNTZiZWNkMzE1ZmJjZS90YWJsZXJhbmdlOjdhMDYzMjI3MGYzMzRmNjM4M2E1NmJlY2QzMTVmYmNlXzMtMy0xLTEtMA_8be6bf49-a357-4290-95e1-635cd8531257"
      unitRef="number">0.009</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90YWJsZTo3YTA2MzIyNzBmMzM0ZjYzODNhNTZiZWNkMzE1ZmJjZS90YWJsZXJhbmdlOjdhMDYzMjI3MGYzMzRmNjM4M2E1NmJlY2QzMTVmYmNlXzMtNS0xLTEtMA_72533fc5-df28-4bd7-9a93-47568bbe1df4"
      unitRef="number">0.006</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90YWJsZTo3YTA2MzIyNzBmMzM0ZjYzODNhNTZiZWNkMzE1ZmJjZS90YWJsZXJhbmdlOjdhMDYzMjI3MGYzMzRmNjM4M2E1NmJlY2QzMTVmYmNlXzMtNy0xLTEtMA_c0eaad23-50e6-441c-b4f0-3729d8a454b6"
      unitRef="number">0.007</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90YWJsZTo3YTA2MzIyNzBmMzM0ZjYzODNhNTZiZWNkMzE1ZmJjZS90YWJsZXJhbmdlOjdhMDYzMjI3MGYzMzRmNjM4M2E1NmJlY2QzMTVmYmNlXzQtMS0xLTEtMA_8e70ad3f-11c7-4b9e-8ca7-ebd0ddfd673c"
      unitRef="number">-0.030</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90YWJsZTo3YTA2MzIyNzBmMzM0ZjYzODNhNTZiZWNkMzE1ZmJjZS90YWJsZXJhbmdlOjdhMDYzMjI3MGYzMzRmNjM4M2E1NmJlY2QzMTVmYmNlXzQtMy0xLTEtMA_97d0a73a-e0bf-46e0-818e-697536e4d8fd"
      unitRef="number">-0.050</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90YWJsZTo3YTA2MzIyNzBmMzM0ZjYzODNhNTZiZWNkMzE1ZmJjZS90YWJsZXJhbmdlOjdhMDYzMjI3MGYzMzRmNjM4M2E1NmJlY2QzMTVmYmNlXzQtNS0xLTEtMA_4bcaa2ea-d916-47c4-a5eb-f29d2b745732"
      unitRef="number">-0.036</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90YWJsZTo3YTA2MzIyNzBmMzM0ZjYzODNhNTZiZWNkMzE1ZmJjZS90YWJsZXJhbmdlOjdhMDYzMjI3MGYzMzRmNjM4M2E1NmJlY2QzMTVmYmNlXzQtNy0xLTEtMA_e4075ca0-c15f-447f-aafc-f6a23960f6b2"
      unitRef="number">-0.047</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90YWJsZTo3YTA2MzIyNzBmMzM0ZjYzODNhNTZiZWNkMzE1ZmJjZS90YWJsZXJhbmdlOjdhMDYzMjI3MGYzMzRmNjM4M2E1NmJlY2QzMTVmYmNlXzUtMS0xLTEtMA_3d463eff-4e87-4afd-ac50-ce20f661923a"
      unitRef="number">0.023</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90YWJsZTo3YTA2MzIyNzBmMzM0ZjYzODNhNTZiZWNkMzE1ZmJjZS90YWJsZXJhbmdlOjdhMDYzMjI3MGYzMzRmNjM4M2E1NmJlY2QzMTVmYmNlXzUtMy0xLTEtMA_ac8746d0-e340-45e6-a829-24c95430f8a4"
      unitRef="number">0.015</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90YWJsZTo3YTA2MzIyNzBmMzM0ZjYzODNhNTZiZWNkMzE1ZmJjZS90YWJsZXJhbmdlOjdhMDYzMjI3MGYzMzRmNjM4M2E1NmJlY2QzMTVmYmNlXzUtNS0xLTEtMA_7c428ca1-2374-446e-b38a-ca4469cd944d"
      unitRef="number">0.013</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90YWJsZTo3YTA2MzIyNzBmMzM0ZjYzODNhNTZiZWNkMzE1ZmJjZS90YWJsZXJhbmdlOjdhMDYzMjI3MGYzMzRmNjM4M2E1NmJlY2QzMTVmYmNlXzUtNy0xLTEtMA_51e12d19-576d-46e5-8067-541da65077fe"
      unitRef="number">0.010</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization
      contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90YWJsZTo3YTA2MzIyNzBmMzM0ZjYzODNhNTZiZWNkMzE1ZmJjZS90YWJsZXJhbmdlOjdhMDYzMjI3MGYzMzRmNjM4M2E1NmJlY2QzMTVmYmNlXzYtMS0xLTEtMA_31706572-8439-4c37-9128-22449b7bd3f4"
      unitRef="number">0.029</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization
      contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90YWJsZTo3YTA2MzIyNzBmMzM0ZjYzODNhNTZiZWNkMzE1ZmJjZS90YWJsZXJhbmdlOjdhMDYzMjI3MGYzMzRmNjM4M2E1NmJlY2QzMTVmYmNlXzYtMy0xLTEtMA_00d1369a-d2f4-400a-8242-896332fe33a2"
      unitRef="number">0.004</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90YWJsZTo3YTA2MzIyNzBmMzM0ZjYzODNhNTZiZWNkMzE1ZmJjZS90YWJsZXJhbmdlOjdhMDYzMjI3MGYzMzRmNjM4M2E1NmJlY2QzMTVmYmNlXzYtNS0xLTEtMA_5cba32bd-4cbb-454e-91ed-0448f2459e93"
      unitRef="number">0.008</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90YWJsZTo3YTA2MzIyNzBmMzM0ZjYzODNhNTZiZWNkMzE1ZmJjZS90YWJsZXJhbmdlOjdhMDYzMjI3MGYzMzRmNjM4M2E1NmJlY2QzMTVmYmNlXzYtNy0xLTEtMA_543bd5a5-109a-40f5-ba69-691116878d9d"
      unitRef="number">0.004</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfAssets
      contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90YWJsZTo3YTA2MzIyNzBmMzM0ZjYzODNhNTZiZWNkMzE1ZmJjZS90YWJsZXJhbmdlOjdhMDYzMjI3MGYzMzRmNjM4M2E1NmJlY2QzMTVmYmNlXzctMS0xLTEtMA_9132b89b-308a-4783-9b4b-7a2f1c057566"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfAssets>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfAssets
      contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90YWJsZTo3YTA2MzIyNzBmMzM0ZjYzODNhNTZiZWNkMzE1ZmJjZS90YWJsZXJhbmdlOjdhMDYzMjI3MGYzMzRmNjM4M2E1NmJlY2QzMTVmYmNlXzctMy0xLTEtMA_d9f8108b-de5e-4bfc-a58d-c5363733d9be"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfAssets>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfAssets
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90YWJsZTo3YTA2MzIyNzBmMzM0ZjYzODNhNTZiZWNkMzE1ZmJjZS90YWJsZXJhbmdlOjdhMDYzMjI3MGYzMzRmNjM4M2E1NmJlY2QzMTVmYmNlXzctNS0xLTEtMA_aaf08030-b50e-4090-a36a-bac9b70465bf"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfAssets>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfAssets
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90YWJsZTo3YTA2MzIyNzBmMzM0ZjYzODNhNTZiZWNkMzE1ZmJjZS90YWJsZXJhbmdlOjdhMDYzMjI3MGYzMzRmNjM4M2E1NmJlY2QzMTVmYmNlXzctNy0xLTEtMA_f9dbc529-83b4-4c42-955a-6b7fa80f57cc"
      unitRef="number">0.015</us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfAssets>
    <biib:EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization
      contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90YWJsZTo3YTA2MzIyNzBmMzM0ZjYzODNhNTZiZWNkMzE1ZmJjZS90YWJsZXJhbmdlOjdhMDYzMjI3MGYzMzRmNjM4M2E1NmJlY2QzMTVmYmNlXzgtMS0xLTEtMA_84202e1a-8762-4029-807c-b65784c3d591"
      unitRef="number">0</biib:EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization>
    <biib:EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization
      contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90YWJsZTo3YTA2MzIyNzBmMzM0ZjYzODNhNTZiZWNkMzE1ZmJjZS90YWJsZXJhbmdlOjdhMDYzMjI3MGYzMzRmNjM4M2E1NmJlY2QzMTVmYmNlXzgtMy0xLTEtMA_5bfe5c9a-7dd0-4edc-88ac-fe0317f140b0"
      unitRef="number">-0.015</biib:EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization>
    <biib:EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90YWJsZTo3YTA2MzIyNzBmMzM0ZjYzODNhNTZiZWNkMzE1ZmJjZS90YWJsZXJhbmdlOjdhMDYzMjI3MGYzMzRmNjM4M2E1NmJlY2QzMTVmYmNlXzgtNS0xLTEtMA_a83b62e7-c14e-4e73-bb7d-6bad3fe9727d"
      unitRef="number">0</biib:EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization>
    <biib:EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90YWJsZTo3YTA2MzIyNzBmMzM0ZjYzODNhNTZiZWNkMzE1ZmJjZS90YWJsZXJhbmdlOjdhMDYzMjI3MGYzMzRmNjM4M2E1NmJlY2QzMTVmYmNlXzgtNy0xLTEtMA_d8d60ddb-c97c-4b4a-977c-901ed00235b3"
      unitRef="number">-0.021</biib:EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses
      contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90YWJsZTo3YTA2MzIyNzBmMzM0ZjYzODNhNTZiZWNkMzE1ZmJjZS90YWJsZXJhbmdlOjdhMDYzMjI3MGYzMzRmNjM4M2E1NmJlY2QzMTVmYmNlXzktMS0xLTEtMA_e90a447d-3066-43a1-91eb-0babc1ddf610"
      unitRef="number">0.035</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses
      contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90YWJsZTo3YTA2MzIyNzBmMzM0ZjYzODNhNTZiZWNkMzE1ZmJjZS90YWJsZXJhbmdlOjdhMDYzMjI3MGYzMzRmNjM4M2E1NmJlY2QzMTVmYmNlXzktMy0xLTEtMA_8b7ba34a-0f20-4ea1-a4c9-494f013aac1b"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90YWJsZTo3YTA2MzIyNzBmMzM0ZjYzODNhNTZiZWNkMzE1ZmJjZS90YWJsZXJhbmdlOjdhMDYzMjI3MGYzMzRmNjM4M2E1NmJlY2QzMTVmYmNlXzktNS0xLTEtMA_b058a21d-9c9c-4103-818a-e9531f437d26"
      unitRef="number">0.019</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90YWJsZTo3YTA2MzIyNzBmMzM0ZjYzODNhNTZiZWNkMzE1ZmJjZS90YWJsZXJhbmdlOjdhMDYzMjI3MGYzMzRmNjM4M2E1NmJlY2QzMTVmYmNlXzktNy0xLTEtMA_54a53d6d-9178-4e15-a5ed-7f7bb82a4118"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses>
    <biib:EffectiveTaxRateReconciliationGILTItax
      contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90YWJsZTo3YTA2MzIyNzBmMzM0ZjYzODNhNTZiZWNkMzE1ZmJjZS90YWJsZXJhbmdlOjdhMDYzMjI3MGYzMzRmNjM4M2E1NmJlY2QzMTVmYmNlXzEwLTEtMS0xLTA_38821726-80be-4119-816b-7fde48044538"
      unitRef="number">0.022</biib:EffectiveTaxRateReconciliationGILTItax>
    <biib:EffectiveTaxRateReconciliationGILTItax
      contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90YWJsZTo3YTA2MzIyNzBmMzM0ZjYzODNhNTZiZWNkMzE1ZmJjZS90YWJsZXJhbmdlOjdhMDYzMjI3MGYzMzRmNjM4M2E1NmJlY2QzMTVmYmNlXzEwLTMtMS0xLTA_aa83301e-7e46-48ca-840d-a21d9c001f8b"
      unitRef="number">0.016</biib:EffectiveTaxRateReconciliationGILTItax>
    <biib:EffectiveTaxRateReconciliationGILTItax
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90YWJsZTo3YTA2MzIyNzBmMzM0ZjYzODNhNTZiZWNkMzE1ZmJjZS90YWJsZXJhbmdlOjdhMDYzMjI3MGYzMzRmNjM4M2E1NmJlY2QzMTVmYmNlXzEwLTUtMS0xLTA_5a186196-8630-4051-96ab-bbaae38422c5"
      unitRef="number">0.013</biib:EffectiveTaxRateReconciliationGILTItax>
    <biib:EffectiveTaxRateReconciliationGILTItax
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90YWJsZTo3YTA2MzIyNzBmMzM0ZjYzODNhNTZiZWNkMzE1ZmJjZS90YWJsZXJhbmdlOjdhMDYzMjI3MGYzMzRmNjM4M2E1NmJlY2QzMTVmYmNlXzEwLTctMS0xLTA_85c7cb81-7998-41db-b4f0-8f03d5f12722"
      unitRef="number">0.016</biib:EffectiveTaxRateReconciliationGILTItax>
    <biib:EffectiveIncomeTaxRateReconciliationChangeInForeignTaxRatePercent
      contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90YWJsZTo3YTA2MzIyNzBmMzM0ZjYzODNhNTZiZWNkMzE1ZmJjZS90YWJsZXJhbmdlOjdhMDYzMjI3MGYzMzRmNjM4M2E1NmJlY2QzMTVmYmNlXzEyLTEtMS0xLTA_c11a1763-b3e7-4494-82bc-0e2f274e2b63"
      unitRef="number">0</biib:EffectiveIncomeTaxRateReconciliationChangeInForeignTaxRatePercent>
    <biib:EffectiveIncomeTaxRateReconciliationChangeInForeignTaxRatePercent
      contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90YWJsZTo3YTA2MzIyNzBmMzM0ZjYzODNhNTZiZWNkMzE1ZmJjZS90YWJsZXJhbmdlOjdhMDYzMjI3MGYzMzRmNjM4M2E1NmJlY2QzMTVmYmNlXzEyLTMtMS0xLTA_2c34e3bb-55d4-40ab-a17f-4f91c233edb8"
      unitRef="number">-0.031</biib:EffectiveIncomeTaxRateReconciliationChangeInForeignTaxRatePercent>
    <biib:EffectiveIncomeTaxRateReconciliationChangeInForeignTaxRatePercent
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90YWJsZTo3YTA2MzIyNzBmMzM0ZjYzODNhNTZiZWNkMzE1ZmJjZS90YWJsZXJhbmdlOjdhMDYzMjI3MGYzMzRmNjM4M2E1NmJlY2QzMTVmYmNlXzEyLTUtMS0xLTA_f39aee3e-5656-4d84-a274-cf0da3330350"
      unitRef="number">0</biib:EffectiveIncomeTaxRateReconciliationChangeInForeignTaxRatePercent>
    <biib:EffectiveIncomeTaxRateReconciliationChangeInForeignTaxRatePercent
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90YWJsZTo3YTA2MzIyNzBmMzM0ZjYzODNhNTZiZWNkMzE1ZmJjZS90YWJsZXJhbmdlOjdhMDYzMjI3MGYzMzRmNjM4M2E1NmJlY2QzMTVmYmNlXzEyLTctMS0xLTA_f1202452-163d-4706-80b2-7e873e691366"
      unitRef="number">-0.010</biib:EffectiveIncomeTaxRateReconciliationChangeInForeignTaxRatePercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
      contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90YWJsZTo3YTA2MzIyNzBmMzM0ZjYzODNhNTZiZWNkMzE1ZmJjZS90YWJsZXJhbmdlOjdhMDYzMjI3MGYzMzRmNjM4M2E1NmJlY2QzMTVmYmNlXzEzLTEtMS0xLTA_92753fdc-2ea0-46f3-934a-eef13667c0fb"
      unitRef="number">-0.006</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
      contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90YWJsZTo3YTA2MzIyNzBmMzM0ZjYzODNhNTZiZWNkMzE1ZmJjZS90YWJsZXJhbmdlOjdhMDYzMjI3MGYzMzRmNjM4M2E1NmJlY2QzMTVmYmNlXzEzLTMtMS0xLTA_075126f9-3c36-46a8-aee8-4b997f738d30"
      unitRef="number">-0.001</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90YWJsZTo3YTA2MzIyNzBmMzM0ZjYzODNhNTZiZWNkMzE1ZmJjZS90YWJsZXJhbmdlOjdhMDYzMjI3MGYzMzRmNjM4M2E1NmJlY2QzMTVmYmNlXzEzLTUtMS0xLTA_611aaa27-bd4e-45a0-9b6c-33504c9e1f9a"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90YWJsZTo3YTA2MzIyNzBmMzM0ZjYzODNhNTZiZWNkMzE1ZmJjZS90YWJsZXJhbmdlOjdhMDYzMjI3MGYzMzRmNjM4M2E1NmJlY2QzMTVmYmNlXzEzLTctMS0xLTA_d8cc623c-6f8c-4d09-b119-9076fdd5a90e"
      unitRef="number">0.002</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90YWJsZTo3YTA2MzIyNzBmMzM0ZjYzODNhNTZiZWNkMzE1ZmJjZS90YWJsZXJhbmdlOjdhMDYzMjI3MGYzMzRmNjM4M2E1NmJlY2QzMTVmYmNlXzE0LTEtMS0xLTA_93b1b9f0-1ded-4e8b-8168-aed3cf594acf"
      unitRef="number">0.005</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90YWJsZTo3YTA2MzIyNzBmMzM0ZjYzODNhNTZiZWNkMzE1ZmJjZS90YWJsZXJhbmdlOjdhMDYzMjI3MGYzMzRmNjM4M2E1NmJlY2QzMTVmYmNlXzE0LTMtMS0xLTA_b66056c1-fbd9-4ea3-8124-4f7bd3386a60"
      unitRef="number">-0.008</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90YWJsZTo3YTA2MzIyNzBmMzM0ZjYzODNhNTZiZWNkMzE1ZmJjZS90YWJsZXJhbmdlOjdhMDYzMjI3MGYzMzRmNjM4M2E1NmJlY2QzMTVmYmNlXzE0LTUtMS0xLTA_1b5c447d-6f44-4583-87db-6ee90731fca6"
      unitRef="number">0.002</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90YWJsZTo3YTA2MzIyNzBmMzM0ZjYzODNhNTZiZWNkMzE1ZmJjZS90YWJsZXJhbmdlOjdhMDYzMjI3MGYzMzRmNjM4M2E1NmJlY2QzMTVmYmNlXzE0LTctMS0xLTA_56d88a76-300b-4033-ba4f-3abef9be02f7"
      unitRef="number">-0.003</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90YWJsZTo3YTA2MzIyNzBmMzM0ZjYzODNhNTZiZWNkMzE1ZmJjZS90YWJsZXJhbmdlOjdhMDYzMjI3MGYzMzRmNjM4M2E1NmJlY2QzMTVmYmNlXzE1LTEtMS0xLTA_ababdb8e-bd7d-49e8-87bc-19b5b3abae6b"
      unitRef="number">0.251</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90YWJsZTo3YTA2MzIyNzBmMzM0ZjYzODNhNTZiZWNkMzE1ZmJjZS90YWJsZXJhbmdlOjdhMDYzMjI3MGYzMzRmNjM4M2E1NmJlY2QzMTVmYmNlXzE1LTMtMS0xLTA_1078ed61-9cdc-420b-bd2b-32367d8fa832"
      unitRef="number">0.119</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90YWJsZTo3YTA2MzIyNzBmMzM0ZjYzODNhNTZiZWNkMzE1ZmJjZS90YWJsZXJhbmdlOjdhMDYzMjI3MGYzMzRmNjM4M2E1NmJlY2QzMTVmYmNlXzE1LTUtMS0xLTA_9714196c-0684-4028-8c2e-2b800245300d"
      unitRef="number">0.209</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90YWJsZTo3YTA2MzIyNzBmMzM0ZjYzODNhNTZiZWNkMzE1ZmJjZS90YWJsZXJhbmdlOjdhMDYzMjI3MGYzMzRmNjM4M2E1NmJlY2QzMTVmYmNlXzE1LTctMS0xLTA_c5586ad5-9e3b-44ab-9394-52d7ec6a806e"
      unitRef="number">0.163</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <biib:IncomeTaxExpenseReductioninDeferredTaxAssetsandLiabilitiesNet
      contextRef="i289872ca5f294cb881aceaa6ffd07da1_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90ZXh0cmVnaW9uOjBjNWQ3YWE1NzU0MjRmYWViNjE3OWFjMDU1ZWQ5NzAyXzM3Njk_e88f8798-ce36-4c2d-b481-c3871d70a7c3"
      unitRef="usd">33300000</biib:IncomeTaxExpenseReductioninDeferredTaxAssetsandLiabilitiesNet>
    <us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation
      contextRef="i5d5bdbbfb1724d7b86e0b6e3ff288ee3_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90ZXh0cmVnaW9uOjBjNWQ3YWE1NzU0MjRmYWViNjE3OWFjMDU1ZWQ5NzAyXzQyNTg_5acf012c-0386-4f7a-a378-4f8a9ba297bf"
      unitRef="usd">64700000</us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="ied38b94db9a74750b51c6e8392d4c5bf_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90ZXh0cmVnaW9uOjBjNWQ3YWE1NzU0MjRmYWViNjE3OWFjMDU1ZWQ5NzAyXzQ3MjM_a71043ae-1af6-4ff4-bcb4-dbeaa1c876e3"
      unitRef="usd">754200000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="ied38b94db9a74750b51c6e8392d4c5bf_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90ZXh0cmVnaW9uOjBjNWQ3YWE1NzU0MjRmYWViNjE3OWFjMDU1ZWQ5NzAyXzQ3NTg_a910f3c6-671f-4af2-a24b-6e55645a5e48"
      unitRef="usd">603400000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible
      contextRef="i626282e786b7454d83b617e9e83963e6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDMvZnJhZzowYzVkN2FhNTc1NDI0ZmFlYjYxNzlhYzA1NWVkOTcwMi90ZXh0cmVnaW9uOjBjNWQ3YWE1NzU0MjRmYWViNjE3OWFjMDU1ZWQ5NzAyXzYxMjY_2fac419d-298f-43a0-9089-c365e66d83fc"
      unitRef="usd">75000000.0</us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible>
    <us-gaap:AdditionalFinancialInformationDisclosureTextBlock
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90ZXh0cmVnaW9uOjEyZjQ1MWU3YWJjZjRiMmZiZTg3NmUwN2MxOWU0YWJlXzE0MDA_ab99102e-d47b-4368-9e90-8eec74f80332">&lt;div style="text-indent:11.25pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Other Income (Expense), Net&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Components of other income (expense), net, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:43.929%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.204%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.204%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.619%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.624%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;30.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;38.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;90.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(56.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(45.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(166.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(141.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gain (loss) on investments, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(82.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(4.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(52.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;198.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Foreign exchange gains (losses), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(4.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(5.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(4.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(3.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(11.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total other income (expense), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(128.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(27.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(186.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;132.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Gain (loss) on investments, net, as reflected in the table above, relate to debt securities, equity securities of certain biotechnology companies, venture capital funds where the underlying investments are in equity securities of certain biotechnology companies and non-marketable equity securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;For the three months ended September 30, 2020, compared to the same period in 2019, the change in other income (expense), net primarily reflects net unrealized losses of approximately $82.1 million recognized on our investments related to our holdings in equity securities, compared to net unrealized losses totaling $4.1 million in the prior year comparative period. The net unrealized losses recognized during the three months ended September 30, 2020, primarily reflect a decrease in the fair value of Ionis common stock of approximately $66.2 million and a decrease in the fair value of Denali common stock of approximately $29.6 million, partially offset by an increase in the fair value of Sangamo common stock of approximately $15.2&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;For the nine months ended September 30, 2020, compared to the same period in 2019, the change in other income (expense), net primarily reflects net unrealized losses of approximately $40.3 million recognized on our investments related to our holdings in equity securities, compared to net unrealized gains totaling $198.9&#160;million in the prior year comparative period. The net unrealized losses recognized during the nine months ended September 30, 2020, primarily reflect a decrease in the fair value of Ionis common stock of approximately $56.7&#160;million and a decrease in the fair value of Denali common stock of approximately $29.6&#160;million, partially offset by an increase in the fair value of Sangamo common stock of approximately $56.1&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table summarizes our gain (loss) on investments, net that relates to our equity securities held as of September 30, 2020 and 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:43.929%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.204%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.204%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.619%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.624%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net gains (losses) recognized during the period on equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(82.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(4.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(40.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;197.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less: Net gains (losses) recognized during the period on equity securities sold during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;46.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unrealized gains (losses) recognized during the period on equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(82.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(9.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(40.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;150.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:11.25pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Accrued Expenses and Other&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Accrued expenses and other consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:58.549%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:18.344%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:18.347%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;As of September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Revenue-related reserves for discounts and allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;1,043.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,001.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Employee compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;279.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;309.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Royalties and licensing fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;222.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;220.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Collaboration expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;277.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;281.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Current portion of contingent consideration obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;164.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;148.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;23.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;78.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;1,274.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;726.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total accrued expenses and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;3,286.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,765.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:11.25pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Other Long-term Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Other long-term liabilities were $1,428.1 million and $1,348.9 million as of September 30, 2020 and December 31, 2019, respectively, and included accrued income taxes totaling $729.3 million and $803.3 million, respectively. Included within accrued taxes as of September 30, 2020 and December 31, 2019, is an accrual for a one-time mandatory deemed repatriation tax on accumulated foreign subsidiaries' previously untaxed foreign earnings (the Transition Toll Tax) of approximately $635.0 million and approximately $697.0 million, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:AdditionalFinancialInformationDisclosureTextBlock>
    <us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90ZXh0cmVnaW9uOjEyZjQ1MWU3YWJjZjRiMmZiZTg3NmUwN2MxOWU0YWJlXzEzOTU_ceafcba1-8904-45b2-bf0b-cfa15e3abc65">&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Components of other income (expense), net, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:43.929%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.204%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.204%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.619%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.624%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;30.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;38.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;90.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(56.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(45.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(166.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(141.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gain (loss) on investments, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(82.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(4.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(52.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;198.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Foreign exchange gains (losses), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(4.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(5.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(4.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(3.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(11.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total other income (expense), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(128.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(27.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(186.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;132.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90YWJsZTowYjA5OTZlOTE4MjY0YmMyOTFjYmVkODFhNWI1NWU5Yy90YWJsZXJhbmdlOjBiMDk5NmU5MTgyNjRiYzI5MWNiZWQ4MWE1YjU1ZTljXzItMi0xLTEtMA_f353690a-4283-41b5-92ce-e29e883e7bff"
      unitRef="usd">6000000.0</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90YWJsZTowYjA5OTZlOTE4MjY0YmMyOTFjYmVkODFhNWI1NWU5Yy90YWJsZXJhbmdlOjBiMDk5NmU5MTgyNjRiYzI5MWNiZWQ4MWE1YjU1ZTljXzItNC0xLTEtMA_44ef183e-4bca-4e03-97e6-d6f9bac4211b"
      unitRef="usd">30500000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90YWJsZTowYjA5OTZlOTE4MjY0YmMyOTFjYmVkODFhNWI1NWU5Yy90YWJsZXJhbmdlOjBiMDk5NmU5MTgyNjRiYzI5MWNiZWQ4MWE1YjU1ZTljXzItNi0xLTEtMA_d69745ba-5af5-4265-baa2-6ad867760d4a"
      unitRef="usd">38000000.0</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90YWJsZTowYjA5OTZlOTE4MjY0YmMyOTFjYmVkODFhNWI1NWU5Yy90YWJsZXJhbmdlOjBiMDk5NmU5MTgyNjRiYzI5MWNiZWQ4MWE1YjU1ZTljXzItOC0xLTEtMA_eeb6baab-92c9-4c4b-8bd6-25f1aa19985c"
      unitRef="usd">90800000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90YWJsZTowYjA5OTZlOTE4MjY0YmMyOTFjYmVkODFhNWI1NWU5Yy90YWJsZXJhbmdlOjBiMDk5NmU5MTgyNjRiYzI5MWNiZWQ4MWE1YjU1ZTljXzMtMi0xLTEtMA_14cd2b58-db2b-48c5-b305-aa0ed23cdec6"
      unitRef="usd">56300000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90YWJsZTowYjA5OTZlOTE4MjY0YmMyOTFjYmVkODFhNWI1NWU5Yy90YWJsZXJhbmdlOjBiMDk5NmU5MTgyNjRiYzI5MWNiZWQ4MWE1YjU1ZTljXzMtNC0xLTEtMA_641e0ed9-40d2-47e0-9510-333d04fc4efb"
      unitRef="usd">45800000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90YWJsZTowYjA5OTZlOTE4MjY0YmMyOTFjYmVkODFhNWI1NWU5Yy90YWJsZXJhbmdlOjBiMDk5NmU5MTgyNjRiYzI5MWNiZWQ4MWE1YjU1ZTljXzMtNi0xLTEtMA_f1d9366d-0f5f-4111-af86-14ae0f77fe43"
      unitRef="usd">166500000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90YWJsZTowYjA5OTZlOTE4MjY0YmMyOTFjYmVkODFhNWI1NWU5Yy90YWJsZXJhbmdlOjBiMDk5NmU5MTgyNjRiYzI5MWNiZWQ4MWE1YjU1ZTljXzMtOC0xLTEtMA_6315c6b4-9f5b-4c46-ac7a-3d5b0237d2eb"
      unitRef="usd">141400000</us-gaap:InterestExpense>
    <us-gaap:RealizedInvestmentGainsLosses
      contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90YWJsZTowYjA5OTZlOTE4MjY0YmMyOTFjYmVkODFhNWI1NWU5Yy90YWJsZXJhbmdlOjBiMDk5NmU5MTgyNjRiYzI5MWNiZWQ4MWE1YjU1ZTljXzQtMi0xLTEtMA_4f560716-7de6-4963-96bf-839a1042170d"
      unitRef="usd">-82100000</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:RealizedInvestmentGainsLosses
      contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90YWJsZTowYjA5OTZlOTE4MjY0YmMyOTFjYmVkODFhNWI1NWU5Yy90YWJsZXJhbmdlOjBiMDk5NmU5MTgyNjRiYzI5MWNiZWQ4MWE1YjU1ZTljXzQtNC0xLTEtMA_1f6958e8-4de1-4c8e-b71a-954a8feeaac6"
      unitRef="usd">-4100000</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:RealizedInvestmentGainsLosses
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90YWJsZTowYjA5OTZlOTE4MjY0YmMyOTFjYmVkODFhNWI1NWU5Yy90YWJsZXJhbmdlOjBiMDk5NmU5MTgyNjRiYzI5MWNiZWQ4MWE1YjU1ZTljXzQtNi0xLTEtMA_0dff469b-a255-450d-a8fd-2a9513fba712"
      unitRef="usd">-52600000</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:RealizedInvestmentGainsLosses
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90YWJsZTowYjA5OTZlOTE4MjY0YmMyOTFjYmVkODFhNWI1NWU5Yy90YWJsZXJhbmdlOjBiMDk5NmU5MTgyNjRiYzI5MWNiZWQ4MWE1YjU1ZTljXzQtOC0xLTEtMA_3c5f19c5-623e-4f92-a33d-d3aeec9a9f99"
      unitRef="usd">198900000</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90YWJsZTowYjA5OTZlOTE4MjY0YmMyOTFjYmVkODFhNWI1NWU5Yy90YWJsZXJhbmdlOjBiMDk5NmU5MTgyNjRiYzI5MWNiZWQ4MWE1YjU1ZTljXzUtMi0xLTEtMA_a460a07d-81de-4fc2-a8f0-94654ae83e42"
      unitRef="usd">3100000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90YWJsZTowYjA5OTZlOTE4MjY0YmMyOTFjYmVkODFhNWI1NWU5Yy90YWJsZXJhbmdlOjBiMDk5NmU5MTgyNjRiYzI5MWNiZWQ4MWE1YjU1ZTljXzUtNC0xLTEtMA_f097051c-2c6b-49c8-a972-606b8cab4ddd"
      unitRef="usd">-4200000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90YWJsZTowYjA5OTZlOTE4MjY0YmMyOTFjYmVkODFhNWI1NWU5Yy90YWJsZXJhbmdlOjBiMDk5NmU5MTgyNjRiYzI5MWNiZWQ4MWE1YjU1ZTljXzUtNi0xLTEtMA_903e5f9e-f72d-416a-807b-a545c633a031"
      unitRef="usd">-5400000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90YWJsZTowYjA5OTZlOTE4MjY0YmMyOTFjYmVkODFhNWI1NWU5Yy90YWJsZXJhbmdlOjBiMDk5NmU5MTgyNjRiYzI5MWNiZWQ4MWE1YjU1ZTljXzUtOC0xLTEtMA_aab29782-0c10-416f-9a5d-edfaeff9701c"
      unitRef="usd">-4700000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90YWJsZTowYjA5OTZlOTE4MjY0YmMyOTFjYmVkODFhNWI1NWU5Yy90YWJsZXJhbmdlOjBiMDk5NmU5MTgyNjRiYzI5MWNiZWQ4MWE1YjU1ZTljXzYtMi0xLTEtMA_c6e655f5-38bf-4a82-bfab-9f5d7c6b1a88"
      unitRef="usd">700000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90YWJsZTowYjA5OTZlOTE4MjY0YmMyOTFjYmVkODFhNWI1NWU5Yy90YWJsZXJhbmdlOjBiMDk5NmU5MTgyNjRiYzI5MWNiZWQ4MWE1YjU1ZTljXzYtNC0xLTEtMA_cbbc32d1-c235-465e-aa2b-92638d81839e"
      unitRef="usd">-3700000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90YWJsZTowYjA5OTZlOTE4MjY0YmMyOTFjYmVkODFhNWI1NWU5Yy90YWJsZXJhbmdlOjBiMDk5NmU5MTgyNjRiYzI5MWNiZWQ4MWE1YjU1ZTljXzYtNi0xLTEtMA_611e127a-8af8-49fa-8aab-ba8991881381"
      unitRef="usd">400000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90YWJsZTowYjA5OTZlOTE4MjY0YmMyOTFjYmVkODFhNWI1NWU5Yy90YWJsZXJhbmdlOjBiMDk5NmU5MTgyNjRiYzI5MWNiZWQ4MWE1YjU1ZTljXzYtOC0xLTEtMA_dfa2cb3c-6d7c-4680-9adb-be16cd558645"
      unitRef="usd">-11000000.0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90YWJsZTowYjA5OTZlOTE4MjY0YmMyOTFjYmVkODFhNWI1NWU5Yy90YWJsZXJhbmdlOjBiMDk5NmU5MTgyNjRiYzI5MWNiZWQ4MWE1YjU1ZTljXzctMi0xLTEtMA_9797ad36-a044-4c1a-97da-f19ad648ba5d"
      unitRef="usd">-128600000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90YWJsZTowYjA5OTZlOTE4MjY0YmMyOTFjYmVkODFhNWI1NWU5Yy90YWJsZXJhbmdlOjBiMDk5NmU5MTgyNjRiYzI5MWNiZWQ4MWE1YjU1ZTljXzctNC0xLTEtMA_0be8925c-dba2-459c-b109-b39cec53a3fb"
      unitRef="usd">-27300000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90YWJsZTowYjA5OTZlOTE4MjY0YmMyOTFjYmVkODFhNWI1NWU5Yy90YWJsZXJhbmdlOjBiMDk5NmU5MTgyNjRiYzI5MWNiZWQ4MWE1YjU1ZTljXzctNi0xLTEtMA_7640d544-1ef7-487a-9f46-b5d67dd81728"
      unitRef="usd">-186100000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90YWJsZTowYjA5OTZlOTE4MjY0YmMyOTFjYmVkODFhNWI1NWU5Yy90YWJsZXJhbmdlOjBiMDk5NmU5MTgyNjRiYzI5MWNiZWQ4MWE1YjU1ZTljXzctOC0xLTEtMA_ac50e3ac-4e63-49ed-9c81-925829796b78"
      unitRef="usd">132600000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90ZXh0cmVnaW9uOjEyZjQ1MWU3YWJjZjRiMmZiZTg3NmUwN2MxOWU0YWJlXzU2NA_acb9dcaf-be48-4184-8f68-ea17ee426670"
      unitRef="usd">-82100000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:RealizedInvestmentGainsLosses
      contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90ZXh0cmVnaW9uOjEyZjQ1MWU3YWJjZjRiMmZiZTg3NmUwN2MxOWU0YWJlXzEwOTk1MTE2MjkzODg_ae791a63-c84a-4ad3-ad00-72970f0db186"
      unitRef="usd">-4100000</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="ib7f7a4e02a2b41bdbe159e1d831b1937_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90ZXh0cmVnaW9uOjEyZjQ1MWU3YWJjZjRiMmZiZTg3NmUwN2MxOWU0YWJlXzEwOTk1MTE2Mjk0OTM_bfd3e4d7-de6a-4e3e-bf66-f3e2cded84c1"
      unitRef="usd">66200000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="ia7dbdd092b034c3189ffed19d675f882_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90ZXh0cmVnaW9uOjEyZjQ1MWU3YWJjZjRiMmZiZTg3NmUwN2MxOWU0YWJlXzEwOTk1MTE2Mjk1MDU_b519eb57-e71d-4298-bcb7-1c5e133e699e"
      unitRef="usd">-29600000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="ia88c862a2922421b9916446a96695a69_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90ZXh0cmVnaW9uOjEyZjQ1MWU3YWJjZjRiMmZiZTg3NmUwN2MxOWU0YWJlXzEwOTk1MTE2Mjk1MTM_9e739bda-6e5c-428d-8f9b-ce2833589869"
      unitRef="usd">15200000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90ZXh0cmVnaW9uOjEyZjQ1MWU3YWJjZjRiMmZiZTg3NmUwN2MxOWU0YWJlXzEwOTk1MTE2Mjk2MjA_3855f299-e7e4-48b6-a6ee-5ac09c2d8003"
      unitRef="usd">40300000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:RealizedInvestmentGainsLosses
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90ZXh0cmVnaW9uOjEyZjQ1MWU3YWJjZjRiMmZiZTg3NmUwN2MxOWU0YWJlXzEwOTk1MTE2Mjk2Mjg_30161c7c-ba0b-4705-a670-301beceb0035"
      unitRef="usd">198900000</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="i671e2b4b86c44e18a9a4518a9d0360e3_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90ZXh0cmVnaW9uOjEyZjQ1MWU3YWJjZjRiMmZiZTg3NmUwN2MxOWU0YWJlXzEwOTk1MTE2Mjk2NjE_bb59f3c4-20ef-45a5-8c1e-7d9cc0836035"
      unitRef="usd">56700000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="i79e678cecceb4e00b17b8c2023042ca8_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90ZXh0cmVnaW9uOjEyZjQ1MWU3YWJjZjRiMmZiZTg3NmUwN2MxOWU0YWJlXzEwOTk1MTE2Mjk2Njg_8ce31c9e-38d0-4952-ab77-9047893c2d69"
      unitRef="usd">29600000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="i4c4c8f3f1c614d79bad90fbadf4e582e_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90ZXh0cmVnaW9uOjEyZjQ1MWU3YWJjZjRiMmZiZTg3NmUwN2MxOWU0YWJlXzEwOTk1MTE2Mjk2NzY_93d74f39-dbf9-403d-828a-2c33219e9058"
      unitRef="usd">56100000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:GainLossOnInvestmentsTextBlock
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90ZXh0cmVnaW9uOjEyZjQ1MWU3YWJjZjRiMmZiZTg3NmUwN2MxOWU0YWJlXzE0MTM_5455c2a9-efaf-4062-897e-d40963122bac">&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table summarizes our gain (loss) on investments, net that relates to our equity securities held as of September 30, 2020 and 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:43.929%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.204%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.204%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.619%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.624%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net gains (losses) recognized during the period on equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(82.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(4.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(40.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;197.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less: Net gains (losses) recognized during the period on equity securities sold during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;46.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unrealized gains (losses) recognized during the period on equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(82.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(9.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;(40.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;150.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:GainLossOnInvestmentsTextBlock>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90YWJsZTozMjBmMzI3OTUxYWY0NWJjOGNiYWU1MWVlNTZlYjg2ZC90YWJsZXJhbmdlOjMyMGYzMjc5NTFhZjQ1YmM4Y2JhZTUxZWU1NmViODZkXzItMi0xLTEtMA_5b47f273-91ce-4a2e-be70-5005f19e305d"
      unitRef="usd">-82300000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90YWJsZTozMjBmMzI3OTUxYWY0NWJjOGNiYWU1MWVlNTZlYjg2ZC90YWJsZXJhbmdlOjMyMGYzMjc5NTFhZjQ1YmM4Y2JhZTUxZWU1NmViODZkXzItNC0xLTEtMA_a75f2517-f9a4-4d4f-a03e-dbc64645ac41"
      unitRef="usd">-4600000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90YWJsZTozMjBmMzI3OTUxYWY0NWJjOGNiYWU1MWVlNTZlYjg2ZC90YWJsZXJhbmdlOjMyMGYzMjc5NTFhZjQ1YmM4Y2JhZTUxZWU1NmViODZkXzItNi0xLTEtMA_aa6c9bde-0f41-42aa-b821-681c9ff7754b"
      unitRef="usd">-40300000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90YWJsZTozMjBmMzI3OTUxYWY0NWJjOGNiYWU1MWVlNTZlYjg2ZC90YWJsZXJhbmdlOjMyMGYzMjc5NTFhZjQ1YmM4Y2JhZTUxZWU1NmViODZkXzItOC0xLTEtMA_4ca7d45b-a352-40e5-a93d-1a1c35640948"
      unitRef="usd">197300000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90YWJsZTozMjBmMzI3OTUxYWY0NWJjOGNiYWU1MWVlNTZlYjg2ZC90YWJsZXJhbmdlOjMyMGYzMjc5NTFhZjQ1YmM4Y2JhZTUxZWU1NmViODZkXzMtMi0xLTEtMA_2627a5fb-4474-4f43-a94a-0d661d641cc0"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90YWJsZTozMjBmMzI3OTUxYWY0NWJjOGNiYWU1MWVlNTZlYjg2ZC90YWJsZXJhbmdlOjMyMGYzMjc5NTFhZjQ1YmM4Y2JhZTUxZWU1NmViODZkXzMtNC0xLTEtMA_9cfaf553-19f3-42e1-a759-201c7cf12f48"
      unitRef="usd">4400000</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90YWJsZTozMjBmMzI3OTUxYWY0NWJjOGNiYWU1MWVlNTZlYjg2ZC90YWJsZXJhbmdlOjMyMGYzMjc5NTFhZjQ1YmM4Y2JhZTUxZWU1NmViODZkXzMtNi0xLTEtMA_3373bb83-bdf6-499f-b59d-7d9815fa4232"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90YWJsZTozMjBmMzI3OTUxYWY0NWJjOGNiYWU1MWVlNTZlYjg2ZC90YWJsZXJhbmdlOjMyMGYzMjc5NTFhZjQ1YmM4Y2JhZTUxZWU1NmViODZkXzMtOC0xLTEtMA_f7b4d3a0-b680-4293-8a17-a4b14af44031"
      unitRef="usd">-46800000</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90YWJsZTozMjBmMzI3OTUxYWY0NWJjOGNiYWU1MWVlNTZlYjg2ZC90YWJsZXJhbmdlOjMyMGYzMjc5NTFhZjQ1YmM4Y2JhZTUxZWU1NmViODZkXzQtMi0xLTEtMA_f254fccd-f295-4982-b4cb-fdab0d5914f9"
      unitRef="usd">-82300000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i1b7ef7e955334d0baaaf4aa6e4cb40c7_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90YWJsZTozMjBmMzI3OTUxYWY0NWJjOGNiYWU1MWVlNTZlYjg2ZC90YWJsZXJhbmdlOjMyMGYzMjc5NTFhZjQ1YmM4Y2JhZTUxZWU1NmViODZkXzQtNC0xLTEtMA_f2b020b4-6323-47aa-abca-bc019a2c4829"
      unitRef="usd">-9000000.0</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90YWJsZTozMjBmMzI3OTUxYWY0NWJjOGNiYWU1MWVlNTZlYjg2ZC90YWJsZXJhbmdlOjMyMGYzMjc5NTFhZjQ1YmM4Y2JhZTUxZWU1NmViODZkXzQtNi0xLTEtMA_ef2d5ff6-0285-4e16-8529-23110aec130c"
      unitRef="usd">-40300000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="ic841a627ff3a42fcb14645743e6a64e0_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90YWJsZTozMjBmMzI3OTUxYWY0NWJjOGNiYWU1MWVlNTZlYjg2ZC90YWJsZXJhbmdlOjMyMGYzMjc5NTFhZjQ1YmM4Y2JhZTUxZWU1NmViODZkXzQtOC0xLTEtMA_7b5305ff-a631-4a33-b31c-2c5ac576f68c"
      unitRef="usd">150500000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90ZXh0cmVnaW9uOjEyZjQ1MWU3YWJjZjRiMmZiZTg3NmUwN2MxOWU0YWJlXzE0MTc_7a0dd0c3-dda1-4331-ba4e-d0dd6adbcbde">&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Accrued expenses and other consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:58.549%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:18.344%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:18.347%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;As of September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Revenue-related reserves for discounts and allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;1,043.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,001.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Employee compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;279.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;309.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Royalties and licensing fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;222.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;220.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Collaboration expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;277.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;281.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Current portion of contingent consideration obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;164.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;148.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;23.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;78.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;1,274.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;726.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total accrued expenses and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;3,286.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,765.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i7eddadc447104f8eb26db7302eace7a5_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90YWJsZToxOGMzMWVlYTE1NDY0NGNkOGNlZDUzZmNmMmRjYWQxYy90YWJsZXJhbmdlOjE4YzMxZWVhMTU0NjQ0Y2Q4Y2VkNTNmY2YyZGNhZDFjXzEtMi0xLTEtMA_9931ad3d-2c42-4999-9675-275a121b78b2"
      unitRef="usd">1043900000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ide07a6c272e244a3be181989da603c09_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90YWJsZToxOGMzMWVlYTE1NDY0NGNkOGNlZDUzZmNmMmRjYWQxYy90YWJsZXJhbmdlOjE4YzMxZWVhMTU0NjQ0Y2Q4Y2VkNTNmY2YyZGNhZDFjXzEtNC0xLTEtMA_d5a528e4-97d1-4c97-9122-ec27beead75d"
      unitRef="usd">1001100000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90YWJsZToxOGMzMWVlYTE1NDY0NGNkOGNlZDUzZmNmMmRjYWQxYy90YWJsZXJhbmdlOjE4YzMxZWVhMTU0NjQ0Y2Q4Y2VkNTNmY2YyZGNhZDFjXzItMi0xLTEtMA_58646d63-81cb-4d17-9f3f-536ad5e3a7d1"
      unitRef="usd">279000000.0</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i626282e786b7454d83b617e9e83963e6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90YWJsZToxOGMzMWVlYTE1NDY0NGNkOGNlZDUzZmNmMmRjYWQxYy90YWJsZXJhbmdlOjE4YzMxZWVhMTU0NjQ0Y2Q4Y2VkNTNmY2YyZGNhZDFjXzItNC0xLTEtMA_7280befc-9b7d-4de2-b196-1280c4cda8fe"
      unitRef="usd">309100000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90YWJsZToxOGMzMWVlYTE1NDY0NGNkOGNlZDUzZmNmMmRjYWQxYy90YWJsZXJhbmdlOjE4YzMxZWVhMTU0NjQ0Y2Q4Y2VkNTNmY2YyZGNhZDFjXzMtMi0xLTEtMA_b285fed5-06c5-45a1-8513-881f41f628b6"
      unitRef="usd">222800000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="i626282e786b7454d83b617e9e83963e6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90YWJsZToxOGMzMWVlYTE1NDY0NGNkOGNlZDUzZmNmMmRjYWQxYy90YWJsZXJhbmdlOjE4YzMxZWVhMTU0NjQ0Y2Q4Y2VkNTNmY2YyZGNhZDFjXzMtNC0xLTEtMA_57499c87-2db9-4159-a25b-e66cb7edc061"
      unitRef="usd">220900000</us-gaap:AccruedRoyaltiesCurrent>
    <biib:Collaborationexpensesaccrual
      contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90YWJsZToxOGMzMWVlYTE1NDY0NGNkOGNlZDUzZmNmMmRjYWQxYy90YWJsZXJhbmdlOjE4YzMxZWVhMTU0NjQ0Y2Q4Y2VkNTNmY2YyZGNhZDFjXzQtMi0xLTEtMA_40ad3edf-54cf-4b39-82ef-d678a420a2e3"
      unitRef="usd">277900000</biib:Collaborationexpensesaccrual>
    <biib:Collaborationexpensesaccrual
      contextRef="i626282e786b7454d83b617e9e83963e6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90YWJsZToxOGMzMWVlYTE1NDY0NGNkOGNlZDUzZmNmMmRjYWQxYy90YWJsZXJhbmdlOjE4YzMxZWVhMTU0NjQ0Y2Q4Y2VkNTNmY2YyZGNhZDFjXzQtNC0xLTEtMA_6297a58d-427f-4301-b925-98c6ca182381"
      unitRef="usd">281600000</biib:Collaborationexpensesaccrual>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90YWJsZToxOGMzMWVlYTE1NDY0NGNkOGNlZDUzZmNmMmRjYWQxYy90YWJsZXJhbmdlOjE4YzMxZWVhMTU0NjQ0Y2Q4Y2VkNTNmY2YyZGNhZDFjXzUtMi0xLTEtMA_493dac42-6f62-4142-a8bf-f7a443340b7b"
      unitRef="usd">164400000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="i626282e786b7454d83b617e9e83963e6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90YWJsZToxOGMzMWVlYTE1NDY0NGNkOGNlZDUzZmNmMmRjYWQxYy90YWJsZXJhbmdlOjE4YzMxZWVhMTU0NjQ0Y2Q4Y2VkNTNmY2YyZGNhZDFjXzUtNC0xLTEtMA_70b2192a-6fb7-4c43-beb7-0fb264247d8c"
      unitRef="usd">148400000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:ConstructionPayableCurrentAndNoncurrent
      contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90YWJsZToxOGMzMWVlYTE1NDY0NGNkOGNlZDUzZmNmMmRjYWQxYy90YWJsZXJhbmdlOjE4YzMxZWVhMTU0NjQ0Y2Q4Y2VkNTNmY2YyZGNhZDFjXzYtMi0xLTEtMA_bf9e27c9-b478-4ba4-a0dd-714281c95e9b"
      unitRef="usd">23400000</us-gaap:ConstructionPayableCurrentAndNoncurrent>
    <us-gaap:ConstructionPayableCurrentAndNoncurrent
      contextRef="i626282e786b7454d83b617e9e83963e6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90YWJsZToxOGMzMWVlYTE1NDY0NGNkOGNlZDUzZmNmMmRjYWQxYy90YWJsZXJhbmdlOjE4YzMxZWVhMTU0NjQ0Y2Q4Y2VkNTNmY2YyZGNhZDFjXzYtNC0xLTEtMA_0652ab1a-34ca-4532-8565-1631fa69a3c1"
      unitRef="usd">78000000.0</us-gaap:ConstructionPayableCurrentAndNoncurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90YWJsZToxOGMzMWVlYTE1NDY0NGNkOGNlZDUzZmNmMmRjYWQxYy90YWJsZXJhbmdlOjE4YzMxZWVhMTU0NjQ0Y2Q4Y2VkNTNmY2YyZGNhZDFjXzctMi0xLTEtMA_2cd2bb6e-86a9-4375-a01e-d595d9450439"
      unitRef="usd">1274800000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i626282e786b7454d83b617e9e83963e6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90YWJsZToxOGMzMWVlYTE1NDY0NGNkOGNlZDUzZmNmMmRjYWQxYy90YWJsZXJhbmdlOjE4YzMxZWVhMTU0NjQ0Y2Q4Y2VkNTNmY2YyZGNhZDFjXzctNC0xLTEtMA_e15f5447-185a-4860-86ba-cb2737f2eb08"
      unitRef="usd">726700000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90YWJsZToxOGMzMWVlYTE1NDY0NGNkOGNlZDUzZmNmMmRjYWQxYy90YWJsZXJhbmdlOjE4YzMxZWVhMTU0NjQ0Y2Q4Y2VkNTNmY2YyZGNhZDFjXzgtMi0xLTEtMA_488c8d0e-af49-40c7-8f24-d64e0b22b8be"
      unitRef="usd">3286200000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i626282e786b7454d83b617e9e83963e6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90YWJsZToxOGMzMWVlYTE1NDY0NGNkOGNlZDUzZmNmMmRjYWQxYy90YWJsZXJhbmdlOjE4YzMxZWVhMTU0NjQ0Y2Q4Y2VkNTNmY2YyZGNhZDFjXzgtNC0xLTEtMA_d9821704-168f-4ee7-a542-d40cf4d60e99"
      unitRef="usd">2765800000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90ZXh0cmVnaW9uOjEyZjQ1MWU3YWJjZjRiMmZiZTg3NmUwN2MxOWU0YWJlXzk5MQ_2b16eb7c-f1c1-4ee4-bde9-782920115bc1"
      unitRef="usd">1428100000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i626282e786b7454d83b617e9e83963e6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90ZXh0cmVnaW9uOjEyZjQ1MWU3YWJjZjRiMmZiZTg3NmUwN2MxOWU0YWJlXzk5OA_5e05d579-c2a2-4155-8371-6d29e0543b20"
      unitRef="usd">1348900000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:AccruedIncomeTaxesNoncurrent
      contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90ZXh0cmVnaW9uOjEyZjQ1MWU3YWJjZjRiMmZiZTg3NmUwN2MxOWU0YWJlXzEwNzU_41f324b1-6d7b-4ff6-ac74-5c3f8924f669"
      unitRef="usd">729300000</us-gaap:AccruedIncomeTaxesNoncurrent>
    <us-gaap:AccruedIncomeTaxesNoncurrent
      contextRef="i626282e786b7454d83b617e9e83963e6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90ZXh0cmVnaW9uOjEyZjQ1MWU3YWJjZjRiMmZiZTg3NmUwN2MxOWU0YWJlXzEwODI_0d9b06f7-27ed-47ab-95c8-1d2250a98175"
      unitRef="usd">803300000</us-gaap:AccruedIncomeTaxesNoncurrent>
    <us-gaap:TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsIncomeTaxExpense
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90ZXh0cmVnaW9uOjEyZjQ1MWU3YWJjZjRiMmZiZTg3NmUwN2MxOWU0YWJlXzEzNTI_93bc5e09-b6ea-4e36-a47b-254523391b4d"
      unitRef="usd">635000000.0</us-gaap:TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsIncomeTaxExpense>
    <us-gaap:TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsIncomeTaxExpense
      contextRef="i9e00b6efba394fb5b58ec5d8f15b5e07_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMDkvZnJhZzoxMmY0NTFlN2FiY2Y0YjJmYmU4NzZlMDdjMTllNGFiZS90ZXh0cmVnaW9uOjEyZjQ1MWU3YWJjZjRiMmZiZTg3NmUwN2MxOWU0YWJlXzEzNzM_3d224ab2-538f-4ef9-b9a5-aef4989574ff"
      unitRef="usd">697000000.0</us-gaap:TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsIncomeTaxExpense>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzE1NzE4_457965c3-ab3f-4dfc-94f0-192cea7053ce">&lt;div style="text-indent:11.25pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Eisai Co., Ltd.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:13.5pt;margin-top:5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;BAN2401 and Elenbecestat Collaboration&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We have a collaboration agreement with Eisai Co., Ltd. (Eisai) to jointly develop and commercialize BAN2401, a monoclonal antibody that targets amyloid beta aggregates, and elenbecestat, the oral BACE (base amyloid cleaving enzyme) inhibitor, two Eisai product candidates for the potential treatment of Alzheimer's disease (the BAN2401 and Elenbecestat Collaboration).&#160;In September 2019 we and Eisai discontinued the global Phase 3 studies of elenbecestat in early Alzheimer's disease. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Eisai serves as the global operational and regulatory lead for BAN2401 and all costs, including research, development, sales and marketing expenses, are shared equally between us and Eisai. If BAN2401 receives marketing approval, we and Eisai will co-promote BAN2401 and share profits equally. In addition, the BAN2401 and Elenbecestat Collaboration provides both parties with certain rights and obligations in the event of a change in control of either party.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The BAN2401 and Elenbecestat Collaboration also provided Eisai with an option to jointly develop and commercialize aducanumab, our anti-amyloid beta antibody candidate for Alzheimer's disease (Aducanumab Option), and an option to jointly develop and commercialize one of our anti-tau monoclonal antibodies (Anti-Tau Option). In October 2017 Eisai exercised its Aducanumab Option and we entered into a new collaboration agreement for the joint development and commercialization of aducanumab (Aducanumab Collaboration Agreement). Eisai has not exercised its Anti-Tau Option.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Under the Aducanumab Collaboration Agreement, the two companies will continue to jointly develop BAN2401 in accordance with the BAN2401 and Elenbecestat Collaboration; however, we are no longer required to pay Eisai any milestone payments in relation to BAN2401 and we are no longer entitled to any potential development and commercial milestone payments from Eisai in relation to aducanumab. For additional information on our BAN2401 and Elenbecestat Collaboration, please read &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Note 18, Collaborative and Other Relationships,&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; to our consolidated financial statements included in our 2019 Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;A summary of development and sales and marketing expense related to the BAN2401 and Elenbecestat Collaboration is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:53.085%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.619%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.619%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.619%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.622%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total development expense incurred by the collaboration related to the advancement of BAN2401 and elenbecestat&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;75.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;168.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;153.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;305.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Biogen's share of BAN2401 and elenbecestat development expense reflected in research and development expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;37.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;84.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;76.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;152.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total sales and marketing expense incurred by the collaboration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;nm&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;6.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;24.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Biogen's share of BAN2401 and elenbecestat sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;nm&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:33.017%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:31.105%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:32.578%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;"&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;vertical-align:top;"&gt;nm&lt;/sup&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;"&gt; - For the three months ended September 30, 2020, sales and marketing expense related to the BAN2401 and Elenbecestat Collaboration was immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:13.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Aducanumab Collaboration Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Under the Aducanumab Collaboration Agreement, we and Eisai will co-promote aducanumab with a region-based profit split and we lead the ongoing development of aducanumab. Beginning January 1, 2019, Eisai is reimbursing us for&#160;45%&#160;of development costs incurred by the collaboration for the advancement of aducanumab (aducanumab development expense). &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In March 2019, based on a pre-specified futility analysis, we discontinued the global Phase 3 trials, EMERGE and ENGAGE, designed to evaluate the efficacy and safety of aducanumab in patients with early Alzheimer's disease. A new analysis of a larger dataset from these trials, conducted in consultation with the FDA, showed that the Phase 3 EMERGE study met its pre-specified primary and secondary endpoints. In the first quarter of 2019, as a result of the decision to discontinue the Phase 3 EMERGE and ENGAGE trials following the futility analysis, we accrued approximately $45.0 million related to the termination of various clinical trials and research and development contracts net of the 45% Eisai reimbursement of development costs incurred under the Aducanumab Collaboration Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In July 2020 we completed the submission of a Biologics License Application (BLA) to the FDA for the approval of aducanumab. For the nine months ended September 30, 2020, we recognized net profit-sharing income of $33.8 million to reflect Eisai's 45% share of the $75.0 million milestone expense related to the submission of the BLA to the FDA for the approval of aducanumab.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Sales and marketing expense are shared in proportion to the same region-based profit split that will be utilized to co-promote aducanumab. For additional information on the Aducanumab Collaboration Agreement, please read &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Note 18,&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Collaborative and Other Relationships,&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; to our consolidated financial statements included in our 2019 Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;A summary of development, sales and marketing and milestone expense related to the Aducanumab Collaboration Agreement is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:53.085%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.619%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.619%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.619%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.622%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total aducanumab development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;37.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;92.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;170.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Biogen's share of aducanumab development expense reflected in research and development expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;20.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;50.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;93.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total aducanumab sales and marketing expense incurred by the collaboration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;90.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;158.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;21.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Biogen's share of aducanumab sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;51.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;88.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total aducanumab collaboration third party milestone expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;75.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Eisai's share of aducanumab milestone expense reflected in collaboration profit sharing in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;33.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In addition, we and Eisai co-promote AVONEX, TYSABRI and TECFIDERA in Japan in certain settings and Eisai distributes AVONEX, TYSABRI, TECFIDERA and PLEGRIDY in India and other Asia-Pacific markets, excluding China.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:13.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;UCB Pharma S.A.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We have a collaboration agreement with UCB Pharma S.A. (UCB) to jointly develop and commercialize dapirolizumab pegol, an anti-CD40L pegylated Fab, for the potential treatment of systemic lupus erythematosus and other future agreed indications. Either we or UCB may propose development of dapirolizumab pegol in additional indications. If the parties do not agree to add an indication as an agreed indication to the collaboration, we or UCB may, at the sole expense of the applicable party, pursue development in such excluded indication(s), subject to an opt-in right of the non-pursuing party after proof of clinical activity. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;All costs incurred for agreed indications, including research, development, sales and marketing expenses, are shared equally between us and UCB. Upon marketing approval, we and UCB will co-promote dapirolizumab pegol and share profits equally. A summary of development expense related to the UCB collaboration agreement is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:53.085%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.619%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.619%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.619%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.622%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total UCB development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;10.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;35.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;21.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Biogen's share of UCB development expense reflected in research and development expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;17.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:11.25pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Other Research and Discovery Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;These arrangements may include the potential for future milestone payments based on the achievement of certain clinical and commercial development payable over a period of several years.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:13.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Denali Therapeutics Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In August 2020 we entered into a collaboration and license agreement with Denali to co-develop and co-commercialize Denali's small molecule inhibitors of leucine-rich repeat kinase 2 (LRRK2) for Parkinson's disease. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In addition to the LRRK2 program, we also received an exclusive option to license two preclinical programs from Denali&#x2019;s Transport Vehicle (TV) platform, including its Antibody Transport Vehicle: Abeta program, and a second program utilizing its TV technology. Further, we have the right of first negotiation on two additional TV-enabled therapeutics, currently at a preclinical stage, should Denali decide to seek a collaboration for such programs.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As part of this collaboration we purchased approximately $465.0&#160;million of Denali common stock in September 2020, or approximately 13&#160;million shares at approximately $34.94 per share, which are subject to transfer restrictions. We recorded an asset in investments and other assets in our condensed consolidated balance sheets to reflect the initial fair value of the Denali common stock acquired and a charge of approximately $41.3&#160;million to research and development expense in our condensed consolidated statements of income to reflect the premium paid for the Denali common stock. We also made an upfront payment of $560.0&#160;million that was recorded as research and development expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We may also pay development and commercial milestone payments that could total up to approximately $1.1&#160;billion if the milestones related to LRRK2 are achieved as well as tiered royalties on potential net commercial sales of LRRK2 licensed products.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:13.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Sangamo Therapeutics, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In February 2020 we entered into a collaboration and license agreement with Sangamo to develop and commercialize ST-501 for tauopathies, including Alzheimer's disease; ST-502 for synucleinopathies, including Parkinson&#x2019;s disease; a third neuromuscular disease target; and up to nine additional neurological disease targets to be identified and selected within a five-year period. The companies are leveraging Sangamo&#x2019;s proprietary zinc finger protein technology delivered via AAV with the aim to modulate the expression of key genes involved in neurological diseases. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In connection with the closing of this transaction in April 2020 we purchased $225.0 million of Sangamo common stock, or approximately 24 million shares at approximately $9.21 per share, which are subject to transfer restrictions. We recorded an asset in investments and other assets in our condensed consolidated balance sheets to reflect the initial fair value of the Sangamo common stock acquired and a charge of&#160;approximately $83.0 million&#160;to research and development expense in our condensed consolidated statements of income to reflect the premium paid for the Sangamo common stock. We also made an upfront payment of $125.0 million that was recorded as research and development expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We may also pay research, development, regulatory and commercial milestone payments that could total up to approximately $2.4 billion if we select all of the targets allowed under this agreement and all the specified milestones set forth in this agreement are achieved. Of this amount, up to $80.0 million relates to the selection of targets, $1.9 billion relates to the achievement of specified research, clinical development, regulatory and first commercial sale milestones and $380.0 million relates to the achievement of specified sales-based milestones if annual worldwide net sales of licensed products reach specified levels. In addition, we may pay tiered royalties on potential net commercial sales of any products developed under this collaboration in the high single digit to double digit sub-teen percentages.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:13.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Skyhawk Therapeutics, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In January 2019 we entered into a collaboration and research and development services agreement with Skyhawk Therapeutics, Inc. (Skyhawk) pursuant to which the companies are leveraging Skyhawk's SkySTAR technology platform with the goal of discovering innovative small molecule treatments for patients with neurological diseases, including MS and SMA. We are responsible for the development and potential commercialization of any therapies resulting from this collaboration and we may also pay Skyhawk up to a total of approximately $2.4&#160;billion in milestone payments as well as potential royalties on net commercial sales. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In connection with this agreement, we made an upfront payment of $74.0&#160;million to Skyhawk, of which $38.5 million was recorded as research and development expense in our condensed consolidated statements of income and $35.5 million was recorded as prepaid research and development expenditures within investments and other assets in our condensed consolidated balance sheets. These prepaid research and development services are &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;expensed as the services are provided. In October 2019 we amended this agreement to add an additional discovery program. In connection with this amendment, we made a payment to Skyhawk of $15.0 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:11.25pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Samsung Bioepis&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:13.5pt;margin-top:5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Joint Venture Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In February 2012 we entered into a joint venture agreement with Samsung BioLogics establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar products.&#160;In June 2018 we exercised our option under our joint venture agreement to increase our ownership percentage in Samsung Bioepis from approximately 5.0% to approximately 49.9%. The share purchase transaction was completed in November 2018 and, upon closing, we paid 759.5 billion South Korean won ($676.6 million) to Samsung BioLogics. As of September 30, 2020, our ownership percentage remained at approximately 49.9%.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We recognize our share of the results of operations related to our investment in Samsung Bioepis under the equity method of accounting one quarter in arrears when the results of the entity become available, which is reflected as equity in income (loss) of investee, net of tax in our condensed consolidated statements of income. During 2015, as our share of losses exceeded the carrying value of our initial investment, we suspended recognizing additional losses. In the first quarter of 2019 we restarted recognizing our share of Samsung Bioepis' (income) losses, and we began recognizing amortization on certain basis differences resulting from our November 2018 investment. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Upon investment, the equity method of accounting requires us to identify and allocate differences between the fair value of our investment and the carrying value of our interest in the underlying net assets of the investee. These basis differences are amortized over their economic life. The total basis difference was approximately $675 million and relates to inventory, developed technology, IPR&amp;amp;D and deferred tax balances. The basis differences related to inventory were amortized, net of tax, over their estimated useful lives of 1.5 years, and the basis differences related to developed technology and IPR&amp;amp;D for marketed products will be amortized, net of tax, over their estimated useful lives of 15 years. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Our joint venture partner, Samsung BioLogics, is currently subject to an ongoing criminal investigation that we continue to monitor. While this investigation could impact the operations of Samsung Bioepis and its business, we have assessed the value of our investment in Samsung Bioepis and continue to believe that the fair value of the investment is in excess of its net book value.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;For the three and nine months ended September 30, 2020, we recognized net losses on our investment of $13.1 million and $12.7 million, respectively, reflecting our share of Samsung Bioepis' operating results and amortization of basis differences.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As of September 30, 2020 and December 31, 2019, the carrying value of our investment in Samsung Bioepis totaled 652.4 billion South Korean won ($557.8 million) and 670.8 billion South Korean won ($580.2 million), respectively, which is classified as a component of investments and other assets in our condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:13.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;2019 Transaction&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In December 2019 we completed a transaction with Samsung Bioepis and secured the exclusive rights to commercialize two potential ophthalmology biosimilar products, SB11 referencing LUCENTIS and SB15 referencing EYLEA, in major markets worldwide, including the U.S., Canada, Europe, Japan and Australia. Samsung Bioepis will be responsible for development and will supply both products to us.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In connection with this transaction, we made an upfront payment of $100.0 million to Samsung Bioepis in January 2020, of which $63.0 million was recorded as research and development expense in 2019 and $37.0 million was recorded as an intangible asset in 2019. Additionally, during the third quarter of 2020, we paid Samsung Bioepis a $15.0&#160;million development milestone, which was included in research and development expense in our consolidated statements of income. We may pay Samsung Bioepis up to $195.0 million in additional development, regulatory and sales-based milestones.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We also acquired an option to extend the term of our 2013 commercial agreement for BENEPALI, IMRALDI and FLIXABI by an additional &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzg3OTYwOTMwNDMxMzk_81c0182f-ea26-4b51-b761-61b3c8a065e8"&gt;five&lt;/span&gt; years, subject to payment of an option exercise fee of $60.0 million, and obtained exclusive rights to commercialize these products in China.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:13.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;2013 Commercial Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We reflect revenues on sales of BENEPALI, IMRALDI and FLIXABI to third parties in product revenues, net in our condensed consolidated statements of income and record the related cost of revenues and sales and marketing expenses in our condensed consolidated statements of income to their respective line items when these costs are incurred. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We share 50% of the profit or loss related to our commercial agreement with Samsung Bioepis, which is recognized in collaboration profit (loss) sharing in our condensed consolidated statements of income. For the three and nine months ended September 30, 2020, we recognized net profit-sharing expense of $72.9 million and $200.1 million, respectively, to reflect Samsung Bioepis' 50% sharing of the net collaboration profits, compared to $60.1 million and $181.6 million, respectively, in the prior year comparative periods. As discussed above, we have an option to extend this agreement by an additional five years, subject to the payment of an option exercise fee of $60.0 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:13.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Other Services&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Simultaneous with the formation of Samsung Bioepis, we also entered into a technical development services agreement, a manufacturing agreement and a license agreement with Samsung Bioepis. For the three and nine months ended September 30, 2020, we recognized $5.4 million and $13.6 million, respectively, in revenues related to these services, which is reflected in collaborative and other relationships revenues as a component of other revenues in our condensed consolidated statements of income, compared to $12.9 million and $89.9 million, respectively, in the prior year comparative periods. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Following the divestiture of our Hiller&#xf8;d, Denmark manufacturing operations in August 2019, FUJIFILM assumed responsibility for the manufacture of clinical and commercial quantities of bulk drug substance of biosimilar products for Samsung Bioepis. We no longer recognize revenues for the manufacturing completed after the Hiller&#xf8;d, Denmark manufacturing operations divestiture date under our technical development services and manufacturing agreements with Samsung Bioepis. For additional information on the divestiture of our Hiller&#xf8;d, Denmark manufacturing operations, please read &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Note 3, Divestitures,&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Amounts receivable from Samsung Bioepis related to the agreements discussed above were $4.3 million and $85.0 million as of September 30, 2020 and December 31, 2019, respectively. Amounts payable to Samsung Bioepis were $26.4&#160;million as of September 30, 2020. Amounts payable to Samsung Bioepis as of December 31, 2019, consisted of the $100.0 million upfront payment related to the 2019 transaction, as discussed above.&lt;/span&gt;&lt;/div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;For additional information on our collaboration arrangements with Samsung Bioepis and our other significant collaboration arrangements, please read &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Note 18,&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Collaborative and Other Relationships,&lt;/span&gt; to our consolidated financial statements included in our 2019 Form 10-K.</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <biib:NumberOfProductCandidates
      contextRef="i99c8bf62c3f747a6825f635a38c876aa_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzg3OTYwOTMwNDMxMTM_5b831a8b-e221-4a05-ab82-69cd87c3a85a"
      unitRef="product">2</biib:NumberOfProductCandidates>
    <biib:SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzE1NzE0_0bd735c7-1393-4a0c-b225-0b016db7830a">&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:53.085%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.619%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.619%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.619%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.622%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total development expense incurred by the collaboration related to the advancement of BAN2401 and elenbecestat&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;75.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;168.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;153.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;305.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Biogen's share of BAN2401 and elenbecestat development expense reflected in research and development expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;37.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;84.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;76.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;152.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total sales and marketing expense incurred by the collaboration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;nm&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;6.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;24.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Biogen's share of BAN2401 and elenbecestat sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;nm&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;</biib:SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock>
    <biib:ExpenseIncurredByCollaboration
      contextRef="i5dd593028df14958ab74c65d6932d514_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90YWJsZTozZjcyNDU4ODdhZDg0YTA5YjViNmI0NTMwYjcyYzcwMS90YWJsZXJhbmdlOjNmNzI0NTg4N2FkODRhMDliNWI2YjQ1MzBiNzJjNzAxXzItMi0xLTEtMA_f6e32faa-d4eb-4841-81c3-148762b88c4a"
      unitRef="usd">75700000</biib:ExpenseIncurredByCollaboration>
    <biib:ExpenseIncurredByCollaboration
      contextRef="ie4289bd550fa4ecf980a7852c83941c9_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90YWJsZTozZjcyNDU4ODdhZDg0YTA5YjViNmI0NTMwYjcyYzcwMS90YWJsZXJhbmdlOjNmNzI0NTg4N2FkODRhMDliNWI2YjQ1MzBiNzJjNzAxXzItNC0xLTEtMA_142a46d8-889b-467d-80b3-f42c7ef479bb"
      unitRef="usd">168700000</biib:ExpenseIncurredByCollaboration>
    <biib:ExpenseIncurredByCollaboration
      contextRef="i99c8bf62c3f747a6825f635a38c876aa_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90YWJsZTozZjcyNDU4ODdhZDg0YTA5YjViNmI0NTMwYjcyYzcwMS90YWJsZXJhbmdlOjNmNzI0NTg4N2FkODRhMDliNWI2YjQ1MzBiNzJjNzAxXzItNi0xLTEtMA_fd4f1db0-9640-40e2-8b54-0e570aabc07d"
      unitRef="usd">153200000</biib:ExpenseIncurredByCollaboration>
    <biib:ExpenseIncurredByCollaboration
      contextRef="iedea87e6fca548b387e737941a938d4d_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90YWJsZTozZjcyNDU4ODdhZDg0YTA5YjViNmI0NTMwYjcyYzcwMS90YWJsZXJhbmdlOjNmNzI0NTg4N2FkODRhMDliNWI2YjQ1MzBiNzJjNzAxXzItOC0xLTEtMA_00974f32-4e33-4833-b851-91f22f34de6e"
      unitRef="usd">305300000</biib:ExpenseIncurredByCollaboration>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i5dd593028df14958ab74c65d6932d514_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90YWJsZTozZjcyNDU4ODdhZDg0YTA5YjViNmI0NTMwYjcyYzcwMS90YWJsZXJhbmdlOjNmNzI0NTg4N2FkODRhMDliNWI2YjQ1MzBiNzJjNzAxXzMtMi0xLTEtMA_13c8c4f3-4ea8-4e01-80e2-170aea9c44ca"
      unitRef="usd">37900000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="ie4289bd550fa4ecf980a7852c83941c9_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90YWJsZTozZjcyNDU4ODdhZDg0YTA5YjViNmI0NTMwYjcyYzcwMS90YWJsZXJhbmdlOjNmNzI0NTg4N2FkODRhMDliNWI2YjQ1MzBiNzJjNzAxXzMtNC0xLTEtMA_f883d048-9fc9-42d3-9085-5b388123e0c6"
      unitRef="usd">84300000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i99c8bf62c3f747a6825f635a38c876aa_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90YWJsZTozZjcyNDU4ODdhZDg0YTA5YjViNmI0NTMwYjcyYzcwMS90YWJsZXJhbmdlOjNmNzI0NTg4N2FkODRhMDliNWI2YjQ1MzBiNzJjNzAxXzMtNi0xLTEtMA_3408dcec-8b17-4e8a-8423-a59bef7862fa"
      unitRef="usd">76600000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="iedea87e6fca548b387e737941a938d4d_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90YWJsZTozZjcyNDU4ODdhZDg0YTA5YjViNmI0NTMwYjcyYzcwMS90YWJsZXJhbmdlOjNmNzI0NTg4N2FkODRhMDliNWI2YjQ1MzBiNzJjNzAxXzMtOC0xLTEtMA_0e8d0f79-a61f-4957-a86d-fc6a77fd7ed2"
      unitRef="usd">152600000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expenseincurredbythecollaboration
      contextRef="i76cadd05cfd9487992bcc01b2fbe54ad_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90YWJsZTozZjcyNDU4ODdhZDg0YTA5YjViNmI0NTMwYjcyYzcwMS90YWJsZXJhbmdlOjNmNzI0NTg4N2FkODRhMDliNWI2YjQ1MzBiNzJjNzAxXzQtNC0xLTEtMA_01e13835-f755-452a-a8e7-a90bde496617"
      unitRef="usd">10200000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="i4df0aa1f099c4275a635ce9719f80079_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90YWJsZTozZjcyNDU4ODdhZDg0YTA5YjViNmI0NTMwYjcyYzcwMS90YWJsZXJhbmdlOjNmNzI0NTg4N2FkODRhMDliNWI2YjQ1MzBiNzJjNzAxXzQtNi0xLTEtMA_7c919780-0c98-44fe-9b85-432c21ed128e"
      unitRef="usd">6300000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="ieaf688a040e748fcb2fb53cc4980b1ae_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90YWJsZTozZjcyNDU4ODdhZDg0YTA5YjViNmI0NTMwYjcyYzcwMS90YWJsZXJhbmdlOjNmNzI0NTg4N2FkODRhMDliNWI2YjQ1MzBiNzJjNzAxXzQtOC0xLTEtMA_8822a0fe-6b65-4833-ad7e-2af392ce77ab"
      unitRef="usd">24800000</biib:Expenseincurredbythecollaboration>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i76cadd05cfd9487992bcc01b2fbe54ad_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90YWJsZTozZjcyNDU4ODdhZDg0YTA5YjViNmI0NTMwYjcyYzcwMS90YWJsZXJhbmdlOjNmNzI0NTg4N2FkODRhMDliNWI2YjQ1MzBiNzJjNzAxXzUtNC0xLTEtMA_e302abc7-fdd6-4ad9-8202-fb20db9af238"
      unitRef="usd">5100000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i4df0aa1f099c4275a635ce9719f80079_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90YWJsZTozZjcyNDU4ODdhZDg0YTA5YjViNmI0NTMwYjcyYzcwMS90YWJsZXJhbmdlOjNmNzI0NTg4N2FkODRhMDliNWI2YjQ1MzBiNzJjNzAxXzUtNi0xLTEtMA_6a43790d-1c02-4a2a-99c6-69d0a642ca76"
      unitRef="usd">3200000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="ieaf688a040e748fcb2fb53cc4980b1ae_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90YWJsZTozZjcyNDU4ODdhZDg0YTA5YjViNmI0NTMwYjcyYzcwMS90YWJsZXJhbmdlOjNmNzI0NTg4N2FkODRhMDliNWI2YjQ1MzBiNzJjNzAxXzUtOC0xLTEtMA_83b08ca0-e983-4243-9f72-9d2196e96402"
      unitRef="usd">12400000</biib:Expensereflectedwithinstatementsofincome>
    <biib:PercentageoffuturedevelopmentcostsrelatedtoEisai
      contextRef="i99c8bf62c3f747a6825f635a38c876aa_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzI2ODE_b56ebfc6-f9f5-48d3-9c78-2d5b3b8fa0df"
      unitRef="number">0.45</biib:PercentageoffuturedevelopmentcostsrelatedtoEisai>
    <us-gaap:LossOnContractTermination
      contextRef="i6fc4449da6e645b3871baa6066b7ba15_D20190401-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzMzNjU_16c12a3e-6a88-4e34-bffc-02acff25c30d"
      unitRef="usd">45000000.0</us-gaap:LossOnContractTermination>
    <biib:PercentageoffuturedevelopmentcostsrelatedtoEisai
      contextRef="i99c8bf62c3f747a6825f635a38c876aa_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzM0NzI_b56ebfc6-f9f5-48d3-9c78-2d5b3b8fa0df"
      unitRef="number">0.45</biib:PercentageoffuturedevelopmentcostsrelatedtoEisai>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i99c8bf62c3f747a6825f635a38c876aa_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzM3NzQ_902e9ab8-5862-418b-b24c-d0d883ead2d6"
      unitRef="usd">33800000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <biib:PercentageoffuturedevelopmentcostsrelatedtoEisai
      contextRef="i99c8bf62c3f747a6825f635a38c876aa_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzM3OTY_b56ebfc6-f9f5-48d3-9c78-2d5b3b8fa0df"
      unitRef="number">0.45</biib:PercentageoffuturedevelopmentcostsrelatedtoEisai>
    <biib:AdditionalMilestonePayment
      contextRef="i99c8bf62c3f747a6825f635a38c876aa_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzM4MTI_5d008e04-e178-4fd0-bcf7-9f4a27ef7017"
      unitRef="usd">75000000.0</biib:AdditionalMilestonePayment>
    <biib:SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzE1NzE5_6c00ea66-6444-4af0-9e35-b258b6b37411">&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;A summary of development, sales and marketing and milestone expense related to the Aducanumab Collaboration Agreement is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:53.085%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.619%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.619%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.619%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.622%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total aducanumab development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;37.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;92.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;170.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Biogen's share of aducanumab development expense reflected in research and development expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;20.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;50.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;93.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total aducanumab sales and marketing expense incurred by the collaboration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;90.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;158.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;21.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Biogen's share of aducanumab sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;51.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;88.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total aducanumab collaboration third party milestone expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;75.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Eisai's share of aducanumab milestone expense reflected in collaboration profit sharing in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);"&gt;33.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</biib:SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock>
    <biib:Expenseincurredbythecollaboration
      contextRef="i84416da07ea446c6a74945f76525350d_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90YWJsZTo5NjIxNWM3MzdiMGY0OWJlODBlZjUyM2Y3MzgwMjY3Mi90YWJsZXJhbmdlOjk2MjE1YzczN2IwZjQ5YmU4MGVmNTIzZjczODAyNjcyXzItMi0xLTEtMA_198ad987-dba2-4813-91ce-476309878254"
      unitRef="usd">37500000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="i0347bcd849ae4267bfea5d50d6b0fbea_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90YWJsZTo5NjIxNWM3MzdiMGY0OWJlODBlZjUyM2Y3MzgwMjY3Mi90YWJsZXJhbmdlOjk2MjE1YzczN2IwZjQ5YmU4MGVmNTIzZjczODAyNjcyXzItNC0xLTEtMA_e5fda941-27d4-4548-b3c3-ea0de6dde137"
      unitRef="usd">4700000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="i74c4058ef32546ab9478606d50a42ff6_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90YWJsZTo5NjIxNWM3MzdiMGY0OWJlODBlZjUyM2Y3MzgwMjY3Mi90YWJsZXJhbmdlOjk2MjE1YzczN2IwZjQ5YmU4MGVmNTIzZjczODAyNjcyXzItNi0xLTEtMA_6535c145-aa82-4e46-b4e2-d7216009be20"
      unitRef="usd">92500000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="i5ab886b24e304952b01a70c3288ca622_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90YWJsZTo5NjIxNWM3MzdiMGY0OWJlODBlZjUyM2Y3MzgwMjY3Mi90YWJsZXJhbmdlOjk2MjE1YzczN2IwZjQ5YmU4MGVmNTIzZjczODAyNjcyXzItOC0xLTEtMA_9af35c7e-fc2d-451f-85d5-e50b0178a7ad"
      unitRef="usd">170500000</biib:Expenseincurredbythecollaboration>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i84416da07ea446c6a74945f76525350d_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90YWJsZTo5NjIxNWM3MzdiMGY0OWJlODBlZjUyM2Y3MzgwMjY3Mi90YWJsZXJhbmdlOjk2MjE1YzczN2IwZjQ5YmU4MGVmNTIzZjczODAyNjcyXzMtMi0xLTEtMA_2f80f8da-e21a-414b-91e3-428a281f7bc6"
      unitRef="usd">20600000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i0347bcd849ae4267bfea5d50d6b0fbea_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90YWJsZTo5NjIxNWM3MzdiMGY0OWJlODBlZjUyM2Y3MzgwMjY3Mi90YWJsZXJhbmdlOjk2MjE1YzczN2IwZjQ5YmU4MGVmNTIzZjczODAyNjcyXzMtNC0xLTEtMA_bef39d9c-bda3-44c4-8611-f81754175913"
      unitRef="usd">2600000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i74c4058ef32546ab9478606d50a42ff6_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90YWJsZTo5NjIxNWM3MzdiMGY0OWJlODBlZjUyM2Y3MzgwMjY3Mi90YWJsZXJhbmdlOjk2MjE1YzczN2IwZjQ5YmU4MGVmNTIzZjczODAyNjcyXzMtNi0xLTEtMA_ed79053f-a5f6-41b5-beca-5cde129324e5"
      unitRef="usd">50900000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i5ab886b24e304952b01a70c3288ca622_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90YWJsZTo5NjIxNWM3MzdiMGY0OWJlODBlZjUyM2Y3MzgwMjY3Mi90YWJsZXJhbmdlOjk2MjE1YzczN2IwZjQ5YmU4MGVmNTIzZjczODAyNjcyXzMtOC0xLTEtMA_e2c7bc2f-c278-4423-a305-432d6d8c2f91"
      unitRef="usd">93800000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expenseincurredbythecollaboration
      contextRef="i108d4b03b28442088d579082f1514805_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90YWJsZTo5NjIxNWM3MzdiMGY0OWJlODBlZjUyM2Y3MzgwMjY3Mi90YWJsZXJhbmdlOjk2MjE1YzczN2IwZjQ5YmU4MGVmNTIzZjczODAyNjcyXzQtMi0xLTEtMA_d2b4c255-ea15-4cdf-93ff-fcdc39f01e7c"
      unitRef="usd">90900000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="i1d21a2127fcd4783820ebe46b0ed050b_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90YWJsZTo5NjIxNWM3MzdiMGY0OWJlODBlZjUyM2Y3MzgwMjY3Mi90YWJsZXJhbmdlOjk2MjE1YzczN2IwZjQ5YmU4MGVmNTIzZjczODAyNjcyXzQtNC0xLTEtMA_96659f5c-2213-46d8-9bb7-3e4f9484aa59"
      unitRef="usd">100000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="i758bfb8a36214bcd99abf2d550c98467_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90YWJsZTo5NjIxNWM3MzdiMGY0OWJlODBlZjUyM2Y3MzgwMjY3Mi90YWJsZXJhbmdlOjk2MjE1YzczN2IwZjQ5YmU4MGVmNTIzZjczODAyNjcyXzQtNi0xLTEtMA_1b30712b-d085-494e-96bd-e7ab8e3a5be7"
      unitRef="usd">158800000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="icd694f937faa421dac86a19acb834bb4_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90YWJsZTo5NjIxNWM3MzdiMGY0OWJlODBlZjUyM2Y3MzgwMjY3Mi90YWJsZXJhbmdlOjk2MjE1YzczN2IwZjQ5YmU4MGVmNTIzZjczODAyNjcyXzQtOC0xLTEtMA_510f9b31-7e2b-4145-914e-cef044687040"
      unitRef="usd">21300000</biib:Expenseincurredbythecollaboration>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i108d4b03b28442088d579082f1514805_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90YWJsZTo5NjIxNWM3MzdiMGY0OWJlODBlZjUyM2Y3MzgwMjY3Mi90YWJsZXJhbmdlOjk2MjE1YzczN2IwZjQ5YmU4MGVmNTIzZjczODAyNjcyXzUtMi0xLTEtMA_31bbf993-93a9-46ec-87bb-030c8ca1c321"
      unitRef="usd">51300000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i1d21a2127fcd4783820ebe46b0ed050b_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90YWJsZTo5NjIxNWM3MzdiMGY0OWJlODBlZjUyM2Y3MzgwMjY3Mi90YWJsZXJhbmdlOjk2MjE1YzczN2IwZjQ5YmU4MGVmNTIzZjczODAyNjcyXzUtNC0xLTEtMA_40720d25-9ad8-4265-b2fb-72c83f3f198c"
      unitRef="usd">0</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i758bfb8a36214bcd99abf2d550c98467_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90YWJsZTo5NjIxNWM3MzdiMGY0OWJlODBlZjUyM2Y3MzgwMjY3Mi90YWJsZXJhbmdlOjk2MjE1YzczN2IwZjQ5YmU4MGVmNTIzZjczODAyNjcyXzUtNi0xLTEtMA_cf279716-8cab-4a98-92ba-efe52a931da6"
      unitRef="usd">88800000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="icd694f937faa421dac86a19acb834bb4_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90YWJsZTo5NjIxNWM3MzdiMGY0OWJlODBlZjUyM2Y3MzgwMjY3Mi90YWJsZXJhbmdlOjk2MjE1YzczN2IwZjQ5YmU4MGVmNTIzZjczODAyNjcyXzUtOC0xLTEtMA_42fa8ddb-ec3f-4105-96cd-d0cf94172c4b"
      unitRef="usd">11700000</biib:Expensereflectedwithinstatementsofincome>
    <biib:AdditionalMilestonePayment
      contextRef="i5dd593028df14958ab74c65d6932d514_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90YWJsZTo5NjIxNWM3MzdiMGY0OWJlODBlZjUyM2Y3MzgwMjY3Mi90YWJsZXJhbmdlOjk2MjE1YzczN2IwZjQ5YmU4MGVmNTIzZjczODAyNjcyXzYtMi0xLTEtMA_cfc98487-11dd-4906-ba4a-2195d3796849"
      unitRef="usd">0</biib:AdditionalMilestonePayment>
    <biib:AdditionalMilestonePayment
      contextRef="ie4289bd550fa4ecf980a7852c83941c9_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90YWJsZTo5NjIxNWM3MzdiMGY0OWJlODBlZjUyM2Y3MzgwMjY3Mi90YWJsZXJhbmdlOjk2MjE1YzczN2IwZjQ5YmU4MGVmNTIzZjczODAyNjcyXzYtNC0xLTEtMA_d62bfe23-bccc-4586-9252-2a804fef4b3b"
      unitRef="usd">0</biib:AdditionalMilestonePayment>
    <biib:AdditionalMilestonePayment
      contextRef="i99c8bf62c3f747a6825f635a38c876aa_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90YWJsZTo5NjIxNWM3MzdiMGY0OWJlODBlZjUyM2Y3MzgwMjY3Mi90YWJsZXJhbmdlOjk2MjE1YzczN2IwZjQ5YmU4MGVmNTIzZjczODAyNjcyXzYtNi0xLTEtMA_cb814bed-5212-415c-b2c6-35aca92f7658"
      unitRef="usd">75000000.0</biib:AdditionalMilestonePayment>
    <biib:AdditionalMilestonePayment
      contextRef="iedea87e6fca548b387e737941a938d4d_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90YWJsZTo5NjIxNWM3MzdiMGY0OWJlODBlZjUyM2Y3MzgwMjY3Mi90YWJsZXJhbmdlOjk2MjE1YzczN2IwZjQ5YmU4MGVmNTIzZjczODAyNjcyXzYtOC0xLTEtMA_d0bdcbd2-1e57-4c3f-9098-138349c1296d"
      unitRef="usd">0</biib:AdditionalMilestonePayment>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i5dd593028df14958ab74c65d6932d514_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90YWJsZTo5NjIxNWM3MzdiMGY0OWJlODBlZjUyM2Y3MzgwMjY3Mi90YWJsZXJhbmdlOjk2MjE1YzczN2IwZjQ5YmU4MGVmNTIzZjczODAyNjcyXzctMi0xLTEtMA_444d8567-6c74-4a43-be46-c65b4ec55317"
      unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ie4289bd550fa4ecf980a7852c83941c9_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90YWJsZTo5NjIxNWM3MzdiMGY0OWJlODBlZjUyM2Y3MzgwMjY3Mi90YWJsZXJhbmdlOjk2MjE1YzczN2IwZjQ5YmU4MGVmNTIzZjczODAyNjcyXzctNC0xLTEtMA_c865e2d9-028b-43c5-89af-8d4f2341b757"
      unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i99c8bf62c3f747a6825f635a38c876aa_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90YWJsZTo5NjIxNWM3MzdiMGY0OWJlODBlZjUyM2Y3MzgwMjY3Mi90YWJsZXJhbmdlOjk2MjE1YzczN2IwZjQ5YmU4MGVmNTIzZjczODAyNjcyXzctNi0xLTEtMA_710bd85b-f617-4a0a-af92-ac7f0901f99a"
      unitRef="usd">33800000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="iedea87e6fca548b387e737941a938d4d_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90YWJsZTo5NjIxNWM3MzdiMGY0OWJlODBlZjUyM2Y3MzgwMjY3Mi90YWJsZXJhbmdlOjk2MjE1YzczN2IwZjQ5YmU4MGVmNTIzZjczODAyNjcyXzctOC0xLTEtMA_9b04ddfa-1b05-467e-92cd-a1759315d81a"
      unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <biib:Expenseincurredbythecollaboration
      contextRef="i1927d71684864d0ea1eab5f146d82d5d_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90YWJsZTphNDNhNTg0MTQ5NzQ0NTI2YTQ3ZDZkMDE5YzAxMzI4MS90YWJsZXJhbmdlOmE0M2E1ODQxNDk3NDQ1MjZhNDdkNmQwMTljMDEzMjgxXzItMi0xLTEtMA_3ef82553-8cce-4e0d-a11c-ab1c043b4774"
      unitRef="usd">10200000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="icab43be754b749fe968e868f7a639cd7_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90YWJsZTphNDNhNTg0MTQ5NzQ0NTI2YTQ3ZDZkMDE5YzAxMzI4MS90YWJsZXJhbmdlOmE0M2E1ODQxNDk3NDQ1MjZhNDdkNmQwMTljMDEzMjgxXzItNi0xLTEtMA_324e276e-2a26-4fb8-9dec-0be300fbf476"
      unitRef="usd">35700000</biib:Expenseincurredbythecollaboration>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i1927d71684864d0ea1eab5f146d82d5d_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90YWJsZTphNDNhNTg0MTQ5NzQ0NTI2YTQ3ZDZkMDE5YzAxMzI4MS90YWJsZXJhbmdlOmE0M2E1ODQxNDk3NDQ1MjZhNDdkNmQwMTljMDEzMjgxXzMtMi0xLTEtMA_541232ae-6839-4bb4-ba55-76e12443760c"
      unitRef="usd">5200000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="icab43be754b749fe968e868f7a639cd7_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90YWJsZTphNDNhNTg0MTQ5NzQ0NTI2YTQ3ZDZkMDE5YzAxMzI4MS90YWJsZXJhbmdlOmE0M2E1ODQxNDk3NDQ1MjZhNDdkNmQwMTljMDEzMjgxXzMtNi0xLTEtMA_519baa41-1dcb-4b9a-929a-6dc1b6cc9860"
      unitRef="usd">17900000</biib:Expensereflectedwithinstatementsofincome>
    <biib:GlobalLicensingCollaborationAgreementAmountSharesPurchased
      contextRef="id8caeb1ba3904b97aa01e55d54bcfdd0_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzEwOTk1MTE2NDQ3MjI_c189351d-c195-4036-8874-44977a957323"
      unitRef="usd">465000000.0</biib:GlobalLicensingCollaborationAgreementAmountSharesPurchased>
    <biib:Investmentincommonstocksharespurchased
      contextRef="i309c31a67fb24e66812ca6f278d681d1_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzEwOTk1MTE2NDQ3Mzg_b2235e7e-5bfb-434c-bbd3-ea9181120aca"
      unitRef="shares">13000000</biib:Investmentincommonstocksharespurchased>
    <biib:GlobalLicensingCollaborationAgreementSharesPurchasedPerShare
      contextRef="id8caeb1ba3904b97aa01e55d54bcfdd0_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzEwOTk1MTE2NDQ3NTA_84dcbe06-c43a-43aa-9831-da135cd9728b"
      unitRef="usdPerShare">34.94</biib:GlobalLicensingCollaborationAgreementSharesPurchasedPerShare>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="id8caeb1ba3904b97aa01e55d54bcfdd0_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzEwOTk1MTE2NDQ3NTg_f269d3ec-542b-4e90-9d21-74dfff2014a8"
      unitRef="usd">41300000</us-gaap:ResearchAndDevelopmentExpense>
    <biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner
      contextRef="id8caeb1ba3904b97aa01e55d54bcfdd0_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzEwOTk1MTE2NDUwMDQ_510b0b5e-d33f-40ec-b0f5-320b4d4d97a6"
      unitRef="usd">560000000.0</biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner>
    <biib:GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments
      contextRef="id8caeb1ba3904b97aa01e55d54bcfdd0_D20200101-20200930"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzEwOTk1MTE2NDUzMTQ_424a97b9-8b81-4b18-a2e9-8208c92ff11a"
      unitRef="usd">1100000000</biib:GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments>
    <biib:GlobalLicensingCollaborationAgreementAmountSharesPurchased
      contextRef="i00bfaa56f846452aa021215b0332f13a_D20200201-20200229"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzY1Nzg_3c7f818b-c28e-4e05-b043-4cb2ed5383e0"
      unitRef="usd">225000000.0</biib:GlobalLicensingCollaborationAgreementAmountSharesPurchased>
    <biib:GlobalLicensingCollaborationAgreementSharesPurchased
      contextRef="i00bfaa56f846452aa021215b0332f13a_D20200201-20200229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzY2MjM_bf80819d-ebb8-4a20-9669-019c769ec3df"
      unitRef="shares">24000000</biib:GlobalLicensingCollaborationAgreementSharesPurchased>
    <biib:GlobalLicensingCollaborationAgreementSharesPurchasedPerShare
      contextRef="i00bfaa56f846452aa021215b0332f13a_D20200201-20200229"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzY2MzY_024e895d-63fe-4b27-bbfc-ab32901479ac"
      unitRef="usdPerShare">9.21</biib:GlobalLicensingCollaborationAgreementSharesPurchasedPerShare>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i00bfaa56f846452aa021215b0332f13a_D20200201-20200229"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzY4OTM_d64a322b-a8a5-4153-bf92-c27455708fe2"
      unitRef="usd">83000000.0</us-gaap:ResearchAndDevelopmentExpense>
    <biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner
      contextRef="i00bfaa56f846452aa021215b0332f13a_D20200201-20200229"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzcwNzY_f55e3871-f8d3-49a0-9851-520dba389e12"
      unitRef="usd">125000000.0</biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner>
    <biib:GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments
      contextRef="i00bfaa56f846452aa021215b0332f13a_D20200201-20200229"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzcyNTU_deaf01ab-6050-4c4b-8b19-fc0c6b6da9d6"
      unitRef="usd">2400000000</biib:GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments>
    <biib:GlobalLicensingCollaborationAgreementPaymentSelectionofTargets
      contextRef="i00bfaa56f846452aa021215b0332f13a_D20200201-20200229"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzc0MTY_81ab86c5-0355-405d-b561-95c9f7ae5a3d"
      unitRef="usd">80000000.0</biib:GlobalLicensingCollaborationAgreementPaymentSelectionofTargets>
    <biib:GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones
      contextRef="i00bfaa56f846452aa021215b0332f13a_D20200201-20200229"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzc0NTY_880bea5c-670a-41fe-b85d-f363de269ed8"
      unitRef="usd">1900000000</biib:GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones>
    <biib:GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones
      contextRef="i00bfaa56f846452aa021215b0332f13a_D20200201-20200229"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzc1ODM_1db9f639-27f6-4c4e-8f20-7f73bb37d907"
      unitRef="usd">380000000.0</biib:GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones>
    <biib:GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments
      contextRef="i626bc76978584f20bed3f3c65385234a_D20190101-20190131"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzEwOTk1MTE2NDM1MjI_b777ac4d-0d5f-41bd-a7e3-dae7b8cc485a"
      unitRef="usd">2400000000</biib:GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments>
    <biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner
      contextRef="i83f7cd89dae046c59b442f0c3d6955d3_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzEwOTk1MTE2NDM1NTU_8ddd346e-bcd7-4e52-b1f3-b469922fd15e"
      unitRef="usd">74000000.0</biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i83f7cd89dae046c59b442f0c3d6955d3_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzg2NDQ_56618a5a-e97b-48a3-a935-952d76c90eb6"
      unitRef="usd">38500000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:PrepaidExpenseAndOtherAssets
      contextRef="i6b31731f10d3438bbb21a6d76e82951d_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzg3NTE_c99a0e96-8055-495b-a440-cba464f1d2d4"
      unitRef="usd">35500000</us-gaap:PrepaidExpenseAndOtherAssets>
    <biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner
      contextRef="ib83f121fe8084d6189d5e4c28193f59f_D20191001-20191031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzkxMzg_a19a7b4e-ca87-4485-aee0-0915e95d024e"
      unitRef="usd">15000000.0</biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner>
    <biib:EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction
      contextRef="ide3b267ed539403d9aea0f7cee18e938_I20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzk1MDc_62ee03bb-1ff1-4dab-a8ab-5f8ae8bdbbc8"
      unitRef="number">0.050</biib:EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i982da4cced9d4ae2b09cb6c0c35fbf7b_I20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzk1Mjc_d3369dea-3025-41d6-b93c-e74f0a07172d"
      unitRef="number">0.499</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="i4d505177b87243539cc2ef4baf3b7b2d_D20181101-20181130"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzk2MjA_7c2debff-1b56-4680-afb0-2af413520cb1"
      unitRef="krw">759500000000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="i65733f4ace874e1e89159f8c95744460_D20190101-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzk2NDE_c258ea0a-53d2-414d-a0c2-a26fc20da67d"
      unitRef="usd">676600000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i982da4cced9d4ae2b09cb6c0c35fbf7b_I20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzk3Mjg_d3369dea-3025-41d6-b93c-e74f0a07172d"
      unitRef="number">0.499</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity
      contextRef="i7967ad33dbdb48e89dd02f434444b459_I20181107"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzEwNzQz_fcb5c6c9-0a41-4bdd-a377-23dc4dcb3cc2"
      unitRef="usd">675000000</us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity>
    <biib:Equitymethodinvestmentbasisdifferenceamortizationperiod
      contextRef="i071c5b3fcf304751900b25afea18d401_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzEwOTYz_386e5e25-2427-4dcf-959f-ba4d43c0dc38">P1Y6M</biib:Equitymethodinvestmentbasisdifferenceamortizationperiod>
    <biib:Equitymethodinvestmentbasisdifferenceamortizationperiod
      contextRef="i16f85f52b2ce4a3e92746ecfebd0be40_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzEwOTc2_b801c911-5dfa-4aa1-9498-770813d29e08">P15Y</biib:Equitymethodinvestmentbasisdifferenceamortizationperiod>
    <us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions
      contextRef="i0fbd288a2a484b2092b7fb912c7e80ae_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzExNDkx_ceb657d4-09fb-4611-bb03-0e16f8d9587b"
      unitRef="usd">13100000</us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions>
    <us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions
      contextRef="ia4cc37c0d62c49b58b4a17e71a0852f4_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzExNDk4_1fc74a8d-f49d-4ce4-b033-fa665be4480f"
      unitRef="usd">12700000</us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions>
    <us-gaap:EquityMethodInvestments
      contextRef="i982da4cced9d4ae2b09cb6c0c35fbf7b_I20200930"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzExNjY3_d66f5a79-a8a7-4979-84f4-b6eb4c4f6688"
      unitRef="krw">652400000000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i982da4cced9d4ae2b09cb6c0c35fbf7b_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzExNjg4_43a1d265-2286-4cde-81e7-642a91432520"
      unitRef="usd">557800000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="if66718fccef241c1b9e6ef3161a2fd8a_I20191231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzExNjk2_a0f8beda-3815-4bd3-948d-7e4b0813361e"
      unitRef="krw">670800000000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="if66718fccef241c1b9e6ef3161a2fd8a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzExNzE3_084e7577-ea8d-4489-ad11-f62dd362ea16"
      unitRef="usd">580200000</us-gaap:EquityMethodInvestments>
    <biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner
      contextRef="ia29071dbf1dd4669a9f529d1af16da0e_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzEyMzI1_9c200e0b-3d24-43e9-8ecc-141ea90a9518"
      unitRef="usd">100000000.0</biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ia29071dbf1dd4669a9f529d1af16da0e_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzEyMzcz_cc1f9ef8-5164-44de-a634-85c022029041"
      unitRef="usd">63000000.0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:PrepaidExpenseAndOtherAssets
      contextRef="i10d0b368c77e476286c6d631057ae023_I20200131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzEyNDM3_949ae6c2-1461-4ac6-90a9-d335f858f421"
      unitRef="usd">37000000.0</us-gaap:PrepaidExpenseAndOtherAssets>
    <biib:AdditionalMilestonePayment
      contextRef="icb12afc98a00406dbfbbf375974469a1_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzEwOTk1MTE2NDc1MzE_512024c4-a7a1-4300-bbb4-da04ebad2b0b"
      unitRef="usd">15000000.0</biib:AdditionalMilestonePayment>
    <biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones
      contextRef="i5da3d551e877481482c2c617be75f347_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzEyNTE4_cc8393f7-14bc-43c9-9886-6eb5a62a9312"
      unitRef="usd">195000000.0</biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones>
    <biib:ContractOptionExerciseFee
      contextRef="ia29071dbf1dd4669a9f529d1af16da0e_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzEyODc4_675d094e-b732-4519-8922-05abb0e74c01"
      unitRef="usd">60000000.0</biib:ContractOptionExerciseFee>
    <biib:Biogenshareofcopromotionprofitsorlosses
      contextRef="ia4cc37c0d62c49b58b4a17e71a0852f4_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzEzMzMx_095ec44b-ee47-4e9e-bd41-05508cb08300"
      unitRef="number">0.50</biib:Biogenshareofcopromotionprofitsorlosses>
    <biib:Collaborationprofitlosssharing
      contextRef="i0fbd288a2a484b2092b7fb912c7e80ae_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzEzNjA0_4c4c0b62-25a8-484e-bf13-7b74b4af7f25"
      unitRef="usd">72900000</biib:Collaborationprofitlosssharing>
    <biib:Collaborationprofitlosssharing
      contextRef="ia4cc37c0d62c49b58b4a17e71a0852f4_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzEzNjEx_2228082f-1797-48c5-ad51-c5b53071238b"
      unitRef="usd">200100000</biib:Collaborationprofitlosssharing>
    <biib:Biogenshareofcopromotionprofitsorlosses
      contextRef="ia4cc37c0d62c49b58b4a17e71a0852f4_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzEzNjU3_095ec44b-ee47-4e9e-bd41-05508cb08300"
      unitRef="number">0.50</biib:Biogenshareofcopromotionprofitsorlosses>
    <biib:Collaborationprofitlosssharing
      contextRef="i64047abc9e1e47a6a0d61a0e7591f7e1_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzEzNzE0_744c5ebc-14a0-421b-982d-d595c3b6dec4"
      unitRef="usd">60100000</biib:Collaborationprofitlosssharing>
    <biib:Collaborationprofitlosssharing
      contextRef="i80a9168a435d4f6a98b2450218498ef3_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzEzNzIx_94662f99-7e3a-44fa-ad25-57ac878923a8"
      unitRef="usd">181600000</biib:Collaborationprofitlosssharing>
    <biib:ContractOptionExerciseFee
      contextRef="ia29071dbf1dd4669a9f529d1af16da0e_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzEzOTIy_675d094e-b732-4519-8922-05abb0e74c01"
      unitRef="usd">60000000.0</biib:ContractOptionExerciseFee>
    <us-gaap:Revenues
      contextRef="ib22568b42dea422aad4788445cea0a41_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzE0MTc5_61b43fe3-c850-4ade-991e-424c837a839f"
      unitRef="usd">5400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i00616e2d34c848588546a4eb3b7e17e1_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzE0MTg2_8a338065-f358-4cea-89ef-75d0e6815ca6"
      unitRef="usd">13600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i035b83abf8f74352b8844936a4c053e5_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzE0NDA5_278b7681-81eb-4a13-9ebc-af0ef1832552"
      unitRef="usd">12900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if62153afc8b048fea1ecd3d555faaf6d_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzE0NDE2_1c385eac-461c-4c37-a70b-a6f0c07b54fa"
      unitRef="usd">89900000</us-gaap:Revenues>
    <us-gaap:DueFromRelatedParties
      contextRef="i27257060fb394740a54642f97bef35f3_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzE1MjAx_3a41be02-eba1-434a-8fb1-31e11d70f0f1"
      unitRef="usd">4300000</us-gaap:DueFromRelatedParties>
    <us-gaap:DueFromRelatedParties
      contextRef="i068f3b4714364e10a6f8a38a28733f78_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzE1MjA4_6cefaae1-daf6-4f6f-84f8-4532ef36436b"
      unitRef="usd">85000000.0</us-gaap:DueFromRelatedParties>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="i27257060fb394740a54642f97bef35f3_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzE1MjUz_6b313bbf-ca3e-4457-95de-9dc1a3f98c75"
      unitRef="usd">26400000</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="i068f3b4714364e10a6f8a38a28733f78_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzE1MzYz_7a262d9c-1205-4177-8fe6-d0f3678b5a44"
      unitRef="usd">100000000.0</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:VariableInterestEntityDisclosureTextBlock
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTgvZnJhZzo0OWRmMGZhZDBiNTg0NWU5YjcyZTc3Njg4NmQzMGE1Ny90ZXh0cmVnaW9uOjQ5ZGYwZmFkMGI1ODQ1ZTliNzJlNzc2ODg2ZDMwYTU3XzU3MjM_267df1ac-a257-40f5-9677-fc21a32dbe1d">&lt;div style="text-indent:11.25pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Consolidated Variable Interest Entities&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Our condensed consolidated financial statements include the financial results of variable interest entities in which we are the primary beneficiary. The following are our significant variable interest entities.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:13.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Neurimmune SubOne AG&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We have a collaboration and license agreement with Neurimmune SubOne AG (Neurimmune) for the development and commercialization of antibodies for the potential treatment of Alzheimer's disease, including aducanumab (as amended, the Neurimmune Agreement). We are responsible for the development, manufacturing and commercialization of all collaboration products. The Neurimmune Agreement is effective for the longer of the duration of certain patents relating to a licensed product or 12 years from the first commercial sale of a licensed product.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We consolidate the results of Neurimmune as we determined that we are the primary beneficiary of Neurimmune because we have the power through the collaboration to direct the activities that most significantly impact the entity&#x2019;s economic performance and we are required to fund 100% of the research and development costs incurred in support of the collaboration. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In October 2017 we amended the terms of the Neurimmune Agreement and made a $150.0 million payment to Neurimmune in exchange for a 15% reduction in the previously negotiated royalty rates payable on products developed under the Neurimmune Agreement, including royalties payable on potential commercial sales of aducanumab. In May 2018 we made an additional $50.0 million payment to Neurimmune to further reduce the previously negotiated royalty rates payable on products developed under the Neurimmune Agreement, including royalties payable on potential commercial sales of aducanumab, by an additional 5%. Our royalty rates payable on products developed under the Neurimmune Agreement, including royalty rates payable on potential commercial sales of aducanumab, now range from the high single digits to sub-teens. As we consolidate the results of Neurimmune, we treated these payments as distributions and recognized them as charges to noncontrolling interests in the fourth quarter of 2017 and the second quarter of 2018, as applicable.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Additionally, under the terms of the Neurimmune Agreement, we are required to pay Neurimmune a milestone payment of&#160;$75.0 million&#160;upon the regulatory filing with the FDA for approval of aducanumab and a milestone payment of&#160;$100.0 million&#160;if aducanumab is launched in the U.S. In July 2020 we completed the submission of a BLA to the FDA for the approval of aducanumab. During the third quarter of 2020, we paid Neurimmune $75.0 million upon the completed submission of the BLA for aducanumab with the FDA, which was recognized as a charge to noncontrolling interests for the nine months ended September 30, 2020. In addition, for the nine months ended September 30, 2020, we recognized net profit-sharing income of $33.8 million to reflect Eisai's 45% share of the $75.0 million milestone payment.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Research and development costs for which we reimburse Neurimmune are reflected in research and development expense in our condensed consolidated statements of income. During the three and nine months ended September 30, 2020 and 2019, amounts reimbursed were immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The assets and liabilities of Neurimmune are not significant to our condensed consolidated financial position or results of operations as it is a research and development organization. We have provided no financing to Neurimmune other than contractually required amounts.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Under the Aducanumab Collaboration Agreement, Eisai had an option to share in the benefit and cost associated with the royalty reductions discussed above; however, Eisai did not elect to share in the benefit and cost with respect to either the October 2017 or May 2018 royalty reductions, which will impact the amount of profits (losses) on potential commercial sales of aducanumab to be shared with Eisai.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;For additional information on our collaboration arrangements with Eisai, please read &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Note 17, Collaborative and Other Relationships, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:11.25pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Unconsolidated Variable Interest Entities&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We have relationships with various variable interest entities that we do not consolidate as we lack the power to direct the activities that significantly impact the economic success of these entities. These relationships include investments in certain biotechnology companies and research collaboration agreements. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As of September 30, 2020 and December 31, 2019, the carrying value of our investments in certain biotechnology companies representing potential unconsolidated variable interest entities totaled $21.9 million and $22.7 million, respectively. Our maximum exposure to loss related to these variable interest entities is limited to the carrying value of our investments.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We have also entered into research collaboration agreements with certain variable interest entities where we are required to fund certain development activities. These development activities are included in research and development expense in our condensed consolidated statements of income as they are incurred. We have provided no financing to these variable interest entities other than previously contractually required amounts. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;For additional information on our investments in Neurimmune and other variable interest entities, please read &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Note 19, Investments in Variable Interest Entities,&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; to our consolidated financial statements included in our 2019 Form 10-K.&lt;/span&gt;&lt;/div&gt;</us-gaap:VariableInterestEntityDisclosureTextBlock>
    <biib:CollaborationAgreementTerm
      contextRef="i1478c61cb1ee4cfa8414bded1c551b30_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTgvZnJhZzo0OWRmMGZhZDBiNTg0NWU5YjcyZTc3Njg4NmQzMGE1Ny90ZXh0cmVnaW9uOjQ5ZGYwZmFkMGI1ODQ1ZTliNzJlNzc2ODg2ZDMwYTU3Xzc1MQ_0024a72b-6726-40a1-8838-f5c74b5db50f">P12Y</biib:CollaborationAgreementTerm>
    <biib:ResearchAndDevelopmentCostsPercentage
      contextRef="i1478c61cb1ee4cfa8414bded1c551b30_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTgvZnJhZzo0OWRmMGZhZDBiNTg0NWU5YjcyZTc3Njg4NmQzMGE1Ny90ZXh0cmVnaW9uOjQ5ZGYwZmFkMGI1ODQ1ZTliNzJlNzc2ODg2ZDMwYTU3XzExMTg_7a898314-e9ed-493b-a360-b8b3412169e8"
      unitRef="number">1</biib:ResearchAndDevelopmentCostsPercentage>
    <us-gaap:PaymentsToMinorityShareholders
      contextRef="i1f3660b791194af5a26e2a9ceab00343_D20171001-20171031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTgvZnJhZzo0OWRmMGZhZDBiNTg0NWU5YjcyZTc3Njg4NmQzMGE1Ny90ZXh0cmVnaW9uOjQ5ZGYwZmFkMGI1ODQ1ZTliNzJlNzc2ODg2ZDMwYTU3XzEyNzg_8df2fce6-42a7-45fd-a048-b04c438e5f70"
      unitRef="usd">150000000.0</us-gaap:PaymentsToMinorityShareholders>
    <biib:Reductioninroyaltyratepayableoncommercialsales
      contextRef="i1f3660b791194af5a26e2a9ceab00343_D20171001-20171031"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTgvZnJhZzo0OWRmMGZhZDBiNTg0NWU5YjcyZTc3Njg4NmQzMGE1Ny90ZXh0cmVnaW9uOjQ5ZGYwZmFkMGI1ODQ1ZTliNzJlNzc2ODg2ZDMwYTU3XzEzMjE_3cf6e04e-3639-4e14-b3f0-b472f8bf834a"
      unitRef="number">0.15</biib:Reductioninroyaltyratepayableoncommercialsales>
    <us-gaap:PaymentsToMinorityShareholders
      contextRef="i61fb7e1bb0fd421bbf82c79ee9784cc5_D20180501-20180531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTgvZnJhZzo0OWRmMGZhZDBiNTg0NWU5YjcyZTc3Njg4NmQzMGE1Ny90ZXh0cmVnaW9uOjQ5ZGYwZmFkMGI1ODQ1ZTliNzJlNzc2ODg2ZDMwYTU3XzE1NDY_8513e8fb-68b0-43cc-bd4a-757dc809317c"
      unitRef="usd">50000000.0</us-gaap:PaymentsToMinorityShareholders>
    <biib:Additionalreductioninroyaltyratepayableoncommercialsales
      contextRef="i61fb7e1bb0fd421bbf82c79ee9784cc5_D20180501-20180531"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTgvZnJhZzo0OWRmMGZhZDBiNTg0NWU5YjcyZTc3Njg4NmQzMGE1Ny90ZXh0cmVnaW9uOjQ5ZGYwZmFkMGI1ODQ1ZTliNzJlNzc2ODg2ZDMwYTU3XzE3ODE_a20bec30-289c-45a8-8302-b52ac8513291"
      unitRef="number">0.05</biib:Additionalreductioninroyaltyratepayableoncommercialsales>
    <biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately
      contextRef="id7b514880c7944a69bca92a1890a1999_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTgvZnJhZzo0OWRmMGZhZDBiNTg0NWU5YjcyZTc3Njg4NmQzMGE1Ny90ZXh0cmVnaW9uOjQ5ZGYwZmFkMGI1ODQ1ZTliNzJlNzc2ODg2ZDMwYTU3XzIzMzQ_1044fd74-71ff-4aae-948d-f5199c37ea26"
      unitRef="usd">75000000.0</biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately>
    <biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately
      contextRef="id248e9039d774acdb784eeea9df07f64_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTgvZnJhZzo0OWRmMGZhZDBiNTg0NWU5YjcyZTc3Njg4NmQzMGE1Ny90ZXh0cmVnaW9uOjQ5ZGYwZmFkMGI1ODQ1ZTliNzJlNzc2ODg2ZDMwYTU3XzI0MzE_36dd0589-90a5-412f-af2b-db2dfdc2d456"
      unitRef="usd">100000000.0</biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately>
    <biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately
      contextRef="id7b514880c7944a69bca92a1890a1999_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTgvZnJhZzo0OWRmMGZhZDBiNTg0NWU5YjcyZTc3Njg4NmQzMGE1Ny90ZXh0cmVnaW9uOjQ5ZGYwZmFkMGI1ODQ1ZTliNzJlNzc2ODg2ZDMwYTU3XzI2NzU_1044fd74-71ff-4aae-948d-f5199c37ea26"
      unitRef="usd">75000000.0</biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i99c8bf62c3f747a6825f635a38c876aa_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTgvZnJhZzo0OWRmMGZhZDBiNTg0NWU5YjcyZTc3Njg4NmQzMGE1Ny90ZXh0cmVnaW9uOjQ5ZGYwZmFkMGI1ODQ1ZTliNzJlNzc2ODg2ZDMwYTU3XzI5NjU_27b1e1fe-8928-464c-9920-b06b2781f73c"
      unitRef="usd">33800000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <biib:PercentageoffuturedevelopmentcostsrelatedtoEisai
      contextRef="i99c8bf62c3f747a6825f635a38c876aa_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTgvZnJhZzo0OWRmMGZhZDBiNTg0NWU5YjcyZTc3Njg4NmQzMGE1Ny90ZXh0cmVnaW9uOjQ5ZGYwZmFkMGI1ODQ1ZTliNzJlNzc2ODg2ZDMwYTU3XzI5ODc_48b0a58b-fb2a-42f6-8383-7646d1c9a609"
      unitRef="number">0.45</biib:PercentageoffuturedevelopmentcostsrelatedtoEisai>
    <biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately
      contextRef="id7b514880c7944a69bca92a1890a1999_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTgvZnJhZzo0OWRmMGZhZDBiNTg0NWU5YjcyZTc3Njg4NmQzMGE1Ny90ZXh0cmVnaW9uOjQ5ZGYwZmFkMGI1ODQ1ZTliNzJlNzc2ODg2ZDMwYTU3XzMwMDM_1044fd74-71ff-4aae-948d-f5199c37ea26"
      unitRef="usd">75000000.0</biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately>
    <biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities
      contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTgvZnJhZzo0OWRmMGZhZDBiNTg0NWU5YjcyZTc3Njg4NmQzMGE1Ny90ZXh0cmVnaW9uOjQ5ZGYwZmFkMGI1ODQ1ZTliNzJlNzc2ODg2ZDMwYTU3XzQ5MDM_6e2ebd99-15a0-4b20-b912-20ab809e1c16"
      unitRef="usd">21900000</biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities>
    <biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities
      contextRef="i626282e786b7454d83b617e9e83963e6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTgvZnJhZzo0OWRmMGZhZDBiNTg0NWU5YjcyZTc3Njg4NmQzMGE1Ny90ZXh0cmVnaW9uOjQ5ZGYwZmFkMGI1ODQ1ZTliNzJlNzc2ODg2ZDMwYTU3XzQ5MTA_04610f0b-6b64-4924-99fe-3eb85a32c7a9"
      unitRef="usd">22700000</biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities>
    <us-gaap:LegalMattersAndContingenciesTextBlock
      contextRef="ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMjQvZnJhZzpiODYzYmI4YzAwZWE0YzQ1YTFlMDU1M2EyMmMzMzJhOC90ZXh0cmVnaW9uOmI4NjNiYjhjMDBlYTRjNDVhMWUwNTUzYTIyYzMzMmE4XzEzODE1_9f41ae75-2d9e-4b7f-aa54-e5fad970b9f9">&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We are currently involved in various claims and legal proceedings, including the matters described below. For information as to our accounting policies relating to claims and legal proceedings, including use of estimates and contingencies, please read &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Note 1, Summary of Significant Accounting Policies,&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; to our consolidated financial statements included in our 2019 Form 10-K.&lt;/span&gt;&lt;div style="text-indent:22.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;With respect to some loss contingencies, an estimate of the possible loss or range of loss cannot be made until management has further information, including, for example, (i) which claims, if any, will survive dispositive motion practice; (ii) information to be obtained through discovery; (iii) information as to the parties' damages claims and supporting evidence; (iv) the parties&#x2019; legal theories; and (v) the parties' settlement positions. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The claims and legal proceedings in which we are involved also include challenges to the scope, validity or enforceability of the patents relating to our products, pipeline or processes and challenges to the scope, validity or enforceability of the patents held by others. These include claims by third parties that we infringe their patents. An adverse outcome in any of these proceedings could result in one or more of the following and have a material impact on our business or consolidated results of operations and financial position: (i) loss of patent protection; (ii) inability to continue to engage in certain activities; and (iii) payment of significant damages, royalties, penalties and/or license fees to third parties.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:11.25pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Loss Contingencies &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:13.5pt;margin-top:5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;IMRALDI Patent Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In September 2018 Fresenius Kabi Deutschland GmbH (Fresenius Kabi) commenced proceedings for damages and injunctive relief against Biogen France SAS in the Tribunal de Grande Instance de Paris, alleging that IMRALDI, the adalimumab biosimilar product of Samsung Bioepis UK Limited that Biogen has commercialized in Europe, infringes the French counterpart of European Patent No. 3 148 510 (the '510 Patent), which was issued in June 2018 and expires in May 2035. No hearing has been scheduled. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In October 2018 Fresenius Kabi commenced preliminary injunction proceedings against Biogen (Denmark) Manufacturing ApS and Biogen Denmark A/S in Denmark's Maritime and Commercial High Court alleging infringement of Danish Utility Models. In June 2019 the Danish court denied Fresenius Kabi's request for a preliminary injunction. Fresenius Kabi has appealed that decision and a hearing has been set for January 2021. In July 2020 the Danish Patent Board of Appeal revoked the Utility Models that were the subject of Fresenius Kabi&#x2019;s October 2018 request for a preliminary injunction and Fresenius Kabi has appealed those revocations.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In June 2020 Fresenius Kabi commenced preliminary injunction proceedings against Biogen (Denmark) Manufacturing ApS and Biogen (Denmark) A/S in Denmark&#x2019;s Maritime and Commercial High Court alleging infringement of another Danish Utility Model. A hearing has been scheduled for May 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In November 2018 Fresenius Kabi commenced infringement proceedings for damages and injunctive relief against Biogen Italia S.R.L. in the District Court of Milan relating to the Italian counterpart of the &#x2018;510 Patent, and against Biogen GmbH in the D&#xfc;sseldorf Regional Court relating to the German counterpart of the &#x2018;510 Patent. In Italy, Fresenius Kabi has surrendered the Italian counterpart of the &#x2018;510 Patent and the court dismissed its infringement action in October 2020. A hearing in the proceeding in Germany has been set for August 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In July 2019 Gedeon Richter PLC (Gedeon Richter) commenced proceedings against Biogen GmbH in the D&#xfc;sseldorf Regional Court alleging infringement of the German counterpart of European Patent No. 3 212 667 (the '667 Patent), which was issued in September 2018 and expires in October 2035, and seeking damages and injunctive relief. The November 2020 hearing has been postponed and a new hearing date has not been set.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In August 2019 Biogen B.V. (Netherlands) and Samsung Bioepis UK Limited filed an action in the District Court of the Hague, Netherlands to revoke the Dutch counterpart of the '667 Patent. Gedeon Richter filed a separate action for infringement in the same court. A hearing was held in May 2020 and in July 2020 the court revoked the Dutch counterpart of the '667 Patent.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;An estimate of the possible loss or range of loss in the pending IMRALDI patent litigation described above cannot be made at this time. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:11.25pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Qui Tam Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In July 2015 a qui tam action filed by Michael Bawduniak on behalf of the U.S. and certain states was unsealed by the U.S. District Court for the District of Massachusetts. The action alleges sales and promotional activities in violation of the federal False Claims Act and state law counterparts and seeks single and treble damages, civil penalties, interest, attorneys&#x2019; fees and costs. No trial date has been set. The U.S. has not made an intervention decision. An estimate of the possible loss or range of loss cannot be made at this time.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:11.25pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Dispute with Former Convergence Shareholders&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In November and December 2019 Shareholder Representative Services LLC, on behalf of the former shareholders of Convergence, sent us correspondence asserting claims of $200.0 million for alleged breach of the contract under which we acquired Convergence. We dispute the claims.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:11.25pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:174%;"&gt;Dispute with Jacobs Switzerland GmbH&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Jacobs Switzerland GmbH, the general contractor for the construction of our large-scale biologics manufacturing facility in Solothurn, Switzerland, claims approximately 31.0 million Swiss Francs (approximately $33.0 million) relating to construction costs. We dispute the claim.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:13.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Other Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:11.25pt;margin-top:5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Petition for Inter Partes Review&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In July 2018 Mylan Pharmaceuticals, Inc. (Mylan) filed a petition that was granted by the U.S. Patent Trial and Appeal Board (PTAB) for &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;inter partes&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; review of our U.S. Patent No. 8,399,514 (the '514 Patent). The '514 Patent includes claims covering treatment of MS with 480 mg of dimethyl fumarate per day as provided for in our TECFIDERA label. In February 2020 the PTAB issued a final written decision upholding the patentability of the &#x2018;514 Patent and in April 2020 Mylan filed an appeal in the U.S. Court of Appeals for the Federal Circuit (the Federal Circuit), which is pending. Oral argument has been scheduled for December 8, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:11.25pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Hatch-Waxman Act Litigation relating to TECFIDERA Orange-Book Listed Patents&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In 2017, 2018 and 2019 we filed patent infringement proceedings relating to TECFIDERA Orange-Book listed patents pursuant to the Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch-Waxman Act (the Delaware Actions), against Accord Healthcare Inc., Alkem Laboratories Ltd., Amneal Pharmaceuticals LLC, Aurobindo Pharma U.S.A., Inc., Cipla Limited, Glenmark Pharmaceuticals Ltd., Graviti Pharmaceuticals Pvt. Ltd., Hetero USA, Inc.,&#160;Lupin Atlantis Holdings SA, Macleods Pharmaceuticals, Ltd., MSN Laboratories Pvt. Ltd., Pharmathen S.A., Prinston Pharmaceutical Inc., Sandoz Inc., Sawai USA, Inc., Shilpa Medicare Limited, Slayback Pharma LLC, Torrent Pharmaceuticals Ltd., TWi Pharmaceuticals, Inc., Windlas Healthcare Pvt. Ltd. and Zydus Pharmaceuticals (USA) Inc. (the Delaware Defendants) in the U.S. District Court for the District of Delaware (the Delaware Court) and against Mylan in the U.S. District Court for the Northern District of West Virginia (the West Virginia Court). The litigation against Aurobindo Pharma U.S.A., Inc., Glenmark Pharmaceuticals Ltd. and Sawai USA, Inc. was dismissed in the fourth quarter of 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On June 22, 2020, the West Virginia Court entered judgment for Mylan that the asserted claims of the &#x2018;514 Patent are invalid for lack of written description. We appealed the judgment to the Federal Circuit and the appeal is pending. Oral argument has been scheduled for December 8, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On September 22, 2020, the Delaware Court entered judgment for the Delaware Defendants on the grounds that the judgment of the West Virginia Court applies to the Delaware Actions under principles of collateral estoppel. We have appealed the judgment and the appeal is pending. Multiple generic versions of TECFIDERA have entered the U.S. market prior to resolution of the appeals.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On August 31, 2020, we filed a patent infringement action under the Hatch-Waxman Act against Sun Pharmaceutical Industries Limited, Sun Pharmaceutical Industries, Inc. and Sun Pharma Global SZE in the Delaware Court. No trial has been scheduled in this action.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:11.25pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;European Patent Office Oppositions&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In 2016 the European Patent Office (EPO) revoked our European Patent No. 2 137 537, which covers the treatment of MS with 480 mg of dimethyl fumarate as provided for in our TECFIDERA label. We have appealed to the Technical Boards of Appeal of the EPO and a hearing has been set for January 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In March 2018 the EPO revoked Forward Pharma A/S' (Forward Pharma) European Patent No. 2 801 355, which expires in October 2025. Forward Pharma has filed an appeal to the Technical Boards of Appeal of the EPO and a hearing has been set for February 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:13.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;TYSABRI Patent Revocation Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In November 2017 Bioeq GMBH, affiliated with the Polpharma Group, brought an action in the Polish Patent Office seeking to revoke Polish Patent No. 215263 (the Polish '263 Patent), which corresponds to our European Patent No. 1 485 127 (the E.U. '127 Patent) and covers administration of natalizumab (TYSABRI) to treat MS. The Polish '263 Patent expires in February 2023. No hearing has been set in this matter.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Swiss Pharma International AG, also affiliated with the Polpharma Group, filed actions in the District Court of the Hague, Netherlands (January 2016), the German Patents Court (March 2016) and the Commercial Court of Rome (November 2017) seeking to invalidate the Dutch, German and Italian counterparts, respectively, of the E.U. '127 Patent, which also cover administration of natalizumab (TYSABRI) to treat MS and expire in February 2023. The Dutch and German counterparts were ruled invalid. The decision in the Dutch action was affirmed on appeal and the German appeal has been withdrawn. No hearing has been set in the Italian action.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:11.25pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;'755 Patent Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In May&#160;2010 Biogen MA Inc. (formerly Biogen Idec MA Inc.) filed a complaint in the U.S.&#160;District Court for the District of New Jersey alleging infringement by Bayer Healthcare Pharmaceuticals Inc. (Bayer) (manufacturer, marketer and seller of BETASERON and manufacturer of EXTAVIA), EMD Serono, Inc. (EMD Serono) (manufacturer, marketer and seller of REBIF), Pfizer (co-marketer of REBIF) and Novartis Pharmaceuticals Corp. (Novartis) (marketer and seller of EXTAVIA) of our U.S. Patent No. 7,588,755 (the '755 Patent), which claims, among other things, the use of interferon beta for immunomodulation. The complaint seeks monetary damages, including lost profits and royalties. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Bayer, Pfizer, Novartis and EMD Serono all filed counterclaims seeking declaratory judgments of patent invalidity and non-infringement and seeking monetary relief in the form of costs and attorneys' fees. Bayer had previously filed a complaint against us in the same court, on May 27, 2010, seeking a declaratory judgment that it does not infringe the '755 Patent and that the '755 Patent is invalid, and seeking monetary relief in the form of attorneys' fees, costs and expenses. Bayer has also requested &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;ex parte&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; reexamination by the U.S. Patent and Trademark Office of Claim 1 of the &#x2018;755 Patent, which request was granted in January 2020 and is pending.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In September 2020 the Federal Circuit reversed the trial court's judgment against EMD Serono and Pfizer that the '755 patent is valid. We intend to file a petition for panel rehearing and rehearing en banc.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:11.25pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Annulment Proceeding in General Court of the European Union relating to TECFIDERA&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In October 2018 Pharmaceutical Works Polpharma SA (Polpharma) filed an application in the General Court of the European Union seeking to annul a decision of the European Medicines Agency (EMA) in which the EMA refused to validate Polpharma&#x2019;s application to market a generic version of TECFIDERA on the grounds that TECFIDERA benefits from regulatory data protection (RDP). Polpharma disputes that TECFIDERA benefits from RDP. Biogen and the European Commission were granted leave to intervene in the case in support of the EMA and the case is pending. A hearing was held on&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#ff0000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;July 13, 2020, and we are awaiting a decision.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:11.25pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Government Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We have learned that state and U.S. governmental authorities are investigating our sales and promotional practices and have received related subpoenas. We are cooperating with the investigation.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We have received subpoenas and other requests from the U.S. government for documents and information relating to our relationship with non-profit organizations that assist patients taking drugs sold by Biogen and the government has challenged some of our contributions to these organizations. We have reached an agreement in principle with the government to resolve this matter. We have accrued the amount of our best estimate of the minimum probable loss in this matter.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:13.5pt;margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Product Liability and Other Legal Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We are also involved in product liability claims and other legal proceedings generally incidental to our normal business activities. While the outcome of any of these proceedings cannot be accurately predicted, we do not believe the ultimate resolution of any of these existing matters would have a material adverse effect on our business or financial condition.&lt;/span&gt;&lt;/div&gt;</us-gaap:LegalMattersAndContingenciesTextBlock>
    <us-gaap:LossContingencyEstimateOfPossibleLoss
      contextRef="i626282e786b7454d83b617e9e83963e6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMjQvZnJhZzpiODYzYmI4YzAwZWE0YzQ1YTFlMDU1M2EyMmMzMzJhOC90ZXh0cmVnaW9uOmI4NjNiYjhjMDBlYTRjNDVhMWUwNTUzYTIyYzMzMmE4XzU0MzM_d1afe22f-50b0-47e0-bba4-68ee4be39095"
      unitRef="usd">200000000.0</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <biib:DisputedClaimsRelatingtoConstructionCosts
      contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMjQvZnJhZzpiODYzYmI4YzAwZWE0YzQ1YTFlMDU1M2EyMmMzMzJhOC90ZXh0cmVnaW9uOmI4NjNiYjhjMDBlYTRjNDVhMWUwNTUzYTIyYzMzMmE4XzU3Mzc_a222fd20-aa04-43de-9fd2-df32a5f4a9ba"
      unitRef="chf">31000000.0</biib:DisputedClaimsRelatingtoConstructionCosts>
    <biib:DisputedClaimsRelatingtoConstructionCosts
      contextRef="ibfe5725c9917439e83ae4f911eb7a60e_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMjQvZnJhZzpiODYzYmI4YzAwZWE0YzQ1YTFlMDU1M2EyMmMzMzJhOC90ZXh0cmVnaW9uOmI4NjNiYjhjMDBlYTRjNDVhMWUwNTUzYTIyYzMzMmE4XzU3Njg_18262c68-3667-46fb-a25f-0a6de4cd575e"
      unitRef="usd">33000000.0</biib:DisputedClaimsRelatingtoConstructionCosts>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140388912514248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Oct. 20, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">0-19311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">BIOGEN INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000875045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">33-0112644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">225 Binney Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cambridge<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">679-2000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0005 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BIIB<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">153,881,597<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 13<br> -Subsection a-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1-<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140388901113048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Income (Unaudited) - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">$ 3,376.1<span></span>
</td>
<td class="nump">$ 3,600.1<span></span>
</td>
<td class="nump">$ 10,592.0<span></span>
</td>
<td class="nump">$ 10,706.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Cost and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales, excluding amortization and impairment of acquired intangible assets</a></td>
<td class="nump">449.1<span></span>
</td>
<td class="nump">430.0<span></span>
</td>
<td class="nump">1,314.6<span></span>
</td>
<td class="nump">1,508.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">1,140.9<span></span>
</td>
<td class="nump">540.4<span></span>
</td>
<td class="nump">2,264.8<span></span>
</td>
<td class="nump">1,588.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">573.1<span></span>
</td>
<td class="nump">554.5<span></span>
</td>
<td class="nump">1,698.3<span></span>
</td>
<td class="nump">1,709.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization and impairment of acquired intangible assets</a></td>
<td class="nump">63.3<span></span>
</td>
<td class="nump">68.0<span></span>
</td>
<td class="nump">196.3<span></span>
</td>
<td class="nump">206.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Collaborationprofitlosssharing', window );">Collaboration profit (loss) sharing</a></td>
<td class="nump">73.0<span></span>
</td>
<td class="nump">60.2<span></span>
</td>
<td class="nump">166.5<span></span>
</td>
<td class="nump">181.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown', window );">Loss on divestiture of Hiller&#248;d, Denmark manufacturing operations</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">95.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">(Gain) loss on fair value remeasurement of contingent consideration</a></td>
<td class="num">(29.0)<span></span>
</td>
<td class="num">(57.8)<span></span>
</td>
<td class="num">(23.5)<span></span>
</td>
<td class="num">(66.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">75.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total cost and expenses</a></td>
<td class="nump">2,289.7<span></span>
</td>
<td class="nump">1,793.8<span></span>
</td>
<td class="nump">5,711.3<span></span>
</td>
<td class="nump">5,441.7<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income from operations</a></td>
<td class="nump">1,086.4<span></span>
</td>
<td class="nump">1,806.3<span></span>
</td>
<td class="nump">4,880.7<span></span>
</td>
<td class="nump">5,264.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="num">(128.6)<span></span>
</td>
<td class="num">(27.3)<span></span>
</td>
<td class="num">(186.1)<span></span>
</td>
<td class="nump">132.6<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income before income tax expense and equity in loss of investee, net of tax</a></td>
<td class="nump">957.8<span></span>
</td>
<td class="nump">1,779.0<span></span>
</td>
<td class="nump">4,694.6<span></span>
</td>
<td class="nump">5,397.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">240.8<span></span>
</td>
<td class="nump">211.3<span></span>
</td>
<td class="nump">979.0<span></span>
</td>
<td class="nump">881.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax', window );">Equity in (income) loss of investee, net of tax</a></td>
<td class="nump">13.1<span></span>
</td>
<td class="nump">21.8<span></span>
</td>
<td class="nump">12.7<span></span>
</td>
<td class="nump">66.8<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">703.9<span></span>
</td>
<td class="nump">1,545.9<span></span>
</td>
<td class="nump">3,702.9<span></span>
</td>
<td class="nump">4,448.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net&#160;income (loss) attributable to noncontrolling interests, net&#160;of&#160;tax</a></td>
<td class="nump">2.4<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">60.2<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">$ 701.5<span></span>
</td>
<td class="nump">$ 1,545.9<span></span>
</td>
<td class="nump">$ 3,642.7<span></span>
</td>
<td class="nump">$ 4,448.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net income per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic earnings per share attributable to Biogen Inc.</a></td>
<td class="nump">$ 4.47<span></span>
</td>
<td class="nump">$ 8.40<span></span>
</td>
<td class="nump">$ 22.29<span></span>
</td>
<td class="nump">$ 23.38<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted earnings per share attributable to Biogen Inc.</a></td>
<td class="nump">$ 4.46<span></span>
</td>
<td class="nump">$ 8.39<span></span>
</td>
<td class="nump">$ 22.25<span></span>
</td>
<td class="nump">$ 23.35<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted-average shares used in calculating:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic earnings per share attributable to Biogen Inc.</a></td>
<td class="nump">156.9<span></span>
</td>
<td class="nump">184.0<span></span>
</td>
<td class="nump">163.4<span></span>
</td>
<td class="nump">190.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted earnings per share attributable to Biogen Inc.</a></td>
<td class="nump">157.2<span></span>
</td>
<td class="nump">184.2<span></span>
</td>
<td class="nump">163.7<span></span>
</td>
<td class="nump">190.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">$ 2,690.3<span></span>
</td>
<td class="nump">$ 2,894.7<span></span>
</td>
<td class="nump">$ 8,390.6<span></span>
</td>
<td class="nump">$ 8,455.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember', window );">Revenues from anti-CD20 therapeutic programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">560.1<span></span>
</td>
<td class="nump">595.8<span></span>
</td>
<td class="nump">1,558.8<span></span>
</td>
<td class="nump">1,689.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">$ 125.7<span></span>
</td>
<td class="nump">$ 109.6<span></span>
</td>
<td class="nump">$ 642.6<span></span>
</td>
<td class="nump">$ 562.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Collaborationprofitlosssharing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration profit (loss) sharing</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Collaborationprofitlosssharing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income (Loss) from Equity Method Investments, Net of Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_IncomeLossFromEquityMethodInvestmentsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of (gain) loss recognized for the (reversal of write-down) write-down to fair value, less cost to sell, of a disposal group. Excludes discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2443-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=117327953&amp;loc=d3e4984-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=SL5780133-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=117327953&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591551-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591551-111686<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3000-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68048583&amp;loc=d3e3636-108311<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1448-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140388977265592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Income (Unaudited) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">$ 701.5<span></span>
</td>
<td class="nump">$ 1,545.9<span></span>
</td>
<td class="nump">$ 3,642.7<span></span>
</td>
<td class="nump">$ 4,448.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized gains (losses) on securities available for sale, net of tax</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
<td class="nump">10.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax', window );">Unrealized gains (losses) on cash flow hedges, net of tax</a></td>
<td class="num">(83.7)<span></span>
</td>
<td class="nump">59.1<span></span>
</td>
<td class="num">(101.1)<span></span>
</td>
<td class="nump">38.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease', window );">Gains (losses) on net investment hedges</a></td>
<td class="num">(11.3)<span></span>
</td>
<td class="nump">21.2<span></span>
</td>
<td class="nump">5.5<span></span>
</td>
<td class="nump">46.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax', window );">Unrealized gains (losses) on pension benefit obligation, net of tax</a></td>
<td class="num">(0.5)<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Currency translation adjustment</a></td>
<td class="nump">50.9<span></span>
</td>
<td class="nump">79.4<span></span>
</td>
<td class="nump">3.9<span></span>
</td>
<td class="nump">51.3<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Total other comprehensive income (loss), net of tax</a></td>
<td class="num">(44.5)<span></span>
</td>
<td class="nump">160.6<span></span>
</td>
<td class="num">(90.3)<span></span>
</td>
<td class="nump">148.1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income</a></td>
<td class="nump">657.0<span></span>
</td>
<td class="nump">1,706.5<span></span>
</td>
<td class="nump">3,552.4<span></span>
</td>
<td class="nump">4,596.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Comprehensive income (loss) attributable to noncontrolling interests, net of tax</a></td>
<td class="nump">1.5<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">61.1<span></span>
</td>
<td class="num">(0.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive income attributable to Biogen Inc.</a></td>
<td class="nump">$ 658.5<span></span>
</td>
<td class="nump">$ 1,706.5<span></span>
</td>
<td class="nump">$ 3,613.5<span></span>
</td>
<td class="nump">$ 4,596.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e557-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591552-111686<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4613674-111683<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b,c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the cumulative translation adjustment from gain (loss), after tax, on foreign currency derivatives, that are designated as, and are effective as, economic hedges of a net investment in a foreign entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b),(c),(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140388902071000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 2,224.8<span></span>
</td>
<td class="nump">$ 2,913.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">1,355.0<span></span>
</td>
<td class="nump">1,562.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">2,024.9<span></span>
</td>
<td class="nump">1,880.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DuefromantiCD20therapeuticprograms', window );">Due from anti-CD20 therapeutic programs</a></td>
<td class="nump">527.2<span></span>
</td>
<td class="nump">590.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">1,027.7<span></span>
</td>
<td class="nump">804.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">683.5<span></span>
</td>
<td class="nump">631.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">7,843.1<span></span>
</td>
<td class="nump">8,381.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Marketable securities</a></td>
<td class="nump">1,009.8<span></span>
</td>
<td class="nump">1,408.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">3,359.9<span></span>
</td>
<td class="nump">3,247.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease assets</a></td>
<td class="nump">434.2<span></span>
</td>
<td class="nump">427.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">3,323.6<span></span>
</td>
<td class="nump">3,527.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">5,755.7<span></span>
</td>
<td class="nump">5,757.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax asset</a></td>
<td class="nump">1,372.9<span></span>
</td>
<td class="nump">3,232.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Investments and other assets</a></td>
<td class="nump">1,834.9<span></span>
</td>
<td class="nump">1,252.8<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">24,934.1<span></span>
</td>
<td class="nump">27,234.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Current portion of notes payable</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">1,495.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Taxes payable</a></td>
<td class="nump">119.4<span></span>
</td>
<td class="nump">71.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">398.4<span></span>
</td>
<td class="nump">530.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Accrued expenses and other</a></td>
<td class="nump">3,286.2<span></span>
</td>
<td class="nump">2,765.8<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">3,804.0<span></span>
</td>
<td class="nump">4,863.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Notes payable</a></td>
<td class="nump">7,425.0<span></span>
</td>
<td class="nump">4,459.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liability</a></td>
<td class="nump">1,123.4<span></span>
</td>
<td class="nump">2,810.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liabilities</a></td>
<td class="nump">409.1<span></span>
</td>
<td class="nump">412.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">1,428.1<span></span>
</td>
<td class="nump">1,348.9<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">14,189.6<span></span>
</td>
<td class="nump">13,895.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Biogen Idec Inc. shareholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, par value $0.001 per share</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, par value $0.0005 per share</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(225.5)<span></span>
</td>
<td class="num">(135.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">13,961.0<span></span>
</td>
<td class="nump">16,455.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock, at cost</a></td>
<td class="num">(2,977.1)<span></span>
</td>
<td class="num">(2,977.1)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Biogen Inc. shareholders&#8217; equity</a></td>
<td class="nump">10,758.5<span></span>
</td>
<td class="nump">13,343.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interests</a></td>
<td class="num">(14.0)<span></span>
</td>
<td class="num">(4.1)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
<td class="nump">10,744.5<span></span>
</td>
<td class="nump">13,339.1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity</a></td>
<td class="nump">$ 24,934.1<span></span>
</td>
<td class="nump">$ 27,234.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DuefromantiCD20therapeuticprograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Receivable from anti-CD20 therapeutic programs for our share of the pre-tax co-promotion profits generated from our co-promotion arrangement for sales of RITUXAN.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DuefromantiCD20therapeuticprograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118952595&amp;loc=d3e4428-111522<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=118952595&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669686-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e31931-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116846819&amp;loc=d3e3927-108312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4590271-111686<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140388894808040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0005<span></span>
</td>
<td class="nump">$ 0.0005<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140388905869592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 3,702.9<span></span>
</td>
<td class="nump">$ 4,448.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation, amortization and impairments</a></td>
<td class="nump">366.8<span></span>
</td>
<td class="nump">567.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development</a></td>
<td class="nump">75.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">149.3<span></span>
</td>
<td class="nump">143.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Contingent consideration</a></td>
<td class="num">(23.5)<span></span>
</td>
<td class="num">(66.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax', window );">Loss on divestiture of Hiller&#248;d, Denmark manufacturing operations</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">95.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="nump">211.9<span></span>
</td>
<td class="nump">28.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi', window );">Unrealized (gain) loss on strategic investments</a></td>
<td class="nump">41.8<span></span>
</td>
<td class="num">(189.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Loss on equity method investment</a></td>
<td class="nump">14.7<span></span>
</td>
<td class="nump">63.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other</a></td>
<td class="nump">110.1<span></span>
</td>
<td class="nump">87.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities, net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(135.7)<span></span>
</td>
<td class="num">(2.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDueFromRelatedParties', window );">Due from anti-CD20 therapeutic programs</a></td>
<td class="nump">63.0<span></span>
</td>
<td class="num">(55.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(270.6)<span></span>
</td>
<td class="nump">47.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">372.9<span></span>
</td>
<td class="num">(109.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable', window );">Income tax assets and liabilities</a></td>
<td class="nump">15.3<span></span>
</td>
<td class="nump">64.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet', window );">Other changes in operating assets and liabilities, net</a></td>
<td class="num">(97.0)<span></span>
</td>
<td class="num">(5.6)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash flows provided by operating activities</a></td>
<td class="nump">4,596.9<span></span>
</td>
<td class="nump">5,118.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Proceeds from sales and maturities of marketable securities</a></td>
<td class="nump">5,240.7<span></span>
</td>
<td class="nump">3,867.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of marketable securities</a></td>
<td class="num">(4,649.1)<span></span>
</td>
<td class="num">(4,052.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireOtherProductiveAssets', window );">Contingent consideration paid related to Fumapharm AG acquisition</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(300.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired', window );">Acquisition of Nightstar Therapeutics plc, net of cash acquired</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(744.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from divestiture of Hiller&#248;d, Denmark manufacturing operations</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">923.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, plant and equipment</a></td>
<td class="num">(338.8)<span></span>
</td>
<td class="num">(404.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment', window );">Acquired in-process research and development</a></td>
<td class="num">(75.0)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquisitions of intangible assets</a></td>
<td class="num">(37.0)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity', window );">Proceeds from sales of strategic investments</a></td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">476.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other</a></td>
<td class="num">(18.0)<span></span>
</td>
<td class="num">(4.6)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash flows provided by (used in) investing activities</a></td>
<td class="num">(442.2)<span></span>
</td>
<td class="num">(237.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchases of treasury stock</a></td>
<td class="num">(6,279.1)<span></span>
</td>
<td class="num">(3,775.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Payments related to issuance of stock for share-based compensation arrangements, net</a></td>
<td class="num">(11.8)<span></span>
</td>
<td class="num">(16.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from borrowings</a></td>
<td class="nump">2,967.3<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment of borrowings</a></td>
<td class="num">(1,500.0)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToMinorityShareholders', window );">Net distribution to noncontrolling interest</a></td>
<td class="num">(70.9)<span></span>
</td>
<td class="nump">4.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other</a></td>
<td class="nump">22.9<span></span>
</td>
<td class="nump">43.8<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash flows used in financing activities</a></td>
<td class="num">(4,871.6)<span></span>
</td>
<td class="num">(3,744.0)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="num">(716.9)<span></span>
</td>
<td class="nump">1,136.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="num">(28.0)<span></span>
</td>
<td class="nump">17.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, beginning of the period</a></td>
<td class="nump">2,913.7<span></span>
</td>
<td class="nump">1,224.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, end of the period</a></td>
<td class="nump">2,224.8<span></span>
</td>
<td class="nump">2,343.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SangamoCommonStockMember', window );">Sangamo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates', window );">Purchase of Sangamo Therapeutics, Inc. stock</a></td>
<td class="num">(141.8)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_DenaliTherapeuticsIncMember', window );">Denali Therapeutics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates', window );">Purchase of Sangamo Therapeutics, Inc. stock</a></td>
<td class="num">$ (423.7)<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of income (loss) from an individually significant component disposed of or held-for-sale attributable to parent. Excludes discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=SL51724579-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in receivables to be collected from other entities that could exert significant influence over the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3444-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with a second acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of or advances to an entity that is related to it but not strictly controlled (for example, an unconsolidated subsidiary, affiliate, and joint venture or equity method investment) or the acquisition of an additional interest in a subsidiary (controlled entity).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireOtherProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for the purchase of or improvements to tangible or intangible assets, used to produce goods or deliver services, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireOtherProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToMinorityShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToMinorityShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3151-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of equity securities classified as available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26853-111562<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591551-111686<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3000-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SangamoCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SangamoCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_DenaliTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_DenaliTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140388911076264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statement of Equity Statement - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Preferred stock</div></th>
<th class="th"><div>Common stock</div></th>
<th class="th"><div>Additional paid-in capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income</div></th>
<th class="th"><div>Retained earnings</div></th>
<th class="th"><div>Treasury stock</div></th>
<th class="th"><div>Parent</div></th>
<th class="th"><div>Noncontrolling interest</div></th>
<th class="th"><div>2018 Share Repurchase Program</div></th>
<th class="th">
<div>2018 Share Repurchase Program </div>
<div>Common stock</div>
</th>
<th class="th">
<div>2018 Share Repurchase Program </div>
<div>Additional paid-in capital</div>
</th>
<th class="th">
<div>2018 Share Repurchase Program </div>
<div>Retained earnings</div>
</th>
<th class="th">
<div>2018 Share Repurchase Program </div>
<div>Treasury stock</div>
</th>
<th class="th">
<div>2018 Share Repurchase Program </div>
<div>Parent</div>
</th>
<th class="th"><div>2019 Share Repurchase Program</div></th>
<th class="th">
<div>2019 Share Repurchase Program </div>
<div>Common stock</div>
</th>
<th class="th">
<div>2019 Share Repurchase Program </div>
<div>Additional paid-in capital</div>
</th>
<th class="th">
<div>2019 Share Repurchase Program </div>
<div>Retained earnings</div>
</th>
<th class="th">
<div>2019 Share Repurchase Program </div>
<div>Treasury stock</div>
</th>
<th class="th">
<div>2019 Share Repurchase Program </div>
<div>Parent</div>
</th>
<th class="th"><div>December 2019 Share Repurchase Program</div></th>
<th class="th">
<div>December 2019 Share Repurchase Program </div>
<div>Common stock</div>
</th>
<th class="th">
<div>December 2019 Share Repurchase Program </div>
<div>Additional paid-in capital</div>
</th>
<th class="th">
<div>December 2019 Share Repurchase Program </div>
<div>Retained earnings</div>
</th>
<th class="th">
<div>December 2019 Share Repurchase Program </div>
<div>Treasury stock</div>
</th>
<th class="th">
<div>December 2019 Share Repurchase Program </div>
<div>Parent</div>
</th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(221.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2018</a></td>
<td class="nump">$ 13,031.6<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="num">$ (240.4)<span></span>
</td>
<td class="nump">$ 16,257.0<span></span>
</td>
<td class="num">$ (2,977.1)<span></span>
</td>
<td class="nump">$ 13,039.6<span></span>
</td>
<td class="num">$ (8.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">4,448.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,448.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,448.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">147.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">148.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">148.1<span></span>
</td>
<td class="num">(0.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Noncontrollinginterestincreasedecreaseother', window );">Noncontrolling interest, increase (decrease) other</a></td>
<td class="nump">4.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">4.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock, at cost, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock, at cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,147.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,147.4)<span></span>
</td>
<td class="num">$ (2,147.4)<span></span>
</td>
<td class="num">$ (1,627.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,627.8)<span></span>
</td>
<td class="num">$ (1,627.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Retirement of common stock pursuant to Share Repurchase Programs, at cost, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockRetiredCostMethodAmount', window );">Retirement of common stock pursuant to Share Repurchase Progams, at cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="num">$ (110.5)<span></span>
</td>
<td class="num">$ (2,036.9)<span></span>
</td>
<td class="nump">$ 2,147.4<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (74.8)<span></span>
</td>
<td class="num">$ (1,553.0)<span></span>
</td>
<td class="nump">$ 1,627.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans</a></td>
<td class="nump">33.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">33.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock under award plan, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock under stock award plan</a></td>
<td class="num">(50.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(50.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(50.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation related to share-based payments</a></td>
<td class="nump">151.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">151.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">151.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Sep. 30, 2019</a></td>
<td class="nump">13,991.8<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(92.3)<span></span>
</td>
<td class="nump">17,065.2<span></span>
</td>
<td class="num">$ (2,977.1)<span></span>
</td>
<td class="nump">13,995.9<span></span>
</td>
<td class="num">(4.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, shares at Sep. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(205.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance, shares at Jun. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(208.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Jun. 30, 2019</a></td>
<td class="nump">12,948.8<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(252.9)<span></span>
</td>
<td class="nump">16,182.8<span></span>
</td>
<td class="num">$ (2,977.1)<span></span>
</td>
<td class="nump">12,952.9<span></span>
</td>
<td class="num">(4.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">1,545.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,545.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,545.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">160.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">160.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">160.6<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock, at cost, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock, at cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (717.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (717.9)<span></span>
</td>
<td class="num">(717.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Retirement of common stock pursuant to Share Repurchase Programs, at cost, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockRetiredCostMethodAmount', window );">Retirement of common stock pursuant to Share Repurchase Progams, at cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(55.1)<span></span>
</td>
<td class="num">(662.8)<span></span>
</td>
<td class="nump">$ 717.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans</a></td>
<td class="nump">7.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">7.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock under award plan, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock under stock award plan</a></td>
<td class="num">(0.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation related to share-based payments</a></td>
<td class="nump">47.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Sep. 30, 2019</a></td>
<td class="nump">13,991.8<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(92.3)<span></span>
</td>
<td class="nump">17,065.2<span></span>
</td>
<td class="num">$ (2,977.1)<span></span>
</td>
<td class="nump">13,995.9<span></span>
</td>
<td class="num">(4.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, shares at Sep. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(205.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(198.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="nump">13,339.1<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(135.2)<span></span>
</td>
<td class="nump">16,455.4<span></span>
</td>
<td class="num">$ (2,977.1)<span></span>
</td>
<td class="nump">13,343.2<span></span>
</td>
<td class="num">(4.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">3,702.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,642.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,642.7<span></span>
</td>
<td class="nump">60.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(89.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(90.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(90.3)<span></span>
</td>
<td class="nump">0.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Noncontrollinginterestincreasedecreaseother', window );">Noncontrolling interest, increase (decrease) other</a></td>
<td class="num">(75.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(75.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock, at cost, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock, at cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,279.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,279.1)<span></span>
</td>
<td class="num">$ (1,279.1)<span></span>
</td>
<td class="num">$ (5,000.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (5,000.0)<span></span>
</td>
<td class="num">$ (5,000.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Retirement of common stock pursuant to Share Repurchase Programs, at cost, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockRetiredCostMethodAmount', window );">Retirement of common stock pursuant to Share Repurchase Progams, at cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (71.0)<span></span>
</td>
<td class="num">$ (1,208.1)<span></span>
</td>
<td class="nump">$ 1,279.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (121.3)<span></span>
</td>
<td class="num">$ (4,878.7)<span></span>
</td>
<td class="nump">$ 5,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans</a></td>
<td class="nump">38.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">38.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock under award plan, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock under stock award plan</a></td>
<td class="num">(50.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(50.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(50.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation related to share-based payments</a></td>
<td class="nump">154.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">154.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">154.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other</a></td>
<td class="num">(0.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Sep. 30, 2020</a></td>
<td class="nump">10,744.5<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(225.5)<span></span>
</td>
<td class="nump">13,961.0<span></span>
</td>
<td class="num">$ (2,977.1)<span></span>
</td>
<td class="nump">10,758.5<span></span>
</td>
<td class="num">(14.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, shares at Sep. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(177.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance, shares at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(182.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Jun. 30, 2020</a></td>
<td class="nump">11,289.2<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(181.0)<span></span>
</td>
<td class="nump">14,466.7<span></span>
</td>
<td class="num">$ (2,977.1)<span></span>
</td>
<td class="nump">11,308.7<span></span>
</td>
<td class="num">(19.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">703.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">701.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">701.5<span></span>
</td>
<td class="nump">2.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(45.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(44.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(44.5)<span></span>
</td>
<td class="num">(0.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Noncontrollinginterestincreasedecreaseother', window );">Noncontrolling interest, increase (decrease) other</a></td>
<td class="nump">4.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">4.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock, at cost, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock, at cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,250.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,250.0)<span></span>
</td>
<td class="num">(1,250.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Retirement of common stock pursuant to Share Repurchase Programs, at cost, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockRetiredCostMethodAmount', window );">Retirement of common stock pursuant to Share Repurchase Progams, at cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="num">$ (45.1)<span></span>
</td>
<td class="num">$ (1,204.9)<span></span>
</td>
<td class="nump">$ 1,250.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans</a></td>
<td class="nump">9.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">9.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock under award plan, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock under stock award plan</a></td>
<td class="num">(2.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation related to share-based payments</a></td>
<td class="nump">35.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Sep. 30, 2020</a></td>
<td class="nump">$ 10,744.5<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="num">$ (225.5)<span></span>
</td>
<td class="nump">$ 13,961.0<span></span>
</td>
<td class="num">$ (2,977.1)<span></span>
</td>
<td class="nump">$ 10,758.5<span></span>
</td>
<td class="num">$ (14.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, shares at Sep. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(177.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Noncontrollinginterestincreasedecreaseother">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncontrolling interest, increase (decrease) other</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Noncontrollinginterestincreasedecreaseother</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118951672&amp;loc=d3e1436-108581<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591551-111686<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3000-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased and retired during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4590271-111686<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockRetiredCostMethodAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease of par value, additional paid in capital (APIC) and retained earnings of common and preferred stock retired from treasury when treasury stock is accounted for under the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockRetiredCostMethodAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140388899699080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of significant accounting policies</a></td>
<td class="text"><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">References in these notes to "Biogen," the "company," "we," "us" and "our" refer to Biogen Inc. and its consolidated subsidiaries.</span></div><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Business Overview</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Biogen is a global biopharmaceutical company focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. Our core growth areas include multiple sclerosis (MS) and neuroimmunology; Alzheimer's disease and dementia; neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS); movement disorders, including Parkinson's disease; and ophthalmology. We are also focused on discovering, developing and delivering worldwide innovative therapies in our emerging growth areas of immunology; neurocognitive disorders; acute neurology; and pain. In addition, we commercialize biosimilars of advanced biologics. We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities. </span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; and FUMADERM for the treatment of severe plaque psoriasis. We also have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of primary progressive MS and relapsing MS; and other potential anti-CD20 therapies pursuant to our collaboration arrangements with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group. For additional information on our collaboration arrangements with Genentech, please read </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Note 18, Collaborative and Other Relationships,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> to our consolidated financial statements included in our Annual Report on Form&#160;10-K for the year ended December 31, 2019 (2019 Form&#160;10-K).</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our innovative drug development and commercialization activities are complemented by our biosimilar business that expands access to medicines and reduces the cost burden for healthcare systems. Through Samsung Bioepis Co., Ltd. (Samsung Bioepis), our joint venture with Samsung BioLogics Co., Ltd. (Samsung BioLogics), we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL, IMRALDI, an adalimumab biosimilar referencing HUMIRA, and FLIXABI, an infliximab biosimilar referencing REMICADE, in certain countries in Europe and have exclusive rights to commercialize these products in China. Additionally, we have exclusive rights to commercialize two potential ophthalmology biosimilar products, SB11 referencing LUCENTIS and SB15 referencing EYLEA, in major markets worldwide, including the United States (U.S.), Canada, Europe, Japan and Australia. For additional information on our collaboration arrangements with Samsung Bioepis, please read </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Note 17, Collaborative and Other Relationships,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> to these unaudited condensed consolidated financial statements (condensed consolidated financial statements). </span></div><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Basis of Presentation</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In the opinion of management, our condensed consolidated financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair statement of our financial statements for interim periods in accordance with accounting principles generally accepted in the United States (U.S.&#160;GAAP). The information included in this quarterly report on Form&#160;10-Q should be read in conjunction with our audited consolidated financial statements and the accompanying notes included in our 2019 Form&#160;10-K. Our accounting policies are described in the </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Notes to Consolidated Financial Statements</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> in our 2019 Form&#160;10-K and updated, as necessary, in this report. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from our audited financial statements but does not include all disclosures required by U.S.&#160;GAAP. The results of operations for the three and nine months ended September 30, 2020, are not necessarily indicative of the operating results for the full year or for any other subsequent interim period. </span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We operate as one operating segment, focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies.</span></div><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Consolidation</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our condensed consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and those of certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than 100% of the economics, we record net income (loss) attributable to noncontrolling interests in our condensed consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. </span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In determining whether we are the primary beneficiary of a variable interest entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. These considerations impact the way we account for our existing collaborative relationships and other arrangements. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.</span></div><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Use of Estimates</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. Actual results may differ from these estimates.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The length of time and full extent to which the COVID-19 pandemic directly or indirectly impacts our business, results of operations and financial condition, including sales, expenses, reserves and allowances, manufacturing, clinical trials, research and development costs and employee-related amounts, depends on future developments that are highly uncertain, subject to change and are difficult to predict, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19 as well as the economic impact on local, regional, national and international customers and markets. We have made estimates of the impact of COVID-19 within our condensed consolidated financial statements and there may be changes to those estimates in future periods. </span></div><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">New Accounting Pronouncements</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed below, we do not believe that the adoption of recently issued standards have or may have a material impact on our condensed consolidated financial statements or disclosures.</span></div><div style="text-indent:13.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#528134;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Credit Losses</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2016 the FASB issued Accounting Standards Update (ASU) No. 2016-13, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The FASB subsequently issued amendments to ASU 2016-13, which have the same effective date and transition date of January 1, 2020. This standard requires entities to estimate an expected lifetime credit loss on financial assets ranging from short-term trade accounts receivable to long-term financings and report credit losses using an expected losses model rather than the incurred losses model that was previously used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, this standard now requires allowances to be recorded instead of reducing the amortized cost of the investment. This standard limits the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit losses if fair value increases.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">This standard became effective for us on January 1, 2020, and based on the composition of our trade receivables, investment portfolio and other financial assets, current economic conditions and historical credit loss activity, the adoption of this standard did not have a material impact on our condensed consolidated financial statements and related disclosures. During the three and nine months ended September 30, 2020, we recorded an immaterial amount associated with expected credit losses related to outstanding trade receivables in certain foreign countries that have been disproportionately impacted by the COVID-19 pandemic.</span></div><div style="text-indent:13.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#528134;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Fair Value Measurements</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In August 2018 the FASB issued ASU No. 2018-13,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"> Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. This standard modifies certain disclosure requirements on fair value measurements. This standard became effective for us on January 1, 2020, and did not have a material impact on our disclosures. For the new disclosures regarding our Level 3 instruments, please read </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Note 7, Fair Value Measurements,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> to these condensed consolidated financial statements.</span></div><div style="text-indent:13.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#528134;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Internal Use Software</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In August 2018 the FASB issued ASU No. 2018-15, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Intangibles&#8212;Goodwill and Other&#8212;Internal-Use Software (Subtopic 350-40): Customer&#8217;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. This standard clarifies the accounting for implementation costs in cloud computing arrangements. This standard, which became effective for us on January 1, 2020, and was adopted on a prospective basis, resulted in an immaterial amount of additional assets being recorded on our condensed consolidated balance sheets.</span></div><div style="text-indent:13.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#528134;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Collaborative Arrangements</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In November 2018 the FASB issued ASU No. 2018-18, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. This standard makes targeted improvements for collaborative arrangements as follows:</span></div><div style="text-indent:-18pt;padding-left:40.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">Clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under Accounting Standards Codification (ASC) 606, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Revenue from Contracts with Customers</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, when the collaborative arrangement participant is a customer in the context of a unit of account. In those situations, all the guidance in ASC 606 should be applied, including recognition, measurement, presentation and disclosure requirements;</span></div><div style="text-indent:-18pt;padding-left:40.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">Adds unit-of-account guidance to ASC 808, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Collaborative Arrangements</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, to align with the guidance in ASC 606 (that is, a distinct good or service) when an entity is assessing whether the collaborative arrangement or a part of the arrangement is within the scope of ASC 606; and</span></div><div style="text-indent:-18pt;padding-left:40.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">Precludes a company from presenting transactions with collaborative arrangement participants that are not directly related to sales to third parties with revenue recognized under ASC 606 if the collaborative arrangement participant is not a customer.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">This standard became effective for us on January 1, 2020, and did not have a material impact on our condensed consolidated financial statements and related disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140388989881336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Acquisitions</a></td>
<td class="text"><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">BIIB118 Acquisition</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In March 2020 we acquired BIIB118 (formerly known as PF-05251749), a novel CNS-penetrant small molecule inhibitor of casein kinase 1, for the potential treatment of patients with behavioral and neurological symptoms across various psychiatric and neurological diseases from Pfizer Inc. (Pfizer). We plan to develop this Phase 1 asset for the potential treatment of sundowning in Alzheimer's disease and irregular sleep wake rhythm disorder in Parkinson&#8217;s disease. </span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In connection with this acquisition, we made an upfront payment of $75.0 million to Pfizer, which was accounted for as an asset acquisition and recorded as acquired in-process research and development (IPR&amp;D) in our condensed consolidated statements of income as BIIB118 has not yet reached technological feasibility. We may also pay Pfizer up to $635.0 million in potential additional development and commercialization milestone payments as well as tiered royalties in the high single digits to sub-teens.</span></div><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Acquisition of Nightstar Therapeutics plc</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2019 we completed our acquisition of all of the outstanding shares of Nightstar Therapeutics plc (NST), a clinical-stage gene therapy company focused on adeno-associated virus (AAV) treatments for inherited retinal disorders. As a result of this acquisition, we added two mid- to late-stage clinical assets as well as preclinical programs in ophthalmology. These assets include BIIB111 (timrepigene emparvovec), which is in Phase 3 development for the potential treatment of choroideremia, a rare, degenerative, X-linked inherited retinal disorder that leads to blindness and currently has no approved treatments, and BIIB112 (RPGR gene therapy), which is in Phase 2/3 development for the potential treatment of X-linked retinitis pigmentosa, which is a rare inherited retinal disease with no currently approved treatments.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the terms of this acquisition, we paid NST shareholders $25.50 in cash for each issued and outstanding NST share, which totaled $847.6 million. In addition, we paid $4.6 million in cash for equity compensation, which is attributable to pre-combination services and was reflected as a component of the total purchase price paid. The fair value of equity compensation attributable to the post-combination service period was $26.2 million, of which $18.4 million was recognized as a charge to selling, general and administrative expense with the remaining $7.8 million as a charge to research and development expense in our condensed consolidated statements of income. These amounts were associated with the accelerated vesting of stock options previously granted to NST employees and were fully paid in cash as of June 30, 2019. We funded this acquisition through available cash and accounted for it as an acquisition of a business. We finalized purchase accounting for this acquisition in the fourth quarter of 2019.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For additional information on our acquisition of NST, please read </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Note 2, Acquisitions,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> to our consolidated financial statements included in our 2019 Form 10-K.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140388899924280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Divestitures Divestitures<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DivestituresAbstract', window );"><strong>Divestitures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">Divestitures</a></td>
<td class="text"><div style="text-indent:13.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Divestiture of Hiller&#248;d, Denmark Manufacturing Operations </span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In March 2019 we entered into a share purchase agreement with FUJIFILM Corporation (FUJIFILM) to sell all of the outstanding shares of our subsidiary that owned our biologics manufacturing operations in Hiller&#248;d, Denmark. We determined that the assets and liabilities related to our Hiller&#248;d, Denmark manufacturing operations met the criteria to be classified as held for sale. For the nine months ended September 30, 2019, we recorded a loss of approximately $160.2 million in our condensed consolidated statements of income. This estimated loss included a pre-tax loss of $95.5 million, which reflected a $17.7 million decrease to our previously recorded pre-tax loss, reflecting our estimated fair value of the assets and liabilities held for sale as of September 30, 2019, adjusted for our expected costs to sell our Hiller&#248;d, Denmark manufacturing operations of approximately $11.2 million and included our initial estimate of the fair value of an adverse commitment of approximately $114.0 million associated with the guarantee of future minimum batch production at the Hiller&#248;d facility. The value of this adverse commitment was determined using a probability-weighted estimate of future manufacturing activity. In addition, we recorded a tax expense of $64.7 million related to the transaction during the nine months ended September 30, 2019.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In August 2019 this transaction closed and we received approximately $881.9 million in cash, which may be adjusted based on the contractual terms discussed below. We determined that the operations disposed of in this transaction did not meet the criteria to be classified as discontinued operations under the applicable guidance.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As part of this transaction, we provided FUJIFILM with certain minimum batch production commitment guarantees. There is a risk that the minimum contractual batch production commitments will not be met. Our estimate of the adverse commitment obligation is approximately $74.0 million as of September 30, 2020 and December 31, 2019. We developed this estimate using a probability-weighted estimate of future manufacturing activity and may adjust this estimate based upon changes in business conditions, which may result in the increase or reduction of this adverse commitment obligation in subsequent periods. We also may be obligated to indemnify FUJIFILM for liabilities that existed relating to certain business activities incurred prior to the closing of this transaction. Our estimate of the fair value of the adverse commitment obligation is a Level 3 measurement and is based on forecasted batch production at the Hiller&#248;d facility.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, we may earn certain contingent payments based on future manufacturing activities at the Hiller&#248;d facility. For the disposition of a business, our policy is to recognize contingent consideration when the consideration is realizable. Consistent with our assessment as of the transaction date, we currently believe the probability of earning these payments is remote and therefore we did not include these contingent payments in our calculation of the fair value of the operations.</span></div>As part of this transaction, we entered into certain manufacturing services agreements with FUJIFILM pursuant to which FUJIFILM will use the Hiller&#248;d facility to produce commercial products for us, such as TYSABRI, as well as other third-party products. In addition, we sold to FUJIFILM $41.8 million of raw materials that were remaining at the Hiller&#248;d facility on the closing date of this transaction in the third quarter of 2019. These materials were sold at cost, which approximated fair value.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DivestituresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Divestitures [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DivestituresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=2122178<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140388898326584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenues</a></td>
<td class="text"><div style="text-indent:13.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2472b9;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Product Revenues</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Revenues by product are summarized as follows:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:31.550%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.441%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.295%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.441%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.295%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.441%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.445%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="33" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Three Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In millions)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">United<br/>States</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Rest of<br/>World</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">United<br/>States</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Rest of<br/>World</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Multiple Sclerosis (MS):</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fumarate*</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">684.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">283.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">967.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">842.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">280.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,122.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interferon**</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">327.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">146.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">474.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">360.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">169.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">530.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">TYSABRI</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">304.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">212.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">516.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">263.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">220.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">483.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">FAMPYRA</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">26.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">26.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Subtotal: MS product revenues</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">1,315.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">669.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">1,984.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,465.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">694.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,160.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Spinal Muscular Atrophy:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">SPINRAZA</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">182.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">311.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">494.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">236.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">310.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">547.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Biosimilars:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">BENEPALI</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">124.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">124.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">115.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">115.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">IMRALDI</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">56.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">56.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">49.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">49.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">FLIXABI</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">27.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">27.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Subtotal: Biosimilar product revenues</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">207.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">207.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">183.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">183.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">FUMADERM</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">3.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">3.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total product revenues</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">1,498.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">1,192.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2,690.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,702.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,192.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,894.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/></tr></table></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%;"><tr><td style="width:1.0%;"/><td style="width:33.017%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:31.105%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:32.578%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">*Fumarate includes TECFIDERA and VUMERITY. VUMERITY became commercially available in the U.S. in November 2019.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">**Interferon includes AVONEX and PLEGRIDY.</span></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%;"><tr><td style="width:1.0%;"/><td style="width:31.300%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.536%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.503%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.536%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.356%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.536%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.356%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.536%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.356%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.536%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.503%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.536%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.510%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="33" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In millions)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">United<br/>States</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Rest of<br/>World</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">United<br/>States</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Rest of<br/>World</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Multiple Sclerosis (MS):</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fumarate*</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2,383.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">875.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">3,258.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,429.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">841.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,271.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interferon**</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">965.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">456.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">1,421.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,067.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">518.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,585.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">TYSABRI</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">826.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">644.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">1,470.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">772.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">647.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,419.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">FAMPYRA</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">78.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">78.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">71.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">71.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Subtotal: MS product revenues</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">4,174.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2,054.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">6,229.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,269.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,078.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,347.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Spinal Muscular Atrophy:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">SPINRAZA</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">628.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">925.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">1,554.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">690.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">863.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,553.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Biosimilars:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">BENEPALI</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">363.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">363.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">360.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">360.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">IMRALDI</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">162.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">162.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">132.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">132.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">FLIXABI</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">71.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">71.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">49.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">49.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Subtotal: Biosimilar product revenues</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">598.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">598.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">542.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">542.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">FUMADERM</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">9.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">9.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total product revenues</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">4,803.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">3,587.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">8,390.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,959.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,495.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,455.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/></tr></table></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%;"><tr><td style="width:1.0%;"/><td style="width:33.017%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:31.105%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:32.578%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">*Fumarate includes TECFIDERA and VUMERITY. VUMERITY became commercially available in the U.S. in November 2019.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">**Interferon includes AVONEX and PLEGRIDY.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We recognized revenues from two wholesalers accounting for 31.2% and 15.6% of gross product revenues for the three months ended September 30, 2020, and 30.9% and 16.0% of gross product revenues for the nine months ended September 30, 2020.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We recognized revenues from two wholesalers accounting for 28.7% and 18.4% of gross product revenues for the three months ended September 30, 2019, and 30.1% and 17.0% of gross product revenues for the nine months ended September 30, 2019.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">An analysis of the change in reserves for discounts and allowances is summarized as follows:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:47.155%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.526%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.109%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.526%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.109%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.526%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.109%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.526%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.114%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In millions)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Discounts</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contractual<br/>Adjustments</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Returns</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, December 31, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">131.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">1,027.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">40.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">1,198.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current provisions relating to sales in current year</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">589.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2,465.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">14.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">3,070.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Adjustments relating to prior years</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(1.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(41.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">1.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(40.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Payments/credits relating to sales in current year</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(457.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(1,704.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(2,162.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Payments/credits relating to sales in prior years</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(120.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(658.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(15.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(794.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, September 30, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">141.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">1,088.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">41.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">1,271.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/></tr></table></div><div style="text-indent:24.75pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The total reserves above, which are included in our condensed consolidated balance sheets, are summarized as follows:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:65.808%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.525%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.720%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.525%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.722%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In millions)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">As of September 30, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Reduction of accounts receivable, net</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">227.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">197.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Component of accrued expenses and other</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">1,043.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,001.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total revenue-related reserves</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">1,271.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,198.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/></tr></table></div><div style="text-indent:13.5pt;margin-top:7pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2472b9;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Revenues from Anti-CD20 Therapeutic Programs</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Revenues from anti-CD20 therapeutic programs are summarized below. For the purposes of this footnote we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:49.338%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.595%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.595%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.595%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.603%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Three Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In millions)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Biogen&#8217;s share of pre-tax profits in the U.S. for RITUXAN and GAZYVA</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">275.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">393.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">873.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,161.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other revenues from anti-CD20 therapeutic programs</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">285.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">202.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">685.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">528.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total revenues from anti-CD20 therapeutic programs</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">560.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">595.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">1,558.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,689.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/></tr></table></div><div style="text-indent:24.75pt;padding-right:2.25pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For additional information on our collaboration arrangements with Genentech, please read </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Note 18,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Collaborative and Other Relationships, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">to our consolidated financial statements included in our 2019 Form 10-K.</span></div><div style="text-indent:13.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2472b9;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Other Revenues</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Other revenues are summarized as follows:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:49.192%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.595%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.595%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.595%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.603%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Three Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In millions)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenues from collaborative and other relationships:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Profit (loss) earned under our 50% share of the co-promotion losses on ZINBRYTA in the U.S. with AbbVie Inc.</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">0.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenues earned under our technical development agreement, manufacturing services agreements and royalty revenues on biosimilar products with Samsung Bioepis</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">5.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">13.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">89.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other royalty and corporate revenues:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Royalty</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">10.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">28.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other corporate</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">110.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">93.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">599.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">462.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total other revenues</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">125.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">109.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">642.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">562.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/></tr></table></div><div style="text-indent:22.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the third quarter of 2019, we amended our agreement with a contract manufacturing customer pursuant to which we licensed certain of our manufacturing-related intellectual property to the customer. In the second quarter of 2020, the customer received regulatory approval for its product that is being manufactured using certain of our manufacturing-related intellectual property. As a result, we are entitled to $500.0 million in a series of three payments. The first payment became due upon regulatory approval of such product and was received during the second quarter of 2020. Subsequent payments are due on the first and second anniversaries of the regulatory approval. </span></div>Other corporate revenues for the nine months ended September 30, 2020, reflect $333.2 million related to the delivery of the license for certain of our manufacturing-related intellectual property under the amended agreement discussed above and the performance of manufacturing product supply services for such customer. We have allocated the remaining $166.8&#160;million of the $500.0 million transaction price to the performance of manufacturing product supply services for the customer, which we expect to perform through 2026. The value allocated to the manufacturing services was based on expected demand for supply and the fair value of comparable manufacturing and development services.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140388900047336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory</a></td>
<td class="text"><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The components of inventory are summarized as follows:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.830%;"><tr><td style="width:1.0%;"/><td style="width:58.071%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.539%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:18.574%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.539%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:18.577%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In millions)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">As of September 30, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Raw materials</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">288.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">169.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Work in process</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">539.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">460.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Finished goods</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">199.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">174.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total inventory</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">1,027.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">804.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140388898405480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Intangible Assets and Goodwill</a></td>
<td class="text"><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Intangible Assets</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Intangible assets, net of accumulated amortization, impairment charges and adjustments, are summarized as follows:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%;"><tr><td style="width:1.0%;"/><td style="width:22.394%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.493%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:7.710%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.032%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:7.710%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:7.710%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.032%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:7.715%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">As of September 30, 2020</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of December 31, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Estimated Life</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated<br/>Amortization</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated<br/>Amortization</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Completed technology</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4-28 years</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">7,394.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(5,077.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2,316.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,379.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4,881.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,497.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">In-process research and development</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Indefinite until commercialization</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">943.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">943.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">965.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">965.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Trademarks&#160;and trade names</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Indefinite</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">64.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">64.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">64.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">64.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total intangible assets</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">8,401.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(5,077.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">3,323.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,408.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4,881.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,527.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/></tr></table></div><div style="text-indent:24.75pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the three and nine months ended September 30, 2020, amortization and impairment of acquired intangible assets totaled $82.6 million and $215.6 million, respectively, compared to $283.9 million and $422.2 million, respectively, in the prior year comparative periods. </span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the three and nine months ended September 30, 2020, amortization and impairment of acquired intangible assets reflects the impact of a $19.3&#160;million impairment charge related to one of our IPR&amp;D intangible assets. </span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the three and nine months ended September 30, 2019, amortization and impairment of acquired intangible assets reflects the impact of a $215.9&#160;million impairment charge related to certain IPR&amp;D assets associated with the Phase 2b study of BG00011 (STX-100) for the potential treatment of idiopathic pulmonary fibrosis, which was discontinued in the third quarter of 2019.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the three and nine months ended September 30, 2020, amortization of acquired intangible assets, excluding impairment charges, totaled $63.3&#160;million and $196.3&#160;million, respectively, compared to $68.0&#160;million and $206.3&#160;million, respectively, in the prior year comparative periods.</span></div><div style="text-indent:13.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Completed Technology</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Completed technology primarily relates to our acquisition of all remaining rights to TYSABRI from Elan Pharma International Ltd., an affiliate of Elan Corporation plc, and milestone payments made to Alkermes Pharma Ireland Limited, a subsidiary of Alkermes plc, following the approval of VUMERITY in the U.S. in October 2019, net of accumulated amortization.</span></div><div style="text-indent:13.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">IPR&amp;D Related to Business Combinations</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">IPR&amp;D represents the fair value assigned to research and development assets that we acquired as part of a business combination and had not yet reached technological feasibility at the date of acquisition. Included in IPR&amp;D balances are adjustments related to foreign currency exchange rate fluctuations. We review amounts capitalized as acquired IPR&amp;D for impairment annually, as of October 31, and whenever events or changes in circumstances indicate to us that the carrying value of the assets might not be recoverable. The carrying value associated with our IPR&amp;D assets as of September 30, 2020, relates to the various IPR&amp;D programs we acquired in connection with our acquisitions of NST, Convergence Pharmaceuticals Holdings Ltd. (Convergence) and Biogen International Neuroscience GmbH (BIN). The majority of the balance relates to our acquisition of NST in June 2019 whereby we acquired IPR&amp;D programs with an estimated fair value of approximately $700.0 million.</span></div><div style="text-indent:13.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Vixotrigine</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In the periods since we acquired vixotrigine (BIIB074), there have been numerous delays in the initiation of Phase 3 studies for the potential treatment of trigeminal neuralgia (TGN) as we engaged with the U.S. Food and Drug Administration (FDA) regarding the design of the Phase 3 studies and awaited data and insights from mid-stage clinical trials of vixotrigine in other indications that have since been completed. The fair value of the TGN asset is not significantly in excess of carrying value. As of September 30, 2020, the carrying value associated with our vixotrigine IPR&amp;D assets was $167.6 million.</span></div><div style="text-indent:13.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Estimated Future Amortization of Intangible Assets</span><span style="background-color:rgb(255,255,255, 0.0);color:#679acb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"> </span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The estimated future amortization of finite-lived intangible assets for the next five years is expected to be as follows:</span></div><div style="text-align:justify;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:78.724%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:18.346%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In millions)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">As of September 30, 2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020 (remaining three months)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">60.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">205.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">215.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">215.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2024</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">225.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2025</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">220.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr></table></div><div style="text-indent:11.25pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Goodwill</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table provides a roll forward of the changes in our goodwill balance:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:78.724%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:18.346%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In millions)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">As of September 30, 2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Goodwill, December 31, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">5,757.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(2.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Goodwill, September 30, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">5,755.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/></tr></table></div>As of September 30, 2020, we had no accumulated impairment losses related to goodwill. Other includes adjustments related to foreign currency exchange rate fluctuations.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140388899905304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="text-indent:24.75pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:40.420%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.788%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.788%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.788%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.796%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">As of September 30, 2020</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In millions)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Quoted&#160;Prices<br/>in Active<br/>Markets<br/>(Level 1)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level 2)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-style:italic;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash equivalents</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">1,570.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">1,570.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Marketable debt securities:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">1,443.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">1,443.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Government securities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">767.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">767.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Mortgage and other asset backed securities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">153.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">153.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Marketable equity securities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">868.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">276.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">592.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Derivative contracts</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">26.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">26.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Plan assets for deferred compensation</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">26.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">26.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:29.25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">4,856.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">276.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">4,579.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-style:italic;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Liabilities:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Derivative contracts</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">99.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">99.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration obligations</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">322.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">322.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:29.25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">422.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">99.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">322.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/></tr></table></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:40.420%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.788%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.788%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.788%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.796%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of December 31, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In millions)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Quoted&#160;Prices<br/>in Active<br/>Markets<br/>(Level 1)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level 2)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-style:italic;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash equivalents</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,541.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,541.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Marketable debt securities:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,695.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,695.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Government securities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,013.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,013.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Mortgage and other asset backed securities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">261.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">261.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Marketable equity securities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">337.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">329.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Derivative contracts</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">43.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">43.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Plan assets for deferred compensation</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">27.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">27.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:29.25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,920.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,912.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-style:italic;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Liabilities:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Derivative contracts</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration obligations</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">346.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">346.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:29.25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">354.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">346.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/></tr></table></div><div style="text-indent:24.75pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">There have been no material impairments of our assets measured and carried at fair value during the three and nine months ended September 30, 2020. In addition, there were no changes in valuation techniques during the three and nine months ended September 30, 2020. The fair value of Level 2 instruments classified as cash equivalents and marketable debt securities was determined through third-party pricing services. The fair value of Level 2 instruments classified as marketable equity securities represents our investments in Sangamo Therapeutics, Inc. (Sangamo) common stock and Denali Therapeutics Inc. (Denali) common stock and are valued using an option pricing valuation model as the investments are each subject to certain holding period restrictions. For additional information on our investments in Sangamo and Denali common stock, please read </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Note 8, Financial Instruments,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> to these condensed consolidated financial statements.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our investments in marketable equity securities also include shares of Ionis Pharmaceuticals, Inc. (Ionis) common stock acquired in June 2018. Our shares of Ionis common stock were initially subject to certain holding period restrictions that expired during the first quarter of 2020. The fair value of this investment was a Level 1 measurement as of September 30, 2020. </span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For a description of our validation procedures related to prices provided by third-party pricing services and our option pricing valuation model, please read </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Note 1, Summary of Significant Accounting Policies - Fair Value Measurements,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> to our consolidated financial statements included in our 2019 Form 10-K. </span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the significant unobservable inputs in the fair value measurement of our contingent consideration obligations as of September 30, 2020:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:24.266%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.724%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.416%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:21.773%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.536%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.020%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="27" style="padding-top:2px;padding-bottom:2px;background-color:#dbdbdb;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#026dce;background-color:rgb(255,255,255, 0.0);">As of September 30, 2020</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In millions)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Valuation Technique</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unobservable Input</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Range</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted Average</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-style:italic;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Liabilities:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dbdbdb;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dbdbdb;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dbdbdb;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:6pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration obligation</span></td><td colspan="3" rowspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dbdbdb;text-align:left;vertical-align:middle;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dbdbdb;text-align:right;vertical-align:middle;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">322.6&#160;</span></td><td rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dbdbdb;text-align:right;vertical-align:middle;padding-right:1pt;"/><td colspan="3" rowspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Discounted cash flow</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Discount rate</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dbdbdb;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#026dce;background-color:rgb(255,255,255, 0.0);">0.57% to 0.89%</span></td><td colspan="3" style="background-color:#dbdbdb;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dbdbdb;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#026dce;background-color:rgb(255,255,255, 0.0);">0.63%</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected timing of achievement of development milestones</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dbdbdb;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#026dce;background-color:rgb(255,255,255, 0.0);">2021 to 2027</span></td><td colspan="3" style="background-color:#dbdbdb;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dbdbdb;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#026dce;background-color:rgb(255,255,255, 0.0);">&#8212;</span></td></tr></table></div><div style="text-indent:22.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The weighted average discount rate was calculated based on the relative fair value of our contingent consideration obligations. In addition, we apply various probabilities of technological and regulatory success, ranging from high single digits to certain probability, to the valuation models to estimate the fair values of our contingent consideration obligations.</span></div><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Debt Instruments</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair and carrying values of our debt instruments, which are Level&#160;2 liabilities, are summarized as follows:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:42.091%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.369%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.369%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.369%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.374%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">As of September 30, 2020</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of December 31, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In millions)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair<br/>Value</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Carrying<br/>Value</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair<br/>Value</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Carrying<br/>Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">2.900% Senior Notes due September 15, 2020</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;vertical-align:top;">(1)</sup></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,509.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,495.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.625% Senior Notes due September 15, 2022</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">1,058.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">997.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,038.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">996.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.050% Senior Notes due September 15, 2025</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">1,988.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">1,740.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,897.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,739.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.250% Senior Notes due May 1, 2030</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">1,532.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">1,491.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.200% Senior Notes due September 15, 2045</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2,286.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">1,723.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,107.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,722.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.150% Senior Notes due May 1, 2050</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">1,470.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">1,472.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">8,336.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">7,425.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,553.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,954.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/></tr></table></div><div style="text-align:center;margin-top:6pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%;"><tr><td style="width:1.0%;"/><td style="width:33.017%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:31.105%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:32.578%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr></table></div><div style="margin-top:1pt;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;vertical-align:top;">(1) </sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">Our 2.900% Senior Notes due September 15, 2020, were redeemed in full in May 2020 using the net proceeds from the issuance on April 30, 2020, of our senior unsecured notes for an aggregate principal amount of $3.0 billion. For additional information, please read </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;">Note 11, Indebtedness,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;"> to these condensed consolidated financial statements.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair values of each of our series of Senior Notes were determined through market, observable and corroborated sources. For additional information related to our Senior Notes issued on September 15, 2015, please read </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Note 12,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Indebtedness,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> to our consolidated financial statements included in our 2019 Form 10-K. For additional information related to our Senior Notes issued on April 30, 2020, please read </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Note 11, Indebtedness,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> to these condensed consolidated financial statements.</span></div><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Contingent Consideration Obligations</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In connection with our acquisitions of Convergence and BIN, we agreed to make additional payments based upon the achievement of certain milestone events. The following table provides a roll forward of the fair values of our contingent consideration obligations, which includes Level 3 measurements:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:47.438%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.034%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.034%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.034%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.040%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Three Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In millions)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair value, beginning of period</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">351.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">401.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">346.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">409.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Changes in fair value</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(29.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(57.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(23.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(66.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Payments</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair value, end of period</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">322.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">343.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">322.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">343.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/></tr></table></div><div style="text-indent:24.75pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of September 30, 2020 and December 31, 2019, approximately $173.2 million and $197.7 million, respectively, of the fair value of our total contingent consideration obligations was reflected as a component of other long-term liabilities in our condensed consolidated balance sheets with the remaining balance reflected as a component of accrued expenses and other.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the three and nine months ended September 30, 2020, changes in the fair value of our contingent consideration obligations were primarily due to changes in the probability and the expected timing of the achievement of certain remaining developmental milestones as well as changes in the interest rates used to revalue our contingent consideration liabilities and the passage of time.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the three and nine months ended September 30, 2019, changes in the fair value of our contingent consideration obligations were primarily due to the discontinuation of the Phase 2b study of BG00011 for the potential treatment of idiopathic pulmonary fibrosis resulting in a reduction of our contingent consideration obligations of $61.2&#160;million, partially offset by a decrease in interest rates used to revalue our contingent consideration liabilities and the passage of time.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140388899916840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock', window );">Financial Instruments</a></td>
<td class="text"><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes our financial assets with maturities of less than 90&#160;days from the date of purchase included in cash and cash equivalents in our condensed consolidated balance sheets:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:58.549%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:18.344%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:18.347%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In millions)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">As of September 30, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">649.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">384.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Overnight reverse repurchase agreements</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">465.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">368.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">270.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,628.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Short-term debt securities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">185.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">159.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">1,570.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,541.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/></tr></table></div><div style="text-indent:24.75pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The carrying values of our commercial paper, including accrued interest, overnight reverse repurchase agreements, money market funds and short-term debt securities approximate fair value due to their short-term maturities. </span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our marketable equity securities gains (losses) are recorded in other income (expense), net in our condensed consolidated statements of income. The following tables summarize our marketable debt and equity securities:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%;"><tr><td style="width:1.0%;"/><td style="width:41.252%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.535%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.576%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.535%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.576%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.535%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.576%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.535%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.580%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">As of September 30, 2020</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In millions)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized<br/>Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">963.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">1.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(0.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">964.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-current</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">475.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">3.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(0.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">479.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Government securities:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">389.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">0.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">389.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-current</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">376.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">1.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">377.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Mortgage and other asset backed securities:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">0.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">0.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-current</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">152.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">0.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(0.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">153.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total marketable debt securities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2,358.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">6.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(0.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2,364.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Marketable equity securities, non-current</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">851.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">63.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(46.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">868.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"/></tr></table></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%;"><tr><td style="width:1.0%;"/><td style="width:41.252%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.535%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.576%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.535%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.576%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.535%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.576%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.535%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.580%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of December 31, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In millions)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized<br/>Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,057.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,058.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-current</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">633.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">636.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Government securities:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">502.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">503.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-current</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">510.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">510.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Mortgage and other asset backed securities:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-current</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">260.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">260.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total marketable debt securities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,965.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,970.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Marketable equity securities, non-current</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">218.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">132.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(13.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">337.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"/></tr></table></div><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Summary of Contractual Maturities: Available-for-Sale Debt Securities</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The estimated fair value and amortized cost of our marketable debt securities available-for-sale by contractual maturity are summarized as follows:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%;"><tr><td style="width:1.0%;"/><td style="width:41.924%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.409%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.409%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.409%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.413%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">As of September 30, 2020</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of December 31, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In millions)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Estimated<br/>Fair Value</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized<br/>Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Estimated<br/>Fair Value</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized<br/>Cost</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Due in one year or less</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">1,355.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">1,353.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,562.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,560.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Due after one year through five years</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">902.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">897.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,234.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,230.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Due after five years</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">107.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">107.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">173.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">173.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total marketable debt securities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2,364.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2,358.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,970.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,965.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/></tr></table></div><div style="text-indent:24.75pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The average maturity of our marketable debt securities available-for-sale as of September 30, 2020 and December 31, 2019, was approximately 12 months and 14 months, respectively.</span></div><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Proceeds from Marketable Debt Securities</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:44.075%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.204%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.204%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.619%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.624%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Three Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In millions)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Proceeds from maturities and sales</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">1,360.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">611.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">5,240.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,867.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Realized gains</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">1.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">12.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Realized losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(0.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(25.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr></table></div><div style="text-indent:11.25pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Strategic Investments</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of September 30, 2020 and December 31, 2019, our strategic investment portfolio was comprised of investments totaling $925.1 million and $393.9 million, respectively, which are included in investments and other assets in our condensed consolidated balance sheets. </span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our strategic investment portfolio includes investments in equity securities of certain biotechnology companies, which are reflected within our disclosures included in </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Note 7, Fair Value Measurements,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> to these condensed consolidated financial statements, venture capital funds where the underlying investments are in equity securities of certain biotechnology companies and non-marketable equity securities. </span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The increase in our strategic investment portfolio for the three and nine months ended September 30, 2020, was primarily due to our purchases of Denali and Sangamo common stock, as discussed below.</span></div><div style="text-indent:13.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Denali Therapeutics Inc.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In August 2020 we entered into a collaboration and license agreement with Denali. As part of this collaboration we purchased approximately 13&#160;million shares of Denali common stock in September 2020. This investment is classified as a Level 2 marketable equity security due to certain holding period restrictions and is remeasured each reporting period and carried at fair value. The effects of certain holding period restrictions on the investment are estimated using an option pricing valuation model. The most significant assumptions within the model are the term of the restrictions and the stock price volatility, which is based upon historical volatility of similar companies. We also use a constant maturity risk free-interest rate to match the remaining term of the restrictions on our investment in Denali's common stock and a dividend yield of zero based upon the fact that Denali and similar companies generally have not historically granted cash dividends.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For additional information on our collaboration agreements with Denali, please read </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Note 17, Collaborative and Other Relationships,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;to these condensed consolidated financial statements.</span></div><div style="text-indent:13.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Sangamo Therapeutics, Inc.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In February 2020 we entered into a collaboration and license agreement with Sangamo. In connection with the closing of this transaction in April 2020 we purchased approximately&#160;24 million&#160;shares of Sangamo common stock.&#160;This equity method investment will be remeasured each reporting period and carried at fair value due to our election of the fair value option. The effects of certain holding period restrictions on the investment are estimated </span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">using an option pricing valuation model. The most significant assumptions within the model are the term of the restrictions and the stock price volatility, which is based upon historical volatility of similar companies. We also use a constant maturity risk free-interest rate to match the remaining term of the restrictions on our investment in Sangamo&#8217;s common stock and a dividend yield of zero based upon the fact that Sangamo and similar companies generally have not historically granted cash dividends.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For additional information on our collaboration agreement with Sangamo, please read </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Note 17, Collaborative and Other Relationships,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;to these condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140389016986408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock', window );">Derivative Instruments</a></td>
<td class="text"><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Foreign Currency Forward Contracts - Hedging Instruments</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Due to the global nature of our operations, portions of our revenues and operating expenses are recorded in currencies other than the U.S.&#160;dollar. The value of revenues and operating expenses measured in U.S.&#160;dollars is therefore subject to changes in foreign currency exchange rates. In order to mitigate these changes, we use foreign currency forward contracts to lock in exchange rates associated with a portion of our forecasted international revenues and operating expenses.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Foreign currency forward contracts in effect as of September 30, 2020 and December 31, 2019, had durations of 1 to 24 months and 1 to 15 months, respectively. These contracts have been designated as cash flow hedges and unrealized gains or losses on the portion of these foreign currency forward contracts that are included in the effectiveness test are reported in accumulated other comprehensive income (loss) (referred to as AOCI in the tables below). Realized gains and losses of such contracts are recognized in revenues when the sale of product in the currency being hedged is recognized and in operating expenses when the expense in the currency being hedged is recorded. We recognize all cash flow hedge reclassifications from accumulated other comprehensive income (loss) and fair value changes of excluded portions in the same line item in our condensed consolidated statements of income that has been impacted by the hedged item.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The notional value of foreign currency forward contracts that were entered into to hedge forecasted revenues and operating expenses is summarized as follows:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:58.549%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:18.344%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:18.347%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Notional Amount</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In millions)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">As of September 30, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Euro</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2,717.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,892.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">British pound</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">62.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Swiss franc</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">34.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Japanese yen</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">27.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Canadian dollar</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">25.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total foreign currency forward contracts</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2,866.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,892.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/></tr></table></div><div style="text-indent:24.75pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The pre-tax portion of the fair value of these foreign currency forward contracts that were included in accumulated other comprehensive income (loss) in total equity reflected net losses of $114.6 million and net gains of $0.5 million as of September 30, 2020 and December 31, 2019, respectively. We expect the net losses of $114.6 million to be settled over the next 24 months, of which $94.1 million of these losses are expected to be settled over the next 12 months, with any amounts in accumulated other comprehensive income (loss) to be reported as an adjustment to revenues or operating expenses. We consider the impact of our and our counterparties&#8217; credit risk on the fair value of the contracts as well as the ability of each party to execute its contractual obligations. As of September 30, 2020 and December 31, 2019, credit risk did not materially change the fair value of our foreign currency forward contracts.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following tables summarize the effect of foreign currency forward contracts designated as hedging instruments in our condensed consolidated statements of income:</span></div><div style="text-align:justify;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:22.765%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.198%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.345%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:21.154%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.637%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.641%;"/><td style="width:0.1%;"/></tr><tr><td colspan="33" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Three Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net Gains/(Losses)<br/>Reclassified from AOCI into Operating Income (in millions)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net Gains/(Losses)<br/>Recognized in Operating Income (in millions)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Location</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Location</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenues</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(9.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">35.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenues</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(8.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating expenses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">1.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating expenses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">0.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr></table></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%;"><tr><td style="width:1.0%;"/><td style="width:22.611%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.536%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.123%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.536%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.418%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.536%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:21.138%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.536%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.712%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.536%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.718%;"/><td style="width:0.1%;"/></tr><tr><td colspan="33" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net Gains/(Losses)<br/>Reclassified from AOCI into Operating Income (in millions)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net Gains/(Losses)<br/>Recognized in Operating Income (in millions)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Location</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Location</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenues</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">41.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">79.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenues</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(1.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating expenses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">1.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating expenses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(0.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr></table></div><div style="text-indent:11.25pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Interest Rate Contracts - Hedging Instruments</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have entered into interest rate lock contracts or interest rate swap contracts on certain borrowing transactions to manage our exposure to interest rate changes and to reduce our overall cost of borrowing. </span></div><div style="text-indent:13.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#528134;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Interest Rate Swap Contracts</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In connection with the issuance of our 2.90% Senior Notes due September 15, 2020, we entered into interest rate swaps with an aggregate notional amount of $675.0 million, which were originally set to expire on September 15, 2020. The interest rate swap contracts were designated as hedges of the fair value changes in our 2.90% Senior Notes attributable to changes in interest rates. The carrying value of our 2.90% Senior Notes as of December 31, 2019, included approximately $2.3 million related to changes in the fair value of these interest rate swap contracts. In May 2020 we settled our interest rate swap contracts, in conjunction with our early redemption of our 2.90% Senior Notes, resulting in a gain of approximately $3.3 million for the nine months ended September 30, 2020, which was recorded as a component of interest expense in our condensed consolidated statements of income.</span></div><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Net Investment Hedges - Hedging Instruments</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In February 2012 we entered into a joint venture agreement with Samsung BioLogics establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar products. In June 2018 we exercised our option under our joint venture agreement to increase our ownership percentage in Samsung Bioepis from approximately 5.0% to approximately 49.9%. The share purchase transaction was completed in November 2018 and, upon closing, we paid 759.5 billion South Korean won ($676.6 million) to Samsung BioLogics. Our investment in the equity of Samsung Bioepis is exposed to the currency fluctuations in the South Korean won. </span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In order to mitigate the currency fluctuations between the U.S. dollar and South Korean won, we have entered into foreign currency forward contracts. Foreign currency forward contracts in effect as of September 30, 2020, had a remaining duration of one month. These contracts have been designated as net investment hedges. We recognize changes in the spot exchange rate in accumulated other comprehensive income (loss). The pre-tax portion of the fair value of these foreign currency forward contracts that were included in accumulated other comprehensive income (loss) in total equity reflected net gains of $3.5 million and net losses of $1.5 million as of September 30, 2020 and December 31, 2019, respectively. We exclude fair value changes related to the forward rate from our hedging relationship and will amortize the forward points in other income (expense), net in our condensed consolidated statements of income over the term of the contract. The pre-tax portion of the fair value of the forward points that were included in accumulated other comprehensive income (loss) in total equity reflected gains of $0.3 million and $2.9 million as of September 30, 2020 and December 31, 2019, respectively.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following tables summarize the effect of our net investment hedge in our condensed consolidated financial statements:</span></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:18.372%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:5.195%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:5.195%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:20.715%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:5.195%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:5.195%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.980%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:5.195%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:5.202%;"/><td style="width:0.1%;"/></tr><tr><td colspan="51" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Three Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net Gains/(Losses)<br/>Recognized in Other Comprehensive Income (Effective Portion) (in millions)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net Gains/(Losses)<br/>Recognized in Other Comprehensive Income (Amounts Excluded from Effectiveness Testing) <br/>(in millions)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net Gains/(Losses)<br/>Recognized in Net Income <br/>(Amounts Excluded from Effectiveness Testing) (in millions)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Location</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Location</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Location</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gains (losses) on net investment hedge</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(10.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">22.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gains (losses) on net investment hedge</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(0.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other income (expense)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">0.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr></table></div><div style="text-align:center;margin-top:11pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.122%;"><tr><td style="width:1.0%;"/><td style="width:18.369%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.537%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:5.242%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.537%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:4.947%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.537%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:20.876%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.537%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:5.242%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.537%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:4.947%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.537%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.091%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.537%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:5.242%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.537%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:5.248%;"/><td style="width:0.1%;"/></tr><tr><td colspan="51" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net Gains/(Losses)<br/>Recognized in Other Comprehensive Income (Effective Portion) (in millions)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net Gains/(Losses)<br/>Recognized in Other Comprehensive Income (Amounts Excluded from Effectiveness Testing) <br/>(in millions)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net Gains/(Losses)<br/>Recognized in Net Income <br/>(Amounts Excluded from Effectiveness Testing) (in millions)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Location</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Location</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Location</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gains (losses) on net investment hedge</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">5.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">45.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gains (losses) on net investment hedge</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">3.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other income (expense)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr></table></div><div style="text-indent:24.75pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For additional information on our collaboration arrangements with Samsung Bioepis, please read </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Note 17, Collaborative and Other Relationships,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> to these condensed consolidated financial statements.</span></div><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Foreign Currency Forward Contracts - Other Derivative Instruments</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We also enter into other foreign currency forward contracts, usually with durations of one month or less, to mitigate the foreign currency risk related to certain balance sheet positions. We have not elected hedge accounting for these transactions.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The aggregate notional amount of these outstanding foreign currency forward contracts was $990.0 million and $793.8 million as of September 30, 2020 and December 31, 2019, respectively. Net gains of $7.8 million and $13.7 million related to these contracts were recorded as a component of other income (expense), net for the three and nine months ended September 30, 2020, respectively, compared to net losses of $10.3 million and $14.2 million, respectively, in the prior year comparative periods.</span></div><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Summary of Derivative Instruments</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">While certain of our derivative instruments are subject to netting arrangements with our counterparties, we do not offset derivative assets and liabilities in our condensed consolidated balance sheets. The amounts in the table below would not be substantially different if the derivative assets and liabilities were offset.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the fair value and presentation in our condensed consolidated balance sheets of our outstanding derivative instruments, including those designated as hedging instruments:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:28.328%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:28.328%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:18.372%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:18.376%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In millions)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance Sheet Location</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">As of September 30, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-style:italic;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash Flow Hedging Instruments:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Asset derivative instruments</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other current assets</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">3.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">33.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Investments and other assets</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Liability derivative instruments</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued expenses and other</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">70.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other long-term liabilities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">21.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-style:italic;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net Investment Hedging Instruments:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Asset derivative instruments</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other current assets</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">10.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-style:italic;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value Hedging Instruments:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Liability derivative instruments</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued expenses and other</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-style:italic;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other Derivative Instruments:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Asset derivative instruments</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other current assets</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">10.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Liability derivative instruments</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued expenses and other</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">7.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -URI http://asc.fasb.org/topic&amp;trid=2229140<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140388898327704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment Property, Plant and Equipment<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text"><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Property, plant and equipment are recorded at historical cost, net of accumulated depreciation. Accumulated depreciation on property, plant and equipment was $1,734.8 million and $1,590.9 million as of September 30, 2020 and December 31, 2019, respectively. For the three and nine months ended September 30, 2020, depreciation expense totaled $51.5 million and $151.2 million, respectively, compared to $45.5 million and $145.4 million, respectively, in the prior year comparative periods.</span></div><div style="text-indent:13.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Solothurn, Switzerland Manufacturing Facility</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In order to support our future growth and drug development pipeline, we are building a large-scale biologics manufacturing facility in Solothurn, Switzerland. We expect this facility to be partially operational during the first half of 2021. Upon completion, this facility will include 393,000 square feet related to a large-scale biologics manufacturing facility, 290,000 square feet of warehouse, utilities and support space and 51,000 square feet of administrative space. As of September 30, 2020 and December 31, 2019, we had approximately $1.8 billion and $1.9 billion, respectively, capitalized as construction in progress related to this facility. For the nine months ended September 30, 2020, we placed approximately $256.8 million of fixed assets in service related to this facility. As of September 30, 2020, we had contractual commitments of approximately $14.8 million outstanding related to the construction of this facility.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140388898409144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Indebtedness (Notes)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Indebtedness</a></td>
<td class="text"><span style="background-color:rgb(255,255,255, 0.0);color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Indebtedness</span><span style="background-color:rgb(255,255,255, 0.0);color:#006ebf;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> </span><div style="text-indent:13.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#006ebf;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">2020 Senior Notes </span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On April 30, 2020, we issued senior unsecured notes for an aggregate principal amount of $3.0 billion (2020 Senior Notes), consisting of the following:</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.5pt;">$1.5 billion of 2.25% Senior Notes due May 1, 2030, valued at 99.973% of par; and</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.5pt;">$1.5 billion of 3.15% Senior Notes due May 1, 2050, valued at 99.174% of par.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our 2020 Senior Notes are senior unsecured obligations and may be redeemed at our option at any time at 100% of the principal amount plus accrued interest and, until a specified period before maturity, a specified make-whole amount. Our 2020 Senior Notes contain a change-of-control provision that, under certain circumstances, may require us to purchase our 2020 Senior Notes at a price equal to 101% of the principal amount plus accrued and unpaid interest to the date of repurchase.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We incurred approximately $24.4 million of costs associated with this offering which have been recorded as a reduction to the carrying amount of the debt on our condensed consolidated balance sheet. These costs will be amortized as additional interest expense using the effective interest rate method over the period from issuance through maturity. The discounts will be amortized as additional interest expense over the period from issuance through maturity using the effective interest rate method. Interest on our 2020 Senior Notes is payable May 1 and November 1 of each year, commencing November 1, 2020. </span></div><div style="text-indent:13.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#006ebf;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">2.90% Senior Notes due September 15, 2020 </span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On September 15, 2015, we issued $1.5 billion aggregate principal amount of 2.90% Senior Notes due September 15, 2020, at 99.792% of par. Our 2.90% Senior Notes were senior unsecured obligations. We also entered into interest rate swap contracts where we received a fixed rate and paid a variable rate. In May 2020 we used the net proceeds from the sale of our 2020 Senior Notes to redeem our 2.90% Senior Notes prior to their maturity and recognized a net pre-tax charge of $9.4 million upon the extinguishment of these notes. This charge, which was recognized in interest expense in other income (expense), net in our condensed consolidated statements of income for the nine months ended September 30, 2020, reflects the payment of a $12.7 million early call premium and the write off of remaining unamortized original debt issuance costs and discount balances, partially offset by a $3.3 million gain related to the settlement of the associated interest rate swap contracts. For additional information on our interest rate swap contracts, please read </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Note 9, Derivative Instruments,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> to these condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140389008938904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Equity</a></td>
<td class="text"><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Share Repurchases</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In October 2020 our Board of Directors authorized a program to repurchase up to $5.0 billion of our common stock (2020 Share Repurchase Program). Our 2020 Share Repurchase Program does not have an expiration date. All share repurchases under our 2020 Share Repurchase Program will be retired.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In December 2019 our Board of Directors authorized a program to repurchase up to $5.0 billion of our common stock (December 2019 Share Repurchase Program) that was completed as of September 30, 2020. All shares repurchased under our December 2019 Share Repurchase Program were retired. Under our December 2019 Share Repurchase Program, we repurchased and retired approximately 4.5 million and 16.7 million shares of our common stock at a cost of approximately $1.3 billion and $5.0 billion during the three and nine months ended September 30, 2020, respectively.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In March 2019 our Board of Directors authorized a program to repurchase up to $5.0 billion of our common stock (March 2019 Share Repurchase Program) that was completed as of March 31, 2020. All shares repurchased under our March 2019 Share Repurchase Program were retired. Under our March 2019 Share Repurchase Program, we repurchased and retired approximately 4.1 million shares of our common stock at a cost of approximately $1.3 billion during the nine months ended September 30, 2020. </span></div><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Accumulated Other Comprehensive Income (Loss)</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following tables summarize the changes in accumulated other comprehensive income (loss), net of tax by component:</span></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:31.696%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.295%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.002%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.295%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.466%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.295%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.859%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In millions)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gains (Losses) on Net Investment Hedge</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unfunded Status of Postretirement Benefit Plans, Net of Tax</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Currency Translation Adjustments</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, December 31, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">4.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">7.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">25.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(32.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(139.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(135.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(8.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(58.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">8.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">0.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">3.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(54.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amounts reclassified from accumulated other comprehensive income (loss)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">9.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(43.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(2.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(35.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">1.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(101.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">5.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">0.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">3.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(90.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, September 30, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">5.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(93.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">30.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(32.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(135.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(225.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/></tr></table></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:31.696%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.295%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.002%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.295%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.466%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.295%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.859%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In millions)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gains (Losses) on Net Investment Hedge</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unfunded Status of Postretirement Benefit Plans, Net of Tax</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Currency Translation Adjustments</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, December 31, 2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">34.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(31.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(243.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(240.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">115.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">53.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">51.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">233.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amounts reclassified from accumulated other comprehensive income (loss)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(77.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(6.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(85.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">38.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">46.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">51.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">148.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, September 30, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">72.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">50.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(29.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(192.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(92.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/></tr></table></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the amounts reclassified from accumulated other comprehensive income:</span></div><div style="text-align:justify;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:33.987%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:21.707%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.695%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.695%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.695%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.701%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" rowspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In millions)</span></td><td colspan="3" rowspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income Statement Location</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amounts Reclassified from Accumulated Other Comprehensive Income</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Three Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gains (losses) on securities available for sale</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other income (expense)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">0.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(12.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income tax benefit (expense)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gains (losses) on cash flow hedges</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenues</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(9.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">35.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">41.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">79.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating expenses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">1.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">1.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other income (expense)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">0.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income tax benefit (expense)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">0.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(0.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gains (losses) on net investment hedge</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other income (expense)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">0.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total reclassifications, net of tax</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(6.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">37.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">35.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">85.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140388899848312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings per Share</a></td>
<td class="text"><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Basic and diluted earnings per share are calculated as follows:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:43.929%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.204%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.204%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.619%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.624%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Three Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In millions)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-style:italic;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Numerator:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income attributable to Biogen Inc.</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">701.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,545.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">3,642.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,448.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-style:italic;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Denominator:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted average number of common shares outstanding</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">156.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">184.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">163.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">190.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Time-vested restricted stock units</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">0.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">0.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Market stock units</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">0.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">0.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Performance stock units settled in stock</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">0.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">0.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Dilutive potential common shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">0.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">0.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares used in calculating diluted earnings per share</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">157.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">184.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">163.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">190.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/></tr></table></div><div style="text-indent:24.75pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Amounts excluded from the calculation of net income per diluted share because their effects were anti-dilutive were insignificant.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140388900189416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Payments<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-based Payments</a></td>
<td class="text"><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Share-based Compensation Expense</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes share-based compensation expense included in our condensed consolidated statements of income:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:49.119%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.613%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.613%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.613%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.614%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Three Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In millions)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">14.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">63.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">65.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Selling, general and administrative</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">25.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">34.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">98.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">116.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Subtotal</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">39.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">49.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">161.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">182.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Capitalized share-based compensation costs </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(1.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(4.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(7.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Share-based compensation expense included in total cost and expenses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">37.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">47.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">156.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">174.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income tax effect</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(5.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(8.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(25.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(29.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Share-based compensation expense included in net income attributable to Biogen Inc.</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">32.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">39.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">130.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">145.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/></tr></table></div><div style="text-indent:24.75pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:49.119%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.613%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.613%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.613%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.614%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Three Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In millions)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Market stock units</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">5.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">32.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Time-vested restricted stock units</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">35.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">37.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">107.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">104.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash settled performance units</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(1.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Performance units</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(0.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Performance stock units settled in stock</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(8.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">4.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Performance stock units settled in cash</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">4.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">9.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Employee stock purchase plan</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">3.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">11.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">NST stock options</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">26.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Subtotal</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">39.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">49.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">161.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">182.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Capitalized share-based compensation costs</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(1.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(4.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(7.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Share-based compensation expense included in total cost and expenses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">37.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">47.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">156.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">174.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/></tr></table></div><div style="text-indent:24.75pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We estimate the fair value of our obligations associated with our performance units settled in cash at the end of each reporting period through expected settlement.&#160;Cumulative adjustments to these obligations are recognized each quarter to reflect changes in the stock price and estimated outcome of the performance-related conditions.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140389008918776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Coronavirus Aid, Relief and Economic Security Act</span></div><div style="text-indent:22.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In response to the COVID-19 pandemic, the Coronavirus Aid, Relief and Economic Security Act (CARES Act) was signed into law in the U.S. in March 2020. The CARES Act adjusted a number of provisions of the tax code, including the calculation and eligibility of certain deductions and the treatment of net operating losses and tax credits. The enactment of the CARES Act did not result in any material adjustments to our income tax provision for the three and nine months ended September 30, 2020, or to our net deferred tax assets as of September 30, 2020.</span></div><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">TECFIDERA</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2020 and September 2020 judgments were entered in favor of the defendants in the patent infringement proceedings relating to TECFIDERA Orange-Book listed patents pursuant to the Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch-Waxman Act, in West Virginia and Delaware. We have appealed the judgments in both actions. For additional information, please read </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Note 19, Litigation,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> to these condensed consolidated financial statements.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Multiple TECFIDERA generic entrants are now in the U.S. market, some of which have deeply discounted prices compared to TECFIDERA. The generic competition for TECFIDERA significantly reduced our TECFIDERA revenues during the third quarter of 2020 and is expected to have a substantial negative impact on our TECFIDERA revenues for as long as there is generic competition.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of September 30, 2020, we have assessed the realizability of our deferred tax assets that are dependent on future expected sales of TECFIDERA in the U.S. and reduced the value of certain deferred tax assets by approximately $1,627.9 million and reduced the value of deferred tax liabilities associated with global intangible low-taxed income (GILTI) and tax credits by approximately $1,538.6 million. For the three and nine months ended September 30, 2020, the income tax expense associated with these reductions was approximately $33.3 million and $89.3&#160;million, respectively. </span></div><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Tax Rate</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A reconciliation between the U.S.&#160;federal statutory tax rate and our effective tax rate is summarized as follows:</span></div><div style="text-align:justify;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:44.514%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.350%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.350%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.619%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.623%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Three Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Statutory rate</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">21.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">21.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">State taxes</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">0.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">0.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Taxes on foreign earnings</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(3.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(5.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(3.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Tax credits</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(2.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(1.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Purchased intangible assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">0.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Divestiture of Denmark manufacturing operations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Internal reorganization of certain intellectual property rights</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">TECFIDERA impairment</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">3.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">1.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">GILTI</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">1.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Swiss tax reform</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;</span><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;</span><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other permanent items</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(0.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">0.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">0.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Effective tax rate</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">25.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">20.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><div style="text-indent:13.5pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#00823b;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Changes in Tax Rate</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the three months ended September 30, 2020, compared to the same period in 2019, the increase in our effective tax rate was primarily due to an internal reorganization of certain intellectual property rights related to the intercompany sale of such intellectual property in 2019, the enactment of a new taxing regime in the country and certain cantons of Switzerland in 2019 (Swiss Tax Reform) and the net $33.3 million income tax expense related to the establishment of a valuation allowance against certain deferred tax assets, the realization of which is dependent on future sales of TECFIDERA in the U.S., as discussed above. </span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the nine months ended September 30, 2020, compared to the same period in 2019, the increase in our effective tax rate was primarily due to the $89.3 million impact from the valuation allowance described above, the internal reorganization of certain intellectual property rights and Swiss Tax Reform, partially offset by the $64.7 million tax expense recognized in September 30, 2019, related to the divestiture of our Hiller&#248;d, Denmark manufacturing operations. Although we recognized a loss on the divestiture of our Hiller&#248;d, Denmark manufacturing operations, the divestiture required us to write off certain deferred tax assets and resulted in a taxable gain in certain jurisdictions. For additional information on the divestiture of our Hiller&#248;d, Denmark manufacturing operations, please read </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Note 3, Divestitures,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> to our condensed consolidated financial statements included in this report.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As a result of the internal reorganization of certain intellectual property rights, we recorded a deferred tax asset of $754.2 million and a deferred tax liability of $603.4 million as of September 30, 2019.</span></div><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Accounting for Uncertainty in Income Taxes</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We and our subsidiaries are routinely examined by various taxing authorities. We file income tax returns in various U.S. states and in U.S. federal and other foreign jurisdictions. With few exceptions, we are no longer subject to U.S. federal tax examination for years before 2013 or state, local or non-U.S. income tax examinations for years before 2012.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The U.S. Internal Revenue Service and other national tax authorities routinely examine our intercompany transfer pricing with respect to intellectual property related transactions and it is possible that they may disagree with one or more positions we have taken with respect to such valuations.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">It is reasonably possible that we will adjust the value of our uncertain tax positions related to certain transfer pricing, collaboration matters and other issues as we receive additional information from various taxing authorities, including reaching settlements with such authorities.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We estimate that it is reasonably possible that our gross unrecognized tax benefits, exclusive of interest, could decrease by up to approximately $75.0 million in the next 12 months as a result of various audit closures, settlements and expiration of the statute of limitations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140388899828296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Consolidated Financial Statement Detail<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock', window );">Other Consolidated Financial Statement Detail</a></td>
<td class="text"><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Other Income (Expense), Net</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Components of other income (expense), net, are summarized as follows:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:43.929%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.204%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.204%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.619%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.624%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Three Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In millions)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest income</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">6.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">30.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">38.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">90.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest expense</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(56.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(45.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(166.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(141.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gain (loss) on investments, net</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(82.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(52.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">198.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign exchange gains (losses), net</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">3.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(5.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other, net</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">0.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">0.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(11.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total other income (expense), net</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(128.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(27.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(186.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">132.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/></tr></table></div><div style="text-indent:24.75pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Gain (loss) on investments, net, as reflected in the table above, relate to debt securities, equity securities of certain biotechnology companies, venture capital funds where the underlying investments are in equity securities of certain biotechnology companies and non-marketable equity securities.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the three months ended September 30, 2020, compared to the same period in 2019, the change in other income (expense), net primarily reflects net unrealized losses of approximately $82.1 million recognized on our investments related to our holdings in equity securities, compared to net unrealized losses totaling $4.1 million in the prior year comparative period. The net unrealized losses recognized during the three months ended September 30, 2020, primarily reflect a decrease in the fair value of Ionis common stock of approximately $66.2 million and a decrease in the fair value of Denali common stock of approximately $29.6 million, partially offset by an increase in the fair value of Sangamo common stock of approximately $15.2&#160;million.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the nine months ended September 30, 2020, compared to the same period in 2019, the change in other income (expense), net primarily reflects net unrealized losses of approximately $40.3 million recognized on our investments related to our holdings in equity securities, compared to net unrealized gains totaling $198.9&#160;million in the prior year comparative period. The net unrealized losses recognized during the nine months ended September 30, 2020, primarily reflect a decrease in the fair value of Ionis common stock of approximately $56.7&#160;million and a decrease in the fair value of Denali common stock of approximately $29.6&#160;million, partially offset by an increase in the fair value of Sangamo common stock of approximately $56.1&#160;million.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes our gain (loss) on investments, net that relates to our equity securities held as of September 30, 2020 and 2019:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:43.929%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.204%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.204%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.619%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.624%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Three Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In millions)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net gains (losses) recognized during the period on equity securities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(82.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(40.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">197.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: Net gains (losses) recognized during the period on equity securities sold during the period</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">46.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized gains (losses) recognized during the period on equity securities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(82.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(9.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(40.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">150.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/></tr></table></div><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Accrued Expenses and Other</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Accrued expenses and other consists of the following:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:58.549%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:18.344%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:18.347%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In millions)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">As of September 30, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue-related reserves for discounts and allowances</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">1,043.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,001.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Employee compensation and benefits</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">279.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">309.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Royalties and licensing fees</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">222.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">220.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Collaboration expenses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">277.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">281.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current portion of contingent consideration obligations</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">164.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">148.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Construction in progress</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">23.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">78.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">1,274.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">726.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total accrued expenses and other</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">3,286.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,765.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/></tr></table></div><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Other Long-term Liabilities</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Other long-term liabilities were $1,428.1 million and $1,348.9 million as of September 30, 2020 and December 31, 2019, respectively, and included accrued income taxes totaling $729.3 million and $803.3 million, respectively. Included within accrued taxes as of September 30, 2020 and December 31, 2019, is an accrual for a one-time mandatory deemed repatriation tax on accumulated foreign subsidiaries' previously untaxed foreign earnings (the Transition Toll Tax) of approximately $635.0 million and approximately $697.0 million, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalFinancialInformationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140388898390120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborative and Other Relationships</a></td>
<td class="text"><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Eisai Co., Ltd.</span></div><div style="text-indent:13.5pt;margin-top:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">BAN2401 and Elenbecestat Collaboration</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have a collaboration agreement with Eisai Co., Ltd. (Eisai) to jointly develop and commercialize BAN2401, a monoclonal antibody that targets amyloid beta aggregates, and elenbecestat, the oral BACE (base amyloid cleaving enzyme) inhibitor, two Eisai product candidates for the potential treatment of Alzheimer's disease (the BAN2401 and Elenbecestat Collaboration).&#160;In September 2019 we and Eisai discontinued the global Phase 3 studies of elenbecestat in early Alzheimer's disease. </span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Eisai serves as the global operational and regulatory lead for BAN2401 and all costs, including research, development, sales and marketing expenses, are shared equally between us and Eisai. If BAN2401 receives marketing approval, we and Eisai will co-promote BAN2401 and share profits equally. In addition, the BAN2401 and Elenbecestat Collaboration provides both parties with certain rights and obligations in the event of a change in control of either party.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The BAN2401 and Elenbecestat Collaboration also provided Eisai with an option to jointly develop and commercialize aducanumab, our anti-amyloid beta antibody candidate for Alzheimer's disease (Aducanumab Option), and an option to jointly develop and commercialize one of our anti-tau monoclonal antibodies (Anti-Tau Option). In October 2017 Eisai exercised its Aducanumab Option and we entered into a new collaboration agreement for the joint development and commercialization of aducanumab (Aducanumab Collaboration Agreement). Eisai has not exercised its Anti-Tau Option.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the Aducanumab Collaboration Agreement, the two companies will continue to jointly develop BAN2401 in accordance with the BAN2401 and Elenbecestat Collaboration; however, we are no longer required to pay Eisai any milestone payments in relation to BAN2401 and we are no longer entitled to any potential development and commercial milestone payments from Eisai in relation to aducanumab. For additional information on our BAN2401 and Elenbecestat Collaboration, please read </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Note 18, Collaborative and Other Relationships,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> to our consolidated financial statements included in our 2019 Form 10-K.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A summary of development and sales and marketing expense related to the BAN2401 and Elenbecestat Collaboration is as follows:</span></div><div style="margin-top:8pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%;"><tr><td style="width:1.0%;"/><td style="width:53.085%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.619%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.619%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.619%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.622%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Three Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In millions)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total development expense incurred by the collaboration related to the advancement of BAN2401 and elenbecestat</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">75.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">168.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">153.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">305.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Biogen's share of BAN2401 and elenbecestat development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">37.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">84.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">76.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">152.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total sales and marketing expense incurred by the collaboration</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">nm</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">6.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Biogen's share of BAN2401 and elenbecestat sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">nm</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">3.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr></table></div><div style="margin-top:9pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%;"><tr><td style="width:1.0%;"/><td style="width:33.017%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:31.105%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:32.578%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr></table></div><div style="margin-top:3pt;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;vertical-align:top;">nm</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;"> - For the three months ended September 30, 2020, sales and marketing expense related to the BAN2401 and Elenbecestat Collaboration was immaterial.</span></div><div style="text-indent:13.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Aducanumab Collaboration Agreement</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the Aducanumab Collaboration Agreement, we and Eisai will co-promote aducanumab with a region-based profit split and we lead the ongoing development of aducanumab. Beginning January 1, 2019, Eisai is reimbursing us for&#160;45%&#160;of development costs incurred by the collaboration for the advancement of aducanumab (aducanumab development expense). </span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In March 2019, based on a pre-specified futility analysis, we discontinued the global Phase 3 trials, EMERGE and ENGAGE, designed to evaluate the efficacy and safety of aducanumab in patients with early Alzheimer's disease. A new analysis of a larger dataset from these trials, conducted in consultation with the FDA, showed that the Phase 3 EMERGE study met its pre-specified primary and secondary endpoints. In the first quarter of 2019, as a result of the decision to discontinue the Phase 3 EMERGE and ENGAGE trials following the futility analysis, we accrued approximately $45.0 million related to the termination of various clinical trials and research and development contracts net of the 45% Eisai reimbursement of development costs incurred under the Aducanumab Collaboration Agreement.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In July 2020 we completed the submission of a Biologics License Application (BLA) to the FDA for the approval of aducanumab. For the nine months ended September 30, 2020, we recognized net profit-sharing income of $33.8 million to reflect Eisai's 45% share of the $75.0 million milestone expense related to the submission of the BLA to the FDA for the approval of aducanumab.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Sales and marketing expense are shared in proportion to the same region-based profit split that will be utilized to co-promote aducanumab. For additional information on the Aducanumab Collaboration Agreement, please read </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Note 18,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Collaborative and Other Relationships,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> to our consolidated financial statements included in our 2019 Form 10-K.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A summary of development, sales and marketing and milestone expense related to the Aducanumab Collaboration Agreement is as follows:</span></div><div style="margin-top:10pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%;"><tr><td style="width:1.0%;"/><td style="width:53.085%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.619%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.619%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.619%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.622%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Three Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In millions)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total aducanumab development expense</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">37.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">92.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">170.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Biogen's share of aducanumab development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">20.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">50.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">93.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total aducanumab sales and marketing expense incurred by the collaboration</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">90.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">158.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Biogen's share of aducanumab sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">51.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">88.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total aducanumab collaboration third party milestone expense</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">75.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Eisai's share of aducanumab milestone expense reflected in collaboration profit sharing in our condensed consolidated statements of income</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">33.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr></table></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, we and Eisai co-promote AVONEX, TYSABRI and TECFIDERA in Japan in certain settings and Eisai distributes AVONEX, TYSABRI, TECFIDERA and PLEGRIDY in India and other Asia-Pacific markets, excluding China.</span></div><div style="text-indent:13.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">UCB Pharma S.A.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have a collaboration agreement with UCB Pharma S.A. (UCB) to jointly develop and commercialize dapirolizumab pegol, an anti-CD40L pegylated Fab, for the potential treatment of systemic lupus erythematosus and other future agreed indications. Either we or UCB may propose development of dapirolizumab pegol in additional indications. If the parties do not agree to add an indication as an agreed indication to the collaboration, we or UCB may, at the sole expense of the applicable party, pursue development in such excluded indication(s), subject to an opt-in right of the non-pursuing party after proof of clinical activity. </span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">All costs incurred for agreed indications, including research, development, sales and marketing expenses, are shared equally between us and UCB. Upon marketing approval, we and UCB will co-promote dapirolizumab pegol and share profits equally. A summary of development expense related to the UCB collaboration agreement is as follows:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%;"><tr><td style="width:1.0%;"/><td style="width:53.085%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.619%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.619%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.619%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.622%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Three Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In millions)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total UCB development expense</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">10.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">35.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Biogen's share of UCB development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">5.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">17.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr></table></div><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Other Research and Discovery Arrangements</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">These arrangements may include the potential for future milestone payments based on the achievement of certain clinical and commercial development payable over a period of several years.</span></div><div style="text-indent:13.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Denali Therapeutics Inc.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In August 2020 we entered into a collaboration and license agreement with Denali to co-develop and co-commercialize Denali's small molecule inhibitors of leucine-rich repeat kinase 2 (LRRK2) for Parkinson's disease. </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition to the LRRK2 program, we also received an exclusive option to license two preclinical programs from Denali&#8217;s Transport Vehicle (TV) platform, including its Antibody Transport Vehicle: Abeta program, and a second program utilizing its TV technology. Further, we have the right of first negotiation on two additional TV-enabled therapeutics, currently at a preclinical stage, should Denali decide to seek a collaboration for such programs.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As part of this collaboration we purchased approximately $465.0&#160;million of Denali common stock in September 2020, or approximately 13&#160;million shares at approximately $34.94 per share, which are subject to transfer restrictions. We recorded an asset in investments and other assets in our condensed consolidated balance sheets to reflect the initial fair value of the Denali common stock acquired and a charge of approximately $41.3&#160;million to research and development expense in our condensed consolidated statements of income to reflect the premium paid for the Denali common stock. We also made an upfront payment of $560.0&#160;million that was recorded as research and development expense.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We may also pay development and commercial milestone payments that could total up to approximately $1.1&#160;billion if the milestones related to LRRK2 are achieved as well as tiered royalties on potential net commercial sales of LRRK2 licensed products.</span></div><div style="text-indent:13.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Sangamo Therapeutics, Inc.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In February 2020 we entered into a collaboration and license agreement with Sangamo to develop and commercialize ST-501 for tauopathies, including Alzheimer's disease; ST-502 for synucleinopathies, including Parkinson&#8217;s disease; a third neuromuscular disease target; and up to nine additional neurological disease targets to be identified and selected within a five-year period. The companies are leveraging Sangamo&#8217;s proprietary zinc finger protein technology delivered via AAV with the aim to modulate the expression of key genes involved in neurological diseases. </span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In connection with the closing of this transaction in April 2020 we purchased $225.0 million of Sangamo common stock, or approximately 24 million shares at approximately $9.21 per share, which are subject to transfer restrictions. We recorded an asset in investments and other assets in our condensed consolidated balance sheets to reflect the initial fair value of the Sangamo common stock acquired and a charge of&#160;approximately $83.0 million&#160;to research and development expense in our condensed consolidated statements of income to reflect the premium paid for the Sangamo common stock. We also made an upfront payment of $125.0 million that was recorded as research and development expense.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We may also pay research, development, regulatory and commercial milestone payments that could total up to approximately $2.4 billion if we select all of the targets allowed under this agreement and all the specified milestones set forth in this agreement are achieved. Of this amount, up to $80.0 million relates to the selection of targets, $1.9 billion relates to the achievement of specified research, clinical development, regulatory and first commercial sale milestones and $380.0 million relates to the achievement of specified sales-based milestones if annual worldwide net sales of licensed products reach specified levels. In addition, we may pay tiered royalties on potential net commercial sales of any products developed under this collaboration in the high single digit to double digit sub-teen percentages.</span></div><div style="text-indent:13.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Skyhawk Therapeutics, Inc.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In January 2019 we entered into a collaboration and research and development services agreement with Skyhawk Therapeutics, Inc. (Skyhawk) pursuant to which the companies are leveraging Skyhawk's SkySTAR technology platform with the goal of discovering innovative small molecule treatments for patients with neurological diseases, including MS and SMA. We are responsible for the development and potential commercialization of any therapies resulting from this collaboration and we may also pay Skyhawk up to a total of approximately $2.4&#160;billion in milestone payments as well as potential royalties on net commercial sales. </span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In connection with this agreement, we made an upfront payment of $74.0&#160;million to Skyhawk, of which $38.5 million was recorded as research and development expense in our condensed consolidated statements of income and $35.5 million was recorded as prepaid research and development expenditures within investments and other assets in our condensed consolidated balance sheets. These prepaid research and development services are </span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">expensed as the services are provided. In October 2019 we amended this agreement to add an additional discovery program. In connection with this amendment, we made a payment to Skyhawk of $15.0 million.</span></div><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Samsung Bioepis</span></div><div style="text-indent:13.5pt;margin-top:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Joint Venture Agreement</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In February 2012 we entered into a joint venture agreement with Samsung BioLogics establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar products.&#160;In June 2018 we exercised our option under our joint venture agreement to increase our ownership percentage in Samsung Bioepis from approximately 5.0% to approximately 49.9%. The share purchase transaction was completed in November 2018 and, upon closing, we paid 759.5 billion South Korean won ($676.6 million) to Samsung BioLogics. As of September 30, 2020, our ownership percentage remained at approximately 49.9%.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We recognize our share of the results of operations related to our investment in Samsung Bioepis under the equity method of accounting one quarter in arrears when the results of the entity become available, which is reflected as equity in income (loss) of investee, net of tax in our condensed consolidated statements of income. During 2015, as our share of losses exceeded the carrying value of our initial investment, we suspended recognizing additional losses. In the first quarter of 2019 we restarted recognizing our share of Samsung Bioepis' (income) losses, and we began recognizing amortization on certain basis differences resulting from our November 2018 investment. </span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Upon investment, the equity method of accounting requires us to identify and allocate differences between the fair value of our investment and the carrying value of our interest in the underlying net assets of the investee. These basis differences are amortized over their economic life. The total basis difference was approximately $675 million and relates to inventory, developed technology, IPR&amp;D and deferred tax balances. The basis differences related to inventory were amortized, net of tax, over their estimated useful lives of 1.5 years, and the basis differences related to developed technology and IPR&amp;D for marketed products will be amortized, net of tax, over their estimated useful lives of 15 years. </span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our joint venture partner, Samsung BioLogics, is currently subject to an ongoing criminal investigation that we continue to monitor. While this investigation could impact the operations of Samsung Bioepis and its business, we have assessed the value of our investment in Samsung Bioepis and continue to believe that the fair value of the investment is in excess of its net book value.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the three and nine months ended September 30, 2020, we recognized net losses on our investment of $13.1 million and $12.7 million, respectively, reflecting our share of Samsung Bioepis' operating results and amortization of basis differences.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of September 30, 2020 and December 31, 2019, the carrying value of our investment in Samsung Bioepis totaled 652.4 billion South Korean won ($557.8 million) and 670.8 billion South Korean won ($580.2 million), respectively, which is classified as a component of investments and other assets in our condensed consolidated balance sheets.</span></div><div style="text-indent:13.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">2019 Transaction</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In December 2019 we completed a transaction with Samsung Bioepis and secured the exclusive rights to commercialize two potential ophthalmology biosimilar products, SB11 referencing LUCENTIS and SB15 referencing EYLEA, in major markets worldwide, including the U.S., Canada, Europe, Japan and Australia. Samsung Bioepis will be responsible for development and will supply both products to us.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In connection with this transaction, we made an upfront payment of $100.0 million to Samsung Bioepis in January 2020, of which $63.0 million was recorded as research and development expense in 2019 and $37.0 million was recorded as an intangible asset in 2019. Additionally, during the third quarter of 2020, we paid Samsung Bioepis a $15.0&#160;million development milestone, which was included in research and development expense in our consolidated statements of income. We may pay Samsung Bioepis up to $195.0 million in additional development, regulatory and sales-based milestones.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We also acquired an option to extend the term of our 2013 commercial agreement for BENEPALI, IMRALDI and FLIXABI by an additional <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmIxOWZmODk2MDhjODQxNjhhNjM1MTYwZjJlZmE0OGYzL3NlYzpiMTlmZjg5NjA4Yzg0MTY4YTYzNTE2MGYyZWZhNDhmM18xMTIvZnJhZzo3YmVmNTMwYWE5OTQ0MGVmOTdlYzU4Yjc1OTVhN2E2Yi90ZXh0cmVnaW9uOjdiZWY1MzBhYTk5NDQwZWY5N2VjNThiNzU5NWE3YTZiXzg3OTYwOTMwNDMxMzk_81c0182f-ea26-4b51-b761-61b3c8a065e8">five</span> years, subject to payment of an option exercise fee of $60.0 million, and obtained exclusive rights to commercialize these products in China.</span></div><div style="text-indent:13.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">2013 Commercial Agreement</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We reflect revenues on sales of BENEPALI, IMRALDI and FLIXABI to third parties in product revenues, net in our condensed consolidated statements of income and record the related cost of revenues and sales and marketing expenses in our condensed consolidated statements of income to their respective line items when these costs are incurred. </span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We share 50% of the profit or loss related to our commercial agreement with Samsung Bioepis, which is recognized in collaboration profit (loss) sharing in our condensed consolidated statements of income. For the three and nine months ended September 30, 2020, we recognized net profit-sharing expense of $72.9 million and $200.1 million, respectively, to reflect Samsung Bioepis' 50% sharing of the net collaboration profits, compared to $60.1 million and $181.6 million, respectively, in the prior year comparative periods. As discussed above, we have an option to extend this agreement by an additional five years, subject to the payment of an option exercise fee of $60.0 million.</span></div><div style="text-indent:13.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Other Services</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Simultaneous with the formation of Samsung Bioepis, we also entered into a technical development services agreement, a manufacturing agreement and a license agreement with Samsung Bioepis. For the three and nine months ended September 30, 2020, we recognized $5.4 million and $13.6 million, respectively, in revenues related to these services, which is reflected in collaborative and other relationships revenues as a component of other revenues in our condensed consolidated statements of income, compared to $12.9 million and $89.9 million, respectively, in the prior year comparative periods. </span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Following the divestiture of our Hiller&#248;d, Denmark manufacturing operations in August 2019, FUJIFILM assumed responsibility for the manufacture of clinical and commercial quantities of bulk drug substance of biosimilar products for Samsung Bioepis. We no longer recognize revenues for the manufacturing completed after the Hiller&#248;d, Denmark manufacturing operations divestiture date under our technical development services and manufacturing agreements with Samsung Bioepis. For additional information on the divestiture of our Hiller&#248;d, Denmark manufacturing operations, please read </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Note 3, Divestitures,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> to these condensed consolidated financial statements.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Amounts receivable from Samsung Bioepis related to the agreements discussed above were $4.3 million and $85.0 million as of September 30, 2020 and December 31, 2019, respectively. Amounts payable to Samsung Bioepis were $26.4&#160;million as of September 30, 2020. Amounts payable to Samsung Bioepis as of December 31, 2019, consisted of the $100.0 million upfront payment related to the 2019 transaction, as discussed above.</span></div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For additional information on our collaboration arrangements with Samsung Bioepis and our other significant collaboration arrangements, please read </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Note 18,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Collaborative and Other Relationships,</span> to our consolidated financial statements included in our 2019 Form 10-K.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140388989607400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Variable Interest Entities<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_InvestmentsInVariableInterestEntitiesAbstract', window );"><strong>Investments in Variable Interest Entities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityDisclosureTextBlock', window );">Investments in Variable Interest Entities</a></td>
<td class="text"><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Consolidated Variable Interest Entities</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our condensed consolidated financial statements include the financial results of variable interest entities in which we are the primary beneficiary. The following are our significant variable interest entities.</span></div><div style="text-indent:13.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Neurimmune SubOne AG</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have a collaboration and license agreement with Neurimmune SubOne AG (Neurimmune) for the development and commercialization of antibodies for the potential treatment of Alzheimer's disease, including aducanumab (as amended, the Neurimmune Agreement). We are responsible for the development, manufacturing and commercialization of all collaboration products. The Neurimmune Agreement is effective for the longer of the duration of certain patents relating to a licensed product or 12 years from the first commercial sale of a licensed product.  </span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We consolidate the results of Neurimmune as we determined that we are the primary beneficiary of Neurimmune because we have the power through the collaboration to direct the activities that most significantly impact the entity&#8217;s economic performance and we are required to fund 100% of the research and development costs incurred in support of the collaboration. </span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In October 2017 we amended the terms of the Neurimmune Agreement and made a $150.0 million payment to Neurimmune in exchange for a 15% reduction in the previously negotiated royalty rates payable on products developed under the Neurimmune Agreement, including royalties payable on potential commercial sales of aducanumab. In May 2018 we made an additional $50.0 million payment to Neurimmune to further reduce the previously negotiated royalty rates payable on products developed under the Neurimmune Agreement, including royalties payable on potential commercial sales of aducanumab, by an additional 5%. Our royalty rates payable on products developed under the Neurimmune Agreement, including royalty rates payable on potential commercial sales of aducanumab, now range from the high single digits to sub-teens. As we consolidate the results of Neurimmune, we treated these payments as distributions and recognized them as charges to noncontrolling interests in the fourth quarter of 2017 and the second quarter of 2018, as applicable.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Additionally, under the terms of the Neurimmune Agreement, we are required to pay Neurimmune a milestone payment of&#160;$75.0 million&#160;upon the regulatory filing with the FDA for approval of aducanumab and a milestone payment of&#160;$100.0 million&#160;if aducanumab is launched in the U.S. In July 2020 we completed the submission of a BLA to the FDA for the approval of aducanumab. During the third quarter of 2020, we paid Neurimmune $75.0 million upon the completed submission of the BLA for aducanumab with the FDA, which was recognized as a charge to noncontrolling interests for the nine months ended September 30, 2020. In addition, for the nine months ended September 30, 2020, we recognized net profit-sharing income of $33.8 million to reflect Eisai's 45% share of the $75.0 million milestone payment.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Research and development costs for which we reimburse Neurimmune are reflected in research and development expense in our condensed consolidated statements of income. During the three and nine months ended September 30, 2020 and 2019, amounts reimbursed were immaterial.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The assets and liabilities of Neurimmune are not significant to our condensed consolidated financial position or results of operations as it is a research and development organization. We have provided no financing to Neurimmune other than contractually required amounts.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the Aducanumab Collaboration Agreement, Eisai had an option to share in the benefit and cost associated with the royalty reductions discussed above; however, Eisai did not elect to share in the benefit and cost with respect to either the October 2017 or May 2018 royalty reductions, which will impact the amount of profits (losses) on potential commercial sales of aducanumab to be shared with Eisai.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For additional information on our collaboration arrangements with Eisai, please read </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Note 17, Collaborative and Other Relationships, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">to these condensed consolidated financial statements.</span></div><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Unconsolidated Variable Interest Entities</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have relationships with various variable interest entities that we do not consolidate as we lack the power to direct the activities that significantly impact the economic success of these entities. These relationships include investments in certain biotechnology companies and research collaboration agreements. </span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of September 30, 2020 and December 31, 2019, the carrying value of our investments in certain biotechnology companies representing potential unconsolidated variable interest entities totaled $21.9 million and $22.7 million, respectively. Our maximum exposure to loss related to these variable interest entities is limited to the carrying value of our investments.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have also entered into research collaboration agreements with certain variable interest entities where we are required to fund certain development activities. These development activities are included in research and development expense in our condensed consolidated statements of income as they are incurred. We have provided no financing to these variable interest entities other than previously contractually required amounts. </span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For additional information on our investments in Neurimmune and other variable interest entities, please read </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Note 19, Investments in Variable Interest Entities,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> to our consolidated financial statements included in our 2019 Form 10-K.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InvestmentsInVariableInterestEntitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investments In Variable Interest Entities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InvestmentsInVariableInterestEntitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a variable interest entity (VIE), including but not limited to, judgments and assumptions in determining whether to consolidate and in identifying the primary beneficiary, gain (loss) recognized on the initial consolidation of the VIE, terms of arrangements, amounts and classification of the VIE's assets and liabilities, and the entity's maximum exposure to loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140388898438360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Litigation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract', window );"><strong>Loss Contingency, Information about Litigation Matters [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LegalMattersAndContingenciesTextBlock', window );">Litigation</a></td>
<td class="text"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are currently involved in various claims and legal proceedings, including the matters described below. For information as to our accounting policies relating to claims and legal proceedings, including use of estimates and contingencies, please read </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Note 1, Summary of Significant Accounting Policies,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> to our consolidated financial statements included in our 2019 Form 10-K.</span><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">With respect to some loss contingencies, an estimate of the possible loss or range of loss cannot be made until management has further information, including, for example, (i) which claims, if any, will survive dispositive motion practice; (ii) information to be obtained through discovery; (iii) information as to the parties' damages claims and supporting evidence; (iv) the parties&#8217; legal theories; and (v) the parties' settlement positions. </span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The claims and legal proceedings in which we are involved also include challenges to the scope, validity or enforceability of the patents relating to our products, pipeline or processes and challenges to the scope, validity or enforceability of the patents held by others. These include claims by third parties that we infringe their patents. An adverse outcome in any of these proceedings could result in one or more of the following and have a material impact on our business or consolidated results of operations and financial position: (i) loss of patent protection; (ii) inability to continue to engage in certain activities; and (iii) payment of significant damages, royalties, penalties and/or license fees to third parties.</span></div><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Loss Contingencies </span></div><div style="text-indent:13.5pt;margin-top:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">IMRALDI Patent Litigation</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In September 2018 Fresenius Kabi Deutschland GmbH (Fresenius Kabi) commenced proceedings for damages and injunctive relief against Biogen France SAS in the Tribunal de Grande Instance de Paris, alleging that IMRALDI, the adalimumab biosimilar product of Samsung Bioepis UK Limited that Biogen has commercialized in Europe, infringes the French counterpart of European Patent No. 3 148 510 (the '510 Patent), which was issued in June 2018 and expires in May 2035. No hearing has been scheduled. </span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In October 2018 Fresenius Kabi commenced preliminary injunction proceedings against Biogen (Denmark) Manufacturing ApS and Biogen Denmark A/S in Denmark's Maritime and Commercial High Court alleging infringement of Danish Utility Models. In June 2019 the Danish court denied Fresenius Kabi's request for a preliminary injunction. Fresenius Kabi has appealed that decision and a hearing has been set for January 2021. In July 2020 the Danish Patent Board of Appeal revoked the Utility Models that were the subject of Fresenius Kabi&#8217;s October 2018 request for a preliminary injunction and Fresenius Kabi has appealed those revocations.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2020 Fresenius Kabi commenced preliminary injunction proceedings against Biogen (Denmark) Manufacturing ApS and Biogen (Denmark) A/S in Denmark&#8217;s Maritime and Commercial High Court alleging infringement of another Danish Utility Model. A hearing has been scheduled for May 2021.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In November 2018 Fresenius Kabi commenced infringement proceedings for damages and injunctive relief against Biogen Italia S.R.L. in the District Court of Milan relating to the Italian counterpart of the &#8216;510 Patent, and against Biogen GmbH in the D&#252;sseldorf Regional Court relating to the German counterpart of the &#8216;510 Patent. In Italy, Fresenius Kabi has surrendered the Italian counterpart of the &#8216;510 Patent and the court dismissed its infringement action in October 2020. A hearing in the proceeding in Germany has been set for August 2021.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In July 2019 Gedeon Richter PLC (Gedeon Richter) commenced proceedings against Biogen GmbH in the D&#252;sseldorf Regional Court alleging infringement of the German counterpart of European Patent No. 3 212 667 (the '667 Patent), which was issued in September 2018 and expires in October 2035, and seeking damages and injunctive relief. The November 2020 hearing has been postponed and a new hearing date has not been set.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In August 2019 Biogen B.V. (Netherlands) and Samsung Bioepis UK Limited filed an action in the District Court of the Hague, Netherlands to revoke the Dutch counterpart of the '667 Patent. Gedeon Richter filed a separate action for infringement in the same court. A hearing was held in May 2020 and in July 2020 the court revoked the Dutch counterpart of the '667 Patent.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">An estimate of the possible loss or range of loss in the pending IMRALDI patent litigation described above cannot be made at this time. </span></div><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Qui Tam Litigation</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In July 2015 a qui tam action filed by Michael Bawduniak on behalf of the U.S. and certain states was unsealed by the U.S. District Court for the District of Massachusetts. The action alleges sales and promotional activities in violation of the federal False Claims Act and state law counterparts and seeks single and treble damages, civil penalties, interest, attorneys&#8217; fees and costs. No trial date has been set. The U.S. has not made an intervention decision. An estimate of the possible loss or range of loss cannot be made at this time.</span></div><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Dispute with Former Convergence Shareholders</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In November and December 2019 Shareholder Representative Services LLC, on behalf of the former shareholders of Convergence, sent us correspondence asserting claims of $200.0 million for alleged breach of the contract under which we acquired Convergence. We dispute the claims.</span></div><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:174%;">Dispute with Jacobs Switzerland GmbH</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Jacobs Switzerland GmbH, the general contractor for the construction of our large-scale biologics manufacturing facility in Solothurn, Switzerland, claims approximately 31.0 million Swiss Francs (approximately $33.0 million) relating to construction costs. We dispute the claim.</span></div><div style="text-indent:13.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Other Matters</span></div><div style="text-indent:11.25pt;margin-top:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Petition for Inter Partes Review</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In July 2018 Mylan Pharmaceuticals, Inc. (Mylan) filed a petition that was granted by the U.S. Patent Trial and Appeal Board (PTAB) for </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">inter partes</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> review of our U.S. Patent No. 8,399,514 (the '514 Patent). The '514 Patent includes claims covering treatment of MS with 480 mg of dimethyl fumarate per day as provided for in our TECFIDERA label. In February 2020 the PTAB issued a final written decision upholding the patentability of the &#8216;514 Patent and in April 2020 Mylan filed an appeal in the U.S. Court of Appeals for the Federal Circuit (the Federal Circuit), which is pending. Oral argument has been scheduled for December 8, 2020.</span></div><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Hatch-Waxman Act Litigation relating to TECFIDERA Orange-Book Listed Patents</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In 2017, 2018 and 2019 we filed patent infringement proceedings relating to TECFIDERA Orange-Book listed patents pursuant to the Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch-Waxman Act (the Delaware Actions), against Accord Healthcare Inc., Alkem Laboratories Ltd., Amneal Pharmaceuticals LLC, Aurobindo Pharma U.S.A., Inc., Cipla Limited, Glenmark Pharmaceuticals Ltd., Graviti Pharmaceuticals Pvt. Ltd., Hetero USA, Inc.,&#160;Lupin Atlantis Holdings SA, Macleods Pharmaceuticals, Ltd., MSN Laboratories Pvt. Ltd., Pharmathen S.A., Prinston Pharmaceutical Inc., Sandoz Inc., Sawai USA, Inc., Shilpa Medicare Limited, Slayback Pharma LLC, Torrent Pharmaceuticals Ltd., TWi Pharmaceuticals, Inc., Windlas Healthcare Pvt. Ltd. and Zydus Pharmaceuticals (USA) Inc. (the Delaware Defendants) in the U.S. District Court for the District of Delaware (the Delaware Court) and against Mylan in the U.S. District Court for the Northern District of West Virginia (the West Virginia Court). The litigation against Aurobindo Pharma U.S.A., Inc., Glenmark Pharmaceuticals Ltd. and Sawai USA, Inc. was dismissed in the fourth quarter of 2019.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On June 22, 2020, the West Virginia Court entered judgment for Mylan that the asserted claims of the &#8216;514 Patent are invalid for lack of written description. We appealed the judgment to the Federal Circuit and the appeal is pending. Oral argument has been scheduled for December 8, 2020.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On September 22, 2020, the Delaware Court entered judgment for the Delaware Defendants on the grounds that the judgment of the West Virginia Court applies to the Delaware Actions under principles of collateral estoppel. We have appealed the judgment and the appeal is pending. Multiple generic versions of TECFIDERA have entered the U.S. market prior to resolution of the appeals.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On August 31, 2020, we filed a patent infringement action under the Hatch-Waxman Act against Sun Pharmaceutical Industries Limited, Sun Pharmaceutical Industries, Inc. and Sun Pharma Global SZE in the Delaware Court. No trial has been scheduled in this action.</span></div><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">European Patent Office Oppositions</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In 2016 the European Patent Office (EPO) revoked our European Patent No. 2 137 537, which covers the treatment of MS with 480 mg of dimethyl fumarate as provided for in our TECFIDERA label. We have appealed to the Technical Boards of Appeal of the EPO and a hearing has been set for January 2021. </span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In March 2018 the EPO revoked Forward Pharma A/S' (Forward Pharma) European Patent No. 2 801 355, which expires in October 2025. Forward Pharma has filed an appeal to the Technical Boards of Appeal of the EPO and a hearing has been set for February 2021. </span></div><div style="text-indent:13.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">TYSABRI Patent Revocation Matters</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In November 2017 Bioeq GMBH, affiliated with the Polpharma Group, brought an action in the Polish Patent Office seeking to revoke Polish Patent No. 215263 (the Polish '263 Patent), which corresponds to our European Patent No. 1 485 127 (the E.U. '127 Patent) and covers administration of natalizumab (TYSABRI) to treat MS. The Polish '263 Patent expires in February 2023. No hearing has been set in this matter.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Swiss Pharma International AG, also affiliated with the Polpharma Group, filed actions in the District Court of the Hague, Netherlands (January 2016), the German Patents Court (March 2016) and the Commercial Court of Rome (November 2017) seeking to invalidate the Dutch, German and Italian counterparts, respectively, of the E.U. '127 Patent, which also cover administration of natalizumab (TYSABRI) to treat MS and expire in February 2023. The Dutch and German counterparts were ruled invalid. The decision in the Dutch action was affirmed on appeal and the German appeal has been withdrawn. No hearing has been set in the Italian action.</span></div><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">'755 Patent Litigation</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In May&#160;2010 Biogen MA Inc. (formerly Biogen Idec MA Inc.) filed a complaint in the U.S.&#160;District Court for the District of New Jersey alleging infringement by Bayer Healthcare Pharmaceuticals Inc. (Bayer) (manufacturer, marketer and seller of BETASERON and manufacturer of EXTAVIA), EMD Serono, Inc. (EMD Serono) (manufacturer, marketer and seller of REBIF), Pfizer (co-marketer of REBIF) and Novartis Pharmaceuticals Corp. (Novartis) (marketer and seller of EXTAVIA) of our U.S. Patent No. 7,588,755 (the '755 Patent), which claims, among other things, the use of interferon beta for immunomodulation. The complaint seeks monetary damages, including lost profits and royalties. </span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Bayer, Pfizer, Novartis and EMD Serono all filed counterclaims seeking declaratory judgments of patent invalidity and non-infringement and seeking monetary relief in the form of costs and attorneys' fees. Bayer had previously filed a complaint against us in the same court, on May 27, 2010, seeking a declaratory judgment that it does not infringe the '755 Patent and that the '755 Patent is invalid, and seeking monetary relief in the form of attorneys' fees, costs and expenses. Bayer has also requested </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">ex parte</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> reexamination by the U.S. Patent and Trademark Office of Claim 1 of the &#8216;755 Patent, which request was granted in January 2020 and is pending.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In September 2020 the Federal Circuit reversed the trial court's judgment against EMD Serono and Pfizer that the '755 patent is valid. We intend to file a petition for panel rehearing and rehearing en banc.</span></div><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Annulment Proceeding in General Court of the European Union relating to TECFIDERA</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In October 2018 Pharmaceutical Works Polpharma SA (Polpharma) filed an application in the General Court of the European Union seeking to annul a decision of the European Medicines Agency (EMA) in which the EMA refused to validate Polpharma&#8217;s application to market a generic version of TECFIDERA on the grounds that TECFIDERA benefits from regulatory data protection (RDP). Polpharma disputes that TECFIDERA benefits from RDP. Biogen and the European Commission were granted leave to intervene in the case in support of the EMA and the case is pending. A hearing was held on</span><span style="background-color:rgb(255,255,255, 0.0);color:#ff0000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">July 13, 2020, and we are awaiting a decision.</span></div><div style="text-indent:11.25pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Government Matters</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have learned that state and U.S. governmental authorities are investigating our sales and promotional practices and have received related subpoenas. We are cooperating with the investigation.</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have received subpoenas and other requests from the U.S. government for documents and information relating to our relationship with non-profit organizations that assist patients taking drugs sold by Biogen and the government has challenged some of our contributions to these organizations. We have reached an agreement in principle with the government to resolve this matter. We have accrued the amount of our best estimate of the minimum probable loss in this matter.</span></div><div style="text-indent:13.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Product Liability and Other Legal Proceedings</span></div><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are also involved in product liability claims and other legal proceedings generally incidental to our normal business activities. While the outcome of any of these proceedings cannot be accurately predicted, we do not believe the ultimate resolution of any of these existing matters would have a material adverse effect on our business or financial condition.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalMattersAndContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalMattersAndContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyInformationAboutLitigationMattersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140388894781064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_BusinessOverviewPolicyTextBlock', window );">Overview</a></td>
<td class="text"><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Biogen is a global biopharmaceutical company focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. Our core growth areas include multiple sclerosis (MS) and neuroimmunology; Alzheimer's disease and dementia; neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS); movement disorders, including Parkinson's disease; and ophthalmology. We are also focused on discovering, developing and delivering worldwide innovative therapies in our emerging growth areas of immunology; neurocognitive disorders; acute neurology; and pain. In addition, we commercialize biosimilars of advanced biologics. We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities. </span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; and FUMADERM for the treatment of severe plaque psoriasis. We also have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of primary progressive MS and relapsing MS; and other potential anti-CD20 therapies pursuant to our collaboration arrangements with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group. For additional information on our collaboration arrangements with Genentech, please read </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Note 18, Collaborative and Other Relationships,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> to our consolidated financial statements included in our Annual Report on Form&#160;10-K for the year ended December 31, 2019 (2019 Form&#160;10-K).</span></div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our innovative drug development and commercialization activities are complemented by our biosimilar business that expands access to medicines and reduces the cost burden for healthcare systems. Through Samsung Bioepis Co., Ltd. (Samsung Bioepis), our joint venture with Samsung BioLogics Co., Ltd. (Samsung BioLogics), we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL, IMRALDI, an adalimumab biosimilar referencing HUMIRA, and FLIXABI, an infliximab biosimilar referencing REMICADE, in certain countries in Europe and have exclusive rights to commercialize these products in China. Additionally, we have exclusive rights to commercialize two potential ophthalmology biosimilar products, SB11 referencing LUCENTIS and SB15 referencing EYLEA, in major markets worldwide, including the United States (U.S.), Canada, Europe, Japan and Australia. For additional information on our collaboration arrangements with Samsung Bioepis, please read </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Note 17, Collaborative and Other Relationships,</span> to these unaudited condensed consolidated financial statements (condensed consolidated financial statements).<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of presentation</a></td>
<td class="text"><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In the opinion of management, our condensed consolidated financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair statement of our financial statements for interim periods in accordance with accounting principles generally accepted in the United States (U.S.&#160;GAAP). The information included in this quarterly report on Form&#160;10-Q should be read in conjunction with our audited consolidated financial statements and the accompanying notes included in our 2019 Form&#160;10-K. Our accounting policies are described in the </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Notes to Consolidated Financial Statements</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> in our 2019 Form&#160;10-K and updated, as necessary, in this report. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from our audited financial statements but does not include all disclosures required by U.S.&#160;GAAP. The results of operations for the three and nine months ended September 30, 2020, are not necessarily indicative of the operating results for the full year or for any other subsequent interim period. </span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We operate as one operating segment, focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Consolidation</a></td>
<td class="text"><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our condensed consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and those of certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than 100% of the economics, we record net income (loss) attributable to noncontrolling interests in our condensed consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. </span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In determining whether we are the primary beneficiary of a variable interest entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. These considerations impact the way we account for our existing collaborative relationships and other arrangements. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text">The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. Actual results may differ from these estimates.The length of time and full extent to which the COVID-19 pandemic directly or indirectly impacts our business, results of operations and financial condition, including sales, expenses, reserves and allowances, manufacturing, clinical trials, research and development costs and employee-related amounts, depends on future developments that are highly uncertain, subject to change and are difficult to predict, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19 as well as the economic impact on local, regional, national and international customers and markets. We have made estimates of the impact of COVID-19 within our condensed consolidated financial statements and there may be changes to those estimates in future periods.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New accounting pronouncements</a></td>
<td class="text"><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed below, we do not believe that the adoption of recently issued standards have or may have a material impact on our condensed consolidated financial statements or disclosures.</span></div><div style="text-indent:13.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#528134;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Credit Losses</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2016 the FASB issued Accounting Standards Update (ASU) No. 2016-13, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The FASB subsequently issued amendments to ASU 2016-13, which have the same effective date and transition date of January 1, 2020. This standard requires entities to estimate an expected lifetime credit loss on financial assets ranging from short-term trade accounts receivable to long-term financings and report credit losses using an expected losses model rather than the incurred losses model that was previously used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, this standard now requires allowances to be recorded instead of reducing the amortized cost of the investment. This standard limits the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit losses if fair value increases.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">This standard became effective for us on January 1, 2020, and based on the composition of our trade receivables, investment portfolio and other financial assets, current economic conditions and historical credit loss activity, the adoption of this standard did not have a material impact on our condensed consolidated financial statements and related disclosures. During the three and nine months ended September 30, 2020, we recorded an immaterial amount associated with expected credit losses related to outstanding trade receivables in certain foreign countries that have been disproportionately impacted by the COVID-19 pandemic.</span></div><div style="text-indent:13.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#528134;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Fair Value Measurements</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In August 2018 the FASB issued ASU No. 2018-13,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"> Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. This standard modifies certain disclosure requirements on fair value measurements. This standard became effective for us on January 1, 2020, and did not have a material impact on our disclosures. For the new disclosures regarding our Level 3 instruments, please read </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Note 7, Fair Value Measurements,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> to these condensed consolidated financial statements.</span></div><div style="text-indent:13.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#528134;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Internal Use Software</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In August 2018 the FASB issued ASU No. 2018-15, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Intangibles&#8212;Goodwill and Other&#8212;Internal-Use Software (Subtopic 350-40): Customer&#8217;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. This standard clarifies the accounting for implementation costs in cloud computing arrangements. This standard, which became effective for us on January 1, 2020, and was adopted on a prospective basis, resulted in an immaterial amount of additional assets being recorded on our condensed consolidated balance sheets.</span></div><div style="text-indent:13.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#528134;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Collaborative Arrangements</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In November 2018 the FASB issued ASU No. 2018-18, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. This standard makes targeted improvements for collaborative arrangements as follows:</span></div><div style="text-indent:-18pt;padding-left:40.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">Clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under Accounting Standards Codification (ASC) 606, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Revenue from Contracts with Customers</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, when the collaborative arrangement participant is a customer in the context of a unit of account. In those situations, all the guidance in ASC 606 should be applied, including recognition, measurement, presentation and disclosure requirements;</span></div><div style="text-indent:-18pt;padding-left:40.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">Adds unit-of-account guidance to ASC 808, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Collaborative Arrangements</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, to align with the guidance in ASC 606 (that is, a distinct good or service) when an entity is assessing whether the collaborative arrangement or a part of the arrangement is within the scope of ASC 606; and</span></div><div style="text-indent:-18pt;padding-left:40.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt;">Precludes a company from presenting transactions with collaborative arrangement participants that are not directly related to sales to third parties with revenue recognized under ASC 606 if the collaborative arrangement participant is not a customer.</span></div><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">This standard became effective for us on January 1, 2020, and did not have a material impact on our condensed consolidated financial statements and related disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_BusinessOverviewPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes an overview of the company and its operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_BusinessOverviewPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.3A-02)<br> -URI http://asc.fasb.org/extlink&amp;oid=116822174&amp;loc=d3e355033-122828<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.3A-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=116822174&amp;loc=d3e355100-122828<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140388898297144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Revenues by product</a></td>
<td class="text"><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Revenues by product are summarized as follows:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:31.550%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.441%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.295%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.441%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.295%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.441%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.445%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="33" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Three Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In millions)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">United<br/>States</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Rest of<br/>World</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">United<br/>States</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Rest of<br/>World</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Multiple Sclerosis (MS):</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fumarate*</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">684.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">283.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">967.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">842.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">280.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,122.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interferon**</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">327.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">146.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">474.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">360.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">169.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">530.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">TYSABRI</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">304.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">212.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">516.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">263.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">220.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">483.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">FAMPYRA</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">26.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">26.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Subtotal: MS product revenues</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">1,315.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">669.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">1,984.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,465.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">694.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,160.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Spinal Muscular Atrophy:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">SPINRAZA</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">182.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">311.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">494.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">236.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">310.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">547.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Biosimilars:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">BENEPALI</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">124.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">124.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">115.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">115.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">IMRALDI</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">56.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">56.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">49.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">49.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">FLIXABI</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">27.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">27.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Subtotal: Biosimilar product revenues</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">207.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">207.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">183.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">183.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">FUMADERM</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">3.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">3.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total product revenues</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">1,498.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">1,192.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2,690.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,702.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,192.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,894.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/></tr></table></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%;"><tr><td style="width:1.0%;"/><td style="width:33.017%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:31.105%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:32.578%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">*Fumarate includes TECFIDERA and VUMERITY. VUMERITY became commercially available in the U.S. in November 2019.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">**Interferon includes AVONEX and PLEGRIDY.</span></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%;"><tr><td style="width:1.0%;"/><td style="width:31.300%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.536%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.503%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.536%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.356%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.536%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.356%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.536%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.356%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.536%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.503%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.536%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.510%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="33" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In millions)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">United<br/>States</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Rest of<br/>World</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">United<br/>States</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Rest of<br/>World</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Multiple Sclerosis (MS):</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fumarate*</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2,383.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">875.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">3,258.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,429.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">841.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,271.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interferon**</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">965.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">456.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">1,421.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,067.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">518.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,585.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">TYSABRI</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">826.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">644.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">1,470.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">772.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">647.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,419.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">FAMPYRA</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">78.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">78.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">71.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">71.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Subtotal: MS product revenues</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">4,174.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2,054.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">6,229.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,269.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,078.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,347.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Spinal Muscular Atrophy:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">SPINRAZA</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">628.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">925.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">1,554.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">690.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">863.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,553.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Biosimilars:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">BENEPALI</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">363.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">363.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">360.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">360.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">IMRALDI</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">162.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">162.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">132.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">132.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">FLIXABI</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">71.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">71.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">49.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">49.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Subtotal: Biosimilar product revenues</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">598.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">598.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">542.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">542.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">FUMADERM</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">9.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">9.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total product revenues</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">4,803.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">3,587.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">8,390.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,959.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,495.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,455.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/></tr></table></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%;"><tr><td style="width:1.0%;"/><td style="width:33.017%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:31.105%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:32.578%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">*Fumarate includes TECFIDERA and VUMERITY. VUMERITY became commercially available in the U.S. in November 2019.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">**Interferon includes AVONEX and PLEGRIDY.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock', window );">Analysis of change In reserves</a></td>
<td class="text"><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">An analysis of the change in reserves for discounts and allowances is summarized as follows:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:47.155%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.526%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.109%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.526%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.109%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.526%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.109%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.526%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.114%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In millions)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Discounts</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contractual<br/>Adjustments</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Returns</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, December 31, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">131.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">1,027.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">40.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">1,198.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current provisions relating to sales in current year</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">589.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2,465.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">14.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">3,070.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Adjustments relating to prior years</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(1.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(41.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">1.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(40.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Payments/credits relating to sales in current year</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(457.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(1,704.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(2,162.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Payments/credits relating to sales in prior years</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(120.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(658.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(15.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(794.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, September 30, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">141.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">1,088.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">41.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">1,271.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock', window );">Total reserves included in consolidated balance sheets</a></td>
<td class="text"><div style="text-indent:24.75pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The total reserves above, which are included in our condensed consolidated balance sheets, are summarized as follows:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:65.808%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.525%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.720%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.525%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.722%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In millions)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">As of September 30, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Reduction of accounts receivable, net</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">227.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">197.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Component of accrued expenses and other</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">1,043.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,001.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total revenue-related reserves</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">1,271.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,198.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock', window );">Revenues from anti-CD20 therapeutic programs</a></td>
<td class="text"><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Revenues from anti-CD20 therapeutic programs are summarized below. For the purposes of this footnote we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:49.338%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.595%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.595%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.595%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.603%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Three Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In millions)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Biogen&#8217;s share of pre-tax profits in the U.S. for RITUXAN and GAZYVA</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">275.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">393.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">873.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,161.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other revenues from anti-CD20 therapeutic programs</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">285.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">202.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">685.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">528.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total revenues from anti-CD20 therapeutic programs</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">560.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">595.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">1,558.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,689.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_OtherrevenuesTableTextBlock', window );">Other revenues</a></td>
<td class="text"><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Other revenues are summarized as follows:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:49.192%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.595%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.595%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.595%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.603%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Three Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In millions)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenues from collaborative and other relationships:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Profit (loss) earned under our 50% share of the co-promotion losses on ZINBRYTA in the U.S. with AbbVie Inc.</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">0.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenues earned under our technical development agreement, manufacturing services agreements and royalty revenues on biosimilar products with Samsung Bioepis</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">5.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">13.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">89.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other royalty and corporate revenues:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Royalty</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">10.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">28.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other corporate</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">110.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">93.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">599.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">462.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total other revenues</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">125.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">109.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">642.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">562.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Analysis of amount of and change in product revenue reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_OtherrevenuesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other revenues [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_OtherrevenuesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenues from anti-CD20 therapeutic programs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of total product revenue reserves included in consolidated balance sheets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140388898308440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Components of inventory</a></td>
<td class="text"><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The components of inventory are summarized as follows:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.830%;"><tr><td style="width:1.0%;"/><td style="width:58.071%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.539%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:18.574%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.539%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:18.577%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In millions)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">As of September 30, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Raw materials</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">288.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">169.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Work in process</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">539.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">460.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Finished goods</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">199.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">174.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total inventory</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">1,027.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">804.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140388896893256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_IntangibleAssetsExcludingGoodwillTableTextBlock', window );">Intangible assets</a></td>
<td class="text"><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Intangible assets, net of accumulated amortization, impairment charges and adjustments, are summarized as follows:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%;"><tr><td style="width:1.0%;"/><td style="width:22.394%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.493%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:7.710%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.032%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:7.710%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:7.710%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.032%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:7.715%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">As of September 30, 2020</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of December 31, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Estimated Life</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated<br/>Amortization</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated<br/>Amortization</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Completed technology</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4-28 years</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">7,394.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(5,077.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2,316.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,379.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4,881.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,497.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">In-process research and development</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Indefinite until commercialization</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">943.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">943.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">965.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">965.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Trademarks&#160;and trade names</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Indefinite</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">64.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">64.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">64.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">64.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total intangible assets</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">8,401.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(5,077.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">3,323.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,408.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4,881.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,527.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Estimated future amortization for acquired intangible assets</a></td>
<td class="text">he estimated future amortization of finite-lived intangible assets for the next five years is expected to be as follows:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:78.724%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:18.346%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In millions)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">As of September 30, 2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020 (remaining three months)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">60.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">205.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">215.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">215.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2024</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">225.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2025</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">220.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Summary of roll forward of the changes in goodwill</a></td>
<td class="text"><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table provides a roll forward of the changes in our goodwill balance:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:78.724%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:18.346%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In millions)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">As of September 30, 2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Goodwill, December 31, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">5,757.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(2.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Goodwill, September 30, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">5,755.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_IntangibleAssetsExcludingGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intangible assets excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_IntangibleAssetsExcludingGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13854-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140388989865832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Summary of assets and liabilities recorded at fair value</a></td>
<td class="text"><div style="text-indent:24.75pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:40.420%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.788%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.788%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.788%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.796%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">As of September 30, 2020</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In millions)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Quoted&#160;Prices<br/>in Active<br/>Markets<br/>(Level 1)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level 2)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-style:italic;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash equivalents</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">1,570.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">1,570.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Marketable debt securities:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">1,443.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">1,443.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Government securities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">767.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">767.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Mortgage and other asset backed securities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">153.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">153.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Marketable equity securities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">868.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">276.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">592.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Derivative contracts</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">26.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">26.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Plan assets for deferred compensation</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">26.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">26.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:29.25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">4,856.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">276.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">4,579.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-style:italic;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Liabilities:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Derivative contracts</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">99.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">99.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration obligations</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">322.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">322.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:29.25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">422.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">99.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">322.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:40.420%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.788%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.788%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.788%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.796%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of December 31, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In millions)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Quoted&#160;Prices<br/>in Active<br/>Markets<br/>(Level 1)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level 2)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-style:italic;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash equivalents</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,541.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,541.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Marketable debt securities:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,695.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,695.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Government securities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,013.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,013.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Mortgage and other asset backed securities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">261.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">261.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Marketable equity securities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">337.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">329.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Derivative contracts</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">43.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">43.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Plan assets for deferred compensation</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">27.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">27.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:29.25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,920.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,912.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-style:italic;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Liabilities:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Derivative contracts</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration obligations</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">346.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">346.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:29.25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">354.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">346.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock', window );">Summary of fair and carrying value of debt instruments</a></td>
<td class="text"><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair and carrying values of our debt instruments, which are Level&#160;2 liabilities, are summarized as follows:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:42.091%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.369%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.369%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.369%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.374%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">As of September 30, 2020</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of December 31, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In millions)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair<br/>Value</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Carrying<br/>Value</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair<br/>Value</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Carrying<br/>Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">2.900% Senior Notes due September 15, 2020</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;vertical-align:top;">(1)</sup></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,509.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,495.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.625% Senior Notes due September 15, 2022</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">1,058.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">997.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,038.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">996.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.050% Senior Notes due September 15, 2025</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">1,988.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">1,740.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,897.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,739.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.250% Senior Notes due May 1, 2030</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">1,532.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">1,491.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.200% Senior Notes due September 15, 2045</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2,286.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">1,723.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,107.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,722.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.150% Senior Notes due May 1, 2050</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">1,470.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">1,472.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">8,336.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">7,425.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,553.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,954.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Fair value of contingent consideration obligations</a></td>
<td class="text">The following table provides a roll forward of the fair values of our contingent consideration obligations, which includes Level 3 measurements:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:47.438%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.034%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.034%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.034%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.040%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Three Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In millions)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair value, beginning of period</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">351.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">401.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">346.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">409.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Changes in fair value</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(29.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(57.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(23.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(66.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Payments</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair value, end of period</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">322.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">343.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">322.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">343.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140388899950808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Summary of financial assets with maturities of less than 90 days included within cash and cash equivalents</a></td>
<td class="text"><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes our financial assets with maturities of less than 90&#160;days from the date of purchase included in cash and cash equivalents in our condensed consolidated balance sheets:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:58.549%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:18.344%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:18.347%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In millions)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">As of September 30, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">649.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">384.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Overnight reverse repurchase agreements</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">465.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">368.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">270.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,628.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Short-term debt securities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">185.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">159.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">1,570.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,541.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesTextBlock', window );">Marketable debt and equity securities</a></td>
<td class="text">The following tables summarize our marketable debt and equity securities:<div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%;"><tr><td style="width:1.0%;"/><td style="width:41.252%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.535%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.576%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.535%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.576%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.535%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.576%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.535%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.580%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">As of September 30, 2020</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In millions)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized<br/>Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">963.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">1.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(0.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">964.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-current</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">475.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">3.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(0.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">479.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Government securities:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">389.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">0.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">389.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-current</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">376.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">1.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">377.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Mortgage and other asset backed securities:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">0.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">0.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-current</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">152.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">0.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(0.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">153.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total marketable debt securities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2,358.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">6.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(0.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2,364.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Marketable equity securities, non-current</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">851.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">63.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(46.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">868.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"/></tr></table></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%;"><tr><td style="width:1.0%;"/><td style="width:41.252%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.535%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.576%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.535%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.576%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.535%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.576%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.535%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.580%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of December 31, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In millions)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized<br/>Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,057.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,058.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-current</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">633.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">636.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Government securities:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">502.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">503.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-current</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">510.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">510.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Mortgage and other asset backed securities:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-current</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">260.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">260.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total marketable debt securities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,965.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,970.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Marketable equity securities, non-current</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">218.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">132.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(13.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">337.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Summary of contractual maturities: available-for-sale securities</a></td>
<td class="text"><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The estimated fair value and amortized cost of our marketable debt securities available-for-sale by contractual maturity are summarized as follows:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%;"><tr><td style="width:1.0%;"/><td style="width:41.924%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.409%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.409%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.409%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.413%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">As of September 30, 2020</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of December 31, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In millions)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Estimated<br/>Fair Value</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized<br/>Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Estimated<br/>Fair Value</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized<br/>Cost</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Due in one year or less</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">1,355.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">1,353.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,562.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,560.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Due after one year through five years</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">902.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">897.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,234.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,230.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Due after five years</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">107.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">107.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">173.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">173.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total marketable debt securities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2,364.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2,358.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,970.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,965.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock', window );">Proceeds from marketable debt securities</a></td>
<td class="text"><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:44.075%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.204%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.204%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.619%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.624%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Three Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In millions)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Proceeds from maturities and sales</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">1,360.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">611.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">5,240.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,867.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Realized gains</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">1.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">12.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Realized losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(0.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(25.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of realized gains and losses on investments reported in the statement of income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RealizedGainLossOnInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140388894762680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock', window );">Foreign currency forward contracts that were entered into to hedge forecasted revenue</a></td>
<td class="text"><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The notional value of foreign currency forward contracts that were entered into to hedge forecasted revenues and operating expenses is summarized as follows:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:58.549%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:18.344%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:18.347%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Notional Amount</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In millions)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">As of September 30, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Euro</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2,717.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,892.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">British pound</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">62.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Swiss franc</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">34.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Japanese yen</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">27.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Canadian dollar</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">25.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total foreign currency forward contracts</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2,866.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,892.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock', window );">Summary of the effect of cash flow derivatives designated as hedging instruments on the condensed consolidated statements of income</a></td>
<td class="text"><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following tables summarize the effect of foreign currency forward contracts designated as hedging instruments in our condensed consolidated statements of income:</span></div><div style="text-align:justify;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:22.765%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.198%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.345%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:21.154%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.637%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.641%;"/><td style="width:0.1%;"/></tr><tr><td colspan="33" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Three Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net Gains/(Losses)<br/>Reclassified from AOCI into Operating Income (in millions)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net Gains/(Losses)<br/>Recognized in Operating Income (in millions)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Location</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Location</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenues</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(9.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">35.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenues</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(8.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating expenses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">1.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating expenses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">0.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr></table></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%;"><tr><td style="width:1.0%;"/><td style="width:22.611%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.536%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.123%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.536%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.418%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.536%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:21.138%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.536%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.712%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.536%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.718%;"/><td style="width:0.1%;"/></tr><tr><td colspan="33" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net Gains/(Losses)<br/>Reclassified from AOCI into Operating Income (in millions)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net Gains/(Losses)<br/>Recognized in Operating Income (in millions)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Location</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Location</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenues</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">41.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">79.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenues</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(1.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating expenses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">1.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating expenses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(0.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Summary of the effect of derivatives designated as net investment hedging instruments on our consolidated statement of income</a></td>
<td class="text"><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following tables summarize the effect of our net investment hedge in our condensed consolidated financial statements:</span></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:18.372%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:5.195%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:5.195%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:20.715%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:5.195%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:5.195%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.980%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:5.195%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:5.202%;"/><td style="width:0.1%;"/></tr><tr><td colspan="51" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Three Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net Gains/(Losses)<br/>Recognized in Other Comprehensive Income (Effective Portion) (in millions)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net Gains/(Losses)<br/>Recognized in Other Comprehensive Income (Amounts Excluded from Effectiveness Testing) <br/>(in millions)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net Gains/(Losses)<br/>Recognized in Net Income <br/>(Amounts Excluded from Effectiveness Testing) (in millions)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Location</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Location</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Location</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gains (losses) on net investment hedge</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(10.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">22.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gains (losses) on net investment hedge</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(0.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other income (expense)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">0.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr></table></div><div style="text-align:center;margin-top:11pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.122%;"><tr><td style="width:1.0%;"/><td style="width:18.369%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.537%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:5.242%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.537%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:4.947%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.537%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:20.876%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.537%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:5.242%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.537%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:4.947%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.537%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.091%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.537%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:5.242%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.537%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:5.248%;"/><td style="width:0.1%;"/></tr><tr><td colspan="51" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net Gains/(Losses)<br/>Recognized in Other Comprehensive Income (Effective Portion) (in millions)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net Gains/(Losses)<br/>Recognized in Other Comprehensive Income (Amounts Excluded from Effectiveness Testing) <br/>(in millions)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net Gains/(Losses)<br/>Recognized in Net Income <br/>(Amounts Excluded from Effectiveness Testing) (in millions)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Location</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Location</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Location</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gains (losses) on net investment hedge</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">5.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">45.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gains (losses) on net investment hedge</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">3.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other income (expense)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock', window );">Summary of fair value and presentation of derivatives</a></td>
<td class="text"><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the fair value and presentation in our condensed consolidated balance sheets of our outstanding derivative instruments, including those designated as hedging instruments:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:28.328%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:28.328%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:18.372%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:18.376%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In millions)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance Sheet Location</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">As of September 30, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-style:italic;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash Flow Hedging Instruments:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Asset derivative instruments</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other current assets</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">3.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">33.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Investments and other assets</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Liability derivative instruments</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued expenses and other</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">70.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other long-term liabilities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">21.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-style:italic;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net Investment Hedging Instruments:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Asset derivative instruments</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other current assets</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">10.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-style:italic;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value Hedging Instruments:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Liability derivative instruments</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued expenses and other</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-style:italic;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other Derivative Instruments:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Asset derivative instruments</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other current assets</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">10.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Liability derivative instruments</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued expenses and other</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">7.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4E<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624181-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5618551-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the effective portion of gains and losses on derivative instruments (and nonderivative instruments) designated and qualifying in net investment hedges recorded in accumulated other comprehensive income (loss) during the term of the hedging relationship and reclassified into earnings during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CCC<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL109998896-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the notional amounts of outstanding derivative positions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140388899739048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income (Loss) (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of Accumulated Other Comprehensive Income (Loss)</a></td>
<td class="text"><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following tables summarize the changes in accumulated other comprehensive income (loss), net of tax by component:</span></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:31.696%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.295%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.002%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.295%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.466%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.295%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.859%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In millions)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gains (Losses) on Net Investment Hedge</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unfunded Status of Postretirement Benefit Plans, Net of Tax</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Currency Translation Adjustments</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, December 31, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">4.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">7.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">25.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(32.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(139.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(135.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(8.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(58.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">8.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">0.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">3.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(54.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amounts reclassified from accumulated other comprehensive income (loss)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">9.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(43.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(2.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(35.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">1.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(101.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">5.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">0.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">3.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(90.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, September 30, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">5.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(93.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">30.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(32.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(135.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(225.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/></tr></table></div><div style="text-align:center;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:31.696%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.295%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.002%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.295%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.466%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.295%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.859%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In millions)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gains (Losses) on Net Investment Hedge</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unfunded Status of Postretirement Benefit Plans, Net of Tax</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Currency Translation Adjustments</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, December 31, 2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">34.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(31.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(243.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(240.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">115.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">53.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">51.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">233.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amounts reclassified from accumulated other comprehensive income (loss)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(77.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(6.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(85.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">38.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">46.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">51.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">148.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, September 30, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">72.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">50.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(29.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(192.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(92.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock', window );">Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text"><div style="text-indent:22.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the amounts reclassified from accumulated other comprehensive income:</span></div><div style="text-align:justify;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:33.987%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:21.707%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.695%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.695%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.695%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.701%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" rowspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In millions)</span></td><td colspan="3" rowspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income Statement Location</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amounts Reclassified from Accumulated Other Comprehensive Income</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Three Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gains (losses) on securities available for sale</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other income (expense)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">0.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(12.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income tax benefit (expense)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gains (losses) on cash flow hedges</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenues</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(9.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">35.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">41.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">79.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating expenses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">1.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">1.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other income (expense)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">0.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income tax benefit (expense)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">0.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(0.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gains (losses) on net investment hedge</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other income (expense)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">0.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total reclassifications, net of tax</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(6.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">37.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">35.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">85.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140388898370424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Basic and diluted earnings per share</a></td>
<td class="text"><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Basic and diluted earnings per share are calculated as follows:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:43.929%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.204%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.204%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.619%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.624%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Three Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In millions)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-style:italic;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Numerator:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income attributable to Biogen Inc.</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">701.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,545.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">3,642.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,448.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-style:italic;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Denominator:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted average number of common shares outstanding</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">156.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">184.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">163.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">190.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#dddddd;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Time-vested restricted stock units</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">0.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">0.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Market stock units</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">0.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">0.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Performance stock units settled in stock</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">0.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">0.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Dilutive potential common shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">0.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">0.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares used in calculating diluted earnings per share</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">157.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">184.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">163.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">190.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140388899774888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Share-based compensation expense included in condensed consolidated statements of income</a></td>
<td class="text"><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes share-based compensation expense included in our condensed consolidated statements of income:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:49.119%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.613%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.613%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.613%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.614%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Three Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In millions)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">14.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">63.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">65.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Selling, general and administrative</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">25.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">34.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">98.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">116.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Subtotal</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">39.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">49.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">161.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">182.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Capitalized share-based compensation costs </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(1.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(4.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(7.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Share-based compensation expense included in total cost and expenses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">37.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">47.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">156.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">174.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income tax effect</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(5.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(8.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(25.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(29.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Share-based compensation expense included in net income attributable to Biogen Inc.</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">32.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">39.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">130.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">145.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Summary of share-based compensation expense associated with each of our share-based compensating programs</a></td>
<td class="text"><div style="text-indent:24.75pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:49.119%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.613%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.613%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.613%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.614%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Three Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In millions)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Market stock units</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">5.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">32.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Time-vested restricted stock units</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">35.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">37.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">107.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">104.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash settled performance units</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(1.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Performance units</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(0.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Performance stock units settled in stock</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(8.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">4.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Performance stock units settled in cash</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">4.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">9.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Employee stock purchase plan</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">3.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">11.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">NST stock options</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">26.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Subtotal</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">39.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">49.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">161.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">182.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Capitalized share-based compensation costs</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(1.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(4.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(7.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Share-based compensation expense included in total cost and expenses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">37.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">47.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">156.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">174.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140388899783144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation between the U.S. federal statutory tax rate and effective tax rate</a></td>
<td class="text"><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A reconciliation between the U.S.&#160;federal statutory tax rate and our effective tax rate is summarized as follows:</span></div><div style="text-align:justify;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:44.514%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.350%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.350%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.619%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.623%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Three Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Statutory rate</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">21.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">21.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">State taxes</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">0.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">0.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Taxes on foreign earnings</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(3.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(5.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(3.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Tax credits</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(2.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(1.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Purchased intangible assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">0.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Divestiture of Denmark manufacturing operations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Internal reorganization of certain intellectual property rights</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">TECFIDERA impairment</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">3.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">1.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">GILTI</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">1.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Swiss tax reform</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;</span><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;</span><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other permanent items</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(0.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">0.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">0.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Effective tax rate</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">25.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">20.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140388989399096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Consolidated Financial Statement Detail (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock', window );">Other income (expense), net</a></td>
<td class="text"><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Components of other income (expense), net, are summarized as follows:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:43.929%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.204%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.204%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.619%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.624%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Three Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In millions)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest income</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">6.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">30.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">38.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">90.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest expense</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(56.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(45.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(166.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(141.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gain (loss) on investments, net</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(82.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(52.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">198.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign exchange gains (losses), net</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">3.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(5.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other, net</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">0.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">0.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(11.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total other income (expense), net</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(128.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(27.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(186.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">132.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnInvestmentsTextBlock', window );">Gain (loss) on investments in equity securities</a></td>
<td class="text"><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes our gain (loss) on investments, net that relates to our equity securities held as of September 30, 2020 and 2019:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:43.929%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.204%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.204%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.619%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.624%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Three Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In millions)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net gains (losses) recognized during the period on equity securities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(82.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(40.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">197.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: Net gains (losses) recognized during the period on equity securities sold during the period</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">46.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized gains (losses) recognized during the period on equity securities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(82.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(9.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">(40.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">150.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Accrued expenses and other</a></td>
<td class="text"><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Accrued expenses and other consists of the following:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:58.549%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:18.344%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:18.347%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In millions)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">As of September 30, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue-related reserves for discounts and allowances</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">1,043.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,001.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Employee compensation and benefits</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">279.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">309.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Royalties and licensing fees</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">222.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">220.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Collaboration expenses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">277.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">281.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current portion of contingent consideration obligations</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">164.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">148.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Construction in progress</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">23.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">78.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">1,274.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">726.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total accrued expenses and other</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">3,286.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,765.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of realized and unrealized gain (loss) on investment in security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140388986923752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock', window );">Summary of Activity Related to BAN2401 and Elenbecestat Collaboration</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%;"><tr><td style="width:1.0%;"/><td style="width:53.085%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.619%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.619%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.619%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.622%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Three Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In millions)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total development expense incurred by the collaboration related to the advancement of BAN2401 and elenbecestat</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">75.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">168.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">153.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">305.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Biogen's share of BAN2401 and elenbecestat development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">37.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">84.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">76.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">152.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total sales and marketing expense incurred by the collaboration</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">nm</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">6.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Biogen's share of BAN2401 and elenbecestat sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">nm</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">3.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock', window );">Summary of Activity Related to Aducanumab Collaboration</a></td>
<td class="text"><div style="text-indent:24.75pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A summary of development, sales and marketing and milestone expense related to the Aducanumab Collaboration Agreement is as follows:</span></div><div style="margin-top:10pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%;"><tr><td style="width:1.0%;"/><td style="width:53.085%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.619%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.619%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.619%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.622%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Three Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Nine Months Ended September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In millions)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total aducanumab development expense</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">37.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">92.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">170.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Biogen's share of aducanumab development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">20.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">50.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">93.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total aducanumab sales and marketing expense incurred by the collaboration</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">90.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">158.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Biogen's share of aducanumab sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">51.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">88.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total aducanumab collaboration third party milestone expense</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">75.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Eisai's share of aducanumab milestone expense reflected in collaboration profit sharing in our condensed consolidated statements of income</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#257acb;background-color:rgb(255,255,255, 0.0);">33.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#dddddd;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Franklin Gothic Book',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>[Table Text Block] for Summary of Activity Related to Aducanumab Collaboration [Table]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>[Table Text Block] for Summary of Activity Related to E2609 and BAN2401 Collaboration [Table]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140388896450760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2020 </div>
<div>segment </div>
<div>product</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NumberOfOphthalmolgyBiosimilarProductsExclusiveRights', window );">Number of potential products, exclusive rights | product</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | segment</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_InterestInSubsidiary', window );">Interest in subsidiary (less than given percentage)</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InterestInSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest in subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InterestInSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NumberOfOphthalmolgyBiosimilarProductsExclusiveRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Ophthalmolgy Biosimilar Products, Exclusive Rights</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NumberOfOphthalmolgyBiosimilarProductsExclusiveRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140388976940776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Acquisition (Details Textual)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>Assets</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 07, 2019 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 75.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ClinicalAssetsAcquired', window );">Clinical Assets Acquired | Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_BIIB118Member', window );">BIIB118</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development</a></td>
<td class="nump">$ 75.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones', window );">Estimated additional payments upon achievement of development and commercial milestones</a></td>
<td class="nump">$ 635.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_NightstarMember', window );">Nightstar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Total transaction value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">847.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPaymentsToAcquireBusinesses', window );">Payments for pre-combination equity compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative | Nightstar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized', window );">Fair value of post-combination equity compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development | Nightstar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized', window );">Fair value of post-combination equity compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis=biib_PostacquisitionequitycompensationMember', window );">Post-acquisition equity compensation | Nightstar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized', window );">Fair value of post-combination equity compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ClinicalAssetsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Clinical Assets Acquired</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ClinicalAssetsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated additional payments upon achievement of development and commercial milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The expenses and losses recorded for each transaction with the acquiree that was recognized separately from the acquisition of assets and assumptions of liabilities in the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPaymentsToAcquireBusinesses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with other payments to acquire businesses including deposit on pending acquisitions and preacquisition costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPaymentsToAcquireBusinesses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_BIIB118Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_BIIB118Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_NightstarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_NightstarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis=biib_PostacquisitionequitycompensationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis=biib_PostacquisitionequitycompensationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140388987494264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Business Acquisition (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jun. 07, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 5,755.7<span></span>
</td>
<td class="nump">$ 5,757.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_NightstarMember', window );">Nightstar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_NightstarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_NightstarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140388902148840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Divestitures (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Aug. 01, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown', window );">Loss on divestiture of Hiller&#248;d, Denmark manufacturing operations</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 95.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_InventoryrawmaterialssoldtoFUJIFILM', window );">Inventory raw materials sold to FUJIFILM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_DenmarkManufacturingOperationsMember', window );">Denmark Manufacturing Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration', window );">Consideration expected to be received for sale of Denmark Manufacturing Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 881.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted', window );">Future minimum batch production for Denmark Manufacturing Operations</a></td>
<td class="nump">$ 74.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 114.0<span></span>
</td>
<td class="nump">74.0<span></span>
</td>
<td class="nump">114.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax', window );">Loss on divestiture of Hiller&#248;d, Denmark manufacturing operations, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">160.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown', window );">Loss on divestiture of Hiller&#248;d, Denmark manufacturing operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 95.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense', window );">Expected costs to sell disposal group</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation', window );">Tax expense on disposal group</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InventoryrawmaterialssoldtoFUJIFILM">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventory raw materials sold to FUJIFILM</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InventoryrawmaterialssoldtoFUJIFILM</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of (gain) loss recognized for the (reversal of write-down) write-down to fair value, less cost to sell, of a discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of (gain) loss recognized for the (reversal of write-down) write-down to fair value, less cost to sell, of a disposal group. Excludes discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2443-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_DenmarkManufacturingOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_DenmarkManufacturingOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140388900578968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues by Product (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">$ 3,376.1<span></span>
</td>
<td class="nump">$ 3,600.1<span></span>
</td>
<td class="nump">$ 10,592.0<span></span>
</td>
<td class="nump">$ 10,706.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FumarateMember', window );">Fumarate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">967.5<span></span>
</td>
<td class="nump">1,122.4<span></span>
</td>
<td class="nump">3,258.6<span></span>
</td>
<td class="nump">3,271.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FumarateMember', window );">Fumarate | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">684.2<span></span>
</td>
<td class="nump">842.0<span></span>
</td>
<td class="nump">2,383.4<span></span>
</td>
<td class="nump">2,429.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FumarateMember', window );">Fumarate | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">283.3<span></span>
</td>
<td class="nump">280.4<span></span>
</td>
<td class="nump">875.2<span></span>
</td>
<td class="nump">841.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_InterferonMember', window );">Interferon</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">474.1<span></span>
</td>
<td class="nump">530.0<span></span>
</td>
<td class="nump">1,421.5<span></span>
</td>
<td class="nump">1,585.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_InterferonMember', window );">Interferon | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">327.3<span></span>
</td>
<td class="nump">360.3<span></span>
</td>
<td class="nump">965.5<span></span>
</td>
<td class="nump">1,067.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_InterferonMember', window );">Interferon | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">146.8<span></span>
</td>
<td class="nump">169.7<span></span>
</td>
<td class="nump">456.0<span></span>
</td>
<td class="nump">518.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_TysabriProductMember', window );">TYSABRI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">516.5<span></span>
</td>
<td class="nump">483.6<span></span>
</td>
<td class="nump">1,470.9<span></span>
</td>
<td class="nump">1,419.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_TysabriProductMember', window );">TYSABRI | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">304.2<span></span>
</td>
<td class="nump">263.0<span></span>
</td>
<td class="nump">826.0<span></span>
</td>
<td class="nump">772.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_TysabriProductMember', window );">TYSABRI | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">212.3<span></span>
</td>
<td class="nump">220.6<span></span>
</td>
<td class="nump">644.9<span></span>
</td>
<td class="nump">647.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FAMPYRAMember', window );">FAMPYRA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">26.8<span></span>
</td>
<td class="nump">24.2<span></span>
</td>
<td class="nump">78.1<span></span>
</td>
<td class="nump">71.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FAMPYRAMember', window );">FAMPYRA | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FAMPYRAMember', window );">FAMPYRA | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">26.8<span></span>
</td>
<td class="nump">24.2<span></span>
</td>
<td class="nump">78.1<span></span>
</td>
<td class="nump">71.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_MSProductRevenuesMember', window );">MS Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">1,984.9<span></span>
</td>
<td class="nump">2,160.2<span></span>
</td>
<td class="nump">6,229.1<span></span>
</td>
<td class="nump">6,347.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_MSProductRevenuesMember', window );">MS Product Revenues | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">1,315.7<span></span>
</td>
<td class="nump">1,465.3<span></span>
</td>
<td class="nump">4,174.9<span></span>
</td>
<td class="nump">4,269.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_MSProductRevenuesMember', window );">MS Product Revenues | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">669.2<span></span>
</td>
<td class="nump">694.9<span></span>
</td>
<td class="nump">2,054.2<span></span>
</td>
<td class="nump">2,078.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_SPINRAZAMember', window );">SPINRAZA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">494.4<span></span>
</td>
<td class="nump">547.1<span></span>
</td>
<td class="nump">1,554.0<span></span>
</td>
<td class="nump">1,553.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_SPINRAZAMember', window );">SPINRAZA | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">182.5<span></span>
</td>
<td class="nump">236.7<span></span>
</td>
<td class="nump">628.2<span></span>
</td>
<td class="nump">690.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_SPINRAZAMember', window );">SPINRAZA | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">311.9<span></span>
</td>
<td class="nump">310.4<span></span>
</td>
<td class="nump">925.8<span></span>
</td>
<td class="nump">863.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BENEPALIMember', window );">BENEPALI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">124.2<span></span>
</td>
<td class="nump">115.9<span></span>
</td>
<td class="nump">363.9<span></span>
</td>
<td class="nump">360.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BENEPALIMember', window );">BENEPALI | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BENEPALIMember', window );">BENEPALI | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">124.2<span></span>
</td>
<td class="nump">115.9<span></span>
</td>
<td class="nump">363.9<span></span>
</td>
<td class="nump">360.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_IMRALDIMember', window );">IMRALDI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">56.2<span></span>
</td>
<td class="nump">49.3<span></span>
</td>
<td class="nump">162.6<span></span>
</td>
<td class="nump">132.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_IMRALDIMember', window );">IMRALDI | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_IMRALDIMember', window );">IMRALDI | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">56.2<span></span>
</td>
<td class="nump">49.3<span></span>
</td>
<td class="nump">162.6<span></span>
</td>
<td class="nump">132.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FLIXABIMember', window );">FLIXABI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">27.5<span></span>
</td>
<td class="nump">18.4<span></span>
</td>
<td class="nump">71.8<span></span>
</td>
<td class="nump">49.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FLIXABIMember', window );">FLIXABI | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FLIXABIMember', window );">FLIXABI | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">27.5<span></span>
</td>
<td class="nump">18.4<span></span>
</td>
<td class="nump">71.8<span></span>
</td>
<td class="nump">49.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BiosimilarsMember', window );">Biosimilars</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">207.9<span></span>
</td>
<td class="nump">183.6<span></span>
</td>
<td class="nump">598.3<span></span>
</td>
<td class="nump">542.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BiosimilarsMember', window );">Biosimilars | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BiosimilarsMember', window );">Biosimilars | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">207.9<span></span>
</td>
<td class="nump">183.6<span></span>
</td>
<td class="nump">598.3<span></span>
</td>
<td class="nump">542.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FUMADERMMember', window );">FUMADERM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">3.1<span></span>
</td>
<td class="nump">3.8<span></span>
</td>
<td class="nump">9.2<span></span>
</td>
<td class="nump">11.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FUMADERMMember', window );">FUMADERM | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FUMADERMMember', window );">FUMADERM | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">3.1<span></span>
</td>
<td class="nump">3.8<span></span>
</td>
<td class="nump">9.2<span></span>
</td>
<td class="nump">11.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">2,690.3<span></span>
</td>
<td class="nump">2,894.7<span></span>
</td>
<td class="nump">8,390.6<span></span>
</td>
<td class="nump">8,455.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product, net | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">1,498.2<span></span>
</td>
<td class="nump">1,702.0<span></span>
</td>
<td class="nump">4,803.1<span></span>
</td>
<td class="nump">4,959.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product, net | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">$ 1,192.1<span></span>
</td>
<td class="nump">$ 1,192.7<span></span>
</td>
<td class="nump">$ 3,587.5<span></span>
</td>
<td class="nump">$ 3,495.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_FumarateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_FumarateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_InterferonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_InterferonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_TysabriProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_TysabriProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_FAMPYRAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_FAMPYRAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_MSProductRevenuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_MSProductRevenuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_SPINRAZAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_SPINRAZAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_BENEPALIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_BENEPALIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_IMRALDIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_IMRALDIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_FLIXABIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_FLIXABIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_BiosimilarsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_BiosimilarsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_FUMADERMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_FUMADERMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140388912156440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reserves for Discounts and Allowances (Details 1)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning Balance</a></td>
<td class="nump">$ 1,198.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear', window );">Current Provisions Relating To Sales In Current Year</a></td>
<td class="nump">3,070.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears', window );">Adjustments Relating To Prior Years</a></td>
<td class="num">(40.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear', window );">Payments/Returns Relating To Sales in Current Year</a></td>
<td class="num">(2,162.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear', window );">Payments/Returns Relating To Sales in Prior Year</a></td>
<td class="num">(794.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Ending Balance</a></td>
<td class="nump">1,271.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ReserveforCashDiscountsMember', window );">Discounts</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning Balance</a></td>
<td class="nump">131.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear', window );">Current Provisions Relating To Sales In Current Year</a></td>
<td class="nump">589.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears', window );">Adjustments Relating To Prior Years</a></td>
<td class="num">(1.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear', window );">Payments/Returns Relating To Sales in Current Year</a></td>
<td class="num">(457.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear', window );">Payments/Returns Relating To Sales in Prior Year</a></td>
<td class="num">(120.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Ending Balance</a></td>
<td class="nump">141.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ContractualAdjustmentsMember', window );">Contractual adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning Balance</a></td>
<td class="nump">1,027.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear', window );">Current Provisions Relating To Sales In Current Year</a></td>
<td class="nump">2,465.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears', window );">Adjustments Relating To Prior Years</a></td>
<td class="num">(41.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear', window );">Payments/Returns Relating To Sales in Current Year</a></td>
<td class="num">(1,704.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear', window );">Payments/Returns Relating To Sales in Prior Year</a></td>
<td class="num">(658.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Ending Balance</a></td>
<td class="nump">1,088.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_SalesReturnsAndAllowancesMember', window );">Returns</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning Balance</a></td>
<td class="nump">40.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear', window );">Current Provisions Relating To Sales In Current Year</a></td>
<td class="nump">14.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears', window );">Adjustments Relating To Prior Years</a></td>
<td class="nump">1.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear', window );">Payments/Returns Relating To Sales in Current Year</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear', window );">Payments/Returns Relating To Sales in Prior Year</a></td>
<td class="num">(15.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Ending Balance</a></td>
<td class="nump">$ 41.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments to product revenue reserves relating to sales in prior years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Current provisions to product revenue reserves relating to sales in current year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments/ returns applied against product revenue reserves relating to current year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments/ returns applied against product revenue reserves relating to prior year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ValuationAndQualifyingAccountsDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ReserveforCashDiscountsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ReserveforCashDiscountsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ContractualAdjustmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ContractualAdjustmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_SalesReturnsAndAllowancesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_SalesReturnsAndAllowancesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140388894839896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Reserves for Discounts and Allowances (Details 2) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Total Reserves</a></td>
<td class="nump">$ 1,271.8<span></span>
</td>
<td class="nump">$ 1,198.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember', window );">Reduction of accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Total Reserves</a></td>
<td class="nump">227.9<span></span>
</td>
<td class="nump">197.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Component of accrued expenses and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Total Reserves</a></td>
<td class="nump">$ 1,043.9<span></span>
</td>
<td class="nump">$ 1,001.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140388900208840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues from Anti-CD20 Therapeutic Programs (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues from anti-CD20 therapeutic programs</a></td>
<td class="nump">$ 3,376.1<span></span>
</td>
<td class="nump">$ 3,600.1<span></span>
</td>
<td class="nump">$ 10,592.0<span></span>
</td>
<td class="nump">$ 10,706.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=biib_RocheGroupGenentechMember', window );">Genentech</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ShareOfCoPromotionProfits', window );">Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA</a></td>
<td class="nump">275.0<span></span>
</td>
<td class="nump">393.2<span></span>
</td>
<td class="nump">873.8<span></span>
</td>
<td class="nump">1,161.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_OtherrevenuesfromantiCD20therapeuticprograms', window );">Other revenues from anti-CD20 therapeutic programs</a></td>
<td class="nump">285.1<span></span>
</td>
<td class="nump">202.6<span></span>
</td>
<td class="nump">685.0<span></span>
</td>
<td class="nump">528.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember', window );">Revenues from anti-CD20 therapeutic programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues from anti-CD20 therapeutic programs</a></td>
<td class="nump">$ 560.1<span></span>
</td>
<td class="nump">$ 595.8<span></span>
</td>
<td class="nump">$ 1,558.8<span></span>
</td>
<td class="nump">$ 1,689.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_OtherrevenuesfromantiCD20therapeuticprograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other revenues from anti-CD20 therapeutic programs consists of revenue on sales of RITUXAN outside the U.S., which consist of our share of pre-tax co-promotion profits in Canada and royalty revenue on sales of Ocrevus.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_OtherrevenuesfromantiCD20therapeuticprograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ShareOfCoPromotionProfits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share of co promotion profits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ShareOfCoPromotionProfits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=biib_RocheGroupGenentechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=biib_RocheGroupGenentechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140389005322728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Revenues (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">$ 3,376.1<span></span>
</td>
<td class="nump">$ 3,600.1<span></span>
</td>
<td class="nump">$ 10,592.0<span></span>
</td>
<td class="nump">$ 10,706.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">10.3<span></span>
</td>
<td class="nump">3.3<span></span>
</td>
<td class="nump">28.8<span></span>
</td>
<td class="nump">9.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_OthercorporaterevenuesMember', window );">Other corporate revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">110.0<span></span>
</td>
<td class="nump">93.1<span></span>
</td>
<td class="nump">599.5<span></span>
</td>
<td class="nump">462.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenues related to amendment of contract manufacturing agreement</a></td>
<td class="nump">166.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">166.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">125.7<span></span>
</td>
<td class="nump">109.6<span></span>
</td>
<td class="nump">642.6<span></span>
</td>
<td class="nump">562.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative arrangement | Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative arrangement | ZINBRYTA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">$ 5.4<span></span>
</td>
<td class="nump">$ 12.9<span></span>
</td>
<td class="nump">$ 13.6<span></span>
</td>
<td class="nump">$ 89.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_OthercorporaterevenuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_OthercorporaterevenuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=biib_SamsungBiosimilarAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=biib_SamsungBiosimilarAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=biib_ZINBRYTAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=biib_ZINBRYTAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140388901596328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues (Details Textual)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($) </div>
<div>wholesaler</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($) </div>
<div>wholesaler</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Other Revenues</a></td>
<td class="nump">$ 3,376.1<span></span>
</td>
<td class="nump">$ 3,600.1<span></span>
</td>
<td class="nump">$ 10,592.0<span></span>
</td>
<td class="nump">$ 10,706.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NumberOfWholesalers', window );">Number of wholesalers | wholesaler</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=biib_DistributorOneMember', window );">Distributor One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EntityWidePercentageOfRevenueFromMajorDistributors', window );">Percentage of revenues from major distributors</a></td>
<td class="nump">31.20%<span></span>
</td>
<td class="nump">28.70%<span></span>
</td>
<td class="nump">30.90%<span></span>
</td>
<td class="nump">30.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=biib_DistributorTwoMember', window );">Distributor Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EntityWidePercentageOfRevenueFromMajorDistributors', window );">Percentage of revenues from major distributors</a></td>
<td class="nump">15.60%<span></span>
</td>
<td class="nump">18.40%<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_OthercorporaterevenuesMember', window );">Other corporate revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenues related to amendment of contract manufacturing agreement</a></td>
<td class="nump">$ 166.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 166.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Other Revenues</a></td>
<td class="nump">110.0<span></span>
</td>
<td class="nump">$ 93.1<span></span>
</td>
<td class="nump">599.5<span></span>
</td>
<td class="nump">$ 462.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_OthercorporaterevenuesMember', window );">Other corporate revenues | Contract Manufacturing Customer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Other Revenues</a></td>
<td class="nump">333.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Other Revenues</a></td>
<td class="nump">$ 125.7<span></span>
</td>
<td class="nump">$ 109.6<span></span>
</td>
<td class="nump">$ 642.6<span></span>
</td>
<td class="nump">$ 562.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EntityWidePercentageOfRevenueFromMajorDistributors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity wide percentage of revenue from major distributors.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EntityWidePercentageOfRevenueFromMajorDistributors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NumberOfWholesalers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Wholesalers</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NumberOfWholesalers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=biib_DistributorOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=biib_DistributorOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=biib_DistributorTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=biib_DistributorTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_OthercorporaterevenuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_OthercorporaterevenuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=biib_ContractManufacturingCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=biib_ContractManufacturingCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140388895217016">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNetAbstract', window );"><strong>Components of inventories</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 288.4<span></span>
</td>
<td class="nump">$ 169.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in process</a></td>
<td class="nump">539.9<span></span>
</td>
<td class="nump">460.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">199.4<span></span>
</td>
<td class="nump">174.5<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Inventorynetcurrentandnoncurrent', window );">Total inventory</a></td>
<td class="nump">$ 1,027.7<span></span>
</td>
<td class="nump">$ 804.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Inventorynetcurrentandnoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventory, net current and noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Inventorynetcurrentandnoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140388912440840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jun. 07, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of Intangible Assets (Excluding Goodwill)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Contingent consideration impairment</a></td>
<td class="nump">$ 29,000,000.0<span></span>
</td>
<td class="nump">57,800,000<span></span>
</td>
<td class="nump">23,500,000<span></span>
</td>
<td class="nump">66,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Total intangible assets, gross</a></td>
<td class="nump">8,401,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,401,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,408,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(5,077,700,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,077,700,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,881,400,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">3,323,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,323,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,527,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets', window );">Amortization and impairment of acquired intangible assets</a></td>
<td class="nump">82,600,000<span></span>
</td>
<td class="nump">283,900,000<span></span>
</td>
<td class="nump">215,600,000<span></span>
</td>
<td class="nump">422,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="num">(63,300,000)<span></span>
</td>
<td class="num">(68,000,000.0)<span></span>
</td>
<td class="num">(196,300,000)<span></span>
</td>
<td class="num">(206,300,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">Expected future amortization expense, 2019 (remaining three months)</a></td>
<td class="nump">60,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">Expected future amortization expense, 2020</a></td>
<td class="nump">205,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">205,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">Expected future amortization expense, 2021</a></td>
<td class="nump">215,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">215,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">Expected future amortization expense, 2022</a></td>
<td class="nump">215,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">215,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">Expected future amortization expense, 2023</a></td>
<td class="nump">225,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">225,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">Expected future amortization expense, 2024</a></td>
<td class="nump">220,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">220,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In Process Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets', window );">Amortization and impairment of acquired intangible assets</a></td>
<td class="nump">19,300,000<span></span>
</td>
<td class="nump">$ 215,900,000<span></span>
</td>
<td class="nump">19,300,000<span></span>
</td>
<td class="nump">$ 215,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OutLicensedPatentsMember', window );">Out-licensed patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">7,394,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,394,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,379,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">2,316,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,316,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,497,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(5,077,700,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (5,077,700,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,881,400,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OutLicensedPatentsMember', window );">Out-licensed patents | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life, (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">13 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OutLicensedPatentsMember', window );">Out-licensed patents | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life, (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">23 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technology | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life, (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technology | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life, (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">28 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_InLicensedPatentsMember', window );">Acquired and in-licensed rights and patents | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life, (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_InLicensedPatentsMember', window );">Acquired and in-licensed rights and patents | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life, (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In Process Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_IndefiniteLivedIntangibleAssetsUsefulLife', window );">Indefinite lived intangible assets useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Indefinite until commercialization<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Cost and Net</a></td>
<td class="nump">943,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 943,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">965,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember', window );">Trademarks and Trade Names</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_IndefiniteLivedIntangibleAssetsUsefulLife', window );">Indefinite lived intangible assets useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Indefinite<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Cost and Net</a></td>
<td class="nump">64,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_NightstarMember', window );">Nightstar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ResearchanddevelopmentassetAxis=biib_TGNMember', window );">TGN [Member] | In Process Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Cost and Net</a></td>
<td class="nump">$ 167,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 167,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortization and Impairment of Acquired Intangible Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_IndefiniteLivedIntangibleAssetsUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indefinite lived intangible assets useful life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_IndefiniteLivedIntangibleAssetsUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>us-types:durationStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OutLicensedPatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OutLicensedPatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_InLicensedPatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_InLicensedPatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_NightstarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_NightstarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ResearchanddevelopmentassetAxis=biib_TGNMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ResearchanddevelopmentassetAxis=biib_TGNMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140388898183976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill (Details 1)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Summary of roll forward of the changes in goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, beginning of period</a></td>
<td class="nump">$ 5,757.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Other</a></td>
<td class="num">(2.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, end of period</a></td>
<td class="nump">5,755.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Accumulated impairment losses related to goodwill</a></td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairedAccumulatedImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillOtherIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease), classified as other, of an asset representing the future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillOtherIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140388905837432">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">$ 2,364.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,970.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">1,570.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,541.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable equity securities</a></td>
<td class="nump">868.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">337.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">26.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure', window );">Plan assets for deferred compensation</a></td>
<td class="nump">26.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">4,856.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,920.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">99.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="nump">322.6<span></span>
</td>
<td class="nump">$ 351.6<span></span>
</td>
<td class="nump">346.1<span></span>
</td>
<td class="nump">$ 343.5<span></span>
</td>
<td class="nump">$ 401.3<span></span>
</td>
<td class="nump">$ 409.8<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">422.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">354.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">1,443.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,695.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">767.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,013.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Mortgage and other asset backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">153.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">261.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets (Level 1) | Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable equity securities</a></td>
<td class="nump">276.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure', window );">Plan assets for deferred compensation</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">276.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets (Level 1) | Fair Value, Measurements, Recurring | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets (Level 1) | Fair Value, Measurements, Recurring | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets (Level 1) | Fair Value, Measurements, Recurring | Mortgage and other asset backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">1,570.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,541.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable equity securities</a></td>
<td class="nump">592.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">329.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">26.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure', window );">Plan assets for deferred compensation</a></td>
<td class="nump">26.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">4,579.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,912.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">99.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">99.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">1,443.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,695.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">767.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,013.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring | Mortgage and other asset backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">153.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">261.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable equity securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure', window );">Plan assets for deferred compensation</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="nump">322.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">346.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">322.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">346.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring | Mortgage and other asset backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair values as of the balance sheet date of all assets of deferred compensation plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PlanAssetsForDeferredCompensationFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26610-111562<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward contracts, and swaps.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyContractAssetFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of liability contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward (delivery or nondelivery) contracts, and swaps entered into.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140388901101368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset impairment charges</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration obligations</a></td>
<td class="nump">173,200,000<span></span>
</td>
<td class="nump">173,200,000<span></span>
</td>
<td class="nump">$ 197,700,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1', window );">Reduction in contingent consideration</a></td>
<td class="nump">$ 61,200,000<span></span>
</td>
<td class="nump">$ 61,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember', window );">2.900% Senior Notes due 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="nump">2.90%<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember', window );">3.625% Senior Notes due 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="nump">3.625%<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember', window );">4.050% Senior Notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="nump">4.05%<span></span>
</td>
<td class="nump">4.05%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember', window );">5.200% Senior Notes due 2045</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="nump">5.20%<span></span>
</td>
<td class="nump">5.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionContingentConsiderationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of right to a contingent consideration asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140388986939672">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements Fair Value Measurements - Contingent Consideration (Details) - Discount rate<br></strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Discount rate</a></td>
<td class="nump">0.0083<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Discount rate</a></td>
<td class="nump">0.0118<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">Weighted Average</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Discount rate</a></td>
<td class="nump">0.0063<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure contingent consideration liability from business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140388906350152">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details 1) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Apr. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable, carrying value</a></td>
<td class="nump">$ 7,425,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,954,800,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Debt instruments, fair value</a></td>
<td class="nump">8,336,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,553,600,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember', window );">2.900% Senior Notes due 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,509,600,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable, carrying value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,495,800,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="nump">2.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember', window );">3.625% Senior Notes due 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">$ 1,058,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,038,900,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable, carrying value</a></td>
<td class="nump">$ 997,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">996,600,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="nump">3.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember', window );">4.050% Senior Notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">$ 1,988,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,897,200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable, carrying value</a></td>
<td class="nump">$ 1,740,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,739,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="nump">4.05%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_A2.25SeniorNotesdueMay12030Member', window );">2.250% Senior Notes due May 1, 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">$ 1,532,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable, carrying value</a></td>
<td class="nump">$ 1,491,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember', window );">5.200% Senior Notes due 2045</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">$ 2,286,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,107,900,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable, carrying value</a></td>
<td class="nump">$ 1,723,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,722,900,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="nump">5.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_A3.15SeniorNotesdueMay12050Member', window );">3.150% Senior Notes due May 1, 2050</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">$ 1,470,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable, carrying value</a></td>
<td class="nump">$ 1,472,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="nump">3.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 2.250% Senior Notes due May 1, 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 3.150% Senior Notes due May 1, 2050</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13433-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of notes payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20,22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_A2.25SeniorNotesdueMay12030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_A2.25SeniorNotesdueMay12030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_A3.15SeniorNotesdueMay12050Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_A3.15SeniorNotesdueMay12050Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140388977252856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Details 2) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Contingent consideration impairment</a></td>
<td class="nump">$ 29.0<span></span>
</td>
<td class="nump">$ 57.8<span></span>
</td>
<td class="nump">$ 23.5<span></span>
</td>
<td class="nump">$ 66.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Payments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value, beginning of period</a></td>
<td class="nump">351.6<span></span>
</td>
<td class="nump">401.3<span></span>
</td>
<td class="nump">346.1<span></span>
</td>
<td class="nump">409.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value, end of period</a></td>
<td class="nump">$ 322.6<span></span>
</td>
<td class="nump">$ 343.5<span></span>
</td>
<td class="nump">$ 322.6<span></span>
</td>
<td class="nump">$ 343.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionContingentConsiderationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140388911918872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">$ 1,570.3<span></span>
</td>
<td class="nump">$ 2,541.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">649.2<span></span>
</td>
<td class="nump">384.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_RepurchaseAgreementsMember', window );">Overnight reverse repurchase agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">465.4<span></span>
</td>
<td class="nump">368.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">270.2<span></span>
</td>
<td class="nump">1,628.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_DebtSecuritiesMember', window );">Short-term debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">$ 185.5<span></span>
</td>
<td class="nump">$ 159.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_RepurchaseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_RepurchaseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_DebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_DebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140388912552936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">$ 2,358.4<span></span>
</td>
<td class="nump">$ 2,965.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">6.8<span></span>
</td>
<td class="nump">6.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(0.4)<span></span>
</td>
<td class="num">(0.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">2,364.8<span></span>
</td>
<td class="nump">2,970.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable equity securities, fair value</a></td>
<td class="nump">2,364.8<span></span>
</td>
<td class="nump">2,970.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_CorporateDebtSecuritiesCurrentMember', window );">Corporate debt securities Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">963.5<span></span>
</td>
<td class="nump">1,057.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">1.4<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(0.1)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">964.8<span></span>
</td>
<td class="nump">1,058.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_CorporateDebtSecuritiesNonCurrentMember', window );">Corporate debt securities Non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">475.9<span></span>
</td>
<td class="nump">633.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">3.2<span></span>
</td>
<td class="nump">3.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(0.1)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">479.0<span></span>
</td>
<td class="nump">636.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_GovernmentSecuritiesCurrentMember', window );">Government securities Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">389.4<span></span>
</td>
<td class="nump">502.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">389.6<span></span>
</td>
<td class="nump">503.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_GovernmentSecuritiesNonCurrentMember', window );">Government securities Non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">376.4<span></span>
</td>
<td class="nump">510.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">1.4<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(0.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">377.8<span></span>
</td>
<td class="nump">510.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember', window );">Mortgage and other asset backed securities Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">0.6<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">0.6<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember', window );">Mortgage and other asset backed securities Non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">152.6<span></span>
</td>
<td class="nump">260.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0.6<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(0.2)<span></span>
</td>
<td class="num">(0.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">153.0<span></span>
</td>
<td class="nump">260.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember', window );">Marketable equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Marketable equity securities, amortized cost</a></td>
<td class="nump">851.7<span></span>
</td>
<td class="nump">218.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Marketable equity securities, gross unrealized gains</a></td>
<td class="nump">63.6<span></span>
</td>
<td class="nump">132.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Marketable equity securities, gross unrealized losses</a></td>
<td class="num">(46.8)<span></span>
</td>
<td class="num">(13.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable equity securities, fair value</a></td>
<td class="nump">$ 868.5<span></span>
</td>
<td class="nump">$ 337.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of unrealized gain in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of unrealized loss in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26610-111562<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_CorporateDebtSecuritiesCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_CorporateDebtSecuritiesCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_CorporateDebtSecuritiesNonCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_CorporateDebtSecuritiesNonCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_GovernmentSecuritiesCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_GovernmentSecuritiesCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_GovernmentSecuritiesNonCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_GovernmentSecuritiesNonCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140388896641000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Details 2) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract', window );"><strong>Summary of Contractual Maturities: Available-for-Sale Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost', window );">Due in one year or less, amortized cost</a></td>
<td class="nump">$ 1,355.0<span></span>
</td>
<td class="nump">$ 1,562.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Due in one year or less, estimated fair value</a></td>
<td class="nump">1,353.4<span></span>
</td>
<td class="nump">1,560.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost', window );">Due after one year through five years, amortized cost</a></td>
<td class="nump">902.2<span></span>
</td>
<td class="nump">1,234.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Due after one year through five years, estimated fair value</a></td>
<td class="nump">897.9<span></span>
</td>
<td class="nump">1,230.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost', window );">Due after five years, amortized cost</a></td>
<td class="nump">107.6<span></span>
</td>
<td class="nump">173.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue', window );">Due after five years, estimated fair value</a></td>
<td class="nump">107.1<span></span>
</td>
<td class="nump">173.8<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">2,358.4<span></span>
</td>
<td class="nump">2,965.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Available-for-sale Securities</a></td>
<td class="nump">$ 2,364.8<span></span>
</td>
<td class="nump">$ 2,970.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents debt securities, at cost, net of adjustments made for accretion, amortization, other-than-temporary impairments, and hedging, if any, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the fair value of debt securities, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27198-111563<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=75019621&amp;loc=d3e62586-112803<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), maturing in next fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27198-111563<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=75019621&amp;loc=d3e62586-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140388903501672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Details 3) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Proceeds from maturities and sales</a></td>
<td class="nump">$ 1,360.9<span></span>
</td>
<td class="nump">$ 611.8<span></span>
</td>
<td class="nump">$ 5,240.7<span></span>
</td>
<td class="nump">$ 3,867.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain', window );">Realized gains</a></td>
<td class="nump">1.0<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
<td class="nump">12.8<span></span>
</td>
<td class="nump">2.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss', window );">Realized losses</a></td>
<td class="num">$ (0.9)<span></span>
</td>
<td class="num">$ (0.1)<span></span>
</td>
<td class="num">$ (25.2)<span></span>
</td>
<td class="num">$ (0.7)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3151-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140388901281448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Details Textual)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AverageMaturityOfMarketableSecurities', window );">Average maturity of marketable securities, months</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">14 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AverageMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average remaining time to maturity of marketable debt securities, available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AverageMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140388905871704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments Financial Instruments (Details Textual 2) - USD ($)<br> shares in Millions, number in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity', window );">Proceeds from sales of strategic investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="nump">$ 476.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_StrategicInvestmentsMember', window );">Strategic Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_StrategicInvestmentPortfolio', window );">Strategic investment portfolio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 925.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember', window );">Other noncurrent assets | Strategic Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_StrategicInvestmentPortfolio', window );">Strategic investment portfolio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 393.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=biib_DenaliTherapeuticsIncMember', window );">Denali Therapeutics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Investmentincommonstocksharespurchased', window );">Investment in common stock, shares purchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DividendYieldPercentage', window );">Dividend yield percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=biib_SangamoCommonStockMember', window );">Sangamo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Investmentincommonstocksharespurchased', window );">Investment in common stock, shares purchased</a></td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DividendYieldPercentage', window );">Dividend yield percentage</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DividendYieldPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Dividend Yield Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DividendYieldPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Investmentincommonstocksharespurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment in common stock, shares purchased</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Investmentincommonstocksharespurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_StrategicInvestmentPortfolio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Strategic investment portfolio.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_StrategicInvestmentPortfolio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of equity securities classified as available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26853-111562<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_StrategicInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_StrategicInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=biib_DenaliTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=biib_DenaliTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=biib_SangamoCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=biib_SangamoCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140388902287368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments (Details)<br> $ in Millions, &#8361; in Billions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Nov. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2018 </div>
<div>KRW (&#8361;)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax', window );">Gain/Loss on fair value of foreign currency forward contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 114.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 114.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease', window );">Gains (losses) on net investment hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.5<span></span>
</td>
<td class="nump">$ 46.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments', window );">Net gains (losses) of other income (expense) related to foreign currency forward contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (13.7)<span></span>
</td>
<td class="nump">14.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeRemainingMaturity1', window );">Range of durations of foreign currency forward contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 month<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 month<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeRemainingMaturity1', window );">Range of durations of foreign currency forward contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Not designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">990.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 990.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 793.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember', window );">Other current assets | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Derivative asset, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember', window );">Other current assets | Not designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Derivative asset, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember', window );">Other noncurrent assets | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Derivative asset, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember', window );">Accrued expenses and other | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative liability, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember', window );">Accrued expenses and other | Not designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative liability, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign exchange contract | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,866.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,866.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,892.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest rate swap | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">675.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">675.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging [Member] | Foreign exchange contract | Other long-term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative liability, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember', window );">Fair Value Hedging [Member] | Interest rate swap | Accrued expenses and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative liability, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net Investment Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeTermOfContract', window );">Remaining duration of Net Investment Hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 month<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax', window );">Unrealized gain (loss) on net investment hedges in AOCI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax', window );">Derivative qualifying as net investment hedge, excluded component</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease', window );">Gains (losses) on net investment hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.0<span></span>
</td>
<td class="nump">45.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease', window );">Gains (losses) on net investment hedge, excluded component</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.1<span></span>
</td>
<td class="nump">8.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net Investment Hedging | Foreign exchange contract | Other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Derivative asset, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember', window );">Interest Expense | Interest rate swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Gain on interest rate swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember', window );">Revenue | Cash flows, revenue | Foreign exchange contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet', window );">Gain (loss) on reclassification of cash flow hedges, effective portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8.7)<span></span>
</td>
<td class="num">(1.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet', window );">Gain (loss) recognized in net income, excluded component</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
<td class="nump">8.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember', window );">Operating expense | Cash flows, operating expenses | Foreign exchange contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet', window );">Gain (loss) on reclassification of cash flow hedges, effective portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
<td class="num">(0.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet', window );">Gain (loss) recognized in net income, excluded component</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
<td class="num">(0.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember', window );">Other income (expense) | Net Investment Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet', window );">Gain (loss) recognized in net income, excluded component</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.6<span></span>
</td>
<td class="nump">$ 6.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_EUR', window );">Euro | Foreign exchange contract | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,717.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,717.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,892.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_GBP', window );">British pound | Foreign exchange contract | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_CHF', window );">Swiss franc | Foreign exchange contract | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_JPY', window );">Japan, Yen | Foreign exchange contract | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_CAD', window );">Canadian dollar | Foreign exchange contract | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember', window );">2.900% Senior Notes due 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction', window );">Percentage of stake in entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity Method Investment, Ownership Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Payments to acquire additional investment in equity method investment</a></td>
<td class="nump">$ 676.6<span></span>
</td>
<td class="nump">&#8361; 759.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 676.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DerivativeMaturityAxis=biib_ShorttermderivativeMember', window );">Short-term derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeRemainingMaturity1', window );">Range of durations of foreign currency forward contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax', window );">Gain/Loss on fair value of foreign currency forward contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 94.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 94.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Derivatives used in net investment hedge, net of tax, excluded component increase (decrease)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Ownership Percentage Before Additional Purchase Transaction</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of net unrealized gain (loss) related to the change in fair value of foreign currency exchange rate derivatives designated as cash flow hedging instruments. Recorded in accumulated other comprehensive income to the extent that the cash flow hedge is determined to be effective.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated gain (loss) from increase (decrease) in value of excluded component of derivative hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=112277219&amp;loc=d3e80784-113994<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118948506&amp;loc=SL51823488-111719<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118948506&amp;loc=SL51823488-111719<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624163-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The effective portion of net gain (loss) reclassified from accumulated other comprehensive income into income on derivative instruments designated and qualifying as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624177-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of gains and losses (net) on derivative instruments designated and qualifying as hedging instruments representing (a) the amount of the hedge ineffectiveness and (b) the amount, if any, excluded from the assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624171-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 25<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1),(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109977999&amp;loc=d3e76258-113986<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeRemainingMaturity1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period remaining until the derivative contract matures, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeRemainingMaturity1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period the derivative contract is outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesFairValueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesFairValueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDerivativeInstrumentsNetPretax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in earnings in the period from the increase (decrease) in fair value of foreign currency derivatives not designated as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5618551-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the cumulative translation adjustment from gain (loss), after tax, on foreign currency derivatives, that are designated as, and are effective as, economic hedges of a net investment in a foreign entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b),(c),(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of net unrealized gain (loss) related to the change in fair value of foreign currency exchange rate derivatives designated as cash flow hedging instruments. Recorded in accumulated other comprehensive income to the extent that the cash flow hedge is determined to be effective.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=biib_CashflowsrevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=biib_CashflowsrevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=biib_CashflowsoperatingexpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=biib_CashflowsoperatingexpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_EUR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_EUR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_GBP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_GBP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_CHF">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_CHF</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_JPY">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_JPY</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_CAD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_CAD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DerivativeMaturityAxis=biib_ShorttermderivativeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DerivativeMaturityAxis=biib_ShorttermderivativeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140388901067992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="nump">$ 1,734.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,734.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,590.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">51.5<span></span>
</td>
<td class="nump">$ 45.5<span></span>
</td>
<td class="nump">$ 151.2<span></span>
</td>
<td class="nump">$ 145.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FacilityTypeAxis=biib_BiologicsManufacturingMember', window );">Biologics Manufacturing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NumberOfSquareFeet', window );">Number of square feet | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">393,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FacilityTypeAxis=biib_WarehouseUtilitiesAndSupportSpaceMember', window );">Warehouse, Utilities and Support Space</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NumberOfSquareFeet', window );">Number of square feet | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">290,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FacilityTypeAxis=biib_AdministrativeSpaceMember', window );">Administrative Space</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NumberOfSquareFeet', window );">Number of square feet | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FacilityLocationAxis=biib_SolothurnSwitzerlandMember', window );">Solothurn, Switzerland</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Construction in progress</a></td>
<td class="nump">1,800.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Fixed assets placed into service</a></td>
<td class="nump">256.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">256.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Contractual commitments for the construction of the facility</a></td>
<td class="nump">$ 14.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NumberOfSquareFeet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Square Feet</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NumberOfSquareFeet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionInProgressGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionInProgressGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FacilityTypeAxis=biib_BiologicsManufacturingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FacilityTypeAxis=biib_BiologicsManufacturingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FacilityTypeAxis=biib_WarehouseUtilitiesAndSupportSpaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FacilityTypeAxis=biib_WarehouseUtilitiesAndSupportSpaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FacilityTypeAxis=biib_AdministrativeSpaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FacilityTypeAxis=biib_AdministrativeSpaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FacilityLocationAxis=biib_SolothurnSwitzerlandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FacilityLocationAxis=biib_SolothurnSwitzerlandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140388977108568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Indebtedness (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Apr. 30, 2020</div></th>
<th class="th"><div>Sep. 15, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Payments of financing costs</a></td>
<td class="nump">$ 24,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_A2.25SeniorNotesdueMay12030Member', window );">2.250% Senior Notes due May 1, 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_A3.15SeniorNotesdueMay12050Member', window );">3.150% Senior Notes due May 1, 2050</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="nump">3.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Debt instrument, redemption price, percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage', window );">Debt instrument, make whole provision redemption price, percentage</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 2.250% Senior Notes due May 1, 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageParValueOfSeniorNotes', window );">Percentage par value of senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.973%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 3.150% Senior Notes due May 1, 2050</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageParValueOfSeniorNotes', window );">Percentage par value of senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.174%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 2.90% Senior Notes Due Sept 15, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageParValueOfSeniorNotes', window );">Percentage par value of senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.792%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts', window );">Payment of early call premium and write off of remaining unamortized debt issuance costs</a></td>
<td class="nump">$ 12,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember', window );">Interest Expense | Senior Notes | 2.90% Senior Notes Due Sept 15, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain', window );">Pre-tax charge, payment of early call premium and write off of remaining unamortized debt issuance costs, net of derivative gain</a></td>
<td class="nump">9,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember', window );">Interest Expense | Interest rate swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Derivative, gain on derivative</a></td>
<td class="nump">$ 3,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Make Whole Provision Redemption Price, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Early Call Premium and Write off of Remaining Unamortized Debt Issuance Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageParValueOfSeniorNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage Par Value Of Senior Notes</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageParValueOfSeniorNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Pre-tax Charge, Payment of Early Call Premium and Write off of Remaining Unamortized Debt Issuance Costs, Net of Derivative Gain</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph e<br> -URI http://asc.fasb.org/extlink&amp;oid=75038535&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDerivativeInstrumentsNetPretax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_A2.25SeniorNotesdueMay12030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_A2.25SeniorNotesdueMay12030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_A3.15SeniorNotesdueMay12050Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_A3.15SeniorNotesdueMay12050Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_A2.90SeniorNotesDueSept152020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_A2.90SeniorNotesDueSept152020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140388896995992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Repurchases (Details) - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for repurchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,279.1<span></span>
</td>
<td class="nump">$ 3,775.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=biib_December2019ShareRepurchaseProgramMember', window );">December 2019 Share Repurchase Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Stock Repurchase Program, Authorized Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock, at cost, shares</a></td>
<td class="nump">4.5<span></span>
</td>
<td class="nump">16.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for repurchase of common stock</a></td>
<td class="nump">$ 1,300.0<span></span>
</td>
<td class="nump">$ 5,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=biib_March2019ShareRepurchaseProgramMember', window );">2019 Share Repurchase Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Stock Repurchase Program, Authorized Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock, at cost, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for repurchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=biib_December2019ShareRepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=biib_December2019ShareRepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=biib_March2019ShareRepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=biib_March2019ShareRepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140388976833640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income (Loss) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (135.2)<span></span>
</td>
<td class="num">$ (240.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, January 1, 2018</a></td>
<td class="num">$ (225.5)<span></span>
</td>
<td class="num">$ (92.3)<span></span>
</td>
<td class="num">(225.5)<span></span>
</td>
<td class="num">(92.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss), before reclassifications, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(54.4)<span></span>
</td>
<td class="nump">233.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(35.9)<span></span>
</td>
<td class="num">(85.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(45.4)<span></span>
</td>
<td class="nump">160.6<span></span>
</td>
<td class="num">(89.4)<span></span>
</td>
<td class="nump">147.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax ending balance</a></td>
<td class="num">(225.5)<span></span>
</td>
<td class="num">(92.3)<span></span>
</td>
<td class="num">(225.5)<span></span>
</td>
<td class="num">(92.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(44.5)<span></span>
</td>
<td class="nump">160.6<span></span>
</td>
<td class="num">(90.3)<span></span>
</td>
<td class="nump">148.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Unrealized gains (losses) on securities available for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.2<span></span>
</td>
<td class="num">(4.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, January 1, 2018</a></td>
<td class="nump">5.2<span></span>
</td>
<td class="nump">6.3<span></span>
</td>
<td class="nump">5.2<span></span>
</td>
<td class="nump">6.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss), before reclassifications, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8.8)<span></span>
</td>
<td class="nump">11.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.8<span></span>
</td>
<td class="num">(1.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
<td class="nump">10.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax ending balance</a></td>
<td class="nump">5.2<span></span>
</td>
<td class="nump">6.3<span></span>
</td>
<td class="nump">5.2<span></span>
</td>
<td class="nump">6.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember', window );">Unrealized gains (losses) on cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.8<span></span>
</td>
<td class="nump">34.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, January 1, 2018</a></td>
<td class="num">(93.3)<span></span>
</td>
<td class="nump">72.8<span></span>
</td>
<td class="num">(93.3)<span></span>
</td>
<td class="nump">72.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss), before reclassifications, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(58.0)<span></span>
</td>
<td class="nump">115.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(43.1)<span></span>
</td>
<td class="num">(77.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(101.1)<span></span>
</td>
<td class="nump">38.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax ending balance</a></td>
<td class="num">(93.3)<span></span>
</td>
<td class="nump">72.8<span></span>
</td>
<td class="num">(93.3)<span></span>
</td>
<td class="nump">72.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember', window );">Gains (losses) on net investment hedge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.1<span></span>
</td>
<td class="nump">3.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, January 1, 2018</a></td>
<td class="nump">30.6<span></span>
</td>
<td class="nump">50.4<span></span>
</td>
<td class="nump">30.6<span></span>
</td>
<td class="nump">50.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss), before reclassifications, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.1<span></span>
</td>
<td class="nump">53.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.6)<span></span>
</td>
<td class="num">(6.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.5<span></span>
</td>
<td class="nump">46.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax ending balance</a></td>
<td class="nump">30.6<span></span>
</td>
<td class="nump">50.4<span></span>
</td>
<td class="nump">30.6<span></span>
</td>
<td class="nump">50.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember', window );">Unfunded status of postretirement benefit plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(32.8)<span></span>
</td>
<td class="num">(31.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, January 1, 2018</a></td>
<td class="num">(32.4)<span></span>
</td>
<td class="num">(29.8)<span></span>
</td>
<td class="num">(32.4)<span></span>
</td>
<td class="num">(29.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss), before reclassifications, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax ending balance</a></td>
<td class="num">(32.4)<span></span>
</td>
<td class="num">(29.8)<span></span>
</td>
<td class="num">(32.4)<span></span>
</td>
<td class="num">(29.8)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember', window );">Currency translation adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(139.5)<span></span>
</td>
<td class="num">(243.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, January 1, 2018</a></td>
<td class="num">(135.6)<span></span>
</td>
<td class="num">(192.0)<span></span>
</td>
<td class="num">(135.6)<span></span>
</td>
<td class="num">(192.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss), before reclassifications, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.9<span></span>
</td>
<td class="nump">51.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.9<span></span>
</td>
<td class="nump">51.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax ending balance</a></td>
<td class="num">$ (135.6)<span></span>
</td>
<td class="num">$ (192.0)<span></span>
</td>
<td class="num">$ (135.6)<span></span>
</td>
<td class="num">$ (192.0)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669686-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669686-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118951672&amp;loc=d3e1436-108581<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118951672&amp;loc=d3e1436-108581<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17B<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL34724394-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669686-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118951672&amp;loc=d3e1436-108581<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140388905863480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reclassification out of Accumulated Other Comprehensive Income (Loss) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Nonoperating Income (Expense)</a></td>
<td class="num">$ (128.6)<span></span>
</td>
<td class="num">$ (27.3)<span></span>
</td>
<td class="num">$ (186.1)<span></span>
</td>
<td class="nump">$ 132.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="nump">240.8<span></span>
</td>
<td class="nump">211.3<span></span>
</td>
<td class="nump">979.0<span></span>
</td>
<td class="nump">881.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="num">(3,376.1)<span></span>
</td>
<td class="num">(3,600.1)<span></span>
</td>
<td class="num">(10,592.0)<span></span>
</td>
<td class="num">(10,706.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">701.5<span></span>
</td>
<td class="nump">1,545.9<span></span>
</td>
<td class="nump">3,642.7<span></span>
</td>
<td class="nump">4,448.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember', window );">Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="num">(6.6)<span></span>
</td>
<td class="nump">37.1<span></span>
</td>
<td class="nump">35.9<span></span>
</td>
<td class="nump">85.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Unrealized gains (losses) on securities available for sale | Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Nonoperating Income (Expense)</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
<td class="num">(12.4)<span></span>
</td>
<td class="nump">1.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
<td class="nump">2.6<span></span>
</td>
<td class="num">(0.3)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember', window );">Unrealized gains (losses) on cash flow hedges | Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Nonoperating Income (Expense)</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
<td class="num">(0.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">9.1<span></span>
</td>
<td class="nump">35.2<span></span>
</td>
<td class="num">(41.6)<span></span>
</td>
<td class="nump">79.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Operating Expenses</a></td>
<td class="nump">1.5<span></span>
</td>
<td class="num">(0.8)<span></span>
</td>
<td class="nump">1.4<span></span>
</td>
<td class="nump">2.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember', window );">Gains (losses) on net investment hedge | Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Nonoperating Income (Expense)</a></td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="nump">$ 2.2<span></span>
</td>
<td class="nump">$ 2.6<span></span>
</td>
<td class="nump">$ 6.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140388901621384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share (Details) - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">$ 701.5<span></span>
</td>
<td class="nump">$ 1,545.9<span></span>
</td>
<td class="nump">$ 3,642.7<span></span>
</td>
<td class="nump">$ 4,448.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted-average shares used in calculating:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of common shares outstanding</a></td>
<td class="nump">156.9<span></span>
</td>
<td class="nump">184.0<span></span>
</td>
<td class="nump">163.4<span></span>
</td>
<td class="nump">190.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Dilutive potential common shares</a></td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Shares used in calculating diluted earnings per share</a></td>
<td class="nump">157.2<span></span>
</td>
<td class="nump">184.2<span></span>
</td>
<td class="nump">163.7<span></span>
</td>
<td class="nump">190.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_TimeVestedRestrictedStockUnitsMember', window );">Time-vested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Stock units</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_MarketStockUnitsMember', window );">Market stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Stock units</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_PerformanceStockUnitsSettledinStockMember', window );">Performance stock units settled in stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Stock units</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DilutiveSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DilutiveSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1500-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1448-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_TimeVestedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_TimeVestedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_MarketStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_MarketStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_PerformanceStockUnitsSettledinStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_PerformanceStockUnitsSettledinStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140388896641928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Share-based Compensation Expense included in consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="num">$ (35.4)<span></span>
</td>
<td class="num">$ (47.8)<span></span>
</td>
<td class="num">$ (154.2)<span></span>
</td>
<td class="num">$ (151.8)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax', window );">Subtotal</a></td>
<td class="nump">39.6<span></span>
</td>
<td class="nump">49.6<span></span>
</td>
<td class="nump">161.5<span></span>
</td>
<td class="nump">182.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount', window );">Capitalized share-based compensation costs</a></td>
<td class="num">(1.9)<span></span>
</td>
<td class="num">(1.7)<span></span>
</td>
<td class="num">(4.9)<span></span>
</td>
<td class="num">(7.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses', window );">Share-based compensation expense included in total costs and expenses</a></td>
<td class="nump">37.7<span></span>
</td>
<td class="nump">47.9<span></span>
</td>
<td class="nump">156.6<span></span>
</td>
<td class="nump">174.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense', window );">Income tax effect</a></td>
<td class="num">(5.4)<span></span>
</td>
<td class="num">(8.1)<span></span>
</td>
<td class="num">(25.7)<span></span>
</td>
<td class="num">(29.1)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Share-based Compensation Expense included in consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">14.6<span></span>
</td>
<td class="nump">15.4<span></span>
</td>
<td class="nump">63.1<span></span>
</td>
<td class="nump">65.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Share-based Compensation Expense included in consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">25.0<span></span>
</td>
<td class="nump">34.2<span></span>
</td>
<td class="nump">98.4<span></span>
</td>
<td class="nump">116.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ParentMember', window );">Total share-based compensation expense, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Share-based Compensation Expense included in consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 32.3<span></span>
</td>
<td class="nump">$ 39.8<span></span>
</td>
<td class="nump">$ 130.9<span></span>
</td>
<td class="nump">$ 145.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation expense included in costs and expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of expense for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost capitalized for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax benefit for recognition of expense of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140388906115000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="num">$ (35.4)<span></span>
</td>
<td class="num">$ (47.8)<span></span>
</td>
<td class="num">$ (154.2)<span></span>
</td>
<td class="num">$ (151.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax', window );">Subtotal</a></td>
<td class="nump">39.6<span></span>
</td>
<td class="nump">49.6<span></span>
</td>
<td class="nump">161.5<span></span>
</td>
<td class="nump">182.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount', window );">Capitalized share-based compensation costs</a></td>
<td class="num">(1.9)<span></span>
</td>
<td class="num">(1.7)<span></span>
</td>
<td class="num">(4.9)<span></span>
</td>
<td class="num">(7.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses', window );">Share-based compensation expense included in total costs and expenses</a></td>
<td class="nump">37.7<span></span>
</td>
<td class="nump">47.9<span></span>
</td>
<td class="nump">156.6<span></span>
</td>
<td class="nump">174.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_MarketStockUnitsMember', window );">Market stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">5.5<span></span>
</td>
<td class="nump">9.3<span></span>
</td>
<td class="nump">32.0<span></span>
</td>
<td class="nump">24.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_TimeVestedRestrictedStockUnitsMember', window );">Time-vested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">35.3<span></span>
</td>
<td class="nump">37.9<span></span>
</td>
<td class="nump">107.3<span></span>
</td>
<td class="nump">104.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_CashSettledPerformanceSharesMember', window );">Cash settled performance shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="num">(1.7)<span></span>
</td>
<td class="num">(0.3)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinStockMember', window );">Performance stock units settled in stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="num">(8.4)<span></span>
</td>
<td class="num">(1.1)<span></span>
</td>
<td class="nump">4.0<span></span>
</td>
<td class="nump">13.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinCashMember', window );">Performance stock units settled in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">4.1<span></span>
</td>
<td class="nump">1.3<span></span>
</td>
<td class="nump">9.0<span></span>
</td>
<td class="nump">3.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_EmployeeStockPurchasePlanMember', window );">Employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">3.1<span></span>
</td>
<td class="nump">1.7<span></span>
</td>
<td class="nump">11.0<span></span>
</td>
<td class="nump">9.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_NightstarMember', window );">Nightstar | Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized', window );">NST stock options</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 26.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation expense included in costs and expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of share-based compensation expense associated with different programs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of expense for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The expenses and losses recorded for each transaction with the acquiree that was recognized separately from the acquisition of assets and assumptions of liabilities in the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost capitalized for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_MarketStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_MarketStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_TimeVestedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_TimeVestedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_CashSettledPerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_CashSettledPerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinCashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinCashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_NightstarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_NightstarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140388976689912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Deferred tax assets, other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 754.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Deferred tax liabilities, other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 603.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible', window );">Decrease in unrecognized tax benefits is reasonably possible</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_DenmarkManufacturingOperationsMember', window );">Denmark Manufacturing Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation', window );">Tax expense on disposal group</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64.7<span></span>
</td>
<td class="nump">$ 64.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_TECFIDERAMember', window );">TECFIDERA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DeferredTaxAssetsValueReductioninValue', window );">Deferred tax assets, decrease in value</a></td>
<td class="nump">$ 1,627.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,627.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DeferredTaxLiabilitiesValueReductioninValue', window );">Deferred tax liabilities, decrease in value</a></td>
<td class="nump">1,538.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,538.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_IncomeTaxExpenseReductioninDeferredTaxAssetsandLiabilitiesNet', window );">Income tax expense associated with reductions in deferred tax assets and liabilities</a></td>
<td class="nump">$ 33.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 89.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DeferredTaxAssetsValueReductioninValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Value, Reduction in Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DeferredTaxAssetsValueReductioninValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DeferredTaxLiabilitiesValueReductioninValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Value, Reduction in Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DeferredTaxLiabilitiesValueReductioninValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_IncomeTaxExpenseReductioninDeferredTaxAssetsandLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income Tax Expense, Reduction in Deferred Tax Assets and Liabilities, Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_IncomeTaxExpenseReductioninDeferredTaxAssetsandLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_DenmarkManufacturingOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_DenmarkManufacturingOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_TECFIDERAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_TECFIDERAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140388902077240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Reconciliation between the U.S. federal statutory tax rate and effective tax rate</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes</a></td>
<td class="nump">0.90%<span></span>
</td>
<td class="nump">0.90%<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
<td class="nump">0.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Taxes on foreign earnings</a></td>
<td class="num">(3.00%)<span></span>
</td>
<td class="num">(5.00%)<span></span>
</td>
<td class="num">(3.60%)<span></span>
</td>
<td class="num">(4.70%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Credits and net operating loss utilization</a></td>
<td class="num">(2.30%)<span></span>
</td>
<td class="num">(1.50%)<span></span>
</td>
<td class="num">(1.30%)<span></span>
</td>
<td class="num">(1.00%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization', window );">Purchased intangible assets</a></td>
<td class="nump">2.90%<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">0.80%<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets', window );">Denmark assets held for sale</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization', window );">Internal reorganization of certain intellectual property rights</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(1.50%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(2.10%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses', window );">TECFIDERA impairment</a></td>
<td class="nump">3.50%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">1.90%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EffectiveTaxRateReconciliationGILTItax', window );">GILTI</a></td>
<td class="nump">2.20%<span></span>
</td>
<td class="nump">1.60%<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
<td class="nump">1.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EffectiveIncomeTaxRateReconciliationChangeInForeignTaxRatePercent', window );">Swiss tax reform</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(3.10%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(1.00%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther', window );">Permanent items</a></td>
<td class="num">(0.60%)<span></span>
</td>
<td class="num">(0.10%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="num">(0.80%)<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
<td class="num">(0.30%)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">25.10%<span></span>
</td>
<td class="nump">11.90%<span></span>
</td>
<td class="nump">20.90%<span></span>
</td>
<td class="nump">16.30%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EffectiveIncomeTaxRateReconciliationChangeInForeignTaxRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation Change in Foreign Tax Rate Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EffectiveIncomeTaxRateReconciliationChangeInForeignTaxRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Intellectual Property Rights Reorganization</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EffectiveTaxRateReconciliationGILTItax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Tax Rate Reconciliation, GILTI tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EffectiveTaxRateReconciliationGILTItax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to disposition of asset. Includes, but is not limited to, intra-entity transfer of asset other than inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to depreciation and amortization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to impairment loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140388976942344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Consolidated Financial Statement Detail (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNetAbstract', window );"><strong>Other Income (Expense), Net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">$ 6.0<span></span>
</td>
<td class="nump">$ 30.5<span></span>
</td>
<td class="nump">$ 38.0<span></span>
</td>
<td class="nump">$ 90.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(56.3)<span></span>
</td>
<td class="num">(45.8)<span></span>
</td>
<td class="num">(166.5)<span></span>
</td>
<td class="num">(141.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RealizedInvestmentGainsLosses', window );">Gain (loss) on investments, net</a></td>
<td class="num">(82.1)<span></span>
</td>
<td class="num">(4.1)<span></span>
</td>
<td class="num">(52.6)<span></span>
</td>
<td class="nump">198.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign exchange gains (losses), net</a></td>
<td class="nump">3.1<span></span>
</td>
<td class="num">(4.2)<span></span>
</td>
<td class="num">(5.4)<span></span>
</td>
<td class="num">(4.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other, net</a></td>
<td class="nump">0.7<span></span>
</td>
<td class="num">(3.7)<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
<td class="num">(11.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense), net</a></td>
<td class="num">(128.6)<span></span>
</td>
<td class="num">(27.3)<span></span>
</td>
<td class="num">(186.1)<span></span>
</td>
<td class="nump">132.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract', window );"><strong>Equity Securities, FV-NI, Gain (Loss), Alternative [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLoss', window );">Net gains (losses) recognized during the period on equity securities</a></td>
<td class="num">(82.3)<span></span>
</td>
<td class="num">(4.6)<span></span>
</td>
<td class="num">(40.3)<span></span>
</td>
<td class="nump">197.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss', window );">Less: Net gains (losses) recognized during the period on equity securities sold during the period</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">4.4<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(46.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized gains (losses) recognized during the period on equity securities</a></td>
<td class="num">(82.3)<span></span>
</td>
<td class="num">$ (9.0)<span></span>
</td>
<td class="num">(40.3)<span></span>
</td>
<td class="nump">$ 150.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Expenses and Other</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Revenue-related reserves for discounts and allowances</a></td>
<td class="nump">1,271.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,271.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,198.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Collaboration expenses</a></td>
<td class="nump">279.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">279.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">309.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrent', window );">Royalties and licensing fees</a></td>
<td class="nump">222.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">222.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">220.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Collaborationexpensesaccrual', window );">Collaboration expenses</a></td>
<td class="nump">277.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">277.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">281.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Current portion of contingent consideration obligations</a></td>
<td class="nump">164.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">164.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">148.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionPayableCurrentAndNoncurrent', window );">Construction in progress</a></td>
<td class="nump">23.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">1,274.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,274.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">726.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Total accrued expenses and other</a></td>
<td class="nump">3,286.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,286.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,765.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Component of accrued expenses and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Expenses and Other</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Revenue-related reserves for discounts and allowances</a></td>
<td class="nump">$ 1,043.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,043.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,001.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Collaborationexpensesaccrual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration expenses accrual</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Collaborationexpensesaccrual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for the acquisition of merchandise, materials, supplies and services pertaining to construction projects such as a housing development or factory expansion not classified as trade payables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116654751&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116654751&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116654751&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30700-110894<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30690-110894<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RealizedInvestmentGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net realized gains or losses on investments during the period, not including gains or losses on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.3(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RealizedInvestmentGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140388905837848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Consolidated Financial Statement (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RealizedInvestmentGainsLosses', window );">Gain (loss) on investments, net</a></td>
<td class="num">$ (82.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (4.1)<span></span>
</td>
<td class="num">$ (52.6)<span></span>
</td>
<td class="nump">$ 198.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">1,428.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,428.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,348.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesNoncurrent', window );">Accrued income taxes</a></td>
<td class="nump">729.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">729.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 803.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Net gains recognized on the increase in fair value of equity securities</a></td>
<td class="num">(82.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (9.0)<span></span>
</td>
<td class="num">(40.3)<span></span>
</td>
<td class="nump">150.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity', window );">Proceeds from sale of available-for-sale securities, equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">$ 476.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsIncomeTaxExpense', window );">Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Income Tax Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 697.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 635.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=biib_IonisPharmaceuticalsMember', window );">Ionis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Net gains recognized on the increase in fair value of equity securities</a></td>
<td class="nump">66.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=biib_DenaliTherapeuticsIncMember', window );">Denali Therapeutics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Net gains recognized on the increase in fair value of equity securities</a></td>
<td class="num">(29.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=biib_SangamoCommonStockMember', window );">Sangamo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Net gains recognized on the increase in fair value of equity securities</a></td>
<td class="nump">$ 15.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116654751&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of equity securities classified as available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26853-111562<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RealizedInvestmentGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net realized gains or losses on investments during the period, not including gains or losses on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.3(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RealizedInvestmentGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsIncomeTaxExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income tax expense from transition tax on accumulated earnings of controlled foreign corporation deemed repatriated pursuant to Tax Cuts and Jobs Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsIncomeTaxExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=biib_IonisPharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=biib_IonisPharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=biib_DenaliTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=biib_DenaliTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=biib_SangamoCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=biib_SangamoCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140388902329688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships - Collaborations (Details)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Feb. 29, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($) </div>
<div>product </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Loss on equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.7<span></span>
</td>
<td class="nump">$ 63.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized Gain (Loss) on Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 82.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (40.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_IonisPharmaceuticalsMember', window );">Ionis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized Gain (Loss) on Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(56.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_DenaliTherapeuticsIncMember', window );">Denali Therapeutics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized Gain (Loss) on Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(29.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SangamoTherapeuticsInc.AgreementMember', window );">Sangamo Therapeutics, Inc. Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized Gain (Loss) on Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (56.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember', window );">Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NumberOfProductCandidates', window );">Number of product candidates | product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ExpenseIncurredByCollaboration', window );">Expense Incurred By Collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">168.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 153.2<span></span>
</td>
<td class="nump">305.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Expense reflected within statements of income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 76.6<span></span>
</td>
<td class="nump">152.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai', window );">Percentage of future development costs related to Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossOnContractTermination', window );">Loss on research and development contracts terminated with Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Loss on equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33.8<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_SangamoTherapeuticsInc.AgreementMember', window );">Sangamo Therapeutics, Inc. Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased', window );">Global Licensing Collaboration Agreement, Amount, Shares Purchased</a></td>
<td class="nump">$ 225.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_GlobalLicensingCollaborationAgreementSharesPurchased', window );">Global Licensing Collaboration Agreement, Shares, Purchased | shares</a></td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare', window );">Global Licensing Collaboration Agreement, Shares Purchased Per Share | $ / shares</a></td>
<td class="nump">$ 9.21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner', window );">Upfront and milestone payments made to collaborative partner</a></td>
<td class="nump">$ 125.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments', window );">Global Licensing Collaboration Agreement, Research, Development, Regulatory and Commercial Milestone Payments</a></td>
<td class="nump">2,400.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets', window );">Global Licensing Collaboration Agreement, Payment, Selection of Targets</a></td>
<td class="nump">80.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones', window );">Global Licensing Collaboration Agreement, Payment, Achievement of First Commercial Sale Milestones</a></td>
<td class="nump">1,900.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones', window );">Global Licensing Collaboration Agreement, Payment, Achievement of Specific Sales Based Milestones</a></td>
<td class="nump">380.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">$ 83.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_SkyhawkTherapeuticsMember', window );">Skyhawk Therapeutics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner', window );">Upfront and milestone payments made to collaborative partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments', window );">Global Licensing Collaboration Agreement, Research, Development, Regulatory and Commercial Milestone Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssets', window );">Prepaid research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_DenaliTherapeuticsIncMember', window );">Denali Therapeutics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased', window );">Global Licensing Collaboration Agreement, Amount, Shares Purchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 465.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare', window );">Global Licensing Collaboration Agreement, Shares Purchased Per Share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner', window );">Upfront and milestone payments made to collaborative partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 560.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments', window );">Global Licensing Collaboration Agreement, Research, Development, Regulatory and Commercial Milestone Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner', window );">Upfront and milestone payments made to collaborative partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationAgreementTerm', window );">Collaboration agreement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 63.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssets', window );">Prepaid research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development | Eisai | Aducanumab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expenseincurredbythecollaboration', window );">Expense incurred by the collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 92.5<span></span>
</td>
<td class="nump">170.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Expense reflected within statements of income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.9<span></span>
</td>
<td class="nump">93.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development | UCB Pharma S.A. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expenseincurredbythecollaboration', window );">Expense incurred by the collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Expense reflected within statements of income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative | Eisai | BAN2401 and Elenbecestat</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expenseincurredbythecollaboration', window );">Expense incurred by the collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.3<span></span>
</td>
<td class="nump">24.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Expense reflected within statements of income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.2<span></span>
</td>
<td class="nump">12.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative | Eisai | Aducanumab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expenseincurredbythecollaboration', window );">Expense incurred by the collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">158.8<span></span>
</td>
<td class="nump">21.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Expense reflected within statements of income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 88.8<span></span>
</td>
<td class="nump">$ 11.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CollaborationAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CollaborationAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ExpenseIncurredByCollaboration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total expense incurred by collaboration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ExpenseIncurredByCollaboration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Expenseincurredbythecollaboration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expense incurred by the collaboration</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Expenseincurredbythecollaboration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Expensereflectedwithinstatementsofincome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expense reflected within statements of income</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Expensereflectedwithinstatementsofincome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Global Licensing Collaboration Agreement, Amount, Shares Purchased</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Global Licensing Collaboration Agreement, Payment, Achievement of First Commercial Sale Milestones</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Global Licensing Collaboration Agreement, Payment, Achievement of Specific Sales Based Milestones</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Global Licensing Collaboration Agreement, Payment, Selection of Targets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Global Licensing Collaboration Agreement, Research, Development, Regulatory and Commercial Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_GlobalLicensingCollaborationAgreementSharesPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Global Licensing Collaboration Agreement, Shares, Purchased</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_GlobalLicensingCollaborationAgreementSharesPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Global Licensing Collaboration Agreement, Shares Purchased Per Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NumberOfProductCandidates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Product Candidates</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NumberOfProductCandidates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of future development costs related to Eisai</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageoffuturedevelopmentcostsrelatedtoEisai</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total upfront and milestone payments made to collaborative partner.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossOnContractTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The loss recognized on termination of a contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 275<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84167019&amp;loc=d3e54681-109401<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossOnContractTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of investments, not including unrealized gains or losses on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, held at each balance sheet date and included in earnings for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_IonisPharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_IonisPharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_DenaliTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_DenaliTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SangamoTherapeuticsInc.AgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SangamoTherapeuticsInc.AgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_EisaiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_SangamoTherapeuticsInc.AgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_SangamoTherapeuticsInc.AgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_SkyhawkTherapeuticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_SkyhawkTherapeuticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_DenaliTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_DenaliTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_AducanumabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_AducanumabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_UCBPharmaS.A.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_UCBPharmaS.A.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_E2609andBAN2401Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_E2609andBAN2401Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140388911244488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships - Equity Method Investments (Details)<br> $ in Millions, &#8361; in Billions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="5">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2018 </div>
<div>KRW (&#8361;)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>KRW (&#8361;)</div>
</th>
<th class="th">
<div>Jan. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>KRW (&#8361;)</div>
</th>
<th class="th">
<div>Nov. 07, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Our share of Samsung Bioepis gains (losses)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (14.7)<span></span>
</td>
<td class="num">$ (63.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Collaborationprofitlosssharing', window );">Collaboration profit (loss) sharing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 73.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">166.5<span></span>
</td>
<td class="nump">181.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,376.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,600.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,592.0<span></span>
</td>
<td class="nump">$ 10,706.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction', window );">Percentage of stake in entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Percentage of stake in entity maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Payments to acquire additional investment in equity method investment</a></td>
<td class="nump">$ 676.6<span></span>
</td>
<td class="nump">&#8361; 759.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 676.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity', window );">Amortization of basis differences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 675.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions', window );">Loss recorded on Samsung Bioepis joint venture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">557.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 557.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8361; 652.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 580.2<span></span>
</td>
<td class="nump">&#8361; 670.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Biogenshareofcopromotionprofitsorlosses', window );">Biogen share of co-promotion profits or losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Collaborationprofitlosssharing', window );">Collaboration profit (loss) sharing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200.1<span></span>
</td>
<td class="nump">$ 181.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember', window );">Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossOnContractTermination', window );">Loss on research and development contracts terminated with Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Our share of Samsung Bioepis gains (losses)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(33.8)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdditionalMilestonePayment', window );">Additional Milestone Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner', window );">Upfront and milestone payments made to collaborative partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssets', window );">Prepaid research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones', window );">Estimated additional payments upon achievement of development and commercial milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">195.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdditionalMilestonePayment', window );">Additional Milestone Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ContractOptionExerciseFee', window );">Contract Option Exercise Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromRelatedParties', window );">Due from Related Parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Due to Related Parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative arrangement | Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.6<span></span>
</td>
<td class="nump">$ 89.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_InventoriesMember', window );">Inventory | Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod', window );">Equity method investment basis difference amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technology | Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod', window );">Equity method investment basis difference amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis=biib_NeurimmuneMember', window );">Neurimmune | Regulatory Milestones [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately', window );">Potential Future Milestone Payments Commitment To Third Party Approximately</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AdditionalMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional milestone payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AdditionalMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Biogenshareofcopromotionprofitsorlosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Biogen share of co-promotion profits or losses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Biogenshareofcopromotionprofitsorlosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Collaborationprofitlosssharing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration profit (loss) sharing</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Collaborationprofitlosssharing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ContractOptionExerciseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract Option Exercise Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ContractOptionExerciseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Ownership Percentage Before Additional Purchase Transaction</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity method investment basis difference amortization period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Equitymethodinvestmentbasisdifferenceamortizationperiod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated additional payments upon achievement of development and commercial milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential future milestone payments commitment to third party approximately.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total upfront and milestone payments made to collaborative partner.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, amounts due from related parties including affiliates, employees, joint ventures, officers and stockholders, immediate families thereof, and pension funds.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(3),(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between amount at which an investment accounted for under the equity method of accounting is carried (reported) on the balance sheet and amount of underlying equity in net assets the reporting Entity has in the investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the undistributed income (or loss) of equity method investments, net of dividends or other distributions received from unconsolidated subsidiaries, certain corporate joint ventures, and certain noncontrolled corporations; such investments are accounted for under the equity method of accounting. This element excludes distributions that constitute a return of investment, which are classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossOnContractTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The loss recognized on termination of a contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 275<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84167019&amp;loc=d3e54681-109401<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossOnContractTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_EisaiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_InventoriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_InventoriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis=biib_NeurimmuneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis=biib_NeurimmuneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FutureContingentMilestoneTypesAxis=biib_RegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FutureContingentMilestoneTypesAxis=biib_RegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140388976816856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Variable Interest Entities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 31, 2018</div></th>
<th class="th"><div>Oct. 31, 2017</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToMinorityShareholders', window );">Payments to Noncontrolling Interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70.9<span></span>
</td>
<td class="num">$ (4.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities', window );">Investment in biotechnology companies that are determined to be unconsolidated variable interest entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Loss on equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.7<span></span>
</td>
<td class="nump">63.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis=biib_NeurimmuneMember', window );">Neurimmune</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationAgreementTerm', window );">Collaboration agreement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ResearchAndDevelopmentCostsPercentage', window );">Research and development costs, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToMinorityShareholders', window );">Payments to Noncontrolling Interests</a></td>
<td class="nump">$ 50.0<span></span>
</td>
<td class="nump">$ 150.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Reductioninroyaltyratepayableoncommercialsales', window );">Reduction in royalty rate payable on commercial sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Additionalreductioninroyaltyratepayableoncommercialsales', window );">Additional reduction in royalty rate payable on commercial sales</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FutureContingentMilestoneTypesAxis=biib_RegulatoryMilestonesMember', window );">Regulatory Milestones [Member] | Neurimmune</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately', window );">Potential Future Milestone Payments Commitment To Third Party Approximately</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FutureContingentMilestoneTypesAxis=biib_RegulatoryApprovalMilestoneMember', window );">Regulatory Approval Milestone [Member] | Neurimmune</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately', window );">Potential Future Milestone Payments Commitment To Third Party Approximately</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember', window );">Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Loss on equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 33.8<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai', window );">Percentage of future development costs related to Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Additionalreductioninroyaltyratepayableoncommercialsales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional reduction in royalty rate payable on commercial sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Additionalreductioninroyaltyratepayableoncommercialsales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CollaborationAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CollaborationAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment in biotechnology companies that are determined to be unconsolidated variable interest entities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of future development costs related to Eisai</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageoffuturedevelopmentcostsrelatedtoEisai</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential future milestone payments commitment to third party approximately.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Reductioninroyaltyratepayableoncommercialsales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reduction in royalty rate payable on commercial sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Reductioninroyaltyratepayableoncommercialsales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ResearchAndDevelopmentCostsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and Development Costs, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ResearchAndDevelopmentCostsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToMinorityShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToMinorityShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis=biib_NeurimmuneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis=biib_NeurimmuneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FutureContingentMilestoneTypesAxis=biib_RegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FutureContingentMilestoneTypesAxis=biib_RegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FutureContingentMilestoneTypesAxis=biib_RegulatoryApprovalMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FutureContingentMilestoneTypesAxis=biib_RegulatoryApprovalMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_EisaiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140388894086520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Litigation (Details)<br> SFr in Millions, $ in Millions</strong></div></th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>CHF (SFr)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyEstimateOfPossibleLoss', window );">Loss Contingency, Estimate of Possible Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DisputedClaimsRelatingtoConstructionCosts', window );">Disputed claims relating to construction costs</a></td>
<td class="nump">$ 33.0<span></span>
</td>
<td class="nump">SFr 31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DisputedClaimsRelatingtoConstructionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disputed Claims Relating to Construction Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DisputedClaimsRelatingtoConstructionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyEstimateOfPossibleLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14435-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14557-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118943654&amp;loc=d3e12021-110248<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyEstimateOfPossibleLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>120
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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MVRY 8*&73'V\!Z*36)%3K"^B$KQ<[1H]UI!UN3QH03#*D=T"&GC3U.!LPT)
M!09K&\58%$P3@S529Y@D@SK/6,<GUK&3]2,LG9 15V0K"E'">-/L^1I6@*Q2
M)=>K*R9 ;#.+?:O/$5083$.#OXVB43KLSI8_ HN]="#3&?_DQ#]Q\O_P(T="
M8C4Q\DT>\\0:")'1U0L[#DTC2Q ;Q;QH;!2D)SW2-Z:,/.=/LFP%.91RDRER
MD<NJ:E=@R!6,>6J1BDW>J2V.-S5FUX4-HE%D9LP2025T+!.HUUL4S\G][\"2
M .LU)'VE,E670N? [^ O1/G+3RQ(?EU?D84HP.I^ W-4U!OPG[76A("C;C7#
M;8AGZ6/.?6]#EAUDR#L-!^*<TQXX,^JD??$W\/F7)._8;R#]R3//:P%K[U[P
MJB[%<3BLP.X 6WT'EU6V[DBCG*E%Z)J9,V0'&E*Z#F-S[EM@,.9;>8'!HM$A
M05FO$'MK:5!E?>SJ%0R#+6Y(NCB.3IQWD&$;/7-H+]Z.LT3BT-%<Z"T7=7NN
M#_U\=PV#?R4@)\KO6!B[\$X!WH0L$$AL];4KS#G[WH/1X!V.<V5:,91H@*S:
M23J-3;8VCL:I;V>XC0MC2JU)'\,% 1W4>\Z]MXK4[16[O=>FE/NW)C/$?WE)
M9/J:.89+/&L=6R"X($D\4\HE@@NU41IQ0+0W?M3M_/ZI=J*$C&\WGUVO7UZ1
M0N Y;CNQ:\H2TZ;.,1R+;?I8N,3:Q2P1'/79V+Z#]@:0NAU@U_%/8B-AO>M4
M4/SUF/[M4(!I0?VE=]OM,K&!2[U("M'(I!] $50MV[>E]@P_[V#AV3B)4U,K
M.U@0I?8. <&%?AJ/SH^]6Z1NN_C1D@?EC%@S,/X69P1F#_D%M1UC:BJS1&(E
MX(G&QD9O!ZG;#RY/'7_1IL;E]V< 8M?LO0*"8M2>)I%8S)XI$*\9C?E#UOM#
MYO:'_P":K0@836:[L]CSK3TA J-A$)JX!8+S8X^9N"6""X(@&67;VT+FMH7
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MHV 2)]ZT"UO:L"B-0V_<A:UL6!S'$V_2P#H<) T'R2#EOZH<"[#I<%UQ<C7
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M,<JP* 'Z^Y9S]?Q0!FA^NYC_!U!+ P04    "  +BE51!YK]\.X&  #V'
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M6$U1FVV\TPK>%C!.7US).H=-$3F"JU:61<XUW%SRDM>90'=&<8M^_5;S35[
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MC19P.$ZXRPV'P-&:3&A$K+850#P3E*N2WY951Z\3P[D8PK!E&(Y#["+/Y<Y
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MI=76H49(S4?(%_T@_]6\5'426)K[MN?H.SOD?0FIYP?RVZR.^P#AL$\")1P
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MB!LQ$[<&Q3"QG]\3Z&P>*(9!G/X,OW*(_\13?-W]!-A 8C=0A;10)-=E!""
M!O,$_R-F_F>]I "O/Y6J(4)().=FGUC;EH,28EE_UM[F*:!3"Q%E78T@W0/*
M61N57:XJIEF H#<HD:>>0"KJ%Z!@N,3,<,VE,%'))PE]M44 X0**E6>A(VX"
MX +M60D17):8N6SC@ID +<%NU*9^Y1^2<PMJ=/H*V7.#30"8KR/Y1-!E8J;+
M+W/A@4"'_DPVP RJ&R!(+6E\.<! 9S\1H%E(E2+3"74-H5 @IWBO9\7572%(
M-+&=Z#^KZT" YAW"H;(M7[D"O[@"KXG*QEN,KR3%8VZX$RNN?KM+4&[Z>K<
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M,U](#23&#KP7Y##(<8@?U I00?][D['N<@XKH73Z"?H4"9OA7>VADS=J@?#
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M+1TOP.\KB_"[+^Q@^/? S1]02P,$%     @ "XI542%^A1A>!@  P!   !D
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M-IR,=VR8-ANF''=RQ%%>RR@OSKQ;"D^K88U^<*J\&\%I2T7Y$#V^:NR+%]?
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M< !=YOMR>HBNXCOJS$7<>/EGH21J1 OP?>Z 2_- #KK_M+CX!U!+ P04
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MM+DV ZAL1AEETABAX;C16A6&='*3T2&NA@BY9 N94I#9:I(K[>;=*82.($X
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M P?BUQ4RCM(T >-4G6S^T ;]AZ7#_P)02P,$%     @ "XI542_RI-1X @
M- 4  !D   !X;"]W;W)K<VAE971S+W-H965T,3(N>&ULG53!;MLP#/T5PNAA
M PK;<9PF#I( 2;MB/10HVFX]##LH-AT+E25/4NIV7S]*=KP,6#-@%TNB^!X?
M:5*+5NEG4R%:>*V%-,N@LK:91Y')*ZR9"56#DFY*I6MFZ:AWD6DTLL*#:A$E
M<7P1U8S+8+7PMCN]6JB]%5SBG0:SKVNFWS8H5+L,1L'!<,]WE76&:+5HV X?
MT'YI[C2=HH&EX#5*PY4$C>4R6(_FF]3Y>X>O'%MSM >7R5:I9W>X*99![ 2A
MP-PZ!D;+"UZB$(Z(9/SH.8,AI ,>[P_LUSYWRF7+#%XJ\<0+6RV#60 %EFPO
M[+UJ/V.?S\3QY4H8_X6V\QTG >1[8U7=@TE!S66WLM>^#D> 6?P.(.D!B=?=
M!?(JKYAEJX56+6CG36QNXU/U:!+'I?LI#U;3+2><7=W(%Y16Z;=%9(G.&:.\
MAVXZ:/(.-(-;)6UEX),LL/@3'Y&,04MRT+))3A(^8!/".#Z')$[B$WSC(;>Q
MYQO_*S>XXB87RNPUPK?UUEA-S?#]1(1TB)#Z".G_5.\DU W;W#0LQV5 TV10
MOV"P>JP0<E4W2A*M 54"'W)@)+X;'?X3"V &2B5HILP</MQ(Z@TAJ,W-1UA[
M(!738KU%/52TO[C"O+>/G'V4P3UKJ:4L:LZ$@3-(9K,PI75TD853>**I(AG0
M:)6C,3 99V$&Z44<QG#-):?>*V"G5&%@E&4$'$W3< */RC)Q))_HSN-D2H1G
M,(O3,(&_U3\ZZN0:]<[/JZ&:[*7MFGJP#D_"NIN$W^[=>W++](Y+ P)+@L;A
M=!* [F:T.UC5^+G8*DM3YK<5/6NHG0/=ETK9P\$%&![*U2]02P,$%     @
M"XI548TA\S]Z"   @Q4  !D   !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL
MQ5AM;]LX$OXKA"]8)( BV[(=V]TD0-+T)8MMMTC2[BT.]X&6:)M;B51)*H[W
MU]\SI&3+B9,6ASW<AS@4Q7F?>6:HTY4V7^U2",<>BES9L\[2N?)5MVO3I2BX
MC74I%-[,M2FXPZ-9=&UI!,\\49%WDU[OI%MPJ3KGIW[ODSD_U97+I1*?#+-5
M47"SOA2Y7IUU^IUFXT8NEHXVNN>G)5^(6^$^EY\,GKH;+IDLA+)2*V;$_*QS
MT7]U.:3S_L 7*5:VM69DR4SKK_1PG9UU>J20R$7JB /'OWOQ6N0Y,8(:WVJ>
MG8U((FRO&^YOO>VP9<:M>*WSWV7FEF>=28=E8LZKW-WHU7M1VS,B?JG.K?]E
MJW!V-.BPM+).%S4Q-"BD"O_Y0^V'%L&D]PQ!4A,D7N\@R&MYQ1T_/S5ZQ0R=
M!C=:>%,]-923BH)RZPS>2M"Y\VOEN%K(62[8A;7"6<95QMYIG:UDGI]V'630
MR6Y:\[L,_))G^$W9!ZW<TK(W*A/9+GT7NFT43!H%+Y,7&=Z*,F:#7L227M)[
M@=]@8_# \QL\PZ\QS=OYU/HK:=-<V\H(]J^+F74&:?/O%\0.-V*'7NSP;_/S
MB_RH5E_9DJ?BK(-BM,+<B\X>(:T=[G<BIE#I>HYR2*NBRKD3&>.%-D[^Q:E.
M(B:+DDN#PG,L77*S$$%7GOV)=*1M,.'P3ZAC^1<QL&RN<Q2X?07)Q!YA<Z*8
M";.)7?WB2J3U?I_V^U-V>*V0V7D.X?:(O;%.%EZK7^5<L-?:.G;1TO4CU']F
MLRAS04].I$NE<[U8L^%Q,F%KP8UE!VP<#:;#>(#5X2CJC<?Q^ CK)!KT3^*3
M\'X\#>^'T632CX?A_7 ZCJ=PY7%I="JL9>1P;M*E]TLF[@%MI??7-9)^+I5T
M@E7*R9RENBB$227/:_>RZ7 0]]A/_Y@D_>3G^FEZ,HI'VSW_=&=X!OP%-GLI
MCAZ9XH6P;2DGPQ8S__!TYTX[GC/Y.!-@VB0:]OI/'#*(!LG .X3>3^+)(X<,
MHE$RCH<,J,C<4N#/".&55$A25H3Z%U3_>](@VLDV3]9*.)^8WRII0/M48T>6
MX,W!)(%^=<YX%@=)?[3=BBA"I?" GZ\CBD+)B:73.#D9()H[Q,,DB9/GB*7R
M5I9&PEY*I9H=IP.L%-C/;/Q_\ ;:%_4VZ\4251HHV$&?LKBQ\$DY@S!4#;RA
MH2)H=&78]:>;GWA1_GSU5-1_9UU_^K^QCD(]_3'S4F$<!I.6;35W_-.H2CJV
MDF[IA7Q:HKNS9,:LJ[(U";M\U^OU^GUV>'OWS^-^KW<$E M^*+6#1)0U"E-P
MU]@C,ZE+[I8R9665PSN8<]A<SHRV$JBYPHLE6P$M,[09^$ZJRAM?^U::C'VK
MN''P(;B1"_^FQ'K1UQ$3#VE>95(M]H!_M"V[DT$KKWSE]*<GVZT7R^YD BC:
M+=G>"[0_6'5;T+_;@O[>3@!.U*WR=9T?UJ<_\M[[Q<J-FS :&$'C++G#T%#G
MC][]<7MQ>7/-YD87[$W.%>4+QD)JL<(H[V:DPZ\NB^%[F#B?RYPRC)CZ\Z^U
M*;4)\2CS-/)>@/D"0QX"6O*U;ZZ8[H#TD'B1?Q6&\+X11(HKZHL%H#\#/5KP
MS"+G*,L@94/@N8>&3$:0(WF)YG4/!7'NR^</;VZN[_YHG/PYOHUI_5OJ-.50
M*-WOS EQJZANMA5W65ED)WHD@C"3P2VV==0(/ZZHNK#G2#8&M2J?BW*A I=G
M&VS3");<L978YC1*"LE1(\2LT2'=ZN Y+3F*1SODDX,(C@M.*T5D"N_,!;=R
MAL"Y-8,(4C&K8]C*$]BNJ&!"[6Z-FW$$**5Y">-1:UYJ0Q(0!#<%A=G>&*'2
M-=7>$O4(W")!\[Q*717<%K/?"<WNZ6X#UU?$*>6E=#1-!*,W#M@J01#5JF*N
M5(6<1DEQ/W\U0:;QBWRR6@H%!QN&'Q( ZJ"/)=M2:1!^ZX)94F7PDO/96=51
M(!>EW)@U95J()*3XE NQ*JB$O-MG9$VJ(8P#?&)V]Y3T,2[O-J8->.^?,*-V
M:9,&]RAX7;73#T6P,+RP.\E#=FJEZGOB1FXKX%[@Q]N["&FMH/\"D1-U7::B
M<I0[EKW7.6&H]2# #EM'C[RK+Z7&TR/ ^"@J=(=4>H[OBME[=GAY_?$H>*?@
M?VI#N5B[M$ZP[T 8%"6;?JF *G["1HR-F*UWC-[G$[(<0"4V(WBK/*D""$,>
M_"O Z,&XU]M">LR^R ?M@)?4G*YK] XPS5".4+HM_;YU&/9>7_;&PZ.(B% Y
M2PZ(GPFX2E68GBF"&0Q>VP:P:/:5F\86^O; MVTI[/=Z-(D5N$EC7\'W/%](
MS@[OWGT\HL2"DD(M^*(]&'A\?(NKFH_BE:D6["(#!TG70Z_%X=NKBR-$9<%-
MUB!N)@C/FL@]5M+?J%:<@)P0AH?A2-G0;WR3*61VC,H#,J2X_7EX@NZ4:.#9
M=B"\HLES37WZA/7%Z3T9O._]F3:=,:37;GA)3;@A5!F3UM<LV2#GX*H<8@Y)
M@"N"5IS?+=WXV8M?M \C]A5ZVZ8G14]3TT'_9+R=\N/67?%MY>C*?O%HYGEZ
M(2:S6_D=R!Z/2N%R=9QCU-@WFC8)IL2#PUFX.-PPX3+Q0#-,0/J9V+D7[UYS
MG[TE^Y_#[002QKXP[='MZX2*#H?Z^!F%9<)H)/;+P78Y9$E2+T=8$MGFVX</
M_G8^(#@F&+B7&:4F,WA%5JZ0SDUFM)H"Q6K1L*HAZ8?M:W2(]GP).&"C:#P:
MX\;YF\_GPR3N'[4H]K +)*-XS/9]I.FV/HP5A,7T^8_F O32\(ULL[OYPG@1
M/JQMCX?/DQ\P#*,^62[F(.W%XU$G3(?-@].E_\PVT\[IPB^7 J.<H0-X/]?
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M;H FE*4)>+\R,%<[H VV_PWR_']02P,$%     @ "XI540X^!XBO"0  'QT
M !D   !X;"]W;W)K<VAE971S+W-H965T,34N>&UL[5EM;]LX$OXK1"[8:P#7
MMB2_=M, :=KN%KB^H.GN?CC<!UJB+2&2J"6II-Y??\\,)5E.8K?;+G!WP'U(
M+%'D#&?FF8<STOF=-C<V5<J)ST5>VN<GJ7/5L]'(QJDJI!WJ2I5XLM:FD ZW
M9C.RE5$RX45%/@K'X]FHD%EY<G'.8Q_,Q;FN79Z5ZH,1MBX*:;8O5*[OGI\$
M)^W QVR3.AH879Q7<J.NE?NE^F!P-^JD)%FA2IOI4ABU?GYR&3Q[,:'Y/.'7
M3-W9WK4@2U9:W]#-F^3YR9@VI'(5.Y(@\7.KKE2>DR!LX_=&YDFGDA;VKUOI
MK]EVV+*25EWI_+<L<>GSD\6)2-1:UKG[J.]^5HT]4Y(7Z]SR?W'GYTZA,:ZM
MTT6S&/=%5OI?^;GQ0V_!8GQ@0=@L"'G?7A'O\J5T\N+<Z#MA:#:DT06;RJNQ
MN:RDH%P[@Z<9UKF+UUDIRSB3N7A36F=J^-O9\Y&#:)HPBALQ+[R8\("8I7BK
M2Y=:\:I,5+*_?H0M=?L*VWV]"(\*O%;54$3C@0C'X?B(O*BS,V)YT0%Y;\I;
M91U;-Q OU<H)62;BU>]UYK;B6L6UR5RFK/CGY0IN %;^=43II%,Z8:63[W7N
M<3&?4B76.D?^9.5&.+G*59-$V1_8LJZ-6'>:I+7*6:#(I<"):^W2:Y$K:X5+
M92F68Y'(K15KHPN,*-PY15.JVL0I,"ZR,LYK1!(7(I8V96_QA8++;F5.EM!#
M4AYK!+VTF(TKJ_.,Q"5(EAQ[PE8)G/:9>/*F!(+S',EHS\0E[PEA=JI8*=/%
MNGGP4L7->$#CP5)<Z:)0AFVL9(4GIV(V60Y#_$:+R7 BWM\J4U(2@BQP"2N,
MZ@R2&Z,4^U],9E/,CF:+X8)0J[;PD[D!_ZWK,K$BG(\A-!C,PL5P*JY3;=Q3
MITR!7 =J[ XJP6**"<%T"6F?M,.^3K%LBN41KL+!=!(, T'!BZ4Q6XH='%?[
M8'B_[5LT:-Q.,V4<FYK]#]U [D#HKS-O((J'-E'T[&%+9%49_3DK" 5KF1F_
M3Y'@SVD""(9ZRW>P&HKWL,.K8E@JGU ]V1L<#%8\R35PB;!+0_N.M6G I2'=
MD-VZ4.*)^EP1D,X&HL3>C\/+.OSXB,*?7L)0/)(K=I<L+*^WW:0E@@?[?G88
MH/=P7, O$)V(GPQL;/Z_)B]>:5-I0TZ]Y_!GXJHV!EL'3I:S""@"<H"B4_%D
M/ S.>'0"=+[3Y=.XF3F93X=+$0&:?LYDOAR.Q4^,"O+"H^*C!8&3\/S#WQ9A
M$/[(([,]P=%\ACFDOILSGW-J&+?!N<S^\6%B;D%>QS?D_T?TC2&[E=+^CN_I
M"Z8A1F@4AH1GN(]@B$^@^Z'IX8@R*IHNV$LS;(]]-3GSX^RMMT=@"$#UMG J
M%M-@."=)$?8!41.()%F+&27](0KZ:R,?#,;3.?-7  ><=@[S3Q9XTG?;+(HX
M_N-NWBR:8>0+")B.0TP:]Z(['4<@J+[H:0!$8<Z"7!J=\?WL&^,_?R3^\SUM
MX8SPV&A# .E^]G7Q7X*YQQS_L8__W,=_R9S[9^(?!AY)013"=,@*X%D2%D5S
M8GU?HA(*KE#74#U08WMO.^(#/=S*+"=E3U$9/[W&B>C+BEXM05P$ZF9>3?K$
M2AZ5'7IB;5U[)!QQ@-Q3:$GA:DN4V&VOX>4MDVS'>5!E&TH\QFI?A_E7G3D[
M]#\V]K)63-^E$ELEC=#&EQ^$[6CJHTA7D8_"8#H+?2;@BJ!!Z^4:I\U.A$N-
MKC<I2IU;/V)1Q]"JQ7(.B >#,)K0>8Q?@OM.0F]!,)X#:_0_$,&<<I_^+[Z2
M?9AE^CS4(F^'30JY1$)2WG3A^*;8RD.!(O \"-- W,F]<SS?BB"D4H"*<EH2
M3)J[ <Y?6RGNAO+M4'PP.E8J::K!7A(]!N=J;W*OON0*0^:^N#EF*>9!/WHF
M.I_11N:,%U\ET$-?*!R#,+HQ+EH_I:AY]OJ.>^YJ)[Y#/7ULWC[$V<D,_=W5
MAR^;S7@&=I?$3T' 2)D.PLF8SYEHL)@1]#[N&TS$3Q."$/-#(*E[WK@!'+<\
M:T[\)^&4SDM/>^@/$.5-%HM>9W,XNP^ AF!I.TE9)TG@]')P>*895RBM*I-1
M!<:5UDZ?H[RA0)XNL;F@]2*K.XV6=&(U0_NH US3+$XYROU6HR_[WK'SY[H-
M7YA^P;1&L]U3"RT/BUB8'2OC$#.QRK13<5KJ7&^V[!E9\@&SL\BH-;UTP*:H
M"VNVG60V1E!KP_IV)K^#.#$?^+KA5SX>WBI)\YIRWE?@J/$/&+YK_785\4#<
MX@<RT'I4&7&;[P/NX$[%.8%;97)N2O:<S@'Y)@]PP.B4/=8.^ (=]B/SK6I#
M^H4XK9L\=ISPK(8RNB$W]4A&$^8])0*WQ"&@PZ:;(7UMV]0<>24PS&*O9;G!
MN<R-&5!LG8YO!L0]%+S:DNM7]!IKV"Z",0:=6^VRV"(1XR'^B<MZ4^-$Y[R[
M@P^X@^-.3@L)V3F8GHK#-E'R+*:P[GHXW[Q[%4/*Z4H:KA  )GM/ !2TUB3W
M^3_J\M&FTNQ9V[>0HK!S'VV;HI3UTT*0WAQYF*TSS\92_ -=:"["P]U?Y_(6
M.*G.N;=%JYMI/@:<R?CEG </E!#J&?QHR232"2TNE12[1?X]A#&\#=<KJCRR
MU'J-S-N#ZS&M<(%C/':&4@+L:K;:<B\.E%;L;: I;OMX[_]")RKWN@NJXVRV
M*>&D6)(LBQ.L\IH:)G \#TM8$8.:.FJ.K7KH$1KT,2+-2MSJ'&IS^+;E&_AL
MQ;&O*^P&47,:,Y'PNZDDW6: @C2[;!V*WX"XW&K8J!B6)>@#F^ZJ%A#^#<X[
MI9ZV[R $=S0(*.9 M=\QO?CE5ON0'=KG>!],90/#O]M](')=C&2[S4!TB=AF
M*N<CYP]E=-],TK%&T4MOLUP_@1^8*3:J1(KF2(<4=1GXR?6<A-&-@=&J>;?5
M:H9WJ':029*1#?!F5OKWWQ1RW9Y#>XF\>[_4R]Z!J'(F.GI?[JD^ -=?[9;>
M>D)[SP?=1Y6S-)MFU3<R_[ CL3XW#3IR>JU6IJ;6YGOIJ5'#0K&KLGG+SL\H
M/G38$2Y:V@+%EU;Z20# )0"==YLX1&'AY!$*>XRE&\9J"*A0+M5)'W)WD +N
M_@Y^Z9\?W3>%!N^]69XH_D]&_TMDU "*7UC,?_Q+.*G%Z'\)*>VE['^ E![[
MEC+J?;0JE-GPISER?ETZ__VJ&^V^_EWZCUZ[Z?[3(9K6#;53N5IC*?JCZ0D0
MPY_C_(W3%7\"6VGG=,&7*8Q7AB;@^5K#"\T-*>B^B5[\&U!+ P04    "  +
MBE51$>VP+78,  "!*0  &0   'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6S5
M6OMSVS82_E<P/O?&GE%IO?R0FWC&=IIK>FG2B=OFAYO[ 2(A"0E)L !IV??7
MW[<+D**>MEK?W=Q,8DEX+/;Y[2[(5W-CO[J94J5XR-+<O3Z8E65Q>7+BXIG*
MI(M,H7+,3(S-9(F?=GKB"JMDPINR]*3?[9Z=9%+G!U>O>.QG>_7*5&6J<_6S
M%:[*,FD?;U1JYJ\/>@?UP"<]G94T<'+UJI!3=:?*7XN?+7Z=-%02G:G<:9,+
MJR:O#ZY[ES=#6L\+?M-J[EK?!4DR-N8K_7B7O#[H$D,J57%)%"0^[M6M2E,B
M!#9^#S0/FB-I8_M[3?TMRPY9QM*I6Y-^UDDY>WUP<2 2-9%56GXR\Q]4D.>4
MZ,4F=?Q7S/W:,RR.*U>:+&P&!YG._:=\"'IH;;CH;MG0#QOZS+<_B+E\(TMY
M]<J:N;"T&M3H"XO*N\&<SLDH=Z7%K,:^\NJ-LOI>DF;$N]R5MH+"2_?JI 1M
M6G$2!SHWGDY_"YV1^,GDY<R)[_-$)<O[3\!3PUB_9NRFOY/@G2HB,>AV1+_;
M[^Z@-V@$'3"]P5Z""IDGX@>53'4^%=?D(;K4RHDWVL6I<955XA_78RR']_QS
M!Q?#AHLA<S'\T^K>28="]=(5,E:O#Q"+3ME[=7 %-X43YN*VLE;E\:/ P%S:
M1-S"-"2!$]\VPK:5\*92HC2BG"DQ3<U8IB*7)<EN)L)45@ "K*0@<AU1&,O?
MZCFK[E5>*:_)L!#DU0-@P]$PR%@5&PNW$#J'3S-SI&2# RU.E3D?_6MT%XG$
MI*FTD?@% _<RK9B'I\[(E"13,?T6%2>T(\J(<V@&N#/^ BP@26.<.<5&K)\$
MI<6UTM2#GQ4X1;D(BA+$O*5]&;QCBF&BZE1-IB/F2E3XO49K$@P0-P8 D=3$
M7^GDY8.$=,[$&E\30$ Y$[)6=:UIHAY+5[*<I;(YFP3&>D(]D7C[-%_$SV1"
MZI%L6H1?J;(QQ*YCD*F_47$8[=%H;]01,YF(I K^05M[)&1_*#(/"+2-AWJG
M8:@#CEVA&(_31[8U*;/A9281'F.E<L"K ]^L$[ %X6=B@C0B9G#B(&^5(Q>E
M^E]8,D4. @<6&G;D%L;[54N-WFS/,=-,ENRZ.H_3*K@N$?-* N.Y<EBF7!D\
MG$[QRV0<5UF5,M?>Q6.3(4IGE,KNF:3)E#@B+H_%$;Q367)>J A"7G^\?5<?
M5LIQ"CG&E#J/(_%I65"2OI9T N^.9RT!ZK";YKQ#YPLOF8,1)N]DRN%56)-4
ML'PXM5'+6)$;L:X3"J46/3H;RS?$8D,]C#R+*H%#)#ZW6!8R35<-3K,IPD1/
M=!S<;6)-MJ?"B?6)U#; 2PT%T ,"TMNZP3A=*PK;"8*%1E"PX!4=@E0'"=EO
MG$EUPARX$A\>5T$SG,W^-)/.N[7. -VT=OS(]&ME8)]'OMR$T&X@\+D^.P?:
M"47PX&'"D%MY[;7PXRE A5E\E>:-#3T#4,W<78H/-6?7F:GR4AP!'C.=IJ2N
M8W&]#3O\Q!IZB.\K:\2AZ'?.>^=1%]]ZG8M1/QJ*&PNHA?4+G)*(LSXF__J7
MBWZO_YVXFVM'EI=Y+ ;#Z+29^%$6,J< ?X2.^^=1KYFYE;E,-/*,3PRB?QJ-
MFLE?3 EYGJ%@XO/B[ PG+O@D:\'5OBWEPPK0M)UL;^AA,[:Q9S\?)[]EJ=3O
ME2X?J7JF,AA[<]3Y"] X[/6&T5EM0/8&6A" %/-="-O,[ID8ED'^LT<$RK_D
MX+O8@,>.$72J+%.2]IZ+!-KS4"[R2H<VSF<:J'<X&L+6]>Y&UX$^(:$_V6/L
M5M*]?D/:)^#\44CV<K>_!?Q!35J0%&I")E]0T1,VT'P3A,9NS-J?.2<ZG00F
M/6K4U0!'+J-01=%>2$N%*_OT^7<B1OCK4ECMOM9I<,T=V]D"N(W&B#YI0HYU
M2FY#F"BA8"+^2"RK!Q57)<&@:W97<#,S3JDN(A"(MH/ %C]I\YKHA, /'0YD
MTL@!CP&@-XA0UT2[X\D#JL<OTF_(J0V\M;+Z,W%VN2B9A7I:M^KI_1/$)=5H
MS,HO,ZO44C.UHLH/")V_48">'+UG#S_>-/3>^!3I-<]8NV'H4^V"A^)H%/6.
M\3DXC?I+XQ?1.8UWHPOQ<3U3]  01Y@[WC39!4#2_UJV#Y1"__NB#7L ET-Q
M/H((;<EZ49<DNX# &R4;BJ,^+=DP"9&A%2_X.\ZV* 0_46?P5*^%J.;Z=BE'
MZYH$M0*^05CX&Y2W/._FLFC/PUN5+:$D,3;6!C='>G0R]F4,=2[(@(@B<DL(
MX3O;M8/K6H@"E0$*9:'?0TC)%9EQ'";-0=&*^'?$VT('J [ :!ZN8!A6&<J<
MJY"^FS#N1Z/N-W"&7$-8E!C@(4&0+[RC=^HQA%NM':HCU;@:OH6<3JWB?JTI
MJ#R@<](Y.S]%51'21B?D$DZ\QFK8C=$'J<(#7Z%I(M_ DT>8G29BJNNXX;/?
M"K*U>M,MJI%E:?6X8B1;Z6:7N C8%TMK'\DGEI!S$]W-15IG48C( KW"@R9T
MAFX.^]&@2;M6^=2XS,^V.FB7MKCE_DD^^F">M])UM3L2.GR_8/(O5=[R-W9Y
M:5.J@A*5%>V6>ET)7+94:>DA'4TXU4*T?$7T04OT28"WG. M=+UJ [P%!_9^
M)A>=#U<'7$V87'GG;,1L=5%[II2(L?-=?J]"R?&#][C-L 25OU5C6TE+>D<I
MM!IG4GPQ^"( GWPU)!%:?*37\IW,7 6:-]J\-U,=0P..'!0U/!V%8,12U!2=
M]DI5:"@<Q!.@<FJ*#L%4-:&B@DX "B%'?X448VV<AKI1NH=FU7O)CQ4T#G8O
MF-T'96/M@J,8;VAT#] ^#6QCGS$$-8AT >KFN;+@NA" _1@K"#>A_A6^0^NY
MY!7 DV^XC5\:'8ZBT3<^%-V,JM&BL@@1'-<":78(<H%4A6N$#\!<=AV6#\KH
MB*H@K$>!"94R$A82]=+YZ0A)>!R<\<Y4,,??4<9 YW,,' 'HSA;5-9>F:]:*
MQ$<.KL99ZNL.WS]0/;<B/OYQ(O$AO]3A3]**RL*E%GJ5K>WW:EOHC%4Y5VKM
MII"]9)4XZV8]RSZG6'R1JS)_*281X/18A/R_OB!CX*E1XODW7]0NM8SC<\?*
MA<D*ZKK"E,M7C'LW,='_97>[:%X'[>8U7^]]7[:W96DV)?)69F3%!9VP21A$
M"'7J-H(7D\,3 -'A<YURU0+EAV:E)E 0H/DZ@556*RFDC.-.<)N]+ZN:MABQ
MDZTVB_LYQ2JS_UGSM^\M!DNF1ZDR>B%C[]5.DNHW!>\39IF@^LQC]+\M [UX
MB_B'6ZL-0TS'&XCH8&ZCU-1TH2&DKJM/5WK/W]:-^K2+FK*/&[V=6]01$48[
M][(-Y_]$4:=\'3H\A<#/WC.(>MS/]K;KJ,^M,-4#I".9)#HT1CKW3_@YFFOG
M1(9%I^<'T440GGFP6*WY?"6'XH7*&GHY@*MIT3OOH!ELJ-S[HLXS]ZF%=+X*
M+.ML^-R06*3KG8\\_7E;'@!_ID<-SOA*P=<)'H*>3F8HR-#&4I?(ZEAZ"-8D
M>7X>I9R7<*G.63N ;\#:?53=U<N4FV7_E@9J+AUNVNJ[!+HQ4P$#O2\ 4:G/
M)80*W<ERN1E:PYT-LM^$T@H*SY- ZJG\3F7LX6C47736'G_/1X/HXH40^,-2
MEC]OTZ6C>H/H?%-;6JX46YR&=O1@N[)JW?*5#,5<7#RK^6L+TN'C9'CTMUJ<
MK&6PWA# UMQ6+!,*-5]AJ8]]1+<;2'MW1Q^C30*3W_DW;WR7OSD:9CI5C>.%
M!)8LUK9O.>7R,W4(P/ZVCA/KU]1<H">&'==,)G3)TCI$0@OAU8Q4^[MHK9ZZ
M55T*DMJ]%[?WS>-4_S0574*5^JOF,4M!/E[Z"^=$(WU;;H)\#?,T:_[6B 79
M6" LZ@.W6B<1*7Z% XTFX^P^8C8O:+2"=+.UZDL<9FF&MNWI:^S+E8=[-^'H
M.X:A)K?M_<SOEI[JOB4C;+B(N,2V%7=H^YR'<H\_96T-2GQ#^DL0L[CP"$\W
M>4=821=6]6._][I^S+'EK.LXMA6TLWB5I2%WW@7$4 'C^4E-/OV6B^6V4_3I
MVKF'A1ON85Y :B!$CWEX2\[T&SO31M)_1M!:6:2X76GT#PK01['2_7.6 &/T
M'';3NUDGK=?B,F6G_/*?\U#DWY!K1IOW"Z_]:W6+Y?[EQ)^DG5+"2=4$6V']
MTP.D:W[AS_\H3<$OV8U-69J,O\Y0!BE+"S _,:B'P@\ZH'GK\NK?4$L#!!0
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MN'3$QQJW/#+! -\KI=S^)208[HVK_P%02P,$%     @ "XI544M85=OT!0
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MRYJS;R!+K1T%SR;*,]QM9<DS=%]$D>!',F*- ,]9=D"5)%51Y8+!O(2:IG.
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M8ZR9%1R8*J$4LG=8 AZCVL#:?YQ)WDOF-9B%2DNZ5_8:J$;!-0B?&X-X<B!
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M&<Q/D('#T\[*"YEB>SXC.H24%?:I4I!!LETY[S$A8F6@BD.O/H9C>IO"*O;
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M+%&#&WT$4\-J*"<U!>7.6\Q*K/-7/_F5L.S&:&>4G',OYNP[J;DN)5?LSF,
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MN\?XTS\Z,7^'!]T!_A[TAMV#X$RE4YG RYK8MFFE-I*1(E'^9,3KHCD_VGY
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M]RBAD;K+"HF0XP"48GKZ!/:0_XD*[Z/[U*VVC0>$1BTM\I.JH;-K68:U@/;
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M#*<0O/^MB'62X_%'=7#*.8"Y3K)XF7]$UWK07[U>UELM'VIK#]?/G;CO=WZ
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MQ@Z\%^0P2#&([]4"F4K_%R;1)<24<U@)I>-OT"<CT^^I3U4!G0JC9K SSM,
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M"YC0*EC?O,-GMJH13B*T^T>I=J 9GBQ$W;O^;EJ)!NI;%<]:4@C?5FDN]N7
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M=GFI=.-!XK.@0<3]N?YP;P8K[ZG[C%D^;[M M\8EI/+DS@E]2L)L,G;<\]9
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M%-4I!H/>9Q@!WE<6E)/&F<,8!B1Y=]UTMQ[M-Q)Q7S6B$-L8N(S58.6S\,'
M.JVV.6 HBS5)!C<"G&8 5NI>O:#6CKB#FA49XY.Y^:U ]X709F_Q1QODLIJ_
M=V]:7T]KN#6,Z ,G/!9DE"\7:^O<PM3T?IT]7G^_3M$4#!W84!OWK/X+@[X9
MRE'];>:3'<[%LT4I@[:(ZY=M];>I$ML=#A\R)-C:3G\LI$F(-JS_;VC%S^#)
MJX9@^YT_3.'A(_WYC1=**G^CTEQM_L)G*'_8TCXN?QYTK>D;<Z\2,\72@[VW
MK[?D35S]"XH\_YG+Q)6P'/\X![TQ!3V ^U,'GA-^H0.:OWOZ\-]02P,$%
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MF"9JBA<>(FZ*'V.]#RJZ;=G5>=QX-BJ_QWKRK/&&/Z,%4/%=WGM69+N&[2Z
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M28?:;:#UI5+VB7$&^D?B_#]02P,$%     @ "XI54:?=.<@2!@  7!$  !D
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M9(&(7A#1(7<?M81!.]5KEO&K$42EYNJ%CV9/!2?&'B"98]P1.U09(JHFCFU
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MGJW]")=J''N^N(>>?79<NRRGOO4OH!6#OOH4=T4'E1=T4-F>X6_V)YV!2^Y
M%"5[BI.! VXK_$FK!R[BMX?=Y:8B7WE>]1;ER"CH50>Y5Y+/92;=PZ&Y9G%L
MULA.M>/LW(VP]S J$P6>3*OE+SA$YRPKG=+K2$1[7HB!I-(=K*>*&N4J]!A>
M$)D^>#+5NOZ>0+?)HL05*.I?R;XQ@ @EH?M]*P%@AT[6G;U7[5R8I?^@8*$G
MO(H4;]U5:_7-8E:\JN^&%Q\\7G.SI%*7B05,L?HX[YKB(T+QX/3*O[C/M7,Z
M][>IX(B'!J!_H;7;/M $U9><Z7]02P,$%     @ "XI541,A=4@6!0  @ X
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M6V!W#0^"0(T#GE".F#^F#++Q-6-GTR).(;L>Q05D-VD\@OOMEJ>'MPTD\_P
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M+97%AN?) BLU:\> [VNE[/[B#!R6]/E?4$L#!!0    (  N*55'H/I;!> ,
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MAS8?EEN\JVR\ /Z76KO#QAOH7^KY%U!+ P04    "  +BE51.YYYF\H$  !
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M&5+"]WZ=4:5^4C15R*#ANSHZ]25TZ.C(=XF68LCVQ9"U%L-EGIL-V=24H@T
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M/!0P*@"C5X!>&\ O +Z9W7PZS%PNB"+3B> [)'1O8-,/IB ,&J:0);IV[Y2
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M<FMS:&5E=',O<VAE970T-"YX;6RU7%UOX[@5_2N"L0^[P-;F]\<@$\")-6B
MR2)P.MUNBSYX$B4QUK9229GL OWQE6W9EQ*O**$:S</$=@[)D$?W7/J(5Q?O
M:?9[_I(D1?3'=K/+/TY>BN+UPVR6/[PDVU4^35^37?F;IS3;KHKR;?8\RU^S
M9/5X:+3=S!@A:K9=K7>3RXO#9W?9Y47Z5FS6N^0NB_*W[7:5_7F5;-+WCQ,Z
M.7VP7#^_%/L/9I<7KZOGY#XIOKS>9>6[V;F7Q_4VV>7K=!=ER=/'R9Q^B"EE
M^Q8'R-_7R7ONO([V<_F:IK_OW]P\?IR0_9^4;)*'8M_'JOSQ+;E.-IM]5^4?
M\I^JU\EYT'U#]_6I]T^'V9>S^;K*D^MT\^OZL7CY.#&3Z#%Y6KUMBF7Z_M>D
MFI'<]_>0;O+#_]'[$2O%)'IXRXMT6S4N_X+M>G?\N?JC6@FG0=D/WH!5#5BS
M0=L(O&K ^XX@J@:B[PBR:G"8^NPX]\/"+5;%ZO(B2]^C;(\N>]N_.*S^H76Y
M7NO=_DJY+[+RM^NR77&Y3+XEN[<DC[[^&=UEZ>/;0Q']N$B*U7J3_Q3])?IR
MOXA^_.&GZ(=HO8MNUYM-R6Y^,2O*H?<=S!ZJ8:Z.P["687ATF^Z*ESR*=X_)
M(])^$6YO ^UGY93/\V:G>5^Q8(?WR>LTXN3GB!%&D+_GNG=S:K'I#!L]_K]'
MKRT&/U\$_- ?;^EOL<Y7S\]9\KPZ!&_Z%%671?2OSR4TNBF2;?[OP$#B/) X
M#"1:!CI=85EUU6$7TK$'=>AAKW/?+CG7:DHO9M]<?A"8(J0)6QQAVH%1(BVK
MHV*_,THT45-UQM6F*\_3E<'I?GHKU7=5)(&54^>NU+@4Z?- >C!%QQZ,LUQ6
MZ:EL,.2CRH3"IJ+!D _C3!IGZ8\483!-G=YJLS7GV9I>#$7_C;Y,[Z>!];/G
M'NVX1%$"TDT&4U5UX:Z;,F+:"(#K"B8=F!$-T +IBW'#FXS&&$XPZUP@]0D[
MN8KV96N9Y,5^<7]-LTTH'U &G;.1B0.YI7PX<=Q?Q'*M>9,X#$:\($-@1LOF
M91!C,$&GMH4XD'T:UOV;79%D3TF6[D+K![)*Y<A4@>Q2-9PJY:V:T,++6!7,
MC3')29,HOR\J&&V*:XSAI)'.]5&?,,@_#>L_4-6MB11DEIJ1&0/]I78X8Q;+
M)GYP(3!%FK % K-*^I3Y,$J4;J.,01Y@X3Q0HZRO,#)074;'Y8Z!!C,VF+NJ
MBWJ$J*EI<(?!E)WJ!G<5S U*(9M[#P0DJ6FA#;( "V>!O_UV/[]:WH06#@26
MB9$Y O%EX4UM+XZDM_B2*F^'B,!$F>-4DR,?1H4F3EJJ:,)PU+8&&"0!%DX"
M%5/=@LA 9ID>F3#07A;>X_8BS/A*1_QM8@5S X&IIAPB(,.\D/('U)JU4@7J
MS\+J#U3U%4(..LO)N)QQT%P>WNGVX:SJHK;UH\Q+8AB,$2_($)@2PHNQ"B9K
M,(VSQD'W>5CW/\UO[WY;SD-+YW@9(YL9'%27#[<SJBYJR^]G*PSEA=\"06DS
M)=;]U^0+:4*=CNLSAR3 .YR-(V'=BLA!9/G(#@<'\>7#/8ZJ"_=")TW2.B&+
M;D@<A-0G")+/.VR-,SV]51 4EH]L< @07#'<X!"(V>#'%X;RXPM!=<47UJ0U
MO@3HOPCK_^W]V8U?HI.O]PM"*T8V.03HL!AN<@C?;Z#6>%GG&L$Q6GX3\PCT
M<8HQV_PJ'F,X+G0K;XZ_'<X("&_=&BE =L7(QH< .1;#C0^!F!"<RN:7K&L,
M)Y3TOD@C.$&UOPG!<$RY--<G#8E!A!,#3E]?#16@SV)D.T2 7(OA=HCPG0E5
M+F=S]X_!K,?. H$Q(CVUC5%<J;<M+$I(&S*<-N[O;GY9SO\9VDY*4&(YLOLA
M09SE</=#^K:&*#EH^+W7"$R6^M:\.R9]8X-*V?3SD<Y*%)^V." 24H0,IX@3
M4=T2*4&!Y<A.B'3N[@UW0B3B21CF.2$(C''EN54(3#'C118&LZ3U;B;D!!G.
M"0Y??351@O;*D1T1"?(KASLB$G%$*/5V)BC,O_^"P"R3S6UJC,",XFW;$@E)
M0(:3P%7\2WPW_QSR&A7(JQK9!E$@OFJX#:)\XX+Z>_MK#%9N59K)"X'QDH'F
M#@2%D3:B%*0 %4X!)Z*Z%5&!RJJ1#1$%XJN&&R)5%Z$OUMV013<D#D+J$P3)
M5V')=_CIJX#*.>(QL@.B0&S5< =$(0<XL,#"SGD@@84<X, ""X.U!Q9(O@I+
M_LWM<OYY$11 4%,UL@.B06OU< =$^Q:$5!Y-"$I8[QL8@J**^8=Q$!AO=>\U
MZ+T.ZWW%4K?Z:5!4/;+CH4%H]7#'H^HBI'[=D$4W) Y"ZA,$>=<=QSC.]/05
M/PW*JD>V-C3HK!YN;6C?8L"""C$BD*!"[ \LJ# WI3VHG -]8:W_]/GF'_.K
MD/1ID%$]LG&A067U<.-"(Q8"<A 1.7AA_'.(/DI3;X>.H$K&6PY(&=!Y$];Y
MBJ-NX3.@I69DX\* QIKAQH7QK8:F\'5#%MV0. BI3Q"4W825'>CI*WP&1-6,
M;%@8T%@SW+ PB!/AAQ2"0D(*02$AA: "(04J;\(J?[5.\_5VO5EEH5LG!F34
MC.Q/&.=0\G!_POA6 2/:\R<0&$6.V" P:4TSD\483+#60]B@]:;#GP"N>IS$
M!E6U(SL5%M36#G<JK']VHBF!W9!%-R0.0NH3!(VW'<Y$C:*^,FA!8NW(+H4%
MQ;7#70J+',A P@N!8>&%P+#PPF#MX65!]VW':8TOM_-%O+P-K1[HJAW9I; @
MN7:X2V$1P\ [>HV"3),DI*QE2FWH[C_2A-(VG]V"_MN.XQL57SVTT"E+&;TN
MQ2U,^1Z5*7[-25,.>V 6/3!Q&-.8IE..0CKJ48"GWO4HQ"E((6-7I!"G)(5\
MAYH4XI^;\(,-1S6C#4-UA1O6ICW>*''J4TBOE/!SM$N*X((Z-2ID["(5XE2I
MD.]0ID)\@X'M[PMZ90\8T%CAW8[$@(9;[W!I? +6Z\MD6T$8<:I52*\4<2"N
M1\$*<2I6R-@E*\2I62'?H6B%(#Z&L-[MW^L3L'9;7Q._G _Q,@SQ CI&@5:Z
MQ12-@CXG4_2K83SQUUM&:T6#(QLAU"TBI,.MD%,?M7IC:IFOI&U +Q 1()?&
M^]X>H\"22\]EG#F/%-@FV?/A60YY])"^[8IC8?GYT_,#(^:'IR0T/K^B'ZXI
M\OEB_X")PR,,H/OCTREN5]GS>I='F^2I'(I,]\9Q=GS>P_%-D;X>'FCP-2V*
M='MX^9*L'I-L#RA__Y2FQ>G-?H#S8S<N_P=02P,$%     @ "XI546$"\EA=
M!   0!0  !D   !X;"]W;W)K<VAE971S+W-H965T-#4N>&ULS9AM;]LV$,>_
M"F'T10LDDDC)EE38!N*DPP(L@!>O'89A+QB+MK52HD=2<?/M1TJ*J,PB761&
MD3>V'GAW?QYY/],W/3#^5>P(D>!;04LQ&^VDW'_T?;'>D0(+C^U)J=YL&"^P
M5+=\ZXL])SBKC0KJHR"8^ 7.R]%\6C];\OF459+F)5ER(*JBP/QI02@[S$9P
M]/S@/M_NI'[@SZ=[O"4K(C_OEUS=^9V7+"](*7)6 DXVL]$5_+@(0VU0C_B2
MDX/H70,]E0?&ONJ;VVPV"K0B0LE::A=8?3V2:T*I]J1T_-,Z'74QM6'_^MG[
M3_7DU60>L"#7C/Z>9W(W&R4CD)$-KJB\9X>?23NAL?:W9E34G^#0C(W3$5A7
M0K*B-58*BKQLOO&W-A$] P0M!J@U0+7N)E"M\@9+/)]R=@!<CU;>]$4]U=I:
MB<M+O2HKR=7;7-G)^3T1A#\2 =0"@YM<K%E52@%PF8$KJI8,EVOU\OT-D3BG
M L /X!W(2W"74ZJ2*J:^5"*T*W_=!EPT 9$E8 KN6"EW GPJ,Y*]M/>5^&X&
MZ'D&"^1TN")[#X3!!4 !"CZO;L#[=Q\<;L,N,6'M-K2Y_70-5JH&LHJ2"P#1
M99!>@"^85KC932I!OU:8YINGO-R"JW6;.)U"RD3%"?CS%^42W$I2B+\<@J).
M4%0+BBR"%F2;EZ4.ML!4+\M0[AL7D]J%+LC'.81IXJ53_W$@]+@+/7:&OJXX
M)Z4$2\X><UV/ MP3JA*AQ/S&P I3M4=N2_ \[@^"^9"Z)DK24Q<&<>"A8763
M3MW$J>XJ^UO5B2*%?"EKR7.UI[66P6TZ.1)S&05>,JPE[K3$3BU+_%0+\>^)
MK/A@GO+3>8J/I2$X05XT+"[IQ"5G$&?2-B0M.986IY$'AY6EG;+4J4RQX,3&
M3H_B0A1#VW+!P. O<$;ND.>H4-B#*7P;T(#(2$+_'QNMCQ?I#:%M5:%A* Q_
M"#C:,'U]XR3U)A9]!JG0S=17HJ/U.NY7@2U7AK'0#=GSH ,>,_8R&L>V7P!H
M( O=E#T'/.  <R$*O- BSE 7NK%[FA_PF*DP@M[8$MD@%;J9>JT.,UP=+555
M VQVDZMT#11A^C9H@@PND1N7WT63UL>+7 <HMBTS,GA%\(?@I W3%XBBR=CV
M:X(,;)$;MJ_D"3K&[Z7:G!:\(8-?Y,;O>9""CN%[">,@LA4/,OA%;OR>@REM
MB!?J)N/$=E9"AL?(S>/33$''K(5!DEC7S; 6N5G;IL-5L0:-*'XC$#',1&YF
M?A]$CD^:ZGANVW*&J<A]TCP;0@8.I)$-(*'A:^CFZRL!$@X0URK&X#9TX_8\
M^&B#] ]+@469X6SHYNPYP!$.0!>.;=P(>WT#-W1/<Z-UT/^7KF@?_R>PWVOJ
M%(1OZ]:5 '5]-OV=[FG7'KMJFD)F>--;N\-<59P E&R4:>#%:C%XTZYJ;B3;
MURVB!R8E*^K+'<$9X7J >K]A3#[?Z !=TW#^+U!+ P04    "  +BE51,Q+@
MWF,"   >!@  &0   'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6RE5=N.VC 0
M_14KVH==J2476"ZK$&D75+4/*R'8;9]-,A!K'3NU':!_W[$3HE NJK0OQ)<Y
M,^<<VT.\E^I#YP"&' HN]-3+C2F??%^G.114]V0) G<V4A74X%1M?5TJH)D#
M%=R/@F#H%Y0)+XG=VD(EL:P,9P(6BNBJ**CZ\P)<[J=>Z!T7EFR;&[O@)W%)
MM[ "\UXN%,[\-DO&"A":24$4;*;><_@T&]IX%_"3P5YWQL0J64OY82<_LJD7
M6$+ (34V \7/#F; N4V$-'XW.;VVI 5VQ\?LWYQVU+*F&F:2_V*9R:?>V",9
M;&C%S5+NOT.CY]'F2R77[I?LZ]C1P"-II8TL&C R*)BHO_30^- !A-< 40.(
M_A?0;P!])[1FYF3-J:%)K.2>*!N-V>S >>/0J(8)>XHKHW"7(<XD2]"@=J )
M7@@R9SJ5E3":4)&19XY'3$6*F_=S,)1Q3:('\I6\K^;D_NZ!W!$FR"OC',]#
MQ[Y!.C:IGS:E7^K2T972*RA[I!]\(5$0!1?@L]OP.:0(#RT\G)S"?32A=2)J
MG8A<OL&5?&_24$Z.?ER24^.'#F]?QRX)HU'8&\?^KDO[0E@X&?<F;=@)O7Y+
MKW^3WA*RJK[Y<H.7OSDG!2FP'5USN.' H"TQ^*0#-7[<D19%HXZRVH#SJ' R
MZMAT0NZQ)?=XD]Q,%J44($RC7U60$3A@-]-0WU=I<E W;!BVE8:?M&%X?L+!
MH'_FPZ6P(.R%_QCA=UZO[9RO5&V9T(3#!H%!;X3&J+H;U1,C2_>@U])@>W##
M'!LX*!N ^QLIS7%B>T3[EY#\!5!+ P04    "  +BE51A(SJZGD#  "?"P
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M1EIH](S0+14XDP=/NQAQ4XRB58QE78Q]I59I!%I#G9 /,\\+ ].96 _M#/;
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MQ'FQT2U.)-OG&[-7)M4V+S_<41)0K@'J_I8Q>3S1#JJ?&^;_ 5!+ P04
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M&,C?EXR)UXMB@.;5P8O_ %!+ P04    "  +BE513[4==H "   (!@  &0
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M_7V:%K]VRM<9MJ_@7/P/4$L#!!0    (  N*55'SD95%<@,  !,.   9
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ME.-DOSS0?6J;!6VSH-8C!_7N%;HN*B4WIDOH[R]Z +I6(J_^\<B35I[4\O2
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M&8PC&D9.YPX:1R1A/N<6QWA('A\1,_'S!1DLD,$/9!B#,\@W_ G52TWB6T&
MY3*<A,O06<P.R&5P<)D1B%VI@#Z7#X0!+(YA8!Q#'\=ZH8"=ZTSH\_B08<MA
M&)+#1\1,YKSIM1@&/X;9& XL?*D/PV Q#"?!,%@,PX 8ACZ& >()<::@CV'
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M^O-EJ9O5[)A''>VSL-G_4$L#!!0    (  N*55'"P]XC) ,  %\*   9
M>&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;,5636_:,!C^*U;40RNQ)"0A0 5(
MY:-:I2&AHG:':0=#7L!J$J>V ^V_G^V$-$ (:#OL K'S?/BQ7SON[2A[XQL
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MC;P! E, ^7Y%J=@WE$%QIQS\ 5!+ P04    "  +BE513\@WZ1@#  "0"P
M&0   'AL+W=O<FMS:&5E=',O<VAE970U."YX;6S55DV/FS 0_2L6ZJ&56L!\
M9$F51&JSJMK#JJN-VIZ], G6&DQMDW3_?<>&);1):*4][278,&_\YKTPS.(@
MU8,N 0SY58E:+[W2F.9]$.B\A(II7S90XY.M5!4SN%6[0#<*6.% E0BB,)P%
M%>.UMUJX>[=JM9"M$;R&6T5T6U5,/7X$(0]+CWI/-^[XKC3V1K!:-&P'&S#?
MFEN%NV#(4O *:LUE311LE]X'^GY-4PMP$=\Y'/1H36PI]U(^V,V78NF%EA$(
MR(U-P?"RAS4(83,ACY]]4F\XTP+'ZZ?LGUSQ6,P]T["6X@<O3+GT,H\4L&6M
M,'?R\!GZ@AS!7 KM?LFACPT]DK?:R*H'(X.*U]V5_>J%& %H<@$0]8#H?P%Q
M#XA=H1TS5]8U,VRU4/) E(W&;';AM'%HK(;7UL:-4?B4(\ZL/O&:U3EG@GRI
MM5$M.F0T>7T-AG&AWY!WY-OFFKQ^]8:\(KPF-UP(5%\O H.'VQ1!WA_TL3LH
MNG#0!AJ?Q.%;$H51> :^GH9?0XYP:N%T_B<\P)*'NJ.A[LCEBR_1Z?ZV1&[)
M=I" :0U8_8&;DDC%=_A H-BF5=QPT#98@-;$E*PF\Y 4[%&C*KEH"R@<#"7*
MF2X)JXMN 3];OF?"JCK!.AY8QXYU<H'U>C)E9T.78>8RV)=XOZ+I5>C'BV _
MEOLT+$H3ZM,A[ ^"R4 PF28HJPJ4$[-A#:B)FM,A9?J"G)H-K&?/=JK+D(TL
MF"5S/_K+J-.H.$O\Y+Q/5P.]JTEZ7_>@:MOAL!7C4@->FU;E)79$PG8*H/J'
M$-EP4O:"[)L/K.?/MF]^8DPR2T?&=/:=1L6SS,_.VT?#8]L.)PG>R!H>43+U
M@)_Z;5L74U73T=> OB"WZ+&;T^C9?O4IQE9$V!C_?M_.A-%9E/GI!<N.O9M.
M-^]-*95Y9T!5.&?<&Z(A[Q6<DN#8>6GRDJP[MG>:/M^Z]/2CEJ4C2WKKSH2E
M\Y->&8S&)3NKWC"%PFA48HNXT+_"-*H;_[J-D8V;H.ZEP7G,+4L<F4'9 'R^
ME=(\;>Q0-@SAJ]]02P,$%     @ "XI545.F<.&M!0  21\  !D   !X;"]W
M;W)K<VAE971S+W-H965T-3DN>&ULO9E;;^(X%,>_BH7F848:(+[DPH@B=:@Z
M.])T54TUNP^K?7#!0-0D9AQ39O;3KQ/2.. +H%:\M 3.L?_VR?GYY&2\Y>*I
M7#$FP:\\*\JKWDK*]:?AL)RM6$[+ 5^S0OVRX"*G4EV*Y;!<"T;GM5.>#5$0
M1,.<ID5O,JZ_NQ>3,=_(+"W8O0#E)L^I^/V997Q[U8.]ER^^I\N5K+X83L9K
MNF0/3/Y8WPMU-6Q'F:<Y*\J4%T"PQ57O&GZ:DE'E4%O\E;)MV?D,JJ4\<OY4
M77R=7_6"2A'+V$Q60U#U[YE-6995(RD=/YM!>^V<E6/W\\OHM_7BU6(>:<FF
M//L[G<O552_I@3E;T$TFO_/M'ZQ94%B--^-96?\%VYUMJ(QGFU+RO'%6"O*T
MV/VGOYJ-Z#A XG! C0,ZU0$W#KA>Z$Y9O:P;*NED+/@6B,I:C59]J/>F]E:K
M28LJC ]2J%]3Y2<GMVE!BUE*,_"U**78J C)$KR_89*F60G@!] '/QYNP/MW
M'\ [D!;@+LTRM?_E>"C5]-4@PUDSU>?=5,@QU0-;#P ./@(4H,#B/O6[W["9
M<H>5.QSMNP_5HMN5HW;EJ!X/.\=[E."!S38BE2DK/X+K9[5D^IBQOLJ.?DDS
M!O[YIIS 5\GR\E_/E+B=$M=3$L>4USD7,OV/S<&,E]*V@SO_J/:O,O!Y@G"8
M#,AX^-S=J9U9W#4;16%KM">.M.*(5]P7P<L2; H%@ZS6N%00L(9Y-T[2F3T:
M) <*=S9AU\8N+VSEA>?)R]0UL^H+#7W]P-A"JU%LUQBU&B.OQEN:"O!,LPVS
MR8J,&1&.B+%S%K-1' RP75K<2HN]TNZH>%(YK>YNP'YN4OD;E)U;?^$5'I\F
MW&+F$9ZTPA.O\"D7:RZH9 K.*F&U:C#="*%HY<G+43O'Z%(H@($&;_!*&#0#
M='=T%.%!>+#O%C,8A/$ V3<>=HX&^$9$: ;:DV!D7&/490)T2-0,A^BMJ-",
M=)#Q\% D,D0&#I&:^M"/?3\6&N?]*)O993%344Z<4=;8AW[NNQ/L3U[T9T>3
M#&J"P_!B:::1#/U,/B'-3.*2.!R,#@-@FD48=\SV!6HP0S^9S\@RD["X$_]&
M9FS<P X"0XU@Z&?P.5F6G)1ER<E9IAD.1Z_)LI$Q(XF-$(\L(8Y<(48:]<B/
M^B_\F8FB*JW/.[^01C6"ETHMU"F@_? ]GEK(9"Y.1L;)8#$+ ^3<=PU>Y ?O
MZ:F%3+H&1FI9C8A#I.8O.K/N=B<7,JOJX%"CSV1?H>8V\I?>_LQ"9B5=Q3@Z
M%&::A0%V58=(\QWY^6[/K=..+J0AC>*+Y9?&+O)C]X3\,FF+X\C,+],LA%TJ
M[PO4R$5^Y)Z17R99S0+18A1TZJ#]1VX-7WP$OJ?G5S.2+[^P66SWG<\X6/,;
M^TMM?XIAL[S&<6R4B!:S*LR.!V^L.8_]G+]3M^&2+AF@Q1QPN6("4+6%$CS2
MV9/:T+/.--QIEN"+-6@TC;&?QB>T:,SV1V#0SFKDZ"Y@#6)\9@_$F6_-0-X[
MV6>R+U##&!^!\1FY%AU7Z#/95ZA!COW5]I%$,RML2VQM1J[8:MAC/^S/2++3
M#C>L,8XOUOX@&LODM>T/8NEKA,@(A\4,18'KN9AH)).WZGX0D[OF76,U<AQN
M1*.9O%G_@UC['X<UKMW*4>02S7+RFA9(X[S7&0KQH3*S^J[B[#C=2*?M[2>^
MKS/JN],UM<G%VAY$DYCX2>SO]]+CR6=V.Y(0=C#7!,72K8:)\W[1F":O:5<O
M3T]-D]41-G/3M((8N>ICHIE.CC#]O%5X<M?252&6ERYF6Z4/';4IT<<#\5?Y
MKWEUT S=?:&51(G1PK:881P/#M]H#3OO.:N7S$K94@4>9&RA_-0AK%8N=N]M
M=Q>2K^M7GX]<2I[7'U>,SIFH#-3O"\[ERT7U-K5]>S[Y'U!+ P04    "  +
MBE51(07:VQ,#  "I"0  &0   'AL+W=O<FMS:&5E=',O<VAE970V,"YX;6RM
MEMM.XS 0AE_%BK@ "7)L3JBM!$5HN4!"5.Q>N^FDL7#BKNVTL$^_=A)"VJ2E
MB_:FC>/YQ]\_/F6\9?Q59  2O>6T$!,CDW)];5DBR2#'PF1K*%1/RGB.I6KR
ME276'/"R$N74<FT[L'),"F,ZKMX]\>F8E9*2 IXX$F6>8_Y^"Y1M)X9C?+QX
M)JM,ZA?6=+S&*YB#?%D_<=6RVBQ+DD,A""L0AW1BW#C7,\?6@BKB)X&MZ#PC
M;67!V*MN/"PGAJV)@$(B=0JL_C8P TIU)L7QNTEJM&-J8??Y(_M]95Z966 !
M,T9_D:7,)D9DH"6DN*3RF6U_0&/(U_D21D7UB[9U;. ;*"F%9'DC5@0Y*>I_
M_-84HB-P1@<$;B-P3Q5XC<"KC-9DE:T[+/%TS-D6<1VMLNF'JC:56KDAA9[&
MN>2JERB=G-Z3 A<)P10]%$+R4LV0%.C\#B0F5"#W EVAE_D=.C^[0&>(%.B1
M4*KJ+\:65,/K)%;2#'5;#^4>&&H.:Q-Y]B5R;=<>D,^.R^\@47)'RYUX5VXI
MTZUSMW7N5OF\0SCUPD4L13-62*X65*G*\(AER8DD(*[1S485 2\H7*G]<C7'
M%- <DJ;["(+7(G@5PNB0I1)T25D!Z!TP1XPC"D)<(IPS+LD?6**$"3E4ZCIQ
M6"766W4S=3S?'UN;;D'KH* ;Y >NZ;9A.]2CEGKT/6H0DJB-I:A33#C:8%K"
M$'N=/MIE]\S1'OU F!_89C1,[[?T_I?T.)7 /PW(C+-RE:%4'2C5FY-FP._A
MQ7:WMK6)?I3C>B/3'S81M":"_V'BU D)>I!1')KQGI5^E+)B=Z9MQTK86@E/
MM/)OY0_[-'9H!GO, U&AUXG:08Y:Y.@;R*<6.QH$=_; !Z(4^(&U'[?@\5'P
MFR^K&O>&=3T_ZFW-.LSOAL7!@37MV)]7D7T<;^>X%<>.V^:^L7L'G.L%HTZ9
MFHME("X.;=/;([8Z]ZC^B'G$?$4*H8ZW5 EM,U2.>?U=4#<D6U=7ZX))=5%7
MCYGZE@*N U1_RIC\:.C;NOTZF_X%4$L#!!0    (  N*55&ALRILW@(  'X(
M   9    >&PO=V]R:W-H965T<R]S:&5E=#8Q+GAM;*56VV[:,!A^%2OJ12NU
M.9*45H!4"-5Z40D5=;N8=F&2'[#JV-1V2KNGG^V$C$- :+L!V_D._GX[=GIK
M+M[D$D"ASX(RV7>62JWN/4]F2RBP=/D*F'XRYZ+ 2G?%PI,K 3BWI()ZH>\G
M7H$)<P8].S81@QXO%24,)@+)LBBP^!H"Y>N^$SB;@1>R6"HSX UZ*[R *:C7
MU43HGM>HY*0 )@EG2,"\[SP$]^/$X"W@.X&UW&HCDV3&^9OI/.5]QS<3 @J9
M,@I8_WW ""@U0GH:[[6FTU@:XG9[H_YHL^LL,RQAQ.D/DJMEW^DZ*(<Y+JEZ
MX>MO4.>)C5[&J;2_:%UA8PW.2JEX49/U# K"JG_\6==ABZ!UV@EA30CW"9TC
MA*@F1.<Z=&I"YUR'N";8Z%Z5W18NQ0H/>H*OD3!HK68:MOJ6K>M%F-DG4R7T
M4Z)Y:O!(&&89P10],:E$J;> DN@R!84)E2BZ0C?H=9JBRXLK=($(0\^$4KW"
MLN<I;6]$O*RV&E96X1&K"#USII82C5D.>0L_/<V_.\'W=.PF>[C)/@Q/"DYA
MY:+(OT:A'_HM\QF=30_NVN+\G_OXG]UWBA$U&R&R>M$1O2?V 5+9Y;]&*<P4
MPBQ'X_>2J"\TA:P41!&0Z.?#3.\3_7[_.F'::4P[UK1SQ'0B> :02S07O-#;
M6FU<C+?$%%JW6:696$US#GX,@BCQ75V%C^W5.X0E0>!V=U'I(2H..[Y[NPL;
M'\*B;G+K)@UL)W_<Y(]/YG\!3,EOR-%"G^BM62M^O)UU+V:%Z&XA#F:?'F*"
M<+\2XT-0Z$;M^9(F7W)>/LJE;%_,Y*"P-X=+V0K:*T3: @IC-]Q+V2IUNQ?3
MVSI0"Q +>Y-)E/&2J>J5:D:;R_+!WA%[X\/@?A2TC*?Z<JWNPK_RU<W\C,5"
M[P5$8:ZM]-3TLHCJMJLZBJ_L<3[C2E\.MKG4'P@@#$ _GW.N-AUCT'QR#/X
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MZUZ_32_<;(6R3,*&H%'_"PVGJ>>]-E"7?F02C32 ?IG3$PG&.=#Y1FL\&RY
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M4P'R^R8E7,F^T ;J_QO@XO]02P,$%     @ "XI54;/M.[P,!   'P\  !D
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MG=%=26-DY2X7P-$1.P#?SR6NKN;&3M">"T_^ U!+ P04    "  +BE51 J=
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M:5KAJ3.>-H8Q@#5?C)E3^<&-# ' ;-96_,4I*8N!UB@>;^P+U,VBUU1= F;
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MO1<^S+#NZ:;J"9WHR0:W-!,[#H(L(I'&?C5N[X_8FS+J)G1T#/T&C3I<D]P
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M,&617Y'G7Q0_ZBO=)ZX43_7C@090=C, _+[C7+U^R08H_U"Q^@=02P,$%
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MX+\OXIAM+[(&=F_E7/P/4$L#!!0    (  N*55'JP1C][P<  *TE   9
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ML,B:;394T'"EQ:J;PN:DYDP'-V#%I9@87?D"/  0N>(">G($[C2Y[;^<01T
M0F4BJ':ADC:@D18VZJ3L"@'6W5>LC,VTO*@M%2,&%MXZ+:89CR<5IBG<;5.Q
M1NQS(59;2.[8'CIUN:7.W+3%E==:<Q.KBP>Q:@&PN0> A&QIJ!J8%?\ C4#
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M152 D4'$X_R7/1:!J '03C/ +0#N<T#W , K -ZI'KH%H'NJAUX!Z)WJH5\
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M14)8(@6G/4#1DOF=3][0(LEN$!9":Q%ECVM@ 4@S -\O!>[:HF$<E#=ODW\
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M UE47?:-##OL9=TS4O+H6F@G:A:^.:-D'3AJMNQPPJD19 (@DR-"_I-$D"F
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M.X'>@7H'@=Z!>@>!WH%Z!X'>@7H'@=Z!>@>!WH%Z!X'>@7H'@=XQ^5F00.]
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M9_/?P*_^ %!+ 0(4 Q0    (  N*55$'04UB@0   +$    0
M  "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ "XI547N4?FSM
M    *P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L!
M A0#%     @ "XI549E<G",0!@  G"<  !,              ( !RP$  'AL
M+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    "  +BE51M8;5N T%  "\%
M&               @($,"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L!
M A0#%     @ "XI547";/3CZ!P  (R(  !@              ("!3PT  'AL
M+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    (  N*55$J#(@KCP0
M ,<0   8              " @7\5  !X;"]W;W)K<VAE971S+W-H965T,RYX
M;6Q02P$"% ,4    "  +BE51!YK]\.X&  #V'   &               @(%$
M&@  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ "XI546BG
MS45! @  /04  !@              ("!:"$  'AL+W=O<FMS:&5E=',O<VAE
M970U+GAM;%!+ 0(4 Q0    (  N*55&;+R/UQ0@  *\E   8
M  " @=\C  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    "  +
MBE51->W 69,,   K50  &               @(':+   >&PO=V]R:W-H965T
M<R]S:&5E=#<N>&UL4$L! A0#%     @ "XI542W?$'SE$@  )S0  !@
M         ("!HSD  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0
M   (  N*55$KE"<Q(P<  "H0   8              " @;Y,  !X;"]W;W)K
M<VAE971S+W-H965T.2YX;6Q02P$"% ,4    "  +BE51(7Z%&%X&  # $
M&0              @($75   >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+
M 0(4 Q0    (  N*55$_KZQP1PH  &0:   9              " @:Q:  !X
M;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ "XI542_RI-1X
M @  - 4  !D              ("!*F4  'AL+W=O<FMS:&5E=',O<VAE970Q
M,BYX;6Q02P$"% ,4    "  +BE51C2'S/WH(  "#%0  &0
M@('99P  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    (  N*
M55$ML!V;0 L  !DB   9              " @8IP  !X;"]W;W)K<VAE971S
M+W-H965T,30N>&UL4$L! A0#%     @ "XI540X^!XBO"0  'QT  !D
M         ("! 7P  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4
M    "  +BE51$>VP+78,  "!*0  &0              @('GA0  >&PO=V]R
M:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    (  N*55& FE!#'@0  $,*
M   9              " @922  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL
M4$L! A0#%     @ "XI544M85=OT!0  APX  !D              ("!Z98
M 'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    "  +BE51]25G
MF" &  #L$@  &0              @($4G0  >&PO=V]R:W-H965T<R]S:&5E
M=#$Y+GAM;%!+ 0(4 Q0    (  N*55%3A'\L6@,  %X'   9
M  " @6NC  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @
M"XI54=-+RWVE!   RPL  !D              ("!_*8  'AL+W=O<FMS:&5E
M=',O<VAE970R,2YX;6Q02P$"% ,4    "  +BE51V)K,]&,*  !0&P  &0
M            @('8JP  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4
M Q0    (  N*55$20?L]V@8  $\4   9              " @7*V  !X;"]W
M;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ "XI541%]EN'6%P
MEE(  !D              ("!@[T  'AL+W=O<FMS:&5E=',O<VAE970R-"YX
M;6Q02P$"% ,4    "  +BE51BZ7;#Z\(   Y&@  &0              @(&0
MU0  >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    (  N*55&#
M-U](7A0  +8Y   9              " @7;>  !X;"]W;W)K<VAE971S+W-H
M965T,C8N>&UL4$L! A0#%     @ "XI54=?QHCW.$@   S4  !D
M     ("!"_,  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    (  N*55%/N(_YYP4  &@0   9              "
M@7 < 0!X;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ "XI5
M4<5@DJM3!0  U1$  !D              ("!CB(! 'AL+W=O<FMS:&5E=',O
M<VAE970S,RYX;6Q02P$"% ,4    "  +BE51$R%U2!8%  " #@  &0
M        @($8* $ >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0
M   (  N*55$1$Z8R-@,   P'   9              " @64M 0!X;"]W;W)K
M<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @ "XI540G)WZ%"!   L L
M !D              ("!TC ! 'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q0
M2P$"% ,4    "  +BE51Z#Z6P7@#  "U!P  &0              @(%+-0$
M>&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    (  N*55$[GGF;
MR@0  $ ,   9              " @?HX 0!X;"]W;W)K<VAE971S+W-H965T
M,S@N>&UL4$L! A0#%     @ "XI5434\". 8!   7@P  !D
M ("!^ST! 'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4    "  +
MBE51OSP<078"  #$!0  &0              @(%*0@$ >&PO=V]R:W-H965T
M<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    (  N*55'1_\K8=00  %02   9
M          " @?=$ 0!X;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#
M%     @ "XI54=T2'YI0 @  "@8  !D              ("!HTD! 'AL+W=O
M<FMS:&5E=',O<VAE970T,BYX;6Q02P$"% ,4    "  +BE515=^. AL$  !/
M#@  &0              @($J3 $ >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM
M;%!+ 0(4 Q0    (  N*55$X\+Z=L0D  ()#   9              " @7Q0
M 0!X;"]W;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @ "XI546$"
M\EA=!   0!0  !D              ("!9%H! 'AL+W=O<FMS:&5E=',O<VAE
M970T-2YX;6Q02P$"% ,4    "  +BE51,Q+@WF,"   >!@  &0
M    @('X7@$ >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    (
M  N*55&$C.KJ>0,  )\+   9              " @9)A 0!X;"]W;W)K<VAE
M971S+W-H965T-#<N>&UL4$L! A0#%     @ "XI541$.1: 4!   >A   !D
M             ("!0F4! 'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q02P$"
M% ,4    "  +BE51S (/*C\$  "X$0  &0              @(&-:0$ >&PO
M=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    (  N*55$%D"U$8P(
M "@&   9              " @0-N 0!X;"]W;W)K<VAE971S+W-H965T-3 N
M>&UL4$L! A0#%     @ "XI543R,[T@[!P  1B@  !D              ("!
MG7 ! 'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6Q02P$"% ,4    "  +BE51
M3[4==H "   (!@  &0              @($/> $ >&PO=V]R:W-H965T<R]S
M:&5E=#4R+GAM;%!+ 0(4 Q0    (  N*55%GEQ:1< <  (XS   9
M      " @<9Z 0!X;"]W;W)K<VAE971S+W-H965T-3,N>&UL4$L! A0#%
M  @ "XI54?.1E45R P  $PX  !D              ("!;8(! 'AL+W=O<FMS
M:&5E=',O<VAE970U-"YX;6Q02P$"% ,4    "  +BE516LNC/F@"  !1!P
M&0              @($6A@$ >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+
M 0(4 Q0    (  N*55&OL4TFP00  !<;   9              " @;6( 0!X
M;"]W;W)K<VAE971S+W-H965T-38N>&UL4$L! A0#%     @ "XI54<+#WB,D
M P  7PH  !D              ("!K8T! 'AL+W=O<FMS:&5E=',O<VAE970U
M-RYX;6Q02P$"% ,4    "  +BE513\@WZ1@#  "0"P  &0
M@($(D0$ >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4 Q0    (  N*
M55%3IG#AK04  $D?   9              " @5>4 0!X;"]W;W)K<VAE971S
M+W-H965T-3DN>&UL4$L! A0#%     @ "XI542$%VML3 P  J0D  !D
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M=#8T+GAM;%!+ 0(4 Q0    (  N*55&S[3N\# 0  !\/   9
M  " @>6Q 0!X;"]W;W)K<VAE971S+W-H965T-C4N>&UL4$L! A0#%     @
M"XI54>%@7K.U!   (Q8  !D              ("!*+8! 'AL+W=O<FMS:&5E
M=',O<VAE970V-BYX;6Q02P$"% ,4    "  +BE51 J= "2\#  "3"P  &0
M            @($4NP$ >&PO=V]R:W-H965T<R]S:&5E=#8W+GAM;%!+ 0(4
M Q0    (  N*55'*:&/((0<  '\L   9              " @7J^ 0!X;"]W
M;W)K<VAE971S+W-H965T-C@N>&UL4$L! A0#%     @ "XI542NJT1+U!
M^Q8  !D              ("!TL4! 'AL+W=O<FMS:&5E=',O<VAE970V.2YX
M;6Q02P$"% ,4    "  +BE51P+LTDP4$  !_#P  &0              @('^
MR@$ >&PO=V]R:W-H965T<R]S:&5E=#<P+GAM;%!+ 0(4 Q0    (  N*55$%
MW6^'&@0  *X0   9              " @3K/ 0!X;"]W;W)K<VAE971S+W-H
M965T-S$N>&UL4$L! A0#%     @ "XI5443.I(4A!0  GAD  !D
M     ("!B],! 'AL+W=O<FMS:&5E=',O<VAE970W,BYX;6Q02P$"% ,4
M"  +BE51@*]);YL#   T#   &0              @('CV $ >&PO=V]R:W-H
M965T<R]S:&5E=#<S+GAM;%!+ 0(4 Q0    (  N*55$ADO74?P0  +H5   9
M              " @;7< 0!X;"]W;W)K<VAE971S+W-H965T-S0N>&UL4$L!
M A0#%     @ "XI54?D3.K;U!0  M!@  !D              ("!:^$! 'AL
M+W=O<FMS:&5E=',O<VAE970W-2YX;6Q02P$"% ,4    "  +BE51Z2K?(&@$
M   I$   &0              @(&7YP$ >&PO=V]R:W-H965T<R]S:&5E=#<V
M+GAM;%!+ 0(4 Q0    (  N*55&NM]D?4 D  *$S   9              "
M@3;L 0!X;"]W;W)K<VAE971S+W-H965T-S<N>&UL4$L! A0#%     @ "XI5
M4>K!&/WO!P  K24  !D              ("!O?4! 'AL+W=O<FMS:&5E=',O
M<VAE970W."YX;6Q02P$"% ,4    "  +BE51N1  7/ $  "%$P  &0
M        @('C_0$ >&PO=V]R:W-H965T<R]S:&5E=#<Y+GAM;%!+ 0(4 Q0
M   (  N*55%PGO$96@(  )<%   9              " @0H# @!X;"]W;W)K
M<VAE971S+W-H965T.# N>&UL4$L! A0#%     @ "XI544H5$K:, @  H \
M  T              ( !FP4" 'AL+W-T>6QE<RYX;6Q02P$"% ,4    "  +
MBE51EXJ[',     3 @  "P              @ %2" ( 7W)E;',O+G)E;'-0
M2P$"% ,4    "  +BE515_1G*<H%  !L-   #P              @ $["0(
M>&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ "XI54;3%"JYH @  1R\  !H
M             ( !,@\" 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L!
M A0#%     @ "XI542P!9SL; @  #BX  !,              ( !TA$" %M#
G;VYT96YT7U1Y<&5S72YX;6Q02P4&     %@ 6  ?&   'A0"

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>666</ContextCount>
  <ElementCount>461</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>152</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>11</UnitCount>
  <MyReports>
    <Report instance="biib-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="biib-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Condensed Consolidated Statements of Income (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Income (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="biib-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Income (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="biib-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="biib-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="biib-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="biib-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - Condensed Consolidated Statement of Equity Statement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement</Role>
      <ShortName>Condensed Consolidated Statement of Equity Statement</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="biib-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="biib-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2104102 - Disclosure - Acquisitions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Acquisitions</Role>
      <ShortName>Acquisitions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="biib-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2108103 - Disclosure - Divestitures Divestitures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DivestituresDivestitures</Role>
      <ShortName>Divestitures Divestitures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="biib-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2110104 - Disclosure - Revenues</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Revenues</Role>
      <ShortName>Revenues</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="biib-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2118105 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="biib-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2121106 - Disclosure - Intangible Assets and Goodwill</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IntangibleAssetsandGoodwill</Role>
      <ShortName>Intangible Assets and Goodwill</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="biib-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2125107 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="biib-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2132108 - Disclosure - Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstruments</Role>
      <ShortName>Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="biib-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2140109 - Disclosure - Derivative Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DerivativeInstruments</Role>
      <ShortName>Derivative Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="biib-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2143110 - Disclosure - Property, Plant and Equipment Property, Plant and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/PropertyPlantandEquipmentPropertyPlantandEquipment</Role>
      <ShortName>Property, Plant and Equipment Property, Plant and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="biib-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2145111 - Disclosure - Indebtedness (Notes)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.biogenidec.com/role/IndebtednessNotes</Role>
      <ShortName>Indebtedness (Notes)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="biib-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2147112 - Disclosure - Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Equity</Role>
      <ShortName>Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="biib-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2152113 - Disclosure - Earnings per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EarningsperShare</Role>
      <ShortName>Earnings per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="biib-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2155114 - Disclosure - Share-based Payments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SharebasedPayments</Role>
      <ShortName>Share-based Payments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="biib-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2159115 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="biib-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2163116 - Disclosure - Other Consolidated Financial Statement Detail</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail</Role>
      <ShortName>Other Consolidated Financial Statement Detail</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="biib-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2167117 - Disclosure - Collaborative and Other Relationships</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeandOtherRelationships</Role>
      <ShortName>Collaborative and Other Relationships</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="biib-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2171118 - Disclosure - Investments in Variable Interest Entities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InvestmentsinVariableInterestEntities</Role>
      <ShortName>Investments in Variable Interest Entities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="biib-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2173119 - Disclosure - Litigation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Litigation</Role>
      <ShortName>Litigation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="biib-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="biib-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2311302 - Disclosure - Revenues (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesTables</Role>
      <ShortName>Revenues (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/Revenues</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="biib-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2319303 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/Inventory</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="biib-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2322304 - Disclosure - Intangible Assets and Goodwill (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables</Role>
      <ShortName>Intangible Assets and Goodwill (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IntangibleAssetsandGoodwill</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="biib-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2326305 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurements</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="biib-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2333306 - Disclosure - Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsTables</Role>
      <ShortName>Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstruments</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="biib-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2341307 - Disclosure - Derivative Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DerivativeInstrumentsTables</Role>
      <ShortName>Derivative Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/DerivativeInstruments</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="biib-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2348308 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables</Role>
      <ShortName>Accumulated Other Comprehensive Income (Loss) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="biib-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2353309 - Disclosure - Earnings per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EarningsperShareTables</Role>
      <ShortName>Earnings per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/EarningsperShare</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="biib-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2356310 - Disclosure - Share-Based Payments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsTables</Role>
      <ShortName>Share-Based Payments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="biib-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2360311 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IncomeTaxes</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="biib-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2364312 - Disclosure - Other Consolidated Financial Statement Detail (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables</Role>
      <ShortName>Other Consolidated Financial Statement Detail (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="biib-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2368313 - Disclosure - Collaborative and Other Relationships (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables</Role>
      <ShortName>Collaborative and Other Relationships (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/CollaborativeandOtherRelationships</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="biib-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2403401 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="biib-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Business Acquisition (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual</Role>
      <ShortName>Business Acquisition (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="biib-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Business Acquisition (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/BusinessAcquisitionDetails</Role>
      <ShortName>Business Acquisition (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="biib-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2409404 - Disclosure - Divestitures (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DivestituresDetailsTextual</Role>
      <ShortName>Divestitures (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/DivestituresDivestitures</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="biib-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2412405 - Disclosure - Revenues by Product (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesbyProductDetails</Role>
      <ShortName>Revenues by Product (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="biib-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2413406 - Disclosure - Reserves for Discounts and Allowances (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ReservesforDiscountsandAllowancesDetails1</Role>
      <ShortName>Reserves for Discounts and Allowances (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="biib-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2414407 - Disclosure - Reserves for Discounts and Allowances (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ReservesforDiscountsandAllowancesDetails2</Role>
      <ShortName>Reserves for Discounts and Allowances (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="biib-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2415408 - Disclosure - Revenues from Anti-CD20 Therapeutic Programs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesfromAntiCD20TherapeuticProgramsDetails</Role>
      <ShortName>Revenues from Anti-CD20 Therapeutic Programs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="biib-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2416409 - Disclosure - Other Revenues (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/OtherRevenuesDetails</Role>
      <ShortName>Other Revenues (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="biib-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2417410 - Disclosure - Revenues (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesDetailsTextual</Role>
      <ShortName>Revenues (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/RevenuesTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="biib-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2420411 - Disclosure - Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InventoryDetails</Role>
      <ShortName>Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/InventoryTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="biib-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2423412 - Disclosure - Intangible Assets and Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails</Role>
      <ShortName>Intangible Assets and Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="biib-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2424413 - Disclosure - Intangible Assets and Goodwill (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails1</Role>
      <ShortName>Intangible Assets and Goodwill (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="biib-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2427414 - Disclosure - Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsDetails</Role>
      <ShortName>Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="biib-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2428415 - Disclosure - Fair Value Measurements (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual</Role>
      <ShortName>Fair Value Measurements (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="biib-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2429416 - Disclosure - Fair Value Measurements Fair Value Measurements - Contingent Consideration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails</Role>
      <ShortName>Fair Value Measurements Fair Value Measurements - Contingent Consideration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="biib-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2430417 - Disclosure - Fair Value Measurements (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsDetails1</Role>
      <ShortName>Fair Value Measurements (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="biib-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2431418 - Disclosure - Fair Value Measurements (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsDetails2</Role>
      <ShortName>Fair Value Measurements (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="biib-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2434419 - Disclosure - Financial Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetails</Role>
      <ShortName>Financial Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="biib-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2435420 - Disclosure - Financial Instruments (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetails1</Role>
      <ShortName>Financial Instruments (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="biib-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2436421 - Disclosure - Financial Instruments (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetails2</Role>
      <ShortName>Financial Instruments (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="biib-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2437422 - Disclosure - Financial Instruments (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetails3</Role>
      <ShortName>Financial Instruments (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="biib-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2438423 - Disclosure - Financial Instruments (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual</Role>
      <ShortName>Financial Instruments (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="biib-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2439424 - Disclosure - Financial Instruments Financial Instruments (Details Textual 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2</Role>
      <ShortName>Financial Instruments Financial Instruments (Details Textual 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="biib-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2442425 - Disclosure - Derivative Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DerivativeInstrumentsDetails</Role>
      <ShortName>Derivative Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/DerivativeInstrumentsTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="biib-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2444426 - Disclosure - Property, Plant and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails</Role>
      <ShortName>Property, Plant and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/PropertyPlantandEquipmentPropertyPlantandEquipment</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="biib-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2446427 - Disclosure - Indebtedness (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IndebtednessDetails</Role>
      <ShortName>Indebtedness (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IndebtednessNotes</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="biib-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2449428 - Disclosure - Share Repurchases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareRepurchasesDetails</Role>
      <ShortName>Share Repurchases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="biib-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2450429 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails</Role>
      <ShortName>Accumulated Other Comprehensive Income (Loss) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="biib-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>2451430 - Disclosure - Reclassification out of Accumulated Other Comprehensive Income (Loss) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails</Role>
      <ShortName>Reclassification out of Accumulated Other Comprehensive Income (Loss) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="biib-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>2454431 - Disclosure - Earnings per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EarningsperShareDetails</Role>
      <ShortName>Earnings per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/EarningsperShareTables</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="biib-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>2457432 - Disclosure - Share-Based Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsDetails</Role>
      <ShortName>Share-Based Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/ShareBasedPaymentsTables</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="biib-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>2458433 - Disclosure - Share-Based Payments (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsDetails1</Role>
      <ShortName>Share-Based Payments (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/ShareBasedPaymentsTables</ParentRole>
      <Position>72</Position>
    </Report>
    <Report instance="biib-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>2461434 - Disclosure - Income Taxes (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxesDetailsTextual</Role>
      <ShortName>Income Taxes (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IncomeTaxesTables</ParentRole>
      <Position>73</Position>
    </Report>
    <Report instance="biib-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>2462435 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IncomeTaxesTables</ParentRole>
      <Position>74</Position>
    </Report>
    <Report instance="biib-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>2465436 - Disclosure - Other Consolidated Financial Statement Detail (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails</Role>
      <ShortName>Other Consolidated Financial Statement Detail (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables</ParentRole>
      <Position>75</Position>
    </Report>
    <Report instance="biib-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>2466437 - Disclosure - Other Consolidated Financial Statement (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual</Role>
      <ShortName>Other Consolidated Financial Statement (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables</ParentRole>
      <Position>76</Position>
    </Report>
    <Report instance="biib-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>2469438 - Disclosure - Collaborative and Other Relationships - Collaborations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails</Role>
      <ShortName>Collaborative and Other Relationships - Collaborations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="biib-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>2470439 - Disclosure - Collaborative and Other Relationships - Equity Method Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails</Role>
      <ShortName>Collaborative and Other Relationships - Equity Method Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="biib-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>2472440 - Disclosure - Investments in Variable Interest Entities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails</Role>
      <ShortName>Investments in Variable Interest Entities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/InvestmentsinVariableInterestEntities</ParentRole>
      <Position>79</Position>
    </Report>
    <Report instance="biib-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>2474441 - Disclosure - Litigation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/LitigationDetails</Role>
      <ShortName>Litigation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/Litigation</ParentRole>
      <Position>80</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="biib-20200930.htm">biib-20200930.htm</File>
    <File>biib-20200930.xsd</File>
    <File>biib-20200930_cal.xml</File>
    <File>biib-20200930_def.xml</File>
    <File>biib-20200930_lab.xml</File>
    <File>biib-20200930_pre.xml</File>
    <File>biib-2020930xex311.htm</File>
    <File>biib-2020930xex312.htm</File>
    <File>biib-2020930xex321.htm</File>
    <File>exhibit101-severancepo.htm</File>
    <File>exhibit102-mcdonnellof.htm</File>
    <File>exhibit103-capellosepa.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>biib-20200930_g1.jpg</File>
    <File>biib-20200930_g10.jpg</File>
    <File>biib-20200930_g11.jpg</File>
    <File>biib-20200930_g12.jpg</File>
    <File>biib-20200930_g13.jpg</File>
    <File>biib-20200930_g14.jpg</File>
    <File>biib-20200930_g15.jpg</File>
    <File>biib-20200930_g16.jpg</File>
    <File>biib-20200930_g17.jpg</File>
    <File>biib-20200930_g18.jpg</File>
    <File>biib-20200930_g19.jpg</File>
    <File>biib-20200930_g2.jpg</File>
    <File>biib-20200930_g20.jpg</File>
    <File>biib-20200930_g21.jpg</File>
    <File>biib-20200930_g22.jpg</File>
    <File>biib-20200930_g23.jpg</File>
    <File>biib-20200930_g3.jpg</File>
    <File>biib-20200930_g4.jpg</File>
    <File>biib-20200930_g5.jpg</File>
    <File>biib-20200930_g6.jpg</File>
    <File>biib-20200930_g7.jpg</File>
    <File>biib-20200930_g8.jpg</File>
    <File>biib-20200930_g9.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2017-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/currency/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>126
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "biib-20200930.htm": {
   "axisCustom": 6,
   "axisStandard": 32,
   "contextCount": 666,
   "dts": {
    "calculationLink": {
     "local": [
      "biib-20200930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "biib-20200930_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml",
      "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "biib-20200930.htm"
     ]
    },
    "labelLink": {
     "local": [
      "biib-20200930_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "biib-20200930_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-ref-2019-01-31.xml",
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "biib-20200930.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd",
      "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd",
      "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-parts-codification-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 744,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2019-01-31": 23,
    "http://www.biogenidec.com/20200930": 4,
    "http://xbrl.sec.gov/dei/2019-01-31": 6,
    "total": 33
   },
   "keyCustom": 75,
   "keyStandard": 386,
   "memberCustom": 71,
   "memberStandard": 68,
   "nsprefix": "biib",
   "nsuri": "http://www.biogenidec.com/20200930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.biogenidec.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2108103 - Disclosure - Divestitures Divestitures",
     "role": "http://www.biogenidec.com/role/DivestituresDivestitures",
     "shortName": "Divestitures Divestitures",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2110104 - Disclosure - Revenues",
     "role": "http://www.biogenidec.com/role/Revenues",
     "shortName": "Revenues",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2118105 - Disclosure - Inventory",
     "role": "http://www.biogenidec.com/role/Inventory",
     "shortName": "Inventory",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2121106 - Disclosure - Intangible Assets and Goodwill",
     "role": "http://www.biogenidec.com/role/IntangibleAssetsandGoodwill",
     "shortName": "Intangible Assets and Goodwill",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2125107 - Disclosure - Fair Value Measurements",
     "role": "http://www.biogenidec.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2132108 - Disclosure - Financial Instruments",
     "role": "http://www.biogenidec.com/role/FinancialInstruments",
     "shortName": "Financial Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2140109 - Disclosure - Derivative Instruments",
     "role": "http://www.biogenidec.com/role/DerivativeInstruments",
     "shortName": "Derivative Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2143110 - Disclosure - Property, Plant and Equipment Property, Plant and Equipment",
     "role": "http://www.biogenidec.com/role/PropertyPlantandEquipmentPropertyPlantandEquipment",
     "shortName": "Property, Plant and Equipment Property, Plant and Equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2145111 - Disclosure - Indebtedness (Notes)",
     "role": "http://www.biogenidec.com/role/IndebtednessNotes",
     "shortName": "Indebtedness (Notes)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2147112 - Disclosure - Equity",
     "role": "http://www.biogenidec.com/role/Equity",
     "shortName": "Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Condensed Consolidated Statements of Income (Unaudited)",
     "role": "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
     "shortName": "Condensed Consolidated Statements of Income (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2152113 - Disclosure - Earnings per Share",
     "role": "http://www.biogenidec.com/role/EarningsperShare",
     "shortName": "Earnings per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2155114 - Disclosure - Share-based Payments",
     "role": "http://www.biogenidec.com/role/SharebasedPayments",
     "shortName": "Share-based Payments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2159115 - Disclosure - Income Taxes",
     "role": "http://www.biogenidec.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2163116 - Disclosure - Other Consolidated Financial Statement Detail",
     "role": "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail",
     "shortName": "Other Consolidated Financial Statement Detail",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2167117 - Disclosure - Collaborative and Other Relationships",
     "role": "http://www.biogenidec.com/role/CollaborativeandOtherRelationships",
     "shortName": "Collaborative and Other Relationships",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:VariableInterestEntityDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2171118 - Disclosure - Investments in Variable Interest Entities",
     "role": "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntities",
     "shortName": "Investments in Variable Interest Entities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:VariableInterestEntityDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2173119 - Disclosure - Litigation",
     "role": "http://www.biogenidec.com/role/Litigation",
     "shortName": "Litigation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "biib:BusinessOverviewPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2202201 - Disclosure - Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "biib:BusinessOverviewPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2311302 - Disclosure - Revenues (Tables)",
     "role": "http://www.biogenidec.com/role/RevenuesTables",
     "shortName": "Revenues (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2319303 - Disclosure - Inventory (Tables)",
     "role": "http://www.biogenidec.com/role/InventoryTables",
     "shortName": "Inventory (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited)",
     "role": "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited",
     "shortName": "Condensed Consolidated Statements of Comprehensive Income (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "biib:IntangibleAssetsExcludingGoodwillTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2322304 - Disclosure - Intangible Assets and Goodwill (Tables)",
     "role": "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables",
     "shortName": "Intangible Assets and Goodwill (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "biib:IntangibleAssetsExcludingGoodwillTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2326305 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.biogenidec.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2333306 - Disclosure - Financial Instruments (Tables)",
     "role": "http://www.biogenidec.com/role/FinancialInstrumentsTables",
     "shortName": "Financial Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2341307 - Disclosure - Derivative Instruments (Tables)",
     "role": "http://www.biogenidec.com/role/DerivativeInstrumentsTables",
     "shortName": "Derivative Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2348308 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables)",
     "role": "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables",
     "shortName": "Accumulated Other Comprehensive Income (Loss) (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2353309 - Disclosure - Earnings per Share (Tables)",
     "role": "http://www.biogenidec.com/role/EarningsperShareTables",
     "shortName": "Earnings per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2356310 - Disclosure - Share-Based Payments (Tables)",
     "role": "http://www.biogenidec.com/role/ShareBasedPaymentsTables",
     "shortName": "Share-Based Payments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2360311 - Disclosure - Income Taxes (Tables)",
     "role": "http://www.biogenidec.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2364312 - Disclosure - Other Consolidated Financial Statement Detail (Tables)",
     "role": "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables",
     "shortName": "Other Consolidated Financial Statement Detail (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "biib:SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2368313 - Disclosure - Collaborative and Other Relationships (Tables)",
     "role": "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables",
     "shortName": "Collaborative and Other Relationships (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "biib:SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "ibfe5725c9917439e83ae4f911eb7a60e_I20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Condensed Consolidated Balance Sheets (Unaudited)",
     "role": "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
     "shortName": "Condensed Consolidated Balance Sheets (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "ibfe5725c9917439e83ae4f911eb7a60e_I20200930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "ix:continuation",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "biib:NumberOfOphthalmolgyBiosimilarProductsExclusiveRights",
      "reportCount": 1,
      "unique": true,
      "unitRef": "product",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403401 - Disclosure - Summary of Significant Accounting Policies (Details)",
     "role": "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesDetails",
     "shortName": "Summary of Significant Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "ix:continuation",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "biib:NumberOfOphthalmolgyBiosimilarProductsExclusiveRights",
      "reportCount": 1,
      "unique": true,
      "unitRef": "product",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentInProcess",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Business Acquisition (Details Textual)",
     "role": "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual",
     "shortName": "Business Acquisition (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "i34259f1058d543a0ab98f22062f2e5ab_D20190601-20190630",
      "decimals": "INF",
      "lang": "en-US",
      "name": "biib:ClinicalAssetsAcquired",
      "reportCount": 1,
      "unique": true,
      "unitRef": "assets",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "ibfe5725c9917439e83ae4f911eb7a60e_I20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - Business Acquisition (Details)",
     "role": "http://www.biogenidec.com/role/BusinessAcquisitionDetails",
     "shortName": "Business Acquisition (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409404 - Disclosure - Divestitures (Details Textual)",
     "role": "http://www.biogenidec.com/role/DivestituresDetailsTextual",
     "shortName": "Divestitures (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "i174c6f6dc0974a4a9f1635f5f4a03baf_I20190801",
      "decimals": "-5",
      "lang": "en-US",
      "name": "biib:InventoryrawmaterialssoldtoFUJIFILM",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412405 - Disclosure - Revenues by Product (Details)",
     "role": "http://www.biogenidec.com/role/RevenuesbyProductDetails",
     "shortName": "Revenues by Product (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "i1b5da4a47c7b46c7a859d909b06ba52c_D20200701-20200930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "i626282e786b7454d83b617e9e83963e6_I20191231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413406 - Disclosure - Reserves for Discounts and Allowances (Details 1)",
     "role": "http://www.biogenidec.com/role/ReservesforDiscountsandAllowancesDetails1",
     "shortName": "Reserves for Discounts and Allowances (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "ibfe5725c9917439e83ae4f911eb7a60e_I20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414407 - Disclosure - Reserves for Discounts and Allowances (Details 2)",
     "role": "http://www.biogenidec.com/role/ReservesforDiscountsandAllowancesDetails2",
     "shortName": "Reserves for Discounts and Allowances (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "ieabb7bcb048b432c908c601e832af027_I20200930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415408 - Disclosure - Revenues from Anti-CD20 Therapeutic Programs (Details)",
     "role": "http://www.biogenidec.com/role/RevenuesfromAntiCD20TherapeuticProgramsDetails",
     "shortName": "Revenues from Anti-CD20 Therapeutic Programs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:RevenuesfromantiCD20therapeuticprogramsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "i144bad8e98d44b9283666efd91ae814b_D20200701-20200930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "biib:ShareOfCoPromotionProfits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416409 - Disclosure - Other Revenues (Details)",
     "role": "http://www.biogenidec.com/role/OtherRevenuesDetails",
     "shortName": "Other Revenues (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:OtherrevenuesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "i7aaebf479efd4e5988b193f96cfea104_D20200701-20200930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417410 - Disclosure - Revenues (Details Textual)",
     "role": "http://www.biogenidec.com/role/RevenuesDetailsTextual",
     "shortName": "Revenues (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "biib:NumberOfWholesalers",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930",
      "decimals": "INF",
      "lang": "en-US",
      "name": "biib:NumberOfWholesalers",
      "reportCount": 1,
      "unique": true,
      "unitRef": "wholesaler",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": null,
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)",
     "role": "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InventoryDisclosureTextBlock",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "ibfe5725c9917439e83ae4f911eb7a60e_I20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420411 - Disclosure - Inventory (Details)",
     "role": "http://www.biogenidec.com/role/InventoryDetails",
     "shortName": "Inventory (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InventoryDisclosureTextBlock",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "ibfe5725c9917439e83ae4f911eb7a60e_I20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423412 - Disclosure - Intangible Assets and Goodwill (Details)",
     "role": "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails",
     "shortName": "Intangible Assets and Goodwill (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:IntangibleAssetsExcludingGoodwillTableTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "i626282e786b7454d83b617e9e83963e6_I20191231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsGrossExcludingGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "i626282e786b7454d83b617e9e83963e6_I20191231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424413 - Disclosure - Intangible Assets and Goodwill (Details 1)",
     "role": "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails1",
     "shortName": "Intangible Assets and Goodwill (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:GoodwillOtherIncreaseDecrease",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "ibfe5725c9917439e83ae4f911eb7a60e_I20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427414 - Disclosure - Fair Value Measurements (Details)",
     "role": "http://www.biogenidec.com/role/FairValueMeasurementsDetails",
     "shortName": "Fair Value Measurements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "i3733833dc5534d8e823879ef2ca35162_I20200930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetImpairmentCharges",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428415 - Disclosure - Fair Value Measurements (Details Textual)",
     "role": "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual",
     "shortName": "Fair Value Measurements (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetImpairmentCharges",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "icfebb7d3ca564ab9adac39367dcd18ff_I20200930",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429416 - Disclosure - Fair Value Measurements Fair Value Measurements - Contingent Consideration (Details)",
     "role": "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails",
     "shortName": "Fair Value Measurements Fair Value Measurements - Contingent Consideration (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "icfebb7d3ca564ab9adac39367dcd18ff_I20200930",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "ibfe5725c9917439e83ae4f911eb7a60e_I20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NotesPayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430417 - Disclosure - Fair Value Measurements (Details 1)",
     "role": "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
     "shortName": "Fair Value Measurements (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "ibfe5725c9917439e83ae4f911eb7a60e_I20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NotesPayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431418 - Disclosure - Fair Value Measurements (Details 2)",
     "role": "http://www.biogenidec.com/role/FairValueMeasurementsDetails2",
     "shortName": "Fair Value Measurements (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "ibfe5725c9917439e83ae4f911eb7a60e_I20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434419 - Disclosure - Financial Instruments (Details)",
     "role": "http://www.biogenidec.com/role/FinancialInstrumentsDetails",
     "shortName": "Financial Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "ibfe5725c9917439e83ae4f911eb7a60e_I20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "ibfe5725c9917439e83ae4f911eb7a60e_I20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435420 - Disclosure - Financial Instruments (Details 1)",
     "role": "http://www.biogenidec.com/role/FinancialInstrumentsDetails1",
     "shortName": "Financial Instruments (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "ibfe5725c9917439e83ae4f911eb7a60e_I20200930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "role": "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
     "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "ibfe5725c9917439e83ae4f911eb7a60e_I20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436421 - Disclosure - Financial Instruments (Details 2)",
     "role": "http://www.biogenidec.com/role/FinancialInstrumentsDetails2",
     "shortName": "Financial Instruments (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "ibfe5725c9917439e83ae4f911eb7a60e_I20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RealizedGainLossOnInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2437422 - Disclosure - Financial Instruments (Details 3)",
     "role": "http://www.biogenidec.com/role/FinancialInstrumentsDetails3",
     "shortName": "Financial Instruments (Details 3)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RealizedGainLossOnInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "biib:AverageMaturityOfMarketableSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438423 - Disclosure - Financial Instruments (Details Textual)",
     "role": "http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual",
     "shortName": "Financial Instruments (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "biib:AverageMaturityOfMarketableSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesEquity",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2439424 - Disclosure - Financial Instruments Financial Instruments (Details Textual 2)",
     "role": "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2",
     "shortName": "Financial Instruments Financial Instruments (Details Textual 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "i9fda89e7ff7d4684af34961dfcf9aa55_I20200930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "biib:StrategicInvestmentPortfolio",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "ibfe5725c9917439e83ae4f911eb7a60e_I20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2442425 - Disclosure - Derivative Instruments (Details)",
     "role": "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
     "shortName": "Derivative Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "i626282e786b7454d83b617e9e83963e6_I20191231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "ibfe5725c9917439e83ae4f911eb7a60e_I20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2444426 - Disclosure - Property, Plant and Equipment (Details)",
     "role": "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails",
     "shortName": "Property, Plant and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "i626282e786b7454d83b617e9e83963e6_I20191231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsOfFinancingCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2446427 - Disclosure - Indebtedness (Details)",
     "role": "http://www.biogenidec.com/role/IndebtednessDetails",
     "shortName": "Indebtedness (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsOfFinancingCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsForRepurchaseOfCommonStock",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2449428 - Disclosure - Share Repurchases (Details)",
     "role": "http://www.biogenidec.com/role/ShareRepurchasesDetails",
     "shortName": "Share Repurchases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "i50a2f9335d324e4986eea98f35621996_I20191231",
      "decimals": "-8",
      "lang": "en-US",
      "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "i626282e786b7454d83b617e9e83963e6_I20191231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2450429 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details)",
     "role": "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
     "shortName": "Accumulated Other Comprehensive Income (Loss) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "ib98dd789f3514452acc95f9b041d2a7e_I20181231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NonoperatingIncomeExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2451430 - Disclosure - Reclassification out of Accumulated Other Comprehensive Income (Loss) (Details)",
     "role": "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails",
     "shortName": "Reclassification out of Accumulated Other Comprehensive Income (Loss) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "i42f682d87cc74a01aeb1af535a8ccb75_D20200701-20200930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "i88af2b9941924871abe610dc3e71811b_I20181231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - Condensed Consolidated Statement of Equity Statement",
     "role": "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
     "shortName": "Condensed Consolidated Statement of Equity Statement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "i88af2b9941924871abe610dc3e71811b_I20181231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2454431 - Disclosure - Earnings per Share (Details)",
     "role": "http://www.biogenidec.com/role/EarningsperShareDetails",
     "shortName": "Earnings per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2457432 - Disclosure - Share-Based Payments (Details)",
     "role": "http://www.biogenidec.com/role/ShareBasedPaymentsDetails",
     "shortName": "Share-Based Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2458433 - Disclosure - Share-Based Payments (Details 1)",
     "role": "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1",
     "shortName": "Share-Based Payments (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "i8ba330fe0fb04518b2ecb6db02b6b97f_D20200701-20200930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "ied38b94db9a74750b51c6e8392d4c5bf_I20190930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOther",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2461434 - Disclosure - Income Taxes (Details Textual)",
     "role": "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual",
     "shortName": "Income Taxes (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "ied38b94db9a74750b51c6e8392d4c5bf_I20190930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOther",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2462435 - Disclosure - Income Taxes (Details)",
     "role": "http://www.biogenidec.com/role/IncomeTaxesDetails",
     "shortName": "Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentIncomeInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2465436 - Disclosure - Other Consolidated Financial Statement Detail (Details)",
     "role": "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
     "shortName": "Other Consolidated Financial Statement Detail (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentIncomeInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RealizedInvestmentGainsLosses",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2466437 - Disclosure - Other Consolidated Financial Statement (Details Textual)",
     "role": "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual",
     "shortName": "Other Consolidated Financial Statement (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "i626282e786b7454d83b617e9e83963e6_I20191231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:AccruedIncomeTaxesNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromEquityMethodInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2469438 - Disclosure - Collaborative and Other Relationships - Collaborations (Details)",
     "role": "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
     "shortName": "Collaborative and Other Relationships - Collaborations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "i6da78dc59b2b49559b06d22f5860fa5e_D20200701-20200930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:UnrealizedGainLossOnInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromEquityMethodInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2470439 - Disclosure - Collaborative and Other Relationships - Equity Method Investments (Details)",
     "role": "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
     "shortName": "Collaborative and Other Relationships - Equity Method Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "i7967ad33dbdb48e89dd02f434444b459_I20181107",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsToMinorityShareholders",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2472440 - Disclosure - Investments in Variable Interest Entities (Details)",
     "role": "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails",
     "shortName": "Investments in Variable Interest Entities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:VariableInterestEntityDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "i1478c61cb1ee4cfa8414bded1c551b30_D20200101-20200930",
      "decimals": null,
      "lang": "en-US",
      "name": "biib:CollaborationAgreementTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.biogenidec.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "i626282e786b7454d83b617e9e83963e6_I20191231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyEstimateOfPossibleLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2474441 - Disclosure - Litigation (Details)",
     "role": "http://www.biogenidec.com/role/LitigationDetails",
     "shortName": "Litigation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "i626282e786b7454d83b617e9e83963e6_I20191231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyEstimateOfPossibleLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2104102 - Disclosure - Acquisitions",
     "role": "http://www.biogenidec.com/role/Acquisitions",
     "shortName": "Acquisitions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20200930.htm",
      "contextRef": "ib59ad3c4cf564cc9ab279e6f4f94ad6f_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 152,
   "tag": {
    "biib_A2.25SeniorNotesdueMay12030Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "2.25% Senior Notes due May 1, 2030 [Member]",
        "label": "2.25% Senior Notes due May 1, 2030 [Member]",
        "terseLabel": "2.250% Senior Notes due May 1, 2030"
       }
      }
     },
     "localname": "A2.25SeniorNotesdueMay12030Member",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_A2.90SeniorNotesDueSept152020Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "2.90% Senior Notes Due Sept 15, 2020 [Member]",
        "label": "2.90% Senior Notes Due Sept 15, 2020 [Member]",
        "terseLabel": "2.90% Senior Notes Due Sept 15, 2020"
       }
      }
     },
     "localname": "A2.90SeniorNotesDueSept152020Member",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_A2018ShareRepurchaseProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "2018 Share Repurchase Program [Member]",
        "label": "2018 Share Repurchase Program [Member]",
        "terseLabel": "2018 Share Repurchase Program"
       }
      }
     },
     "localname": "A2018ShareRepurchaseProgramMember",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_A3.15SeniorNotesdueMay12050Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "3.15% Senior Notes due May 1, 2050 [Member]",
        "label": "3.15% Senior Notes due May 1, 2050 [Member]",
        "terseLabel": "3.150% Senior Notes due May 1, 2050"
       }
      }
     },
     "localname": "A3.15SeniorNotesdueMay12050Member",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_AVONEXMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "AVONEX",
        "label": "AVONEX [Member]",
        "terseLabel": "AVONEX"
       }
      }
     },
     "localname": "AVONEXMember",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_AcquisitionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Acquisitions [Abstract]",
        "label": "Acquisitions [Abstract]",
        "terseLabel": "Acquisitions [Abstract]"
       }
      }
     },
     "localname": "AcquisitionsAbstract",
     "nsuri": "http://www.biogenidec.com/20200930",
     "xbrltype": "stringItemType"
    },
    "biib_AdditionalMilestonePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Additional milestone payment.",
        "label": "Additional Milestone Payment",
        "terseLabel": "Additional Milestone Payment"
       }
      }
     },
     "localname": "AdditionalMilestonePayment",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_Additionalreductioninroyaltyratepayableoncommercialsales": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Additional reduction in royalty rate payable on commercial sales",
        "label": "Additional reduction in royalty rate payable on commercial sales",
        "terseLabel": "Additional reduction in royalty rate payable on commercial sales"
       }
      }
     },
     "localname": "Additionalreductioninroyaltyratepayableoncommercialsales",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Adjustments to product revenue reserves relating to sales in prior years.",
        "label": "Adjustments To Product Revenue Reserves Relating To Sales In Prior Years",
        "negatedLabel": "Adjustments Relating To Prior Years"
       }
      }
     },
     "localname": "AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/ReservesforDiscountsandAllowancesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_AdministrativeSpaceMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Administrative Space",
        "label": "Administrative Space [Member]",
        "terseLabel": "Administrative Space"
       }
      }
     },
     "localname": "AdministrativeSpaceMember",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_AducanumabMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aducanumab [Member]",
        "label": "Aducanumab [Member]",
        "terseLabel": "Aducanumab"
       }
      }
     },
     "localname": "AducanumabMember",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amortization and Impairment of Acquired Intangible Assets",
        "label": "Amortization and Impairment of Acquired Intangible Assets",
        "terseLabel": "Amortization and impairment of acquired intangible assets"
       }
      }
     },
     "localname": "AmortizationAndImpairmentOfAcquiredIntangibleAssets",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Analysis of amount of and change in product revenue reserves.",
        "label": "Analysis Of Amount Of And Change In Product Revenue Reserves [Table Text Block]",
        "terseLabel": "Analysis of change In reserves"
       }
      }
     },
     "localname": "AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This item represents debt securities, at cost, net of adjustments made for accretion, amortization, other-than-temporary impairments, and hedging, if any, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.",
        "label": "Available For Sale Securities Debt Maturities After Five Years Amortized Cost",
        "verboseLabel": "Due after five years, amortized cost"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This item represents the fair value of debt securities, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.",
        "label": "Available For Sale Securities Debt Maturities After Five Years Fair Value",
        "verboseLabel": "Due after five years, estimated fair value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_AverageMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Average remaining time to maturity of marketable debt securities, available-for-sale securities.",
        "label": "Average Maturity Of Marketable Securities",
        "verboseLabel": "Average maturity of marketable securities, months"
       }
      }
     },
     "localname": "AverageMaturityOfMarketableSecurities",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual"
     ],
     "xbrltype": "durationItemType"
    },
    "biib_BAN2401Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "BAN2401 [Member]",
        "label": "BAN2401 [Member]",
        "terseLabel": "BAN2401"
       }
      }
     },
     "localname": "BAN2401Member",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_BENEPALIMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "BENEPALI [Member]",
        "label": "BENEPALI [Member]",
        "terseLabel": "BENEPALI"
       }
      }
     },
     "localname": "BENEPALIMember",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_BIIB111Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "BIIB111 [Member]",
        "label": "BIIB111 [Member]",
        "terseLabel": "BIIB111"
       }
      }
     },
     "localname": "BIIB111Member",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_BIIB112Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "BIIB112 [Member]",
        "label": "BIIB112 [Member]",
        "terseLabel": "BIIB112"
       }
      }
     },
     "localname": "BIIB112Member",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_BIIB118Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "BIIB118 [Member]",
        "label": "BIIB118 [Member]",
        "terseLabel": "BIIB118"
       }
      }
     },
     "localname": "BIIB118Member",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_BasicAndDilutedEarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Basic and diluted earnings per share.",
        "label": "Basic And Diluted Earnings Per Share [Abstract]",
        "verboseLabel": "Basic and diluted earnings per share"
       }
      }
     },
     "localname": "BasicAndDilutedEarningsPerShareAbstract",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_Biogenshareofcopromotionprofitsorlosses": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Biogen share of co-promotion profits or losses",
        "label": "Biogen share of co-promotion profits or losses",
        "terseLabel": "Biogen share of co-promotion profits or losses"
       }
      }
     },
     "localname": "Biogenshareofcopromotionprofitsorlosses",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_BiologicsManufacturingMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Biologics Manufacturing",
        "label": "Biologics Manufacturing [Member]",
        "terseLabel": "Biologics Manufacturing"
       }
      }
     },
     "localname": "BiologicsManufacturingMember",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_BiosimilarsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Biosimilars",
        "label": "Biosimilars [Member]",
        "terseLabel": "Biosimilars"
       }
      }
     },
     "localname": "BiosimilarsMember",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_BioverativMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Bioverativ [Member]",
        "label": "Bioverativ [Member]",
        "terseLabel": "Bioverativ"
       }
      }
     },
     "localname": "BioverativMember",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_BusinessOverviewPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Describes an overview of the company and its operations.",
        "label": "Business Overview [Policy Text Block]",
        "verboseLabel": "Overview"
       }
      }
     },
     "localname": "BusinessOverviewPolicyTextBlock",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_CashSettledPerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash settled performance shares [Member]",
        "label": "Cash settled performance shares [Member]",
        "terseLabel": "Cash settled performance shares"
       }
      }
     },
     "localname": "CashSettledPerformanceSharesMember",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_CashflowsoperatingexpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash flows, operating expenses [Member]",
        "label": "Cash flows, operating expenses [Member]",
        "terseLabel": "Cash flows, operating expenses"
       }
      }
     },
     "localname": "CashflowsoperatingexpensesMember",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_CashflowsrevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash flows, revenue [Member]",
        "label": "Cash flows, revenue [Member]",
        "terseLabel": "Cash flows, revenue"
       }
      }
     },
     "localname": "CashflowsrevenueMember",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_ClinicalAssetsAcquired": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Clinical Assets Acquired",
        "label": "Clinical Assets Acquired",
        "terseLabel": "Clinical Assets Acquired"
       }
      }
     },
     "localname": "ClinicalAssetsAcquired",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual"
     ],
     "xbrltype": "integerItemType"
    },
    "biib_CollaborationAgreementTerm": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration Agreement Term",
        "label": "Collaboration Agreement Term",
        "terseLabel": "Collaboration agreement term"
       }
      }
     },
     "localname": "CollaborationAgreementTerm",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "biib_Collaborationexpensesaccrual": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration expenses accrual",
        "label": "Collaboration expenses accrual",
        "terseLabel": "Collaboration expenses"
       }
      }
     },
     "localname": "Collaborationexpensesaccrual",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_Collaborationprofitlosssharing": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration profit (loss) sharing",
        "label": "Collaboration profit (loss) sharing",
        "terseLabel": "Collaboration profit (loss) sharing"
       }
      }
     },
     "localname": "Collaborationprofitlosssharing",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_ContractManufacturingCustomerMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contract Manufacturing Customer [Member]",
        "label": "Contract Manufacturing Customer [Member]",
        "terseLabel": "Contract Manufacturing Customer"
       }
      }
     },
     "localname": "ContractManufacturingCustomerMember",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_ContractOptionExerciseFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contract Option Exercise Fee",
        "label": "Contract Option Exercise Fee",
        "terseLabel": "Contract Option Exercise Fee"
       }
      }
     },
     "localname": "ContractOptionExerciseFee",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_ContractualAdjustmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractual adjustments.",
        "label": "Contractual Adjustments [Member]",
        "terseLabel": "Contractual adjustments"
       }
      }
     },
     "localname": "ContractualAdjustmentsMember",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/ReservesforDiscountsandAllowancesDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_CorporateDebtSecuritiesCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Corporate debt securities Current.",
        "label": "Corporate Debt Securities Current [Member]",
        "verboseLabel": "Corporate debt securities Current"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesCurrentMember",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_CorporateDebtSecuritiesNonCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Corporate Debt Securities Non Current.",
        "label": "Corporate Debt Securities Non Current [Member]",
        "verboseLabel": "Corporate debt securities Non-current"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesNonCurrentMember",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Current provisions to product revenue reserves relating to sales in current year.",
        "label": "Current Provisions To Product Revenue Reserves Relating To Sales In Current Year",
        "terseLabel": "Current Provisions Relating To Sales In Current Year"
       }
      }
     },
     "localname": "CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/ReservesforDiscountsandAllowancesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Make Whole Provision Redemption Price, Percentage",
        "label": "Debt Instrument, Make Whole Provision Redemption Price, Percentage",
        "terseLabel": "Debt instrument, make whole provision redemption price, percentage"
       }
      }
     },
     "localname": "DebtInstrumentMakeWholeProvisionRedemptionPricePercentage",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_December2019ShareRepurchaseProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "December 2019 Share Repurchase Program [Member]",
        "label": "December 2019 Share Repurchase Program [Member]",
        "terseLabel": "December 2019 Share Repurchase Program"
       }
      }
     },
     "localname": "December2019ShareRepurchaseProgramMember",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_DeferredTaxAssetsValueReductioninValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Deferred Tax Assets, Value, Reduction in Value",
        "label": "Deferred Tax Assets, Value, Reduction in Value",
        "terseLabel": "Deferred tax assets, decrease in value"
       }
      }
     },
     "localname": "DeferredTaxAssetsValueReductioninValue",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_DeferredTaxLiabilitiesValueReductioninValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Deferred Tax Liabilities, Value, Reduction in Value",
        "label": "Deferred Tax Liabilities, Value, Reduction in Value",
        "terseLabel": "Deferred tax liabilities, decrease in value"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesValueReductioninValue",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_DeferredtaxliabilityMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Deferred tax liability [Member]",
        "label": "Deferred tax liability [Member]",
        "terseLabel": "Deferred tax liability"
       }
      }
     },
     "localname": "DeferredtaxliabilityMember",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_DenaliTherapeuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Denali Therapeutics Inc",
        "label": "Denali Therapeutics Inc [Member]",
        "terseLabel": "Denali Therapeutics"
       }
      }
     },
     "localname": "DenaliTherapeuticsIncMember",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_DenmarkManufacturingOperationsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Denmark Manufacturing Operations [Member]",
        "label": "Denmark Manufacturing Operations [Member]",
        "terseLabel": "Denmark Manufacturing Operations"
       }
      }
     },
     "localname": "DenmarkManufacturingOperationsMember",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/DivestituresDetailsTextual",
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_DerivativeMaturityAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Derivative Maturity [Axis]",
        "label": "Derivative Maturity [Axis]",
        "terseLabel": "Derivative Maturity [Axis]"
       }
      }
     },
     "localname": "DerivativeMaturityAxis",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_DerivativeMaturityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "[Domain] for Derivative Maturity [Axis]",
        "label": "Derivative Maturity [Domain]",
        "terseLabel": "Derivative Maturity [Domain]"
       }
      }
     },
     "localname": "DerivativeMaturityDomain",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Derivatives used in net investment hedge, net of tax, excluded component increase (decrease)",
        "label": "Derivatives used in net investment hedge, net of tax, excluded component increase (decrease)",
        "terseLabel": "Gains (losses) on net investment hedge, excluded component"
       }
      }
     },
     "localname": "Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_DisputedClaimsRelatingtoConstructionCosts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disputed Claims Relating to Construction Costs",
        "label": "Disputed Claims Relating to Construction Costs",
        "terseLabel": "Disputed claims relating to construction costs"
       }
      }
     },
     "localname": "DisputedClaimsRelatingtoConstructionCosts",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/LitigationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_DistributorOneMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Distributor one.",
        "label": "Distributor One [Member]",
        "terseLabel": "Distributor One"
       }
      }
     },
     "localname": "DistributorOneMember",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_DistributorTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Distributor two.",
        "label": "Distributor Two [Member]",
        "terseLabel": "Distributor Two"
       }
      }
     },
     "localname": "DistributorTwoMember",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_DivestituresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Divestitures [Abstract]",
        "label": "Divestitures [Abstract]",
        "terseLabel": "Divestitures [Abstract]"
       }
      }
     },
     "localname": "DivestituresAbstract",
     "nsuri": "http://www.biogenidec.com/20200930",
     "xbrltype": "stringItemType"
    },
    "biib_DividendYieldPercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Dividend Yield Percentage",
        "label": "Dividend Yield Percentage",
        "terseLabel": "Dividend yield percentage"
       }
      }
     },
     "localname": "DividendYieldPercentage",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_DuefromantiCD20therapeuticprograms": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Receivable from anti-CD20 therapeutic programs for our share of the pre-tax co-promotion profits generated from our co-promotion arrangement for sales of RITUXAN.",
        "label": "Due from anti-CD20 therapeutic programs",
        "verboseLabel": "Due from anti-CD20 therapeutic programs"
       }
      }
     },
     "localname": "DuefromantiCD20therapeuticprograms",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_E2609andBAN2401Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "E2609 and BAN2401 [Member]",
        "label": "E2609 and BAN2401 [Member]",
        "terseLabel": "BAN2401 and Elenbecestat"
       }
      }
     },
     "localname": "E2609andBAN2401Member",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Early Call Premium and Write off of Remaining Unamortized Debt Issuance Costs",
        "label": "Early Call Premium and Write off of Remaining Unamortized Debt Issuance Costs",
        "terseLabel": "Payment of early call premium and write off of remaining unamortized debt issuance costs"
       }
      }
     },
     "localname": "EarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCosts",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_EffectiveIncomeTaxRateReconciliationChangeInForeignTaxRatePercent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation Change in Foreign Tax Rate Percent",
        "label": "Effective Income Tax Rate Reconciliation Change in Foreign Tax Rate Percent",
        "terseLabel": "Swiss tax reform"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInForeignTaxRatePercent",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Intellectual Property Rights Reorganization",
        "label": "Effective Income Tax Rate Reconciliation, Intellectual Property Rights Reorganization",
        "terseLabel": "Internal reorganization of certain intellectual property rights"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_EffectiveTaxRateReconciliationGILTItax": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Effective Tax Rate Reconciliation, GILTI tax",
        "label": "Effective Tax Rate Reconciliation, GILTI tax",
        "terseLabel": "GILTI"
       }
      }
     },
     "localname": "EffectiveTaxRateReconciliationGILTItax",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_EisaiMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Eisai [Member]",
        "label": "Eisai [Member]",
        "terseLabel": "Eisai"
       }
      }
     },
     "localname": "EisaiMember",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_ElenbecestatCollaborationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Elenbecestat Collaboration [Member]",
        "label": "Elenbecestat Collaboration [Member]",
        "terseLabel": "Elenbecestat Collaboration"
       }
      }
     },
     "localname": "ElenbecestatCollaborationMember",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_EmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Employee stock purchase plan.",
        "label": "Employee Stock Purchase Plan [Member]",
        "verboseLabel": "Employee stock purchase plan"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanMember",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_EntityWidePercentageOfRevenueFromMajorDistributors": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Entity wide percentage of revenue from major distributors.",
        "label": "Entity Wide Percentage Of Revenue From Major Distributors",
        "terseLabel": "Percentage of revenues from major distributors"
       }
      }
     },
     "localname": "EntityWidePercentageOfRevenueFromMajorDistributors",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesDetailsTextual"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity Method Investment, Ownership Percentage Before Additional Purchase Transaction",
        "label": "Equity Method Investment, Ownership Percentage Before Additional Purchase Transaction",
        "terseLabel": "Percentage of stake in entity"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_Equitymethodinvestmentbasisdifferenceamortizationperiod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity method investment basis difference amortization period",
        "label": "Equity method investment basis difference amortization period",
        "terseLabel": "Equity method investment basis difference amortization period"
       }
      }
     },
     "localname": "Equitymethodinvestmentbasisdifferenceamortizationperiod",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Estimated additional payments upon achievement of development and commercial milestones.",
        "label": "Estimated Additional Payments Upon Achievement Of Development And Commercial Milestones",
        "terseLabel": "Estimated additional payments upon achievement of development and commercial milestones"
       }
      }
     },
     "localname": "EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_ExpenseIncurredByCollaboration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total expense incurred by collaboration.",
        "label": "Expense Incurred By Collaboration",
        "terseLabel": "Expense Incurred By Collaboration"
       }
      }
     },
     "localname": "ExpenseIncurredByCollaboration",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_Expenseincurredbythecollaboration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Expense incurred by the collaboration",
        "label": "Expense incurred by the collaboration",
        "terseLabel": "Expense incurred by the collaboration"
       }
      }
     },
     "localname": "Expenseincurredbythecollaboration",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_Expensereflectedwithinstatementsofincome": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Expense reflected within statements of income",
        "label": "Expense reflected within statements of income",
        "terseLabel": "Expense reflected within statements of income"
       }
      }
     },
     "localname": "Expensereflectedwithinstatementsofincome",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_FAMPYRAMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "FAMPYRA [Member]",
        "label": "FAMPYRA [Member]",
        "terseLabel": "FAMPYRA"
       }
      }
     },
     "localname": "FAMPYRAMember",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_FLIXABIMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "FLIXABI [Member]",
        "label": "FLIXABI [Member]",
        "terseLabel": "FLIXABI"
       }
      }
     },
     "localname": "FLIXABIMember",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_FUMADERMMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "FUMADERM [Member]",
        "label": "FUMADERM [Member]",
        "terseLabel": "FUMADERM"
       }
      }
     },
     "localname": "FUMADERMMember",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_FacilityLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "-- None. No documentation exists for this element. --",
        "label": "Facility Location [Axis]",
        "terseLabel": "Facility Location [Axis]"
       }
      }
     },
     "localname": "FacilityLocationAxis",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_FacilityLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "-- None. No documentation exists for this element. --",
        "label": "Facility Location [Domain]",
        "terseLabel": "Facility Location [Domain]"
       }
      }
     },
     "localname": "FacilityLocationDomain",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_FacilityTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Facility Type",
        "label": "Facility Type [Axis]",
        "terseLabel": "Facility Type [Axis]"
       }
      }
     },
     "localname": "FacilityTypeAxis",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_FacilityTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Facility Type",
        "label": "Facility Type [Domain]",
        "terseLabel": "Facility Type [Domain]"
       }
      }
     },
     "localname": "FacilityTypeDomain",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair Value, Indefinite Lived Intangible Assets, Discount Rate",
        "label": "Fair Value, Indefinite Lived Intangible Assets, Discount Rate",
        "terseLabel": "Fair value, in-process research and development, discount rate"
       }
      }
     },
     "localname": "FairValueIndefiniteLivedIntangibleAssetsDiscountRate",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_FumarateMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fumarate [Member]",
        "label": "Fumarate [Member]",
        "terseLabel": "Fumarate"
       }
      }
     },
     "localname": "FumarateMember",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails",
      "http://www.biogenidec.com/role/RevenuesbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_FutureContingentMilestoneTypesAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Future Contingent Milestone Types [Axis]",
        "label": "Future Contingent Milestone Types [Axis]",
        "terseLabel": "Future Contingent Milestone Types [Axis]"
       }
      }
     },
     "localname": "FutureContingentMilestoneTypesAxis",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_FutureContingentMilestoneTypesDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "[Domain] for Future Contingent Milestone Types [Axis]",
        "label": "Future Contingent Milestone Types [Domain]",
        "terseLabel": "Future Contingent Milestone Types [Domain]"
       }
      }
     },
     "localname": "FutureContingentMilestoneTypesDomain",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Global Licensing Collaboration Agreement, Amount, Shares Purchased",
        "label": "Global Licensing Collaboration Agreement, Amount, Shares Purchased",
        "terseLabel": "Global Licensing Collaboration Agreement, Amount, Shares Purchased"
       }
      }
     },
     "localname": "GlobalLicensingCollaborationAgreementAmountSharesPurchased",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Global Licensing Collaboration Agreement, Payment, Achievement of First Commercial Sale Milestones",
        "label": "Global Licensing Collaboration Agreement, Payment, Achievement of First Commercial Sale Milestones",
        "terseLabel": "Global Licensing Collaboration Agreement, Payment, Achievement of First Commercial Sale Milestones"
       }
      }
     },
     "localname": "GlobalLicensingCollaborationAgreementPaymentAchievementofFirstCommercialSaleMilestones",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Global Licensing Collaboration Agreement, Payment, Achievement of Specific Sales Based Milestones",
        "label": "Global Licensing Collaboration Agreement, Payment, Achievement of Specific Sales Based Milestones",
        "terseLabel": "Global Licensing Collaboration Agreement, Payment, Achievement of Specific Sales Based Milestones"
       }
      }
     },
     "localname": "GlobalLicensingCollaborationAgreementPaymentAchievementofSpecificSalesBasedMilestones",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_GlobalLicensingCollaborationAgreementPaymentSelectionofTargets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Global Licensing Collaboration Agreement, Payment, Selection of Targets",
        "label": "Global Licensing Collaboration Agreement, Payment, Selection of Targets",
        "terseLabel": "Global Licensing Collaboration Agreement, Payment, Selection of Targets"
       }
      }
     },
     "localname": "GlobalLicensingCollaborationAgreementPaymentSelectionofTargets",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Global Licensing Collaboration Agreement, Research, Development, Regulatory and Commercial Milestone Payments",
        "label": "Global Licensing Collaboration Agreement, Research, Development, Regulatory and Commercial Milestone Payments",
        "terseLabel": "Global Licensing Collaboration Agreement, Research, Development, Regulatory and Commercial Milestone Payments"
       }
      }
     },
     "localname": "GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryandCommercialMilestonePayments",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_GlobalLicensingCollaborationAgreementSharesPurchased": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Global Licensing Collaboration Agreement, Shares, Purchased",
        "label": "Global Licensing Collaboration Agreement, Shares, Purchased",
        "terseLabel": "Global Licensing Collaboration Agreement, Shares, Purchased"
       }
      }
     },
     "localname": "GlobalLicensingCollaborationAgreementSharesPurchased",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "biib_GlobalLicensingCollaborationAgreementSharesPurchasedPerShare": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Global Licensing Collaboration Agreement, Shares Purchased Per Share",
        "label": "Global Licensing Collaboration Agreement, Shares Purchased Per Share",
        "terseLabel": "Global Licensing Collaboration Agreement, Shares Purchased Per Share"
       }
      }
     },
     "localname": "GlobalLicensingCollaborationAgreementSharesPurchasedPerShare",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "biib_GovernmentSecuritiesCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Government securities Current.",
        "label": "Government Securities Current [Member]",
        "verboseLabel": "Government securities Current"
       }
      }
     },
     "localname": "GovernmentSecuritiesCurrentMember",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_GovernmentSecuritiesNonCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Government Securities Non Current.",
        "label": "Government Securities Non-current [Member]",
        "verboseLabel": "Government securities Non-current"
       }
      }
     },
     "localname": "GovernmentSecuritiesNonCurrentMember",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_IMRALDIMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "IMRALDI [Member]",
        "label": "IMRALDI [Member]",
        "terseLabel": "IMRALDI"
       }
      }
     },
     "localname": "IMRALDIMember",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_InLicensedPatentsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "In-licensed patents.",
        "label": "In Licensed Patents [Member]",
        "terseLabel": "Acquired and in-licensed rights and patents"
       }
      }
     },
     "localname": "InLicensedPatentsMember",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_IncomeLossFromEquityMethodInvestmentsNetOfTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Income (Loss) from Equity Method Investments, Net of Tax",
        "label": "Income (Loss) from Equity Method Investments, Net of Tax",
        "negatedLabel": "Equity in (income) loss of investee, net of tax"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestmentsNetOfTax",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_IncomeTaxExpenseReductioninDeferredTaxAssetsandLiabilitiesNet": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Income Tax Expense, Reduction in Deferred Tax Assets and Liabilities, Net",
        "label": "Income Tax Expense, Reduction in Deferred Tax Assets and Liabilities, Net",
        "terseLabel": "Income tax expense associated with reductions in deferred tax assets and liabilities"
       }
      }
     },
     "localname": "IncomeTaxExpenseReductioninDeferredTaxAssetsandLiabilitiesNet",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_IndefiniteLivedIntangibleAssetsUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indefinite lived intangible assets useful life.",
        "label": "Indefinite Lived Intangible Assets Useful Life",
        "terseLabel": "Indefinite lived intangible assets useful life"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsUsefulLife",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "durationStringItemType"
    },
    "biib_IntangibleAssetsExcludingGoodwillTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Intangible assets excluding goodwill.",
        "label": "Intangible Assets Excluding Goodwill [Table Text Block]",
        "verboseLabel": "Intangible assets"
       }
      }
     },
     "localname": "IntangibleAssetsExcludingGoodwillTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_InterestInSubsidiary": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Interest in subsidiary.",
        "label": "Interest In Subsidiary",
        "verboseLabel": "Interest in subsidiary (less than given percentage)"
       }
      }
     },
     "localname": "InterestInSubsidiary",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_InterferonMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Interferon",
        "label": "Interferon [Member]",
        "terseLabel": "Interferon"
       }
      }
     },
     "localname": "InterferonMember",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_Inventorynetcurrentandnoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/InventoryDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inventory, net current and noncurrent",
        "label": "Inventory, net current and noncurrent",
        "totalLabel": "Total inventory"
       }
      }
     },
     "localname": "Inventorynetcurrentandnoncurrent",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_InventoryrawmaterialssoldtoFUJIFILM": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inventory raw materials sold to FUJIFILM",
        "label": "Inventory raw materials sold to FUJIFILM",
        "terseLabel": "Inventory raw materials sold to FUJIFILM"
       }
      }
     },
     "localname": "InventoryrawmaterialssoldtoFUJIFILM",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/DivestituresDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Investment in biotechnology companies that are determined to be unconsolidated variable interest entities.",
        "label": "Investment in biotechnology companies that are determined to be unconsolidated variable interest entities",
        "verboseLabel": "Investment in biotechnology companies that are determined to be unconsolidated variable interest entities"
       }
      }
     },
     "localname": "InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_Investmentincommonstocksharespurchased": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Investment in common stock, shares purchased",
        "label": "Investment in common stock, shares purchased",
        "terseLabel": "Investment in common stock, shares purchased"
       }
      }
     },
     "localname": "Investmentincommonstocksharespurchased",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "sharesItemType"
    },
    "biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Investments By Consolidated And Nonconsolidated Entities [Axis]",
        "label": "Investments By Consolidated And Nonconsolidated Entities [Axis]",
        "terseLabel": "Investments By Consolidated And Nonconsolidated Entities [Axis]"
       }
      }
     },
     "localname": "InvestmentsByConsolidatedAndNonconsolidatedEntitiesAxis",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "[Domain] for Investments By Consolidated And Nonconsolidated Entities [Axis]",
        "label": "Investments By Consolidated And Nonconsolidated Entities [Domain]",
        "terseLabel": "Investments By Consolidated And Nonconsolidated Entities [Domain]"
       }
      }
     },
     "localname": "InvestmentsByConsolidatedAndNonconsolidatedEntitiesDomain",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_InvestmentsInVariableInterestEntitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Investments In Variable Interest Entities.",
        "label": "Investments in Variable Interest Entities [Abstract]",
        "terseLabel": "Investments in Variable Interest Entities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsInVariableInterestEntitiesAbstract",
     "nsuri": "http://www.biogenidec.com/20200930",
     "xbrltype": "stringItemType"
    },
    "biib_IonisPharmaceuticalsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Ionis Pharmaceuticals [Member]",
        "label": "Ionis Pharmaceuticals [Member]",
        "terseLabel": "Ionis"
       }
      }
     },
     "localname": "IonisPharmaceuticalsMember",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_MSProductRevenuesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "MS Product Revenues [Member]",
        "label": "MS Product Revenues [Member]",
        "terseLabel": "MS Product Revenues"
       }
      }
     },
     "localname": "MSProductRevenuesMember",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_March2019ShareRepurchaseProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "March 2019 Share Repurchase Program [Member]",
        "label": "March 2019 Share Repurchase Program [Member]",
        "terseLabel": "2019 Share Repurchase Program"
       }
      }
     },
     "localname": "March2019ShareRepurchaseProgramMember",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_MarketStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Market stock units.",
        "label": "Market Stock Units [Member]",
        "verboseLabel": "Market stock units"
       }
      }
     },
     "localname": "MarketStockUnitsMember",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Mortgage and other asset backed securities Current.",
        "label": "Mortgage And Other Asset Backed Securities Current [Member]",
        "verboseLabel": "Mortgage and other asset backed securities Current"
       }
      }
     },
     "localname": "MortgageAndOtherAssetBackedSecuritiesCurrentMember",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Mortgage And Other Asset Backed Securities Non Current.",
        "label": "Mortgage And Other Asset Backed Securities Non Current [Member]",
        "verboseLabel": "Mortgage and other asset backed securities Non-current"
       }
      }
     },
     "localname": "MortgageAndOtherAssetBackedSecuritiesNonCurrentMember",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_NeurimmuneMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Neurimmune.",
        "label": "Neurimmune [Member]",
        "terseLabel": "Neurimmune"
       }
      }
     },
     "localname": "NeurimmuneMember",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_NightstarMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Nightstar [Member]",
        "label": "Nightstar [Member]",
        "terseLabel": "Nightstar"
       }
      }
     },
     "localname": "NightstarMember",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetails",
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_Noncontrollinginterestincreasedecreaseother": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Noncontrolling interest, increase (decrease) other",
        "label": "Noncontrolling interest, increase (decrease) other",
        "terseLabel": "Noncontrolling interest, increase (decrease) other"
       }
      }
     },
     "localname": "Noncontrollinginterestincreasedecreaseother",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_NumberOfNeurologicalDiseaseTargets": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of Neurological Disease Targets",
        "label": "Number of Neurological Disease Targets",
        "terseLabel": "Number of neurological disease targets"
       }
      }
     },
     "localname": "NumberOfNeurologicalDiseaseTargets",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "integerItemType"
    },
    "biib_NumberOfOphthalmolgyBiosimilarProductsExclusiveRights": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of Ophthalmolgy Biosimilar Products, Exclusive Rights",
        "label": "Number of Ophthalmolgy Biosimilar Products, Exclusive Rights",
        "terseLabel": "Number of potential products, exclusive rights"
       }
      }
     },
     "localname": "NumberOfOphthalmolgyBiosimilarProductsExclusiveRights",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "biib_NumberOfProductCandidates": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of Product Candidates",
        "label": "Number of Product Candidates",
        "terseLabel": "Number of product candidates"
       }
      }
     },
     "localname": "NumberOfProductCandidates",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "biib_NumberOfSquareFeet": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of Square Feet",
        "label": "Number of Square Feet",
        "terseLabel": "Number of square feet"
       }
      }
     },
     "localname": "NumberOfSquareFeet",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "biib_NumberOfWholesalers": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of Wholesalers",
        "label": "Number of Wholesalers",
        "terseLabel": "Number of wholesalers"
       }
      }
     },
     "localname": "NumberOfWholesalers",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesDetailsTextual"
     ],
     "xbrltype": "integerItemType"
    },
    "biib_October2020ShareRepurchaseProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "October 2020 Share Repurchase Program",
        "label": "October 2020 Share Repurchase Program [Member]",
        "terseLabel": "October 2020 Share Repurchase Program"
       }
      }
     },
     "localname": "October2020ShareRepurchaseProgramMember",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_OthercorporaterevenuesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other corporate revenues [Member]",
        "label": "Other corporate revenues [Member]",
        "terseLabel": "Other corporate revenues"
       }
      }
     },
     "localname": "OthercorporaterevenuesMember",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/OtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_OtherrevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other revenues [Abstract]",
        "label": "Other revenues [Abstract]",
        "terseLabel": "Other revenues [Abstract]"
       }
      }
     },
     "localname": "OtherrevenuesAbstract",
     "nsuri": "http://www.biogenidec.com/20200930",
     "xbrltype": "stringItemType"
    },
    "biib_OtherrevenuesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other revenues [Table Text Block]",
        "label": "Other revenues [Table Text Block]",
        "terseLabel": "Other revenues"
       }
      }
     },
     "localname": "OtherrevenuesTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_OtherrevenuesfromantiCD20therapeuticprograms": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other revenues from anti-CD20 therapeutic programs consists of revenue on sales of RITUXAN outside the U.S., which consist of our share of pre-tax co-promotion profits in Canada and royalty revenue on sales of Ocrevus.",
        "label": "Other revenues from anti-CD20 therapeutic programs",
        "terseLabel": "Other revenues from anti-CD20 therapeutic programs"
       }
      }
     },
     "localname": "OtherrevenuesfromantiCD20therapeuticprograms",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_OutLicensedPatentsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Out-licensed patents.",
        "label": "Out Licensed Patents [Member]",
        "terseLabel": "Out-licensed patents"
       }
      }
     },
     "localname": "OutLicensedPatentsMember",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payments/ returns applied against product revenue reserves relating to current year.",
        "label": "Payments Returns Applied Against Product Revenue Reserves Relating To Current Year",
        "negatedLabel": "Payments/Returns Relating To Sales in Current Year"
       }
      }
     },
     "localname": "PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/ReservesforDiscountsandAllowancesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payments/ returns applied against product revenue reserves relating to prior year.",
        "label": "Payments Returns Applied Against Product Revenue Reserves Relating To Prior Year",
        "negatedLabel": "Payments/Returns Relating To Sales in Prior Year"
       }
      }
     },
     "localname": "PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/ReservesforDiscountsandAllowancesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_PercentageParValueOfSeniorNotes": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage Par Value Of Senior Notes",
        "label": "Percentage Par Value Of Senior Notes",
        "terseLabel": "Percentage par value of senior notes"
       }
      }
     },
     "localname": "PercentageParValueOfSeniorNotes",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_PercentageoffuturedevelopmentcostsrelatedtoEisai": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of future development costs related to Eisai",
        "label": "Percentage of future development costs related to Eisai",
        "terseLabel": "Percentage of future development costs related to Eisai"
       }
      }
     },
     "localname": "PercentageoffuturedevelopmentcostsrelatedtoEisai",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_PerformanceStockUnitsSettledinCashMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Performance Stock Units Settled in Cash [Member]",
        "label": "Performance Stock Units Settled in Cash [Member]",
        "terseLabel": "Performance stock units settled in cash"
       }
      }
     },
     "localname": "PerformanceStockUnitsSettledinCashMember",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_PerformanceStockUnitsSettledinStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Performance Stock Units Settled in Stock [Member]",
        "label": "Performance Stock Units Settled in Stock [Member]",
        "terseLabel": "Performance stock units settled in stock"
       }
      }
     },
     "localname": "PerformanceStockUnitsSettledinStockMember",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_PlanAssetsForDeferredCompensationFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair values as of the balance sheet date of all assets of deferred compensation plans.",
        "label": "Plan Assets For Deferred Compensation Fair Value Disclosure",
        "verboseLabel": "Plan assets for deferred compensation"
       }
      }
     },
     "localname": "PlanAssetsForDeferredCompensationFairValueDisclosure",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_PostacquisitionequitycompensationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Post-acquisition equity compensation [Member]",
        "label": "Post-acquisition equity compensation [Member]",
        "terseLabel": "Post-acquisition equity compensation"
       }
      }
     },
     "localname": "PostacquisitionequitycompensationMember",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Potential future milestone payments commitment to third party approximately.",
        "label": "Potential Future Milestone Payments Commitment To Third Party Approximately",
        "terseLabel": "Potential Future Milestone Payments Commitment To Third Party Approximately"
       }
      }
     },
     "localname": "PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Pre-tax Charge, Payment of Early Call Premium and Write off of Remaining Unamortized Debt Issuance Costs, Net of Derivative Gain",
        "label": "Pre-tax Charge, Payment of Early Call Premium and Write off of Remaining Unamortized Debt Issuance Costs, Net of Derivative Gain",
        "terseLabel": "Pre-tax charge, payment of early call premium and write off of remaining unamortized debt issuance costs, net of derivative gain"
       }
      }
     },
     "localname": "PretaxChargePaymentofEarlyCallPremiumandWriteoffofRemainingUnamortizedDebtIssuanceCostsNetofDerivativeGain",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reclassification Out of Accumulated Other Comprehensive Income (Loss) [Abstract]",
        "label": "Reclassification Out of Accumulated Other Comprehensive Income (Loss) [Abstract]",
        "terseLabel": "Reclassification Out of Accumulated Other Comprehensive Income (Loss) [Abstract]"
       }
      }
     },
     "localname": "ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract",
     "nsuri": "http://www.biogenidec.com/20200930",
     "xbrltype": "stringItemType"
    },
    "biib_Reductioninroyaltyratepayableoncommercialsales": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reduction in royalty rate payable on commercial sales",
        "label": "Reduction in royalty rate payable on commercial sales",
        "terseLabel": "Reduction in royalty rate payable on commercial sales"
       }
      }
     },
     "localname": "Reductioninroyaltyratepayableoncommercialsales",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_RegulatoryApprovalMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Regulatory Approval Milestone [Member]",
        "label": "Regulatory Approval Milestone [Member]",
        "terseLabel": "Regulatory Approval Milestone [Member]"
       }
      }
     },
     "localname": "RegulatoryApprovalMilestoneMember",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_RegulatoryMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Regulatory Milestones [Member]",
        "label": "Regulatory Milestones [Member]",
        "terseLabel": "Regulatory Milestones [Member]"
       }
      }
     },
     "localname": "RegulatoryMilestonesMember",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_ResearchAndDevelopmentCostsPercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Research and Development Costs, Percentage",
        "label": "Research and Development Costs, Percentage",
        "terseLabel": "Research and development costs, percentage"
       }
      }
     },
     "localname": "ResearchAndDevelopmentCostsPercentage",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_ResearchanddevelopmentassetAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Research and development asset [Axis]",
        "label": "Research and development asset [Axis]",
        "terseLabel": "Research and development asset [Axis]"
       }
      }
     },
     "localname": "ResearchanddevelopmentassetAxis",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_ResearchanddevelopmentassetDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "[Domain] for Research and development asset [Axis]",
        "label": "Research and development asset [Domain]",
        "terseLabel": "Research and development asset [Domain]"
       }
      }
     },
     "localname": "ResearchanddevelopmentassetDomain",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_ReserveforCashDiscountsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reserve for Cash Discounts [Member]",
        "label": "Reserve for Cash Discounts [Member]",
        "terseLabel": "Discounts"
       }
      }
     },
     "localname": "ReserveforCashDiscountsMember",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/ReservesforDiscountsandAllowancesDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenues from anti-CD20 therapeutic programs",
        "label": "Revenues from anti-CD20 therapeutic programs [Table Text Block]",
        "terseLabel": "Revenues from anti-CD20 therapeutic programs"
       }
      }
     },
     "localname": "RevenuesfromantiCD20therapeuticprogramsTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_Revenuesfromanticd20therapeuticprogramsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenues from anti-cd20 therapeutic programs",
        "label": "Revenues from anti-cd20 therapeutic programs [Member]",
        "terseLabel": "Revenues from anti-CD20 therapeutic programs"
       }
      }
     },
     "localname": "Revenuesfromanticd20therapeuticprogramsMember",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/RevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_RocheGroupGenentechMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Roche group Genentech.",
        "label": "Roche Group Genentech Member",
        "terseLabel": "Genentech"
       }
      }
     },
     "localname": "RocheGroupGenentechMember",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SPINRAZAMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "SPINRAZA [Member]",
        "label": "SPINRAZA [Member]",
        "terseLabel": "SPINRAZA"
       }
      }
     },
     "localname": "SPINRAZAMember",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SamsungBiosimilarAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Samsung bio-similar agreement.",
        "label": "Samsung Biosimilar Agreement [Member]",
        "terseLabel": "Samsung Bioepis"
       }
      }
     },
     "localname": "SamsungBiosimilarAgreementMember",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/OtherRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SangamoCommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sangamo Common Stock [Member]",
        "label": "Sangamo Common Stock [Member]",
        "terseLabel": "Sangamo"
       }
      }
     },
     "localname": "SangamoCommonStockMember",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SangamoTherapeuticsInc.AgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sangamo Therapeutics, Inc. Agreement [Member]",
        "label": "Sangamo Therapeutics, Inc. Agreement [Member]",
        "terseLabel": "Sangamo Therapeutics, Inc. Agreement"
       }
      }
     },
     "localname": "SangamoTherapeuticsInc.AgreementMember",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Senior Notes Five Point Two Percent Due Twenty Forty Five [Member]",
        "label": "Senior Notes Five Point Two Percent Due Twenty Forty Five [Member]",
        "terseLabel": "5.200% Senior Notes due 2045"
       }
      }
     },
     "localname": "SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Senior Notes Four Point Zero Five Percent Due Twenty Twenty Five [Member]",
        "label": "Senior Notes Four Point Zero Five Percent Due Twenty Twenty Five [Member]",
        "terseLabel": "4.050% Senior Notes due 2025"
       }
      }
     },
     "localname": "SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Senior Notes Three Point Six Two Five Percent Due Twenty Twenty Two [Member]",
        "label": "Senior Notes Three Point Six Two Five Percent Due Twenty Twenty Two [Member]",
        "terseLabel": "3.625% Senior Notes due 2022"
       }
      }
     },
     "localname": "SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Senior Notes Two Point Nine Percent Due Twenty Twenty [Member]",
        "label": "Senior Notes Two Point Nine Percent Due Twenty Twenty [Member]",
        "terseLabel": "2.900% Senior Notes due 2020"
       }
      }
     },
     "localname": "SeniorNotesTwoPointNinePercentDueTwentyTwentyMember",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share based compensation expense included in costs and expenses.",
        "label": "Share Based Compensation Expense Included In Costs And Expenses",
        "terseLabel": "Share-based compensation expense included in total costs and expenses"
       }
      }
     },
     "localname": "ShareBasedCompensationExpenseIncludedInCostsAndExpenses",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_ShareOfCoPromotionProfits": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/RevenuesfromAntiCD20TherapeuticProgramsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share of co promotion profits.",
        "label": "Share Of Co Promotion Profits",
        "terseLabel": "Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA"
       }
      }
     },
     "localname": "ShareOfCoPromotionProfits",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_ShorttermderivativeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Short-term derivative [Member]",
        "label": "Short-term derivative [Member]",
        "terseLabel": "Short-term derivative"
       }
      }
     },
     "localname": "ShorttermderivativeMember",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SkyhawkTherapeuticsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Skyhawk Therapeutics [Member]",
        "label": "Skyhawk Therapeutics [Member]",
        "terseLabel": "Skyhawk Therapeutics"
       }
      }
     },
     "localname": "SkyhawkTherapeuticsMember",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SolothurnSwitzerlandMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Solothurn, Switzerland [Member]",
        "label": "Solothurn, Switzerland [Member]",
        "terseLabel": "Solothurn, Switzerland"
       }
      }
     },
     "localname": "SolothurnSwitzerlandMember",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_StrategicInvestmentPortfolio": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Strategic investment portfolio.",
        "label": "Strategic Investment Portfolio",
        "verboseLabel": "Strategic investment portfolio"
       }
      }
     },
     "localname": "StrategicInvestmentPortfolio",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_StrategicInvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Strategic investments.",
        "label": "Strategic Investments [Member]",
        "terseLabel": "Strategic Investments"
       }
      }
     },
     "localname": "StrategicInvestmentsMember",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Summary of total product revenue reserves included in consolidated balance sheets.",
        "label": "Summary Of Product Revenue Reserves Included In Consolidated Balance Sheets [Table Text Block]",
        "terseLabel": "Total reserves included in consolidated balance sheets"
       }
      }
     },
     "localname": "SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Summary of share-based compensation expense associated with different programs.",
        "label": "Summary of share based compensation expense associated with different programs [Abstract]",
        "terseLabel": "Summary of share based compensation expense associated with different programs [Abstract]"
       }
      }
     },
     "localname": "SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "[Table Text Block] for Summary of Activity Related to Aducanumab Collaboration [Table]",
        "label": "Summary of Activity Related to Aducanumab Collaboration [Table Text Block]",
        "terseLabel": "Summary of Activity Related to Aducanumab Collaboration"
       }
      }
     },
     "localname": "SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "[Table Text Block] for Summary of Activity Related to E2609 and BAN2401 Collaboration [Table]",
        "label": "Summary of Activity Related to E2609 and BAN2401 Collaboration [Table Text Block]",
        "terseLabel": "Summary of Activity Related to BAN2401 and Elenbecestat Collaboration"
       }
      }
     },
     "localname": "SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_TECFIDERAMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "TECFIDERA [Member]",
        "label": "TECFIDERA [Member]",
        "terseLabel": "TECFIDERA"
       }
      }
     },
     "localname": "TECFIDERAMember",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_TGNMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "TGN",
        "label": "TGN [Member]",
        "terseLabel": "TGN [Member]"
       }
      }
     },
     "localname": "TGNMember",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_TimeVestedRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Time vested restricted stock units.",
        "label": "Time Vested Restricted Stock Units [Member]",
        "verboseLabel": "Time-vested restricted stock units"
       }
      }
     },
     "localname": "TimeVestedRestrictedStockUnitsMember",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_TysabriProductMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "TYSABRI product [Member]",
        "label": "TYSABRI product [Member]",
        "terseLabel": "TYSABRI"
       }
      }
     },
     "localname": "TysabriProductMember",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails",
      "http://www.biogenidec.com/role/RevenuesbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_UCBPharmaS.A.Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "UCB Pharma S.A. [Member]",
        "label": "UCB Pharma S.A. [Member]",
        "terseLabel": "UCB Pharma S.A. [Member]"
       }
      }
     },
     "localname": "UCBPharmaS.A.Member",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of net unrealized gain (loss) related to the change in fair value of foreign currency exchange rate derivatives designated as cash flow hedging instruments. Recorded in accumulated other comprehensive income to the extent that the cash flow hedge is determined to be effective.",
        "label": "Unrealized Gain (Losses) on Foreign Currency Derivatives, Net, before Tax",
        "negatedLabel": "Gain/Loss on fair value of foreign currency forward contracts"
       }
      }
     },
     "localname": "UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total upfront and milestone payments made to collaborative partner.",
        "label": "Upfront And Milestone Payments Made To Collaborative Partner",
        "terseLabel": "Upfront and milestone payments made to collaborative partner"
       }
      }
     },
     "localname": "UpfrontAndMilestonePaymentsMadeToCollaborativePartner",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_WarehouseUtilitiesAndSupportSpaceMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Warehouse, Utilities and Support Space",
        "label": "Warehouse, Utilities and Support Space [Member]",
        "terseLabel": "Warehouse, Utilities and Support Space"
       }
      }
     },
     "localname": "WarehouseUtilitiesAndSupportSpaceMember",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_ZINBRYTAMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "ZINBRYTA [Member]",
        "label": "ZINBRYTA [Member]",
        "terseLabel": "ZINBRYTA"
       }
      }
     },
     "localname": "ZINBRYTAMember",
     "nsuri": "http://www.biogenidec.com/20200930",
     "presentation": [
      "http://www.biogenidec.com/role/OtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_BR": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "BRAZIL",
        "terseLabel": "Brazil"
       }
      }
     },
     "localname": "BR",
     "nsuri": "http://xbrl.sec.gov/country/2017-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "U.S."
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2017-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_AllCurrenciesDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "All Currencies [Domain]",
        "terseLabel": "All Currencies [Domain]"
       }
      }
     },
     "localname": "AllCurrenciesDomain",
     "nsuri": "http://xbrl.sec.gov/currency/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_CAD": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Canada, Dollars",
        "verboseLabel": "Canadian dollar"
       }
      }
     },
     "localname": "CAD",
     "nsuri": "http://xbrl.sec.gov/currency/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_CHF": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Switzerland, Francs",
        "terseLabel": "Swiss franc"
       }
      }
     },
     "localname": "CHF",
     "nsuri": "http://xbrl.sec.gov/currency/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_EUR": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Euro Member Countries, Euro",
        "verboseLabel": "Euro"
       }
      }
     },
     "localname": "EUR",
     "nsuri": "http://xbrl.sec.gov/currency/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_GBP": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "United Kingdom, Pounds",
        "terseLabel": "British pound"
       }
      }
     },
     "localname": "GBP",
     "nsuri": "http://xbrl.sec.gov/currency/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_JPY": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Japan, Yen",
        "terseLabel": "Japan, Yen"
       }
      }
     },
     "localname": "JPY",
     "nsuri": "http://xbrl.sec.gov/currency/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r493"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r494"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r495"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r495"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r495"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r496"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r495"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r495"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r495"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r495"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r491"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r492"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_CurrencyAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Currency [Axis]",
        "terseLabel": "Currency [Axis]"
       }
      }
     },
     "localname": "CurrencyAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Investment, Name [Domain]",
        "terseLabel": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r175",
      "r280",
      "r284",
      "r478"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesDetailsTextual",
      "http://www.biogenidec.com/role/RevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum",
        "verboseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum",
        "verboseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesDetailsTextual",
      "http://www.biogenidec.com/role/RevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r173",
      "r280",
      "r282",
      "r475",
      "r476"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails",
      "http://www.biogenidec.com/role/OtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesDetailsTextual",
      "http://www.biogenidec.com/role/RevenuesbyProductDetails",
      "http://www.biogenidec.com/role/RevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails",
      "http://www.biogenidec.com/role/OtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesDetailsTextual",
      "http://www.biogenidec.com/role/RevenuesbyProductDetails",
      "http://www.biogenidec.com/role/RevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r200"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Investment, Name [Axis]",
        "terseLabel": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r174",
      "r280",
      "r283",
      "r477",
      "r488",
      "r489"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesbyProductDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsAbstract",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureLineItems",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ReservesforDiscountsandAllowancesDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureTable": {
     "auth_ref": [
      "r141"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureTable",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ReservesforDiscountsandAllowancesDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_WeightedAverageMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Weighted Average [Member]",
        "terseLabel": "Weighted Average"
       }
      }
     },
     "localname": "WeightedAverageMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Reduction of accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ReservesforDiscountsandAllowancesDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r21",
      "r41",
      "r176",
      "r177",
      "r281"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "verboseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesNoncurrent": {
     "auth_ref": [
      "r37",
      "r436",
      "r460"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.",
        "label": "Accrued Income Taxes, Noncurrent",
        "terseLabel": "Accrued income taxes"
       }
      }
     },
     "localname": "AccruedIncomeTaxesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accrued Liabilities, Current [Abstract]",
        "verboseLabel": "Accrued Expenses and Other"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccruedLiabilitiesMember": {
     "auth_ref": [
      "r62"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This item represents obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered.",
        "label": "Accrued Liabilities [Member]",
        "terseLabel": "Accrued expenses and other"
       }
      }
     },
     "localname": "AccruedLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccruedRoyaltiesCurrent": {
     "auth_ref": [
      "r25",
      "r26",
      "r62"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Royalties, Current",
        "verboseLabel": "Royalties and licensing fees"
       }
      }
     },
     "localname": "AccruedRoyaltiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": {
     "auth_ref": [
      "r83",
      "r88",
      "r89",
      "r288",
      "r358"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent.",
        "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]",
        "terseLabel": "Unfunded status of postretirement benefit plans"
       }
      }
     },
     "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r56",
      "r242"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "terseLabel": "Accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": {
     "auth_ref": [
      "r88",
      "r96",
      "r357"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.",
        "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]",
        "terseLabel": "Unrealized gains (losses) on cash flow hedges"
       }
      }
     },
     "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": {
     "auth_ref": [
      "r80",
      "r81",
      "r82",
      "r88",
      "r89"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.",
        "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]",
        "terseLabel": "Unrealized gains (losses) on securities available for sale"
       }
      }
     },
     "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r88",
      "r395"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) from increase (decrease) in value of excluded component of derivative hedge, including portion attributable to noncontrolling interest.",
        "label": "Accumulated Other Comprehensive Income (Loss), Derivative Qualifying as Hedge, Excluded Component, Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Gains (losses) on net investment hedge"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r86",
      "r87",
      "r88"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "periodEndLabel": "Accumulated other comprehensive income (loss), net of tax ending balance",
        "periodStartLabel": "Accumulated other comprehensive income (loss), net of tax beginning balance",
        "terseLabel": "Balance, January 1, 2018",
        "verboseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r85",
      "r88",
      "r89",
      "r358"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedTranslationAdjustmentMember": {
     "auth_ref": [
      "r78",
      "r88",
      "r89",
      "r358"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.",
        "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]",
        "terseLabel": "Currency translation adjustments"
       }
      }
     },
     "localname": "AccumulatedTranslationAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalFinancialInformationDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.",
        "label": "Additional Financial Information Disclosure [Text Block]",
        "verboseLabel": "Other Consolidated Financial Statement Detail"
       }
      }
     },
     "localname": "AdditionalFinancialInformationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
        "label": "Additional Paid in Capital",
        "verboseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentForAmortization": {
     "auth_ref": [
      "r129",
      "r232"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.",
        "label": "Amortization",
        "negatedTerseLabel": "Amortization of basis differences"
       }
      }
     },
     "localname": "AdjustmentForAmortization",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Adjustments to reconcile net income to net cash flows from operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r291",
      "r297",
      "r300"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "negatedTerseLabel": "Compensation related to share-based payments",
        "verboseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after tax, of expense for award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Expense, after Tax",
        "totalLabel": "Subtotal",
        "verboseLabel": "Subtotal"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpenseNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r129",
      "r225",
      "r232"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "negatedTerseLabel": "Amortization of intangible assets",
        "verboseLabel": "Amortization and impairment of acquired intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r151"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share, by Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r151"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax": {
     "auth_ref": [
      "r396"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after tax, of accumulated gain (loss) from increase (decrease) in value of excluded component of derivative hedge.",
        "label": "AOCI, Derivative Qualifying as Hedge, Excluded Component, after Tax",
        "terseLabel": "Derivative qualifying as net investment hedge, excluded component"
       }
      }
     },
     "localname": "AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails",
      "http://www.biogenidec.com/role/OtherRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetBackedSecuritiesMember": {
     "auth_ref": [
      "r191",
      "r286"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.",
        "label": "Asset-backed Securities [Member]",
        "verboseLabel": "Mortgage and other asset backed securities"
       }
      }
     },
     "localname": "AssetBackedSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetImpairmentCharges": {
     "auth_ref": [
      "r129",
      "r238"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.",
        "label": "Asset Impairment Charges",
        "terseLabel": "Asset impairment charges"
       }
      }
     },
     "localname": "AssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r169",
      "r434",
      "r459"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets [Abstract]",
        "verboseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r22",
      "r23",
      "r74"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "verboseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r398"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "verboseLabel": "Total"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "verboseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r184"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross unrealized gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r185"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross unrealized losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r182",
      "r208"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Amortized cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1",
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesAmortizedCost",
       "weight": 1.0
      },
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.",
        "label": "Available-for-sale Securities",
        "terseLabel": "Marketable equity securities, fair value",
        "totalLabel": "Available-for-sale Securities"
       }
      }
     },
     "localname": "AvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1",
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r184"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesAmortizedCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before tax of unrealized gain in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.",
        "label": "Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Marketable equity securities, gross unrealized gains"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before tax of unrealized loss in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.",
        "label": "Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax",
        "negatedTerseLabel": "Marketable equity securities, gross unrealized losses"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesAmortizedCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This item represents the cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.",
        "label": "Available-for-sale Securities, Amortized Cost Basis",
        "totalLabel": "Marketable equity securities, amortized cost"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Available-for-sale Securities, Debt Maturities [Abstract]",
        "verboseLabel": "Summary of Contractual Maturities: Available-for-Sale Securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost": {
     "auth_ref": [
      "r189"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.",
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after One Through Five Years, Amortized Cost",
        "verboseLabel": "Due after one year through five years, amortized cost"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "auth_ref": [
      "r186",
      "r189",
      "r453"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.",
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after One Through Five Years, Fair Value",
        "verboseLabel": "Due after one year through five years, estimated fair value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": {
     "auth_ref": [
      "r188"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.",
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Amortized Cost",
        "verboseLabel": "Due in one year or less, amortized cost"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r186",
      "r188",
      "r452"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), maturing in next fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.",
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Fair Value",
        "verboseLabel": "Due in one year or less, estimated fair value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r179",
      "r183",
      "r208"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Marketable debt securities",
        "verboseLabel": "Fair value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r181",
      "r208"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-sale, Current",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": {
     "auth_ref": [
      "r181",
      "r208"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.",
        "label": "Debt Securities, Available-for-sale, Noncurrent",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.",
        "label": "Available-for-sale Securities [Table Text Block]",
        "verboseLabel": "Marketable debt and equity securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r292",
      "r299"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/ReservesforDiscountsandAllowancesDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r376",
      "r380"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/ReservesforDiscountsandAllowancesDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "verboseLabel": "Basis of presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetails",
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r327",
      "r328"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetails",
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionContingentConsiderationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition, Contingent Consideration [Line Items]",
        "terseLabel": "Business Acquisition, Contingent Consideration [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionContingentConsiderationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails2",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetails",
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionSharePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.",
        "label": "Business Acquisition, Share Price",
        "terseLabel": "Price per share"
       }
      }
     },
     "localname": "BusinessAcquisitionSharePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1": {
     "auth_ref": [
      "r128",
      "r340"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of right to a contingent consideration asset.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Asset",
        "terseLabel": "Reduction in contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r334",
      "r335",
      "r338"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "periodEndLabel": "Fair value, end of period",
        "periodStartLabel": "Fair value, beginning of period",
        "terseLabel": "Contingent consideration obligations"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails2",
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": {
     "auth_ref": [
      "r334",
      "r336"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Current",
        "verboseLabel": "Current portion of contingent consideration obligations"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": {
     "auth_ref": [
      "r403"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of input used to measure contingent consideration liability from business combination.",
        "label": "Business Combination, Contingent Consideration, Liability, Measurement Input",
        "terseLabel": "Discount rate"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": {
     "auth_ref": [
      "r334",
      "r336"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Noncurrent",
        "verboseLabel": "Contingent consideration obligations"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r343"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "Acquisitions"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/Acquisitions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "auth_ref": [
      "r330"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "terseLabel": "Cash and Equivalents"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities": {
     "auth_ref": [
      "r330"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investments in debt and equity securities, including, but not limited to, held-to-maturity, trading and available-for-sale expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Marketable Securities",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": {
     "auth_ref": [
      "r304",
      "r330"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities",
        "negatedTerseLabel": "Deferred Tax Liability"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets": {
     "auth_ref": [
      "r330"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets",
        "terseLabel": "In-process research and development"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetails",
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r329",
      "r330"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net",
        "terseLabel": "Total purchase price"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets": {
     "auth_ref": [
      "r330"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Assets",
        "terseLabel": "Other, net"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis": {
     "auth_ref": [
      "r325"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosures related to transactions that are recognized separately from the acquisition of assets and assumptions of liabilities in the business combination by type of transaction.",
        "label": "Business Combination, Separately Recognized Transactions [Axis]",
        "terseLabel": "Business Combination, Separately Recognized Transactions [Axis]"
       }
      }
     },
     "localname": "BusinessCombinationSeparatelyRecognizedTransactionsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain": {
     "auth_ref": [
      "r325"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of transaction that is recognized separately from the acquisition of assets and assumptions of liabilities in a business combination by transaction.",
        "label": "Business Combination, Separately Recognized Transactions [Domain]",
        "terseLabel": "Business Combination, Separately Recognized Transactions [Domain]"
       }
      }
     },
     "localname": "BusinessCombinationSeparatelyRecognizedTransactionsDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized": {
     "auth_ref": [
      "r326"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The expenses and losses recorded for each transaction with the acquiree that was recognized separately from the acquisition of assets and assumptions of liabilities in the business combination.",
        "label": "Business Combination, Separately Recognized Transactions, Expenses and Losses Recognized",
        "terseLabel": "Fair value of post-combination equity compensation",
        "verboseLabel": "NST stock options"
       }
      }
     },
     "localname": "BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Business Combinations [Abstract]",
        "terseLabel": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "verboseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Cash and Cash Equivalents [Line Items]",
        "terseLabel": "Cash and Cash Equivalents [Line Items]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock": {
     "auth_ref": [
      "r29",
      "r197"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).",
        "label": "Cash, Cash Equivalents, and Marketable Securities [Text Block]",
        "verboseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "CashCashEquivalentsAndMarketableSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r125",
      "r131",
      "r132"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents, end of the period",
        "periodStartLabel": "Cash and cash equivalents, beginning of the period",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "auth_ref": [
      "r125",
      "r414"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r53"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash Equivalents, at Carrying Value",
        "verboseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsAtCarryingValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Cash Equivalents, at Carrying Value [Abstract]",
        "verboseLabel": "Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents"
       }
      }
     },
     "localname": "CashEquivalentsAtCarryingValueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashFlowHedgingMember": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.",
        "label": "Cash Flow Hedging [Member]",
        "terseLabel": "Cash Flow Hedging [Member]"
       }
      }
     },
     "localname": "CashFlowHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual",
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r344",
      "r345",
      "r347"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "verboseLabel": "Collaborative and Other Relationships"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationships"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementMember": {
     "auth_ref": [
      "r346"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.",
        "label": "Collaborative Arrangement [Member]",
        "terseLabel": "Collaborative arrangement"
       }
      }
     },
     "localname": "CollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/OtherRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r260"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "verboseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r67",
      "r253",
      "r446",
      "r467"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "verboseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r40"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "verboseLabel": "Common stock, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r40",
      "r267"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "negatedPeriodEndLabel": "Ending balance, shares",
        "negatedPeriodStartLabel": "Beginning balance, shares"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common stock, par value $0.0005 per share"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r92",
      "r94",
      "r95"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r92",
      "r94",
      "r351",
      "r352",
      "r366"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest",
        "terseLabel": "Comprehensive income (loss) attributable to noncontrolling interests, net of tax"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r92",
      "r94",
      "r350",
      "r366"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Comprehensive income attributable to Biogen Inc."
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r133",
      "r353",
      "r367",
      "r368"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "verboseLabel": "Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressGross": {
     "auth_ref": [
      "r241"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress, Gross",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionInProgressGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConstructionPayableCurrentAndNoncurrent": {
     "auth_ref": [
      "r445",
      "r468"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for the acquisition of merchandise, materials, supplies and services pertaining to construction projects such as a housing development or factory expansion not classified as trade payables.",
        "label": "Construction Payable",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionPayableCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r286",
      "r289",
      "r479"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "verboseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r103"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of sales, excluding amortization and impairment of acquired intangible assets"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total cost and expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "verboseLabel": "Cost and expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Indebtedness"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessNotes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r33",
      "r35",
      "r36",
      "r435",
      "r437",
      "r457"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r419",
      "r421"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Face amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFairValue": {
     "auth_ref": [
      "r410"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.",
        "label": "Debt Instrument, Fair Value Disclosure",
        "verboseLabel": "Debt instruments, fair value"
       }
      }
     },
     "localname": "DebtInstrumentFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r64"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Senior notes interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r65"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPricePercentage": {
     "auth_ref": [
      "r455"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.",
        "label": "Debt Instrument, Redemption Price, Percentage",
        "terseLabel": "Debt instrument, redemption price, percentage"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPricePercentage",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r65",
      "r136",
      "r268",
      "r271",
      "r272",
      "r273",
      "r418",
      "r419",
      "r421",
      "r456"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedGain": {
     "auth_ref": [
      "r195"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Realized Gain",
        "terseLabel": "Realized gains"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRealizedGain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss": {
     "auth_ref": [
      "r195"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Realized Loss",
        "negatedLabel": "Realized losses"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRealizedLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesMember": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt instrument issued by corporations, governments and governmental agencies, municipalities, and other institutions.",
        "label": "Debt Securities [Member]",
        "verboseLabel": "Short-term debt securities"
       }
      }
     },
     "localname": "DebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible": {
     "auth_ref": [
      "r309"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit.",
        "label": "Decrease in Unrecognized Tax Benefits is Reasonably Possible",
        "terseLabel": "Decrease in unrecognized tax benefits is reasonably possible"
       }
      }
     },
     "localname": "DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r314"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Deferred tax asset"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r129",
      "r134",
      "r317",
      "r321"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r305",
      "r314"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "verboseLabel": "Deferred tax liability"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r303",
      "r315",
      "r316"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Deferred tax assets, other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill": {
     "auth_ref": [
      "r303",
      "r315",
      "r316",
      "r341",
      "r342"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from goodwill.",
        "label": "Deferred Tax Liabilities, Goodwill",
        "terseLabel": "Deferred tax liabilities, goodwill"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "auth_ref": [
      "r303",
      "r315",
      "r316"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.",
        "label": "Deferred Tax Liabilities, Other",
        "terseLabel": "Deferred tax liabilities, other"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r129",
      "r240"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r129",
      "r166"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "verboseLabel": "Depreciation, amortization and impairments"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeAsset": {
     "auth_ref": [
      "r75",
      "r76",
      "r378",
      "r430"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.",
        "label": "Derivative Asset, Fair Value, Gross Asset",
        "terseLabel": "Derivative asset, fair value"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeAsset",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeLiability": {
     "auth_ref": [
      "r75",
      "r76",
      "r378",
      "r430"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.",
        "label": "Derivative Liability, Fair Value, Gross Liability",
        "terseLabel": "Derivative liability, fair value"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r377",
      "r379",
      "r386",
      "r391"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]",
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r397"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.",
        "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]",
        "verboseLabel": "Derivative Instruments"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": {
     "auth_ref": [
      "r375",
      "r377",
      "r386"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of hedging relationship.",
        "label": "Hedging Relationship [Axis]",
        "terseLabel": "Hedging Relationship [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet": {
     "auth_ref": [
      "r383",
      "r390"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The effective portion of net gain (loss) reclassified from accumulated other comprehensive income into income on derivative instruments designated and qualifying as hedging instruments.",
        "label": "Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net",
        "terseLabel": "Gain (loss) on reclassification of cash flow hedges, effective portion"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet": {
     "auth_ref": [
      "r384",
      "r394"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of gains and losses (net) on derivative instruments designated and qualifying as hedging instruments representing (a) the amount of the hedge ineffectiveness and (b) the amount, if any, excluded from the assessment of hedge effectiveness.",
        "label": "Derivative Instruments, Gain (Loss) Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing, Net",
        "terseLabel": "Gain (loss) recognized in net income, excluded component"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeNotionalAmount": {
     "auth_ref": [
      "r370",
      "r371"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payment on derivative.",
        "label": "Derivative, Notional Amount",
        "terseLabel": "Derivative, Notional Amount"
       }
      }
     },
     "localname": "DerivativeNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeRemainingMaturity1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period remaining until the derivative contract matures, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Derivative, Remaining Maturity",
        "verboseLabel": "Range of durations of foreign currency forward contracts"
       }
      }
     },
     "localname": "DerivativeRemainingMaturity1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DerivativeTermOfContract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period the derivative contract is outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Derivative, Term of Contract",
        "terseLabel": "Remaining duration of Net Investment Hedges"
       }
      }
     },
     "localname": "DerivativeTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DerivativesFairValueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivatives, Fair Value [Line Items]",
        "terseLabel": "Derivatives [Line Items]"
       }
      }
     },
     "localname": "DerivativesFairValueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DesignatedAsHedgingInstrumentMember": {
     "auth_ref": [
      "r375"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Designated as Hedging Instrument [Member]",
        "verboseLabel": "Designated as hedging instrument"
       }
      }
     },
     "localname": "DesignatedAsHedgingInstrumentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DevelopedTechnologyRightsMember": {
     "auth_ref": [
      "r333"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.",
        "label": "Developed Technology Rights [Member]",
        "terseLabel": "Developed technology"
       }
      }
     },
     "localname": "DevelopedTechnologyRightsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DilutiveSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]",
        "verboseLabel": "Effect of dilutive securities:"
       }
      }
     },
     "localname": "DilutiveSecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Disaggregation of Revenue [Abstract]",
        "terseLabel": "Disaggregation of Revenue [Abstract]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesDetailsTextual",
      "http://www.biogenidec.com/role/RevenuesbyProductDetails",
      "http://www.biogenidec.com/role/RevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesDetailsTextual",
      "http://www.biogenidec.com/role/RevenuesbyProductDetails",
      "http://www.biogenidec.com/role/RevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r280"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Revenues by product"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r301"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "verboseLabel": "Share-based Payments"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SharebasedPayments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax": {
     "auth_ref": [
      "r1",
      "r3",
      "r5",
      "r15"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of (gain) loss recognized for the (reversal of write-down) write-down to fair value, less cost to sell, of a discontinued operation.",
        "label": "Discontinued Operation, Provision for Loss (Gain) on Disposal, Net of Tax",
        "terseLabel": "Loss on divestiture of Hiller\u00f8d, Denmark manufacturing operations, net of tax"
       }
      }
     },
     "localname": "DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DivestituresDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation": {
     "auth_ref": [
      "r2",
      "r3",
      "r4",
      "r5",
      "r12",
      "r15",
      "r306",
      "r323"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal.",
        "label": "Discontinued Operation, Tax Effect of Discontinued Operation",
        "terseLabel": "Tax expense on disposal group"
       }
      }
     },
     "localname": "DiscontinuedOperationTaxEffectOfDiscontinuedOperation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DivestituresDetailsTextual",
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Consideration",
        "terseLabel": "Consideration expected to be received for sale of Denmark Manufacturing Operations"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationConsideration",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DivestituresDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense": {
     "auth_ref": [
      "r13"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of other expense attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Other Expense",
        "terseLabel": "Expected costs to sell disposal group"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DivestituresDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown": {
     "auth_ref": [
      "r129",
      "r239",
      "r244"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of (gain) loss recognized for the (reversal of write-down) write-down to fair value, less cost to sell, of a disposal group. Excludes discontinued operations.",
        "label": "Disposal Group, Not Discontinued Operation, Loss (Gain) on Write-down",
        "terseLabel": "Loss on divestiture of Hiller\u00f8d, Denmark manufacturing operations"
       }
      }
     },
     "localname": "DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/DivestituresDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": {
     "auth_ref": [
      "r19",
      "r249"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]",
        "terseLabel": "Divestitures"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DivestituresDivestitures"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of disposal group.",
        "label": "Disposal Group Name [Domain]",
        "terseLabel": "Disposal Group Name [Domain]"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DivestituresDetailsTextual",
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DueFromRelatedParties": {
     "auth_ref": [
      "r139",
      "r424",
      "r443",
      "r470"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For an unclassified balance sheet, amounts due from related parties including affiliates, employees, joint ventures, officers and stockholders, immediate families thereof, and pension funds.",
        "label": "Due from Related Parties",
        "terseLabel": "Due from Related Parties"
       }
      }
     },
     "localname": "DueFromRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r139",
      "r424",
      "r444",
      "r469"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties.",
        "label": "Due to Related Parties",
        "terseLabel": "Due to Related Parties"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]",
        "verboseLabel": "Net income per share:"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r101",
      "r143",
      "r146",
      "r148",
      "r149",
      "r150",
      "r153",
      "r449",
      "r473"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "verboseLabel": "Basic earnings per share attributable to Biogen Inc."
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r101",
      "r143",
      "r146",
      "r148",
      "r149",
      "r150",
      "r153",
      "r449",
      "r473"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "verboseLabel": "Diluted earnings per share attributable to Biogen Inc."
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r154"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "verboseLabel": "Earnings per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents": {
     "auth_ref": [
      "r414"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.",
        "label": "Effect of Exchange Rate on Cash and Cash Equivalents",
        "negatedTerseLabel": "Effect of exchange rate changes on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r138",
      "r307",
      "r308"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Effective tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]",
        "verboseLabel": "Reconciliation between the U.S. federal statutory tax rate and effective tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r307",
      "r308",
      "r320"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "verboseLabel": "Statutory rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets": {
     "auth_ref": [
      "r307",
      "r320"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to disposition of asset. Includes, but is not limited to, intra-entity transfer of asset other than inventory.",
        "label": "Effective Income Tax Rate Reconciliation, Disposition of Asset, Percent",
        "terseLabel": "Denmark assets held for sale"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationDispositionOfAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r307",
      "r308",
      "r320"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "verboseLabel": "Taxes on foreign earnings"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization": {
     "auth_ref": [
      "r307",
      "r308",
      "r320"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to depreciation and amortization.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Depreciation and Amortization, Percent",
        "verboseLabel": "Purchased intangible assets"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses": {
     "auth_ref": [
      "r307",
      "r308",
      "r320"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to impairment loss.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Percent",
        "terseLabel": "TECFIDERA impairment"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther": {
     "auth_ref": [
      "r307",
      "r308",
      "r320"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent",
        "verboseLabel": "Permanent items"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r307",
      "r308",
      "r320"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "order": 11.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "verboseLabel": "Other"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r307",
      "r308",
      "r320"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "verboseLabel": "State taxes"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": {
     "auth_ref": [
      "r307",
      "r308",
      "r320"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent",
        "negatedLabel": "Credits and net operating loss utilization"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r62"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Collaboration expenses"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount": {
     "auth_ref": [
      "r298"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost capitalized for award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Amount Capitalized",
        "negatedTerseLabel": "Capitalized share-based compensation costs"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": {
     "auth_ref": [
      "r297"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Expense, Tax Benefit",
        "negatedLabel": "Income tax effect"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity": {
     "auth_ref": [
      "r201"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Difference between amount at which an investment accounted for under the equity method of accounting is carried (reported) on the balance sheet and amount of underlying equity in net assets the reporting Entity has in the investee.",
        "label": "Equity Method Investment, Difference Between Carrying Amount and Underlying Equity",
        "terseLabel": "Amortization of basis differences"
       }
      }
     },
     "localname": "EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r200"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Ownership Percentage",
        "terseLabel": "Equity Method Investment, Ownership Percentage",
        "verboseLabel": "Percentage of stake in entity maximum"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EquityMethodInvestments": {
     "auth_ref": [
      "r54",
      "r170",
      "r199"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.",
        "label": "Equity Method Investments",
        "terseLabel": "Investment in Samsung Bioepis"
       }
      }
     },
     "localname": "EquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiGainLoss": {
     "auth_ref": [
      "r198"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Gain (Loss)",
        "totalLabel": "Net gains (losses) recognized during the period on equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Equity Securities, FV-NI, Gain (Loss), Alternative [Abstract]",
        "terseLabel": "Equity Securities, FV-NI, Gain (Loss), Alternative [Abstract]"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiGainLossAlternativeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquitySecuritiesFvNiRealizedGainLoss": {
     "auth_ref": [
      "r198"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EquitySecuritiesFvNiGainLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Realized Gain (Loss)",
        "verboseLabel": "Less: Net gains (losses) recognized during the period on equity securities sold during the period"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiRealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": {
     "auth_ref": [
      "r198"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EquitySecuritiesFvNiGainLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)",
        "terseLabel": "Net gains recognized on the increase in fair value of equity securities",
        "verboseLabel": "Unrealized gains (losses) recognized during the period on equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesMember": {
     "auth_ref": [
      "r30",
      "r34",
      "r197",
      "r442",
      "r458",
      "r487"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants.",
        "label": "Equity Securities [Member]",
        "terseLabel": "Marketable equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]",
        "verboseLabel": "Summary of assets and liabilities recorded at fair value"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r398",
      "r399",
      "r400",
      "r408"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r404"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]",
        "terseLabel": "Fair Value by Asset Class",
        "verboseLabel": "Asset Class [Domain]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r398",
      "r408"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class [Axis]"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r286",
      "r287",
      "r289",
      "r399",
      "r426"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r398",
      "r399",
      "r402",
      "r403",
      "r409"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r407"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "verboseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueHedgingMember": {
     "auth_ref": [
      "r372"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A hedge of the exposure to changes in the fair value of a recognized asset or liability, or of an unrecognized firm commitment, that are attributable to a particular risk.",
        "label": "Fair Value Hedging [Member]",
        "terseLabel": "Fair Value Hedging [Member]"
       }
      }
     },
     "localname": "FairValueHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r286",
      "r287",
      "r289",
      "r399",
      "r427"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "verboseLabel": "Quoted Prices in Active Markets (Level 1)"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r286",
      "r287",
      "r289",
      "r399",
      "r428"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "verboseLabel": "Significant Other Observable Inputs (Level 2)"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r286",
      "r287",
      "r289",
      "r399",
      "r429"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "verboseLabel": "Significant Unobservable Inputs (Level 3)"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r404",
      "r408"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "verboseLabel": "Fair value of contingent consideration obligations"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "auth_ref": [
      "r405"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "negatedLabel": "(Gain) loss on fair value remeasurement of contingent consideration",
        "negatedTerseLabel": "Contingent consideration",
        "terseLabel": "Contingent consideration impairment"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails2",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": {
     "auth_ref": [
      "r406"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements",
        "negatedLabel": "Payments"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r407",
      "r409"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "verboseLabel": "Fair Value, Measurements, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable": {
     "auth_ref": [
      "r376",
      "r381",
      "r393"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule that discloses the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.",
        "label": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]",
        "terseLabel": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]"
       }
      }
     },
     "localname": "FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r209",
      "r210",
      "r211",
      "r212"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "verboseLabel": "Estimated life, (in years)"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r231"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r233"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months",
        "terseLabel": "Expected future amortization expense, 2020"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year",
        "terseLabel": "Expected future amortization expense, 2019 (remaining three months)"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r233"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Five",
        "terseLabel": "Expected future amortization expense, 2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r233"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Four",
        "verboseLabel": "Expected future amortization expense, 2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r233"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Three",
        "terseLabel": "Expected future amortization expense, 2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r233"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Two",
        "verboseLabel": "Expected future amortization expense, 2021"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r226",
      "r228",
      "r231",
      "r235",
      "r433"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r231",
      "r433"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "verboseLabel": "Cost"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r226",
      "r230"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r231"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyContractAssetFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of asset contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward contracts, and swaps.",
        "label": "Foreign Currency Contract, Asset, Fair Value Disclosure",
        "verboseLabel": "Derivative contracts"
       }
      }
     },
     "localname": "ForeignCurrencyContractAssetFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of liability contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward (delivery or nondelivery) contracts, and swaps entered into.",
        "label": "Foreign Currency Contracts, Liability, Fair Value Disclosure",
        "verboseLabel": "Derivative contracts"
       }
      }
     },
     "localname": "ForeignCurrencyContractsLiabilityFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r411",
      "r412",
      "r413"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), before Tax",
        "verboseLabel": "Foreign exchange gains (losses), net"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignExchangeContractMember": {
     "auth_ref": [
      "r286",
      "r389"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.",
        "label": "Foreign Exchange Contract [Member]",
        "verboseLabel": "Foreign exchange contract"
       }
      }
     },
     "localname": "ForeignExchangeContractMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnDerivativeInstrumentsNetPretax": {
     "auth_ref": [
      "r377"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.",
        "label": "Gain (Loss) on Derivative Instruments, Net, Pretax",
        "negatedTerseLabel": "Gain on interest rate swap",
        "terseLabel": "Derivative, gain on derivative",
        "verboseLabel": "Gain on interest rate swap"
       }
      }
     },
     "localname": "GainLossOnDerivativeInstrumentsNetPretax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments": {
     "auth_ref": [
      "r377",
      "r385"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in earnings in the period from the increase (decrease) in fair value of foreign currency derivatives not designated as hedging instruments.",
        "label": "Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments",
        "negatedLabel": "Net gains (losses) of other income (expense) related to foreign currency forward contracts"
       }
      }
     },
     "localname": "GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnInvestmentsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of realized and unrealized gain (loss) on investment in security.",
        "label": "Gain (Loss) on Securities [Table Text Block]",
        "terseLabel": "Gain (loss) on investments in equity securities"
       }
      }
     },
     "localname": "GainLossOnInvestmentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r217",
      "r218"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "netLabel": "Goodwill",
        "periodEndLabel": "Goodwill, end of period",
        "periodStartLabel": "Goodwill, beginning of period",
        "verboseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r237"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "verboseLabel": "Intangible Assets and Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwill"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": {
     "auth_ref": [
      "r219",
      "r221"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impaired, Accumulated Impairment Loss",
        "verboseLabel": "Accumulated impairment losses related to goodwill"
       }
      }
     },
     "localname": "GoodwillImpairedAccumulatedImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillOtherIncreaseDecrease": {
     "auth_ref": [
      "r220"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease), classified as other, of an asset representing the future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Other Increase (Decrease)",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "GoodwillOtherIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "verboseLabel": "Summary of roll forward of the changes in goodwill"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationAxis": {
     "auth_ref": [
      "r375",
      "r392"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Axis]",
        "terseLabel": "Hedging Designation [Axis]"
       }
      }
     },
     "localname": "HedgingDesignationAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationDomain": {
     "auth_ref": [
      "r375"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Domain]",
        "terseLabel": "Hedging Designation [Domain]"
       }
      }
     },
     "localname": "HedgingDesignationDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HedgingRelationshipDomain": {
     "auth_ref": [
      "r375"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Nature or intent of a hedge.",
        "label": "Hedging Relationship [Domain]",
        "terseLabel": "Hedging Relationship [Domain]"
       }
      }
     },
     "localname": "HedgingRelationshipDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r129",
      "r236"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.",
        "label": "Impairment of Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Impairment of Intangible Assets (Excluding Goodwill)"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.",
        "label": "In Process Research and Development [Member]",
        "terseLabel": "In Process Research and Development"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r137"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.",
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income before income tax expense and equity in loss of investee, net of tax"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r99",
      "r129",
      "r167",
      "r199",
      "r447",
      "r471"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).",
        "label": "Income (Loss) from Equity Method Investments",
        "negatedTerseLabel": "Our share of Samsung Bioepis gains (losses)",
        "terseLabel": "Loss on equity method investment"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions": {
     "auth_ref": [
      "r129"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This element represents the undistributed income (or loss) of equity method investments, net of dividends or other distributions received from unconsolidated subsidiaries, certain corporate joint ventures, and certain noncontrolled corporations; such investments are accounted for under the equity method of accounting. This element excludes distributions that constitute a return of investment, which are classified as investing activities.",
        "label": "Income (Loss) from Equity Method Investments, Net of Dividends or Distributions",
        "terseLabel": "Loss recorded on Samsung Bioepis joint venture"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax": {
     "auth_ref": [
      "r247"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before tax of income (loss) from an individually significant component disposed of or held-for-sale attributable to parent. Excludes discontinued operations.",
        "label": "Income (Loss) from Individually Significant Component Disposed of or Held-for-sale, Excluding Discontinued Operations, Attributable to Parent, before Income Tax",
        "negatedTerseLabel": "Loss on divestiture of Hiller\u00f8d, Denmark manufacturing operations"
       }
      }
     },
     "localname": "IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by name of disposal group.",
        "label": "Disposal Group Name [Axis]",
        "terseLabel": "Disposal Group Name [Axis]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DivestituresDetailsTextual",
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]",
        "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DivestituresDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": {
     "auth_ref": [
      "r0",
      "r6",
      "r7",
      "r8",
      "r9",
      "r10",
      "r11",
      "r14",
      "r16",
      "r17",
      "r18",
      "r246",
      "r248"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations [Table]",
        "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DivestituresDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/IndebtednessDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/IndebtednessDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r310"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LitigationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxContingencyLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Tax Contingency [Line Items]",
        "terseLabel": "Income Tax Contingency [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxContingencyLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual",
      "http://www.biogenidec.com/role/LitigationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxContingencyTable": {
     "auth_ref": [
      "r311",
      "r312",
      "r313",
      "r319"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.",
        "label": "Income Tax Contingency [Table]",
        "terseLabel": "Income Tax Contingency [Table]"
       }
      }
     },
     "localname": "IncomeTaxContingencyTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual",
      "http://www.biogenidec.com/role/LitigationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r324"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "verboseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r134",
      "r168",
      "r322"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income Tax Expense (Benefit)",
        "verboseLabel": "Income tax expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r128"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": {
     "auth_ref": [
      "r128"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.",
        "label": "Increase (Decrease) in Income Taxes Payable",
        "terseLabel": "Income tax assets and liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r128"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDueFromRelatedParties": {
     "auth_ref": [
      "r128"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in receivables to be collected from other entities that could exert significant influence over the reporting entity.",
        "label": "Increase (Decrease) in Due from Related Parties",
        "negatedLabel": "Due from anti-CD20 therapeutic programs"
       }
      }
     },
     "localname": "IncreaseDecreaseInDueFromRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi": {
     "auth_ref": [
      "r123"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Increase (Decrease) in Equity Securities, FV-NI",
        "negatedLabel": "Unrealized (gain) loss on strategic investments"
       }
      }
     },
     "localname": "IncreaseDecreaseInEquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r128"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "verboseLabel": "Changes in operating assets and liabilities, net:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": {
     "auth_ref": [
      "r128"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net",
        "negatedLabel": "Other changes in operating assets and liabilities, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingCapitalNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r147",
      "r152"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/EarningsperShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements",
        "verboseLabel": "Stock units"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r227",
      "r234"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets [Axis]",
        "terseLabel": "Indefinite-lived Intangible Assets [Axis]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r234"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)",
        "verboseLabel": "Cost and Net"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r227",
      "r234"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.",
        "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IntangibleAssetsGrossExcludingGoodwill": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.",
        "label": "Intangible Assets, Gross (Excluding Goodwill)",
        "terseLabel": "Total intangible assets, gross"
       }
      }
     },
     "localname": "IntangibleAssetsGrossExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r224",
      "r229"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "totalLabel": "Intangible assets, net",
        "verboseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Intangible Assets, Net (Excluding Goodwill) [Abstract]",
        "verboseLabel": "Intangible assets"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwillAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r97",
      "r165",
      "r417",
      "r420",
      "r450"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseMember": {
     "auth_ref": [
      "r390"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing interest expense.",
        "label": "Interest Expense [Member]",
        "terseLabel": "Interest Expense"
       }
      }
     },
     "localname": "InterestExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InterestIncomeExpenseNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Interest Income (Expense), Net [Abstract]",
        "verboseLabel": "Other Income (Expense), Net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestRateSwapMember": {
     "auth_ref": [
      "r388"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.",
        "label": "Interest Rate Swap [Member]",
        "terseLabel": "Interest rate swap"
       }
      }
     },
     "localname": "InterestRateSwapMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoriesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tangible personal property held for sale in the ordinary course of business, or in process of, or to be consumed in, production for sale.",
        "label": "Inventories [Member]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoriesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Inventory Disclosure [Abstract]",
        "terseLabel": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r216"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "verboseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/Inventory"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r47",
      "r215"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/InventoryDetails": {
       "order": 3.0,
       "parentTag": "biib_Inventorynetcurrentandnoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "verboseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r20",
      "r72",
      "r214"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "verboseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Inventory, Net [Abstract]",
        "verboseLabel": "Components of inventories"
       }
      }
     },
     "localname": "InventoryNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r49",
      "r215"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/InventoryDetails": {
       "order": 1.0,
       "parentTag": "biib_Inventorynetcurrentandnoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "verboseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r48",
      "r215"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/InventoryDetails": {
       "order": 2.0,
       "parentTag": "biib_Inventorynetcurrentandnoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "verboseLabel": "Work in process"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r105",
      "r164"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r480",
      "r482",
      "r484",
      "r486"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r480",
      "r482",
      "r484",
      "r486"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investment Type Categorization [Domain]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsAllOtherInvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Investments, All Other Investments [Abstract]",
        "terseLabel": "Investments, All Other Investments [Abstract]"
       }
      }
     },
     "localname": "InvestmentsAllOtherInvestmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "verboseLabel": "Summary of contractual maturities: available-for-sale securities"
       }
      }
     },
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]",
        "terseLabel": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "auth_ref": [
      "r398"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.",
        "label": "Investments, Fair Value Disclosure",
        "terseLabel": "Marketable equity securities"
       }
      }
     },
     "localname": "InvestmentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LegalMattersAndContingenciesTextBlock": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.",
        "label": "Legal Matters and Contingencies [Text Block]",
        "verboseLabel": "Litigation"
       }
      }
     },
     "localname": "LegalMattersAndContingenciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/Litigation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r46",
      "r440",
      "r465"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "verboseLabel": "LIABILITIES AND EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "verboseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r398"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "verboseLabel": "Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r36",
      "r262",
      "r437",
      "r461"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "verboseLabel": "Notes payable"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r65"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r65",
      "r261"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingencyDamagesSoughtValue": {
     "auth_ref": [
      "r253",
      "r254",
      "r256"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The value (monetary amount) of the award the plaintiff seeks in the legal matter.",
        "label": "Loss Contingency, Damages Sought, Value",
        "terseLabel": "Brazil tax assessment, including interest and penalties"
       }
      }
     },
     "localname": "LossContingencyDamagesSoughtValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LitigationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyEstimateOfPossibleLoss": {
     "auth_ref": [
      "r255",
      "r257",
      "r259"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.",
        "label": "Loss Contingency, Estimate of Possible Loss",
        "terseLabel": "Loss Contingency, Estimate of Possible Loss"
       }
      }
     },
     "localname": "LossContingencyEstimateOfPossibleLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LitigationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyInformationAboutLitigationMattersAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Loss Contingency, Information about Litigation Matters [Abstract]",
        "terseLabel": "Loss Contingency, Information about Litigation Matters [Abstract]"
       }
      }
     },
     "localname": "LossContingencyInformationAboutLitigationMattersAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossOnContractTermination": {
     "auth_ref": [
      "r432"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The loss recognized on termination of a contract.",
        "label": "Loss on Contract Termination",
        "terseLabel": "Loss on research and development contracts terminated with Eisai"
       }
      }
     },
     "localname": "LossOnContractTermination",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "auth_ref": [
      "r401"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement input using interest rate to determine present value of future cash flows.",
        "label": "Measurement Input, Discount Rate [Member]",
        "terseLabel": "Discount rate"
       }
      }
     },
     "localname": "MeasurementInputDiscountRateMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r401"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r71",
      "r439",
      "r464"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "verboseLabel": "Noncontrolling interests"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r286"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r125"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash flows used in financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "verboseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r125"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash flows provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "verboseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r125",
      "r126",
      "r130"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash flows provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r90",
      "r93",
      "r100",
      "r130",
      "r152",
      "r448",
      "r472"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited_1": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net income attributable to Biogen Inc.",
        "totalLabel": "Net income attributable to Biogen Inc."
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/EarningsperShareDetails",
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Income (Loss) Attributable to Parent [Abstract]",
        "verboseLabel": "Numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r90",
      "r93",
      "r355",
      "r365"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "terseLabel": "Net\u00a0income (loss) attributable to noncontrolling interests, net\u00a0of\u00a0tax"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetInvestmentHedgingMember": {
     "auth_ref": [
      "r374"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Hedges of a net investment in a foreign operation.",
        "label": "Net Investment Hedging [Member]",
        "terseLabel": "Net Investment Hedging"
       }
      }
     },
     "localname": "NetInvestmentHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "New accounting pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonUsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Countries excluding the United States of America (US).",
        "label": "Non-US [Member]",
        "terseLabel": "Rest of World"
       }
      }
     },
     "localname": "NonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r348"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Noncontrolling interest"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NondesignatedMember": {
     "auth_ref": [
      "r375"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Not Designated as Hedging Instrument [Member]",
        "terseLabel": "Not designated as hedging instrument"
       }
      }
     },
     "localname": "NondesignatedMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r106"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      },
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "terseLabel": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income (expense), net",
        "verboseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayable": {
     "auth_ref": [
      "r36",
      "r437",
      "r461"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.",
        "label": "Notes Payable",
        "verboseLabel": "Notes payable, carrying value"
       }
      }
     },
     "localname": "NotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableCurrent": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.",
        "label": "Notes Payable, Current",
        "terseLabel": "Current portion of notes payable"
       }
      }
     },
     "localname": "NotesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableFairValueDisclosure": {
     "auth_ref": [
      "r60"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of notes payable.",
        "label": "Notes Payable, Fair Value Disclosure",
        "verboseLabel": "Notes payable, fair value"
       }
      }
     },
     "localname": "NotesPayableFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segments"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenseMember": {
     "auth_ref": [
      "r390"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing expenses associated with normal operations.",
        "label": "Operating Expense [Member]",
        "terseLabel": "Operating expense"
       }
      }
     },
     "localname": "OperatingExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "negatedTerseLabel": "Operating Expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Income from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r423"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Long-term operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r422"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r25",
      "r26",
      "r27",
      "r62"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "verboseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "verboseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "verboseLabel": "Investments and other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.",
        "label": "Other Commitment",
        "terseLabel": "Contractual commitments for the construction of the facility"
       }
      }
     },
     "localname": "OtherCommitment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r80",
      "r81",
      "r86"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities. Excludes amounts related to other than temporary impairment (OTTI) loss.",
        "label": "Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, after Tax",
        "verboseLabel": "Unrealized gains (losses) on securities available for sale, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": {
     "auth_ref": [
      "r88",
      "r96"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax",
        "terseLabel": "Other comprehensive income (loss), before reclassifications, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments, of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).",
        "label": "Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax",
        "terseLabel": "Unrealized gains (losses) on cash flow hedges, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r77",
      "r416"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "verboseLabel": "Currency translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r91",
      "r94",
      "r96",
      "r267"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Other comprehensive income (loss), net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r91",
      "r94",
      "r350",
      "r351",
      "r357"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited_1": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Other comprehensive income (loss), net of tax",
        "totalLabel": "Total other comprehensive income (loss), net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "verboseLabel": "Other comprehensive income:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax": {
     "auth_ref": [
      "r84",
      "r86"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax",
        "negatedLabel": "Unrealized gains (losses) on pension benefit obligation, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCurrentAssetsMember": {
     "auth_ref": [
      "r376",
      "r393"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other current assets.",
        "label": "Other Current Assets [Member]",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherCurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherCurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other current liabilities.",
        "label": "Other Current Liabilities [Member]",
        "terseLabel": "Component of accrued expenses and other"
       }
      }
     },
     "localname": "OtherCurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/ReservesforDiscountsandAllowancesDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r24",
      "r25",
      "r62"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Total accrued expenses and other",
        "verboseLabel": "Accrued expenses and other"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "verboseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r130"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedTerseLabel": "Other"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent assets.",
        "label": "Other Noncurrent Assets [Member]",
        "terseLabel": "Other noncurrent assets"
       }
      }
     },
     "localname": "OtherNoncurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNoncurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.",
        "label": "Other Noncurrent Liabilities [Member]",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherNoncurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r107"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other nonoperating income (expense).",
        "label": "Other Nonoperating Income (Expense) [Member]",
        "terseLabel": "Other income (expense)"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherPaymentsToAcquireBusinesses": {
     "auth_ref": [
      "r115"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with other payments to acquire businesses including deposit on pending acquisitions and preacquisition costs.",
        "label": "Other Payments to Acquire Businesses",
        "terseLabel": "Payments for pre-combination equity compensation"
       }
      }
     },
     "localname": "OtherPaymentsToAcquireBusinesses",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ParentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests.",
        "label": "Parent [Member]",
        "terseLabel": "Parent",
        "verboseLabel": "Total share-based compensation expense, net of tax"
       }
      }
     },
     "localname": "ParentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsForProceedsFromDerivativeInstrumentFinancingActivities": {
     "auth_ref": [
      "r140"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net cash outflow or inflow from derivative instruments during the period, which are classified as financing activities, excluding those designated as hedging instruments.",
        "label": "Payments for (Proceeds from) Derivative Instrument, Financing Activities",
        "negatedTerseLabel": "Cash proceeds from settlement of swap"
       }
      }
     },
     "localname": "PaymentsForProceedsFromDerivativeInstrumentFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "auth_ref": [
      "r113",
      "r117",
      "r140"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.",
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r120"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedTerseLabel": "Purchases of treasury stock",
        "terseLabel": "Payments for repurchase of common stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfFinancingCosts": {
     "auth_ref": [
      "r122"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for loan and debt issuance costs.",
        "label": "Payments of Financing Costs",
        "terseLabel": "Payments of financing costs"
       }
      }
     },
     "localname": "PaymentsOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r120"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-based Payment Arrangement",
        "negatedLabel": "Payments related to issuance of stock for share-based compensation arrangements, net"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r109",
      "r114",
      "r180"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-sale",
        "negatedTerseLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired": {
     "auth_ref": [
      "r117"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with a second acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Business Two, Net of Cash Acquired",
        "negatedLabel": "Acquisition of Nightstar Therapeutics plc, net of cash acquired"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessTwoNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r115",
      "r337"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "terseLabel": "Total transaction value"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireEquityMethodInvestments": {
     "auth_ref": [
      "r115"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.",
        "label": "Payments to Acquire Equity Method Investments",
        "terseLabel": "Payments to acquire additional investment in equity method investment"
       }
      }
     },
     "localname": "PaymentsToAcquireEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r115"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination.",
        "label": "Payments to Acquire in Process Research and Development",
        "negatedTerseLabel": "Acquired in-process research and development"
       }
      }
     },
     "localname": "PaymentsToAcquireInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "auth_ref": [
      "r116"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Payments to Acquire Intangible Assets",
        "negatedTerseLabel": "Acquisitions of intangible assets"
       }
      }
     },
     "localname": "PaymentsToAcquireIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates": {
     "auth_ref": [
      "r115"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of or advances to an entity that is related to it but not strictly controlled (for example, an unconsolidated subsidiary, affiliate, and joint venture or equity method investment) or the acquisition of an additional interest in a subsidiary (controlled entity).",
        "label": "Payments to Acquire Interest in Subsidiaries and Affiliates",
        "negatedTerseLabel": "Purchase of Sangamo Therapeutics, Inc. stock"
       }
      }
     },
     "localname": "PaymentsToAcquireInterestInSubsidiariesAndAffiliates",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireOtherProductiveAssets": {
     "auth_ref": [
      "r116"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow for the purchase of or improvements to tangible or intangible assets, used to produce goods or deliver services, classified as other.",
        "label": "Payments to Acquire Other Productive Assets",
        "negatedTerseLabel": "Contingent consideration paid related to Fumapharm AG acquisition"
       }
      }
     },
     "localname": "PaymentsToAcquireOtherProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r116"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property, plant and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToMinorityShareholders": {
     "auth_ref": [
      "r122"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest.",
        "label": "Payments to Noncontrolling Interests",
        "negatedTerseLabel": "Net distribution to noncontrolling interest",
        "terseLabel": "Payments to Noncontrolling Interests"
       }
      }
     },
     "localname": "PaymentsToMinorityShareholders",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]",
        "terseLabel": "Performance units"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]",
        "terseLabel": "Preferred stock"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r39"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "verboseLabel": "Preferred stock, par value"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "verboseLabel": "Preferred stock, par value $0.001 per share"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.",
        "label": "Prepaid Expense and Other Assets",
        "terseLabel": "Prepaid research and development expenses"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromHedgeInvestingActivities": {
     "auth_ref": [
      "r113",
      "r127"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow for a financial contract that meets the hedge criteria as either a cash flow hedge, fair value hedge, or hedge of a net investment in a foreign operation.",
        "label": "Proceeds from Hedge, Investing Activities",
        "terseLabel": "Proceeds from settlement of net investment hedge"
       }
      }
     },
     "localname": "ProceedsFromHedgeInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r118"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-term Debt",
        "terseLabel": "Proceeds from borrowings"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "auth_ref": [
      "r119",
      "r122",
      "r140"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.",
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r109",
      "r110",
      "r180"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-sale",
        "terseLabel": "Proceeds from maturities and sales",
        "verboseLabel": "Proceeds from sales and maturities of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity": {
     "auth_ref": [
      "r111",
      "r180"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow associated with the sale of equity securities classified as available-for-sale securities.",
        "label": "Proceeds from Sale of Available-for-sale Securities, Equity",
        "terseLabel": "Proceeds from sales of strategic investments",
        "verboseLabel": "Proceeds from sale of available-for-sale securities, equity"
       }
      }
     },
     "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "auth_ref": [
      "r112"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.",
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "terseLabel": "Proceeds from divestiture of Hiller\u00f8d, Denmark manufacturing operations"
       }
      }
     },
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductAndServiceOtherMember": {
     "auth_ref": [
      "r282"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery and act of providing assistance, classified as other.",
        "label": "Product and Service, Other [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "ProductAndServiceOtherMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/OtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r282"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Product, net"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/RevenuesbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r90",
      "r93",
      "r124",
      "r169",
      "r172",
      "r350",
      "r354",
      "r356",
      "r365",
      "r366"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income",
        "totalLabel": "Net income",
        "verboseLabel": "Net income"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]",
        "terseLabel": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property, Plant and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentPropertyPlantandEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r55",
      "r241"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Fixed assets placed into service"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r31",
      "r32",
      "r243",
      "r466"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "verboseLabel": "Property, plant and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted": {
     "auth_ref": [
      "r38",
      "r438",
      "r462"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Minimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations.",
        "label": "Purchase Commitment, Remaining Minimum Amount Committed",
        "terseLabel": "Future minimum batch production for Denmark Manufacturing Operations"
       }
      }
     },
     "localname": "PurchaseCommitmentRemainingMinimumAmountCommitted",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DivestituresDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RealizedGainLossOnInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of realized gains and losses on investments reported in the statement of income.",
        "label": "Realized Gain (Loss) on Investments [Table Text Block]",
        "verboseLabel": "Proceeds from marketable debt securities"
       }
      }
     },
     "localname": "RealizedGainLossOnInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RealizedInvestmentGainsLosses": {
     "auth_ref": [
      "r474"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net realized gains or losses on investments during the period, not including gains or losses on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity.",
        "label": "Realized Investment Gains (Losses)",
        "terseLabel": "Gain (loss) on investments, net"
       }
      }
     },
     "localname": "RealizedInvestmentGainsLosses",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]",
        "terseLabel": "Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]"
       }
      }
     },
     "localname": "ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": {
     "auth_ref": [
      "r88",
      "r89",
      "r96"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss).",
        "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax",
        "terseLabel": "Amounts reclassified from accumulated other comprehensive income, net of tax"
       }
      }
     },
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Axis]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Axis]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Domain]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Domain]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identifies item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Member]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about items reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Table]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Table]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r121"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-term Debt",
        "negatedLabel": "Repayment of borrowings"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepurchaseAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Investments represented by an agreement between the entity and another party for the sale and repurchase of identical or substantially the same securities at a date certain for a specified price. Such agreements are generally short-term in nature.",
        "label": "Repurchase Agreements [Member]",
        "terseLabel": "Overnight reverse repurchase agreements"
       }
      }
     },
     "localname": "RepurchaseAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r302",
      "r490"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "auth_ref": [
      "r302"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentInProcess": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.",
        "label": "Research and Development in Process",
        "terseLabel": "Acquired in-process research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentInProcess",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringCharges": {
     "auth_ref": [
      "r129",
      "r250",
      "r251",
      "r252"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 9.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Charges",
        "terseLabel": "Restructuring charges"
       }
      }
     },
     "localname": "RestructuringCharges",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r43",
      "r274",
      "r463"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "verboseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]",
        "terseLabel": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r285"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/Revenues"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r279"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "terseLabel": "Revenues related to amendment of contract manufacturing agreement"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r98",
      "r162",
      "r163",
      "r171"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      },
      "http://www.biogenidec.com/role/RevenuesfromAntiCD20TherapeuticProgramsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "negatedTerseLabel": "Product revenues",
        "netLabel": "Other Revenues",
        "terseLabel": "Product revenues",
        "totalLabel": "Total revenues from anti-CD20 therapeutic programs",
        "verboseLabel": "Total revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/OtherRevenuesDetails",
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/RevenuesDetailsTextual",
      "http://www.biogenidec.com/role/RevenuesbyProductDetails",
      "http://www.biogenidec.com/role/RevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyMember": {
     "auth_ref": [
      "r282"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Money for usage-based right to asset.",
        "label": "Royalty [Member]",
        "terseLabel": "Royalty"
       }
      }
     },
     "localname": "RoyaltyMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SalesMember": {
     "auth_ref": [
      "r390"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing revenue from sale of goods and services rendered in the normal course of business.",
        "label": "Sales [Member]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "SalesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SalesReturnsAndAllowancesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A revision in the estimated reserve needed for product returns and price or other concessions granted to customers.",
        "label": "Sales Returns and Allowances [Member]",
        "terseLabel": "Returns"
       }
      }
     },
     "localname": "SalesReturnsAndAllowancesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ReservesforDiscountsandAllowancesDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "verboseLabel": "Accrued expenses and other"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r88"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Schedule of Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r151"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": {
     "auth_ref": [
      "r187",
      "r190",
      "r192",
      "r193",
      "r194",
      "r196",
      "r451",
      "r454"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.",
        "label": "Schedule of Available-for-sale Securities [Table]",
        "terseLabel": "Schedule of Available-for-sale Securities [Table]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable": {
     "auth_ref": [
      "r339"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of information about a contingent payment arrangement including the terms that will result in payment and the accounting treatment that will be followed if such contingency occurs, including the potential impact on earnings per share if the contingency is to be settled in shares of common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.",
        "label": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]",
        "terseLabel": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails2",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r327",
      "r328"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetails",
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements.",
        "label": "Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]",
        "verboseLabel": "Summary of fair and carrying value of debt instruments"
       }
      }
     },
     "localname": "ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of cash and cash equivalent balances. This table excludes restricted cash balances.",
        "label": "Schedule of Cash and Cash Equivalents [Table]",
        "terseLabel": "Schedule of Cash and Cash Equivalents [Table]"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash and cash equivalents.",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "verboseLabel": "Summary of financial assets with maturities of less than 90 days included within cash and cash equivalents"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r346"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.",
        "label": "Share-based Payment Arrangement, Cost by Plan [Table Text Block]",
        "verboseLabel": "Summary of share-based compensation expense associated with each of our share-based compensating programs"
       }
      }
     },
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": {
     "auth_ref": [
      "r377",
      "r386",
      "r392"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.",
        "label": "Derivative Instruments, Gain (Loss) [Table Text Block]",
        "verboseLabel": "Summary of the effect of cash flow derivatives designated as hedging instruments on the condensed consolidated statements of income"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": {
     "auth_ref": [
      "r381"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.",
        "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]",
        "verboseLabel": "Summary of fair value and presentation of derivatives"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r152"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "verboseLabel": "Basic and diluted earnings per share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "verboseLabel": "Reconciliation between the U.S. federal statutory tax rate and effective tax rate"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r291",
      "r296",
      "r300"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r291",
      "r296",
      "r300"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "verboseLabel": "Share-based compensation expense included in condensed consolidated statements of income"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule of Equity Method Investments [Line Items]",
        "terseLabel": "Schedule of Equity Method Investments [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsTable": {
     "auth_ref": [
      "r202"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Summarization of information required and determined to be disclosed concerning equity method investments in common stock. The summarized information includes: (a) the name of each investee or group of investees for which combined disclosure is appropriate, (2) the percentage ownership of common stock, (3) the difference, if any, between the carrying amount of an investment and the value of the underlying equity in the net assets and the accounting treatment of difference, if any, and (4) the aggregate value of each identified investment based on its quoted market price, if available.",
        "label": "Schedule of Equity Method Investments [Table]",
        "terseLabel": "Schedule of Equity Method Investments [Table]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r398",
      "r399"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "verboseLabel": "Summary of assets and liabilities recorded at fair value"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r226",
      "r230"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r222",
      "r223"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "verboseLabel": "Summary of roll forward of the changes in goodwill"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r28",
      "r50",
      "r51",
      "r52"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "verboseLabel": "Components of inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r387"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the effective portion of gains and losses on derivative instruments (and nonderivative instruments) designated and qualifying in net investment hedges recorded in accumulated other comprehensive income (loss) during the term of the hedging relationship and reclassified into earnings during the current period.",
        "label": "Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Summary of the effect of derivatives designated as net investment hedging instruments on our consolidated statement of income"
       }
      }
     },
     "localname": "ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock": {
     "auth_ref": [
      "r370"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the notional amounts of outstanding derivative positions.",
        "label": "Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block]",
        "verboseLabel": "Foreign currency forward contracts that were entered into to hedge forecasted revenue"
       }
      }
     },
     "localname": "ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.",
        "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]",
        "verboseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r56",
      "r243"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "auth_ref": [
      "r331"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofseparatelyidentifiableassetsacquiredandliabilitiesassumedTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r68",
      "r135",
      "r264",
      "r265",
      "r266",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual",
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfVariableInterestEntitiesTable": {
     "auth_ref": [
      "r359",
      "r360",
      "r361",
      "r362",
      "r363"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of qualitative and quantitative information related to variable interests the entity holds, whether or not such variable interest entity (VIE) is included in the reporting entity's consolidated financial statements. Includes, but is not limited to, description of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a tabular comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.",
        "label": "Schedule of Variable Interest Entities [Table]",
        "terseLabel": "Schedule of Variable Interest Entities [Table]"
       }
      }
     },
     "localname": "ScheduleOfVariableInterestEntitiesTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r230"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Estimated future amortization for acquired intangible assets"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r104",
      "r213"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "verboseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [
      "r108"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling, general and administrative",
        "verboseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.",
        "label": "Senior Notes [Member]",
        "terseLabel": "Senior Notes"
       }
      }
     },
     "localname": "SeniorNotesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r128"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "verboseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Abstract]",
        "verboseLabel": "Share-based Compensation Expense included in consolidated statements of income"
       }
      }
     },
     "localname": "ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r290",
      "r293"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareRepurchaseProgramAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by share repurchase program.",
        "label": "Share Repurchase Program [Axis]",
        "terseLabel": "Share Repurchase Program [Axis]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareRepurchaseProgramDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the share repurchase program.",
        "label": "Share Repurchase Program [Domain]",
        "terseLabel": "Share Repurchase Program [Domain]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r142"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of significant accounting policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r70",
      "r267"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/ReservesforDiscountsandAllowancesDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/ReservesforDiscountsandAllowancesDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r39",
      "r40",
      "r267",
      "r274",
      "r294"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "terseLabel": "Issuance of common stock under award plan, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued": {
     "auth_ref": [
      "r40",
      "r267",
      "r274"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.",
        "label": "Stock Issued During Period, Shares, Treasury Stock Reissued",
        "terseLabel": "Issuance of common stock under stock option and stock purchase plans, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesTreasuryStockReissued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r70",
      "r267",
      "r274"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Issuance of common stock under stock award plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued": {
     "auth_ref": [
      "r39",
      "r40",
      "r267",
      "r274",
      "r276"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.",
        "label": "Stock Issued During Period, Value, Treasury Stock Reissued",
        "terseLabel": "Issuance of common stock under stock option and stock purchase plans"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueTreasuryStockReissued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Authorized Amount",
        "terseLabel": "Stock Repurchase Program, Authorized Amount"
       }
      }
     },
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount remaining of a stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount",
        "terseLabel": "Amount remaining under 2019 Share Repurchase Program"
       }
      }
     },
     "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": {
     "auth_ref": [
      "r39",
      "r40",
      "r267",
      "r274"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares that have been repurchased and retired during the period.",
        "label": "Stock Repurchased and Retired During Period, Shares",
        "negatedTerseLabel": "Retirement of common stock pursuant to Share Repurchase Programs, at cost, shares"
       }
      }
     },
     "localname": "StockRepurchasedAndRetiredDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r40",
      "r44",
      "r45",
      "r178"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total Biogen Inc. shareholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "verboseLabel": "Biogen Idec Inc. shareholders' equity"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r348",
      "r349",
      "r364"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "verboseLabel": "Equity:"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r278"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/Equity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityOther": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.",
        "label": "Stockholders' Equity, Other",
        "negatedTerseLabel": "Other"
       }
      }
     },
     "localname": "StockholdersEquityOther",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r425"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual",
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r425"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual",
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxBasisOfInvestmentsCostForIncomeTaxPurposes": {
     "auth_ref": [
      "r481",
      "r483",
      "r485"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate cost of investments for Federal income tax purposes.",
        "label": "Tax Basis of Investments, Cost for Income Tax Purposes",
        "terseLabel": "Tax Basis of Investments, Cost for Income Tax Purposes"
       }
      }
     },
     "localname": "TaxBasisOfInvestmentsCostForIncomeTaxPurposes",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/BusinessAcquisitionDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsIncomeTaxExpense": {
     "auth_ref": [
      "r318"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income tax expense from transition tax on accumulated earnings of controlled foreign corporation deemed repatriated pursuant to Tax Cuts and Jobs Act.",
        "label": "Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Income Tax Expense",
        "terseLabel": "Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Income Tax Expense"
       }
      }
     },
     "localname": "TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsIncomeTaxExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxesPayableCurrent": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Taxes Payable, Current",
        "verboseLabel": "Taxes payable"
       }
      }
     },
     "localname": "TaxesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TrademarksAndTradeNamesMember": {
     "auth_ref": [
      "r332"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style, or rights either acquired through registration of a business name to gain or protect exclusive use thereof.",
        "label": "Trademarks and Trade Names [Member]",
        "terseLabel": "Trademarks and Trade Names"
       }
      }
     },
     "localname": "TrademarksAndTradeNamesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r431"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease": {
     "auth_ref": [
      "r415"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in the cumulative translation adjustment from gain (loss), after tax, on foreign currency derivatives, that are designated as, and are effective as, economic hedges of a net investment in a foreign entity.",
        "label": "Derivatives used in Net Investment Hedge, Net of Tax, Period Increase (Decrease)",
        "terseLabel": "Gains (losses) on net investment hedges"
       }
      }
     },
     "localname": "TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r69",
      "r276"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]",
        "terseLabel": "Treasury stock"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockRetiredCostMethodAmount": {
     "auth_ref": [
      "r40",
      "r267",
      "r275"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of decrease of par value, additional paid in capital (APIC) and retained earnings of common and preferred stock retired from treasury when treasury stock is accounted for under the cost method.",
        "label": "Treasury Stock, Retired, Cost Method, Amount",
        "negatedTerseLabel": "Retirement of common stock pursuant to Share Repurchase Progams, at cost"
       }
      }
     },
     "localname": "TreasuryStockRetiredCostMethodAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "auth_ref": [
      "r40",
      "r267",
      "r274"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.",
        "label": "Treasury Stock, Shares, Acquired",
        "negatedTerseLabel": "Repurchase of common stock, at cost, shares",
        "terseLabel": "Repurchase of common stock, at cost, shares"
       }
      }
     },
     "localname": "TreasuryStockSharesAcquired",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r69",
      "r276",
      "r277"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "negatedLabel": "Treasury stock, at cost"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "auth_ref": [
      "r267",
      "r274",
      "r276"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.",
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "negatedTerseLabel": "Repurchase of common stock, at cost"
       }
      }
     },
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r346"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails",
      "http://www.biogenidec.com/role/OtherRevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USTreasuryAndGovernmentMember": {
     "auth_ref": [
      "r286",
      "r441",
      "r479"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This category includes investments in debt securities issued by the United States Department of the Treasury, US Government Agencies and US Government-sponsored Enterprises. Such securities may include treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years), debt securities issued by the Government National Mortgage Association (Ginnie Mae) and debt securities issued by the Federal National Mortgage Association (Fannie Mae) or the Federal Home Loan Mortgage Corporation (Freddie Mac).",
        "label": "US Treasury and Government [Member]",
        "verboseLabel": "Government securities"
       }
      }
     },
     "localname": "USTreasuryAndGovernmentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax": {
     "auth_ref": [
      "r382"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of net unrealized gain (loss) related to the change in fair value of foreign currency exchange rate derivatives designated as cash flow hedging instruments. Recorded in accumulated other comprehensive income to the extent that the cash flow hedge is determined to be effective.",
        "label": "Unrealized Gain (Loss) on Foreign Currency Derivatives, Net, before Tax",
        "terseLabel": "Unrealized gain (loss) on net investment hedges in AOCI"
       }
      }
     },
     "localname": "UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrealizedGainLossOnInvestments": {
     "auth_ref": [
      "r129"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of investments, not including unrealized gains or losses on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, held at each balance sheet date and included in earnings for the period.",
        "label": "Unrealized Gain (Loss) on Investments",
        "negatedTerseLabel": "Unrealized Gain (Loss) on Investments"
       }
      }
     },
     "localname": "UnrealizedGainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "verboseLabel": "Use of estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesBalance": {
     "auth_ref": [
      "r141"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "terseLabel": "Total Reserves",
        "verboseLabel": "Revenue-related reserves for discounts and allowances"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesBalance",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/ReservesforDiscountsandAllowancesDetails1",
      "http://www.biogenidec.com/role/ReservesforDiscountsandAllowancesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ReservesforDiscountsandAllowancesDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesTypeAxis": {
     "auth_ref": [
      "r141"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ReservesforDiscountsandAllowancesDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableInterestEntityDisclosureTextBlock": {
     "auth_ref": [
      "r369"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for a variable interest entity (VIE), including but not limited to, judgments and assumptions in determining whether to consolidate and in identifying the primary beneficiary, gain (loss) recognized on the initial consolidation of the VIE, terms of arrangements, amounts and classification of the VIE's assets and liabilities, and the entity's maximum exposure to loss.",
        "label": "Variable Interest Entity Disclosure [Text Block]",
        "verboseLabel": "Investments in Variable Interest Entities"
       }
      }
     },
     "localname": "VariableInterestEntityDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableInterestEntityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Variable Interest Entity [Line Items]",
        "terseLabel": "Variable Interest Entity [Line Items]"
       }
      }
     },
     "localname": "VariableInterestEntityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "auth_ref": [
      "r150"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/EarningsperShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.",
        "label": "Weighted Average Number Diluted Shares Outstanding Adjustment",
        "totalLabel": "Dilutive potential common shares"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r145",
      "r150"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/EarningsperShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted earnings per share attributable to Biogen Inc.",
        "totalLabel": "Shares used in calculating diluted earnings per share"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "verboseLabel": "Weighted-average shares used in calculating:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r144",
      "r150"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/EarningsperShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average number of common shares outstanding",
        "verboseLabel": "Basic earnings per share attributable to Biogen Inc."
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 11
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e957-107759"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3151-108585"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3444-108585"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3000-108585"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "27",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3581-108585"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(d),(e))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(1)(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24092-122690"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1448-109256"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1505-109256"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1500-109256"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8813-108599"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9054-108599"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4428-111522"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4531-111522"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26610-111562"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26853-111562"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26626-111562"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27198-111563"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27198-111563"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/subtopic&trid=2122178"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27198-111563"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27232-111563"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27290-111563"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27337-111563"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27340-111563"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27357-111563"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27357-111563"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=116654751&loc=SL75117546-209714"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721523-107759"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(b)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919244-210447"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919253-210447"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919258-210447"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919230-210447"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118942338&loc=SL82898722-210454"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922888-210455"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922895-210455"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922900-210455"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118942371&loc=SL82922954-210456"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=68048583&loc=d3e3636-108311"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116846819&loc=d3e3927-108312"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=77989000&loc=SL49117168-202975"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13854-109267"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2420-110228"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2443-110228"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6904-107765"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6911-107765"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14326-108349"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14435-108349"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14435-108349"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14557-108349"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14557-108349"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=118943654&loc=d3e12021-110248"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6935-107765"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e7018-107765"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130556-203045"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(j)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=117330534&loc=d3e28680-109314"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e31917-109318"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e31931-109318"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=117331294&loc=d3e36027-109320"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116868840&loc=d3e2207-128464"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116869197&loc=d3e4845-128472"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116869197&loc=d3e4845-128472"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5263-128473"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5504-128473"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "b",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "c",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "740",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=117412053&loc=d3e9972-128506"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "740",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=117412053&loc=d3e9979-128506"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "http://asc.fasb.org/topic&trid=2303972"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4613674-111683"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=118582676&loc=d3e5710-111685"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=118582676&loc=d3e5728-111685"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=118582676&loc=SL6759159-111685"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=118582676&loc=d3e5747-111685"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=118582676&loc=SL6228884-111685"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4590271-111686"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4591551-111686"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4591552-111686"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3A-02)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116822174&loc=d3e355033-122828"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3A-03)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116822174&loc=d3e355100-122828"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579245-113959"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5580258-113959"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(i)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41620-113959"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(ii)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41620-113959"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(iii)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41620-113959"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41620-113959"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(25))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CCC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL109998896-113959"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624181-113959"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "182",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=116861445&loc=SL5629052-113961"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Subparagraph": "(a)(1),(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109977999&loc=d3e76258-113986"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=112277219&loc=d3e80784-113994"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=112277219&loc=d3e80784-113994"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "815",
   "URI": "http://asc.fasb.org/topic&trid=2229140"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1012-107759"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13433-108611"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30690-110894"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30700-110894"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b),(c),(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b,c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=SL51823488-111719"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "275",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=84167019&loc=d3e54681-109401"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(17))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6)(a)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.10(3))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(3),(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62557-112803"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "e",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(b))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.17)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.3)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04.3(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117420044&loc=d3e19393-158473"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(2)(i))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611133-123010"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(8)(d))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611133-123010"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12C(1)(a))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611225-123010"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12C(11)(d))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611225-123010"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13(1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611282-123010"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13(7)(d))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611282-123010"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611379-123010"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611379-123010"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=6589523&loc=d3e617274-123014"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r491": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r492": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r493": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-13"
  },
  "r494": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1-"
  },
  "r495": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r496": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20,22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(b),(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i),(j),(k)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i-k)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e681-108580"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669686-108580"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL34724394-108580"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e557-108580"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118951672&loc=d3e1436-108581"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(12))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>127
<FILENAME>0000875045-20-000036-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000875045-20-000036-xbrl.zip
M4$L#!!0    (  N*55'GA0,I@Y8$ #,W/@ 1    8FEI8BTR,#(P,#DS,"YH
M=&WLO6M[$\>R-OQ]_XJ\?-Y*^E!]RK56G@MBPL-ZL E@DF5_R55570T"']B2
M#9A?_U;;F-,B.Q",1C,H$&Q)HQEI[KNK[NJNJO['_WEY>/#=<UDLY\='_[QF
MOS?7OOL_/_WC_YO-_GWC_IWOMH[Y]%".3K[[>2%X(O6[%_.3Q]_]7F7Y]+NV
M.#[\[O?CQ=/Y<YS-SM_S\_&SL\7\T>.3[YQQYH,7%S^6FK.ST<Z80YJ!9#<K
MI< L&V,AE5R@Q?]^]",F<H3<9D'$S: %FI4&989@Q &ZX#/_=_V1;&DMEV@R
M9[ Q8_3!1M.<-(3<?+_LXQ/]=OH-CY8_\O'IT<GB[)_7'I^<//OQAQ]>TN+@
M^Z7P]X^.G__P^L4?G+%I9NS,VVNOWU9E_O&WZ O]\/+^X?V0MV]X\>+%]^=O
M.EX\TH.-_V%^M#S!(Y8WQR_?/_J%OSS6_O#O[3L/^+$<XNS#=\U?GLST<[SW
MSLO/-3\ZF!])1^^'DP4>+=OQXA!/%-W^:</,Y'<^+9\N%G+$?W937K_ZD:\Y
M?_EGW]'Z=S[!NW>E?G ?7W_-^,/%BY>'GIXL_O3VE1_TU=<'?NRN6673#R\[
MYI=G6RY.WAS8<$GGA^F3'_U*)Q^_\%_=4#=S\?(D-)_3>V>A^?$C.9I7O:5\
M?/A#'Q:F>//FQNBIG_[Y5^FOOOE\RV-P-OUOW+HXXO(-_W'J]X_N+Q,NWW#J
M=#E[A/CL/V_7ZQ<^O&4_'N#1HW]>DZ/9PP?7=*0)UI_^<2@G^%T_P4S^YW3^
M_)_7?CX^.E'[,=L]>Z97XHM'_[QV(B]/?C@'ZH>?_NN__NL?)_.3 _FIW[W9
MY2WZQP\73_[CAXM3TW$]^^D?=?[\N^7)V8'\\UJ=+Y\=X-F/1\='HA]@_O+'
M?J L+GZ=URI'Y[_JZSMJQ!9SOKC^RY/[TOYY;4ZA8/4,W$($YH+D4I'8H!7
M&ML?6^<?Q>I7?@O;$1[V2\O\QYM'^OG.?M:OL\"#VT=57OX_.;OVW;SJJ:O_
M[8RVCI_?<?>?[_GMT_KDYO/]6^7)W</;+^_^OG]X=^NIV]YZ_.3NUKV7.T\>
M/]YYLFVW=_=>[#_YU\'^X4US]];>JSM^YV#OU;/Y]N[!X?Z31V'GR778>_7(
MZ'&PM[OW:F?WIMN^M7>V__O^XYVMQX?;-IL[;O]L[W>.^UOW7NQO_7:X[>X_
MW7MRS^_<NNWVGSP^O'MK_V#[UG;8V=U^H3]A9VO[>;WURYQN/8S;O^\_V=F]
M[?8.?WFZO77SU<ZMG</]6S>#GLMO'][6ZSZ$G5</P_ZMO=?O^4VO%8[V=X]?
M[NO5MY_LS_=^O_=B>W?;[+G]IWN[!T]WMOA,K_]R9_>1W]''^P?YY9W=FR?;
M#XS^O/X'6A\"A#;C;N0!39UA9:,4 R>4"IIFKOUD]+^<@H'PCQ_>P_/JX;T8
MV_KNER<_5G5XAWK&QQ7/W@7^YW.S>/++?,EXL">XN'E4M_38#?9_A?W9N]A;
MU0!826;82IR!"7E6DO<S=>+L?#'18KCVDW4_>/O587\+[J7@>8ON+_K,<H/M
M7V'[ZEUL(^28/<(L8E0%QX5FV:&=42U9=5XV >':3_W^#P;MKWK^X[H!]Y/
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MDX=+::<'=^9MX$DAMW-)A,.;L//DMMFY=?/L[M8CN__D_L'>X;:*QMM*#!6
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MC1%C0 (4:UJP,23K0<T(;W@Q,"^V=Z^?O,D@N/Y';0J*1C&SF(LR(U"9:;Q
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M>X6Q4+ZRCM\:!X66Q.A(<A"0].X%K%B2#WH;?9@,.JN*A:X.FD"^0$@NI-K
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MW?!CK2:&!NJ"0\;6H!*!DBI)U[ YU0Q<JTO&NXONF-\"448)7O.F[_\BPA3
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M\\/Y 2[&7UDVD%(HKD)+0"XEI40D=%!S]A'T'ULFL)W5ZC@R^9C 0(MHG+>
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M$E!=D#QGUP(*M6 *2> Q=$S<D&E=U$IP6:Q)R367H/1=67QF0E^CCP7"&++
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MC& L2G%VC1,?5X_9W_E(;W[]O_HEN]4_N]-M_I]\JMM'STY/EN='V)$0*-8
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M,A!.HR6AP9E"/T;2+7SG$L;57H#[I^YDY5<\%[DIH5;4,960(ZR@,N8M9&D
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MS: -C40[KKUW=5 0?9*,!B,(%X0(KQ0-#GTTFZ3G@K8H\M5Q[;U9V9,VK_(
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MV9O_F1:3LWN?7Y#GZ_X@[?RV]Q%JY_>^9UB[(G4'MMM"V'O"D5]CP YLK][
M.K#=@>TV#OP'-)K.&\E-8)R;\7\%=5]7Z]Q9X8:2_I[P+.6=&;XW ^L:HBRB
M(0KK&J)T"OF66F&1!T^VW= =5N#@O/G^1C$.T_$X-\G/WOOZT W.QD45N[O
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M.R-OK=HFM2+&0>4+:WX8YZ^G.$)$;3 [#74^WF$PS<^[=*_+]TCEZ+C6AT5
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MNJ5&3!8FM0O^]LW+"".W:-RECL,EM.*ZZVEL^*A8=-(Q0NVZ1\6]=#P"  &
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M($HI$%HZ\(%S,#9PJ7THK"D2CFQP+?:'BAW4.O<0\(;X60)^YIQ?PG!I!*-
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MQA2),X0)B*9Z396(X+*58&1PU"IE5!P' '*K&U^D @, []NI.N=&;89OM E
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ML'*R3J?R9^-EW7NYJ88R.NU0?39"?2[!:7>'(!6DU=IH-7/F624]"<J"8]2
MD%9!,2MD4:5EH7*RV"!45UHU/6G5XP/8(Q!6C8^K0V2M#5DS'Y\D*A$>+21%
M,XAH$WAK#$2AC2OZVAH2*K($^OCN'5*HLE;JXT-D-1E9,]^?L2&9) AH70.$
MI8E@E*>@8C:D#)^83*AG]]>P+8&NOP?C^GMZ.1BD7OC8&LV<^RWW>=JB6^]A
M)JE[UA^4ENA=]?YX9V=RB07J-^[S(,#O /#C^91U0GAOJ3) '"EF<DBRF,E1
M F?966D"U[P>0"/KV+Q!T8FBLSGQ>$BJ)I!JYM!+SO"H2$T318K4#,2!X9*!
M$9%2RQG/(6_M:KL.\Q@]>JBIFA.=AZ1J JGF_'A.IZBS!)%8T51<,/ B<%!"
M>:U"LED74G&45 U $TJJAAR<15"M"U0S[YU7.;D<*(1BY(-@D8.U-H/B(AF:
MB6-6%^/OIG-8FR*I-M)]US!DG/9'KMOJ?[6$SR0R[\<;(^_N54@N5J-N U1F
M,P[0?@OCGX.L^X,QK4>C0<=?CFJFTM/^;ZZP?82\7H37\]GKBI+DV00"R48/
M92E6X"F38)WS/A.:#>5;NT(T*P3OH13:;(+B;#S1'HJ'#SFV=([-7'D^:R:9
M)$!9M9*]%>"5C)"DU#%JFQ-E6[M%8.ZHA@M/9!OJLSOJL_L)[$.N+9UK<Y4L
MI.*$:PV!R51/2%!P+&J01#D3C1?!N:U=>U.Z>-1G36$8ZK--<!<BQY;.L;FH
M/I^2K0F9N/ "A&(6'&?%[-0YN104D['J,]'\-'M8\OO>R/'T)D^AFYNGK5&_
M]4NG_SKU6F5>[Z#+\+XWII<>['<#NW'3Y@YP/CK=JV">. +W_L<I3YEF#9K'
M(C-]I& I=9!$4M(FSV+P6[M*Z@:63$.QB6*S(<[ W!^<NU'YK ^C)[W+\]@?
M39]'C*T08Q\_8XR$6(R!J( %8T%4N]D**T!'YKES0<94ZSYN:Z(:?WX$L8:B
MZ]ZB 1%D]P"R]DR/,9MT,CZ"]$+4 K8<?- 9?$XU7XH-VO&M7;XM)6O@V5U$
M%RJRAKC_$&3W ;*9(J.4>VF*#A.!UOV+R,%DFR Z085,195IN[4KMJ5M?C(_
M]/PUR_,WB1'\BP.P#*!*D4&_6R[D=7GQ* W2<'1SU5L\E?(PG'_7=VO:UX;
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MR_9Y^^Q5^6OYOSC>?_&FS5Z6O[TZ._[S#WGTZ?!#>S_PEV_^H+,@BM>L_>F
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MM."&LG74PT85UU@5-PZ<;74_:SG4;INBW>X<&XV O2-@7U]+X.>I*GT4(--
M:WCT^ "<!6V8+>L?E3[0<=(H9E#1H:)[H(H.(70/$)JI/)F(C%);",RQ6@E&
M@N&:@HK,EJ<$]XR,2V4+LXXRBH]1YVW6&8W&R;O&!SEOMO:;(RYR=B'.OIT7
M>U8HX41TH*0V$VO:N );:04-UAEK,BN<%=O4V!W5.+6'IS+P5,:&Z$0$UG<
M:RX]BPZ9<Z.AK%T*! NY'MXMU"K=%QQCFND:4,*WC97KR!^ YS$VTSWXM']^
MWAF=IYI<KZ9MJ3@HUYQZX5L*<FE5?KX'MM,&78T<^S#L/.EUNO_?UFAPF;YD
MV%RC[?7BT_DF0Y+]/<D^72N489D(P9H(7HHBO2PU8'7TP+72C.@L<TUF]Q>"
M-5W!K.AJUCIA%I$#.&%6.V%F2W_(.N=(,AB:&0A%.5@E*&3&BRJ@K,+LJQ,&
MU\SO7S,/_N^R,_J(-? VY6IPS'__F/^ETR_ ;AWVPDYK>.8&Z:S?+0O1<%S
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M MME$S+9[%R-U1>]L>TM=TEBV_>LY_H^<Q&9B>E>B>G2$68E?;N.7E NOMN
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M$DQRRE.D8*)K'/SS3L>Z2AOU-,$_$_-2Q'RE6CDIDH@&1!--%,W5:X'656&
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M\VJ?^CY::6_$>&(\,9X83XPGQA/CB?'$>&(\,9X83^N IV4V7T&,VL8299
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M!5M(Z,Q%&0T1A%/&"TBJ-/$"U[2,2&8?;5.V-5(PSN6\>R[GR_'Q"8VFV%/
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MU9O5F_'$>'I^>%KE=+O^R3=]*OCT]>\TR<,I.\(E'>'KQ72[2+[&;%!$G[4
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MVQRC\F B!8,$M4D()8].?F2>B^.15=>2A<YCU#R!<TYX'90 ;4!@;H]:V*G
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M;Q[&5/0%4!&+("./D<?(8^0Q\AAY*V3\[R&CB8W_@QO_A80FKPN56*2(I**
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MXB0F0%@2QPM*K0Q*%7XLDE<DKTC>4Y*\E<B0*\K8'2ECL[2XN"!""22!]8$
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M:)OQ2,=)/ND?]GMI=(-^)\[*Q_TXSLA'H\)"R[+0K'(?Y@H;0A&@ED% I;%
MN>  =QISSPFFU!866C$6*FKYBN'F0K7<6N^11TXQ'?'3*!EQDV LC7<8$X:N
MA\ZB@-\9]#4*+#.$A# >@4"LC/C'!9#..B "-8$SCRE&&]L8L@4G" OP%?6[
MJ-^K+LOK1B,+$NEOB4.*HOTP;#-3M!D5.*XB ES) "A5 6@G.!#61]6;>X%(
M6(=R_H5K"M<4KGF,7$,AM3($R BU$9Z$EHQ 1HF4-E#A17'UK"$#-0YV204#
MA,0!2:T"-$3R438P8!SC7#GLF*#%U5-8J+#0^LKRBK+0,N6Y/%1:<@N9P8XZ
MQZ77"%LLO!8>,:2OIZ%O5>4JS'/O08;$.G5F4B070J3P0#)K 64H $D$!%@[
M8Y&7GBB[L:WP@A:Z*U.KJU!.H9Q".6M#.4LPCK/I:*Y+ASXPI8(8YZ2 DD C
M95#<WLSPZ8V[KC^J/R\<M"(<-,N.3:5'J+$0<$0DH((BH'%J:J%"M(<DA4RA
MC6TD-B%G6[C8/ZM!1B74O6H:^\)8M[ 2"6Q5\()11:Q6$#D6(/,V:*Q<B74_
M"/J]G:*?4 )2B!@P@@M  T1 ,6P @A9CBH153FQL8[+@;$#1P(L&7C3P%9;E
MM:.0JRKXC_/'U.E3=/%59R,[8R/I$!:< \:#!50Z Y0( 5@<I A0QI7#D8TV
ME1 + N*%D HA%4):85E>44):)N]*!25D4-1P3R&1.JA@4+!:!\F<]\4EM+XT
MU.BKI9DE7$-@;<" (AG-(\05X! &:3D13D:C")%-I=B6*BZA0D:%C-9.EE>4
MC)8*B6,"&>18(APHE48[(8051@MDXCUQ"8FO"?=\FH7$*:326AJ \M@ *KP%
MFC(%K)?(*:6XQWQCFQ;SIS!.89SUDN4599QE",<1:11U1FE!!8.&(<N]) H[
M:ID)Q?Q97PIJU(O2G%,A' @<NE316@)IF0"8*V*PD4AZ7)L_:.5K1MT5&>6*
M4[]D(8Q_N_:7[?^*?TQ>LS$XZY-,3G;^]G^9P2_;T\DIUY7KRG7W>-V26N,\
MI2Y'QS-R1W !M\=+/3BM_HUPU@V.O6]I:_O=.-"+"#NM7G_DAZDUZ>C4#WUD
M9AV),'4KC93G4EW$_%/&M-S$-+1[NF?;NA-?,_XB=S#=NO7)/>L/VPGI?\V]
M4]M?_&_G;3<ZC:\9WZ)^(XJW!*O@<M&5VL1!CT?^MQIZ8?,6&X]@*1&:G[[F
MGZ>#&1M^], ,O/X,=(BO]JONG.N+X<8O<S/0;?? I6F],EL_.R4A_/"4+"I8
M>&5&\BI&E:\_R&4]?XVR')DW?2V]@%[/@;=.!TDM_H^V02H$J3B45E+$I>:$
M124H8!\TE8%\$!O;)TE5:/5#ZV72J'-K8;V]2$CN3O:195JX'Y=]?),)V]A^
ML7_T^]YA:__PY59KYW"W=?SVQ?'^[O[.F_V]X_M"['MZU9='A[M[A\=[NZWX
MT_'1'_N[.R?Q'\<G\:^#O<.3X];1J];>GV_W3]ZU0.M96OIV;^S=\T<V#\^F
MU+39BC>.S^FDAO;+O&97#SY&H$N*>D*X^I\U/]14DM7MZ414RGM\T8X^&_I?
M)S_\YMK#LXZ^^+7=RR/-%UVV#N)C9B"Z!6L@K2O(U@^H/]^J/KMDR-0?JBTN
MU/6?PRWTC8N_=6>R18CXP1M_YT-"?_3:[XR8,;)F(UZ_.1;B&Q^OX(CI%L/K
M-<=B"V&V5B/F6Y#BM1KQ.LIQ5._6:L3K)\=B"R*^5B-F6PS*&][X$=6HOQJM
MN+<J]8N]R]/Y5'<[G[6N^JAF]'4T8OU@X)/L]NWG:Z=V)JH3!;O7K\SWV_GJ
M*IPF*^*SM/A41[.*[*31#/KG]W(J\3'*T4X<9/*PZ4[V/I_IM@/M7O[9ZK/V
M*/[^^])5Y&#]Y<#:<7?<2?&,O/CQ[GY0B4&_>S;PI[XW;'_Q^3>=_G!8I.(I
M2,4;/]+M7BT27@]Z<<CKLO1%J5AZN4\&7@_'@XNB5A3@^$E)ZH]JC>)%N__1
M]UK[/;N5_YT+%M299KFZH?BM0I><=;8FV%*DXZ>D8SY[,"]_NTXA7!=V*1)P
M2_BP8-]_QV6W(LO_8$O^S=S*-96'JKS,?>_]6YC)(AEW;9AVXY=&Z\,*9?$+
M+!3)*+#P6*S@,O#"(&N,$X5!BF04!BD#O^V!/Z*THD4',NYE![[0'=VS?K.U
MZZWO&C]H$;39PA#):W?EJM8=_L[\K]L9](55A:74 1NE*%*82H&T\1Q!9XD7
M2")D\C%TB3!!/]*1Z@G4&MX[?]]]B][OOKTXW-V/S_GSGW>?XKWC\]]]VH$'
M^"V+S_]Z</+JZKGRDQ?=]R=_?3X\B==]BN^T>]@^[.ZA^*[M^*Q_WI]TXKON
M?3WX^S <M.L>4\?P_(,WV"I$&?!0(4 UYD!2+H"EE+D@) _,/8HN4Z5^R>WJ
MI*L(5^M1GF2]D?]J]9&[A?U2>.0A".*?*4$(QJ6/-  H$R;^01V0@C$@K0Y2
M\Z"H?QQM"->(((JVNP+:+O*(!>$A@0Q3IDW:%=II)0ACD!)V/>P5O?:N8 M-
M80L:YIRR!D!/.* X2&"@0(!C)YE1G#LA-[8Q1ENP@%;1:HM66[3:NX'WHK\^
M!!&0*1$8[X(13  A*8Q$X$347Z$!P2!N)2+*0KZQ#1<4;BTT4&A@A;"KT,!#
MT  S1$7+%S/A H46:DIU+N1-%'=*RN+<6#]R8%-RH$0J0ZT VLI(#L1C(!WB
M@ <A?#"!>ER<&X4@"D$\,8)8IML#CW8"@X9*@Q053NM@+9+>2B&X-%I?SQ"E
MV\,*D<+7JLQV)(:=#]0K)K3D0#.J )6! 1D7&5"KM:,<>9S[W5&X1=>TW4/A
M@\('JRB)*\H'R]"!0@A*C[F5CFH;-*<,&QPY02GJ-+J9P5!Z,:P@05Q,"<)A
MB$U0!C#//(AV80":4 20)\:80+S5:F,;\2A$H@082E1TG:.BU^O""\.B&EM%
MD) :D4"1($9:@;&#VGIHD1<E+/H T'4XTVTEYT*;J,RRP"F@&OJ4RN$ <IH:
M@SPUSD7=EBSH(%-4VZ+:K@8F%=7V05P=/X[M4U='47)7G"EF2BYD 5&(":!.
MP,H+HD5D"B^E$T)B:!B)3+&IA%C;MI>%+ I9K*(DKBA9+,$55% ?./(N2$T]
ME3(XXZ$6B%)$D2M^D+6EB*.9,<$(=M)H!1"T%E"E*)#>>& @#D@:PS6%N24E
M)&J+%S]((8I"%$^"*):Q*B1-^97<8R88#5)H[HUQRH5H7RBK80F@K@4O7#0"
MJ%H0:*A7(*YFM!^4(4"[@(!@1&J%F94DF@YR@6N\F V%#58#P@H;/(398)1T
M3D@5"(N6 L/:6L6",C#:#%@+7\R&M:6'F6>)J2 (800$J*+9 )D!BB@(=%Q\
MSXW'@>/:;$"/U6QXQ/5A[@U7#OVHU8Z;L^M7L1[,W89[3]I=/VP=^O/6FWY7
M]VZGAU?.<UZM[;5&JE81NB)T1>B*T!6A6W^AN[L^F47RBN05R2N25R2O2%Z1
MO-5Q/#*B"9,>2FFHH$0+KB6BR'"-+%+DPRZ&2$$$$<@_* )_V /Y>M /[=$?
M_>&P>!&7\2)>S!W"P$[9("@$2&D-*.<!R" =X$P[!B$VT+J-;;I)J5R0S%S0
MJ*!1X<$B>47R'GHJB^0]8LE;0@.#/FB.':5>0RH"E5HR:#1Q3$6&EZ)H8"NA
M@372/XE30;B @78< 6J]!$9X!!3D7GD4 DII/D4#*VBT(FA4>+!(WLKSH)44
M12(4(1!-<; &44Z9H,1SS:F'A0=7@0?G\ID0]E!;GHY32T -], X+0"$V M#
MO0T.K3\/EHREGX>!H]&I'\39ZYX-_*GO#=M??)W!U'K6B;OP^6:KYT>M?FB-
M]->2U%0HOU!^$;HB=$7HBM 5H5M9XZ9(7I&\(GE%\IZ2Y"WAT!%(8H-<P(8(
MZC"4B./ (0J:"Z68NH%#9]YKDZW(ETTC<C_;D,F/<^A'1^%$?RW^G"7\.8<O
MY^H_H\ =0UH 28D 5- 0?PKQGTX*I97V2K*-;43ERG>-*5#T!*"HD&"1O")Y
M1?**Y!7)*Y*W0HK_+60T%<7_SA7_9CT[H0/D7(.(+1Q0RPE02CG J1;84NVQ
M-47Q+U"T(E"T3)4UH04GQ 9/.(E %.U8X6"JXLRD<5R;&V#1->76"BC=/B@U
MBZD%(HF+G $\\A10QS@P 3D0L"1*T" ,)*F#[0KWHBIH] 30Z'Y3W H&W3T&
MS3+<*-4H:JT>2&$PH,0@$-58"A1%SOG@N2<A*49B2ZRM8E3RVWX> U[JL_9(
M=_)NSR7T$A"8BU9OKH9>JUT7T2L9;L454AB_"%T1NB)T1>B*T*VL;5,DKTA>
MD;PB>47RBN05R2N25R2O2%Z1O")Y1?**Y*V[Y#U<B:9__*#O]/!T$LTS[;;Y
M=;[=SB12T.[9@==#'V^6_^ZG@%^)Z"T3T3N>2W7R 5F13C98IB&@6$L@E0Z
M$X0]-=9X)Z>HM+8QO0)33Q&F;B'7J0#2?0!2,\V)",R10QX(R3&@7CF@K*.
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M!("I1XYPQ E4M5VVJ))<L<L>E"5S@;Q?\NZ(?[OVE^W_BG],7K,Q..O39IE
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M!K7+SM424*L)1<$$J[!#U*:RY]@R)"'SB/NXG6_0<J) [6U +9U!;8 8.8Z
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MT &R(H#,@O<8M'+>.V&JPBX0E!11J6J56^.RJ:LO@ZOZ']H/%&_N .D 62U
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M\G4A\O7!.S%3-B'I&(4RMM57<BB:ET H;U$E;SEQ6=M0=S#X 7897N3.&UC
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MR^72Z*RZO^5V&#RSEGG&,$;=RB)(F20&JRE7PTXJ19F*(W8]%__FF34+8E9
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M@#IE24A,)##[(JH"%82W*7+]KX1<OK[\T=LD.986(1BB'+F=(80A2I5EQAC
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MG3&5+=Z[P\#.P(9X: =?AI-9S]N[H_Q9O7:OD[RB:6C;S'&>85_9QFVF GU
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MD29,;C/G\3X#QOYUJ!J6Y_*F8W6# + H+8[<**J\YM91PZRAS,MD)?;<UJ'
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M:9BXX"D)P*P+K2YH7="Z@6-U [1VP@7GC(O11AXY,8E0RF4(6$>BO"BTNI%
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MPRH-^H?UJYWA\-CV?*Q A#:.!IUNQ?#9U?NIZH.D#<<C.>X-HS^&FU6]>DS
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MYB11T43-C&11SJ%1:W&+/F:_A]V-4:N#O]<J=N,SE3)RJPER+&C$&?7 [9-
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MND7O=C9N&23@]9FY]6\W^-?ZFVQR_3>;7(L6AD>8V2(I\T7Z,_N[EI2<PE\
MXS<4@P(815(>!3 :QM\6-O\+,]@WCV,%5P7.7)U&.ZCZ@ZH;A\^W#.8U5OL2
ME3FXJ_G^F+EBU\S<,A4VN.O4W2'WRZ4H%!7>&*(XR_4,;.3)$!*=LA+'G/MU
M%@2;2V&#:93O8P<FH;?=BWNPF9_C4<JM[ZW-;N?3IL>M+U]//VV^^]':/8#[
M;]$V;7_9^_$)QML^_/3QK\Z5]+$OKT^V/_[UM?WCW>GV+OR[V?J^_1:N]V6/
M[<%WVX<MWJ*?NGN'?Z569Z8G4(B,1&,UHLERQ)US2*LHD W4&$VB,%BNK)-5
M)A92^G)^^_ >^<1W@]."\@7EFS5USP#ELW55&U<%X>^&\-.V2CKHG$[AD(G!
M(JZ#0EI:CV@TSM&@!3=^C/!L$8?E&X7P2\'J2RFS9J6F-T(7S/&TQY.7,BN,
M__'UP;21E?0J$>L#4KF'%5?>(,<D14P)0X#M@[(@61\(21O?![1HAZ(=EDP.
MBW8HED*C-,.TSYB+7 GK<HNQ*! '/8&LU: 9&-8J*JF5,F/-T/PFK*7XY9-&
M7>KC?=/ R^@ OKA_4*7.M_$K#8_!G(_F8>TG[VCK_F*,OZ^/Z7[J82/+(&B'
MW;'PO0'9RXKB619A7)"V.)V)' @I$H\AH!1SJ61% M*<"$0DY\8S@H-2*^L&
M+\2*N.=.:V1HH(#/,P:?0E/O"3Q3A[;RDD>)&9*,:,2UR@X,JE%27&(7 (VT
M75G71JV9YP<\2\>!2@ONI;"E"UF: V9-G:[,.889Q2@Y YAEF$*:>HJ,(THQ
MFH+&=1".,M[X*CT%PPJ&+16&%<YU3_R:N@8MEHDX8Q %XHPXE@+91#@*1EH6
ML!"*\3%^X<97W"_>O\5X_XJSK^EJH<'VMNMTW-V OU#6!T-^^]6,?P],:6H%
M58A1PQ 7B8.9+01RGH!VIY'KA 'RL5J3S\_,+OZ]@C>WQ9M"+^^)-5.7'@_<
M1,4#PBGFGKN,@GEL&:*6)ADY6!C)CK%F 6TVBDNOF,-/8 X7WO.46#1UU7%L
M(F8 /HHZX#TA:*0YD!\!JV<LMSIZ!5BDV")X3W'4%61:?F0J#.F>J#1UP$GA
MF*/.(T,%1YS%B)RS%L5DJ#/"V93<&)6:GIFWI.XWO23^M]W^J*[K>E-1V&;[
MXIIQ++:)G72>R[G9)K;.::1?XA'"8T7=WD7=[LPZ/WTDE(L(^E58Q*F42$>;
M4(#?N(L>%&U<6:>K3/)%*-PGW( -<YX6!5$41%$0#U,0V52;:>XYZS9Z:8>=
MHC;NJ#:F?FS&B12,1Y0,HX@'F9"3+B%)>23:F)",J]6&T,M6:Z&T[YSO<=LF
MJI3G>1ZWB0JFD7Z_8H$L7)7,E&F((07G)<(XG\B-5B+CK$$Q1F>=,(9CE56)
M47B--=SE5Q1+42Q%L13%4BR7AJF;F?B25,PS8U  &P5Q:B1RV#*4NWU;+&BD
M5M;J1BZD#FAC-NF5^-35+M(W](S^14?"NB/@LK0DM##1=C].VP7>J_>@O:'?
M4MW<\$H#G=7J!+Y@CXX&_>]UO?WN:?7H;3MGD @FR+\(QX-#N.C!I:!W_?1G
M+3NW4^O\L6>9[C("SKW;=F[O?@70(#@$Z@)25"< #>*08Q@X*A7$>B*8-[F4
M&+V\3:IZCH?UNO]L27&PP@KCHK:&!ZIMT,;*8(PA<'5+\I(2,UG2,U53EO2^
MG5AW-\3V[H?OK3R>S7>T]>XSAYF7&)8UL)QUX&- )@B)(L<I<1.XSD>M";]A
M@5>K01P>1= 1WV#WKOV\%_1S;%S\GT'?QQB&51KT#ZNIC#UE;^+W$48/I.FM
M[?3^[@^'V[V9;L6_?2OB[7>?J7(Z@L&-B Q@>2OKD198(YA4(K44W'/VF[0B
M/KH@OX?GZ5TU<F>=7FOTG[$ ^!Q@P'%W!)0*?AN+7K4/LC=^LPL2F#^W/.V'
M"8;%P/B>_8?Y&E9B7FUF?W+C![69I7A.+9.9GE=GW+D->5ZS3-8DF5O_X;D-
M^=:]M!N=V[<DJ7V_4?_AW["/[)M^KI,8J]V#08Q5:VPAO08:$2Z:S*4[<9&J
MNTM5&YC-TPK5,]8 I5OQW%I*WK41??.;2-XUE^R6'>F;U@JRM!:=*Q+<LL5\
M 8#F+74!@ ( <P" AO&KY]=-^#^_=(8V&Y";<72BG(Q8ID8R<SSX((-5.GAA
M''7<"/@7RT!I$EKB9$6<A++4A5#6/?.(SK;N&]BY.8]HHQ>FH=]GG[WZX<>G
M37AM\R^XWFO>^O$.?M_/H5[<>KOU?>_'RR][AUNXM?F!74XG:N^VO[;SV&#L
MK=W]'_ ]#,\HVKOO3O:^O/G2>MON['UY=]+>#1?;"G.?E&.4(9M#D9Q0C*SV
M$BFOE.4>*YIBW712X@96Z2YMQ4I;L<8GLCVO9%+B5$PJ@AY@C ?LK+6)6RLC
M]XYCKR:I/FJ2ZO/K1@T%\A<"^=.S;U1YG"ACB# M$6>)( ,KA92-0B;0!=;@
ME75)2.,KE!3X+X2_@51CV0G_O7+7"N%O,OK/5,T3$0<B$S)&8\2Q$L@(:Y$B
M6"=OM#3.K:R#['"\I@KA;Q[B%\*_7,QCV0F_UYQ8255*S'*:O"-<<J$XB])*
M'O&EW/ZB#9JO#68Z"8,5ET 3( )KC+A@"=G( G(A:DMAY;7U*^ML5<N%5(\O
MG827,^+R_D*^>+.C*^>C*57]&Q4CN*@)+AT@O@3]LT=C"OC?!?QG&P,KXDF@
M*B =5$(<S#QD!8U@&7CL4B#!\K"R3A9QC+B4\I^G9FP"^"R32[J S[S 9^J%
MUII[HBA&U 0!X(,IX(Y3*&*J?3[6YX):65^(#Z+4[B_,YRF=I05\%@,^,TY0
M#?R448*L#!QQ*3$RC!'XP2,/WBFA1*Z'T,"2P;\?WA3J,U?G7$&?Q: /GPG!
M, J0 \"C.=A=B7ID S'(!)*< Y,LJEPQL/'5 HM/;2$^M7'EA>)4:R:XWY5:
M_M%\KUHN-E/0_0[H?J$=+R'"4*\)$LYYQ GGR*H$AJWRRI%H-=8Q&[97LVFO
M'!0MK+*PRL<[DMQ\CUH!GKL#SXQ'+8*"8%0@S:)%W"L 'JTDHI'*& 4%W:$S
M\%SMS/N8P%.<:87QW!]XGLB;5H#G[L S]:9ID6*47*"8'?@@5PI,6:L!AX !
M)28$4!ZP9\4:+92G4)Z&4IXG\J05Y+D[\DP]:1B(J8;50M@SC;C-1UD<P(^5
M#DAKYJZ>7Q]$7 +*<_\JYM>4YB5T:6OS[HP&=A3WX?(S]6]O5:)XB8NZ;MRQ
M!'LN\CX\GZC.^4151_W!*/6[G7Y=I=WW#X\&G6$,^>K33PVK4>Y&#')8_9\[
M8*9)H.9-!,Q4@4L-^X]Q(TE(/AEKA7A 2[RZ^/?YRD\7_C]GC[/LH/F ZM];
MHK7_61G*E=(:$1X2XBY)9*FA",B8)DH3)WU863? NJ[:>V>ER6IANLN"!YU(
M$CYPX1.W,CB%HY$,6Y^DC%X\H)-(6?"?+?CVN\]:!T6\-,A$QQ!GFB-#B$<4
M5IT%2Q,A<F6=&7:-9_%LP2_6>5^M3@"M#NJ:SIV>[Q[G:H. 8K.XD"4$0 VP
MQ@Z'$5Z ]S/6@%@ Q&8@@=_J5&M8N% YV[4]'ZOA080/KU7/'::W?PV[DYD=
M7IA6&$3\W^/<H&.F!C= L@>.8.%-U^F/HC_HP</LG]:H;7OPD=D5&\34A96$
M23_IP..,ER5TAK[;'QX/ZOM-E_1L'1HPH3>J_QNFN TS4:G5ZHWM#*K_VNYQ
MK%K1YD>LIW*U08_V\P<!'9LK? [C39LG=7JP>3JV"X\!+XP?K_H&_\##5MX>
MY4FK$CS5$.0@PFNY8"C\&0?=TZR[+VS<>E/?2\KJ30_P@6;JQ5^YSO/?V[FN
M/NRA 0A;/(.]7^SU-"GB.JI+ ]?3F,NY3KJHQ*OE7&M.-VZ@ [PL5]7OGE8!
M1!QD)=_OZ'C@#^QPO&R;L0>;IK[LCNWMV\-^7C.X. RK[[^NYFK\&0".AUFT
M7.SV3V[9RH.M/?8:":8I$T\ %Y-)@L4;V*-X#!;7$.P&?[N)6$II)76;@JU>
MM7&\?SP<C<V$$]BRN<Q>#?\@3#8[D;K6]4%^SY@?S&A&H<KN@[36DIPUR43,
MUBHP08[L8)0E#P8YO'0!N,&9<(;KFS]=)93# T"EX25.R;#QC%BI$A"C**4F
MU%N9J-(!?@_D!B-"WI933JDD;.9ZN]2[93R6\T?XC=GEM)E0Z\L6;>]_=A2V
M;E01"9<<,$WND7.!H6@-T03VF?6YF=!-Z4EGQL5XAF> :Q:L,J!.D3"O\!KL
MV<XL2ZJRS'6!=G929]QJQ%9_1R"N%:UNU$SGZ'FFXP[ZW>Q?J8Y@7_7K'B>C
M0:<>[EC/P4TRDZ@)1:BB!78UB!G19[Z4/^?M8% /8U2ES$2^92:2QPPC2 F(
MV 7-^K.[PA2,:M5R_J!95\/O]?X)U?$P?Q/@IG]4;Q]0##Z_DN\XWGN'_1"[
MXWL?]F''#SO[/9@D;_.UAL/CPZ/QG2;$<%1_#KY2WZC63W%P.-[7\>J,Y!?'
M:Y3O'*MO_2[<M@MS>T8_8<Y<O>^/CV TL&JC_B![MF8^FJ\^[( HV,&46*Q5
M'P%MNL,^/&.L(0GV8A[T>;NZ06?XM4H 1X#(&;W@X;+"S0L*GX%;CT=\"'.<
MI^3&Y^B/U?6L,/4F8OC_#B\*8GYD"WKS6P=40*A..[%;>T=N1#& &I#92RBF
M ,.P]D8J0CACT27-!2<V&!^$8/17@2MYM1\:W.>D/PC#V+N 9YN3D>[E@?XG
M#G(Y5;L?SP$,T=\,P;8W?1Z7:/W8^-'^\EJTWGWV1@GF24#*Y'YW2E%D C=(
M$4,\)U@1AU?6?\1!_ZJI/"/96:P2O Z_P+:?H5]7)+O:CST@'%W0?@?V6P3V
M/)K9%_#J/FC\O+F]'1Z<"]OP&;.2,1O+70VR@SM/+>!#IS<6\KR?^F>.A NT
MY(R*#&>YR&IUU*U9.'#QL/2V+ %C]M7TJ;^-#87MVLGR/G;KB1@>=(Z6R+0=
M*_[[V+>_GX%R9KK-6BBKS]Q$&3\YF"AOHAL<V\'I@XV4R2RNP<1E(>O%L9*N
MW\NPG;U@F2&<&2]@M_>&$TT.#[4!U*9[/H@;#)E)MOV=K!F;>,* 4HQRS:46
M3C/IO!/"!VD]21-KAA=K9C[6#(RKM?'984^T\!1YZQGBT7/DN$U(LQ"8]$JG
M*%;6*;_143Y>^JD%<YV_96W\H=IJF1@AAW%TT ^SM/,$KE>Y^  ;8]8=%+L3
M.9]PWIE/C8V%N1@D%W$I3UD6^4YO;(U<0*HCV'7YQ1>#6I%]B]->C/_SYP0-
M^*3GXW5?LP[4Q?$H_CF)M^/9[U_3O?-"1X%EP$ J+LWFS,^#P30+83\B!VSG
M*[()'NV%[9[8T^'*ORXVU@3\GUQ=JEI!7IFLA\Y(2O>>D>L:+ER9D'H1 ><F
MB/]BXLWNC-M1V>4<>'4PR+K@'QU'3$K:2# ,-2=26\D$0$:B,5FN$_NL5M;K
M1KYYI[[*:J3.;+#K/V<"CR?TQ NKPN,)_0T9'"^WMM^^;E=;[5=KU49[L]KY
M\')G:W-KX_W6ZYUG]JCM[=W7.Q/%L%V]VFYOOF[OO-[,O^UL_[VUN;$+?[S9
M:F^T7VUM_%WM[,(+K=?MW><V#W\<]^PQV'TQK%83;1'#/Z_#ODOJ9,Q7=%"1
M1**32HQ''2V+B=C(123)!L57;NHPO"Q<N#CYYN3DFS"U_^<?FA+UYUQ\?=*[
MJ!5520G%%7..:.-PE-A;:BQC$U\?/_/U_9SL%U_?O7U]6]];^Y^-T-AZ)1 W
MW"..C49."8=<3( <GIN8X>*.OKXSOE^<?8MP]ETPZ8NS[\F?=$'.ONLMR1K/
M?LV<S<HO-A*B:N:40GULH7YE-BF:/]B+J#0Q\OY33F_'ILS$UW#UYR9<\=M8
ML+9 SPZ.Q\[SBQ-](6O\$0Y<73[H<#:$F1%L],+_C0$F>G\C9QO6*4.;Y\EI
MNW#_EUW0R$^LOK9W)NKK\"]05UM\CWY@GS[^==#^\8ZU=D.G_?;#]_;'-U_:
M7_S)]MNMT_;N_LEE];5W^/ID[\O!ET^[H0N_L_:F_]ZFH YW7Y.]CRW:_@'C
M^+)%MC=?IO:7KWS[W>=$!"%"6IA29Q 7VB*'O4!:6R:$A1^2K$QI\T8F"DK"
M*C!IK9.<*XMM"IZR?$J%QNQM7*DBD(*CO D&Q_$:5\G-9P/,TAX- (T#?_>J
M5\>#0>SYTPI>.+&#4!O36<L/*U1-Y'!V?SQW3;PY=AEF3K/?[3L X9ZMDPB!
MZV8]W#^*8QT\7*VSU\9T>OS>('Z+('63U-_Q!V'VXO>CC/+#2>ZIS\66Z]12
M/Y[[.K6P5FM H,9TZL/:S@2W0M: @[$Q,W%7IE_>Z-QA"C>Y?*EA-D_RW2)P
M#+!DCMV7F+E;O_)P]_TZ^S63[%HZ_)ETQ._C=VMS8UC'#NJ:T;7E 1"U7ULA
M8ZTVOLQJ#@]D.^;*M=)$TORYI,%%NI/,EHLWRN9:'U3A6:XNF""323^;\WQU
M((NC<2 D#GIVPJ%^,4>_ Z7\U;3GZ:[]W3E#Z$YG9@Z 7X;CR4:8,0.O591)
M$C#OP*@ JX++1*TT8 3JE"A7PC!RK:*\;.;!W>I<T)M5Z/LSL_>L[CWY[53D
MEO@,<YIYB$0V894K$V.D+?Q&C,X-"9W'#FPZ<OD\7-Z"/UM#PIWA2@*?)(3G
M(L<@\U*F)+@RA,58UO"QUK!%/AMM8Q"P<M@'B[CC&ME()9)!4R#V@@3L9V-P
MYXLXR9;.F_9GBTF=C493*CP)G 5L-2P75]'@Z*2R[-*!W?&AI+*8]UC,=^)S
MDLQBS@0RD03$"4M 5KU"PNF@DU?)$GN/#1F$T(X0*J(FG.-D,+;>28-U]IYQ
M4M;PL=;P _E,DJ PQPE18L'J,)0C)XA!D:CD"&PD$7*Y=W'#AKQX=JSF<F/K
M?Z*':U>8B[%7A9A]U37=R4=.LQ,L=?LGU0$0\0F5.>X-+K2, !XVJ7-W%HV>
M84AC1G8;!I9==Y=/LXW. ^(P\%X<PL>RQWE,8_-=QA^SWA\?'G?K48]Y;'U6
M-AX T<K6=9UN$:L_\BC_6?T!Q#,.,CG-:2O#:F/[U=;9S>JTY.'X_,4_UZJ+
MO3'&.2V3)TU 7/W!S .<<>O]7OT-N. Y 3R!@8R]]G8<+SP:],.Q'YW=]7Q:
M7,P,L9[K27;S^?7J?.?>=5S[_V?OS9O:2+;TX:]2P<R-Z(YP<G-?W/,2@0WV
M<'^-:!O<#OL?(E<0%A*CI3%\^O=DE4 "!$:L):B9VQBT5&5EGGS.<TZ>Y?SJ
MXU=N==5L 93>_O-;%+;3N;S@^=UQ%+<?4ZVR+_M\$YZ'/A7M<,;R81Z :U=K
M?6[(M,\F"KZ>.671!D+XB\3%B9.JRHPN[UW*T[X=5&+=/CRR9;Z=.RFO?S89
M\+WEI_2W;'NX\Z@3MU*K5YD)JX= VX>#K;0U&N:SENSQFJ#?7^/@BD%YU/R*
M72\Y,MB%H+&E$26G/8"@X\A**I!5VCIM,*>>WM:5LL!V53;$NV/IF5CDMX78
MXYQ[>"%R#_Y7;?8I2_97]CV@R&!TF'/>3BM-D<"T[QT/WEYKU$Y-]-2\CT.%
MQE%%55+(V=Q7+:'*8X>C07Q[]LL?H3TXZMB3M^UN.3GEERX7Z(#;3 )JEO$X
MJ&9<U79\@_'[R]5[EVJ)5&\*O2RXN?Y]O$SN_*9@-]SXQN_>.&2BEQGGBS=D
M=<LK_Z(\<1TJ/=5K-.9QZTZ-XUH>OWBS>JK*4V>:N:A4\RV*-Y\A$A"'^ N)
MF/G1%UQR^\E6[;>-[ED \.!*@:B:;LW[+?&,FGDW;L;Y&L@^QYK/6YWRND)+
M3[W\#S"S#RP;]X/M^DO*O.BP.LYEOG2.<$%0ZH+"F;L^V0H\63W']5$.XJHS
M+#\L%"]0)^]Y8?<A.WD_7@_Y6M93GJ->F[4J,.9))-AQE:Q)/$=4L\!HTO#.
M/0KT7?6R7_1&U28%[8Z.IJJHZ6'KH+43?FSM?/KY_>/FR>;!IY/-TT[[V\[&
MZ=;7#_#=UN'FZ=_[WS_^9_]R4=-O=).TZ"?16OOPX]LI7'<M?P?&<+ IOGW=
MP-\HC/<KO'?X(??DGC208)HJ[#1#4OE\<.8)TEPYI*/43D3%&,WM@=XHHFK8
MFO6.7;A?$I(_'0VLGXI^2%Q_JF[PM:Q=/4_1?)J,8YY2'W+6,3>2.AM$S">H
MGN-PCZJ<#<H_+,I/NG4(D;1FB2)F14)<1XIT\ E19A*6*@;EXM(*>:,-7;Z:
MIURO1G!WQ/PZ&4L+:0^]RZ48!_O%4?YLO0VC!VIA\ K:I<S3LX!H(7RB(C'#
M,376&L(I<$1LJ60B74_O&W1_>'0_F>+PF%*CI<(H!:D1ITHBZV)$4@M0U-I%
MFHLU2UI# K] '/V!0.75]469IP6E-5HH[T-DD2<-HHN=8 JGA(/FD=^.6^;L
MRV '-X3H-<!S'^"9T$HOJ/):Y.Z3UB-NF49&XHATDMH:RI*Q,J?P:4KH'S6G
ME0US?#0$V#YN#W(<GNWZAC?6$]0?D3=2$9AEWOF4)*=&V&A49HG6VT2I4@UO
M?$+XOM \V.FH9::,A":#N,Z9H4P2E+@3PF@5*.-+*XPOBX8W/CNH-+SQAM90
ME"BM/):*)LZ(<$H1186FF$OK$VMX8QV !T]U+7?48FD13X+"CT21D\$C':11
M.D=%"]KPQE?/&_]C83PY&^<D=AOB6$]4?T3BZ/(ADP\8*^5Y\MQXDUMUA)"B
M8MI<UZNC(8Z/@M_;4\21X"B8#B$GLC#$ ];(.DT18]9JR1WEV>ZG:D8WP(8X
M-L2Q/L0Q!,R!BU!"?"ZNYYWT8)42!7""B7*X(8YU )X)<8S"DX0-1X'ES'";
M> Y4\D@%D8PE)A!-&N+XZHGC>]NUH0U#JNKW--RQGL#^F(?5S <I%,!%--QP
MK;TV-"E!G=0I.MYPQZ>$\.F 4Z,8D3X11+AVB#O,D:66 J(+S"Q/A*J0*]?/
M:"S<<,>&.]:'.WK*..7.N"@=#U:81+2)3B@08\*Q;KAC'8!GPAVM<* #!$%)
M88*X\0$9C1UB5)+ I2,XMVEKN.,C<4=9E:]8!/JXTRM;7_^R/D6]>64]LL/&
M;X[OQN#]T!OEHAE-^MB]@YUO/;<O@],30V-2"@<3#$]4&Z\QD0'^Q$)XC)O\
MLIIHW>G85(:=$=X%Q)/DB <ID2'$(2J2Q3R&B#W.^65:RAJ&&3SD]JNUO5#'
M!+0ZJHZ7F:%61T7RB)9;I&"A$26S.XC+Z"W6$@OEHN>!&T>:%+;:*)*I6./<
M2%L;CI@2H$BT9<C)Y)#SGB?#+)7\9:2PW4.ME,;?O\OZ<M-M3Z;*J\Y17;"L
M[K<HY06/^KFNWL]+A5POM"R=M[1K67=PNK;K?#5$<UW0THX<=VOMQY3[J<)W
MNW$X593UO^>)B$A1*"J\,41Q9J)F-H+P$Q*=LA+'ZQEPKI$+O]VV\>^7\XJY
M'VV[^V<YV*WNN#[^6?^+"<8-6G'XKFR.L&-_+CK$W;GHYR9\O_5I5VHN.: -
MLL8YE#/D<M%/@XRGV#)KO".YG#SAR_+:CL!E%<LL)^-ZQ?.)B:22:AJ5EDYQ
MP8-F3A(5L[P8R:*\AWYKI.,>TG$"TA&=U"H2@;3S%.PA$I"C8!0I28/SS 1/
MU-(*GF$+361CSLX3%RMI?ZW*+I>]YV*#12]7VGCK^&&P:-C+/<4'<3CL9,WW
M3]EU)XO.SV'3 *,6:_WCY];J+J&.,LX]K'5(B'-ND5'P)Q,^BL1AM8.YH07&
MFPP 53/6N72-5H0  V>:.&Z=-8*FI*BVR9' DFY@X)E%XQ1$PT=8#=CS"%9)
M("ZU1T8:BK )@KB(+8;E63%\1KSF.0J<\^>QNLC= RI%4O4EN!-$"$L#-6#9
M<4LX8UR3X)TF/'(2A.*R@8@'DP,!<F!$"CKPA!2+%G&;ZWRIDH8P%K &L X:
MU &]%B*JAF+=D\)630#F-XLJ23GOA6%SP?;"AH/1N*DRO']>RKW7G]6%+#.8
MW$VA'<925K5*..MN5M9_+ULOC'+!T"/;S]T@QQV:"]^/H3VLFD*?]^&]9"-.
MM\@8@!G8Z>1_\QO6G7>BCA: ,E_\) \Y_HQ^-,R]'P;GWQZ![==SG=SG+9?X
M72ZN*_YZ'6^;'FMHA[+S+P@^K$C9]W?<].WJ(YSU>+O9R)W1'O4:/\'1N*7#
MVW[90O:?."E4_Z\_QJ8X'Q?$G_4UZP:]#LS.'V.7!I[^_HR&!P_7?OZ)'!!4
MSFHU7_W<[T^\3'L1.5!B/Y!-\&AO;>?8G@R6_GVQZT"[>W9UJ9;SK%Z9K/O.
M2$IWGI%9Y7"O3$BYB"&W;"DE_RW0!]BJ^6/Y >QB#KS8[V>-]5^W:!:\M%+V
M/LE;,7<&K5J VI6;NR<^G- 3+ZP*#R?TUW1#?;>Q]7&]56RTW@.RM=:*[2_O
MMC?6-E8_;ZQOO[!';6WMK&]7'N2=K>+]5FMMO;6]OI9_V][Z<V-M=0?^^+#1
M6FV]WUC]L]C>@1<VUUL[+VT>?AMU[0A44@QO)OV"?Y^%?9=Z;5=DZ]=-A2\V
M(7:PM6BPBIB8CV64P911823-'8L-UDM/U_MH9M?I,SMDH[M]UL]I*WTXZT3^
M5^R71+7K7V\7I-/5X\WC72S XH#5 -9)">(N:F1ISMP(A"@:A'/&O9(N2%73
MH4QGQWW;SGL2376.NV5SI(N-[_;'?:?;4WW9YV]"=GTWI"G$RER]G4[^>*X&
M2<8L:\'NUA^)TF4EQ6,U&Z*/TFR(+!.C%VW(C"_6+%.89?%H7:@>:Y8ENVT7
MJOH,F=]V5+-#F6O09F1\@Q?2:>1#KW*C[("%$XO-TM-3K'?SH?<%7\43M)5J
M/OJ$[;J(>/Z=]((:]K3BL,@6P>#?OU6'$[__C^O_>^7S>3]:V$]E*]IQ]]YA
MK]@Z=VYNC'VD[?E:@M53VA:T?U6S'YYH/TPUG'ZA.Z N25@O5KC^[%7=O9N^
M>4U/Q:9_8J-^9DG%I6:)M4NY:11#HQ@:Q= HAN?&AP67BGLKAM=*UI\L,^_S
M.)ZKWNJX'N42FFH(B]1F<=ZI^VVN_ J1<.+8"&8YI\3ERMC))B-T,"KY<?R"
MNA"_<$V$]75QL3."&:;]E1_ZO</5273GUON-C>ZP5WEJULNC:KC&7U7&72N^
ME-S6+_@;C._[P>I)BVZP;Z>?VZW#3?Y]!\9Z&@Z_G?X'Q@*O??W$+N>V?H?7
MOQU\.-Q<@^\=A(/6QPWZ[72_LY7'2;\?;,)UX37R?2U<;.!%+.,L:H(<IC)7
M2L#(:"N1CUS1@)/CD2^MF!GAV5=\9+7<C$WI@_JK@7FU^F)4-GA9A0L>0"?,
MIPK&KOJ-;@7Z&]UX"?97NZ$J;+#^LTJ4SCKC7#=TXV"P$P?9P=_HA[GUPZ3V
M@4Z:><,,"C@W:9?&(">X1)8(0D.T02>WM,+$,EWDP@<+I#,:.[&Q$QL[L;$3
M:V G!DT"E3820A/G0F@9<W\40H$D4./8S#CWQDY<(![ )S60E&8!\XB4UQQQ
M%3#2)C+$1*[%8(UD@2ZMZ&75V(FU O[&3EPL[KGH=N(#Z(3&3EP8_?!S\SW^
M6>J(U5WL?>+6:*0$D8A3XY$SW"#)8Z!@*B:5>"XOI%^FH5BSL[R%-,.VKI1<
MJ+=!=CZ:IG_.PVD0[2A. M-@@N=28"W@5YD<%MQ@1\6#>QH;8^()E,6%[M\Q
M>JDQCBC12!#'1B)G<4 JUW'C!MB"8$LKI(95N1?(:'@@<'IU?7CF\8 \ %;=
MT0/2T-YG1++)\8CCVA!?UC;TF?0ZB0PU%@4>E#5>>YS\;-+[D&Z11VKH4U](
M:WAUPZL;7CT?KT[8NL U\5Y@'I)Q+OG$B.).^BC)[*HT#:^NOS::..D-3D1H
MK)&WS" >L$>:J(1HP%H3R@-1+&NC)VA2T/#JAE<O#E0U;/H9\6O:B:R4P$%Y
MAIS""O@TID@#A48^.#"J'-9<TB="L,?LDGFQ4<J-U?F>L=05E>;.I:XDN7L%
MH%^4!Y*/5>J*LD4;,B>/5IWK48:<2UVQQ1HRS+(B=ZU(]8Q#ONTL-Z6NGK34
M50N@MZET]1(_VE2Z:BI=/?='ZQ;FW52Z:BI=-96N%E2XFH(F34&3IJ!)HWZ:
M2E?/+<8U6_9&,32*H5$,C6)H*EW5YW2UR6"N=>I:D\%<QY"H0)UQBFFE@N+)
M$T,CIXS@J(/"7),<9T#,.'P7?FE"HNX54G#PA6V>[AVW#O[N;!ZLGWP[_7SP
M?>V+^':Z(>!:N+6S 6-=I:V/'PXOAQ2T=OSIUAJ\]_7+R>;.?PY:'UL_6CN=
M@\V#'\??#CX1N!X\[S?\[>OW2_6M C:8:($HYQ)QQ@.RB6+D(BRK4=QR1I96
M.)G1A?RY8Z*:[.4F>[D.L2QU4PB/&'CVY JA"3Q[1BTQ2>,0T48N*$%.)0):
M@GJDK5+(8N6M#LQ839=6E'FIR<NUTQF-C=C8B(V-V-B(-:ARY2GU2A&L<^%+
MEHBSU.M 4^*:.RO%F!.0&SA!4^6JUCQ@DD##O)4\,84(S>'GQ G@ 2(B&I2.
MF#)IC,R)Z;BI<E4KX&_LQ,7BGHMN)SZ 3FCLQ(71#],)2E0PH0CC*'B2<AU$
MBK0R#!G)"%."$^-=KH/X0LLAU^P<;R'-L"8;?U%27!^SRA55@5'+F!6))ZNM
MH]0Z(SDW-E MFJ.G1506%ZI<!0U,P)39^!2,":,E: FI$,@4X]9+@9/)QD23
MC?_\X/3JLO'GJG)U?ZQJJEPM'I)-CD<HMQ(S89!5VB&NI4#.>8[ OJ&,)O@I
MT](*?62W2%/EJN'5#:]^C;QZ'F7%K<&2.>.,=5SA8$ 9J!B2CRZJ(&7CKE]T
MO31QUW/LN>3:(Q-R\T*E$K*.492P("PJJP@NZUW5JBG%(FJBAEP_&KE^/KQJ
MR/4S@MBT3]D(10R)$8EL0G$=%++1.A0]\V!L&5@7LK!%9&?4NQH_10LDLM_V
M5^M?M;L!1#67L:%3):]*5S6]RCQO^2 3ZL&<G1,&)I!"\!FFE'=_VQ["-/@K
M239E@:W]ZF]"2XS:R E L%V*S\ )BO?PA;R(@P(5_QO#7KO,SC_?I>?+.K,^
MV'A^*%]6E^9'WG=ZQDAW_^F9@MP9D_$U%OOVGUB465%EE8)A+_^H9JB?9ZC3
M\S]*I*RFJ=>_]/[@V!Y-O]\M/$@FH%OA>OU^[SC/*+S7'51;95# '0YMU^[%
MHC?J9Q.A-QCU8W'EQG[?=O?BH+#=D-^$X8U\]9T>R+[M=."N\-E>FMQHN;C5
M@A&V?&F]S'W72U!-&'],<;YF!2^*\W9>C'.9?NG2N]'-@M>-E6X_;@_WR]).
M[<%@9+M95E(I+M>2@.XHEWNZQ .,M8D$+@WACD=%;0Q,:.&CT=$EAG<W9I6Z
MW&A]N*KVW7 ")6?KE)=I>YC-D;]B/V<CPD8XU]F(+J;2[L3__0S7"4>.<OGM
M<!T4[?[!]YW0@=]9:\W_;-$-_'UGG7S[NDE;IS".@PVRM?8N@5(^V?JTRT&U
M8NLLHIIIQ#F-R"2LD=+",LL3,4EGOY:YZMCZ5[$=NVU I59O"& 11G&JD!<!
MN<RK]:8XOA'C,H8-*@$"D;=[>_VXEU_O]O(];*>P)?W* O7?\T0G,&\5V$"&
M<L,Q8UI104"4,"/!@,DT6Y0RDTR]_J$=PB5^#M^"E(;></S^]=RR-1YKQ107
MG0;>7:).5_'FWFYB+'*L,=(X< 02Y) .V"&:C!/66H>#6UJ12LSPE9[5Y &I
M :#:!]D!]=0#1M6&Z>V<%(,XS H)-%<[O]&=(7#+Q4X&HIL497G5$+/-D-&@
ML(-B'P@(R#!(68:Q9-O]XA_;&4U4(:!G V@U%[]UT3I^0$"SPV&_[49595F0
MNBE1N"!>@TKDO.WW3S+EJ@2GT8#U%Y@-#GCU@ )3 LA:].-:EB0C$C%O0%PJ
MYT%ACX[ZO9^P;,,(:#:/0B-*$DLE2(<QG(C@<,3$1ZL8C=1(FR4#+&C*R ,H
MM ^ ?W]G*=Y*DQ?_;%O7[K2')Z]8P<'_?]K-$0S2,HR,5Q)Q)PC\QB/RR5(J
MB0/F$;+ L&O5&UA4I5O\$JI<4CV5,AK<K,R6P68N-NU)J?LRUP(5.>S I3/X
MW/3%+)7YKX-1=XK$EW:A[8-P E^+AT?E.PV4U5\ROQP_))E_ \L_&'7*DT00
M$UOL9:\"R,'= <SS8*763D<.$A&29LX2>(%$>$%S>8N&!K=&LC,/[U9WI@.X
M%8=_]>/0_GS%2/:%;A[ODLB<I]XC8.,>\: ]TBD)1(T)BBH8F,9+*^PF)$OC
MHL[=7-3YL"KJ'*\6=3ZS!2M6#XJR'WT.ORW)MP5).3SJ=6-EYYVCUO@,^XQ[
M@SB%_'<^E.F6T;HEA@XR"I3K6GTY._*7;^>,NNI=O;<WZMF<J[D.ZD;W'YBW
M/!>E1S6^4M<J:,0/T?5'MI_5(J%77!"V..C!+\4_\&IV@-J]?BQ%J%*"V_9P
M,((I>]?N_=G;:WN0Z$&V MJ#_3R3\/3P42!";Z8_&8_: )MP\1#_B9W>T9OL
M:ATEV"_E';H!_N[_@$5R[=Z@#<]N^P5@:1B=*?'_C& 'P7!U.=R?H-7:@[$>
M[QV-T37 ;LHO7#?\TKWB^]$.QN[:XV[LPZB/BJ-S+9FWTZ5Q5P6C+V+[?-H^
M ))0J6(0+/M;@K'1XJ1\C$1'PW1%3R^#.CT#;M=NN[?K_S>"2=V,P_U>F$CR
MUMDC3/3\NPBH$U=#:%=^E[]&?6!1@[@S\76_7BK06EMEK=5=26/$S#E$4D[G
M#]:A'+6(1-(V:A><\T %9OE@_I6EZ#ZR8#0-EGL?@PG<1NJP\4YZ[)E(+BDW
MF_FQRTK\UN+PJM=:P%H'QJ0)T2*&J4"<!(F<81Y%Q8$.8D44!8.$FV5S=;$K
MW\5@WP*.'(WWT?2A4:FLLWKNQ&%52[O5^Z=2ZR56 ;"]*49'^>RI [C6W2L=
MOD>V':Z7FA_]X\L1 $%@091R6E'. $.\IS%Q9Q-SRM%01@!H,HX @%\ND4,]
M!SG\RYZ46G"GM^I!Q/IQMJ -SL7*O#JI6N>MXUWE:0!++2'B!)BY4F-DD\.(
MVL0)$Q1[1Y96E# S>E2#DJOHX79O! KU_P%<@]8\AA=^F\=FN*]8S&,SS"T6
MK\UF:*UM'&\!V& 5I90>&>4MXLD8Y)@BB*6DO686<%YF][Z<44[LS&KX/:N8
M*RQKN=@J?1;G'';L$HGE0F1R?YFVP/_*0^S*DY(_ZT?]?NSZDR)U@%B-;'7N
M/;[096&\Y9GU8C/A,LFQ//D'ME0>K5T_3RX.CV.L)NO+\O9R$7+CM'[)7B]/
M7HGS5R,8,C-K[W6G;M#K']M^F/98??CE9_**5:%88Z?J+&-RWX+U"(;D(5C[
MF9>'4=^>^:O^YT)\S26NFIT.1L6D2.1:,Q.CE489+34CSMJ9GH@I'('5\&_A
M9L<PM8/8O=Z-NA/[AUOI+";@U<'%%[ZYNNL9J!#G" J\S "3-/-0@TCV8@LF
MLH-P::5WYCRX'!A5TA-@)!/)*$7.92F]>(+7C<-I[*@.]):+K[%T-91Q?I=]
MK8.C7G8R5*]6/M+L[)J$+1>P$6._I#_]N!^[ UC4L8>A^ WHSN#WBC[!NVAH
M?Q9'5=#@C&/$<U_NK_<'?- .JS/*\W.#>8=5/F%O:#MGX-F/J0.[";Z;YRE[
M\P;S'JG?:=O<41E_Z0+,=')HYL25-T:-]^.)FVRS[,^K3,*=5^S2:ZW]P#DY
MWQ.<0EX#(44N]AF1L58CZW34*M+D-,\NO1F<[<REE]$^2TFG;*<SKYA0"[?A
M!D9!'3<&[ ]&@HY$\(!U5/ZRF+![G%@U8G(7,:&;GW:52!)@6: @4S89DP46
M%S'\$!28O10ZJ9R8>Y.87*.82_F9<0C:CX.C*FRZ<U+B<JQ"JF=%6TR=CY5
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MLIW.204A852ARZ#H)8"=6!SFFF<%0%,'M/N;++&'@%![((UE7;0K-^BW!S\
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M^-_WRI#G<B@;V;VX!YQU\+'?&PS.I<N\-NG:666[7GHGG4Z -L0@T ,..69
MJ!*-5, B<!%SN\09[F9W1TO/\B DMPIK#__@9**-G*C@!?7*)G^-N[E9[OLN
M]SK>99)XYAU'&,QKQ!F8>L9JE4UJRW#RT@66EWN&]]A=X]FQ1Z4-=)K/P09Y
MI<]G/C/LH_'<3Y.:"\QWXE"^G1L9T.:H SCU#( SCXOAVA.,BT+XZIP..ZMD
M<W77LI"LY@[AA#V(H8C(Q"B0QHQYQ;-#SP#E$?*F8RY04JG]LQ2[G!Z=I0W,
MT7_:/MX@;-<IMW,UE@4EWVI4GN0>'K;++G_EMVHM<&7&^/OS ;]B"5NGK=5=
MKK'71G'D?0*]AKE"%E8!Y> S;UG*_LSLV+I1P$;#P1"T6S:Q+DA4O AS(!H7
MI>Q2;,^E4-,Y B+UTDL)#2+GDW(?WY2,[N[!C%?&>HUOZKH8IK,'>-SXI+7H
M:AB*M/7^;!>'SO>#'^(;_?M':^U#N[7VB7VC7T3KXSIN??QRLKD6]K]7(>X_
MKNQB^O?AUD[GX/O73WCSZP9NK86#[SL_\+>=3_C[SL9QBW[X\7UGG7S[^CEM
M'GPZ:1WONN2ILF#C2,\9XI8"._4F(0^O)>%4<E@L38+J5C-0TJA5"AJ,9I4X
M#](QYX2,B7E@#4 ]KX0NU7[S;  9<@ ^7>!1"[.+)D%]ER/MSX+\IL/M*^G^
MY=+-<5#P )[P^\W3G0\*2EM[.W;S\4FK-XR#XG:G ?01IN!)#@.VNL7J4;_=
MN4C&VH-!3F$=5!,QZ@ZB'^43Y&XY)<"+P/ L[!Y8%WN@F?-Q4]>WCX"UV4-X
MOM*_,=?YHS"<R6A8"H8'KXP2'F#&!&\8U]:-*1J_BU]K&MLG%><^@%"OEF.M
MC4WZY#"_LRIVA= N AM&F12#,> =,EPJQ P5*MH0M0$>Q&;4,CAW0?QV9<_\
M7L9:#]J#869O)4.+L%"=3N\87GC[PG=4KFA.Y1\/H2R>8+P7<B&K[)VEE7GV
M+DT8*ZXB4_ /)<X(%835!L.6IL[39N\^RM[]=KI+5?)2^8#RE",>@*5I:1E2
M+C=.L()+D_N5S@H4<1,S_MJE[I9G 0^WVC<MZ49.*(F#X6?0)MO#;.S]%?LY
MS<3NQ?-%1O3UK;+8]9(#TP:$CEX1Q(VP"&QIAJ)20M%@14PQ9XC2J\O\KXM,
M)HQBL6E/BO+P(*O[?W)*;QE!_\1"4)XU35;X+WN675R-MQSN*U[V@]7370NS
M1[%S2#J;$(\T(:!' NGLIB"8R92+$1BS;-35>@3_RAO[R/;_R.<#C;JMT7CO
MK6Z#"D01X&6"82X=L#;*%4@*2S0)D)5&W3[*CESGNTRP0+0-B 8O$"=& U4V
M\)M,8"D[2B+6#ZUN[[':C;J=?Y4W\"Y7TE!K+<(I1,2U",@9JU ,TD1NJ>;<
M9H.(S*=NQ3W4[;V%H%&W-R_[%[[KJ"78$MC-VH&Z92XB#?L<)0,;W1OA5(RE
MNB7J:C#NF;J]75SMXJK:K5&_N.H@RT$M5QQ%/==I[Y7>Q2H ZA V@LMG@R'&
MPVH3Y)#3WE$I_S9G69X4P_9AG'][$&J#YDQKFV!?!*\EM9I3YXCW0<=;14?=
M!):?8<R'1U5F7-O'!BEARYSZTUTN53XYDV!O>@E:4#ED"#,(,_@G)1^2-3DO
M_:KKZ%]G/J$K?L.CSFB0TW;+ GKML9;* O0&A&#8AL\5.?ZAG=KP?A7-#F(%
MQ":"A.6 S!R'.?V90_LCHN/]7B>.;[%<S);B+%(6=HLM_+[M[D742Z@\CNYU
M<AS%/^U!EL3AOAV^J6IL%#[VRV_X=M^/#O-AI8^#-Z6D]W.^,(P)'F;8*XY&
M?;CF()82/V/_P /FF? QIQG#7,!7GFL'E)KBHOAOP@Q^S1/XU]DL-!OBRH9H
M'7S#NXQ[3(22* 3!@2 &BDP* KE@=' D4:QSAB@F=]T0&4A'W2/;GMH;XS/Q
MD-WP<)%^/).VEZZ,ON92JF61_OM$(SUEEN-?]J0,9]E*']I=0 NP ]_W!L/Z
M!"0]^:XY]6S7!QN%#!8%QF'7.)^03<"\(HN2I6"5CWYIA?(;DJ"RX.?"#X,<
MC=3+N64@$\?MX7X5&M)+*9:A^L<@>OO%OOTG@M*(W:D:$O#-S$W&,25G<2:V
MWS\I<UO.#[7*K0;P6)01*CFY*F^C02Q#EP:]3CN4]W:VD[5!,=B/$33.SGX<
MQ/$(RUP35VJCG'$_OGD([7$FR_G&/LO2'@W.,ELB/(<?UQ >?ZB?M_UA'.Z#
M'NS]$ZM8OK%>3/W>87F05PYEN \;>&__7$V6HRI">^#SL]UA7//=[M:/L5R<
M&:=G<WQ58\*:'MF3LF!5:6"5P-B" 951920O5+2PTCG_K4Q_A6V7=]O49ZJS
MSN7;G>Z^J /N98-G&*J3H#PBQA'G+UQ_;'6O/'3^.3G\GD>-9%M<!)ZBU9@K
MCC512I) L"2@] TNPZH%-D0T7KD'/![YE)._ E/$B$@1L*Y<MA>XE^%&(:>"
MR2EY40CS"[_<S9$,\Y'Q>XA"X[*[@PC@K4^[0@M)G#:(!$,0Q\8CK8E&426M
MK%$J.%9!WVV<=E>Q\,W\7HE[BT'CM/O%PHO-O5W"C8F*"\2L O(HB4>&.HRX
MH41BAA.WN'3;*7.U7L:YVZYT"32[O,:+_>6X=;RK1! T$HDBSHV>&/SFA+"(
M6EAJ'J4V@MQNEQ_'7_@LRRQT6+)>49:ZK)Q1O4N$=7!LC\Y3%N"B^_FJQV5I
MN@CT%ACT.$>B_'3FJ*7I;HM_;+]=LM?\1B:\)8TM2==Q)OPYU#WGY,1A=CWY
M&,.@HM?YU8&MZK3.IL8PR,K'6K[?R'2-9=J3UJ==;+4/E#L4B1F?.S@C$](P
MU9'#+!,K;R?35<F/RG1M]R>&5Y:[;.CN=2NK;BQ6$0WMS^SK[._%><,U1<36
M2<$2V.G KHFSE."4*,"M,0EL^@=PFE3JKQ]AE._+08Z])[VT;ON=D_>VTX%W
M#]NC0WC K_"D$<S\7OH<#VV["[;>E^ZY)5N*X]@P+1TNK0B7F12R_PC?>+4^
MF,V=O=/6ZJ[P8(<1X1#U,@"#DOEPFW!D&0Y6*JFC%Z!(;W+"C(YZ5?$9D!-8
M@%%[L%_6#*G<)H-8!0]GOP/8[Y7@O1F[9')1S2D9;7>ONAO@M;*'3G;Z]0YC
M\=OXC=^K:I_M&_TQ@PP[YZEDXRNDN5(?^S%U8H;YTN51R6*9ES;7SN&!2,F3
M\8P;KA/74N2L-):PA'E.],%VSOTWR>O=$0>K#'8$"6!82L,1(00(I4H$V(;-
MZX*-(H#/WN7H2KJLKM\2,:]" =.8SY#*=2CA.(O0<5Z-[)JLO/;C!0'9F3C@
M>OWV7KNL;I,]CN>NM;&G,Y?G&7OOSOR-@S?3Y7%2RHV+W<F<(NHY;'BMG8ZP
M_UU(FCF;&Q>1""]H+A_2(YZ1]\_>8+#5G:#Q5%=XP.E* [QB6=SX658I8<Y3
M[Y%4PB,>--BW*0E$C0F*@C0RG>O;S.A,="Z*>_FH\E(B)<C'L!.G0'K:?WX3
MUZWRQB]XAZLU'Y=0SE!\T_=S:>683T3[T8:B1J%[UWI3KW$B9NI5F#?%1'R+
M*?E]4Z,G^T7"6"41Y2G%3 V:JA,K6.J)+IV1:MMT<;ES%Q?S$%U<#&^ZN#1=
M7)HN+B_D45M-%Y>[=W&9/J9$5$VU^2N#[\M7%K*< [VVTTLN=#,\>=*6+MO#
MGO^QW^L 7@VJVV=.5+LB"J)UQMP/OU%@WO#YUOXF_7S06OM\"$Q[O_5UXW3S
MM+/?^OBY\VUG[WAS[?,5YO[]X'OG.XQMDZZ??O^X"4S_.[!\8.H'FZ=;7]?Q
M]X]_[V^MK1[#-=+FSN9):V^7.2E)S#$MTDG$=2ZB((1"GL3@30PYZ_YR$05C
M(Z6..YV(X\GKW'H4QX 3B3"*8&[;_X609?IR*OCNYSCCS^?A;8,7'IZPT2VV
M_+"7G5"EES^;5.]ZMA^R=E]K]R.\V1\4=C3<[_7'GMVRWI<]K X!SJ-.1T=E
MX7>QC*?S4"IOV>%A+T\#;,^S-.Y+TUS\55WS]^FXV6L^4X1>'&0O7Q5B9<M.
M$^V*TI0!BJ"O.V! [%?]>\Y7<AQ/V_OE]<]BE/IQ"!,07GJ$(XC ><7'7)7O
M_C(PCX\?6YH,8R(PRB,W6L9H#=!,(2DQYKJ^-/,4"BQ5QV29QZN\>OXT57@+
MJ4M\RS.HD-6?NTQI[)3VB(O<#L!2B2P/%BD2DV"8P*ML:47<5*!AYFZ_*%G7
M;OLRXKWTSX_+9U>!@3/+N$UM[\&4\(6I_7V[NU;GLV>[O/@RY]??5(>PD_M7
M1V#EU2Z%"E]?A;=\BBN5Y((F6EFB@^8F2<<$BTIX&[&U[CS._D&:W^R O0[\
MZ:3<).63#E9]F540ZN(-??H-<?KC>#<*E[R##4&I->/RA5)9Y#"31F%&!;-+
M*_Q7[3'F6_G@#">" $U6D2M)-"'>6DMC))XP;A[2*=ZL_,R59[N$"$Y4+NL>
M8T!@M#@$:HDA+X O:RM$Y#F_0MYT(C-&IUF06.;AY,.5^Y:;?#J0.,LH^-#K
M3V!P*[TO'ZN4GU>K/%MK7_"N"MP:EDNB2 K*$P<)6*$-8AHKK[B&/5T66)YQ
M;G+7 LM/B13-\M^P_-]^[H+M'*-0">F2.Z4<'0C;$3FG0O(,2R'2+[C35&.1
M>7ON7>C<]PIZRFQ:$,"G-U1<;HI&.>.,$"XH=8)@*WEB1 05I:X,E7L5L&\,
ME5]LM@//=ZE41'(-YHG)D6S!4-ALB2"/8]38>J/CKS;;3$-E2JSN8*54WV;D
MUA;*+6YWK7ERB^\^FFV";<(" "_!9'--I-4R&9)X4LJ':'W#4!]W#VSM?/JY
MBU,0@N3B7%B:W$TF(1L3J!Y/$M!5 E"5LFUR-0/X"0GJ?25E'N1L&,H- O.#
M[P9"J ->B%C"N<:RH,AZ25# 43,7&/4V_8*@3C&4V_"2VZ8\OJ2S@^EN[V6I
M_@($\*@?]V-W4(7L5"&E.13M]R<]///[,8PZL".FAGC63& RP&I\>73E^?XK
M/E+[V3K>)4 TL!$$88%3KM?CD0N"(>PHU=X2&K-/^G9'9(M[.+ S75*W&&:Y
M&!2#T2$\"ERFRE\O"YF4O3GLU ZHPJC]A1UP%E3=R3N@BJC.$8'V9XX?S1_M
M=?-TS1%6,#6E4S,\CMX:!WJ5HSZ?Y;(G99[ACCT:Q+=GO_P1VH.CCCUYV^Z6
MTU!^Z8]_8G_8!L4QOBG<9ARN9,PR6'MEQ-*P#_^%L^N/HYF6JVBF?P_#U3<9
M699&7O\^7B9W?E,P>L?OWCADLTR-6+ 18WS7"S=S?+L1$[S,92/(CSMB#4!C
M;GGA?Y=85.$1 %M&T?]OB2U-(C2KP*2,EO3HYWF@TA@N\TNW5$)30)RCG"[C
M9'7!BX%09"HRJE^IF*LZ\.: QOF4W45%><L'6UKY;:-[9B5-L;3QU,^8U&>8
ML1M&\RA+/-:U+VB1OW3[<=S0+B>'#"I2'@>_Y[2"[9RH6S557?W'MCLE?<AI
M7-M@0;XI6A5KV;$_&^EXA=+QW@[VBP] B(O_C6$O)T,U O'2!>*J%.0UW^C^
M$P=E)[Y*%)K5?YFK_Z6;1I6;:VB'H])I^E=O,*S<Z>7ROXO=F-K#(G<";0#A
M%8C$^UP0LNM/BAVXP:!3Q9ZNAH-1A0>#9MU?YKKO](:V<V%Q:V9RC=U;9:;)
MT; H,RN+L\=\R"GG3S7E[ZJD\S=7V]+7>Y/=0P#^*Y3_]RA+_O@+3(6RWMU^
M@?_[\CH^[,R5BW.?J:M6M_+0U&SJYNF?9G&4*49F)>:>&VUC,CQAIZ67T=AK
M NW%Y;.D6YX@ 07:2COU*:EPUU.D_6^'/SM;AZV#[VM?CK=V_/'FSN<?W^$[
MWS]^;V^>PN=.6S\V=];%MX/]SK>OG_#9=^!>H^_TB_Q&6S]:.ZNB=;KZ$Z[]
MH_7Q^X_OAQNG6VNKIYOTTT]XAO;6Q[_WX9II<QN?_+FS/H1_CW>QD%8QRI$N
MRWPS+I$VAB$?O5!4P ):G@_YKQ:<N]C*N-:[ZM?$Y)[@V&!V@]GUFKHY,)MX
M1YCTG$B+N<7"&4^4IE%1)X6DJL'L6F V/L=LS4QD@1'DO ;,UD&CW",3):5M
M#LP0A/NE%;6L&\QN,+O![)>(V=X0[K!EN<DX%]1K@Z.0,E%O?"Y?V6!V+3";
MGF-V<-$I:@ABD@%F*^:1LU$@0@(E0O DRM*H8D8T;0/:#6@WH%U7T/YM'N^(
MQ %;S16P;.XC=C$91[7V/M<"M_1ZU![ C,%O#7P_*7SS<_AVVL?@-$.& G+S
MI".R@DI$+6'1.R=\2DLKC,[@W%>B>VJYMQKD;I"[0>YKD3MQ35D2W!@'7(U+
M1Z6.8(0'ADTBX0:_=H/<SX'</S??XY\E>J_N@JT4%4\J<VV'N(P<6<]S<7@M
M>4YRX3*W5&)F1I6-!KP;\&[ NX93-P]X2RII]F=KZ107/&CF)%'11,V,9/&Z
MZE\->#\;>+>GP%O!_U.#!(X2\<@M<M11) VE6!+!I? 9O,6,$\K% ^^:A?E<
MA-!Q$NTB1/-L_2HK\*S/>C_ZCAT,V@D>ONR55>]HG_/1T'O)Q)S"_(LQ+KY^
M4(H1+J3D(7!AA;;)*7@M9(61U&VJ'%VC*&[2#N]*"?Q\60 ;I7$7I=&>"FGA
MBJ3<AQLQXD-6&1399!5*@D1*..4Q\WU=+U=-K0E] SN/X@TFD<?DG"5,\JB#
M43;XJ"VFR0I/;E/DIH&=YX:=252&29PJG@(*7&F '8.1=M(A)B/WDAMO&%U:
M$7I&S:@&=QK<>;+0 > XU#*;8E2*$^P,%TE%IJ@V20/KN07L-&CS3&@SB2<
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MU':%[:C/C;16:OJ3L]3)PWY_^!:)5J<A5)WQY3F^"=YEW$'YZ;AOW)[KT6U
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M;K-O?2''*H\MDL<N&JC?5QQ_6(#]-J;[C]C\]X!$F$OM@K^]"!?/Y+I9[GT
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MU4F(NA=%6$>7:>N^Q^<XG*5XV4]'^=.1^L6->V%W$/=Z_<M)BB=EIOZXHW?
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MZ.+U6Y^/[E3J HYP&FW$6 KV25\N_"POUV"F9S9G8Q4U!<Z5<4I(G-Z9I^S
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MB/:*B6:U+JV4O7T@7BG[9I&)C:?L5B@!%E0T :('&RE/H'TR-@DJ4LUG;P?
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M I^HT49124LYO4A#J,M+VX(Z"]%&0RV32A"P( FDE(BC7).DHM"<.S#2;^U
M"TOH_7A@\\-1GV7<;3P5+[_3V7/@/)LL2KDWDQE/0G!:W6WM@)[%M#:J2L:*
M(8X;12!(26SY$<%H'JTU49>5[:+ZVZJ_[>O^MN#&9]7=UD[,O\^4MZ2=]CEE
MD J,,<Y0SVP6.F=MM:>UBEL;,#\L.MD$==D[GHD!:0CD#,32; B+627II4T&
M"MW\W,BM=+/2S?;0S5*PS2HILC<!5$$=)9T17*O(?(BI)K:U WH6_&M".1R
MH B5!J$G94X\V@GX@S*6&!J[V1;_6EU*VC8@JJSGH[PV17E"JS8)+D"99#5C
MH=3G45GQF'1ULK4$>A9JN-FLM;0.44=X E%9XHU-*%6E&DI@.(:J;#U4G6S?
M'VPJZ_G*(O;H0PC>.BDE>.],C#Y;314$#\&8ZF1K!_0L.-E$5!KYJ"#4!$W
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M_EE>Z=DUZ^T-FK];%!]<MVU]((].7ORE< 1BLHQXKQTI-C.QKK&MK<G!)R.
M;^VPGQ2_*?^P@[.E?\U!;I2?C^2FWYO*<R]]'A9ZV1_ZAAT@R*"]@LC;'[XE
M>%7#O1JCX)]/#WX].?C7IU;(QLCAK_/7K\+XL3 >ONON[?\5F5-*<DFHB(D
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M'!+-J&P)&X4%\8AZZ1 W7B-K%$422Z>]=1RP(:ML5^O]%96MD*#GKK(5$'I
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MG'!P$$[/3V%Y9H03[PA(!DAZ$FU_8DK 9+].H7&MVH>OS#>K&2,.8(U@7[>
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MB[.#>':Y[T3[-6L5L7MZ<A1_K=K=P[9K0U"Q6EU+PX"LA9$?7J9BQFN7)(6
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M+UR?*QX?\8R73C3G Z&3$\KGZ3V/QQEW!Y6S63^H:_# '?UA.WZ-TP/)T\0
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MAW2]]ZR$[ZL"XTY)!JIRQ5L<E)4;\(^4_O?CT*P49 ?-!I$_SDHV$=@AXZJ
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M1V9JZY'CA:%EI8GI\F<O?>?F'.-"28 !DHN0LNM&--N(VVKZ.,-ZBE/7\\R
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M]T?_QR;3%[LRBP+V#%U\*")D]H7(NUC*WQH9V;P&>&:7XKLB9] C_VI&U)S
M^>9I#<P]NQ#U$9*V#^L)L)IXKB[(-V,WLM,XM0W'=\%*,2++92EG9I XAKD4
MMK%#Q\"^XI^3ND3DKR4>,\&(6E9!4VYGW.7\ C;L"=+I.QC+J1UXW.6@:%J.
MY>M F:D>@C&I1\Q)'#LVDMBF4K2&3N5NOA2-YP8-#UY)5,L(ENYL:18S\(5+
MN%O(<PEG 6'@OA49FEX:N*EK15;,'6;ST/(=C\<ICQ(CXLYR]- M&3XL&<;6
M:1089AR:INXF*=,=QDP]=,) ]WTC,,&@#KF!9'@-%6Z\SO5N(;XQ%8'@P:*[
M8( &1=N6I@-5Q%#+/2M0 8K+;)+EC>:>G0DE6,!D\":I08 :YM@L::C]>9YA
M&0X&W?MW";B';#)E$LNE8WTM:NAT[K%)3U17,-.J:MORH$I65=+BN$[I6V*U
M"5B*=L@1'V.%H9C.HA;9ZGOB@92[B-9.)6PD&!LRF0CV3=RTZ6;U&UG]-#LO
MN0C.$5(G[/SL'.Q LN26>9\N.^9X0FLF3<<BG]^UNV+RI%%B!0&SF!,XD66$
M5N2G46A:L<\#@W')E_V':!:P3_;B6QCY&S#NKO%O'O+9NW0WP_26/*G>E;L9
MHGU%-5'Y4U9WL5GYY].81Y[K)XYNA-AKQ0-.'D6&K1L<)6P2NH$?8:^5)8#-
M/7WW+C2";DG;!Q7%LV(GC-P@<ICI<]]D1N""8?20#26V-/*U-.*<FFGL.RQ(
M]-0)$]T!A4M'& !@;)[G@K+E!$:*0$Y#_UH:&5#1)N: @3YY-5!^LYN=0E(B
MD3="^.;(^]!S *6+.NRF,_[K @NB!3B/Y;?F@#QR@Y7.EE4"FOPA_$[!S_L%
M'NX4\]R&.)><U(]_V:>)YZ4N\T/,C@"C,(2_ B>%X^KQR(F=U/,"T,8]=R56
MT]?%..^Y_7?AZ=M(YK+M/W-.'9N9B>6YNF4%"/J1<#TPN:][CL5"T[$MUS*>
MO71=?QBL"&4B"[G#>0>B\LT@A1U/+<>,S2CD'D]MTS.9E28!$]E2IG6/4O7M
M>5^UX9^L4V:D0<03IMN!Z:*ST@;K&P2USYT([6_;,SDZ*XUE&_XPY_V>V[\]
M[U^Y_5_V[%,C<+CO^K[.43L#/0P8?P(:?.I926)[%F<F-DP*C*%U_7F?5\V:
MV&8\!K->=G"H"+MD,BUR:1,^7$7ADX/'H1AI)[WS=JJJ,_0?J:ZZG[<:J8H/
MMREXK)^>-Y>WW'B)*A[7I70PM:VNJ15T)7J*=SNK4,/K!@RCF)[/SMEX(KS7
M2_*6!]KQ*]-$HX3,!]21WWYXO7=XLB_!9UZ9;N_7O;_>[HT&!,C!/C;^[ZK%
MN>HBV."0/PR/AP/M-<M9P@;:7EV"73/0?F.X=_B&40T6)XR=#1=FKSSI\Z@W
M\X@W=%U53Z=CF"-L7NN+A^6I;VL1/6HR6UIGU"&OAX3\8%9H^&82I6:2.)X7
MLC!UK3 Q66IZ"3/XO!/C/KE\VSJC^\C&JX,O^^9I&,.B<R/2[<1R=,?&'F0\
MCG73,3D+#1:Z)@8FC)4 >/VL/CJ.61?CBS+Y[H/]\3VH9XO]<3.AQ%].X]A,
M0YX&NFMZV*D<C";FV8X>N+%AP>*'AF."#KT*;O]>X!\D"N_J.C6-Q(AL+XA]
M4/%]#\R\V$L\V\2*56Y8MK2NYW'!MH@>#T MA[L']FGHA(Q[L05\Q#-UA\6>
MCLP$6Y:Z:> &J6,!M=C^7:B%85K6C.5G)-N;CB-(($.MK0Q"Y3P1Z7\BYH,=
MW'JY=S*T0^4*"TK4G>@LCDR+I7$8,,-P# \8512EMN^&ON, MS(?(HQ#TJV=
MWKQT>\JTUD&MBN&>O5,7E!S+B1V=^0S(SC8,/8HB1P=9X?"()59D1->4S?91
MJ[K,J &34T8?$J;06T5MS!TPC&[*6_VSQ6Q=2-V],P:[FS [<5V3![[O!*83
M6+$5>Z8?@36<VH[_8#V=]U1N2J<^3^I>F$W9@2-^EW9DZV@I-N(3YYXG>P[(
MVL .[=0'[AG%0,9QJ(=!X.D>CUSF62RTJ25(N+(E2-9''%@!BKT<EWC38T.J
MRTZG4Y0JNH5S!E/D,O,+Y,9$A8% V-A=D,BV#!=MS5=[AWOO1V_W!]K^P='H
M[>X^+>^;M_O_';W:UZ*K.12(WAIAII6>?=;/LP06]N<G1/1G]CL8]SMX#Z@.
MGP^^?#H-S-@P RO5.;,\W8E<4X]\T",\,[)CD+6>R\$HP<ZHDD95LEXG&:AC
MK[8;JTJLM93SM;5D$: (Q_..QKPGA_R&/VTCY-UN[)QZOIL8H<.!'&Q+=UP3
MK-70LG3#95%D<-\!N@$C9)6Q*C(ZBV@FRL=NX2232&[22P0\Z/5YEK/A%JWM
M =':PBU:VQ:M;8O6MD5KVZ*UK4!KNQ%];0ZMS63<-GW7\&T_<<S$9Y%K&V&<
M!E;$C(2Q):)C,P.)MM8:FD\&%XF*B44#TA*L/Z *2EQNVKNLME:HF0VZSC 3
M'Q'R86Q2"6H>)XI5[HG0+%Q[LIY85-+$144*>S/<QCKM("JA8T\Z5FX*H5_7
MEU54U+3Q? U73X-C.6F+G"M.PQ%UD7 K%APD&U^(\:="A;D;BL)7IBKW,:%>
M9<49;"8.HTCC HAN4E %45FDV:PJ2I&$_Y21%/:^''PY^'QJA"Z/'2?2.7<0
MI#\$]1@8/9A#+BA7$0@% Q/9EL$]R3(1L:9:45)EPSR6P%)'Q[+<@UZI?U,P
MD>5S[6'DVV2]/^ZP:(ES]_K^AZOH$&/2U6"4RW8-ZSFD<Z"SH&+LN)IR^$_9
M0_ %QF6<.K$3&Y%GZ9;+ ATV XY$:MJZ'_D.,*743RWWV4O?6M9[<)T+-;:;
M?]/F[WT^M2PK,-!O:/HA\,,@=G66N*8>NZCX^J9E!Q'J@\:*,IWY/+].&_>%
MJHNMD%QWHOA@?XV05$)!"DO1(&I1H%4#T3*N%)+S3E!GCN& 61:'W(31,0_,
M,@_H@?MN:*8^-Q^L(]*6=5Q/)5_VC%/?<6*71YCXQ S=L<Q(QQ(-/7%#-[8C
M#];4(<_R Q;X@6(0HO_+L=W$23T6!I'EN(9E!DX8\-2>Q[G;;OZWV/S]SZ>A
MXWE6&H:ZSVVF.T[*0&Y8KN[Z+ [\(+1LADEP@;D"VVY>;DA0GFF9@:J*X2G)
M(T3O1X&&(*#O$ R^IK)PV*,+WBD77QJ0[*'++\04,2BV)!I&0]E&Q#:*=-^=
M[%\]1$3LZ9464*H>V(>BM<.F9WP?9Y-Z/&,Y+^JJ;4XK3IXL#%XTYV5RQ!R.
M.J';S#=97]*"=P#7MGCHA$77L"PJ3%8]K6_P*SR4H7^GSAB6Y7J@FUL)9XYE
M,98X?A XCALC_*GS(#E];<ZQ<'0^93X&XXG=4\^,'#OEMAX'+NA?+.%Z&)H<
M-#$G#FR?!7:8(G3YDH+<^ZI?AN&9'K<2&][@!&X0N([''![9$2C>4O=^*'R%
M[4;31I]9IP&S[<#P7#VUW0!1$A@(+)[J*,>X%YANS#Q"TKB3JM5$##H>3.'$
M5\QI*1IIWT-YP3LU>B)5H\@1OK?J1"062OS4Y?*"NWLS[V\]&K8;!3:+TB#U
MP8BP(N13H0U4'!NNS=V';8VZI6#C<'?DGEI^$/E J5@T'@&K,FT]1,N1I09/
MS< &.6\1SL<#NAA3SS)=FZ5Q$!E.@"B"/$XPN==-&4N]Y"%,Q>U.]W9ZSSHU
M8SMP.8L1\ ?^$]N^SGPCTIF7&K'A1RY8BL]>!LN@JK_2+-QTG?0-<-WB4M5H
M)!G!K1'PFTRT_166CY?_]P_+"5XD VV7YQC]G5,J.SAL,+I1?597,XGD\N;#
M;_MO]M\>8)U(/2& 95D7FHT1R3>5>F6W:P^\.H:QDGXK(->:\-?_:H8@UYF(
MG$?U^).6E/49FMC TK%,&[]>+)FE]RPHM7]R+2^T<9&?D>10@-^-#%D<'&':
MM<7 F/U&5]QUF;HKC1*ITU_H)MV> O!+5?IJA>[><4UD><?FR!]HXP<:K EV
M+RDY2YICLP;T?U>;]+" W;!APNV25(,UFL_JT;?ZUC6*3YKE<$SP*+4JT,;7
M6@O\:(J)\^R"4AH)7WV^M*>OM'8/UIQO4& 6WT5QL'S+]0W/2",[='S'8&#D
M.%8:^A$'!3RU'P!G:+?F"!IW)";Q7J0+/67EP3SX./I\:C/'C+AAZ3RB6C0'
M#)TT,G7;Y*:9^$9JI.:SE\[0?D"+U@M2.W)\T[$]AYL&Z"E@;@7,"K"ACA\\
M ,C,=K.7;+9SZL4<%'%NZ@EHX[J3>BDBBH%]Z]H6'#0/-B0"37%EP1:[(UA=
M5[$<:HK73-D5,9HE-?EKRCQ.BCXUO1;8OJ,\.2QR"?3[Q"GLPY=3+[)-.XI2
M/68VUQW']?7012]9$IO,3L,@]MUG+RUOB8>L7]IZ'9G=BH3$S4N($85]5J$0
MD\'R]>-;6SJ[B<Z^_/7EU&>69R5AK(,.@^V9?!_$%O?TQ  VY@>1RQSG1D"0
M>="8.06',!UZ@#-L0=6Y2WW5[=3%Y0W0;TJ1GTNI3YW(MBQN VER=+FQ(#',
M.$@]Q[?2B(>/02U=;9<)[V4WRX65,(:S%::><)MBJS;RA589V+,IF)+Y?+Y,
M]TF;9;F9P2,RUM9HI'==[-<+[GH1S#WJNNN;K5CD&FLPY=437,ZF;F8[;<[V
M#59W#[I"UK2'Z*N9:*:A_V>XN&A+O)$TJ!L+^4S$CEIMW>N6#^LR17:4G^EC
MG@(']_OLVW2^.M' #\S0N__66;>K[C(#V=E[\;\=/$Y<]C]8F9&*M:]Z>.TI
M]V)_K5>T=HG<D"5V[,2IZSEQ'++(\D/NI4X:.BSQTJ7AR[Y2I(:A1D&#N-H%
M03PNJKKD)_"R5^,B_O3#E:$SI0P9[_X\FAS\\O?YW[NOLL.3,^/PSP\N*$%7
M?Y_$-J+['DY^_W+PRYYY>#6O#/WN_OT+C&7RYM/!+_LFC-'\^V0,2M!OX\,O
ML?5N]\SZ>Q>4K),/]G^_?+ //AZ<6IZ?I":+=09VD.X8J:N''BA$:6R!SFTE
M$3>3104A@5U(;,_FB8,JK&5R.TACV_$BT"_B9QH'%7.*QZ"L^8H*/'-H/73"
M#<S"CMBWY-K7G(S77:9T/?%ONC_PW?6!X56<6O:05!=TNF]>J*5L>@%RQ4=@
MX!*MB%,)FXPZ31"1+^(Y!_TL@[]%Q[2T"<=0@X&ZK\-=_Y:GESIVR&M8Q$F=
M<^VXCM[!/Z-?-IUL_U3YJ//:/&A?U^1Q+5LF[7G[[4X3XYK'9^V";S3Y:1A\
MBXHDZ\3&6MS:&1@031.>T?@+#!Z>\!-9E&A@=$%F65(#2=<3%FG/,95C0AED
MHO%#9\Q-B? .!>OP4,SCRLZ-?3 ?'+MV*N/Q8A$!Q0K%45PV"DQ:X6DJBU75
MVV7\4/I;DKILWJ$:O4X982?(7!8,MA9MZEW3A0ZK_U;VD'/\(/;,.#(Y!VV#
M@:[G1+!J9NRZ9F3?OX=<+RV]F>P)+R=/3M^(S8/?3PW#<IAO1;KG(^R1P4P]
M".Q 3]W8=R(WB5S10&9YDS@16FK;#7>BUUA"3;2WL/=#;>-3#?[D74D[W[^Z
M<]P8>LCA3"/>%V$#J6YQ*\3GW",B'K.ZXDT&OV!4EQ2LAW4Y$ZFW_>./[2.S
MDLO6<N@0NQ 2G%X_P9+XCC >7W4;T8G.V__W#U R_1=5VZEWRDLZ@)B8(-M#
M"QXFH<[@G6F]JG_%T@*V>S&"UE]K] [_<KC=UUAR_Q[(%OYF9WR=RM>^-TO8
MPW>>^BP( ]MT=![R1'=".]*9[1EZ%$2V8UJF%W*!SWQ]C?>U\)0"WT!A&Z#&
MB+CH13E3=_8(=3XI:8X);?&N[L"3'&.+=[7%N]KB76WQKK9X5ROPKF[TI6VB
MOKJ?:^_B62';P/BDNPDSM4&CK92 7FHLBDQ-[-YQ-\S\U/8\(_)#TPP=EKK,
M\KC%PIBSR#!L1U0C^R!5*,4<_O@:\'R)#GU2'&1Y48(.>XQ(!N?%&-CG.J43
M?7>E[^KPR]EID*16&G.P 2WL3^BFB<X,)] CPXD=.^!NZAL(8[XR!J]B[Z#K
M=\A$=((^QR@L.1+876V KZ,2:\X&0!L47IKE97'%QK,KD*-<II\4>6O!$@;8
MDS8&OAQ\W#NUX]3CAL-UX(BA[G P"R([!6, HX!!E :VP[I=Y#NV0*F6NJU
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M7J[H4Y:%<] 7"]Q["X!Q$P"&N07 V )@; $PM@ 86P",%0 8-ZN'?74RMHS
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MM#%UY*O3[1QKZ&_S[=9EX ^=;[? ]YMM'AJ+QPFMW#&[^CG+:=#1N(@_O;A
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M%9:Z"!!VHII-I'AV);=P$?+A?EMR(FL)QEULT;[8[BLC"Z2'P6RI7<RE9ZD
MUZ";'XYOET"H'4S05IAFUXQT/BK1RT9OJY&ZD;^%;MS;!.M[)UA[VP3K;8+U
MVB=8;XCD0$\2MKB,9?$[B@:1?C"780M"HTU:I3RE!IU=I:R())BX+$3<#P;8
M-P7;2'+/P[ TVZ'1[BK>35BH&IE4YZ3PD3]*@DS+5!HI]EHKM8&+[@_G%H-
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M]G[@T]68I<.:3G+G6PQ_NH'$9-\B91T"=3HA73SR,P8DSP1ENH".]Q<_OR>
MO__\\QG\5?HK,\"B?TW.+U9MBHY##*CH)G2 -A#SMAW$6+"7+[KH]<UV4G-1
M,&-AQV!S)";L%;C)?AR6UI]NN>,D&CF%RH?"A;$X@^I<>_UGTD_*NU;PN[*+
M4O(*B91J><I5,:D">Z9D>@($]\6.? RE4%.J:Q%R$>!EG@?;M:FTF$4M>2<&
MRS;H_E%**9C[CPDW .4WCC_GGKQ1@+2:$1)2KY"'PD3-;V!,6<10DB9]N&XE
M7"F8@JS3)*H)/A$]"7:!LX"-0ZRQ B*)L89D'@.Q^GCAG;0=T&-!+$F-]XMY
M:1H G+_'0.\88,+5,,3D<E5J'<:3I1.&DLZ9\>;CF>(!5)T)::D7G1I=I:A(
MHAJ.*-L%8)5YM0G(BJD&H>BVZBK3^ 5-Z[(2HP!.)^[@M>1&X%!4+1YF'6Q_
MQ0-U=4P(IX167"P]PLVIG=!52]=5-T/3N_!*HK6R9VBIIHCPE+A3B#]556XM
M4J]TG6IJ<)#Y:%N GK[&>O<X3-FQZ22S=^U8BM@P9X+H@K''/NHC%8S5L*BZ
ML4V.+CE8AWC#^6>PZ0,I4\\R]W.N^#[]CGI;FOOT#M0+6=T_JXNP//1-B%"A
M;)Y!&<NA+'MMGIS3J=$U>\]:ZS5SN9J0%3F['G<+M^SSZ6"7@;&YN).=5-^;
M@T>HLM\'C^!5,W@SB%W0)7=O/#_HE@G(Q@JW!VG_WM\B\OH'%GDU9!QL2\"R
M>$A$4Y@ZJA0W //"7\)+R1U=KA*D.3FD.2FN&.%*=#Y88C_4[#7&M=_)CA*Y
MXF+9]K1EG/WZY?/[?[:27K6M)/1*6_CV_NV'\W?O+\Z,Y^ ZT#ZN_<"=ODA[
MCJ1]&=)V&XJ^5'>VI(,:R(>)#+Z$Q>I$G9"[,ZT-VCHAIQ-RM4K(U5BRW[4"
MC!6U<E[ )U)S78++QC8B'J3Z&F!,[ZDU5M,1DZN$Z:+REF]6]GM)PP4 .@AL
M&Z7RQCCW\_.O%W]BR]7K=R_*],^IV+[[()KR($= = =LJO$>F+:!-<%R-A(,
M)M9 2?.N Y3'GG_]D$W6%N/>&RMS[NQ $1*;2D5KXF(KV;3 ME01WC6BP 9<
MV/X*'GPZZ!:E!5U(ML:#PN?Y6\%YO^[I8.WZLKS6?-LJCNI5Y@!(L'&87%>X
M?+(6MO$>]6^$>R?"]C-7%#U$\(GLH6Q:A.GO8)IIE8? H7"S9W/3.%?]]=((
MM.RUIWK<4F(G5-Y$*,V(&VJ3I)R&@-O4@$UFR4287\QAD14$:1,X6!1QYX.4
MH#RL;,E%85+13<@ ]X#RKZ'(L2?+7JO^<O%*!%!%FD$-N*'.-SD'!LC6FR?E
M?+@9VUG1D]BW$!L(I7.:9(P&Y!Z_8J)OL^PLB%>#?%ML3HR5P?XZ4[!8X P$
M=]GY+G_DI*B!WITT.BYUY H^U1:QSL(<!ZU@_Y1T5N7??I '9886E%#=!C$/
MJR6<*YYI>83+B49'\BF"59)#.L7A.:DFO,@4J2C/]&W&,VUX(BL%1*:A)95U
M@.8PKI@;$^$"@0D8;>[=**@[*<-1#(!M,60?1U;J^]-*"S:E7K W'&41LQ?X
M-M6>EDHQ9L"):M"4%&K4@TDI0^'>F\9O)!$<3/D3Q\*[&'70(CG%,@&)].AH
MSF1T)?,\RFQ2$0NLKXH.NEB_)+I!>=C?4HEL>%K(*7&GT GL>"DF6(6)+$;8
MQ1F!;+,@(!$L0"QEEP3B$C%$\*!6G-0^%'VXQM_A_"+ZO8NK+PED<@)US89U
MJ,4QIZ.+1H"J^2B6\R#8<EGO1#7ARHE4E"I$-IK#-JQD>>/T,I#5/')$]V3:
MB21";//*[9@4Y0R$KR-F!<!?1-D92Q^]XC*7OK8"V,4SH#HC9*#-1!MFCHLQ
M^R8-#&+-B1P:5UJ8E.3^9YQ/$:\"?BYRIU!VJ=I<+SI29P9U.5$[H\]$HSR<
MGA#;Z!K.8E2*HOI(U&%1?:$=XW"V1"ZH5K+B[HA7;"1HK,B]D"D!#ZB66%:V
ME:8+!2X-O..(?A8I*R5%&_P,_!E/]BD,L\U@2Q%.=Z/ 6##6NAQ3@H'/'?S]
M1KE6^ZQM#<4 .07I5(<L.@(G!/+.B%M%;_A#3-7-?/ VDCBZ8A&AXU,G&OL?
M _"DE07,!DZ3,#4#(C)B1!6+!]_6F\K/4JH$81L#!=VHL88 U!O!JJG%+OD*
MS5!L;'R3&X>8;P==*"62X1C3>)L>-<\'=& )J-0Q5&TR9?1]!]M:6JSR8&(5
M_* H:'>T$KM%W7-O(_'1BEI^=;[[(+3@(.OI_V;I75G*JUP0,-)LGK/BKE)0
MR$X3P]Z+ENR>2;U6J>6I%R]Y@,X,]3Y-FH/+8CI)7-G6JLCBMP23\+4<JW1=
M4!<QZ/6YPXSGWW[^_$),.3"X-P>)/LT5;19X<,J1\/,7P-,-4,KYFCFD'Y&!
M*4SGA0@A.:UUZ4Q?BKNU116,9<,9X"";BHZSF8;W9/41E 1D"59)@:;P3S/V
MMMPF'%&P'IHX: QFF)>\4Q1::$RC4,F9DZ9Q)H9.ED222HS/LMO$V3.MF5P8
MU'MJ#8;F0!56-SY0L[W@3P8(M@5ZMT<%FE4(.&BM5Q,02'[V_>DU4$RK0B?<
M?A[C: 6 ^U2L#$ZJ8N5MKG3V:^#CA*[G'_TP?&%<+AC.R=ZG-F6PI39EH&M3
M\M!>26B[!.U00#M3,9=,E2D,X/X_H]]^EA^T(9?"?ND^)19S$=)TL'>8'0J>
M--D4JNA.8[[K:X?=-3UTS;/3$/ >D@#^2X5 %:;&*?##CCDN-J%MFY:Q(5%#
M03\Q2V4CSF6@0+CT4;%=!&TE+.2-,F\LZ4:GZW_N7O]CZ?H?7?]3^?J?&DKG
MI];(2EV>NR6TFQ[!WZ]$'$,,;NC?HKS YI##89YVN^8H41L9S42WJ?XOI.NV
M.2/DZ3![_3?MX5Z2MQ4W;M6MR?R-2?RNY,[DO>Y+UM=DO/_MMX(ED5X<;)8C
MO/N-N J=].$<XA)AN*M'/'Y2XY1,8SUW]-%1!+P#4@\CAY*K(!K_!N*7!W_Z
MH=,;O9ZV<' "ID.-3R N9\R&7Z&4_Y+4H^SCW ^W./?#4N=^--[;N5_3QMV:
M".K\S7:*E4=<!B!IUBZIRE4,/V'9"2%"2'_XY>_G'\X_?A*I;IPF[+I*&?IQ
MA"4.%&&G54(5Y,0:*F?J8$=4BGO[UU@Z(EU^JN; M%06\VDE$@J(<F(107(:
MFLK$G#4<]2=$RED\C\/H?A6D=5*]N]E7LJL$FE;!E/H84!C&GQ4;I(!D-3O9
MD9M;Q'M&J-,U)#3,$#4@TU5F<BK>D\A\AB5N+R/V/7G_TW'?[*=FM*AI2R?.
M8B7[T!PF.TKZ0TG-HRKFJ$Q 'B[[BI9:JU@[,"U)LK T..TZHOP!4T(+[HHN
M"M@-098!E59W3W\'TN/BM_0NU?A%%%<HSL&O-DC!C;Q0@BDK@RB1I)) %D7\
M#F7/U''5$?.'SE0^BJEZ225Z\5V]C.%<5B@^C\&Y 7G",Y4T>&]S&2^-"8OL
M9,8T+2#*GG(P2":."^;.X 4MPO5-4BTY%SU[<.AG**M0TL(5R3S8G"(#!+6W
M'*#EK.$;ZIRBC-DBQR!)94-G@UZ&+HN]A#*R:2K>L2NCGH34VIX]F^8MACOP
M2[,\AVXK:T2=J'^@8\*'B@EWMH-R1Z]KV'FB(\DZDERQ2')CO>GG/S/'>V$H
MI_H#VG&_DI%T 8*3A: 8E/'VEFIGY_@O^&N(+2@)U?NXTJ,MKO1(Y\ES<#56
M[(9X >U^=;U2VBVE#0[2Q+FT1F&!I;QL ;9Q6O\\3\K8H_5;2]F*:W%O*;DX
M)F\^H.F*-KX_ =Y)^T:&,9CCF1?8Q<.(O<!.LMZ"+&Q*KU?0E0MZ$WR!%K#\
MH=#WY8NG.P$#F)&GA\J=R@HH*9*K<5UW6'9=O"4+[^AZFBH0E@U^U %;LO]%
MDFV@+J7/Y\1GKN2SS.N#(I]MW,A=W.93L/KO-!WE$.2P83QB8>VU2P_9WJWI
M#0C!!@L'6"VA!,GTHBD1=5!.R[?!O$U23:$H4\7P65A\O4/A.+Q_227=<:@N
M6>W 5]EP17*' _QT+%+%+3M 8IK"RN-BQZ2P#>,Q<%5UD3ZY([/#-?K2'MZY
MGND/3T2[N@M]G:2IH%F9Z?CU\JOL^G&1O8OR+A5D^]B/XRWVX_A ]F.C+B&+
MCO(CT8)-&%A-%]B9A)1H4YV4Q"M@T'6+KS-8-+A-/N:' 4WX@ETYONHAB'=%
MDLO#X<UR%?G4C2Q *T\U>E^%-Z#5613 Z=8>DMV:0XH0V]@2TLXV!W?"K&5,
MD>,EFZ(6 O,=3H&7N(39*:HNLW4H()[%$7,S+6P;+RS+9 )^X,G['UD+7-QG
M4Q'JTNO,^]NBN)!"P(*%NU_%/@TC=GNM2Q8[R;#14;/"T9U65DKI</2>AM"H
MS$C)]B_JW5N)#4?6>'!W<'9VB2,^^4F4+IT+H?'\O4B-O6@9G_D^ID*GO=E4
M4-\53(7!X(1"3<=HF$S5C4DW'75'4>"1)W@4U9?*H]'YET/E7[JZ)E]G4BJ?
M2:FAJ$R:)*+DBCU@'M'H!X.YO*R&9M3)7#S*1(*E,>=XF'07=D#AQMK"=['<
MC:)&'&RAZ$8T@*'H25X*EV^&6N]AI/!I+[.'7>X-B *9\E4S9\B4G>RH.E)9
MKRKI\[&E]>C8N>\YXL8>=MJ)@,I*@#P8% J5;EOU'0?CVKEMV<XX>_UBA^EV
MZR^Z! W(EOYM;[+Z9B?7OO!D0JD'[.U_%Y-C;W[NM<WN0_,SYHNR[&R-1VO]
M6(_"U;LAYTA,W1^8P_56GX?C[$*[T&.R-QS%.BWV_DWEM=)T@2ILQ(8,JOE6
M;AQ*V0Q')PQC)M/15.W-/:3PV!.]T*B+G^SI@N$K-;T3:=+#'F1NII'FTZ[9
M-B:2EIY31/!2+(<QA_"%:=P>?%E[JEEQ%\O"5AI3/@&YA34%.O"R5^!E9-4Y
M U7' )$,#7UCW[%QQQ7->]TG,F1MB0Q999$A(+\3B@SAE!?1G!+-""Q/QZ2O
M,7-C.XHI_4OY$S(X@ 'ISTQ>6HZ/]%BVSCK3"%AVHK(C/Y"%2<61,M@"1';1
M*]^*Y.%<BATO9K!K$,VB0:,HMU ]G5U@C5R6''Y.SC'LW2/[##0&V#]+T$(.
MR';C=["'PJECRZJ?3'-FZL2W8#B-%^#[O]RJ&QL\IK,MDZ:98;;  ^21N,,@
M,N2@&D$?8251)AXN[X_8L!"9:NE5@.:W,#]6L#)KZ&V@-<R:K=5?,%D1X5&+
M13^8,R]#"@JK^!,7;>,8>Y(&R - DX%H^5:XV4'+J0Z/="%(-$5=;%@E=PPP
M?^WTC@WU:H?]B_FK<^Q?+OF <G^JFZ3<)#*<O ET>>U$_^.!*V[]B/M\S^'#
M,"19>\'1,GJ1U'"@4X&7Y1/7Z#AVPS<X0&A\AC-=^$OFW==DJ(UQ([W8[/6@
M LV @0U"S D7*>K3#ILH\Z[)BF;D2D8983/C- $<EU:MX417>_0/$S(66>-<
MZV.L7!2EI6*"+_PJG=CEI).B3T$>E?L,#7,-0,!\A%.*:C3M&#25EH\0E+NK
M:J6&*J-Q)N F;4$R.E7/]J*,F_+0#IP)EJM,_"O>2G7J/50T*KJB^FOIA.7!
M$I8]G;#4"4N=L#Q";_N2L#;)U=S=\KQEF:0"8"=EY>P%V_/^=ZE-X\R-%C2N
M-=]:DB6W9 YU:;NX3L!E/6-,W1.N X<N\<^VF<BR*!+CU )(+ DBS(4F29[.
M!0]N"S#KB^FW7TROTH&V;U_;G0<L>DT]8' UFT3?5K]EI$%LW7EAWXQ+KRFE
MKN]%20"L^5S0@[J)/0/Z0 '(.=6]4J"%?2])<H@/)L&//^V3 >ELR8!T=&WL
MN6=\X),@QOYB8/UT2KJ:_>[#7PR\%8U*>W-'\8^B&5D2JJ.V0!ZN!HAO%7M4
M4B=LF3AH990]ET,L<;Y7IJMY.GZRZ<H",/+WV..(C1%AXSOV<@]E5RJ?IHX*
MMX,^V(2=;.$!/7CM\0";8V(( UUG)NJ(BJU#*?:0K^_HF^UGE K(?=H;F^-G
M(L55Z'N7;=UT+>=SBBZP\+[/_I6PM^E\@.N6N)Z/_>> 8NCBSXHY4V/8'YO]
MI)[ATH^!VO[APX%@42QP>#H8#M+ZM1>XP35BW#:Y92-0Q!5DM,ZCTB,WO.7P
M;QD/1=2D9!L ETX\+9:"I55B910F:)>B^D(G+#DX1U,Q>I+R-F3P PNH>=8.
M];SE.-L AT46-R+R0BAEC D7]Z^N& @-<%A::6@_TQ$O5&]&;>1(;:3:Z3F)
M-O*$-D+':.T.F)YC]_"4N4,/B'?"6P39TA?C1K/T*VL!<<P31R.M?'!HGH!)
M'H5QN!)Q8L49I-M2BUZL3#<;J8C."<*H.(U=N/ZP[2 J+)3;Y-I0B!R!HH=(
M,U-QZM6<>?D-Y:::IT[ZA.&P:#5QVJ9R2&0>?$;,E8R#@EQ. =#X%NM?UI0H
MQI0\O$RZID]:*$CD*&G0!V$\^1UK $6:W/?F/H+4#APQ7TT 4?6-4:-\LZ6!
M<EBY:?RV<%PN7(;\4V*0MLP+4 N;7$?+LL;?.!Q$-<TA\J51:1C:"4-)]1N(
MO4Q:BW&,Z98GW,6^'48R>G>]"6AVP3 _6,V1I<@3P)L<KM9P\CK<#!I5LUVL
MQ*;:3ZM;& #SU.JD =#B<(5"1]?-PD=2&Y57"'U+1<HY03-;%S"--](/WK*_
M65%-W:C_2.&@85/"09]]#[5* $2"TN5<5M'O$]GI;HGL=$LC._W]:UM/3N_D
M;QFAWE%WC,0,.Q9%@3.)(TH'X5V>/"+5=8@PYSYM+G_8,$]&M?JXWSP9JF6]
MSTR96F/_)*JV1BT9/E82U_A53JU/9(KQ'F,#CLX]Z"*>^Q7Q]'41CR[BJ7P1
MS\X*;$,N;5=;=-RNW66P#;NMH_W\(5$!0'MJVL9'Y[^Q,U7-5]^R%6I3;$8(
MN@2\\J8[Y1C)2U6CK>""0:@P7J+Q*7L4SWRLI@U?;01(YO 96$C%IFA$F, *
M(-A!+GA)7O\JY*_47UX7B)4>VDRL6;D0!?#_TX+<,,5W/T;3]2_[77,TW/)]
MV[3N_&6_>]>%MV[9ZIG]7K=N6^Z.A_7:<ML<M'==^4>B.T%[0,7((7]]TDU\
MZ16Z%=Z<>*,#+K3ZMV0._&A'X9"Q ET^BXI,(19,UL>?O+* \]0'@6#]==FT
MW1K83PCE!=B.!WORT_-S3SFUX AC^'L595+,X8M$\DATE #Z$:"X93=W0?L/
M4_K?ZW5SO\*H[O2'S)[LCNI-!08G@>%;-UQ]?._+V@+?[[@MT6V)JG&-[F:B
M6\S2$,UMGN607#$]*0U0<F) V5"PR%#'/23H>P\%^M3%$=<27M6.QW;1B,=%
M:7U!]<B\H %W'\!53#;F=CX0\8TZ2,"W+!0-5FS\"]8L7C%7Q!FK+ D/ZS+L
MLZWCHW!?]^!I$56'!0[!_Q;H"!P)][]BT.FT.IV>.1+F554@56D-4 4)6DUA
M>4A.NQ54%>.[?6'5:8VMKFH_6DVX59H+D]UTCFO3[ *N#3NN)-T][W3-P5KP
M\[$A6&43L-(QA[K:U9_H=J%(WR4MJHT__3#J6)W7JKZ_VC;V@230'0VEQY0Y
M^]J85JO;[YMM;6-J[79DL6*U^H..&G10:26GZ:Y)=/<<;/ENM:TJ;;T\E/7B
M^=Y+;<%4FK_WMV#:[;&.DFE-\@ 63*\]4K-<JJ]0--TUA.Z>=T;:@KDO<8YJ
M8K]\PT%?E-)LK24V,\V?"@9.M8V9!TMY[I>AKYXM\XCYT)U 5V$SL-?JCY*Y
M;K4 8Z5U=2WJ]*HGO2N39JT:.^\+R'YK-.H=(2[]4$"M-'-7P1"_3S%=)2GV
M>:<#?ZDOJ58,G/5)[=:E8OR-'P3^->SRI&O%N\ -4S]&]TG7/&O(U0!R599]
M-4H,O15I'P/;OLC&2&)\](K=8#2EVC)15XU7(DI2@T"(3'4^=B"D1IJ@"H*T
MFC*S,N&,&OA_5JLW[A\A#ZVS@SH[N+V^";OB5";P4 =3L#ZQA1K9UY_K8TSK
MXJI=D3IL]3JZ/%RKL>.+CUZKUQ]7+>&CZ:[Q=#<8F/VZ$%V5+96:%5A-DF1(
MM4T573I5_:!@U6HM:FKD-:6Z0I=.U3O66#5VWK]T:MP_1ML873I5$3.[<:53
MV%6][N1:,9#6)\19E_*IW_S@#P<'6(K! ;J&2E<":<C5!7)5%H URO&H&BK1
M<KC:$E!73%4B.%*+^,>HUSW"O>[F)KFJ(#:K*2$K$\6H@=LW:G5'5M4"%37B
MPBK$(NH8;G@^,'NZ7JJ1P80:VM*NPR:.6X,N#KIJ:F<!TVV-VKW#%F4VUYC4
M:NR.:JS7&@VZYJC:JDS37*-HKF/5@N"J;*/4K%+J.I_WJ+:-4HUR*?FE?-LN
MD>OJV3!5K:?:&;85M@][K79W_/@!QT/"N=+:OHH56564$;4-=M9.8NP+Z6ZK
M;XVJ=COB9.1'%;R% PN3&M"\5:\BQKL1?,5@7A+I_9%ZS<*?4^?JI[_ ?PQG
M^M<GSL0:SV:C\: ]LD<]:S!B@VX?<#7K\!GKC6;=_UCC[I/L4_*0U\XT6KRB
M.\MM07:9+Z=.N'+9S2O'@[/QEQ/7M_\HX@*@_UHLTAN8O;%57(-PZ7A3[D6O
ML+"POP[H'<&1A^%^\$]Q:;5+D$G'6XA_6QV"PP<_,*(%-SSXREC"[Q>AP>$8
M4^.2KR(Y3[V-\]0[\%\;@,+@_2& Q)D!>+Q(M N>N?YU:%SS@!LL-&:^B_].
MB]6*Z,A"ZV7.,R51T>F8"+\E"^:.1X0_J DXL0U*9Y"(CHKO-R^?.P3CIP.S
M:TP<U\5N17$(A# #$@D7#% ;\%4<V L6\O"UQFVU]UN*VYXY2' +[_)XCGU7
M@7_E(.M/;@Q_Q0,6802&V9%S18DBC?.*[[<4YUVS7<0Y(-KF?!H"0]O<N4(>
M#_PEZ0$G#&/FV1P;E?EQ0'(?5('G@!"@7@N:""J^WU(BL,Q^0@0K=K/$%/"2
M33D)=\1[P*=\N5(MZ@CSYKC]+(=Z8QKSC%E@]959L KP-Y&/*SD!+!SA@( ;
M32H5WV\IJ0S['74O9IF*C8BB\I)T0B(;Q[/])3<B]EU+A<KOM]P<Z'2+J":+
M#SA9&7HD'-YQ#[P@ ] -'@(<$OTCC?!J[[?<%NB.S)&Q+%KWB56/LA^, [#]
MHAL0ZR[Z=SC]!:?!K)#S-=HKOM]R[=^SBF@OLO@E\^9LZ6L>KSVRAWTP^!6N
MX4\.N/1X8O4!XC]S,,^6RQ@^O8PG7^"/LY^-Y^FG+S3B*[[?VQ&OT!UPET6"
MW]&H9S9(\M!1=OZ;\_,WEC42[M_7&6P@>(T"7^._VOLM5^[#$OP#WB_9,HR]
MN?'&\?G*"=&:MWW/XS91P;43+4@#=-K6V(A@IR&C;\R=B,"RS$X!Y>/[HKS3
M'W8G[  @I+>_POHAQ\X!=5A.!%^N>'#E\.N=3JZB_+4B=JN/Y_R-&PMV!?]Q
M0#<$F.5P;XR9XV'@9TIR(A/^ _-/%F$9_/N*>U,'O'OLN0G:@@6P1: >..!\
MD0TE<A9X*'7D-YDE?2\TC2^><0;/N\+W2/,+U]S(PWX- [OF:I: $I&O&9AM
M:_@,T/1=?C 4'Y2EB>Z0">H4,T$UI <,^DG$K\7[R$& _;/Y/.!ST"6(>,]V
M5D /8##&(&- D62CC*8!](6D8D<%6LK2#[@7#.$:NRP@&O)#GM56\!,@(GM!
M!#CE5]SUR0-I&3:< /$!PLIA+BR$-BL/;/B'\S^63%G@U^C*3&-;3K!TO(@'
M'GTO2!D@AK^-T.CU8'\QQ[\#<JY-XV_^-;PR((J41\G^;@;XPP/A\6QU.QG>
M@1X3TGUZY !=IX"+J,DN+$.J.,\OF%*[YJZ+?^(W_#OPK2B.A*<!4/"AS<4I
M[Q/:-8V?N0<D9"-$5SP29@+B_]O[MQ_.W[V_.*-0$*SUBWEI@@P)C0F?QQZ]
M&2 UX:X#8(-?,( 72)?<0M= 'AAGC'$+"#AU=GGF]+SP$MH<+8M/D;1BN;0C
MFP)^@&2<Y8HAH7FTYBQ&XLJ"M; V$6=NGSF((F*!HJX7')7D<N(@2DA%TI)S
MA ]1:''+N%5A8 $F0B065-&2V(1H%>0@D=4R'*11/N73EH&YM3">P<D<J;-#
M6#:<W>3YIU6LBFV!5,'MS %E(,,=Q&YKW>9OE0EPR5>3R A1Z=D\3ZHJ+@Q_
M B-R&OPJ@&L:YUYR.&*0);LQ[(6/#(QFY@IGG<0>0E1HEH##<YZ ()X-<XD+
MWYT"_@3-Q@'('P/$&0^,21P"T$,D G@#G/N*@.79;CP5Z:C4@L6'0;5S8.1<
MHHJ0#+MJ2>)WEK0S_!. [8:P!\[_R&%(,K3B2R:QGQ,G()1=-O$#VA0(Q( +
M8)6A09PL\P8$;G230CVA">#I0)(3 4!Q<[CP8Y?8RD%[PP%JR', ;BD!=G2S
MF[U62ZLE+57( -3Q@#:7$D%>4IH0..$?H>!LFP#HH=8"A $A*EF!@D* 'V/:
MOO*'$O$!)!^[$47#4A;'>!AGI*38M$)^PD8C=P,8C?.(+XVN:?P_T 8@FB4U
M UW"!Z[Z]SLGM%T_)$OO;.+'D?&))D ;%P#?"IW^EK-F?-D*;/9NJ++.S J=
MX98=5VBG^T(;*=OX  +"#\(*'>,6@ O-R*?",G/0\$.58);Y46N:0<F^5V1X
M ]^_3@KEGKV6+^IUDFJVLB?9)/3=..*O90EB.[M$28V<<*) 9X,U7@NU,QAL
M!N4B2*M"Y^ O@FKXXR6;P=%>,?>:W81/?LS[AJ!R"V!=@]9]03*;W1DDQ0+0
MTC )87'*;5_HQ5<&[(T'^#,\ *OGQHU%P&=_??+#[06FPR<_?2-K&(R#M_!*
M- #_\B/[Z9:XQ8,6H#8J*/<6W(:6@?\UWH,-?<5<<E#08!$F"6'CDMM8<Y)M
M9]!0,_@7,-I<Y:Q-97A&N XQ^L/"$59N%#EHT<U*NF*.!^Y4E+K?Z-P%\!$^
M-H&M@F]"DCT4M;[D:D0B+RR_R89;P,%<89 $6&J%7,7%;,L6A0=$; _1A#XD
MD+ Q]X&F/0I+.QZX3+'TGNAC/")L1SCU::%IQLT2/C8=E&(Y<)"7$\X"]-N6
M*260=Y59'X\&7KD?3"GX0<X\GE^ 8BF&<P(MWH!C"P^*$(OX!)W&)1 5A;UL
M@+83D7^A@)P'(6XOLX\PH4BLIUR";X+^"3FJ%,UY":0)AP40 Q919<_@G;[P
M7%P'7AN2 Y[&V,!Y)X,<PT"P,3PB>/+""U<E5S+2E9P,,"\<]D\42Z.H"D(0
MX "K@+!&@'-X'U#3%)^WX7PB1X O5W$#<:QBS(Y "<=7X;',B>DKN2E'T(]+
M<9$%0V^-&S> N!85E(FR,>/MEU_/W[VTQO *8-&E8YO&-S1G*#8I/3<$5.!0
M( 46S+Q.XB.%(D7,#!9%6-0F HH@^0/RW_"7Y7AR,<PH02A_;)/T <=/A =@
MY=4J\+\[<#;T*)]:';.7)%W0_>08A80W@O,4\C2.LDM]_7IL"H-X&.NR19 I
M8G]P#ZDI"<%]X*#" $$7@@AQ@]Q;$*&G.*7H61A1PY?_451^#;/)/BE6,N%P
MV,;'$\Z(+,NN.5QC?F0J<4],S@N:IYQ^J$B..#Q/)-FR:XR(LD"09.%G?7.<
M_(S1YMX!_L7>K!8EZ) I.-7P)N3L>/MO%$BK[-P4A5I[9XMD11J[EDQ+K]M\
M0:!U_[)27"!7FJ2*5/!@)35I+5'<O',QDP@^JI)&*H?-54>T9$J<?E?(HDI1
M2$K5G\U">#'PY>:X,ZV1J[W>(RZ_&R?6-O=^GNBKK(X7W5X35>OC*9':X&]T
M!8["\!/F$NC"!<<?LPTL+2EFC;"E\RPE8A#<(/,"^\0),C*Z%'923*5CYJO?
M'V:*J_!%3_NCMME1'[64BJ08I&F V%G+R*,J!@:[(D$ T'&!2C$V!W1+205J
MU47FB)#J:(_<OCN,RT^X,"8 5C))@Y]*+94-)P,=IQH:X9& (8S!<DC?I/1R
MYM6A#*K'D]^E*:!,/I$< TN*?P>F].8<N".VHU@E8[:AOK4W.FD769S.F!-L
MP^>Y[XDD52)#"*6=(4BI/$J[G3$(\0TH;3Q_KA6,")9,TB&Y7$S&9A<_EF*;
M]*J2SM."\NND5A2IDIR\SR'(D;4#TF3:K,77"2 J$"[JM:?6>)@BFVQE78+P
M\#1V.X'1QT+K;Z4DJYNO:$_)J<1D(+&9T,Z!**H[[JDV*XJL&BXAMJ?F=BL\
MS.77ZIQ'0)O-Z+2,L_3(8:M"Y[DEH2 K13<87&G>%!S*B*L(2WD.PKB=+@I*
M) C02!"K2MU1,+O7?8!F$8XU;!EO\X4&<-(O9!==4)8&T+%P5@"*"AUU^\$.
M1U(5.O*^V-W13&Q4[/[-^KS39BK \ZQ12C4[!RVI;!''R!HU,CNX;+(!'^@V
M&Q7?[ZTWLK<30@<$0DG$[!/X\>3Y=MOZSD;SJ:!K6ENIH-]NNI/Q+2OT1,PL
MC)=PD!L5W)&EV!B2C2,P)D1-9RA@1N%O$,F4HE3RF2J-K;[QG/Z;A>X++58K
MOM\-#-7>F:$&I7)U+1/1T=<A*[[?#90PW%6V]LSV3I30UXKV!*BA;W9NS5"*
MZ%ZGW>LW/DW^I=2%4?==UO2F: (HU2N+0$E/G=!&V.*U&@<O= 54U1)$5(R
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M)*<+T;ED?_!2V0O?T0%@@];(!&N4\G@>BHIK/W"GUR")R<A$!R]4S3X[V9G
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MLP1D/)8(T?,]UZ!*)K*)5M[FS#@D60VO$/"3\$>%?X5A[#0U^L^[C-/<]5W
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M<M7LI+9 W_VIO<QKI<^@/?X]L#WA35XT43Z6UOZ[>)T10.KI-\] 0/J+K"=
M4U\\^Y;25=]+N@H,L*@?+=YNRPTY=?C8TV>+S[[]_O7;S^=*-L@FZB"65;-R
MXGM23)PW+[SYAEI/8<*H-4V"Z>7G&P4WS6I 1HTF5*FM+#<ILO.5DY<'Z455
MJ+"E90%):9*S@#$)S)4TH3,4\)Y\R&J5C[. [QKS:&F9K B;P2%^F&I-B$#6
MIVX$@I_17".77X'8DMZ;["UOI&!U 1!!>Y!P5VZ".2U1V>XTJUL+*[\XI9+!
M;K@>WQ#C*3DH^:J84P1Q$+*75,RB*"Y<&ZM84[6/T-T51JF<H[1H%-*M5<RZ
M:RJA@*&([T(Z;2-&;E^L8FTXLBTE%\&Z##YGQT7A&D\"TW&L4LN6R<1";IRJ
M*W'*X#?A7#&7FTP2^916&:7W)G33XBH/M];J(+ S=N;1L"-<=DQ?CRHU:X\0
M&JQ@P%,4(1NU=>6UD>>%I65A;-WG96>.++/9E%2R;M[SMX\2&-&9&''J<!G8
M/3HJC/H+.?;)&G0+O2E&3[@N@BNQDFSS]59"#_.\AZX@FJ8*9M,5F<238JVX
MHJA9A[6@UW4 -@]F(IEMV<!163M.JFXC/OY@S6Y)5ZXZ8)4@JRWSJ8?%9O8P
M0JZE#)E=GU!C\F\?;#RB7JH(V'"KAE^.UV'PLZ02HXU=F1Q5CWO; #IK%?*Z
M*])2;#<L^4L2X&*QXM)0,Q']\Q;DE\3B=E5$;XSJRA4NOW6Z7+39L XC< "*
M1VQ4QT2(>E76 I*<<<<>Y]U$E;!-L%\-] ]@.N#AH\Q?ZN%U&37^3!;+I+'&
M"NZ1Z)&)VB'Y!#CFC^!.H_0CVXF[3*PV2W?F_0)RDG?;)\3=ZV/G!#%TAT??
MH/\8$]PC%.SD=[S?(I<>&";$TFF3)P9IVT$P:=3T?=GFZQB%+4. X_%Q?H=Q
M=LN@&O:"M,TZ0V?)7(A3&4.GY,;C7<?%2"9GD[K^W7Y/WG$Z\2B1]T@'<@7F
MH#G<NSS8O;= F$8$MK/@IV/+R*F$\>N7=1(]Q7#"0 9/%M\+"F]B,#V4B@EE
M(I],HGRZRML6KWYDJ_C=28N<W."\YR.O'>?TK5T,EU(*Z:>VT-V^'R/K.R4Z
MZK<M/@KBRL[X"^:V, ,=(.M*2*\0  %:P7=SLEJ_8_DYFD68-(0VVIATXQ&I
M2=8U?*KBUC;LI<=WL;R#>&WP0\@UK1NZK0?( AGN% 4P68R"=]A^"$X\^0J0
M/>XLN-=/3S\!H7A-24$'Y.0!72\)Q +\!+F:]/]I%W[;4']+V)+?E>'L B I
M*8>_AVEB&6DW?6$[!].\2Q"R]!A*1B[>XM-OXJ=?\Z<YIR]X7R3QC,]J_ ,3
MAKA5OJ?-L\BO\K)2:PZ+.+066#@:V_D'BD5>TBUCUXV<0WR#W$CM*9<O3"08
ML)$4CAJ1K#!$UI.<X*R%5BU.B+ZQX)<=-G*Z1;%SST"63P&R_.D,9#D#61XA
MD(5E;1;#'B3%#A)M_0T:+2R".PS1/9@R)TTO.&NQOJUC>(<?%G->OCLN.QXB
M9R,@M=4LINYM,-.'1@RK2O5ZBD,"_5&O7'&5$S'Z<X?I14XOFGYLDVPA&6E6
M0A(7+[O]VDIK-G5QR5B-M%#3]<WJ/7L0*(&2YR)EVAO<ESLY)!FII%$BKJH>
MGQ_X<^$SW'J=YJSTP<&$. 8QAZ#1#/D"P2]P><PXM>$AP\F[>C)Y75&\MREK
M;ILU:M @X2\NV23J3YM!XV_8C,NBEMP:@-$N&TVF@9 *R!+R3V7VFTCSK4LC
MJ0>W$S$[E:LBM3 S7!^N%L7NY UO,LY<,W .Y]@W?[FF,**0Z^G7%U<-N5/F
M9:[+KAWV'&=SUKPJ\C4FRYJOY*,Q8U"&0R\YFN!:!1O;M"VEL#7C3'&?AO%(
M'5])#D=3CD??+9K-;EY;K5DR;88\@*H*R?<W!CJB%&P\%71<DLR1IN70G]OQ
M*P%WHC4_5)Q6S65--:?TX\$=EIYP24(0,F4VH:14I7%86N.7\8I$HWCJEBUY
M?/:0BX%T9(HU#L0-:;JH=J1]*V/I@7VX]%GDK17($M @(Q##HU'=&$\NP5LN
M"Q@@A'[-I$)B-(0)*";&Q)'7"A61YI!78>:%^LCWGR7R2R0I'$R*L!L&BUC
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M G>(,:0ZI]X8$K@]QU"L9E2&DH6\CP#Y6,[Y6'JG^XUEMW'L.HAB=:C(C@2
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MN)2CD7(5O+>>JNGR84_FJ%OC-%".1LZDGMG+'195,JE59WXWQ$.>19 [\OR
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MIC>;4#'!4>(,_($1*R7F@;#O03P+[,3WHU[F>7A_&).@U&<L;'MPZ8J^ ?1
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MD9%<"M94B9U<7]Z,KJZKPN"Y9MIE-''I8N/D$C2K.'>H=@(+(+0[>M$9*7\
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M@A_ZG;Z8=:I75:ZP)?3JKI54U.'_/+W]RS',U+?F>(%^_>G_ 5!+ P04
M"  +BE51K%W)^' L  # V@$ %0   &)I:6(M,C R,# Y,S!?8V%L+GAM;.5]
M67-;.9+N>_\*WYK7BS;VI6.Z)UQV58TCJLJ^MFMJ[A,#2\(ZMRE2PT6VY]??
MQ"$E:R$E+@!U[(F.=FFA@ ^9'X!,()'YK__V^7S\[!)F\VXZ^?L/[*_TAV<P
MB=/433[^_8<_/OQ,[ __]H^__.5?_Q<A__GCNU^?O9K&Y3E,%L]>SL O(#W[
MU"W.GOV98/[/9WDV/7_VYW3VS^[2$_*/_H]>3B^^S+J/9XMGG')Z][>SO[ED
M+6>:D1B5(1(L)\XY22RE3!IGG<SZ?W_\FS>!!Q\S40"<R*P"<5DZXB4%+CU7
MPL:^T7$W^>??RC_!S^$9#FXR[[_]^P]GB\7%WYX___3ITU\_A]GXK]/9Q^><
M4O'\ZM,_K#_^^=[G/XG^TPR1/>]_>_W1>;?I@]@L>_Z?O_WZ/I[!N2?=9+[P
MDU@ZF'=_F_<__'4:_:*7^:.XGFW]1/F.7'V,E!\1QHE@?_T\3S_\XR_/GJW$
M,9N.X1WD9^6_?[Q[?:O+T$T_PJ1+$/\:I^?/RT>>OYPB(=[ZCP5PW\#BRP7\
M_8=Y=WXQOO[9V0SRWW\(71=(T2QU@I9N_^7K'S__BB#Z<5R.^P'_BM^OFRB=
M'0H&/B]@DB#=[&7_<6(+DSDD_&(^'7>I$/K] O\M#)]/\VN<">?PQ\0O4X>_
M.DP<>_912VK'#.U:N 7+%9KQ--[ZT+@P>#J[^LNQ#S#N?SI:SLE'[R]&+Z?S
MQ?S%)/WT^:)@F8\D!VZ-"R0%*8F,DI-@DL9_LDK)>*6#N2W0]3![VF<_#SWW
MU^WC'&#N.8P7\ZN?D/(30MEZ"OS+-B K(1\WL#?YE^DTE5;?P^RRBS!_/QVG
MD;>4<4\IR2H&(KGSQ$9$9%T*.4("D*S5$#=#NCW8&YQZ,8O/IK,$,USW?WCV
M"<HJO=X"5OC\+-XCV^T%:/V)Y_/E^7G?)D$RG5_]?=D/*C)B,6VBA972<23'
MLN(=S &;.4,PK^ 2QM.+,M?60_WI<QPORZ[Z(O[7LIM!>CUY.YLBWGD9QDAZ
M#4%S19P/GLBD''':.Y)9%$Z #H[;%K0Y O,NO.+?(J].I<=JQ'L/8_S5QU]@
M C,_1M@OTGDWZ>:+&<KN$M;(1\IIX4 #\5"P*87SP?-,;(( RMO$DV[!L=W@
M[4(G\2W2J8%VJC'G53>_F,[]^)?9='GQ^W2!W\?I9-%-EI#>7,!L97M,Y_-?
M?#=Y,_ESAG)[-?TT&9D8G$2F$VN#)5);39S):'OZQ',,PL7H6G#I4,"[L$M^
MB^PZB0:K\>W%^72VZ/Z[!_4&;5!TBSYV80POYG-8S$?">QH9-[A9*THDS11E
MH"71"25CT%5DWK=@U<.P=N&.^A:Y4U$;1S.D>$XXNC'^:+HB[<5LFKO%&*D[
M/_,S7$%'SDKI$VK0*^-P<V5 7/*<0))!ZT09LO@Q?VR'?G;1M_Z6]%U;MHTM
MYFN+:B3 4*^U)4XX3F0(@@0OT+BB,O+$!:)4I[.*KW'M0A#S+1&DA3ZJD>1G
MW\W^PX^7\!OX^7+6'V#\V2W._IA,PQR=/H\KUNO)Q7(Q?P>X]<5NW/6"P^^6
ML\+M'_V\F__:^8"_67PI^V#9#U]/BB%?[/>?_&R"'YN/T%H7,5-'< /$.9 -
M)2XX1J+C/M'LJ-)-?/>3C7 7XMJOQ"7?#G.'29*:"^5BMHR+98'Z$I?LCR@O
M2-QEA6LT3Q(]!I<M\0(7;^XA<\]XB%XV6AWO@=F%6>X;71*/DWPU#JRM^<G'
MU=%MH>=(^4@11R1<<8$C\XX$*2+107(A4XC9YA84V(#E>(I? CHM\Y%S@47-
M!/'!&#0[32 .F"$9@HV"&IE4HTU_!6!(YZ7'ZOP^FP\0<C4&WYN8SOK(I=($
MU\Q$I$TXCW@&DK6C.>-J*EF34\^'[P,>/<ILNR_6UOE14J^F^Z^#^1E'_')U
M1(&#O#ZCF/\(>3J#U><^^,\P_ZV;3&>X&:-C"C-<AG$,MUOYZ;^6^.O?8'$V
MQ=]<XD?ZRRTT4[.*1F0B?%1(;N>(<[CR0^06I.)9B28KR G'V&(S$4[BP+@D
M0@3<)KW&-<'A0)G@B4HJE4I-S-]'-Y.G78.'RMR[\_Q8E5:;ZK]/)]/;6*[.
MN$VB'C>60,"I8CM']"1MT"0*P2/^#+]NLMYO132D.ZQOA6=UU%N-;6_[HZR>
M[2%Q*CG:^9QIW-B2]20XDPF+GIF@F$?CO 6]OD+XEG9)+C)G4F4"5*%-(:(D
MEN-2H0W/01MC4VHBK2?;)9]V&SF0IW=GWU 94ME01.#K5>5'F  *;F2]HR \
M)8&G@(N+#\0G*PAU,4AMJ/:QB:N[!<^@7(:JW#I.]'4N@G;BY^^P>),1[<B!
MSD$(0R @.Z5RB7B)NQEGE-(01::.WJ;&EGNAO;H=4L#"D01H+/-ZEB4L;ABW
MVD2K>&"$BA0++2FQ8!TZLT)R9;VR')I8DS=15#1?N+?<.Z&)=0Z-LBPI<9 4
M2=I&#59SJ^(IS9>GW2\/U_7=9>U $;=A[8O%8M:%Y:)<2'R8HBU=HC50,./>
MFEYMT*,@6.*:.A)RP#D<K<8Y+"BA/L9LL@3G:7-F[X)T4+M@/<:TU=@=8OWK
M\[O"^Q6_;QC5_G)Z?C&#,_Q,=PFG"'%_L,,3Q;OO/NAJP>_W.KS>/$UT/B0*
MQ,2$AC5CAKADT;".@5)P("QM% >_%=/Q9_M;F]YI AF7J HLDD0]QPD$CCBE
M#<G,@@XZ^2R:F/='XMYSQVQ]HUZ'<O=O$$ZGVXJ735M!KV[U$>';$O^&NMIE
M$#F$D 7@+A(B$%DN8YP'26B@5LCL,A/\Q 0]9!Q#.O%\ KXV5WV]Z_[%&<PV
MC*28)%>CV3B(MWZ&6]XH:X/&K-)H\* 4I4A K,5O@4>>A*":J2;1_D?B;BFV
M%Y>^&Y?.?I[.WOLQO"_!/]VB@_F+]/^6*P_WFH#"HYU(A2 :(EIT@:,?S;PE
M4:,I:;GUG#69[[4&,"1?[I1<OG<M]A2$.,DJ\ IFW67_AF3^?Y9^W.4OY5G2
M_-\A?80;!S4N"VZ-(=%)3:05B3B./HHU+$KG(K>NR67XT<B'M%,-E<#U*5"-
MN1]F?C)?*^QZ,N$\ZWWKJ_/$'NBU '$PY; QSL#/X16L_CM2DG.J@R4FV8#H
MN<;=UU+"*$>W&C)-ILD]5:T!#.F<^"EY_"2$.,E"_+;\ $<U2?VGWD[GBQDL
MNE44\OH2Y>T81[]A5]&<\YRT)0%L)E(RA;Y1N3WG7G*6O#'IY,OS$>/9\YU=
MXTBZ@:[:I^++2<B/,QB5.7FYG*',XI=^EONX6(UOXYR_'DL,BGO!@$2+!)60
M4=)."F)95L"HI+E- 'N;X0SIF>!0F7\BL@SYA'UT)^#N!&?LV.4 3MGO#OP4
MY^PJ>F;!D.0XNFQ>H*6@K"-:.I6I<3K()IMKPW/VVY=<.1EM>/1$4HN6O::1
M!)TLD2;'+'GV1C0YY'G@"ORI$\S48<.#-X)[B7TP!X+&H;L'7I' E43DM+R"
M<I8X%CBNJ\'<>ST]P /! 1]8'\&N4ZKV*?;&'_VXY+][?P:PF->_:][2?,,]
M;Y<!5=K?ULD8G$(*<2T)E>7)86:9A(1.KW(\&\9!AM D)&13"HQ#![$R^Q8C
M]&!,2H&2[+)!'X9:8LLS<L&<\310A3Y\N[&L40QIUSI Q_=R>1PLX7K)7;:>
MIK^"L/CZ7;EE6^/,U#NC'2<.:"!214-<R B6ZH2[JH5&EU3[0QW2-E2#+FUU
M5?-UQP7,%E_*<4@)7"]AJ1=KOW"4L[$Q9H5[+"\"" C&E-RQ2'#I@2;6[+W'
M5E!#.NVMP)-J\J__#/[7<AC\KHCQ3?YCODI:-&)6*RZB+6M>*'%X!1(/:!A)
M85-,WN30Q,A]"-60DH]5X$0]#51\-'([=Q6R\SI18TD0^JD;CT>1YLP4XDEH
M4A*9(L>UBR6B:##&!<]Q$6OS@N1Q<$,Z/*Q D>KZJ,:4Z]Z3%HH[QHD!&]%?
MRR7?(NYN1H9B.RDI>9-H^WTT?JHL8Q4T?I!<Z^6QA RS/AGK^@73->W0-[8\
M@[;$@TKEH0IZR=1Y0K6D@M'D,FURR; =TI#2AU70?"79USTG6V.X8;U*!8+E
M3$1_9,>HP6W)I/*TT8/D6H%M%\YU%\V>>;B&SH#C)5Y-^5<9O-!UN?*%?8C:
M1A])Y)")!*F(Z\$H1RE8)7QJ$FQ_'\KQB146,'_KOQ2_[6IT 2+'N62)[I?;
M*(!X*0))R61OK/< 37B] <N03E2.Y,']G ?'2;Y>5%5YT'T'"#6!&B4T,='H
M$IZLB4^"$C2XJ64N:J^:[' ;L SIE*0R!8Z5?+UCMABGR\GB'A9&%2ZK@D2J
M$8LQBOA8L  D"LEYW2:=PV8X0SH&J4R$"O*O:^ML&%^B):C3.**41\.+94^"
M*DN5-2$'M,AXFT3:6_ ,Z0"D,AMJ:*!>(8C%-/[S;#I&@<Y7#_A'3.D43+&^
M?;'K4DGXGB0E.2>O@L[,MPF!N _E^*/@M:/1-]TG>QT9XQ0*6A =7;GGR XU
MQQ/ZGD$I:SWSNLEQWP8L0[)^CN3!_4/@XR1?\TW?^71R X73R5IE2DH:PXG4
M/A!'E2+)H^.AD]"2-='_72!#LGLJ*_\HF=<S>E+JRMC]^*WOTNO)2W_1+?QX
M%*A3(N'BZ@3MLYU08J6.Q+(D4Y+!1]?DV? 6/$,R>RKSH(8&:MK R_,B6DB[
MQ,Z,@D&(5%ABI ;<C5,B+EA/A R1ZY!D#$V\Y#UQ#LE.JDV?AAJKF&9]X;L)
MI*MD[S= OX+<Q6XQBMYE'Y0FW.622]R6T#]5\AY)3F62GD*3TZ3'H0WI"JDR
M>2KKI>(;M[[:P)<;NR//SB,43FRI$2 3 '$N&>(Y#S9J#Z9-D;7[4/:\8&K[
M%*<R(8X4?+U]Z%;454X\2.$L"3X(M(QT(+ZD XHBT:QD2 Z:)"1[(*[M !O;
MS\_*_XN6+OVXQ/7W-1"ZB+.M_.+%)-W^P8U/CI1SVN8@"91['NFB)UYP3Q(P
MI2( S:Q-9IMC4 _)=3N<4?<,]Y,I\N01A->'+"% %-03P\LA2_! K->91,]%
MI$I3GMM,N/UP#LD[K,>OELJJ?EC^#B)T?14@M#"O$ F58W*&$6T5<IS+3*RR
M&44@K;&4!M;F]. A4$/R("MRI98:ZJ27?;6$,EH_670O7W%:_!%_ <M%%R]F
MTX\S?X[K'Z/4F\A*YL!(I &T)"*NA,:4<JQ,4YKNA =MR2G[>%]#\OJ.5WD+
M 5>,$[S$<4UG7TIT"G<QZ\" @,SED2L:H [0SU3&&N:I2XDUV3UN@AB2TU9O
MNA\LYA9!0-?W]<8P<,@P[DMT:ME_O"X'V%3HP*F!:-N]?]O[Z<EI0_]J*/U(
MD;<( 4(+=X/C*<$)M&=QO4E.X_)#\2O%<:1:FNB$X(PWN1)[#%C]V[^#LMTE
M9K@HF?>$!E>R!3'BRO6EC@H"2TEXVJ0,4!WX0_+EJC+Q7EGYTVN[Q10=<0;)
ME.-=1@5'1Y/AXN.\)$P+GBQC,8?6X7E#\L^:<N90N5>]P.U6E01P=*OJ)1]A
M$@L@#[C!R%)3U:H"J!\3_L.XT%ZSJ(43K>YRMV :DC/6E!BU]-(PDN6@U2W:
MC%Z&8H2EF-'V-()X"Y+D'$2&C&N<=-_*7E8E',@E=+)+J&JTH(A4.J,Q[FVI
M_B5$ID(QU>2^_#%K9VCQ,LW9]OAVOI>NJDV\N\6B1ES;*'D.J%&+*+0UQ!G<
M-B)73J =#Z'-B\J[0(:T20^ +T?IJ8DA9UAFT@AT]A)%9\_CD!S-Q;#D/F7L
MWO@F2\M60Z[*ZQ$9,NM#O%TLN5-9D"1DGM"%958'M)TR;4+_PX)HG\"SV4OO
M#QBDAPB\'H^GDX\?8'9>;BY&U&0O4I:XT ; =3=3XK)0)$2E,E?:6]XD6.@F
MB"&M=M64?:B0VST3O3&T_KVBT#E#J;"-@RJ5L06Q,09"-?ZAT0#4-)GLC^ :
MJ!MR%!EJJJ)1;HDK1%]N/&I,@C$O48.^U Z36AMB-<(R*O*,Q-4IMZFJ\!BR
M(5TBU>)(774T>W1S P^/U/2/7$VPZ#!'#<13@_]D%X7/UDO;+J/M1DA#NF"J
MQHLZ"AA.)KQ5&K\S6'38^VUXU=/BW>[KY#GR'ACJ=<*\YY6%?BM#K9^?_3R>
M?FJ0AO"1;DZ5@O>1 59*2UCB-["GM[/I)0),/W[Y8UXV\U4F_U*$(BZZR]54
M9SJA"^H]*1% N)][]$REDL2@2)E4FDK=Y!!N=X@5LI1%@-07SBVA4"\FZ3>_
M*/%/7][D[7%2HQ2YY3XZDDHY9<E3)#Y*2XQC%A<L S8W<9D/Q#LD#[01_S;D
M/VNNV7K)\OR7?A'X,'T1_VO9S>#A$+V1C-%8#8RX4%+66LWQ*V<)L]XD+EA6
M;<K,[HES:$5F3\*[AJILQ[=5.8O9-"V+%-:YOT;11Z9M$(0Y*]%(YZHX_9($
M<"92F;7B30)O=H.WIW/]?;+K>,6U(]6/RWDW@?G\PZ=I_SJL#UU?_2J-.$^:
M4VV) !Y1"H*CJ5]67) )7<(<K&WS 'P?E(,JBO-4%*NFQG9,N[I+>3UYOPSS
M+G5^MKIM?Y$SNIIH8\]'W@2:-7ABG4 'DVE6TEM*0B.3*4I&<5Z<A' [@-W3
M]_\^>5=;J>WHMS77[L@8R[4N83HIE(4XXNZ>I"$Y"!6XRDKY)KDJ=X<XJ,>&
M3T6U.@ILN;[U[LR\O ,#[*"\ 'L%ES">KE!J;:CW$(EPP1,9LB.!"R L6/")
MZB1]D\#8?8'NF4#S^R1;364VW5)O)0(>^<2XLI"($)8BK/(:P,1$</F-7"9F
MF&T2[ODHLCUS<GZOI#I"7363_E\?NO0%03>-&UU<PZ@-)#.*2ZKTB"RCQUNR
MCQN7+*>I4>JGQ\'MPB7W_1Z45=%9$S:5DY.'SNW6D7?><6[ZH/C(>'F;5H+N
M!'J_VH,PZ!6[KZ?J+<]E'X>ZTY$L_7ZIUD"AU3=#!'43<G_6LDDF)G/0(1D2
MC#%$*F])D+((1G)><BHEWR2V8$^<.U&.?:<[90M=UGM=<4S&A\W%MJ^K-N 7
M9V@:P#MTF'_*&>)B)+52W$9TDTNR4UGR-'EM@? ,C%-I'-=-WL^>=I@5"G9N
M(NAU;,L-T@@)-JJ@"+<)5REO$FZ/.A 0S#EF1&*JR7W,[A"'= ,X8+9OJ![:
M@@/5%HX]%M$0J+,Z1U)":8C4@I$@O",1C$5/4V;+F_AOAU[F/W'!T&^>H\=R
MH#5'?^XF?A)OXU-E1Y>1$RCUZ22-Y25<0#<CL!"-I241P0DYN@'BD")ZOWV.
M'LN!I^ H]Y9;A@XPIUF4DKV46*<X.BB(+'"#_VM5N?L@CA[E_KR#B^4,F3!'
M7^U&/N$1"UD8!HH(2I$+H 3Q(2N" K#@:>0I-(T,V YM3T/G27R<8VGU@(]3
M0V'5_>AWT&?\_##]X#__V2W.R@,\''WQ^<_\#'[T?53D^05,YKU41]1YG35-
M)*'AM J*\>#[! >"1P2?&]4'/1#PMQ#HU(IT397;Y"SQ]7R^+ '.;_*MATTA
M9,:%$"3D<L9)4R(A!B!,,9D$]RSI)J_''H<V)*/C5.RJJZ^*B:8OUKR_BT8K
M[L +')T,1 H<IW<:E:V-=(8IP=O4<MH&Z%L(7:I-FBK*:7V*_ H-[TN_Z).G
MHVV^+)_9)(@4'#7416* ,R)3*<\L1$:V&S3 F70V-HU7.@SVMQ"YU-#\:JWH
M!O?]5_D(^MUZG1JAI/[#?9D&DGTP)9@O$DL5)2G;;&76H5$9JH=A?0NQ2JW(
M54%138RI&^3O[U0VC;\D(1(TXX"U967\N%-+KD@IM)B8C]8U,N?WPSFD\KY/
M8&;5UF3KPYE-A_!:*0G>*^),7]P*YX2GH3PK=BG'DDY+-3F7./0BYJ"YE[M%
MJ;@RRMKY*'"[\(GI$N6//I30?0D%:;2UBD*3?(]?(0SI5JD12S;,F$/D7S$3
MQL4,8M=+!+\>0R_N27IQ7O(7_??*Q;8 SH#NLPDALF!QFH92X59SSIB,: 4W
M*IW^.+@AW?*<B#/5=5;1G=T4@GH=H3JB&5R0D$ART"?S""2H:$BTBO.<LJ>R
MD5?[(*YOX$"D-H=J:JI>LL?-)WS1H%H5+HPFIEA*J$827'+(9^.5@EC"!5NP
MYO##V5,E6#D162KHI1I'?O'=I&R7;R:;'.*2,NCM#!;^\TB;Q*75FE +);%(
M9L0F[XD%)G)@(O$V:=YW!?@M'&W4)E(3Y56CUL^^F_4UQ'[KBXKUB33*%<0?
MDVF8PZPO5_)Z<K'LRY=,T9<9K_;@=R7*=(92PBG2S:_3$UT-=I42LHCSJFS=
MR(:<:=*6!"%2R6QE2/#6$"V"4EQZ)5D34_MD(_P6CE9JDWN8]*E8,N6J-F=_
MB3))*+.T]./QE_?=QTF7N^@GB[(_3"<X\%?=_&**8GZ3W\S^'<9I'9!]'1""
MOX]]=NDE?F:EB.ED?CM;ZBI%T(^0IS.X3@\W2I2[Q)PG$ 1:)B9;8KU"%7EC
MRK$!%:*)#3F0\7\+;]YJSZR!B'XOZK7+5?G3YV*"P8\P@=PM1EXY--7+@SZ:
MH B6$>]*%DW*I>24\]#F3? CN/9\1O<]T+2FIFHNV[="\G ;Z9_"?'T:\_/E
M[]U(T>BHB)9X8SF1@@,)4 +F@DTJA9Q,;'*FOAN\/=_1?2^+7FW%U<U\6;(M
MHAQ6;%]3O5P@.6G1'=0A4"*3<<1);DCT2E.%8]:Q35[4;8CV?1CW77"GCGX:
MKD'WZT".C#()S5I-2KI[W%S+JSP&^"T5,FI&14I-D@[L NZ;>.K6?@$Z4FL-
M^?1J"<4T7 </HO76C]X[H1"!+?E?3;E108\)9""9<R:93IS1)N^H=L2W$ZN>
M.LZS/:N.UUU#8EU5L"R0T-$&F3S:;Q$$D3F5#&BV)&\)&5UNQ46;@G@/HMJ)
M1$^=MZX]B0[54]L];H8NYJUDUXFR'+4BW*12\!8RL9P!H5SY*"$8#:W.+AX%
MMQ.1OK.+C>I*:T^G:^<2YF_]EWX/%FCF1X5&G(PY(4"--IWWGAC)E3;"&QE/
MM"YMQ;@3N4Z5?OZIR76D"AMRK/<;KN7PTE]T"S\N53BH5S1QZ8@5O@3'BT1L
M5HHD3I.2U+-P*HIM@[@3P[ZW*X=&&FQT9[ ZO_@-%F?EI6AY3MS?^HV$ )6%
MTB0!4^A#*" NHDN!D&04+D2A6YT]/8YN)UY]WP?N-?3V%#4VKJLA3//ZZ.SJ
M![=1U2CU<+^+4Y1Y>&1@-0IIO"_,G'V9YAM7+>MS@+[*X;CK"^0>(- =6ZXC
MQT.&<3KQ[?:I]L+>$\<I57.,B$ZGR%>P\-VXH8:N.CBEZ#<.JH9,^V23\ZZ_
M?SU$9+?^OHY$MD.J2J(Y7'C<L6'\!3^ PLY=<0-\GVO3KY.A^TD:?W5#\7?+
M<T@?RN>.X]>Q?5>F7E51U%#258+Z&U18SX /V/SRL,)<CS=:1ZQ[@F\KK[J"
M:BZA^J)YU?5)DQ;+&:ZB-[X^1#!;VZHCEMV@5A?*T1/K@=8:"*;Q5'H'ES!9
M'L:/Z[^M,^S-4&H.\O"M[$X+=0?<:ENY:C]\6=?7.6*1W-I675$\#+6.4$ID
M+,SS=-:'Y97;9=SL7XS'TT\E1\?5C&.'26G7QFN)[:#!G%*.O*4<^8GER-M-
MTG+R]@*-T9>O./UP!C-_ <M%%W$Z?)SY\V/<O#U[J#NA#QE6I3JA5Q!&F8)@
M+-$2LDY+\A1)7+29>,FIRCR+K)M<)=S>'_<?2%'EZB54286&(CN?%E6L'O#.
M1YQ;S6W,Q()W1'I5RFQP2K)C3')K4[J;#_4^-Q[N8DBOHP_2YM4I<T5)-CY6
M[F]3KL9ZQ*3?V$Z=J?TXQ)KKXO'V^I:6ZJYSK>WTJVB3+X=(X.L?UQGT%C!5
MQWFXK7ZWB<IC;F6M7W=PQ*R_UT;EL;?8KONU^;J'"2S*VS0HU8#29#I9?S,2
MX*-S3A.IH"07T)Q8!Y2HS+A.P24+=*?-[K&>CK^ 7K?_SG_ZS2]@UOGQO"\[
M>65DCB!E:J,/Q,=0\D<R3X*DCO"H@LX9/(NBS>WS8]"&L.'7Y\/]N^:J*JH8
MN[#&]>=T]L_KQ BW@=&L=&!H^$0:%%H_+A$G$9U""\8+0ZEJ4_EB!VQ#R(MR
M0O)44E)]]OS<3;KY&:1?IM-T!QBS(GLF#0FI%+LU'DKZ?$&8D5EQEWC@C:)!
M'\4VA(PH)V1/)24U]D;N%N5#013 G[KQ09;X0\W5LE1V!%S'8MO:V3'6ZV.-
M-I=4.PMW:Y='V;R/MMI<8BV/L<I*L8!?N\L2=G<;08FRM-HZ:H,EB98BORID
M8G6()$>G:33 LF]2%>=A6,=O9@GR]AZN7]9?*6!D>%!>*$,@9XD&FX)2(H82
MAU9<<IIY09LD&]X7Z! L[ ;,NK_/-=1?O?0[VQ&^B'%YONS?A]U*<L>EDP94
M)@;*YB^L)]:P2/ [+[)* +E)[=?]H0ZJI$-#JC56XBG(]LNL9.,,'@+C$9U,
M87S)A(Q3()?\B<ID]!N\U:Y)^K#'@ W!,G]:'NVOGXI>W;U1WE\\<6144P-$
MR%2*&ZM 0K"92!]SD(IRX$W2%>X"[BG6:&YY*OERO/&VO! WQ"=TH!QHZ0RX
MU.B^K\T:?;)'_M6I5F.EWD.5S>9</_TWF"S6&.H#)SIP1R0UB@1C*>&.2NY<
M2,HU,05V@S>$T[B3,:N!QI[N9.68 *1=FCV5-]P@Z&A3PL.##@TV-U1',CN
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M4FS\D9<A6<$3[I$2+?P4''$I4.(U#U%*'3EM\J#E(5!'[\,;VGYWHZ),/_!
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M7E3?$&5VU46;TM!WU\3I.>;+>/<"H_%<("V"R+6N72P- TU+I*M[-J?_8;.
M[H/@OB':[*F9-M65UV.\43GZ'7Q=;*P0A9"UB0(:YYDVV3.?%3*GR>?4,8+U
M38IN;H'QV^/2GGIJ<XBU*I'J9:Z*A7P1<C)U[2/FF92%R)]48$'SPH)5GLMH
MI;.M(DX=(7Y#A.I%2PW.8+IGP ZR],X4:UD4E?DI9 8V:9;J#[A(H$N7P@<-
M+S7\&0EHI<\UKMS^O5?60[T(MZZ7C%<N(Y?(E**M7"NC&?D+N=9<S"%Z65)J
MXM9M#_58[]7TI9TV-_D38E[$[^L!^<DXOX;:;F[^]6TY^0+#4=W EZ?GUT=(
M R^TC 44*Q%H!:9)QP!,9$FF')WDSEC=@E0[XGTRMR1ZH\+=&SO-]=B"?O!U
MN0\L6\]OAOH2XWS@'$3@D>P+DVL28;$L\. 93Q!Y]I(F:I,B<EOB/'ZZ-=1;
M@]#5';@+RW)94&/XY;(YN5:8R4K5C/P5D@,*6V-K]<J&YE",3@*:&&O=X'U[
MI-I?2PVB6W=0_G@^(^.!;-;?)XNV-%5DRQ_E@<F%6QV!A5KO41=+\C#!,,ZM
M*3[PZ&.3&]U;H?SVF-6;SAH$P.Z O>QC\FK\X3S.AGD(-<I;KYJ5LD@LQMH!
M(R<'@CP?$;#NXU!;G'AF0N$E1:M#&S]S%[#?'MWZUF"#&-FJ ?FVT'?( 9Y_
M?3>"<:TZ5=-[%K?0!@*CE!8+RR[6?CHN,-K</5,I<8[2)6P3=MT"X_%SK)&^
M6C1)6YT.FY$:;=! !F;1>*:=2<R+R%FV]?2A%L#")G>>NT,\?F*UT5:#C.4U
MR^SR>NSZV[,#(:STB[K;MK:)DAZ8S]PQH:RU0I/QJ ZU2=X+]-OC6)^::Y"M
MO&Y#A_'ID/S=I5,B,>7%A1"?9"W""(9YFRPK.:E@46;OFZ0_/(CL6^32'KII
MD']\<Z?^=\RGN$82@QQ4]-K24FI5;0Y + ]2U91I@T+DG#2V*IO\(+CCIU#?
M&FJ1?GS7X-L<<[O(Q!]X4=!+'9GS) Z=1;WP3XLHV8,F1IV\;;3?;0WUFZ)8
M ^VU2#J^7%@)WTWTBZ#<N@G";= !>62VFH2:&\? HV*UZYHH +*TZ76W)<[C
MIUI#O3WND?; 90B(G#P,+P6)!33SA1?&0>H"!6J"[.,>91\]NQII:PVQ]H[4
M;X#Z\W ,X[1>,C1;9*DNK#&!/%J5.0N)OK3TIY227(YPR%R)>Z >:ZY$7]II
M>(I("^M[_'Q.7BK,:"-_,3D[FXP_S"?I'P-T*@DN:O-9I9B. EDT@,QCD=K[
M9$1IO0=N@/9D%J;>%+QYV^M#.PV3'9;7.CY./L(?M6C,I\FHEJ2H=N#Z<EU%
M9<%++HS^)-P8:9J!]"0;$]&GX%QI&A7=%O WP[6FFFRQ@MVP!U_-9N>U0OW;
M\NMD?/H1IV>+3 TKN5;<:^9L*DQ#*2P43;+QPD5O0E&A>6+7>FC'SZI^M=,@
M]X$6UB7S5W!%J0W6&]DF:21<$%C(3C(3O4Z$S#K=I*+R)D!'SY5>--$P>6'%
M^5Q7&W"-: 8FD3-*1B,3))/:RP@9%&Z8*%AB4 %CFR:Q^\$^>K8=4*LM4ANN
M3@A>#\>3FA*[V)WK9HW3V8!K2^!0,A^,9=K5KGJ0 LM920@.=-%MLAGNA?7-
M<*H'K;3(6;A!\QOL7P31UE'<"Z^TMLA0DU>AE4@$' ,K:"%%7TJQ3<IB;8GS
M^%G54&\-4ABZ2V?@@S8:)&<R\LRT1$6FGXGDQBJ,R?K(V_0&Z@[QZ,G52%L-
M$A8JS/K_>I3T!487OBI)8)C(75TDNX[S[6_<^.0[VM9K!:_;US&O2F?2/S[!
M^!3?D^O[4RE(0@6CB\D@F.:U)J8OR(*6M,&;D+6!P)5N<IG_L,-\]B'7)\R*
M!L[J!8JWY2:RM^/E,%<&-Q!6".6R9#89<JPE1^:Y]<QJ;J)6EFO=)/"_#<AG
MS[]F&FG@R.XU5P8V*0O*&1(+$/B4(HN1P&L0!8SBP$,3GV(OU,^>7X?360,O
M=3_PNJ@0LA$,A"=[(P?.(&;'O/*J0("4?)-4GQX)M[W(KNCS<5%E1"27@N.&
M8:Z7#'DM>X0A,!VB%.C)$N--)MUM&#W.(AB-#C9W]I#ENJ.R[^J@\ORO:52K
ML/_M^_GT'*^_.1G/\8_Y3Z/%"__V_0Q/[Z8]=Z=#;;G^(7W"?%[SJM97H;W[
M7<0W<(8G?PSKS+<8I.(,"V"U5B+-&ZN8+#8['< YV^5\C7#<( U]M4J8?8'V
M2*U/)--I.H_(Z+NU(_ADW(%J.W!C\@@ZZO'LMN+>A.OE8I/KA&Q RH+ST;PO
M%MT/J<^-_)(=;&4$URPYK&HG3?5R6.8HJ8I#< RTKRG%T;% %@A#FWS67 93
MNIRU/EG&7#SZV1!F&W7T2)3:=7WP@?PA.)O<R%9YO;"=!Y:'*+B7C"!(1GY/
M9"&!9LX8 "4$F:@K>]/=+N[WON%P5G_?*ICT+;\>^U8O0+W$,8R&'S_A%#[C
M^7R8:H.G)2X=:'#12.:@;J(E(:LX6=+>ZVQ2N9/*ND&O][SD.%3;EQ0W3ME_
M_6%%/F11_V/Q@\7WZ_C?8_FN_OW;^U=7LOK]]]__$H>34QP/,Z:_I,G9#PM1
MO9B,<RU8G^D?L\EHF&N*T)4)-5DN>%??N UO-CS[/,*'%+_M*WZX'LWM42[?
M<XL#3<9%YC[2K]-4&Y(W,!0FAH@A<^F-M@@>G2_DH!3/38G:#K9]64^.Y+4O
M5?<1:91F7B@R;3W/-2M>L(+:Y&1\(8(U=2:OH.P=6+A>$Q<GK+.WY_/9',8U
M:CO0T1K@2C)21CT.474"J<RXSBD+Z53$)@FK]X%Z$G&H;?1_)P[5E\1[W)"N
MATJHEH?L%Y/HHND@07M7&U>3F&\U0:NM.,A=)VG2$T\O"UD,HO.NU"+!4B4:
M!9ECK*9QU):>BY^@Y$TZ1_<#_]DS[!&TV*;X8!G.:[W/0=8^@HF%A1@7M>W)
M8+,Y,87 N>.HI6MU_W4)X=ES8D=I-D@S7F1;U+SG*7ZJON 7O*[LNBBW5/LH
MTGI79'"2E4)J(8R:A:R1I4QFH1*NA#;1VB[@GCT7>M= C^>S"Z/^]H(T7"Y(
MP^7I<EZ>+D_J, ;:D=V+*;-L:6W2F<!ZK <<W.L2# B^6FMT@ZNTQ4N?+0.:
M2K?!.>O'Z:*#\M<;UM)5(38)7LC .2/G@+R[$ 3M3"DQ$4O)2O 0;),EXAY,
MSY87?<N[P0GH+6B+[MJ7R%Y,9O.+P,+ B%"4EI&96$V6H!WSW!F6E,OT?>Y3
MF^[J7< =%SGZT$"#S-P%MNL;?GEQP#RO&%^>U\[J%WE*%\P>^*31ZD71A,R7
M-12DD,R%FD*LI(8VQ^+;@'SVK&FFD08)M[<8OD1YS>V3L]JZ;2"\L$&!8TJY
M1!A-O:_@ZI4:B3GX+!(VB?UT ??LV=*[!AJDSRZPU2MXZRB\,H#AXF,#GHU.
MV6:6G#(UO!T(L<[, T;)8U+0IB#^]E"?/8,::Z=!"; -B!<[['K Q=0>-C&Q
M+&I)6%\BBXM<=:X"@# JI29FSM9(CY5-/>FF126P>_F_^.';SU4%LY_^P&D:
MTHX\B,8H9V1F1@7-M [(8M*:ME[GDRL6LFX7KMT*ZK'RJ2_MM*CT==\46(]8
M21%-1,-$XJ;V^2(!U10PX6J+R6RAV";AVJV1'BN=>M)-BWI>)Z/%9S"OKX%Q
MV<Z=*R,D>$5K9S7Q$!,+P#E3W@5G)40=FU"H&[QGSYL&6FA1H^ON0=8B=#UP
MTM.@36(8?"0'(&<6ZA_. VB>4<<8#W.^^/99AX/[E/,:_>\=_NWI(#,#2%&S
MB:2O1QE!6Q9BDLPC_20HG66KU/_^CZ-[SO!0*D&U2%E.9&'HR"6#2B(H4'R1
M6"SZ%J+IGN&Q_\4/0.X,M\RAK-[=XDYO5JR49)"&S76;JB%/YN+'?BO#SK)\
M[(L?5T.H_+H.0+Z;3DZG<':1*LR+K08TDPA IG5T+!:4S(CLM-)&6].$_9LA
M/95+'-OH>94R_<B[04;)>F27%P(Z8-OBHD9/G'B,*QM]*[(3/_;0PJ&9 E)K
MDR0I40;%M!6&11"628?)Z:*D;U,X_? ,V7!%XS$)LHWP^[Z&<4**\>O1+3/.
M(1JI 1294[6&:+V@'D3)3!5>>UL"_;7BF&Q(1GGP58_@<_2FEDDSF?9]1^,U
M/>I3G8[W(L2(UBFGF*WET76F+3>2Y<P$8I%9B^0[WL+I]+ICT7S_LNU[OK_$
MM #Q(,B,)JE,?G+!"M*3#+S+M3&D2XO.(*8C ;J^\5@XT$3"#7)6K\SC"S>^
MQLHFXUJD8+'9J:*U<+'&1:1EFJ<:7RB&)2M%4('<+]OH_.0>5,?@2?0F]0:4
M6,%T>8^M ZB67L1:5(_D/O2GO=5*0;V)OH'KL!Z<U8FK3 N6#U$R+8#LX6P]
MRP4(;7)%IB9!J /RX2%GX<!TV$;B36ZO8,'IM%Y+O+YNC*D6<;>9Q5BSJ8V4
MM6J58$9G]")SSF.;4OUKP!S>A.A!3W<NM>PIY 97Z.Y>,D<>LHDR,1GJ?9N4
M"@LAUPQ9#6AD NZ;:/T1+_.W4_E^XFTPT4]R7@@11N]@F%^-7\#GX1Q&2W!D
M#UNAI&)(;&0:R(,%X0HK'FSV)6@1FG3^O!?5,?"@/[$WL U/4CH_.U]T_]AT
MUVH)E <P*HG$D!Q=IJ,AOT8836N7<,J47%QI8A=T1G@47&FBCB8=-.8T5LP_
MP70\')_.EJA,P61K-Y@$=>S:<185]TR"$UX7+8UM<@U_/9QC8$0/@FY]VVT)
M26BBG?*!J>(YTZB0!4Z&,5=)"LU1&]XD$6H-EF-0_+XB;M* 8DIC6V(IVM:<
M&\&"M32VY 3S*A@6?716Z)KOV:93P T0QZ#GG87:X$[:^K2>)39?LC<N!>8C
M$+8"B7D-AJ%4J:A:+[$T*8Y^'ZAC($!O0M]XS:SGPE ?SL_.8/IU4CX,3\?#
M,DPPGI/A4B\\+?+%1L-4NRC<0M6M'E3')_=2!FJ74:Q4?RI<:(Q*N^)M33 ,
MWBJ;>; N%FLD#+8?3QM==/M4>\UMB>. >MY'0BNLB,D%RUUT(A:-5@7O7421
M.2@-//..K-A=5FTX]+(:HJ.&Y+A\P0&UOG9,=R8Y0LV]C3X8'8(+"$8:\K%"
M";&$KNI<,[IM];2XPSY;B&,G-=SZ_5ZDO!G1BA"] I2B)"Q):/#H#7DK7+M<
M1$P^V,$F;#MS>8:?84I^].@K?8 T48;UD ]F,YS/8%D, ,9Y1-\>CA:];NAG
MYV>8%X>!^]%\WW?W.P-ZE<2*7GE1,:)6H1C0I9JN1I-& 9RR]!,U:"&3;3GQ
MX_F,/.C9[ ;'EK/Q(PWG'$:[*/OAA_:BQ2VQKZ@G*U&J7DQ62:=@HS4^E6Q%
M,5[I$@8//WX_AV+-\W^]RO9&$XLD[K"<C*KM*6H;:UO]6F,##\%$:)*=>!^H
M_>-B,ZS90B?C_!*_X&CRN1XDOAHO^KG-9@.'F$0NM6ZOD[6U@69@I6 N672"
MB]H[N4V [%Y<A_>C>F/&W8!9?QKH.TGOI]E\>%:#NS?/!"Z:^_U&_N1)^C0D
MR/7KM^4&^-I5:')V5B]&PNCUD);#.3F?LT%$- IU9*8X8#H)24-1DE5/5&>N
M:C)KIV2N?G$= 9D>6UM]YP>^H.^283HZ6>RWUX6R,M?!&\=H"R=(TDH6:BJT
M2+7I7[ (R7<BT/KG'PL1>I!>@Z.[-6-=)":^FPX3#L@8R[33)^:4#DQS$ QJ
MJ-@87C@9X"J7)M'X>U$= 2'ZEWZ#T[GKGL1+LEZBQ=DOTUI8501O2W"6T=^9
M\-6&6Y:0DFD8D@L0 )H<]C\$[(@(TJL.&ASA+<Z7[P$YB-86"<8PZ:&V1R(Q
MA!P30UK?G-;6*M>$(P\!.R*.]*J#!@=^ETC(GHG#\:+@PH<K/_X]ILGI>/@_
MY*)/84Q._+)^QZ(@PXRLH%JD%V?7'QMD".AJB=:$OE[OE4#<=X5EQUU"JPN$
M)K7%^AW&$?'O$?7;X^GEPD;[&8;313&95^.E2O#7X9?:UGH.X]-A'.&%]?9R
M.%N$9FO/UH%U@)I;9-Y&DEVB/^HA#D/4+O' /=?=FM?L\O8CX-%A)-^@?.8:
MXE_S^-6- .5MD[^2_CI >7(1H'Q@V .=G,I.>";K'YIS8&"@T#I5I$A>^+3:
M(:G9JM=JC$= Y:?.C ;503_"'S_";#A[6Z[[U<UJ"=.?)].+7$/ZQ+OSZ>=)
M-47(XHA12<YB29+I6*MT2"D8M\$$3>+%W*:8[#8HCXB([;33H##HR^7M!H)T
M8QK\,IGDWX>C$4V.5>Y?_FA@53U#"HD9*^N=:6?(PB5/62!RI<!F'9K<2-P9
M\1%1[#!::U(Z]*KMYAKAS'[\>N.KB\N=V5FK55:,.T7"\20PSPU9JM704%*(
M($T+FFT+]%#%EYIQJJEFGDRAIO,XPW^>URN"7^K]8?JUQ=U B2GXK!VS4/M(
MFQKV*R(RJZ(79--*@VVJ_:W'\V@7JYMR8)5P/>BB15V>N["6N:)=@#4MW[0)
MV2-=ONY#?P]S8@_A'Y0=P4$QA@=F:MA/UXZ_$:,C)6IGM;!6B291UP.SXJ$K
MV <EQ38R;T"&':)P"V$4"(+62V3%DOVE-5<5MF#"12\%V79>-BD6NB/>;V(W
M.H0N&YXE;P%[.7>Z &^YF^V,_'%VNX/P8W].[J'<I[% +@> '$7)8!GP>B\'
M;6*^]FXOIA1TSO+8QB!_8JQ\8+=]7J3<1J=]YU&]F\SF<+U?X.(R6+I1C_ZR
MTH/-S@4#S!M,-1S'F4^TA<C"E16\&->QU6?'%SY>4*JQ_B:-A=]WAN=E]BF,
M<[Y."5RDN2^F3!3<",,]LU)GIA46!M%%EB!YLD)!)NR6LOG BX[:V.I=TGUW
M!;X'VW(2=$&WWFS:G@^/8>_TKZ*.NM]#OGUO%@^C3-( SXXS5,X2^7U@(6G#
M1(1HD])"R/24M;_!KGALY6\CUKZ5_N.K5S\*(2ZKM%@'P=)R)K2DO4[5^_R:
M#"91H&CC@I"AFX)O/?9PNWT+@4]ZD5;?&_<%$GE9A\$4@R;1JS.OU74*UC*Q
MM#\E*,B],UZ$+?0FCU-ONTBK@7MX<1I^W4ZD_D*5:EUE$AB9<VT3(VJ39ZQ]
M@4(-[3EPC@-":1-.O0?349MF?>ND0>+S!FB74Z(#N);QK'O1/4[,JC===N/(
M'HHXW.)R>7+ ?0R)4!E;ZITN\"PHY.1JTNX51 S@FF2O/ )+'H@A/0Y)MI%_
MBV,\7-3L^07'.(6:,'.2STC8L_F40'[!RUSIR^I=-J><M6+621(#632T3>;(
MP*=B=4Q*^C;-1K=!>?A(4H\:7CWQ:Z:>!M5XU]];7F*\*A9J0K0A,^ IT8Z,
MCODH'=,FJF*]081&Y14?Q'9,O.E;%0V/1&X8;1=+K5 E"9-8%-6%$CPR'RJV
M)',M5Z4*-+UBLX+GF[!U^]!%P\M;-V%=9*M?YCUT 7B(L]N-"!_WC'8O?7;@
MR/[*.-#"<ANH+EG$2/,0:%(PK>I!BTB%J1"*E6C!F28V[R.QI>/9Z6')LHT.
MVD0X_7(?#&"Y1GJ_S)&L)LF1!:TD2YK^$HEL>[]BDMP;*?./?9[9D\SO!LMV
M$5C?0<XWP]-/M7GQ]-*(08D1-&?6)C)= KEHL<C"$I?2I*11RV[*6WGP4:EO
M'Z%MG'L]EV3=7,?K-I)]:YNU+FIV&^UJL3ERQ*14/)OHM2O2%Q^=E&A*R.BY
MNZ>:6<LR9D5G9[+V3/@0R=.PM.:G*.B/D S-;%KNF[1F;EG&K,];D"]@5CVI
M6CCY"XSJ+;8!Z<U8B(JIXLC:CL(Q**4P[4+4(6M9VIH0;8;U)%:]W7C9\A;L
MGOIO$&KI=73GTUJ__>*3KV'Z#UIPZ#<_8#J?+CXWR!)\<3HQ([1AVM3J[K+6
M\!=2&1L2<M>D4/Y!1_DG]P_ CL.DUC:[[@Y)\5A0LV0CU(P/R:+)F0PG,,$I
MX-X_^8GPO HA/)5IT"<S&MQ^N+K6K++7W-K !"Y\! (3(7 6"C@!!;/(34RY
M)WJW?!_Z["33!J7P^J3Q^OOR@Y"CRCDZ9DMMQ:5-8<18&G *7(EB2Q!-ZQBW
M&]H1\?&)\:!!7DN?(ZP]:6Z:+@-5*U=J'EFH74IU3=(#) />%4/>N"LB^"?O
ML:T.ZD]V]Z_[PQ0AW'UL.!\(RXM!I1AZ%YB6F%G,*K)$,@Z))_"F29/;GL?Q
M)WM[T7"#+FI;'SYSG0*J7!A/B7S VL83,AE+V<8D(@(HU:9LR',L3K,/T9IJ
MYJD4I]ET(HE16*B-#\C\)B?+DG\59>0LHRG L9!8FS3P?>ZI(5MQH&-JR#:Z
M>)1#_BX _TP-V4V?6Y_V[Z*,1V%-X"'SXC1#4[M5&J^8MS1?G,3:#P^E:%/,
M[WFEAK0ERS8ZZ#LU9/6H7 "!P"SJ!6_.-%E>+" O#&.Q7&K"*58,F^>;7["5
MW._++]A&:!L/QWK.+W@YK"5(A_/S*<YN_GN7[(*-S^HEMZ ;TI7, LN3XFB%
MST)I$"7FK$-TGKP&:U&)01?,>\ET[WYT]SRM?[EV[T 7%4@E;"H^2AT42=2B
M]XJK:&(02@WN>6ZO%W=^A!&,$W[XA#A?W 2X;.E4RY*3=5[?_^-7^N+S9 :C
M7Z:3\\\S>L3H/ _'IXO2Y;6=YSGFMV1K+ES4V;5/DE0QH$Q@(,'74VS!P 1D
MW*6DHC="N28AA0..<>\*P3??>O]+7]![B7P77PR"=#JE8%B6M5^;!9*RD\ R
M=U&&[,'X)AWS=@7\Z!<AG@S3[Y0;/@0%&J2+O#NOEZAG6+NZ#1=UN-]C50R!
M?TU_GIV?G9S5Q@87/Y]C'I E8$4,GAE<Q"@$,D K&8;$,\]*EM2$LULC_9.L
MF\C:5ND-O+.UPG@WG7P95F?EY\FTMFOYA4;P=GPISC<X?UL^PA\#QPMXX3@S
M00JF07&:8!F9L$)FY;B5H4DER3TP_\G<>Y;9@Q"A02+&+6F]F<S7#N4:_M^G
MPSFY7[^/!PC%I@"UA$RI%<MIVL6"]2(7#SYQ'KEN<NUM5\!_LK>3D="* @WR
M3+8P;A9=WY:W20<BZE(<P29O,Q%L37Z_(-A<H_.05)!M4HYVQ/LG<7NP;G<F
M0(.LD;4 :2OXJ11,M;'QNI\/L@F*#._$DB>#1Q>)+"CG&&T>/M2B#EPU.4O:
M">V?G-W*5.A5^3WF@RR"I;47TIA^_G4*O]?>W-,AC&:SR2C/)S__]G]>_?SJ
MU]<#89 GP,B\DIK6?UN8]T$Q7K+@PEKA2[>B:QU>]B>WUL:T^U93@RR-]G*\
M.#Y&BSI*99E2Q=9POF,^6\UXM. T5P[PF<8&#YH3\M1I_Y1I]50R4]K+YN)\
M53FIM9-,15M%8Y!\ JV8HM5%<2&DD4W2J0XSO,?*FWF2Q#[XY-N:8&TB?=T!
MOX&SJS22#K!;YO3LB/M)%#U\$E2ZS^-LS(,G1&/AE)&T&C#I5(4?R8+,BK.2
MG,5 F[/RK8+53X>^VU5C/";V;J/^OO.;7N+X#*;_> WC\P)I?CXEP-<@E_D[
MRN: 6BHF VU;&A 8U"-+5$)CD#;*U2)]&]S/+F\[O/]Y$+U-6@K]4$E3[Y&<
MX//=DJ2N?K>7Y)WU2%92=600-JH2I7!)"\PQ.2ZE-YZ[[$2$P3I,N\ID8>OM
M)9GE$WJ5SSI4*U(J+DH#6"2JI+72D2Q20XPNX.IE93O8C&]76<6O[Z:3?)[F
M>Y3TV?BL7N5W/](52:(@2S^G1#8]6?R1@]51@ZK-'X0660\V/G5ONP-.3Z=X
M>A&++\O77+O_)D3A?2ZLQ.#(_=>F%H(M#%S)A1<IHVY2,_XA8/M7F+V0YR";
M+%T"P4(TNN;3T-B"R<P9!33Y?2$!M!C@[07DP)M6?SJ_6RYV![DVR%/:,,@+
MMSH1)*6U9Z"B8-I8PT*PG$%V44GMBRI-&J#?!^I0L<.FVN]-ZH\=I9M-YX/E
M0OMV^@&G7X;IHNEN#7OFY#D3SH9:&U<RLM>029^"-U'HT"F;C9Y_@S;TU2IE
M-@%XK(A7?YJ=]"CA'GV:&WAFY!8N$5WVZ>L":HMPT3;JOXOFL$&@?A1U5^L]
M2?E@%! A9*6T9='4@Q O.8&C_4T*]*GX%$OJ$FIYBJK?$$ YH.:W$6[?@8R?
MS\\6K3J7WG.4G@LA,@O:9Z91) 8\"):,RO2?Y1[@(0]CS7,/9^?U*.E)/V+J
MNW3O*]KKIP6G5UU.DS!<<5M'4<C8E+'"RK*&/7B Y$7,HI/.5I_\[+6VEZCZ
MGFD?O\X@3H?+82X!^2R\X]PRM; WC2DL6HUD>;H877%(_^^DNW5/?_;ZVUMD
M/68F7RP#)Z_?_=?[DR42FYV-.22F7*X][J)CP9(AZ+R+R2I/SMZ#X9B[CWWV
M6MM=2'UWW_WO5V]^?/]?'R^A"$DOC,XS4]NUZ)"15FUE64@6%7J;G.ZV4-Y^
M[K-7V!YBZC$/=0'E]8?E^"Y#*9<LBMK2@!23RL=E(HZH-Z,#@(P6D/-N4VW#
M"YZ]#OL07-\IFA_>O7KS_N2_+WFE=<I%@&8EY=I6*QCRD>M!#="@2N**MN).
M.KS]W&>ONCW$U&,VY$6#BI_>_/3NY-=7EVUXI9(Q><D$6;NTU?+ (HK(:L5N
M"X0L8,>6'K>>^^PUMH>8[FK,[><-O'Y_\NO+2R3&D1?B2F3<HB'[UI)OZJ-F
M+BBMM//@$N^DL%N/??;ZVEU(=]7E]S,@?WWUGR<_7B)Q 6,NQC)$$Y@NB8@3
MG6#.UE,"PI-"-X/DUF.?O;IV%])==87]UL/A9#8\&XY@>I5>(#--:^2LY&H<
M65^[_7%3FSL5+I)R KJI[,ZCG[W:]A/6&G=[OSC)S[^]/GGYT_O72RQH,[=>
M<):AMB97M9A.$H&@:0!4F8O5H\Y-<^W6<Y^]UO80TQJ5[9T+>-O7%QF2 Z-H
ME29_1%M-!)+6+DPC*S!R3$W:G!Y-&&5_L:Y1\LXQE#J^JU3$7W!R.H7/GX8)
M1HO N@?NP$)FD==K0 G)2\D$363:HQ./.:4N%V [G3%L1'%41XS]R+K'(-H"
MU,7A]$U(2X)W =7W.>-&-(<_9^Q)6Y-6HN[YL'$SN*@\.<#1,P^U]D1"QX(F
M \*K'%$G[[3NTD;A*>K_GL/&0ZI_&PGWJ/94Z^1,OPY^^S  B\%*VKT 8F$Z
MQ$3;FJJ=&#VB*C0LN4;'LTLQSS#]Y73RY8?E$ZN>W>475<WNAIJOWWK8G;PG
M\4_VDEV#[+(WD_%OEQ9^31(VY(@QS$C45-HP2(6@D*&HN#$05).B%3<P/&>E
M[BO20W45?8\SLD5Q5B;317H_47$&XWPR&DU^K_=)+@LVKK@&73.2NSZ\IQ3E
MG<:RDK.<A#'&20 =BO8&8L9HHI1DA9>@L>;(=WW-[EOH?\#H?&$ODK/P_YW#
M:%B^#L>G)^GB;==7>GZ]RF]4.GI3M&:>$Z6T#(&%@I9!Y%%D1QXY[Y+1W&EK
MW1K=O@O3]0NOA$ROOE3$\NK3($@AN,/$;*C->;*JT5HLS$$60>8 $D*+):L3
MNL,N9FWYL[K(]:^>OE-KEDT:KTJDS3Y.;I^J78)]CR,:R?CTX^0#C'#V:KS\
MS?]"F Y""06"\ 39U2231.::$\B*3#RXD*+J&&GJ!<XQ,NJ1E-5W1M!)_K_G
MLT5%R>[8WTV'DVE%/AM8KSW/7C++:S^]6FO2*ZL8*C()L\@Y9M6)9_OA.%J"
M'5 ]?><IO8.O"]SO<7X^'<]./G\>#3&?G))T9_.'AG)S>MBHL_5>,RE4;4H+
MB@91 U&R%(?:%0>^$\?Z0G2T;'L4E?6=<+77(*[FSD!E- #2,Y)FS4 JG(4H
M%7,QHLTDX;3:1[,%ZZ[P_,FY_M35H'!A1[NRA.B<=$S:%,FNI#79H[0L.RY!
MVES([GPB9G\;)_#B*"$[8WF-4B2:*[4YB67>1L.,U1)H>?"&=ZF/VZL#>) K
M@(>;6FV5\MB7 [OQ^B,]Y2)VK80&)SF3NN9HT^;#@BN*[&M/W]$YVC8=#;O!
M._1I7V-J;.5P[Z2B!M5_[D=Y>5[5 6/+BE5=0#Y.>:H62MZ*1WMHZ-'8Q)VG
M.25K7E(M.*H<BU$H)J26":SPH)NDE3P>BQZH$O5D2+2%8OJ.QBRAE,GT!<P^
M7<7LEZ<R@1>5/:E41D7K,*1"0X^.96U4T&!=L=TN:MW[FL/7P^A?+9,F,NT]
MU$M6T;06D8+1C3C/$ICTWF()B4$M *%]$,R#RDR4A E,BF6U4N^F".X];SDV
M7?<FT0:[PB(Z=^GEWCR$N\S@%S:A)N,^15K3M-?U,!T+$\$(D<'Z5-KTW;X?
MUQ%1I(4F-D9-'^GT6[8\_9:'/?U>&<O*Z7>MD0-&HE:@2%G!:Q>CUMQ$*8J+
MW4^_Y9XEO*Z2IJY==I&CCH8\)@ ;F>:!D\ON@65::D*)6@IH4K3K+I3#!+:$
M3D9G[QB7-<D>DF8!<ZFE-X.-6>JR>JWN*,^S>V+$;H?6V^B@04;6U9@O8@;&
M.Z<=>(;U#XW",1"T2-.LY=)H02MVD^;;MV$<JJ97SPK?0Y9/)31WL\COK_73
M5>K5?RLID-7E [,F6*9C!!;)V&;9:\7119MMDQCX)D"/E6R_CXY7V[#W(>L&
M%N\Z7$OSK0NREK&TS= >)X+6CPH[\&(/^1^8(;1 9K2.A:Q2-?"10;"294GN
MN@\<),IC8,8#4;&#$V,+L3<@Q.41Q'M,./Q25\;+B@0N%8$@F%.J%L6$2-8-
M)A:44JED:Z-L8F%N G1XH[(OI4T:2+R!/;EH2[C,*?EU"'$X(OE>N>@FJ22-
MX4QB(7#9>^9MEF1B!4G>H(Y.-VF[<"^JH^%$?[(_W.6 BXHS540GX_GPQ4O)
M/](@X#.>SX?IW;1>E3B;]5"SO.,;>JUDOLNH5J(E -I&)7@P)6BN;$0;/'IE
MDR+',)3!EN]J7/7<<:F"]9'Y2'ZLKE>,@^2!UB(HL7B,V30)AK:J>GY19.<3
M3/%M>5$3.<\F]07TCS*<SP9&&INR048..TW6E)&&2[ZC%$:@<\Z+U"U=>^,K
MGF"5\VUT?+M842]R[/LT9[%H3F_,(EC.HOGU+/J\G$4#D8-W44:&5M2<'E58
M#+2DTI:;>(F R&,GA6_SUF/B0#-I-S!JKTKR)Z>D2%$SGVM9+8>%-LVTZ#F*
M5D/,M*^V6-6><*N#70BPEUQ[3'/O5#<!:,?5$0KC4F0:8'3DIP5@MN3 T:>@
M8I- Z+-H=;"/]GN3^F.'3#=6^=86,TC%F?%.D8M/^&,IF4'1WBIA"IC>BI$\
MFU8'6VGVH58'VTCX8'7NNX#ZUEH=;*6H3@7O=Y'RP2@@I7$!'6<Q)D[.>U(L
M6.0U(2%"(/['W,7]>8JJW[;50?^:WT:X_2?XW;984UYKL5[6KBNU<R7AJZL:
MT]G5ZDM<LZ),2DZH9'0W+V&KUSZ56F-;Z6ER$"'WZ#/6L;^&_SN9OCB?S2=G
M.+UH8JHX<JXQ,0E95+H[YD,]Q4?,M2=BQM7ZX+O/_+NO/ZH=?T_I]EQRK#8?
M?5MN85KRO NHOO?[C6@.O]_OJZ9)*QGWO-MO!I>2CS:@91%K*<1<J^HIGYG0
M7)E@;2BKP:!GH_A[=ON#Z'T;T?:^UT_2)UPT)OX%Q^0?8OITV;K'2 <J9N;
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MI![FCY@^C2>CR>G7]XO(_A*>R#D4DPM+WA6F95;,1_(&R/(WH12#Q32)DS^
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M*X&H6$'41ELH479K!KCNZ<]>=WN+K._Y]O/Y&4S)Y%M"X::(9,G44S*3 0F
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MHY,CT69^;8U?!:-CKA'M(AA'04 #+1\<1V:0N^@*:B[[-G5] -P).P^WTNH
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ME!+U5RGWZ3#R$*C#)OLN:LSKPSC=](QX0W9AF5Z,IR.R]%()4K-L=:T=)9.
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MIBC5P[(>FX4^!:F,5:#)A.W7).(;Z MP,!\:R/V(?0&X3F"Y)"^FUL-IK/-
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MF^;FH4!_& +'UW?#@H>*>Q>NJX]R"+(].HT,8N3#D(YK6QQ7M=.N>FEX: U
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MWL<72G39"\EL*+4".@8Z'8FX):,!%8K3FW>H77:(\V5&4PUTN)Z[[V>MK"8
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M],NXAJ%VH\[* 2\\,^NK>^- UWI9R4).152[6< P7_W)$+YMEAQ1_!T2EM[
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M(+N_6$X^@3:>5F&R9."U9REPSZ4I)+\N\> ',)TJ<^E@==^;Q]%&[!UZR^V
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M_C&9(5S4$H_?)E]POJAR6$^FN;H4"RIG:Y)@W-96#1$]B]H7$DB6PO$2>/=
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M"\N\*\5ZIWR&+C&V;R5MJ#T=]I'X<T@;,MH;J5QF6D55:^EIR]2"D]U7LK?
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M*S*ZVE QL. =?<J%UQ:+X*/L,O/B 4RGS]HZ&6&V3M0Y7'$=H@,[H*W'# X
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MGS<IE-N)9Z,RCNQ&[X)"XYW1/#D?T7F74$H.AGL^VH'L /D\O1_Y_8>TEM6
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MC"3G5'#@Q,F,7TI*NDRL-40XQJ7&KR>I/LF@P;M5;X1G9VQM=71*ZF4IC+3
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MGO,T@(JR;<&B^R>Z()-;-,!LG()0BL-+B:*D6A'T."+QZ/HJ;Y*EHA&+]Q+
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M!>*CHR3B8O$G,:E=4?I\+>HYQ)\NIU__MGIB4;E9_Z5HVVQH^_ZM)_0E#]+
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M;&WA)P<O)MW(L<)'M"(G>@2"%DM(^4+X"/WMW."[L-M>_<[5CMP]ZL1_LAB
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M\-"\6 YT.2\OE;QG"G!SUHD\1 :%+C0&1_;S+JB06UTT[?1(7$:'-<8NNRO
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MFXV4C.*4P \QT?:QZ3)0Y0K"]9VB/Q[-YSUS'K-VS^,Q+LB+NAM-BYV:O4P
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M.NQR2\AP$K58BP>*V>PC%BSW8U>2Q(3CLO+$+QNYN?0#K,IGP:H5529;F\F
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MJE5,])&<+"FO&<Y A>W !NDI?!CDC-B18T<>3Y-6,;?$''B6Z@GSN(=U<$T
MODM-^;B8BR%ON)D 9K :!9H@B5+,UCLN'_6E 5HGO##P +Q?I@U9K>"^U6LM
M>JL!J$\GJN'%MF:D$N[:AJ-C-M?#R'F#PQ(AZ4XZF-OU)FVAR$GM%ED/4'8Y
MPI=)G6KPN1WTB084\DJ^"FM28[3.]=*DQA,2VI^7\O:,J0&<.VH%%C8(+;56
MQKT\=Y=-">R!II?]\3(<BH1 D#EOR8'<\,)0KXAX H,B5%YGF>+$DR$W:4V=
M;F]>]9&)UU^4N9;+<8N%@01%5:E;_<F2+EJ<.L0FH53U(%MM-V1!7EIH):M/
MZ:0)\$:\6/\%N& ,,3/35]ZD-"Z/(!,%ENC;?5.:]XKC<AS@2<:W4-R)^D-N
MDBH(.:\UF5IEM%RL!%5FE$RG(TZJ34=#F0>^8*Z0T1JYEZ&*9*J0IX4S8^8/
M02'3[)3B)&<7'"9T=;^A5(3,0N:.,.8 $,$&(U5P&WX)CJPIJ+JT@0'L31P8
MC)D1)32:]OO%[JKO2,%TPCMH.]1DEVHV%;M,XAZ^&  <J"$Q;#24ZJRWQ@!M
MS,8R2%>@?F:O)-S# "9O=8KSLD1JHH3B%#QRW7Y/M!M]HM[+/5EO)(L)0_38
M 3\5=:T]I055RY(\:\L*,VXTH$D#:K26+7IMFZ#Z<&>S&=LCFJ1(Z 0Q(H/I
M"JTM#0D*NXQ7-#6\P=(M4#"GCF=X#($C35IIMQV/F;-3FN4[DVE]-F]"Y3JS
M]GIK)/(2QS>]9*HI3*#6.V+@R_EX5JR8$AH[C,L$?!.8_)_P!P$ #1[IJR0(
M'_FDJ*S:1C)CA%@S9SK G%7!'9>Q)N6T,F1@ZS.J:RUT6JY%<D9-EFQJ*A&/
MT:"\Q/'%&CF0>"E;RE1E/BU6N9"?V#)=EZ".7N]J:'=&5<HU'^N,*2_$*,@,
MAD2.-@DXJ:NR U6$D(:;B]9*@AO6(!]M;4J8"?-4Y@2R/8C+I6$/:4]U)XOL
MFB:&@80[R]6*79DQXT94V,Q,WZEC02EF$UVM)7H&9%R?]QAYS$<>P.3]?E\2
M"<*<(V2C,5\@!,&2O;1Q3[^HMN&:=]&=ST >>=;Q]H<U_\B3N??PQ.?_T?.Y
M@O"_/W0;!'<\I#M/),O^WZGGZT=+X=N?+ 7D9]XYF5DF?\YD9FF%R9E'/>TK
M"(?Y<)YHH6'Q],5@X +7-0\7<;R((-5RL8H6*SB"X"A*U"@,*R)%"BFB[+;$
M[CKU:(YT9"S6CV3?QM'\,S@>-?5HCIW8==Q0\X^ZO5@ MAB-%O$:6JZ52)8F
M$:2&E D<JQ7I$H(5<0J_G>T]S#^:O62%IKO6)^5K\_G%TSB*[,-3T[Y]^MWN
MW^6L5NPN+9.-H^"//0M\X;:N#[MW"FW[#!6M8ILUU#QDEFO((:Q2KA[2,5T_
MI!M%RZ[A9;-D%R^$?V_N77B:]R#QTMTD7L1+#,,@!%VB:)K ;F=IWDTDM[.,
M_F*1_\'Y=^$?_T&9W^/].SWUKD*_BS(X=YY$<7[T(]NR-?OS']G>]JO#FK'M
M]W,-++7>U5%C=Z-T?]^%6*;*WMW@6:1$,F6*Q&L5[':&OZ?1.YBF8RN\\R%X
M5$'*ATO%PPAR^T/P1U'=;>8\LI-4BRW" 7+_4YZ#OZ=I=^-IC+70L<R+X=NI
M;Q^XYQ#[?U?8?SRZ_'G"_OUO'/C_M+"/7-YAZ;=[R='>\)>G,_?.L]QSICF*
MX,C73]RVBZ/&#\N)%B>+:3>.;->W+N[&0!H7PO\+Q?_9GJ?F'TBIX ;88^F.
M/8+KPV!)<V%8\6VZZ]+L =_58RW.#R#%"XK(A?!=J/[@SHX,2C2[_@X6^(XO
M80%7!_XOM+\N\M=%_KK(7Q?YZR)_7>2OB_QUD;\N\M=%_KK(_\\6N?,;'ZW0
MO.C<]-Q++K[U6\<.>(IZ1%?JL'R+*6QL% K'<BTWC'8<7R@$81)+=?+ 8#@Z
ML/=3A1V%_84]!:10T(SY5)!99?W%DSQ#'9@#HL)=VB^^5-A8OW_^$-<]<*#P
MY[43C&F<% H;7= OF: , OTG@;Z?)M/U^ V@?[+NK?L[=JW[,=@@Z-]WW7>.
M]!^\37.D?^FZ;P:A"?KK/4_-P%SW/PCZ?[=<6*"_LP7Z3UFZ5@KZ7P#]L_Q%
MX(+^S>NY@:7-"X5=QZ['$\L8@WX1](^-%8D"_0L+A7W'.D?U]:/ZB94EZT-1
MT32/U]^R=^ \XT$'D%H-/\!9J6\ER:$N4(H6FP>H*)AJ85XH'#GS=CMQ+=L#
M0,@5I%:I'$(O0(X2U/]Z\T]L:]T>Z?U,W-;9QBF?O'/LGNBB*PH%_"8@FV?=
M.::_J%"XYLF%PGV_=N?86?]8*!P']';UIX\ZSREK>SGJ^SM=R[A@+= [VA\E
M^!/:4>M=L&9WAW@.T$>^7_/ 6FY&Y$>+^, <^(1UX-#=C?@OGGC/^WBP9-E6
M;(5@1A]8F1LZ0-VW?01YP W_D!+_PFEW:T?L&K237OV[PLF/N*!P_*=/+NS\
MGT\6=IUT3&'GPUX.[FS<H;?6_GYA[7GJ&=\]8O?;;>/WN>YXYOIE[CK;\RA)
M.6 LXN61>VNW+.PN;!:.*YQ<.+5P>N',PGF%0P6T4"T\I'!I@2DT"IV"4A@6
M_J9@%,:%H! 7TL*C"X\O/*7P],*S"L\OO+CPBL*K"U<6WE1X:^&:PKL+[R]\
MN/")PF<*7RQ\O7!=X3N%'Q9N*/RB<,O&QL;>C:V-DS9.W3ACX^P-: /=P#<N
MWF V6AO2QG#CD1O.1KBQV'CTQA,WGK[QG(T7;[QRX\J-MVR\<^/]&Q_;^.S&
M5S>NW_C^QD\W?KUCYXYC=YR\XP$[SMD![\!W$#N:.Y0=#]_A[)CM6.UXTHY_
MV/'"'5?L>...JW>\?\<G=GQQQW4[?KCCIIV%G<?L/&7G W<>VHGOI'9V=HYV
MVCOCG8_=>=G.RW=>L?--.]^U\R,[/[_SNIT_VOFK77MVG;3KP*Y#NQZRB]O5
MVV7LFNUZ[*YG['KQKM?MNGK7!W=]?M?UNV[8];O=6[OOOQO:?7@WOWNPV]F=
M[G[*[LMWOV;W5;L_M/N+N[^S^Q=[]NPY9<^Y>ZI[N#W#/9,]C]KSC#TOV_/F
M/>_;\]D]W]YST]Z]>T_="^V]:&]GK[8WV?N4O2_:^\:][]W[N;W?V7OSOF/V
MG;$/W<?N&^T+]SUAW^7[7K_O/?L^M^^[^V[9?_S^L_<?WM_9;^[/]S]S_ZOW
MOVO_I_=_9_\MFR=LGKMYT::R.=E\_.8+-]^T^:'-;VS^[)ACCCEX3.T8\1CW
MF+\]YH7'_,LQ'SWF^F-^=>R)QYY_+'7LPXY='/L/Q[[VV/<=^]5C?[:UM77.
MUJ5;HZUDZQ^VKMSZP-8WMVZ^UTGWNN!>_+W,>SWN7B^YU]7W^MR]?GS<_N/.
M/HXX[F^.6QUW^7%O.^[3Q_WH^/W'GW,\=;QV_&./?\GQ[SS^R\??=,)))R G
M=$X(3GC&":\_X6,G?._$O2>><R)SHGGBDTY\U8D?./';)^T\Z<R3J).,DYYX
MTJM/^M!)WSEYS\GGGLR?/#GYZ2?_\\F?.OF&>Y]X[_*]^_?.[OV2>__;O:\[
M9><IYYS"G^*?\LQ3WGK*ET[Y]7T><!_B/M9]GG:?-]WG<_?YY7WO=]]+[VO=
M][+[OOF^7[SOKT\]<"ISJG?JLT^]YM3_.&W7:>>?)IZ6GO;RTSYTVH_N=_+]
M'G(_XWZ7W>^M]_O:_7?<__S[2_=_U/U?=?]/WO^F!YS^@/H#I@]XT0,^\( ?
MG7[*Z9>>/CG]>:>_Y_3OGW'2&1>?X9[QO#/>>\8/#MS[ '' /_#" Q\\<,,#
M[_] [H&+![[R@9]ZX"T'SSW8._B$@V\^^!]G;IZ)GVF?^;PSKSWSAK/..$LX
MZ]%GO>&LKYV]_VS\[/'9+SC[(V?_\IQSSU'/>>HYUYSSO7/O>RY_[NK<-YS[
MC?.VSKODO-EY5YSWA0?M>1#^(.]!+WO09\[?<3YV_OC\EYS_:6@'5(%<Z&70
M9Q^\^\&U!X</ON+!7SYT["'BT/+0&PY=?\$I%[0N>,(%UUSP8_@L> 0_&_X(
M_+LB5O2+KRY^'3D1:2!/0-Z%_!0]'S70EZ!?*&V5V-+C2N\HW5B&RE;YY>6O
M8"=A O94[%KLMY5J):Z\J?+]ZEG51U9?6OTR?C+>Q9^!?[2VNT;6'E=[=^U7
MARN'D\-O/?R3AQQZB/>0US_D>Q>>>Z%UX:LO_/9%!R_2+GKE1===?.#B1U[\
MCQ=?=\D#+]$NN>*2;UUZYJ7FI:^Y]+O$@X@)\4;BQV21C,FKR%]2AZG'4.^C
M=])U^C+Z4\R)3(]Y,?--]B#KL&]@;ZAC]4?5W\?MYIK<L[DO\P_@#?Y*_H9&
MM?&8Q@>;QS;EYHN;WVJ=WXI;[Q)V" WAN<(WVF>WP_8UG4*'[SRW\Q_=<[NS
M[K^*>\2N^!+QOR5$>K3T$?DD^1'RZ^5?**3R3.7KO?-ZB]ZU_>/Z#^M?V?^E
M2JO/4:\;P(/'##XQ/&WH#M\QVCOJCUXSNNFAS$.?_]#O/ Q[V%,>]J6'G_OP
M[.$?^YO3_L;_FW][Q'&/T![QMD?N?J3ZR-<_\C=:1[M"NTGG]9?J-QB4\0+C
MA^:EYO/,[UL76<^QOFM?9#_'_IYSD?-<Y_OC2\:7CW_D4NZ+W1LGW.05DU]Z
M'>^UWJV^ZK\YV!<\,GAG>&+HA1^,3H^RZ+-3:/J4Z76SP[/GSVZ(F_%KYAOS
MA\_?D9P,P-0G%^<MGKRX?GGQ\B7+F]-^^K;LA"S,/IF?GS\M_^Z*7?W3HW8]
MRGC4M8]^X*,?_^CK'T,\YI6/W7BL_MAK'W?FXY[TN._\;?UO7_?XS<=[C__W
M)Q2?\)PG_/R)ZA/?]:0'/.EOG_3M)]>?_(:GW.LI\5.^_-2'//45?[?K[]R_
M^]332D][T=-^=YEYV<>?7GSZY4__S3.,9WS\[Y&_?^'?W_H/]C]\ZIF59[[\
M67N>%3[K2\^^Y-FO>\X)SUD]Y]O/%9Y[]?,./.^RY_W\^8]X_L<N+U_^BA=L
MOF#Q@NM>V'KA.UYTUHN>]:+?O'C\XB^^A'S)FU]Z_Y<^[:6_?)GYLL^]_-*7
MO^D5#WC%TU_QZW]T__$KKZR_\NHKSKGB\E?M>=7R5?_]ZOZK/_)/^#]=^9K3
M7O/TU_SVM>%KKWN=]+H/7EF]\LK7W__USWS#CC<LWO#]-S[LC9_Y9_J?W_&F
M0V]ZY9M/>?/3_Z7P+XM_^<%;'OF6+[VU^=9KWX:_[4UO/_OM+[WJI*LNNWKC
MZOSJ&ZX97W/=.X;O^.P[&^^\]ET/>==5_WK!O[[VW0]\]TO^[=[_]LSW;+[G
M2>^Y];VK]][TONG[?O1^Y_W?OO81UW[] X,/?.&#X@<_]:'FAS[Z8?;#'_@(
M\9'W?O2BC[[[8X<_]LZ/XQ^_YA.53US]2>R35_T[]N]7?:KRJ:L_7?WT.SY3
M^\R[/GOA9]_SN4L^]_[/TY__\!?X+WSBB^TO?O9+O2]]Y<L/^_)U7S&_\KVO
M^E^]\6O+K]WR];_]QNYO7/8?Q__'Y=^\_S>O^,\'_>>;KZM<]V_7T]=_\EOR
MM[[^;>/;/_RO^7_]YCM/^N^M_[[\NV=\]\KOH=][]_?9[W_F!P_]P7=^./WA
M+3]ZRO^<\#\O_?%Y/W[[3R[]R2=O&-SPG1OC&V_]Z3-^=NK/7OOS\L^OO:E[
MTS=_$?SBEE]>=O.I-[_N5_BO/O)K]=??O27]S=[?O/"W#_KMNW[7_-TW;@UN
MO?76KQ>HPHZ-C?7_V]K.W3O7;<^N73MW[]T#TA7XV;?_F/W[]FWNV[MW<VMS
M\YAC0=N[_U[';1U[KW5_S60]?3T+_#]VW]Y]Q_[9[=;W%4[8MW%PYWCGQL'"
MCA,V=IZP<>L'"V< 3+-[8[O=#F@V=NS<M7L/V-+F,8#@JN/!]G?NW $VNWL7
MP#,;CP'W"[M.V'WB Q%BSTFBMO?@[&3T\<]^Y;XSR;>\_][29V\XJZ3'3]B_
M><I][GOJ:6>?<^YY#SJ_C%6J>.TP13-LG>,;LM+KJP!H&:9E.V-W,D\6RS3+
M5T]\TI.?\M2_>]IESWGN\YY_^0M>^*(77_&J5__3:U[[NBM?_]:WO?VJJZ]Y
MQSO?=>T'/OBA#W_DHQ_[^.<^_X4O?NG+7_GJUZ[_UK?_ZSO__=WO??\'-_[T
M9S^_Z1>_O/E7OUZ?:Z.P<^/V=H_G.@&<:P?0P:Z]ZW-M[$C7!"?LVOU 9,^)
MA+A7FYUT$'W\OI/)9[_R+>_??V9)NN'>>OS9S5/.*E]_]HWKHVV?[$\[V!/^
MHI/=<; [S_6UPK$[-X#R=IY0N*3PV]]<<=EYA2LNN_;F)]]XO_K-#[W^15<%
MDQN#0+MNY\\N_/>OGK!ZVQG$37CAQ:\CY><\H_?U<R3Q89];<E]_#O.$BFWU
MQ,OU:>'-+WW<&+[YO&N>^I[3KOKP*Z[/7G7CQ6^^[_F.^J%G;/WXVR]"OO?"
MO;=\Z]V7_.*YO_WGWQ WOH=_^RW]%[ W?),[9?:>L]YU^MN*MWSU=]_[5?T6
MVG[W.;_^1.'&1\R>=\.[RU<^X\NWO.&FQUUQ<;7\+=[K[+^U\/A+/ONX%_WZ
MT"T'?O>%7[SB[:]XXEFWD.]WOO5P^)C7C>K/>L9Q__'B(O^0XUKF\R\\_?6=
M-Y=V[7[AD\6/G7O58YN_.73S*][PZ!-O?K+VK4.G"]?TX9]]N/.Q^:FWW'C-
MZ__E-_^P[[]VJN]U7_'U%WSX/T__R9O\"+X?\YE3WR.<_[&/?_"'7__WQYXF
M_^Z7GWCVLZYXP[W?__DK+[NUX$S*WWS7SW_:?/.SM'>\_O@///:W5>PU+WOT
M3S[_R5N>^>W.;TY6KW_OM?O/N>JIW>=^\&MO/.O*JS_WE@>/O_GWR$'DTWM=
M^_3G__36PH<Z-T-[G_EN^;OUZQ_U@'.O_<RS'GV->4OPT8O_Y\ )MQ;^Z^+?
M_O [9UX)7W7^#QK>-U[[_G?&KSI??O=+G_NP+[]-_<$_7^&]YKM/O.Q;_L+Y
M\7MZ7WW<RV\M//L+V==_\9:;7_;M=[[ZX0_]R.GG/GOPK!OJJU_<\-WW&,]X
M_6/_'^K=.ZC)[MW[C0510% 4:4)40) B(-)+'A\$! 2D1D"(BHATD=X2%>DE
MTA]I$1"0&NE*"QVID1KIA-Y)*$E(/7&?<^9]9_]^<]YWSIPS>_8?*YG<F;FR
M[K6N\OU<ZTYJFXM:^002E.GO[>4K2US]V!ATI!AL]LZ79Q9(7ED2F@D*A='L
M4],A U<A'=]G$%=QOXM5=;;XU:<,#UU+UJD9[MJ7)+<RC.K7OH)UL.BXG-LX
MG]*;R8N(B\YQ1=>F-LVU&8#/WRK\8HX#ADS]8U^-W'&>59C7$H:U&6G)!9S(
M!^,OJ]%J FC=Y2[)$>2?C8X@XFRH&,Z3SBZ$G?5=JL6C(O?N\O.%*T]P>.PT
M3WY\=X/+\> \-& T'^X-+@Y'5_Z&1;A7H"%HR(_L0X6'EN)?=ALU36:X(E&7
MJ)IXAXZ-D@#/Q]\FRH!PI8E'%"[B8U\K!L#QK=9X,R0:Q$$7#8C$*D?ECS<I
MET%>37T(H.W4A/O#=QMH& CA\850J3W$I#:=+;2(A-_Q 46=\\S;1$<MCCL<
M2U>8F,R=HA? K]+:]2EA,92KU3%?P2[9L#>0L./#8]K:Z-/J$M_FJ9PM*@BY
MN8:I,7=(?*GCZ.CX[..]GS>R(1;!]W0N/SKQWV[P?%ID *X\)@EVI =5%"@G
M.SGR)T[_V+[,N6T,$.KE,8U-7K&-,3,%!_-#KFA);J!8J6)*Y<7RG@OU]=K1
MMU]LEU)[MU4)($[J4U)V68@S_GY&6K'(V;'4VEHK+:,\X3Y-XS.VQ2*_ ,I:
M4B%Z8UIW2=U&9D2?U[<=:NK.I]3!-4YL]A1KHC\#.$3RGZF!9QU5W>02UW*J
M89%)-).8085SSPMZN=Y!M=P6D7>;\PN>;J:I>]N'%6_86N"?=%<[U"L>IK@^
M.2:G;+\.2JVW6:(Z?5&<S=>_0#O4>,LZ)]3E3^YJ408K%G>]=YW(%QDLOM0[
MA R;R,I #4YDXM7UW;E,;;]BKA#U$/>AWZE!=-^!PO(]L&2\^AT']M+L#VJH
M9B/I6#^-+LI\#QVTAL(D&)^W133;**G539ACIB=:7&-(?A&!;].N%";9M$/Z
M9?>#%:>'NE.6-_K6)_,^72V]<P:RR+^5%>J\>4Z1&A[7/MZ.R1%H6,FR-0K,
M'XM+!O]=LJOH,G=U]%JD8JZK^Q.SQ#('+T+=9+FMND'"$$81Z>#TI/:FGWEA
MJ B%%SHC$-GVR;U)?=&Y0A%XKO)BQW6QU9%&Q^ :[0:_S>9QU%\UY588NU&9
M/;>*ZPTU#?&.$:^R[AA\>"$G\OXL\J>[%KH@5(_"#AVM"E$9P^)R&KT8@,NT
MPTQWL8_XHH<]F!HW$\UWJ@M7%(]F%+HX4R:X>&6]UC,WEJDH6:.6]-M=!J#&
MG%FN[Q)Y,;0'Q),Q$I__6XT6$UIYBZPR/,29 3A[%#<P91][W3JFOM_KM8K#
MH;%%\"X!&4#+A=Z$M1>3;+^ZR/^\0GXJXQ8)4]T_P0"\?3O( )Q QFLHOAQM
M69T9Z!%-3C(*O:D=9K-8-*JS-8Y0SWD^9<C%V8 RCAH;/K3K4RE7O2NM1W3U
M[IBZ?60O]7SKWB37+$UJJCB*6!: R\]=(<^E5]K&+/I2-!M+QYM,BK:M%IO6
M.G\Y^ :IV*2K>%W>#ASZP<D.%B\I''&MP9^D#CZ)J,BJ#>44RA'S\:)+#XO@
MSR1ZN8H+/Z>6P[_/PA=<VSQOBXWLK=;]XY;!*K'T*X9\DQ*AR(SL&ME(6+7G
MSE$ F.A_6EM+705XB_J7"/VDIFO^1=[>H0:^1^G-?0/J[F#-+;-^"V+%#8QY
M[Y8-&5J0<]0C$&GQ.8@SK)2Z):AT$>[=JH5:(X.U3ULCU4<]J^$9S:?:P0S
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M]'U8#P2? @>]<1WW@2F^;#8I:I_Z<AEC9J?54\337/A;6.5KS:!&HP1[4@"
MLW9\O87_.4\A[?<6?!&$A2C:Y&X_RIOK#%+ZB.$XB1PC\&"<!9Y/2DP?R&^Z
M2$DYOCN9%VXS6I/PPZIBK=P8<>O-D!JYD>".OX<'=K _?N$^ZNSF+@B:Y;O%
M "1\!"TH[@^F/,'40WO5*L-LQZ790^HO2"\ +=R8=2"4GDJ@7HKQ49#H^3(:
M2\4LHBX5BC>:ZO!0G)_]ERN4__W!NAJ>\'6JL%1S-'0KVL:,JY0;5N[?<J5A
MLCYC?X]K9J'<7^!,;HWL(*1DL?A0;S4@<,LO:"B\+- 4J>A@A:GOA'I.?&\&
MV4PA@F)I_A)0%[R]\/Z/S6!/'^1BMF& A^M0DZ'_CXP&39CEC& &-N1>:*/B
M-M;Y\3Y>\;:WS>&QS).TTIOZJ_5'I5F[%0[FZ:*87X^B%R<2DP,F%:V*?KB/
MLP1=5,E9"Z./$TIR9$=>3A_HN_PT^0H6A:WK'53P&O!W^<W7K.9EP.'E[N!5
M):7/H&IY&7B_,]4U<<2],@97*3"1K(?4,S!8)21/-92+U'IG/%3I\B$_M)-R
M>=6=NPD\\3)0PYP@)IBQKR'YKO_.OCS) YE[5S;2^T*Y3S\;TZ]#!NFGCI#9
M6JQVV>J++\/%B4B16#AA"$W+:&E&KB"%Y%#@(>?GUXMJ"I%;5\;I6[*)1UG*
M?&/YMSWBRHM>$<@VS_G&E/_N20/%VT7[6_@^/XWL\)ANU"J1-[QO7?=P(C7+
MUWA<RGA(;;/HTN,\6HKE!JHZ:Q6SZ!M#R%%U !';/%?SFG:[)0^YWE6ZDU*_
M,  M\^13X.$7_@EJ<>D'>@>ZPWHC%J8Z4*K<_TFG_RW&*2;?=2H985%7706"
MSY<[A&K^X.L>2;IS2)6"/!@CA*_6, "N#  GD 4Z0K\9Z?$;661+&M)B +)R
M?S, \XX]V"<>F<7/@C!;*5/E?_/P6B#FX/TNX@8UQ2WQR.][,K59XG.%LUL0
M\;F*YS*V[!.?O$M7@B;L.\Q-W'-='X_[GQI\$S1.WQEW-1T[R''-&O>LSMC+
M->@1<HGP*/=.<LU!I=^L\17,2GZ,>;.,*3<0SS33L9[/Z,0C8W>:+GXV"GWM
M7>,>(P=UAE3!#UH'U;OH\E6X\/1L7_&A#J*7['P*A6MKI$F]&RK:A)^K))0B
MT^[^C+@ ?0S^%90\0Z2^E><YYDE;S-<9G-WVKL<H"U^;N"U;D1G:-1:AI[4V
M^MN'S#8RZN:5(&EHI\!:X/K;N>D0*2GGWZC);YA[.]UYI,%(<KK ?-0M**3V
MEW-:ME1=EK%-DCKRK0V["P-PJ2;\W(]GF3OGZ3_O-8+^ 48C2Z4&F#@N&SZX
M0+M8:_A[P)_\'A#5<9[#[B^MG3;0/?M/D&ZZO)<8!T:#$  >9)-?;ICLV^E%
M2FVLN9;S$V= 8:D<BFM-V70[T, ;3I>Q<X_^^E%:UPM);1,^-$Q+G"A/L9-D
M>G&Y ^_L8J-SY\3-\ ^:4L,M)W\?,P 7RP2!TE(B" KV+>U!!;M)I K2EI99
M@U" -#>*K-2_U3N4GE\H;"F*?!7\L#T.?"!.="4+'O[83F$Z]++^*J@6LR/O
M0+E!Y1BC^A8[^V<T%V;>O5!;7A-[%;[:5_F>W:O-#5$0$LS\(<X 97KT?#0*
MI\:%0SYG -Y/P/HTFRP9 *:VH:=V0:(4R9A3KW-L/SGN=SY?F$F9FBWGCEVG
MHOM51F,4.!J! GS6!;R7"2964YM-\'$T*<J[#75H3#5BEOU?L' @_L):&&P]
MFY3) )SZS "P4?/S6OKIU^>8E4]KGLXB>Z"E1X,.H=:8\K'5@:ZWN4:]K[HP
M3Q:'WF1>6 >UP_^30:CIL!Y5NPE.#T51V2"KP"V"+P, XJ6? NZ#P*#%Z^@S
M#,"P.EZ9SGJ/?AG6J9USG@'(\U_TI'*&4:7V$V) BT++L(,=!F#!C &08]YE
M-?*8A,+Q,0")Y!__:3G*C93IG-PDQUNQ.SGL^!G!RM5C*>?;Z,*7=O,)4OM:
M,6:X+=%@<U?Z'&Q5A?0NJWP506M _:1]P<&IO'H+>M%"5OMK73G \W&9M&L_
M>;<(_NE%=:XS6CS0F?FS6DHFE[4$2-'8X*W&L#HI?8^N\K'(X6>9+R)Q-O2@
M=:0"#];/5I$2DQQ[K$BT!G4>?IL3>WD!UO+A18LSC>B* Q7V2>'T",Q]>I]*
MM:0E'PD^/BP/6GJ"VQ8]=U?&1O=[]:T9O>2&2[W7NO\:NL/W&@8!/8=-3[?!
MZO;"1!M^O717[A0(DG+)$.OGJIE,[C[2%(W*.?5U]P1; '*0%/L>/VE&J")N
M, !W-NABHWA[?]#?/P,Z6#) CL W1?LM+7#D A7^)B]&:@E=QK;  #@C$PBP
M:ME6U(6 37+[FGDU[E"^7ZR,DUM?VR!QX<K"T^\:9' @1)T!:'L,6Q%&<3,
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M,)PG+VF8 >!B(0$9 !W;5A1).9;J.D4(['%!':LN!S\L:@914T;_U6PCFBU
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MN!=NNBUI0#.YV>O\]-9&V=S>H5WZJN.M)TR52^C]CT<=3/_="0DEE%FRRQB
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MZ&=(W#T=]I>&MP\UN4SLODW;WCX3W"A_G#U=JLX]$"B:<:PEO11C_:2E/-+
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MLATN7ON2>KB5A*8+-I"::YJ+Q5!FR\6%/E^:;]Q;>8:ZKWNVTN.WV8B&6MC
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MEI##AT/!!(O68,-*;<!XLM2F!H&',)Y'6(U<"2)N[F?#>BQ3,3$3SLQP>V
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MXET0L6A5VVYOH!3H?[;O"73&FD082:(/=5LEPEM (<1722EHZIZM# 76 D5
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MJE9#%FI(2<<%D =CMD13G6AV8*"B/&_>4>^)X9++#YR'%IK_ZW./2@<:C!N
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M5>TQG+;@D'2Q2E!'.\'YC?W5S<,^6Q?;#:8L9DW,]Z?-&X=\L)K/2L.H@CT
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MY-;TO?FTSSU:"X7OQ50O/=!R^SVV( ^;[L.OAY>ZXNQ&Z#J[GT[D*5_9J\Q
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MB<QEP'FMOG^0]?P2*S_P=>4C695C9FLG3P 5XS+UCBK ,7C(^ZT*8'%,;DM
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M8]SFNJ]KKOMUO5[/YVNY+ORU'[[9Y,-ZS08^'^?8[W@.DFWU8C6S@=R__4R
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MMBN=NV1-@TJI\.!*+JPJZPVX<<7O/(0Z"C51NPQZYG2]'T"I)RAM,:H!DFS
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MH[TD2I_6>6;6H3CG@YI]%?=RA>241935][2_V77O!M=20H3F1X0H&F5!-<K
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M,BN5#1S4-/IE6A#BB-YWZ9.G&-]-+*"\F$?C3%72$IE(7\]9S_=MWQ?\0 P
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M)^9K($F;L;&)Q8MB VMBJ7>1Q;!FV'!7\^7"#'*\'FOQV2;$)I8XOY]L:_E
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M(#,K2*]M>J%:RAZP8' ?([.'%'OM]ZAFI% 5SF\[WV5U*;O\3FU[9B6>C)+
M:[N@BXED9$_RR%"#^H@M@<]F<KDL4M?IR/T;BWXIOGW.'RK.A^@K>%CHAR8M
MQ4!2B&631CE5QF)(T,XL_RERW_,;VJ?C,DV#7P\V/WEC6[\UT7BCCO)K=$30
M[2&&.98  [E0!C<'!UQL.8X.*]2F\!"""*8'OXW]_N<]FO*9-X'O[[>7WGS4
MY_>C?\X*1OO:<]*66%"10,Y(GYDC4;?<U_M<8SD_!R#5\,%%9\ '07O0P_>[
MWX<A8634,R["ZY**@(N/ QV]E/@&=;5HJB*-<K)OF+A(7Z49C8&S'U6J]69%
M[J<)GM'UV3WO=,&H*Z\[<J4:)=4*U\-'W=PU-P'4"5T2@0F+^1A!)9^KWLM5
M^?H*D3?$\EA)=5'5V!N/K;3QW&Q/FNY=L<LZ+$LF?"6)B&S]/>NB+&MB5M2F
M,15O:Y;:7%82.IYF^IQNL/;A\.7'B(!K#C U$DY@:_$0K88\Q$>#"1YB:^XW
MJO?Y6P-*AVT+<;.'O26G-PJ_<,BY&%S^_ '$"O ]R]P5@Z/A-@Z!7C^<[Z@>
M_VCK>ID@_>#R\>>WF8^EYF9 #T(O"8K5@LZJH<$6%*,7501P17&<YPX ,V6(
MK7Z AR"J\Q#OL$LR0_W66MPU[?#%".2LS^"GKHMA'^$(,JS>J6WX[F=5@0OE
M['P) I@J4O\$9>V3G!NM'W:]DPC<<^$QXL!IA%A)-JA8FP+ENN=/#6YI5\/E
MG/; >4W+)[I?>\RY\_'D-<H:*\$_3B\#DI9GP=-.AU7R?AP%4C=B77'B(?2<
M5QC,+)*>DPJ%P7YN&*:^ZNW9.YJIBR'%0YL^T.@ZM5(&-;D'@^AGA0\JO U:
M^!3J)\-.H:&IA>@K/,2RTM#2B2H>8D0#J+^,;^$AYLU(LPDW>8A&%^C3)]+$
M)]@ )*!CW))[P!=3-&<C>CS 8NS)RV?N.^.Y.==JE463MMX]H)WV-+Q6KE._
M7FX] Q?F^;R0X7RKN&7'5FS0F\FDS?W99:\WOUK#[O[OSBKK9=G3;_A=;6.M
MND89-F[BYB&*Q35EUI?N.A^Z?.'8J)_8!/'GU_;'.5ZY@IT;!T 87[=!?1](
MWW81(7[4W!'4J;;Y%A%,E'%K\3=55<\O"N)=;W*\&S/2LUXAD!?-NQ_R$+]*
MAX>(?,^%.<VW#&!LQQP/<;N5^^@10'D$#U:-$\YVW\5#/$T!0!G@T_QWE195
MD@>RMVMV7,<$B Y\_J#.D-0KX;CG-&)<>;ZBKE1:)*JL)#R>5>$^I_VFYZO<
M?O3%L^JEG%R=@-X(4;/SLHK_@UKK_K<<78N>;I \.#9"MSW)1+V;Z?.:>R>1
M$G2@WL]5+3*WQ!-M9J1T+$G06E+[P2'_4?W(;:-6X?AWQ *K^&VMT%;\%V*Q
M%=G3RKZS:BNU.17'!Y[&(8U>]/M?HY]T?.MWU,8DIF]_6= M!%*H+H&U4W35
M7%,CL6>"!H<O:[OI&/8NSM5B!CK.MUI.5IW,DNH*T515MX^4VY;TVQ9YLJY[
MQ);=ARV$0H2\^KB)/,1E6?UA_AC=B\QP6A1Y-^<:4[II\8P)#1!ISMSY>(?D
MIA?5N24510*7XD_K,55#3N]#L/J4^)KQF_ 4.47&S+MXQV$"79")GZ,%3.6_
M,GCMEE(24^KJX16*+12;NZQC(?E4IYQRS &VN(V=W!<3X!EBH>PBO5R!N'9$
MQ4.CDW'?T2%X-_9JN_#,HV)#A."XP%RQ9W_1:'Z1R]/U>A*,KHAADK#KX$9&
M3:ILTJ/G/?7.F=9U^^X>V[+FCB;+X@Q_6_[*9KU^J(4(:\E.6$O>H^>5:2IE
MW%3T:#5H M7?!;Z=6[6L I.V=8H-=5944K2DG&&4'X$]N["4R>HG_GZ"3RQ7
M!7RRLMS=@&;QP=2[50W[:*%:QE)E8\H++6F6)]YHKSQ?:*/&5-MM>IF&>=E@
M#+[_VN]'_K0:]7L!*P?R*"NK '3=9@B -7<U,'X-N#0Z-"\,7R (2UNXI1._
M'\233BC]RD.L'/)SSN(S_&#1H-W4_.@:%&B?A5'^7K.KI)IH8G'TS(M7T<WE
M1;7<V0L7)H@GT<5S:DM<- <6X<._OZLL^M\>K<3VI/Q^%I#!17\>@L8?5B,&
M:IT!(Y@2#:4I>C$OCDVX:3^9K]Q1=BJTG.!U G56!7;2SD _@67%S='5SP%M
M68%@ 3)&+0B]P>?[!]R+@;J[SV];2!IK*"6N/D>X6_:70Y"K_ \)ZOV[0.PP
M39@^ON'%Z<[AP_B='"\FN30\HTG[Z+W/!'F*^H3'?@.IXGLGKI[XS=)C]Z%W
M"M> (@H]DZV-[]!^^8)*N96FE>3I;!3CU#$O;&M<WC[S-"9::'?8N,:-VV-X
MW[7'G-:$'<U@8U9\X(K;(RY%L?::\A!'.V#O(,!#)$QA/<MYB#02^"V#7H:>
M@P,-63&Q(.H(#E11F]X^C!9UTQ/MA/;9VS5GV%>7EOL]!VW-JDK:7UCV->]A
M]!<[\F^C*TJ.$_[N3:)ZRK6X?# "O).'C-J(?[Q]U+ :RE^-1@@OGHE&;^1@
MG'*^I92\(9[NF%]JN$O9.J)<_R5,X+O MI!C8OE&K#38J: S>8A0]!QRVBX5
M"GT-X_1F'D+>I-ZJ3+$A )A!C['VUK-II-/9<_SUZ-G]DSS$ E<"BE297WZ3
M&]- 4Z5?&?/,Z^=\SCDHQ!^.Z3&_K492/@F5'C,0M>0W_I^T(MD-=9%FO=)V
M\Q#YHK#1MG9O_T..*(_$*EGQ $P,%P;R.W="T'I_Z4!^ @V+!BL<^R#P(9"1
MS(W:]GL-S[PE+*<-Z)@A6$SZ*V(B<;<L+!&Q+U$B)%A04= [/V!YY]2<WN_S
MW5$CD>MX8)(B]54R];WK,244:K?'M=LCFDN"P_9:+&,&H8&R!G2'UOLQ*'9M
MG)OJ_@EZBO[W:&(/YN^Z2Q!T=]4%VKYO5KQ;\..<2^R.:Y1/6TD.,_'?"AY.
M9F\NGTV=IEVZ(='47"DS<NBS"G7F-DF<Y(G9S/$# Y_Z4R#83E]BW4F,>##I
ML^R1FNVN[=_Z*IIE8YOWNR(>;#?-LMF]8[#N:/;;L*/\W6ADT';&'?9P8]0P
M99U1YM2@D*EXG[",Z75-E<!L!8-93.IV0-?38GM/P2%^A3GL(7Q+UT$;'$>L
MGA7RICV'5A:FQ@=:7XH4J-N!+)I'7%T;@)Q.9J!I4=.F; $70&"Z^!RS.RYH
M__.!TQ6&Q-<[GUN5F=LU^WA>3!L1DMJ=W&P5M%I$8<.POUK]8=)PNIP MPC:
M#G64 8S3*DN>03?3)Z5\7%685L>1CJQ#+(UXQ<=![P:NBCH.ANC@^FZH -$H
MAB6F=XY*BJ%#[<]=Y*2ZJXS=G93'=ZLU7#GTXH*_ZN9X>XR%EY&Y"=N%S!\"
M##]'%_(0#; WZK^IG58.Y('7;!+%QEEDNJ/+R#UVLTRB;JS.%HS;=\ +&0I(
M[:W9&W2 6T"Z,B-D"\:1 >&]^9X+:H(8?%*4?9O:CMF)V,//E\1=&-9\%[:,
MSEI8E ^M]>=GQ7+S (_\-5 ;2;IFG4.0%L.Y+E?M# ]QR^IXUX)MX!-]RTZ<
MXZ9FW1BO3P4&,FX'(W7*E.2WW_F"S)UJ0;M@;I/X@,O(4)LR B?8Z6+FMX,?
M=AQ+M[8QS,VR-WT;=^(B0M#I49SWG>F6B T&%"'_?%9H#?=9D!E532Q(]4TA
MZ.?XPL:$BA,COS9<E(KOSTJ-3MN\W;]NR[LML1L/[:HY7,,HXXBBR-C2=<_8
M1D%^*^W2A_R_4^JU"O49J4?+P"?/^B8K1%>]9[O&&C]Z675W#4ZS[OX144_,
M'KX!V 0?H%9!VR *4% 33\7$5*BQ]+*SOB?WM?M?WV(8)];1>&)ZZ9O9/FL@
MXDF4&=;(2H(AWP2(UVP'=\(>ZC:,J)G@S1S5^82]H==H*J9F*9NR+'':'?=7
MQ5PL>]5+,;-_@7!@4#BW P N8 !SP%BN7OXGU 8>XGT3#)K=\]AER?SV[_^_
MV7;Y_UCSY.YI"4^:,7ZC6\OS[Y9,6!*"C44/DK8TH5V]KMD[T\W<:6]7VGJ)
M'(&RW15V?-!*/WI,ON5T9 'ZGT#D%_X)\E\-^@905/&5U*2V/O=Q5N(3-Y3J
M@,^J@:]66_\8&?^\9*7W]Q<]Z2&'AF+$\0>P40%+1.OBRU*JL,Y?$I0S<:[&
M^W1/1C7,P)+?OB+Y(2@F@$/YFP=ZA?6WK4])CMZC:_7*):G=S<;.G)R)-=YT
MH%^A7[?3\/LS3O%G;;K< _P?<;N2^JZIX> J 7YZP06B/8UD#/VTGM;[BSH]
MW?!7Z9+2E?()Y.9(N>VDC<?0GLD* 3.:)_]E_]F:'\G"'\!%!0B&6Q>?TU;-
M([M?.B%W<J3:,SBN$=8?:1AWWCE"FG\H:?YI/"0TR26B''/'0=GV@\685,>@
M8_JP2.6;_-:4_TREQ2!06)T?.\HE5AU@2>7F7$U5["&L4D!J+J?\Q:[R8J:;
MO?R06U?^)MS@#MN[)UB:K_]",W^M(X?)GSL6OANL7=VQP+=O4W?_:2!U%$7\
MRZ[X_QJ31_VJ1/GMR%_=\E\6 TM4J:_@!!'&B5;@VR42YH\\ZW]@^?6OL>SH
M?PM)>(@B9WAR@D"/#Y*[_FTLG8>X0EE2PV]9J=I'+8LA\+$K#4"BF#JPG**!
M:7[8#:4[D-2GYNMI?K"D-L%2V3@#BZH:[_R7,+YVYE>_P*G]U=C_I]5$_<IW
M5YI="I4R%4C\FE?:?%7\TV$6,F+]L5G0D5A<=CBOB/6JA&D'%"W&P"_;HB1Q
M\^74UFW;$L8S]8^BUOT^P"92*4!O9I[MMV)FUF)Z_:CV79G ,.QQD9FWJQR]
M:8?FISP/!/8WWPC[O'WLP\[ZD_&%QY]9:B;$*,1G3BN#&=!Z"3;*'[]<#ZMD
M<=.[_#L!$^$<D^SO$.H-,XGXO'GM8&J6G<$K:[*G:F=.2*CN]A'O2+L(!.%)
M#&(9-QS5H!8OI\&(S,@*\@;7!PGGN"[F;["QR(S9WIE1<\OP3E&]QHG'ZNJ[
MFBPNG!F]$(8WY*;I'F/[X_N&BI[,T%.?0_U,CEY@[X)QT)'A>'2=N,ADWSG+
M>R9;Z@-5ZS0*Q?>+7U%4SI-$4N4RV,KX]B'4.!/9.!,*R.9=QV[UCQMNN''-
M%B36'S1L4[VADWK8RS'RQ#&GR+%3MK+F8VL+",G7_-6F'[$%@O9PWZ(O5\[T
M ;3,QES N O:U0*\!L/Z:U-N:U^)>OGIW@=)HS?QNH]8 AT?NZ7[]-\67:L(
MT8OF$J$#4#M0FL\1F:@=DL!O!9-_8Z#N5&$V]M-MV(9:2:S7PJ.E<W;Z'A,;
MV_;H77:9<)E;9\RGV**G"X:S8#(6%D09AED5I,K-Q])($27 UAX7A]V,4A)5
M2%;O4MFICXI%B3WKK.QD##XN'D:,5,/?"("Z;+Q@%5DSTHIV01&D(J.H=/5Z
MR^2D@,CLBY=*;VRQM;8[4G5-?XV;&%^6<O2(G<3']-NW)(%U54),(6B]&-.O
MGH<HY6\"-MI]0V_05?57@S:"J[D'*:\H/,2>A?Z%SWR.XV%[;X1)'UIZB8##
M\K"X('MP<7@F;FBMWF:.*/<9#73E)V@^N=3OP!1=7AOY-,'(TU6&66!"5D;H
M1&T@ HE7U_H-%7;78_N,ZBOHW;?QROC!UB [!K<KC<72#LX/U:@^J+0WJ$'/
M_VVA0OGZO%0DJHIB(=;%\>0^0CL3^HS.M':/Y-<?42$?\ <^)Y\L[BPSEI&[
M0?;;[]6W--OA='^$7_)#_H-B3"1*F'09#:I@ZF<BB(4/WGR9QT7K"7?FZ>WT
M5SM5?J6@Q-;%?CJ_*O%$Q*#%;*VDY!J$5NDPLB*;1HC0D^<6\!!>I!B2N"9!
M"-^5C%ZO@8KB(3:K52D^\W?49[R('_M$<!'1*L-=S_FD,+A?<CO>BN\EIE>\
M1IE!7HS>6Z7H1-,1++%52K0=.*#2X!YWW<LB;9_?ML.2"@CW870OP')E.'-$
MW<EH<9(KZK:>#A,5I?FHRO>5OWW5D6%9B^N.3D[.)3LD<E?/5+W=_MG!IQZ!
M6!WRE.\; =PU1!=A6K%B0,5\"C,]6&^Q04^(R7I--1D C,LVV[H#COMI+ V4
M<M3<OAN<\N-'$724/?XGKPN'I8)J(T=.8B)J=,%U3NUJ\\1;I"V^J/5@(+;M
M>H^G?,<T57E2(69UCNFA0;\*Y.,WCDD[^W^@>@>\L"/)$9:?+8Q/ER"3?I0C
M?OQ0XIN_$MO$EHB'@5#+B8<(:>*X_'RU^H\1=09VRQ[.9=+&A3F](I?W&K:Y
MWTL;MN@F40(X8W])P(0&MZYL\8$=9_XWTOQ^;&;G4N@_9(8KS9ZAO^2Q?VCH
M;#]8S9"G-?2-33=3K];^&-T>,<]WV)$RE$5D/-/; Y/#US#N?@&8'VE06W,R
MIR8*6D/ZM%$O=AI-/1YD#=\"YCZ*L(L>N0_4W0)AGWL\$\+ 7*Q)"?X\:6(>
MS=@)7?">M[K(0ZP7H5&XZXE+1_AY")D,2%213%P60\\&(*'#1JPD>QX"#7.2
M4+4Y/D)Z)1(\0Q2'F1',L+ZAP3'4+X-!%Q?.+'&1'$'@H4RP6,^OC^8A(@29
MSE $AI,&,_L[9MP7R0#E&XSOG'<CW_+J?WXT1PD3!VL',#J/XO@0Z'LJ(0!^
M::NQX_PH@QM_>/ ?9NWJ-#2WC )A"K /??37=("/WNHV75^G84_QSZ:6;0>C
MC$L-XY]^.+O#['9X.,&FZR>-<2_0Z/PB+?:' \EFAOXYD7[)O_4_Q:EN0A]9
M-2KW6'A&<X];:4&=!_&2[IJ[NMW?7?BZ7'(J=3#B+]J.L'+=F.NXM)WE:PB.
M-G]ZO-+_0=HL-H>CKQ39#X$B;'UK-^A@JYYT7[__A%5-N\.B=5DW[CKSIJB6
MY3A6U_9DMDIPFI;%WAQ]SVVO5T6UG3O#+\LP8N%!=?8A_V-50@PCZ@(AJOC#
M7AL:3>5HR\Y/GQ '6O9$/'_T'H&[<>4=GZX5 21"@IKL+?Y$^XX%"Q#(<;4,
M&&NV<T]#,7B(N!(A8?4S"37,Q"[!I'W(JZ%&)<'R!HB;Q 9TSPS+'<QD*%-8
MSDQB7:6QKE#F$NH2@QXQ0+Y_9DGA(:.KS9"SQ7BIYI+QX5U5M'I(<*5?%0_1
M]N-I]1MP?Y;1SJI8!A$\;\-<__&8C/2TW!.DV/P3T56C,(GPFS9GHZ%.J9</
M:&IQVNM>]97&X/9(G<Y/!V/G,&]+8X^__$T8I[QN@P7F$_+T?J-I*GLS#&^%
M3Z 7^4&R#"';*9N/:SHY^EENZD/?)=P$=&P"H_R$'IPU._E:67 KHCO'[*@,
M/I2!I&I%0.KN\//$(ZAH>3*DU$[/\6W!TN?*^BZ$K(W1?7FW(?7X'3/1QSZF
M-Y/):N NO^E[3"Q-_#438\:X4Y ^%3#GW*#E(,HT^)%44?##2[[L@=F'#\T7
MU+<8*SSNKFD]*I-9BPL=$H3#>%Q4*; >6@_NH-0O"\=<":O[M+^Y;#!AX,--
M&6:RS_GARTP'\D]KD=G1O^:OS_!_RX49H23PRU(DZ92>(O#A(!/)#?D!Z[1)
M]WCPWP( "3H<_*U="^YF[[9%1^1567@"(V>[SI*I@;9"V1\2NVS?IB>Z6G;*
MU*WQFDZ[:#\M9N5] ?F4(\Y]CA>!6J'U'4$XAGH#,N_82_L/3KXX[XO>%S6L
M8J0^C!K+=K@P2WLWC>;M>S>'W8;_2EI%<L6%U&B F>SC03N^!&F-H-8'G>D,
M4M0CO72SN6?MUN<Y%C&68\FL55$Q4-CRQD(G>O>XL^1QVTF@5X=5WD9R5=4G
MIPEVUXB[RZUE=H?.J.9RG*BRWNF)MN:Z3L-)A]-W*L;^9JD\LE7HL:?R>;YF
MW4 VCH>H/:XG"<I;@?$C1' G-Y*8X6+CT;V<.TV4TZC;5A8C5#ELDW@URQ]&
MJ]6FUY>CZ,S\;UC&Z;5<4I Q8V=.'DJ?8$&HQ=#V)(79DB/7L;&]34BAID-Z
MF%6LN<7L9-A:\]Q3RAJJD=29:=1PY=*.SAH-_QII4VMZ_V)2GUBJ:@MG1.;V
M6D)XO=+=@.XB?#NZ<"8*<,'UXLYSDS2XSM#F:L5S[9Y[MI47%8D$WQD4?.;[
MV^W"\-F&39>9C^=N;]K(3R70==AXL)TL)9P?1QI.3>I#1I68-'N_\@_%JT]V
M7ZEK,[1?1#F;^-Z\L5UU+$S(44;$(8IMQ#'E9D H@XQ>_&>@Z!QZ4]Z"^%OH
M2\HBF;5L4'K_E7S/Y[:,XA?-;]:'RU]4B%V*8B45<[-)PRER@G"0ZUHMSZI@
M\C=@U[DL5\<3XX.VCI@>^/+(X^6#"W-[QL,T7"X;.O6%.-XUOO#"=GHH5@IH
M\+1ZIYWVA'&O(>!& NWP!3[CCI+ =16E8:;UJ@HG/]IY?MTGZ0.K&_".TG^-
MYE7$UJ]E[X8Z446I'!UF9':Z219XB5;?8.96<:,(MYG[_?FKZ$L/$(X%H53!
MG3ZA-7?R(_3D)E=\LRA0B]$51WL]\6EJU-O.)$24F"!OX7<QWHNG>-U7'1$9
MLJV.(01\8B:P64G'2CKW?S;_48%8LH6DVUGA8/4(4JP?WP@4[G'099#"2EX7
MQV,:^IKB+[9)F).BY(*K8W4QXVL4D)K19\_?&&6CIG/9)J *JQ#4<F0&UEI*
MI/@GT=R/V!IVW%7M2@X6FD[KNJ!]H&P\)Y/O4#[,.76(?0 D.)ZVGYNFP+VK
M:\V4-JAF)CW+\><GRPE7%>^SJ[U![1)JUWWE:2\=>3=2YO'JK*UPK+C&.(JV
MQ=]\Y#YIT[:2.S\P=P**')HR3<=M7CX;JV>51"QKJSPX4Q^&T%BUZ!P)C#JV
M\Q!3RVK<#5:3"_@+H#-D> 0-D>" [@L93_S;NB9%F\"Y!?O"O!9.B[ZY&WIV
M$Q&JU)K3%,:KH^-#S S$MOU9H!O,1^4AEA ]L"MZC%U&9/N:PQ1_=A5,</,/
MD>9764ZQM-&UA/1_89]S]IG_F_[YM_2/WFEN)0SM0WT9YQE -,> 4<1*[\#J
M=_H.2%T<MN4A^(Z]YB8:=.QI9+NVCCR2-SRF(W\S+L)[-G+/$0S+GGM?@A7<
M%63/E&]$BRR@I,&9INZD;CE5IL,S)[&G;\5;)7.?1O:I)0HX&EX0%4?O;Y9!
M' F(13"G,+VZ7Z%^/Z 4$Z<;S'W)@C9@-H+F]<1>!QN7UD>ZS3&<&<VJ7H5+
M(SLT^@AEX^\TNSDW&1@R@.+HIAX#=S,)T";,9J%75XJ8?"YF;B="I=5$^C]^
MS,LK/WLMX?&=HWD?8Q%+BO;<T)5F1'UJ#5)BF?1*MHTKI,2X$IJC#Y._.A$J
MFG_7HXVYWIL'-E<^?/^C-?QQP[J-_LI'-:=(Q<[UR+[\1IO&1S14;R;K83M'
MU(-^.<JLM22?GYQEX[;GT_H3=A7&0KL$E@Y(:LF'.A09(((&&,ZL'>!+8K%<
M,OL<U(TJQG#VH,3]KYF6%S+P3U[Z!QQ1-_G21;V!4?#.5C=1>:8ROI]?.$S:
M36Q!32A(";SW#/I2HP26Y01YDSJJU/-<+9,JC$+&"OIQ&2U;7B52=\Z=GMN^
M)F$L3\M7<ZCU*$J;8PFN77&-3-QMS6Q,%%!V.H$Z(S@EX:.9HTAM$'$+.%*Y
M$";(^5*X2;W4:E7DM0X^AU2V!O29B$0[8<,KK&J!R*M?I84/Z29+E+4M)6LM
M'MA_,\\Y2'A6)]'XVSI11!9BQN7/HI5P*G%)<IZ'6(9@SZPOMAS\M]8%NM__
MMQF;ON(AWA\'EJ>'/G5H@I^@@[#5GPOY,[XYCX2CT5$^1]BPO(%OJW,[,4CX
MJ^N:H"H:K,QK;?-[OO$0Z_2B_[2?1A-6"K@R!!K7[/$/;T Q'BVA/#IW)G^
M/@\4*1ZB/%1?LCQ4=4.";ZWR;&& Q]#H0Y2NF4,M#[$A@X<PGX'.\A!L3Q3C
M(WI!CX<8@\VZM)M_>64AC#+$2<*.\A-:_^&'6Z&5<<S!=KPS>6G5R+S5&Z >
MCE,ZV#S$?1+4;\0Y0.!B2$MP4$8O!G(.HSE<&(&<H*/^7+'IGV_TRT.F5A95
MT<"L-7!7#FT0R/_3C7YZQ']]M M_.)=DST^WQMI#%$B*A[B%'AZ/H.:7<C.F
MDW)J_)*+\)<=VQ5E@]VS!5,N[.^443I-5YGN(FJ$3+NDQ\[_:YU(?'F(DGPX
M?(D%ILCH^>N^[X%?SN[(Y^8",-C"P80#C)D9&4^1E+]$ZU\7;+U_79E'<,56
M4!GYA^7:OTSQ_&LQ^_\W5E"EU@2[%FTW8 'D(3ZO;/K_^^L:QSA@ !99W#R?
M7*Q2?OB?-_+ @?!KV+'W"0]AAX%NN3>H]$/P[-['90+=(C!#EUI.@W_AB2!P
M;AU=U R+_]/,) 7[QKXL9B=X./O@O=>V9 F.HM1GR_,F,MP7Y2V^Q!*#_-@1
M+K'JU.)R;L[=.(7!F%5K")K:4@W_K9Q++_1YRH>'D*E2+O7).NG[*JC,]SV_
MG[>=TR_+^"%ZW'^PCN-^*18Q@E>P!C_@9:?&@Z^TWG4IL^WTC%:XJ9JVL-3\
M%V[RS_[M!:_N9PJ''%_%]CBOV.V?W_93@NQ@T"_IFU=\J&D'+1[BZ4 RQ(=B
M9OS]Q4K/BXFXX3K6A5&1\=(3"RT&_S(K"K2,<Q[9U9J[0:HE_5DIX5))@8)P
MANSW[K_?#645A.8AMDFCEN=@93TJYD5RS.!(+F_;_].R$G-&2O6C?_Z9E74(
M"=5Q[;VK#D^K#+K7K6RFDW^9"<^#P)D:/U3&;2."I*/[OZ7'@OO^5#0+%$0?
MF(?A[ZF.S':7V25?(+?ZA#3!W,'(88A!@7ZSUX'>$KD"W1T,(ALVH/KEIWO^
MK,X_/9;-^+/;_TG_-WN [KZ2B: 1EV$")2OK@_K'BQC?^.9H?[4WO1+H+8*Y
MXRW2]&%^*,+.X%?=0ANLM%RJ_V,9WO+%7Y-$W_ZJ@=3JQ?\S--F?G_Z C?M.
M*L(1=%<QD%3%6FE*#$H$4L3@=16IYWW?7F]V*BN,<:JLK*QZ8&=+EM(>$9B>
MV'XNP>+D_2E,DA!VMO,'/ZD5BP)JE=&NJ'[W$50=FK\7WP84!?2[) ]N=&>C
M8DMYB$U/.^YD:W^*W?ZV>!]9=TMAY1O<D_V":T/E]8R942,2] )F(+3>FWF/
M=14,AAG)D79H#:A#A4*IV;E2E#-@X%.WN)N:W$>)%M:X3H7WUU7C9Q89JT-4
ML@ZMOU,\6;[S8][ CS*3Z9>+@;8=R-:/*LT ;*E10\7\=<A;R0$XN@3[#(5)
MM M<RL_AF*#"]URW9&^/1.]M59TFW <O)]RZ]0.GPQ\AQFB:SJ01P=W)'%$C
MEDD'>OCILB)'] 8J@O#JZY0Z:$7]_&#8=.^$<>NV@K=I:\LZ=E7$9R8\?&<]
M<,="P9(O/2;S%NLQY8G2RP<+15ZLTN1OBR>0[2DJ<U,K)VT5<*X7P;\$CL'3
M.QQ.?1$&LD:.G8!5(Z5/WU&LMVOC ]:('+U.A%"<Y26_(;N2W]<'*"'%H(=?
MD!BFF-X) ^Y;WQE0Z2E85YHRF(",P\NZ.?"UT:]S;ZCTCD1DM.\LB;\2W_&A
M0E>D_%S1:M$,]PVEQ2_>C]X;]S8>LE:Q=TGY7G*#;[XQ5F4$U9_)*N0^TSW&
M/N\?" F.L%&<4U\XJ_*^^A_$;0TZ!6;GNR9@C:A'UBJR=1U^$]F\(?E 2]/,
MZ8ZSF:B#HZ//CI^/?9Q].K<ZT?XH6SMV:8ZE!!YC&W!TJSLXQYCRT/KM:DV8
M]6X'3Z8<'_ W/U626$?'+B:J#L0TO&^>7?+0.U[.?P][K*,S+%-+3&4I&WJ-
M?H=\^@NX9/D#T-&#Z(4)"2A$>0!/,@+WSQ\5H^+A3R6TPR"?WP3Y_GCP\_6<
MC"TTB>%@GTK.FQD$2?YILC80J$<O;;X^LTP#YN4=MO\5F&BY_%_D^"?(846!
M&2%QVHA1SR(QC<)]YT$R#14U),)9TQT0%:KK.-QR5LE71R#S7.28S6ZQ)%K7
M*<-"^;U(H7+]-[BG*A_1KH2>0)8U]XU3ZPS:!7>+X5Y6@SH \RVWTN4G@\3@
MS)B#2V'2V8<OI>SKE]ANQU=L^3 @[6-6LKJ#*Y;AJ3@QRE]+9)Q"]Z%85=P4
M76^V!OXC((Y7 ?UHZ) :+5#-NIQ1<8PZVKZ0+W PU:M;Y\J^<I-LYZW'5%[Y
M+(W=N A]64D-K&E=*0B#6H$MOD.WL5N!*^CU_I4-%=/>MF[+C04B7YNC=YPW
M$[F6L.J< :I2P.? 385NF >OZ5TY?2U(B!M9(_6MXBM*<-Y?3]'D:6Y4K.[Y
ME/C/&=[[D&_)&Q9/4405!4YYWSI^SLE?=.@.FF&DUN,^,D,^<FU$,4Y7E=:B
M8\\TK:/08JJTF$*6[=3.QX8%XRX7WVZ>C<VZH3R*='!O;;AT=:[Q<)V7])1H
MB5_-AVP5V[S2ZA*^6F X,4T5@(?12"Q%3<\QS*TZJJP9R<.D6-4)T-[IX/-%
M=T_=4BOSH4GQN8)+9[=2[^PK/^2\Q^=SPU+4-,PHUGP&56 00G$C?=7ZU4>P
M="0M&-D 2/[0/.),/DA$EKAH ,*3ZB\^%0B,MN_ %'V=/G_N4[?MX-GSE9=_
MH%^BBX#I>H8(ZS?0UI6!A0';*=/?O/Z&3_'KS!Y^QSTY"-<728:NBG<CSEQ.
M>!1ML?6=) .U%:@5YB&&'T/[F;L*<C/K!H#?WC!WCMC[WZL;E& .9K]T67Z>
M@[^2]'F0N@,QKR)I,/+"I4C*H>MY^MBZK\&C][P^?OX^1<//=5_5.P?#\C.2
M),Q,A@=DU4?.U0@SKFN79KY2#''NZ*\K;3H6A8':@@]]Q_9^"AOZ.&N.NU?T
M84O95P'=BG#6 OSJO#DR\,^+4&. (KV<H3/2'>L[(Q*TM>/Z$_VZ9:N&)Y=D
MW8]U*21]EY22+%XR_UARP]B:%GA,FERD5+^J>[YNBN7 3<.AG=O9N[]RY+ZD
M4C^T-B;S$ ) SSEK(;/W1\.?;>"+XO?W)NG4N#&PJX#:3:3A)S6KF0XQ-"<0
MF^]>"DE4F>0+^0>2T[0[-4T5C1X@WW_I_?I5%ZMV5-8.F:\Q>>60BVF)?Y[S
MKD3,HR/I"Y;?*W*/+F,P()%ZKEU7 ]K;-:VABB&+M]8\RG#S8Y*]=1LU_<(4
M?')57@X+F"5\7<_I!1?9\D&JX"0/P2]13\7VQ9G88VKQ2N#FC45/_7V6J4GU
M#381$5]NV5 D+Y3IG7STHRKIO9S-_K/:4 3'BOL0OXZ# ^.&L7$H45TD]S4-
M&5F1TY<<YHNDZSQ$%^5=,3!6Z-V0=<_)S+#7HL,QY' .MJ^2I<!-!3PQR$D;
M%'W5\*Z.*PSN9!5CO"33S;S'S<:@%J&1U&WY.9'\)+M<W],S^ZULALSY4Z:Z
M&OVF>2[%?9/!*=T.3RI"9_EKU2*(&]&..' OE9L&.')WH)"@2A.:;R<3V8!9
M[7+'\%&FV[XA24]<%^*&[8EO6XYDB5XZ[CT7CDU?& $*@6DD6PU/CK+IP*\!
MUP<&.S<4/D]38.J597_]'I#WROR'8%[>DU'EZKN;0N9NCW876OI_9.:;'2J=
M3JP<Z,\>:@^^BSH*_KWK.<?@(3@A'L#49S4NPJ*">XG </P6HO(SH1U0^<<$
M-SM]*D K>OZM)@7IQBIC6>VNZ9O]2'6*M8!F*Q(E \.Q</Q8>Y*'<*/<YB&$
MT2[84%(AIBX_/@!=YXZ-\ZOXT(57G@HPK9Y@^?38-BG<L'Q] ]_"2HVZO^U
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M ;2ER6J=9$[<G@>+6_C@=U":4$P2<GUS*\S49LS1R#5E_^(V@TN?GA?>?::
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MGXFM,J]O8V$KC/OH#I;=5)L/U3GS[E=U12#! O9*6]':8VBG9K4^K;,K#$O
ME/RY[)5KF9P<-"B5?)>5+"R$TM47\'B@N&K?$8S-8@5H"PGW\!#WO6R WM^8
M6M#C%_D5[AM\#YDU=MP22_3<IB?Q!M;5=&@ )0H=X)B!./8>H%95E0-D<-28
MW)D(3=3F%F8[IDV8W%+37CF]>##PGH_V0;Y#T@5O[[I/D4(=]H*Y(Y1;RUIQ
M>"T."H, LU@2GHYU<*P@:WV]>TM%EM!;"_E4GS5!6;=Q_1U22SO8D* (L[EN
M:!->D6/!32,-OTA#@\%90;\Q8<N.[3[96G7DXJYDW,VKAIUI6Q\,CBH_=\$\
M#(E0=/D@]@W-,$;VL6E#]&"VIKL?ME@X[7&-'NC-%+)DJ,6K7?=GV;AI+=^,
M+NDP#A'5-MVZ_6IEN-AZ 8M)LGG]YR@]6<./W65:![-S!W(#I_D[M?TXMV"[
MSFOFD(.%L;J30[.;PJ%*M3FQ><U@"0&.6+7C\DI=">MHT-S?+Y <S. AML/T
M:JH(4#_3/:(.]JP5-3O[IW5 7_10*[A!X-XDP[BQOLQ"]T\K3=8S2/#GWD_"
M?+8;)H/:*Z=Z_?2'I3NJ/,3U3$CMRX8 F*%N^-,,:S6)2H2YF1_7&[V\.7_3
MKY5,W_TQW&6 RCTC76QF$ S^J]WYK<!'*W>!YVQG!-U2^?CKAN)?**,/3'>_
MNL%T!WN/KP'&3D[TZK=#!-+:8E0?DAK174<1<2M+LO0+N//$?U%<1_<+R^^+
MPS;I6DEG6#;!78=J:_,^QGK??[9S9P4,I;L1%L+HNL&M;9HFN==.,L8B<NG,
M%OI8=8I"&7_G5P26N2N_U:#O/SCMOQZ1G?L9O>>1T>A1OF"8J/OP$-_6U>#S
MHV@SM+9YX"DL%:P<?SV)88[J=69U=W/X:4-B'#%NL:8S8[",AD-^1496$.O=
M/9VG#^2]SLQ_Y'Q-)L'.2!0G6>X_],E.(5Q)\@V+V%//VH;M=6Z0TP'+X==Y
M.R6_ 8@ABBP(Z>3+^@]9M#\KD#!Q%@QKZQML0P[T'Q/UJ#TCCGLX%KV>OZK5
M_FRC91*JYUMRXDFV5QO)9&FA!QF.=E$#=P+T&?913@"#T!3O#JU_\;+/(>@P
M4_Q9%N=(,3;$\K0&H40MR?&&5%A<;L$:TS:UG7X71+".04*,9#*!+VAWFZX*
MLYDVKW>$:9%^4A,GW@]ZJ6[77.?ZY&[<B><)V_NE%?PW^'D,U'IL+(VU*+#(
M;K^MZ*Z:*YG_0;%[AN\=Z0*QYSK4**5%6% 3X:PT11EJ1(GH;<>"^>0T96U%
M%D!4K96S+]2?,"U4.K<IXR:;'K+JW13:#1?!0Q3#\8V:T&0*=KJ<?:Z7H]1!
MS_]4D91]DP$-->Q@"=\2^,V<LBDZ<GM9&$:R2?.[QCF3S986U3DE>%?-19NA
M$)0D4'L8/9P"E!"F^78E#UNO-'-F.>P#/9U?N5DM0@(H?GKQ$FZO5\,=.RRW
MU-512">G\OC=XQ[#,@0\PZH6&5<CS<VJ<F5V.W"?^QYQK!V4;]WC,8^*O.;Z
M0O6Z4+38;]UF+1-:#]O%%/+O/QSHS.YPR<J.RW7P>4R_D3-ODKNLREF<XQLA
M2$$?AAA6_0-65HS%4/3PZT&I0L;@ZV"?+JUNV/?1G3KG ZUE8X])Y[Z[<R-&
MP"#IZ-;2'[K=1?BZH0*_>D*/&BNH !1B3)SO\/51^Z%Y!&BP^10ZHYE[FEJ&
MN;E?QNN2V-'IZ)"D;04LJ=T=Y*YL3$*OFL(#KL>#=ZD_A; 33W2@XYN ;B?H
M4DUD?BX5%5:6 YQ9"63?_T\)9,>'"$,,$TQO$RL6?.#+-"*GR3/S'@3Z;3!K
M=J;F;PZ^\\7#SNO\K<OKCIQ?5$A[^98$^DA,I_(0!M(T(B3>Q$/$6_5TG.%O
M0C-&U7JUH%@M,IKSO]I[\ZBFMF]=, C2"E%: 2$H*"H@*IT")BB'3D3$!@2$
MV* T(48$)4A(!*3O! 2.($1I5<1(KX")]"HBTDL0TB!@0R !#1N3;&ISWJNJ
M5[][[W@U:M2M]VJ,]\=FA '9>^ZUYOKF]ZUF3J.,59A&";@E3K!C+<$D4+$*
MBX-:9.H,WTQ9C-<G/"C'=UG+,\F#FE<.:IHN*$0D;"6^H_URH^Y:A;&"2<!P
M5)H=C!"Z"E,X(LHF?2LA0!C4!H5BWE,4ZRVZ!B=2QB63 &\$:(:^Y&:#*"1I
MT9C9Z-J\=D820M[:Z!&PS#89QU=V+%QX8C::,C:Q;6.>Y'Y=36_=)Y*OK?X=
MRWX9=Z%B+<D=#&U O)-O.:1:#3%PX\=?VDV#O5C'[,QW:2D<CZ <?@A/)_W+
M\QW^[>M4S@7M%)\B_YN6<OMW7D>@D0P#9O^M1:=)[7=I?HP_.QG*$-MJ0 F#
MJ%W%MY$'_VU+(?ZUY2G5C_]GM/,:K6Y4J*C$#P3<N$J=J$T$,\CGD_:COVMX
MNP;E4??Y)_V]%[$_L567[(9^J-)-_(3>L$#=+U3CJ;6)3$XEOY_R'LRG&SSY
M5&/O)*6GX,B^C?3@N@HW7>*[C[:HEV+R:)N0.PU'FRZW+#[S-=UJ:QW4+?Z>
MZ3="_G?>^R=.)F  "&W+]T^HN.\7*8_4#,^4%+^7=CIS+L3K/\E%MZS"_K6E
M,OZG'$O_]PV=785QUD3C'5$^49D@P7/M0,NOY5\\EO?'/G>07K:0ZLF^LD'J
M0_%>Q]DA#U<F&=C6/5=%P9LXCAH3MQ%.>%+">B*FS[8$'(G'#Z=+Y;QY1WD*
MA>?X<(8Z40Y(81'O/^F\'%+UO1>K,O3-4U<O-DM*+\0'?J<ND'"0Y6+2/OBA
MYE \6;[Y;:S8>_NGCOP##^%9_].Y_?]?AN>_;^='VAAJ[?SS0<(E $=BDU7P
MRVQ3#W-0?RA8UQNN5A=P,?YBHN,^<H%X=A%FD/:O_G0$["5)WD!%%ZU[S8VO
MK#I,VCZ:B*M7R9\T/W.FZ"1K;^3M:YA/ ?^C7S(75(24H2[M"BT6K?C+-;E(
MC3?:X9WF<'A(<?&CO'-GEW=XIH)-IG7UZRC[",J3_T[1VH.D5(8&57%M F/#
M;UPJ;0NX+1"IS'T>AYO]09]OQ+_P'G^TU<-PPO/OIT]3:TUV/]:+1N\&I$ %
M.*0E3Q .\VYFLAQ1 3\G%(TW^<B1%/"QG:#DB"E6]_3=!V(JOSG/KL$BU<*D
M1EH20-G6AX&T>E>AJ@5_KR@6:>B]?;G=*H&GG][BQ.JAY8_Z4@>#"^<NYILL
M?LBT/NYEOMY3_^Y>G=$)4KW#7"LWA=\B>D#P$.PG7.16Y3YB490#0@.7QONN
M/C,Z^VC3.3OR[^MM K^TT?7JRC'2#V50@7UT,M-X#L?U=Q,]7*NAA.AFT:0#
M3XYW1E::Q75.CNGG7(Q3-0CXFFL?H75:XLAU3!O*GP3L\1 JN?+S@7?EQ#Y0
M')B-*@-HOECJEOX6?R;GE"WV/-_;G]J8?/ <5W7O^.>[*D[/Y4#YQP!K"D<W
M :4'N=D=))4],T/UAV!!&LI><7R?V<87U'PY^QZ_["URRMY-,[M7,D!9 \$9
MH:VHD7J(V(NJ97 N"-2 6OXE;EE%MX]FASM9%:E_YY6:1MRC4,FD2WL>U-IB
M0F]ZK_-.8MN=36K'KKN-\L,D#- "5F&Q&@R._#/B^WQT:@L#$8!4J^.I5D%O
MZW^.DEG^I5=O8]_LWQU&38ZE/LG375]R8#&1R3RX++&+QDTEM1X1H@41I+;N
M)<C=# !T&1X%;D+/1=$N"U2F>_OHU,%9+0'8W]BSF'?UPT(P$X:O2(,(.!L%
MZ"7<;KGP&' ^+2JC4'3[S52K1^LYFF\LA^=SRL\9!.\R^JJ:!I=OW?VAQ#K_
MS_(;AC)RB_ 8$%Y!. =$314:>'*IE/+GC\KQL<>I3L'S6,_PI-PS5D>QLP>G
MI X9=)%PQO3P?RIXX8G=3:,I5'W Y%CVD5>-V?9<1GN:P=%46O(-S;(;*8[U
M=7]M\WAY\?W[C;?+)N(_==$.64=PG?DI:\7'2*W%U+W !9X&W\>XZSOS7=>3
MLNZ#J,]W,4T_])KPP0],;X[.IXOI. [ '%MU$)<!"U!N' H.3WFSG1CXG4DM
M4<69TN'?[24!U!VON-0*R>C'/ZR21?GR[LXWZC)3UHG+W-R',#"W)[938E=A
MN(4Q6^8,A B27&"93ZCEUM^Y)16#\C]X0UY!;%U<_,+10>0XSI+741YY Q*>
M$?<_9SEO$:U?V[T+W&=GI$(X<)P6C5(EX$C;)^O9QG>TMPR9I;Q"AW[Q<2Y_
M,_#>]?I'3QKSM!AGZ+\]!T1FTU0 ])NBS4/6F"G2IL_?_IAG7S::J7SZ(SQP
M?7UA2Y"O4UGFV[/]IU4-.V!B.^H,EB)!!:.F(>J.;^A:X[E#I*=?QO"V4V3.
M]H<!J(U>=%:Q1=-?UV7T:@Q+-\U8V;=3OWE,WCZD@ (.U((RFCM>&/5Q]!^7
M)],3/GMT#1!0(Z,V%E8-P> G<Z*]1<C,U47!?+?9[_!T$$50![!<"S=168L/
M3^EXPALOCX0"GQ:>R[/R'Y\"*]4>7,U\J' YM7M)?#/V3:K_MJISPLV 0P0W
M$UQW3FCRJ: 57DRZU'@G/4^-'\XGY4U'Y<T);DHW$)KWI8:@81#V-2[_R8BC
MRH.?&-5VT[]'GK!PMR&MV9=,T&)&F*F91'A9>X@5-_1D-P<7A0HBVNFW#Z%8
MJS#A%@.HP<E  D_<$8C "NR"-/2HVYJ]T? @< ]W1VW)]Z;49S9GG)M[SK+/
MS<;JZB!?;:,.4]ZB >,\3@0//>4PQV,S/F=/(>;TV91X] :A[52/"_R,J%08
M$=P(:G\*YOQV_'"KY5K@DY #2\*RL\<F;1"!)^9;DD67N)*%98':$OVFA7+G
M+ O3GF=BY8M*!Y-<OC@K/G5YC8]Z+WYURY:9VP<7E(C]D!=9:_%FVQBUB$3A
M93YN"W[08<@,O>$;>6S4F-_CC##@G(SH48\_5!1&,FBJO;IB>WZJ@X1! T8D
MH>(L7QW(C.1&\A^*GM?A%(!*ET527<LA;&F01LXTN5#65:U ):VE5_5;:5H7
M<__SBD<JX\)CHC02ZR(X29(C8?N LZMK58#C,,Q5V,8 -(03EU;(=!0]?FB%
M$;B4]VZ1VKMLW<B@+>PYN*()*N0"X=Q5F",TXDR$P3PPF^FC,>H[7 _?0 KZ
M>?./GU-X1*WWX"57\\LG%K%__:69U%8<_0;"KZ,R,+]\8- '0K#;)&;VI#:0
M=(,++O/)2^<'?V>6_O UKN66/T$E!"^DK-_XKM(A.'@TZ^&[F<U=\^=",XBB
M^A8U'H+M.H?AX5B,UIZD;3PBC=OC.]AB8'A2PF^H8K B>2Q6T3S39*N4KLI*
MB$"?U/H7B7F?* $]C_1(E$$(9;^6[>G.Q[5-.+<6Z0(J-_PS%-' HP%,!#;[
MV/ALCU'GSY48F])=>:'[[V$?(JKY'@VW<AY8IA>&JW2^[G#64VK5"<O<?-GS
M[+7#$AL=)#1RJ=K0K:]2=^)KV0O"32BF0W)+8)11+Z<\X?$W7M\^O0(LROWU
MBX83KB=>>/]%YFH(XO_/*/P5M%R; 1>8"W5X\.Z,5*_.D4(63O8[Y3'F3UIN
M6OCC0V5/+WTH>%N7[%EX@O#AC&90_*6XDPZ>)WYH1,5774#F/!VS#<6$RMF%
M8D,VXJ?3HC>D5L2?E)'0EC852^,VLC/:%]+(\G7&J0A9@F?@<[Q_!_VT1F[<
ML[.O]OG0/T1/95X74S]Y0&?C=6F)3>CM^&Y0 7J9&!1>X0IZ$SAB<03!,1C?
M;#Q'U "RY@?F,4Z$^[VO.S1".T,TWN4L70Q/2[3RK$9O) 0 . $&[&#4J2P+
M-\KQ[7EZEJ1V%#W4_>4PJ B,1!T345B4A'.NJ*1?;W51I@6;MHQO>+Z^?>.,
MAQ'BY^S<N,!*J"_*1DH WOQK@!;K[U\9L@#*,<.U?RX[]_,K([TTX?6WTZ7A
MULW-^[[FPU84&* "%K)3UZ<N!2.X[.MX\7I6(J@,/)Z[,'S<E JOOP7O(@-[
M+(1*XOQ;0P3-4H*7J(02]I.6B(#7K<(T@:,CHRQ&HK$?]1,N-6:$6U5U)UYK
M1E]RU\VC!<2P<ZDK:L*-)-#9F#,(A5,RFSPM[P_T@.ZON631?0GRGVS?3U(#
MY)H$H0H$CMT"'+Y.B!3=)V$0\D!"QT7S3&NSZWD:5RMV/_XR;61<'!^Q+MT[
M2*LD.QIM-SJ+$&X9YLJ]\2!QC^,V$L>UMPQBPU I"(G?49H=:+@PZI)LY^//
MQYO*GAE)/Y#G:.I]^,LO9TG5O.NT!P,EU1(8P=-EZ<=1MP6I8G A%/SU;K>B
M"9/$HLBPG'O^#]9U$)7%<A <!/<BCGX4-Z:(4O=G:]&BV;P[D]K@QU<K89[&
M>C7.%%3/HL+5;6&+'47GQU^6#VP6=O,L0 6(6<8<%^[DS==R!1VHNIN/(E#Q
M]>K!UJ>>!"#7C=1KH>Q?IO$MS_EXTZUM*OVTGGUN_6@PAJ5=0M="L.RX0&(^
M0G"KE_BT:#X#CF)M KL%1<>KD67\A?J(+[-]BRUD@[3FEO;"1[0&',=$8 1]
MR7(5=MF(Q.[K[-4\]H+;(6-4GW'GUVMS8Y,.R[2/B_DWZFN>ZQ=-]ZQK=FP-
M)^QNAL%= 4]HU&=TK<+BZ:Y=QG>0U@-"!Q;V9B?.-"W2L<6SZNK#@RO#0U,Q
MTCJ+98XZ&VU6<)!0B?D#/6OG;USR-:%1C>@Q>]N4#]C1P,, _B?1"BZ/Y\?Y
MEX?I7SR5BC)F5OQK\U?4VM!0> [H W8PA!I5/(>C0/0EX[B6RT\!9Y_AA/CB
MG%B\^[A7R^<&Z5O=>M?.J5YH=?(+&0Y%.PB]1=E4^4X(Q*<QB%H_HNK@:/L?
M]%S3LGO(W\K;T./?&%?3 5Z&!2=QC_-OX]P? >(+&@:SQH">6@=#A0 A;\PY
MPCH@8RK-WKD7[0:<*2$%3'Z8+GV5:W4ZJ?SZK>9[D]W#:5&:_\=,OG*+$^7[
MI#*7LPI+OG'CE7D^]EZCQY'W7=Y/4D,>W5QDQ?DZD6'L \.%Z>N>Z,E.K<*N
MH.FQ3 M.!A?M*'I$ND));*#NXA)?S:19>30TYLOW*J<I)_*.)QGN>9Y:IF=W
M(=UA6S-=&"6B>?,;(.,LB,,:'[.A.+K4;UK9)PO2FWX$4%6X\X^(#?Q)22#G
MAN$)+2_E\QYSRQO?+IF>5UEZJ-E0O.V U!AYK?!?$YKKC!H;[=;6!<)Y_OS\
MHKY3W+Q$U(N6(V$,&.9/3GUY^3;%UV1Z\+/+T3-V*$O=ZE0AI?[E<UD4<+ 1
ME$XS^I ;0ASS2#.U4;^(CD/N-KS]ZRW8\[8W2G[-(E$"58O4>HAT.4V<?XTK
M_[4II_>Y8!6FBL]?VO&SPVL(B.RU9_V=ZY][O"!%Q>ZO=](&TXS/.-!=0_2*
M-N<*X%9AY;=@OVG:I-90%#,/O0&$$PX OZ=<Z4?G!]L8:@K/D=IH!^YRAU)/
MI=8>%I92C56)=87G&#P%_YA.*GS]\LHLG+^6GGN,U&I("R(EWJ3)(.7!ST4(
M<J?:4F+8*@P.Q+I2/RT8;]=?M_/B$+,QT$^_6,<P4I9+ G:/"LM'09EV*/A*
M=>!$IM^'.22NM^N8)I/,@:*DQ 30B..YMFF$_:'< 1$_0!UN0F)Y@UMX<9"[
M>9;/86NE*8(MX>ASY31>[1/F)ZF1G': P<\ ]G&GIG#1)'^4.M S1]P/Y.$J
M79F%F@++&5?.YE]O+^8#*]5=_;;3W=8N23YR\VU7=:*GR5Q'6KJVI:@4BI@H
M<:J9\/A0&96G^HK[\W@4YD1A4A9_YH P[^7U6RWQ)KH(#[-7O&:^&<08W@FP
M!#E1-8T%.?$52 3G#@H],:LPZ5D^JE!4*VH,#,0U<[2OB\CO!'OF(JY'%/#N
MC6>)O26.DKF>%&"'PQQBZAU5%1Q&U1>EL<B*XW;*>5X2ECY@2<2ZH]%3@5NK
M&^]/;4A])B=V]_!WM'.@957\JS)OS*W3(+9JNLD5NV>@>>K&A@J)=?NEF:FC
MLVM\[Q5W@06N)>X)%#T$MY[%J]G'HH=,>]<;_WX;]C9W<?K4N4$W5:>8A6M/
MU]UV>@-3,/B)U@ PW40345(]24JX9TB^(JD>%Y>G2M1J\KRY&3<]Z&GTQ4(S
MQ&!K7_ )J3C\+"BW -W],1#),S@%8)Z# PL6?-7GII2-^(*CW/3*R$>!X65M
M$4H_KGD?>KJQ8]WD!3O]F0NQ&2],T]!./(5L#.6;1MGKWVF_F\YY^HY]K&D/
MD7OLEZGEY.%^4OJ\HTZ, 6\*E'F]"EN_MC\H2"@)_=1H%V@3;O"0<<5X07N1
MRJBUT10ENJF^R-KNZ<^!WM MN4_*<Y:>?VW*.DU_^TPJ7^7^T;WH4A3SLW$2
M<2^0!QGK 1P%+9KSV0LV46C;F,C4!?.&IL(/-[_W!;#'I+5R=:Q.2#%^_0>9
M!_[;B[!6H_B2*)9H"7ZB+[=EC!OP#4;#(N'I9!C!-O0IWKRO8[_I+5)B\)Z2
ML_7RV]AVK:FNBNL]3>)ZGI\XZN=Z'X4S!@R-A<KZQP#L0V+/K66A4L])42'A
M$B_/#;FA!JCG673QPWU5N</3'RYKGVX>''$S+'".V'%XHZ$%J^-J_9^>LP@E
MHC+!"!AER8#:0C\ \Q#?:-.49='T2>A2<ICD;Z(K91_@[VZ_^\U>O6LVVVXC
M P 2%\7N$RIZ@#(]W 7^+5$\Z<H[HODDH&SK7_E-O-.\266D9$M79(K(?M?5
M6K7\JZ7[I66F_79J[I8G] DN06SX9!]@R(]E&8]IKIV&#@MBB%$U':9ZC7V
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M/3IXUO:WEK+8"E9PAM2*13'+2-64N<$=-($]%/GU?B-D\0T'J^HB:8G7 ?K
M\AN^6J/"UHR3^=ZV1A_<(]_>[?@A_;[C\H;6C$:PE5SCT64,[/ 7*MF>1$F8
M5AE/,;K@RC^6@(5.12]\KM;^OJY;DR6F\.O\T=I=Z0? #T^KCS(-5HY.>WS8
MC7S'(\4*=7E2;<N@-&\AKHX3:C>,]1T_/6 6N7D>B],)B4\^6[I>[\B!W6]B
M+)-QL=9*S+X$;9477/WV/NGO^0H)9=Y&U/LE 0V;Z'3/MM>ZR9MS3IIIY=A
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M'R/,*(O@;K#)M[C2PF![,X[RMX:IFUW4W_]D4MM%'$!PO<G #M>Y;%Z/CZB
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M?('GT""SHKU*B363]V3<[H+_#:-GX98MHYDMHXHNAG"JZ>ZGDE]9;7O4.A<
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MC_%[(&P7R]+QB;+I)9@P$8GDQHPY3<AV5\!8H U^6H4UQ,UVNXH1^Y':/-N
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M+^>[NRKE!QW?D-BZ99ZW-6""+I6C^M>6FMO$VB#2)B(BH,)!HSN]#F/+WC4
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M&=S%KC;_(:%U<O^[*&2)=BO_ &?3=B-=EGJ_BASN%)JB0BX#G-N:=CR)>!Y
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MHTD20F_!45+KVM;+*J(5X#VU0AU\BG=FDF+K!96]^CZC?A?[/Z/BC3F3CO3
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M9.W=V.WECX*R_^H(>_]2!SRS([,D4!LQ>+'_E]9N>M? ^O'U50_DE$,R[,[
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M.ZX;5IE-3;;R57&!M)AAMD[#J\'5OMX<G2*E*\-GM70NO?(GA;WM?1-KAHG
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M\2*Y/FX,]PN=76CQ7(9GZJ\WI]?Y8BK<3#4.#ENU/%"[$-/==/QQV>GL]#W
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M]Z8VOZ?-,M\QRZT^;?SCELSAGH_#MA'BYOIJ'W^B+P7L^.PY9G54ZB-5$A5
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M+DQ[7.OB/]SW X[G43[P(I4(;B=W+,Z!-^,I1E"4+G1I/Q\ 8?G[Y[(6Y/9
M'>V$B0XD4QHZR2M[S@>ZS%'<3>CQ>_Y<'1/&+CY@#*O0O5L)7->Z2G#-2&%@
M*U7(1T,:"YM4AO52\ILES>4S:0-GFO0N"&Y?TR7"!4FP]G7!+.M2-Q+ZD_C
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M7C_\SKEX;]8IT:20ECB;IRF"%J+1CGT57\;</JMZ_:SM?Q5I9TY\G5]U9$:
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M[[\DT<7$+>HRCI^8FE\^T)Y[^,.+G<3DJS7;?X[49<#-;#Q :%"[QE2-+M,
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M%_40SH 569MZ?0@KY S7&[$;0L!RS0GHO0B] 9)@SM"J?&)'@L@;RQ;+=)L
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M(1DRYOOTN ?5G_7S!:R<Y*ZD#ALKH!8R,A"Z-$T$&Y37W@O*5SX')/H0+8[
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ML ?$AO[G YW_R#]$M:VU:8BE1F[-OG+:XL,):(]?;-;5(T9B+]> >"*;QT]
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M$YF?ED$ &2;@\-@:D(5>K6]L$V5W\B6J76T=>*$L8\^ZU#<\O;>>]Z8-,Y?
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M8"A@(O/M+XK6_B/_?[(V^C=02P,$%     @ "XI541/0IX@;(0$ S$X! !4
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MWW@>VX$BA<X9<VX0KN<\CEZZ* ]%TP(1 XTD &IQ=X@^.- 3P2S"=JGP*@6
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MJ4V7YQ'WIC:R<-28?4/[G8%0N.3SQY\X=]*4#YR5V$1Y;CAM($)'9B"81TU
MO12HX<!B*/1AQ@'FT7"-);XQL6T\DK@%'.L[F C!JVMY=)MQ,U(CRHTE?#0V
MN.*<;%U?R.(JJ+W*4*?C[T!S>P))LJ8?9V&:Z,@DE 3W!KT-%^^YFAY6&K2.
MD@RR[ LYO3.\R.L:ZT0Z+^NWD*N2^P""^IS(/&\R$\ F\!JXSM!D](%$CI=)
M9W@\'QB_V$\/3[5K^CYI<_OVUJ2=S/6TYB02:<!;=4^8>L@)H6,?- ;^8+M@
MJ;A:%'<K9"=F6>KL2_\L =?ALPEWLXW(2S0B^9#<B=;&QI&.B>>.HM?N%AF0
M930^S "+K?K[A%C#RW'0)2^!0IQ@B/YV+6.ORI&TC;U0O&>09;6G]\MS W$7
MVS+<1BU"DFZ76%2KZKH2DF<Q'\MTA23=M@'Q'1R.Y'>,-'3)[]A.9;[TD@!H
MCBK'!]__&2'!*FG.F%?]/<D2FRN(B'W^GI#K97;<IZ3,O#UPX*'!$> 2:++L
M#Z&@G%=,]$6"NKT%RPT<NQ#W#@U>&5PNYBA69)#IPW%L"0TY,VF<SVC\7NUS
M#A&81<-\//;B!+"H#RC.<F'@:B6VLQ6:^G"';N,0=A;3XMMJ1N.0134#O4-B
MY1NNYV#3T,+S9L7!A!U;TO0\_ Z0FC]NM;[J!JQ1R)5L#5X^@EJ$:NY?SGL!
MY6^$UK3J'KX'/P".7"X/F=O,;&Z(U2.D<I65R&X/^21'[Y-[#>[]?28LTH8>
M4FO$O/VG?9CK1 8#^N4."$E)43Q8$8<UZ7(VH465LYSFD4FOPQ>:,WK%]LQU
M(YO>!!9Z5,^WW'OO^]Y][LC7'2AE:-X\_SVLAZ7FWY+H\R &4T@4OO0N6G@J
MI<FA]Z5Q8U45&2'WLQS)['T]>B>4-JOJUT06J[=^U5XH'C#8H)$;5\R7MI[/
MD)M6Y\O F&?YTAFLL#DVF;:SE4EP =U9$KT/)\\,2R3KA4P1QU;V]%QZD.#Q
MS?3O(U*;%*)+4MSA3H<L]]_-SI/8SFL="IAA1#VFT"2)KX 9FQ-AR7H2N]];
M2/F-&=G8EGGQZB(- []%_=)RBJLUJU$B*"9$,7AP_$>8-/?*/PL@=N$?"M [
M0#I'/\1IGI*$K1< \>UV$7CNT;JF/,Z>)=0D@]^O51AN;J#XX7[HXP<?:B87
MMP?\_LFH49AT:$B[Z*)JJF,I8KE?E*WZ1.Y>A_&_A]&9[MGB/R]JL[#Q6&J.
MIR6!2MD\-RL3$LL_0'+ +S7O;;L3'1JD^3BG;]3^Z>CL-[.2#RVRU_1Y3XC4
M>H0L'.*B3LT%**Y.KAKH'TE';;;,KD"=CSG#<5>[\,MBKCKTN5.XT9)25Z]>
M>\-Q]>"##8?/:>R-^#O(,>"B_M41.HA7:A&>#F.Z9F=AE;B1'"^G>6>?[AZ4
M:-Z\>]KOMVZ;O,,KG8Q5CH_N:WNDY!/3VW+F:;E;3L9!X.B\ /B4CECDIT<"
M<716-E_&D./)_U2J-8(('LY&,9UE5F7Y0Z2^NDK2;,S*ZKQ>%9AH5]M1LJ-I
MPJ3Q[MV_\@U.RM]MZ+J82[*V_)6W#7QI(6B.M[+DEBM9,K3%Y4'.(?[P'X0R
M?!_:M709=.HT#:G[\;!YTC)5:\FEHSU'PXO<)]G__N1=,_SVJ4?8SH\?7D+X
MM *74Y\(509> O:+<+#.>#CO#3KN"1_R+V[#,VM\:1,6=_8\=\<$?U,P;%.3
M -B6X;BSD=G\TKAKCH2,<CG?J]FY4W[G7FE3'^&%^/T"0!4SBFM4Z9,#3226
MW9F5[%>\ F0W3 -$' ?S8R,V%\[[33:&7NSB'$D*77F]ZF;P*$<O_X.C:$Y5
MCZO<QWI#V*0:MP1,X]Q "_.:L%0J;GH>.U/0LVM^6!H\>Q3,"#');FS1;*QV
M.%U@ZU[41_KZPJN@.3-TSE;5#]7\Y!/C':;NM$0G!;+9U 0$T^$<DYC%-^./
MH:0")L,ME,8MB"KH$RQ\5J1R1]U1OU+'4>RA,Y/[W?5$ U^]2MS1.IR"Z<0V
M$QBF'#B$DT:M/;R:]KCY.%^O">Z.)S'9?"5$:OOY3#T&^Q'!)+1\]D(:/$CX
M_5(\Y9;!6)UX>P ;HIV$+DP7!-(S2+*$-Z^ &+Q*&B734,M$9EL/W"$5;6'\
M_(E%>(9G4V/_G[/JYR^0?L@[:D4I>^S<<4I$R5( W.+>'D<$R(&&?[@*$O/#
M7410GY!U$RL?Z%F9N-IN14,NQ\&=U/<W6>_7+B+U^A;M;W_1G>%'.[J;J DI
M6'TPCR]9P8&#T7S)11-&RG-L^!&.2Q!.6J[G#[B =KIE\=?F5!&6_;BX,BCB
M:X-X\[2[L-FV3'I<7 &SH0L.>:>$#]A.([Y"#(X=/X5VKB"#BUVW3%)MG& )
M:#O+'+TA9G/O4.M#8=@RPS3/-,%,^)<I2ATLYLOX<BRA^9%LLUHF5OS<*.EG
M&+]"[T3((B'/OVQ=/J_+.CN-]7^?&>P[^\THJ7*N7TPE#-U=WS$!RLS+)<*8
M#MF@7G;7D 2[!RRX3',VI/U)N.FMV$,:OS\4(7JKO"=MMP'!X<K9ZY^4$N[;
M2^T36G/@JH<R<>\H0MQP3B!W*^A?,>A/HTCQQXN:\YZ2D+'&W=TA80D&^16%
M18Z2KJH!/CV_'"U4^G")Q,U8ZC,<$X53P;RG-,\V\G> (<P\ZO-B/"A"RURH
MV*=V!?_BXJF,&U5#LF'$H)CVL3 K?W>9OB/#>1 DH+Y&A:JF5CF%X\T?UQ*=
MP ;RS#2]Z%B&]PL4U[ ^U.PW(=48?T6>-*"ZQ<=4ISY>S\ ^5K@#!\UL^Y%_
M3[F^ <G4PG\/Y"%@^ X%[MFQ?5(U7!G(%LF"B6<^1Z;^GLRG/Y1<ESDV_:.=
MN.)G-+A@OOM%3@80.[6\Z24:SDO 4MM@6Q'4?%1#1W5$"+.X!R&YS(TL!S77
M@_94<_7P1B,5O4U/\F>>I,_/N5P?600>L>-;\..>W%0HACV8#P) I,, 2N64
MS3^*WL++:5>9C\%(Q=R@=3(#[MK$T4.*?ZPCT@ZN#WU_,QZY4"H K,S[TLO&
MCW/.)=W;[IV5L;%Z6&RKR_^>X4M&VS#%"E(I?988\1':Q-?APE>]SX\1C$M;
M'^RAXZJO0OOX?8<+,ZV2PE<B43*@N>-8&%[**MI2[>;I@0/Z"&OMA"]K0R$N
MAV'F,3)L>18L!4NM1"@1P^048K+MQM&F+$5:5@8MQF8?^]-:K][CK%&;SJG!
MP"^6@"C.!74\D+0GDS9KIJG8O>'<E)3_AD%H;+CCDZ[WZ=J+)V*JAY(\RN*E
MAUA6B38PNM?Y9;0_S=G*+4&?LO5@R;T;959_XJ\=AJ]7V %F)!+ITZRQ$6/4
MH.QPCIV:V+G3>P&1>(D*^'][]D,$T<U78.+OEA7)28,!R#&%!5^+KB"V2Y?>
M_?4H2?$%>&51="K:G$94_E%=!N*[V0=+BFL#&L>-%0(?9=VM2I#B[E[?*H0Z
M,;JO6N)4QO'/OP=O&QY7N:K<?/]U1-]!FNMA(&YW[];30A[*.+EVL<OS!VPN
M^U(SM34O7OC[YIGG5:?K?Y<*CZX<V)A\NQ5PB\JFR4G%W.*ON7ZV,:D\/QNL
M$$YL;:C/VK7'"U=D?UJF%*E_*,0^'5@+5\1\0$G:^'+.@"AV)\N^./HV74X,
MA/3)468#,K+8VU)]1B?DY7R&QH7C=;KV)Q<'/]#S<(YEZ8 !-#ZU,E/NKMK8
M2F34<$TJG5Z1[7V;Q[_69]9HVSY^]=[^FT:IT IT&0/@!7[9*-)KU\W94Q\,
MBX/HIL/A-I='C^F(>2!%Y:?'&T^+.<MT;\@E_6YI1,A^?U@4^6#[7\LHRT%9
MEZ]?&<> S8XVT@2[K4(E D 2>Y=(@ZS+W4&^?)PUQW?@%[8)TPLCH8DKL2VS
M!/+^:C6#)\)/QG^_-?<:6QB-+#DHT^:4^N&"E_?1>H?=I:\^O$O6ZJLLBS<,
M4H/GT*"Z5CDRRGA]E9'G_[;BF<Q6%Y,_KN> \FGI!KNM@ MTR<<=6YA%,3GM
M?ATJ8\DUS+_.KS(,^*.^?%J!>C,G0*D<VLTM.@T-HYFH>3POH<-D@DA-[=>E
M=!+/UF7==-?<9I@@] <*2:BV>U/CKO!PA7Z-8"5Y%:'#5$#BR*G_/HO_OQMX
M!5Z"A3/2';1X]>4GZ=Z?,R:9ZW<]]NP,N%3V-;[5)T;D">,B^7\/N:!].5>P
MG>$(7^0,@KXGFZEFDF8X#U,D@5UC2##Q6<R-KHV:!OV4U_Z$4OM<^S'&-[O6
M31HQ!"/_W9_0[;MTEG]R8T RYP"VTPY!?813*UVD$M[AQ;GAX V6(OM-\3PR
MF=;(NC1B<Y:'QP;%^(_6>/ZT)#RT<+VAP?F%;K>D[-T-8.[_(#8/=V/3L74+
M3SF^_ &2<ATKX+CWP5_A<M]+U<86"!V38:$+MZ,;LPR?9<X_<%;OZ[+SKCB?
MTXLN9@7PI5D01>OP<KC*Q,9L!N0N1./SNA"2QC6,L9Z-J22XZ70(J3^YNB+?
MUZLJP^")78GMP63Y]Y8KWUH6?\) _4H&C3G&EY9@>IT%GU*1PB%S\A/M%O/D
M5=F8U<Z+NQK.1\+DEIJ+X1,!>X^ZIJ[))R:^C[C_6E7EFPFX*P"ROBK83E>X
M=@B*:8^8+N4.5<353&"#<!ENWW5KF5$/\XRJR\G$6=RY%M.KIK*IXP<)\*!X
MD=]>W5IZG]%!M&KK/KCRA';'F$7(MO!]Y.G-9^:E3MM<-VDP%#Z4&://J.*X
M8&:(XNU>M-5D 5"'YRH* !>P_]52E/ELL-KL:F8H&E'V/3#K1=GMPI&/]74^
MQTQ?^KQ""K^=>L??Q!0 W7BQ0 $@UZ[GSPXU/#K*^,TPH\2&[YZ3G-P_II^7
M=-HLSE"'GM(O=Y?2$-X5&DW']2,TIV-"NC!JM2%#(9[C%62E=J?^JP51/DHN
M1P*NN)[VB-\.,^'W$YGGPC,0\HB004A[+3)&.-N_H%7 >KY2N$*,IZ&)LFW-
M=[[^F )RCX=QS7S6H=RG$GOK\U*_Y.[=2N'50>:=CP!1G!,S?$@%UL&6JVZS
MVNBZI3#OVSUJAUE&:I8YM%!CLE^T6A+W/4WW_IKFFY?1%S1JOLY^HS"1PRE8
M503U"8Y@0V%Z"("L#O%Q&T7J($QLD(::Z7]7U Z_6+XSTR;9<9WS6_3O&6_A
M8RX!J8\5[]<-Z ]AZU??X4ET=@74Y2F86;@$TXKAC^?"/M^D*,8$TWM) B#Q
M]Z"CC>VK?K:4[ZC1TY;VK'--3<<58C6>^3_ZZ_18"T"<POK"[F&;K7KQFT."
M. &8_DF4E,70[HW]C=.-.!@Y)F'8@W#3*$P[=QL]T++6P#<GVD]<-,$00@JU
MEL(\ORJ%[=R%%GH>K(;H-"2F:YF-5U^9T&-&X6HR]P>1-#;G7 @FN,./\8]I
MQU933_9S9JY(5^Z>7D--#[)_@'\Y^NAPWDNB+XZ\2+<8[ADR8=]@VA%[-LG,
M!XX\370=M['0>U!PPVNV&SC_M37>7ND",%KR]7$H?MB$E,)F\]+X"&SG;FQ0
M.,EDGLCPH@ZAV/F\IS>'K)<Q8O7$V$5F94IUDU/0S=7-7KEWCB0KW<Y(:$,/
MIND:21T.%-F0 V_/$T&DC<A3D+X,\^//C##P'8,+?TN1)0H##5'BRV%]U\SO
M4=W3L)V.1.J3.97_6,&M(Y@=WFC3B?;(>9PJ^*&["[&9*_7TBZZ*&K_U%FJ9
M/7<S_K4DNGEVAUL_8*@,K$"J"P%%> ?69+5<14-I88:QBK^'E0,WPO)#RBG!
M:N?NC73'B;W6NKFI1:[$J@93UN$#K5I24[CX$D(,LYFK,&)C_.HG0K4=Q2+:
M(QH8*WFO>RM+)'K8O:7&GK'?DOTXQF]:UWQ,#]P_KG3TL>,V\=),B#_.\VHQ
MHIC/6%GX)B@ 1RP5]Q A>Q-QK]0@HQLNQ2(F\G<>F5?WBKL>P<^LO-C3S-KG
MO.NOFZO1LT7@59O)G.M?,<YY\#9[%53EG,$,XM00U'K8%AM5%H+FEL^Z<;*6
M^1LA9?1L5/$PJ[KK^)LP_ ORA6._4)WJ1H]^^<?;]T=DMJ0CITC_I:[!A$J1
MR,TYY,7O?QL@ $XXWZZ(07$5*?SCI=4"P'>N00!4['P[^E^^3?N?P:7SFK$^
MJ^"NI)0>9(K\?VX*Y =OX%(LD%DCWM\G,=J@B>_KBS%&3D$O3Q#$?^UZRK%[
MK;KWU86^B(7>0OCIZHT#=@"ZDGF#+Y7_&C-$J9/H0<U44N48+O/..O-6O9O<
MW::X+JSN<Z/S;>.++.6*6N_@!))5\K[0%U4:$6]B+Y]+GI/!08[!#P_JR'&W
M$MF:($+BW?!,)5]&CT:4^RY_<3CN>C7'*(A@93659_DCK"9LYX2:5]HCJJKN
M%6O7<Y==#_.,RN+A_YZNRXG19Z^R3)97F2E4Q#*19=TC11^*GG=/N;D*0SLS
M9^_7>B,<$U2O3%@X^M@;REZ/W>'VQ73PB^ZETJ9A""V>1.H#F!J1^KS#& R/
MHZ'(P;"4.57P-N2!0@@)%JCDB)B,DY.1?M<NM;U)=R+??'2LU379-0<>35^\
MA"%!,5SD/1( _M!D]G?+99"P&=@@)+@[+)N%Z&1/KE7\233B T$;(K/6QP85
M,]Z;^,?TA+FR[UHW,_9+6'S$C&&9SOCL&_RI*0% ('(5Z>SG8WQEM"W+(<6X
M$9%*0J:U:UM4R_5&37[Q1.X[>OY9PD^E+J,7_0;ICTY?(,YL/2TQB& B__VW
M_,3J<N7\<!JV48ZQB=45GH';AC'S]D+TR*G.?7<Y[ZGN%'C/\DUD16[#:^41
M^]YK'O<>G9F6?F5%I#Z%O#Q2+H5""%_VI^-GS!W:1]HWW:!;R]P.;'</I1W'
MPY"FL[81[4?KCZ*TM1^MJ:BOY=V#E1D\D5,"ASF[P=5>1)TKY(&;.-9H= OH
M,N_8J&ZXR63>)*51+_;WWR>!5E^JZYV5%W*T_72&1*7D/D8D=F'F$$SG \10
M2CQJ,U=3GR%7'>,TC^V*BW9FR<7SC7Z0KMX8#JGV[-$)*:SVBVOH-1VTT>L[
MCGH4;QOW[_$HD5A()[SB$01 ,"X#M]G&XS^W]-_N@VF YC141C7:Y2GZ$(AE
MTFXZQ?EZ- W/A*U+S<V[1:@:<^Z>OJ>9[*Z/P+K8 5O_I\=%7XXGUQ-D,6_3
MSBQA&Y#+,Y$L9-_!Y)>;<14QUP_=HC@UQ;^O&8J-C88?LQRYJY=>U6:NO3MW
M!M JL<-@Y_COL4P4)?MLMB+:&4)N+=H&W*VGUY_(ET=O2[Q B(>]2>:XY>A'
M:?@E29^Z!O3M_,P5$@ 2(ICW]]Z0T;=!#XX7>(LL+@".3')-87?:'??Y@E<K
MF\W.%P@ ?)8ZY]W:85B<RWD!L)E[]D4,G<9/HGM[=6X4I-0T96I-;BP>GG15
M7CN9>_ZA?=-C';,T7R.7KCKU!]2<H:NG)9*@6C@D +ZF_:2P#RTA-LZ$S!I"
M#9X*N>-?Q];#.5KK.-XNBY4'_WS!?W4(T:.)2NUQ2E_K'/"7W=RDX8,J .Q/
ML GHA=J"_7Y)  P<)X+I7>/8KSL0O*CPA6 U;I''0Y]G B .P942 /\'>V\"
M#N7;]XV/5!*:9*<,49)0V4HRE6Q)HK(S2;*%%!D9<XGL,4G1QF1+99FR9INQ
MJX3L(68KLF4F-2YF^U^>]SF.]]=]=[_/_;SO^W^/YWF.YSA,CDMS;>=W^WR^
MW^]YG@^V(3B:A 3DS[W EWP4QQ3!J"(J\6$?F_BPNVD 4ZK;]@RW ++*GFGH
M!6PXC=_X,&H YB@?EA/#A^W8SH?1=O%AL95,(5X<G',OF0]+*+V:A*PH1RQS
M_\GKF[,R//DP9"$?=A.Y*)CW-U?+XTD/MR)69)$_[+1YVVO>0YSI S#U$S(T
M-=[Y$.#WJTD"S:,@]%PF0KP3D#]K=3AHBAAUPG%X>-Y:/NS#)MQO%\/]/D93
MN_+85OOX,'P_']:(7[[Y4Q%G5.UL6C*P4/.ERNQZ^_X3T392EUZB =X1?>2O
M*1E>U.YQ+,&R^H0FZPBDTCX"IA"G_B<_0BV&01Q)?YI!RQA^K)INTQ8D[O@9
MXLWH <\JALTM]Z%=\LI!U$_:CS_</VNI7E_W9'?F!1F!,UNGVI&>^"2 <88/
M&^FA9\Y!IXZIL=X"B3>TYUT\(A&)]0(15)'#2-[F+.N*L"%-XQ95V*'<W7H5
M+S\=S?KD65$JQ)&^MFHO*F@XZ\4@)H!]!C2A+=TVBKQ&'=L61".T$*)[(H-]
M7_K*8^6'EEKM>RVWO8I3/1J783'6>4[MZ\9!EG:;!GY$L(-4;3#70-=.N-&1
MM*<^2"V.8_6<L[G77D Q3<>JH(W[]-*&V\;#VV['=)HH"8@6"+3(PU:RDR!'
M)P+=/ (:<8E!TES$$/ S?[C6X0_V\G]EA1K!J2QSWC&(*0Q?XEW*>5&)6-X
M^7>WQ\N/XDAR^/9&""S<^5-0-[X),09.U&5@MEN;"SM7^X+*ARW#/D'7>8):
M@16%LK<A*!V]D/5)/?_W4$Q$,HIA1TXA;EJ=KN6'K!YN08WF-3NWIR/F32DU
M0<1-G)/)1]_4O1K66EU)IUM^[=+F/&X&6BVEOB)]@]W5KW>DQJ?)$'B9=Z!H
M@[N7YE^P-8ZR9:>=)QLHB!&2-6G8>"?F-/Y8S>M^E8%+'Q];5_>6J-:DR-.N
MJ7[X$:6?T'\U4T[E(Q_F$S3&YFTLH@%C'33D'(HMRVM&BA!W@JA&5NW%VIY$
MC"G]H*;R:[9;?ICXF'N\K>R;"VY#LO7MXN%V!T[3WFR _$ AB>%J$PM4[,B<
M*Z?#054^K/E!:!%^T[A_MC2#E<X\ZT1(NESBMN[S#;=.E;&'M$5/[^@C=]>E
MH3S.U$8ASWXC**].]+F,@_$F2.6(>#[,-RA^ C&HZQCJ75,QB#E4>GS+DME
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MY.Q&&JU;8Z+."BZ\7&T;U^8)+_!AJC;V?-CK!8C(]:6[3[O+0'X2TK:[:D7
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MF?7(U20-A *:3I0:'P*;^UDJW*=\F!=!G+,-K*/B8T>#$@)"#GO;50T4_UJ
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MBO_E4OOAYLF\'>"8%?,P*\NC)/Q*R]5.^<A'.E'PD_>[KEXZ>%^T[%'6V='
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M?#W]W53'ESV7BYNJK.Y.?95]]V5U;;-H@&';DV"\OP_CP(9CQX@R8&CAV'2
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MZ=*JD:,O%VKS*O*)\AEQB7#WP.M;%T8-'&HYH5Q2>@M/&C0(8N_E&,5W\#3
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MAC@Y,UGQNU&*3]-<I^8+(#N56%VS)-M]VT<C6_8%3% %(Y20%&K67V],*)A
MV408EDX)KWNB8_7ZJ%N?U(:"CSIK9N!PMM J3R9*\CXAR_BPVR0?>,*$1!UX
MYB5&?2A44X&.B#5R0!?S)$C]_1]JG78*''_U$M/L5O1D[^C&-%0FBF&/6P]A
MHEKHA2]Q(&N.;N"$,WX-WIK0'\;LR^6L8505BCL9Z5"""<Z6V\;,T%9=ULWC
M[[$77G&S]XY=K1!@9S*U:2C(?<=@84/&NSGGF*EXR+F+@=AFJW%_Y\'2#(6(
M0^AV=_/K%!A2)^J@WB)NK@MZU9?0K8*QD!BD*WJB$4)$0VC(F\UI(N%:1FJ^
M-)L-,X_VHY,DW;I96\@NK9F.J,=^^ZZ2]MH)J$!^F_*E*!$:H4.8M=PGOW3V
M,1;:>D9)3>Z2S/NU6[8L6&6X)'ZYR0@74]U<A9S&5YZ#GBU+MT2!2N!(6)ES
M(0O,,_6F!46OXB9-&D)@PM'EI57A9_/GID%?6QW6;>[8N5%4?=<33!X,D2]E
MTN:NSB#?K-_W CW<[CQ?FIGOPY)PGZF]_Y.V2U,SUT3U[MOYYMS<<FDCF'#1
M+T;U?$N)'X)ABQ_M[N )FS!8+$_&4LOF$32>E3<T]VSWINR>R6FBU*9X#4UV
MQ]0I ;NJM"<2D_>?PO-(GHBQ(I;]ZBI<&/4ZD,Q6PIQ1U&8TI-;HXT)?BFU9
M:?&:LS7=DQ8>]LI$N=E&_+/D"W*4Y5JX"Z&; .HOG.K_B;N)JDA-S__4XN_O
MS[X(SBCX^Z.CS27]69N?O]PK=61ULJ/#MY)_1P'.08:^,*I!\6X1FZ;CDV[H
MW>[ELFTJ$P.%N&6X:WP8O7(XJO/:UN'-S\\_[RXFC]QR+5@RU;]*W_=I*S&Y
M)*E(_HJ;UPZII:JT48=))$=2FV<CV,:'+4%LIS^R,A+"IF*)$73$.&8C%U_O
M2>LBSX0*S[5G>:@]4\.O/"=  .9R@%6'(6D>03ML1;.)FP])\4.]?MREW[W0
MDRK .K!&0(F:VG4KK=V2,(O(0VZ<<H)OH_E-;D[19_2[IEYA%2U5N(WO4+-3
M=^YZK^Y6$%&^W-F1K?R^'+LYQT9(3;>H;7&7S0@?MNEEV7/Z.[72WO3K=9\6
M=^_*);W!?<D;15*R\3_0BA#@?A//>_S=_R>-I('T?+R@Z$NJ .*UB7+?KCMG
M5\N,B67%Y5SU2/)@'>2T:1E/_UBB_/R\'DVHX<.HA%#R.IP&O6-N%B)V(M#[
MN#S_U%A;$'TCW6B;\6-K8!-WYP&7@SUO%L0<!&0'_,76O7UYAD58JLRB6[X[
M>S>LDBZG\:P:68)93]M*V$7=^)-Y]YX$0:V;BKQ$"K-T&K"]DMSO:WG(*7O$
M-!@)_Y>FDYLHR2JUFUCU;TOEEDN:\M],K@#SMQ]?Y,,Z_*L(7^:P3@^]'.--
M%,Q"GA$_T.C:M98Z*SI"N,9)W7.7=S@.Q,S*J6LWZ$<G[2I5*?Y/,06$L)=;
M7"_%/H=>H+:EXMA*G,L?,>M6]QH-.,Q[34.(I=@)5WR%3XWM,8T;OGIF"["I
M?]8=C]*#_.79>AVV%+J<=3'&BMM@C)Q!B-5O,K+U8:+C3S)OCVY-P6Y_8BHT
MZJ&<X+4_*VM38\1I(66V-;:'Q'"&RW&"A^NMV9K058YA%=#:C6%V1S!(:DH8
M=;^?P_7=5<SB7*MTI?W?'YR@IPK&SJ\NF@U#4LH5A<'Y',@-E*Y&%HP!DQ2E
MB1WDDJ@0%#[FFQE65^)E8527IKQO+BOG#G-QSV52&VH#Y!'3(.<%"7!:"[N7
M#VN],P" +UDD4,V[N0=4#HM'7@:$9E&O.SB2+JW9A\ T."N>HY(M20)'(HK:
M(K.,OP8:.)^XWEGVN4>I9WQ?_-;G3^$#N__!-"0"4X=WW,V<]P;'W>!P#_B;
MGNE!WD[@;3+D,8;%(2"]\4L'9!B#D)Q(.X42;$VEEC?_D5)=1@ORS*UU>"2)
MY:'#?SD8/B7"_8$',R>CEDY %H?Z']*\PX<%U.%&<10D#D*/R'*A.85"C@5C
M*<%((82H26)  S 6*7@&(K27W_?;>*/MNGG[X/?LC\T:EKU1N GCAMNB'$=F
MKI_QK8TMLPX*EC UVJ]UKC=.SN+[!E7[BJ+AW/P7[PIV>%\:'/8>#]>1?W-#
MZK.;A?J!NJ+\.79I3Q?B+L"P6%VE0QJ[!]M/+B^<!YAXZD(T47P,5&.=Z>-H
M4+=MU)9W)(/I-%T)1Y?P&P4?],DS>_IV=;:)QA;8(_?*GL>?XJQ.&HV!E.,D
M41ICQK1IX<KP-A#H<'GGD=FP.VBU-F-YL#"W%%_ZJ;A8,]![T='RO)N^C+G]
M[C!%M-0"61J* U%\F!11^AM>1"A6A<%1E'@=/=QDB(N'5=0P9HXDW=',>\H=
MW9XK@!AOUI:#X0XR4//[F XL)Z9I9A-N[*Y/8=_W2>D):;#.=WWG-A/V'?+-
MMF)PIN/K =4GZG?8GTZF9@3</-,Y^=5=?;$/D+":MZMN+V&:T%T*=HT3!&6R
MA][O^RYW6_+*#_^[9=B9H%/.U: "(/HK9N3-^W?@%$=BD2=L2X\T9SF!BU#,
M:++2C=P/2/(&)@X1F0:M@!!XQCXM0-?%J6I#R*?2"^>[F;$7^O(VAZT398>1
MXH"F<P#E<U#LZ,*<U?_'WGM'-=5M[>)1$ 3$(%*D2)0B(,U"44%B T1>1$!
M:FQ($Q ! 0D)HO2F(*(H1$1$:J0$E!;I B+2.RGT$D@H84/:W9SOCM\][SGO
M^;[[C=O'^/V!L#/<.VNO-><SGV>5.0L"/>C<H':&"S$O.-I?EM2/+&2Z]2J4
M:4<'\WW3=\I!EN/E=[0MG=YEV/E6= /./)O,YF-Q( 8;'(B:HPT(&2#@19:@
MZ^#XV5H.9"H?)!0K:F[LCS0,2\ '!AS)X4!DG=DU#\Q8@J#K /J@/I8/$J>
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M18%1TIF'/DFE]I]"5)TEFJZH;T_N6US[GRHQ)%C?JETR ^5(NQ*RR!J#G?;
MC*<OV=[$FHIZ2EHX>]7^]H+B5G##H_KCTN>$?NG?FMZSUS182V3'YBH((7:
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MB^'.O-3E9PJE:P,LDG>DY=O<Q&@M@A!@R;CML[=O);QL3[L,<20V*/) L^Y
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MMKFOW?]<U:?YK.AU")S?6--3UM-:[9'GT:'E]]$?(FCO+55]BG>]0$CP7Y8
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M,+5IJ4_U%(,9EY@Z:6;B'IXY(ZV>).6P2_4G&!]'&U,F@ <>N'_1D@>L+*8
M>5D,>0,P+@1\SV<L]5RD/4NU*Z.&6O?OYU)Z-/,I$(OX'V^M_K&_;D 66T*%
MS1_,@1@=IY:"84< RU:O[?R0N#A:Q4:")KD#,<G;_,]/U\8P5+>/!VM6#>*D
MH,/!I+N^%TA9:.!BT=7=RV&#V!+7'.DJC;CDZ[?3V//;7P^&LG!C< Q!D,WZ
M^K<Q5'V)KO\(-J@6;-#HWQHD=F6K)&:1:TH@\2F&:A.;'X##T'' C5994= *
MGDF:/S?<31R _TMCN&%=3RH6///%HL(/,_T7C?;[9\L:&%JSAO\O,R$PF$C6
M\J'K_M 70AX=T#_B#B_S;C")TO38[Z.JG2'\[C)1Z%CV8%'0DLKRX]7$X>7Z
M##E:YV+/!&PW8'3Y%0=B@>\:5M$]!=%06;(L<\'_>3S=J0.+37\K!@Z-U&2A
M8,,VI,<*ZR]M=B<%7IAY&'GNN[3^R4[WJG_16_9,_>*J;B97YEQ:>)7!V=I$
M3Q$:_+I_]$7E#>Y]]O\++>>O!\&<]385W?D:351AA@)M\"%=-C]:)%857390
M_[WM>R[8;/V9,#C1_S?XY7]A,^,)4M!(?$E8/$,>_Y\PM4%HW$=6,CC>*S^Z
M6QFF2%75GR8PX.)2D"*;U_1?#GN1QN+H-PZD_;^VMN$ONB$1N(L%E)=9TBWU
MG4QY=3Q0R="/@9<^7-Y<A3)WH9__YT#.B.[ER('HW^) 0K$K7,3$> 0WGO@)
MMEM?U .S7PLVK$/*;I34BO[Z2LJ,[ZK\@]T'+!9M]#9$*TC8(5#6^)!A>]VV
MF/ R;/V:R8)2T3YY:OBOJ;U/0D\A73+ZUK"4 )+9/F"&[D9+?(:4^VB"SD7,
M4D33WT'$4S:4AT\28A;8L!MC<Z@=O]<Z+HQ]R" 8E<<$8O+.-&:^9(3M_K,/
MK!C]GP:F_]B\-B\0B#-,47+_F-I-5B%*[*CA$W,TB><E<4?H:4T.!+@.0@]A
M2W?[@1=:$=;FCM'R!:&;9FQ11:8H^&(3X(L)E5B+9?X;_FF9#/F#;'T; )/_
MF/JX#8"&QLNAVP!8L'!K]K:PU<V/U=WH_VQ8 R7@_\FXQH7\M[CF2?4<B-7$
M#RN2:LH>#8]-9W2- U=N3[U_GGFK.'38IP5M1T'_4]L61N&W,3N!*M)&?8C)
M)=JGI_KI 3IQ6B:?B5\A)R_*3[T SNZ>M,%V_;W+_^]VH@GH/SU\M&>[^$R=
M@V;P[K4.77HQ8"LM5"1G!EQ0."71:6&,+9@M="4=^QKD:Y%S "^?.LG["RV@
M+XFN,UW#1#TVS*;YTE\! ?F![E)?AG^]S08N7%97/US7UG*8))6CM>8L8O/O
MUQ>S+*'!(G%JAA-&/;@1E=BJB^P4CUW=>L]7$]//M[&U-C?!ETH&,+3$B4B*
M#4,/72>K+X"T[$="W6AM'(AU'TH)*&T(.$*P>-I@YXC'J*67-1P1JQQ1O7?^
MAU+,1;G*,LQ!/'%T>5"L@1@RPFZ$[<&",<F>.OU68: !&XT2HFEG[LUQRS,,
MS]01KE[TNO/BNRWW&P7'\I13A[C65)_S&.?9P:.1I\ERQZALO',(/6#(AZ[[
M,;7-*]#S(T5/!IJ]K9>X-V@M#1A ?8.YK^K[XV5*)DF#,EAM"AW2"\F^,2\N
M^1 Q?\9Q]=+=>V5).I?>%$ZD9QE:-68?KYC"1NHK %QL/C,HY19#OXX#X5E?
M$%.F-6O$;-W-4 ;AW*I@?O]<5EW4C7EL?EE"?_VHQLMC+3]#IJX?/W2-=RE$
MQ*9]>_^'"S1N2Y$I=I$,I]CD!>JT4??64.4:V >[_9<I4O=6UU4\K]"#WJ]P
M1SB/2!>7T\]%/N(2W@V!F8X!D>>^]!*[O''MI[S5GVB7)XU^:#\&&[OP<$R7
M_QL" SNXO;*)H!I">9 ':3--A&$-4OS(3U4-'%X4:4>#QZ]+^,<>L0JR6U??
MP[CM^D5BG]#AH^^S[CZ=P)=V4GH8"'8GG.J>WD))I7DC^I9J#[NAN&LBZ]BR
M T^"-SV+_ U[UN(O>&ZN'KR=,6YU;VQ:WJ=*;-P8PD(D.G3=Z_OX^W:_FMV6
MTK.D(;7Z-^9[CS6=?'Y:>J+&#@N2[F$=]NY"!IS]DT"]#&J;$5[BXN/^1,8?
M2"W #[_/!2"(1WG+]R^O5]G?^NP.U4M4X?OPQIH,5ZZ[5O"ME1O3XSW8.0$V
M["SC,%.-E;5\?Z+\*VVYH4.J4=RZ>*<8'U8U,^-R<[#*CW;@&F_VGZ4$4@.T
M22+K,TJ7>0B 47OHMUFOD!X:X>S#J"Z$F!\V<M@LUO/):IF ;KGL$EMXK_4E
MQZ@#MYY?^97M*!(*K>"-8NKY9Y&*BX;0KE$;;Z$XQ7?B$F.ENL4)0'X*]1*!
MZAG %'[/E-/G*0;@!?:!-3=/--$>P\40Z'J+RHR3K%QZIPX/^N3&VT>;MA/M
M(TWW0.>%U2H'+M#9K&?Z:NQ&1$5BE!?2GNP=#A=BGJ<FDO=6[5KKK] _7(:3
M5:@,RO1_(1\X1G83?19W2_U&J=@A&.H&\+8A+2-'/_83$-9,7NE%?QP^_RA1
MU6%B^MK#Z@QRT0 )QA3)H0>"V'@$*4OU'ZC# _(AA>7)C+M <'-_);Q!39$$
MB_(W7A]Q]")<NXP]5'4O9>+R1+0Z<N#K3?%VN YV"?',LO$%8&F2V&QY_LB7
M2C\NJZ3>VT>^K0QT*+-_L0;I[P4E5:82$Q"ED<WH ^ KV>OO9/=D2%.]AY%0
M(CZ"?;R[VK20 W$=41Q<6HY/'+JS8G=>\RWSC?Y=0ZN15=$?G0T8JC^4N3^2
M'H >?#HASA0Y:=>KYYS'/&?2*6B4=?XST$99BQ<U74K/N:RFN>[_1*>NNGP*
MV:J9<*Q1: =#U$I^H.P4+I )5R]UK5AIOAO35"3RQ^S)5WSIC0^"6MQ701N[
M2'9)T!= M:#%](\SCQ>+.RE0,0VF ;;4]>*HRPJUN)Z9#.[AP/L_HHX33F';
MEH<:V'Q6C%U(3[#;Y(Q FX$ A9\1\W@)YD4J&"]:MEHH7+[DA4Y*AT[C\3JM
MSG>I%V[*BI5>.KSRG4M(Z'OQD5"XBQ+V%9X8@\!AX]%><$ !7[<\C" [TJIH
M1W"DN0+F^<=MHD7+]S44>Z:_WGP/Z:[)?1D*^?D.<AQA\?N_;?04;4']QNS0
M%T/U8KB19@P]YGUJHUU+.!*1U?YIP0Y9+1[=,FXXGR2WR\^G[8S*'E&>4%U)
M%=I( YYJ"1O&LOG2J<F-' C5""L%!%C2!BB*)-:%E@9XR72QUE,]_5._<5SR
MC[UR'TZ*(!;7$@R^C5^8'A,JEK4UPB-E.)"G[GABVAUB0(3>28834B22C&W4
MO5&D4>U&XS6G\>1X^&,]=)+>QH[D"N)^VC=<:;KV557N$G=RTCGXA5EL(PR0
M1S.%EME\SHS+3%-601DT'ET2GO'-C3I#QPPP58A?[](,L5"ZUPLOV17/\Q&4
M/4\"8!D7?OFV2U*V9Q0!1<3B+=H,>R\,L&5((!T!"><BY$FJ]Z*&LS<)RS_F
M;A-[\.4CR75*X7OAC_4N*R2%'0&W?5_)KYZ#%6O:3"8R13#T?5UP8C0:\I;-
MOSU[DTMSB47RP1H</4R_TF;J;:N=T;F!WDUIFAO/ASM%7E64FD[^_'3WUM%C
M@V$7WNOWP_*==M,>)4^ PS\GH_=;HB.A(GN$,"0AON=6FM:+$[H'"Y2X+'()
M@9'G>C0H:X4F#J45E=6GRLHSIH2-.S\HG_:JR9\VT1AJF-"#4^T=S>A5R75?
M@2 ?ANH-0!\FM.T/R.%>E'Q533!"[N=JL]J4T>H>E.U8F3[Q>E!.LS=P*(>Y
MKTV#/Y Q8431H"9Y6BR;FQHYT (:\0<")\R#&;MT9Y)(BB?S[#[**>R4S7LF
M(?CKG/Y*7I9#E[V-/LSQ=B^A0-_#5B!\]5E0,^O-6 7A +;->]"&/LCZ#'<!
M^U?;J F&6V[4$%ZPZ\>3S 2!2+9H0%3U]4*U]>EWZN,#1E7?A"=_B([Q+_V:
MO7WU\J$!^(0&((M>9! 3 ;F7' AN(R*BRIMQ;1;-CR;=JVC1I*DM>*P":2I0
MRNG2TR\CH@?/?KGPD?LF 3WS'CIX1J4%_;<BTU>Q#'M4 YP/[H;>-](BEC_A
M'3ELG5]@Q.\9[^U<?O&!T",SW9\CE!CZT?\VV93G)$^=?C(!VTL C)H>:Y5G
M9\^76PS-V_DOJLCK6*]D&LN^D#K<E1*3HB=T&=OJ*4[_V8LGCAWT)?,N*M)R
M&FH/T0(:/#I.+#3BBQ?[J:;^OKDF9^L_9@@&B9P,>C[F8-CU;<\EX9/)KQ(.
M[=BB&* \V3\1U'/PH9:)R#H^_6W2;(\2MF6: E,TN4;A0#Q9+%>[.-A5LZJ5
M?#W6N,)#-PKDM 4D ?[,>^?JVIA5YS93Z== Z !C<)UJK2SXKPO< SH4T PZ
M0/IR*/M@H$>=N-.>WU)-DI7J;]7H;V<<OZ2H-Y8$)2$'7PQJ&'PGA\*]/V-;
MS "02##W8^CJU U*)VC!)/"AC^?@7)[[B3/TSL8?9F%W^[SO1GTLIXLO?0IX
M_<O7CZ*Q]8OO>WVH2C?>RQN0)=0E#D;2[] P%#1X>QI-(TZ?!WD%<"8Q\"*V
M=H!W<UI\_PMLD_-^AXY;P;>"]7[_3#*0CLG;6;3R]JF2;"C\FBM6CO6$ W$K
M9MQC-V$$.!#W(,W7B^IZ_L1\09MK7T*3#^)&7T#++CU+NJ):;V 1='2'UC0&
MI[%(HF'(<*8HC&[.RM*3(!+* W5(GQ)I_% I#_BP-LAY78QSYX:1VG)M20:O
MO$]<5G!H3-COA7 ]]!R:.XMM10"G.1 V7Q-#%TBFBP-]##2 O49[E3M1*&?R
M.[6A/R#C1#6[I1M*3PE/KJD).U,O00X8==!W;'_PP&@6'Z_G0\9&((KU"VF*
MWRNOX?N99ZDE(6:&Q<I?'1S/?RHK-DI@I(O<&0\]*QL2?!'7=_NWE__;R\M%
M0M5B9@\^V(JXJ'Z^>IFXPGO'>H$&@LCV>1!V':$<SMS7KS$R0W]374W3:(9)
M Y8W: '1M;J$P$^S'I+:A=P5JJ7GS[0)#]J6\7\XMA-%C. 65J$D H?PE*<T
M+OH4^)SKR*/ .LW;)MF<=F=NX[%1U+IRU FGT4$G4U=UAX02$VGSMAFNF1>?
MN1;_LN3>/_S =>'$$@(4I8;<P2H NQ0!J,S48R(>=\:M8<+$AVM?T! -3M)E
M.I+1U/%<[TEC-+<<#Z)DZ97AN<>5QX>CY8H26PC J2PV'TW\>_[;SL&>"5FF
M(Y!+=CQ-04DB-:E>L4&^^>Z/RXJ_5"38^^X.OFO=\.,N_P6Y6[9?<M;X:Y&L
M8CCQ#:9D@X(1>U( -!CVZLF10244^.I@<#UF'QMFS/,6.Z?3]46!7'GLA\1=
M?M%N _^;.^0>YD.@/*S0M<ZG8&@ZUPG(B]=C=J%&V;J)]6Q3DIFXQSZWU?&1
M00_)=P/B&9<^]<D??7'77J)X:BG>^.8!R4U+-G\BPPR]G27 J]"2" I)#4 ^
MFLJ!Q(%VJN(=LZ6>0US>S]2@5C7I1*C>PNBD!J1V-4BVN,J="AQKRY NVO^
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M5V9^X\3\>J_O*3CI'"AF>C/57ISVV9A\8$6MN-L10'$$*O\3U6W$P)$T):8
MU"$=S!DJ*=XA8)M1(C:#<::_(EV<QMB(5TRU-"R=1S..>C4[Z)XX5O/Q)NV]
ML2$,&V>'.H%=0 )VZ/,,NPF.-,L0J-S8K 8W5WP'^4L6W^#WWAL+6%ZP4(G[
MY-N=L_:GSQ0=&%!C.,RH^WR@(OP$'6J>2'ZV6[4\D1A X..\10!V6G/44<K%
M5OJ)CS]M$CV/ D-9"K._T0$_/A[6&RQ6+[D ][]7CUF3MQR-$UOEBC$:+>N^
MRBXG[BY&'=-*--(,[-[/SB.2B[IEZ$D)][2#;K&\J./IC 6#V7E:6;XY#2TR
MXYLVFF.6A-F(+5$^A.Z3P(ZC (=/?"O;&]IT+4:C35P[(<G0#HC&F%:RSH/7
M7P78I16K>$S0"J,R#%Z57S1S.NAJ,;U7317]F->/9RU C4*"0I= )/,FKL=$
M%Y^$ES?D@W(6+:L7]X^AW4VE658P-2LEC/J37T+R5^%(OWOUTJ+9G41APT11
MU7=I4K:"-S"GH=19QUG$MZ 8LP-P4'F6)9IF0]_NM59Q:9MLPB4;&8!5\"2;
MM(J6?P?.?&\9G G[N2=UI'%DI,9DCYI"64STY*L(4@]6:OHW$0[F#OSUQ.-J
MEW1E-/(8I7(.J)'JMO)8^0>6/9&'30[==<O[$P@->Q9(7\'!.!\0@ TQRU.3
MC6<98ZYP#*>"7F$EO[6&;;>G!LRZJ9NW6UZNJ3-?OWL\?OSU!>['@GND";=
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MB8N-,>HM(QJQSD(!+I8-T5N_X(P=F S29P<VU\CA[R[1I$OVX)(AJ#NS-7Z
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M&V*9X:WM]^Q'^0S^R/^;MUJR]RD\#O/?I32(E?B-@X?TQC>R=[5(7L\J ['
M-*,+<+>?,7WG%C-]8ZIR6D-9Z$[V^(&<7W<2O9T.C$WRX7?K11EB/W0K09^C
M')(3$;#+D@?#ODY> /D!E!7@DX8.O>65T1GXTKWF+WL)EEZ5P3=OOJ(]+,U3
MR$:7Q2#%NA58)T >YF[)7C<H=_E!*:)T!]8</$B(Y4B#0Z_\NU5!.SK?&[SH
M%DX(Q*%,_+PZZCH*!^*MPF^1]X@>P'0^B1DFKD$AR3<>27YD= @<I@>OV&R<
M8;IBSH&C*ZJ&DO[E$8L#R]KTP6JJE-/$@C\:O=+5Y9'3\.CF&:]L5G/0N4UI
MYKHGL)G$<GAN40;BSS5.U7P9*O+'!>1> +_GW39A5?TU2BN/"+=.NPAP<M%>
MOMRTN(_O>5-/#96]C(']M>6CK,8;2;!LZ 4LF2WF,<QUT /XNP,;:,1(@$7/
M,*8SG=K/%A^_:M;0L9X-/1PJ9Y>UE6 ??#SK1_]0\WT"2T*6(Z#!5,#UN."N
M=T"X",<27:1F5 Y KBN/.?]T\?MIHU@OPQSP_GN2?7-WVY0>["WQ1J98ZQSU
M7,V>^)6 >L2KK:+=8O(<^:E76UEPT,&ZOF,*$<V>+DX/L;@S__ZF-ZQM6$7E
MK!\/E.DX G"F#4:?G48DDQ$Q.(ENG>Y21+P&T;<XT(:NDE)>G_]%5U5I2D")
M/?MOS3#LT7G9T705?%NRK76@)_8#DA]"?D3@*GY^<0A5CTI=H>/CB#YX@8B^
M*V *7?!<!LE2TNU3O)-$X=5PTW/6)QW&CB4D#F+DRFE_\52^C;,0RY#&]5SI
M%&1BAJ@T)<Q9"BK^-.'!)@:I:R];G?+CQTQHWN63D==-[/G?VUC^1?0M2P&S
M\?<FRB-L^F9.>SP*"PFL=%,43E11:GG*H](&Q;=_(,L1%N8;PB_F&S\(81.:
M/[C+/=1 WT8Z_)F 3%G9$27/68R]PK4#$^I9T8DY\\?)\2^7*0RK%(%DH,!:
MYDWH><G_:DHUSO8(*5N?'W!KI:6L!(XA+L5S?O[9T(M6L WT&XI4LG+*X L+
ME5]#";!VY2QE,8[L)ZV8^]"_[=B/R[+19N=.!V<:B49,,A+H)E.W*B+2G>];
M#^9_>?8:]OCP39?/%GP\MPTY<TZ7EGF LT,I#H/A!_=]O#FC8%M5;50LW&;[
M#TPD;^G4]E/X6-9"TAO<OFYISAP1L,(E(?XIFW+N61"?Z?*BF&_E'FZW/JTE
M^":_6O\13\H>RYA$6-QQXR,=.S!035J!(V#'Y*H[A01:6<8GSB+K,Z+94%_=
MU_#-JQM0V-BS#+WN.F>"*+P#0X\GGZ=L)QD=PYP$KG9ST_?7/_?0RZ^YI?&U
MM3W3H"QE]IT%7/5RR!BVU+\]([^^TGUM =T[A@[EM@X^]OO>-6D7WZD# 0&J
M/, .[ +HQ3R)'4("=J@%!TH!2^PNXRWX!3BBE8*3T&)% QT#):)@<TV$;Y^1
MZF0HSU<+_OSA?)[( #"!]9'0>DW:<0\[<+=XY*X<L8@*(_HCS@^^Z,ZXPZ[K
M]%IA"NE;?2Q:@?>3$&"'PZQPSH@LH>&\^-9/G^\?]>_Q"UIL4](Q T[=;+ID
M DN'RM;]MJP.T#*K?-Y+U^K)7B@YTE>Z0$[/JK!Y[G_?)^VZ1%ZY_P<WMS=%
MAUJ:$[PR]7X[VL(.]L8@!3>ZY3F3R[SLIQI$\G>2%&>L_4:$K^/LLR(7$ E/
M^K!^7[_O>\U*8U(_I>=/LXD N\RQ9ZPS:?7"DN@W&U##AN8,C)X#MYA<V#DC
M 0L6FEQ*5[.;+>L !G))9P<?_KUJH[&A?5%P](M[X](M6]3V!:Z.5+8#H0AY
M:W,N:Q#?-$MS9)YDX0!2>E/7Z3YR0<:61K!;?7?F^9.EXF-9\_FG!+A+'V"&
M0GC$N.C;-!+3B_,>!3C!%X(9]NQ<Y#5D2CY*)!0IP,)]Z#X:L=+O*9EI4</2
M*OWV_4S'U:MH_GV3NE3=<^%\7*XF]X2^H*2ZI3%[V;DX<AVB:?_N-@L_NPJK
MAQ$!P@>KNV3[D0+="A&"5!\"94S0+>)69]K8Z;]1_PC73NU'ABDK"/\P0&GS
M<-Y]PXH!K8F*[05]GC*3OQG=^/==@;*ZR4L6[.VY?QC;!GJ:'10VWX#,S4*5
ME'M6UA='KAFN6ZU[%ZKTO!TY=8AS) 8)D6%RX;+P?Y5RTE;&!Q 9B'H$+90N
MNF*6>8O%M3]E!2X>T3=42$@F)_9:> 9&W>SJ<I!+/ZAR+?LMQ\7GK0>+!KEO
MP]LTR'I.@0=*C?EL9D_ MF:WU&>7%C23RB*"+Z69 C^R J__%[-'/MU(U?[V
M\BD7*-!LC$A' I<U;#C\$(FXA7BCM1?78ZOG]WLS":M,]VE^/A>HH[$FK^]\
M\/!LD$:0Q->Q2_F7RI9M&W->\.\=$D$'Y3(4P6W)/B)XS*QW?![/X>^!1E$-
M?,#<+?2K&5N[Q/*<, RLA5*U%5\,C=Q,JKS:5Q-Y[/JO(.3MEB]%SV>&[QW]
M2XOT]7_A-NR%"Y0#+!.4$F_NRZQ\<0@P:[8#QA]T*I"KE2<Q\A2TOD5KI&!7
M]V,ON;UC;.H+F,IR#'(_T@>9A&CPW;A.'UH)WH :XE5EMW/.8KCHMF!;+9C;
MTUJH/Q@=W&<D0T^,C58M)-DU!_JZ^[Y>R^4.3Q1XUJCP$IL,#=Y!%GP7 #0!
ML_V;:?@ZOB&D-,NRB6Z33DT:.JA/QR?KR3MYV%QI;KZD&Q[^C7"G6HQ>E2=8
MJN!WPS9VJS6E4YZ"D)G7+%I!"/JW-[>;RVMLG9%:-0W>Y+UM;+1U__W[29OF
MS,'>F5.'4KA-]ZF*"YL9P\CP %A.JNI3[O^OOUV-$W(I3@)[""/$SNI$T:TH
M041V <$?-[\#N][-5'?XX^E3BA9DY2J4^QC(1SJD?[X6$TA4&UWW^5.\3TCB
MW[7WQ]/"&^[FI';EAG7,#'?<\\47^>B>P+SJ-FH($KM^=%C-XX7I<$58WD93
MAR7;CB;F3-W>E<<3X/D_\GAJ_U<>SQCWOW7F*G _-;!C.S"1/X.XW\))NU)@
MN)_E=*W_5QZ^2=<9>G_ '+4PRHAAO\!1KN-Z?T-QCK'*0#!L&"B69:U&9]89
M6G<P*VK@X,8?._;&2K#4\/B"^!^DZ&V&?L+=]C9/3;L\2TSK;?30<FIA8X"6
MO]JW9F+5WVU!^D&^M#O'#%[M/Y%Q^LF,@X75IW^?_LC-6=:<";:ZSRMFYRF\
MF2#F_ 8'.!,S22T%NTJ/^'E]AB7[X0XLH(TC,D3'>] ="U(-3=#D6BWWZ/R3
M)UN/"^\O%8R-^TAX.XS743EC#$-@[5!%$KC=U;-<#C\TYKR'06&F,F<6U?Q\
MM\HA90=&$U1NK/0_O8'??XMUIC8BW*XNSB!6^_OJ<,D_OTKM!^[P:/_!U'^-
M3F%>PY)0#>$;" I-Q9-=::0V4#I*E6UI I;3?"NOKLF4U)^.<=6X5:N0$]GR
MP^-=57/X*VI'HO'9S%2ZUMPV1T"!J<#YE/9J'@I]HM[$:9:&;@B([Y.928E\
MMK9@9<Z?/NX;)>9P[#C?K5A+N0.RAV*_'#P%Q9:?N!X=0\$5Z_">CZSK=(EF
MR81F:75#&RJ"GZ4W&YJA8-66GJUX9WE^?IA?+>M1^2GY<3X8XH:=IR/3&+M(
M;&C=: 8.SC(>@=OTHDO 9MR6%*W(<CK(*]]L2H:BWR/>W.DWN63Y_=?>\HN8
M?\[<KI3SW7@,C9(].P6'1B;KD_8:";"LIX[0\_&50A>#]T:T]K8G)E59W#3G
M7E/5(J=4IBEZER])*H2=.,'UVU3\YS8-0M.\Z>P'.._@M-.S;T@IW6?I9TFI
MF!,/+:C%^KWX_:&U-_WJQX+EW]G<U2M^EFW6+NV5&_1S\:J( <$!O,OTYKQ#
M21)]CN)N[:K^2NE^BJ(\DQ%?KD>FZK[^DJ?0U&P6E3-Q+')4\8:^$+^-[HF\
M^8Y4V.\UM2_C#TB *PX"H#0ANF\O[A\C'@RZDXZM7U'S\YU4^<!"O+3POJ74
MK!]B%GYO9E3HR=C>3Y_?#1_+X3F2P_4>W%6A?@.-=A &#A)>823H?(,9[E=G
M.X]JY5%!%IQLC4*U?I 3D=9<G:3YI*K82YT(TDPP]]YS(\:HJ8QXEDA^1@1L
MK;4HX8.;<T4KOK$X?RW0#+N?=9ZN7%4-5KOIC_E7!BSP,:2Z6O-7W@E@:FL:
M>*_)*N[S367LP.;O<@2YF%R<.9S,37:)D2#F&M'H!-I@2U[_'$3O]<Y*H)V&
M==JI'U"+O9H'8.[\^0LUBV%5AWB^OU0EY'+.0''P%HY<@FHD].,/L([NUNXD
MBBZM=</;3W*T<_MP^[8^.4V>N_VR_^K2@NNPP'47$9YZZ<\"L+^]J3]_,?VQ
MHP2FZE7.4B%N4$/?%G3PI[1M?6=Y/1O0^\S=>V#0_\)MA9%W"?)NQQ--;WH?
MDQ+V%*)J@5JK+)&DOH.*D[IGK1@E7EY57<]PP+\]%"$W:Y&1P$<?S:^U3_$2
MYFD5BT>",\V<XG,:DD?J8(B;$YYWF3;8&5(C?L,?\/S%>,"NZ%;S7Y8 ,G('
M9 -:3;[HBPQS7DD=2?!T3T'MJ0E1TQ;HW\=M]@;7C&=)("A90\0,7,-XW [,
M2RNK6W$B5,B=4?!!EY!<(CRMJ\86M.^8"'K:?JS1#75>+-?-<B+=/+9<_?62
M;"J,?:XL]4\U Z)G<6V<'F(#W\ 6R$M/HKXOUTJ?O.QA9@^LQK,.5ZVWNCFF
MP4S'J/Z,7]&%9RO<MQ_=J*D1J_HGQBBOK%L6>MJ>,_NWE89F>G)F"I\_H ^S
MT, O<WI!HBREJ0[UA^&4+^DF=_=U"X?:&=^H93N_AWOOJP=#1,!S'%3"]Q'D
MUY;Y9HA^'=5O,6=?XGS W $91-P6!+\_!FWS_@S2.Q/HW'Q.*L;\X4M\I_/_
M=F34"G(1R? "^#(XDA@C.G(@S7P+GB$RCNCCK[WU0_-6\TSJ?)!YYD^IY86S
M']H[L;=25GV%-PT=20L*C&J0GZGZO41JNOLL^(NY'RD-C@SUEDADGM5<8Z"M
M7#O5-6J/I,X<551GRGX])GXNYQTO[+Z\.!G53&*)K3*.LY-8CL\PI\$MNN47
M0W?"HFRQ;$^)-+#%:*[^Y!YW99QAM=<[^\A(G<@I1R4I;LML=V(CCM;,U.,L
MXGB;@]/P#<2!0)RP_]^[2_,!QUH:%SS]G2=*-8)# V]GCZ./ 6%O4\U[I/?(
MP!@":M0L4*& %A)=#5FS6+<49Y;4XCR$.&'.TG@18*1-'T\+/? Z4\/RA[;Z
MQQ:=^ LF2Y0KW.;B'S'<T)20H&?TB/[(U+_P'GP22CZXMID@F6,H@G$@=[F;
M-M,UH3AJW-;=DJH6=YF[K&55D==)=_>D QGBZBHLL5F&'#L-$^T/M#(*P4TT
M!7=@S4@VUV-2MZHI<#U%Z]9'"IIX!TT.S?=YG"?RR>+Q\!^[&.4B)@+7<PGG
MA5LL[X=H5,P.S'<SI>!N1'GOQ+/NPT!2BN&9Z/* &=LV+I5 JV\W\LK.Y&ZG
M2IN$[HE[8\O798=283E";_YI]\VQ!]9+E( P(GUMVY8N&8]QB*)\PO5R$( 3
M 5?ECEI01]\Q&A>J/M,CE6^X].*X=UR*(*89GH8CM^&!2UJ"&"6@=3!*:\$X
M(LF27E*LQXGUI2#VK;F]*F/4C=PHB:RAU2Y'F:]DNTJ_$CDN+1UY/17V=R&5
MW+T'.X5LA-*?-H"P8E=B^5A7/FZ1N-9E, 4M6*54AWW<4J/\E[K]G&(&WZZM
M'W)*+_\']@!UV@\/H'"@DG.R8; _11:^8'FO;DHO:Z,8.3CK*31="GP:^\$N
ML0SXZ9:F\XO;L$\U?27INS'BIIVG"=,.NTQJ4-EPK0+=+2' ?O([9Q].YK_:
M609&5?ZWT3^P?4&:0:TV<F@QV2.'DPJ'.Q]6M26[49'>P: :<4.<Z<VZT<:&
MP"KFZA0\O7029=\$T;>43H6J;P4R&3E/9(L<B:U)M+T&BLHNJNI78-:P: U3
MK$^$.V>_%!MOJ+:[W W2F4:L4! ?Z0V0>B0*]2KC5"8AVINXMK5EG/.\6FX'
MYM.0;Z.A;*R076Z^=%?V+5$/F_^]/>$Y :*0+2(Z/:'<5H*ZMYZ5PTR.O1'N
MD3NP=]-8U YU!CN#!!Q1<P\8FF""-Q"^8C9@-=P9^,(ENAW."YKUR21VO*QX
M'L)(0?\&E?R._/8/^Z=GL>.?=E0\";!%S,NN$#>&J[%S"#XC#4(*AO?IHL?H
MJX#3FFG1(>'7T [1_2?F%)7I*A?ZI/89^7S<:R\EPK7QKW/F,@>R_/K!8J8<
M@27&_6ME.1//1[K@X6H8(.(EZ*[SY]K><Y%?@W7_H'Q_LC;UMZ/T6<W%]$J.
M@ -3E//>:#\ S^(8L=!9/>UF_8L6KS#RD51K'MM&2>T!/RU%G9I\2DWJF_/B
M;<(G+[\+_N/'L_2-4(CST0+5"!O23 _,S>#Y;0I\H/@B0GJXTJB\ L0-E,"G
M?JME> Z;*'\="Q6,P$X5F=PRRQ>H2$W8,[-*BX+&_P0['8*]X\+?EKE!-MT^
M N-(596)%NSIEON@%5I\@W' 7$>C./W$2+WW57YY1_Z+L)QGN][B:<54Y2R1
M&F9IK<#['1AU?&.2[D3J/^V4%:64WR$XM^3F^5W?+KVK:[JBW_]L9\S=Y@]!
M<J\H8Q$2S3LP/CBN1^$W\1]_U('?FPM!VZX3>F<4(C5+GT;P7.WT.#9GK6B$
M_CODX]DOF<*H6<L<X7G9<*(>QO1,_4E,1;5L;A0#*(9/%N,MF$V?/5<'>H=4
MNJ-<(]H-%JC+#-D,HN])JGCX:W]]S?X,UT7#_4*1.[#_:KSXL=.(@<&I,Z0]
M6(F(W %&B2IQ\CGQ8Q-1@J4WTX2B";K$G+#:T]J2/7#(UF20/6< B[G-];M"
M_!>2!A%+WOOL..)-7&HC1@"LI/O:==,KBE.7U[HE 5\($&!_635[+REW6!LM
M7P^H,+^F=&S Y;C],YDM"$L,,?(AA.N!.?R18\@9(XHVD20CK%R=3LH,/J(U
M-1039,L3<J3%$V4,Q#UL]CW]P'?7- 37I$^# Q 7!\_68*+!'=B*"^LL10-F
MPJZNMO _._2O[^O,97%AXRSU]%_68@$O:@:>P-3ZH(A'!-5;6:+;C'_!T>><
M\9*]8%6M_T'MV1LY*"&_DE/ R=JG%K6#:6T910$2'YY]UAJK=X^4/GQ[/\SH
M65DG#Z-MMQ@&=A!7C\C0Q260Y#B* 7R#,NPTE/_!?0 A84LHV*GD@\'Y.^B:
MPWDK27?J1,S%7<IY%:MX:MDYN%O$^6T&&0S%T<\S[M$OEU9]+[S<H9E68U8=
M<8=IV5XWI9 HO;SL'C5W(\_%+$1PU=]>44HYYJQE*G7WY,D"@KRZ40%$N8!,
M""X-9H-1O6ZP!TQGIYSW45FJXR'RG<?JH>YF[G8W.1WJK@'A$9+"WH'5.; 8
M[8C!%*KAD"$29GC9WG1CM.C ;;,C,4:3_Y,0Y6[5K=5/7E0MEEBJO.>:O"CC
M#AA]-N=J^X*U?MIGYYQ#0U['%WO4XLP""#LP036.0. .[.($L I],4""A7^/
MI?[UH^\75R0VUFU^<=Z!Y>.U-.4&1JQW8/XW)-\7[,".&H7NP!)VZV?H[<#*
M_<"[T+<G>)9U1"M+3&=P!]9ZL9Z)B"!>!H> ,SWWD8F?.>.<B:E[>-&S _VG
MIC32HQ2.\?@8IT;SB"YT_R(4(\DU^)]9FX@=V!(4+R^WA/[&',9?KPX)0EE?
M4S5M_YWWL2KT?O:T9[6S>_5S0KOO.SH>3GT!8+WLOHI_+C_7^"4HK[AJU"S
M8GYC8[)E#)$V96>*"\>_45E 0C12A#.YJ]*0 "'[?:O 9%_)D5_$!EP+CG)H
MQFUR V0&YWVA\6$W1O'6U>N[0A>]NTI&A3NPB2:, ?3MO0U'N1OJ8!S$;<=<
M=F"OX9S/@;_=B.F=SN_KP,O(0?M\@8R+7?@N/8?'RWGZ! WSVI-.5C:=G 4@
M3;'?R]"PQRGS=+,NN[*#SR;/K=FT4L_@+#H\;"OX>=)[(M! )#\G_D8C]N.
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MQU^.8A99B$1%.KEX9U)GS+\F3$]A)MIS!(\JN<9^V8$%XD&5\(T,YIT(=Q.
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M[&6[R]T0UA%?O83Z"Q>D&+LRRF6D6[^-_!:Z@IF59OP68H76$IPG4/*6CZ^
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MIA,VTLB)MZJW?^WQJZ<3]_+1C#(RX)ZG% H'C\=)$H.L IL7#>N?5I.;! S
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M_:P,;C@O'UJD81B_'\$\D@/N<&%(,\LC]+K;-7DU? -X<O06\X:W!5;->LT
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M<\:-LKPIX)N'>-*/ YM'KR+>_*X.LQQ:@P^%YT:0L\BG9.B$(TPY570'DEF
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M?/+7M_%/ZMQB+FPV/P [@#* GOP8/3*WF8=K@W&TH<YUB.AO![O[M[#'.)0
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M14F/RS)[%91<U+C);R9K;^/H)WKK7.*C^HVT)H(V8@@B_+<V$\;'(9535]Z
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M]KDT%$5;C_6?NI<=%?E =>>ZD7W\L;(A8?\=<&VUHUC5'Q_.!<H#9AHA:WJ
MS&'\UUE&91?VHB$LPL:S1H2^*3LK<,O^X%/T;^,G8AFJ!0?;YMQ+5(4#=A@&
ME6FGVTA^V-P,\?ABO>G5S64.@@[TRL/TV1E)Z""^"LRC],-*(,$?*(@,=85_
MEK(E^ZI=N<CH6.Y8OF9D@\9A/WS%V.N,8TL"6**0O"D GS,O!Y8S>M@X+"5O
M4 ,T#:(6Z#9;I1 '9<'@<U> TM(PMP3#R"!;Y%["4P5S ZT&Y0M'!#5=FB'1
MPK>Z5@LCA(94RP[T%<B?B2"1FA-10B[%>@?"[$#WK,D.[W3W_#=F%=2!._>6
MKU9=VT (K)>@60(AV#\6&GAV 79DP @")M==7" SL_#07RVG=L'.^*RVF%-Q
M*W0KMIP<@$'_LO'F9YS*BRXD,RZM=FH/:3!%3" 1>5)@HN ?((4EYP-8$EK#
M2);X;-V*_#U:'$=P^Y"A#'X]>&_'NS?=:$O*Y.(&^4&J6%[4NX1=FUI"BI(2
MFO8>81>DPSJU3PH,2[%$F]IK*P)F]&CR"% 9&5V%O#*4E\@W98WIMA?]]ET,
M/-\S_A[1EQ\YOK0+T\OG?E9YG<'.^6LK,+H61XCW+W< 5>FJ#62!FCV<+I)5
M!,MR2)50/'7S2''.0*."7G+1KCO+VSV$[V1MCO-O=E7M0WC@PRM@T^,T!R*.
MEZ7Q:A#IQ=G2E=S6^0.B3T]5UIQ GA5*#^9Q7ED*1TM3TZ)WLZR&U+6LD[^.
MD9R9Z\8\$ZX]W)V%-W[ 0TMDB5IW3E&MFE&D*$8;B*7L-R,2UM>H@_,6[T ?
M5.XDWIW]0EU]W&+ ?I_LVM,_LI/U>3?J;:R=RX*M/L[]+N0!UMBS6,@7ZPXA
MW >PINS,ZWW3''&6*5V*I:;?>[R:]\B 9_)PX)XU7*#:S&K@Q\C-:\B"K?P\
MMF=%0B&S\&/K7(Q5R)Q>',VLU6<8-GV**F?3R!'O0>47^K]$[Q*FNWP?A-\Z
M.5>Z\[F][0.>T7U7PAX-W]>WOC:/94E8,2#"&&Z%OLZ.TD;>Y@(TRQEEXA9\
MDW.K#221(W9ELK1IE4Y3*[N?RWT3N3 @8:[^XKWUR;$CTL8YPHAS/GK':1ZW
M%BR=AET_5^UZ04*ZBOG-^EYR2W"<NQI0$>J<'J3-,P87)?@D I@VS%[0A&8X
M[-OS7"..H^I2=B_CXXO3,>HCW5O#E9^T]"'5UZ/#>58$Z\%Y*)(/LV]Q 7=R
MW!(<NFS/1!+,DA80<[:3TFW?Y5ST+D%_)EM-=/C1X?.84V$G^\-D[VRT(MAC
MHZNV#UE)D;)3XHRT<K[?;>I/DCO2HO_%*E=DW=I0Q'X")7U0DT:>@>@ ?SA(
M9 9Q/E7P?T?+IPRY)][.H9])M2V[,:A.YPNX<LR/(I:A7;]YFZ?T^_<RA@;C
M"Q<?^_CXNOO*/7U8=9DHQA^[\ZY*1@( 7!8H-0[=O_0SCG[/^;D U,'C*C?<
MOBQ;BEAA8<==AW][=$#Z5V4DR9];Y *?!GL0D<NB);,K5.R"X@&9![_?KHX+
MK*X=XN=C1V/=6IT^$LFEL!D["HK7V^F.?$A""A6^D<C_K6,D4>>L^MCFN77D
M<C\3Z=9K."AZ*'D$FB47(#E0$U)H5A3EF30*8E-@L1-DB"(T(F/*0J>U]S[?
M_8]O!%S>F"KB3 _Z#*G#A\M98KB_/)/C Z<[%7(EMV:D\ \C7VJ(&7$E)YQE
M,1QW%-5[HM/A:+AN9T!+T@8#SZQ3RLF#2)Q$AT$*Z6!(,%,+TX^@'=&((\B4
M6$7ABK"-Y/";.0T;#LT@OFXR%BTNMCR"W$UR])B[<R5R<[EYW%EV;=\P1/:>
M_C'9*R0P2E>[Z"%0A+A=0L([V.\:!?TA&8YGI>7$8J<:$0O7K_,LTW^E'%S^
ML@'8]MEZ)$,6<L2#A0J5V+YBC@7Y-F%:7X 3<0">4?(_H:\0K\<N0'@&$_J<
M*;K%]*9FBED#+.;JI)A3!J@WA(U*>%E #NH5K3^^J2[ED^ARNMN<;E/"0%ZG
MZB>$#U8*\V5P#7C2R(TICU:@M2>BK7*\[UEB*;-B@6$EF7E>=<BVR,Y9'S/^
M/I1:YG&C?($-X28 G">0R!%\25.EPJ-_H-V@BP%U"8RB7IW@SA?S=CT(=POG
MM,<MN:8::@F.KU^]VGMB35B'0P:'2"YKKM6(PY5*11K+!ZIRUIG2AREM.;DA
MY=-DL2H/IH'3A(%?XFB?E6I0[^>G'4&OXOW>,F<-E,U>^FN ^_(8CN#!YH/L
M$L)%5"*2SQ\4^5B-:$(*_2A43S?I[G?YNOSY6X.5D )%[XQ@<2:$U'YH1^:I
M]T:KRVT[5_DL&@GB<K\]O0L2FE*E:;C;^5#DJ"MW:V@ISL U(_<=3U@KE;23
M=S95%3XTSE(FTT(]L;120A%B:!>GN8P+W$[A0/BO-PTGR5NS,Z<' V:-$O4P
MK5Q M[7R7>NE?QV>\-^[9/Y_W*_]=^#A/\X%7KN4QVP']?-T[[]T;I1B*6]I
MLS]M(<O.?M?JCRLUQ<<.LW%5QY=6"O+OQBD-QO#P)>H8; ' O;]2AS\CS!G3
M&]CBBF^$9@W!@B>ODIYZP]4'KO(,?(,LT2J9R-"0@2;&[R,7X$D$/_]TU+&V
M\=_O_Y_>%XC]R4&=.^KG3HZ(CY4=76PU_?,UH;:),LQ>WRT==?DD%1E/AJJS
MV &2YF!!2%P3%UB0*>("M6X<;9XW/V7^XI].I'></+.I?!>]J]$B2*4JTRGM
MT_4S:P)N2-+/^#;!O]]8FZSX-=@UZ&I_6C))+WBNA2G[J,KAR]ELGV\KUK'@
M8"RKGZ.8PK: F >44J[N0Y0AWD'!4&O\/J-&+R,13$ N0O#40F"_____G=\G
MF?G=-4OLAP5H!^5IYE#4ZR^^;K?[C!L"UV\-PG?W]EUVB"9,1;K9""TBW3^(
M^,S/(VT+_(XN#8[;B\LMODHP*BNJ@7@IS#&C:'K&R"GEZ!*I-*]!9BDZ>41L
M?[RWPV34LS^W>V\%Q'!Z.99=C8A%"!(-#$80O[NAT\OI(<SYI4-XBI?@ I\_
M=PB,-_X*Z&Y  M2#E4)8C_UZ%<86?!L[L[I9XK(&1FQU-3=\11+ Q'[^+^P(
MG\<QDB$ 9U)G_]>2W$;,-4XG>0Z)=OE?2W)9SDWMRV+G"%/C'%*[LBY'..2$
M?.Q._!BQ[@]U/EN0G80=^<92A5 :,GEF.F&_SX(JPQSB7-=H^+^L7+S)3JRS
M6MY)AR]"%S!Y>?_Q''!N@7UJHON4*?8X[L"_[?2/MI-J-#C)-&-)L%-9^K[4
MQ'A7H_+/OOC"QL*GHN'.<6E][]L?\E>MF_LT^#Y';JJ-X*;1O[J:<,8K<S(=
M7O1E\&/3O*>933=+7S<JQ/M-?9&*]MT/5\2R/M]2<KNJ=;6^6C#HA+L#K]J%
MG1\ZXXH?/JU8+,TOR)O,7C)]92>KW]FQU*(ZANA',9A@)5.QL7"J1I8=AS:A
MSFX _5H&QQWHUP<5R[NT%QT=)=0N?5!+*BI^=3?WLM6SUA#IH?T!'+%$(:_T
M[4R->^S,'*+_"&I@=#D:[G=9Z\[P/NF%3/&'PY<?&02^NG?FX>Z,[HQ%<]U4
MR[>5YH;FRKG'G@Q+*A=K[\0GOV!7<HQ9Y^D)U=F<!ES1^< E(D;J2W:7#F*+
M3\V>J*-%U=71U-.7'F;>>&I+NSBTUV"CB7$BW8+Q^A8CF)VTFPMX:Y 4AUK'
M(PNUJW7U_9'K^[U%7=LW?$O*UR1E?8@>55=\)K+GK6]SJ$]&X:''GU^>>)+Q
M[KN.)/\^_4%G97[EG>7LD:IIF\Q3VA4U*0[,1->,FD-T)$M"E?$,%!UBJT+D
M9<:%*:I\NT;>VX%1MI)0G!WX7?W@T@'G2"'9E!OU?"T_W#>4%F4-)V^SZGT8
MB5!I<G]S.V_[1]6LX9VM>C+75.M*_?W]@[^GMPI>'[?<L;),GA-4;<1Z)_;#
M.!+*,55Z-.P0OA[*)M$(,;3;&"$*+?.";.;-7W5HK\O F:."_0>J]5X;1F\5
MV1P/Z^NE)LZX#+N@3G5P 2^-/@RQENY,4B+YX;/ 'CE[H2;UR-L938GBN<0+
MHZ?E#;:@=C4UKWES]=2=+155E.SMP:Y[KEHGU:28%\ ]W/JL[C^>^4Y0[,G[
M??RS%O$=^#YECF5[/6$1NOP5_:E%.#]B)+,!VYL#!7?MPE[<\,>N1;/,4Z:2
M[+TA?VK-UQ07\$$NZUE!P=X;BYV8F+K[']?TX;A?ZNI^3BMNSI6U'0JO]X@%
M%:IJ.3L-,5(-6G"(=[$3MCPKJO^U]Y;:L"1GCL5L',0#$9P(9*;D<CO3 OLA
MA![ CE)>9>=TE QBQ#P2&H)C^A@]Z0<U%_?=W)E!2(/Q+9,9']E/,?J!7=#D
M$Q&D.,:U-&)%5 Q'NN9%W!!VDX62_<VGI0N[)&K.?,[;K'P2IRI:\F,D]"UJ
M+S2EES%]#CWI6T WICKK,BB>%VCHT%NE<TTCU'^)$+YD11>VK_VP+^$HK>.8
M^)CFOO? A7!;O<](>6,Q]%4ZHR [,(X2,*,31!%J-98^7UF20K0GE49F))R\
MI296M,=?Y3+]?92PR7N\ #L,>YZPQ223M9?]C MXXF-)A=5Y@7K$%-U! =J3
M0?E$BS+:..E!\^4?H24IXB5N?LOK 'FI",4?EQ]5590+GT@VN)RB4")F)WFT
MTOZ!7:<M:?SA0'^)^W;_W;;^32<#;[SH24-ARN;(*U^G")37N+EX?"R6L;X$
MDD1,[\7H\1Y?K/OH.]KD76]1D$\G)FYV?42RC3SS3>S<;#^6H<-^CO69D3H-
M^C[']);5B-)V5+ZH\\T%76KD3'*/SLIF'-I:J:=YM/*QS2AO?/4)RP!"L4"]
M!HF7PH@(>H:^PLZ:J=E6_]JI[GD(KFZC)[GO\^'"PIR65"0B4'/N:__HTK<K
MXR=>K)'5.Y+:<-!NF[6=K+HUXX%74^_EDQ6C 4L%OFDW-WZ3Y'OWL*NZ=&[N
M#=V*)3;+N,K.K='DU-9LIJ>$<X%+(:BAF?SUN43*4R&BP?Y,DFIS\+ZD,4@'
MQ8]4!.T^G%4X:G?@F;]"!0Z.Z4F78&<A*(E;RN.Q/E9 >][WBL@LM&JN)T>V
MPL*A6^<MZO:-N?Z6E@]K710?)>7GE=8>.:-ZT_4I<RVFB\SOULN1X[R'ERZF
MW#*&@[=LWM64=Y2B^%\\]Q_ZL'MSR<=SB">X;>>/985.&X6?3M[ONMK2U0MN
M#V!N:&1N..U-*BB\[Q=WQ9>J=%=FH;L'6Q+R-IU7_U&20]CK!WS"HHN;ORTI
M-5STD7;*<DI6D-PV31FV?FKXH?7$,4T_ARLD:[]35RU=9S/\7Q[+T<)ZZ;A?
M3''&Z6!ZC7G9%2QIIK:G\4YV-=IWB""'5J6-Y;PXPSI*(]RR[?O>>U>]P4(Z
MF7KT3H#W_<VDP_%G][IM>X#^N**>[7W#J>>Q;_[D_1C?0HIYP0@0/]$B?0)F
M%*XZ@I/EU&'+-&9@0T+(<'BIWDQQSA06-EQ1'N+73DQ?:XFPI@N??%^DY""^
MW/8Z_/V=X]Y7'>CX(#"%=JUY4)7>3IS!#LTVI;6O]TR'=6]/.4,;B(]Z#(M6
MO^-YK__HH'?0L31S 1_VC_ JM5G)T.9SN:?\7[XT_7+_^M"^+O/<MX6N=K,?
M&E]TWQBQONGUT.O@E=B*J:(;+ A>0M'!=(\ZL@QG%[;.>Q$'H/>!.8CP9%1X
M&3Z8ZF.Q+H=0WBDV<_QN7U!=)F3_ZVL/9KV*4DROR:;I-7,!.-8#UU^":21L
MJM$BLTQIO;%HF'(T:QM^JNRNV<O)3J)F@H]YNJ3IXW7"0RWA(AV:K3=A,WI,
M!3"/FM((W\#IA//4J">N@::V!J>;MA9_)4N=G9[SHJ5_L.7'6G>UL+GO+;69
M6AO7D^QQT[-,V<"I.H*<OQ6IF/$ ;(<G<+:2/2TRO)*^>N;E3))VI"K-.PT.
MROWXU+KC]/O6RB3-#\I%-5>2J7/1KXHB,DUL&&A<%>--YUZ;T7XOO;:2JB"_
MQ1S[)R^]>WI*2PG!_8O[.82#A NX93V$((2><9!^'\>W._T5*ZVY_UL*JM>"
M3=2P^B(?;RKAL/!AX4\N__QGJ:[XC",WLH+!8A2>;"(52XL)4LEE"LL"(S#*
M*RRM RZ%F/"%TJ(0EJ.'O&?5A)&Z_<1E"PE[ \YZ/2_O$V7E 6(?+Y1*SENQ
MM 4:VU=DL','H6^/_\P%-O#0KW$BR:R[D L.^R/H6]XZ<] ]D+@[QP4^\K,+
M(J>Y &S>.#FCQHL+1(:"[[C (13GJ#.4#RL00\^,=V,[(*:9M EBNWZ)8/P9
M=2Y@[(.E[.$"HV'_TT<C#K-^KN:^X<@/?$." H=J*N^CBST9G<>^\JJ=MSXA
M(&=YR6'JNO>1TIW=":W*2^FI 0Z"K'%V-F&D!JSD$.]#(6"WHHE\P@5*REDI
M9"E(XV#9@H0M]&+.X4>HE64N4%;<TDJX!;>)RHA577Y-._A'=:<_%54$-YH-
MYYB1&?LF=N4,S&87QZ@:87M31^(4LDNYXT]N;_5W%^@EU^:\FKRIGN9MT)2-
M\O(K?-7U[=.;9Q?/OA+2Y-W^:.>BDL@"SWX)NY!#]ITE#\V^^!L&N]]C'/';
M82L\>$OY_LR!3?]O52_OZW>2_8O.%VDO^[]IPXK.\;6,Z2Y<DH?);0!.KQ:[
M?Q^6#J*_OPWP#/;Y_V'O7<"A?-N^T2EEDTI"0DQ%R+9"RFXJ(17^""&FDNQ"
MBBC#'4*(*84B1DFRG;(MFQE[(<D^8S.&LA]FQ+B9F7O6[?^\S_,^]>_]GF>]
M:WWK6]\Z5L?1X;COF?NZKKGN\SK/W^^\SNL\[?[=(HRJ&)C/2:MD<!#H+N!O
M-1@YB(^M;^!97B2OI:IF":+!A27@&1U['7X[>WZ?# 3W+Y*!  $CJ$$W( (5
MK]>"7/\[Z4@C%_LE%.,D*ZWG=QCWCC</ E5HM<8+ZYZ#8:%9]UIS+.]EMZ8R
MC63RKQ9_OS<TQU2UG#B"._0BD7))*[OXNZ?R0%O&9_E\U;=V0+LJ*Z"#P6^V
M\AUFON*L>6A?1AS<B=P6#B*D!Y9PN08@WQ98:)]#LQZE&+@%A79!MX&Q1NS?
M'^4@MG<T 8M",'*MGH91+PSC[0KAYW"#Q!7IP]&=S(U9K 58N\4B+\)H+0T-
MTC-^[6(/5.(,:R#4!V#!T%,D\Q^#T:N!UZ,.D3YFQ#IC) DK65,)#H(KEX-H
MT6>[PP0I$;@!*_@'),4SLSMP/^ ;4NK_&!Z8&*?-0:0_UX1X;#B()Y&K/4D<
MA!($M]LL5FR=]%49-9$$Z;C^Y^CHRKO\.8CC1[Q96_$<Q'Z!I5Q5R)8--QJO
M]A>'"(C\>X<:RQ.SKV*0LTN4>\?O*N&X(%)5D#\W:%R?AAP7.=@?:V=Y;^QC
MPE&3BM),O,8113O5_'E/@5>4YQ/\SYSD3./CW35[A_JNMI^ 967Q)C7TW\MO
M\RLONA#YK[PM"!;XY\9/.WK :0S?B(PE[PQ6@-IWH"7S*M>]8&EW8Z2E<)2/
MZBFV?BBAYL#;;M*.42KZ(A%#_;SGSWT+'SZF;39IA8%?P493, 56 0QZ8V0^
M2P]<H;"UNII6N;,S[;\.>T"2[TL^)#?C/:\\)SGFK%/7._GXF\R];(&%L+!C
M2"N6TA>"(FL;Z%DPC D"J7+U.[J& YD.5\VV#+B5"=K*;&H4VTX6_$B)-_RQ
MOD#_KI$8ZCEJ Z0$U<"*4/3>D@#)']JT+AW,&#5[H#&3DC)DIZMMT*,A*5TM
M;OZLE_2QY(V@/7;_#NL9V5T[:F3*.@&:2?OFP8#7J-@T7M"_(*#PQ\@^=D-F
M4FU*NTA):W.I_5$A\QVQ?E')'<Y7!!-'1D82A\W@J=[ 9&=S$%?17T49YMU$
M9V\2OG['L "=&.*7:J5C_,)='!/AZ>/\(?&4E^>3/:)N2LJ[W,\]O]]X/=,8
ML:@ZD&L PH*RU9NN%\E4.YN<%/:-UA8:8#8K>F,H2GG O.SK_84=CS[*>?7N
M"Y$PVQW]0Z _K!9),Y34'#,*]8V5&W$L&<'>/W/;S8^BC1/K]RAW1[L+"E]Q
M%1]'[Q_XQ%\"@X!PQ./H11PHAX\I]O[J ?&5O0#G&:_LV[E=RQSW5%26%E:]
M2[/IH*KB'?*=$H_TI!WPYT&IMHZ'?EUY5P/4&'$0[MC^><84:/4BN!59B(R^
M3%^N]_1O*/?K#=$+<5(*JYO9/-TYO?W3'TH*V1_X/A][^+A:]JZV*JBPW,3F
M.@4^HK4R;.CDABWZ-1 ?W0/M3A;T\]QK:\&8-RDYMK?KXL+QA.3IJPO1C9JX
M)YM#JP?8D<5X<%];5M/78G)_!44JF\9!C.JEOFCYXCHLT^5GHK*P;/80L<!;
M0/9L8:5/C/L4EW')/H8VZ5)TD10LU9,FP!BG#X?Y!([@UD_[K_K'JKPH# QY
ME5F_P9:LM?NJ8(/V#A>N[PI/FW=;H^KQ#W#\@"<.E#>J=B->H=Y1%<9%BMJ]
MSA_S%G6E?2CN4I(K/=_9,T$2&;YJ;;Y33FSY&B*H [T#J#' F.5#W0_!"885
M".2:\(3#S$AEOAZ]HR3PZ*:5OOT>,JNW[A>@HHT,WJ=([HVUV?U!9#$KG.AF
M%C%\@/T"8\X\Y$H%. @^S7OJN2;Z-MM)U+(%+RL[W7BOE;B=5RY>)ISH)5[&
M#N 87NPGD,QDL@TU:(2J?X;8L43U;KAQ@774"<AKUZTLO-"\KZ9<[I.?!-?8
M]TWIFY4105M^4Q J%_C)UXDQA[\3_H6@XH9Z)QKJ';P79)KT+.:2M]H:4^PE
M)"5F.]T2*R0.M,DR?@P<T:95:=F0?G:?WD49N/Z[J8BJZ"C6@W(L&S#YCU1$
M/YO#/IH!,-;: [DTZM9&R^?=^VW^U>1_6:4A@3UVEX/PR81V0J>8\AA>Q1_S
M#!C$Q$^-XIE;3/YTJ.X+#H(Z@ 4''2L.XE(V<5&!&;>-@\!D0\@>)->H "MF
M$K8@BRZB,$,@XQZ'_PYX!\TS%8%F N@$5>(X",,JC" Z$&HA+W@38'.,EX-'
M@D<K-I#GX'9%)]LK:4S(L 2HYB 6WZ2%P<U.9,V$_,\F'C8'Z3&4JU@ZKEH3
M*>!'-1SO)8TS6KYG%0^,<Y=61$PA!GEK7,]):0D]D/+(@B%*5A"%RG6.4-:C
MH;OU\^CXE_'>T< KM_>@9@^*H6L+S(_QR?BT21@HN7]LT5?<'"KPAX%%!^8@
MA;@ERJ:.(/7NK=#AJ?"$EP;C2&L2MUDO_C??M^Y85!:JZWU==ZPC7^FBRODZ
M%Z]WLF/=E&-BN>?^;P^R"'8$<9"A@Q%$?/T?F7KAE_(HR7PM4R]Q4>V<![B7
M2/\.@PZU,2F*XU&F*=1#BJR>%P6U1SB(.FRXIIXF?1Y[M4)*DK9HEW=KF]*.
M=U$J\+]7UML:HUL?2*OMNLLG,NLW!I3(S6:/($DV:%KC6Z*0!HX[8+F&>O,V
M!2D$HO^(4V2>^FX5YW?PO7,RSXI(=X& 2;4:-[4%5001D06Y7<45)!8^*24A
M^T:V?4I"5FN@NX.**0 XK>4MN</R8><09%E':&WX)E3(#'>"/^6QOQM]$U*L
M#N/'=R_ZY?[\!^:MFQ^(W?=.]1$3V_!@ :!9MHM P[B-T$ZPE1$)RC&-0*"6
M($0C/'/32(L1"'M!Z%;==_MRQ'&9ON,9L?ZG3I$>7#_8/?X>^55NS(RZCP8#
MMO5$%]Q]\K9%M 2H/UH6OF2\N#'&T%[7LL[$B=^LU%)")(U'[+@THJ'H8W\D
M@P@JR;$R/$9Q[%!/U"*!1/A\WO5BP/"]H 2YTR4GX\UOAL7D4.1:+1@)8_)5
MVZTQY;:II@H[B_/RR#DEU.YEW :/Y(A,&OD473:+,#T]IE_VX?U"QKK7CUY8
M7Y.O;I:A'3B*CT:YI *,.78)RN4,>4#M-+LL \0L%TW'@X$UXL"]:W)=Q6_R
M91/W13#L[[E=4;JL],G4ZL(!2>&@$ HU>*(65]2&C;Y67$9(,:%=L3&W-;S>
MMT4RW6>G7IXA2ART9YBP[Q%V! \B"SV7J2BZY9@I,=,#$+I*[&8=]QP9,I14
MT^]Z;?SM@?17P[2SS WNSAZQU#V#MH7^4DK11W3TA$3NXULWY%A&IV2)EQ*+
MO12V6Y\V=FCU:VW!?Z(*WW;B,Y[*Z>V;S\2:=W,0(R]Q._*)(]@OT/!U<'L;
MYI)>W#OV_0%BO_0'K4==4*^E=F4&5D?ESJ&"ZS<O3%"1!<%#Z+=E-9YJC+<P
MTO4$0%L/SYRI=R"V1G-XV]NRHIZQ\@1IUUF9,H.$7:(M%U-;^+?Y%"\LXTJ3
MZEO;P;V>D0U'==0H3Y<D9GIHF#XJ97+K(Y&D@>2/Y*"HQ\T+K%=-264MVY$?
MBJ^](7K,?XVA8&>%F ?<T"4NM=@8:'?/TGR$:+G?>$@6.&&!/=>Q)!<_*F]W
M9/:;F<I0],<VB8%95\;W4XW?5\]*<7&%-P4YEL@?[VZP"HW<F_TY:>^Y#Z2J
M(PTM+3[+.$VU,X\DM]V3UK..KTPNP0<5$\W0*.E%+P(:5FVN^ >K?52AEU #
ML<@L;A'/X_XCX#):")P?W8J_)$D*\#]EBWG*>NJ\5R[-.( ]L2G35,^S=5$Y
M"8O1*167 !^?*^KT7@(%\]1;F?5Q;L[R!1V&><<?)=WBY=+KH?4U"O03*1Q$
M Q%4?NXH!;*S8$/ /\-!\&;TJ =MG[NZXTX/-;7ZOGW+W1#4D]?V6*5OF/OU
MEPEJ$0>>VCJY=S?D[^]\WC/Z.B4.Q^]VFE2AV>HW[W;SL<#.#V4J46M;T!-=
MZ,*F.G1L&G\YL1?CPW1KIGO4E?7FE+L/!MRJ'9J=$X'\[6/THZR28A_H61P2
MD*U*)LB"5C".J4$6(5DB'UFB[.3BK\7>F\ BBGIR7RQ&.O/@CL.:[QR>4N=Z
M=]^JGJVP=$5<:F[ZK$A-'AL5WYIV2.3<DPQKP>1E:9/^(=M:J6E_,RNZXIEL
MC9Y7.+^@?%!ZL>M?Y1G'4\_R,&-5:4T+1KWZ(\?1.* 8S4HR$P&^NGNS-Q&/
M_]5@#EZ/9'XWHT%O0.0VX!O:B 5D'"F7?TE@L9[_-L9F'NBWATR6ZY!+:UG,
M-69&HIED!FRO'@?1FMBW45#LG15'%0[B>B1(- R:B"0O:.1"/##U.+DH+O^2
MJ(NZ\#OZK'>''4JM-%:M:;,M3CT]+$^D'.F]45A[?H*J_-DCCYVCC+%!SK)'
M78@]GE?NV<HNGN*5N9W]I5?NWZ0WO_M?T,[PMT\"OU.LBA(L+//UOU<4'-.N
MB![[=7]H>?YKI3>,KBI46=RH,:-_OOBSRM;__^E_?LKS?2**2T 0';D;5]H:
MK^N?G/D_PH&5\V-ELR^8J.#.3K<DE+B>9$.N@^NP"\,T8PN[(74HC5U1[[^C
MTTB!F_1AW=OKBAWR69'UHP<2K.R$KL?W-Q3WM;D+/GDYEXI=QXX@7N0@[N$*
MO4.*JZR1D7>N..H^/F5O M0;!^K.=F[I/]B@7*=F)%C+NB]H;-ZTOB08M0;%
M4%?,2#$-\V/$.("_H*3*],P1JLPCC%6.G>&71F.#@_87FL1JY%(_Z+:OKWH=
M/9]V^[G9@<2C-L_=6Z"%)X^+)E/GO5H8RKVY[>V?YFZ7S5*9>Z%V<F%L::X;
M#5GCKZ5^I^/NM+'/*#\3AB'-6Z6;2!-)K=6/H/'!B><C3FTL>/%M>,Z.PI@4
MN-_)8:%ZU7-U;WPOT&@7F)12Z5;R;3MAB#H8WRN6>$#@Y4:IGL58X>R)9VV[
M3L[4"9F;WAI/TL$K>OH'5O@2AM99Y[PB/:[X<90?>Q>]<8ZP!=D_#D0DZP?(
M3(7!DW_/8_:N78S/QV,9+S9P#RV78?J'VFX+P !LY GNG4T82S_3(W=$$FT=
M>:S<'BLP2=A+]WKQQHUT+3K84J3XASKFUM:=FU8/1S_0\TFY=.E(!_Y(=NEW
M-XU;R]X.]M/+E\1++B=;W'D.U)O=Q?$1% ,&:M&"F""*6=F,WL;N?01:_L1
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M*&K@(+A\!]@FD!S,+6GM.ECM8Z&U@16!M[:;>>Q*Z;^[8J0=TI)[ P;^1@'
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M!H.=;&-*R]-3H%$CXZ"]F"/=HSWJ>($+9U[WUWDJ)186VZSO[Z'<E-NW.>7
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M$E[G+U M#W-ZK6HLS"D+X$D[(;R.CF4=\F:;D5?@^]1BH$Z6@^AF<Q!/\-"
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M:X*?I=^&Q%$GF3,2.]8EJV^)X\/C. @W;RRN9)ZE'&M9.RP.RY0J]KY6Z2-
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M0CD>R\77F34X,+#'S(_R7)J_&9I0ZS:?A[XZ$_O-0;RCLEYX&V*";++9!0T
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MIM'"T0"\:D4.?4#M7#N+IG,^@;;3-P$Z3_7=!KU'AR]:?:OQ::UF/[XF=M.
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M&_)-R(D8.#V:*DQ) .S!7KGY9]#UHW\NG%GX/H=Q90*V(^B (VDK,Z]#*WW
MVPPHG7,7]#HE: )Y8,%>ZB/9?!<4N9S_H_)30:PQ]N4YQ7*CBJY;GA\@G3>F
M2GOG+9G_+*II9F)$$F;5EUDK/O\&04Q#KR72#,_L@E#]P.I";;]@_*'0YX\?
MP'Z^&<#/#+?RHA\VW)N!_X/N@O]B." +X'W([T6 70P]B5P[RLCY#=DS#S@
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M+#)P92?'33R,C7^2/;M/&X[5;\$,[6QM)8_2/*BP1BPOHQIY[PV8D^H,ZYM
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M4$7$6%A^6EF^DQUS,NKW=K3V7\-$$&X!7DP=!? .(_9O0<N6<' K1 )""]J
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M*!U.CE_%U 86%!#])LI.-Q*E31^:ZI>L]HXO=+DO%KQ<;ULZ25.GVY*$6W
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M @R804,< [#/:X#=\@-38^";G+N@%"CMVE9H#!V2G4A-0^Z\W@7-0)@+$+(
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M1P=$EL\+\K&$Y?S <WL>8\ACL_ )%Q#/*OC:,(<1IYA9TA2N>%UD^6*&B"6
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M=K;'2T1UDZ/W4)SL\)JE%W0WJGV)#?D]@5U=8T.6S\((--3&??Q6,!NR*8F
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MJ&723&-YS&(P4L!!*R+9+]Q<9=EL8KDNRV\1;QZET$W,C75X6?DA\[%LVNA
MFIQ4=M7OQZ+M&)P]4;4-@SO>34NF>"VJ5'U85'/&=8:H7XG4YHFJ\6^]A].6
M4H^3.-5U($2--8VM&&O72>1G&#%?HEP5$_>!JM(@V_\>;GHE!K<Z?$&40[#I
MF925UR-.LA(J\#7$7@%I_ZZL8^XP[XWOA?H_4Q]ZR0LMIR:[&\L/X@,'&Q:C
M^GW''6J'DT=J"LT^C&3%NM<V!-A-/+);1HHRS(&0V41(T&1;C@J@[D(T,^VH
MOZ.)VUL7$#)G3-BR'*^D8M)G;MT\+^/GXF/MQ+=41>V>A;7TN^M>HYK2O.JH
M7\MN%>'P/T6_ 3->)^]+B<QP&$H(*$T\R)_OTB1Q:?RHM-OX=.8QI8![9KB*
M?%(YV?'TL$F?37%.S?3+P:ZQMV=,-!LU&V]O>OW.=&]H$F]PTC2L18[#*_$M
M6)SG]6;J2AA(1<43]P(5#F/F;TL]DX-^>QFKC"2U=RCC9F0352QK5,U>=FL0
MUBWMG[59MGRSN8=/\PHVL5MMS'JTA'E[N-CVOE>@8TE=#LT$IJ,OAUS&H?]M
M;\W=__+66/VO>VMF&$+,_.:SK*^_/DXBCE+7ZYVJ,15TJS9/Q9"&ZTVOQN^$
MS6O+^&EI<M^(RR2C0#B;]"1FD"^1S$Q-,[IQ<<W[S&Q+*\_M*B94Q*C7[#:6
M?GJQYV@?8OG:$_D<S_9[I6*NM=PN(B>'$ROM-XLQ)55-F !/^4$GR;(OOH-M
MN@H%JG?)>=/UOSQQ7S<]B\I 0<8!\U'%Y=/N4]X%*<YB.[*\H.8)RZ;OXQO5
M/TP;E=?N>FGJZ[W*^^3,]--Q?P<4%.:!3L!6;G2]"J36=(EL-V:>>>E.WAOA
MZCJWE<?[BJYT:F4@'1URIOMPST".I;FVMQ.OQ:B+P?[\-;]2K\#1L;'O5E].
MK;6'.MN^_\6&J*K/#7NINKP#+*CP;K JS<?<T<)(49!Z33QF)2H:Y\.9Z2<9
MZ7?NC2^]NB8^]PBJEM-<];S0P[[^:[YOL8=U<(:6?^.8@!='2(6(RQ.(F"SE
MS,<3I7DFF1]_GRB]F]Q45=Z41E=L4-7T/YLFJ6&^DJ8SF3==2IZ>"/W\&\%/
MS2>ZM2?N#<HEK(3KFM+.0;O2'^" ](&E!SVTS[?]J*5;_)FZI^1/V.3\B E\
MTGP&<1782?$6 KA:6/+T@RDDTWW%##-WV@DY^AW^"K7CO\#715Q2%<R#-7HM
MK_4=B$1KG1:<=V\2*7'LW_3H'<C+N$UZWG$I(]W+[T,ZYO+*PP;YP(#1E;I1
MA"1 H!K.\CU?1KA18CNAX]LEHQEZ:+G5B0OJ)8TMW+O%DAJKC[I\N7)&K)TW
M\\?/=Y4V!0:Y']^E9I>2BZK'0KT"O<>.?2\X<4)S">,Z" ]1U5&,0&[LW V)
MG8.B>;%+/%JL- MX6!I]C WA+&5#4I$(-3;DDQ)^V_8<TI.(9CP_P8:,=;(A
M[S\S!=MA6Q(@7F- ^VKR_,],LV?0ZHA_$4R6$OW;'M=".,46NF6XT(&G[VYG
M0_*NVLN0!B:B6/MWS5J(XG^ARQ+)/+,8'D#Z-P%S;*C1]%W5'&ZZ-W!*Q^@6
MHDA;[OP9#@[) 7ZJ-0U<56%UB/M : %#"<BFVR*4OJ]+WN47R;L%2OBI3UN?
M)6\<H)XOQ:H5;#D\+)VJ$>25<C%H'/80C,NN*7=O"'X='"D5U+C'\=",;ZHM
MK<', ZD["'^+HLRB<3!6U$ $.J>,#>D$Z<-!;B;(;'XB@&M;BU"&+7)Z)TTU
M:N<.)#AC+Y3Q"AAC7+JRR4):T>=V\O-STN3>U&M9\O#+H^=54^;<D QJC<3"
MN5/P-VS(7PJW!N=*V#[6T&A%WDA-AVK$8(]X9,)EKYO"-_WVZ=1JOV=8$>BH
M_1@6!Q_KBF?[%1H;TI&_"2J;%]J8?:RQYCW )@7>;8^OUEIJ\"0><)ZTI\R_
M(BK#V\:L?SDV%ZAX$R.#D_R2ISID;HIZ1$U71NP_14!7NCW=213@9$.8U0$K
MO @NZO2O>LJS7YJQ)8W\3?V5]IKW@!=")^>E;QSN\Y*(;SG9 LV;.<),1\WF
M/X:W9P<:C&#=85%:>K+U.>UT06>O_=>.AYUH)&AEZ;3=#3Q&&J?'JHASNJ$E
M@0#P(R^9S4@1A&,&*3^<I<,X#1>>TFAM&-4X'& Z5K?6>JUQT+?ISLSA, ?!
M?D0I1\+J%SF/@7%CZU1'FY7^O;@8^_E'8<;&(073)J.;ENOCR]Q??&T*5'U$
MK91A[M[7Y(*URANSO,XY5L2O@.(;5#W9T$JW[@'< C$22]=A#2-/-5.Q[=F>
M;9D1W3'P#@\540,'PMT8FK:#]]-TL\+:H[M;GJ9Q(F3@!?#*Q*6=-/,]LBD6
MH$IJL1!"N /VM]XC+H]DF=574**BO$^/+[^\[,#,(]@DY2J^L#47/W,T)FK6
MGB'@25ME9F[TX?D98D /)<6T\;O7GJJIFB,:<S^#PO="E(>,BCYS*>S:[ R8
MU;W4^\E6<312K',@_5NB0CPII*=):>YA]IOUF"T_4BV/>I?U6X.@"+F#GE_M
M_2JJWJ776%:-_*A*T=NY4:,-U3,/BO+;R.?@&K0<ZQ?5$Z-*YD2!H@7+A]?_
MX&PRB/-0<SS;JH.9L7D17VQP\+RN_2*LRV?<FK4_C7X!.+Y&P'>NX+0(4ICW
MO_="JUK!55)9O0I+D^Z1D@OC3#I_Q_I)^YG6S[+V>TI1K5(H4'D)(&2^L?9X
MP@^S1,P(\ /X*5 <V8]O"--UUY)=41KGDS9%=-4/J;<(5UL2S3DXTK^UV^8J
MM@T^JKA1X%TZ6O.KJFK^IVLF$)S0-2]<)K1H,-R8MHQ6#]&1SZM?"57^OE7!
MX@:%LEPX49Z99 %2UY^U17/U3'"=T85 9++3VQ^DT$Y8:5?%61!$7KW_E5[B
MXP8BSKZL+XN"IVZ7*%639<*,Z5\\!UA:J-9C*&\+G&HG-6B%Q-6Y\JP^IV!/
MV#5]7Y\\^+43$9+3]GW51M^RA[2G['V_<K<<_B-'[N;)^:JBD;=RW!_S[F9M
M^GCFNY9L;%:N\=I'!?U^Y7KD]&+GUX-FTZ>;%N&V@7D-GC^0M\9 R=FJ P--
M.6B_QW^Y[MCR[^B_+&F[L78,( TGHRCH;D?[#@R($T(L$??MF>>/,QZ[KB05
MFO[X$J4P*3L5'S[Q5&KDITNCZ>>R,PJ5+N8E<V)R >).'["O":U! =F$LM3?
MO7DZ!L8-V@]!>G%L.U$?X<^&[(>S>*ZS(89)%+ VW%#6?"Y+",L0J6$ERA#<
M6 (P9C\\"EJ!-OY7?H@)M #R*Y9R#2X:](@-:4,>8V+T1&ZX;^>E5F> <$Z)
M*0_^]#E",E"YUK6W3(R3/V<?YC6*T JK1#'YT#RP<RYL2 SF&R ?Z[<L_M;Q
M\$MS<R^-WI2)<RNR"%&Q!]6W.C0^#APXD<<Y/._E/3H:"SMW O,-"SRP($/9
MD$L+;0,##FP(<2>SG),UR(:LZR&4&!N)+(5F$DLZ@V]GNP\6X(5MJ8-\BWC$
M#;NVFH%799UG;)57:=6\F% :[+J;=M58G:S?T^5 XZC##&(G&EKA%!O\,Q2'
MKMELDT;&C;+J[^OW&M7JERMN%?Y4^]50JO_M6EX2R=0K[$"+6GF<U_Z@8LQ?
MZU/T]AMV%EQ357I/*8L=T ->"$]*=C%#/]#%-U@&==_'H$I=:'+MH9Z_VT_%
MKJ^(\SWJ)J?RC_B5NU>=]4WO/P=[7/(.65,UNH!)?:#BGSZ:9FP3CW/WLTD-
M-/.DYX<ZKL\,N,RKXJ[/^D3![O%-+G2A>+&WT =_U7] *W6%RIL/KAR+'+TF
M716_(C*2G:X6=DNOY?U)#NZD2OLR5"L,=A>5@"_SZ9AVHZ4S"QLU5)^RH#^;
M1;\K5XT'](WGGOV5+E VWKW/;UA=;Y3CL!Q$XH6B-PPXZD.6%XI5<H8!CL7O
MA5V];AXR]%VST^I& 3+Y9"T0X @Y152=;E#_["G$_10Y?C?ZQJ) [Z%#FMWS
M/94!&[L_=?K.V\,AGTY^I]V($?!^?6,Z+<N*UN-46JHRX&3V:8K_U=5N74\;
M9KYZJM7K5.'IH3F:V83>Z]Y%,[[TYMW(7FQE37>VXE4J9FEKUG/ZWD\MRT[$
MPRP@M[[:72CU9L3(A!&OUM&C+J_ON/VR$ O2(<FW8(#CV$0$!]WGMU]GT>(V
M*T6U#<X;%&YK6F+2ZY!_G/;[],P*IS)?S_B=/UK6+GBGM*(HEWQPW@LFPPPX
M8>4Y_,!2SO)7G6C9!*^[VI9.'! 3&!?7ZR-UX%QKY8)Y2-XF;QRX#C(YG8(?
M]+4ILQ*=FI%7/1K5ZAT2^>+1L9F9^6(&)M]) \N5Y'YRR=W1$D.'&JBZDORN
M^9>ZNJD2$G-B^C/OZ\[]&-D*35NWN#Q'E=UV +(Z0!W6H;H?P47!D\4*2Q(9
M,CD*WY>+3^=*?OW%F'SDFO+894[,.CPEDPZEO0'LZ78(%TI^&YR?U>I>Z@$[
MH-RX)W_2_9$SUP@C;UA#?\H[8LC@MQ4IV&JU=O%U]86BOQ(1VVE%UKYK=(=[
MQDJ/Y3LQ49J>9\G97BH;M1WA@]6U R0#]0[>?&&K;)L/<UR*)ZUCX_/>F878
MKNB[]X<&#,(O<;>\^G DV\2L/=U#:ZY 3K';;IAF8; Q5YWI0=X!J59[[].=
MP-M9,U'GT=-D4Z)(!F72K!+(_>A>(9OC_>EI^//W%NG&(Q<CO=_?7X<@,/"W
M;JQ]PG0CP102_O](E1ZY-LL\8,&?1D*3B^OL&)^<'ZNZOUNJ5Y1)^0.<A7K=
M)'EX3O)\B+_9EL>61BC>OH#BTYZX=>(Q'S.R!+7N-[:>#T_-]&$<\J1E#6F(
MA]I; !&4<IW8:\D.LEVEC^I?V,R6<7$>K%K',$ZB &4?II1AVP!#%D7/;-:*
M!]"[.BK>4,I2@X4P7Y+QZ:.5:)?%6JU(ZI3._C[!$\V!XG[5M.9-TSJ:AC!U
MX*\%) )6(" ZXK=U$R/0@!$;LJF!.$;K)F7\<THE,OHWG'(!@_.Q_^ZMX72)
M*-K6HZ+R(=@MY4CMU)*QRY,6WN3'-K"_C*3]RB'JI:-Q @\+?V+3=_AC'$-C
MP%5SQ.3QU@ZW^W=A$_-/J*D&^T?,7'^'O0@N\W^&[ER6A" =I'[?MB@5:Z,P
MH!!&//F #6%L%[$A3T JGL('1+Y:83#R-O^K&G7-?Z!:A9K/(:" *ZAC1ADN
M%%R(V9$O4Q8',FAE:=\/_=$PI1*\[.G6CJ5<A.)D.O2@96-DA#^E2;JY(H:H
MD4&'/[ _WR*AJ1Z.2P1B;L# 02\$B=H?H"!N9QW[ ,IAV,G0U9UMH4_^O4;_
M#Z4,F"BNJ_ZMF7_KAW_L.+"4:/<<\,]>. *[Q;$V%,/D^1>?_7O-HO/ /EO[
M_1_L_!][GZG,S (K,\W8 ](UYPR0KB79N\-%@GQH("4.ZP4,VZNE!"F;Y&!*
M.=YB:.E=95D-&_+,%MT;>7I?;%U)GZ;P^1[9UWYF3FQ(A"I(2DO8D-S/P#7P
MG40VQ-^>H#%?.)8ZVE^S64'K/?3P9Q??PV0&7UG1UC98.FC(>M80-CL1$%!V
M7<(,[^PW_MM,9E)%6?O P6$X4$>+J(I$KDY81&9D3<E,TTQ^R ^/I.!A[3[-
MS[1W/VA7N:I" _?XBO!$G:KRO.UR/$]<Q2:K:?CWX&KCK1<N9\*YS-.E+,W5
M&N:]'GJ^<YL?$=X6_1L*0/\Z_W]!J4*U*%:H+4BU=VX21H/=WW%Z +4PI]H,
M9SS=^J6/C&!#VL-0]]B0;:B>"/(QJ/R%#1EGY&E@#[Q=([@M%*.H-J@.JYV-
M>AOV;,@N$,&.0ZD'U/%;6Z8K8)<?13ZV_'?$W%]J$O7/2B[5?A+.B9J-ATNP
M- &3A<YZKEBDQ&2[5['3K^4,DNU!9^[]Z@<2#(8,)9F>9?]7SE7&.F8&"\@%
M,G+7"!G,IW=!JEBP"/;JWUC2#$N8]1E-L5<-0_%5@OW)B_+ 1&3>#<^]>'OX
M/HP@GNXCQU.1U.P@-CE_%Z8N546=<N^ZYL8_]_WGK;>G27IN7]ZE%8\9GPO0
MJPD'#-4(C+8 JF"X5:)J_61@?>CM!JB_)5R9(0> ([3GSB!+[F=F?A<4ET48
M+2$$:7"&!EX91OQQN[:NFFO!"/_9J=CP4E+,=C)6 W9Y_XEW3_[/3^$C9QD*
M+>_CU+WM1PVNOH'W4$,E-^L-DZ5\USYJP[N>J%A>.,J;8E.)$@#\.PQN$9C(
M7OK22CEI*=!8-76*,FF,"]*%FD!6\3A82[,*U:TS\5DF/NJTV#+Y-.RP<4"1
MQ;X]7K?^4(OR?NP6L[&]<ZI ?B!1<G>[=;A^\Y@2H;&>$X<S]8M5:D$%</<]
M7%*8@PC9.FSTBW@YFNU5OCV">1=MK)P\=3+M$(G76ILCZ:O.2.'?SA$[4>C2
M@90Z.T@9'[N/K;P<TA^%2_G*$[<\D3W>C;#MA2A^A7EB]P<E=L,J+.(0,@1)
MZ>M,$U AW"M>FH4T8NK,!W,8]@$N1)^#'H]?;ZMD$7G$8_LL62GN>W"Z9?Z)
MKR[TKH;$-)P_S(;P%7NO8R$_']]]ZSUHX9,[J:]K,2)Y^VIO:"NG7>=.IJVP
ME5G(I5C[Q/;51<U8E-)=HV)'PN6OX=HW7TT9<KU^](;GX;_8;;CS!'>3 PD6
M_, "S9V:^ PA\]X450#_21;.?@T13=L\B5/'QRRRH [3OY"[OJWW7YQ^EX,W
MK(X)0A>>[7B;2@_;5_)G]D9^*%&2XPJV9JA*V>_KS&\*<0@7DFHLKQ?]?JZ>
M]H8GU=+6H.Y==2E"K[ZS .N &"T7Y5G8MQ9/5V_P:3YU7N3COSBD;>=9Y1O/
M!T<7"*6@K09UW=\,Y#OUDPY8_3ZC N']UJ-]!\EW45MX<?T_O5K"5J$AEZI&
M;G_S#L@R6BD]U"AB\>#=-2$WI8_F1K.K7"YV/__E03]_S4-9:V?QR%-A)&@W
M'PY#"P*A^S)"!,@O!J2&26FLDD*&)=4M<MFL.8\KLK(!I7==QSWRBG) M<.7
M\!>60I&& >YZ.JC6.OPGY:@6>@TS6D_,&7$4J"'T:YIBHN "C&-$KXN2YL,V
M\3P7O>6"QZ>Z99Z4<ZN9-'@I/-!' 4HU[?A8. 3E"9L88^W?HN03<BI(Y^1G
M(VB8]PA[REB4\H&N=PBMPNM; O#6?:T92PUY22^D2N,>O3-:S*5NL@[N[!!%
MZ%,4YM=HIX'/6%&D0E"&>0@\$GU 5_S=S(W?N)P2I?O*I/2I-JD)X4^K8KM?
M1(_;W3\)&=W960J0" ,,T1#6ONG9<X&T;Y0,VI+S\:BE'+VAX@">>&W5#4F5
MK7=JZH[&XN^NC%*_#N8J$*U>3JZ.M:,%&+O8$,[\*-HG)OHF&Q+^>"-6""")
M=H:J60B!@K9P-(![?7"V0RG ?@1GZ'G+6[3WL,N\WFKAX1>*9-@XWQ4 A&-.
M7K .%Q G*?;D 5(M0_7'C!#U49D(^ARY*;*LH-\W^(>)E]7% A']LBPIYY_?
MTW<]Q:3!9D$,K=QD"&)IOT?T^!C28!%&:#Y@@)9<#6#>_48>I,+:V!">1NN@
MVUUB:\&!P:$2IXH?A:E'Q4\5$'H)6A ^W.,MEYU<70(5O>.X_(PP9!9N6.S=
M<MXUULP9A&JO-V]BYMZ?0>9Y%3@/G)8Z_^)+@TNZYLSG0\LMMR]P_'X,SA@2
M"<LX9,K:USH[$-ZL"S30]1FG&H(C(F@U1$RLLSRU.5>E[$XO1M$YKQ5]WTR$
M0UJ:4\Y&Z/X+1" MF%F/VG&9+[ .6-<RRUG*B]M-8QW*JBT9GP!8AR-%%:5<
M]?4C#IGTT0RKYU)L/=E;/-G8D:!U>[)'3Y%*8O'LG%6X!=;[+6L,-+<'L/>Q
MN'QS(("NPE"D'M8$H<-GG7RA"AJ#:VJ84_'IK#QX=.CM S'EEU%I3]R%)/8A
M*<RZ^RQ^5"MH9&=C4$(,2?JNH/KNSDR+:,0I96RXN%%Y\I!X$5EE7O'ETFWC
M9+6LO$H'>P4A;PE2)F0KEA8/?EH1.<"&5&@Q!-38$%HKH"-5E<L:AAY 2JIV
M7&-I=1+%>S0:F-ZCXQY'P@=D>MON?;"M3>Q]8*.HXG=!?GV2I@XL^-(MD)]1
M/*A[],DSY%+=$,J: 77/2/'YB##/OA-NR:=R>E?56,);V70C5*L'%K2%.!?6
MODT479EQ9%2U"HO3(@:VYP$[3IB+8T9U3H\'G!NJCX0RU,\/)BJ<";Q1ET9[
MZ]!]]#7?$!LRCIUU'5MJIT,92LS7&CRURRJ-7)05 PIS^LN5:\<SAWH/RR89
M+WV-:\]W#L^#/';]1[\Y8H?TS3(_(G481P$H99AVFYF.\%2-8!U##L)%'F*B
M<!:Q7D_7*GETJJ6760('[2X[11^^]<+D:YZ34&*](@$&J,*6!JF3Q(Q6U4A8
M%6RI:3:884L:F!@@SJ=1][:W:3[)BD>VC21.*KV]JC94OO0@5VE1\%WDHZOG
M%<S8D+UCJ%8%OC;U64]H^'9G3>PHAQ)<-)?JNLF04RP@P7#H^VL/W-9@P34^
M:3FZ38UV/@Q^.C$C >NS,GZ)B%_2IP<!D0N=S<<!:RI?!W0?Z^CB)[B9IS]1
MW-1*^GI^IN@U </XF>-)#D9= G.QIURJ8 P)D-5Q9L##.8BA^>0]NMOTR6=1
MA/N/]XPQY/@*H*GNZ%NKJRJ\[_5?;UVO6]-DC/2 <O6$KG8Q^ .<>C>AL;":
M!880S*B>HEE!#226EE O=6^;_$J9OA%T=]*Z/N:,UWPDI[MQHN^K[\>".KX4
MO\F%[*)N,H3R_\3=XPAI2L!8*Q:0#2VI3J'? 4*Z1NMA[<KR!&AT@/'&I),W
M_JH1YFC#W322$>FY"F*L]J9H'TP+LPQ_9MV1!%B;)G997SC^J?XAAVWR]]O'
MZU;'^D^ROC+':1B0M0)*;N0UL'7>S"JLBP4_0Y*9MH+0H+J1\N/<GB!.#+,D
M@(ONC1<.-F[R]T@2;QCN[KE_=3E8+/O:F-^ASFC,*'1BP1AX]0:QBZ(90<VW
MH0?&W6^$?KA G,3_ <-IG*Z*]WX_=<9KF$M;TO^\%#^UC_8 &"!! 46W%CC.
MOSWG -WB*4.4@N\Z:_^\"DL6OT.7G*:6T960ID;'4U I\E^B>QN0M^O$ '_6
MP;=@7SQ@?5VA'T+<!G^-]'2,BJN"1W,'$SZNW]. BCDU)[TK:!JN_+7G0T[I
MI^. 5OH4YM7QI*[#8;#;1:LPUL%R)A9UAP<*R'=WPL:E5DBN,0BG)I^#SH[
MB?'IX-7S&M<5RUD^:3](G^/Q>]8BNIU/<*QGT+X!KTB)8?@R?&=B'(KWOO[8
M<X0\9=AI%''N_FT!;I^2AUL+3S5SQ-6D>0._*JXVT$#%&F:+;(6+HV:C0=K;
M>EY/T4-T&].%.L10P5)99?3S4T#]&MW?C,K[P,Q_0>[;RWT1Q8/[$)\@'9Q_
M*!ECAN$3/#0VA!D'(M%;*<FQ*NR$#,DNFU2B=;XV9AB>/&Q>'Z'\XY58LN;U
ME[G3=;;UN\_,8X\U:P5EL0X,5@'V&"=6)UI(-Y0J>)UJ,WP#$*=94]R>(R[C
MI&J(UQ(6 [+.N]HD:-1RRR:9<%Z049#Q25?;M1T(3@$K9@G"D^X+5EF9Q8<<
MVCG8)![_7 /#9^9&Y!F]6A(8<BM8#ZW1O@>R-XU\Y3UD[YW973';Z<T[>6UG
MD=TY)YEAL-E,*#?,U4=J7T:'E"2%D2$E'2-V.7;OVY" <\POQUJ/=?A--=Z*
MXC381Q)>[_QO]B7<C?R&W@7JJ.]H3H0%79=QG]+AV!V!@.?V?5AT1#2*/N^>
M,?B=++/GH6_O645>X;T-1TYP4"=!46\-Q6%8W-F4E Y00QIBQ(% :^H869[
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M_7B$7GI?<= +S5<!#X;Z[J$(QQ(W599-=52GE3J2#2Q.[]H<B,)Z)4[":,T
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M+3QNB680.!(TR A)=-N=Q?T2'4 MB!#'6B1 ;S5E:<X@M:C.M5.!?C$H_9'
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MELGZ]*H^?)_Y<OL0[Z7M=YPKQ3F^S>_7SDY?*EC3SO;S5,Q^DC7!?3QF#])
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M<O5+8ERGEON7=L+/+"T&+V^<4F+[JTO:)'M21VBG]B#1( IY/V<),2Z-*^
M=FI/)^YHB_A:<#96B_;ZPUMWJXK:P-=?9]T:O,Y6^6 R^@WJN" ;:&(AC&(T
M\"N#9@=.J![2%,2HUN8C:"CC"@7=(5'RPVKN;5YC +-@+M;#E)84_$<SQG>N
M^=;KJ]>X5*[$GHX1@=UFR("_-&2<HM2N5],-6=_V(.)Z:/4DQAGZ):0M%9X4
M>*MF^,A;[1<-C8:K?GQGO\MG31+-^8DQ1TGFSUW9NU#@$K1)[*<X5\'7,6CZ
M0=80@F);8FE$>BC.,:*9.R-"NG()ZV5^\,"=AL+>YBF]ZPV&?^0-SY]"?M%[
MIW&?;1T#*-8R7JFW[D'H<BPQD#+95B/]Z8^1VI1E,'JSN*,IVRS.(;I)1.T-
M0)>(GMQ=F\LK(J:%JPJ[*([#',1O<P?)NFET'9RS,?1O#)$I.0T/1PT@N. D
M(\9!"KQUD[Q)1@!&>K"/'@@\QNV/_B3-PI[,V%0/V EG-$_I:$_/^W=[@W?W
M@P.*B$XH7F0>'8E^2)@THD5;Q6#$6R3M9U;#_)ZK(_4;REZ7KFPK/L$_>.]U
M/ZG)Z<_*[[8"]P>0FFX#:'HI^EYJ%(A1B@Q)8[I>B!'-KP+3,<LQT2(4TG^C
MFG)4Y&MOD<<$ZV;A=YK_MQ^T^W6VM6K\=W5:[2'.)>7,%T@MT.;0-: Y[[?L
M KV7<3T'EK3EO0F=!$P=T_K*,,46I-#A<>(+S@,G/ @R_-H3'QDBX,I=9PW>
M(E"N6^V?C+% >PU,A<$E@<T.?=&Q)RJX8ZO2AYPU3%+Z?JN57[J'\PZNY6V<
M-OMCOJQ'/MV;9)+?+$)*90CT@-&"G:7.&MV#2+3 4,/6GCE[$++X0_?!37*3
MBH0YL:3?4MF"P]?NQ]MA9I:I0WO#Y7K+9Z?! +V$6)\@6@$*V>N9Q/WF-SQH
M8BF&8K[Y',>I?\(S>)S/>_]\C/7'F=\73I7.&:=QCJ))LA4-0487^W:F$'PF
ML,,)!\>V8&0%"J8#0[%.!=0VWH-"=S2X%E_4AHY&'%'5LQ/IL*\V+_W29(Y%
MN#QTZA^+22N3C5)5[NXLKALPE[=;;3F/;CL%^@&F9J+#A)F)]D4#2MO16IO/
M[+9I-X$&Z"&&I+/B;:I:<_5WNY-^\IOAJMJ7"F-$F\YD_)D7E;<K1DWN02B6
M5I)()^;[II-T/U0WHNHN *=BVE$2:![S+],A_EH1*IUAW!;+Z =>PJGR;D-N
M.\,VCU:N/>IR53KP'34,JYQ87P:7S(_Y%.>Q!\$'T"" 0A$@TBG T,O:(3]Y
M[1Y^'.UYN,]A1NU+RF"WJ_?'X#]CR-8$F*Z)?L 0G A.7 6J KQ 8C0M8=2G
M^J2^WBQ#'O%<G6Z B]^$UTYTEGY,-D!P#^C("F5S+_[[$P?2V%"$#U*(F0G2
MPP$QQED@@S+!XK*BFX<@YEJ2J0*&SH(A=NUY$'%AS(=)/;LSSL7?W'/"X^K,
M!X6#I!&3$W<.O\+D%(#F<QXTF\O[[W,>[">E>A(HMIFI-.0%SR$^!.F-VCP'
MXP+*J(#'E"Q];4#FE=X>1/%1ZB*'R,([J!@P05V;<W^^7RD/7@%CB/1TG;;4
M243QS7KV4KW^X D/<[)CM>XU7,.>ORQZ[S[OS\3D3P^"#AA@PY@?_;[@_+"
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MFPX)(#%T$EOFG4<"@\Z&W+SW]K:9K_#9A&._2NG$B97:=37Z:72', HDS<=
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M96'4QI<7.$8F*B\W1/P_!)*_TS**CMZ&%&LOPU@*L5".3G%7^><>,*;^*\O
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MS@ KRSN/#\/DV%>ZT!:7MJQW=16KV-)*NI.66Z3_14D4C=R1-ZXDE^1X(C)
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MZK-/?QB<>QQ3D9F@7Z4B)-,I%(T?D)Y1XHFOLBUX7Q ,5Q3IP1H+SQB?.\#
M)W?H!84^C9%E.Y<>U28//N7]XLV+E;@M!&2>.Y11?._XPEYSN*T?Y%LOH[%@
MF8['D+&OHKN+V;_!4$9U3\07-/PS'O^M555;M3919YQUS?+EIU<&*1*[=(7J
M=]2;;)<>2Y_ULQL+#UM>5W<CSH6VFGE:6_[,-,%&"ASV6]YC:AA]<J0B7AWI
MT=!PIPK==KZUY<+'8>Z$E UM6?]7,V_K#R@L?IB!-\T<N6X*DM[,3'@7K6$&
MEH15PJNI9-G0(_GCP]3O8:OAPC6E)< _UBC9O2M[J]DS_OED"P8\@)L0WB'
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M-+/=8M+F3_,_/?6:"@"[N O7M!C/\6#'QM3SQ/E *&7VG.&=+J2T@:5W=.V
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M@-KAH'MI+9<;'VI$Q O\)B]WLCVQG2Z8/>B04;0,VP&2<)I7>0HQ!U8L$EZ
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M=Y;N-.$U?.Z5T?2-Q4%6MM$ '_"&6@4^X-:R2/[^>$N'$:. (Z?$>@1N97N
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MQ\(J1Q,]RN(DAICF"98PFM>%970 U='<+5Z7+'^D).-&F?E&W+5C\/4*:^
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M80A9;!''G*4:==#^:^ V6/SY;<-"QEO]T?=>5(:VX:;8FPFU[AJ$"Z38M+4
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MRM@ MDQ7YXYGJ:B>DC7:E<$>G6<K$W796@X?37< #UPNOVE&5K;.\F#>Q(%
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MMY''Y6M6'3L_,7^*Q87XT2&(.1[4GAM<9%WC1O%@;M2!@O9#3.7$*EOE:/W
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M\N "9P3)I0L$(>!8@XQJ,!F+/EY][\2VUB#7S7F2$H?":AZ>OTV\<A3[T.
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M<M^18VA@&[+NS<+XS:%'M@WF%AZK!4L/]HS+FER6;!F_53.5]IUO>>L_<Z)
M**'V,)*6AA2AT)Z@A:]25@/MC9O:;W"LZ&K7Y ET:@-2]-VV'GV-W+HK\MUB
MG*,7^9LLUL*VY#XYB%N!='GN/23M_^GMZL*:.M)PJM((B"D0B))B% &I"!'Y
MT59,4$0JN(("QH*0"BA$I)05-G$).?P8) A$411A(8 _0 ,"!D4Q)H2H*:B
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MGQ$7M1N;D* !5LF!=6QA597EOBNOO[()N>[\MD]YZ3IN\B?45SC)[%WH+"Z
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MUPR23F FO8W5M 3+PFO@M52*7-C^PM$AZH_PY0B1NO(RX(Y]I-RNI5VU[,G
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MNSG;=AV127S1QS&D@/IIG;ED,D\I]PN1>AI$^'TB4A5XW:L8/!%?*%;&PAU
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MRC#/R;=890A7NTCKK_<'A,-2)[=$B)ZL)61B.J3YP"7*)(X5]((9RY'/8B6
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M$T\+*_VYALC8OS;XX_5H]%PY'[ RZ\VL''5BGTRYO<TO)VMC^:"(@OO_F!9
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M-HG>.HTDFUO!#TR4H8HMS!T$\CLWW4]_H!R]7"QG#.G<Q,R_7R=NWXV>1C;
M4H@7WIBQ.EH9X?7%T?^.O3>/A_+K_\='DCW*EG542B5I0R$CA21)98F82K*%
M2A@9<[78MRDJ14P1*LMDEVWL6BS9&3&&HC#,H'$Q,]=\+_?G\[OOZMWG7KZ/
M^_[\/K_/[_YC'N8:YSK7N<YK.<_GZ[S..1[:T=Y)M0!9;82T89.P8C/:XV;V
M)<OQW3*^EP;N^MV6I>LR]>'[[V*W,4Q"AI>SQL?KRMIN%PI'N4Y72*5#K4M>
M#Q1;@FW1>0U[M;,]3S_MRP[W$SEW-=(6R.IXMO55Q&E_NY>NQ1WM[C.>\XZ!
M_-W=-"Y"!$8I1IVDR0@8V<1@0@*!.M3BFNLS2R/ _$9'DB 70;)@HU[Q^D5N
M(9+^I]-&M5HV3(LV9L#6@L:S)P=_N?X,EG Z""#)8-?7U$APYV]' R87$0K,
M;OA&^0Z+]ZMQA6$EB4I@AY?Y<ZZBEM807U)1"]^XB+#O!E[M1E(+PW\O5:KX
M7:#CGS=A^=<^OP#1Y:'VIQ^P!&DNHNP4%R'S==4!24OT*AXCR1-_^#A2Z&W0
M80==J)3 $>@-MREA[^$B[LD<YR)R8>IIJ/E=3Q7BH.C0"U$R/$BR_Q(=40O]
MTZ9>WC<)^2:UR8=& 9HJP^8(W3_D>FV6;]:DMKSXV_Y^27>>@/3+BGG&V5/&
M4N8(_[TVX],PN>6K 'L96UO365) C1+@"D24\8RU-=P8NR<34L@YJI_J85W5
M'-=HLCYQ[X$\.\?5L&W0L?OHCD4>U#9P"W+*FY'$]-!.$.8C1>+6@Y:9] _O
MZ_GP++M.K&7>@6.1X4]OG^6MYA^2M'(0=FC7LTP] R;5Z;3DIF5,:.4-NBV%
MA-2V\'6MW8+Y$GMXDX/LD7/5=P^N5) K,E#Z78"*^)L8T!^[\5_Q<92!8<JB
MHB9JB0V,+X?/?KC\@57@_X-5_,<LX4^?/PAS1.I7QQ!D\5]X@FR"-(:_NNJ
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MC'HR7Y*;_XW+_L@!B47D@0$+5$K49N,ZR;S/-"&"(:Z90C<1ZR]G6H&#J=A
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MQ_BRB-$M<8DI;?5IW&87.]U#7NJQEQ^X_E V[6+B5LG=9?=N/U=Z&KO+ )F
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M9@E@PMC-A:-;4DGH%9GAJ,^\05R$XS78E:VJPA&?8G\)KF!1,H!T0AIGF82
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M%K>P9E=SW)64Z)7WA];W.AGFO'1T\.A)D(L>5K+>.-;\*E/E\"M!E;4&N@'
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M(^8P8G)4ZE:?R=:@I;W)JRQ\?#%R1.;$NPTZ<;)GCBC'"BCW1K.]ELF+.32
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M9EJ85NA^ :[@-H_[+88@T>UKU$ :1?FF$=N!0&O*"X@U*';*B=A6GVNG%?1
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MAY""J1-T<[+?\.N_>$<@>J=+PP=LHOL7F\)M=EVW33<6ZT5<BIA,%&RNY2#
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M)*!WA+:8L*8ZGR?1XBQ:/=3A6T;JMF\)KM9/TIT,(C0HW;ID<#E9[U7,+@D
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M:[D*$==Q-VF>R_I[=B1BC[D1A]/Q*C"YJJ#G>PD0BC[(Y2@]PD$M*>ABEEG
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M7V6G;,&>>@5YZ)JGMIWKD1OX G^)EBO+L?G"M,H^K4V#GUZO?9TFTEM)%Q'
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M54-+;^23^I T.NKSZ8I==B/V=^:JI@N(;ENXV[Q5GY,9?CU#IWY+-*' W!]
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M!TO$6TJO%KM&+PXW0^ND!!M.85W;'C-(Q6837FUT[Z^$&ZBY:.\!=1H:/&%
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ML3]>(Y?L_)I ,S[G$NB999@0,[-[T0Y1BAP4-8XE'@0+D)G[)F7+I]GT>EB
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M'TU 2!!J OS\@B*"0L)_#NA,5$18],^;/S?YETNY^7AX^(0%^ 6$_U\?G+>
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M&]2]SC-J5F\&J,<=M>]Q"^Z"6RK4=/42J4<14UV=&*J=US#!JFL+C0NF+=F
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M<HV0K#9Q@#IX'YT#:/L._;281KW@ %&W?,<F\]!S,.J),"7V)X2RA0#C(GN
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MXSH\#PA8GOBO7OS_6JN(6="3<L2N-&W="[<#S.774]/84C!1S,=+8HP?.(>
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M>UO"+\BBI3UQ;N5"$S&0K+97##S5%P,[S::M]&$1A@OGR]$1[OP;NT6]=DX
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MU+B?5&W([2_IL-$F'O.RQGQX?&P'ZMVH0?8%G;_'_PZX[%@F!OX,^JF8*2]
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MCJ,/@ZQ7E5^RQ5IWUWJ^.CJ@_%RW\"7-2]YVA_77[)HH40H2*<!B,B= ((4
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M5.;TH;::"S*].-VD*C.6+C1&^]TR9SM@;AN4KUW^8N[ P>8)D\P2IZK4M=3
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M+?C.3[%]DUO8^$8$4P6N7$<)[F:(^^N9[7I^M9#3-$$,6C,__/SJ2$A?O/>
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M]^><%#WXN$!G%_X&Y\L %YCM0##_Z+6!4S!#6CJZ$LA47<&QMQLO/.(19X3
M? ^YFPN0GEG_B_.SIP])< %O7RZP3!%GK\N __U4UECF'ZO^L>H?J_YG5TEJ
M)3VZIFJV+R/VR)L(2]M_(FK_=O"009H]N*9^IY:=<J>7\RA[]3@-[K,)K-2#
M+IS.]]Y<X+C=W2) YK3E?]D1AF9)DSC'\LJY@/MD)1<HTG[?WZ3 QIGS,T$H
MI>5.32'3!'.79AUK;LH%A+U>X<8FM]%:)[Z%Y[LB5Y<%E8_IW1L7:/!;C$71
M'%RW]*V@); CA,WNE?>]0BLA3'^WH'V&XE?#+I4+Y\X]]3W\Q44K=(EW3DF/
M@J^&<?$(^///!JC&1!IP3A920=HIW/I!&'#)^8E<(+WT(Q>X< -<8\(,Z1,K
M@BF7 ,W]VSDE3#1+1H>38MV*@'S4N<#WWZCAK3@.%CY[RP6V(=L+F@[\W13D
M"-RO"G.!PCY:)T=)B+!V(&4E5H<+X AK.PD?Q=_XX).;_G[*WPO,OMP%H_<B
MQ]9@B7?>^3^D4\G_(I72OB @W1G\K6RO1*879+DPZ_]X+IB6O8^R\TZ 9^.5
MPF_;U\];(+NOVATQ-K[COR&ODMX/%'0.1W,DK9NE1..@(UW6K!WVD-XB6Z6S
MI9>EYH&_)%ZJBW_D!3G!IKA5&5^Q2/##QXB*'7=SEX]X[B6R?Q]_A(X*CP:R
MX.W?&[0N*.NQ*-"/-T/[*[/2_Z/6*4WY+V32_U)10M79^+.A$],**']QT<R;
M]\5I,=OVW/%@UTUA9=]P 9%TC@@\VSJ(!J>PD)->@^"3RX:_WDF]K^TK9Y_A
M_=W][SF[X@.RK*#)[/;&&X5?ZV/ <8L6\E=R"T8M[D%R'2I $1&M0]SX#O7G
M#E*!"[0>AEL7'<<$*%;GY"1L!*W,-1Z&OBQ]Y.\GG680(%U[MFI*#(KVU9(+
M= V"9?M1+#9\YLDY%)YHB0G^NQGA>(Z(-*Q.(3F%M5<27 I&S&VQYP(H<,D)
M?(BXTH=6^?L9?K"![G.!OI^0.Q?8S(=FY5JOMZ9S@5X2ZS'ZN^!HE6,G^B_F
M_(7 G-??X1JQ^O^_5KJMM$J.R*_;4A.CG!&TF)+B.7-M-,^QLG-+>W@EMAR(
M.'G0SHPCJ\.27>4D4\C>'(FWCI5RS],/A3M98HK_/@AV+&U@0NJM=:_J#4S8
M->6?*>I'R]ZO(7: ZM5XIO5;R;KC+@.5Z _-QQO+\G),U[0%1_?^1ZWD*/A_
MFG7_M\>,0U%**P[2VU7ODXV/Y0)^I)BW3I^->"<Q2)\BC>+/"0LRWU4?^)4*
M9U\R'-JJ>Y*J-S^,VQNQWI&PUDOV;K6'MC>ET\6/#3;MPO:3MJP$;K8(478:
MN$40LN%O;]NW_\)W<XU;,TT/\(<V)>CF_]LA+@JK<1>VD_008?[N,/CG^4@I
MZP072)4_S04J-+C $=D?B'_-95; >-R2^F_42AOX\T@]C%4+QF"K0=>]:9@V
M8(_^5:_#XZ(*P+<<@.^+;^,$I_SKRX%(+H IYFBMY1_L3]#%CWQX.2V^!I#
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M!KQ:#*5QQ)3PW.8#$UFJF=V))\"E[9UXVZ-U@UKRU:/\NWT3FO9_V'>W!SA
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M"IN3H>^MJQV5#2&K-<Q-^@5,H&?#-U\ZFQ!P3E58VK75H*!1-(Y.8DF<MNA
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MVMWW#7CCR\2U?.6@Z5Q^+:;W$RX.XOV1&9&!"J"X"C8)<BS+IN#?Q:&U4D$
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M@$$E]'9I7&T-<U@C_99@M\XKT_JK2F?.9E5%2I]9<?(--;&EE-*6"WK&C$R
M33?D"&C3[6U!'?7&@#J.,Z<E).TH /TS/:LZ=$.LQ[#Y4Y?8D"+735D?XQK/
MKE& I>ABB( :+9#L-]M&"ZPCKL:(328L*X6Q]F0?RIID8)S6!8?9M@Y7WIU+
ML/^B^T9I>\ZG0 0@I\W:%'C\RY$DYC[7LSEZ<QHO7.B(^@)5DQ$;5U<YA[Y7
M4S :<GY ]3 [01/:G]]"OM)&ZSJS5XH+V3#J?__DFP"SUJ("ID69T/7L]V<N
MWC[2N7;W_LS(G-"'^[LR=RAGO[QFO>CWJ8=AK5#^N1^]DHX=PKY)X.>T8==6
M@GU;HTA#-;1M<B%MU!.F(  S;U5U*;<)F_9=)3OPO%)&7?CZ N/*=U/K;LD?
M'A*X)TY8!@+I.48]&*B_%$6]096M79L<<:<X5<OD:]4IMIS\B?(R4TP#++FZ
M6?G2NXV.=[L:T.PQ/+"5Q!(IJX5K=NEYY;#VT?FB%=L_]TX8=E5>HZ8B+0L*
M'F)FU$I:YT3&KJZ.H@[I]56Q_-F/X&LQ70@:"%EJYVD(!HDE-[J[B(X,(U*<
M?-P9:M9]?G%>G%B5@!2_LL\?1[:TM69'^=\Q$B@F'S_U("_(VG1@L%F5V/"M
M?3UJ4(JAQ(Y#N'F*.EM/S"G1# _22Y^2;6QN=5SLB\N^^T$WZ\X[=,BHC:?6
M5+B/0H##*O@5EB,3@091'W,3ML:[;;:"*5'06<E/186>!B(HQG4C.LNFQ6R1
M4U$3CB73C59AQ?%*#U+V+SE]T"KG^8::NPAZ\C[V ^(5DJ0+3@2^%_!"Q=8O
MPQ.\1W3KX9+T\*>9YYLN.[BLYYLMVJ:3Z.N99#J1YXIYRX6L3+0N0Z:DATA.
MA4LH)CX'0HSNU\O*=6M*1;/-3E\PE?7I::F\\R3>8-7&3<>'XYTSH[+-A)0/
M-(]HMGCZ:/=A4O*T>:NY$ _GCW0^ECB*H=2!UGHV;:U?%OM-W_I<\WM"VO*Q
MC2%CV/7QJX)QE.5D9E0E+SEV%D>]Q2:@@Y@>+,>>KX$O\O7V.)&A88-VB==V
M9INV4SV+1\RN.MR&O'E=<:E>[D)<??0G.#46FX\V-WFG09; G!OZ-)1(#D0'
M+_/5<2$+/ 4@N=Q/_,IS=CH[ D2>O" ;M;N&G5R5US>C@0V%'>:QDZ""#%]&
M$[',PD[83?WP%;6G@?CY 1?2L,P3"YK:FM^96HAE&6O?2MSL.&A>03]LH$GY
M!>8&(4$N242R$"]Y?4$*2_R.NI*)SL1!FS&EV3A:]@F Q#1EG>G4DR';[GXY
MXKK\OK%^KY:OD62PG8L-WY63.;K"8:</RKP76V*^P-9XPC591[U>8!I0-&/<
M((SB$1P 8O(WSXS([HA3L<^3>_!%"@5Q;R_'0*^<30PECE7"-NA)Y%D#7AP!
M/J84ZS([^?UX;8TG!1>)$75A[5THX+'G]!:31*\@3V]+5Y9+A-!X%L/$+ WZ
MO)&BS@D81=J'(K?G4^4QN7[6F*<7KQ8=\ED=)7O /H[?\LBIS;L5-A[B6YMW
M@B\,M/3_851I(?8_ NCG'W$ABY)$<N+':KJ <CIQVRHADVGYXZ]U#&H]ZJ&,
MDU=-[C2'EOD>&'KL)$TA[L<Z0^]B:2>AXN#R%&#MH?-R^*]EN,*WRVZD8W">
MF8@&6\6)@WWQ_L7=:;XN(>]E*@-/IFVY.-JB;#%J*+QL9I4<&\)2R@&RC]$)
M+\A#NC$HHQ"*C-*I!,CEXKMC<JGV'B]A[V*OROBJ9WJ3"X2?*@Z+EHVRDR?[
MVFB\9.A&;(TJ89M_(&<=- =;L]_']@:I7G9? 2VH9RYG:KQUDVOS<P)>*/7-
M5:D6D35E9^4V5=Y[HZ*?74<JB6U"Q1)I9N_W,;+9T1R9<T ;Y2QQ+-K*&R'D
MJG-'ZU[^*RNU^6U)$_$::P=/7K7:TA50IKQ9?"TA*1>[AJ5/@]8%P2=, ;^Q
M(-C!DJINIVYUM6+;O:KG)BI26]Y?G=GTW,7ANM7P^*/'\>8N.QU>-BU&S:>D
MM*!N(Y0<7\&2N9!7:>!26*/,CM5(]6I,4P6]RD$@I8DDQO+R5L?(LY"]&#U_
M*T_-Z%ARN,87D]+BR(N7R@Q+#LKX-PV!]-:X 7>7M $#G;)3!$"D.8*V?-/M
MD1':D"901%>+R65H7;=YVVF2-;%H&;9=N/[2*4%^0=XP.::0:(Z]V(UWSU[D
M+'FYC=.=$\W.0=M(MV!%2G/\S N<'I(01QM4REAO/$@@R.HU*<P\SUHLM'.Y
MT=VL'B.7IGE;/=^^0/9,\8DUPU'(1^<=/ELNP<'5?8O$R.1"PANYD+  +D3
MYMA*W0TN9!W?$)%\ >MFQ&@#3.!]14S$[*A?TC@;MYCF]+!,S[--;%K#HJ?A
M:%&O2K.5FO=,T'S@-S_>L4 D!-./HIG/#_%1)>JQ-W&%X2_H]\E^C>^OJXL:
M.9)M,>^Z3M$F(M<[[NH\ES^R^M6P]KQ>M]+EGM5.^$QLC3K6,3:&"^%K:T -
M!C)>=FJPY2FH)J@4UM.-(-.EWCFMQHL,V2<4_M@)F> 7I174N6/0+UAG$R;_
MN:::]O'>XID8V+FNL8KBBIOD\I(WD:;2':]4WDY7AY_B7RV[;O_+%S&I1SW4
M% 9-JSPZA_+*U1)*>2DK5?$_Q2DU0F-PQ3B6J):&DBE I"O*J-;X'4:7#<K>
MY'7I72S ?3:72Y%-EPM2_<R%0+!OI[*P?12LSGCEUC$NA!\-IU5%A.BM(;OK
M'N[PSK$H[?P:LZU1U\UF_\:+VZ*4JTTZC'DL('R';)'!B(_>78@9.B+5Y7A9
M6>M3C=PWZ8GIA:@0WA&0?;,O"*2!*/.>T"([H(4+>2*YM$RX"5K_8$_BS <4
M&]+7UD-CV;*L[6*_KD3AJ;]E\"D_!'4G4K^/[)6282%EN=@3*QL ;Z%I/M]%
M=;.ZL1^W(MB^GI]<)5F7L5+@"U0._N[Y?^D89KW_^QU#+D[<GZ^:H"]YE=X6
MJI'GX+S\^$9"O*:MCFYL@=V1W!=>$H^R6QZ>&>:76,];"E4L>?X$NH'F-#='
M2VQ(.P LDH?>*YWN+$8-?/+?2D^,5J_'7GKME9F??5UN7:.!VICW)HDS2RF"
MK]?W?2 6-+'$+RTRFH$78VVA7$BQ!$MDI@&U'BU"'SK<[<'A]\]IN-&0ENE$
MM=$-Q!:;B37D.@M%-[N4.]PUW/8N>.[R&K-KQ%(_UJ8^CH A%;0Q,+@TIPDK
M11"?@O&!W-@M>@=GNSEULR9O/G#YD*-0>+IW3]EIH7<C-@=YK)*NGG_>S_<H
MB$F9GU6GQF 9*>QX%#F3<-^1AF<$V%I/G+;)^22Q\$YC7Z:++^U(P9S#2?G*
M.U;^9R#2CR%!AF3<>L"K!B/5Q9(98Z]M.]JID;(YM[A*_7CI.??9N?2#<8:B
MSJL:(Z->OGP"@4 NG)E6?@)-(UZHNL2I&_N4MZ;TYK7K1-IC-Z76R#M.<VI-
MFM,$>)^/*IZ/9/.>G/+\3#KDW>QKU",?O.Y?;I5]%SC?^.>!\R[:^4X; (],
M4_5]&#]^M#'5)BVD2-6^&K:@XX+[!N ^E%]%S8-:54_4X,O'UIKE@"KR%'QQ
MD!J,%C_-A7Q5MN-"2&8VHI8S8U[E?9$E5AINKTFUB<Z2@P=MDZX2=WRJ//OW
MK[>$AJC1VAK3;6?D-K#ZRD"(^]U[_>_^R"/_/7Z^&<2'WTEDS%(H)[(%)(B+
MG;T-8HR#:#JZ 7_YTC,1U4U0#U>5E.^WVMSH2:PKJZ*47_PNCL\[6(P2=BV8
M[(W+#MLUK%9\0:>03#CYWAHT\XF6('HP6.0L6U?\=DN&!YP"_EUX<#;"YME?
M2ZBC&LEFL6+3(BT>'?N&"YQ)+[^T]U7V_=W[-#-I/*!.H/CZA^K(*2\>7I([
M>N>UYZ.O>'F\)^"T$C<$!^@\DG/+;=H?R5[&DMDGQ*]\FSOZ:4HNI4[[1(Z6
MI*5C+3.Y^^=-.H1ZB7I_1"V"=AH'[)B8DQB##3%7?N2 WYL4OJ@CBA"$BTQB
M]I=W%'>W[_+^&%=R4RPG8T2C#(,VUYJ5K^THT#UY>E)]P(NS#F11JQGLNP1=
M9U2Q7_4\GW]M5P-<FFG)L&W,H4N=)=[$=+BIY:8\>?W:G[0'*2?U8.Q>W6I>
ME!JVY@*!%UO#@]G,Z9FC5S"6@3SJD&<T85]I5"!L R#?<*-[.78@7K34,JH-
M.<(PL;HP/6K]MGFKU"/-E=.[L@11\,_U\!V8CG:T%?LF7(=UI!NCX+]J]!.%
M6C.J0\]_(]-3K"V^8&VZ,QF3;G'^R*8)J7:=QODMV\_E03#9';_)E?MA?[DR
MXR]V+Q41[$8\X+BT6\\ M)QO@W^GVM^OK8*9WR^TOX5<@/^[(1=9[4!:=E/G
MJ-G.&QO.9%[*GCMY'?0#-])!Z&)&Y^. &)J5$LV%1.-=T@F.M*SS(TO9BWC.
M8:CXSS=D<,34ZV'+$J!#\U#G[*K*BD)-I]FROC#[0-7DB\;69@*@33< ==Z\
M ?16'2! 2J1 V8+@ M(&&TG8=1G!_M]JL,9=EM_=.]K&JLNMZ4K4S..Q,,A=
ME?>BEIV-*L(G;2&JM2SL2O@MFPM!Q;)F1G[Z/NY?QN[$ <2#>R;3HX#=O[7B
M#!!M8A>V39&^U7,ADT<J#:J(9!PKLMR/?0VQ+/S=QH4':%46Q_ZP)G8HIA7K
M*#N+(X[>7T"'SF8P-:Q99^C2HW*E)56T.=*=N6+-TJYA1*K_KEUB#UL=Y!:"
MAX< /4D((%]+*LF>!65<#:*JD'),ITX?2]1@TE_>"JC ID^3!#@[W08U.J>6
M2V^N3?2\LGQ,^QJ(AR^[!48^(XE<V6"U>6(Q((@T=Y*Y"URTQQ!CA8@BXEW$
M6.H7Z)81-"RB7INX&;[3^89&^Q3#6G,T4;,D/TZM.^Y)18"'K:W\FEN!MGUQ
MBB07=C%&!UN#S 1R*-!;J/78L2@"%.BA]?8&>J4#B?5$26^;S=_.#S4NZ+HL
MWM,U.'4V86N%0N3BALT6Q )$$Q+8T8*VHJUL!D>C:$8@0F=M IRN]IGG +@Z
ME*2&NX&^<EYNX6%+9-%-R=,[I]8K>6C=]DL3;><;[/Y]6BJ*X@0.>RS[&FQY
M(U[Y%Q^-]Y\X5M6KIQ28Y=(></_]1N&LL;U^O-WW5%.DMB#Y3NVQ]%!?N.!O
M+@8JU%^I&"H!',U/B"^?L #X?W('WJEF_,5*C)T=;N*@V[@0'NQ'O@-&WEC:
M"PQH#-J)7,C]:UBZ]R]:S4X!F6_;RO%-=5;PA')^[$_/ RR(&[&3*+"'KXE
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M9_3=) HB!B&L9TJ%"A]KVNET_U1RAPAB^%R>O$!&F P$OQO@'XL%5-MF1?A
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MQLI!<E=@R7'5#D<L;:OB99QGQR#&<A$"<%UG.P0[$_13Q3!:*5KD(@,_1XP
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M\+?#=W^61W#P;Z?@_M?.?<<_?]O?'"?<UN/0D0^:*MLG;BX\OHZUK.QDNC6
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MJZA@634OQ.L[JA/WYU3G%1I.A]]T'&L1M*DZJ_S1)-+!_NU2C#\[T+(N4/4
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M\S,,C RQDI9UW_VY:YS5T67WL+DO-H9>5S<^HL8[WC7<M.^B6>3P<X6Y*Q<
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M;I^,]8W%G OD-$3V"8S-YB0";/?ZT55]AW-JH@MNU4F;9#'W\>[KI;M>&V=
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M?%4P:@MDC3J[WI1 [&N5B2!9?<6831PI!/7/# 7+V$4O.1P\43?@WJ'Y9EV
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M6XT.P0ZA=: [/\'T3VUEXYM@3#6H<ATE>%G [FUF=^@'UH&N,P1Q<,/2ZGG
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MQ[OI0]_W:&U+"HW@ IW+$T>FXQ<GZ MDB<7WE(2:2S.(^Z.;J;CI")/>?0Y
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M@:GLD%LO/M9EN.\]=CF_T+C)K_N1GA5P$31<](%04,3.(W@Y@MH=V8M53.M
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MW$%:/;;R"P8=//-&8.%@6 >^P,WM+24@X^K]\,4(9E_1D;N#0AT#A-V\'%H
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M./VT5*XVF[[_T?K&@)39B]C\R_(;G2(+^99C ;T)YR;*L F#'@N;02H#F2>
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MVLQ&[ 8PO1F#?@*&3-!1X6GSB*.1AA4#%)Y]'@W'':T-570/O)68FV8PK_I
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M%-V_+WK@]MA>R4/WU'Z\&[EU#SW:MQJBP)>P&CE/G=2PCRI&[*5)T@*PU^G
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M4[PWF.&MGJB6[N;X7][2^;_SAV]EZ/\#4$L#!!0    (  N*55%^2((L(N<
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MHX-9.S6GK2U.T3(!CYTT6"_*+-$W"]?1P^5MH #X!%&ZX&2T45UY_.C,HNE
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M)IYE:QYY1,3N+E'ZV(SF(>[-DS+RY^3O2MB[V4L_.5XU5/-^>.'TMO%*N8_
MQ##4K2J-:&M6_B]UR!%V,VB&L&4'ARM7T:-86NM.$I@12<#<&H!1+$W[]<(I
MF,L#F]IJ;KV!"<O:*ZN:GZ=?5"0$N^TM/Z8(JA,RSUA' PHXAI C+6 G;)BC
MH?7$:+/,FHW.55&$/["H\*&,8T%TA-^>A^LI18SX'\PZF/[I:G6OHXJ5:<KC
MQ-08)5%#GL5ICH/+$)2C%0$Y=!=DDQJ#F\QA9P=&!C8I4#G)I$56<3 __4?J
M-OE*?=J(8I!>/>J/YN[9M/L_0O$C@2"K&__AN$U/;OZ_ CDP7623'L.':-;(
MXQW05F;X33&IRDONIN4/E,$F]'P)F.RR^K_$&1E*7K>%_]4HJ.M<><;N_U8(
MTS^[_;/;_SW=;/CA(L$1:P^JJ@9OAT@3#UC*#V[_65H$(Y:)UH-R,/UQ+V[J
M+;+*_3$';\WP!MS!":3) FKJXC4*K8 :>;4/OAP3)5^%E7SPLAA68;2+UJ9V
M*&-\5Y9>E4K^*0E,Y<X>#C=K;UX!PR5ZEB;>BW3[K(=043RXAE"LIHPN0MR^
MK%=GZ85,NIS$0=1.9ORVI$T".Z5Z?PTA?=@@"888L)OS=+*/#?)&)81JM08A
M1:H:A(DKJ=4.-M/-(0D"M.(@_CUU=UI$6H)V8Y6+MI"42VQ0/(1R!2X8T9^!
M;M;G((;Y+;H*ZV<H.$9^P+JEEM#2!;U2/Q 8(G,[C7P%5Y5D/,[U/8<,U^?>
M??LM!![1AZP$M^!&+*?$$M@@+TB"W1FK8'B3SNYN3$E5U(>,@'U*]B6>)VO&
MN SE]Z6D[C%EN#%3H5.EL)TR=RVTC!@6GPV'5N;,3PSMO$66;&,V]#&$>W_6
M!^=AA/ZGB<>%SIJVI:)#F!-7VZ_>N,UUB?C4"T[/X=CG\.6=ZP$$F)E(-^@(
MNH4-JL*A-L/MK"BP>$QE@N\?ZRW;KDX6P0_T\WN'%)7&[#7*N\6Y^_7L$ED3
M2,H5S)@N[1&SMIZ7[A71!:WBJ-!Z20*XGC_@/1#4TG@*"-U>DHQX%Z27OW4=
M"_&.<LUV=(7?M7]R_L(7R!OR'!LT"J%9 T9TJP59KCJ@I6"",,;0IBX7) 8*
MZ.AFI:TM5)=;R%2F\T;.E%Q\F&)]*"0^,:"2;R,#Q+C'?!(AS%$@%P,)P%D(
M>1"5#/4A<"^$-B81X;N=&%=QE8#GS836#&O#?;9I*<Q"9K0-ZKC[CTR4KLFE
M#?4H=*5Z$QL$R"LR1/MIF1RSXP.IL)Y_2GUT_ZH)M:,%#/&FK:FEAST0J'RV
M\%#(Z?B+9*);^/?$<TKODO>51S,MBF3E*-AHQ*W\+*FV1IF/@RJ=,:<SDC(L
M#]SJK?XL)U?>!HKPXHQ.JUX8S!"!TJJ8GW!3[T)M4Y"NE JR&BH?H0\XEA#F
M^PRW)U^[%NCGK12(W(\*@,NW[;MKV"US1?(T]Z/_8=4X0MVA@((BQXYCB6-I
M<U3-;#" I_!N.N^A$QO:GK)!?E2YA,ZXRJU^4&)"X<HU^Q1Y:ZSV?5N-$J3+
MH2?\]D*CHR+)9W^J^+]_5/3V)HC'</?5 02$J ISK*2JE1+#=1:O?=QEOR!V
MT*J>]F5S[=>A3Q&[KO)\A5#@6TLU5!/:3L2;8S!/$U1:3U\-1587'%]P4:+*
MHO04M%7<!^!'/R?S"JZEJ@B  OVLMHY-^RSS*;W=^Q](<_#K-93EY<@:K3]P
M&CA:5#1/ >D%E(!V&3U2V\M=<!/$4)Y _BETEPKY2^_7B)E5P ;U)$*WYJS^
M].?U@:N[H".C2 ; 8>F(*,B?_K0P_F>7_RN[V!VFXDE[XBAAQ.@"LM=2:5*K
M58@#0EV0N=Q)E21_[OF!'+%V#F?E%,S;HI!%,"/?7:X:%OY*%ZQ6+/]H5&/6
M&&A[$83JW;RF>O8N'G#Q'-6 AR7<,&KSOT].VW?V9G'4KB!U0\@UQ'XJ+8:*
M)*:])B?X*+ME!"/J@&LGZ<5/2<8TB5_(3U^VRK!_BF7')$-OPCB 3HD+WH9'
MAS8,C4$$$4.9J .32N3YAG.P^X7*2Z.@F+\:!_^A\.U>Y%^-8,^(_SMUB5.Y
MFW.3.M):HB.:^,=QA__5NU7NY*@I%)B%U]EB',91OG&\((34V_#T]H,5P8LL
M(::"#P;KZ0KUQ%:MQ:Z5.2:5$91F-;DHZ"@VR!.5B*-<A(TZDK%/65H1+;"#
M!D<8&D --<@*2)A:C8?P((YKM3^QN*ADT)N_8+LP1YOA>51R7RCH@[BXA(SZ
MTCP9B8)2K'N 8^@6U-B]B ZTH,%^A@( F>HY,.R9@6YSE@@LA;=+9G],^UGI
MY5J3I3(5/_[U4X5@-V-?JEBO@0Y"F8-JF]YLD+B>\0=6#Z3*8VDK!Y -OV9"
M:4PGP?Y8."-&&[K#B--+^6SW;'^NO[/B4@QEEL6O3L0D/O-&5Q.6(123ULG=
MDHA%_SQ N&EKR"'2Z9E>NM"/MO/<62T?WH*+Y_Z-Q,^_7_1X46TC-L?SH,4'
MG]&&TI>UX?2$NJ@DL84?AB)<WO'K^JZT"L#8-WC4Y&G9 XC( G]?9XN.S\3)
MC=^/]IKT)G%LB:=D6@ZU:6SGO%#2+FH9MD((+KBJ\=UNP A\?+(KQ5"VU*DG
MR> 4XCCP4#RXLZ/6-S%NJS3[EQYA:UYCEB+*\1);= %"&QM4#^"HB["!WIKP
M,Q?X"QQ2F.T'?GW>.JO5'ZP^)=:$BVESHV!;)G0DGDW[S<;TO(' -"Q^0+D-
MI7L8FNT?2+@)A#2@2K(\L(<-LBMT/J^BDCENK@[+WPVA)$<,&>C,NE"''D^-
MF>B-S3V\N+8(SS$[-EHPH3Q8^!8, CHI 43+9GA,:$PK+DXGOYPL<&U2/\.+
MJE:TEC,!W5LL^=*YYM<''KZ"OL9301K:*8\ZI;.*0(R82TQ%((620-QJ&Y/R
M/4,Z^'0[JN%-OF.P\0:EJ$9\_,*5NN2S$MT:_@/XPVS0/AOZ*62O)AOTO8OC
M\<F^!4=J,L]O7<)%7N_W<Y%*\$JS5T@DYCPX5 R^9ZBU?8JB2PI/YY EVL$C
M635>I;]EFM",7OM./)L2'AT"6?JHO_B:\_(X\S5N+@,Y[;[%!J'L8!0"49$#
M>4\?BNG 6B8$-NAA-4\KFN'YKV]\:2?.U/F>_7*V_=ZIGU=YS/X]^X0P#623
M%4.*+@WT$\$Q)5!?\)BN Z#XMHUT3N$E9@XM"B4*IVZO+JVA*K3:I]?3.]58
MMJ%OX41,_F(SU \M@E#IU43] 2!)/4M:&(;_1RHDV3>PL"00!AI=I #^,[;6
M19-'OXWY^DJF@36>7#<X$6 (04,H[Y!3D= --"X6 F1P[TRKCF,$:!N(_DMQ
MH:-T<XYA_@G&$ UH0XO5WZS5'S6:FG"EH605HLWOYW2]&OZ=]/EM$QB5KEUF
M2<9T$(;'IM#MX ,(A7(V*/)NHPKP'0)>2+W10<+LB?BAHS7SLF@7=''9727?
M/K/"5V(#P[$XGD1$]!(J9EM[1H^/-1/V(Z>B"0<-_O"&YTZ8X@3K810I"PKS
MA5+1&<?,SB"U4D7#5RVN&2!Z^]\D^^#_LQ4N3BI09J/N)N>1PB,ZKV!E/!IK
M39^OW]X=0LNA.R T,J@;:)#]HH%:@XL +D;S@X*-/E9WMU/8$T_N_CG,,0ZS
M9-(P5+PLA+(G:FK19#X  Y.JRVHLEC;R1M-<4(![ED\;NA[HH&);(PX)L"HL
M/[WPHODNW4[ X(\\TD%),D(!7<I&980R$)7?I!&^:)^_G@^A=>MW;=NILT$"
MHF1UL8A5#CI\00IZ?QU7R"GQ[2\U9:U5OE;3_RCP8)(/4*:@B<,7*?!'FF/'
MK%?&$^ZM(PGX3G1W;3QH#0V<QWG#I*?K':F6II32XLU/E/9LCU>8=QE^5@U#
M)?.03Q[-]G [.^I3!W0\!L^"(2P^F-T/9UU^*C?\ 6/Q_M'QN>V#<<3%H_V!
M K)#[1,12P<?+@J!WQ?^4?K_X[ B(IC &H%1[&%CNN39-B0?9RU/([@HX&8"
MV.  XGP]Q> ="9YDO; EMKU2=2=%:P0;>>7P+:R1QJ,[NW#?FY)O6.,YGJ>J
M'(L_P(V:QC%K_0CB$3_PC2!6SQNG<Q2L)3YG,&F()]4&8_ER>E:WHOMD_&]E
M8A2*(2I&>\SD2(,7+(Y ,5<78:@#QI1^$Z @@ @7G^>HUN6R!^=(&#$O&HWJ
MLGC2H1D]=[<W,W@X-[9B;^^(\Y8&TX=^F*'-X<=.P(<L+UFPC*6;, Y0SSR^
MB-89]XK810G?3'N+EP<?;:TX>?71[+T%3^Z%[;]7<I#RJ=;&4Q14I*K!!(D@
M/.SUC'QXM:SO$,&BU6-.B?M*_-H89K3S2T96"\=EVH?0(H'%G8I]H<.AUJ^L
M<&-IAN],/G\MY/BE4!^X#/(KM"5;AF*<PP9U6IS_M2 6KROX(79]:8!KH?61
MQA70@D\<-7U9@F+])7EH=*M5>4\-#WQXR6F\J^[34NQ)GL7XV8ZE.DC<UTPR
MI TM%%R(WDRS"*+I*K!!U2?(D$@[WRE"%$0@0K9=K"F"IS]PAELV\&#QS,>M
M9].95$VN5H[_0@<RR<+3C*-,]&9F+'K%.^+HRT  Q )L.TUQER6A1*>(OLFS
MOQE!U/<]+4,]6QNK/)SU,] WZ#W373"W%V/+H2_A'/.%P;YYNQP[?* Y^L "
MI -)\L'7!VT7(V)8OS'G^BN[SIA66D#-^J>JGIR,G<+&'E&B\8%$]?_S#A9_
MXTFK@$(/0[2E"5JUU08;%:/I[-0T8!A0P-&-"HMDZSJ*S6IS4SC/FQ3YDQ.F
MLI?#2UJD_;]IANGU2DIP:T3+=G(8;@< ZX*YR?*RAYF?D'ZK,3A!/:%:!+6'
M2-B/4+<X/KUB#SY^[IXT\?JOEQW:F @@AWXAHH<-XL[%QI#M.J \P?JK@@WO
M@PM:AS)"LLXU*2FF!.VCIMP@[.>L]8@E62PNO0FYER,6F)C&XT,N8J\UT?N#
M^]JWIW/.I?F+:%2\E.D^H?N3Y]U__O&IZ Q$D'48Z#A/39IYF><C:U/O DN'
MC)#ONFLIIN9N*C08U#N2\(P7,D:L$>1<+B:+Y+WY$=C[_<4;F,;@Z5KSCSP,
M54PL=.,$\E<NC&$,H50W'F*#?C9Q!"@%217MMH(),/-><1P7#G-,63*^;*G'
M9%2_*P-T>FP&_?3&XA ]&A:/ ^+$]X.XWXJ6RZ>T2)EKQL?FJ/RX!]I4J ]J
MJ84ORY%D)&5.-<G*4;9B*N7'53>U?647MB^7JR&JF<-<"5S9P3P-,!3M^D^]
M<X=J.<8U3VNVVG/=C$DVZ)JG+]>F_6TY>/]9S(#&[TO!?->>U_DG$;YQ59 (
MHSY3J,@"^NY5E"I<G=_77$9>JN8&KBXV$A3^*IYCMD2-4#/;T8K-A!'ZU6@>
MJ%H!:?'E)V.9S&\203S#^!"B>HS!'Q1IB ?%([)RXH1OBU;6>SDL_<>>&899
M:=$B]W<DT9KU,^+T[T8Y1A#K&Q:)RP?4OIY#Y;6^?KZA54#$C+A.I<?X<<1=
MK5Y>*W,MX"@+I^MB.CL0Q^M$CQ*="[RZZV%U6O7I>2\W7^F3%T^D7'AL8_*6
M^_&UO\GYM0N,?CEB<'(O,PU)%.!HU/XO+(TA-HAXFAJ%B=%<!2[H::GET'3C
MUJO#,"IL4,Z8FH%79A3I$?1,!!>#@_]/[( M%A\/_?HH1Y5<5XLX"*#)^W!B
M*WX(%9S(YN*-6[#=5:4XFI,M;X#B<WJJVN'7@B'E]6%W0'=[1@B?@I:('- -
M -RHH1 15AL,',$]WZAMSDM^,DO<J+TU8%S!-<M%<U?_F.BWO B#L(;1PM"I
MJ&V[96-RJ2YM9P/I N(\M2#I%E5DD007G<>!_*JDPJ\M0;*#5UZ6ZY2S3@[5
M$0 %,(K#@ZC&(\PB7TW"< N+-X6,C(HXHW.4?(XT$335T!X#E_EH-=/LEWN;
MR_^1&%!N",G=^-L<]P=CVS"_E71BF)_8H%XSEWZ7&U3K*9YD1CA9HMZ<2$CT
M>N?8*>)#$Z7\"E*\7\:?'G+1[,L4",2=^ L-T>U<=+<W[<OM\S9;C.@*M/PL
MK27*&<:^3*H'*]F.#5(9A@(<O^T;[B!R;AJYUA7)!B7C.Y%%(:CUEE4D(U8&
MUS(!::,&G^^WH^!C!>/TFD?#U]S5Y&^M?9P.2&1:^+91>>BGC:NHV7'^^=IG
MA<D_'J,J,)8%WC53$ $7 -I$DY4<J H<4%,]/**UX!ARY*%\*OW,Z;Z 5*[V
M@,3]>RK+C?7<C^78711WN_7,I*\1*_"H-*JE67/!P4R^?^O]J,/<$OX;QE#"
M*\RCT!!K>\:J2SA\Y,B][\@#U_#Z(93%RV8<)FHY4S$OIOHM[#1S#-D@,86Z
M%9] AW<82)-AO6+66!=LZ$WFE&RIQ$+$&UN"0['))0KV3?@TRV<%^TI&2S3S
M'8!K:3SR.[#!0O+<UEMDFO'F]VR?2[7S@P4.T@.C/K4#''U=_#>XU7D--R9%
M:P0.TX49^X98F@A?X!T1N=_8(V_2[-U8<&;K01ID[,S/T4X=^['?W8V!:WN_
MVO>KA7$;RGXPCG#="1^/?-HH# BS>&\1<:A) >9[%M<BNE(Q45-@OS(\9MNN
M54I;-5 ?9NUIQ*R&5-53SMU)K;O2I_'HI^"/QY].X6ZO BIN^";"Z+.('VP0
ME@W:L;=N CE$C%"P;#BR!7VPGI<TH7RYJG=3.2S6%7VQ<>S^+6=JMSSVV5+(
M+HTGXK\.\<QCDAC&#XB0/=XLE8^4"5J%07K>N'-+KI=_3$UC,-E#\'SNHSOW
MZZX+:?Q0)L%''%D<XY%NB/#E".$C3S;H8T='#Z" CVT4^$:"QN ;57\^0(D
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MGIZ[]\.5^WVDV@E@/6&JE+D.-*E>RZ>PJ;O' )JM$9:3J %Y< CO,51HUW]
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MYK+J' C[7UY[5KQT\/<DQM%9ZO.O2,W0:(RWC8%%+(L0"1#&(=UV)"I$JLE
M?WEB<VBAABU$#>B![^0J2O7[FL637H:R]"_3W%UFJAQ=S!6K9([_LB4'U.P_
M?-[*6; G]RYV#W6B A"C3KQ#5_JRMS&Q=\>E@4M=7BSL?&V>#>$]-&<-=K<F
MR38O>UH,R&7:8W[;=3[.4MGJX:6O;,/K3ZO;HF+U%S=ORFGG-G/:WNDT2R>/
M@W;^_]&=;=.TFEJ2A6D86;9BF\^W+X&JCL-6^#=[\2$7RAH?;M[$33Y.>86
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MILS/,7$CP$3'K' 3+-5/[[91+AK.F>PPJHLEWG.^\9W]560KY1@ELT$*_@:
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MP?TF-F_/M.Y=!%CF<Y'EYSHAQ$/-%'*V4MU78#WKZ%EFMWAP[]9/EU[E,G6
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MZI,T>#XQ_95.U_>;:?_('=_=S%>P%.Z4 *"\LYB30#K[#9/4VU8^9;0)"=9
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MI'NJ'E-A PEZ-CG_[S>6_/_E([(Y\W\ 4$L#!!0    (  N*55&91OG 8XP
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MWY1?^B$'D /"&IMU^8!653X?N AB?@L@\S&$L"6HR$VR*OA ?*R5+GL_Y^)
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M4E=U.6DJ>GEE1K<"C+=YVU*TO6[$"'_OWA_96@>E!2N:#OJBM#5O^7TM3U(
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M6&30/@*SH6"$62E[NBG5 ,:3\T+R$J3([!\!D.C/<^,#SXZN\S8\@/&2:CY
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M[#\)G,&A/9\V(<S(N%N.XY20N'3"7U$OXLO(H<4XM>D1MVV0"4BNK52LZ*[
M@@6UR<;)W,BPGZWF);&.'W>_?_UD#3.Q>OR$0_;8A@,9U/</^'>KF%@6HKU
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MW-#C?SG>\H1>!=_'/Z/FPX4?@>8&+]X_7IT8'H8RRTJ+W2!>,\]7D-"X;YK
M5YNF"#<:CHA0<MBO%EW :+0(U19QU>JWA7L\VTL07486GL?,K<@["/#C\6#S
MQ,F@"/DC^,3?9BWG?_:-H=BOESJQHUSL(_?N7PXN,6F,C2)4#,D;?0F!NVE0
MZ?Q"!_MQOYT!UBNR\\[?LES"1@0_=)R&IOU Q.Z[4@ J^_$C1^?4N<^1CQPW
M.I?A)L4?(JS!!N3#$8@E/$"H1%PZXH>UXW,(;9@(P,.;RG;J8,:^E,/$6A%*
M#/]5 G%/J136C!"A,[/&""M2M!)HXZ,84\B_7[_0!*Z7+AT1/D@!6N\!3!U!
MZ!"6=51@)D(]13C'^F\B%/O''ZO+2XC%%EP8GYU$"Q8!MU8/_7UI&/ %"0.T
MT42HI L(?;G<WF[%"W 5H<Q.(7A.G?@+K=\ ?VBF#;5@005X]T7*WQ>'\*,,
M*$2$VHNXL"T23^I[K"PPO:6!@MDH> &M:?DU;(296*Q%\BZ)I3E2E"*;:@RH
M_<,[K20]LI8U/O8DG?1.OPEQ@-S0V2$D#-ZZ(4)-]]+N/_?UMX+WRHE0/6?@
M,T^I#5[<5U(;TI[]J><\(6)%J#4JF+G).!%JMT+ RZ!?W9/4: 5MF9H/F+[_
MD;ERB09*88I@I7$M30KP"0GF60H? N[X.(:JP(\YZF==<8FV[-)V/ X<=6G0
M#)-^4/IMGUR%Q_;=2QI(_N]'RC$%Q@)Y/UXBQ.66[X..#(Y#FIB&ULBR0]D\
M2A'45_\A"_#R&; K+-!_\/5C*[\Q_I3+QMEO+DR/GH_*K9Q%_!-_FVID9M(*
M%8:JYQ>Z* VX6-IRLPV^J6;E%]FXI8Y5::J^>INDKWY(-Y&YZ+<NYV34EL)C
M%IO53K_JF\*,S4]1&0F?8KWQ"71%I(#50+46R92XK6,:* K);H"WY1?:&MM.
MY'H^(@ZNSJEM\>Y6J.)/9/G^PU6N;,'!^7E_9(3RU)&Q5OB& 7' [+IK)4+R
MM5;X3NHT$$.96#>"G:X#?NPMW2)"_30$:O7?76<C_4[:]Z>=[*R&L/O$3J1<
M:AU\F?SWAYUA(A0Q"]:<?;*K(W8#M>=/UZ_^^/L7LB W M]I#]_9A;BX^Y0P
M<MP,4\W=_,Y/>%V_7BSHTFZ*-YFC!GR^3C&S>E#@+4*=*# ]\W;=_$H^I,#%
M\D*APZ9:H#,OE6M<@U?PF7OFE!S!%J&6T:LOR09]ZC(/]#F7J=-G*:L*;G&M
M/QQY]$F;1*,(]9D!7O82+J.\BA+RN0A4*%/W">]<:H6V+V8,_KQNS"EA8WJW
M I'B'#R89 &^,[4T;!"A+!Z,,<[PSYY&0[,3TN/8D8H6XN<\]:,08C,2JL3%
M[JP/SCPS2)K[<T#N=6==Y3+NEX&5I:4WSVF4%G<%6MY^G)._!??STR/,;A$J
M/ SK=V)Q#->\#EB"]:1)?KPRHJ@FK<^FK2P#Y,_9F.GJS2Q]GN)7)O=F8]43
M=*5W#A#U> 4"/2',9>@J+)@T,L?@J9']$:'H'Q0VR3&>@0_:8.B;/*LFO4+*
M^T%CDRU5'\X>EFC%O\)'CAD2PE.+/K7T2-4V*K]G;WQ_,R2C7&H:CPG"V;X"
M0Z:_&BM:W%ZS.SCYU$S4$;? _S/T.HM9[CUNZI!%?]^RTN:N_8;/NX+5/MW_
MAW9[$5X1H@Z3" "H-_^Z%&:_"$5YP!!(^WY.H^'%,?_X:BCB/BR)#NS0=Z31
M"^AD:,\4>786H:M5Q;E(N/R?<Z=94.7AE((U'Q?F+"85*=@BUYOV G-CC)8N
M0Z@%-D(<Z?B?K4**<9STPPU>3/E9/_X^IE@<'^V<*7Y7P>_?*GHY+WB_BKN+
M4&[G@1\+<GO&+@'AF'V+L8(U<U8"P0#"-YP1I%ABEBA"88UIT,I/^1:^__0J
M"BFK!OT,:/TP#B\JPH#APYC)200AK_L[RQ_^U[O3LQ>RL<TOLWD3L"G.LO?P
MC*X56^?HGR<1_*NQK[_R IS9U2[@ZUJL\ KANZ_R@U\QWX][7W 6@?07?_JH
M/S (RVU:W A7(&C:MLCYY6/,O XF"Z_6(SI8J@2?WPXO#5F!<'RG/UW]_G=^
M8BS@GP3%BO3?\XFHW&WP/E<K^ U9N,1A/5;80(4\9S>;[D4B7E/H-S-#H@>(
MK\)&I6#EX#6VY]52_$(\?72<ZE0%S=EO_-=5:9S_?NC^#M:%8(?C";?7W#9>
MFK,U9_D>M2*H?5Y"M!.WL,CT N11Y[]/@)$0N%.A0W.$Q>30 3VXI:++=,M3
MG_Q^)P1NG9MNR2;W7(!%J/.)2OV!B[15Q6'$@ZIW^@/,QV68*G^'.BQXR#_8
MH@PA@ 6;G@)^3_P4%3?W#LS*Y"3.*BYO/=.P?9"@?M;]49_E!"X=+ZZ\??\G
MV^*YOOY/6GZ,R\'^;WMLS3M,E_%M!-N@1.YX ZV@)%RC\FTWK-8[/ &]GC Y
MPM/92)5Y%M;Y06\2]TT_M>E)A(-MW<H%%;5U .B A[3T(VC>SIA>W#'A<X,7
MI#6^9KKD6B-8M;.P?+31]L1/B^>%R<Y!:ALPK:>4)E7W/ORIOI \G^6]4(6Q
MFE2]C'\TZ!Z!BVF@1#_6X$9%9[HG;WOWPM8[AO)3USXQXDA-0JB#"M)ECT&K
M,($ZUYRWNQS,NF'P=JNK#:\%+.I.W_0HJU':%:?97-Z\UF)1__W[<4;6NM8[
M#,_5G()INJ;4C.[X@.2W:BDX7!VZ%-87G(2\0&E6'I4;-8BYF2/ LAY)?<9E
M^RF.[;-O3SZ^D"EK?<8.M<#Z)$JCYR-M?A^:8AIH2T&XATPA.5)-&9H^[_X\
M*(%U$OS0$V.J^6+8_EK%S=W'P[[_'-A^+U];?MO&T^_E97=3GQ/WL&C+H9(#
M27NX]N&>+SZ_YU84.T6\M)5[O;/I1GJ8I(/=R?.U&]1OZ3!IT*;,%VFD3A%J
MN0$:TLRJ%BY'KQ"X0'?SALLB']ZJ_P[4J&30!ZST&DHO#,*[TI>0%SR,O&6[
M+G-PXN&YXZ^F1[0O'AI_Z;,ACW-BH._M8<PIN ,H0L)VKP0KI+$!3\>R/:,B
M*DP(YY)%J("W#E<>!RY\MKE>MC#I_=Y\F8:<.IW5IZS5_/G&0/4Q$>HTGI[%
MOB"0A_#<O;R^!KD3;_O)D17'6 ^$RC_G^O><2>[7/W7ST(+L+3+))Y^W[$:E
M@@Q([SOE69!T+1X!H,;('DX10TY@ )6> EA E"+H@KL\V)=[?=FCE\[F.L)7
M_@X)YDKQJQ[5!RZ=[:E#)\R)4!PJ,KXFPM1+A 1:P7@,UJN:Z6IUK*?"\")W
M75N&"'63X-0O4Y@MZ?^)D^C@6Y&M46-EOSM_2&GXZ?7T8U(O34:>C5_.VC3
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MK^SZ-P;X .ZB@8A2I6)9-CX4,)/&0O$#!;IHCG<E8G22$G0>X"5\\''2E%8
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MZ'_PB8?'\Y0K6W<Z?"?4M"8@%'2\-QR6?&HLD+-JH($'R?(E"16JX/>9&B-
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M-MQVHK>WZI:3DU.=>NR2Q+UIZYZ+'4>AQ$,7ZPP!\0P01X-< / H)@P/'B9
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MR84>RAGLI?X,6PD7J2PJ!![9H>3V+.\I9X_YYTQ9,> !W/CP)@$^T&S#DUR
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MY%OCT1OSW:P,XRX^X .U"GS@W/OYJ9_/!)N,&;D<>6764W +VQ-<I94M06Q
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MXY:34/(W+,8:NXT8TI?#*6&EM1OZ62=O7U9X^F[3_0NPNC)FRPICR"S=8EN
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MQ^GGE.;E.XF[JP3YMOUV,E?NP,63MF*G7^ 82)PRYO-4W40M;R<8RLB>?EF
M!X6H:7.E^U4#\:\NGDR]4=XC'4X*B6D<"+<,\)#JL.G-AD("JFO34-:\54IB
M^_ &-86'L,%<4PUO&I;N\PK),:@.,UTC)AOA V7)72K;?$VTJ^_JZMO?$FS"
M099MM/G[E.L'D#*=]_>!/ 0,WR3'<1O8+U'%D8+:(FDP_LSWR.2UX1S:8_%U
MJ6.COQI)R_Z&W7-F>UYEI@*W1I:VO$;#N7'8Z0:8 F(Z!UG35!D1RBAH0X@O
M<2)+0(WUD+V5'%V\85]I.^%9SMBSE)G)T]?[YH$GK+OO\8->G&1(AKV8+WQ
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M3BF?$&H^,NG(".Y$/2N=&JZH2>/OQV[#-?L3J>FX]<;^Q6@E5W \]#IF+V;
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M/)S:\0'F]$OXN_;7XMO  '8.@HF]X0G) '#Z=R#Z#XH-'?F+2QUYXM_SH4,
M')Z,?;O">VXD\?IEO:=BV;L([8E1E"K<K3'WHQU6S'52^[K#C<V6]O1\?;G1
MKHW[[/66W?YQ=R23H]]LDF8@SN$C<< QQ' HZRFHPEQ@U7*3B30+C"XW(T@C
MFP8709DJ11P;X+@0W,:)0^VS01$BWOX"FFI6PQO<HRF.W.%Z3Z"718":48S]
MC-AB*N8'K_%NQ=\DKN&MGESRCH+LI/48F7[/'GTNEA=F(+)8)=*P/[O^DMBE
M.YL.N,A;7"HN=E^&;:CG9SNO;/,E4I_ !8C>7[DOL8J8*Z U<X3M^B'W/4]G
MPGZB<1LPDN69VYEO&1:0KZ[4?;%3PE+Y0N&]<+EU;^OV(RSS5[(@)EDB ]I3
MIAO\WKOZ2$MK+,/6MI=C7MUNQ_9\NN(Q#!6UH+::1<YPYZJ^_&,BQO^@A.Z_
M*OZ7*XIF:C^LFGI[,MSK[ %&E_F)G_/+=1'Q$".5W/J[I1KJ&$O7=#21[=$#
M<H8CJ^.$'-T,W^PM0OZ\4<8)\ULJ Z'MSXVH#VU/L@ZD-YA=\R=O#TW1E)OW
MN"Z[D/9?HC=7FO9-YZ"H;#DT1C=X=_&AM?:IZW\H)'\)_K<9\ZJNS(8"M\_*
M$NCS$Y+G28>G7B"OG'KPLP&WHNV;X)7='#$"A L-["OH;!8%7+NREYR);Y%;
MAHG[#IP*]3&5!E0>W(VU\9$4UTC5W4ILS;QP>W - _[8?LTQP4MW<<U"R[
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M^//ZK-&+5"^[FX.'+CBX^?.TI^;(,NQSY?J%6=<DFUM"CF$S'1;-WP+0YO>
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MVT2P9>%/:M"$-0B: .Q"1 D.X/KAXA_80?&_B:) LD#J6=B%(;UJ +[]D#+
M9/1+J3LR([JDZJ[K>6;[&F=>%JKE*H*1WYCLC0>TD#S)B2Y.'[^2,210PUX=
MALO-]/L2I'@GB*['0&0P?$[!GG+G[B[/K9"'_KL>?^X;EC$L.^=Y4 G"SWV7
M?9?\PF]903[[?*5OH.ZK'#U&=:V#CPLAO3GE$BL8G@YT<\\)QO 504D(&@C
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MOR>U< A5;JZ7%[CZ!+UN@N]HLN'\R-,$F@,_D4PCX%D?$2QK79A@ZS@H>XQ
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MOPIZ8.\[>%K(T7)./+^23/<! 1B^6; &>6 NV$N80ZIQQ;A0JY06 =QTF>M
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M$@\*GN*WP[)(XCEN$P&FOY":E8\\2P,A$BEY;C_-*%,JW5VI^_SQ!P]V'@E
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MS.CAJ)M0D9+?46I1R6A4#><,0HP*)F^$1_SB&K4X19[?;3T=7],0&5>$VO9
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MDO.5WTOYAU;V_QE[JP"X16=29<1C;_#6SGRV-JXX.Q,B%T%JJGN=L6.W%Z[
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M-UY^K2($'7*JN$/,F*I95F79\1 /F% /BG6* \_,RX>+/$03.D)!#)QD3#B
MVJ,B;F=+BWK?]AYL[BA]?!63E1APOK--6#U)_E-\BYDO>K\]3*-K5_=(O7.M
M@,Q-G.E[8W)G;&.:!=.LH9+B,;01*+E1<UM@1S6:5?(O6_VWXLL*\K,"\*-I
MX7Z1O9R#/KK$2$( T&BW8C/TY$Q126$>^?/=AS&[M]??&I5\>N?]B5+:KA/F
MR@^7;?KVF.O.^I7[8?8:&8#^#/U:'H)Q$@^JY]3Q$&&HXIPX#,?R%=2A(-WG
MU+R"COVIU./W5.36(*;$<=@L]R/>V\G+10:UTT%F?^?Q0)\,U''U*F_JD%FC
M?J9 %\?IE56^5\=+<D2B",?'SULVQ/I[E-Z"+?_Y^VO:)4>!HDB.N!W+@!M;
M9?$Z@$T%ZI;%&QT;20.+:&DPS*&BQ\_IT8V<%K;EMV0=SQ.OSAQZ,RAQ_T2<
MO]'_>/1]-K;!NJ'M8%FWS^V'WV?[7'2Z\CK7S.5PI/L@2PIUB?ND.8RT<&MQ
MR1)+8@Y"@JO[BHUPLR&5*9(TI,?A)_5R#N>C5<:S_'D(83[7LOB)<^?L[!6)
MQ[.VGW.[J$4XX]V[*B &CE)1,S<9K%$:>F:6RLX7/_*AYU)W3G$E<QWK9=M-
M9=^FV?'A=IT0R9A])7J=<2$;E-_T[/U:=^2)TWC\DKF&3]]C^C7R\IH?I854
MT65YG?85CM6$_>*?+AS.DRBPC(O&>8K>@AEKD?&?&'<:!78#W[>CN+<QXU=D
M,OY,E-[,QYS5MY.O^>;8D) Y>S^N'UF,;+"*1Y=:U> W!I@U0QO MH( A8F&
M%3U"'O%I@9=,Q.-<A\/>(F\_QV\LZ_K#Y.#'?8]OK%=2@6JYD<"U(6E690_6
MES'= /.*'XQ(^"V0W!6I5-)F0X$1LPB'M^GC.Y-[ PJVJVB>3]6YF+SQDJ9O
M299^ NPS)X'+^$$TFH&,Q=HQ[%@=/7@8"J*K4->-9*8 D?Q2_+N6BE>9Q,M/
M/]\P\96SKKHX-@KLNYZ\\=G%>C+@)MI_%RZ_.6!V9"(1VG^%) ;MQ%IUJ_^L
M\AL-MCL5T>"B\62GL(5WT'&4OP^_=?$Z8P>B6ZKB+H7&*R5[+D^3=<9+;,>)
M,6I.>9X/J\_,\]7##IR#GDM&]7M#+:K1J(5!D>".SV^R'X<@+B7?L:LEE4AS
MMI!82]QGN$,!9J--I7!WSW3Y:!G)@;&G>W *9*T:-549,W):Z[Y*D<,FO?VA
M.R>EDRO?;2"@N2\ -S0YC)7 #=4D78+'YUORY+!VKYO>L"J8_3)@O9I[]UNR
MOW^YDV#!?6."L/+&,U>+LL27!KSWM(H:G+M MXUI-_<*U ?"73\M]%(#4$W
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M".#EY;V&1V :^ACRVW:ZU2#G#+SPBR#^2^'TGRXJKJ-G'_ 0#20=@0IX,%?
M_]RT%=)PZE]GU#(7'LHCP,H,Y7.W+O@9TH.K./?;&A9$(WF([WRPHG;U!7ZL
MS>^Q$H6+KF^&JD9@DUSG1.B'0];U1E'_+&_C]G]RWN8?FYJ?B  ^3KX"^D8
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MI&# C+>&<H$NF!GA!I;Q5;QXC_Z'.^R$V99 [7:4.SX<N<;P+%.ZWA4%IJA
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M41 &-DXJ>C ':D<UHEIDVIEIG/P@&HJ]?P-J<6<U =9*H190"PH)N*.C\:5
ME)$^*,S>TCZ"INL3P.):;>"*XS=8>OY8VJ&U<T)J[D/D[2[VAR/'][7$S&$&
M[:A+' DU&IHCM52/9IR>'<"PQ"K!-IHL:J 4*QHLDM80+WXXP$^ZEW#M&]!0
MYW=[@_B1&TI[L-_6M[Q#2*&HXX00U[65<!-N!H2Q^AGC&=[/.?:@:MZ/X1TP
M_$YOM=4PK?/KT;C@>8R*\1S8>5%)F?"HL&S_"^(R>&C4HCT:N0$6Y^*GBYV"
MXH/J4PWB6)-/CLT/OGR;94B54F(0OE#('BP_^/%Y,">YJ^M@!O)8;[GIV$-L
M/2P?>K/#%;18R3B8Z#-BM26@3-8A->#M!9]#N#9O\>-1GS^//4R2DR*[8;J$
MA84U]C3):UN6) A[>Z:J!>PP?BVS:XV-,16!0 2=%H@9Q#61/.!:DH;A:HZ@
M:&X3=("/3E0 ZI2XB4N&3R\&6] I5^8_M./' HWL9/T#(P\>!:ZNMLUI]1Q@
MJ,61AVC$QZ;K/;Y B]KBY(W<,'GGJJM'E)_LTS&=:>_+SE:'6E/7W4X*_0G:
MW%8812?V#0O !1O!44A(]PU$)I4"G"WB-F#>96KPJ2#TP%+=;:2\H5;.CTR)
MTF$SUO/RS+'A">O'-K+M][<G@M8G&G8@T!NPTJNJ,0-@7"EOE%<;61='E&*F
MYM$T_&T59&)L16A./E?F+_9OGY9+JKWN$+E.):G9IBT8R<2P3H'ZTAS9AV]Q
M;4F@DQ5:=!(HFAYR:#I_.AK 9 57'!QM,J24*7[0ZB8ZO28X,Z7KVV-)C#.)
MH.I$@]9=9.G23$\@P\*>^3/R]0\1&IL@91\0:J$<8%S>S<]2OW!19<=AA1L;
MG1<)L:6WX3[V!@Q"&T9(C./P2(&JRUU5;G[4CY#"%0I2F3F>"4E"-9MC=_M=
M-@%*J[XZK"4:QQU7OL$V-7R#8'M &]8Q]1O1JZFL-"2"J 2.6B?/VW7C)#TI
M9/WB UZ:EQ-Z=G@]R2P8TR]<=$.;]HFRM;&"#-),)=L@0)QUC6'3D.)EQ,=(
M>/K,WOGD,W/#VZF3B(<UHT$SWX9GO-__ZQM@$A+ ]'+S2=1X2JEI\>J9W88+
MEGOFZTAE!17I6N'8@[GH_.KRNT05%PL) =OPK9+L0PW[#=NVKL/^6$_/C4ID
MKT-+P"J$A[@$D,593\$>MA)83O6OGZ6WH6B)].U98$ZS/I+<FTH9J#C)O^W:
M[6\GXO4HRQ.; T4OZZRAHQE6J/X@6A]'O(]EWX'R$$4,6[QV)L^2F![1A/W7
MJDSRK2*KNJ]MBW8/O#3YOO#<N9/W0XDNW @>8NP"83 #:N AX+]7/ @=*V 7
MZQSW <Z(HP</_2>H!U_J$8]=Q])"<$XP**$^6$D"C :?N%FZ$1G?APA)<ODZ
M1LYXS<O'1'HL-GGRM< CG8>>RT"#JJ+<.*08::$KQP[&RUH?U"5,*%#JSQ'W
M'QDB-:($O;JFB.(@D >&U2GL2!\P&8Y^;4\V]^-G6,4S19A[WI_1;_J2$^9J
M!VO=4"Z>Y(,7AX:01:KT<+8BU"+.<2H#=^>"3=.-=R3+XTORQ6JZU1?809>W
M3(F;;AJ5HS^P:WX8,?C!O(:;2T=1RTB,LX1[9,),H.J, XTP$%:KH%-FX-$@
MB@S(&<F.C"X]H!-]O=RV5^J._2[EU/V=*3IW'>3[]B4KA!@]@4?!A'.=V4=7
M@JG^$RC/)(S<SM98BBIMCW2\.>UX;^9D6OF^YN_5]2D]W_<]WKKR(;\]GE)(
MX&A:#7I3T70X9!=&LO4AB3+\2"L:-$,5<F;I>'JEA44PQ7,^;0:R&O!W:TWY
M3(E[]0UOS,5#@J XRPO<1A,=F*:%/TB%%!A6$3,EEC('GNC@/<K"+YK>1ER[
M(7U3S\A=>:F &((Z!(_X6'LD( I'F:"2%5V *51?4Z$C SU_Y;D;*#CZZEAY
MVI[T\?2HHI/20>&G)=:>0B!\T8Y@7[WK029^QC(/1-%N/_,QM,S#JK\O9M"_
MMKZK!S33/UVCO1^,=M@4=)&XNFQ[.> L)+2/;0]]1F]&G<<,6$ ;!H-'@\6;
M*C13.SBGK&(<I9ZNRV\PB).^87Q5RR/&0]%I'>5^3AN_AY?D0O.,&#.(100?
M4C,HHE O^ETV;!#F50?<<LB>>!\P]B48QKX>>$/]"VG@"\5C[K,O4W5X/N(;
M_0J" \O74 Q0>QCN9#II#8D:\0YJQLMCK9Y[9AHQ)L+]VH4#IJG7\CT2Q:Y4
M+!0[-ZN\\<K&3G_0?/E0KTAMS7BX^YDXZ4E14$]X!!UGI )7*PD'B/$_Q]]7
M=B#M.JB9HP?;\@MR;LI7W"3_479$X'+4IIX6C@^X>L8C"NP*S@,/TI"<S>3Z
M6O1675F'DJ?:H^C8JIO/AKPRY1-,/".RY;\)7<L9V#9\_T6D "+/9P_E/%![
M$'!#;@!65^Q<;(?CY,*E,#^WW$%0VV2OZY5XZ306>S([*+;RZ8>#_&GB)VCF
M!VU"OX_"/JSS=XYYN,O4IYG54>)QF_&TV2:KB J!V%O"KY6"\D4;R#K2K)O[
M]]YRC_"[=/$MWUHS_K5JN!A$3%U=\XG"2(NO,R_*RLJB+Y:7E\<I^YH^6V=B
M79>+0 @@A%+_[=VE^ XV0J*,Q :D, 54:B9*=96V2=N4!OF</=XSX_:AM.IN
MD\SNB_<ED@2I>6L%IW83-S*LPHSD FSK:_"BADJO/ T4'EXM6W&/?]%OYNWE
M(;20L.NBS>KR2H10US]/Z/Q7_Z!X _\-4$L#!!0    (  N*55$;IT^*JW4
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M8.O_7>L!2B.^;YFD E^7-<\Q-54-65]F.; ,IHAUR,$@5H3!X,I7]M'E-\2
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M\J#&NTKMZ:G3LJJ7X"[A% S3OL4.>+X7]WZ;-KQXNK!-&$A_X2UV!V1&U]R
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MT_/P3F7I@"$\/K: *4G+-K9B&34<TTKGYV1[_^:QK_69-5ML'SQ_9_]M4ZG
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M#MQEI1][=!?)9.2ZG7Q9V>X/>MU[I,B^T?MY!CAJ ,Z?0FN;J([G(=!P;B3
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M@9<[3TA7>?UWU]S_CJ]QPW#*F,AH-G%</ 74^9:O_/O +,9TO(CE3+>I['R
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MJ@E*3_L7+#Z:$RK"I]I:<BI&C"'U(H:'A@I ?Z_W@0-F4'X>H,"-YU2!A<.
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MZ!EY'#LLA"^CXI6CQQ24$U4";NYII*S#G/80^98NR$[/A?$Z4I8,6PCL,YV
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MOSAP)>X.(.+-OA OC?,LU>TQN^YH/LUM7_\5ICE[J>ROP(6F@Z*CQ)U@MY?
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MHXS+5_3S3\,>*UI&+UH)@G70Q7N+,>*/8:%$L*CW)S-RBM$.R53Y;_FX+KQ
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M,BO**FO^9<]DE!?NOQ5R56OD RK0R*81Z%YZEHAQ=_@VPL"$<+#X)D6L+9/
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MKTOR1B=1EX_COQT>X<,2;?XQ3U39K>,C4Z QKR1Z#A)N2\AWV8TH/BPZ%V!
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M?F8_LE37IX=BUJ>'AD/;)&TP;^$)?WP>,*1 FC3)W^#$K>0Y40,P%8V)3.5
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MR'$LI';4[L\AIY&+2W8%<V_^V+XU77Q!1^##.4.>"YV^ZIN=P2?:L*<I+WM
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M:>T<$1Z68511?D> DVH0?[*/_N$0\#@NXA!0LT>X7,CH0YQG</^RM7I+NC+
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MLKH#4_FM:/V9R<D]F&&UK@S"P(\V_@\/]_>B@!VMP2:' *C&=NLF[F'3@T-
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M%-_H\BPB-<0MUS#)FEY^SU/T"3(J($H/=J4Q?\^O+;OTV^[:31PX]$SZ'2P
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MKFM!,C& TRJ%DS>$&$>0LDK]H[F/IYU]%CUMX!3MW/U_D,:-4?;\;,L-O"L
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MD ID%94B$WPP;VR(^BUD-52HNJ08N'\\3&;/RIXJUI1O'L421/IQXD/;^7A
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M#C3<UO;LZJ"#:N6?:I\V=[E[V8M;O5)WTEW(?\YZ&[PVQ!4_0GQ505=AQ3B
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M7R%Y?!]U+SBV$FKQ^,H:?[=;)$"+P/Q\"I<F56(8&355=AJN69$7X/<NTNV
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M"]"RD90L!"2UOD$L^W5' 5O-S,=<D!FQ8.5CP\^<7?ROU-#M+T*VL2?AIHV
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M(Y\ .B^X>:?F$*U@WI)BM(O)!7FQ /8*>'*,A*\ K)CZT%"M^34;3>(1)+Z
MN"]]R>OS-=]C#9PC5L,T6C N%I4,0TPOFZ\D#?MT,!=IA7Z!+W',H<Z</<2!
M^3IR8*T6T@.'^JUO.(DE=!DX3V0)OKTX/_-<[V=\-/T.#<\409J \\D03I>K
MUP-#C7J@LQR10)'JT]HV=NZ!C]EQL\\.S, %GM=#'_<H+$R+/3V[Y1F"L)F>
MV0!%JG]8J8A9'IP3H53SFX].YKFYJ#44TEJ*/P8_387;.C9\JF#O\9%BXYP
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M;W9D.VB3CS%JLH#1YG\.1-Z=CGL;DY^KE*J[?RW8X]C(EBILY4PNUPR::E@
MRN/G(!FW;2]U>X#-*$&HW8FV'[G%UFLM# MWH>09&;&_>@<^6#ZP_=,+M<H*
MP;.7XV4C;SMHAKM8W*()L'DK&)@9R'B=6@2&U.EJ4(BZ;HXU*P?5,Z?W0YHP
M6 Y<S@"!+]'7>E-J0_8/NO^FP]V&/Q[!+I#.'TU-W#Q_$8JJ^C8TX 6.CUT'
ME*+G*L:,_&HU(D9WAV0S-?I6)71(UWNU;)+-OYLU.<X[YM$F]-NDWL[?]=#9
M+1:B)("BZ;)WD&@!3?"RS;Q!8L4HDBDT/H9N\$&-M:2ED>],L7=_*Z47O[#G
MUQ _RE_W$>5=N-61<>DBT@O%(Q[(TPN49#1'$%%C(G-L,H1DCQ:'SF-5:0T^
MA16-U48'B;--N=HU814#M-:]IV"[3X?Y%;H$KPN.53"%UMB\BPPD5K,?> 19
M+YRJ'6*(I'0%')?NJ[FU/8 V>[6O;%C9,,B@RX..F?=U\73V=P^#/\N8A.V7
M^,7<&T%O9:5"S1&V8TU9D.Y^;(C2&\#)8;>":=ZCA#U@R<5B<WNGO8T'_"OZ
MM&*X[D>V4-N2;SK<\#M^TY/,W']C\V -\IAR/3E$!. &'I&W$.JGF9JG9I'\
MN:JGTL'HZ]^B.H'2N<,#L@9O'L2[FK^*H#L_E\^GA+X22$%H0'-^#7@8\1Q/
M-1)'@\<0J6Y9,[B= ]A3&7:U(KVY#KKT\"*E]T6LX,]'@\8\/&_I1_LVQE)V
M%@A^ T;S\&6M]>A@.'\I !Z38PJ6X00P<F-K@0XK KR8WBM@Y/:JJM-%3]/R
M5%EFTA6!)-6/"I,Y*CE26TZ(Q4T22(PQB*"%(*D& J </AQI@^<QHBSZQN%+
M*QIOBYSOFU!!)&1<$/X)M_X8+=>YM^:WB,-?Z;>PS/X%B%:Z#B81J%<^X0R%
MY.@SV//42FH[<A8B"_1<3:T:%X+3V]YWCN\%NNW6^>CUD&G%8J^#+@R3:72A
M[IPV0TD@%"ZBA)4?D:/)Y">/?5RY"V_8T'T[H7UN@J1]3*5#5OC0K1^7%/9Q
MB6W0"1K(4?S8C<WC;=@C>6,^!"+W!?")JM&I@N_((O,O2QS8]V6M3]_' 8M'
MW".$38RC&MLODGB:T7L1,*P=*.Q)S1E7;C#4)PZVD@46U=ZLBD:)9WXICZ-[
M.&<K=I:V\6TGIF&VWH])F"8RIT'S7P5,"1G:.2Q""H+I-K/[-('H)#>N/%((
M<.J@$P/!M$G\V(P+^2<+^W_-PBSN,\Q!2WH)3;GA&0=6A&Z&;-:F5<,Q2W@^
M&S-^,8JA-W!(^\F&SV!4AUK-T_TFRY0O@9:B6T_QKFSN+5J[#EE5(5"O6[OM
M)/77O![$O#7!O,R9/1)X$L!=UF$D;$OT/[.<>FMI\OGM):G73L8#N5-0<%QC
M[D?2JUYAG.B6F]<[UE,O_?91TP:,9%S&A/$-'6.T*.YK91VQ/=]NN'1<NU!T
M7&VM4X@K@KJL0[,)T.)*!KU;:R&9Y!MQM[![/F^U8/._]#)X>AKQ<H[:8*38
M,9XW%'S']5OJ#@=YOT.HOCY+YRNG21-XU![VN"E@4J":XZ:?.W9:0CYVML"!
M(0*IAREUB$4\:V7:M_V9HKWFBJ KBT-,Q;&# ^.* +_%6JB.J,^Z>[M\50QW
M-H?,;QPY'\:XBNL#*I#S:!KWZ+F(^3A+:H@VJ,VXQD12X_S8XH]&Q'KSW8;U
M]<H2D1TTU27R\?!NZ9Z=]\*E]Q2&74Y^]@6?22X):(0372A  V5T,8)<N@(7
MTKJT.T<K$M, ;#>;ZNE\6(_-M"XO11B]"<"H'+HV^K+,2'@=BI7;RL!A:.HO
M@]-C.<K;V/T60MVE0+#D?K"=DB?>+%)[E!J>G#JS)BD18EX>81Q+OA8L[5U]
MROI7E99*Y<W'F3IJ0T#]R5H^=@^R%#DGP#!D<H%PVNP8W+]6",QI1FWHSC6.
M<V"!Y6LN=@-F0@/M!Y?/*X5Z&#X4K2*5"#WA*Y2O&^6>= *56\-K-D6G*.M-
M[1'<@!D\<"$5%*,JMQZ  $R$%7^]$-/;M)AC;C:S06GM4$PK=5 ,*Q*/&5ZP
M,H&[$QX ]HO?\:/J\Q3J%Z8@*X<M;LL^2?7U:M)(+(]P SQM)H8O1TD_]8R-
MOOR+[_A+\4*/IV<@GX/:BV(%(4=3X45KS+W91KY)9UA%;#%[]$ZFA \E4<&(
M:N./$$A4&I6W,^DF$8AA/WUCXAY'G3IF>W6L];@9X2%@<XYOG-P(O# 90)8-
MM@ "8&.SNZ++Z9*Q/,'&1IUBC%8+!HH@7XIWT+5+3XF<E3</'7N&/ P\6@2E
M *9@P!7(@AO97R#G49[S9IRT98OUE3[$CT6T*)JU-FFD40(N%+XU:>F.G9FY
M=:NRYI+X*^&Z1VUG+/$]2/ H>=Z3)D<W V^E@W*C_7EQ@0@5)FI UZ]V%P;]
M>5VZW_JZ!7O\A7;B:\U\FZ>G_4*/*4QRHS=SK'D?.P'V\&!"*9RY7ZXY]NE>
M6D%KU",X'W%BQVGV[N[;1',5[K D;&:+]D&1<OZ^^'G C@S*"<P/T>38O$+X
MBH"Y;H8MJ-X0=P!X%MW %N_6LJ'VKS9W'_;$DMH=C(AC5WY^?/+\Y\Y)H?,)
MY<Q2KE$\%=( <[\ A@)N&%^A7,>/'.-?"UQ5Y&FRV*K1&NPV8.NH%J;CH[0Q
M2:?_%G7)T$6U9[Z=1! [TXE+-R>"+6>[%]S,STKM4G__+.O^=%+_N@QDL)[@
M?8:/+8%J:D2<9[HP;F(T;X1<H-GXMC:OE((8AZ[@>,,#BW,/O[#2""4UR9"7
MSFI] ?AQ45A^5CE[)_L;OA1H7ARRI"S/M#8CM^:OA #B?+-<PH4^^CLSRI>D
M?V"[BWF&&^;/')Q\AE2%_#H;H%XU&AJGV["J *LN8D;]&D*Y'^LV3B8973CP
MM6@LXH"%W;%M9<U?*@QM';9&_"0U%,MOO?E;=DNVN%C7[+M8G*K*R1#3$KZ/
M\]N__Q3X2C@$O;.20+T%@'*3)9#_=R)WJW81C7Z+,P>/,>[:'HAK%N=*M_#_
MIOA8\E'^Q*LWI]ND@->!(='?#[",66^0=EU#:_2OH*XMC4RW!*/MQ[IVHN\:
M.=CG$LVZ>/6.*UV_Q:<A%9:[8\)Y.AXV4]L\#FSP#P&C)SFP X@_%KZG/#O)
M_O_JUW6(/1!9;PF/\4%C3H% B>X\.9-Y-IY<OW; O80BC@^@XP[WJ+W2FMZ:
MLM-"['WED4OPMT*-AZ\).]2P3FK#<%C(.F4W+^;:6\-#P;\DE&?,&].6S6@5
M$2O(YP?4_6NV4<(,&HH>Q5ILZ9DL+O?,K?WBE_:QANNRRITO]23[+2$-!=8T
M%_IOFY=(#3-U:(:M=6A0?O'E"GX'YJ5Y3<VW%0YL'W-W64V?EK*]5BZ->$'C
MQ[;J/?[$"(V??M=T%.;UCW)/1'RO8.],@,^=92B"7:, )+LCB!-KX8C#PW;$
MP5#<2?O308@\GS'S*7T)\_8'EEMD=TQS/42_6GAHX^XD"4*&MA6B\"^ZL-Y4
M1!I$:1TW71SC@-V9/X3 CQF:-\"Y'5Q9WC<+(_4-=T3/*PJGZOMF11V.X7GF
MR;-R! (<[W$YYCZ [@A"0F;K7-DFQI%:@10,WV7J?%B$[ZJY>.A,O/9\PO%R
M8I3!LP/.*NOA3U(,E[B?_42]F@:H$(Z2C,;7FLC^%9OW!"R"1[?'T5!UA!U8
M7:<Q.#^HV8C?;=F-I!P94+P98L"R,'96?O.@0SWZ@._3^>@7EWPX,&T89K$)
M/[3V^V6D$,_P0TLRU1FW9I(.4H'G>6J!-=;4V@X]%5/PLT&UB3]1+WUYL)UQ
MW/>W]\U*8Q\_NQ4<9.5!MIT %\?:,U"VFU=7SFDR#+]C%<!*$;\(?RU35@GE
M?NZC)(6>K;6/3]XU]RS2<KD,*FB<?"R? 4-]+[W&\YE<J,L4S&A!%]L$XXZP
MN^%B. 0^B ,31RC-F,1):M"&!WSC?4K=RR-%\U1GQ2][[#%O\'T>)T/EL^05
MF8878<CLE^YH<!?04G[T_2[@#^6(__IO I,%8X?NT[CO[KZ )*F;2@UVVK7F
MX?]AO9I=E\H\NB&UKE% LYYI"#Z:M^,O-P2F* _U=+48,A"8/8VY1'GX]FEO
MX;R@0SY1QSWR._YX4$4N<HC -B37H>DRT\"&GK![##,@A /SSF++K>/[WZ#7
MS  *.O+O*<7@J =3Z+#C#?HPF%(1E?-9R]IS4D.)2Y/!RWYAO[[QMQ-8VI>Q
M-R&8Z5GCP"X5]-0H<&"190 5F&]C+C>1UX6_<6!P-K%+-"5XKI8/UT46!1XY
MX'XUHGEJ]B**G*WM'-UV7NZN=[+9,?XEWO/M$3^?87]OU'R__?5DP[X<&=$\
MDKM!?PDM^V;V8&96;\CKI':%BJ4S1(4?@#W^.WJL8JXRQTYC?N1U'(X_Q.R
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M%6 -;,BCUR_7<F#C0D"C*_LSI*-O$I:"(%QJ.<IN^8J<DLQ@<REOYB#EL%]
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M>=JL305(M.7H-\=F(+_V1P-S5%"1P![-$_R_9'@%__GQW5OT?.5!^@S&F<C
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M,_JO$DHU[G6?(R+7N(E"\(<T#^6(;):5$\"IZ?13E$D/\/IH2!+)4*@XUG9
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MGPD(%ZGD*IEVGTNIBGUQZL8Y=%?RJ"*%7H!FO5TX$1(OF6DM= [%\=O41FD
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M^$0LTRB2,?;@SUB9E:S.\KN(WR97OOR*V1)H;UN'CIR-9L%T32*72P45>?Y
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M=>Y!-7>I"SITL0WVQP,*+"^*(&*UC^((;!XW$3S#;N62!'76J-FL*0R*<XK
M7D><9&>6,0F)1/K@43KH'WXMIEHRF%-)H.H*Y*8/>E:8ABG9BZ008285MP?H
MBH)DH<\$D0Y1NC-5E"E,8[?SS]2&<G]\_6/2XQTN:9:CVMZ(21]N:,Z1#=ER
M>?(%[_>9Y-^[A'X&IOU&<=/^'C?V=Y(O$"B=1FWM0J;0E)L-8(4*AIL5]+5H
M2+%]:NNRI.U[=A K/RY7G_#//&Z%$<IY94#EZ_%<\4.D X+2<L'3#@,.H6<<
MD*Q^_V5,-$/1Y>CS$[MZE'5CE&XK.=6IF2LK*[MO$D9(<=/XM7"#)4#7#7(
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MW_,3VW)L>XQ)!D!_A62?) AC>RZPG]*4^$>?>F%1I_,IO20=-K''.]KM0]-
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MCZB%UU')BN&[BR9&J-\C5B/%ZBO*@3LN48K;5K;5<6:"BLB.3'@P+SFR4T@
M=.WC2_^$V&**\0?R))=7)0#"+'70QUGB> >NL:9]R;GK5:&O@^(:_6=_W-A5
M[-=T,[1^TJ+F]K'!A=4_]\7."W$8)RW6&9M73Y0Y$R8CC-XT'YU2C?YBYB&_
M1V;+KF/O?CI.T01 KQS)AB^MPE&%)A3BZ\5[]>GJ@C64>@PB=Q-%[O9N?';'
M/58P+@G?4%_ZGN;F/@>?OK=V>J8ZXZ56?YFAED)=*<C@&**-F+BWZJM$2CF,
MZ6))(E-K!P2 M'O4TW@1NMA"V6.9'S$'O[KFKSL631F%/VE0/M1HX**OL'56
M75U9B//P9$S.51?F>OY$$^_\9/^7'5Y[OG7W)E8D7Y6W\27*QHPHQ^.H^+0.
M#SIV<V=^_<7=.C4?\8]:>WP#W*6=7N@B3;\5/^6\"5\;X4OO)[ZH96AQKGLP
M_>A\J01:'JF1;IG,E3E;RL>%//<GA78JCIN4TFX&M18??9/T4>MIQP]#48.#
MK-M#B8F W%CHA4R:4874R=$)Z]WVSB+OMN1654ZLUVNYG,+Y?JZ/$%V3K'2P
M>8X)2JO:3K,>^'05=1_!W)<0/H"2Q$8@2840N"FH]$YET*!;I'M>GXGM1BJ
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M<0)'?XQG[L=J_T3H^/<Z1-3/A1?O=CXS;%@LCIHG'?SXZ4V[B/8=*UD9JQL
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MV,=R. 52M:=*87_#_S2__/'+EU!L-?M"X:%O_NDKPKEF\^N6X#8'1AAG+SJ
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M,M0EG(!@.K#<!1WOQ[O?H0<MGB%D$QHT7GJ+V0%:T74VH9$W Y]_><>W^=2
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M@#_D6&'>PP@#7,4ZOB2KF@\5M%?%B;;83*QZATE56=_H:M.)QL:IF+HA 4!
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M8_?KXP(#9:U#YQ,?GC[8K'+[C+QI3-@3) &PCQ;WT:2VP! T2'6?GMGJ9_1
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MC/GDM<J87LVR<WD+2@)]073CDCM\<LYV3K0>\K"^U;<59) 5-ZCYH<\<PU
MLUR(:E%'EC*7SZH41"+V7'DA:U0U^^P; QM!_(.Z'% IS- &=^+/>2*K#D,"
MW6<3O-P&[5"=4^Z%)5KZC6=D(@V>'7?WFT,Y4#>'Y3/G?MB7G-<LV"AQBH,5
M):H]0ZG3YWIN5T6T38>.SLD29RPP0-X<)KX"JDDKBK.D=9@70"]DUMU)DN4R
MV\FG8$B%H<"NZ"X)C1TIOPB=%.G T.UI/SD9%Z#<[;13Q-:(BG__JO"F/$T.
MY*0,UY/VXB7Q/X350/O/( 0$T,C.-.>G:RV7L4"14E=KA*NJ>81JH__-W(/C
M:A.?^3,(% -BX/!NG!8UI*Z2YP?2#@MP>>8UU/&74HTB@DY-FL_L>B!\7NZD
M;.!DJ,T%WOIJY7<3+L-Y$C4H\D"M6<H'*BL-V9O]OG?M7KA@ACIWK8&9PYF:
M8_>:OJX<+PF19)$.J!J(7L; #+)*,QMGY$71&TN"^LR0 1]Z/E"5XP@LV4."
MVNN-HZM YQ4OD7*LP5[DV?>V$;=PY3@G^0,Y/_59I1,[W_9K&D:^EE_H+CD<
MB2X?7/0L&MPXN-YGQG6P)L\@0#SZYSONT,5%H8VA7/<"7N*R6'3)VSH&/Y6O
M81[3Q_&5AJ'<.')/0SK$HBNB7HG2G7D&:^42#XDOC/@=+SJ]C'@_$(UX%Y"M
M K'?'O,2]1M92J+>:K@6-7Z/\+Y-HL[$<?1Y[!TUQ]3D$;^]3ON.?P^I08P<
MY2SLF1O:":Y2_2 VV C\;C"?MR9[W?GD4Z$A-H,_T*66,=EC=2?/^TM[C,ZE
MBP-LWPP'?MS-03H/[P-;N9Z)[*@\B,-6!-P&!WG0%*R!GL_1S>>'N2V(-)^*
MB8%P#*?_4(-S6YM8XE&.]_EO]%=6+Q1FQU)O%6PA C>KW(R-F4/99-JXD?-"
M4)6KZ:TD.YA+QY<C7Y2BRLI(RV?1/YAQP,A'4C&Q/H)L78WA.MO&:SZW>:\X
MJ\KZ\4B@FOK].'/[A1'4P: 3&R=,/"(W?J9_BGSHP!6 R5?Y2@PC48S#7$?Y
MGF=^)(P.Q8Y9:MW\DM.I<W^RJ/!:].*=@1[E-UX7I>@!D^HR?428K\F3RVCJ
MVU6]V7MIAJ",]YA((%Z^PQV<'[,M'"S )ILCASK6AI6-'K<BO31V."FTMO/!
MG#.'-1@F.'<(H&1,T"?\#YIH39BS&!D9Z+_0_NH/)QCYNRW-Z?KO_Q'S8-0P
M5\)/\T*?[#41OL#&GR>ZI23K.:5TAQWK'#+7_+O7'9=>WH@YXX\[*:)\._+Q
MW4FIE'%!IK]$4J=I_\#5F);$=BH:MAG?@CD!NR E+E:'RJ,=!4)(W3=#N&.4
MBJ57ZO7^G\Y$KXAU_CCK]^#!COEC$D_W?F6L$LMA\K'<STU+9+X%'*OH5QE/
M@M9$]H WQ@VZRO7&Z<QKR%P'XXY+I[FX7R#O*Q8$7PXM;ONV3P$C>Q]@*;>D
M3C6,V=6C7A0=5B:S^JDXE"94?(<,7Y+;U'S%PA#' P=\SR@$KS]2N\'!<2''
M[]-LLOYJ9X3T5)3]M1M+R_?B/7X5+C&^SW.%UE:_FTIW+59J5/F^R$,X8VQL
MGFKK['&C>0 Z .:;,".0(PE8^C6&M.<#C6,,3>I"J3@A"-]R-%;@WBM'-OM;
M/[\XRTV\/O"=5;KF@]'9MO!*\>[M&FH2^'BZ 4/OP)#G%N+K%N( :92_N_QR
M4=I1<O9;I?06#@N>FT+C+].ED#5?WL6<!ZJ!O5B@< O!X X"8%5[3J/.6:F#
MSN.SA9]Q9Z)._)R[H-DE;A.Y^^Z^T"B1M]<>OO>PW4T29,AG0HTBE!N6*C0[
M,#'HSOBP,.X*_&T8%->\&#7S4=3U[;O"1^9E6QG2X;G@U^WZXP-+F#?7XGZ"
MV6;-%D(DG[&A3F"6 8I9=.?/CS>+<S"CM#A<"3.56>$L.N$@^;%R 8SZGWL&
ML;$)*T80S#=6<89;B-R.7UN(*\29PR0"$90D, @J=2BZD#RP=H$I4TW:$$1O
M(5BAGQ%M:OI;B%>67-0MQ&(F%?;65LSG^)V>>K2WS#2< L6UP:RP+COZ<^'W
MWA!;Z>2ZIBI'61AK!1;OF%!XOFMMG_8$>M$S4U]66.#Q'.[T#52[3#[UI[)P
MBCPW.P\D51";X:[UVL(^+CHAN8(Y1%"[:9FA]*GCJM%)]CJ3#Z+[6';NOW!
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M-DL_\IO&[/(!2-,D@H*"&8#=J>W"2+HBXQ'0ZXB9PW"PF<C?? W#7'NN#15
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ME);6=#,RRN]A@6%4\ W.C).1Y>[Z&$M/YP$8.WA1 A9:Z-<=2%QXH6$+U.A
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M*Z+6M3Q&U6$MW^5$O=G]RTN/VM,UJTHM7A3IS]V(=QUN:G6!E%8JO%&+XG!
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M.1X#OH"(QE%[*UE*2ADBP.C'>H:!+/?GXZ]'5K(S6632]H5^>.V[@]B*(8=
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M"BMC(H0/RJW?>5E$3-L]P E^W44'M^0#OT,V)8Q(-#8FZ]PTD=$*>;SSV09
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MIJP7PD])%:BVH,7H!=\[Z7]U6%C.OV=(GTBL6A'0:)@(=O$TZK@BX', &&C
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M U'^-R6:+-X5'ZZ12TA_A_&=,W,"@Q-_RWDNG/Z K.PH-DRN!5[\U+-_NOG
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MO/N+3R,TP&=9&'S\O4\^6)WA&=Y9/F 8P<W$Q\2T[+U]CRD#[L)QRJ^SDOA
M VQAA&L^=T+L P+@ Y0:),,SFQA)&4GA \$RB7R <5C=V+.[=,]8V423IJ,[
ML=P1'Y81(GKRX^ES1NE8QQ/QU;]MCD[6DGJLB$OW5K3'(M3Z=DZ$![1[R7\Z
M?.>YO4%WG7T.(2&JB%/+!Q(1G.W0ZU HF7$<>:>(W TC65,^95.\.F0J!\N#
M#PQT5U=7LV]K1$D72-UZ]2O\_;RL-*MVFK4 WGR&Z;+'4%IY@M#\*/2HM<HF
M090CPX9_X9R81,EH/;-LQMYKCIUR+!;T$R\\QGC7'NB@KSYUR.[LA4,(%XLY
M=[<IH_*)WYF'I:I#'"^UMCP\L.^3F:J+6([+JV6UX\F7_I:VO?+Q(CDZLC/:
MIBS./Y%NE!6S]5ST3$2+@4(\B4@^(#(*NK#AO($#-^:5023;@6/+U"C= X8'
MW3;\876@,T>,>&G2F)KSV&=0]^*%"\5G,K\$,)=@C&-\ -SIM%+)AHSF RT%
MV80PLO 0;4[?F8OK\*V,N]Y%[']Y[<W9PJO'3*ZC'S&=TS;-=1\<";SJ)3][
M6.G++,"]*RSW(*R?$)!-LNDB-Y/3X,;@[6X_V8G?+^%R*,\)E%BU2U7'%?QT
MS(,NPR_V=4^.=%,/;4GY\.3>1GNF@NN;45A/@7(HZY1W<8CQS!,+AYA\_5HK
M)C('VEE'R#;=2HY"01]! Q&"5(G+9IUF<.<K&.6LUBD+0FK!-??K[4>:ZE/=
M2\>VU1N(^.<7]M,']'.#A59ALTXL.E-_()O(!UC%W%+;<.I;%<=1M#"8;3?>
M5'/9,-7+I(PPGCF1?34@_)Y'RBA>2/,FKJ(FH@877M[1T)H5''B(Z:J0XGG*
M3%PG47P-F8MI-.$HK+/BN*T0"NMA^".$9F1JA"V2BMP:-]Z-G)T7?CL1E.U2
M]-=7H7CYL7:TBKF3VLVHF\6/3"UZMWP4)[#EP85EGD03F7'*/0$KL-"6]P[;
M&/]0RQSTI88?9?E4-;TT09E??S7D+Y=?V$? 1A2?CNH_ARU\_$!FTJ?DMGWC
MY/;1/1O%SKB(,\W-3PHD&SZ(G:HZ?DY:*ZG9!]<5.1M$45EI9A]!]Q^ ]<&(
MJ3P)(;8W!PGBF28]5\&D7EB32'Y*8=3MJ*JY@:6^VQ5?.ML5?+JV@IR[<D?:
M==R87QNF?^(X\C+>W-IH+*B/Z-'CMMM:UX1@E"RX9DO'F;9^.TZR9ON:OS)\
MSA^WM_JAUYPU[W3)Y7*,ONYBPGX^0,2Q"!#TRU%:(*$&]&%=@]XX>G%.,QQ+
M(H7?8+*^<9]9E$C@\#[/\V3JOG@/&OF=3W%N\R<,?=F[39*1/;/)DS*%0.S(
M;8-+@OZL/%"(#P@?:IS@""VTIX\?9PICFU;S(OKWF>@UMF(:1RH'3 :-Y.\K
MJ;<$7+5#E*.-^4".YVD^4(<B_Q7 W450IF%_[)S>C; +"1OZDU5"LY@ $U)[
M+Z9)A6[#=D7),\FI%KX*3J J+=S:86PCN-;7FZ5>+'=U[+RJ>FB=?U/XNX&W
M\2:149$W(S7GGO\P.O4TKB(SR?"EJK!<EW L;E!F5H4GL<:VX7U!,#PB28_6
M63C&Q+P9 Y?::1 <]CQ.GGVR]* N>>@Y[Q=O0;SD[&)@YJE]]XOOVBWNMH8[
M^4.^]3&:"U;H.#094Q?;4\S^#88QJGNCOJ#@GW&X;VUJNFJUR7H3K*NVKS_5
M&:5)[M 7;M1H-)>5&<^8\W<>CPA?V= \2YP/:[/R=K#]F6F.B1;8[[^RR](X
M]LAH1:(FTJNIZ?9+5/N9MM9S'T>XD]*.M!7#7WC>EA_0MOBC!]_@.0H]%"0=
MSTQZ%ZME!9:$5\*KJ63YL /Y$R/4[^%K$2(UI27  X=(^=VKNZO9LP'Y9!L&
M/)";%-$IP >Z['B2/R&VF*;_@3S)XI;Q@1 33=0IIBC.FK-3S:KPXLVRX#<!
ML8T^I!^W]A=X-]\.KIDRKKA[<G!Q[<]CD4L";+J'\09]Z]J98ONFJ7"]MRTG
MII6COABZRAZ4VK[_Y/N?-M,+?*!7AFC.DU1B*T,+"O!VQ)WNT]("*R@U:$36
M%HK,W0.X^QV/F('81%QM3=&'!2>7.?C,H_7SL^7I]>K]Q;KJ<M5%()VMB])C
M8-]M6R-02F ,!Q,BF5HYP <D72)?Q@G11!:+7TC]B';^ZIBS89,_K1=65:MX
MM%''05MN%VG;-D4!]C./Z,SK#HR-G(EF[J6I_B][3Q_\UMV;4)IT7=;<BR =
M/:(8AZ7B4CM<:9BMG3DUH0<T*S[AGK?V>/FZ2-K6:;D;?"MXR7X;MC["DSQ,
MJ*NDJ[-ONC*\:3R)^(5L8B/-)(DC=:&(APUZ[4,,[I0?UR]:N!W06G#B;>(G
M]9<=/W2%=9R9=X<2$@"9L>#+]Q;T2B4\1B?,#EC9"[W?GE7V=&*C1MWA'-9K
MLB9<>%W\J;7Y:W1 :MF>!;.!S]>1CQ$,N_BP :0X)MR=F >!FX),ZU0$=;J%
MNN>U&9AN=SGP$\DO4GRPBGA\^FI7=+@MDUL:XUSI_,C^VZH.\ BW"X**&J8+
M*H@7^0 IB"?Q#JV'GB9OB4!O#U7#W^_PN/@L,\B[_5R'><";FH^7C0_L^W8&
M'_O8]>KX[C_W?U'JSQP"$$%ABP1P=R5]_#6Z"\-P7TLG-"]U#\/LF7 \9=N*
MU7=B,DD])C?^Z-1H;J1>TC,IF[VJ8KMM+A.L;V")/:PGC &.NBG57>H'4BTZ
M#86LY7@@Q*E@VF9$Y&^N<8=+U(4]ME\2:UNBXDN0.QXJ;4\1J/;A20U#D SB
MIF#\,:!.07:G 7H0*[.3H46@JFNJD<Y,-M$O?1U::-\5'6:@US)I[7QV_4:N
MT[77/[TNWY%4%$X48)N4D>&5Y<304T_/MK9DG?7X+F6PCQM&-0%WP3@JIR$W
MW"))Q53L2CD30='LKZ"ZJW]O*<*E=^K9+[CO1$AZN[^$8UGI-? /"^=.N1NT
M%Y:_RP/D@<BV#CT^H%U;R <N@)C? LA"##YR!2IR)%8U'TA*L-5C[^-<&.W;
M3.D(8:O&I1Z=?+KMBTZ!QP,)66R[MM6LW)OJLKJO)\1F,(R3)J1:Q(P^%787
MOKN/,8CR*S4$2YZ"=E>FS[/%\6H/%W?$Z/ZZO&[;$?&+T;Z>N3S5;J(&#K$J
MQ@FA.&%0OPLF]CO>G@HO?_KS=!RM/U:MP>GV\Y]RR6Q%.9]"^Z.YN:3'.B(#
MNIZTR $9HM#":4P7 @5A07B16]F<T@JVL<W0TW" 4=L8NW_'!EUXWN8[L5M4
MKW!GD^3S7!]3492J*3**-XGX5<<'5BKX0 !F /EWCQK IIV<:*)K?7!S/4M(
MG"(J?<2KF-T]HFGFE2:(_2_RK"WZ'\]B2+F;$,]^^0^>1?^7>-;LCPKB$B'M
M+R0@;K\C,$[))"$%T=/628@@B6],1#=V2VA!KF]?>?-TZHL)[P_FAN92'J5*
M.R3VB<Q\*TP'N#ZMT[\-W<YJ2BY[-]W[2Y7RF1V\5FWTRCP7*KI7;VV=C""(
M(BYC9DFL<^ Z6^D[0A;2HQA05XQ^G>F^L-:+D?*)2_7E/GO=Q#6CG6B;K*7Z
MI&UH[J%O?"\RC"O\3*K*VNN?:?O^UT?#C3">Q([7O*DB,J1TJ $$/")E(]QP
MH>9%NF5JAG'TBOJLVM2OV\'Z3Q)C72R;3AP;SCWWP>5K$;". 8TJ.4IK4-5+
M/!9WG;J99H&;C5E>2(HCG9C4:6ML8)X8UQNO>6TL,M?W3G0JRFKFR'W/S3@Y
M;''I03Y <Z>G,C"4Z96+./273>^/M[(3F[(!1,:5U0L/]5F9SYK9#F^.],**
M+HR67;TV9J+TRYVC;-+C+7,?4C]/D778)(Y'A3VFXB=9L<,UZ.6Y+WN^KQI_
M^SRKFYD:'7A)_+?E+T2/\>E^A%(Y>)T/B(Z#8V&D94(* 88[O6#<MZ#,^PSZ
M/GL<_5:O<E]W#:5MG*Z@"1].W"]]"'$$0\DB,T[71/(D:]BV<7A:4#HA2+53
M^:>?+%B(H=#MNS?A.WF3#]Q#0@)M<RU>3)'\(]I-'[,TMC6VKG9S3UG.R35?
MIVY,A6_YV[?8G-:*W*>_V1(4<Y!YCQ/!S8,V:03&&T0PCF:#NYSH4HRR2)W>
M3G5N#4\/GAPC:]KX)M^B5:<58!QS,W@H*+X3;J=:V]-/9AQ!S/1T8QC./B-$
M^YZ_:%P8<\D1/,P'9"^!?U32(YW2*IA&WB$3WLS:#GJ_=?[1;7_%2=E/) R$
M-FJKSRU[6[V\?CWH1>@47L%K\-M<G_!/.B1OHM_M/]U%^>M)2Z7C:";JF"[H
M>H'NX$[/^YUZ(,'C<_1(.EGAAC[3$4]MSPN,TRUVR8G<V9)KJQ[T4.+H@>LJ
M19*_RM["6&5<J$NZC 1WPNC+[!VH*&Y2IY9)3P8?4$<A(P7B5H<<)VI+2;VW
MW.CW?REU9(6</\;LL)ER_(-_T-NHK02PB[NQ+4N)'"]V?%PC3X(/A%'F3AG?
M[D;*&-GZQM8.ZF+\2^=_4M[5/16+RSGZ-=<T*Z4MW(<USWQ4#.FUJ'$$I:2\
MZZ\G1P=/;H3X3#:0*>6RO<.U=2/G@O&[D8)O5_ZL9Y+:%SJ580Q7)*C/!^AB
M?$!,AG,5Q# +6/Z?F[EJ:Y26 II4L=1@[6&76K^?N?&OP)6',+-C3^[3EQ(,
M,:QR[CV>+'H4R;@ZTH.=+>^7)9-0^Z%NY5*W9:1XB/=S5EV8=S@^+2!EB]FW
MA>@<^I&4^;/9<?+QA2<W=<SJQ'[6YK\.4=O(_>FM51U^^\K7NZU-)0&.VRD)
M'YSWV9Z)Y>DQ%O.K[)[_+.+F-T].<VZ1SOMJNUCO^W/F"1Z>_Z>>;8X>04)Q
MH91@&,@"[F-$@/L6_%VX&N<DM^@R$Y&&D@J\;?YC=#G&NYODA)&^9B/^A)2G
M*I40:]KO#MN+?X>=K62=86+[?-UY4A ?"E>!.4S#T]/H[3__5DS3+2N^CX-8
MA[PCCV+"G')=P[(13O>V63U-UQ$1I$EU)\C,[09I/$D=*-36$,_HH">0XH0
MD]ERUHYL&N(^;\^/6W.K^?XFO23,EIJ&'SE.%N4?VYJ+K#\>HS^ZP0<\$[;5
MX<HA>(2[4EIJV <@OF1%3N^8Z(3A[UI\8[C]5LG]8D0\17)LJ1Q^7'C^CYV
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MDK<E37'K>_94GAN]=M7LXR&-Z4^WW.D$FJ8[3Y+Z$L*<#8$J,T:@:C9PL1?
M))6T4UY;:'.#KXME&G.P)A]FUY?4\;%]J#8:)H&\!4.I@N38>4(&3 AS)5S-
M79%CR7T"UP3#.V ,VLGVG!O5<SY>R:LO)H/N;)-*ES=E11$,1.?-S*YB+B%F
MK:D#*T$0K^F"FU2QKN+V[[::^BL9HN54W!;?T-/G>ZCO]9@: BO&QSX.:Q)*
M\S[5!X6JO_ 0.%P%<#W^FV^N6?*!+:K_<7.ME ]0=7G]?.#NVKN_^%1,,V^
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M9I\;M0S&:I3>S-8^I4.3%VP3%EH=(6ZRVD&H-Q4F<)]T;*&&J[PKU6%NIFU
M'1H$%TF4T N_UT6X]&8372=AMRC3;@/GS>'K.P\GN$A_?#4?2,6!NZ;IT0P?
M&J:'G()@G$+,F+N#7E0^D '7S>@IE6*.W.7I]2P8&OK&1%]N'FL65OYL(>]6
MG[_3C=EX_P+PD2"'GD0TBM'=J6O@SLT5.;8+>EH.=>H^2KIDH/^EK4CUO'=<
M=0_1ZMF5!WTO)8RSB6==#2[="9I!O=,ZU*/^X:]UBC%$SW<1FKS=J#V,?!Q'
M*9;FV:\9L[X@FED5I]!U #< DP5SK:>TVQR;BF[O.I(1H>/_*#=JVQ'RHQ-N
M0+P^<XDG.<TD=),9)];D,5T6B,N8F4N8M,X#8QRE2C#;;7*)^>76Y:*6\5S]
MHC_SD[Q!:=W>I\\*%W,#'(Y\2UE:@2J+B"4XRTR%MEZ)$#!R'U._ .JP[H-!
M5%&F<@%CCA.UI3^?)J4J]VAL<<A#5D##[/S-J\YK$K_4 M]?J\U81Z03PDT2
M8?5(CD8R,[4/UH1^C=I/E9'E2#$^%5MG1=!]F[A:FY]"MM_[%7C*N/R)T:N&
M-HE%Q[3CYSV#V-JHDXQ4CJ(33ZIO 4MJ9%TB8+U!!P:!=2N;^K'T(!Y_HPX2
MT%'5)7:4IIQ)]*BBJ7EDX'LO05B[MCD0A65$DNE06RNRG3G0?3M["]C(LDOJ
M]9/H ,<7@COLF-;G0*K&=!'L;]B?EOH?O[R:"DQ)=7+/O'+.7Q/,,IS?, %W
M6]-#V(=0OLSI.P1*$:S.MZ /(84R8VH.I':<9BI :D'^(F.U!/.:=(=5@G"S
MC[3Y\GA(."QE5C9"]$PU_AZF2YH/7"'/XEB!=<Q8CD(&*P%\6"H'3D:Q#\<U
M7[$5J?D1>V(.J3>\/AQI(7WIU]=[SK\&MX>_%K7K$N9,L]4X5MP'B$M81=1Q
M;A:$ XA7\2,#(PE:^SZC=9>]L:G_;K-8A:'5&$L9-VQ>?IPBUJ3.EH27.DF?
M]1!V:97.).4#"(??D:"1=7*'/90$7\!Z=K071W2R":)*CF*XCQN8P<CVFY*?
M7S\Z?8..#1Z?7]WWW/&PIN8>9:NS3F+!-ODH;#_4YT&9NT0EKT!5A0] E7P
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MZWN13(TW[_)4@6^?:-ZU/;A&)UEK-@C?*G_SHNZE%.U7L7M$  1/4I5)8%%
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M*R@^XNW6*X2*GW]+!NC&KU [$=+N4,^_8E.^H,L\/8,)?)\9ZC_WS2BY<GY
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MQ\*5CHO KZIQRS0,Q;AN3/(0&)WS3$[H#'8-.9CEESW34_9F"74 M__I^?V
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M_\ZB:_P;B*\[^I\6N&GWC!CN??;=/[.1^7$TI%[1I!TF =8?KC/$G('B4PS
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MV3BH?:8+8SD<[!]54/1SVF=D@/7,TDT1J2]TX^,Q[7";Y\]O!O"$N84D'_1
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MNZT<KV4W$=Z,F-D2HL"&)QDB7HR6YWCP@81BNAA;V(HS]:.S.(C*"PM 0QO
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M2[_\"\OQD_*^$J+"M:'+DY)([6_S%6F2GP7[;\&\X;]Z[99=#!;^-,8IL?Y
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M(XQ5-\:99FWND5%,UDNY&NH681YC)G!WOYWMF58;M#!'0XDG# ^LH #42E_
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MMW>@9MT8K%L(VP]N;GN?JA#CGORZ^D#"FM?1S0<F6A#L!8TQ%.0!QI$6C/C
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MSJ6T6T2YO*X!=1@D+<CYEYE+>WM)&X L#/B7?;%,(C!'+S1_#R0PUIA7X6#
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MD4T0+?+?'M_EJOI']:_NYMC$[8?3S6&CA12SSS QM@E]&,=5[,#F(WP-BSR
MUBREJY_1G0H[D\)--/]8<;.QTT3.>ZPGMK^GF;MWG6R">0DH;WUU5T5.[.O3
MZ2+'9HM)(,=/3H0X:<KLS\G2\7PX<^<D$O9/_!Q;!%]E_;U!.OS5-_XZ%J0)
MIN!O^)#M?\ Z^-]0_23[+V4=N;^#V,[53V>@HS[([)<9X^K5;/+=^EV1&[GI
MG\+6+[-DXH&YOS.33Y$?V%W_N5KTM^;AW&XD6D^L^5<G:@[1(3.@8$#Y[V8W
M*X[=)JB0O*[)$YR0$?+J"IT701C77O@[^-_!J/_&=JO&S(RM&[0PW5!^H^W!
MA53-Z 8L0\F*HV"%H-FMM:DQM';OF+654KP[KUI(A[&%/9E.PPW2^<ATHK#1
M4;7A.J^&Y1(/[4/&!C[M.SHG;_3^,UL=Q0_@_VK5?S;G0<V-<)[<VP0Q&[>:
MB,#^-PMDME' ^P=Q&<X=@983?\U1MKHD5.<2[?Y&FN2%I /QUQJ7!RUC?$P]
MC@$;.IEMC=ZQ)3TGB2RQ*C+G2%)=Y]_S#T*3\'0$SG,L?B;>;&3PK^2NX6\,
MJ/AK=T4/S=(V!JK^BDF<3[IX4W3ACBT/M<K^MLD=*?]@<QST_^> 5;^%)V[=
M20@H#B_.,'"43YN@>+3C%#FV]\H8D&W[/O&V@4=O3KQT_*&#;9C;0C8A>)M_
M@N[_#L)7N6V\:,B.88LN#\7_K420]_]%_'!RM^XDY(TH&6VT50TE;MCKA$#_
M%N2'OG"RX+SP<#0LU!FLJ75@$=H]P-O^6"9=&:ZK&>+ RM_BT[@BFZ!&!>)-
M8B1<9!46GR7)&&YQ2S0[-R"R_$W0JK7-+2A9Z&RR0?FG<-,0_#O5"</]_ZPL
M_.^_C]C'9!F""/?;)FC?']1CHASW,,)(C%X6A9J;)_VN#7[O-I9SR%EMW.5Y
M4='C2JUC;Q4?PH\!?%PA,&^2E]#G&/>3*>;06POC(IK"[@)8H>#(5N[N(6U?
M!8<GF=O$_]!*[H#")._Q#3TPZLMM8#$S.>^XV[?,M#L00@(SDQELC"P]^IEZ
M@W-=Y>4K[K24$*>CMM=KDBQN>"</GKV@K-2@P.0IG8@9;"-/,"+PCS.\%WF:
M YH41((G_)D=HW3+MF&$!K5UA\!>-6$+P7G/>K9Y"GZ*V^:0 5K#/L;N#H3&
M$0SI? F+@6_5/>E!L7#;C]&W1JJ;GL??MCLCE[GB$6ER9\.9!J%[NG%RJG&C
M]E:,])=3-+XF9M;AP2K(XL*S9>VQ%_D1TNP5J:A:"[&$\BL?QE)>[S?G\S=!
M6TUA@5,X[MY#DYI2/D8B@U $<N'+JK5)22 MS)0N5!U6@$CG'^.W"MF59]Q\
MQ[+R:(\2X1-=KQ4< Q4U.O"++&D$"9ZS'$)K%O\J?HO(.MB/3W'3?^GD3O5Z
M9M/W,N1;<&./)6@\EV! 1[$E:[E[':=ZXH<@>QOT63;%%L4+,::]:.N[E' ;
MP1VV T'B+&V9DK0%A(+$SMTBB]>-G&X_YL3\%QWHA(UG.U.PVX,]+S'PB6PS
MS[R?).NGM1EEQ>_&\R6&[C/>A2BEF1WR-+ETN7(_CYV#ON<2#N&X0FH\$YAV
ME C<95G,J^36Y##%&579X#_5WP6_T5Y"JP2SDQ-_A+QL(+#*N\/=IX@X\FZ,
M+%IP (M 2:(O].?0)9Y19H=1!O9(E;HJ&9_6.=G\6SM>>)Y@?VZ3O:,@_>6U
M4-.')9( Y=5:&SR">QB O_'Q=[F"#+WK9A)X1L*\X^#TPPXYYRXLS^<F*7!
M<1/4 HV5,6ON0I%4+_4>88B32$"8,R/HH<XKB/6 U_7M1>X3KNTB<P;2TMO^
M=(@S2T'>@)5I>G.6&(] &W0IC"#H8PVQQ^7R??)QGO'?RR MY"IL(XX/'4*O
M76RG0J7#7[;+:_?^$71N/J/,#.SB5/2U=[(<L@+:KN&\7T$Z?Y>,$2Z-G&)
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MCV$H)S584+J(&<,>A/[;KQ:O9V@M?TTVL''5W>6B_.3XP>%Q;+798B,]@=G
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M8%_<,T44LT!0+]_K@DHOA#[^;M@UYO'US:DIULFB5M4'^!G59_#C;T'K6*[
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MW'26QJ?!S)N[]J0S-_3&\@@&GMVLZP(I'*N9NHP_/<)H Z">YQI'MZJLZ/.
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M"<KRYWO"M#\K/\A;G15.#.$ MM$0ZY6X@WF'+CA=]ZR[C,4S6'#&BM)"B^L
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M4NREQ(!R]\FO:-M6KO&GDV>[IG/N78\,U9$R)85MNK2/\5$F\"N$-IGN'@$
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MV TVC<\U*OTX2G"&1L 2+H?AP#[.^URXD_E1>^LP*@"UJ+KJ).;ICSSN[MN
M+[4O<Q :F">2QF]F/^8M&<=^^[/RIBV].!H)0##!"G^$S_(8VU.HB*BE+%K
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M$;9A!_8#'Q!J,X1=.6'UEZ)EN1FM*K.16(G(&[1VT.^>510],/_'*BII_^K
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M)6C6'FZ%!Y[]=&':\ &)GMKL1_*]J(#@&UYDEHD&'_@<W,\'!-*AB0P^T'Z
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M_P!B&S>AC@>K.-^%/:LO9F5 <]1EW6<_Y"1C^=@"G_H!% \F\ .%$%:O )<
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M>%_8'"EIW4N!PGXL=@J_/$=9.Y%3/[(O6. Y3<8JZATYH015%"0R%P07\C)
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MV6K!W:\8<_%Z5W3/>!7UYS#I_@)]E4#$;,__X9=>JXUXED_=9?)AVFKE:H/
M#W<9:QGZX6J1O\Q AP*%.+;$K#U8Q;)'):;LHR]$8W?8N>.W8U CFQ>79MT]
M?_([VD2&K1Z(C9G>(N?G%<_JW;Y,:%*1P'9+BX$OZ91Z@+]Z^W3 RM,24[M
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M=$,Z&W&BM5EZ+^0D3'?@W-V+VA21"-<(W=4!8J!6\^Z63G.J&?D5\P_0G^:
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M$EBMBA[V)?S^HUB12.<>!$U2RDE-.#L#]U,$62:$EOTHHCHW%#M^16#&>7W
M"H&M&3[0]0"2)26EJ1^:Q?#TU[/*)9U:+!-O1PH/MA47BIA2%^ L.ZI"#F<7
ME^"I^;F_[ TFN:)YMYW_$(6HW>&J5M9I,QX,OQM8^/96$*"_ )VXP5< B@50
MYT3#K6T_RX,%67;.S2.XF)L\&/$<[N\?'QU9/R;AKU\R_]/O62.*BGFP5488
MER/XIX^PS#]]QY!]6&\W#_;V.WRE]SJW ](&DTUPUI+"GSYNP/_I._"_F6;I
M_7>3T__7^O^U_G_:>L06S-VO7+7>H<MG>X]M03"[<HZ5Z-R#,?(_0L+W148S
M-^H_,QU)ICRN5J;_0&S2@8N5-RBVTCQUCLNG2G3U7_M36VT0&W*/VE-QP2]S
M4V5!Z\LM)W"KS)ARPM^M(:K\A5DQ!=>9U3_XU7K4;)[@M8DR[\X0G""=81 C
M[D8<GS)8XZ3]W5-*C&#FCPLXYF<P//;#%1U+GT>;8:N_85Y?_V_F50::,81I
MKD^+69R](_B:6;2DO:/)OL2571"[7WEX)_7QKM;=SHKDS]8&>ZX8*/4A4#B2
M=[VJAYX6B*"C:J2P"9E^279/T&+@$]V;"Y-]U1WGZ[(;-H;*>5=X;#"&!\8)
M=XA9ZWPLSK2U\.UI)V>:D$T>_M).C<R[')RQ%]7WE=DWPZPN6RA]I4H"G(DD
M:^K"W&36=+5&+^!JS-8?J5)DVLZ5]#)>E[J%3UTY6+;3*(SO59S_4$_$A-Y)
MC"FH/MHI:N.'HY75^&.4"W_:1WL,3S9>G5'Z4%3^<8]?_%?^'7K7)P'/M$IF
M!&J[L96/3\4O(&&^_V.*8M';K-/W"3^;?Y6L*<UF+92[-@,#P1>^IS%"7[&D
M/#RSR&V'R[KSV?Y'R^]_V6'QT:VLG#^XH%#X?*Q-M3@G[UT\,_<5,PMLH9,Z
M&_L+KY>T!9RJU/AX_F3:NTW&QGXAEN="MZ^<E9=1'WUND2LG'C@T9&\U_":Q
M'!/A-Z??FYN[\.ZJM8/=Q<Z)(#Z&,#.-DU@M#R99,,HB>3"G(;L5NUYG_[L^
M>_$1_9>;SFF=QK9M[J5NV@V#;8:)CQ.%*P$J?JN?:F/*/H9F7:LIQ#L=>T:"
M#7I_'F.7=3E;W>HYM.I9^?& D])*0/*86W:H5(+6_1SRY;SYTH5S'K=F+?$Z
M>4'8-BO6<"LR94CXRGH ,&]UZQRJW@]VLO1F H93Q=OB# E3PXJ!QHX:38?\
M+I[<^4YD]XU?P=\LB3'XXHYG# %:7RS]-$VE;DIG+_4-W#SH[(.N#U7C[<NS
M1\Y[Z71LGA T$A3@*XC;$+)X46&M1/[:FZ&JE8?$C#F5/"N+JN1"4_L+\:BB
MAY^LYP38HN2&M4U)<^[4T_955@ICIL>N?&F.Y<8J8Q']<]9LT>JO'<@!8LU)
M8W?1$]WCK6HWXKGQRGY_I1$KX+_1B%GFL *=,S:+0F4W+)ZJ.Y1BG+,L8C-H
M4#M:],SF@=+NC18EC+#AOTT2^0/SKBSC&:"POSX2'FYG/3?+V#MR)ZGZ0&DW
M^0SH]/98Q@?[W-J6BCB90YYE.)?]OYJ6J1-5YRKQS!:(0XSS8"&&</;I4:XX
M@BV/)^]<I= _ Q"V%2**F,83HRS-E6$L#Z9T%WL)W:GU5C@&H'Y [.?!7%2>
M421+X(^0Q2OLG=ZC/%@S&=A2:3ZM=YK>7#OEH[35RNW0F\80\'/,C4?$I -7
MT]N>/19P4T>P1<BCG7,]]%\C$WB6-K8-23^'PQ&+EI,BMT'B>?@4P[H6?%"E
M@2@BM=][PN7!YD4NU4:Y* 0G2M_^FK[W61X.G$%Q<_EY,)6 )>%!;RY\F@<3
M(I^#6M('76>@UCAS$R",TF0K4L"+0!DPVH<LXB3-\V 0(6?\&D-#U.-H93M1
M@P1;X_Z/U\32O9L1BZ=1<*8XI':ZHFTMGT&>PP%;\]B^>;6:$?3IG!\YPA\[
M:T4^(FIMX?1O\"V0W9Z0=4+KY7B9Y_*.Z2^H5+(C'BAY(WPX;7,?\C6Y4OPT
M.&<[<?7@7RO:'H&&/-AY--=HO::/X&FRFC1L]I' )OQT==;W(O[30PW9:@)U
MB+6]P.+ZT%1TUWP6<))5/V#-M5Y1+4S[M+X:\BFPI $Y(V2]-BO]GWZ.^9WX
M,H@VIP1%".OEH/EU]#\];GU1'QW'#:6P__A+65F@![*MFLX4Y\$2_E/FZY:H
M3"#] @5YL*_<B8<6UGO_^8% _9GU,Z!2(<DN>PP!#DF3DGZI5.J& .. -^*M
M\+_,D%X/F^/XH@&Z9*UD7QPZ KW%O?#"@(RBI],!ZJ_N\C7V5P)#;J:S;QH0
MU M78J"94+C$5X#/(#!SH'##D,4)8!D+#?ENB'V!!RO(7X!,);S]=\8"KOPN
M# @#/!@H[\I^Z?H(F!-7X3YO1<:(_TYT3'Z*YW3#1SA[EMA*7 Z"SOW 3(8>
M>YSU[6^/6M]$.!1SG*[22'DL42T,/F;=!8G4[:_ N#XC#)J*WV\/!C#]GUS,
M<F+FA"BV'!YI.J!YXID1ZWU5WR=*#+RHLZ:39%_W<)B?\Q8K.J5WHNO.LI&/
MDH-*@_9]A[/B8V>?7LO6.J ==D?3_-,W@4FS&"(U!5E$J>/!Q(= T1$D>U\+
MR\3/]WK/X"9N=#ZWAV29,51PV]I<]F1=_DL#JSW\!Q]/Z0<(S^FR3F([X,*
MA\HVO_H:)!V)B()++:,0I9QX6E($X&:J>OUCG^_@Y>B)@9HGQNSG+I\<,L?<
MQ#L%4;B_'"JZ?LJ8M!^:6<V0K.?!(O%TT]D%DM"H'6EPV&^FE4:H/3'B><W,
ML"S:,WGM6H%YU%;IWF,V!RX]$AQ;+PU??U%/D+/$4H&G:H1!,G>+-2.82HER
MYG[C-H.Q(_C!)MW-]49-^/O.O]!]5L?]/SZ[X;B#^>8:.,6_-/P_CA"KU\%T
M'DQ.M0')W%\!842GC64%PY![T36<.'?:EP=+3_F8,S=*3Z=)T_3%KNW\75D#
MYQRW%5B\0]Q!G+O0C5B*4/PY^Y23"!D[B-T/##Q[!TR+60[U-W6.NO[H 27?
M6O]RA_2A%@_V_ G[!A33/UD\F($4-VYVM7A]LW_@ZUGL<6!@)0CZ[>T!+\T8
M&5/^I_KI,K-KTN+Z8M:5&.KO5NA;+]E#$?T(>N@=M@*DF,4H:[:Z@+8E1P)R
MW '$^%Z$(&)NDR8WT<S1RI.]98T;1H@'*EM[E@V['YCK^PET_[D& IX0T#Q/
MIG:"\I)L\<S1E7KA8'P1T #E"WZNQ'62?$1EX'N,./WZ6FD!5=?R 3B?V$?7
M^"+W9$0L9N*DO%5(R@7G@\_[OR.*--GB=U>8S\&A-(S8*^[66)8M6\<!-7^*
M$=9 >?IQ.ED:/T8V0:R9?AW^XD09]S=^>CHC3GWTH6&[-G%>A64,U&H3J9G$
M8ED\%!+41.+^:D6V#IB:X[:V/!F!@=.<O3872"2A-]9UG!M747:P5*ULH+?%
M*X@<V82-X"0AJ%EX"<!M(88D68L7!6H5UT\?".W3[B15\F!2X$K=%;MI;=]X
MU-'1S@3Y6]5.%PY=XG\I=Y:BQK?,^7=+5'\3FW\;>_CO7 *+G_\YZGQ'<.SG
MG;N @8<0Z!GJWK0>;*89UNG612B\/_"[2%X+^=>@V\I2AHPM9&M#<29J!,&<
M0DX%(1K?U/DYDZYRAC#1PQ6$TL"136#M.GM<X4:I<^3Z?QN?RR?QHR;?%KT)
M5,/^)1W%" 6"WVK-;_%VJHR[E8\'4Q@$(2UWXPAQJ3" ^R!G;?V\Y3/ 5PVL
M&# @B.8<3:G,)8.[ECG"R,,\F']2Y@SNW51:!%TXXQ_F%I5^X1R#N8)RD$6[
M.55ZVA@%T)F%F<'#]/9AMO<7$X3=UR2#*P\Z!^:@^JVU[VAV(W_\<'AR*_S9
MDX9PP4+J'WN$$,7<-@K=C$A:H88US8N.A#7"027#1K-GY1))3'R9GTQ#BG3W
MV\+OE:WN-\U.S(_82K;ZBSB3#.SD!)ZX\<]J0U;H!7">S%<:J]2VVQ:_N3BL
M0*1I]=TOK+.9G%?N0)'_8;G[(N)?"YK^@Q7N__O__Y__'U "1(.%G^D=W'$6
M04[RE^GO"*C/HT0@%J_IZ/-@-\E$SK[E$*0K/ 2^907J%"^>_&X 89K(O%G$
MB,>V(X6W2;6GI=(UX@OL!N($!D:: W[^0XA.(IR)JQK(,"3SD#M\35_<UX=1
M! ZNJ'$W3?VCI>KL,:#6)'$<@>Z,C/17K$QOUAQV2J.*3CP4Y\C_MU$"Q=VZ
M%S7R&4%]#0@.UUN6Q(BFMA=(;S""H_!9A,E$8AH%E!5@I[O2##F/WD/(U3+[
MM9WX&([\MKR(7GD9@/VPPCIM)I'1K<O,\V!LYHS(?=Z(<[)[;N[(M_2W 6'S
MH6$[FS-W"?GIH7)-TW+WLE5KQKXG4!'TJV]4F1L987,MFG4X\,CEHG>V;!5&
M4O@#CN+<+&EH^*6K\F([,\<B<;'/*'G /[&VK#@V55'\U83@&3T,)QV@/@<D
MJX]BR=)'.25Z6X!:ATI7^JLK#*N7SIEF;T'K\SV.0Y[*J18Q1R(_L6RM58UP
M)XN:)\M3+4<JT(,F3'$. ;N='?0-*XN!$/))*_AKI#KD/2=G?AC65ZF:84_V
M2''.[3J\"B&F7_6U\DL:RVYG=$2O[PCCP38W [7\&+-TLE]8/;(@(3\U<[BN
MR)9BP[9D'/W6N7=;F*'II9PC^[?(2OV@&[)%3+A;'* L]HHQ_))U?QHN5'F:
MCK>B!PR]46ERE -3<_TEFD;Z4+8)3L3OTGL<:"D66\Q?'=.(KC6"L4HCFL'
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M"/MO%W(XOVC8JPHY_N*_?R'9P/II!/:JG\C;C&@6[AU\7E'ZYW9/K*?6*[N
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MVG-)M8JR@8G$7+Y*.$',-S9ZT[!>W\2BG=;3S$/P5ATFF.[(J":R3 5YY.X
MU:WSR&=9,F#8(U7_S<03JY#G3Z82+)XMV@C5= [SMZ1OP8DY-&'F5#I=VV)<
MCF+"R B:YI[%Q:F(+>\"+!M'E(1I79H#:8@;:.G[G3#G3EZ  9=)]%$9^GC1
MRR6;9\,?LO.5L>A= *DMUO%Z3!H(6[43/+GV*Q)$4V%B=P&U\6WP\9!.<&U(
M5]KX&H0L1FWH/+WLB$;B^T54<I2G7Q^5JJ]^]IM?)%&K9:GZ*?=53J!R^"Z
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M ;"6F84'2"9\3_14!G44.(C'PXL,"*!"/WS_D5#,IXFNE-?>&0)1TNB/J%0
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MV7^\L6HAWXFS<+ZB[E'!N&KZZR_2)P9^;7H#)% JJ"(3_!B='<RK1X(AA@N
M920,1U$>P0@N8"ET%!YC4';Q[*_^L7<?;9I^(%P4?^O$Z@+-_<S5,&8& SH
M*7G8?I)\H<</1FT^.XWG=9EY),%LSH9P\U+@U(<7.B[/XJ-#MO]S;#OJF,S,
MW@T*F?AU!!IX!2U2OM7*7&/6A)F /\.7UI$KK7*=VP5DU4%#D)?+/UN@:1W
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M=FT,/YJ-2S*UIBM .8>CCW^J25(W,'YS^J[=5;,]NEL<5ZY8O1<59?R5JH%
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M;AK<#V?CQ]R]7-1;FM8/F ]-C+UC*I<7)TJ6[DN6$^=Q-'4N)*]HNBYY8^"
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MDFY!;YL0, 2GR,WA=FY?-8YX)J R7_N&X(NKC\FDD#L!!#()Z)2_!G7/R(/
MJW&D;^1[Y%_[]/T2SL7?=(]?7:IBK'[/_O&'5]R-[H3YL<J=ZZ"227P[%=IB
MSMM12, JDM61>]#7YV(HZG9NA;WY3-(E?EJJE?$86K[9[H(L]=R;&K?0F\=M
M[#TV?;7I=XVZ%_RYP4BR&WN.,FK;3'E5QTU@H4<-W]G.>P=.2(._3F(8RFUK
MJ.6R@69FAU?LT_0/]]LB.S;E8[AV]M>_FZM7)0_0*K$\6;X6+.\G-",/VRM
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MLW45HSN*T%-_(=)JV\XI]7V6Z;&H83>AO.@0OZ0#.Y+%FFMGQO^E"]+B&T^
MU%9&Q]MG$7G;R8.WKCT=Z[5K.G/X64[1C:!G+PJWHU!21(>293Z%R(GHR.MS
M(QD8G4GV\MH5'^)'O +BD P18UJD=W4T@LJS=V?(_-UY9UY$-TX9L[VV!^-"
M,H4D0(!%>]>K)0B$0ED/342*3XCA5J;FK<-N/6'*@3/J]TS'?ZZ?.#$ZGZEK
M<6X@>X$ZZ@;+4H1KX#9 NO&$T![^@%G9&2/:..GYZ*>=2V':FEGWJ'FGLB'&
M_JGQ,\XFIV-.A&@9:;Q'+7BK&_+J^6\$.DC79L\RJ_"\2?[%L6,0EI_8'^'/
M,F\S=3]:^9D-BK]5^\TUVMZR6G,@I09[:^7G"PY>S_H/<6\0@&9SX"*:D07+
MR?/=.(:\*H#3DXL67&]\$R3)<K\]]:G,)\<K=NAXEKW^ZURV\'A"L4.JQH'$
MVY(_DRM?)DOD/$7,J!9A#@ZYZSIV6SJ*[UOG. ?<7N,Y1CK+]PV(WL%V/X&Z
MZB0BC-4@,3^8BRLG=T^L%R>&4J.'U2F*=IM?[G_QW5ZG@7^A5._!8HA75YCV
M4UYYRL ;_W3FI8S*A>J4)PAWA^5O_VLG:Q/"ADF?X97(,ZU$!_VE2T$JV[N0
M3Y@\8[O3NFS6^[O:XK'6U3D-1+^M79O*OL3UC%KL27XI8[V8ER7<1P0F9;A!
M&)X3Z'-ZO(28Q&[FF\=2#^M6ZM4:<)2[K[[),JX_M-UO0VI!Y&[[1B;+D)LB
MW$W^0-;C3R?;RQ)1,^NH;4PU%PY>>U;EXF)8U<7LQXU6Q>7%=]LB?4TLN D2
M&]=<)2RDP;*3;(1?U/%Z$)/_ SKRWBQW$<%M_Y"=>Z'WQ360YQE(DOWH^LB$
M?&F\VN;R<[&;3]K,2P2N#=MP?E_MU@AC-FXY*VR\N)#&&J<NSX,<,C'EVFWD
M[W)"9)03>\ JR6BZT@OGDC$U'AS$J5<N[."A(E+7[U?#/S0[),, JC'<3*$]
M>6"X26X WDF4%%Z88P\GEY%.L-Z\#R6\V5S]UF,L[/Z5#(\>K>U:J>>O]ME+
M?PTJU,'P/\.K$!J_LD%<1+8A9@H2H6;ACHL[XY(;O:ZIPKI#)F0]*.FH\%+Z
MOKL=O8IY^:K.M58G)(ZMEIUULN_\7W2TF\4H$A7IKDT4D8I;"ZV*MASNUAL+
M(F@ 2N1,.9K3T:"XV+:;_'T6?>Y*G4T1;K>0+MV5[JGT_C8_[LMVZC.KW"VM
M^_O+JEVVH+<,?1S?4)L4$I1>$..:X;0==?7HQ?;_=NNBNX30E82H]M@,2+V<
MM!8AW85"=2&!R^1;"M49)(K![.8EU."<R^A\K9B=,CJML5N\]OKT%C>WU)EQ
M4OSSHVN?-UQS=[$2:X(8T?8QN#QZ"65"@7F%L#82K-V1^/T MX2Z,<R\YUXL
MKGNTA*+36[!?P[&SL.L2RIXV'P@\8F%?,9>KCRF<0ZBXH\@+#3EAV7I"=5&S
M?:<@N$I<".<XT\(HO)2W"YTTUX/AOW\,M@V&;MG5M81JO;[;SEXG52VQV,G#
MV ]:WIU::2.W0&/8"EPA*:'']PE-$ FQ4BQSZ)"):/VD,UJ->!7#<R[%51+4
M/.'>:SF!/MLN+6 6+WO8C"\8G_7I,WJ"WL5/XQ:#\IW,:O]H&@&G!LGS "62
M1#%S9F)YV4[Q '"V]JU+EL4?6:,HKQ\=,[H7\&QC[X2#JA(<G=4(Z%R!.^PE
MQ&G6^!'U%KPTW 5F>=8U1?\#4D1Z'LEYU\,RK89U>;@KE]U)J;WW[ZW]J(Z2
M\"YC8>(FT- Y</$@=((5H7GI%WKU]R'&T;22:OK6J(^K'F@4F!M;-HWTN5][
MX).<X610&_ $G0-C@&9=@)7'E-\$ 8$L?*2B7R!([=@9E]BD,Y/"X7D3=JN<
M?#MRV6Q3W0->@:Z1IJY? /O"C01=_ZM,!R^&!Y[1<PX(T@9Q6HY6EAM\TU<U
MGY2)6K5]P\"]8S(]><BX1YDCOF9CYR\T)GH*#/B&W+F0$+"S6<<@JTU'%>R&
MIL^D"2U=[WZQ=%G?[9T4:1EZY<"%_1K;E%65+&+ $GC5\@*72LB0;]NZG)YY
M'4SW^!873S)_Z7FQ83V7J6;G>OVN5_.F+I5JRUF<ZI.=T94'?"^=C9)=*Y!2
ME>#7M:5!B%G LA9\?TY<HOTV:%K@,W#9SG'2Y>8/#_[NWY2V)93R:/'OWVTI
M>I^M;/XF'GB3^Y#WSPG-=Z@0;Z;0 &[!5BQR3=F>5!ER%[9J.HZ$]G^VLZG8
M+/.BQRQ4?D,KZ9&SB_V76J;%V.7)9-_A,M<].F&LX%%'EGIK,$.K$UOC']4H
M)3#'D Y7?0XB$:C 12\G<:'B'7N7@C_*AS^U?NN<G]+;-WZJ8NJM\O_FM^+I
M8,8D?/A@ECB2LX3J^^S^P+U_":5N+P&T#/#U=#8B;EG%U7%)'/N#/;MP+>[&
M.,4"H"7[U%QE@IV8WZZT^72$>)?^^E 8ORW9S//P?8_:C).$!_@"[ 8ZT7-W
MQX7?I7V%Q*YQ^P#J1Z<\7?Q9D25"&(,1^BF48 #?[U$1Q1&[?0GU(F4)=2\-
M'O=N9N=JP6OHBC.PCA"7*Y#7*!/Q<L*X>]Y49"9/;N^B8A*O7:)9Y!_='KY@
M-?Z+4)+M^*;YD4[@/<X+^EK<_<.;3<___6/CC:A[#OW3O[Y'OT^1$2A#.X17
M$(-"^'RMPWW^K79ON_Y)<"ZF"=-S?D*:/P['SELQMDFK6#^.OX!R>+/?__+1
MG=E_=R&D2F@BVBE.H['B@&K_YN7U28N)->M-2!;\M7,,D@\GI^S\PH<'GV(Q
M 0UAF6<96^O?3:\GS.(ER=U85),6^=/$#G&IW5J6>051R#F1ET.8]+HE/#Z+
MXVE<VC@?I/X^XV0LQ@R;9;%);;8]S;J>3V716_$,8S8F'EXI\@&9@LX8DF<A
MO1B*.RST'5I"$:H?R3EA<B2+TK\Y::7?CSMO)/D1RWJ$GT^ACR[ [Y>7]/ZB
M$_#F/[#S-1<REU 7-C#_9O5Z!5%%6LO39%<K:E.[>P1GAL_%:K0<5,5KB#Q>
M)$JOB+0^@Y)!R?TU; 9>37/?@,+)I]%"9Z(SNW",R&S%RI?!ZP,:N-F_1;TR
ML?D4WIJ1A]]R"^XFD(-W]Y7L5K@3L@>S8GGJN7$M!P.9NO,TT:(UA0+RX/4Q
M117VMP9BYV1P6VFN1;!**R*CM@6N.Z(Y<\WRL.^]S2>5?*6WWT=_PH(.E#%E
M.D>=2[DEW$$* 3LR69A$;-4E5V@7I^Y.69]IV?7?5=%!M<4K(E5/GQEKG]9]
M)CO_7OW;"9]?CMQ1X0;X([/2@,()P@K(4+@XGN3/2:*L@<H%TR??#)C]#CK.
MBC;]L&B;T6.5'/+.O":<(7TT?"Z!"1Y=0HT($:-OIZB1KO$[6Q(H[=Z[H'#;
MVXT^I8%DPX%?DR\#MD7I#!%Y9N=3'1@W7GXC?3WVHM+H&$KF&TVD4B5(1G J
M670<2N(OPG+F8 Z\:O$9*0BLXVWF=&T"Z0F_T<D-Z+A/1-R1A>H?QA)^P*-(
M1L:?Y'TF15&JD1I_.T5*TQQ<.S8.J$#S9)#QZ1(7DG4F(/-.?)7P(N4L&/N\
M;&S65LU>:\C48,#JJ^T-;M^XZK:C>;Z^S_!&I'HY[!%8CJ0!^0AWDG3!Z7>4
M*%@Y;A](N5,=;T5#SRBYZ"41"')2!YC&5ADVTLYO+"OT'SU*,+S7)%[>UA6Q
M7Q#'E^&=#@%'J&DD=U8PM%_D6-9<YMW6$)M"(]9EC!LH649M-9P7?</?.Z2>
MB!*]1%YW^;.D"M8'\7D5>!43_,Q1[T CREF]NDODR8YP%%[8C>9TY >6[$EZ
MYM5Q^+1ES8NG(\U;^NX9AIR]2G 4$,7Y)$_^,*R8+"ZQV\PQZ N^CCC53O^4
M1BDV3IEXZT#=YY>B_84C'KH>S$ZI2CTC37^+S'4Q/K(^#TQP@P\H8%"8:,W-
MSB,NRF,"AX&#40J*NYM,B,_+NJ?UCSBZ&77C3FR(SCL886W+/2<TL^52;PF5
M3Y$T^J\S8V[&Q4WWF35J%80_4./Y;#]G=:[LD9Y#Q,_>3:_N5EFJ?7%ZLAJ
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MW,@=C7DVZL'W)([LOZI<++GZY"V,]80+J:0+2' 'C+[(UD)%<9/:-(T[,_F
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M1E86NI_M"*7*J_@7-MRF3S'!,2:?H@["MH+&//%F1B,"U%U)1U >S"KS=LZ
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MC*,8I,?%:H^,'"XZ"P9)H_<T,^:HRO;Q=G31+64'MZC?VCQOFYCL;/?'Q1Y
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MFR,ZAH>@DJ,0[NL*9C)R_,?E9M:.3%RC8T-&9I;W/G4XI*&Q6\G2TU$LQ+H
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M70VH&XG7_.2[2*-W!Z*$;Y1WI>_2)SA><+_R23'QKH.$N<":(T<]G(%]-RO
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MTXHG!45'N!0\0>->?:?&!WI+2M:HX;;5*(]:,/+=_K:JIR$3NRX/#<:'ANH
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M],K2GZ:>)FKNF/DIW=2C$U!E/?*LO*3E!>:; [:@)NE%A(J[<(@37\I<0%I
M2/*IVC0^!9XFTK6%!UAA3B3@A'Y$>G\[:(9LF?@1N[.TAZ!QKJUPK.V@:Q*_
MQ?FG%1;']QEN>N%2X_/O8XWM2),,LCK=R^N.=8:!]CGS5@ULIK&4PJ!.@*_B
M]G G1%3R_R_F0DAXPG#$!4X*5@([B#WZ%0[[/B W5E^_0U.V8F9ES)X'$\>W
M\9CWL151#2YE'\0T)?W[O]V\M+DK^6;XI0O;>^8N:)M-BY$TN @?U#  "9A0
M%Y 8-3HZ#J \2\;N?]0^/L=?!PN*<.R1'\;7:7?L3,SF^GL:0B:ZG!1'$GXZ
MW(R\:,J3\.DUSVS7H'D=N?@482[\59 !<V_?+Q. LCRJA1_T'?1,\&":;&M<
M;/7UF;0W4IS;9;1_]QYHSN54GHC"JEISQBXZ(11%F10*^R9%1S_RY\B:EG,2
MB?&\CU*<I:M5<?-WM:_&\"+O$^#>#-7#-I%AWKP.#.70]*>:S#:#V)8FDK#N
M83",M@/THLPNGT _BEULW-OME>-\;I_8)O.]%C%J3S98;"4K!C6O0((:-#QX
M&!>VGC\*NVJ=B,;C6]4J]"A6W>V@2] 776%W;[D/U9[QM^59IJ)7-<?2MFAW
M!E_BGPW!&,$8Y,A)XR*\T%&D4I6Y7L8*4Q%$4W$B'J3-;+NBF<IL0C3[@GJ[
MB%VAUES\W;B\Q?)C)V]H#T(+FXK.%)5  KRL .@+\GW$7 V]G,9_'XOXL8(4
MJ94'5QJP(N]!WT(/O+M895QF[($.PK"RM5RA=['9\Z>KY\YVI1/[H&$T46@^
MGJ4=E'4&SPR!>R+8$RV%40FY?C(HE(MHD-'J+9WER/QP.&>H[".0]CK>6/I3
MPW53OP_7>-I1-]??0IR:WP:P7-<S,6'[#(V$VBQ1@EBYV5KI#P-8I"=6C(%B
MUH;11HPQ:<\H\5E&>S,.6/I)A5YH_AS@HBK/PS"@!+)%@RD 6U1\/'#^+DL*
MVT'>QKY.)3QV%*+7/O=1B:N^-WPKH2S-1R'^6MSF[UY-4XJ5/LK8BS%AJ68/
M@$V C]!(%R0029^%!.19=MC/1G2UCW@>C&JA-5N3[I)/L_,RL^]?WF8Y.#PZ
M-A;RY-G\*^O=#Z2DJ>-7>/B5:O,9"\SE]7JS14 2#;4AZ,\Y)*''&=)EM4.4
M!<D@/9IIW#O/';O['GT(#;"Y97C[4^"C34<8=1OOGQ "Y9%L$4M81?)0\$A0
MA8:JF[>C6C4APRN7@H)I^/MWMID<N=G]TU'3K6AOI;Y%ZC<+&\GC 7%.M_@N
M%7$1J62Z&6$DC*:R_A+]I@[&PEPD78C)PS";1U* C3,9\KV_\'$R&[LG=,49
MSC5-7QO?CSHJT04CJQ^HG5$EQLUH&M^2BWNI$9(/E^[G/$"YM_MSWI!@I!G)
M,NO5D68(,_-JRDW,ZVHEOHJMZLAGVUJ/VMC8$=N01X*3XB9-%B04 O;QR^6M
M(N=0XR10$<T6YF>>[2%1\#".;L)_U57PS. QGD=]!';H2(]S#H[ "K Z1<V$
MMVE@V-FHX)US0W[1I"#^*1$1LE[_O: %12443S>"?VS'2K!O]]3*N8O5RE14
M1#=+(M.8QA5%A)_>.5'[CKW.>]>ADTQU/A>/B3DANS&LG409)VP/,L2VH;?J
M'INMU>A^]16[&Q-"'XAB*U.\ @2?T\ ';T=TZG1.[=%\UZ&4.)K_P:186\H.
MVZ>\WQ/;@'J?,E\!UZ ,'L9C=FPY4)\^VT#>I7O2G>39GTG_XVMF2<]DG\HR
M2M=._4.RX>4KNP_X/*O,US%PW_=48GT^"_D^<#Z,98@YSL&C/%!#+&IG; '&
M$A1E\)LP"A<:MIG9Q_6/V.J>C6[?[/T\YO+G(D2<E==]_GV1'Z\)I9+<R<.)
M363Z)?1(/A,%NK*,H-;:HYQG2CK*C(#VYGO(*$C9)@G?6%F8^3.ZP=:_+%=.
M846EY+/=\Y>NUE^4;K%VDJYY+BXQ,[X E$PTW5I(&B,.JM%0H'QR%5T1UC7W
M=57<H),,<FSMWJ"2BQ65 ;V8^F3).S4O$G1BY=/V"C_).ZIVWQ#UUG]]?1]A
M58<O%6>+34$B5LU=(AAI+N+130B&[X<^-JD-+ -(V$QV7L;."4AAR@_A35ID
MB"OIV*U W6DNXCL3*\]%#([?Y2)>#4QG[/EN8QGRW#([+J=K=_T/1V.[;*8M
M2IJ1$E7R4Z3UCZ^+>=\Z_7+;R$K.=]K&"K5;O2L]0B*XB)V;N8BOF5S$!*RL
M1D6 QK.H93?2*@"L\&*]NM$$H/$$A;S&RT6TS@"+KDLD]GFS7:CIDUS$(1@S
M)UQ_R+//R7(1EM%<1 I,:W]<_C<W%%TMUT<RMG_0@AX B_?P[&= XTV&+!1&
M6DQ"0I;8A+\^#\G8@>/8JD!H,J<.G>8/WVK';!@P#3.F?"[\_(C_.Q\=TL4Z
MBO&!!_T)*$@EQ<*Z,09P NKU7):X")>0\GFDZXAB2_GGP31HTJ_T#F&JA^1'
MHCQ#+5X'MG$1<T(J4)()&@]&UU=LUW_:4_@@J_60R<'5-[\F$LMK#I8;<@+K
M.G5HG8=I N"MWIWS^R1-C6Z;QV9W\0;7JP9K];?47-87!7]P)$4NZR/^[>=W
MJT_5OQ,U_S5)6C?!G(]8049-<WP@#9;?0QY7IB7?>Z0JI23/[GM?8_@]UGM_
MU^@3N?=OKW=*1]QC<QA";/$E%C^Z%@ZMJ(D8<K&C,3_,R5LFQUA[BN9"'HYK
M=Q[SP/_]0%D-MS34JB:87(>'!6 _7WU1?8-.V^4;-&_%.0$WLZVKYX+BD@^T
M?R<7D:_/1;2SN(@/"ES$XX? 3#>P"'$1/P4 >%S;_QQ7^ 8HAH0.#*4O%]C9
M=EQ$$CZSDA2.427,2 84%H&WZYFSAA5:)TPZQE*-#CQMDE234_KX;#2K4LQ>
MNJ#AE0:6I,E%T/8AUTK1;!*)%8H#'QM A;#-J2Q E"QHWX $\$4%,H.E<:(0
M&),AQ45\"82N_ >KB:))^Z9P8%G^'0XE5X_"%UNI) X_,'&8S"[@R&7^MWTV
MDDJ.1E%U0>!5T"P+-8<?L=6 +PUAR&JM2YDVFMX?QV('._E\7P@,$J)?'##U
MWC7FADVY\%K1/-;PY)M$QQA%NA,DP \[=@D#!;5(=7&VD^[._N-WUO1HR& W
M;@VVFG)9NM!K+7;B!]3:&A?Q*U+FE+Z(U4++HN'E?\K0^KN/U<] F)6ABRIP
MBQ],P/Z1FT]O_HW+)@7!!+C_,')Y&?AQ#!6\=@J&&:LH+H(@Q$68GE[)4\@D
MX85FO_QFAR>>*<*@BC7I'7@\_XS72WM[ EM>LG5IOZP$R]BW(]B'+5=)X@B(
MDU9Z!N)A50O?]WOD#)EY:A:U=L5S3($'">UR0$/A@F36#S>89%*L8/(XNP*M
MV0YFWE>%/>D 3#W3EVJXB-ID'&AT!U@340$6L@NC_J?D?[^2J!<+C[?:M:2.
MB.Y-=_S^)!B[G+^_3'<?%_&)BR@"!F],<1'GB4X#S&PDI:4;.>DMSYG$$I8$
M%(I(E*F/Z&@ 29S%;<?(T6^N$9O2BS^0GIKLV6%[5GOI8*J+-0T=>#VCS[+0
M0,BH+__ [L*1 ..O[QJHQ;LK&5EGM_LE1ZF:E$\G%WQ7('AP8+U[ QV%*M',
M?^N98FOK )Y5ONF^AJT1([C>=K0\?\?HRA:)S-L[.R6LPG,PVSF)& W:0K@Y
M](6$K%6U WD^MN=*GS2I.7$U9:"R:3BV0Y18*:J4I_OKX;QYB_:MN[/'VYU#
MXXYHB+Q2/-!^5Y,\=$'+V]'(X<XIUX:[?7['*?+Z]:_-;T^6[HKZ9GK%X_"I
MUV,9R?>R&J>+6.,1][%;0#/;WNL@/Z-HJIEI12_&SSM*IIA^>/],LUM8MF2+
MUL;--[6GI/6#M1[_&6OV4L6CE72W0E_P93OI*SC"WC)/CHHI_59YV0F=DKSJ
MR_;VJZV)Q"_)%AOT7',.6';^H;YOBUGJDDEVJY;B^=&.)H/G!^X$]-@631>@
MMKD\RR->-TOH&[V:/>^NX&CE>\';8]?MDO=7? Q"TFOM,FM:&E#O%J)_HKPW
M S=0TF 1V:!OQ#S8AIAFIW=G5\Z0[<SQY&.,9"O<=<3[>%+&^<-=C2I#LTP%
M.CY"(PV_%4L6E^ROR+'MO.6O1\^ !AU',]/?W>TX;KUR5+ ZE,^O0SY]XEN_
M"&U"7KO9.%DX=2)IU<XWVNCDJ>%AUG8=U1?! DFNN^O,7_QHSR@\[).QY7C3
M>;^8U^-W[H@L!XS2;14(-V'U[5S(0S-H\ H<GVI&1QE3" @0"RF?,+%1SZFM
M[-/8(G)BV.YT0=6S?5L_6_-NW;YYU*I</*:!XL:R[6S[X9;F57XSP:AL9#I^
M<F(U0$6]D;55QT=1\V??%2.'B@LFYP\IVWG)-D\3KG,R2<X=XE37^YB3C!:J
M?"/(]J2H"(^:N+L6I*O.%2D1;DS,'[GFXH4K/V!X8[?B#D2=[JGSPN(1+9>9
MI0Y?A[^J]YIVJ/>XYV29V*MM)8DGT1RVGO-2E,^Z8F)T,/6I74RBB7JO._Z+
MT!R+IFR)NI^Q.5;G4  5L^_-_9GV1UR$/BYU]N^=L)CD"JS"S ^3W&#Z&^"'
MG,7@ *-3B[.8 ^(GNWX%K^\Z?P=)-U@\C_H+(%-=YQGJ*<BRB,;6B7*WYVQT
MD*W6# FEAZZY ZY/Y/+ E#<$XF&]%3L%1:#?@C#!RL88<(+A"#$>M.J1@HQ&
MD9P08.T<3B8S2G%E?%5.(?--G_^8@4%MXL6O!0>)%>%E'3Y^.PWTIBWN[^6X
M.S@VE! _N65&W1 X[/O&P^3&'?W>*<VV$5O*.<R[$"TGB;>'#F8TN!?61V6$
MJ%TA$N.84V89VBY<A+EZ_([W(5MVH\+/G'6?VZ9=<S9*X<U>P@@)/(BMRK6%
MZDG;"ZGTCKZ9RG,O+\1\\/GUO-**=@ [!=0=!;[70S!G#\J@.8=328<9?M"Y
MJZC9&9@*;V)7?L%-22"(<A&.2.C%@[G^>\QL/_\G)M2TMQ9IVQ3?4T,Z/"[K
M [K(@5?Z(I<V_)L/?_@_$IIB/1P/9G 1B^>6?5@RRWC.(8V?3_^!E?\3GPWL
M*;8>/(I<A#T7\:ZI"XKU:"G$/0864;-XYFZ8O+L+K9<YN0:@ZB^#U;1(+N(N
M/I]=7S/ O S.TP/K <':O5 G7D9VX!;F%(-7?<IG)^@BESQK]J'D^6L<QO1T
MJICRDL+QW13G][6BC@_HKK3 N@5>]]3D<$88$T-D%!;^*C;V\D,^EN]5N67#
MLW%_ZH$[AT<>68Q?3]IT;4#,,R).?A.%>LA3[*GME>J;KU-ONSNH9Q1U]@\X
M]7SRO5WG<CDO[ZSD!>6."Y=\G]H[2R@<NM 3[;MB\?5GZE@P:7Z>=6C8(2B"
MAIR7H(>-'WQ.*U33'Z#@FBOWVW2XA[QJ/;ZSWE&KK4,">&J8(Z'#\TAQ%.,
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M8UL4%*_G,/$'\)[$3A-JP+%VE *<_8^JVMA7RAG9,UW32BCZOFG27L)D&B0
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MF6\[@Y9A2_G2\VEBQ9DSDOBPN5H9@[<VTGIFY2Q-L+!(M[,<Z89K7W)6"IC
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MTH'&U*G&&A\#8M^197=EX(Y,1([@PB__]#K7 .? S=.7^'8#W1X@ 1*88"Q
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MW+6*%^VY@: ';R5&FH.&18[6Z,@L5O>>,LW.&UQT<+#/,5EWS7M%O'\C]^7
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MV^?3-NBQ92+^L3\X#'>P3MW60^147K;IA\E1\$ZW^"-P>7Y$[Q7R +&]2-C
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M4*<U=KR5/S_]=450EO_^AP8>WM'!W60YHOG3+0WR# 5"6RRF!#XF'SJEEF=
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MI P']'D_X)=M?6"R+> E?@ZH>4ME\8L0V\ :TK#="&[. P!QVA#+?[+?\S4
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M>.J#(0V>VHTX7CW1_!ZZ;WVP5Y[.UU8?K4Y$G^,5G3:7UR]WROP0 H5R:VZ
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M47TCRCR#-METH__GEYH5:?5/QZ]'G1CNC%/V\S !U0^U8RC7MQF8]^(9_AX
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MRF!R-7@V,X/"_2N(Y.VX$I_*YB"J[X0<6JSV,+@[=ZM-I<][@>N+@%LG)!<
M#A;<^YWO+R*+54@?U),G8U3])*"88@)I\8NN48YS2.!&Q2,E_" '_R'JH<&$
M WO_UZ6JEM7R0"#I$T93+$]$0B$"4U(/VB*_#?;$]&!JAK5[.U>OL^'-,F/]
M@PF%&$!:TG#'[HZ->][N##I5F>XXI0Q2A*H4?C#$Y3FQ\MM1# K?#[05[^+-
M<^9YD<>@)/\9C8/.773_T&YNGNM3M1#/Z'TG\Z+2!NQL]+<IZ\)1$8[.RI6<
M40,MR*VB\Q.=W]?DF60,0#4"L6+N)QZ%Z](0^])LF=(T07O?K^4W;6@EEA+Q
MG+JQM#^<[3P\?X>HB6@7R68J$0V@5#;R.B ?-6;RI/X53Z[TF8+Q4)_LBS3M
MKB6E(R]T J0O=]ZM9E#$FU;/I#I16Z_QT$/\Q*+X>&Z;'=AP8.UWL6+J)_)[
M\_ZJY5C5#:=V?"!63"X7DD(_PPKUCM;6$8!5"%0A.RD3/\4RJ!)?@H8G])KG
M[@8]FA7MO/)NL=+6+.S9E/U6RY]V:\U+NE_V?I-O.G_1S?5D @(2B&5.KW*N
M$EJ!8/V=Q10JHD<FCHIJB =F<;ZHF;P<D-QA7?*76TG#/]5QO^5;>XQ7$M&1
MC\9-[I&=HQ2._C%I,V ?$1J4=L\:/,SQ\+5>\_Q=J*F2SS+NRYT51!")$^<^
MNX(0JICQE^&^69$8S.JR&^)-XO=_6M2A6MY0E]D;].:0%<0FXG;SZ6VI?G$W
M/F?Q=FM?N]"@'V-[\\.+[Z^DSG>X?T=R?I8(CW]$(R"-P]#0\_C7799^R*%M
MO+"ENRBN>H%7%^U4^%;+A:3[6:\>(J6@.<$^8A"/+%2N99EP]\_T;Q"5O1'+
M0OA93<,.!I.?61.?M0B-B?(P.TN4CM+?Y7SY)]"7;NIS<Q73DJM9R?N H!C1
M#;0IT&IG46'7Y47M6-<$?KIJKDZ^6<D\,G!F>H%Q)7'(Q=U#B:C1$^[>FW-D
M=N,A5/7999A7)3U)3'K->K)0:99-X2!C>#6=Z-W3M%038^+F2^%-R]O4*W+'
M :OW/R(^.RPE+K?-4C>O^>LD""8>YW6WXL>6V-U=F!3+'=\[6I2@D,KO:*T&
M4^EUM)%&XL\WA2YR]Q0VV,PK+_L*]@&MN^CGJ)ET\)_@_QQ(4ZZ7%;G/8FZ0
M5+'0"L)#]#"<Z!LK>O4$2MFG^^KG[:_'UQT>";Z.]D"<7[M%16=T@<I)%@#B
M+@!T)6_ZSF!RLGGE)W@CA0]][$.H[T+*? _G_3A^\YV&<>_)Q<GG4VNV1F)O
M,36:G&'R_,H0&HY6PL%9?[H6&DJK@)Z'5!+E! :064?+CC"D-\^H.ZJQ[^'>
MYX[JD^MN'RE=NRT[5X'6HX80P2%MH@%II,5"]!)N,RR_)>DA0%I,UU)'P6CJ
MDUK>^N_Z;J^;JYHH+@4SB0D2Q_A/3B$D]OZ+Z(QWPL)*O%43$]"_6=R* IV1
MURDU-/(Z)S9R$T1R(BO8;WQLG^3:W%@D_B+/NL7>'^ZWISU1>UU$^M_S_Z7
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M'R:^03VQ(/-DNUN4H+,LS4AV*CD*7Q7LIS&P&.4<*GA[&UO+\.X8<M9]._R
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MW<:-.HK@N4 [1I-7[Y.S%W_T6[WJ6X>(R^LZ^>)=Q"PE$27_:$BQE\#H.C*
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MQ!R4.V(4Y0"1#;AU U7]?\[D_C:5MJN2DR"DPUQAS*GEWV6T5= :Z$M.3(_
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M6'A,H'A%: I<Y>;1QQ/Y]<^QI*X[E_Y\>3Y].LN08+;UH^=^P[]>TR70]_O
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M-0Q5A&XG[!OV,71XFJDC4VT=+R/K):V0\$*4)T'Z&7S:>NA^G")@', +M$R
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M487&@"_/^A3O6P%Y7BG@9>_LGI"GD2N<BQM-/EK1#?=_Z,I(1((<>_D9P(C
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M=_2?==C*EW/_:]^ _^M1:2HJI?GW)JR!ZNP>,6,,IU46DB#)#)7;)%V (+
M#CN7D6TR,-]4RJEF'R:R[_'>55[XKQN&_B<#9DUC#IDBXES$F^)88,#%KR\_
MBD)2)K1]4#&[9KO,3VSIG,*N@1X01JEK('W/CSR$*K:T)]P2L&ED?\LN=CW
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MFH8<UIY%Y#B-VZN9'VZJ+__Q0>B3AQ^KQQ>V!?S^1:N6&[>O2[EP2L58VUS
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M?\YOO#[T0@?+.B%T^?6*F_[C+-W<CXZ"695=KM*?:@U@XZKL(C"%=1W%SVG
MD,G8R3G,5%[7SKE!<?#,$3 MQ"BSODFCOLK^9)Z->T$/\5N%5UYC>NBLC8H?
MLO'I9]I[=,U)D782)+/)<0BZ_5DZ(8-KPAU!B@6,AYLICIH1E%''&+B,2*6V
MFB-^Q8[#F$.GQ_>[ZPH&OGH5O[UY, G=CFG$TXQ9<"A/ZC7W<*I;8^=B?;W&
MV-N?QF1R%1')K>?2=6G,QWBCT-*9\RGP(/X/BW=(M_1':H1; Y@0[,1UH#N@
M)#WM,BWBS<DC!*\0AZ<IR"4"O:4+;I^,,C-\\=0L/,VSH;YWXXS:N?/$G[*.
MFE%*'CNVGQ!0-.<!M]BW1Q$!TJ#!!EM.9&ZP@P#JX3-N8&0#/<OC5UHM*"Y+
ML7 GM?T-EONU"HC=O@7[6RLZT_PH1W81-" &JP?F<$7+6' PFBNZ8$1+>H$)
MMV:="L**2W=M@/,HIUMF?ZQ.%&"83PK+@R*^U0DW3KKSFVQ-I\;&YM'K.N"0
M=HK[B&G?S96+P3+O3*"<RZ;!A8Y;1LE63K XE*UYENX O;%[H/D1/VR)9IQC
M'&?"OVJ,5 ,+N1*^+',H/J(M%DN$LE^;1;TTPU>H'0A)%TCS+UF6SNDPSDQB
M_#^D!_O.?-^=4#[;*Z0<ANJL;1L#)>:DXV%T^TQ0-[-C0(39!>9=HC@;4#;B
M;GC+=Q%''PQ$"-XJ[4K9I8^WOWSFVF?%N =V8OOXUNS9:J%T['L2'SN<%<A6
M /W+^OTI)#'N:$%CSC.BRTW#SLZ0L#C]W++\ D=15Y4 GZY51S/E'FP\80N&
M_!Q+1V*5T1](C3/UW.U@"#V'_*(0!PI0TN?+]JE>QE5<.)%VO7) ,HP0%-,Z
M$F;A[R[18SV8 Z4$U-?(4-6\44IB>7-'-07',($<$PTO*H;F78%D&]2&FOS&
M)QOB+LL2^U1D?(RU:^_HZMO=Y&_#0I%MM?[[ENM;<)J<__>%/ 0,UR;'/C.R
M3ZR:+0')(DDP_O27R.3?X[G41Z+K$D<G?[82EOUV]\^;[JK(2@-N3BQ)O43!
M.7$8<@M, 4'.1=:U546$T N[$*)+[,A24&,]:$\56Q>W>ZBLN^%I[M33U+G9
M4]>&%H#'S#M-N%%/=C)DPQ[T1QX@T*8/N7+"ZB]$RW"R6I7G8M!B,=<I[?2
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MMP_X@+]]Y13PNV"V[;^+C/NG]/^4_O^^],LKK#MS3X+WKK?;RM:5L'P*TYR
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MAPT,F<N7/Y!BCUTY-_+JPG$LLFN.1&#SOF8$8TPA#:XJS0XQ=K-)Q@+4^RM
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M1L_VFD31>X.R2.0#DPH7FV^J!MO9F!WM?2#TUIJT<8S-KT*+9O-94Y7H4UW
M:*+4ZX)K=1%*C2L8$C<32WUTY+F@7?O,V^T6]!O;1%C?^;3\[P<3GA%7?Z==
M'!C-OSS!%,MJ=61=!<YU=[$-PVH'/DT-2]70RF]\!^5X'V06HD6G?"BEK],5
MS;/W)YLR8FZAGI_/G9%2YIZ'*-MC%.,RML$81EV:H9$UP6VA\:55ZDC7V F*
M9N-L(#V!6L9^G(]T,<]><B;VJZ1/N;E9JQ\Q/&4:_?BR-5,<2?=D/3.&8X<
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M6D4KWF\8W.C-W:],:(5_ZFI$4NV0H&K[#"-B=>4%: O]*XI8JP,70UTNQLB
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M.D+#QWB^F9QR]]S--3LC,DV4S^:?],OWO5EVRU*]L "=-1HV-Z/.D J#TR5
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M7A?D!0AHC>O4;C#GAGU'&<G)92D6YZHX,7PBL L\4W?$C[L\L/PQ*,Y_R.3
MMFU 3$.A70MYR'[@ J[.N1>Q>A0P\MP_9"9P$8C'?]\^A5AL!+X>K'[T;P0W
M102KF0!Z+.\R.IB@3'@3^4LYW7^'AD73/S0J+R#G;G-@C42=O_@'\#_F'ZZL
M?XRI],P,R-,M[>(/DSLI6!W^.>)!YK/7G\9@H;K@$,,+<PR:?&+8#J!,,@JK
M,*WUEAQAM728IL#60_.'!=IV8&PWEIYX\TFR(FKS^,VE]_K;+.3SRRE-?>FL
MNX7Z3<1UI7!)IB\UM)DQ9/==_5#=Y9 "KS,^F]H5@XB;Z@\IFLX0^D_Z;V"T
MW:<ESVQ4W.R4;,78EUF)@ P&)@01'T_5_I/L#?AL5VA"GYWY]NTYO#Y0LU&7
M=B>I<0G?7X"9]MA!.2P5<*%\O+._9>Y1P.NX8$\X+[L+#@-&[Q/+T%<7$)_R
MV;SY-.L6Q!;F)4JFU;M6LY>]3&0^RD"I?I;7?WMXVX%U'[:6R1U#>G&/WWX>
M8[_V*3!H9QNL/+5!?JU(G<2A_51\3+6*^(LPYP8G;/JMM^-6Z1'I!Q6 N5W[
M=T>T^1W:';3S:,Y)R_*/5IW$QY67\PM@-&L2@M[#BN7 SG:2B:NGG6LV#ADV
M;+K<FV!_R%IX,K#-(W1=^9M^.=MXBCWRQNS%G(FM,C*88.H816EFC'$2J/,Q
M%L= EA)UYNL+:_(<7YA%HS 3H!&OEFY1"_([.AQ^6F= )>?[6/(4V1]V0WCS
MZ$.!PVIB"P..':76(I-S.> ULS)BV2V61]EL9:MTA.V5]6EFG4%H(1_:I-3Z
M6W[N/L*-=N47U([G=IZ"J4KM>79*I<ID7J>KSS+H=<% >P0F<AY8A^TC;J@.
M9]B&=='W=CC_MI.Y]O*.Y'P"[_,H$BMKUO;A]R^#H>4RYTZ?K>&"1%T"Z@X"
M[N&98G5 R6VXS'GIYIJUK =&6L_ D@.,=7WW<AT'2F]:JB+N%$7EQ)F;G@V]
M(*2[@C>QDA8Y)!279+]^]B.]+[]_\@MX90)9 I_U8AAA^P$A?V-5[/L1,3^,
M/9GA:F>I%W'T8V^8K<:CY+URZB7-23=N-@=>QPQ=[LON-+G85O?V>[[F/D!:
M\PUOZ=SR!F@>N*8M)ZQ(U5SJ(G[>QL,*08ZK?O5E6(F JI=;%E=/ZIZ)_/O/
M/?W_ :Y_)>CY?P'#]%GQL[[CP;3QR*6CRME$Y)K<.,1G;@A1NEV$'.SZ&BSA
M >8/+@N#D 0VI3UBK;H^\)=**?XXHLL35JMC"%_L!^X2'N;/OC0;+9B&KQ['
M3RC^>:-Q8: =V$/]('MB? O&(M;BFAW</2,*8HY%MAP8.12C":F+A[HJ=_5'
MP>;W7A@1V:OW(AB@ND A8EXN^%8N>]Z: ^/&+6>Z2KP#ZK^MUBT.(=A'K/]Z
MIF$5&6 )0'%K!S3((B?9!0%P%A?4<76!D'ILTEOB5T4\FP<^;U"I"KGLF"$J
MD1T+,&_B5\]39$N&UD.$% I&WX\"[.VX112$8;YN)+#Y\<L\]%Z(^1[0X<"H
M>SBP>SV=+KE,C3D(CBUH0^,&W6KU$,2J&DF(MK=S8#=/_G8*8KZ+&=29?Q4>
M45Z,7N&%U+K2POQ0F/ %\0=EE?\H#LN)@ECASH?F]03[ *OL%M!AB6!N1(P'
M!]FK_%%1LS\),[5J.!VR2*8DXKO0[/,,=I0/!S8*D6WM_.S_C[MW@8;R;?N&
MIW\;1<@^Q)1M$5/959BIA"1$18@IFY"8RFYDS%5DORN%(DW9)B&RJ6PF^[))
M-MG&F)$0PS5D7,SNN]SW\[[O??__S_<\]_NMYUOO>M[6TEJSF/.ZSN,\CM_Q
M^UW7<9['>RO(B2( S\V#A_@,C[5^;N5?;L;V71+WSB_X.^_AA05\W"B_Q?YN
M>)+M/X796;"H0ZI.JA>G0?+WNWB"4;FU[=$F^=!7'&+:Z4,)A_->]YCFI"=_
M^,\+VWS_1V';U?]?-CG^3]3X:Q%;(?O,^BBP^Q0KPJ-(3"+_F4O\QB8Y[X'1
M]QQ5Z#T-6;K*0[A7V"X2.C/(^.QBH:-KMA>F+S2?39$YO9CLI4DO5"[.6-$J
MLLWDMRG0\VS6Y4B^7E13;P.H^9A?IWB(MK2_O9F3\>/F)+$+ .:'520417"%
M'86\:HCAGEFE++=&86!QQC7'<$\N7_O3-_,N<?LJF8$]3J/X(ZZQ2BBEI()Q
MM;O)5O-K&TS91G4'>8CG./8S>!U5D+-10@#LC.Q4@!TSJVTWV0& ]E;#[1,K
M+:0HI!C&?6&PWY&"^%4IK\)MZ*V@Q( SR?@6]:"*Z-%RK-M]A^B+F$?*2N2G
MK3\0DFN-+<@*5?H&QD9F0/(2%;A3WK6!??*;_RFEM^'-4MDVE=TXY)7D(_?X
M-[>F"A1;5[Y%W+;5/BP6>Q/3V$CI2M\7RAZ>\<C][7%5-;KLDN+I(K>,F<+0
M"C/=U[V6S+>VZ-0LL@YP67C$CCG1@_%%Q2/?>M #&,/M-/>J"().%G:&SQ*L
M2(W;_+3J6L^I'<=%4H^'%;(^R\[_V/#4;OV@-L3ZZS/BUQML<\B=M9/[V>\B
M9-K"0XBC<"IUC")ZS>TDMN*PX2-GGR;&2%N87N92)>; (?>=.P34-9/'Y57C
MR&66>I-D;9^0X7ZR[IH/=,UJK369A85O8O(GY XN+CDSJQI+J.]7FB56J\"'
MS"Y.,=D5-V)>3X'Y-OT@(Q4;]TP *LWY)3C>)3)[]$)>9L&,3%&\BU=1;LBI
MU",ODG4WFZMPYI_OV#'/TO^'I<<UCNT/4-YZUF8R,/"I9*75ZX=#)8IJ3R_<
M[XY7/CILYA12]LVI9'(^W= AELV$2L<IT-Z5))A"(67PIES^FX40NF7B_'M2
M U&FAR@SO3@T(YG[.6S;F.>P8T]AN5;U/M\;FV'T,5^ ]GDTEPS[,1WBFGF(
M701D[AB4?9(AG_W\6OK/J)L_[+TUO#3K0_BO7WXU?B<P,[>[+6*3VHQ=8YU:
MSH2$\9'3:_M,<TNJS4MN)$FX:66KO:JJEGQ(*)L-"26IA-8ZRB/6TRD<025-
MW  :!NPE+2L!D^8PY1JP +W7C^NZ%T?+N_L":%#\P2DY%XO1H[,J?RRWIFJM
M?K,>E]=H[$]P>.QMHJ&[.C.721E6(4F"G&NQ3]6=JMSGNX)X"%^2,YSQEEN[
M4_[W9/??E,$E4AA7"U)L)8O4N()5C2M:ND7CWB/F3H%'7/E?S/LH?DAJ/Z(<
ME:;F-GZE3-].BN7 '<.4K<QAW%]\YW;783[T># ,JD2@(*O>&DQHP:5?*$1"
M[D5:>:2)[,G2'Y7=2T+>I[H+C[PTT:CJQE7P$!K'F/SJ<!)Q@TV.FL.QKN/#
M+X!V'X7C,#X,^2A?31V<P*R,X=B3 L<3IY.T1T:;96N"_3=_/500L"GL(](_
MUR;EM-9DNA?S-L(:N_=O]',(J#]*W$XX,<"5AEII\U4JV51#FU#]YG->:$0_
M3L,_X_&EG-+.FX*%IH]V_\@^L%/GMU4])9XD@/%$1@[;M2##ZH[VUIA3,V]]
M[\R=/7J)ZZ;UTN6UUC=[^-_.+;:VMH@PM5]72L6?YQ_6?M:9=V?F959LTW](
MW7S_D;JQ^QBJ['@[F+JQ4-S(:RE.__R1^$WX+K+S B:: \NJ5[M76<SV];H6
M@@CGH0^IH8JH7DEFE'I+9X$5Q:2 D$,.YD';;2S4AEM^[E ,<EOB7[C\JCH.
M 6-U.+F";_TT+RDJLX@A.Y[X/JADV'- S('BH/G0SRM KN_F_KS!>K]=M_9'
M.!W@7ZIQJ<-PJM$;B+U8!,&;X<B,@C#/\=XMSF)0;B'^-+##ZW9J3K]#W9/@
M*R'>$C6VBV7E-L?5-Y^K"8L\,['5G*/'4N(.K-G142^AJH]K/$1#D<='H@&H
M0:\@Q[.1Q>4VYIX#(D\T)A,]8\RCW8Q=B@_>?]_2DUOSZO"KQ=;3*7;M0_:S
MKU_WE7CXE^!2RCUJHS]2KZ2>J-TTR>[YZ> ED"_KIY2S>JYNC3)V:K%$@OB=
M7+40;B ;PLAO(H%G/M,-I'.':^>SK_,0HD5(Q]C/&SS>L11.F$P>N]A8#6QR
M"US&1".K@(\\Q 9B<SYS)G@!1]BC&8%[.5B_:;?3)>WY!\:X\J?[GWE'CZCR
M&XG>>%\LQ9SA9!/L::.G)YA;.(_HV?WHO5#[:7Q =?>2/:1WZDF@Q4OGPZQ$
M5[])XY4G3QSY]I;Y42K)C<)#4TR8R819M[..XEF-1\FQ!H;N.3-C\CW:'#1=
M Q>@89%OM*E073U'R)?OZ<5"M8@K%:V?_%*N&Z-\VL\],4'9*[NCQW[9+3F,
M&%V\\N9Q4F%!]X]'/VL'JX*L"@D]@4#;?$GAD HJ#C.>!52@/EH)S6!@)NB-
M'?0QV /.GB-75/4%%*FVWO^E-X9TC!003PO,VM0V[RY86I8SL3GZ'%..>)T[
MB-[ J6%+L YZHO=RR 8WJ27RA+W@6$'N*,$<K K[.O1K)77VIFB+^[MD1;GA
MUH,).:?ZOW^NVI.V@)IFIA0,SMYVJGR;9ZE<65UE5C2)2)C^)6UEL+BUZ(U.
MH>5KJG6MN(.-F;DCQ4<C+Q,'*))T&JDS7_-MDA.+S=X=.3S3[KZ@NUHQD&VI
MX>WWD>R%'+%K10K783QYB#*/N4EP3]UNMM$W@Z-KG.6B_EKY)U=RO.+VW;MD
MI:^8['"\W*20]"1X]9$T<-5JQ*@%*XX^C(]BVG*>$[=\7F\,H!?U>V]%4R]]
MN:EO+L!"X\?%NF^X&]%/MTE;/TC;_=3M?CTAA)F>1)-JLH+V_4QZ06P.LKTM
MW(P28.MAP&?XJJ9#V[0CO^:_%Q8B:62UN+U[VF%SP3]9(US:8UR)7'8)V(&6
M7R^4,W"BXD84''UPM*X8HIRQ'Q4E-2UZO7ND\8&3B_E6GS/>RN59X\%)/PVJ
MF3\.C0<_G96(7IM\3T)A--M3^X>9/W^2V];D<!OO<;^0%7XR"2-U(900;%KJ
M\/! 99W'R"-KXQ"/#E(V11!FIIG32.9F&"6[U1TOQ($4KMD8+,PO.V(YHA45
MV'A;KG:M/4<1ENR!45GLL#]O!*TS@MI9QX$&?<8Y[%<R562I[G-!.S*#R:E^
M<WNB_3![MKFSS*#7,%?FH@QA,:[:+K875][=^?CJX^VOT@MB26J^[2;+JRJ!
MXG8P/VZT!/H>\! I*.Z *5M[BF.&7+6!$WG ."PB]">0:YMA>C@#7]WC(?<=
M.,5>+WWZ#'/E3\^*C(.M_N$+_NVDX=2Q+\/FU25\^V^>C/CQ8-E@\]E#9AS*
M,9A!1P>U8'[#\W[8"\^]D7.#VK6Z/E(RS,D>&%Z-9;]/X@KL8]D3B% O.$'S
MF*MER;2'C,O9-C91!AT"JQEHN4-6.YM]F:6RE7%SR0+6 GR+]W+2EAZS[_PQ
MULR"J7S]^3H-8A>FU  KQ=8 )055:<AHBD6/O\5&AW[1>3EUVSIWB[?E:I+N
M]]*.V/)/(CX)ID\F;6)HS[Q_)?_+#I>NBTW\8#\3*CW=9=!6T!^A>L'/;$C#
ML9;^RMSB',S++*>^/[*;M&K!#?MQ^6&NOFD43(R![]>94_H3JJ:&:-QJ&:!%
MA5>0^&;Z=W!2?UV(*/8?\MEC=AF?V3(X^.'-Y8N$=QCB"+?OQNBQ--LQ07O%
M!QM-9@M^''IPWW1^S>7#%'5!HN5M/K^:A=)H_N9:>DW:U9OML64[K1/L'$<?
M>J'M?8N MSVS"^NVFN!D8WRZAGN9J9QWFH +,)1!BV*K66RL'Q,*=V9TQ5WW
M;_<Q/]^G\OY&)=.VX9=*["9^H_(, 5'^'T*RYDQ=#AGP7(C$5$3%D2\CAZM;
M BDBRX;Z#?U<=5 OT2)>QFER/G5Q573$J='WF;FY>,YF_PN:+YZ\'S=="V_B
M?K8:4G]_:R1=C^P]-JH_,O7B+<W@"7:EVMB*FM9 +Q[SMJ 7O29&6#O#6"EX
MA(>P,>6>)[.<D/_ A+X!_^Q7JFL3C:2E=6]0AJFZPNV*?]X&)0?\@X=B[=F;
M&<)L96"K/V8')^D3ZT*AWL.?N!%6B]P-K=Z>VC/Y$6_G8FL*75\N&A>J=DH5
M]595JS#/++0OS17JO)JA7O,S4Z]5*A]YY?2E#I;CA.6&?W<W*_ER-4[4'/2S
M]5&UJ8I%098Z3U^_23W",O=+7Q:. 81JL S%C\-)=^?9UEX^\ME;$_(=%9H/
MU+]-:#0T]&XA7RV!20</<35ITR^2(-< &FYO6)N%"FW(3EKG;I5E>.5?C;VT
MU^#0HOI76.;#DM(-6$,Y"'.X %>E.-.LYV6^U-7,@5=:1:<S;]ODZ^ _:W/D
MXY>LH""3%SR$\34D6Y3$-31EZV>?Y2&R*H2YVV M*E\"FS9RB@/;:;K6$[,"
M1Q>4COG3X+5)RTE'_D<A(ZRM]&%MU<JUP'!/_7ET:RP<44>'U:5S^KB:PQIE
M32W4_.XW=P\N278,CL1/&;C4&G%E24Q8TF<M/^<A*+!$HUU3IXQX,PWZKD_V
M+G /0[<]56.RTZ6=GKB9[%0[[GQ\4]AZ?>82Z=_J,\,YEC &,&!$@.\^&:-4
M!_^V7H2H2H1947E40XD %R8YX-G<K[\M@AJXAP9J5//Q7<;AYT%NPO9]^=\M
M-AU*HTCDM@Y+Q-]]VJ*HJ9=ZG6,$AV4^%$J#E4'4G""<-9AU#)-J;VJ1>7/@
M0"&0Z^B%4Q+0R5UNSF@7T!XZ>*K_I_&74T);'&631!A([K9P^.MH!A]==APE
M"ED=!U/2&@L%,<XP91]H. NM.(6U_?P)E&:@5%KTD][F',]^=\CDKLAB1O\9
M3<I; T>&'G=;]H35T*]9IG4?VXL:8A65=AO1C6R4D9AL>;+]*/Y8V)CDVX.&
M'R(0POONQ]\P]OOZQ6^_%O%+;DE/&T7I6]JGV>8;/\WCS4>L+8JKDD.7O49G
M1]^.4X;\F(=J^GF(\6I8=#8J0Q&[?+((!J ;'>_?<'(LH/AF5<?JS=F'Z04L
M=VZK#VC*%?!FJ8U!$S0WVV&I)HP E-$HXUNK^]1&(-3V,&&ZZ*GTP3H_-=.=
MG_:W(G;)+,MB(64L6Q:;Y=U.$T!MSG&X-W]W00&JG=@2--06=>7ET[LC01*_
MN^@^)?#R:)!]<?>2V3LX+PF.U"0Q*+3$M;8BUGPV+B1.]M/2Y*CCI1,VCL%I
M?@A&V5.M?6UO_^ A*OTTG;%>N:N5B2NUS(5%J;6JY*4EED9P,'H?P:"FDE*9
M1ODR!8N$JI4Y/]5HS'@QMK1KKI6*C+GYZ^C",-N"5K(C-,-JV-]';>S+0;FF
M]I]B95ZNR>*JB#*1I^DLAU:F,IA70&,M1 U[T.5>?)]=NR3253!]P]%D)?7!
MJ0UFRO>LZG0NFP@@A/#%04Q=R/QO_8<B#*R+"<:0],2L60V69GZ^?,# AT:1
MH,PZU'Y[M<-FA&Z7I-BZ52VJ/>E:Z<G].U\]&(5,8;$(GD']0>SA:G+>$/9-
M9&X9H.DE_@[10#4[*W!':A_2^U-C"W'(H=$.D>M;L_UO%NJB7:Y125>_/LV5
M26^WRPE1'BD[5-#P7M#AQKV7,^(]*_E9/N2?\V-3T<0^$GBLZQZVTOVI0U03
M9EBO6?*!RD/E1S:0W85W;^]F7=UO/V'6<>B^V>2WR"U;F_$D]H[L<;YH'L(3
M,Y31^HP?*>[O6"1 %6YQ"ODH+\(PB:$^?E[.4$F[?,539V?/EE-1CU4-GC=>
M%K6/$YOF8F .ZPG4;T0KX*LN,G2S)YQ<K2H8\ODW7^*3&M-1S;7$7O.^8DVE
M0Y:+CLJ?+HCJ'W1/<EGZ*+'L\1%(P(*6PD/A5,L'H#Z3R$@*)RA3#?DW2J:\
MF)[N;MRZW_XQ.Z?ZK9:6ONB7#OL8I?2(S*O6Q;/[AJW,AX^NS13DO/-6?B9]
M9?(T:#GC9VXZN>"$Z_43X\IUOP2Z':+6@Y>'2+(EWR%?L7#\^$RKU\#=AX'>
M]J/7M\?_WLQFHY0C+83>I+9J*\@7&$)RX_KA@ 7@C!&3_1<H\K9G;,'9"!TJ
MR.ZE)JWN[*5J(K.MST?(:L_7SLR3Z1/D_ZALZ,Y_#J0UKM-?*+;=A( "KZ"C
M_LZ*;R.*-<9T'MO/#]J?&@T+;O&+74R"W'%Q/,3O&P?63VF5XB&DG/A@,CJ7
M!(/L+*PGR3#S:>J&DV072Q%F@;>_ @MP#F1H.SR$9AJPM'NJ*W[&(S]NT0[X
MW[0X\EX=V#^%Y*B<YB&TX!E'VD)D'L)THS!73 1@^ .-Z@08K[/OPC;<%DV&
M/DS_^7Z3_FRR_/8('N+Y;2RDDL9#[/8#W*A >CY7L!#.R4]Y"/:A*MC=UP[O
M!,#'\!SB2IYBQHO(91CZ1 %0CT8K#'';D!++%GXM&E=\7;IKM/*4G^6'N&B^
MT"NU;RMZ9]E?=^,"]LG["ZM/C$.Q?YFASD=B+Q(\N[ 5KT55GHKA(=Q+1"&Q
M%B[J[8>J$$  ']6TZ'7@ER3W6EQTS\+G^T:HE'?91\6_(WR%O Y?<:AZDU.[
M[YS5CS[-6NNS;6#?SYQ<_>+E:SI+ECX8TQ?0,NQ%:^N=T#=Y,<CT[!)HRVQ+
M*5N),99!XR&$G0B:7[E*>$=KD%LK]R-0,DGID)E!6\G!6CO;,+,<EI%NX+O[
M'LL#$^1ZS+  %=-0ZTT#PBHXYJT?^I/<R59@211!YVK:6HS7#NVSY8LYEW^[
MOK^SQ_ F-@5.69AF4AP6/$\28P=ST@A&+!V\.=6]J@D3C1;N"UB(KM.!DO*N
M68U[SFG3]0GIA$!YM[2@<\:^]7+;/44#S:3-+I.S,95Z;(F%LYP,G2YA\MP*
MRZ"906Z4<KA. >]C\2&TS8F9!5YV>]L4K'UN2]&]%5*5LR^?S=\]/W'Z8;X=
M]*B@O3]%;[7)INU-6="M AXB_-HZN6HBO75.8_@Q88@-^^[IK,C)^@WGWZ&E
M5N(6R/6E(Z18SST,LWK+&C_O(P":=F2/5:FYCV_1'I'<IAX^N\LO+K01X:#Z
MLX-!4M16^N;U\OF]JFSQI?$%^C>6)23;N"[#Y;E=:ZAHOGO^@AXMMA_R:FD^
MIG;ECF;.[F6"<D4U-U_=3QQ9496]E]^^MO01"]IX56!'9%M)P@8$@E0N6[;G
MM^!18 .>*[S#5/EGQ<M3T;[TR4I[AU.I*IH;M4_)XC:_.G)CX;8XJ4C-=^PT
MHSM8@S_5/C+=K.VV.B"9Q:(;8C/Z%K$C7<VDRH&Y*-]*\B:,.R4:(_N<=/(9
M-R1I(P18)HYM8[=L&3X?O'V.OM*5LCTG<MI* @8-\!AJR#*D"U(M(L5QQ8C]
M:&2?*T,U?CG4T;E'6WC[Z<HQV;Z?CX/7CB727=+%$.<WRRM-5NW=VT9_/X&!
M4#BZ^GBGGSWH7L46_;72I,<<3NB01_9K8Q)D=O947)0TN:CI;'_ZLZ?2L=?=
M'[1,DP\-=OH"]3M+N/+$%AX"41-<S.W#E$N%*4 )C#0:]SU#L45&-7)!W@EC
M]*$O'CM]H.[[*9$KF]ZT1=YZ]>657-P5'F*J4SV0>7Z.8Z=!2F'VCX2U'V@3
M,NA]RT/D5Z#R288#[<1JY-F_8 .&FE*'@L/Q([Q8]YJP;"=_)/@=5N@8CE01
M'Y>'@/.#F.E?@>J?\,*4:2FU^@H8'R:SGT1YL30)SI75L9-UZ!.T(Q*Q0(/6
MCM'PIQY!$K/ /Q9#WOA7KM-3H0R>NP<T;FW@UA1@?P9<>?/H3<'B$7T>0GL2
M5?VDFI#(0_R_EC@6;_Q+(O#\*Y8+/?Q2(0RI/LL& $,6P2[BS))V!% :TV)V
MF(=P7( I=>,''>$U];/K'2]@N/KUF_POY)N12\9/<W'>?V.V2>D$9&/1*,SM
M/\,)[;.\%P\A--V'F2Z"^6D8+(M:7_(04?[7D+]M7_R]L\;$MQG@7UD#;ND4
M9FD%EDE)JP+_S)[U@?$<)&BZ,"(Y0"7%&OB! '.V3T=0ZAQ#Y<X$]5M7P[L*
MDPJ_5X,GW2N>Z=][HA"=5%YS7<FI]--Z9:$C)Y,\'B&O (G6&3#&2EB71Z%\
MFEW3U4@K$6C!&KQW]JYRC:!@5J/'KK%+-QI>GTJZJ9$L(!(?BOMK\@(:_;B?
MX*3G7(YDL>$\8N&WGW+H0FU).6$L,)1I8>_+G/\RT+BJU<A"NCPB%)=4TO5K
M4^9'YTI*5RM )%>PE%,)RZ;IY1FT%%#O7/X85V-=6)=/,W2UYCPK*D$%J.=U
M=6DO78N?VV+Y[<NW[TV(BP_IY)WD\7MK*W042Z&=I4/L)E<\&0@HZ%9):Y4Q
M#1>S2$&Y/.W<W!'X^=:,]!D%B>U!>WV/7T\J\N!4 V[FG@[!: //B/-NT<.F
MF#OGE;CB/S@? #>/LQ,37R+"#FDIAJ]*T+*>>23E6O0FF+;UVMXN-/P=!"=A
MAR&5"\YEA6KFF=J]#OI%%;:X[FEB #3"%5S@?(")&45@A"W >0W[4-Y1R;?@
MF'YA4+\/00MLG#N:'TT+,WZ@\/[QZ*&/ @I:.QO=2BR7?ZLV+4!*PLW"DO@%
MZE0T6HX[V L9&8&^V?N'%R*O$]1ZC&BRKC)*@3UZP[UMYX=/Z6,7_"5^)_T+
MC$+G;.?27N=O\I7?AFIU'&I])BLY':]N<"W.I?Z^D#*7TK.2DE'FY51<^:&L
M\A.4QH3S?1@_P8V!I OZL)R);9C*@+2[-7@# VW#6P/VH!TS,JWXXNMG+ON[
M.2^<]6Q;E&PL14SXE#ZS=('ZS<3]D/X$,YOE1.P#*B_D)W+WC$'^G@XN,T0!
M;E>OMJ%^IVBY+B/TQ9.AIZ)N+L(=C;L>8KW_XC3_#E P*UWI1SAY575M PO>
M#CP$RK"5<_=1"-)]+J6HO9J,\O5><IRJS/@OB[4!N[56F AU4=BIF!\W>(B"
M[S"G0&,6X?$733VH\%7PO<>^7B_?6W/<0V'(P?2/]^6*-XP%GGHDIOC][T,2
MP^U[S@@Z^6"\0E:E*?#/!>^1^!6F^+>:H E#JQ8[C-AXF,5I^A3>Y/[%/:Y/
M/3JEV87E_SE=_? &/V?[AZ^_<MM8ANIJWHV?TLX;=6#9]*+CX8=O142+_SJS
MO?@'C)*W6LML)"VM%[^OOTH/SO_3$XN7L*0<S_21B.^Y!DCY2 ZYN-[HG1X\
M]G@U[NIUGQ:_9P>=7_S5F246Z!4L^6NZMV96UM_>&6J+-75W;B_N*%/<+K&[
M9'?8<7'@=7 7FP,#KROW.#?_QA0;^C<@1B9CQ8'Q:+(8&2;ZPT;4]</D+Z]3
M&)OIVRK55$#:>TRLM\8CJ_X5'C")%.^=5PF3-E^([9F@\[<<^^(JDB;;KAMJ
MQ/3A1$6QI4RYV\2HN!B*!,'?8%L!GK;O9Z2/ZFDOD[177FN/F-UCCI*/I6)^
M5(Z)/WWT*(]-G?6F8=AB?-RMH33A8;V/SLK@LW"J.BK*5H98N[[_Y-X+QGSU
MYI3.#A["5=?9(CX(Z7$JW/2&6\(?BI-ZKQ\[D:^PC1GYZ\V[:&ES0T&LW?C\
M9K18'+5V+$XRF:">];TKKW[S4^/MUB=\#*KN[$G@?SQT:OC@I?N=-W]3]YH0
MYZIL;>E9%:F9KX/Z/I6]JKAB<YXSK9\?%#*V5CZ_/.!(>H %[6%3J.+H2^ "
M$_461-&/LSSP4LT?2-$&5[(A@ K<)6P8'Z+KX.2]SSF9BH86Y3U)U8E5W#^Y
M^T3D\9W*MRK6DO*X]419")L#V5$'XLE>3EM:S]=5Q%EUTW%%/=(!1U[$&!5]
M,*#F7:G?<WRWR'WU,$X*V8T$[8$S>A$C<(09 0714OIKO/.,E>NB:%;1\@>^
M!11F*NAN.C0LL!(0OOO!3X6HQ@.CD;M9IBU86%#5'R![(F.1PF@M@A/C2W@A
ME$:U+$47C,N9LWR9%);FO-O)5"M-J5-3;5F";]5?MB)$K\UX',F42;SY<K['
MHMI0<B3_^Q>RD-N[=.O<H^JI&N4/;]H%UG4&FG:0R@'VCGQF&(F9%,YLX,0#
M,)7>#@6UWH("_#%BGL\.@.4#,B;O7<IP,3F+5Y=<4G9>/CIUXX+T65F@G52:
MSQ9KG4#"1&6\%GVTE%%"/Y(+S5Z$ /"J"$.OB2L'+AW/GK[=.=E35'S71R0E
MXT=%?(<])?BF[N3VK25DS/6%<!)XBC+2V")CVH1-)$G-CS/DH_)T,ZX40^:M
M:\4)-_:G&ZD[DH>43SX02*8<2I4^K%"=-"1['@[="\0&0("OGCSDV.0L#N9%
MKB0%W[[OU&78S.F](T_[2;NU=.GTL8V$Q"8$XB-B:W#QY:DOO[R)OJGD$ ?*
MW=>W]N=I9^J8V;>F!1&=!VKI2VQ8G5%'9:(X$B\!\#0 +2/!^00C;FP?!E+&
ML&_7HOX5<)O]QZ=^29A_(BX&O7]2_W:5;&TH -9JD=PMO37"7K0X\\>_I\]X
MZ]M+H%(UGOH>GIV]M/"O)+W/<9TWH;5K$E/^F4QS;+(I$7M_TOZ"W3D!JU0+
M^UG5/([CW&VYS/PXFQEYEFT%/IS($/T>9EI:='HIB9\X +RU2B28>E&16]FN
MW0O+ZJN$0OW#RBZ+=5KE[K<9SDG.P;,1_T[-F?3MJC #J1)G.:-+8&1:R(WS
M^YXM6"6:[O:7?6+6;,M#1#B!7=R8L8CU%GP E#Z:=>< F6I'T((M&/0"&,]"
MKBOU"Y3ML/DRI['07M@J,47#>S<*<"6"&C%KJK>EN/Q[_F[E_Z]#36&'TSX2
MM[R!VD&'X=;Z]#,'1_%CY]\GRAU5MK>;ZPA\(["TG:E#)X.%==*P/?6_DD%K
M81CKS^(I5*M[Q-U07..SO8Q=6A64B J5NIXS6H\N/'YQXB*PHW[&21EQ!6@H
M7C]>Z^3""3@^3V+6<_F?!G(L/[M%BJVV$ G\MOR-8HL;_7W]^*NI)(Y8K<#Z
MD1?KZU=M_-]^,+X].<0NRA_E<D&V#'0"&-2H.QQ9K7W.6^K^]/UM*/F]J3N'
MC:I^JLNH"1][;D?BCB"%:S;F<MN<C_1I=VWR9*Z(>/IV6VUY(GI4KOW3Y?=;
M:NM*T4H$-#C5C/WC%R#$=A(OR?O5WR+0'&:3>/8^_LI7QK&=V.U<&<)A$K4U
M:HI$Y4;/KREGZ]>E;-M_9E^RY9B%#P_QY_N^YCE\(2\\>]CS]NTW86W#AW<+
M#>T1.5%LY7='K?.__0+\UZYF-/$_6Z%J(!(01.^R B<:E[I >,"@4-'N3,KI
M>ZDJXI]5<2I5Q/]X_1P<=%.\GD\ST^6?O=Y=5IFX=6/EJ9-G"Q]^'^='M/\E
MY#%_"O<JS^?;47\.^>P_(8=W8"RBX?_VH58'F%M!Y-T*(-RAZ$OA>*?*+V-&
MW9LXY99,L3?6MXY=2C'8\-6N\J_!<!RL6L<X87P@( !I2O?T3-B\J[M_R=(-
M=]1C;$JU\K;0MY[_(Q[J.LA&@T)IP?(O\O"*IE7O8JJ,#63<3DV'&FW^I%/Z
M[YQW^X^;0<9)X-D2:*]=_3J_\VB0P]"DFBP$[!F:9%KH+4&!C_(;P(J281V<
MV*^E7<9>/LA?7_#6=S;J*V"^8'8 XZ\ \!PP%/ZQA&5"',* ID/:F(A ZZ*N
MV KA#6SGLH%ELL"0Q\_W[TL=\:E416RZD?@=DQ=/HB\HP<RZWJBN796]2X.U
MK9FA',56-#K.:,=[^98R_8J!JR1G@X[0-(]0KO.19F(DP3RI_A#["&,35K2Y
M%)SP3'-M^F-%WFJ0D+K$[F"\;:>0KG_E2R><XA2P[8N)GX\"='V6 $'6*C%-
M7K'T32T8>#</RJ.8)%VH^.#&83F-%I@').H=.APPIBL^4AV[&KO"Y1]A72=V
M8"1J-E,IT#Z +18X0JVZRU6"&GH;UE2;,%L(9RL9@G5/"IU$-8H6+E]4P'=_
M.O)8[KGB%<=<6!&%VV6T%,$DQ12R(;BX'P0\O2>,ECZ/,E'TN-K:X)&?P=4A
M/B.)!YWYX&53 M/8XGSC4@E$?F(W -IBXN6%(#(+C<?0YA,"7D/>U,1$PA'=
MM"+M/$.,;76LV[M0DWZ^P-'K:2*^'I<B+WWEFW/"1T5@KI= 9C"+?$%$<<(!
MZJ5@)!A+0/747($%@QVS9:$BM'+QY\@<^>JB22?)8_1G<%$U45?S4&C=NU!U
MY@WH8!;QZW KW2X7TFMC,&NI(59"OX97F GMP6L^Y3U6V^6/WV^H=DLU&7NY
M:[[>!8'8^ .UWJ?I)'G\C<C(+%*4N NH%YDO9HMEM=]@'"]A>[PI8TB6>HE<
M[]KRM')QY]-7J1?EXI,^;MRO#NM"CW6;SC6S3@#U:%BUA3WR'%X>>P#.8[9C
MO1UZKWW=_*$GM:FMZKZYC-B'BS\B3VXP6]IJDQ%>C,=!^_+9XNK-P 9-;=S@
M!/,(.">OS<DE[G4TX[M3LS<Y2?5XY9Y4"^#<=1&<.R[R2O633-V]NX]@4V'#
M9&'?]&'7SZV'= IIJG,/Q[&BW[T=HJ)J4.YZT0&#7PNOV:4Y+.>V9!_F2XE>
M?:M6\%E$+<QLTWVA,2RDB:0'C7>%W=:CTQGYW&W>K_!^3,_^R?)WZ$/A-.4*
M2G1YK<S\^<21B^][1#>PHI84_61.V]L<&[KRF2/_=;D6V32L3(HQ,"PP"KGR
MTJ'5SS789S=^*M)X>[*Z$'_9_>/S@@28H6[>%D>%U6?8#L+%Q(,^G'ODMY*Y
MG =5\LXFD137D1&.Q\,JRLX2&"#"K.0(L.TU84-JT>[N)<-8*$?%E@?S$ !F
M2'=PE-M_\.G2LYJ?=]!W_NDD675..?DZZ2[I#69N$A:6X<PHQJ9^M!S(5MNN
M>V.UZG9$1[RHK+EGF<'GW%L2Q_>8[N]X^;KQF_J2*U=(FJ7./LZ)><Y8VC N
MQ2FIT36PT3S(=-7K8EY!$[$HI.=H=4+URXW9&5Q^V.$V![V%;@.>,)>'%'1H
M;(RC$: 2+M4B:\((\QH)XCR?(;DC.B?9%%?*U,;%T%]K1E0^^L@X;KB:N0L[
M@F7N W,I38\#D,+?G?%^#?M"A3)#0EX:OW<T?_)31=^^J<WEZBUKJPZ!/;;H
M&6PZ!?19C/[=-<Q$;EX%P))>YB=&&"3N2/HNX/-UZC-],ACP:#G\97[UN2 J
MG@S:H:!]R#E7ZAZ6$7$,"9JI P*$/16UE7'-: 70JL51 [ !^[0Z[N<L.2C7
M %YGYU\1*A&2?&CRBV'-M[E0G$DY8TO,[31=.V;W=_OOIBON,7V'#C/5CK.]
M%^.X C!MX_+[(3]B=K%/0\N,M/HQ#.>Q-E9<T+N5M+5&+%\OBF#\$N\@NYPN
M:U30D:9@&W-24"]58_A"1$-9ZA_DLT0!:.#C^MEG0I 5#=6XLQ+OC04[(W.I
M/Q8)M95:(SEO!$GUK$JKM*K3B"5L#*G2CJU>,M)%Q<W!LHI_@DX"RVJ0-,$@
MKBA 3T*Q]%G[AY-4Y\;,@\=PPT0>XG&&;FA_%U(']IUSY/%R<KDI6^RVE314
M: S[E".^O86'$&9O4WF<WM5$-VV!B<6#&P.%UQ4E,UZ\>S9U?<7,=\1UU<U,
M*\+F&Q,;0_80#I<_""U1<<-^341!EE6B@53V+QF[R  R7?812RYW)87YDIUR
MWTB%AU#!/.E^$LC.O>7',&7+P5)N[Q&HFH>X(BS(0\QP&^Z@60QR/!L%3M2G
MDYLPLK,'O88UPW._7SM:]P(=Z#!<+VN^O^B.Y3?CJX?GU)?(\%S#^KG?T6A(
M*H1UF[T7_FAY[7;5W(R[X)<7PM&:=<K#COALZZ_TT7O#Y3+'[R3$%BB^UM"=
MNKBB[G/YVXH=_3AH.\!\Q$E'*Q"_I U7>X%X'N+C!W*4"OGD=Y_DM3;'<WNE
MI=641^,34U8SP+<346SQ:N;E]3?A,'ILZF:4L,44FS4F2O@(1VK!!%+SQ>7.
MP_CM7M:.GS?=[EO)PQV1U+]TADF33.EPNV+/?,[W2^IC5P)6"/!<""=*02M@
MG+/3N4;Y U_I%3Y"[#U&&N6,&+%;SZSO''8S*/Q#:*O.-[MZ,GC]D;Q*%7Q-
M.8) 4K.7VG=9C9M%3:NC3-N!"K$-4U6/SN%8^MX+:O]KCV4BYX4!CF%%+:E'
MBK&/0ZI@(@J)+S3NGJSI)DAI5G/2 YZXRM9UI*'/-.R3,]K4X28UG/-2>: T
MZXX!'],&OE(2\0M0H3JGY\,*'L&G(@7QMETGW]<P*NK>HI7!HLYT,< CZ*.Z
MTO;70N>EG!*SA=ZO3E%);(ES7/Z[+&.VPE>,)VXHB+LUCW!N/$FJ=G0@HJ2"
M/"QF\74AOZ?'3R[W!S,M4/K>=Y.Z6UDUKT0>Q>P\H+-D2E]B\4VG84$'R@9B
M$UH8RBR$@/%\>G#PS0E2 EE(N_E\^;<*C'"CSO>,G3N^MA(^\PW_X7,5OY+J
MLD-U+B\EURM=\HE/EN<'?\G P!M*DJFII5MI84IG7T:_0EQ (!#C&V(1[*[U
M]B/C%5CP/&4XW)&Q$D7D!^JWSRU[DR.=]:K!I 2%A\RL'HVZQL(1GZ6B^@Q+
MZP-.C2L/YHV>[1P(88QP^2DL#[8!YXW!9M96M@)L*!=[?!?-(Q:]\2+!E*$9
M%<!HZS)/:EPT#S#,'4O7E&\XY<OMTMYS<OJ7,B4E?L/#%-AID#Q$<CO+GX<8
MFH+R5XWLN8=XB)02@BH/<?6X*C=GH'S#D"<6M%^0(TA#U51,. \!GBL9%&A!
MOJUGC)7(/Z1:R9K3"H5%(9>)LP\Y%UZO):1V>RLNE9OMW+F]P_K\&U8E&4,>
MG[X B@'UHG6HJD2#I"-N7[NB.AXOF61S2CTF@PU7Z$M:52141Y=T2261KRI.
M=KSDGFQK71!S!JQ[%E!2/M7!P@YE+U5Y0%7S7;6(X.8J>@HS"=HGM[!^DI-$
M"_HSB!ZA(=G*E!$D\*5?M9?8R,2JQ@?+XS)_+E7C4@^^@U")/ 1N 5*?F)6!
MR39:8+V1X]4^MNSS:U(W'2QH0(*DS-6W- &\DOL2_?KFFD@YJKG"Z9&G$A]_
M>,S"; )&E!W<GG/$@9N0'G+'O(&P5/A/AC SH:LSJS58^9?#JKS'_8,WU<F/
M%9>$Z+G,.]D-P'@N;"EK0ROFQ?*OL"W)0VD-UM 2,QYZ5N(%-E+9HG]H+.Y$
ME[Z43UT+K9,>^E[RV-5]T^8'$XA?ZP\3]V'GIE@.Q 9S.&5M["[!$73&9P45
MK6L9[N3H*T-^U)5>=E>5\8V":A74OD&)+S_4/@H.(O?KL:54F76]Q(V.0/UQ
M]CHD%'V#>95Y?NP<_CU:P:&=AO<_<E6DM:@N?D_K?2/UU1,N];(=8ZZKL\\X
MA3#JR=EQM[7R$%O:V<Z<#/\NJ4X:2MQT/&,4VRJO4'DBVZ:O!.>:89VR 1%]
M0JOE/>)Q]N8[2@/=&*ELB ",W^$JQL<!D G?7%3 CW'A_?:P,-$<T9U*>E^%
MC$"$NHXO2$$>-.%[_B7R$,HAW*:[HE97T,BLSR?CX*BCA<QG\9<AA8KJ&Z>]
M3]<YPZZLF@EC7[TBV4.1AM&C(\&7_E:H+[,_0E,,DAH_+S+HL6N1_W/7XCY\
M\A3V+4CG3$5H9_@8G8]ML^N]CL*E#\MFW+G7NNOA_EL['V3P7S*9/*[J[<KW
M$1C/Q(!G*=N)8]BM;".:U0X".H,ZD$380#/O$F:?@WQ>7ROT"Z"&FHP.^@17
MFJA$GAKH2+P1FZAWMTT7'5?R"06A2'/5KR%SYD?(; (8ZIW0+05I"\P/#)-,
MT''B[M<])W2*5()?+"X<^*[Q_<8VGYH.7T^WK?S%X^/R<+R3(/5\>B'+V@NM
M N7#:\2 9VO?R@BAYJ5,Q)&%((^6X:@6%DH(*6IZ[86OCFQ(2+4DTFUIQ5CV
M=;';8-,]M4^'<1N ^FOD\0*RV'I5NCSW\S-83(9)#XWBEZB9J4^")@SER-<T
M%'1*X\Y&=95?T9IIV!?4^D7QJGKW&WQ)-S(<R4>4Y78!VVKT00R5+Z+H-W8[
M_MRI\#-??U=;+SJ.--T5=UOL.-9^L%U+M"G9K"2"?(6\>M&;^9.'*,50R=PG
MTQNMF,GP%=\3AS%O4Z;FJ&"4[?HAZ\/.!%?.\V+".03DK=JJOC?K*_(47FY#
M7T_#*<VZ;N^C74^-)Y&CF?1DZ0D4I,%'%V$I&R;%8L;S =#<2H8@"\K-9TND
MM#:5".!GK1BI#W)JBD64ZEBBQCJOC6.+EZ25RB)L526Z8,>P)4_JDD%+)&LG
M6A&8R;<LR<>,OXX!UZP@%2GZ%K(XL9,3 S,/OR:36?K%%D;^&9<1TJK7S]60
M@U\XCZ?$-RPX:%9D0P]AUB0556$>,BO \IR_CO-1L5=X%]%WZ%1B3J2MS5;%
ML*TZ$QA9,BQ@S@&5 Q_)@U-<B59F&ELS$],,YX8'/,3U8,P@93 U-4V6V/6C
M:MA@H<*GZPDR[>WAT,%=&+;(MAK8E\%3I*&AFIM3G&JNA.7#24Z^?EW[CZ2R
M93H34)4?+,$QR+ !76F8%LH?W.YG6B!NQ, =[*'8AM<?[6(F= !#W;]N- N"
MB]D/7#(Z$K>F'<I^-/)HV$QIXP\LI(9E2RHRH]</A&^D\1"2ZVT>PR=0T?*;
M08W,B-9HHI(S_DN743<C\*M)G&^7^-*ELO8;#PZ<>D=@;DJJF*L)SD8UXNM4
M\8DT#92EC,*OM,7O%H_I>Q8) U<)PBEV2D^%MMS$2L &[T0NAI-@%&4*=V-^
M\Q#Y=GUK58VRP@GD,N6N^@2[L\D] \T408KQ^P\1M\#6@/S'TGUN;G?W*#[K
MV\# 1 'CY93*E1;L/9D2^EO6(:!^7PG;CH7VP@4;IL7H",<$]LLK#ORN-I/3
M#) U5"X:I&,U3]ROR9@48>?O1[ *F;Z<%V@IXC<>8@-;E76*(-D_8@U6Q?^^
M&& H\_,4TVSRU!$SL<QD15]3*ZK_E6&R#N!N%;N>J;"#?DR!<.ZV!S0,I(*-
M#:#(X3''^PSTJ4!LNF]UONK=XM?2>2QT43!^*<;'9F\.10E][C37C"IC4? +
M"5X;K8K1 ,9AZPHH#J0;^09@1>3V/-TATS=K]]A=\-,YU733C<4A7_FF_[V'
MZ'_IOK#A[T]"PO#L]>Z),03E'K;8!$;<&RW&,+U7,1W 0T0!.]BH W'GP;J2
M;1U!9_48^SX*2^\^@ @KCIX!]=CB04PW^)O4$;8*V-6POA@5MKF,PG'?][2=
MVMCX?IBI2#7G0+2E$VE;%Z//?]_?764V4<E_6I2_W)<%..]]+OP'1(+ETJER
M3K*!(BC%W3;$&,/<6<2?,#0DH$)5PQ2_C3L=W2I_,/^[O?.A@_82?=6E8NIY
M$TM7Z_P84FQ15^9/3JF!#Q5VA[#GL$N<^$W:13@*XF+H%5"=%-L PLE'>153
M''59@>0/7CDI--O9/^(/J&Y_O5'X:_K?&P\MJ8[GLT6$N?P'6?H$[_5FL7]C
MR6TSUE K+; 89W".!NP@=MH>S<O6/L;]U>FKJ6/B692]X43CSE,MWQKNO)*:
M(_-QV^4Q#,I<>#&W'5.5WS)K%?\6*CG3YT\6@V)[Z]]  ;CKFBGW3U96+IU^
M4W.S<E,LJVHO<6N)=]8=C(XR?#45[@CQ,"21#6O\.CUX'I893<BWEG'*F:_3
M-Y,:/[UF6Q=ZIB9GCW@.'$W_+G'QK*FH=/+N^5+$^8UWUXX_]SR*BO!71VW'
MX\S#6BU[?10KWI15QBL%@BTO1+6M&UZ]1&SXRE_UI[[7/WB(RJDY+*C/Y"$X
M&<LPVP*88=W%FOYR 2(3U6\>&P?G.36-C-=4/@J?[)2]TW9*S>1"RH,G5J^M
MCR$?D2J[YF!1PL='["*7">53K>Y2P+,HZ)(\LD<QLM<ZW @*$(QJ4A_=6MD>
M45ZSI)(8\B,JXJ%+UY[-WVJ^JX?>9!WAMJ)EUS?5;VH!>8BY]O7B0D90+)H/
M%L-C4XUH)895>/_$I9X29[?WZ:$F#;]-5-X_8#>EZ_&3]=6N_+%A64Y\P^H
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MFQX8F-&L'#S:0WA>&F^!AUPH6-01AQ7>7VH_((@4/K70^UEX%.SC5G2?7K#
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MV8R$P:[A2/R.?L#<4JM@@ZT X#;=QPJ[IO@O(U)LL<4W$M43[>.YI-QNHVX
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MQ?.-&L+%9<[?_6.9/>J/1,>L8.TP"\$AXZFGCYQ]2 )E7N(81RSV0QI$OEV
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M=$&^)*80(Q+!./%#P83T0F)T>?9T*.=F0[5);,I5X;AEKD8$Z&6WB=P':Q%
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MKP9\ 11DG=:N ^TR8,:8(;?Q,L>[G3A<QIB'E]$RYJ\.3+%6)V[[*MBRK$]
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M:_(H&^%!(WW;E;-I&2]O0*="FW/9*1&\:^=E_$9HVMDCQ!1Z=E[&R+)EI\5
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MB4='+0#I9HSM@44Q31EG!')3YE%_>1C$(BL@%9A0F2&*HMQMWWH87.-L3GL
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M\4:*+T]M)Y;:6.[>&)2J!"5$F!0N!A&.4LA$1B IHKC *6.)=&K?-U".J5G
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M0">W><DZR<$GYSH&=FM@1U3>D0W,4SY =68I)Y!\DI3=Q*-RE!,6QQ3E=O.
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M;U*^4LJ%;Y3/YUUXGVE@Z+XNZK4K??#AQ^>R^VC=SC6)+AH)NMW]&$<$IZB
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M_C\1PO^;ZV!(:S\]'MA/I:5Q/[,5,;^6.@=I9[19'59I:FY<[,,"]G#91<=
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MU& KNP7_&"Z  :G[AW5D3G]=1"T(W3^R$_&Y%X3MV-P.JT$R-QQJ.BZWT^V
MRBT?=0T0OW\4U;VN#%>5?ZT?M&] 5L\+&BF[/$\DQ%(7/Z:IA#F2"))0$3E!
MH4ARHXI-%^:9&V-W(=%>5M *"SII;4/&IZ$U#1Q?#=@TX6-;K!R"R(-(7!U*
M/CWZQ 'E016/P\K#'W<++G]2LNK3ZW*I/G3_L>L-T16,P8+3) X3F(4T4VZZ
M$)"P.((LX2S%><9D$-@$B(<FFQLI',JZ[9IA%Y8=1-<LM.H+LY%YX05<O9P>
M>ZW9 .(S.CDXWZ011A/-7T8)C9YQ3%<1S9B_B)6HR/)VQ6_Y8[$J]!&VCBB^
M__&D?%*QD"E3E@3*8<0TB40B@9@E 4S2E$0Q%SP3@5T)?[.);5Z.:8JG=7+?
M@/M6<J";$9(#V2WS6,Q6P(QH_*,Z,N5LX?QE#\Y#H4$GM<<D%RN4O*:[F,T\
M;>*+%1I'*3!V3SNV;.MJ7S>'(!]7K!+*@7HGVC\7,D&$R3R%(=%'X$1F,,<H
MA&&6,XHI%HAQJQY50[/-S<1IA+3L/S6(IAG1>,-H9'[IY;SI#G-[4<%/O; >
M"^4;@>*UG]3@A-,VD3+1_:ASE-%#KI;-JBBK3^5:U'WQUR#)D@ G,$ZIKNLB
M4D@21A1MQ%+9-33FF5&AP;,SS(T;6@%!(Z&M4?(2/%/[XPI(1C<U=FB,X-*<
M5=VO_?!RDHE-A3,Z'EL%YS[H<&SU5OD]A);M/9/V.$R?A>EPJK(\%AF6.*&)
M@"S*)$0BI# G.8$!3_*8T#REDAD?5PW/-;<7_$#:[LP6_+1L^BIV(EN<I5S
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M=(?P.*59QA(&DRBC$&4T@7DN)$P2&@:$Y&%JUCS,?NJY<4XO&[A7PEF;Q,:
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MP 7U,J!+&H%0+Y]Z,^]U$]GF/BD7W\6R;%+0FK[IW0NS+M\7-2D6"2=I*O(
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M'QB>[.+B96"'B-?+4[7=>9L^??N-K/O3-ZFX[8.2XS\%J>IM)_,%)A$*TY1
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M"Y(0P9(X1M*.=SUI-C\&?E^N1?&P DW[&O:BM\]_D37?I:E78/-(-N OL19
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M^95P=O^C6+_Y)GRLOPG?#KX)']IO00\"T&+0#2S:UJ> [9>D?M<<  %:).Z
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MB_RC:N8X+ BBB%&1*.PSIEM^,DAQ2J!(49KRG.59:E3I9R1M;I[:3EFPK/,
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M+=,T_6%5-Z$65?7[NJR4QQ&',F="P"C1DQ*Y+MB.8PPS)(1ZHP5IG'*;K?Z
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MFS_#%TD>Y"EB4@_ZY&H[PSC$%!&8HRP/ QQ)EIJW67718&Y4U=@ =D:  RO
MSHP[T!AR!W:F6#SB3FMEP(1CK\#(E#EC\"V(>.Q%F(BQQU@,.WJ_!<C!]X#3
MC:=[8=QB]\&;Y:8;N6V6OZ[;%JKUT,)Z+[X@(A&4JUUQ&L<(HIR%$+,XA@@%
M,I)1E&"$[/;'9Z3,;TN\4Q)46LL[\$S6[2SH_Q;\(PA"\"S6S?Q1NYWS.8S-
M-LLWXC8R_>\!^]X 5BMX!SY4U=8'J1B@X'6>_1DQTXZNOVSGR93Z@8^Z$8'.
M-[I?<?T_>F:I^M[KM)8SK?<6-$%)B@6"@DL,$6$$DC3)8):$*4V2/(^097*0
ML>SYD4:=C2?V2MLQ@SGH9GPQ"I CLTB-H#Z#K__14_L.G&W+Z8]7K-'RR3;F
MPB?E(&M,CIG)_@:.,Y%UEL;;\NFIJ$\1%WFF]KZZ\SJ7@=1C^1*8IQ&#G"4H
MEKE,F%W?H*/[SVW?V_58WBJ7G^VTK( L=>J* +J<:K-NYR&4LOZ=)$PGU5L.
M2C\&VHR);H!O9+YITGOVJGD<C'S>9J\3D8]$3#L*^;Q])S.0+WS,,2MP77>P
M?MD[.EV=B#["^B0VCR5?!%&(TE"Y) DGH:[5B"#&2, H(7G$HB#)&7:8!6DB
MV^B;/?U$R&]B5W2GGG[-$(H'VGT-V:A?V![_&:V#&3=X@W4:PNC4/=KE=#K?
M :TU:-3VF!QH 9+77$$3N=.F#EH@<9)):'.M'4%Q42R^"[9=JS?J;W_K8<0/
M0D]B6["0AX&@BH?R1!>.91)2E",821$++N)(_=[$$[DD8&ZN2*<CZ)2L9PZ:
ML<M%$(>9Q <T([.&)2K&_'#-]#T75!T95(+]XZ'\^3_4I0T/J'\</_X7;SO)
MHW[-J.ZQOOHYAW.X>[YE9+5](K0]PXT#RC*<8YA2H78241)!&L8IC% 8"R:"
M2#D9QF=LQW>?V\.[U\_B1.8$,H.CKEN &/E1W:OF<OQ_ H;%T=,MH$QTK&0#
MCMUQT27C!X^"3BZ:[ICGDKX'1S@7/_3Z[4MZP_)Z?US$.&4DHAILM6-"4E*(
MN4BAY"P,:"[2C,4.>Z?Q-9_ISNM@\F2GKF7,98)E-]NJS605_U.W1CG[A1@:
MXONJ_5*&5VFN+50N:/V?MJO*\"J,V6CEBF0'!_M=436-U<OUEY5HG21"(QQ'
M+(0A2ZE^Z^201@A#2HG$'(<DRXQJ[RY*F)NCW=,1*"4M',RS^!EXW+>B,C+;
M'@'BXGJ?1<;"_;X5H8E<\#Y2Y4K\PY/_/63]H ]^]L+I_/ AO0]\\<$/NG9/
M.<>.OY<E_ZM8+A6AGM0?M']:9)'4)0($$IDQB!(10XQ2!N,4!SSB89I+JW92
MSIK,CA@[]VBCW*-E?SS[0ZNQ;6\5UR4R<XDG 7YL[KW@DMZ!WZ]A[M!_Y4:\
M_#9E<55FXDXM-V)VVK[EUAO>WFUJD7(9QICH1-)4MW)1[EX>R00*E% 1$2Y(
M8G0P<N[F\V.UO6[NO:$<>D#-BF4,,+BIG],X%-&[_ZOU9[K\()_YC'O&9R]%
MZW[SEJS7+\7JH3DGI56=8+20*)9)EL8ZG2IIBAY)$DJ8$YZE6(19(@/[=,_K
M@FV^R-/D>G[?/CV1]8M.J)!JF[U2R[ $I D#_55L'A7ZQ8/ZPQ(\$3WTO@X#
MJ0\O=4RI[B>$ \#)2P6*>MR>>O_JRXJV?Z8.(+&;TTD-5M2,5/ROTLAT<YH_
M2C:@4[I-(_VST]MC@P<[H'SGD!I(GCR!U!R-<]FC%E>[$9\6L'EIDC]Z7>D7
M J><QED,PRP/%--E N*,IA"1+,E3P7&4"AO_Y(*<N;DJO=9'BHJ^DZ=JJYZ7
M-T4IG@M+ KJ$K!GC>,!K9(II-&QSO4!/1W]L<@4$G_1Q2=2D?''%WF."N/9Q
M-T;X6*X>U*/V]$[0?5>S.(_"A/,<ICBJV\0D,&<)@Q%#49:@4" :VM#!.2%S
MXP*M(]1* JWEG7N7N+.(FM' K3B-S $N$%FSP! &/BG@K)Q)G_\A2X\?_L'/
M.FZ"RB>UH7K4!;<_13-(^[/8?)$_R-^[F=A?=8O;<M6?#_RC;$;6;)2IZNX/
M'U9*+T5&"Q8E212G"8P$RB%B<0[S@!/(,%*^!$M1PHQ:Q(RDW]SXYL \O2U2
M]BFW_7 0LW)%'L1*O6[9Y:./21;7<./T>DLV]@[K8+4:T_K#"?1F5UEY!W9V
M@M;0D^':A[:"SEB/N[)Q5L'K]LVSBM/N\\;!]V1#.)(8M[?%-\&6I*H*6; Z
M O=EJU3IS6_H2I^.5:Z]'TEH3C#FD&>)3K2C&&*<$$@R&K$@B'*:6,T'OT69
MN;T'CFT!Y;9FD_XHE%WAWBD'N7BH-ZVEV9M@JA4:F?;'71QK9O>!JD\:OTF?
M23G;!W+'!.WEGHX3O7Z28JG9_GVY_DZ6HJT,*42E-PC[G]YNUWI\SH)SPN(X
MU359.85() '$@:9B(3'#C*6"6,7W+.7/C7,_D?6_B<8AJW:Z6D[NLEP!,]H<
M$=?13SSI!NP5O ,[4Z LU[!2QMR!5FV/<[K<\/(ZI\M2A6GG=+GA<S*GR_$V
M;N36C@#[NBY_%ESP-R]_5+J[[9=GH?N!K1[NV:;XV:3RXRP(0L(C2"*=6J:3
MS+!$"0QYAK-<BB1)TL5&3V(UXS5ST5:4ME-@O.=/[T%WLP@K\-Q: .@+*#OM
M =FI;T=V%BMBQG/CX#PRQ6F(ZY/6KSUP?]&:@V+U*]@I#^ZOPVS-=/:(^20Y
M"^F3\IL]*L?4YG"'6XY>M3M8KA1'OBN?2+%:<!)%7.8$(A8@B*(\@CF-U8]<
ML# 302!X;'_P>B1E;NY7>Y:XTQ+\V>AIN8T]CZC-@>L-.$USW&H!D>-QZP4(
M_!^V'@MZA:/6"[:>/VB]]&&',J WI"K8_8J_*Y9;M2_\C:Q7BEFJKV)==S3=
MYYME5"9QJ'9I61Y#)$4(<TX3B%D2A2EFZJ^&^68V8N>7;58K7B>%\49U(%K=
M;?N06L$_S!QC03HRD318*I5!JS/HE 9*ZZ8ALDENF#NL%E5)(\ [4:&2R5?6
M5_62)4J#!4VF]YJNQLG2NH.R)]MKW3RY=F+3-[&LOU358_'<^AYIFD8H(QP&
MG$J(<!Q#*B728UO57C10](ZL1JY=E#0WCZZ;(=;7U-&KNXRNF6?G!;.12=D-
M+FL/[RH4/KV\R\(F]?2NVGSL[5V_P+XYVKOVI?-C3595T12E/Y?KS8(2Y<^)
M!,,\Y<K#"[,(DC#-()<B0.IW 9.Y:8.T2T+FQ@V=GF"O*&@T-6^4=A'084[P
M!=/8L7-[A*R:IEV#X(;&:1=O/5GSM&O&]1NH7?WL+0V9F]AWK\:PK<K/*>4(
MY2$," X@8FI_1Z*4*J<@(H$,%0>H6UFW9[X@;6X/_SZ 44I &%MOM6O\][-8
M5:*J_>52F^/2E_D2WF9N@C<41^:&-KN@4?2@RX[_>:U&F/COZ7Q)X"MT>+YB
M^_E^S]<N<HP7/STORQ<AZOZM7YXU6;5?\(CH@>TA@1G&!"*1,>5$R!QF),BI
MS'*<!5;9^1<ES8U,&MUL"W,NXF@8*?:!SL@D4>]N(=5#D<!7\E+[$O?KM>X1
MVLR]:O0>@3*NHN,UD'Q1V+3!Y&LVGP24KU[@,IV5K)<O;\ER^74MGHKMDWJ7
M_O.ZV(A2RE)^$WH'H[8U?ZBOC<X1_0_=WHIN]'PBHHS4+:"K19ZD:8+S%.K9
MS\HS(3G$2:"()&<1R0+!H\"\$]7M^LR-;KHG27DN0AL'F+(./#?FU;[+7]I
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M+KT8^@OX4?WK?_^7[C?J/[I?_/_^+_\_4$L#!!0    (  N*55$C*'J.O.,
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M/W\_#[/)"!+UG$5'@@H6">>\E#$GXK7@5CKME>G#,;CUTMW4WW"Z\W 1-F(
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M?T5#:@-&5Q+E$:PO9I0*3JLDW+;0,FQVK><CJV-EW0!<?IM-9[>YV&0#%=<
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M*EM'@ZTS87PO*H?-<0X-SM[TUT1D?X^]S;B M]//J[ 8I[&?7W9Y/\FYN_6
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MNH;EXWQV.O?G)]_&Z"O0K+/VB7#PGDB)D@D9.%$L&2FDDEI5F0#P,$F-0.D
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MQ$6/O^'&A*S.4B>C-"V;?D2(H*6VFE@=%(I"<F] 6D5WZ0'8 ^]W*!O.9:Z
MFIO!5#W]-+#973-WM;J1S:M;Q?B4RT!4,.D-IX3+4C"6C2?.9$$RM_@3F8(6
M5<;M[$9>J] ["ANSZHIJ'G[K.,=28U%JO!R5E!94PI 0F"",2QZ]9M;+*NGG
M78@;UD>K 8J]<'> AH8^S%J3CL[-2[\XNW)PUK&PHUDDBUC@H31.P#@8114,
M2:6;@O3:9+U;B?&CKVD9-8>H=%9%OD,C97.I&.WZ2?K/U:+KQ;YAA%NK(;N(
MX0X&/M(Z1JP7B; <(7H50[X[J?$!H#SVEF&/,NKBI#?I-K"-??836'R"Y6H^
M+2*ZEM>F=HOI"-(Y$@/:7FEE2;M")LPIQI+7-N8J[M,3= V;D*H&KQI:&?CL
M;%<_\SH[(V2P*I>.*30C<QS9="7X\8$&EHPPC.Z2!.TU3MPO$UHEFU[?8:^O
MK@8,WN-K=]W39^0X8]1 )-H%]#N3*"6KN,",3\SQY#ROT\AO)^K:#QH/1,=>
M#OPAJCH8?Q<P'\_2YZ6?+WOPSE;S(NBK$2&++[/M?:<^P03YGYY^F74;PMOI
M^E_^.WCT1[/+WC&+C)IR)S*BHV$88&@4J3,N!K%C+5LOY+1O%X_#Y$"*&SJ0
MN.'?[LSK1UPJ\\+I8J2MM#2A#Z2IXT26&4]6:$% 2!<22RDDL1-&CZ-CN NR
MSPC.9U35_JATEZB<EC.Y]6>/PN5'_[WC=.,C7UQ,QI!.3M'Q7BR?8O[F8M1!
M)FVM))P)#->4%\AV.4WF.:.;9++Q=B>$]D71<%=[GQ&K@ZCO!T?MU5H=B03*
M>VX)RK]<FLV4N, %,2& 3JB3R'9K&M(//</=3_Y1$'N8Z@;%ZYX^>';!&&X(
MUS&@#XX[B 6N23*4>ZY3YJQ*O4E_X5*5^]--ADM[J.K(<.GU]"8&!RM=X;?9
MZ;=TA3]WZ<H=;IZO=$7[G,!E051FQ4'D0()BBOB<I74V\KS3T/<&2E>NLJR;
MZO7+E)FRQDCT%TK+P](^EQGBF3"$64NYDDQ:(6H8L=MDM)K<.0@']_+:ATN\
M@=3AS8;?[\JGBZS**76.SGIA'='*:2)#\"0DJ4BR4E P02==9?M[B*!A#VF/
M4?*L@L0;1<[ZF CW6Y] E[%#(I9C(B#>:4X23Y9:1ST'_ES8::$PI!^5[X"C
M ^3? )(VYO@31!A_+0MLTU+%Q,S ,V*$*#7-/A '$(D30L2<M Y\E^UY;QP]
M1%![*#I$X;,*TF\ 15U[^'4>Y=W8A_%DO!Q?G2ZK*")7BA(.&9E)UA*K$\=(
MQ'$AG0Q&5ND0_BA5PQ:45,)3?WIH %17^_YU.,M2D$$%2[S7&&Q21Y%XZTG*
M$5W((%%T5>XSW2=E6/CTZ!(=*>4&<+);GH+)J!#RAE!>NHSX*-&BIDS0 W Z
M)"[SW:YJK:64ZCO8!T+@H+S1/OIH^;K3]6"=D_5@G2_7@W4^K@?K]#!+9,<W
M]#QAY!"^GGE&IG%"L<P=8;P<?Y=6,IY:3CASFDJ9F#%_KS,R1]ZI+(//N(@8
M+B(5#,8PSA.=DZ-@HQ.A2HJIW3DD-5"SUSR2?532QIR)V^,4I(;DN: $G0J!
M83&2'G).Q&=IM6 J>]5;XYH?;![)7JI]:A[)/G)N R=;FCYQKHP#0TD(D6*L
M$@5Q&F@I(P[>H;!"VJ6:^^]J'LE>BMUI'LD^4AZZP.ONI,&8MDX:W+3^RTX(
MBOR4M8,1J2EM%Z@D6:@8#1/H(NXV1W>OUPX.F&-U_-AHQ_X$/K#5>>__<S;?
M[-N+;FD)"I1*B(3[Q,K2,L2Z$C, ).Z83G"W(?[AYN;^ZQONIG;HSG2DC =&
MR&_^'#[D6SRL5U.,-F@'F@0H+013Z=\B;"),4J&<UB[3WO:E!ZD8SLP<J]99
MWS(>?%>:Q3/X=3Y;7?P*4Q0>Q+/-]"?%C1<A$>-UZ3BI$@G.92(URS)FSF+@
MN^U #[UB.!CTI+M9[X)L(&GX9$\?0[EPV@9B0Y2E$I01QZDC1O@<LH605)6+
MBC]PZZQ#=J$J^AC:W'P^0V%^R"]+V?SYK#"$7^3Q<C%27.F8%!!(.1(9$R 7
MP1+.% -CC&5QMTLV#[ZBR?CY0#7.>I?IT,BX-4?[B6GL(Y:<-8$' EV;'BXR
MFE2%,4%FD>;@ >YZ,;O,+7_BK4UZN3W@IYKD&]C,KGK(12/*1BN)364.CH%,
M7([EY@T'+7U(D5>92[U7G[[GWIR. \]1,CX<&[.EG]0\N.J6PX:G(XZGMCZG
MIT.HIVD\\JCIOF&X.A^@@EKG7<1-I1R 2BF(H]D0YXU05&DNF=S?]C[+H5#(
M(:H$&."I8KQ*+6V@WA, %Y2RV>=<I4=P>X="/>EWK_.??:3?P-91.F-]R"?_
M/WEOMN1&DJL-OLK8W*./[XO9W$BJ4A^-54D:2?WW]'^3Y@M<XE0FJ4-F5I7Z
MZ0?.7$61F4$RG.%9W>J2<HW \CD<@,.!Y3+,/Z]K -;9 NUK/L *"+[V)E(Y
M@$-B0BLLGF>!>7,HV3@0VDI-EQ[M <I>C"WY#N#S@/R:U'Z[F(?[KWRBCU:T
MV.K-]MNZ1L$4URJ!+37Q("T)3"@&WMC,"N.U^WJ3JM+]Z)P6<B,@8[/.M*&:
M.D#AJ\4Y?76Q) W]C@]XO>VTIJT0F I@JA65OI[U"^F@Z-IP64NIL$F%R.-D
M38NQIHA8-%-/'R?AWQ_X2G1)!<_KF5HMJQ6B)E,1I"-?0KAZKC;V(?C^%1/3
MG$L=LC^.(N<^<++EG#?YS# X!TD[ 2I:"Z%@6D\AR4+F6.20#? O53&QEV('
M54SL(^4.]J\/BV_A_/+;[>CJP&PNT8)U==01]V:=6X!<&-;.W+2"FL1OWU$Q
M.42.U>IF^N9@$7>1,DZ+Y=>Z@>)M('O#2,B9T9]:0,VK(&J_DA 3Y#K**'K#
M8QEVGO#86Z;KQ34N%L859P=VXT8\]])9,W<[9]/I; S%"\A8G7*E)<14-)00
M VHC<A@T'F%O,_(84=,USFIC54930'^U5DI&*] %$+D*HY"O'Y!V9B2FO$5.
MQ$]=:S7-*?>A/NV1,NZVUDJ9K%)!<M=TC0Q3G9D60UIW(T3#DBAIR(7SOU"M
MU5YJ'51KM8^,I_97/H:+U=7\\_V<[Q>TDA[&^T&$5!0&X+8VF[:TW7I3;[E&
M%6B79<YMSC#<50/QQ)MZK+S:2Y.+5F*=&B/_^\W;EQ_^]>G%'>E6&!T8%"RT
M4RJO(!IF(' =BPV2%3:L"._[YT[GMS;0_Q$BZ\!3??IH7NB40Q0071V[:((#
MIWC-!J".S 1ML8FW.DJYW>CM,YL?/HVJCP[P=5>=49(427,'K$I&D2# "_I+
M%I%L$&@*;]+^YIE,JMQ+K;LJ8/:1\<'8^!V7<3$N.CY@-<&S^>?WN"R+Y46]
MA_XNGL^NI77&,_EF"B/DPB.Q%6HU@,Q@LRRRN,3\YAR;4:'S.'5=)OE'Q=6(
MVNF_7\!--=,G_+-._3FD\&K'DT:^__\8G2>^YQ\CK[,I.6C),D&LT,8GHX*@
MDM V*1]5F[1X!_?\BTDZ&>WJZ2LM+Q%K"2-%E#K[A))[7NQ_2$E72]3L5>>U
MCTKZ.(W\_M"-J6ASR E<UG43]P6"T 6TE@*Y%Q;SD%+AO^(]_[U4^]2I]3YR
M[@,G6W+D)D7R\E0!%%J"LCZ!3U:!0YXU+RES.Z0>\"]U:KV78@>=6N\CY:DS
M.(\>HV5-9C>)VK.N>H/!D;T-M:]ORM;J4%#:])1_,\ZIY(E/J/?2X.!3R7W$
MV4$L_OBAF*V]*QU"8;0+*U8#!:8Y%(\R&Y:U9TTZ%AU]*GGB\^U#D#2Z OH[
ME=0AJ92- VD](Z-;<UZFWFI73%HE'?-YM/*I9]4!XE"?Y4@9=WLJ&4+FPG*R
MF1@(YE8B..Z($YZ3RR4I849K8_4\3B7W4NN@4\E]9#RUOT*+YW(YBU?T(^_F
MMUV6=1+!<\W(^-5N.$IG")HD5'BP2@F>PL!Q<MN>WN/IXUX:6XPIOH[T_^F/
MQ2T#OL3 DH<H<P%%?A34LWF(Z*QVZ%C8-!)/Z__NZ3V>/HZA_\/$-[7^7\X6
MO^/Z!L(-\=8*69!E(KZ:P^ E1"<\D!74%,PQI[4=I/O-)T]7X]9 [T>);6J=
MWR8&?PWSJT+_7BUG\\^WDKEM6T-1NF;H:3^O^4&%]0@C1$C:&AXP8[3#[OD.
M>-ETHQ@;(&-LX780N#YYRJ43;6TA6+"Z3H?TCG#OF0+I*"BK/8YR+MT6*4Q3
M+7E(7-)$'QW@:]A!9TXQ%*T$>)F)*;N66&1@,,<4)2LR-ZF$&>\8>KKRAKT
M<= Q]#[:Z0=R*[+S@4*^B,#7M>VE%++SNH"AZ*_$.E5&-;EXO5==S'3U"R,
M9S\9'S&,]?)XS^CG^>7L\ML_9QD)Y:EJXC/>2:6>J:Y=A0=._^HL%=JSL7#(
MWI*$(KG]KC9W*R)%5#Z9H(<Y2ON_N\OM[3CLG$(+4[O?;Z^J$_BN_/,+/705
MSNFI9\PR:4RDD#%X7=NN> B) @FN,GI3C#=LV*CI+0_OLE1S!)@<*\=^JZ'>
MS$E&A*!OAQ1 W?_R2#5/.Z@9J<SI[NGW8YKOBE2X+"5&9\ (5D=^)0JO=4 H
M1F0*F(3(O$GEX2,T'>MX;'ET+2)[23_SVUG"Q#(A%33MB*#JV)]09 ',7A4A
MG<UMBG0?(VI:SW8L=&SZ)J.I8<0ZWG9F9!UR'M3&;O,18YN4;92=P+!$3ICA
MT8%S-E+T[1"<<@SJ133MM3)8FO3Q:FA8/J8OF*_.R5&Z>\G-P,.UC._1C9AR
M040(*!UYXQ@@Z.HY(=(G4B7EF_3"'$I@OP9G']3\,$ZPA7J>A?$YHHGF#\\8
MV_RTG-/V&)(L%HT\(3!9>Y:ADJ1N6[NN9E^2D*;H4VWTHSLV;_'R?H:]K2,1
MZV15*3THPXA/S1&R"S)H$TQ.37)VVXCIUZ[L@X:=CLRA8N_B(M(=%Q_"'[_6
M0K]9.%\11S5<O!Z/>9:4U=S&#,)5IXPS"R'(1,JWR=J08BE-"N2>)JT38!T,
M@%V(&D<7?>'KGXOE;V]JA_R$JPVF'+G]7ED%(EWG(0QXB0I*%L(SSDWV3>Z2
M#*!MVB1Q.X2-I(V^(/9Z-I^MR-G[^V*1-YC*LOA<-"V9(.LL&%>':Q:*,ZTO
MF'2VQ%=3B.VF;=I<<CN(C:2-22&VSG;><33'RW0=.81YGB_F-Y\0.X:<B.+!
M%X6@9#$0E1>UBYN/*0AI\["BK:?>-&T^>32HC"_5?J<:O*EL?9Y1H/EBM<++
M%?%8%\0?L_.#[M@^]KC10K2!%(\4K=T^_,4\;[YZB\<NO69%9 3.,N$-+9D.
MXSCHD"6/(K"PV9AE'$.^%Y7'[FB#7G:?N(BHG#;> ',N@DJA%K])L4['2J9=
M$:9)$=!^9$[KK+=#V>8&V%!Y?6>==IJ-8Y+@3SVTO=%KF"C?#Y2*6Y,J%(NG
M758Y5B#8F""*Z!WCPF;=I&G\24S?C4_P_>-__C.=7^79_/-WNKA?.TXP:1V2
MXZB, :5%J0EB R4I8SG*& 8.:][SQ<_)E.V#F@T'K9TRNH@;;P\&%J6&*I?X
MR^QW_$&BKZ\NJS0O%LO+V;_7*O[YSZ\X7^$&]S(%##D$8-:M[S)%\,))L$YZ
MX6.,JLTMTC&9F#;9T1[6DRN^@_++^].PNV5\QTI6=5QN<(!.9/)Z0CU]#PH8
M8Q2B.\E\&S_R$9JF38Z<'I+'JN69>HA'G50^^=3V/F++T\S]0!AEB$8Q0EVL
M-^"$KH?8%%A(86R='ZJC:+(/G30^OE\MCQCPV]L>Q>OD)4@6UY,\+,1B&$@E
M'6<B>\&;5)D/)_$Y.9/[H&NWB1M5:5/7%->D-KW]"UF#C+_C^>)K[8 <*C?K
M2^X)22HI(7BIZI T\A0BSQF""<(I4T1*PY+#3[QH6ABU4NZBD:0[1LWM$ @T
MIDB?0(>:_HY>@,^1G ")Z&E7$69@)X G7S7A)-1153H0*P?(=VJT?/K[V]O&
M2XKLK3,"M&/U<BP%&O2S!D@>&97UHLAATW7N'MFG]@]1TN)HB740G[V\6LWF
MN%J]2/]S-5O-UGJH*X'B2!=J8@73NN0:$:(N$GR1*6*IE4I-8K,=]$R;*FB\
MVXRIBTXA53]<(MXL,Q12^!(U>)Y9K7RM;3.\ YT+RE@P!QPR66<4<'U'V;1.
MS2CZ'X"IPY4Q]<;T=O;YR^7J,MRU<LNTR=16VT'Q7"\#%G!2%0@R62E2#!+U
MH.UIX\']X> (G2U&$F 'IN7-/&/9;8)??KMN\'%.>_IZY;@B9?0Y@+3:@?))
M0C0Q 4,K D_9\-BHE'0O.J?-.IYH=VNIN_ZA><]<[41SLXQS<9IS[P&C\K6C
M?Z1(PX3UK6;FL^:Z-"J:WYO6J4N?&V)G/YP>K<@NL'I3B7L;$;V8YY_N(Z+;
M 4N,I%=L@N@5+79$!E%2;&R#9\I*IZQM<GUL$'5=X_%XC/R R;$5U@$*/RU#
MQHNP_*TV_UU_4J5UV_+9JZA8J-TY)870*DH%Y.O2?B-<]@Z9$PY;H.]1JJ8N
MSS\MZL934 =H>\2W^6'[T-GQXJ4!F;VJK D(WGI(C-7^7<4ST:3R:0\:IRW-
M/I'+V$IG?<-QZSI.G#P:5B.^VE]4*:; V=INMDB!BN5:^'YB2/;G)C;#RW!<
M'JV\#K YS-L0G#N7L98?2=I/F+'@T23(T=J HA0_:"+*7]$];(J/@US#?90U
M=9+OW=7E+[-42]_R^W!)/-Q- 1'*EL \1)VJ!U,X!,XSQ&P9TRP[N8FX74-5
M=KQA6O?N%*@93\ =V*D;F&/^A.G+?'&^^/SMPSJ_><,.S]D7G0LD9VOU2);@
M(CFLY)QJ7XK&HIMD_YZ@:]ILWREMTY@*FMHJO9EO7S-<H0J1(JJT#KIST;1Z
MC &G=311!XO<#S)*.UXPK:-_,ILTAGC[&![W_8RT2.YE$1(AIT(F5<7:[B='
MP,*T8#$)+X<TMFL[9%"W@D_C.'$4J?>!FBT#L()*16:7('$AZK&O@R!< 6U%
M8CZ%8/1H WR>R\C!O10[:.3@/E*>>@]Z\;_>O?WY_[W-OPE)3GM@9& %B2*Y
M6B5K$)@PFAOR]:,9Y@T_?.KDZCY60XLQQ#6UGC]]6X6XG-V(Y(:!8H/P) G(
MH8X5)X<<8H@2"J+2RH02Q;#VT]N>WN, P(/U?K3XIM;_ZZN+4*=@WI#.=.')
MD/LC1:[3+P."JYQ(GPF[3%L?Q2#-?__<Z<;T--#Y$2*;V 'X0,[0S>:&1D>B
MCDA-% XEBKR=# JBC1&%D?*'H;&';_AW;QV$ O.,'<3#Y-L#*&YG"+'"T.;:
MXZ80V<0!A5/<@;'1%N54$'PT/_#!>Z=S!0[4V*;.#Q#?U.->:0U<7%W<#AHC
MNC4&6?M$D@VS6""L!VU30.R*289OFOW#]?[=FR?6_"%Z6XPAQ$F[!%S/+/WS
M >G%12:$T*!5\D2ZR>"YLW682E9%NZ#<D!+\@9-^_]Q3_TV<P5'T?[ 0N^@2
M\<@^^,O])(V8N/6:_*)UOR".'&@/E,!]<586*[ T&9<PA+A!Z+'/U*%HIJ4.
MCE/>7'P-LV4]-*RMRY]HQG(F-5/1YT@R(R==&>+0IZ3!A<S1!%ND;W*'8R\J
MNST&/A DFV>_S336 QPW&'J+ES_P='=1/&1?AW@C</0(2CMR&6EQ PD14PK.
M&,W:%",,)[+;T^61P-A*7YUOR_]88;DZ_V56D,(5SKV6!5B-692N[=T5,R"\
M8]%(+/[4=8/WQ$U=,-T*'(,WY@/UU$,_X$?+?A_P)14:=(Q<7*U#S9X9\-%R
MX+)$BSD:XF_@6?3 5TY=$-T850WEW\$.^\B6\/?E8K4Z8S$8:8L&XUP-GG0$
M)TL"@;(8XC5)TZ2 YBG"IFYA/KDM.T _7>RB3RRE'WW6PC@JH1*$N)[V:25X
M+Q@D621#F53,C>8"[D?HU)W23X3(IOKK J&O*:#Z7^'\"G_%4%M1U>#JG[/+
M+_^8+V*=)E S!V_F7Z\N5Q\P+>9I=CY;JYD^NUHNB?67834CCSI$^L[EM[^'
MV?P76JIOYE4R56(_AV6=K;TZ"\5HHT)50:CAF''@(BW>A#$6(2/3H4EG\9-Q
M.&WIT>FL=)>(Z=N](&6<,1UETF054F3U9IH*X'DL4+)!JTO.Y#J=V+D@LJ8]
M#NW!M=A7-Z/-PA@O5;3VCG[<C+3D:)GVM&"L)7>I=HQ.]2Q((Q<^<>YDH[E/
M0\B;-F]^0A=B=%WU;>M>I'1U<74>+C$_[.Y\EH1#DJ$&&[T$Q8(F)RE'"$)Q
MYA3J))ITV-J?U$'(=,\>F8UUN#]*_35*Y_BYOOAD2?4S9RTON8[;MMZ 2MK4
M4CD'NC"GK4-O59.=>0AQ@[#HGST61]?3A+OT=2WN@V53>_\^.+FZZ6WUPZ([
MLSZ84(B_X#!<-Z?R6G,PS),#DJ.SFW<G=E4X[__R;B]I'7=8<Q)==+ ?/V3Q
MQ[/1LWH.:EUD8(7/H)Q1X'*N'>^S<AJS#*')X?7C9'5[U6N< \(1=7+L7OII
M]&:7KQ87<3:_#>P7G^>S?Y,<,\E]5F;A@2-QO;YHV=U&_#-<T?>N+JK8'\VN
MG26*]@,Z"T5S56<?:HB1T?YBN7>A7O%.L05J3\CCM#FCYDN@5[1T8+$?\[Y_
M'(KS >MU 4)#K?-:I7#^+PS+LQRUP&PR,(ODCLO P?O,('(?I25W2YAPZI!J
M(.W3YIV: __4VGUV@'Z+?UY^^@//?\=?%_/++W4[1);H#\0B!2BEL%:],Y"6
M25U2T0Y/GAYXFNQIDUB=P?@HG3X[!-<U^NF/Q9E73IAB.;!0EVDH]OKV!K+B
M@PM<H.K "-]0.VUJJS.\'J+!/@YM]V>3D(=GIJ"0,D7:3&J;6*=\=9$4<)Z8
M\L)R^GXG4*WT3IO[ZA&L>VOQ65K5UXNKY1ER*TW@ 2R/ 93G#(*D#819F24O
M,:G-Z_Y38;62.ZS:E/T'875O)3Y3R_J:?O8L>D.N3DR0HJ$E*>LM@TQLFY R
MHM%.ER:MHP\C=QA8G^\UD1,H<32[.L$4T(VLXEAC0/GIYH!N<##)(% 2CBLZ
MDIBT9030VF'220\V!\&L]03;YS\(]/9E'Q;GYZ\7RS_",I\9J=%Y92!DU!34
ME02."0-:8F)">;+O33KS;J'E.8WVW <OFP;M6#5TL;7>'>-&DTOA,8.TMMI9
M2^&6,0E0NB2B$(F+)F5)?5R2/%J7.["QEU@/!L177,X6^>-E6%Z."HIWEU]P
M^6:>EAA6^!->_WOF-5-HHX6D9+T2'PJQY /0-LW(.;#<MRG,>)2J::\ M8+/
M\0KH(-2\6PO6!"V8Y]<E2JJ8 E$PA.*2-<HQG4N3BXE[F9AFU13-3,P^8CW2
MQ/P\'Z< [);VZZ(/S \JV^[K0&K]^5D2P5#4X2 GG6O=98'@?8&LBF+)\XRA
MR6GS8 K[,#RG\W;&5=F(/M#H,=NV*Q6K0Z*T[0\:*2X;0.5(D=C=F^Z1M;J'
M5C0RHTR@4)+2@\O@:OI3AA"2=XYKT?8>T1:B1KN%]>#9GTB8+^F'?CO31D87
MD$-RS-:#X#K=+7."N4[))JY,HVNICU$U<:N1L1"R\W;3T9IX=@9GW25H/+-S
M\[B6QF<;Q:<P08DPY:UPH!D*@H'7Y$PY!%=DXEQEGP9UJN[*!#UH)'7[EIN4
MZ7?%6#?BS^\V[O.M57&_4*0,7HF"M.$+6H*RCN9#%B 9E1!)L]8TN<<\*A<=
MF[A]$+AIXJ;3=!=YJ'OV7X7E\ANQM19!Y?[GU>7LHOJ9=X)9O2L_8;Q\,R>Y
M7]W;G'OVB_6F".NA]E8$)1SM"%)K"-P5-#9BSDVBAE&YF+A34WN@GUK370#]
MCK4!B_J'R]O?W]U^( 44Y#U9#<636Z5L$N"CLQ"S8X)KF:UN<]+9@)F)[[RT
M@OWD>G]VGN_-L>)HKN_M\UKZOEMI/H7SRP-MZ3)',*GFA(50$)"1'32T=&W&
M2+'7<W-^]W6$Z ?>+N;+'_VB,ZSI<A8EZ%!HES"18D^-%AQ'],X$"D3;E"V-
MQ4''3N\^R-MI%$^JX0[.1.X8?_GM[L/_GN&2B/KR[9<ZL&[=>3XGK@/6&13<
M1U!!2'!9)! Q9<^$S$JTS3$]2EXGH#PM=G8A>#Q%]@3/AWO;C_S=C$OQ,KI(
MS@>4G,D"E%0@2!<A.R%14_#I5)NIT/M0V0E81X3)@ Y0X^BL)T!>][!:2XS?
M-M>G'<C1@@6%7M3SSTA"2Q%X9DS0DN:!-[E&_0A-G8!M?"3LPMR1:NDK,G_
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M0MM>6GFFYSB'#6M\['GM3W+:C&K<(_DN-**/,8##1+X:)]<JE'K1W7.!F?&
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M&^Y%'#;V:^ +I]V'NX;;4;J9'G%_7]"CYE5 NU90DBQ3G"1!8R)^HLC@LQ*
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MAKP?2.^S.=[:!W&;YNT4NNR@#&K#6]C@Z^&$W#-EA:$-H4#REI,TG04G5('
MF=!%DBRY;8'2X23V,J&J*3 ;:>S98+%6:)U%E,ERZ\%(3@(4UD*TQ"A*KT(2
M''ULLI<,)[&7"5<=8'%OC8UX"^247F&=%GX5SD?V#6^?VMY#W$K_!(5/7$L?
M:<M4Q:GK^#0$C5#O@7J,&%AZIJ,8;I),N R?\=Z9N)X45]?- S="1JZD% P\
MA5) *S%!D-(!:NY,,)%[4P:F_@:\[MEX=/M@8R.U-[;4G]MTF*<7_FAEFD->
MU="<[<WI^#;NQ?GYNA7-PR_=8KB(X+WU$8JJW6=*T! E.O F*!XL:NF:7'T=
M1MYX/4->7JUF<URM7B1:S:M9U>[JY;<'GUUWND"T+BM7CQQ#K/T7R1,Q/H!&
MY772K X8:R&.?0GMQD:.A:W=;4,::&["\"+C[.P7<@S/?YY?DNE?MU4.+ 2K
M:U53H;]4U"0B(6IW,JY<HB"]I"VQ[.H6=2LR09\7O_\7/?H:</3!)LZVO+:7
M%A\M]+L81]@3X^2:ZIL&4#XEGCC7Y /P>MB,'"B*49!9#"&7Y'C>8IGV!LG#
M=TZ#D*.5MAA!@E,W#?\)YQ2N?B+#&K[BU>4LK=[,TVT/5\]91.-!>$=FE6M5
M6X$5L-IKKGDP)3WI*#WUDNE4?[C*%@WD-S4./H;YYW"Q>+6XN%C,/UXNTF\W
M3$2=HDL4%Q2?R1RBUV08(_%DN$Q>L^3$L)!LUQNF25^.AX!1)-=!'G+G@"Q7
M:OHT24@&/2CI#+@Z050J'3Q'8[)H4A9\U("Z$_19:NA/C*J33K%UL^Y0E.2#
M4[3:$NVX=8%X25Z\UL5%KJU!T>1\Y=G-J=M+Y</GU.TC_PZ0M'-2FN=%..$1
M;*E-;DQ.M65IO;0NO'3,*FV;Y$^?W9RZO10^=$[=/M+O!44[9J09E6Q,:"!8
M3-5>K\O":=D)J8VL"073;N#A,YM3=S261M!!!W#:-<:*J11,K2P+=;:/0EV'
M8' %*)FR2B3ZTV0&ZS%SZD[0P.\$CM,8&ND 6*-V]D9NZ'_. KIL00DRSTY8
M1N+U-A4A>,I-ZJW^^N/J]D)5RW%U^ZAX\HS#91U3]7F6'F3T;X<4""FU2G5B
M?*@#-$R$Z$R!FC<QTBE+P?BPG,/.=_R%1M/MI?3%^!KHP$YNV5%^N>M?9.HT
M%E0...,U#2<"1&_)5962U\]2+DVZ1#Y&5"\]2D^1PQA+-QT:K/>+Y659G,\6
M9T*S5#QM =G4>C(9#3%B$FC'7."UNB*D0TW6W5LFCBE'4^031N@PJ79QM6RS
M?OJQHNGK<I^SB):A-!),-A0ZBUP@J&)!"@S,)LY0-.EXM3^I$X>A8\/O1#J;
MVFS=KZO9/*T/*5;UD&+UA:2^^GJU3%_""O.9TM$'I1V$P,B']5*"=YF#\($E
MQQ(WG \R8,/>-VTLVL:4-9#TU.#Y:?;[+.,\_VN&Y_D]+E/5TF=R"#Q+M5<.
M,,-U[6[OP1=#88_R%.L8YOQ M.QXP;3^41MXC"'+J?'P]JJ&!^_*6[RBQRYH
MVP[G/\U62,#^%):?\9*"X<*MLBR"X='=I((Y>@@R2L\C)B'\(&@\_:YI>TBT
M0<G($IX:,*\6Y_2E.I&Z:N7S$K':QT^XO#C#0/&J9!8**_4*1D'P7'#@VHKD
M4K!!#^OSL/L=T[9P: .0D23:;TO=GW Y^YV>\SL^R'4<4J2]_4$CE6 /H'*D
M NNM;WHQS_^-^?-L_OE%HF]=7W>?K=+Y8G6UQ+O*6!-ST29[,*5VM"LE0:R-
MCDH10LL8(]=-3D6/H/GX^W1[O[K6Q[^D9_QVEL@O4\PKDI*/H*(G+\UG!8SI
M@"5P6W233N''$#UM5N!4Z/SQ$MZ)U-SSC9>M0EBG[,8SF#>/:VDVMU'<@?%T
M.822I*D=Z@DE)5GPR -8BM:TREZKV*028$+C>9\9?KNHZ@WG+RX65_3Z=^7=
MU>7J,LPS47!/X/O%3=)XK<+[!19=L<IQ!I+B68II2DV0N-I\)[O"0@G8IJ/B
M2/0_7Y.Z#V9W7X4YG?*[R-K>,[Y5]+6K0+W-_6;^D4"P=K<?',A1)%\6RXM:
M(O-@@T'.?&((*=<KE4'4$^%:"ER8C3&XFM=NB_^1.)DVYSO]2I@"$)VMB;=X
M>9_9K))'8OS!+*'KHL#%!='Z!>>KM:AHO\<JH0W+H-':2*8!I+>*=*(IZ%44
M^?K")-F%R(1JO"S&8V;:#/;T*V,B6'10;?"$==AA%6XVR[N^F??LAZ)RUEP1
MO\*"TDR 3TI!UCHQPXLIO$F0/C(?T^;LIU\0IP?#LPM-;_H1C!:;WCZO97"Z
ME>8.HE,,J'TV&J(0"(KQ7+,9G"QG\DX4J4J;<LX)H].[Y;*Z)V*UK3S]Y;?[
M'WBUF*]?7@OI7GZ[H?(G7,T^S\-]A1-CW*5<;RP(G4#9G.NX;H1(",QU#^*\
M25/5=BP]WQAV'V3_4/C=!T2F/G:[Y^VV]\^Z4#DCLTBN%G N79U\1IN+HX]D
MR240=ZXX_90A?N3Y$U=G=Z+ZQ;AZZ ]*-W7'M:H].,X!U[WM++DK(9!04M(Z
M9FVD5L,.^G>]81HXC::WQW%P@!"G1L+'+XOE)3WK(M]S<UTN7E@*:)RIG0X"
M*!0D%U_7AR/7V=9:324'06'G*[K"PB&Z6XPNR GAL%I>/@A\KHLB?\7++XM\
MGQ+X\:N(;\,%KA<2K^DP)C3D0LPJE8C/[,FT*J5##-99/L1Y)3H>N%KTV::;
M=2RATZ8_.]O13JKUB=&]BX^;I5]<\MH%09)3$92K%U0-=V"5U(+^GZ09TLUN
M$'X?)V4:PWA:*"R:Z&7R[31<K*[FGU_.%JO9Q>P\+.^*N6XV VFL320/2,%2
M'*1T[5;L$'0(S#NCD?EA!7)/O6DZ#(VISD4KV7:0<JX=8C<NG9K,B[>8(66[
M'E9:(,1Z1<_R;$52&"T.,$$'-0/OZ5YY9YOD2!KK#G,/5F5$G1*G*"B'H$!)
M\H CTP)T--X':U"71IG'[01-G>DZ3M&/XN9 J4^^M>%\MEB^75SBZM,?B_>+
M&7$RF^/-I8>?KO#3'_3OM^N_;RRR]MR50$(3HM0!7=R"XZB@:)UDRD)B'GB#
M<O^7]X2@0U6^.*'\)W;.KSL0I>N<#-IZZ4%),(F1D6;9@=.)@PFA("KNXZ#V
M=(-<\8<OGO:XL[-=[RBM3(BF=$/SV8OS\QOZZYG$]?)S/H048P&"?P:EHP:'
M+H$/(@1>+Q^S+4'>#YUP;]]Q#:_;SS;A]1@ET_GGA^MT,;* >P#)S__X<!9,
M(&.8#:#21+-'#LXQ0833%B](*,QLZ29Q+"CHS=. 8#S];0)B7V%.6A5W1_7?
M7[XGMHTO2@G@#BO5,I![QUF-(D4LL8[FV'))Y%@(T)NGR4:V@\"^PNS!!KSZ
M[]=GUG#&ZK2[4&K;NV 5.)DB2%$[_BH9K![2(GU/ -";IXFTVP%@7V'V (#_
M^_V_SJP.3A4CB4M&-.>0(8KZ461%*QG);&VIV#L6 /3F:9S.=@#85Y@] .#5
MBY_.,OILO":4<EFK]&3=LYB$5#Q#1[9+NP9; +UYFBOO#2W GL+LHC;^NI#Y
MKK#S-M1:.\DR2BN%LB#0VEKH'\"+4@=V,2PQ*>^-_!$98\PYVDG3M&T2.HM4
MQ]9A!XG:':S<+L\D&2U/ 2(48H8% ]&4BA_.57;$9S$G!&0/*=O1=#\,4P<H
MH@M4T;-P=?GSGU]QOKHK4.'*\:A)/'5XJC*.0ZRVG_;H++V),<1&8]RV4-,E
MB@[1]@\X.E;T'>"G-DZ[;2?*G.(B8P3%O0$E/(=@O8>HLBJ852J\S;2[>QJF
MGI+="BN'BKD#A+S[BK6+S?SS]S@/GCS_*!5@5:K2#,';P"#P)%P*6@O;9,/:
M3L[4$ZU;X68$X?< H9LA HM;;JX%]CU/W/@<ZWQ;7>J6[K*"@*X LS:1X30^
MJ"9-7880-^TI4D-XC:V8#L#VZ%WPNRCE YZOA;CZ,ONZ]BAU0!8YB3$[9FLO
M;0[.I$2?AFR#3:E11'@8N=.V3.LT6#R!YCO ]Q8V;BQ!+35(TB2PKM"N8+&
M+S8"3VB*D*[H;0GOXR&\DZ*I"S;:PV'10C<=@.Q56'UY?;[XXX:AFYW I1)1
M8(+BJOLJ2KWW$&B%)J$%DX)X:.+S;:5F6G"-I.G%V&+O #MWN\/W7!2D]62]
M!>;JI1FF H0@/4@9N7'66I/:C%G:2LZT@68;](P@^*E+$NL"*+0 5DO\'>=7
MMRZH)9\@\2 A%JRGCUG63H :K(TBD7L0A!XVWG;[\Z>-'L<%PUAB[ 8)=[$)
M7D<EMVD4K1,650<UN^HI<EK\/L0,,11AI/",.-T/$SO>-&WPUQ(=8XBV@PWG
MAQY'#VQ?I-!82P<U#@:ER H2(_07,J%#+E:WF5N[FZ1IC_G:;#PC*: #*&V+
M&3[,5K]='SH5[H,K%I)W$A1B!L]M@$QFTS'EDI4G2Q'<$C4(3K85G)Y1(N @
M+7:%R(=RNUFTQBD>4J*@0#E'AAHEN! "E(*&9RU]C(T;8?](5']!_V&JWXFI
M(_70 :9>+Y9(J^WG/].70)O_+4.W7J(,247A(0?'24JIT,J+!>J"E-;K6$23
M1G>/4M4+JHY5_F;(-IHF.BFYNCX2_Q N\>,?X>L-'U$*;KU2->2(U;>H1Q12
M@2G9E*@RBFW5^..5(WQ/3B_-<D>&T@BR[\ T;7,>KF]KHK4B"@0;ZC" P UX
M@1&2"B;0-S0737J5[R)H$(K<?YCC-8KV.D7A;3LA;C$S;4$;A76*M(-@F(&0
M#3?1U&N838* W21-/&]T%)4/P-$!\N\ 2=?]E==UU)<O5BN\F]W,3(R*<]K,
M4S*@)-EE[Q2QI9307B?E>),]<1=!_:'H$(5OJV\X5OJ]H.CM8IZVL$+F.(:X
M[D-6KV,X*2!89% D-RE8:41JDN)ZA*:)1] VQ-((.N@ 3B]26E[16V<ASL[7
M_5WON@N0T49:%B*84F]Y:8A>:A!)<">T\2PW.:/;1=#$\V?; &D4Z7> HHT%
M\2,_OD2;'1=@?!UTZ*,G#X 62<FH@_3%JLU3NR:6Z3!4M1M;>Q+S=)PV.D#7
MC^')M5<9@A-$,3@E?;6T'$*=S1RLBAQ=L$DVF?:UG9Q!2/*MD-1I$#B"YKK$
MWVV[G^*4"\X!FLAK=V$$+P-"2 4+R0=+FZ%INPCJH@[J*&4_B9\#)-\!@FX9
MP/QB=</3_9G$;1R"W'NF%7B;!<4A.D.L<8@2IBBIA*- I<T!SI.T]8:K0T#P
MPQG.N!KI(N=.>WZ^X^NV8M"KS+$0_=Z7VMK.D@]!D8DT6;-L1!$\MX#5%EJZ
M*+0;%T;'2GSBOFP?ZDG3]7DHE\6@0-"JCO#0*"%:32XA?602:N[ED(+Q04W9
M[MXZS*ZP_Q"GZ7"%]("B6_"'6"PZ1<2F4AL *W"63&A$97P4108]6G._!^^=
MKN':@1K;U/D!XIM8Z[_.YK.+JXO;]LP,0XB*09".0DJN./A(T$?'2O#)2,5&
MT_MW;YY8\X?H;3&&$*?6?OCS >'*9!8R*C"QW@ODQD'@QH/43CMTGF$<<A(V
M3/L/WSR-2S&:]@\68A<QS=V>>;>1_C*;XYM+O%B=8;T[E<D.,G3U*JKE)!)1
M0++@0\!H@FER >U1JH;9BO^4>5?C*[(K5'[ ZMW7\N.;(4#\C",FYNJM:%W'
MAOKLR-,W E+RB7C,WK49\OT84;U4LQVM^YVH.E(1DT;6ZTL2_Y@O,9S/_HWY
M]LHHKM[-;^KU;AON/I#D6[Q\B86^_2G\>6:XL(6D!4)DDF'" #'( LZ'[&1-
M*OAA7=*/H:*7.K>Q0'9:M>R/0'^-P#E^KGF!]KT,/F Z#ZO5K,PPOR;Y/YSJ
M_>K-F_GEXJ:;0RE8!WGB^\6R:I]$<J9R4$$Y2?(/=41>]N"SB9 C)BY02ZV:
M'*.T8JB7,>_M#.J$ .AJA]\NA\7G>;4);^;7'+^9XP;/+^;YQ<7B:G[Y\Y_I
M_"I?"^Q.,'-<K3[AJEZ%J\)A)>7LR1_WR=^T:2(=U1A?8KU,:] W*:DY*9>]
M#((_]9*9#BI=K*.'0TR^*QFO[87RS>R1\!G/E/0Y.IV!9^;J91E-@45D@"1_
M+HU.Z!MM$4-)G/8J94L$-U%2!_"[78;OYEM7*2VH]TN\K)Z:]5[8:&L6C$);
M5*:.N;%0K-04\]+2"DW.18<2.&W_I7;0:Z*@+HY)[_EYNZAZ"N?71OY,FF3)
MXW' @ZM9%)[!:1O)C&N==$2^M4O\F)O]]P1->Z/W%/OR$0J8NBO%]AFJ[_Z8
MT^._S+[>6^;KH/-%SK-K7M]?+=.7L,)/RS!?A52_>,8ERYH%1=;:>_(=@@1?
M> 3MO1%:6++?&\C;D248DZII[S4URAI,IK8.]MS!O)^YHAD/44(B?$&=\$M>
MK3&042F>M.=>-;F2,IC":<LMVYG&-BKJ 'OOP[>UW_!I\2(1CTO<SNGJS!MG
M@\H&9"CU%D4M%4Q,@2W,UN(<H423BP=#"9RX:*4=])IHJ /DW4OL$RXOWI7;
M$[6S$JNH; :T]9*%KR>VM'+ &*F*1RVS:V+D=A$T\?'D*?R](S30 9)^/'$8
M?-[@<J0PG(2FO<J@BN:T9I"DR2Q)S[E"K+; VN$D#T/C,SHT.K$6.\#KBT6:
MW;/R_UP1U^7;;/[YNN09;Y.:KQ877Q?S>I&QT+LKGUI*+61A(*/DU^TBG+ :
M>"X4CZ%";9L4#1]*\#"L/L-#GY-HL .DKH.JZT9T+_+_=W7M:="B_*&='-)7
MWA7BD#SA675+$BWF%?Z$U_^>,<1B=/* WBA03FD(40FP4L44@D4KFR!W+ :&
M(?D9GL5,HN&I<T0/Q'FUPCR;S_%R=L?ME\HM?651+L.?>+.4T^U2GMTPGF\9
M1UUL2:R 2#K4Y%B$R((#HT-&H>O8]XT.;SMR1&-2-0ROS^CD95J]=6"*!SA%
M#X\!%I>/7J5:G868=/%U]E5=M"K42\PJ"1*$"39FC38U\7Q'YF,8T)_U.<_I
M]=U99=6=9-^5^R^NNWN<61L+2F%!:D7^E)"TZR1':]J5&&W2ROO&]<R[B1L&
MS6=]3C229CHPKT_P=-NLX=N9BBXYY D\LUB'.25P,2-X%"0RR5AIT\QG*('#
M4/>,CH>::F@TY/U?__6#O(GMW];?6G^G_M8'+/]'_?<?']Y\]_PX6Y#G,B/7
MY&_DKUR_X/VR]GZ__/;^/-#SYKEF?;]64[[S&]_SM)I=?#W'IQS/ ][R7_<\
M;7)[\[(? -6"/_SS$N?DX/V?1YY_/'S;BP=O>Q%7U\E00^X@_9X#FVT$E0BS
M,?$"3OH<4A8BNB8C=9ZD[.BCGUTO^&FV2N>+U=42/Y&47]+O_';&0C;%.E'G
M]V90M56\TYZBO2QB2;57O&_25'$?(J>]LS$NDGXX!6JEK&=H 7_"RS [7XUJ
M[VZ?V=JZ;:7]9+9,"8&RF-KLLSA0.<6Z_QI0NB!W+#(EGJ<M^Y@H^K\Z)X]@
MYZNN;^3EZ WSV8,3@J)^P3P$1 M"12F$S\XPT4("0PGLW8;M@Z ?1BRW4-+4
MN<37(:W=SMM+HNN> ]$*R1 ]%(IS2%2UDYM1!KR.O@A5;-J<E+LC)[CMZ=-"
MI(T2%V-*M#=(W,[O<;5?  N0F*\7R7D EZR&C$70QIR1#[QRN/WYT\!B)(T]
MIO\#Q#<U CXNSA>77ZZ6\X]_S"[_C4M:(;=MB()QWII4(#E'8L&B((B@@!N5
M? R&/+0X" 6[W]$1$@[1W6)\04Z-AUNQU&X!Z\412B*V-0,=N:!MM$Z&ES%
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M>)&XK8@HCN=4C(&8R!U3.A?P/"B0J4C#2$@N-<DX?9:J8='8F^Z[8>H 18P
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M3KY-[WWBIA9W$B[.12PYY)*!9*[(6V<%?-$*<K2HHY**LR:!5A_$#WNB_EH
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MG*'NEGG6B]LVQ#C,O=2YEX>VCVQ'X*&]:-7_N"E"8V35DY4&#'/D#A2*87Q
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MR@).4I$!SA"R-[BJ @6@.A3KE7*1I4H#P"%A@.^)+!CT";:O@*@*N!?H:'.
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M@G*KF=K.3# [;M>JU7]V"J[NZ4FL$@L#:NC ?_7];/1F^:TM42E&2=O-"3O
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M3CSYJ/R#[U3DG_X5#_>RR>G_ %!+ P04    "  +BE51-C%91>\%  "Q+@
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MSTGIWAU@6@\ ,Y-J1G"36H"BD0EM%AB1@$XIG!,Y)AE5C>$UIPO8C[09,<#
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M._M@]?3RLRCFMF7E>_\ 4$L#!!0    (  N*55%SPID3FAX  &_/   :
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MP(24'[9;#SL45V.9..15PWL+D)B.@%N78@GXM!N7 K."LH,PZ<0:D8Y>MG,
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M@B(4*R >:M=<#0*:BGXAWK9F)IF2UD\Y"!)_'QT&C>Z1;*FVY0EXBJ4O(9T
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MTX$7%FY\-)! ]!JS;20Q[PZFDM$PV0 T(.AB]C]H3I-C.VUI,J0?^XJ21&C
MK"( B:8K+B]MXT5MO.B1\:*7;;RHC1>U\:+GCR6>':K#7-)"40G!@K+"6VRW
M2<<,UB3:(0Q*&CO?N!N',H F\&73]5[FG"^YLOY:> #AVF<PK4F[1 N>+>G4
M&M*P9L,184J7#\5&)QY6YAC!H"K( O$7]\!?N@@';ALA%SCT ,9VJDH88G#
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MP<BYB"3L@Z,@'-H02(DT*-=Z(E&CULJ?'P1UDE)[@O7H- '.$(O'/.UI&0\
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M/UNB<SP.);QC=*#%O25Y7^+)F*+,AOUB8FB> M8*4#3'1/-:-35:^C#.*4%
M^@&08L%E8LG/:J:6'!W]X<I)G9) WR62O@,S*K5&C6T,=LHO%D(6.V= 8XKW
MICP&W?86YN&(MPJ :0T7!SY6:0XZ8.OO$T/TM9C3%QW .7X(U+YE?_R-/1&/
M/)P?%(C8:Z !=@:R,2-+9^7.:&#4-9DPT#PCN^I2F$++"*V#JT)%-^PS'#_#
MUB^O/IL-.@@?N;Z!<S1Q]2-=!>H')IV)R"GBCF@CE0(51\3D<8HIZB8+#(Y
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MJ(',)APD9,/ %DJN87[2UXU(^G.58N0UB2@"B'2$*]0]$_-U 7%:7\7C/Y=
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M!TMT>9G,3#7?S*9,!->(5=2(;,H^?9>H'A ,*/>8UU+A@=32!H4.<DJ)GRH
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M("=E]2R,C ZO/@E?Y]A*.#R04WC=TJ*G,RI1%'.,TL52XEEETEU91W#(?;\
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M_W[VB"Y\_LLT30IX6P9W\Z_\D+5'+?TPA GNTVR>'O5&\+B%G\W@#46Z?'I
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MFHDHAA,P->!)*HYFD7@?JOU69*4F; :W;/#//PT/GX'JW+K//><$#]PM"[J
M>1O/">U5.S'H,\-/TH;"DKVU2SSJ1<%N0E [7'(7\L[ PNIM!6TDKBTD^T]2
MF+;ZM%1)KF#,N"JH^F=JYF>A\>+P>XF+YG5EOC+LHQA&(+$<?#4,XN3E.[=)
M+_PH/P3JC/("KDTS#LL8_P+/BOD%7RT>I@50-HQ-&$+#Q4 >X,J1AM;3LH!A
MX(2F=?=I1+ZC;[CYMU'3EEZ+[=-\/M.RZ.^X*LGB+^B<^-MH6@#ESM"\)J)*
M)W#R^ ##T0.# )B!]GW.*P:Z=S#Z[\?&WYG <.? >RDNN(]<#]5F$8+7:1G;
MP0:@2W)&&I\JJMY&HM(;C;"LXK&G?CYW+O'Q;Q/;U:#(.\#WOP&QSO&3(Q1>
MWJ&07Z;$_9H32;&?%:C/_X1> Q18"TJ(A8O*N*BB%7J5>($L[[$>8K586Q+/
MMU8F#P>=R/L).T<\6QKE("71FW6M8J"G/6]@6YO*^+'2L@"&'+"7"$9W!<(M
MYV/G8Z@BG24PSE _/C/>97-M3GK36@QN%QS/0Z]VRG=S<V].42J7H+DN6(;6
M?(&[?VHQ#WQT],PY8944U+@@+G-+:;TI<D9*E&\TQ+5(DZ@HXNV\W94IK[P
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ML0@*YK?PE@13SZXQ'PKM7"X-GU3=RPO[Z!5$%*'"K#V_=B&(DU2LW\*XI>Q
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M@\]SMCZ9I.$*_ID7B_CY_P=02P$"% ,4    "  +BE51YX4#*8.6!  S-SX
M$0              @ $     8FEI8BTR,#(P,#DS,"YH=&U02P$"% ,4
M"  +BE5128JGULD;   3.@$ $0              @ &RE@0 8FEI8BTR,#(P
M,#DS,"YX<V102P$"% ,4    "  +BE51K%W)^' L  # V@$ %0
M    @ &JL@0 8FEI8BTR,#(P,#DS,%]C86PN>&UL4$L! A0#%     @ "XI5
M4697N_<MO   S0D( !4              ( !3=\$ &)I:6(M,C R,# Y,S!?
M9&5F+GAM;%!+ 0(4 Q0    (  N*55&D,L/2H[X  *+T   4
M  "  :V;!0!B:6EB+3(P,C P.3,P7V<Q+FIP9U!+ 0(4 Q0    (  N*55'^
M/#\<! H! (=O 0 5              "  8):!@!B:6EB+3(P,C P.3,P7V<Q
M,"YJ<&=02P$"% ,4    "  +BE51N%!./4?:  #-! $ %0
M@ &Y9 < 8FEI8BTR,#(P,#DS,%]G,3$N:G!G4$L! A0#%     @ "XI541/0
MIX@;(0$ S$X! !4              ( !,S\( &)I:6(M,C R,# Y,S!?9S$R
M+FIP9U!+ 0(4 Q0    (  N*55%DZ9>?*L@! !0M @ 5              "
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M2P$"% ,4    "  +BE51F4;YP&.,   +OP  %0              @ %/,@\
M8FEI8BTR,#(P,#DS,%]G,C N:G!G4$L! A0#%     @ "XI54:C:,MD.X0
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M,C R,# Y,S!?9S4N:G!G4$L! A0#%     @ "XI549!64FVDY   *PX! !0
M             ( !NFP4 &)I:6(M,C R,# Y,S!?9S8N:G!G4$L! A0#%
M  @ "XI548I.;(E^^0  B2L! !0              ( !D%$5 &)I:6(M,C R
M,# Y,S!?9S<N:G!G4$L! A0#%     @ "XI541/&L89?.0$ QFX! !0
M         ( !0$L6 &)I:6(M,C R,# Y,S!?9S@N:G!G4$L! A0#%     @
M"XI54?G3<L$ U@  )!<! !0              ( !T807 &)I:6(M,C R,# Y
M,S!?9SDN:G!G4$L! A0#%     @ "XI54=NW(0;C:P$ "L<. !4
M     ( ! UL8 &)I:6(M,C R,# Y,S!?;&%B+GAM;%!+ 0(4 Q0    (  N*
M55$C*'J.O.,  .\X"@ 5              "  1G'&0!B:6EB+3(P,C P.3,P
M7W!R92YX;6Q02P$"% ,4    "  +BE51AM&)SWD(  !6,@  %@
M    @ $(JQH 8FEI8BTR,#(P.3,P>&5X,S$Q+FAT;5!+ 0(4 Q0    (  N*
M55'_%F*4CP@  ,<R   6              "  ;6S&@!B:6EB+3(P,C Y,S!X
M97@S,3(N:'1M4$L! A0#%     @ "XI5438Q647O!0  L2X  !8
M     ( !>+P: &)I:6(M,C R,#DS,'AE>#,R,2YH=&U02P$"% ,4    "  +
MBE51<\*9$YH>  !OSP  &@              @ &;PAH 97AH:6)I=#$P,2US
M979E<F%N8V5P;RYH=&U02P$"% ,4    "  +BE51\%%)^7\:   !C0  &@
M            @ %MX1H 97AH:6)I=#$P,BUM8V1O;FYE;&QO9BYH=&U02P$"
M% ,4    "  +BE51=R (BY\Z  "P> $ &@              @ $D_!H 97AH
M:6)I=#$P,RUC87!E;&QO<V5P82YH=&U02P4&     ", (P J"0  ^S8;

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
